
TTD - Therapeutic Targets Database Full Data Download File
Title - Drug to disease mapping with ICD identifiers
Version 7.1.01 (2019.07.14)
Provided by IDRB   Lab of Innovative Drug Reasearch and Bioinformatics
                   College of Pharmaceutical Sciences
                   Zhejiang University
                   https://idrblab.org/
Provided by BIDD   BioInformatic and Drug Design Group
                   Department of Pharmacy
                   National Unviersity of Singapore
                   http://bidd.nus.edu.sg/
Any question about data provided here, please contact with:
Dr. Wang (lfwyx@zju.edu.cn) and Dr. Li (lifengcheng@zju.edu.cn)

--------------------------------------------------------------------------------------------------------
Abbreviations:
TTDDRUID	TTD Drug ID
DRUGNAME	Drug Name
INDICATI	Indication	Disease entry	ICD-11	Clinical status
--------------------------------------------------------------------------------------------------------

D01FFA	TTDDRUID	D01FFA
D01FFA	DRUGNAME	(+-)-tetrahydropalmatine
D01FFA	INDICATI	Analgesia [ICD-11: MB40.8] Approved
D01FFA	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
D01FFA	INDICATI	Irritability [ICD-11: MB24] Approved

D0ZJ1C	TTDDRUID	D0ZJ1C
D0ZJ1C	DRUGNAME	(S)-(+)-Dimethindene maleate
D0ZJ1C	INDICATI	Pruritus [ICD-11: EC90] Approved

D02JRT	TTDDRUID	D02JRT
D02JRT	DRUGNAME	111In-imciromab pentetate
D02JRT	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D05WVU	TTDDRUID	D05WVU
D05WVU	DRUGNAME	131i-chtnt
D05WVU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0IH2I	TTDDRUID	D0IH2I
D0IH2I	DRUGNAME	13C-urea
D0IH2I	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved

D0XE0U	TTDDRUID	D0XE0U
D0XE0U	DRUGNAME	14C-urea
D0XE0U	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved

D0R3BC	TTDDRUID	D0R3BC
D0R3BC	DRUGNAME	153Sm-EDTMP
D0R3BC	INDICATI	Bone metastases [ICD-11: 2D50] Approved

D0H3KI	TTDDRUID	D0H3KI
D0H3KI	DRUGNAME	2-deoxyglucose
D0H3KI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D0H3KI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05UEI	TTDDRUID	D05UEI
D05UEI	DRUGNAME	99mTc-besilesomab
D05UEI	INDICATI	Bone metastases [ICD-11: 2D50] Approved

D05HWX	TTDDRUID	D05HWX
D05HWX	DRUGNAME	99mTc-depreotide
D05HWX	INDICATI	Melanoma [ICD-11: 2C30] Approved

D07WLI	TTDDRUID	D07WLI
D07WLI	DRUGNAME	99mTc-fanolesomab
D07WLI	INDICATI	Appendicitis [ICD-11: DB10] Approved

D09BIW	TTDDRUID	D09BIW
D09BIW	DRUGNAME	99mTc-sestamibi
D09BIW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0E3RC	TTDDRUID	D0E3RC
D0E3RC	DRUGNAME	99mTc-sulesomab
D0E3RC	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Approved

D0YP2R	TTDDRUID	D0YP2R
D0YP2R	DRUGNAME	99mTc-teboroxime
D0YP2R	INDICATI	Myocardial disease [ICD-11: BC43.20] Approved

D05HFN	TTDDRUID	D05HFN
D05HFN	DRUGNAME	99mTc-tetrofosmin
D05HFN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0A4IJ	TTDDRUID	D0A4IJ
D0A4IJ	DRUGNAME	Abacavir
D0A4IJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D02CII	TTDDRUID	D02CII
D02CII	DRUGNAME	Abaloparatide
D02CII	INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Approved

D01AHO	TTDDRUID	D01AHO
D01AHO	DRUGNAME	Abarelix
D01AHO	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0EW4L	TTDDRUID	D0EW4L
D0EW4L	DRUGNAME	Abatacept
D0EW4L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0P3TX	TTDDRUID	D0P3TX
D0P3TX	DRUGNAME	Abciximab
D0P3TX	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D09YJT	TTDDRUID	D09YJT
D09YJT	DRUGNAME	Abilify Maintena
D09YJT	INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Approved

D02STN	TTDDRUID	D02STN
D02STN	DRUGNAME	ABIRATERONE
D02STN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D06CNP	TTDDRUID	D06CNP
D06CNP	DRUGNAME	Abiraterone acetate
D06CNP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0M7IH	TTDDRUID	D0M7IH
D0M7IH	DRUGNAME	Abobotulinum toxin A
D0M7IH	INDICATI	Cervical cancer [ICD-11: 2C77.0] Approved

D01HKL	TTDDRUID	D01HKL
D01HKL	DRUGNAME	ABT-335
D01HKL	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Approved

D09PQZ	TTDDRUID	D09PQZ
D09PQZ	DRUGNAME	Acalabrutinib
D09PQZ	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved

D0AR0B	TTDDRUID	D0AR0B
D0AR0B	DRUGNAME	ACAM-2000
D0AR0B	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0GC2M	TTDDRUID	D0GC2M
D0GC2M	DRUGNAME	Acamprosate
D0GC2M	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved

D0AD5C	TTDDRUID	D0AD5C
D0AD5C	DRUGNAME	Acarbose
D0AD5C	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D0AD5C	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0HD9K	TTDDRUID	D0HD9K
D0HD9K	DRUGNAME	Acebutolol
D0HD9K	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0R7WU	TTDDRUID	D0R7WU
D0R7WU	DRUGNAME	ACECLIDINE
D0R7WU	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0T8VY	TTDDRUID	D0T8VY
D0T8VY	DRUGNAME	Aceclofenac
D0T8VY	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0W1BV	TTDDRUID	D0W1BV
D0W1BV	DRUGNAME	Acel-Immune
D0W1BV	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0R1JB	TTDDRUID	D0R1JB
D0R1JB	DRUGNAME	Acellular pertussis vaccine
D0R1JB	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D0WP0B	TTDDRUID	D0WP0B
D0WP0B	DRUGNAME	Acemannan
D0WP0B	INDICATI	Canine and feline spontaneous neoplasm [ICD-11: 2A00-2F9Z] Approved
D0WP0B	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D05HFY	TTDDRUID	D05HFY
D05HFY	DRUGNAME	Acenocoumarol
D05HFY	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D06EQP	TTDDRUID	D06EQP
D06EQP	DRUGNAME	Aceprometazine
D06EQP	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Approved

D0U5QK	TTDDRUID	D0U5QK
D0U5QK	DRUGNAME	Acetaminophen
D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0E1SW	TTDDRUID	D0E1SW
D0E1SW	DRUGNAME	Acetazolamide
D0E1SW	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0F1LZ	TTDDRUID	D0F1LZ
D0F1LZ	DRUGNAME	Acetic Acid, Glacial
D0F1LZ	INDICATI	infection in the ear canal [ICD-11: AA0Y] Approved

D07WFK	TTDDRUID	D07WFK
D07WFK	DRUGNAME	Acetohexamide
D07WFK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0SZ2E	TTDDRUID	D0SZ2E
D0SZ2E	DRUGNAME	Acetohydroxamic
D0SZ2E	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0R9BG	TTDDRUID	D0R9BG
D0R9BG	DRUGNAME	Acetohydroxamic Acid
D0R9BG	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0L0MB	TTDDRUID	D0L0MB
D0L0MB	DRUGNAME	Acetophenazine
D0L0MB	INDICATI	Bipolar disorder [ICD-11: 6A60] Approved

D00UXT	TTDDRUID	D00UXT
D00UXT	DRUGNAME	Acetrizoate Sodium
D00UXT	INDICATI	Radiographic contrast medium [ICD-11: N.A.] Approved

D0Q9HF	TTDDRUID	D0Q9HF
D0Q9HF	DRUGNAME	Acetylcholine
D0Q9HF	INDICATI	Cataract [ICD-11: 9B10] Approved

D06XGW	TTDDRUID	D06XGW
D06XGW	DRUGNAME	Acetylcysteine
D06XGW	INDICATI	Liver disease [ICD-11: DB90-BD99] Approved

D0V3GA	TTDDRUID	D0V3GA
D0V3GA	DRUGNAME	Acetyldigitoxin
D0V3GA	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0P5DW	TTDDRUID	D0P5DW
D0P5DW	DRUGNAME	Ach-02
D0P5DW	INDICATI	Analgesia [ICD-11: MB40.8] Approved

D0B5MP	TTDDRUID	D0B5MP
D0B5MP	DRUGNAME	Aciclovir
D0B5MP	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 3
D0B5MP	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0S1NZ	TTDDRUID	D0S1NZ
D0S1NZ	DRUGNAME	Acipimox
D0S1NZ	INDICATI	Arteriosclerosis [ICD-11: BD40] Approved

D06MRT	TTDDRUID	D06MRT
D06MRT	DRUGNAME	Acitazanolast
D06MRT	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D05QDC	TTDDRUID	D05QDC
D05QDC	DRUGNAME	Acitretin
D05QDC	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D01UBX	TTDDRUID	D01UBX
D01UBX	DRUGNAME	Aclarubicin
D01UBX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0VP1V	TTDDRUID	D0VP1V
D0VP1V	DRUGNAME	Aclidinium
D0VP1V	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D04VKS	TTDDRUID	D04VKS
D04VKS	DRUGNAME	Acrisorcin
D04VKS	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0O4EU	TTDDRUID	D0O4EU
D0O4EU	DRUGNAME	Acrivastine
D0O4EU	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D02AQY	TTDDRUID	D02AQY
D02AQY	DRUGNAME	Actarit
D02AQY	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D09CHG	TTDDRUID	D09CHG
D09CHG	DRUGNAME	Activated protein c concn
D09CHG	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D0MD8O	TTDDRUID	D0MD8O
D0MD8O	DRUGNAME	Adacel
D0MD8O	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0K5KS	TTDDRUID	D0K5KS
D0K5KS	DRUGNAME	Adalimumab
D0K5KS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0JC9N	TTDDRUID	D0JC9N
D0JC9N	DRUGNAME	Adapalene
D0JC9N	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0D6QU	TTDDRUID	D0D6QU
D0D6QU	DRUGNAME	ADCON-L
D0D6QU	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D06MMW	TTDDRUID	D06MMW
D06MMW	DRUGNAME	ADCON-T/N
D06MMW	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D0ML1F	TTDDRUID	D0ML1F
D0ML1F	DRUGNAME	Adefovir Dipivoxil
D0ML1F	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D08IBS	TTDDRUID	D08IBS
D08IBS	DRUGNAME	Adenine
D08IBS	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D06IAR	TTDDRUID	D06IAR
D06IAR	DRUGNAME	Adenosine
D06IAR	INDICATI	Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Approved

D06ACW	TTDDRUID	D06ACW
D06ACW	DRUGNAME	Adenosine monophosphate
D06ACW	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D01BYB	TTDDRUID	D01BYB
D01BYB	DRUGNAME	Adenosine triphosphate
D01BYB	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0E7FS	TTDDRUID	D0E7FS
D0E7FS	DRUGNAME	Adinazolam
D0E7FS	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0S5EB	TTDDRUID	D0S5EB
D0S5EB	DRUGNAME	Adoniside
D0S5EB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D07QQD	TTDDRUID	D07QQD
D07QQD	DRUGNAME	Aescin
D07QQD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0C9ET	TTDDRUID	D0C9ET
D0C9ET	DRUGNAME	Aflibercept
D0C9ET	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Approved

D0E1DF	TTDDRUID	D0E1DF
D0E1DF	DRUGNAME	Afrezza
D0E1DF	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved

D0C3XN	TTDDRUID	D0C3XN
D0C3XN	DRUGNAME	AG-1321002
D0C3XN	INDICATI	Fever [ICD-11: MG26] Approved

D0V5XJ	TTDDRUID	D0V5XJ
D0V5XJ	DRUGNAME	AG-AFZ709
D0V5XJ	INDICATI	Genitourinary disease [ICD-11: GA0Z-GC8Z] Approved

D05ILN	TTDDRUID	D05ILN
D05ILN	DRUGNAME	Agalsidase alfa
D05ILN	INDICATI	Fabry disease [ICD-11: 5C56.01] Approved

D00FIX	TTDDRUID	D00FIX
D00FIX	DRUGNAME	Agalsidase beta
D00FIX	INDICATI	Fabry disease [ICD-11: 5C56.01] Approved

D0Q6BH	TTDDRUID	D0Q6BH
D0Q6BH	DRUGNAME	Agriflu
D0Q6BH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0WY9N	TTDDRUID	D0WY9N
D0WY9N	DRUGNAME	Agrimophol
D0WY9N	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved

D0W0DY	TTDDRUID	D0W0DY
D0W0DY	DRUGNAME	Agrippal S1/MF-59 influenza vaccine
D0W0DY	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D06CDN	TTDDRUID	D06CDN
D06CDN	DRUGNAME	AG-TMB711
D06CDN	INDICATI	Gastric motility disorder [ICD-11: DA21] Approved

D07GTF	TTDDRUID	D07GTF
D07GTF	DRUGNAME	Aipusheng
D07GTF	INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved

D01JGV	TTDDRUID	D01JGV
D01JGV	DRUGNAME	Ajmalicine
D01JGV	INDICATI	Circulatory disorder [ICD-11: BE2Z] Approved

D02GUG	TTDDRUID	D02GUG
D02GUG	DRUGNAME	Ajmaline
D02GUG	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved

D0X5SJ	TTDDRUID	D0X5SJ
D0X5SJ	DRUGNAME	Alacepril
D0X5SJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D01MGA	TTDDRUID	D01MGA
D01MGA	DRUGNAME	Alatrofloxacin mesylate
D01MGA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00KVO	TTDDRUID	D00KVO
D00KVO	DRUGNAME	Albendazole
D00KVO	INDICATI	Worm infection [ICD-11: 1F90.Z] Approved

D0F1DY	TTDDRUID	D0F1DY
D0F1DY	DRUGNAME	Albiglutide
D0F1DY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0I0VI	TTDDRUID	D0I0VI
D0I0VI	DRUGNAME	Albumin Human
D0I0VI	INDICATI	Hypoalbuminemia [ICD-11: 5C53.2] Approved

D03VRX	TTDDRUID	D03VRX
D03VRX	DRUGNAME	Albumin Iodinated Serum
D03VRX	INDICATI	Imaging [ICD-11: QA0B] Approved

D0C8PW	TTDDRUID	D0C8PW
D0C8PW	DRUGNAME	Albunex
D0C8PW	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D0O7JW	TTDDRUID	D0O7JW
D0O7JW	DRUGNAME	Alcaftadine
D0O7JW	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D0C6OQ	TTDDRUID	D0C6OQ
D0C6OQ	DRUGNAME	Alclofenac
D0C6OQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0F1EX	TTDDRUID	D0F1EX
D0F1EX	DRUGNAME	Alclometasone
D0F1EX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0L1OY	TTDDRUID	D0L1OY
D0L1OY	DRUGNAME	ALCURONIUM
D0L1OY	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D05PUD	TTDDRUID	D05PUD
D05PUD	DRUGNAME	Aldesleukin
D05PUD	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D05PUD	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D0I1LH	TTDDRUID	D0I1LH
D0I1LH	DRUGNAME	Aldosterone
D0I1LH	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0U3SY	TTDDRUID	D0U3SY
D0U3SY	DRUGNAME	Alectinib
D0U3SY	INDICATI	Lung cancer [ICD-11: 2C25.0] Approved
D0U3SY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D09ZSO	TTDDRUID	D09ZSO
D09ZSO	DRUGNAME	Alefacept
D09ZSO	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D01ZYG	TTDDRUID	D01ZYG
D01ZYG	DRUGNAME	Alemtuzumab
D01ZYG	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
D01ZYG	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D09KLR	TTDDRUID	D09KLR
D09KLR	DRUGNAME	Alendronate
D09KLR	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
D09KLR	INDICATI	Paget's disease [ICD-11: FB85] Approved

D0L7QB	TTDDRUID	D0L7QB
D0L7QB	DRUGNAME	Alfaferone
D0L7QB	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved

D0G5QB	TTDDRUID	D0G5QB
D0G5QB	DRUGNAME	Alfentanil
D0G5QB	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D09MWJ	TTDDRUID	D09MWJ
D09MWJ	DRUGNAME	Alfuzosin
D09MWJ	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D0D4HM	TTDDRUID	D0D4HM
D0D4HM	DRUGNAME	Alglucerase
D0D4HM	INDICATI	Enzyme deficiency [ICD-11: 5C51-5C57] Approved

D07DUU	TTDDRUID	D07DUU
D07DUU	DRUGNAME	Alglucosidase alfa
D07DUU	INDICATI	Pompe disease [ICD-11: 5C51.3] Approved

D03SVX	TTDDRUID	D03SVX
D03SVX	DRUGNAME	Aliskiren
D03SVX	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0G3PI	TTDDRUID	D0G3PI
D0G3PI	DRUGNAME	Alitretinoin
D0G3PI	INDICATI	Kaposi sarcoma [ICD-11: 2B57] Approved

D06GJT	TTDDRUID	D06GJT
D06GJT	DRUGNAME	Alizapride
D06GJT	INDICATI	Vomiting [ICD-11: MD90] Approved

D0Y2MC	TTDDRUID	D0Y2MC
D0Y2MC	DRUGNAME	Alkavervir
D0Y2MC	INDICATI	High blood pressure [ICD-11: BA00] Approved

D01HNL	TTDDRUID	D01HNL
D01HNL	DRUGNAME	Allantoin
D01HNL	INDICATI	Vulnerary [ICD-11: ND56.Z] Approved

D0EW5Y	TTDDRUID	D0EW5Y
D0EW5Y	DRUGNAME	AlloDerm
D0EW5Y	INDICATI	Periodontal disease [ICD-11: DA0C] Approved

D05IWE	TTDDRUID	D05IWE
D05IWE	DRUGNAME	Alloferon
D05IWE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D00VZZ	TTDDRUID	D00VZZ
D00VZZ	DRUGNAME	ALLOPREGNANOLONE
D00VZZ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
D00VZZ	INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2
D00VZZ	INDICATI	Postpartum depression [ICD-11: 6E20.0] Approved
D00VZZ	INDICATI	Status epilepticus seizure [ICD-11: 8A66.1Y] Phase 3

D04KYY	TTDDRUID	D04KYY
D04KYY	DRUGNAME	Allopurinol
D04KYY	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved

D0BQ8Y	TTDDRUID	D0BQ8Y
D0BQ8Y	DRUGNAME	Allyl isothiocyanate
D0BQ8Y	INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Approved

D0D9NA	TTDDRUID	D0D9NA
D0D9NA	DRUGNAME	Almitrine
D0D9NA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0P0SM	TTDDRUID	D0P0SM
D0P0SM	DRUGNAME	Almogran
D0P0SM	INDICATI	Migraine [ICD-11: 8A80] Approved

D0NJ5H	TTDDRUID	D0NJ5H
D0NJ5H	DRUGNAME	Alogliptin
D0NJ5H	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D04ACW	TTDDRUID	D04ACW
D04ACW	DRUGNAME	Alogliptin/metformin
D04ACW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0Q7YI	TTDDRUID	D0Q7YI
D0Q7YI	DRUGNAME	Alogliptin/pioglitazone
D0Q7YI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D06GKN	TTDDRUID	D06GKN
D06GKN	DRUGNAME	Alosetron
D06GKN	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0I0DL	TTDDRUID	D0I0DL
D0I0DL	DRUGNAME	Alpha 1-PI
D0I0DL	INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Approved
D0I0DL	INDICATI	Cancer related pain [ICD-11: MG30] Withdrawn from market

D0L4SD	TTDDRUID	D0L4SD
D0L4SD	DRUGNAME	Alpha-acetyldigoxin
D0L4SD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D02IOH	TTDDRUID	D02IOH
D02IOH	DRUGNAME	Alphaprodine
D02IOH	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D01XOD	TTDDRUID	D01XOD
D01XOD	DRUGNAME	ALPIDEM
D01XOD	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0L9GG	TTDDRUID	D0L9GG
D0L9GG	DRUGNAME	Alprazolam
D0L9GG	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0I4DQ	TTDDRUID	D0I4DQ
D0I4DQ	DRUGNAME	Alprostadil
D0I4DQ	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
D0I4DQ	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved

D0I3IG	TTDDRUID	D0I3IG
D0I3IG	DRUGNAME	Alseroxylon
D0I3IG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07BQE	TTDDRUID	D07BQE
D07BQE	DRUGNAME	Alteplase
D07BQE	INDICATI	Pulmonary embolism [ICD-11: BB00] Approved

D02LPF	TTDDRUID	D02LPF
D02LPF	DRUGNAME	Altretamine
D02LPF	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D0A8XY	TTDDRUID	D0A8XY
D0A8XY	DRUGNAME	Altropane
D0A8XY	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved

D0V8TQ	TTDDRUID	D0V8TQ
D0V8TQ	DRUGNAME	Aluminium
D0V8TQ	INDICATI	Hyperhidrosis [ICD-11: EE00] Approved

D0D7KC	TTDDRUID	D0D7KC
D0D7KC	DRUGNAME	Alvimopan
D0D7KC	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D02KRS	TTDDRUID	D02KRS
D02KRS	DRUGNAME	Amantadine
D02KRS	INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved

D06IAQ	TTDDRUID	D06IAQ
D06IAQ	DRUGNAME	Ambenonium
D06IAQ	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved

D0X5ZI	TTDDRUID	D0X5ZI
D0X5ZI	DRUGNAME	Ambrisentan
D0X5ZI	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved

D03DSR	TTDDRUID	D03DSR
D03DSR	DRUGNAME	Ambroxol
D03DSR	INDICATI	Bronchitis [ICD-11: CA20] Approved

D06XHC	TTDDRUID	D06XHC
D06XHC	DRUGNAME	Amcinonide
D06XHC	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0M1VC	TTDDRUID	D0M1VC
D0M1VC	DRUGNAME	Amdinocillin
D0M1VC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00DPJ	TTDDRUID	D00DPJ
D00DPJ	DRUGNAME	Amezinium
D00DPJ	INDICATI	Hypotension [ICD-11: BA20-BA21] Approved

D0B7OD	TTDDRUID	D0B7OD
D0B7OD	DRUGNAME	Amfepramone
D0B7OD	INDICATI	Migraine [ICD-11: 8A80] Approved
D0B7OD	INDICATI	Obesity [ICD-11: 5B81] Approved

D0V7QT	TTDDRUID	D0V7QT
D0V7QT	DRUGNAME	AMI-121
D0V7QT	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D0HE0Y	TTDDRUID	D0HE0Y
D0HE0Y	DRUGNAME	Amifampridine
D0HE0Y	INDICATI	LambertEaton myasthenic syndrome [ICD-11: 8C62] Approved

D06CIE	TTDDRUID	D06CIE
D06CIE	DRUGNAME	Amifostine
D06CIE	INDICATI	Mucositis [ICD-11: CA00] Approved

D0Y3MO	TTDDRUID	D0Y3MO
D0Y3MO	DRUGNAME	Amikacin
D0Y3MO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D0Y3MO	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Investigative

D0I0RJ	TTDDRUID	D0I0RJ
D0I0RJ	DRUGNAME	Amiloride
D0I0RJ	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0O7FJ	TTDDRUID	D0O7FJ
D0O7FJ	DRUGNAME	Amino Acids
D0O7FJ	INDICATI	Nutritional deficiency [ICD-11: 5B50-5B71] Approved

D0FD0H	TTDDRUID	D0FD0H
D0FD0H	DRUGNAME	Aminocaproic Acid
D0FD0H	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
D0FD0H	INDICATI	Postoperative hemorrhage [ICD-11: NE81.0Z] Approved

D0M6DO	TTDDRUID	D0M6DO
D0M6DO	DRUGNAME	Aminoglutethimide
D0M6DO	INDICATI	Cushing disease [ICD-11: 5A70] Approved

D06OAV	TTDDRUID	D06OAV
D06OAV	DRUGNAME	Aminohippurate sodium
D06OAV	INDICATI	Kidney disease [ICD-11: GC2Z] Approved

D0Y7ZD	TTDDRUID	D0Y7ZD
D0Y7ZD	DRUGNAME	Aminolevulinic acid hci
D0Y7ZD	INDICATI	Acne vulgaris [ICD-11: ED80] Approved
D0Y7ZD	INDICATI	Actinic keratosis [ICD-11: EK90.0] Approved

D0O4GY	TTDDRUID	D0O4GY
D0O4GY	DRUGNAME	Aminolevulinic Acid Hydrochloride
D0O4GY	INDICATI	Actinic keratosis [ICD-11: EK90.0] Approved

D03TYI	TTDDRUID	D03TYI
D03TYI	DRUGNAME	Aminophylline
D03TYI	INDICATI	Asthma [ICD-11: CA23] Phase 2
D03TYI	INDICATI	Bronchial asthma [ICD-11: CA23] Approved

D01WJL	TTDDRUID	D01WJL
D01WJL	DRUGNAME	Aminosalicylic Acid
D01WJL	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Approved
D01WJL	INDICATI	Pulmonary and extrapulmonary tuberculosis [ICD-11: 1B10.Z] Approved

D0L5WM	TTDDRUID	D0L5WM
D0L5WM	DRUGNAME	Amiodarone
D0L5WM	INDICATI	Tachyarrhythmias [ICD-11: BC71] Approved

D03ELL	TTDDRUID	D03ELL
D03ELL	DRUGNAME	Amisulpride
D03ELL	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0Y5UG	TTDDRUID	D0Y5UG
D0Y5UG	DRUGNAME	Amitriptyline
D0Y5UG	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0G5UB	TTDDRUID	D0G5UB
D0G5UB	DRUGNAME	Amlexanox
D0G5UB	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Approved

D08JIV	TTDDRUID	D08JIV
D08JIV	DRUGNAME	Amlodipine
D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0FT7Y	TTDDRUID	D0FT7Y
D0FT7Y	DRUGNAME	Ammonia
D0FT7Y	INDICATI	Coronary artery disease [ICD-11: BA80] Approved

D08YPZ	TTDDRUID	D08YPZ
D08YPZ	DRUGNAME	Ammoniated mercury
D08YPZ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D06WEK	TTDDRUID	D06WEK
D06WEK	DRUGNAME	Ammonium chloride
D06WEK	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D08QGD	TTDDRUID	D08QGD
D08QGD	DRUGNAME	Ammonium lactate
D08QGD	INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved

D0R6BR	TTDDRUID	D0R6BR
D0R6BR	DRUGNAME	Amobarbital
D0R6BR	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D04NQI	TTDDRUID	D04NQI
D04NQI	DRUGNAME	Amodiaquine
D04NQI	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0QC3M	TTDDRUID	D0QC3M
D0QC3M	DRUGNAME	Amorolfine
D0QC3M	INDICATI	Onychomycosis [ICD-11: EE12.1] Approved

D0D0YM	TTDDRUID	D0D0YM
D0D0YM	DRUGNAME	Amosulalol
D0D0YM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09IOI	TTDDRUID	D09IOI
D09IOI	DRUGNAME	Amoxapine
D09IOI	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0F6EO	TTDDRUID	D0F6EO
D0F6EO	DRUGNAME	Amoxicillin
D0F6EO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05BMG	TTDDRUID	D05BMG
D05BMG	DRUGNAME	Amphetamine
D05BMG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
D05BMG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative

D02DWM	TTDDRUID	D02DWM
D02DWM	DRUGNAME	Amphotericin B
D02DWM	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0YA9Z	TTDDRUID	D0YA9Z
D0YA9Z	DRUGNAME	Ampicillin
D0YA9Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07OHO	TTDDRUID	D07OHO
D07OHO	DRUGNAME	Ampiroxicam
D07OHO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0A0OO	TTDDRUID	D0A0OO
D0A0OO	DRUGNAME	Amprenavir
D0A0OO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0G9YH	TTDDRUID	D0G9YH
D0G9YH	DRUGNAME	Amsacrine
D0G9YH	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0S5RZ	TTDDRUID	D0S5RZ
D0S5RZ	DRUGNAME	Amtolmetin guacil
D0S5RZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D01QLH	TTDDRUID	D01QLH
D01QLH	DRUGNAME	Amyl nitrite
D01QLH	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0T8XB	TTDDRUID	D0T8XB
D0T8XB	DRUGNAME	Anagliptin
D0T8XB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0D1HW	TTDDRUID	D0D1HW
D0D1HW	DRUGNAME	Anagrelide
D0D1HW	INDICATI	Thrombocythemia [ICD-11: 3B63] Approved

D02DES	TTDDRUID	D02DES
D02DES	DRUGNAME	Anakinra
D02DES	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D00OGX	TTDDRUID	D00OGX
D00OGX	DRUGNAME	Anapsos
D00OGX	INDICATI	Atopic dermatitis [ICD-11: EA80] Approved

D0W0BF	TTDDRUID	D0W0BF
D0W0BF	DRUGNAME	Anastrozole
D0W0BF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D04VIS	TTDDRUID	D04VIS
D04VIS	DRUGNAME	Andrographolide
D04VIS	INDICATI	Bacillary dysentery [ICD-11: 1A02] Approved

D02CNR	TTDDRUID	D02CNR
D02CNR	DRUGNAME	Anecortave acetate
D02CNR	INDICATI	Macular degeneration [ICD-11: 9B78.3] Approved

D0G6SE	TTDDRUID	D0G6SE
D0G6SE	DRUGNAME	ANGIOTENSIN II
D0G6SE	INDICATI	Increase blood pressure [ICD-11: BA04] Approved

D0F9BY	TTDDRUID	D0F9BY
D0F9BY	DRUGNAME	Anidulafungin
D0F9BY	INDICATI	Convulsion [ICD-11: 8A68.Z] Approved

D0X6HD	TTDDRUID	D0X6HD
D0X6HD	DRUGNAME	Anileridine
D0X6HD	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D05ZTJ	TTDDRUID	D05ZTJ
D05ZTJ	DRUGNAME	Anileridine Hydrochloride
D05ZTJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D02DPU	TTDDRUID	D02DPU
D02DPU	DRUGNAME	Aniracetam
D02DPU	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved

D09WKB	TTDDRUID	D09WKB
D09WKB	DRUGNAME	Anisindione
D09WKB	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved

D06VFO	TTDDRUID	D06VFO
D06VFO	DRUGNAME	Anisodamine
D06VFO	INDICATI	Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved

D05ZJG	TTDDRUID	D05ZJG
D05ZJG	DRUGNAME	Anisodine
D05ZJG	INDICATI	Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved

D07CNL	TTDDRUID	D07CNL
D07CNL	DRUGNAME	Anisotropine Methylbromide
D07CNL	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D0K4DI	TTDDRUID	D0K4DI
D0K4DI	DRUGNAME	Anistreplase
D0K4DI	INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved

D02CKO	TTDDRUID	D02CKO
D02CKO	DRUGNAME	Anoro
D02CKO	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D06AJL	TTDDRUID	D06AJL
D06AJL	DRUGNAME	Antacids
D06AJL	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Approved

D06FZX	TTDDRUID	D06FZX
D06FZX	DRUGNAME	Antazoline
D06FZX	INDICATI	Nasal congestion [ICD-11: MD11.9] Approved

D09EBL	TTDDRUID	D09EBL
D09EBL	DRUGNAME	Antegren
D09EBL	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0ZZ3P	TTDDRUID	D0ZZ3P
D0ZZ3P	DRUGNAME	Antiadhesion barrier gel
D0ZZ3P	INDICATI	Fibrosis [ICD-11: GA14-GC01] Approved

D06AWD	TTDDRUID	D06AWD
D06AWD	DRUGNAME	Anti-D human immunoglobulin
D06AWD	INDICATI	Acquired haemolytic anemia [ICD-11: 3A4Z] Approved

D05YFY	TTDDRUID	D05YFY
D05YFY	DRUGNAME	Anti-inhibitor coagulant complex
D05YFY	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D05JRG	TTDDRUID	D05JRG
D05JRG	DRUGNAME	Antithrombin alfa
D05JRG	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D0V5AJ	TTDDRUID	D0V5AJ
D0V5AJ	DRUGNAME	Antithrombin iii
D0V5AJ	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved

D0M7XS	TTDDRUID	D0M7XS
D0M7XS	DRUGNAME	Antithymocyte globulin
D0M7XS	INDICATI	Aplastic anemia [ICD-11: 3A70] Approved

D06MRL	TTDDRUID	D06MRL
D06MRL	DRUGNAME	Antral
D06MRL	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved

D0B8RJ	TTDDRUID	D0B8RJ
D0B8RJ	DRUGNAME	AP vaccine
D0B8RJ	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0R5OS	TTDDRUID	D0R5OS
D0R5OS	DRUGNAME	Apalcillin sodium
D0R5OS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0I5HF	TTDDRUID	D0I5HF
D0I5HF	DRUGNAME	Apixaban
D0I5HF	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D07XCG	TTDDRUID	D07XCG
D07XCG	DRUGNAME	Apligraf
D07XCG	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved

D0H6QU	TTDDRUID	D0H6QU
D0H6QU	DRUGNAME	Apomorphine
D0H6QU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0MT0M	TTDDRUID	D0MT0M
D0MT0M	DRUGNAME	Apraclonidine
D0MT0M	INDICATI	Intra ocular pressure reduction [ICD-11: 9C40] Approved

D07ESC	TTDDRUID	D07ESC
D07ESC	DRUGNAME	Apremilast
D07ESC	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
D07ESC	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 4

D0GU4K	TTDDRUID	D0GU4K
D0GU4K	DRUGNAME	Aprepitant
D0GU4K	INDICATI	Nausea [ICD-11: MD90] Approved

D0W7OE	TTDDRUID	D0W7OE
D0W7OE	DRUGNAME	Aprindine
D0W7OE	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Approved

D05TMQ	TTDDRUID	D05TMQ
D05TMQ	DRUGNAME	Aprobarbital
D05TMQ	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
D05TMQ	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D08XYX	TTDDRUID	D08XYX
D08XYX	DRUGNAME	Aprotinin
D08XYX	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D07JPC	TTDDRUID	D07JPC
D07JPC	DRUGNAME	Arbekacin
D07JPC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02VIT	TTDDRUID	D02VIT
D02VIT	DRUGNAME	Arbidol
D02VIT	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D06KYN	TTDDRUID	D06KYN
D06KYN	DRUGNAME	Arbutamine
D06KYN	INDICATI	Coronary artery disease [ICD-11: BA80] Approved

D06URS	TTDDRUID	D06URS
D06URS	DRUGNAME	Arcitumomab
D06URS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D01ZJK	TTDDRUID	D01ZJK
D01ZJK	DRUGNAME	Ardeparin
D01ZJK	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D0Y6NL	TTDDRUID	D0Y6NL
D0Y6NL	DRUGNAME	Arepanrix
D0Y6NL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0D1DI	TTDDRUID	D0D1DI
D0D1DI	DRUGNAME	Arformoterol
D0D1DI	INDICATI	Asthma [ICD-11: CA23] Phase 4
D0D1DI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D07UWV	TTDDRUID	D07UWV
D07UWV	DRUGNAME	Argatroban
D07UWV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D0F5DO	TTDDRUID	D0F5DO
D0F5DO	DRUGNAME	Arginine
D0F5DO	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved

D0A2AJ	TTDDRUID	D0A2AJ
D0A2AJ	DRUGNAME	Arglabin
D0A2AJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0L9WF	TTDDRUID	D0L9WF
D0L9WF	DRUGNAME	ARH-1
D0L9WF	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D09RHS	TTDDRUID	D09RHS
D09RHS	DRUGNAME	Arilvax
D09RHS	INDICATI	Yellow fever virus infection [ICD-11: 1D47] Approved

D0H3HM	TTDDRUID	D0H3HM
D0H3HM	DRUGNAME	Aripiprazole
D0H3HM	INDICATI	Bipolar disorder [ICD-11: 6A60] Application submitted
D0H3HM	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
D0H3HM	INDICATI	Schizophrenia [ICD-11: 6A20] Approved
D0H3HM	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0J5RN	TTDDRUID	D0J5RN
D0J5RN	DRUGNAME	Armodafinil
D0J5RN	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Approved

D0S7LG	TTDDRUID	D0S7LG
D0S7LG	DRUGNAME	ARN-509
D0S7LG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
D0S7LG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0V9TN	TTDDRUID	D0V9TN
D0V9TN	DRUGNAME	Aromatic ammonia spirits
D0V9TN	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D0C4LF	TTDDRUID	D0C4LF
D0C4LF	DRUGNAME	ARRY-162
D0C4LF	INDICATI	Melanoma [ICD-11: 2C30] Approved
D0C4LF	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D07VIK	TTDDRUID	D07VIK
D07VIK	DRUGNAME	Arsenic trioxide
D07VIK	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0Y5ZA	TTDDRUID	D0Y5ZA
D0Y5ZA	DRUGNAME	Arteether
D0Y5ZA	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0EK1D	TTDDRUID	D0EK1D
D0EK1D	DRUGNAME	Arteflene
D0EK1D	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved

D0M9BW	TTDDRUID	D0M9BW
D0M9BW	DRUGNAME	Artemether
D0M9BW	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
D0M9BW	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D0S3WH	TTDDRUID	D0S3WH
D0S3WH	DRUGNAME	Artemisinin
D0S3WH	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D03KEK	TTDDRUID	D03KEK
D03KEK	DRUGNAME	Artemisinin SP
D03KEK	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0D4JO	TTDDRUID	D0D4JO
D0D4JO	DRUGNAME	Artesunate
D0D4JO	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
D0D4JO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D0I5HV	TTDDRUID	D0I5HV
D0I5HV	DRUGNAME	Articaine
D0I5HV	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D06LOQ	TTDDRUID	D06LOQ
D06LOQ	DRUGNAME	ARZOXIFENE
D06LOQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0W1DI	TTDDRUID	D0W1DI
D0W1DI	DRUGNAME	AS-1670542
D0W1DI	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
D0W1DI	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D0F3IP	TTDDRUID	D0F3IP
D0F3IP	DRUGNAME	Asasantin
D0F3IP	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved

D00JRA	TTDDRUID	D00JRA
D00JRA	DRUGNAME	Asenapine
D00JRA	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D05XSJ	TTDDRUID	D05XSJ
D05XSJ	DRUGNAME	Asfotase alfa
D05XSJ	INDICATI	Genetic disease [ICD-11: 8E02] Approved

D0P2IT	TTDDRUID	D0P2IT
D0P2IT	DRUGNAME	Asiaticoside
D0P2IT	INDICATI	Vulnerary [ICD-11: ND56.Z] Approved

D0H5XB	TTDDRUID	D0H5XB
D0H5XB	DRUGNAME	Asparaginase Erwinia chrysanthemi
D0H5XB	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0GY5Z	TTDDRUID	D0GY5Z
D0GY5Z	DRUGNAME	Aspirin
D0GY5Z	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D0GY5Z	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
D0GY5Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D07DPI	TTDDRUID	D07DPI
D07DPI	DRUGNAME	Aspirin/ esomeprazole fixed-dose combination
D07DPI	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0FD6E	TTDDRUID	D0FD6E
D0FD6E	DRUGNAME	Aspoxicillin
D0FD6E	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06ZVG	TTDDRUID	D06ZVG
D06ZVG	DRUGNAME	AST-120
D06ZVG	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
D06ZVG	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
D06ZVG	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D09MPU	TTDDRUID	D09MPU
D09MPU	DRUGNAME	Astromycin sulfate
D09MPU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07IQS	TTDDRUID	D07IQS
D07IQS	DRUGNAME	Atazanavir
D07IQS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D01UXC	TTDDRUID	D01UXC
D01UXC	DRUGNAME	Atenolol
D01UXC	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04CRN	TTDDRUID	D04CRN
D04CRN	DRUGNAME	Atomoxetine
D04CRN	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved

D01QIN	TTDDRUID	D01QIN
D01QIN	DRUGNAME	Atorvastatin
D01QIN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D06ZEE	TTDDRUID	D06ZEE
D06ZEE	DRUGNAME	Atovaquone
D06ZEE	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0Q1PR	TTDDRUID	D0Q1PR
D0Q1PR	DRUGNAME	Atracurium
D0Q1PR	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0RG3O	TTDDRUID	D0RG3O
D0RG3O	DRUGNAME	Atropine
D0RG3O	INDICATI	Organophosphate poisoning [ICD-11: NE6Z] Approved
D0RG3O	INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 1

D0AW9T	TTDDRUID	D0AW9T
D0AW9T	DRUGNAME	ATryn antithrombin
D0AW9T	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0DF9Z	TTDDRUID	D0DF9Z
D0DF9Z	DRUGNAME	Attapulgite
D0DF9Z	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0L2UN	TTDDRUID	D0L2UN
D0L2UN	DRUGNAME	Auranofin
D0L2UN	INDICATI	Inflammatory arthritis [ICD-11: FA2Z] Approved

D0W8FU	TTDDRUID	D0W8FU
D0W8FU	DRUGNAME	Autologous cartilage system
D0W8FU	INDICATI	Cartilage lesions [ICD-11: NC93.3Z] Approved

D0Y5JC	TTDDRUID	D0Y5JC
D0Y5JC	DRUGNAME	Avanafil
D0Y5JC	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved

D0A7GE	TTDDRUID	D0A7GE
D0A7GE	DRUGNAME	Avanz
D0A7GE	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0P1JL	TTDDRUID	D0P1JL
D0P1JL	DRUGNAME	Avaxim
D0P1JL	INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved

D0K7SX	TTDDRUID	D0K7SX
D0K7SX	DRUGNAME	Avelumab
D0K7SX	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Approved
D0K7SX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D0K7SX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D01ZRI	TTDDRUID	D01ZRI
D01ZRI	DRUGNAME	Axitinib
D01ZRI	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D09FAZ	TTDDRUID	D09FAZ
D09FAZ	DRUGNAME	Azacitidine
D09FAZ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Approved

D0BU0J	TTDDRUID	D0BU0J
D0BU0J	DRUGNAME	Azanidazole
D0BU0J	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved

D09SIK	TTDDRUID	D09SIK
D09SIK	DRUGNAME	Azaribine
D09SIK	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D0N7AD	TTDDRUID	D0N7AD
D0N7AD	DRUGNAME	Azatadine
D0N7AD	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D07QCE	TTDDRUID	D07QCE
D07QCE	DRUGNAME	Azathioprine
D07QCE	INDICATI	Organ transplant rejection [ICD-11: NE84] Approved

D0E4WR	TTDDRUID	D0E4WR
D0E4WR	DRUGNAME	Azelaic Acid
D0E4WR	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D00JVR	TTDDRUID	D00JVR
D00JVR	DRUGNAME	Azelastine
D00JVR	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D05FGG	TTDDRUID	D05FGG
D05FGG	DRUGNAME	Azilsartan
D05FGG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0PA2N	TTDDRUID	D0PA2N
D0PA2N	DRUGNAME	Azlocillin
D0PA2N	INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved

D04LYD	TTDDRUID	D04LYD
D04LYD	DRUGNAME	Azosemide
D04LYD	INDICATI	Edema [ICD-11: MG29] Approved

D0F2XV	TTDDRUID	D0F2XV
D0F2XV	DRUGNAME	Aztreonam
D0F2XV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D04CFW	TTDDRUID	D04CFW
D04CFW	DRUGNAME	Bacampicillin
D04CFW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0M1IO	TTDDRUID	D0M1IO
D0M1IO	DRUGNAME	Bacitracin
D0M1IO	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved

D01AJY	TTDDRUID	D01AJY
D01AJY	DRUGNAME	Baclofen
D01AJY	INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 3
D01AJY	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D00XHD	TTDDRUID	D00XHD
D00XHD	DRUGNAME	Balofloxacin
D00XHD	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved

D0O5AG	TTDDRUID	D0O5AG
D0O5AG	DRUGNAME	Baloxavir marboxil
D0O5AG	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0A6KR	TTDDRUID	D0A6KR
D0A6KR	DRUGNAME	Balsalazide
D0A6KR	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Approved

D07BDD	TTDDRUID	D07BDD
D07BDD	DRUGNAME	BAM-002
D07BDD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
D07BDD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D07XYV	TTDDRUID	D07XYV
D07XYV	DRUGNAME	Bambuterol
D07XYV	INDICATI	Asthma [ICD-11: CA23] Approved

D0O7SP	TTDDRUID	D0O7SP
D0O7SP	DRUGNAME	Bamifylline
D0O7SP	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0G3EC	TTDDRUID	D0G3EC
D0G3EC	DRUGNAME	Baquting
D0G3EC	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D0E0WQ	TTDDRUID	D0E0WQ
D0E0WQ	DRUGNAME	Barbital
D0E0WQ	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0WB9V	TTDDRUID	D0WB9V
D0WB9V	DRUGNAME	Barbiturate
D0WB9V	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
D0WB9V	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0Y7IC	TTDDRUID	D0Y7IC
D0Y7IC	DRUGNAME	Baricitinib
D0Y7IC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
D0Y7IC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0T5DE	TTDDRUID	D0T5DE
D0T5DE	DRUGNAME	Barium sulfate
D0T5DE	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D06SBB	TTDDRUID	D06SBB
D06SBB	DRUGNAME	Basiliximab
D06SBB	INDICATI	Organ transplant rejection [ICD-11: NE84] Approved

D0S5LD	TTDDRUID	D0S5LD
D0S5LD	DRUGNAME	BAY 80-6946
D0S5LD	INDICATI	Follicular lymphoma [ICD-11: 2A80] Approved
D0S5LD	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
D0S5LD	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D08MEF	TTDDRUID	D08MEF
D08MEF	DRUGNAME	BAY-86-4884
D08MEF	INDICATI	Liver disease [ICD-11: DB90-BD99] Approved

D0JY8T	TTDDRUID	D0JY8T
D0JY8T	DRUGNAME	Bazedoxifene
D0JY8T	INDICATI	Osteopetrosis [ICD-11: LD24.10] Approved

D0A8LZ	TTDDRUID	D0A8LZ
D0A8LZ	DRUGNAME	BCG vaccine
D0A8LZ	INDICATI	Bladder cancer [ICD-11: 2C94] Approved

D0T5QT	TTDDRUID	D0T5QT
D0T5QT	DRUGNAME	Becaplermin
D0T5QT	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D00DZN	TTDDRUID	D00DZN
D00DZN	DRUGNAME	Beclamide
D00DZN	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Approved

D07DVK	TTDDRUID	D07DVK
D07DVK	DRUGNAME	Beclomethasone
D07DVK	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
D07DVK	INDICATI	Asthma [ICD-11: CA23] Approved

D0Y4QG	TTDDRUID	D0Y4QG
D0Y4QG	DRUGNAME	Bedaquiline
D0Y4QG	INDICATI	Multi-drug resistant tuberculosis [ICD-11: MG52.00] Approved

D06REO	TTDDRUID	D06REO
D06REO	DRUGNAME	Befunolol hci
D06REO	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0N4HB	TTDDRUID	D0N4HB
D0N4HB	DRUGNAME	Belatacept
D0N4HB	INDICATI	Heart transplant rejection [ICD-11: NE84] NDA filed
D0N4HB	INDICATI	Kidney transplant rejection [ICD-11: NE84] Approved

D05IQX	TTDDRUID	D05IQX
D05IQX	DRUGNAME	Belimumab
D05IQX	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Approved

D0MG1Y	TTDDRUID	D0MG1Y
D0MG1Y	DRUGNAME	Belladonna
D0MG1Y	INDICATI	Colitis [ICD-11: 1A40.Z] Approved

D06VYE	TTDDRUID	D06VYE
D06VYE	DRUGNAME	Belotecan hydrocholoride
D06VYE	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Approved

D0F0EP	TTDDRUID	D0F0EP
D0F0EP	DRUGNAME	Bemetizide
D0F0EP	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0U3EC	TTDDRUID	D0U3EC
D0U3EC	DRUGNAME	Benazepril
D0U3EC	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D01CYA	TTDDRUID	D01CYA
D01CYA	DRUGNAME	Bendamustine hydrochloride
D01CYA	INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved

D02PAH	TTDDRUID	D02PAH
D02PAH	DRUGNAME	Bendroflumethiazide
D02PAH	INDICATI	High blood pressure [ICD-11: BA00] Approved

D08GJO	TTDDRUID	D08GJO
D08GJO	DRUGNAME	Benorilate
D08GJO	INDICATI	Arthritis [ICD-11: FA20] Approved

D0X7QQ	TTDDRUID	D0X7QQ
D0X7QQ	DRUGNAME	Benperidol
D0X7QQ	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D02PIO	TTDDRUID	D02PIO
D02PIO	DRUGNAME	Benralizumab
D02PIO	INDICATI	Asthma [ICD-11: CA23] Approved
D02PIO	INDICATI	Asthma [ICD-11: CA23] Phase 1/2
D02PIO	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0N8DP	TTDDRUID	D0N8DP
D0N8DP	DRUGNAME	Bentazepam
D0N8DP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0L0SW	TTDDRUID	D0L0SW
D0L0SW	DRUGNAME	Bentiromide
D0L0SW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved

D0W3YL	TTDDRUID	D0W3YL
D0W3YL	DRUGNAME	Bentoquatam
D0W3YL	INDICATI	Contact dermatitis [ICD-11: EK0Z] Approved

D07VRO	TTDDRUID	D07VRO
D07VRO	DRUGNAME	Benzalkonium chloride
D07VRO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Z3DY	TTDDRUID	D0Z3DY
D0Z3DY	DRUGNAME	Benzbromarone
D0Z3DY	INDICATI	Gout [ICD-11: FA25] Approved

D04XGT	TTDDRUID	D04XGT
D04XGT	DRUGNAME	Benznidazole
D04XGT	INDICATI	Chagas disease [ICD-11: 1F53] Approved
D04XGT	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Approved

D0Q8ZX	TTDDRUID	D0Q8ZX
D0Q8ZX	DRUGNAME	Benzocaine
D0Q8ZX	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0X9RY	TTDDRUID	D0X9RY
D0X9RY	DRUGNAME	Benzoic Acid
D0X9RY	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0Q2ES	TTDDRUID	D0Q2ES
D0Q2ES	DRUGNAME	Benzonatate
D0Q2ES	INDICATI	Cough [ICD-11: MD12] Approved

D04DXN	TTDDRUID	D04DXN
D04DXN	DRUGNAME	Benzoyl peroxide
D04DXN	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0T5UL	TTDDRUID	D0T5UL
D0T5UL	DRUGNAME	Benzphetamine
D0T5UL	INDICATI	Obesity [ICD-11: 5B81] Approved

D02DKD	TTDDRUID	D02DKD
D02DKD	DRUGNAME	Benzquinamide
D02DKD	INDICATI	Nausea [ICD-11: MD90] Approved

D0L2MX	TTDDRUID	D0L2MX
D0L2MX	DRUGNAME	Benzthiazide
D0L2MX	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0HQ6N	TTDDRUID	D0HQ6N
D0HQ6N	DRUGNAME	Benztropine
D0HQ6N	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D05OIS	TTDDRUID	D05OIS
D05OIS	DRUGNAME	Benzyl alcohol
D05OIS	INDICATI	Head and body lice [ICD-11: 1G00.0] Approved

D0G1VX	TTDDRUID	D0G1VX
D0G1VX	DRUGNAME	BENZYL BENZOATE
D0G1VX	INDICATI	Infestations of lice and scabies [ICD-11: 1G00.Z] Approved

D0J7TM	TTDDRUID	D0J7TM
D0J7TM	DRUGNAME	Benzylpenicilloyl Polylysine
D0J7TM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0U5VZ	TTDDRUID	D0U5VZ
D0U5VZ	DRUGNAME	Bepotastine
D0U5VZ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0Y4JJ	TTDDRUID	D0Y4JJ
D0Y4JJ	DRUGNAME	Bepridil
D0Y4JJ	INDICATI	Chronic/stable angina [ICD-11: BA40.1] Approved

D02VLX	TTDDRUID	D02VLX
D02VLX	DRUGNAME	Beractant
D02VLX	INDICATI	Neonatal respiratory distress [ICD-11: CB04.2] Approved

D0DV4J	TTDDRUID	D0DV4J
D0DV4J	DRUGNAME	Beriplast-P
D0DV4J	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D02GDN	TTDDRUID	D02GDN
D02GDN	DRUGNAME	Berirab
D02GDN	INDICATI	Rabies [ICD-11: 1C82] Approved

D00TRV	TTDDRUID	D00TRV
D00TRV	DRUGNAME	Besifloxacin
D00TRV	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Approved

D0RA5Q	TTDDRUID	D0RA5Q
D0RA5Q	DRUGNAME	Bestatin
D0RA5Q	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0M9QK	TTDDRUID	D0M9QK
D0M9QK	DRUGNAME	Beta-acetyldigoxin
D0M9QK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0MY8N	TTDDRUID	D0MY8N
D0MY8N	DRUGNAME	Beta-carotene
D0MY8N	INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved

D02KJX	TTDDRUID	D02KJX
D02KJX	DRUGNAME	Betain anhydrous
D02KJX	INDICATI	Inborn homocystinuria [ICD-11: 5C50] Approved

D0XB8P	TTDDRUID	D0XB8P
D0XB8P	DRUGNAME	Betaine
D0XB8P	INDICATI	Inborn error of metabolism [ICD-11: 5C50-5C59] Approved

D0CW1P	TTDDRUID	D0CW1P
D0CW1P	DRUGNAME	Betamethasone
D0CW1P	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D06CWH	TTDDRUID	D06CWH
D06CWH	DRUGNAME	Betamethasone Benzoate
D06CWH	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0X2LV	TTDDRUID	D0X2LV
D0X2LV	DRUGNAME	Betamethasone butyrate propion
D0X2LV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D03SXE	TTDDRUID	D03SXE
D03SXE	DRUGNAME	Betamethasone Valerate
D03SXE	INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved

D03ROX	TTDDRUID	D03ROX
D03ROX	DRUGNAME	Betaxolol
D03ROX	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D01OUE	TTDDRUID	D01OUE
D01OUE	DRUGNAME	Betazole
D01OUE	INDICATI	Gastric secretory disorder [ICD-11: DD90] Approved

D07ZTO	TTDDRUID	D07ZTO
D07ZTO	DRUGNAME	Bethanechol
D07ZTO	INDICATI	Urinary retention [ICD-11: MF50.3] Approved

D0J0BU	TTDDRUID	D0J0BU
D0J0BU	DRUGNAME	BETRIXABAN
D0J0BU	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
D0J0BU	INDICATI	Venous thromboembolism [ICD-11: BD72] Approved

D04KBL	TTDDRUID	D04KBL
D04KBL	DRUGNAME	Bevacizumab
D04KBL	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D01SAT	TTDDRUID	D01SAT
D01SAT	DRUGNAME	Bevantolol
D01SAT	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0N0RU	TTDDRUID	D0N0RU
D0N0RU	DRUGNAME	Bexarotene
D0N0RU	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved

D00WCX	TTDDRUID	D00WCX
D00WCX	DRUGNAME	Bezafibrate
D00WCX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved

D09KRE	TTDDRUID	D09KRE
D09KRE	DRUGNAME	Bezlotoxumab
D09KRE	INDICATI	C. difficile infection [ICD-11: 1A04] Approved

D0E7QN	TTDDRUID	D0E7QN
D0E7QN	DRUGNAME	Biapenem
D0E7QN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05UFG	TTDDRUID	D05UFG
D05UFG	DRUGNAME	BIBW 2992
D05UFG	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D0V9BD	TTDDRUID	D0V9BD
D0V9BD	DRUGNAME	Bicalutamide
D0V9BD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0AZ8Y	TTDDRUID	D0AZ8Y
D0AZ8Y	DRUGNAME	Biciromab
D0AZ8Y	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D01IRG	TTDDRUID	D01IRG
D01IRG	DRUGNAME	Bictegravir, emtricitabine and tenofovir alafenamide
D01IRG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0AA2D	TTDDRUID	D0AA2D
D0AA2D	DRUGNAME	Bifonazole
D0AA2D	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0U4HZ	TTDDRUID	D0U4HZ
D0U4HZ	DRUGNAME	Bilive
D0U4HZ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0Q2XF	TTDDRUID	D0Q2XF
D0Q2XF	DRUGNAME	Bimatoprost
D0Q2XF	INDICATI	Alopecia [ICD-11: ED70] Approved

D08MYF	TTDDRUID	D08MYF
D08MYF	DRUGNAME	Bio-Hep-B
D08MYF	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D07RRC	TTDDRUID	D07RRC
D07RRC	DRUGNAME	BioHib
D07RRC	INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved

D08NLN	TTDDRUID	D08NLN
D08NLN	DRUGNAME	Biolimus a9
D08NLN	INDICATI	Artery stenosis [ICD-11: BD52] Approved

D07ZGF	TTDDRUID	D07ZGF
D07ZGF	DRUGNAME	Biothrax
D07ZGF	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Approved

D0B4TN	TTDDRUID	D0B4TN
D0B4TN	DRUGNAME	Biperiden
D0B4TN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D05NMJ	TTDDRUID	D05NMJ
D05NMJ	DRUGNAME	Biphasic porcine insulin
D05NMJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D02VJY	TTDDRUID	D02VJY
D02VJY	DRUGNAME	Biricodar
D02VJY	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D07IEF	TTDDRUID	D07IEF
D07IEF	DRUGNAME	Bisacodyl
D07IEF	INDICATI	Constipation [ICD-11: DD91.1] Approved

D0OG5K	TTDDRUID	D0OG5K
D0OG5K	DRUGNAME	Bismuth
D0OG5K	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0K3ZR	TTDDRUID	D0K3ZR
D0K3ZR	DRUGNAME	Bisoprolol
D0K3ZR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06RUL	TTDDRUID	D06RUL
D06RUL	DRUGNAME	Bitolterol
D06RUL	INDICATI	Asthma [ICD-11: CA23] Withdrawn from market
D06RUL	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D09HVL	TTDDRUID	D09HVL
D09HVL	DRUGNAME	Bivalirudin
D09HVL	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved

D0IY3Z	TTDDRUID	D0IY3Z
D0IY3Z	DRUGNAME	Bivigam
D0IY3Z	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D09RRG	TTDDRUID	D09RRG
D09RRG	DRUGNAME	BK-4SP
D09RRG	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D04AIT	TTDDRUID	D04AIT
D04AIT	DRUGNAME	B-Lactams
D04AIT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06UVD	TTDDRUID	D06UVD
D06UVD	DRUGNAME	Bleomycin
D06UVD	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved

D0K4RK	TTDDRUID	D0K4RK
D0K4RK	DRUGNAME	Blinatumomab
D0K4RK	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0H8VY	TTDDRUID	D0H8VY
D0H8VY	DRUGNAME	BMS-201038
D0H8VY	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Approved

D0V3YT	TTDDRUID	D0V3YT
D0V3YT	DRUGNAME	BOCEPREVIR
D0V3YT	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D05LQX	TTDDRUID	D05LQX
D05LQX	DRUGNAME	BOL-303259-X
D05LQX	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
D05LQX	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D0U7KM	TTDDRUID	D0U7KM
D0U7KM	DRUGNAME	Boostrix
D0U7KM	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0H5MB	TTDDRUID	D0H5MB
D0H5MB	DRUGNAME	Bopindolol
D0H5MB	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D08NNW	TTDDRUID	D08NNW
D08NNW	DRUGNAME	Boric acid
D08NNW	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved

D05MPX	TTDDRUID	D05MPX
D05MPX	DRUGNAME	Bornaprine
D05MPX	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D03EOT	TTDDRUID	D03EOT
D03EOT	DRUGNAME	Borocaptate sodium B 10
D03EOT	INDICATI	Brain cancer [ICD-11: 2A00] Approved

D0SH3I	TTDDRUID	D0SH3I
D0SH3I	DRUGNAME	Bortezomib
D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
D0SH3I	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D0U4CE	TTDDRUID	D0U4CE
D0U4CE	DRUGNAME	Bosentan
D0U4CE	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved

D0OB0F	TTDDRUID	D0OB0F
D0OB0F	DRUGNAME	Bosutinib
D0OB0F	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0D1RM	TTDDRUID	D0D1RM
D0D1RM	DRUGNAME	Botulinum Toxin Type A
D0D1RM	INDICATI	Blepharospasm [ICD-11: 9A05.Z] Approved

D02FXK	TTDDRUID	D02FXK
D02FXK	DRUGNAME	Botulinum Toxin Type B
D02FXK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D09YEY	TTDDRUID	D09YEY
D09YEY	DRUGNAME	Botulinum toxin type F
D09YEY	INDICATI	Dystonia [ICD-11: 8A02] Approved

D09ITH	TTDDRUID	D09ITH
D09ITH	DRUGNAME	Botulism immune globulin
D09ITH	INDICATI	Clostridium infection [ICD-11: 1A04] Approved

D04VCN	TTDDRUID	D04VCN
D04VCN	DRUGNAME	Bovactant
D04VCN	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Approved

D03TIS	TTDDRUID	D03TIS
D03TIS	DRUGNAME	Brentuximab vedotin
D03TIS	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved

D02YYF	TTDDRUID	D02YYF
D02YYF	DRUGNAME	Bretylium
D02YYF	INDICATI	Ventricular fibrillation [ICD-11: BC71.1] Approved

D08PIE	TTDDRUID	D08PIE
D08PIE	DRUGNAME	Brigatinib
D08PIE	INDICATI	Anaplastic large cell lymphoma [ICD-11: 2A90.A] Approved
D08PIE	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D0WF7L	TTDDRUID	D0WF7L
D0WF7L	DRUGNAME	Brilinta
D0WF7L	INDICATI	Arterial thrombosis [ICD-11: DB61-DD30] Phase 3
D0WF7L	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 3
D0WF7L	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D0AE3X	TTDDRUID	D0AE3X
D0AE3X	DRUGNAME	Brimonidine
D0AE3X	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3
D0AE3X	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Approved

D01MUR	TTDDRUID	D01MUR
D01MUR	DRUGNAME	Brinzolamide
D01MUR	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D0CT4D	TTDDRUID	D0CT4D
D0CT4D	DRUGNAME	Brivaracetam
D0CT4D	INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
D0CT4D	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
D0CT4D	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D05CEO	TTDDRUID	D05CEO
D05CEO	DRUGNAME	Brodalumab
D05CEO	INDICATI	Asthma [ICD-11: CA23] Phase 2
D05CEO	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
D05CEO	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D06QKV	TTDDRUID	D06QKV
D06QKV	DRUGNAME	Brodimoprim
D06QKV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0E3FD	TTDDRUID	D0E3FD
D0E3FD	DRUGNAME	Bromazepam
D0E3FD	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
D0E3FD	INDICATI	Panic attacks [ICD-11: MB23.H] Approved

D0U1OM	TTDDRUID	D0U1OM
D0U1OM	DRUGNAME	Bromfenac
D0U1OM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market
D0U1OM	INDICATI	Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved

D07UWJ	TTDDRUID	D07UWJ
D07UWJ	DRUGNAME	Bromhexine
D07UWJ	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Approved

D06YFA	TTDDRUID	D06YFA
D06YFA	DRUGNAME	Bromocriptine
D06YFA	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0Y5GK	TTDDRUID	D0Y5GK
D0Y5GK	DRUGNAME	Bromodiphenhydramine
D0Y5GK	INDICATI	Hay fever [ICD-11: CA08.00] Approved

D09WEJ	TTDDRUID	D09WEJ
D09WEJ	DRUGNAME	Bromopride
D09WEJ	INDICATI	Dyspepsia [ICD-11: MD92] Approved

D00SHQ	TTDDRUID	D00SHQ
D00SHQ	DRUGNAME	Bromperidol
D00SHQ	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D08VXO	TTDDRUID	D08VXO
D08VXO	DRUGNAME	Brompheniramine
D08VXO	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D07WON	TTDDRUID	D07WON
D07WON	DRUGNAME	Bronchostat
D07WON	INDICATI	Bronchitis [ICD-11: CA20] Approved

D0Y5RZ	TTDDRUID	D0Y5RZ
D0Y5RZ	DRUGNAME	Brovincamine fumarate
D0Y5RZ	INDICATI	Cerebral vasodilator [ICD-11: BA00-BE2Z] Approved

D01FJT	TTDDRUID	D01FJT
D01FJT	DRUGNAME	Bucillamine
D01FJT	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0NP1J	TTDDRUID	D0NP1J
D0NP1J	DRUGNAME	Bucladesine sodium
D0NP1J	INDICATI	Skin ulcer [ICD-11: ME60.Z] Approved

D03XSJ	TTDDRUID	D03XSJ
D03XSJ	DRUGNAME	Buclizine
D03XSJ	INDICATI	Nausea [ICD-11: MD90] Approved

D0Y7IU	TTDDRUID	D0Y7IU
D0Y7IU	DRUGNAME	Budesonide
D0Y7IU	INDICATI	Asthma [ICD-11: CA23] Approved

D0RM9Q	TTDDRUID	D0RM9Q
D0RM9Q	DRUGNAME	Budipine
D0RM9Q	INDICATI	Migraine [ICD-11: 8A80] Approved

D02HXS	TTDDRUID	D02HXS
D02HXS	DRUGNAME	Bufexamac
D02HXS	INDICATI	Dermatitis [ICD-11: EA80-EA89] Approved

D0Z6ST	TTDDRUID	D0Z6ST
D0Z6ST	DRUGNAME	Buflomedil
D0Z6ST	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Approved

D0R7HO	TTDDRUID	D0R7HO
D0R7HO	DRUGNAME	Bumetanide
D0R7HO	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0S0AF	TTDDRUID	D0S0AF
D0S0AF	DRUGNAME	Bunazosin
D0S0AF	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0A0FL	TTDDRUID	D0A0FL
D0A0FL	DRUGNAME	Bupivacaine
D0A0FL	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D06AWE	TTDDRUID	D06AWE
D06AWE	DRUGNAME	Buprenorphine
D06AWE	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0H2JP	TTDDRUID	D0H2JP
D0H2JP	DRUGNAME	Buprenorphine + naloxone
D0H2JP	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
D0H2JP	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved

D0X4ZR	TTDDRUID	D0X4ZR
D0X4ZR	DRUGNAME	Bupropion
D0X4ZR	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Approved

D0DJ9D	TTDDRUID	D0DJ9D
D0DJ9D	DRUGNAME	Burosumab
D0DJ9D	INDICATI	X-linked hypophosphataemia [ICD-11: 5C63.22] Approved

D04GSY	TTDDRUID	D04GSY
D04GSY	DRUGNAME	Buserelin acetate
D04GSY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0U2OO	TTDDRUID	D0U2OO
D0U2OO	DRUGNAME	Buspirone
D0U2OO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D07SUG	TTDDRUID	D07SUG
D07SUG	DRUGNAME	Busulfan
D07SUG	INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Approved

D0A4JK	TTDDRUID	D0A4JK
D0A4JK	DRUGNAME	Butabarbital
D0A4JK	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D06ORU	TTDDRUID	D06ORU
D06ORU	DRUGNAME	Butacaine
D06ORU	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D05BQK	TTDDRUID	D05BQK
D05BQK	DRUGNAME	Butalbital
D05BQK	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
D05BQK	INDICATI	Headache [ICD-11: 8A80-8A84] Approved

D0B4DC	TTDDRUID	D0B4DC
D0B4DC	DRUGNAME	Butenafine
D0B4DC	INDICATI	Dermatologic infection [ICD-11: 1F28] Approved

D0O3AB	TTDDRUID	D0O3AB
D0O3AB	DRUGNAME	Butethal
D0O3AB	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0W1QI	TTDDRUID	D0W1QI
D0W1QI	DRUGNAME	Butizide
D0W1QI	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0N3SP	TTDDRUID	D0N3SP
D0N3SP	DRUGNAME	Butoconazole
D0N3SP	INDICATI	Candidiasis [ICD-11: 1F23] Approved

D0X9RG	TTDDRUID	D0X9RG
D0X9RG	DRUGNAME	Butorphanol
D0X9RG	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D05EMG	TTDDRUID	D05EMG
D05EMG	DRUGNAME	Butylscopolamine
D05EMG	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved

D02GOG	TTDDRUID	D02GOG
D02GOG	DRUGNAME	BY-963
D02GOG	INDICATI	Myocardial disease [ICD-11: BC43.20] Approved

D0YI5E	TTDDRUID	D0YI5E
D0YI5E	DRUGNAME	Bydureon Dual Chamber Pen
D0YI5E	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D02HSB	TTDDRUID	D02HSB
D02HSB	DRUGNAME	Cabazitaxel
D02HSB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
D02HSB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04EGX	TTDDRUID	D04EGX
D04EGX	DRUGNAME	Cabergoline
D04EGX	INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved

D0IQ6P	TTDDRUID	D0IQ6P
D0IQ6P	DRUGNAME	Cabozantinib
D0IQ6P	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0IQ6P	INDICATI	Thyroid cancer [ICD-11: 2D10] Approved
D0IQ6P	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 1b

D09CIQ	TTDDRUID	D09CIQ
D09CIQ	DRUGNAME	Cadralazine
D09CIQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0B3HD	TTDDRUID	D0B3HD
D0B3HD	DRUGNAME	Caffeine
D0B3HD	INDICATI	Orthostatic hypotension [ICD-11: BA21] Approved

D0C9DA	TTDDRUID	D0C9DA
D0C9DA	DRUGNAME	Calaspargase pegol
D0C9DA	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved

D02VPX	TTDDRUID	D02VPX
D02VPX	DRUGNAME	Calcidiol
D02VPX	INDICATI	Vitamin D deficiency [ICD-11: 5B57] Approved

D06GSS	TTDDRUID	D06GSS
D06GSS	DRUGNAME	Calcifediol
D06GSS	INDICATI	Vitamin D deficiency [ICD-11: 5B57] Approved

D01QUS	TTDDRUID	D01QUS
D01QUS	DRUGNAME	Calcipotriol
D01QUS	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D02QCM	TTDDRUID	D02QCM
D02QCM	DRUGNAME	Calcitonin Human
D02QCM	INDICATI	Paget's disease [ICD-11: FB85] Approved

D0T2PL	TTDDRUID	D0T2PL
D0T2PL	DRUGNAME	Calcitriol
D0T2PL	INDICATI	Congenital alopecia [ICD-11: LC30] Approved

D0PJ4K	TTDDRUID	D0PJ4K
D0PJ4K	DRUGNAME	Calcium
D0PJ4K	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0F1GS	TTDDRUID	D0F1GS
D0F1GS	DRUGNAME	Calcium Acetate
D0F1GS	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Approved

D0A9KF	TTDDRUID	D0A9KF
D0A9KF	DRUGNAME	Calcium carbimide
D0A9KF	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved

D0XQ2X	TTDDRUID	D0XQ2X
D0XQ2X	DRUGNAME	Calcium Chloride
D0XQ2X	INDICATI	Magnesium intoxication [ICD-11: 5C64.4] Approved

D0MT9X	TTDDRUID	D0MT9X
D0MT9X	DRUGNAME	Calcium dobesilate
D0MT9X	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Approved

D0B8SY	TTDDRUID	D0B8SY
D0B8SY	DRUGNAME	Calcium Gluceptate
D0B8SY	INDICATI	Mild hypocalcemia [ICD-11: 5B5K.1] Approved

D0V7RH	TTDDRUID	D0V7RH
D0V7RH	DRUGNAME	Calcium levofolinate
D0V7RH	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D07IRG	TTDDRUID	D07IRG
D07IRG	DRUGNAME	Calcium polycarbophil
D07IRG	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D03MUT	TTDDRUID	D03MUT
D03MUT	DRUGNAME	Calfactant
D03MUT	INDICATI	Acute lung injury [ICD-11: NB32.3] Approved

D0H1QY	TTDDRUID	D0H1QY
D0H1QY	DRUGNAME	Camphor
D0H1QY	INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Approved

D08DFX	TTDDRUID	D08DFX
D08DFX	DRUGNAME	Canagliflozin
D08DFX	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
D08DFX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D08DFX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D08DFX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0TD2G	TTDDRUID	D0TD2G
D0TD2G	DRUGNAME	Canakinumab
D0TD2G	INDICATI	Cryopyrin-associated periodic syndromes [ICD-11: 4A60.1] Approved
D0TD2G	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
D0TD2G	INDICATI	Urticaria [ICD-11: EB00-EB05] Phase 2
D0TD2G	INDICATI	Vasculitis [ICD-11: 4A44] Phase 2

D0D5SQ	TTDDRUID	D0D5SQ
D0D5SQ	DRUGNAME	Candesartan
D0D5SQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0I6IP	TTDDRUID	D0I6IP
D0I6IP	DRUGNAME	Candicidin
D0I6IP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09QBG	TTDDRUID	D09QBG
D09QBG	DRUGNAME	Cangrelor
D09QBG	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D0O1UZ	TTDDRUID	D0O1UZ
D0O1UZ	DRUGNAME	Cannabidiol
D0O1UZ	INDICATI	Dravet syndrome [ICD-11: 8A61.11] Approved
D0O1UZ	INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Approved

D0Z2RA	TTDDRUID	D0Z2RA
D0Z2RA	DRUGNAME	CANTHARIDIN
D0Z2RA	INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Approved

D00HCQ	TTDDRUID	D00HCQ
D00HCQ	DRUGNAME	Capecitabine
D00HCQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D00HCQ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved

D0E7MV	TTDDRUID	D0E7MV
D0E7MV	DRUGNAME	Capreomycin
D0E7MV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D0E7MV	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2

D06EZI	TTDDRUID	D06EZI
D06EZI	DRUGNAME	Capreomycin Sulfate
D06EZI	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D09PGL	TTDDRUID	D09PGL
D09PGL	DRUGNAME	Capromab
D09PGL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0U5CE	TTDDRUID	D0U5CE
D0U5CE	DRUGNAME	Capsaicin
D0U5CE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Approved

D0I0EG	TTDDRUID	D0I0EG
D0I0EG	DRUGNAME	Captopril
D0I0EG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0U7BW	TTDDRUID	D0U7BW
D0U7BW	DRUGNAME	Carbachol
D0U7BW	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D04MSM	TTDDRUID	D04MSM
D04MSM	DRUGNAME	Carbamazepine
D04MSM	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D01BQK	TTDDRUID	D01BQK
D01BQK	DRUGNAME	Carbamide peroxide
D01BQK	INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Approved

D08QJS	TTDDRUID	D08QJS
D08QJS	DRUGNAME	Carbazochrome salicylate
D08QJS	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D02TBI	TTDDRUID	D02TBI
D02TBI	DRUGNAME	Carbenicillin
D02TBI	INDICATI	Infection of the upper and lower urinary tract [ICD-11: GC08] Approved

D0PN1F	TTDDRUID	D0PN1F
D0PN1F	DRUGNAME	Carbenicillin Indanyl Sodium
D0PN1F	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09VBC	TTDDRUID	D09VBC
D09VBC	DRUGNAME	Carbetapentane
D09VBC	INDICATI	Cough [ICD-11: MD12] Approved

D08FJL	TTDDRUID	D08FJL
D08FJL	DRUGNAME	Carbetocin
D08FJL	INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved

D0P7JZ	TTDDRUID	D0P7JZ
D0P7JZ	DRUGNAME	Carbidopa
D0P7JZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D02CKX	TTDDRUID	D02CKX
D02CKX	DRUGNAME	Carbimazole
D02CKX	INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved

D00FGV	TTDDRUID	D00FGV
D00FGV	DRUGNAME	Carbinoxamine
D00FGV	INDICATI	Vasomotor/allergic rhinitis [ICD-11: CA08] Approved

D0X5SI	TTDDRUID	D0X5SI
D0X5SI	DRUGNAME	Carbocisteine
D0X5SI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D07CTM	TTDDRUID	D07CTM
D07CTM	DRUGNAME	Carbol-fuchsin topical solution
D07CTM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X7HM	TTDDRUID	D0X7HM
D0X7HM	DRUGNAME	Carboplatin
D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D07PCI	TTDDRUID	D07PCI
D07PCI	DRUGNAME	Carboprost Tromethamine
D07PCI	INDICATI	Abortion [ICD-11: JA00] Approved

D0B8MZ	TTDDRUID	D0B8MZ
D0B8MZ	DRUGNAME	Careram
D0B8MZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D00UVA	TTDDRUID	D00UVA
D00UVA	DRUGNAME	Carfilzomib
D00UVA	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D0Z0MG	TTDDRUID	D0Z0MG
D0Z0MG	DRUGNAME	Carglumic acid
D0Z0MG	INDICATI	Acute hyperammonaemia [ICD-11: 5C50.A] Approved

D07JHV	TTDDRUID	D07JHV
D07JHV	DRUGNAME	Carimune NF
D07JHV	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D05XGO	TTDDRUID	D05XGO
D05XGO	DRUGNAME	Cariprazine
D05XGO	INDICATI	Bipolar disorder [ICD-11: 6A60] Approved

D05PLH	TTDDRUID	D05PLH
D05PLH	DRUGNAME	Carisoprodol
D05PLH	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved

D03VNJ	TTDDRUID	D03VNJ
D03VNJ	DRUGNAME	Carperitide
D03VNJ	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D01QML	TTDDRUID	D01QML
D01QML	DRUGNAME	Carphenazine
D01QML	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
D01QML	INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market

D0IT2X	TTDDRUID	D0IT2X
D0IT2X	DRUGNAME	Carprofen
D0IT2X	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03GCJ	TTDDRUID	D03GCJ
D03GCJ	DRUGNAME	Carteolol
D03GCJ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0U4XC	TTDDRUID	D0U4XC
D0U4XC	DRUGNAME	Carticel
D0U4XC	INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Approved

D0O2PV	TTDDRUID	D0O2PV
D0O2PV	DRUGNAME	Carumonam
D0O2PV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0W9LX	TTDDRUID	D0W9LX
D0W9LX	DRUGNAME	Carvedilol
D0W9LX	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0J5TS	TTDDRUID	D0J5TS
D0J5TS	DRUGNAME	Carzinophilin
D0J5TS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D00ZCN	TTDDRUID	D00ZCN
D00ZCN	DRUGNAME	Caspofungin
D00ZCN	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D09XKW	TTDDRUID	D09XKW
D09XKW	DRUGNAME	Castor oil
D09XKW	INDICATI	Constipation [ICD-11: DD91.1] Approved

D0P9OU	TTDDRUID	D0P9OU
D0P9OU	DRUGNAME	Cat allergy vaccine
D0P9OU	INDICATI	Non-cystic fibrosis bronchiectasis [ICD-11: CA24] Approved

D0O5ER	TTDDRUID	D0O5ER
D0O5ER	DRUGNAME	Catumaxomab
D0O5ER	INDICATI	Malignant pleural effusion [ICD-11: 2D72] Approved

D0O9RJ	TTDDRUID	D0O9RJ
D0O9RJ	DRUGNAME	CDX-011
D0O9RJ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Approved

D01ZEC	TTDDRUID	D01ZEC
D01ZEC	DRUGNAME	Cefacetrile
D01ZEC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0PW7C	TTDDRUID	D0PW7C
D0PW7C	DRUGNAME	Cefaclor
D0PW7C	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X9ZC	TTDDRUID	D0X9ZC
D0X9ZC	DRUGNAME	Cefadroxil
D0X9ZC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01PLN	TTDDRUID	D01PLN
D01PLN	DRUGNAME	Cefalotin
D01PLN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06YHL	TTDDRUID	D06YHL
D06YHL	DRUGNAME	Cefamandole
D06YHL	INDICATI	Microorganisms infection [ICD-11: 1A00-1A09] Approved

D0N1MC	TTDDRUID	D0N1MC
D0N1MC	DRUGNAME	Cefatrizine
D0N1MC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09KDN	TTDDRUID	D09KDN
D09KDN	DRUGNAME	Cefazolin
D09KDN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0KG4B	TTDDRUID	D0KG4B
D0KG4B	DRUGNAME	Cefbuperazone sodium
D0KG4B	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01KTN	TTDDRUID	D01KTN
D01KTN	DRUGNAME	Cefcapene pivoxil
D01KTN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0WS1X	TTDDRUID	D0WS1X
D0WS1X	DRUGNAME	Cefdinir
D0WS1X	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0E3RW	TTDDRUID	D0E3RW
D0E3RW	DRUGNAME	Cefditoren
D0E3RW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0A1CB	TTDDRUID	D0A1CB
D0A1CB	DRUGNAME	Cefepime
D0A1CB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0T6IP	TTDDRUID	D0T6IP
D0T6IP	DRUGNAME	Cefetamet pivoxil hcl
D0T6IP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06OVY	TTDDRUID	D06OVY
D06OVY	DRUGNAME	Cefixime
D06OVY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06QCC	TTDDRUID	D06QCC
D06QCC	DRUGNAME	Cefmenoxime
D06QCC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05UBX	TTDDRUID	D05UBX
D05UBX	DRUGNAME	Cefmetazole
D05UBX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X6OW	TTDDRUID	D0X6OW
D0X6OW	DRUGNAME	Cefminox sodium
D0X6OW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0O4QR	TTDDRUID	D0O4QR
D0O4QR	DRUGNAME	Cefodizime sodium
D0O4QR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01BQC	TTDDRUID	D01BQC
D01BQC	DRUGNAME	Cefonicid
D01BQC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0C2YB	TTDDRUID	D0C2YB
D0C2YB	DRUGNAME	Cefoperazone
D0C2YB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06OUL	TTDDRUID	D06OUL
D06OUL	DRUGNAME	Ceforanide
D06OUL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09HKX	TTDDRUID	D09HKX
D09HKX	DRUGNAME	Cefoselis
D09HKX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0D1HA	TTDDRUID	D0D1HA
D0D1HA	DRUGNAME	Cefotaxime
D0D1HA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0AP9T	TTDDRUID	D0AP9T
D0AP9T	DRUGNAME	Cefotetan
D0AP9T	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0K3DQ	TTDDRUID	D0K3DQ
D0K3DQ	DRUGNAME	Cefotiam
D0K3DQ	INDICATI	Respiratory tract infection [ICD-11: CA45] Approved

D02VFC	TTDDRUID	D02VFC
D02VFC	DRUGNAME	Cefoxitin
D02VFC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0B5FZ	TTDDRUID	D0B5FZ
D0B5FZ	DRUGNAME	Cefozopran
D0B5FZ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved

D02MZY	TTDDRUID	D02MZY
D02MZY	DRUGNAME	Cefpiramide
D02MZY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0YQ0V	TTDDRUID	D0YQ0V
D0YQ0V	DRUGNAME	Cefpirome sulfate
D0YQ0V	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0W6CA	TTDDRUID	D0W6CA
D0W6CA	DRUGNAME	Cefpodoxime
D0W6CA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0YX4S	TTDDRUID	D0YX4S
D0YX4S	DRUGNAME	Cefprozil
D0YX4S	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06KKS	TTDDRUID	D06KKS
D06KKS	DRUGNAME	Cefradine
D06KKS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X4CS	TTDDRUID	D0X4CS
D0X4CS	DRUGNAME	Cefroxadine
D0X4CS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Q8XH	TTDDRUID	D0Q8XH
D0Q8XH	DRUGNAME	Cefsoludin sodium
D0Q8XH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0XQ0Q	TTDDRUID	D0XQ0Q
D0XQ0Q	DRUGNAME	Cefsulodin
D0XQ0Q	INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved

D0PH5Z	TTDDRUID	D0PH5Z
D0PH5Z	DRUGNAME	Ceftazidime
D0PH5Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D03CAT	TTDDRUID	D03CAT
D03CAT	DRUGNAME	Cefteram pivoxil
D03CAT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D03PIR	TTDDRUID	D03PIR
D03PIR	DRUGNAME	Ceftezole
D03PIR	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D05JDR	TTDDRUID	D05JDR
D05JDR	DRUGNAME	Ceftibuten
D05JDR	INDICATI	Chronic bronchitis [ICD-11: CA20.1] Approved

D0V7OH	TTDDRUID	D0V7OH
D0V7OH	DRUGNAME	Ceftiofur
D0V7OH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Y7BD	TTDDRUID	D0Y7BD
D0Y7BD	DRUGNAME	Ceftizoxime
D0Y7BD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07ACT	TTDDRUID	D07ACT
D07ACT	DRUGNAME	Ceftriaxone
D07ACT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Y2IE	TTDDRUID	D0Y2IE
D0Y2IE	DRUGNAME	Cefuroxime
D0Y2IE	INDICATI	Acute bronchitis [ICD-11: CA42] Approved

D0P0OE	TTDDRUID	D0P0OE
D0P0OE	DRUGNAME	Cefuzonam sodium
D0P0OE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0K5CX	TTDDRUID	D0K5CX
D0K5CX	DRUGNAME	Celacade
D0K5CX	INDICATI	Chronic heart failure [ICD-11: BD1Z] Approved

D03RTS	TTDDRUID	D03RTS
D03RTS	DRUGNAME	Celecoxib
D03RTS	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
D03RTS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0AY7K	TTDDRUID	D0AY7K
D0AY7K	DRUGNAME	Celiprolol hcl
D0AY7K	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0V4AS	TTDDRUID	D0V4AS
D0V4AS	DRUGNAME	Cellulose Sodium Phosphate
D0V4AS	INDICATI	Hypercalciuria [ICD-11: MF98.0] Approved

D0BU8L	TTDDRUID	D0BU8L
D0BU8L	DRUGNAME	Celmoleukin
D0BU8L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Z4BH	TTDDRUID	D0Z4BH
D0Z4BH	DRUGNAME	Celtura
D0Z4BH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D01ILJ	TTDDRUID	D01ILJ
D01ILJ	DRUGNAME	Celvapan
D01ILJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0KG4Q	TTDDRUID	D0KG4Q
D0KG4Q	DRUGNAME	Cemiplimab
D0KG4Q	INDICATI	Cutaneous squamous cell carcinoma [ICD-11: 2C30] Approved

D02KUO	TTDDRUID	D02KUO
D02KUO	DRUGNAME	Cenegermin
D02KUO	INDICATI	Neurotrophic keratitis [ICD-11: 9A74] Approved

D0N6YV	TTDDRUID	D0N6YV
D0N6YV	DRUGNAME	Cenestin
D0N6YV	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved
D0N6YV	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0Z5EM	TTDDRUID	D0Z5EM
D0Z5EM	DRUGNAME	Cephalexin
D0Z5EM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07WZH	TTDDRUID	D07WZH
D07WZH	DRUGNAME	Cephaloglycin
D07WZH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07JVS	TTDDRUID	D07JVS
D07JVS	DRUGNAME	Cephalosporin
D07JVS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0DT5E	TTDDRUID	D0DT5E
D0DT5E	DRUGNAME	Cephalothin Sodium
D0DT5E	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01DSP	TTDDRUID	D01DSP
D01DSP	DRUGNAME	Cephapirin
D01DSP	INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved

D04LVK	TTDDRUID	D04LVK
D04LVK	DRUGNAME	Ceritinib
D04LVK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D03KIA	TTDDRUID	D03KIA
D03KIA	DRUGNAME	Cerivastatin
D03KIA	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
D03KIA	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D06CAS	TTDDRUID	D06CAS
D06CAS	DRUGNAME	Cerliponase Alfa
D06CAS	INDICATI	Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Approved
D06CAS	INDICATI	Tripeptidyl peptidase 1 deficiency [ICD-11: 5C50] Approved

D01FWE	TTDDRUID	D01FWE
D01FWE	DRUGNAME	Certiva
D01FWE	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0CA0P	TTDDRUID	D0CA0P
D0CA0P	DRUGNAME	Certolizumab
D0CA0P	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0U7HJ	TTDDRUID	D0U7HJ
D0U7HJ	DRUGNAME	Certoparin sodium
D0U7HJ	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D03ZFG	TTDDRUID	D03ZFG
D03ZFG	DRUGNAME	Cerulenin
D03ZFG	INDICATI	Weight loss [ICD-11: MG43.5] Approved

D0Y9TS	TTDDRUID	D0Y9TS
D0Y9TS	DRUGNAME	Ceruletide
D0Y9TS	INDICATI	Caerulein stimulated gastric and pancreatic secretion [ICD-11: 5A4Y] Approved
D0Y9TS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0Q7SR	TTDDRUID	D0Q7SR
D0Q7SR	DRUGNAME	Cervarix
D0Q7SR	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Approved

D0S5NG	TTDDRUID	D0S5NG
D0S5NG	DRUGNAME	Cetiedil
D0S5NG	INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Approved

D0DK8V	TTDDRUID	D0DK8V
D0DK8V	DRUGNAME	Cetirizine
D0DK8V	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0V9ZG	TTDDRUID	D0V9ZG
D0V9ZG	DRUGNAME	Cetraxate
D0V9ZG	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D0U3IG	TTDDRUID	D0U3IG
D0U3IG	DRUGNAME	Cetrimide
D0U3IG	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved

D09OLZ	TTDDRUID	D09OLZ
D09OLZ	DRUGNAME	Cetrorelix
D09OLZ	INDICATI	Ovarian stimulation [ICD-11: LB45.1] Approved

D0N5OV	TTDDRUID	D0N5OV
D0N5OV	DRUGNAME	Cetuximab
D0N5OV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved

D0Q4CS	TTDDRUID	D0Q4CS
D0Q4CS	DRUGNAME	Cevimeline
D0Q4CS	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Approved

D01CZH	TTDDRUID	D01CZH
D01CZH	DRUGNAME	Chanllergen
D01CZH	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D0U5OB	TTDDRUID	D0U5OB
D0U5OB	DRUGNAME	Charybdotoxin
D0U5OB	INDICATI	Scorpion envenoming syndrome [ICD-11: 8D43] Approved

D03ZTE	TTDDRUID	D03ZTE
D03ZTE	DRUGNAME	Chenodiol
D03ZTE	INDICATI	Cholelithiasis [ICD-11: DC11] Approved

D0EC6Q	TTDDRUID	D0EC6Q
D0EC6Q	DRUGNAME	Chlophedianol
D0EC6Q	INDICATI	Anaesthesia [ICD-11: 9A78.6] Withdrawn from market
D0EC6Q	INDICATI	Dry cough [ICD-11: MD12] Approved

D02OAV	TTDDRUID	D02OAV
D02OAV	DRUGNAME	Chloral hydrate
D02OAV	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved

D0V8QT	TTDDRUID	D0V8QT
D0V8QT	DRUGNAME	Chlorambucil
D0V8QT	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved

D0X6IU	TTDDRUID	D0X6IU
D0X6IU	DRUGNAME	Chloramphenicol
D0X6IU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06BEP	TTDDRUID	D06BEP
D06BEP	DRUGNAME	Chlordiazepoxide
D06BEP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0V4GY	TTDDRUID	D0V4GY
D0V4GY	DRUGNAME	Chlorhexidine
D0V4GY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06EMT	TTDDRUID	D06EMT
D06EMT	DRUGNAME	Chlormerodrin
D06EMT	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D0S1OE	TTDDRUID	D0S1OE
D0S1OE	DRUGNAME	Chlormezanone
D0S1OE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D07NAJ	TTDDRUID	D07NAJ
D07NAJ	DRUGNAME	Chloroprocaine
D07NAJ	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D09EGZ	TTDDRUID	D09EGZ
D09EGZ	DRUGNAME	Chloroquine
D09EGZ	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0M9WM	TTDDRUID	D0M9WM
D0M9WM	DRUGNAME	Chlorothiazide
D0M9WM	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D02HWP	TTDDRUID	D02HWP
D02HWP	DRUGNAME	CHLOROXINE
D02HWP	INDICATI	Erythema [ICD-11: ME64.0] Approved

D0VB0U	TTDDRUID	D0VB0U
D0VB0U	DRUGNAME	Chlorphenesin
D0VB0U	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Withdrawn from market
D0VB0U	INDICATI	Injury [ICD-11: NA00-ND5Z] Approved
D0VB0U	INDICATI	Muscular pain [ICD-11: FB56] Approved

D0B7NG	TTDDRUID	D0B7NG
D0B7NG	DRUGNAME	Chlorpheniramine
D0B7NG	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D06CDO	TTDDRUID	D06CDO
D06CDO	DRUGNAME	Chlorphentermine Hydrochloride
D06CDO	INDICATI	Appetite suppressant [ICD-11: MG43] Approved

D0Y2DI	TTDDRUID	D0Y2DI
D0Y2DI	DRUGNAME	Chlorproguanil
D0Y2DI	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D01ZII	TTDDRUID	D01ZII
D01ZII	DRUGNAME	Chlorpromazine
D01ZII	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D00BCP	TTDDRUID	D00BCP
D00BCP	DRUGNAME	Chlorpropamide
D00BCP	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Approved

D0B0CP	TTDDRUID	D0B0CP
D0B0CP	DRUGNAME	Chlorprothixene
D0B0CP	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved

D0R6RC	TTDDRUID	D0R6RC
D0R6RC	DRUGNAME	Chlortetracycline
D0R6RC	INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved

D09NIA	TTDDRUID	D09NIA
D09NIA	DRUGNAME	Chlorthalidone
D09NIA	INDICATI	Edema [ICD-11: MG29] Approved
D09NIA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D08ZEB	TTDDRUID	D08ZEB
D08ZEB	DRUGNAME	Chlorzoxazone
D08ZEB	INDICATI	Acute pain [ICD-11: MG31] Approved

D0K5WS	TTDDRUID	D0K5WS
D0K5WS	DRUGNAME	Cholecalciferol
D0K5WS	INDICATI	Vitamin D deficiency [ICD-11: 5B57] Approved

D00USS	TTDDRUID	D00USS
D00USS	DRUGNAME	Cholera vaccine
D00USS	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved

D06ZYM	TTDDRUID	D06ZYM
D06ZYM	DRUGNAME	Cholestyramine
D06ZYM	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0OR2L	TTDDRUID	D0OR2L
D0OR2L	DRUGNAME	Cholic Acid
D0OR2L	INDICATI	Peroxisomal disorder [ICD-11: 5C57] Approved
D0OR2L	INDICATI	Synthesis disorder [ICD-11: 5C52-5C59] Approved

D06QDR	TTDDRUID	D06QDR
D06QDR	DRUGNAME	Choline alfoscerate
D06QDR	INDICATI	Amnesia [ICD-11: MB21.1] Approved

D0C1QZ	TTDDRUID	D0C1QZ
D0C1QZ	DRUGNAME	Choline C-11
D0C1QZ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0I2VR	TTDDRUID	D0I2VR
D0I2VR	DRUGNAME	Choline magnesium trisalicylate
D0I2VR	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D05QPW	TTDDRUID	D05QPW
D05QPW	DRUGNAME	Choline salicylate
D05QPW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D09QRS	TTDDRUID	D09QRS
D09QRS	DRUGNAME	Chondrocelect
D09QRS	INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Approved

D02HYK	TTDDRUID	D02HYK
D02HYK	DRUGNAME	Chondroitin
D02HYK	INDICATI	Cataract [ICD-11: 9B10] Approved

D0W6SS	TTDDRUID	D0W6SS
D0W6SS	DRUGNAME	Choriogonadotropin alfa
D0W6SS	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D0Z8AE	TTDDRUID	D0Z8AE
D0Z8AE	DRUGNAME	Chromic Chloride
D0Z8AE	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D02CYR	TTDDRUID	D02CYR
D02CYR	DRUGNAME	Chromic phosphate P 32
D02CYR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D03KTD	TTDDRUID	D03KTD
D03KTD	DRUGNAME	Chromomycin a3
D03KTD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Y1AA	TTDDRUID	D0Y1AA
D0Y1AA	DRUGNAME	Chymopapain
D0Y1AA	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved

D08NAB	TTDDRUID	D08NAB
D08NAB	DRUGNAME	Chymotrypsin
D08NAB	INDICATI	Asthma [ICD-11: CA23] Approved

D0K7HU	TTDDRUID	D0K7HU
D0K7HU	DRUGNAME	Ciclesonide
D0K7HU	INDICATI	Asthma [ICD-11: CA23] Approved
D0K7HU	INDICATI	Obstructive airway disease [ICD-11: CB40.Y] Approved

D07GRH	TTDDRUID	D07GRH
D07GRH	DRUGNAME	Ciclopirox
D07GRH	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D04AAW	TTDDRUID	D04AAW
D04AAW	DRUGNAME	Cidofovir
D04AAW	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Approved

D02GIU	TTDDRUID	D02GIU
D02GIU	DRUGNAME	Cilastatin
D02GIU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D04GKO	TTDDRUID	D04GKO
D04GKO	DRUGNAME	Cilazapril
D04GKO	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D03VPC	TTDDRUID	D03VPC
D03VPC	DRUGNAME	Cilostazol
D03VPC	INDICATI	Intermittent claudication [ICD-11: BD40.00] Approved

D02DPA	TTDDRUID	D02DPA
D02DPA	DRUGNAME	Cimetidine
D02DPA	INDICATI	Acid-reflux disorder [ICD-11: DA22] Approved

D02KIE	TTDDRUID	D02KIE
D02KIE	DRUGNAME	Cimetropium bromide
D02KIE	INDICATI	Gastric motility disorder [ICD-11: DA21] Approved
D02KIE	INDICATI	Spasm [ICD-11: MB47.3] Approved

D03YGR	TTDDRUID	D03YGR
D03YGR	DRUGNAME	Cinacalcet
D03YGR	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Approved
D03YGR	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 3

D06PEB	TTDDRUID	D06PEB
D06PEB	DRUGNAME	Cinalukast
D06PEB	INDICATI	Asthma [ICD-11: CA23] Approved

D0Q3YO	TTDDRUID	D0Q3YO
D0Q3YO	DRUGNAME	Cinnarizine
D0Q3YO	INDICATI	Vertigo meniere disease [ICD-11: AB31.0] Approved

D0Q9WO	TTDDRUID	D0Q9WO
D0Q9WO	DRUGNAME	Cinolazepam
D0Q9WO	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved

D07UXP	TTDDRUID	D07UXP
D07UXP	DRUGNAME	Cinoxacin
D07UXP	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0BK4X	TTDDRUID	D0BK4X
D0BK4X	DRUGNAME	Cinryze
D0BK4X	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved

D0EJ6O	TTDDRUID	D0EJ6O
D0EJ6O	DRUGNAME	Ciprofibrate
D0EJ6O	INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Approved

D0O1WX	TTDDRUID	D0O1WX
D0O1WX	DRUGNAME	Ciprofloxacin XR
D0O1WX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D0O1WX	INDICATI	Biliary cancer [ICD-11: 2E92.7] Phase 1
D0O1WX	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved

D03KPZ	TTDDRUID	D03KPZ
D03KPZ	DRUGNAME	Ciprofloxacin+dexamethasone
D03KPZ	INDICATI	Acute otitis media [ICD-11: AB00] Approved
D03KPZ	INDICATI	Otitis externa [ICD-11: AA00-AA13] Approved

D0BD8D	TTDDRUID	D0BD8D
D0BD8D	DRUGNAME	Cisapride
D0BD8D	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved
D0BD8D	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D08ALK	TTDDRUID	D08ALK
D08ALK	DRUGNAME	Cisatracurium
D08ALK	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved

D0U5HU	TTDDRUID	D0U5HU
D0U5HU	DRUGNAME	Cisplatin
D0U5HU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D08RHU	TTDDRUID	D08RHU
D08RHU	DRUGNAME	Cissampeline
D08RHU	INDICATI	Skeletal muscle relaxant [ICD-11: NE60] Approved

D0Y5DO	TTDDRUID	D0Y5DO
D0Y5DO	DRUGNAME	Citalopram
D0Y5DO	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D02CFP	TTDDRUID	D02CFP
D02CFP	DRUGNAME	Citicoline
D02CFP	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved

D0GQ4N	TTDDRUID	D0GQ4N
D0GQ4N	DRUGNAME	Citrate salts
D0GQ4N	INDICATI	Kidney disease [ICD-11: GC2Z] Approved

D00TGR	TTDDRUID	D00TGR
D00TGR	DRUGNAME	Citric acid, magnesium oxide, sodium picosulfate
D00TGR	INDICATI	Crohn disease [ICD-11: DD70] Approved

D0P6UK	TTDDRUID	D0P6UK
D0P6UK	DRUGNAME	Citrofen
D0P6UK	INDICATI	Arthritis [ICD-11: FA20] Approved

D05GJW	TTDDRUID	D05GJW
D05GJW	DRUGNAME	Cladribine
D05GJW	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved

D0Z1ZM	TTDDRUID	D0Z1ZM
D0Z1ZM	DRUGNAME	Clarithromycin
D0Z1ZM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X7JN	TTDDRUID	D0X7JN
D0X7JN	DRUGNAME	Clavulanate
D0X7JN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0C5XC	TTDDRUID	D0C5XC
D0C5XC	DRUGNAME	Clemastine
D0C5XC	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0X5NX	TTDDRUID	D0X5NX
D0X5NX	DRUGNAME	Clenbuterol
D0X5NX	INDICATI	Chronic breathing disorder [ICD-11: 7A4Z] Approved

D09ELP	TTDDRUID	D09ELP
D09ELP	DRUGNAME	Clevidipine butyrate
D09ELP	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0Q1BT	TTDDRUID	D0Q1BT
D0Q1BT	DRUGNAME	Clidinium
D0Q1BT	INDICATI	Abdominal stomach pain [ICD-11: DD91.4] Approved
D0Q1BT	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0R0ZL	TTDDRUID	D0R0ZL
D0R0ZL	DRUGNAME	Clindamycin
D0R0ZL	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0S9MC	TTDDRUID	D0S9MC
D0S9MC	DRUGNAME	Clobazam - Lundbeck
D0S9MC	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
D0S9MC	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D0FL5V	TTDDRUID	D0FL5V
D0FL5V	DRUGNAME	Clobetasol
D0FL5V	INDICATI	Rosacea [ICD-11: ED90.0] Approved

D00GOS	TTDDRUID	D00GOS
D00GOS	DRUGNAME	Clocortolone
D00GOS	INDICATI	Rosacea [ICD-11: ED90.0] Approved

D00HNB	TTDDRUID	D00HNB
D00HNB	DRUGNAME	Clodronate
D00HNB	INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved

D0R5RR	TTDDRUID	D0R5RR
D0R5RR	DRUGNAME	Clofarabine
D0R5RR	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
D0R5RR	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Approved

D0S5UH	TTDDRUID	D0S5UH
D0S5UH	DRUGNAME	Clofazimine
D0S5UH	INDICATI	Crohn disease [ICD-11: DD70] Approved
D0S5UH	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0J5DC	TTDDRUID	D0J5DC
D0J5DC	DRUGNAME	Clofibrate
D0J5DC	INDICATI	Dysbetalipoproteinemia [ICD-11: 5C80.2] Approved

D00NJL	TTDDRUID	D00NJL
D00NJL	DRUGNAME	Clofoctol
D00NJL	INDICATI	Bronchitis [ICD-11: CA20] Approved

D0CT9Y	TTDDRUID	D0CT9Y
D0CT9Y	DRUGNAME	Clomifene
D0CT9Y	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D0I5WB	TTDDRUID	D0I5WB
D0I5WB	DRUGNAME	Clomiphene Citrate
D0I5WB	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D0ZS8P	TTDDRUID	D0ZS8P
D0ZS8P	DRUGNAME	Clomipramine
D0ZS8P	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D02GAC	TTDDRUID	D02GAC
D02GAC	DRUGNAME	Clomocycline
D02GAC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0CP4E	TTDDRUID	D0CP4E
D0CP4E	DRUGNAME	Clonazepam
D0CP4E	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
D0CP4E	INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2

D03SKR	TTDDRUID	D03SKR
D03SKR	DRUGNAME	Clonidine
D03SKR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09SOA	TTDDRUID	D09SOA
D09SOA	DRUGNAME	Clonixin
D09SOA	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved

D0S2JI	TTDDRUID	D0S2JI
D0S2JI	DRUGNAME	Clopamide
D0S2JI	INDICATI	Edema [ICD-11: MG29] Approved

D0O8IS	TTDDRUID	D0O8IS
D0O8IS	DRUGNAME	Cloperastine
D0O8IS	INDICATI	Cough [ICD-11: MD12] Approved

D0N0TZ	TTDDRUID	D0N0TZ
D0N0TZ	DRUGNAME	Clopidogrel
D0N0TZ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D0P3JU	TTDDRUID	D0P3JU
D0P3JU	DRUGNAME	Clorazepate
D0P3JU	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D09QDP	TTDDRUID	D09QDP
D09QDP	DRUGNAME	Clorgyline
D09QDP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
D09QDP	INDICATI	Skin imperfections [ICD-11: EK71] Patented

D06BYG	TTDDRUID	D06BYG
D06BYG	DRUGNAME	Clostridium butyricum MIYAIRI 588
D06BYG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0PX8L	TTDDRUID	D0PX8L
D0PX8L	DRUGNAME	Clothiapine
D0PX8L	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0R4DP	TTDDRUID	D0R4DP
D0R4DP	DRUGNAME	Clotiazepam
D0R4DP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D09GOS	TTDDRUID	D09GOS
D09GOS	DRUGNAME	Clotrimazole
D09GOS	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D04UAL	TTDDRUID	D04UAL
D04UAL	DRUGNAME	Clovoxamine
D04UAL	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D04KTZ	TTDDRUID	D04KTZ
D04KTZ	DRUGNAME	Cloxacillin
D04KTZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Z1RV	TTDDRUID	D0Z1RV
D0Z1RV	DRUGNAME	Clozapine
D0Z1RV	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D03HSN	TTDDRUID	D03HSN
D03HSN	DRUGNAME	CNTO-1959
D03HSN	INDICATI	Asthma [ICD-11: CA23] Phase 3
D03HSN	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved

D0Q5KL	TTDDRUID	D0Q5KL
D0Q5KL	DRUGNAME	Coagulation Factor IX
D0Q5KL	INDICATI	Haemophilia B [ICD-11: 3B11.0] Approved

D03YET	TTDDRUID	D03YET
D03YET	DRUGNAME	Coal tar
D03YET	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D02VJP	TTDDRUID	D02VJP
D02VJP	DRUGNAME	Cobicistat
D02VJP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0V4ZN	TTDDRUID	D0V4ZN
D0V4ZN	DRUGNAME	Cobicistat/darunavir
D0V4ZN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D0V4ZN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D04XPW	TTDDRUID	D04XPW
D04XPW	DRUGNAME	Cocaine
D04XPW	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0X1RR	TTDDRUID	D0X1RR
D0X1RR	DRUGNAME	Coccidioidin
D0X1RR	INDICATI	Dermatomycosis [ICD-11: EA60] Approved

D03DIG	TTDDRUID	D03DIG
D03DIG	DRUGNAME	Codeine
D03DIG	INDICATI	Cough [ICD-11: MD12] Phase 1
D03DIG	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0J6LP	TTDDRUID	D0J6LP
D0J6LP	DRUGNAME	Colchiceine amide
D0J6LP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D09DHY	TTDDRUID	D09DHY
D09DHY	DRUGNAME	Colchicine
D09DHY	INDICATI	Acute gouty arthritis [ICD-11: FA25.0] Approved

D01YVT	TTDDRUID	D01YVT
D01YVT	DRUGNAME	Colesevelam
D01YVT	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D08ZFJ	TTDDRUID	D08ZFJ
D08ZFJ	DRUGNAME	Colestilan
D08ZFJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0GJ8R	TTDDRUID	D0GJ8R
D0GJ8R	DRUGNAME	Colestipol
D0GJ8R	INDICATI	Primary hypercholesterolemia [ICD-11: 5C80.00] Approved

D0H2MO	TTDDRUID	D0H2MO
D0H2MO	DRUGNAME	Colforsin daropate hci
D0H2MO	INDICATI	Asthma [ICD-11: CA23] Approved

D0A1XS	TTDDRUID	D0A1XS
D0A1XS	DRUGNAME	Colfosceril palmitate
D0A1XS	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved

D0Q3BV	TTDDRUID	D0Q3BV
D0Q3BV	DRUGNAME	Colistimethate
D0Q3BV	INDICATI	Respiratory tract infection [ICD-11: CA45] Approved

D0K7NQ	TTDDRUID	D0K7NQ
D0K7NQ	DRUGNAME	Colistin
D0K7NQ	INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved

D0Y4KE	TTDDRUID	D0Y4KE
D0Y4KE	DRUGNAME	Collagenase
D0Y4KE	INDICATI	Dermal ulcers [ICD-11: 1A36] Approved
D0Y4KE	INDICATI	Skin burns [ICD-11: ME65.0] Approved

D0I4ZQ	TTDDRUID	D0I4ZQ
D0I4ZQ	DRUGNAME	Collagenase clostridium histolyticum
D0I4ZQ	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Approved

D07NPH	TTDDRUID	D07NPH
D07NPH	DRUGNAME	Colostrinin
D07NPH	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0O9FE	TTDDRUID	D0O9FE
D0O9FE	DRUGNAME	Combo with MEKi
D0O9FE	INDICATI	Melanoma [ICD-11: 2C30] Approved

D05HIP	TTDDRUID	D05HIP
D05HIP	DRUGNAME	Comvac4-HB
D05HIP	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D03FON	TTDDRUID	D03FON
D03FON	DRUGNAME	Comvac5
D03FON	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D09XRD	TTDDRUID	D09XRD
D09XRD	DRUGNAME	Comvax
D09XRD	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0VU2X	TTDDRUID	D0VU2X
D0VU2X	DRUGNAME	Conivaptan
D0VU2X	INDICATI	Euvolemic hyponatremia [ICD-11: 5C72] Approved

D0T0LU	TTDDRUID	D0T0LU
D0T0LU	DRUGNAME	Conjugated Estrogens
D0T0LU	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved
D0T0LU	INDICATI	Vasomotor symptom [ICD-11: CA08] Approved

D0A2RG	TTDDRUID	D0A2RG
D0A2RG	DRUGNAME	Conjugated estrogens a
D0A2RG	INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved

D01ICU	TTDDRUID	D01ICU
D01ICU	DRUGNAME	Conjugated estrogens b
D01ICU	INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved

D0WD8M	TTDDRUID	D0WD8M
D0WD8M	DRUGNAME	Connexyn
D0WD8M	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved

D0MH3P	TTDDRUID	D0MH3P
D0MH3P	DRUGNAME	Contraceptive combination
D0MH3P	INDICATI	Contraception [ICD-11: QA21] Approved

D0M2QH	TTDDRUID	D0M2QH
D0M2QH	DRUGNAME	Convallatoxin
D0M2QH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D01WMJ	TTDDRUID	D01WMJ
D01WMJ	DRUGNAME	Copper
D01WMJ	INDICATI	Contraception [ICD-11: QA21] Approved

D0L1QF	TTDDRUID	D0L1QF
D0L1QF	DRUGNAME	Corifollitropin alfa
D0L1QF	INDICATI	Infertility [ICD-11: GB04] Approved

D0Y2PQ	TTDDRUID	D0Y2PQ
D0Y2PQ	DRUGNAME	Corticorelin Ovine Triflutate
D0Y2PQ	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D0R4HQ	TTDDRUID	D0R4HQ
D0R4HQ	DRUGNAME	Corticotropin
D0R4HQ	INDICATI	Cushing disease [ICD-11: 5A70] Approved

D0D0BM	TTDDRUID	D0D0BM
D0D0BM	DRUGNAME	Corticotropin-zinc Hydroxide
D0D0BM	INDICATI	Ulcerative colitis [ICD-11: DD71] Approved

D0IX6I	TTDDRUID	D0IX6I
D0IX6I	DRUGNAME	cortisone
D0IX6I	INDICATI	Atopic dermatitis [ICD-11: EA80] Approved

D0X4RS	TTDDRUID	D0X4RS
D0X4RS	DRUGNAME	Cortisone Acetate
D0X4RS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0W6LI	TTDDRUID	D0W6LI
D0W6LI	DRUGNAME	Cosyntropin
D0W6LI	INDICATI	Adrenocortical insufficiency [ICD-11: 5A74] Approved

D0TY5N	TTDDRUID	D0TY5N
D0TY5N	DRUGNAME	Cotinine
D0TY5N	INDICATI	Insecticide [ICD-11: N.A.] Approved

D0T0YB	TTDDRUID	D0T0YB
D0T0YB	DRUGNAME	Cotrimazine
D0T0YB	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0P0VD	TTDDRUID	D0P0VD
D0P0VD	DRUGNAME	Co-trimoxazole
D0P0VD	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D06KPV	TTDDRUID	D06KPV
D06KPV	DRUGNAME	CreaVax-RCC
D06KPV	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D04XGU	TTDDRUID	D04XGU
D04XGU	DRUGNAME	Crestor/TriLipix
D04XGU	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Approved

D08NWF	TTDDRUID	D08NWF
D08NWF	DRUGNAME	crisaborole
D08NWF	INDICATI	Atopic dermatitis [ICD-11: EA80] Approved

D03ZBT	TTDDRUID	D03ZBT
D03ZBT	DRUGNAME	Crizotinib
D03ZBT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D06LBO	TTDDRUID	D06LBO
D06LBO	DRUGNAME	Croconazole
D06LBO	INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved

D09VXM	TTDDRUID	D09VXM
D09VXM	DRUGNAME	Crofelemer
D09VXM	INDICATI	HIV-associated diarrhoea [ICD-11: 1A2Z] Approved

D0G7IY	TTDDRUID	D0G7IY
D0G7IY	DRUGNAME	Cromolyn sodium
D0G7IY	INDICATI	Atopic dermatitis [ICD-11: EA80] Approved

D03TME	TTDDRUID	D03TME
D03TME	DRUGNAME	Crotalidae fab
D03TME	INDICATI	Venom poisoning [ICD-11: NE61] Approved

D0T3NY	TTDDRUID	D0T3NY
D0T3NY	DRUGNAME	Crotamiton
D0T3NY	INDICATI	Pruritus [ICD-11: EC90] Approved

D0F7AT	TTDDRUID	D0F7AT
D0F7AT	DRUGNAME	Cryptenamine Acetates
D0F7AT	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D01XAJ	TTDDRUID	D01XAJ
D01XAJ	DRUGNAME	CSL-425
D01XAJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0U5SC	TTDDRUID	D0U5SC
D0U5SC	DRUGNAME	CT-102
D0U5SC	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved

D0M5YS	TTDDRUID	D0M5YS
D0M5YS	DRUGNAME	Cupric Chloride
D0M5YS	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0BG4W	TTDDRUID	D0BG4W
D0BG4W	DRUGNAME	Cupric Sulfate
D0BG4W	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
D0BG4W	INDICATI	Herbicide [ICD-11: N.A.] Approved
D0BG4W	INDICATI	Pest attack [ICD-11: N.A.] Approved

D0TZ1C	TTDDRUID	D0TZ1C
D0TZ1C	DRUGNAME	Curemisinin
D0TZ1C	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D02DNA	TTDDRUID	D02DNA
D02DNA	DRUGNAME	Cureskin
D02DNA	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Approved

D05EIT	TTDDRUID	D05EIT
D05EIT	DRUGNAME	CVT-E002
D05EIT	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0FR6I	TTDDRUID	D0FR6I
D0FR6I	DRUGNAME	Cyanocobalamin
D0FR6I	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D0I5TC	TTDDRUID	D0I5TC
D0I5TC	DRUGNAME	Cyanocobalamin Co-57
D0I5TC	INDICATI	Vitamin B12 deficiency [ICD-11: 5B5F] Approved

D08ZBU	TTDDRUID	D08ZBU
D08ZBU	DRUGNAME	Cyanocobalamin Co-60
D08ZBU	INDICATI	Vitamin B12 deficiency [ICD-11: 5B5F] Approved

D00HWO	TTDDRUID	D00HWO
D00HWO	DRUGNAME	Cyclacillin
D00HWO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05VQI	TTDDRUID	D05VQI
D05VQI	DRUGNAME	Cyclandelate
D05VQI	INDICATI	Dementia [ICD-11: 6D80-6D86] Approved

D08HRJ	TTDDRUID	D08HRJ
D08HRJ	DRUGNAME	Cyclizine
D08HRJ	INDICATI	Nausea [ICD-11: MD90] Approved

D01KHH	TTDDRUID	D01KHH
D01KHH	DRUGNAME	Cyclobenzaprine
D01KHH	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0X1EZ	TTDDRUID	D0X1EZ
D0X1EZ	DRUGNAME	Cyclofenil
D0X1EZ	INDICATI	Infertility [ICD-11: GB04] Approved

D0B1EV	TTDDRUID	D0B1EV
D0B1EV	DRUGNAME	Cyclopentolate
D0B1EV	INDICATI	Examination of eyes or vision [ICD-11: QA00.6] Approved

D0CT9C	TTDDRUID	D0CT9C
D0CT9C	DRUGNAME	Cyclophosphamide
D0CT9C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D02WFK	TTDDRUID	D02WFK
D02WFK	DRUGNAME	Cycloserine
D02WFK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D02WFK	INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Phase 2
D02WFK	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D0O3YF	TTDDRUID	D0O3YF
D0O3YF	DRUGNAME	Cyclosporine
D0O3YF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
D0O3YF	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative

D03CNS	TTDDRUID	D03CNS
D03CNS	DRUGNAME	Cyclothiazide
D03CNS	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D02LRQ	TTDDRUID	D02LRQ
D02LRQ	DRUGNAME	Cycrimine
D02LRQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0KN2M	TTDDRUID	D0KN2M
D0KN2M	DRUGNAME	Cynarin
D0KN2M	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved

D00TLN	TTDDRUID	D00TLN
D00TLN	DRUGNAME	Cyproheptadine
D00TLN	INDICATI	Rhinitis [ICD-11: FA20] Approved

D06AEO	TTDDRUID	D06AEO
D06AEO	DRUGNAME	Cyproterone
D06AEO	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0V0LB	TTDDRUID	D0V0LB
D0V0LB	DRUGNAME	Cysteamine
D0V0LB	INDICATI	Nephropathic cystinosis [ICD-11: 5C60] Approved

D0P0QK	TTDDRUID	D0P0QK
D0P0QK	DRUGNAME	Cysteine Hydrochloride
D0P0QK	INDICATI	Adverse reactions to acetaminophen or acetaminophen overdose [ICD-11: PB24] Approved

D07XSN	TTDDRUID	D07XSN
D07XSN	DRUGNAME	Cytarabine
D07XSN	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0H3ZR	TTDDRUID	D0H3ZR
D0H3ZR	DRUGNAME	CytoGam
D0H3ZR	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Approved

D0M7JT	TTDDRUID	D0M7JT
D0M7JT	DRUGNAME	Dabigatran
D0M7JT	INDICATI	Stroke [ICD-11: 8B20] Approved

D05ROI	TTDDRUID	D05ROI
D05ROI	DRUGNAME	Dabrafenib
D05ROI	INDICATI	Melanoma [ICD-11: 2C30] Approved
D05ROI	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0Y7ZU	TTDDRUID	D0Y7ZU
D0Y7ZU	DRUGNAME	Dacarbazine
D0Y7ZU	INDICATI	Melanoma [ICD-11: 2C30] Approved

D09SGV	TTDDRUID	D09SGV
D09SGV	DRUGNAME	Daclatasvir
D09SGV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D0P1BZ	TTDDRUID	D0P1BZ
D0P1BZ	DRUGNAME	Daclizumab
D0P1BZ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D06XXH	TTDDRUID	D06XXH
D06XXH	DRUGNAME	Dacomitinib
D06XXH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
D06XXH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0P8IV	TTDDRUID	D0P8IV
D0P8IV	DRUGNAME	Dactinomycin
D0P8IV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D07QAR	TTDDRUID	D07QAR
D07QAR	DRUGNAME	Dalbavancin
D07QAR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D08YIN	TTDDRUID	D08YIN
D08YIN	DRUGNAME	Dalfampridine
D08YIN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D05AFC	TTDDRUID	D05AFC
D05AFC	DRUGNAME	Dalfopristin
D05AFC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0P3SY	TTDDRUID	D0P3SY
D0P3SY	DRUGNAME	Danaparoid
D0P3SY	INDICATI	Deep venous clot [ICD-11: BD71] Approved

D09IPV	TTDDRUID	D09IPV
D09IPV	DRUGNAME	Danazol
D09IPV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D09IPV	INDICATI	Menorrhagia [ICD-11: GA20.50] Approved

D0I8DD	TTDDRUID	D0I8DD
D0I8DD	DRUGNAME	Dantrolene
D0I8DD	INDICATI	Hyperthermia [ICD-11: MG26] Approved

D01TNW	TTDDRUID	D01TNW
D01TNW	DRUGNAME	Dapagliflozin
D01TNW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0Y6QC	TTDDRUID	D0Y6QC
D0Y6QC	DRUGNAME	Dapagliflozin Propanediol
D0Y6QC	DRUGNAME	Saxagliptin Hydrochloride
D0Y6QC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0T2IA	TTDDRUID	D0T2IA
D0T2IA	DRUGNAME	Dapiprazole
D0T2IA	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0MA9N	TTDDRUID	D0MA9N
D0MA9N	DRUGNAME	Dapsone
D0MA9N	INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Approved

D0EZ5J	TTDDRUID	D0EZ5J
D0EZ5J	DRUGNAME	Daptacel
D0EZ5J	INDICATI	Pediatric immunological disease [ICD-11: GB4Z] Approved

D05HPI	TTDDRUID	D05HPI
D05HPI	DRUGNAME	Daptomycin
D05HPI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0RV4P	TTDDRUID	D0RV4P
D0RV4P	DRUGNAME	Daratumumab
D0RV4P	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D02LVZ	TTDDRUID	D02LVZ
D02LVZ	DRUGNAME	Darbepoetin alfa
D02LVZ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D0Y5AM	TTDDRUID	D0Y5AM
D0Y5AM	DRUGNAME	Darifenacin
D0Y5AM	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D03IGH	TTDDRUID	D03IGH
D03IGH	DRUGNAME	Darunavir
D03IGH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0E6XR	TTDDRUID	D0E6XR
D0E6XR	DRUGNAME	Dasatinib
D0E6XR	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved
D0E6XR	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D01XWG	TTDDRUID	D01XWG
D01XWG	DRUGNAME	Daunorubicin
D01XWG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
D01XWG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06ILK	TTDDRUID	D06ILK
D06ILK	DRUGNAME	Daunorubicin citrate liposome injection
D06ILK	INDICATI	Kaposi sarcoma [ICD-11: 2B57] Approved

D0MP5H	TTDDRUID	D0MP5H
D0MP5H	DRUGNAME	Debrisoquin
D0MP5H	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D05QNO	TTDDRUID	D05QNO
D05QNO	DRUGNAME	Decamethonium
D05QNO	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved

D0X5XU	TTDDRUID	D0X5XU
D0X5XU	DRUGNAME	Decitabine
D0X5XU	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Approved

D0N0OU	TTDDRUID	D0N0OU
D0N0OU	DRUGNAME	Deferiprone
D0N0OU	INDICATI	Thalassemia [ICD-11: 3A50] Approved

D0FJ8A	TTDDRUID	D0FJ8A
D0FJ8A	DRUGNAME	Deferoxamine Mesylate
D0FJ8A	INDICATI	Acute iron or aluminum toxicity [ICD-11: FB83.20] Approved

D0FM2W	TTDDRUID	D0FM2W
D0FM2W	DRUGNAME	Defibrotide
D0FM2W	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
D0FM2W	INDICATI	Hepatic veno-occlusive disease [ICD-11: DB98.6] Approved

D09WYX	TTDDRUID	D09WYX
D09WYX	DRUGNAME	Deflazacort
D09WYX	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Approved

D0Y7KH	TTDDRUID	D0Y7KH
D0Y7KH	DRUGNAME	DEGARELIX
D0Y7KH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D02ARR	TTDDRUID	D02ARR
D02ARR	DRUGNAME	Dehydrocholic acid
D02ARR	INDICATI	Constipation [ICD-11: DD91.1] Approved

D04XDT	TTDDRUID	D04XDT
D04XDT	DRUGNAME	Delafloxacin Meglumine
D04XDT	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Approved
D04XDT	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved

D0G8QW	TTDDRUID	D0G8QW
D0G8QW	DRUGNAME	Delapril
D0G8QW	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0G6SD	TTDDRUID	D0G6SD
D0G6SD	DRUGNAME	Delavirdine
D0G6SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0Z5OV	TTDDRUID	D0Z5OV
D0Z5OV	DRUGNAME	Delorazepam
D0Z5OV	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D06IDT	TTDDRUID	D06IDT
D06IDT	DRUGNAME	Demecarium bromide
D06IDT	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D0R9WP	TTDDRUID	D0R9WP
D0R9WP	DRUGNAME	Demeclocycline
D0R9WP	INDICATI	Acne vulgaris [ICD-11: ED80] Approved
D0R9WP	INDICATI	Bronchitis [ICD-11: CA20] Approved
D0R9WP	INDICATI	Lyme disease [ICD-11: 1C1G] Approved

D02LZB	TTDDRUID	D02LZB
D02LZB	DRUGNAME	Demecolcine
D02LZB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0J3RY	TTDDRUID	D0J3RY
D0J3RY	DRUGNAME	Denileukin diftitox
D0J3RY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0J3RY	INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved

D0Q9ON	TTDDRUID	D0Q9ON
D0Q9ON	DRUGNAME	Denopamine
D0Q9ON	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Approved

D08WSY	TTDDRUID	D08WSY
D08WSY	DRUGNAME	Denosumab
D08WSY	INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Approved
D08WSY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
D08WSY	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0RX7Z	TTDDRUID	D0RX7Z
D0RX7Z	DRUGNAME	DEOXYCYTIDINE
D0RX7Z	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0OY5X	TTDDRUID	D0OY5X
D0OY5X	DRUGNAME	DermaGraft
D0OY5X	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D02LTL	TTDDRUID	D02LTL
D02LTL	DRUGNAME	Dermatan sulfate
D02LTL	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D09HDR	TTDDRUID	D09HDR
D09HDR	DRUGNAME	Deserpidine
D09HDR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0H4GN	TTDDRUID	D0H4GN
D0H4GN	DRUGNAME	Desflurane
D0H4GN	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D01UTL	TTDDRUID	D01UTL
D01UTL	DRUGNAME	Desipramine
D01UTL	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
D01UTL	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D00UOR	TTDDRUID	D00UOR
D00UOR	DRUGNAME	Desirudin
D00UOR	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D03LWO	TTDDRUID	D03LWO
D03LWO	DRUGNAME	Desirudin Recombinant
D03LWO	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved

D07TGN	TTDDRUID	D07TGN
D07TGN	DRUGNAME	Deslanoside
D07TGN	INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
D07TGN	INDICATI	Congestive cardiac insufficiency [ICD-11: BD1Z] Approved
D07TGN	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D01GBY	TTDDRUID	D01GBY
D01GBY	DRUGNAME	Desloratadine
D01GBY	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D03KUB	TTDDRUID	D03KUB
D03KUB	DRUGNAME	Deslorelin
D03KUB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0U7SH	TTDDRUID	D0U7SH
D0U7SH	DRUGNAME	Desmopressin
D0U7SH	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D06CGB	TTDDRUID	D06CGB
D06CGB	DRUGNAME	Desogestrel
D06CGB	INDICATI	Contraception [ICD-11: QA21] Approved

D02JNM	TTDDRUID	D02JNM
D02JNM	DRUGNAME	Desonide
D02JNM	INDICATI	Atopic dermatitis [ICD-11: EA80] Approved

D0CZ1Q	TTDDRUID	D0CZ1Q
D0CZ1Q	DRUGNAME	Desoximetasone
D0CZ1Q	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0W5LS	TTDDRUID	D0W5LS
D0W5LS	DRUGNAME	Desoxycorticosterone Pivalate
D0W5LS	INDICATI	Addison disease [ICD-11: 5A74.0] Approved

D0U6BJ	TTDDRUID	D0U6BJ
D0U6BJ	DRUGNAME	Desoxyribonuclease
D0U6BJ	INDICATI	Female genital tract inflammation [ICD-11: GA0Z] Approved

D03CEF	TTDDRUID	D03CEF
D03CEF	DRUGNAME	Desvenalfaxine succinate
D03CEF	INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved

D0O3FG	TTDDRUID	D0O3FG
D0O3FG	DRUGNAME	Desvenlafaxine
D0O3FG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
D0O3FG	INDICATI	Menopause symptom [ICD-11: GA30.0] Phase 3

D0E7ZU	TTDDRUID	D0E7ZU
D0E7ZU	DRUGNAME	Deutetrabenazine
D0E7ZU	INDICATI	Huntington disease [ICD-11: 8A01.10] Approved
D0E7ZU	INDICATI	Tardive dyskinesia [ICD-11: 8A02.10] Approved

D0IT2G	TTDDRUID	D0IT2G
D0IT2G	DRUGNAME	Dexamethasone
D0IT2G	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0NA8U	TTDDRUID	D0NA8U
D0NA8U	DRUGNAME	Dexamethasone sodium phosphate
D0NA8U	INDICATI	Ataxia-telangiectasia [ICD-11: 4A01.31] Approved

D02WIW	TTDDRUID	D02WIW
D02WIW	DRUGNAME	Dexbrompheniramine
D02WIW	INDICATI	Hay fever [ICD-11: CA08.00] Approved

D05ZGQ	TTDDRUID	D05ZGQ
D05ZGQ	DRUGNAME	Dexchlorpheniramine Maleate
D05ZGQ	INDICATI	Rhinitis [ICD-11: FA20] Approved

D06YPU	TTDDRUID	D06YPU
D06YPU	DRUGNAME	Dexibuprofen
D06YPU	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Approved

D06YYD	TTDDRUID	D06YYD
D06YYD	DRUGNAME	Dexlansoprazole
D06YYD	INDICATI	Erosive esophagitis [ICD-11: DA25.0] Approved
D06YYD	INDICATI	NSAID-associated gastric ulcer [ICD-11: DA60] Phase 3
D06YYD	INDICATI	Non-erosive gastro-esophageal reflux disease [ICD-11: DA22.0] Approved
D06YYD	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D0U3DU	TTDDRUID	D0U3DU
D0U3DU	DRUGNAME	Dexmedetomidine
D0U3DU	INDICATI	Irritability [ICD-11: MB24] Approved

D02QCD	TTDDRUID	D02QCD
D02QCD	DRUGNAME	DEXMETHYLPHENIDATE HYDROCHLORIDE
D02QCD	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved

D0H9ZQ	TTDDRUID	D0H9ZQ
D0H9ZQ	DRUGNAME	Dexpanthenol
D0H9ZQ	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D07XVN	TTDDRUID	D07XVN
D07XVN	DRUGNAME	Dexrazoxane
D07XVN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
D07XVN	INDICATI	Chemoprotection [ICD-11: N.A.] Approved
D07XVN	INDICATI	Respiratory tract disease [ICD-11: CB7Z] Investigative

D00UJF	TTDDRUID	D00UJF
D00UJF	DRUGNAME	Dextran
D00UJF	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D0FX6P	TTDDRUID	D0FX6P
D0FX6P	DRUGNAME	Dextranomer
D0FX6P	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved

D0T3LF	TTDDRUID	D0T3LF
D0T3LF	DRUGNAME	Dextroamphetamine
D0T3LF	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
D0T3LF	INDICATI	Narcolepsy [ICD-11: 7A20] Approved

D09OBB	TTDDRUID	D09OBB
D09OBB	DRUGNAME	Dextromethorphan
D09OBB	INDICATI	Cough [ICD-11: MD12] Approved

D00KFB	TTDDRUID	D00KFB
D00KFB	DRUGNAME	Dextromethorphan Polistirex
D00KFB	INDICATI	Dry cough [ICD-11: MD12] Approved

D0D4PB	TTDDRUID	D0D4PB
D0D4PB	DRUGNAME	Dextropropoxyphene
D0D4PB	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03TPR	TTDDRUID	D03TPR
D03TPR	DRUGNAME	Dextrothyroxine Sodium
D03TPR	INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Approved

D0P6VV	TTDDRUID	D0P6VV
D0P6VV	DRUGNAME	Dezocine
D0P6VV	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D07SNG	TTDDRUID	D07SNG
D07SNG	DRUGNAME	DF-098
D07SNG	INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved

D08FPM	TTDDRUID	D08FPM
D08FPM	DRUGNAME	Dhaq diacetate
D08FPM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0N6UJ	TTDDRUID	D0N6UJ
D0N6UJ	DRUGNAME	Diacol
D0N6UJ	INDICATI	Gastrointestinal infection [ICD-11: 1A40.Z] Approved

D0T9DT	TTDDRUID	D0T9DT
D0T9DT	DRUGNAME	Diatrizoate
D0T9DT	INDICATI	Urinary tract disease [ICD-11: GC2Z] Approved

D07JVL	TTDDRUID	D07JVL
D07JVL	DRUGNAME	Diazepam
D07JVL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D07WEP	TTDDRUID	D07WEP
D07WEP	DRUGNAME	Diazoxide
D07WEP	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0P8AY	TTDDRUID	D0P8AY
D0P8AY	DRUGNAME	Dibenzepin
D0P8AY	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0P5GE	TTDDRUID	D0P5GE
D0P5GE	DRUGNAME	Dibucaine
D0P5GE	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0J4GO	TTDDRUID	D0J4GO
D0J4GO	DRUGNAME	Dichlorphenamide
D0J4GO	INDICATI	Chronic glaucoma [ICD-11: 9C61.0Z] Approved

D0TG1H	TTDDRUID	D0TG1H
D0TG1H	DRUGNAME	Diclofenac
D0TG1H	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D0R2KJ	TTDDRUID	D0R2KJ
D0R2KJ	DRUGNAME	Dicloxacillin
D0R2KJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02TJS	TTDDRUID	D02TJS
D02TJS	DRUGNAME	Dicumarol
D02TJS	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
D02TJS	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D07XJM	TTDDRUID	D07XJM
D07XJM	DRUGNAME	Dicyclomine
D07XJM	INDICATI	Functional bowel syndrome [ICD-11: DD91.0] Approved

D06FDR	TTDDRUID	D06FDR
D06FDR	DRUGNAME	Didanosine
D06FDR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D09ZQN	TTDDRUID	D09ZQN
D09ZQN	DRUGNAME	Dienestrol
D09ZQN	INDICATI	Atrophic vaginitis [ICD-11: GA30.2] Approved

D06RCB	TTDDRUID	D06RCB
D06RCB	DRUGNAME	Diethylcarbamazine
D06RCB	INDICATI	Lymphatic filariasis [ICD-11: 1F66.3] Approved

D0Y2NE	TTDDRUID	D0Y2NE
D0Y2NE	DRUGNAME	Diethylstilbestrol
D0Y2NE	INDICATI	Gonorrheal vaginitis [ICD-11: GA02] Approved

D0G7KJ	TTDDRUID	D0G7KJ
D0G7KJ	DRUGNAME	Diflorasone
D0G7KJ	INDICATI	Rosacea [ICD-11: ED90.0] Approved

D08LFZ	TTDDRUID	D08LFZ
D08LFZ	DRUGNAME	Diflunisal
D08LFZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D01ZOG	TTDDRUID	D01ZOG
D01ZOG	DRUGNAME	Difluprednate
D01ZOG	INDICATI	Ocular pain [ICD-11: MC18] Approved

D04RYU	TTDDRUID	D04RYU
D04RYU	DRUGNAME	Digitalin
D04RYU	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0M3QP	TTDDRUID	D0M3QP
D0M3QP	DRUGNAME	Digitoxin
D0M3QP	INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
D0M3QP	INDICATI	Congestive cardiac insufficiency [ICD-11: BD1Z] Approved
D0M3QP	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D02OZE	TTDDRUID	D02OZE
D02OZE	DRUGNAME	Digoxin
D02OZE	INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
D02OZE	INDICATI	Congestive cardiac insufficiency [ICD-11: BD1Z] Approved
D02OZE	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D0QS1U	TTDDRUID	D0QS1U
D0QS1U	DRUGNAME	Dihydralazine
D0QS1U	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0N6FH	TTDDRUID	D0N6FH
D0N6FH	DRUGNAME	Dihydroartemisinin
D0N6FH	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D09NNH	TTDDRUID	D09NNH
D09NNH	DRUGNAME	Dihydroergocristine
D09NNH	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved

D0V3ZA	TTDDRUID	D0V3ZA
D0V3ZA	DRUGNAME	Dihydroergotamine
D0V3ZA	INDICATI	Migraine [ICD-11: 8A80] Approved

D0O4CV	TTDDRUID	D0O4CV
D0O4CV	DRUGNAME	Dihydroergotamine nasal
D0O4CV	INDICATI	Migraine [ICD-11: 8A80] Approved

D0SP3D	TTDDRUID	D0SP3D
D0SP3D	DRUGNAME	Dihydroergotoxine
D0SP3D	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0G8OC	TTDDRUID	D0G8OC
D0G8OC	DRUGNAME	Dihydrotachysterol
D0G8OC	INDICATI	Hypocalcemia [ICD-11: 5B5K.1] Approved

D09KDV	TTDDRUID	D09KDV
D09KDV	DRUGNAME	Dihydroxyacetone
D09KDV	INDICATI	Sunburn [ICD-11: EJ40] Approved

D0L9YX	TTDDRUID	D0L9YX
D0L9YX	DRUGNAME	Dihydroxyaluminium
D0L9YX	INDICATI	Skin inflammation [ICD-11: EF20.Y] Approved

D02WAB	TTDDRUID	D02WAB
D02WAB	DRUGNAME	Diloxanide
D02WAB	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved

D0OB1J	TTDDRUID	D0OB1J
D0OB1J	DRUGNAME	Diltiazem
D0OB1J	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0U8UV	TTDDRUID	D0U8UV
D0U8UV	DRUGNAME	Dimenhydrinate
D0U8UV	INDICATI	Nausea [ICD-11: MD90] Approved

D0X2IE	TTDDRUID	D0X2IE
D0X2IE	DRUGNAME	Dimercaprol
D0X2IE	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D08CTT	TTDDRUID	D08CTT
D08CTT	DRUGNAME	Dimethindene
D08CTT	INDICATI	Respiratory allergy [ICD-11: 4A80] Approved

D08HVE	TTDDRUID	D08HVE
D08HVE	DRUGNAME	Dimethyl Sulfoxide
D08HVE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D04RGA	TTDDRUID	D04RGA
D04RGA	DRUGNAME	Dinoprost Tromethamine
D04RGA	INDICATI	Abortion [ICD-11: JA00] Approved

D06FEA	TTDDRUID	D06FEA
D06FEA	DRUGNAME	Dinoprostone
D06FEA	INDICATI	Medical abortion [ICD-11: JA00.1Z] Approved

D0X9XP	TTDDRUID	D0X9XP
D0X9XP	DRUGNAME	Diosmin
D0X9XP	INDICATI	Hemorrhoids [ICD-11: DB60] Approved

D0OK5Q	TTDDRUID	D0OK5Q
D0OK5Q	DRUGNAME	Diphemanil Methylsulfate
D0OK5Q	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D01FGR	TTDDRUID	D01FGR
D01FGR	DRUGNAME	Diphenhydramine
D01FGR	INDICATI	Meniere disease [ICD-11: AB31.0] Approved

D0W9VB	TTDDRUID	D0W9VB
D0W9VB	DRUGNAME	Diphenidol
D0W9VB	INDICATI	Nausea [ICD-11: MD90] Approved

D0J2TN	TTDDRUID	D0J2TN
D0J2TN	DRUGNAME	Diphenoxylate
D0J2TN	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0W6DY	TTDDRUID	D0W6DY
D0W6DY	DRUGNAME	Diphenylpyraline
D0W6DY	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0P0YT	TTDDRUID	D0P0YT
D0P0YT	DRUGNAME	Diphtheria antitoxin
D0P0YT	INDICATI	Corynebacterium diphtheriae infection [ICD-11: 1C17.Z] Approved

D04OLA	TTDDRUID	D04OLA
D04OLA	DRUGNAME	Diphtheria toxoid adsorbed
D04OLA	INDICATI	Corynebacterium diphtheriae infection [ICD-11: 1C17.Z] Approved

D0DR6Q	TTDDRUID	D0DR6Q
D0DR6Q	DRUGNAME	Diphtheria, tetanus, acellular pertussis vaccine
D0DR6Q	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0D5AR	TTDDRUID	D0D5AR
D0D5AR	DRUGNAME	Diphtheria/tetanus toxoids
D0D5AR	INDICATI	Clostridium infection [ICD-11: 1A04] Approved

D0B6GW	TTDDRUID	D0B6GW
D0B6GW	DRUGNAME	Diphtheria-tetanus vaccine
D0B6GW	INDICATI	Clostridium infection [ICD-11: 1A04] Approved

D01JFT	TTDDRUID	D01JFT
D01JFT	DRUGNAME	Dipivefrin
D01JFT	INDICATI	Chronic open-angle glaucoma [ICD-11: 9C61.0] Approved

D0F9GE	TTDDRUID	D0F9GE
D0F9GE	DRUGNAME	Dipyridamole
D0F9GE	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06ZUP	TTDDRUID	D06ZUP
D06ZUP	DRUGNAME	Dirithromycin
D06ZUP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0M4YC	TTDDRUID	D0M4YC
D0M4YC	DRUGNAME	Disopyramide
D0M4YC	INDICATI	Urinary incontinence [ICD-11: MF50.2] Withdrawn from market
D0M4YC	INDICATI	Ventricular arrhythmias [ICD-11: BC71] Approved

D0X5SD	TTDDRUID	D0X5SD
D0X5SD	DRUGNAME	Disulfiram
D0X5SD	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved

D0QO7H	TTDDRUID	D0QO7H
D0QO7H	DRUGNAME	Dithranol cream
D0QO7H	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D03LGY	TTDDRUID	D03LGY
D03LGY	DRUGNAME	Divalproex sodium
D03LGY	INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved

D0RU6U	TTDDRUID	D0RU6U
D0RU6U	DRUGNAME	Dixyrazine
D0RU6U	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0J7RK	TTDDRUID	D0J7RK
D0J7RK	DRUGNAME	Dobutamine
D0J7RK	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D0K2TB	TTDDRUID	D0K2TB
D0K2TB	DRUGNAME	Docarpamine
D0K2TB	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0O5WP	TTDDRUID	D0O5WP
D0O5WP	DRUGNAME	Docetaxel
D0O5WP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D0O5WP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00AOJ	TTDDRUID	D00AOJ
D00AOJ	DRUGNAME	Docosanol
D00AOJ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved

D0X4FM	TTDDRUID	D0X4FM
D0X4FM	DRUGNAME	Docusate
D0X4FM	INDICATI	Constipation [ICD-11: DD91.1] Approved

D0NW3X	TTDDRUID	D0NW3X
D0NW3X	DRUGNAME	Dofetilide
D0NW3X	INDICATI	Sinus rhythm disorder [ICD-11: BC9Y] Approved

D00YLW	TTDDRUID	D00YLW
D00YLW	DRUGNAME	Dolasetron
D00YLW	INDICATI	Nausea [ICD-11: MD90] Approved

D00YZD	TTDDRUID	D00YZD
D00YZD	DRUGNAME	Dolutegravir
D00YZD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D00YZD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0AV3G	TTDDRUID	D0AV3G
D0AV3G	DRUGNAME	Domperidone
D0AV3G	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D0NS6H	TTDDRUID	D0NS6H
D0NS6H	DRUGNAME	Donepezil
D0NS6H	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0T7OW	TTDDRUID	D0T7OW
D0T7OW	DRUGNAME	Dopamine
D0T7OW	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 1
D0T7OW	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0V7XF	TTDDRUID	D0V7XF
D0V7XF	DRUGNAME	Dopexamine
D0V7XF	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Approved

D03QWT	TTDDRUID	D03QWT
D03QWT	DRUGNAME	Doripenem
D03QWT	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 3
D03QWT	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0JE4D	TTDDRUID	D0JE4D
D0JE4D	DRUGNAME	Dornase Alfa
D0JE4D	INDICATI	Cystic fibrosis [ICD-11: CA25] Approved

D0A7WT	TTDDRUID	D0A7WT
D0A7WT	DRUGNAME	Dornase alpha
D0A7WT	INDICATI	Cystic fibrosis [ICD-11: CA25] Approved

D05UYW	TTDDRUID	D05UYW
D05UYW	DRUGNAME	Dorzolamide
D05UYW	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D0K5SN	TTDDRUID	D0K5SN
D0K5SN	DRUGNAME	Dosmalfate
D0K5SN	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Approved

D0Q2MN	TTDDRUID	D0Q2MN
D0Q2MN	DRUGNAME	Dothiepin
D0Q2MN	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0Y7TO	TTDDRUID	D0Y7TO
D0Y7TO	DRUGNAME	Doxacurium
D0Y7TO	INDICATI	Spasm [ICD-11: MB47.3] Approved

D0M7BT	TTDDRUID	D0M7BT
D0M7BT	DRUGNAME	Doxapram
D0M7BT	INDICATI	Respiratory disease [ICD-11: CB40] Approved

D03MIR	TTDDRUID	D03MIR
D03MIR	DRUGNAME	Doxazosin
D03MIR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06FES	TTDDRUID	D06FES
D06FES	DRUGNAME	Doxepin
D06FES	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0G5CF	TTDDRUID	D0G5CF
D0G5CF	DRUGNAME	Doxercalciferol
D0G5CF	INDICATI	Chronic kidney disease [ICD-11: GB61] Approved

D03KXY	TTDDRUID	D03KXY
D03KXY	DRUGNAME	Doxifluridine
D03KXY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D07NCN	TTDDRUID	D07NCN
D07NCN	DRUGNAME	Doxofylline
D07NCN	INDICATI	Asthma [ICD-11: CA23] Approved

D07VLY	TTDDRUID	D07VLY
D07VLY	DRUGNAME	Doxorubicin
D07VLY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D07VLY	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Investigative

D0S0LZ	TTDDRUID	D0S0LZ
D0S0LZ	DRUGNAME	Doxycycline
D0S0LZ	INDICATI	Advanced gum disease [ICD-11: DA0D] Approved
D0S0LZ	INDICATI	Chronic periodontitis [ICD-11: DA0C.Y] Approved
D0S0LZ	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D0Y2LR	TTDDRUID	D0Y2LR
D0Y2LR	DRUGNAME	Doxylamine
D0Y2LR	INDICATI	Morning sickness [ICD-11: SC00] Approved

D0C2WV	TTDDRUID	D0C2WV
D0C2WV	DRUGNAME	DPT-HBV
D0C2WV	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0D9FW	TTDDRUID	D0D9FW
D0D9FW	DRUGNAME	DP-VPA
D0D9FW	INDICATI	Bipolar disorder [ICD-11: 6A60] Approved

D09NNA	TTDDRUID	D09NNA
D09NNA	DRUGNAME	Dromostanolone
D09NNA	INDICATI	Mammary tumour [ICD-11: 2C60-2C6Z] Approved

D05CPV	TTDDRUID	D05CPV
D05CPV	DRUGNAME	Dronedarone
D05CPV	INDICATI	Angina pectoris [ICD-11: BA40] Approved
D05CPV	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Withdrawn from market

D03CJL	TTDDRUID	D03CJL
D03CJL	DRUGNAME	Droperidol
D03CJL	INDICATI	Nausea [ICD-11: MD90] Approved

D0Z4ZT	TTDDRUID	D0Z4ZT
D0Z4ZT	DRUGNAME	Drospirenone
D0Z4ZT	INDICATI	Contraception [ICD-11: QA21] Approved

D06XAE	TTDDRUID	D06XAE
D06XAE	DRUGNAME	Drotaverine
D06XAE	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0PG0G	TTDDRUID	D0PG0G
D0PG0G	DRUGNAME	Drotrecogin alfa
D0PG0G	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved
D0PG0G	INDICATI	Severe sepsis [ICD-11: 1G40-1G41] Approved

D0I3RO	TTDDRUID	D0I3RO
D0I3RO	DRUGNAME	Droxidopa
D0I3RO	INDICATI	Neurogenic orthostatic hypotension [ICD-11: 8D87.0Y] Approved

D0R4NY	TTDDRUID	D0R4NY
D0R4NY	DRUGNAME	DTaP-IPV
D0R4NY	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D01OXI	TTDDRUID	D01OXI
D01OXI	DRUGNAME	DTI-015
D01OXI	INDICATI	Brain cancer [ICD-11: 2A00] Approved
D01OXI	INDICATI	Liver cancer [ICD-11: 2C12] Approved

D0W5MX	TTDDRUID	D0W5MX
D0W5MX	DRUGNAME	DTP vaccine
D0W5MX	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0C3BS	TTDDRUID	D0C3BS
D0C3BS	DRUGNAME	DU-176b
D0C3BS	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved

D0G2ZG	TTDDRUID	D0G2ZG
D0G2ZG	DRUGNAME	Duac low dose
D0G2ZG	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D06QGH	TTDDRUID	D06QGH
D06QGH	DRUGNAME	Dukoral
D06QGH	INDICATI	Escherichia coli infection [ICD-11: 1A03] Approved

D03NAW	TTDDRUID	D03NAW
D03NAW	DRUGNAME	Dulaglutide
D03NAW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D01AXB	TTDDRUID	D01AXB
D01AXB	DRUGNAME	Duloxetine
D01AXB	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D07FUP	TTDDRUID	D07FUP
D07FUP	DRUGNAME	Dupilumab
D07FUP	INDICATI	Asthma [ICD-11: CA23] Phase 3
D07FUP	INDICATI	Atopic dermatitis [ICD-11: EA80] Approved

D0LS9E	TTDDRUID	D0LS9E
D0LS9E	DRUGNAME	Durvalumab
D0LS9E	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Approved

D0A9YA	TTDDRUID	D0A9YA
D0A9YA	DRUGNAME	Dutasteride
D0A9YA	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
D0A9YA	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0J3BU	TTDDRUID	D0J3BU
D0J3BU	DRUGNAME	Duteplase
D0J3BU	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D04QLR	TTDDRUID	D04QLR
D04QLR	DRUGNAME	Dyclonine
D04QLR	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0F1UL	TTDDRUID	D0F1UL
D0F1UL	DRUGNAME	Dydrogesterone
D0F1UL	INDICATI	Menstrual disorder [ICD-11: GA20.3] Approved

D02PWM	TTDDRUID	D02PWM
D02PWM	DRUGNAME	Dyphylline
D02PWM	INDICATI	Acute bronchial asthma [ICD-11: CA23] Approved

D0U3ED	TTDDRUID	D0U3ED
D0U3ED	DRUGNAME	E-2007
D0U3ED	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Approved
D0U3ED	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 3

D0T8KD	TTDDRUID	D0T8KD
D0T8KD	DRUGNAME	Eberconazole
D0T8KD	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0B1FE	TTDDRUID	D0B1FE
D0B1FE	DRUGNAME	Ebselen
D0B1FE	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Approved

D01CKY	TTDDRUID	D01CKY
D01CKY	DRUGNAME	Ecabet sodium
D01CKY	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
D01CKY	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2

D0P5AE	TTDDRUID	D0P5AE
D0P5AE	DRUGNAME	Ecallantide
D0P5AE	INDICATI	Retina venous occlusion [ICD-11: 9B74.1] Approved

D09JJU	TTDDRUID	D09JJU
D09JJU	DRUGNAME	EchiTAb
D09JJU	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D0U8AT	TTDDRUID	D0U8AT
D0U8AT	DRUGNAME	Echothiophate Iodide
D0U8AT	INDICATI	Chronic glaucoma [ICD-11: 9C61.0Z] Approved

D0A7GX	TTDDRUID	D0A7GX
D0A7GX	DRUGNAME	Echovist
D0A7GX	INDICATI	Gynecological disease [ICD-11: GA6Z] Approved

D0EV8E	TTDDRUID	D0EV8E
D0EV8E	DRUGNAME	Econazole
D0EV8E	INDICATI	Cutaneous candidiasis [ICD-11: 1F23.14] Approved
D0EV8E	INDICATI	Tinea corporis [ICD-11: 1F28.Y] Approved
D0EV8E	INDICATI	Tinea cruris [ICD-11: 1F28.3] Approved
D0EV8E	INDICATI	Tinea pedis [ICD-11: 1F28.2] Approved
D0EV8E	INDICATI	Tinea versicolor [ICD-11: 1F2D.0] Approved

D01RQV	TTDDRUID	D01RQV
D01RQV	DRUGNAME	Eculizumab
D01RQV	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Approved

D00PRI	TTDDRUID	D00PRI
D00PRI	DRUGNAME	Edetate calcium disodium
D00PRI	INDICATI	Toxicity [ICD-11: N.A.] Approved

D08RIB	TTDDRUID	D08RIB
D08RIB	DRUGNAME	Edetate disodium
D08RIB	INDICATI	Heart arrhythmia [ICD-11: BC65] Approved

D0SL8X	TTDDRUID	D0SL8X
D0SL8X	DRUGNAME	Edoxaban tosylate
D0SL8X	INDICATI	Embolism [ICD-11: JB42] Approved
D0SL8X	INDICATI	Stroke [ICD-11: 8B20] Approved
D0SL8X	INDICATI	Venous thromboembolism [ICD-11: BD72] Approved

D0S5LH	TTDDRUID	D0S5LH
D0S5LH	DRUGNAME	Edrophonium
D0S5LH	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved

D09PLI	TTDDRUID	D09PLI
D09PLI	DRUGNAME	Efalith
D09PLI	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D03SGR	TTDDRUID	D03SGR
D03SGR	DRUGNAME	Efalizumab
D03SGR	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
D03SGR	INDICATI	Renal transplantation [ICD-11: NE84] Phase 2

D07HVY	TTDDRUID	D07HVY
D07HVY	DRUGNAME	Efavirenz
D07HVY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0G4BI	TTDDRUID	D0G4BI
D0G4BI	DRUGNAME	Efinaconazole
D0G4BI	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0X7JR	TTDDRUID	D0X7JR
D0X7JR	DRUGNAME	Eflornithine
D0X7JR	INDICATI	African trypanosomiasis [ICD-11: 1F51] Approved

D0EL2O	TTDDRUID	D0EL2O
D0EL2O	DRUGNAME	Egualen sodium
D0EL2O	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved

D0VG7Y	TTDDRUID	D0VG7Y
D0VG7Y	DRUGNAME	Elagolix sodium
D0VG7Y	INDICATI	Endometriosis [ICD-11: GA10] Approved

D01VEJ	TTDDRUID	D01VEJ
D01VEJ	DRUGNAME	Elapegademase
D01VEJ	INDICATI	Adenosine deaminase defciency [ICD-11: 4A01.1] Approved

D0I0AW	TTDDRUID	D0I0AW
D0I0AW	DRUGNAME	elbasvir + grazoprevir
D0I0AW	INDICATI	HCV-1 and HCV-4 infection [ICD-11: 1E51] Approved

D03WWG	TTDDRUID	D03WWG
D03WWG	DRUGNAME	Elcatonin
D03WWG	INDICATI	Disorder of calcium metabolism [ICD-11: 5C64.5] Approved

D02DMQ	TTDDRUID	D02DMQ
D02DMQ	DRUGNAME	Eletriptan
D02DMQ	INDICATI	Migraine [ICD-11: 8A80] Approved

D0J8IJ	TTDDRUID	D0J8IJ
D0J8IJ	DRUGNAME	Eliglustat tartrate
D0J8IJ	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Approved

D0JO3U	TTDDRUID	D0JO3U
D0JO3U	DRUGNAME	Elliptinium acetate
D0JO3U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0UQ1R	TTDDRUID	D0UQ1R
D0UQ1R	DRUGNAME	Eloctate
D0UQ1R	INDICATI	Haemophilia A [ICD-11: 3B10.0] Approved

D0J1UA	TTDDRUID	D0J1UA
D0J1UA	DRUGNAME	Elosulfase alfa
D0J1UA	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved

D05DZR	TTDDRUID	D05DZR
D05DZR	DRUGNAME	Elotuzumab
D05DZR	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D00PEH	TTDDRUID	D00PEH
D00PEH	DRUGNAME	Eltrombopag
D00PEH	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3
D00PEH	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved

D09ZXR	TTDDRUID	D09ZXR
D09ZXR	DRUGNAME	Eluxadoline
D09ZXR	INDICATI	Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Approved

D0QD1G	TTDDRUID	D0QD1G
D0QD1G	DRUGNAME	Elvitegravir
D0QD1G	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0MM2L	TTDDRUID	D0MM2L
D0MM2L	DRUGNAME	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
D0MM2L	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D0MM2L	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0UI7K	TTDDRUID	D0UI7K
D0UI7K	DRUGNAME	Emapalumab
D0UI7K	INDICATI	Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Approved

D00IDP	TTDDRUID	D00IDP
D00IDP	DRUGNAME	Emdogain
D00IDP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D02XJI	TTDDRUID	D02XJI
D02XJI	DRUGNAME	Emedastine
D02XJI	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D0W2AN	TTDDRUID	D0W2AN
D0W2AN	DRUGNAME	Emepronium
D0W2AN	INDICATI	Urinary incontinence [ICD-11: MF50.2] Approved

D07DJQ	TTDDRUID	D07DJQ
D07DJQ	DRUGNAME	Emetine
D07DJQ	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved

D09XTN	TTDDRUID	D09XTN
D09XTN	DRUGNAME	Emicizumab
D09XTN	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Approved

D06ALD	TTDDRUID	D06ALD
D06ALD	DRUGNAME	Empagliflozin
D06ALD	INDICATI	Type-1 diabetes [ICD-11: 5A10] Approved

D0P7PD	TTDDRUID	D0P7PD
D0P7PD	DRUGNAME	Empagliflozin/linagliptin
D0P7PD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0S9SD	TTDDRUID	D0S9SD
D0S9SD	DRUGNAME	Emtricitabine
D0S9SD	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
D0S9SD	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved
D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D00SEB	TTDDRUID	D00SEB
D00SEB	DRUGNAME	Enalapril
D00SEB	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0N5HJ	TTDDRUID	D0N5HJ
D0N5HJ	DRUGNAME	Enalaprilat
D0N5HJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0WH4P	TTDDRUID	D0WH4P
D0WH4P	DRUGNAME	ENASIDENIB MESYLATE
D0WH4P	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D05LTY	TTDDRUID	D05LTY
D05LTY	DRUGNAME	Enbrel
D05LTY	INDICATI	Arthritis [ICD-11: FA20] Approved

D0AO9S	TTDDRUID	D0AO9S
D0AO9S	DRUGNAME	Enflurane
D0AO9S	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D06GBQ	TTDDRUID	D06GBQ
D06GBQ	DRUGNAME	Enfuvirtide
D06GBQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0D2IU	TTDDRUID	D0D2IU
D0D2IU	DRUGNAME	Engerix B
D0D2IU	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D00STJ	TTDDRUID	D00STJ
D00STJ	DRUGNAME	Enocitabine
D00STJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0R8ER	TTDDRUID	D0R8ER
D0R8ER	DRUGNAME	Enoxacin
D0R8ER	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0MX5S	TTDDRUID	D0MX5S
D0MX5S	DRUGNAME	Enoxaparin
D0MX5S	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
D0MX5S	INDICATI	Venous thrombosis [ICD-11: BA43] Approved

D0E0SW	TTDDRUID	D0E0SW
D0E0SW	DRUGNAME	Enoximone
D0E0SW	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D09AMZ	TTDDRUID	D09AMZ
D09AMZ	DRUGNAME	Enprofylline
D09AMZ	INDICATI	Asthma [ICD-11: CA23] Approved

D0QQ6Q	TTDDRUID	D0QQ6Q
D0QQ6Q	DRUGNAME	Enprostil
D0QQ6Q	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved

D0J1VY	TTDDRUID	D0J1VY
D0J1VY	DRUGNAME	Entacapone
D0J1VY	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0KR2J	TTDDRUID	D0KR2J
D0KR2J	DRUGNAME	Entecavir
D0KR2J	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D06MRY	TTDDRUID	D06MRY
D06MRY	DRUGNAME	Enteric-coated mycophenolate sodium
D06MRY	INDICATI	Transplant rejection [ICD-11: NE84] Approved

D0QK5X	TTDDRUID	D0QK5X
D0QK5X	DRUGNAME	Enzalutamide
D0QK5X	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D03KOZ	TTDDRUID	D03KOZ
D03KOZ	DRUGNAME	Epalrestat
D03KOZ	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Approved
D03KOZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0G7WY	TTDDRUID	D0G7WY
D0G7WY	DRUGNAME	Epanova
D0G7WY	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Approved

D01XTN	TTDDRUID	D01XTN
D01XTN	DRUGNAME	Epaxal
D01XTN	INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved

D0R2KF	TTDDRUID	D0R2KF
D0R2KF	DRUGNAME	Epervudine
D0R2KF	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0LG8E	TTDDRUID	D0LG8E
D0LG8E	DRUGNAME	Ephedrine
D0LG8E	INDICATI	Asthma [ICD-11: CA23] Approved

D0UA2Z	TTDDRUID	D0UA2Z
D0UA2Z	DRUGNAME	Epicillin
D0UA2Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D08TPS	TTDDRUID	D08TPS
D08TPS	DRUGNAME	Epidermal growth factor
D08TPS	INDICATI	Vulnerary [ICD-11: ND56.Z] Approved
D08TPS	INDICATI	Wound healing [ICD-11: EL8Y] Phase 2

D0DV3O	TTDDRUID	D0DV3O
D0DV3O	DRUGNAME	Epinastine
D0DV3O	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D04PHC	TTDDRUID	D04PHC
D04PHC	DRUGNAME	Epinephrine
D04PHC	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D09NIB	TTDDRUID	D09NIB
D09NIB	DRUGNAME	Epipodophyllotoxin
D09NIB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0C9XJ	TTDDRUID	D0C9XJ
D0C9XJ	DRUGNAME	Epirubicin
D0C9XJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Q4SD	TTDDRUID	D0Q4SD
D0Q4SD	DRUGNAME	Eplerenone
D0Q4SD	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D07PBZ	TTDDRUID	D07PBZ
D07PBZ	DRUGNAME	Epoetin alfa
D07PBZ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D0Q7RA	TTDDRUID	D0Q7RA
D0Q7RA	DRUGNAME	Epoietin delta
D0Q7RA	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved

D0V0IX	TTDDRUID	D0V0IX
D0V0IX	DRUGNAME	Epoprostenol
D0V0IX	INDICATI	Pulmonary hypertension [ICD-11: BB01] Approved

D0T7US	TTDDRUID	D0T7US
D0T7US	DRUGNAME	Eprosartan
D0T7US	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0YC7U	TTDDRUID	D0YC7U
D0YC7U	DRUGNAME	Eptaplatin
D0YC7U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D03XES	TTDDRUID	D03XES
D03XES	DRUGNAME	Eptazocine hbr
D03XES	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D09ZIO	TTDDRUID	D09ZIO
D09ZIO	DRUGNAME	Eptifibatide
D09ZIO	INDICATI	Acute cardiac ischemic events [ICD-11: BA40.Z] Approved

D0K3VA	TTDDRUID	D0K3VA
D0K3VA	DRUGNAME	Erdosteine
D0K3VA	INDICATI	Bronchitis [ICD-11: CA20] Approved

D0KX1Y	TTDDRUID	D0KX1Y
D0KX1Y	DRUGNAME	Erenumab
D0KX1Y	INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved

D06JPB	TTDDRUID	D06JPB
D06JPB	DRUGNAME	Ergocalciferol
D06JPB	INDICATI	Hypoparathyroidism [ICD-11: 5A50] Approved

D02IQY	TTDDRUID	D02IQY
D02IQY	DRUGNAME	Ergoloid mesylate
D02IQY	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0C1IW	TTDDRUID	D0C1IW
D0C1IW	DRUGNAME	Ergonovine
D0C1IW	INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved

D01TSI	TTDDRUID	D01TSI
D01TSI	DRUGNAME	Ergotamine
D01TSI	INDICATI	Headache [ICD-11: 8A80-8A84] Approved

D04USC	TTDDRUID	D04USC
D04USC	DRUGNAME	Ergotidine
D04USC	INDICATI	Respiratory allergy [ICD-11: 4A80] Approved

D0KK2E	TTDDRUID	D0KK2E
D0KK2E	DRUGNAME	Eribulin
D0KK2E	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D07POC	TTDDRUID	D07POC
D07POC	DRUGNAME	Erlotinib
D07POC	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 2
D07POC	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
D07POC	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0Q1MS	TTDDRUID	D0Q1MS
D0Q1MS	DRUGNAME	Ertapenem
D0Q1MS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06IZM	TTDDRUID	D06IZM
D06IZM	DRUGNAME	Erythrityl Tetranitrate
D06IZM	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D02YIZ	TTDDRUID	D02YIZ
D02YIZ	DRUGNAME	Erythromycin
D02YIZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0TG7I	TTDDRUID	D0TG7I
D0TG7I	DRUGNAME	Erythromycin/sulfisoxazole
D0TG7I	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved

D0DE4U	TTDDRUID	D0DE4U
D0DE4U	DRUGNAME	Erythropoietin beta
D0DE4U	INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Approved

D08RBC	TTDDRUID	D08RBC
D08RBC	DRUGNAME	Escitalopram
D08RBC	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D04QZD	TTDDRUID	D04QZD
D04QZD	DRUGNAME	Eslicarbazepine
D04QZD	INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved

D03XTC	TTDDRUID	D03XTC
D03XTC	DRUGNAME	Esmolol
D03XTC	INDICATI	Acute supraventricular tachycardia [ICD-11: BC81] Approved

D0C6DT	TTDDRUID	D0C6DT
D0C6DT	DRUGNAME	Esomeprazole
D0C6DT	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D0P2CK	TTDDRUID	D0P2CK
D0P2CK	DRUGNAME	Estazolam
D0P2CK	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0R6RE	TTDDRUID	D0R6RE
D0R6RE	DRUGNAME	Esterified estrogens
D0R6RE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D08QMX	TTDDRUID	D08QMX
D08QMX	DRUGNAME	Estradiol
D08QMX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0T7ZQ	TTDDRUID	D0T7ZQ
D0T7ZQ	DRUGNAME	Estradiol Acetate
D0T7ZQ	INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved

D0U0XD	TTDDRUID	D0U0XD
D0U0XD	DRUGNAME	Estradiol Cypionate
D0U0XD	INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved

D07VBA	TTDDRUID	D07VBA
D07VBA	DRUGNAME	Estradiol Valerate
D07VBA	INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved

D03SRY	TTDDRUID	D03SRY
D03SRY	DRUGNAME	Estramustine
D03SRY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0Z1FX	TTDDRUID	D0Z1FX
D0Z1FX	DRUGNAME	Estriol
D0Z1FX	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved

D0M8PD	TTDDRUID	D0M8PD
D0M8PD	DRUGNAME	Estrogen
D0M8PD	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D00ZFP	TTDDRUID	D00ZFP
D00ZFP	DRUGNAME	Estrone
D00ZFP	INDICATI	Menopausal and postmenopausal disorder [ICD-11: GA30] Approved

D03IUY	TTDDRUID	D03IUY
D03IUY	DRUGNAME	Estropipate
D03IUY	INDICATI	Hypogonadism [ICD-11: 5A61.0] Approved

D06ZII	TTDDRUID	D06ZII
D06ZII	DRUGNAME	Eszopiclone
D06ZII	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0I5QX	TTDDRUID	D0I5QX
D0I5QX	DRUGNAME	Etanercept
D0I5QX	INDICATI	Arthritis [ICD-11: FA20] Approved
D0I5QX	INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 2
D0I5QX	INDICATI	Sciatica [ICD-11: ME84.3] Phase 3

D0LJ6P	TTDDRUID	D0LJ6P
D0LJ6P	DRUGNAME	Etanidazole
D0LJ6P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D07RYI	TTDDRUID	D07RYI
D07RYI	DRUGNAME	Etelcalcetide
D07RYI	INDICATI	Secondary hyperparathyroidism [ICD-11: 5A51.1] Approved

D04AIV	TTDDRUID	D04AIV
D04AIV	DRUGNAME	Eteplirsen
D04AIV	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Approved

D0E3WQ	TTDDRUID	D0E3WQ
D0E3WQ	DRUGNAME	Eterobarb
D0E3WQ	INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved

D0W5UV	TTDDRUID	D0W5UV
D0W5UV	DRUGNAME	Ethacrynate Sodium
D0W5UV	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0V1QC	TTDDRUID	D0V1QC
D0V1QC	DRUGNAME	Ethacrynic
D0V1QC	INDICATI	Edema [ICD-11: MG29] Approved

D06TNL	TTDDRUID	D06TNL
D06TNL	DRUGNAME	Ethacrynic acid
D06TNL	INDICATI	High blood pressure [ICD-11: BA00] Approved

D08QME	TTDDRUID	D08QME
D08QME	DRUGNAME	Ethambutol
D08QME	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved

D0YF3X	TTDDRUID	D0YF3X
D0YF3X	DRUGNAME	Ethamsylate
D0YF3X	INDICATI	Menorrhagia [ICD-11: GA20.50] Approved

D00AMQ	TTDDRUID	D00AMQ
D00AMQ	DRUGNAME	Ethanol
D00AMQ	INDICATI	Chronic pain [ICD-11: MG30] Approved
D00AMQ	INDICATI	Cystitis [ICD-11: GC00] Approved

D0O1PH	TTDDRUID	D0O1PH
D0O1PH	DRUGNAME	Ethanolamine oleate
D0O1PH	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D03VZH	TTDDRUID	D03VZH
D03VZH	DRUGNAME	Ethchlorvynol
D03VZH	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0CK3G	TTDDRUID	D0CK3G
D0CK3G	DRUGNAME	Ethinamate
D0CK3G	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D06NXY	TTDDRUID	D06NXY
D06NXY	DRUGNAME	Ethinyl Estradiol
D06NXY	INDICATI	Female hypogonadism [ICD-11: GA30.6] Approved

D01DGN	TTDDRUID	D01DGN
D01DGN	DRUGNAME	Ethiodized oil
D01DGN	INDICATI	Lymphatic disease [ICD-11: BD9Z] Approved

D0P0HB	TTDDRUID	D0P0HB
D0P0HB	DRUGNAME	Ethionamide
D0P0HB	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D0Q0RC	TTDDRUID	D0Q0RC
D0Q0RC	DRUGNAME	Ethopropazine
D0Q0RC	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0Q4XQ	TTDDRUID	D0Q4XQ
D0Q4XQ	DRUGNAME	Ethosuximide
D0Q4XQ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D05EPM	TTDDRUID	D05EPM
D05EPM	DRUGNAME	Ethotoin
D05EPM	INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved

D07INV	TTDDRUID	D07INV
D07INV	DRUGNAME	Ethoxzolamide
D07INV	INDICATI	Duodenal ulcer [ICD-11: DA63] Withdrawn from market
D07INV	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D05KEZ	TTDDRUID	D05KEZ
D05KEZ	DRUGNAME	Ethyl chloride
D05KEZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0SC8F	TTDDRUID	D0SC8F
D0SC8F	DRUGNAME	Ethylestrenol
D0SC8F	INDICATI	Testosterone deficiency [ICD-11: 5A81.1] Approved

D0R2KY	TTDDRUID	D0R2KY
D0R2KY	DRUGNAME	Ethynodiol Diacetate
D0R2KY	INDICATI	Contraception [ICD-11: QA21] Approved

D09VOS	TTDDRUID	D09VOS
D09VOS	DRUGNAME	ETI-204
D09VOS	INDICATI	Anthrax [ICD-11: 1B97] Approved

D0G7DJ	TTDDRUID	D0G7DJ
D0G7DJ	DRUGNAME	Etidocaine
D0G7DJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D00XUN	TTDDRUID	D00XUN
D00XUN	DRUGNAME	Etidronate Disodium
D00XUN	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D00NNC	TTDDRUID	D00NNC
D00NNC	DRUGNAME	Etidronic acid
D00NNC	INDICATI	Paget's disease [ICD-11: FB85] Approved

D0N1WU	TTDDRUID	D0N1WU
D0N1WU	DRUGNAME	Etodolac
D0N1WU	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D09YVX	TTDDRUID	D09YVX
D09YVX	DRUGNAME	Etofenamate
D09YVX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D02YPG	TTDDRUID	D02YPG
D02YPG	DRUGNAME	Etomidate
D02YPG	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D02KIU	TTDDRUID	D02KIU
D02KIU	DRUGNAME	Etonogestrel
D02KIU	INDICATI	Contraception [ICD-11: QA21] Approved

D0B7EB	TTDDRUID	D0B7EB
D0B7EB	DRUGNAME	Etoposide
D0B7EB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D09MGR	TTDDRUID	D09MGR
D09MGR	DRUGNAME	Etoricoxib
D09MGR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0Q2AS	TTDDRUID	D0Q2AS
D0Q2AS	DRUGNAME	Etozolin
D0Q2AS	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0BP9C	TTDDRUID	D0BP9C
D0BP9C	DRUGNAME	Etravirine
D0BP9C	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved

D0B1IP	TTDDRUID	D0B1IP
D0B1IP	DRUGNAME	Etretinate
D0B1IP	INDICATI	Keratosis [ICD-11: ED56] Approved

D06GCK	TTDDRUID	D06GCK
D06GCK	DRUGNAME	Eupatilin
D06GCK	INDICATI	Chronic diarrhoea [ICD-11: 1A36.0Z] Approved
D06GCK	INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved

D0P2CS	TTDDRUID	D0P2CS
D0P2CS	DRUGNAME	EVANS BLUE
D0P2CS	INDICATI	Abdominal aortic aneurysm [ICD-11: BD50.4] Approved

D0K3QS	TTDDRUID	D0K3QS
D0K3QS	DRUGNAME	Everolimus
D0K3QS	INDICATI	Kidney cancer [ICD-11: 2C90.0] Phase 3
D0K3QS	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D0D2VS	TTDDRUID	D0D2VS
D0D2VS	DRUGNAME	Exemestane
D0D2VS	INDICATI	Hormonally-responsive breast cancer [ICD-11: 2C60-2C65] Approved

D00YVF	TTDDRUID	D00YVF
D00YVF	DRUGNAME	Exenatide
D00YVF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0Q5UQ	TTDDRUID	D0Q5UQ
D0Q5UQ	DRUGNAME	Exjade
D0Q5UQ	INDICATI	Iron overload disease [ICD-11: 5C64.10] Approved

D0K2FH	TTDDRUID	D0K2FH
D0K2FH	DRUGNAME	Extract of serenoa repens
D0K2FH	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D01MMB	TTDDRUID	D01MMB
D01MMB	DRUGNAME	Extrothyroxine
D01MMB	INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Approved

D09LWS	TTDDRUID	D09LWS
D09LWS	DRUGNAME	Ezetimibe
D09LWS	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D00PRY	TTDDRUID	D00PRY
D00PRY	DRUGNAME	Ezogabine extended release
D00PRY	INDICATI	Behcet disease [ICD-11: 4A62] Approved

D07TRF	TTDDRUID	D07TRF
D07TRF	DRUGNAME	F18-florbetaben
D07TRF	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D06XOT	TTDDRUID	D06XOT
D06XOT	DRUGNAME	F18-flutemetamol
D06XOT	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0M2BR	TTDDRUID	D0M2BR
D0M2BR	DRUGNAME	Factor 8
D0M2BR	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D0V0RY	TTDDRUID	D0V0RY
D0V0RY	DRUGNAME	Factor ix human
D0V0RY	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D0C9IW	TTDDRUID	D0C9IW
D0C9IW	DRUGNAME	Factor viia
D0C9IW	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D01THX	TTDDRUID	D01THX
D01THX	DRUGNAME	Factor viii
D01THX	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D0ZX1P	TTDDRUID	D0ZX1P
D0ZX1P	DRUGNAME	FADROZOLE
D0ZX1P	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D01UFN	TTDDRUID	D01UFN
D01UFN	DRUGNAME	Falecalcitrol
D01UFN	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Approved

D0VT8P	TTDDRUID	D0VT8P
D0VT8P	DRUGNAME	Famciclovir
D0VT8P	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0K0OZ	TTDDRUID	D0K0OZ
D0K0OZ	DRUGNAME	Famotidine
D0K0OZ	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D02IIW	TTDDRUID	D02IIW
D02IIW	DRUGNAME	Faropenem
D02IIW	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved

D04IWT	TTDDRUID	D04IWT
D04IWT	DRUGNAME	Fat emulsion
D04IWT	INDICATI	Nutritional deficiency [ICD-11: 5B50-5B71] Approved

D0E9WO	TTDDRUID	D0E9WO
D0E9WO	DRUGNAME	Febarbamate
D0E9WO	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D0A5SE	TTDDRUID	D0A5SE
D0A5SE	DRUGNAME	Febuxostat
D0A5SE	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved

D05KON	TTDDRUID	D05KON
D05KON	DRUGNAME	Felbamate
D05KON	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D0Y7EM	TTDDRUID	D0Y7EM
D0Y7EM	DRUGNAME	Felbinac
D0Y7EM	INDICATI	Arthritis [ICD-11: FA20] Approved

D0WN0U	TTDDRUID	D0WN0U
D0WN0U	DRUGNAME	Felodipine
D0WN0U	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0H3MG	TTDDRUID	D0H3MG
D0H3MG	DRUGNAME	Felypressin
D0H3MG	INDICATI	Localisation [ICD-11: N.A.] Approved

D06LHG	TTDDRUID	D06LHG
D06LHG	DRUGNAME	FENBUFEN
D06LHG	INDICATI	Arthritis [ICD-11: FA20] Approved

D0TL1L	TTDDRUID	D0TL1L
D0TL1L	DRUGNAME	Fendrix
D0TL1L	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0D0GV	TTDDRUID	D0D0GV
D0D0GV	DRUGNAME	Fenhexamid
D0D0GV	INDICATI	Plant grey mould disease [ICD-11: N.A.] Approved

D07XGR	TTDDRUID	D07XGR
D07XGR	DRUGNAME	Fenofibrate
D07XGR	INDICATI	High cholesterol level [ICD-11: 5C80.0] Approved

D0NF1U	TTDDRUID	D0NF1U
D0NF1U	DRUGNAME	FENOFIBRIC ACID
D0NF1U	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0R6BI	TTDDRUID	D0R6BI
D0R6BI	DRUGNAME	Fenoldopam
D0R6BI	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03XYW	TTDDRUID	D03XYW
D03XYW	DRUGNAME	Fenoprofen
D03XYW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D04XEG	TTDDRUID	D04XEG
D04XEG	DRUGNAME	Fenoterol
D04XEG	INDICATI	Asthma [ICD-11: CA23] Approved

D02WUC	TTDDRUID	D02WUC
D02WUC	DRUGNAME	Fenquizone
D02WUC	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0E1WI	TTDDRUID	D0E1WI
D0E1WI	DRUGNAME	Fentanyl
D0E1WI	INDICATI	Analgesia [ICD-11: MB40.8] Approved

D0Z5QI	TTDDRUID	D0Z5QI
D0Z5QI	DRUGNAME	Fentanyl/droperidol
D0Z5QI	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0YB1G	TTDDRUID	D0YB1G
D0YB1G	DRUGNAME	Fentiazac
D0YB1G	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved

D0Y1KF	TTDDRUID	D0Y1KF
D0Y1KF	DRUGNAME	Feraheme/Rienso
D0Y1KF	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved

D04CJL	TTDDRUID	D04CJL
D04CJL	DRUGNAME	Ferric citrate
D04CJL	INDICATI	Chronic kidney disease [ICD-11: GB61] Approved

D0L9BK	TTDDRUID	D0L9BK
D0L9BK	DRUGNAME	Ferric Hexacyanoferrate(II)
D0L9BK	INDICATI	Thllium and radioactive isotopes of caesium poisoning [ICD-11: NE61] Approved

D0W5BS	TTDDRUID	D0W5BS
D0W5BS	DRUGNAME	FerriSeltz
D0W5BS	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D01EKQ	TTDDRUID	D01EKQ
D01EKQ	DRUGNAME	Ferrous Citrate, Fe-59
D01EKQ	INDICATI	Iron deficiency [ICD-11: 5B5K.0] Approved

D08QAC	TTDDRUID	D08QAC
D08QAC	DRUGNAME	Ferumoxides
D08QAC	INDICATI	Liver cancer [ICD-11: 2C12] Approved
D08QAC	INDICATI	Liver disease [ICD-11: DB90-BD99] Approved

D06CTM	TTDDRUID	D06CTM
D06CTM	DRUGNAME	Ferumoxytol
D06CTM	INDICATI	Chronic kidney disease [ICD-11: GB61] Approved

D00BLL	TTDDRUID	D00BLL
D00BLL	DRUGNAME	Fesoterodine fumarate
D00BLL	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D01KPV	TTDDRUID	D01KPV
D01KPV	DRUGNAME	Fexofenadine
D01KPV	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0E5UK	TTDDRUID	D0E5UK
D0E5UK	DRUGNAME	Fibrin Sealant
D0E5UK	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D0V4JR	TTDDRUID	D0V4JR
D0V4JR	DRUGNAME	Fibrinogen
D0V4JR	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
D0V4JR	INDICATI	Pulmonary embolism [ICD-11: BB00] Approved

D0O9CF	TTDDRUID	D0O9CF
D0O9CF	DRUGNAME	Fibrinogen, I-125
D0O9CF	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D0J0KD	TTDDRUID	D0J0KD
D0J0KD	DRUGNAME	Fibrinolysin
D0J0KD	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D06LNW	TTDDRUID	D06LNW
D06LNW	DRUGNAME	Fidaxomicin
D06LNW	INDICATI	Clostridium difficile associated diarrhea [ICD-11: 1A04] Approved

D02VVS	TTDDRUID	D02VVS
D02VVS	DRUGNAME	Filgrastim
D02VVS	INDICATI	Neutropenia [ICD-11: 4B00.0] Approved

D07WKC	TTDDRUID	D07WKC
D07WKC	DRUGNAME	Filgrastim-SNDZ
D07WKC	INDICATI	Neutropenia [ICD-11: 4B00.0] Approved

D01IXD	TTDDRUID	D01IXD
D01IXD	DRUGNAME	Finafloxacin
D01IXD	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D08IWD	TTDDRUID	D08IWD
D08IWD	DRUGNAME	Finasteride
D08IWD	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D07UHS	TTDDRUID	D07UHS
D07UHS	DRUGNAME	Fingolimod
D07UHS	INDICATI	Primary progressive multiple sclerosis [ICD-11: 8A40.1] Approved

D0MS1G	TTDDRUID	D0MS1G
D0MS1G	DRUGNAME	Fish oil triglycerides
D0MS1G	INDICATI	Cholestasis of parenteral nutrition [ICD-11: DB99.60] Approved

D0ND2J	TTDDRUID	D0ND2J
D0ND2J	DRUGNAME	Flavoxate
D0ND2J	INDICATI	Dysuria [ICD-11: MF50.7] Approved
D0ND2J	INDICATI	Nocturia [ICD-11: MF55] Approved
D0ND2J	INDICATI	Suprapubic pain [ICD-11: MG30-MG3Z] Approved
D0ND2J	INDICATI	Urgency [ICD-11: N.A.] Approved

D03DAP	TTDDRUID	D03DAP
D03DAP	DRUGNAME	Flecainide
D03DAP	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
D03DAP	INDICATI	Tachyarrhythmias [ICD-11: BC71] Approved

D06GAM	TTDDRUID	D06GAM
D06GAM	DRUGNAME	Fleroxacin
D06GAM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0S9CB	TTDDRUID	D0S9CB
D0S9CB	DRUGNAME	Flibanserin
D0S9CB	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 3
D0S9CB	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Approved

D02JWA	TTDDRUID	D02JWA
D02JWA	DRUGNAME	Flomoxef sodium
D02JWA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09CGE	TTDDRUID	D09CGE
D09CGE	DRUGNAME	Florbetapir F-18
D09CGE	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D0TS1Z	TTDDRUID	D0TS1Z
D0TS1Z	DRUGNAME	Floxuridine
D0TS1Z	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
D0TS1Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0E7US	TTDDRUID	D0E7US
D0E7US	DRUGNAME	Flu (pre-) pandemic
D0E7US	INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved

D0V0YH	TTDDRUID	D0V0YH
D0V0YH	DRUGNAME	Flu vaccine, GlaxoSmithKline
D0V0YH	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Approved

D0C3IO	TTDDRUID	D0C3IO
D0C3IO	DRUGNAME	Fluarix
D0C3IO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D02XHV	TTDDRUID	D02XHV
D02XHV	DRUGNAME	FluBlok
D02XHV	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0C6EF	TTDDRUID	D0C6EF
D0C6EF	DRUGNAME	Flucelvax
D0C6EF	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D03QIP	TTDDRUID	D03QIP
D03QIP	DRUGNAME	fluciclovine F-18
D03QIP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0Q2AT	TTDDRUID	D0Q2AT
D0Q2AT	DRUGNAME	Flucloxacillin
D0Q2AT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09LNI	TTDDRUID	D09LNI
D09LNI	DRUGNAME	Fluconazole
D09LNI	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0S5WG	TTDDRUID	D0S5WG
D0S5WG	DRUGNAME	Flucytosine
D0S5WG	INDICATI	Endocarditis [ICD-11: BB40-BA42] Approved

D0F2XQ	TTDDRUID	D0F2XQ
D0F2XQ	DRUGNAME	Fludarabine
D0F2XQ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Approved

D0H2RI	TTDDRUID	D0H2RI
D0H2RI	DRUGNAME	Fludeoxyglucose F 18
D0H2RI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D06FWC	TTDDRUID	D06FWC
D06FWC	DRUGNAME	Fludiazepam
D06FWC	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0R7JT	TTDDRUID	D0R7JT
D0R7JT	DRUGNAME	Fludrocortisone
D0R7JT	INDICATI	Cerebral salt-wasting syndrome [ICD-11: 5C72] Approved

D0B2WJ	TTDDRUID	D0B2WJ
D0B2WJ	DRUGNAME	Flufenamic Acid
D0B2WJ	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved

D04RZE	TTDDRUID	D04RZE
D04RZE	DRUGNAME	FluLaval FluLaval
D04RZE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D09TQS	TTDDRUID	D09TQS
D09TQS	DRUGNAME	Flulaval QIV
D09TQS	INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved

D0D5GD	TTDDRUID	D0D5GD
D0D5GD	DRUGNAME	Flumazenil
D0D5GD	INDICATI	Benzodiazepine overdose [ICD-11: PC91] Approved

D0F7NQ	TTDDRUID	D0F7NQ
D0F7NQ	DRUGNAME	Flumethasone Pivalate
D0F7NQ	INDICATI	Contact dermatitis [ICD-11: EK0Z] Approved

D0B3WM	TTDDRUID	D0B3WM
D0B3WM	DRUGNAME	FluMist
D0B3WM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D05CEU	TTDDRUID	D05CEU
D05CEU	DRUGNAME	Flunarizine
D05CEU	INDICATI	Migraine [ICD-11: 8A80] Approved

D0FM2P	TTDDRUID	D0FM2P
D0FM2P	DRUGNAME	Flunisolide
D0FM2P	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0W2NM	TTDDRUID	D0W2NM
D0W2NM	DRUGNAME	Flunitrazepam
D0W2NM	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D02QJH	TTDDRUID	D02QJH
D02QJH	DRUGNAME	Fluocinolone Acetonide
D02QJH	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D03ZZK	TTDDRUID	D03ZZK
D03ZZK	DRUGNAME	Fluocinonide
D03ZZK	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D06TJJ	TTDDRUID	D06TJJ
D06TJJ	DRUGNAME	FLUORESCEIN
D06TJJ	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Approved

D07FUJ	TTDDRUID	D07FUJ
D07FUJ	DRUGNAME	Fluorescein Sodium
D07FUJ	INDICATI	Diagnostic fluorescein angiography or angioscopy of vasculature [ICD-11: BA00-BE2Z] Approved

D0P0HT	TTDDRUID	D0P0HT
D0P0HT	DRUGNAME	Fluorometholone
D0P0HT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D08HFH	TTDDRUID	D08HFH
D08HFH	DRUGNAME	Fluoroquinolone
D08HFH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05LEO	TTDDRUID	D05LEO
D05LEO	DRUGNAME	Fluorouracil
D05LEO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D05LEO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
D05LEO	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Investigative

D0TR5X	TTDDRUID	D0TR5X
D0TR5X	DRUGNAME	Fluoxetine
D0TR5X	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0L2LS	TTDDRUID	D0L2LS
D0L2LS	DRUGNAME	Fluoxymesterone
D0L2LS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0P5SA	TTDDRUID	D0P5SA
D0P5SA	DRUGNAME	Fluphenazine
D0P5SA	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved

D0V9DZ	TTDDRUID	D0V9DZ
D0V9DZ	DRUGNAME	Fluprednisolone
D0V9DZ	INDICATI	Asthma [ICD-11: CA23] Approved

D0Y2YP	TTDDRUID	D0Y2YP
D0Y2YP	DRUGNAME	Flurandrenolide
D0Y2YP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D08XFV	TTDDRUID	D08XFV
D08XFV	DRUGNAME	Flurazepam
D08XFV	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0A1PX	TTDDRUID	D0A1PX
D0A1PX	DRUGNAME	Flurbiprofen
D0A1PX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D04JMQ	TTDDRUID	D04JMQ
D04JMQ	DRUGNAME	Flurithromycin ethylsuccinate
D04JMQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0U5FS	TTDDRUID	D0U5FS
D0U5FS	DRUGNAME	Fluspirilene
D0U5FS	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0Y0SW	TTDDRUID	D0Y0SW
D0Y0SW	DRUGNAME	Flutamide
D0Y0SW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0LC6K	TTDDRUID	D0LC6K
D0LC6K	DRUGNAME	Fluticasone
D0LC6K	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D01VMO	TTDDRUID	D01VMO
D01VMO	DRUGNAME	Flutrimazole
D01VMO	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0J6WX	TTDDRUID	D0J6WX
D0J6WX	DRUGNAME	Flutropium bromide
D0J6WX	INDICATI	Cough [ICD-11: MD12] Approved

D08GHB	TTDDRUID	D08GHB
D08GHB	DRUGNAME	Fluvastatin
D08GHB	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D0I3TJ	TTDDRUID	D0I3TJ
D0I3TJ	DRUGNAME	Fluvax
D0I3TJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D05TJR	TTDDRUID	D05TJR
D05TJR	DRUGNAME	Fluvirin
D05TJR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0SR5C	TTDDRUID	D0SR5C
D0SR5C	DRUGNAME	Fluvirin A(H1N1)
D0SR5C	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D03HFG	TTDDRUID	D03HFG
D03HFG	DRUGNAME	Fluvoxamine
D03HFG	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D05GFQ	TTDDRUID	D05GFQ
D05GFQ	DRUGNAME	Fluzone QIV ID
D05GFQ	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D09FHM	TTDDRUID	D09FHM
D09FHM	DRUGNAME	Fluzone QIV IM
D09FHM	INDICATI	Influenza [ICD-11: 1E30-1E32] Approved

D0O4RQ	TTDDRUID	D0O4RQ
D0O4RQ	DRUGNAME	Focetria A(H1N1)
D0O4RQ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D08OTA	TTDDRUID	D08OTA
D08OTA	DRUGNAME	Folic
D08OTA	INDICATI	Folate-deficiency anemia [ICD-11: 3A02.Y] Approved

D0Z0DW	TTDDRUID	D0Z0DW
D0Z0DW	DRUGNAME	Folic Acid
D0Z0DW	INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved

D05HAJ	TTDDRUID	D05HAJ
D05HAJ	DRUGNAME	Follitropin alfa/lutropin alfa
D05HAJ	INDICATI	Infertility [ICD-11: GB04] Approved

D0OM3A	TTDDRUID	D0OM3A
D0OM3A	DRUGNAME	Follitropin beta
D0OM3A	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D02NJA	TTDDRUID	D02NJA
D02NJA	DRUGNAME	Fomepizole
D02NJA	INDICATI	Athylene glycol or methanol poisoning [ICD-11: NE61] Approved

D0ID4Z	TTDDRUID	D0ID4Z
D0ID4Z	DRUGNAME	Fomivirsen sodium
D0ID4Z	INDICATI	Cytomegalovirus retinitis [ICD-11: 9B72.00] Approved

D0NE9T	TTDDRUID	D0NE9T
D0NE9T	DRUGNAME	Fondaparinux sodium
D0NE9T	INDICATI	Venous thrombosis [ICD-11: BA43] Approved

D00NVX	TTDDRUID	D00NVX
D00NVX	DRUGNAME	Forasartan
D00NVX	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04KJO	TTDDRUID	D04KJO
D04KJO	DRUGNAME	Formoterol
D04KJO	INDICATI	Asthma [ICD-11: CA23] Approved

D0P2AG	TTDDRUID	D0P2AG
D0P2AG	DRUGNAME	Formoterol/budesonide
D0P2AG	INDICATI	Asthma [ICD-11: CA23] Approved

D0F5MT	TTDDRUID	D0F5MT
D0F5MT	DRUGNAME	Fosamprenavir
D0F5MT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0OT0O	TTDDRUID	D0OT0O
D0OT0O	DRUGNAME	Foscavir
D0OT0O	INDICATI	Cytomegalovirus retinitis [ICD-11: 9B72.00] Approved

D0JO8Z	TTDDRUID	D0JO8Z
D0JO8Z	DRUGNAME	Fosfestrol
D0JO8Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0L6DO	TTDDRUID	D0L6DO
D0L6DO	DRUGNAME	Fosfluconazole
D0L6DO	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D01GYT	TTDDRUID	D01GYT
D01GYT	DRUGNAME	Fosfomycin
D01GYT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0N3UL	TTDDRUID	D0N3UL
D0N3UL	DRUGNAME	Fosfosal
D0N3UL	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0X8KY	TTDDRUID	D0X8KY
D0X8KY	DRUGNAME	Fosinopril
D0X8KY	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09UXE	TTDDRUID	D09UXE
D09UXE	DRUGNAME	Fosmidomycin
D09UXE	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0J5YC	TTDDRUID	D0J5YC
D0J5YC	DRUGNAME	Fosphenytoin
D0J5YC	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D02EZM	TTDDRUID	D02EZM
D02EZM	DRUGNAME	Fospropofol disodium
D02EZM	INDICATI	Monitored anaesthesia care [ICD-11: N.A.] Approved

D0V8HJ	TTDDRUID	D0V8HJ
D0V8HJ	DRUGNAME	Fostamatinib
D0V8HJ	INDICATI	Immune thrombocytopenic purpura [ICD-11: 3B64.13] Approved
D0V8HJ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0S1ZB	TTDDRUID	D0S1ZB
D0S1ZB	DRUGNAME	Fotemustine
D0S1ZB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D05JNI	TTDDRUID	D05JNI
D05JNI	DRUGNAME	Framycetin
D05JNI	INDICATI	Acute liver failure [ICD-11: DB91] Approved
D05JNI	INDICATI	Alcoholic cirrhosis of liver [ICD-11: DB94] Approved
D05JNI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D08PLK	TTDDRUID	D08PLK
D08PLK	DRUGNAME	Fremanezumab
D08PLK	INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved

D06FPQ	TTDDRUID	D06FPQ
D06FPQ	DRUGNAME	Frovatriptan
D06FPQ	INDICATI	Migraine [ICD-11: 8A80] Approved

D06HZY	TTDDRUID	D06HZY
D06HZY	DRUGNAME	Fructose
D06HZY	INDICATI	Vomiting [ICD-11: MD90] Approved

D03CHT	TTDDRUID	D03CHT
D03CHT	DRUGNAME	Fudosteine
D03CHT	INDICATI	Bronchitis [ICD-11: CA20] Approved
D03CHT	INDICATI	Expectorant [ICD-11: MD10] Approved

D0JO7Y	TTDDRUID	D0JO7Y
D0JO7Y	DRUGNAME	Fulvestrant
D0JO7Y	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D03QBS	TTDDRUID	D03QBS
D03QBS	DRUGNAME	Furazolidinone
D03QBS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D03CUF	TTDDRUID	D03CUF
D03CUF	DRUGNAME	Furazolidone
D03CUF	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0PQ3G	TTDDRUID	D0PQ3G
D0PQ3G	DRUGNAME	Furosemide
D0PQ3G	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0X7XG	TTDDRUID	D0X7XG
D0X7XG	DRUGNAME	Fusidic Acid
D0X7XG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0J0ZS	TTDDRUID	D0J0ZS
D0J0ZS	DRUGNAME	Gabapentin
D0J0ZS	INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
D0J0ZS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D05KBU	TTDDRUID	D05KBU
D05KBU	DRUGNAME	Gabapentin enacarbil
D05KBU	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2

D05PHH	TTDDRUID	D05PHH
D05PHH	DRUGNAME	Gabexate
D05PHH	INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved

D00EEL	TTDDRUID	D00EEL
D00EEL	DRUGNAME	Gaboxadol
D00EEL	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D01OIL	TTDDRUID	D01OIL
D01OIL	DRUGNAME	Gadobenate Dimeglumine
D01OIL	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0P1IZ	TTDDRUID	D0P1IZ
D0P1IZ	DRUGNAME	Gadobutrol
D0P1IZ	INDICATI	Blood brain barrier [ICD-11: 5C61.5] Approved

D03EEH	TTDDRUID	D03EEH
D03EEH	DRUGNAME	Gadodiamide
D03EEH	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved

D0H0WK	TTDDRUID	D0H0WK
D0H0WK	DRUGNAME	Gadofosveset
D0H0WK	INDICATI	Imaging [ICD-11: QA0B] Approved

D0RQ2W	TTDDRUID	D0RQ2W
D0RQ2W	DRUGNAME	Gadopentetate dimeglumine
D0RQ2W	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Approved

D0M1PL	TTDDRUID	D0M1PL
D0M1PL	DRUGNAME	Gadoteridol
D0M1PL	INDICATI	Brain disease [ICD-11: 8C70-8E61] Approved

D0X0GI	TTDDRUID	D0X0GI
D0X0GI	DRUGNAME	Gadoversetamide
D0X0GI	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D0X2FT	TTDDRUID	D0X2FT
D0X2FT	DRUGNAME	Gadoxetate disodium
D0X2FT	INDICATI	Imaging [ICD-11: QA0B] Approved

D0R9VR	TTDDRUID	D0R9VR
D0R9VR	DRUGNAME	Galantamine
D0R9VR	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D05WTS	TTDDRUID	D05WTS
D05WTS	DRUGNAME	Galavit
D05WTS	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved

D0C8VF	TTDDRUID	D0C8VF
D0C8VF	DRUGNAME	Galcanezumab
D0C8VF	INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved

D05SJW	TTDDRUID	D05SJW
D05SJW	DRUGNAME	Gallamine Triethiodide
D05SJW	INDICATI	Stabilize muscle contraction [ICD-11: FB3Z] Approved

D0QC5D	TTDDRUID	D0QC5D
D0QC5D	DRUGNAME	Gallium Citrate Ga-67
D0QC5D	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved

D07KKZ	TTDDRUID	D07KKZ
D07KKZ	DRUGNAME	gallium Ga 68 dotatate
D07KKZ	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Approved

D0R4ZT	TTDDRUID	D0R4ZT
D0R4ZT	DRUGNAME	Gallium nitrate
D0R4ZT	INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved

D05UHF	TTDDRUID	D05UHF
D05UHF	DRUGNAME	Galsulfase
D05UHF	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved

D0EP8X	TTDDRUID	D0EP8X
D0EP8X	DRUGNAME	Gamma Hydroxybutyric Acid
D0EP8X	INDICATI	Narcolepsy [ICD-11: 7A20] Approved

D0O1TC	TTDDRUID	D0O1TC
D0O1TC	DRUGNAME	Gamma-Homolinolenic acid
D0O1TC	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D08FWW	TTDDRUID	D08FWW
D08FWW	DRUGNAME	Gammaplex
D08FWW	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0UE9X	TTDDRUID	D0UE9X
D0UE9X	DRUGNAME	Gamolenic acid
D0UE9X	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D05ARP	TTDDRUID	D05ARP
D05ARP	DRUGNAME	Ganciclovir
D05ARP	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D06KDP	TTDDRUID	D06KDP
D06KDP	DRUGNAME	Ganglioside gm1
D06KDP	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Withdrawn from market
D06KDP	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D00RJJ	TTDDRUID	D00RJJ
D00RJJ	DRUGNAME	Ganirelix
D00RJJ	INDICATI	Ovulation dysfunction [ICD-11: 5A80] Approved

D0ZK8H	TTDDRUID	D0ZK8H
D0ZK8H	DRUGNAME	Gardasil
D0ZK8H	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Approved

D03CQE	TTDDRUID	D03CQE
D03CQE	DRUGNAME	Gatifloxacin
D03CQE	INDICATI	Respiratory tract infection [ICD-11: CA45] Approved

D09TYX	TTDDRUID	D09TYX
D09TYX	DRUGNAME	GC-501
D09TYX	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D00PBX	TTDDRUID	D00PBX
D00PBX	DRUGNAME	GDC-0199
D00PBX	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
D00PBX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D00PBX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D09XZB	TTDDRUID	D09XZB
D09XZB	DRUGNAME	Gefitinib
D09XZB	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
D09XZB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D09XZB	INDICATI	Urethral cancer [ICD-11: 2C93] Phase 2

D03UVS	TTDDRUID	D03UVS
D03UVS	DRUGNAME	Gemcitabine
D03UVS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D05VIX	TTDDRUID	D05VIX
D05VIX	DRUGNAME	Gemfibrozil
D05VIX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved

D0VR7W	TTDDRUID	D0VR7W
D0VR7W	DRUGNAME	Gemifloxacin
D0VR7W	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06EWO	TTDDRUID	D06EWO
D06EWO	DRUGNAME	Gemtuzumab ozogamicin
D06EWO	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0L9UU	TTDDRUID	D0L9UU
D0L9UU	DRUGNAME	Gentamicin
D0L9UU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09PEQ	TTDDRUID	D09PEQ
D09PEQ	DRUGNAME	Gentamicine sulfate
D09PEQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D04GZA	TTDDRUID	D04GZA
D04GZA	DRUGNAME	Gentian violet
D04GZA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01GPA	TTDDRUID	D01GPA
D01GPA	DRUGNAME	Gepon
D01GPA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0M5RF	TTDDRUID	D0M5RF
D0M5RF	DRUGNAME	Gestrinone
D0M5RF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D08VRX	TTDDRUID	D08VRX
D08VRX	DRUGNAME	GHRP-2
D08VRX	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved

D04KZY	TTDDRUID	D04KZY
D04KZY	DRUGNAME	Gilteritinib
D04KZY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0L5AP	TTDDRUID	D0L5AP
D0L5AP	DRUGNAME	Gitalin
D0L5AP	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D04ELD	TTDDRUID	D04ELD
D04ELD	DRUGNAME	Glassia
D04ELD	INDICATI	Emphysema [ICD-11: CA21] Approved

D04CRL	TTDDRUID	D04CRL
D04CRL	DRUGNAME	Glatiramer Acetate
D04CRL	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0J4IX	TTDDRUID	D0J4IX
D0J4IX	DRUGNAME	Glaziovine
D0J4IX	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0C4DH	TTDDRUID	D0C4DH
D0C4DH	DRUGNAME	Glecaprevir
D0C4DH	DRUGNAME	pibrentasvir
D0C4DH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D05LYX	TTDDRUID	D05LYX
D05LYX	DRUGNAME	Glibenclamide
D05LYX	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0M2MR	TTDDRUID	D0M2MR
D0M2MR	DRUGNAME	Gliclazide
D0M2MR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0B2GI	TTDDRUID	D0B2GI
D0B2GI	DRUGNAME	Glimepiride
D0B2GI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0Z4SB	TTDDRUID	D0Z4SB
D0Z4SB	DRUGNAME	Glipizide
D0Z4SB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D06HBQ	TTDDRUID	D06HBQ
D06HBQ	DRUGNAME	Gliquidone
D06HBQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0I0DQ	TTDDRUID	D0I0DQ
D0I0DQ	DRUGNAME	Glisolamide
D0I0DQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D04NTJ	TTDDRUID	D04NTJ
D04NTJ	DRUGNAME	Glisoxepide
D04NTJ	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Approved

D0L6BI	TTDDRUID	D0L6BI
D0L6BI	DRUGNAME	Glucagon rdna
D0L6BI	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved

D0H8WF	TTDDRUID	D0H8WF
D0H8WF	DRUGNAME	Glucagon recombinant
D0H8WF	INDICATI	Hypoglycemia [ICD-11: 5A41] Approved

D0P4PZ	TTDDRUID	D0P4PZ
D0P4PZ	DRUGNAME	Glucarpidase
D0P4PZ	INDICATI	Delayed methotrexate clearance [ICD-11: N.A.] Approved

D07NSU	TTDDRUID	D07NSU
D07NSU	DRUGNAME	Glucosamine
D07NSU	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D02HFD	TTDDRUID	D02HFD
D02HFD	DRUGNAME	Glutathione
D02HFD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0Z9NZ	TTDDRUID	D0Z9NZ
D0Z9NZ	DRUGNAME	Glutethimide
D0Z9NZ	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0E0BD	TTDDRUID	D0E0BD
D0E0BD	DRUGNAME	Glycerol phenylbutyrate
D0E0BD	INDICATI	Hepatic encephalopathy [ICD-11: DB99.5] Approved

D0M8AB	TTDDRUID	D0M8AB
D0M8AB	DRUGNAME	Glycine
D0M8AB	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D03JAA	TTDDRUID	D03JAA
D03JAA	DRUGNAME	Glycodiazine
D03JAA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0X2HE	TTDDRUID	D0X2HE
D0X2HE	DRUGNAME	GlycoPEG-GCSF
D0X2HE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0M0AM	TTDDRUID	D0M0AM
D0M0AM	DRUGNAME	Glycopyrrolate
D0M0AM	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D09WZV	TTDDRUID	D09WZV
D09WZV	DRUGNAME	GMA-161
D09WZV	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved (orphan drug)

D01YQH	TTDDRUID	D01YQH
D01YQH	DRUGNAME	GM-CSF
D01YQH	INDICATI	Neurological disorder [ICD-11: 6B60] Approved

D0D0SH	TTDDRUID	D0D0SH
D0D0SH	DRUGNAME	GMDP
D0D0SH	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved

D0FH7C	TTDDRUID	D0FH7C
D0FH7C	DRUGNAME	Gold sodium thiomalate
D0FH7C	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D09FSG	TTDDRUID	D09FSG
D09FSG	DRUGNAME	Golimumab
D09FSG	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2/3
D09FSG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D04ODH	TTDDRUID	D04ODH
D04ODH	DRUGNAME	Gonadorelin
D04ODH	INDICATI	Hypothalamic hypogonadism [ICD-11: 5A61.2] Approved

D06GCO	TTDDRUID	D06GCO
D06GCO	DRUGNAME	Gonadoreline-6-d-trp acetate
D06GCO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0J0LI	TTDDRUID	D0J0LI
D0J0LI	DRUGNAME	Gonadotropin, Chorionic
D0J0LI	INDICATI	Fertility problem [ICD-11: 5A61] Approved

D00BCG	TTDDRUID	D00BCG
D00BCG	DRUGNAME	Goserelin
D00BCG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0J7XL	TTDDRUID	D0J7XL
D0J7XL	DRUGNAME	Gramicidin D
D0J7XL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0J5KF	TTDDRUID	D0J5KF
D0J5KF	DRUGNAME	Granisetron
D0J5KF	INDICATI	Nausea and vomiting [ICD-11: MD90] Approved

D06ANT	TTDDRUID	D06ANT
D06ANT	DRUGNAME	Grass pollen extract sublingual vaccine
D06ANT	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Approved

D0Z6BF	TTDDRUID	D0Z6BF
D0Z6BF	DRUGNAME	Grastek
D0Z6BF	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0WL5F	TTDDRUID	D0WL5F
D0WL5F	DRUGNAME	Grazax
D0WL5F	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0D7DH	TTDDRUID	D0D7DH
D0D7DH	DRUGNAME	Green soap
D0D7DH	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0JL2K	TTDDRUID	D0JL2K
D0JL2K	DRUGNAME	Grepafloxacin
D0JL2K	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market
D0JL2K	INDICATI	Chronic bronchitis [ICD-11: CA20.1] Approved

D0C1SF	TTDDRUID	D0C1SF
D0C1SF	DRUGNAME	Griseofulvin
D0C1SF	INDICATI	Ringworm infection [ICD-11: 1F28] Approved

D0QF9P	TTDDRUID	D0QF9P
D0QF9P	DRUGNAME	GSK-208108
D0QF9P	INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved

D0F0RR	TTDDRUID	D0F0RR
D0F0RR	DRUGNAME	GSK2592984A
D0F0RR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D08CCE	TTDDRUID	D08CCE
D08CCE	DRUGNAME	Guaimesal
D08CCE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0L4HY	TTDDRUID	D0L4HY
D0L4HY	DRUGNAME	Guanabenz
D0L4HY	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0U3CR	TTDDRUID	D0U3CR
D0U3CR	DRUGNAME	Guanadrel Sulfate
D0U3CR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0N3PE	TTDDRUID	D0N3PE
D0N3PE	DRUGNAME	Guanethidine
D0N3PE	INDICATI	Moderate and severe hypertension [ICD-11: BA00.Z] Approved

D07ILQ	TTDDRUID	D07ILQ
D07ILQ	DRUGNAME	Guanfacine extended release
D07ILQ	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved

D0F7NZ	TTDDRUID	D0F7NZ
D0F7NZ	DRUGNAME	Guanidine Hydrochloride
D0F7NZ	INDICATI	Muscle fatigue [ICD-11: FB32.5] Approved

D09NLC	TTDDRUID	D09NLC
D09NLC	DRUGNAME	Guar gum
D09NLC	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D0G8BV	TTDDRUID	D0G8BV
D0G8BV	DRUGNAME	Guggulsterone
D0G8BV	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D05RQW	TTDDRUID	D05RQW
D05RQW	DRUGNAME	Guglipid
D05RQW	INDICATI	Lipoprotein disorder [ICD-11: 5C80-5C8Z] Approved

D0UP9M	TTDDRUID	D0UP9M
D0UP9M	DRUGNAME	Gusperimus trihydrochloride
D0UP9M	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0FG6M	TTDDRUID	D0FG6M
D0FG6M	DRUGNAME	GW642444
D0FG6M	INDICATI	Asthma [ICD-11: CA23] Approved

D0Y7JU	TTDDRUID	D0Y7JU
D0Y7JU	DRUGNAME	GW685698X
D0Y7JU	INDICATI	Asthma [ICD-11: CA23] Approved

D04FZL	TTDDRUID	D04FZL
D04FZL	DRUGNAME	H.P. Acthar Gel
D04FZL	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Approved

D0W3SQ	TTDDRUID	D0W3SQ
D0W3SQ	DRUGNAME	H-101
D0W3SQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D05TFW	TTDDRUID	D05TFW
D05TFW	DRUGNAME	H1N1 HA flu vaccine
D05TFW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D02ORJ	TTDDRUID	D02ORJ
D02ORJ	DRUGNAME	H1N1 influenza vaccine
D02ORJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0G0MM	TTDDRUID	D0G0MM
D0G0MM	DRUGNAME	H1N1 influenza vaccine
D0G0MM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0UH0S	TTDDRUID	D0UH0S
D0UH0S	DRUGNAME	H1N1 influenza vaccine
D0UH0S	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0W6GR	TTDDRUID	D0W6GR
D0W6GR	DRUGNAME	H1N1 influenza vaccine
D0W6GR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D04SOA	TTDDRUID	D04SOA
D04SOA	DRUGNAME	H1N1 pandemic influenza A vaccine
D04SOA	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D00ALE	TTDDRUID	D00ALE
D00ALE	DRUGNAME	H1N1 pandemic influenza vaccine
D00ALE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0B3VR	TTDDRUID	D0B3VR
D0B3VR	DRUGNAME	H5N1 avian influenza vaccine
D0B3VR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D09AWJ	TTDDRUID	D09AWJ
D09AWJ	DRUGNAME	H5N1 influenza vaccine
D09AWJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0B6ZI	TTDDRUID	D0B6ZI
D0B6ZI	DRUGNAME	H5N1 influenza vaccine
D0B6ZI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D00EIB	TTDDRUID	D00EIB
D00EIB	DRUGNAME	Ha-1a
D00EIB	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
D00EIB	INDICATI	Congestive heart failure [ICD-11: BD10] Approved
D00EIB	INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved

D0FR9L	TTDDRUID	D0FR9L
D0FR9L	DRUGNAME	Haem arginate
D0FR9L	INDICATI	Porphyria [ICD-11: 5C58.1] Approved

D03LTA	TTDDRUID	D03LTA
D03LTA	DRUGNAME	Haemophilus influenzae B (Hib) vaccine
D03LTA	INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved

D0Z9VB	TTDDRUID	D0Z9VB
D0Z9VB	DRUGNAME	Halazepam
D0Z9VB	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D06IIB	TTDDRUID	D06IIB
D06IIB	DRUGNAME	Halcinonide
D06IIB	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Approved

D00XPC	TTDDRUID	D00XPC
D00XPC	DRUGNAME	Halobetasol Propionate
D00XPC	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D07MVK	TTDDRUID	D07MVK
D07MVK	DRUGNAME	Halofantrine
D07MVK	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0C8HR	TTDDRUID	D0C8HR
D0C8HR	DRUGNAME	Halometasone
D0C8HR	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0D1AL	TTDDRUID	D0D1AL
D0D1AL	DRUGNAME	Haloperidol
D0D1AL	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D08BDT	TTDDRUID	D08BDT
D08BDT	DRUGNAME	Halopredone acetate
D08BDT	INDICATI	Arthritis [ICD-11: FA20] Approved

D06ZAY	TTDDRUID	D06ZAY
D06ZAY	DRUGNAME	Haloprogin
D06ZAY	INDICATI	Candidiasis [ICD-11: 1F23] Approved
D06ZAY	INDICATI	Dermatophytosis [ICD-11: 1F28.2] Approved

D0D8VE	TTDDRUID	D0D8VE
D0D8VE	DRUGNAME	Halothane
D0D8VE	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D09LLS	TTDDRUID	D09LLS
D09LLS	DRUGNAME	Havrix
D09LLS	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved

D0T5WA	TTDDRUID	D0T5WA
D0T5WA	DRUGNAME	Healive
D0T5WA	INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved

D0O7ES	TTDDRUID	D0O7ES
D0O7ES	DRUGNAME	Heberpenta L
D0O7ES	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D05GGP	TTDDRUID	D05GGP
D05GGP	DRUGNAME	HEGF
D05GGP	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved

D00IAH	TTDDRUID	D00IAH
D00IAH	DRUGNAME	Hemiacidrin
D00IAH	INDICATI	Urolithiasis [ICD-11: GB7Z] Approved

D0I6FA	TTDDRUID	D0I6FA
D0I6FA	DRUGNAME	Hemoglobin crosfumaril
D0I6FA	INDICATI	Hypotension [ICD-11: BA20-BA21] Approved

D0H0SL	TTDDRUID	D0H0SL
D0H0SL	DRUGNAME	Hemoglobin glutamer
D0H0SL	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D0V6XJ	TTDDRUID	D0V6XJ
D0V6XJ	DRUGNAME	Hemsleyadin
D0V6XJ	INDICATI	Bacillary dysentery [ICD-11: 1A02] Approved

D03VMW	TTDDRUID	D03VMW
D03VMW	DRUGNAME	HepaGam B
D03VMW	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0A2GM	TTDDRUID	D0A2GM
D0A2GM	DRUGNAME	Heparin Calcium
D0A2GM	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved

D0UX6Z	TTDDRUID	D0UX6Z
D0UX6Z	DRUGNAME	Heparin Sodium
D0UX6Z	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
D0UX6Z	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D0L4ET	TTDDRUID	D0L4ET
D0L4ET	DRUGNAME	Hepatect CP
D0L4ET	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D07KKQ	TTDDRUID	D07KKQ
D07KKQ	DRUGNAME	Hepatitis A vaccine
D07KKQ	INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved

D04WFV	TTDDRUID	D04WFV
D04WFV	DRUGNAME	Hepatitis B immune globulin
D04WFV	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0I8YO	TTDDRUID	D0I8YO
D0I8YO	DRUGNAME	Hepatitis B vaccine
D0I8YO	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D09GMH	TTDDRUID	D09GMH
D09GMH	DRUGNAME	Hepatitis B virus vaccine
D09GMH	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
D09GMH	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D09SMG	TTDDRUID	D09SMG
D09SMG	DRUGNAME	Hepatyrix
D09SMG	INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved

D03WAJ	TTDDRUID	D03WAJ
D03WAJ	DRUGNAME	Heptabarbital
D03WAJ	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D07DIM	TTDDRUID	D07DIM
D07DIM	DRUGNAME	Herbimycin A
D07DIM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0T6WT	TTDDRUID	D0T6WT
D0T6WT	DRUGNAME	Heroin diacetylmorphine
D0T6WT	INDICATI	Neurological disorder [ICD-11: 6B60] Approved

D07MGA	TTDDRUID	D07MGA
D07MGA	DRUGNAME	Hesperetin
D07MGA	INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Approved

D0I9HF	TTDDRUID	D0I9HF
D0I9HF	DRUGNAME	Hesperidin
D0I9HF	INDICATI	Vascular purpura [ICD-11: 3B60] Approved

D0W7RJ	TTDDRUID	D0W7RJ
D0W7RJ	DRUGNAME	Hetacillin
D0W7RJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D0W7RJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market

D0D6NQ	TTDDRUID	D0D6NQ
D0D6NQ	DRUGNAME	HEV-239
D0D6NQ	INDICATI	Hepatitis E virus infection [ICD-11: 1E50.4] Approved

D0ZX2G	TTDDRUID	D0ZX2G
D0ZX2G	DRUGNAME	Hexachlorophene
D0ZX2G	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Q2MH	TTDDRUID	D0Q2MH
D0Q2MH	DRUGNAME	Hexafluronium bromide
D0Q2MH	INDICATI	Spasm [ICD-11: MB47.3] Approved

D0Q9TC	TTDDRUID	D0Q9TC
D0Q9TC	DRUGNAME	Hexaxim
D0Q9TC	INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved

D00ETS	TTDDRUID	D00ETS
D00ETS	DRUGNAME	Hexobarbital
D00ETS	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D03QNW	TTDDRUID	D03QNW
D03QNW	DRUGNAME	Hextend
D03QNW	INDICATI	Blood transfusion [ICD-11: QB98] Approved

D0AY9Q	TTDDRUID	D0AY9Q
D0AY9Q	DRUGNAME	Hexyl aminolevulinate
D0AY9Q	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0AY9Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D08MRN	TTDDRUID	D08MRN
D08MRN	DRUGNAME	Hexylcaine
D08MRN	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
D08MRN	INDICATI	Anaesthesia [ICD-11: 9A78.6] Withdrawn from market

D0TC7C	TTDDRUID	D0TC7C
D0TC7C	DRUGNAME	Hidrosmin
D0TC7C	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0EN0G	TTDDRUID	D0EN0G
D0EN0G	DRUGNAME	Histamine Phosphate
D0EN0G	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D00NTR	TTDDRUID	D00NTR
D00NTR	DRUGNAME	Histoplasmin
D00NTR	INDICATI	Histoplasma infection [ICD-11: 1F2A.Z] Approved

D0O7DG	TTDDRUID	D0O7DG
D0O7DG	DRUGNAME	Histrelin
D0O7DG	INDICATI	Central precocious puberty [ICD-11: 5A60.3] Approved
D0O7DG	INDICATI	Endometriosis [ICD-11: GA10] Approved
D0O7DG	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Approved

D0H0GY	TTDDRUID	D0H0GY
D0H0GY	DRUGNAME	HL-001
D0H0GY	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0D6ZL	TTDDRUID	D0D6ZL
D0D6ZL	DRUGNAME	HMPL-002
D0D6ZL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0O5SZ	TTDDRUID	D0O5SZ
D0O5SZ	DRUGNAME	Homatropine Methylbromide
D0O5SZ	INDICATI	Peptic ulcer [ICD-11: DA61] Approved
D0O5SZ	INDICATI	Uveitis [ICD-11: 9A96.Z] Approved

D00RJN	TTDDRUID	D00RJN
D00RJN	DRUGNAME	House dust mite allergen
D00RJN	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D0O2YE	TTDDRUID	D0O2YE
D0O2YE	DRUGNAME	HTF 919
D0O2YE	INDICATI	Constipation [ICD-11: DD91.1] Approved

D05CVH	TTDDRUID	D05CVH
D05CVH	DRUGNAME	Hu neutral insulin
D05CVH	INDICATI	Type-1 diabetes [ICD-11: 5A10] Approved

D06KGV	TTDDRUID	D06KGV
D06KGV	DRUGNAME	HUMAN CORTICOTROPIN-RELEASING HORMONE
D06KGV	INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved

D0Y9FF	TTDDRUID	D0Y9FF
D0Y9FF	DRUGNAME	Human factor viii
D0Y9FF	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D05OSR	TTDDRUID	D05OSR
D05OSR	DRUGNAME	Human immune globulin
D05OSR	INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Approved

D0XV5B	TTDDRUID	D0XV5B
D0XV5B	DRUGNAME	Human insulin zinc suspension
D0XV5B	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D07AQC	TTDDRUID	D07AQC
D07AQC	DRUGNAME	Human insulin zn suspension
D07AQC	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D02EHV	TTDDRUID	D02EHV
D02EHV	DRUGNAME	Human neutral insulin
D02EHV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D07KFG	TTDDRUID	D07KFG
D07KFG	DRUGNAME	Human prothrombin complex concentrate
D07KFG	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D0P2BV	TTDDRUID	D0P2BV
D0P2BV	DRUGNAME	Human thrombin
D0P2BV	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D06XWB	TTDDRUID	D06XWB
D06XWB	DRUGNAME	Huperzine A
D06XWB	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D07BSE	TTDDRUID	D07BSE
D07BSE	DRUGNAME	Hyaluronate sodium
D07BSE	INDICATI	Enthesopathy [ICD-11: FB53-FB55] Phase 3
D07BSE	INDICATI	Joint lubricant [ICD-11: FA30-FA38] Approved
D07BSE	INDICATI	Pancytopenia [ICD-11: 3A70.Z] Investigative

D04GPZ	TTDDRUID	D04GPZ
D04GPZ	DRUGNAME	Hyaluronidase (ovine)
D04GPZ	INDICATI	Resorption of radiopaque agents [ICD-11: N.A.] Approved

D07YUH	TTDDRUID	D07YUH
D07YUH	DRUGNAME	HybriCell
D07YUH	INDICATI	Melanoma [ICD-11: 2C30] Approved

D0K1XK	TTDDRUID	D0K1XK
D0K1XK	DRUGNAME	Hydralazine
D0K1XK	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D05JFY	TTDDRUID	D05JFY
D05JFY	DRUGNAME	Hydralazine hydrochloride/ isosorbide dinitrate
D05JFY	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D0L1JW	TTDDRUID	D0L1JW
D0L1JW	DRUGNAME	Hydrastine
D0L1JW	INDICATI	Haemostatic astringent [ICD-11: MG27] Approved

D02PJA	TTDDRUID	D02PJA
D02PJA	DRUGNAME	Hydriodic acid iodine-125
D02PJA	INDICATI	Asthma [ICD-11: CA23] Approved

D03VXJ	TTDDRUID	D03VXJ
D03VXJ	DRUGNAME	Hydrochloric acid
D03VXJ	INDICATI	Alkalosis [ICD-11: 5C74] Approved

D0U4UQ	TTDDRUID	D0U4UQ
D0U4UQ	DRUGNAME	Hydrochlorothiazide
D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0X5KF	TTDDRUID	D0X5KF
D0X5KF	DRUGNAME	Hydrocodone
D0X5KF	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D0X5KF	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D05RXI	TTDDRUID	D05RXI
D05RXI	DRUGNAME	Hydrocortamate
D05RXI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0KR5B	TTDDRUID	D0KR5B
D0KR5B	DRUGNAME	Hydrocortisone
D0KR5B	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D00WAM	TTDDRUID	D00WAM
D00WAM	DRUGNAME	Hydroflumethiazide
D00WAM	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D03IDU	TTDDRUID	D03IDU
D03IDU	DRUGNAME	Hydrogen peroxide
D03IDU	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved

D04JHN	TTDDRUID	D04JHN
D04JHN	DRUGNAME	Hydromorphone
D04JHN	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D04JHN	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D03UOT	TTDDRUID	D03UOT
D03UOT	DRUGNAME	Hydroquinone
D03UOT	INDICATI	Melasma [ICD-11: ED60.1] Approved

D0VF4H	TTDDRUID	D0VF4H
D0VF4H	DRUGNAME	Hydroxocobalamin
D0VF4H	INDICATI	Lung injury [ICD-11: NB32.3Z] Phase 2
D0VF4H	INDICATI	Vitamin B12 deficiency [ICD-11: 5B5F] Approved

D0W1RY	TTDDRUID	D0W1RY
D0W1RY	DRUGNAME	Hydroxyamphetamine Hydrobromide
D0W1RY	INDICATI	Horner syndrome [ICD-11: 8D8A.1] Approved

D0OJ4L	TTDDRUID	D0OJ4L
D0OJ4L	DRUGNAME	Hydroxychloroquine
D0OJ4L	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0M5OG	TTDDRUID	D0M5OG
D0M5OG	DRUGNAME	Hydroxyethyl starch
D0M5OG	INDICATI	Haemorrhage [ICD-11: MG27] Approved

D0BC2E	TTDDRUID	D0BC2E
D0BC2E	DRUGNAME	Hydroxyflutamide
D0BC2E	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D00AEQ	TTDDRUID	D00AEQ
D00AEQ	DRUGNAME	Hydroxyprogesterone
D00AEQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0E6CH	TTDDRUID	D0E6CH
D0E6CH	DRUGNAME	Hydroxypropyl Cellulose
D0E6CH	INDICATI	Insufficient tear production [ICD-11: 5B55.Y] Approved

D0O1AN	TTDDRUID	D0O1AN
D0O1AN	DRUGNAME	Hydroxypropyl methylcellulose
D0O1AN	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D02RIV	TTDDRUID	D02RIV
D02RIV	DRUGNAME	Hydroxystilbamidine Isethionate
D02RIV	INDICATI	Blastomycosis [ICD-11: 1F22] Approved

D07CWD	TTDDRUID	D07CWD
D07CWD	DRUGNAME	Hydroxyurea
D07CWD	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved

D0O6SX	TTDDRUID	D0O6SX
D0O6SX	DRUGNAME	Hydroxyzine
D0O6SX	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0N3UG	TTDDRUID	D0N3UG
D0N3UG	DRUGNAME	Hylenex
D0N3UG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0RD5W	TTDDRUID	D0RD5W
D0RD5W	DRUGNAME	Hyoscyamine
D0RD5W	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D0IP9E	TTDDRUID	D0IP9E
D0IP9E	DRUGNAME	Hyqvia
D0IP9E	INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Approved

D00JVX	TTDDRUID	D00JVX
D00JVX	DRUGNAME	Ibalizumab
D00JVX	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D0E7AD	TTDDRUID	D0E7AD
D0E7AD	DRUGNAME	Ibalizumab 
D0E7AD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D08SJZ	TTDDRUID	D08SJZ
D08SJZ	DRUGNAME	Ibandronate
D08SJZ	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0U9QU	TTDDRUID	D0U9QU
D0U9QU	DRUGNAME	Ibopamine hci
D0U9QU	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Approved

D01TVQ	TTDDRUID	D01TVQ
D01TVQ	DRUGNAME	Ibritumomab
D01TVQ	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
D01TVQ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D09KTS	TTDDRUID	D09KTS
D09KTS	DRUGNAME	Ibrutinib
D09KTS	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved

D0S2VD	TTDDRUID	D0S2VD
D0S2VD	DRUGNAME	Ibrutinib companion diagnostic
D0S2VD	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved

D0R1QE	TTDDRUID	D0R1QE
D0R1QE	DRUGNAME	Ibuprofen
D0R1QE	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D02NEH	TTDDRUID	D02NEH
D02NEH	DRUGNAME	Ibutamoren
D02NEH	INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved

D02MLW	TTDDRUID	D02MLW
D02MLW	DRUGNAME	Ibutilide
D02MLW	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved

D04ZBT	TTDDRUID	D04ZBT
D04ZBT	DRUGNAME	Icatibant
D04ZBT	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved

D02YCH	TTDDRUID	D02YCH
D02YCH	DRUGNAME	Icodextrin
D02YCH	INDICATI	Kidney disease [ICD-11: GC2Z] Approved

D0G2MW	TTDDRUID	D0G2MW
D0G2MW	DRUGNAME	Icosapent
D0G2MW	INDICATI	Hyperglyceridemia [ICD-11: 5C80.1] Approved
D0G2MW	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3
D0G2MW	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D01XDL	TTDDRUID	D01XDL
D01XDL	DRUGNAME	Idarubicin
D01XDL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0MM8N	TTDDRUID	D0MM8N
D0MM8N	DRUGNAME	Idebenone
D0MM8N	INDICATI	Cognitive impairment [ICD-11: 6D71] Approved
D0MM8N	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Approved

D0J5VR	TTDDRUID	D0J5VR
D0J5VR	DRUGNAME	Idelalisib
D0J5VR	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved

D09PZO	TTDDRUID	D09PZO
D09PZO	DRUGNAME	Idoxuridine
D09PZO	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved

D06CZJ	TTDDRUID	D06CZJ
D06CZJ	DRUGNAME	Idursulfase
D06CZJ	INDICATI	Hunter syndrome [ICD-11: 5C56.31] Approved
D06CZJ	INDICATI	Infertility [ICD-11: GB04] Approved

D02TLO	TTDDRUID	D02TLO
D02TLO	DRUGNAME	Ifosfamide
D02TLO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0L0JM	TTDDRUID	D0L0JM
D0L0JM	DRUGNAME	Igiv-hb
D0L0JM	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0E2ML	TTDDRUID	D0E2ML
D0E2ML	DRUGNAME	IG-RD-001
D0E2ML	INDICATI	Respiratory disease [ICD-11: CB40] Approved

D0Y8KN	TTDDRUID	D0Y8KN
D0Y8KN	DRUGNAME	Ilaris canakinumab
D0Y8KN	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D0M8VE	TTDDRUID	D0M8VE
D0M8VE	DRUGNAME	Iloperidone
D0M8VE	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D05ZTH	TTDDRUID	D05ZTH
D05ZTH	DRUGNAME	Iloprost
D05ZTH	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved

D0AZ3C	TTDDRUID	D0AZ3C
D0AZ3C	DRUGNAME	Imatinib
D0AZ3C	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved
D0AZ3C	INDICATI	Intestinal cancer [ICD-11: 2C0Z] Phase 3
D0AZ3C	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
D0AZ3C	INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Investigative

D0S0ES	TTDDRUID	D0S0ES
D0S0ES	DRUGNAME	Imidapril hci
D0S0ES	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0F5ZM	TTDDRUID	D0F5ZM
D0F5ZM	DRUGNAME	Imidazole salicylate
D0F5ZM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0QW9H	TTDDRUID	D0QW9H
D0QW9H	DRUGNAME	Imiglucerase
D0QW9H	INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Approved

D0H3TD	TTDDRUID	D0H3TD
D0H3TD	DRUGNAME	Imipenem
D0H3TD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06ZUK	TTDDRUID	D06ZUK
D06ZUK	DRUGNAME	Imipramine
D06ZUK	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D06CTE	TTDDRUID	D06CTE
D06CTE	DRUGNAME	Imiquimod
D06CTE	INDICATI	Skin cancer [ICD-11: 2C30-2C37] Approved

D04GSL	TTDDRUID	D04GSL
D04GSL	DRUGNAME	ImmuCyst
D04GSL	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Approved

D09ADS	TTDDRUID	D09ADS
D09ADS	DRUGNAME	Immuncell-LC
D09ADS	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Approved

D01OWB	TTDDRUID	D01OWB
D01OWB	DRUGNAME	Immune globulin high dose
D01OWB	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0T4IP	TTDDRUID	D0T4IP
D0T4IP	DRUGNAME	Immune globulin intravenous
D0T4IP	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Approved

D0JQ9D	TTDDRUID	D0JQ9D
D0JQ9D	DRUGNAME	Immune Globulin intravenous (human)
D0JQ9D	INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Approved

D0P2AK	TTDDRUID	D0P2AK
D0P2AK	DRUGNAME	Immune globulin subcutaneous, 20% liquid
D0P2AK	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0E1LW	TTDDRUID	D0E1LW
D0E1LW	DRUGNAME	Immunoglobulin intravenous
D0E1LW	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D04RCZ	TTDDRUID	D04RCZ
D04RCZ	DRUGNAME	Immunosuppressant synthetic peptide
D04RCZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved

D05EHJ	TTDDRUID	D05EHJ
D05EHJ	DRUGNAME	IMOVAX
D05EHJ	INDICATI	Poliovirus infection [ICD-11: 1C8Y] Approved

D03GOP	TTDDRUID	D03GOP
D03GOP	DRUGNAME	Imvamune smallpox vaccine
D03GOP	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0R6TI	TTDDRUID	D0R6TI
D0R6TI	DRUGNAME	Inamrinone Lactate
D0R6TI	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Approved
D0R6TI	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0N4PZ	TTDDRUID	D0N4PZ
D0N4PZ	DRUGNAME	Incadronate
D0N4PZ	INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved

D0H3AB	TTDDRUID	D0H3AB
D0H3AB	DRUGNAME	Incobotulinum toxin A
D0H3AB	INDICATI	Cervical cancer [ICD-11: 2C77.0] Approved

D09ZOQ	TTDDRUID	D09ZOQ
D09ZOQ	DRUGNAME	Incruse Ellipta
D09ZOQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D03DJL	TTDDRUID	D03DJL
D03DJL	DRUGNAME	Indacaterol
D03DJL	INDICATI	Asthma [ICD-11: CA23] Phase 4
D03DJL	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0H8FH	TTDDRUID	D0H8FH
D0H8FH	DRUGNAME	Indapamide
D0H8FH	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0K4CQ	TTDDRUID	D0K4CQ
D0K4CQ	DRUGNAME	Indecainide
D0K4CQ	INDICATI	Dysrhythmias [ICD-11: BC9Z] Approved

D07TGY	TTDDRUID	D07TGY
D07TGY	DRUGNAME	Indeloxazine
D07TGY	INDICATI	Dementia [ICD-11: 6D80-6D86] Approved

D0A6AP	TTDDRUID	D0A6AP
D0A6AP	DRUGNAME	Indigotindisulfonate
D0A6AP	INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Approved

D0V7CF	TTDDRUID	D0V7CF
D0V7CF	DRUGNAME	Indinavir
D0V7CF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0GA5T	TTDDRUID	D0GA5T
D0GA5T	DRUGNAME	Indiplon
D0GA5T	INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved
D0GA5T	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D06YEG	TTDDRUID	D06YEG
D06YEG	DRUGNAME	Indirab
D06YEG	INDICATI	Rabies [ICD-11: 1C82] Approved

D0TB1L	TTDDRUID	D0TB1L
D0TB1L	DRUGNAME	Indium In-111 Chloride
D0TB1L	INDICATI	Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved

D02JYY	TTDDRUID	D02JYY
D02JYY	DRUGNAME	Indium In-111 Oxyquinoline
D02JYY	INDICATI	Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved

D00KRT	TTDDRUID	D00KRT
D00KRT	DRUGNAME	Indocyanine green
D00KRT	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D0R1RS	TTDDRUID	D0R1RS
D0R1RS	DRUGNAME	Indomethacin
D0R1RS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0CV2L	TTDDRUID	D0CV2L
D0CV2L	DRUGNAME	Infanrix
D0CV2L	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D02YXB	TTDDRUID	D02YXB
D02YXB	DRUGNAME	Infanrix Hep B
D02YXB	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0P3HK	TTDDRUID	D0P3HK
D0P3HK	DRUGNAME	Infanrix-DTaP-Hib
D0P3HK	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D04IBG	TTDDRUID	D04IBG
D04IBG	DRUGNAME	Infanrix-DTaP-IPV-Hep B
D04IBG	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0O0ZH	TTDDRUID	D0O0ZH
D0O0ZH	DRUGNAME	Infanrix-DTaP-IPV-Hep B-Hib
D0O0ZH	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0YU6I	TTDDRUID	D0YU6I
D0YU6I	DRUGNAME	Infanrix-DTaP-IPV-Hib
D0YU6I	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D05SPU	TTDDRUID	D05SPU
D05SPU	DRUGNAME	Infanrix-IPV
D05SPU	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D06HWG	TTDDRUID	D06HWG
D06HWG	DRUGNAME	Inflexal V
D06HWG	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0PG5G	TTDDRUID	D0PG5G
D0PG5G	DRUGNAME	Infliximab
D0PG5G	INDICATI	Asthma [ICD-11: CA23] Phase 3
D0PG5G	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
D0PG5G	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0O9MX	TTDDRUID	D0O9MX
D0O9MX	DRUGNAME	Influenza vaccine
D0O9MX	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0W2LR	TTDDRUID	D0W2LR
D0W2LR	DRUGNAME	Influenza virus vaccine
D0W2LR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D07BPO	TTDDRUID	D07BPO
D07BPO	DRUGNAME	Ingavirin
D07BPO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0E9KA	TTDDRUID	D0E9KA
D0E9KA	DRUGNAME	Ingenol mebutate
D0E9KA	INDICATI	Actinic keratosis [ICD-11: EK90.0] Approved
D0E9KA	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0Q2QU	TTDDRUID	D0Q2QU
D0Q2QU	DRUGNAME	Inosine pranobex
D0Q2QU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
D0Q2QU	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0R3BV	TTDDRUID	D0R3BV
D0R3BV	DRUGNAME	Inotersen
D0R3BV	INDICATI	Hereditary amyloidosis [ICD-11: 5D00.2] Approved

D00QEP	TTDDRUID	D00QEP
D00QEP	DRUGNAME	Inotuzumab ozogamicin
D00QEP	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
D00QEP	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved

D0R6CD	TTDDRUID	D0R6CD
D0R6CD	DRUGNAME	Insulin
D0R6CD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0L2CI	TTDDRUID	D0L2CI
D0L2CI	DRUGNAME	Insulin degludec
D0L2CI	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved

D0F3LS	TTDDRUID	D0F3LS
D0F3LS	DRUGNAME	Insulin determir
D0F3LS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D03VXG	TTDDRUID	D03VXG
D03VXG	DRUGNAME	Insulin Lyspro recombinant
D03VXG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D06SVW	TTDDRUID	D06SVW
D06SVW	DRUGNAME	Insulin recombinant
D06SVW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D08ENK	TTDDRUID	D08ENK
D08ENK	DRUGNAME	Insulin Susp Isophane Recombinant Human
D08ENK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0I1PY	TTDDRUID	D0I1PY
D0I1PY	DRUGNAME	Insulin Susp Protamine Zinc Beef/Pork
D0I1PY	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D03FIL	TTDDRUID	D03FIL
D03FIL	DRUGNAME	Insulin Zinc Susp Recombinant Human
D03FIL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D05ELO	TTDDRUID	D05ELO
D05ELO	DRUGNAME	Insulin, porcine
D05ELO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0I3LE	TTDDRUID	D0I3LE
D0I3LE	DRUGNAME	Insulin-aspart
D0I3LE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0QE5U	TTDDRUID	D0QE5U
D0QE5U	DRUGNAME	Insulin-detemir
D0QE5U	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved

D07NGZ	TTDDRUID	D07NGZ
D07NGZ	DRUGNAME	Insulin-glargine
D07NGZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0M2XE	TTDDRUID	D0M2XE
D0M2XE	DRUGNAME	Insulin-glulisine
D0M2XE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0L6JE	TTDDRUID	D0L6JE
D0L6JE	DRUGNAME	Insulin-lispro
D0L6JE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0MY1U	TTDDRUID	D0MY1U
D0MY1U	DRUGNAME	Intanza
D0MY1U	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D09HNV	TTDDRUID	D09HNV
D09HNV	DRUGNAME	Intedanib
D09HNV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
D09HNV	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved
D09HNV	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D09HNV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0T4GA	TTDDRUID	D0T4GA
D0T4GA	DRUGNAME	INTEGRA Artificial Skin
D0T4GA	INDICATI	Skin burns [ICD-11: ME65.0] Approved

D09PMV	TTDDRUID	D09PMV
D09PMV	DRUGNAME	Interferon Alfa-2a, Recombinant
D09PMV	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Approved

D0P0WV	TTDDRUID	D0P0WV
D0P0WV	DRUGNAME	Interferon Alfa-2b
D0P0WV	INDICATI	Melanoma [ICD-11: 2C30] Approved

D04RZD	TTDDRUID	D04RZD
D04RZD	DRUGNAME	Interferon Alfa-2b, Recombinant
D04RZD	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved

D0GA0A	TTDDRUID	D0GA0A
D0GA0A	DRUGNAME	Interferon alfacon-1
D0GA0A	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D03QCW	TTDDRUID	D03QCW
D03QCW	DRUGNAME	Interferon alfa-n1
D03QCW	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved

D07CMM	TTDDRUID	D07CMM
D07CMM	DRUGNAME	Interferon alfa-n3
D07CMM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0V4JQ	TTDDRUID	D0V4JQ
D0V4JQ	DRUGNAME	Interferon beta-1a
D0V4JQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0CQ2O	TTDDRUID	D0CQ2O
D0CQ2O	DRUGNAME	Interferon beta-1b
D0CQ2O	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0Z1KC	TTDDRUID	D0Z1KC
D0Z1KC	DRUGNAME	Interferon gamma
D0Z1KC	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0R7US	TTDDRUID	D0R7US
D0R7US	DRUGNAME	Interferon gamma-1a
D0R7US	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0U8US	TTDDRUID	D0U8US
D0U8US	DRUGNAME	Interferon gamma-1b
D0U8US	INDICATI	Chronic granulomatous disease [ICD-11: 4A00.0Y] Approved

D0AM4P	TTDDRUID	D0AM4P
D0AM4P	DRUGNAME	Interferon gamma-n1
D0AM4P	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0CH1U	TTDDRUID	D0CH1U
D0CH1U	DRUGNAME	Interleukin-3
D0CH1U	INDICATI	Aplastic anemia [ICD-11: 3A70] Approved

D0I2NF	TTDDRUID	D0I2NF
D0I2NF	DRUGNAME	Intragam P
D0I2NF	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D02QHJ	TTDDRUID	D02QHJ
D02QHJ	DRUGNAME	Intratect
D02QHJ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0E5HO	TTDDRUID	D0E5HO
D0E5HO	DRUGNAME	Intrathecal electrolyte solution
D0E5HO	INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved

D01IWS	TTDDRUID	D01IWS
D01IWS	DRUGNAME	Inulin
D01IWS	INDICATI	Measure kidney function [ICD-11: MG02] Approved

D02KFP	TTDDRUID	D02KFP
D02KFP	DRUGNAME	Invert sugar
D02KFP	INDICATI	Nutritional deficiency [ICD-11: 5B50-5B71] Approved

D02JIS	TTDDRUID	D02JIS
D02JIS	DRUGNAME	Iobenguane I-123
D02JIS	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Approved

D0TP8R	TTDDRUID	D0TP8R
D0TP8R	DRUGNAME	Iobenguane Sulfate I-131
D0TP8R	INDICATI	Pheochromocytoma [ICD-11: 5A75] Approved

D07ZBE	TTDDRUID	D07ZBE
D07ZBE	DRUGNAME	Iobitridol
D07ZBE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0P5CD	TTDDRUID	D0P5CD
D0P5CD	DRUGNAME	Iocetamic acid
D0P5CD	INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Approved

D06LHU	TTDDRUID	D06LHU
D06LHU	DRUGNAME	Iodamide
D06LHU	INDICATI	Brain disease [ICD-11: 8C70-8E61] Withdrawn from market
D06LHU	INDICATI	Contrast medium for intravenous urography [ICD-11: GC2Z] Approved

D01JQJ	TTDDRUID	D01JQJ
D01JQJ	DRUGNAME	Iodinated glycerol
D01JQJ	INDICATI	Asthma [ICD-11: CA23] Approved

D05EVF	TTDDRUID	D05EVF
D05EVF	DRUGNAME	Iodine-123-iodophenylpentadecanoic acid
D05EVF	INDICATI	Coronary artery disease [ICD-11: BA80] Approved

D07OIX	TTDDRUID	D07OIX
D07OIX	DRUGNAME	Iodipamide
D07OIX	INDICATI	Gallbladder disease [ICD-11: DC11.3] Approved

D0Y4YG	TTDDRUID	D0Y4YG
D0Y4YG	DRUGNAME	Iodixanol
D0Y4YG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0P1RL	TTDDRUID	D0P1RL
D0P1RL	DRUGNAME	Iodofiltic acid I-123
D0P1RL	INDICATI	Myocardial disease [ICD-11: BC43.20] Approved

D0G2MH	TTDDRUID	D0G2MH
D0G2MH	DRUGNAME	Iodohippurate Sodium
D0G2MH	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D06AEB	TTDDRUID	D06AEB
D06AEB	DRUGNAME	Iodoquinol
D06AEB	INDICATI	Amoebiasis [ICD-11: 1A36] Approved

D02DJS	TTDDRUID	D02DJS
D02DJS	DRUGNAME	Iodoxamate Meglumine
D02DJS	INDICATI	Bile duct disease [ICD-11: LB20] Approved

D02GJZ	TTDDRUID	D02GJZ
D02GJZ	DRUGNAME	Ioflupane i-123
D02GJZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D09RUW	TTDDRUID	D09RUW
D09RUW	DRUGNAME	Iomeprol
D09RUW	INDICATI	Brain disease [ICD-11: 8C70-8E61] Approved

D0O2HQ	TTDDRUID	D0O2HQ
D0O2HQ	DRUGNAME	Iopamidol
D0O2HQ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0A5JP	TTDDRUID	D0A5JP
D0A5JP	DRUGNAME	Iopanoic acid
D0A5JP	INDICATI	Vascular disease [ICD-11: BE2Z] Approved

D05MIL	TTDDRUID	D05MIL
D05MIL	DRUGNAME	Iopentol
D05MIL	INDICATI	Urinary tract disease [ICD-11: GC2Z] Approved

D0G2KD	TTDDRUID	D0G2KD
D0G2KD	DRUGNAME	Iophendylate
D0G2KD	INDICATI	Spinal cord injury [ICD-11: ND51.2] Approved

D07GNP	TTDDRUID	D07GNP
D07GNP	DRUGNAME	Iopromide
D07GNP	INDICATI	X-rays imaging [ICD-11: N.A.] Approved

D02KCV	TTDDRUID	D02KCV
D02KCV	DRUGNAME	Iothalamate
D02KCV	INDICATI	Arthropathy [ICD-11: FA11-FA38] Approved

D0B8LN	TTDDRUID	D0B8LN
D0B8LN	DRUGNAME	Iotrolan
D0B8LN	INDICATI	Radiocontrast agent [ICD-11: N.A.] Approved

D0U1ZD	TTDDRUID	D0U1ZD
D0U1ZD	DRUGNAME	Ioversol
D0U1ZD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0X7IT	TTDDRUID	D0X7IT
D0X7IT	DRUGNAME	Ioxaglate
D0X7IT	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0D8ZB	TTDDRUID	D0D8ZB
D0D8ZB	DRUGNAME	Ioxithalamate
D0D8ZB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D08CSE	TTDDRUID	D08CSE
D08CSE	DRUGNAME	IP-880
D08CSE	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D03FEO	TTDDRUID	D03FEO
D03FEO	DRUGNAME	Ipecac
D03FEO	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D0RU0O	TTDDRUID	D0RU0O
D0RU0O	DRUGNAME	IPI-145
D0RU0O	INDICATI	Arthritis [ICD-11: FA20] Phase 3
D0RU0O	INDICATI	Follicular lymphoma [ICD-11: 2A80] Approved
D0RU0O	INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Approved

D07BVI	TTDDRUID	D07BVI
D07BVI	DRUGNAME	Ipilimumab
D07BVI	INDICATI	Melanoma [ICD-11: 2C30] Approved

D06AAP	TTDDRUID	D06AAP
D06AAP	DRUGNAME	Ipodate
D06AAP	INDICATI	Graves disease [ICD-11: 5A02.0] Approved

D0S0AS	TTDDRUID	D0S0AS
D0S0AS	DRUGNAME	Ipratropium
D0S0AS	INDICATI	Obstructive lung disease [ICD-11: CA22.Z] Approved

D0R2OA	TTDDRUID	D0R2OA
D0R2OA	DRUGNAME	Ipriflavone
D0R2OA	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0C1QS	TTDDRUID	D0C1QS
D0C1QS	DRUGNAME	Iprodione
D0C1QS	INDICATI	Plant grey mould disease [ICD-11: N.A.] Approved

D00JAU	TTDDRUID	D00JAU
D00JAU	DRUGNAME	Irbesartan
D00JAU	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07HOB	TTDDRUID	D07HOB
D07HOB	DRUGNAME	Irinotecan
D07HOB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved

D0Y3TM	TTDDRUID	D0Y3TM
D0Y3TM	DRUGNAME	Iron
D0Y3TM	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
D0Y3TM	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Phase 2

D08OKJ	TTDDRUID	D08OKJ
D08OKJ	DRUGNAME	Iron Dextran
D08OKJ	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved

D08JMO	TTDDRUID	D08JMO
D08JMO	DRUGNAME	Iron proteinsuccinylate
D08JMO	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D04MRQ	TTDDRUID	D04MRQ
D04MRQ	DRUGNAME	Irsogladine
D04MRQ	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Approved

D0L3WJ	TTDDRUID	D0L3WJ
D0L3WJ	DRUGNAME	IRT-103
D0L3WJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0PI3Z	TTDDRUID	D0PI3Z
D0PI3Z	DRUGNAME	Isepamicin
D0PI3Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00OTT	TTDDRUID	D00OTT
D00OTT	DRUGNAME	ISIS 1570
D00OTT	INDICATI	Lleum inflammation [ICD-11: 1A40.0] Approved

D0I2VK	TTDDRUID	D0I2VK
D0I2VK	DRUGNAME	Isocarboxazid
D0I2VK	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D08HUC	TTDDRUID	D08HUC
D08HUC	DRUGNAME	Isoetharine
D08HUC	INDICATI	Asthma [ICD-11: CA23] Approved

D0DP6L	TTDDRUID	D0DP6L
D0DP6L	DRUGNAME	Isoflurane
D0DP6L	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0B2OT	TTDDRUID	D0B2OT
D0B2OT	DRUGNAME	Isoflurophate
D0B2OT	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D09XQF	TTDDRUID	D09XQF
D09XQF	DRUGNAME	Isoniazid
D09XQF	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D0Z9PX	TTDDRUID	D0Z9PX
D0Z9PX	DRUGNAME	Isopropamide iodide
D0Z9PX	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0I8FI	TTDDRUID	D0I8FI
D0I8FI	DRUGNAME	Isoproterenol
D0I8FI	INDICATI	Heart block [ICD-11: BC63] Approved
D0I8FI	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0I1SK	TTDDRUID	D0I1SK
D0I1SK	DRUGNAME	Isosorbide Dinitrate
D0I1SK	INDICATI	Anal fissure [ICD-11: DB50.0] Approved
D0I1SK	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0YS7D	TTDDRUID	D0YS7D
D0YS7D	DRUGNAME	Isosorbide Mononitrate
D0YS7D	INDICATI	Hydrocephalus [ICD-11: 8D64] Approved

D0P2YD	TTDDRUID	D0P2YD
D0P2YD	DRUGNAME	Isosulfan blue
D0P2YD	INDICATI	Investigative surgical procedure [ICD-11: QB8Z] Approved

D00DKK	TTDDRUID	D00DKK
D00DKK	DRUGNAME	Isotretinoin
D00DKK	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0E9CD	TTDDRUID	D0E9CD
D0E9CD	DRUGNAME	Isovanillin
D0E9CD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0I8CA	TTDDRUID	D0I8CA
D0I8CA	DRUGNAME	Isoxyl
D0I8CA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Q0JG	TTDDRUID	D0Q0JG
D0Q0JG	DRUGNAME	Ispaghula
D0Q0JG	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0Z7KE	TTDDRUID	D0Z7KE
D0Z7KE	DRUGNAME	Isradipine
D0Z7KE	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0V4IB	TTDDRUID	D0V4IB
D0V4IB	DRUGNAME	Itraconazole
D0V4IB	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D02OBL	TTDDRUID	D02OBL
D02OBL	DRUGNAME	Iv human immunoglobulin
D02OBL	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0S9QA	TTDDRUID	D0S9QA
D0S9QA	DRUGNAME	Ivabradine
D0S9QA	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0W7WC	TTDDRUID	D0W7WC
D0W7WC	DRUGNAME	Ivacaftor
D0W7WC	INDICATI	Cystic fibrosis [ICD-11: CA25] Approved

D09YHJ	TTDDRUID	D09YHJ
D09YHJ	DRUGNAME	Ivermectin
D09YHJ	INDICATI	Intestinal strongyloidiasis due to nematode parasite [ICD-11: 1F6B] Approved

D07DCG	TTDDRUID	D07DCG
D07DCG	DRUGNAME	Ivosidenib
D07DCG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0W2EK	TTDDRUID	D0W2EK
D0W2EK	DRUGNAME	Ixabepilone
D0W2EK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D08NMV	TTDDRUID	D08NMV
D08NMV	DRUGNAME	Ixekizumab
D08NMV	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
D08NMV	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3

D0Z5IP	TTDDRUID	D0Z5IP
D0Z5IP	DRUGNAME	Ixiaro
D0Z5IP	INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved

D01HRJ	TTDDRUID	D01HRJ
D01HRJ	DRUGNAME	JEBIK V
D01HRJ	INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved

D0X1WJ	TTDDRUID	D0X1WJ
D0X1WJ	DRUGNAME	Josamycin
D0X1WJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0K6VD	TTDDRUID	D0K6VD
D0K6VD	DRUGNAME	Juniper tar
D0K6VD	INDICATI	Eczema [ICD-11: EA80-EA89] Approved

D0YV1Q	TTDDRUID	D0YV1Q
D0YV1Q	DRUGNAME	Kanamycin
D0YV1Q	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Q2ZT	TTDDRUID	D0Q2ZT
D0Q2ZT	DRUGNAME	Kaolin/pectin
D0Q2ZT	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0L1WV	TTDDRUID	D0L1WV
D0L1WV	DRUGNAME	Kawain
D0L1WV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0UM7O	TTDDRUID	D0UM7O
D0UM7O	DRUGNAME	Ketamine
D0UM7O	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D08VRO	TTDDRUID	D08VRO
D08VRO	DRUGNAME	Ketanserin
D08VRO	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04BCW	TTDDRUID	D04BCW
D04BCW	DRUGNAME	Ketobemidone
D04BCW	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0B4IF	TTDDRUID	D0B4IF
D0B4IF	DRUGNAME	Ketoconazole
D0B4IF	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0W9WF	TTDDRUID	D0W9WF
D0W9WF	DRUGNAME	Ketoprofen
D0W9WF	INDICATI	Musculoskeletal pain [ICD-11: MG30] Approved
D0W9WF	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0D9JW	TTDDRUID	D0D9JW
D0D9JW	DRUGNAME	Ketorolac
D0D9JW	INDICATI	Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved

D0YG7M	TTDDRUID	D0YG7M
D0YG7M	DRUGNAME	Ketotifen
D0YG7M	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D0G4KG	TTDDRUID	D0G4KG
D0G4KG	DRUGNAME	Khellin
D0G4KG	INDICATI	Asthma [ICD-11: CA23] Approved

D0O9KY	TTDDRUID	D0O9KY
D0O9KY	DRUGNAME	KI-0401
D0O9KY	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved

D0LC4L	TTDDRUID	D0LC4L
D0LC4L	DRUGNAME	KI-0806
D0LC4L	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D03OIW	TTDDRUID	D03OIW
D03OIW	DRUGNAME	Kinetin
D03OIW	INDICATI	Skin photodamage [ICD-11: EJ40] Approved

D05IPF	TTDDRUID	D05IPF
D05IPF	DRUGNAME	Kombiglyze XR/Komboglyze FDC
D05IPF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0KL9X	TTDDRUID	D0KL9X
D0KL9X	DRUGNAME	Krypton, Kr-81m
D0KL9X	INDICATI	Asthma [ICD-11: CA23] Approved

D09LSX	TTDDRUID	D09LSX
D09LSX	DRUGNAME	KU-0058948
D09LSX	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D0A8XN	TTDDRUID	D0A8XN
D0A8XN	DRUGNAME	Labetalol
D0A8XN	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D05OFX	TTDDRUID	D05OFX
D05OFX	DRUGNAME	Lacosamide
D05OFX	INDICATI	Convulsion [ICD-11: 8A68.Z] Approved
D05OFX	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3
D05OFX	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
D05OFX	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 4

D0C1BG	TTDDRUID	D0C1BG
D0C1BG	DRUGNAME	Lactitol
D0C1BG	INDICATI	Liver disease [ICD-11: DB90-BD99] Approved

D0QD6R	TTDDRUID	D0QD6R
D0QD6R	DRUGNAME	Lactobacillus
D0QD6R	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0O5WD	TTDDRUID	D0O5WD
D0O5WD	DRUGNAME	Lactoferrin
D0O5WD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0T5BC	TTDDRUID	D0T5BC
D0T5BC	DRUGNAME	Lactulose
D0T5BC	INDICATI	Constipation [ICD-11: DD91.1] Approved

D09PUL	TTDDRUID	D09PUL
D09PUL	DRUGNAME	L-Alanine
D09PUL	INDICATI	Dietary shortage [ICD-11: 5B5K] Approved
D09PUL	INDICATI	Glioma [ICD-11: 2A00.0] Approved

D07WXE	TTDDRUID	D07WXE
D07WXE	DRUGNAME	L-alanyl-l-glutamine
D07WXE	INDICATI	Mucositis [ICD-11: CA00] Approved

D07TQV	TTDDRUID	D07TQV
D07TQV	DRUGNAME	Lamivudine
D07TQV	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Approved
D07TQV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D07TQV	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved

D03FLC	TTDDRUID	D03FLC
D03FLC	DRUGNAME	Lamotrigine
D03FLC	INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
D03FLC	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D08LEY	TTDDRUID	D08LEY
D08LEY	DRUGNAME	Lanadelumab
D08LEY	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved

D09HTS	TTDDRUID	D09HTS
D09HTS	DRUGNAME	Lanatoside a
D09HTS	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0P6IK	TTDDRUID	D0P6IK
D0P6IK	DRUGNAME	Lanatoside b
D0P6IK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0SL2V	TTDDRUID	D0SL2V
D0SL2V	DRUGNAME	Lanatoside c
D0SL2V	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0JV4Q	TTDDRUID	D0JV4Q
D0JV4Q	DRUGNAME	Lanoconazole
D0JV4Q	INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved

D0M2YE	TTDDRUID	D0M2YE
D0M2YE	DRUGNAME	Lanreotide acetate
D0M2YE	INDICATI	Acromegaly [ICD-11: 5A60.0] Approved

D0H1LO	TTDDRUID	D0H1LO
D0H1LO	DRUGNAME	Lanthanum carbonate
D0H1LO	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Approved

D08CDI	TTDDRUID	D08CDI
D08CDI	DRUGNAME	Lapatinib
D08CDI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D03LUN	TTDDRUID	D03LUN
D03LUN	DRUGNAME	Laronidase
D03LUN	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved

D07TOK	TTDDRUID	D07TOK
D07TOK	DRUGNAME	Larotrectinib
D07TOK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D07KHH	TTDDRUID	D07KHH
D07KHH	DRUGNAME	LAS-34273
D07KHH	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D09NMD	TTDDRUID	D09NMD
D09NMD	DRUGNAME	Lasofoxifene
D09NMD	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
D09NMD	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1

D0O5LU	TTDDRUID	D0O5LU
D0O5LU	DRUGNAME	Latamoxef
D0O5LU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0C6NM	TTDDRUID	D0C6NM
D0C6NM	DRUGNAME	Latanoprost
D0C6NM	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2
D0C6NM	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
D0C6NM	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D01TMF	TTDDRUID	D01TMF
D01TMF	DRUGNAME	Latrodectus antivenin
D01TMF	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D0UW3X	TTDDRUID	D0UW3X
D0UW3X	DRUGNAME	Laxatives
D0UW3X	INDICATI	Constipation [ICD-11: DD91.1] Approved

D0K8KE	TTDDRUID	D0K8KE
D0K8KE	DRUGNAME	Laxatives bulk forming
D0K8KE	INDICATI	Constipation [ICD-11: DD91.1] Approved

D0PO7P	TTDDRUID	D0PO7P
D0PO7P	DRUGNAME	Laxatives stimulant
D0PO7P	INDICATI	Constipation [ICD-11: DD91.1] Approved

D0Q3UQ	TTDDRUID	D0Q3UQ
D0Q3UQ	DRUGNAME	LC16m8
D0Q3UQ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D08ROP	TTDDRUID	D08ROP
D08ROP	DRUGNAME	Leflunomide
D08ROP	INDICATI	Arthritis [ICD-11: FA20] Approved
D08ROP	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0Q5NX	TTDDRUID	D0Q5NX
D0Q5NX	DRUGNAME	Lenalidomide
D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D00OAY	TTDDRUID	D00OAY
D00OAY	DRUGNAME	Lenampicillin hci
D00OAY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0L7JR	TTDDRUID	D0L7JR
D0L7JR	DRUGNAME	Lenogastrim
D0L7JR	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved

D07XBE	TTDDRUID	D07XBE
D07XBE	DRUGNAME	Lentinan
D07XBE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0R0FO	TTDDRUID	D0R0FO
D0R0FO	DRUGNAME	Lenvatinib
D0R0FO	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D0R0FO	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0R0FO	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0R0FO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D09LPN	TTDDRUID	D09LPN
D09LPN	DRUGNAME	Lepirudin
D09LPN	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved

D0P2LR	TTDDRUID	D0P2LR
D0P2LR	DRUGNAME	Leprovac
D0P2LR	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved

D0P6ZH	TTDDRUID	D0P6ZH
D0P6ZH	DRUGNAME	Lercanidipine
D0P6ZH	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D0P6ZH	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0C3SW	TTDDRUID	D0C3SW
D0C3SW	DRUGNAME	Lesinurad
D0C3SW	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved

D0V9WF	TTDDRUID	D0V9WF
D0V9WF	DRUGNAME	Lestaurtinib
D0V9WF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved (orphan drug)
D0V9WF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0V9WF	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 3
D0V9WF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2/3

D0C1WH	TTDDRUID	D0C1WH
D0C1WH	DRUGNAME	Letrozole
D0C1WH	INDICATI	Hormonally-responsive breast cancer [ICD-11: 2C60-2C65] Approved

D0B6TW	TTDDRUID	D0B6TW
D0B6TW	DRUGNAME	Leucovorin Calcium
D0B6TW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0M3MN	TTDDRUID	D0M3MN
D0M3MN	DRUGNAME	Leucovorin/5-fluorouracil
D0M3MN	INDICATI	Colon cancer [ICD-11: 2B90.Z] Approved

D0U5FF	TTDDRUID	D0U5FF
D0U5FF	DRUGNAME	Leuprolide
D0U5FF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D04ASH	TTDDRUID	D04ASH
D04ASH	DRUGNAME	Leuprorelin acetate
D04ASH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0T5XN	TTDDRUID	D0T5XN
D0T5XN	DRUGNAME	LEURUBICIN
D0T5XN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0G8SQ	TTDDRUID	D0G8SQ
D0G8SQ	DRUGNAME	Levacecarnine hci
D0G8SQ	INDICATI	Cognitive impairment [ICD-11: 6D71] Approved
D0G8SQ	INDICATI	Nutritional deficiency [ICD-11: 5B50-5B71] Approved

D02ZJI	TTDDRUID	D02ZJI
D02ZJI	DRUGNAME	Levalbuterol
D02ZJI	INDICATI	Asthma [ICD-11: CA23] Approved

D04QWE	TTDDRUID	D04QWE
D04QWE	DRUGNAME	Levallorphan
D04QWE	INDICATI	Narcotic depression [ICD-11: 6A7Z] Approved

D0CF2Q	TTDDRUID	D0CF2Q
D0CF2Q	DRUGNAME	Levamisole
D0CF2Q	INDICATI	Colon cancer [ICD-11: 2B90.Z] Withdrawn from market
D0CF2Q	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved

D0E1XL	TTDDRUID	D0E1XL
D0E1XL	DRUGNAME	Levetiracetam
D0E1XL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
D0E1XL	INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved

D0A6CQ	TTDDRUID	D0A6CQ
D0A6CQ	DRUGNAME	Levobetaxolol
D0A6CQ	INDICATI	Chronic open-angle glaucoma [ICD-11: 9C61.0] Approved

D00IUG	TTDDRUID	D00IUG
D00IUG	DRUGNAME	Levobunolol
D00IUG	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D09QUQ	TTDDRUID	D09QUQ
D09QUQ	DRUGNAME	Levobupivacaine
D09QUQ	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D08SEI	TTDDRUID	D08SEI
D08SEI	DRUGNAME	Levocabastine
D08SEI	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D0M8PW	TTDDRUID	D0M8PW
D0M8PW	DRUGNAME	Levocetirizine dihydrochloride
D0M8PW	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D08HVR	TTDDRUID	D08HVR
D08HVR	DRUGNAME	Levodopa
D08HVR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0X5WJ	TTDDRUID	D0X5WJ
D0X5WJ	DRUGNAME	Levodropropizine
D0X5WJ	INDICATI	Cough [ICD-11: MD12] Approved

D02RSN	TTDDRUID	D02RSN
D02RSN	DRUGNAME	Levofloxacin
D02RSN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Q6LA	TTDDRUID	D0Q6LA
D0Q6LA	DRUGNAME	Levoleucovorin
D0Q6LA	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D09LZT	TTDDRUID	D09LZT
D09LZT	DRUGNAME	Levomepromazine
D09LZT	INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
D09LZT	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved

D05PIZ	TTDDRUID	D05PIZ
D05PIZ	DRUGNAME	Levomethadyl Acetate
D05PIZ	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved

D02XOK	TTDDRUID	D02XOK
D02XOK	DRUGNAME	Levomilnacipran
D02XOK	INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved

D0BA9U	TTDDRUID	D0BA9U
D0BA9U	DRUGNAME	Levonorgestrel
D0BA9U	INDICATI	Contraception [ICD-11: QA21] Approved

D0G6CT	TTDDRUID	D0G6CT
D0G6CT	DRUGNAME	Levonorgestrel
D0G6CT	INDICATI	Contraception [ICD-11: QA21] Approved

D0HF0W	TTDDRUID	D0HF0W
D0HF0W	DRUGNAME	Levopropoxyphene Napsylate Anhydrous
D0HF0W	INDICATI	Cough [ICD-11: MD12] Approved

D0W9GA	TTDDRUID	D0W9GA
D0W9GA	DRUGNAME	Levormeloxifene non-steroidal
D0W9GA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0T3HY	TTDDRUID	D0T3HY
D0T3HY	DRUGNAME	Levorphanol
D0T3HY	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Terminated
D0T3HY	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0C4HG	TTDDRUID	D0C4HG
D0C4HG	DRUGNAME	Levosimendan
D0C4HG	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D06RGG	TTDDRUID	D06RGG
D06RGG	DRUGNAME	Levothyroxine
D06RGG	INDICATI	Hypothyroidism [ICD-11: 5A00] Approved

D02NDV	TTDDRUID	D02NDV
D02NDV	DRUGNAME	Levovist
D02NDV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D00ENY	TTDDRUID	D00ENY
D00ENY	DRUGNAME	L-Glutamic Acid
D00ENY	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D01JIA	TTDDRUID	D01JIA
D01JIA	DRUGNAME	L-glutamine
D01JIA	INDICATI	Short bowel syndrome [ICD-11: KB89.1] Approved

D0TK7R	TTDDRUID	D0TK7R
D0TK7R	DRUGNAME	LGX818
D0TK7R	INDICATI	Melanoma [ICD-11: 2C30] Approved
D0TK7R	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0X4RN	TTDDRUID	D0X4RN
D0X4RN	DRUGNAME	Lidocaine
D0X4RN	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
D0X4RN	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 2

D0L7VL	TTDDRUID	D0L7VL
D0L7VL	DRUGNAME	LIDOFLAZINE
D0L7VL	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0Q9EV	TTDDRUID	D0Q9EV
D0Q9EV	DRUGNAME	lifitegrast
D0Q9EV	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3
D0Q9EV	INDICATI	Dry eye disease [ICD-11: 9E1Z] Approved

D0N3NO	TTDDRUID	D0N3NO
D0N3NO	DRUGNAME	Limaprost
D0N3NO	INDICATI	Spinal stenosis [ICD-11: FA82] Approved

D00GNJ	TTDDRUID	D00GNJ
D00GNJ	DRUGNAME	Linaclotide
D00GNJ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D02EYG	TTDDRUID	D02EYG
D02EYG	DRUGNAME	Linagliptin
D02EYG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0Q0EX	TTDDRUID	D0Q0EX
D0Q0EX	DRUGNAME	Lincomycin
D0Q0EX	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved

D0Q5IN	TTDDRUID	D0Q5IN
D0Q5IN	DRUGNAME	Lindane
D0Q5IN	INDICATI	Infestations of lice and scabies [ICD-11: 1G00.Z] Approved

D07UYO	TTDDRUID	D07UYO
D07UYO	DRUGNAME	Linezolid
D07UYO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0S6JG	TTDDRUID	D0S6JG
D0S6JG	DRUGNAME	Liothyronine
D0S6JG	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3
D0S6JG	INDICATI	Hypothyroidism [ICD-11: 5A00] Approved

D07RSI	TTDDRUID	D07RSI
D07RSI	DRUGNAME	Lipobean
D07RSI	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Approved

D0G5LX	TTDDRUID	D0G5LX
D0G5LX	DRUGNAME	Liposomal tretinoin
D0G5LX	INDICATI	Acute promyelocytic leukaemia [ICD-11: 2A60.0] Approved

D03GOI	TTDDRUID	D03GOI
D03GOI	DRUGNAME	Liraglutide
D03GOI	INDICATI	Obesity [ICD-11: 5B81] Phase 2
D03GOI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0G4YT	TTDDRUID	D0G4YT
D0G4YT	DRUGNAME	Liranaftate
D0G4YT	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D00DEF	TTDDRUID	D00DEF
D00DEF	DRUGNAME	Lisdexamfetamine
D00DEF	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved

D07HGR	TTDDRUID	D07HGR
D07HGR	DRUGNAME	Lisinopril
D07HGR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0X7KB	TTDDRUID	D0X7KB
D0X7KB	DRUGNAME	Lisuride
D0X7KB	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 3
D0X7KB	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D04UUH	TTDDRUID	D04UUH
D04UUH	DRUGNAME	Lithium Carbonate
D04UUH	INDICATI	Manic depression disorder [ICD-11: 6A71] Approved

D0Q4EW	TTDDRUID	D0Q4EW
D0Q4EW	DRUGNAME	Lithium Citrate
D0Q4EW	INDICATI	Bipolar disorder [ICD-11: 6A60] Approved

D01EHI	TTDDRUID	D01EHI
D01EHI	DRUGNAME	Live attenuated H1N1 pandemic influenza vaccine
D01EHI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0BI1C	TTDDRUID	D0BI1C
D0BI1C	DRUGNAME	Live attenuated influenza vaccine
D0BI1C	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D05MKA	TTDDRUID	D05MKA
D05MKA	DRUGNAME	Lixisenatide
D05MKA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D08PSU	TTDDRUID	D08PSU
D08PSU	DRUGNAME	Lmw heparin
D08PSU	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
D08PSU	INDICATI	Hematologic disease [ICD-11: 3C0Z] Approved

D0S4QZ	TTDDRUID	D0S4QZ
D0S4QZ	DRUGNAME	Lobaplatin
D0S4QZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0OG3K	TTDDRUID	D0OG3K
D0OG3K	DRUGNAME	Lodoxamide
D0OG3K	INDICATI	Asthma [ICD-11: CA23] Approved

D0K3MC	TTDDRUID	D0K3MC
D0K3MC	DRUGNAME	Lofepramine
D0K3MC	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0K0MW	TTDDRUID	D0K0MW
D0K0MW	DRUGNAME	Lofexidine
D0K0MW	INDICATI	Heroin and opiate withdrawal [ICD-11: 6C43] Approved
D0K0MW	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved

D02KOF	TTDDRUID	D02KOF
D02KOF	DRUGNAME	Lomefloxacin
D02KOF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0N3ZJ	TTDDRUID	D0N3ZJ
D0N3ZJ	DRUGNAME	LOMERIZINE
D0N3ZJ	INDICATI	Migraine [ICD-11: 8A80] Approved

D04JPJ	TTDDRUID	D04JPJ
D04JPJ	DRUGNAME	Lomustine
D04JPJ	INDICATI	Brain cancer [ICD-11: 2A00] Approved

D0CS2F	TTDDRUID	D0CS2F
D0CS2F	DRUGNAME	Loperamide
D0CS2F	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0U5GB	TTDDRUID	D0U5GB
D0U5GB	DRUGNAME	Lopinavir
D0U5GB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0E9WL	TTDDRUID	D0E9WL
D0E9WL	DRUGNAME	Loracarbef
D0E9WL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06ABF	TTDDRUID	D06ABF
D06ABF	DRUGNAME	Loratadine
D06ABF	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
D06ABF	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D0E0OG	TTDDRUID	D0E0OG
D0E0OG	DRUGNAME	Lorazepam
D0E0OG	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0Y9LL	TTDDRUID	D0Y9LL
D0Y9LL	DRUGNAME	Lorcainide
D0Y9LL	INDICATI	Heart arrhythmia [ICD-11: BC65] Approved

D01JMC	TTDDRUID	D01JMC
D01JMC	DRUGNAME	Lorcaserin
D01JMC	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Phase 1
D01JMC	INDICATI	Obesity [ICD-11: 5B81] Approved

D0AF6O	TTDDRUID	D0AF6O
D0AF6O	DRUGNAME	Lorlatinib
D0AF6O	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D0M6LN	TTDDRUID	D0M6LN
D0M6LN	DRUGNAME	L-ornithine L-aspartate
D0M6LN	INDICATI	Hepatic encephalopathy [ICD-11: DB99.5] Approved

D0UL2L	TTDDRUID	D0UL2L
D0UL2L	DRUGNAME	Lornoxicam
D0UL2L	INDICATI	Migraine [ICD-11: 8A80] Approved

D0DD0K	TTDDRUID	D0DD0K
D0DD0K	DRUGNAME	Losartan
D0DD0K	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0X6GN	TTDDRUID	D0X6GN
D0X6GN	DRUGNAME	Loteprednol Etabonate
D0X6GN	INDICATI	Eye inflammation [ICD-11: 9A02] Approved

D06WTZ	TTDDRUID	D06WTZ
D06WTZ	DRUGNAME	Lovastatin
D06WTZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D06WTZ	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D0U5OE	TTDDRUID	D0U5OE
D0U5OE	DRUGNAME	Loxapine
D0U5OE	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0LR4B	TTDDRUID	D0LR4B
D0LR4B	DRUGNAME	Loxoprofen gel
D0LR4B	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0R1CR	TTDDRUID	D0R1CR
D0R1CR	DRUGNAME	L-Phenylalanine
D0R1CR	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0R9NB	TTDDRUID	D0R9NB
D0R9NB	DRUGNAME	Lprivask
D0R9NB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D0DZ3X	TTDDRUID	D0DZ3X
D0DZ3X	DRUGNAME	L-Proline
D0DZ3X	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D05EJG	TTDDRUID	D05EJG
D05EJG	DRUGNAME	L-Tryptophan
D05EJG	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D01CRB	TTDDRUID	D01CRB
D01CRB	DRUGNAME	L-Tyrosine
D01CRB	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0Y7OJ	TTDDRUID	D0Y7OJ
D0Y7OJ	DRUGNAME	LU302146
D0Y7OJ	INDICATI	Pulmonary hypertension [ICD-11: BB01] Approved

D00CTS	TTDDRUID	D00CTS
D00CTS	DRUGNAME	Lubiprostone
D00CTS	INDICATI	Chronic idiopathic constipation [ICD-11: DC32] Approved

D09OZC	TTDDRUID	D09OZC
D09OZC	DRUGNAME	Lucanthone
D09OZC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0F4HB	TTDDRUID	D0F4HB
D0F4HB	DRUGNAME	Lucinactant
D0F4HB	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved

D0U4XJ	TTDDRUID	D0U4XJ
D0U4XJ	DRUGNAME	Luliconazole
D0U4XJ	INDICATI	Tinea pedis [ICD-11: 1F28.2] Approved

D06XLD	TTDDRUID	D06XLD
D06XLD	DRUGNAME	Luliconazole 1.3%
D06XLD	INDICATI	Tinea pedis [ICD-11: 1F28.2] Approved

D0S9WB	TTDDRUID	D0S9WB
D0S9WB	DRUGNAME	Lumacaftor + ivacaftor
D0S9WB	INDICATI	Acute lung injury [ICD-11: NB32.3] Approved
D0S9WB	INDICATI	Cystic fibrosis [ICD-11: CA25] Approved

D06MQM	TTDDRUID	D06MQM
D06MQM	DRUGNAME	Lumefantrine
D06MQM	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D04YMH	TTDDRUID	D04YMH
D04YMH	DRUGNAME	Lumiracoxib
D04YMH	INDICATI	Knee osteoarthritis [ICD-11: FA01] Approved

D01QGX	TTDDRUID	D01QGX
D01QGX	DRUGNAME	Lurasidone hydrochloride
D01QGX	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0TD1R	TTDDRUID	D0TD1R
D0TD1R	DRUGNAME	Lusutrombopag
D0TD1R	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved

D0DQ7V	TTDDRUID	D0DQ7V
D0DQ7V	DRUGNAME	Lutetium Lu 177 dotatate
D0DQ7V	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Approved

D0Z2CM	TTDDRUID	D0Z2CM
D0Z2CM	DRUGNAME	Lutropin alfa
D0Z2CM	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D0M5JI	TTDDRUID	D0M5JI
D0M5JI	DRUGNAME	Luvox
D0M5JI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D05SBO	TTDDRUID	D05SBO
D05SBO	DRUGNAME	LY2835219
D05SBO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
D05SBO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0E5TI	TTDDRUID	D0E5TI
D0E5TI	DRUGNAME	Lyme disease vaccine
D0E5TI	INDICATI	Lyme disease [ICD-11: 1C1G] Approved

D04VEJ	TTDDRUID	D04VEJ
D04VEJ	DRUGNAME	Lymecycline
D04VEJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07KJH	TTDDRUID	D07KJH
D07KJH	DRUGNAME	LYMErix
D07KJH	INDICATI	Lyme disease [ICD-11: 1C1G] Approved

D0I5WO	TTDDRUID	D0I5WO
D0I5WO	DRUGNAME	Lymphocyte immune globulin, anti-thymocyte globulin
D0I5WO	INDICATI	Aplastic anemia [ICD-11: 3A70] Approved

D09PZZ	TTDDRUID	D09PZZ
D09PZZ	DRUGNAME	Lypressin
D09PZZ	INDICATI	Amnesia [ICD-11: MB21.1] Approved

D09MVZ	TTDDRUID	D09MVZ
D09MVZ	DRUGNAME	mab17-1a
D09MVZ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved

D0BV3J	TTDDRUID	D0BV3J
D0BV3J	DRUGNAME	Macimorelin
D0BV3J	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
D0BV3J	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3
D0BV3J	INDICATI	Somatotropin deficiency [ICD-11: 5A61.0] Approved

D0S7JH	TTDDRUID	D0S7JH
D0S7JH	DRUGNAME	Macitentan
D0S7JH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0Q6OS	TTDDRUID	D0Q6OS
D0Q6OS	DRUGNAME	Macrolides
D0Q6OS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0B8QB	TTDDRUID	D0B8QB
D0B8QB	DRUGNAME	Magnesium
D0B8QB	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Approved

D02LDN	TTDDRUID	D02LDN
D02LDN	DRUGNAME	Magnesium Sulfate
D02LDN	INDICATI	Acute pain [ICD-11: MG31] Approved

D03UFQ	TTDDRUID	D03UFQ
D03UFQ	DRUGNAME	Malaria vaccine
D03UFQ	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0K3LW	TTDDRUID	D0K3LW
D0K3LW	DRUGNAME	Malathion
D0K3LW	INDICATI	Pediculus capitis infestation [ICD-11: 1G00.0] Approved

D04BKZ	TTDDRUID	D04BKZ
D04BKZ	DRUGNAME	Mangafodipir Trisodium
D04BKZ	INDICATI	Magnetic resonance imaging of liver [ICD-11: ME21] Approved

D02QPR	TTDDRUID	D02QPR
D02QPR	DRUGNAME	Manganese Chloride
D02QPR	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D0C6QG	TTDDRUID	D0C6QG
D0C6QG	DRUGNAME	Manganese Chloride Tetrahydrate
D0C6QG	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D0VB3Y	TTDDRUID	D0VB3Y
D0VB3Y	DRUGNAME	Manganese Sulfate
D0VB3Y	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D0P7EK	TTDDRUID	D0P7EK
D0P7EK	DRUGNAME	Mannitol
D0P7EK	INDICATI	Bronchiectasis [ICD-11: CA24] Approved
D0P7EK	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Approved

D03KQF	TTDDRUID	D03KQF
D03KQF	DRUGNAME	Maprotiline
D03KQF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0NR6S	TTDDRUID	D0NR6S
D0NR6S	DRUGNAME	Maraviroc
D0NR6S	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
D0NR6S	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0P1FO	TTDDRUID	D0P1FO
D0P1FO	DRUGNAME	Marinol
D0P1FO	INDICATI	Anorexia nervosa cachexia [ICD-11: 6B80] Approved

D0U3YB	TTDDRUID	D0U3YB
D0U3YB	DRUGNAME	Masoprocol
D0U3YB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D05BTM	TTDDRUID	D05BTM
D05BTM	DRUGNAME	Maxacalcitol
D05BTM	INDICATI	Disorder of calcium metabolism [ICD-11: 5C64.5] Approved

D0H8QL	TTDDRUID	D0H8QL
D0H8QL	DRUGNAME	Mazindol
D0H8QL	INDICATI	Obesity [ICD-11: 5B81] Approved

D0E3SF	TTDDRUID	D0E3SF
D0E3SF	DRUGNAME	MCB-3837
D0E3SF	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D06DLI	TTDDRUID	D06DLI
D06DLI	DRUGNAME	MCI-186
D06DLI	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved

D06WKA	TTDDRUID	D06WKA
D06WKA	DRUGNAME	MD-1100
D06WKA	INDICATI	Constipation [ICD-11: DD91.1] Approved
D06WKA	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D0M1YR	TTDDRUID	D0M1YR
D0M1YR	DRUGNAME	MDV3101
D0M1YR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0T5VQ	TTDDRUID	D0T5VQ
D0T5VQ	DRUGNAME	Mearubik
D0T5VQ	INDICATI	Measles [ICD-11: 1F03] Approved

D06JLX	TTDDRUID	D06JLX
D06JLX	DRUGNAME	Measles vaccine
D06JLX	INDICATI	Measles [ICD-11: 1F03] Approved

D0J1MI	TTDDRUID	D0J1MI
D0J1MI	DRUGNAME	Mebendazole
D0J1MI	INDICATI	Worm infection [ICD-11: 1F90.Z] Approved

D0VU8Q	TTDDRUID	D0VU8Q
D0VU8Q	DRUGNAME	Mebeverine
D0VU8Q	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0F2QS	TTDDRUID	D0F2QS
D0F2QS	DRUGNAME	Mebiphon
D0F2QS	INDICATI	Bone metastases [ICD-11: 2D50] Approved

D02KBD	TTDDRUID	D02KBD
D02KBD	DRUGNAME	Mebutamate
D02KBD	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0V8HA	TTDDRUID	D0V8HA
D0V8HA	DRUGNAME	Mecamylamine
D0V8HA	INDICATI	Essential hypertension [ICD-11: BA00] Approved

D0F3JT	TTDDRUID	D0F3JT
D0F3JT	DRUGNAME	Mecasermin
D0F3JT	INDICATI	Growth failure [ICD-11: LD2F.1Y] Approved

D03SSE	TTDDRUID	D03SSE
D03SSE	DRUGNAME	Mechlorethamine
D03SSE	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 3
D03SSE	INDICATI	T-cell lymphoma [ICD-11: 2A90] Approved

D0T1XW	TTDDRUID	D0T1XW
D0T1XW	DRUGNAME	Meclizine
D0T1XW	INDICATI	Dizziness [ICD-11: MB48] Approved

D07JHH	TTDDRUID	D07JHH
D07JHH	DRUGNAME	Meclocycline
D07JHH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0MN9K	TTDDRUID	D0MN9K
D0MN9K	DRUGNAME	Meclofenamate Sodium
D0MN9K	INDICATI	Arthritis [ICD-11: FA20] Approved

D08IFL	TTDDRUID	D08IFL
D08IFL	DRUGNAME	Meclofenamic acid
D08IFL	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Approved
D08IFL	INDICATI	Joint pain [ICD-11: ME82] Approved

D09ZHZ	TTDDRUID	D09ZHZ
D09ZHZ	DRUGNAME	Mecobalamin
D09ZHZ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D04KUK	TTDDRUID	D04KUK
D04KUK	DRUGNAME	Medium chain triglycerides
D04KUK	INDICATI	Lymphatic disease [ICD-11: BD9Z] Approved

D0I2SD	TTDDRUID	D0I2SD
D0I2SD	DRUGNAME	Medroxyprogesterone
D0I2SD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D04SFH	TTDDRUID	D04SFH
D04SFH	DRUGNAME	Medrysone
D04SFH	INDICATI	Eye inflammation [ICD-11: 9A02] Approved

D09PHB	TTDDRUID	D09PHB
D09PHB	DRUGNAME	Mefenamic
D09PHB	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D05FTJ	TTDDRUID	D05FTJ
D05FTJ	DRUGNAME	Mefenamic acid
D05FTJ	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved

D0GQ7K	TTDDRUID	D0GQ7K
D0GQ7K	DRUGNAME	Mefloquine
D0GQ7K	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0PS6X	TTDDRUID	D0PS6X
D0PS6X	DRUGNAME	Mega-3-acid ethyl esters
D0PS6X	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Approved

D02IRD	TTDDRUID	D02IRD
D02IRD	DRUGNAME	Megesterol acetate
D02IRD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D04GJN	TTDDRUID	D04GJN
D04GJN	DRUGNAME	Megestrol
D04GJN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D07MEH	TTDDRUID	D07MEH
D07MEH	DRUGNAME	Meglitinides
D07MEH	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 4
D07MEH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0T6VD	TTDDRUID	D0T6VD
D0T6VD	DRUGNAME	Meglumine antimoniate
D0T6VD	INDICATI	Leishmania braziliensis infection [ICD-11: 1F54.2] Approved

D0JW1S	TTDDRUID	D0JW1S
D0JW1S	DRUGNAME	Meglumine gadoterate
D0JW1S	INDICATI	Blood brain barrier [ICD-11: 5C61.5] Approved

D0HV7K	TTDDRUID	D0HV7K
D0HV7K	DRUGNAME	Melacine
D0HV7K	INDICATI	Melanoma [ICD-11: 2C30] Approved

D06HCP	TTDDRUID	D06HCP
D06HCP	DRUGNAME	MELARSOPROL
D06HCP	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Approved

D0AN7B	TTDDRUID	D0AN7B
D0AN7B	DRUGNAME	Melatonin
D0AN7B	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0U0OT	TTDDRUID	D0U0OT
D0U0OT	DRUGNAME	Melevodopa
D0U0OT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0OR6A	TTDDRUID	D0OR6A
D0OR6A	DRUGNAME	Melinamide
D0OR6A	INDICATI	Hypocholesterolemia [ICD-11: 5C81] Approved

D0E0RY	TTDDRUID	D0E0RY
D0E0RY	DRUGNAME	Melitracen
D0E0RY	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0G7FJ	TTDDRUID	D0G7FJ
D0G7FJ	DRUGNAME	Meloxicam
D0G7FJ	INDICATI	Arthritis [ICD-11: FA20] Approved

D00FGO	TTDDRUID	D00FGO
D00FGO	DRUGNAME	Melphalan
D00FGO	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D01JEU	TTDDRUID	D01JEU
D01JEU	DRUGNAME	Memantine
D01JEU	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0B7VC	TTDDRUID	D0B7VC
D0B7VC	DRUGNAME	Menactra
D0B7VC	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D09KGQ	TTDDRUID	D09KGQ
D09KGQ	DRUGNAME	Menadiol sodium diphosphate
D09KGQ	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved

D03GET	TTDDRUID	D03GET
D03GET	DRUGNAME	Menadione
D03GET	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D03GET	INDICATI	Vitamin K deficiency [ICD-11: 5B59] Approved

D0WY9F	TTDDRUID	D0WY9F
D0WY9F	DRUGNAME	MenAfriVac
D0WY9F	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D0M0AA	TTDDRUID	D0M0AA
D0M0AA	DRUGNAME	MenHibrix
D0M0AA	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D04HXB	TTDDRUID	D04HXB
D04HXB	DRUGNAME	Meningitec
D04HXB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01NTO	TTDDRUID	D01NTO
D01NTO	DRUGNAME	Meningitis B
D01NTO	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D02NMJ	TTDDRUID	D02NMJ
D02NMJ	DRUGNAME	Meningococcal B vaccine
D02NMJ	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D0V7DW	TTDDRUID	D0V7DW
D0V7DW	DRUGNAME	Meningococcal groups A, C, Y and W-135 conjugate vaccine
D0V7DW	INDICATI	Meningococcal infection [ICD-11: 1C1C] Approved

D0SX6O	TTDDRUID	D0SX6O
D0SX6O	DRUGNAME	Meninvact
D0SX6O	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D0S4KI	TTDDRUID	D0S4KI
D0S4KI	DRUGNAME	Menitorix
D0S4KI	INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved

D02GTV	TTDDRUID	D02GTV
D02GTV	DRUGNAME	Menomune
D02GTV	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D04WBY	TTDDRUID	D04WBY
D04WBY	DRUGNAME	Menotropins
D04WBY	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D0P2EX	TTDDRUID	D0P2EX
D0P2EX	DRUGNAME	M-enoxaparin
D0P2EX	INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved

D0L4EG	TTDDRUID	D0L4EG
D0L4EG	DRUGNAME	Mentat
D0L4EG	INDICATI	Cognitive impairment [ICD-11: 6D71] Approved

D04CSZ	TTDDRUID	D04CSZ
D04CSZ	DRUGNAME	Menthol
D04CSZ	INDICATI	Throat irritation [ICD-11: CA0Y] Approved

D09KKH	TTDDRUID	D09KKH
D09KKH	DRUGNAME	Mepartricin
D09KKH	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0FV3V	TTDDRUID	D0FV3V
D0FV3V	DRUGNAME	Mepenzolate
D0FV3V	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
D0FV3V	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D00UYE	TTDDRUID	D00UYE
D00UYE	DRUGNAME	Meperidine
D00UYE	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0G1OZ	TTDDRUID	D0G1OZ
D0G1OZ	DRUGNAME	Mephentermine
D0G1OZ	INDICATI	High blood pressure [ICD-11: BA00] Approved

D07RGW	TTDDRUID	D07RGW
D07RGW	DRUGNAME	Mephenytoin
D07RGW	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D0O5YZ	TTDDRUID	D0O5YZ
D0O5YZ	DRUGNAME	Mepindolol
D0O5YZ	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0WO8W	TTDDRUID	D0WO8W
D0WO8W	DRUGNAME	Mepivacaine
D0WO8W	INDICATI	Analgesia [ICD-11: MB40.8] Approved

D03MTN	TTDDRUID	D03MTN
D03MTN	DRUGNAME	Mepolizumab
D03MTN	INDICATI	Asthma [ICD-11: CA23] Phase 2/3
D03MTN	INDICATI	Severe asthma [ICD-11: CA23] Approved

D0I5DS	TTDDRUID	D0I5DS
D0I5DS	DRUGNAME	Meprednisone
D0I5DS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0Y4AW	TTDDRUID	D0Y4AW
D0Y4AW	DRUGNAME	Meprobamate
D0Y4AW	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
D0Y4AW	INDICATI	Ischemic reperfusion injury [ICD-11: DB98.B] Discontinued in Phase 1
D0Y4AW	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0S5YC	TTDDRUID	D0S5YC
D0S5YC	DRUGNAME	MEPTAZINOL
D0S5YC	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D08JZS	TTDDRUID	D08JZS
D08JZS	DRUGNAME	Mepyramine
D08JZS	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D01NJI	TTDDRUID	D01NJI
D01NJI	DRUGNAME	Mepyramine maleate
D01NJI	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
D01NJI	INDICATI	Headache [ICD-11: 8A80-8A84] Approved

D09IMS	TTDDRUID	D09IMS
D09IMS	DRUGNAME	Mequitazine
D09IMS	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D09UZO	TTDDRUID	D09UZO
D09UZO	DRUGNAME	Mercaptopurine
D09UZO	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0O5FY	TTDDRUID	D0O5FY
D0O5FY	DRUGNAME	Meropenem
D0O5FY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0N5KF	TTDDRUID	D0N5KF
D0N5KF	DRUGNAME	Meropenem + vaborbactam
D0N5KF	INDICATI	Intra-abdominal infection [ICD-11: 1A40] Approved
D0N5KF	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0C4YC	TTDDRUID	D0C4YC
D0C4YC	DRUGNAME	Mesalazine
D0C4YC	INDICATI	Ulcerative colitis [ICD-11: DD71] Approved

D0C3YQ	TTDDRUID	D0C3YQ
D0C3YQ	DRUGNAME	Mesna
D0C3YQ	INDICATI	Urinary dysfunction [ICD-11: GC2Z] Approved

D01LUS	TTDDRUID	D01LUS
D01LUS	DRUGNAME	Mesoglycan
D01LUS	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Approved

D04AAN	TTDDRUID	D04AAN
D04AAN	DRUGNAME	Mesoridazine
D04AAN	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0J1ML	TTDDRUID	D0J1ML
D0J1ML	DRUGNAME	Mestranol
D0J1ML	INDICATI	Contraception [ICD-11: QA21] Approved

D0YH0N	TTDDRUID	D0YH0N
D0YH0N	DRUGNAME	Metadoxine
D0YH0N	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D02UFG	TTDDRUID	D02UFG
D02UFG	DRUGNAME	Metaproterenol Sulfate
D02UFG	INDICATI	Asthma [ICD-11: CA23] Approved

D04EYC	TTDDRUID	D04EYC
D04EYC	DRUGNAME	Metaraminol
D04EYC	INDICATI	Hypotension [ICD-11: BA20-BA21] Approved

D0S5CH	TTDDRUID	D0S5CH
D0S5CH	DRUGNAME	Metaxalone
D0S5CH	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0UA0I	TTDDRUID	D0UA0I
D0UA0I	DRUGNAME	Metergolin
D0UA0I	INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved

D0D7LA	TTDDRUID	D0D7LA
D0D7LA	DRUGNAME	Metformin
D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D09PPG	TTDDRUID	D09PPG
D09PPG	DRUGNAME	Metformin arginine-hemisuccinimide
D09PPG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D04MWJ	TTDDRUID	D04MWJ
D04MWJ	DRUGNAME	Methacholine Chloride
D04MWJ	INDICATI	Asthma [ICD-11: CA23] Approved
D04MWJ	INDICATI	bronchial hyperreactivity [ICD-11: CB40] Approved

D0H1AR	TTDDRUID	D0H1AR
D0H1AR	DRUGNAME	Methacycline
D0H1AR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09OJQ	TTDDRUID	D09OJQ
D09OJQ	DRUGNAME	Methadone
D09OJQ	INDICATI	Dry cough [ICD-11: MD12] Approved

D0GR0T	TTDDRUID	D0GR0T
D0GR0T	DRUGNAME	Methadyl Acetate
D0GR0T	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved

D0P6UB	TTDDRUID	D0P6UB
D0P6UB	DRUGNAME	Methamphetamine
D0P6UB	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
D0P6UB	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0JY5S	TTDDRUID	D0JY5S
D0JY5S	DRUGNAME	Methantheline
D0JY5S	INDICATI	Gastritis [ICD-11: DA42] Approved
D0JY5S	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
D0JY5S	INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved
D0JY5S	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D02OZY	TTDDRUID	D02OZY
D02OZY	DRUGNAME	Metharbital
D02OZY	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D0C2II	TTDDRUID	D0C2II
D0C2II	DRUGNAME	Methazolamide
D0C2II	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0LR0R	TTDDRUID	D0LR0R
D0LR0R	DRUGNAME	Methdilazine
D0LR0R	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D02LJR	TTDDRUID	D02LJR
D02LJR	DRUGNAME	Methenamine
D02LJR	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0S4BR	TTDDRUID	D0S4BR
D0S4BR	DRUGNAME	Methimazole
D0S4BR	INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved

D0FN7J	TTDDRUID	D0FN7J
D0FN7J	DRUGNAME	Methocarbamol
D0FN7J	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved

D0S8TD	TTDDRUID	D0S8TD
D0S8TD	DRUGNAME	Methohexital
D0S8TD	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0SV8E	TTDDRUID	D0SV8E
D0SV8E	DRUGNAME	Methotrexate
D0SV8E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
D0SV8E	INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved

D0D3DU	TTDDRUID	D0D3DU
D0D3DU	DRUGNAME	Methotrexate Sodium
D0D3DU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D09GYT	TTDDRUID	D09GYT
D09GYT	DRUGNAME	Methoxamine
D09GYT	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D08SKH	TTDDRUID	D08SKH
D08SKH	DRUGNAME	Methoxsalen
D08SKH	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved
D08SKH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D0K3XP	TTDDRUID	D0K3XP
D0K3XP	DRUGNAME	Methoxy polyethylene glycol-epoetin beta
D0K3XP	INDICATI	Kidney transplant rejection [ICD-11: NE84] Approved

D07SOO	TTDDRUID	D07SOO
D07SOO	DRUGNAME	Methoxyflurane
D07SOO	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D04LHJ	TTDDRUID	D04LHJ
D04LHJ	DRUGNAME	Methscopolamine Bromide
D04LHJ	INDICATI	Nausea and vomiting [ICD-11: MD90] Approved

D08EOD	TTDDRUID	D08EOD
D08EOD	DRUGNAME	Methsuximide
D08EOD	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Approved

D03GVC	TTDDRUID	D03GVC
D03GVC	DRUGNAME	Methyclothiazide
D03GVC	INDICATI	Edema [ICD-11: MG29] Approved
D03GVC	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0OL6O	TTDDRUID	D0OL6O
D0OL6O	DRUGNAME	Methyl aminolevulinate
D0OL6O	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0BA6T	TTDDRUID	D0BA6T
D0BA6T	DRUGNAME	Methyldopa
D0BA6T	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0Y6KO	TTDDRUID	D0Y6KO
D0Y6KO	DRUGNAME	Methyldopate Hydrochloride
D0Y6KO	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09NYS	TTDDRUID	D09NYS
D09NYS	DRUGNAME	Methylene blue
D09NYS	INDICATI	Acquired methemoglobinemia [ICD-11: 3A93] Approved

D05AHE	TTDDRUID	D05AHE
D05AHE	DRUGNAME	Methylergonovine
D05AHE	INDICATI	Spontaneous abortion [ICD-11: JA00.0] Approved

D03YVO	TTDDRUID	D03YVO
D03YVO	DRUGNAME	Methylnaltrexone bromide
D03YVO	INDICATI	Obesity [ICD-11: 5B81] Preclinical
D03YVO	INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Approved

D02PPN	TTDDRUID	D02PPN
D02PPN	DRUGNAME	Methylphenidate
D02PPN	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
D02PPN	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 4

D08UMH	TTDDRUID	D08UMH
D08UMH	DRUGNAME	Methylphenobarbital
D08UMH	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D08PIQ	TTDDRUID	D08PIQ
D08PIQ	DRUGNAME	Methylprednisolone Acetate
D08PIQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D08PIQ	INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative

D0M6VK	TTDDRUID	D0M6VK
D0M6VK	DRUGNAME	Methylscopolamine
D0M6VK	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D0Z1XD	TTDDRUID	D0Z1XD
D0Z1XD	DRUGNAME	Methyltestosterone
D0Z1XD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D05OQJ	TTDDRUID	D05OQJ
D05OQJ	DRUGNAME	Methyprylon
D05OQJ	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0O6GC	TTDDRUID	D0O6GC
D0O6GC	DRUGNAME	Methysergide
D0O6GC	INDICATI	Migraine [ICD-11: 8A80] Approved

D06TQZ	TTDDRUID	D06TQZ
D06TQZ	DRUGNAME	Meticillin
D06TQZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D06TQZ	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0L5FY	TTDDRUID	D0L5FY
D0L5FY	DRUGNAME	Metipranolol
D0L5FY	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D0NF0W	TTDDRUID	D0NF0W
D0NF0W	DRUGNAME	Metixene
D0NF0W	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D08VYV	TTDDRUID	D08VYV
D08VYV	DRUGNAME	Metoclopramide
D08VYV	INDICATI	Nausea [ICD-11: MD90] Approved

D0Y6CE	TTDDRUID	D0Y6CE
D0Y6CE	DRUGNAME	Metocurine Iodide
D0Y6CE	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D01WLC	TTDDRUID	D01WLC
D01WLC	DRUGNAME	Metolazone
D01WLC	INDICATI	Edema [ICD-11: MG29] Approved
D01WLC	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0I2MK	TTDDRUID	D0I2MK
D0I2MK	DRUGNAME	Metoprolol
D0I2MK	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0Z9EO	TTDDRUID	D0Z9EO
D0Z9EO	DRUGNAME	Metreleptin
D0Z9EO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D02VCJ	TTDDRUID	D02VCJ
D02VCJ	DRUGNAME	Metrizamide
D02VCJ	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved

D0A2ZX	TTDDRUID	D0A2ZX
D0A2ZX	DRUGNAME	Metronidazole
D0A2ZX	INDICATI	Amoebiasis [ICD-11: 1A36] Approved
D0A2ZX	INDICATI	Crohn disease [ICD-11: DD70] Phase 3

D0Q9JT	TTDDRUID	D0Q9JT
D0Q9JT	DRUGNAME	Metyrapone
D0Q9JT	INDICATI	Cushing disease [ICD-11: 5A70] Approved

D0B3QM	TTDDRUID	D0B3QM
D0B3QM	DRUGNAME	Metyrosine
D0B3QM	INDICATI	Pheochromocytoma [ICD-11: 5A75] Approved

D0X0RI	TTDDRUID	D0X0RI
D0X0RI	DRUGNAME	Mexiletine
D0X0RI	INDICATI	Ventricular tachycardia [ICD-11: BC71] Approved

D00NJJ	TTDDRUID	D00NJJ
D00NJJ	DRUGNAME	Mezlocillin
D00NJJ	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0R6RO	TTDDRUID	D0R6RO
D0R6RO	DRUGNAME	Mianserin
D0R6RO	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D06TOE	TTDDRUID	D06TOE
D06TOE	DRUGNAME	Micafungin
D06TOE	INDICATI	Candidiasis [ICD-11: 1F23] Approved

D0I7PO	TTDDRUID	D0I7PO
D0I7PO	DRUGNAME	Micardis telmisartan
D0I7PO	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00AXJ	TTDDRUID	D00AXJ
D00AXJ	DRUGNAME	Miconazole
D00AXJ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D04YKM	TTDDRUID	D04YKM
D04YKM	DRUGNAME	Microfibrillar collagen hemostat
D04YKM	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D09DBR	TTDDRUID	D09DBR
D09DBR	DRUGNAME	Micronomicin sulfate
D09DBR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0O0ZG	TTDDRUID	D0O0ZG
D0O0ZG	DRUGNAME	Micrurus fulvius antivenin
D0O0ZG	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D0U6LM	TTDDRUID	D0U6LM
D0U6LM	DRUGNAME	Midazolam
D0U6LM	INDICATI	Irritability [ICD-11: MB24] Approved

D0J7OG	TTDDRUID	D0J7OG
D0J7OG	DRUGNAME	Midecamycin
D0J7OG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02XJY	TTDDRUID	D02XJY
D02XJY	DRUGNAME	Midodrine
D02XJY	INDICATI	Orthostatic hypotension [ICD-11: BA21] Approved

D07NVU	TTDDRUID	D07NVU
D07NVU	DRUGNAME	Midostaurin
D07NVU	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
D07NVU	INDICATI	Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 2
D07NVU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D07NVU	INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Approved

D01NTX	TTDDRUID	D01NTX
D01NTX	DRUGNAME	Mifamurtide
D01NTX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Z4EI	TTDDRUID	D0Z4EI
D0Z4EI	DRUGNAME	Mifepristone
D0Z4EI	INDICATI	Cushing disease [ICD-11: 5A70] Approved

D0MU9L	TTDDRUID	D0MU9L
D0MU9L	DRUGNAME	Migalastat
D0MU9L	INDICATI	Fabry disease [ICD-11: 5C56.01] Approved
D0MU9L	INDICATI	Fabry disease [ICD-11: 5C56.01] Preregistration

D0D0ZD	TTDDRUID	D0D0ZD
D0D0ZD	DRUGNAME	Miglitol
D0D0ZD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0HR8Z	TTDDRUID	D0HR8Z
D0HR8Z	DRUGNAME	Miglustat
D0HR8Z	INDICATI	Type 1 gaucher disease [ICD-11: 5C56.0Y] Approved

D09VGC	TTDDRUID	D09VGC
D09VGC	DRUGNAME	Milnacipran
D09VGC	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0Y9ZE	TTDDRUID	D0Y9ZE
D0Y9ZE	DRUGNAME	Milrinone
D0Y9ZE	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D00FGR	TTDDRUID	D00FGR
D00FGR	DRUGNAME	Miltefosine
D00FGR	INDICATI	Leishmaniasis [ICD-11: 1F54] Approved
D00FGR	INDICATI	Visceral leishmaniasis [ICD-11: 1F54.0] Phase 2

D0W8SJ	TTDDRUID	D0W8SJ
D0W8SJ	DRUGNAME	Minaprine
D0W8SJ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0GT9I	TTDDRUID	D0GT9I
D0GT9I	DRUGNAME	Mineral oil
D0GT9I	INDICATI	Constipation [ICD-11: DD91.1] Approved

D08LTU	TTDDRUID	D08LTU
D08LTU	DRUGNAME	Minocycline
D08LTU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00NPT	TTDDRUID	D00NPT
D00NPT	DRUGNAME	Minodronate
D00NPT	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0Y2CJ	TTDDRUID	D0Y2CJ
D0Y2CJ	DRUGNAME	Minoxidil
D0Y2CJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06EEL	TTDDRUID	D06EEL
D06EEL	DRUGNAME	Miokamycin
D06EEL	INDICATI	Bronchitis [ICD-11: CA20] Approved

D08CVQ	TTDDRUID	D08CVQ
D08CVQ	DRUGNAME	Mipomersen
D08CVQ	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Approved

D0X5UN	TTDDRUID	D0X5UN
D0X5UN	DRUGNAME	Mirabegron
D0X5UN	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D0P5VC	TTDDRUID	D0P5VC
D0P5VC	DRUGNAME	Mirimostim
D0P5VC	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved

D05ZIK	TTDDRUID	D05ZIK
D05ZIK	DRUGNAME	Mirtazapine
D05ZIK	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D09ANG	TTDDRUID	D09ANG
D09ANG	DRUGNAME	Misoprostol
D09ANG	INDICATI	Medical abortion [ICD-11: JA00.1Z] Approved

D0P2YU	TTDDRUID	D0P2YU
D0P2YU	DRUGNAME	Mitiglinide
D0P2YU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0Y0GH	TTDDRUID	D0Y0GH
D0Y0GH	DRUGNAME	Mitomycin
D0Y0GH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
D0Y0GH	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Approved
D0Y0GH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0B9EJ	TTDDRUID	D0B9EJ
D0B9EJ	DRUGNAME	Mitomycin A
D0B9EJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Z5OE	TTDDRUID	D0Z5OE
D0Z5OE	DRUGNAME	Mitotane
D0Z5OE	INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Approved

D0R3JB	TTDDRUID	D0R3JB
D0R3JB	DRUGNAME	Mitoxantrone
D0R3JB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0OB2M	TTDDRUID	D0OB2M
D0OB2M	DRUGNAME	Mivacurium
D0OB2M	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D06MAJ	TTDDRUID	D06MAJ
D06MAJ	DRUGNAME	Mizolastine
D06MAJ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0G5AG	TTDDRUID	D0G5AG
D0G5AG	DRUGNAME	Mizoribine
D0G5AG	INDICATI	Transplant rejection [ICD-11: NE84] Approved

D0K3WO	TTDDRUID	D0K3WO
D0K3WO	DRUGNAME	MK-08887A
D0K3WO	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0R0TS	TTDDRUID	D0R0TS
D0R0TS	DRUGNAME	MK-1439
D0R0TS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D0R0TS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D07DMY	TTDDRUID	D07DMY
D07DMY	DRUGNAME	MK-3475
D07DMY	INDICATI	Melanoma [ICD-11: 2C30] Approved

D0Y5OY	TTDDRUID	D0Y5OY
D0Y5OY	DRUGNAME	MK-3641
D0Y5OY	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D0G8PA	TTDDRUID	D0G8PA
D0G8PA	DRUGNAME	MK-8228
D0G8PA	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Approved
D0G8PA	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3

D08RID	TTDDRUID	D08RID
D08RID	DRUGNAME	MK-8616
D08RID	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D08WIN	TTDDRUID	D08WIN
D08WIN	DRUGNAME	MK-869
D08WIN	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0PK5M	TTDDRUID	D0PK5M
D0PK5M	DRUGNAME	MLN0002
D0PK5M	INDICATI	Crohn disease [ICD-11: DD70] Approved

D01MML	TTDDRUID	D01MML
D01MML	DRUGNAME	MLN9708
D01MML	INDICATI	Amyloidosis [ICD-11: 5D00] Approved
D01MML	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D07JTH	TTDDRUID	D07JTH
D07JTH	DRUGNAME	MM-Q01
D07JTH	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D07CGI	TTDDRUID	D07CGI
D07CGI	DRUGNAME	M-M-R II
D07CGI	INDICATI	Measles [ICD-11: 1F03] Approved

D0M1PQ	TTDDRUID	D0M1PQ
D0M1PQ	DRUGNAME	Mobenakin
D0M1PQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D01ZSO	TTDDRUID	D01ZSO
D01ZSO	DRUGNAME	Moclobemide
D01ZSO	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
D01ZSO	INDICATI	Skin imperfections [ICD-11: EK71] Patented

D07HQC	TTDDRUID	D07HQC
D07HQC	DRUGNAME	Modafinil
D07HQC	INDICATI	Narcolepsy [ICD-11: 7A20] Approved

D00HDU	TTDDRUID	D00HDU
D00HDU	DRUGNAME	Moexipril
D00HDU	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0W2HD	TTDDRUID	D0W2HD
D0W2HD	DRUGNAME	Mogamulizumab
D0W2HD	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3
D0W2HD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
D0W2HD	INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 2

D04MML	TTDDRUID	D04MML
D04MML	DRUGNAME	Mogamulizumab 
D04MML	INDICATI	Mycosis fungoides [ICD-11: 2B01] Approved
D04MML	INDICATI	Sezary syndrome [ICD-11: 2B02] Approved

D09TPF	TTDDRUID	D09TPF
D09TPF	DRUGNAME	Molindone
D09TPF	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D08VXL	TTDDRUID	D08VXL
D08VXL	DRUGNAME	Molsidomine
D08VXL	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D03HYX	TTDDRUID	D03HYX
D03HYX	DRUGNAME	Mometasone
D03HYX	INDICATI	Skin allergy [ICD-11: 4A82] Approved

D0XW2H	TTDDRUID	D0XW2H
D0XW2H	DRUGNAME	Mometasone furoate/ formoterol fumarate
D0XW2H	INDICATI	Asthma [ICD-11: CA23] Approved

D0H6TP	TTDDRUID	D0H6TP
D0H6TP	DRUGNAME	Monobenzone
D0H6TP	INDICATI	Vitiligo [ICD-11: ED63.0] Approved

D0G6AB	TTDDRUID	D0G6AB
D0G6AB	DRUGNAME	Monocrotaline
D0G6AB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Z1QC	TTDDRUID	D0Z1QC
D0Z1QC	DRUGNAME	Monoctanoin
D0Z1QC	INDICATI	Gallstone [ICD-11: DC11.3] Approved

D05SPL	TTDDRUID	D05SPL
D05SPL	DRUGNAME	Monofer
D05SPL	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved

D02GKJ	TTDDRUID	D02GKJ
D02GKJ	DRUGNAME	Monosialoganglioside
D02GKJ	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved

D0I6LD	TTDDRUID	D0I6LD
D0I6LD	DRUGNAME	Monovalent oral polio vaccine 1
D0I6LD	INDICATI	Poliovirus infection [ICD-11: 1C8Y] Approved

D00QET	TTDDRUID	D00QET
D00QET	DRUGNAME	Montelukast
D00QET	INDICATI	Asthma [ICD-11: CA23] Approved

D0X6LC	TTDDRUID	D0X6LC
D0X6LC	DRUGNAME	Monteplase
D0X6LC	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D0Q4TK	TTDDRUID	D0Q4TK
D0Q4TK	DRUGNAME	Morantel tartrate
D0Q4TK	INDICATI	Mature gastrointestinal nematode infection [ICD-11: 1F6Y] Approved

D04VPA	TTDDRUID	D04VPA
D04VPA	DRUGNAME	Moricizine
D04VPA	INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
D04VPA	INDICATI	Heart arrhythmia [ICD-11: BC65] Withdrawn from market

D00BDC	TTDDRUID	D00BDC
D00BDC	DRUGNAME	Morniflumate
D00BDC	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved

D0T2RZ	TTDDRUID	D0T2RZ
D0T2RZ	DRUGNAME	Moroctocog alfa
D0T2RZ	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D0WE3O	TTDDRUID	D0WE3O
D0WE3O	DRUGNAME	Morphine
D0WE3O	INDICATI	Chronic pain [ICD-11: MG30] Approved

D0G6WW	TTDDRUID	D0G6WW
D0G6WW	DRUGNAME	Morrhuate sodium
D0G6WW	INDICATI	Hemorrhoids [ICD-11: DB60] Approved

D05BJD	TTDDRUID	D05BJD
D05BJD	DRUGNAME	Motexafin gadolinium
D05BJD	INDICATI	Brain cancer [ICD-11: 2A00] Approved
D05BJD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D04VXN	TTDDRUID	D04VXN
D04VXN	DRUGNAME	Moxalactam Disodium
D04VXN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00HPD	TTDDRUID	D00HPD
D00HPD	DRUGNAME	Moxetumomab pasudotox
D00HPD	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D00HPD	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Phase 3

D0CR9C	TTDDRUID	D0CR9C
D0CR9C	DRUGNAME	Moxetumomab pasudotox 
D0CR9C	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved

D01ORS	TTDDRUID	D01ORS
D01ORS	DRUGNAME	Moxidectin
D01ORS	INDICATI	Onchocerciasis [ICD-11: 1F6A] Phase 3

D05AWP	TTDDRUID	D05AWP
D05AWP	DRUGNAME	Moxidectin 
D05AWP	INDICATI	River blindness [ICD-11: 1F6A.0] Approved

D0ZV0Z	TTDDRUID	D0ZV0Z
D0ZV0Z	DRUGNAME	Moxifloxacin
D0ZV0Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0A7QN	TTDDRUID	D0A7QN
D0A7QN	DRUGNAME	Moxisylyte
D0A7QN	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved

D0E9PK	TTDDRUID	D0E9PK
D0E9PK	DRUGNAME	MOXONIDINE
D0E9PK	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved

D0F4NS	TTDDRUID	D0F4NS
D0F4NS	DRUGNAME	Mozavaptan
D0F4NS	INDICATI	Hyponatraemia [ICD-11: 5C72] Approved

D0Z3FV	TTDDRUID	D0Z3FV
D0Z3FV	DRUGNAME	MPL-containing Pollinex allergy desensitization vaccine
D0Z3FV	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D0TY0G	TTDDRUID	D0TY0G
D0TY0G	DRUGNAME	Mumps skin test antigen
D0TY0G	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D03JSJ	TTDDRUID	D03JSJ
D03JSJ	DRUGNAME	Mupirocin
D03JSJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0C6PS	TTDDRUID	D0C6PS
D0C6PS	DRUGNAME	Muromonab
D0C6PS	INDICATI	Organ transplant rejection [ICD-11: NE84] Approved

D05GVQ	TTDDRUID	D05GVQ
D05GVQ	DRUGNAME	Muromonab-cd3
D05GVQ	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Approved

D09JNP	TTDDRUID	D09JNP
D09JNP	DRUGNAME	MVax
D09JNP	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D04FBR	TTDDRUID	D04FBR
D04FBR	DRUGNAME	Mycophenolate mofetil
D04FBR	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
D04FBR	INDICATI	Organ transplant rejection [ICD-11: NE84] Approved
D04FBR	INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 3

D0T6XU	TTDDRUID	D0T6XU
D0T6XU	DRUGNAME	Myelopid
D0T6XU	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D09OQV	TTDDRUID	D09OQV
D09OQV	DRUGNAME	N-0923
D09OQV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D07FND	TTDDRUID	D07FND
D07FND	DRUGNAME	Nabi-HB (intramuscular)
D07FND	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0L7AS	TTDDRUID	D0L7AS
D0L7AS	DRUGNAME	NABILONE
D0L7AS	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D05CKR	TTDDRUID	D05CKR
D05CKR	DRUGNAME	Nabumetone
D05CKR	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D05ZYM	TTDDRUID	D05ZYM
D05ZYM	DRUGNAME	N-Acetyl-D-glucosamine
D05ZYM	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved

D0B8SV	TTDDRUID	D0B8SV
D0B8SV	DRUGNAME	NADH
D0B8SV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0I0RB	TTDDRUID	D0I0RB
D0I0RB	DRUGNAME	Nadifloxacin
D0I0RB	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D05SHK	TTDDRUID	D05SHK
D05SHK	DRUGNAME	Nadolol
D05SHK	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0TB8C	TTDDRUID	D0TB8C
D0TB8C	DRUGNAME	Nadrolone phenylpropionate
D0TB8C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0N2BX	TTDDRUID	D0N2BX
D0N2BX	DRUGNAME	Nadroparin calcium
D0N2BX	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved

D07XHO	TTDDRUID	D07XHO
D07XHO	DRUGNAME	Nafamostat
D07XHO	INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved
D07XHO	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D08WYM	TTDDRUID	D08WYM
D08WYM	DRUGNAME	Nafarelin
D08WYM	INDICATI	Endometriosis [ICD-11: GA10] Approved

D0A0JH	TTDDRUID	D0A0JH
D0A0JH	DRUGNAME	Nafcillin
D0A0JH	INDICATI	Arthritis [ICD-11: FA20] Approved

D07YWY	TTDDRUID	D07YWY
D07YWY	DRUGNAME	Nafronyl
D07YWY	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved

D00HPK	TTDDRUID	D00HPK
D00HPK	DRUGNAME	Naftifine
D00HPK	INDICATI	Dermatomycosis [ICD-11: EA60] Approved

D04DKH	TTDDRUID	D04DKH
D04DKH	DRUGNAME	NAFTOPIDIL
D04DKH	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D01KQA	TTDDRUID	D01KQA
D01KQA	DRUGNAME	Nalbuphine
D01KQA	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0Q2HO	TTDDRUID	D0Q2HO
D0Q2HO	DRUGNAME	Naldemedine Tosylate
D0Q2HO	INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Approved

D02RXG	TTDDRUID	D02RXG
D02RXG	DRUGNAME	Nalfurafine hcl
D02RXG	INDICATI	Uremic pruritus [ICD-11: EC90.10] Approved

D07JGT	TTDDRUID	D07JGT
D07JGT	DRUGNAME	Nalidixic Acid
D07JGT	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D05VIL	TTDDRUID	D05VIL
D05VIL	DRUGNAME	Nalmefene
D05VIL	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved

D07LCF	TTDDRUID	D07LCF
D07LCF	DRUGNAME	Naloxegol
D07LCF	INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Approved

D0X3FX	TTDDRUID	D0X3FX
D0X3FX	DRUGNAME	Naloxone
D0X3FX	INDICATI	Narcotic depression [ICD-11: 6A7Z] Approved

D0PG8O	TTDDRUID	D0PG8O
D0PG8O	DRUGNAME	Naltrexone
D0PG8O	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
D0PG8O	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D00YWP	TTDDRUID	D00YWP
D00YWP	DRUGNAME	Nandrolone
D00YWP	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0B8NH	TTDDRUID	D0B8NH
D0B8NH	DRUGNAME	Nanogam
D0B8NH	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0O6IZ	TTDDRUID	D0O6IZ
D0O6IZ	DRUGNAME	Naphazoline
D0O6IZ	INDICATI	Hyperaemia [ICD-11: 9A61-9B7Y] Approved
D0O6IZ	INDICATI	Itching [ICD-11: 1F28-1G07] Approved

D0DJ1B	TTDDRUID	D0DJ1B
D0DJ1B	DRUGNAME	Naproxen
D0DJ1B	INDICATI	Endometriosis [ICD-11: GA10] Investigative
D0DJ1B	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
D0DJ1B	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0T3KI	TTDDRUID	D0T3KI
D0T3KI	DRUGNAME	Naratriptan
D0T3KI	INDICATI	Migraine [ICD-11: 8A80] Approved

D04IEM	TTDDRUID	D04IEM
D04IEM	DRUGNAME	Nartograstim
D04IEM	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved

D0A9ZA	TTDDRUID	D0A9ZA
D0A9ZA	DRUGNAME	NasoVac
D0A9ZA	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D02FEM	TTDDRUID	D02FEM
D02FEM	DRUGNAME	Natamycin
D02FEM	INDICATI	Conjunctivitis [ICD-11: 9A60] Approved

D06PSS	TTDDRUID	D06PSS
D06PSS	DRUGNAME	Nateglinide
D06PSS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0B1EM	TTDDRUID	D0B1EM
D0B1EM	DRUGNAME	Nateplase
D0B1EM	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
D0B1EM	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D0Z1UA	TTDDRUID	D0Z1UA
D0Z1UA	DRUGNAME	Nebivolol
D0Z1UA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03WPP	TTDDRUID	D03WPP
D03WPP	DRUGNAME	Necitumumab
D03WPP	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved

D00UTD	TTDDRUID	D00UTD
D00UTD	DRUGNAME	Nedaplatin
D00UTD	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D06FVX	TTDDRUID	D06FVX
D06FVX	DRUGNAME	Nedocromil sodium
D06FVX	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D0X7DE	TTDDRUID	D0X7DE
D0X7DE	DRUGNAME	Nefazodone
D0X7DE	INDICATI	Depression [ICD-11: 6A70-6A7Z] Withdrawn from market
D0X7DE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D05AFX	TTDDRUID	D05AFX
D05AFX	DRUGNAME	Nefopam
D05AFX	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0G7QH	TTDDRUID	D0G7QH
D0G7QH	DRUGNAME	NeisVac-C
D0G7QH	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D0B8UJ	TTDDRUID	D0B8UJ
D0B8UJ	DRUGNAME	Nelarabine
D0B8UJ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved

D0IN7I	TTDDRUID	D0IN7I
D0IN7I	DRUGNAME	Nemonapride
D0IN7I	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0S0NK	TTDDRUID	D0S0NK
D0S0NK	DRUGNAME	Neoandrographolide
D0S0NK	INDICATI	Bacillary dysentery [ICD-11: 1A02] Approved

D0H0SJ	TTDDRUID	D0H0SJ
D0H0SJ	DRUGNAME	Neocarzinostatin
D0H0SJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D08USJ	TTDDRUID	D08USJ
D08USJ	DRUGNAME	Neostigmine
D08USJ	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved

D02IHW	TTDDRUID	D02IHW
D02IHW	DRUGNAME	Nepafenac
D02IHW	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D0U1ZV	TTDDRUID	D0U1ZV
D0U1ZV	DRUGNAME	NERATINIB MALEATE
D0U1ZV	INDICATI	HER2/NEU overexpressing breast cancer [ICD-11: 2C60-2C65] Approved

D0V8PA	TTDDRUID	D0V8PA
D0V8PA	DRUGNAME	NERIDRONIC ACID
D0V8PA	INDICATI	Bone disease [ICD-11: FC0Z] Approved

D05GRY	TTDDRUID	D05GRY
D05GRY	DRUGNAME	Nesiritide
D05GRY	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D04WYX	TTDDRUID	D04WYX
D04WYX	DRUGNAME	Netarsudil
D04WYX	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D07JZF	TTDDRUID	D07JZF
D07JZF	DRUGNAME	Netilmicin
D07JZF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0EC5T	TTDDRUID	D0EC5T
D0EC5T	DRUGNAME	Neurox
D0EC5T	INDICATI	Neuromuscular disease [ICD-11: 8C6Y] Approved

D0O2EM	TTDDRUID	D0O2EM
D0O2EM	DRUGNAME	Nevirapine
D0O2EM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0T0KA	TTDDRUID	D0T0KA
D0T0KA	DRUGNAME	Nicardipine
D0T0KA	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0V2GH	TTDDRUID	D0V2GH
D0V2GH	DRUGNAME	Nicergoline
D0V2GH	INDICATI	Brain ischaemia [ICD-11: 8B1Z] Approved
D0V2GH	INDICATI	Senile dementia [ICD-11: 6D8Z] Approved

D0J9ZR	TTDDRUID	D0J9ZR
D0J9ZR	DRUGNAME	Niclosamide
D0J9ZR	INDICATI	Cestodes infection [ICD-11: 1F70-1F76] Approved

D0O2SR	TTDDRUID	D0O2SR
D0O2SR	DRUGNAME	Nicorandil
D0O2SR	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D06NVJ	TTDDRUID	D06NVJ
D06NVJ	DRUGNAME	Nicotinamide
D06NVJ	INDICATI	Inflammatory skin condition [ICD-11: EF20.Y] Approved

D0T8GD	TTDDRUID	D0T8GD
D0T8GD	DRUGNAME	Nicotine
D0T8GD	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Approved

D04OSE	TTDDRUID	D04OSE
D04OSE	DRUGNAME	Nifedipine
D04OSE	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D00HGB	TTDDRUID	D00HGB
D00HGB	DRUGNAME	Niflumic Acid
D00HGB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0N7AU	TTDDRUID	D0N7AU
D0N7AU	DRUGNAME	Nifurzide
D0N7AU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00STL	TTDDRUID	D00STL
D00STL	DRUGNAME	Nilotinib
D00STL	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved

D0SN9T	TTDDRUID	D0SN9T
D0SN9T	DRUGNAME	Nilutamide
D0SN9T	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0L4XW	TTDDRUID	D0L4XW
D0L4XW	DRUGNAME	Nimenrix
D0L4XW	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D0XN1F	TTDDRUID	D0XN1F
D0XN1F	DRUGNAME	Nimodipine
D0XN1F	INDICATI	Cerebral vasospasm [ICD-11: BA85.Z] Approved

D05BKS	TTDDRUID	D05BKS
D05BKS	DRUGNAME	Nimotuzumab
D05BKS	INDICATI	Head and neck cancer [ICD-11: 2D42] Approved

D09SSC	TTDDRUID	D09SSC
D09SSC	DRUGNAME	Nipradilol
D09SSC	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0DN0W	TTDDRUID	D0DN0W
D0DN0W	DRUGNAME	Niraparib Tosylate
D0DN0W	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Approved
D0DN0W	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Approved

D0S5CU	TTDDRUID	D0S5CU
D0S5CU	DRUGNAME	Nisoldipine
D0S5CU	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D08EBN	TTDDRUID	D08EBN
D08EBN	DRUGNAME	Nitazoxanide
D08EBN	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0V1UW	TTDDRUID	D0V1UW
D0V1UW	DRUGNAME	Nitisinone
D0V1UW	INDICATI	Hereditary tyrosinemia type 1 [ICD-11: 5C50.11] Approved

D0T5WK	TTDDRUID	D0T5WK
D0T5WK	DRUGNAME	Nitrazepam
D0T5WK	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
D0T5WK	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0A1DH	TTDDRUID	D0A1DH
D0A1DH	DRUGNAME	Nitrendipine
D0A1DH	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0A5FM	TTDDRUID	D0A5FM
D0A5FM	DRUGNAME	Nitric Oxide
D0A5FM	INDICATI	Respiratory failure [ICD-11: CB41] Approved
D0A5FM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0R0BX	TTDDRUID	D0R0BX
D0R0BX	DRUGNAME	Nitrofurantoin
D0R0BX	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0IE1E	TTDDRUID	D0IE1E
D0IE1E	DRUGNAME	Nitrofurazone
D0IE1E	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
D0IE1E	INDICATI	Skin burns [ICD-11: ME65.0] Approved

D07YDE	TTDDRUID	D07YDE
D07YDE	DRUGNAME	Nitroglycerin
D07YDE	INDICATI	Angina pectoris [ICD-11: BA40] Approved
D07YDE	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved

D00PLV	TTDDRUID	D00PLV
D00PLV	DRUGNAME	Nitroprusside
D00PLV	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0O8DI	TTDDRUID	D0O8DI
D0O8DI	DRUGNAME	Nitrous oxide
D0O8DI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D00GOV	TTDDRUID	D00GOV
D00GOV	DRUGNAME	Nivolumab
D00GOV	INDICATI	Melanoma [ICD-11: 2C30] Approved
D00GOV	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D0D9NP	TTDDRUID	D0D9NP
D0D9NP	DRUGNAME	Nix-0699
D0D9NP	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Approved

D0Q9DK	TTDDRUID	D0Q9DK
D0Q9DK	DRUGNAME	Nizatidine
D0Q9DK	INDICATI	Acid-reflux disorder [ICD-11: DA22] Approved

D0K0SB	TTDDRUID	D0K0SB
D0K0SB	DRUGNAME	NKM
D0K0SB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0V2JK	TTDDRUID	D0V2JK
D0V2JK	DRUGNAME	Nomegestrol acetate
D0V2JK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D01TQR	TTDDRUID	D01TQR
D01TQR	DRUGNAME	Nonoxynol-9
D01TQR	INDICATI	Contraception [ICD-11: QA21] Approved

D0NK7X	TTDDRUID	D0NK7X
D0NK7X	DRUGNAME	Nordimmun
D0NK7X	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved

D07MOX	TTDDRUID	D07MOX
D07MOX	DRUGNAME	Norepinephrine
D07MOX	INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved

D0GL7U	TTDDRUID	D0GL7U
D0GL7U	DRUGNAME	Norethindrone
D0GL7U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Q2PE	TTDDRUID	D0Q2PE
D0Q2PE	DRUGNAME	Norfloxacin
D0Q2PE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09QZI	TTDDRUID	D09QZI
D09QZI	DRUGNAME	Norgestimate
D09QZI	INDICATI	Contraception [ICD-11: QA21] Approved

D04WFD	TTDDRUID	D04WFD
D04WFD	DRUGNAME	Nortriptyline
D04WFD	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D04TDQ	TTDDRUID	D04TDQ
D04TDQ	DRUGNAME	Noscapine (narcotine)
D04TDQ	INDICATI	Cough [ICD-11: MD12] Approved

D0Q0PR	TTDDRUID	D0Q0PR
D0Q0PR	DRUGNAME	Novobiocin
D0Q0PR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D03FCF	TTDDRUID	D03FCF
D03FCF	DRUGNAME	Novolimus
D03FCF	INDICATI	Artery stenosis [ICD-11: BD52] Approved

D06NNU	TTDDRUID	D06NNU
D06NNU	DRUGNAME	NSC-631570
D06NNU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D05MZI	TTDDRUID	D05MZI
D05MZI	DRUGNAME	nusinersen
D05MZI	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Approved

D08XAC	TTDDRUID	D08XAC
D08XAC	DRUGNAME	Nystatin
D08XAC	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0M4WA	TTDDRUID	D0M4WA
D0M4WA	DRUGNAME	obeticholic acid
D0M4WA	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Clinical trial
D0M4WA	INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Approved

D0S8WA	TTDDRUID	D0S8WA
D0S8WA	DRUGNAME	Obinutuzumab
D0S8WA	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved

D0G0AI	TTDDRUID	D0G0AI
D0G0AI	DRUGNAME	Obizur
D0G0AI	INDICATI	Haemophilia A [ICD-11: 3B10.0] Approved

D07BDW	TTDDRUID	D07BDW
D07BDW	DRUGNAME	OC-108
D07BDW	INDICATI	Hemorrhoids [ICD-11: DB60] Approved

D0YV4F	TTDDRUID	D0YV4F
D0YV4F	DRUGNAME	Ocrelizumab
D0YV4F	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved
D0YV4F	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
D0YV4F	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D0YV4F	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0Y7XG	TTDDRUID	D0Y7XG
D0Y7XG	DRUGNAME	Ocriplasmin
D0Y7XG	INDICATI	Symptomatic vitreomacular adhesion [ICD-11: 9B8Z] Approved

D0G5BK	TTDDRUID	D0G5BK
D0G5BK	DRUGNAME	Octafluoropropane perflutren lipid microsphere
D0G5BK	INDICATI	Heart disease [ICD-11: BA41-BA42] Approved

D03KXV	TTDDRUID	D03KXV
D03KXV	DRUGNAME	Octagam
D03KXV	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0J7CP	TTDDRUID	D0J7CP
D0J7CP	DRUGNAME	OctreoScan
D0J7CP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D02XIY	TTDDRUID	D02XIY
D02XIY	DRUGNAME	Octreotide
D02XIY	INDICATI	Acromegaly [ICD-11: 5A60.0] Approved

D0I4EL	TTDDRUID	D0I4EL
D0I4EL	DRUGNAME	Odulimomab
D0I4EL	INDICATI	Transplant rejection [ICD-11: NE84] Approved

D04CBI	TTDDRUID	D04CBI
D04CBI	DRUGNAME	Oestradiol valerate and dienogest
D04CBI	INDICATI	Contraception [ICD-11: QA21] Approved
D04CBI	INDICATI	Endometriosis [ICD-11: GA10] Approved

D0Y8ZN	TTDDRUID	D0Y8ZN
D0Y8ZN	DRUGNAME	Ofatumumab
D0Y8ZN	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
D0Y8ZN	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D0Y8ZN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D03NHW	TTDDRUID	D03NHW
D03NHW	DRUGNAME	Ofloxacin
D03NHW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0V4QS	TTDDRUID	D0V4QS
D0V4QS	DRUGNAME	Olanzapine
D0V4QS	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D01VJN	TTDDRUID	D01VJN
D01VJN	DRUGNAME	Olanzapine/fluoxetine combination
D01VJN	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0J9HW	TTDDRUID	D0J9HW
D0J9HW	DRUGNAME	Olaparib
D0J9HW	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D09QZS	TTDDRUID	D09QZS
D09QZS	DRUGNAME	Olaratumab
D09QZS	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D09QZS	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Approved

D07UBG	TTDDRUID	D07UBG
D07UBG	DRUGNAME	Olmesartan medoxomil
D07UBG	INDICATI	High blood pressure [ICD-11: BA00] Approved

D04UTT	TTDDRUID	D04UTT
D04UTT	DRUGNAME	Olodaterol
D04UTT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D05GPO	TTDDRUID	D05GPO
D05GPO	DRUGNAME	Olopatadine
D05GPO	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
D05GPO	INDICATI	Ocular allergy [ICD-11: 4A81] Phase 3

D03ZBN	TTDDRUID	D03ZBN
D03ZBN	DRUGNAME	Olprinone
D03ZBN	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D00KRE	TTDDRUID	D00KRE
D00KRE	DRUGNAME	Olsalazine
D00KRE	INDICATI	Ulcerative colitis [ICD-11: DD71] Approved

D0E1VD	TTDDRUID	D0E1VD
D0E1VD	DRUGNAME	OM-89
D0E1VD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0M4XY	TTDDRUID	D0M4XY
D0M4XY	DRUGNAME	Omacetaxine mepesuccinate
D0M4XY	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Approved

D09GUJ	TTDDRUID	D09GUJ
D09GUJ	DRUGNAME	Omadacycline
D09GUJ	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Approved
D09GUJ	INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Approved

D02GEC	TTDDRUID	D02GEC
D02GEC	DRUGNAME	Omalizumab
D02GEC	INDICATI	Asthma [ICD-11: CA23] Approved
D02GEC	INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2

D0T9TE	TTDDRUID	D0T9TE
D0T9TE	DRUGNAME	Ombitasvir + paritaprevir + ritonavir
D0T9TE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0H3WU	TTDDRUID	D0H3WU
D0H3WU	DRUGNAME	Omega-3-acid ethyl esters 90
D0H3WU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved

D01XNB	TTDDRUID	D01XNB
D01XNB	DRUGNAME	Omeprazole
D01XNB	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved

D0K7WK	TTDDRUID	D0K7WK
D0K7WK	DRUGNAME	Ondansetron
D0K7WK	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D0K7WK	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Approved

D0F8EM	TTDDRUID	D0F8EM
D0F8EM	DRUGNAME	Op-1
D0F8EM	INDICATI	Tibial nonunions [ICD-11: FB80.8] Approved

D0P0OU	TTDDRUID	D0P0OU
D0P0OU	DRUGNAME	OPC-34712
D0P0OU	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0D7TB	TTDDRUID	D0D7TB
D0D7TB	DRUGNAME	Opipramol
D0D7TB	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0L1CR	TTDDRUID	D0L1CR
D0L1CR	DRUGNAME	Opium (class)
D0L1CR	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0T1IJ	TTDDRUID	D0T1IJ
D0T1IJ	DRUGNAME	Oprelvekin
D0T1IJ	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved

D08RHR	TTDDRUID	D08RHR
D08RHR	DRUGNAME	Optaflu
D08RHR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D06NXD	TTDDRUID	D06NXD
D06NXD	DRUGNAME	Oral paclitaxel
D06NXD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D02EPS	TTDDRUID	D02EPS
D02EPS	DRUGNAME	Oralair grasses
D02EPS	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
D02EPS	INDICATI	Grass pollen hypersensitivity [ICD-11: 4B07] Approved

D0V2KE	TTDDRUID	D0V2KE
D0V2KE	DRUGNAME	Oralgen
D0V2KE	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0OH4N	TTDDRUID	D0OH4N
D0OH4N	DRUGNAME	Oraqix
D0OH4N	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D00DCY	TTDDRUID	D00DCY
D00DCY	DRUGNAME	OraTest
D00DCY	INDICATI	Oral cancer [ICD-11: 2B6E] Approved

D00XZY	TTDDRUID	D00XZY
D00XZY	DRUGNAME	ORC-Vax
D00XZY	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved

D02IBU	TTDDRUID	D02IBU
D02IBU	DRUGNAME	Oritavancin
D02IBU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D02IBU	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated

D0T9TJ	TTDDRUID	D0T9TJ
D0T9TJ	DRUGNAME	Orlistat
D0T9TJ	INDICATI	Obesity [ICD-11: 5B81] Approved

D0D0BE	TTDDRUID	D0D0BE
D0D0BE	DRUGNAME	Ornidazole
D0D0BE	INDICATI	Amoebiasis [ICD-11: 1A36] Approved

D0ZI4H	TTDDRUID	D0ZI4H
D0ZI4H	DRUGNAME	Ornoprostil
D0ZI4H	INDICATI	Gastritis [ICD-11: DA42] Approved
D0ZI4H	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved

D0D3KS	TTDDRUID	D0D3KS
D0D3KS	DRUGNAME	Orochol
D0D3KS	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved

D0D9FV	TTDDRUID	D0D9FV
D0D9FV	DRUGNAME	Orphenadrine
D0D9FV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0J1PW	TTDDRUID	D0J1PW
D0J1PW	DRUGNAME	Orthokine
D0J1PW	INDICATI	Arthritis [ICD-11: FA20] Approved

D0O5NK	TTDDRUID	D0O5NK
D0O5NK	DRUGNAME	Oseltamivir
D0O5NK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0O8GK	TTDDRUID	D0O8GK
D0O8GK	DRUGNAME	Osimertinib
D0O8GK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D0W9OR	TTDDRUID	D0W9OR
D0W9OR	DRUGNAME	OspA lipoprotein
D0W9OR	INDICATI	Lyme disease [ICD-11: 1C1G] Approved

D02CTS	TTDDRUID	D02CTS
D02CTS	DRUGNAME	Ospemifene
D02CTS	INDICATI	Dyspareunia [ICD-11: GA12] Approved
D02CTS	INDICATI	Postmenopausal vaginal atrophy [ICD-11: GA30.2] Phase 3

D0JP4A	TTDDRUID	D0JP4A
D0JP4A	DRUGNAME	OsteoCel
D0JP4A	INDICATI	Injury [ICD-11: NA00-ND5Z] Approved

D0K8CI	TTDDRUID	D0K8CI
D0K8CI	DRUGNAME	Otilonium bromide
D0K8CI	INDICATI	Gastric motility disorder [ICD-11: DA21] Approved

D0AR3J	TTDDRUID	D0AR3J
D0AR3J	DRUGNAME	Ouabain
D0AR3J	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
D0AR3J	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D05ZSB	TTDDRUID	D05ZSB
D05ZSB	DRUGNAME	Ovine corticotropin-releasing hormone
D05ZSB	INDICATI	Cushing disease [ICD-11: 5A70] Approved

D0MB8I	TTDDRUID	D0MB8I
D0MB8I	DRUGNAME	Oxacillin
D0MB8I	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Y3ME	TTDDRUID	D0Y3ME
D0Y3ME	DRUGNAME	Oxaliplatin
D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved

D0P4MT	TTDDRUID	D0P4MT
D0P4MT	DRUGNAME	Oxamniquine
D0P4MT	INDICATI	Schistosomiasis [ICD-11: 1F86] Approved

D0U3GL	TTDDRUID	D0U3GL
D0U3GL	DRUGNAME	Oxandrolone
D0U3GL	INDICATI	Alcoholic hepatitis [ICD-11: DB94.1] Approved

D08PCE	TTDDRUID	D08PCE
D08PCE	DRUGNAME	Oxantel pamoate
D08PCE	INDICATI	Trichuris trichiura infection [ICD-11: 1F6G] Approved

D0M9DC	TTDDRUID	D0M9DC
D0M9DC	DRUGNAME	Oxaprozin
D0M9DC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0AJ5L	TTDDRUID	D0AJ5L
D0AJ5L	DRUGNAME	Oxatomide
D0AJ5L	INDICATI	Hay fever [ICD-11: CA08.00] Approved

D09LDR	TTDDRUID	D09LDR
D09LDR	DRUGNAME	Oxazepam
D09LDR	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0QL3P	TTDDRUID	D0QL3P
D0QL3P	DRUGNAME	Oxcarbazepine
D0QL3P	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D04GYO	TTDDRUID	D04GYO
D04GYO	DRUGNAME	Oxiconazole
D04GYO	INDICATI	Tinea pedis [ICD-11: 1F28.2] Approved

D02BLO	TTDDRUID	D02BLO
D02BLO	DRUGNAME	Oxilan iohexol
D02BLO	INDICATI	Vascular disease [ICD-11: BE2Z] Approved

D07QLG	TTDDRUID	D07QLG
D07QLG	DRUGNAME	Oxilofrine
D07QLG	INDICATI	Orthostatic hypotension [ICD-11: BA21] Approved

D0Z4BV	TTDDRUID	D0Z4BV
D0Z4BV	DRUGNAME	Oxiracetam
D0Z4BV	INDICATI	Dementia [ICD-11: 6D80-6D86] Approved

D0D4IH	TTDDRUID	D0D4IH
D0D4IH	DRUGNAME	Oxitropium bromide
D0D4IH	INDICATI	Asthma [ICD-11: CA23] Approved

D00AEV	TTDDRUID	D00AEV
D00AEV	DRUGNAME	Oxothiazolidine carboxylate
D00AEV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0X2MB	TTDDRUID	D0X2MB
D0X2MB	DRUGNAME	Oxprenolol
D0X2MB	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0B0SH	TTDDRUID	D0B0SH
D0B0SH	DRUGNAME	Oxtriphylline
D0B0SH	INDICATI	Cough [ICD-11: MD12] Approved

D0H2SY	TTDDRUID	D0H2SY
D0H2SY	DRUGNAME	Oxybuprocaine
D0H2SY	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0R1DH	TTDDRUID	D0R1DH
D0R1DH	DRUGNAME	Oxybutynin hydrochloride
D0R1DH	INDICATI	Urinary incontinence [ICD-11: MF50.2] Approved

D03SKD	TTDDRUID	D03SKD
D03SKD	DRUGNAME	Oxycodone
D03SKD	INDICATI	Back pain [ICD-11: ME84.Z] Phase 3
D03SKD	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D03SKD	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09EBS	TTDDRUID	D09EBS
D09EBS	DRUGNAME	Oxymetazoline
D09EBS	INDICATI	Eye inflammation [ICD-11: 9A02] Approved
D09EBS	INDICATI	Nasal congestion [ICD-11: MD11.9] Approved

D0Q6NZ	TTDDRUID	D0Q6NZ
D0Q6NZ	DRUGNAME	Oxymetholone
D0Q6NZ	INDICATI	Aplastic anemia [ICD-11: 3A70] Approved

D02NSF	TTDDRUID	D02NSF
D02NSF	DRUGNAME	Oxymorphone
D02NSF	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D02NSF	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 4

D06ZPS	TTDDRUID	D06ZPS
D06ZPS	DRUGNAME	Oxyphenbutazone
D06ZPS	INDICATI	Arthritis [ICD-11: FA20] Approved

D0H5DU	TTDDRUID	D0H5DU
D0H5DU	DRUGNAME	Oxyphencyclimine
D0H5DU	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D0D1MA	TTDDRUID	D0D1MA
D0D1MA	DRUGNAME	Oxyphenonium
D0D1MA	INDICATI	Visceral spasms [ICD-11: MD81.4] Approved

D0J2NK	TTDDRUID	D0J2NK
D0J2NK	DRUGNAME	Oxytetracycline
D0J2NK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0M3FJ	TTDDRUID	D0M3FJ
D0M3FJ	DRUGNAME	Oxytocin
D0M3FJ	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Approved

D00ZTD	TTDDRUID	D00ZTD
D00ZTD	DRUGNAME	OZ277
D00ZTD	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0X1HE	TTDDRUID	D0X1HE
D0X1HE	DRUGNAME	Ozenoxacin
D0X1HE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
D0X1HE	INDICATI	Impetigo [ICD-11: 1B72] Approved

D0L0MK	TTDDRUID	D0L0MK
D0L0MK	DRUGNAME	Pachycarpine
D0L0MK	INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved

D03VGD	TTDDRUID	D03VGD
D03VGD	DRUGNAME	PACIS
D03VGD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0O7GU	TTDDRUID	D0O7GU
D0O7GU	DRUGNAME	Palifermin
D0O7GU	INDICATI	Oral mucositis [ICD-11: DA01.11] Approved

D0B3UJ	TTDDRUID	D0B3UJ
D0B3UJ	DRUGNAME	Paliperidone
D0B3UJ	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0A1AS	TTDDRUID	D0A1AS
D0A1AS	DRUGNAME	Palivizumab
D0A1AS	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Approved

D09XOR	TTDDRUID	D09XOR
D09XOR	DRUGNAME	Palladium Pd 103
D09XOR	INDICATI	Melanoma [ICD-11: 2C30] Approved

D04FVU	TTDDRUID	D04FVU
D04FVU	DRUGNAME	Palonosetron
D04FVU	INDICATI	Nausea [ICD-11: MD90] Approved

D0K5IP	TTDDRUID	D0K5IP
D0K5IP	DRUGNAME	Palonosetron and fosnetupitant
D0K5IP	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Approved

D0BF8G	TTDDRUID	D0BF8G
D0BF8G	DRUGNAME	Pamidronate
D0BF8G	INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved

D0V7IE	TTDDRUID	D0V7IE
D0V7IE	DRUGNAME	Pamiteplase
D0V7IE	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D0AA0L	TTDDRUID	D0AA0L
D0AA0L	DRUGNAME	Pancuronium
D0AA0L	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D07WXH	TTDDRUID	D07WXH
D07WXH	DRUGNAME	Pandemrix
D07WXH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0S8LV	TTDDRUID	D0S8LV
D0S8LV	DRUGNAME	Panipenem
D0S8LV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0HU9H	TTDDRUID	D0HU9H
D0HU9H	DRUGNAME	Panitumumab
D0HU9H	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
D0HU9H	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D0E3SH	TTDDRUID	D0E3SH
D0E3SH	DRUGNAME	Panobinostat
D0E3SH	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
D0E3SH	INDICATI	Primary myelofibrosis [ICD-11: 2A20.2] Phase 2
D0E3SH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0T6XX	TTDDRUID	D0T6XX
D0T6XX	DRUGNAME	Pantoprazole
D0T6XX	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved

D07SJT	TTDDRUID	D07SJT
D07SJT	DRUGNAME	Pantothenic acid
D07SJT	INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved

D0NJ3V	TTDDRUID	D0NJ3V
D0NJ3V	DRUGNAME	Papaverine
D0NJ3V	INDICATI	Spasm [ICD-11: MB47.3] Approved

D0P9EA	TTDDRUID	D0P9EA
D0P9EA	DRUGNAME	Paraldehyde
D0P9EA	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D09JBP	TTDDRUID	D09JBP
D09JBP	DRUGNAME	Paramethadione
D09JBP	INDICATI	Fetal trimethadione syndrome [ICD-11: LD2F.0Y] Approved
D09JBP	INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved

D03IKT	TTDDRUID	D03IKT
D03IKT	DRUGNAME	Paramethasone
D03IKT	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3
D03IKT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0M6SD	TTDDRUID	D0M6SD
D0M6SD	DRUGNAME	Parenteral amino acids
D0M6SD	INDICATI	Nutritional deficiency [ICD-11: 5B50-5B71] Approved

D0R0UJ	TTDDRUID	D0R0UJ
D0R0UJ	DRUGNAME	Pargyline
D0R0UJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D0R0UJ	INDICATI	Muscular dystrophy [ICD-11: 8C70] Patented
D0R0UJ	INDICATI	Skin imperfections [ICD-11: EK71] Patented

D0N1TP	TTDDRUID	D0N1TP
D0N1TP	DRUGNAME	Paricalcitol
D0N1TP	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Approved

D04NDM	TTDDRUID	D04NDM
D04NDM	DRUGNAME	Paromomycin
D04NDM	INDICATI	Intestinal amebiasis [ICD-11: 1A36] Approved

D06GDY	TTDDRUID	D06GDY
D06GDY	DRUGNAME	Paroxetine
D06GDY	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0TV0C	TTDDRUID	D0TV0C
D0TV0C	DRUGNAME	Pasireotide
D0TV0C	INDICATI	Cushing disease [ICD-11: 5A70] Approved

D0Z2YQ	TTDDRUID	D0Z2YQ
D0Z2YQ	DRUGNAME	Patiromer calcium
D0Z2YQ	INDICATI	Hyperkalemia [ICD-11: 5C76] Approved

D02UYB	TTDDRUID	D02UYB
D02UYB	DRUGNAME	Patisiran
D02UYB	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3

D0Z3PC	TTDDRUID	D0Z3PC
D0Z3PC	DRUGNAME	Patisiran 
D0Z3PC	INDICATI	Hereditary amyloidosis [ICD-11: 5D00.2] Approved

D0F0ZY	TTDDRUID	D0F0ZY
D0F0ZY	DRUGNAME	Pazopanib HCl
D0F0ZY	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D0Y2FY	TTDDRUID	D0Y2FY
D0Y2FY	DRUGNAME	Pediarix Vaccine
D0Y2FY	INDICATI	Diphtheria [ICD-11: 1C17] Approved

D04NXQ	TTDDRUID	D04NXQ
D04NXQ	DRUGNAME	Pefloxacin
D04NXQ	INDICATI	Gonococcal urethritis [ICD-11: 1A70.0Y] Approved

D0H1WY	TTDDRUID	D0H1WY
D0H1WY	DRUGNAME	Pegademase bovine
D0H1WY	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0UF9W	TTDDRUID	D0UF9W
D0UF9W	DRUGNAME	Pegaptanib
D0UF9W	INDICATI	Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Approved

D0U8JN	TTDDRUID	D0U8JN
D0U8JN	DRUGNAME	Pegaspargase
D0U8JN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0AT8C	TTDDRUID	D0AT8C
D0AT8C	DRUGNAME	Pegfilgrastim
D0AT8C	INDICATI	Malignant solid tumour [ICD-11: 2C10-2F32] Approved

D0I3JZ	TTDDRUID	D0I3JZ
D0I3JZ	DRUGNAME	Peginesatide acetate
D0I3JZ	INDICATI	Anaemia [ICD-11: 3A90] Approved

D0Y8OK	TTDDRUID	D0Y8OK
D0Y8OK	DRUGNAME	Peginterferon alfa-2a
D0Y8OK	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved

D08NWC	TTDDRUID	D08NWC
D08NWC	DRUGNAME	Peginterferon alfa-2b
D08NWC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D06ZIT	TTDDRUID	D06ZIT
D06ZIT	DRUGNAME	Pegloticase
D06ZIT	INDICATI	Gout [ICD-11: FA25] Approved

D0T8HZ	TTDDRUID	D0T8HZ
D0T8HZ	DRUGNAME	Pegvaliase
D0T8HZ	INDICATI	Phenylketonuria [ICD-11: 5C50.0] Approved

D0D6VE	TTDDRUID	D0D6VE
D0D6VE	DRUGNAME	Pegvisomant
D0D6VE	INDICATI	Acromegaly [ICD-11: 5A60.0] Approved

D04YXL	TTDDRUID	D04YXL
D04YXL	DRUGNAME	PEGylated IFN beta 1-a
D04YXL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0X4JN	TTDDRUID	D0X4JN
D0X4JN	DRUGNAME	Pelubiprofen
D0X4JN	INDICATI	Back pain [ICD-11: ME84.Z] Approved

D08ANZ	TTDDRUID	D08ANZ
D08ANZ	DRUGNAME	Pembrolizumab
D08ANZ	INDICATI	Melanoma [ICD-11: 2C30] Approved

D0Y4GO	TTDDRUID	D0Y4GO
D0Y4GO	DRUGNAME	Pemetrexed
D0Y4GO	INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Approved

D0K5LQ	TTDDRUID	D0K5LQ
D0K5LQ	DRUGNAME	Pemirolast
D0K5LQ	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved

D0D5GG	TTDDRUID	D0D5GG
D0D5GG	DRUGNAME	Pemoline
D0D5GG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved

D0W8SB	TTDDRUID	D0W8SB
D0W8SB	DRUGNAME	Penbutolol
D0W8SB	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07BYK	TTDDRUID	D07BYK
D07BYK	DRUGNAME	Penciclovir
D07BYK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0CQ0Z	TTDDRUID	D0CQ0Z
D0CQ0Z	DRUGNAME	Penfluridol
D0CQ0Z	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D08HZC	TTDDRUID	D08HZC
D08HZC	DRUGNAME	Penicillamine
D08HZC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0R1BD	TTDDRUID	D0R1BD
D0R1BD	DRUGNAME	Penicillin
D0R1BD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0U4YG	TTDDRUID	D0U4YG
D0U4YG	DRUGNAME	Penicillin G Benzathine
D0U4YG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0A5LH	TTDDRUID	D0A5LH
D0A5LH	DRUGNAME	Penicillin G Procaine
D0A5LH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0K5OT	TTDDRUID	D0K5OT
D0K5OT	DRUGNAME	Penicillin G Sodium
D0K5OT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09CPR	TTDDRUID	D09CPR
D09CPR	DRUGNAME	Penicillin V
D09CPR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02IIE	TTDDRUID	D02IIE
D02IIE	DRUGNAME	Penicillin V Potassium
D02IIE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00SGD	TTDDRUID	D00SGD
D00SGD	DRUGNAME	Pentacel
D00SGD	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0W9TE	TTDDRUID	D0W9TE
D0W9TE	DRUGNAME	Pentaerythritol tetranitrate
D0W9TE	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0O5TQ	TTDDRUID	D0O5TQ
D0O5TQ	DRUGNAME	Pentagastrin
D0O5TQ	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D05EAM	TTDDRUID	D05EAM
D05EAM	DRUGNAME	Pentamidine
D05EAM	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
D05EAM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Withdrawn from market

D0A9ZX	TTDDRUID	D0A9ZX
D0A9ZX	DRUGNAME	Pentamycin vaginal tablets
D0A9ZX	INDICATI	Vulvovaginitis [ICD-11: GA02.0] Approved

D0J6BR	TTDDRUID	D0J6BR
D0J6BR	DRUGNAME	Pentastarch
D0J6BR	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D03JUM	TTDDRUID	D03JUM
D03JUM	DRUGNAME	Pentaxim
D03JUM	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0W6DG	TTDDRUID	D0W6DG
D0W6DG	DRUGNAME	Pentazocine
D0W6DG	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D09NFN	TTDDRUID	D09NFN
D09NFN	DRUGNAME	Pentetate calcium trisodium
D09NFN	INDICATI	Acute radiation syndrome [ICD-11: NF00] Approved

D0L5QT	TTDDRUID	D0L5QT
D0L5QT	DRUGNAME	Pentetate zinc trisodium
D0L5QT	INDICATI	Acute radiation syndrome [ICD-11: NF00] Approved

D0F0YZ	TTDDRUID	D0F0YZ
D0F0YZ	DRUGNAME	Pentobarbital
D0F0YZ	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0IX1A	TTDDRUID	D0IX1A
D0IX1A	DRUGNAME	Pentolinium
D0IX1A	INDICATI	Hypotension [ICD-11: BA20-BA21] Approved

D0F8CM	TTDDRUID	D0F8CM
D0F8CM	DRUGNAME	Pentosan Polysulfate
D0F8CM	INDICATI	Interstitial cystitis [ICD-11: GC00.3] Approved
D0F8CM	INDICATI	Painful bladder syndrome [ICD-11: MG30.50] Approved

D0T3AD	TTDDRUID	D0T3AD
D0T3AD	DRUGNAME	Pentostatin
D0T3AD	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved

D09QEI	TTDDRUID	D09QEI
D09QEI	DRUGNAME	Pentoxifylline
D09QEI	INDICATI	Intermittent claudication [ICD-11: BD40.00] Approved

D08HJT	TTDDRUID	D08HJT
D08HJT	DRUGNAME	Peplomycin
D08HJT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0P2IW	TTDDRUID	D0P2IW
D0P2IW	DRUGNAME	Peramivir
D0P2IW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D07JWT	TTDDRUID	D07JWT
D07JWT	DRUGNAME	Perazine
D07JWT	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved

D06JDK	TTDDRUID	D06JDK
D06JDK	DRUGNAME	Perflexane-lipid microsphere
D06JDK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D04PAN	TTDDRUID	D04PAN
D04PAN	DRUGNAME	Perflubron
D04PAN	INDICATI	Contrast imaging [ICD-11: N.A.] Approved

D05RIY	TTDDRUID	D05RIY
D05RIY	DRUGNAME	Perflubutane lipid microsphere-encapsulated
D05RIY	INDICATI	Heart disease [ICD-11: BA41-BA42] Approved

D0M3KK	TTDDRUID	D0M3KK
D0M3KK	DRUGNAME	Perfluorochemical emulsion
D0M3KK	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D04JCN	TTDDRUID	D04JCN
D04JCN	DRUGNAME	Pergolide
D04JCN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D00SBN	TTDDRUID	D00SBN
D00SBN	DRUGNAME	Perhexiline
D00SBN	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D03KYG	TTDDRUID	D03KYG
D03KYG	DRUGNAME	Perindopril
D03KYG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0K8MP	TTDDRUID	D0K8MP
D0K8MP	DRUGNAME	Permethrin
D0K8MP	INDICATI	Sarcoptes scabiei infection [ICD-11: 1G04] Approved

D0F6GV	TTDDRUID	D0F6GV
D0F6GV	DRUGNAME	Perospirone
D0F6GV	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved

D02HED	TTDDRUID	D02HED
D02HED	DRUGNAME	Perphenazine
D02HED	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0CI4E	TTDDRUID	D0CI4E
D0CI4E	DRUGNAME	Pertuzumab
D0CI4E	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0Y9GM	TTDDRUID	D0Y9GM
D0Y9GM	DRUGNAME	Pexiganan
D0Y9GM	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved

D0S5LO	TTDDRUID	D0S5LO
D0S5LO	DRUGNAME	PF-04449913
D0S5LO	INDICATI	Chronic myelomonocytic leukaemia [ICD-11: 2A40] Approved
D0S5LO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D0S5LO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Q3VE	TTDDRUID	D0Q3VE
D0Q3VE	DRUGNAME	PF-04971729
D0Q3VE	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D0Q3VE	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
D0Q3VE	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03PGE	TTDDRUID	D03PGE
D03PGE	DRUGNAME	PG-2
D03PGE	INDICATI	Fatigue [ICD-11: MG22] Approved

D0N0WX	TTDDRUID	D0N0WX
D0N0WX	DRUGNAME	PhageBioDerm
D0N0WX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07ONP	TTDDRUID	D07ONP
D07ONP	DRUGNAME	Phenacemide
D07ONP	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D00VUL	TTDDRUID	D00VUL
D00VUL	DRUGNAME	Phenazopyridine
D00VUL	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0T6SU	TTDDRUID	D0T6SU
D0T6SU	DRUGNAME	Phendimetrazine
D0T6SU	INDICATI	Obesity [ICD-11: 5B81] Approved

D0P9AC	TTDDRUID	D0P9AC
D0P9AC	DRUGNAME	Phenelzine
D0P9AC	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
D0P9AC	INDICATI	Skin imperfections [ICD-11: EK71] Patented

D06UDO	TTDDRUID	D06UDO
D06UDO	DRUGNAME	Phenindamine
D06UDO	INDICATI	Common cold [ICD-11: CA00] Approved

D08FTG	TTDDRUID	D08FTG
D08FTG	DRUGNAME	Phenindione
D08FTG	INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
D08FTG	INDICATI	Pulmonary embolism [ICD-11: BB00] Approved

D04OBB	TTDDRUID	D04OBB
D04OBB	DRUGNAME	Pheniramine
D04OBB	INDICATI	Hay fever [ICD-11: CA08.00] Approved

D0M2MC	TTDDRUID	D0M2MC
D0M2MC	DRUGNAME	Phenmetrazine
D0M2MC	INDICATI	Obesity [ICD-11: 5B81] Approved

D0Y7RW	TTDDRUID	D0Y7RW
D0Y7RW	DRUGNAME	Phenobarbital
D0Y7RW	INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved

D0X2DK	TTDDRUID	D0X2DK
D0X2DK	DRUGNAME	Phenoxybenzamine
D0X2DK	INDICATI	Malignant essential hypertension [ICD-11: BA00] Approved

D0QV5T	TTDDRUID	D0QV5T
D0QV5T	DRUGNAME	Phenprocoumon
D0QV5T	INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved

D06BYV	TTDDRUID	D06BYV
D06BYV	DRUGNAME	Phensuximide
D06BYV	INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved

D0U0RZ	TTDDRUID	D0U0RZ
D0U0RZ	DRUGNAME	Phentermine
D0U0RZ	INDICATI	Obesity [ICD-11: 5B81] Approved

D01JUF	TTDDRUID	D01JUF
D01JUF	DRUGNAME	Phentolamine
D01JUF	INDICATI	Dermal necrosis [ICD-11: MC85] Approved

D0L5PO	TTDDRUID	D0L5PO
D0L5PO	DRUGNAME	Phenyl Aminosalicylate
D0L5PO	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved

D07VHR	TTDDRUID	D07VHR
D07VHR	DRUGNAME	Phenylbutazone
D07VHR	INDICATI	Chronic pain [ICD-11: MG30] Approved

D0O6IU	TTDDRUID	D0O6IU
D0O6IU	DRUGNAME	Phenylephrine
D0O6IU	INDICATI	Ophthalmic graves disease [ICD-11: 5A02.0] Approved

D0D7QO	TTDDRUID	D0D7QO
D0D7QO	DRUGNAME	Phenylephrine hydrochloride gel
D0D7QO	INDICATI	Fecal incontinence [ICD-11: ME07] Approved

D0KS6W	TTDDRUID	D0KS6W
D0KS6W	DRUGNAME	Phenyltoloxamine
D0KS6W	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D0E4DW	TTDDRUID	D0E4DW
D0E4DW	DRUGNAME	Phenytoin
D0E4DW	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D07EXH	TTDDRUID	D07EXH
D07EXH	DRUGNAME	Phloroglucinol
D07EXH	INDICATI	Urinary tract disease [ICD-11: GC2Z] Approved

D08VYC	TTDDRUID	D08VYC
D08VYC	DRUGNAME	Phosphate
D08VYC	INDICATI	Constipation [ICD-11: DD91.1] Approved

D00FSV	TTDDRUID	D00FSV
D00FSV	DRUGNAME	Phytonadione
D00FSV	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
D00FSV	INDICATI	Vitamin K deficiency [ICD-11: 5B59] Approved

D0KR9U	TTDDRUID	D0KR9U
D0KR9U	DRUGNAME	Picrotoxin
D0KR9U	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved

D06HLY	TTDDRUID	D06HLY
D06HLY	DRUGNAME	Pilocarpine
D06HLY	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0H7AV	TTDDRUID	D0H7AV
D0H7AV	DRUGNAME	Pilsicainide
D0H7AV	INDICATI	Heart arrhythmia [ICD-11: BC65] Approved

D0J8JP	TTDDRUID	D0J8JP
D0J8JP	DRUGNAME	Pimavanserin
D0J8JP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
D0J8JP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D0Z4UN	TTDDRUID	D0Z4UN
D0Z4UN	DRUGNAME	Pimecrolimus
D0Z4UN	INDICATI	Atopic dermatitis [ICD-11: EA80] Approved

D00KHM	TTDDRUID	D00KHM
D00KHM	DRUGNAME	Pimozide
D00KHM	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D02KMO	TTDDRUID	D02KMO
D02KMO	DRUGNAME	Pinacidil
D02KMO	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0XM9Y	TTDDRUID	D0XM9Y
D0XM9Y	DRUGNAME	Pinazepam
D0XM9Y	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0F2PO	TTDDRUID	D0F2PO
D0F2PO	DRUGNAME	Pindolol
D0F2PO	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03OFF	TTDDRUID	D03OFF
D03OFF	DRUGNAME	Pioglitazone
D03OFF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
D03OFF	INDICATI	Obesity [ICD-11: 5B81] Investigative
D03OFF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0XX6Y	TTDDRUID	D0XX6Y
D0XX6Y	DRUGNAME	Pipecuronium
D0XX6Y	INDICATI	Spasm [ICD-11: MB47.3] Approved

D0AO6B	TTDDRUID	D0AO6B
D0AO6B	DRUGNAME	Piperacetazine
D0AO6B	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D04ZAH	TTDDRUID	D04ZAH
D04ZAH	DRUGNAME	Piperacillin
D04ZAH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0P0SZ	TTDDRUID	D0P0SZ
D0P0SZ	DRUGNAME	Piperaquine
D0P0SZ	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D01XLM	TTDDRUID	D01XLM
D01XLM	DRUGNAME	Piperazine
D01XLM	INDICATI	Ascariasis [ICD-11: 1F62] Approved
D01XLM	INDICATI	Enterobiasis [ICD-11: 1F65] Approved

D03FNJ	TTDDRUID	D03FNJ
D03FNJ	DRUGNAME	Pipobroman
D03FNJ	INDICATI	Refractory chronic myeloid leukaemia [ICD-11: 2A20] Approved

D0Z6QG	TTDDRUID	D0Z6QG
D0Z6QG	DRUGNAME	Pipotiazine
D0Z6QG	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0Q4YK	TTDDRUID	D0Q4YK
D0Q4YK	DRUGNAME	Piracetam
D0Q4YK	INDICATI	Cognitive impairment [ICD-11: 6D71] Approved

D0T8EH	TTDDRUID	D0T8EH
D0T8EH	DRUGNAME	Pirarubicin
D0T8EH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0SS4P	TTDDRUID	D0SS4P
D0SS4P	DRUGNAME	Pirbuterol
D0SS4P	INDICATI	Asthma [ICD-11: CA23] Approved

D0T0LM	TTDDRUID	D0T0LM
D0T0LM	DRUGNAME	Pirenzepine
D0T0LM	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D02WCI	TTDDRUID	D02WCI
D02WCI	DRUGNAME	Pirfenidone
D02WCI	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved

D0RX3C	TTDDRUID	D0RX3C
D0RX3C	DRUGNAME	Piritramide
D0RX3C	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0T7WL	TTDDRUID	D0T7WL
D0T7WL	DRUGNAME	Pirmenol
D0T7WL	INDICATI	Heart arrhythmia [ICD-11: BC65] Approved

D00IBN	TTDDRUID	D00IBN
D00IBN	DRUGNAME	Piroxicam
D00IBN	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0S9ET	TTDDRUID	D0S9ET
D0S9ET	DRUGNAME	Pirprofen
D0S9ET	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved

D0G1WL	TTDDRUID	D0G1WL
D0G1WL	DRUGNAME	PITAVASTATIN CALCIUM
D0G1WL	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Approved

D04KAQ	TTDDRUID	D04KAQ
D04KAQ	DRUGNAME	Pivampicillin
D04KAQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D08HDY	TTDDRUID	D08HDY
D08HDY	DRUGNAME	Pivmecillinam
D08HDY	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D06XZR	TTDDRUID	D06XZR
D06XZR	DRUGNAME	Pizotyline
D06XZR	INDICATI	Headache [ICD-11: 8A80-8A84] Approved

D05XQE	TTDDRUID	D05XQE
D05XQE	DRUGNAME	Plaunotol
D05XQE	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved

D0E6BB	TTDDRUID	D0E6BB
D0E6BB	DRUGNAME	Plazomicin
D0E6BB	INDICATI	Bronchitis [ICD-11: CA20] Approved
D0E6BB	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
D0E6BB	INDICATI	Prostate disease [ICD-11: GA91] Approved
D0E6BB	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D07FEC	TTDDRUID	D07FEC
D07FEC	DRUGNAME	Plecanatide
D07FEC	INDICATI	Chronic idiopathic constipation [ICD-11: DC32] Approved
D07FEC	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0LW4O	TTDDRUID	D0LW4O
D0LW4O	DRUGNAME	PLEGRIDY
D0LW4O	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0L5RW	TTDDRUID	D0L5RW
D0L5RW	DRUGNAME	Plerixafor
D0L5RW	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D06EPF	TTDDRUID	D06EPF
D06EPF	DRUGNAME	Plicamycin
D06EPF	INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved
D06EPF	INDICATI	Testicular cancer [ICD-11: 2C80] Approved

D09LEN	TTDDRUID	D09LEN
D09LEN	DRUGNAME	Pneumococcal 13-valent conjugate vaccine
D09LEN	INDICATI	Streptococcus infection [ICD-11: 1B53] Approved

D02MGH	TTDDRUID	D02MGH
D02MGH	DRUGNAME	Pneumococcal vaccine
D02MGH	INDICATI	Streptococcus infection [ICD-11: 1B53] Approved

D01IEM	TTDDRUID	D01IEM
D01IEM	DRUGNAME	Pneumovax 23
D01IEM	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved

D0D4HN	TTDDRUID	D0D4HN
D0D4HN	DRUGNAME	Podofilox
D0D4HN	INDICATI	Condyloma [ICD-11: 1A61.3] Approved
D0D4HN	INDICATI	External genital and perianal wart [ICD-11: 1A95] Approved

D01PPQ	TTDDRUID	D01PPQ
D01PPQ	DRUGNAME	Podophyllum
D01PPQ	INDICATI	Verruca vulgaris [ICD-11: 1E80] Approved

D09NYU	TTDDRUID	D09NYU
D09NYU	DRUGNAME	Polaprezinc
D09NYU	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved
D09NYU	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved

D05ZPL	TTDDRUID	D05ZPL
D05ZPL	DRUGNAME	Polidocanol
D05ZPL	INDICATI	Reticular veins [ICD-11: EF20] Approved
D05ZPL	INDICATI	Spider veins [ICD-11: EF20] Approved

D0LW9U	TTDDRUID	D0LW9U
D0LW9U	DRUGNAME	Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co
D0LW9U	INDICATI	Varicose veins [ICD-11: BD74-BD75] Approved

D0R5JL	TTDDRUID	D0R5JL
D0R5JL	DRUGNAME	Polio IPV
D0R5JL	INDICATI	Poliovirus infection [ICD-11: 1C8Y] Approved

D03DXN	TTDDRUID	D03DXN
D03DXN	DRUGNAME	Polyestradiol Phosphate
D03DXN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0IV3M	TTDDRUID	D0IV3M
D0IV3M	DRUGNAME	Polyethylene glycol
D0IV3M	INDICATI	Constipation [ICD-11: DD91.1] Approved

D0W3NN	TTDDRUID	D0W3NN
D0W3NN	DRUGNAME	Polygeline
D0W3NN	INDICATI	Blood transfusion [ICD-11: QB98] Approved

D09OOV	TTDDRUID	D09OOV
D09OOV	DRUGNAME	Polymyxin B Sulfate
D09OOV	INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved

D0F0ID	TTDDRUID	D0F0ID
D0F0ID	DRUGNAME	Polyoxidonium
D0F0ID	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved

D0V0OP	TTDDRUID	D0V0OP
D0V0OP	DRUGNAME	Polyphenon e
D0V0OP	INDICATI	Perianal wart [ICD-11: 1A95] Approved

D06TNG	TTDDRUID	D06TNG
D06TNG	DRUGNAME	Polythiazide
D06TNG	INDICATI	Edema [ICD-11: MG29] Approved
D06TNG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04JZD	TTDDRUID	D04JZD
D04JZD	DRUGNAME	Polyvalent crotalid antivenin ovine fab
D04JZD	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D0A3ZU	TTDDRUID	D0A3ZU
D0A3ZU	DRUGNAME	Pomalidomide
D0A3ZU	INDICATI	Systemic sclerosis [ICD-11: 4A42] Approved

D0H0EQ	TTDDRUID	D0H0EQ
D0H0EQ	DRUGNAME	Ponatinib
D0H0EQ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D08SCQ	TTDDRUID	D08SCQ
D08SCQ	DRUGNAME	Poractant alfa
D08SCQ	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved

D08BKM	TTDDRUID	D08BKM
D08BKM	DRUGNAME	Porcine isophane insulin
D08BKM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D07DGQ	TTDDRUID	D07DGQ
D07DGQ	DRUGNAME	Porcine lung surfactant
D07DGQ	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved

D0EA5U	TTDDRUID	D0EA5U
D0EA5U	DRUGNAME	Porcine neutral insulin
D0EA5U	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D02JDL	TTDDRUID	D02JDL
D02JDL	DRUGNAME	Porfimer Sodium
D02JDL	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D07ABV	TTDDRUID	D07ABV
D07ABV	DRUGNAME	Posaconazole
D07ABV	INDICATI	Aspergillosis [ICD-11: 1F20] Approved

D0RN2W	TTDDRUID	D0RN2W
D0RN2W	DRUGNAME	Potassium
D0RN2W	INDICATI	Hypokalemia [ICD-11: 5C77] Approved

D0C1PY	TTDDRUID	D0C1PY
D0C1PY	DRUGNAME	Potassium Acetate
D0C1PY	INDICATI	Kidney stone [ICD-11: GB70.0Z] Approved

D0S2BT	TTDDRUID	D0S2BT
D0S2BT	DRUGNAME	Potassium Aminosalicylate
D0S2BT	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved

D0E9JM	TTDDRUID	D0E9JM
D0E9JM	DRUGNAME	Potassium Chloride
D0E9JM	INDICATI	Hypokalemia [ICD-11: 5C77] Approved

D07QPM	TTDDRUID	D07QPM
D07QPM	DRUGNAME	Potassium Citrate
D07QPM	INDICATI	Kidney stone [ICD-11: GB70.0Z] Approved

D02URS	TTDDRUID	D02URS
D02URS	DRUGNAME	Potassium iodide
D02URS	INDICATI	Thyrotoxicosis [ICD-11: 5A02] Approved

D0MF9G	TTDDRUID	D0MF9G
D0MF9G	DRUGNAME	Potassium Perchlorate
D0MF9G	INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved

D03EXK	TTDDRUID	D03EXK
D03EXK	DRUGNAME	Povidone-iodine
D03EXK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0KD1U	TTDDRUID	D0KD1U
D0KD1U	DRUGNAME	Practolol
D0KD1U	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Approved

D02LWU	TTDDRUID	D02LWU
D02LWU	DRUGNAME	Pralatrexate
D02LWU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
D02LWU	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Approved

D0X7NU	TTDDRUID	D0X7NU
D0X7NU	DRUGNAME	Pralidoxime Chloride
D0X7NU	INDICATI	Poisoning due to pesticides and chemicals [ICD-11: NE6Z] Approved

D0G8NN	TTDDRUID	D0G8NN
D0G8NN	DRUGNAME	Pramipexole
D0G8NN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0P7VJ	TTDDRUID	D0P7VJ
D0P7VJ	DRUGNAME	Pramiracetam
D0P7VJ	INDICATI	Brain disease [ICD-11: 8C70-8E61] Approved (orphan drug)

D0C4AM	TTDDRUID	D0C4AM
D0C4AM	DRUGNAME	Pramlintide
D0C4AM	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved

D0V4UF	TTDDRUID	D0V4UF
D0V4UF	DRUGNAME	Pramoxine
D0V4UF	INDICATI	Anal fistula [ICD-11: DB50.1] Approved

D08QIP	TTDDRUID	D08QIP
D08QIP	DRUGNAME	Pranlukast
D08QIP	INDICATI	Asthma [ICD-11: CA23] Approved

D0K0EK	TTDDRUID	D0K0EK
D0K0EK	DRUGNAME	Prasterone
D0K0EK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 4
D0K0EK	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D07IRF	TTDDRUID	D07IRF
D07IRF	DRUGNAME	Prasugrel
D07IRF	INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved

D02RQU	TTDDRUID	D02RQU
D02RQU	DRUGNAME	Pravastatin
D02RQU	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D0G3AQ	TTDDRUID	D0G3AQ
D0G3AQ	DRUGNAME	Prazepam
D0G3AQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D0L9ZR	TTDDRUID	D0L9ZR
D0L9ZR	DRUGNAME	Praziquantel
D0L9ZR	INDICATI	Flatworm infection [ICD-11: 1F70-1F86] Approved

D0WV3U	TTDDRUID	D0WV3U
D0WV3U	DRUGNAME	Prazosin
D0WV3U	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
D0WV3U	INDICATI	Congestive heart failure [ICD-11: BD10] Approved
D0WV3U	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09IEE	TTDDRUID	D09IEE
D09IEE	DRUGNAME	Prednicarbate
D09IEE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D06LYS	TTDDRUID	D06LYS
D06LYS	DRUGNAME	Prednimustine
D06LYS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0D1SG	TTDDRUID	D0D1SG
D0D1SG	DRUGNAME	Prednisolone
D0D1SG	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D0D1SG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0IL7L	TTDDRUID	D0IL7L
D0IL7L	DRUGNAME	Prednisone
D0IL7L	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved

D0G0IA	TTDDRUID	D0G0IA
D0G0IA	DRUGNAME	Preflucel
D0G0IA	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D00WUF	TTDDRUID	D00WUF
D00WUF	DRUGNAME	Pregabalin
D00WUF	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0S1UW	TTDDRUID	D0S1UW
D0S1UW	DRUGNAME	Premarin/Trimegestone
D0S1UW	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D0M1PR	TTDDRUID	D0M1PR
D0M1PR	DRUGNAME	Prevnar
D0M1PR	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved

D0C3LP	TTDDRUID	D0C3LP
D0C3LP	DRUGNAME	Prezatide copper acetate
D0C3LP	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved

D0E8LT	TTDDRUID	D0E8LT
D0E8LT	DRUGNAME	Prifinium
D0E8LT	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D06LYG	TTDDRUID	D06LYG
D06LYG	DRUGNAME	Prilocaine
D06LYG	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0T1LK	TTDDRUID	D0T1LK
D0T1LK	DRUGNAME	Primaquine
D0T1LK	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0U5RT	TTDDRUID	D0U5RT
D0U5RT	DRUGNAME	Primidone
D0U5RT	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D00MDP	TTDDRUID	D00MDP
D00MDP	DRUGNAME	Prinomastat
D00MDP	INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 3
D00MDP	INDICATI	Lung cancer [ICD-11: 2C25.0] Approved

D0M5GX	TTDDRUID	D0M5GX
D0M5GX	DRUGNAME	Priorix
D0M5GX	INDICATI	Measles [ICD-11: 1F03] Approved

D0E5EG	TTDDRUID	D0E5EG
D0E5EG	DRUGNAME	Priorix-Tetra
D0E5EG	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved

D07XGH	TTDDRUID	D07XGH
D07XGH	DRUGNAME	Pristinamycin
D07XGH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0L7FM	TTDDRUID	D0L7FM
D0L7FM	DRUGNAME	Probenecid
D0L7FM	INDICATI	Gout [ICD-11: FA25] Approved
D0L7FM	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved

D0H2DQ	TTDDRUID	D0H2DQ
D0H2DQ	DRUGNAME	Probucol
D0H2DQ	INDICATI	Coronary artery disease [ICD-11: BA80] Approved

D0U5SI	TTDDRUID	D0U5SI
D0U5SI	DRUGNAME	Procainamide
D0U5SI	INDICATI	Ventricular arrhythmias [ICD-11: BC71] Approved

D0TZ1G	TTDDRUID	D0TZ1G
D0TZ1G	DRUGNAME	Procaine
D0TZ1G	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D08GYO	TTDDRUID	D08GYO
D08GYO	DRUGNAME	Procarbazine
D08GYO	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved

D0Z1WA	TTDDRUID	D0Z1WA
D0Z1WA	DRUGNAME	Procaterol
D0Z1WA	INDICATI	Asthma [ICD-11: CA23] Approved

D0B2UZ	TTDDRUID	D0B2UZ
D0B2UZ	DRUGNAME	Prochlorperazine
D0B2UZ	INDICATI	Nausea [ICD-11: MD90] Approved

D0R1WR	TTDDRUID	D0R1WR
D0R1WR	DRUGNAME	Procyclidine
D0R1WR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0P5AL	TTDDRUID	D0P5AL
D0P5AL	DRUGNAME	Profezyme
D0P5AL	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D08GSF	TTDDRUID	D08GSF
D08GSF	DRUGNAME	Proflavine
D08GSF	INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved

D0O5LA	TTDDRUID	D0O5LA
D0O5LA	DRUGNAME	Progabide
D0O5LA	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D07BSQ	TTDDRUID	D07BSQ
D07BSQ	DRUGNAME	Progesterone
D07BSQ	INDICATI	Contraception [ICD-11: QA21] Phase 3
D07BSQ	INDICATI	Premature labour [ICD-11: JB00] Approved

D0BD0Q	TTDDRUID	D0BD0Q
D0BD0Q	DRUGNAME	Proglumetacin
D0BD0Q	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D0P8RS	TTDDRUID	D0P8RS
D0P8RS	DRUGNAME	Proguanil
D0P8RS	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0V3SB	TTDDRUID	D0V3SB
D0V3SB	DRUGNAME	Prolastin
D0V3SB	INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Approved

D03NTJ	TTDDRUID	D03NTJ
D03NTJ	DRUGNAME	Prolixin decanoate
D03NTJ	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D03PYO	TTDDRUID	D03PYO
D03PYO	DRUGNAME	PROMACTA
D03PYO	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved

D00NAX	TTDDRUID	D00NAX
D00NAX	DRUGNAME	Promazine
D00NAX	INDICATI	Psychomotor agitation [ICD-11: MB23.M] Approved

D0F2AK	TTDDRUID	D0F2AK
D0F2AK	DRUGNAME	Promegestone
D0F2AK	INDICATI	Gynecological disease [ICD-11: GA6Z] Approved

D0C4NY	TTDDRUID	D0C4NY
D0C4NY	DRUGNAME	Promestriene
D0C4NY	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0T2XU	TTDDRUID	D0T2XU
D0T2XU	DRUGNAME	Promethazine
D0T2XU	INDICATI	Nausea [ICD-11: MD90] Approved

D0J2KV	TTDDRUID	D0J2KV
D0J2KV	DRUGNAME	Propafenone
D0J2KV	INDICATI	Tachyarrhythmias [ICD-11: BC71] Approved

D0V5ZZ	TTDDRUID	D0V5ZZ
D0V5ZZ	DRUGNAME	Propantheline
D0V5ZZ	INDICATI	Excessive sweating [ICD-11: EE00.Z] Approved
D0V5ZZ	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Approved

D0Q7ZG	TTDDRUID	D0Q7ZG
D0Q7ZG	DRUGNAME	Proparacaine
D0Q7ZG	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0UU9Y	TTDDRUID	D0UU9Y
D0UU9Y	DRUGNAME	Propentofylline propionate
D0UU9Y	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D00AWT	TTDDRUID	D00AWT
D00AWT	DRUGNAME	Propericiazine
D00AWT	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Approved

D0WV4M	TTDDRUID	D0WV4M
D0WV4M	DRUGNAME	Propicillin
D0WV4M	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Z8AA	TTDDRUID	D0Z8AA
D0Z8AA	DRUGNAME	Propiolactone
D0Z8AA	INDICATI	Sterilant [ICD-11: N.A.] Approved

D0R9ZB	TTDDRUID	D0R9ZB
D0R9ZB	DRUGNAME	Propiomazine
D0R9ZB	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0TV9K	TTDDRUID	D0TV9K
D0TV9K	DRUGNAME	Propiverine
D0TV9K	INDICATI	Urinary incontinence [ICD-11: MF50.2] Approved

D0A3HB	TTDDRUID	D0A3HB
D0A3HB	DRUGNAME	Propofol
D0A3HB	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0N6CR	TTDDRUID	D0N6CR
D0N6CR	DRUGNAME	Propoxycaine
D0N6CR	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03HCZ	TTDDRUID	D03HCZ
D03HCZ	DRUGNAME	Propoxyphene Hydrochloride
D03HCZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D04JEE	TTDDRUID	D04JEE
D04JEE	DRUGNAME	Propranolol
D04JEE	INDICATI	Migraine [ICD-11: 8A80] Approved

D03DVJ	TTDDRUID	D03DVJ
D03DVJ	DRUGNAME	Propylhexedrine
D03DVJ	INDICATI	Obesity [ICD-11: 5B81] Approved

D0NU2H	TTDDRUID	D0NU2H
D0NU2H	DRUGNAME	Propyliodone
D0NU2H	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Approved

D00MIN	TTDDRUID	D00MIN
D00MIN	DRUGNAME	Propylthiouracil
D00MIN	INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved

D06IXT	TTDDRUID	D06IXT
D06IXT	DRUGNAME	Propyphenazone
D06IXT	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0IP2J	TTDDRUID	D0IP2J
D0IP2J	DRUGNAME	ProQuad
D0IP2J	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved

D0J6WW	TTDDRUID	D0J6WW
D0J6WW	DRUGNAME	Proquazone
D0J6WW	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D00PJY	TTDDRUID	D00PJY
D00PJY	DRUGNAME	Prosorba
D00PJY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D09RED	TTDDRUID	D09RED
D09RED	DRUGNAME	Prostat
D09RED	INDICATI	Prostate hyperplasia [ICD-11: GA90] Approved

D03FXM	TTDDRUID	D03FXM
D03FXM	DRUGNAME	Protamine
D03FXM	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D0ZR1P	TTDDRUID	D0ZR1P
D0ZR1P	DRUGNAME	Protein c concentrate
D0ZR1P	INDICATI	Purpura fulminans [ICD-11: 3B20] Approved

D0L7UQ	TTDDRUID	D0L7UQ
D0L7UQ	DRUGNAME	Prothionamide
D0L7UQ	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D0E9TD	TTDDRUID	D0E9TD
D0E9TD	DRUGNAME	Protirelin
D0E9TD	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved

D02FCQ	TTDDRUID	D02FCQ
D02FCQ	DRUGNAME	Protokylol Hydrochloride
D02FCQ	INDICATI	Asthma [ICD-11: CA23] Approved

D00MYQ	TTDDRUID	D00MYQ
D00MYQ	DRUGNAME	Protriptyline
D00MYQ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D03VNX	TTDDRUID	D03VNX
D03VNX	DRUGNAME	Pro-urokinase
D03VNX	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D0M3TM	TTDDRUID	D0M3TM
D0M3TM	DRUGNAME	Prussian blue
D0M3TM	INDICATI	Metal intoxication [ICD-11: NE60] Approved

D03AJX	TTDDRUID	D03AJX
D03AJX	DRUGNAME	PS-341
D03AJX	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved

D00HHS	TTDDRUID	D00HHS
D00HHS	DRUGNAME	Pseudoephedrine
D00HHS	INDICATI	Nasal congestion [ICD-11: MD11.9] Approved

D0H2TE	TTDDRUID	D0H2TE
D0H2TE	DRUGNAME	Pseudoephedrine, nor
D0H2TE	INDICATI	Cardiac arrest [ICD-11: MC82] Approved

D0D4YZ	TTDDRUID	D0D4YZ
D0D4YZ	DRUGNAME	PSI-7977
D0D4YZ	INDICATI	HCV 1-6 infection [ICD-11: 1E51] Approved
D0D4YZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D04DFJ	TTDDRUID	D04DFJ
D04DFJ	DRUGNAME	Pulmonary insulin
D04DFJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D03PTH	TTDDRUID	D03PTH
D03PTH	DRUGNAME	Pyrantel
D03PTH	INDICATI	Worm infection [ICD-11: 1F90.Z] Approved

D0XF8W	TTDDRUID	D0XF8W
D0XF8W	DRUGNAME	Pyrazinamide
D0XF8W	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved

D0O2WB	TTDDRUID	D0O2WB
D0O2WB	DRUGNAME	Pyridostigmine
D0O2WB	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved

D06JGH	TTDDRUID	D06JGH
D06JGH	DRUGNAME	Pyridoxal Phosphate
D06JGH	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0C0SK	TTDDRUID	D0C0SK
D0C0SK	DRUGNAME	Pyrimethamine
D0C0SK	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D04UZN	TTDDRUID	D04UZN
D04UZN	DRUGNAME	Pyrimethamine/sulfadoxine
D04UZN	INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Approved

D0C8FX	TTDDRUID	D0C8FX
D0C8FX	DRUGNAME	Pyrithione Zinc
D0C8FX	INDICATI	Seborrhoeic dermatitis [ICD-11: EA81] Approved

D0E0KQ	TTDDRUID	D0E0KQ
D0E0KQ	DRUGNAME	Pyronaridine
D0E0KQ	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0G4JI	TTDDRUID	D0G4JI
D0G4JI	DRUGNAME	Pyruvic acid
D0G4JI	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0A0SP	TTDDRUID	D0A0SP
D0A0SP	DRUGNAME	Pyrvinium
D0A0SP	INDICATI	Worm infection [ICD-11: 1F90.Z] Approved

D06WGK	TTDDRUID	D06WGK
D06WGK	DRUGNAME	Q-LAIV
D06WGK	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Approved

D0U6EX	TTDDRUID	D0U6EX
D0U6EX	DRUGNAME	Quadracel
D0U6EX	INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved

D0EW9I	TTDDRUID	D0EW9I
D0EW9I	DRUGNAME	Quadrivalent
D0EW9I	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D02QQT	TTDDRUID	D02QQT
D02QQT	DRUGNAME	Quattvaxem
D02QQT	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D03NPH	TTDDRUID	D03NPH
D03NPH	DRUGNAME	Quazepam
D03NPH	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0K8KX	TTDDRUID	D0K8KX
D0K8KX	DRUGNAME	Quercetin
D0K8KX	INDICATI	Obesity [ICD-11: 5B81] Approved

D0H7KF	TTDDRUID	D0H7KF
D0H7KF	DRUGNAME	Quetiapine
D0H7KF	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0W9ZF	TTDDRUID	D0W9ZF
D0W9ZF	DRUGNAME	Quinagolide
D0W9ZF	INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved

D0I7SZ	TTDDRUID	D0I7SZ
D0I7SZ	DRUGNAME	Quinapril
D0I7SZ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04UZT	TTDDRUID	D04UZT
D04UZT	DRUGNAME	Quinestrol
D04UZT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0J8ZA	TTDDRUID	D0J8ZA
D0J8ZA	DRUGNAME	Quinethazone
D0J8ZA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03DDR	TTDDRUID	D03DDR
D03DDR	DRUGNAME	Quinine
D03DDR	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D09VTE	TTDDRUID	D09VTE
D09VTE	DRUGNAME	Quinolone
D09VTE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Z3EI	TTDDRUID	D0Z3EI
D0Z3EI	DRUGNAME	Quinolones
D0Z3EI	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D0E2OU	TTDDRUID	D0E2OU
D0E2OU	DRUGNAME	Quinupristin
D0E2OU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05URO	TTDDRUID	D05URO
D05URO	DRUGNAME	Quinvaxem
D05URO	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D04QSJ	TTDDRUID	D04QSJ
D04QSJ	DRUGNAME	R0-93877
D04QSJ	INDICATI	Constipation [ICD-11: DD91.1] Approved
D04QSJ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0KL4J	TTDDRUID	D0KL4J
D0KL4J	DRUGNAME	Rabeprazole
D0KL4J	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0FY3O	TTDDRUID	D0FY3O
D0FY3O	DRUGNAME	Rabies immune globulin
D0FY3O	INDICATI	Rabies [ICD-11: 1C82] Approved

D0JY3V	TTDDRUID	D0JY3V
D0JY3V	DRUGNAME	Racecadotril
D0JY3V	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D02HNF	TTDDRUID	D02HNF
D02HNF	DRUGNAME	Radium-223 chloride
D02HNF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0E6AF	TTDDRUID	D0E6AF
D0E6AF	DRUGNAME	Radium-223-Dichloride
D0E6AF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved

D0D2FZ	TTDDRUID	D0D2FZ
D0D2FZ	DRUGNAME	Ragweed allergy vaccine sublingual
D0D2FZ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Approved

D0C8QS	TTDDRUID	D0C8QS
D0C8QS	DRUGNAME	Ragwitek
D0C8QS	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D01XBA	TTDDRUID	D01XBA
D01XBA	DRUGNAME	Raloxifene
D01XBA	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
D01XBA	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 4

D0I1FQ	TTDDRUID	D0I1FQ
D0I1FQ	DRUGNAME	Raltegravir
D0I1FQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D01KKQ	TTDDRUID	D01KKQ
D01KKQ	DRUGNAME	Raltitrexed
D01KKQ	INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Approved

D0U0KW	TTDDRUID	D0U0KW
D0U0KW	DRUGNAME	Ramelteon
D0U0KW	INDICATI	Circadian rhythm sleep disorder [ICD-11: 7A60-7A65] Terminated
D0U0KW	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D01STB	TTDDRUID	D01STB
D01STB	DRUGNAME	Ramipril
D01STB	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0RA9E	TTDDRUID	D0RA9E
D0RA9E	DRUGNAME	Ramosetron
D0RA9E	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 4
D0RA9E	INDICATI	Nausea and vomiting [ICD-11: MD90] Approved

D09HVD	TTDDRUID	D09HVD
D09HVD	DRUGNAME	Ramucirumab
D09HVD	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Approved

D04EYG	TTDDRUID	D04EYG
D04EYG	DRUGNAME	Ranibizumab
D04EYG	INDICATI	Hereditary hemorrhagic telangiectasia [ICD-11: LA90.00] Approved

D0B8WN	TTDDRUID	D0B8WN
D0B8WN	DRUGNAME	Ranitidine
D0B8WN	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D03HYQ	TTDDRUID	D03HYQ
D03HYQ	DRUGNAME	Ranolazine
D03HYQ	INDICATI	Chronic/stable angina [ICD-11: BA40.1] Approved
D03HYQ	INDICATI	Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 2

D0KD4X	TTDDRUID	D0KD4X
D0KD4X	DRUGNAME	Rapacuronium bromide
D0KD4X	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved

D0T6DK	TTDDRUID	D0T6DK
D0T6DK	DRUGNAME	Rapamycin
D0T6DK	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D06OMW	TTDDRUID	D06OMW
D06OMW	DRUGNAME	Rasagiline
D06OMW	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
D06OMW	INDICATI	Skin cancer [ICD-11: 2C30-2C37] Patented
D06OMW	INDICATI	Skin imperfections [ICD-11: EK71] Patented

D08LJP	TTDDRUID	D08LJP
D08LJP	DRUGNAME	Rasburicase
D08LJP	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved

D0NW7Y	TTDDRUID	D0NW7Y
D0NW7Y	DRUGNAME	Ravulizumab
D0NW7Y	INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Approved

D02JYA	TTDDRUID	D02JYA
D02JYA	DRUGNAME	Raxibacumab
D02JYA	INDICATI	Anthrax [ICD-11: 1B97] Approved

D0LP4Q	TTDDRUID	D0LP4Q
D0LP4Q	DRUGNAME	RBPI-21
D0LP4Q	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0N8FQ	TTDDRUID	D0N8FQ
D0N8FQ	DRUGNAME	Reboxetine
D0N8FQ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0C8RW	TTDDRUID	D0C8RW
D0C8RW	DRUGNAME	Rec-antihemophilic factor
D0C8RW	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D0P8QN	TTDDRUID	D0P8QN
D0P8QN	DRUGNAME	Recombinant Factor IX
D0P8QN	INDICATI	Factor IX deficiency [ICD-11: 3B11] Terminated

D09SRZ	TTDDRUID	D09SRZ
D09SRZ	DRUGNAME	Recombinant factor IX-Fc
D09SRZ	INDICATI	Haemophilia B [ICD-11: 3B11.0] Approved

D0P5AP	TTDDRUID	D0P5AP
D0P5AP	DRUGNAME	Recombinant factor viii
D0P5AP	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D05YAG	TTDDRUID	D05YAG
D05YAG	DRUGNAME	Recombinant human endostatin
D05YAG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0XE1C	TTDDRUID	D0XE1C
D0XE1C	DRUGNAME	Regadenoson
D0XE1C	INDICATI	Radionuclide imaging [ICD-11: N.A.] Approved

D00GNI	TTDDRUID	D00GNI
D00GNI	DRUGNAME	REGN-727
D00GNI	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Approved
D00GNI	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
D00GNI	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D09GDD	TTDDRUID	D09GDD
D09GDD	DRUGNAME	Regorafenib
D09GDD	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Approved

D00WMK	TTDDRUID	D00WMK
D00WMK	DRUGNAME	Relvar/Breo
D00WMK	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0T5OX	TTDDRUID	D0T5OX
D0T5OX	DRUGNAME	Remifentanil
D0T5OX	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0C2EP	TTDDRUID	D0C2EP
D0C2EP	DRUGNAME	Remikiren
D0C2EP	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0N7KV	TTDDRUID	D0N7KV
D0N7KV	DRUGNAME	Reniale
D0N7KV	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D0N5YA	TTDDRUID	D0N5YA
D0N5YA	DRUGNAME	Repaglinide
D0N5YA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0O6KE	TTDDRUID	D0O6KE
D0O6KE	DRUGNAME	Repirinast
D0O6KE	INDICATI	Asthma [ICD-11: CA23] Approved

D0G8NJ	TTDDRUID	D0G8NJ
D0G8NJ	DRUGNAME	Rescinnamine
D0G8NJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0J4JM	TTDDRUID	D0J4JM
D0J4JM	DRUGNAME	Reserpine
D0J4JM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0O8KX	TTDDRUID	D0O8KX
D0O8KX	DRUGNAME	Reslizumab
D0O8KX	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0O8KX	INDICATI	Eosinophilic asthma [ICD-11: CB02.0] Phase 3
D0O8KX	INDICATI	Severe asthma [ICD-11: CA23] Approved

D00GBG	TTDDRUID	D00GBG
D00GBG	DRUGNAME	Resp syncytial virus ig
D00GBG	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Approved

D0S8FU	TTDDRUID	D0S8FU
D0S8FU	DRUGNAME	Resultz
D0S8FU	INDICATI	Head and body lice [ICD-11: 1G00.0] Approved

D03UQM	TTDDRUID	D03UQM
D03UQM	DRUGNAME	Retapamulin
D03UQM	INDICATI	Impetigo [ICD-11: 1B72] Approved

D0T1UJ	TTDDRUID	D0T1UJ
D0T1UJ	DRUGNAME	Reteplase
D0T1UJ	INDICATI	Heart attack [ICD-11: BA41] Approved

D0K1ST	TTDDRUID	D0K1ST
D0K1ST	DRUGNAME	Revefenacin
D0K1ST	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D08VSI	TTDDRUID	D08VSI
D08VSI	DRUGNAME	Revolade/Promacta
D08VSI	INDICATI	Chronic liver disease [ICD-11: DB99.0] Phase 3
D08VSI	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved
D08VSI	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 2

D0P1AS	TTDDRUID	D0P1AS
D0P1AS	DRUGNAME	Rexin-G
D0P1AS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0G2TA	TTDDRUID	D0G2TA
D0G2TA	DRUGNAME	Rfsh/rhfsh
D0G2TA	INDICATI	Infertility [ICD-11: GB04] Approved

D0OZ4J	TTDDRUID	D0OZ4J
D0OZ4J	DRUGNAME	RG-7446
D0OZ4J	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
D0OZ4J	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Approved

D08WWN	TTDDRUID	D08WWN
D08WWN	DRUGNAME	RG7853
D08WWN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved

D0M1CZ	TTDDRUID	D0M1CZ
D0M1CZ	DRUGNAME	Rh-alphaglucosidase
D0M1CZ	INDICATI	Pompe disease [ICD-11: 5C51.3] Approved

D0I6FS	TTDDRUID	D0I6FS
D0I6FS	DRUGNAME	Rh-bmp-2/acs
D0I6FS	INDICATI	Bone induction [ICD-11: FC0Z] Approved

D0S1HE	TTDDRUID	D0S1HE
D0S1HE	DRUGNAME	Rhenium-186 etidronate
D0S1HE	INDICATI	Bone metastases [ICD-11: 2D50] Approved

D05VFO	TTDDRUID	D05VFO
D05VFO	DRUGNAME	Rh-erythropoietin-alfa
D05VFO	INDICATI	Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved

D0S2NI	TTDDRUID	D0S2NI
D0S2NI	DRUGNAME	Rhpth
D0S2NI	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0DT1E	TTDDRUID	D0DT1E
D0DT1E	DRUGNAME	Rh-thrombin
D0DT1E	INDICATI	Haemorrhage [ICD-11: MG27] Approved

D0OF2K	TTDDRUID	D0OF2K
D0OF2K	DRUGNAME	Rh-thrombomodulin
D0OF2K	INDICATI	Stroke [ICD-11: 8B20] Approved

D0Z7ZM	TTDDRUID	D0Z7ZM
D0Z7ZM	DRUGNAME	Rhucin
D0Z7ZM	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
D0Z7ZM	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved

D0U1TA	TTDDRUID	D0U1TA
D0U1TA	DRUGNAME	RHuEPO
D0U1TA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0L7YL	TTDDRUID	D0L7YL
D0L7YL	DRUGNAME	Rhuph20
D0L7YL	INDICATI	Reproduction [ICD-11: JA00-JA02] Approved

D0H3WI	TTDDRUID	D0H3WI
D0H3WI	DRUGNAME	Ribavirin
D0H3WI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D01HVT	TTDDRUID	D01HVT
D01HVT	DRUGNAME	Ribociclib Succinate
D01HVT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
D01HVT	INDICATI	Hormone receptor positive and HER2-negative advanced or metastatic breast cancer [ICD-11: 2C60-2C65] Approved

D04QST	TTDDRUID	D04QST
D04QST	DRUGNAME	Riboflavin
D04QST	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0E3BH	TTDDRUID	D0E3BH
D0E3BH	DRUGNAME	Ridogrel
D0E3BH	INDICATI	Acute myocardial infarction [ICD-11: BA41] Approved

D0YH5F	TTDDRUID	D0YH5F
D0YH5F	DRUGNAME	Ridostin
D0YH5F	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D05CHI	TTDDRUID	D05CHI
D05CHI	DRUGNAME	Rifabutin
D05CHI	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved
D05CHI	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D0G3DL	TTDDRUID	D0G3DL
D0G3DL	DRUGNAME	Rifampin
D0G3DL	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D0FX2Q	TTDDRUID	D0FX2Q
D0FX2Q	DRUGNAME	Rifamycin
D0FX2Q	INDICATI	Diarrhea [ICD-11: ME05.1] Approved
D0FX2Q	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3

D0S9AW	TTDDRUID	D0S9AW
D0S9AW	DRUGNAME	Rifamycin b
D0S9AW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0G9IU	TTDDRUID	D0G9IU
D0G9IU	DRUGNAME	Rifapentine
D0G9IU	INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative
D0G9IU	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D04ITO	TTDDRUID	D04ITO
D04ITO	DRUGNAME	Rifaximin
D04ITO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06OFS	TTDDRUID	D06OFS
D06OFS	DRUGNAME	Rilmenidine
D06OFS	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09DBY	TTDDRUID	D09DBY
D09DBY	DRUGNAME	Rilonacept
D09DBY	INDICATI	Acute gout flare [ICD-11: FA25.0] Phase 3
D09DBY	INDICATI	Arthritis [ICD-11: FA20] Approved

D0T6WN	TTDDRUID	D0T6WN
D0T6WN	DRUGNAME	Rilpivirine
D0T6WN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D0T6WN	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0H0KB	TTDDRUID	D0H0KB
D0H0KB	DRUGNAME	Riluzole
D0H0KB	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved

D0TQ1G	TTDDRUID	D0TQ1G
D0TQ1G	DRUGNAME	Rimantadine
D0TQ1G	INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved

D0D2TN	TTDDRUID	D0D2TN
D0D2TN	DRUGNAME	Rimexolone
D0D2TN	INDICATI	Arthritis [ICD-11: FA20] Approved

D03NOS	TTDDRUID	D03NOS
D03NOS	DRUGNAME	Rimiterol
D03NOS	INDICATI	Asthma [ICD-11: CA23] Approved

D04UKC	TTDDRUID	D04UKC
D04UKC	DRUGNAME	Riociguat
D04UKC	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved

D0PA5S	TTDDRUID	D0PA5S
D0PA5S	DRUGNAME	Risedronate
D0PA5S	INDICATI	Paget's disease [ICD-11: FB85] Approved

D01AZG	TTDDRUID	D01AZG
D01AZG	DRUGNAME	Risperidone
D01AZG	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D00LFB	TTDDRUID	D00LFB
D00LFB	DRUGNAME	Ritodrine
D00LFB	INDICATI	Premature labour [ICD-11: JB00] Approved

D0ZU9R	TTDDRUID	D0ZU9R
D0ZU9R	DRUGNAME	Ritonavir
D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0YM7U	TTDDRUID	D0YM7U
D0YM7U	DRUGNAME	Rituxan Hemotalogy/oncology
D0YM7U	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D01IES	TTDDRUID	D01IES
D01IES	DRUGNAME	Rituxan rituxumab
D01IES	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D09EXD	TTDDRUID	D09EXD
D09EXD	DRUGNAME	Rituximab
D09EXD	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D09EXD	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D0KG3R	TTDDRUID	D0KG3R
D0KG3R	DRUGNAME	Rivaroxaban
D0KG3R	INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved

D0WY5Q	TTDDRUID	D0WY5Q
D0WY5Q	DRUGNAME	Rivastigmine
D0WY5Q	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0S9MU	TTDDRUID	D0S9MU
D0S9MU	DRUGNAME	Rizatriptan
D0S9MU	INDICATI	Migraine [ICD-11: 8A80] Approved

D02HFB	TTDDRUID	D02HFB
D02HFB	DRUGNAME	Rizatriptan oral film
D02HFB	INDICATI	Migraine [ICD-11: 8A80] Approved

D0L5CZ	TTDDRUID	D0L5CZ
D0L5CZ	DRUGNAME	Rocuronium
D0L5CZ	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved

D05VLS	TTDDRUID	D05VLS
D05VLS	DRUGNAME	Rofecoxib
D05VLS	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D0R4UW	TTDDRUID	D0R4UW
D0R4UW	DRUGNAME	Roflumilast
D0R4UW	INDICATI	Asthma [ICD-11: CA23] Approved
D0R4UW	INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2
D0R4UW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Withdrawn from market
D0R4UW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0L6QI	TTDDRUID	D0L6QI
D0L6QI	DRUGNAME	Rokitamycin
D0L6QI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0CF0Y	TTDDRUID	D0CF0Y
D0CF0Y	DRUGNAME	Rolapitant
D0CF0Y	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Approved

D05AFR	TTDDRUID	D05AFR
D05AFR	DRUGNAME	Rolitetracycline
D05AFR	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0L7LC	TTDDRUID	D0L7LC
D0L7LC	DRUGNAME	Romidepsin
D0L7LC	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved
D0L7LC	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
D0L7LC	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D01PZD	TTDDRUID	D01PZD
D01PZD	DRUGNAME	Romiplostim
D01PZD	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D01PZD	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D01PZD	INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved

D09COD	TTDDRUID	D09COD
D09COD	DRUGNAME	Romurtide
D09COD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0R9EQ	TTDDRUID	D0R9EQ
D0R9EQ	DRUGNAME	Ropinirole
D0R9EQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D09RHQ	TTDDRUID	D09RHQ
D09RHQ	DRUGNAME	Ropivacaine
D09RHQ	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0Y8DP	TTDDRUID	D0Y8DP
D0Y8DP	DRUGNAME	Rorifone
D0Y8DP	INDICATI	Cough [ICD-11: MD12] Approved

D0XN8C	TTDDRUID	D0XN8C
D0XN8C	DRUGNAME	Rosaprostol
D0XN8C	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved

D0Q1SA	TTDDRUID	D0Q1SA
D0Q1SA	DRUGNAME	Rosaramicin
D0Q1SA	INDICATI	Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Approved

D0OY9S	TTDDRUID	D0OY9S
D0OY9S	DRUGNAME	Rose Bengal Sodium I-131
D0OY9S	INDICATI	Ophthalmic disease [ICD-11: 5A02.0] Approved

D0K5ER	TTDDRUID	D0K5ER
D0K5ER	DRUGNAME	Rosiglitazone XR
D0K5ER	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D0K5ER	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D07CPU	TTDDRUID	D07CPU
D07CPU	DRUGNAME	Rosoxacin
D07CPU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0JE2E	TTDDRUID	D0JE2E
D0JE2E	DRUGNAME	Rosuvastatin
D0JE2E	INDICATI	Elevated C-reactive protein [ICD-11: MA14.15] Phase 3
D0JE2E	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D0R7KX	TTDDRUID	D0R7KX
D0R7KX	DRUGNAME	Rotarix
D0R7KX	INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved

D02KOY	TTDDRUID	D02KOY
D02KOY	DRUGNAME	RotaTeq
D02KOY	INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved

D00HEN	TTDDRUID	D00HEN
D00HEN	DRUGNAME	Rotavirus vaccine, , Lanzhou Institute of Biological Products
D00HEN	INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved

D0F7CS	TTDDRUID	D0F7CS
D0F7CS	DRUGNAME	Rotenone
D0F7CS	INDICATI	Piscicide [ICD-11: N.A.] Approved

D0R2CZ	TTDDRUID	D0R2CZ
D0R2CZ	DRUGNAME	Rsv Immune Globulin
D0R2CZ	INDICATI	Bronchopulmonary dysplasia [ICD-11: KB29.0] Approved

D01RLG	TTDDRUID	D01RLG
D01RLG	DRUGNAME	RTU-007
D01RLG	INDICATI	Diabetic cataract [ICD-11: 9B10.21] Approved

D02OJN	TTDDRUID	D02OJN
D02OJN	DRUGNAME	Ru-41740
D02OJN	INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Approved

D02WHY	TTDDRUID	D02WHY
D02WHY	DRUGNAME	Rubidium chloride Rb82
D02WHY	INDICATI	Coronary artery disease [ICD-11: BA80] Approved

D01SHZ	TTDDRUID	D01SHZ
D01SHZ	DRUGNAME	Rucaparib
D01SHZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
D01SHZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0MD2L	TTDDRUID	D0MD2L
D0MD2L	DRUGNAME	Rufinamide
D0MD2L	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved (orphan drug)
D0MD2L	INDICATI	Pediatric lennox-gastaut syndrome [ICD-11: 8A62.1] Approved
D0MD2L	INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved

D04LKS	TTDDRUID	D04LKS
D04LKS	DRUGNAME	Ruxolitinib
D04LKS	INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Approved
D04LKS	INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 4
D04LKS	INDICATI	High-risk myelofibrosis [ICD-11: 2A20.2] Approved
D04LKS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0E4SI	TTDDRUID	D0E4SI
D0E4SI	DRUGNAME	Rv-11
D0E4SI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0L2WJ	TTDDRUID	D0L2WJ
D0L2WJ	DRUGNAME	Ryzodeg
D0L2WJ	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved

D0Y3VQ	TTDDRUID	D0Y3VQ
D0Y3VQ	DRUGNAME	Ryzodeq
D0Y3VQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0K7OO	TTDDRUID	D0K7OO
D0K7OO	DRUGNAME	SA-14-14-2
D0K7OO	INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved

D0N5VL	TTDDRUID	D0N5VL
D0N5VL	DRUGNAME	Saccharomyces boulardii
D0N5VL	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0A1VS	TTDDRUID	D0A1VS
D0A1VS	DRUGNAME	Safflower Oil
D0A1VS	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0TV6I	TTDDRUID	D0TV6I
D0TV6I	DRUGNAME	Safinamide
D0TV6I	INDICATI	Idiopathic parkinson disease [ICD-11: 8A00.0Z] Phase 3
D0TV6I	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0XM1A	TTDDRUID	D0XM1A
D0XM1A	DRUGNAME	SAFINAMIDE MESYLATE
D0XM1A	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D0K5CB	TTDDRUID	D0K5CB
D0K5CB	DRUGNAME	Salbutamol
D0K5CB	INDICATI	Acute asthma [ICD-11: CA23] Approved

D06BQU	TTDDRUID	D06BQU
D06BQU	DRUGNAME	Salicin
D06BQU	INDICATI	Analgesia [ICD-11: MB40.8] Approved

D07HBX	TTDDRUID	D07HBX
D07HBX	DRUGNAME	Salicyclic acid
D07HBX	INDICATI	Seborrhoeic dermatitis [ICD-11: EA81] Approved

D07MCK	TTDDRUID	D07MCK
D07MCK	DRUGNAME	Salicylamide
D07MCK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0L5YV	TTDDRUID	D0L5YV
D0L5YV	DRUGNAME	Salmeterol
D0L5YV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0I1XG	TTDDRUID	D0I1XG
D0I1XG	DRUGNAME	Salmon Calcitonin
D0I1XG	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0X5UL	TTDDRUID	D0X5UL
D0X5UL	DRUGNAME	Salmonella typhi vaccine
D0X5UL	INDICATI	Salmonella infection [ICD-11: 1A09] Approved

D0Y0JH	TTDDRUID	D0Y0JH
D0Y0JH	DRUGNAME	Salsalate
D0Y0JH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D04YHR	TTDDRUID	D04YHR
D04YHR	DRUGNAME	Samarium Sm-153 Lexidronam Pentasodium
D04YHR	INDICATI	Cancer related pain [ICD-11: MG30] Approved

D0T3NB	TTDDRUID	D0T3NB
D0T3NB	DRUGNAME	Sanguinarine
D0T3NB	INDICATI	Dental plaque [ICD-11: DA08.4] Approved

D0K7LU	TTDDRUID	D0K7LU
D0K7LU	DRUGNAME	Santonin
D0K7LU	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved

D0B9AO	TTDDRUID	D0B9AO
D0B9AO	DRUGNAME	Saprisartan
D0B9AO	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0S2IQ	TTDDRUID	D0S2IQ
D0S2IQ	DRUGNAME	Sapropterin hydrochloride
D0S2IQ	INDICATI	Hyperphenylalaninemia [ICD-11: 5C50] Approved

D0WI3T	TTDDRUID	D0WI3T
D0WI3T	DRUGNAME	Saquinavir
D0WI3T	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0K0AT	TTDDRUID	D0K0AT
D0K0AT	DRUGNAME	SARALASIN
D0K0AT	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00VFE	TTDDRUID	D00VFE
D00VFE	DRUGNAME	Saralasin Acetate
D00VFE	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0L4JH	TTDDRUID	D0L4JH
D0L4JH	DRUGNAME	Sarecycline
D0L4JH	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D0T6EI	TTDDRUID	D0T6EI
D0T6EI	DRUGNAME	Sarecycline 
D0T6EI	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0XT5Y	TTDDRUID	D0XT5Y
D0XT5Y	DRUGNAME	Sargramostim
D0XT5Y	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Approved

D0Z8CQ	TTDDRUID	D0Z8CQ
D0Z8CQ	DRUGNAME	Sarilumab
D0Z8CQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0Z8SF	TTDDRUID	D0Z8SF
D0Z8SF	DRUGNAME	Sarkomycin
D0Z8SF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0G6VL	TTDDRUID	D0G6VL
D0G6VL	DRUGNAME	Sarpogrelate
D0G6VL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0V6RC	TTDDRUID	D0V6RC
D0V6RC	DRUGNAME	Satumomab Pendetide
D0V6RC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0K9MY	TTDDRUID	D0K9MY
D0K9MY	DRUGNAME	Saxagliptin
D0K9MY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0CH4A	TTDDRUID	D0CH4A
D0CH4A	DRUGNAME	SBC-102
D0CH4A	INDICATI	Enzyme deficiency [ICD-11: 5C51-5C57] Approved

D0XL6C	TTDDRUID	D0XL6C
D0XL6C	DRUGNAME	SB-M00026
D0XL6C	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0A8RX	TTDDRUID	D0A8RX
D0A8RX	DRUGNAME	Schizophyllan
D0A8RX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0D6QH	TTDDRUID	D0D6QH
D0D6QH	DRUGNAME	Sci-DaPT-Vac
D0D6QH	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0B7YT	TTDDRUID	D0B7YT
D0B7YT	DRUGNAME	Scopolamine
D0B7YT	INDICATI	Addictive disorder [ICD-11: 6C50-6C5Z] Approved
D0B7YT	INDICATI	Nausea [ICD-11: MD90] Approved

D02ZGI	TTDDRUID	D02ZGI
D02ZGI	DRUGNAME	Secalciferol
D02ZGI	INDICATI	Disorder of calcium metabolism [ICD-11: 5C64.5] Approved

D0V5IW	TTDDRUID	D0V5IW
D0V5IW	DRUGNAME	Secnidazole
D0V5IW	INDICATI	Amoebiasis [ICD-11: 1A36] Approved
D0V5IW	INDICATI	Bacterial vaginosis [ICD-11: MF3A] Approved

D00SJE	TTDDRUID	D00SJE
D00SJE	DRUGNAME	Secobarbital
D00SJE	INDICATI	Intractable insomnia [ICD-11: 7A00] Approved

D0O8JB	TTDDRUID	D0O8JB
D0O8JB	DRUGNAME	Secretin
D0O8JB	INDICATI	Gastrinoma [ICD-11: 2C10.1] Approved
D0O8JB	INDICATI	Pancreatic exocrine dysfunction [ICD-11: DC3Z] Approved

D0Q0OD	TTDDRUID	D0Q0OD
D0Q0OD	DRUGNAME	Secukinumab
D0Q0OD	INDICATI	Alopecia [ICD-11: ED70] Phase 2
D0Q0OD	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D0Q0OD	INDICATI	Dry eye disease [ICD-11: 9E1Z] Phase 2
D0Q0OD	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D0Q0OD	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
D0Q0OD	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
D0Q0OD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0Q0OD	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D0P7PW	TTDDRUID	D0P7PW
D0P7PW	DRUGNAME	Seebri
D0P7PW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D06LDT	TTDDRUID	D06LDT
D06LDT	DRUGNAME	Segesterone acetate and ethinyl estradiol vaginal system
D06LDT	INDICATI	Contraception [ICD-11: QA21] Approved

D0S2UG	TTDDRUID	D0S2UG
D0S2UG	DRUGNAME	Selegiline
D0S2UG	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 3
D0S2UG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
D0S2UG	INDICATI	Skin imperfections [ICD-11: EK71] Patented

D0J2MJ	TTDDRUID	D0J2MJ
D0J2MJ	DRUGNAME	Selegiline Hydrochloride
D0J2MJ	INDICATI	Motor symptoms [ICD-11: 6A25.4] Investigative
D0J2MJ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D04VGS	TTDDRUID	D04VGS
D04VGS	DRUGNAME	Selenium sulfide
D04VGS	INDICATI	Erythema [ICD-11: ME64.0] Approved

D01OPV	TTDDRUID	D01OPV
D01OPV	DRUGNAME	Selenomethionine Se-75
D01OPV	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D0N2SR	TTDDRUID	D0N2SR
D0N2SR	DRUGNAME	Selexipag
D0N2SR	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved

D02ULU	TTDDRUID	D02ULU
D02ULU	DRUGNAME	Semaglutide
D02ULU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D02ULU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0Z2LG	TTDDRUID	D0Z2LG
D0Z2LG	DRUGNAME	Sennoside a
D0Z2LG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D09LBS	TTDDRUID	D09LBS
D09LBS	DRUGNAME	Sennoside b
D09LBS	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D04WOM	TTDDRUID	D04WOM
D04WOM	DRUGNAME	Seractide Acetate
D04WOM	INDICATI	Essential hypertension [ICD-11: BA00] Approved

D04AQH	TTDDRUID	D04AQH
D04AQH	DRUGNAME	Sermorelin
D04AQH	INDICATI	Pediatric growth disorder [ICD-11: FB86] Approved

D06VML	TTDDRUID	D06VML
D06VML	DRUGNAME	Seroxat
D06VML	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D00YLF	TTDDRUID	D00YLF
D00YLF	DRUGNAME	Serpacwa
D00YLF	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D0O6UZ	TTDDRUID	D0O6UZ
D0O6UZ	DRUGNAME	Sertaconazole
D0O6UZ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0K0TC	TTDDRUID	D0K0TC
D0K0TC	DRUGNAME	Sertraline
D0K0TC	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0G7XO	TTDDRUID	D0G7XO
D0G7XO	DRUGNAME	Sevelamer carbonate tablet
D0G7XO	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Approved

D03MZQ	TTDDRUID	D03MZQ
D03MZQ	DRUGNAME	Sevelamer hydrochloride
D03MZQ	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Approved

D0W6ZF	TTDDRUID	D0W6ZF
D0W6ZF	DRUGNAME	Sevoflurane
D0W6ZF	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D05IBA	TTDDRUID	D05IBA
D05IBA	DRUGNAME	Shanvac-B
D05IBA	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D08KVZ	TTDDRUID	D08KVZ
D08KVZ	DRUGNAME	Sibutramine
D08KVZ	INDICATI	Obesity [ICD-11: 5B81] Approved

D05NDR	TTDDRUID	D05NDR
D05NDR	DRUGNAME	Sifalimumab
D05NDR	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
D05NDR	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D0U0VU	TTDDRUID	D0U0VU
D0U0VU	DRUGNAME	SILODOSIN
D0U0VU	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D0K2GA	TTDDRUID	D0K2GA
D0K2GA	DRUGNAME	Silteplase
D0K2GA	INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved

D07NJN	TTDDRUID	D07NJN
D07NJN	DRUGNAME	Siltuximab
D07NJN	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D0A2HR	TTDDRUID	D0A2HR
D0A2HR	DRUGNAME	Silver nitrate
D0A2HR	INDICATI	Chlamydia infection [ICD-11: 1A81] Approved

D08JCA	TTDDRUID	D08JCA
D08JCA	DRUGNAME	Silver sulfadiazine
D08JCA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06IJG	TTDDRUID	D06IJG
D06IJG	DRUGNAME	Silyman DD
D06IJG	INDICATI	Liver disease [ICD-11: DB90-BD99] Approved

D00TLP	TTDDRUID	D00TLP
D00TLP	DRUGNAME	Simeprevir
D00TLP	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Approved

D01XRP	TTDDRUID	D01XRP
D01XRP	DRUGNAME	Simethicone
D01XRP	INDICATI	Dyspepsia [ICD-11: MD92] Approved

D0H0ND	TTDDRUID	D0H0ND
D0H0ND	DRUGNAME	Simvastatin
D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D03LJR	TTDDRUID	D03LJR
D03LJR	DRUGNAME	Sirolimus
D03LJR	INDICATI	Dutch elm disease [ICD-11: 8D64] Phase 1/2
D03LJR	INDICATI	Organ transplant rejection [ICD-11: NE84] Approved

D0U2JP	TTDDRUID	D0U2JP
D0U2JP	DRUGNAME	Sitagliptin
D0U2JP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D0U2JP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0Y7LD	TTDDRUID	D0Y7LD
D0Y7LD	DRUGNAME	Sitosterol
D0Y7LD	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved

D0IL0C	TTDDRUID	D0IL0C
D0IL0C	DRUGNAME	SK-1306X
D0IL0C	INDICATI	Arthritis [ICD-11: FA20] Approved

D03MNN	TTDDRUID	D03MNN
D03MNN	DRUGNAME	SKI-758
D03MNN	INDICATI	Ischemia [ICD-11: 8B10-8B11] Approved

D0H6VY	TTDDRUID	D0H6VY
D0H6VY	DRUGNAME	SM-101
D0H6VY	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Preclinical
D0H6VY	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved (orphan drug)
D0H6VY	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D05KZK	TTDDRUID	D05KZK
D05KZK	DRUGNAME	SMT-D002
D05KZK	INDICATI	Seborrhea [ICD-11: ED91.2] Approved

D0Z4UY	TTDDRUID	D0Z4UY
D0Z4UY	DRUGNAME	Sodium Acetate Anhydrous
D0Z4UY	INDICATI	Hyponatraemia [ICD-11: 5C72] Approved

D02FLB	TTDDRUID	D02FLB
D02FLB	DRUGNAME	Sodium bicarbonate
D02FLB	INDICATI	Metabolic acidosis [ICD-11: 5C73] Approved

D0YB5G	TTDDRUID	D0YB5G
D0YB5G	DRUGNAME	Sodium cellulose po4
D0YB5G	INDICATI	Hypercalciuria [ICD-11: MF98.0] Approved

D04YZL	TTDDRUID	D04YZL
D04YZL	DRUGNAME	Sodium chloride
D04YZL	INDICATI	Skin burns [ICD-11: ME65.0] Approved

D02DSD	TTDDRUID	D02DSD
D02DSD	DRUGNAME	Sodium Chromate Cr-51
D02DSD	INDICATI	Hemorrhage [ICD-11: MG27] Approved

D0B9GH	TTDDRUID	D0B9GH
D0B9GH	DRUGNAME	Sodium chromoglycate
D0B9GH	INDICATI	Asthma [ICD-11: CA23] Approved

D0VM8K	TTDDRUID	D0VM8K
D0VM8K	DRUGNAME	Sodium ferric gluconate complex
D0VM8K	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved

D02IUD	TTDDRUID	D02IUD
D02IUD	DRUGNAME	Sodium Fluoride F-18
D02IUD	INDICATI	Bone related disease [ICD-11: FB82-FB85] Approved
D02IUD	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0O6OZ	TTDDRUID	D0O6OZ
D0O6OZ	DRUGNAME	Sodium iodide I 131
D0O6OZ	INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved

D07AAN	TTDDRUID	D07AAN
D07AAN	DRUGNAME	Sodium Iodide I-123
D07AAN	INDICATI	Thyroid disease [ICD-11: 5A00-5A06] Approved

D06NBK	TTDDRUID	D06NBK
D06NBK	DRUGNAME	Sodium Iodide I-131 Capsules
D06NBK	INDICATI	Thyroid disease [ICD-11: 5A00-5A06] Approved

D00ZOF	TTDDRUID	D00ZOF
D00ZOF	DRUGNAME	Sodium lactate
D00ZOF	INDICATI	Acidosis [ICD-11: 5C73] Approved

D05ATI	TTDDRUID	D05ATI
D05ATI	DRUGNAME	Sodium lauryl sulfate
D05ATI	INDICATI	Constipation [ICD-11: DD91.1] Approved

D07FTD	TTDDRUID	D07FTD
D07FTD	DRUGNAME	Sodium Monofluorophosphate
D07FTD	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0MA7C	TTDDRUID	D0MA7C
D0MA7C	DRUGNAME	Sodium nitrite
D0MA7C	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D07XVR	TTDDRUID	D07XVR
D07XVR	DRUGNAME	Sodium nitroprusside
D07XVR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0Q5SP	TTDDRUID	D0Q5SP
D0Q5SP	DRUGNAME	Sodium phenylacetate/sodium benzoate
D0Q5SP	INDICATI	Hepatic encephalopathy [ICD-11: DB99.5] Approved

D0P2GK	TTDDRUID	D0P2GK
D0P2GK	DRUGNAME	Sodium phenylbutyrate
D0P2GK	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Approved

D0V2DV	TTDDRUID	D0V2DV
D0V2DV	DRUGNAME	Sodium phosphate dibasic/sodium phosphate monobasic
D0V2DV	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D0I6JF	TTDDRUID	D0I6JF
D0I6JF	DRUGNAME	Sodium phosphate P 32
D0I6JF	INDICATI	Bone metastases [ICD-11: 2D50] Approved

D0DS5U	TTDDRUID	D0DS5U
D0DS5U	DRUGNAME	Sodium polystyrene sulfonate
D0DS5U	INDICATI	Mineral-electrolyte metabolism disorder [ICD-11: 5C64] Approved

D0X7ZL	TTDDRUID	D0X7ZL
D0X7ZL	DRUGNAME	Sodium salicylate
D0X7ZL	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03RCJ	TTDDRUID	D03RCJ
D03RCJ	DRUGNAME	Sodium Succinate
D03RCJ	INDICATI	Arthritis [ICD-11: FA20] Approved

D0O0AF	TTDDRUID	D0O0AF
D0O0AF	DRUGNAME	Sodium sulfide sulfur
D0O0AF	INDICATI	Ischemia [ICD-11: 8B10-8B11] Approved

D0Z5SM	TTDDRUID	D0Z5SM
D0Z5SM	DRUGNAME	Sodium Tetradecyl Sulfate
D0Z5SM	INDICATI	Hemangioma [ICD-11: 2E81-2F2Y] Approved
D0Z5SM	INDICATI	Varicose and spider veins of leg [ICD-11: BD74.1] Approved

D0Y1IT	TTDDRUID	D0Y1IT
D0Y1IT	DRUGNAME	Sodium thiosalicylate
D0Y1IT	INDICATI	Gout [ICD-11: FA25] Approved

D0P9NT	TTDDRUID	D0P9NT
D0P9NT	DRUGNAME	Sodium thiosulfate
D0P9NT	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D03AZK	TTDDRUID	D03AZK
D03AZK	DRUGNAME	Sodium zirconium cyclosilicate
D03AZK	INDICATI	Hyperkalemia [ICD-11: 5C76] Approved

D06BLQ	TTDDRUID	D06BLQ
D06BLQ	DRUGNAME	Sofalcone
D06BLQ	INDICATI	Ulcer [ICD-11: CA02-CB40] Approved

D0RM5Z	TTDDRUID	D0RM5Z
D0RM5Z	DRUGNAME	Sofosbuvir + velpatasvir + voxilaprevir
D0RM5Z	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D07ORO	TTDDRUID	D07ORO
D07ORO	DRUGNAME	Solamargine
D07ORO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0L4YD	TTDDRUID	D0L4YD
D0L4YD	DRUGNAME	Solifenacin
D0L4YD	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D0YG3K	TTDDRUID	D0YG3K
D0YG3K	DRUGNAME	Soluble insulin
D0YG3K	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0N3NZ	TTDDRUID	D0N3NZ
D0N3NZ	DRUGNAME	Somatomedin-1
D0N3NZ	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved

D0JS2A	TTDDRUID	D0JS2A
D0JS2A	DRUGNAME	Somatotropin rdna original
D0JS2A	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved

D08GUZ	TTDDRUID	D08GUZ
D08GUZ	DRUGNAME	Somatrem
D08GUZ	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved

D0V2NJ	TTDDRUID	D0V2NJ
D0V2NJ	DRUGNAME	Somatropin biosimilar
D0V2NJ	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved

D0P4DJ	TTDDRUID	D0P4DJ
D0P4DJ	DRUGNAME	Somatropin recombinant
D0P4DJ	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved

D04IUQ	TTDDRUID	D04IUQ
D04IUQ	DRUGNAME	SonoRx
D04IUQ	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D0W5HK	TTDDRUID	D0W5HK
D0W5HK	DRUGNAME	Sorafenib
D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D0W5HK	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D0W5HK	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D09MXS	TTDDRUID	D09MXS
D09MXS	DRUGNAME	Sorbitol
D09MXS	INDICATI	Constipation [ICD-11: DD91.1] Approved

D03TGJ	TTDDRUID	D03TGJ
D03TGJ	DRUGNAME	Sorivudine
D03TGJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D04VMT	TTDDRUID	D04VMT
D04VMT	DRUGNAME	Sotalol
D04VMT	INDICATI	Sinus rhythm disorder [ICD-11: BC9Y] Approved

D06SFX	TTDDRUID	D06SFX
D06SFX	DRUGNAME	Soybean Oil
D06SFX	INDICATI	Bupicavaine toxicity [ICD-11: NE6Z] Approved

D0K6GZ	TTDDRUID	D0K6GZ
D0K6GZ	DRUGNAME	Sparfloxacin
D0K6GZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02PCR	TTDDRUID	D02PCR
D02PCR	DRUGNAME	Spectinomycin
D02PCR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06UTT	TTDDRUID	D06UTT
D06UTT	DRUGNAME	Sphingosomal topotecan
D06UTT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D09WCM	TTDDRUID	D09WCM
D09WCM	DRUGNAME	Spinosad
D09WCM	INDICATI	Head and body lice [ICD-11: 1G00.0] Approved

D0F5OR	TTDDRUID	D0F5OR
D0F5OR	DRUGNAME	Spiramycin
D0F5OR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05MFG	TTDDRUID	D05MFG
D05MFG	DRUGNAME	Spirapril
D05MFG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0EP0C	TTDDRUID	D0EP0C
D0EP0C	DRUGNAME	Spironolactone
D0EP0C	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0L9MM	TTDDRUID	D0L9MM
D0L9MM	DRUGNAME	Split virion H1N1 influenza vaccine
D0L9MM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D05EFR	TTDDRUID	D05EFR
D05EFR	DRUGNAME	SprayGel
D05EFR	INDICATI	Abdominal surgical procedure [ICD-11: N.A.] Approved
D05EFR	INDICATI	Gastric disease [ICD-11: DA40-DA7Z] Approved
D05EFR	INDICATI	Pelvic inflammatory disease [ICD-11: GA05] Approved

D0O3OS	TTDDRUID	D0O3OS
D0O3OS	DRUGNAME	SR141716A
D0O3OS	INDICATI	Obesity [ICD-11: 5B81] Approved
D0O3OS	INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market

D08QKJ	TTDDRUID	D08QKJ
D08QKJ	DRUGNAME	Stanozolol
D08QKJ	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved

D0Z8EX	TTDDRUID	D0Z8EX
D0Z8EX	DRUGNAME	Stavudine
D0Z8EX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D03TVW	TTDDRUID	D03TVW
D03TVW	DRUGNAME	Stepronin
D03TVW	INDICATI	Bronchitis [ICD-11: CA20] Approved

D0SQ1W	TTDDRUID	D0SQ1W
D0SQ1W	DRUGNAME	Sterile Water
D0SQ1W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D04MRG	TTDDRUID	D04MRG
D04MRG	DRUGNAME	Stevioside
D04MRG	INDICATI	Sweetener [ICD-11: N.A.] Approved

D0R6RU	TTDDRUID	D0R6RU
D0R6RU	DRUGNAME	STI571
D0R6RU	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D02XSA	TTDDRUID	D02XSA
D02XSA	DRUGNAME	Stiripentol
D02XSA	INDICATI	Dravet syndrome [ICD-11: 8A61.11] Approved
D02XSA	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D04URO	TTDDRUID	D04URO
D04URO	DRUGNAME	Streptokinase
D04URO	INDICATI	Pulmonary embolism [ICD-11: BB00] Approved

D0N0EQ	TTDDRUID	D0N0EQ
D0N0EQ	DRUGNAME	Streptomycin
D0N0EQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0I8RR	TTDDRUID	D0I8RR
D0I8RR	DRUGNAME	Streptozocin
D0I8RR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved

D0R6HN	TTDDRUID	D0R6HN
D0R6HN	DRUGNAME	Strontium Chloride Sr-89
D0R6HN	INDICATI	Cancer related pain [ICD-11: MG30] Approved

D0X7KZ	TTDDRUID	D0X7KZ
D0X7KZ	DRUGNAME	Strontium ranelate
D0X7KZ	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D0F9HK	TTDDRUID	D0F9HK
D0F9HK	DRUGNAME	Strontium-89
D0F9HK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D06JED	TTDDRUID	D06JED
D06JED	DRUGNAME	Subcuvia
D06JED	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D01GYK	TTDDRUID	D01GYK
D01GYK	DRUGNAME	Succimer
D01GYK	INDICATI	Metal intoxication [ICD-11: NE60] Approved

D06VNK	TTDDRUID	D06VNK
D06VNK	DRUGNAME	Succinic acid
D06VNK	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0Q7ZQ	TTDDRUID	D0Q7ZQ
D0Q7ZQ	DRUGNAME	Succinylcholine
D0Q7ZQ	INDICATI	Spasm [ICD-11: MB47.3] Approved

D06ULU	TTDDRUID	D06ULU
D06ULU	DRUGNAME	Sucralfate
D06ULU	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0D8DD	TTDDRUID	D0D8DD
D0D8DD	DRUGNAME	Sufentanil
D0D8DD	INDICATI	Analgesia [ICD-11: MB40.8] Approved

D0H0BG	TTDDRUID	D0H0BG
D0H0BG	DRUGNAME	Sulbactam sodium
D0H0BG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X8XA	TTDDRUID	D0X8XA
D0X8XA	DRUGNAME	Sulconazole
D0X8XA	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0M4VM	TTDDRUID	D0M4VM
D0M4VM	DRUGNAME	Sulfacetamide
D0M4VM	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0T1GT	TTDDRUID	D0T1GT
D0T1GT	DRUGNAME	Sulfacytine
D0T1GT	INDICATI	Cystitis [ICD-11: GC00] Approved
D0T1GT	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D05LKP	TTDDRUID	D05LKP
D05LKP	DRUGNAME	Sulfadiazine
D05LKP	INDICATI	Rheumatic fever [ICD-11: 1B40] Approved

D0H1GJ	TTDDRUID	D0H1GJ
D0H1GJ	DRUGNAME	Sulfamerazine
D0H1GJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07SYJ	TTDDRUID	D07SYJ
D07SYJ	DRUGNAME	Sulfameter
D07SYJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0V9YR	TTDDRUID	D0V9YR
D0V9YR	DRUGNAME	Sulfamethazine
D0V9YR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D07JJS	TTDDRUID	D07JJS
D07JJS	DRUGNAME	Sulfamethizole
D07JJS	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0R9OH	TTDDRUID	D0R9OH
D0R9OH	DRUGNAME	Sulfamethoxazole
D0R9OH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D0R9OH	INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative

D0K1QD	TTDDRUID	D0K1QD
D0K1QD	DRUGNAME	Sulfamylon
D0K1QD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0L4JT	TTDDRUID	D0L4JT
D0L4JT	DRUGNAME	Sulfanilamide
D0L4JT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0A4YE	TTDDRUID	D0A4YE
D0A4YE	DRUGNAME	Sulfaphenazole
D0A4YE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0D4CY	TTDDRUID	D0D4CY
D0D4CY	DRUGNAME	Sulfapyridine
D0D4CY	INDICATI	Dermatitis herpetiformis [ICD-11: EB44] Approved

D02ZTJ	TTDDRUID	D02ZTJ
D02ZTJ	DRUGNAME	Sulfasalazine
D02ZTJ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
D02ZTJ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D03DEI	TTDDRUID	D03DEI
D03DEI	DRUGNAME	Sulfinpyrazone
D03DEI	INDICATI	Gout [ICD-11: FA25] Approved

D09TBD	TTDDRUID	D09TBD
D09TBD	DRUGNAME	Sulfisoxazole
D09TBD	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0T1EO	TTDDRUID	D0T1EO
D0T1EO	DRUGNAME	Sulfonamides
D0T1EO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0PI2E	TTDDRUID	D0PI2E
D0PI2E	DRUGNAME	Sulfoxone
D0PI2E	INDICATI	Dermatitis herpetiformis [ICD-11: EB44] Approved

D0P2JH	TTDDRUID	D0P2JH
D0P2JH	DRUGNAME	Sulfur hexafluoride lipid-type a microspheres
D0P2JH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0TX7T	TTDDRUID	D0TX7T
D0TX7T	DRUGNAME	Sulglycotide
D0TX7T	INDICATI	Active duodenal ulcer [ICD-11: DA63] Approved

D0Z5IU	TTDDRUID	D0Z5IU
D0Z5IU	DRUGNAME	Sulindac
D0Z5IU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0E9TP	TTDDRUID	D0E9TP
D0E9TP	DRUGNAME	Sulodexide
D0E9TP	INDICATI	Tinnitus [ICD-11: MC41] Approved

D07PAO	TTDDRUID	D07PAO
D07PAO	DRUGNAME	Sulphadoxine
D07PAO	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D0V9OZ	TTDDRUID	D0V9OZ
D0V9OZ	DRUGNAME	Sulphasalazine
D0V9OZ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D0K0MI	TTDDRUID	D0K0MI
D0K0MI	DRUGNAME	Sulphur hexafluoride microbubble ultrasound agent
D0K0MI	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D03QGM	TTDDRUID	D03QGM
D03QGM	DRUGNAME	Sulpiride
D03QGM	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0X2UE	TTDDRUID	D0X2UE
D0X2UE	DRUGNAME	Sulprostone
D0X2UE	INDICATI	Medical abortion [ICD-11: JA00.1Z] Approved

D0OG8A	TTDDRUID	D0OG8A
D0OG8A	DRUGNAME	Sultamicillin tosilate
D0OG8A	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Z6UC	TTDDRUID	D0Z6UC
D0Z6UC	DRUGNAME	Sumatriptan
D0Z6UC	INDICATI	Migraine [ICD-11: 8A80] Approved

D0R0MW	TTDDRUID	D0R0MW
D0R0MW	DRUGNAME	Sunitinib
D0R0MW	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Approved

D08UXL	TTDDRUID	D08UXL
D08UXL	DRUGNAME	SunitinibMalate
D08UXL	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved

D06IPN	TTDDRUID	D06IPN
D06IPN	DRUGNAME	Sunscreens
D06IPN	INDICATI	Skin cancer [ICD-11: 2C30-2C37] Approved

D02RBB	TTDDRUID	D02RBB
D02RBB	DRUGNAME	SUPERVAX
D02RBB	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0P8MI	TTDDRUID	D0P8MI
D0P8MI	DRUGNAME	Suplatast tosilate
D0P8MI	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved

D07BPS	TTDDRUID	D07BPS
D07BPS	DRUGNAME	Suprofen
D07BPS	INDICATI	Miosis [ICD-11: LA11.62] Approved

D0H2UB	TTDDRUID	D0H2UB
D0H2UB	DRUGNAME	Suramin
D0H2UB	INDICATI	African trypanosomiasis [ICD-11: 1F51] Phase 1

D0P4EC	TTDDRUID	D0P4EC
D0P4EC	DRUGNAME	Surfactant ta
D0P4EC	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved

D0O0NY	TTDDRUID	D0O0NY
D0O0NY	DRUGNAME	Sutilains
D0O0NY	INDICATI	Skin burns [ICD-11: ME65.0] Approved

D00OVU	TTDDRUID	D00OVU
D00OVU	DRUGNAME	Suvorexant
D00OVU	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D04QNO	TTDDRUID	D04QNO
D04QNO	DRUGNAME	Symbicort
D04QNO	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D08SVH	TTDDRUID	D08SVH
D08SVH	DRUGNAME	Tacalcitol
D08SVH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D0M3AH	TTDDRUID	D0M3AH
D0M3AH	DRUGNAME	TachoComb
D0M3AH	INDICATI	Wound healing [ICD-11: EL8Y] Approved

D0E6YQ	TTDDRUID	D0E6YQ
D0E6YQ	DRUGNAME	Tacrine
D0E6YQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D06OMK	TTDDRUID	D06OMK
D06OMK	DRUGNAME	Tacrolimus
D06OMK	INDICATI	Ocular allergy [ICD-11: 4A81] Phase 3
D06OMK	INDICATI	Organ transplant rejection [ICD-11: NE84] Approved

D05MQK	TTDDRUID	D05MQK
D05MQK	DRUGNAME	Tadalafil
D05MQK	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved

D07TWN	TTDDRUID	D07TWN
D07TWN	DRUGNAME	Tafenoquine
D07TWN	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
D07TWN	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
D07TWN	INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Approved

D04LCQ	TTDDRUID	D04LCQ
D04LCQ	DRUGNAME	Tafluprost
D04LCQ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0R7NI	TTDDRUID	D0R7NI
D0R7NI	DRUGNAME	Tagraxofusp
D0R7NI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
D0R7NI	INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Approved

D04WJO	TTDDRUID	D04WJO
D04WJO	DRUGNAME	Talaporfin
D04WJO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0GV8J	TTDDRUID	D0GV8J
D0GV8J	DRUGNAME	Talazoparib
D0GV8J	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0W0MF	TTDDRUID	D0W0MF
D0W0MF	DRUGNAME	Talbutal
D0W0MF	INDICATI	Irritability [ICD-11: MB24] Approved

D03VDC	TTDDRUID	D03VDC
D03VDC	DRUGNAME	Talc
D03VDC	INDICATI	Pleural disease [ICD-11: CB27] Approved

D0G6HA	TTDDRUID	D0G6HA
D0G6HA	DRUGNAME	Taliglucerase alfa
D0G6HA	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Approved

D05BXY	TTDDRUID	D05BXY
D05BXY	DRUGNAME	Talimogene Laherparepvec
D05BXY	INDICATI	Melanoma [ICD-11: 2C30] Approved

D0N4EC	TTDDRUID	D0N4EC
D0N4EC	DRUGNAME	Taltirelin
D0N4EC	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved

D07KSG	TTDDRUID	D07KSG
D07KSG	DRUGNAME	Tamoxifen
D07KSG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D05MBZ	TTDDRUID	D05MBZ
D05MBZ	DRUGNAME	Tamsulosin
D05MBZ	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D06OSM	TTDDRUID	D06OSM
D06OSM	DRUGNAME	Tandospirone
D06OSM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D05QIM	TTDDRUID	D05QIM
D05QIM	DRUGNAME	TA-NIC
D05QIM	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Approved

D0K4MH	TTDDRUID	D0K4MH
D0K4MH	DRUGNAME	Tapentadol hydrochloride
D0K4MH	INDICATI	Acute pain [ICD-11: MG31] Approved

D0Q5MQ	TTDDRUID	D0Q5MQ
D0Q5MQ	DRUGNAME	Tasimelteon
D0Q5MQ	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D05TUZ	TTDDRUID	D05TUZ
D05TUZ	DRUGNAME	Tasonermin
D05TUZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0M7TO	TTDDRUID	D0M7TO
D0M7TO	DRUGNAME	Tasosartan
D0M7TO	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D05VGL	TTDDRUID	D05VGL
D05VGL	DRUGNAME	Tavaborole
D05VGL	INDICATI	Onychomycosis [ICD-11: EE12.1] Approved

D0C4RB	TTDDRUID	D0C4RB
D0C4RB	DRUGNAME	Taxol
D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0BM5G	TTDDRUID	D0BM5G
D0BM5G	DRUGNAME	Tazarotene
D0BM5G	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D0QQ7D	TTDDRUID	D0QQ7D
D0QQ7D	DRUGNAME	Tazobactam
D0QQ7D	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09WDK	TTDDRUID	D09WDK
D09WDK	DRUGNAME	Tbo-Filgrastim
D09WDK	INDICATI	Neutropenia [ICD-11: 4B00.0] Approved

D09XVS	TTDDRUID	D09XVS
D09XVS	DRUGNAME	Tc-99m tilmanocept
D09XVS	INDICATI	Melanoma [ICD-11: 2C30] Approved

D08SZR	TTDDRUID	D08SZR
D08SZR	DRUGNAME	T-cell therapy
D08SZR	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Approved
D08SZR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0HA7E	TTDDRUID	D0HA7E
D0HA7E	DRUGNAME	TD-Pur
D0HA7E	INDICATI	Diphtheria [ICD-11: 1C17] Approved

D0Q1YZ	TTDDRUID	D0Q1YZ
D0Q1YZ	DRUGNAME	Teceleukin
D0Q1YZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0A7MY	TTDDRUID	D0A7MY
D0A7MY	DRUGNAME	TECFIDERA
D0A7MY	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved

D04MGU	TTDDRUID	D04MGU
D04MGU	DRUGNAME	Technetium (99m Tc) bicisate
D04MGU	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved

D0B4KH	TTDDRUID	D0B4KH
D0B4KH	DRUGNAME	Technetium TC 99M medronate
D0B4KH	INDICATI	Bone disease [ICD-11: FC0Z] Approved

D0X2RJ	TTDDRUID	D0X2RJ
D0X2RJ	DRUGNAME	Technetium TC 99M votumumab
D0X2RJ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved

D0M2WF	TTDDRUID	D0M2WF
D0M2WF	DRUGNAME	Technetium Tc-99m Albumin Microspheres Kit
D0M2WF	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0ZS6R	TTDDRUID	D0ZS6R
D0ZS6R	DRUGNAME	Technetium Tc-99m Apcitide
D0ZS6R	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D06TFE	TTDDRUID	D06TFE
D06TFE	DRUGNAME	Technetium Tc-99m Depreotide
D06TFE	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0X9KI	TTDDRUID	D0X9KI
D0X9KI	DRUGNAME	Technetium Tc-99m Disofenin Kit
D0X9KI	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0DK8G	TTDDRUID	D0DK8G
D0DK8G	DRUGNAME	Technetium Tc-99m Etidronate Kit
D0DK8G	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0O8YO	TTDDRUID	D0O8YO
D0O8YO	DRUGNAME	Technetium Tc-99m Exametazime Kit
D0O8YO	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D06ZAS	TTDDRUID	D06ZAS
D06ZAS	DRUGNAME	Technetium Tc-99m Ferpentetate Kit
D06ZAS	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0T1QY	TTDDRUID	D0T1QY
D0T1QY	DRUGNAME	Technetium Tc-99m Gluceptate Kit
D0T1QY	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D08ZVY	TTDDRUID	D08ZVY
D08ZVY	DRUGNAME	Technetium Tc-99m Lidofenin Kit
D08ZVY	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D02AUI	TTDDRUID	D02AUI
D02AUI	DRUGNAME	Technetium Tc-99m Mebrofenin Kit
D02AUI	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0I1DH	TTDDRUID	D0I1DH
D0I1DH	DRUGNAME	Technetium Tc-99m Mertiatide Kit
D0I1DH	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D07ZRI	TTDDRUID	D07ZRI
D07ZRI	DRUGNAME	Technetium Tc-99m Oxidronate Kit
D07ZRI	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D03WLI	TTDDRUID	D03WLI
D03WLI	DRUGNAME	Technetium Tc-99m Pentetate Kit
D03WLI	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0H3PC	TTDDRUID	D0H3PC
D0H3PC	DRUGNAME	Technetium Tc-99m Polyphosphate Kit
D0H3PC	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0V4YE	TTDDRUID	D0V4YE
D0V4YE	DRUGNAME	Technetium Tc-99m Pyro/Trimeta Phosphates Kit
D0V4YE	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0P6NL	TTDDRUID	D0P6NL
D0P6NL	DRUGNAME	Technetium Tc-99m Pyrophosphate Kit
D0P6NL	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D01OGL	TTDDRUID	D01OGL
D01OGL	DRUGNAME	Technetium Tc-99m Red Blood Cell Kit
D01OGL	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0J1TU	TTDDRUID	D0J1TU
D0J1TU	DRUGNAME	Technetium Tc-99m Sestamibi Kit
D0J1TU	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0BP4Y	TTDDRUID	D0BP4Y
D0BP4Y	DRUGNAME	Technetium Tc-99m Sodium Pertechnetate Generator
D0BP4Y	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D05OEU	TTDDRUID	D05OEU
D05OEU	DRUGNAME	Technetium Tc-99m Succimer Kit
D05OEU	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0V9UY	TTDDRUID	D0V9UY
D0V9UY	DRUGNAME	Technetium Tc-99m Sulfur Colloid Kit
D0V9UY	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D0N7PF	TTDDRUID	D0N7PF
D0N7PF	DRUGNAME	Technetium Tc-99m Tetrofosmin Kit
D0N7PF	INDICATI	Radioactive tracer [ICD-11: N.A.] Approved

D08FOR	TTDDRUID	D08FOR
D08FOR	DRUGNAME	Tecovirimat
D08FOR	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3

D0MD8D	TTDDRUID	D0MD8D
D0MD8D	DRUGNAME	Tecovirimat 
D0MD8D	INDICATI	Smallpox [ICD-11: 1E70] Approved

D08KBK	TTDDRUID	D08KBK
D08KBK	DRUGNAME	Tedizolid
D08KBK	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved

D00RCI	TTDDRUID	D00RCI
D00RCI	DRUGNAME	Teduglutide
D00RCI	INDICATI	Short bowel syndrome [ICD-11: KB89.1] Approved

D0F3SY	TTDDRUID	D0F3SY
D0F3SY	DRUGNAME	Tegafur
D0F3SY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D00XWD	TTDDRUID	D00XWD
D00XWD	DRUGNAME	Tegaserod
D00XWD	INDICATI	Dyspepsia [ICD-11: MD92] Withdrawn from market
D00XWD	INDICATI	Gastro-oesophageal reflux [ICD-11: DA22] Withdrawn from market
D00XWD	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
D00XWD	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Withdrawn from market

D0K6MW	TTDDRUID	D0K6MW
D0K6MW	DRUGNAME	Teicoplanin
D0K6MW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X9CH	TTDDRUID	D0X9CH
D0X9CH	DRUGNAME	Telaprevir
D0X9CH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved

D0B9JO	TTDDRUID	D0B9JO
D0B9JO	DRUGNAME	Telavancin
D0B9JO	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Approved

D0CL9S	TTDDRUID	D0CL9S
D0CL9S	DRUGNAME	Telbivudine
D0CL9S	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D09HNR	TTDDRUID	D09HNR
D09HNR	DRUGNAME	Telithromycin
D09HNR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0N6RF	TTDDRUID	D0N6RF
D0N6RF	DRUGNAME	Telmisartan
D0N6RF	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0RE6T	TTDDRUID	D0RE6T
D0RE6T	DRUGNAME	Telotristat ethyl
D0RE6T	INDICATI	Carcinoid syndrome [ICD-11: 5B10] Approved
D0RE6T	INDICATI	Carcinoid syndrome [ICD-11: 5B10] Phase 3
D0RE6T	INDICATI	Carcinoid syndrome diarrhea [ICD-11: DA90.0] Approved

D04BNP	TTDDRUID	D04BNP
D04BNP	DRUGNAME	Temazepam
D04BNP	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D02DSZ	TTDDRUID	D02DSZ
D02DSZ	DRUGNAME	Temocapril hydrochloride
D02DSZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D0HU0W	TTDDRUID	D0HU0W
D0HU0W	DRUGNAME	Temocillin disodium
D0HU0W	INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved

D0P5DG	TTDDRUID	D0P5DG
D0P5DG	DRUGNAME	Temoporfin
D0P5DG	INDICATI	Bone metastases [ICD-11: 2D50] Approved

D0C8EU	TTDDRUID	D0C8EU
D0C8EU	DRUGNAME	Temozolomide
D0C8EU	INDICATI	Grade IV astrocytoma [ICD-11: 2A00.0] Approved

D0ES1Q	TTDDRUID	D0ES1Q
D0ES1Q	DRUGNAME	Temsirolimus
D0ES1Q	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved

D0FX8A	TTDDRUID	D0FX8A
D0FX8A	DRUGNAME	Tenecteplase
D0FX8A	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D01DBQ	TTDDRUID	D01DBQ
D01DBQ	DRUGNAME	Teniposide
D01DBQ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0D9HW	TTDDRUID	D0D9HW
D0D9HW	DRUGNAME	Tenofovir
D0D9HW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D0I6IB	TTDDRUID	D0I6IB
D0I6IB	DRUGNAME	Tenoxicam
D0I6IB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D09XWD	TTDDRUID	D09XWD
D09XWD	DRUGNAME	Teprenone
D09XWD	INDICATI	Peptic ulcer [ICD-11: DA61] Approved

D0P9RF	TTDDRUID	D0P9RF
D0P9RF	DRUGNAME	Terazosin
D0P9RF	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D01AYJ	TTDDRUID	D01AYJ
D01AYJ	DRUGNAME	Terbinafine
D01AYJ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0M8RC	TTDDRUID	D0M8RC
D0M8RC	DRUGNAME	Terbutaline
D0M8RC	INDICATI	Asthma [ICD-11: CA23] Approved

D0Q2WS	TTDDRUID	D0Q2WS
D0Q2WS	DRUGNAME	Terbutyline
D0Q2WS	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D01AQT	TTDDRUID	D01AQT
D01AQT	DRUGNAME	Terconazole
D01AQT	INDICATI	Candidiasis [ICD-11: 1F23] Approved

D07QFP	TTDDRUID	D07QFP
D07QFP	DRUGNAME	Teriflunomide
D07QFP	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
D07QFP	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
D07QFP	INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
D07QFP	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0YA2L	TTDDRUID	D0YA2L
D0YA2L	DRUGNAME	Teriparatide
D0YA2L	INDICATI	Osteogenesis imperfecta [ICD-11: LD24.K0] Approved

D0P4VX	TTDDRUID	D0P4VX
D0P4VX	DRUGNAME	Terlipressin
D0P4VX	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07QKN	TTDDRUID	D07QKN
D07QKN	DRUGNAME	Terpin hydrate
D07QKN	INDICATI	Cough [ICD-11: MD12] Approved

D03SFU	TTDDRUID	D03SFU
D03SFU	DRUGNAME	TERTATOLOL
D03SFU	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0UL9R	TTDDRUID	D0UL9R
D0UL9R	DRUGNAME	Tesamorelin
D0UL9R	INDICATI	HIV-associated lipodystrophy [ICD-11: 1C62.1] Approved

D0C7JF	TTDDRUID	D0C7JF
D0C7JF	DRUGNAME	Testolactone
D0C7JF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D06XMU	TTDDRUID	D06XMU
D06XMU	DRUGNAME	Testosterone
D06XMU	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Phase 2
D06XMU	INDICATI	Male hormonal deficiency [ICD-11: 5A81] Investigative
D06XMU	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D02AXG	TTDDRUID	D02AXG
D02AXG	DRUGNAME	Testosterone undecanoate
D02AXG	INDICATI	Hypogonadism [ICD-11: 5A61.0] Approved

D0S7XV	TTDDRUID	D0S7XV
D0S7XV	DRUGNAME	Tetanus immune globulin
D0S7XV	INDICATI	Clostridium infection [ICD-11: 1A04] Approved

D0Y2TK	TTDDRUID	D0Y2TK
D0Y2TK	DRUGNAME	Tetanus toxoid
D0Y2TK	INDICATI	Clostridium infection [ICD-11: 1A04] Approved

D09PJX	TTDDRUID	D09PJX
D09PJX	DRUGNAME	Tetrabenazine
D09PJX	INDICATI	Huntington disease [ICD-11: 8A01.10] Approved
D09PJX	INDICATI	Hyperkinetic movement disorder [ICD-11: 6B60.8] Approved

D08HQK	TTDDRUID	D08HQK
D08HQK	DRUGNAME	Tetracaine
D08HQK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
D08HQK	INDICATI	Spinal anesthesia [ICD-11: MB40.3] Approved

D08NQZ	TTDDRUID	D08NQZ
D08NQZ	DRUGNAME	Tetracycline
D08NQZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Z5PF	TTDDRUID	D0Z5PF
D0Z5PF	DRUGNAME	Tetracyclines
D0Z5PF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Q9YT	TTDDRUID	D0Q9YT
D0Q9YT	DRUGNAME	Tetrahydrobiopterin
D0Q9YT	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D0H2QO	TTDDRUID	D0H2QO
D0H2QO	DRUGNAME	Tetrahydrofolic acid
D0H2QO	INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved

D05IHU	TTDDRUID	D05IHU
D05IHU	DRUGNAME	Tetrahydrozoline
D05IHU	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Approved

D00CEE	TTDDRUID	D00CEE
D00CEE	DRUGNAME	Tetraxim
D00CEE	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved

D0C7ET	TTDDRUID	D0C7ET
D0C7ET	DRUGNAME	Tetrodotoxin
D0C7ET	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0E1HC	TTDDRUID	D0E1HC
D0E1HC	DRUGNAME	Tezacaftor and ivacaftor
D0E1HC	INDICATI	Acute lung injury [ICD-11: NB32.3] Approved

D0U7GK	TTDDRUID	D0U7GK
D0U7GK	DRUGNAME	Thalidomide
D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Approved

D0R1WQ	TTDDRUID	D0R1WQ
D0R1WQ	DRUGNAME	Thallous Chloride Tl-201
D0R1WQ	INDICATI	Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved

D0F4QO	TTDDRUID	D0F4QO
D0F4QO	DRUGNAME	THE-320
D0F4QO	INDICATI	Prostate hyperplasia [ICD-11: GA90] Approved

D0I0DS	TTDDRUID	D0I0DS
D0I0DS	DRUGNAME	Theobromine
D0I0DS	INDICATI	Asthma [ICD-11: CA23] Approved

D0F8RA	TTDDRUID	D0F8RA
D0F8RA	DRUGNAME	Theophylline
D0F8RA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D08QCJ	TTDDRUID	D08QCJ
D08QCJ	DRUGNAME	Thiabendazole
D08QCJ	INDICATI	Dutch elm disease [ICD-11: 8D64] Approved
D08QCJ	INDICATI	Helminth infection [ICD-11: 1F90.0] Approved

D0UF6M	TTDDRUID	D0UF6M
D0UF6M	DRUGNAME	Thiacetazone
D0UF6M	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved

D02LDV	TTDDRUID	D02LDV
D02LDV	DRUGNAME	Thiamine Hydrochloride
D02LDV	INDICATI	Thiamine deficiency [ICD-11: 5B5A] Approved
D02LDV	INDICATI	Wernicke-Korsakoff Syndrome [ICD-11: 5B5A.1] Approved

D03YLZ	TTDDRUID	D03YLZ
D03YLZ	DRUGNAME	Thiamphenicol
D03YLZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06NSA	TTDDRUID	D06NSA
D06NSA	DRUGNAME	Thiamylal
D06NSA	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0K8IX	TTDDRUID	D0K8IX
D0K8IX	DRUGNAME	Thiazolidinedione
D0K8IX	INDICATI	Alzheimer disease [ICD-11: 8A20] Approved

D0Y0ER	TTDDRUID	D0Y0ER
D0Y0ER	DRUGNAME	Thiethylperazine
D0Y0ER	INDICATI	Nausea [ICD-11: MD90] Approved

D0IG4I	TTDDRUID	D0IG4I
D0IG4I	DRUGNAME	THIOCOLCHICOSIDE
D0IG4I	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved

D02ZXM	TTDDRUID	D02ZXM
D02ZXM	DRUGNAME	Thioguanine
D02ZXM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D00MYT	TTDDRUID	D00MYT
D00MYT	DRUGNAME	Thiopental
D00MYT	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0U1OE	TTDDRUID	D0U1OE
D0U1OE	DRUGNAME	Thioridazine
D0U1OE	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D00YZA	TTDDRUID	D00YZA
D00YZA	DRUGNAME	Thiotepa
D00YZA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0E0LQ	TTDDRUID	D0E0LQ
D0E0LQ	DRUGNAME	Thiothixene
D0E0LQ	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D0KT3X	TTDDRUID	D0KT3X
D0KT3X	DRUGNAME	Thrombin/fibrinogen matrix patch
D0KT3X	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D0C8TD	TTDDRUID	D0C8TD
D0C8TD	DRUGNAME	Thrombin-JMI
D0C8TD	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved

D0I5KX	TTDDRUID	D0I5KX
D0I5KX	DRUGNAME	Thymalfasin
D0I5KX	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved
D0I5KX	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
D0I5KX	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D06GIP	TTDDRUID	D06GIP
D06GIP	DRUGNAME	Thymol
D06GIP	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D0TP2W	TTDDRUID	D0TP2W
D0TP2W	DRUGNAME	Thymopentin
D0TP2W	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D0QD9R	TTDDRUID	D0QD9R
D0QD9R	DRUGNAME	Thyroglobulin
D0QD9R	INDICATI	Hypothyroidism [ICD-11: 5A00] Approved

D03EER	TTDDRUID	D03EER
D03EER	DRUGNAME	Thyrotropin
D03EER	INDICATI	Hypothyroidism [ICD-11: 5A00] Approved

D0H4TQ	TTDDRUID	D0H4TQ
D0H4TQ	DRUGNAME	Thyrotropin Alfa
D0H4TQ	INDICATI	Thyroid cancer [ICD-11: 2D10] Approved

D0ED7U	TTDDRUID	D0ED7U
D0ED7U	DRUGNAME	Tiagabine
D0ED7U	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
D0ED7U	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D0D7EN	TTDDRUID	D0D7EN
D0D7EN	DRUGNAME	Tiamenidine
D0D7EN	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06CVT	TTDDRUID	D06CVT
D06CVT	DRUGNAME	Tianeptine
D06CVT	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D02LCR	TTDDRUID	D02LCR
D02LCR	DRUGNAME	Tiapride
D02LCR	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
D02LCR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D0S7VO	TTDDRUID	D0S7VO
D0S7VO	DRUGNAME	Tiaprofenic acid
D0S7VO	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0S7DV	TTDDRUID	D0S7DV
D0S7DV	DRUGNAME	Tiazofurin
D0S7DV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0W3OS	TTDDRUID	D0W3OS
D0W3OS	DRUGNAME	Tibolone
D0W3OS	INDICATI	Anabolic metabolism [ICD-11: 5C50-5C8Z] Approved

D08USU	TTDDRUID	D08USU
D08USU	DRUGNAME	Ticarcillin
D08USU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05LBU	TTDDRUID	D05LBU
D05LBU	DRUGNAME	Ticlopidine
D05LBU	INDICATI	Stroke [ICD-11: 8B20] Approved

D0G4OD	TTDDRUID	D0G4OD
D0G4OD	DRUGNAME	Tigecycline
D0G4OD	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved

D0FT3R	TTDDRUID	D0FT3R
D0FT3R	DRUGNAME	Tildrakizumab
D0FT3R	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved

D0U9MR	TTDDRUID	D0U9MR
D0U9MR	DRUGNAME	Tilidine
D0U9MR	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0Q8CS	TTDDRUID	D0Q8CS
D0Q8CS	DRUGNAME	Tiludronic acid
D0Q8CS	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D05UVD	TTDDRUID	D05UVD
D05UVD	DRUGNAME	Timolol
D05UVD	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0O4SE	TTDDRUID	D0O4SE
D0O4SE	DRUGNAME	Tindamax
D0O4SE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0CA6J	TTDDRUID	D0CA6J
D0CA6J	DRUGNAME	Tioconazole
D0CA6J	INDICATI	Onychomycosis [ICD-11: EE12.1] Approved

D0A8CJ	TTDDRUID	D0A8CJ
D0A8CJ	DRUGNAME	Tiopronin
D0A8CJ	INDICATI	Cystine urolithiasis [ICD-11: GB70-GB7Z] Approved
D0A8CJ	INDICATI	Cystinuria [ICD-11: 5C60.2] Approved

D0P1WA	TTDDRUID	D0P1WA
D0P1WA	DRUGNAME	Tiotropium
D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0EV6T	TTDDRUID	D0EV6T
D0EV6T	DRUGNAME	Tipranavir
D0EV6T	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D04APR	TTDDRUID	D04APR
D04APR	DRUGNAME	Tirilazad mesylate
D04APR	INDICATI	Cataract [ICD-11: 9B10] Approved
D04APR	INDICATI	Subarachnoid hemorrhage [ICD-11: 8B01] Approved

D0BN9X	TTDDRUID	D0BN9X
D0BN9X	DRUGNAME	Tirofiban
D0BN9X	INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved

D0VL8Q	TTDDRUID	D0VL8Q
D0VL8Q	DRUGNAME	Tiropramide
D0VL8Q	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0E0ST	TTDDRUID	D0E0ST
D0E0ST	DRUGNAME	Tisokinase
D0E0ST	INDICATI	Acute myocardial infarction [ICD-11: BA41] Approved

D01MDT	TTDDRUID	D01MDT
D01MDT	DRUGNAME	Tizanidine
D01MDT	INDICATI	Spasm [ICD-11: MB47.3] Approved

D07BCT	TTDDRUID	D07BCT
D07BCT	DRUGNAME	Tobramycin
D07BCT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01PJR	TTDDRUID	D01PJR
D01PJR	DRUGNAME	Tocainide
D01PJR	INDICATI	Ventricular arrhythmias [ICD-11: BC71] Approved

D08HPZ	TTDDRUID	D08HPZ
D08HPZ	DRUGNAME	Tocilizumab
D08HPZ	INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3
D08HPZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D03VFL	TTDDRUID	D03VFL
D03VFL	DRUGNAME	TOCOTRIENOL
D03VFL	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved

D0EG1I	TTDDRUID	D0EG1I
D0EG1I	DRUGNAME	Tofacitinib
D0EG1I	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D09FJB	TTDDRUID	D09FJB
D09FJB	DRUGNAME	Tolazamide
D09FJB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D03RZV	TTDDRUID	D03RZV
D03RZV	DRUGNAME	Tolazoline
D03RZV	INDICATI	Pulmonary hypertension [ICD-11: BB01] Approved

D06OIV	TTDDRUID	D06OIV
D06OIV	DRUGNAME	Tolbutamide
D06OIV	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Approved

D0Y7PG	TTDDRUID	D0Y7PG
D0Y7PG	DRUGNAME	Tolcapone
D0Y7PG	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D09BHB	TTDDRUID	D09BHB
D09BHB	DRUGNAME	Tolmetin
D09BHB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D02NTO	TTDDRUID	D02NTO
D02NTO	DRUGNAME	Tolnaftate
D02NTO	INDICATI	Dermatophytosis [ICD-11: 1F28.2] Approved
D02NTO	INDICATI	Jock itch [ICD-11: 1F28.3] Approved

D05YBZ	TTDDRUID	D05YBZ
D05YBZ	DRUGNAME	Tolonium chloride
D05YBZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0X0WU	TTDDRUID	D0X0WU
D0X0WU	DRUGNAME	Tolperisone
D0X0WU	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved

D0BZ7W	TTDDRUID	D0BZ7W
D0BZ7W	DRUGNAME	Tolterodine
D0BZ7W	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved

D03KZM	TTDDRUID	D03KZM
D03KZM	DRUGNAME	Tolvaptan
D03KZM	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
D03KZM	INDICATI	Hyponatraemia [ICD-11: 5C72] Approved

D0Z4XW	TTDDRUID	D0Z4XW
D0Z4XW	DRUGNAME	Topetecan
D0Z4XW	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Approved

D07VDZ	TTDDRUID	D07VDZ
D07VDZ	DRUGNAME	Topiramate
D07VDZ	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
D07VDZ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D02PMO	TTDDRUID	D02PMO
D02PMO	DRUGNAME	Topotecan
D02PMO	INDICATI	Ovarian cancer [ICD-11: 2C73] Approved

D0J9XZ	TTDDRUID	D0J9XZ
D0J9XZ	DRUGNAME	Torasemide
D0J9XZ	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D04VFJ	TTDDRUID	D04VFJ
D04VFJ	DRUGNAME	Toremifene
D04VFJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0I2AV	TTDDRUID	D0I2AV
D0I2AV	DRUGNAME	Tositumomab
D0I2AV	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D0LZ7E	TTDDRUID	D0LZ7E
D0LZ7E	DRUGNAME	TP-434
D0LZ7E	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
D0LZ7E	INDICATI	Intra-abdominal infection [ICD-11: 1A40] Approved

D03RTK	TTDDRUID	D03RTK
D03RTK	DRUGNAME	Trabectedin
D03RTK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D05GKD	TTDDRUID	D05GKD
D05GKD	DRUGNAME	Tramadol
D05GKD	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D04XVN	TTDDRUID	D04XVN
D04XVN	DRUGNAME	Trametinib
D04XVN	INDICATI	Melanoma [ICD-11: 2C30] Approved

D06AGH	TTDDRUID	D06AGH
D06AGH	DRUGNAME	Trametinib + dabrafenib
D06AGH	INDICATI	Melanoma [ICD-11: 2C30] Approved

D0M5OC	TTDDRUID	D0M5OC
D0M5OC	DRUGNAME	Trandolapril
D0M5OC	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D05HXX	TTDDRUID	D05HXX
D05HXX	DRUGNAME	Tranexamic Acid
D05HXX	INDICATI	Excessive bleeding [ICD-11: GA30.02] Approved

D0E6OC	TTDDRUID	D0E6OC
D0E6OC	DRUGNAME	Tranilast
D0E6OC	INDICATI	Ocular allergy [ICD-11: 4A81] Approved

D0H0HJ	TTDDRUID	D0H0HJ
D0H0HJ	DRUGNAME	Tranylcypromine
D0H0HJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
D0H0HJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Patented

D04WFL	TTDDRUID	D04WFL
D04WFL	DRUGNAME	Trastuzumab
D04WFL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D09CZA	TTDDRUID	D09CZA
D09CZA	DRUGNAME	Travoprost
D09CZA	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D00USF	TTDDRUID	D00USF
D00USF	DRUGNAME	Trazodone
D00USF	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D04YPN	TTDDRUID	D04YPN
D04YPN	DRUGNAME	Treosulfan
D04YPN	INDICATI	Melanoma [ICD-11: 2C30] Approved

D01WUA	TTDDRUID	D01WUA
D01WUA	DRUGNAME	Treprostinil
D01WUA	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved

D02DGU	TTDDRUID	D02DGU
D02DGU	DRUGNAME	Tretinoin
D02DGU	INDICATI	Acne vulgaris [ICD-11: ED80] Approved
D02DGU	INDICATI	Acute promyelocytic leukaemia [ICD-11: 2A60.0] Phase 2

D07NJI	TTDDRUID	D07NJI
D07NJI	DRUGNAME	Treximet
D07NJI	INDICATI	Migraine [ICD-11: 8A80] Approved

D0Q6DX	TTDDRUID	D0Q6DX
D0Q6DX	DRUGNAME	Triacetin
D0Q6DX	INDICATI	Onychomycosis [ICD-11: EE12.1] Approved

D03BLF	TTDDRUID	D03BLF
D03BLF	DRUGNAME	Triamcinolone
D03BLF	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D00NKB	TTDDRUID	D00NKB
D00NKB	DRUGNAME	Triamterene
D00NKB	INDICATI	Congestive heart failure [ICD-11: BD10] Approved
D00NKB	INDICATI	Edema [ICD-11: MG29] Approved
D00NKB	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0U3LS	TTDDRUID	D0U3LS
D0U3LS	DRUGNAME	Triazolam
D0U3LS	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0Y2IZ	TTDDRUID	D0Y2IZ
D0Y2IZ	DRUGNAME	Trichlormethiazide
D0Y2IZ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D02VMJ	TTDDRUID	D02VMJ
D02VMJ	DRUGNAME	TRICLABENDAZOLE
D02VMJ	INDICATI	Helminth infection [ICD-11: 1F90.0] Approved

D0B2DP	TTDDRUID	D0B2DP
D0B2DP	DRUGNAME	Triclofos Sodium
D0B2DP	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D00CSQ	TTDDRUID	D00CSQ
D00CSQ	DRUGNAME	Triclosan
D00CSQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D00CSQ	INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative
D00CSQ	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D05YMT	TTDDRUID	D05YMT
D05YMT	DRUGNAME	Tricomin
D05YMT	INDICATI	Alopecia [ICD-11: ED70] Approved

D0OK5I	TTDDRUID	D0OK5I
D0OK5I	DRUGNAME	Tridihexethyl
D0OK5I	INDICATI	Acquired nystagmus [ICD-11: 9C84] Approved

D09VAZ	TTDDRUID	D09VAZ
D09VAZ	DRUGNAME	TRIENTINE
D09VAZ	INDICATI	Inborn error of metabolism [ICD-11: 5C50-5C59] Approved

D09VOK	TTDDRUID	D09VOK
D09VOK	DRUGNAME	Trientine Hydrochloride
D09VOK	INDICATI	Wilson disease [ICD-11: 5C64.00] Approved

D03BDP	TTDDRUID	D03BDP
D03BDP	DRUGNAME	Triferic
D03BDP	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved

D0R4OM	TTDDRUID	D0R4OM
D0R4OM	DRUGNAME	Trifluoperazine
D0R4OM	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D05NOS	TTDDRUID	D05NOS
D05NOS	DRUGNAME	Triflupromazine
D05NOS	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved

D05RHI	TTDDRUID	D05RHI
D05RHI	DRUGNAME	Trifluridine
D05RHI	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D09GFL	TTDDRUID	D09GFL
D09GFL	DRUGNAME	Trihexyphenidyl
D09GFL	INDICATI	Dystonia [ICD-11: 8A02] Approved
D09GFL	INDICATI	Obesity [ICD-11: 5B81] Investigative
D09GFL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved

D03XOC	TTDDRUID	D03XOC
D03XOC	DRUGNAME	Trilostane
D03XOC	INDICATI	Cushing disease [ICD-11: 5A70] Approved

D0T4WA	TTDDRUID	D0T4WA
D0T4WA	DRUGNAME	Trimazosin
D0T4WA	INDICATI	Congestive heart failure [ICD-11: BD10] Approved

D0E0CT	TTDDRUID	D0E0CT
D0E0CT	DRUGNAME	Trimebutine
D0E0CT	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved

D04ATM	TTDDRUID	D04ATM
D04ATM	DRUGNAME	Trimegestone
D04ATM	INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved

D08HZL	TTDDRUID	D08HZL
D08HZL	DRUGNAME	Trimeprazine
D08HZL	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D0Q4YI	TTDDRUID	D0Q4YI
D0Q4YI	DRUGNAME	Trimetazidine
D0Q4YI	INDICATI	Angina pectoris [ICD-11: BA40] Approved

D0U4VT	TTDDRUID	D0U4VT
D0U4VT	DRUGNAME	Trimethadione
D0U4VT	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
D0U4VT	INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved

D0B6CC	TTDDRUID	D0B6CC
D0B6CC	DRUGNAME	Trimethaphan
D0B6CC	INDICATI	Aneurysm [ICD-11: BD51.Z] Approved
D0B6CC	INDICATI	Hypertensive emergency [ICD-11: BA03] Approved

D0A8FB	TTDDRUID	D0A8FB
D0A8FB	DRUGNAME	Trimethobenzamide
D0A8FB	INDICATI	Nausea and vomiting [ICD-11: MD90] Approved

D0AO5H	TTDDRUID	D0AO5H
D0AO5H	DRUGNAME	Trimethoprim
D0AO5H	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0Y7TS	TTDDRUID	D0Y7TS
D0Y7TS	DRUGNAME	Trimetrexate
D0Y7TS	INDICATI	Toxoplasmosis [ICD-11: 1F57] Approved

D00HZV	TTDDRUID	D00HZV
D00HZV	DRUGNAME	Trimipramine
D00HZV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0FA2O	TTDDRUID	D0FA2O
D0FA2O	DRUGNAME	Trioxsalen
D0FA2O	INDICATI	Vitiligo [ICD-11: ED63.0] Approved

D0B4JQ	TTDDRUID	D0B4JQ
D0B4JQ	DRUGNAME	Tripelennamine
D0B4JQ	INDICATI	Hypersensitivity [ICD-11: 4A80-4A85] Approved

D06NQJ	TTDDRUID	D06NQJ
D06NQJ	DRUGNAME	Triproamylin acetate
D06NQJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0E8CI	TTDDRUID	D0E8CI
D0E8CI	DRUGNAME	Triprolidine
D0E8CI	INDICATI	Hay fever [ICD-11: CA08.00] Approved

D03QRS	TTDDRUID	D03QRS
D03QRS	DRUGNAME	Triptorelin
D03QRS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0Q9VA	TTDDRUID	D0Q9VA
D0Q9VA	DRUGNAME	Tritanrix HB
D0Q9VA	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D0Y1UC	TTDDRUID	D0Y1UC
D0Y1UC	DRUGNAME	Trofosfamide
D0Y1UC	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved

D06XZW	TTDDRUID	D06XZW
D06XZW	DRUGNAME	Troglitazone
D06XZW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D09NIY	TTDDRUID	D09NIY
D09NIY	DRUGNAME	Trolamine Polypeptide Oleate Condensate
D09NIY	INDICATI	Impacted cerumen [ICD-11: AA42] Approved

D0A5CM	TTDDRUID	D0A5CM
D0A5CM	DRUGNAME	Trolamine salicylate
D0A5CM	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D06IGU	TTDDRUID	D06IGU
D06IGU	DRUGNAME	Troleandomycin
D06IGU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D03ZFN	TTDDRUID	D03ZFN
D03ZFN	DRUGNAME	Tromethamine
D03ZFN	INDICATI	Acidosis [ICD-11: 5C73] Approved

D09PNY	TTDDRUID	D09PNY
D09PNY	DRUGNAME	Tropicamide
D09PNY	INDICATI	Mydriasis [ICD-11: LA11.62] Approved

D0K0KH	TTDDRUID	D0K0KH
D0K0KH	DRUGNAME	Tropisetron
D0K0KH	INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved

D05TIB	TTDDRUID	D05TIB
D05TIB	DRUGNAME	Trospium
D05TIB	INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
D05TIB	INDICATI	Spasm [ICD-11: MB47.3] Approved

D03WPA	TTDDRUID	D03WPA
D03WPA	DRUGNAME	Trovafloxacin
D03WPA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D00BZJ	TTDDRUID	D00BZJ
D00BZJ	DRUGNAME	Trumenba
D00BZJ	INDICATI	Meningitis [ICD-11: 1D01] Approved

D03TTQ	TTDDRUID	D03TTQ
D03TTQ	DRUGNAME	TRYPAN BLUE
D03TTQ	INDICATI	Ophthalmic surgery injury [ICD-11: PK97] Approved

D0GY5T	TTDDRUID	D0GY5T
D0GY5T	DRUGNAME	Tuberculin
D0GY5T	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved

D05HSC	TTDDRUID	D05HSC
D05HSC	DRUGNAME	Tubocurarine
D05HSC	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
D05HSC	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Approved

D02BTZ	TTDDRUID	D02BTZ
D02BTZ	DRUGNAME	Twinrix
D02BTZ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D00ASJ	TTDDRUID	D00ASJ
D00ASJ	DRUGNAME	Typherix
D00ASJ	INDICATI	Salmonella infection [ICD-11: 1A09] Approved

D0L2VV	TTDDRUID	D0L2VV
D0L2VV	DRUGNAME	Typhim Vi
D0L2VV	INDICATI	Salmonella infection [ICD-11: 1A09] Approved

D0R2RR	TTDDRUID	D0R2RR
D0R2RR	DRUGNAME	Typhoid vaccine
D0R2RR	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved

D08EVN	TTDDRUID	D08EVN
D08EVN	DRUGNAME	Tyropanoate sodium
D08EVN	INDICATI	Gallbladder disease [ICD-11: DC11.3] Approved

D0F0ZE	TTDDRUID	D0F0ZE
D0F0ZE	DRUGNAME	Tyverb/Tykerb
D0F0ZE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
D0F0ZE	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D0F0ZE	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D0F0ZE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Patented
D0F0ZE	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2

D01GUS	TTDDRUID	D01GUS
D01GUS	DRUGNAME	Udenafil
D01GUS	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved

D0Y8PT	TTDDRUID	D0Y8PT
D0Y8PT	DRUGNAME	UFT
D0Y8PT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0V4WD	TTDDRUID	D0V4WD
D0V4WD	DRUGNAME	Ulipristal
D0V4WD	INDICATI	Contraception [ICD-11: QA21] Approved

D03FKQ	TTDDRUID	D03FKQ
D03FKQ	DRUGNAME	Ultrase
D03FKQ	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Approved

D00SLY	TTDDRUID	D00SLY
D00SLY	DRUGNAME	Umeclidinium
D00SLY	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0Z5BC	TTDDRUID	D0Z5BC
D0Z5BC	DRUGNAME	Undecylenic acid
D0Z5BC	INDICATI	Dermatitis [ICD-11: EA80-EA89] Approved

D0D7MZ	TTDDRUID	D0D7MZ
D0D7MZ	DRUGNAME	UniGAM SD
D0D7MZ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved

D06UNR	TTDDRUID	D06UNR
D06UNR	DRUGNAME	Unithiol
D06UNR	INDICATI	Metal intoxication [ICD-11: NE60] Approved

D09SRR	TTDDRUID	D09SRR
D09SRR	DRUGNAME	Unoprostone
D09SRR	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0H2YX	TTDDRUID	D0H2YX
D0H2YX	DRUGNAME	Unoprostone isopropyl ester
D0H2YX	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved

D0J9UN	TTDDRUID	D0J9UN
D0J9UN	DRUGNAME	Uracil mustard
D0J9UN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved

D0K0VO	TTDDRUID	D0K0VO
D0K0VO	DRUGNAME	Urapidil
D0K0VO	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D0K0VO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1/2

D02XBW	TTDDRUID	D02XBW
D02XBW	DRUGNAME	Urea
D02XBW	INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved

D0D5NN	TTDDRUID	D0D5NN
D0D5NN	DRUGNAME	Urea, C-14
D0D5NN	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D0Y7DP	TTDDRUID	D0Y7DP
D0Y7DP	DRUGNAME	Uridine
D0Y7DP	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0OL7F	TTDDRUID	D0OL7F
D0OL7F	DRUGNAME	Uridine triacetate
D0OL7F	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
D0OL7F	INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved

D02SBQ	TTDDRUID	D02SBQ
D02SBQ	DRUGNAME	Urofollitropin
D02SBQ	INDICATI	Female infertility [ICD-11: GA31.Z] Approved

D0E8UO	TTDDRUID	D0E8UO
D0E8UO	DRUGNAME	Urokinase
D0E8UO	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D0G3SH	TTDDRUID	D0G3SH
D0G3SH	DRUGNAME	Ursodeoxycholic acid
D0G3SH	INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Approved

D0A2UV	TTDDRUID	D0A2UV
D0A2UV	DRUGNAME	Ustekinumab
D0A2UV	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2/3
D0A2UV	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
D0A2UV	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
D0A2UV	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D01PQM	TTDDRUID	D01PQM
D01PQM	DRUGNAME	Vaccinia immune globulin
D01PQM	INDICATI	Vaccination [ICD-11: N.A.] Approved

D03ALS	TTDDRUID	D03ALS
D03ALS	DRUGNAME	VA-DIFTET
D03ALS	INDICATI	Clostridium infection [ICD-11: 1A04] Approved

D04QJD	TTDDRUID	D04QJD
D04QJD	DRUGNAME	Valaciclovir
D04QJD	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D05MFA	TTDDRUID	D05MFA
D05MFA	DRUGNAME	Valacyclovir Hydrochloride
D05MFA	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved

D0JJ7S	TTDDRUID	D0JJ7S
D0JJ7S	DRUGNAME	Valbenazine Tosylate
D0JJ7S	INDICATI	Tardive dyskinesia [ICD-11: 8A02.10] Approved

D0L6DA	TTDDRUID	D0L6DA
D0L6DA	DRUGNAME	Valdecoxib
D0L6DA	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D06GWF	TTDDRUID	D06GWF
D06GWF	DRUGNAME	Valganciclovir
D06GWF	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved

D0Y3KG	TTDDRUID	D0Y3KG
D0Y3KG	DRUGNAME	Valproate
D0Y3KG	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D0Y3KG	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D07IPB	TTDDRUID	D07IPB
D07IPB	DRUGNAME	Valrubicin
D07IPB	INDICATI	Bladder cancer [ICD-11: 2C94] Approved
D07IPB	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D06UDG	TTDDRUID	D06UDG
D06UDG	DRUGNAME	Valsartan
D06UDG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0B1IV	TTDDRUID	D0B1IV
D0B1IV	DRUGNAME	Vancomycin
D0B1IV	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative
D0B1IV	INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Approved

D0G6QF	TTDDRUID	D0G6QF
D0G6QF	DRUGNAME	Vandetanib
D0G6QF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D07DSQ	TTDDRUID	D07DSQ
D07DSQ	DRUGNAME	Vapreotide acetate
D07DSQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D02KII	TTDDRUID	D02KII
D02KII	DRUGNAME	Vaqta
D02KII	INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved

D0C9SY	TTDDRUID	D0C9SY
D0C9SY	DRUGNAME	Vardenafil
D0C9SY	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved

D0LM4A	TTDDRUID	D0LM4A
D0LM4A	DRUGNAME	Varenicline
D0LM4A	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Approved

D0UW7D	TTDDRUID	D0UW7D
D0UW7D	DRUGNAME	Varicella zoster virus vaccine live
D0UW7D	INDICATI	Herpes zoster [ICD-11: 1E91] Approved

D0ZA4G	TTDDRUID	D0ZA4G
D0ZA4G	DRUGNAME	Varicella-zoster immune globulin
D0ZA4G	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved

D04HIS	TTDDRUID	D04HIS
D04HIS	DRUGNAME	Varilrix
D04HIS	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved

D07ISO	TTDDRUID	D07ISO
D07ISO	DRUGNAME	VariZIG
D07ISO	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Approved

D0R8PX	TTDDRUID	D0R8PX
D0R8PX	DRUGNAME	Vasicine
D0R8PX	INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved

D0N4OW	TTDDRUID	D0N4OW
D0N4OW	DRUGNAME	Vasopressin
D0N4OW	INDICATI	Diabetes insipidus [ICD-11: 5A61.5] Approved
D0N4OW	INDICATI	Enuresis [ICD-11: 6C00] Approved
D0N4OW	INDICATI	Polyuria [ICD-11: MF55] Approved

D0F8HU	TTDDRUID	D0F8HU
D0F8HU	DRUGNAME	VaxiFlu-S
D0F8HU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D04LCX	TTDDRUID	D04LCX
D04LCX	DRUGNAME	Vax-SPIRAL
D04LCX	INDICATI	Leptospira infection [ICD-11: 1B91] Approved

D0E9AZ	TTDDRUID	D0E9AZ
D0E9AZ	DRUGNAME	Vax-TET
D0E9AZ	INDICATI	Clostridium infection [ICD-11: 1A04] Approved

D0Z8HG	TTDDRUID	D0Z8HG
D0Z8HG	DRUGNAME	Vecuronium
D0Z8HG	INDICATI	Spasm [ICD-11: MB47.3] Approved

D0N5ZS	TTDDRUID	D0N5ZS
D0N5ZS	DRUGNAME	Vedolizmab
D0N5ZS	INDICATI	Crohn disease [ICD-11: DD70] Approved
D0N5ZS	INDICATI	Ulcerative colitis [ICD-11: DD71] Approved

D0G5ET	TTDDRUID	D0G5ET
D0G5ET	DRUGNAME	Velaglucerase alfa
D0G5ET	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Approved

D0Y9EW	TTDDRUID	D0Y9EW
D0Y9EW	DRUGNAME	Vemurafenib
D0Y9EW	INDICATI	Melanoma [ICD-11: 2C30] Approved

D0P1UX	TTDDRUID	D0P1UX
D0P1UX	DRUGNAME	Venlafaxine
D0P1UX	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0M4OC	TTDDRUID	D0M4OC
D0M4OC	DRUGNAME	Venofer
D0M4OC	INDICATI	Fatigue [ICD-11: MG22] Approved

D0R0FE	TTDDRUID	D0R0FE
D0R0FE	DRUGNAME	Verapamil
D0R0FE	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D01XCL	TTDDRUID	D01XCL
D01XCL	DRUGNAME	Veratrum Viride Root
D01XCL	INDICATI	High blood pressure [ICD-11: BA00] Approved

D0I3XG	TTDDRUID	D0I3XG
D0I3XG	DRUGNAME	Verteporfin
D0I3XG	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D0L0ZF	TTDDRUID	D0L0ZF
D0L0ZF	DRUGNAME	VESNARINONE
D0L0ZF	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Approved

D0OY4K	TTDDRUID	D0OY4K
D0OY4K	DRUGNAME	Vestronidase alfa
D0OY4K	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved

D0NI0C	TTDDRUID	D0NI0C
D0NI0C	DRUGNAME	Vidarabine
D0NI0C	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved

D0R3QY	TTDDRUID	D0R3QY
D0R3QY	DRUGNAME	Vigabatrin
D0R3QY	INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
D0R3QY	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
D0R3QY	INDICATI	Infantile spasm [ICD-11: 8A62.0] Approved

D0L0GM	TTDDRUID	D0L0GM
D0L0GM	DRUGNAME	Vilanterol
D0L0GM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
D0L0GM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0X6BV	TTDDRUID	D0X6BV
D0X6BV	DRUGNAME	Vilazodone
D0X6BV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0L3DK	TTDDRUID	D0L3DK
D0L3DK	DRUGNAME	Vildagliptin
D0L3DK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0V9JR	TTDDRUID	D0V9JR
D0V9JR	DRUGNAME	Viloxazine
D0V9JR	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved

D0W9MM	TTDDRUID	D0W9MM
D0W9MM	DRUGNAME	Vinblastine
D0W9MM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D08UGJ	TTDDRUID	D08UGJ
D08UGJ	DRUGNAME	Vincamine
D08UGJ	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Approved

D09QVV	TTDDRUID	D09QVV
D09QVV	DRUGNAME	Vincristine
D09QVV	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D04RLY	TTDDRUID	D04RLY
D04RLY	DRUGNAME	Vindesine
D04RLY	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved

D0OT9S	TTDDRUID	D0OT9S
D0OT9S	DRUGNAME	Vinflunine
D0OT9S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D01HTL	TTDDRUID	D01HTL
D01HTL	DRUGNAME	Vinorelbine
D01HTL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D06BCB	TTDDRUID	D06BCB
D06BCB	DRUGNAME	Vinpocetine
D06BCB	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Approved

D0Q8NJ	TTDDRUID	D0Q8NJ
D0Q8NJ	DRUGNAME	Viomycin sulfate
D0Q8NJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0QE1Y	TTDDRUID	D0QE1Y
D0QE1Y	DRUGNAME	ViperaTAb
D0QE1Y	INDICATI	Poison intoxication [ICD-11: NE6Z] Approved

D05MNW	TTDDRUID	D05MNW
D05MNW	DRUGNAME	Virginiamycin
D05MNW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0X4BZ	TTDDRUID	D0X4BZ
D0X4BZ	DRUGNAME	Virulizin
D0X4BZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D03EDQ	TTDDRUID	D03EDQ
D03EDQ	DRUGNAME	Vismodegib
D03EDQ	INDICATI	Basal cell carcinoma [ICD-11: 2C32] Approved
D03EDQ	INDICATI	Primitive neuroectodermal tumour medulloblastoma [ICD-11: 2A00.11] Phase 2

D02ICI	TTDDRUID	D02ICI
D02ICI	DRUGNAME	VIT-45
D02ICI	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved

D01PAR	TTDDRUID	D01PAR
D01PAR	DRUGNAME	Vitamin
D01PAR	INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved

D0S7WX	TTDDRUID	D0S7WX
D0S7WX	DRUGNAME	Vitamin A
D0S7WX	INDICATI	Kinetoplastids [ICD-11: 1F61-1G2Z] Investigative
D0S7WX	INDICATI	Night blindness [ICD-11: 9D45] Approved

D06PQT	TTDDRUID	D06PQT
D06PQT	DRUGNAME	Vitamin B1
D06PQT	INDICATI	Vitamin B1 deficiency [ICD-11: 5B5A] Approved

D0N0ES	TTDDRUID	D0N0ES
D0N0ES	DRUGNAME	Vitamin B3
D0N0ES	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Approved

D07MUN	TTDDRUID	D07MUN
D07MUN	DRUGNAME	Vitamin B6
D07MUN	INDICATI	Vitamin B6 deficiency [ICD-11: 5B5D] Approved

D07AHW	TTDDRUID	D07AHW
D07AHW	DRUGNAME	Vitamin C
D07AHW	INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2
D07AHW	INDICATI	Vitamin C deficiency [ICD-11: 5B56] Approved

D02TQO	TTDDRUID	D02TQO
D02TQO	DRUGNAME	Vitamin E
D02TQO	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D07GNR	TTDDRUID	D07GNR
D07GNR	DRUGNAME	Vivaglobin
D07GNR	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Approved

D04ZTY	TTDDRUID	D04ZTY
D04ZTY	DRUGNAME	Voglibose
D04ZTY	INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved

D0XE8H	TTDDRUID	D0XE8H
D0XE8H	DRUGNAME	Von willebrand factor
D0XE8H	INDICATI	Hemophilia [ICD-11: 3B10.0] Approved

D0VA0I	TTDDRUID	D0VA0I
D0VA0I	DRUGNAME	Vorapaxar
D0VA0I	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D0N3VR	TTDDRUID	D0N3VR
D0N3VR	DRUGNAME	Voriconazole
D0N3VR	INDICATI	Invasive aspergillosis [ICD-11: 1F20.0] Approved

D0E7PQ	TTDDRUID	D0E7PQ
D0E7PQ	DRUGNAME	Vorinostat
D0E7PQ	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved

D03WEX	TTDDRUID	D03WEX
D03WEX	DRUGNAME	Vortioxetine
D03WEX	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
D03WEX	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3

D01CHI	TTDDRUID	D01CHI
D01CHI	DRUGNAME	VR315
D01CHI	INDICATI	Asthma [ICD-11: CA23] Approved

D09NTM	TTDDRUID	D09NTM
D09NTM	DRUGNAME	VR506
D09NTM	INDICATI	Asthma [ICD-11: CA23] Approved

D07BXQ	TTDDRUID	D07BXQ
D07BXQ	DRUGNAME	VR632
D07BXQ	INDICATI	Asthma [ICD-11: CA23] Approved

D0L3MP	TTDDRUID	D0L3MP
D0L3MP	DRUGNAME	VRX496
D0L3MP	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Approved
D0L3MP	INDICATI	Coronavirus infection [ICD-11: 1D92] Approved

D0E3OF	TTDDRUID	D0E3OF
D0E3OF	DRUGNAME	Warfarin
D0E3OF	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved

D0A4SU	TTDDRUID	D0A4SU
D0A4SU	DRUGNAME	WinRho SDF
D0A4SU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved

D0H1YQ	TTDDRUID	D0H1YQ
D0H1YQ	DRUGNAME	Xatral
D0H1YQ	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D02AEW	TTDDRUID	D02AEW
D02AEW	DRUGNAME	Xenon Xe-127
D02AEW	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D0E1OJ	TTDDRUID	D0E1OJ
D0E1OJ	DRUGNAME	Xenon Xe-133
D0E1OJ	INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved

D0B5LF	TTDDRUID	D0B5LF
D0B5LF	DRUGNAME	Ximelegatran
D0B5LF	INDICATI	Asthma [ICD-11: CA23] Terminated
D0B5LF	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved

D0H2ZW	TTDDRUID	D0H2ZW
D0H2ZW	DRUGNAME	Xipamide
D0H2ZW	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0N1NE	TTDDRUID	D0N1NE
D0N1NE	DRUGNAME	Xp-828l
D0N1NE	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D07HZY	TTDDRUID	D07HZY
D07HZY	DRUGNAME	Xylose
D07HZY	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved

D00SVU	TTDDRUID	D00SVU
D00SVU	DRUGNAME	Y-25130
D00SVU	INDICATI	Nausea and vomiting [ICD-11: MD90] Approved

D00TCM	TTDDRUID	D00TCM
D00TCM	DRUGNAME	Yellow fever vaccine
D00TCM	INDICATI	Yellow fever virus infection [ICD-11: 1D47] Approved

D00WVW	TTDDRUID	D00WVW
D00WVW	DRUGNAME	YM443
D00WVW	INDICATI	Functional dyspepsia [ICD-11: DD90.3] Approved

D0SZ6E	TTDDRUID	D0SZ6E
D0SZ6E	DRUGNAME	YN-968D1
D0SZ6E	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved

D0H4JM	TTDDRUID	D0H4JM
D0H4JM	DRUGNAME	Yohimbine
D0H4JM	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved

D0C0YG	TTDDRUID	D0C0YG
D0C0YG	DRUGNAME	Youerjian
D0C0YG	INDICATI	Hantavirus infection [ICD-11: 1D62] Approved

D0P9JE	TTDDRUID	D0P9JE
D0P9JE	DRUGNAME	Yuganning
D0P9JE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved

D0QB7K	TTDDRUID	D0QB7K
D0QB7K	DRUGNAME	Yunaoning
D0QB7K	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved

D05DVP	TTDDRUID	D05DVP
D05DVP	DRUGNAME	Zafirlukast
D05DVP	INDICATI	Asthma [ICD-11: CA23] Approved

D0Z9QR	TTDDRUID	D0Z9QR
D0Z9QR	DRUGNAME	Zalcitabine
D0Z9QR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D09DWL	TTDDRUID	D09DWL
D09DWL	DRUGNAME	Zaleplon
D09DWL	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D00NPP	TTDDRUID	D00NPP
D00NPP	DRUGNAME	Zanamivir
D00NPP	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
D00NPP	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D01NLB	TTDDRUID	D01NLB
D01NLB	DRUGNAME	Ziconotide
D01NLB	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D01NLB	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 1/2

D01XYJ	TTDDRUID	D01XYJ
D01XYJ	DRUGNAME	Zidovudine
D01XYJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D01XYJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
D01XYJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D09JUG	TTDDRUID	D09JUG
D09JUG	DRUGNAME	Zileuton
D09JUG	INDICATI	Asthma [ICD-11: CA23] Approved

D0Z4NI	TTDDRUID	D0Z4NI
D0Z4NI	DRUGNAME	Zinc Acetate
D0Z4NI	INDICATI	Wilson disease [ICD-11: 5C64.00] Approved

D05ELV	TTDDRUID	D05ELV
D05ELV	DRUGNAME	Zinc Chloride
D05ELV	INDICATI	Common cold [ICD-11: CA00] Approved

D0K0DY	TTDDRUID	D0K0DY
D0K0DY	DRUGNAME	Zinc hyaluronate
D0K0DY	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D0K8AA	TTDDRUID	D0K8AA
D0K8AA	DRUGNAME	Zinc salts
D0K8AA	INDICATI	Arthritis [ICD-11: FA20] Approved

D07CEI	TTDDRUID	D07CEI
D07CEI	DRUGNAME	Zinc Sulfate
D07CEI	INDICATI	Zinc deficiency [ICD-11: 5B5K.2] Approved

D0G7SR	TTDDRUID	D0G7SR
D0G7SR	DRUGNAME	Zinforo
D0G7SR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0Z4PE	TTDDRUID	D0Z4PE
D0Z4PE	DRUGNAME	Zinostatin stimalamer
D0Z4PE	INDICATI	Brain cancer [ICD-11: 2A00] Approved

D0X9MP	TTDDRUID	D0X9MP
D0X9MP	DRUGNAME	Zipeprol
D0X9MP	INDICATI	Cough [ICD-11: MD12] Approved

D0R1JV	TTDDRUID	D0R1JV
D0R1JV	DRUGNAME	Ziprasidone
D0R1JV	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D03HJK	TTDDRUID	D03HJK
D03HJK	DRUGNAME	Zithromax
D03HJK	INDICATI	Syphilis infection [ICD-11: 1A6Z] Approved

D0T8ZA	TTDDRUID	D0T8ZA
D0T8ZA	DRUGNAME	Zohydro ER
D0T8ZA	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0VM2L	TTDDRUID	D0VM2L
D0VM2L	DRUGNAME	Zoledronate
D0VM2L	INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved

D0NG7O	TTDDRUID	D0NG7O
D0NG7O	DRUGNAME	Zolmitriptan
D0NG7O	INDICATI	Migraine [ICD-11: 8A80] Approved

D0T1WN	TTDDRUID	D0T1WN
D0T1WN	DRUGNAME	Zolpidem
D0T1WN	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
D0T1WN	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 1

D09ZIS	TTDDRUID	D09ZIS
D09ZIS	DRUGNAME	Zonisamide
D09ZIS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved

D0ZB7K	TTDDRUID	D0ZB7K
D0ZB7K	DRUGNAME	Zopiclone
D0ZB7K	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D0B8WS	TTDDRUID	D0B8WS
D0B8WS	DRUGNAME	Zostavax
D0B8WS	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved

D06SBO	TTDDRUID	D06SBO
D06SBO	DRUGNAME	Zoster
D06SBO	INDICATI	Herpes zoster [ICD-11: 1E91] Approved

D09WKH	TTDDRUID	D09WKH
D09WKH	DRUGNAME	Zosyn/Tazocin
D09WKH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0V7WS	TTDDRUID	D0V7WS
D0V7WS	DRUGNAME	Zotarolimus
D0V7WS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D0T6QX	TTDDRUID	D0T6QX
D0T6QX	DRUGNAME	ZOTEPINE
D0T6QX	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved

D03LGG	TTDDRUID	D03LGG
D03LGG	DRUGNAME	Zucapsacin
D03LGG	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D0I8LU	TTDDRUID	D0I8LU
D0I8LU	DRUGNAME	Zuclopenthixol
D0I8LU	INDICATI	Schizophrenia [ICD-11: 6A20] Approved

D09RBQ	TTDDRUID	D09RBQ
D09RBQ	DRUGNAME	Zutectra
D09RBQ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved

D01KCE	TTDDRUID	D01KCE
D01KCE	DRUGNAME	BLB-750
D01KCE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered

D04ZXP	TTDDRUID	D04ZXP
D04ZXP	DRUGNAME	Dicycloplatin
D04ZXP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Registered

D0R6IM	TTDDRUID	D0R6IM
D0R6IM	DRUGNAME	Empagliflozin/metformin
D0R6IM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Registered

D02XGF	TTDDRUID	D02XGF
D02XGF	DRUGNAME	H5N1 influenza vaccine
D02XGF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered

D00SQN	TTDDRUID	D00SQN
D00SQN	DRUGNAME	HBI-8000
D00SQN	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D00SQN	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2
D00SQN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered
D00SQN	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
D00SQN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Registered

D06WRJ	TTDDRUID	D06WRJ
D06WRJ	DRUGNAME	Icotinib hydrochloride
D06WRJ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered

D0SX4D	TTDDRUID	D0SX4D
D0SX4D	DRUGNAME	KD-295
D0SX4D	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Registered

D0Q2ZV	TTDDRUID	D0Q2ZV
D0Q2ZV	DRUGNAME	OLANEXIDINE HYDROCHLORIDE
D0Q2ZV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Registered

D0SR6S	TTDDRUID	D0SR6S
D0SR6S	DRUGNAME	PandyFlu
D0SR6S	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered

D0QL9W	TTDDRUID	D0QL9W
D0QL9W	DRUGNAME	Quadrivalent pediatric combination vaccine
D0QL9W	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Registered

D0Y4LX	TTDDRUID	D0Y4LX
D0Y4LX	DRUGNAME	T-705
D0Y4LX	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered

D04DXA	TTDDRUID	D04DXA
D04DXA	DRUGNAME	Tofogliflozin
D04DXA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Registered

D0F4CG	TTDDRUID	D0F4CG
D0F4CG	DRUGNAME	18F-AV-1451
D0F4CG	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 4

D01KYA	TTDDRUID	D01KYA
D01KYA	DRUGNAME	6-mercaptopurine (oral delayed-release, Crohn's disease), Teva
D01KYA	INDICATI	Crohn disease [ICD-11: DD70] Phase 4

D0Q1IT	TTDDRUID	D0Q1IT
D0Q1IT	DRUGNAME	Aclidinium/formoterol
D0Q1IT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D0U3YU	TTDDRUID	D0U3YU
D0U3YU	DRUGNAME	Ademetionine
D0U3YU	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 4

D0Y5LR	TTDDRUID	D0Y5LR
D0Y5LR	DRUGNAME	AEN-100
D0Y5LR	INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 4

D0O7IZ	TTDDRUID	D0O7IZ
D0O7IZ	DRUGNAME	Anti-MIF antibodies
D0O7IZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 4

D05HUQ	TTDDRUID	D05HUQ
D05HUQ	DRUGNAME	BIOVANCE
D05HUQ	INDICATI	Wound healing [ICD-11: EL8Y] Phase 4

D05LCN	TTDDRUID	D05LCN
D05LCN	DRUGNAME	BMP-7 bone morphogenetic protein
D05LCN	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 4

D03IUD	TTDDRUID	D03IUD
D03IUD	DRUGNAME	Ceftolozane sulfate
D03IUD	INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 4

D0N6FI	TTDDRUID	D0N6FI
D0N6FI	DRUGNAME	ChimeriVax-JE
D0N6FI	INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Phase 4

D05FNF	TTDDRUID	D05FNF
D05FNF	DRUGNAME	Ciclosporin intravenous
D05FNF	INDICATI	Brain injury [ICD-11: NA07.Z] Phase 4

D01ZUA	TTDDRUID	D01ZUA
D01ZUA	DRUGNAME	Coenzyme Q10
D01ZUA	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 4

D04FIP	TTDDRUID	D04FIP
D04FIP	DRUGNAME	Cyclodextrin
D04FIP	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4

D0H5LK	TTDDRUID	D0H5LK
D0H5LK	DRUGNAME	Dapoxetine
D0H5LK	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 4

D0T6RC	TTDDRUID	D0T6RC
D0T6RC	DRUGNAME	Dihydrocodeine
D0T6RC	INDICATI	Cancer related pain [ICD-11: MG30] Phase 4

D04DJN	TTDDRUID	D04DJN
D04DJN	DRUGNAME	Dihydrotestosterone
D04DJN	INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 4

D08YVZ	TTDDRUID	D08YVZ
D08YVZ	DRUGNAME	Flavonoids
D08YVZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 4

D0X3AK	TTDDRUID	D0X3AK
D0X3AK	DRUGNAME	GL-438
D0X3AK	INDICATI	Hepatitis E virus infection [ICD-11: 1E50.4] Phase 4

D0LJ5Q	TTDDRUID	D0LJ5Q
D0LJ5Q	DRUGNAME	GSK2340274A
D0LJ5Q	INDICATI	Influenza A virus H1N1/H5N1 infection [ICD-11: 1E30] Phase 4

D0E8IT	TTDDRUID	D0E8IT
D0E8IT	DRUGNAME	HBVax
D0E8IT	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 4

D0B0AX	TTDDRUID	D0B0AX
D0B0AX	DRUGNAME	HIF-1alpha
D0B0AX	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 4

D0D6GT	TTDDRUID	D0D6GT
D0D6GT	DRUGNAME	Iota-carrageenan
D0D6GT	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 4

D0WL5V	TTDDRUID	D0WL5V
D0WL5V	DRUGNAME	LAROPIPRANT
D0WL5V	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3

D0LJ8C	TTDDRUID	D0LJ8C
D0LJ8C	DRUGNAME	LCZ696
D0LJ8C	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D0FW2A	TTDDRUID	D0FW2A
D0FW2A	DRUGNAME	LEO 80185
D0FW2A	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D0FW2A	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 4

D0I2WV	TTDDRUID	D0I2WV
D0I2WV	DRUGNAME	Levamlodipine
D0I2WV	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D06PTA	TTDDRUID	D06PTA
D06PTA	DRUGNAME	Levosalbutamol/ipratropium
D06PTA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D02DPP	TTDDRUID	D02DPP
D02DPP	DRUGNAME	MTHF
D02DPP	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 4

D03SHD	TTDDRUID	D03SHD
D03SHD	DRUGNAME	Myo-inositol
D03SHD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0FC1J	TTDDRUID	D0FC1J
D0FC1J	DRUGNAME	Nifurtimox
D0FC1J	INDICATI	Chagas disease [ICD-11: 1F53] Phase 3
D0FC1J	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 4

D0S0ST	TTDDRUID	D0S0ST
D0S0ST	DRUGNAME	NPS-31807
D0S0ST	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 4

D0C7AA	TTDDRUID	D0C7AA
D0C7AA	DRUGNAME	Ozagrel
D0C7AA	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 4

D0O4YY	TTDDRUID	D0O4YY
D0O4YY	DRUGNAME	Paliperidone palmitate IM long acting injectable
D0O4YY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 4

D06GYJ	TTDDRUID	D06GYJ
D06GYJ	DRUGNAME	PD-01
D06GYJ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 4

D07HOF	TTDDRUID	D07HOF
D07HOF	DRUGNAME	Picibanil
D07HOF	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 4

D0B4RU	TTDDRUID	D0B4RU
D0B4RU	DRUGNAME	Pregnenolone
D0B4RU	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 4

D0FT4R	TTDDRUID	D0FT4R
D0FT4R	DRUGNAME	Sivelestat
D0FT4R	INDICATI	Anterior uveitis [ICD-11: 9A96] Application submitted
D0FT4R	INDICATI	Axial spondyloarthritis [ICD-11: FA92.0] Application submitted
D0FT4R	INDICATI	Crohn disease [ICD-11: DD70] Phase 3
D0FT4R	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D0FT4R	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
D0FT4R	INDICATI	Pyoderma gangrenosum [ICD-11: EB21] Phase 3
D0FT4R	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
D0FT4R	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D05QHL	TTDDRUID	D05QHL
D05QHL	DRUGNAME	Sivelestat sodium hydrate
D05QHL	INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 4
D05QHL	INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2

D0Q9PT	TTDDRUID	D0Q9PT
D0Q9PT	DRUGNAME	Synflorix
D0Q9PT	INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 4

D05GGD	TTDDRUID	D05GGD
D05GGD	DRUGNAME	SYNVISC-ONE
D05GGD	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 4

D04VOZ	TTDDRUID	D04VOZ
D04VOZ	DRUGNAME	TKM-ApoB
D04VOZ	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4

D0U2CV	TTDDRUID	D0U2CV
D0U2CV	DRUGNAME	Trapidil
D0U2CV	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0ER2C	TTDDRUID	D0ER2C
D0ER2C	DRUGNAME	Triptoreline
D0ER2C	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 4

D07NLI	TTDDRUID	D07NLI
D07NLI	DRUGNAME	Vismed
D07NLI	INDICATI	Eye disorder [ICD-11: 9A01-9A0Z] Phase 4

D0Y4DY	TTDDRUID	D0Y4DY
D0Y4DY	DRUGNAME	Xylometazoline
D0Y4DY	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 4

D0T3FN	TTDDRUID	D0T3FN
D0T3FN	DRUGNAME	RLX030
D0T3FN	INDICATI	Acute heart failure [ICD-11: BD10-BD13] Approval submitted

D0G9FL	TTDDRUID	D0G9FL
D0G9FL	DRUGNAME	CT-064
D0G9FL	INDICATI	Osteoporosis [ICD-11: FB83.0] NDA filed

D01BOJ	TTDDRUID	D01BOJ
D01BOJ	DRUGNAME	I.V. carbamazepine
D01BOJ	INDICATI	Type-1 diabetes [ICD-11: 5A10] NDA filed

D0A5DJ	TTDDRUID	D0A5DJ
D0A5DJ	DRUGNAME	Pancrecarb
D0A5DJ	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] NDA filed

D09RJA	TTDDRUID	D09RJA
D09RJA	DRUGNAME	RELVARTM or BREOTM ELLIPTATM
D09RJA	INDICATI	Asthma [ICD-11: CA23] NDA filed

D0IJ0U	TTDDRUID	D0IJ0U
D0IJ0U	DRUGNAME	TS-071
D0IJ0U	INDICATI	Type-2 diabetes [ICD-11: 5A11] NDA filed

D02DJF	TTDDRUID	D02DJF
D02DJF	DRUGNAME	BAX-111
D02DJF	INDICATI	Pain [ICD-11: MG30-MG3Z] Preregistration

D0A5SJ	TTDDRUID	D0A5SJ
D0A5SJ	DRUGNAME	B-cell lymphoma vaccine
D0A5SJ	INDICATI	Follicular lymphoma [ICD-11: 2A80] Preregistration

D0BU5G	TTDDRUID	D0BU5G
D0BU5G	DRUGNAME	BiovaxlD
D0BU5G	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Preregistration

D01VNT	TTDDRUID	D01VNT
D01VNT	DRUGNAME	COL-003
D01VNT	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Preregistration

D03EWD	TTDDRUID	D03EWD
D03EWD	DRUGNAME	CTAP101 Capsules
D03EWD	INDICATI	Kidney disease [ICD-11: GC2Z] Preregistration

D0L4WV	TTDDRUID	D0L4WV
D0L4WV	DRUGNAME	Grass pollen extract
D0L4WV	INDICATI	Allergy [ICD-11: 4A80-4A85] Preregistration

D0F4QV	TTDDRUID	D0F4QV
D0F4QV	DRUGNAME	GSK2696273
D0F4QV	INDICATI	Chronic pain [ICD-11: MG30] Preregistration
D0F4QV	INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 2/3

D0FC7P	TTDDRUID	D0FC7P
D0FC7P	DRUGNAME	Hepatitis B vaccine 1018-ISS conjugate
D0FC7P	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Preregistration

D01KPS	TTDDRUID	D01KPS
D01KPS	DRUGNAME	IP-112
D01KPS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preregistration

D02MBM	TTDDRUID	D02MBM
D02MBM	DRUGNAME	Mosquirix malaria recombinant vaccine
D02MBM	INDICATI	Malaria [ICD-11: 1F40-1F45] Preregistration
D02MBM	INDICATI	Parkinson disease [ICD-11: 8A00.0] Preregistration

D01FWR	TTDDRUID	D01FWR
D01FWR	DRUGNAME	MPL-containing Pollinex allergy desensitization vaccine
D01FWR	INDICATI	Melanoma [ICD-11: 2C30] Preregistration

D08KNK	TTDDRUID	D08KNK
D08KNK	DRUGNAME	MPL-containing Pollinex allergy desensitization vaccine
D08KNK	INDICATI	Allergy [ICD-11: 4A80-4A85] Preregistration

D0FP8S	TTDDRUID	D0FP8S
D0FP8S	DRUGNAME	Neugranin
D0FP8S	INDICATI	Neutropenia [ICD-11: 4B00.0] Preregistration

D0UR1Z	TTDDRUID	D0UR1Z
D0UR1Z	DRUGNAME	OncoVAX
D0UR1Z	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0UR1Z	INDICATI	Melanoma [ICD-11: 2C30] Preregistration

D0B0BE	TTDDRUID	D0B0BE
D0B0BE	DRUGNAME	PR-5-I
D0B0BE	INDICATI	Fertility problem [ICD-11: 5A61] Preregistration

D00TIG	TTDDRUID	D00TIG
D00TIG	DRUGNAME	RG3806
D00TIG	INDICATI	Acromegaly [ICD-11: 5A60.0] Preregistration

D0ZL1T	TTDDRUID	D0ZL1T
D0ZL1T	DRUGNAME	SK-NBP601
D0ZL1T	INDICATI	Hemophilia [ICD-11: 3B10.0] Preregistration

D0V6RL	TTDDRUID	D0V6RL
D0V6RL	DRUGNAME	Stempeucel
D0V6RL	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preregistration

D08AMJ	TTDDRUID	D08AMJ
D08AMJ	DRUGNAME	TK-DLI
D08AMJ	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Preregistration

D0C5DC	TTDDRUID	D0C5DC
D0C5DC	DRUGNAME	TT-063
D0C5DC	INDICATI	Myalgia [ICD-11: FB56.2] Preregistration
D0C5DC	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Preregistration
D0C5DC	INDICATI	Scapulohumeral periarthritis [ICD-11: FB53] Preregistration

D07JEW	TTDDRUID	D07JEW
D07JEW	DRUGNAME	Human coagulation factor X
D07JEW	INDICATI	Renal cell carcinoma [ICD-11: 2C90] BLA submitted

D0B4VH	TTDDRUID	D0B4VH
D0B4VH	DRUGNAME	CDR-134F194
D0B4VH	INDICATI	Diabetic complication [ICD-11: 5A2Y] IND submitted

D07CIN	TTDDRUID	D07CIN
D07CIN	DRUGNAME	(-)-Phenserine
D07CIN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D08CEA	TTDDRUID	D08CEA
D08CEA	DRUGNAME	122-0551 foam
D08CEA	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D0B4OF	TTDDRUID	D0B4OF
D0B4OF	DRUGNAME	123I-iometopane
D0B4OF	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D07PTH	TTDDRUID	D07PTH
D07PTH	DRUGNAME	13-cis-retinoic acid, UCSD
D07PTH	INDICATI	Glioma [ICD-11: 2A00.0] Phase 3

D02ZHW	TTDDRUID	D02ZHW
D02ZHW	DRUGNAME	177Lu-DOTA-octreotate (neuroendocrine tumors), Advanced Accelerator Applications
D02ZHW	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D02ZHW	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3

D0M5VV	TTDDRUID	D0M5VV
D0M5VV	DRUGNAME	177Lu-DOTATATE
D0M5VV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D01MXK	TTDDRUID	D01MXK
D01MXK	DRUGNAME	2PX
D01MXK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0QR5G	TTDDRUID	D0QR5G
D0QR5G	DRUGNAME	5-methoxypsoralen
D0QR5G	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D00VQT	TTDDRUID	D00VQT
D00VQT	DRUGNAME	99mTc-EC-DG
D00VQT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D04BLE	TTDDRUID	D04BLE
D04BLE	DRUGNAME	A-3309
D04BLE	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3

D01SRB	TTDDRUID	D01SRB
D01SRB	DRUGNAME	AAV2-hRPE65v2
D01SRB	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 3

D04HQJ	TTDDRUID	D04HQJ
D04HQJ	DRUGNAME	AB-103
D04HQJ	INDICATI	Necrotizing soft tissue infection [ICD-11: 1B71] Phase 3

D00MLX	TTDDRUID	D00MLX
D00MLX	DRUGNAME	Abacavir/dolutegravir/lamivudine
D00MLX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D05LPP	TTDDRUID	D05LPP
D05LPP	DRUGNAME	ABH001
D05LPP	INDICATI	Liver cancer [ICD-11: 2C12] Phase 3

D0LB3Z	TTDDRUID	D0LB3Z
D0LB3Z	DRUGNAME	ABL 001
D0LB3Z	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 3
D0LB3Z	INDICATI	Promyelocytic leukaemia [ICD-11: 2A82.1] Phase 2
D0LB3Z	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D06FMO	TTDDRUID	D06FMO
D06FMO	DRUGNAME	ABP 501
D06FMO	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
D06FMO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0E8NJ	TTDDRUID	D0E8NJ
D0E8NJ	DRUGNAME	ABP 798
D0E8NJ	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
D0E8NJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
D0E8NJ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0WZ0X	TTDDRUID	D0WZ0X
D0WZ0X	DRUGNAME	ABP 980
D0WZ0X	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0WZ0X	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D0E2RD	TTDDRUID	D0E2RD
D0E2RD	DRUGNAME	Abraxane
D0E2RD	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D00NPO	TTDDRUID	D00NPO
D00NPO	DRUGNAME	ABT-199/GDC-0199
D00NPO	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3

D0LF5Q	TTDDRUID	D0LF5Q
D0LF5Q	DRUGNAME	ABT-267
D0LF5Q	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0V9BU	TTDDRUID	D0V9BU
D0V9BU	DRUGNAME	ABT-492
D0V9BU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D07JAG	TTDDRUID	D07JAG
D07JAG	DRUGNAME	ABT-494
D07JAG	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D07JAG	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D07JAG	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
D07JAG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D07JAG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
D07JAG	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D08PXR	TTDDRUID	D08PXR
D08PXR	DRUGNAME	ABT-761
D08PXR	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0M9QZ	TTDDRUID	D0M9QZ
D0M9QZ	DRUGNAME	ABT-869
D0M9QZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0H1TL	TTDDRUID	D0H1TL
D0H1TL	DRUGNAME	ABT-874
D0H1TL	INDICATI	Crohn disease [ICD-11: DD70] Discontinued in Phase 2
D0H1TL	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D0H1TL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0Q7UD	TTDDRUID	D0Q7UD
D0Q7UD	DRUGNAME	ABT-888
D0Q7UD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0Q7UD	INDICATI	Epithelial ovarian cancer [ICD-11: 2B5D] Phase 3
D0Q7UD	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0Q7UD	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0Q7UD	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0Y1RN	TTDDRUID	D0Y1RN
D0Y1RN	DRUGNAME	AC-1204
D0Y1RN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D0Y1RN	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2/3

D01JFM	TTDDRUID	D01JFM
D01JFM	DRUGNAME	AC-170
D01JFM	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3

D07KYT	TTDDRUID	D07KYT
D07KYT	DRUGNAME	AC220
D07KYT	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D07KYT	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D0R3MT	TTDDRUID	D0R3MT
D0R3MT	DRUGNAME	Acadesine
D0R3MT	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D02QQV	TTDDRUID	D02QQV
D02QQV	DRUGNAME	ACAM-1000
D02QQV	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3

D07UQQ	TTDDRUID	D07UQQ
D07UQQ	DRUGNAME	ACE-536
D07UQQ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
D07UQQ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
D07UQQ	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2

D0X9KB	TTDDRUID	D0X9KB
D0X9KB	DRUGNAME	ACER-002
D0X9KB	INDICATI	Ehlers-Danlos syndrome [ICD-11: LD28.1] Phase 3

D0XB0T	TTDDRUID	D0XB0T
D0XB0T	DRUGNAME	Acolbifene
D0XB0T	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D01CPZ	TTDDRUID	D01CPZ
D01CPZ	DRUGNAME	ACP-196
D01CPZ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3

D04WBT	TTDDRUID	D04WBT
D04WBT	DRUGNAME	Act1
D04WBT	INDICATI	Wound healing [ICD-11: EL8Y] Phase 3

D0I1KL	TTDDRUID	D0I1KL
D0I1KL	DRUGNAME	ACT-2
D0I1KL	INDICATI	Wound healing [ICD-11: EL8Y] Phase 3

D0GW1P	TTDDRUID	D0GW1P
D0GW1P	DRUGNAME	Actacel
D0GW1P	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 3

D0U9EN	TTDDRUID	D0U9EN
D0U9EN	DRUGNAME	Actimmune
D0U9EN	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 3

D04JCF	TTDDRUID	D04JCF
D04JCF	DRUGNAME	Active specific immunotherapy
D04JCF	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D0ER5F	TTDDRUID	D0ER5F
D0ER5F	DRUGNAME	Ad5FGF-4
D0ER5F	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3

D09KRV	TTDDRUID	D09KRV
D09KRV	DRUGNAME	Adhexil
D09KRV	INDICATI	Injury [ICD-11: NA00-ND5Z] Phase 3

D05QKZ	TTDDRUID	D05QKZ
D05QKZ	DRUGNAME	Adipose-derived regenerative cell therapy
D05QKZ	INDICATI	Chronic myocardial ischemia [ICD-11: BA6Z] Phase 3

D08MCS	TTDDRUID	D08MCS
D08MCS	DRUGNAME	ADS-5102
D08MCS	INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 3

D0GW6K	TTDDRUID	D0GW6K
D0GW6K	DRUGNAME	ADX N05
D0GW6K	INDICATI	Excessive daytime sleepiness [ICD-11: MG42] Phase 2
D0GW6K	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3

D02HBB	TTDDRUID	D02HBB
D02HBB	DRUGNAME	AEZS-108
D02HBB	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3

D0H4YL	TTDDRUID	D0H4YL
D0H4YL	DRUGNAME	Afluria Quadrivalent
D0H4YL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0K7FT	TTDDRUID	D0K7FT
D0K7FT	DRUGNAME	AG-221
D0K7FT	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 3
D0K7FT	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0X1VJ	TTDDRUID	D0X1VJ
D0X1VJ	DRUGNAME	AGI-1067
D0X1VJ	INDICATI	Artery stenosis [ICD-11: BD52] Phase 3

D0K6PP	TTDDRUID	D0K6PP
D0K6PP	DRUGNAME	AG-NPP709
D0K6PP	INDICATI	Bronchitis [ICD-11: CA20] Phase 3

D0E6UU	TTDDRUID	D0E6UU
D0E6UU	DRUGNAME	AG-SCT101
D0E6UU	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0V3ZN	TTDDRUID	D0V3ZN
D0V3ZN	DRUGNAME	AG-SPT201
D0V3ZN	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D06BGS	TTDDRUID	D06BGS
D06BGS	DRUGNAME	AIDSVAX
D06BGS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0C6ND	TTDDRUID	D0C6ND
D0C6ND	DRUGNAME	AIR-insulin
D0C6ND	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0M1WU	TTDDRUID	D0M1WU
D0M1WU	DRUGNAME	AJM-300
D0M1WU	INDICATI	Crohn disease [ICD-11: DD70] Phase 3
D0M1WU	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D0H1FN	TTDDRUID	D0H1FN
D0H1FN	DRUGNAME	AL-02
D0H1FN	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3

D0G2CG	TTDDRUID	D0G2CG
D0G2CG	DRUGNAME	AL3818
D0G2CG	INDICATI	Alveolar soft part sarcoma [ICD-11: 2A60-2C35] Phase 3
D0G2CG	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
D0G2CG	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1/2
D0G2CG	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1/2
D0G2CG	INDICATI	Leiomyosarcoma [ICD-11: 2B58] Phase 3
D0G2CG	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D0G2CG	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1/2
D0G2CG	INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 3

D0O5XQ	TTDDRUID	D0O5XQ
D0O5XQ	DRUGNAME	AL-60371
D0O5XQ	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D00TJX	TTDDRUID	D00TJX
D00TJX	DRUGNAME	Albinterferon alfa-2b
D00TJX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0XN5L	TTDDRUID	D0XN5L
D0XN5L	DRUGNAME	Albutropin
D0XN5L	INDICATI	Growth failure [ICD-11: LD2F.1Y] Phase 3

D0RC2V	TTDDRUID	D0RC2V
D0RC2V	DRUGNAME	Albuvirtide
D0RC2V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0C3CZ	TTDDRUID	D0C3CZ
D0C3CZ	DRUGNAME	Aldoxorubicin
D0C3CZ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0C3CZ	INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2
D0C3CZ	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0C3CZ	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 3

D0G8UL	TTDDRUID	D0G8UL
D0G8UL	DRUGNAME	Alferminogene tadenovec
D0G8UL	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
D0G8UL	INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 3

D0O9UZ	TTDDRUID	D0O9UZ
D0O9UZ	DRUGNAME	Alfimeprase
D0O9UZ	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 3

D00HSK	TTDDRUID	D00HSK
D00HSK	DRUGNAME	Algenpantucel-L
D00HSK	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D05ZHA	TTDDRUID	D05ZHA
D05ZHA	DRUGNAME	Alilusem
D05ZHA	INDICATI	Diuretic vasodilator [ICD-11: BA00] Phase 3

D0CE0O	TTDDRUID	D0CE0O
D0CE0O	DRUGNAME	Alisporivir
D0CE0O	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3

D02DOZ	TTDDRUID	D02DOZ
D02DOZ	DRUGNAME	ALKS 3831
D02DOZ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0EO5G	TTDDRUID	D0EO5G
D0EO5G	DRUGNAME	ALKS 6428
D0EO5G	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 3

D0TD7J	TTDDRUID	D0TD7J
D0TD7J	DRUGNAME	ALKS 8700
D0TD7J	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D02LEO	TTDDRUID	D02LEO
D02LEO	DRUGNAME	Allergy immunotherapy tablet
D02LEO	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3

D02FID	TTDDRUID	D02FID
D02FID	DRUGNAME	ALN-TTR02
D02FID	INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
D02FID	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3

D0E9AF	TTDDRUID	D0E9AF
D0E9AF	DRUGNAME	ALN-TTRsc
D0E9AF	INDICATI	Cardiomyopathy [ICD-11: BC43] Phase 3

D03YZJ	TTDDRUID	D03YZJ
D03YZJ	DRUGNAME	ALO-02 Oxycodone- naltrexone core
D03YZJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0Y2SE	TTDDRUID	D0Y2SE
D0Y2SE	DRUGNAME	Alpha-glucosidase
D0Y2SE	INDICATI	Muscle disease [ICD-11: FB3Z] Phase 3

D0FL0R	TTDDRUID	D0FL0R
D0FL0R	DRUGNAME	ALS-L1023
D0FL0R	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D0I4XF	TTDDRUID	D0I4XF
D0I4XF	DRUGNAME	ALT 005
D0I4XF	INDICATI	Ophthalmic infection [ICD-11: 1F00.1] Phase 3

D0R4NZ	TTDDRUID	D0R4NZ
D0R4NZ	DRUGNAME	Alunbrigbrigatinib
D0R4NZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D08POF	TTDDRUID	D08POF
D08POF	DRUGNAME	ALX-0081
D08POF	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 2
D08POF	INDICATI	Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Phase 3

D0CH6B	TTDDRUID	D0CH6B
D0CH6B	DRUGNAME	ALZT-OP1
D0CH6B	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0Q8WX	TTDDRUID	D0Q8WX
D0Q8WX	DRUGNAME	AM-101
D0Q8WX	INDICATI	Tinnitus [ICD-11: MC41] Phase 3

D0N7WG	TTDDRUID	D0N7WG
D0N7WG	DRUGNAME	AM-111
D0N7WG	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 3

D0G6ZG	TTDDRUID	D0G6ZG
D0G6ZG	DRUGNAME	Amediplase
D0G6ZG	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 3
D0G6ZG	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3

D0OW2S	TTDDRUID	D0OW2S
D0OW2S	DRUGNAME	AMG 145
D0OW2S	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D0K8NR	TTDDRUID	D0K8NR
D0K8NR	DRUGNAME	AMG 386
D0K8NR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0K8NR	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
D0K8NR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0K8NR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
D0K8NR	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Preclinical

D07RDG	TTDDRUID	D07RDG
D07RDG	DRUGNAME	AMG 416
D07RDG	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3

D04PXS	TTDDRUID	D04PXS
D04PXS	DRUGNAME	Amitifadine
D04PXS	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D04PXS	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D0F1UZ	TTDDRUID	D0F1UZ
D0F1UZ	DRUGNAME	Amitriptyline+ketamine
D0F1UZ	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D0F1UZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
D0F1UZ	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2

D02NZO	TTDDRUID	D02NZO
D02NZO	DRUGNAME	Amlodipine/ irbesartan fixed-dose combination
D02NZO	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0SH2X	TTDDRUID	D0SH2X
D0SH2X	DRUGNAME	Amocarzine
D0SH2X	INDICATI	Helminth infection [ICD-11: 1F90.0] Phase 3

D0HR7P	TTDDRUID	D0HR7P
D0HR7P	DRUGNAME	Amonafide
D0HR7P	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0HR7P	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0HR7P	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0M5BI	TTDDRUID	D0M5BI
D0M5BI	DRUGNAME	Ampion
D0M5BI	INDICATI	Bronchiectasis [ICD-11: CA24] Phase 3

D04BEN	TTDDRUID	D04BEN
D04BEN	DRUGNAME	Amrubicin
D04BEN	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D01RNV	TTDDRUID	D01RNV
D01RNV	DRUGNAME	AMT-011
D01RNV	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 3

D0SM0W	TTDDRUID	D0SM0W
D0SM0W	DRUGNAME	AN2728
D0SM0W	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3

D07HLS	TTDDRUID	D07HLS
D07HLS	DRUGNAME	Anacetrapib
D07HLS	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 3
D07HLS	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0WM6I	TTDDRUID	D0WM6I
D0WM6I	DRUGNAME	Analatro
D0WM6I	INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 3

D03WAU	TTDDRUID	D03WAU
D03WAU	DRUGNAME	Anamorelin
D03WAU	INDICATI	Carbohydrate metabolism disorder [ICD-11: 5C51.Z] Phase 3

D09WZG	TTDDRUID	D09WZG
D09WZG	DRUGNAME	Anascorp
D09WZG	INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 3

D03QBY	TTDDRUID	D03QBY
D03QBY	DRUGNAME	Anavip
D03QBY	INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 3

D05BII	TTDDRUID	D05BII
D05BII	DRUGNAME	Ancrod
D05BII	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 3

D08PGC	TTDDRUID	D08PGC
D08PGC	DRUGNAME	Andolast
D08PGC	INDICATI	Rhinitis [ICD-11: FA20] Phase 3

D0MH8O	TTDDRUID	D0MH8O
D0MH8O	DRUGNAME	Angiotensin-(1-7)
D0MH8O	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
D0MH8O	INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 1
D0MH8O	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3

D04QXF	TTDDRUID	D04QXF
D04QXF	DRUGNAME	Anti-CD3 monoclonal antibody
D04QXF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3

D06ARV	TTDDRUID	D06ARV
D06ARV	DRUGNAME	Anti-IL-23
D06ARV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 3

D0WQ0R	TTDDRUID	D0WQ0R
D0WQ0R	DRUGNAME	Anti-T-lymphocyte immune globulin
D0WQ0R	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3

D01YKI	TTDDRUID	D01YKI
D01YKI	DRUGNAME	ANX-510
D01YKI	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D08KSU	TTDDRUID	D08KSU
D08KSU	DRUGNAME	AP12009
D08KSU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D0F1JD	TTDDRUID	D0F1JD
D0F1JD	DRUGNAME	Apabetalone
D0F1JD	INDICATI	Cardiac events [ICD-11: MC82] Phase 3
D0F1JD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3

D0QG9A	TTDDRUID	D0QG9A
D0QG9A	DRUGNAME	Apadenoson
D0QG9A	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3

D0FP0R	TTDDRUID	D0FP0R
D0FP0R	DRUGNAME	Apaziquone
D0FP0R	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
D0FP0R	INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3

D0S3QH	TTDDRUID	D0S3QH
D0S3QH	DRUGNAME	AP-CDLD
D0S3QH	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D01KYP	TTDDRUID	D01KYP
D01KYP	DRUGNAME	APL-130277
D01KYP	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3

D0P5LH	TTDDRUID	D0P5LH
D0P5LH	DRUGNAME	APL-2
D0P5LH	INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3

D08XLN	TTDDRUID	D08XLN
D08XLN	DRUGNAME	Apomorphine infusion
D08XLN	INDICATI	Idiopathic parkinson disease [ICD-11: 8A00.0Z] Phase 3

D02XMN	TTDDRUID	D02XMN
D02XMN	DRUGNAME	Application submitted
D02XMN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0V9QR	TTDDRUID	D0V9QR
D0V9QR	DRUGNAME	Apricitabine
D0V9QR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D05SNX	TTDDRUID	D05SNX
D05SNX	DRUGNAME	APT070
D05SNX	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Phase 3

D0LF1E	TTDDRUID	D0LF1E
D0LF1E	DRUGNAME	AQST-117
D0LF1E	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3

D0R8LQ	TTDDRUID	D0R8LQ
D0R8LQ	DRUGNAME	AQST-203
D0R8LQ	INDICATI	Acute repetitive seizure [ICD-11: 8A67] Phase 3

D0Z0NX	TTDDRUID	D0Z0NX
D0Z0NX	DRUGNAME	AR-06
D0Z0NX	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D0O8TJ	TTDDRUID	D0O8TJ
D0O8TJ	DRUGNAME	AR101
D0O8TJ	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3

D0Y8IE	TTDDRUID	D0Y8IE
D0Y8IE	DRUGNAME	AR-13165
D0Y8IE	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3

D07UXF	TTDDRUID	D07UXF
D07UXF	DRUGNAME	AR19
D07UXF	INDICATI	Mental disease [ICD-11: 6E8Z] Phase 3

D0K8GD	TTDDRUID	D0K8GD
D0K8GD	DRUGNAME	AR20
D0K8GD	INDICATI	Mental disease [ICD-11: 6E8Z] Phase 3

D0GX3L	TTDDRUID	D0GX3L
D0GX3L	DRUGNAME	Arbaclofen placarbil
D0GX3L	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D0GX3L	INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 3

D06GRK	TTDDRUID	D06GRK
D06GRK	DRUGNAME	ARC029
D06GRK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0LC3C	TTDDRUID	D0LC3C
D0LC3C	DRUGNAME	ARD-3150
D0LC3C	INDICATI	Bronchiectasis [ICD-11: CA24] Phase 3

D0T0NG	TTDDRUID	D0T0NG
D0T0NG	DRUGNAME	Arofylline
D0T0NG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D03WIC	TTDDRUID	D03WIC
D03WIC	DRUGNAME	Arzerraofatumumab
D03WIC	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D0D7UD	TTDDRUID	D0D7UD
D0D7UD	DRUGNAME	AS-013
D0D7UD	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3

D0HK3X	TTDDRUID	D0HK3X
D0HK3X	DRUGNAME	ASF-1057
D0HK3X	INDICATI	Erythema [ICD-11: ME64.0] Phase 3

D07TQN	TTDDRUID	D07TQN
D07TQN	DRUGNAME	Asimadoline
D07TQN	INDICATI	Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Phase 3
D07TQN	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D0S4WA	TTDDRUID	D0S4WA
D0S4WA	DRUGNAME	ASP0113
D0S4WA	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3

D06EIC	TTDDRUID	D06EIC
D06EIC	DRUGNAME	ASP-015K
D06EIC	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
D06EIC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0SO4Z	TTDDRUID	D0SO4Z
D0SO4Z	DRUGNAME	ASP1585
D0SO4Z	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3

D07FBM	TTDDRUID	D07FBM
D07FBM	DRUGNAME	ASP1941
D07FBM	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 3

D07PXQ	TTDDRUID	D07PXQ
D07PXQ	DRUGNAME	ASP-2151
D07PXQ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 3

D0C4QO	TTDDRUID	D0C4QO
D0C4QO	DRUGNAME	ASP2215
D0C4QO	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D01WYT	TTDDRUID	D01WYT
D01WYT	DRUGNAME	ASP3550
D01WYT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0ZM8F	TTDDRUID	D0ZM8F
D0ZM8F	DRUGNAME	ASP7374
D0ZM8F	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 3

D02XYA	TTDDRUID	D02XYA
D02XYA	DRUGNAME	Astuprotimut-R
D02XYA	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0NH3R	TTDDRUID	D0NH3R
D0NH3R	DRUGNAME	ASTX727
D0NH3R	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 3
D0NH3R	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3

D00GZY	TTDDRUID	D00GZY
D00GZY	DRUGNAME	AT1001
D00GZY	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3

D05PZB	TTDDRUID	D05PZB
D05PZB	DRUGNAME	AT9283
D05PZB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D04YWM	TTDDRUID	D04YWM
D04YWM	DRUGNAME	Atacicept
D04YWM	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
D04YWM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D04YWM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D04YWM	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D09IRQ	TTDDRUID	D09IRQ
D09IRQ	DRUGNAME	Ataluren
D09IRQ	INDICATI	Aniridia [ICD-11: LA11.3] Phase 1
D09IRQ	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 3
D09IRQ	INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 2
D09IRQ	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Application submitted
D09IRQ	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1
D09IRQ	INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2

D0B4ES	TTDDRUID	D0B4ES
D0B4ES	DRUGNAME	Atamestane-plus- Toremifene
D0B4ES	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0O0QB	TTDDRUID	D0O0QB
D0O0QB	DRUGNAME	ATG-Fresenius S
D0O0QB	INDICATI	Transplant rejection [ICD-11: NE84] Phase 3

D09TLJ	TTDDRUID	D09TLJ
D09TLJ	DRUGNAME	ATOFLUDING
D09TLJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0L4LX	TTDDRUID	D0L4LX
D0L4LX	DRUGNAME	Atorvastatin/ ezetimibe
D0L4LX	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D0Y6UU	TTDDRUID	D0Y6UU
D0Y6UU	DRUGNAME	Atrasentan
D0Y6UU	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
D0Y6UU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Withdrawn from market

D02PQB	TTDDRUID	D02PQB
D02PQB	DRUGNAME	ATX-101
D02PQB	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D0V6ZC	TTDDRUID	D0V6ZC
D0V6ZC	DRUGNAME	Aurograb
D0V6ZC	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 3

D0DP9O	TTDDRUID	D0DP9O
D0DP9O	DRUGNAME	Autologous chondrocyte implantation
D0DP9O	INDICATI	Cartilage disorder [ICD-11: FA34] Phase 3
D0DP9O	INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Phase 3

D0NI9X	TTDDRUID	D0NI9X
D0NI9X	DRUGNAME	Autologous stem cell therapy
D0NI9X	INDICATI	Ischemia [ICD-11: 8B10-8B11] Clinical trial
D0NI9X	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 3

D09NAF	TTDDRUID	D09NAF
D09NAF	DRUGNAME	AV 133
D09NAF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0C0NH	TTDDRUID	D0C0NH
D0C0NH	DRUGNAME	Avastin+/-Tarceva
D0C0NH	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
D0C0NH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0P9YQ	TTDDRUID	D0P9YQ
D0P9YQ	DRUGNAME	Avotermin
D0P9YQ	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 3

D0Z6IB	TTDDRUID	D0Z6IB
D0Z6IB	DRUGNAME	AVP-786
D0Z6IB	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D0Z6IB	INDICATI	Neurobehavioral disorder [ICD-11: 8A00-8A0Z] Phase 2
D0Z6IB	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
D0Z6IB	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0G8NK	TTDDRUID	D0G8NK
D0G8NK	DRUGNAME	Axanum
D0G8NK	INDICATI	Peptic ulcer [ICD-11: DA61] Phase 3

D0D8QV	TTDDRUID	D0D8QV
D0D8QV	DRUGNAME	AXS-02
D0D8QV	INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
D0D8QV	INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 3
D0D8QV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3

D0T5DP	TTDDRUID	D0T5DP
D0T5DP	DRUGNAME	AZD6244
D0T5DP	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0T5DP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0T5DP	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 3

D0RT2C	TTDDRUID	D0RT2C
D0RT2C	DRUGNAME	AZD9291
D0RT2C	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D02QBT	TTDDRUID	D02QBT
D02QBT	DRUGNAME	AZETIRELIN
D02QBT	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0J6II	TTDDRUID	D0J6II
D0J6II	DRUGNAME	Azimilide
D0J6II	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 3

D0S2BU	TTDDRUID	D0S2BU
D0S2BU	DRUGNAME	BA-058
D0S2BU	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 3

D07FKQ	TTDDRUID	D07FKQ
D07FKQ	DRUGNAME	BAF312
D07FKQ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D07FKQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D07FKQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D08HVG	TTDDRUID	D08HVG
D08HVG	DRUGNAME	BAL-8557
D08HVG	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 3

D0F3NH	TTDDRUID	D0F3NH
D0F3NH	DRUGNAME	Balaglitazone
D0F3NH	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D0A1MX	TTDDRUID	D0A1MX
D0A1MX	DRUGNAME	Bapineuzumab
D0A1MX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0JU5X	TTDDRUID	D0JU5X
D0JU5X	DRUGNAME	Bardoxolone methyl
D0JU5X	INDICATI	Mixed connective tissue disease [ICD-11: 4A43.3] Phase 3
D0JU5X	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
D0JU5X	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2

D09SHH	TTDDRUID	D09SHH
D09SHH	DRUGNAME	BAX-817
D09SHH	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3

D0C4FA	TTDDRUID	D0C4FA
D0C4FA	DRUGNAME	BAX-855
D0C4FA	INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3

D06ZEO	TTDDRUID	D06ZEO
D06ZEO	DRUGNAME	BAY 1021189
D06ZEO	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 3
D06ZEO	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D03SKL	TTDDRUID	D03SKL
D03SKL	DRUGNAME	BAY 86-9766
D03SKL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D05LDQ	TTDDRUID	D05LDQ
D05LDQ	DRUGNAME	BAY 94-9027
D05LDQ	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3
D05LDQ	INDICATI	Stroke [ICD-11: 8B20] Phase 3

D01ODU	TTDDRUID	D01ODU
D01ODU	DRUGNAME	BAY-35-3377
D01ODU	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Phase 3

D0Z1SL	TTDDRUID	D0Z1SL
D0Z1SL	DRUGNAME	Bazedoxifene/ conjugated estrogens
D0Z1SL	INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3

D0MY7F	TTDDRUID	D0MY7F
D0MY7F	DRUGNAME	BB3
D0MY7F	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
D0MY7F	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3
D0MY7F	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3

D0V9WA	TTDDRUID	D0V9WA
D0V9WA	DRUGNAME	BBI-608
D0V9WA	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
D0V9WA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D03OTH	TTDDRUID	D03OTH
D03OTH	DRUGNAME	Belagenpumatucel-L
D03OTH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D03OTH	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0E4VQ	TTDDRUID	D0E4VQ
D0E4VQ	DRUGNAME	Beloranib
D0E4VQ	INDICATI	Obesity [ICD-11: 5B81] Phase 1
D0E4VQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0VZ5B	TTDDRUID	D0VZ5B
D0VZ5B	DRUGNAME	Bempedoic acid + ezetimibe
D0VZ5B	INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Phase 3

D0N1YF	TTDDRUID	D0N1YF
D0N1YF	DRUGNAME	Beperminogene perplasmid
D0N1YF	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 3
D0N1YF	INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 3

D0LA6Z	TTDDRUID	D0LA6Z
D0LA6Z	DRUGNAME	Beraprost 314d
D0LA6Z	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3

D0C6QQ	TTDDRUID	D0C6QQ
D0C6QQ	DRUGNAME	Besipirdine
D0C6QQ	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D09BKY	TTDDRUID	D09BKY
D09BKY	DRUGNAME	Bevacizumab + Erlotinib
D09BKY	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D09BKY	INDICATI	Hypopharyngeal squamous cell carcinoma [ICD-11: 2B6D.0] Phase 1/2
D09BKY	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3
D09BKY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D08CGU	TTDDRUID	D08CGU
D08CGU	DRUGNAME	Bevacizumab + Rituximab
D08CGU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
D08CGU	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D04SLF	TTDDRUID	D04SLF
D04SLF	DRUGNAME	Bevacizumab + Trastuzumab
D04SLF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D04SLF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0UB9C	TTDDRUID	D0UB9C
D0UB9C	DRUGNAME	Bevacizumab biosimilar
D0UB9C	INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
D0UB9C	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0UB9C	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
D0UB9C	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1
D0UB9C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0OR3G	TTDDRUID	D0OR3G
D0OR3G	DRUGNAME	Bexagliflozin
D0OR3G	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0UT4W	TTDDRUID	D0UT4W
D0UT4W	DRUGNAME	BGB-3111
D0UT4W	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0UT4W	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
D0UT4W	INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 3
D0UT4W	INDICATI	Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 3

D06KJQ	TTDDRUID	D06KJQ
D06KJQ	DRUGNAME	BI 201335
D06KJQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0Z4VX	TTDDRUID	D0Z4VX
D0Z4VX	DRUGNAME	BI 695501
D0Z4VX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0X3HV	TTDDRUID	D0X3HV
D0X3HV	DRUGNAME	BI-695500
D0X3HV	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
D0X3HV	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Application submitted
D0X3HV	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
D0X3HV	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
D0X3HV	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
D0X3HV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial

D03QIE	TTDDRUID	D03QIE
D03QIE	DRUGNAME	Bicifadine
D03QIE	INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
D03QIE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3

D0BO7P	TTDDRUID	D0BO7P
D0BO7P	DRUGNAME	Bictegravir + emtricitabine  +  tenofovir alafenamide
D0BO7P	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D0L8PH	TTDDRUID	D0L8PH
D0L8PH	DRUGNAME	Biferonex
D0L8PH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D00RRU	TTDDRUID	D00RRU
D00RRU	DRUGNAME	BIIB037
D00RRU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D04EQX	TTDDRUID	D04EQX
D04EQX	DRUGNAME	BIIB-098
D04EQX	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0F4QW	TTDDRUID	D0F4QW
D0F4QW	DRUGNAME	Bimatoprost sustained release
D0F4QW	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3

D05ZOT	TTDDRUID	D05ZOT
D05ZOT	DRUGNAME	BIND-014
D05ZOT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0XM4G	TTDDRUID	D0XM4G
D0XM4G	DRUGNAME	Bindarit
D0XM4G	INDICATI	Nephritis [ICD-11: GB40] Phase 3

D08TJM	TTDDRUID	D08TJM
D08TJM	DRUGNAME	Binodenoson
D08TJM	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D05UAV	TTDDRUID	D05UAV
D05UAV	DRUGNAME	Bis(olanzapine) pamoate monohydrate
D05UAV	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 3

D0UL0R	TTDDRUID	D0UL0R
D0UL0R	DRUGNAME	BK-C-0701
D0UL0R	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3

D0Q3WB	TTDDRUID	D0Q3WB
D0Q3WB	DRUGNAME	BK-PIFA
D0Q3WB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0I5WJ	TTDDRUID	D0I5WJ
D0I5WJ	DRUGNAME	Blisibimod
D0I5WJ	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3

D08GJH	TTDDRUID	D08GJH
D08GJH	DRUGNAME	Blonanserin
D08GJH	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0OQ9V	TTDDRUID	D0OQ9V
D0OQ9V	DRUGNAME	BMN-110
D0OQ9V	INDICATI	Morquio syndrome [ICD-11: 5C56.32] Phase 3

D0X5LR	TTDDRUID	D0X5LR
D0X5LR	DRUGNAME	BMN-673
D0X5LR	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3

D05JEG	TTDDRUID	D05JEG
D05JEG	DRUGNAME	BMN-701
D05JEG	INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 3
D05JEG	INDICATI	Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 3

D04MCY	TTDDRUID	D04MCY
D04MCY	DRUGNAME	BMS 650032
D04MCY	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D03WQS	TTDDRUID	D03WQS
D03WQS	DRUGNAME	BMS-582664
D03WQS	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D00ZCT	TTDDRUID	D00ZCT
D00ZCT	DRUGNAME	BMS-663068
D00ZCT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0V9VG	TTDDRUID	D0V9VG
D0V9VG	DRUGNAME	BMS-927711
D0V9VG	INDICATI	Migraine [ICD-11: 8A80] Phase 2
D0V9VG	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D0DP5I	TTDDRUID	D0DP5I
D0DP5I	DRUGNAME	BMS-986205
D0DP5I	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D0DP5I	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D0DP5I	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0DP5I	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D0DP5I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03DJT	TTDDRUID	D03DJT
D03DJT	DRUGNAME	Bococizumab
D03DJT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0Z8MC	TTDDRUID	D0Z8MC
D0Z8MC	DRUGNAME	Botulinum toxin type A gel
D0Z8MC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D08IXA	TTDDRUID	D08IXA
D08IXA	DRUGNAME	BQ788
D08IXA	INDICATI	Acute kidney injury [ICD-11: GB60] Phase 3
D08IXA	INDICATI	Encephalopathy [ICD-11: 8E47] Phase 3
D08IXA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
D08IXA	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 3
D08IXA	INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 3

D0R9HF	TTDDRUID	D0R9HF
D0R9HF	DRUGNAME	Brentuximab vedotin companion diagnostic
D0R9HF	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3

D0HS5V	TTDDRUID	D0HS5V
D0HS5V	DRUGNAME	Brivanib
D0HS5V	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0HS5V	INDICATI	Liver cancer [ICD-11: 2C12] Phase 3

D0IK5F	TTDDRUID	D0IK5F
D0IK5F	DRUGNAME	BSI-201
D0IK5F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D04MZR	TTDDRUID	D04MZR
D04MZR	DRUGNAME	Bucelipase alfa
D04MZR	INDICATI	Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 3

D01QSO	TTDDRUID	D01QSO
D01QSO	DRUGNAME	Buparlisib
D01QSO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D01TMQ	TTDDRUID	D01TMQ
D01TMQ	DRUGNAME	Bupropion+naltrexone
D01TMQ	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D02ENG	TTDDRUID	D02ENG
D02ENG	DRUGNAME	BVT.2733
D02ENG	INDICATI	Lupus [ICD-11: 4A40] Phase 3
D02ENG	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
D02ENG	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
D02ENG	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3

D0L1DL	TTDDRUID	D0L1DL
D0L1DL	DRUGNAME	Bydureon
D0L1DL	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D0L1DL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0S5FF	TTDDRUID	D0S5FF
D0S5FF	DRUGNAME	BYM338
D0S5FF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3
D0S5FF	INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 3
D0S5FF	INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 2

D0P4DE	TTDDRUID	D0P4DE
D0P4DE	DRUGNAME	Cabotegravir LA
D0P4DE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0B9RG	TTDDRUID	D0B9RG
D0B9RG	DRUGNAME	Cabotegravir LA + rilpivirine LA combination
D0B9RG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0V0JR	TTDDRUID	D0V0JR
D0V0JR	DRUGNAME	Cadi-05
D0V0JR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D01JJO	TTDDRUID	D01JJO
D01JJO	DRUGNAME	Calaspargase pegol
D01JJO	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Application submitted
D01JJO	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3

D04MSX	TTDDRUID	D04MSX
D04MSX	DRUGNAME	Calcitonin oral
D04MSX	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
D04MSX	INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3

D0X5PZ	TTDDRUID	D0X5PZ
D0X5PZ	DRUGNAME	Calquenceacalabrutinib
D0X5PZ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
D0X5PZ	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 3

D09YDM	TTDDRUID	D09YDM
D09YDM	DRUGNAME	Camptothecin
D09YDM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0WF7K	TTDDRUID	D0WF7K
D0WF7K	DRUGNAME	Candoxatril
D0WF7K	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0A9SA	TTDDRUID	D0A9SA
D0A9SA	DRUGNAME	Canfosfamide
D0A9SA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0M4TF	TTDDRUID	D0M4TF
D0M4TF	DRUGNAME	Canvaxin
D0M4TF	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0J2HL	TTDDRUID	D0J2HL
D0J2HL	DRUGNAME	Cardiovascular disease medicine
D0J2HL	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3

D0LK4X	TTDDRUID	D0LK4X
D0LK4X	DRUGNAME	Carebastine
D0LK4X	INDICATI	Ocular allergy [ICD-11: 4A81] Phase 3

D0S0FZ	TTDDRUID	D0S0FZ
D0S0FZ	DRUGNAME	Carisbamate
D0S0FZ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
D0S0FZ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
D0S0FZ	INDICATI	Focal dystonia [ICD-11: 8A02.1] Phase 3
D0S0FZ	INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 3

D0OH5E	TTDDRUID	D0OH5E
D0OH5E	DRUGNAME	Cartistem
D0OH5E	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0J4IT	TTDDRUID	D0J4IT
D0J4IT	DRUGNAME	Cat peptide allergy desensitization agent
D0J4IT	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3

D04ZYP	TTDDRUID	D04ZYP
D04ZYP	DRUGNAME	Cat-SPIRE
D04ZYP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0S3EM	TTDDRUID	D0S3EM
D0S3EM	DRUGNAME	CAZ AVI
D0S3EM	INDICATI	Serious infection [ICD-11: 1H0Z] Phase 3

D08TEJ	TTDDRUID	D08TEJ
D08TEJ	DRUGNAME	CB-03-01
D08TEJ	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
D08TEJ	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D03PIA	TTDDRUID	D03PIA
D03PIA	DRUGNAME	CB-183315
D03PIA	INDICATI	Malignant carcinoid syndrome [ICD-11: 5B10] Phase 3

D06XVF	TTDDRUID	D06XVF
D06XVF	DRUGNAME	CBT-1
D06XVF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D06XVF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Application submitted

D09NTC	TTDDRUID	D09NTC
D09NTC	DRUGNAME	CC-486
D09NTC	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D09NTC	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D09NTC	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3

D08KXO	TTDDRUID	D08KXO
D08KXO	DRUGNAME	CCP-020
D08KXO	INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 3

D0E6XN	TTDDRUID	D0E6XN
D0E6XN	DRUGNAME	Cedar pollen allergen extract
D0E6XN	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3

D09VMI	TTDDRUID	D09VMI
D09VMI	DRUGNAME	Cediranib
D09VMI	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 3

D0Z1BQ	TTDDRUID	D0Z1BQ
D0Z1BQ	DRUGNAME	Cefluprenam
D0Z1BQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D09WRG	TTDDRUID	D09WRG
D09WRG	DRUGNAME	CEP-41750
D09WRG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0D7TD	TTDDRUID	D0D7TD
D0D7TD	DRUGNAME	Cethromycin
D0D7TD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
D0D7TD	INDICATI	Pneumonia [ICD-11: CA40] Phase 3

D04NRB	TTDDRUID	D04NRB
D04NRB	DRUGNAME	Cetilistat
D04NRB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
D04NRB	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D07DTM	TTDDRUID	D07DTM
D07DTM	DRUGNAME	Cetraxal Otic
D07DTM	INDICATI	Otitis externa [ICD-11: AA00-AA13] Phase 3

D0W2CX	TTDDRUID	D0W2CX
D0W2CX	DRUGNAME	CG-100649
D0W2CX	INDICATI	Arthritis [ICD-11: FA20] Phase 3

D07VKT	TTDDRUID	D07VKT
D07VKT	DRUGNAME	Ch14.18 mab
D07VKT	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D09YTX	TTDDRUID	D09YTX
D09YTX	DRUGNAME	Ch14.18,
D09YTX	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 3

D07QKK	TTDDRUID	D07QKK
D07QKK	DRUGNAME	CHLORIDE
D07QKK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D05KKC	TTDDRUID	D05KKC
D05KKC	DRUGNAME	CHML
D05KKC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0H3NN	TTDDRUID	D0H3NN
D0H3NN	DRUGNAME	Chondrocyte tissue grafts
D0H3NN	INDICATI	Back pain [ICD-11: ME84.Z] Phase 3

D05FOF	TTDDRUID	D05FOF
D05FOF	DRUGNAME	CHS-0214
D05FOF	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 3
D05FOF	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D05FOF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0X5YN	TTDDRUID	D0X5YN
D0X5YN	DRUGNAME	CHS-1420
D0X5YN	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D0IQ1V	TTDDRUID	D0IQ1V
D0IQ1V	DRUGNAME	CIGB-300
D0IQ1V	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3

D0Z2MB	TTDDRUID	D0Z2MB
D0Z2MB	DRUGNAME	Cilansetron
D0Z2MB	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3

D09ZXO	TTDDRUID	D09ZXO
D09ZXO	DRUGNAME	Cilengitide
D09ZXO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0N3SR	TTDDRUID	D0N3SR
D0N3SR	DRUGNAME	Cilnidipine
D0N3SR	INDICATI	High blood pressure [ICD-11: BA00] Phase 3

D0L3EO	TTDDRUID	D0L3EO
D0L3EO	DRUGNAME	Cinitapride
D0L3EO	INDICATI	Functional dyspepsia [ICD-11: DD90.3] Phase 3

D0G6RB	TTDDRUID	D0G6RB
D0G6RB	DRUGNAME	Cintredekin besudotox
D0G6RB	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3

D0MW3H	TTDDRUID	D0MW3H
D0MW3H	DRUGNAME	CIPEMASTAT
D0MW3H	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0F2CS	TTDDRUID	D0F2CS
D0F2CS	DRUGNAME	Cipro DPI
D0F2CS	INDICATI	Non-cystic fibrosis bronchiectasis [ICD-11: CA24] Phase 3
D0F2CS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0P6GT	TTDDRUID	D0P6GT
D0P6GT	DRUGNAME	Cipro Inhale
D0P6GT	INDICATI	Lung infection [ICD-11: CA4Z] Phase 3

D0C8YK	TTDDRUID	D0C8YK
D0C8YK	DRUGNAME	Cipro oxacin dry powder
D0C8YK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0P9UP	TTDDRUID	D0P9UP
D0P9UP	DRUGNAME	Civacir
D0P9UP	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
D0P9UP	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0WL8I	TTDDRUID	D0WL8I
D0WL8I	DRUGNAME	CJ-30001
D0WL8I	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3

D0T1VK	TTDDRUID	D0T1VK
D0T1VK	DRUGNAME	CJ-30002
D0T1VK	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3

D02TAB	TTDDRUID	D02TAB
D02TAB	DRUGNAME	CJ-50300
D02TAB	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3

D09MHC	TTDDRUID	D09MHC
D09MHC	DRUGNAME	CJC-1134-PC
D09MHC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D07EBF	TTDDRUID	D07EBF
D07EBF	DRUGNAME	CK-2017357
D07EBF	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
D07EBF	INDICATI	Muscle fatigue [ICD-11: FB32.5] Phase 2

D0C2XI	TTDDRUID	D0C2XI
D0C2XI	DRUGNAME	Claritin/Singulair
D0C2XI	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3

D0B3ZC	TTDDRUID	D0B3ZC
D0B3ZC	DRUGNAME	Claudiximab
D0B3ZC	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2
D0B3ZC	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D0H2RJ	TTDDRUID	D0H2RJ
D0H2RJ	DRUGNAME	Clazosentan
D0H2RJ	INDICATI	Cerebral vasospasm [ICD-11: BA85.Z] Phase 3
D0H2RJ	INDICATI	Vasospasm [ICD-11: 9B74.0] Discontinued in Phase 3

D0T1WY	TTDDRUID	D0T1WY
D0T1WY	DRUGNAME	Clevudine
D0T1WY	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D0G3LM	TTDDRUID	D0G3LM
D0G3LM	DRUGNAME	Clomethiazole
D0G3LM	INDICATI	Stroke [ICD-11: 8B20] Phase 3

D0NX5K	TTDDRUID	D0NX5K
D0NX5K	DRUGNAME	Clonidine topical gel
D0NX5K	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3

D05PGU	TTDDRUID	D05PGU
D05PGU	DRUGNAME	Clostridium difficile toxoid vaccine
D05PGU	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3

D0UU4B	TTDDRUID	D0UU4B
D0UU4B	DRUGNAME	CLS006
D0UU4B	INDICATI	Verruca vulgaris [ICD-11: 1E80] Phase 3

D0X6XH	TTDDRUID	D0X6XH
D0X6XH	DRUGNAME	CM-2395
D0X6XH	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0Q9HM	TTDDRUID	D0Q9HM
D0Q9HM	DRUGNAME	CM-AT
D0Q9HM	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
D0Q9HM	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 3

D0D2TZ	TTDDRUID	D0D2TZ
D0D2TZ	DRUGNAME	CMS-024-02
D0D2TZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0UK2N	TTDDRUID	D0UK2N
D0UK2N	DRUGNAME	CMT-02
D0UK2N	INDICATI	Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 3

D0W5NW	TTDDRUID	D0W5NW
D0W5NW	DRUGNAME	CMX-001
D0W5NW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0M4AV	TTDDRUID	D0M4AV
D0M4AV	DRUGNAME	CO-1686
D0M4AV	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D00OXQ	TTDDRUID	D00OXQ
D00OXQ	DRUGNAME	Companion diagnostic test EGFR-TKI
D00OXQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00ZVS	TTDDRUID	D00ZVS
D00ZVS	DRUGNAME	Condoliase
D00ZVS	INDICATI	Herniation disk [ICD-11: ND51.2] Phase 3

D04FYL	TTDDRUID	D04FYL
D04FYL	DRUGNAME	Contusugene ladenovec
D04FYL	INDICATI	Liver metastasis [ICD-11: 2D80] Phase 1
D04FYL	INDICATI	Oral cancer [ICD-11: 2B6E] Phase 3

D06WPM	TTDDRUID	D06WPM
D06WPM	DRUGNAME	Coprexa
D06WPM	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 3

D0ES9U	TTDDRUID	D0ES9U
D0ES9U	DRUGNAME	COR-003
D0ES9U	INDICATI	Cushing disease [ICD-11: 5A70] Phase 3

D0FJ9I	TTDDRUID	D0FJ9I
D0FJ9I	DRUGNAME	Cotellic
D0FJ9I	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0FJ9I	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0FJ9I	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0FJ9I	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
D0FJ9I	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1

D0J1GR	TTDDRUID	D0J1GR
D0J1GR	DRUGNAME	CP-868596
D0J1GR	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2
D0J1GR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0J1GR	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 3
D0J1GR	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 3
D0J1GR	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1

D0SB1B	TTDDRUID	D0SB1B
D0SB1B	DRUGNAME	CPX-351
D0SB1B	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D0SB1B	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D07GJZ	TTDDRUID	D07GJZ
D07GJZ	DRUGNAME	CQA 206-291
D07GJZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D01WZG	TTDDRUID	D01WZG
D01WZG	DRUGNAME	Creatine ALS-08
D01WZG	INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 3

D04TFE	TTDDRUID	D04TFE
D04TFE	DRUGNAME	CreaVax-HCC
D04TFE	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D0R7EQ	TTDDRUID	D0R7EQ
D0R7EQ	DRUGNAME	Crenezumab
D0R7EQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0R7EQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0W0SM	TTDDRUID	D0W0SM
D0W0SM	DRUGNAME	CRL-8131
D0W0SM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
D0W0SM	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 3

D0F5JH	TTDDRUID	D0F5JH
D0F5JH	DRUGNAME	CS-038
D0F5JH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D04VSM	TTDDRUID	D04VSM
D04VSM	DRUGNAME	CS-8958
D04VSM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D01EDJ	TTDDRUID	D01EDJ
D01EDJ	DRUGNAME	CSE-1034
D01EDJ	INDICATI	Nosocomial infection [ICD-11: PL10] Phase 3

D04AYZ	TTDDRUID	D04AYZ
D04AYZ	DRUGNAME	CSL-654
D04AYZ	INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 3

D0V0DI	TTDDRUID	D0V0DI
D0V0DI	DRUGNAME	CT-2584
D0V0DI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D07SDQ	TTDDRUID	D07SDQ
D07SDQ	DRUGNAME	Curcumin
D07SDQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D07SDQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0N1YG	TTDDRUID	D0N1YG
D0N1YG	DRUGNAME	CureXcell
D0N1YG	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D0K3XS	TTDDRUID	D0K3XS
D0K3XS	DRUGNAME	Custirsen
D0K3XS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0K3XS	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
D0K3XS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D01EZI	TTDDRUID	D01EZI
D01EZI	DRUGNAME	CVT-301
D01EZI	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D02GDK	TTDDRUID	D02GDK
D02GDK	DRUGNAME	Cx-601
D02GDK	INDICATI	Perianal fistula [ICD-11: DB50.1] Phase 3

D01FTV	TTDDRUID	D01FTV
D01FTV	DRUGNAME	Cyramza
D01FTV	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3

D01QWT	TTDDRUID	D01QWT
D01QWT	DRUGNAME	Cyramzaramucirumab
D01QWT	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D01QWT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0VP9E	TTDDRUID	D0VP9E
D0VP9E	DRUGNAME	Cyrtominetin
D0VP9E	INDICATI	Phlegmy cough [ICD-11: SA80-SA8Z] Phase 3

D08XPW	TTDDRUID	D08XPW
D08XPW	DRUGNAME	CYTISINE
D08XPW	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 3

D0Y9TQ	TTDDRUID	D0Y9TQ
D0Y9TQ	DRUGNAME	Cytotect CP
D0Y9TQ	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3

D0W8CW	TTDDRUID	D0W8CW
D0W8CW	DRUGNAME	D-5519
D0W8CW	INDICATI	Asthma [ICD-11: CA23] Phase 3

D01REE	TTDDRUID	D01REE
D01REE	DRUGNAME	DA-3031
D01REE	INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 3

D01FDL	TTDDRUID	D01FDL
D01FDL	DRUGNAME	Dabelotine
D01FDL	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D0KI5R	TTDDRUID	D0KI5R
D0KI5R	DRUGNAME	Dabigatran etexilate
D0KI5R	INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 3

D05SSC	TTDDRUID	D05SSC
D05SSC	DRUGNAME	Dalcetrapib
D05SSC	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3
D05SSC	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3

D00HAP	TTDDRUID	D00HAP
D00HAP	DRUGNAME	Dapagliflozin/metformin
D00HAP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0DV6D	TTDDRUID	D0DV6D
D0DV6D	DRUGNAME	Darolutamide
D0DV6D	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0CR9L	TTDDRUID	D0CR9L
D0CR9L	DRUGNAME	Daromun
D0CR9L	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0H0UB	TTDDRUID	D0H0UB
D0H0UB	DRUGNAME	Darotropium + 642444
D0H0UB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0R7YY	TTDDRUID	D0R7YY
D0R7YY	DRUGNAME	Darusentan
D0R7YY	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 3

D00PTZ	TTDDRUID	D00PTZ
D00PTZ	DRUGNAME	Dasiprotimut-T
D00PTZ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3

D0W6KM	TTDDRUID	D0W6KM
D0W6KM	DRUGNAME	Dasotraline
D0W6KM	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
D0W6KM	INDICATI	Eating disorder [ICD-11: 6B82] Phase 3
D0W6KM	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3

D0V1FF	TTDDRUID	D0V1FF
D0V1FF	DRUGNAME	Davunetide intranasal spray
D0V1FF	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D09AAK	TTDDRUID	D09AAK
D09AAK	DRUGNAME	DCC-2618
D09AAK	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
D09AAK	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 3
D09AAK	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
D09AAK	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D09AAK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D09AAK	INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Phase 1

D0D0HB	TTDDRUID	D0D0HB
D0D0HB	DRUGNAME	DCVax
D0D0HB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0D0HB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D02RED	TTDDRUID	D02RED
D02RED	DRUGNAME	DCVax-Brain
D02RED	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3

D02XEI	TTDDRUID	D02XEI
D02XEI	DRUGNAME	DCVax-Ovarian
D02XEI	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
D02XEI	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D02XEI	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
D02XEI	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3

D0FJ1W	TTDDRUID	D0FJ1W
D0FJ1W	DRUGNAME	DE-766
D0FJ1W	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D0FJ1W	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
D0FJ1W	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0O4FF	TTDDRUID	D0O4FF
D0O4FF	DRUGNAME	Debrase
D0O4FF	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 2
D0O4FF	INDICATI	Skin burns [ICD-11: ME65.0] Phase 3

D0S3NU	TTDDRUID	D0S3NU
D0S3NU	DRUGNAME	Delamanid
D0S3NU	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3
D0S3NU	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Phase 3

D01XHG	TTDDRUID	D01XHG
D01XHG	DRUGNAME	DENBUFYLLINE
D01XHG	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D09OHW	TTDDRUID	D09OHW
D09OHW	DRUGNAME	Dendritic cell therapy
D09OHW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D08ZXP	TTDDRUID	D08ZXP
D08ZXP	DRUGNAME	Dengue
D08ZXP	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 3
D08ZXP	INDICATI	Spasm [ICD-11: MB47.3] Phase 3

D0Z5SC	TTDDRUID	D0Z5SC
D0Z5SC	DRUGNAME	Dengue fever vaccine
D0Z5SC	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 3

D0S5LT	TTDDRUID	D0S5LT
D0S5LT	DRUGNAME	Deoxynojirimycin
D0S5LT	INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 3

D0TC4R	TTDDRUID	D0TC4R
D0TC4R	DRUGNAME	Desmoteplase
D0TC4R	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 3

D0Y9RO	TTDDRUID	D0Y9RO
D0Y9RO	DRUGNAME	Dexanabinol
D0Y9RO	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 3

D0VL3L	TTDDRUID	D0VL3L
D0VL3L	DRUGNAME	DFD-03
D0VL3L	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D09RPB	TTDDRUID	D09RPB
D09RPB	DRUGNAME	DFD-06
D09RPB	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D05ZIF	TTDDRUID	D05ZIF
D05ZIF	DRUGNAME	DFN-02
D05ZIF	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D03BIH	TTDDRUID	D03BIH
D03BIH	DRUGNAME	DFN-15
D03BIH	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D01KNA	TTDDRUID	D01KNA
D01KNA	DRUGNAME	Diamyd
D01KNA	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D0G6TL	TTDDRUID	D0G6TL
D0G6TL	DRUGNAME	DiaPep-277
D0G6TL	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3

D0K3OK	TTDDRUID	D0K3OK
D0K3OK	DRUGNAME	Difelikefalin
D0K3OK	INDICATI	Pruritus [ICD-11: EC90] Phase 3

D05KZM	TTDDRUID	D05KZM
D05KZM	DRUGNAME	Dimesna
D05KZM	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
D05KZM	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3

D0U1HX	TTDDRUID	D0U1HX
D0U1HX	DRUGNAME	DIMS-0150
D0U1HX	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D06RBJ	TTDDRUID	D06RBJ
D06RBJ	DRUGNAME	DIPROTEVERINE HYDROCHLORIDE
D06RBJ	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3

D0S6AE	TTDDRUID	D0S6AE
D0S6AE	DRUGNAME	Diquafosol
D0S6AE	INDICATI	Dry eye disease [ICD-11: 9E1Z] Phase 3

D0F3WG	TTDDRUID	D0F3WG
D0F3WG	DRUGNAME	Disufenton sodium
D0F3WG	INDICATI	Ischemia [ICD-11: 8B10-8B11] Phase 3
D0F3WG	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D04FYU	TTDDRUID	D04FYU
D04FYU	DRUGNAME	DMP-444
D04FYU	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3

D02UVT	TTDDRUID	D02UVT
D02UVT	DRUGNAME	Dolutegravir + abacavir sulphate + lamivudine
D02UVT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0K9FA	TTDDRUID	D0K9FA
D0K9FA	DRUGNAME	Dolutegravir + lamivudine
D0K9FA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0Y2IN	TTDDRUID	D0Y2IN
D0Y2IN	DRUGNAME	DORANIDAZOLE
D0Y2IN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0WG2R	TTDDRUID	D0WG2R
D0WG2R	DRUGNAME	Doravirine + lamivudine + tenofovir disoproxil fumarate
D0WG2R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D04PWT	TTDDRUID	D04PWT
D04PWT	DRUGNAME	DP-b99
D04PWT	INDICATI	Stroke [ICD-11: 8B20] Phase 3

D0X2LW	TTDDRUID	D0X2LW
D0X2LW	DRUGNAME	DPT/Hib vaccine
D0X2LW	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3

D00IXM	TTDDRUID	D00IXM
D00IXM	DRUGNAME	DR-3001
D00IXM	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 3

D08PHD	TTDDRUID	D08PHD
D08PHD	DRUGNAME	DR-5001
D08PHD	INDICATI	Adenovirus infection [ICD-11: 1A20] Phase 3

D0X4DB	TTDDRUID	D0X4DB
D0X4DB	DRUGNAME	Drisapersen
D0X4DB	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3

D01TEA	TTDDRUID	D01TEA
D01TEA	DRUGNAME	DSC-127
D01TEA	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D0G4BF	TTDDRUID	D0G4BF
D0G4BF	DRUGNAME	DTaP-HepB prophylactic vaccine
D0G4BF	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D06RFK	TTDDRUID	D06RFK
D06RFK	DRUGNAME	DTaP-IPV-Hib
D06RFK	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 3

D08BNJ	TTDDRUID	D08BNJ
D08BNJ	DRUGNAME	DTP-HepB-Polio-Hib
D08BNJ	INDICATI	Diphtheria [ICD-11: 1C17] Phase 3
D08BNJ	INDICATI	Pertussis [ICD-11: 1C12.Z] Phase 3
D08BNJ	INDICATI	Tetanus [ICD-11: 1C13] Phase 3

D00CBP	TTDDRUID	D00CBP
D00CBP	DRUGNAME	DTPw-HBV/Hib
D00CBP	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D0S0LD	TTDDRUID	D0S0LD
D0S0LD	DRUGNAME	DTwP-HBV vaccine
D0S0LD	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D0G6ZS	TTDDRUID	D0G6ZS
D0G6ZS	DRUGNAME	DTwP-HepB prophylactic vaccine
D0G6ZS	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D05GZB	TTDDRUID	D05GZB
D05GZB	DRUGNAME	Dupixent
D05GZB	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3

D09JFY	TTDDRUID	D09JFY
D09JFY	DRUGNAME	Dutasteride + tamsulosin
D09JFY	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Phase 3
D09JFY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D04XIO	TTDDRUID	D04XIO
D04XIO	DRUGNAME	Dutogliptin
D04XIO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03HDV	TTDDRUID	D03HDV
D03HDV	DRUGNAME	DWP-431
D03HDV	INDICATI	Bone development disorder [ICD-11: FB86] Phase 3

D08UVZ	TTDDRUID	D08UVZ
D08UVZ	DRUGNAME	E004
D08UVZ	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0V8GT	TTDDRUID	D0V8GT
D0V8GT	DRUGNAME	E-0116
D0V8GT	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D0XD5A	TTDDRUID	D0XD5A
D0XD5A	DRUGNAME	E-101
D0XD5A	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3

D08MHD	TTDDRUID	D08MHD
D08MHD	DRUGNAME	E-2609
D08MHD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D08MHD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D02WVT	TTDDRUID	D02WVT
D02WVT	DRUGNAME	E-3810
D02WVT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0Z5AV	TTDDRUID	D0Z5AV
D0Z5AV	DRUGNAME	E5501
D0Z5AV	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3

D0J7QU	TTDDRUID	D0J7QU
D0J7QU	DRUGNAME	E-913
D0J7QU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0Z8LN	TTDDRUID	D0Z8LN
D0Z8LN	DRUGNAME	Ebola virus vaccine
D0Z8LN	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3

D00BHL	TTDDRUID	D00BHL
D00BHL	DRUGNAME	EC20
D00BHL	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0V3LF	TTDDRUID	D0V3LF
D0V3LF	DRUGNAME	ECCS-50
D0V3LF	INDICATI	Scleroderma [ICD-11: 4A42] Phase 3

D0Y6HW	TTDDRUID	D0Y6HW
D0Y6HW	DRUGNAME	Ecopipam
D0Y6HW	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 3
D0Y6HW	INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2

D02CDS	TTDDRUID	D02CDS
D02CDS	DRUGNAME	Edarbi
D02CDS	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0H2AP	TTDDRUID	D0H2AP
D0H2AP	DRUGNAME	EDG-004
D0H2AP	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 3

D05JSU	TTDDRUID	D05JSU
D05JSU	DRUGNAME	Edivoxetine
D05JSU	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
D05JSU	INDICATI	Pediatric attention deficit hyperactivity disorder [ICD-11: 6A05] Phase 3

D0I1DW	TTDDRUID	D0I1DW
D0I1DW	DRUGNAME	Edotecarin
D0I1DW	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D0NE8F	TTDDRUID	D0NE8F
D0NE8F	DRUGNAME	EDS-EP
D0NE8F	INDICATI	Ataxia-telangiectasia [ICD-11: 4A01.31] Phase 3

D03HVV	TTDDRUID	D03HVV
D03HVV	DRUGNAME	Efaproxyn
D03HVV	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3

D07BCU	TTDDRUID	D07BCU
D07BCU	DRUGNAME	Eflornithine + sulindac
D07BCU	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 3
D07BCU	INDICATI	Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 3

D0R8FL	TTDDRUID	D0R8FL
D0R8FL	DRUGNAME	Egalet-002
D0R8FL	INDICATI	Chronic pain [ICD-11: MG30] Phase 3

D0K7FY	TTDDRUID	D0K7FY
D0K7FY	DRUGNAME	EGF816
D0K7FY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
D0K7FY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0Q5XX	TTDDRUID	D0Q5XX
D0Q5XX	DRUGNAME	Eicosapentaenoic acid/docosa-hexaenoic acid
D0Q5XX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D0Q5XX	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Approved

D0PY5D	TTDDRUID	D0PY5D
D0PY5D	DRUGNAME	Elacytarabine
D0PY5D	INDICATI	Late-stage acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D04LQN	TTDDRUID	D04LQN
D04LQN	DRUGNAME	ELAD
D04LQN	INDICATI	Acute liver failure [ICD-11: DB91] Phase 3
D04LQN	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2/3

D0UI3T	TTDDRUID	D0UI3T
D0UI3T	DRUGNAME	Elagolix
D0UI3T	INDICATI	Uterine fibroids [ICD-11: 2E86.0] Phase 3

D0BN2C	TTDDRUID	D0BN2C
D0BN2C	DRUGNAME	Elamipretide
D0BN2C	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D0BN2C	INDICATI	Mitochondrial myopathy [ICD-11: 8C73] Phase 3

D05IRV	TTDDRUID	D05IRV
D05IRV	DRUGNAME	Elesclomol
D05IRV	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D04RAL	TTDDRUID	D04RAL
D04RAL	DRUGNAME	Emplicitielotuzumab
D04RAL	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0A2CP	TTDDRUID	D0A2CP
D0A2CP	DRUGNAME	Emtricitabine/tenofovir alafenamide
D0A2CP	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D09KHE	TTDDRUID	D09KHE
D09KHE	DRUGNAME	EN3488
D09KHE	INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3

D0O6BW	TTDDRUID	D0O6BW
D0O6BW	DRUGNAME	Encepur
D0O6BW	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 3

D0XH6P	TTDDRUID	D0XH6P
D0XH6P	DRUGNAME	Encepur (new formulation)
D0XH6P	INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 3

D0KX7I	TTDDRUID	D0KX7I
D0KX7I	DRUGNAME	Ensartinib
D0KX7I	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0R2NE	TTDDRUID	D0R2NE
D0R2NE	DRUGNAME	Entacapone+levodopa+carbidopa
D0R2NE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
D0R2NE	INDICATI	Restless legs syndrome [ICD-11: 7A80] Phase 3

D0KQ8X	TTDDRUID	D0KQ8X
D0KQ8X	DRUGNAME	Entresto
D0KQ8X	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 3
D0KQ8X	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D0Y9GF	TTDDRUID	D0Y9GF
D0Y9GF	DRUGNAME	Entyvio
D0Y9GF	INDICATI	Crohn disease [ICD-11: DD70] Phase 3
D0Y9GF	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D0I6VU	TTDDRUID	D0I6VU
D0I6VU	DRUGNAME	Enzastaurin
D0I6VU	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
D0I6VU	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D0I6VU	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0I6VU	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D0PM5U	TTDDRUID	D0PM5U
D0PM5U	DRUGNAME	Epacadostat
D0PM5U	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0PM5U	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0PM5U	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0PM5U	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
D0PM5U	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0PM5U	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0PM5U	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
D0PM5U	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0PM5U	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0P8TS	TTDDRUID	D0P8TS
D0P8TS	DRUGNAME	Eperisone
D0P8TS	INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 3

D0U2BH	TTDDRUID	D0U2BH
D0U2BH	DRUGNAME	Epigallocatechin gallate
D0U2BH	INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Phase 3

D0DV3T	TTDDRUID	D0DV3T
D0DV3T	DRUGNAME	Epoetin zeta
D0DV3T	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 3

D07WPE	TTDDRUID	D07WPE
D07WPE	DRUGNAME	Epothilon
D07WPE	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0I9VO	TTDDRUID	D0I9VO
D0I9VO	DRUGNAME	Epratuzumab
D0I9VO	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3
D0I9VO	INDICATI	Graft rejection in heart transplantation [ICD-11: NE84] Phase 3
D0I9VO	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3

D02KRI	TTDDRUID	D02KRI
D02KRI	DRUGNAME	Epristeride
D02KRI	INDICATI	Hirsutism [ICD-11: ED72] Phase 3

D01LYX	TTDDRUID	D01LYX
D01LYX	DRUGNAME	Eptastigmine
D01LYX	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D0H6QD	TTDDRUID	D0H6QD
D0H6QD	DRUGNAME	Eptinezumab
D0H6QD	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D0O2NQ	TTDDRUID	D0O2NQ
D0O2NQ	DRUGNAME	Eraxis/Vfend
D0O2NQ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 3

D04YHG	TTDDRUID	D04YHG
D04YHG	DRUGNAME	ErepoXen
D04YHG	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 3

D0SJ8Q	TTDDRUID	D0SJ8Q
D0SJ8Q	DRUGNAME	ERITORAN
D0SJ8Q	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3

D0F2BP	TTDDRUID	D0F2BP
D0F2BP	DRUGNAME	Erleadaapalutamide
D0F2BP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0TP5H	TTDDRUID	D0TP5H
D0TP5H	DRUGNAME	Esketamine
D0TP5H	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3

D0B2ZZ	TTDDRUID	D0B2ZZ
D0B2ZZ	DRUGNAME	Esomeprazole magnesium + Aspirin
D0B2ZZ	INDICATI	Peptic ulcer [ICD-11: DA61] Phase 3

D0MY7X	TTDDRUID	D0MY7X
D0MY7X	DRUGNAME	Esonarimod
D0MY7X	INDICATI	Arthritis [ICD-11: FA20] Phase 3

D0CO3N	TTDDRUID	D0CO3N
D0CO3N	DRUGNAME	esuberaprost
D0CO3N	INDICATI	Gout [ICD-11: FA25] Phase 3
D0CO3N	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3

D0D9NY	TTDDRUID	D0D9NY
D0D9NY	DRUGNAME	ETC-1002
D0D9NY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D0D9NY	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2

D05YMB	TTDDRUID	D05YMB
D05YMB	DRUGNAME	Eteplirsen
D05YMB	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3

D0N6UP	TTDDRUID	D0N6UP
D0N6UP	DRUGNAME	ETHIMIZOL
D0N6UP	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D0H5IZ	TTDDRUID	D0H5IZ
D0H5IZ	DRUGNAME	Etirinotecan pegol
D0H5IZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0H5IZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0UH7R	TTDDRUID	D0UH7R
D0UH7R	DRUGNAME	Etrolizumab
D0UH7R	INDICATI	Crohn disease [ICD-11: DD70] Phase 3
D0UH7R	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D0CW2B	TTDDRUID	D0CW2B
D0CW2B	DRUGNAME	ETX-101
D0CW2B	INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 3

D02XXN	TTDDRUID	D02XXN
D02XXN	DRUGNAME	Evacetrapib
D02XXN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3

D0T5VD	TTDDRUID	D0T5VD
D0T5VD	DRUGNAME	EVK-001
D0T5VD	INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 3

D0D3TX	TTDDRUID	D0D3TX
D0D3TX	DRUGNAME	EVP-6124
D0D3TX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D0D3TX	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D01FUC	TTDDRUID	D01FUC
D01FUC	DRUGNAME	Exatecan
D01FUC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0M9VE	TTDDRUID	D0M9VE
D0M9VE	DRUGNAME	EXISULIND
D0M9VE	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D0V5KW	TTDDRUID	D0V5KW
D0V5KW	DRUGNAME	EZN-2279
D0V5KW	INDICATI	Adenosine deaminase defciency [ICD-11: 4A01.1] Phase 3
D0V5KW	INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 3

D0V1SA	TTDDRUID	D0V1SA
D0V1SA	DRUGNAME	FANG vaccine
D0V1SA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0V1SA	INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 2/3
D0V1SA	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0V1SA	INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
D0V1SA	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2/3
D0V1SA	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0V1SA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0M0SS	TTDDRUID	D0M0SS
D0M0SS	DRUGNAME	FARGLITAZAR
D0M0SS	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D06XVN	TTDDRUID	D06XVN
D06XVN	DRUGNAME	Farletuzumab
D06XVN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D06XVN	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D06XVN	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0M0WV	TTDDRUID	D0M0WV
D0M0WV	DRUGNAME	Fasiglifam hemihydrate
D0M0WV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0AD4Z	TTDDRUID	D0AD4Z
D0AD4Z	DRUGNAME	Fasinumab
D0AD4Z	INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
D0AD4Z	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
D0AD4Z	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3
D0AD4Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D07WHN	TTDDRUID	D07WHN
D07WHN	DRUGNAME	FASORACETAM
D07WHN	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D0X6DE	TTDDRUID	D0X6DE
D0X6DE	DRUGNAME	FemiVac
D0X6DE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D01PKG	TTDDRUID	D01PKG
D01PKG	DRUGNAME	Fenofibrate/ simvastatin
D01PKG	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3

D08JAC	TTDDRUID	D08JAC
D08JAC	DRUGNAME	Fenretinide
D08JAC	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 3

D0R0CF	TTDDRUID	D0R0CF
D0R0CF	DRUGNAME	Fentanyl inhalation
D0R0CF	INDICATI	Cancer related pain [ICD-11: MG30] Phase 3

D03YKE	TTDDRUID	D03YKE
D03YKE	DRUGNAME	FG-4592
D03YKE	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 3

D00EWR	TTDDRUID	D00EWR
D00EWR	DRUGNAME	Fidarestat
D00EWR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0QM1T	TTDDRUID	D0QM1T
D0QM1T	DRUGNAME	Finazosin
D0QM1T	INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 3

D0NV5O	TTDDRUID	D0NV5O
D0NV5O	DRUGNAME	Finerenone
D0NV5O	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3

D07MCA	TTDDRUID	D07MCA
D07MCA	DRUGNAME	FK949E
D07MCA	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 3

D0X8VV	TTDDRUID	D0X8VV
D0X8VV	DRUGNAME	Flobufen
D0X8VV	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D06TKS	TTDDRUID	D06TKS
D06TKS	DRUGNAME	FluMist/Fluenz
D06TKS	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0SB8X	TTDDRUID	D0SB8X
D0SB8X	DRUGNAME	FluNhance
D0SB8X	INDICATI	Adenosine deaminase defciency [ICD-11: 4A01.1] Phase 3
D0SB8X	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0U1VZ	TTDDRUID	D0U1VZ
D0U1VZ	DRUGNAME	Flurpiridaz F 18
D0U1VZ	INDICATI	Myocardial disease [ICD-11: BC43.20] Phase 3

D01IWJ	TTDDRUID	D01IWJ
D01IWJ	DRUGNAME	Fluticasone furoate/ fluticasone propionate
D01IWJ	INDICATI	Asthma [ICD-11: CA23] Phase 3

D08SHP	TTDDRUID	D08SHP
D08SHP	DRUGNAME	Fluzone QIV HD
D08SHP	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D05RUH	TTDDRUID	D05RUH
D05RUH	DRUGNAME	FMX101
D05RUH	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D07JIN	TTDDRUID	D07JIN
D07JIN	DRUGNAME	FMX103
D07JIN	INDICATI	Rosacea [ICD-11: ED90.0] Phase 3

D0W5LC	TTDDRUID	D0W5LC
D0W5LC	DRUGNAME	Forigerimod
D0W5LC	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3

D05MNV	TTDDRUID	D05MNV
D05MNV	DRUGNAME	Fosclin
D05MNV	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D00OPX	TTDDRUID	D00OPX
D00OPX	DRUGNAME	Fostamatinib disodium
D00OPX	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 3

D0ST3I	TTDDRUID	D0ST3I
D0ST3I	DRUGNAME	Fostemsavir
D0ST3I	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D01HHD	TTDDRUID	D01HHD
D01HHD	DRUGNAME	Fovepta
D01HHD	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3

D0EF2H	TTDDRUID	D0EF2H
D0EF2H	DRUGNAME	FP-001
D0EF2H	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D05LOB	TTDDRUID	D05LOB
D05LOB	DRUGNAME	FP-1201
D05LOB	INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 3

D02YEY	TTDDRUID	D02YEY
D02YEY	DRUGNAME	FPL-62064
D02YEY	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 3

D07ZSU	TTDDRUID	D07ZSU
D07ZSU	DRUGNAME	Freeze-dried bee venom
D07ZSU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D03JTG	TTDDRUID	D03JTG
D03JTG	DRUGNAME	Fruquintinib
D03JTG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D03JTG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D00TPW	TTDDRUID	D00TPW
D00TPW	DRUGNAME	FST-201
D00TPW	INDICATI	Otitis externa [ICD-11: AA00-AA13] Phase 3

D0O1GS	TTDDRUID	D0O1GS
D0O1GS	DRUGNAME	Fulranumab
D0O1GS	INDICATI	Arthralgia [ICD-11: ME82] Phase 3
D0O1GS	INDICATI	Back pain [ICD-11: ME84.Z] Phase 3
D0O1GS	INDICATI	Cancer related pain [ICD-11: MG30] Phase 3

D03GOO	TTDDRUID	D03GOO
D03GOO	DRUGNAME	Fumaric acid
D03GOO	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D03GOO	INDICATI	Pustular palmoplantar psoriasis [ICD-11: EA90] Phase 3

D0X5CX	TTDDRUID	D0X5CX
D0X5CX	DRUGNAME	Fusidic aci
D0X5CX	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 3

D04QPD	TTDDRUID	D04QPD
D04QPD	DRUGNAME	FV-100
D04QPD	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 3

D08YWK	TTDDRUID	D08YWK
D08YWK	DRUGNAME	FX-006
D08YWK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0G8ZQ	TTDDRUID	D0G8ZQ
D0G8ZQ	DRUGNAME	G17DT
D0G8ZQ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D0I1QI	TTDDRUID	D0I1QI
D0I1QI	DRUGNAME	Ganetespib
D0I1QI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0Q7YZ	TTDDRUID	D0Q7YZ
D0Q7YZ	DRUGNAME	Gantenerumab
D0Q7YZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D09XUH	TTDDRUID	D09XUH
D09XUH	DRUGNAME	GASTRAZOLE
D09XUH	INDICATI	Duodenal ulcer [ICD-11: DA63] Phase 3

D04JYK	TTDDRUID	D04JYK
D04JYK	DRUGNAME	GC-1107
D04JYK	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3

D0E1AW	TTDDRUID	D0E1AW
D0E1AW	DRUGNAME	GC5101B
D0E1AW	INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 3

D07RHF	TTDDRUID	D07RHF
D07RHF	DRUGNAME	GDC 695
D07RHF	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 3

D0UP1Z	TTDDRUID	D0UP1Z
D0UP1Z	DRUGNAME	GDC-0032
D0UP1Z	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0UP1Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D0I4TH	TTDDRUID	D0I4TH
D0I4TH	DRUGNAME	GDC-0068
D0I4TH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0I4TH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0I4TH	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D0I4TH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09FKY	TTDDRUID	D09FKY
D09FKY	DRUGNAME	GED-0301
D09FKY	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D09FKY	INDICATI	Crohn disease [ICD-11: DD70] Phase 3
D09FKY	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0PL3N	TTDDRUID	D0PL3N
D0PL3N	DRUGNAME	Gefapixant
D0PL3N	INDICATI	Cough [ICD-11: MD12] Phase 3

D0ZD3C	TTDDRUID	D0ZD3C
D0ZD3C	DRUGNAME	Gemigliptin
D0ZD3C	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
D0ZD3C	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0BD9K	TTDDRUID	D0BD9K
D0BD9K	DRUGNAME	Gilotrif
D0BD9K	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0BD9K	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D0BD9K	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3

D0I8MT	TTDDRUID	D0I8MT
D0I8MT	DRUGNAME	Girentuximab
D0I8MT	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D0T3JF	TTDDRUID	D0T3JF
D0T3JF	DRUGNAME	GliAtak, TN
D0T3JF	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
D0T3JF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D08NXW	TTDDRUID	D08NXW
D08NXW	DRUGNAME	GLP-1
D08NXW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0L9IA	TTDDRUID	D0L9IA
D0L9IA	DRUGNAME	Glufosfamide
D0L9IA	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2
D0L9IA	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0W7PQ	TTDDRUID	D0W7PQ
D0W7PQ	DRUGNAME	Glufosfomide
D0W7PQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0T8QB	TTDDRUID	D0T8QB
D0T8QB	DRUGNAME	GLYCYRRHIZIN
D0T8QB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0I0ZP	TTDDRUID	D0I0ZP
D0I0ZP	DRUGNAME	Glyminox
D0I0ZP	INDICATI	Sexually transmitted infection [ICD-11: 1A9Z] Phase 3

D01YVZ	TTDDRUID	D01YVZ
D01YVZ	DRUGNAME	GLYX-13
D01YVZ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
D01YVZ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3

D0C4VN	TTDDRUID	D0C4VN
D0C4VN	DRUGNAME	GM3 ganglioside vaccine
D0C4VN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0N4EO	TTDDRUID	D0N4EO
D0N4EO	DRUGNAME	GMI-1070
D0N4EO	INDICATI	Asthma [ICD-11: CA23] Phase 3
D0N4EO	INDICATI	Vaso-occlusive crisis [ICD-11: BE2Y] Phase 3

D04ORP	TTDDRUID	D04ORP
D04ORP	DRUGNAME	GMK
D04ORP	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0R9VC	TTDDRUID	D0R9VC
D0R9VC	DRUGNAME	GnRH
D0R9VC	INDICATI	Female infertility [ICD-11: GA31.Z] Phase 3

D03QBT	TTDDRUID	D03QBT
D03QBT	DRUGNAME	Golnerminogene pradenovac
D03QBT	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3

D09OOC	TTDDRUID	D09OOC
D09OOC	DRUGNAME	Gp100
D09OOC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0S7JN	TTDDRUID	D0S7JN
D0S7JN	DRUGNAME	GP-2017
D0S7JN	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
D0S7JN	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D0S7JN	INDICATI	Psoriatic arthritis [ICD-11: FA21] Application submitted
D0S7JN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D01NWV	TTDDRUID	D01NWV
D01NWV	DRUGNAME	Granexin gel
D01NWV	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D03TSR	TTDDRUID	D03TSR
D03TSR	DRUGNAME	Grass pollen immunotherapy
D03TSR	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3

D04SNL	TTDDRUID	D04SNL
D04SNL	DRUGNAME	Grippol Plus
D04SNL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D05ZAI	TTDDRUID	D05ZAI
D05ZAI	DRUGNAME	Grippol TC
D05ZAI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D03TBJ	TTDDRUID	D03TBJ
D03TBJ	DRUGNAME	GRT-6005
D03TBJ	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D03TBJ	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3

D0S3BK	TTDDRUID	D0S3BK
D0S3BK	DRUGNAME	GS010
D0S3BK	INDICATI	Leber hereditary optic neuropathy [ICD-11: 8C73.Y] Phase 3

D0A4UC	TTDDRUID	D0A4UC
D0A4UC	DRUGNAME	GS-6615
D0A4UC	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 3
D0A4UC	INDICATI	Long QT syndrome [ICD-11: BC65.0] Phase 3

D0F3HC	TTDDRUID	D0F3HC
D0F3HC	DRUGNAME	GS-9268
D0F3HC	INDICATI	Non-cystic fibrosis bronchiectasis [ICD-11: CA24] Phase 3

D0UQ5B	TTDDRUID	D0UQ5B
D0UQ5B	DRUGNAME	GSK-1437173A
D0UQ5B	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D08XNH	TTDDRUID	D08XNH
D08XNH	DRUGNAME	GSK221149
D08XNH	INDICATI	Preterm labour [ICD-11: JB00] Phase 3

D06SJO	TTDDRUID	D06SJO
D06SJO	DRUGNAME	GSK-2282512A
D06SJO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D00JZD	TTDDRUID	D00JZD
D00JZD	DRUGNAME	GSK2321138A
D00JZD	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0PE2L	TTDDRUID	D0PE2L
D0PE2L	DRUGNAME	GSK2402968
D0PE2L	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3

D07GNL	TTDDRUID	D07GNL
D07GNL	DRUGNAME	GSK-523338
D07GNL	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3

D0T6TW	TTDDRUID	D0T6TW
D0T6TW	DRUGNAME	GSK642444
D0T6TW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D03RLP	TTDDRUID	D03RLP
D03RLP	DRUGNAME	GT160-246
D03RLP	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 3

D0NE3W	TTDDRUID	D0NE3W
D0NE3W	DRUGNAME	GTx-024
D0NE3W	INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 3

D0VZ4N	TTDDRUID	D0VZ4N
D0VZ4N	DRUGNAME	Guadecitabine
D0VZ4N	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3

D08FCA	TTDDRUID	D08FCA
D08FCA	DRUGNAME	Guanilib
D08FCA	INDICATI	Crohn disease [ICD-11: DD70] Phase 3

D0N0QC	TTDDRUID	D0N0QC
D0N0QC	DRUGNAME	GV1001
D0N0QC	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0UI3Z	TTDDRUID	D0UI3Z
D0UI3Z	DRUGNAME	H1N1 influenza A inactivated split virion vaccine
D0UI3Z	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D03ERR	TTDDRUID	D03ERR
D03ERR	DRUGNAME	H1N1 influenza vaccine
D03ERR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0HE7I	TTDDRUID	D0HE7I
D0HE7I	DRUGNAME	H1N1 influenza vaccine
D0HE7I	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D08ZJJ	TTDDRUID	D08ZJJ
D08ZJJ	DRUGNAME	H1N1 pandemic influenza vaccine
D08ZJJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D00HYF	TTDDRUID	D00HYF
D00HYF	DRUGNAME	H5N1 influenza vaccine
D00HYF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D07EUY	TTDDRUID	D07EUY
D07EUY	DRUGNAME	H5N1 influenza vaccine
D07EUY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0D5NZ	TTDDRUID	D0D5NZ
D0D5NZ	DRUGNAME	H5N1 influenza vaccine
D0D5NZ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0QO0D	TTDDRUID	D0QO0D
D0QO0D	DRUGNAME	H5N1 influenza vaccine
D0QO0D	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0Z7UN	TTDDRUID	D0Z7UN
D0Z7UN	DRUGNAME	H5N1 influenza vaccine
D0Z7UN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0AR8G	TTDDRUID	D0AR8G
D0AR8G	DRUGNAME	Habeo
D0AR8G	INDICATI	Scleroderma [ICD-11: 4A42] Phase 3

D03FFA	TTDDRUID	D03FFA
D03FFA	DRUGNAME	HB-AS02V
D03FFA	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D01AIM	TTDDRUID	D01AIM
D01AIM	DRUGNAME	HBsAG-HBIG complex
D01AIM	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D01WTV	TTDDRUID	D01WTV
D01WTV	DRUGNAME	HDL-200
D01WTV	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D02KXW	TTDDRUID	D02KXW
D02KXW	DRUGNAME	HE3286
D02KXW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0M2IS	TTDDRUID	D0M2IS
D0M2IS	DRUGNAME	Hebergel
D0M2IS	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3

D0S7KQ	TTDDRUID	D0S7KQ
D0S7KQ	DRUGNAME	Hematide
D0S7KQ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 3

D0WV4H	TTDDRUID	D0WV4H
D0WV4H	DRUGNAME	Hemomex I
D0WV4H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0C3YN	TTDDRUID	D0C3YN
D0C3YN	DRUGNAME	Heparin low molecular weight
D0C3YN	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3

D01VSR	TTDDRUID	D01VSR
D01VSR	DRUGNAME	Hepatitis C immune globulin
D01VSR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0E0HE	TTDDRUID	D0E0HE
D0E0HE	DRUGNAME	Hexyl
D0E0HE	INDICATI	Radiation syndrome [ICD-11: NF00] Phase 3

D0H8MH	TTDDRUID	D0H8MH
D0H8MH	DRUGNAME	HGH-CTP
D0H8MH	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3

D06OIG	TTDDRUID	D06OIG
D06OIG	DRUGNAME	Hib-MenCY-TT vaccine
D06OIG	INDICATI	Meningitis [ICD-11: 1D01] Phase 3

D0Q9CY	TTDDRUID	D0Q9CY
D0Q9CY	DRUGNAME	HKI-272
D0Q9CY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D04OGP	TTDDRUID	D04OGP
D04OGP	DRUGNAME	HL-10
D04OGP	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Phase 3

D0R8QX	TTDDRUID	D0R8QX
D0R8QX	DRUGNAME	HMGB-1 protein and its fragments
D0R8QX	INDICATI	Bone disease [ICD-11: FC0Z] Phase 3

D0G6DF	TTDDRUID	D0G6DF
D0G6DF	DRUGNAME	HMPL-004
D0G6DF	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 3

D0B2LC	TTDDRUID	D0B2LC
D0B2LC	DRUGNAME	HP3070
D0B2LC	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0NN7Q	TTDDRUID	D0NN7Q
D0NN7Q	DRUGNAME	HP-802-247
D0NN7Q	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3

D0D5AV	TTDDRUID	D0D5AV
D0D5AV	DRUGNAME	HPV 16/18 vaccine
D0D5AV	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 3

D0Y1FG	TTDDRUID	D0Y1FG
D0Y1FG	DRUGNAME	HSV-Tk
D0Y1FG	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D00SHS	TTDDRUID	D00SHS
D00SHS	DRUGNAME	Human hemoglobin
D00SHS	INDICATI	Blood transfusion [ICD-11: QB98] Phase 3

D0I3NA	TTDDRUID	D0I3NA
D0I3NA	DRUGNAME	Human-cl rhFVIII
D0I3NA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0DD9F	TTDDRUID	D0DD9F
D0DD9F	DRUGNAME	HumaSPECT
D0DD9F	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0VS1Y	TTDDRUID	D0VS1Y
D0VS1Y	DRUGNAME	Hydromorphone intrathecal
D0VS1Y	INDICATI	Chronic pain [ICD-11: MG30] Phase 3

D08QDM	TTDDRUID	D08QDM
D08QDM	DRUGNAME	HyperAcute Pancreas
D08QDM	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0B7DW	TTDDRUID	D0B7DW
D0B7DW	DRUGNAME	Hyqvia + Kiovia
D0B7DW	INDICATI	Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 3

D0B0UF	TTDDRUID	D0B0UF
D0B0UF	DRUGNAME	IBI-308
D0B0UF	INDICATI	Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 3

D0Y6ZK	TTDDRUID	D0Y6ZK
D0Y6ZK	DRUGNAME	IB-MECA
D0Y6ZK	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2/3
D0Y6ZK	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
D0Y6ZK	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0Y6ZK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0XS4X	TTDDRUID	D0XS4X
D0XS4X	DRUGNAME	Ibodutant
D0XS4X	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3

D04DJS	TTDDRUID	D04DJS
D04DJS	DRUGNAME	ICI 118,551
D04DJS	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D04DJS	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3

D04LBC	TTDDRUID	D04LBC
D04LBC	DRUGNAME	Iclaprim
D04LBC	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Application submitted
D04LBC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
D04LBC	INDICATI	Pneumonia [ICD-11: CA40] Phase 2

D0M1RD	TTDDRUID	D0M1RD
D0M1RD	DRUGNAME	ICT-107
D0M1RD	INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
D0M1RD	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
D0M1RD	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0M1RD	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3

D0O1UT	TTDDRUID	D0O1UT
D0O1UT	DRUGNAME	ICX-PRO
D0O1UT	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D01ZNH	TTDDRUID	D01ZNH
D01ZNH	DRUGNAME	IDAZOXAN HYDROCHLORIDE
D01ZNH	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 3

D0V0KJ	TTDDRUID	D0V0KJ
D0V0KJ	DRUGNAME	IDDBCP161883
D0V0KJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0B5VV	TTDDRUID	D0B5VV
D0B5VV	DRUGNAME	IDegLira
D0B5VV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0W8FK	TTDDRUID	D0W8FK
D0W8FK	DRUGNAME	Idelalisib
D0W8FK	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3

D0RR2E	TTDDRUID	D0RR2E
D0RR2E	DRUGNAME	IDP-122
D0RR2E	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D06GOF	TTDDRUID	D06GOF
D06GOF	DRUGNAME	IDP-123 lotion
D06GOF	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D0XU3D	TTDDRUID	D0XU3D
D0XU3D	DRUGNAME	IDP-124 lotion
D0XU3D	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3

D01CON	TTDDRUID	D01CON
D01CON	DRUGNAME	IGIV3I Grifols 10%
D01CON	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D02UNP	TTDDRUID	D02UNP
D02UNP	DRUGNAME	IMA-901
D02UNP	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D05DBY	TTDDRUID	D05DBY
D05DBY	DRUGNAME	Imagabalin
D05DBY	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 3

D0VU5M	TTDDRUID	D0VU5M
D0VU5M	DRUGNAME	Imiglitazar
D0VU5M	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03QPF	TTDDRUID	D03QPF
D03QPF	DRUGNAME	Immune globulin subcutaneous 20%
D03QPF	INDICATI	Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 3

D0B6WP	TTDDRUID	D0B6WP
D0B6WP	DRUGNAME	Improved influenza vaccine
D0B6WP	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D09NDM	TTDDRUID	D09NDM
D09NDM	DRUGNAME	IN-001
D09NDM	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 3

D00COJ	TTDDRUID	D00COJ
D00COJ	DRUGNAME	Inclisiran
D00COJ	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D0BO0K	TTDDRUID	D0BO0K
D0BO0K	DRUGNAME	INCSHR1210
D0BO0K	INDICATI	Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 3
D0BO0K	INDICATI	Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 3
D0BO0K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07JRF	TTDDRUID	D07JRF
D07JRF	DRUGNAME	Influenza A virus H1N1 vaccine
D07JRF	INDICATI	Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 3

D06LEG	TTDDRUID	D06LEG
D06LEG	DRUGNAME	Influenza A virus H5N1 vaccine
D06LEG	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0A8PC	TTDDRUID	D0A8PC
D0A8PC	DRUGNAME	Influenza cell culture vaccine
D0A8PC	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D00QJL	TTDDRUID	D00QJL
D00QJL	DRUGNAME	Influvac TC
D00QJL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0W8MS	TTDDRUID	D0W8MS
D0W8MS	DRUGNAME	Injectable MPL allergy vaccine
D0W8MS	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 3

D0K4GW	TTDDRUID	D0K4GW
D0K4GW	DRUGNAME	INL-002
D0K4GW	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D05UXU	TTDDRUID	D05UXU
D05UXU	DRUGNAME	INM-176
D05UXU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0E4PQ	TTDDRUID	D0E4PQ
D0E4PQ	DRUGNAME	Inno-LC-01
D0E4PQ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3

D0ZY3E	TTDDRUID	D0ZY3E
D0ZY3E	DRUGNAME	INO-1001
D0ZY3E	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3

D0OX9W	TTDDRUID	D0OX9W
D0OX9W	DRUGNAME	Inolimomab
D0OX9W	INDICATI	Heart transplant rejection [ICD-11: NE84] Phase 3

D0V6EC	TTDDRUID	D0V6EC
D0V6EC	DRUGNAME	INOmax nitric oxide inhalation
D0V6EC	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3

D0Z5UT	TTDDRUID	D0Z5UT
D0Z5UT	DRUGNAME	INOpulse
D0Z5UT	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3

D0KN2C	TTDDRUID	D0KN2C
D0KN2C	DRUGNAME	Insulin long-acting iv
D0KN2C	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0T8LE	TTDDRUID	D0T8LE
D0T8LE	DRUGNAME	INTERCEPT Blood System
D0T8LE	INDICATI	Blood transfusion [ICD-11: QB98] Phase 3

D05DZK	TTDDRUID	D05DZK
D05DZK	DRUGNAME	Interferon alpha 2a
D05DZK	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0IV6S	TTDDRUID	D0IV6S
D0IV6S	DRUGNAME	Intravenous carbamazepine
D0IV6S	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Application submitted
D0IV6S	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D0E2DO	TTDDRUID	D0E2DO
D0E2DO	DRUGNAME	Intravenous glibenclamide
D0E2DO	INDICATI	Stroke [ICD-11: 8B20] Phase 3

D08BBL	TTDDRUID	D08BBL
D08BBL	DRUGNAME	Iomab-B
D08BBL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D08BBL	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 3

D0Z0MI	TTDDRUID	D0Z0MI
D0Z0MI	DRUGNAME	Iomab-B CD45
D0Z0MI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D03PGS	TTDDRUID	D03PGS
D03PGS	DRUGNAME	IONIS-TTRRX
D03PGS	INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3

D0N3SA	TTDDRUID	D0N3SA
D0N3SA	DRUGNAME	IR-201
D0N3SA	INDICATI	Arthritis [ICD-11: FA20] Phase 3

D0C0MN	TTDDRUID	D0C0MN
D0C0MN	DRUGNAME	Irbesartan/ trichlormethiazide fixed-dose combination
D0C0MN	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0CZ1A	TTDDRUID	D0CZ1A
D0CZ1A	DRUGNAME	IRISQUINONE
D0CZ1A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D07VHS	TTDDRUID	D07VHS
D07VHS	DRUGNAME	Isavuconazole
D07VHS	INDICATI	Candidemia [ICD-11: 1F23.3Y] Phase 3
D07VHS	INDICATI	Invasive aspergillosis [ICD-11: 1F20.0] Phase 3
D07VHS	INDICATI	Invasive candidiasis [ICD-11: 1F23] Phase 3

D07TMR	TTDDRUID	D07TMR
D07TMR	DRUGNAME	ISIS 23722
D07TMR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0M7NS	TTDDRUID	D0M7NS
D0M7NS	DRUGNAME	ISIS-APOCIIIRx
D0M7NS	INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Phase 3

D0HL1X	TTDDRUID	D0HL1X
D0HL1X	DRUGNAME	ISIS-PKK
D0HL1X	INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3

D0M7HZ	TTDDRUID	D0M7HZ
D0M7HZ	DRUGNAME	ISIS-SMNRx
D0M7HZ	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 3

D0QM6U	TTDDRUID	D0QM6U
D0QM6U	DRUGNAME	ISIS-TTRRx
D0QM6U	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3

D05PFH	TTDDRUID	D05PFH
D05PFH	DRUGNAME	Isolagen Process
D05PFH	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 3

D0D4ZM	TTDDRUID	D0D4ZM
D0D4ZM	DRUGNAME	ISRAPAFANT
D0D4ZM	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0M2GQ	TTDDRUID	D0M2GQ
D0M2GQ	DRUGNAME	ISS-1018
D0M2GQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3

D0TA8H	TTDDRUID	D0TA8H
D0TA8H	DRUGNAME	Istodaxromidepsin
D0TA8H	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 3

D06PEW	TTDDRUID	D06PEW
D06PEW	DRUGNAME	IT-101
D06PEW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D09GRT	TTDDRUID	D09GRT
D09GRT	DRUGNAME	ITCA 650
D09GRT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0GH3Q	TTDDRUID	D0GH3Q
D0GH3Q	DRUGNAME	ITF2357
D0GH3Q	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3
D0GH3Q	INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2
D0GH3Q	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
D0GH3Q	INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2

D0Q0EF	TTDDRUID	D0Q0EF
D0Q0EF	DRUGNAME	ITI-007
D0Q0EF	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3
D0Q0EF	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 3
D0Q0EF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
D0Q0EF	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D06QSN	TTDDRUID	D06QSN
D06QSN	DRUGNAME	Itolizumab
D06QSN	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D0EV2U	TTDDRUID	D0EV2U
D0EV2U	DRUGNAME	IV aprepitant
D0EV2U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0Y2SW	TTDDRUID	D0Y2SW
D0Y2SW	DRUGNAME	Ixazomib
D0Y2SW	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D09MHN	TTDDRUID	D09MHN
D09MHN	DRUGNAME	Ixmyelocel-T
D09MHN	INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 3
D09MHN	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D09MHN	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D0D8KQ	TTDDRUID	D0D8KQ
D0D8KQ	DRUGNAME	Jakafi
D0D8KQ	INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 3

D08PCH	TTDDRUID	D08PCH
D08PCH	DRUGNAME	Javelin
D08PCH	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D03EBV	TTDDRUID	D03EBV
D03EBV	DRUGNAME	JNS-001
D03EBV	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D0KD8P	TTDDRUID	D0KD8P
D0KD8P	DRUGNAME	Juvenile rheumatoid arthritis therapeutic
D0KD8P	INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3

D0HB0V	TTDDRUID	D0HB0V
D0HB0V	DRUGNAME	JX-594
D0HB0V	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0HB0V	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D0HB0V	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2

D0M3CV	TTDDRUID	D0M3CV
D0M3CV	DRUGNAME	JZP-110
D0M3CV	INDICATI	Narcolepsy [ICD-11: 7A20] Phase 3

D0R4OI	TTDDRUID	D0R4OI
D0R4OI	DRUGNAME	K-103-IP
D0R4OI	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D04QIE	TTDDRUID	D04QIE
D04QIE	DRUGNAME	K-877
D04QIE	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D04QIE	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3

D0AY0U	TTDDRUID	D0AY0U
D0AY0U	DRUGNAME	Kadcyla
D0AY0U	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D02CZK	TTDDRUID	D02CZK
D02CZK	DRUGNAME	Karenitecin
D02CZK	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
D02CZK	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D06WRF	TTDDRUID	D06WRF
D06WRF	DRUGNAME	KD019
D06WRF	INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
D06WRF	INDICATI	Meningioma metastases [ICD-11: 2D51] Phase 2
D06WRF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D06WRF	INDICATI	Polycystic kidney disease [ICD-11: GB8Y] Phase 2
D06WRF	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0O9XO	TTDDRUID	D0O9XO
D0O9XO	DRUGNAME	KH-902
D0O9XO	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3

D09LIZ	TTDDRUID	D09LIZ
D09LIZ	DRUGNAME	KI-0502
D09LIZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0S6HR	TTDDRUID	D0S6HR
D0S6HR	DRUGNAME	KI-0802
D0S6HR	INDICATI	Gastrointestinal ulcer [ICD-11: DA60.Z] Phase 3

D0QP9A	TTDDRUID	D0QP9A
D0QP9A	DRUGNAME	KI-1001
D0QP9A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0ZG5K	TTDDRUID	D0ZG5K
D0ZG5K	DRUGNAME	Kiacta
D0ZG5K	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3

D0D0RW	TTDDRUID	D0D0RW
D0D0RW	DRUGNAME	KMB-17
D0D0RW	INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 3

D01WWD	TTDDRUID	D01WWD
D01WWD	DRUGNAME	KPS-0373
D01WWD	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D0E9NU	TTDDRUID	D0E9NU
D0E9NU	DRUGNAME	KRN-23
D0E9NU	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3
D0E9NU	INDICATI	X-linked hypophosphataemia [ICD-11: 5C63.22] Phase 3

D06XMF	TTDDRUID	D06XMF
D06XMF	DRUGNAME	KT&G-101
D06XMF	INDICATI	Atrophy [ICD-11: 9A2Y-9C40] Phase 3

D0C6ZX	TTDDRUID	D0C6ZX
D0C6ZX	DRUGNAME	KW-3357
D0C6ZX	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 3

D0F4ZY	TTDDRUID	D0F4ZY
D0F4ZY	DRUGNAME	KW-6002
D0F4ZY	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
D0F4ZY	INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1

D0TY3L	TTDDRUID	D0TY3L
D0TY3L	DRUGNAME	KX-01 ointment
D0TY3L	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 3

D05IIP	TTDDRUID	D05IIP
D05IIP	DRUGNAME	L-651582
D05IIP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D07JZT	TTDDRUID	D07JZT
D07JZT	DRUGNAME	LA-EP2006
D07JZT	INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 3

D0Y0EP	TTDDRUID	D0Y0EP
D0Y0EP	DRUGNAME	Lanabecestat
D0Y0EP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0O9VW	TTDDRUID	D0O9VW
D0O9VW	DRUGNAME	Lanperisone
D0O9VW	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 3

D09INF	TTDDRUID	D09INF
D09INF	DRUGNAME	Laquinamod
D09INF	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0JN5N	TTDDRUID	D0JN5N
D0JN5N	DRUGNAME	Laquinimod
D0JN5N	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
D0JN5N	INDICATI	Lupus [ICD-11: 4A40] Phase 3
D0JN5N	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D0JN5N	INDICATI	Primary progressive multiple sclerosis [ICD-11: 8A40.1] Phase 2

D0E5DB	TTDDRUID	D0E5DB
D0E5DB	DRUGNAME	Laromustine
D0E5DB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D00QNW	TTDDRUID	D00QNW
D00QNW	DRUGNAME	Laropiprant/niacin/ simvastatin combination
D00QNW	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3

D0O0HU	TTDDRUID	D0O0HU
D0O0HU	DRUGNAME	LAS-41007
D0O0HU	INDICATI	Keratosis [ICD-11: ED56] Phase 3

D01NQM	TTDDRUID	D01NQM
D01NQM	DRUGNAME	Lasmiditan
D01NQM	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D0H1UW	TTDDRUID	D0H1UW
D0H1UW	DRUGNAME	LATIN T1D
D0H1UW	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D00JJZ	TTDDRUID	D00JJZ
D00JJZ	DRUGNAME	LaViv
D00JJZ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D05GJP	TTDDRUID	D05GJP
D05GJP	DRUGNAME	LBVH-0101
D05GJP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D02ZBW	TTDDRUID	D02ZBW
D02ZBW	DRUGNAME	LC-150444
D02ZBW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03AJU	TTDDRUID	D03AJU
D03AJU	DRUGNAME	LCI699
D03AJU	INDICATI	Cushing disease [ICD-11: 5A70] Phase 3

D0F1CE	TTDDRUID	D0F1CE
D0F1CE	DRUGNAME	LCQ908
D0F1CE	INDICATI	Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 3
D0F1CE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
D0F1CE	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3

D0A4DP	TTDDRUID	D0A4DP
D0A4DP	DRUGNAME	LCS 16
D0A4DP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D0A4DP	INDICATI	Contraception [ICD-11: QA21] Phase 3

D0SM8S	TTDDRUID	D0SM8S
D0SM8S	DRUGNAME	Lebrikizumab
D0SM8S	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D0SM8S	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
D0SM8S	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
D0SM8S	INDICATI	Severe asthma [ICD-11: CA23] Phase 3

D08MXP	TTDDRUID	D08MXP
D08MXP	DRUGNAME	LEE011
D08MXP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D08MXP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D03KSK	TTDDRUID	D03KSK
D03KSK	DRUGNAME	Lenvima
D03KSK	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D02ZZG	TTDDRUID	D02ZZG
D02ZZG	DRUGNAME	LEO 43204
D02ZZG	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
D02ZZG	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
D02ZZG	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3

D06QZL	TTDDRUID	D06QZL
D06QZL	DRUGNAME	Lerisetron
D06QZL	INDICATI	Nausea [ICD-11: MD90] Phase 3
D06QZL	INDICATI	Testicular germ cell tumour [ICD-11: 2C80.2] Phase 3
D06QZL	INDICATI	Vomiting [ICD-11: MD90] Phase 3

D0X0GB	TTDDRUID	D0X0GB
D0X0GB	DRUGNAME	Letibotulinumtoxina
D0X0GB	INDICATI	Glabellar frown line [ICD-11: NA0Z] Phase 3

D0L2JM	TTDDRUID	D0L2JM
D0L2JM	DRUGNAME	Levomequitazine
D0L2JM	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 3

D0ZO2Z	TTDDRUID	D0ZO2Z
D0ZO2Z	DRUGNAME	Lingliptin + pioglitazone
D0ZO2Z	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D08YHS	TTDDRUID	D08YHS
D08YHS	DRUGNAME	Linopirdine
D08YHS	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D0X4UP	TTDDRUID	D0X4UP
D0X4UP	DRUGNAME	Liposomal amikacin
D0X4UP	INDICATI	Bronchiectasis [ICD-11: CA24] Phase 2
D0X4UP	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3

D08RTN	TTDDRUID	D08RTN
D08RTN	DRUGNAME	Liposomal encapsulated paclitaxel (LEP)
D08RTN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0T9LR	TTDDRUID	D0T9LR
D0T9LR	DRUGNAME	Liprotamase
D0T9LR	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 3

D0O3EX	TTDDRUID	D0O3EX
D0O3EX	DRUGNAME	LIQ861
D0O3EX	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3

D07AHC	TTDDRUID	D07AHC
D07AHC	DRUGNAME	LITOXETINE
D07AHC	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3

D0Z0HL	TTDDRUID	D0Z0HL
D0Z0HL	DRUGNAME	Lixisenatide + Lantus
D0Z0HL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D07EEN	TTDDRUID	D07EEN
D07EEN	DRUGNAME	Lixivaptan
D07EEN	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
D07EEN	INDICATI	Hyponatraemia [ICD-11: 5C72] Phase 3
D07EEN	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2

D0CE6C	TTDDRUID	D0CE6C
D0CE6C	DRUGNAME	LMI070
D0CE6C	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 3

D0VN3O	TTDDRUID	D0VN3O
D0VN3O	DRUGNAME	Lmprime P66
D0VN3O	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D05XDZ	TTDDRUID	D05XDZ
D05XDZ	DRUGNAME	LMT-X
D05XDZ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D05XDZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0Y2RF	TTDDRUID	D0Y2RF
D0Y2RF	DRUGNAME	Lnfluvac TC
D0Y2RF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D04BCB	TTDDRUID	D04BCB
D04BCB	DRUGNAME	Lobeglitazone
D04BCB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0PM0Y	TTDDRUID	D0PM0Y
D0PM0Y	DRUGNAME	Lonsurf
D0PM0Y	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D0C8DD	TTDDRUID	D0C8DD
D0C8DD	DRUGNAME	Losmapimod
D0C8DD	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3

D0O8YC	TTDDRUID	D0O8YC
D0O8YC	DRUGNAME	Low dose fentanyl
D0O8YC	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D03XWL	TTDDRUID	D03XWL
D03XWL	DRUGNAME	Low dose ITI-007
D03XWL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0A0NZ	TTDDRUID	D0A0NZ
D0A0NZ	DRUGNAME	LP-02
D0A0NZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D09IRN	TTDDRUID	D09IRN
D09IRN	DRUGNAME	LU AE58054
D09IRN	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D04NPR	TTDDRUID	D04NPR
D04NPR	DRUGNAME	Lu AF35700
D04NPR	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0V6OA	TTDDRUID	D0V6OA
D0V6OA	DRUGNAME	Lurbinectedin
D0V6OA	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
D0V6OA	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0V6OA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D0V6OA	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D0S0WR	TTDDRUID	D0S0WR
D0S0WR	DRUGNAME	Luspatercept
D0S0WR	INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 3
D0S0WR	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3

D0U7IL	TTDDRUID	D0U7IL
D0U7IL	DRUGNAME	LX-4211
D0U7IL	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D0U7IL	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
D0U7IL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
D0U7IL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0X2LQ	TTDDRUID	D0X2LQ
D0X2LQ	DRUGNAME	LY03004
D0X2LQ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
D0X2LQ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0L6NW	TTDDRUID	D0L6NW
D0L6NW	DRUGNAME	LY2605541
D0L6NW	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 3

D0XZ9H	TTDDRUID	D0XZ9H
D0XZ9H	DRUGNAME	LY2951742
D0XZ9H	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D01LOE	TTDDRUID	D01LOE
D01LOE	DRUGNAME	LY2963016
D01LOE	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 3

D0B6RA	TTDDRUID	D0B6RA
D0B6RA	DRUGNAME	LY404039
D0B6RA	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0N8UY	TTDDRUID	D0N8UY
D0N8UY	DRUGNAME	LY-686017
D0N8UY	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D0N8UY	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3

D06SVC	TTDDRUID	D06SVC
D06SVC	DRUGNAME	M-0011
D06SVC	INDICATI	Alpha-mannosidosis [ICD-11: 5C56.21] Phase 3

D0HZ2E	TTDDRUID	D0HZ2E
D0HZ2E	DRUGNAME	M100907
D0HZ2E	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 3

D04WVI	TTDDRUID	D04WVI
D04WVI	DRUGNAME	M-17 E. Coli
D04WVI	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3

D0K5ET	TTDDRUID	D0K5ET
D0K5ET	DRUGNAME	M207
D0K5ET	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D0A8KX	TTDDRUID	D0A8KX
D0A8KX	DRUGNAME	M-518101
D0A8KX	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D0A8KX	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D0J0FD	TTDDRUID	D0J0FD
D0J0FD	DRUGNAME	MACI
D0J0FD	INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Phase 3
D0J0FD	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D02MPT	TTDDRUID	D02MPT
D02MPT	DRUGNAME	MAGE-A3 immunotherapeutic
D02MPT	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D02MPT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D02MPT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D01IUS	TTDDRUID	D01IUS
D01IUS	DRUGNAME	Mapracorat
D01IUS	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 3

D01YYP	TTDDRUID	D01YYP
D01YYP	DRUGNAME	Margetuximab
D01YYP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D01YYP	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D01YYP	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 2

D07WXI	TTDDRUID	D07WXI
D07WXI	DRUGNAME	Maribavir
D07WXI	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3

D05VZE	TTDDRUID	D05VZE
D05VZE	DRUGNAME	Marimastat
D05VZE	INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3
D05VZE	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 3
D05VZE	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0MW0N	TTDDRUID	D0MW0N
D0MW0N	DRUGNAME	Masitinib
D0MW0N	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
D0MW0N	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 3
D0MW0N	INDICATI	Metastatic gastric or gastroesophageal junction cancer [ICD-11: 2D8Y] Phase 3
D0MW0N	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D0MW0N	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0MW0N	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0J9VL	TTDDRUID	D0J9VL
D0J9VL	DRUGNAME	MC2-01 PAD cream
D0J9VL	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D0R7UL	TTDDRUID	D0R7UL
D0R7UL	DRUGNAME	MD1003
D0R7UL	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D06ICW	TTDDRUID	D06ICW
D06ICW	DRUGNAME	MDI-P
D06ICW	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0OG1V	TTDDRUID	D0OG1V
D0OG1V	DRUGNAME	MDX-066
D0OG1V	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 3

D04RRZ	TTDDRUID	D04RRZ
D04RRZ	DRUGNAME	MEDI4736
D04RRZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0N3ZN	TTDDRUID	D0N3ZN
D0N3ZN	DRUGNAME	MEDI-8662
D0N3ZN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0U9MJ	TTDDRUID	D0U9MJ
D0U9MJ	DRUGNAME	Melanoma vaccine
D0U9MJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0Z3ES	TTDDRUID	D0Z3ES
D0Z3ES	DRUGNAME	Melanoma vaccine, University of Virginia
D0Z3ES	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D06ZJD	TTDDRUID	D06ZJD
D06ZJD	DRUGNAME	Melapuldencel-T
D06ZJD	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0KW4J	TTDDRUID	D0KW4J
D0KW4J	DRUGNAME	Melphalan drug delivery system
D0KW4J	INDICATI	Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3

D00BVB	TTDDRUID	D00BVB
D00BVB	DRUGNAME	Men Quad TT
D00BVB	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3

D0OD3T	TTDDRUID	D0OD3T
D0OD3T	DRUGNAME	Meningococcal ACYW-135 vaccine
D0OD3T	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3

D0B3SV	TTDDRUID	D0B3SV
D0B3SV	DRUGNAME	Meningococcal vaccine group B quadrivalent recombinant vaccine
D0B3SV	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3

D0F8VM	TTDDRUID	D0F8VM
D0F8VM	DRUGNAME	Meningococcal vaccine groups A,C,Y,W-135 conjugate
D0F8VM	INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 3

D0C5MG	TTDDRUID	D0C5MG
D0C5MG	DRUGNAME	Methylphenidate sustained release
D0C5MG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D0S7PJ	TTDDRUID	D0S7PJ
D0S7PJ	DRUGNAME	Metronidazole 10% ointment
D0S7PJ	INDICATI	Perianal crohn disease [ICD-11: DD70.4] Phase 3

D02GLD	TTDDRUID	D02GLD
D02GLD	DRUGNAME	MF-101
D02GLD	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 3

D07VAQ	TTDDRUID	D07VAQ
D07VAQ	DRUGNAME	MG-1109
D07VAQ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0F7YW	TTDDRUID	D0F7YW
D0F7YW	DRUGNAME	MGN-1703
D0F7YW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0F7YW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04IJZ	TTDDRUID	D04IJZ
D04IJZ	DRUGNAME	Microplasmin
D04IJZ	INDICATI	Eye disorder [ICD-11: 9A01-9A0Z] Phase 3

D0UE8H	TTDDRUID	D0UE8H
D0UE8H	DRUGNAME	Midazolam intranasal spray
D0UE8H	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3

D0C2OR	TTDDRUID	D0C2OR
D0C2OR	DRUGNAME	MIM-D3
D0C2OR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0E7QB	TTDDRUID	D0E7QB
D0E7QB	DRUGNAME	Mirikizumab
D0E7QB	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D07VFD	TTDDRUID	D07VFD
D07VFD	DRUGNAME	Mirogabalin
D07VFD	INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
D07VFD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D07VFD	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 3
D07VFD	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Registered

D0RP2W	TTDDRUID	D0RP2W
D0RP2W	DRUGNAME	Mirvetuximab soravtansine
D0RP2W	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1
D0RP2W	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D04FNR	TTDDRUID	D04FNR
D04FNR	DRUGNAME	Mitumomab
D04FNR	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D07CCV	TTDDRUID	D07CCV
D07CCV	DRUGNAME	MK-0431C
D07CCV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D01KEB	TTDDRUID	D01KEB
D01KEB	DRUGNAME	MK-1293
D01KEB	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
D01KEB	INDICATI	Type-1 diabetes [ICD-11: 5A10] Application submitted
D01KEB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted

D07GXR	TTDDRUID	D07GXR
D07GXR	DRUGNAME	MK-1602
D07GXR	INDICATI	Migraine [ICD-11: 8A80] Phase 2
D07GXR	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D0M3XR	TTDDRUID	D0M3XR
D0M3XR	DRUGNAME	MK-3102
D0M3XR	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0P1ME	TTDDRUID	D0P1ME
D0P1ME	DRUGNAME	MK-3222
D0P1ME	INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Phase 3
D0P1ME	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D0P1ME	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D0O9OS	TTDDRUID	D0O9OS
D0O9OS	DRUGNAME	MK-3222/SCH 900222
D0O9OS	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D06IBG	TTDDRUID	D06IBG
D06IBG	DRUGNAME	MK-3415A
D06IBG	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3
D06IBG	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D07FPJ	TTDDRUID	D07FPJ
D07FPJ	DRUGNAME	MK-4214
D07FPJ	INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 3

D02TJT	TTDDRUID	D02TJT
D02TJT	DRUGNAME	MK-8109
D02TJT	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0G3OI	TTDDRUID	D0G3OI
D0G3OI	DRUGNAME	MK-8237
D0G3OI	INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 3

D03GCR	TTDDRUID	D03GCR
D03GCR	DRUGNAME	MK-8742
D03GCR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0GP8N	TTDDRUID	D0GP8N
D0GP8N	DRUGNAME	MK-8808
D0GP8N	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
D0GP8N	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D09UVK	TTDDRUID	D09UVK
D09UVK	DRUGNAME	MK-8835A
D09UVK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0RA5E	TTDDRUID	D0RA5E
D0RA5E	DRUGNAME	MK-8835B
D0RA5E	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0FP5B	TTDDRUID	D0FP5B
D0FP5B	DRUGNAME	MK-8962
D0FP5B	INDICATI	Fertility problem [ICD-11: 5A61] Phase 3

D0ZD2M	TTDDRUID	D0ZD2M
D0ZD2M	DRUGNAME	MLN4924
D0ZD2M	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2
D0ZD2M	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D0ZD2M	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
D0ZD2M	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D0S4JK	TTDDRUID	D0S4JK
D0S4JK	DRUGNAME	MLN8237
D0S4JK	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0S4JK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D07HOH	TTDDRUID	D07HOH
D07HOH	DRUGNAME	MM-398
D07HOH	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D04VRN	TTDDRUID	D04VRN
D04VRN	DRUGNAME	MMR
D04VRN	INDICATI	Measles [ICD-11: 1F03] Phase 3
D04VRN	INDICATI	Mumps virus infection [ICD-11: 1D80] Phase 3
D04VRN	INDICATI	Rubella prophylaxis [ICD-11: 1F02] Phase 3

D00ZGT	TTDDRUID	D00ZGT
D00ZGT	DRUGNAME	MMR vaccine
D00ZGT	INDICATI	Measles [ICD-11: 1F03] Phase 3
D00ZGT	INDICATI	Mumps virus infection [ICD-11: 1D80] Phase 3
D00ZGT	INDICATI	Rubella prophylaxis [ICD-11: 1F02] Phase 3

D0ZH4J	TTDDRUID	D0ZH4J
D0ZH4J	DRUGNAME	MOB015B
D0ZH4J	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 3

D0D5ZJ	TTDDRUID	D0D5ZJ
D0D5ZJ	DRUGNAME	Momelotinib
D0D5ZJ	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 3
D0D5ZJ	INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
D0D5ZJ	INDICATI	Thrombocythemia [ICD-11: 3B63] Phase 2

D01UXW	TTDDRUID	D01UXW
D01UXW	DRUGNAME	Morphine-6-glucuronide
D01UXW	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0O3OK	TTDDRUID	D0O3OK
D0O3OK	DRUGNAME	Motavizumab
D0O3OK	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3

D0U3RV	TTDDRUID	D0U3RV
D0U3RV	DRUGNAME	Motexafin lutetium
D0U3RV	INDICATI	Artery stenosis [ICD-11: BD52] Phase 3

D0Y5IH	TTDDRUID	D0Y5IH
D0Y5IH	DRUGNAME	MPDL-3280A
D0Y5IH	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D08UZP	TTDDRUID	D08UZP
D08UZP	DRUGNAME	MPL-containing Pollinex allergy desensitization injectable vaccine
D08UZP	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3

D0T4GZ	TTDDRUID	D0T4GZ
D0T4GZ	DRUGNAME	MPL-S
D0T4GZ	INDICATI	Endotoxic shock [ICD-11: 1G41] Phase 3

D0ZR8T	TTDDRUID	D0ZR8T
D0ZR8T	DRUGNAME	MSB 11022
D0ZR8T	INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 3

D06GGL	TTDDRUID	D06GGL
D06GGL	DRUGNAME	MSB11022
D06GGL	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D07TSS	TTDDRUID	D07TSS
D07TSS	DRUGNAME	MSC-100-IV
D07TSS	INDICATI	Crohn disease [ICD-11: DD70] Phase 3

D04MMW	TTDDRUID	D04MMW
D04MMW	DRUGNAME	MST-188
D04MMW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0P5TG	TTDDRUID	D0P5TG
D0P5TG	DRUGNAME	Multi-epitope peptide melanoma vaccine
D0P5TG	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0ZP3Q	TTDDRUID	D0ZP3Q
D0ZP3Q	DRUGNAME	Multikine
D0ZP3Q	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3

D00IVF	TTDDRUID	D00IVF
D00IVF	DRUGNAME	Murepavadin
D00IVF	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 3

D04OQT	TTDDRUID	D04OQT
D04OQT	DRUGNAME	Musculoskeletal mab therapeutic
D04OQT	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 3

D0H1PK	TTDDRUID	D0H1PK
D0H1PK	DRUGNAME	MVA-BN
D0H1PK	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3

D0NL5M	TTDDRUID	D0NL5M
D0NL5M	DRUGNAME	Mycobacterial cell wall-DNA complex
D0NL5M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0DR4W	TTDDRUID	D0DR4W
D0DR4W	DRUGNAME	MyoCell SDF-1
D0DR4W	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D00UUL	TTDDRUID	D00UUL
D00UUL	DRUGNAME	N8-GP
D00UUL	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Phase 3

D05RBH	TTDDRUID	D05RBH
D05RBH	DRUGNAME	N9-GP
D05RBH	INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1

D0Y3TY	TTDDRUID	D0Y3TY
D0Y3TY	DRUGNAME	NAB-001
D0Y3TY	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 3

D0C5CE	TTDDRUID	D0C5CE
D0C5CE	DRUGNAME	Nabiximols
D0C5CE	INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
D0C5CE	INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 3

D0X4TK	TTDDRUID	D0X4TK
D0X4TK	DRUGNAME	Nadofaragene firadenovec
D0X4TK	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3

D01ASJ	TTDDRUID	D01ASJ
D01ASJ	DRUGNAME	Nalbuphine hydrochloride ER
D01ASJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0IO1H	TTDDRUID	D0IO1H
D0IO1H	DRUGNAME	Naloxone sublingual spray
D0IO1H	INDICATI	Respiratory depression [ICD-11: MD11.5] Phase 3

D0L6XH	TTDDRUID	D0L6XH
D0L6XH	DRUGNAME	Naloxone topical
D0L6XH	INDICATI	Pruritus [ICD-11: EC90] Phase 3

D01IGZ	TTDDRUID	D01IGZ
D01IGZ	DRUGNAME	Napabucasin
D01IGZ	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2
D01IGZ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D01IGZ	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1/2
D01IGZ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D01IGZ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D01IGZ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
D01IGZ	INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2
D01IGZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D01IGZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0U5OU	TTDDRUID	D0U5OU
D0U5OU	DRUGNAME	Naproxcinod
D0U5OU	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 3

D0M2EG	TTDDRUID	D0M2EG
D0M2EG	DRUGNAME	Nasal glucagon
D0M2EG	INDICATI	Hypoglycemia [ICD-11: 5A41] Phase 3

D0U4SM	TTDDRUID	D0U4SM
D0U4SM	DRUGNAME	NASVAC
D0U4SM	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D05WDG	TTDDRUID	D05WDG
D05WDG	DRUGNAME	Natroba
D05WDG	INDICATI	Sarcoptes scabiei infection [ICD-11: 1G04] Phase 3

D0X8HB	TTDDRUID	D0X8HB
D0X8HB	DRUGNAME	NAV5001
D0X8HB	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 3

D02UOZ	TTDDRUID	D02UOZ
D02UOZ	DRUGNAME	NB-001
D02UOZ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0IX1I	TTDDRUID	D0IX1I
D0IX1I	DRUGNAME	NBI-98854
D0IX1I	INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Phase 3
D0IX1I	INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2

D0DY7W	TTDDRUID	D0DY7W
D0DY7W	DRUGNAME	Nebracetam
D0DY7W	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D0F8UV	TTDDRUID	D0F8UV
D0F8UV	DRUGNAME	Nelipepimut S
D0F8UV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0F8UV	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0F8UV	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D04ETV	TTDDRUID	D04ETV
D04ETV	DRUGNAME	Nemonaxacin
D04ETV	INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 3

D0P0RX	TTDDRUID	D0P0RX
D0P0RX	DRUGNAME	Nemonoxacin
D0P0RX	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
D0P0RX	INDICATI	infection associated with diabetic foot ulcers [ICD-11: BD54] Phase 3

D04VCS	TTDDRUID	D04VCS
D04VCS	DRUGNAME	Neocartilage
D04VCS	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0XP7T	TTDDRUID	D0XP7T
D0XP7T	DRUGNAME	NEOD001
D0XP7T	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3

D03LVV	TTDDRUID	D03LVV
D03LVV	DRUGNAME	Neridronate intravenous
D03LVV	INDICATI	Complex regional pain syndrome [ICD-11: 8D8A.0] Phase 3

D02HUB	TTDDRUID	D02HUB
D02HUB	DRUGNAME	Nestorone transdermal spray
D02HUB	INDICATI	Endometriosis [ICD-11: GA10] Phase 3

D04OXD	TTDDRUID	D04OXD
D04OXD	DRUGNAME	Netivudine
D04OXD	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3

D0G3YC	TTDDRUID	D0G3YC
D0G3YC	DRUGNAME	Netupitant
D0G3YC	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 3

D01JGE	TTDDRUID	D01JGE
D01JGE	DRUGNAME	Netupitant/palonosetron
D01JGE	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 3

D00ZPR	TTDDRUID	D00ZPR
D00ZPR	DRUGNAME	Neucardin
D00ZPR	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2
D00ZPR	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D04VRB	TTDDRUID	D04VRB
D04VRB	DRUGNAME	NeuVax
D04VRB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00JCA	TTDDRUID	D00JCA
D00JCA	DRUGNAME	NewGam
D00JCA	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 3

D0T9DA	TTDDRUID	D0T9DA
D0T9DA	DRUGNAME	NGF-hTNF
D0T9DA	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D08GIH	TTDDRUID	D08GIH
D08GIH	DRUGNAME	NGR-hTNF
D08GIH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D08GIH	INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3

D0Z2GF	TTDDRUID	D0Z2GF
D0Z2GF	DRUGNAME	NI-101
D0Z2GF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0Z2UW	TTDDRUID	D0Z2UW
D0Z2UW	DRUGNAME	Nicaraven
D0Z2UW	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Phase 3

D08XMM	TTDDRUID	D08XMM
D08XMM	DRUGNAME	NicVAX
D08XMM	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 3

D0FO7G	TTDDRUID	D0FO7G
D0FO7G	DRUGNAME	Nintedanib
D0FO7G	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 3

D0N5GV	TTDDRUID	D0N5GV
D0N5GV	DRUGNAME	Nivolumab + ipilimumab
D0N5GV	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
D0N5GV	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 3
D0N5GV	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
D0N5GV	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0N5GV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0K2ID	TTDDRUID	D0K2ID
D0K2ID	DRUGNAME	NKTR-181
D0K2ID	INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
D0K2ID	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
D0K2ID	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D06LFV	TTDDRUID	D06LFV
D06LFV	DRUGNAME	NM-702
D06LFV	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3

D0V2OL	TTDDRUID	D0V2OL
D0V2OL	DRUGNAME	NN1841
D0V2OL	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3

D0U8YK	TTDDRUID	D0U8YK
D0U8YK	DRUGNAME	NN5401
D0U8YK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D06PBH	TTDDRUID	D06PBH
D06PBH	DRUGNAME	NN8640
D06PBH	INDICATI	Growth failure [ICD-11: LD2F.1Y] Phase 3

D0X3GA	TTDDRUID	D0X3GA
D0X3GA	DRUGNAME	NN8717
D0X3GA	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3

D0L6BH	TTDDRUID	D0L6BH
D0L6BH	DRUGNAME	NN9068
D0L6BH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D06WQT	TTDDRUID	D06WQT
D06WQT	DRUGNAME	Nolatrexed
D06WQT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D09FNI	TTDDRUID	D09FNI
D09FNI	DRUGNAME	Nonocog beta pegol
D09FNI	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 3

D09HOJ	TTDDRUID	D09HOJ
D09HOJ	DRUGNAME	NPB-01
D09HOJ	INDICATI	Pemphigoid [ICD-11: EB41] Phase 3

D0VF3C	TTDDRUID	D0VF3C
D0VF3C	DRUGNAME	NPC-01
D0VF3C	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 3

D0IA0N	TTDDRUID	D0IA0N
D0IA0N	DRUGNAME	NRL-1
D0IA0N	INDICATI	Acute repetitive seizure [ICD-11: 8A67] Phase 3
D0IA0N	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3

D0VW4J	TTDDRUID	D0VW4J
D0VW4J	DRUGNAME	NT0102
D0VW4J	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3

D04IUB	TTDDRUID	D04IUB
D04IUB	DRUGNAME	NT0202
D04IUB	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D0D0LH	TTDDRUID	D0D0LH
D0D0LH	DRUGNAME	NU-100
D0D0LH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0U7AH	TTDDRUID	D0U7AH
D0U7AH	DRUGNAME	NurOwn
D0U7AH	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3

D0B3FV	TTDDRUID	D0B3FV
D0B3FV	DRUGNAME	NVP-LAQ824
D0B3FV	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3
D0B3FV	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
D0B3FV	INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2

D0TY5K	TTDDRUID	D0TY5K
D0TY5K	DRUGNAME	NWP-09
D0TY5K	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D07YAR	TTDDRUID	D07YAR
D07YAR	DRUGNAME	NX-1207
D07YAR	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D0S0HA	TTDDRUID	D0S0HA
D0S0HA	DRUGNAME	O6-Benzylguanine alkylade
D0S0HA	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3

D03SIA	TTDDRUID	D03SIA
D03SIA	DRUGNAME	OBI-1
D03SIA	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Phase 3

D05RJP	TTDDRUID	D05RJP
D05RJP	DRUGNAME	Oblimersen
D05RJP	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D05RJP	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0U8VL	TTDDRUID	D0U8VL
D0U8VL	DRUGNAME	Octagam 10%
D0U8VL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D01CXY	TTDDRUID	D01CXY
D01CXY	DRUGNAME	ODM-201
D01CXY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D02RNS	TTDDRUID	D02RNS
D02RNS	DRUGNAME	Oglufanide
D02RNS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D08BMC	TTDDRUID	D08BMC
D08BMC	DRUGNAME	Olea europaea-containing vaccine
D08BMC	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3

D0Q3HO	TTDDRUID	D0Q3HO
D0Q3HO	DRUGNAME	Oligonucleotide decoys (NFkappaB)
D0Q3HO	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3

D0Z7AB	TTDDRUID	D0Z7AB
D0Z7AB	DRUGNAME	Olodaterol/tiotropium bromide
D0Z7AB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D00NUG	TTDDRUID	D00NUG
D00NUG	DRUGNAME	Olokizumab
D00NUG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D00NUG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0W4NM	TTDDRUID	D0W4NM
D0W4NM	DRUGNAME	Oltipraz
D0W4NM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D07IFS	TTDDRUID	D07IFS
D07IFS	DRUGNAME	Omadacycline intravenous
D07IFS	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Approved
D07IFS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D0E9CC	TTDDRUID	D0E9CC
D0E9CC	DRUGNAME	Ombrabulin
D0E9CC	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3

D0YL8U	TTDDRUID	D0YL8U
D0YL8U	DRUGNAME	Omecamtiv mecarbil
D0YL8U	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D0YL8U	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D0JW7D	TTDDRUID	D0JW7D
D0JW7D	DRUGNAME	Omiganan
D0JW7D	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
D0JW7D	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D0JW7D	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
D0JW7D	INDICATI	External genital and perianal wart [ICD-11: 1A95] Phase 2
D0JW7D	INDICATI	Rosacea [ICD-11: ED90.0] Phase 3
D0JW7D	INDICATI	Vulvar intraepithelial neoplasia [ICD-11: 2E67.10] Phase 2

D07HAR	TTDDRUID	D07HAR
D07HAR	DRUGNAME	OMS-302
D07HAR	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D03QTM	TTDDRUID	D03QTM
D03QTM	DRUGNAME	Oncophage vitespen
D03QTM	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D05JEL	TTDDRUID	D05JEL
D05JEL	DRUGNAME	Onzeald
D05JEL	INDICATI	Brain metastases [ICD-11: 2D50] Phase 3
D05JEL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D02MLV	TTDDRUID	D02MLV
D02MLV	DRUGNAME	Onzetra Xsail
D02MLV	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D01SGK	TTDDRUID	D01SGK
D01SGK	DRUGNAME	Opicapone
D01SGK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D0U8ZD	TTDDRUID	D0U8ZD
D0U8ZD	DRUGNAME	OPT-822/OPT-821
D0U8ZD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D06CMA	TTDDRUID	D06CMA
D06CMA	DRUGNAME	Oral controlled-release therapy
D06CMA	INDICATI	Drug delivery platform [ICD-11: N.A.] Phase 3

D0VD8S	TTDDRUID	D0VD8S
D0VD8S	DRUGNAME	Oral-lyn
D0VD8S	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D04UWU	TTDDRUID	D04UWU
D04UWU	DRUGNAME	Oraxol
D04UWU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D04UWU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D04UWU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D07HUW	TTDDRUID	D07HUW
D07HUW	DRUGNAME	Oregovomab
D07HUW	INDICATI	Epithelial ovarian cancer [ICD-11: 2B5D] Phase 2
D07HUW	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D01KIC	TTDDRUID	D01KIC
D01KIC	DRUGNAME	ORV-116E
D01KIC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0A4FE	TTDDRUID	D0A4FE
D0A4FE	DRUGNAME	OS-320
D0A4FE	INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 3
D0A4FE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D09OHH	TTDDRUID	D09OHH
D09OHH	DRUGNAME	OS-440
D09OHH	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D09OHH	INDICATI	Muscle spasm [ICD-11: MB47.3] Application submitted

D01CBK	TTDDRUID	D01CBK
D01CBK	DRUGNAME	OSE2101
D01CBK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D01CBK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0BC0F	TTDDRUID	D0BC0F
D0BC0F	DRUGNAME	OSE-300
D0BC0F	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D01GFX	TTDDRUID	D01GFX
D01GFX	DRUGNAME	OSI-906
D01GFX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D05WUN	TTDDRUID	D05WUN
D05WUN	DRUGNAME	OTI-020
D05WUN	INDICATI	Myocardial disease [ICD-11: BC43.20] Phase 3

D07EDB	TTDDRUID	D07EDB
D07EDB	DRUGNAME	Ozanimod
D07EDB	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D07EDB	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D07EDB	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D0V8KD	TTDDRUID	D0V8KD
D0V8KD	DRUGNAME	P-1101
D0V8KD	INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 3
D0V8KD	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
D0V8KD	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2

D01NKW	TTDDRUID	D01NKW
D01NKW	DRUGNAME	P2B-001
D01NKW	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2/3
D01NKW	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D02AYL	TTDDRUID	D02AYL
D02AYL	DRUGNAME	PA-824
D02AYL	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3

D0PN8H	TTDDRUID	D0PN8H
D0PN8H	DRUGNAME	Pacritinib
D0PN8H	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 3

D09DJO	TTDDRUID	D09DJO
D09DJO	DRUGNAME	Pafuramidine
D09DJO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D0F4ZN	TTDDRUID	D0F4ZN
D0F4ZN	DRUGNAME	PAMAQUESIDE
D0F4ZN	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3

D00RJE	TTDDRUID	D00RJE
D00RJE	DRUGNAME	Pancopride
D00RJE	INDICATI	Nausea [ICD-11: MD90] Phase 3

D08PBQ	TTDDRUID	D08PBQ
D08PBQ	DRUGNAME	Pancreas algenpantucel-L
D08PBQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0Z5TW	TTDDRUID	D0Z5TW
D0Z5TW	DRUGNAME	Parietaria Judaica-containing vaccine
D0Z5TW	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3

D03QFN	TTDDRUID	D03QFN
D03QFN	DRUGNAME	Patrome
D03QFN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D06KNJ	TTDDRUID	D06KNJ
D06KNJ	DRUGNAME	PB-127
D06KNJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3

D0R3ML	TTDDRUID	D0R3ML
D0R3ML	DRUGNAME	PC-213
D0R3ML	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0V2WO	TTDDRUID	D0V2WO
D0V2WO	DRUGNAME	PC-DAC:Insulin
D0V2WO	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
D0V2WO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D04BVN	TTDDRUID	D04BVN
D04BVN	DRUGNAME	PDGF-BB
D04BVN	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D0O1UX	TTDDRUID	D0O1UX
D0O1UX	DRUGNAME	Peanut allergy desensitization vaccine
D0O1UX	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
D0O1UX	INDICATI	Hypersensitivity [ICD-11: 4A80-4A85] Phase 2

D07UAS	TTDDRUID	D07UAS
D07UAS	DRUGNAME	PEG arginine deiminase
D07UAS	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D07UAS	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D03ZAE	TTDDRUID	D03ZAE
D03ZAE	DRUGNAME	Peg-G-CSF
D03ZAE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0T6IN	TTDDRUID	D0T6IN
D0T6IN	DRUGNAME	Peginterferon lambda-1a
D0T6IN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D0BF8Y	TTDDRUID	D0BF8Y
D0BF8Y	DRUGNAME	Pelareorep
D0BF8Y	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0BF8Y	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
D0BF8Y	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
D0BF8Y	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
D0BF8Y	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0BF8Y	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0BF8Y	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0BF8Y	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D0BF8Y	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 2

D0LF8Z	TTDDRUID	D0LF8Z
D0LF8Z	DRUGNAME	Pentasa Sachet
D0LF8Z	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D0Y9BX	TTDDRUID	D0Y9BX
D0Y9BX	DRUGNAME	Peptide p277
D0Y9BX	INDICATI	Grass pollen hypersensitivity [ICD-11: 4B07] Phase 3
D0Y9BX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D05TOJ	TTDDRUID	D05TOJ
D05TOJ	DRUGNAME	Peretinoin
D05TOJ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D0T4WX	TTDDRUID	D0T4WX
D0T4WX	DRUGNAME	Pertuzumab companion diagnostic
D0T4WX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D03FBV	TTDDRUID	D03FBV
D03FBV	DRUGNAME	PF-04950615
D03FBV	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D05PCM	TTDDRUID	D05PCM
D05PCM	DRUGNAME	PF-04965842
D05PCM	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
D05PCM	INDICATI	Lupus [ICD-11: 4A40] Phase 2

D0EH2Q	TTDDRUID	D0EH2Q
D0EH2Q	DRUGNAME	PF-05212366
D0EH2Q	INDICATI	Adolescent meningitis [ICD-11: 1D01.10] Phase 3

D0HR7Z	TTDDRUID	D0HR7Z
D0HR7Z	DRUGNAME	PF-05280014
D0HR7Z	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0O9DK	TTDDRUID	D0O9DK
D0O9DK	DRUGNAME	PF-05280586
D0O9DK	INDICATI	Cluster headache [ICD-11: 8A81.0] Phase 3
D0O9DK	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3

D0Y8TZ	TTDDRUID	D0Y8TZ
D0Y8TZ	DRUGNAME	PF-06410293
D0Y8TZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0Y8TZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0N8IL	TTDDRUID	D0N8IL
D0N8IL	DRUGNAME	PF-06425090
D0N8IL	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
D0N8IL	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3

D0D9HZ	TTDDRUID	D0D9HZ
D0D9HZ	DRUGNAME	PF-06438179
D0D9HZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0D9HZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D02MUA	TTDDRUID	D02MUA
D02MUA	DRUGNAME	PF-06439535
D02MUA	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D02MUA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08JWJ	TTDDRUID	D08JWJ
D08JWJ	DRUGNAME	PF-1228305
D08JWJ	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 3

D0MW7B	TTDDRUID	D0MW7B
D0MW7B	DRUGNAME	PF-4494700
D0MW7B	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D0MW7B	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 3

D0V6SV	TTDDRUID	D0V6SV
D0V6SV	DRUGNAME	PG-201
D0V6SV	INDICATI	Arthralgia [ICD-11: ME82] Phase 3

D00JRD	TTDDRUID	D00JRD
D00JRD	DRUGNAME	PGF2ALPHA-IE
D00JRD	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3

D04FQD	TTDDRUID	D04FQD
D04FQD	DRUGNAME	PH-80
D04FQD	INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Phase 3

D09VSV	TTDDRUID	D09VSV
D09VSV	DRUGNAME	PH80-PMD
D09VSV	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D0J1ZH	TTDDRUID	D0J1ZH
D0J1ZH	DRUGNAME	PH94B NS
D0J1ZH	INDICATI	Social anxiety disorder [ICD-11: 6B04] Phase 3

D0VA4Y	TTDDRUID	D0VA4Y
D0VA4Y	DRUGNAME	Phentermine+topiramate
D0VA4Y	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D04ZJG	TTDDRUID	D04ZJG
D04ZJG	DRUGNAME	PI-88
D04ZJG	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D04ZJG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0T7GV	TTDDRUID	D0T7GV
D0T7GV	DRUGNAME	Picoplatin
D0T7GV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0T7GV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0T7GV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
D0T7GV	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0J1NQ	TTDDRUID	D0J1NQ
D0J1NQ	DRUGNAME	Pinaverium bromide
D0J1NQ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3

D0H4VA	TTDDRUID	D0H4VA
D0H4VA	DRUGNAME	Pioglitazone companion diagnostic
D0H4VA	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3

D01UUD	TTDDRUID	D01UUD
D01UUD	DRUGNAME	Pitolisant
D01UUD	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0Q4OW	TTDDRUID	D0Q4OW
D0Q4OW	DRUGNAME	Pixantrone
D0Q4OW	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D0Q4OW	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
D0Q4OW	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D0Q4OW	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1

D0T0YG	TTDDRUID	D0T0YG
D0T0YG	DRUGNAME	Pixuvripixantrone
D0T0YG	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D04INP	TTDDRUID	D04INP
D04INP	DRUGNAME	Pixykine
D04INP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D09APA	TTDDRUID	D09APA
D09APA	DRUGNAME	Plasma derived factor VIII PEGylated liposomal
D09APA	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Phase 3

D0ZE1O	TTDDRUID	D0ZE1O
D0ZE1O	DRUGNAME	Plinabulin
D0ZE1O	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0ZE1O	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D07QJK	TTDDRUID	D07QJK
D07QJK	DRUGNAME	Plitidepsin
D07QJK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D07QJK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D09TAB	TTDDRUID	D09TAB
D09TAB	DRUGNAME	PLX-3397
D09TAB	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D09TAB	INDICATI	Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 3
D09TAB	INDICATI	Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 3

D0LG3Q	TTDDRUID	D0LG3Q
D0LG3Q	DRUGNAME	PLX-PAD cell therapy
D0LG3Q	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 3

D0K6AL	TTDDRUID	D0K6AL
D0K6AL	DRUGNAME	PM1183
D0K6AL	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0HC8Q	TTDDRUID	D0HC8Q
D0HC8Q	DRUGNAME	PN-200
D0HC8Q	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 3

D05QOL	TTDDRUID	D05QOL
D05QOL	DRUGNAME	Polatuzumab vedotin
D05QOL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D05QOL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D05QOL	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
D05QOL	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2

D05BJN	TTDDRUID	D05BJN
D05BJN	DRUGNAME	Polyclonal antiboby stimulator
D05BJN	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D05BJN	INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 3

D04WMN	TTDDRUID	D04WMN
D04WMN	DRUGNAME	Polyclonal antibody stimulator
D04WMN	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D04WMN	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D04WMN	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 2
D04WMN	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
D04WMN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D00IWL	TTDDRUID	D00IWL
D00IWL	DRUGNAME	PolyHeme
D00IWL	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 3

D06BBO	TTDDRUID	D06BBO
D06BBO	DRUGNAME	Polymerized vaccine
D06BBO	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3

D0P0ZY	TTDDRUID	D0P0ZY
D0P0ZY	DRUGNAME	Pomaglumetad
D0P0ZY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0Y4SI	TTDDRUID	D0Y4SI
D0Y4SI	DRUGNAME	Ponesimod
D0Y4SI	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0PM9D	TTDDRUID	D0PM9D
D0PM9D	DRUGNAME	Porfiromycin
D0PM9D	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3

D03GHV	TTDDRUID	D03GHV
D03GHV	DRUGNAME	PR1 peptide antigen vaccine
D03GHV	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D03BFU	TTDDRUID	D03BFU
D03BFU	DRUGNAME	Pradaxa
D03BFU	INDICATI	Stroke [ICD-11: 8B20] Phase 3

D05FUU	TTDDRUID	D05FUU
D05FUU	DRUGNAME	Pratosartan
D05FUU	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0G7IV	TTDDRUID	D0G7IV
D0G7IV	DRUGNAME	Premarin/Pravachol
D0G7IV	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3

D0F4SY	TTDDRUID	D0F4SY
D0F4SY	DRUGNAME	Pridopidine
D0F4SY	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2/3
D0F4SY	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 3

D05PWU	TTDDRUID	D05PWU
D05PWU	DRUGNAME	PRo antigen cancer vaccine
D05PWU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
D05PWU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0CG0N	TTDDRUID	D0CG0N
D0CG0N	DRUGNAME	PRO-140
D0CG0N	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0CG0N	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0W6BS	TTDDRUID	D0W6BS
D0W6BS	DRUGNAME	PRO-2000
D0W6BS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D03KDO	TTDDRUID	D03KDO
D03KDO	DRUGNAME	Prochyma
D03KDO	INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 3
D03KDO	INDICATI	Crohn disease [ICD-11: DD70] Phase 3
D03KDO	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3

D0MB8B	TTDDRUID	D0MB8B
D0MB8B	DRUGNAME	Prochymal
D0MB8B	INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 3

D0DA3T	TTDDRUID	D0DA3T
D0DA3T	DRUGNAME	Prostate dendritic cell-based vaccine
D0DA3T	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0G2MR	TTDDRUID	D0G2MR
D0G2MR	DRUGNAME	ProstaVac
D0G2MR	INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 3

D0J3ZT	TTDDRUID	D0J3ZT
D0J3ZT	DRUGNAME	PRT-201
D0J3ZT	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 3

D00ITC	TTDDRUID	D00ITC
D00ITC	DRUGNAME	PRT4445
D00ITC	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 3

D08KGY	TTDDRUID	D08KGY
D08KGY	DRUGNAME	PRX-302
D08KGY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D08KGY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0T0JF	TTDDRUID	D0T0JF
D0T0JF	DRUGNAME	PseudIgY
D0T0JF	INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 3

D0V3WE	TTDDRUID	D0V3WE
D0V3WE	DRUGNAME	Pseudomonas aeruginosa protein vaccine
D0V3WE	INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 3

D0Q7QA	TTDDRUID	D0Q7QA
D0Q7QA	DRUGNAME	PT001 GP
D0Q7QA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0S1KP	TTDDRUID	D0S1KP
D0S1KP	DRUGNAME	PT003
D0S1KP	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0YS2W	TTDDRUID	D0YS2W
D0YS2W	DRUGNAME	PT005
D0YS2W	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0L3VU	TTDDRUID	D0L3VU
D0L3VU	DRUGNAME	Pumactant
D0L3VU	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0L2VT	TTDDRUID	D0L2VT
D0L2VT	DRUGNAME	PV-10
D0L2VT	INDICATI	Cutaneous melanoma [ICD-11: 2C30] Phase 3
D0L2VT	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D0L2VT	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0L2VT	INDICATI	Metastatic liver cancer [ICD-11: 2C12] Phase 1
D0L2VT	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1

D05BDY	TTDDRUID	D05BDY
D05BDY	DRUGNAME	PXT-3003
D05BDY	INDICATI	Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 2
D05BDY	INDICATI	Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 3

D02YPU	TTDDRUID	D02YPU
D02YPU	DRUGNAME	Pyridoxamine
D02YPU	INDICATI	Diabetic kidney disease [ICD-11: GB61.Z] Phase 3
D02YPU	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3

D06XDI	TTDDRUID	D06XDI
D06XDI	DRUGNAME	QAW-039
D06XDI	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0J7CH	TTDDRUID	D0J7CH
D0J7CH	DRUGNAME	QGE-031
D0J7CH	INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 3
D0J7CH	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 2

D0E0XL	TTDDRUID	D0E0XL
D0E0XL	DRUGNAME	QMF149
D0E0XL	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0D5ZU	TTDDRUID	D0D5ZU
D0D5ZU	DRUGNAME	QPI-1002
D0D5ZU	INDICATI	Renal artery disease [ICD-11: BD40.2] Phase 1/2
D0D5ZU	INDICATI	Renal transplantation [ICD-11: NE84] Phase 3

D06ZFV	TTDDRUID	D06ZFV
D06ZFV	DRUGNAME	QPI-1007
D06ZFV	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2/3
D06ZFV	INDICATI	Ischemic optic neuropathy [ICD-11: 9C40.4] Phase 3
D06ZFV	INDICATI	Non-arteritic anterior ischemic optic neuropathy [ICD-11: 9C40.40] Phase 3

D03WOW	TTDDRUID	D03WOW
D03WOW	DRUGNAME	QS-21
D03WOW	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0D8RT	TTDDRUID	D0D8RT
D0D8RT	DRUGNAME	Quattro
D0D8RT	INDICATI	Grass pollen hypersensitivity [ICD-11: 4B07] Phase 3
D0D8RT	INDICATI	Ragweed hypersensitivity allergic disease [ICD-11: 4A8Z] Phase 3

D09YDO	TTDDRUID	D09YDO
D09YDO	DRUGNAME	Quinotolast
D09YDO	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0Q5AT	TTDDRUID	D0Q5AT
D0Q5AT	DRUGNAME	QVA-149
D0Q5AT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0B6IZ	TTDDRUID	D0B6IZ
D0B6IZ	DRUGNAME	R1678
D0B6IZ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0A3FQ	TTDDRUID	D0A3FQ
D0A3FQ	DRUGNAME	Rabies vaccine
D0A3FQ	INDICATI	Rabies [ICD-11: 1C82] Phase 3

D0L3UI	TTDDRUID	D0L3UI
D0L3UI	DRUGNAME	Rabies VRVg
D0L3UI	INDICATI	Rabies [ICD-11: 1C82] Phase 2
D0L3UI	INDICATI	Rabies [ICD-11: 1C82] Phase 3

D0X4NF	TTDDRUID	D0X4NF
D0X4NF	DRUGNAME	Radiosensitizer gene therapy
D0X4NF	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D01NIR	TTDDRUID	D01NIR
D01NIR	DRUGNAME	Radotinib
D01NIR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D02NHD	TTDDRUID	D02NHD
D02NHD	DRUGNAME	Ragaglitazar
D02NHD	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D01EUO	TTDDRUID	D01EUO
D01EUO	DRUGNAME	Ragweed extract
D01EUO	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3

D0T8LF	TTDDRUID	D0T8LF
D0T8LF	DRUGNAME	Ragweed pollen extract
D0T8LF	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3

D00GEG	TTDDRUID	D00GEG
D00GEG	DRUGNAME	Ralfinamide
D00GEG	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3

D03NGH	TTDDRUID	D03NGH
D03NGH	DRUGNAME	Ramoplanin
D03NGH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D0K8TI	TTDDRUID	D0K8TI
D0K8TI	DRUGNAME	Ranirestat
D0K8TI	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3

D0Q4GL	TTDDRUID	D0Q4GL
D0Q4GL	DRUGNAME	RAVAX
D0Q4GL	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
D0Q4GL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0U8NN	TTDDRUID	D0U8NN
D0U8NN	DRUGNAME	RBP-6000
D0U8NN	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 3

D0O5TR	TTDDRUID	D0O5TR
D0O5TR	DRUGNAME	RBP-7000
D0O5TR	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0O5TR	INDICATI	Schizophrenia [ICD-11: 6A20] Application submitted

D0NO0K	TTDDRUID	D0NO0K
D0NO0K	DRUGNAME	RBT-101
D0NO0K	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D0NO0K	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
D0NO0K	INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 3

D01RBP	TTDDRUID	D01RBP
D01RBP	DRUGNAME	RE-024
D01RBP	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1
D01RBP	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 3

D03BQP	TTDDRUID	D03BQP
D03BQP	DRUGNAME	Rebamipide
D03BQP	INDICATI	Peptic ulcer [ICD-11: DA61] Phase 3

D07WTG	TTDDRUID	D07WTG
D07WTG	DRUGNAME	Recombinant acidic fibroblast growth factor
D07WTG	INDICATI	Skin burns [ICD-11: ME65.0] Phase 3

D0W4TG	TTDDRUID	D0W4TG
D0W4TG	DRUGNAME	Recombinant botulinum neurotoxin vaccine
D0W4TG	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D0S4RK	TTDDRUID	D0S4RK
D0S4RK	DRUGNAME	Recombinant factor VIII-Fc
D0S4RK	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 3

D0UE8P	TTDDRUID	D0UE8P
D0UE8P	DRUGNAME	Recombinant grass pollen allergens
D0UE8P	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3

D0L1DR	TTDDRUID	D0L1DR
D0L1DR	DRUGNAME	Recombinant human iduronate-2-sulfatase
D0L1DR	INDICATI	Hunter syndrome [ICD-11: 5C56.31] Phase 3

D0O5KY	TTDDRUID	D0O5KY
D0O5KY	DRUGNAME	Recombinant human neuregulin-1 beta
D0O5KY	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 3

D0B3XG	TTDDRUID	D0B3XG
D0B3XG	DRUGNAME	Recombinant von Willebrand factor/recombinant Factor VIII complex
D0B3XG	INDICATI	Von willebrand disease [ICD-11: 3B12] Phase 3

D0U0EM	TTDDRUID	D0U0EM
D0U0EM	DRUGNAME	Reformulated raltegravir
D0U0EM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D05ALP	TTDDRUID	D05ALP
D05ALP	DRUGNAME	REG1
D05ALP	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3

D0S6OH	TTDDRUID	D0S6OH
D0S6OH	DRUGNAME	Relaxin
D0S6OH	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Phase 3

D0P0FQ	TTDDRUID	D0P0FQ
D0P0FQ	DRUGNAME	Relenza IV
D0P0FQ	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 3

D05JET	TTDDRUID	D05JET
D05JET	DRUGNAME	Remacemide
D05JET	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0L5KU	TTDDRUID	D0L5KU
D0L5KU	DRUGNAME	Remimazolam
D0L5KU	INDICATI	Anaesthesia [ICD-11: 9A78.6] Phase 3

D05WTT	TTDDRUID	D05WTT
D05WTT	DRUGNAME	Remune
D05WTT	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 3
D05WTT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D05WTT	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Application submitted

D03PLR	TTDDRUID	D03PLR
D03PLR	DRUGNAME	RemuneX
D03PLR	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
D03PLR	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 3

D0K1XV	TTDDRUID	D0K1XV
D0K1XV	DRUGNAME	RemUnity
D0K1XV	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3

D04MKJ	TTDDRUID	D04MKJ
D04MKJ	DRUGNAME	Renzapride
D04MKJ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3

D0LJ1B	TTDDRUID	D0LJ1B
D0LJ1B	DRUGNAME	Reparixin
D0LJ1B	INDICATI	Graft rejection in heart transplantation [ICD-11: NE84] Phase 2
D0LJ1B	INDICATI	Ischemia-reperfusion injury [ICD-11: DB98.B] Phase 2
D0LJ1B	INDICATI	Pancreatic islet transplantation failure [ICD-11: NE84] Phase 3
D0LJ1B	INDICATI	lung transplantation [ICD-11: PK80.20] Phase 2

D0ZG3S	TTDDRUID	D0ZG3S
D0ZG3S	DRUGNAME	Reproxalap
D0ZG3S	INDICATI	Sjogren-Larsson syndrome [ICD-11: 5C52.03] Phase 3

D0E4GG	TTDDRUID	D0E4GG
D0E4GG	DRUGNAME	Resatorvid
D0E4GG	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3

D04QZI	TTDDRUID	D04QZI
D04QZI	DRUGNAME	Retosiban
D04QZI	INDICATI	Preterm labour [ICD-11: JB00] Phase 3

D01ZHB	TTDDRUID	D01ZHB
D01ZHB	DRUGNAME	Revusiran
D01ZHB	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3

D0H9PT	TTDDRUID	D0H9PT
D0H9PT	DRUGNAME	RG3638
D0H9PT	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D0H9PT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D08YTF	TTDDRUID	D08YTF
D08YTF	DRUGNAME	RG6013
D08YTF	INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 1/2
D08YTF	INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3

D04WQT	TTDDRUID	D04WQT
D04WQT	DRUGNAME	RG7201
D04WQT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0I5EU	TTDDRUID	D0I5EU
D0I5EU	DRUGNAME	RG7421+RG7204
D0I5EU	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0I6OI	TTDDRUID	D0I6OI
D0I6OI	DRUGNAME	RG7601
D0I6OI	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3

D0V1FP	TTDDRUID	D0V1FP
D0V1FP	DRUGNAME	RHB-104
D0V1FP	INDICATI	Crohn disease [ICD-11: DD70] Phase 3

D06PFT	TTDDRUID	D06PFT
D06PFT	DRUGNAME	Rhumab Beta7
D06PFT	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D0O3CV	TTDDRUID	D0O3CV
D0O3CV	DRUGNAME	Ridaforolimus
D0O3CV	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3

D0SQ2Z	TTDDRUID	D0SQ2Z
D0SQ2Z	DRUGNAME	Ridaforolimus eluting coronary stent
D0SQ2Z	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3

D0XW9L	TTDDRUID	D0XW9L
D0XW9L	DRUGNAME	Rifalazil
D0XW9L	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D0AJ5E	TTDDRUID	D0AJ5E
D0AJ5E	DRUGNAME	Rifaximin DR
D0AJ5E	INDICATI	Crohn disease [ICD-11: DD70] Phase 3

D0KF9Q	TTDDRUID	D0KF9Q
D0KF9Q	DRUGNAME	Rigosertib
D0KF9Q	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
D0KF9Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0XF4B	TTDDRUID	D0XF4B
D0XF4B	DRUGNAME	RIGS CC49
D0XF4B	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D0A3FZ	TTDDRUID	D0A3FZ
D0A3FZ	DRUGNAME	Rilimogene galvacirepvec
D0A3FZ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D05FRP	TTDDRUID	D05FRP
D05FRP	DRUGNAME	Rindopepimut
D05FRP	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
D05FRP	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3

D0GR5Q	TTDDRUID	D0GR5Q
D0GR5Q	DRUGNAME	Risperidone controlled-release implant
D0GR5Q	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D0X4CU	TTDDRUID	D0X4CU
D0X4CU	DRUGNAME	Rituxan
D0X4CU	INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 3

D03FIA	TTDDRUID	D03FIA
D03FIA	DRUGNAME	Rituxan Immunology
D03FIA	INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 3

D08PFA	TTDDRUID	D08PFA
D08PFA	DRUGNAME	Rivoglitazone
D08PFA	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 3

D0J0GR	TTDDRUID	D0J0GR
D0J0GR	DRUGNAME	Rocapuldencel-T
D0J0GR	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D0BN7W	TTDDRUID	D0BN7W
D0BN7W	DRUGNAME	Roclatan
D0BN7W	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3

D0X0IY	TTDDRUID	D0X0IY
D0X0IY	DRUGNAME	Rolofylline
D0X0IY	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D0K3LO	TTDDRUID	D0K3LO
D0K3LO	DRUGNAME	Romosozumab
D0K3LO	INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3

D0R0MB	TTDDRUID	D0R0MB
D0R0MB	DRUGNAME	Ropeginterferon alfa-2b
D0R0MB	INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 3

D0A1AQ	TTDDRUID	D0A1AQ
D0A1AQ	DRUGNAME	Rosiglitazone + metformin
D0A1AQ	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
D0A1AQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0Q6IW	TTDDRUID	D0Q6IW
D0Q6IW	DRUGNAME	Rosiglitazone + simvastatin
D0Q6IW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03RQW	TTDDRUID	D03RQW
D03RQW	DRUGNAME	Rostaporfin
D03RQW	INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 1
D03RQW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D03RQW	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 3
D03RQW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U1LQ	TTDDRUID	D0U1LQ
D0U1LQ	DRUGNAME	Rotavirus vaccine
D0U1LQ	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 3
D0U1LQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0L9HG	TTDDRUID	D0L9HG
D0L9HG	DRUGNAME	Rotavirus vaccine I321
D0L9HG	INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Phase 3

D06WOF	TTDDRUID	D06WOF
D06WOF	DRUGNAME	Rova-T
D06WOF	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
D06WOF	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D07YMX	TTDDRUID	D07YMX
D07YMX	DRUGNAME	RPC-1063
D07YMX	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D05BCU	TTDDRUID	D05BCU
D05BCU	DRUGNAME	RQ-00000004
D05BCU	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3

D0C6KK	TTDDRUID	D0C6KK
D0C6KK	DRUGNAME	RT002 injectable
D0C6KK	INDICATI	Glabellar frown line [ICD-11: NA0Z] Phase 3

D0DU9I	TTDDRUID	D0DU9I
D0DU9I	DRUGNAME	RT-100
D0DU9I	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3

D0B7AB	TTDDRUID	D0B7AB
D0B7AB	DRUGNAME	R-TPR-013
D0B7AB	INDICATI	Female infertility [ICD-11: GA31.Z] Phase 3

D0Y1FO	TTDDRUID	D0Y1FO
D0Y1FO	DRUGNAME	Rubitecan
D0Y1FO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0MV4W	TTDDRUID	D0MV4W
D0MV4W	DRUGNAME	RUBOXISTAURIN HYDROCHLORIDE
D0MV4W	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3

D0NA8B	TTDDRUID	D0NA8B
D0NA8B	DRUGNAME	Rubraca rucaparib
D0NA8B	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0NA8B	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D0NA8B	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0H6BS	TTDDRUID	D0H6BS
D0H6BS	DRUGNAME	Rydaptmidostaurin
D0H6BS	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D0E6ES	TTDDRUID	D0E6ES
D0E6ES	DRUGNAME	S. flexneri type 2a-rEPA Asucc
D0E6ES	INDICATI	Shigella infection [ICD-11: 1A02] Phase 3

D0RM2O	TTDDRUID	D0RM2O
D0RM2O	DRUGNAME	S. sonnei-rEPA
D0RM2O	INDICATI	Shigella infection [ICD-11: 1A02] Phase 3

D0U8CR	TTDDRUID	D0U8CR
D0U8CR	DRUGNAME	S-06911
D0U8CR	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 3

D0S8LJ	TTDDRUID	D0S8LJ
D0S8LJ	DRUGNAME	S-1
D0S8LJ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D0A2BO	TTDDRUID	D0A2BO
D0A2BO	DRUGNAME	S-110
D0A2BO	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D0A2BO	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 3
D0A2BO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0H9QC	TTDDRUID	D0H9QC
D0H9QC	DRUGNAME	S-474474
D0H9QC	INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 3

D0Y1ZU	TTDDRUID	D0Y1ZU
D0Y1ZU	DRUGNAME	SA-237
D0Y1ZU	INDICATI	Encephalopathy [ICD-11: 8E47] Phase 3
D0Y1ZU	INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 3
D0Y1ZU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0IF0U	TTDDRUID	D0IF0U
D0IF0U	DRUGNAME	Sacituzumab govitecan
D0IF0U	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0IF0U	INDICATI	Metastatic endometrial cancer [ICD-11: 2E05.Y] Phase 2
D0IF0U	INDICATI	Metastatic lung cancer [ICD-11: 2D70] Phase 2
D0IF0U	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D0IF0U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D0IF0U	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2

D0Z6LI	TTDDRUID	D0Z6LI
D0Z6LI	DRUGNAME	Samarium SM-153 lexidronam
D0Z6LI	INDICATI	Bone metastases [ICD-11: 2D50] Phase 3

D0N7JZ	TTDDRUID	D0N7JZ
D0N7JZ	DRUGNAME	SAND-26
D0N7JZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3

D0D4RF	TTDDRUID	D0D4RF
D0D4RF	DRUGNAME	Sapacitabine
D0D4RF	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 3
D0D4RF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D0D4RF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0D4RF	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D0D4RF	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0D4RF	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D09HTB	TTDDRUID	D09HTB
D09HTB	DRUGNAME	SAR153191
D09HTB	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 3

D0O9UN	TTDDRUID	D0O9UN
D0O9UN	DRUGNAME	SAR231893
D0O9UN	INDICATI	Asthma [ICD-11: CA23] Phase 3
D0O9UN	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3

D09VFX	TTDDRUID	D09VFX
D09VFX	DRUGNAME	SAR342434
D09VFX	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
D09VFX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
D09VFX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0SS1J	TTDDRUID	D0SS1J
D0SS1J	DRUGNAME	SAR399063
D0SS1J	INDICATI	Pre-sarcopenia [ICD-11: FB32.Y] Phase 3

D08NAI	TTDDRUID	D08NAI
D08NAI	DRUGNAME	SAR438584
D08NAI	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3

D0L9NX	TTDDRUID	D0L9NX
D0L9NX	DRUGNAME	Satavaptan
D0L9NX	INDICATI	Acute and chronic heart failure [ICD-11: BD1Z] Phase 3

D0MD0T	TTDDRUID	D0MD0T
D0MD0T	DRUGNAME	Satralizumab
D0MD0T	INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 3

D0LW0T	TTDDRUID	D0LW0T
D0LW0T	DRUGNAME	Savolitinib
D0LW0T	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D09XMX	TTDDRUID	D09XMX
D09XMX	DRUGNAME	SaxaDapa FDC
D09XMX	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0CU1T	TTDDRUID	D0CU1T
D0CU1T	DRUGNAME	SB2
D0CU1T	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Application submitted
D0CU1T	INDICATI	Crohn disease [ICD-11: DD70] Application submitted
D0CU1T	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D0CU1T	INDICATI	Psoriatic arthritis [ICD-11: FA21] Application submitted
D0CU1T	INDICATI	Ulcerative colitis [ICD-11: DD71] Application submitted

D06UNY	TTDDRUID	D06UNY
D06UNY	DRUGNAME	SB204
D06UNY	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D0R9HI	TTDDRUID	D0R9HI
D0R9HI	DRUGNAME	SB-742457
D0R9HI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0R9HI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0V6IM	TTDDRUID	D0V6IM
D0V6IM	DRUGNAME	SBG
D0V6IM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D01HRU	TTDDRUID	D01HRU
D01HRU	DRUGNAME	SBR-759
D01HRU	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3

D08RJM	TTDDRUID	D08RJM
D08RJM	DRUGNAME	SD-101
D08RJM	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
D08RJM	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D08RJM	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Phase 2
D08RJM	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2

D02MBN	TTDDRUID	D02MBN
D02MBN	DRUGNAME	SD-6010
D02MBN	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3

D00ZEN	TTDDRUID	D00ZEN
D00ZEN	DRUGNAME	Seasonal influenza vaccine
D00ZEN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0Z1VU	TTDDRUID	D0Z1VU
D0Z1VU	DRUGNAME	Second generation therapeutics
D0Z1VU	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D01LXD	TTDDRUID	D01LXD
D01LXD	DRUGNAME	Semagacestat
D01LXD	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D0X3JU	TTDDRUID	D0X3JU
D0X3JU	DRUGNAME	Semaglutide oral
D0X3JU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D09XFO	TTDDRUID	D09XFO
D09XFO	DRUGNAME	Semuloparin
D09XFO	INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 3

D09ZJQ	TTDDRUID	D09ZJQ
D09ZJQ	DRUGNAME	Seocalcitol
D09ZJQ	INDICATI	Rickets [ICD-11: 5B57] Phase 3

D0E7OC	TTDDRUID	D0E7OC
D0E7OC	DRUGNAME	Serelsa
D0E7OC	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 3

D0CB2B	TTDDRUID	D0CB2B
D0CB2B	DRUGNAME	Serlopitant
D0CB2B	INDICATI	Prurigo nodularis [ICD-11: EC91.0] Phase 3
D0CB2B	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0MD6C	TTDDRUID	D0MD6C
D0MD6C	DRUGNAME	Sernivo
D0MD6C	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D0SP5V	TTDDRUID	D0SP5V
D0SP5V	DRUGNAME	Setipiprant
D0SP5V	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0SP5V	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0V0AF	TTDDRUID	D0V0AF
D0V0AF	DRUGNAME	Seviprotimut-L
D0V0AF	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0V0AF	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 3

D0K8WJ	TTDDRUID	D0K8WJ
D0K8WJ	DRUGNAME	Sf-1019
D0K8WJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0Q5KZ	TTDDRUID	D0Q5KZ
D0Q5KZ	DRUGNAME	SGI110
D0Q5KZ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D0NC9E	TTDDRUID	D0NC9E
D0NC9E	DRUGNAME	SGX301
D0NC9E	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3

D0YT1P	TTDDRUID	D0YT1P
D0YT1P	DRUGNAME	SGX-301 ointment
D0YT1P	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3

D0EQ5W	TTDDRUID	D0EQ5W
D0EQ5W	DRUGNAME	Sh-28-GST
D0EQ5W	INDICATI	Schistosomiasis [ICD-11: 1F86] Phase 3

D07YPW	TTDDRUID	D07YPW
D07YPW	DRUGNAME	Shigamabs
D07YPW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
D07YPW	INDICATI	Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2

D0E9SZ	TTDDRUID	D0E9SZ
D0E9SZ	DRUGNAME	SI-657
D0E9SZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D02HJR	TTDDRUID	D02HJR
D02HJR	DRUGNAME	SID-530
D02HJR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0CF3M	TTDDRUID	D0CF3M
D0CF3M	DRUGNAME	Sifuvirtide
D0CF3M	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0M6HE	TTDDRUID	D0M6HE
D0M6HE	DRUGNAME	Simplirix
D0M6HE	INDICATI	Genital herpes [ICD-11: 1A94] Phase 3

D0XK2N	TTDDRUID	D0XK2N
D0XK2N	DRUGNAME	Sinbaro
D0XK2N	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3

D03MUI	TTDDRUID	D03MUI
D03MUI	DRUGNAME	Single Tablet Regimen
D03MUI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0J9HO	TTDDRUID	D0J9HO
D0J9HO	DRUGNAME	Single Tablet Regimen of sofosbuvir and ledipasvir
D0J9HO	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3

D01SAY	TTDDRUID	D01SAY
D01SAY	DRUGNAME	Sipuleucel-T
D01SAY	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
D01SAY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0QR4F	TTDDRUID	D0QR4F
D0QR4F	DRUGNAME	Sirolimus ophthalmic
D0QR4F	INDICATI	Uveitis [ICD-11: 9A96.Z] Phase 3

D01XVF	TTDDRUID	D01XVF
D01XVF	DRUGNAME	Sirukumab
D01XVF	INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 3
D01XVF	INDICATI	Giant cell arteritis [ICD-11: 4A44.2] Phase 3
D01XVF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
D01XVF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0IT7F	TTDDRUID	D0IT7F
D0IT7F	DRUGNAME	Sitagliptin + metformin
D0IT7F	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0DI6L	TTDDRUID	D0DI6L
D0DI6L	DRUGNAME	Sivextro
D0DI6L	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 3

D0D7KU	TTDDRUID	D0D7KU
D0D7KU	DRUGNAME	SNA-001
D0D7KU	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D00CZT	TTDDRUID	D00CZT
D00CZT	DRUGNAME	Solanezumab
D00CZT	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0W2FZ	TTDDRUID	D0W2FZ
D0W2FZ	DRUGNAME	Solithromycin oral
D0W2FZ	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 3

D0Y2JM	TTDDRUID	D0Y2JM
D0Y2JM	DRUGNAME	Soluble ferric pyrophosphate
D0Y2JM	INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Phase 3

D0L5WF	TTDDRUID	D0L5WF
D0L5WF	DRUGNAME	Somavaratan
D0L5WF	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3

D0QL4X	TTDDRUID	D0QL4X
D0QL4X	DRUGNAME	SOT-107
D0QL4X	INDICATI	Brain cancer [ICD-11: 2A00] Phase 3

D06VFP	TTDDRUID	D06VFP
D06VFP	DRUGNAME	SOTB07
D06VFP	INDICATI	Asthma [ICD-11: CA23] Phase 3

D05DPU	TTDDRUID	D05DPU
D05DPU	DRUGNAME	SP-102
D05DPU	INDICATI	Sciatica/lumbar radicular pain [ICD-11: ME84.3] Phase 3

D08JLH	TTDDRUID	D08JLH
D08JLH	DRUGNAME	Spartalizumab
D08JLH	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0CZ5Z	TTDDRUID	D0CZ5Z
D0CZ5Z	DRUGNAME	SPD-465
D0CZ5Z	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D08BXT	TTDDRUID	D08BXT
D08BXT	DRUGNAME	Spermidine
D08BXT	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D08BXT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0J1WI	TTDDRUID	D0J1WI
D0J1WI	DRUGNAME	Sphingosine-1-phosphate receptor-1 agonist
D0J1WI	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 3

D03ESR	TTDDRUID	D03ESR
D03ESR	DRUGNAME	Sphingosome Encapsulated Vinorelbine
D03ESR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D04CKG	TTDDRUID	D04CKG
D04CKG	DRUGNAME	SPI-2012
D04CKG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D06VZN	TTDDRUID	D06VZN
D06VZN	DRUGNAME	SPK-843
D06VZN	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 3

D0O7GB	TTDDRUID	D0O7GB
D0O7GB	DRUGNAME	SPK-RPE65
D0O7GB	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 3

D03AJF	TTDDRUID	D03AJF
D03AJF	DRUGNAME	SPN-810
D03AJF	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D07PVB	TTDDRUID	D07PVB
D07PVB	DRUGNAME	Squalamine
D07PVB	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
D07PVB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D04PLI	TTDDRUID	D04PLI
D04PLI	DRUGNAME	SR46349B
D04PLI	INDICATI	Primary insomnia [ICD-11: 7A00] Phase 3
D04PLI	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
D04PLI	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 3

D0R1GJ	TTDDRUID	D0R1GJ
D0R1GJ	DRUGNAME	SRP-4045
D0R1GJ	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3

D0M6ER	TTDDRUID	D0M6ER
D0M6ER	DRUGNAME	SRP-4053
D0M6ER	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3

D0P2RO	TTDDRUID	D0P2RO
D0P2RO	DRUGNAME	SSR-126517E
D0P2RO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3

D02EXZ	TTDDRUID	D02EXZ
D02EXZ	DRUGNAME	ST10-021
D02EXZ	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 3

D0OZ6W	TTDDRUID	D0OZ6W
D0OZ6W	DRUGNAME	STAGR320
D0OZ6W	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3

D06KLJ	TTDDRUID	D06KLJ
D06KLJ	DRUGNAME	STAMP
D06KLJ	INDICATI	Dental caries [ICD-11: DA08.0] Phase 3

D05YES	TTDDRUID	D05YES
D05YES	DRUGNAME	StaphVAX
D05YES	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 3

D0A0QH	TTDDRUID	D0A0QH
D0A0QH	DRUGNAME	Stapuldencel-T
D0A0QH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0EE4O	TTDDRUID	D0EE4O
D0EE4O	DRUGNAME	Stapuldencel-T
D0EE4O	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0D1UD	TTDDRUID	D0D1UD
D0D1UD	DRUGNAME	STI-001
D0D1UD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
D0D1UD	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D0I6UE	TTDDRUID	D0I6UE
D0I6UE	DRUGNAME	STI-002
D0I6UE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0Y6DO	TTDDRUID	D0Y6DO
D0Y6DO	DRUGNAME	Streptokinase rectal suppository
D0Y6DO	INDICATI	Hemorrhoids [ICD-11: DB60] Phase 3

D07YVK	TTDDRUID	D07YVK
D07YVK	DRUGNAME	Sumanirole
D07YVK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D04RNN	TTDDRUID	D04RNN
D04RNN	DRUGNAME	SUN-101
D04RNN	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0MZ9A	TTDDRUID	D0MZ9A
D0MZ9A	DRUGNAME	Suronacrine maleate
D0MZ9A	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D04KMP	TTDDRUID	D04KMP
D04KMP	DRUGNAME	SUVN-G3031
D04KMP	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3

D0D5IS	TTDDRUID	D0D5IS
D0D5IS	DRUGNAME	SYNSORB-Pk
D0D5IS	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3

D02BAE	TTDDRUID	D02BAE
D02BAE	DRUGNAME	Synthetic conjugated estrogen
D02BAE	INDICATI	Vaginal disease [ICD-11: GA1Y] Phase 3

D0M3BB	TTDDRUID	D0M3BB
D0M3BB	DRUGNAME	Synthetic hypericin
D0M3BB	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3

D0A2WE	TTDDRUID	D0A2WE
D0A2WE	DRUGNAME	Syntocinon nasal spray
D0A2WE	INDICATI	Lactation failure [ICD-11: JB46.3] Phase 3

D0N6SO	TTDDRUID	D0N6SO
D0N6SO	DRUGNAME	SYR-472
D0N6SO	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 3
D0N6SO	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0HM6B	TTDDRUID	D0HM6B
D0HM6B	DRUGNAME	T-121
D0HM6B	INDICATI	Complex regional pain syndrome [ICD-11: 8D8A.0] Phase 3

D05QUL	TTDDRUID	D05QUL
D05QUL	DRUGNAME	T89
D05QUL	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
D05QUL	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0U6UK	TTDDRUID	D0U6UK
D0U6UK	DRUGNAME	Tabalumab
D0U6UK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0GY4H	TTDDRUID	D0GY4H
D0GY4H	DRUGNAME	Taberminogene vadenovec
D0GY4H	INDICATI	Vascular restinosis [ICD-11: BE2Z] Phase 3

D03MGL	TTDDRUID	D03MGL
D03MGL	DRUGNAME	Tafamidis meglumine
D03MGL	INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Application submitted
D03MGL	INDICATI	Transthyretin amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
D03MGL	INDICATI	Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3

D0I3GZ	TTDDRUID	D0I3GZ
D0I3GZ	DRUGNAME	TAK-003
D0I3GZ	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2
D0I3GZ	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 3

D0F2WP	TTDDRUID	D0F2WP
D0F2WP	DRUGNAME	TAK-385
D0F2WP	INDICATI	Endometriosis [ICD-11: GA10] Phase 2
D0F2WP	INDICATI	Endometriosis [ICD-11: GA10] Phase 3
D0F2WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D02CPP	TTDDRUID	D02CPP
D02CPP	DRUGNAME	TAK-438
D02CPP	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3

D0A2RA	TTDDRUID	D0A2RA
D0A2RA	DRUGNAME	TAK-491
D0A2RA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D0X3OI	TTDDRUID	D0X3OI
D0X3OI	DRUGNAME	TAK-700
D0X3OI	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0V1WQ	TTDDRUID	D0V1WQ
D0V1WQ	DRUGNAME	TAK-875
D0V1WQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0FQ2U	TTDDRUID	D0FQ2U
D0FQ2U	DRUGNAME	Talabostat
D0FQ2U	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Phase 3
D0FQ2U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IM6O	TTDDRUID	D0IM6O
D0IM6O	DRUGNAME	Talactoferrin
D0IM6O	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D0Q0SQ	TTDDRUID	D0Q0SQ
D0Q0SQ	DRUGNAME	Talimogene
D0Q0SQ	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0W2UX	TTDDRUID	D0W2UX
D0W2UX	DRUGNAME	Talminogene laherparepvec
D0W2UX	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D00BVS	TTDDRUID	D00BVS
D00BVS	DRUGNAME	Tanezumab
D00BVS	INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
D00BVS	INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
D00BVS	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
D00BVS	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3
D00BVS	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D04CDO	TTDDRUID	D04CDO
D04CDO	DRUGNAME	TAS-102
D04CDO	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D0X0KM	TTDDRUID	D0X0KM
D0X0KM	DRUGNAME	Tasisulam
D0X0KM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D0B1EQ	TTDDRUID	D0B1EQ
D0B1EQ	DRUGNAME	Taspoglutide
D0B1EQ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D02JMU	TTDDRUID	D02JMU
D02JMU	DRUGNAME	Tasquinimod
D02JMU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D01JLO	TTDDRUID	D01JLO
D01JLO	DRUGNAME	Tat-NR2B9c
D01JLO	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
D01JLO	INDICATI	Stroke [ICD-11: 8B20] Phase 3

D0J6PY	TTDDRUID	D0J6PY
D0J6PY	DRUGNAME	Taxol/Paraplatin/Herceptin
D0J6PY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0Q6RG	TTDDRUID	D0Q6RG
D0Q6RG	DRUGNAME	TD-1792
D0Q6RG	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2
D0Q6RG	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 3

D0XV4Z	TTDDRUID	D0XV4Z
D0XV4Z	DRUGNAME	TD-4208
D0XV4Z	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D07VIB	TTDDRUID	D07VIB
D07VIB	DRUGNAME	Tecarfarin
D07VIB	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
D07VIB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3

D06BGO	TTDDRUID	D06BGO
D06BGO	DRUGNAME	Telcyta canfosfamide
D06BGO	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D06BGO	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 3
D06BGO	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D04UKP	TTDDRUID	D04UKP
D04UKP	DRUGNAME	Tenatumomab
D04UKP	INDICATI	Glioma [ICD-11: 2A00.0] Phase 3

D02RQT	TTDDRUID	D02RQT
D02RQT	DRUGNAME	TENIDAP
D02RQT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0VH4V	TTDDRUID	D0VH4V
D0VH4V	DRUGNAME	Teplizumab
D0VH4V	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0VH4V	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D0VH4V	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D0Y3ZP	TTDDRUID	D0Y3ZP
D0Y3ZP	DRUGNAME	Terodiline
D0Y3ZP	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 3

D0H1NL	TTDDRUID	D0H1NL
D0H1NL	DRUGNAME	TESAGLITAZAR
D0H1NL	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D0F9VH	TTDDRUID	D0F9VH
D0F9VH	DRUGNAME	Tesetaxel
D0F9VH	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0F9VH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0F9VH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0F9VH	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D0F9VH	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0F9VH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0AW8E	TTDDRUID	D0AW8E
D0AW8E	DRUGNAME	Tezosentan
D0AW8E	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Phase 3

D0G8BM	TTDDRUID	D0G8BM
D0G8BM	DRUGNAME	TG101348
D0G8BM	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1/2
D0G8BM	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 3

D0DP3V	TTDDRUID	D0DP3V
D0DP3V	DRUGNAME	TG-C
D0DP3V	INDICATI	Arthritis [ICD-11: FA20] Phase 3

D0L1LV	TTDDRUID	D0L1LV
D0L1LV	DRUGNAME	TGFK07AD
D0L1LV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3

D0C4DZ	TTDDRUID	D0C4DZ
D0C4DZ	DRUGNAME	ThermoProfen
D0C4DZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0G1WV	TTDDRUID	D0G1WV
D0G1WV	DRUGNAME	Thiophanate-methyl
D0G1WV	INDICATI	Plant grey mould disease [ICD-11: N.A.] Phase 3

D09FQW	TTDDRUID	D09FQW
D09FQW	DRUGNAME	THVD-201
D09FQW	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 3

D00OZC	TTDDRUID	D00OZC
D00OZC	DRUGNAME	THX-TS01
D00OZC	INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 3

D06CIR	TTDDRUID	D06CIR
D06CIR	DRUGNAME	Thymosin beta-4
D06CIR	INDICATI	Alopecia [ICD-11: ED70] Phase 2
D06CIR	INDICATI	Neurotrophic keratitis [ICD-11: 9A74] Phase 3

D0B7VK	TTDDRUID	D0B7VK
D0B7VK	DRUGNAME	Tifacogin
D0B7VK	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3

D06OQI	TTDDRUID	D06OQI
D06OQI	DRUGNAME	Tilarginine acetate
D06OQI	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 3

D09XQU	TTDDRUID	D09XQU
D09XQU	DRUGNAME	Tirapazamine
D09XQU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
D09XQU	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D02KSP	TTDDRUID	D02KSP
D02KSP	DRUGNAME	Tislelizumab
D02KSP	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D0ZI1F	TTDDRUID	D0ZI1F
D0ZI1F	DRUGNAME	Tivantinib
D0ZI1F	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D0ZI1F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0W7JZ	TTDDRUID	D0W7JZ
D0W7JZ	DRUGNAME	Tivozanib
D0W7JZ	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D0NN8N	TTDDRUID	D0NN8N
D0NN8N	DRUGNAME	TNX-102
D0NN8N	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 3
D0NN8N	INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 3

D00UBX	TTDDRUID	D00UBX
D00UBX	DRUGNAME	TNX-355
D00UBX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D09MED	TTDDRUID	D09MED
D09MED	DRUGNAME	Toca 511/Toca FC
D09MED	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2
D09MED	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3
D09MED	INDICATI	Glioma [ICD-11: 2A00.0] Phase 3
D09MED	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D09MED	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08CVC	TTDDRUID	D08CVC
D08CVC	DRUGNAME	Tocofersolan
D08CVC	INDICATI	Vitamin E deficiency [ICD-11: 5B58] Phase 3

D07TPT	TTDDRUID	D07TPT
D07TPT	DRUGNAME	Toujeo
D07TPT	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3

D03OQI	TTDDRUID	D03OQI
D03OQI	DRUGNAME	Tozadenant
D03OQI	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D0YA1U	TTDDRUID	D0YA1U
D0YA1U	DRUGNAME	Trabectedin
D0YA1U	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0KV1Q	TTDDRUID	D0KV1Q
D0KV1Q	DRUGNAME	Trafermin
D0KV1Q	INDICATI	Periodontitis [ICD-11: DA0C] Phase 3

D0I1ZY	TTDDRUID	D0I1ZY
D0I1ZY	DRUGNAME	Tralokinumab
D0I1ZY	INDICATI	Asthma [ICD-11: CA23] Phase 1/2
D0I1ZY	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
D0I1ZY	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D09DLP	TTDDRUID	D09DLP
D09DLP	DRUGNAME	Tramiprosate
D09DLP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0HL5N	TTDDRUID	D0HL5N
D0HL5N	DRUGNAME	Trastuzumab duocarmazine
D0HL5N	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0P4TH	TTDDRUID	D0P4TH
D0P4TH	DRUGNAME	Trastuzumab-DM1
D0P4TH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0J6DQ	TTDDRUID	D0J6DQ
D0J6DQ	DRUGNAME	Tremelimumab
D0J6DQ	INDICATI	Malignant mesothelioma [ICD-11: 2C26.0] Phase 3
D0J6DQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0J6DQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0P4XW	TTDDRUID	D0P4XW
D0P4XW	DRUGNAME	Tremfya
D0P4XW	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3

D09MKH	TTDDRUID	D09MKH
D09MKH	DRUGNAME	TRI-102
D09MKH	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D06FOU	TTDDRUID	D06FOU
D06FOU	DRUGNAME	Trifarotene
D06FOU	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D0M5EN	TTDDRUID	D0M5EN
D0M5EN	DRUGNAME	Trigriluzole
D0M5EN	INDICATI	Hereditary spinocerebellar ataxia [ICD-11: 8A03.1] Phase 3

D00MLW	TTDDRUID	D00MLW
D00MLW	DRUGNAME	Triheptanoin
D00MLW	INDICATI	Fatty acid disorder [ICD-11: 5C52.0] Phase 3
D00MLW	INDICATI	Genetic epileptic syndromes with variable age of onset [ICD-11: 8A61.4Y] Phase 3

D0C6XR	TTDDRUID	D0C6XR
D0C6XR	DRUGNAME	Trimegestone/ethinyl estradiol
D0C6XR	INDICATI	Contraception [ICD-11: QA21] Phase 3

D0I6LH	TTDDRUID	D0I6LH
D0I6LH	DRUGNAME	Triptolide
D0I6LH	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3

D0L1OT	TTDDRUID	D0L1OT
D0L1OT	DRUGNAME	TroVax
D0L1OT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0NS3O	TTDDRUID	D0NS3O
D0NS3O	DRUGNAME	TT10
D0NS3O	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 3

D0ML8G	TTDDRUID	D0ML8G
D0ML8G	DRUGNAME	Turoctocog alfa
D0ML8G	INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3

D0D2TT	TTDDRUID	D0D2TT
D0D2TT	DRUGNAME	TV-1106
D0D2TT	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3

D0LX9H	TTDDRUID	D0LX9H
D0LX9H	DRUGNAME	Tysuberprost
D0LX9H	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3

D0N6IY	TTDDRUID	D0N6IY
D0N6IY	DRUGNAME	TZ101
D0N6IY	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
D0N6IY	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0IC7A	TTDDRUID	D0IC7A
D0IC7A	DRUGNAME	TZTX-001
D0IC7A	INDICATI	Endometriosis [ICD-11: GA10] Phase 3

D0X5AN	TTDDRUID	D0X5AN
D0X5AN	DRUGNAME	U300
D0X5AN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0A8GM	TTDDRUID	D0A8GM
D0A8GM	DRUGNAME	Ublituximab
D0A8GM	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D0A8GM	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
D0A8GM	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0A8GM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D0A8GM	INDICATI	Nodal marginal zone lymphoma [ICD-11: 2A85.0] Phase 1/2

D0L5WD	TTDDRUID	D0L5WD
D0L5WD	DRUGNAME	Ularitide
D0L5WD	INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 3
D0L5WD	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D0DF1R	TTDDRUID	D0DF1R
D0DF1R	DRUGNAME	Ulinastatin
D0DF1R	INDICATI	Premature labour [ICD-11: JB00] Phase 3

D0T8IW	TTDDRUID	D0T8IW
D0T8IW	DRUGNAME	Ultimab IgG1 antibody
D0T8IW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D00ZUY	TTDDRUID	D00ZUY
D00ZUY	DRUGNAME	Umirolimus
D00ZUY	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3

D02WST	TTDDRUID	D02WST
D02WST	DRUGNAME	Unfractionated heparin
D02WST	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
D02WST	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3

D0E2YL	TTDDRUID	D0E2YL
D0E2YL	DRUGNAME	UNI-rhIL-11
D0E2YL	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 3

D0ER8I	TTDDRUID	D0ER8I
D0ER8I	DRUGNAME	Ushercell
D0ER8I	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D03ZKM	TTDDRUID	D03ZKM
D03ZKM	DRUGNAME	UX-001
D03ZKM	INDICATI	Hereditary inclusion body myositis [ICD-11: 4A41.2] Phase 3
D03ZKM	INDICATI	Myopathy [ICD-11: 8C7Y] Phase 2

D04UFY	TTDDRUID	D04UFY
D04UFY	DRUGNAME	UX-003
D04UFY	INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Phase 3
D04UFY	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 3

D09PTY	TTDDRUID	D09PTY
D09PTY	DRUGNAME	V-212
D09PTY	INDICATI	Herpes zoster [ICD-11: 1E91] Phase 3
D09PTY	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 3

D03BVW	TTDDRUID	D03BVW
D03BVW	DRUGNAME	V-419
D03BVW	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 3
D03BVW	INDICATI	Poliovirus infection [ICD-11: 1C8Y] Application submitted

D0I5RR	TTDDRUID	D0I5RR
D0I5RR	DRUGNAME	V-503
D0I5RR	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 3

D0P5DZ	TTDDRUID	D0P5DZ
D0P5DZ	DRUGNAME	V920
D0P5DZ	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3

D0W2BF	TTDDRUID	D0W2BF
D0W2BF	DRUGNAME	Vadastuximab talirine
D0W2BF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D0W2BF	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D01VQA	TTDDRUID	D01VQA
D01VQA	DRUGNAME	VAL BRO 03
D01VQA	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3

D0A1IL	TTDDRUID	D0A1IL
D0A1IL	DRUGNAME	VAL-083
D0A1IL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0A1IL	INDICATI	Grade IV malignant glioma [ICD-11: 2A00.0] Phase 1/2
D0A1IL	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3
D0A1IL	INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 3

D08NCO	TTDDRUID	D08NCO
D08NCO	DRUGNAME	Vanadate
D08NCO	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
D08NCO	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
D08NCO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D07KFB	TTDDRUID	D07KFB
D07KFB	DRUGNAME	Varespladib methyl
D07KFB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D00VMA	TTDDRUID	D00VMA
D00VMA	DRUGNAME	Vatreptacog alfa (activated)
D00VMA	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 3

D08VWK	TTDDRUID	D08VWK
D08VWK	DRUGNAME	Vaxchora
D08VWK	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 3

D0I6PP	TTDDRUID	D0I6PP
D0I6PP	DRUGNAME	VaxiGrip QIV IM
D0I6PP	INDICATI	Influenza [ICD-11: 1E30-1E32] Phase 3
D0I6PP	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0S4LV	TTDDRUID	D0S4LV
D0S4LV	DRUGNAME	VB-111
D0S4LV	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0S4LV	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 3
D0S4LV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0S4LV	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3

D0D0QQ	TTDDRUID	D0D0QQ
D0D0QQ	DRUGNAME	Velac Gel
D0D0QQ	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D0Y9YN	TTDDRUID	D0Y9YN
D0Y9YN	DRUGNAME	Velimogene aliplasmid
D0Y9YN	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0K3UQ	TTDDRUID	D0K3UQ
D0K3UQ	DRUGNAME	Vercirnon
D0K3UQ	INDICATI	Crohn disease [ICD-11: DD70] Phase 3

D0Y8ND	TTDDRUID	D0Y8ND
D0Y8ND	DRUGNAME	VERED
D0Y8ND	INDICATI	Rosacea [ICD-11: ED90.0] Phase 3

D00OTL	TTDDRUID	D00OTL
D00OTL	DRUGNAME	Vernakalant
D00OTL	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 3

D0G2ZX	TTDDRUID	D0G2ZX
D0G2ZX	DRUGNAME	Vernakalant IV
D0G2ZX	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 3

D02EXB	TTDDRUID	D02EXB
D02EXB	DRUGNAME	Vero cell seasonal influenza vaccine
D02EXB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D0R4KK	TTDDRUID	D0R4KK
D0R4KK	DRUGNAME	verubecestat
D0R4KK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D00PMB	TTDDRUID	D00PMB
D00PMB	DRUGNAME	VGX-3100
D00PMB	INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2
D00PMB	INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 3
D00PMB	INDICATI	Dysplasia [ICD-11: LB30-LD2F] Phase 3
D00PMB	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
D00PMB	INDICATI	Vulvar intraepithelial neoplasia [ICD-11: 2E67.10] Phase 2
D00PMB	INDICATI	Vulvar squamous intraepithelial lesion [ICD-11: 2E66.1] Phase 2

D09JLI	TTDDRUID	D09JLI
D09JLI	DRUGNAME	Vicriviroc
D09JLI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0R9HL	TTDDRUID	D0R9HL
D0R9HL	DRUGNAME	Vildagliptin/metformin
D0R9HL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0E5VO	TTDDRUID	D0E5VO
D0E5VO	DRUGNAME	Vinanterol inhalation/ fluticasone furoate powder
D0E5VO	INDICATI	Asthma [ICD-11: CA23] Phase 3

D09XUB	TTDDRUID	D09XUB
D09XUB	DRUGNAME	Viramidine
D09XUB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0OH8W	TTDDRUID	D0OH8W
D0OH8W	DRUGNAME	Visilizumab
D0OH8W	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3

D0UK2Z	TTDDRUID	D0UK2Z
D0UK2Z	DRUGNAME	Vitespen
D0UK2Z	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D0UK2Z	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D00TUP	TTDDRUID	D00TUP
D00TUP	DRUGNAME	Vitreosolve
D00TUP	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 3

D0RL5B	TTDDRUID	D0RL5B
D0RL5B	DRUGNAME	VLB-01
D0RL5B	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3

D0D4OS	TTDDRUID	D0D4OS
D0D4OS	DRUGNAME	VM-202
D0D4OS	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
D0D4OS	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
D0D4OS	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
D0D4OS	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 3
D0D4OS	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 3

D05XKW	TTDDRUID	D05XKW
D05XKW	DRUGNAME	VM-501
D05XKW	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 3

D0L9HX	TTDDRUID	D0L9HX
D0L9HX	DRUGNAME	Voclosporin
D0L9HX	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2
D0L9HX	INDICATI	Lupus [ICD-11: 4A40] Phase 2
D0L9HX	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3

D00BYM	TTDDRUID	D00BYM
D00BYM	DRUGNAME	Volasertib
D00BYM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D00BYM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D0K9IB	TTDDRUID	D0K9IB
D0K9IB	DRUGNAME	Vonapanitase
D0K9IB	INDICATI	Arterial thrombosis [ICD-11: DB61-DD30] Phase 3
D0K9IB	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 3

D01SPW	TTDDRUID	D01SPW
D01SPW	DRUGNAME	VR647
D01SPW	INDICATI	Asthma [ICD-11: CA23] Phase 3

D04EVE	TTDDRUID	D04EVE
D04EVE	DRUGNAME	VR876
D04EVE	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3

D0Y7VP	TTDDRUID	D0Y7VP
D0Y7VP	DRUGNAME	VRS-317
D0Y7VP	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3

D0Z5HR	TTDDRUID	D0Z5HR
D0Z5HR	DRUGNAME	VX-661
D0Z5HR	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
D0Z5HR	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 3

D01MGV	TTDDRUID	D01MGV
D01MGV	DRUGNAME	WC-3048
D01MGV	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 3

D0ET9N	TTDDRUID	D0ET9N
D0ET9N	DRUGNAME	WC-3049
D0ET9N	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3

D0Q9TB	TTDDRUID	D0Q9TB
D0Q9TB	DRUGNAME	White blood cell therapy
D0Q9TB	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3

D01FWI	TTDDRUID	D01FWI
D01FWI	DRUGNAME	Wound healing agents
D01FWI	INDICATI	Wound healing [ICD-11: EL8Y] Phase 3

D0D1JP	TTDDRUID	D0D1JP
D0D1JP	DRUGNAME	WR-279396
D0D1JP	INDICATI	Leishmania infection [ICD-11: 1F54.0] Phase 3

D02OJC	TTDDRUID	D02OJC
D02OJC	DRUGNAME	Xaliproden
D02OJC	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3
D02OJC	INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3
D02OJC	INDICATI	Lateral sclerosis [ICD-11: 8B61] Discontinued in Phase 3
D02OJC	INDICATI	Peripheral sensory neuropathies [ICD-11: LD27.3] Discontinued in Phase 3
D02OJC	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3

D06RVQ	TTDDRUID	D06RVQ
D06RVQ	DRUGNAME	Xenon
D06RVQ	INDICATI	Brain injury [ICD-11: NA07.Z] Phase 3

D0YO4C	TTDDRUID	D0YO4C
D0YO4C	DRUGNAME	Xilonix
D0YO4C	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3

D05AJT	TTDDRUID	D05AJT
D05AJT	DRUGNAME	XL019
D05AJT	INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 1
D05AJT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0C4KT	TTDDRUID	D0C4KT
D0C4KT	DRUGNAME	XOMA 052
D0C4KT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D05CGO	TTDDRUID	D05CGO
D05CGO	DRUGNAME	XP-28
D05CGO	INDICATI	Muscle fatigue [ICD-11: FB32.5] Phase 3

D0V6AB	TTDDRUID	D0V6AB
D0V6AB	DRUGNAME	XR-1500
D0V6AB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0T8AI	TTDDRUID	D0T8AI
D0T8AI	DRUGNAME	Y-90 Clivatuzumab
D0T8AI	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D0T9FD	TTDDRUID	D0T9FD
D0T9FD	DRUGNAME	YKP-3089
D0T9FD	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3

D08OGB	TTDDRUID	D08OGB
D08OGB	DRUGNAME	YourDex
D08OGB	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3

D00NWV	TTDDRUID	D00NWV
D00NWV	DRUGNAME	Ypeginterferon alfa-2a (chronic hepatitis B/C) Amoytop
D00NWV	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3

D0V2KR	TTDDRUID	D0V2KR
D0V2KR	DRUGNAME	Yttrium (90Y) clivatuzumab tetraxetan
D0V2KR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D09LHG	TTDDRUID	D09LHG
D09LHG	DRUGNAME	YY-162
D09LHG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3

D0CF8T	TTDDRUID	D0CF8T
D0CF8T	DRUGNAME	Z-521
D0CF8T	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3

D07MXF	TTDDRUID	D07MXF
D07MXF	DRUGNAME	Zabofloxacin
D07MXF	INDICATI	Pneumonia [ICD-11: CA40] Phase 3

D0U5GZ	TTDDRUID	D0U5GZ
D0U5GZ	DRUGNAME	Zadaxin/transarterial chemoembolization(TACE)(cisplatin)
D0U5GZ	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 3

D0R4PW	TTDDRUID	D0R4PW
D0R4PW	DRUGNAME	Zalutumumab
D0R4PW	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3

D0Z8KS	TTDDRUID	D0Z8KS
D0Z8KS	DRUGNAME	Zanolimumab
D0Z8KS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3

D04NNJ	TTDDRUID	D04NNJ
D04NNJ	DRUGNAME	ZANOTERONE
D04NNJ	INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 3

D00IJQ	TTDDRUID	D00IJQ
D00IJQ	DRUGNAME	ZATOSETRON MALEATE
D00IJQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 3

D02YVM	TTDDRUID	D02YVM
D02YVM	DRUGNAME	Zicronapine
D02YVM	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D07ZCK	TTDDRUID	D07ZCK
D07ZCK	DRUGNAME	ZK-93423
D07ZCK	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 3

D0C8PI	TTDDRUID	D0C8PI
D0C8PI	DRUGNAME	Zoniporide hydrochloride
D0C8PI	INDICATI	Angina pectoris [ICD-11: BA40] Phase 3

D0T2MS	TTDDRUID	D0T2MS
D0T2MS	DRUGNAME	ZX002
D0T2MS	INDICATI	Back pain [ICD-11: ME84.Z] Phase 3

D0M5BE	TTDDRUID	D0M5BE
D0M5BE	DRUGNAME	ZX-008
D0M5BE	INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 3
D0M5BE	INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 3

D0T7MN	TTDDRUID	D0T7MN
D0T7MN	DRUGNAME	ZYH-1
D0T7MN	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3

D04EGR	TTDDRUID	D04EGR
D04EGR	DRUGNAME	1-MNA
D04EGR	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
D04EGR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2/3

D0R1QH	TTDDRUID	D0R1QH
D0R1QH	DRUGNAME	99m-Tc-tropantiol
D0R1QH	INDICATI	Brain disease [ICD-11: 8C70-8E61] Phase 2/3

D02LPY	TTDDRUID	D02LPY
D02LPY	DRUGNAME	A-623
D02LPY	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2/3

D00KGB	TTDDRUID	D00KGB
D00KGB	DRUGNAME	Abagovomab
D00KGB	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2/3

D0C0CE	TTDDRUID	D0C0CE
D0C0CE	DRUGNAME	Activated recombinant FVII-albumin fusion protein
D0C0CE	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 2/3

D0B5JH	TTDDRUID	D0B5JH
D0B5JH	DRUGNAME	ACU-4429
D0B5JH	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2/3

D0T9ZD	TTDDRUID	D0T9ZD
D0T9ZD	DRUGNAME	Adrenoleucodystrophy
D0T9ZD	INDICATI	Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 2/3

D0G5PF	TTDDRUID	D0G5PF
D0G5PF	DRUGNAME	AFQ056
D0G5PF	INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2/3

D0IJ0F	TTDDRUID	D0IJ0F
D0IJ0F	DRUGNAME	AG-013
D0IJ0F	INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 2/3

D07JLM	TTDDRUID	D07JLM
D07JLM	DRUGNAME	Alagebrium chloride
D07JLM	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2/3

D0B3CC	TTDDRUID	D0B3CC
D0B3CC	DRUGNAME	AlloStim
D0B3CC	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
D0B3CC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D01AKK	TTDDRUID	D01AKK
D01AKK	DRUGNAME	ALXN1101
D01AKK	INDICATI	Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Phase 2
D01AKK	INDICATI	Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Phase 2/3

D0H4YD	TTDDRUID	D0H4YD
D0H4YD	DRUGNAME	AMG520
D0H4YD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D08NMM	TTDDRUID	D08NMM
D08NMM	DRUGNAME	AMG520 
D08NMM	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D07DBE	TTDDRUID	D07DBE
D07DBE	DRUGNAME	Amolimogene
D07DBE	INDICATI	Dysplasia [ICD-11: LB30-LD2F] Phase 2/3

D0A7GA	TTDDRUID	D0A7GA
D0A7GA	DRUGNAME	AMT-2003
D0A7GA	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2/3

D08ANJ	TTDDRUID	D08ANJ
D08ANJ	DRUGNAME	AP-30663
D08ANJ	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1/2

D09PVO	TTDDRUID	D09PVO
D09PVO	DRUGNAME	Aramchol
D09PVO	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2/3

D0F2PD	TTDDRUID	D0F2PD
D0F2PD	DRUGNAME	Arimoclomol
D0F2PD	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2/3
D0F2PD	INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 2/3

D06OZW	TTDDRUID	D06OZW
D06OZW	DRUGNAME	Artemisone
D06OZW	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2/3

D0G3DC	TTDDRUID	D0G3DC
D0G3DC	DRUGNAME	ASP-1001
D0G3DC	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2/3

D02ZUG	TTDDRUID	D02ZUG
D02ZUG	DRUGNAME	Atogepant
D02ZUG	INDICATI	Migraine [ICD-11: 8A80] Phase 2/3

D0P1SA	TTDDRUID	D0P1SA
D0P1SA	DRUGNAME	Autologous endothelial progenitor cell therapy
D0P1SA	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2/3

D0F7TR	TTDDRUID	D0F7TR
D0F7TR	DRUGNAME	Autologous skeletal myoblast therapy
D0F7TR	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Phase 2/3

D0WH4L	TTDDRUID	D0WH4L
D0WH4L	DRUGNAME	AVN 211
D0WH4L	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
D0WH4L	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3

D0V4HO	TTDDRUID	D0V4HO
D0V4HO	DRUGNAME	Avoralstat
D0V4HO	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 2/3

D0DG4X	TTDDRUID	D0DG4X
D0DG4X	DRUGNAME	AXS-05
D0DG4X	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
D0DG4X	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3

D01AYX	TTDDRUID	D01AYX
D01AYX	DRUGNAME	AZD3293
D01AYX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D0NU0U	TTDDRUID	D0NU0U
D0NU0U	DRUGNAME	AZD4547
D0NU0U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D0NU0U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D08NAD	TTDDRUID	D08NAD
D08NAD	DRUGNAME	Batabulin
D08NAD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D03DEA	TTDDRUID	D03DEA
D03DEA	DRUGNAME	BCX-4161
D03DEA	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 2/3

D02AIZ	TTDDRUID	D02AIZ
D02AIZ	DRUGNAME	BIL010t
D02AIZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
D02AIZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D01BEL	TTDDRUID	D01BEL
D01BEL	DRUGNAME	Blincytoblinatumomab
D01BEL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3

D03MZJ	TTDDRUID	D03MZJ
D03MZJ	DRUGNAME	BUCINDOLOL
D03MZJ	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2/3
D03MZJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0I3VT	TTDDRUID	D0I3VT
D0I3VT	DRUGNAME	CAD-106
D0I3VT	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D0FI1L	TTDDRUID	D0FI1L
D0FI1L	DRUGNAME	CAD-1883
D0FI1L	INDICATI	Ataxic disorder [ICD-11: 8A03] Phase 1/2

D0N2CG	TTDDRUID	D0N2CG
D0N2CG	DRUGNAME	Carlecortemcel-L
D0N2CG	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2/3
D0N2CG	INDICATI	Lung infection [ICD-11: CA4Z] Phase 2/3

D03IOM	TTDDRUID	D03IOM
D03IOM	DRUGNAME	CART-19
D03IOM	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3

D09VKP	TTDDRUID	D09VKP
D09VKP	DRUGNAME	C-Cure
D09VKP	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2/3

D04GGG	TTDDRUID	D04GGG
D04GGG	DRUGNAME	CD123/CLL1 CAR-T Cells
D04GGG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3

D04YSC	TTDDRUID	D04YSC
D04YSC	DRUGNAME	CD19 CAR T cells
D04YSC	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3
D04YSC	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2/3

D0F4JK	TTDDRUID	D0F4JK
D0F4JK	DRUGNAME	CE-224535
D0F4JK	INDICATI	Arthralgia [ICD-11: ME82] Phase 2/3

D09AHZ	TTDDRUID	D09AHZ
D09AHZ	DRUGNAME	Celivarone
D09AHZ	INDICATI	Ventricular arrhythmias [ICD-11: BC71] Phase 2/3

D0R9DP	TTDDRUID	D0R9DP
D0R9DP	DRUGNAME	CEM-102
D0R9DP	INDICATI	Joint infection [ICD-11: FA10] Phase 2/3

D03QLG	TTDDRUID	D03QLG
D03QLG	DRUGNAME	CEP1347
D03QLG	INDICATI	Asthma [ICD-11: CA23] Phase 2/3

D0RF4J	TTDDRUID	D0RF4J
D0RF4J	DRUGNAME	CLL1 CAR-T Cell
D0RF4J	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3

D04PBH	TTDDRUID	D04PBH
D04PBH	DRUGNAME	CONTIGOSIDE B
D04PBH	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2/3

D08NJE	TTDDRUID	D08NJE
D08NJE	DRUGNAME	CR-845 iv infusion
D08NJE	INDICATI	Chronic pain [ICD-11: MG30] Phase 2
D08NJE	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2/3

D03DHQ	TTDDRUID	D03DHQ
D03DHQ	DRUGNAME	CX-516
D03DHQ	INDICATI	Pervasive developmental disorder [ICD-11: 6A00-6A0Z] Phase 2/3
D03DHQ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3

D0B7LK	TTDDRUID	D0B7LK
D0B7LK	DRUGNAME	CY-1503
D0B7LK	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2/3

D0AL8T	TTDDRUID	D0AL8T
D0AL8T	DRUGNAME	Darbufelone
D0AL8T	INDICATI	Asthma [ICD-11: CA23] Phase 2/3

D06VCN	TTDDRUID	D06VCN
D06VCN	DRUGNAME	Denagliptin
D06VCN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3

D0J8SE	TTDDRUID	D0J8SE
D0J8SE	DRUGNAME	DFD-07
D0J8SE	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2/3

D0M4GX	TTDDRUID	D0M4GX
D0M4GX	DRUGNAME	Digoxin immune Fab
D0M4GX	INDICATI	Eclampsia [ICD-11: JA25] Phase 2/3

D0EP9A	TTDDRUID	D0EP9A
D0EP9A	DRUGNAME	Dinutuximab
D0EP9A	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3

D04TNR	TTDDRUID	D04TNR
D04TNR	DRUGNAME	Dronabinol oral solution
D04TNR	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 2/3

D04QSH	TTDDRUID	D04QSH
D04QSH	DRUGNAME	DW-167
D04QSH	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2/3

D00HGF	TTDDRUID	D00HGF
D00HGF	DRUGNAME	ERYTHRITOL
D00HGF	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2/3

D0Q8DZ	TTDDRUID	D0Q8DZ
D0Q8DZ	DRUGNAME	EX-404
D0Q8DZ	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 2/3

D00RWW	TTDDRUID	D00RWW
D00RWW	DRUGNAME	Fexinidazole
D00RWW	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2/3

D04DFR	TTDDRUID	D04DFR
D04DFR	DRUGNAME	FX005
D04DFR	INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3

D03RDQ	TTDDRUID	D03RDQ
D03RDQ	DRUGNAME	Gavilimomab
D03RDQ	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2/3

D09JKS	TTDDRUID	D09JKS
D09JKS	DRUGNAME	GRASPA
D09JKS	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3

D09CNO	TTDDRUID	D09CNO
D09CNO	DRUGNAME	Grass pollen allergy vaccine tablet
D09CNO	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 2/3

D06GKE	TTDDRUID	D06GKE
D06GKE	DRUGNAME	GZ402665
D06GKE	INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 2/3

D0R5TV	TTDDRUID	D0R5TV
D0R5TV	DRUGNAME	HD-0801
D0R5TV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2/3

D09OWI	TTDDRUID	D09OWI
D09OWI	DRUGNAME	HDV-insulin
D09OWI	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D09OWI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3

D0H4CB	TTDDRUID	D0H4CB
D0H4CB	DRUGNAME	Hemoglobin raffimer
D0H4CB	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2/3

D0XM9E	TTDDRUID	D0XM9E
D0XM9E	DRUGNAME	Human plasminogen
D0XM9E	INDICATI	Ligneous conjunctivitis [ICD-11: 9A02.2] Phase 2/3

D0U4LQ	TTDDRUID	D0U4LQ
D0U4LQ	DRUGNAME	HyperAcute Lung
D0U4LQ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3

D0YX4Z	TTDDRUID	D0YX4Z
D0YX4Z	DRUGNAME	IC-43
D0YX4Z	INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Phase 2/3

D04XEQ	TTDDRUID	D04XEQ
D04XEQ	DRUGNAME	Imetelstat
D04XEQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D04XEQ	INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2
D04XEQ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D04XEQ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2/3
D04XEQ	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
D04XEQ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D00KLP	TTDDRUID	D00KLP
D00KLP	DRUGNAME	Immune globulin + albumin
D00KLP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3

D0P6MW	TTDDRUID	D0P6MW
D0P6MW	DRUGNAME	Imprime PGG immunotherapeutic
D0P6MW	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2/3

D0F3KC	TTDDRUID	D0F3KC
D0F3KC	DRUGNAME	Indium-111
D0F3KC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D0P2OW	TTDDRUID	D0P2OW
D0P2OW	DRUGNAME	IR208
D0P2OW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2/3
D0P2OW	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0T2FP	TTDDRUID	D0T2FP
D0T2FP	DRUGNAME	JNJ-54861911
D0T2FP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D02URX	TTDDRUID	D02URX
D02URX	DRUGNAME	KamRAB
D02URX	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2/3

D02FDZ	TTDDRUID	D02FDZ
D02FDZ	DRUGNAME	LCP-AtorFen
D02FDZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3

D0E2IN	TTDDRUID	D0E2IN
D0E2IN	DRUGNAME	LECOZOTAN HYDROCHLORIDE
D0E2IN	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2/3

D0PV4H	TTDDRUID	D0PV4H
D0PV4H	DRUGNAME	Legumain-cleavable doxorubicin prodrugs
D0PV4H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D00SMU	TTDDRUID	D00SMU
D00SMU	DRUGNAME	Lenti-D
D00SMU	INDICATI	Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 2/3

D08UGX	TTDDRUID	D08UGX
D08UGX	DRUGNAME	LIAROZOLE
D08UGX	INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 2/3

D0G0YL	TTDDRUID	D0G0YL
D0G0YL	DRUGNAME	LT-NS001
D0G0YL	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 2/3

D0JG8O	TTDDRUID	D0JG8O
D0JG8O	DRUGNAME	Luliconazole 10%
D0JG8O	INDICATI	Dry eye disease [ICD-11: 9E1Z] Phase 2/3

D06TFI	TTDDRUID	D06TFI
D06TFI	DRUGNAME	LY2157299
D06TFI	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2/3
D06TFI	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
D06TFI	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D06TFI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3
D06TFI	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D06TFI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0X7VB	TTDDRUID	D0X7VB
D0X7VB	DRUGNAME	MBX-102
D0X7VB	INDICATI	Gout [ICD-11: FA25] Phase 2/3

D01WLE	TTDDRUID	D01WLE
D01WLE	DRUGNAME	MC-1101
D01WLE	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 2/3

D0G0TS	TTDDRUID	D0G0TS
D0G0TS	DRUGNAME	Meclinertant
D0G0TS	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2/3

D0T9CO	TTDDRUID	D0T9CO
D0T9CO	DRUGNAME	MelCancerVac
D0T9CO	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2/3

D0U3LK	TTDDRUID	D0U3LK
D0U3LK	DRUGNAME	Metformin glycinate
D0U3LK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3

D0W9AI	TTDDRUID	D0W9AI
D0W9AI	DRUGNAME	MTC-DOX
D0W9AI	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2/3

D0O7CO	TTDDRUID	D0O7CO
D0O7CO	DRUGNAME	MyoCell
D0O7CO	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2/3
D0O7CO	INDICATI	Heart injury [ICD-11: NB31] Phase 2/3

D0KN1U	TTDDRUID	D0KN1U
D0KN1U	DRUGNAME	Myo-inositol hexaphosphate
D0KN1U	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
D0KN1U	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3
D0KN1U	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative

D02SDY	TTDDRUID	D02SDY
D02SDY	DRUGNAME	NaBen
D02SDY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3

D00OCL	TTDDRUID	D00OCL
D00OCL	DRUGNAME	Nalbuphine extended release
D00OCL	INDICATI	Prurigo nodularis [ICD-11: EC91.0] Phase 2/3
D00OCL	INDICATI	Uremic pruritus [ICD-11: EC90.10] Phase 2/3

D01FDN	TTDDRUID	D01FDN
D01FDN	DRUGNAME	NAL-GLU
D01FDN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2/3

D07ZUW	TTDDRUID	D07ZUW
D07ZUW	DRUGNAME	Nanoemulsion
D07ZUW	INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 2/3

D0T8HR	TTDDRUID	D0T8HR
D0T8HR	DRUGNAME	Naptumomab estafenatox
D0T8HR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D0H0VI	TTDDRUID	D0H0VI
D0H0VI	DRUGNAME	Neo-GAA
D0H0VI	INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 2/3

D0B5HS	TTDDRUID	D0B5HS
D0B5HS	DRUGNAME	NLG8189
D0B5HS	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0B5HS	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
D0B5HS	INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
D0B5HS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D0B5HS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0A7WO	TTDDRUID	D0A7WO
D0A7WO	DRUGNAME	NT-501
D0A7WO	INDICATI	Macular telangiectasia type 2 [ICD-11: 9B75.3] Phase 2
D0A7WO	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 2/3
D0A7WO	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 2/3

D07WJE	TTDDRUID	D07WJE
D07WJE	DRUGNAME	NVC-422 nasal
D07WJE	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2/3

D00GZW	TTDDRUID	D00GZW
D00GZW	DRUGNAME	ONO-2506
D00GZW	INDICATI	Stroke [ICD-11: 8B20] Phase 2/3
D00GZW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0HK6O	TTDDRUID	D0HK6O
D0HK6O	DRUGNAME	OT-101
D0HK6O	INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
D0HK6O	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2/3
D0HK6O	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2/3
D0HK6O	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2/3

D04WTN	TTDDRUID	D04WTN
D04WTN	DRUGNAME	Oxabact
D04WTN	INDICATI	Hyperoxaluria [ICD-11: 5C51.2Z] Phase 2/3

D08FWK	TTDDRUID	D08FWK
D08FWK	DRUGNAME	Oxypurinol
D08FWK	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2/3

D02GWF	TTDDRUID	D02GWF
D02GWF	DRUGNAME	PACTIMIBE
D02GWF	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2/3

D04YSK	TTDDRUID	D04YSK
D04YSK	DRUGNAME	Pagibaximab
D04YSK	INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Phase 2/3

D0O0PY	TTDDRUID	D0O0PY
D0O0PY	DRUGNAME	Pagoclone
D0O0PY	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2/3

D0A6LT	TTDDRUID	D0A6LT
D0A6LT	DRUGNAME	PEG-bHb-CO
D0A6LT	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3
D0A6LT	INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 2
D0A6LT	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2

D0ZM5O	TTDDRUID	D0ZM5O
D0ZM5O	DRUGNAME	Pexacerfont
D0ZM5O	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2/3

D06ZXH	TTDDRUID	D06ZXH
D06ZXH	DRUGNAME	PHN-131
D06ZXH	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2/3

D0J3BY	TTDDRUID	D0J3BY
D0J3BY	DRUGNAME	Pimagedine HCl
D0J3BY	INDICATI	Diabetic kidney disease [ICD-11: GB61.Z] Phase 2/3

D0S4YT	TTDDRUID	D0S4YT
D0S4YT	DRUGNAME	Plasminogen concentrate
D0S4YT	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D01CTR	TTDDRUID	D01CTR
D01CTR	DRUGNAME	Plasminogen intravenous
D01CTR	INDICATI	Congenital plasminogen activator inhibitor type 1 deficiency [ICD-11: 3B50.1] Phase 2/3
D01CTR	INDICATI	Hypoplasminogenemia [ICD-11: DA0D.3] Phase 2/3

D0E3MA	TTDDRUID	D0E3MA
D0E3MA	DRUGNAME	Polyacrylic acid
D0E3MA	INDICATI	Contraception [ICD-11: QA21] Phase 2/3

D0GC5H	TTDDRUID	D0GC5H
D0GC5H	DRUGNAME	Ramatroban
D0GC5H	INDICATI	Perennial allergic rhinitis [ICD-11: CA08.03] Phase 2/3

D0Z9YF	TTDDRUID	D0Z9YF
D0Z9YF	DRUGNAME	Recombinant Bet v 1 immunotherapy
D0Z9YF	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2/3

D05ZDD	TTDDRUID	D05ZDD
D05ZDD	DRUGNAME	Recombinant human cartilage-derived retinoic acid-sensitive protein depot
D05ZDD	INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Phase 2/3

D0RP5T	TTDDRUID	D0RP5T
D0RP5T	DRUGNAME	RG6206
D0RP5T	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2/3

D06APK	TTDDRUID	D06APK
D06APK	DRUGNAME	Rinfabate
D06APK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3

D01ADL	TTDDRUID	D01ADL
D01ADL	DRUGNAME	Roledumab
D01ADL	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2/3

D0Z9LP	TTDDRUID	D0Z9LP
D0Z9LP	DRUGNAME	RP101
D0Z9LP	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2/3
D0Z9LP	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2/3

D0VD6Q	TTDDRUID	D0VD6Q
D0VD6Q	DRUGNAME	RP103
D0VD6Q	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2/3

D08RFZ	TTDDRUID	D08RFZ
D08RFZ	DRUGNAME	RSV mAb
D08RFZ	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3

D0SB5K	TTDDRUID	D0SB5K
D0SB5K	DRUGNAME	SAR164877
D0SB5K	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2/3

D0W5EH	TTDDRUID	D0W5EH
D0W5EH	DRUGNAME	Sarizotan
D0W5EH	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
D0W5EH	INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 2/3

D08QGE	TTDDRUID	D08QGE
D08QGE	DRUGNAME	SI-614
D08QGE	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D02ADM	TTDDRUID	D02ADM
D02ADM	DRUGNAME	Silibinin
D02ADM	INDICATI	Hepatic failure [ICD-11: DB99.7] Phase 2/3

D0SC6I	TTDDRUID	D0SC6I
D0SC6I	DRUGNAME	Sodium benzoate
D0SC6I	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3

D0YS1U	TTDDRUID	D0YS1U
D0YS1U	DRUGNAME	sparsentan
D0YS1U	INDICATI	Focal segmental glomerulosclerosis [ICD-11: MF8Y] Phase 2/3
D0YS1U	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
D0YS1U	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D0VL4V	TTDDRUID	D0VL4V
D0VL4V	DRUGNAME	SR-123781A
D0VL4V	INDICATI	Venous thrombosis [ICD-11: BA43] Phase 2/3

D0Z6OW	TTDDRUID	D0Z6OW
D0Z6OW	DRUGNAME	Staphylococcus aureus vaccine
D0Z6OW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2/3
D0Z6OW	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1

D0D9ZB	TTDDRUID	D0D9ZB
D0D9ZB	DRUGNAME	TAK-583
D0D9ZB	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2/3

D02GTY	TTDDRUID	D02GTY
D02GTY	DRUGNAME	Tamibarotene
D02GTY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3

D0ZW3R	TTDDRUID	D0ZW3R
D0ZW3R	DRUGNAME	TG-4010
D0ZW3R	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2/3
D0ZW3R	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3

D06XPL	TTDDRUID	D06XPL
D06XPL	DRUGNAME	TOCA-511
D06XPL	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2/3

D00SUK	TTDDRUID	D00SUK
D00SUK	DRUGNAME	Tonapofylline
D00SUK	INDICATI	Acute and chronic heart failure [ICD-11: BD1Z] Phase 2

D0Y9XU	TTDDRUID	D0Y9XU
D0Y9XU	DRUGNAME	Turgenpumatucel-L
D0Y9XU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3

D07PML	TTDDRUID	D07PML
D07PML	DRUGNAME	Ublituximab + umbralisib
D07PML	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
D07PML	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2/3

D0AS4D	TTDDRUID	D0AS4D
D0AS4D	DRUGNAME	Unituxindinutuximab
D0AS4D	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3

D0SQ8R	TTDDRUID	D0SQ8R
D0SQ8R	DRUGNAME	V-710
D0SQ8R	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2/3

D00NYJ	TTDDRUID	D00NYJ
D00NYJ	DRUGNAME	Varlitinib
D00NYJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D00NYJ	INDICATI	Metastatic biliary tract neoplasms [ICD-11: 2C14-2C17] Phase 2/3

D0Q3IS	TTDDRUID	D0Q3IS
D0Q3IS	DRUGNAME	VB4-845
D0Q3IS	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2/3

D01BBB	TTDDRUID	D01BBB
D01BBB	DRUGNAME	VM-1500
D01BBB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3

D01SNZ	TTDDRUID	D01SNZ
D01SNZ	DRUGNAME	VTS-270
D01SNZ	INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 2/3

D04QWQ	TTDDRUID	D04QWQ
D04QWQ	DRUGNAME	VX-509
D04QWQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2/3

D01WXU	TTDDRUID	D01WXU
D01WXU	DRUGNAME	ZK-205367
D01WXU	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2/3

D07FGA	TTDDRUID	D07FGA
D07FGA	DRUGNAME	ZYC101a
D07FGA	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2/3

D0C0KP	TTDDRUID	D0C0KP
D0C0KP	DRUGNAME	AllerB
D0C0KP	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2b

D0X9PF	TTDDRUID	D0X9PF
D0X9PF	DRUGNAME	Bremelanotide
D0X9PF	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 3
D0X9PF	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Phase 2a

D0ME1L	TTDDRUID	D0ME1L
D0ME1L	DRUGNAME	Digibind
D0ME1L	INDICATI	Eclampsia [ICD-11: JA25] Phase 2b
D0ME1L	INDICATI	Pre-eclampsia [ICD-11: JA24] Phase 2

D0G9XP	TTDDRUID	D0G9XP
D0G9XP	DRUGNAME	LB80380
D0G9XP	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2b

D0Q9XE	TTDDRUID	D0Q9XE
D0Q9XE	DRUGNAME	MEDI4893
D0Q9XE	INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 1
D0Q9XE	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2b

D06CVO	TTDDRUID	D06CVO
D06CVO	DRUGNAME	OrM3
D06CVO	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2b

D0W9VW	TTDDRUID	D0W9VW
D0W9VW	DRUGNAME	TZP-101
D0W9VW	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2b
D0W9VW	INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 2b
D0W9VW	INDICATI	Ileus [ICD-11: DA93.0] Phase 2b

D0BW3P	TTDDRUID	D0BW3P
D0BW3P	DRUGNAME	Aerovant
D0BW3P	INDICATI	Asthma [ICD-11: CA23] Phase 2a

D04TIL	TTDDRUID	D04TIL
D04TIL	DRUGNAME	ANA773
D04TIL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2a

D0MM3A	TTDDRUID	D0MM3A
D0MM3A	DRUGNAME	BIIB104
D0MM3A	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2a

D02AUB	TTDDRUID	D02AUB
D02AUB	DRUGNAME	Bimosiamose
D02AUB	INDICATI	Asthma [ICD-11: CA23] Phase 2
D02AUB	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2a
D02AUB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2a
D02AUB	INDICATI	Psoriatic disorder [ICD-11: EA90] Phase 2a

D09EFC	TTDDRUID	D09EFC
D09EFC	DRUGNAME	CAP-232
D09EFC	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
D09EFC	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2a

D0U9OD	TTDDRUID	D0U9OD
D0U9OD	DRUGNAME	CreaVax-RA
D0U9OD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2a

D05XLO	TTDDRUID	D05XLO
D05XLO	DRUGNAME	INCB13739
D05XLO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
D05XLO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2a

D0Y7NA	TTDDRUID	D0Y7NA
D0Y7NA	DRUGNAME	INCB9471
D0Y7NA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0Y7NA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2a

D08UQS	TTDDRUID	D08UQS
D08UQS	DRUGNAME	MEM-1003
D08UQS	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2a
D08UQS	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2

D0J0KT	TTDDRUID	D0J0KT
D0J0KT	DRUGNAME	RhuDex
D0J0KT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2a

D06GDR	TTDDRUID	D06GDR
D06GDR	DRUGNAME	VAP-1 monoclonal antibody
D06GDR	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2a

D0D9AH	TTDDRUID	D0D9AH
D0D9AH	DRUGNAME	VX-702
D0D9AH	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
D0D9AH	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2a
D0D9AH	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
D0D9AH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2a

D00AUC	TTDDRUID	D00AUC
D00AUC	DRUGNAME	(99M)-TC-CPI
D00AUC	INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 2

D0C2ET	TTDDRUID	D0C2ET
D0C2ET	DRUGNAME	(R)-mequitazine (incontinence/respiratory disease), Pierre Fabre
D0C2ET	INDICATI	Respiratory disease [ICD-11: CB40] Phase 2

D0E0AS	TTDDRUID	D0E0AS
D0E0AS	DRUGNAME	(S)-oxybutynin
D0E0AS	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2

D0G5OE	TTDDRUID	D0G5OE
D0G5OE	DRUGNAME	[131I]-BC8
D0G5OE	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0E5BW	TTDDRUID	D0E5BW
D0E5BW	DRUGNAME	[131I]-Metuximab injection
D0E5BW	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2

D05QPC	TTDDRUID	D05QPC
D05QPC	DRUGNAME	[L/D]-aminopterin
D05QPC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0G4YZ	TTDDRUID	D0G4YZ
D0G4YZ	DRUGNAME	11C-PBR-28
D0G4YZ	INDICATI	Brain disease [ICD-11: 8C70-8E61] Phase 2

D03NMQ	TTDDRUID	D03NMQ
D03NMQ	DRUGNAME	131I-CLR-1404
D03NMQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0K9WP	TTDDRUID	D0K9WP
D0K9WP	DRUGNAME	131I-TM-601
D0K9WP	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2

D0NS8T	TTDDRUID	D0NS8T
D0NS8T	DRUGNAME	13-DEOXYADRIAMYCIN HYDROCHLORIDE
D0NS8T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0U7WF	TTDDRUID	D0U7WF
D0U7WF	DRUGNAME	16,16-dimethyl-PGE2
D0U7WF	INDICATI	Stem cell engraftment [ICD-11: QB63.8] Phase 2

D0G4YN	TTDDRUID	D0G4YN
D0G4YN	DRUGNAME	177 Lu PSMA-617 targeted radioligand therapy
D0G4YN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0A1RP	TTDDRUID	D0A1RP
D0A1RP	DRUGNAME	18F-fluorothymidine
D0A1RP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04IKF	TTDDRUID	D04IKF
D04IKF	DRUGNAME	18F-LMI-1195
D04IKF	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0A5IL	TTDDRUID	D0A5IL
D0A5IL	DRUGNAME	18F-NST-ML-10
D0A5IL	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D02JIN	TTDDRUID	D02JIN
D02JIN	DRUGNAME	264W94
D02JIN	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D06NYA	TTDDRUID	D06NYA
D06NYA	DRUGNAME	2-Methoxyestradiol
D06NYA	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0SZ9R	TTDDRUID	D0SZ9R
D0SZ9R	DRUGNAME	2X-121
D0SZ9R	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0WM6E	TTDDRUID	D0WM6E
D0WM6E	DRUGNAME	3,5-diiodothyropropionic acid
D0WM6E	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2

D00LDB	TTDDRUID	D00LDB
D00LDB	DRUGNAME	3,5-diiodothyropropionic acid (Allan-Herndon-Dudley syndrome), Zarion Pharmaceuticals
D00LDB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0M1YS	TTDDRUID	D0M1YS
D0M1YS	DRUGNAME	32-P BioSilicon
D0M1YS	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2

D01AEF	TTDDRUID	D01AEF
D01AEF	DRUGNAME	3F8
D01AEF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0UT7F	TTDDRUID	D0UT7F
D0UT7F	DRUGNAME	3K3A-APC
D0UT7F	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
D0UT7F	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2

D0D1LS	TTDDRUID	D0D1LS
D0D1LS	DRUGNAME	5-Fluoro-2-deoxycytidine
D0D1LS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0E9BF	TTDDRUID	D0E9BF
D0E9BF	DRUGNAME	5-hydroxymethyl-2-furfural (sickle cell disease), AesRx LLC
D0E9BF	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D0X1XA	TTDDRUID	D0X1XA
D0X1XA	DRUGNAME	62Cu-ETS
D0X1XA	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2

D0E5FA	TTDDRUID	D0E5FA
D0E5FA	DRUGNAME	62Cu-PTSM
D0E5FA	INDICATI	Occlusive coronary artery disease [ICD-11: BA80] Phase 2

D04RKW	TTDDRUID	D04RKW
D04RKW	DRUGNAME	7-methylxanthine
D04RKW	INDICATI	Myopia [ICD-11: 9D00.0] Phase 2

D0Q7NB	TTDDRUID	D0Q7NB
D0Q7NB	DRUGNAME	842166X
D0Q7NB	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D06XSB	TTDDRUID	D06XSB
D06XSB	DRUGNAME	870086 (topical, atopic dermatitis), GlaxoSmithKline
D06XSB	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0T4IW	TTDDRUID	D0T4IW
D0T4IW	DRUGNAME	8H9 I-131 mab
D0T4IW	INDICATI	Leptomeningeal sarcoma [ICD-11: 2A01.0] Phase 2
D0T4IW	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1
D0T4IW	INDICATI	Small round cell desmoplastic tumour [ICD-11: 2A20.5] Phase 1/2
D0T4IW	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 1

D01HVM	TTDDRUID	D01HVM
D01HVM	DRUGNAME	99mTc-DI-DD3B6/22-80B3
D01HVM	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D0WN1T	TTDDRUID	D0WN1T
D0WN1T	DRUGNAME	99mTc-labelled adrenomedullin (pulmonary disease), PulmoScience
D0WN1T	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2

D08FTP	TTDDRUID	D08FTP
D08FTP	DRUGNAME	99mTc-MIP-1404
D08FTP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D00QOJ	TTDDRUID	D00QOJ
D00QOJ	DRUGNAME	99MTC-RP-128
D00QOJ	INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 2

D07UHX	TTDDRUID	D07UHX
D07UHX	DRUGNAME	9-AMINOCAMPTOTHECIN
D07UHX	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2

D0M8CL	TTDDRUID	D0M8CL
D0M8CL	DRUGNAME	A-0001
D0M8CL	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2

D07TZT	TTDDRUID	D07TZT
D07TZT	DRUGNAME	A-007
D07TZT	INDICATI	Skin cancer [ICD-11: 2C30-2C37] Phase 2

D04QUG	TTDDRUID	D04QUG
D04QUG	DRUGNAME	A-101
D04QUG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0CT7M	TTDDRUID	D0CT7M
D0CT7M	DRUGNAME	A-6
D0CT7M	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D0NA5L	TTDDRUID	D0NA5L
D0NA5L	DRUGNAME	AAV2-REP1
D0NA5L	INDICATI	Choroidal dystrophy [ICD-11: 9B61] Phase 2

D07KTA	TTDDRUID	D07KTA
D07KTA	DRUGNAME	Ab-01
D07KTA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2

D01DGZ	TTDDRUID	D01DGZ
D01DGZ	DRUGNAME	ABBV-2222
D01DGZ	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0X6BX	TTDDRUID	D0X6BX
D0X6BX	DRUGNAME	ABC294640
D0X6BX	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 3
D0X6BX	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
D0X6BX	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D0X6BX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0V0SL	TTDDRUID	D0V0SL
D0V0SL	DRUGNAME	Abexinostat
D0V0SL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0V0SL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0V0SL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D0V0SL	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
D0V0SL	INDICATI	Gynecologic cancer [ICD-11: 2F33-2F76] Phase 2
D0V0SL	INDICATI	Kidney cancer [ICD-11: 2C90.0] Phase 3
D0V0SL	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
D0V0SL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02YIP	TTDDRUID	D02YIP
D02YIP	DRUGNAME	AbGn-168
D02YIP	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0W3UV	TTDDRUID	D0W3UV
D0W3UV	DRUGNAME	ABI-009
D0W3UV	INDICATI	Malignant perivascular epithelioid cell tumour [ICD-11: 2B5Y] Phase 2
D0W3UV	INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 1/2
D0W3UV	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
D0W3UV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0CJ7Z	TTDDRUID	D0CJ7Z
D0CJ7Z	DRUGNAME	Abicipar pegol
D0CJ7Z	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D0I4LM	TTDDRUID	D0I4LM
D0I4LM	DRUGNAME	ABIO-05/01
D0I4LM	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2

D0F9QH	TTDDRUID	D0F9QH
D0F9QH	DRUGNAME	Abituzumab
D0F9QH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0OX5H	TTDDRUID	D0OX5H
D0OX5H	DRUGNAME	ABT-122
D0OX5H	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
D0OX5H	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D08XOY	TTDDRUID	D08XOY
D08XOY	DRUGNAME	ABT-126
D08XOY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D08XOY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D07MKL	TTDDRUID	D07MKL
D07MKL	DRUGNAME	ABT-229
D07MKL	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D06ETI	TTDDRUID	D06ETI
D06ETI	DRUGNAME	ABT-263
D06ETI	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
D06ETI	INDICATI	Relapsed or refractory chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D06ETI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0N8QK	TTDDRUID	D0N8QK
D0N8QK	DRUGNAME	ABT-288
D0N8QK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0N3WN	TTDDRUID	D0N3WN
D0N3WN	DRUGNAME	ABT-308
D0N3WN	INDICATI	Asthma [ICD-11: CA23] Phase 1
D0N3WN	INDICATI	Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2

D08HOM	TTDDRUID	D08HOM
D08HOM	DRUGNAME	ABT-348
D08HOM	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2

D05WCI	TTDDRUID	D05WCI
D05WCI	DRUGNAME	ABT-384
D05WCI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D05WCI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D06XIT	TTDDRUID	D06XIT
D06XIT	DRUGNAME	ABT-414
D06XIT	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
D06XIT	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D06XIT	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0RC0J	TTDDRUID	D0RC0J
D0RC0J	DRUGNAME	ABT-436
D0RC0J	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D07OHT	TTDDRUID	D07OHT
D07OHT	DRUGNAME	ABT-450
D07OHT	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0G4MB	TTDDRUID	D0G4MB
D0G4MB	DRUGNAME	ABT-510
D0G4MB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04TNT	TTDDRUID	D04TNT
D04TNT	DRUGNAME	ABT-639
D04TNT	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0S5BV	TTDDRUID	D0S5BV
D0S5BV	DRUGNAME	ABT-652
D0S5BV	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D0S5BV	INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 2

D09EHO	TTDDRUID	D09EHO
D09EHO	DRUGNAME	ABT-751
D09EHO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01WQQ	TTDDRUID	D01WQQ
D01WQQ	DRUGNAME	ABT-981
D01WQQ	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D0K7NI	TTDDRUID	D0K7NI
D0K7NI	DRUGNAME	ABT-RTA-408
D0K7NI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0BF9K	TTDDRUID	D0BF9K
D0BF9K	DRUGNAME	ABX-IL8
D0BF9K	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D00HDB	TTDDRUID	D00HDB
D00HDB	DRUGNAME	AC-105
D00HDB	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2

D01IHR	TTDDRUID	D01IHR
D01IHR	DRUGNAME	AC-1202
D01IHR	INDICATI	Memory loss [ICD-11: MB21.1Z] Phase 2

D05ELM	TTDDRUID	D05ELM
D05ELM	DRUGNAME	AC-150
D05ELM	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2

D0WP2R	TTDDRUID	D0WP2R
D0WP2R	DRUGNAME	AC-201
D0WP2R	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D05MHI	TTDDRUID	D05MHI
D05MHI	DRUGNAME	AC-607
D05MHI	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2

D08XDV	TTDDRUID	D08XDV
D08XDV	DRUGNAME	ACAM-Cdiff
D08XDV	INDICATI	Traveler's diarrhea [ICD-11: ME05.1] Phase 2

D0U9MN	TTDDRUID	D0U9MN
D0U9MN	DRUGNAME	ACAM-Cdiff)Toxoid vaccine)
D0U9MN	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2

D0J7EH	TTDDRUID	D0J7EH
D0J7EH	DRUGNAME	ACCLAIM
D0J7EH	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
D0J7EH	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0T6EE	TTDDRUID	D0T6EE
D0T6EE	DRUGNAME	ACE-031
D0T6EE	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0R5HH	TTDDRUID	D0R5HH
D0R5HH	DRUGNAME	ACE-083
D0R5HH	INDICATI	Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 2
D0R5HH	INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2

D0JH9T	TTDDRUID	D0JH9T
D0JH9T	DRUGNAME	ACE-393
D0JH9T	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2

D05QHO	TTDDRUID	D05QHO
D05QHO	DRUGNAME	ACE-527
D05QHO	INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 2

D0M1IN	TTDDRUID	D0M1IN
D0M1IN	DRUGNAME	acelarin
D0M1IN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0M1IN	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0JO8T	TTDDRUID	D0JO8T
D0JO8T	DRUGNAME	ACER-003
D0JO8T	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2

D06FRB	TTDDRUID	D06FRB
D06FRB	DRUGNAME	ACH-0137171
D06FRB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D07ZAH	TTDDRUID	D07ZAH
D07ZAH	DRUGNAME	ACH-1625
D07ZAH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0U6QN	TTDDRUID	D0U6QN
D0U6QN	DRUGNAME	ACH-3102
D0U6QN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D07GAA	TTDDRUID	D07GAA
D07GAA	DRUGNAME	ACP-001
D07GAA	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D0Z7TR	TTDDRUID	D0Z7TR
D0Z7TR	DRUGNAME	ACP-01
D0Z7TR	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 2

D0Q4WG	TTDDRUID	D0Q4WG
D0Q4WG	DRUGNAME	ACT-1 topical gel
D0Q4WG	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D06RLU	TTDDRUID	D06RLU
D06RLU	DRUGNAME	ACT-128800
D06RLU	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0J8EC	TTDDRUID	D0J8EC
D0J8EC	DRUGNAME	ACT-280778
D0J8EC	INDICATI	Essential hypertension [ICD-11: BA00] Phase 2

D06XBN	TTDDRUID	D06XBN
D06XBN	DRUGNAME	ACT-GRO-777
D06XBN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03HSA	TTDDRUID	D03HSA
D03HSA	DRUGNAME	Actimab-A
D03HSA	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D02MSG	TTDDRUID	D02MSG
D02MSG	DRUGNAME	AcVx-25 cream
D02MSG	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0F0UT	TTDDRUID	D0F0UT
D0F0UT	DRUGNAME	ACYLINE
D0F0UT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D08OYF	TTDDRUID	D08OYF
D08OYF	DRUGNAME	Ad/PSA
D08OYF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0S1BF	TTDDRUID	D0S1BF
D0S1BF	DRUGNAME	AD02 vaccine
D0S1BF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0GU9J	TTDDRUID	D0GU9J
D0GU9J	DRUGNAME	Ad2/HIF-1alpha/VP16
D0GU9J	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D03YKQ	TTDDRUID	D03YKQ
D03YKQ	DRUGNAME	AD-452
D03YKQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0L9OF	TTDDRUID	D0L9OF
D0L9OF	DRUGNAME	Adagloxad simolenin
D0L9OF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2/3

D02JND	TTDDRUID	D02JND
D02JND	DRUGNAME	ADC-3680
D02JND	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0F4IM	TTDDRUID	D0F4IM
D0F4IM	DRUGNAME	Adcetris
D0F4IM	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3
D0F4IM	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D0F4IM	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 3
D0F4IM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D0F4IM	INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 3

D0J6VE	TTDDRUID	D0J6VE
D0J6VE	DRUGNAME	Ad-IFNg
D0J6VE	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D0B9OG	TTDDRUID	D0B9OG
D0B9OG	DRUGNAME	Adipiplon
D0B9OG	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2

D0N9VZ	TTDDRUID	D0N9VZ
D0N9VZ	DRUGNAME	ADL-5747
D0N9VZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0W9ZT	TTDDRUID	D0W9ZT
D0W9ZT	DRUGNAME	ADL-5859
D0W9ZT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0P7SO	TTDDRUID	D0P7SO
D0P7SO	DRUGNAME	ADMVA
D0P7SO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0G3GF	TTDDRUID	D0G3GF
D0G3GF	DRUGNAME	AdPEDR
D0G3GF	INDICATI	Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2

D02WZW	TTDDRUID	D02WZW
D02WZW	DRUGNAME	ADPS topical
D02WZW	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0EX1W	TTDDRUID	D0EX1W
D0EX1W	DRUGNAME	Ad-RTS-IL-12
D0EX1W	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
D0EX1W	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0G4XE	TTDDRUID	D0G4XE
D0G4XE	DRUGNAME	Adult stem cell therapy
D0G4XE	INDICATI	Chronic myocardial ischemia [ICD-11: BA6Z] Phase 2
D0G4XE	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D0O1CJ	TTDDRUID	D0O1CJ
D0O1CJ	DRUGNAME	AdVac tuberculosis vaccine
D0O1CJ	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D05PGM	TTDDRUID	D05PGM
D05PGM	DRUGNAME	AdV-tK
D05PGM	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 2

D0P4WO	TTDDRUID	D0P4WO
D0P4WO	DRUGNAME	ADX10059
D0P4WO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0I5TL	TTDDRUID	D0I5TL
D0I5TL	DRUGNAME	ADX-48621
D0I5TL	INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 2
D0I5TL	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
D0I5TL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0TS8E	TTDDRUID	D0TS8E
D0TS8E	DRUGNAME	ADX71149
D0TS8E	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Discontinued in Phase 2

D0YJ2G	TTDDRUID	D0YJ2G
D0YJ2G	DRUGNAME	ADXS11-001
D0YJ2G	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2

D0YO6R	TTDDRUID	D0YO6R
D0YO6R	DRUGNAME	ADXS-DUAL
D0YO6R	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3

D04FFM	TTDDRUID	D04FFM
D04FFM	DRUGNAME	ADXS-HPV
D04FFM	INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2
D04FFM	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2

D0G3BN	TTDDRUID	D0G3BN
D0G3BN	DRUGNAME	AE-37
D0G3BN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0G3BN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0L0RO	TTDDRUID	D0L0RO
D0L0RO	DRUGNAME	AE37 peptide vaccine
D0L0RO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0LA1R	TTDDRUID	D0LA1R
D0LA1R	DRUGNAME	AEB07
D0LA1R	INDICATI	Transplant rejection [ICD-11: NE84] Phase 2

D09POH	TTDDRUID	D09POH
D09POH	DRUGNAME	AEG-33773
D09POH	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D07ADU	TTDDRUID	D07ADU
D07ADU	DRUGNAME	AEM-28
D07ADU	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2
D07ADU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1/2

D07YRV	TTDDRUID	D07YRV
D07YRV	DRUGNAME	AER-002
D07YRV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0O7PS	TTDDRUID	D0O7PS
D0O7PS	DRUGNAME	AERAS-402
D0O7PS	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2

D0D8XG	TTDDRUID	D0D8XG
D0D8XG	DRUGNAME	AeroLEF
D0D8XG	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0QC2V	TTDDRUID	D0QC2V
D0QC2V	DRUGNAME	AEVI-1
D0QC2V	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D0IR6K	TTDDRUID	D0IR6K
D0IR6K	DRUGNAME	AF-219
D0IR6K	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2

D0D8UM	TTDDRUID	D0D8UM
D0D8UM	DRUGNAME	Afabicin
D0D8UM	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2

D0V2OX	TTDDRUID	D0V2OX
D0V2OX	DRUGNAME	afamelanotide
D0V2OX	INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Phase 3
D0V2OX	INDICATI	Vitiligo [ICD-11: ED63.0] Phase 2

D09NST	TTDDRUID	D09NST
D09NST	DRUGNAME	Afimoxifene
D09NST	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D09NST	INDICATI	Ductal carcinoma [ICD-11: 2E65.2] Phase 2

D0SU4D	TTDDRUID	D0SU4D
D0SU4D	DRUGNAME	Aflibercept + nesvacumab
D0SU4D	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D00DUK	TTDDRUID	D00DUK
D00DUK	DRUGNAME	AFM-13
D00DUK	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
D00DUK	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
D00DUK	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D00HYK	TTDDRUID	D00HYK
D00HYK	DRUGNAME	AFN-1252
D00HYK	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2

D0X6NZ	TTDDRUID	D0X6NZ
D0X6NZ	DRUGNAME	AFN-1720
D0X6NZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D09HFS	TTDDRUID	D09HFS
D09HFS	DRUGNAME	AFP464
D09HFS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D05YFL	TTDDRUID	D05YFL
D05YFL	DRUGNAME	AFTVac
D05YFL	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D0R3OP	TTDDRUID	D0R3OP
D0R3OP	DRUGNAME	AG-120
D0R3OP	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0R3OP	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D06KZL	TTDDRUID	D06KZL
D06KZL	DRUGNAME	AG140699
D06KZL	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0C8AP	TTDDRUID	D0C8AP
D0C8AP	DRUGNAME	AG-348
D0C8AP	INDICATI	Pyruvate kinase deficiency [ICD-11: 5C53.00] Phase 2

D06KIJ	TTDDRUID	D06KIJ
D06KIJ	DRUGNAME	AG-858
D06KIJ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D04TPQ	TTDDRUID	D04TPQ
D04TPQ	DRUGNAME	Aganepag isopropyl
D04TPQ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D0A2XY	TTDDRUID	D0A2XY
D0A2XY	DRUGNAME	AGB101
D0A2XY	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0WJ7H	TTDDRUID	D0WJ7H
D0WJ7H	DRUGNAME	AGEN2034
D0WJ7H	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
D0WJ7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01FHL	TTDDRUID	D01FHL
D01FHL	DRUGNAME	AGN-150998
D01FHL	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D05CFH	TTDDRUID	D05CFH
D05CFH	DRUGNAME	AGN-199981
D05CFH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D02PNP	TTDDRUID	D02PNP
D02PNP	DRUGNAME	AGN-214868
D02PNP	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2

D09OWK	TTDDRUID	D09OWK
D09OWK	DRUGNAME	AGN-2979
D09OWK	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D00BWF	TTDDRUID	D00BWF
D00BWF	DRUGNAME	AGN-XX/YY
D00BWF	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
D00BWF	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2

D0Q5OC	TTDDRUID	D0Q5OC
D0Q5OC	DRUGNAME	AGS-003
D0Q5OC	INDICATI	Migraine [ICD-11: 8A80] Phase 2
D0Q5OC	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D04ZZT	TTDDRUID	D04ZZT
D04ZZT	DRUGNAME	AGS-004
D04ZZT	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0XT5Q	TTDDRUID	D0XT5Q
D0XT5Q	DRUGNAME	AGS-16C3F
D0XT5Q	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0QF2W	TTDDRUID	D0QF2W
D0QF2W	DRUGNAME	AGTC-0106
D0QF2W	INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 2

D03MZU	TTDDRUID	D03MZU
D03MZU	DRUGNAME	AHCQ
D03MZU	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0B7QU	TTDDRUID	D0B7QU
D0B7QU	DRUGNAME	AIM-102
D0B7QU	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0N9PQ	TTDDRUID	D0N9PQ
D0N9PQ	DRUGNAME	Aimspro
D0N9PQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D04KBU	TTDDRUID	D04KBU
D04KBU	DRUGNAME	AIR-001
D04KBU	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D04KBU	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0TI4C	TTDDRUID	D0TI4C
D0TI4C	DRUGNAME	AK002
D0TI4C	INDICATI	Urticaria [ICD-11: EB00-EB05] Phase 2

D0QH5K	TTDDRUID	D0QH5K
D0QH5K	DRUGNAME	AK-106-001616
D0QH5K	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D07KEH	TTDDRUID	D07KEH
D07KEH	DRUGNAME	AKB-6548
D07KEH	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D08VIS	TTDDRUID	D08VIS
D08VIS	DRUGNAME	AKB-9778
D08VIS	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
D08VIS	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D0H3ST	TTDDRUID	D0H3ST
D0H3ST	DRUGNAME	AKCEA-ANGPTL3-LRX
D0H3ST	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0PV0I	TTDDRUID	D0PV0I
D0PV0I	DRUGNAME	AKCEA-APO(a)-LRX
D0PV0I	INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Phase 2

D0V4IJ	TTDDRUID	D0V4IJ
D0V4IJ	DRUGNAME	AKCEA-APOCIII-LRX
D0V4IJ	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2

D08PYC	TTDDRUID	D08PYC
D08PYC	DRUGNAME	AL-38583
D08PYC	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2

D0O8KI	TTDDRUID	D0O8KI
D0O8KI	DRUGNAME	AL-43546
D0O8KI	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2

D00XNW	TTDDRUID	D00XNW
D00XNW	DRUGNAME	AL-54478
D00XNW	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2

D08XHN	TTDDRUID	D08XHN
D08XHN	DRUGNAME	AL-59412C
D08XHN	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2

D0HN7I	TTDDRUID	D0HN7I
D0HN7I	DRUGNAME	Alacizumab pegol
D0HN7I	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0G6QV	TTDDRUID	D0G6QV
D0G6QV	DRUGNAME	Albaconazole
D0G6QV	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D05UTV	TTDDRUID	D05UTV
D05UTV	DRUGNAME	Albuterpenoids
D05UTV	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 2

D0V6BE	TTDDRUID	D0V6BE
D0V6BE	DRUGNAME	ALC-919
D0V6BE	INDICATI	Verruca vulgaris [ICD-11: 1E80] Phase 2

D00ABE	TTDDRUID	D00ABE
D00ABE	DRUGNAME	ALD-301
D00ABE	INDICATI	Ischemia [ICD-11: 8B10-8B11] Phase 2
D00ABE	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D0D8SN	TTDDRUID	D0D8SN
D0D8SN	DRUGNAME	ALD-401
D0D8SN	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2

D0Z1OT	TTDDRUID	D0Z1OT
D0Z1OT	DRUGNAME	ALD-403
D0Z1OT	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D0N0BW	TTDDRUID	D0N0BW
D0N0BW	DRUGNAME	ALD-518
D0N0BW	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
D0N0BW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0XO7Q	TTDDRUID	D0XO7Q
D0XO7Q	DRUGNAME	Alequel
D0XO7Q	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D0XO7Q	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1/2

D01FBS	TTDDRUID	D01FBS
D01FBS	DRUGNAME	ALF-5755
D01FBS	INDICATI	Liver failure [ICD-11: DB99.7] Phase 2

D0B1VZ	TTDDRUID	D0B1VZ
D0B1VZ	DRUGNAME	ALG-1001
D0B1VZ	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D0EQ6V	TTDDRUID	D0EQ6V
D0EQ6V	DRUGNAME	Alhydrogel
D0EQ6V	INDICATI	Hookworm infection [ICD-11: 1F68] Phase 2

D0P9BT	TTDDRUID	D0P9BT
D0P9BT	DRUGNAME	Alicaforsen
D0P9BT	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D0P9BT	INDICATI	Lleum inflammation [ICD-11: 1A40.0] Phase 3
D0P9BT	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0LH4J	TTDDRUID	D0LH4J
D0LH4J	DRUGNAME	Aliskiren/valsartan
D0LH4J	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2

D0B9RD	TTDDRUID	D0B9RD
D0B9RD	DRUGNAME	ALK-001
D0B9RD	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
D0B9RD	INDICATI	Stargardt disease [ICD-11: 9B70] Phase 2

D0U9IZ	TTDDRUID	D0U9IZ
D0U9IZ	DRUGNAME	Alkaline Phosphatase
D0U9IZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0T0ZW	TTDDRUID	D0T0ZW
D0T0ZW	DRUGNAME	ALKS33
D0T0ZW	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2

D0N4DF	TTDDRUID	D0N4DF
D0N4DF	DRUGNAME	ALKS-37
D0N4DF	INDICATI	Constipation [ICD-11: DD91.1] Phase 2

D0YC9M	TTDDRUID	D0YC9M
D0YC9M	DRUGNAME	AllerT
D0YC9M	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0CO5F	TTDDRUID	D0CO5F
D0CO5F	DRUGNAME	ALLOD-2
D0CO5F	INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 2
D0CO5F	INDICATI	Migraine [ICD-11: 8A80] Phase 2
D0CO5F	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D0Z5FC	TTDDRUID	D0Z5FC
D0Z5FC	DRUGNAME	Allogeneic cytotoxic T-cell therapy
D0Z5FC	INDICATI	Epstein barr virus infection [ICD-11: 1C80] Phase 2

D0Q6TW	TTDDRUID	D0Q6TW
D0Q6TW	DRUGNAME	ALN-RSV01
D0Q6TW	INDICATI	Respiratory infection [ICD-11: CA07-CA4Z] Phase 2

D0U2KX	TTDDRUID	D0U2KX
D0U2KX	DRUGNAME	Aloradine
D0U2KX	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2

D05NDN	TTDDRUID	D05NDN
D05NDN	DRUGNAME	Alovudine
D05NDN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04TEF	TTDDRUID	D04TEF
D04TEF	DRUGNAME	Alpha-1 antitrypsin
D04TEF	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1/2
D04TEF	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2

D0Z0WQ	TTDDRUID	D0Z0WQ
D0Z0WQ	DRUGNAME	Alpha1-proteinase inhibitor
D0Z0WQ	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D08KVW	TTDDRUID	D08KVW
D08KVW	DRUGNAME	Alpha1-proteinase inhibitor (human) modified process
D08KVW	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D0VT2B	TTDDRUID	D0VT2B
D0VT2B	DRUGNAME	ALS-8176
D0VT2B	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D0V5JH	TTDDRUID	D0V5JH
D0V5JH	DRUGNAME	ALT-801
D0V5JH	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0V5JH	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
D0V5JH	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0V5JH	INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 1/2

D04DKL	TTDDRUID	D04DKL
D04DKL	DRUGNAME	ALT-836
D04DKL	INDICATI	Adult respiratory distress syndrome [ICD-11: CB00] Phase 2

D03PXT	TTDDRUID	D03PXT
D03PXT	DRUGNAME	Altastaph
D03PXT	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2

D0O5KH	TTDDRUID	D0O5KH
D0O5KH	DRUGNAME	Altrakincept
D0O5KH	INDICATI	Asthma [ICD-11: CA23] Phase 2

D00WBN	TTDDRUID	D00WBN
D00WBN	DRUGNAME	ALV-003
D00WBN	INDICATI	Coeliac disease [ICD-11: DA95] Phase 2

D02KYR	TTDDRUID	D02KYR
D02KYR	DRUGNAME	ALVAC HIV vaccine program
D02KYR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D02KYR	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D05NIR	TTDDRUID	D05NIR
D05NIR	DRUGNAME	ALX-0061
D05NIR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
D05NIR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D05NIR	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D0CT5O	TTDDRUID	D0CT5O
D0CT5O	DRUGNAME	ALX-101
D0CT5O	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0Y2NU	TTDDRUID	D0Y2NU
D0Y2NU	DRUGNAME	ALX-40-4C
D0Y2NU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D07HOT	TTDDRUID	D07HOT
D07HOT	DRUGNAME	ALXN1007
D07HOT	INDICATI	Phospholipid syndrome [ICD-11: 4A45] Phase 2

D0OY9L	TTDDRUID	D0OY9L
D0OY9L	DRUGNAME	ALXN6000
D0OY9L	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0OY9L	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0OY9L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07VAI	TTDDRUID	D07VAI
D07VAI	DRUGNAME	ALZ-801
D07VAI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D07VAI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D08DFF	TTDDRUID	D08DFF
D08DFF	DRUGNAME	AM-001
D08DFF	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
D08DFF	INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 2

D08MPA	TTDDRUID	D08MPA
D08MPA	DRUGNAME	AMA-76
D08MPA	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D06ZWL	TTDDRUID	D06ZWL
D06ZWL	DRUGNAME	Amdoxovir
D06ZWL	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0KA9L	TTDDRUID	D0KA9L
D0KA9L	DRUGNAME	AME-133v
D0KA9L	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0QG2D	TTDDRUID	D0QG2D
D0QG2D	DRUGNAME	Amelubant
D0QG2D	INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2

D0T3AP	TTDDRUID	D0T3AP
D0T3AP	DRUGNAME	Amfetamine transdermal
D0T3AP	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D07JHK	TTDDRUID	D07JHK
D07JHK	DRUGNAME	AMG 151
D07JHK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D04FWP	TTDDRUID	D04FWP
D04FWP	DRUGNAME	AMG 157
D04FWP	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0OK2N	TTDDRUID	D0OK2N
D0OK2N	DRUGNAME	AMG 208
D0OK2N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0CO2W	TTDDRUID	D0CO2W
D0CO2W	DRUGNAME	AMG 301
D0CO2W	INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Investigative
D0CO2W	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D04YLQ	TTDDRUID	D04YLQ
D04YLQ	DRUGNAME	AMG 334
D04YLQ	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D0G0BL	TTDDRUID	D0G0BL
D0G0BL	DRUGNAME	AMG 337
D0G0BL	INDICATI	Clear cell sarcoma [ICD-11: 2A60-2C35] Phase 2
D0G0BL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00AKR	TTDDRUID	D00AKR
D00AKR	DRUGNAME	AMG 479
D00AKR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0V0UH	TTDDRUID	D0V0UH
D0V0UH	DRUGNAME	AMG 557
D0V0UH	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
D0V0UH	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D00UFZ	TTDDRUID	D00UFZ
D00UFZ	DRUGNAME	AMG 745
D00UFZ	INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 2

D04NIZ	TTDDRUID	D04NIZ
D04NIZ	DRUGNAME	AMG 747
D04NIZ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0YB2Y	TTDDRUID	D0YB2Y
D0YB2Y	DRUGNAME	AMG 853
D0YB2Y	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0KR8L	TTDDRUID	D0KR8L
D0KR8L	DRUGNAME	AMG 899
D0KR8L	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D07LCA	TTDDRUID	D07LCA
D07LCA	DRUGNAME	AMG0714
D07LCA	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D04WQJ	TTDDRUID	D04WQJ
D04WQJ	DRUGNAME	AMG-181
D04WQJ	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D04WQJ	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0A5EN	TTDDRUID	D0A5EN
D0A5EN	DRUGNAME	AMG-714
D0A5EN	INDICATI	Coeliac disease [ICD-11: DA95] Phase 2
D0A5EN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0BS5E	TTDDRUID	D0BS5E
D0BS5E	DRUGNAME	AMO-02
D0BS5E	INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Phase 2

D0QH7H	TTDDRUID	D0QH7H
D0QH7H	DRUGNAME	AMP-579
D0QH7H	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D08GVB	TTDDRUID	D08GVB
D08GVB	DRUGNAME	AMR-001
D08GVB	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0I9HG	TTDDRUID	D0I9HG
D0I9HG	DRUGNAME	Amsilarotene
D0I9HG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03QSS	TTDDRUID	D03QSS
D03QSS	DRUGNAME	AMX0035
D03QSS	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D03VPJ	TTDDRUID	D03VPJ
D03VPJ	DRUGNAME	AN0128
D03VPJ	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D03VPJ	INDICATI	Psoriatic disorder [ICD-11: EA90] Phase 2

D04BXX	TTDDRUID	D04BXX
D04BXX	DRUGNAME	AN-019
D04BXX	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2

D0X4ZL	TTDDRUID	D0X4ZL
D0X4ZL	DRUGNAME	AN-1792
D0X4ZL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D00JED	TTDDRUID	D00JED
D00JED	DRUGNAME	AN-2898
D00JED	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0V8BQ	TTDDRUID	D0V8BQ
D0V8BQ	DRUGNAME	Anagrelide controlled-release
D0V8BQ	INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2

D0B8IZ	TTDDRUID	D0B8IZ
D0B8IZ	DRUGNAME	Analog insulin-PH20
D0B8IZ	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2

D09BPN	TTDDRUID	D09BPN
D09BPN	DRUGNAME	Anatibant
D09BPN	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2

D09AOO	TTDDRUID	D09AOO
D09AOO	DRUGNAME	ANAVEX 2-73
D09AOO	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D09AOO	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
D09AOO	INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 1
D09AOO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
D09AOO	INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 1

D05TSG	TTDDRUID	D05TSG
D05TSG	DRUGNAME	ANB-020
D05TSG	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0UL2H	TTDDRUID	D0UL2H
D0UL2H	DRUGNAME	Androgen restored contraceptive
D0UL2H	INDICATI	Contraception [ICD-11: QA21] Phase 2

D0M6XK	TTDDRUID	D0M6XK
D0M6XK	DRUGNAME	ANG1005
D0M6XK	INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
D0M6XK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0M6XK	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0M6XK	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0Q4WR	TTDDRUID	D0Q4WR
D0Q4WR	DRUGNAME	Angiotensin therapeutic vaccine
D0Q4WR	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D03ING	TTDDRUID	D03ING
D03ING	DRUGNAME	Anrukinzumab
D03ING	INDICATI	Asthma [ICD-11: CA23] Phase 2
D03ING	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D02BFC	TTDDRUID	D02BFC
D02BFC	DRUGNAME	Anti-alpha5Beta1-integrin antibody
D02BFC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00GHZ	TTDDRUID	D00GHZ
D00GHZ	DRUGNAME	Antiandrogens
D00GHZ	INDICATI	Endocrine disease [ICD-11: 5B3Z] Phase 2

D06NAG	TTDDRUID	D06NAG
D06NAG	DRUGNAME	Anti-CD137
D06NAG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0E8KO	TTDDRUID	D0E8KO
D0E8KO	DRUGNAME	Anti-CD3 activated vaccine-primed lymphocytes
D0E8KO	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0P7KI	TTDDRUID	D0P7KI
D0P7KI	DRUGNAME	Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
D0P7KI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0N4NH	TTDDRUID	D0N4NH
D0N4NH	DRUGNAME	Anti-CD45 mAb 131I-BC8
D0N4NH	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D08RJY	TTDDRUID	D08RJY
D08RJY	DRUGNAME	Anti-EGFRvIII CAR transduced PBL
D08RJY	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1/2
D08RJY	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2
D08RJY	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2

D06EVZ	TTDDRUID	D06EVZ
D06EVZ	DRUGNAME	Anti-GD2 CART
D06EVZ	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2

D0MI0S	TTDDRUID	D0MI0S
D0MI0S	DRUGNAME	Antigen-pulsed dendritic cell vaccine
D0MI0S	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0G9EI	TTDDRUID	D0G9EI
D0G9EI	DRUGNAME	Anti-IL-5 Receptor mab
D0G9EI	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0L7LH	TTDDRUID	D0L7LH
D0L7LH	DRUGNAME	Anti-IP10
D0L7LH	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D0L7LH	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0T7OI	TTDDRUID	D0T7OI
D0T7OI	DRUGNAME	Anti-LAG3
D0T7OI	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D0T7OI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0T7OI	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0A5ZL	TTDDRUID	D0A5ZL
D0A5ZL	DRUGNAME	Anti-LINGO
D0A5ZL	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0L1OC	TTDDRUID	D0L1OC
D0L1OC	DRUGNAME	Anti-LT alpha
D0L1OC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D04CWS	TTDDRUID	D04CWS
D04CWS	DRUGNAME	Anti-M1 prime
D04CWS	INDICATI	Asthma [ICD-11: CA23] Phase 2

D00YXG	TTDDRUID	D00YXG
D00YXG	DRUGNAME	Anti-mesothelin CAR transduced PBL
D00YXG	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
D00YXG	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
D00YXG	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1/2
D00YXG	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D00YXG	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D04QRG	TTDDRUID	D04QRG
D04QRG	DRUGNAME	Antineoplaston A-10
D04QRG	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D08NTW	TTDDRUID	D08NTW
D08NTW	DRUGNAME	Antineoplaston A10 + antineoplaston AS2-2
D08NTW	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2

D01MUW	TTDDRUID	D01MUW
D01MUW	DRUGNAME	Antineoplaston AS2-1
D01MUW	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D00ODH	TTDDRUID	D00ODH
D00ODH	DRUGNAME	Antineoplaston therapy
D00ODH	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2

D0G7ZT	TTDDRUID	D0G7ZT
D0G7ZT	DRUGNAME	Anti-PSCA mab
D0G7ZT	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D01FFG	TTDDRUID	D01FFG
D01FFG	DRUGNAME	Antistasin
D01FFG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D0W2KA	TTDDRUID	D0W2KA
D0W2KA	DRUGNAME	ANTI-TWEAK
D0W2KA	INDICATI	Lupus [ICD-11: 4A40] Phase 2

D0S2CQ	TTDDRUID	D0S2CQ
D0S2CQ	DRUGNAME	Anti-VLA-1 mab
D0S2CQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0T3AW	TTDDRUID	D0T3AW
D0T3AW	DRUGNAME	Antroquinonol
D0T3AW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0T3AW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0ZZ3Q	TTDDRUID	D0ZZ3Q
D0ZZ3Q	DRUGNAME	AOB101
D0ZZ3Q	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D01DTO	TTDDRUID	D01DTO
D01DTO	DRUGNAME	AOB102
D01DTO	INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2

D0CK7F	TTDDRUID	D0CK7F
D0CK7F	DRUGNAME	AOB103
D0CK7F	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D06PDQ	TTDDRUID	D06PDQ
D06PDQ	DRUGNAME	AOP-200704
D06PDQ	INDICATI	Heart arrhythmia [ICD-11: BC65] Phase 2

D0J4YV	TTDDRUID	D0J4YV
D0J4YV	DRUGNAME	AP-214
D0J4YV	INDICATI	Candidiasis [ICD-11: 1F23] Phase 2

D0O9PQ	TTDDRUID	D0O9PQ
D0O9PQ	DRUGNAME	AP26113
D0O9PQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Q5CH	TTDDRUID	D0Q5CH
D0Q5CH	DRUGNAME	AP-301-IH
D0Q5CH	INDICATI	Pneumonia [ICD-11: CA40] Phase 2

D0ZT1L	TTDDRUID	D0ZT1L
D0ZT1L	DRUGNAME	AP33
D0ZT1L	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D01HBG	TTDDRUID	D01HBG
D01HBG	DRUGNAME	Apadoline
D01HBG	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0BA5K	TTDDRUID	D0BA5K
D0BA5K	DRUGNAME	Apaxifylline
D0BA5K	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0XH8X	TTDDRUID	D0XH8X
D0XH8X	DRUGNAME	APC-8015F
D0XH8X	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D03LQC	TTDDRUID	D03LQC
D03LQC	DRUGNAME	APD-209
D03LQC	INDICATI	Cachexia [ICD-11: MG20] Phase 2

D0L9KH	TTDDRUID	D0L9KH
D0L9KH	DRUGNAME	APD-334
D0L9KH	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
D0L9KH	INDICATI	Pyoderma gangrenosum [ICD-11: EB21] Phase 2
D0L9KH	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0I4PW	TTDDRUID	D0I4PW
D0I4PW	DRUGNAME	APD371
D0I4PW	INDICATI	Crohn disease [ICD-11: DD70] Phase 2

D0T1HE	TTDDRUID	D0T1HE
D0T1HE	DRUGNAME	APD-403
D0T1HE	INDICATI	Vomiting [ICD-11: MD90] Phase 2

D0XQ6V	TTDDRUID	D0XQ6V
D0XQ6V	DRUGNAME	APD-515
D0XQ6V	INDICATI	Xerostomia [ICD-11: DA02.1] Phase 2

D01HVS	TTDDRUID	D01HVS
D01HVS	DRUGNAME	APD-811
D01HVS	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2

D0N4JI	TTDDRUID	D0N4JI
D0N4JI	DRUGNAME	APG-101
D0N4JI	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2

D08VAR	TTDDRUID	D08VAR
D08VAR	DRUGNAME	APH-0812
D08VAR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
D08VAR	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0OT1A	TTDDRUID	D0OT1A
D0OT1A	DRUGNAME	API-31510
D0OT1A	INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 1
D0OT1A	INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2
D0OT1A	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D0OT1A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0OT1A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D0OT1A	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D03SUQ	TTDDRUID	D03SUQ
D03SUQ	DRUGNAME	Apilimod dimesylate
D03SUQ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D03ZLR	TTDDRUID	D03ZLR
D03ZLR	DRUGNAME	Apimostinel
D03ZLR	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0M8NI	TTDDRUID	D0M8NI
D0M8NI	DRUGNAME	Aplidinplitidepsin
D0M8NI	INDICATI	Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 2

D0XE0X	TTDDRUID	D0XE0X
D0XE0X	DRUGNAME	Aplindore fumarate
D0XE0X	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0NS7A	TTDDRUID	D0NS7A
D0NS7A	DRUGNAME	APN-301
D0NS7A	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0NS7A	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2

D06KMH	TTDDRUID	D06KMH
D06KMH	DRUGNAME	APN-401
D06KMH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D06KMH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06HQM	TTDDRUID	D06HQM
D06HQM	DRUGNAME	Apo805K1
D06HQM	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0W6WC	TTDDRUID	D0W6WC
D0W6WC	DRUGNAME	Apolizumab
D0W6WC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00HTO	TTDDRUID	D00HTO
D00HTO	DRUGNAME	APOMINE
D00HTO	INDICATI	Osteopetrosis [ICD-11: LD24.10] Phase 2

D0HG5M	TTDDRUID	D0HG5M
D0HG5M	DRUGNAME	Apratastat
D0HG5M	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0FA0A	TTDDRUID	D0FA0A
D0FA0A	DRUGNAME	Apristor
D0FA0A	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0QG1B	TTDDRUID	D0QG1B
D0QG1B	DRUGNAME	Aprocitentan
D0QG1B	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0L1VI	TTDDRUID	D0L1VI
D0L1VI	DRUGNAME	AQ-13
D0L1VI	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D0H1AY	TTDDRUID	D0H1AY
D0H1AY	DRUGNAME	AQW-051
D0H1AY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D02HDG	TTDDRUID	D02HDG
D02HDG	DRUGNAME	AQX-1125
D02HDG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0MY3C	TTDDRUID	D0MY3C
D0MY3C	DRUGNAME	AR08
D0MY3C	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D07EJY	TTDDRUID	D07EJY
D07EJY	DRUGNAME	AR-12286
D07EJY	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D0VT9O	TTDDRUID	D0VT9O
D0VT9O	DRUGNAME	AR28
D0VT9O	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Phase 2

D0A5FD	TTDDRUID	D0A5FD
D0A5FD	DRUGNAME	AR30
D0A5FD	INDICATI	Mental disease [ICD-11: 6E8Z] Phase 2

D0S1ME	TTDDRUID	D0S1ME
D0S1ME	DRUGNAME	AR-301
D0S1ME	INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2
D0S1ME	INDICATI	Pneumonia [ICD-11: CA40] Phase 1/2
D0S1ME	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2

D0M6BA	TTDDRUID	D0M6BA
D0M6BA	DRUGNAME	AR-67
D0M6BA	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0M6BA	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0KL3U	TTDDRUID	D0KL3U
D0KL3U	DRUGNAME	AR9281
D0KL3U	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0T1QV	TTDDRUID	D0T1QV
D0T1QV	DRUGNAME	ARA 290
D0T1QV	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
D0T1QV	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
D0T1QV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
D0T1QV	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2

D07GCK	TTDDRUID	D07GCK
D07GCK	DRUGNAME	ARC-100
D07GCK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D07GCK	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D07GCK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D08COR	TTDDRUID	D08COR
D08COR	DRUGNAME	ARC-520
D08COR	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D01MVO	TTDDRUID	D01MVO
D01MVO	DRUGNAME	ARG201
D01MVO	INDICATI	Diffuse systemic sclerosis [ICD-11: 4A42.1] Phase 2
D01MVO	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2

D0D0BB	TTDDRUID	D0D0BB
D0D0BB	DRUGNAME	ARI-3037M0
D0D0BB	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2

D01VMZ	TTDDRUID	D01VMZ
D01VMZ	DRUGNAME	ARI-3037MO
D01VMZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
D01VMZ	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
D01VMZ	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2

D00JFE	TTDDRUID	D00JFE
D00JFE	DRUGNAME	ARN-810
D00JFE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0A3NN	TTDDRUID	D0A3NN
D0A3NN	DRUGNAME	Aroplatin
D0A3NN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0DR0P	TTDDRUID	D0DR0P
D0DR0P	DRUGNAME	ARQ 761
D0DR0P	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D0DR0P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07PQJ	TTDDRUID	D07PQJ
D07PQJ	DRUGNAME	ARQ-087
D07PQJ	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
D07PQJ	INDICATI	Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3
D07PQJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05JAA	TTDDRUID	D05JAA
D05JAA	DRUGNAME	ARRY-382
D05JAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D05JAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05STL	TTDDRUID	D05STL
D05STL	DRUGNAME	ARRY-502
D05STL	INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 2

D04VWJ	TTDDRUID	D04VWJ
D04VWJ	DRUGNAME	ARRY-520
D04VWJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D04VWJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02LBK	TTDDRUID	D02LBK
D02LBK	DRUGNAME	ARRY-797
D02LBK	INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 2
D02LBK	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
D02LBK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0N1CH	TTDDRUID	D0N1CH
D0N1CH	DRUGNAME	Arverapamil
D0N1CH	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D08EAI	TTDDRUID	D08EAI
D08EAI	DRUGNAME	AS-101
D08EAI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D04VOE	TTDDRUID	D04VOE
D04VOE	DRUGNAME	AS-1402
D04VOE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04GKP	TTDDRUID	D04GKP
D04GKP	DRUGNAME	AS-902330
D04GKP	INDICATI	Arthropathy [ICD-11: FA11-FA38] Phase 2

D0B1OH	TTDDRUID	D0B1OH
D0B1OH	DRUGNAME	ASB17061
D0B1OH	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D04KYB	TTDDRUID	D04KYB
D04KYB	DRUGNAME	ASCJ-9 topical
D04KYB	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
D04KYB	INDICATI	Alopecia [ICD-11: ED70] Phase 2

D0SL8J	TTDDRUID	D0SL8J
D0SL8J	DRUGNAME	Ascrolimus
D0SL8J	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0G3TJ	TTDDRUID	D0G3TJ
D0G3TJ	DRUGNAME	ASKP-1240
D0G3TJ	INDICATI	Transplant rejection [ICD-11: NE84] Phase 2

D08NYZ	TTDDRUID	D08NYZ
D08NYZ	DRUGNAME	ASM-024
D08NYZ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0L3IL	TTDDRUID	D0L3IL
D0L3IL	DRUGNAME	ASM8
D0L3IL	INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 2

D0TG4S	TTDDRUID	D0TG4S
D0TG4S	DRUGNAME	ASN002
D0TG4S	INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2
D0TG4S	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0TG4S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0Z2NJ	TTDDRUID	D0Z2NJ
D0Z2NJ	DRUGNAME	ASN100
D0Z2NJ	INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2
D0Z2NJ	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2

D0IC5I	TTDDRUID	D0IC5I
D0IC5I	DRUGNAME	ASP-0819
D0IC5I	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2

D02ROU	TTDDRUID	D02ROU
D02ROU	DRUGNAME	ASP-1707
D02ROU	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D0B2SW	TTDDRUID	D0B2SW
D0B2SW	DRUGNAME	ASP-3291
D0B2SW	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D00NNI	TTDDRUID	D00NNI
D00NNI	DRUGNAME	ASP-3652
D00NNI	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2

D0BT7R	TTDDRUID	D0BT7R
D0BT7R	DRUGNAME	ASP-4901
D0BT7R	INDICATI	Genitourinary disease [ICD-11: GA0Z-GC8Z] Phase 2

D01OXH	TTDDRUID	D01OXH
D01OXH	DRUGNAME	ASP-7035
D01OXH	INDICATI	Nocturia [ICD-11: MF55] Phase 2

D03CDK	TTDDRUID	D03CDK
D03CDK	DRUGNAME	ASP-7147
D03CDK	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D0E1RT	TTDDRUID	D0E1RT
D0E1RT	DRUGNAME	ASP7373
D0E1RT	INDICATI	H5N1 influenza infection [ICD-11: 1E30] Phase 2

D07YRW	TTDDRUID	D07YRW
D07YRW	DRUGNAME	ASP7991
D07YRW	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Phase 2

D0JM7Z	TTDDRUID	D0JM7Z
D0JM7Z	DRUGNAME	ASP8062
D0JM7Z	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2

D01VLT	TTDDRUID	D01VLT
D01VLT	DRUGNAME	ASP8232
D01VLT	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
D01VLT	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1

D02BYZ	TTDDRUID	D02BYZ
D02BYZ	DRUGNAME	ASP8273
D02BYZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0K4CD	TTDDRUID	D0K4CD
D0K4CD	DRUGNAME	ASP-8477
D0K4CD	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D0U9FC	TTDDRUID	D0U9FC
D0U9FC	DRUGNAME	ASP-9831
D0U9FC	INDICATI	Steatohepatitis [ICD-11: DB92] Phase 2

D07KAB	TTDDRUID	D07KAB
D07KAB	DRUGNAME	AST-VAC1
D07KAB	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D01NUR	TTDDRUID	D01NUR
D01NUR	DRUGNAME	ASTX660
D01NUR	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D01NUR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
D01NUR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0S6KI	TTDDRUID	D0S6KI
D0S6KI	DRUGNAME	AT-101
D0S6KI	INDICATI	Hemorrhagic shock [ICD-11: MG40.1] Phase 2

D03MXK	TTDDRUID	D03MXK
D03MXK	DRUGNAME	AT-406
D03MXK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D03MXK	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D03MXK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07DTV	TTDDRUID	D07DTV
D07DTV	DRUGNAME	AT7519
D07DTV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0T6IL	TTDDRUID	D0T6IL
D0T6IL	DRUGNAME	Atacicept EMD Serono
D0T6IL	INDICATI	Lupus [ICD-11: 4A40] Phase 2

D0C2ZL	TTDDRUID	D0C2ZL
D0C2ZL	DRUGNAME	Ataciguat
D0C2ZL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D03TYJ	TTDDRUID	D03TYJ
D03TYJ	DRUGNAME	ATHX-105
D03TYJ	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0N1TH	TTDDRUID	D0N1TH
D0N1TH	DRUGNAME	ATI-2042
D0N1TH	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D0CG0K	TTDDRUID	D0CG0K
D0CG0K	DRUGNAME	ATI-502 topical
D0CG0K	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D0CG0K	INDICATI	Vitiligo [ICD-11: ED63.0] Phase 2

D06URI	TTDDRUID	D06URI
D06URI	DRUGNAME	ATL101
D06URI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D04XBU	TTDDRUID	D04XBU
D04XBU	DRUGNAME	ATL-104
D04XBU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0E6SQ	TTDDRUID	D0E6SQ
D0E6SQ	DRUGNAME	ATL1102
D0E6SQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0A6DY	TTDDRUID	D0A6DY
D0A6DY	DRUGNAME	ATM AVI
D0A6DY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D00QVT	TTDDRUID	D00QVT
D00QVT	DRUGNAME	ATN-161
D00QVT	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0T8MA	TTDDRUID	D0T8MA
D0T8MA	DRUGNAME	ATN-224
D0T8MA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06FYE	TTDDRUID	D06FYE
D06FYE	DRUGNAME	Atorvastatin + aspirin + ramipril
D06FYE	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D02LMZ	TTDDRUID	D02LMZ
D02LMZ	DRUGNAME	ATPase
D02LMZ	INDICATI	Bradycardia [ICD-11: MC81.1] Discontinued in Phase 2
D02LMZ	INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 2

D01UFK	TTDDRUID	D01UFK
D01UFK	DRUGNAME	ATX-MS-1467
D01UFK	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D01HXA	TTDDRUID	D01HXA
D01HXA	DRUGNAME	AUS-131
D01HXA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
D01HXA	INDICATI	Hot flushes [ICD-11: GA30] Phase 2

D00ZHM	TTDDRUID	D00ZHM
D00ZHM	DRUGNAME	Autologous adipose-derived stem cells
D00ZHM	INDICATI	Anal fistula [ICD-11: DB50.1] Phase 2

D0I3VS	TTDDRUID	D0I3VS
D0I3VS	DRUGNAME	Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes
D0I3VS	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0XW6B	TTDDRUID	D0XW6B
D0XW6B	DRUGNAME	Autologous dendritic cell vaccine
D0XW6B	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D08RBV	TTDDRUID	D08RBV
D08RBV	DRUGNAME	Autologous dendritic cell vaccine, St Anna Children's Hospital
D08RBV	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D0B2XS	TTDDRUID	D0B2XS
D0B2XS	DRUGNAME	Autologous myoblast cell therapy
D0B2XS	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D08FKD	TTDDRUID	D08FKD
D08FKD	DRUGNAME	Autologous renal cell carcinoma vaccine
D08FKD	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D07TYM	TTDDRUID	D07TYM
D07TYM	DRUGNAME	Autologous T-lymphocyte cell therapy
D07TYM	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D0U0AY	TTDDRUID	D0U0AY
D0U0AY	DRUGNAME	AV-101
D0U0AY	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
D0U0AY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D02ITL	TTDDRUID	D02ITL
D02ITL	DRUGNAME	AV-201
D02ITL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0E2RA	TTDDRUID	D0E2RA
D0E2RA	DRUGNAME	AV-7909
D0E2RA	INDICATI	Anthrax [ICD-11: 1B97] Phase 2

D0X3QR	TTDDRUID	D0X3QR
D0X3QR	DRUGNAME	AVA-101
D0X3QR	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2

D0A9HT	TTDDRUID	D0A9HT
D0A9HT	DRUGNAME	Avastin
D0A9HT	INDICATI	Brain metastases [ICD-11: 2D50] Phase 2

D01ICY	TTDDRUID	D01ICY
D01ICY	DRUGNAME	AVE-0657
D01ICY	INDICATI	Cheyne-stokes respiration [ICD-11: MD11.Y] Phase 2

D0B6QZ	TTDDRUID	D0B6QZ
D0B6QZ	DRUGNAME	AVE-2268
D0B6QZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0J6FE	TTDDRUID	D0J6FE
D0J6FE	DRUGNAME	AVI-4557
D0J6FE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D01VDI	TTDDRUID	D01VDI
D01VDI	DRUGNAME	AVI-5126
D01VDI	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0R9PS	TTDDRUID	D0R9PS
D0R9PS	DRUGNAME	Aviscumine
D0R9PS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01NDF	TTDDRUID	D01NDF
D01NDF	DRUGNAME	AVN 101
D01NDF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D01NDF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D01NDF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
D01NDF	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D02KEL	TTDDRUID	D02KEL
D02KEL	DRUGNAME	AVO113
D02KEL	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 2

D07XBI	TTDDRUID	D07XBI
D07XBI	DRUGNAME	AVR118
D07XBI	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0F4TV	TTDDRUID	D0F4TV
D0F4TV	DRUGNAME	AWD-12-281
D0F4TV	INDICATI	Rhinitis [ICD-11: FA20] Phase 2

D03GRD	TTDDRUID	D03GRD
D03GRD	DRUGNAME	AX-200
D03GRD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0OT1Q	TTDDRUID	D0OT1Q
D0OT1Q	DRUGNAME	Axalimogene filolisbac
D0OT1Q	INDICATI	Anal cancer [ICD-11: 2C00] Phase 2
D0OT1Q	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3
D0OT1Q	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D0VV5Z	TTDDRUID	D0VV5Z
D0VV5Z	DRUGNAME	Axalimogene filolisbac
D0VV5Z	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3
D0VV5Z	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D01SJS	TTDDRUID	D01SJS
D01SJS	DRUGNAME	AXL-1717
D01SJS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01BDY	TTDDRUID	D01BDY
D01BDY	DRUGNAME	Axomadol
D01BDY	INDICATI	Back pain [ICD-11: ME84.Z] Phase 2

D01OIR	TTDDRUID	D01OIR
D01OIR	DRUGNAME	AYX-1
D01OIR	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D04HJE	TTDDRUID	D04HJE
D04HJE	DRUGNAME	AZ-01, PEGylated interferon-beta
D04HJE	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D09PYV	TTDDRUID	D09PYV
D09PYV	DRUGNAME	AZ-40140
D09PYV	INDICATI	Obesity [ICD-11: 5B81] Phase 2
D09PYV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0M0XB	TTDDRUID	D0M0XB
D0M0XB	DRUGNAME	AZD0530
D0M0XB	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
D0M0XB	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2
D0M0XB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0S0EQ	TTDDRUID	D0S0EQ
D0S0EQ	DRUGNAME	AZD-0865
D0S0EQ	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2

D00HBE	TTDDRUID	D00HBE
D00HBE	DRUGNAME	AZD0914
D00HBE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D01MAU	TTDDRUID	D01MAU
D01MAU	DRUGNAME	AZD-1446
D01MAU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0MP0X	TTDDRUID	D0MP0X
D0MP0X	DRUGNAME	AZD1480
D0MP0X	INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Phase 2

D0O8BS	TTDDRUID	D0O8BS
D0O8BS	DRUGNAME	AZD1656
D0O8BS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D04TQO	TTDDRUID	D04TQO
D04TQO	DRUGNAME	AZD1722
D04TQO	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2

D04AIB	TTDDRUID	D04AIB
D04AIB	DRUGNAME	AZD1772//RDX5791
D04AIB	INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 2

D0T4SG	TTDDRUID	D0T4SG
D0T4SG	DRUGNAME	AZD1981
D0T4SG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0Z2UQ	TTDDRUID	D0Z2UQ
D0Z2UQ	DRUGNAME	AZD2014
D0Z2UQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0L9CD	TTDDRUID	D0L9CD
D0L9CD	DRUGNAME	AZD-2115
D0L9CD	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D04DQZ	TTDDRUID	D04DQZ
D04DQZ	DRUGNAME	AZD-2327
D04DQZ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0E5NY	TTDDRUID	D0E5NY
D0E5NY	DRUGNAME	AZD-2423
D0E5NY	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0Z0GH	TTDDRUID	D0Z0GH
D0Z0GH	DRUGNAME	AZD-2563
D0Z0GH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D02IWC	TTDDRUID	D02IWC
D02IWC	DRUGNAME	AZD2624
D02IWC	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D04TGF	TTDDRUID	D04TGF
D04TGF	DRUGNAME	AZD-2927
D04TGF	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D0L6LD	TTDDRUID	D0L6LD
D0L6LD	DRUGNAME	AZD-3199
D0L6LD	INDICATI	Asthma [ICD-11: CA23] Phase 2

D08TRG	TTDDRUID	D08TRG
D08TRG	DRUGNAME	AZD-3241
D08TRG	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0R8IU	TTDDRUID	D0R8IU
D0R8IU	DRUGNAME	AZD-4017
D0R8IU	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2

D08VDM	TTDDRUID	D08VDM
D08VDM	DRUGNAME	AZD4694
D08VDM	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D02AAO	TTDDRUID	D02AAO
D02AAO	DRUGNAME	AZD-4877
D02AAO	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0RG6P	TTDDRUID	D0RG6P
D0RG6P	DRUGNAME	AZD4901
D0RG6P	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0I6ZO	TTDDRUID	D0I6ZO
D0I6ZO	DRUGNAME	AZD-5213
D0I6ZO	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0C9EN	TTDDRUID	D0C9EN
D0C9EN	DRUGNAME	AZD5312
D0C9EN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
D0C9EN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D01ZAQ	TTDDRUID	D01ZAQ
D01ZAQ	DRUGNAME	AZD5363
D01ZAQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D01ZAQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02AIN	TTDDRUID	D02AIN
D02AIN	DRUGNAME	AZD5718
D02AIN	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0Z6KK	TTDDRUID	D0Z6KK
D0Z6KK	DRUGNAME	AZD-5847
D0Z6KK	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2

D03OGQ	TTDDRUID	D03OGQ
D03OGQ	DRUGNAME	AZD-7009
D03OGQ	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D0R0EF	TTDDRUID	D0R0EF
D0R0EF	DRUGNAME	AZD-7268
D0R0EF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0HO2T	TTDDRUID	D0HO2T
D0HO2T	DRUGNAME	AZD7325
D0HO2T	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0X9YP	TTDDRUID	D0X9YP
D0X9YP	DRUGNAME	AZD7594
D0X9YP	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D04SPJ	TTDDRUID	D04SPJ
D04SPJ	DRUGNAME	AZD7624
D04SPJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0B3YK	TTDDRUID	D0B3YK
D0B3YK	DRUGNAME	AZD8601
D0B3YK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D08WSG	TTDDRUID	D08WSG
D08WSG	DRUGNAME	AZD-8683
D08WSG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D04XCO	TTDDRUID	D04XCO
D04XCO	DRUGNAME	AZD-8848
D04XCO	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0BM7M	TTDDRUID	D0BM7M
D0BM7M	DRUGNAME	AZD8931
D0BM7M	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0CS2C	TTDDRUID	D0CS2C
D0CS2C	DRUGNAME	AZD9056
D0CS2C	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D05GNW	TTDDRUID	D05GNW
D05GNW	DRUGNAME	AZD-9164
D05GNW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D09IGR	TTDDRUID	D09IGR
D09IGR	DRUGNAME	AZX-100
D09IGR	INDICATI	Asthma [ICD-11: CA23] Phase 2

D03NIW	TTDDRUID	D03NIW
D03NIW	DRUGNAME	B244
D03NIW	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0G6CF	TTDDRUID	D0G6CF
D0G6CF	DRUGNAME	B-701
D0G6CF	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0G6CF	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1

D0G0VV	TTDDRUID	D0G0VV
D0G0VV	DRUGNAME	Bafetinib
D0G0VV	INDICATI	Bone disease [ICD-11: FC0Z] Phase 2

D0GG9P	TTDDRUID	D0GG9P
D0GG9P	DRUGNAME	Balixafortide
D0GG9P	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0WK1M	TTDDRUID	D0WK1M
D0WK1M	DRUGNAME	Baltaleucel-T
D0WK1M	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D0WK1M	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
D0WK1M	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D0WK1M	INDICATI	Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 2

D08XVR	TTDDRUID	D08XVR
D08XVR	DRUGNAME	Baminercept
D08XVR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D06XVR	TTDDRUID	D06XVR
D06XVR	DRUGNAME	BAN2401
D06XVR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D04TQT	TTDDRUID	D04TQT
D04TQT	DRUGNAME	Barusiban
D04TQT	INDICATI	Androgen deficiency [ICD-11: 5A81.1] Phase 2

D0CH7C	TTDDRUID	D0CH7C
D0CH7C	DRUGNAME	Basmisanil
D0CH7C	INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 2
D0CH7C	INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 2

D0B9JC	TTDDRUID	D0B9JC
D0B9JC	DRUGNAME	Bavencio avelumab
D0B9JC	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0B9JC	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0B9JC	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
D0B9JC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M8OC	TTDDRUID	D0M8OC
D0M8OC	DRUGNAME	Bavisant
D0M8OC	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D00UAE	TTDDRUID	D00UAE
D00UAE	DRUGNAME	Bavituximab
D00UAE	INDICATI	Asthma [ICD-11: CA23] Phase 2
D00UAE	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D00UAE	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D00UAE	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0NV9O	TTDDRUID	D0NV9O
D0NV9O	DRUGNAME	BAY 10-00394
D0NV9O	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2

D0M7BL	TTDDRUID	D0M7BL
D0M7BL	DRUGNAME	BAY 1067197
D0M7BL	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0M0YB	TTDDRUID	D0M0YB
D0M0YB	DRUGNAME	BAY 11-42524
D0M0YB	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
D0M0YB	INDICATI	Left ventricular dysfunction [ICD-11: BD11] Phase 2

D05ZXZ	TTDDRUID	D05ZXZ
D05ZXZ	DRUGNAME	BAY 57-1293
D05ZXZ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 2

D0A0SI	TTDDRUID	D0A0SI
D0A0SI	DRUGNAME	BAY 85-8501
D0A0SI	INDICATI	Bronchiectasis [ICD-11: CA24] Phase 2

D0L3HU	TTDDRUID	D0L3HU
D0L3HU	DRUGNAME	BAY 86-5044
D0L3HU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0E7VY	TTDDRUID	D0E7VY
D0E7VY	DRUGNAME	BAY 98-7196
D0E7VY	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D02VTB	TTDDRUID	D02VTB
D02VTB	DRUGNAME	BAY1193397
D02VTB	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D0J4WA	TTDDRUID	D0J4WA
D0J4WA	DRUGNAME	BAY1213790
D0J4WA	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D01VRQ	TTDDRUID	D01VRQ
D01VRQ	DRUGNAME	BAY-1902607a
D01VRQ	INDICATI	Cough [ICD-11: MD12] Phase 2

D0E7XM	TTDDRUID	D0E7XM
D0E7XM	DRUGNAME	BAY-2253651a
D0E7XM	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Phase 2

D06HBJ	TTDDRUID	D06HBJ
D06HBJ	DRUGNAME	BAY2306001
D06HBJ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D07NOI	TTDDRUID	D07NOI
D07NOI	DRUGNAME	BAY-57-9352
D07NOI	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D07NOI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01SPD	TTDDRUID	D01SPD
D01SPD	DRUGNAME	BAY-85-3934
D01SPD	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D0W3MH	TTDDRUID	D0W3MH
D0W3MH	DRUGNAME	BAY-94-9392
D0W3MH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0GY0O	TTDDRUID	D0GY0O
D0GY0O	DRUGNAME	BAY-X-7195
D0GY0O	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0K4QT	TTDDRUID	D0K4QT
D0K4QT	DRUGNAME	BAY-Y-5959
D0K4QT	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0ZK3X	TTDDRUID	D0ZK3X
D0ZK3X	DRUGNAME	BBI-2000
D0ZK3X	INDICATI	Allergic contact dermatitis [ICD-11: EK00] Phase 2

D0L9XF	TTDDRUID	D0L9XF
D0L9XF	DRUGNAME	BBI503
D0L9XF	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
D0L9XF	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D0L9XF	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D0L9XF	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0L9XF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00WZK	TTDDRUID	D00WZK
D00WZK	DRUGNAME	BC-3781 intravenous
D00WZK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0R6EC	TTDDRUID	D0R6EC
D0R6EC	DRUGNAME	BC-7013
D0R6EC	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 1
D0R6EC	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2

D0K0KQ	TTDDRUID	D0K0KQ
D0K0KQ	DRUGNAME	BC-819
D0K0KQ	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0K0KQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0P8NV	TTDDRUID	D0P8NV
D0P8NV	DRUGNAME	BCI-952
D0P8NV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0M6PA	TTDDRUID	D0M6PA
D0M6PA	DRUGNAME	BCT-197
D0M6PA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D03KVY	TTDDRUID	D03KVY
D03KVY	DRUGNAME	BCT303
D03KVY	INDICATI	Hypothyroidism [ICD-11: 5A00] Phase 2

D02ZKR	TTDDRUID	D02ZKR
D02ZKR	DRUGNAME	BCX-3408
D02ZKR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
D02ZKR	INDICATI	Gout [ICD-11: FA25] Phase 2
D02ZKR	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D0HK3N	TTDDRUID	D0HK3N
D0HK3N	DRUGNAME	Belnacasan
D0HK3N	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2

D0W1OA	TTDDRUID	D0W1OA
D0W1OA	DRUGNAME	BEMA buprenorphine transmucosal
D0W1OA	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D08HKT	TTDDRUID	D08HKT
D08HKT	DRUGNAME	BEMORADAN
D08HKT	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D07TDV	TTDDRUID	D07TDV
D07TDV	DRUGNAME	Bendavia
D07TDV	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2

D0N5NI	TTDDRUID	D0N5NI
D0N5NI	DRUGNAME	Benlysta + Rituxan
D0N5NI	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2

D0V9LY	TTDDRUID	D0V9LY
D0V9LY	DRUGNAME	Bertilimumab
D0V9LY	INDICATI	Bullous pemphigoid [ICD-11: EB41.0] Phase 2
D0V9LY	INDICATI	Ocular allergy [ICD-11: 4A81] Phase 2
D0V9LY	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
D0V9LY	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D03AZR	TTDDRUID	D03AZR
D03AZR	DRUGNAME	Berubicin
D03AZR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0W0VD	TTDDRUID	D0W0VD
D0W0VD	DRUGNAME	Beta-Lapachone
D0W0VD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0L5IL	TTDDRUID	D0L5IL
D0L5IL	DRUGNAME	Betamarc
D0L5IL	INDICATI	Cachexia [ICD-11: MG20] Phase 2

D04MPB	TTDDRUID	D04MPB
D04MPB	DRUGNAME	Bevirimat
D04MPB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0VG0D	TTDDRUID	D0VG0D
D0VG0D	DRUGNAME	BEZ235
D0VG0D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04OTY	TTDDRUID	D04OTY
D04OTY	DRUGNAME	BFH-772
D04OTY	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0E8PG	TTDDRUID	D0E8PG
D0E8PG	DRUGNAME	BGB-3112
D0E8PG	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2

D0Y4ZE	TTDDRUID	D0Y4ZE
D0Y4ZE	DRUGNAME	BGC-20-0582
D0Y4ZE	INDICATI	Pediculus capitis infestation [ICD-11: 1G00.0] Phase 2

D0HJ5H	TTDDRUID	D0HJ5H
D0HJ5H	DRUGNAME	BGC-20-1531
D0HJ5H	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D03LWG	TTDDRUID	D03LWG
D03LWG	DRUGNAME	BGJ398
D03LWG	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
D03LWG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08LRV	TTDDRUID	D08LRV
D08LRV	DRUGNAME	BGP-15
D08LRV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D02XMD	TTDDRUID	D02XMD
D02XMD	DRUGNAME	BGS-649
D02XMD	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D04QZV	TTDDRUID	D04QZV
D04QZV	DRUGNAME	BHQ-880
D04QZV	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0C5FQ	TTDDRUID	D0C5FQ
D0C5FQ	DRUGNAME	BHT-3009
D0C5FQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D06BMO	TTDDRUID	D06BMO
D06BMO	DRUGNAME	BI 1026706
D06BMO	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
D06BMO	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1

D08WQH	TTDDRUID	D08WQH
D08WQH	DRUGNAME	BI 1361849
D08WQH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0T7QJ	TTDDRUID	D0T7QJ
D0T7QJ	DRUGNAME	BI 1361849
D0T7QJ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D07QAF	TTDDRUID	D07QAF
D07QAF	DRUGNAME	BI 207127
D07QAF	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0O0LQ	TTDDRUID	D0O0LQ
D0O0LQ	DRUGNAME	BI 2536
D0O0LQ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0A0MS	TTDDRUID	D0A0MS
D0A0MS	DRUGNAME	BI 655066
D0A0MS	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 2
D0A0MS	INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 3
D0A0MS	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D0A0MS	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2

D06LQY	TTDDRUID	D06LQY
D06LQY	DRUGNAME	BI-1
D06LQY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04UME	TTDDRUID	D04UME
D04UME	DRUGNAME	BI-144807
D04UME	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0J0YH	TTDDRUID	D0J0YH
D0J0YH	DRUGNAME	BI-187004 CL
D0J0YH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0W7UN	TTDDRUID	D0W7UN
D0W7UN	DRUGNAME	BI-409306
D0W7UN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0W7UN	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 2
D0W7UN	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0VZ5X	TTDDRUID	D0VZ5X
D0VZ5X	DRUGNAME	BI-44370 TA
D0VZ5X	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D0Q7OE	TTDDRUID	D0Q7OE
D0Q7OE	DRUGNAME	BI-505
D0Q7OE	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0Q7OE	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0W8DA	TTDDRUID	D0W8DA
D0W8DA	DRUGNAME	BI-54903
D0W8DA	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0W0YI	TTDDRUID	D0W0YI
D0W0YI	DRUGNAME	BI-54903/olodaterol fixed-dose combination
D0W0YI	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0W9YW	TTDDRUID	D0W9YW
D0W9YW	DRUGNAME	BI655130
D0W9YW	INDICATI	Palmoplantar pustulosis [ICD-11: EA90.42] Phase 2
D0W9YW	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D06EYC	TTDDRUID	D06EYC
D06EYC	DRUGNAME	BI-671800
D06EYC	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0G4DE	TTDDRUID	D0G4DE
D0G4DE	DRUGNAME	BIA 3-202
D0G4DE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0N7LA	TTDDRUID	D0N7LA
D0N7LA	DRUGNAME	BIBH 1
D0N7LA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08YHB	TTDDRUID	D08YHB
D08YHB	DRUGNAME	BIIB 023
D08YHB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0J8BZ	TTDDRUID	D0J8BZ
D0J8BZ	DRUGNAME	BIIB 2024
D0J8BZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0J8BZ	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 2

D0Z3PO	TTDDRUID	D0Z3PO
D0Z3PO	DRUGNAME	BIIB014
D0Z3PO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D05HWN	TTDDRUID	D05HWN
D05HWN	DRUGNAME	BIIB-021
D05HWN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D07DSN	TTDDRUID	D07DSN
D07DSN	DRUGNAME	BIIB-033
D07DSN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0TU9W	TTDDRUID	D0TU9W
D0TU9W	DRUGNAME	BIIB054
D0TU9W	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0OX9F	TTDDRUID	D0OX9F
D0OX9F	DRUGNAME	BIIB074
D0OX9F	INDICATI	Lumbosacral radiculopathy [ICD-11: 8B93.Y] Phase 2
D0OX9F	INDICATI	Trigeminal neuralgia [ICD-11: 8B82.0] Phase 2

D0XV2U	TTDDRUID	D0XV2U
D0XV2U	DRUGNAME	BIIB093
D0XV2U	INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 2

D0OZ7P	TTDDRUID	D0OZ7P
D0OZ7P	DRUGNAME	BILN-2061
D0OZ7P	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2

D0L6KC	TTDDRUID	D0L6KC
D0L6KC	DRUGNAME	BILR-355
D0L6KC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D04FNQ	TTDDRUID	D04FNQ
D04FNQ	DRUGNAME	BIM23A760
D04FNQ	INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 2
D04FNQ	INDICATI	Carcinoid syndrome [ICD-11: 5B10] Phase 2
D04FNQ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3

D01ISE	TTDDRUID	D01ISE
D01ISE	DRUGNAME	Bimakalim
D01ISE	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D0WJ5M	TTDDRUID	D0WJ5M
D0WJ5M	DRUGNAME	Bimekizumab
D0WJ5M	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D0WJ5M	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2

D0C3XD	TTDDRUID	D0C3XD
D0C3XD	DRUGNAME	BIO-11006
D0C3XD	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
D0C3XD	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0Q5LF	TTDDRUID	D0Q5LF
D0Q5LF	DRUGNAME	BIO-1211
D0Q5LF	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0OU9J	TTDDRUID	D0OU9J
D0OU9J	DRUGNAME	BioBypass
D0OU9J	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D07TKZ	TTDDRUID	D07TKZ
D07TKZ	DRUGNAME	BIOD-123
D07TKZ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D07TKZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0Q0IX	TTDDRUID	D0Q0IX
D0Q0IX	DRUGNAME	BIOD-531
D0Q0IX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0RI4I	TTDDRUID	D0RI4I
D0RI4I	DRUGNAME	BioE-743
D0RI4I	INDICATI	Leigh syndrome [ICD-11: 5C53.24] Phase 2
D0RI4I	INDICATI	Pontocerebellar hypoplasia type 6 [ICD-11: LD20.01] Phase 2

D0H5NT	TTDDRUID	D0H5NT
D0H5NT	DRUGNAME	Birch pollen allergy desensitization tablet
D0H5NT	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0E8NP	TTDDRUID	D0E8NP
D0E8NP	DRUGNAME	Birinapant
D0E8NP	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D0E8NP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0L6OA	TTDDRUID	D0L6OA
D0L6OA	DRUGNAME	BL-1020
D0L6OA	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0M3GQ	TTDDRUID	D0M3GQ
D0M3GQ	DRUGNAME	BL-22
D0M3GQ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2

D02GIA	TTDDRUID	D02GIA
D02GIA	DRUGNAME	BL-7040
D02GIA	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D0T6CN	TTDDRUID	D0T6CN
D0T6CN	DRUGNAME	BL-8040
D0T6CN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0T6CN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
D0T6CN	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D0T6CN	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0E2EY	TTDDRUID	D0E2EY
D0E2EY	DRUGNAME	BLI-1005
D0E2EY	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D02GGG	TTDDRUID	D02GGG
D02GGG	DRUGNAME	BLI-1100
D02GGG	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D07TFL	TTDDRUID	D07TFL
D07TFL	DRUGNAME	Blosozumab
D07TFL	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D06SCY	TTDDRUID	D06SCY
D06SCY	DRUGNAME	BM-32
D06SCY	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D02XXF	TTDDRUID	D02XXF
D02XXF	DRUGNAME	BMN044
D02XXF	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D03LKV	TTDDRUID	D03LKV
D03LKV	DRUGNAME	BMN045
D03LKV	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0O1BL	TTDDRUID	D0O1BL
D0O1BL	DRUGNAME	BMN053
D0O1BL	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D06QAK	TTDDRUID	D06QAK
D06QAK	DRUGNAME	BMN-111
D06QAK	INDICATI	Achondroplasia [ICD-11: LD24.00] Phase 2

D0DV2Q	TTDDRUID	D0DV2Q
D0DV2Q	DRUGNAME	BMN-190
D0DV2Q	INDICATI	Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Phase 1/2
D0DV2Q	INDICATI	Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Phase 2

D0B4SZ	TTDDRUID	D0B4SZ
D0B4SZ	DRUGNAME	BMS 790052
D0B4SZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0H7QU	TTDDRUID	D0H7QU
D0H7QU	DRUGNAME	BMS 791325
D0H7QU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D07LAP	TTDDRUID	D07LAP
D07LAP	DRUGNAME	BMS-184476
D07LAP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00AYA	TTDDRUID	D00AYA
D00AYA	DRUGNAME	BMS-188797
D00AYA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08PMW	TTDDRUID	D08PMW
D08PMW	DRUGNAME	BMS-223131
D08PMW	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 2

D0DI8J	TTDDRUID	D0DI8J
D0DI8J	DRUGNAME	BMS-275183
D0DI8J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Q0AP	TTDDRUID	D0Q0AP
D0Q0AP	DRUGNAME	BMS-582949
D0Q0AP	INDICATI	Atherosclerosis [ICD-11: BD40] Phase 2
D0Q0AP	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0U4FF	TTDDRUID	D0U4FF
D0U4FF	DRUGNAME	BMS-599626
D0U4FF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0R6UV	TTDDRUID	D0R6UV
D0R6UV	DRUGNAME	BMS-690514
D0R6UV	INDICATI	Chronic pain [ICD-11: MG30] Phase 2

D02JOH	TTDDRUID	D02JOH
D02JOH	DRUGNAME	BMS-708163
D02JOH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0L4US	TTDDRUID	D0L4US
D0L4US	DRUGNAME	BMS-770767
D0L4US	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2

D0B1SG	TTDDRUID	D0B1SG
D0B1SG	DRUGNAME	BMS-813160
D0B1SG	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
D0B1SG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0UX2V	TTDDRUID	D0UX2V
D0UX2V	DRUGNAME	BMS-817399
D0UX2V	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0J9PT	TTDDRUID	D0J9PT
D0J9PT	DRUGNAME	BMS-820836
D0J9PT	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0S2PD	TTDDRUID	D0S2PD
D0S2PD	DRUGNAME	BMS-823778
D0S2PD	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2

D00ORZ	TTDDRUID	D00ORZ
D00ORZ	DRUGNAME	BMS-824393
D00ORZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0DK8X	TTDDRUID	D0DK8X
D0DK8X	DRUGNAME	BMS-911543
D0DK8X	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2

D0O3VP	TTDDRUID	D0O3VP
D0O3VP	DRUGNAME	BMS-914392
D0O3VP	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D04LOR	TTDDRUID	D04LOR
D04LOR	DRUGNAME	BMS-919373
D04LOR	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D0ZK0N	TTDDRUID	D0ZK0N
D0ZK0N	DRUGNAME	BMS-931699
D0ZK0N	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D00YWL	TTDDRUID	D00YWL
D00YWL	DRUGNAME	BMS-936557
D00YWL	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2

D0J1KS	TTDDRUID	D0J1KS
D0J1KS	DRUGNAME	BMS-945429
D0J1KS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D00QKS	TTDDRUID	D00QKS
D00QKS	DRUGNAME	BMS-954561
D00QKS	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D0K5TE	TTDDRUID	D0K5TE
D0K5TE	DRUGNAME	BMS-955176
D0K5TE	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0PO0T	TTDDRUID	D0PO0T
D0PO0T	DRUGNAME	BMS-986036
D0PO0T	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D08AOZ	TTDDRUID	D08AOZ
D08AOZ	DRUGNAME	BMS-986142
D08AOZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0AG8L	TTDDRUID	D0AG8L
D0AG8L	DRUGNAME	BMS-986231
D0AG8L	INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 2

D06FER	TTDDRUID	D06FER
D06FER	DRUGNAME	BMX-010
D06FER	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D06FER	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D0I8QS	TTDDRUID	D0I8QS
D0I8QS	DRUGNAME	BN82451
D0I8QS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D01AZP	TTDDRUID	D01AZP
D01AZP	DRUGNAME	BNC-105
D01AZP	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2

D0U2DA	TTDDRUID	D0U2DA
D0U2DA	DRUGNAME	BNC-210
D0U2DA	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D09WDO	TTDDRUID	D09WDO
D09WDO	DRUGNAME	BNZ-1
D09WDO	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
D09WDO	INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 2

D0UQ5I	TTDDRUID	D0UQ5I
D0UQ5I	DRUGNAME	Botulinum toxin vaccine
D0UQ5I	INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2

D0N8PV	TTDDRUID	D0N8PV
D0N8PV	DRUGNAME	Bovine alkaline phosphatase iv
D0N8PV	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Phase 2

D0CO5Y	TTDDRUID	D0CO5Y
D0CO5Y	DRUGNAME	Bowman Birk Inhibitor Concentrate
D0CO5Y	INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 2

D08IVF	TTDDRUID	D08IVF
D08IVF	DRUGNAME	BP1001
D08IVF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0L3KA	TTDDRUID	D0L3KA
D0L3KA	DRUGNAME	BP-100-1-01
D0L3KA	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
D0L3KA	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0L3KA	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2
D0L3KA	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
D0L3KA	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0XY4A	TTDDRUID	D0XY4A
D0XY4A	DRUGNAME	BPS-804
D0XY4A	INDICATI	Metabolic bone disease [ICD-11: FB8Y] Phase 2

D0R5ER	TTDDRUID	D0R5ER
D0R5ER	DRUGNAME	BPX-01
D0R5ER	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0FB1C	TTDDRUID	D0FB1C
D0FB1C	DRUGNAME	BPX-04
D0FB1C	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D09LQK	TTDDRUID	D09LQK
D09LQK	DRUGNAME	BQ-123
D09LQK	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0OH2H	TTDDRUID	D0OH2H
D0OH2H	DRUGNAME	BR-4628
D0OH2H	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D05BXO	TTDDRUID	D05BXO
D05BXO	DRUGNAME	Brasofensine
D05BXO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0HM5L	TTDDRUID	D0HM5L
D0HM5L	DRUGNAME	Breast cancer vaccine
D0HM5L	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D08CQY	TTDDRUID	D08CQY
D08CQY	DRUGNAME	Brilacidin
D08CQY	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2
D08CQY	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2

D05NZV	TTDDRUID	D05NZV
D05NZV	DRUGNAME	BRL 35135
D05NZV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0OY5G	TTDDRUID	D0OY5G
D0OY5G	DRUGNAME	Brostallicin
D0OY5G	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D08YJN	TTDDRUID	D08YJN
D08YJN	DRUGNAME	BRT-FC-83C
D08YJN	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0E6AH	TTDDRUID	D0E6AH
D0E6AH	DRUGNAME	Bryostatin-1
D0E6AH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D00PUT	TTDDRUID	D00PUT
D00PUT	DRUGNAME	BT-016
D00PUT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0NQ0V	TTDDRUID	D0NQ0V
D0NQ0V	DRUGNAME	BT-061
D0NQ0V	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0NQ0V	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D04PUI	TTDDRUID	D04PUI
D04PUI	DRUGNAME	BT-062
D04PUI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D04PUI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0FZ1W	TTDDRUID	D0FZ1W
D0FZ1W	DRUGNAME	BTA-798
D0FZ1W	INDICATI	Rhinovirus infection [ICD-11: CA07] Phase 2

D0EV9B	TTDDRUID	D0EV9B
D0EV9B	DRUGNAME	BTD-001
D0EV9B	INDICATI	Narcolepsy [ICD-11: 7A20] Phase 2

D0HM2S	TTDDRUID	D0HM2S
D0HM2S	DRUGNAME	BTI-320
D0HM2S	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D06ZPX	TTDDRUID	D06ZPX
D06ZPX	DRUGNAME	BTL-TML-001
D06ZPX	INDICATI	Herpes simplex labialis [ICD-11: 1F00.01] Phase 2
D06ZPX	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0E5TH	TTDDRUID	D0E5TH
D0E5TH	DRUGNAME	BTL-TML-HSV
D0E5TH	INDICATI	Oral herpes [ICD-11: 1F00.02] Phase 2

D0IA9E	TTDDRUID	D0IA9E
D0IA9E	DRUGNAME	BTRX-246040
D0IA9E	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D06GUG	TTDDRUID	D06GUG
D06GUG	DRUGNAME	BTT-1023
D06GUG	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D05PXA	TTDDRUID	D05PXA
D05PXA	DRUGNAME	BTX1503
D05PXA	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0E2RG	TTDDRUID	D0E2RG
D0E2RG	DRUGNAME	Bupivacaine transdermal
D0E2RG	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D04LTQ	TTDDRUID	D04LTQ
D04LTQ	DRUGNAME	Buproprion+zonisamide
D04LTQ	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D03IGB	TTDDRUID	D03IGB
D03IGB	DRUGNAME	BVT.28949
D03IGB	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D07NCV	TTDDRUID	D07NCV
D07NCV	DRUGNAME	BXT-51072
D07NCV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0W7HE	TTDDRUID	D0W7HE
D0W7HE	DRUGNAME	BYL719
D0W7HE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0W7HE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08KPA	TTDDRUID	D08KPA
D08KPA	DRUGNAME	BZL-101
D08KPA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D09OKZ	TTDDRUID	D09OKZ
D09OKZ	DRUGNAME	CA4P
D09OKZ	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
D09OKZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D08FAC	TTDDRUID	D08FAC
D08FAC	DRUGNAME	CaCP-29
D08FAC	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2

D05VTE	TTDDRUID	D05VTE
D05VTE	DRUGNAME	CAI orotate
D05VTE	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2

D06FOL	TTDDRUID	D06FOL
D06FOL	DRUGNAME	CALDARET HYDRATE
D06FOL	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D05UYQ	TTDDRUID	D05UYQ
D05UYQ	DRUGNAME	Camicinal
D05UYQ	INDICATI	Delayed gastric emptying [ICD-11: DA41.00] Phase 2
D05UYQ	INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2

D0Y6SQ	TTDDRUID	D0Y6SQ
D0Y6SQ	DRUGNAME	Camostat
D0Y6SQ	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0F1NW	TTDDRUID	D0F1NW
D0F1NW	DRUGNAME	Cancer Vac
D0F1NW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0R5LL	TTDDRUID	D0R5LL
D0R5LL	DRUGNAME	Cancer vaccine
D0R5LL	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0R5LL	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2

D0Y7TC	TTDDRUID	D0Y7TC
D0Y7TC	DRUGNAME	Cancer vaccine
D0Y7TC	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0V8AR	TTDDRUID	D0V8AR
D0V8AR	DRUGNAME	Candin
D0V8AR	INDICATI	Verruca vulgaris [ICD-11: 1E80] Phase 2

D0CU2G	TTDDRUID	D0CU2G
D0CU2G	DRUGNAME	Cannabidiol oral solution
D0CU2G	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
D0CU2G	INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 3

D0N3JT	TTDDRUID	D0N3JT
D0N3JT	DRUGNAME	Cantuzumab mertansine
D0N3JT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D02UKX	TTDDRUID	D02UKX
D02UKX	DRUGNAME	CAP1-6D
D02UKX	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0M2WQ	TTDDRUID	D0M2WQ
D0M2WQ	DRUGNAME	CAP-7.1
D0M2WQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0I3YX	TTDDRUID	D0I3YX
D0I3YX	DRUGNAME	Capadenoson
D0I3YX	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D0BM4T	TTDDRUID	D0BM4T
D0BM4T	DRUGNAME	CaPre
D0BM4T	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2

D04LXB	TTDDRUID	D04LXB
D04LXB	DRUGNAME	Captisol-enabled Melphalan
D04LXB	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D05TLP	TTDDRUID	D05TLP
D05TLP	DRUGNAME	Carabersat
D05TLP	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2

D0MU7U	TTDDRUID	D0MU7U
D0MU7U	DRUGNAME	Carbamates
D0MU7U	INDICATI	Propagation of disease by mosquito [ICD-11: 1C80-1D48] Phase 2

D0G0GP	TTDDRUID	D0G0GP
D0G0GP	DRUGNAME	Carbon dioxide intranasal
D0G0GP	INDICATI	Trigeminal neuralgia [ICD-11: 8B82.0] Phase 2

D0F5LB	TTDDRUID	D0F5LB
D0F5LB	DRUGNAME	Carbon monoxide
D0F5LB	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D00DAE	TTDDRUID	D00DAE
D00DAE	DRUGNAME	Carboxyamidotriazole orotate
D00DAE	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D0KF3O	TTDDRUID	D0KF3O
D0KF3O	DRUGNAME	CardioPET
D0KF3O	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D06WUK	TTDDRUID	D06WUK
D06WUK	DRUGNAME	Carlumab
D06WUK	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Phase 2

D0G0RT	TTDDRUID	D0G0RT
D0G0RT	DRUGNAME	Carmoterol
D0G0RT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0C3DA	TTDDRUID	D0C3DA
D0C3DA	DRUGNAME	CaroRx
D0C3DA	INDICATI	Dental caries [ICD-11: DA08.0] Phase 2

D09BWG	TTDDRUID	D09BWG
D09BWG	DRUGNAME	CAR-T cells targeting CD19
D09BWG	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0OR6L	TTDDRUID	D0OR6L
D0OR6L	DRUGNAME	CAR-T cells targeting CD20
D0OR6L	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D01AAH	TTDDRUID	D01AAH
D01AAH	DRUGNAME	CAR-T cells targeting CD22
D01AAH	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0T4FY	TTDDRUID	D0T4FY
D0T4FY	DRUGNAME	CAR-T cells targeting CD30
D0T4FY	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0C9TP	TTDDRUID	D0C9TP
D0C9TP	DRUGNAME	CaspaCIDe donor lymphocyte infusion
D0C9TP	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2

D06TZZ	TTDDRUID	D06TZZ
D06TZZ	DRUGNAME	CAT 1004
D06TZZ	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
D06TZZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0S3AQ	TTDDRUID	D0S3AQ
D0S3AQ	DRUGNAME	CAT-2003
D0S3AQ	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2

D0NT1S	TTDDRUID	D0NT1S
D0NT1S	DRUGNAME	CB-10-01
D0NT1S	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0L1PH	TTDDRUID	D0L1PH
D0L1PH	DRUGNAME	CB-5300
D0L1PH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D01PBW	TTDDRUID	D01PBW
D01PBW	DRUGNAME	CB-839
D01PBW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D01PBW	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D01PBW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D01PBW	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0V4TV	TTDDRUID	D0V4TV
D0V4TV	DRUGNAME	CBLB-502
D0V4TV	INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 2

D0N3BB	TTDDRUID	D0N3BB
D0N3BB	DRUGNAME	CBX-129801
D0N3BB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0U2DH	TTDDRUID	D0U2DH
D0U2DH	DRUGNAME	CC-1088
D0U2DH	INDICATI	Crohn disease [ICD-11: DD70] Phase 2

D0LE6F	TTDDRUID	D0LE6F
D0LE6F	DRUGNAME	CC-11050
D0LE6F	INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2

D01XVX	TTDDRUID	D01XVX
D01XVX	DRUGNAME	CC-220
D01XVX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D01XVX	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2
D01XVX	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D04BFC	TTDDRUID	D04BFC
D04BFC	DRUGNAME	CC-292
D04BFC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D04UUD	TTDDRUID	D04UUD
D04UUD	DRUGNAME	CC-401
D04UUD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0X4MN	TTDDRUID	D0X4MN
D0X4MN	DRUGNAME	CC-930
D0X4MN	INDICATI	Discoid lupus erythematosus [ICD-11: EB51.0] Phase 2
D0X4MN	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2

D06IME	TTDDRUID	D06IME
D06IME	DRUGNAME	CCX-140
D06IME	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0MR4Q	TTDDRUID	D0MR4Q
D0MR4Q	DRUGNAME	CCX-168
D0MR4Q	INDICATI	Eosinophilic granulomatosis with polyangiitis [ICD-11: 4A44.A2] Phase 2
D0MR4Q	INDICATI	Hereditary haemolytic anemia [ICD-11: 3A10.3] Phase 2
D0MR4Q	INDICATI	Vasculitis [ICD-11: 4A44] Phase 2

D05VTN	TTDDRUID	D05VTN
D05VTN	DRUGNAME	CCX-354
D05VTN	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
D05VTN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0Q3PB	TTDDRUID	D0Q3PB
D0Q3PB	DRUGNAME	CCX872
D0Q3PB	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1
D0Q3PB	INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2

D0D3QN	TTDDRUID	D0D3QN
D0D3QN	DRUGNAME	CD11301
D0D3QN	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2

D0L5HM	TTDDRUID	D0L5HM
D0L5HM	DRUGNAME	CD19 CAR T cells
D0L5HM	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2
D0L5HM	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D0L5HM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0GR0I	TTDDRUID	D0GR0I
D0GR0I	DRUGNAME	CD19-targeted allogeneic T-cell therapy
D0GR0I	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2

D0Y3HP	TTDDRUID	D0Y3HP
D0Y3HP	DRUGNAME	CD20 CAR T cells
D0Y3HP	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2
D0Y3HP	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D0Y3HP	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0I3AS	TTDDRUID	D0I3AS
D0I3AS	DRUGNAME	CD-2475/101
D0I3AS	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0V7DQ	TTDDRUID	D0V7DQ
D0V7DQ	DRUGNAME	CD40LGVAX
D0V7DQ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D08MJO	TTDDRUID	D08MJO
D08MJO	DRUGNAME	CDP323
D08MJO	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D08MJO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D07TCS	TTDDRUID	D07TCS
D07TCS	DRUGNAME	CDP-6038
D07TCS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D04REV	TTDDRUID	D04REV
D04REV	DRUGNAME	CDX-1307
D04REV	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D09TCY	TTDDRUID	D09TCY
D09TCY	DRUGNAME	CDX-1401
D09TCY	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D09TCY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Q8CV	TTDDRUID	D0Q8CV
D0Q8CV	DRUGNAME	CDX-301
D0Q8CV	INDICATI	Hematopoietic stem cell transplantation [ICD-11: QB63] Phase 2
D0Q8CV	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0Q8CV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0TF2D	TTDDRUID	D0TF2D
D0TF2D	DRUGNAME	CDX-301 + CDX-1401
D0TF2D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0O5XF	TTDDRUID	D0O5XF
D0O5XF	DRUGNAME	CeaVac
D0O5XF	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0L5AH	TTDDRUID	D0L5AH
D0L5AH	DRUGNAME	CELIKALIM
D0L5AH	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0O6UH	TTDDRUID	D0O6UH
D0O6UH	DRUGNAME	Cell-based gene therapy
D0O6UH	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0K6CW	TTDDRUID	D0K6CW
D0K6CW	DRUGNAME	CEN-109
D0K6CW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0OK3O	TTDDRUID	D0OK3O
D0OK3O	DRUGNAME	Cenderitide
D0OK3O	INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 2
D0OK3O	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0UR4K	TTDDRUID	D0UR4K
D0UR4K	DRUGNAME	Cenerimod
D0UR4K	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D0K4VW	TTDDRUID	D0K4VW
D0K4VW	DRUGNAME	Cenersen
D0K4VW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0YQ7U	TTDDRUID	D0YQ7U
D0YQ7U	DRUGNAME	Cenicriviroc
D0YQ7U	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0YQ7U	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D00UGX	TTDDRUID	D00UGX
D00UGX	DRUGNAME	Cenplacel-L
D00UGX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0EH2P	TTDDRUID	D0EH2P
D0EH2P	DRUGNAME	Centanafadine
D0EH2P	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D03AKH	TTDDRUID	D03AKH
D03AKH	DRUGNAME	CER-001
D03AKH	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2
D03AKH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D06EMM	TTDDRUID	D06EMM
D06EMM	DRUGNAME	CERC-301
D06EMM	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0BI3N	TTDDRUID	D0BI3N
D0BI3N	DRUGNAME	Cerdulatinib
D0BI3N	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
D0BI3N	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
D0BI3N	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
D0BI3N	INDICATI	Vitiligo [ICD-11: ED63.0] Phase 1

D0MP1M	TTDDRUID	D0MP1M
D0MP1M	DRUGNAME	CERE-110
D0MP1M	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0U1MO	TTDDRUID	D0U1MO
D0U1MO	DRUGNAME	CERE-120
D0U1MO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0K9MC	TTDDRUID	D0K9MC
D0K9MC	DRUGNAME	CetuGEX
D0K9MC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0U0KR	TTDDRUID	D0U0KR
D0U0KR	DRUGNAME	CF102
D0U0KR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
D0U0KR	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D0U0KR	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D0SD6V	TTDDRUID	D0SD6V
D0SD6V	DRUGNAME	CFZ533
D0SD6V	INDICATI	Graves disease [ICD-11: 5A02.0] Phase 2
D0SD6V	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
D0SD6V	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0SD6V	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2

D0N6EB	TTDDRUID	D0N6EB
D0N6EB	DRUGNAME	CG-0070
D0N6EB	INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 2/3
D0N6EB	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0N6EB	INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 2

D08LMS	TTDDRUID	D08LMS
D08LMS	DRUGNAME	CG201
D08LMS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05PIX	TTDDRUID	D05PIX
D05PIX	DRUGNAME	CG-400549
D05PIX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D08EUS	TTDDRUID	D08EUS
D08EUS	DRUGNAME	CGC-11047
D08EUS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0P5TR	TTDDRUID	D0P5TR
D0P5TR	DRUGNAME	CGP-28014
D0P5TR	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D09QAD	TTDDRUID	D09QAD
D09QAD	DRUGNAME	CGS-15873A
D09QAD	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D02OTK	TTDDRUID	D02OTK
D02OTK	DRUGNAME	CH-4051
D02OTK	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D04RCT	TTDDRUID	D04RCT
D04RCT	DRUGNAME	CHF-3381
D04RCT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D03MFQ	TTDDRUID	D03MFQ
D03MFQ	DRUGNAME	CHF-5074
D03MFQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D08ZYZ	TTDDRUID	D08ZYZ
D08ZYZ	DRUGNAME	Chikungunya vaccine
D08ZYZ	INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2

D07AYN	TTDDRUID	D07AYN
D07AYN	DRUGNAME	Chikungunya virus vaccine
D07AYN	INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2

D08JHG	TTDDRUID	D08JHG
D08JHG	DRUGNAME	ChimeriVax-Dengue
D08JHG	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2

D0P0QB	TTDDRUID	D0P0QB
D0P0QB	DRUGNAME	ChimeriVax-West Nile vaccine
D0P0QB	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D03FFL	TTDDRUID	D03FFL
D03FFL	DRUGNAME	Chitosan-thiomer
D03FFL	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2

D02VLT	TTDDRUID	D02VLT
D02VLT	DRUGNAME	CholeraGarde cholera vaccine live attenuated
D02VLT	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 2

D0F2JS	TTDDRUID	D0F2JS
D0F2JS	DRUGNAME	CHR-2797
D0F2JS	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0F2JS	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0P5SU	TTDDRUID	D0P5SU
D0P5SU	DRUGNAME	CHS-131
D0P5SU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D09ZSY	TTDDRUID	D09ZSY
D09ZSY	DRUGNAME	CI-1012
D09ZSY	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2

D0YB3W	TTDDRUID	D0YB3W
D0YB3W	DRUGNAME	CI-1033
D0YB3W	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D0F5AR	TTDDRUID	D0F5AR
D0F5AR	DRUGNAME	Cibinetide
D0F5AR	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1
D0F5AR	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2

D0K2WK	TTDDRUID	D0K2WK
D0K2WK	DRUGNAME	Cicletanine
D0K2WK	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0VJ4N	TTDDRUID	D0VJ4N
D0VJ4N	DRUGNAME	CIGB-230
D0VJ4N	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0U8OD	TTDDRUID	D0U8OD
D0U8OD	DRUGNAME	CIMICOXIB
D0U8OD	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0ZT0G	TTDDRUID	D0ZT0G
D0ZT0G	DRUGNAME	Cinaciguat
D0ZT0G	INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2

D00KXO	TTDDRUID	D00KXO
D00KXO	DRUGNAME	Ciraparantag
D00KXO	INDICATI	Harmful effects of drugs, medicaments or biological substances [ICD-11: NE60] Phase 2

D04CQV	TTDDRUID	D04CQV
D04CQV	DRUGNAME	Cis-urocanic acid
D04CQV	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0E5DP	TTDDRUID	D0E5DP
D0E5DP	DRUGNAME	Cixutumumab
D0E5DP	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
D0E5DP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D04BUH	TTDDRUID	D04BUH
D04BUH	DRUGNAME	Cizolirtine
D04BUH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D08KTQ	TTDDRUID	D08KTQ
D08KTQ	DRUGNAME	CJC-1295
D08KTQ	INDICATI	Cachexia [ICD-11: MG20] Phase 2

D07ZUZ	TTDDRUID	D07ZUZ
D07ZUZ	DRUGNAME	CK-2127107
D07ZUZ	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
D07ZUZ	INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 1
D07ZUZ	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 2

D07WGE	TTDDRUID	D07WGE
D07WGE	DRUGNAME	C-KAD ophthalmic solution
D07WGE	INDICATI	Cataract [ICD-11: 9B10] Phase 2

D0U6ML	TTDDRUID	D0U6ML
D0U6ML	DRUGNAME	CKD602
D0U6ML	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0C2FJ	TTDDRUID	D0C2FJ
D0C2FJ	DRUGNAME	CL-275838
D0C2FJ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2

D03OPE	TTDDRUID	D03OPE
D03OPE	DRUGNAME	CL-284027
D03OPE	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Phase 2

D07WHS	TTDDRUID	D07WHS
D07WHS	DRUGNAME	CL-316,243
D07WHS	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D02BBC	TTDDRUID	D02BBC
D02BBC	DRUGNAME	CL-329167
D02BBC	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D04RMM	TTDDRUID	D04RMM
D04RMM	DRUGNAME	Clazakizumab
D04RMM	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D04RMM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0G1HX	TTDDRUID	D0G1HX
D0G1HX	DRUGNAME	CLBS03
D0G1HX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D0K1TL	TTDDRUID	D0K1TL
D0K1TL	DRUGNAME	Clobetasol propionate oral
D0K1TL	INDICATI	Oral lichen planus [ICD-11: EA91.4] Phase 2

D0D1ZS	TTDDRUID	D0D1ZS
D0D1ZS	DRUGNAME	CLP-1001
D0D1ZS	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2

D03KHN	TTDDRUID	D03KHN
D03KHN	DRUGNAME	CLR-1404
D03KHN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06EWT	TTDDRUID	D06EWT
D06EWT	DRUGNAME	CLR1404-I-124
D06EWT	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1/2
D06EWT	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D06EWT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D04VHK	TTDDRUID	D04VHK
D04VHK	DRUGNAME	CLR-3001
D04VHK	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0R1UE	TTDDRUID	D0R1UE
D0R1UE	DRUGNAME	CLR325
D0R1UE	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2

D09BXF	TTDDRUID	D09BXF
D09BXF	DRUGNAME	CLS003
D09BXF	INDICATI	Plantar wart [ICD-11: 1E80.1] Phase 2

D0N4JA	TTDDRUID	D0N4JA
D0N4JA	DRUGNAME	CLT-008
D0N4JA	INDICATI	Blood transfusion [ICD-11: QB98] Phase 2

D0WP0U	TTDDRUID	D0WP0U
D0WP0U	DRUGNAME	CMB305
D0WP0U	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
D0WP0U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00WMJ	TTDDRUID	D00WMJ
D00WMJ	DRUGNAME	CMC-001
D00WMJ	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2

D03EZR	TTDDRUID	D03EZR
D03EZR	DRUGNAME	CMD-003
D03EZR	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D03EZR	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0D5ZV	TTDDRUID	D0D5ZV
D0D5ZV	DRUGNAME	CMI-392
D0D5ZV	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0V0VR	TTDDRUID	D0V0VR
D0V0VR	DRUGNAME	CMVpp65-A0201
D0V0VR	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2

D0TW2J	TTDDRUID	D0TW2J
D0TW2J	DRUGNAME	CMX-020
D0TW2J	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D01TBJ	TTDDRUID	D01TBJ
D01TBJ	DRUGNAME	CMX-2043
D01TBJ	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Phase 2
D01TBJ	INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Phase 2

D0V6OZ	TTDDRUID	D0V6OZ
D0V6OZ	DRUGNAME	CN-105
D0V6OZ	INDICATI	Nontraumatic intracerebral hemorrhage [ICD-11: 8B00.4] Phase 2

D01UGN	TTDDRUID	D01UGN
D01UGN	DRUGNAME	CNI-1493
D01UGN	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D09BEG	TTDDRUID	D09BEG
D09BEG	DRUGNAME	CNS-5161
D09BEG	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D0D7MJ	TTDDRUID	D0D7MJ
D0D7MJ	DRUGNAME	CNSB-001
D0D7MJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D0HT2X	TTDDRUID	D0HT2X
D0HT2X	DRUGNAME	CNT0-1959
D0HT2X	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0CD6I	TTDDRUID	D0CD6I
D0CD6I	DRUGNAME	CNTF, Syntex-Synergen, cell therapy
D0CD6I	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2

D0A7NZ	TTDDRUID	D0A7NZ
D0A7NZ	DRUGNAME	CNTO-6785
D0A7NZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0XW8Y	TTDDRUID	D0XW8Y
D0XW8Y	DRUGNAME	CNTX-4975
D0XW8Y	INDICATI	Morton neuroma [ICD-11: 8C11.6] Phase 2
D0XW8Y	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3
D0XW8Y	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D01UDS	TTDDRUID	D01UDS
D01UDS	DRUGNAME	CNV-2197944
D01UDS	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0V0CJ	TTDDRUID	D0V0CJ
D0V0CJ	DRUGNAME	CO-101
D0V0CJ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0C5WR	TTDDRUID	D0C5WR
D0C5WR	DRUGNAME	Cobalt chelate complex CTC-96 dermatological
D0C5WR	INDICATI	Conjunctivitis [ICD-11: 9A60] Phase 2

D0J1AU	TTDDRUID	D0J1AU
D0J1AU	DRUGNAME	CODA-001
D0J1AU	INDICATI	Cornea epithelial defect [ICD-11: 9A78] Phase 2

D0P0BY	TTDDRUID	D0P0BY
D0P0BY	DRUGNAME	Codrituzumab
D0P0BY	INDICATI	Hepatic metastasis [ICD-11: 2D80] Phase 2

D0MM6A	TTDDRUID	D0MM6A
D0MM6A	DRUGNAME	Coenzyme Q10 analog
D0MM6A	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
D0MM6A	INDICATI	Leigh syndrome [ICD-11: 5C53.24] Phase 2
D0MM6A	INDICATI	Mitochondrial respiratory chain disease [ICD-11: 5C53.2] Phase 2
D0MM6A	INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 2

D0E8DK	TTDDRUID	D0E8DK
D0E8DK	DRUGNAME	COL-1077
D0E8DK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0I6MZ	TTDDRUID	D0I6MZ
D0I6MZ	DRUGNAME	Colorectal cancer vaccine
D0I6MZ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0I6MZ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D00UNK	TTDDRUID	D00UNK
D00UNK	DRUGNAME	Coltuximab ravtansine
D00UNK	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D00UNK	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D01MHI	TTDDRUID	D01MHI
D01MHI	DRUGNAME	Coluracetam
D01MHI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0G1JO	TTDDRUID	D0G1JO
D0G1JO	DRUGNAME	Combidex
D0G1JO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06OUC	TTDDRUID	D06OUC
D06OUC	DRUGNAME	Combination autologous stem cell therapy
D06OUC	INDICATI	Ischemia [ICD-11: 8B10-8B11] Phase 2

D0O8AY	TTDDRUID	D0O8AY
D0O8AY	DRUGNAME	Combined PR1/WT1 vaccine
D0O8AY	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 2

D00WME	TTDDRUID	D00WME
D00WME	DRUGNAME	Conatumumab
D00WME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D00WME	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D06JTZ	TTDDRUID	D06JTZ
D06JTZ	DRUGNAME	Contepo
D06JTZ	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2

D0I2GS	TTDDRUID	D0I2GS
D0I2GS	DRUGNAME	Contezolid
D0I2GS	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2

D0BE0Z	TTDDRUID	D0BE0Z
D0BE0Z	DRUGNAME	Contezolid acefosamil
D0BE0Z	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2

D0H9MA	TTDDRUID	D0H9MA
D0H9MA	DRUGNAME	COR-1
D0H9MA	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D02NOC	TTDDRUID	D02NOC
D02NOC	DRUGNAME	Cotara
D02NOC	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D02NOC	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0Y6OA	TTDDRUID	D0Y6OA
D0Y6OA	DRUGNAME	COUMATE
D0Y6OA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0C4BL	TTDDRUID	D0C4BL
D0C4BL	DRUGNAME	Coxsackievirus A21
D0C4BL	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D04WUA	TTDDRUID	D04WUA
D04WUA	DRUGNAME	CP-101,606
D04WUA	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0T0PN	TTDDRUID	D0T0PN
D0T0PN	DRUGNAME	CP-122721
D0T0PN	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D00BOY	TTDDRUID	D00BOY
D00BOY	DRUGNAME	CP-18770
D00BOY	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0MM2K	TTDDRUID	D0MM2K
D0MM2K	DRUGNAME	CP-195543
D0MM2K	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D03FLT	TTDDRUID	D03FLT
D03FLT	DRUGNAME	CP-331684
D03FLT	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0M7OU	TTDDRUID	D0M7OU
D0M7OU	DRUGNAME	CP-461
D0M7OU	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D0G6EI	TTDDRUID	D0G6EI
D0G6EI	DRUGNAME	CP-533536
D0G6EI	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D00YPR	TTDDRUID	D00YPR
D00YPR	DRUGNAME	CP-547632
D00YPR	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D00YPR	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D00YPR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0R7AK	TTDDRUID	D0R7AK
D0R7AK	DRUGNAME	CP-601927
D0R7AK	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2

D07FXF	TTDDRUID	D07FXF
D07FXF	DRUGNAME	CP-613
D07FXF	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0CN9Q	TTDDRUID	D0CN9Q
D0CN9Q	DRUGNAME	CP-724714
D0CN9Q	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D0M5CW	TTDDRUID	D0M5CW
D0M5CW	DRUGNAME	CP-741952
D0M5CW	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D03XLX	TTDDRUID	D03XLX
D03XLX	DRUGNAME	CP-778875
D03XLX	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2

D0V3UN	TTDDRUID	D0V3UN
D0V3UN	DRUGNAME	CP-80794
D0V3UN	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0PN4D	TTDDRUID	D0PN4D
D0PN4D	DRUGNAME	CPC-201
D0PN4D	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0C6ZS	TTDDRUID	D0C6ZS
D0C6ZS	DRUGNAME	CpG-10101
D0C6ZS	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D07NVI	TTDDRUID	D07NVI
D07NVI	DRUGNAME	CPI-613
D07NVI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D07NVI	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
D07NVI	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
D07NVI	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1
D07NVI	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D07NVI	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
D07NVI	INDICATI	Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 2
D07NVI	INDICATI	T-cell lymphoma [ICD-11: 2A90] Phase 1

D08DGC	TTDDRUID	D08DGC
D08DGC	DRUGNAME	CPL-7075
D08DGC	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
D08DGC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D08DGC	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
D08DGC	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
D08DGC	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 3

D0I8ZM	TTDDRUID	D0I8ZM
D0I8ZM	DRUGNAME	CR-3294
D0I8ZM	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2

D02WMX	TTDDRUID	D02WMX
D02WMX	DRUGNAME	CR-6261
D02WMX	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D0L1KX	TTDDRUID	D0L1KX
D0L1KX	DRUGNAME	CR-665
D0L1KX	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0B1IC	TTDDRUID	D0B1IC
D0B1IC	DRUGNAME	CR8020 mab
D0B1IC	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D06JNC	TTDDRUID	D06JNC
D06JNC	DRUGNAME	CRD-007
D06JNC	INDICATI	Aortic aneurysm [ICD-11: BD50] Phase 2

D0CC8L	TTDDRUID	D0CC8L
D0CC8L	DRUGNAME	CRILVASTATIN
D0CC8L	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0ND9T	TTDDRUID	D0ND9T
D0ND9T	DRUGNAME	CRLX101
D0ND9T	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0ND9T	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0ND9T	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D0ND9T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0ND9T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0K4MU	TTDDRUID	D0K4MU
D0K4MU	DRUGNAME	CROBENETINE HYDROCHLORIDE
D0K4MU	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0VZ9S	TTDDRUID	D0VZ9S
D0VZ9S	DRUGNAME	CROMOGLYCATE LISETIL HYDROCHLORIDE
D0VZ9S	INDICATI	Asthma [ICD-11: CA23] Phase 2

D02WSB	TTDDRUID	D02WSB
D02WSB	DRUGNAME	CRS-207
D02WSB	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D02WSB	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
D02WSB	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D02WSB	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0J8WE	TTDDRUID	D0J8WE
D0J8WE	DRUGNAME	CRYPTOPHYCIN 52
D0J8WE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0MX6K	TTDDRUID	D0MX6K
D0MX6K	DRUGNAME	Crysvita
D0MX6K	INDICATI	Complex epidermal hamartoma [ICD-11: LC02] Phase 2

D0L8VA	TTDDRUID	D0L8VA
D0L8VA	DRUGNAME	CSL-112
D0L8VA	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
D0L8VA	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D04WDA	TTDDRUID	D04WDA
D04WDA	DRUGNAME	CSL-412
D04WDA	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0M7GM	TTDDRUID	D0M7GM
D0M7GM	DRUGNAME	CSP-1103
D0M7GM	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0ED6O	TTDDRUID	D0ED6O
D0ED6O	DRUGNAME	CSTC1
D0ED6O	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0B7OY	TTDDRUID	D0B7OY
D0B7OY	DRUGNAME	CT 327
D0B7OY	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D0B7OY	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0R0BI	TTDDRUID	D0R0BI
D0R0BI	DRUGNAME	CT-1
D0R0BI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D06HEY	TTDDRUID	D06HEY
D06HEY	DRUGNAME	CTL019
D06HEY	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D0I0UM	TTDDRUID	D0I0UM
D0I0UM	DRUGNAME	CTL019
D0I0UM	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
D0I0UM	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2

D0J6UA	TTDDRUID	D0J6UA
D0J6UA	DRUGNAME	CTP-499
D0J6UA	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0Z0ZT	TTDDRUID	D0Z0ZT
D0Z0ZT	DRUGNAME	CTX-4430
D0Z0ZT	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0W8FE	TTDDRUID	D0W8FE
D0W8FE	DRUGNAME	CV-301
D0W8FE	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0W8FE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0W8FE	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D0W8FE	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0Q3ER	TTDDRUID	D0Q3ER
D0Q3ER	DRUGNAME	CVBT-141B
D0Q3ER	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D06HMO	TTDDRUID	D06HMO
D06HMO	DRUGNAME	CVBT-141B topical
D06HMO	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D06ANS	TTDDRUID	D06ANS
D06ANS	DRUGNAME	CVBT-141H
D06ANS	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
D06ANS	INDICATI	Coronary heart disease [ICD-11: BA80.Z] Phase 2
D06ANS	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D0S0KP	TTDDRUID	D0S0KP
D0S0KP	DRUGNAME	CVX-045
D0S0KP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0ZI4L	TTDDRUID	D0ZI4L
D0ZI4L	DRUGNAME	CX-01
D0ZI4L	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0ZI4L	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0Z2BO	TTDDRUID	D0Z2BO
D0Z2BO	DRUGNAME	CX-072
D0Z2BO	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 2
D0Z2BO	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0Z2BO	INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 2
D0Z2BO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
D0Z2BO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00RWQ	TTDDRUID	D00RWQ
D00RWQ	DRUGNAME	CX157
D00RWQ	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D0R6JV	TTDDRUID	D0R6JV
D0R6JV	DRUGNAME	CX-1739
D0R6JV	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D0FR7E	TTDDRUID	D0FR7E
D0FR7E	DRUGNAME	CX1789
D0FR7E	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Phase 2

D0G6VC	TTDDRUID	D0G6VC
D0G6VC	DRUGNAME	Cx-501
D0G6VC	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2

D0G3AR	TTDDRUID	D0G3AR
D0G3AR	DRUGNAME	CX-717
D0G3AR	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
D0G3AR	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2

D0A0YQ	TTDDRUID	D0A0YQ
D0A0YQ	DRUGNAME	CX-8998
D0A0YQ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
D0A0YQ	INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2
D0A0YQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D08DGW	TTDDRUID	D08DGW
D08DGW	DRUGNAME	CXL
D08DGW	INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 2

D0AD4D	TTDDRUID	D0AD4D
D0AD4D	DRUGNAME	CXL-1020
D0AD4D	INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2

D0C2IO	TTDDRUID	D0C2IO
D0C2IO	DRUGNAME	CXL-1427
D0C2IO	INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2

D07GTW	TTDDRUID	D07GTW
D07GTW	DRUGNAME	Cyclic pyranopterin monophosphate
D07GTW	INDICATI	Encephalopathy [ICD-11: 8E47] Phase 2

D00DPP	TTDDRUID	D00DPP
D00DPP	DRUGNAME	CYCLOPLATAM
D00DPP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0N3RK	TTDDRUID	D0N3RK
D0N3RK	DRUGNAME	CYSTEMUSTINE
D0N3RK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0P1CE	TTDDRUID	D0P1CE
D0P1CE	DRUGNAME	CYT 99007
D0P1CE	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2

D09CEJ	TTDDRUID	D09CEJ
D09CEJ	DRUGNAME	CYT003
D09CEJ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D08KAD	TTDDRUID	D08KAD
D08KAD	DRUGNAME	CYT-004-MelQbG10
D08KAD	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0D4NJ	TTDDRUID	D0D4NJ
D0D4NJ	DRUGNAME	CYT-005-allQbG10
D0D4NJ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0I7BD	TTDDRUID	D0I7BD
D0I7BD	DRUGNAME	CYT-006-AngQb
D0I7BD	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0KN5B	TTDDRUID	D0KN5B
D0KN5B	DRUGNAME	CYT107
D0KN5B	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0B4MH	TTDDRUID	D0B4MH
D0B4MH	DRUGNAME	Cytorex-EBV
D0B4MH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0T4MQ	TTDDRUID	D0T4MQ
D0T4MQ	DRUGNAME	Cytotropic heterogeneous molecular lipids
D0T4MQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01KHW	TTDDRUID	D01KHW
D01KHW	DRUGNAME	CZEN-002
D01KHW	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D0F8HN	TTDDRUID	D0F8HN
D0F8HN	DRUGNAME	DA-8031
D0F8HN	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 2

D03GPK	TTDDRUID	D03GPK
D03GPK	DRUGNAME	DA-9801
D03GPK	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D07SNO	TTDDRUID	D07SNO
D07SNO	DRUGNAME	Dabrafenib + trametinib
D07SNO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D00GIR	TTDDRUID	D00GIR
D00GIR	DRUGNAME	DAC-060
D00GIR	INDICATI	Keratosis [ICD-11: ED56] Phase 2

D04BOT	TTDDRUID	D04BOT
D04BOT	DRUGNAME	Dalotuzumab
D04BOT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D09UJD	TTDDRUID	D09UJD
D09UJD	DRUGNAME	D-amphetamine transdermal
D09UJD	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D01AHI	TTDDRUID	D01AHI
D01AHI	DRUGNAME	Dance-501
D01AHI	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D01AHI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0KQ0C	TTDDRUID	D0KQ0C
D0KQ0C	DRUGNAME	Danegaptide
D0KQ0C	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D0R9MN	TTDDRUID	D0R9MN
D0R9MN	DRUGNAME	Danoprevir
D0R9MN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0TH5H	TTDDRUID	D0TH5H
D0TH5H	DRUGNAME	Dapansutrile
D0TH5H	INDICATI	Acute gout flare [ICD-11: FA25.0] Phase 2
D0TH5H	INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 2

D05CFV	TTDDRUID	D05CFV
D05CFV	DRUGNAME	Dapirolizumab pegol
D05CFV	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D0DM6I	TTDDRUID	D0DM6I
D0DM6I	DRUGNAME	DAPITANT
D0DM6I	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0H9SX	TTDDRUID	D0H9SX
D0H9SX	DRUGNAME	Daporinad
D0H9SX	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D03ZME	TTDDRUID	D03ZME
D03ZME	DRUGNAME	Darinaparsin
D03ZME	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
D03ZME	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
D03ZME	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D03ZME	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2

D0YO7Y	TTDDRUID	D0YO7Y
D0YO7Y	DRUGNAME	DAS-181
D0YO7Y	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0BJ2W	TTDDRUID	D0BJ2W
D0BJ2W	DRUGNAME	DAS-431 IV
D0BJ2W	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2

D0LJ4J	TTDDRUID	D0LJ4J
D0LJ4J	DRUGNAME	DB104
D0LJ4J	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2

D09BCL	TTDDRUID	D09BCL
D09BCL	DRUGNAME	DCB-AD1
D09BCL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D03VLG	TTDDRUID	D03VLG
D03VLG	DRUGNAME	DCB-WH1
D03VLG	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D0D9VE	TTDDRUID	D0D9VE
D0D9VE	DRUGNAME	DCCR
D0D9VE	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2
D0D9VE	INDICATI	Prader-Willi syndrome [ICD-11: LD90.3] Phase 1

D0PA1B	TTDDRUID	D0PA1B
D0PA1B	DRUGNAME	DCDS-4501A
D0PA1B	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D0PA1B	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D00IZY	TTDDRUID	D00IZY
D00IZY	DRUGNAME	DCN01
D00IZY	INDICATI	Ocular infection [ICD-11: 1F00.1] Phase 2

D0YB5S	TTDDRUID	D0YB5S
D0YB5S	DRUGNAME	DCVax-Prostate cancer vaccine
D0YB5S	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0E4RH	TTDDRUID	D0E4RH
D0E4RH	DRUGNAME	DDB-S
D0E4RH	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2

D04EFK	TTDDRUID	D04EFK
D04EFK	DRUGNAME	DDP-225
D04EFK	INDICATI	Chronic functional vomiting [ICD-11: DD90.4] Discontinued in Phase 2
D04EFK	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D07PRH	TTDDRUID	D07PRH
D07PRH	DRUGNAME	DE-098
D07PRH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D00THG	TTDDRUID	D00THG
D00THG	DRUGNAME	DE-105
D00THG	INDICATI	Corneal disease [ICD-11: 9A78.Z] Phase 2

D0I1DZ	TTDDRUID	D0I1DZ
D0I1DZ	DRUGNAME	DE-110
D0I1DZ	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2

D00SOZ	TTDDRUID	D00SOZ
D00SOZ	DRUGNAME	DE-117
D00SOZ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D04SQO	TTDDRUID	D04SQO
D04SQO	DRUGNAME	DEBIO 1562
D04SQO	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D04SQO	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2

D0VO0T	TTDDRUID	D0VO0T
D0VO0T	DRUGNAME	Delanzomib
D0VO0T	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0ZN1R	TTDDRUID	D0ZN1R
D0ZN1R	DRUGNAME	Delphinidin
D0ZN1R	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D05EUI	TTDDRUID	D05EUI
D05EUI	DRUGNAME	DeltaFLU
D05EUI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D01OMM	TTDDRUID	D01OMM
D01OMM	DRUGNAME	DeltaFLU-LAIV
D01OMM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D05XTQ	TTDDRUID	D05XTQ
D05XTQ	DRUGNAME	DELTIBANT
D05XTQ	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2

D0GJ7N	TTDDRUID	D0GJ7N
D0GJ7N	DRUGNAME	Demcizumab
D0GJ7N	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D09NFW	TTDDRUID	D09NFW
D09NFW	DRUGNAME	Dendritic cell vaccine
D09NFW	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D00TMK	TTDDRUID	D00TMK
D00TMK	DRUGNAME	Dengvaxia
D00TMK	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2

D01QMK	TTDDRUID	D01QMK
D01QMK	DRUGNAME	Denintuzumab mafodotin
D01QMK	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2

D0N1VG	TTDDRUID	D0N1VG
D0N1VG	DRUGNAME	DeNVax
D0N1VG	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2

D0QL1U	TTDDRUID	D0QL1U
D0QL1U	DRUGNAME	DeOvo
D0QL1U	INDICATI	Pediculus capitis infestation [ICD-11: 1G00.0] Phase 2

D00GJK	TTDDRUID	D00GJK
D00GJK	DRUGNAME	Depigoid birch pollen extract vaccine
D00GJK	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2

D02KTA	TTDDRUID	D02KTA
D02KTA	DRUGNAME	DER-45-EV
D02KTA	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D0J9SB	TTDDRUID	D0J9SB
D0J9SB	DRUGNAME	Derlotuximan biotin
D0J9SB	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0VW0A	TTDDRUID	D0VW0A
D0VW0A	DRUGNAME	Dermacyn
D0VW0A	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D0ZI0C	TTDDRUID	D0ZI0C
D0ZI0C	DRUGNAME	Dersalazine
D0ZI0C	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D03QWO	TTDDRUID	D03QWO
D03QWO	DRUGNAME	Dexefaroxan
D03QWO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
D03QWO	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D07TXJ	TTDDRUID	D07TXJ
D07TXJ	DRUGNAME	Dextofisopam
D07TXJ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D0J8RR	TTDDRUID	D0J8RR
D0J8RR	DRUGNAME	Dextromethorphan+quinidine
D0J8RR	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D0Q2WE	TTDDRUID	D0Q2WE
D0Q2WE	DRUGNAME	DFD-04
D0Q2WE	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D0NJ2R	TTDDRUID	D0NJ2R
D0NJ2R	DRUGNAME	DFD-05
D0NJ2R	INDICATI	Common wart [ICD-11: 1E80] Phase 2

D0KE4Q	TTDDRUID	D0KE4Q
D0KE4Q	DRUGNAME	DFD-29
D0KE4Q	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D0Y3JI	TTDDRUID	D0Y3JI
D0Y3JI	DRUGNAME	DG-17
D0Y3JI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D04BOK	TTDDRUID	D04BOK
D04BOK	DRUGNAME	DiabeCell
D04BOK	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 2

D0UF2N	TTDDRUID	D0UF2N
D0UF2N	DRUGNAME	DIADENOSINE TETRAPHOSPHATE
D0UF2N	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2

D07FQL	TTDDRUID	D07FQL
D07FQL	DRUGNAME	Diannexin
D07FQL	INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Phase 2

D00AES	TTDDRUID	D00AES
D00AES	DRUGNAME	Dicopp
D00AES	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0W0WU	TTDDRUID	D0W0WU
D0W0WU	DRUGNAME	Diethylnorspermine
D0W0WU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00XCX	TTDDRUID	D00XCX
D00XCX	DRUGNAME	DIFLOMOTECAN
D00XCX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Y1MW	TTDDRUID	D0Y1MW
D0Y1MW	DRUGNAME	Difluoromethylornithine
D0Y1MW	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2

D0KX6E	TTDDRUID	D0KX6E
D0KX6E	DRUGNAME	DI-Leu16-IL2
D0KX6E	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
D0KX6E	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0K0JQ	TTDDRUID	D0K0JQ
D0K0JQ	DRUGNAME	Dilmapimod
D0K0JQ	INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2

D0T9DN	TTDDRUID	D0T9DN
D0T9DN	DRUGNAME	Dimiracetam
D0T9DN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D02XXT	TTDDRUID	D02XXT
D02XXT	DRUGNAME	Diphencyprone
D02XXT	INDICATI	Alopecia [ICD-11: ED70] Phase 2

D0C4WC	TTDDRUID	D0C4WC
D0C4WC	DRUGNAME	Disitertide
D0C4WC	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D0K4OC	TTDDRUID	D0K4OC
D0K4OC	DRUGNAME	DI-VAL-L-DC
D0K4OC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04AKF	TTDDRUID	D04AKF
D04AKF	DRUGNAME	DKN-01
D04AKF	INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 1/2
D04AKF	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2
D04AKF	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
D04AKF	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2
D04AKF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D04AKF	INDICATI	Oesophagogastric junction cancer [ICD-11: 2B71.Z] Phase 1/2
D04AKF	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D05CJU	TTDDRUID	D05CJU
D05CJU	DRUGNAME	DLX-105
D05CJU	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D0T5YX	TTDDRUID	D0T5YX
D0T5YX	DRUGNAME	DM-71
D0T5YX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D06MOY	TTDDRUID	D06MOY
D06MOY	DRUGNAME	DM-99
D06MOY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D02ZZU	TTDDRUID	D02ZZU
D02ZZU	DRUGNAME	DM-CHOC-PEN
D02ZZU	INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
D02ZZU	INDICATI	Brain metastases [ICD-11: 2D50] Phase 2

D0Q9QC	TTDDRUID	D0Q9QC
D0Q9QC	DRUGNAME	DMD-02
D0Q9QC	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0CO4E	TTDDRUID	D0CO4E
D0CO4E	DRUGNAME	DMT210 topical gel
D0CO4E	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D0CO4E	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D03ZZM	TTDDRUID	D03ZZM
D03ZZM	DRUGNAME	DMT310
D03ZZM	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D06KOM	TTDDRUID	D06KOM
D06KOM	DRUGNAME	DN24-02
D06KOM	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D06KOM	INDICATI	Urogenital cancer [ICD-11: 2C95-2C9Z] Phase 2

D0R8KR	TTDDRUID	D0R8KR
D0R8KR	DRUGNAME	DNA fusion vaccine
D0R8KR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0TB4C	TTDDRUID	D0TB4C
D0TB4C	DRUGNAME	DNA vaccine, University of Southampton/Inovio
D0TB4C	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0A3JC	TTDDRUID	D0A3JC
D0A3JC	DRUGNAME	DNA vaccines
D0A3JC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D0QG8F	TTDDRUID	D0QG8F
D0QG8F	DRUGNAME	DNCB
D0QG8F	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2

D0PF3J	TTDDRUID	D0PF3J
D0PF3J	DRUGNAME	DOLASTATIN-10
D0PF3J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0OK1N	TTDDRUID	D0OK1N
D0OK1N	DRUGNAME	Domagrozumab
D0OK1N	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0MT5U	TTDDRUID	D0MT5U
D0MT5U	DRUGNAME	DopaFuse
D0MT5U	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
D0MT5U	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0ZO7A	TTDDRUID	D0ZO7A
D0ZO7A	DRUGNAME	Dorgenmeltucel-L
D0ZO7A	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0S3ZP	TTDDRUID	D0S3ZP
D0S3ZP	DRUGNAME	Dorolac Nasal Solution
D0S3ZP	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D06AXY	TTDDRUID	D06AXY
D06AXY	DRUGNAME	DOV 21947
D06AXY	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D0M5CD	TTDDRUID	D0M5CD
D0M5CD	DRUGNAME	Doxorubicin-eluting beads
D0M5CD	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2

D0N5XI	TTDDRUID	D0N5XI
D0N5XI	DRUGNAME	DP-001
D0N5XI	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D07WGN	TTDDRUID	D07WGN
D07WGN	DRUGNAME	DP9
D07WGN	INDICATI	Myocardial ischemia [ICD-11: BA6Z] Phase 2

D06DSQ	TTDDRUID	D06DSQ
D06DSQ	DRUGNAME	DPIV/CD26
D06DSQ	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D06XMW	TTDDRUID	D06XMW
D06XMW	DRUGNAME	DPK-060
D06XMW	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D02TYV	TTDDRUID	D02TYV
D02TYV	DRUGNAME	DPS-102
D02TYV	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D03VPM	TTDDRUID	D03VPM
D03VPM	DRUGNAME	DPV-001
D03VPM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D03VPM	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D07UJA	TTDDRUID	D07UJA
D07UJA	DRUGNAME	DRL-17822
D07UJA	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2

D01NYQ	TTDDRUID	D01NYQ
D01NYQ	DRUGNAME	Drug 2696274
D01NYQ	INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2

D01QIX	TTDDRUID	D01QIX
D01QIX	DRUGNAME	Drug 2696275
D01QIX	INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 2

D07LMO	TTDDRUID	D07LMO
D07LMO	DRUGNAME	Drug 2862277
D07LMO	INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2

D0E8IQ	TTDDRUID	D0E8IQ
D0E8IQ	DRUGNAME	DS-8201
D0E8IQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0E8IQ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0E8IQ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D03AOP	TTDDRUID	D03AOP
D03AOP	DRUGNAME	DS-8500
D03AOP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
D03AOP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0D7YA	TTDDRUID	D0D7YA
D0D7YA	DRUGNAME	DSP-6952
D0D7YA	INDICATI	Constipation [ICD-11: DD91.1] Phase 2

D0I1EX	TTDDRUID	D0I1EX
D0I1EX	DRUGNAME	DTI-0009 (oral)
D0I1EX	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D09TQY	TTDDRUID	D09TQY
D09TQY	DRUGNAME	Dusigitumab
D09TQY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D06JKO	TTDDRUID	D06JKO
D06JKO	DRUGNAME	Dust mite allergen extract
D06JKO	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0F0NW	TTDDRUID	D0F0NW
D0F0NW	DRUGNAME	Dust mite peptide allergy desensitization
D0F0NW	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D04XPD	TTDDRUID	D04XPD
D04XPD	DRUGNAME	DV-0100
D04XPD	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D00IZD	TTDDRUID	D00IZD
D00IZD	DRUGNAME	DVC1-0101
D00IZD	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2

D04WXG	TTDDRUID	D04WXG
D04WXG	DRUGNAME	DVC-LVS
D04WXG	INDICATI	Tularemia [ICD-11: 1B94] Phase 2

D05AVB	TTDDRUID	D05AVB
D05AVB	DRUGNAME	DW-1029M
D05AVB	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0FC8O	TTDDRUID	D0FC8O
D0FC8O	DRUGNAME	DWP-05195
D0FC8O	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D0M0PY	TTDDRUID	D0M0PY
D0M0PY	DRUGNAME	DX-890
D0M0PY	INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2

D01GSE	TTDDRUID	D01GSE
D01GSE	DRUGNAME	E-10030
D01GSE	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D09RZM	TTDDRUID	D09RZM
D09RZM	DRUGNAME	E-1101
D09RZM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D01ZBF	TTDDRUID	D01ZBF
D01ZBF	DRUGNAME	E-1224
D01ZBF	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D0A7ZK	TTDDRUID	D0A7ZK
D0A7ZK	DRUGNAME	E2006
D0A7ZK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0A7ZK	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D08TLI	TTDDRUID	D08TLI
D08TLI	DRUGNAME	E-4716
D08TLI	INDICATI	Respiratory disease [ICD-11: CB40] Phase 2

D0PU8T	TTDDRUID	D0PU8T
D0PU8T	DRUGNAME	E5555
D0PU8T	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2

D0TT4H	TTDDRUID	D0TT4H
D0TT4H	DRUGNAME	E6005
D0TT4H	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D01CNB	TTDDRUID	D01CNB
D01CNB	DRUGNAME	E6201
D01CNB	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0K9UK	TTDDRUID	D0K9UK
D0K9UK	DRUGNAME	E-6700
D0K9UK	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0G3GR	TTDDRUID	D0G3GR
D0G3GR	DRUGNAME	E7/HSP70 DNA vaccine
D0G3GR	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D06DHB	TTDDRUID	D06DHB
D06DHB	DRUGNAME	E7016
D06DHB	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D02BQE	TTDDRUID	D02BQE
D02BQE	DRUGNAME	E7820
D02BQE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00EPT	TTDDRUID	D00EPT
D00EPT	DRUGNAME	E7850
D00EPT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D09RXG	TTDDRUID	D09RXG
D09RXG	DRUGNAME	EA-230
D09RXG	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 2

D0O1VU	TTDDRUID	D0O1VU
D0O1VU	DRUGNAME	EB-001
D0O1VU	INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 2

D0ZZ6C	TTDDRUID	D0ZZ6C
D0ZZ6C	DRUGNAME	EB-001A
D0ZZ6C	INDICATI	Glabellar frown line [ICD-11: NA0Z] Phase 2
D0ZZ6C	INDICATI	Keloidal surgical scar [ICD-11: EL50.0] Phase 2

D03AYQ	TTDDRUID	D03AYQ
D03AYQ	DRUGNAME	EB-1020
D03AYQ	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D0XA4U	TTDDRUID	D0XA4U
D0XA4U	DRUGNAME	Ebola recombinant viral vector vaccine
D0XA4U	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 2

D0CG1A	TTDDRUID	D0CG1A
D0CG1A	DRUGNAME	EBV-CTL
D0CG1A	INDICATI	Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 2

D09JGH	TTDDRUID	D09JGH
D09JGH	DRUGNAME	EC-145
D09JGH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0J1CL	TTDDRUID	D0J1CL
D0J1CL	DRUGNAME	EcoNail
D0J1CL	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D05KIV	TTDDRUID	D05KIV
D05KIV	DRUGNAME	Ecopipam hydrochloride
D05KIV	INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2

D0QR3X	TTDDRUID	D0QR3X
D0QR3X	DRUGNAME	Edasalonexent
D0QR3X	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D06BSE	TTDDRUID	D06BSE
D06BSE	DRUGNAME	EDI1200
D06BSE	INDICATI	Ectodermal dysplasia [ICD-11: LD27.0] Phase 2

D0GX0I	TTDDRUID	D0GX0I
D0GX0I	DRUGNAME	EDI200
D0GX0I	INDICATI	X-linked hypophosphataemia [ICD-11: 5C63.22] Phase 2

D0J8PI	TTDDRUID	D0J8PI
D0J8PI	DRUGNAME	Edotreotide
D0J8PI	INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 2

D03PVQ	TTDDRUID	D03PVQ
D03PVQ	DRUGNAME	EDP-420
D03PVQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0Y8NZ	TTDDRUID	D0Y8NZ
D0Y8NZ	DRUGNAME	Efatutazone
D0Y8NZ	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
D0Y8NZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D09DFB	TTDDRUID	D09DFB
D09DFB	DRUGNAME	EFEGATRAN SULFATE HYDRATE
D09DFB	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D0P0LD	TTDDRUID	D0P0LD
D0P0LD	DRUGNAME	Efgartigimod
D0P0LD	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2

D05OZQ	TTDDRUID	D05OZQ
D05OZQ	DRUGNAME	Efpeglenatide
D05OZQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D07XOV	TTDDRUID	D07XOV
D07XOV	DRUGNAME	EFT508
D07XOV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D07XOV	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D07XOV	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D07XOV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
D07XOV	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D0Y9PZ	TTDDRUID	D0Y9PZ
D0Y9PZ	DRUGNAME	Efungumab
D0Y9PZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0OS7K	TTDDRUID	D0OS7K
D0OS7K	DRUGNAME	EGEN-001
D0OS7K	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
D0OS7K	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0OS7K	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 2

D0D4ZW	TTDDRUID	D0D4ZW
D0D4ZW	DRUGNAME	EGS-21
D0D4ZW	INDICATI	Crohn disease [ICD-11: DD70] Phase 2

D07CLO	TTDDRUID	D07CLO
D07CLO	DRUGNAME	EGT-0001442
D07CLO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0BO6I	TTDDRUID	D0BO6I
D0BO6I	DRUGNAME	EHT-899
D0BO6I	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0Z3RZ	TTDDRUID	D0Z3RZ
D0Z3RZ	DRUGNAME	EISO ointment
D0Z3RZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D0YB4D	TTDDRUID	D0YB4D
D0YB4D	DRUGNAME	Eldacimibe
D0YB4D	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0S2DU	TTDDRUID	D0S2DU
D0S2DU	DRUGNAME	Eligen insulin (oral)
D0S2DU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0S8CI	TTDDRUID	D0S8CI
D0S8CI	DRUGNAME	ELIPRODIL
D0S8CI	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D08GIM	TTDDRUID	D08GIM
D08GIM	DRUGNAME	Elisidepsin
D08GIM	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D01TCB	TTDDRUID	D01TCB
D01TCB	DRUGNAME	ELND005
D01TCB	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0E3EY	TTDDRUID	D0E3EY
D0E3EY	DRUGNAME	Elsamitrucin
D0E3EY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0EV1L	TTDDRUID	D0EV1L
D0EV1L	DRUGNAME	Elsiglutide
D0EV1L	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2

D07MDY	TTDDRUID	D07MDY
D07MDY	DRUGNAME	Elsulfavirine
D07MDY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D06FKC	TTDDRUID	D06FKC
D06FKC	DRUGNAME	Eltoprazine
D06FKC	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D06FKC	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
D06FKC	INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 2
D06FKC	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D06FKC	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0O0JP	TTDDRUID	D0O0JP
D0O0JP	DRUGNAME	EMA-401
D0O0JP	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
D0O0JP	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2

D0R8QG	TTDDRUID	D0R8QG
D0R8QG	DRUGNAME	EMD-1214063
D0R8QG	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D0R8QG	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0R8QG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J7OZ	TTDDRUID	D0J7OZ
D0J7OZ	DRUGNAME	EMD-387008
D0J7OZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D05BPD	TTDDRUID	D05BPD
D05BPD	DRUGNAME	Emepepimut-S
D05BPD	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0FE7D	TTDDRUID	D0FE7D
D0FE7D	DRUGNAME	Emibetuzumab
D0FE7D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0GK4E	TTDDRUID	D0GK4E
D0GK4E	DRUGNAME	EMIVIRINE
D0GK4E	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0GP1O	TTDDRUID	D0GP1O
D0GP1O	DRUGNAME	Emixustat
D0GP1O	INDICATI	Proliferative diabetic retinopathy [ICD-11: 9B71.01] Phase 2

D04NAQ	TTDDRUID	D04NAQ
D04NAQ	DRUGNAME	Emricasan
D04NAQ	INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Phase 2
D04NAQ	INDICATI	Liver cirrhosis [ICD-11: DB93.1] Phase 2

D02VBL	TTDDRUID	D02VBL
D02VBL	DRUGNAME	EMZ701
D02VBL	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D09ALE	TTDDRUID	D09ALE
D09ALE	DRUGNAME	Enadoline
D09ALE	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D04VMM	TTDDRUID	D04VMM
D04VMM	DRUGNAME	Encapsulated cancer cells
D04VMM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01DLT	TTDDRUID	D01DLT
D01DLT	DRUGNAME	Encapsulated live cells converting ifosfamide
D01DLT	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0V6AH	TTDDRUID	D0V6AH
D0V6AH	DRUGNAME	Endostatin
D0V6AH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0W4EB	TTDDRUID	D0W4EB
D0W4EB	DRUGNAME	Endoxifen
D0W4EB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D01WUT	TTDDRUID	D01WUT
D01WUT	DRUGNAME	Enfortumab vedotin
D01WUT	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2

D09QOR	TTDDRUID	D09QOR
D09QOR	DRUGNAME	Eniluracil
D09QOR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0S7HM	TTDDRUID	D0S7HM
D0S7HM	DRUGNAME	ENMD-2076
D0S7HM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0S7HM	INDICATI	Fibrolamellar liver cancer [ICD-11: 2C12.02] Phase 2
D0S7HM	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D0S7HM	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D0C8UG	TTDDRUID	D0C8UG
D0C8UG	DRUGNAME	Enobosarm
D0C8UG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00KIE	TTDDRUID	D00KIE
D00KIE	DRUGNAME	Ensaculin hydrochloride
D00KIE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0KL4T	TTDDRUID	D0KL4T
D0KL4T	DRUGNAME	Ensitiximab
D0KL4T	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0W5FG	TTDDRUID	D0W5FG
D0W5FG	DRUGNAME	EP-100
D0W5FG	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0W5FG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0KX9B	TTDDRUID	D0KX9B
D0KX9B	DRUGNAME	EP-101
D0KX9B	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0KX9B	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D05GYU	TTDDRUID	D05GYU
D05GYU	DRUGNAME	EP-201
D05GYU	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0UK1L	TTDDRUID	D0UK1L
D0UK1L	DRUGNAME	EP-217609
D0UK1L	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D0ET2S	TTDDRUID	D0ET2S
D0ET2S	DRUGNAME	Epetirimod
D0ET2S	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D09XJF	TTDDRUID	D09XJF
D09XJF	DRUGNAME	EPI 589
D09XJF	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
D09XJF	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D00IJM	TTDDRUID	D00IJM
D00IJM	DRUGNAME	EPI-A0001
D00IJM	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2

D05TPI	TTDDRUID	D05TPI
D05TPI	DRUGNAME	EPICATECHIN
D05TPI	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
D05TPI	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2

D03XEY	TTDDRUID	D03XEY
D03XEY	DRUGNAME	Epstein-barr virus-specific immunotherapy
D03XEY	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2

D0H4GU	TTDDRUID	D0H4GU
D0H4GU	DRUGNAME	EPX-200
D0H4GU	INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 2

D00EQL	TTDDRUID	D00EQL
D00EQL	DRUGNAME	EPZ-6438
D00EQL	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
D00EQL	INDICATI	Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2
D00EQL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D00EQL	INDICATI	Malignant rhabdoid tumour [ICD-11: 2A00.1Y] Phase 2
D00EQL	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
D00EQL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
D00EQL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D00EQL	INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 1

D06XCF	TTDDRUID	D06XCF
D06XCF	DRUGNAME	EQ-917
D06XCF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07LZH	TTDDRUID	D07LZH
D07LZH	DRUGNAME	ERB-041
D07LZH	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D0M7MB	TTDDRUID	D0M7MB
D0M7MB	DRUGNAME	ERC-124
D0M7MB	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0W1AR	TTDDRUID	D0W1AR
D0W1AR	DRUGNAME	ERC-1671
D0W1AR	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D0W1AR	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D0W1AR	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0NW0T	TTDDRUID	D0NW0T
D0NW0T	DRUGNAME	Erdafitinib
D0NW0T	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2

D0R2SK	TTDDRUID	D0R2SK
D0R2SK	DRUGNAME	Erteberel
D0R2SK	INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 2

D0O2JI	TTDDRUID	D0O2JI
D0O2JI	DRUGNAME	Ertumaxomab
D0O2JI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0O2JI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0P0SD	TTDDRUID	D0P0SD
D0P0SD	DRUGNAME	Eryaspase
D0P0SD	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D06FGE	TTDDRUID	D06FGE
D06FGE	DRUGNAME	Erythropoiesis stimulants
D06FGE	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D0T5GO	TTDDRUID	D0T5GO
D0T5GO	DRUGNAME	Erythropoietin gene therapy
D0T5GO	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D0I1JG	TTDDRUID	D0I1JG
D0I1JG	DRUGNAME	ES-1
D0I1JG	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D0G9ZU	TTDDRUID	D0G9ZU
D0G9ZU	DRUGNAME	ESBA-105
D0G9ZU	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 2

D08VZH	TTDDRUID	D08VZH
D08VZH	DRUGNAME	ESS
D08VZH	INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Phase 2

D0L3TR	TTDDRUID	D0L3TR
D0L3TR	DRUGNAME	Estetrol
D0L3TR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0DW8G	TTDDRUID	D0DW8G
D0DW8G	DRUGNAME	Estrogen receptor beta-selective phytoestrogenic formulation
D0DW8G	INDICATI	Menopause symptom [ICD-11: GA30.0] Phase 2

D0X5ZU	TTDDRUID	D0X5ZU
D0X5ZU	DRUGNAME	ET-01 topical
D0X5ZU	INDICATI	Facial wrinkles [ICD-11: EJ9Y] Phase 2

D0H5HZ	TTDDRUID	D0H5HZ
D0H5HZ	DRUGNAME	Etamicastat
D0H5HZ	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0J6LN	TTDDRUID	D0J6LN
D0J6LN	DRUGNAME	Etazolate
D0J6LN	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 2

D0OR8W	TTDDRUID	D0OR8W
D0OR8W	DRUGNAME	ETIPREDNOL DICLOACETATE
D0OR8W	INDICATI	Rhinitis [ICD-11: FA20] Phase 2

D04BKO	TTDDRUID	D04BKO
D04BKO	DRUGNAME	Etripamil
D04BKO	INDICATI	Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Phase 2

D0J5HG	TTDDRUID	D0J5HG
D0J5HG	DRUGNAME	ETS-6103
D0J5HG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D02JZJ	TTDDRUID	D02JZJ
D02JZJ	DRUGNAME	ETS-6218
D02JZJ	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2

D00EGN	TTDDRUID	D00EGN
D00EGN	DRUGNAME	ETX-9101
D00EGN	INDICATI	Asthma [ICD-11: CA23] Phase 2

D08PKI	TTDDRUID	D08PKI
D08PKI	DRUGNAME	EV-077
D08PKI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D03WOG	TTDDRUID	D03WOG
D03WOG	DRUGNAME	Evinacumab
D03WOG	INDICATI	Elevated C-reactive protein [ICD-11: MA14.15] Phase 2

D08DZN	TTDDRUID	D08DZN
D08DZN	DRUGNAME	Evinacumab
D08DZN	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2

D01ADH	TTDDRUID	D01ADH
D01ADH	DRUGNAME	Evitar
D01ADH	INDICATI	Wound healing [ICD-11: EL8Y] Phase 2

D0OB4R	TTDDRUID	D0OB4R
D0OB4R	DRUGNAME	EVP-0962
D0OB4R	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D00WCT	TTDDRUID	D00WCT
D00WCT	DRUGNAME	EVP-1001-1
D00WCT	INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 2

D00OVC	TTDDRUID	D00OVC
D00OVC	DRUGNAME	EVT-201
D00OVC	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D06PHS	TTDDRUID	D06PHS
D06PHS	DRUGNAME	EVT302
D06PHS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0R3LQ	TTDDRUID	D0R3LQ
D0R3LQ	DRUGNAME	EXC 001
D0R3LQ	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2

D0KK9E	TTDDRUID	D0KK9E
D0KK9E	DRUGNAME	Exherin
D0KK9E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0F5VD	TTDDRUID	D0F5VD
D0F5VD	DRUGNAME	Ezatiostat
D0F5VD	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0F1ZI	TTDDRUID	D0F1ZI
D0F1ZI	DRUGNAME	F-16-IL-2 fusion protein
D0F1ZI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0K9NJ	TTDDRUID	D0K9NJ
D0K9NJ	DRUGNAME	F18-ML-10
D0K9NJ	INDICATI	Brain cancer [ICD-11: 2A00] Phase 2

D00AKV	TTDDRUID	D00AKV
D00AKV	DRUGNAME	F-351
D00AKV	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2

D05GBH	TTDDRUID	D05GBH
D05GBH	DRUGNAME	F4co vaccine
D05GBH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D07BUH	TTDDRUID	D07BUH
D07BUH	DRUGNAME	F-627
D07BUH	INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 2

D0T4KG	TTDDRUID	D0T4KG
D0T4KG	DRUGNAME	F-8-IL-10 fusion protein
D0T4KG	INDICATI	Endometriosis [ICD-11: GA10] Phase 2
D0T4KG	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
D0T4KG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0VO6J	TTDDRUID	D0VO6J
D0VO6J	DRUGNAME	FAD-104
D0VO6J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0U1NA	TTDDRUID	D0U1NA
D0U1NA	DRUGNAME	Fadolmidine
D0U1NA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
D0U1NA	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0Z6MT	TTDDRUID	D0Z6MT
D0Z6MT	DRUGNAME	Famitinib
D0Z6MT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Q4NX	TTDDRUID	D0Q4NX
D0Q4NX	DRUGNAME	FANG
D0Q4NX	INDICATI	Adjuvant ovarian cancer [ICD-11: 2C73] Phase 2
D0Q4NX	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D06QEL	TTDDRUID	D06QEL
D06QEL	DRUGNAME	FARANOXI
D06QEL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05ENJ	TTDDRUID	D05ENJ
D05ENJ	DRUGNAME	Fasitibant chloride
D05ENJ	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D0D8TE	TTDDRUID	D0D8TE
D0D8TE	DRUGNAME	FBS-0701
D0D8TE	INDICATI	Iron overload disease [ICD-11: 5C64.10] Phase 2

D01YKR	TTDDRUID	D01YKR
D01YKR	DRUGNAME	FCR001
D01YKR	INDICATI	Organ transplant rejection [ICD-11: NE84] Phase 2

D0E9MI	TTDDRUID	D0E9MI
D0E9MI	DRUGNAME	FDY-5301
D0E9MI	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D0S3YN	TTDDRUID	D0S3YN
D0S3YN	DRUGNAME	FE-202158
D0S3YN	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2

D07LWT	TTDDRUID	D07LWT
D07LWT	DRUGNAME	FE-202767
D07LWT	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 2

D0I6YM	TTDDRUID	D0I6YM
D0I6YM	DRUGNAME	Ferroquine
D0I6YM	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D0RU3J	TTDDRUID	D0RU3J
D0RU3J	DRUGNAME	Fexapotide
D0RU3J	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D01AIN	TTDDRUID	D01AIN
D01AIN	DRUGNAME	Fezakinumab
D01AIN	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0N6CS	TTDDRUID	D0N6CS
D0N6CS	DRUGNAME	FG-2216
D0N6CS	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2

D08ZHL	TTDDRUID	D08ZHL
D08ZHL	DRUGNAME	FGF-1
D08ZHL	INDICATI	Coronary heart disease [ICD-11: BA80.Z] Phase 2

D06CCR	TTDDRUID	D06CCR
D06CCR	DRUGNAME	Fialuridine
D06CCR	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0L2CN	TTDDRUID	D0L2CN
D0L2CN	DRUGNAME	Fibroblast growth factor-18
D0L2CN	INDICATI	Cartilage lesions [ICD-11: NC93.3Z] Phase 2

D03UBW	TTDDRUID	D03UBW
D03UBW	DRUGNAME	Ficlatuzumab
D03UBW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D03UBW	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D03UBW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D03UBW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D03UBW	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D0U0GZ	TTDDRUID	D0U0GZ
D0U0GZ	DRUGNAME	Filibuvir
D0U0GZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D05LGX	TTDDRUID	D05LGX
D05LGX	DRUGNAME	Fipamezole
D05LGX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0H8FY	TTDDRUID	D0H8FY
D0H8FY	DRUGNAME	Firategrast
D0H8FY	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2
D0H8FY	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D04HQA	TTDDRUID	D04HQA
D04HQA	DRUGNAME	FIT-06
D04HQA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0WH9U	TTDDRUID	D0WH9U
D0WH9U	DRUGNAME	FK-070
D0WH9U	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D0J3CT	TTDDRUID	D0J3CT
D0J3CT	DRUGNAME	FK-143
D0J3CT	INDICATI	Prostate disease [ICD-11: GA91] Phase 2

D0Z9YW	TTDDRUID	D0Z9YW
D0Z9YW	DRUGNAME	FK-3311
D0Z9YW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0ZM8B	TTDDRUID	D0ZM8B
D0ZM8B	DRUGNAME	FK-409
D0ZM8B	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D0VT2C	TTDDRUID	D0VT2C
D0VT2C	DRUGNAME	FK-505
D0VT2C	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Phase 2

D00PJJ	TTDDRUID	D00PJJ
D00PJJ	DRUGNAME	FK-614
D00PJJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D00MZK	TTDDRUID	D00MZK
D00MZK	DRUGNAME	FK-788
D00MZK	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0O3TC	TTDDRUID	D0O3TC
D0O3TC	DRUGNAME	FK-962
D0O3TC	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0H6PK	TTDDRUID	D0H6PK
D0H6PK	DRUGNAME	FKF02SC
D0H6PK	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0SQ6A	TTDDRUID	D0SQ6A
D0SQ6A	DRUGNAME	FKW00GA
D0SQ6A	INDICATI	Social phobia [ICD-11: 6B04] Phase 2

D00NVO	TTDDRUID	D00NVO
D00NVO	DRUGNAME	Flezelastine
D00NVO	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0H9YO	TTDDRUID	D0H9YO
D0H9YO	DRUGNAME	FLUASTERONE
D0H9YO	INDICATI	Arthritis [ICD-11: FA20] Phase 2

D0X4IH	TTDDRUID	D0X4IH
D0X4IH	DRUGNAME	Fluciclatide F-18
D0X4IH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06JHV	TTDDRUID	D06JHV
D06JHV	DRUGNAME	Flumatinib
D06JHV	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2

D0C8AL	TTDDRUID	D0C8AL
D0C8AL	DRUGNAME	Fluoropeptide vaccine
D0C8AL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0SD9V	TTDDRUID	D0SD9V
D0SD9V	DRUGNAME	Flupirtine
D0SD9V	INDICATI	Cancer related pain [ICD-11: MG30] Phase 2
D0SD9V	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2

D0TI3R	TTDDRUID	D0TI3R
D0TI3R	DRUGNAME	FLX-787
D0TI3R	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
D0TI3R	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D0TI3R	INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 2

D01ZPY	TTDDRUID	D01ZPY
D01ZPY	DRUGNAME	FMP2.1/AS02A
D01ZPY	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D06JTW	TTDDRUID	D06JTW
D06JTW	DRUGNAME	FM-VP4
D06JTW	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0T8QE	TTDDRUID	D0T8QE
D0T8QE	DRUGNAME	FMX102
D0T8QE	INDICATI	Impetigo [ICD-11: 1B72] Phase 2

D0Z8EA	TTDDRUID	D0Z8EA
D0Z8EA	DRUGNAME	FMX104
D0Z8EA	INDICATI	Chronic post cancer treatment pain [ICD-11: 8E43] Phase 2

D0M7YU	TTDDRUID	D0M7YU
D0M7YU	DRUGNAME	Folate binding protein vaccine
D0M7YU	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
D0M7YU	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0N8JG	TTDDRUID	D0N8JG
D0N8JG	DRUGNAME	FolateImmune
D0N8JG	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D0N8JG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0DG8W	TTDDRUID	D0DG8W
D0DG8W	DRUGNAME	Foliglurax
D0DG8W	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0KM1B	TTDDRUID	D0KM1B
D0KM1B	DRUGNAME	Follicle stimulating hormone
D0KM1B	INDICATI	Infertility [ICD-11: GB04] Phase 2

D0YC8W	TTDDRUID	D0YC8W
D0YC8W	DRUGNAME	Folotynpralatrexate
D0YC8W	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2

D0V8HB	TTDDRUID	D0V8HB
D0V8HB	DRUGNAME	Food allergy epicutaneous immunotherapy
D0V8HB	INDICATI	Peanut hypersensitivity [ICD-11: 4A83] Phase 2

D07JVO	TTDDRUID	D07JVO
D07JVO	DRUGNAME	Fosbretabulin
D07JVO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0E8ZI	TTDDRUID	D0E8ZI
D0E8ZI	DRUGNAME	FOV-2304
D0E8ZI	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D0OU0S	TTDDRUID	D0OU0S
D0OU0S	DRUGNAME	FP-0110
D0OU0S	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2

D0U2DO	TTDDRUID	D0U2DO
D0U2DO	DRUGNAME	FP-1039
D0U2DO	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2

D02MMF	TTDDRUID	D02MMF
D02MMF	DRUGNAME	FP-1097
D02MMF	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2

D00ICY	TTDDRUID	D00ICY
D00ICY	DRUGNAME	FP-187
D00ICY	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0RG8Z	TTDDRUID	D0RG8Z
D0RG8Z	DRUGNAME	FPI-01
D0RG8Z	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D09XLS	TTDDRUID	D09XLS
D09XLS	DRUGNAME	FR139317
D09XLS	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
D09XLS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
D09XLS	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D01CJY	TTDDRUID	D01CJY
D01CJY	DRUGNAME	FR-146687
D01CJY	INDICATI	Prostate disease [ICD-11: GA91] Phase 2

D02XKK	TTDDRUID	D02XKK
D02XKK	DRUGNAME	FRM-0962
D02XKK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D03OMZ	TTDDRUID	D03OMZ
D03OMZ	DRUGNAME	Fulvestrant intraductal microcatheter delivery
D03OMZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D06ZHZ	TTDDRUID	D06ZHZ
D06ZHZ	DRUGNAME	FX-125L
D06ZHZ	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2

D0MD5M	TTDDRUID	D0MD5M
D0MD5M	DRUGNAME	G100
D0MD5M	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0WU1O	TTDDRUID	D0WU1O
D0WU1O	DRUGNAME	G1T38
D0WU1O	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0WU1O	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D05MOZ	TTDDRUID	D05MOZ
D05MOZ	DRUGNAME	G-202
D05MOZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0C2AR	TTDDRUID	D0C2AR
D0C2AR	DRUGNAME	Gadocoletic acid
D0C2AR	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0P2SI	TTDDRUID	D0P2SI
D0P2SI	DRUGNAME	Galiximab
D0P2SI	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D00ERV	TTDDRUID	D00ERV
D00ERV	DRUGNAME	Gallopamil
D00ERV	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0A6WA	TTDDRUID	D0A6WA
D0A6WA	DRUGNAME	GAM-501
D0A6WA	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D0Q6MA	TTDDRUID	D0Q6MA
D0Q6MA	DRUGNAME	Gamma-sarcoglycan gene-containing recombinant AAV1 vector based therapy
D0Q6MA	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0N6MX	TTDDRUID	D0N6MX
D0N6MX	DRUGNAME	Gamunex-C
D0N6MX	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D0N6MX	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2

D0X0CH	TTDDRUID	D0X0CH
D0X0CH	DRUGNAME	Ganaxolone
D0X0CH	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
D0X0CH	INDICATI	Postpartum depression [ICD-11: 6E20.0] Phase 2

D0F6SS	TTDDRUID	D0F6SS
D0F6SS	DRUGNAME	Ganglioside vaccine
D0F6SS	INDICATI	Metastatic sarcoma [ICD-11: 2D50-2E2Z] Phase 2

D0C4GX	TTDDRUID	D0C4GX
D0C4GX	DRUGNAME	GBL-310
D0C4GX	INDICATI	Keratosis [ICD-11: ED56] Phase 2

D0JQ2W	TTDDRUID	D0JQ2W
D0JQ2W	DRUGNAME	GBM-Lamp-Vax
D0JQ2W	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D03DUI	TTDDRUID	D03DUI
D03DUI	DRUGNAME	GBR 830
D03DUI	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0V6CE	TTDDRUID	D0V6CE
D0V6CE	DRUGNAME	GBT-009
D0V6CE	INDICATI	Scar conditions [ICD-11: QB83] Phase 2
D0V6CE	INDICATI	Skin fibrosis [ICD-11: EM0Z] Phase 2

D0MX7C	TTDDRUID	D0MX7C
D0MX7C	DRUGNAME	GBT-101 topical gel
D0MX7C	INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 2
D0MX7C	INDICATI	Pressure ulcers [ICD-11: EH90] Phase 2

D09RII	TTDDRUID	D09RII
D09RII	DRUGNAME	GBT440
D09RII	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2

D0W1QA	TTDDRUID	D0W1QA
D0W1QA	DRUGNAME	GC-1102
D0W1QA	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0D5NV	TTDDRUID	D0D5NV
D0D5NV	DRUGNAME	GC-1109
D0D5NV	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 2

D0PV9N	TTDDRUID	D0PV9N
D0PV9N	DRUGNAME	GC4419
D0PV9N	INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 2
D0PV9N	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D03TNG	TTDDRUID	D03TNG
D03TNG	DRUGNAME	GCAN 101
D03TNG	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0JW0V	TTDDRUID	D0JW0V
D0JW0V	DRUGNAME	GCS-100
D0JW0V	INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 2

D08QGT	TTDDRUID	D08QGT
D08QGT	DRUGNAME	GDC0941
D08QGT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D08QGT	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D08QGT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0O6VZ	TTDDRUID	D0O6VZ
D0O6VZ	DRUGNAME	GDC-0980/RG7422
D0O6VZ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0O6VZ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D0O6VZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07QCA	TTDDRUID	D07QCA
D07QCA	DRUGNAME	GDNF-producing adult stem cell therapy
D07QCA	INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2

D0E6ME	TTDDRUID	D0E6ME
D0E6ME	DRUGNAME	GED-0507-34-Levo
D0E6ME	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D0R4MT	TTDDRUID	D0R4MT
D0R4MT	DRUGNAME	Gemcabene
D0R4MT	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2

D0O7UU	TTDDRUID	D0O7UU
D0O7UU	DRUGNAME	GEM-SP
D0O7UU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D04YCQ	TTDDRUID	D04YCQ
D04YCQ	DRUGNAME	GEN-003
D04YCQ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1/2
D04YCQ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 2

D0L4FS	TTDDRUID	D0L4FS
D0L4FS	DRUGNAME	Genistein
D0L4FS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D05TRI	TTDDRUID	D05TRI
D05TRI	DRUGNAME	GeNOsyl
D05TRI	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D08RSL	TTDDRUID	D08RSL
D08RSL	DRUGNAME	Genz-644470
D08RSL	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 2

D04SFN	TTDDRUID	D04SFN
D04SFN	DRUGNAME	Genz-682452
D04SFN	INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 2

D04COD	TTDDRUID	D04COD
D04COD	DRUGNAME	Gepotidacin
D04COD	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2

D0RJ0V	TTDDRUID	D0RJ0V
D0RJ0V	DRUGNAME	GFT14
D0RJ0V	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0LW1Y	TTDDRUID	D0LW1Y
D0LW1Y	DRUGNAME	GFT-505
D0LW1Y	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0N4SF	TTDDRUID	D0N4SF
D0N4SF	DRUGNAME	GI-4000
D0N4SF	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0N4SF	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0KK9V	TTDDRUID	D0KK9V
D0KK9V	DRUGNAME	GI-4000 in combination with gemcitabine
D0KK9V	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0J6NV	TTDDRUID	D0J6NV
D0J6NV	DRUGNAME	GI-5005
D0J6NV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0ZL1I	TTDDRUID	D0ZL1I
D0ZL1I	DRUGNAME	GI-5005-02
D0ZL1I	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D0L7VC	TTDDRUID	D0L7VC
D0L7VC	DRUGNAME	GI-6207
D0L7VC	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 1
D0L7VC	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 2

D0S9WW	TTDDRUID	D0S9WW
D0S9WW	DRUGNAME	GI-6301
D0S9WW	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D0S9WW	INDICATI	Chordoma [ICD-11: 5A61.0] Phase 2
D0S9WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00BZS	TTDDRUID	D00BZS
D00BZS	DRUGNAME	Gimatecan
D00BZS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0BH7Z	TTDDRUID	D0BH7Z
D0BH7Z	DRUGNAME	Girentuximab I-124
D0BH7Z	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0D7VO	TTDDRUID	D0D7VO
D0D7VO	DRUGNAME	GK1-399
D0D7VO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
D0D7VO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D04XVU	TTDDRUID	D04XVU
D04XVU	DRUGNAME	GKT-137831
D04XVU	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2

D08DUF	TTDDRUID	D08DUF
D08DUF	DRUGNAME	GL-0817
D08DUF	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D08DUF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D08DUF	INDICATI	Oral cavity squamous cell carcinoma [ICD-11: 2B6E.0] Phase 2
D08DUF	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D0SG7B	TTDDRUID	D0SG7B
D0SG7B	DRUGNAME	GLPG-0634
D0SG7B	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D0SG7B	INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
D0SG7B	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0TA4A	TTDDRUID	D0TA4A
D0TA4A	DRUGNAME	GLPG0974
D0TA4A	INDICATI	Abortion [ICD-11: JA00] Phase 2

D0E0JO	TTDDRUID	D0E0JO
D0E0JO	DRUGNAME	GLPG-1837
D0E0JO	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0K9WL	TTDDRUID	D0K9WL
D0K9WL	DRUGNAME	Glucagon injection
D0K9WL	INDICATI	Hypoglycemia [ICD-11: 5A41] Phase 2

D00NBF	TTDDRUID	D00NBF
D00NBF	DRUGNAME	GM06
D00NBF	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D02DEH	TTDDRUID	D02DEH
D02DEH	DRUGNAME	GM-602
D02DEH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D02DEH	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2

D01LXS	TTDDRUID	D01LXS
D01LXS	DRUGNAME	GM604
D01LXS	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D0JV0O	TTDDRUID	D0JV0O
D0JV0O	DRUGNAME	GM608
D0JV0O	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D03AQZ	TTDDRUID	D03AQZ
D03AQZ	DRUGNAME	GMB-Vax
D03AQZ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D09SHX	TTDDRUID	D09SHX
D09SHX	DRUGNAME	GM-CSF cancer vaccine
D09SHX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01ILA	TTDDRUID	D01ILA
D01ILA	DRUGNAME	GNbAC-1
D01ILA	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D07OAD	TTDDRUID	D07OAD
D07OAD	DRUGNAME	GO-203-2c
D07OAD	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D07OAD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D04JQT	TTDDRUID	D04JQT
D04JQT	DRUGNAME	Goat polyclonal antibodies
D04JQT	INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 2

D02MRN	TTDDRUID	D02MRN
D02MRN	DRUGNAME	Golotimod
D02MRN	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
D02MRN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2

D0KW3Z	TTDDRUID	D0KW3Z
D0KW3Z	DRUGNAME	GORALATIDE
D0KW3Z	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Phase 2

D0Z0HH	TTDDRUID	D0Z0HH
D0Z0HH	DRUGNAME	Gossypol
D0Z0HH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D09WPI	TTDDRUID	D09WPI
D09WPI	DRUGNAME	GOVX-B11
D09WPI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D08DWM	TTDDRUID	D08DWM
D08DWM	DRUGNAME	Gp100:209-217(210M) peptide vaccine
D08DWM	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D07CPM	TTDDRUID	D07CPM
D07CPM	DRUGNAME	GP2013
D07CPM	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
D07CPM	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D07CPM	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
D07CPM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D05HZJ	TTDDRUID	D05HZJ
D05HZJ	DRUGNAME	GPC-3298306
D05HZJ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D01XFZ	TTDDRUID	D01XFZ
D01XFZ	DRUGNAME	GPD-1116
D01XFZ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D09RMU	TTDDRUID	D09RMU
D09RMU	DRUGNAME	GPI-0100
D09RMU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0N0AR	TTDDRUID	D0N0AR
D0N0AR	DRUGNAME	GPI-1485
D0N0AR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D07QIT	TTDDRUID	D07QIT
D07QIT	DRUGNAME	GPX-150D
D07QIT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D07QIT	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2

D05OIO	TTDDRUID	D05OIO
D05OIO	DRUGNAME	Granexin Gel
D05OIO	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
D05OIO	INDICATI	Keloidal surgical scar [ICD-11: EL50.0] Phase 2
D05OIO	INDICATI	Radiation syndrome [ICD-11: NF00] Phase 3

D0F2KX	TTDDRUID	D0F2KX
D0F2KX	DRUGNAME	Granotapide
D0F2KX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0GA7H	TTDDRUID	D0GA7H
D0GA7H	DRUGNAME	Grass peptide allergy desensitization agent
D0GA7H	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0A3EX	TTDDRUID	D0A3EX
D0A3EX	DRUGNAME	GRC-15300
D0A3EX	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0P2ED	TTDDRUID	D0P2ED
D0P2ED	DRUGNAME	GRC-17536
D0P2ED	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D06BKH	TTDDRUID	D06BKH
D06BKH	DRUGNAME	GR-MD-02
D06BKH	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D06BKH	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D0Y5MY	TTDDRUID	D0Y5MY
D0Y5MY	DRUGNAME	GRN1005
D0Y5MY	INDICATI	Brain metastases [ICD-11: 2D50] Phase 2

D0I6RI	TTDDRUID	D0I6RI
D0I6RI	DRUGNAME	GRNVAC1
D0I6RI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D04SRO	TTDDRUID	D04SRO
D04SRO	DRUGNAME	GRT-3983Y
D04SRO	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D0H0KH	TTDDRUID	D0H0KH
D0H0KH	DRUGNAME	GS-4059
D0H0KH	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
D0H0KH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0T5NB	TTDDRUID	D0T5NB
D0T5NB	DRUGNAME	GS-4774
D0T5NB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0D0OT	TTDDRUID	D0D0OT
D0D0OT	DRUGNAME	GS-4977
D0D0OT	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0RN3S	TTDDRUID	D0RN3S
D0RN3S	DRUGNAME	GS-4997
D0RN3S	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
D0RN3S	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0WL0Q	TTDDRUID	D0WL0Q
D0WL0Q	DRUGNAME	GS-5745
D0WL0Q	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D0WL0Q	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D0WL0Q	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0WL0Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D0WL0Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
D0WL0Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3

D0QY1M	TTDDRUID	D0QY1M
D0QY1M	DRUGNAME	GS-5806
D0QY1M	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D09KTI	TTDDRUID	D09KTI
D09KTI	DRUGNAME	GS-5816
D09KTI	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D06LUZ	TTDDRUID	D06LUZ
D06LUZ	DRUGNAME	GS-5885
D06LUZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D09NCU	TTDDRUID	D09NCU
D09NCU	DRUGNAME	GS-6624
D09NCU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0D1BR	TTDDRUID	D0D1BR
D0D1BR	DRUGNAME	GS-7340
D0D1BR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D05TKB	TTDDRUID	D05TKB
D05TKB	DRUGNAME	GS-9256
D05TKB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D02HTD	TTDDRUID	D02HTD
D02HTD	DRUGNAME	GS-9451
D02HTD	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D08JWC	TTDDRUID	D08JWC
D08JWC	DRUGNAME	GS-9620
D08JWC	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
D08JWC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0W1JJ	TTDDRUID	D0W1JJ
D0W1JJ	DRUGNAME	GS-9669
D0W1JJ	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D07TYE	TTDDRUID	D07TYE
D07TYE	DRUGNAME	GS-9857
D07TYE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0BW6F	TTDDRUID	D0BW6F
D0BW6F	DRUGNAME	GS-9876
D0BW6F	INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
D0BW6F	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0G9AW	TTDDRUID	D0G9AW
D0G9AW	DRUGNAME	GS-9973
D0G9AW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0G9AW	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
D0G9AW	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2

D0D0OC	TTDDRUID	D0D0OC
D0D0OC	DRUGNAME	G-series prophage vaccine
D0D0OC	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D0R1SV	TTDDRUID	D0R1SV
D0R1SV	DRUGNAME	GSK1014802
D0R1SV	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2

D06XDS	TTDDRUID	D06XDS
D06XDS	DRUGNAME	GSK-1070806
D06XDS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D00EMB	TTDDRUID	D00EMB
D00EMB	DRUGNAME	GSK-1247446A
D00EMB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D08LDB	TTDDRUID	D08LDB
D08LDB	DRUGNAME	GSK1265744
D08LDB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0F6JC	TTDDRUID	D0F6JC
D0F6JC	DRUGNAME	GSK1278863
D0F6JC	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
D0F6JC	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1

D0S4II	TTDDRUID	D0S4II
D0S4II	DRUGNAME	GSK1292263
D0S4II	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D0S4II	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0S7BQ	TTDDRUID	D0S7BQ
D0S7BQ	DRUGNAME	GSK1322322
D0S7BQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0R7XD	TTDDRUID	D0R7XD
D0R7XD	DRUGNAME	GSK1325756
D0R7XD	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0J1GA	TTDDRUID	D0J1GA
D0J1GA	DRUGNAME	GSK-1399686
D0J1GA	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D02NXM	TTDDRUID	D02NXM
D02NXM	DRUGNAME	GSK2110183
D02NXM	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0R9US	TTDDRUID	D0R9US
D0R9US	DRUGNAME	GSK2140944
D0R9US	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D01NEC	TTDDRUID	D01NEC
D01NEC	DRUGNAME	GSK2141795
D01NEC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D01NEC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D03SVG	TTDDRUID	D03SVG
D03SVG	DRUGNAME	GSK-2189242A
D03SVG	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2

D03STV	TTDDRUID	D03STV
D03STV	DRUGNAME	GSK-2197870A
D03STV	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D02NDC	TTDDRUID	D02NDC
D02NDC	DRUGNAME	GSK-2202083A
D02NDC	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D04PAU	TTDDRUID	D04PAU
D04PAU	DRUGNAME	GSK2245035
D04PAU	INDICATI	Asthma [ICD-11: CA23] Phase 2

D04JNI	TTDDRUID	D04JNI
D04JNI	DRUGNAME	GSK2245840
D04JNI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D00NXM	TTDDRUID	D00NXM
D00NXM	DRUGNAME	GSK-2251052
D00NXM	INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2

D06YRR	TTDDRUID	D06YRR
D06YRR	DRUGNAME	GSK2254233A
D06YRR	INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2
D06YRR	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 1
D06YRR	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2

D06GUA	TTDDRUID	D06GUA
D06GUA	DRUGNAME	GSK2269557
D06GUA	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0X0SK	TTDDRUID	D0X0SK
D0X0SK	DRUGNAME	GSK-2302025A
D0X0SK	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0B2HC	TTDDRUID	D0B2HC
D0B2HC	DRUGNAME	GSK-2302032A
D0B2HC	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0X8CH	TTDDRUID	D0X8CH
D0X8CH	DRUGNAME	GSK2330672
D0X8CH	INDICATI	Pruritus [ICD-11: EC90] Phase 2
D0X8CH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0K4JQ	TTDDRUID	D0K4JQ
D0K4JQ	DRUGNAME	GSK2336805
D0K4JQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D05KXJ	TTDDRUID	D05KXJ
D05KXJ	DRUGNAME	GSK233705
D05KXJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D00EJP	TTDDRUID	D00EJP
D00EJP	DRUGNAME	GSK2339345
D00EJP	INDICATI	Cough [ICD-11: MD12] Phase 2

D07IEC	TTDDRUID	D07IEC
D07IEC	DRUGNAME	GSK2340273A
D07IEC	INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2

D07YGH	TTDDRUID	D07YGH
D07YGH	DRUGNAME	GSK239512
D07YGH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D07YGH	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2

D09HFL	TTDDRUID	D09HFL
D09HFL	DRUGNAME	GSK2398852 + GSK2315698
D09HFL	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 2

D0JP8D	TTDDRUID	D0JP8D
D0JP8D	DRUGNAME	GSK249320
D0JP8D	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D04ODO	TTDDRUID	D04ODO
D04ODO	DRUGNAME	GSK-256073
D04ODO	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0S9LK	TTDDRUID	D0S9LK
D0S9LK	DRUGNAME	GSK-2584786A
D0S9LK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D06HZA	TTDDRUID	D06HZA
D06HZA	DRUGNAME	GSK2586184
D06HZA	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D0ET2T	TTDDRUID	D0ET2T
D0ET2T	DRUGNAME	GSK2586881
D0ET2T	INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2
D0ET2T	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1

D09BTH	TTDDRUID	D09BTH
D09BTH	DRUGNAME	GSK2696266
D09BTH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0P6LE	TTDDRUID	D0P6LE
D0P6LE	DRUGNAME	GSK2696274
D0P6LE	INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2

D0OU6W	TTDDRUID	D0OU6W
D0OU6W	DRUGNAME	GSK2696275
D0OU6W	INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 2

D07HSR	TTDDRUID	D07HSR
D07HSR	DRUGNAME	GSK2798745
D07HSR	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0I1FU	TTDDRUID	D0I1FU
D0I1FU	DRUGNAME	GSK2830930A
D0I1FU	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2

D0BD5J	TTDDRUID	D0BD5J
D0BD5J	DRUGNAME	GSK2838497A
D0BD5J	INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2

D09AGG	TTDDRUID	D09AGG
D09AGG	DRUGNAME	GSK2890457
D09AGG	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D03DMB	TTDDRUID	D03DMB
D03DMB	DRUGNAME	GSK2894512
D03DMB	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D03DMB	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D0PC9R	TTDDRUID	D0PC9R
D0PC9R	DRUGNAME	GSK2941266
D0PC9R	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0BF4Z	TTDDRUID	D0BF4Z
D0BF4Z	DRUGNAME	GSK2981278
D0BF4Z	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D0LQ3L	TTDDRUID	D0LQ3L
D0LQ3L	DRUGNAME	GSK2982772
D0LQ3L	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D0LQ3L	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
D0LQ3L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0LQ3L	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D0L7TN	TTDDRUID	D0L7TN
D0L7TN	DRUGNAME	GSK3003891A
D0L7TN	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D0C4YQ	TTDDRUID	D0C4YQ
D0C4YQ	DRUGNAME	GSK315234
D0C4YQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0CF9E	TTDDRUID	D0CF9E
D0CF9E	DRUGNAME	GSK-315234A
D0CF9E	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0C7ZB	TTDDRUID	D0C7ZB
D0C7ZB	DRUGNAME	GSK3196165
D0C7ZB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D08FWJ	TTDDRUID	D08FWJ
D08FWJ	DRUGNAME	GSK3377794
D08FWJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D08FWJ	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
D08FWJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D08FWJ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D08FWJ	INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 2

D09WYL	TTDDRUID	D09WYL
D09WYL	DRUGNAME	GSK-557296
D09WYL	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 2

D0ZC0M	TTDDRUID	D0ZC0M
D0ZC0M	DRUGNAME	GSK561679
D0ZC0M	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D0ZC0M	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D03RIO	TTDDRUID	D03RIO
D03RIO	DRUGNAME	GSK598809
D03RIO	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Phase 2

D0T3QR	TTDDRUID	D0T3QR
D0T3QR	DRUGNAME	GSK679586
D0T3QR	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0K1WT	TTDDRUID	D0K1WT
D0K1WT	DRUGNAME	GSK-679586A
D0K1WT	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0C9XA	TTDDRUID	D0C9XA
D0C9XA	DRUGNAME	GSK683699
D0C9XA	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D08IYF	TTDDRUID	D08IYF
D08IYF	DRUGNAME	GSK-692342
D08IYF	INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2

D0UV4H	TTDDRUID	D0UV4H
D0UV4H	DRUGNAME	GSK-706769
D0UV4H	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0F5WX	TTDDRUID	D0F5WX
D0F5WX	DRUGNAME	GSK768974
D0F5WX	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D03PKL	TTDDRUID	D03PKL
D03PKL	DRUGNAME	GSK933776
D03PKL	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D0T6KV	TTDDRUID	D0T6KV
D0T6KV	DRUGNAME	GSK933776A
D0T6KV	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0GP8P	TTDDRUID	D0GP8P
D0GP8P	DRUGNAME	GSK961081
D0GP8P	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0O3DK	TTDDRUID	D0O3DK
D0O3DK	DRUGNAME	GTP-010
D0O3DK	INDICATI	Dyspepsia [ICD-11: MD92] Phase 2
D0O3DK	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D03RFK	TTDDRUID	D03RFK
D03RFK	DRUGNAME	GTP-200
D03RFK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0ZC3C	TTDDRUID	D0ZC3C
D0ZC3C	DRUGNAME	GTS-21
D0ZC3C	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0M3SS	TTDDRUID	D0M3SS
D0M3SS	DRUGNAME	GTU-based DNA vaccine
D0M3SS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0E7FM	TTDDRUID	D0E7FM
D0E7FM	DRUGNAME	GTx-758
D0E7FM	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D03OSE	TTDDRUID	D03OSE
D03OSE	DRUGNAME	GVAX Multiple
D03OSE	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0J4PB	TTDDRUID	D0J4PB
D0J4PB	DRUGNAME	GW 597599
D0J4PB	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D05QJT	TTDDRUID	D05QJT
D05QJT	DRUGNAME	GW274150
D05QJT	INDICATI	Asthma [ICD-11: CA23] Phase 2

D08BBU	TTDDRUID	D08BBU
D08BBU	DRUGNAME	GW-42003
D08BBU	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D05BMC	TTDDRUID	D05BMC
D05BMC	DRUGNAME	GW-42004
D05BMC	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2

D0A5EF	TTDDRUID	D0A5EF
D0A5EF	DRUGNAME	GW-427353
D0A5EF	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2

D0ID3W	TTDDRUID	D0ID3W
D0ID3W	DRUGNAME	GW-813893
D0ID3W	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D0M8VL	TTDDRUID	D0M8VL
D0M8VL	DRUGNAME	GW-870086-X
D0M8VL	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0LR4Q	TTDDRUID	D0LR4Q
D0LR4Q	DRUGNAME	GZ402671
D0LR4Q	INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 2
D0LR4Q	INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Phase 1

D04SBI	TTDDRUID	D04SBI
D04SBI	DRUGNAME	H.P. Acthar Gel (repository corticotropin injection) Gel
D04SBI	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D08ZPO	TTDDRUID	D08ZPO
D08ZPO	DRUGNAME	H-1152
D08ZPO	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D02FPT	TTDDRUID	D02FPT
D02FPT	DRUGNAME	H5N1 influenza vaccine
D02FPT	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D08PSI	TTDDRUID	D08PSI
D08PSI	DRUGNAME	H5N1 influenza vaccine
D08PSI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0Y5VR	TTDDRUID	D0Y5VR
D0Y5VR	DRUGNAME	H5N1 influenza vaccine
D0Y5VR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0Z9AV	TTDDRUID	D0Z9AV
D0Z9AV	DRUGNAME	H5N1 vaccine
D0Z9AV	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0GM8E	TTDDRUID	D0GM8E
D0GM8E	DRUGNAME	Haemophilus recombinant vaccine
D0GM8E	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D02SVQ	TTDDRUID	D02SVQ
D02SVQ	DRUGNAME	HBI-3000
D02SVQ	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1
D02SVQ	INDICATI	Heart arrhythmia [ICD-11: BC65] Phase 2

D0QW0E	TTDDRUID	D0QW0E
D0QW0E	DRUGNAME	HBV infection vaccine
D0QW0E	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0Q1XV	TTDDRUID	D0Q1XV
D0Q1XV	DRUGNAME	HBV vaccine
D0Q1XV	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D07ZMQ	TTDDRUID	D07ZMQ
D07ZMQ	DRUGNAME	HD-003
D07ZMQ	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2

D05DQR	TTDDRUID	D05DQR
D05DQR	DRUGNAME	HDV-interferon
D05DQR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0N3IA	TTDDRUID	D0N3IA
D0N3IA	DRUGNAME	HE3235
D0N3IA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D08QYS	TTDDRUID	D08QYS
D08QYS	DRUGNAME	Heat shock protein vaccine
D08QYS	INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 2

D03HAW	TTDDRUID	D03HAW
D03HAW	DRUGNAME	HemaMax
D03HAW	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D07OJB	TTDDRUID	D07OJB
D07OJB	DRUGNAME	Hemporfin photodynamic therapy
D07OJB	INDICATI	Vasculitis [ICD-11: 4A44] Phase 2

D05XZQ	TTDDRUID	D05XZQ
D05XZQ	DRUGNAME	HepaStem
D05XZQ	INDICATI	Liver failure [ICD-11: DB99.7] Phase 2

D09TUW	TTDDRUID	D09TUW
D09TUW	DRUGNAME	Hepatitis C vaccine
D09TUW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D00GOH	TTDDRUID	D00GOH
D00GOH	DRUGNAME	HepeX-B
D00GOH	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2

D0C3LL	TTDDRUID	D0C3LL
D0C3LL	DRUGNAME	HER1-VSSP vaccine
D0C3LL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04PMS	TTDDRUID	D04PMS
D04PMS	DRUGNAME	HER2 antigen-specific cancer immunotherapeutic
D04PMS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D09XHU	TTDDRUID	D09XHU
D09XHU	DRUGNAME	HER-2 Protein AutoVac
D09XHU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0QF7Z	TTDDRUID	D0QF7Z
D0QF7Z	DRUGNAME	HER2/neu peptide vaccine
D0QF7Z	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0B1TL	TTDDRUID	D0B1TL
D0B1TL	DRUGNAME	Her2-targeted autologous T-cell therapy
D0B1TL	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D08LXJ	TTDDRUID	D08LXJ
D08LXJ	DRUGNAME	Heterologous liver cell therapy
D08LXJ	INDICATI	Urea cycle disorder [ICD-11: 5C50.A] Phase 2

D02AOD	TTDDRUID	D02AOD
D02AOD	DRUGNAME	HF-0220
D02AOD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D07OIR	TTDDRUID	D07OIR
D07OIR	DRUGNAME	HF-10
D07OIR	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D07OIR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0C9AM	TTDDRUID	D0C9AM
D0C9AM	DRUGNAME	H-Gly-PMe-Glu-OH
D0C9AM	INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2
D0C9AM	INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 2
D0C9AM	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2

D0E5RA	TTDDRUID	D0E5RA
D0E5RA	DRUGNAME	HGT-1111
D0E5RA	INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2

D0Q5BK	TTDDRUID	D0Q5BK
D0Q5BK	DRUGNAME	HGT-1410
D0Q5BK	INDICATI	Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 2

D0JZ8X	TTDDRUID	D0JZ8X
D0JZ8X	DRUGNAME	HGTV43
D0JZ8X	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
D0JZ8X	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0R6VH	TTDDRUID	D0R6VH
D0R6VH	DRUGNAME	HI-1640V
D0R6VH	INDICATI	Asthma [ICD-11: CA23] Phase 2

D06RNK	TTDDRUID	D06RNK
D06RNK	DRUGNAME	Hi8 HBV vaccine
D06RNK	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2

D04HMK	TTDDRUID	D04HMK
D04HMK	DRUGNAME	Hi8 melanoma vaccine
D04HMK	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0A9BI	TTDDRUID	D0A9BI
D0A9BI	DRUGNAME	Hi-8 PrimeBoost therapeutic melanoma vaccine
D0A9BI	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D09RMZ	TTDDRUID	D09RMZ
D09RMZ	DRUGNAME	HibTITER
D09RMZ	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2

D0W8YY	TTDDRUID	D0W8YY
D0W8YY	DRUGNAME	HI-con1
D0W8YY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0ZP2E	TTDDRUID	D0ZP2E
D0ZP2E	DRUGNAME	HinsBet
D0ZP2E	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 2

D0JV8Z	TTDDRUID	D0JV8Z
D0JV8Z	DRUGNAME	HIV recombinant proteins vaccine
D0JV8Z	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0Y7YB	TTDDRUID	D0Y7YB
D0Y7YB	DRUGNAME	HIV recombinant vaccine
D0Y7YB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D05KLQ	TTDDRUID	D05KLQ
D05KLQ	DRUGNAME	HIV vaccines
D05KLQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0H2EM	TTDDRUID	D0H2EM
D0H2EM	DRUGNAME	HIV-1 vaccine
D0H2EM	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D07PFG	TTDDRUID	D07PFG
D07PFG	DRUGNAME	HL-009
D07PFG	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0V0AR	TTDDRUID	D0V0AR
D0V0AR	DRUGNAME	HLA-A, B7.1-transfected adenocarcinoma vaccine
D0V0AR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D09MPO	TTDDRUID	D09MPO
D09MPO	DRUGNAME	HLD100
D09MPO	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D0R0YW	TTDDRUID	D0R0YW
D0R0YW	DRUGNAME	HM-5016504
D0R0YW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00YER	TTDDRUID	D00YER
D00YER	DRUGNAME	HM-78136B
D00YER	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 2
D00YER	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D00YER	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0O3XU	TTDDRUID	D0O3XU
D0O3XU	DRUGNAME	HO/03/03
D0O3XU	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D07DPM	TTDDRUID	D07DPM
D07DPM	DRUGNAME	HP-011-101
D07DPM	INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2

D02TIK	TTDDRUID	D02TIK
D02TIK	DRUGNAME	HP-184
D02TIK	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D09ZKS	TTDDRUID	D09ZKS
D09ZKS	DRUGNAME	HP-228
D09ZKS	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 2

D0A0SK	TTDDRUID	D0A0SK
D0A0SK	DRUGNAME	HPH-116
D0A0SK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D06VLI	TTDDRUID	D06VLI
D06VLI	DRUGNAME	HPPH photodynamic therapy
D06VLI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0D4VN	TTDDRUID	D0D4VN
D0D4VN	DRUGNAME	HPV-16 E7 vaccine
D0D4VN	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2

D0E6SB	TTDDRUID	D0E6SB
D0E6SB	DRUGNAME	HQK-1001
D0E6SB	INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 2

D05RRA	TTDDRUID	D05RRA
D05RRA	DRUGNAME	HQK-1004
D05RRA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0F3EO	TTDDRUID	D0F3EO
D0F3EO	DRUGNAME	HS-110
D0F3EO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0M1II	TTDDRUID	D0M1II
D0M1II	DRUGNAME	HS-25
D0M1II	INDICATI	Hyperbilirubinemia [ICD-11: 5C58] Phase 2

D0LO2G	TTDDRUID	D0LO2G
D0LO2G	DRUGNAME	HSRx-888
D0LO2G	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D07OCV	TTDDRUID	D07OCV
D07OCV	DRUGNAME	HT-0712
D07OCV	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0U3KP	TTDDRUID	D0U3KP
D0U3KP	DRUGNAME	HT-100
D0U3KP	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0CQ1X	TTDDRUID	D0CQ1X
D0CQ1X	DRUGNAME	HTERT RNA vaccine
D0CQ1X	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D01VWD	TTDDRUID	D01VWD
D01VWD	DRUGNAME	HTI-101
D01VWD	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0YB3N	TTDDRUID	D0YB3N
D0YB3N	DRUGNAME	HTNV + PUUV DNA vaccine
D0YB3N	INDICATI	Hemorrhagic fever [ICD-11: 1D61] Phase 2

D06KLD	TTDDRUID	D06KLD
D06KLD	DRUGNAME	HTS-519 insert
D06KLD	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D04OZL	TTDDRUID	D04OZL
D04OZL	DRUGNAME	Hu3S193
D04OZL	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2

D05XDX	TTDDRUID	D05XDX
D05XDX	DRUGNAME	HuCAL-derived fully human antibodies
D05XDX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0K2KS	TTDDRUID	D0K2KS
D0K2KS	DRUGNAME	HuCNS-SC
D0K2KS	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 2

D0ZW8B	TTDDRUID	D0ZW8B
D0ZW8B	DRUGNAME	Human anti-rabies mab
D0ZW8B	INDICATI	Rabies [ICD-11: 1C82] Phase 2

D0N7XW	TTDDRUID	D0N7XW
D0N7XW	DRUGNAME	Human enterovirus 71 vaccine
D0N7XW	INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 2

D0NK8M	TTDDRUID	D0NK8M
D0NK8M	DRUGNAME	Human heterologous liver cells
D0NK8M	INDICATI	Urea cycle disorder [ICD-11: 5C50.A] Phase 2

D00QGV	TTDDRUID	D00QGV
D00QGV	DRUGNAME	Human interferon alpha oral
D00QGV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D04OJM	TTDDRUID	D04OJM
D04OJM	DRUGNAME	Human interleukin-2
D04OJM	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D05DWM	TTDDRUID	D05DWM
D05DWM	DRUGNAME	Hydrocortisone modified release capsules
D05DWM	INDICATI	Congenital adrenal hyperplasia [ICD-11: 5A71.01] Phase 2

D02SQJ	TTDDRUID	D02SQJ
D02SQJ	DRUGNAME	HyperAcute Melanoma
D02SQJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D07IUN	TTDDRUID	D07IUN
D07IUN	DRUGNAME	HyperAcute vaccine
D07IUN	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0SA3J	TTDDRUID	D0SA3J
D0SA3J	DRUGNAME	Ibrolipim
D0SA3J	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D03QJL	TTDDRUID	D03QJL
D03QJL	DRUGNAME	Ibudilast
D03QJL	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D03QJL	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
D03QJL	INDICATI	Methamphetamine dependence [ICD-11: 6C46.2] Phase 2
D03QJL	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D03QJL	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D07RST	TTDDRUID	D07RST
D07RST	DRUGNAME	Ibuprofenamine
D07RST	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D0UB5A	TTDDRUID	D0UB5A
D0UB5A	DRUGNAME	IC14
D0UB5A	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2

D0X9LC	TTDDRUID	D0X9LC
D0X9LC	DRUGNAME	IC-41
D0X9LC	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2

D09USN	TTDDRUID	D09USN
D09USN	DRUGNAME	IC-485
D09USN	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D08OJF	TTDDRUID	D08OJF
D08OJF	DRUGNAME	ICA-105665
D08OJF	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2

D00BUR	TTDDRUID	D00BUR
D00BUR	DRUGNAME	ICA-17043
D00BUR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D00BUR	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2

D0L0BX	TTDDRUID	D0L0BX
D0L0BX	DRUGNAME	ICARITIN
D0L0BX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D01YGD	TTDDRUID	D01YGD
D01YGD	DRUGNAME	ICO-25
D01YGD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D09XUY	TTDDRUID	D09XUY
D09XUY	DRUGNAME	Icofungipen
D09XUY	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
D09XUY	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D0GL0Q	TTDDRUID	D0GL0Q
D0GL0Q	DRUGNAME	ICX-RHY
D0GL0Q	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2

D01KQW	TTDDRUID	D01KQW
D01KQW	DRUGNAME	ID-93/GLA-SE
D01KQW	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D02COS	TTDDRUID	D02COS
D02COS	DRUGNAME	IdB-1016
D02COS	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2

D03QMY	TTDDRUID	D03QMY
D03QMY	DRUGNAME	IDM-2101
D03QMY	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D07RDU	TTDDRUID	D07RDU
D07RDU	DRUGNAME	IDP-107
D07RDU	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0N0PW	TTDDRUID	D0N0PW
D0N0PW	DRUGNAME	IDP-113
D0N0PW	INDICATI	Tinea pedis [ICD-11: 1F28.2] Phase 2

D0IV7F	TTDDRUID	D0IV7F
D0IV7F	DRUGNAME	IDP-115
D0IV7F	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D0X2LB	TTDDRUID	D0X2LB
D0X2LB	DRUGNAME	IDP-120 gel
D0X2LB	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0FS3H	TTDDRUID	D0FS3H
D0FS3H	DRUGNAME	IDP-126 gel
D0FS3H	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D02SPX	TTDDRUID	D02SPX
D02SPX	DRUGNAME	IDX899
D02SPX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0B2WK	TTDDRUID	D0B2WK
D0B2WK	DRUGNAME	Ifetroban sodium
D0B2WK	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D02JDN	TTDDRUID	D02JDN
D02JDN	DRUGNAME	IFN-alpha
D02JDN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
D02JDN	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D0YB7P	TTDDRUID	D0YB7P
D0YB7P	DRUGNAME	IFN-Kinoid
D0YB7P	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D05YWJ	TTDDRUID	D05YWJ
D05YWJ	DRUGNAME	IFX-1
D05YWJ	INDICATI	Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2

D0N5LJ	TTDDRUID	D0N5LJ
D0N5LJ	DRUGNAME	Igmesine
D0N5LJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
D0N5LJ	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1
D0N5LJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0B0NH	TTDDRUID	D0B0NH
D0B0NH	DRUGNAME	IK-5001
D0B0NH	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2

D05RRU	TTDDRUID	D05RRU
D05RRU	DRUGNAME	IL-2/CD40L-expressing leukemia vaccine
D05RRU	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D07JWO	TTDDRUID	D07JWO
D07JWO	DRUGNAME	IL-21
D07JWO	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0Q1RN	TTDDRUID	D0Q1RN
D0Q1RN	DRUGNAME	IL22-Fc
D0Q1RN	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D0PR4O	TTDDRUID	D0PR4O
D0PR4O	DRUGNAME	Ilixadencel
D0PR4O	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0O5ZB	TTDDRUID	D0O5ZB
D0O5ZB	DRUGNAME	Ilodecakin
D0O5ZB	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2

D0Z3EV	TTDDRUID	D0Z3EV
D0Z3EV	DRUGNAME	Imbruvicaibrutinib
D0Z3EV	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
D0Z3EV	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D0Z3EV	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
D0Z3EV	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 3
D0Z3EV	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
D0Z3EV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
D0Z3EV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00UYR	TTDDRUID	D00UYR
D00UYR	DRUGNAME	IMC-1
D00UYR	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2

D0S0BJ	TTDDRUID	D0S0BJ
D0S0BJ	DRUGNAME	IMCgp100
D0S0BJ	INDICATI	Cutaneous melanoma [ICD-11: 2C30] Phase 2
D0S0BJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0X4YJ	TTDDRUID	D0X4YJ
D0X4YJ	DRUGNAME	ImCOOH
D0X4YJ	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0V3CK	TTDDRUID	D0V3CK
D0V3CK	DRUGNAME	IMD-1041
D0V3CK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D08PMB	TTDDRUID	D08PMB
D08PMB	DRUGNAME	Imeglimin
D08PMB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0Z5XT	TTDDRUID	D0Z5XT
D0Z5XT	DRUGNAME	Imexon
D0Z5XT	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D03EOZ	TTDDRUID	D03EOZ
D03EOZ	DRUGNAME	IMG-7289
D03EOZ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D03EOZ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D03EOZ	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1/2

D0C0LO	TTDDRUID	D0C0LO
D0C0LO	DRUGNAME	IMGN529
D0C0LO	INDICATI	Metastatic non-hodgkin's lymphoma [ICD-11: 2B33.5] Phase 1
D0C0LO	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D09THN	TTDDRUID	D09THN
D09THN	DRUGNAME	IMGN901
D09THN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08PRP	TTDDRUID	D08PRP
D08PRP	DRUGNAME	IMGX003
D08PRP	INDICATI	Coeliac disease [ICD-11: DA95] Phase 2

D07TJT	TTDDRUID	D07TJT
D07TJT	DRUGNAME	Imilecleucel-T
D07TJT	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D00OYQ	TTDDRUID	D00OYQ
D00OYQ	DRUGNAME	Imisopasem manganese
D00OYQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D04NRV	TTDDRUID	D04NRV
D04NRV	DRUGNAME	IMM-101
D04NRV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02OME	TTDDRUID	D02OME
D02OME	DRUGNAME	IMMU-132
D02OME	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 2

D0Q1MX	TTDDRUID	D0Q1MX
D0Q1MX	DRUGNAME	ImmunoPulse IL-12
D0Q1MX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00AKL	TTDDRUID	D00AKL
D00AKL	DRUGNAME	Immunose FLU
D00AKL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0W6HO	TTDDRUID	D0W6HO
D0W6HO	DRUGNAME	IMO-2055
D0W6HO	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D0W6HO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0I0XF	TTDDRUID	D0I0XF
D0I0XF	DRUGNAME	IMO-8400
D0I0XF	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D0I0XF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0I0XF	INDICATI	Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 1/2

D0F6YK	TTDDRUID	D0F6YK
D0F6YK	DRUGNAME	Implitapide
D0F6YK	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0H0YD	TTDDRUID	D0H0YD
D0H0YD	DRUGNAME	Impoyz
D0H0YD	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D02XKC	TTDDRUID	D02XKC
D02XKC	DRUGNAME	Imvamune
D02XKC	INDICATI	Smallpox [ICD-11: 1E70] Phase 3

D09AFI	TTDDRUID	D09AFI
D09AFI	DRUGNAME	INCB039110
D09AFI	INDICATI	Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 2
D09AFI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0G7MV	TTDDRUID	D0G7MV
D0G7MV	DRUGNAME	INCB24360
D0G7MV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07OJZ	TTDDRUID	D07OJZ
D07OJZ	DRUGNAME	INCB28060
D07OJZ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D07OJZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D07OJZ	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D07RHP	TTDDRUID	D07RHP
D07RHP	DRUGNAME	INCB50465
D07RHP	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D07RHP	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
D07RHP	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
D07RHP	INDICATI	Marginal zone lymphoma [ICD-11: 2A85.0] Phase 2

D0HJ1R	TTDDRUID	D0HJ1R
D0HJ1R	DRUGNAME	INCB54707
D0HJ1R	INDICATI	Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2

D0O6UY	TTDDRUID	D0O6UY
D0O6UY	DRUGNAME	INCB54828
D0O6UY	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0O6UY	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
D0O6UY	INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Phase 2

D00CQI	TTDDRUID	D00CQI
D00CQI	DRUGNAME	Indatuximab ravtansine
D00CQI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D00CQI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D04NXL	TTDDRUID	D04NXL
D04NXL	DRUGNAME	Indibulin
D04NXL	INDICATI	Advanced sarcoma [ICD-11: 2A60-2C35] Phase 2

D04IIU	TTDDRUID	D04IIU
D04IIU	DRUGNAME	INDISULAM
D04IIU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D0XH3V	TTDDRUID	D0XH3V
D0XH3V	DRUGNAME	Inebilizumab
D0XH3V	INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 2

D0R8IE	TTDDRUID	D0R8IE
D0R8IE	DRUGNAME	Inecalcitol oral
D0R8IE	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0R8IE	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0C0DY	TTDDRUID	D0C0DY
D0C0DY	DRUGNAME	Influenza A virus H7N9 vaccine
D0C0DY	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
D0C0DY	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D07AUI	TTDDRUID	D07AUI
D07AUI	DRUGNAME	Influenza A virus vaccine H5N1
D07AUI	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 2
D07AUI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D05ELY	TTDDRUID	D05ELY
D05ELY	DRUGNAME	Influenza A virus vaccine H9N2
D05ELY	INDICATI	Influenza A virus H9N2 infection [ICD-11: 1E30] Phase 2

D0LR1W	TTDDRUID	D0LR1W
D0LR1W	DRUGNAME	Influenza virus vaccine quadrivalent
D0LR1W	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
D0LR1W	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 3

D0EY1E	TTDDRUID	D0EY1E
D0EY1E	DRUGNAME	Influsome-Vac
D0EY1E	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0N4VN	TTDDRUID	D0N4VN
D0N4VN	DRUGNAME	INGAP peptide
D0N4VN	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2

D0V2SP	TTDDRUID	D0V2SP
D0V2SP	DRUGNAME	INGN-225
D0V2SP	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D02FTV	TTDDRUID	D02FTV
D02FTV	DRUGNAME	INGN-241
D02FTV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00UXD	TTDDRUID	D00UXD
D00UXD	DRUGNAME	Inhaled alprazolam
D00UXD	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2

D06VES	TTDDRUID	D06VES
D06VES	DRUGNAME	Inhaled lipid-complexed cisplatin
D06VES	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2

D00FCV	TTDDRUID	D00FCV
D00FCV	DRUGNAME	Inhaled liposomal ciprofloxacin
D00FCV	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D03DPZ	TTDDRUID	D03DPZ
D03DPZ	DRUGNAME	INK128
D03DPZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D03DPZ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0H1MK	TTDDRUID	D0H1MK
D0H1MK	DRUGNAME	INN-202
D0H1MK	INDICATI	Coeliac disease [ICD-11: DA95] Phase 2

D00CZL	TTDDRUID	D00CZL
D00CZL	DRUGNAME	INNO-206
D00CZL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0P2ME	TTDDRUID	D0P2ME
D0P2ME	DRUGNAME	INO-5401
D0P2ME	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0P2ME	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0I6LN	TTDDRUID	D0I6LN
D0I6LN	DRUGNAME	INP103
D0I6LN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D01JMX	TTDDRUID	D01JMX
D01JMX	DRUGNAME	INS-1
D01JMX	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2

D07QQP	TTDDRUID	D07QQP
D07QQP	DRUGNAME	INS-37217
D07QQP	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0W4JI	TTDDRUID	D0W4JI
D0W4JI	DRUGNAME	INS-50589
D0W4JI	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D07CNY	TTDDRUID	D07CNY
D07CNY	DRUGNAME	Instiladrin
D07CNY	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D00LJF	TTDDRUID	D00LJF
D00LJF	DRUGNAME	INT0001/2004
D00LJF	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D06QBY	TTDDRUID	D06QBY
D06QBY	DRUGNAME	INT131
D06QBY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D05JFA	TTDDRUID	D05JFA
D05JFA	DRUGNAME	INTERCEPT
D05JFA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2

D00EFO	TTDDRUID	D00EFO
D00EFO	DRUGNAME	Interferon alpha-2b
D00EFO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0U7SU	TTDDRUID	D0U7SU
D0U7SU	DRUGNAME	Interferon-alpha lozenge
D0U7SU	INDICATI	Behcet disease [ICD-11: 4A62] Phase 2
D0U7SU	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
D0U7SU	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2

D0U3AL	TTDDRUID	D0U3AL
D0U3AL	DRUGNAME	Interleukin-12 gene therapy
D0U3AL	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
D0U3AL	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0U3AL	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2

D09WCN	TTDDRUID	D09WCN
D09WCN	DRUGNAME	Intetumumab
D09WCN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D01ZYY	TTDDRUID	D01ZYY
D01ZYY	DRUGNAME	Intranasal apomorphine
D01ZYY	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Phase 2

D0YX5H	TTDDRUID	D0YX5H
D0YX5H	DRUGNAME	Intravenous minocycline
D0YX5H	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2

D0P8UN	TTDDRUID	D0P8UN
D0P8UN	DRUGNAME	INV103
D0P8UN	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D08TQP	TTDDRUID	D08TQP
D08TQP	DRUGNAME	INX-189
D08TQP	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0GI6O	TTDDRUID	D0GI6O
D0GI6O	DRUGNAME	Iodine-124-labeled F-16 scFv antibody
D0GI6O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0MZ2B	TTDDRUID	D0MZ2B
D0MZ2B	DRUGNAME	IODOSTEARIC ACID
D0MZ2B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02FDJ	TTDDRUID	D02FDJ
D02FDJ	DRUGNAME	Ioforminol
D02FDJ	INDICATI	Pulmonary embolism [ICD-11: BB00] Phase 2

D0A0TT	TTDDRUID	D0A0TT
D0A0TT	DRUGNAME	IONIS-AGT-LRX
D0A0TT	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0R0HY	TTDDRUID	D0R0HY
D0R0HY	DRUGNAME	IONIS-DMPK-2.5RX
D0R0HY	INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Phase 2

D01HYQ	TTDDRUID	D01HYQ
D01HYQ	DRUGNAME	IONIS-GCCRRX
D01HYQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0AU9U	TTDDRUID	D0AU9U
D0AU9U	DRUGNAME	IONIS-GCGRRX
D0AU9U	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D07OAO	TTDDRUID	D07OAO
D07OAO	DRUGNAME	IONIS-HTTRX
D07OAO	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2

D0V4XT	TTDDRUID	D0V4XT
D0V4XT	DRUGNAME	IONIS-HTTRX
D0V4XT	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2

D0LI5N	TTDDRUID	D0LI5N
D0LI5N	DRUGNAME	IONIS-PTP1BRX
D0LI5N	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D01SKT	TTDDRUID	D01SKT
D01SKT	DRUGNAME	IONIS-SOD111RX
D01SKT	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D0N4PW	TTDDRUID	D0N4PW
D0N4PW	DRUGNAME	iOWH032
D0N4PW	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2

D0E3HY	TTDDRUID	D0E3HY
D0E3HY	DRUGNAME	IP10 C8
D0E3HY	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D05VCA	TTDDRUID	D05VCA
D05VCA	DRUGNAME	IP10.C8-1
D05VCA	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D05HYT	TTDDRUID	D05HYT
D05HYT	DRUGNAME	IPAZILIDE FUMARATE
D05HYT	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2

D04IXD	TTDDRUID	D04IXD
D04IXD	DRUGNAME	IPH-2101
D04IXD	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D00RYU	TTDDRUID	D00RYU
D00RYU	DRUGNAME	IPH-2102
D00RYU	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0I8CK	TTDDRUID	D0I8CK
D0I8CK	DRUGNAME	IPL-512602
D0I8CK	INDICATI	Asthma [ICD-11: CA23] Phase 2

D05LDK	TTDDRUID	D05LDK
D05LDK	DRUGNAME	IPX203
D05LDK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0Z1CZ	TTDDRUID	D0Z1CZ
D0Z1CZ	DRUGNAME	IR502
D0Z1CZ	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D0Z1CZ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
D0Z1CZ	INDICATI	Psoriatic disorder [ICD-11: EA90] Phase 2

D0X9LK	TTDDRUID	D0X9LK
D0X9LK	DRUGNAME	Iralukast
D0X9LK	INDICATI	Asthma [ICD-11: CA23] Phase 2

D00MBR	TTDDRUID	D00MBR
D00MBR	DRUGNAME	Iratumumab
D00MBR	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D04PEO	TTDDRUID	D04PEO
D04PEO	DRUGNAME	IRT-101
D04PEO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0J5UK	TTDDRUID	D0J5UK
D0J5UK	DRUGNAME	IRT-102
D0J5UK	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0KS6F	TTDDRUID	D0KS6F
D0KS6F	DRUGNAME	IRX-2
D0KS6F	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0KS6F	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0KS6F	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D0KS6F	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D0K8YG	TTDDRUID	D0K8YG
D0K8YG	DRUGNAME	ISA-HPV-01
D0K8YG	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2

D05AAD	TTDDRUID	D05AAD
D05AAD	DRUGNAME	Isatoribine
D05AAD	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D04ELS	TTDDRUID	D04ELS
D04ELS	DRUGNAME	ISCAR
D04ELS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D06ZCP	TTDDRUID	D06ZCP
D06ZCP	DRUGNAME	Ischemic tolerant allogeneic mesenchymal stem cell therapy
D06ZCP	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2

D0HD8X	TTDDRUID	D0HD8X
D0HD8X	DRUGNAME	ISF35
D0HD8X	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D0HD8X	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
D0HD8X	INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 2

D0J1WO	TTDDRUID	D0J1WO
D0J1WO	DRUGNAME	ISIS 113715
D0J1WO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0Y0KY	TTDDRUID	D0Y0KY
D0Y0KY	DRUGNAME	ISIS-APO(a)
D0Y0KY	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0H1TG	TTDDRUID	D0H1TG
D0H1TG	DRUGNAME	ISIS-CRPRx
D0H1TG	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D08HQI	TTDDRUID	D08HQI
D08HQI	DRUGNAME	ISIS-EIF4E
D08HQI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0M1JC	TTDDRUID	D0M1JC
D0M1JC	DRUGNAME	ISIS-EIF4ERx
D0M1JC	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0M1JC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0UJ0D	TTDDRUID	D0UJ0D
D0UJ0D	DRUGNAME	ISIS-FGFR4Rx
D0UJ0D	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0S5PJ	TTDDRUID	D0S5PJ
D0S5PJ	DRUGNAME	ISIS-FXIRx
D0S5PJ	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2

D0J3RP	TTDDRUID	D0J3RP
D0J3RP	DRUGNAME	ISIS-GCCRrx
D0J3RP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0I0EO	TTDDRUID	D0I0EO
D0I0EO	DRUGNAME	ISIS-GCGRrx
D0I0EO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D08NDA	TTDDRUID	D08NDA
D08NDA	DRUGNAME	ISIS-HBV
D08NDA	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0SM6N	TTDDRUID	D0SM6N
D0SM6N	DRUGNAME	ISIS-PTP1Brx
D0SM6N	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0B4WH	TTDDRUID	D0B4WH
D0B4WH	DRUGNAME	Islet Neogenesis Therapy (I.N.T.)
D0B4WH	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D04BQV	TTDDRUID	D04BQV
D04BQV	DRUGNAME	Isofagomine tartrate
D04BQV	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2

D07KWN	TTDDRUID	D07KWN
D07KWN	DRUGNAME	Isosteviol
D07KWN	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 2

D0PW4N	TTDDRUID	D0PW4N
D0PW4N	DRUGNAME	Ispinesib
D0PW4N	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D0PW4N	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0PW4N	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D0PW4N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0P4ZR	TTDDRUID	D0P4ZR
D0P4ZR	DRUGNAME	Istiratumab
D0P4ZR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D09ENR	TTDDRUID	D09ENR
D09ENR	DRUGNAME	Itarnafloxin
D09ENR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0Z0TU	TTDDRUID	D0Z0TU
D0Z0TU	DRUGNAME	ITCA-638
D0Z0TU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0K2RY	TTDDRUID	D0K2RY
D0K2RY	DRUGNAME	Itriglumide
D0K2RY	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D03DAY	TTDDRUID	D03DAY
D03DAY	DRUGNAME	ITV-1
D03DAY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D09TSD	TTDDRUID	D09TSD
D09TSD	DRUGNAME	I-vation
D09TSD	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 2

D04EMB	TTDDRUID	D04EMB
D04EMB	DRUGNAME	IW-1973
D04EMB	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0BT6H	TTDDRUID	D0BT6H
D0BT6H	DRUGNAME	IW-2143
D0BT6H	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0FH5N	TTDDRUID	D0FH5N
D0FH5N	DRUGNAME	IW-6118
D0FH5N	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2

D04SEJ	TTDDRUID	D04SEJ
D04SEJ	DRUGNAME	IW-9179
D04SEJ	INDICATI	Dyspepsia [ICD-11: MD92] Phase 2

D02EEK	TTDDRUID	D02EEK
D02EEK	DRUGNAME	J 591 Lu-177
D02EEK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D02FIC	TTDDRUID	D02FIC
D02FIC	DRUGNAME	JB-004/A
D02FIC	INDICATI	Inner ear disease [ICD-11: AB30-AB37] Phase 2

D0Y5JZ	TTDDRUID	D0Y5JZ
D0Y5JZ	DRUGNAME	JB991
D0Y5JZ	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2

D0K3XB	TTDDRUID	D0K3XB
D0K3XB	DRUGNAME	JCAR015
D0K3XB	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2

D0S9SQ	TTDDRUID	D0S9SQ
D0S9SQ	DRUGNAME	JCAR015
D0S9SQ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
D0S9SQ	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2

D0Z7IW	TTDDRUID	D0Z7IW
D0Z7IW	DRUGNAME	JI-101
D0Z7IW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0RK8U	TTDDRUID	D0RK8U
D0RK8U	DRUGNAME	JKB-122
D0RK8U	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2

D05XUY	TTDDRUID	D05XUY
D05XUY	DRUGNAME	JM216
D05XUY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08UGS	TTDDRUID	D08UGS
D08UGS	DRUGNAME	JNJ 63723283
D08UGS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D08UGS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
D08UGS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D08UGS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
D08UGS	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0O6NA	TTDDRUID	D0O6NA
D0O6NA	DRUGNAME	JNJ-10229570
D0O6NA	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D01YIO	TTDDRUID	D01YIO
D01YIO	DRUGNAME	JNJ-10311795
D01YIO	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0M5WS	TTDDRUID	D0M5WS
D0M5WS	DRUGNAME	JNJ-16269110
D0M5WS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D02REJ	TTDDRUID	D02REJ
D02REJ	DRUGNAME	JNJ-17216498
D02REJ	INDICATI	Narcolepsy [ICD-11: 7A20] Phase 2

D0T8KA	TTDDRUID	D0T8KA
D0T8KA	DRUGNAME	JNJ-18038683
D0T8KA	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0K9KN	TTDDRUID	D0K9KN
D0K9KN	DRUGNAME	JNJ-26113100
D0K9KN	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D09XIZ	TTDDRUID	D09XIZ
D09XIZ	DRUGNAME	JNJ-26481585
D09XIZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0C2KF	TTDDRUID	D0C2KF
D0C2KF	DRUGNAME	JNJ-26489112
D0C2KF	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2

D0C8PE	TTDDRUID	D0C8PE
D0C8PE	DRUGNAME	JNJ-37822681
D0C8PE	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D04VBF	TTDDRUID	D04VBF
D04VBF	DRUGNAME	JNJ-38518168
D04VBF	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D04VBF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0EQ9T	TTDDRUID	D0EQ9T
D0EQ9T	DRUGNAME	JNJ-39220675
D0EQ9T	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2

D02NTS	TTDDRUID	D02NTS
D02NTS	DRUGNAME	JNJ-39393406
D02NTS	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
D02NTS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
D02NTS	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 2

D07NUO	TTDDRUID	D07NUO
D07NUO	DRUGNAME	JNJ-39588146
D07NUO	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0M4UZ	TTDDRUID	D0M4UZ
D0M4UZ	DRUGNAME	JNJ-39758979
D0M4UZ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0C5JQ	TTDDRUID	D0C5JQ
D0C5JQ	DRUGNAME	JNJ-40346527
D0C5JQ	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2

D03FZT	TTDDRUID	D03FZT
D03FZT	DRUGNAME	JNJ-40411813
D03FZT	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
D03FZT	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0ER9I	TTDDRUID	D0ER9I
D0ER9I	DRUGNAME	JNJ-40929837
D0ER9I	INDICATI	Asthma [ICD-11: CA23] Phase 2

D01UBY	TTDDRUID	D01UBY
D01UBY	DRUGNAME	JNJ-41443532
D01UBY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D02GPG	TTDDRUID	D02GPG
D02GPG	DRUGNAME	JNJ-42165279
D02GPG	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
D02GPG	INDICATI	Social anxiety disorder [ICD-11: 6B04] Phase 2

D0V4WJ	TTDDRUID	D0V4WJ
D0V4WJ	DRUGNAME	JNJ-42847922
D0V4WJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0E6HT	TTDDRUID	D0E6HT
D0E6HT	DRUGNAME	JNJ-63871860
D0E6HT	INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 2

D0AO5F	TTDDRUID	D0AO5F
D0AO5F	DRUGNAME	JOT101
D0AO5F	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2

D0K4JI	TTDDRUID	D0K4JI
D0K4JI	DRUGNAME	JOT106
D0K4JI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0VE3U	TTDDRUID	D0VE3U
D0VE3U	DRUGNAME	JT02
D0VE3U	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D01EJJ	TTDDRUID	D01EJJ
D01EJJ	DRUGNAME	JTE-051
D01EJJ	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
D01EJJ	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D04ZBU	TTDDRUID	D04ZBU
D04ZBU	DRUGNAME	JTT-302
D04ZBU	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2

D01THN	TTDDRUID	D01THN
D01THN	DRUGNAME	JTT-654
D01THN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0U8QB	TTDDRUID	D0U8QB
D0U8QB	DRUGNAME	JTT-851
D0U8QB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0EL5Q	TTDDRUID	D0EL5Q
D0EL5Q	DRUGNAME	JTX-2011
D0EL5Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08DJH	TTDDRUID	D08DJH
D08DJH	DRUGNAME	Juvenile chondrocyte grafts
D08DJH	INDICATI	Contraception [ICD-11: QA21] Phase 2

D00WHL	TTDDRUID	D00WHL
D00WHL	DRUGNAME	Juvidex
D00WHL	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2

D0D4LP	TTDDRUID	D0D4LP
D0D4LP	DRUGNAME	JVRS-100
D0D4LP	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0S4SX	TTDDRUID	D0S4SX
D0S4SX	DRUGNAME	K-134
D0S4SX	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2

D0MT1Q	TTDDRUID	D0MT1Q
D0MT1Q	DRUGNAME	K-201
D0MT1Q	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D03PRC	TTDDRUID	D03PRC
D03PRC	DRUGNAME	K562/GM-CSF
D03PRC	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D03PYD	TTDDRUID	D03PYD
D03PYD	DRUGNAME	K-604
D03PYD	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2

D0YC4F	TTDDRUID	D0YC4F
D0YC4F	DRUGNAME	K-828-AB
D0YC4F	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2

D00IUD	TTDDRUID	D00IUD
D00IUD	DRUGNAME	K-832
D00IUD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D03MBC	TTDDRUID	D03MBC
D03MBC	DRUGNAME	KAE609
D03MBC	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D03QHC	TTDDRUID	D03QHC
D03QHC	DRUGNAME	KAF156
D03QHC	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D08YDT	TTDDRUID	D08YDT
D08YDT	DRUGNAME	KAI-4169
D08YDT	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Phase 2

D00ULY	TTDDRUID	D00ULY
D00ULY	DRUGNAME	KAI-9803/ BMS-875944
D00ULY	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Phase 2

D02PLE	TTDDRUID	D02PLE
D02PLE	DRUGNAME	KB-001
D02PLE	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2

D09SJE	TTDDRUID	D09SJE
D09SJE	DRUGNAME	KB002/003
D09SJE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0F0ZK	TTDDRUID	D0F0ZK
D0F0ZK	DRUGNAME	KB-003
D0F0ZK	INDICATI	Severe asthma [ICD-11: CA23] Phase 2

D0E2JN	TTDDRUID	D0E2JN
D0E2JN	DRUGNAME	KB-6806
D0E2JN	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 2

D0NB9T	TTDDRUID	D0NB9T
D0NB9T	DRUGNAME	KD018
D0NB9T	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2

D0U5UC	TTDDRUID	D0U5UC
D0U5UC	DRUGNAME	KD025
D0U5UC	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
D0U5UC	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1
D0U5UC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0U5UC	INDICATI	Scleroderma [ICD-11: 4A42] Phase 1
D0U5UC	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0LS3U	TTDDRUID	D0LS3U
D0LS3U	DRUGNAME	KD-332
D0LS3U	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 2

D0MJ2H	TTDDRUID	D0MJ2H
D0MJ2H	DRUGNAME	KD-7040
D0MJ2H	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D03NLV	TTDDRUID	D03NLV
D03NLV	DRUGNAME	KDT-501
D03NLV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
D03NLV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0K7DV	TTDDRUID	D0K7DV
D0K7DV	DRUGNAME	Kevetrin
D0K7DV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0K7DV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U3PM	TTDDRUID	D0U3PM
D0U3PM	DRUGNAME	Keytruda pembrolizumab
D0U3PM	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D0U3PM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0U3PM	INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Application submitted
D0U3PM	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D0U3PM	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
D0U3PM	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0U3PM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0V4YA	TTDDRUID	D0V4YA
D0V4YA	DRUGNAME	KHK4083
D0V4YA	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D00FBC	TTDDRUID	D00FBC
D00FBC	DRUGNAME	KHK-6188
D00FBC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D0Z5TS	TTDDRUID	D0Z5TS
D0Z5TS	DRUGNAME	KI-0503
D0Z5TS	INDICATI	Arthropathy [ICD-11: FA11-FA38] Phase 2

D08FKH	TTDDRUID	D08FKH
D08FKH	DRUGNAME	KLH-2109
D08FKH	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D02HRD	TTDDRUID	D02HRD
D02HRD	DRUGNAME	KLS-0611
D02HRD	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2

D0W9JM	TTDDRUID	D0W9JM
D0W9JM	DRUGNAME	KNI-272
D0W9JM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0X0FU	TTDDRUID	D0X0FU
D0X0FU	DRUGNAME	KP-1461
D0X0FU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0X0FU	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2

D07JKY	TTDDRUID	D07JKY
D07JKY	DRUGNAME	KP-496
D07JKY	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0E7WH	TTDDRUID	D0E7WH
D0E7WH	DRUGNAME	KPAX002-2
D0E7WH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D08GSC	TTDDRUID	D08GSC
D08GSC	DRUGNAME	KPE-02001003
D08GSC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0WB0R	TTDDRUID	D0WB0R
D0WB0R	DRUGNAME	KPP203
D0WB0R	INDICATI	Subacute cutaneous lupus erythematosus [ICD-11: EB50] Phase 2

D00LNW	TTDDRUID	D00LNW
D00LNW	DRUGNAME	KPT-330
D00LNW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D00LNW	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D00LNW	INDICATI	Liposarcoma [ICD-11: 2B59] Phase 3
D00LNW	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
D00LNW	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3
D00LNW	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D00LNW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0A0MT	TTDDRUID	D0A0MT
D0A0MT	DRUGNAME	KRL-103
D0A0MT	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2

D05GEF	TTDDRUID	D05GEF
D05GEF	DRUGNAME	KRN-5500
D05GEF	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2

D03SKC	TTDDRUID	D03SKC
D03SKC	DRUGNAME	KRP-104
D03SKC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0Y5ZT	TTDDRUID	D0Y5ZT
D0Y5ZT	DRUGNAME	KRP-203
D0Y5ZT	INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2

D02UMF	TTDDRUID	D02UMF
D02UMF	DRUGNAME	KT6-971
D02UMF	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2

D0A4PJ	TTDDRUID	D0A4PJ
D0A4PJ	DRUGNAME	KTE-C19 CAR-T cell therapy
D0A4PJ	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2

D0F4SN	TTDDRUID	D0F4SN
D0F4SN	DRUGNAME	KUR-111
D0F4SN	INDICATI	Bone disease [ICD-11: FC0Z] Phase 2

D0BL6E	TTDDRUID	D0BL6E
D0BL6E	DRUGNAME	KUR-113
D0BL6E	INDICATI	Bone injury [ICD-11: ND56.Y] Phase 2

D0W4AR	TTDDRUID	D0W4AR
D0W4AR	DRUGNAME	KUR-211
D0W4AR	INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2

D09BAP	TTDDRUID	D09BAP
D09BAP	DRUGNAME	KUR-212
D09BAP	INDICATI	Wound healing [ICD-11: EL8Y] Phase 2

D08PYO	TTDDRUID	D08PYO
D08PYO	DRUGNAME	KW-2478
D08PYO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02LJW	TTDDRUID	D02LJW
D02LJW	DRUGNAME	KX2-391
D02LJW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0FW8Z	TTDDRUID	D0FW8Z
D0FW8Z	DRUGNAME	Kybiqo
D0FW8Z	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
D0FW8Z	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0HM1V	TTDDRUID	D0HM1V
D0HM1V	DRUGNAME	KYMRIAH
D0HM1V	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2

D07KAQ	TTDDRUID	D07KAQ
D07KAQ	DRUGNAME	L19-IL-2 fusion protein
D07KAQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D0GZ3A	TTDDRUID	D0GZ3A
D0GZ3A	DRUGNAME	L19-TNF-alpha
D0GZ3A	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D08PBB	TTDDRUID	D08PBB
D08PBB	DRUGNAME	L-694,458
D08PBB	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D02SUR	TTDDRUID	D02SUR
D02SUR	DRUGNAME	L-697,661
D02SUR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0N1HW	TTDDRUID	D0N1HW
D0N1HW	DRUGNAME	L-745,870
D0N1HW	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D01RAN	TTDDRUID	D01RAN
D01RAN	DRUGNAME	LA-419
D01RAN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D03RDS	TTDDRUID	D03RDS
D03RDS	DRUGNAME	Labetuzumab govitecan
D03RDS	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0XP4A	TTDDRUID	D0XP4A
D0XP4A	DRUGNAME	Labetuzumab I-131
D0XP4A	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0E1ZV	TTDDRUID	D0E1ZV
D0E1ZV	DRUGNAME	Labetuzumab-SN-38
D0E1ZV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02NBY	TTDDRUID	D02NBY
D02NBY	DRUGNAME	LACTIN-V
D02NBY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0VQ8Q	TTDDRUID	D0VQ8Q
D0VQ8Q	DRUGNAME	Ladiratuzumab vedotin
D0VQ8Q	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D07WRW	TTDDRUID	D07WRW
D07WRW	DRUGNAME	LADIRUBICIN
D07WRW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0C3UC	TTDDRUID	D0C3UC
D0C3UC	DRUGNAME	Ladostigil
D0C3UC	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D01QMC	TTDDRUID	D01QMC
D01QMC	DRUGNAME	LAI338
D01QMC	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D02ELS	TTDDRUID	D02ELS
D02ELS	DRUGNAME	L-alanosine
D02ELS	INDICATI	Brain cancer [ICD-11: 2A00] Phase 2

D0G5BI	TTDDRUID	D0G5BI
D0G5BI	DRUGNAME	Lamivudine /lopinavir/ritonavir fixed-dose combination
D0G5BI	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D01SKR	TTDDRUID	D01SKR
D01SKR	DRUGNAME	Lamivudine /maraviroc/zidovudine fixed-dose combination
D01SKR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0H8XB	TTDDRUID	D0H8XB
D0H8XB	DRUGNAME	Lancovutide inhaled
D0H8XB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D06HCC	TTDDRUID	D06HCC
D06HCC	DRUGNAME	LANEPITANT
D06HCC	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0J1AV	TTDDRUID	D0J1AV
D0J1AV	DRUGNAME	LAS 100977
D0J1AV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D05RXW	TTDDRUID	D05RXW
D05RXW	DRUGNAME	LAS-41002
D05RXW	INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2

D05QBH	TTDDRUID	D05QBH
D05QBH	DRUGNAME	LAS-41003
D05QBH	INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2

D04TJL	TTDDRUID	D04TJL
D04TJL	DRUGNAME	LAS-41004
D04TJL	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0I7MX	TTDDRUID	D0I7MX
D0I7MX	DRUGNAME	LB-30870
D0I7MX	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D0K1AK	TTDDRUID	D0K1AK
D0K1AK	DRUGNAME	LCAR-B38M CAR-T Cell
D0K1AK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D01KNY	TTDDRUID	D01KNY
D01KNY	DRUGNAME	LCB-2183
D01KNY	INDICATI	Asthma [ICD-11: CA23] Phase 2

D09MIN	TTDDRUID	D09MIN
D09MIN	DRUGNAME	LCL161
D09MIN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D09MIN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D09MIN	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
D09MIN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0D6XS	TTDDRUID	D0D6XS
D0D6XS	DRUGNAME	LD-02GIFRO
D0D6XS	INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 2

D09BNZ	TTDDRUID	D09BNZ
D09BNZ	DRUGNAME	LDE225
D09BNZ	INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 2
D09BNZ	INDICATI	Skin cancer [ICD-11: 2C30-2C37] Phase 2

D00ZHX	TTDDRUID	D00ZHX
D00ZHX	DRUGNAME	L-DOS47
D00ZHX	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
D00ZHX	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0J2NX	TTDDRUID	D0J2NX
D0J2NX	DRUGNAME	LE-DT
D0J2NX	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0EB5N	TTDDRUID	D0EB5N
D0EB5N	DRUGNAME	Lefamulin
D0EB5N	INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2

D06OFZ	TTDDRUID	D06OFZ
D06OFZ	DRUGNAME	LEISH-F1
D06OFZ	INDICATI	Leishmania infection [ICD-11: 1F54.0] Phase 2

D01GVM	TTDDRUID	D01GVM
D01GVM	DRUGNAME	Lemuteporfin
D01GVM	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0A5SR	TTDDRUID	D0A5SR
D0A5SR	DRUGNAME	Lenapenem hydrochloride hydrate
D0A5SR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D05UGH	TTDDRUID	D05UGH
D05UGH	DRUGNAME	LEO 124249
D05UGH	INDICATI	Asthma [ICD-11: CA23] Phase 2
D05UGH	INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2

D01FZX	TTDDRUID	D01FZX
D01FZX	DRUGNAME	LEO 22811
D01FZX	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0V5VR	TTDDRUID	D0V5VR
D0V5VR	DRUGNAME	LEO 90100
D0V5VR	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D04XVJ	TTDDRUID	D04XVJ
D04XVJ	DRUGNAME	LEO-29102
D04XVJ	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0U9WS	TTDDRUID	D0U9WS
D0U9WS	DRUGNAME	LEO-32731
D0U9WS	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D0U9WS	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D00GFV	TTDDRUID	D00GFV
D00GFV	DRUGNAME	Leridistim
D00GFV	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2

D08SSP	TTDDRUID	D08SSP
D08SSP	DRUGNAME	Lersivirine
D08SSP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0B6YB	TTDDRUID	D0B6YB
D0B6YB	DRUGNAME	LE-SN38
D0B6YB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0B6YB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00FJQ	TTDDRUID	D00FJQ
D00FJQ	DRUGNAME	Leucine + metformin
D00FJQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0M0OT	TTDDRUID	D0M0OT
D0M0OT	DRUGNAME	Leukemia cancer vaccine
D0M0OT	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0N6UA	TTDDRUID	D0N6UA
D0N6UA	DRUGNAME	Leukemia DNA vaccine
D0N6UA	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D01WHC	TTDDRUID	D01WHC
D01WHC	DRUGNAME	Leuvectin
D01WHC	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D03SZY	TTDDRUID	D03SZY
D03SZY	DRUGNAME	Levosimendan IV
D03SZY	INDICATI	Cardiac output syndrome [ICD-11: BC43] Phase 3
D03SZY	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2

D03IBI	TTDDRUID	D03IBI
D03IBI	DRUGNAME	Levotofisopam
D03IBI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0MW7S	TTDDRUID	D0MW7S
D0MW7S	DRUGNAME	Lexatumumab
D0MW7S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0I1FT	TTDDRUID	D0I1FT
D0I1FT	DRUGNAME	Lexgenleucel-T
D0I1FT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D01JNE	TTDDRUID	D01JNE
D01JNE	DRUGNAME	Lexibulin iv infusion
D01JNE	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D0I0UE	TTDDRUID	D0I0UE
D0I0UE	DRUGNAME	Lexipafant
D0I0UE	INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative
D0I0UE	INDICATI	Nerve injury [ICD-11: ND56.4] Phase 2

D00CSA	TTDDRUID	D00CSA
D00CSA	DRUGNAME	LFF-269
D00CSA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D08VWO	TTDDRUID	D08VWO
D08VWO	DRUGNAME	LFF571
D08VWO	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2

D04HOT	TTDDRUID	D04HOT
D04HOT	DRUGNAME	LFG-316
D04HOT	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D0RI9A	TTDDRUID	D0RI9A
D0RI9A	DRUGNAME	LFX453
D0RI9A	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
D0RI9A	INDICATI	External genital and perianal wart [ICD-11: 1A95] Phase 2

D00URZ	TTDDRUID	D00URZ
D00URZ	DRUGNAME	LG-740
D00URZ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D04BFI	TTDDRUID	D04BFI
D04BFI	DRUGNAME	LGD-4665
D04BFI	INDICATI	Immune thrombocytopenic purpura [ICD-11: 3B64.13] Phase 2

D0D8VU	TTDDRUID	D0D8VU
D0D8VU	DRUGNAME	LGD-6972
D0D8VU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
D0D8VU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D08AHH	TTDDRUID	D08AHH
D08AHH	DRUGNAME	LHW090
D08AHH	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
D08AHH	INDICATI	Kidney failure [ICD-11: GB6Z] Phase 2

D04BFU	TTDDRUID	D04BFU
D04BFU	DRUGNAME	LIDORESTAT
D04BFU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0X2UI	TTDDRUID	D0X2UI
D0X2UI	DRUGNAME	LIK-066
D0X2UI	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D0X2UI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D06RIM	TTDDRUID	D06RIM
D06RIM	DRUGNAME	LIM-0705
D06RIM	INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Phase 2

D0R8SY	TTDDRUID	D0R8SY
D0R8SY	DRUGNAME	Limtop
D0R8SY	INDICATI	Keratosis [ICD-11: ED56] Phase 2

D0Q8MI	TTDDRUID	D0Q8MI
D0Q8MI	DRUGNAME	Lintopride
D0Q8MI	INDICATI	Nausea [ICD-11: MD90] Phase 2

D0R0SP	TTDDRUID	D0R0SP
D0R0SP	DRUGNAME	LIPO-5
D0R0SP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0M0WJ	TTDDRUID	D0M0WJ
D0M0WJ	DRUGNAME	Liposomal encapsulated doxorubicin (LED)
D0M0WJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0W1XJ	TTDDRUID	D0W1XJ
D0W1XJ	DRUGNAME	Liposome encapsulated paclitaxel
D0W1XJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0PN8L	TTDDRUID	D0PN8L
D0PN8L	DRUGNAME	LIposome entrapped paclitaxel
D0PN8L	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D0PN8L	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0V5SC	TTDDRUID	D0V5SC
D0V5SC	DRUGNAME	Liproca Depot
D0V5SC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0U3GB	TTDDRUID	D0U3GB
D0U3GB	DRUGNAME	LIQ-001
D0U3GB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0I7PU	TTDDRUID	D0I7PU
D0I7PU	DRUGNAME	Lirilumab
D0I7PU	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0I7PU	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D0I7PU	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D0I7PU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0F5IY	TTDDRUID	D0F5IY
D0F5IY	DRUGNAME	LIRIMILAST
D0F5IY	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D03WRJ	TTDDRUID	D03WRJ
D03WRJ	DRUGNAME	Lisofylline
D03WRJ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D09VFA	TTDDRUID	D09VFA
D09VFA	DRUGNAME	Live attenuated cholera vaccine
D09VFA	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 2

D0I3GT	TTDDRUID	D0I3GT
D0I3GT	DRUGNAME	Live attenuated recombinant vaccine
D0I3GT	INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2

D05EUR	TTDDRUID	D05EUR
D05EUR	DRUGNAME	LJN452
D05EUR	INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Phase 2

D0W0WP	TTDDRUID	D0W0WP
D0W0WP	DRUGNAME	LL-3858
D0W0WP	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2

D04MYS	TTDDRUID	D04MYS
D04MYS	DRUGNAME	LL-4218
D04MYS	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D04FRU	TTDDRUID	D04FRU
D04FRU	DRUGNAME	LLG783
D04FRU	INDICATI	Intermittent claudication [ICD-11: BD40.00] Phase 2
D04FRU	INDICATI	Vascular systems peripheral arterial disorder [ICD-11: BD5Z] Phase 2

D08HGR	TTDDRUID	D08HGR
D08HGR	DRUGNAME	LLL-3348
D08HGR	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0ND3F	TTDDRUID	D0ND3F
D0ND3F	DRUGNAME	LM-030
D0ND3F	INDICATI	Congenital ichthyosiform erythroderma [ICD-11: EC20.02] Phase 2

D0OG6N	TTDDRUID	D0OG6N
D0OG6N	DRUGNAME	LM-1507.NA
D0OG6N	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0X0IU	TTDDRUID	D0X0IU
D0X0IU	DRUGNAME	LMB-2
D0X0IU	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D07RWY	TTDDRUID	D07RWY
D07RWY	DRUGNAME	LMI1195
D07RWY	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D08DIU	TTDDRUID	D08DIU
D08DIU	DRUGNAME	LN-144
D08DIU	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0TR4Y	TTDDRUID	D0TR4Y
D0TR4Y	DRUGNAME	LN-145
D0TR4Y	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
D0TR4Y	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D0D3AI	TTDDRUID	D0D3AI
D0D3AI	DRUGNAME	L-NAME
D0D3AI	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D01IVE	TTDDRUID	D01IVE
D01IVE	DRUGNAME	Lobeline
D01IVE	INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 2

D07CQW	TTDDRUID	D07CQW
D07CQW	DRUGNAME	Lomab B
D07CQW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0W4HZ	TTDDRUID	D0W4HZ
D0W4HZ	DRUGNAME	Lonafarnib
D0W4HZ	INDICATI	Hepatitis D virus infection [ICD-11: 1E51.2] Phase 2
D0W4HZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3

D04INS	TTDDRUID	D04INS
D04INS	DRUGNAME	Long-acting exenatide
D04INS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0U1XG	TTDDRUID	D0U1XG
D0U1XG	DRUGNAME	Long-acting hGH conjugate
D0U1XG	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D0WG8A	TTDDRUID	D0WG8A
D0WG8A	DRUGNAME	Long-actingloop diuretic
D0WG8A	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2

D0I7NG	TTDDRUID	D0I7NG
D0I7NG	DRUGNAME	LOR-2040
D0I7NG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0I7NG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0I7NG	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
D0I7NG	INDICATI	Metastatic renal cancer [ICD-11: 2D50] Phase 2
D0I7NG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D06HFI	TTDDRUID	D06HFI
D06HFI	DRUGNAME	L-ornithine phenylacetate
D06HFI	INDICATI	Acute liver failure [ICD-11: DB91] Phase 2

D02EVF	TTDDRUID	D02EVF
D02EVF	DRUGNAME	Losartan/thioctic acid
D02EVF	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0C0OB	TTDDRUID	D0C0OB
D0C0OB	DRUGNAME	LOU064
D0C0OB	INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2

D0K7LA	TTDDRUID	D0K7LA
D0K7LA	DRUGNAME	Low molecular weight dextran sulphate
D0K7LA	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 2

D0G1RM	TTDDRUID	D0G1RM
D0G1RM	DRUGNAME	Low-dose oral interferon
D0G1RM	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D04EIF	TTDDRUID	D04EIF
D04EIF	DRUGNAME	LOXORIBINE
D04EIF	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2

D01MZJ	TTDDRUID	D01MZJ
D01MZJ	DRUGNAME	LR3001
D01MZJ	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 2

D0N0PU	TTDDRUID	D0N0PU
D0N0PU	DRUGNAME	LTB 019
D0N0PU	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0O4NR	TTDDRUID	D0O4NR
D0O4NR	DRUGNAME	LTB4
D0O4NR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D05PFS	TTDDRUID	D05PFS
D05PFS	DRUGNAME	LTI-291
D05PFS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D04LEH	TTDDRUID	D04LEH
D04LEH	DRUGNAME	LTX-03
D04LEH	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0J5ED	TTDDRUID	D0J5ED
D0J5ED	DRUGNAME	LTX-109
D0J5ED	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0A8QM	TTDDRUID	D0A8QM
D0A8QM	DRUGNAME	Lu-AA34893
D0A8QM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D01WLB	TTDDRUID	D01WLB
D01WLB	DRUGNAME	Lu-AA39959
D01WLB	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2

D03BBU	TTDDRUID	D03BBU
D03BBU	DRUGNAME	Lucatumumab
D03BBU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D01NCH	TTDDRUID	D01NCH
D01NCH	DRUGNAME	Lufironil
D01NCH	INDICATI	Liver cirrhosis [ICD-11: DB93.1] Phase 2

D0GB5X	TTDDRUID	D0GB5X
D0GB5X	DRUGNAME	Lulizumab pegol
D0GB5X	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D09JXH	TTDDRUID	D09JXH
D09JXH	DRUGNAME	LUM001
D09JXH	INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Phase 2
D09JXH	INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2
D09JXH	INDICATI	Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 2
D09JXH	INDICATI	Progressive familial intrahepatic cholestasis [ICD-11: 5C58.03] Phase 2
D09JXH	INDICATI	Structural developmental anomalies of liver [ICD-11: LB20.0] Phase 2

D0X0CB	TTDDRUID	D0X0CB
D0X0CB	DRUGNAME	Lumacaftor
D0X0CB	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0M5JA	TTDDRUID	D0M5JA
D0M5JA	DRUGNAME	Lumiliximab
D0M5JA	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D00DYK	TTDDRUID	D00DYK
D00DYK	DRUGNAME	Lunacalcipol
D00DYK	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D05BYP	TTDDRUID	D05BYP
D05BYP	DRUGNAME	Lupron 3-month depot
D05BYP	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 2

D0H9WR	TTDDRUID	D0H9WR
D0H9WR	DRUGNAME	LX-1031
D0H9WR	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D0FA5Z	TTDDRUID	D0FA5Z
D0FA5Z	DRUGNAME	LX-1033
D0FA5Z	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D09ZWH	TTDDRUID	D09ZWH
D09ZWH	DRUGNAME	LX2931
D09ZWH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0FS6S	TTDDRUID	D0FS6S
D0FS6S	DRUGNAME	LX3305
D0FS6S	INDICATI	Hereditary acantholytic dermatoses [ICD-11: EC20.2] Phase 2

D0B8TK	TTDDRUID	D0B8TK
D0B8TK	DRUGNAME	LX-6171
D0B8TK	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2

D0D8FN	TTDDRUID	D0D8FN
D0D8FN	DRUGNAME	LY-156735
D0D8FN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0Z1DH	TTDDRUID	D0Z1DH
D0Z1DH	DRUGNAME	LY2090314
D0Z1DH	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D02DJG	TTDDRUID	D02DJG
D02DJG	DRUGNAME	LY-2189102
D02DJG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D09RON	TTDDRUID	D09RON
D09RON	DRUGNAME	LY-2300559
D09RON	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D0Z1BM	TTDDRUID	D0Z1BM
D0Z1BM	DRUGNAME	LY-2382770
D0Z1BM	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0ZW5D	TTDDRUID	D0ZW5D
D0ZW5D	DRUGNAME	LY-2409021
D0ZW5D	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0U9LV	TTDDRUID	D0U9LV
D0U9LV	DRUGNAME	LY-2428757
D0U9LV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D07YHM	TTDDRUID	D07YHM
D07YHM	DRUGNAME	LY-2456302
D07YHM	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1
D07YHM	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D07YHM	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D00TUR	TTDDRUID	D00TUR
D00TUR	DRUGNAME	LY2495655
D00TUR	INDICATI	Disuse muscle atrophy [ICD-11: 8B61] Phase 2

D0W9SL	TTDDRUID	D0W9SL
D0W9SL	DRUGNAME	LY2523355
D0W9SL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D08PKG	TTDDRUID	D08PKG
D08PKG	DRUGNAME	LY2541546
D08PKG	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D05SLM	TTDDRUID	D05SLM
D05SLM	DRUGNAME	LY-2590443
D05SLM	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D01CGV	TTDDRUID	D01CGV
D01CGV	DRUGNAME	LY-2599506
D01CGV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D00NZL	TTDDRUID	D00NZL
D00NZL	DRUGNAME	LY2603618
D00NZL	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D08UUL	TTDDRUID	D08UUL
D08UUL	DRUGNAME	LY2606368
D08UUL	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D08UUL	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D08UUL	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D08UUL	INDICATI	Squamous cell anal carcinoma [ICD-11: 2C00.3] Phase 1

D0E1WH	TTDDRUID	D0E1WH
D0E1WH	DRUGNAME	LY-2608204
D0E1WH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D05RZE	TTDDRUID	D05RZE
D05RZE	DRUGNAME	LY-2623091
D05RZE	INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 2

D04HAF	TTDDRUID	D04HAF
D04HAF	DRUGNAME	LY-2624803
D04HAF	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D05TSJ	TTDDRUID	D05TSJ
D05TSJ	DRUGNAME	LY2784544
D05TSJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D05TSJ	INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 2

D06EGV	TTDDRUID	D06EGV
D06EGV	DRUGNAME	LY2801653
D06EGV	INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 2
D06EGV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06UIS	TTDDRUID	D06UIS
D06UIS	DRUGNAME	LY-2828360
D06UIS	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0D4VV	TTDDRUID	D0D4VV
D0D4VV	DRUGNAME	LY2874455
D0D4VV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03SXS	TTDDRUID	D03SXS
D03SXS	DRUGNAME	LY-2875358
D03SXS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0F8GK	TTDDRUID	D0F8GK
D0F8GK	DRUGNAME	LY2886721
D0F8GK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0B0NQ	TTDDRUID	D0B0NQ
D0B0NQ	DRUGNAME	LY293558
D0B0NQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0Z9GM	TTDDRUID	D0Z9GM
D0Z9GM	DRUGNAME	LY-2940094
D0Z9GM	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D08FMK	TTDDRUID	D08FMK
D08FMK	DRUGNAME	LY2944876
D08FMK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0BA8M	TTDDRUID	D0BA8M
D0BA8M	DRUGNAME	LY-295501
D0BA8M	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0X2RL	TTDDRUID	D0X2RL
D0X2RL	DRUGNAME	LY3012212
D0X2RL	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
D0X2RL	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D07SKJ	TTDDRUID	D07SKJ
D07SKJ	DRUGNAME	LY3015014
D07SKJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0H1WC	TTDDRUID	D0H1WC
D0H1WC	DRUGNAME	LY3023414
D0H1WC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D0H1WC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0H1WC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0O6OK	TTDDRUID	D0O6OK
D0O6OK	DRUGNAME	LY3074828
D0O6OK	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0C8IF	TTDDRUID	D0C8IF
D0C8IF	DRUGNAME	LY3154207
D0C8IF	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0XD5N	TTDDRUID	D0XD5N
D0XD5N	DRUGNAME	LY3202626
D0XD5N	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0W3LI	TTDDRUID	D0W3LI
D0W3LI	DRUGNAME	LY333531
D0W3LI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D09GHO	TTDDRUID	D09GHO
D09GHO	DRUGNAME	LY-334370
D09GHO	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D0D1FC	TTDDRUID	D0D1FC
D0D1FC	DRUGNAME	LY-362884
D0D1FC	INDICATI	Obesity [ICD-11: 5B81] Phase 2
D0D1FC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D06UKG	TTDDRUID	D06UKG
D06UKG	DRUGNAME	LY-377604
D06UKG	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D07BRZ	TTDDRUID	D07BRZ
D07BRZ	DRUGNAME	LY-517717
D07BRZ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D0I5IM	TTDDRUID	D0I5IM
D0I5IM	DRUGNAME	LY-518674
D0I5IM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D02QZR	TTDDRUID	D02QZR
D02QZR	DRUGNAME	LY-545694
D02QZR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D07KIE	TTDDRUID	D07KIE
D07KIE	DRUGNAME	LYC-30937
D07KIE	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D07KIE	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0T7YE	TTDDRUID	D0T7YE
D0T7YE	DRUGNAME	LYC-55716
D0T7YE	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0T7YE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0H1YZ	TTDDRUID	D0H1YZ
D0H1YZ	DRUGNAME	LymPro
D0H1YZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0T4LZ	TTDDRUID	D0T4LZ
D0T4LZ	DRUGNAME	Lynparzaolaparib
D0T4LZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0T4LZ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
D0T4LZ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D07XJJ	TTDDRUID	D07XJJ
D07XJJ	DRUGNAME	M118
D07XJJ	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2

D0V4UO	TTDDRUID	D0V4UO
D0V4UO	DRUGNAME	M-16209
D0V4UO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0QX8X	TTDDRUID	D0QX8X
D0QX8X	DRUGNAME	M2951
D0QX8X	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D0QX8X	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0QX8X	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0M1ZH	TTDDRUID	D0M1ZH
D0M1ZH	DRUGNAME	M4112
D0M1ZH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0A8MH	TTDDRUID	D0A8MH
D0A8MH	DRUGNAME	M-516102
D0A8MH	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D05FPZ	TTDDRUID	D05FPZ
D05FPZ	DRUGNAME	M7824
D05FPZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0OO8M	TTDDRUID	D0OO8M
D0OO8M	DRUGNAME	MAA868
D0OO8M	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D08XPN	TTDDRUID	D08XPN
D08XPN	DRUGNAME	mab 1-7F9
D08XPN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D09AYM	TTDDRUID	D09AYM
D09AYM	DRUGNAME	MABp1
D09AYM	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
D09AYM	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D09AYM	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D09AYM	INDICATI	Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2
D09AYM	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
D09AYM	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D09AYM	INDICATI	Pyoderma gangrenosum [ICD-11: EB21] Phase 2
D09AYM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0Q0SK	TTDDRUID	D0Q0SK
D0Q0SK	DRUGNAME	MAGE-3-transduced autologous T-cell vaccine
D0Q0SK	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0E2OK	TTDDRUID	D0E2OK
D0E2OK	DRUGNAME	MAL formulation
D0E2OK	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D04VVL	TTDDRUID	D04VVL
D04VVL	DRUGNAME	Malaria next generation vaccine
D04VVL	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D06LVJ	TTDDRUID	D06LVJ
D06LVJ	DRUGNAME	Mam-06.301
D06LVJ	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0G2ZL	TTDDRUID	D0G2ZL
D0G2ZL	DRUGNAME	Managlinat dialanetil
D0G2ZL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D00XQO	TTDDRUID	D00XQO
D00XQO	DRUGNAME	MANOALIDE
D00XQO	INDICATI	Arthritis [ICD-11: FA20] Phase 2

D0KG5D	TTDDRUID	D0KG5D
D0KG5D	DRUGNAME	Mapatumumab
D0KG5D	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D00IYB	TTDDRUID	D00IYB
D00IYB	DRUGNAME	Maraciclatide
D00IYB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0N0RN	TTDDRUID	D0N0RN
D0N0RN	DRUGNAME	Marizomib
D0N0RN	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D0N0RN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05BHF	TTDDRUID	D05BHF
D05BHF	DRUGNAME	Masilukast
D05BHF	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0BZ7V	TTDDRUID	D0BZ7V
D0BZ7V	DRUGNAME	Matuzumab
D0BZ7V	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D06KCF	TTDDRUID	D06KCF
D06KCF	DRUGNAME	Mavrilimumab
D06KCF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D05ZXS	TTDDRUID	D05ZXS
D05ZXS	DRUGNAME	MAXY-G34
D05ZXS	INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 2

D04JZP	TTDDRUID	D04JZP
D04JZP	DRUGNAME	Mazapertine succinate
D04JZP	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D0KU4M	TTDDRUID	D0KU4M
D0KU4M	DRUGNAME	MB07803
D0KU4M	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D07ZTD	TTDDRUID	D07ZTD
D07ZTD	DRUGNAME	MB-07811
D07ZTD	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D03JCA	TTDDRUID	D03JCA
D03JCA	DRUGNAME	MB-11055
D03JCA	INDICATI	Fatty liver disease [ICD-11: DB92.Z] Phase 2

D05TUL	TTDDRUID	D05TUL
D05TUL	DRUGNAME	MB-11316
D05TUL	INDICATI	Injury [ICD-11: NA00-ND5Z] Phase 2

D0TU7V	TTDDRUID	D0TU7V
D0TU7V	DRUGNAME	MB-12066
D0TU7V	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0F1HT	TTDDRUID	D0F1HT
D0F1HT	DRUGNAME	MB-CART19.1
D0F1HT	INDICATI	Precursor B-lymphoblastic neoplasm [ICD-11: 2A70] Phase 2

D05PZI	TTDDRUID	D05PZI
D05PZI	DRUGNAME	MB-CART20.1
D05PZI	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0T3QU	TTDDRUID	D0T3QU
D0T3QU	DRUGNAME	MBL-HCV1
D0T3QU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D08NPG	TTDDRUID	D08NPG
D08NPG	DRUGNAME	MBX-2044
D08NPG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D01HTO	TTDDRUID	D01HTO
D01HTO	DRUGNAME	MBX-2982
D01HTO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D03OSG	TTDDRUID	D03OSG
D03OSG	DRUGNAME	MBX-8025
D03OSG	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2
D03OSG	INDICATI	Obesity [ICD-11: 5B81] Phase 2/3
D03OSG	INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Phase 2

D0P1DI	TTDDRUID	D0P1DI
D0P1DI	DRUGNAME	MCLA-128
D0P1DI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04EAT	TTDDRUID	D04EAT
D04EAT	DRUGNAME	MCS-110
D04EAT	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2
D04EAT	INDICATI	Bone metastases [ICD-11: 2D50] Phase 2
D04EAT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D04EAT	INDICATI	Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 2
D04EAT	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D03ONZ	TTDDRUID	D03ONZ
D03ONZ	DRUGNAME	MCS-18
D03ONZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D02GWJ	TTDDRUID	D02GWJ
D02GWJ	DRUGNAME	MCT-125
D02GWJ	INDICATI	Fatigue [ICD-11: MG22] Phase 2

D0O6RK	TTDDRUID	D0O6RK
D0O6RK	DRUGNAME	MD-0727
D0O6RK	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2

D02EFJ	TTDDRUID	D02EFJ
D02EFJ	DRUGNAME	MDAB-16
D02EFJ	INDICATI	Bone disease [ICD-11: FC0Z] Phase 2

D03RHZ	TTDDRUID	D03RHZ
D03RHZ	DRUGNAME	MDL-27192
D03RHZ	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2

D08GLX	TTDDRUID	D08GLX
D08GLX	DRUGNAME	MDT-2004
D08GLX	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0G6EB	TTDDRUID	D0G6EB
D0G6EB	DRUGNAME	MDX-1097
D0G6EB	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2

D0C1UF	TTDDRUID	D0C1UF
D0C1UF	DRUGNAME	MDX-1100
D0C1UF	INDICATI	Crohn disease [ICD-11: DD70] Phase 2

D05MGQ	TTDDRUID	D05MGQ
D05MGQ	DRUGNAME	MDX-1342
D05MGQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0JS8H	TTDDRUID	D0JS8H
D0JS8H	DRUGNAME	ME1111
D0JS8H	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D0L8MO	TTDDRUID	D0L8MO
D0L8MO	DRUGNAME	ME-3407
D0L8MO	INDICATI	Duodenal ulcer [ICD-11: DA63] Phase 2

D0F2ML	TTDDRUID	D0F2ML
D0F2ML	DRUGNAME	MEDETOMIDINE
D0F2ML	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0F9XG	TTDDRUID	D0F9XG
D0F9XG	DRUGNAME	MEDI2070
D0F9XG	INDICATI	Crohn disease [ICD-11: DD70] Phase 2

D05IYA	TTDDRUID	D05IYA
D05IYA	DRUGNAME	MEDI3902
D05IYA	INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1
D05IYA	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2

D0WV8Z	TTDDRUID	D0WV8Z
D0WV8Z	DRUGNAME	MEDI4166
D0WV8Z	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0FI5C	TTDDRUID	D0FI5C
D0FI5C	DRUGNAME	MEDI-528
D0FI5C	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0L2BC	TTDDRUID	D0L2BC
D0L2BC	DRUGNAME	MEDI-534
D0L2BC	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2
D0L2BC	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D0A4TU	TTDDRUID	D0A4TU
D0A4TU	DRUGNAME	MEDI-545
D0A4TU	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D06TME	TTDDRUID	D06TME
D06TME	DRUGNAME	MEDI-546
D06TME	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0R3ZE	TTDDRUID	D0R3ZE
D0R3ZE	DRUGNAME	MEDI-551
D0R3ZE	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0R3ZE	INDICATI	Encephalopathy [ICD-11: 8E47] Phase 2
D0R3ZE	INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 2

D0T0QU	TTDDRUID	D0T0QU
D0T0QU	DRUGNAME	MEDI-559
D0T0QU	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D0AG7N	TTDDRUID	D0AG7N
D0AG7N	DRUGNAME	MEDI-575
D0AG7N	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D08JNI	TTDDRUID	D08JNI
D08JNI	DRUGNAME	MEDI5872
D08JNI	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
D08JNI	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D03WMZ	TTDDRUID	D03WMZ
D03WMZ	DRUGNAME	MEDI5884
D03WMZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0T5YB	TTDDRUID	D0T5YB
D0T5YB	DRUGNAME	MEDI6012
D0T5YB	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 1
D0T5YB	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0G0MB	TTDDRUID	D0G0MB
D0G0MB	DRUGNAME	MEDI7510
D0G0MB	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D00CTZ	TTDDRUID	D00CTZ
D00CTZ	DRUGNAME	MEDI9929
D00CTZ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D01LES	TTDDRUID	D01LES
D01LES	DRUGNAME	MEGF0444A
D01LES	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
D01LES	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D09BZJ	TTDDRUID	D09BZJ
D09BZJ	DRUGNAME	MEHD-7945A
D09BZJ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D09BZJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06VMJ	TTDDRUID	D06VMJ
D06VMJ	DRUGNAME	Melogliptin
D06VMJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0U5JP	TTDDRUID	D0U5JP
D0U5JP	DRUGNAME	MEM-3454
D0U5JP	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D01LSB	TTDDRUID	D01LSB
D01LSB	DRUGNAME	MEMP1972A
D01LSB	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
D01LSB	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0WK7Y	TTDDRUID	D0WK7Y
D0WK7Y	DRUGNAME	Men ABCWY vaccine
D0WK7Y	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2

D09WWB	TTDDRUID	D09WWB
D09WWB	DRUGNAME	MenABCWY
D09WWB	INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 2

D0E5QY	TTDDRUID	D0E5QY
D0E5QY	DRUGNAME	MEN-B
D0E5QY	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2

D0OQ5W	TTDDRUID	D0OQ5W
D0OQ5W	DRUGNAME	Meninge ACYW
D0OQ5W	INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 2
D0OQ5W	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0O3DW	TTDDRUID	D0O3DW
D0O3DW	DRUGNAME	Meningococcal meningitis polysaccharide serogroups A,C,Y and W-135 vaccine
D0O3DW	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2

D0VG7I	TTDDRUID	D0VG7I
D0VG7I	DRUGNAME	MENK
D0VG7I	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0TN1J	TTDDRUID	D0TN1J
D0TN1J	DRUGNAME	MENK 
D0TN1J	INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2

D0O0LC	TTDDRUID	D0O0LC
D0O0LC	DRUGNAME	MER-101
D0O0LC	INDICATI	Bone metastases [ICD-11: 2D50] Phase 2

D00ARS	TTDDRUID	D00ARS
D00ARS	DRUGNAME	MER-3001
D00ARS	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
D00ARS	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D00ARS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0D3RY	TTDDRUID	D0D3RY
D0D3RY	DRUGNAME	Merozoite surface protein 3 long synthetic peptide vaccine
D0D3RY	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D04XIV	TTDDRUID	D04XIV
D04XIV	DRUGNAME	Mesenchymal precursor cell
D04XIV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0H7TS	TTDDRUID	D0H7TS
D0H7TS	DRUGNAME	Mesenchymal stem cell therapy
D0H7TS	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2
D0H7TS	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2

D0XE4G	TTDDRUID	D0XE4G
D0XE4G	DRUGNAME	Mesenchymal stromal cells secreting neurotrophic factors
D0XE4G	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D05FQD	TTDDRUID	D05FQD
D05FQD	DRUGNAME	Metaiodobenzylguanidine I-131
D05FQD	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
D05FQD	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
D05FQD	INDICATI	Pheochromocytoma [ICD-11: 5A75] Application submitted

D0V5WL	TTDDRUID	D0V5WL
D0V5WL	DRUGNAME	Met-enkephalin
D0V5WL	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D09SJK	TTDDRUID	D09SJK
D09SJK	DRUGNAME	Metformin delayed-release formulation
D09SJK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0E6GX	TTDDRUID	D0E6GX
D0E6GX	DRUGNAME	Metformin DR
D0E6GX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0W3BA	TTDDRUID	D0W3BA
D0W3BA	DRUGNAME	Methanesulfonyl fluoride
D0W3BA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D02AIM	TTDDRUID	D02AIM
D02AIM	DRUGNAME	Metoprine
D02AIM	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 2

D0F4UM	TTDDRUID	D0F4UM
D0F4UM	DRUGNAME	MG-4101
D0F4UM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0PG5O	TTDDRUID	D0PG5O
D0PG5O	DRUGNAME	MGA012
D0PG5O	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
D0PG5O	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
D0PG5O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G5GB	TTDDRUID	D0G5GB
D0G5GB	DRUGNAME	MGAH22
D0G5GB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00FHR	TTDDRUID	D00FHR
D00FHR	DRUGNAME	MGCD-0103
D00FHR	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D00FHR	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D00FHR	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D00FHR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08FDX	TTDDRUID	D08FDX
D08FDX	DRUGNAME	MGCD265
D08FDX	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D08FDX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0RF3F	TTDDRUID	D0RF3F
D0RF3F	DRUGNAME	MGCD-290
D0RF3F	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D03MYO	TTDDRUID	D03MYO
D03MYO	DRUGNAME	MGL-3196
D03MYO	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2
D03MYO	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D01WBD	TTDDRUID	D01WBD
D01WBD	DRUGNAME	Mibampator
D01WBD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0C9AV	TTDDRUID	D0C9AV
D0C9AV	DRUGNAME	Mical (1)
D0C9AV	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D09IUR	TTDDRUID	D09IUR
D09IUR	DRUGNAME	Midismase
D09IUR	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Phase 2

D0JI8B	TTDDRUID	D0JI8B
D0JI8B	DRUGNAME	Milataxel
D0JI8B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0L7TA	TTDDRUID	D0L7TA
D0L7TA	DRUGNAME	MIN-101
D0L7TA	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
D0L7TA	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0Z4FE	TTDDRUID	D0Z4FE
D0Z4FE	DRUGNAME	MIN-117
D0Z4FE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0FK6O	TTDDRUID	D0FK6O
D0FK6O	DRUGNAME	MIN-202
D0FK6O	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D04AYG	TTDDRUID	D04AYG
D04AYG	DRUGNAME	Minocycline topical
D04AYG	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2

D04EMN	TTDDRUID	D04EMN
D04EMN	DRUGNAME	Mipsagargin
D04EMN	INDICATI	Adenocarcinoma [ICD-11: 2D40] Phase 2

D0E1SV	TTDDRUID	D0E1SV
D0E1SV	DRUGNAME	MIQ-001
D0E1SV	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0SQ2K	TTDDRUID	D0SQ2K
D0SQ2K	DRUGNAME	Miravirsen
D0SQ2K	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0V9EX	TTDDRUID	D0V9EX
D0V9EX	DRUGNAME	Mirvetuximab soratansine
D0V9EX	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D01UHA	TTDDRUID	D01UHA
D01UHA	DRUGNAME	MIS-416
D01UHA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0XH0K	TTDDRUID	D0XH0K
D0XH0K	DRUGNAME	Mitemcinal fumarate
D0XH0K	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D00SWQ	TTDDRUID	D00SWQ
D00SWQ	DRUGNAME	Mitoglitazone
D00SWQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D00SWQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0PG0F	TTDDRUID	D0PG0F
D0PG0F	DRUGNAME	Mitumprotimut-t
D0PG0F	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D02FCU	TTDDRUID	D02FCU
D02FCU	DRUGNAME	MIV-210
D02FCU	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D02HNG	TTDDRUID	D02HNG
D02HNG	DRUGNAME	MK-0752
D02HNG	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0RV6F	TTDDRUID	D0RV6F
D0RV6F	DRUGNAME	MK-0773
D0RV6F	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D0TG9Q	TTDDRUID	D0TG9Q
D0TG9Q	DRUGNAME	MK-0812
D0TG9Q	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0M7CB	TTDDRUID	D0M7CB
D0M7CB	DRUGNAME	MK-0873
D0M7CB	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0N4ZX	TTDDRUID	D0N4ZX
D0N4ZX	DRUGNAME	MK-1029
D0N4ZX	INDICATI	Asthma [ICD-11: CA23] Phase 2

D02KKA	TTDDRUID	D02KKA
D02KKA	DRUGNAME	MK-1775
D02KKA	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D02KKA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09TGC	TTDDRUID	D09TGC
D09TGC	DRUGNAME	MK-1903
D09TGC	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2

D0W3RW	TTDDRUID	D0W3RW
D0W3RW	DRUGNAME	MK-2206
D0W3RW	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
D0W3RW	INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Phase 2

D0E1LB	TTDDRUID	D0E1LB
D0E1LB	DRUGNAME	MK-2578
D0E1LB	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D0GW6Q	TTDDRUID	D0GW6Q
D0GW6Q	DRUGNAME	MK-3118
D0GW6Q	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D00MXN	TTDDRUID	D00MXN
D00MXN	DRUGNAME	MK-3207
D00MXN	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D08SCL	TTDDRUID	D08SCL
D08SCL	DRUGNAME	MK-3697
D08SCL	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D0DH5X	TTDDRUID	D0DH5X
D0DH5X	DRUGNAME	MK-4618
D0DH5X	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2

D00BMF	TTDDRUID	D00BMF
D00BMF	DRUGNAME	MK-4827
D00BMF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D00BMF	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D07SMH	TTDDRUID	D07SMH
D07SMH	DRUGNAME	MK-5172
D07SMH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0H8OA	TTDDRUID	D0H8OA
D0H8OA	DRUGNAME	MK-5442
D0H8OA	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D0NN5A	TTDDRUID	D0NN5A
D0NN5A	DRUGNAME	MK-6096
D0NN5A	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D0NN5A	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D02WFN	TTDDRUID	D02WFN
D02WFN	DRUGNAME	MK-7622
D02WFN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D02VSP	TTDDRUID	D02VSP
D02VSP	DRUGNAME	MK-7655
D02VSP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D05PTH	TTDDRUID	D05PTH
D05PTH	DRUGNAME	MK-8175A
D05PTH	INDICATI	Contraception [ICD-11: QA21] Phase 2

D0YH5V	TTDDRUID	D0YH5V
D0YH5V	DRUGNAME	MK-8189
D0YH5V	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0NT6P	TTDDRUID	D0NT6P
D0NT6P	DRUGNAME	MK8242
D0NT6P	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0NT6P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S0RS	TTDDRUID	D0S0RS
D0S0RS	DRUGNAME	MK-8245
D0S0RS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D01KMY	TTDDRUID	D01KMY
D01KMY	DRUGNAME	MK-8342
D01KMY	INDICATI	Contraception [ICD-11: QA21] Phase 2

D0U3GT	TTDDRUID	D0U3GT
D0U3GT	DRUGNAME	MK-8342B
D0U3GT	INDICATI	Contraception [ICD-11: QA21] Phase 2

D08PXL	TTDDRUID	D08PXL
D08PXL	DRUGNAME	MK-8457
D08PXL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D04CQK	TTDDRUID	D04CQK
D04CQK	DRUGNAME	MK-8521
D04CQK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0F4GF	TTDDRUID	D0F4GF
D0F4GF	DRUGNAME	MK-8998
D0F4GF	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0J7MQ	TTDDRUID	D0J7MQ
D0J7MQ	DRUGNAME	MKC-1106-MT
D0J7MQ	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0X9HB	TTDDRUID	D0X9HB
D0X9HB	DRUGNAME	MKT-077
D0X9HB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08DOE	TTDDRUID	D08DOE
D08DOE	DRUGNAME	ML-04
D08DOE	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0C0TT	TTDDRUID	D0C0TT
D0C0TT	DRUGNAME	MLN0128
D0C0TT	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0U7VU	TTDDRUID	D0U7VU
D0U7VU	DRUGNAME	MLN0264
D0U7VU	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 2

D06KCU	TTDDRUID	D06KCU
D06KCU	DRUGNAME	MLN1202
D06KCU	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 2
D06KCU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D06KCU	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated

D07IEU	TTDDRUID	D07IEU
D07IEU	DRUGNAME	MLN2480
D07IEU	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D07IEU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
D07IEU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0H5ER	TTDDRUID	D0H5ER
D0H5ER	DRUGNAME	MLN-591RL
D0H5ER	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0ZU4U	TTDDRUID	D0ZU4U
D0ZU4U	DRUGNAME	MLR-1023
D0ZU4U	INDICATI	Obesity [ICD-11: 5B81] Phase 2
D0ZU4U	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D05RQY	TTDDRUID	D05RQY
D05RQY	DRUGNAME	MM-093
D05RQY	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0Q2KM	TTDDRUID	D0Q2KM
D0Q2KM	DRUGNAME	MM-111
D0Q2KM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0Q2KM	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D06SBL	TTDDRUID	D06SBL
D06SBL	DRUGNAME	MM-121
D06SBL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D06SBL	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D00BUO	TTDDRUID	D00BUO
D00BUO	DRUGNAME	MM-141
D00BUO	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D00BUO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0QK4D	TTDDRUID	D0QK4D
D0QK4D	DRUGNAME	MM36 topical ointment
D0QK4D	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0YF4I	TTDDRUID	D0YF4I
D0YF4I	DRUGNAME	MN-221
D0YF4I	INDICATI	Aging skin [ICD-11: EE40] Phase 2
D0YF4I	INDICATI	Exacerbation of acute asthma [ICD-11: CA23.30] Phase 2

D09UMP	TTDDRUID	D09UMP
D09UMP	DRUGNAME	MN-305
D09UMP	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D0L5VX	TTDDRUID	D0L5VX
D0L5VX	DRUGNAME	MNK-1411
D0L5VX	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0ZA6V	TTDDRUID	D0ZA6V
D0ZA6V	DRUGNAME	MNPR-201
D0ZA6V	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2

D0F5VX	TTDDRUID	D0F5VX
D0F5VX	DRUGNAME	MNX-100
D0F5VX	INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 2
D0F5VX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05JJO	TTDDRUID	D05JJO
D05JJO	DRUGNAME	MOB-015
D05JJO	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D0FF0I	TTDDRUID	D0FF0I
D0FF0I	DRUGNAME	MOD-5014
D0FF0I	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 2

D0O0QM	TTDDRUID	D0O0QM
D0O0QM	DRUGNAME	Modified hepatocyte growth factor gene therapy
D0O0QM	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0M5HV	TTDDRUID	D0M5HV
D0M5HV	DRUGNAME	Montelukast/mometasone
D0M5HV	INDICATI	Asthma [ICD-11: CA23] Phase 2

D02CYL	TTDDRUID	D02CYL
D02CYL	DRUGNAME	MOR-208
D02CYL	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
D02CYL	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2
D02CYL	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D02CYL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3
D02CYL	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D02RKG	TTDDRUID	D02RKG
D02RKG	DRUGNAME	MORAb-004
D02RKG	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D02RKG	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D02RKG	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
D02RKG	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2

D0R6MJ	TTDDRUID	D0R6MJ
D0R6MJ	DRUGNAME	MORAb-009
D0R6MJ	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2

D00OYC	TTDDRUID	D00OYC
D00OYC	DRUGNAME	Motolimid
D00OYC	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D09WFL	TTDDRUID	D09WFL
D09WFL	DRUGNAME	MP-12
D09WFL	INDICATI	Rift valley fever [ICD-11: 1D44] Phase 2

D0O6BJ	TTDDRUID	D0O6BJ
D0O6BJ	DRUGNAME	MP40X
D0O6BJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0T1GF	TTDDRUID	D0T1GF
D0T1GF	DRUGNAME	MP470
D0T1GF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0H9VP	TTDDRUID	D0H9VP
D0H9VP	DRUGNAME	MP-4-CO
D0H9VP	INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Phase 2

D01AET	TTDDRUID	D01AET
D01AET	DRUGNAME	MPC-150-IM
D01AET	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3

D0MM0N	TTDDRUID	D0MM0N
D0MM0N	DRUGNAME	MPC-300-IV
D0MM0N	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
D0MM0N	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D07YES	TTDDRUID	D07YES
D07YES	DRUGNAME	MPL-containing Pollinex allergy desensitization sublingual vaccine
D07YES	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0B1TI	TTDDRUID	D0B1TI
D0B1TI	DRUGNAME	MPSK3169A
D0B1TI	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
D0B1TI	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1

D0F9NA	TTDDRUID	D0F9NA
D0F9NA	DRUGNAME	MRC-375
D0F9NA	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D06MIQ	TTDDRUID	D06MIQ
D06MIQ	DRUGNAME	MRE-0094
D06MIQ	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D0F2JT	TTDDRUID	D0F2JT
D0F2JT	DRUGNAME	MRX-1
D0F2JT	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 2

D03VYZ	TTDDRUID	D03VYZ
D03VYZ	DRUGNAME	MRX-4
D03VYZ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D07RKO	TTDDRUID	D07RKO
D07RKO	DRUGNAME	MRX-6
D07RKO	INDICATI	Contact dermatitis [ICD-11: EK0Z] Phase 2

D03LAI	TTDDRUID	D03LAI
D03LAI	DRUGNAME	MSB0010445
D03LAI	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D03CHM	TTDDRUID	D03CHM
D03CHM	DRUGNAME	MSC1936369B
D03CHM	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D00AUX	TTDDRUID	D00AUX
D00AUX	DRUGNAME	MSDC-0602
D00AUX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0Q5BU	TTDDRUID	D0Q5BU
D0Q5BU	DRUGNAME	MSH-1001
D0Q5BU	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2

D0KX5H	TTDDRUID	D0KX5H
D0KX5H	DRUGNAME	MSP-2017
D0KX5H	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D00ISN	TTDDRUID	D00ISN
D00ISN	DRUGNAME	MT-1303
D00ISN	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D00ISN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0AG6K	TTDDRUID	D0AG6K
D0AG6K	DRUGNAME	MT201
D0AG6K	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0H6SH	TTDDRUID	D0H6SH
D0H6SH	DRUGNAME	MT203
D0H6SH	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D0G4YR	TTDDRUID	D0G4YR
D0G4YR	DRUGNAME	MT-3995
D0G4YR	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0R4AE	TTDDRUID	D0R4AE
D0R4AE	DRUGNAME	MT-7117
D0R4AE	INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Phase 2

D08ZCC	TTDDRUID	D08ZCC
D08ZCC	DRUGNAME	MTC-896
D08ZCC	INDICATI	Seborrhea [ICD-11: ED91.2] Phase 2

D0X1RQ	TTDDRUID	D0X1RQ
D0X1RQ	DRUGNAME	MTR105
D0X1RQ	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2

D0WQ5U	TTDDRUID	D0WQ5U
D0WQ5U	DRUGNAME	MTR107
D0WQ5U	INDICATI	Intradialytic hypotension [ICD-11: BA20-BA21] Phase 2

D0T5ES	TTDDRUID	D0T5ES
D0T5ES	DRUGNAME	MUC-1 cancer vaccine
D0T5ES	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D02HKC	TTDDRUID	D02HKC
D02HKC	DRUGNAME	MUC1-Poly-ICLC
D02HKC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0N7FD	TTDDRUID	D0N7FD
D0N7FD	DRUGNAME	Multi-epitope tyrosinase/gp100 vaccine
D0N7FD	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0K0TZ	TTDDRUID	D0K0TZ
D0K0TZ	DRUGNAME	Multimeric-001
D0K0TZ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0D7GS	TTDDRUID	D0D7GS
D0D7GS	DRUGNAME	MultiStem
D0D7GS	INDICATI	AIDS-related lymphoma [ICD-11: 2B33.5] Phase 2
D0D7GS	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2
D0D7GS	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1
D0D7GS	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2
D0D7GS	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
D0D7GS	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
D0D7GS	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D0M7MR	TTDDRUID	D0M7MR
D0M7MR	DRUGNAME	Multivalent carbohydrate-based vaccine
D0M7MR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01LFC	TTDDRUID	D01LFC
D01LFC	DRUGNAME	Mutant ras vaccine
D01LFC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0KK1I	TTDDRUID	D0KK1I
D0KK1I	DRUGNAME	MVA E2 vaccine
D0KK1I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04IAJ	TTDDRUID	D04IAJ
D04IAJ	DRUGNAME	MVA62B
D04IAJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D07GMF	TTDDRUID	D07GMF
D07GMF	DRUGNAME	MVA-85A
D07GMF	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2

D0L3SP	TTDDRUID	D0L3SP
D0L3SP	DRUGNAME	MVA-BN Filo
D0L3SP	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3
D0L3SP	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D0G5ZA	TTDDRUID	D0G5ZA
D0G5ZA	DRUGNAME	MVA-BN RSV
D0G5ZA	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
D0G5ZA	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D0KB6S	TTDDRUID	D0KB6S
D0KB6S	DRUGNAME	MVA-mBN85B
D0KB6S	INDICATI	Measles [ICD-11: 1F03] Phase 2

D09PGG	TTDDRUID	D09PGG
D09PGG	DRUGNAME	MVI-816
D09PGG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D01IJJ	TTDDRUID	D01IJJ
D01IJJ	DRUGNAME	MV-NIS
D01IJJ	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
D01IJJ	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D01IJJ	INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 1
D01IJJ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D01NXF	TTDDRUID	D01NXF
D01NXF	DRUGNAME	Mydicar
D01NXF	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0U0NS	TTDDRUID	D0U0NS
D0U0NS	DRUGNAME	Myeloma cancer vaccine
D0U0NS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0U7HL	TTDDRUID	D0U7HL
D0U7HL	DRUGNAME	N-5984
D0U7HL	INDICATI	Obesity [ICD-11: 5B81] Phase 2
D0U7HL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D09LPV	TTDDRUID	D09LPV
D09LPV	DRUGNAME	N6022
D09LPV	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0P2MF	TTDDRUID	D0P2MF
D0P2MF	DRUGNAME	N91115
D0P2MF	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D04DLW	TTDDRUID	D04DLW
D04DLW	DRUGNAME	NA-1 neuroprotectant
D04DLW	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D0Z1UB	TTDDRUID	D0Z1UB
D0Z1UB	DRUGNAME	NAI-acne
D0Z1UB	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D09RTQ	TTDDRUID	D09RTQ
D09RTQ	DRUGNAME	NanoEmulsion NSAID
D09RTQ	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D0FZ7Q	TTDDRUID	D0FZ7Q
D0FZ7Q	DRUGNAME	NanoPac
D0FZ7Q	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0FZ7Q	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0EH9J	TTDDRUID	D0EH9J
D0EH9J	DRUGNAME	NanoPac Ointment
D0EH9J	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
D0EH9J	INDICATI	Skin metastasis [ICD-11: 2D50] Phase 2

D0KY6Y	TTDDRUID	D0KY6Y
D0KY6Y	DRUGNAME	NanoPacpaclitaxel nanoformulation
D0KY6Y	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0O9EX	TTDDRUID	D0O9EX
D0O9EX	DRUGNAME	NANT merkel cell cancer vaccine
D0O9EX	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2

D0S5XO	TTDDRUID	D0S5XO
D0S5XO	DRUGNAME	NasoVAX
D0S5XO	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
D0S5XO	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 2

D03IQM	TTDDRUID	D03IQM
D03IQM	DRUGNAME	NAV therapeutic
D03IQM	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 2

D04BPS	TTDDRUID	D04BPS
D04BPS	DRUGNAME	Naveglitazar
D04BPS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0HI5D	TTDDRUID	D0HI5D
D0HI5D	DRUGNAME	Naxitamab
D0HI5D	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 3
D0HI5D	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2

D0G7XA	TTDDRUID	D0G7XA
D0G7XA	DRUGNAME	NB-002
D0G7XA	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D05QKO	TTDDRUID	D05QKO
D05QKO	DRUGNAME	NBI-5788
D05QKO	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D03NVS	TTDDRUID	D03NVS
D03NVS	DRUGNAME	NC-003
D03NVS	INDICATI	Myalgia [ICD-11: FB56.2] Phase 2

D0T2YQ	TTDDRUID	D0T2YQ
D0T2YQ	DRUGNAME	N-chlorotaurine
D0T2YQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0E8YH	TTDDRUID	D0E8YH
D0E8YH	DRUGNAME	NCX 1022
D0E8YH	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D09BTK	TTDDRUID	D09BTK
D09BTK	DRUGNAME	NCX-1000
D09BTK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D05OQX	TTDDRUID	D05OQX
D05OQX	DRUGNAME	NCX-4016
D05OQX	INDICATI	Claudication [ICD-11: FA11] Discontinued in Phase 2
D05OQX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
D05OQX	INDICATI	Nephropathy [ICD-11: GC2Z] Discontinued in Phase 2
D05OQX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0VA9Z	TTDDRUID	D0VA9Z
D0VA9Z	DRUGNAME	ND0612
D0VA9Z	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0B7LZ	TTDDRUID	D0B7LZ
D0B7LZ	DRUGNAME	NDD-094
D0B7LZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D00HUZ	TTDDRUID	D00HUZ
D00HUZ	DRUGNAME	NDDP
D00HUZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0K4HW	TTDDRUID	D0K4HW
D0K4HW	DRUGNAME	N-DESMETHYLCLOZAPINE
D0K4HW	INDICATI	Schizoaffective disorder [ICD-11: 6A21] Phase 2
D0K4HW	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0VX5O	TTDDRUID	D0VX5O
D0VX5O	DRUGNAME	Neboglamine
D0VX5O	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2

D0S3CX	TTDDRUID	D0S3CX
D0S3CX	DRUGNAME	Necuparanib
D0S3CX	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0Y2VA	TTDDRUID	D0Y2VA
D0Y2VA	DRUGNAME	Nefecon
D0Y2VA	INDICATI	IgA nephropathy [ICD-11: MF8Y] Phase 2

D0KD5P	TTDDRUID	D0KD5P
D0KD5P	DRUGNAME	Nefiracetam
D0KD5P	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0I6IQ	TTDDRUID	D0I6IQ
D0I6IQ	DRUGNAME	Neihulizumab
D0I6IQ	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2

D0UD1Y	TTDDRUID	D0UD1Y
D0UD1Y	DRUGNAME	Neladenoson bialanate
D0UD1Y	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2

D0GJ7B	TTDDRUID	D0GJ7B
D0GJ7B	DRUGNAME	NELOTANSERIN
D0GJ7B	INDICATI	Lewy body dementia [ICD-11: 6D82] Phase 2
D0GJ7B	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Discontinued in Phase 2

D0B2IR	TTDDRUID	D0B2IR
D0B2IR	DRUGNAME	Nemolizumab
D0B2IR	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0N5YD	TTDDRUID	D0N5YD
D0N5YD	DRUGNAME	Nepicastat oral
D0N5YD	INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2

D01KMR	TTDDRUID	D01KMR
D01KMR	DRUGNAME	Neramexane
D01KMR	INDICATI	Cancer related pain [ICD-11: MG30] Phase 2

D03MSF	TTDDRUID	D03MSF
D03MSF	DRUGNAME	Nerenone
D03MSF	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D01FWL	TTDDRUID	D01FWL
D01FWL	DRUGNAME	Neridronate
D01FWL	INDICATI	Bone disease [ICD-11: FC0Z] Phase 2

D02TGD	TTDDRUID	D02TGD
D02TGD	DRUGNAME	Netoglitazone
D02TGD	INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2

D08ZXQ	TTDDRUID	D08ZXQ
D08ZXQ	DRUGNAME	Neublastin
D08ZXQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D00CVJ	TTDDRUID	D00CVJ
D00CVJ	DRUGNAME	Neu-P11
D00CVJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D00CVJ	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2
D00CVJ	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D00ZLC	TTDDRUID	D00ZLC
D00ZLC	DRUGNAME	NeuroCell-PD
D00ZLC	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D09NSE	TTDDRUID	D09NSE
D09NSE	DRUGNAME	Neuromyelitis optica therapeutic
D09NSE	INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 2

D0V7SY	TTDDRUID	D0V7SY
D0V7SY	DRUGNAME	Neuronal transplant cells
D0V7SY	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D09BIX	TTDDRUID	D09BIX
D09BIX	DRUGNAME	Nexagon
D09BIX	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D06BUA	TTDDRUID	D06BUA
D06BUA	DRUGNAME	Nexopamil
D06BUA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D02BPX	TTDDRUID	D02BPX
D02BPX	DRUGNAME	NGM 282
D02BPX	INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2
D02BPX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0R1YL	TTDDRUID	D0R1YL
D0R1YL	DRUGNAME	NGX-267
D0R1YL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0X0PQ	TTDDRUID	D0X0PQ
D0X0PQ	DRUGNAME	NHS-IL2-LT
D0X0PQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0QV4A	TTDDRUID	D0QV4A
D0QV4A	DRUGNAME	NI-0501
D0QV4A	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
D0QV4A	INDICATI	Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Phase 2

D03VNB	TTDDRUID	D03VNB
D03VNB	DRUGNAME	NI-0801
D03VNB	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0MC2S	TTDDRUID	D0MC2S
D0MC2S	DRUGNAME	NIC-002
D0MC2S	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2

D0W0NU	TTDDRUID	D0W0NU
D0W0NU	DRUGNAME	NIC5-15
D0W0NU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D03TYY	TTDDRUID	D03TYY
D03TYY	DRUGNAME	Nicotine-Q
D03TYY	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 2

D0LJ4E	TTDDRUID	D0LJ4E
D0LJ4E	DRUGNAME	NIR178
D0LJ4E	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D0LJ4E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0PW4C	TTDDRUID	D0PW4C
D0PW4C	DRUGNAME	Niravoline
D0PW4C	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0LI1C	TTDDRUID	D0LI1C
D0LI1C	DRUGNAME	NITD609
D0LI1C	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D0C9AN	TTDDRUID	D0C9AN
D0C9AN	DRUGNAME	Nitrite inhalation
D0C9AN	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0Z2JF	TTDDRUID	D0Z2JF
D0Z2JF	DRUGNAME	Nivocasan
D0Z2JF	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2

D0V7US	TTDDRUID	D0V7US
D0V7US	DRUGNAME	NKP 608
D0V7US	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D0Y0VC	TTDDRUID	D0Y0VC
D0Y0VC	DRUGNAME	NLS-1
D0Y0VC	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D0H0BQ	TTDDRUID	D0H0BQ
D0H0BQ	DRUGNAME	NM-IL-12
D0H0BQ	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2

D0X4CE	TTDDRUID	D0X4CE
D0X4CE	DRUGNAME	NMK-36
D0X4CE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00LGA	TTDDRUID	D00LGA
D00LGA	DRUGNAME	NN-8226
D00LGA	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D06JUE	TTDDRUID	D06JUE
D06JUE	DRUGNAME	NN8555
D06JUE	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D06JUE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D02ZZC	TTDDRUID	D02ZZC
D02ZZC	DRUGNAME	NN-8630
D02ZZC	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D07YNM	TTDDRUID	D07YNM
D07YNM	DRUGNAME	NN8765
D07YNM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0V3YY	TTDDRUID	D0V3YY
D0V3YY	DRUGNAME	NN9828
D0V3YY	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D0M2LI	TTDDRUID	D0M2LI
D0M2LI	DRUGNAME	NNC-0123-0000-0338
D0M2LI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0J4PM	TTDDRUID	D0J4PM
D0J4PM	DRUGNAME	NNC-0151-0000-0000
D0J4PM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D02QFW	TTDDRUID	D02QFW
D02QFW	DRUGNAME	NNZ-2566
D02QFW	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D03DRR	TTDDRUID	D03DRR
D03DRR	DRUGNAME	Noberastine
D03DRR	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0JM0G	TTDDRUID	D0JM0G
D0JM0G	DRUGNAME	Non-Hodgkin's lymphoma vaccine
D0JM0G	INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2

D0R6TY	TTDDRUID	D0R6TY
D0R6TY	DRUGNAME	Noribogaine
D0R6TY	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D05AHC	TTDDRUID	D05AHC
D05AHC	DRUGNAME	NOV-205
D05AHC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D04PIH	TTDDRUID	D04PIH
D04PIH	DRUGNAME	Novaferon
D04PIH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D00PSG	TTDDRUID	D00PSG
D00PSG	DRUGNAME	NOX-100
D00PSG	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2

D09LKU	TTDDRUID	D09LKU
D09LKU	DRUGNAME	NOX-E36
D09LKU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D02CAF	TTDDRUID	D02CAF
D02CAF	DRUGNAME	NOX-H94
D02CAF	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D0A5IN	TTDDRUID	D0A5IN
D0A5IN	DRUGNAME	NP-001
D0A5IN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0A5IN	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D03VCJ	TTDDRUID	D03VCJ
D03VCJ	DRUGNAME	NP-01
D03VCJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D03GVG	TTDDRUID	D03GVG
D03GVG	DRUGNAME	NP-2
D03GVG	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D06ZQL	TTDDRUID	D06ZQL
D06ZQL	DRUGNAME	NP-2 gene therapy
D06ZQL	INDICATI	Cancer related pain [ICD-11: MG30] Phase 2

D04LJB	TTDDRUID	D04LJB
D04LJB	DRUGNAME	NP-213
D04LJB	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D01ASM	TTDDRUID	D01ASM
D01ASM	DRUGNAME	NPC-15199
D01ASM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2

D0T2FC	TTDDRUID	D0T2FC
D0T2FC	DRUGNAME	NPC-1C
D0T2FC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0T2FC	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D0T2FC	INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2

D0XX2I	TTDDRUID	D0XX2I
D0XX2I	DRUGNAME	NPH-30907
D0XX2I	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D07ENB	TTDDRUID	D07ENB
D07ENB	DRUGNAME	NPI-32101
D07ENB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0LG1H	TTDDRUID	D0LG1H
D0LG1H	DRUGNAME	NPL-2003
D0LG1H	INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Phase 2

D0R7IU	TTDDRUID	D0R7IU
D0R7IU	DRUGNAME	NPSP-795
D0R7IU	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D0R1JM	TTDDRUID	D0R1JM
D0R1JM	DRUGNAME	NRT inhibitor
D0R1JM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D08MCC	TTDDRUID	D08MCC
D08MCC	DRUGNAME	NRX-101
D08MCC	INDICATI	Suicidal ideation [ICD-11: MB26.A] Phase 2

D06XXW	TTDDRUID	D06XXW
D06XXW	DRUGNAME	NRX-1074
D06XXW	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D06QXI	TTDDRUID	D06QXI
D06QXI	DRUGNAME	NRX-4204
D06QXI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0H7GQ	TTDDRUID	D0H7GQ
D0H7GQ	DRUGNAME	NS 1209
D0H7GQ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
D0H7GQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D07QXU	TTDDRUID	D07QXU
D07QXU	DRUGNAME	NS 2359
D07QXU	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2
D07QXU	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Discontinued in Phase 2
D07QXU	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
D07QXU	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D0G6DR	TTDDRUID	D0G6DR
D0G6DR	DRUGNAME	NS-065
D0G6DR	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0M2WZ	TTDDRUID	D0M2WZ
D0M2WZ	DRUGNAME	NS-2710
D0M2WZ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D04XZE	TTDDRUID	D04XZE
D04XZE	DRUGNAME	NS-7
D04XZE	INDICATI	Nerve injury [ICD-11: ND56.4] Phase 2

D0D1EV	TTDDRUID	D0D1EV
D0D1EV	DRUGNAME	NSC-364432
D0D1EV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07JTD	TTDDRUID	D07JTD
D07JTD	DRUGNAME	NSC-645809
D07JTD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D06VHG	TTDDRUID	D06VHG
D06VHG	DRUGNAME	NSI-189
D06VHG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
D06VHG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0J9VG	TTDDRUID	D0J9VG
D0J9VG	DRUGNAME	NSI-566
D0J9VG	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
D0J9VG	INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2
D0J9VG	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1

D0X0QK	TTDDRUID	D0X0QK
D0X0QK	DRUGNAME	NSI-566RSC
D0X0QK	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2

D0K1AP	TTDDRUID	D0K1AP
D0K1AP	DRUGNAME	NSL-101
D0K1AP	INDICATI	Facial pain [ICD-11: MB6Y] Phase 2

D03PRM	TTDDRUID	D03PRM
D03PRM	DRUGNAME	NST-141
D03PRM	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D08APZ	TTDDRUID	D08APZ
D08APZ	DRUGNAME	NT-100
D08APZ	INDICATI	Implantation failure [ICD-11: QB50] Phase 2

D0ZT5T	TTDDRUID	D0ZT5T
D0ZT5T	DRUGNAME	NTHi-Pneumo vaccine
D0ZT5T	INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2

D0Q0TI	TTDDRUID	D0Q0TI
D0Q0TI	DRUGNAME	NT-KO-003
D0Q0TI	INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 2

D0B8ZR	TTDDRUID	D0B8ZR
D0B8ZR	DRUGNAME	NTO-1151
D0B8ZR	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2

D0X3JY	TTDDRUID	D0X3JY
D0X3JY	DRUGNAME	NTX-010
D0X3JY	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0L4AL	TTDDRUID	D0L4AL
D0L4AL	DRUGNAME	NTx-265
D0L4AL	INDICATI	Stroke [ICD-11: 8B20] Phase 2

D0H9RN	TTDDRUID	D0H9RN
D0H9RN	DRUGNAME	NU-172
D0H9RN	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D0R0GK	TTDDRUID	D0R0GK
D0R0GK	DRUGNAME	NU300
D0R0GK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0ZR4W	TTDDRUID	D0ZR4W
D0ZR4W	DRUGNAME	Nuedexta
D0ZR4W	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0ZR4W	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D07TBJ	TTDDRUID	D07TBJ
D07TBJ	DRUGNAME	NuThrax
D07TBJ	INDICATI	Anthrax [ICD-11: 1B97] Phase 2

D05BYA	TTDDRUID	D05BYA
D05BYA	DRUGNAME	NVP-AUY922
D05BYA	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D05BYA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03XAO	TTDDRUID	D03XAO
D03XAO	DRUGNAME	NVX-108
D03XAO	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0W5VV	TTDDRUID	D0W5VV
D0W5VV	DRUGNAME	NVXT topical
D0W5VV	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D05OTL	TTDDRUID	D05OTL
D05OTL	DRUGNAME	NW-3509
D05OTL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
D05OTL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0FW2D	TTDDRUID	D0FW2D
D0FW2D	DRUGNAME	NX-101
D0FW2D	INDICATI	Dermal neurofibromatoses [ICD-11: LD2D] Phase 2

D0O2XJ	TTDDRUID	D0O2XJ
D0O2XJ	DRUGNAME	NXN-188
D0O2XJ	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D0W9IT	TTDDRUID	D0W9IT
D0W9IT	DRUGNAME	NXN-462
D0W9IT	INDICATI	Headache [ICD-11: 8A80-8A84] Phase 2

D0AO8L	TTDDRUID	D0AO8L
D0AO8L	DRUGNAME	NY-ESO-1 T-cell receptor therapy
D0AO8L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0U2TZ	TTDDRUID	D0U2TZ
D0U2TZ	DRUGNAME	NYX-2925
D0U2TZ	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
D0U2TZ	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2

D02OZK	TTDDRUID	D02OZK
D02OZK	DRUGNAME	Obatoclax
D02OZK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
D02OZK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08WOJ	TTDDRUID	D08WOJ
D08WOJ	DRUGNAME	OBE-101
D08WOJ	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0O4WB	TTDDRUID	D0O4WB
D0O4WB	DRUGNAME	OBP-601
D0O4WB	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0X7EG	TTDDRUID	D0X7EG
D0X7EG	DRUGNAME	OC-000459
D0X7EG	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D01FQR	TTDDRUID	D01FQR
D01FQR	DRUGNAME	Ocaperidone
D01FQR	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1b
D01FQR	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
D01FQR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D01FQR	INDICATI	Schizoaffective disorder [ICD-11: 6A21] Phase 2
D01FQR	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
D01FQR	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D04GLJ	TTDDRUID	D04GLJ
D04GLJ	DRUGNAME	OCFENTANIL
D04GLJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D09YGZ	TTDDRUID	D09YGZ
D09YGZ	DRUGNAME	OCT-002
D09YGZ	INDICATI	Acute hyperammonaemia [ICD-11: 5C50.A] Phase 2

D0LX8Z	TTDDRUID	D0LX8Z
D0LX8Z	DRUGNAME	OCV-101
D0LX8Z	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0S6SQ	TTDDRUID	D0S6SQ
D0S6SQ	DRUGNAME	Odelepran
D0S6SQ	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2

D00AKQ	TTDDRUID	D00AKQ
D00AKQ	DRUGNAME	O-desulfated heparin
D00AKQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0N6EA	TTDDRUID	D0N6EA
D0N6EA	DRUGNAME	Odiparcil
D0N6EA	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D09AWM	TTDDRUID	D09AWM
D09AWM	DRUGNAME	ODSH
D09AWM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0L8KJ	TTDDRUID	D0L8KJ
D0L8KJ	DRUGNAME	Oglemilast
D0L8KJ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0AX1N	TTDDRUID	D0AX1N
D0AX1N	DRUGNAME	OGX-427
D0AX1N	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0AX1N	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0AX1N	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
D0AX1N	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0AX1N	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0A4ZZ	TTDDRUID	D0A4ZZ
D0A4ZZ	DRUGNAME	OHR/AVR118
D0A4ZZ	INDICATI	Cachexia [ICD-11: MG20] Phase 2

D06QWM	TTDDRUID	D06QWM
D06QWM	DRUGNAME	OI338GT
D06QWM	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D06QWM	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2
D06QWM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D08WYK	TTDDRUID	D08WYK
D08WYK	DRUGNAME	OJP-2028
D08WYK	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0L5GH	TTDDRUID	D0L5GH
D0L5GH	DRUGNAME	Olcegepant
D0L5GH	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D0N5CW	TTDDRUID	D0N5CW
D0N5CW	DRUGNAME	Oleoyl-estrone
D0N5CW	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0N5CW	INDICATI	Obesity [ICD-11: 5B81] Phase 2
D0N5CW	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D0V9UA	TTDDRUID	D0V9UA
D0V9UA	DRUGNAME	OligoG CF-5/20
D0V9UA	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0YX3D	TTDDRUID	D0YX3D
D0YX3D	DRUGNAME	Olipudase alfa
D0YX3D	INDICATI	Sphingolipidosis [ICD-11: 5C56.0] Phase 2

D02VIF	TTDDRUID	D02VIF
D02VIF	DRUGNAME	OLT1177 gel
D02VIF	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0JB3H	TTDDRUID	D0JB3H
D0JB3H	DRUGNAME	Omaveloxolone
D0JB3H	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
D0JB3H	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D06KSV	TTDDRUID	D06KSV
D06KSV	DRUGNAME	Omigapil
D06KSV	INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2
D06KSV	INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 1

D0KZ3Q	TTDDRUID	D0KZ3Q
D0KZ3Q	DRUGNAME	Omnitram
D0KZ3Q	INDICATI	Chronic pain [ICD-11: MG30] Phase 2

D05HUG	TTDDRUID	D05HUG
D05HUG	DRUGNAME	OMS-403
D05HUG	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2
D05HUG	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D0W0JP	TTDDRUID	D0W0JP
D0W0JP	DRUGNAME	OMS405
D0W0JP	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2
D0W0JP	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D0QU0H	TTDDRUID	D0QU0H
D0QU0H	DRUGNAME	OMS721
D0QU0H	INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Phase 2
D0QU0H	INDICATI	Lupus [ICD-11: 4A40] Phase 2
D0QU0H	INDICATI	Thrombotic microangiopathy [ICD-11: 3B65] Phase 2

D0U3QK	TTDDRUID	D0U3QK
D0U3QK	DRUGNAME	OMS824
D0U3QK	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2

D05AKH	TTDDRUID	D05AKH
D05AKH	DRUGNAME	OnabotulinumtoxinA
D05AKH	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D07XQS	TTDDRUID	D07XQS
D07XQS	DRUGNAME	ONC201
D07XQS	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
D07XQS	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D07XQS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D07XQS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D07XQS	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
D07XQS	INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 2
D07XQS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D07XQS	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D05HJR	TTDDRUID	D05HJR
D05HJR	DRUGNAME	Oncoprex
D05HJR	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0F5JR	TTDDRUID	D0F5JR
D0F5JR	DRUGNAME	ONO-1603
D0F5JR	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D08UYM	TTDDRUID	D08UYM
D08UYM	DRUGNAME	ONO-2333Ms
D08UYM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D05CMZ	TTDDRUID	D05CMZ
D05CMZ	DRUGNAME	ONO-2952
D05CMZ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D02ALZ	TTDDRUID	D02ALZ
D02ALZ	DRUGNAME	ONO-3307
D02ALZ	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2

D04NWU	TTDDRUID	D04NWU
D04NWU	DRUGNAME	ONO-4053
D04NWU	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0I2RB	TTDDRUID	D0I2RB
D0I2RB	DRUGNAME	ONO-4641
D0I2RB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0PP8G	TTDDRUID	D0PP8G
D0PP8G	DRUGNAME	ONO-5129
D0PP8G	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0M5BS	TTDDRUID	D0M5BS
D0M5BS	DRUGNAME	ONO-6126
D0M5BS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0U5YM	TTDDRUID	D0U5YM
D0U5YM	DRUGNAME	ONO-6950
D0U5YM	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0V5QH	TTDDRUID	D0V5QH
D0V5QH	DRUGNAME	ONO-9054
D0V5QH	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D03YAS	TTDDRUID	D03YAS
D03YAS	DRUGNAME	ONO-AE1-437
D03YAS	INDICATI	Asthma [ICD-11: CA23] Phase 2

D08ZKJ	TTDDRUID	D08ZKJ
D08ZKJ	DRUGNAME	Ontazolast
D08ZKJ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0FK9H	TTDDRUID	D0FK9H
D0FK9H	DRUGNAME	Ontuxizumab
D0FK9H	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0FK9H	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
D0FK9H	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2

D09RSY	TTDDRUID	D09RSY
D09RSY	DRUGNAME	Onyvax-P
D09RSY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0R8GR	TTDDRUID	D0R8GR
D0R8GR	DRUGNAME	OPC-14523
D0R8GR	INDICATI	Bulimia nervosa [ICD-11: 6B81] Phase 2
D0R8GR	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1
D0R8GR	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D02VYE	TTDDRUID	D02VYE
D02VYE	DRUGNAME	Opdivo + Yervoy
D02VYE	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D02VYE	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3
D02VYE	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D02VYE	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
D02VYE	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 3

D08ANE	TTDDRUID	D08ANE
D08ANE	DRUGNAME	Opdivo nivolumab +Yervoy ipilimumab
D08ANE	INDICATI	Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2

D02CKH	TTDDRUID	D02CKH
D02CKH	DRUGNAME	OPI-1002
D02CKH	INDICATI	Acute kidney injury [ICD-11: GB60] Phase 2

D0DQ3H	TTDDRUID	D0DQ3H
D0DQ3H	DRUGNAME	Opicinumab
D0DQ3H	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0VI9P	TTDDRUID	D0VI9P
D0VI9P	DRUGNAME	OPN-305
D0VI9P	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D04PUO	TTDDRUID	D04PUO
D04PUO	DRUGNAME	OPNT001
D04PUO	INDICATI	Eating disorder [ICD-11: 6B82] Phase 2

D0B6LT	TTDDRUID	D0B6LT
D0B6LT	DRUGNAME	OPNT002
D0B6LT	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2

D0OF1R	TTDDRUID	D0OF1R
D0OF1R	DRUGNAME	Oportuzumab monatox
D0OF1R	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
D0OF1R	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D0AV1O	TTDDRUID	D0AV1O
D0AV1O	DRUGNAME	Oral contraceptive
D0AV1O	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Phase 2

D04NDK	TTDDRUID	D04NDK
D04NDK	DRUGNAME	Oral human gammaglobulin
D04NDK	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
D04NDK	INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 2

D0A6YS	TTDDRUID	D0A6YS
D0A6YS	DRUGNAME	Oral immunoglobulin
D0A6YS	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 2

D0E2WF	TTDDRUID	D0E2WF
D0E2WF	DRUGNAME	ORG 34517/34850
D0E2WF	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
D0E2WF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00QOF	TTDDRUID	D00QOF
D00QOF	DRUGNAME	ORG-13011
D00QOF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
D00QOF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Application submitted
D00QOF	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D0LT0U	TTDDRUID	D0LT0U
D0LT0U	DRUGNAME	ORG-25935
D0LT0U	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D09PLF	TTDDRUID	D09PLF
D09PLF	DRUGNAME	Org-30029
D09PLF	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D05MDJ	TTDDRUID	D05MDJ
D05MDJ	DRUGNAME	ORG-34517
D05MDJ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2

D0D5FR	TTDDRUID	D0D5FR
D0D5FR	DRUGNAME	Organosphosphates
D0D5FR	INDICATI	Candidiasis [ICD-11: 1F23] Phase 2
D0D5FR	INDICATI	Propagation of disease by mosquito [ICD-11: 1C80-1D48] Phase 2

D0B3ZF	TTDDRUID	D0B3ZF
D0B3ZF	DRUGNAME	ORM-12741
D0B3ZF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D05XXF	TTDDRUID	D05XXF
D05XXF	DRUGNAME	ORMD-0901
D05XXF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D06MGW	TTDDRUID	D06MGW
D06MGW	DRUGNAME	OrniFlu
D06MGW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0YX7E	TTDDRUID	D0YX7E
D0YX7E	DRUGNAME	Ortataxel
D0YX7E	INDICATI	Heart transplant rejection [ICD-11: NE84] Preclinical
D0YX7E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02WRV	TTDDRUID	D02WRV
D02WRV	DRUGNAME	OrthoDerm
D02WRV	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 2

D0P1YE	TTDDRUID	D0P1YE
D0P1YE	DRUGNAME	Orvepitant
D0P1YE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
D0P1YE	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2

D07KAK	TTDDRUID	D07KAK
D07KAK	DRUGNAME	OSH-101
D07KAK	INDICATI	Alopecia [ICD-11: ED70] Phase 2

D01SAV	TTDDRUID	D01SAV
D01SAV	DRUGNAME	Oshadi D
D01SAV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08UQC	TTDDRUID	D08UQC
D08UQC	DRUGNAME	Oshadi R
D08UQC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0H7XL	TTDDRUID	D0H7XL
D0H7XL	DRUGNAME	OSI-027
D0H7XL	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0S7FR	TTDDRUID	D0S7FR
D0S7FR	DRUGNAME	Ostabolin-C
D0S7FR	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D0P1FZ	TTDDRUID	D0P1FZ
D0P1FZ	DRUGNAME	Osteoblast cell therapy
D0P1FZ	INDICATI	Osteonecrosis [ICD-11: FB81] Phase 2

D0P1IX	TTDDRUID	D0P1IX
D0P1IX	DRUGNAME	OT-551
D0P1IX	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 2

D0O2VZ	TTDDRUID	D0O2VZ
D0O2VZ	DRUGNAME	Otelixizumab
D0O2VZ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D03TVY	TTDDRUID	D03TVY
D03TVY	DRUGNAME	OTI-030
D03TVY	INDICATI	Knee injuries [ICD-11: NC9Z] Phase 2

D0I9IL	TTDDRUID	D0I9IL
D0I9IL	DRUGNAME	OTL38
D0I9IL	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D08JGB	TTDDRUID	D08JGB
D08JGB	DRUGNAME	Otlertuzumab
D08JGB	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D08JGB	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2

D0TR3Y	TTDDRUID	D0TR3Y
D0TR3Y	DRUGNAME	Ovapuldencel-T
D0TR3Y	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0TR3Y	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 2

D05EKO	TTDDRUID	D05EKO
D05EKO	DRUGNAME	OvaSave
D05EKO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0A3ES	TTDDRUID	D0A3ES
D0A3ES	DRUGNAME	OX-51
D0A3ES	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0RJ1W	TTDDRUID	D0RJ1W
D0RJ1W	DRUGNAME	OX-914
D0RJ1W	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0F9FR	TTDDRUID	D0F9FR
D0F9FR	DRUGNAME	Oxazolidinones
D0F9FR	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2

D0K2OV	TTDDRUID	D0K2OV
D0K2OV	DRUGNAME	Oxytrex
D0K2OV	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D04TBC	TTDDRUID	D04TBC
D04TBC	DRUGNAME	OZ-439
D04TBC	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D0P6CF	TTDDRUID	D0P6CF
D0P6CF	DRUGNAME	Ozanezumab
D0P6CF	INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2

D0S9BH	TTDDRUID	D0S9BH
D0S9BH	DRUGNAME	Ozarelix
D0S9BH	INDICATI	Prostate disease [ICD-11: GA91] Phase 2

D05EPV	TTDDRUID	D05EPV
D05EPV	DRUGNAME	Ozoralizumab
D05EPV	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0JF3M	TTDDRUID	D0JF3M
D0JF3M	DRUGNAME	P-144
D0JF3M	INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2

D01CEG	TTDDRUID	D01CEG
D01CEG	DRUGNAME	P-1736
D01CEG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0V8BU	TTDDRUID	D0V8BU
D0V8BU	DRUGNAME	P-2202
D0V8BU	INDICATI	Syndrome X [ICD-11: 5C53.4] Phase 2

D0W8IY	TTDDRUID	D0W8IY
D0W8IY	DRUGNAME	P-276
D0W8IY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D05IRT	TTDDRUID	D05IRT
D05IRT	DRUGNAME	P276-00
D05IRT	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2

D0H2IO	TTDDRUID	D0H2IO
D0H2IO	DRUGNAME	P32/98
D0H2IO	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2

D0V3LM	TTDDRUID	D0V3LM
D0V3LM	DRUGNAME	P54
D0V3LM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0C9IS	TTDDRUID	D0C9IS
D0C9IS	DRUGNAME	P-9808
D0C9IS	INDICATI	Porphyria [ICD-11: 5C58.1] Phase 2

D0G4AL	TTDDRUID	D0G4AL
D0G4AL	DRUGNAME	PA101
D0G4AL	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D0G4CY	TTDDRUID	D0G4CY
D0G4CY	DRUGNAME	PA101B
D0G4CY	INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Phase 2

D01CXJ	TTDDRUID	D01CXJ
D01CXJ	DRUGNAME	PAC-113
D01CXJ	INDICATI	Oral candidiasis [ICD-11: 1F23.0] Phase 2

D09BDE	TTDDRUID	D09BDE
D09BDE	DRUGNAME	PAC-14028
D09BDE	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0L3YP	TTDDRUID	D0L3YP
D0L3YP	DRUGNAME	Paclitaxel liposomal
D0L3YP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0GO0R	TTDDRUID	D0GO0R
D0GO0R	DRUGNAME	Padeliporfin di-potassium
D0GO0R	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D04FDN	TTDDRUID	D04FDN
D04FDN	DRUGNAME	Palifosfamide
D04FDN	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2

D05KVC	TTDDRUID	D05KVC
D05KVC	DRUGNAME	Paliroden
D05KVC	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0H8OH	TTDDRUID	D0H8OH
D0H8OH	DRUGNAME	Palovarotene
D0H8OH	INDICATI	Emphysema [ICD-11: CA21] Phase 2
D0H8OH	INDICATI	Fibrodysplasia ossificans progressiva [ICD-11: FB31.1] Phase 2

D09TJJ	TTDDRUID	D09TJJ
D09TJJ	DRUGNAME	Pamrevlumab
D09TJJ	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
D09TJJ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D06BIE	TTDDRUID	D06BIE
D06BIE	DRUGNAME	PanBlok
D06BIE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
D06BIE	INDICATI	Pandemic influenza infection [ICD-11: 1E30] Phase 2

D0JK2U	TTDDRUID	D0JK2U
D0JK2U	DRUGNAME	Pancreatic cancer cell therapy
D0JK2U	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D08EFL	TTDDRUID	D08EFL
D08EFL	DRUGNAME	Pancreatic cancer vaccine
D08EFL	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0T1KL	TTDDRUID	D0T1KL
D0T1KL	DRUGNAME	Pankomab-GEX
D0T1KL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03PSP	TTDDRUID	D03PSP
D03PSP	DRUGNAME	Panobacumab
D03PSP	INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2
D03PSP	INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1/2
D03PSP	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2

D0G5SU	TTDDRUID	D0G5SU
D0G5SU	DRUGNAME	Paquinimod
D0G5SU	INDICATI	Lupus [ICD-11: 4A40] Phase 2

D06MNF	TTDDRUID	D06MNF
D06MNF	DRUGNAME	Pardoprunox
D06MNF	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0D8LK	TTDDRUID	D0D8LK
D0D8LK	DRUGNAME	Parvovirus B19 vaccine
D0D8LK	INDICATI	Parvovirus infection [ICD-11: 1D93] Phase 2

D0NO1L	TTDDRUID	D0NO1L
D0NO1L	DRUGNAME	Pascolizumab
D0NO1L	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0GD4Q	TTDDRUID	D0GD4Q
D0GD4Q	DRUGNAME	Patidegib
D0GD4Q	INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 2
D0GD4Q	INDICATI	Basal cell nevus syndrome [ICD-11: 2C32] Phase 2

D0H9WY	TTDDRUID	D0H9WY
D0H9WY	DRUGNAME	PAZ-320
D0H9WY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D03UKJ	TTDDRUID	D03UKJ
D03UKJ	DRUGNAME	Pazopanib + Tyverb/Tykerb
D03UKJ	INDICATI	Inflammatory breast cancer [ICD-11: 2C62] Phase 2

D03MSV	TTDDRUID	D03MSV
D03MSV	DRUGNAME	PB-1023
D03MSV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0A4YK	TTDDRUID	D0A4YK
D0A4YK	DRUGNAME	PBI-05204
D0A4YK	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D0A4YK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00GXL	TTDDRUID	D00GXL
D00GXL	DRUGNAME	PBT-2
D00GXL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D00GXL	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2

D09TFL	TTDDRUID	D09TFL
D09TFL	DRUGNAME	PCI-27483
D09TFL	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D01PHK	TTDDRUID	D01PHK
D01PHK	DRUGNAME	PCL-016
D01PHK	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0U6PJ	TTDDRUID	D0U6PJ
D0U6PJ	DRUGNAME	PC-SOD
D0U6PJ	INDICATI	Interstitial lung disease [ICD-11: CB0Z] Phase 2

D0K0YC	TTDDRUID	D0K0YC
D0K0YC	DRUGNAME	PD-0325901
D0K0YC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D02UJD	TTDDRUID	D02UJD
D02UJD	DRUGNAME	PD-143188
D02UJD	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D0OW4A	TTDDRUID	D0OW4A
D0OW4A	DRUGNAME	PD-145065
D0OW4A	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0VF6E	TTDDRUID	D0VF6E
D0VF6E	DRUGNAME	PD173074
D0VF6E	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D07CMN	TTDDRUID	D07CMN
D07CMN	DRUGNAME	PD-200390
D07CMN	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D00UZR	TTDDRUID	D00UZR
D00UZR	DRUGNAME	PD-332991
D00UZR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D00UZR	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
D00UZR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0S1UZ	TTDDRUID	D0S1UZ
D0S1UZ	DRUGNAME	PD-360324
D0S1UZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D04PVE	TTDDRUID	D04PVE
D04PVE	DRUGNAME	PDA-002
D04PVE	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
D04PVE	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D04PVE	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
D04PVE	INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2

D06APO	TTDDRUID	D06APO
D06APO	DRUGNAME	PDC-748
D06APO	INDICATI	Cough [ICD-11: MD12] Phase 2

D0XT6W	TTDDRUID	D0XT6W
D0XT6W	DRUGNAME	PDX-101
D0XT6W	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0XT6W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0I4HS	TTDDRUID	D0I4HS
D0I4HS	DRUGNAME	PE0139
D0I4HS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
D0I4HS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0D4CX	TTDDRUID	D0D4CX
D0D4CX	DRUGNAME	Pegamotecan
D0D4CX	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2

D00FZZ	TTDDRUID	D00FZZ
D00FZZ	DRUGNAME	PEG-FGF-21
D00FZZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D08BMV	TTDDRUID	D08BMV
D08BMV	DRUGNAME	PEG-hGH
D08BMV	INDICATI	Dwarfism [ICD-11: 5B11] Phase 2

D0K8FI	TTDDRUID	D0K8FI
D0K8FI	DRUGNAME	Pegmusirudin
D0K8FI	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D05INV	TTDDRUID	D05INV
D05INV	DRUGNAME	PEGPH20
D05INV	INDICATI	Gallbladder disease [ICD-11: DC11.3] Phase 1
D05INV	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D05INV	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D05INV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D05UFP	TTDDRUID	D05UFP
D05UFP	DRUGNAME	PEG-SN38
D05UFP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D05UFP	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2

D04GTA	TTDDRUID	D04GTA
D04GTA	DRUGNAME	Pegsunercept
D04GTA	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D03FUG	TTDDRUID	D03FUG
D03FUG	DRUGNAME	Pegylated carboxyhemoglobin
D03FUG	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2

D00KQN	TTDDRUID	D00KQN
D00KQN	DRUGNAME	PEGylated pitrakinra
D00KQN	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
D00KQN	INDICATI	Asthma [ICD-11: CA23] Phase 2

D07AOL	TTDDRUID	D07AOL
D07AOL	DRUGNAME	PEITC
D07AOL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0S3PO	TTDDRUID	D0S3PO
D0S3PO	DRUGNAME	Pelitinib
D0S3PO	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D0J9IH	TTDDRUID	D0J9IH
D0J9IH	DRUGNAME	PELITREXOL
D0J9IH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0A3JJ	TTDDRUID	D0A3JJ
D0A3JJ	DRUGNAME	Pentacea
D0A3JJ	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0J8YA	TTDDRUID	D0J8YA
D0J8YA	DRUGNAME	PentaLyte
D0J8YA	INDICATI	Blood transfusion [ICD-11: QB98] Phase 2

D08CJM	TTDDRUID	D08CJM
D08CJM	DRUGNAME	Peptide YY 3-36
D08CJM	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0W4VH	TTDDRUID	D0W4VH
D0W4VH	DRUGNAME	Peptide-T
D0W4VH	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 2

D0CH9G	TTDDRUID	D0CH9G
D0CH9G	DRUGNAME	Pepvax
D0CH9G	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2

D03ZIS	TTDDRUID	D03ZIS
D03ZIS	DRUGNAME	PERFOSFAMIDE
D03ZIS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0U8IU	TTDDRUID	D0U8IU
D0U8IU	DRUGNAME	PerioPatch
D0U8IU	INDICATI	Periodontal disease [ICD-11: DA0C] Phase 2

D07WAA	TTDDRUID	D07WAA
D07WAA	DRUGNAME	Personalized peptide vaccine
D07WAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0W9SN	TTDDRUID	D0W9SN
D0W9SN	DRUGNAME	Pertuzumab + trastuzumab
D0W9SN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D01JTW	TTDDRUID	D01JTW
D01JTW	DRUGNAME	PEV3A
D01JTW	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D07HZG	TTDDRUID	D07HZG
D07HZG	DRUGNAME	PF-00734200
D07HZG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0OH2W	TTDDRUID	D0OH2W
D0OH2W	DRUGNAME	PF-02545920
D0OH2W	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
D0OH2W	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D00GPQ	TTDDRUID	D00GPQ
D00GPQ	DRUGNAME	PF-03084014
D00GPQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D00GPQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08JBL	TTDDRUID	D08JBL
D08JBL	DRUGNAME	PF-03446962
D08JBL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0A1WN	TTDDRUID	D0A1WN
D0A1WN	DRUGNAME	PF-03715455
D0A1WN	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D01PLR	TTDDRUID	D01PLR
D01PLR	DRUGNAME	PF-04171327
D01PLR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D06NXG	TTDDRUID	D06NXG
D06NXG	DRUGNAME	PF-04236921
D06NXG	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D06NXG	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D0JT5I	TTDDRUID	D0JT5I
D0JT5I	DRUGNAME	PF-04457845
D0JT5I	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2

D01VVL	TTDDRUID	D01VVL
D01VVL	DRUGNAME	PF-04523655
D01VVL	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D0D9HA	TTDDRUID	D0D9HA
D0D9HA	DRUGNAME	PF-04634817
D0D9HA	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0N5JZ	TTDDRUID	D0N5JZ
D0N5JZ	DRUGNAME	PF-04691502
D0N5JZ	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2

D0M5PH	TTDDRUID	D0M5PH
D0M5PH	DRUGNAME	PF-04937319
D0M5PH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0G8UY	TTDDRUID	D0G8UY
D0G8UY	DRUGNAME	PF-04958242
D0G8UY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
D0G8UY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0C6MS	TTDDRUID	D0C6MS
D0C6MS	DRUGNAME	PF-04991532
D0C6MS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0O7QA	TTDDRUID	D0O7QA
D0O7QA	DRUGNAME	PF-05089771
D0O7QA	INDICATI	Chronic pain [ICD-11: MG30] Phase 2

D03KHO	TTDDRUID	D03KHO
D03KHO	DRUGNAME	PF-05175157
D03KHO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0G1YA	TTDDRUID	D0G1YA
D0G1YA	DRUGNAME	PF-05212377
D0G1YA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0D8JB	TTDDRUID	D0D8JB
D0D8JB	DRUGNAME	PF-05212384
D0D8JB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05KKP	TTDDRUID	D05KKP
D05KKP	DRUGNAME	PF-06252616
D05KKP	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
D05KKP	INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2

D01DXI	TTDDRUID	D01DXI
D01DXI	DRUGNAME	PF-06290510
D01DXI	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
D01DXI	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2

D0V7SO	TTDDRUID	D0V7SO
D0V7SO	DRUGNAME	PF-06291874
D0V7SO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D06TQR	TTDDRUID	D06TQR
D06TQR	DRUGNAME	PF-06372865
D06TQR	INDICATI	Chronic pain [ICD-11: MG30] Phase 2

D04DYC	TTDDRUID	D04DYC
D04DYC	DRUGNAME	PF-06463922
D04DYC	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D04DYC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D02TUL	TTDDRUID	D02TUL
D02TUL	DRUGNAME	PF-06651600
D02TUL	INDICATI	Asthma [ICD-11: CA23] Phase 2
D02TUL	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D0V4DX	TTDDRUID	D0V4DX
D0V4DX	DRUGNAME	PF-06700841
D0V4DX	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0V4DX	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D0V4DX	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0F7PZ	TTDDRUID	D0F7PZ
D0F7PZ	DRUGNAME	PF-232798
D0F7PZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0O0BM	TTDDRUID	D0O0BM
D0O0BM	DRUGNAME	PF-3463275
D0O0BM	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0I5XU	TTDDRUID	D0I5XU
D0I5XU	DRUGNAME	PF-3635659
D0I5XU	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D06IFR	TTDDRUID	D06IFR
D06IFR	DRUGNAME	PF-3654764
D06IFR	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D02DTQ	TTDDRUID	D02DTQ
D02DTQ	DRUGNAME	PF-3893787
D02DTQ	INDICATI	Asthma [ICD-11: CA23] Phase 1
D02DTQ	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D02DTQ	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D06EPO	TTDDRUID	D06EPO
D06EPO	DRUGNAME	PF-4136309
D06EPO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0L5XG	TTDDRUID	D0L5XG
D0L5XG	DRUGNAME	PF-4191834
D0L5XG	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0A9IY	TTDDRUID	D0A9IY
D0A9IY	DRUGNAME	PF-4447943
D0A9IY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0A9IY	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1

D04QUX	TTDDRUID	D04QUX
D04QUX	DRUGNAME	PF-446687
D04QUX	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 2

D0NN5H	TTDDRUID	D0NN5H
D0NN5H	DRUGNAME	PF-4523655
D0NN5H	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
D0NN5H	INDICATI	Diabetic macular degeneration [ICD-11: 9B78] Phase 2

D09TOK	TTDDRUID	D09TOK
D09TOK	DRUGNAME	PF-4531083
D09TOK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0M9FQ	TTDDRUID	D0M9FQ
D0M9FQ	DRUGNAME	PF-489791
D0M9FQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
D0M9FQ	INDICATI	Raynaud disease [ICD-11: BD42.0] Phase 2

D04IQH	TTDDRUID	D04IQH
D04IQH	DRUGNAME	PF-655
D04IQH	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D07SKN	TTDDRUID	D07SKN
D07SKN	DRUGNAME	PF-885706
D07SKN	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 2

D07LUA	TTDDRUID	D07LUA
D07LUA	DRUGNAME	PfSPZ-GA1
D07LUA	INDICATI	Plasmodium falciparum malaria [ICD-11: 1F40] Phase 2

D05KAC	TTDDRUID	D05KAC
D05KAC	DRUGNAME	PG-102
D05KAC	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D03PBW	TTDDRUID	D03PBW
D03PBW	DRUGNAME	PG-760564
D03PBW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0I3RN	TTDDRUID	D0I3RN
D0I3RN	DRUGNAME	PGL-2
D0I3RN	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D04ZND	TTDDRUID	D04ZND
D04ZND	DRUGNAME	PGL-2001
D04ZND	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D0L1VF	TTDDRUID	D0L1VF
D0L1VF	DRUGNAME	PH-10
D0L1VF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0F7IG	TTDDRUID	D0F7IG
D0F7IG	DRUGNAME	PH10 nasal spray
D0F7IG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0H4IM	TTDDRUID	D0H4IM
D0H4IM	DRUGNAME	PH-284
D0H4IM	INDICATI	Cachexia [ICD-11: MG20] Phase 2

D0K1SR	TTDDRUID	D0K1SR
D0K1SR	DRUGNAME	PH-794428
D0K1SR	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D0K2ZF	TTDDRUID	D0K2ZF
D0K2ZF	DRUGNAME	PH-797804
D0K2ZF	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0WR7C	TTDDRUID	D0WR7C
D0WR7C	DRUGNAME	PH-94B
D0WR7C	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D02RJY	TTDDRUID	D02RJY
D02RJY	DRUGNAME	PHA-739358
D02RJY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0Q9UX	TTDDRUID	D0Q9UX
D0Q9UX	DRUGNAME	PHA848125
D0Q9UX	INDICATI	Thymic cancer [ICD-11: 2C27] Phase 2

D00IDR	TTDDRUID	D00IDR
D00IDR	DRUGNAME	Phenylalanine hydroxylase
D00IDR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0B7CH	TTDDRUID	D0B7CH
D0B7CH	DRUGNAME	Phenylbutyrate
D0B7CH	INDICATI	Urea cycle disorder [ICD-11: 5C50.A] Phase 2

D0U0DD	TTDDRUID	D0U0DD
D0U0DD	DRUGNAME	Phleum pratense-containing vaccine
D0U0DD	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2

D0H5MW	TTDDRUID	D0H5MW
D0H5MW	DRUGNAME	PHN-021
D0H5MW	INDICATI	Motion sickness [ICD-11: NF08.3] Phase 2

D0IK1I	TTDDRUID	D0IK1I
D0IK1I	DRUGNAME	PHN-031
D0IK1I	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D09DHT	TTDDRUID	D09DHT
D09DHT	DRUGNAME	phorbol 12-myristate 13-acetate
D09DHT	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D09DHT	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2

D01DJI	TTDDRUID	D01DJI
D01DJI	DRUGNAME	PHY-906
D01DJI	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D0Y0PY	TTDDRUID	D0Y0PY
D0Y0PY	DRUGNAME	PI-2301
D0Y0PY	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0K8LB	TTDDRUID	D0K8LB
D0K8LB	DRUGNAME	PI-88/Taxotere
D0K8LB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0X2XF	TTDDRUID	D0X2XF
D0X2XF	DRUGNAME	Piboserod
D0X2XF	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D0Z2FB	TTDDRUID	D0Z2FB
D0Z2FB	DRUGNAME	Piclamilast
D0Z2FB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0K1EO	TTDDRUID	D0K1EO
D0K1EO	DRUGNAME	Picroliv
D0K1EO	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2

D09MRL	TTDDRUID	D09MRL
D09MRL	DRUGNAME	Pidilizumab
D09MRL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2

D03YXI	TTDDRUID	D03YXI
D03YXI	DRUGNAME	PIKAMILONE
D03YXI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D09AYQ	TTDDRUID	D09AYQ
D09AYQ	DRUGNAME	PIRITREXIM
D09AYQ	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D0S2UR	TTDDRUID	D0S2UR
D0S2UR	DRUGNAME	PIRODOMAST
D0S2UR	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0O2AG	TTDDRUID	D0O2AG
D0O2AG	DRUGNAME	Pirsidomine
D0O2AG	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D01ZMS	TTDDRUID	D01ZMS
D01ZMS	DRUGNAME	PK1
D01ZMS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05PXL	TTDDRUID	D05PXL
D05PXL	DRUGNAME	PL-3394
D05PXL	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2

D0X8QO	TTDDRUID	D0X8QO
D0X8QO	DRUGNAME	PL-3994
D0X8QO	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0X8QO	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
D0X8QO	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0BL5U	TTDDRUID	D0BL5U
D0BL5U	DRUGNAME	PL-3994 NPR-A
D0BL5U	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D00ALJ	TTDDRUID	D00ALJ
D00ALJ	DRUGNAME	Placental expanded stem cell therapy
D00ALJ	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D0J1FZ	TTDDRUID	D0J1FZ
D0J1FZ	DRUGNAME	Plague injectable vaccine
D0J1FZ	INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2

D0W3GE	TTDDRUID	D0W3GE
D0W3GE	DRUGNAME	Plague vaccine injectable
D0W3GE	INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2
D0W3GE	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0K4OF	TTDDRUID	D0K4OF
D0K4OF	DRUGNAME	PlaMavax
D0K4OF	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D0L9XS	TTDDRUID	D0L9XS
D0L9XS	DRUGNAME	Plasmin
D0L9XS	INDICATI	Occlusive disease [ICD-11: BD4Z] Phase 2
D0L9XS	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D0W1US	TTDDRUID	D0W1US
D0W1US	DRUGNAME	PLECONARIL
D0W1US	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D0I9GR	TTDDRUID	D0I9GR
D0I9GR	DRUGNAME	Plevitrexed
D0I9GR	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D04FYZ	TTDDRUID	D04FYZ
D04FYZ	DRUGNAME	Plevitrexed (R)-isomer
D04FYZ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D0BT6G	TTDDRUID	D0BT6G
D0BT6G	DRUGNAME	Plovamer acetate
D0BT6G	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D05HTS	TTDDRUID	D05HTS
D05HTS	DRUGNAME	PLX8394
D05HTS	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D05HTS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0G4HO	TTDDRUID	D0G4HO
D0G4HO	DRUGNAME	PLX-PAD
D0G4HO	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D0M7PU	TTDDRUID	D0M7PU
D0M7PU	DRUGNAME	PM-00104
D0M7PU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06YSM	TTDDRUID	D06YSM
D06YSM	DRUGNAME	PM01183
D06YSM	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D05BGY	TTDDRUID	D05BGY
D05BGY	DRUGNAME	PM184
D05BGY	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0T2LR	TTDDRUID	D0T2LR
D0T2LR	DRUGNAME	PMX-30063 topical oral rinse
D0T2LR	INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 2

D0G2XE	TTDDRUID	D0G2XE
D0G2XE	DRUGNAME	PMX-53
D0G2XE	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D08HXG	TTDDRUID	D08HXG
D08HXG	DRUGNAME	PMX-60056
D08HXG	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2

D03YIX	TTDDRUID	D03YIX
D03YIX	DRUGNAME	Pneumostem
D03YIX	INDICATI	Bronchopulmonary dysplasia [ICD-11: KB29.0] Phase 1/2
D03YIX	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Phase 2

D07ACL	TTDDRUID	D07ACL
D07ACL	DRUGNAME	PNT-2258
D07ACL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D07ACL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Q9IY	TTDDRUID	D0Q9IY
D0Q9IY	DRUGNAME	PNU-142731A
D0Q9IY	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0FV8P	TTDDRUID	D0FV8P
D0FV8P	DRUGNAME	POL-6326
D0FV8P	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0FV8P	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D06LXP	TTDDRUID	D06LXP
D06LXP	DRUGNAME	POL-7080
D06LXP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0K0IS	TTDDRUID	D0K0IS
D0K0IS	DRUGNAME	Polyglutamate camptothecin
D0K0IS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0V8AG	TTDDRUID	D0V8AG
D0V8AG	DRUGNAME	Poly-ICLC
D0V8AG	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D0V8AG	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
D0V8AG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00DSV	TTDDRUID	D00DSV
D00DSV	DRUGNAME	Polynoma-1
D00DSV	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0B5EB	TTDDRUID	D0B5EB
D0B5EB	DRUGNAME	Ponezumab
D0B5EB	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D01SQI	TTDDRUID	D01SQI
D01SQI	DRUGNAME	POT-4
D01SQI	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D03QWZ	TTDDRUID	D03QWZ
D03QWZ	DRUGNAME	PP-099
D03QWZ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D06CFT	TTDDRUID	D06CFT
D06CFT	DRUGNAME	PP-4001
D06CFT	INDICATI	Cystitis [ICD-11: GC00] Phase 2

D0HD7C	TTDDRUID	D0HD7C
D0HD7C	DRUGNAME	PPA-904
D0HD7C	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0D6MV	TTDDRUID	D0D6MV
D0D6MV	DRUGNAME	PPI-668
D0D6MV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0UD4Y	TTDDRUID	D0UD4Y
D0UD4Y	DRUGNAME	PQ-912
D0UD4Y	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2

D05CFG	TTDDRUID	D05CFG
D05CFG	DRUGNAME	PR104
D05CFG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0L2UQ	TTDDRUID	D0L2UQ
D0L2UQ	DRUGNAME	Pracinostat
D0L2UQ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D0L2UQ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D0L2UQ	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2

D0D5CY	TTDDRUID	D0D5CY
D0D5CY	DRUGNAME	Pradefovir
D0D5CY	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2

D0U6WQ	TTDDRUID	D0U6WQ
D0U6WQ	DRUGNAME	PRALNACASAN
D0U6WQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0E2RS	TTDDRUID	D0E2RS
D0E2RS	DRUGNAME	PRAME immunotherapeutic
D0E2RS	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0Y2HA	TTDDRUID	D0Y2HA
D0Y2HA	DRUGNAME	Pramiconazole
D0Y2HA	INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 2

D03WAT	TTDDRUID	D03WAT
D03WAT	DRUGNAME	PRC-4016
D03WAT	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2

D0R4NR	TTDDRUID	D0R4NR
D0R4NR	DRUGNAME	Prednisone/ dipyridamole
D0R4NR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0DJ4A	TTDDRUID	D0DJ4A
D0DJ4A	DRUGNAME	Preverex
D0DJ4A	INDICATI	Artery stenosis [ICD-11: BD52] Phase 2

D0W3GR	TTDDRUID	D0W3GR
D0W3GR	DRUGNAME	Prexigebersen
D0W3GR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0W3GR	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2

D0H6ZA	TTDDRUID	D0H6ZA
D0H6ZA	DRUGNAME	Pritumumab
D0H6ZA	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2

D09EDA	TTDDRUID	D09EDA
D09EDA	DRUGNAME	PRM-151
D09EDA	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
D09EDA	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
D09EDA	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
D09EDA	INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
D09EDA	INDICATI	Thrombocythemia [ICD-11: 3B63] Phase 2

D0GH7L	TTDDRUID	D0GH7L
D0GH7L	DRUGNAME	PRN1008
D0GH7L	INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 2

D0K6HE	TTDDRUID	D0K6HE
D0K6HE	DRUGNAME	PRO-001
D0K6HE	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 2

D05DFV	TTDDRUID	D05DFV
D05DFV	DRUGNAME	PRO-044
D05DFV	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D05MJS	TTDDRUID	D05MJS
D05MJS	DRUGNAME	PRO22 topical gel
D05MJS	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D07TYJ	TTDDRUID	D07TYJ
D07TYJ	DRUGNAME	PRO-98498
D07TYJ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D08HHT	TTDDRUID	D08HHT
D08HHT	DRUGNAME	Procervix
D08HHT	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2

D0Y1XD	TTDDRUID	D0Y1XD
D0Y1XD	DRUGNAME	ProCord
D0Y1XD	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2

D0M0UT	TTDDRUID	D0M0UT
D0M0UT	DRUGNAME	Procysteine
D0M0UT	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2

D04HQT	TTDDRUID	D04HQT
D04HQT	DRUGNAME	proglumide
D04HQT	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0C6VV	TTDDRUID	D0C6VV
D0C6VV	DRUGNAME	Prolarix
D0C6VV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02TSJ	TTDDRUID	D02TSJ
D02TSJ	DRUGNAME	Promethazine + sumatriptan
D02TSJ	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D02TGJ	TTDDRUID	D02TGJ
D02TGJ	DRUGNAME	Prophage
D02TGJ	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0R8AG	TTDDRUID	D0R8AG
D0R8AG	DRUGNAME	Prophage cancer vaccine
D0R8AG	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2

D0U2TH	TTDDRUID	D0U2TH
D0U2TH	DRUGNAME	Prophage cancer vaccine G-series
D0U2TH	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D03ZYZ	TTDDRUID	D03ZYZ
D03ZYZ	DRUGNAME	Prophylactic dengue fever vaccine
D03ZYZ	INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 2

D0UK1Q	TTDDRUID	D0UK1Q
D0UK1Q	DRUGNAME	Prosaptide TX14(A)
D0UK1Q	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D05PGG	TTDDRUID	D05PGG
D05PGG	DRUGNAME	Prostvac
D05PGG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D02DWX	TTDDRUID	D02DWX
D02DWX	DRUGNAME	Prostvac-VF
D02DWX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D00TLM	TTDDRUID	D00TLM
D00TLM	DRUGNAME	PRUVANSERIN
D00TLM	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2

D08QHX	TTDDRUID	D08QHX
D08QHX	DRUGNAME	PRX00933
D08QHX	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
D08QHX	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0W4XY	TTDDRUID	D0W4XY
D0W4XY	DRUGNAME	PRX-08066
D0W4XY	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D05BWH	TTDDRUID	D05BWH
D05BWH	DRUGNAME	PRX-3140
D05BWH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D05BWH	INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2

D0C5VQ	TTDDRUID	D0C5VQ
D0C5VQ	DRUGNAME	PRX-321
D0C5VQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0H8GW	TTDDRUID	D0H8GW
D0H8GW	DRUGNAME	PS-938285
D0H8GW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D08VJC	TTDDRUID	D08VJC
D08VJC	DRUGNAME	PSMA ADC
D08VJC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0A7LL	TTDDRUID	D0A7LL
D0A7LL	DRUGNAME	PSMA ADC therapeutic
D0A7LL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0Z5EJ	TTDDRUID	D0Z5EJ
D0Z5EJ	DRUGNAME	PSMA-617
D0Z5EJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D02SEU	TTDDRUID	D02SEU
D02SEU	DRUGNAME	PT-107
D02SEU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D02SEU	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2

D0C9PZ	TTDDRUID	D0C9PZ
D0C9PZ	DRUGNAME	PT2385
D0C9PZ	INDICATI	Brain cancer [ICD-11: 2A00] Investigative
D0C9PZ	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D0C9PZ	INDICATI	Von hippel-lindau disease [ICD-11: 5A75] Phase 2

D05VVX	TTDDRUID	D05VVX
D05VVX	DRUGNAME	PTC299
D05VVX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D05VVX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01UAD	TTDDRUID	D01UAD
D01UAD	DRUGNAME	PTX-022
D01UAD	INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 2

D0E4DO	TTDDRUID	D0E4DO
D0E4DO	DRUGNAME	PTX-111
D0E4DO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0X7CV	TTDDRUID	D0X7CV
D0X7CV	DRUGNAME	PTX-200
D0X7CV	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0X7CV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0X7CV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0X7CV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0I7MT	TTDDRUID	D0I7MT
D0I7MT	DRUGNAME	Puerarin
D0I7MT	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2

D0N5KS	TTDDRUID	D0N5KS
D0N5KS	DRUGNAME	Pumosetrag
D0N5KS	INDICATI	Gastro-oesophageal reflux [ICD-11: DA22] Phase 1
D0N5KS	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D05DZA	TTDDRUID	D05DZA
D05DZA	DRUGNAME	PUR-0110
D05DZA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2

D0A6VA	TTDDRUID	D0A6VA
D0A6VA	DRUGNAME	PVP-ILH liposomes
D0A6VA	INDICATI	Conjunctivitis [ICD-11: 9A60] Phase 2

D04JTD	TTDDRUID	D04JTD
D04JTD	DRUGNAME	PX-12
D04JTD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0AW5T	TTDDRUID	D0AW5T
D0AW5T	DRUGNAME	PX-866
D0AW5T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05ERA	TTDDRUID	D05ERA
D05ERA	DRUGNAME	PXL-01
D05ERA	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2

D0M2TG	TTDDRUID	D0M2TG
D0M2TG	DRUGNAME	PYM-50028
D0M2TG	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2

D0L5MF	TTDDRUID	D0L5MF
D0L5MF	DRUGNAME	PYRAZOLOACRIDINE
D0L5MF	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D09LEP	TTDDRUID	D09LEP
D09LEP	DRUGNAME	Pyrethroids
D09LEP	INDICATI	Pest attack [ICD-11: N.A.] Phase 2

D09QMX	TTDDRUID	D09QMX
D09QMX	DRUGNAME	Q-301
D09QMX	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D09QMX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0QZ3P	TTDDRUID	D0QZ3P
D0QZ3P	DRUGNAME	QAL964
D0QZ3P	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0K1EG	TTDDRUID	D0K1EG
D0K1EG	DRUGNAME	QAV-680
D0K1EG	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D04XVE	TTDDRUID	D04XVE
D04XVE	DRUGNAME	QAX-028
D04XVE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D02QDQ	TTDDRUID	D02QDQ
D02QDQ	DRUGNAME	QAX-576
D02QDQ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D06SCQ	TTDDRUID	D06SCQ
D06SCQ	DRUGNAME	QBM076
D06SCQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0X8OW	TTDDRUID	D0X8OW
D0X8OW	DRUGNAME	QBX258
D0X8OW	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0C1JV	TTDDRUID	D0C1JV
D0C1JV	DRUGNAME	QGC-001
D0C1JV	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D00THA	TTDDRUID	D00THA
D00THA	DRUGNAME	QLT-091001
D00THA	INDICATI	Leber congenital amaurosis [ICD-11: 9B70] Phase 1
D00THA	INDICATI	Restless legs syndrome [ICD-11: 7A80] Phase 2
D00THA	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1

D0B4XX	TTDDRUID	D0B4XX
D0B4XX	DRUGNAME	QR-333
D0B4XX	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D0939G	TTDDRUID	D0939G
D0939G	DRUGNAME	Quisinostat
D0939G	INDICATI	Advanced stage follicular lymphoma [ICD-11: 2A80] Phase 2

D03BHM	TTDDRUID	D03BHM
D03BHM	DRUGNAME	R1507
D03BHM	INDICATI	Graves ophthalmopathy [ICD-11: 9C82.3] Phase 2

D0BE1A	TTDDRUID	D0BE1A
D0BE1A	DRUGNAME	R-209130
D0BE1A	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D04YJN	TTDDRUID	D04YJN
D04YJN	DRUGNAME	R411
D04YJN	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0W8BO	TTDDRUID	D0W8BO
D0W8BO	DRUGNAME	RA101495
D0W8BO	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
D0W8BO	INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 2

D09BDH	TTDDRUID	D09BDH
D09BDH	DRUGNAME	Rabeximod
D09BDH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D08ECW	TTDDRUID	D08ECW
D08ECW	DRUGNAME	Racotumomab
D08ECW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D07KUN	TTDDRUID	D07KUN
D07KUN	DRUGNAME	RAD-1901
D07KUN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0W5PN	TTDDRUID	D0W5PN
D0W5PN	DRUGNAME	Radezolid iv
D0W5PN	INDICATI	Pneumonia [ICD-11: CA40] Phase 2

D0QL8W	TTDDRUID	D0QL8W
D0QL8W	DRUGNAME	Radezolid topical
D0QL8W	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D02LWR	TTDDRUID	D02LWR
D02LWR	DRUGNAME	Radium Ra 223 dichloride
D02LWR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0B1KA	TTDDRUID	D0B1KA
D0B1KA	DRUGNAME	Radretumab
D0B1KA	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2

D03AND	TTDDRUID	D03AND
D03AND	DRUGNAME	RAF265
D03AND	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0ZJ6W	TTDDRUID	D0ZJ6W
D0ZJ6W	DRUGNAME	Ragweed peptide allergy desensitization
D0ZJ6W	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0M4TJ	TTDDRUID	D0M4TJ
D0M4TJ	DRUGNAME	Ralinepag
D0M4TJ	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0ML2V	TTDDRUID	D0ML2V
D0ML2V	DRUGNAME	RALURIDINE
D0ML2V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0AA6Z	TTDDRUID	D0AA6Z
D0AA6Z	DRUGNAME	Rambazole
D0AA6Z	INDICATI	Asthma [ICD-11: CA23] Investigative
D0AA6Z	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0I8QJ	TTDDRUID	D0I8QJ
D0I8QJ	DRUGNAME	Ranpirnase
D0I8QJ	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2

D00JJG	TTDDRUID	D00JJG
D00JJG	DRUGNAME	RAP101
D00JJG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D01EKN	TTDDRUID	D01EKN
D01EKN	DRUGNAME	RAV-12
D01EKN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04GKL	TTDDRUID	D04GKL
D04GKL	DRUGNAME	RAXOFELAST
D04GKL	INDICATI	Ischemia [ICD-11: 8B10-8B11] Phase 2

D00OWU	TTDDRUID	D00OWU
D00OWU	DRUGNAME	RBP-8000
D00OWU	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2

D06UNI	TTDDRUID	D06UNI
D06UNI	DRUGNAME	RBx-10017609
D06UNI	INDICATI	Respiratory disease [ICD-11: CB40] Phase 2

D00XWF	TTDDRUID	D00XWF
D00XWF	DRUGNAME	RBX2660
D00XWF	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2

D0AC8W	TTDDRUID	D0AC8W
D0AC8W	DRUGNAME	RC-3095
D0AC8W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0P3ZN	TTDDRUID	D0P3ZN
D0P3ZN	DRUGNAME	RDEA3170
D0P3ZN	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Phase 2

D06UTH	TTDDRUID	D06UTH
D06UTH	DRUGNAME	RDEA-684
D06UTH	INDICATI	Gout [ICD-11: FA25] Phase 2

D09VYF	TTDDRUID	D09VYF
D09VYF	DRUGNAME	RDEN1delta30
D09VYF	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2

D0A8JM	TTDDRUID	D0A8JM
D0A8JM	DRUGNAME	RDP58
D0A8JM	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2

D05GBV	TTDDRUID	D05GBV
D05GBV	DRUGNAME	RDX-5791
D05GBV	INDICATI	Constipation [ICD-11: DD91.1] Phase 2

D0I3OS	TTDDRUID	D0I3OS
D0I3OS	DRUGNAME	Rebmab-100
D0I3OS	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2

D00SBD	TTDDRUID	D00SBD
D00SBD	DRUGNAME	Recoflavone eye drops
D00SBD	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D04BHS	TTDDRUID	D04BHS
D04BHS	DRUGNAME	Recombinant batroxobin
D04BHS	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 2

D04SUX	TTDDRUID	D04SUX
D04SUX	DRUGNAME	Recombinant birch pollen allergen
D04SUX	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D01IZE	TTDDRUID	D01IZE
D01IZE	DRUGNAME	Recombinant botulinum toxin vaccine
D01IZE	INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2

D0V7KJ	TTDDRUID	D0V7KJ
D0V7KJ	DRUGNAME	Recombinant Clostridium botulinum A/B vaccine
D0V7KJ	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2

D01SNV	TTDDRUID	D01SNV
D01SNV	DRUGNAME	Recombinant human nerve growth factor
D01SNV	INDICATI	Neurotrophic keratitis [ICD-11: 9A74] Phase 2

D0BA7K	TTDDRUID	D0BA7K
D0BA7K	DRUGNAME	Recombinant human relaxin
D0BA7K	INDICATI	Scleroderma [ICD-11: 4A42] Phase 2

D0F7OY	TTDDRUID	D0F7OY
D0F7OY	DRUGNAME	Recombinant plague F1V vaccine
D0F7OY	INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2

D0GG5I	TTDDRUID	D0GG5I
D0GG5I	DRUGNAME	Recombinant RGD-hirudin
D0GG5I	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D07FZC	TTDDRUID	D07FZC
D07FZC	DRUGNAME	Recombinant vaccine
D07FZC	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D03CII	TTDDRUID	D03CII
D03CII	DRUGNAME	Refametinib
D03CII	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03RYJ	TTDDRUID	D03RYJ
D03RYJ	DRUGNAME	REL-1015
D03RYJ	INDICATI	Chronic pain [ICD-11: MG30] Phase 2

D06AIH	TTDDRUID	D06AIH
D06AIH	DRUGNAME	Relamorelin
D06AIH	INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2

D04XJE	TTDDRUID	D04XJE
D04XJE	DRUGNAME	REM-001
D04XJE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00NBJ	TTDDRUID	D00NBJ
D00NBJ	DRUGNAME	Remetinostat
D00NBJ	INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 2
D00NBJ	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2

D0I5ZM	TTDDRUID	D0I5ZM
D0I5ZM	DRUGNAME	Remogli ozin-etabonate
D0I5ZM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0V4MB	TTDDRUID	D0V4MB
D0V4MB	DRUGNAME	Remogliflozin etabonate
D0V4MB	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2
D0V4MB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D00CPQ	TTDDRUID	D00CPQ
D00CPQ	DRUGNAME	RemoSynch
D00CPQ	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0B5RO	TTDDRUID	D0B5RO
D0B5RO	DRUGNAME	REN-1654
D0B5RO	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0VV6V	TTDDRUID	D0VV6V
D0VV6V	DRUGNAME	Reovirus
D0VV6V	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D0VP5X	TTDDRUID	D0VP5X
D0VP5X	DRUGNAME	Research programme: peroxisome proliferator-activated receptor gamma agonist, Omeros
D0VP5X	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Phase 2

D0C3TI	TTDDRUID	D0C3TI
D0C3TI	DRUGNAME	Resimmune
D0C3TI	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
D0C3TI	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D05XJW	TTDDRUID	D05XJW
D05XJW	DRUGNAME	Resiniferatoxin
D05XJW	INDICATI	Cancer related pain [ICD-11: MG30] Phase 1
D05XJW	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
D05XJW	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
D05XJW	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01UXJ	TTDDRUID	D01UXJ
D01UXJ	DRUGNAME	Resminostat
D01UXJ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D06PLP	TTDDRUID	D06PLP
D06PLP	DRUGNAME	Resten-MP
D06PLP	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0M4MG	TTDDRUID	D0M4MG
D0M4MG	DRUGNAME	Resten-NG
D0M4MG	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
D0M4MG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0RD0Y	TTDDRUID	D0RD0Y
D0RD0Y	DRUGNAME	RetinoStat
D0RD0Y	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D03BAC	TTDDRUID	D03BAC
D03BAC	DRUGNAME	Revacept
D03BAC	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2

D0X0PW	TTDDRUID	D0X0PW
D0X0PW	DRUGNAME	Revamilast
D0X0PW	INDICATI	Asthma [ICD-11: CA23] Phase 2

D07DWB	TTDDRUID	D07DWB
D07DWB	DRUGNAME	Revascor
D07DWB	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D0M1MZ	TTDDRUID	D0M1MZ
D0M1MZ	DRUGNAME	Reviroc
D0M1MZ	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2

D04BNA	TTDDRUID	D04BNA
D04BNA	DRUGNAME	RF1V
D04BNA	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Phase 2

D06EIJ	TTDDRUID	D06EIJ
D06EIJ	DRUGNAME	RFT-5.dgA
D06EIJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0O6DE	TTDDRUID	D0O6DE
D0O6DE	DRUGNAME	RG-101
D0O6DE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D02PSS	TTDDRUID	D02PSS
D02PSS	DRUGNAME	RG1577
D02PSS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0A6DI	TTDDRUID	D0A6DI
D0A6DI	DRUGNAME	RG-1662
D0A6DI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0A6DI	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D09DIB	TTDDRUID	D09DIB
D09DIB	DRUGNAME	RG-4929
D09DIB	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2

D04QKU	TTDDRUID	D04QKU
D04QKU	DRUGNAME	RG-7090
D04QKU	INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2

D06NQH	TTDDRUID	D06NQH
D06NQH	DRUGNAME	RG7155
D06NQH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D06NQH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06FTM	TTDDRUID	D06FTM
D06FTM	DRUGNAME	RG7221
D06FTM	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D06FTM	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2

D04ZNL	TTDDRUID	D04ZNL
D04ZNL	DRUGNAME	RG-7234
D04ZNL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0L4HL	TTDDRUID	D0L4HL
D0L4HL	DRUGNAME	RG7314
D0L4HL	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2

D0B3SL	TTDDRUID	D0B3SL
D0B3SL	DRUGNAME	RG7321
D0B3SL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0OC4O	TTDDRUID	D0OC4O
D0OC4O	DRUGNAME	RG7388
D0OC4O	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D0OC4O	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0OC4O	INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
D0OC4O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D0Z4SP	TTDDRUID	D0Z4SP
D0Z4SP	DRUGNAME	RG7426
D0Z4SP	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D0V0GZ	TTDDRUID	D0V0GZ
D0V0GZ	DRUGNAME	RG7440
D0V0GZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03KIZ	TTDDRUID	D03KIZ
D03KIZ	DRUGNAME	RG7596
D03KIZ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2

D05YYP	TTDDRUID	D05YYP
D05YYP	DRUGNAME	RG-7599
D05YYP	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0DQ2D	TTDDRUID	D0DQ2D
D0DQ2D	DRUGNAME	RG7625
D0DQ2D	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 2
D0DQ2D	INDICATI	Coeliac disease [ICD-11: DA95] Phase 1
D0DQ2D	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2

D06XAA	TTDDRUID	D06XAA
D06XAA	DRUGNAME	RG7667
D06XAA	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2

D02ONR	TTDDRUID	D02ONR
D02ONR	DRUGNAME	RG7686
D02ONR	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D07MED	TTDDRUID	D07MED
D07MED	DRUGNAME	RG7716
D07MED	INDICATI	Choroidal neovascularization [ICD-11: 9B76] Phase 2

D0Q1WI	TTDDRUID	D0Q1WI
D0Q1WI	DRUGNAME	RG7745
D0Q1WI	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2

D0U7KH	TTDDRUID	D0U7KH
D0U7KH	DRUGNAME	RG7845
D0U7KH	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
D0U7KH	INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2

D03UZP	TTDDRUID	D03UZP
D03UZP	DRUGNAME	RG7888
D03UZP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D03UZP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D03UZP	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2

D0N5MH	TTDDRUID	D0N5MH
D0N5MH	DRUGNAME	RG7916
D0N5MH	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 2

D05AEE	TTDDRUID	D05AEE
D05AEE	DRUGNAME	RG7935
D05AEE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
D05AEE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0N3EJ	TTDDRUID	D0N3EJ
D0N3EJ	DRUGNAME	RGH-896
D0N3EJ	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2

D0T3CH	TTDDRUID	D0T3CH
D0T3CH	DRUGNAME	RGI-2001
D0T3CH	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1/2
D0T3CH	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2

D0P6JD	TTDDRUID	D0P6JD
D0P6JD	DRUGNAME	RGN-259 eye drops
D0P6JD	INDICATI	Vaginal infection [ICD-11: GA02.0] Phase 2

D0V4IQ	TTDDRUID	D0V4IQ
D0V4IQ	DRUGNAME	RhGDF-5
D0V4IQ	INDICATI	Periodontal disease [ICD-11: DA0C] Phase 2

D0X2AT	TTDDRUID	D0X2AT
D0X2AT	DRUGNAME	Rhopressa
D0X2AT	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D0Y5KL	TTDDRUID	D0Y5KL
D0Y5KL	DRUGNAME	RI-001
D0Y5KL	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D0B3RL	TTDDRUID	D0B3RL
D0B3RL	DRUGNAME	R-IFN-1a
D0B3RL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D05GZD	TTDDRUID	D05GZD
D05GZD	DRUGNAME	Rilapladib
D05GZD	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
D05GZD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D00RJB	TTDDRUID	D00RJB
D00RJB	DRUGNAME	Rilopirox
D00RJB	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D06PHH	TTDDRUID	D06PHH
D06PHH	DRUGNAME	Rimacalib
D06PHH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0E2QC	TTDDRUID	D0E2QC
D0E2QC	DRUGNAME	RK-023
D0E2QC	INDICATI	Alopecia [ICD-11: ED70] Phase 2

D0U2CE	TTDDRUID	D0U2CE
D0U2CE	DRUGNAME	RM-131
D0U2CE	INDICATI	Cachexia [ICD-11: MG20] Phase 2
D0U2CE	INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2

D01EXL	TTDDRUID	D01EXL
D01EXL	DRUGNAME	RNF43-721
D01EXL	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0N9AD	TTDDRUID	D0N9AD
D0N9AD	DRUGNAME	RNS-60
D0N9AD	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
D0N9AD	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0N9AD	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D01UMT	TTDDRUID	D01UMT
D01UMT	DRUGNAME	Ro 31-7453
D01UMT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0XP3W	TTDDRUID	D0XP3W
D0XP3W	DRUGNAME	Ro-24-7429
D0XP3W	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0M7VE	TTDDRUID	D0M7VE
D0M7VE	DRUGNAME	RO-4905417
D0M7VE	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2

D0I3WC	TTDDRUID	D0I3WC
D0I3WC	DRUGNAME	RO-4929097
D0I3WC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D08OTE	TTDDRUID	D08OTE
D08OTE	DRUGNAME	RO-4995819
D08OTE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0U7SR	TTDDRUID	D0U7SR
D0U7SR	DRUGNAME	RO-4998452
D0U7SR	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D04TPU	TTDDRUID	D04TPU
D04TPU	DRUGNAME	RO-5323441
D04TPU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0I8YS	TTDDRUID	D0I8YS
D0I8YS	DRUGNAME	RO5520985
D0I8YS	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0EM1D	TTDDRUID	D0EM1D
D0EM1D	DRUGNAME	RO6867461
D0EM1D	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D05KED	TTDDRUID	D05KED
D05KED	DRUGNAME	Rocilinostat
D05KED	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0H5ES	TTDDRUID	D0H5ES
D0H5ES	DRUGNAME	Rontalizumab
D0H5ES	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D08UUK	TTDDRUID	D08UUK
D08UUK	DRUGNAME	Rostafuroxin
D08UUK	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0C4QN	TTDDRUID	D0C4QN
D0C4QN	DRUGNAME	ROTIGAPTIDE
D0C4QN	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2

D01GEB	TTDDRUID	D01GEB
D01GEB	DRUGNAME	ROXINDOLE
D01GEB	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D01TWG	TTDDRUID	D01TWG
D01TWG	DRUGNAME	Rozanolixizumab
D01TWG	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2

D09KYR	TTDDRUID	D09KYR
D09KYR	DRUGNAME	RP-49356
D09KYR	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D06XVX	TTDDRUID	D06XVX
D06XVX	DRUGNAME	RP-5000
D06XVX	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D05XEA	TTDDRUID	D05XEA
D05XEA	DRUGNAME	RP5063
D05XEA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D05XEA	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1
D05XEA	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
D05XEA	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
D05XEA	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
D05XEA	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D08MIG	TTDDRUID	D08MIG
D08MIG	DRUGNAME	RPA-102
D08MIG	INDICATI	Anthrax [ICD-11: 1B97] Phase 2

D0FF2S	TTDDRUID	D0FF2S
D0FF2S	DRUGNAME	RP-G28
D0FF2S	INDICATI	Lactose intolerance [ICD-11: 5C61.6] Phase 2

D0O5GK	TTDDRUID	D0O5GK
D0O5GK	DRUGNAME	R-phenserine
D0O5GK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
D0O5GK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0O5GK	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
D0O5GK	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1/2

D08VHG	TTDDRUID	D08VHG
D08VHG	DRUGNAME	RPL-554
D08VHG	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0Z6DE	TTDDRUID	D0Z6DE
D0Z6DE	DRUGNAME	RPSGL-Ig
D0Z6DE	INDICATI	Delayed graft function [ICD-11: 4B24.0] Phase 2

D0UO4B	TTDDRUID	D0UO4B
D0UO4B	DRUGNAME	RQ-00000005
D0UO4B	INDICATI	Frailty [ICD-11: MG2A] Phase 2

D00IQH	TTDDRUID	D00IQH
D00IQH	DRUGNAME	RQ-00000007 (oral)
D00IQH	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D05ADP	TTDDRUID	D05ADP
D05ADP	DRUGNAME	R-roscovitine
D05ADP	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
D05ADP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D05ADP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0R3KL	TTDDRUID	D0R3KL
D0R3KL	DRUGNAME	RRV-TV rotavirus vaccine
D0R3KL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0X8TS	TTDDRUID	D0X8TS
D0X8TS	DRUGNAME	RRx-001
D0X8TS	INDICATI	Anaplastic glioma [ICD-11: 2A00.0] Phase 1
D0X8TS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D0X8TS	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
D0X8TS	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0X8TS	INDICATI	Ovarian epithelial cancer [ICD-11: 2C73] Phase 2
D0X8TS	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D0X8TS	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0X8TS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09CMK	TTDDRUID	D09CMK
D09CMK	DRUGNAME	R-salbutamol sulphate
D09CMK	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2

D0F3JL	TTDDRUID	D0F3JL
D0F3JL	DRUGNAME	RSLV-132
D0F3JL	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
D0F3JL	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D04VHB	TTDDRUID	D04VHB
D04VHB	DRUGNAME	RSV recombinant vaccine
D04VHB	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D09KNG	TTDDRUID	D09KNG
D09KNG	DRUGNAME	RSV-604
D09KNG	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D0EE3Y	TTDDRUID	D0EE3Y
D0EE3Y	DRUGNAME	RSV-F
D0EE3Y	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D00UWY	TTDDRUID	D00UWY
D00UWY	DRUGNAME	RT-001
D00UWY	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
D00UWY	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2

D0X3UL	TTDDRUID	D0X3UL
D0X3UL	DRUGNAME	RT-400
D0X3UL	INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2

D0S0SE	TTDDRUID	D0S0SE
D0S0SE	DRUGNAME	Rupintrivir
D0S0SE	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D01NTH	TTDDRUID	D01NTH
D01NTH	DRUGNAME	Ruthenium-based complexes
D01NTH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04IHB	TTDDRUID	D04IHB
D04IHB	DRUGNAME	RUTI
D04IHB	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2

D0EN0W	TTDDRUID	D0EN0W
D0EN0W	DRUGNAME	RV001
D0EN0W	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
D0EN0W	INDICATI	Graves ophthalmopathy [ICD-11: 9C82.3] Phase 2

D0A5HC	TTDDRUID	D0A5HC
D0A5HC	DRUGNAME	RV-568
D0A5HC	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0AF5P	TTDDRUID	D0AF5P
D0AF5P	DRUGNAME	RVT-505
D0AF5P	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D0AF5P	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D07SYZ	TTDDRUID	D07SYZ
D07SYZ	DRUGNAME	RX-0201
D07SYZ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D07SYZ	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D07SYZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0P3PB	TTDDRUID	D0P3PB
D0P3PB	DRUGNAME	RX-10045
D0P3PB	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 2

D0L7WS	TTDDRUID	D0L7WS
D0L7WS	DRUGNAME	RX-3117
D0L7WS	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0L7WS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D0L7WS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S1TI	TTDDRUID	D0S1TI
D0S1TI	DRUGNAME	RX-5902
D0S1TI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0S1TI	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D0O0LS	TTDDRUID	D0O0LS
D0O0LS	DRUGNAME	RXDX 101
D0O0LS	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0O0LS	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
D0O0LS	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0O0LS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0O0LS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05DXZ	TTDDRUID	D05DXZ
D05DXZ	DRUGNAME	RXI-109
D05DXZ	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2
D05DXZ	INDICATI	Hypertrophic scars [ICD-11: EE60] Phase 2

D0QZ7V	TTDDRUID	D0QZ7V
D0QZ7V	DRUGNAME	RXI-SCP
D0QZ7V	INDICATI	Cutaneous wart [ICD-11: 1E80] Phase 2

D0C7DY	TTDDRUID	D0C7DY
D0C7DY	DRUGNAME	S. pneumococcal next-generation vaccine
D0C7DY	INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 2

D0SC1I	TTDDRUID	D0SC1I
D0SC1I	DRUGNAME	S. pneumoniae paediatric next generation
D0SC1I	INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 2

D0H5WM	TTDDRUID	D0H5WM
D0H5WM	DRUGNAME	S-0509
D0H5WM	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D02DMW	TTDDRUID	D02DMW
D02DMW	DRUGNAME	S-1360
D02DMW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0P2QO	TTDDRUID	D0P2QO
D0P2QO	DRUGNAME	S-15535
D0P2QO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0T6BA	TTDDRUID	D0T6BA
D0T6BA	DRUGNAME	S-16924
D0T6BA	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D01MPE	TTDDRUID	D01MPE
D01MPE	DRUGNAME	S-2150
D01MPE	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D0Q3PD	TTDDRUID	D0Q3PD
D0Q3PD	DRUGNAME	S-297995
D0Q3PD	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D09HOW	TTDDRUID	D09HOW
D09HOW	DRUGNAME	S-364735
D09HOW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0XW6Y	TTDDRUID	D0XW6Y
D0XW6Y	DRUGNAME	S-38093
D0XW6Y	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0HH0U	TTDDRUID	D0HH0U
D0HH0U	DRUGNAME	S-488410
D0HH0U	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2

D0B9DM	TTDDRUID	D0B9DM
D0B9DM	DRUGNAME	S-555739
D0B9DM	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0Q7MA	TTDDRUID	D0Q7MA
D0Q7MA	DRUGNAME	S-649266
D0Q7MA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D02SXZ	TTDDRUID	D02SXZ
D02SXZ	DRUGNAME	S-707106
D02SXZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0J6KZ	TTDDRUID	D0J6KZ
D0J6KZ	DRUGNAME	S-777469
D0J6KZ	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D02MNR	TTDDRUID	D02MNR
D02MNR	DRUGNAME	S-888711
D02MNR	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2

D02FEV	TTDDRUID	D02FEV
D02FEV	DRUGNAME	S-8921
D02FEV	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D01UGG	TTDDRUID	D01UGG
D01UGG	DRUGNAME	Sabarubicin
D01UGG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06BHG	TTDDRUID	D06BHG
D06BHG	DRUGNAME	Safotibant
D06BHG	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2

D0S5IR	TTDDRUID	D0S5IR
D0S5IR	DRUGNAME	SAGE-217
D0S5IR	INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2
D0S5IR	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
D0S5IR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D05PDJ	TTDDRUID	D05PDJ
D05PDJ	DRUGNAME	SAGE-217b
D05PDJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0F6YW	TTDDRUID	D0F6YW
D0F6YW	DRUGNAME	Sagopilone
D0F6YW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0F6YW	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0F6YW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D00KTV	TTDDRUID	D00KTV
D00KTV	DRUGNAME	Salirasib
D00KTV	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
D00KTV	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2
D00KTV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1/2

D03FVS	TTDDRUID	D03FVS
D03FVS	DRUGNAME	Salvicine
D03FVS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0V4ZQ	TTDDRUID	D0V4ZQ
D0V4ZQ	DRUGNAME	SAM-531
D0V4ZQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D09CLH	TTDDRUID	D09CLH
D09CLH	DRUGNAME	Samarium SM-153 lexidronam injection
D09CLH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D09JES	TTDDRUID	D09JES
D09JES	DRUGNAME	Sampatrilat
D09JES	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2

D0B5VA	TTDDRUID	D0B5VA
D0B5VA	DRUGNAME	SAN-300
D0B5VA	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D06OVF	TTDDRUID	D06OVF
D06OVF	DRUGNAME	Santalum
D06OVF	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
D06OVF	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
D06OVF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0C8KP	TTDDRUID	D0C8KP
D0C8KP	DRUGNAME	Santalum album cream
D0C8KP	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D07WCT	TTDDRUID	D07WCT
D07WCT	DRUGNAME	SAR-100842
D07WCT	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2
D07WCT	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2

D0O0EX	TTDDRUID	D0O0EX
D0O0EX	DRUGNAME	SAR-110894
D0O0EX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0AE3U	TTDDRUID	D0AE3U
D0AE3U	DRUGNAME	SAR-113945
D0AE3U	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D07ARN	TTDDRUID	D07ARN
D07ARN	DRUGNAME	SAR-125844
D07ARN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0O4SH	TTDDRUID	D0O4SH
D0O4SH	DRUGNAME	SAR-156597
D0O4SH	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
D0O4SH	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Phase 2
D0O4SH	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2

D01PGR	TTDDRUID	D01PGR
D01PGR	DRUGNAME	SAR245409
D01PGR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
D01PGR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D01PGR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05YLN	TTDDRUID	D05YLN
D05YLN	DRUGNAME	SAR256212 companion diagnostic
D05YLN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07QHF	TTDDRUID	D07QHF
D07QHF	DRUGNAME	SAR-260093
D07QHF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D00MTG	TTDDRUID	D00MTG
D00MTG	DRUGNAME	SAR279356
D00MTG	INDICATI	Serious infection [ICD-11: 1H0Z] Phase 2

D03SLK	TTDDRUID	D03SLK
D03SLK	DRUGNAME	SAR292833
D03SLK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0R9IH	TTDDRUID	D0R9IH
D0R9IH	DRUGNAME	SAR-339658
D0R9IH	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D07FGK	TTDDRUID	D07FGK
D07FGK	DRUGNAME	SAR-3419
D07FGK	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D09GIA	TTDDRUID	D09GIA
D09GIA	DRUGNAME	SAR391786
D09GIA	INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 2

D00UET	TTDDRUID	D00UET
D00UET	DRUGNAME	SAR-407899
D00UET	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
D00UET	INDICATI	Microvascular angina [ICD-11: BA86] Phase 2

D0G5YR	TTDDRUID	D0G5YR
D0G5YR	DRUGNAME	SAR-566658
D0G5YR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0G5YR	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D02ETY	TTDDRUID	D02ETY
D02ETY	DRUGNAME	SAR97276
D02ETY	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2

D05BBB	TTDDRUID	D05BBB
D05BBB	DRUGNAME	Saratin
D05BBB	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2

D0T3HU	TTDDRUID	D0T3HU
D0T3HU	DRUGNAME	Sarcoma cancer vaccine
D0T3HU	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2

D00EOK	TTDDRUID	D00EOK
D00EOK	DRUGNAME	Sarcoma mab vaccine
D00EOK	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2

D02XYB	TTDDRUID	D02XYB
D02XYB	DRUGNAME	SARIPIDEM
D02XYB	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0E8LA	TTDDRUID	D0E8LA
D0E8LA	DRUGNAME	Saroglitazar
D0E8LA	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D0G5UW	TTDDRUID	D0G5UW
D0G5UW	DRUGNAME	Saruplase
D0G5UW	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2

D0ES6N	TTDDRUID	D0ES6N
D0ES6N	DRUGNAME	SB-030
D0ES6N	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D0Q1VD	TTDDRUID	D0Q1VD
D0Q1VD	DRUGNAME	SB206
D0Q1VD	INDICATI	External genital and perianal wart [ICD-11: 1A95] Phase 2
D0Q1VD	INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 2

D01MBV	TTDDRUID	D01MBV
D01MBV	DRUGNAME	SB-207266A
D01MBV	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D08JSA	TTDDRUID	D08JSA
D08JSA	DRUGNAME	SB208
D08JSA	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
D08JSA	INDICATI	Tinea pedis [ICD-11: 1F28.2] Phase 2

D02JXG	TTDDRUID	D02JXG
D02JXG	DRUGNAME	SB-265610
D02JXG	INDICATI	Asthma [ICD-11: CA23] Phase 2
D02JXG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D08IST	TTDDRUID	D08IST
D08IST	DRUGNAME	SB-509
D08IST	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Phase 2

D0VE1W	TTDDRUID	D0VE1W
D0VE1W	DRUGNAME	SB-623
D0VE1W	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
D0VE1W	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
D0VE1W	INDICATI	Stroke [ICD-11: 8B20] Phase 2
D0VE1W	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2

D06CKX	TTDDRUID	D06CKX
D06CKX	DRUGNAME	SB-649868
D06CKX	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2

D0SN7I	TTDDRUID	D0SN7I
D0SN7I	DRUGNAME	SB-656933
D0SN7I	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
D0SN7I	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D06FIT	TTDDRUID	D06FIT
D06FIT	DRUGNAME	SB-728-T
D06FIT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
D06FIT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0U4EU	TTDDRUID	D0U4EU
D0U4EU	DRUGNAME	SB-743921
D0U4EU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0A6MN	TTDDRUID	D0A6MN
D0A6MN	DRUGNAME	SB773812
D0A6MN	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D01LRM	TTDDRUID	D01LRM
D01LRM	DRUGNAME	SBC-014
D01LRM	INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 2

D0W9QG	TTDDRUID	D0W9QG
D0W9QG	DRUGNAME	SBI-087
D0W9QG	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D0W9QG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0EJ0O	TTDDRUID	D0EJ0O
D0EJ0O	DRUGNAME	SC401
D0EJ0O	INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Phase 2

D0O1HL	TTDDRUID	D0O1HL
D0O1HL	DRUGNAME	SC-49483
D0O1HL	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2

D0VH3D	TTDDRUID	D0VH3D
D0VH3D	DRUGNAME	SC-599
D0VH3D	INDICATI	Shigella infection [ICD-11: 1A02] Phase 2

D02DYU	TTDDRUID	D02DYU
D02DYU	DRUGNAME	SC-75416
D02DYU	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D07TEP	TTDDRUID	D07TEP
D07TEP	DRUGNAME	SCH 420814
D07TEP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D00QKI	TTDDRUID	D00QKI
D00QKI	DRUGNAME	SCH-527123
D00QKI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
D00QKI	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
D00QKI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D00QKI	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D01DDN	TTDDRUID	D01DDN
D01DDN	DRUGNAME	SCH-900271
D01DDN	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2

D05FWH	TTDDRUID	D05FWH
D05FWH	DRUGNAME	SCH-900776
D05FWH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0P3JF	TTDDRUID	D0P3JF
D0P3JF	DRUGNAME	SCH-900978
D0P3JF	INDICATI	Cough [ICD-11: MD12] Phase 2

D07INL	TTDDRUID	D07INL
D07INL	DRUGNAME	SCY-078
D07INL	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2

D02EEJ	TTDDRUID	D02EEJ
D02EEJ	DRUGNAME	SCY-635
D02EEJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D07YLO	TTDDRUID	D07YLO
D07YLO	DRUGNAME	SDF-1
D07YLO	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D07YLO	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D0O5OF	TTDDRUID	D0O5OF
D0O5OF	DRUGNAME	SDZ-281-240
D0O5OF	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D08FKX	TTDDRUID	D08FKX
D08FKX	DRUGNAME	SDZ-MAR-327
D08FKX	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
D08FKX	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0H2CV	TTDDRUID	D0H2CV
D0H2CV	DRUGNAME	SDZ-SCV-106
D0H2CV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0C8MG	TTDDRUID	D0C8MG
D0C8MG	DRUGNAME	SELA-212
D0C8MG	INDICATI	Gout [ICD-11: FA25] Phase 2

D0A9ML	TTDDRUID	D0A9ML
D0A9ML	DRUGNAME	SelG1
D0A9ML	INDICATI	Vaso-occlusive crisis [ICD-11: BE2Y] Phase 1
D0A9ML	INDICATI	Vaso-occlusive crisis [ICD-11: BE2Y] Phase 2

D0A2BS	TTDDRUID	D0A2BS
D0A2BS	DRUGNAME	SelG2
D0A2BS	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2

D0VI7R	TTDDRUID	D0VI7R
D0VI7R	DRUGNAME	Selinexor oral
D0VI7R	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D04YAJ	TTDDRUID	D04YAJ
D04YAJ	DRUGNAME	SELODENOSON
D04YAJ	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2

D02RVN	TTDDRUID	D02RVN
D02RVN	DRUGNAME	Selurampanel
D02RVN	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2

D01WKE	TTDDRUID	D01WKE
D01WKE	DRUGNAME	Semapimod
D01WKE	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D0E3LP	TTDDRUID	D0E3LP
D0E3LP	DRUGNAME	SEN-196
D0E3LP	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2

D05ZWG	TTDDRUID	D05ZWG
D05ZWG	DRUGNAME	Senktide
D05ZWG	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
D05ZWG	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2

D0R9FM	TTDDRUID	D0R9FM
D0R9FM	DRUGNAME	SentoClone
D0R9FM	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D04ZKY	TTDDRUID	D04ZKY
D04ZKY	DRUGNAME	SEP-363856
D04ZKY	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
D04ZKY	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
D04ZKY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D08FSD	TTDDRUID	D08FSD
D08FSD	DRUGNAME	SER-100
D08FSD	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D0Q0LI	TTDDRUID	D0Q0LI
D0Q0LI	DRUGNAME	SER-109
D0Q0LI	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2

D0NZ2D	TTDDRUID	D0NZ2D
D0NZ2D	DRUGNAME	SERCA 2a gene therapy
D0NZ2D	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D06DOJ	TTDDRUID	D06DOJ
D06DOJ	DRUGNAME	Seribantumab
D06DOJ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D06DOJ	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D06DOJ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0YP7B	TTDDRUID	D0YP7B
D0YP7B	DRUGNAME	Setmelanotide
D0YP7B	INDICATI	Prader-Willi syndrome [ICD-11: LD90.3] Phase 2

D06PGZ	TTDDRUID	D06PGZ
D06PGZ	DRUGNAME	Setrobuvir
D06PGZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0Q9KR	TTDDRUID	D0Q9KR
D0Q9KR	DRUGNAME	Seviteronel
D0Q9KR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0Q9KR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D03NJY	TTDDRUID	D03NJY
D03NJY	DRUGNAME	SF1126
D03NJY	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D03NJY	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D03NJY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P7MO	TTDDRUID	D0P7MO
D0P7MO	DRUGNAME	SFV IL-12 gene therapy
D0P7MO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0S0MP	TTDDRUID	D0S0MP
D0S0MP	DRUGNAME	SGN-30
D0S0MP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01RBR	TTDDRUID	D01RBR
D01RBR	DRUGNAME	SGS742
D01RBR	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D04TFL	TTDDRUID	D04TFL
D04TFL	DRUGNAME	SGX203
D04TFL	INDICATI	Crohn disease [ICD-11: DD70] Phase 2

D00ICD	TTDDRUID	D00ICD
D00ICD	DRUGNAME	SH-529
D00ICD	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D0RQ5Z	TTDDRUID	D0RQ5Z
D0RQ5Z	DRUGNAME	Shan 6
D0RQ5Z	INDICATI	Diphtheria [ICD-11: 1C17] Phase 2
D0RQ5Z	INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2
D0RQ5Z	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
D0RQ5Z	INDICATI	Pertussis [ICD-11: 1C12.Z] Phase 2
D0RQ5Z	INDICATI	Poliomyelitis [ICD-11: 1C81] Phase 2
D0RQ5Z	INDICATI	Poliovirus infection [ICD-11: 1C8Y] Phase 2
D0RQ5Z	INDICATI	Tetanus [ICD-11: 1C13] Phase 2

D0N6AC	TTDDRUID	D0N6AC
D0N6AC	DRUGNAME	SHAPE
D0N6AC	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
D0N6AC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0V2RF	TTDDRUID	D0V2RF
D0V2RF	DRUGNAME	Shigella conjugated and outer membrane vaccine
D0V2RF	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2

D0J6NW	TTDDRUID	D0J6NW
D0J6NW	DRUGNAME	Shigella vaccine
D0J6NW	INDICATI	Shigella infection [ICD-11: 1A02] Phase 1
D0J6NW	INDICATI	Shigella infection [ICD-11: 1A02] Phase 2

D0L3XE	TTDDRUID	D0L3XE
D0L3XE	DRUGNAME	Short ragweed pollen extracts
D0L3XE	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0R1JO	TTDDRUID	D0R1JO
D0R1JO	DRUGNAME	SHP607
D0R1JO	INDICATI	Retinopathy [ICD-11: 9B71] Phase 2

D0ZS5X	TTDDRUID	D0ZS5X
D0ZS5X	DRUGNAME	SHP610
D0ZS5X	INDICATI	Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 2

D04GNX	TTDDRUID	D04GNX
D04GNX	DRUGNAME	SHP615
D04GNX	INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2

D0S1QY	TTDDRUID	D0S1QY
D0S1QY	DRUGNAME	SHP620
D0S1QY	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2

D06DLN	TTDDRUID	D06DLN
D06DLN	DRUGNAME	SHP621
D06DLN	INDICATI	Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2

D02QWK	TTDDRUID	D02QWK
D02QWK	DRUGNAME	SHP647
D02QWK	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D02QWK	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D0C0TU	TTDDRUID	D0C0TU
D0C0TU	DRUGNAME	SI-613
D0C0TU	INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 2

D06MJD	TTDDRUID	D06MJD
D06MJD	DRUGNAME	SiG12D-LODER
D06MJD	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D00EVP	TTDDRUID	D00EVP
D00EVP	DRUGNAME	Simenepag isopropyl
D00EVP	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2

D0S4JL	TTDDRUID	D0S4JL
D0S4JL	DRUGNAME	Simtuzumab
D0S4JL	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0S4JL	INDICATI	Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 2

D0A7NB	TTDDRUID	D0A7NB
D0A7NB	DRUGNAME	Siplizumab
D0A7NB	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D0A7NB	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D06XJQ	TTDDRUID	D06XJQ
D06XJQ	DRUGNAME	SIRS-T
D06XJQ	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0Q1LO	TTDDRUID	D0Q1LO
D0Q1LO	DRUGNAME	Sitamaquine
D0Q1LO	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2

D0P4RC	TTDDRUID	D0P4RC
D0P4RC	DRUGNAME	SITOSTANOL ASCORBYL PHOSPHATE
D0P4RC	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D05ECK	TTDDRUID	D05ECK
D05ECK	DRUGNAME	SKF-110679
D05ECK	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D03YJC	TTDDRUID	D03YJC
D03YJC	DRUGNAME	SKL-NP
D03YJC	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D06MYP	TTDDRUID	D06MYP
D06MYP	DRUGNAME	SK-MS10
D06MYP	INDICATI	Gastritis [ICD-11: DA42] Phase 2

D0M2TC	TTDDRUID	D0M2TC
D0M2TC	DRUGNAME	SLC-022
D0M2TC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D01HDP	TTDDRUID	D01HDP
D01HDP	DRUGNAME	SLV 306
D01HDP	INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2

D0F5UN	TTDDRUID	D0F5UN
D0F5UN	DRUGNAME	SLV320
D0F5UN	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D03CPM	TTDDRUID	D03CPM
D03CPM	DRUGNAME	SLV-334
D03CPM	INDICATI	Brain injury [ICD-11: NA07.Z] Phase 2

D05NWJ	TTDDRUID	D05NWJ
D05NWJ	DRUGNAME	SLV-337
D05NWJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D05YTG	TTDDRUID	D05YTG
D05YTG	DRUGNAME	SLx-4090
D05YTG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
D05YTG	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2
D05YTG	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0I9AC	TTDDRUID	D0I9AC
D0I9AC	DRUGNAME	SM04554
D0I9AC	INDICATI	Alopecia [ICD-11: ED70] Phase 2

D05ZIS	TTDDRUID	D05ZIS
D05ZIS	DRUGNAME	SM-04690
D05ZIS	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D03ZDX	TTDDRUID	D03ZDX
D03ZDX	DRUGNAME	SM-88
D03ZDX	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D03ZDX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D05OTZ	TTDDRUID	D05OTZ
D05OTZ	DRUGNAME	SMP-986
D05OTZ	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2

D04FXY	TTDDRUID	D04FXY
D04FXY	DRUGNAME	SMT-19969
D04FXY	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2

D0Y7YD	TTDDRUID	D0Y7YD
D0Y7YD	DRUGNAME	SMT-C1100
D0Y7YD	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
D0Y7YD	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D04QYS	TTDDRUID	D04QYS
D04QYS	DRUGNAME	SNA-120
D04QYS	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
D04QYS	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D0M8FD	TTDDRUID	D0M8FD
D0M8FD	DRUGNAME	SNDX-275
D0M8FD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0M8FD	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0M8FD	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0M8FD	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0M8FD	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D02LSR	TTDDRUID	D02LSR
D02LSR	DRUGNAME	SNK-882
D02LSR	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D00NVM	TTDDRUID	D00NVM
D00NVM	DRUGNAME	SNS-595
D00NVM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D00NVM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D04TLJ	TTDDRUID	D04TLJ
D04TLJ	DRUGNAME	Soblidotin
D04TLJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0I7IB	TTDDRUID	D0I7IB
D0I7IB	DRUGNAME	Sodium butyrate
D0I7IB	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0I7IB	INDICATI	Refractory sickle cell ulcers [ICD-11: 3A51] Phase 2

D09BBW	TTDDRUID	D09BBW
D09BBW	DRUGNAME	Sodium stibogluconate
D09BBW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D05RSC	TTDDRUID	D05RSC
D05RSC	DRUGNAME	Sofinicline
D05RSC	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D0VK9O	TTDDRUID	D0VK9O
D0VK9O	DRUGNAME	Sofpironium bromide
D0VK9O	INDICATI	Hyperhidrosis [ICD-11: EE00] Phase 2

D02CFV	TTDDRUID	D02CFV
D02CFV	DRUGNAME	Solubilized type 1 native bovine collagen
D02CFV	INDICATI	Scleroderma [ICD-11: 4A42] Phase 2

D03AXQ	TTDDRUID	D03AXQ
D03AXQ	DRUGNAME	Soluble FePPi
D03AXQ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D0ZW1W	TTDDRUID	D0ZW1W
D0ZW1W	DRUGNAME	SoluMatrix naproxen
D0ZW1W	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
D0ZW1W	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D04OTH	TTDDRUID	D04OTH
D04OTH	DRUGNAME	SomaKit-TOC
D04OTH	DRUGNAME	gallium (68Ga) edotreotide
D04OTH	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2

D08YNI	TTDDRUID	D08YNI
D08YNI	DRUGNAME	Somatoprim
D08YNI	INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 2

D0C9SW	TTDDRUID	D0C9SW
D0C9SW	DRUGNAME	Somatropin intranasal rhGH
D0C9SW	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D08JGE	TTDDRUID	D08JGE
D08JGE	DRUGNAME	SonoLysis Prolyse
D08JGE	INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 2

D0W3DV	TTDDRUID	D0W3DV
D0W3DV	DRUGNAME	Sotatercept
D0W3DV	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0AA8R	TTDDRUID	D0AA8R
D0AA8R	DRUGNAME	Sotirimod
D0AA8R	INDICATI	Keratosis [ICD-11: ED56] Phase 2

D0F5HB	TTDDRUID	D0F5HB
D0F5HB	DRUGNAME	Sotrastaurin acetate
D0F5HB	INDICATI	Renal transplantation [ICD-11: NE84] Phase 2

D0W8GT	TTDDRUID	D0W8GT
D0W8GT	DRUGNAME	SP160412
D0W8GT	INDICATI	Sunburn [ICD-11: EJ40] Phase 2

D05YLP	TTDDRUID	D05YLP
D05YLP	DRUGNAME	SP-333
D05YLP	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2

D02ZAN	TTDDRUID	D02ZAN
D02ZAN	DRUGNAME	SparVax recombinant protective antigen anthrax vaccine
D02ZAN	INDICATI	Anthrax [ICD-11: 1B97] Phase 2
D02ZAN	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2

D0Z8DO	TTDDRUID	D0Z8DO
D0Z8DO	DRUGNAME	SPD-556
D0Z8DO	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D06HCF	TTDDRUID	D06HCF
D06HCF	DRUGNAME	SPD-557
D06HCF	INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2

D02SNJ	TTDDRUID	D02SNJ
D02SNJ	DRUGNAME	SPD602
D02SNJ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2

D03LKU	TTDDRUID	D03LKU
D03LKU	DRUGNAME	Spheramine
D03LKU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D04WVY	TTDDRUID	D04WVY
D04WVY	DRUGNAME	SPI-026
D04WVY	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D07WYI	TTDDRUID	D07WYI
D07WYI	DRUGNAME	SPI-1620
D07WYI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0XR0B	TTDDRUID	D0XR0B
D0XR0B	DRUGNAME	SPI-205
D0XR0B	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D04KHY	TTDDRUID	D04KHY
D04KHY	DRUGNAME	Spiroglumide
D04KHY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1
D04KHY	INDICATI	Stomach disease [ICD-11: DA43-DA4Y] Phase 2

D01BAU	TTDDRUID	D01BAU
D01BAU	DRUGNAME	SPN-812
D01BAU	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2

D07JXN	TTDDRUID	D07JXN
D07JXN	DRUGNAME	SPP-600
D07JXN	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0S1YX	TTDDRUID	D0S1YX
D0S1YX	DRUGNAME	S-PRAnt
D0S1YX	INDICATI	Uterine fibroids [ICD-11: 2E86.0] Phase 2

D0K8DI	TTDDRUID	D0K8DI
D0K8DI	DRUGNAME	SQ-109
D0K8DI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
D0K8DI	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D02PYN	TTDDRUID	D02PYN
D02PYN	DRUGNAME	SR 16234
D02PYN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0W3GL	TTDDRUID	D0W3GL
D0W3GL	DRUGNAME	SR-147778
D0W3GL	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D00MHP	TTDDRUID	D00MHP
D00MHP	DRUGNAME	SR-2640
D00MHP	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0D4JI	TTDDRUID	D0D4JI
D0D4JI	DRUGNAME	SR-31747
D0D4JI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0H8WZ	TTDDRUID	D0H8WZ
D0H8WZ	DRUGNAME	SR-43845
D0H8WZ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D0L5WA	TTDDRUID	D0L5WA
D0L5WA	DRUGNAME	SR-46559A
D0L5WA	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D02QLQ	TTDDRUID	D02QLQ
D02QLQ	DRUGNAME	SRD-174
D02QLQ	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D0J6ZA	TTDDRUID	D0J6ZA
D0J6ZA	DRUGNAME	SRD-441
D0J6ZA	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D04XTK	TTDDRUID	D04XTK
D04XTK	DRUGNAME	SRM003
D04XTK	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D0AD5S	TTDDRUID	D0AD5S
D0AD5S	DRUGNAME	SRP-4053
D0AD5S	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2

D0E0GD	TTDDRUID	D0E0GD
D0E0GD	DRUGNAME	SR-T100 gel
D0E0GD	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2

D0F4VW	TTDDRUID	D0F4VW
D0F4VW	DRUGNAME	SRX-246
D0F4VW	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1/2
D0F4VW	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
D0F4VW	INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2

D05IIN	TTDDRUID	D05IIN
D05IIN	DRUGNAME	SSR125543
D05IIN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0SY9B	TTDDRUID	D0SY9B
D0SY9B	DRUGNAME	SSR149415
D0SY9B	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
D0SY9B	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D09OTU	TTDDRUID	D09OTU
D09OTU	DRUGNAME	SSR-180575
D09OTU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0F1WX	TTDDRUID	D0F1WX
D0F1WX	DRUGNAME	SSR240600
D0F1WX	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2

D03UVL	TTDDRUID	D03UVL
D03UVL	DRUGNAME	SSR-240612
D03UVL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D03DSX	TTDDRUID	D03DSX
D03DSX	DRUGNAME	SSR411298
D03DSX	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D09YRA	TTDDRUID	D09YRA
D09YRA	DRUGNAME	SSTarbaclofen
D09YRA	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
D09YRA	INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2

D07CJN	TTDDRUID	D07CJN
D07CJN	DRUGNAME	ST-101
D07CJN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D07CJN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D0C9NJ	TTDDRUID	D0C9NJ
D0C9NJ	DRUGNAME	STA-5326
D0C9NJ	INDICATI	Crohn disease [ICD-11: DD70] Phase 2
D0C9NJ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0KC9U	TTDDRUID	D0KC9U
D0KC9U	DRUGNAME	Stage IV melanoma vaccine
D0KC9U	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D02JAY	TTDDRUID	D02JAY
D02JAY	DRUGNAME	Stannsoporfin
D02JAY	INDICATI	Neonatal hyperbilirubinemia [ICD-11: KA87] Phase 2

D0Q6YW	TTDDRUID	D0Q6YW
D0Q6YW	DRUGNAME	Stem cell therapy
D0Q6YW	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2

D0N1PZ	TTDDRUID	D0N1PZ
D0N1PZ	DRUGNAME	S-tenatoprazole
D0N1PZ	INDICATI	Peptic ulcer [ICD-11: DA61] Phase 2

D06LPT	TTDDRUID	D06LPT
D06LPT	DRUGNAME	STI-003
D06LPT	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 2

D0J9PD	TTDDRUID	D0J9PD
D0J9PD	DRUGNAME	STP-206
D0J9PD	INDICATI	Enterocolitis [ICD-11: 1A40.Z] Phase 1
D0J9PD	INDICATI	Enterocolitis [ICD-11: 1A40.Z] Phase 1/2
D0J9PD	INDICATI	Necrotizing enterocolitis of newborn [ICD-11: KB88] Phase 2

D0Q2GX	TTDDRUID	D0Q2GX
D0Q2GX	DRUGNAME	Strada
D0Q2GX	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0B1ET	TTDDRUID	D0B1ET
D0B1ET	DRUGNAME	Streptococcal B conjugated vaccine
D0B1ET	INDICATI	Streptococcal B infection [ICD-11: 1G40] Phase 2

D0IL3O	TTDDRUID	D0IL3O
D0IL3O	DRUGNAME	Strontium malonate
D0IL3O	INDICATI	Metabolic bone disease [ICD-11: FB8Y] Phase 2

D0WL4D	TTDDRUID	D0WL4D
D0WL4D	DRUGNAME	STX-100
D0WL4D	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2

D09YDQ	TTDDRUID	D09YDQ
D09YDQ	DRUGNAME	STX-107
D09YDQ	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2

D07ZNI	TTDDRUID	D07ZNI
D07ZNI	DRUGNAME	STX-140
D07ZNI	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D08YOM	TTDDRUID	D08YOM
D08YOM	DRUGNAME	Sulopenem etzadroxil
D08YOM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D0F6TD	TTDDRUID	D0F6TD
D0F6TD	DRUGNAME	SUN N4057
D0F6TD	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0I8FV	TTDDRUID	D0I8FV
D0I8FV	DRUGNAME	SUN13834
D0I8FV	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2

D0W5RE	TTDDRUID	D0W5RE
D0W5RE	DRUGNAME	SUN-13837
D0W5RE	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2

D05RTV	TTDDRUID	D05RTV
D05RTV	DRUGNAME	Superoxide dismutase
D05RTV	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D0VW2F	TTDDRUID	D0VW2F
D0VW2F	DRUGNAME	Sutentsunitinib
D0VW2F	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 2

D0BW4W	TTDDRUID	D0BW4W
D0BW4W	DRUGNAME	Sutezolid
D0BW4W	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D0Z0GX	TTDDRUID	D0Z0GX
D0Z0GX	DRUGNAME	SUVN-502
D0Z0GX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0Z0GX	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2

D0Q8LL	TTDDRUID	D0Q8LL
D0Q8LL	DRUGNAME	SYL-040012
D0Q8LL	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2

D0BA1Y	TTDDRUID	D0BA1Y
D0BA1Y	DRUGNAME	SYL-045001
D0BA1Y	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 2

D0J6HU	TTDDRUID	D0J6HU
D0J6HU	DRUGNAME	Sylvantsiltuximab
D0J6HU	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0CR8H	TTDDRUID	D0CR8H
D0CR8H	DRUGNAME	SYM-004
D0CR8H	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0CR8H	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D0CR8H	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3
D0CR8H	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0CR8H	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D07RQR	TTDDRUID	D07RQR
D07RQR	DRUGNAME	SYN-120
D07RQR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D07RQR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0A3WN	TTDDRUID	D0A3WN
D0A3WN	DRUGNAME	Synthetic surfactants
D0A3WN	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Phase 2

D06QQH	TTDDRUID	D06QQH
D06QQH	DRUGNAME	T-1210
D06QQH	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2

D02TZB	TTDDRUID	D02TZB
D02TZB	DRUGNAME	T2 18C3
D02TZB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D08KDK	TTDDRUID	D08KDK
D08KDK	DRUGNAME	T-2007
D08KDK	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2

D0X6EM	TTDDRUID	D0X6EM
D0X6EM	DRUGNAME	T2c-001
D0X6EM	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2

D09PGT	TTDDRUID	D09PGT
D09PGT	DRUGNAME	T2c-002
D09PGT	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D07QFU	TTDDRUID	D07QFU
D07QFU	DRUGNAME	T-607
D07QFU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0E8HA	TTDDRUID	D0E8HA
D0E8HA	DRUGNAME	T-817MA
D0E8HA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0PC1V	TTDDRUID	D0PC1V
D0PC1V	DRUGNAME	T-82
D0PC1V	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0VU2M	TTDDRUID	D0VU2M
D0VU2M	DRUGNAME	TA-2005
D0VU2M	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0L4SL	TTDDRUID	D0L4SL
D0L4SL	DRUGNAME	TA-270
D0L4SL	INDICATI	Asthma [ICD-11: CA23] Phase 2

D02POH	TTDDRUID	D02POH
D02POH	DRUGNAME	TA-7906
D02POH	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0G7MM	TTDDRUID	D0G7MM
D0G7MM	DRUGNAME	TA-8995
D0G7MM	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0XH9B	TTDDRUID	D0XH9B
D0XH9B	DRUGNAME	Tabimorelin
D0XH9B	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D09XHQ	TTDDRUID	D09XHQ
D09XHQ	DRUGNAME	TA-CD
D09XHQ	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2

D0N2QI	TTDDRUID	D0N2QI
D0N2QI	DRUGNAME	TA-CD cocaine abuse vaccine
D0N2QI	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2

D0C3FK	TTDDRUID	D0C3FK
D0C3FK	DRUGNAME	TA-CD vaccine
D0C3FK	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2

D0TJ0R	TTDDRUID	D0TJ0R
D0TJ0R	DRUGNAME	TA-CIN
D0TJ0R	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2

D0IO9Z	TTDDRUID	D0IO9Z
D0IO9Z	DRUGNAME	Tafinlar + Mekinist
D0IO9Z	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2

D09UZL	TTDDRUID	D09UZL
D09UZL	DRUGNAME	TAK-063
D09UZL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D00KHD	TTDDRUID	D00KHD
D00KHD	DRUGNAME	TAK-128
D00KHD	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D0EE9G	TTDDRUID	D0EE9G
D0EE9G	DRUGNAME	TAK-214
D0EE9G	INDICATI	Norovirus infection [ICD-11: 1A23] Phase 2

D0A5SA	TTDDRUID	D0A5SA
D0A5SA	DRUGNAME	TAK-272
D0A5SA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0A6OS	TTDDRUID	D0A6OS
D0A6OS	DRUGNAME	TAK-379
D0A6OS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D04GEI	TTDDRUID	D04GEI
D04GEI	DRUGNAME	TAK-448
D04GEI	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0J8DD	TTDDRUID	D0J8DD
D0J8DD	DRUGNAME	TAK-653
D0J8DD	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2

D06KTJ	TTDDRUID	D06KTJ
D06KTJ	DRUGNAME	TAK-659
D06KTJ	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D06KTJ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0O6ZO	TTDDRUID	D0O6ZO
D0O6ZO	DRUGNAME	TAK-715
D0O6ZO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0Z4OQ	TTDDRUID	D0Z4OQ
D0Z4OQ	DRUGNAME	TAK-783
D0Z4OQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D08QED	TTDDRUID	D08QED
D08QED	DRUGNAME	TAK-850
D08QED	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D06EHX	TTDDRUID	D06EHX
D06EHX	DRUGNAME	TAK-935
D06EHX	INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 2
D06EHX	INDICATI	Glutamate excitotoxity [ICD-11: 5C73] Phase 1
D06EHX	INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 2
D06EHX	INDICATI	Tuberous sclerosis [ICD-11: LD2D.2] Phase 2

D0O4VW	TTDDRUID	D0O4VW
D0O4VW	DRUGNAME	TAL-0500018
D0O4VW	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
D0O4VW	INDICATI	Peripheral arterial occlusive disorder [ICD-11: BD4Z] Phase 2
D0O4VW	INDICATI	Stroke [ICD-11: 8B20] Phase 1/2

D07MGC	TTDDRUID	D07MGC
D07MGC	DRUGNAME	Talacotuzumab
D07MGC	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D08BEO	TTDDRUID	D08BEO
D08BEO	DRUGNAME	Talampanel
D08BEO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0K5HI	TTDDRUID	D0K5HI
D0K5HI	DRUGNAME	Talnetant
D0K5HI	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2
D0K5HI	INDICATI	Schizoaffective disorder [ICD-11: 6A21] Discontinued in Phase 2
D0K5HI	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D0SC2J	TTDDRUID	D0SC2J
D0SC2J	DRUGNAME	Tanespimycin
D0SC2J	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0SC2J	INDICATI	Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 3

D0Y3LL	TTDDRUID	D0Y3LL
D0Y3LL	DRUGNAME	Taprenepag
D0Y3LL	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D04YEW	TTDDRUID	D04YEW
D04YEW	DRUGNAME	Tarafenacin
D04YEW	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2

D01QLP	TTDDRUID	D01QLP
D01QLP	DRUGNAME	Tarextumab
D01QLP	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D01QLP	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0OR5P	TTDDRUID	D0OR5P
D0OR5P	DRUGNAME	TAS-106
D0OR5P	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D0I0TW	TTDDRUID	D0I0TW
D0I0TW	DRUGNAME	TAS-109
D0I0TW	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0I0TW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0I0TW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Z6KF	TTDDRUID	D0Z6KF
D0Z6KF	DRUGNAME	TAS-114
D0Z6KF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0Z6KF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02IJA	TTDDRUID	D02IJA
D02IJA	DRUGNAME	Tau-binding PET tracer
D02IJA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D09FGD	TTDDRUID	D09FGD
D09FGD	DRUGNAME	Tavokinogene telsaplasmid
D09FGD	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D09FGD	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D09UAI	TTDDRUID	D09UAI
D09UAI	DRUGNAME	TB-402
D09UAI	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2

D03LAB	TTDDRUID	D03LAB
D03LAB	DRUGNAME	TBC-3711
D03LAB	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2

D0FF0N	TTDDRUID	D0FF0N
D0FF0N	DRUGNAME	TBI-1501
D0FF0N	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D0D7YW	TTDDRUID	D0D7YW
D0D7YW	DRUGNAME	TC-5214
D0D7YW	INDICATI	Palmar hyperhidrosis [ICD-11: EE00.00] Phase 2

D04SHH	TTDDRUID	D04SHH
D04SHH	DRUGNAME	TC-6499-12
D04SHH	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2

D0G4GA	TTDDRUID	D0G4GA
D0G4GA	DRUGNAME	TC-6987
D0G4GA	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0A0TF	TTDDRUID	D0A0TF
D0A0TF	DRUGNAME	Tc-99m ethylenedicysteine glucosamine
D0A0TF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D04JAB	TTDDRUID	D04JAB
D04JAB	DRUGNAME	Tcelna
D04JAB	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0L1HK	TTDDRUID	D0L1HK
D0L1HK	DRUGNAME	TCN-032
D0L1HK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D06ECI	TTDDRUID	D06ECI
D06ECI	DRUGNAME	TD-101
D06ECI	INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 2
D06ECI	INDICATI	Pachyonychia [ICD-11: EE10.3] Phase 1

D02INX	TTDDRUID	D02INX
D02INX	DRUGNAME	TD-1211
D02INX	INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Phase 2

D0B3TA	TTDDRUID	D0B3TA
D0B3TA	DRUGNAME	TD-1414
D0B3TA	INDICATI	Impetigo [ICD-11: 1B72] Phase 2

D04GMY	TTDDRUID	D04GMY
D04GMY	DRUGNAME	TD-5108
D04GMY	INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 2

D02JKY	TTDDRUID	D02JKY
D02JKY	DRUGNAME	TD-9855
D02JKY	INDICATI	Orthostatic hypotension [ICD-11: BA21] Phase 1
D02JKY	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0Y6MH	TTDDRUID	D0Y6MH
D0Y6MH	DRUGNAME	Tebipenem
D0Y6MH	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2
D0Y6MH	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0I3XR	TTDDRUID	D0I3XR
D0I3XR	DRUGNAME	Tefibazumab
D0I3XR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D09RVI	TTDDRUID	D09RVI
D09RVI	DRUGNAME	Tegobuvir
D09RVI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0U8AS	TTDDRUID	D0U8AS
D0U8AS	DRUGNAME	Telapristone
D0U8AS	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D0G5ME	TTDDRUID	D0G5ME
D0G5ME	DRUGNAME	Telcagepant
D0G5ME	INDICATI	Cluster headache [ICD-11: 8A81.0] Phase 2
D0G5ME	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D0I3VV	TTDDRUID	D0I3VV
D0I3VV	DRUGNAME	Telomelysin
D0I3VV	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0I3VV	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2

D0N7JP	TTDDRUID	D0N7JP
D0N7JP	DRUGNAME	TEM
D0N7JP	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2

D04GZS	TTDDRUID	D04GZS
D04GZS	DRUGNAME	Tempol
D04GZS	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2

D04WMR	TTDDRUID	D04WMR
D04WMR	DRUGNAME	Tepoxalin
D04WMR	INDICATI	Asthma [ICD-11: CA23] Phase 2

D00UDP	TTDDRUID	D00UDP
D00UDP	DRUGNAME	Terameprocol
D00UDP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01ZOB	TTDDRUID	D01ZOB
D01ZOB	DRUGNAME	Terguride
D01ZOB	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0ZK7B	TTDDRUID	D0ZK7B
D0ZK7B	DRUGNAME	Tesofensine
D0ZK7B	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0G1IV	TTDDRUID	D0G1IV
D0G1IV	DRUGNAME	Testogen TDS
D0G1IV	INDICATI	Hypogonadism [ICD-11: 5A61.0] Phase 2

D0T6IM	TTDDRUID	D0T6IM
D0T6IM	DRUGNAME	Tetomilast
D0T6IM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0I5OR	TTDDRUID	D0I5OR
D0I5OR	DRUGNAME	Tetrahydrouridine
D0I5OR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0F2KY	TTDDRUID	D0F2KY
D0F2KY	DRUGNAME	TetraMen-T
D0F2KY	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2

D09WND	TTDDRUID	D09WND
D09WND	DRUGNAME	TETRAPLATIN TETRANITRATE
D09WND	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0PX0N	TTDDRUID	D0PX0N
D0PX0N	DRUGNAME	TF0023
D0PX0N	INDICATI	Heart attack [ICD-11: BA41] Phase 2
D0PX0N	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
D0PX0N	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D06KGI	TTDDRUID	D06KGI
D06KGI	DRUGNAME	TG-0054
D06KGI	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D0GP9Q	TTDDRUID	D0GP9Q
D0GP9Q	DRUGNAME	TG100801
D0GP9Q	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2

D04ZQO	TTDDRUID	D04ZQO
D04ZQO	DRUGNAME	TG-2349
D04ZQO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0E0MB	TTDDRUID	D0E0MB
D0E0MB	DRUGNAME	TG-4040
D0E0MB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0A0TI	TTDDRUID	D0A0TI
D0A0TI	DRUGNAME	TgAAC-09
D0A0TI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D04FVD	TTDDRUID	D04FVD
D04FVD	DRUGNAME	TGBA01AD
D04FVD	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D0IL4C	TTDDRUID	D0IL4C
D0IL4C	DRUGNAME	TgDCC-E1A
D0IL4C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D09OOQ	TTDDRUID	D09OOQ
D09OOQ	DRUGNAME	TGFK08AA-ER
D09OOQ	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 2

D00CQQ	TTDDRUID	D00CQQ
D00CQQ	DRUGNAME	TGFK09SD-ER
D00CQQ	INDICATI	Hypoactive sexual desire dysfunction [ICD-11: HA00] Phase 2

D06FQS	TTDDRUID	D06FQS
D06FQS	DRUGNAME	TGOF02N
D06FQS	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0O8SJ	TTDDRUID	D0O8SJ
D0O8SJ	DRUGNAME	TGR-1202
D0O8SJ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D0O8SJ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0O8SJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0S8DU	TTDDRUID	D0S8DU
D0S8DU	DRUGNAME	TGWOOAA
D0S8DU	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 2
D0S8DU	INDICATI	Social phobia [ICD-11: 6B04] Phase 2

D0H1EA	TTDDRUID	D0H1EA
D0H1EA	DRUGNAME	TH-302
D0H1EA	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0H1EA	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
D0H1EA	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
D0H1EA	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D09CIF	TTDDRUID	D09CIF
D09CIF	DRUGNAME	TH-9402
D09CIF	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2

D05ZDJ	TTDDRUID	D05ZDJ
D05ZDJ	DRUGNAME	THR-18
D05ZDJ	INDICATI	Asthma [ICD-11: CA23] Phase 2

D04GRB	TTDDRUID	D04GRB
D04GRB	DRUGNAME	THRX-198321
D04GRB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0J4LI	TTDDRUID	D0J4LI
D0J4LI	DRUGNAME	Thymoctonan
D0J4LI	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2

D0UT7X	TTDDRUID	D0UT7X
D0UT7X	DRUGNAME	tideglusib
D0UT7X	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2

D03LTO	TTDDRUID	D03LTO
D03LTO	DRUGNAME	Tigatuzumab
D03LTO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D03LTO	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D03LTO	INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
D03LTO	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D03LTO	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D00FMW	TTDDRUID	D00FMW
D00FMW	DRUGNAME	TIM ETEC vaccine
D00FMW	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2

D0P9QW	TTDDRUID	D0P9QW
D0P9QW	DRUGNAME	Tipapkinogene sovacivec
D0P9QW	INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2

D0Q7UG	TTDDRUID	D0Q7UG
D0Q7UG	DRUGNAME	Tipelukast
D0Q7UG	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0Q7UG	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2

D05BPC	TTDDRUID	D05BPC
D05BPC	DRUGNAME	Tiprelestat
D05BPC	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D06XGB	TTDDRUID	D06XGB
D06XGB	DRUGNAME	Tissue Repair Cells (TRCs)
D06XGB	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2

D0CR1I	TTDDRUID	D0CR1I
D0CR1I	DRUGNAME	TJ-9
D0CR1I	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0E6ZN	TTDDRUID	D0E6ZN
D0E6ZN	DRUGNAME	TKA-731
D0E6ZN	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0T9OC	TTDDRUID	D0T9OC
D0T9OC	DRUGNAME	TL-118
D0T9OC	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D02PAW	TTDDRUID	D02PAW
D02PAW	DRUGNAME	TLC-388
D02PAW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04LTF	TTDDRUID	D04LTF
D04LTF	DRUGNAME	TLN-4601
D04LTF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07SWU	TTDDRUID	D07SWU
D07SWU	DRUGNAME	TM30338
D07SWU	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D0B7QP	TTDDRUID	D0B7QP
D0B7QP	DRUGNAME	TM30339
D0B7QP	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D01LWO	TTDDRUID	D01LWO
D01LWO	DRUGNAME	TM-601
D01LWO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01ZNQ	TTDDRUID	D01ZNQ
D01ZNQ	DRUGNAME	TMC-310911
D01ZNQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0R2QG	TTDDRUID	D0R2QG
D0R2QG	DRUGNAME	TMI-358
D0R2QG	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D0N9KZ	TTDDRUID	D0N9KZ
D0N9KZ	DRUGNAME	TN-871
D0N9KZ	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D04ZHJ	TTDDRUID	D04ZHJ
D04ZHJ	DRUGNAME	TNF alpha kinoid
D04ZHJ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2

D09TFB	TTDDRUID	D09TFB
D09TFB	DRUGNAME	TOFIMILAST
D09TFB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0U0BU	TTDDRUID	D0U0BU
D0U0BU	DRUGNAME	TOK-001
D0U0BU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D03UIB	TTDDRUID	D03UIB
D03UIB	DRUGNAME	TOK-8801
D03UIB	INDICATI	Arthritis [ICD-11: FA20] Phase 2

D0M2QR	TTDDRUID	D0M2QR
D0M2QR	DRUGNAME	TOL-3021
D0M2QR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0GR5X	TTDDRUID	D0GR5X
D0GR5X	DRUGNAME	Tolamba
D0GR5X	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0E8IZ	TTDDRUID	D0E8IZ
D0E8IZ	DRUGNAME	Tonabersat
D0E8IZ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2

D0WZ4Y	TTDDRUID	D0WZ4Y
D0WZ4Y	DRUGNAME	Topical ruxolitinib
D0WZ4Y	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0WK0P	TTDDRUID	D0WK0P
D0WK0P	DRUGNAME	Topiroxostat
D0WK0P	INDICATI	Gout [ICD-11: FA25] Phase 2

D0H5BC	TTDDRUID	D0H5BC
D0H5BC	DRUGNAME	Tosagestin
D0H5BC	INDICATI	Contraception [ICD-11: QA21] Phase 2

D0VS2R	TTDDRUID	D0VS2R
D0VS2R	DRUGNAME	Tovaxin
D0VS2R	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D07IOT	TTDDRUID	D07IOT
D07IOT	DRUGNAME	TPI 287
D07IOT	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D07IOT	INDICATI	Brain metastases [ICD-11: 2D50] Phase 1
D07IOT	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D07IOT	INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1
D07IOT	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D02RPP	TTDDRUID	D02RPP
D02RPP	DRUGNAME	TPI ASM8
D02RPP	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0T5TU	TTDDRUID	D0T5TU
D0T5TU	DRUGNAME	TPI-1020
D0T5TU	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D06KQN	TTDDRUID	D06KQN
D06KQN	DRUGNAME	TPI-926
D06KQN	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2

D0LB8Z	TTDDRUID	D0LB8Z
D0LB8Z	DRUGNAME	TPIV200
D0LB8Z	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0LB8Z	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0LB8Z	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D0LU5Q	TTDDRUID	D0LU5Q
D0LU5Q	DRUGNAME	TPM-1/Morphine
D0LU5Q	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D0R6AI	TTDDRUID	D0R6AI
D0R6AI	DRUGNAME	TPX-100
D0R6AI	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D01TMW	TTDDRUID	D01TMW
D01TMW	DRUGNAME	Tradjeta
D01TMW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0S5WP	TTDDRUID	D0S5WP
D0S5WP	DRUGNAME	Trametinib + 2141795
D0S5WP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D09CUR	TTDDRUID	D09CUR
D09CUR	DRUGNAME	Trans-sodium crocetinate
D09CUR	INDICATI	Brain metastases [ICD-11: 2D50] Phase 1
D09CUR	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2
D09CUR	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D06BHB	TTDDRUID	D06BHB
D06BHB	DRUGNAME	Trastuzumab deruxtecan
D06BHB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0UG0K	TTDDRUID	D0UG0K
D0UG0K	DRUGNAME	Trastuzumab emtansine
D0UG0K	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0UG0K	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3

D0U5YW	TTDDRUID	D0U5YW
D0U5YW	DRUGNAME	Travoprost punctal plug
D0U5YW	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D00YLM	TTDDRUID	D00YLM
D00YLM	DRUGNAME	TRAXOPRODIL MESYLATE
D00YLM	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2

D01JPA	TTDDRUID	D01JPA
D01JPA	DRUGNAME	TRC102
D01JPA	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
D01JPA	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D01JPA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00YQI	TTDDRUID	D00YQI
D00YQI	DRUGNAME	TRC105
D00YQI	INDICATI	Angiosarcoma [ICD-11: 2B56] Phase 3
D00YQI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D00YQI	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
D00YQI	INDICATI	Gestational trophoblastic neoplasia [ICD-11: 2F33-2F76] Phase 2
D00YQI	INDICATI	Hemangiosarcoma [ICD-11: 2B56.1] Phase 3
D00YQI	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D00YQI	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
D00YQI	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
D00YQI	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D00YQI	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 2
D00YQI	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D00YQI	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D00YQI	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2

D0V8AP	TTDDRUID	D0V8AP
D0V8AP	DRUGNAME	TRC-4186
D0V8AP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D0VC8Z	TTDDRUID	D0VC8Z
D0VC8Z	DRUGNAME	Trehalose
D0VC8Z	INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2
D0VC8Z	INDICATI	Oculopharyngeal muscular dystrophy [ICD-11: 9C82.1] Phase 2
D0VC8Z	INDICATI	Spinal cerebellar ataxia type 3 [ICD-11: 8A03] Phase 2

D04NJP	TTDDRUID	D04NJP
D04NJP	DRUGNAME	TRF-1101
D04NJP	INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Phase 2

D0DT1R	TTDDRUID	D0DT1R
D0DT1R	DRUGNAME	Triapine
D0DT1R	INDICATI	Nerve injury [ICD-11: ND56.4] Phase 2

D0X0TM	TTDDRUID	D0X0TM
D0X0TM	DRUGNAME	Trichuris suis ova
D0X0TM	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0X8HP	TTDDRUID	D0X8HP
D0X8HP	DRUGNAME	TRIDMAC
D0X8HP	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2

D0AP9E	TTDDRUID	D0AP9E
D0AP9E	DRUGNAME	Trilaciclib
D0AP9E	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0AP9E	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D06XHD	TTDDRUID	D06XHD
D06XHD	DRUGNAME	Trimesta
D06XHD	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D07TCX	TTDDRUID	D07TCX
D07TCX	DRUGNAME	Triplex
D07TCX	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2

D02XUN	TTDDRUID	D02XUN
D02XUN	DRUGNAME	Trivalent seasonal influenza vaccine
D02XUN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0A2KH	TTDDRUID	D0A2KH
D0A2KH	DRUGNAME	TRK-170
D0A2KH	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2

D06AQJ	TTDDRUID	D06AQJ
D06AQJ	DRUGNAME	TRK-530
D06AQJ	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D02TXV	TTDDRUID	D02TXV
D02TXV	DRUGNAME	TRN-157
D02TXV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D05PZN	TTDDRUID	D05PZN
D05PZN	DRUGNAME	TRO-19622
D05PZN	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2

D09IOF	TTDDRUID	D09IOF
D09IOF	DRUGNAME	Troplasminogen alfa
D09IOF	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D0D6SZ	TTDDRUID	D0D6SZ
D0D6SZ	DRUGNAME	TROXACITABINE
D0D6SZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0M6GC	TTDDRUID	D0M6GC
D0M6GC	DRUGNAME	TRU-015
D0M6GC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D06LRG	TTDDRUID	D06LRG
D06LRG	DRUGNAME	TRV027
D06LRG	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D06GNF	TTDDRUID	D06GNF
D06GNF	DRUGNAME	TS-022
D06GNF	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0YL9G	TTDDRUID	D0YL9G
D0YL9G	DRUGNAME	TS-091
D0YL9G	INDICATI	Hypersomnia [ICD-11: 7A21] Phase 2

D0K4OS	TTDDRUID	D0K4OS
D0K4OS	DRUGNAME	TS-121
D0K4OS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
D0K4OS	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D0T5JS	TTDDRUID	D0T5JS
D0T5JS	DRUGNAME	TT-100
D0T5JS	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0E2LH	TTDDRUID	D0E2LH
D0E2LH	DRUGNAME	TT-173
D0E2LH	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 2

D02FYE	TTDDRUID	D02FYE
D02FYE	DRUGNAME	TT-223
D02FYE	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D0Q8VM	TTDDRUID	D0Q8VM
D0Q8VM	DRUGNAME	TT-401
D0Q8VM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D09FTJ	TTDDRUID	D09FTJ
D09FTJ	DRUGNAME	TTP-054
D09FTJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0DI1B	TTDDRUID	D0DI1B
D0DI1B	DRUGNAME	TTP273
D0DI1B	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0PX8I	TTDDRUID	D0PX8I
D0PX8I	DRUGNAME	TTP435
D0PX8I	INDICATI	Obesity [ICD-11: 5B81] Phase 2

D0PU9C	TTDDRUID	D0PU9C
D0PU9C	DRUGNAME	TTP-448
D0PU9C	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0VT1S	TTDDRUID	D0VT1S
D0VT1S	DRUGNAME	TTP889
D0VT1S	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 2
D0VT1S	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated

D0H4EM	TTDDRUID	D0H4EM
D0H4EM	DRUGNAME	Tuberculosis recombinant subunit vaccine
D0H4EM	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 1
D0H4EM	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D01ZFK	TTDDRUID	D01ZFK
D01ZFK	DRUGNAME	Tuberculosis recombinant vaccine
D01ZFK	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D0VH0X	TTDDRUID	D0VH0X
D0VH0X	DRUGNAME	Tuberculosis vaccine
D0VH0X	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1
D0VH0X	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D00SFN	TTDDRUID	D00SFN
D00SFN	DRUGNAME	TUCARESOL
D00SFN	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2

D09GRX	TTDDRUID	D09GRX
D09GRX	DRUGNAME	Tucatinib
D09GRX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0H8DS	TTDDRUID	D0H8DS
D0H8DS	DRUGNAME	Tumor infiltrating lymphocyte
D0H8DS	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0S3XE	TTDDRUID	D0S3XE
D0S3XE	DRUGNAME	Turosteride
D0S3XE	INDICATI	Prostate disease [ICD-11: GA91] Phase 2

D0D0FB	TTDDRUID	D0D0FB
D0D0FB	DRUGNAME	TV1001
D0D0FB	INDICATI	Diabetic angiopathy [ICD-11: BD53.Y] Phase 2

D01ITB	TTDDRUID	D01ITB
D01ITB	DRUGNAME	TV1001sr
D01ITB	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
D01ITB	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2

D03TPI	TTDDRUID	D03TPI
D03TPI	DRUGNAME	TV-1102
D03TPI	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0J5XS	TTDDRUID	D0J5XS
D0J5XS	DRUGNAME	TV-1380
D0J5XS	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2

D00HMZ	TTDDRUID	D00HMZ
D00HMZ	DRUGNAME	TV1-Kidney-1
D00HMZ	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0J3JN	TTDDRUID	D0J3JN
D0J3JN	DRUGNAME	TV-45070
D0J3JN	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
D0J3JN	INDICATI	Vasodilatation of extremities [ICD-11: EG00] Phase 2

D0K9BV	TTDDRUID	D0K9BV
D0K9BV	DRUGNAME	TVB-2640
D0K9BV	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
D0K9BV	INDICATI	Astrocytoma [ICD-11: 2A00.0Y] Phase 2
D0K9BV	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 2

D0ES7H	TTDDRUID	D0ES7H
D0ES7H	DRUGNAME	TV-Brain-1
D0ES7H	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D07ORE	TTDDRUID	D07ORE
D07ORE	DRUGNAME	TVGV-1 vaccine
D07ORE	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2

D0QF2X	TTDDRUID	D0QF2X
D0QF2X	DRUGNAME	TVI-Brain-1
D0QF2X	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D0QF2X	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2

D0ZR6E	TTDDRUID	D0ZR6E
D0ZR6E	DRUGNAME	TVI-Brain-1 cancer vaccine
D0ZR6E	INDICATI	Astrocytoma [ICD-11: 2A00.0Y] Phase 2
D0ZR6E	INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
D0ZR6E	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D0ZR6E	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0JH5K	TTDDRUID	D0JH5K
D0JH5K	DRUGNAME	TVI-Kidney-1
D0JH5K	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0WZ0E	TTDDRUID	D0WZ0E
D0WZ0E	DRUGNAME	TV-Kidney-1
D0WZ0E	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0XP7V	TTDDRUID	D0XP7V
D0XP7V	DRUGNAME	TWIN
D0XP7V	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D07HHU	TTDDRUID	D07HHU
D07HHU	DRUGNAME	TXA127
D07HHU	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 2
D07HHU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D08VVR	TTDDRUID	D08VVR
D08VVR	DRUGNAME	TY-51924
D08VVR	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2

D00HQE	TTDDRUID	D00HQE
D00HQE	DRUGNAME	Ty800
D00HQE	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2

D0B6VN	TTDDRUID	D0B6VN
D0B6VN	DRUGNAME	TZI-41078
D0B6VN	INDICATI	Arthritis [ICD-11: FA20] Phase 2

D0XG3Y	TTDDRUID	D0XG3Y
D0XG3Y	DRUGNAME	TZP-102
D0XG3Y	INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2

D0NR6T	TTDDRUID	D0NR6T
D0NR6T	DRUGNAME	UB-311
D0NR6T	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0I5US	TTDDRUID	D0I5US
D0I5US	DRUGNAME	UB-421
D0I5US	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D08EWM	TTDDRUID	D08EWM
D08EWM	DRUGNAME	UCB-0942
D08EWM	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
D08EWM	INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2

D0Z3RF	TTDDRUID	D0Z3RF
D0Z3RF	DRUGNAME	UCB-11056
D0Z3RF	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D04JIM	TTDDRUID	D04JIM
D04JIM	DRUGNAME	UCB-35440
D04JIM	INDICATI	Rhinitis [ICD-11: FA20] Phase 2

D0Z9VY	TTDDRUID	D0Z9VY
D0Z9VY	DRUGNAME	UCN-01
D0Z9VY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0OE5S	TTDDRUID	D0OE5S
D0OE5S	DRUGNAME	UE-2343
D0OE5S	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0Q0UA	TTDDRUID	D0Q0UA
D0Q0UA	DRUGNAME	UFT/leucovorin calcium
D0Q0UA	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0D5VJ	TTDDRUID	D0D5VJ
D0D5VJ	DRUGNAME	UK-432097
D0D5VJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0G2FV	TTDDRUID	D0G2FV
D0G2FV	DRUGNAME	Ultra-rapid insulin
D0G2FV	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D0G2FV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0X2EM	TTDDRUID	D0X2EM
D0X2EM	DRUGNAME	UNI-PH (1-34)
D0X2EM	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D0G4QL	TTDDRUID	D0G4QL
D0G4QL	DRUGNAME	UNI-rE-4
D0G4QL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D03KGH	TTDDRUID	D03KGH
D03KGH	DRUGNAME	Upamostat
D03KGH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D05GYL	TTDDRUID	D05GYL
D05GYL	DRUGNAME	UR-63325
D05GYL	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D03BSK	TTDDRUID	D03BSK
D03BSK	DRUGNAME	URC102
D03BSK	INDICATI	Gout [ICD-11: FA25] Phase 2

D0W2HG	TTDDRUID	D0W2HG
D0W2HG	DRUGNAME	Urocortin 2
D0W2HG	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2

D0JU3A	TTDDRUID	D0JU3A
D0JU3A	DRUGNAME	U-Strip Diabetes
D0JU3A	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D0JU3A	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0U3MQ	TTDDRUID	D0U3MQ
D0U3MQ	DRUGNAME	UX001 sialic acid
D0U3MQ	INDICATI	Hereditary inclusion body myositis [ICD-11: 4A41.2] Phase 2

D0L7PK	TTDDRUID	D0L7PK
D0L7PK	DRUGNAME	V-0191
D0L7PK	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0T2AE	TTDDRUID	D0T2AE
D0T2AE	DRUGNAME	V-0251
D0T2AE	INDICATI	Labyrinthitis [ICD-11: AB30.1] Phase 2

D01BVI	TTDDRUID	D01BVI
D01BVI	DRUGNAME	V-101
D01BVI	INDICATI	Erythema [ICD-11: ME64.0] Phase 2

D0D5MU	TTDDRUID	D0D5MU
D0D5MU	DRUGNAME	V10153
D0D5MU	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2

D0T8HI	TTDDRUID	D0T8HI
D0T8HI	DRUGNAME	V-114
D0T8HI	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D0T8HI	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2

D0K6HG	TTDDRUID	D0K6HG
D0K6HG	DRUGNAME	V116517
D0K6HG	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D0X3JK	TTDDRUID	D0X3JK
D0X3JK	DRUGNAME	V120083
D0X3JK	INDICATI	Chronic pain [ICD-11: MG30] Phase 2

D0J9UY	TTDDRUID	D0J9UY
D0J9UY	DRUGNAME	V505
D0J9UY	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
D0J9UY	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2

D06VWL	TTDDRUID	D06VWL
D06VWL	DRUGNAME	VA-106483
D06VWL	INDICATI	Nocturia [ICD-11: MF55] Phase 2

D00LSW	TTDDRUID	D00LSW
D00LSW	DRUGNAME	VA-111913
D00LSW	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 2

D02BRJ	TTDDRUID	D02BRJ
D02BRJ	DRUGNAME	Vabicaserin
D02BRJ	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2

D0F3GL	TTDDRUID	D0F3GL
D0F3GL	DRUGNAME	Vacc-4x
D0F3GL	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D08UOY	TTDDRUID	D08UOY
D08UOY	DRUGNAME	Vadimezan
D08UOY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0Y3BU	TTDDRUID	D0Y3BU
D0Y3BU	DRUGNAME	VAK-694
D0Y3BU	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D0BS7T	TTDDRUID	D0BS7T
D0BS7T	DRUGNAME	VALERGEN-BT (sublingual)
D0BS7T	INDICATI	Asthma [ICD-11: CA23] Phase 2

D03UBI	TTDDRUID	D03UBI
D03UBI	DRUGNAME	VALERGEN-DP (subcutaneous)
D03UBI	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0OX1L	TTDDRUID	D0OX1L
D0OX1L	DRUGNAME	VALERGEN-DP (sublingual)
D0OX1L	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0A1TK	TTDDRUID	D0A1TK
D0A1TK	DRUGNAME	VALERGEN-DS (sublingual)
D0A1TK	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0KN0I	TTDDRUID	D0KN0I
D0KN0I	DRUGNAME	Valetizumab
D0KN0I	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0M7DS	TTDDRUID	D0M7DS
D0M7DS	DRUGNAME	Valomaciclovir stearate
D0M7DS	INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 2

D08GBB	TTDDRUID	D08GBB
D08GBB	DRUGNAME	Valopicitabine dihydrochloride
D08GBB	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2

D0B5GS	TTDDRUID	D0B5GS
D0B5GS	DRUGNAME	Vancomycin hydrochloride
D0B5GS	INDICATI	Lung infection [ICD-11: CA4Z] Phase 2

D06PFI	TTDDRUID	D06PFI
D06PFI	DRUGNAME	Vancomycin inhalation powder
D06PFI	INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 2

D01RXW	TTDDRUID	D01RXW
D01RXW	DRUGNAME	Vaniprevir
D01RXW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D01FBP	TTDDRUID	D01FBP
D01FBP	DRUGNAME	Vanutide cridificar
D01FBP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0E8ZY	TTDDRUID	D0E8ZY
D0E8ZY	DRUGNAME	Vapitadine
D0E8ZY	INDICATI	Allergic skin disorder [ICD-11: 4A82] Phase 2

D0KV3M	TTDDRUID	D0KV3M
D0KV3M	DRUGNAME	Varlilumab
D0KV3M	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0KV3M	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D0KV3M	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0KV3M	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D0KV3M	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D0N2JI	TTDDRUID	D0N2JI
D0N2JI	DRUGNAME	VAS-203
D0N2JI	INDICATI	Brain injury [ICD-11: NA07.Z] Phase 2

D0UH4P	TTDDRUID	D0UH4P
D0UH4P	DRUGNAME	Vasculan
D0UH4P	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2

D0T4TN	TTDDRUID	D0T4TN
D0T4TN	DRUGNAME	Vasoactive intestinal peptide
D0T4TN	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
D0T4TN	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D0P6DJ	TTDDRUID	D0P6DJ
D0P6DJ	DRUGNAME	VATALANIB
D0P6DJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0X9UA	TTDDRUID	D0X9UA
D0X9UA	DRUGNAME	Vatelizumab
D0X9UA	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D0OQ8Q	TTDDRUID	D0OQ8Q
D0OQ8Q	DRUGNAME	Vatiquinone
D0OQ8Q	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2

D00GHG	TTDDRUID	D00GHG
D00GHG	DRUGNAME	VAX-102
D00GHG	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D0A8JB	TTDDRUID	D0A8JB
D0A8JB	DRUGNAME	VAX-125
D0A8JB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0A8JB	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D09SQM	TTDDRUID	D09SQM
D09SQM	DRUGNAME	VAY736
D09SQM	INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 2
D09SQM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D09SQM	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2

D0N2IE	TTDDRUID	D0N2IE
D0N2IE	DRUGNAME	VB-201
D0N2IE	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
D0N2IE	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0UI4K	TTDDRUID	D0UI4K
D0UI4K	DRUGNAME	VB4-847
D0UI4K	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D07WFQ	TTDDRUID	D07WFQ
D07WFQ	DRUGNAME	VBP 926 topical solution
D07WFQ	INDICATI	Paronychia [ICD-11: 1F23.13] Phase 2

D0F6YM	TTDDRUID	D0F6YM
D0F6YM	DRUGNAME	VBP15
D0F6YM	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
D0F6YM	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
D0F6YM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
D0F6YM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0UG3Q	TTDDRUID	D0UG3Q
D0UG3Q	DRUGNAME	VBP-245 topical gel
D0UG3Q	INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 2

D0A6VM	TTDDRUID	D0A6VM
D0A6VM	DRUGNAME	VCL-HB01
D0A6VM	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 2

D06QBX	TTDDRUID	D06QBX
D06QBX	DRUGNAME	VDA-1102 topical ointment
D06QBX	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2

D07NBA	TTDDRUID	D07NBA
D07NBA	DRUGNAME	Veltuzumab
D07NBA	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D07NBA	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D07NBA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D07NBA	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D00AVH	TTDDRUID	D00AVH
D00AVH	DRUGNAME	VEN100
D00AVH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D07WEN	TTDDRUID	D07WEN
D07WEN	DRUGNAME	Venglustat
D07WEN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0HG9P	TTDDRUID	D0HG9P
D0HG9P	DRUGNAME	VentaProst
D0HG9P	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2

D09XGB	TTDDRUID	D09XGB
D09XGB	DRUGNAME	VER 50589
D09XGB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D08YVP	TTDDRUID	D08YVP
D08YVP	DRUGNAME	Vericigiuat
D08YVP	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2

D09BOH	TTDDRUID	D09BOH
D09BOH	DRUGNAME	Verubulin
D09BOH	INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
D09BOH	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
D09BOH	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D09BOH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D08LYZ	TTDDRUID	D08LYZ
D08LYZ	DRUGNAME	VesiGel
D08LYZ	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D0E8QE	TTDDRUID	D0E8QE
D0E8QE	DRUGNAME	Vesigenurtacel-L
D0E8QE	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D0Y1UH	TTDDRUID	D0Y1UH
D0Y1UH	DRUGNAME	Vesigenurtucel-L
D0Y1UH	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D0N2JY	TTDDRUID	D0N2JY
D0N2JY	DRUGNAME	VESTIPITANT MESYLATE
D0N2JY	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D02XUC	TTDDRUID	D02XUC
D02XUC	DRUGNAME	VF001
D02XUC	INDICATI	Venous leg ulcer [ICD-11: BD74.3] Phase 2

D07KGR	TTDDRUID	D07KGR
D07KGR	DRUGNAME	VI-1121
D07KGR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0Q4CQ	TTDDRUID	D0Q4CQ
D0Q4CQ	DRUGNAME	Viagenpumatucel-L
D0Q4CQ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0H5DM	TTDDRUID	D0H5DM
D0H5DM	DRUGNAME	Viaskin Milk
D0H5DM	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2

D0Z2JP	TTDDRUID	D0Z2JP
D0Z2JP	DRUGNAME	Vi-CRM197
D0Z2JP	INDICATI	Salmonella infection [ICD-11: 1A09] Phase 2

D00LSI	TTDDRUID	D00LSI
D00LSI	DRUGNAME	Vidofludimus
D00LSI	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
D00LSI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D07YGK	TTDDRUID	D07YGK
D07YGK	DRUGNAME	Vilaprisan
D07YGK	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D0J0EM	TTDDRUID	D0J0EM
D0J0EM	DRUGNAME	Virexxa
D0J0EM	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2

D06SCP	TTDDRUID	D06SCP
D06SCP	DRUGNAME	VISION 5
D06SCP	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2

D07DTZ	TTDDRUID	D07DTZ
D07DTZ	DRUGNAME	VK0612
D07DTZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0E7AK	TTDDRUID	D0E7AK
D0E7AK	DRUGNAME	VK-2809
D0E7AK	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2

D0SK4Y	TTDDRUID	D0SK4Y
D0SK4Y	DRUGNAME	VLA-84
D0SK4Y	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2

D0S4LP	TTDDRUID	D0S4LP
D0S4LP	DRUGNAME	VLI-03A
D0S4LP	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2

D0J7LV	TTDDRUID	D0J7LV
D0J7LV	DRUGNAME	VLP vaccine
D0J7LV	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D0J6DU	TTDDRUID	D0J6DU
D0J6DU	DRUGNAME	VLP-based influenza vaccine
D0J6DU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D0D7DU	TTDDRUID	D0D7DU
D0D7DU	DRUGNAME	VLTS-589
D0D7DU	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D0Z5HA	TTDDRUID	D0Z5HA
D0Z5HA	DRUGNAME	VLTS-934
D0Z5HA	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2

D02DLP	TTDDRUID	D02DLP
D02DLP	DRUGNAME	VOFOPITANT HYDROCHLORIDE
D02DLP	INDICATI	Vomiting [ICD-11: MD90] Phase 2

D04QEC	TTDDRUID	D04QEC
D04QEC	DRUGNAME	Volitinib
D04QEC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06PVA	TTDDRUID	D06PVA
D06PVA	DRUGNAME	Volociximab
D06PVA	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0UV2E	TTDDRUID	D0UV2E
D0UV2E	DRUGNAME	VOLT02
D0UV2E	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2

D09ZMV	TTDDRUID	D09ZMV
D09ZMV	DRUGNAME	Votucalis ophthalmic
D09ZMV	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2

D01HZQ	TTDDRUID	D01HZQ
D01HZQ	DRUGNAME	VP-102
D01HZQ	INDICATI	Common wart [ICD-11: 1E80] Phase 2
D01HZQ	INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 2

D05IHZ	TTDDRUID	D05IHZ
D05IHZ	DRUGNAME	VP-20621
D05IHZ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2

D00VKK	TTDDRUID	D00VKK
D00VKK	DRUGNAME	VPI-2690B
D00VKK	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2

D0K9CZ	TTDDRUID	D0K9CZ
D0K9CZ	DRUGNAME	VPM-1-002
D0K9CZ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2

D0Q1PS	TTDDRUID	D0Q1PS
D0Q1PS	DRUGNAME	VR096
D0Q1PS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2

D02TNW	TTDDRUID	D02TNW
D02TNW	DRUGNAME	VR179
D02TNW	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0P9XW	TTDDRUID	D0P9XW
D0P9XW	DRUGNAME	VR465
D0P9XW	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2

D07WDW	TTDDRUID	D07WDW
D07WDW	DRUGNAME	VR496
D07WDW	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0U1QE	TTDDRUID	D0U1QE
D0U1QE	DRUGNAME	VR736
D0U1QE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D06NNQ	TTDDRUID	D06NNQ
D06NNQ	DRUGNAME	VRC-HIVADV014-00-VP
D06NNQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0H5KA	TTDDRUID	D0H5KA
D0H5KA	DRUGNAME	VRC-HIVDNA016-00-VP
D0H5KA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D08UGB	TTDDRUID	D08UGB
D08UGB	DRUGNAME	VRX806
D08UGB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D0Y1UO	TTDDRUID	D0Y1UO
D0Y1UO	DRUGNAME	VS-6063
D0Y1UO	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2

D09GVI	TTDDRUID	D09GVI
D09GVI	DRUGNAME	VSF-173
D09GVI	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2

D01ELU	TTDDRUID	D01ELU
D01ELU	DRUGNAME	VSN-16R
D01ELU	INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 2

D0O2XW	TTDDRUID	D0O2XW
D0O2XW	DRUGNAME	VT-111a
D0O2XW	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2

D0UA9J	TTDDRUID	D0UA9J
D0UA9J	DRUGNAME	VT-1129
D0UA9J	INDICATI	Cryptococcal meningitis infection [ICD-11: 1D01.10] Phase 1
D0UA9J	INDICATI	Onchocerciasis [ICD-11: 1F6A] Phase 2
D0UA9J	INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2

D0X8QD	TTDDRUID	D0X8QD
D0X8QD	DRUGNAME	VT-464
D0X8QD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D01XMC	TTDDRUID	D01XMC
D01XMC	DRUGNAME	VTB-38543
D01XMC	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2

D0H3JF	TTDDRUID	D0H3JF
D0H3JF	DRUGNAME	VTX-2337
D0H3JF	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2

D07NKZ	TTDDRUID	D07NKZ
D07NKZ	DRUGNAME	VVP-808
D07NKZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0G9OH	TTDDRUID	D0G9OH
D0G9OH	DRUGNAME	VVZ-149
D0G9OH	INDICATI	Arthritis [ICD-11: FA20] Phase 2

D0I8BH	TTDDRUID	D0I8BH
D0I8BH	DRUGNAME	Vx-001
D0I8BH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0BG3B	TTDDRUID	D0BG3B
D0BG3B	DRUGNAME	VX-135
D0BG3B	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D01KWJ	TTDDRUID	D01KWJ
D01KWJ	DRUGNAME	VX-150
D01KWJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2

D0O9EQ	TTDDRUID	D0O9EQ
D0O9EQ	DRUGNAME	VX-210
D0O9EQ	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2/3

D0F4NH	TTDDRUID	D0F4NH
D0F4NH	DRUGNAME	VX-222
D0F4NH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D02XNW	TTDDRUID	D02XNW
D02XNW	DRUGNAME	VX-680
D02XNW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D02NNV	TTDDRUID	D02NNV
D02NNV	DRUGNAME	VX-745
D02NNV	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D02NNV	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D09ZZW	TTDDRUID	D09ZZW
D09ZZW	DRUGNAME	VX-759
D09ZZW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D08DHN	TTDDRUID	D08DHN
D08DHN	DRUGNAME	VX-787
D08DHN	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D05QIS	TTDDRUID	D05QIS
D05QIS	DRUGNAME	VX-944
D05QIS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0C0ZN	TTDDRUID	D0C0ZN
D0C0ZN	DRUGNAME	VXA-A1.1
D0C0ZN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2

D09THX	TTDDRUID	D09THX
D09THX	DRUGNAME	WBI-1001
D09THX	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D0L2LG	TTDDRUID	D0L2LG
D0L2LG	DRUGNAME	WC-3018
D0L2LG	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0E9RP	TTDDRUID	D0E9RP
D0E9RP	DRUGNAME	WCK-2349
D0E9RP	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 2

D07NTC	TTDDRUID	D07NTC
D07NTC	DRUGNAME	WCK-771
D07NTC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2

D02SNY	TTDDRUID	D02SNY
D02SNY	DRUGNAME	WF-10
D02SNY	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2

D07LWL	TTDDRUID	D07LWL
D07LWL	DRUGNAME	WIN-34B
D07LWL	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2

D03GXU	TTDDRUID	D03GXU
D03GXU	DRUGNAME	WIN-901
D03GXU	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0V9FU	TTDDRUID	D0V9FU
D0V9FU	DRUGNAME	WST11
D0V9FU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0D4ZY	TTDDRUID	D0D4ZY
D0D4ZY	DRUGNAME	WT1
D0D4ZY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0D4ZY	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2

D0T9IX	TTDDRUID	D0T9IX
D0T9IX	DRUGNAME	WT1 immunotherapeutic
D0T9IX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D00QXB	TTDDRUID	D00QXB
D00QXB	DRUGNAME	WT1 peptide vaccine
D00QXB	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D02MLO	TTDDRUID	D02MLO
D02MLO	DRUGNAME	WT1-targeted autologous dendritic cell vaccine
D02MLO	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0DT1Y	TTDDRUID	D0DT1Y
D0DT1Y	DRUGNAME	WTX-101
D0DT1Y	INDICATI	Wilson disease [ICD-11: 5C64.00] Phase 2

D0A7JH	TTDDRUID	D0A7JH
D0A7JH	DRUGNAME	WY-50295-tromethamine
D0A7JH	INDICATI	Asthma [ICD-11: CA23] Phase 2

D04LMZ	TTDDRUID	D04LMZ
D04LMZ	DRUGNAME	X-22
D04LMZ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
D04LMZ	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 2
D04LMZ	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 2

D07QAK	TTDDRUID	D07QAK
D07QAK	DRUGNAME	Xanomeline tartrate
D07QAK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D0OS6P	TTDDRUID	D0OS6P
D0OS6P	DRUGNAME	XBIO-101
D0OS6P	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
D0OS6P	INDICATI	Malignant uterine tumour [ICD-11: 2C76.Z] Phase 2

D0U2XU	TTDDRUID	D0U2XU
D0U2XU	DRUGNAME	XEN-2174
D0U2XU	INDICATI	Cancer related pain [ICD-11: MG30] Phase 2

D04PER	TTDDRUID	D04PER
D04PER	DRUGNAME	XEN-402
D04PER	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2

D04VQH	TTDDRUID	D04VQH
D04VQH	DRUGNAME	XEN-D0501
D04VQH	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2

D03MUN	TTDDRUID	D03MUN
D03MUN	DRUGNAME	Xilonix
D03MUN	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D03MUN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D03KAC	TTDDRUID	D03KAC
D03KAC	DRUGNAME	XL147
D03KAC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D03KAC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00NSD	TTDDRUID	D00NSD
D00NSD	DRUGNAME	XL-820
D00NSD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0D1GF	TTDDRUID	D0D1GF
D0D1GF	DRUGNAME	XL880
D0D1GF	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
D0D1GF	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
D0D1GF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0D1GF	INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2

D0I8OY	TTDDRUID	D0I8OY
D0I8OY	DRUGNAME	XLCART001
D0I8OY	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2

D0R3PY	TTDDRUID	D0R3PY
D0R3PY	DRUGNAME	Xmab 5574/MOR208
D0R3PY	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D00NXT	TTDDRUID	D00NXT
D00NXT	DRUGNAME	Xmab 5871
D00NXT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
D00NXT	INDICATI	IgG4 related disease [ICD-11: 4A43.0] Phase 2
D00NXT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2
D00NXT	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2

D0Y0HR	TTDDRUID	D0Y0HR
D0Y0HR	DRUGNAME	XOMA 358
D0Y0HR	INDICATI	Congenital hyperinsulinism [ICD-11: 5A4Y] Phase 2

D0UF8E	TTDDRUID	D0UF8E
D0UF8E	DRUGNAME	XOMA-629
D0UF8E	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D0P3SJ	TTDDRUID	D0P3SJ
D0P3SJ	DRUGNAME	XP-21279
D0P3SJ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2

D02RDX	TTDDRUID	D02RDX
D02RDX	DRUGNAME	XP-23829
D02RDX	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
D02RDX	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D08EES	TTDDRUID	D08EES
D08EES	DRUGNAME	XR-5000
D08EES	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0C6EA	TTDDRUID	D0C6EA
D0C6EA	DRUGNAME	XZK
D0C6EA	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D06BBV	TTDDRUID	D06BBV
D06BBV	DRUGNAME	XZK-monascus
D06BBV	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D0DK5R	TTDDRUID	D0DK5R
D0DK5R	DRUGNAME	YESCARTA
D0DK5R	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2

D0H7FW	TTDDRUID	D0H7FW
D0H7FW	DRUGNAME	YF-476
D0H7FW	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Phase 2

D01CBE	TTDDRUID	D01CBE
D01CBE	DRUGNAME	Ygalo
D01CBE	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D03RVC	TTDDRUID	D03RVC
D03RVC	DRUGNAME	YH-4808
D03RVC	INDICATI	Duodenal ulcer [ICD-11: DA63] Phase 2

D02ORS	TTDDRUID	D02ORS
D02ORS	DRUGNAME	YKP-GI
D02ORS	INDICATI	Constipation [ICD-11: DD91.1] Phase 2

D06YWH	TTDDRUID	D06YWH
D06YWH	DRUGNAME	YM155
D06YWH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D06YWH	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D0W6AF	TTDDRUID	D0W6AF
D0W6AF	DRUGNAME	YM-264
D0W6AF	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2

D0C3BA	TTDDRUID	D0C3BA
D0C3BA	DRUGNAME	YM-358
D0C3BA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D01VAP	TTDDRUID	D01VAP
D01VAP	DRUGNAME	YM-430
D01VAP	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0H2NI	TTDDRUID	D0H2NI
D0H2NI	DRUGNAME	YM-543
D0H2NI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0XR7C	TTDDRUID	D0XR7C
D0XR7C	DRUGNAME	YM-598
D0XR7C	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D04CLM	TTDDRUID	D04CLM
D04CLM	DRUGNAME	YM-758
D04CLM	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D05RZW	TTDDRUID	D05RZW
D05RZW	DRUGNAME	YM-934
D05RZW	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D0C6RD	TTDDRUID	D0C6RD
D0C6RD	DRUGNAME	Ypeginterferon alfa-2b
D0C6RD	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0VS2W	TTDDRUID	D0VS2W
D0VS2W	DRUGNAME	YSIL6
D0VS2W	INDICATI	Crohn disease [ICD-11: DD70] Phase 2

D0W9NO	TTDDRUID	D0W9NO
D0W9NO	DRUGNAME	YT-146
D0W9NO	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2

D0C3VQ	TTDDRUID	D0C3VQ
D0C3VQ	DRUGNAME	Zadaxin/lamivudine
D0C3VQ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2

D0OP8W	TTDDRUID	D0OP8W
D0OP8W	DRUGNAME	Zalospirone
D0OP8W	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2

D07NPS	TTDDRUID	D07NPS
D07NPS	DRUGNAME	Zarnestra
D07NPS	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2
D07NPS	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D07NPS	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
D07NPS	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D07NPS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D07NPS	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2

D0V9IE	TTDDRUID	D0V9IE
D0V9IE	DRUGNAME	ZD2079
D0V9IE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D04AMD	TTDDRUID	D04AMD
D04AMD	DRUGNAME	ZD-6126
D04AMD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D06TKE	TTDDRUID	D06TKE
D06TKE	DRUGNAME	ZD-7288
D06TKE	INDICATI	Angina pectoris [ICD-11: BA40] Phase 2

D01JIO	TTDDRUID	D01JIO
D01JIO	DRUGNAME	ZK-91587
D01JIO	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2

D02GTN	TTDDRUID	D02GTN
D02GTN	DRUGNAME	ZY-15106
D02GTN	INDICATI	Asthma [ICD-11: CA23] Phase 2

D07XAY	TTDDRUID	D07XAY
D07XAY	DRUGNAME	ZYH-7
D07XAY	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2

D0B1RX	TTDDRUID	D0B1RX
D0B1RX	DRUGNAME	ZYI-1
D0B1RX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2

D09AHK	TTDDRUID	D09AHK
D09AHK	DRUGNAME	ZYN002-CBD gel
D09AHK	INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2

D0LJ7T	TTDDRUID	D0LJ7T
D0LJ7T	DRUGNAME	BT-1718
D0LJ7T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2a

D00BPH	TTDDRUID	D00BPH
D00BPH	DRUGNAME	COVA322
D00BPH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1/2a

D0OK4O	TTDDRUID	D0OK4O
D0OK4O	DRUGNAME	Dalazatide
D0OK4O	INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 1b/2a
D0OK4O	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
D0OK4O	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1b/2a

D01XEO	TTDDRUID	D01XEO
D01XEO	DRUGNAME	Debio-0824
D01XEO	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1b/2a
D01XEO	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1

D0H4GT	TTDDRUID	D0H4GT
D0H4GT	DRUGNAME	131I-radretumab
D0H4GT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D02DWK	TTDDRUID	D02DWK
D02DWK	DRUGNAME	2-hydroxyoleic acid
D02DWK	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1/2

D02GSD	TTDDRUID	D02GSD
D02GSD	DRUGNAME	3VM1001 topical cream
D02GSD	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 1/2

D0BH2M	TTDDRUID	D0BH2M
D0BH2M	DRUGNAME	4SCAR19 and 4SCAR123
D0BH2M	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D03ZCH	TTDDRUID	D03ZCH
D03ZCH	DRUGNAME	4SCAR19 and 4SCAR20
D03ZCH	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0J7VH	TTDDRUID	D0J7VH
D0J7VH	DRUGNAME	4SCAR19 and 4SCAR22
D0J7VH	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0K8YX	TTDDRUID	D0K8YX
D0K8YX	DRUGNAME	4SCAR19 and 4SCAR30
D0K8YX	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0I4HG	TTDDRUID	D0I4HG
D0I4HG	DRUGNAME	4SCAR19 and 4SCAR38
D0I4HG	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D02YRD	TTDDRUID	D02YRD
D02YRD	DRUGNAME	4SCAR19 and 4SCAR70
D02YRD	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0TE0L	TTDDRUID	D0TE0L
D0TE0L	DRUGNAME	4SCAR19 cells
D0TE0L	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D08FVH	TTDDRUID	D08FVH
D08FVH	DRUGNAME	4SCAR19/22 T cells
D08FVH	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
D08FVH	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D09NUH	TTDDRUID	D09NUH
D09NUH	DRUGNAME	4SCAR-FRa
D09NUH	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2

D01YCF	TTDDRUID	D01YCF
D01YCF	DRUGNAME	4SCAR-GD2
D01YCF	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1/2

D0VI8T	TTDDRUID	D0VI8T
D0VI8T	DRUGNAME	4SCAR-PSMA
D0VI8T	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2

D03OVA	TTDDRUID	D03OVA
D03OVA	DRUGNAME	8-chloro-adenosine
D03OVA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0TN4M	TTDDRUID	D0TN4M
D0TN4M	DRUGNAME	8H9 I-124 mAb
D0TN4M	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2

D0O2ZI	TTDDRUID	D0O2ZI
D0O2ZI	DRUGNAME	90Y-labeled humanized anti-Tac mab (anticancer), NCI
D0O2ZI	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0UZ4G	TTDDRUID	D0UZ4G
D0UZ4G	DRUGNAME	99mTc-rBitistatin
D0UZ4G	INDICATI	Embolism [ICD-11: JB42] Phase 1/2

D0T5QC	TTDDRUID	D0T5QC
D0T5QC	DRUGNAME	AAV1-FS344
D0T5QC	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
D0T5QC	INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 1/2
D0T5QC	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1/2

D0M4PV	TTDDRUID	D0M4PV
D0M4PV	DRUGNAME	AAV5-hFIXco
D0M4PV	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2

D07YPV	TTDDRUID	D07YPV
D07YPV	DRUGNAME	AbelaDrug200
D07YPV	INDICATI	Head injury [ICD-11: NA00-NA0Z] Phase 1/2

D08KCJ	TTDDRUID	D08KCJ
D08KCJ	DRUGNAME	ABY-025
D08KCJ	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2

D0Q4DS	TTDDRUID	D0Q4DS
D0Q4DS	DRUGNAME	AC vaccine
D0Q4DS	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D0R6UR	TTDDRUID	D0R6UR
D0R6UR	DRUGNAME	ACI-24
D0R6UR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D0UF0N	TTDDRUID	D0UF0N
D0UF0N	DRUGNAME	ACP-319
D0UF0N	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2

D0TP9M	TTDDRUID	D0TP9M
D0TP9M	DRUGNAME	ACY-1215
D0TP9M	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2

D0H0ZQ	TTDDRUID	D0H0ZQ
D0H0ZQ	DRUGNAME	Ad35.CS.01
D0H0ZQ	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D0W9IH	TTDDRUID	D0W9IH
D0W9IH	DRUGNAME	Ad35-GRIN
D0W9IH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D02CLV	TTDDRUID	D02CLV
D02CLV	DRUGNAME	AdCh63 AMA1
D02CLV	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D0B1TT	TTDDRUID	D0B1TT
D0B1TT	DRUGNAME	AdCh63-MSP1
D0B1TT	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D0I1NV	TTDDRUID	D0I1NV
D0I1NV	DRUGNAME	Adenovirus gene therapy
D0I1NV	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2

D02CZF	TTDDRUID	D02CZF
D02CZF	DRUGNAME	Aderbasib
D02CZF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D06LUI	TTDDRUID	D06LUI
D06LUI	DRUGNAME	Ad-IL-12 DNA therapeutic
D06LUI	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D06LUI	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0X4OJ	TTDDRUID	D0X4OJ
D0X4OJ	DRUGNAME	AdipoCell
D0X4OJ	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1/2
D0X4OJ	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1/2

D06UEC	TTDDRUID	D06UEC
D06UEC	DRUGNAME	ADXS-HER2
D06UEC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D06UEC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D09SCP	TTDDRUID	D09SCP
D09SCP	DRUGNAME	ADXS-PSA
D09SCP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
D09SCP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0G2QH	TTDDRUID	D0G2QH
D0G2QH	DRUGNAME	AEE-788
D0G2QH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0C1JP	TTDDRUID	D0C1JP
D0C1JP	DRUGNAME	AEG35156
D0C1JP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0PY7Z	TTDDRUID	D0PY7Z
D0PY7Z	DRUGNAME	Aflunov
D0PY7Z	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1/2

D0U1VR	TTDDRUID	D0U1VR
D0U1VR	DRUGNAME	AFX-9154
D0U1VR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D03CGQ	TTDDRUID	D03CGQ
D03CGQ	DRUGNAME	AG-013958
D03CGQ	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2

D09SFX	TTDDRUID	D09SFX
D09SFX	DRUGNAME	AGEN1884
D09SFX	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
D09SFX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G4AJ	TTDDRUID	D0G4AJ
D0G4AJ	DRUGNAME	AGN-208397
D0G4AJ	INDICATI	Retina venous occlusion [ICD-11: 9B74.1] Phase 1/2

D0P2YP	TTDDRUID	D0P2YP
D0P2YP	DRUGNAME	AGT-181
D0P2YP	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2

D0P8MB	TTDDRUID	D0P8MB
D0P8MB	DRUGNAME	AIGIV
D0P8MB	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2

D0QK5C	TTDDRUID	D0QK5C
D0QK5C	DRUGNAME	ALAMIFOVIR
D0QK5C	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1/2

D02XXW	TTDDRUID	D02XXW
D02XXW	DRUGNAME	Allogeneic/autologous adult mesenchymal stem cell therapy
D02XXW	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1/2

D01RLS	TTDDRUID	D01RLS
D01RLS	DRUGNAME	Allostrome
D01RLS	INDICATI	Arthropathy [ICD-11: FA11-FA38] Phase 1/2

D04XSP	TTDDRUID	D04XSP
D04XSP	DRUGNAME	Alpha-fetoprotein cancer vaccine
D04XSP	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D0FD7H	TTDDRUID	D0FD7H
D0FD7H	DRUGNAME	ALT-803
D0FD7H	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0FD7H	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0FD7H	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
D0FD7H	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0FD7H	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
D0FD7H	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
D0FD7H	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0FD7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0FD7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0O2XQ	TTDDRUID	D0O2XQ
D0O2XQ	DRUGNAME	AMD-070
D0O2XQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
D0O2XQ	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D0O2XQ	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2
D0O2XQ	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
D0O2XQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0C1WR	TTDDRUID	D0C1WR
D0C1WR	DRUGNAME	AMG 232
D0C1WR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0T8CE	TTDDRUID	D0T8CE
D0T8CE	DRUGNAME	AMG888/U3-1287
D0T8CE	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D05WBV	TTDDRUID	D05WBV
D05WBV	DRUGNAME	Ampligenrintatolimod
D05WBV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0A9PW	TTDDRUID	D0A9PW
D0A9PW	DRUGNAME	AMT-060
D0A9PW	INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1/2

D0N1RH	TTDDRUID	D0N1RH
D0N1RH	DRUGNAME	AMZ-0026
D0N1RH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0O7ZX	TTDDRUID	D0O7ZX
D0O7ZX	DRUGNAME	Annamycin liposomal
D0O7ZX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D06AAG	TTDDRUID	D06AAG
D06AAG	DRUGNAME	Anthrax Immune Globulin (AIG)
D06AAG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2

D0MK7H	TTDDRUID	D0MK7H
D0MK7H	DRUGNAME	Anti-BCMA CAR-T cells
D0MK7H	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D07QIQ	TTDDRUID	D07QIQ
D07QIQ	DRUGNAME	Anti-BCMA-CAR-transduced T cells
D07QIQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D07QIQ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D07QIQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0S1CR	TTDDRUID	D0S1CR
D0S1CR	DRUGNAME	Anti-CD123-CAR-transduced T cells
D0S1CR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D04GIO	TTDDRUID	D04GIO
D04GIO	DRUGNAME	Anti-CD19 and Anti-CD20 CAR-T Cells
D04GIO	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0XG0L	TTDDRUID	D0XG0L
D0XG0L	DRUGNAME	Anti-CD19 CAR T cells
D0XG0L	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0JD4T	TTDDRUID	D0JD4T
D0JD4T	DRUGNAME	Anti-CD19 CAR transduced T cells
D0JD4T	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2
D0JD4T	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0JD4T	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D0KF9T	TTDDRUID	D0KF9T
D0KF9T	DRUGNAME	Anti-CD19 CAR-T
D0KF9T	INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2

D05LIH	TTDDRUID	D05LIH
D05LIH	DRUGNAME	Anti-CD19 CAR-T cells
D05LIH	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2
D05LIH	INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2
D05LIH	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D05LIH	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D05LIH	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
D05LIH	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D0D9BL	TTDDRUID	D0D9BL
D0D9BL	DRUGNAME	Anti-CD19 CAR-T cells
D0D9BL	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2

D0GT3R	TTDDRUID	D0GT3R
D0GT3R	DRUGNAME	Anti-CD19 CAR-T cells
D0GT3R	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0GT3R	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0Q5EH	TTDDRUID	D0Q5EH
D0Q5EH	DRUGNAME	Anti-CD19 CAR-T cells
D0Q5EH	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0Q5EH	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D08JTI	TTDDRUID	D08JTI
D08JTI	DRUGNAME	Anti-CD19/22-CAR vector-transduced T cells
D08JTI	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D08JTI	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2
D08JTI	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D08JTI	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D08JTI	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
D08JTI	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
D08JTI	INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2

D0J3DN	TTDDRUID	D0J3DN
D0J3DN	DRUGNAME	Anti-CD19-CAR PBL
D0J3DN	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D0J3DN	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
D0J3DN	INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 1/2

D0CE0Y	TTDDRUID	D0CE0Y
D0CE0Y	DRUGNAME	Anti-CD19-CAR-T cells
D0CE0Y	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0MA4O	TTDDRUID	D0MA4O
D0MA4O	DRUGNAME	Anti-CD20 CAR-T cells
D0MA4O	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2

D0V6VD	TTDDRUID	D0V6VD
D0V6VD	DRUGNAME	Anti-CD20-CAR vector-transduced autologous T cells
D0V6VD	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0V6VD	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2
D0V6VD	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D0V6VD	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
D0V6VD	INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2
D0V6VD	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
D0V6VD	INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2

D00FIO	TTDDRUID	D00FIO
D00FIO	DRUGNAME	Anti-CD20-CAR-transduced T cells
D00FIO	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D00FIO	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0ZQ3K	TTDDRUID	D0ZQ3K
D0ZQ3K	DRUGNAME	Anti-CD22 CAR-T cells
D0ZQ3K	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0ZQ3K	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D03IHD	TTDDRUID	D03IHD
D03IHD	DRUGNAME	Anti-CD22-CAR-transduced T cells
D03IHD	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D03IHD	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D04ACK	TTDDRUID	D04ACK
D04ACK	DRUGNAME	Anti-CD30 CAR T cells
D04ACK	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D0W2MI	TTDDRUID	D0W2MI
D0W2MI	DRUGNAME	Anti-CD30-CAR-transduced T cells
D0W2MI	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0W2MI	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0K8WE	TTDDRUID	D0K8WE
D0K8WE	DRUGNAME	Anti-CD33 CAR-T cells
D0K8WE	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1/2

D0OO1S	TTDDRUID	D0OO1S
D0OO1S	DRUGNAME	Anti-CD38 CAR-T cells
D0OO1S	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0A3OE	TTDDRUID	D0A3OE
D0A3OE	DRUGNAME	Anti-C-met CAR-T cells
D0A3OE	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D0A3OE	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D0A3OE	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D0A3OE	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D0LW4A	TTDDRUID	D0LW4A
D0LW4A	DRUGNAME	Anti-DR5 cells
D0LW4A	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D02NYA	TTDDRUID	D02NYA
D02NYA	DRUGNAME	Anti-Ebola mAb
D02NYA	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1/2

D0Q4EJ	TTDDRUID	D0Q4EJ
D0Q4EJ	DRUGNAME	Anti-EGFR V III CAR-T cells
D0Q4EJ	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
D0Q4EJ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D0Q4EJ	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D08ZDI	TTDDRUID	D08ZDI
D08ZDI	DRUGNAME	Anti-Factor D
D08ZDI	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2

D0Q1EZ	TTDDRUID	D0Q1EZ
D0Q1EZ	DRUGNAME	Antifungal multivalent oral vaccine
D0Q1EZ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1/2

D05JXT	TTDDRUID	D05JXT
D05JXT	DRUGNAME	Antifungal vaccine
D05JXT	INDICATI	Mycoses [ICD-11: 1F2Z] Phase 1/2

D0Z2UY	TTDDRUID	D0Z2UY
D0Z2UY	DRUGNAME	Antigen-specific melanoma vaccine
D0Z2UY	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D08QZH	TTDDRUID	D08QZH
D08QZH	DRUGNAME	Anti-HER2 CAR-T
D08QZH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D08QZH	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
D08QZH	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
D08QZH	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
D08QZH	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D08QZH	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0W5QJ	TTDDRUID	D0W5QJ
D0W5QJ	DRUGNAME	Anti-HIV ribozyme therapy
D0W5QJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0BE6M	TTDDRUID	D0BE6M
D0BE6M	DRUGNAME	Anti-Mesothelin CAR-T cells
D0BE6M	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
D0BE6M	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1/2
D0BE6M	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0F7FY	TTDDRUID	D0F7FY
D0F7FY	DRUGNAME	Antimicrobial oral vaccine
D0F7FY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2

D07YGQ	TTDDRUID	D07YGQ
D07YGQ	DRUGNAME	Anti-MUC1 AR20.5
D07YGQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D08WII	TTDDRUID	D08WII
D08WII	DRUGNAME	Anti-MUC1 CAR T Cells
D08WII	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D08WII	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D08WII	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0AI7H	TTDDRUID	D0AI7H
D0AI7H	DRUGNAME	Anti-MUC1 CAR T Cells
D0AI7H	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
D0AI7H	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D09KWN	TTDDRUID	D09KWN
D09KWN	DRUGNAME	Anti-MUC1 CAR-T cells
D09KWN	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2

D0C9MJ	TTDDRUID	D0C9MJ
D0C9MJ	DRUGNAME	Anti-MUC1 CAR-T cells
D0C9MJ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D0C9MJ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
D0C9MJ	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2

D0LJ2S	TTDDRUID	D0LJ2S
D0LJ2S	DRUGNAME	Anti-NY-ESO-1 CAR-T cells
D0LJ2S	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2
D0LJ2S	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
D0LJ2S	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0LJ2S	INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 1/2

D0Q1JZ	TTDDRUID	D0Q1JZ
D0Q1JZ	DRUGNAME	Anti-OX40 monoclonal antibody
D0Q1JZ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0U6BQ	TTDDRUID	D0U6BQ
D0U6BQ	DRUGNAME	Anti-VEGFR2 CD8 cell therapy
D0U6BQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05KCJ	TTDDRUID	D05KCJ
D05KCJ	DRUGNAME	ANZ-521
D05KCJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0H3HV	TTDDRUID	D0H3HV
D0H3HV	DRUGNAME	AP-1030
D0H3HV	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1/2

D0K8TO	TTDDRUID	D0K8TO
D0K8TO	DRUGNAME	AP1903
D0K8TO	INDICATI	Transplant rejection [ICD-11: NE84] Phase 1/2

D0E0AX	TTDDRUID	D0E0AX
D0E0AX	DRUGNAME	AP-611074
D0E0AX	INDICATI	Condyloma [ICD-11: 1A61.3] Phase 1/2

D0N7DQ	TTDDRUID	D0N7DQ
D0N7DQ	DRUGNAME	APC-100
D0N7DQ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D09QVU	TTDDRUID	D09QVU
D09QVU	DRUGNAME	APH-0703
D09QVU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D0HE9J	TTDDRUID	D0HE9J
D0HE9J	DRUGNAME	APN-201
D0HE9J	INDICATI	Dermatitis [ICD-11: EA80-EA89] Phase 1/2

D02WEU	TTDDRUID	D02WEU
D02WEU	DRUGNAME	ApoCell
D02WEU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2

D0U8FG	TTDDRUID	D0U8FG
D0U8FG	DRUGNAME	APS-001
D0U8FG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D00IAV	TTDDRUID	D00IAV
D00IAV	DRUGNAME	APS001F
D00IAV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D00IAV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07PCZ	TTDDRUID	D07PCZ
D07PCZ	DRUGNAME	AR20.5
D07PCZ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D07KDI	TTDDRUID	D07KDI
D07KDI	DRUGNAME	AR-42
D07KDI	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D07KDI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0C6YH	TTDDRUID	D0C6YH
D0C6YH	DRUGNAME	ARC-2022
D0C6YH	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 1/2

D02RZV	TTDDRUID	D02RZV
D02RZV	DRUGNAME	ARQ-151 cream
D02RZV	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1/2

D08KCK	TTDDRUID	D08KCK
D08KCK	DRUGNAME	ART621
D08KCK	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1/2
D08KCK	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2

D0U8QC	TTDDRUID	D0U8QC
D0U8QC	DRUGNAME	AS-210
D0U8QC	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1/2

D06PZO	TTDDRUID	D06PZO
D06PZO	DRUGNAME	ASC-101
D06PZO	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0MX5N	TTDDRUID	D0MX5N
D0MX5N	DRUGNAME	ASCT01
D0MX5N	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 1/2

D0K9JO	TTDDRUID	D0K9JO
D0K9JO	DRUGNAME	AskBio009
D0K9JO	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2

D0H7XJ	TTDDRUID	D0H7XJ
D0H7XJ	DRUGNAME	ASP-9521
D0H7XJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D04QPA	TTDDRUID	D04QPA
D04QPA	DRUGNAME	AST-OPC1
D04QPA	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1/2

D0VD9X	TTDDRUID	D0VD9X
D0VD9X	DRUGNAME	AstroStem
D0VD9X	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D04QQZ	TTDDRUID	D04QQZ
D04QQZ	DRUGNAME	AT132
D04QQZ	INDICATI	X-linked myotubular myopathy [ICD-11: 8C72] Phase 1/2

D0X4FW	TTDDRUID	D0X4FW
D0X4FW	DRUGNAME	AT9183
D0X4FW	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0E7MA	TTDDRUID	D0E7MA
D0E7MA	DRUGNAME	ATG002
D0E7MA	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2

D0D9LJ	TTDDRUID	D0D9LJ
D0D9LJ	DRUGNAME	Atiprimod
D0D9LJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D08FHZ	TTDDRUID	D08FHZ
D08FHZ	DRUGNAME	ATL-313
D08FHZ	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1/2

D08OPS	TTDDRUID	D08OPS
D08OPS	DRUGNAME	ATYR 1940
D08OPS	INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 1/2

D0R0NX	TTDDRUID	D0R0NX
D0R0NX	DRUGNAME	AU-011
D0R0NX	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0T9JW	TTDDRUID	D0T9JW
D0T9JW	DRUGNAME	AU101
D0T9JW	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1/2
D0T9JW	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
D0T9JW	INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2
D0T9JW	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1/2

D03TQB	TTDDRUID	D03TQB
D03TQB	DRUGNAME	AU105
D03TQB	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2

D0B8UW	TTDDRUID	D0B8UW
D0B8UW	DRUGNAME	AUTO2
D0B8UW	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D02ONA	TTDDRUID	D02ONA
D02ONA	DRUGNAME	AUTO3
D02ONA	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D02ONA	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2

D03JOA	TTDDRUID	D03JOA
D03JOA	DRUGNAME	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
D03JOA	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D03JOA	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D03JOA	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
D03JOA	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0O6LR	TTDDRUID	D0O6LR
D0O6LR	DRUGNAME	Autologous CD19-targeting CAR T cells
D0O6LR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D01DRB	TTDDRUID	D01DRB
D01DRB	DRUGNAME	Autologous cell vaccine
D01DRB	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0ZH2L	TTDDRUID	D0ZH2L
D0ZH2L	DRUGNAME	Autologous fat-derived stem cell therapy
D0ZH2L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05TWD	TTDDRUID	D05TWD
D05TWD	DRUGNAME	Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy
D05TWD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2
D05TWD	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 1/2

D0EL9Z	TTDDRUID	D0EL9Z
D0EL9Z	DRUGNAME	AV0328
D0EL9Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2

D0OC0W	TTDDRUID	D0OC0W
D0OC0W	DRUGNAME	AVID100
D0OC0W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07DJP	TTDDRUID	D07DJP
D07DJP	DRUGNAME	Avigen Parkinson
D07DJP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2

D08JOY	TTDDRUID	D08JOY
D08JOY	DRUGNAME	Avrina
D08JOY	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 1/2

D05ATD	TTDDRUID	D05ATD
D05ATD	DRUGNAME	AVX-502
D05ATD	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2

D05ENG	TTDDRUID	D05ENG
D05ENG	DRUGNAME	AVX701
D05ENG	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D05ENG	INDICATI	Rectosigmoid junction cancer [ICD-11: 2B91.Z] Phase 1/2

D0F3MT	TTDDRUID	D0F3MT
D0F3MT	DRUGNAME	AVX901
D0F3MT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0V1KS	TTDDRUID	D0V1KS
D0V1KS	DRUGNAME	AZD-2836
D0V1KS	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D07RZW	TTDDRUID	D07RZW
D07RZW	DRUGNAME	AZD9150
D07RZW	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D02YWD	TTDDRUID	D02YWD
D02YWD	DRUGNAME	B27PD
D02YWD	INDICATI	Uveitis [ICD-11: 9A96.Z] Phase 1/2

D04EON	TTDDRUID	D04EON
D04EON	DRUGNAME	BAL-101553
D04EON	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D04EON	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0DY9K	TTDDRUID	D0DY9K
D0DY9K	DRUGNAME	BAX335
D0DY9K	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2

D01CUC	TTDDRUID	D01CUC
D01CUC	DRUGNAME	BCMA CAR T cells
D01CUC	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D02JNC	TTDDRUID	D02JNC
D02JNC	DRUGNAME	BCMA CAR-T
D02JNC	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D06XAT	TTDDRUID	D06XAT
D06XAT	DRUGNAME	BCT-100
D06XAT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D00GAM	TTDDRUID	D00GAM
D00GAM	DRUGNAME	Beclanorsen
D00GAM	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D05NYK	TTDDRUID	D05NYK
D05NYK	DRUGNAME	BEL-0222
D05NYK	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1/2

D0B9XW	TTDDRUID	D0B9XW
D0B9XW	DRUGNAME	Betalutin
D0B9XW	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D0B9XW	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0D9IQ	TTDDRUID	D0D9IQ
D0D9IQ	DRUGNAME	BGB-290
D0D9IQ	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D0D9IQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0D9IQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0X7IN	TTDDRUID	D0X7IN
D0X7IN	DRUGNAME	BGT226
D0X7IN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D04MGW	TTDDRUID	D04MGW
D04MGW	DRUGNAME	BI-836858
D04MGW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D04MGW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D04MGW	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0I1CQ	TTDDRUID	D0I1CQ
D0I1CQ	DRUGNAME	BIIB067
D0I1CQ	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1/2

D02TWR	TTDDRUID	D02TWR
D02TWR	DRUGNAME	BIIB080
D02TWR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
D02TWR	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1/2

D0J2ES	TTDDRUID	D0J2ES
D0J2ES	DRUGNAME	BIO-300
D0J2ES	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0J2ES	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0DJ2H	TTDDRUID	D0DJ2H
D0DJ2H	DRUGNAME	BION-1301
D0DJ2H	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0N6TD	TTDDRUID	D0N6TD
D0N6TD	DRUGNAME	BIW-8962
D0N6TD	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D08OMM	TTDDRUID	D08OMM
D08OMM	DRUGNAME	BL-1040
D08OMM	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2

D0UI0I	TTDDRUID	D0UI0I
D0UI0I	DRUGNAME	BL-3010
D0UI0I	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1/2

D0H2IQ	TTDDRUID	D0H2IQ
D0H2IQ	DRUGNAME	BL-7010
D0H2IQ	INDICATI	Coeliac disease [ICD-11: DA95] Phase 1/2

D0I8KA	TTDDRUID	D0I8KA
D0I8KA	DRUGNAME	BLZ-100
D0I8KA	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
D0I8KA	INDICATI	Malignant primary brain tumour [ICD-11: 2A00.0] Phase 1

D0N2GC	TTDDRUID	D0N2GC
D0N2GC	DRUGNAME	BMS-753493
D0N2GC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D03ISJ	TTDDRUID	D03ISJ
D03ISJ	DRUGNAME	BMS-863233
D03ISJ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D04AHG	TTDDRUID	D04AHG
D04AHG	DRUGNAME	BMS-986012
D04AHG	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D06BHI	TTDDRUID	D06BHI
D06BHI	DRUGNAME	BMS-986089
D06BHI	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2

D0IA8W	TTDDRUID	D0IA8W
D0IA8W	DRUGNAME	BMS-986156
D0IA8W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0ZE0S	TTDDRUID	D0ZE0S
D0ZE0S	DRUGNAME	BMS-986183
D0ZE0S	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
D0ZE0S	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D08YWF	TTDDRUID	D08YWF
D08YWF	DRUGNAME	BMS-986253
D08YWF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0T8JY	TTDDRUID	D0T8JY
D0T8JY	DRUGNAME	BMS-986277
D0T8JY	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 1/2

D0BO7U	TTDDRUID	D0BO7U
D0BO7U	DRUGNAME	BMX-001
D0BO7U	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
D0BO7U	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1

D0AH6V	TTDDRUID	D0AH6V
D0AH6V	DRUGNAME	BN-2629
D0AH6V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0G2MC	TTDDRUID	D0G2MC
D0G2MC	DRUGNAME	BPM 31510 intravenous
D0G2MC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D06LYI	TTDDRUID	D06LYI
D06LYI	DRUGNAME	BPX-501
D06LYI	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D06LYI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D06LYI	INDICATI	Hematopoietic stem cell transplantation [ICD-11: QB63] Phase 1/2
D06LYI	INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2
D06LYI	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1/2
D06LYI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0TY6U	TTDDRUID	D0TY6U
D0TY6U	DRUGNAME	BPX-601
D0TY6U	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
D0TY6U	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D0TY6U	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D08BQJ	TTDDRUID	D08BQJ
D08BQJ	DRUGNAME	Brain dendritic cell-based vaccine
D08BQJ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2

D0M5JC	TTDDRUID	D0M5JC
D0M5JC	DRUGNAME	BrevaRex
D0M5JC	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D08DMY	TTDDRUID	D08DMY
D08DMY	DRUGNAME	Bria-IMT
D08DMY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D08GKU	TTDDRUID	D08GKU
D08GKU	DRUGNAME	BriaVax
D08GKU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0AZ1N	TTDDRUID	D0AZ1N
D0AZ1N	DRUGNAME	BSK01
D0AZ1N	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0AZ1N	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
D0AZ1N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D01IED	TTDDRUID	D01IED
D01IED	DRUGNAME	BVD-523
D01IED	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D01IED	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0AF8E	TTDDRUID	D0AF8E
D0AF8E	DRUGNAME	BXCL101
D0AF8E	INDICATI	Neurofibromatosis type 2 [ICD-11: LD2D.11] Phase 1/2

D09TLT	TTDDRUID	D09TLT
D09TLT	DRUGNAME	BZF961
D09TLT	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0DA5M	TTDDRUID	D0DA5M
D0DA5M	DRUGNAME	C 82
D0DA5M	INDICATI	Scleroderma [ICD-11: 4A42] Phase 1/2

D00OON	TTDDRUID	D00OON
D00OON	DRUGNAME	CAB-AXL-ADC
D00OON	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D08RWO	TTDDRUID	D08RWO
D08RWO	DRUGNAME	CAB-ROR2-ADC
D08RWO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0A0BK	TTDDRUID	D0A0BK
D0A0BK	DRUGNAME	Cal-1
D0A0BK	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2

D0L2WK	TTDDRUID	D0L2WK
D0L2WK	DRUGNAME	CAM2043
D0L2WK	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1/2

D0MC5O	TTDDRUID	D0MC5O
D0MC5O	DRUGNAME	CAP-1002
D0MC5O	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
D0MC5O	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2

D0OP7I	TTDDRUID	D0OP7I
D0OP7I	DRUGNAME	CARCIK-CD19
D0OP7I	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2

D0D4ZN	TTDDRUID	D0D4ZN
D0D4ZN	DRUGNAME	CAR-T cells targeting BCMA
D0D4ZN	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0D4ZN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0D4ZN	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D04JHH	TTDDRUID	D04JHH
D04JHH	DRUGNAME	CAR-T cells targeting CD19
D04JHH	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D04JHH	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D04JHH	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D06TWS	TTDDRUID	D06TWS
D06TWS	DRUGNAME	CAR-T cells targeting CD2
D06TWS	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2

D0PD4C	TTDDRUID	D0PD4C
D0PD4C	DRUGNAME	CAR-T cells targeting CD22
D0PD4C	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0PD4C	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0PD4C	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0UA0U	TTDDRUID	D0UA0U
D0UA0U	DRUGNAME	CAR-T cells targeting CD30
D0UA0U	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0UA0U	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0UA0U	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0T5DC	TTDDRUID	D0T5DC
D0T5DC	DRUGNAME	CAR-T cells targeting CEA
D0T5DC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2

D0DO8E	TTDDRUID	D0DO8E
D0DO8E	DRUGNAME	CAR-T cells targeting CLL1
D0DO8E	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0DO8E	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0DO8E	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D08QYW	TTDDRUID	D08QYW
D08QYW	DRUGNAME	CAR-T Cells targeting EpCAM
D08QYW	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 1/2
D08QYW	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2
D08QYW	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
D08QYW	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D08QYW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D08QYW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D05OHY	TTDDRUID	D05OHY
D05OHY	DRUGNAME	CAR-T cells targeting EphA2
D05OHY	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2

D0E1ST	TTDDRUID	D0E1ST
D0E1ST	DRUGNAME	CAR-T cells targeting GD2
D0E1ST	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2

D0WN2Y	TTDDRUID	D0WN2Y
D0WN2Y	DRUGNAME	CAR-T cells targeting Glypican-3 (GPC3)
D0WN2Y	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D0J2IN	TTDDRUID	D0J2IN
D0J2IN	DRUGNAME	CAR-T cells targeting GPC3
D0J2IN	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D0NA4J	TTDDRUID	D0NA4J
D0NA4J	DRUGNAME	CAR-T cells targeting MAGE-A1
D0NA4J	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D0XZ2S	TTDDRUID	D0XZ2S
D0XZ2S	DRUGNAME	CAR-T cells targeting MAGE-A4
D0XZ2S	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D05FUP	TTDDRUID	D05FUP
D05FUP	DRUGNAME	CAR-T cells targeting Mesothelin
D05FUP	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
D05FUP	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D0KC2S	TTDDRUID	D0KC2S
D0KC2S	DRUGNAME	CAR-T cells targeting mesothelin
D0KC2S	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0R1BA	TTDDRUID	D0R1BA
D0R1BA	DRUGNAME	CAR-T cells targeting Muc1
D0R1BA	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2

D0RO2L	TTDDRUID	D0RO2L
D0RO2L	DRUGNAME	CAR-T cells targeting PSMA
D0RO2L	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2

D0N6PE	TTDDRUID	D0N6PE
D0N6PE	DRUGNAME	CART-123 cells
D0N6PE	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0M3RI	TTDDRUID	D0M3RI
D0M3RI	DRUGNAME	CART-138 cells
D0M3RI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0Y4MA	TTDDRUID	D0Y4MA
D0Y4MA	DRUGNAME	CART-138 cells
D0Y4MA	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0NJ3T	TTDDRUID	D0NJ3T
D0NJ3T	DRUGNAME	CART-19 cells
D0NJ3T	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D05OAI	TTDDRUID	D05OAI
D05OAI	DRUGNAME	CART-19/22
D05OAI	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0AC9S	TTDDRUID	D0AC9S
D0AC9S	DRUGNAME	CART-19/BCMA
D0AC9S	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0E0RP	TTDDRUID	D0E0RP
D0E0RP	DRUGNAME	CART20
D0E0RP	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0FZ1Y	TTDDRUID	D0FZ1Y
D0FZ1Y	DRUGNAME	CART30
D0FZ1Y	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2
D0FZ1Y	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D04VCQ	TTDDRUID	D04VCQ
D04VCQ	DRUGNAME	CART33 cells
D04VCQ	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1/2

D04PIU	TTDDRUID	D04PIU
D04PIU	DRUGNAME	CART-BCMA cells
D04PIU	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D04DHZ	TTDDRUID	D04DHZ
D04DHZ	DRUGNAME	CART-EGFR
D04DHZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0NN7P	TTDDRUID	D0NN7P
D0NN7P	DRUGNAME	CART-HER-2
D0NN7P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0X3IJ	TTDDRUID	D0X3IJ
D0X3IJ	DRUGNAME	CaspaCIDe DLI
D0X3IJ	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1/2

D0Y8AW	TTDDRUID	D0Y8AW
D0Y8AW	DRUGNAME	CB3304
D0Y8AW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0C8ES	TTDDRUID	D0C8ES
D0C8ES	DRUGNAME	CBL0102
D0C8ES	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D02NNN	TTDDRUID	D02NNN
D02NNN	DRUGNAME	CBP-501
D02NNN	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1/2
D02NNN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05EXN	TTDDRUID	D05EXN
D05EXN	DRUGNAME	CC-223
D05EXN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0RA9C	TTDDRUID	D0RA9C
D0RA9C	DRUGNAME	CCT301-38 (targeting ROR2)
D0RA9C	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D0C2PH	TTDDRUID	D0C2PH
D0C2PH	DRUGNAME	CCT301-59 (targeting ROR2)
D0C2PH	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D04MLR	TTDDRUID	D04MLR
D04MLR	DRUGNAME	CD123-specific gene-engineered T cells
D04MLR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D03LUF	TTDDRUID	D03LUF
D03LUF	DRUGNAME	CD137 CAR-T Cell
D03LUF	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D03LUF	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D05CTQ	TTDDRUID	D05CTQ
D05CTQ	DRUGNAME	CD138 CAR T cells
D05CTQ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0QB1O	TTDDRUID	D0QB1O
D0QB1O	DRUGNAME	CD19 and CD20 CAR-T Cells
D0QB1O	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
D0QB1O	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D05VNS	TTDDRUID	D05VNS
D05VNS	DRUGNAME	CD19 and CD22 CAR-T Cells
D05VNS	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
D05VNS	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0W4SM	TTDDRUID	D0W4SM
D0W4SM	DRUGNAME	CD19 and CD22 CAR-T Cells
D0W4SM	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D0HO1A	TTDDRUID	D0HO1A
D0HO1A	DRUGNAME	CD19 CAR Gene Transduced T Lymphocytes
D0HO1A	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D07NHZ	TTDDRUID	D07NHZ
D07NHZ	DRUGNAME	CD19 CAR T cells
D07NHZ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D07NHZ	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0Z8GD	TTDDRUID	D0Z8GD
D0Z8GD	DRUGNAME	CD19 CAR T Cells
D0Z8GD	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0Z8GD	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0Z8GD	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D0Z8GD	INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1/2
D0Z8GD	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D02BCY	TTDDRUID	D02BCY
D02BCY	DRUGNAME	CD19 CART
D02BCY	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0N3GE	TTDDRUID	D0N3GE
D0N3GE	DRUGNAME	CD19 CART
D0N3GE	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D0QF0L	TTDDRUID	D0QF0L
D0QF0L	DRUGNAME	CD19 CAR-T Cells
D0QF0L	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D04FPN	TTDDRUID	D04FPN
D04FPN	DRUGNAME	CD19 CAR-T lymphocytes
D04FPN	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D0FR3J	TTDDRUID	D0FR3J
D0FR3J	DRUGNAME	CD19 specific CAR T cells
D0FR3J	INDICATI	Acute leukaemia [ICD-11: 2A60] Phase 1/2

D0SV4A	TTDDRUID	D0SV4A
D0SV4A	DRUGNAME	CD19 targeted chimeric antigen receptor T cells
D0SV4A	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0MV4T	TTDDRUID	D0MV4T
D0MV4T	DRUGNAME	CD19.CAR T Cells
D0MV4T	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0MV4T	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0MV4T	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
D0MV4T	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D0EH1J	TTDDRUID	D0EH1J
D0EH1J	DRUGNAME	CD19.CAR-T cells
D0EH1J	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D0EH1J	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
D0EH1J	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D0OZ5H	TTDDRUID	D0OZ5H
D0OZ5H	DRUGNAME	CD19-CAR T cell
D0OZ5H	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0OZ5H	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0PN3M	TTDDRUID	D0PN3M
D0PN3M	DRUGNAME	CD19-directed CAR-T cells
D0PN3M	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0PN3M	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0RA1R	TTDDRUID	D0RA1R
D0RA1R	DRUGNAME	CD19-targeting CAR T cells
D0RA1R	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
D0RA1R	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0W8WG	TTDDRUID	D0W8WG
D0W8WG	DRUGNAME	CD19-targeting CAR T Cells
D0W8WG	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0E2CS	TTDDRUID	D0E2CS
D0E2CS	DRUGNAME	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
D0E2CS	INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2

D0Q0RX	TTDDRUID	D0Q0RX
D0Q0RX	DRUGNAME	CD20-Specific CAR T Cells
D0Q0RX	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0Q0RX	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
D0Q0RX	INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1/2
D0Q0RX	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0Q0RX	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
D0Q0RX	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0IN2K	TTDDRUID	D0IN2K
D0IN2K	DRUGNAME	CD22 CAR-T
D0IN2K	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0P0NS	TTDDRUID	D0P0NS
D0P0NS	DRUGNAME	CD22-Targeted CAR-T cells
D0P0NS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0P0NS	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0G9MY	TTDDRUID	D0G9MY
D0G9MY	DRUGNAME	CD33-specific gene-engineered T cells
D0G9MY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0G0PI	TTDDRUID	D0G0PI
D0G0PI	DRUGNAME	CD38 and BCMA CAR-T Cells
D0G0PI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D09UFZ	TTDDRUID	D09UFZ
D09UFZ	DRUGNAME	CD38 CAR T cells
D09UFZ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0M8EF	TTDDRUID	D0M8EF
D0M8EF	DRUGNAME	CD38 CAR-T Cell
D0M8EF	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D0UJ3C	TTDDRUID	D0UJ3C
D0UJ3C	DRUGNAME	CD38-specific gene-engineered T cells
D0UJ3C	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0U1GP	TTDDRUID	D0U1GP
D0U1GP	DRUGNAME	CD56 CAR T cells
D0U1GP	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D03HML	TTDDRUID	D03HML
D03HML	DRUGNAME	CD56-specific gene-engineered T cells
D03HML	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0E2DL	TTDDRUID	D0E2DL
D0E2DL	DRUGNAME	CDCA1-derived epitope peptide vaccine
D0E2DL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D08CDE	TTDDRUID	D08CDE
D08CDE	DRUGNAME	Celgosivir
D08CDE	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1/2

D04MXN	TTDDRUID	D04MXN
D04MXN	DRUGNAME	CEP-32496
D04MXN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D04MXN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0Q9IK	TTDDRUID	D0Q9IK
D0Q9IK	DRUGNAME	CEP-9722
D0Q9IK	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2
D0Q9IK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D00GBZ	TTDDRUID	D00GBZ
D00GBZ	DRUGNAME	CEQ-508
D00GBZ	INDICATI	Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 1
D00GBZ	INDICATI	Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 1/2

D0LM0X	TTDDRUID	D0LM0X
D0LM0X	DRUGNAME	Ceramide nanoliposome
D0LM0X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0AD4H	TTDDRUID	D0AD4H
D0AD4H	DRUGNAME	Cethrin
D0AD4H	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1/2

D05RVA	TTDDRUID	D05RVA
D05RVA	DRUGNAME	CFG920
D05RVA	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0LF6M	TTDDRUID	D0LF6M
D0LF6M	DRUGNAME	Chimeric Antigen Receptor Modified T cells Targeting CD19
D0LF6M	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0LF6M	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D09YVQ	TTDDRUID	D09YVQ
D09YVQ	DRUGNAME	ChondrogenTM
D09YVQ	INDICATI	Arthritis [ICD-11: FA20] Phase 1/2

D0W6QN	TTDDRUID	D0W6QN
D0W6QN	DRUGNAME	Choroid plexus cell therapy
D0W6QN	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1/2

D09ZNL	TTDDRUID	D09ZNL
D09ZNL	DRUGNAME	ChronSeal
D09ZNL	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 1/2

D0V5LG	TTDDRUID	D0V5LG
D0V5LG	DRUGNAME	ChronVac-C hepatitis C DNA vaccine
D0V5LG	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0Y1NC	TTDDRUID	D0Y1NC
D0Y1NC	DRUGNAME	CHS-828
D0Y1NC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0M2XK	TTDDRUID	D0M2XK
D0M2XK	DRUGNAME	CIK-CAR.CD19
D0M2XK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D09BZS	TTDDRUID	D09BZS
D09BZS	DRUGNAME	CK-101
D09BZS	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0YY6O	TTDDRUID	D0YY6O
D0YY6O	DRUGNAME	CLIC-1901
D0YY6O	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0YY6O	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0N8MC	TTDDRUID	D0N8MC
D0N8MC	DRUGNAME	CLL immunotherapeutic
D0N8MC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2

D0A6KA	TTDDRUID	D0A6KA
D0A6KA	DRUGNAME	CLL immunotherapeutic vaccine
D0A6KA	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2

D00QWK	TTDDRUID	D00QWK
D00QWK	DRUGNAME	CLL1-specific gene-engineered T cells
D00QWK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D01DIM	TTDDRUID	D01DIM
D01DIM	DRUGNAME	CLL442
D01DIM	INDICATI	Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 1/2

D07NRL	TTDDRUID	D07NRL
D07NRL	DRUGNAME	CLL442 topical
D07NRL	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2

D07MEX	TTDDRUID	D07MEX
D07MEX	DRUGNAME	CLR-1401
D07MEX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0O4CH	TTDDRUID	D0O4CH
D0O4CH	DRUGNAME	CLR1404-I-131
D0O4CH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D07ACZ	TTDDRUID	D07ACZ
D07ACZ	DRUGNAME	CLR457
D07ACZ	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2

D0P3NZ	TTDDRUID	D0P3NZ
D0P3NZ	DRUGNAME	CMP-1
D0P3NZ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1/2

D0A0CY	TTDDRUID	D0A0CY
D0A0CY	DRUGNAME	CNDO-109
D0A0CY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0A0CY	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D0A0CY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0U0VY	TTDDRUID	D0U0VY
D0U0VY	DRUGNAME	CNTO-2476
D0U0VY	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2

D04YIA	TTDDRUID	D04YIA
D04YIA	DRUGNAME	CNVN-202
D04YIA	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0XB8Y	TTDDRUID	D0XB8Y
D0XB8Y	DRUGNAME	COL-195
D0XB8Y	INDICATI	Chronic pain [ICD-11: MG30] Phase 1/2

D03VLH	TTDDRUID	D03VLH
D03VLH	DRUGNAME	ColoAd1
D03VLH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D03WNG	TTDDRUID	D03WNG
D03WNG	DRUGNAME	CORT-125134
D03WNG	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Clinical trial
D03WNG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0HP2B	TTDDRUID	D0HP2B
D0HP2B	DRUGNAME	Coxsackievirus
D0HP2B	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
D0HP2B	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
D0HP2B	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D0HP2B	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D05FBZ	TTDDRUID	D05FBZ
D05FBZ	DRUGNAME	CPHPC
D05FBZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2

D01LVE	TTDDRUID	D01LVE
D01LVE	DRUGNAME	CPI-0610
D01LVE	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D01LVE	INDICATI	Myelodysplastic neoplasm [ICD-11: 2A60] Phase 1/2
D01LVE	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1/2
D01LVE	INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1/2

D0E6AG	TTDDRUID	D0E6AG
D0E6AG	DRUGNAME	CPI-1205
D0E6AG	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0E6AG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0EV4B	TTDDRUID	D0EV4B
D0EV4B	DRUGNAME	CreaVax-PC
D0EV4B	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D06TJQ	TTDDRUID	D06TJQ
D06TJQ	DRUGNAME	CRLX301
D06TJQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D04RSR	TTDDRUID	D04RSR
D04RSR	DRUGNAME	Crolibulin
D04RSR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0H5MS	TTDDRUID	D0H5MS
D0H5MS	DRUGNAME	CT84.66
D0H5MS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D01TJM	TTDDRUID	D01TJM
D01TJM	DRUGNAME	CTCE-9908
D01TJM	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1/2

D0HH2I	TTDDRUID	D0HH2I
D0HH2I	DRUGNAME	CV-9103
D0HH2I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D02DVK	TTDDRUID	D02DVK
D02DVK	DRUGNAME	CV-9201
D02DVK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D02WSY	TTDDRUID	D02WSY
D02WSY	DRUGNAME	CVX-060
D02WSY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0O3PW	TTDDRUID	D0O3PW
D0O3PW	DRUGNAME	CX-2009
D0O3PW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D09JEJ	TTDDRUID	D09JEJ
D09JEJ	DRUGNAME	CX-4945
D09JEJ	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2
D09JEJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0T3HL	TTDDRUID	D0T3HL
D0T3HL	DRUGNAME	Cx-611
D0T3HL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2

D0U9PV	TTDDRUID	D0U9PV
D0U9PV	DRUGNAME	CXB-909
D0U9PV	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1/2

D0DC6U	TTDDRUID	D0DC6U
D0DC6U	DRUGNAME	Dapivirine
D0DC6U	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D02OZT	TTDDRUID	D02OZT
D02OZT	DRUGNAME	DCR-MYC
D02OZT	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D02BIY	TTDDRUID	D02BIY
D02BIY	DRUGNAME	DCVax-Direct
D02BIY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05TVW	TTDDRUID	D05TVW
D05TVW	DRUGNAME	DCVax-Head/Neck
D05TVW	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2

D00ESH	TTDDRUID	D00ESH
D00ESH	DRUGNAME	DCVax-Liver
D00ESH	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2

D0L7LT	TTDDRUID	D0L7LT
D0L7LT	DRUGNAME	DCVax-Pancreas
D0L7LT	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0O4RB	TTDDRUID	D0O4RB
D0O4RB	DRUGNAME	DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells
D0O4RB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0XT0W	TTDDRUID	D0XT0W
D0XT0W	DRUGNAME	Debio 1347
D0XT0W	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D0XT0W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09PSZ	TTDDRUID	D09PSZ
D09PSZ	DRUGNAME	Deferitrin
D09PSZ	INDICATI	Iron overload disease [ICD-11: 5C64.10] Phase 1/2

D0X7GX	TTDDRUID	D0X7GX
D0X7GX	DRUGNAME	Dendritic cancer vaccine
D0X7GX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07MME	TTDDRUID	D07MME
D07MME	DRUGNAME	Dexamethasone palmitate
D07MME	INDICATI	Choroidal neovascularization [ICD-11: 9B76] Phase 1/2

D0D2CY	TTDDRUID	D0D2CY
D0D2CY	DRUGNAME	DEX-M74
D0D2CY	INDICATI	Myopathy [ICD-11: 8C7Y] Phase 1/2

D0KE1F	TTDDRUID	D0KE1F
D0KE1F	DRUGNAME	DFP-10917
D0KE1F	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0KE1F	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0D3VT	TTDDRUID	D0D3VT
D0D3VT	DRUGNAME	Dihydrexidine
D0D3VT	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1/2

D02WLI	TTDDRUID	D02WLI
D02WLI	DRUGNAME	DM-199
D02WLI	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
D02WLI	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1
D02WLI	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2

D0C6JO	TTDDRUID	D0C6JO
D0C6JO	DRUGNAME	DNA nanoparticles
D0C6JO	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1/2

D0YX2Y	TTDDRUID	D0YX2Y
D0YX2Y	DRUGNAME	DNA topical patch vaccine
D0YX2Y	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D03KHQ	TTDDRUID	D03KHQ
D03KHQ	DRUGNAME	DNA-Ad
D03KHQ	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D0XJ5I	TTDDRUID	D0XJ5I
D0XJ5I	DRUGNAME	DNA-C
D0XJ5I	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0D9YB	TTDDRUID	D0D9YB
D0D9YB	DRUGNAME	DPX E7
D0D9YB	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
D0D9YB	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2

D0R1GV	TTDDRUID	D0R1GV
D0R1GV	DRUGNAME	DPX-Survivac
D0R1GV	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D0R1GV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0R1GV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D0R1GV	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1

D08MKR	TTDDRUID	D08MKR
D08MKR	DRUGNAME	DT388IL-3
D08MKR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D04YRD	TTDDRUID	D04YRD
D04YRD	DRUGNAME	DTX101
D04YRD	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2

D0TU1E	TTDDRUID	D0TU1E
D0TU1E	DRUGNAME	EB-101
D0TU1E	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
D0TU1E	INDICATI	Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 1/2

D0T0BF	TTDDRUID	D0T0BF
D0T0BF	DRUGNAME	EBV CTLs
D0T0BF	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D0RC0P	TTDDRUID	D0RC0P
D0RC0P	DRUGNAME	EBV-targeted autologous T-cell therapy
D0RC0P	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D08ZZP	TTDDRUID	D08ZZP
D08ZZP	DRUGNAME	EchoGen
D08ZZP	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2

D0Q1SQ	TTDDRUID	D0Q1SQ
D0Q1SQ	DRUGNAME	EDO-S101
D0Q1SQ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0Q1SQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D06VFF	TTDDRUID	D06VFF
D06VFF	DRUGNAME	EGFR antisense DNA
D06VFF	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2

D0G1ZU	TTDDRUID	D0G1ZU
D0G1ZU	DRUGNAME	EGFR CART
D0G1ZU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2

D0LU4N	TTDDRUID	D0LU4N
D0LU4N	DRUGNAME	EGFRvIII CAR
D0LU4N	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2

D0OZ0Z	TTDDRUID	D0OZ0Z
D0OZ0Z	DRUGNAME	Elenagen
D0OZ0Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0Q0HZ	TTDDRUID	D0Q0HZ
D0Q0HZ	DRUGNAME	Elpamotide
D0Q0HZ	INDICATI	Biliary cancer [ICD-11: 2E92.7] Phase 1/2

D00MDQ	TTDDRUID	D00MDQ
D00MDQ	DRUGNAME	Eltanexor oral
D00MDQ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D00MDQ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2

D0JF6C	TTDDRUID	D0JF6C
D0JF6C	DRUGNAME	Eltanexor oral
D0JF6C	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0S8BG	TTDDRUID	D0S8BG
D0S8BG	DRUGNAME	EMD 55900
D0S8BG	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2

D0L1FN	TTDDRUID	D0L1FN
D0L1FN	DRUGNAME	Emfilermin
D0L1FN	INDICATI	Infertility [ICD-11: GB04] Phase 1/2

D0XY8C	TTDDRUID	D0XY8C
D0XY8C	DRUGNAME	Encapsulated cell therapy
D0XY8C	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1/2
D0XY8C	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D0XY8C	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0UI8Y	TTDDRUID	D0UI8Y
D0UI8Y	DRUGNAME	Encapsulated human islet allografts
D0UI8Y	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2

D0V6AN	TTDDRUID	D0V6AN
D0V6AN	DRUGNAME	Encapsulated islet cell transplantation therapy
D0V6AN	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2

D0DG6C	TTDDRUID	D0DG6C
D0DG6C	DRUGNAME	Encapsulated transplanted islets
D0DG6C	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2

D07JRL	TTDDRUID	D07JRL
D07JRL	DRUGNAME	Epithalon
D07JRL	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 1/2

D0X1SV	TTDDRUID	D0X1SV
D0X1SV	DRUGNAME	Epratuzumab Y-90
D0X1SV	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D00ANG	TTDDRUID	D00ANG
D00ANG	DRUGNAME	Erythropoietin-transfected autologous cell therapy
D00ANG	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1/2

D0X1ST	TTDDRUID	D0X1ST
D0X1ST	DRUGNAME	ESR0114
D0X1ST	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1/2

D0U1WU	TTDDRUID	D0U1WU
D0U1WU	DRUGNAME	ETBX-011
D0U1WU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D0U1WU	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D0U1WU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D06HRD	TTDDRUID	D06HRD
D06HRD	DRUGNAME	EUR-1100
D06HRD	INDICATI	Eosinophilic esophagitis [ICD-11: DA24.1] Phase 1/2

D05YUI	TTDDRUID	D05YUI
D05YUI	DRUGNAME	Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy
D05YUI	INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2

D01CMX	TTDDRUID	D01CMX
D01CMX	DRUGNAME	Exeporfinium chloride topical
D01CMX	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1/2

D0F5BL	TTDDRUID	D0F5BL
D0F5BL	DRUGNAME	EXO-230
D0F5BL	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2

D05BIN	TTDDRUID	D05BIN
D05BIN	DRUGNAME	F-14512
D05BIN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0G1IG	TTDDRUID	D0G1IG
D0G1IG	DRUGNAME	F-16-131I
D0G1IG	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D09GSV	TTDDRUID	D09GSV
D09GSV	DRUGNAME	FBT-A05
D09GSV	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2

D0WC4Y	TTDDRUID	D0WC4Y
D0WC4Y	DRUGNAME	FCX-007
D0WC4Y	INDICATI	Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 1/2

D0D8KU	TTDDRUID	D0D8KU
D0D8KU	DRUGNAME	Ferritarg P
D0D8KU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D0U9OQ	TTDDRUID	D0U9OQ
D0U9OQ	DRUGNAME	FF-10501
D0U9OQ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D02BVW	TTDDRUID	D02BVW
D02BVW	DRUGNAME	FF-10501-01
D02BVW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D02BVW	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
D02BVW	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2

D08EQD	TTDDRUID	D08EQD
D08EQD	DRUGNAME	FGF401
D08EQD	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
D08EQD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0WW1O	TTDDRUID	D0WW1O
D0WW1O	DRUGNAME	FluBIok
D0WW1O	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2

D0OT3L	TTDDRUID	D0OT3L
D0OT3L	DRUGNAME	Folate binding protein-E39
D0OT3L	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1/2

D02ZUO	TTDDRUID	D02ZUO
D02ZUO	DRUGNAME	Forodesine
D02ZUO	INDICATI	B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1/2
D02ZUO	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1/2

D08ZQI	TTDDRUID	D08ZQI
D08ZQI	DRUGNAME	FPA-008
D08ZQI	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
D08ZQI	INDICATI	Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 1
D08ZQI	INDICATI	Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 1

D03YJW	TTDDRUID	D03YJW
D03YJW	DRUGNAME	Fus-1 tumor suppressor gene therapy - nanoparticle formulation
D03YJW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0M1SP	TTDDRUID	D0M1SP
D0M1SP	DRUGNAME	G-203-2c
D0M1SP	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0YU1M	TTDDRUID	D0YU1M
D0YU1M	DRUGNAME	G-207 virus construct
D0YU1M	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2

D02DEZ	TTDDRUID	D02DEZ
D02DEZ	DRUGNAME	GALE-301
D02DEZ	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1/2
D02DEZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0T7MZ	TTDDRUID	D0T7MZ
D0T7MZ	DRUGNAME	GALE-302
D0T7MZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D0R9GF	TTDDRUID	D0R9GF
D0R9GF	DRUGNAME	GALGT2 gene therapy
D0R9GF	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2

D0P5FA	TTDDRUID	D0P5FA
D0P5FA	DRUGNAME	Galnobax
D0P5FA	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2

D03JJY	TTDDRUID	D03JJY
D03JJY	DRUGNAME	GANTACURIUM CHLORIDE
D03JJY	INDICATI	Anaesthesia [ICD-11: 9A78.6] Phase 1/2

D0MA4F	TTDDRUID	D0MA4F
D0MA4F	DRUGNAME	GD2-CART01
D0MA4F	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1/2

D02XEG	TTDDRUID	D02XEG
D02XEG	DRUGNAME	GEN-1
D02XEG	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D06MLA	TTDDRUID	D06MLA
D06MLA	DRUGNAME	GET 73
D06MLA	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1/2

D09HRS	TTDDRUID	D09HRS
D09HRS	DRUGNAME	GHB-16L2
D09HRS	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2

D0V9PB	TTDDRUID	D0V9PB
D0V9PB	DRUGNAME	Gilotrifafatinib
D0V9PB	INDICATI	Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 2
D0V9PB	INDICATI	Rhabdomyosarcoma [ICD-11: 2B55] Phase 1/2

D0P7IL	TTDDRUID	D0P7IL
D0P7IL	DRUGNAME	GLG-801
D0P7IL	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2

D08XDO	TTDDRUID	D08XDO
D08XDO	DRUGNAME	Glial progenitor cell therapy
D08XDO	INDICATI	Brain injury [ICD-11: NA07.Z] Phase 1/2

D02JCG	TTDDRUID	D02JCG
D02JCG	DRUGNAME	GL-ONC1
D02JCG	INDICATI	Peritoneal carcinomatosis [ICD-11: 2D91] Phase 1/2
D02JCG	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1
D02JCG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
D02JCG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D03PWD	TTDDRUID	D03PWD
D03PWD	DRUGNAME	GMI-1271
D03PWD	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D03PWD	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D03PWD	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D04CKC	TTDDRUID	D04CKC
D04CKC	DRUGNAME	GPC3-CART cells
D04CKC	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D02SWB	TTDDRUID	D02SWB
D02SWB	DRUGNAME	Grass pollen-derived peptides
D02SWB	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 1/2

D00LHF	TTDDRUID	D00LHF
D00LHF	DRUGNAME	GS-9219
D00LHF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05FCR	TTDDRUID	D05FCR
D05FCR	DRUGNAME	GT0918
D05FCR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0P5SC	TTDDRUID	D0P5SC
D0P5SC	DRUGNAME	GTU-TB vaccine
D0P5SC	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1/2

D06QOC	TTDDRUID	D06QOC
D06QOC	DRUGNAME	GX-301
D06QOC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D01FBO	TTDDRUID	D01FBO
D01FBO	DRUGNAME	H5N1 influenza vaccine
D01FBO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2

D05EUH	TTDDRUID	D05EUH
D05EUH	DRUGNAME	H5N1 influenza virus vaccine
D05EUH	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1/2

D09HTE	TTDDRUID	D09HTE
D09HTE	DRUGNAME	HA20
D09HTE	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D0XQ5X	TTDDRUID	D0XQ5X
D0XQ5X	DRUGNAME	Halaven
D0XQ5X	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
D0XQ5X	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0S7CM	TTDDRUID	D0S7CM
D0S7CM	DRUGNAME	HDL-100
D0S7CM	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1/2

D01QQC	TTDDRUID	D01QQC
D01QQC	DRUGNAME	Hematopoietic stem cell gene therapy
D01QQC	INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2

D0U3FP	TTDDRUID	D0U3FP
D0U3FP	DRUGNAME	Her-2/neu vaccine
D0U3FP	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D06KQG	TTDDRUID	D06KQG
D06KQG	DRUGNAME	HER-2-targeting CAR T Cells
D06KQG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0SQ9O	TTDDRUID	D0SQ9O
D0SQ9O	DRUGNAME	Herpes simplex vaccine
D0SQ9O	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1/2

D0KE9G	TTDDRUID	D0KE9G
D0KE9G	DRUGNAME	hESC-derived oligodendrocyte progenitors (AST-OPC1)
D0KE9G	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1/2

D0X1BX	TTDDRUID	D0X1BX
D0X1BX	DRUGNAME	hESC-derived pancreatic endoderm (VC-01)
D0X1BX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2

D04QLL	TTDDRUID	D04QLL
D04QLL	DRUGNAME	hESC-derived RPE (MA09-hRPE)
D04QLL	INDICATI	Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2
D04QLL	INDICATI	Myopic macular degeneration [ICD-11: 9B75.Y] Phase 1/2
D04QLL	INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1

D08YWN	TTDDRUID	D08YWN
D08YWN	DRUGNAME	HIV vaccine
D08YWN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0L9TD	TTDDRUID	D0L9TD
D0L9TD	DRUGNAME	HIV vaccine
D0L9TD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0D8EY	TTDDRUID	D0D8EY
D0D8EY	DRUGNAME	HLF 1-11
D0D8EY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2

D0A7ZB	TTDDRUID	D0A7ZB
D0A7ZB	DRUGNAME	HR24 antibody
D0A7ZB	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0J6WA	TTDDRUID	D0J6WA
D0J6WA	DRUGNAME	HS-10296
D0J6WA	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D00UGC	TTDDRUID	D00UGC
D00UGC	DRUGNAME	HSC660
D00UGC	INDICATI	Alopecia [ICD-11: ED70] Phase 1/2

D0T5CH	TTDDRUID	D0T5CH
D0T5CH	DRUGNAME	HSC835
D0T5CH	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0HI0L	TTDDRUID	D0HI0L
D0HI0L	DRUGNAME	HSV-1716
D0HI0L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0HI0L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D04AHY	TTDDRUID	D04AHY
D04AHY	DRUGNAME	HT-2157
D04AHY	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1/2

D01HHJ	TTDDRUID	D01HHJ
D01HHJ	DRUGNAME	HTU-PA
D01HHJ	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2

D0R4UA	TTDDRUID	D0R4UA
D0R4UA	DRUGNAME	Hu3F8 mAb
D0R4UA	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
D0R4UA	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1/2

D0TV6H	TTDDRUID	D0TV6H
D0TV6H	DRUGNAME	HuM-195-Ac-225
D0TV6H	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2
D0TV6H	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D00WOX	TTDDRUID	D00WOX
D00WOX	DRUGNAME	Human retinal pigment epithelial cell therapy
D00WOX	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1/2

D0MT3A	TTDDRUID	D0MT3A
D0MT3A	DRUGNAME	Human retinal progenitor cells
D0MT3A	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2

D0XY6T	TTDDRUID	D0XY6T
D0XY6T	DRUGNAME	Humanized CD19 CAR-T cells
D0XY6T	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D0QI1K	TTDDRUID	D0QI1K
D0QI1K	DRUGNAME	HuMax-AXL-ADC
D0QI1K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05NYF	TTDDRUID	D05NYF
D05NYF	DRUGNAME	HuMax-TF
D05NYF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05ELZ	TTDDRUID	D05ELZ
D05ELZ	DRUGNAME	IC9/CAR.19/IL15-transduced CB-NK cells
D05ELZ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D05ELZ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0SY7H	TTDDRUID	D0SY7H
D0SY7H	DRUGNAME	IDX-184
D0SY7H	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0W7TQ	TTDDRUID	D0W7TQ
D0W7TQ	DRUGNAME	IDX-719
D0W7TQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0V0HU	TTDDRUID	D0V0HU
D0V0HU	DRUGNAME	IFN alpha kinoid
D0V0HU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0P3ZF	TTDDRUID	D0P3ZF
D0P3ZF	DRUGNAME	IGF-MTX
D0P3ZF	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
D0P3ZF	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2

D08XFA	TTDDRUID	D08XFA
D08XFA	DRUGNAME	IL-2 XL
D08XFA	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D01VWB	TTDDRUID	D01VWB
D01VWB	DRUGNAME	IL-2/gene-modified lymphocytes
D01VWB	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D0H4XV	TTDDRUID	D0H4XV
D0H4XV	DRUGNAME	IM0-8400
D0H4XV	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Discontinued in Phase 1/2

D02BHW	TTDDRUID	D02BHW
D02BHW	DRUGNAME	IM19 CAR-T
D02BHW	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0L8IH	TTDDRUID	D0L8IH
D0L8IH	DRUGNAME	IMA-910
D0L8IH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2

D05NYO	TTDDRUID	D05NYO
D05NYO	DRUGNAME	Imab-027
D05NYO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0I9YM	TTDDRUID	D0I9YM
D0I9YM	DRUGNAME	IMCnyeso
D0I9YM	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D0I9YM	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2

D04UFI	TTDDRUID	D04UFI
D04UFI	DRUGNAME	ImMucin
D04UFI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0U5AN	TTDDRUID	D0U5AN
D0U5AN	DRUGNAME	ImmuFact IMP321
D0U5AN	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D01EYR	TTDDRUID	D01EYR
D01EYR	DRUGNAME	ImmunoVEX-timelan
D01EYR	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0P9MW	TTDDRUID	D0P9MW
D0P9MW	DRUGNAME	IMP-321
D0P9MW	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1/2

D0WC7Z	TTDDRUID	D0WC7Z
D0WC7Z	DRUGNAME	Imprime PGG
D0WC7Z	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0WC7Z	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D0WC7Z	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D0WC7Z	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0H7DM	TTDDRUID	D0H7DM
D0H7DM	DRUGNAME	IMX-110
D0H7DM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D06LHE	TTDDRUID	D06LHE
D06LHE	DRUGNAME	Inactivated H7N7 influenza vaccine
D06LHE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2

D06CJN	TTDDRUID	D06CJN
D06CJN	DRUGNAME	INCAGN1876
D06CJN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D03SXI	TTDDRUID	D03SXI
D03SXI	DRUGNAME	INCAGN1949
D03SXI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07CWH	TTDDRUID	D07CWH
D07CWH	DRUGNAME	INCB40093
D07CWH	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D06FQU	TTDDRUID	D06FQU
D06FQU	DRUGNAME	INCB53914
D06FQU	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2

D0P7FM	TTDDRUID	D0P7FM
D0P7FM	DRUGNAME	INCB57643
D0P7FM	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2

D0R7CD	TTDDRUID	D0R7CD
D0R7CD	DRUGNAME	INCB59872
D0R7CD	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0R7CD	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0BE8H	TTDDRUID	D0BE8H
D0BE8H	DRUGNAME	INCB62079
D0BE8H	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2

D0SS1Q	TTDDRUID	D0SS1Q
D0SS1Q	DRUGNAME	Influenza vaccine patch
D0SS1Q	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2

D0OA0H	TTDDRUID	D0OA0H
D0OA0H	DRUGNAME	INO-3112
D0OA0H	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
D0OA0H	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2

D05KBP	TTDDRUID	D05KBP
D05KBP	DRUGNAME	INO-8875
D05KBP	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2

D0PT9G	TTDDRUID	D0PT9G
D0PT9G	DRUGNAME	INT230-6
D0PT9G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07ISE	TTDDRUID	D07ISE
D07ISE	DRUGNAME	Interferon alpha
D07ISE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0E1FP	TTDDRUID	D0E1FP
D0E1FP	DRUGNAME	Interferon alpha 5
D0E1FP	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1/2

D08POH	TTDDRUID	D08POH
D08POH	DRUGNAME	Invaplex 50
D08POH	INDICATI	Shigella infection [ICD-11: 1A02] Phase 1/2

D0RK4B	TTDDRUID	D0RK4B
D0RK4B	DRUGNAME	IONIS-MAPTRx
D0RK4B	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D08BEA	TTDDRUID	D08BEA
D08BEA	DRUGNAME	Ipamorelin
D08BEA	INDICATI	Postoperative ileus [ICD-11: DA91-DB30] Phase 1/2

D0Z1OR	TTDDRUID	D0Z1OR
D0Z1OR	DRUGNAME	IPP-204106
D0Z1OR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0KK4N	TTDDRUID	D0KK4N
D0KK4N	DRUGNAME	ISA-P53-01
D0KK4N	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2

D0X9WC	TTDDRUID	D0X9WC
D0X9WC	DRUGNAME	ISIS-DMPK
D0X9WC	INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Phase 1/2

D0D9LU	TTDDRUID	D0D9LU
D0D9LU	DRUGNAME	ISIS-STAT3Rx
D0D9LU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07BXC	TTDDRUID	D07BXC
D07BXC	DRUGNAME	IZONSTERIDE
D07BXC	INDICATI	Hirsutism [ICD-11: ED72] Phase 1/2

D07JID	TTDDRUID	D07JID
D07JID	DRUGNAME	JCAR014
D07JID	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D07JID	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D00BSR	TTDDRUID	D00BSR
D00BSR	DRUGNAME	JCAR017
D00BSR	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D00BSR	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D00BSR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0M4WU	TTDDRUID	D0M4WU
D0M4WU	DRUGNAME	JCAR017
D0M4WU	INDICATI	Central nervous system lymphoma [ICD-11: 2B33.5] Phase 2
D0M4WU	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
D0M4WU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D0M4WU	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D0M4WU	INDICATI	Precursor B-lymphoblastic neoplasm [ICD-11: 2A70] Phase 1/2
D0M4WU	INDICATI	Richter syndrome [ICD-11: 2A81.Y] Phase 2

D0EQ6D	TTDDRUID	D0EQ6D
D0EQ6D	DRUGNAME	JCARH125
D0EQ6D	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Clinical trial
D0EQ6D	INDICATI	Follicular lymphoma [ICD-11: 2A80] Clinical trial
D0EQ6D	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Clinical trial
D0EQ6D	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0EQ6D	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Clinical trial

D06IZQ	TTDDRUID	D06IZQ
D06IZQ	DRUGNAME	JKB-121
D06IZQ	INDICATI	Fatty liver disease [ICD-11: DB92.Z] Phase 1/2

D0EE8V	TTDDRUID	D0EE8V
D0EE8V	DRUGNAME	JNJ-42756493
D0EE8V	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D07PJS	TTDDRUID	D07PJS
D07PJS	DRUGNAME	JNJ-68284528
D07PJS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0J6AJ	TTDDRUID	D0J6AJ
D0J6AJ	DRUGNAME	JTCR016
D0J6AJ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0J6AJ	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2

D08NXB	TTDDRUID	D08NXB
D08NXB	DRUGNAME	Juvenon Energy Formula
D08NXB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2

D0O6HP	TTDDRUID	D0O6HP
D0O6HP	DRUGNAME	KAI-9803
D0O6HP	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 1/2

D0FJ9W	TTDDRUID	D0FJ9W
D0FJ9W	DRUGNAME	KB-004
D0FJ9W	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0B1GE	TTDDRUID	D0B1GE
D0B1GE	DRUGNAME	KB103
D0B1GE	INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 1/2

D00DFP	TTDDRUID	D00DFP
D00DFP	DRUGNAME	KBP-5074
D00DFP	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1/2

D0S7AW	TTDDRUID	D0S7AW
D0S7AW	DRUGNAME	KD020
D0S7AW	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 1/2

D0EZ5Y	TTDDRUID	D0EZ5Y
D0EZ5Y	DRUGNAME	KiroVAX-001
D0EZ5Y	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0C6KS	TTDDRUID	D0C6KS
D0C6KS	DRUGNAME	KiroVAX-002
D0C6KS	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0U1DD	TTDDRUID	D0U1DD
D0U1DD	DRUGNAME	KiroVAX-003
D0U1DD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D06CAV	TTDDRUID	D06CAV
D06CAV	DRUGNAME	KiroVAX-004
D06CAV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0I1QJ	TTDDRUID	D0I1QJ
D0I1QJ	DRUGNAME	KP-100
D0I1QJ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2

D0I3HI	TTDDRUID	D0I3HI
D0I3HI	DRUGNAME	KP-413
D0I3HI	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2

D07GNO	TTDDRUID	D07GNO
D07GNO	DRUGNAME	KRN-330
D07GNO	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2

D0G5WV	TTDDRUID	D0G5WV
D0G5WV	DRUGNAME	KTE-C19 CAR
D0G5WV	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2

D0U1SA	TTDDRUID	D0U1SA
D0U1SA	DRUGNAME	KTP-001
D0U1SA	INDICATI	Intervertebral disc displacement [ICD-11: FB1Y] Phase 1/2

D0R0WZ	TTDDRUID	D0R0WZ
D0R0WZ	DRUGNAME	KX01 and paclitaxel
D0R0WZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0P0SR	TTDDRUID	D0P0SR
D0P0SR	DRUGNAME	Kyproliscarfilzomib
D0P0SR	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D04BSV	TTDDRUID	D04BSV
D04BSV	DRUGNAME	L-377202
D04BSV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0E4LS	TTDDRUID	D0E4LS
D0E4LS	DRUGNAME	LAG525
D0E4LS	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D0E4LS	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
D0E4LS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0T2NV	TTDDRUID	D0T2NV
D0T2NV	DRUGNAME	LAMP-Vax + pp65 DC
D0T2NV	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2

D0DX1F	TTDDRUID	D0DX1F
D0DX1F	DRUGNAME	Leber's congenital amaurosis gene therapy
D0DX1F	INDICATI	Leber congenital amaurosis [ICD-11: 9B70] Phase 1/2
D0DX1F	INDICATI	Visual disturbance [ICD-11: 9D90] Phase 1/2

D0C9LQ	TTDDRUID	D0C9LQ
D0C9LQ	DRUGNAME	LentiGlobin
D0C9LQ	INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 1/2
D0C9LQ	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1

D05RTM	TTDDRUID	D05RTM
D05RTM	DRUGNAME	LEZ763
D05RTM	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 1/2
D05RTM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2

D07EHV	TTDDRUID	D07EHV
D07EHV	DRUGNAME	LGH-447
D07EHV	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0IN9G	TTDDRUID	D0IN9G
D0IN9G	DRUGNAME	Liatermin
D0IN9G	INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 1/2

D0HV7A	TTDDRUID	D0HV7A
D0HV7A	DRUGNAME	Lintuzumab Ac-225
D0HV7A	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D00UVU	TTDDRUID	D00UVU
D00UVU	DRUGNAME	Lipoteichoic acid
D00UVU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05ECA	TTDDRUID	D05ECA
D05ECA	DRUGNAME	LJM716
D05ECA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D02XJJ	TTDDRUID	D02XJJ
D02XJJ	DRUGNAME	LM11A-31
D02XJJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D0RJ2V	TTDDRUID	D0RJ2V
D0RJ2V	DRUGNAME	LMP1-CAR-T cells
D0RJ2V	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 1/2

D03ZIP	TTDDRUID	D03ZIP
D03ZIP	DRUGNAME	LOAd703
D03ZIP	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D04JVU	TTDDRUID	D04JVU
D04JVU	DRUGNAME	Long-acting IFN-alpha
D04JVU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D06HBT	TTDDRUID	D06HBT
D06HBT	DRUGNAME	LT-1951
D06HBT	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1/2

D0RE9C	TTDDRUID	D0RE9C
D0RE9C	DRUGNAME	Lucerastat
D0RE9C	INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 1/2

D09XZL	TTDDRUID	D09XZL
D09XZL	DRUGNAME	LX-7101
D09XZL	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2

D0H7LN	TTDDRUID	D0H7LN
D0H7LN	DRUGNAME	Lx-TB-PstS1
D0H7LN	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2

D08WYH	TTDDRUID	D08WYH
D08WYH	DRUGNAME	LY-2228820
D08WYH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D08WYH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07HCH	TTDDRUID	D07HCH
D07HCH	DRUGNAME	LY2812176
D07HCH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0W0SL	TTDDRUID	D0W0SL
D0W0SL	DRUGNAME	LY2940680
D0W0SL	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0W0SL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D08EIK	TTDDRUID	D08EIK
D08EIK	DRUGNAME	LY3016859
D08EIK	INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 1/2

D09PAU	TTDDRUID	D09PAU
D09PAU	DRUGNAME	M87o
D09PAU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0K3ZL	TTDDRUID	D0K3ZL
D0K3ZL	DRUGNAME	MA09-hRPE cells
D0K3ZL	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 1/2
D0K3ZL	INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1/2

D0IL0H	TTDDRUID	D0IL0H
D0IL0H	DRUGNAME	MaC46/M87o
D0IL0H	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2

D0L1CO	TTDDRUID	D0L1CO
D0L1CO	DRUGNAME	MAGE-A10 TCR
D0L1CO	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
D0L1CO	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
D0L1CO	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D0L1CO	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2

D0UO0C	TTDDRUID	D0UO0C
D0UO0C	DRUGNAME	MAK683
D0UO0C	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2

D08DZO	TTDDRUID	D08DZO
D08DZO	DRUGNAME	Malaria DNA vaccine
D08DZO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D0K3SM	TTDDRUID	D0K3SM
D0K3SM	DRUGNAME	MALP-2S
D0K3SM	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0D1CL	TTDDRUID	D0D1CL
D0D1CL	DRUGNAME	MB07133
D0D1CL	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D0AE6Q	TTDDRUID	D0AE6Q
D0AE6Q	DRUGNAME	MBG453
D0AE6Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0UC5G	TTDDRUID	D0UC5G
D0UC5G	DRUGNAME	MBN-101
D0UC5G	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2

D0C3MW	TTDDRUID	D0C3MW
D0C3MW	DRUGNAME	MBO7133
D0C3MW	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2

D03KHX	TTDDRUID	D03KHX
D03KHX	DRUGNAME	MC-D11
D03KHX	INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2

D0L1YM	TTDDRUID	D0L1YM
D0L1YM	DRUGNAME	McN3377
D0L1YM	INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 1/2

D03IXK	TTDDRUID	D03IXK
D03IXK	DRUGNAME	ME-344
D03IXK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D03IXK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0MO0J	TTDDRUID	D0MO0J
D0MO0J	DRUGNAME	MEDI0382
D0MO0J	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2

D0Q6QU	TTDDRUID	D0Q6QU
D0Q6QU	DRUGNAME	MEDI6469
D0Q6QU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D01OBM	TTDDRUID	D01OBM
D01OBM	DRUGNAME	MEDl-559
D01OBM	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2

D07XYT	TTDDRUID	D07XYT
D07XYT	DRUGNAME	Medusa IL-2
D07XYT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D01HPY	TTDDRUID	D01HPY
D01HPY	DRUGNAME	Melphalan flufenamide
D01HPY	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D01HPY	INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1/2

D06FAA	TTDDRUID	D06FAA
D06FAA	DRUGNAME	Metelimumab
D06FAA	INDICATI	Scleroderma [ICD-11: 4A42] Phase 1/2

D0Q5GK	TTDDRUID	D0Q5GK
D0Q5GK	DRUGNAME	MG7-CART
D0Q5GK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D05BLN	TTDDRUID	D05BLN
D05BLN	DRUGNAME	MGCD516
D05BLN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
D05BLN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D05BLN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D08SIF	TTDDRUID	D08SIF
D08SIF	DRUGNAME	Milatuzumab
D08SIF	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D08SIF	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D00NMB	TTDDRUID	D00NMB
D00NMB	DRUGNAME	Milatuzumab-Dox
D00NMB	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0Y6BO	TTDDRUID	D0Y6BO
D0Y6BO	DRUGNAME	Milatuzumab-doxorubicin conjugate
D0Y6BO	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0Q0CR	TTDDRUID	D0Q0CR
D0Q0CR	DRUGNAME	Mitoxantrone liposomal
D0Q0CR	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D00DRL	TTDDRUID	D00DRL
D00DRL	DRUGNAME	MK-2461
D00DRL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D0Y2NS	TTDDRUID	D0Y2NS
D0Y2NS	DRUGNAME	MLN1117
D0Y2NS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0W7FC	TTDDRUID	D0W7FC
D0W7FC	DRUGNAME	MLN-2704
D0W7FC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D05ORA	TTDDRUID	D05ORA
D05ORA	DRUGNAME	MOR-103
D05ORA	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1/2

D0O4IN	TTDDRUID	D0O4IN
D0O4IN	DRUGNAME	MOR-202
D0O4IN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0ME7Q	TTDDRUID	D0ME7Q
D0ME7Q	DRUGNAME	MP0250
D0ME7Q	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0JN8C	TTDDRUID	D0JN8C
D0JN8C	DRUGNAME	MRNA-1325
D0JN8C	INDICATI	Semliki forest virus infection [ICD-11: 1D9Y] Phase 1/2

D0D7AM	TTDDRUID	D0D7AM
D0D7AM	DRUGNAME	MS-1819
D0D7AM	INDICATI	Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 1/2

D0Q4NJ	TTDDRUID	D0Q4NJ
D0Q4NJ	DRUGNAME	MSC2156119
D0Q4NJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0IN7R	TTDDRUID	D0IN7R
D0IN7R	DRUGNAME	MUC-1 CART cell immunotherapy
D0IN7R	INDICATI	Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2

D0IQ3E	TTDDRUID	D0IQ3E
D0IQ3E	DRUGNAME	Muc1-specific gene-engineered T cells
D0IQ3E	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0X2JY	TTDDRUID	D0X2JY
D0X2JY	DRUGNAME	Multiclade DNA recombinant adenovirus-5 (rAd5) vaccine
D0X2JY	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2

D0GY0U	TTDDRUID	D0GY0U
D0GY0U	DRUGNAME	MultiGeneAngio cell therapy
D0GY0U	INDICATI	Vascular systems peripheral arterial disorder [ICD-11: BD5Z] Phase 1/2

D0VJ0Q	TTDDRUID	D0VJ0Q
D0VJ0Q	DRUGNAME	MuStDO 5
D0VJ0Q	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D0H6EF	TTDDRUID	D0H6EF
D0H6EF	DRUGNAME	MVA-BN HIV Multiantigen
D0H6EF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0R4RL	TTDDRUID	D0R4RL
D0R4RL	DRUGNAME	MYO-102
D0R4RL	INDICATI	Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1/2

D0O2JT	TTDDRUID	D0O2JT
D0O2JT	DRUGNAME	MyVax
D0O2JT	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0F2WN	TTDDRUID	D0F2WN
D0F2WN	DRUGNAME	NAHE-001
D0F2WN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0T4GG	TTDDRUID	D0T4GG
D0T4GG	DRUGNAME	NANT
D0T4GG	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0M2UT	TTDDRUID	D0M2UT
D0M2UT	DRUGNAME	NANT squamous cell carcinoma vaccine
D0M2UT	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2

D05CQS	TTDDRUID	D05CQS
D05CQS	DRUGNAME	NB1011
D05CQS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D02YEO	TTDDRUID	D02YEO
D02YEO	DRUGNAME	NBTXR3
D02YEO	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D07YNC	TTDDRUID	D07YNC
D07YNC	DRUGNAME	NCI-4650
D07YNC	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0UI4L	TTDDRUID	D0UI4L
D0UI4L	DRUGNAME	ND-0801
D0UI4L	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1/2

D09JDE	TTDDRUID	D09JDE
D09JDE	DRUGNAME	NDV-3
D09JDE	INDICATI	Candidiasis [ICD-11: 1F23] Phase 1/2

D0T7OE	TTDDRUID	D0T7OE
D0T7OE	DRUGNAME	NEO100
D0T7OE	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2
D0T7OE	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2
D0T7OE	INDICATI	Recurrent malignant glioma [ICD-11: 2A00.0] Phase 1/2

D0S6JV	TTDDRUID	D0S6JV
D0S6JV	DRUGNAME	Nepadutant
D0S6JV	INDICATI	Infantile colics [ICD-11: DD93.1] Phase 1/2
D0S6JV	INDICATI	Postoperative ileus [ICD-11: DA91-DB30] Phase 1/2

D0D1UQ	TTDDRUID	D0D1UQ
D0D1UQ	DRUGNAME	Neu-120
D0D1UQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2

D0R8LV	TTDDRUID	D0R8LV
D0R8LV	DRUGNAME	NI-0401
D0R8LV	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2

D08OES	TTDDRUID	D08OES
D08OES	DRUGNAME	NiCord
D08OES	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D08OES	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 3
D08OES	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2
D08OES	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
D08OES	INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Phase 1/2

D0SN1T	TTDDRUID	D0SN1T
D0SN1T	DRUGNAME	Nikkomycin Z
D0SN1T	INDICATI	Candidiasis [ICD-11: 1F23] Phase 1/2

D0M3HV	TTDDRUID	D0M3HV
D0M3HV	DRUGNAME	Nitric oxide synthase gene therapy
D0M3HV	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1/2

D0C7YE	TTDDRUID	D0C7YE
D0C7YE	DRUGNAME	NKR-2
D0C7YE	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
D0C7YE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D09CXE	TTDDRUID	D09CXE
D09CXE	DRUGNAME	Norovirus bivalent vaccine
D09CXE	INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2

D0J4BO	TTDDRUID	D0J4BO
D0J4BO	DRUGNAME	Norovirus monovalent vaccine
D0J4BO	INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2

D0J1IT	TTDDRUID	D0J1IT
D0J1IT	DRUGNAME	Norovirus vaccine
D0J1IT	INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2

D03DVD	TTDDRUID	D03DVD
D03DVD	DRUGNAME	Norovirus virus-like particle vaccine
D03DVD	INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2

D04TIT	TTDDRUID	D04TIT
D04TIT	DRUGNAME	Nowarta110
D04TIT	INDICATI	Plantar wart [ICD-11: 1E80.1] Phase 1/2

D01SCR	TTDDRUID	D01SCR
D01SCR	DRUGNAME	NPB-001-056
D01SCR	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2

D00MYW	TTDDRUID	D00MYW
D00MYW	DRUGNAME	NS-018
D00MYW	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1/2

D07GWZ	TTDDRUID	D07GWZ
D07GWZ	DRUGNAME	NT-501 CNTF
D07GWZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D0K3FX	TTDDRUID	D0K3FX
D0K3FX	DRUGNAME	NT-503
D0K3FX	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2

D03JDA	TTDDRUID	D03JDA
D03JDA	DRUGNAME	Nu-3
D03JDA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
D03JDA	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2

D0LP2P	TTDDRUID	D0LP2P
D0LP2P	DRUGNAME	Nu-3 topical
D0LP2P	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2

D0B6EA	TTDDRUID	D0B6EA
D0B6EA	DRUGNAME	NV-1020
D0B6EA	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2

D04LZF	TTDDRUID	D04LZF
D04LZF	DRUGNAME	NVX-208
D04LZF	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1/2

D0UD6S	TTDDRUID	D0UD6S
D0UD6S	DRUGNAME	NY-ESO-1/LAGE-1-specific T-cells
D0UD6S	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1/2

D0TN1N	TTDDRUID	D0TN1N
D0TN1N	DRUGNAME	NY-ESO-TCR
D0TN1N	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D0TN1N	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0TN1N	INDICATI	Myxoid round cell liposarcoma [ICD-11: 2B59] Phase 1/2
D0TN1N	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D0TN1N	INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 1/2

D0D8ZK	TTDDRUID	D0D8ZK
D0D8ZK	DRUGNAME	OBP-301
D0D8ZK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D0D8ZK	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
D0D8ZK	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2

D07YFM	TTDDRUID	D07YFM
D07YFM	DRUGNAME	Oligonucleotides
D07YFM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0BI3K	TTDDRUID	D0BI3K
D0BI3K	DRUGNAME	Omburtamab I-124
D0BI3K	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2

D08BZZ	TTDDRUID	D08BZZ
D08BZZ	DRUGNAME	Omburtamab I-131
D08BZZ	INDICATI	Brain metastases [ICD-11: 2D50] Phase 3
D08BZZ	INDICATI	Small round cell desmoplastic tumour [ICD-11: 2A20.5] Phase 1/2

D07MON	TTDDRUID	D07MON
D07MON	DRUGNAME	ONAPRISTONE
D07MON	INDICATI	Contraception [ICD-11: QA21] Phase 1/2

D03CVT	TTDDRUID	D03CVT
D03CVT	DRUGNAME	ONC1-13B
D03CVT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D04FMY	TTDDRUID	D04FMY
D04FMY	DRUGNAME	Oncolym
D04FMY	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D0QP8X	TTDDRUID	D0QP8X
D0QP8X	DRUGNAME	ONO-7579
D0QP8X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0JD9F	TTDDRUID	D0JD9F
D0JD9F	DRUGNAME	Onyvax-105 anti-idiotype cancer vaccine 105AD7
D0JD9F	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0J6NG	TTDDRUID	D0J6NG
D0J6NG	DRUGNAME	OPA-6566
D0J6NG	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2

D0E7IM	TTDDRUID	D0E7IM
D0E7IM	DRUGNAME	OPB-31121
D0E7IM	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D08TBK	TTDDRUID	D08TBK
D08TBK	DRUGNAME	Opdivo + Yervoynivolumab + ipilimumab
D08TBK	INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3
D08TBK	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D08TBK	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0J0XN	TTDDRUID	D0J0XN
D0J0XN	DRUGNAME	OpRegen
D0J0XN	INDICATI	Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2

D02BLD	TTDDRUID	D02BLD
D02BLD	DRUGNAME	Oprozomib
D02BLD	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D09JRL	TTDDRUID	D09JRL
D09JRL	DRUGNAME	Oral peptide cancer vaccine
D09JRL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D08EYQ	TTDDRUID	D08EYQ
D08EYQ	DRUGNAME	ORE-1001
D08EYQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1/2

D04NOE	TTDDRUID	D04NOE
D04NOE	DRUGNAME	OTSGC-A24
D04NOE	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2

D01EMD	TTDDRUID	D01EMD
D01EMD	DRUGNAME	Ovarian dendritic cell-based vaccine
D01EMD	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D01EMD	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1/2

D09GRH	TTDDRUID	D09GRH
D09GRH	DRUGNAME	O-Vax
D09GRH	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D07ZAO	TTDDRUID	D07ZAO
D07ZAO	DRUGNAME	OVI-123
D07ZAO	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D0X8SY	TTDDRUID	D0X8SY
D0X8SY	DRUGNAME	Oxazyme
D0X8SY	INDICATI	Hyperoxaluria [ICD-11: 5C51.2Z] Phase 1/2

D0N4HQ	TTDDRUID	D0N4HQ
D0N4HQ	DRUGNAME	OXi4503
D0N4HQ	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2
D0N4HQ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0N4HQ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0N4HQ	INDICATI	Myelodysplastic malignancy [ICD-11: 2A44] Phase 1/2

D0A2KL	TTDDRUID	D0A2KL
D0A2KL	DRUGNAME	OXS-1550
D0A2KL	INDICATI	B-lineage leukaemia [ICD-11: 2A82.1] Phase 1/2
D0A2KL	INDICATI	B-lineage lymphoma [ICD-11: 2A86] Phase 1/2
D0A2KL	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D00YBW	TTDDRUID	D00YBW
D00YBW	DRUGNAME	OXY-111A
D00YBW	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2

D0I6EK	TTDDRUID	D0I6EK
D0I6EK	DRUGNAME	P10s-Padre/Montanide ISA 51 vaccine
D0I6EK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0C7XM	TTDDRUID	D0C7XM
D0C7XM	DRUGNAME	P2045
D0C7XM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
D0C7XM	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D07MNT	TTDDRUID	D07MNT
D07MNT	DRUGNAME	P52-/p36- GAP vaccine
D07MNT	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D0Q7JC	TTDDRUID	D0Q7JC
D0Q7JC	DRUGNAME	P-552-02
D0Q7JC	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1/2

D0U4JX	TTDDRUID	D0U4JX
D0U4JX	DRUGNAME	Padoporfin photodynamic therapy
D0U4JX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0I0LP	TTDDRUID	D0I0LP
D0I0LP	DRUGNAME	Parvovirus B19 vaccine
D0I0LP	INDICATI	Parvovirus infection [ICD-11: 1D93] Phase 1/2

D00UOQ	TTDDRUID	D00UOQ
D00UOQ	DRUGNAME	PAT-SC1
D00UOQ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2

D0S4IR	TTDDRUID	D0S4IR
D0S4IR	DRUGNAME	PBCAR0191
D0S4IR	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
D0S4IR	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D0E4IB	TTDDRUID	D0E4IB
D0E4IB	DRUGNAME	PBF509
D0E4IB	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0X2QH	TTDDRUID	D0X2QH
D0X2QH	DRUGNAME	PBI-1402
D0X2QH	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1/2

D0M0CO	TTDDRUID	D0M0CO
D0M0CO	DRUGNAME	PCAR-019 (anti-CD19 CAR-T cells)
D0M0CO	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2
D0M0CO	INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2
D0M0CO	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0M0CO	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D0M0CO	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
D0M0CO	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D0L5IA	TTDDRUID	D0L5IA
D0L5IA	DRUGNAME	PEGylated hyaluronidase (human recombinant)
D0L5IA	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D0Z4CY	TTDDRUID	D0Z4CY
D0Z4CY	DRUGNAME	PEN-221
D0Z4CY	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1/2
D0Z4CY	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0RS4X	TTDDRUID	D0RS4X
D0RS4X	DRUGNAME	PEN-866
D0RS4X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0P5RD	TTDDRUID	D0P5RD
D0P5RD	DRUGNAME	PentaStaph
D0P5RD	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1/2

D0S8HD	TTDDRUID	D0S8HD
D0S8HD	DRUGNAME	PEP-223/CoVaccine HT
D0S8HD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0JN6P	TTDDRUID	D0JN6P
D0JN6P	DRUGNAME	PEPIDH1M
D0JN6P	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2

D05PRV	TTDDRUID	D05PRV
D05PRV	DRUGNAME	PerCvax
D05PRV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D0F8SK	TTDDRUID	D0F8SK
D0F8SK	DRUGNAME	Perfluoropropane gas-filled nanobubbles
D0F8SK	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2

D0P7UG	TTDDRUID	D0P7UG
D0P7UG	DRUGNAME	Personalized cancer vaccine
D0P7UG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0O2AW	TTDDRUID	D0O2AW
D0O2AW	DRUGNAME	Pexidartinib
D0O2AW	INDICATI	Neurofibromatosis type 1 [ICD-11: LD2D.10] Phase 1/2

D0V6EV	TTDDRUID	D0V6EV
D0V6EV	DRUGNAME	PF-4554878
D0V6EV	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1/2
D0V6EV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0V6EV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0V6EV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S0VR	TTDDRUID	D0S0VR
D0S0VR	DRUGNAME	PF-5230894
D0S0VR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2

D09NHS	TTDDRUID	D09NHS
D09NHS	DRUGNAME	PfCS-102
D09NHS	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2

D03YOS	TTDDRUID	D03YOS
D03YOS	DRUGNAME	Phenoxodiol
D03YOS	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D00DBO	TTDDRUID	D00DBO
D00DBO	DRUGNAME	Pipamperone
D00DBO	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 1/2

D0H7PW	TTDDRUID	D0H7PW
D0H7PW	DRUGNAME	PIPERINE
D0H7PW	INDICATI	Vitiligo [ICD-11: ED63.0] Phase 1/2

D04JOE	TTDDRUID	D04JOE
D04JOE	DRUGNAME	Placulumab
D04JOE	INDICATI	Sciatica [ICD-11: ME84.3] Phase 1/2

D08HRD	TTDDRUID	D08HRD
D08HRD	DRUGNAME	Plasmodium vivax vaccine
D08HRD	INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Phase 1/2

D0DG9F	TTDDRUID	D0DG9F
D0DG9F	DRUGNAME	PP-1420
D0DG9F	INDICATI	Obesity [ICD-11: 5B81] Phase 1/2

D0Q0ZY	TTDDRUID	D0Q0ZY
D0Q0ZY	DRUGNAME	PRI-724
D0Q0ZY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0P0EI	TTDDRUID	D0P0EI
D0P0EI	DRUGNAME	PRLX93936
D0P0EI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D04KZS	TTDDRUID	D04KZS
D04KZS	DRUGNAME	PRO-045
D04KZS	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2

D09EWK	TTDDRUID	D09EWK
D09EWK	DRUGNAME	PRO-053
D09EWK	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2

D0IR2V	TTDDRUID	D0IR2V
D0IR2V	DRUGNAME	Prodarsan
D0IR2V	INDICATI	Cockayne syndrome [ICD-11: LD2B] Phase 1/2

D04JKE	TTDDRUID	D04JKE
D04JKE	DRUGNAME	Promostem
D04JKE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D05ICS	TTDDRUID	D05ICS
D05ICS	DRUGNAME	ProSavin
D05ICS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2

D0Q8GV	TTDDRUID	D0Q8GV
D0Q8GV	DRUGNAME	Prostate cancer vaccine, FK Biotecnologia
D0Q8GV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0ZC6X	TTDDRUID	D0ZC6X
D0ZC6X	DRUGNAME	PRTX-100
D0ZC6X	INDICATI	Arthritis [ICD-11: FA20] Phase 1/2
D0ZC6X	INDICATI	Behcet disease [ICD-11: 4A62] Phase 1/2
D0ZC6X	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2
D0ZC6X	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1/2

D07URD	TTDDRUID	D07URD
D07URD	DRUGNAME	PRX-102
D07URD	INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 1/2

D0D4LS	TTDDRUID	D0D4LS
D0D4LS	DRUGNAME	PUR003
D0D4LS	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1/2

D0B1TX	TTDDRUID	D0B1TX
D0B1TX	DRUGNAME	PVAXrcPSAv53l
D0B1TX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0QZ1Z	TTDDRUID	D0QZ1Z
D0QZ1Z	DRUGNAME	PVS-10200
D0QZ1Z	INDICATI	Artery stenosis [ICD-11: BD52] Phase 1/2

D06DUS	TTDDRUID	D06DUS
D06DUS	DRUGNAME	PVX-410
D06DUS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D06DUS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D06DUS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W3UH	TTDDRUID	D0W3UH
D0W3UH	DRUGNAME	QLT-091568
D0W3UH	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2

D04GBP	TTDDRUID	D04GBP
D04GBP	DRUGNAME	QR-010
D04GBP	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1/2

D0X9JR	TTDDRUID	D0X9JR
D0X9JR	DRUGNAME	QR-313
D0X9JR	INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 1/2

D0PX7X	TTDDRUID	D0PX7X
D0PX7X	DRUGNAME	Re-188-P-2045
D0PX7X	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D0HZ2A	TTDDRUID	D0HZ2A
D0HZ2A	DRUGNAME	Recombinant factor VIIa PEGylated liposomal
D0HZ2A	INDICATI	Factor VII deficiency [ICD-11: 3B14] Phase 1/2

D06DBJ	TTDDRUID	D06DBJ
D06DBJ	DRUGNAME	REGN-846
D06DBJ	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2

D0D2XA	TTDDRUID	D0D2XA
D0D2XA	DRUGNAME	REIC gene therapy
D0D2XA	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0VU8K	TTDDRUID	D0VU8K
D0VU8K	DRUGNAME	REIC gene therapy vaccine
D0VU8K	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0N0OV	TTDDRUID	D0N0OV
D0N0OV	DRUGNAME	Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
D0N0OV	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D0MI5G	TTDDRUID	D0MI5G
D0MI5G	DRUGNAME	RG2077
D0MI5G	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1/2

D09OTX	TTDDRUID	D09OTX
D09OTX	DRUGNAME	RG7800
D09OTX	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 1/2

D07ZAK	TTDDRUID	D07ZAK
D07ZAK	DRUGNAME	RGX 501
D07ZAK	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 1/2

D0K6UG	TTDDRUID	D0K6UG
D0K6UG	DRUGNAME	RhH1.3
D0K6UG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D08JIP	TTDDRUID	D08JIP
D08JIP	DRUGNAME	Rintatolimod
D08JIP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0JK2R	TTDDRUID	D0JK2R
D0JK2R	DRUGNAME	RMJH-111b
D0JK2R	INDICATI	Essential hypertension [ICD-11: BA00] Phase 1/2

D04EJU	TTDDRUID	D04EJU
D04EJU	DRUGNAME	Ropinirole subdermal implant
D04EJU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2

D0MK2Y	TTDDRUID	D0MK2Y
D0MK2Y	DRUGNAME	Rotavax
D0MK2Y	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2

D0E9UH	TTDDRUID	D0E9UH
D0E9UH	DRUGNAME	RP1
D0E9UH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0RM6A	TTDDRUID	D0RM6A
D0RM6A	DRUGNAME	RST-001
D0RM6A	INDICATI	Retinopathy [ICD-11: 9B71] Phase 1/2

D0Q0TK	TTDDRUID	D0Q0TK
D0Q0TK	DRUGNAME	RST100
D0Q0TK	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2

D0YW6P	TTDDRUID	D0YW6P
D0YW6P	DRUGNAME	RU-101
D0YW6P	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 1/2

D0C6NV	TTDDRUID	D0C6NV
D0C6NV	DRUGNAME	RUT58-60
D0C6NV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2

D0N2NY	TTDDRUID	D0N2NY
D0N2NY	DRUGNAME	Ruxolitinib cream
D0N2NY	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2
D0N2NY	INDICATI	Vitiligo [ICD-11: ED63.0] Phase 1/2

D0N7WW	TTDDRUID	D0N7WW
D0N7WW	DRUGNAME	RVX-208
D0N7WW	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D0N4IV	TTDDRUID	D0N4IV
D0N4IV	DRUGNAME	S-3304
D0N4IV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0PT1Y	TTDDRUID	D0PT1Y
D0PT1Y	DRUGNAME	SAR-161271
D0PT1Y	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2

D05TBQ	TTDDRUID	D05TBQ
D05TBQ	DRUGNAME	SAR408701
D05TBQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D05TBQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0NS1X	TTDDRUID	D0NS1X
D0NS1X	DRUGNAME	SAR-650984
D0NS1X	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D05TRJ	TTDDRUID	D05TRJ
D05TRJ	DRUGNAME	SB-728-HSPC
D05TRJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0L3RZ	TTDDRUID	D0L3RZ
D0L3RZ	DRUGNAME	SBC-103
D0L3RZ	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2

D0Q6EH	TTDDRUID	D0Q6EH
D0Q6EH	DRUGNAME	SBT-20
D0Q6EH	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1/2

D0E4DN	TTDDRUID	D0E4DN
D0E4DN	DRUGNAME	SC16LD6.5
D0E4DN	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D06AWA	TTDDRUID	D06AWA
D06AWA	DRUGNAME	SCIB-1
D06AWA	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D0N1XJ	TTDDRUID	D0N1XJ
D0N1XJ	DRUGNAME	SCID-X stem cell therapy
D0N1XJ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1/2

D0B3HF	TTDDRUID	D0B3HF
D0B3HF	DRUGNAME	SCRI-huCAR19v1
D0B3HF	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0B3HF	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D01MQP	TTDDRUID	D01MQP
D01MQP	DRUGNAME	SECTA belomycin
D01MQP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0X8ID	TTDDRUID	D0X8ID
D0X8ID	DRUGNAME	SEL-24
D0X8ID	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0X8ID	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0TT6L	TTDDRUID	D0TT6L
D0TT6L	DRUGNAME	SF0166
D0TT6L	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1/2

D01KKI	TTDDRUID	D01KKI
D01KKI	DRUGNAME	SGN-CD33A
D01KKI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D01KKI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D0AN3N	TTDDRUID	D0AN3N
D0AN3N	DRUGNAME	SGT-001
D0AN3N	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2

D08KXC	TTDDRUID	D08KXC
D08KXC	DRUGNAME	SGX201
D08KXC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0Q5SI	TTDDRUID	D0Q5SI
D0Q5SI	DRUGNAME	SHP611
D0Q5SI	INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 1/2

D04EJG	TTDDRUID	D04EJG
D04EJG	DRUGNAME	SHR-1314
D04EJG	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1/2

D04WIE	TTDDRUID	D04WIE
D04WIE	DRUGNAME	Sirna-027
D04WIE	INDICATI	Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1/2
D04WIE	INDICATI	Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1

D0R3IG	TTDDRUID	D0R3IG
D0R3IG	DRUGNAME	SJCAR19
D0R3IG	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D0DX9T	TTDDRUID	D0DX9T
D0DX9T	DRUGNAME	Skin tissue replacement therapy
D0DX9T	INDICATI	Skin burns [ICD-11: ME65.0] Phase 1/2

D0Z2ZY	TTDDRUID	D0Z2ZY
D0Z2ZY	DRUGNAME	SL-401
D0Z2ZY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0Z2ZY	INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1/2
D0Z2ZY	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0Z2ZY	INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1/2

D0W8TQ	TTDDRUID	D0W8TQ
D0W8TQ	DRUGNAME	SL-701
D0W8TQ	INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1/2
D0W8TQ	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
D0W8TQ	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0G1EA	TTDDRUID	D0G1EA
D0G1EA	DRUGNAME	SLP vaccine
D0G1EA	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2

D05ETC	TTDDRUID	D05ETC
D05ETC	DRUGNAME	SN-32793
D05ETC	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0E7RQ	TTDDRUID	D0E7RQ
D0E7RQ	DRUGNAME	SNN-0029
D0E7RQ	INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 1/2

D0GB2L	TTDDRUID	D0GB2L
D0GB2L	DRUGNAME	SNN-0031
D0GB2L	INDICATI	Brain injury [ICD-11: NA07.Z] Phase 1/2

D0F8SW	TTDDRUID	D0F8SW
D0F8SW	DRUGNAME	SNS01-T
D0F8SW	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
D0F8SW	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D07MPL	TTDDRUID	D07MPL
D07MPL	DRUGNAME	SNX-5422
D07MPL	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D07MPL	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D07MPL	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
D07MPL	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
D07MPL	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D02ECG	TTDDRUID	D02ECG
D02ECG	DRUGNAME	Sodium pyruvate
D02ECG	INDICATI	Asthma [ICD-11: CA23] Phase 1/2

D03BZN	TTDDRUID	D03BZN
D03BZN	DRUGNAME	Sodium taurocholate
D03BZN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2

D0VQ7Y	TTDDRUID	D0VQ7Y
D0VQ7Y	DRUGNAME	SPK-CHM
D0VQ7Y	INDICATI	Choroidal dystrophy [ICD-11: 9B61] Phase 1/2

D05CGX	TTDDRUID	D05CGX
D05CGX	DRUGNAME	SPK-FIX
D05CGX	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2

D0A5XN	TTDDRUID	D0A5XN
D0A5XN	DRUGNAME	Sprodiamide
D0A5XN	INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1/2

D0C6IQ	TTDDRUID	D0C6IQ
D0C6IQ	DRUGNAME	Stamulumab
D0C6IQ	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2

D0V5QY	TTDDRUID	D0V5QY
D0V5QY	DRUGNAME	StaphTAME
D0V5QY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2

D0F6SY	TTDDRUID	D0F6SY
D0F6SY	DRUGNAME	StarGen
D0F6SY	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2

D0F7QP	TTDDRUID	D0F7QP
D0F7QP	DRUGNAME	StarGen Stargardt's disease gene therapy
D0F7QP	INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1/2

D08UMZ	TTDDRUID	D08UMZ
D08UMZ	DRUGNAME	STD-07
D08UMZ	INDICATI	Constipation [ICD-11: DD91.1] Phase 1/2

D0E9XR	TTDDRUID	D0E9XR
D0E9XR	DRUGNAME	STP705
D0E9XR	INDICATI	Hypertrophic scars [ICD-11: EE60] Phase 1/2

D0C6VO	TTDDRUID	D0C6VO
D0C6VO	DRUGNAME	StrataGraft
D0C6VO	INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Phase 1/2

D0FF2G	TTDDRUID	D0FF2G
D0FF2G	DRUGNAME	Sym013
D0FF2G	INDICATI	Epithelial ovarian cancer [ICD-11: 2B5D] Phase 1/2
D0FF2G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0B4OK	TTDDRUID	D0B4OK
D0B4OK	DRUGNAME	Sym015
D0B4OK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0AO9Q	TTDDRUID	D0AO9Q
D0AO9Q	DRUGNAME	SYNT001
D0AO9Q	INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 1/2

D08DUY	TTDDRUID	D08DUY
D08DUY	DRUGNAME	T-1249
D08DUY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D00QKL	TTDDRUID	D00QKL
D00QKL	DRUGNAME	T2c-003
D00QKL	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2

D0ZT8A	TTDDRUID	D0ZT8A
D0ZT8A	DRUGNAME	T3D-959
D0ZT8A	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D0FY5E	TTDDRUID	D0FY5E
D0FY5E	DRUGNAME	TAI-GPC3-CART cells
D0FY5E	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D0GL7H	TTDDRUID	D0GL7H
D0GL7H	DRUGNAME	Talotrexin
D0GL7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D01ZLU	TTDDRUID	D01ZLU
D01ZLU	DRUGNAME	TAS-120
D01ZLU	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D01ZLU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D09NTG	TTDDRUID	D09NTG
D09NTG	DRUGNAME	Taurocholic Acid
D09NTG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2

D06TWA	TTDDRUID	D06TWA
D06TWA	DRUGNAME	TB-403
D06TWA	INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 2

D01HVZ	TTDDRUID	D01HVZ
D01HVZ	DRUGNAME	TD-8954
D01HVZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D0M1WW	TTDDRUID	D0M1WW
D0M1WW	DRUGNAME	TDENV
D0M1WW	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1/2

D03KXZ	TTDDRUID	D03KXZ
D03KXZ	DRUGNAME	TF 2-targeted bispecific antibody
D03KXZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0P0KN	TTDDRUID	D0P0KN
D0P0KN	DRUGNAME	TG02
D0P0KN	INDICATI	Anaplastic astrocytoma [ICD-11: 2A00.0] Phase 1/2
D0P0KN	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
D0P0KN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C3ZR	TTDDRUID	D0C3ZR
D0C3ZR	DRUGNAME	TG100-115
D0C3ZR	INDICATI	Angioedema [ICD-11: 4A00.15] Phase 1/2
D0C3ZR	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2

D04FSD	TTDDRUID	D04FSD
D04FSD	DRUGNAME	TgAAG76
D04FSD	INDICATI	Blindness [ICD-11: 9D90] Phase 1/2

D0WM3Z	TTDDRUID	D0WM3Z
D0WM3Z	DRUGNAME	TI-061
D0WM3Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0F6TV	TTDDRUID	D0F6TV
D0F6TV	DRUGNAME	Timcodar dimesilate
D0F6TV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0A4GQ	TTDDRUID	D0A4GQ
D0A4GQ	DRUGNAME	Tisotumab vedotin
D0A4GQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0P5UQ	TTDDRUID	D0P5UQ
D0P5UQ	DRUGNAME	Tissue repair stem cell therapy
D0P5UQ	INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 1/2
D0P5UQ	INDICATI	Peripheral ischemia [ICD-11: BD30-BD40] Phase 1/2

D0Y7YH	TTDDRUID	D0Y7YH
D0Y7YH	DRUGNAME	TK-54
D0Y7YH	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1/2

D07OZR	TTDDRUID	D07OZR
D07OZR	DRUGNAME	TKI258
D07OZR	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
D07OZR	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D06WNQ	TTDDRUID	D06WNQ
D06WNQ	DRUGNAME	TKM-PLK1
D06WNQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0G9MC	TTDDRUID	D0G9MC
D0G9MC	DRUGNAME	TLC178
D0G9MC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0D0DH	TTDDRUID	D0D0DH
D0D0DH	DRUGNAME	TLPLDC
D0D0DH	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0D0DH	INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
D0D0DH	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2/3
D0D0DH	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D08UJH	TTDDRUID	D08UJH
D08UJH	DRUGNAME	Toca 511 + Toca FC combination
D08UJH	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2

D07AKD	TTDDRUID	D07AKD
D07AKD	DRUGNAME	TOL-101
D07AKD	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1/2

D05NFR	TTDDRUID	D05NFR
D05NFR	DRUGNAME	TPX-0005
D05NFR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0L6RR	TTDDRUID	D0L6RR
D0L6RR	DRUGNAME	Transplant acceptance inducing cells
D0L6RR	INDICATI	Transplant rejection [ICD-11: NE84] Phase 1/2

D01MDX	TTDDRUID	D01MDX
D01MDX	DRUGNAME	TRBC1
D01MDX	INDICATI	Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1/2
D01MDX	INDICATI	Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 1/2
D01MDX	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
D01MDX	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 1/2

D0JV4R	TTDDRUID	D0JV4R
D0JV4R	DRUGNAME	TriCAR-T-CD19
D0JV4R	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D04GSV	TTDDRUID	D04GSV
D04GSV	DRUGNAME	TRICIRIBINE
D04GSV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D09CCZ	TTDDRUID	D09CCZ
D09CCZ	DRUGNAME	Triciribine prodrug
D09CCZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0T7QC	TTDDRUID	D0T7QC
D0T7QC	DRUGNAME	TRU-016
D0T7QC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2

D0J1MO	TTDDRUID	D0J1MO
D0J1MO	DRUGNAME	TRX-518
D0J1MO	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0J1MO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D01HKZ	TTDDRUID	D01HKZ
D01HKZ	DRUGNAME	TSR-011
D01HKZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0D5TN	TTDDRUID	D0D5TN
D0D5TN	DRUGNAME	TT-034
D0D5TN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2

D00QUZ	TTDDRUID	D00QUZ
D00QUZ	DRUGNAME	TTP-814
D00QUZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1/2

D02KVT	TTDDRUID	D02KVT
D02KVT	DRUGNAME	TUSC2/FUS1 gene therapy
D02KVT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0P3BS	TTDDRUID	D0P3BS
D0P3BS	DRUGNAME	TUTI-16
D0P3BS	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2

D0UM8Q	TTDDRUID	D0UM8Q
D0UM8Q	DRUGNAME	UCART019
D0UM8Q	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
D0UM8Q	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0OI8M	TTDDRUID	D0OI8M
D0OI8M	DRUGNAME	UISH-001
D0OI8M	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 1/2

D0C3LQ	TTDDRUID	D0C3LQ
D0C3LQ	DRUGNAME	Ulocuplumab
D0C3LQ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0C3LQ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D02ZMB	TTDDRUID	D02ZMB
D02ZMB	DRUGNAME	Urelumab
D02ZMB	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D02ZMB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0YO5Z	TTDDRUID	D0YO5Z
D0YO5Z	DRUGNAME	UshStat
D0YO5Z	INDICATI	Deafness [ICD-11: AB52] Phase 1/2
D0YO5Z	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1

D08XQV	TTDDRUID	D08XQV
D08XQV	DRUGNAME	USL311
D08XQV	INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2
D08XQV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D04AEQ	TTDDRUID	D04AEQ
D04AEQ	DRUGNAME	V81444
D04AEQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2

D0W5YC	TTDDRUID	D0W5YC
D0W5YC	DRUGNAME	Vacc-5q
D0W5YC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0E6PF	TTDDRUID	D0E6PF
D0E6PF	DRUGNAME	Vacc-C5
D0E6PF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0M3QT	TTDDRUID	D0M3QT
D0M3QT	DRUGNAME	VAL-201
D0M3QT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D03ZZC	TTDDRUID	D03ZZC
D03ZZC	DRUGNAME	Vascugel
D03ZZC	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 1/2

D0LL9W	TTDDRUID	D0LL9W
D0LL9W	DRUGNAME	VBI-1901
D0LL9W	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2

D0OM5L	TTDDRUID	D0OM5L
D0OM5L	DRUGNAME	VC-01
D0OM5L	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2

D0YI4F	TTDDRUID	D0YI4F
D0YI4F	DRUGNAME	Vecabrutinib
D0YI4F	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2

D0SV5T	TTDDRUID	D0SV5T
D0SV5T	DRUGNAME	Veltuzumab subcutaneous
D0SV5T	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1/2

D0WT9A	TTDDRUID	D0WT9A
D0WT9A	DRUGNAME	Vero-cell H5N1 vaccine
D0WT9A	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2

D01PTS	TTDDRUID	D01PTS
D01PTS	DRUGNAME	VG-101
D01PTS	INDICATI	Menopause symptom [ICD-11: GA30.0] Phase 1/2

D0I5QV	TTDDRUID	D0I5QV
D0I5QV	DRUGNAME	VIR-201
D0I5QV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0Y3AG	TTDDRUID	D0Y3AG
D0Y3AG	DRUGNAME	VIR-576
D0Y3AG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D0J3DC	TTDDRUID	D0J3DC
D0J3DC	DRUGNAME	VLP norovirus bivalent vaccine
D0J3DC	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2

D03CNV	TTDDRUID	D03CNV
D03CNV	DRUGNAME	VMD-30283
D03CNV	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2

D01XDO	TTDDRUID	D01XDO
D01XDO	DRUGNAME	VSSP
D01XDO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D07NVF	TTDDRUID	D07NVF
D07NVF	DRUGNAME	WAS gene therapy
D07NVF	INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2

D0V4VQ	TTDDRUID	D0V4VQ
D0V4VQ	DRUGNAME	WASP gene therapy
D0V4VQ	INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2

D0IV4C	TTDDRUID	D0IV4C
D0IV4C	DRUGNAME	WP-1066
D0IV4C	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
D0IV4C	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
D0IV4C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01MYJ	TTDDRUID	D01MYJ
D01MYJ	DRUGNAME	WT-4869
D01MYJ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D0W5YP	TTDDRUID	D0W5YP
D0W5YP	DRUGNAME	WVE-120101
D0W5YP	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1/2

D04ZFO	TTDDRUID	D04ZFO
D04ZFO	DRUGNAME	WVE-120102
D04ZFO	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1/2

D0O4QS	TTDDRUID	D0O4QS
D0O4QS	DRUGNAME	WX-554
D0O4QS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0L9PA	TTDDRUID	D0L9PA
D0L9PA	DRUGNAME	X-396
D0L9PA	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2

D04DNB	TTDDRUID	D04DNB
D04DNB	DRUGNAME	Xentuzumab
D04DNB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0FN4K	TTDDRUID	D0FN4K
D0FN4K	DRUGNAME	XToll
D0FN4K	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2

D0U9LT	TTDDRUID	D0U9LT
D0U9LT	DRUGNAME	Y-39983
D0U9LT	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2

D05VXF	TTDDRUID	D05VXF
D05VXF	DRUGNAME	YSCMA
D05VXF	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0LS9F	TTDDRUID	D0LS9F
D0LS9F	DRUGNAME	ZEN-3694
D0LS9F	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D02TDV	TTDDRUID	D02TDV
D02TDV	DRUGNAME	ZK-001
D02TDV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1/2

D02XBN	TTDDRUID	D02XBN
D02XBN	DRUGNAME	ZPL521
D02XBN	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2

D03DUY	TTDDRUID	D03DUY
D03DUY	DRUGNAME	BMS-833923
D03DUY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1b

D03KXO	TTDDRUID	D03KXO
D03KXO	DRUGNAME	FP-1039/HGS1036
D03KXO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1b

D09GPI	TTDDRUID	D09GPI
D09GPI	DRUGNAME	FRM-6308
D09GPI	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1b

D08WNO	TTDDRUID	D08WNO
D08WNO	DRUGNAME	GGF
D08WNO	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1b

D0V4XY	TTDDRUID	D0V4XY
D0V4XY	DRUGNAME	S-222611
D0V4XY	INDICATI	Malignant solid tumour [ICD-11: 2C10-2F32] Phase 1b

D0Q6IF	TTDDRUID	D0Q6IF
D0Q6IF	DRUGNAME	Vmab + Y-90 Emab
D0Q6IF	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1b

D0TP9X	TTDDRUID	D0TP9X
D0TP9X	DRUGNAME	852
D0TP9X	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Phase 1

D0NH4L	TTDDRUID	D0NH4L
D0NH4L	DRUGNAME	43778
D0NH4L	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 1

D07MVL	TTDDRUID	D07MVL
D07MVL	DRUGNAME	43781
D07MVL	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0J0WX	TTDDRUID	D0J0WX
D0J0WX	DRUGNAME	(-)-3PPP, Maryland
D0J0WX	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0ZW4W	TTDDRUID	D0ZW4W
D0ZW4W	DRUGNAME	(+)-JQ1
D0ZW4W	INDICATI	Testicular cancer [ICD-11: 2C80] Phase 1

D0B8MB	TTDDRUID	D0B8MB
D0B8MB	DRUGNAME	[99MTC]-CBPAO
D0B8MB	INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1

D0C1ZO	TTDDRUID	D0C1ZO
D0C1ZO	DRUGNAME	[N-methyl-3H(3)]AZ-10419369
D0C1ZO	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1

D03RMN	TTDDRUID	D03RMN
D03RMN	DRUGNAME	1069C
D03RMN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C7WO	TTDDRUID	D0C7WO
D0C7WO	DRUGNAME	1192U90
D0C7WO	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1
D0C7WO	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0ZX2D	TTDDRUID	D0ZX2D
D0ZX2D	DRUGNAME	11C-6-Me-BTA-1
D0ZX2D	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0V0VI	TTDDRUID	D0V0VI
D0V0VI	DRUGNAME	11C-AZD-2184
D0V0VI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D08PIK	TTDDRUID	D08PIK
D08PIK	DRUGNAME	11C-GSK-215083
D08PIK	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1

D0N3UQ	TTDDRUID	D0N3UQ
D0N3UQ	DRUGNAME	123I-MNI-168
D0N3UQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0MU7N	TTDDRUID	D0MU7N
D0MU7N	DRUGNAME	123I-MNI-330
D0MU7N	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D03ZZX	TTDDRUID	D03ZZX
D03ZZX	DRUGNAME	123I-MNI-420
D03ZZX	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1

D0T5LQ	TTDDRUID	D0T5LQ
D0T5LQ	DRUGNAME	123-Iodine-labeled MFE-23
D0T5LQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J7QC	TTDDRUID	D0J7QC
D0J7QC	DRUGNAME	124I-8H9
D0J7QC	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0W1SD	TTDDRUID	D0W1SD
D0W1SD	DRUGNAME	124I-labeled 11-1F4
D0W1SD	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1

D06LQF	TTDDRUID	D06LQF
D06LQF	DRUGNAME	131-I-MIP-1095
D06LQF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0D2WX	TTDDRUID	D0D2WX
D0D2WX	DRUGNAME	1614235 + 2330672
D0D2WX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D02TMO	TTDDRUID	D02TMO
D02TMO	DRUGNAME	177Lu-AMBA
D02TMO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D09EPU	TTDDRUID	D09EPU
D09EPU	DRUGNAME	18F-BAY-85-8050
D09EPU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U1US	TTDDRUID	D0U1US
D0U1US	DRUGNAME	18F-FEDAA-1106
D0U1US	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0DS3J	TTDDRUID	D0DS3J
D0DS3J	DRUGNAME	18-MC
D0DS3J	INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1

D0A2RX	TTDDRUID	D0A2RX
D0A2RX	DRUGNAME	19-28z T CELLS
D0A2RX	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0NU6Y	TTDDRUID	D0NU6Y
D0NU6Y	DRUGNAME	192C86
D0NU6Y	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0R1XF	TTDDRUID	D0R1XF
D0R1XF	DRUGNAME	212-Pb-TCMC-trastuzumab
D0R1XF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06LHK	TTDDRUID	D06LHK
D06LHK	DRUGNAME	2X-111
D06LHK	INDICATI	Brain metastases [ICD-11: 2D50] Phase 1
D06LHK	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0F7NT	TTDDRUID	D0F7NT
D0F7NT	DRUGNAME	349U85.HCL
D0F7NT	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0Q3QS	TTDDRUID	D0Q3QS
D0Q3QS	DRUGNAME	4-aminosalicylate sodium (oral controlled release, ulcerative colitis), AGI Therapeutics
D0Q3QS	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1

D07UUB	TTDDRUID	D07UUB
D07UUB	DRUGNAME	4SC-203
D07UUB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08OPX	TTDDRUID	D08OPX
D08OPX	DRUGNAME	4SC-205
D08OPX	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D07ITH	TTDDRUID	D07ITH
D07ITH	DRUGNAME	4SCAR19 cells
D07ITH	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D02ONT	TTDDRUID	D02ONT
D02ONT	DRUGNAME	5-FP
D02ONT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02MFC	TTDDRUID	D02MFC
D02MFC	DRUGNAME	62Cu-ATSM
D02MFC	INDICATI	Hypoxia [ICD-11: MD11.1] Phase 1

D06JAL	TTDDRUID	D06JAL
D06JAL	DRUGNAME	8H9
D06JAL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M1IM	TTDDRUID	D0M1IM
D0M1IM	DRUGNAME	8H9 mab
D0M1IM	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1

D05CVC	TTDDRUID	D05CVC
D05CVC	DRUGNAME	90Y-cG250
D05CVC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L5DK	TTDDRUID	D0L5DK
D0L5DK	DRUGNAME	99MTC-CYT-379
D0L5DK	INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1

D0F5KN	TTDDRUID	D0F5KN
D0F5KN	DRUGNAME	99mTc-MIP-1405
D0F5KN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D07OSS	TTDDRUID	D07OSS
D07OSS	DRUGNAME	9cUAB-30
D07OSS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0LF3K	TTDDRUID	D0LF3K
D0LF3K	DRUGNAME	A/Anhui/05
D0LF3K	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0W8OJ	TTDDRUID	D0W8OJ
D0W8OJ	DRUGNAME	A-348441
D0W8OJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0NR7H	TTDDRUID	D0NR7H
D0NR7H	DRUGNAME	A-837093
D0NR7H	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D01ZSP	TTDDRUID	D01ZSP
D01ZSP	DRUGNAME	AAB-003/PF-05236812
D01ZSP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D00MBY	TTDDRUID	D00MBY
D00MBY	DRUGNAME	AAD-2004
D00MBY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0T4WK	TTDDRUID	D0T4WK
D0T4WK	DRUGNAME	AAV2 GDNF
D0T4WK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D00TXL	TTDDRUID	D00TXL
D00TXL	DRUGNAME	AAV2-hFIX16
D00TXL	INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1

D08IMP	TTDDRUID	D08IMP
D08IMP	DRUGNAME	AAV-hAADC gene therapy
D08IMP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0J4CV	TTDDRUID	D0J4CV
D0J4CV	DRUGNAME	AAV-sFLT gene therapy
D0J4CV	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1

D0J3EN	TTDDRUID	D0J3EN
D0J3EN	DRUGNAME	AB122
D0J3EN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01RDR	TTDDRUID	D01RDR
D01RDR	DRUGNAME	AB569
D01RDR	INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1

D04UBI	TTDDRUID	D04UBI
D04UBI	DRUGNAME	AB928
D04UBI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A7KI	TTDDRUID	D0A7KI
D0A7KI	DRUGNAME	Abaperidone
D0A7KI	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D07PSX	TTDDRUID	D07PSX
D07PSX	DRUGNAME	ABBV-084
D07PSX	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0T3JZ	TTDDRUID	D0T3JZ
D0T3JZ	DRUGNAME	ABBV-085
D0T3JZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A1WS	TTDDRUID	D0A1WS
D0A1WS	DRUGNAME	ABBV-176
D0A1WS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0WO7R	TTDDRUID	D0WO7R
D0WO7R	DRUGNAME	ABBV-181
D0WO7R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0VT6X	TTDDRUID	D0VT6X
D0VT6X	DRUGNAME	ABBV-2451
D0VT6X	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1

D04DQO	TTDDRUID	D04DQO
D04DQO	DRUGNAME	ABBV-257
D04DQO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0U0QC	TTDDRUID	D0U0QC
D0U0QC	DRUGNAME	ABBV-2737
D0U0QC	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1

D0A1YF	TTDDRUID	D0A1YF
D0A1YF	DRUGNAME	ABBV-3067
D0A1YF	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1

D04OFY	TTDDRUID	D04OFY
D04OFY	DRUGNAME	ABBV-321
D04OFY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01NZH	TTDDRUID	D01NZH
D01NZH	DRUGNAME	ABBV-323
D01NZH	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D0P5JH	TTDDRUID	D0P5JH
D0P5JH	DRUGNAME	ABBV-368
D0P5JH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02EOR	TTDDRUID	D02EOR
D02EOR	DRUGNAME	ABBV-399
D02EOR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0QD4A	TTDDRUID	D0QD4A
D0QD4A	DRUGNAME	ABBV-428
D0QD4A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0NT1R	TTDDRUID	D0NT1R
D0NT1R	DRUGNAME	ABBV-621
D0NT1R	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0NT1R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05ICT	TTDDRUID	D05ICT
D05ICT	DRUGNAME	ABBV-744
D05ICT	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D05ICT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0BB2V	TTDDRUID	D0BB2V
D0BB2V	DRUGNAME	ABBV-838
D0BB2V	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0H7KQ	TTDDRUID	D0H7KQ
D0H7KQ	DRUGNAME	ABBV-8E12
D0H7KQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
D0H7KQ	INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 2

D0Z1AB	TTDDRUID	D0Z1AB
D0Z1AB	DRUGNAME	ABBV-927
D0Z1AB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08NXP	TTDDRUID	D08NXP
D08NXP	DRUGNAME	ABBV-951
D08NXP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D08GZE	TTDDRUID	D08GZE
D08GZE	DRUGNAME	AbGn-107
D08GZE	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D08GZE	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D08GZE	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
D08GZE	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0W6XV	TTDDRUID	D0W6XV
D0W6XV	DRUGNAME	AbGn-7
D0W6XV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P4KU	TTDDRUID	D0P4KU
D0P4KU	DRUGNAME	ABI-011
D0P4KU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0P4KU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05VFZ	TTDDRUID	D05VFZ
D05VFZ	DRUGNAME	ABP-710
D05VFZ	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
D05VFZ	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1

D0Y7CO	TTDDRUID	D0Y7CO
D0Y7CO	DRUGNAME	ABT-072
D0Y7CO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D00CMV	TTDDRUID	D00CMV
D00CMV	DRUGNAME	ABT-102
D00CMV	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D03APM	TTDDRUID	D03APM
D03APM	DRUGNAME	ABT-110
D03APM	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D0PP6A	TTDDRUID	D0PP6A
D0PP6A	DRUGNAME	ABT-165
D0PP6A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05AHH	TTDDRUID	D05AHH
D05AHH	DRUGNAME	ABT-199/GDC-0199/RG7601
D05AHH	INDICATI	Relapsed or refractory chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D04LSD	TTDDRUID	D04LSD
D04LSD	DRUGNAME	ABT-239
D04LSD	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D04KJT	TTDDRUID	D04KJT
D04KJT	DRUGNAME	ABT-333
D04KJT	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0X9HF	TTDDRUID	D0X9HF
D0X9HF	DRUGNAME	ABT-354
D0X9HF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D01QKZ	TTDDRUID	D01QKZ
D01QKZ	DRUGNAME	ABT-413
D01QKZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0SN2I	TTDDRUID	D0SN2I
D0SN2I	DRUGNAME	ABT-555
D0SN2I	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0I2IY	TTDDRUID	D0I2IY
D0I2IY	DRUGNAME	ABT-700
D0I2IY	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1

D0HH0G	TTDDRUID	D0HH0G
D0HH0G	DRUGNAME	ABT-767
D0HH0G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03NLQ	TTDDRUID	D03NLQ
D03NLQ	DRUGNAME	ABT-957
D03NLQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0CW8S	TTDDRUID	D0CW8S
D0CW8S	DRUGNAME	ABX-1431
D0CW8S	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
D0CW8S	INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 1

D0NN7L	TTDDRUID	D0NN7L
D0NN7L	DRUGNAME	AC 165198
D0NN7L	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0FV3K	TTDDRUID	D0FV3K
D0FV3K	DRUGNAME	AC0010
D0FV3K	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0KT8D	TTDDRUID	D0KT8D
D0KT8D	DRUGNAME	AC0058TA
D0KT8D	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D0RO8H	TTDDRUID	D0RO8H
D0RO8H	DRUGNAME	AC-262271
D0RO8H	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1

D08CNP	TTDDRUID	D08CNP
D08CNP	DRUGNAME	AC430
D08CNP	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0J3HE	TTDDRUID	D0J3HE
D0J3HE	DRUGNAME	ACAM529
D0J3HE	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D03DUH	TTDDRUID	D03DUH
D03DUH	DRUGNAME	ACAM-FLU-A
D03DUH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0F7GX	TTDDRUID	D0F7GX
D0F7GX	DRUGNAME	ACE-011
D0F7GX	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D0N9PL	TTDDRUID	D0N9PL
D0N9PL	DRUGNAME	ACE-041
D0N9PL	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1

D07VNH	TTDDRUID	D07VNH
D07VNH	DRUGNAME	Acebilustat
D07VNH	INDICATI	Chronic blistering skin disorder [ICD-11: ME63.3] Phase 1

D06KUY	TTDDRUID	D06KUY
D06KUY	DRUGNAME	ACH-2684
D06KUY	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0C9MA	TTDDRUID	D0C9MA
D0C9MA	DRUGNAME	ACH-4471
D0C9MA	INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Phase 1

D08FKL	TTDDRUID	D08FKL
D08FKL	DRUGNAME	ACHN-975
D08FKL	INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1

D0W9LS	TTDDRUID	D0W9LS
D0W9LS	DRUGNAME	ACI-35
D0W9LS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0X3BG	TTDDRUID	D0X3BG
D0X3BG	DRUGNAME	Acid sphingomyelinase
D0X3BG	INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 1

D0N3NL	TTDDRUID	D0N3NL
D0N3NL	DRUGNAME	Acriflavine
D0N3NL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0AA5K	TTDDRUID	D0AA5K
D0AA5K	DRUGNAME	ACT-101
D0AA5K	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
D0AA5K	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 1

D03XHS	TTDDRUID	D03XHS
D03XHS	DRUGNAME	ACT-178882
D03XHS	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0XE4W	TTDDRUID	D0XE4W
D0XE4W	DRUGNAME	Actimab-M
D0XE4W	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0C8DA	TTDDRUID	D0C8DA
D0C8DA	DRUGNAME	Actimmune interferon gamma-1b
D0C8DA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01ZPT	TTDDRUID	D01ZPT
D01ZPT	DRUGNAME	ACTR087
D01ZPT	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0C6RR	TTDDRUID	D0C6RR
D0C6RR	DRUGNAME	ACTR087 + rituximab
D0C6RR	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D0LZ7G	TTDDRUID	D0LZ7G
D0LZ7G	DRUGNAME	ACTR707
D0LZ7G	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D03XFH	TTDDRUID	D03XFH
D03XFH	DRUGNAME	ACTR-BCMA
D03XFH	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D00WPT	TTDDRUID	D00WPT
D00WPT	DRUGNAME	ACV-1
D00WPT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D0U6PK	TTDDRUID	D0U6PK
D0U6PK	DRUGNAME	ACY-001
D0U6PK	INDICATI	Coronary ischemia [ICD-11: BA50-BA51] Phase 1

D0DR3T	TTDDRUID	D0DR3T
D0DR3T	DRUGNAME	Ad.hIL-12
D0DR3T	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D01JGD	TTDDRUID	D01JGD
D01JGD	DRUGNAME	AD-03
D01JGD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0V3EQ	TTDDRUID	D0V3EQ
D0V3EQ	DRUGNAME	AD03 vaccine
D0V3EQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D08KTO	TTDDRUID	D08KTO
D08KTO	DRUGNAME	AD04
D08KTO	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D08KTO	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1

D02ZCM	TTDDRUID	D02ZCM
D02ZCM	DRUGNAME	Ad26.ENVA.01 HIV-1 recombinant vaccine
D02ZCM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D02ZCE	TTDDRUID	D02ZCE
D02ZCE	DRUGNAME	AD-337
D02ZCE	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 1
D02ZCE	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 1
D02ZCE	INDICATI	Myalgia [ICD-11: FB56.2] Phase 1

D06YTV	TTDDRUID	D06YTV
D06YTV	DRUGNAME	Ad35
D06YTV	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D09ZKB	TTDDRUID	D09ZKB
D09ZKB	DRUGNAME	Ad35-GRIN/ENV
D09ZKB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D07LCP	TTDDRUID	D07LCP
D07LCP	DRUGNAME	Ad5Ag85A
D07LCP	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1

D0G8DV	TTDDRUID	D0G8DV
D0G8DV	DRUGNAME	Ad5CMV-NIS
D0G8DV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0OX1Y	TTDDRUID	D0OX1Y
D0OX1Y	DRUGNAME	Ad5-ENVA-48
D0OX1Y	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0K1LJ	TTDDRUID	D0K1LJ
D0K1LJ	DRUGNAME	Ad5-TRAIL
D0K1LJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0Z1RJ	TTDDRUID	D0Z1RJ
D0Z1RJ	DRUGNAME	Adaphostin
D0Z1RJ	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1

D0C5LJ	TTDDRUID	D0C5LJ
D0C5LJ	DRUGNAME	ADC-1013
D0C5LJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03JRO	TTDDRUID	D03JRO
D03JRO	DRUGNAME	ADCI
D03JRO	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 1

D0X3XV	TTDDRUID	D0X3XV
D0X3XV	DRUGNAME	AdCMV-PR8.ha
D0X3XV	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0LL1N	TTDDRUID	D0LL1N
D0LL1N	DRUGNAME	ADCT-301
D0LL1N	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
D0LL1N	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0W8NW	TTDDRUID	D0W8NW
D0W8NW	DRUGNAME	ADCT-301
D0W8NW	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0W8NW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0W8NW	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0HV4B	TTDDRUID	D0HV4B
D0HV4B	DRUGNAME	ADCT-402
D0HV4B	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0HV4B	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0HV4B	INDICATI	Burkitt cell leukaemia [ICD-11: 2A85.6] Phase 1

D05CRY	TTDDRUID	D05CRY
D05CRY	DRUGNAME	ADCT-502
D05CRY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03QWG	TTDDRUID	D03QWG
D03QWG	DRUGNAME	Ad-IFN-alpha
D03QWG	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1

D0W5UD	TTDDRUID	D0W5UD
D0W5UD	DRUGNAME	Adipose stem cell therapy
D0W5UD	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1

D0V5TP	TTDDRUID	D0V5TP
D0V5TP	DRUGNAME	Adipose-derived stem cell therapy
D0V5TP	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D00ROY	TTDDRUID	D00ROY
D00ROY	DRUGNAME	Adjustable basal insulin
D00ROY	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D02KBE	TTDDRUID	D02KBE
D02KBE	DRUGNAME	Ad-OC-hsvTK/valacyclovir
D02KBE	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0P4JJ	TTDDRUID	D0P4JJ
D0P4JJ	DRUGNAME	Adoptive T-cell therapy
D0P4JJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0D6QX	TTDDRUID	D0D6QX
D0D6QX	DRUGNAME	AD-p53 gene therapy
D0D6QX	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D01RVA	TTDDRUID	D01RVA
D01RVA	DRUGNAME	ADR-851
D01RVA	INDICATI	Nausea and vomiting [ICD-11: MD90] Phase 1

D0A8AX	TTDDRUID	D0A8AX
D0A8AX	DRUGNAME	Ad-RTS-hIL12
D0A8AX	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D09RZH	TTDDRUID	D09RZH
D09RZH	DRUGNAME	AdRTVP-1
D09RZH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0KJ4S	TTDDRUID	D0KJ4S
D0KJ4S	DRUGNAME	ADS-4101
D0KJ4S	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0RV6U	TTDDRUID	D0RV6U
D0RV6U	DRUGNAME	ADU-623
D0RV6U	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0N6VS	TTDDRUID	D0N6VS
D0N6VS	DRUGNAME	ADU-S100
D0N6VS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05LOV	TTDDRUID	D05LOV
D05LOV	DRUGNAME	ADV-1002401
D05LOV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0X7ZE	TTDDRUID	D0X7ZE
D0X7ZE	DRUGNAME	AdVac Malaria Vaccine
D0X7ZE	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D05UJS	TTDDRUID	D05UJS
D05UJS	DRUGNAME	ADVAX
D05UJS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0RS0Q	TTDDRUID	D0RS0Q
D0RS0Q	DRUGNAME	Ad-VirRx 007
D0RS0Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0MK3G	TTDDRUID	D0MK3G
D0MK3G	DRUGNAME	ADXS-NEO
D0MK3G	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 1
D0MK3G	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0MK3G	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0F5GF	TTDDRUID	D0F5GF
D0F5GF	DRUGNAME	AE-08
D0F5GF	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0P8IU	TTDDRUID	D0P8IU
D0P8IU	DRUGNAME	AE37/GP2 peptide vaccine
D0P8IU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0S9GJ	TTDDRUID	D0S9GJ
D0S9GJ	DRUGNAME	AE-443p
D0S9GJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0G7SM	TTDDRUID	D0G7SM
D0G7SM	DRUGNAME	AEA-35p
D0G7SM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D08WQU	TTDDRUID	D08WQU
D08WQU	DRUGNAME	AEB1102
D08WQU	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D08WQU	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D08WQU	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
D08WQU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0B2NF	TTDDRUID	D0B2NF
D0B2NF	DRUGNAME	AEB701
D0B2NF	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D05VAR	TTDDRUID	D05VAR
D05VAR	DRUGNAME	AE-H
D05VAR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D00VVU	TTDDRUID	D00VVU
D00VVU	DRUGNAME	AE-H vaccine
D00VVU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0Z3HF	TTDDRUID	D0Z3HF
D0Z3HF	DRUGNAME	AE-IG
D0Z3HF	INDICATI	Genetic disease [ICD-11: 8E02] Phase 1

D05MEP	TTDDRUID	D05MEP
D05MEP	DRUGNAME	AE-O
D05MEP	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0U0BA	TTDDRUID	D0U0BA
D0U0BA	DRUGNAME	AERAS-407 rBCG
D0U0BA	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1

D0N7GN	TTDDRUID	D0N7GN
D0N7GN	DRUGNAME	Aerucin
D0N7GN	INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1

D07HPJ	TTDDRUID	D07HPJ
D07HPJ	DRUGNAME	AEW-541
D07HPJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0L6AF	TTDDRUID	D0L6AF
D0L6AF	DRUGNAME	AEZS-112
D0L6AF	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0B0ZR	TTDDRUID	D0B0ZR
D0B0ZR	DRUGNAME	AF-05
D0B0ZR	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1

D0K4RU	TTDDRUID	D0K4RU
D0K4RU	DRUGNAME	AF-130
D0K4RU	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D07PMG	TTDDRUID	D07PMG
D07PMG	DRUGNAME	Afeletecan
D07PMG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0X2UK	TTDDRUID	D0X2UK
D0X2UK	DRUGNAME	Affitope AD-01
D0X2UK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0U8NF	TTDDRUID	D0U8NF
D0U8NF	DRUGNAME	AFM-11
D0U8NF	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0U8NF	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D00HHU	TTDDRUID	D00HHU
D00HHU	DRUGNAME	AFO-18
D00HHU	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0M1MN	TTDDRUID	D0M1MN
D0M1MN	DRUGNAME	AFP TCR
D0M1MN	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1

D03BBG	TTDDRUID	D03BBG
D03BBG	DRUGNAME	Afuresertib
D03BBG	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0K6KU	TTDDRUID	D0K6KU
D0K6KU	DRUGNAME	AFX-9901
D0K6KU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IX4B	TTDDRUID	D0IX4B
D0IX4B	DRUGNAME	AG-024322
D0IX4B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A8LP	TTDDRUID	D0A8LP
D0A8LP	DRUGNAME	AG2034
D0A8LP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C2BP	TTDDRUID	D0C2BP
D0C2BP	DRUGNAME	AG-270
D0C2BP	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0C2BP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0I7MG	TTDDRUID	D0I7MG
D0I7MG	DRUGNAME	AG-707
D0I7MG	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D0K9PC	TTDDRUID	D0K9PC
D0K9PC	DRUGNAME	AG-881
D0K9PC	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0K9PC	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1

D0C5NP	TTDDRUID	D0C5NP
D0C5NP	DRUGNAME	AGG-523
D0C5NP	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1

D0LC1J	TTDDRUID	D0LC1J
D0LC1J	DRUGNAME	Aglatimagene besadenovec
D0LC1J	INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
D0LC1J	INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
D0LC1J	INDICATI	Malignant pleural effusion [ICD-11: 2D72] Phase 1
D0LC1J	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D0LC1J	INDICATI	Pediatric glioma [ICD-11: 2A00.0] Phase 2
D0LC1J	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D03BLG	TTDDRUID	D03BLG
D03BLG	DRUGNAME	AGS-009
D03BLG	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0X7MY	TTDDRUID	D0X7MY
D0X7MY	DRUGNAME	AGS-16 mab,
D0X7MY	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D00MCN	TTDDRUID	D00MCN
D00MCN	DRUGNAME	AGS-16M8F
D00MCN	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D0E5BK	TTDDRUID	D0E5BK
D0E5BK	DRUGNAME	AGS-16M8FIAGS-16C3F
D0E5BK	INDICATI	Kidney cancer [ICD-11: 2C90.0] Phase 1

D07ZZS	TTDDRUID	D07ZZS
D07ZZS	DRUGNAME	AGS-22ME
D07ZZS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08WHX	TTDDRUID	D08WHX
D08WHX	DRUGNAME	AGS-348
D08WHX	INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 1

D0H3ND	TTDDRUID	D0H3ND
D0H3ND	DRUGNAME	AGS62P1
D0H3ND	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D04MBK	TTDDRUID	D04MBK
D04MBK	DRUGNAME	AGS-67E
D04MBK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D04MBK	INDICATI	Malignant lymphatic [ICD-11: 2A82] Phase 1
D04MBK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02UPI	TTDDRUID	D02UPI
D02UPI	DRUGNAME	AGS-6MF
D02UPI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01IPT	TTDDRUID	D01IPT
D01IPT	DRUGNAME	AGS-v
D01IPT	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1

D06HPP	TTDDRUID	D06HPP
D06HPP	DRUGNAME	AGT-182
D06HPP	INDICATI	Hunter syndrome [ICD-11: 5C56.31] Investigative
D06HPP	INDICATI	Hunter syndrome [ICD-11: 5C56.31] Phase 1

D0N6WX	TTDDRUID	D0N6WX
D0N6WX	DRUGNAME	AI-128
D0N6WX	INDICATI	Asthma [ICD-11: CA23] Phase 1

D03UDW	TTDDRUID	D03UDW
D03UDW	DRUGNAME	AI-850
D03UDW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D0PB	TTDDRUID	D0D0PB
D0D0PB	DRUGNAME	AIC-292
D0D0PB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D00HBR	TTDDRUID	D00HBR
D00HBR	DRUGNAME	AIKO-150
D00HBR	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1

D06MWK	TTDDRUID	D06MWK
D06MWK	DRUGNAME	Aimpila
D06MWK	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0VO7R	TTDDRUID	D0VO7R
D0VO7R	DRUGNAME	AjvW2
D0VO7R	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D01HQU	TTDDRUID	D01HQU
D01HQU	DRUGNAME	AK107
D01HQU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08OHK	TTDDRUID	D08OHK
D08OHK	DRUGNAME	AKP-501
D08OHK	INDICATI	Female infertility [ICD-11: GA31.Z] Phase 1

D05KNG	TTDDRUID	D05KNG
D05KNG	DRUGNAME	ALB-109564(a)
D05KNG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C9TH	TTDDRUID	D0C9TH
D0C9TH	DRUGNAME	ALD-451
D0C9TH	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D0JI2E	TTDDRUID	D0JI2E
D0JI2E	DRUGNAME	Aleplasinin
D0JI2E	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0SX9C	TTDDRUID	D0SX9C
D0SX9C	DRUGNAME	Alfa-interferon
D0SX9C	INDICATI	Endometriosis [ICD-11: GA10] Phase 1

D02IWY	TTDDRUID	D02IWY
D02IWY	DRUGNAME	ALKS 4230
D02IWY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F3VW	TTDDRUID	D0F3VW
D0F3VW	DRUGNAME	Allergy immunotherapeutic vaccine
D0F3VW	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D03LFA	TTDDRUID	D03LFA
D03LFA	DRUGNAME	Allogeneic CART-19
D03LFA	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0ZL3U	TTDDRUID	D0ZL3U
D0ZL3U	DRUGNAME	Allogeneic CART-33
D0ZL3U	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1

D08ZCI	TTDDRUID	D08ZCI
D08ZCI	DRUGNAME	ALN-AT3SC
D08ZCI	INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 1
D08ZCI	INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1

D08IUV	TTDDRUID	D08IUV
D08IUV	DRUGNAME	ALN-TTR01
D08IUV	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1

D08JMI	TTDDRUID	D08JMI
D08JMI	DRUGNAME	ALN-VSP
D08JMI	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1

D0P4MN	TTDDRUID	D0P4MN
D0P4MN	DRUGNAME	ALO 212
D0P4MN	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 1

D07DIX	TTDDRUID	D07DIX
D07DIX	DRUGNAME	ALO-1567
D07DIX	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1

D0U5HG	TTDDRUID	D0U5HG
D0U5HG	DRUGNAME	Alpha-2c adrenergic receptor antagonist
D0U5HG	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1

D0U5BF	TTDDRUID	D0U5BF
D0U5BF	DRUGNAME	ALPHA-FMH
D0U5BF	INDICATI	Pruritus [ICD-11: EC90] Phase 1

D07UKT	TTDDRUID	D07UKT
D07UKT	DRUGNAME	ALRN-6924
D07UKT	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D07UKT	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
D07UKT	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D07UKT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FA6S	TTDDRUID	D0FA6S
D0FA6S	DRUGNAME	Altiratinib
D0FA6S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0FA6S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03LRU	TTDDRUID	D03LRU
D03LRU	DRUGNAME	Alvespimycin hydrochloride
D03LRU	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D03LRU	INDICATI	Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1

D0MG2R	TTDDRUID	D0MG2R
D0MG2R	DRUGNAME	ALX-0141
D0MG2R	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0S7UH	TTDDRUID	D0S7UH
D0S7UH	DRUGNAME	ALX-0171
D0S7UH	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D09MPD	TTDDRUID	D09MPD
D09MPD	DRUGNAME	ALX-0651
D09MPD	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0B5UH	TTDDRUID	D0B5UH
D0B5UH	DRUGNAME	ALX-0761
D0B5UH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0J7UL	TTDDRUID	D0J7UL
D0J7UL	DRUGNAME	ALX148
D0J7UL	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0J7UL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05WWJ	TTDDRUID	D05WWJ
D05WWJ	DRUGNAME	ALX-5407
D05WWJ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D03MYX	TTDDRUID	D03MYX
D03MYX	DRUGNAME	AM0010
D03MYX	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D03MYX	INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 3
D03MYX	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
D03MYX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U1HN	TTDDRUID	D0U1HN
D0U1HN	DRUGNAME	AM-211
D0U1HN	INDICATI	Asthma [ICD-11: CA23] Phase 1

D06ESU	TTDDRUID	D06ESU
D06ESU	DRUGNAME	AM-461
D06ESU	INDICATI	Respiratory disease [ICD-11: CB40] Phase 1

D0G7BR	TTDDRUID	D0G7BR
D0G7BR	DRUGNAME	AMAP-102
D0G7BR	INDICATI	Arthritis [ICD-11: FA20] Phase 1

D0S2MG	TTDDRUID	D0S2MG
D0S2MG	DRUGNAME	Ambrisentan + tadalafil
D0S2MG	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1

D08XBF	TTDDRUID	D08XBF
D08XBF	DRUGNAME	AMEP
D08XBF	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D05QHB	TTDDRUID	D05QHB
D05QHB	DRUGNAME	AMG 119
D05QHB	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D02DJR	TTDDRUID	D02DJR
D02DJR	DRUGNAME	AMG 167
D02DJR	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0NC1Q	TTDDRUID	D0NC1Q
D0NC1Q	DRUGNAME	AMG 172
D0NC1Q	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D0I5DP	TTDDRUID	D0I5DP
D0I5DP	DRUGNAME	AMG 176
D0I5DP	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0I5DP	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0P9UX	TTDDRUID	D0P9UX
D0P9UX	DRUGNAME	AMG 211
D0P9UX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01EXG	TTDDRUID	D01EXG
D01EXG	DRUGNAME	AMG 224
D01EXG	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D07GDR	TTDDRUID	D07GDR
D07GDR	DRUGNAME	AMG 282
D07GDR	INDICATI	Asthma [ICD-11: CA23] Phase 1

D03FOP	TTDDRUID	D03FOP
D03FOP	DRUGNAME	AMG 319
D03FOP	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
D03FOP	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1

D0V1QH	TTDDRUID	D0V1QH
D0V1QH	DRUGNAME	AMG 330
D0V1QH	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0CO6D	TTDDRUID	D0CO6D
D0CO6D	DRUGNAME	AMG 333
D0CO6D	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D08OVR	TTDDRUID	D08OVR
D08OVR	DRUGNAME	AMG 357
D08OVR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0HS7N	TTDDRUID	D0HS7N
D0HS7N	DRUGNAME	AMG 420
D0HS7N	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D09ZFJ	TTDDRUID	D09ZFJ
D09ZFJ	DRUGNAME	AMG 529
D09ZFJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0Z7NZ	TTDDRUID	D0Z7NZ
D0Z7NZ	DRUGNAME	AMG 570
D0Z7NZ	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0X0PP	TTDDRUID	D0X0PP
D0X0PP	DRUGNAME	AMG 579
D0X0PP	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D07NZC	TTDDRUID	D07NZC
D07NZC	DRUGNAME	AMG 581
D07NZC	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1

D05LMC	TTDDRUID	D05LMC
D05LMC	DRUGNAME	AMG 595
D05LMC	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0U2QN	TTDDRUID	D0U2QN
D0U2QN	DRUGNAME	AMG 596
D0U2QN	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0V8NL	TTDDRUID	D0V8NL
D0V8NL	DRUGNAME	AMG 673
D0V8NL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D08BTY	TTDDRUID	D08BTY
D08BTY	DRUGNAME	AMG 701
D08BTY	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0PP1T	TTDDRUID	D0PP1T
D0PP1T	DRUGNAME	AMG 757
D0PP1T	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D08UHV	TTDDRUID	D08UHV
D08UHV	DRUGNAME	AMG 780
D08UHV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06FLP	TTDDRUID	D06FLP
D06FLP	DRUGNAME	AMG 811
D06FLP	INDICATI	Discoid lupus erythematosus [ICD-11: EB51.0] Phase 1
D06FLP	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0I8DX	TTDDRUID	D0I8DX
D0I8DX	DRUGNAME	AMG 820
D0I8DX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02MZD	TTDDRUID	D02MZD
D02MZD	DRUGNAME	AMG 876
D02MZD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0EJ3B	TTDDRUID	D0EJ3B
D0EJ3B	DRUGNAME	AMG 900
D0EJ3B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0QX9K	TTDDRUID	D0QX9K
D0QX9K	DRUGNAME	AMG 986
D0QX9K	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0VL4M	TTDDRUID	D0VL4M
D0VL4M	DRUGNAME	AMG0103
D0VL4M	INDICATI	Chronic back pain [ICD-11: ME86] Phase 1

D0G3EU	TTDDRUID	D0G3EU
D0G3EU	DRUGNAME	AMG-139
D0G3EU	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D05CFQ	TTDDRUID	D05CFQ
D05CFQ	DRUGNAME	AMG-191
D05CFQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D0V0NL	TTDDRUID	D0V0NL
D0V0NL	DRUGNAME	Aminoguanidine
D0V0NL	INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Discontinued in Phase 2
D0V0NL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0B5TM	TTDDRUID	D0B5TM
D0B5TM	DRUGNAME	AMP-110
D0B5TM	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D00JMY	TTDDRUID	D00JMY
D00JMY	DRUGNAME	AMP-224
D00JMY	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D00JMY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07FEJ	TTDDRUID	D07FEJ
D07FEJ	DRUGNAME	Amphotericin B inhalation powder
D07FEJ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1

D0LP7U	TTDDRUID	D0LP7U
D0LP7U	DRUGNAME	AMV564
D0LP7U	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D09DUQ	TTDDRUID	D09DUQ
D09DUQ	DRUGNAME	AN-2718
D09DUQ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1

D0G4JC	TTDDRUID	D0G4JC
D0G4JC	DRUGNAME	ANB-019
D0G4JC	INDICATI	Palmoplantar pustulosis [ICD-11: EA90.42] Phase 1
D0G4JC	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D0Z6SP	TTDDRUID	D0Z6SP
D0Z6SP	DRUGNAME	Andecaliximab
D0Z6SP	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D0Z6SP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01FYX	TTDDRUID	D01FYX
D01FYX	DRUGNAME	Andes-1537
D01FYX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03UMN	TTDDRUID	D03UMN
D03UMN	DRUGNAME	Anetumab ravantansine
D03UMN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CN9D	TTDDRUID	D0CN9D
D0CN9D	DRUGNAME	Anetumab ravtansine
D0CN9D	INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 2
D0CN9D	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
D0CN9D	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0CN9D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09VAD	TTDDRUID	D09VAD
D09VAD	DRUGNAME	Angiopoietin 2 mAb
D09VAD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04VZD	TTDDRUID	D04VZD
D04VZD	DRUGNAME	Angiotensin inhibitor therapeutic vaccine
D04VZD	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0PS4C	TTDDRUID	D0PS4C
D0PS4C	DRUGNAME	ANGX-1039
D0PS4C	INDICATI	Intermittent claudication [ICD-11: BD40.00] Phase 1

D0FU8R	TTDDRUID	D0FU8R
D0FU8R	DRUGNAME	Anifrolumab
D0FU8R	INDICATI	Lupus [ICD-11: 4A40] Phase 2
D0FU8R	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3

D09PSY	TTDDRUID	D09PSY
D09PSY	DRUGNAME	ANS-6637
D09PSY	INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1

D00FGW	TTDDRUID	D00FGW
D00FGW	DRUGNAME	Anthrax transdermal vaccine
D00FGW	INDICATI	Anthrax [ICD-11: 1B97] Phase 1

D0W7AB	TTDDRUID	D0W7AB
D0W7AB	DRUGNAME	Anti-BCMA CAR T cells
D0W7AB	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0O7XA	TTDDRUID	D0O7XA
D0O7XA	DRUGNAME	Anti-BCMA CAR-T cell therapy
D0O7XA	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0RA7L	TTDDRUID	D0RA7L
D0RA7L	DRUGNAME	Anti-BCMA CART Cells
D0RA7L	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D07HJS	TTDDRUID	D07HJS
D07HJS	DRUGNAME	Anti-BCMA CAR-T cells
D07HJS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0F0VW	TTDDRUID	D0F0VW
D0F0VW	DRUGNAME	Anti-BCMA CAR-T cells
D0F0VW	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0F0VW	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D02SAC	TTDDRUID	D02SAC
D02SAC	DRUGNAME	Anti-CD123 CAR-T cells
D02SAC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D02SAC	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D09HRH	TTDDRUID	D09HRH
D09HRH	DRUGNAME	Anti-CD133-CAR vector-transduced T cells
D09HRH	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
D09HRH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D09HRH	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
D09HRH	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D09HRH	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0O4YE	TTDDRUID	D0O4YE
D0O4YE	DRUGNAME	Anti-CD19
D0O4YE	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0NW8L	TTDDRUID	D0NW8L
D0NW8L	DRUGNAME	Anti-CD19 "armored" CAR-Tcell therapy
D0NW8L	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D07TCV	TTDDRUID	D07TCV
D07TCV	DRUGNAME	Anti-CD19 anti-CD20 Bispecific CAR-T
D07TCV	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D07TCV	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0EO6G	TTDDRUID	D0EO6G
D0EO6G	DRUGNAME	Anti-CD19- CAR
D0EO6G	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0EO6G	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0EO6G	INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1
D0EO6G	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0EO6G	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0O7VZ	TTDDRUID	D0O7VZ
D0O7VZ	DRUGNAME	AntiCD19 CART
D0O7VZ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0TD0O	TTDDRUID	D0TD0O
D0TD0O	DRUGNAME	Anti-CD19 CAR-T
D0TD0O	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0TD0O	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1
D0TD0O	INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1

D0WM7M	TTDDRUID	D0WM7M
D0WM7M	DRUGNAME	Anti-CD19 CAR-T cell therapy
D0WM7M	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0WM7M	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0WM7M	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D02NFE	TTDDRUID	D02NFE
D02NFE	DRUGNAME	Anti-CD19 CART Cells
D02NFE	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0NV6I	TTDDRUID	D0NV6I
D0NV6I	DRUGNAME	Anti-CD19 CAR-T cells
D0NV6I	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0NV6I	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0U7WY	TTDDRUID	D0U7WY
D0U7WY	DRUGNAME	Anti-CD19/BCMA CAR-T cells
D0U7WY	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D03EIA	TTDDRUID	D03EIA
D03EIA	DRUGNAME	Anti-CD19-CAR T
D03EIA	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D03EIA	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D06UTM	TTDDRUID	D06UTM
D06UTM	DRUGNAME	Anti-CD19-CAR T cells
D06UTM	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D06UTM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D01HGT	TTDDRUID	D01HGT
D01HGT	DRUGNAME	Anti-CD22
D01HGT	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0GJ2G	TTDDRUID	D0GJ2G
D0GJ2G	DRUGNAME	Anti-CD22 CAR-T cells
D0GJ2G	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0GJ2G	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0P3WH	TTDDRUID	D0P3WH
D0P3WH	DRUGNAME	Anti-CD27 agonist
D0P3WH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H2LC	TTDDRUID	D0H2LC
D0H2LC	DRUGNAME	Anti-CD30 CAR-T cells
D0H2LC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0H2LC	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0TC6X	TTDDRUID	D0TC6X
D0TC6X	DRUGNAME	Anti-CD30-CAR T cells
D0TC6X	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
D0TC6X	INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1
D0TC6X	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D00DIB	TTDDRUID	D00DIB
D00DIB	DRUGNAME	Anti-CD33
D00DIB	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0Y7LV	TTDDRUID	D0Y7LV
D0Y7LV	DRUGNAME	Anti-CD38 CAR-T cell therapy
D0Y7LV	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D05WET	TTDDRUID	D05WET
D05WET	DRUGNAME	Anti-CD38 CAR-T cells
D05WET	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0I0ZO	TTDDRUID	D0I0ZO
D0I0ZO	DRUGNAME	Anti-CD45 mabs
D0I0ZO	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D09SBE	TTDDRUID	D09SBE
D09SBE	DRUGNAME	Anti-CD7 CAR-T cells
D09SBE	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D09SBE	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0D0WH	TTDDRUID	D0D0WH
D0D0WH	DRUGNAME	Anti-CD73 mAb
D0D0WH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00KDQ	TTDDRUID	D00KDQ
D00KDQ	DRUGNAME	Anti-CEA CAR-T cells
D00KDQ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D00KDQ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D00KDQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D00KDQ	INDICATI	Peritoneal metastasis [ICD-11: 2D91] Phase 1

D08UVN	TTDDRUID	D08UVN
D08UVN	DRUGNAME	Anti-CEA CAR-T cells
D08UVN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0OP1L	TTDDRUID	D0OP1L
D0OP1L	DRUGNAME	Anti-CEA CAR-T therapy
D0OP1L	INDICATI	Liver metastasis [ICD-11: 2D80] Phase 1
D0OP1L	INDICATI	Metastatic liver cancer [ICD-11: 2C12] Phase 1

D0IS5Z	TTDDRUID	D0IS5Z
D0IS5Z	DRUGNAME	Anti-CEA designer T cell therapy
D0IS5Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S1QN	TTDDRUID	D0S1QN
D0S1QN	DRUGNAME	Anti-CEA-CAR T
D0S1QN	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0S1QN	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0S1QN	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
D0S1QN	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D08QTK	TTDDRUID	D08QTK
D08QTK	DRUGNAME	Anti-EGFL7
D08QTK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0T0SE	TTDDRUID	D0T0SE
D0T0SE	DRUGNAME	Anti-EGFR CAR T
D0T0SE	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1

D09OSC	TTDDRUID	D09OSC
D09OSC	DRUGNAME	Anti-EGFRvIII CAR T cells
D09OSC	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0V0BO	TTDDRUID	D0V0BO
D0V0BO	DRUGNAME	Anti-FGFR3
D0V0BO	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D04UNY	TTDDRUID	D04UNY
D04UNY	DRUGNAME	Anti-GD2 T-cells (1RG-CART)
D04UNY	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1

D09DND	TTDDRUID	D09DND
D09DND	DRUGNAME	Anti-GD2-CAR engineered T cells
D09DND	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
D09DND	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1
D09DND	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1

D0ZW6X	TTDDRUID	D0ZW6X
D0ZW6X	DRUGNAME	Anti-GITR antibody
D0ZW6X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IQ4V	TTDDRUID	D0IQ4V
D0IQ4V	DRUGNAME	Anti-GPC3 CAR T
D0IQ4V	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1

D0JO9M	TTDDRUID	D0JO9M
D0JO9M	DRUGNAME	Anti-hCD70 CAR transduced PBL
D0JO9M	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0JO9M	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0JO9M	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D0JW2O	TTDDRUID	D0JW2O
D0JW2O	DRUGNAME	Anti-HER3/EGFR DAF
D0JW2O	INDICATI	Metastatic epithelial tumour [ICD-11: 2D60] Phase 1

D03FGI	TTDDRUID	D03FGI
D03FGI	DRUGNAME	Anti-LAG3 mAb
D03FGI	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0CA3M	TTDDRUID	D0CA3M
D0CA3M	DRUGNAME	Anti-meso-CAR T cells
D0CA3M	INDICATI	Mesothelin Positive tumour [ICD-11: 2C51-2F10] Phase 1

D0G4GY	TTDDRUID	D0G4GY
D0G4GY	DRUGNAME	Anti-meso-CAR vector transduced T cells
D0G4GY	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1
D0G4GY	INDICATI	Malignant mesothelioma [ICD-11: 2C26.0] Phase 1
D0G4GY	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0G4GY	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0G4GY	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1

D0PT5D	TTDDRUID	D0PT5D
D0PT5D	DRUGNAME	Anti-mesothelin CAR T Cells
D0PT5D	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D03OIO	TTDDRUID	D03OIO
D03OIO	DRUGNAME	Anti-Mesothelin CAR-T cells
D03OIO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S3AE	TTDDRUID	D0S3AE
D0S3AE	DRUGNAME	Anti-MUC1 AR20.5 mab
D0S3AE	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0H2CF	TTDDRUID	D0H2CF
D0H2CF	DRUGNAME	Anti-MUC1 mab
D0H2CF	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D05ORO	TTDDRUID	D05ORO
D05ORO	DRUGNAME	Anti-N3pG-Abeta antibody
D05ORO	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0YG4P	TTDDRUID	D0YG4P
D0YG4P	DRUGNAME	Anti-OX40 mab
D0YG4P	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0KP9A	TTDDRUID	D0KP9A
D0KP9A	DRUGNAME	Anti-PD-L1
D0KP9A	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
D0KP9A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W7UD	TTDDRUID	D0W7UD
D0W7UD	DRUGNAME	Anti-PD-L1 CSR T cells
D0W7UD	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0I6NH	TTDDRUID	D0I6NH
D0I6NH	DRUGNAME	Anti-PD-L1 mAb
D0I6NH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00KHI	TTDDRUID	D00KHI
D00KHI	DRUGNAME	Anti-PSMA CAR-T cell therapy
D00KHI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0OC5T	TTDDRUID	D0OC5T
D0OC5T	DRUGNAME	ANX005
D0OC5T	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1

D0SZ5G	TTDDRUID	D0SZ5G
D0SZ5G	DRUGNAME	ANX-042
D0SZ5G	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 1

D0X7BN	TTDDRUID	D0X7BN
D0X7BN	DRUGNAME	AP32788
D0X7BN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0RL4X	TTDDRUID	D0RL4X
D0RL4X	DRUGNAME	AP-761
D0RL4X	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0O9XN	TTDDRUID	D0O9XN
D0O9XN	DRUGNAME	APD-597
D0O9XN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0N1GB	TTDDRUID	D0N1GB
D0N1GB	DRUGNAME	APD-916
D0N1GB	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 1

D04SXL	TTDDRUID	D04SXL
D04SXL	DRUGNAME	APG-115
D04SXL	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D04SXL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0QQ9L	TTDDRUID	D0QQ9L
D0QQ9L	DRUGNAME	APG-1252
D0QQ9L	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0QQ9L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0NP8P	TTDDRUID	D0NP8P
D0NP8P	DRUGNAME	APG-1387
D0NP8P	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0NP8P	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
D0NP8P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Z9NY	TTDDRUID	D0Z9NY
D0Z9NY	DRUGNAME	API-023
D0Z9NY	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1

D0Y2UE	TTDDRUID	D0Y2UE
D0Y2UE	DRUGNAME	APL-2 subcutaneous
D0Y2UE	INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 1

D03UUL	TTDDRUID	D03UUL
D03UUL	DRUGNAME	APN01
D03UUL	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
D03UUL	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1

D0Q6SF	TTDDRUID	D0Q6SF
D0Q6SF	DRUGNAME	APO-010
D0Q6SF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D03XTY	TTDDRUID	D03XTY
D03XTY	DRUGNAME	APR-246
D03XTY	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1
D03XTY	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D03XTY	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D03XTY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D07TRP	TTDDRUID	D07TRP
D07TRP	DRUGNAME	APTO-253
D07TRP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03JTL	TTDDRUID	D03JTL
D03JTL	DRUGNAME	APVO414
D03JTL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D01ZLK	TTDDRUID	D01ZLK
D01ZLK	DRUGNAME	APX005M
D01ZLK	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
D01ZLK	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D01ZLK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U8XW	TTDDRUID	D0U8XW
D0U8XW	DRUGNAME	APX-3330
D0U8XW	INDICATI	Ocular cancer [ICD-11: 2D00-2D07] Discontinued in Phase 2
D0U8XW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09BEJ	TTDDRUID	D09BEJ
D09BEJ	DRUGNAME	AQST-305
D09BEJ	INDICATI	Malignant carcinoid syndrome [ICD-11: 5B10] Phase 1

D0C9JJ	TTDDRUID	D0C9JJ
D0C9JJ	DRUGNAME	AR-12
D0C9JJ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0T0NL	TTDDRUID	D0T0NL
D0T0NL	DRUGNAME	ARC031
D0T0NL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D08FMR	TTDDRUID	D08FMR
D08FMR	DRUGNAME	ARC-1905
D08FMR	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D08IAQ	TTDDRUID	D08IAQ
D08IAQ	DRUGNAME	ARC-AAT
D08IAQ	INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 1

D0E6RX	TTDDRUID	D0E6RX
D0E6RX	DRUGNAME	ARD-1600
D0E6RX	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 1
D0E6RX	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 1

D07EFM	TTDDRUID	D07EFM
D07EFM	DRUGNAME	Arecoline
D07EFM	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D09PJB	TTDDRUID	D09PJB
D09PJB	DRUGNAME	ARG301
D09PJB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D07SPG	TTDDRUID	D07SPG
D07SPG	DRUGNAME	ARGX-110
D07SPG	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0SD9R	TTDDRUID	D0SD9R
D0SD9R	DRUGNAME	ARI-0001 cells
D0SD9R	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0SD9R	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0Z1OS	TTDDRUID	D0Z1OS
D0Z1OS	DRUGNAME	ARI-2243
D0Z1OS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0KE4Z	TTDDRUID	D0KE4Z
D0KE4Z	DRUGNAME	ARL-67085
D0KE4Z	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0U1OO	TTDDRUID	D0U1OO
D0U1OO	DRUGNAME	ARM210
D0U1OO	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D07LOF	TTDDRUID	D07LOF
D07LOF	DRUGNAME	ARN-6039
D07LOF	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
D07LOF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0A0ZW	TTDDRUID	D0A0ZW
D0A0ZW	DRUGNAME	ARN-6039
D0A0ZW	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D07DWF	TTDDRUID	D07DWF
D07DWF	DRUGNAME	ARQ 092
D07DWF	INDICATI	Proteus syndrome [ICD-11: LD2C] Phase 1
D07DWF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0KQ7M	TTDDRUID	D0KQ7M
D0KQ7M	DRUGNAME	ARQ 531
D0KQ7M	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D07BKR	TTDDRUID	D07BKR
D07BKR	DRUGNAME	ARQ 621
D07BKR	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D04AZM	TTDDRUID	D04AZM
D04AZM	DRUGNAME	ARQ 736
D04AZM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L8PZ	TTDDRUID	D0L8PZ
D0L8PZ	DRUGNAME	ARQ 751
D0L8PZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00SIA	TTDDRUID	D00SIA
D00SIA	DRUGNAME	ARQ-171
D00SIA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05NLD	TTDDRUID	D05NLD
D05NLD	DRUGNAME	ARRY-300
D05NLD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M8AI	TTDDRUID	D0M8AI
D0M8AI	DRUGNAME	ARRY-380
D0M8AI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F7ZR	TTDDRUID	D0F7ZR
D0F7ZR	DRUGNAME	ARX-424
D0F7ZR	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D06PTG	TTDDRUID	D06PTG
D06PTG	DRUGNAME	ARX788
D06PTG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D06PTG	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1

D0UM4S	TTDDRUID	D0UM4S
D0UM4S	DRUGNAME	ASG-15ME
D0UM4S	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
D0UM4S	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1

D0R1CG	TTDDRUID	D0R1CG
D0R1CG	DRUGNAME	ASG-22ME
D0R1CG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0BC6M	TTDDRUID	D0BC6M
D0BC6M	DRUGNAME	ASG-5ME
D0BC6M	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0BC6M	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0XL8W	TTDDRUID	D0XL8W
D0XL8W	DRUGNAME	ASN003
D0XL8W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D2XQ	TTDDRUID	D0D2XQ
D0D2XQ	DRUGNAME	ASN007
D0D2XQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L1UH	TTDDRUID	D0L1UH
D0L1UH	DRUGNAME	ASP-0777
D0L1UH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0FO6Z	TTDDRUID	D0FO6Z
D0FO6Z	DRUGNAME	ASP-0892
D0FO6Z	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D04OQU	TTDDRUID	D04OQU
D04OQU	DRUGNAME	ASP2408
D04OQU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0F7FM	TTDDRUID	D0F7FM
D0F7FM	DRUGNAME	ASP2409
D0F7FM	INDICATI	Organ transplant rejection [ICD-11: NE84] Phase 1

D09GEK	TTDDRUID	D09GEK
D09GEK	DRUGNAME	ASP3026
D09GEK	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1

D00UEC	TTDDRUID	D00UEC
D00UEC	DRUGNAME	ASP3662
D00UEC	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0Q0JI	TTDDRUID	D0Q0JI
D0Q0JI	DRUGNAME	ASP-4058
D0Q0JI	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D01ERE	TTDDRUID	D01ERE
D01ERE	DRUGNAME	ASP4345
D01ERE	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D03ACE	TTDDRUID	D03ACE
D03ACE	DRUGNAME	ASP5094
D03ACE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0Z2WV	TTDDRUID	D0Z2WV
D0Z2WV	DRUGNAME	ASP6981
D0Z2WV	INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
D0Z2WV	INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1

D0U9OC	TTDDRUID	D0U9OC
D0U9OC	DRUGNAME	ASP8374
D0U9OC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C1TR	TTDDRUID	D0C1TR
D0C1TR	DRUGNAME	ASP9853
D0C1TR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02PTI	TTDDRUID	D02PTI
D02PTI	DRUGNAME	AST-005
D02PTI	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D05ZLY	TTDDRUID	D05ZLY
D05ZLY	DRUGNAME	AST-008
D05ZLY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04OLK	TTDDRUID	D04OLK
D04OLK	DRUGNAME	AST-1306
D04OLK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X1QM	TTDDRUID	D0X1QM
D0X1QM	DRUGNAME	AT-001
D0X1QM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0NO1A	TTDDRUID	D0NO1A
D0NO1A	DRUGNAME	AT001/r84
D0NO1A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09IYM	TTDDRUID	D09IYM
D09IYM	DRUGNAME	AT13148
D09IYM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06YSP	TTDDRUID	D06YSP
D06YSP	DRUGNAME	AT13387
D06YSP	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0ID9W	TTDDRUID	D0ID9W
D0ID9W	DRUGNAME	ATA188
D0ID9W	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0Q1RZ	TTDDRUID	D0Q1RZ
D0Q1RZ	DRUGNAME	ATA190
D0Q1RZ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D05MVX	TTDDRUID	D05MVX
D05MVX	DRUGNAME	ATA520
D05MVX	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D05MVX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D09BQO	TTDDRUID	D09BQO
D09BQO	DRUGNAME	ATD transdermal gel
D09BQO	INDICATI	Contraception [ICD-11: QA21] Phase 1

D0S0OI	TTDDRUID	D0S0OI
D0S0OI	DRUGNAME	ATEVIRDINE
D0S0OI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0YM2K	TTDDRUID	D0YM2K
D0YM2K	DRUGNAME	Atezolizumab
D0YM2K	INDICATI	Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 0
D0YM2K	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0YM2K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0YM2K	INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 0

D04CJE	TTDDRUID	D04CJE
D04CJE	DRUGNAME	ATF-936
D04CJE	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0N2GQ	TTDDRUID	D0N2GQ
D0N2GQ	DRUGNAME	ATI-0917
D0N2GQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0M8XX	TTDDRUID	D0M8XX
D0M8XX	DRUGNAME	ATI-1123
D0M8XX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M0WM	TTDDRUID	D0M0WM
D0M0WM	DRUGNAME	ATI-355
D0M0WM	INDICATI	Nerve injury [ICD-11: ND56.4] Phase 1

D06NOF	TTDDRUID	D06NOF
D06NOF	DRUGNAME	ATI-9242
D06NOF	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
D06NOF	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0W3BC	TTDDRUID	D0W3BC
D0W3BC	DRUGNAME	ATL1103
D0W3BC	INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 1

D0GA8I	TTDDRUID	D0GA8I
D0GA8I	DRUGNAME	ATLCAR.CD30 cells
D0GA8I	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
D0GA8I	INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1
D0GA8I	INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1
D0GA8I	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0GA8I	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1

D0U5AQ	TTDDRUID	D0U5AQ
D0U5AQ	DRUGNAME	ATLCAR.CD30.CCR4 cells
D0U5AQ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
D0U5AQ	INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1
D0U5AQ	INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1
D0U5AQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0U5AQ	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1

D0D9AL	TTDDRUID	D0D9AL
D0D9AL	DRUGNAME	ATON-005
D0D9AL	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1

D0CM3Z	TTDDRUID	D0CM3Z
D0CM3Z	DRUGNAME	ATON-009
D0CM3Z	INDICATI	Metal intoxication [ICD-11: NE60] Phase 1

D0LM4U	TTDDRUID	D0LM4U
D0LM4U	DRUGNAME	ATR-01
D0LM4U	INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1

D0MB2Z	TTDDRUID	D0MB2Z
D0MB2Z	DRUGNAME	ATR-101
D0MB2Z	INDICATI	Malignant adrenal gland cancer [ICD-11: 2D11] Phase 1

D0M4MH	TTDDRUID	D0M4MH
D0M4MH	DRUGNAME	ATR-107
D0M4MH	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D09TGT	TTDDRUID	D09TGT
D09TGT	DRUGNAME	Atu-027
D09TGT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W1GP	TTDDRUID	D0W1GP
D0W1GP	DRUGNAME	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
D0W1GP	INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1

D01ZJB	TTDDRUID	D01ZJB
D01ZJB	DRUGNAME	Autologous bone marrow-derived mesenchymal stem cells
D01ZJB	INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 1

D04XAB	TTDDRUID	D04XAB
D04XAB	DRUGNAME	Autologous cancer vaccine
D04XAB	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0H3GK	TTDDRUID	D0H3GK
D0H3GK	DRUGNAME	Autologous cell based gene therapy
D0H3GK	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 1

D03UKI	TTDDRUID	D03UKI
D03UKI	DRUGNAME	Autologous dendritic cell vaccines
D03UKI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0BK7D	TTDDRUID	D0BK7D
D0BK7D	DRUGNAME	Autologous dendritic cell-tumor cell fusion vaccine
D0BK7D	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1

D09TGO	TTDDRUID	D09TGO
D09TGO	DRUGNAME	Autologous ET1402L1-CART cells
D09TGO	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D09TGO	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
D09TGO	INDICATI	Metastatic liver cancer [ICD-11: 2C12] Phase 1

D03QBL	TTDDRUID	D03QBL
D03QBL	DRUGNAME	Autologous idiotypic cancer vaccin
D03QBL	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D01HOL	TTDDRUID	D01HOL
D01HOL	DRUGNAME	Autologous idiotypic cancer vaccine
D01HOL	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D07RIJ	TTDDRUID	D07RIJ
D07RIJ	DRUGNAME	Autologous melanoma cell vaccine
D07RIJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C0TV	TTDDRUID	D0C0TV
D0C0TV	DRUGNAME	Autologous stem cell-based cancer immunotherapy
D0C0TV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0EB0Y	TTDDRUID	D0EB0Y
D0EB0Y	DRUGNAME	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
D0EB0Y	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D04UWG	TTDDRUID	D04UWG
D04UWG	DRUGNAME	Autologous T-cell therapy
D04UWG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0T0FT	TTDDRUID	D0T0FT
D0T0FT	DRUGNAME	AutoSynVax
D0T0FT	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D0T0FT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y5ED	TTDDRUID	D0Y5ED
D0Y5ED	DRUGNAME	AV-203
D0Y5ED	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D0KZ	TTDDRUID	D0D0KZ
D0D0KZ	DRUGNAME	AV4025
D0D0KZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0EH0C	TTDDRUID	D0EH0C
D0EH0C	DRUGNAME	AV-965
D0EH0C	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0Y5QA	TTDDRUID	D0Y5QA
D0Y5QA	DRUGNAME	AVB-S6-500
D0Y5QA	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0Y5QA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07LWK	TTDDRUID	D07LWK
D07LWK	DRUGNAME	AVE0118
D07LWK	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Phase 1

D01UJK	TTDDRUID	D01UJK
D01UJK	DRUGNAME	AVE0897
D01UJK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0Q2BB	TTDDRUID	D0Q2BB
D0Q2BB	DRUGNAME	AVE1701
D0Q2BB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D01WZL	TTDDRUID	D01WZL
D01WZL	DRUGNAME	AVE-8112
D01WZL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D07QXM	TTDDRUID	D07QXM
D07QXM	DRUGNAME	AVI-4020
D07QXM	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1

D04LIH	TTDDRUID	D04LIH
D04LIH	DRUGNAME	AVI-6002
D04LIH	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0CB6N	TTDDRUID	D0CB6N
D0CB6N	DRUGNAME	AVI-6003
D0CB6N	INDICATI	Marburg virus infection [ICD-11: 1D60.1] Phase 1

D07CXM	TTDDRUID	D07CXM
D07CXM	DRUGNAME	AVI-7288
D07CXM	INDICATI	Marburg virus infection [ICD-11: 1D60.1] Phase 1

D09ELC	TTDDRUID	D09ELC
D09ELC	DRUGNAME	AVI-7537
D09ELC	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0B9NU	TTDDRUID	D0B9NU
D0B9NU	DRUGNAME	Avian H5N1 influenza vaccine
D0B9NU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D08JGM	TTDDRUID	D08JGM
D08JGM	DRUGNAME	AVID100 IV
D08JGM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0HZ4C	TTDDRUID	D0HZ4C
D0HZ4C	DRUGNAME	AvidinOx
D0HZ4C	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0HZ4C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H7YU	TTDDRUID	D0H7YU
D0H7YU	DRUGNAME	AviFlu
D0H7YU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0O3OI	TTDDRUID	D0O3OI
D0O3OI	DRUGNAME	AVL-3288
D0O3OI	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
D0O3OI	INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
D0O3OI	INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1

D0L8IO	TTDDRUID	D0L8IO
D0L8IO	DRUGNAME	AVN 322
D0L8IO	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0L8IO	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2

D0P9YP	TTDDRUID	D0P9YP
D0P9YP	DRUGNAME	AVP-13358
D0P9YP	INDICATI	Rhinitis [ICD-11: FA20] Phase 1

D0L8OP	TTDDRUID	D0L8OP
D0L8OP	DRUGNAME	AVP-21D9
D0L8OP	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1

D0E2TH	TTDDRUID	D0E2TH
D0E2TH	DRUGNAME	AVX101
D0E2TH	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 1

D03HIG	TTDDRUID	D03HIG
D03HIG	DRUGNAME	AVX-470
D03HIG	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
D03HIG	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D06JLG	TTDDRUID	D06JLG
D06JLG	DRUGNAME	AVX-601
D06JLG	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1

D04DMZ	TTDDRUID	D04DMZ
D04DMZ	DRUGNAME	AVXS-101
D04DMZ	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 1
D04DMZ	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 3

D00JDJ	TTDDRUID	D00JDJ
D00JDJ	DRUGNAME	AX-024
D00JDJ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0V5FQ	TTDDRUID	D0V5FQ
D0V5FQ	DRUGNAME	Axitirome
D0V5FQ	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D0VJ9X	TTDDRUID	D0VJ9X
D0VJ9X	DRUGNAME	AXS-06
D0VJ9X	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
D0VJ9X	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
D0VJ9X	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0S7VI	TTDDRUID	D0S7VI
D0S7VI	DRUGNAME	AXT-914
D0S7VI	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0XD4I	TTDDRUID	D0XD4I
D0XD4I	DRUGNAME	AZD0156
D0XD4I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00BLS	TTDDRUID	D00BLS
D00BLS	DRUGNAME	AZD0284
D00BLS	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1

D0Q7RE	TTDDRUID	D0Q7RE
D0Q7RE	DRUGNAME	AZD-1152-HQPA
D0Q7RE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00IFR	TTDDRUID	D00IFR
D00IFR	DRUGNAME	AZD1208
D00IFR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L6XO	TTDDRUID	D0L6XO
D0L6XO	DRUGNAME	AZD1390
D0L6XO	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D02AWQ	TTDDRUID	D02AWQ
D02AWQ	DRUGNAME	AZD1419
D02AWQ	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0A3CL	TTDDRUID	D0A3CL
D0A3CL	DRUGNAME	AZD1979
D0A3CL	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0M0UB	TTDDRUID	D0M0UB
D0M0UB	DRUGNAME	AZD2184
D0M0UB	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D07OIO	TTDDRUID	D07OIO
D07OIO	DRUGNAME	AZD-2461
D07OIO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E4GE	TTDDRUID	D0E4GE
D0E4GE	DRUGNAME	AZD-2551
D0E4GE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D06JPY	TTDDRUID	D06JPY
D06JPY	DRUGNAME	AZD2995
D06JPY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D06SUS	TTDDRUID	D06SUS
D06SUS	DRUGNAME	AZD-3043
D06SUS	INDICATI	Anaesthesia [ICD-11: 9A78.6] Phase 1

D0P5CM	TTDDRUID	D0P5CM
D0P5CM	DRUGNAME	AZD-3161
D0P5CM	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1

D08AAV	TTDDRUID	D08AAV
D08AAV	DRUGNAME	AZD-3514
D08AAV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D04OSA	TTDDRUID	D04OSA
D04OSA	DRUGNAME	AZD-3839
D04OSA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0M8HV	TTDDRUID	D0M8HV
D0M8HV	DRUGNAME	AZD-4451
D0M8HV	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1

D07KBM	TTDDRUID	D07KBM
D07KBM	DRUGNAME	AZD4573
D07KBM	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0J4XV	TTDDRUID	D0J4XV
D0J4XV	DRUGNAME	AZD4635
D0J4XV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q0RK	TTDDRUID	D0Q0RK
D0Q0RK	DRUGNAME	AZD4721
D0Q0RK	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0DT5H	TTDDRUID	D0DT5H
D0DT5H	DRUGNAME	AZD4785
D0DT5H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07SBP	TTDDRUID	D07SBP
D07SBP	DRUGNAME	AZD4831
D07SBP	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0N3QF	TTDDRUID	D0N3QF
D0N3QF	DRUGNAME	AZD-5122
D0N3QF	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0PH9I	TTDDRUID	D0PH9I
D0PH9I	DRUGNAME	AZD5153
D0PH9I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06WHY	TTDDRUID	D06WHY
D06WHY	DRUGNAME	AZD-5438
D06WHY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O9OC	TTDDRUID	D0O9OC
D0O9OC	DRUGNAME	AZD5658
D0O9OC	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D0O9OC	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D06XCP	TTDDRUID	D06XCP
D06XCP	DRUGNAME	AZD5991
D06XCP	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0FP0D	TTDDRUID	D0FP0D
D0FP0D	DRUGNAME	AZD-6088
D0FP0D	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D06YUM	TTDDRUID	D06YUM
D06YUM	DRUGNAME	AZD6423
D06YUM	INDICATI	Suicidal ideation [ICD-11: MB26.A] Phase 1

D0H9DA	TTDDRUID	D0H9DA
D0H9DA	DRUGNAME	AZD6738
D0H9DA	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0H9DA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N9TY	TTDDRUID	D0N9TY
D0N9TY	DRUGNAME	AZD-7295
D0N9TY	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0EY0A	TTDDRUID	D0EY0A
D0EY0A	DRUGNAME	AZD7687
D0EY0A	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D0EY0A	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0PM7Q	TTDDRUID	D0PM7Q
D0PM7Q	DRUGNAME	AZD7762
D0PM7Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K4FP	TTDDRUID	D0K4FP
D0K4FP	DRUGNAME	AZD-8165
D0K4FP	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D03BHZ	TTDDRUID	D03BHZ
D03BHZ	DRUGNAME	AZD8186
D03BHZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O1ZI	TTDDRUID	D0O1ZI
D0O1ZI	DRUGNAME	AZD8329
D0O1ZI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D0O1ZI	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0IV7Z	TTDDRUID	D0IV7Z
D0IV7Z	DRUGNAME	AZD-8418
D0IV7Z	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0X1OW	TTDDRUID	D0X1OW
D0X1OW	DRUGNAME	AZD9496
D0X1OW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0SZ1G	TTDDRUID	D0SZ1G
D0SZ1G	DRUGNAME	AZD9567
D0SZ1G	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D03QAO	TTDDRUID	D03QAO
D03QAO	DRUGNAME	AZD-9742
D03QAO	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 1

D0U0AU	TTDDRUID	D0U0AU
D0U0AU	DRUGNAME	AZD-9819
D0U0AU	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0X0FW	TTDDRUID	D0X0FW
D0X0FW	DRUGNAME	B1-655075
D0X0FW	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 1

D01QXY	TTDDRUID	D01QXY
D01QXY	DRUGNAME	B7-2/GM-CSF
D01QXY	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1
D01QXY	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
D01QXY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
D01QXY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O8QU	TTDDRUID	D0O8QU
D0O8QU	DRUGNAME	B7-2/GM-CSF cancer gene therapy vaccine
D0O8QU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y6CR	TTDDRUID	D0Y6CR
D0Y6CR	DRUGNAME	Bacteriophages
D0Y6CR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D07PRC	TTDDRUID	D07PRC
D07PRC	DRUGNAME	BAL-30072
D07PRC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D01FUL	TTDDRUID	D01FUL
D01FUL	DRUGNAME	Balapiravir
D01FUL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0W8HN	TTDDRUID	D0W8HN
D0W8HN	DRUGNAME	Bavencio
D0W8HN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0W8HN	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D0W8HN	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0W8HN	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
D0W8HN	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0W8HN	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
D0W8HN	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
D0W8HN	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 3

D0X4ZV	TTDDRUID	D0X4ZV
D0X4ZV	DRUGNAME	BAX-499
D0X4ZV	INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1

D0FW2B	TTDDRUID	D0FW2B
D0FW2B	DRUGNAME	BAX-930
D0FW2B	INDICATI	Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Phase 1

D0FJ0W	TTDDRUID	D0FJ0W
D0FJ0W	DRUGNAME	BAY 1026153
D0FJ0W	INDICATI	Endometriosis [ICD-11: GA10] Phase 1

D0KJ2J	TTDDRUID	D0KJ2J
D0KJ2J	DRUGNAME	BAY 1082439
D0KJ2J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03PQW	TTDDRUID	D03PQW
D03PQW	DRUGNAME	BAY 79-4620
D03PQW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U7NG	TTDDRUID	D0U7NG
D0U7NG	DRUGNAME	BAY 86-8050
D0U7NG	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0F3RQ	TTDDRUID	D0F3RQ
D0F3RQ	DRUGNAME	BAY 87-2243
D0F3RQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P5MG	TTDDRUID	D0P5MG
D0P5MG	DRUGNAME	BAY 94-9343
D0P5MG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O9HG	TTDDRUID	D0O9HG
D0O9HG	DRUGNAME	BAY-1006578
D0O9HG	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0TN7S	TTDDRUID	D0TN7S
D0TN7S	DRUGNAME	BAY-1075553
D0TN7S	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0S9IE	TTDDRUID	D0S9IE
D0S9IE	DRUGNAME	BAY1125976
D0S9IE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00ZVM	TTDDRUID	D00ZVM
D00ZVM	DRUGNAME	BAY1129980
D00ZVM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06PSU	TTDDRUID	D06PSU
D06PSU	DRUGNAME	BAY1143572
D06PSU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J6RV	TTDDRUID	D0J6RV
D0J6RV	DRUGNAME	BAY1161909
D0J6RV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E8PR	TTDDRUID	D0E8PR
D0E8PR	DRUGNAME	BAY1163877
D0E8PR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L6RF	TTDDRUID	D0L6RF
D0L6RF	DRUGNAME	BAY1179470
D0L6RF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06HMN	TTDDRUID	D06HMN
D06HMN	DRUGNAME	BAY1251152
D06HMN	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0C6RM	TTDDRUID	D0C6RM
D0C6RM	DRUGNAME	BAY1436032
D0C6RM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0C6RM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0NF1D	TTDDRUID	D0NF1D
D0NF1D	DRUGNAME	BAY-1817080a
D0NF1D	INDICATI	Endometriosis [ICD-11: GA10] Phase 1

D0QQ7I	TTDDRUID	D0QQ7I
D0QQ7I	DRUGNAME	BAY1834845
D0QQ7I	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D07TYV	TTDDRUID	D07TYV
D07TYV	DRUGNAME	BAY1862864
D07TYV	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D03BYM	TTDDRUID	D03BYM
D03BYM	DRUGNAME	BAY1895344
D03BYM	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D03BYM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08DMH	TTDDRUID	D08DMH
D08DMH	DRUGNAME	BAY2402234
D08DMH	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1

D00JQE	TTDDRUID	D00JQE
D00JQE	DRUGNAME	BAY-60-5521
D00JQE	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D06OFD	TTDDRUID	D06OFD
D06OFD	DRUGNAME	BAY-85-8102
D06OFD	INDICATI	Brain disease [ICD-11: 8C70-8E61] Phase 1

D0X7JC	TTDDRUID	D0X7JC
D0X7JC	DRUGNAME	BAY-86-4367
D0X7JC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A4UW	TTDDRUID	D0A4UW
D0A4UW	DRUGNAME	BAY-86-7548
D0A4UW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04KVQ	TTDDRUID	D04KVQ
D04KVQ	DRUGNAME	BAY-86-9596
D04KVQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CT1S	TTDDRUID	D0CT1S
D0CT1S	DRUGNAME	BB IND-6989
D0CT1S	INDICATI	Salmonella infection [ICD-11: 1A09] Phase 1

D03NPI	TTDDRUID	D03NPI
D03NPI	DRUGNAME	Bb2121
D03NPI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D07CUR	TTDDRUID	D07CUR
D07CUR	DRUGNAME	Bb2121
D07CUR	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D00OXP	TTDDRUID	D00OXP
D00OXP	DRUGNAME	Bb21217
D00OXP	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0L8PE	TTDDRUID	D0L8PE
D0L8PE	DRUGNAME	Bb21217
D0L8PE	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0M2DM	TTDDRUID	D0M2DM
D0M2DM	DRUGNAME	BBI-3000
D0M2DM	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1

D0FY4J	TTDDRUID	D0FY4J
D0FY4J	DRUGNAME	BBI-6000
D0FY4J	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0W1TL	TTDDRUID	D0W1TL
D0W1TL	DRUGNAME	BB-MPI-03
D0W1TL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0W1TL	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0W1TL	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0T9FU	TTDDRUID	D0T9FU
D0T9FU	DRUGNAME	BC-3205
D0T9FU	INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 1

D0T3DG	TTDDRUID	D0T3DG
D0T3DG	DRUGNAME	BCI-632
D0T3DG	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0T3DG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D09WZU	TTDDRUID	D09WZU
D09WZU	DRUGNAME	BCI-838
D09WZU	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
D09WZU	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1

D0C6YQ	TTDDRUID	D0C6YQ
D0C6YQ	DRUGNAME	BCL201
D0C6YQ	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D0C6YQ	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1

D0RD0D	TTDDRUID	D0RD0D
D0RD0D	DRUGNAME	BCMA CART
D0RD0D	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0T8RV	TTDDRUID	D0T8RV
D0T8RV	DRUGNAME	BCMA CART and huCART19
D0T8RV	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0T9CE	TTDDRUID	D0T9CE
D0T9CE	DRUGNAME	BCMA nanobody CAR-T cells
D0T9CE	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0MS2T	TTDDRUID	D0MS2T
D0MS2T	DRUGNAME	BCMA-specific CAR-expressing T Lymphocytes
D0MS2T	INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1

D06CSK	TTDDRUID	D06CSK
D06CSK	DRUGNAME	BCT-194
D06CSK	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D08SIC	TTDDRUID	D08SIC
D08SIC	DRUGNAME	BDB001
D08SIC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0I6AU	TTDDRUID	D0I6AU
D0I6AU	DRUGNAME	BDD-10103
D0I6AU	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0S9LR	TTDDRUID	D0S9LR
D0S9LR	DRUGNAME	Beclomethasone dispropionate
D0S9LR	INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 1

D09ZVC	TTDDRUID	D09ZVC
D09ZVC	DRUGNAME	Begacestat
D09ZVC	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0NT4H	TTDDRUID	D0NT4H
D0NT4H	DRUGNAME	BEL-0218
D0NT4H	INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Phase 1

D0G7MU	TTDDRUID	D0G7MU
D0G7MU	DRUGNAME	Beleodaqbelinostat
D0G7MU	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 1
D0G7MU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05ODU	TTDDRUID	D05ODU
D05ODU	DRUGNAME	Belerofon
D05ODU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D05ISO	TTDDRUID	D05ISO
D05ISO	DRUGNAME	Bemarituzumab
D05ISO	INDICATI	Metastatic gastric or gastroesophageal junction cancer [ICD-11: 2D8Y] Phase 1

D0UW4A	TTDDRUID	D0UW4A
D0UW4A	DRUGNAME	Benzimate
D0UW4A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R9YR	TTDDRUID	D0R9YR
D0R9YR	DRUGNAME	BETULINIC ACID
D0R9YR	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D00BND	TTDDRUID	D00BND
D00BND	DRUGNAME	BF-1
D00BND	INDICATI	Cluster headache [ICD-11: 8A81.0] Phase 1
D00BND	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D0L6VH	TTDDRUID	D0L6VH
D0L6VH	DRUGNAME	BF-389
D0L6VH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D02HFN	TTDDRUID	D02HFN
D02HFN	DRUGNAME	BFCR4350A
D02HFN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D08FHP	TTDDRUID	D08FHP
D08FHP	DRUGNAME	BFKB8488A
D08FHP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0Z1NF	TTDDRUID	D0Z1NF
D0Z1NF	DRUGNAME	BFPET
D0Z1NF	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1

D0NW2H	TTDDRUID	D0NW2H
D0NW2H	DRUGNAME	BG-777
D0NW2H	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0M5XN	TTDDRUID	D0M5XN
D0M5XN	DRUGNAME	BGB-283
D0M5XN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05SGI	TTDDRUID	D05SGI
D05SGI	DRUGNAME	BGB-3113
D05SGI	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D0X9VR	TTDDRUID	D0X9VR
D0X9VR	DRUGNAME	BGB-324
D0X9VR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
D0X9VR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0X9VR	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative
D0X9VR	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2

D08HWV	TTDDRUID	D08HWV
D08HWV	DRUGNAME	BGB-A317
D08HWV	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D08HWV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D08HWV	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3

D03PRV	TTDDRUID	D03PRV
D03PRV	DRUGNAME	BGC-20-1259
D03PRV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D09AIT	TTDDRUID	D09AIT
D09AIT	DRUGNAME	BHT-3201
D09AIT	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D05VUX	TTDDRUID	D05VUX
D05VUX	DRUGNAME	BHV-0223
D05VUX	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1

D0F9AO	TTDDRUID	D0F9AO
D0F9AO	DRUGNAME	BHV-5000
D0F9AO	INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 1

D0R9HE	TTDDRUID	D0R9HE
D0R9HE	DRUGNAME	BI 113823
D0R9HE	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1

D0C8NG	TTDDRUID	D0C8NG
D0C8NG	DRUGNAME	BI 655064
D0C8NG	INDICATI	Lupus [ICD-11: 4A40] Phase 2
D0C8NG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0C8NG	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1

D0YN4S	TTDDRUID	D0YN4S
D0YN4S	DRUGNAME	BI 754111
D0YN4S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08PSC	TTDDRUID	D08PSC
D08PSC	DRUGNAME	BI 860585
D08PSC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J2FU	TTDDRUID	D0J2FU
D0J2FU	DRUGNAME	BI 891065
D0J2FU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06QBV	TTDDRUID	D06QBV
D06QBV	DRUGNAME	BI 894999
D06QBV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00ZPT	TTDDRUID	D00ZPT
D00ZPT	DRUGNAME	BI-11634
D00ZPT	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0B5HF	TTDDRUID	D0B5HF
D0B5HF	DRUGNAME	BI-135585
D0B5HF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0B7TM	TTDDRUID	D0B7TM
D0B7TM	DRUGNAME	BI-137882
D0B7TM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D04JTX	TTDDRUID	D04JTX
D04JTX	DRUGNAME	BI-224436
D04JTX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D00SFY	TTDDRUID	D00SFY
D00SFY	DRUGNAME	BI-44847
D00SFY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D03WDN	TTDDRUID	D03WDN
D03WDN	DRUGNAME	BI-638683
D03WDN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08DVE	TTDDRUID	D08DVE
D08DVE	DRUGNAME	BI-660848
D08DVE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D08CUE	TTDDRUID	D08CUE
D08CUE	DRUGNAME	BI-661051
D08CUE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02EHE	TTDDRUID	D02EHE
D02EHE	DRUGNAME	BI730357
D02EHE	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1

D00NEL	TTDDRUID	D00NEL
D00NEL	DRUGNAME	BI-754091
D00NEL	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D00NEL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P5IZ	TTDDRUID	D0P5IZ
D0P5IZ	DRUGNAME	BI-811283
D0P5IZ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D09KRU	TTDDRUID	D09KRU
D09KRU	DRUGNAME	BI-831266
D09KRU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09WKM	TTDDRUID	D09WKM
D09WKM	DRUGNAME	BI-836826
D09WKM	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D09WKM	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D09WKM	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D09WKM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D09WKM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X4KN	TTDDRUID	D0X4KN
D0X4KN	DRUGNAME	BI-836845
D0X4KN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V7QO	TTDDRUID	D0V7QO
D0V7QO	DRUGNAME	BI-836880
D0V7QO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08DCP	TTDDRUID	D08DCP
D08DCP	DRUGNAME	BI-847325
D08DCP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00KNI	TTDDRUID	D00KNI
D00KNI	DRUGNAME	BI-853520
D00KNI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X2NN	TTDDRUID	D0X2NN
D0X2NN	DRUGNAME	BIBT986
D0X2NN	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0D9LB	TTDDRUID	D0D9LB
D0D9LB	DRUGNAME	BIBV 308
D0D9LB	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 1

D00RMC	TTDDRUID	D00RMC
D00RMC	DRUGNAME	BIBX-1382
D00RMC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D08IRG	TTDDRUID	D08IRG
D08IRG	DRUGNAME	BIIB 015
D08IRG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O7QQ	TTDDRUID	D0O7QQ
D0O7QQ	DRUGNAME	BIIB 022
D0O7QQ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D0O7QQ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0H3VK	TTDDRUID	D0H3VK
D0H3VK	DRUGNAME	BIIB 028
D0H3VK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M0TV	TTDDRUID	D0M0TV
D0M0TV	DRUGNAME	BIIB059
D0M0TV	INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
D0M0TV	INDICATI	Lupus [ICD-11: 4A40] Phase 1
D0M0TV	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D09ALM	TTDDRUID	D09ALM
D09ALM	DRUGNAME	BIIB061
D09ALM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0XE2O	TTDDRUID	D0XE2O
D0XE2O	DRUGNAME	BIIB063
D0XE2O	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1

D0WP9A	TTDDRUID	D0WP9A
D0WP9A	DRUGNAME	BIIB068
D0WP9A	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0WL5T	TTDDRUID	D0WL5T
D0WL5T	DRUGNAME	BIIB076
D0WL5T	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0I8FS	TTDDRUID	D0I8FS
D0I8FS	DRUGNAME	BIIB092
D0I8FS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0I8FS	INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 2

D00FSB	TTDDRUID	D00FSB
D00FSB	DRUGNAME	BIIB095
D00FSB	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01CDE	TTDDRUID	D01CDE
D01CDE	DRUGNAME	BIMU-1
D01CDE	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D0O4KT	TTDDRUID	D0O4KT
D0O4KT	DRUGNAME	Bioadhesive berry gel therapy
D0O4KT	INDICATI	Dysplasia [ICD-11: LB30-LD2F] Phase 1

D0S0WN	TTDDRUID	D0S0WN
D0S0WN	DRUGNAME	Biomed 101
D0S0WN	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
D0S0WN	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Discontinued in Phase 1

D04XNQ	TTDDRUID	D04XNQ
D04XNQ	DRUGNAME	BioScavenger
D04XNQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08DTD	TTDDRUID	D08DTD
D08DTD	DRUGNAME	Biostrophin
D08DTD	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D01UGS	TTDDRUID	D01UGS
D01UGS	DRUGNAME	Bipolar disorder NCE
D01UGS	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1

D0PR5H	TTDDRUID	D0PR5H
D0PR5H	DRUGNAME	BIS-001
D0PR5H	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0W6LW	TTDDRUID	D0W6LW
D0W6LW	DRUGNAME	BIT225
D0W6LW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D05OXZ	TTDDRUID	D05OXZ
D05OXZ	DRUGNAME	BIWA 4
D05OXZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09HJS	TTDDRUID	D09HJS
D09HJS	DRUGNAME	BIZELESIN
D09HJS	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Phase 1

D04XJG	TTDDRUID	D04XJG
D04XJG	DRUGNAME	BKR-013
D04XJG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0FM7Z	TTDDRUID	D0FM7Z
D0FM7Z	DRUGNAME	BL-1021
D0FM7Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0UO2P	TTDDRUID	D0UO2P
D0UO2P	DRUGNAME	BLU-285
D0UO2P	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
D0UO2P	INDICATI	Mast cell leukaemia [ICD-11: 2A21.00] Phase 1
D0UO2P	INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Phase 1

D0XZ1D	TTDDRUID	D0XZ1D
D0XZ1D	DRUGNAME	BLU-554
D0XZ1D	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1

D0OD2I	TTDDRUID	D0OD2I
D0OD2I	DRUGNAME	BLU-667
D0OD2I	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0OD2I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01LMM	TTDDRUID	D01LMM
D01LMM	DRUGNAME	BLY719
D01LMM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08NDE	TTDDRUID	D08NDE
D08NDE	DRUGNAME	BLZ-945
D08NDE	INDICATI	Bone cancer [ICD-11: 2B5Z] Investigative
D08NDE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D4VH	TTDDRUID	D0D4VH
D0D4VH	DRUGNAME	BM-212
D0D4VH	INDICATI	Asthma [ICD-11: CA23] Phase 1

D05YQL	TTDDRUID	D05YQL
D05YQL	DRUGNAME	BM-ca
D05YQL	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0V4XL	TTDDRUID	D0V4XL
D0V4XL	DRUGNAME	BMEC-1217B
D0V4XL	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D0P1RC	TTDDRUID	D0P1RC
D0P1RC	DRUGNAME	BMP-655
D0P1RC	INDICATI	Tendon injuries [ICD-11: NC96.0] Phase 1

D07NFW	TTDDRUID	D07NFW
D07NFW	DRUGNAME	BMS-196085
D07NFW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0Z1NY	TTDDRUID	D0Z1NY
D0Z1NY	DRUGNAME	BMS214662
D0Z1NY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0V9HL	TTDDRUID	D0V9HL
D0V9HL	DRUGNAME	BMS-241027
D0V9HL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0V9HL	INDICATI	Tauopathy [ICD-11: 6D85.Y] Phase 1

D06ERY	TTDDRUID	D06ERY
D06ERY	DRUGNAME	BMS-394136
D06ERY	INDICATI	Arrhythmia [ICD-11: BC9Z] Phase 1

D00QWU	TTDDRUID	D00QWU
D00QWU	DRUGNAME	BMS-779788
D00QWU	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D08VSQ	TTDDRUID	D08VSQ
D08VSQ	DRUGNAME	BMS-816336
D08VSQ	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1

D02AVC	TTDDRUID	D02AVC
D02AVC	DRUGNAME	BMS-820132
D02AVC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0AR5N	TTDDRUID	D0AR5N
D0AR5N	DRUGNAME	BMS-824383
D0AR5N	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D01KMW	TTDDRUID	D01KMW
D01KMW	DRUGNAME	BMS-830216
D01KMW	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0H4DR	TTDDRUID	D0H4DR
D0H4DR	DRUGNAME	BMS-852927
D0H4DR	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D00WDY	TTDDRUID	D00WDY
D00WDY	DRUGNAME	BMS-903452
D00WDY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0O3CX	TTDDRUID	D0O3CX
D0O3CX	DRUGNAME	BMS-906024
D0O3CX	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0O3CX	INDICATI	T-cell acute lymphocytic leukaemia [ICD-11: 2B33.4] Phase 1

D0Z2FD	TTDDRUID	D0Z2FD
D0Z2FD	DRUGNAME	BMS-908662
D0Z2FD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XI4P	TTDDRUID	D0XI4P
D0XI4P	DRUGNAME	BMS-932481
D0XI4P	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D05LRD	TTDDRUID	D05LRD
D05LRD	DRUGNAME	BMS-933043
D05LRD	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 1

D06FHQ	TTDDRUID	D06FHQ
D06FHQ	DRUGNAME	BMS-936561
D06FHQ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0Z8JR	TTDDRUID	D0Z8JR
D0Z8JR	DRUGNAME	BMS-936564
D0Z8JR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0Z8JR	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1

D03ZSA	TTDDRUID	D03ZSA
D03ZSA	DRUGNAME	BMS-986016
D03ZSA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D6ZW	TTDDRUID	D0D6ZW
D0D6ZW	DRUGNAME	BMS-986020
D0D6ZW	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0GG7L	TTDDRUID	D0GG7L
D0GG7L	DRUGNAME	BMS-986104
D0GG7L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D03TBD	TTDDRUID	D03TBD
D03TBD	DRUGNAME	BMS-986148
D03TBD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06ILL	TTDDRUID	D06ILL
D06ILL	DRUGNAME	BMS-986158
D06ILL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S1XX	TTDDRUID	D0S1XX
D0S1XX	DRUGNAME	BMS-986165
D0S1XX	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
D0S1XX	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1

D09PTD	TTDDRUID	D09PTD
D09PTD	DRUGNAME	BMS-986168
D09PTD	INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1

D0G9ZV	TTDDRUID	D0G9ZV
D0G9ZV	DRUGNAME	BMS-986177
D0G9ZV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0F7CR	TTDDRUID	D0F7CR
D0F7CR	DRUGNAME	BMS-986178
D0F7CR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0JI4J	TTDDRUID	D0JI4J
D0JI4J	DRUGNAME	BMS-986179
D0JI4J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00BJV	TTDDRUID	D00BJV
D00BJV	DRUGNAME	BMS-986207
D00BJV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D00BJV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D09QVR	TTDDRUID	D09QVR
D09QVR	DRUGNAME	BMS-986218
D09QVR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0IG7W	TTDDRUID	D0IG7W
D0IG7W	DRUGNAME	BMS-986224
D0IG7W	INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 1

D05WOS	TTDDRUID	D05WOS
D05WOS	DRUGNAME	BMS-986226
D05WOS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XJ9U	TTDDRUID	D0XJ9U
D0XJ9U	DRUGNAME	BMS-986242
D0XJ9U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04FWC	TTDDRUID	D04FWC
D04FWC	DRUGNAME	BMS-986249
D04FWC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0AP7A	TTDDRUID	D0AP7A
D0AP7A	DRUGNAME	BMS-986258
D0AP7A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CK9Q	TTDDRUID	D0CK9Q
D0CK9Q	DRUGNAME	BMS-986299
D0CK9Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D2YZ	TTDDRUID	D0D2YZ
D0D2YZ	DRUGNAME	BMTP-11
D0D2YZ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0GV0Q	TTDDRUID	D0GV0Q
D0GV0Q	DRUGNAME	BMY-43748
D0GV0Q	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0YE6C	TTDDRUID	D0YE6C
D0YE6C	DRUGNAME	BN-brachyury cancer vaccine
D0YE6C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C3ZZ	TTDDRUID	D0C3ZZ
D0C3ZZ	DRUGNAME	BNC375
D0C3ZZ	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D05SJK	TTDDRUID	D05SJK
D05SJK	DRUGNAME	Bone marrow stem cell therapy
D05SJK	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1

D0HY9S	TTDDRUID	D0HY9S
D0HY9S	DRUGNAME	BOS172722
D0HY9S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00DYN	TTDDRUID	D00DYN
D00DYN	DRUGNAME	Botulinum neurotoxin vaccine
D00DYN	INDICATI	Botulism [ICD-11: 1A11] Phase 1

D05NHT	TTDDRUID	D05NHT
D05NHT	DRUGNAME	BP-C1
D05NHT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0IZ8X	TTDDRUID	D0IZ8X
D0IZ8X	DRUGNAME	BPN14770
D0IZ8X	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0L6SS	TTDDRUID	D0L6SS
D0L6SS	DRUGNAME	BPX-101
D0L6SS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0D5BJ	TTDDRUID	D0D5BJ
D0D5BJ	DRUGNAME	BPX-201
D0D5BJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0J0PT	TTDDRUID	D0J0PT
D0J0PT	DRUGNAME	BPX-601
D0J0PT	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0ZA1K	TTDDRUID	D0ZA1K
D0ZA1K	DRUGNAME	BPX-701
D0ZA1K	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0ZA1K	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0A7GI	TTDDRUID	D0A7GI
D0A7GI	DRUGNAME	BPZE-1
D0A7GI	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 1

D00XVE	TTDDRUID	D00XVE
D00XVE	DRUGNAME	BR6819
D00XVE	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0T0KT	TTDDRUID	D0T0KT
D0T0KT	DRUGNAME	Briciclib
D0T0KT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0RN6V	TTDDRUID	D0RN6V
D0RN6V	DRUGNAME	BRL-52656
D0RN6V	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D03UIW	TTDDRUID	D03UIW
D03UIW	DRUGNAME	Brontictuzumab
D03UIW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0F9TL	TTDDRUID	D0F9TL
D0F9TL	DRUGNAME	BT-063
D0F9TL	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D09WSW	TTDDRUID	D09WSW
D09WSW	DRUGNAME	BTK inhibitor
D09WSW	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D09SGL	TTDDRUID	D09SGL
D09SGL	DRUGNAME	BTP-114
D09SGL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J9QS	TTDDRUID	D0J9QS
D0J9QS	DRUGNAME	BTRC4017A
D0J9QS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05OZG	TTDDRUID	D05OZG
D05OZG	DRUGNAME	BTSCAN
D05OZG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0C9DF	TTDDRUID	D0C9DF
D0C9DF	DRUGNAME	Buccal fentanyl
D0C9DF	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0G5UZ	TTDDRUID	D0G5UZ
D0G5UZ	DRUGNAME	BVD-CNV
D0G5UZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04KVA	TTDDRUID	D04KVA
D04KVA	DRUGNAME	BVI-007
D04KVA	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1
D04KVA	INDICATI	Thrombotic stroke [ICD-11: 8B20] Phase 1

D04VJQ	TTDDRUID	D04VJQ
D04VJQ	DRUGNAME	BVS857
D04VJQ	INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Phase 1

D02KLD	TTDDRUID	D02KLD
D02KLD	DRUGNAME	BVT-74316
D02KLD	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0KG1U	TTDDRUID	D0KG1U
D0KG1U	DRUGNAME	BXCL702
D0KG1U	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D07UTU	TTDDRUID	D07UTU
D07UTU	DRUGNAME	BXQ-350
D07UTU	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D07UTU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C2HG	TTDDRUID	D0C2HG
D0C2HG	DRUGNAME	BYK-324677
D0C2HG	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1

D0S4PN	TTDDRUID	D0S4PN
D0S4PN	DRUGNAME	C-1205
D0S4PN	INDICATI	Urinary tract infection [ICD-11: GC08] Phase 1

D09CLC	TTDDRUID	D09CLC
D09CLC	DRUGNAME	C188-9
D09CLC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C1WL	TTDDRUID	D0C1WL
D0C1WL	DRUGNAME	C-2507
D0C1WL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0H5ZS	TTDDRUID	D0H5ZS
D0H5ZS	DRUGNAME	C31510
D0H5ZS	INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 1
D0H5ZS	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D0GJ1U	TTDDRUID	D0GJ1U
D0GJ1U	DRUGNAME	C326
D0GJ1U	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D05YRP	TTDDRUID	D05YRP
D05YRP	DRUGNAME	C4.4a-ADC
D05YRP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0DA1U	TTDDRUID	D0DA1U
D0DA1U	DRUGNAME	C7R-GD2.CART cells
D0DA1U	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1

D0KK9D	TTDDRUID	D0KK9D
D0KK9D	DRUGNAME	CA-011
D0KK9D	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D09PPU	TTDDRUID	D09PPU
D09PPU	DRUGNAME	CA-170
D09PPU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D09PPU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0AY8A	TTDDRUID	D0AY8A
D0AY8A	DRUGNAME	CA-4948
D0AY8A	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0YO4B	TTDDRUID	D0YO4B
D0YO4B	DRUGNAME	Cabiralizumab
D0YO4B	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D0YO4B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0WM8D	TTDDRUID	D0WM8D
D0WM8D	DRUGNAME	CAD-1833
D0WM8D	INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 1
D0WM8D	INDICATI	Spinocerebellar ataxia [ICD-11: 8A03.16] Phase 1

D0P5QB	TTDDRUID	D0P5QB
D0P5QB	DRUGNAME	Cadherin-11
D0P5QB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0R2KO	TTDDRUID	D0R2KO
D0R2KO	DRUGNAME	CAF-01
D0R2KO	INDICATI	Vaccination [ICD-11: N.A.] Phase 1

D0A1GR	TTDDRUID	D0A1GR
D0A1GR	DRUGNAME	CALAA-01
D0A1GR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S6KA	TTDDRUID	D0S6KA
D0S6KA	DRUGNAME	CALANOLIDE A
D0S6KA	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1

D0S8XP	TTDDRUID	D0S8XP
D0S8XP	DRUGNAME	Canagliflozin/metformin
D0S8XP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0FL2K	TTDDRUID	D0FL2K
D0FL2K	DRUGNAME	Cantrixil
D0FL2K	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0KR5K	TTDDRUID	D0KR5K
D0KR5K	DRUGNAME	Capravirine
D0KR5K	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0N2AM	TTDDRUID	D0N2AM
D0N2AM	DRUGNAME	CAR CD30 T cells
D0N2AM	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
D0N2AM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0I5GS	TTDDRUID	D0I5GS
D0I5GS	DRUGNAME	CAR.CD30 cells
D0I5GS	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1/2
D0I5GS	INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1/2
D0I5GS	INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1/2
D0I5GS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D0I5GS	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1/2

D09ZDY	TTDDRUID	D09ZDY
D09ZDY	DRUGNAME	CAR138 T Cells
D09ZDY	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
D09ZDY	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0U8PE	TTDDRUID	D0U8PE
D0U8PE	DRUGNAME	CAR19 T cells carrying cytoplasmic activated PD-1
D0U8PE	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0NU9L	TTDDRUID	D0NU9L
D0NU9L	DRUGNAME	CAR-20/19-T Cells
D0NU9L	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0NU9L	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0NU9L	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0U7OS	TTDDRUID	D0U7OS
D0U7OS	DRUGNAME	CARD-024
D0U7OS	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0L3XN	TTDDRUID	D0L3XN
D0L3XN	DRUGNAME	Cardiac PET imaging agent
D0L3XN	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1

D0C6DX	TTDDRUID	D0C6DX
D0C6DX	DRUGNAME	CardiALLO
D0C6DX	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D06IEX	TTDDRUID	D06IEX
D06IEX	DRUGNAME	Cardiotrophin-1
D06IEX	INDICATI	Acute liver failure [ICD-11: DB91] Phase 1

D0H4UP	TTDDRUID	D0H4UP
D0H4UP	DRUGNAME	CAR-GPC3 T Cells
D0H4UP	INDICATI	Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 1

D06RWM	TTDDRUID	D06RWM
D06RWM	DRUGNAME	Carmeseal-MD
D06RWM	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D0K2PS	TTDDRUID	D0K2PS
D0K2PS	DRUGNAME	Carmoxirole
D0K2PS	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D04RNG	TTDDRUID	D04RNG
D04RNG	DRUGNAME	CAR-T cells recognizing EpCAM
D04RNG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D04RNG	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0B2WU	TTDDRUID	D0B2WU
D0B2WU	DRUGNAME	CAR-T cells targeting BCMA
D0B2WU	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0PE3J	TTDDRUID	D0PE3J
D0PE3J	DRUGNAME	CAR-T Cells targeting CD19
D0PE3J	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0U7VS	TTDDRUID	D0U7VS
D0U7VS	DRUGNAME	CAR-T cells targeting CD19
D0U7VS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0T6KI	TTDDRUID	D0T6KI
D0T6KI	DRUGNAME	CAR-T cells targeting CD80/86
D0T6KI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03CMZ	TTDDRUID	D03CMZ
D03CMZ	DRUGNAME	CAR-T cells targeting EGFRviii
D03CMZ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D01TNK	TTDDRUID	D01TNK
D01TNK	DRUGNAME	CAR-T cells targeting EpCAM
D01TNK	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D01TNK	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1

D0S4GT	TTDDRUID	D0S4GT
D0S4GT	DRUGNAME	CAR-T cells targeting GD2
D0S4GT	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D0S4GT	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D0JI4M	TTDDRUID	D0JI4M
D0JI4M	DRUGNAME	CAR-T cells targeting HER2
D0JI4M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04RDW	TTDDRUID	D04RDW
D04RDW	DRUGNAME	CAR-T cells targeting Lewis-Y
D04RDW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09YXN	TTDDRUID	D09YXN
D09YXN	DRUGNAME	CAR-T cells targeting Mesothelin
D09YXN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0NU9N	TTDDRUID	D0NU9N
D0NU9N	DRUGNAME	CAR-T cells targeting MUC1
D0NU9N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05CSS	TTDDRUID	D05CSS
D05CSS	DRUGNAME	CAR-T cells targeting MucI
D05CSS	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D05CSS	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D0MG3Z	TTDDRUID	D0MG3Z
D0MG3Z	DRUGNAME	CAR-T cells targeting PSCA
D0MG3Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04SKM	TTDDRUID	D04SKM
D04SKM	DRUGNAME	CART-10 cells
D04SKM	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0E0SH	TTDDRUID	D0E0SH
D0E0SH	DRUGNAME	CART-117 cells
D0E0SH	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0E0SH	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0R5NU	TTDDRUID	D0R5NU
D0R5NU	DRUGNAME	CART123 cells
D0R5NU	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0AW4T	TTDDRUID	D0AW4T
D0AW4T	DRUGNAME	CART-123 cells
D0AW4T	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0AW4T	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0CS3A	TTDDRUID	D0CS3A
D0CS3A	DRUGNAME	CART-19
D0CS3A	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D0G4IW	TTDDRUID	D0G4IW
D0G4IW	DRUGNAME	CART-19
D0G4IW	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
D0G4IW	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1
D0G4IW	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0G4IW	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D0G4IW	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D0G4IW	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D0G4IW	INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1
D0G4IW	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
D0G4IW	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D0G4IW	INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1
D0G4IW	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0Q8XO	TTDDRUID	D0Q8XO
D0Q8XO	DRUGNAME	CART-19
D0Q8XO	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D05DKT	TTDDRUID	D05DKT
D05DKT	DRUGNAME	CART19 cell
D05DKT	INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1

D0DR6N	TTDDRUID	D0DR6N
D0DR6N	DRUGNAME	CART-19 cells
D0DR6N	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0I0NJ	TTDDRUID	D0I0NJ
D0I0NJ	DRUGNAME	CART-19 cells
D0I0NJ	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
D0I0NJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0S5BC	TTDDRUID	D0S5BC
D0S5BC	DRUGNAME	CART-19 cells
D0S5BC	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D00YUQ	TTDDRUID	D00YUQ
D00YUQ	DRUGNAME	CART-19 T cells
D00YUQ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0FL5S	TTDDRUID	D0FL5S
D0FL5S	DRUGNAME	CART-20 cells
D0FL5S	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0QV9Q	TTDDRUID	D0QV9Q
D0QV9Q	DRUGNAME	CART22 cells
D0QV9Q	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D02NSS	TTDDRUID	D02NSS
D02NSS	DRUGNAME	CART-22 cells
D02NSS	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D09DIQ	TTDDRUID	D09DIQ
D09DIQ	DRUGNAME	CART22 cells expressing anti-CD22 scFv TCRz:41BB
D09DIQ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0ZP8Z	TTDDRUID	D0ZP8Z
D0ZP8Z	DRUGNAME	CART22-65s cells
D0ZP8Z	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D02LNU	TTDDRUID	D02LNU
D02LNU	DRUGNAME	CART22-65s cells and huCART19 Cells
D02LNU	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0P6YN	TTDDRUID	D0P6YN
D0P6YN	DRUGNAME	CART-33 cells
D0P6YN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0P6YN	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0NY1Y	TTDDRUID	D0NY1Y
D0NY1Y	DRUGNAME	CART-34 cells
D0NY1Y	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0NY1Y	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D06OES	TTDDRUID	D06OES
D06OES	DRUGNAME	CART-38 cells
D06OES	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D06OES	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0YH5L	TTDDRUID	D0YH5L
D0YH5L	DRUGNAME	CART-56 cells
D0YH5L	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0YH5L	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D01YZF	TTDDRUID	D01YZF
D01YZF	DRUGNAME	CART-BCMA
D01YZF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0P2GA	TTDDRUID	D0P2GA
D0P2GA	DRUGNAME	CART-meso cells
D0P2GA	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0V5DD	TTDDRUID	D0V5DD
D0V5DD	DRUGNAME	CART-meso-19 T cells
D0V5DD	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0DJ8S	TTDDRUID	D0DJ8S
D0DJ8S	DRUGNAME	CART-Muc1 cells
D0DJ8S	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0DJ8S	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0K7PD	TTDDRUID	D0K7PD
D0K7PD	DRUGNAME	Cat hair allergen extract
D0K7PD	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D09QKJ	TTDDRUID	D09QKJ
D09QKJ	DRUGNAME	Cavatak
D09QKJ	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
D09QKJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D09QKJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0DE9D	TTDDRUID	D0DE9D
D0DE9D	DRUGNAME	Cavatakcoxsackievirus
D0DE9D	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0DE9D	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0A9BU	TTDDRUID	D0A9BU
D0A9BU	DRUGNAME	CB-24
D0A9BU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09QWN	TTDDRUID	D09QWN
D09QWN	DRUGNAME	CB4211
D09QWN	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1

D08OOJ	TTDDRUID	D08OOJ
D08OOJ	DRUGNAME	CB-5083
D08OOJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D08OOJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R4YQ	TTDDRUID	D0R4YQ
D0R4YQ	DRUGNAME	CB-813
D0R4YQ	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1

D0Z0XM	TTDDRUID	D0Z0XM
D0Z0XM	DRUGNAME	CBL0137
D0Z0XM	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1

D0Q9RP	TTDDRUID	D0Q9RP
D0Q9RP	DRUGNAME	CBLC137
D0Q9RP	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0Q9RP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04XUJ	TTDDRUID	D04XUJ
D04XUJ	DRUGNAME	CBT-101
D04XUJ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2
D04XUJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0JL4D	TTDDRUID	D0JL4D
D0JL4D	DRUGNAME	CBT-101 + CBT-501
D0JL4D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0PB3B	TTDDRUID	D0PB3B
D0PB3B	DRUGNAME	CBT-501
D0PB3B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y3ZC	TTDDRUID	D0Y3ZC
D0Y3ZC	DRUGNAME	CBT-501
D0Y3ZC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0ZA6P	TTDDRUID	D0ZA6P
D0ZA6P	DRUGNAME	CBT-501 + CBT-502
D0ZA6P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0UU1E	TTDDRUID	D0UU1E
D0UU1E	DRUGNAME	CC-100
D0UU1E	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
D0UU1E	INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 1

D0U6CL	TTDDRUID	D0U6CL
D0U6CL	DRUGNAME	CC-10015
D0U6CL	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 1

D0J0JT	TTDDRUID	D0J0JT
D0J0JT	DRUGNAME	CC-11006
D0J0JT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O1IM	TTDDRUID	D0O1IM
D0O1IM	DRUGNAME	CC-115
D0O1IM	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0O1IM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D03QZJ	TTDDRUID	D03QZJ
D03QZJ	DRUGNAME	CC-122
D03QZJ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D03QZJ	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D03QZJ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D03QZJ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D03QZJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D03QZJ	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D03QZJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08KZM	TTDDRUID	D08KZM
D08KZM	DRUGNAME	CC49 humanized radioimmunoconjugates
D08KZM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XO1O	TTDDRUID	D0XO1O
D0XO1O	DRUGNAME	CC8464
D0XO1O	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
D0XO1O	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D03YGP	TTDDRUID	D03YGP
D03YGP	DRUGNAME	CC-8490
D03YGP	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1

D05ODE	TTDDRUID	D05ODE
D05ODE	DRUGNAME	CC-90001
D05ODE	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 1
D05ODE	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1

D0ZL3Z	TTDDRUID	D0ZL3Z
D0ZL3Z	DRUGNAME	CC-90002
D0ZL3Z	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0ZL3Z	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D0ZL3Z	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0ZL3Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L5ZH	TTDDRUID	D0L5ZH
D0L5ZH	DRUGNAME	CC-90006
D0L5ZH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D09WIR	TTDDRUID	D09WIR
D09WIR	DRUGNAME	CC-90009
D09WIR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0UL2X	TTDDRUID	D0UL2X
D0UL2X	DRUGNAME	CC-90010
D0UL2X	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0UL2X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04GNG	TTDDRUID	D04GNG
D04GNG	DRUGNAME	CC-90011
D04GNG	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D04GNG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0HT4Y	TTDDRUID	D0HT4Y
D0HT4Y	DRUGNAME	CC-92480
D0HT4Y	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0W8YI	TTDDRUID	D0W8YI
D0W8YI	DRUGNAME	CC-93269
D0W8YI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0X6FU	TTDDRUID	D0X6FU
D0X6FU	DRUGNAME	C-CAR011
D0X6FU	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0J7OU	TTDDRUID	D0J7OU
D0J7OU	DRUGNAME	C-CAR088
D0J7OU	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0K1OK	TTDDRUID	D0K1OK
D0K1OK	DRUGNAME	CCR5 mab
D0K1OK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D00YXU	TTDDRUID	D00YXU
D00YXU	DRUGNAME	CCX-025
D00YXU	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D03DHM	TTDDRUID	D03DHM
D03DHM	DRUGNAME	CCX507
D03DHM	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D0SM4E	TTDDRUID	D0SM4E
D0SM4E	DRUGNAME	CD101 IV
D0SM4E	INDICATI	Candidiasis [ICD-11: 1F23] Phase 1

D0JX7M	TTDDRUID	D0JX7M
D0JX7M	DRUGNAME	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
D0JX7M	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D05KFH	TTDDRUID	D05KFH
D05KFH	DRUGNAME	CD171 specific CAR T cells expressing EGFRt
D05KFH	INDICATI	Ganglioneuroblastoma [ICD-11: 2A00.11] Phase 1
D05KFH	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1

D0JD6Y	TTDDRUID	D0JD6Y
D0JD6Y	DRUGNAME	CD19 CAR T
D0JD6Y	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0JD6Y	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D0KZ0V	TTDDRUID	D0KZ0V
D0KZ0V	DRUGNAME	CD19 CAR T Cells
D0KZ0V	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
D0KZ0V	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0KZ0V	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0OD8T	TTDDRUID	D0OD8T
D0OD8T	DRUGNAME	CD19 CAR T cells
D0OD8T	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0OD8T	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D06TNO	TTDDRUID	D06TNO
D06TNO	DRUGNAME	CD19 CAR T-cells
D06TNO	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0B1CU	TTDDRUID	D0B1CU
D0B1CU	DRUGNAME	CD19 CAR T-cells
D0B1CU	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0B1CU	INDICATI	Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 1

D00MUC	TTDDRUID	D00MUC
D00MUC	DRUGNAME	CD19 CAR-T cells
D00MUC	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0BQ0C	TTDDRUID	D0BQ0C
D0BQ0C	DRUGNAME	CD19 CAR-T cells
D0BQ0C	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0E2VF	TTDDRUID	D0E2VF
D0E2VF	DRUGNAME	CD19 Redirected Autologous T Cells
D0E2VF	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D01HAT	TTDDRUID	D01HAT
D01HAT	DRUGNAME	CD19.CAR-aNKT cells
D01HAT	INDICATI	B-cell small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1
D01HAT	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D01HAT	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1
D01HAT	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D00JCB	TTDDRUID	D00JCB
D00JCB	DRUGNAME	CD19/CD22 CAR T cells
D00JCB	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D03YEM	TTDDRUID	D03YEM
D03YEM	DRUGNAME	CD19/CD22 CAR T-Cells
D03YEM	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
D03YEM	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D03YEM	INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1
D03YEM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D03YEM	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0D7FV	TTDDRUID	D0D7FV
D0D7FV	DRUGNAME	CD19/CD22 Chimeric Antigen Receptor T Cells
D0D7FV	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0D7FV	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0D7FV	INDICATI	Mediastinal large B-cell lymphoma [ICD-11: 2A60.32] Phase 1

D0PH6Z	TTDDRUID	D0PH6Z
D0PH6Z	DRUGNAME	CD19+ CAR T Cells
D0PH6Z	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0PH6Z	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0J6WE	TTDDRUID	D0J6WE
D0J6WE	DRUGNAME	CD19-CAR-T Cells
D0J6WE	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D05UOU	TTDDRUID	D05UOU
D05UOU	DRUGNAME	CD19-CAR-T2 Cells
D05UOU	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0F1OH	TTDDRUID	D0F1OH
D0F1OH	DRUGNAME	CD19CAT-41BBZ CAR T-cells
D0F1OH	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D02XYW	TTDDRUID	D02XYW
D02XYW	DRUGNAME	CD19-directed CAR-T cells
D02XYW	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0GC3U	TTDDRUID	D0GC3U
D0GC3U	DRUGNAME	CD19-directed CAR-T cells
D0GC3U	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0A6XC	TTDDRUID	D0A6XC
D0A6XC	DRUGNAME	CD19-targeted CART cells
D0A6XC	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0G8YJ	TTDDRUID	D0G8YJ
D0G8YJ	DRUGNAME	CD19-TriCAR-T
D0G8YJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0TW3L	TTDDRUID	D0TW3L
D0TW3L	DRUGNAME	CD20Bi aATC
D0TW3L	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D01SXH	TTDDRUID	D01SXH
D01SXH	DRUGNAME	CD20-CAR-T Cells
D01SXH	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D0GR9H	TTDDRUID	D0GR9H
D0GR9H	DRUGNAME	CD22-specific CAR T-cells also expressing an EGFRt
D0GR9H	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0JY0M	TTDDRUID	D0JY0M
D0JY0M	DRUGNAME	CD28 and CD137 CAR-T Cells
D0JY0M	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0S3YV	TTDDRUID	D0S3YV
D0S3YV	DRUGNAME	CD30 CAR T Cells
D0S3YV	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
D0S3YV	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0C4GN	TTDDRUID	D0C4GN
D0C4GN	DRUGNAME	CD33-CAR-T Cell
D0C4GN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0C4GN	INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1

D09ICH	TTDDRUID	D09ICH
D09ICH	DRUGNAME	CD7.CAR/28zeta CAR T cells
D09ICH	INDICATI	B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1
D09ICH	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1
D09ICH	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D09JCH	TTDDRUID	D09JCH
D09JCH	DRUGNAME	CDNA vaccine
D09JCH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D02KAW	TTDDRUID	D02KAW
D02KAW	DRUGNAME	CDP-7657
D02KAW	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0V7RN	TTDDRUID	D0V7RN
D0V7RN	DRUGNAME	CDR-134D123
D0V7RN	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0R3XI	TTDDRUID	D0R3XI
D0R3XI	DRUGNAME	CDRI-97/78
D0R3XI	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D00HYD	TTDDRUID	D00HYD
D00HYD	DRUGNAME	CDT-fenofibrate
D00HYD	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D09WXY	TTDDRUID	D09WXY
D09WXY	DRUGNAME	CDX-014
D09WXY	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D09WXY	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D03HKR	TTDDRUID	D03HKR
D03HKR	DRUGNAME	CDX-0158
D03HKR	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
D03HKR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D03HKR	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D09RLQ	TTDDRUID	D09RLQ
D09RLQ	DRUGNAME	CDX-1127
D09RLQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D09RLQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D09RLQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0T4NV	TTDDRUID	D0T4NV
D0T4NV	DRUGNAME	CDX-1135
D0T4NV	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D0N5CO	TTDDRUID	D0N5CO
D0N5CO	DRUGNAME	CDX-1140
D0N5CO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06FUE	TTDDRUID	D06FUE
D06FUE	DRUGNAME	CDX-3379
D06FUE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D06FUE	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D0CI9T	TTDDRUID	D0CI9T
D0CI9T	DRUGNAME	Ceftobiprole
D0CI9T	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
D0CI9T	INDICATI	Intensive care unit [ICD-11: DA60.3] Phase 1

D0FD6D	TTDDRUID	D0FD6D
D0FD6D	DRUGNAME	CEP-11981
D0FD6D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08QEF	TTDDRUID	D08QEF
D08QEF	DRUGNAME	CEP-37250
D08QEF	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1

D09QWD	TTDDRUID	D09QWD
D09QWD	DRUGNAME	CEP-37251
D09QWD	INDICATI	Bone metastases [ICD-11: 2D50] Phase 1

D0N6NM	TTDDRUID	D0N6NM
D0N6NM	DRUGNAME	CEP-37440
D0N6NM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06KPR	TTDDRUID	D06KPR
D06KPR	DRUGNAME	CER-002
D06KPR	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1

D04PPK	TTDDRUID	D04PPK
D04PPK	DRUGNAME	CER-522
D04PPK	INDICATI	Aortic valve stenosis [ICD-11: BB70] Phase 1

D08ANF	TTDDRUID	D08ANF
D08ANF	DRUGNAME	Cerebral EDV
D08ANF	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0RQ6F	TTDDRUID	D0RQ6F
D0RQ6F	DRUGNAME	Cergutuzumab amunaleukin
D0RQ6F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07JBE	TTDDRUID	D07JBE
D07JBE	DRUGNAME	CG-200745
D07JBE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q7AG	TTDDRUID	D0Q7AG
D0Q7AG	DRUGNAME	CGM097
D0Q7AG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F4NN	TTDDRUID	D0F4NN
D0F4NN	DRUGNAME	CGTG-102
D0F4NN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0BZ1D	TTDDRUID	D0BZ1D
D0BZ1D	DRUGNAME	CGX1321
D0BZ1D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03XAQ	TTDDRUID	D03XAQ
D03XAQ	DRUGNAME	CH-5132799
D03XAQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V0JQ	TTDDRUID	D0V0JQ
D0V0JQ	DRUGNAME	CHF 5407
D0V0JQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D08OUV	TTDDRUID	D08OUV
D08OUV	DRUGNAME	CHF-4227
D08OUV	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0M4BB	TTDDRUID	D0M4BB
D0M4BB	DRUGNAME	Chi Lob 7/4
D0M4BB	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D036P7	TTDDRUID	D036P7
D036P7	DRUGNAME	Chimeric natriuretic peptide
D036P7	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D06TKI	TTDDRUID	D06TKI
D06TKI	DRUGNAME	CHR-3996
D06TKI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01VQM	TTDDRUID	D01VQM
D01VQM	DRUGNAME	CHR-5154
D01VQM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D0HJ5Y	TTDDRUID	D0HJ5Y
D0HJ5Y	DRUGNAME	ChronsVax
D0HJ5Y	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D0U3UJ	TTDDRUID	D0U3UJ
D0U3UJ	DRUGNAME	CHT-25
D0U3UJ	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1

D07TAS	TTDDRUID	D07TAS
D07TAS	DRUGNAME	CI-959
D07TAS	INDICATI	Asthma [ICD-11: CA23] Phase 1

D08ESA	TTDDRUID	D08ESA
D08ESA	DRUGNAME	CI-966
D08ESA	INDICATI	Convulsion [ICD-11: 8A68.Z] Phase 1

D06NDP	TTDDRUID	D06NDP
D06NDP	DRUGNAME	CIGB-128
D06NDP	INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 1

D0M2YX	TTDDRUID	D0M2YX
D0M2YX	DRUGNAME	CIGB-228
D0M2YX	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1

D0X9GE	TTDDRUID	D0X9GE
D0X9GE	DRUGNAME	CIGB-500
D0X9GE	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D0Z0EP	TTDDRUID	D0Z0EP
D0Z0EP	DRUGNAME	CIGB-M3
D0Z0EP	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0PO0B	TTDDRUID	D0PO0B
D0PO0B	DRUGNAME	Cilobradine
D0PO0B	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 1

D08JAN	TTDDRUID	D08JAN
D08JAN	DRUGNAME	Cipatinib
D08JAN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P7PY	TTDDRUID	D0P7PY
D0P7PY	DRUGNAME	Cirmtuzumab
D0P7PY	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0P7PY	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D01WKZ	TTDDRUID	D01WKZ
D01WKZ	DRUGNAME	Citarinostat
D01WKZ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0C6ID	TTDDRUID	D0C6ID
D0C6ID	DRUGNAME	Citatuzumab bogatox
D0C6ID	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E5GI	TTDDRUID	D0E5GI
D0E5GI	DRUGNAME	CJ-12255
D0E5GI	INDICATI	Eczema [ICD-11: EA80-EA89] Phase 1

D0T5TN	TTDDRUID	D0T5TN
D0T5TN	DRUGNAME	CJM112
D0T5TN	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
D0T5TN	INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 1/2
D0T5TN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0T5TN	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
D0T5TN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FS0F	TTDDRUID	D0FS0F
D0FS0F	DRUGNAME	CK-301
D0FS0F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08OVG	TTDDRUID	D08OVG
D08OVG	DRUGNAME	CKD-516
D08OVG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C3AA	TTDDRUID	D0C3AA
D0C3AA	DRUGNAME	CKD-712
D0C3AA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TZ8J	TTDDRUID	D0TZ8J
D0TZ8J	DRUGNAME	Clade A HIV vaccine
D0TZ8J	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0V2NK	TTDDRUID	D0V2NK
D0V2NK	DRUGNAME	Clade B HIV vaccine
D0V2NK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0T4GX	TTDDRUID	D0T4GX
D0T4GX	DRUGNAME	Clade C HIV vaccine
D0T4GX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D07BAJ	TTDDRUID	D07BAJ
D07BAJ	DRUGNAME	Clade D HIV vaccine
D07BAJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D03JJU	TTDDRUID	D03JJU
D03JJU	DRUGNAME	Cladribine tablets
D03JJU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
D03JJU	INDICATI	Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 3

D06XDJ	TTDDRUID	D06XDJ
D06XDJ	DRUGNAME	Clemizole
D06XDJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0GU4Z	TTDDRUID	D0GU4Z
D0GU4Z	DRUGNAME	CLP-1004
D0GU4Z	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D08NQS	TTDDRUID	D08NQS
D08NQS	DRUGNAME	CLR 131 radiopharmaceutical
D08NQS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0RX6F	TTDDRUID	D0RX6F
D0RX6F	DRUGNAME	CLR-131
D0RX6F	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
D0RX6F	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D0RX6F	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1

D06TWE	TTDDRUID	D06TWE
D06TWE	DRUGNAME	CLX-0921
D06TWE	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0W3JH	TTDDRUID	D0W3JH
D0W3JH	DRUGNAME	CM2489
D0W3JH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D08PCR	TTDDRUID	D08PCR
D08PCR	DRUGNAME	CM3.1-AC100
D08PCR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0NC9M	TTDDRUID	D0NC9M
D0NC9M	DRUGNAME	CM-CS1 T-cell
D0NC9M	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0NC9M	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0NC9M	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D07MCN	TTDDRUID	D07MCN
D07MCN	DRUGNAME	CMP-001
D07MCN	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D07MCN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0V6KU	TTDDRUID	D0V6KU
D0V6KU	DRUGNAME	CMV glycoprotein B subunit vaccine
D0V6KU	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1

D08DFU	TTDDRUID	D08DFU
D08DFU	DRUGNAME	CMX-157
D08DFU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0C7OT	TTDDRUID	D0C7OT
D0C7OT	DRUGNAME	CN54gp140-hsp70 conjugate vaccine
D0C7OT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0P7QG	TTDDRUID	D0P7QG
D0P7QG	DRUGNAME	CNM-Au8
D0P7QG	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1

D03UMA	TTDDRUID	D03UMA
D03UMA	DRUGNAME	CNT0-0007
D03UMA	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1

D01ILP	TTDDRUID	D01ILP
D01ILP	DRUGNAME	CNT0-3157
D01ILP	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0AO0K	TTDDRUID	D0AO0K
D0AO0K	DRUGNAME	CNT0-5
D0AO0K	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D0ZX1E	TTDDRUID	D0ZX1E
D0ZX1E	DRUGNAME	CNT0-5825
D0ZX1E	INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 1

D09ACC	TTDDRUID	D09ACC
D09ACC	DRUGNAME	CNTO-0007
D09ACC	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D0I9WR	TTDDRUID	D0I9WR
D0I9WR	DRUGNAME	CNTO-3157
D0I9WR	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0W7SX	TTDDRUID	D0W7SX
D0W7SX	DRUGNAME	CNTO-3649
D0W7SX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0K0WA	TTDDRUID	D0K0WA
D0K0WA	DRUGNAME	CNTO-5825
D0K0WA	INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 1

D0U0CF	TTDDRUID	D0U0CF
D0U0CF	DRUGNAME	CNTX-0290
D0U0CF	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D0VR7F	TTDDRUID	D0VR7F
D0VR7F	DRUGNAME	CNTX-6970
D0VR7F	INDICATI	Inflammatory pain [ICD-11: MG30.42] Phase 1

D0W6PM	TTDDRUID	D0W6PM
D0W6PM	DRUGNAME	CNV-NT
D0W6PM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P9XM	TTDDRUID	D0P9XM
D0P9XM	DRUGNAME	Cobomarsen
D0P9XM	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0P9XM	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1
D0P9XM	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1

D0MS3Q	TTDDRUID	D0MS3Q
D0MS3Q	DRUGNAME	CodaVax
D0MS3Q	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0NS6Z	TTDDRUID	D0NS6Z
D0NS6Z	DRUGNAME	COH29
D0NS6Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V5JQ	TTDDRUID	D0V5JQ
D0V5JQ	DRUGNAME	COL-172
D0V5JQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01GXB	TTDDRUID	D01GXB
D01GXB	DRUGNAME	Combinations SAR245409 / MSC1936369B SAR245408/SAR256212
D01GXB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06RUK	TTDDRUID	D06RUK
D06RUK	DRUGNAME	Combotox
D06RUK	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0HN7B	TTDDRUID	D0HN7B
D0HN7B	DRUGNAME	COR-001
D0HN7B	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0WS4E	TTDDRUID	D0WS4E
D0WS4E	DRUGNAME	COR-388
D0WS4E	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D06IGW	TTDDRUID	D06IGW
D06IGW	DRUGNAME	Coronary artery disease gene therapy
D06IGW	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1

D0AG1N	TTDDRUID	D0AG1N
D0AG1N	DRUGNAME	Corplex Donepezil
D0AG1N	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0W9RL	TTDDRUID	D0W9RL
D0W9RL	DRUGNAME	Corplex Memantine
D0W9RL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D07UIS	TTDDRUID	D07UIS
D07UIS	DRUGNAME	CORT125281
D07UIS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0S8DV	TTDDRUID	D0S8DV
D0S8DV	DRUGNAME	Cotelliccobimetinib
D0S8DV	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0S8DV	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0G8CU	TTDDRUID	D0G8CU
D0G8CU	DRUGNAME	COTI-2
D0G8CU	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
D0G8CU	INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1
D0G8CU	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D0G8CU	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0G8CU	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0G8CU	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1

D02AIC	TTDDRUID	D02AIC
D02AIC	DRUGNAME	CP-870893
D02AIC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X1XK	TTDDRUID	D0X1XK
D0X1XK	DRUGNAME	CPC-212
D0X1XK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0WI9W	TTDDRUID	D0WI9W
D0WI9W	DRUGNAME	CPC-250
D0WI9W	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0G1TY	TTDDRUID	D0G1TY
D0G1TY	DRUGNAME	CPG 52364
D0G1TY	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0Q2EJ	TTDDRUID	D0Q2EJ
D0Q2EJ	DRUGNAME	CPH-106
D0Q2EJ	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1

D0P9AK	TTDDRUID	D0P9AK
D0P9AK	DRUGNAME	CPI-003
D0P9AK	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1

D0S5RE	TTDDRUID	D0S5RE
D0S5RE	DRUGNAME	CPI-006
D0S5RE	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1

D0DF5Q	TTDDRUID	D0DF5Q
D0DF5Q	DRUGNAME	CPI-444
D0DF5Q	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TP1P	TTDDRUID	D0TP1P
D0TP1P	DRUGNAME	CPP -15
D0TP1P	INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 1

D0EJ7U	TTDDRUID	D0EJ7U
D0EJ7U	DRUGNAME	CPP-115
D0EJ7U	INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 1
D0EJ7U	INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1
D0EJ7U	INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2

D0M1ZT	TTDDRUID	D0M1ZT
D0M1ZT	DRUGNAME	CPX-POM
D0M1ZT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W0GE	TTDDRUID	D0W0GE
D0W0GE	DRUGNAME	CR-002
D0W0GE	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1

D07ZUX	TTDDRUID	D07ZUX
D07ZUX	DRUGNAME	CR-3465
D07ZUX	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D0DD4P	TTDDRUID	D0DD4P
D0DD4P	DRUGNAME	Cresemba
D0DD4P	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0CY2Q	TTDDRUID	D0CY2Q
D0CY2Q	DRUGNAME	CrohnsVax
D0CY2Q	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D0B4DL	TTDDRUID	D0B4DL
D0B4DL	DRUGNAME	CRS-100
D0B4DL	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1

D0EY1Y	TTDDRUID	D0EY1Y
D0EY1Y	DRUGNAME	CRS-207 + GVAX
D0EY1Y	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
D0EY1Y	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D05QHU	TTDDRUID	D05QHU
D05QHU	DRUGNAME	CRS-3123
D05QHU	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1

D0O2MO	TTDDRUID	D0O2MO
D0O2MO	DRUGNAME	CRX-675
D0O2MO	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1

D0J6LU	TTDDRUID	D0J6LU
D0J6LU	DRUGNAME	Cryopreserved human liver cells
D0J6LU	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 1

D0X8XT	TTDDRUID	D0X8XT
D0X8XT	DRUGNAME	CS-0777
D0X8XT	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0B5RU	TTDDRUID	D0B5RU
D0B5RU	DRUGNAME	CS1-CAR T Therapy
D0B5RU	INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1

D0GY1Y	TTDDRUID	D0GY1Y
D0GY1Y	DRUGNAME	CS-8080
D0GY1Y	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D0JF9Z	TTDDRUID	D0JF9Z
D0JF9Z	DRUGNAME	CSL-362
D0JF9Z	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0P2GU	TTDDRUID	D0P2GU
D0P2GU	DRUGNAME	CSL-362-AML
D0P2GU	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D08TRX	TTDDRUID	D08TRX
D08TRX	DRUGNAME	CST-101
D08TRX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FX8N	TTDDRUID	D0FX8N
D0FX8N	DRUGNAME	CT1812
D0FX8N	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0Q1GL	TTDDRUID	D0Q1GL
D0Q1GL	DRUGNAME	CT-200
D0Q1GL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05SOH	TTDDRUID	D05SOH
D05SOH	DRUGNAME	CTAP-201
D05SOH	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Phase 1

D0AZ3Y	TTDDRUID	D0AZ3Y
D0AZ3Y	DRUGNAME	CTCE-0214
D0AZ3Y	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Phase 1

D0DP1O	TTDDRUID	D0DP1O
D0DP1O	DRUGNAME	CTD-02
D0DP1O	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1

D0LE5N	TTDDRUID	D0LE5N
D0LE5N	DRUGNAME	CTL119
D0LE5N	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1

D04CJN	TTDDRUID	D04CJN
D04CJN	DRUGNAME	CTP-298
D04CJN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D01UAU	TTDDRUID	D01UAU
D01UAU	DRUGNAME	CTP-543
D01UAU	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0XV0Y	TTDDRUID	D0XV0Y
D0XV0Y	DRUGNAME	CT-P6
D0XV0Y	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D04VZS	TTDDRUID	D04VZS
D04VZS	DRUGNAME	CTS-21166
D04VZS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0Z9QX	TTDDRUID	D0Z9QX
D0Z9QX	DRUGNAME	CTX-1301
D0Z9QX	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1

D0DQ2T	TTDDRUID	D0DQ2T
D0DQ2T	DRUGNAME	Cu(II)ATSM
D0DQ2T	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1/2
D0DQ2T	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0Z4RC	TTDDRUID	D0Z4RC
D0Z4RC	DRUGNAME	CUDC-101
D0Z4RC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C1IG	TTDDRUID	D0C1IG
D0C1IG	DRUGNAME	CUDC427
D0C1IG	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0C1IG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E6UZ	TTDDRUID	D0E6UZ
D0E6UZ	DRUGNAME	CUDC-907
D0E6UZ	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
D0E6UZ	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D0E6UZ	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
D0E6UZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01LFH	TTDDRUID	D01LFH
D01LFH	DRUGNAME	Curmucin
D01LFH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07JFE	TTDDRUID	D07JFE
D07JFE	DRUGNAME	CVT-427
D07JFE	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D0G4CF	TTDDRUID	D0G4CF
D0G4CF	DRUGNAME	CVT-6883
D0G4CF	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0FC4R	TTDDRUID	D0FC4R
D0FC4R	DRUGNAME	CVX 096
D0FC4R	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D02EOS	TTDDRUID	D02EOS
D02EOS	DRUGNAME	CVX-241
D02EOS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03NTF	TTDDRUID	D03NTF
D03NTF	DRUGNAME	CWP-231
D03NTF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07AYI	TTDDRUID	D07AYI
D07AYI	DRUGNAME	CWP232291
D07AYI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D07AYI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0Z0CU	TTDDRUID	D0Z0CU
D0Z0CU	DRUGNAME	Cx-621
D0Z0CU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D04ERQ	TTDDRUID	D04ERQ
D04ERQ	DRUGNAME	CXD-101
D04ERQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00YDN	TTDDRUID	D00YDN
D00YDN	DRUGNAME	CXR-1002
D00YDN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J6AE	TTDDRUID	D0J6AE
D0J6AE	DRUGNAME	CYAD-01
D0J6AE	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0J6AE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FB4W	TTDDRUID	D0FB4W
D0FB4W	DRUGNAME	CYAD-101
D0FB4W	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0PL7P	TTDDRUID	D0PL7P
D0PL7P	DRUGNAME	CYC065
D0PL7P	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0PL7P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CY1B	TTDDRUID	D0CY1B
D0CY1B	DRUGNAME	CYC116
D0CY1B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01OYS	TTDDRUID	D01OYS
D01OYS	DRUGNAME	Cyclolignan picropodophyllin
D01OYS	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0VW0I	TTDDRUID	D0VW0I
D0VW0I	DRUGNAME	Cyclopentenylcytosine
D0VW0I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FT5T	TTDDRUID	D0FT5T
D0FT5T	DRUGNAME	CYP2001
D0FT5T	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 1

D09YAS	TTDDRUID	D09YAS
D09YAS	DRUGNAME	CYT-013-IL1bQb
D09YAS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D05ONA	TTDDRUID	D05ONA
D05ONA	DRUGNAME	Cyt-1010
D05ONA	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0A4VJ	TTDDRUID	D0A4VJ
D0A4VJ	DRUGNAME	CYT-500
D0A4VJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0DC8J	TTDDRUID	D0DC8J
D0DC8J	DRUGNAME	CYT-609
D0DC8J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07FIC	TTDDRUID	D07FIC
D07FIC	DRUGNAME	CYT-6091
D07FIC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Z5VG	TTDDRUID	D0Z5VG
D0Z5VG	DRUGNAME	CZ-48
D0Z5VG	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0Z5VG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09ISS	TTDDRUID	D09ISS
D09ISS	DRUGNAME	CZEN-001
D09ISS	INDICATI	Pruritus [ICD-11: EC90] Phase 1

D0J7ML	TTDDRUID	D0J7ML
D0J7ML	DRUGNAME	D-20133
D0J7ML	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A2VZ	TTDDRUID	D0A2VZ
D0A2VZ	DRUGNAME	D-3252
D0A2VZ	INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1

D04FKX	TTDDRUID	D04FKX
D04FKX	DRUGNAME	D-3263
D04FKX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05LPW	TTDDRUID	D05LPW
D05LPW	DRUGNAME	DA-1229
D05LPW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0V3ZX	TTDDRUID	D0V3ZX
D0V3ZX	DRUGNAME	DA-3607
D0V3ZX	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1

D0V1OC	TTDDRUID	D0V1OC
D0V1OC	DRUGNAME	DA-3880
D0V1OC	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D00ZGF	TTDDRUID	D00ZGF
D00ZGF	DRUGNAME	DA-6886
D00ZGF	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 1

D0HX1T	TTDDRUID	D0HX1T
D0HX1T	DRUGNAME	DA-697b
D0HX1T	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0HJ7I	TTDDRUID	D0HJ7I
D0HJ7I	DRUGNAME	DA-727
D0HJ7I	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D09URP	TTDDRUID	D09URP
D09URP	DRUGNAME	DABIS MALEATE
D09URP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07BXE	TTDDRUID	D07BXE
D07BXE	DRUGNAME	Daniquidone
D07BXE	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0WH4V	TTDDRUID	D0WH4V
D0WH4V	DRUGNAME	Dapivirine vaginal ring
D0WH4V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0X7PH	TTDDRUID	D0X7PH
D0X7PH	DRUGNAME	Darunavir STR
D0X7PH	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D0K5CJ	TTDDRUID	D0K5CJ
D0K5CJ	DRUGNAME	DAVLB-HYDRAZIDE
D0K5CJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0JN9Z	TTDDRUID	D0JN9Z
D0JN9Z	DRUGNAME	DB103
D0JN9Z	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D08SAX	TTDDRUID	D08SAX
D08SAX	DRUGNAME	DB-772d
D08SAX	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0RH3S	TTDDRUID	D0RH3S
D0RH3S	DRUGNAME	DC/I540/KLH vaccine
D0RH3S	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1

D0E0NM	TTDDRUID	D0E0NM
D0E0NM	DRUGNAME	DCC-2036
D0E0NM	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0E0NM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0M5XJ	TTDDRUID	D0M5XJ
D0M5XJ	DRUGNAME	DCC-3014
D0M5XJ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0M5XJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R8HY	TTDDRUID	D0R8HY
D0R8HY	DRUGNAME	DCCCyB
D0R8HY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D00WJC	TTDDRUID	D00WJC
D00WJC	DRUGNAME	DCDS0780A
D00WJC	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D03OKS	TTDDRUID	D03OKS
D03OKS	DRUGNAME	DC-IL-12 DNA therapeutic
D03OKS	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0K6JZ	TTDDRUID	D0K6JZ
D0K6JZ	DRUGNAME	DCLL9718S
D0K6JZ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0J2LG	TTDDRUID	D0J2LG
D0J2LG	DRUGNAME	DCVax-001
D0J2LG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D02HUY	TTDDRUID	D02HUY
D02HUY	DRUGNAME	Debio 0827
D02HUY	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D02TTL	TTDDRUID	D02TTL
D02TTL	DRUGNAME	Debio 0932
D02TTL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07XXT	TTDDRUID	D07XXT
D07XXT	DRUGNAME	DEDN-6526A
D07XXT	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D08EEO	TTDDRUID	D08EEO
D08EEO	DRUGNAME	Demobesin
D08EEO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0QJ6L	TTDDRUID	D0QJ6L
D0QJ6L	DRUGNAME	Demogastrin
D0QJ6L	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 1

D0Y0RF	TTDDRUID	D0Y0RF
D0Y0RF	DRUGNAME	Dendritic cancer cell vaccine
D0Y0RF	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D03CLP	TTDDRUID	D03CLP
D03CLP	DRUGNAME	Dendritic cell vaccine
D03CLP	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D05CPS	TTDDRUID	D05CPS
D05CPS	DRUGNAME	Dendritic cell vaccine
D05CPS	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1

D0RC1R	TTDDRUID	D0RC1R
D0RC1R	DRUGNAME	Dendritic cell-based exosome vaccine
D0RC1R	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1

D0A6CC	TTDDRUID	D0A6CC
D0A6CC	DRUGNAME	Depatuxizumab
D0A6CC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0ZE7D	TTDDRUID	D0ZE7D
D0ZE7D	DRUGNAME	Depatuxizumab mafodotin
D0ZE7D	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
D0ZE7D	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3

D0E2NQ	TTDDRUID	D0E2NQ
D0E2NQ	DRUGNAME	Depression NCE
D0E2NQ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1

D0Z6AR	TTDDRUID	D0Z6AR
D0Z6AR	DRUGNAME	Descartes-08
D0Z6AR	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0T5AW	TTDDRUID	D0T5AW
D0T5AW	DRUGNAME	Desoxypeganine
D0T5AW	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1

D0L3CQ	TTDDRUID	D0L3CQ
D0L3CQ	DRUGNAME	Dexpirronium
D0L3CQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0U0BP	TTDDRUID	D0U0BP
D0U0BP	DRUGNAME	DFP 13318
D0U0BP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S9MD	TTDDRUID	D0S9MD
D0S9MD	DRUGNAME	DFP-11207
D0S9MD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J9YS	TTDDRUID	D0J9YS
D0J9YS	DRUGNAME	DFRF4539A
D0J9YS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0CU2Q	TTDDRUID	D0CU2Q
D0CU2Q	DRUGNAME	DHES0815A
D0CU2Q	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0XJ6C	TTDDRUID	D0XJ6C
D0XJ6C	DRUGNAME	DIAPLASININ
D0XJ6C	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D01FQV	TTDDRUID	D01FQV
D01FQV	DRUGNAME	Dichloroacetate sodium
D01FQV	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 1

D0GB3Z	TTDDRUID	D0GB3Z
D0GB3Z	DRUGNAME	Dicoppcopper gluconate + disulfiram
D0GB3Z	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D09EFX	TTDDRUID	D09EFX
D09EFX	DRUGNAME	Diphtheria and tetanus toxoids
D09EFX	INDICATI	Poliomyelitis [ICD-11: 1C81] Phase 1

D00POS	TTDDRUID	D00POS
D00POS	DRUGNAME	DL-017
D00POS	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0S0GO	TTDDRUID	D0S0GO
D0S0GO	DRUGNAME	DLYE-5953A
D0S0GO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04ZIZ	TTDDRUID	D04ZIZ
D04ZIZ	DRUGNAME	DMUC-5754A
D04ZIZ	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D04ZIZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D04ZIZ	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1

D02DTG	TTDDRUID	D02DTG
D02DTG	DRUGNAME	DNA vaccine (hepatitis B infection)
D02DTG	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D02CLU	TTDDRUID	D02CLU
D02CLU	DRUGNAME	DNA vaccine, Memorial Sloan-Kettering Cancer Center
D02CLU	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0L2KL	TTDDRUID	D0L2KL
D0L2KL	DRUGNAME	DNA/MVA HIV vaccine
D0L2KL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0K4UT	TTDDRUID	D0K4UT
D0K4UT	DRUGNAME	DNA-2401
D0K4UT	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
D0K4UT	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D08WFH	TTDDRUID	D08WFH
D08WFH	DRUGNAME	DNA-HIV-C/NYVAC-HIV-C
D08WFH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D03YBQ	TTDDRUID	D03YBQ
D03YBQ	DRUGNAME	DNL151
D03YBQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0K6UV	TTDDRUID	D0K6UV
D0K6UV	DRUGNAME	DNL201
D0K6UV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0L9JX	TTDDRUID	D0L9JX
D0L9JX	DRUGNAME	DNX-2401
D0L9JX	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D0L9JX	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
D0L9JX	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0U1HR	TTDDRUID	D0U1HR
D0U1HR	DRUGNAME	Donor-derived CD19/22 bispecific CAR-T cells
D0U1HR	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0N0AJ	TTDDRUID	D0N0AJ
D0N0AJ	DRUGNAME	Double mutant heat-labile toxin
D0N0AJ	INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 1

D0UC5C	TTDDRUID	D0UC5C
D0UC5C	DRUGNAME	DP-1038
D0UC5C	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1

D05HAD	TTDDRUID	D05HAD
D05HAD	DRUGNAME	DP-4088
D05HAD	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 1

D06XYL	TTDDRUID	D06XYL
D06XYL	DRUGNAME	DP-6001
D06XYL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0RW5O	TTDDRUID	D0RW5O
D0RW5O	DRUGNAME	DPX-0907
D0RW5O	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0T2IF	TTDDRUID	D0T2IF
D0T2IF	DRUGNAME	DPX-survivac cancer vaccine
D0T2IF	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D09CZS	TTDDRUID	D09CZS
D09CZS	DRUGNAME	DRF-1042
D09CZS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00XMZ	TTDDRUID	D00XMZ
D00XMZ	DRUGNAME	Drug 1940029
D00XMZ	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1

D0C5OK	TTDDRUID	D0C5OK
D0C5OK	DRUGNAME	Drug 2838232
D0C5OK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0I4QA	TTDDRUID	D0I4QA
D0I4QA	DRUGNAME	Drug 2849330
D0I4QA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Z3BU	TTDDRUID	D0Z3BU
D0Z3BU	DRUGNAME	Drug 2878175
D0Z3BU	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1

D0D3FP	TTDDRUID	D0D3FP
D0D3FP	DRUGNAME	Drug 2881078
D0D3FP	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D06RHC	TTDDRUID	D06RHC
D06RHC	DRUGNAME	DS-1040
D06RHC	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1

D0E0YW	TTDDRUID	D0E0YW
D0E0YW	DRUGNAME	DS-1062
D0E0YW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0E6VR	TTDDRUID	D0E6VR
D0E6VR	DRUGNAME	DS-1093
D0E6VR	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D03UZC	TTDDRUID	D03UZC
D03UZC	DRUGNAME	DS-1150b
D03UZC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D06THG	TTDDRUID	D06THG
D06THG	DRUGNAME	DS-1205
D06THG	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D01RQN	TTDDRUID	D01RQN
D01RQN	DRUGNAME	DS-1971
D01RQN	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D06SBD	TTDDRUID	D06SBD
D06SBD	DRUGNAME	DS-2248
D06SBD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08JSQ	TTDDRUID	D08JSQ
D08JSQ	DRUGNAME	DS-3032
D08JSQ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D08JSQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W3IO	TTDDRUID	D0W3IO
D0W3IO	DRUGNAME	DS3032b
D0W3IO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R9VX	TTDDRUID	D0R9VX
D0R9VX	DRUGNAME	DS-3078
D0R9VX	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0R9VX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0LG8T	TTDDRUID	D0LG8T
D0LG8T	DRUGNAME	DS-3201
D0LG8T	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0LG8T	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0T5FU	TTDDRUID	D0T5FU
D0T5FU	DRUGNAME	DS-3801
D0T5FU	INDICATI	Constipation [ICD-11: DD91.1] Phase 1

D0N0DU	TTDDRUID	D0N0DU
D0N0DU	DRUGNAME	DS-6051
D0N0DU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03MDW	TTDDRUID	D03MDW
D03MDW	DRUGNAME	DS-7309
D03MDW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0X4RT	TTDDRUID	D0X4RT
D0X4RT	DRUGNAME	DS-7423
D0X4RT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C1LH	TTDDRUID	D0C1LH
D0C1LH	DRUGNAME	DS-8273
D0C1LH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0C1LH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03YBJ	TTDDRUID	D03YBJ
D03YBJ	DRUGNAME	DS-8895
D03YBJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M5MW	TTDDRUID	D0M5MW
D0M5MW	DRUGNAME	DSP-0509
D0M5MW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06EDP	TTDDRUID	D06EDP
D06EDP	DRUGNAME	DSP-0565
D06EDP	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0Y2GJ	TTDDRUID	D0Y2GJ
D0Y2GJ	DRUGNAME	DSP-1053
D0Y2GJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D0AI8V	TTDDRUID	D0AI8V
D0AI8V	DRUGNAME	DSP-1200
D0AI8V	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1

D0VE7B	TTDDRUID	D0VE7B
D0VE7B	DRUGNAME	DSP-2230
D0VE7B	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D09INX	TTDDRUID	D09INX
D09INX	DRUGNAME	DSP-3905
D09INX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D0Y8RS	TTDDRUID	D0Y8RS
D0Y8RS	DRUGNAME	DSP-6745
D0Y8RS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0L0RI	TTDDRUID	D0L0RI
D0L0RI	DRUGNAME	DSP-7888
D0L0RI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0L0RI	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0L0RI	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D0L0RI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07IGC	TTDDRUID	D07IGC
D07IGC	DRUGNAME	DSP-8658
D07IGC	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D07IGC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0C4FS	TTDDRUID	D0C4FS
D0C4FS	DRUGNAME	DT-200
D0C4FS	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D0F3NB	TTDDRUID	D0F3NB
D0F3NB	DRUGNAME	DTRMWXHS 12
D0F3NB	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0F3NB	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D0YP0C	TTDDRUID	D0YP0C
D0YP0C	DRUGNAME	DT-TX-30
D0YP0C	INDICATI	Angina pectoris [ICD-11: BA40] Phase 1

D03MTU	TTDDRUID	D03MTU
D03MTU	DRUGNAME	Dual Specificity CD19 and CD22 CAR-T Cell
D03MTU	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D03MTU	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D03MTU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0C5FA	TTDDRUID	D0C5FA
D0C5FA	DRUGNAME	Duvortuxizumab
D0C5FA	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D04WCJ	TTDDRUID	D04WCJ
D04WCJ	DRUGNAME	DV-100
D04WCJ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D00CGX	TTDDRUID	D00CGX
D00CGX	DRUGNAME	DV-1179
D00CGX	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
D00CGX	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 1

D0X8VX	TTDDRUID	D0X8VX
D0X8VX	DRUGNAME	DV281
D0X8VX	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0Z2GQ	TTDDRUID	D0Z2GQ
D0Z2GQ	DRUGNAME	DV-601
D0Z2GQ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D0G0ER	TTDDRUID	D0G0ER
D0G0ER	DRUGNAME	DWJ-208
D0G0ER	INDICATI	Cancer related pain [ICD-11: MG30] Phase 1
D0G0ER	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
D0G0ER	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06KWU	TTDDRUID	D06KWU
D06KWU	DRUGNAME	DWP-09031
D06KWU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0U1UN	TTDDRUID	D0U1UN
D0U1UN	DRUGNAME	DWP-10292
D0U1UN	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1

D05FGP	TTDDRUID	D05FGP
D05FGP	DRUGNAME	DWP-418
D05FGP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08SXV	TTDDRUID	D08SXV
D08SXV	DRUGNAME	DWP-422
D08SXV	INDICATI	Arthritis [ICD-11: FA20] Phase 1

D0H9RD	TTDDRUID	D0H9RD
D0H9RD	DRUGNAME	DZ-2640
D0H9RD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D05HBZ	TTDDRUID	D05HBZ
D05HBZ	DRUGNAME	E 7974
D05HBZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0F0JJ	TTDDRUID	D0F0JJ
D0F0JJ	DRUGNAME	E2012
D0F0JJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0S0FD	TTDDRUID	D0S0FD
D0S0FD	DRUGNAME	E2027
D0S0FD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0I1OS	TTDDRUID	D0I1OS
D0I1OS	DRUGNAME	E-2212
D0I1OS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D00YAH	TTDDRUID	D00YAH
D00YAH	DRUGNAME	E2730
D00YAH	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D01SHJ	TTDDRUID	D01SHJ
D01SHJ	DRUGNAME	E7046
D01SHJ	INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Phase 1

D09ETH	TTDDRUID	D09ETH
D09ETH	DRUGNAME	E-7050
D09ETH	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1

D00OOZ	TTDDRUID	D00OOZ
D00OOZ	DRUGNAME	E-7107
D00OOZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O9ZT	TTDDRUID	D0O9ZT
D0O9ZT	DRUGNAME	Ebola vaccine
D0O9ZT	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0P7TK	TTDDRUID	D0P7TK
D0P7TK	DRUGNAME	Ebola virus vaccine + Matrix-M
D0P7TK	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0M0XU	TTDDRUID	D0M0XU
D0M0XU	DRUGNAME	Ebola/Marburg vaccine
D0M0XU	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D01BPP	TTDDRUID	D01BPP
D01BPP	DRUGNAME	EC0225
D01BPP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06CVN	TTDDRUID	D06CVN
D06CVN	DRUGNAME	EC0489
D06CVN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09HUU	TTDDRUID	D09HUU
D09HUU	DRUGNAME	EC1456
D09HUU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0UD1J	TTDDRUID	D0UD1J
D0UD1J	DRUGNAME	EDP1066
D0UD1J	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
D0UD1J	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0P6NP	TTDDRUID	D0P6NP
D0P6NP	DRUGNAME	EDP-239
D0P6NP	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D09LSY	TTDDRUID	D09LSY
D09LSY	DRUGNAME	EDP-322
D09LSY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0M5KQ	TTDDRUID	D0M5KQ
D0M5KQ	DRUGNAME	Edurant LA
D0M5KQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D07STB	TTDDRUID	D07STB
D07STB	DRUGNAME	EG-1962
D07STB	INDICATI	Subarachnoid hemorrhage [ICD-11: 8B01] Phase 3

D0R9WD	TTDDRUID	D0R9WD
D0R9WD	DRUGNAME	Egalet-004
D0R9WD	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D0I7ZH	TTDDRUID	D0I7ZH
D0I7ZH	DRUGNAME	EGFR806-specific CAR T cell
D0I7ZH	INDICATI	Atypical teratoid/rhabdoid tumour [ICD-11: 2A00.1Y] Phase 1
D0I7ZH	INDICATI	Choroid plexus carcinoma [ICD-11: 2A02.12] Phase 1
D0I7ZH	INDICATI	Ependymoma [ICD-11: 2A00.0Y] Phase 1
D0I7ZH	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0I7ZH	INDICATI	Germ cell tumour [ICD-11: 2C80.2] Phase 1
D0I7ZH	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
D0I7ZH	INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 1
D0I7ZH	INDICATI	Pineoblastoma [ICD-11: 2A00.20] Phase 1

D07TMJ	TTDDRUID	D07TMJ
D07TMJ	DRUGNAME	EGFRt/19-28z/4-1BBL CAR T cells
D07TMJ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D01LWE	TTDDRUID	D01LWE
D01LWE	DRUGNAME	EGFRvIII CAR T cells
D01LWE	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D01LWE	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0PT2M	TTDDRUID	D0PT2M
D0PT2M	DRUGNAME	EGFRvIII-CARs
D0PT2M	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D08OUL	TTDDRUID	D08OUL
D08OUL	DRUGNAME	EGT-0001474
D08OUL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D04VMG	TTDDRUID	D04VMG
D04VMG	DRUGNAME	ELEMENE
D04VMG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0DV8Z	TTDDRUID	D0DV8Z
D0DV8Z	DRUGNAME	Elezanumab
D0DV8Z	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
D0DV8Z	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1

D09VBE	TTDDRUID	D09VBE
D09VBE	DRUGNAME	Elinogrel
D09VBE	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1

D01CYT	TTDDRUID	D01CYT
D01CYT	DRUGNAME	ELND-002
D01CYT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D05JPJ	TTDDRUID	D05JPJ
D05JPJ	DRUGNAME	ELND-004
D05JPJ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0E1VV	TTDDRUID	D0E1VV
D0E1VV	DRUGNAME	ELOMOTECAN HYDROCHLORIDE
D0E1VV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04MGD	TTDDRUID	D04MGD
D04MGD	DRUGNAME	Elpetrigine
D04MGD	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1

D00MJI	TTDDRUID	D00MJI
D00MJI	DRUGNAME	Emactuzumab
D00MJI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0WU7X	TTDDRUID	D0WU7X
D0WU7X	DRUGNAME	EMB-001
D0WU7X	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 1

D05QIU	TTDDRUID	D05QIU
D05QIU	DRUGNAME	Embeconazole
D05QIU	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1

D0Y8UV	TTDDRUID	D0Y8UV
D0Y8UV	DRUGNAME	EMD-1204831
D0Y8UV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q5QC	TTDDRUID	D0Q5QC
D0Q5QC	DRUGNAME	EMD-534085
D0Q5QC	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D05VHB	TTDDRUID	D05VHB
D05VHB	DRUGNAME	EMP-123
D05VHB	INDICATI	Peanut hypersensitivity [ICD-11: 4A83] Phase 1

D0RK4I	TTDDRUID	D0RK4I
D0RK4I	DRUGNAME	Empagliflozin + linagliptin + metformin
D0RK4I	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D00TNZ	TTDDRUID	D00TNZ
D00TNZ	DRUGNAME	Enadenotucirev
D00TNZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07UKJ	TTDDRUID	D07UKJ
D07UKJ	DRUGNAME	Enavatuzumab
D07UKJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08EEU	TTDDRUID	D08EEU
D08EEU	DRUGNAME	Englitazone sodium
D08EEU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D05BSG	TTDDRUID	D05BSG
D05BSG	DRUGNAME	Enkastim-ev
D05BSG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y5QD	TTDDRUID	D0Y5QD
D0Y5QD	DRUGNAME	ENMD-1198
D0Y5QD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S1WV	TTDDRUID	D0S1WV
D0S1WV	DRUGNAME	Enoblituzumab
D0S1WV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
D0S1WV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0WZ3G	TTDDRUID	D0WZ3G
D0WZ3G	DRUGNAME	Entolimod
D0WZ3G	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0WZ3G	INDICATI	Radiation syndrome [ICD-11: NF00] Phase 1
D0WZ3G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X7CI	TTDDRUID	D0X7CI
D0X7CI	DRUGNAME	EP HIV-1090
D0X7CI	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0YH0I	TTDDRUID	D0YH0I
D0YH0I	DRUGNAME	EP HIV-1090 vaccine
D0YH0I	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0Q7AH	TTDDRUID	D0Q7AH
D0Q7AH	DRUGNAME	EP-1043
D0Q7AH	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0L9HZ	TTDDRUID	D0L9HZ
D0L9HZ	DRUGNAME	EP1090
D0L9HZ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0SB2G	TTDDRUID	D0SB2G
D0SB2G	DRUGNAME	EP-1300
D0SB2G	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D04FGX	TTDDRUID	D04FGX
D04FGX	DRUGNAME	EP-302
D04FGX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D04FGX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G6UQ	TTDDRUID	D0G6UQ
D0G6UQ	DRUGNAME	EP-42675
D0G6UQ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D01DFS	TTDDRUID	D01DFS
D01DFS	DRUGNAME	EP4-R antagonist
D01DFS	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
D01DFS	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0Z6WI	TTDDRUID	D0Z6WI
D0Z6WI	DRUGNAME	EP-51216
D0Z6WI	INDICATI	Eating disorder [ICD-11: 6B82] Phase 1

D0O1LU	TTDDRUID	D0O1LU
D0O1LU	DRUGNAME	EP-51389
D0O1LU	INDICATI	Eating disorder [ICD-11: 6B82] Phase 1

D07LPT	TTDDRUID	D07LPT
D07LPT	DRUGNAME	EP-7041
D07LPT	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0W4QB	TTDDRUID	D0W4QB
D0W4QB	DRUGNAME	EPI-12323 combination therapy
D0W4QB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D05QWS	TTDDRUID	D05QWS
D05QWS	DRUGNAME	Epicardial angiogenesis patch
D05QWS	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1

D05IEN	TTDDRUID	D05IEN
D05IEN	DRUGNAME	Epstein Barr-based gene therapy
D05IEN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05GPB	TTDDRUID	D05GPB
D05GPB	DRUGNAME	Eptacog alfa intravenous
D05GPB	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1

D07YKQ	TTDDRUID	D07YKQ
D07YKQ	DRUGNAME	EPX-100
D07YKQ	INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 1

D0C6GK	TTDDRUID	D0C6GK
D0C6GK	DRUGNAME	EPZ-5676
D0C6GK	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0C6GK	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
D0C6GK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0C6GK	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D05KUP	TTDDRUID	D05KUP
D05KUP	DRUGNAME	ERB-257
D05KUP	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 1

D0IK5R	TTDDRUID	D0IK5R
D0IK5R	DRUGNAME	ERY974
D0IK5R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05UTW	TTDDRUID	D05UTW
D05UTW	DRUGNAME	ErythroMax
D05UTW	INDICATI	Hypoxia [ICD-11: MD11.1] Phase 1

D02RHC	TTDDRUID	D02RHC
D02RHC	DRUGNAME	ET190
D02RHC	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0LU4I	TTDDRUID	D0LU4I
D0LU4I	DRUGNAME	ETBX-011 cancer vaccine
D0LU4I	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1

D08LQS	TTDDRUID	D08LQS
D08LQS	DRUGNAME	ETBX-021
D08LQS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D05FKU	TTDDRUID	D05FKU
D05FKU	DRUGNAME	ETC-1922159
D05FKU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J1TN	TTDDRUID	D0J1TN
D0J1TN	DRUGNAME	ETEC vaccine
D0J1TN	INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 1
D0J1TN	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 1

D0JV2E	TTDDRUID	D0JV2E
D0JV2E	DRUGNAME	ETEC vaccine, Vaccine Technologies
D0JV2E	INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 1

D0L5JA	TTDDRUID	D0L5JA
D0L5JA	DRUGNAME	ETS-2101
D0L5JA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09KIG	TTDDRUID	D09KIG
D09KIG	DRUGNAME	ETX201
D09KIG	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D06VAQ	TTDDRUID	D06VAQ
D06VAQ	DRUGNAME	EUK-189
D06VAQ	INDICATI	Skin burns [ICD-11: ME65.0] Phase 1

D0ML5T	TTDDRUID	D0ML5T
D0ML5T	DRUGNAME	EUR-1066
D0ML5T	INDICATI	Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 1

D09ZZB	TTDDRUID	D09ZZB
D09ZZB	DRUGNAME	EV71 vaccine
D09ZZB	INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 1

D0EP3H	TTDDRUID	D0EP3H
D0EP3H	DRUGNAME	EvofosfamideORPHAN DRUG
D0EP3H	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0A1XU	TTDDRUID	D0A1XU
D0A1XU	DRUGNAME	EVP-6308
D0A1XU	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D01TLV	TTDDRUID	D01TLV
D01TLV	DRUGNAME	EVT 401
D01TLV	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0S3EK	TTDDRUID	D0S3EK
D0S3EK	DRUGNAME	EVT100
D0S3EK	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D04SQJ	TTDDRUID	D04SQJ
D04SQJ	DRUGNAME	EW-A-401
D04SQJ	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 1

D0RD1Z	TTDDRUID	D0RD1Z
D0RD1Z	DRUGNAME	Exebryl-1
D0RD1Z	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0EN3B	TTDDRUID	D0EN3B
D0EN3B	DRUGNAME	ExpressGraft
D0EN3B	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1

D0NF5J	TTDDRUID	D0NF5J
D0NF5J	DRUGNAME	EZN-2968
D0NF5J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01GQD	TTDDRUID	D01GQD
D01GQD	DRUGNAME	EZN-3042
D01GQD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09RND	TTDDRUID	D09RND
D09RND	DRUGNAME	EZN-4176
D09RND	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D00XWB	TTDDRUID	D00XWB
D00XWB	DRUGNAME	F-15845
D00XWB	INDICATI	Angina pectoris [ICD-11: BA40] Phase 1

D00EYC	TTDDRUID	D00EYC
D00EYC	DRUGNAME	F-7TG
D00EYC	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1

D0E7DH	TTDDRUID	D0E7DH
D0E7DH	DRUGNAME	Factor VIII gene therapy
D0E7DH	INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1

D0A9GE	TTDDRUID	D0A9GE
D0A9GE	DRUGNAME	FATE-NK100
D0A9GE	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0A9GE	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0A9GE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0LU1O	TTDDRUID	D0LU1O
D0LU1O	DRUGNAME	FAZ053
D0LU1O	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D0LU1O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02IIM	TTDDRUID	D02IIM
D02IIM	DRUGNAME	FCX-013
D02IIM	INDICATI	Scleroderma [ICD-11: 4A42] Phase 1

D08CWP	TTDDRUID	D08CWP
D08CWP	DRUGNAME	Fenretinide intravenous
D08CWP	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D08CWP	INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
D08CWP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
D08CWP	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D03XQI	TTDDRUID	D03XQI
D03XQI	DRUGNAME	Fentanyl transdermal
D03XQI	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D07SQT	TTDDRUID	D07SQT
D07SQT	DRUGNAME	Ferroportin mab
D07SQT	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D0YQ9I	TTDDRUID	D0YQ9I
D0YQ9I	DRUGNAME	FF-10101-01
D0YQ9I	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0U1KE	TTDDRUID	D0U1KE
D0U1KE	DRUGNAME	FF-10502-01
D0U1KE	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0U1KE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00VUG	TTDDRUID	D00VUG
D00VUG	DRUGNAME	FF21101
D00VUG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E1HF	TTDDRUID	D0E1HF
D0E1HF	DRUGNAME	FFC-14A
D0E1HF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03RCB	TTDDRUID	D03RCB
D03RCB	DRUGNAME	FGI-101-1A6
D03RCB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D06EXI	TTDDRUID	D06EXI
D06EXI	DRUGNAME	FGLL
D06EXI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D07XDQ	TTDDRUID	D07XDQ
D07XDQ	DRUGNAME	Figopitant
D07XDQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D05WQT	TTDDRUID	D05WQT
D05WQT	DRUGNAME	Flanvotumab
D05WQT	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0NA1Y	TTDDRUID	D0NA1Y
D0NA1Y	DRUGNAME	Flecainide inhalation
D0NA1Y	INDICATI	Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 1

D0YA1B	TTDDRUID	D0YA1B
D0YA1B	DRUGNAME	Flotetuzumab
D0YA1B	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0YA1B	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0M8RW	TTDDRUID	D0M8RW
D0M8RW	DRUGNAME	FluCell
D0M8RW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0TO2R	TTDDRUID	D0TO2R
D0TO2R	DRUGNAME	Fludarabine phosphate
D0TO2R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V9LJ	TTDDRUID	D0V9LJ
D0V9LJ	DRUGNAME	Flufirvitide-3 nasal spray
D0V9LJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0OO3J	TTDDRUID	D0OO3J
D0OO3J	DRUGNAME	FluGEM
D0OO3J	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0Q0KX	TTDDRUID	D0Q0KX
D0Q0KX	DRUGNAME	Fluorapacin
D0Q0KX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V0XV	TTDDRUID	D0V0XV
D0V0XV	DRUGNAME	FLU-v
D0V0XV	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0XD7V	TTDDRUID	D0XD7V
D0XD7V	DRUGNAME	FLX475
D0XD7V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05FWF	TTDDRUID	D05FWF
D05FWF	DRUGNAME	Fostrap
D05FWF	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 1

D0F470	TTDDRUID	D0F470
D0F470	DRUGNAME	FP-025
D0F470	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0BI7J	TTDDRUID	D0BI7J
D0BI7J	DRUGNAME	FP-045
D0BI7J	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D01OOQ	TTDDRUID	D01OOQ
D01OOQ	DRUGNAME	FP-253-GDEPT
D01OOQ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D06UND	TTDDRUID	D06UND
D06UND	DRUGNAME	FP-85A
D06UND	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1

D06NND	TTDDRUID	D06NND
D06NND	DRUGNAME	FPA144
D06NND	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
D06NND	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1

D0TO0C	TTDDRUID	D0TO0C
D0TO0C	DRUGNAME	FPA150
D0TO0C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G6HI	TTDDRUID	D0G6HI
D0G6HI	DRUGNAME	Friulimicin topical
D0G6HI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0XO9F	TTDDRUID	D0XO9F
D0XO9F	DRUGNAME	FS118
D0XO9F	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D0XO9F	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1

D08COU	TTDDRUID	D08COU
D08COU	DRUGNAME	FSH patch
D08COU	INDICATI	Infertility [ICD-11: GB04] Phase 1

D0Z1GP	TTDDRUID	D0Z1GP
D0Z1GP	DRUGNAME	FT-1050-treated umbilical cord stem cell therapy
D0Z1GP	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1

D0TM0Y	TTDDRUID	D0TM0Y
D0TM0Y	DRUGNAME	FT-1101
D0TM0Y	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D07VYP	TTDDRUID	D07VYP
D07VYP	DRUGNAME	FT-2102
D07VYP	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D07VYP	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D04THH	TTDDRUID	D04THH
D04THH	DRUGNAME	Fulvestrant for injectable suspension
D04THH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D07OXW	TTDDRUID	D07OXW
D07OXW	DRUGNAME	FVh1 DNA-based influenza vaccine
D07OXW	INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1

D04WHM	TTDDRUID	D04WHM
D04WHM	DRUGNAME	G0-203-2c
D04WHM	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D01XZG	TTDDRUID	D01XZG
D01XZG	DRUGNAME	G1T28-1
D01XZG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W2RY	TTDDRUID	D0W2RY
D0W2RY	DRUGNAME	G530L
D0W2RY	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0RU7T	TTDDRUID	D0RU7T
D0RU7T	DRUGNAME	G-619
D0RU7T	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D03DKR	TTDDRUID	D03DKR
D03DKR	DRUGNAME	GALAMUSTINE HYDROCHLORIDE
D03DKR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IW4E	TTDDRUID	D0IW4E
D0IW4E	DRUGNAME	GALE-301 + GALE-302
D0IW4E	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D0M9OO	TTDDRUID	D0M9OO
D0M9OO	DRUGNAME	Galinpepimut-S
D0M9OO	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0M9OO	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
D0M9OO	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2
D0M9OO	INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 2
D0M9OO	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
D0M9OO	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D0M9OO	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0M9OO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0GD9E	TTDDRUID	D0GD9E
D0GD9E	DRUGNAME	GAP T cells
D0GD9E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09BNR	TTDDRUID	D09BNR
D09BNR	DRUGNAME	Gazyva
D09BNR	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D04GAG	TTDDRUID	D04GAG
D04GAG	DRUGNAME	GBR 1342
D04GAG	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0Y5WX	TTDDRUID	D0Y5WX
D0Y5WX	DRUGNAME	GBR 310
D0Y5WX	INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 1

D0D4HO	TTDDRUID	D0D4HO
D0D4HO	DRUGNAME	GC021109
D0D4HO	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0P0TA	TTDDRUID	D0P0TA
D0P0TA	DRUGNAME	GC-1008
D0P0TA	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1
D0P0TA	INDICATI	Pleural disease [ICD-11: CB27] Investigative

D0KV1I	TTDDRUID	D0KV1I
D0KV1I	DRUGNAME	GC-1113
D0KV1I	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D07HYR	TTDDRUID	D07HYR
D07HYR	DRUGNAME	GCC-1290K
D07HYR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D00RGF	TTDDRUID	D00RGF
D00RGF	DRUGNAME	GCC-4401
D00RGF	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0QB7N	TTDDRUID	D0QB7N
D0QB7N	DRUGNAME	GD2 T cells
D0QB7N	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
D0QB7N	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1

D0GW8X	TTDDRUID	D0GW8X
D0GW8X	DRUGNAME	GDC-0077
D0GW8X	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0GW8X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07BGC	TTDDRUID	D07BGC
D07BGC	DRUGNAME	GDC-0084
D07BGC	INDICATI	Glioma [ICD-11: 2A00.0] Discontinued in Phase 1
D07BGC	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0Y1FU	TTDDRUID	D0Y1FU
D0Y1FU	DRUGNAME	GDC0134
D0Y1FU	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1

D07CLV	TTDDRUID	D07CLV
D07CLV	DRUGNAME	GDC-0152
D07CLV	INDICATI	Obesity [ICD-11: 5B81] Phase 1
D07CLV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D01FZZ	TTDDRUID	D01FZZ
D01FZZ	DRUGNAME	GDC0310
D01FZZ	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D0U8QH	TTDDRUID	D0U8QH
D0U8QH	DRUGNAME	GDC-0349
D0U8QH	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D01ZUV	TTDDRUID	D01ZUV
D01ZUV	DRUGNAME	GDC-0425
D01ZUV	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0R3VK	TTDDRUID	D0R3VK
D0R3VK	DRUGNAME	GDC-0623
D0R3VK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A9PN	TTDDRUID	D0A9PN
D0A9PN	DRUGNAME	GDC-0853
D0A9PN	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
D0A9PN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q4IX	TTDDRUID	D0Q4IX
D0Q4IX	DRUGNAME	GDC-0994
D0Q4IX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0VS9E	TTDDRUID	D0VS9E
D0VS9E	DRUGNAME	GDC-5573
D0VS9E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E4MB	TTDDRUID	D0E4MB
D0E4MB	DRUGNAME	GDC-9545
D0E4MB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0S4XZ	TTDDRUID	D0S4XZ
D0S4XZ	DRUGNAME	GE-1170A
D0S4XZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0Y3XA	TTDDRUID	D0Y3XA
D0Y3XA	DRUGNAME	Ge2270a
D0Y3XA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0DD4N	TTDDRUID	D0DD4N
D0DD4N	DRUGNAME	GEH-120714
D0DD4N	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0BN9R	TTDDRUID	D0BN9R
D0BN9R	DRUGNAME	GelVac H5N1 influenza virus vaccine intranasal
D0BN9R	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0H2JD	TTDDRUID	D0H2JD
D0H2JD	DRUGNAME	Gemcitabine prodrug
D0H2JD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CE8J	TTDDRUID	D0CE8J
D0CE8J	DRUGNAME	Genaconazole
D0CE8J	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1

D0Q3BG	TTDDRUID	D0Q3BG
D0Q3BG	DRUGNAME	Gene therapy, IFN-b
D0Q3BG	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D04FYM	TTDDRUID	D04FYM
D04FYM	DRUGNAME	Genital herpes therapy
D04FYM	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D0A1LS	TTDDRUID	D0A1LS
D0A1LS	DRUGNAME	Genz-644282
D0A1LS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07IVS	TTDDRUID	D07IVS
D07IVS	DRUGNAME	Gerilimzumab
D07IVS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0H0YZ	TTDDRUID	D0H0YZ
D0H0YZ	DRUGNAME	GGF-2
D0H0YZ	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D07RKN	TTDDRUID	D07RKN
D07RKN	DRUGNAME	GGTI-2418
D07RKN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05DSS	TTDDRUID	D05DSS
D05DSS	DRUGNAME	GI-13020
D05DSS	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D01FUJ	TTDDRUID	D01FUJ
D01FUJ	DRUGNAME	GIP/GLP-1 co-agonist peptide
D01FUJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0F6ZT	TTDDRUID	D0F6ZT
D0F6ZT	DRUGNAME	GL-0810
D0F6ZT	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D01TJY	TTDDRUID	D01TJY
D01TJY	DRUGNAME	GLPG-0187
D01TJY	INDICATI	Bone metastases [ICD-11: 2D50] Phase 1

D0N3YT	TTDDRUID	D0N3YT
D0N3YT	DRUGNAME	GLPG-0555
D0N3YT	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1

D09EMH	TTDDRUID	D09EMH
D09EMH	DRUGNAME	GLPG-0778
D09EMH	INDICATI	Arthritis [ICD-11: FA20] Phase 1

D0OG0X	TTDDRUID	D0OG0X
D0OG0X	DRUGNAME	GLS-5300
D0OG0X	INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1
D0OG0X	INDICATI	Respiratory syndrome coronavirus infection [ICD-11: 1D92] Phase 1

D0VW1I	TTDDRUID	D0VW1I
D0VW1I	DRUGNAME	GLS-5700
D0VW1I	INDICATI	Semliki forest virus infection [ICD-11: 1D9Y] Phase 1

D06ZEC	TTDDRUID	D06ZEC
D06ZEC	DRUGNAME	Glucagon
D06ZEC	INDICATI	Hypoglycemia [ICD-11: 5A41] Phase 1

D0U4GL	TTDDRUID	D0U4GL
D0U4GL	DRUGNAME	GLWL-01
D0U4GL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0MA2E	TTDDRUID	D0MA2E
D0MA2E	DRUGNAME	GLYCAR T cells
D0MA2E	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1

D0YP8F	TTDDRUID	D0YP8F
D0YP8F	DRUGNAME	Glypican3-ADC
D0YP8F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02XSL	TTDDRUID	D02XSL
D02XSL	DRUGNAME	GlyT1 PET radiotracers
D02XSL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D01QWS	TTDDRUID	D01QWS
D01QWS	DRUGNAME	GM-CT-01
D01QWS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V0FE	TTDDRUID	D0V0FE
D0V0FE	DRUGNAME	GMI-1359
D0V0FE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V7YA	TTDDRUID	D0V7YA
D0V7YA	DRUGNAME	GMX1777
D0V7YA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O1WR	TTDDRUID	D0O1WR
D0O1WR	DRUGNAME	GMZ-2
D0O1WR	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D0KX8B	TTDDRUID	D0KX8B
D0KX8B	DRUGNAME	GNE Lipoplex
D0KX8B	INDICATI	Myopathy [ICD-11: 8C7Y] Phase 1

D04CXX	TTDDRUID	D04CXX
D04CXX	DRUGNAME	GNKG-168
D04CXX	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D01GVC	TTDDRUID	D01GVC
D01GVC	DRUGNAME	GP-3269
D01GVC	INDICATI	Convulsion [ICD-11: 8A68.Z] Phase 1

D0O4UZ	TTDDRUID	D0O4UZ
D0O4UZ	DRUGNAME	Gp41 HIV-1 vaccine
D0O4UZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0JZ5Y	TTDDRUID	D0JZ5Y
D0JZ5Y	DRUGNAME	Gp75 DNA vaccine
D0JZ5Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08UNC	TTDDRUID	D08UNC
D08UNC	DRUGNAME	GPC3 targeting CAR-T cells
D08UNC	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D08UNC	INDICATI	Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 1

D0H4IU	TTDDRUID	D0H4IU
D0H4IU	DRUGNAME	GPI-16072
D0H4IU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D00MAN	TTDDRUID	D00MAN
D00MAN	DRUGNAME	GRC-6211
D00MAN	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0N8QR	TTDDRUID	D0N8QR
D0N8QR	DRUGNAME	GRF6019
D0N8QR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0A3CH	TTDDRUID	D0A3CH
D0A3CH	DRUGNAME	GRN-1201
D0A3CH	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0A3CH	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
D0A3CH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D04HDZ	TTDDRUID	D04HDZ
D04HDZ	DRUGNAME	GRN163
D04HDZ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D01DCJ	TTDDRUID	D01DCJ
D01DCJ	DRUGNAME	GRNOPC-1
D01DCJ	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1

D0Z9RJ	TTDDRUID	D0Z9RJ
D0Z9RJ	DRUGNAME	GS 9667
D0Z9RJ	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 1

D01ICI	TTDDRUID	D01ICI
D01ICI	DRUGNAME	GS-5734
D01ICI	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0N8RA	TTDDRUID	D0N8RA
D0N8RA	DRUGNAME	GS-5829
D0N8RA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0B5RZ	TTDDRUID	D0B5RZ
D0B5RZ	DRUGNAME	GS-6620
D0B5RZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D00IXN	TTDDRUID	D00IXN
D00IXN	DRUGNAME	GS-6637
D00IXN	INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1

D0AE1X	TTDDRUID	D0AE1X
D0AE1X	DRUGNAME	GS-9411
D0AE1X	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Phase 1

D03IJO	TTDDRUID	D03IJO
D03IJO	DRUGNAME	GS-9820
D03IJO	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D03IJO	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0U5PT	TTDDRUID	D0U5PT
D0U5PT	DRUGNAME	GS-9901
D0U5PT	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0U6FT	TTDDRUID	D0U6FT
D0U6FT	DRUGNAME	GSI-136
D0U6FT	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0IQ0Z	TTDDRUID	D0IQ0Z
D0IQ0Z	DRUGNAME	GSK1070916
D0IQ0Z	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1

D0P0HU	TTDDRUID	D0P0HU
D0P0HU	DRUGNAME	GSK1070916A
D0P0HU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P2KG	TTDDRUID	D0P2KG
D0P2KG	DRUGNAME	GSK1144814
D0P2KG	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D08BBC	TTDDRUID	D08BBC
D08BBC	DRUGNAME	GSK-114814
D08BBC	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1

D0U9HM	TTDDRUID	D0U9HM
D0U9HM	DRUGNAME	GSK-1322888
D0U9HM	INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 1

D0K7OW	TTDDRUID	D0K7OW
D0K7OW	DRUGNAME	GSK-1360707
D0K7OW	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D04LWT	TTDDRUID	D04LWT
D04LWT	DRUGNAME	GSK1440115
D04LWT	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0I7BU	TTDDRUID	D0I7BU
D0I7BU	DRUGNAME	GSK1482160
D0I7BU	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0G1YO	TTDDRUID	D0G1YO
D0G1YO	DRUGNAME	GSK1521498
D0G1YO	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D09GLS	TTDDRUID	D09GLS
D09GLS	DRUGNAME	GSK1614235
D09GLS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0MM4H	TTDDRUID	D0MM4H
D0MM4H	DRUGNAME	GSK1795091
D0MM4H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03FVR	TTDDRUID	D03FVR
D03FVR	DRUGNAME	GSK-1827771
D03FVR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D08ENB	TTDDRUID	D08ENB
D08ENB	DRUGNAME	GSK1995057
D08ENB	INDICATI	Adult respiratory distress syndrome [ICD-11: CB00] Phase 1

D0B4CD	TTDDRUID	D0B4CD
D0B4CD	DRUGNAME	GSK-2018682
D0B4CD	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1

D06VVH	TTDDRUID	D06VVH
D06VVH	DRUGNAME	GSK-2115160A
D06VVH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D03EZE	TTDDRUID	D03EZE
D03EZE	DRUGNAME	GSK2126458
D03EZE	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D02JEW	TTDDRUID	D02JEW
D02JEW	DRUGNAME	GSK-2130579A
D02JEW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0JS9U	TTDDRUID	D0JS9U
D0JS9U	DRUGNAME	GSK-2231395A
D0JS9U	INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 1

D00XBC	TTDDRUID	D00XBC
D00XBC	DRUGNAME	GSK-2239633
D00XBC	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0IA5O	TTDDRUID	D0IA5O
D0IA5O	DRUGNAME	GSK-2241658A
D0IA5O	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0B9MR	TTDDRUID	D0B9MR
D0B9MR	DRUGNAME	GSK-2256098
D0B9MR	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
D0B9MR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A8KQ	TTDDRUID	D0A8KQ
D0A8KQ	DRUGNAME	GSK2256294
D0A8KQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0AY1I	TTDDRUID	D0AY1I
D0AY1I	DRUGNAME	GSK-2315698
D0AY1I	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1

D0D3TQ	TTDDRUID	D0D3TQ
D0D3TQ	DRUGNAME	GSK2330811
D0D3TQ	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2

D0O1XV	TTDDRUID	D0O1XV
D0O1XV	DRUGNAME	GSK2374697
D0O1XV	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0EJ8K	TTDDRUID	D0EJ8K
D0EJ8K	DRUGNAME	GSK-2392102A
D0EJ8K	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1

D07LBQ	TTDDRUID	D07LBQ
D07LBQ	DRUGNAME	GSK2398852
D07LBQ	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1

D0L6OY	TTDDRUID	D0L6OY
D0L6OY	DRUGNAME	GSK-2590066A
D0L6OY	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D00SYV	TTDDRUID	D00SYV
D00SYV	DRUGNAME	GSK2618960
D00SYV	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
D00SYV	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1

D0G3MN	TTDDRUID	D0G3MN
D0G3MN	DRUGNAME	GSK2636771
D0G3MN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
D0G3MN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H2HZ	TTDDRUID	D0H2HZ
D0H2HZ	DRUGNAME	GSK2646264
D0H2HZ	INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 1
D0H2HZ	INDICATI	Urticaria [ICD-11: EB00-EB05] Phase 1

D0E6KN	TTDDRUID	D0E6KN
D0E6KN	DRUGNAME	GSK2647544
D0E6KN	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D02EYZ	TTDDRUID	D02EYZ
D02EYZ	DRUGNAME	GSK2654909A
D02EYZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1

D02JYT	TTDDRUID	D02JYT
D02JYT	DRUGNAME	GSK2654911A
D02JYT	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1

D03XRA	TTDDRUID	D03XRA
D03XRA	DRUGNAME	GSK2661380
D03XRA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V4XG	TTDDRUID	D0V4XG
D0V4XG	DRUGNAME	GSK2793660
D0V4XG	INDICATI	Bronchiectasis [ICD-11: CA24] Phase 1

D05FIJ	TTDDRUID	D05FIJ
D05FIJ	DRUGNAME	GSK2816126
D05FIJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0ZX2L	TTDDRUID	D0ZX2L
D0ZX2L	DRUGNAME	GSK2831781
D0ZX2L	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
D0ZX2L	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1

D0I2VW	TTDDRUID	D0I2VW
D0I2VW	DRUGNAME	GSK2838232
D0I2VW	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0D4UT	TTDDRUID	D0D4UT
D0D4UT	DRUGNAME	GSK2849330
D0D4UT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0YV0N	TTDDRUID	D0YV0N
D0YV0N	DRUGNAME	GSK2857916
D0YV0N	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0I4ZN	TTDDRUID	D0I4ZN
D0I4ZN	DRUGNAME	GSK2879552
D0I4ZN	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D01YDH	TTDDRUID	D01YDH
D01YDH	DRUGNAME	GSK2981710
D01YDH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0T3VF	TTDDRUID	D0T3VF
D0T3VF	DRUGNAME	GSK3050002
D0T3VF	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1

D0P0LT	TTDDRUID	D0P0LT
D0P0LT	DRUGNAME	GSK3052230
D0P0LT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O3XS	TTDDRUID	D0O3XS
D0O3XS	DRUGNAME	GSK311739
D0O3XS	INDICATI	Rhinovirus infection [ICD-11: CA07] Phase 1

D04KMQ	TTDDRUID	D04KMQ
D04KMQ	DRUGNAME	GSK3117391
D04KMQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D03HHJ	TTDDRUID	D03HHJ
D03HHJ	DRUGNAME	GSK3174998
D03HHJ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D03HHJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0AX4H	TTDDRUID	D0AX4H
D0AX4H	DRUGNAME	GSK3179106
D0AX4H	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1

D0CR7L	TTDDRUID	D0CR7L
D0CR7L	DRUGNAME	GSK3326595
D0CR7L	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0CR7L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R7BB	TTDDRUID	D0R7BB
D0R7BB	DRUGNAME	GSK3359609
D0R7BB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K9DI	TTDDRUID	D0K9DI
D0K9DI	DRUGNAME	GSK-356278
D0K9DI	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1

D08RMJ	TTDDRUID	D08RMJ
D08RMJ	DRUGNAME	GSK461364
D08RMJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D08RMJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07OFM	TTDDRUID	D07OFM
D07OFM	DRUGNAME	GSK525762
D07OFM	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D07OFM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J1FB	TTDDRUID	D0J1FB
D0J1FB	DRUGNAME	GSK586529
D0J1FB	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
D0J1FB	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1

D0T2IH	TTDDRUID	D0T2IH
D0T2IH	DRUGNAME	GSK610677
D0T2IH	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0HI1K	TTDDRUID	D0HI1K
D0HI1K	DRUGNAME	GSK618334
D0HI1K	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Phase 1
D0HI1K	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D08DPN	TTDDRUID	D08DPN
D08DPN	DRUGNAME	GSK-625433
D08DPN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0MS3Z	TTDDRUID	D0MS3Z
D0MS3Z	DRUGNAME	GSK690693
D0MS3Z	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0F2NF	TTDDRUID	D0F2NF
D0F2NF	DRUGNAME	GSK-958108
D0F2NF	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 1

D01KDM	TTDDRUID	D01KDM
D01KDM	DRUGNAME	GTP-004
D01KDM	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 1

D00OAU	TTDDRUID	D00OAU
D00OAU	DRUGNAME	GW-328267
D00OAU	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D0AX9S	TTDDRUID	D0AX9S
D0AX9S	DRUGNAME	GW-409544
D0AX9S	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D05HGL	TTDDRUID	D05HGL
D05HGL	DRUGNAME	GW-695634
D05HGL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0C1AY	TTDDRUID	D0C1AY
D0C1AY	DRUGNAME	GW-796406
D0C1AY	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 1

D07JVT	TTDDRUID	D07JVT
D07JVT	DRUGNAME	GWN323
D07JVT	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D07JVT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F8ZG	TTDDRUID	D0F8ZG
D0F8ZG	DRUGNAME	GX-G3
D0F8ZG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R3RG	TTDDRUID	D0R3RG
D0R3RG	DRUGNAME	GZ402663
D0R3RG	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D0Q1UB	TTDDRUID	D0Q1UB
D0Q1UB	DRUGNAME	GZ402666
D0Q1UB	INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 1
D0Q1UB	INDICATI	Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 1

D0U0SK	TTDDRUID	D0U0SK
D0U0SK	DRUGNAME	GZ402668
D0U0SK	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0BW2N	TTDDRUID	D0BW2N
D0BW2N	DRUGNAME	GZ402674
D0BW2N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07HLZ	TTDDRUID	D07HLZ
D07HLZ	DRUGNAME	GZ404477
D07HLZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0Z7BE	TTDDRUID	D0Z7BE
D0Z7BE	DRUGNAME	H-100
D0Z7BE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0VZ1C	TTDDRUID	D0VZ1C
D0VZ1C	DRUGNAME	H-103
D0VZ1C	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1

D04TKU	TTDDRUID	D04TKU
D04TKU	DRUGNAME	H1N1 influenza vaccine
D04TKU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0T6LU	TTDDRUID	D0T6LU
D0T6LU	DRUGNAME	H1N1 influenza vaccine
D0T6LU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0C5IZ	TTDDRUID	D0C5IZ
D0C5IZ	DRUGNAME	H1N1 vaccine
D0C5IZ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0K6ZI	TTDDRUID	D0K6ZI
D0K6ZI	DRUGNAME	H2N2 live attenuated influenza vaccine
D0K6ZI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D00ZFQ	TTDDRUID	D00ZFQ
D00ZFQ	DRUGNAME	H2N3 MO 2003/AA
D00ZFQ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0D6XT	TTDDRUID	D0D6XT
D0D6XT	DRUGNAME	H3B-6527
D0D6XT	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1

D0Z5VW	TTDDRUID	D0Z5VW
D0Z5VW	DRUGNAME	H3B-6545
D0Z5VW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0H7BF	TTDDRUID	D0H7BF
D0H7BF	DRUGNAME	H3B-8800
D0H7BF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0H7BF	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
D0H7BF	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D07WUJ	TTDDRUID	D07WUJ
D07WUJ	DRUGNAME	H5N1 influenza vaccine
D07WUJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0VZ0U	TTDDRUID	D0VZ0U
D0VZ0U	DRUGNAME	H5N1 pandemic influenza vaccine
D0VZ0U	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0H4LI	TTDDRUID	D0H4LI
D0H4LI	DRUGNAME	H6N1 influenza vaccine
D0H4LI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0U5JR	TTDDRUID	D0U5JR
D0U5JR	DRUGNAME	H7N3 avian influenza virus live attenuated vaccine
D0U5JR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0WG3X	TTDDRUID	D0WG3X
D0WG3X	DRUGNAME	HAC-1 vaccine
D0WG3X	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0H5OX	TTDDRUID	D0H5OX
D0H5OX	DRUGNAME	HAL-MPE1
D0H5OX	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D0P0YU	TTDDRUID	D0P0YU
D0P0YU	DRUGNAME	HaNK for infusion
D0P0YU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0EL0F	TTDDRUID	D0EL0F
D0EL0F	DRUGNAME	HBV-001-D1
D0EL0F	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1

D09NQX	TTDDRUID	D09NQX
D09NQX	DRUGNAME	HBV-002
D09NQX	INDICATI	West nile virus infection [ICD-11: 1D46] Phase 1

D09XRQ	TTDDRUID	D09XRQ
D09XRQ	DRUGNAME	HCBE-11
D09XRQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04IXL	TTDDRUID	D04IXL
D04IXL	DRUGNAME	HCV vaccine
D04IXL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
D04IXL	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1

D0FY0D	TTDDRUID	D0FY0D
D0FY0D	DRUGNAME	HD-201
D0FY0D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01KTG	TTDDRUID	D01KTG
D01KTG	DRUGNAME	HDM201
D01KTG	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D01KTG	INDICATI	Liposarcoma [ICD-11: 2B59] Phase 1
D01KTG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02DBA	TTDDRUID	D02DBA
D02DBA	DRUGNAME	Helicobacter pylori vaccine
D02DBA	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 1

D0N6VK	TTDDRUID	D0N6VK
D0N6VK	DRUGNAME	Hepapoietin
D0N6VK	INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 1

D02IKQ	TTDDRUID	D02IKQ
D02IKQ	DRUGNAME	Hepatitis B DNA vaccine
D02IKQ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D0WJ3C	TTDDRUID	D0WJ3C
D0WJ3C	DRUGNAME	Hepatitis B prophylactic vaccine
D0WJ3C	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D03WWW	TTDDRUID	D03WWW
D03WWW	DRUGNAME	Hepcidin
D03WWW	INDICATI	Hemochromatosis [ICD-11: 5C64.1Y] Phase 1

D0V4YW	TTDDRUID	D0V4YW
D0V4YW	DRUGNAME	Hepcidin mab
D0V4YW	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D0Q9ZU	TTDDRUID	D0Q9ZU
D0Q9ZU	DRUGNAME	HepTcell
D0Q9ZU	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D0J7HV	TTDDRUID	D0J7HV
D0J7HV	DRUGNAME	HER2.taNK
D0J7HV	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D0J7HV	INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1

D0E7RC	TTDDRUID	D0E7RC
D0E7RC	DRUGNAME	HER-2/HER-1 vaccine
D0E7RC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TN5W	TTDDRUID	D0TN5W
D0TN5W	DRUGNAME	HER2-CAR T Cells
D0TN5W	INDICATI	Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1
D0TN5W	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1

D0U2PS	TTDDRUID	D0U2PS
D0U2PS	DRUGNAME	HER2p63-71 peptide vaccine
D0U2PS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0YF6K	TTDDRUID	D0YF6K
D0YF6K	DRUGNAME	HER2-specific CAR T cell
D0YF6K	INDICATI	Atypical teratoid/rhabdoid tumour [ICD-11: 2A00.1Y] Phase 1
D0YF6K	INDICATI	Choroid plexus carcinoma [ICD-11: 2A02.12] Phase 1
D0YF6K	INDICATI	Ependymoma [ICD-11: 2A00.0Y] Phase 1
D0YF6K	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0YF6K	INDICATI	Germ cell tumour [ICD-11: 2C80.2] Phase 1
D0YF6K	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
D0YF6K	INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 1
D0YF6K	INDICATI	Pineoblastoma [ICD-11: 2A00.20] Phase 1

D06RCE	TTDDRUID	D06RCE
D06RCE	DRUGNAME	HER2-specific T cells
D06RCE	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0U1BR	TTDDRUID	D0U1BR
D0U1BR	DRUGNAME	Herpes simplex DNA vaccine
D0U1BR	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D0F4LP	TTDDRUID	D0F4LP
D0F4LP	DRUGNAME	hESC-derived CD15+ISL-1+cardiac progenitors
D0F4LP	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0J9UA	TTDDRUID	D0J9UA
D0J9UA	DRUGNAME	hESC-derived RPE (PF-05206388)
D0J9UA	INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1

D0K0KG	TTDDRUID	D0K0KG
D0K0KG	DRUGNAME	Heterodimeric IL-15
D0K0KG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04SBW	TTDDRUID	D04SBW
D04SBW	DRUGNAME	Hexavalent conjugate vaccine
D04SBW	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 1

D0L1ZM	TTDDRUID	D0L1ZM
D0L1ZM	DRUGNAME	HF-0299
D0L1ZM	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D02AMG	TTDDRUID	D02AMG
D02AMG	DRUGNAME	HGS-1029
D02AMG	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D02AMG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0ZF8F	TTDDRUID	D0ZF8F
D0ZF8F	DRUGNAME	HIP-2B
D0ZF8F	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1
D0ZF8F	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D00MNG	TTDDRUID	D00MNG
D00MNG	DRUGNAME	HIV gp41 vaccine
D00MNG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D07AJC	TTDDRUID	D07AJC
D07AJC	DRUGNAME	HIV MAG pDNA vaccine
D07AJC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D09FHY	TTDDRUID	D09FHY
D09FHY	DRUGNAME	HIV multiantigen vaccine
D09FHY	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0F2NG	TTDDRUID	D0F2NG
D0F2NG	DRUGNAME	HIV vaccine
D0F2NG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0K2GV	TTDDRUID	D0K2GV
D0K2GV	DRUGNAME	HIV vaccine
D0K2GV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0O4LG	TTDDRUID	D0O4LG
D0O4LG	DRUGNAME	HIV vaccine
D0O4LG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0X6VC	TTDDRUID	D0X6VC
D0X6VC	DRUGNAME	HIV vaccine
D0X6VC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0AD0B	TTDDRUID	D0AD0B
D0AD0B	DRUGNAME	HIV vaccine Ad4-Clade C
D0AD0B	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0QP1X	TTDDRUID	D0QP1X
D0QP1X	DRUGNAME	HIV vaccine Ad4-mGag
D0QP1X	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0O2OU	TTDDRUID	D0O2OU
D0O2OU	DRUGNAME	HIV vaccines
D0O2OU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0LQ7V	TTDDRUID	D0LQ7V
D0LQ7V	DRUGNAME	HIVAX
D0LQ7V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0R3YO	TTDDRUID	D0R3YO
D0R3YO	DRUGNAME	HKT288
D0R3YO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W7AE	TTDDRUID	D0W7AE
D0W7AE	DRUGNAME	HL-018
D0W7AE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0K6UQ	TTDDRUID	D0K6UQ
D0K6UQ	DRUGNAME	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine
D0K6UQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0JA8R	TTDDRUID	D0JA8R
D0JA8R	DRUGNAME	HLA-DQ2 peptide vaccine
D0JA8R	INDICATI	Coeliac disease [ICD-11: DA95] Phase 1

D09KWX	TTDDRUID	D09KWX
D09KWX	DRUGNAME	Hl-con1
D09KWX	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D0Q5SX	TTDDRUID	D0Q5SX
D0Q5SX	DRUGNAME	HMaxi-K
D0Q5SX	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 1

D07FKX	TTDDRUID	D07FKX
D07FKX	DRUGNAME	HMPL-011
D07FKX	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0L3DC	TTDDRUID	D0L3DC
D0L3DC	DRUGNAME	HMR-1031
D0L3DC	INDICATI	Arthritis [ICD-11: FA20] Phase 1

D00AYW	TTDDRUID	D00AYW
D00AYW	DRUGNAME	HMS5552
D00AYW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D07VJI	TTDDRUID	D07VJI
D07VJI	DRUGNAME	Hookworm vaccine
D07VJI	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1

D0M1HH	TTDDRUID	D0M1HH
D0M1HH	DRUGNAME	House dust mite allergy sublingual vaccine
D0M1HH	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D08SDI	TTDDRUID	D08SDI
D08SDI	DRUGNAME	House dust mite allergy vaccine
D08SDI	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D07MTT	TTDDRUID	D07MTT
D07MTT	DRUGNAME	HP-831-064
D07MTT	INDICATI	Wound healing [ICD-11: EL8Y] Phase 1

D04RLB	TTDDRUID	D04RLB
D04RLB	DRUGNAME	HPIV-1 vaccine
D04RLB	INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1

D0P2OK	TTDDRUID	D0P2OK
D0P2OK	DRUGNAME	HPP404
D0P2OK	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D0U8PR	TTDDRUID	D0U8PR
D0U8PR	DRUGNAME	HPP-593
D0U8PR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D0U8PR	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1

D05LKZ	TTDDRUID	D05LKZ
D05LKZ	DRUGNAME	HPP-607
D05LKZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08TVI	TTDDRUID	D08TVI
D08TVI	DRUGNAME	HPP-854
D08TVI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0K5BP	TTDDRUID	D0K5BP
D0K5BP	DRUGNAME	HSP-990
D0K5BP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05RCZ	TTDDRUID	D05RCZ
D05RCZ	DRUGNAME	HSV2 DNA vaccine
D05RCZ	INDICATI	Genital herpes [ICD-11: 1A94] Phase 1

D04NHQ	TTDDRUID	D04NHQ
D04NHQ	DRUGNAME	HSV529
D04NHQ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D01MCB	TTDDRUID	D01MCB
D01MCB	DRUGNAME	HTERT plasmid DNA cancer vaccine
D01MCB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02TVU	TTDDRUID	D02TVU
D02TVU	DRUGNAME	HTERT vaccine
D02TVU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04TUN	TTDDRUID	D04TUN
D04TUN	DRUGNAME	HTI-1066
D04TUN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09JYL	TTDDRUID	D09JYL
D09JYL	DRUGNAME	Hu5F9-G4
D09JYL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D09JYL	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
D09JYL	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D09JYL	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D09JYL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D08IDB	TTDDRUID	D08IDB
D08IDB	DRUGNAME	HuA33
D08IDB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D07YPB	TTDDRUID	D07YPB
D07YPB	DRUGNAME	Hu-CART meso cells
D07YPB	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D07YPB	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
D07YPB	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D07YPB	INDICATI	Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1
D07YPB	INDICATI	Pleural mesothelioma [ICD-11: 2C26.0] Phase 1

D0V7BD	TTDDRUID	D0V7BD
D0V7BD	DRUGNAME	HuCART19
D0V7BD	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0V7BD	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0ZF9J	TTDDRUID	D0ZF9J
D0ZF9J	DRUGNAME	HuCART-meso cells
D0ZF9J	INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1
D0ZF9J	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0ZF9J	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1

D04MDO	TTDDRUID	D04MDO
D04MDO	DRUGNAME	HuL2G7
D04MDO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06JQS	TTDDRUID	D06JQS
D06JQS	DRUGNAME	HuM195/rGel
D06JQS	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D01UAM	TTDDRUID	D01UAM
D01UAM	DRUGNAME	Human and mouse gp100 DNA plasmid vaccines
D01UAM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0RY4N	TTDDRUID	D0RY4N
D0RY4N	DRUGNAME	Human and mouse PSMA DNA vaccines
D0RY4N	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D08LLB	TTDDRUID	D08LLB
D08LLB	DRUGNAME	Human CD19 targeted T Cells
D08LLB	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D08LLB	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1

D0L5NU	TTDDRUID	D0L5NU
D0L5NU	DRUGNAME	Human Factor XIII
D0L5NU	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 1

D05EUS	TTDDRUID	D05EUS
D05EUS	DRUGNAME	Human microbio modulator
D05EUS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V6TP	TTDDRUID	D0V6TP
D0V6TP	DRUGNAME	Humanized SMART Anti-IL-12 Antibody
D0V6TP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0I3QJ	TTDDRUID	D0I3QJ
D0I3QJ	DRUGNAME	HX-100
D0I3QJ	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1

D01KWR	TTDDRUID	D01KWR
D01KWR	DRUGNAME	HyperAcute Renal
D01KWR	INDICATI	Metastatic renal cancer [ICD-11: 2D50] Phase 1

D01VIL	TTDDRUID	D01VIL
D01VIL	DRUGNAME	Hypertension NCE
D01VIL	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0G7OC	TTDDRUID	D0G7OC
D0G7OC	DRUGNAME	Hypoxia therapeutic
D0G7OC	INDICATI	Hypoxia associated with intermittent claudication [ICD-11: MD11] Phase 1

D0I8TW	TTDDRUID	D0I8TW
D0I8TW	DRUGNAME	IBC-VS01
D0I8TW	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D0J6UV	TTDDRUID	D0J6UV
D0J6UV	DRUGNAME	IBI-20089
D0J6UV	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1

D0A8HN	TTDDRUID	D0A8HN
D0A8HN	DRUGNAME	Iboctadekin
D0A8HN	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0A8HN	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0F3PU	TTDDRUID	D0F3PU
D0F3PU	DRUGNAME	Iboctadekin + Doxil
D0F3PU	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0J2VB	TTDDRUID	D0J2VB
D0J2VB	DRUGNAME	Iboctadekin + rituximab
D0J2VB	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
D0J2VB	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D0J2VB	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0WG1T	TTDDRUID	D0WG1T
D0WG1T	DRUGNAME	IC 1001
D0WG1T	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0H4ND	TTDDRUID	D0H4ND
D0H4ND	DRUGNAME	IC31
D0H4ND	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 1

D04GBW	TTDDRUID	D04GBW
D04GBW	DRUGNAME	IC31 seasonal influenza vaccine
D04GBW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D03ODX	TTDDRUID	D03ODX
D03ODX	DRUGNAME	IC-84
D03ODX	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0H0LK	TTDDRUID	D0H0LK
D0H0LK	DRUGNAME	IC9.GD2.CAR.IL-15 T-cells
D0H0LK	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1

D0DU4T	TTDDRUID	D0DU4T
D0DU4T	DRUGNAME	IC9-CAR19 cells
D0DU4T	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0DU4T	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
D0DU4T	INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1

D0PY5I	TTDDRUID	D0PY5I
D0PY5I	DRUGNAME	IC9-CAR19 T cells
D0PY5I	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0PY5I	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
D0PY5I	INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1
D0PY5I	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D01SFN	TTDDRUID	D01SFN
D01SFN	DRUGNAME	IC9-GD2-CD28-OX40
D01SFN	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1

D0OC5C	TTDDRUID	D0OC5C
D0OC5C	DRUGNAME	ICAR19 CAR-T cells
D0OC5C	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0OC5C	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D08ZAC	TTDDRUID	D08ZAC
D08ZAC	DRUGNAME	ICAR30 T cells
D08ZAC	INDICATI	Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1
D08ZAC	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1

D0S9FI	TTDDRUID	D0S9FI
D0S9FI	DRUGNAME	ICasp9M28z T cell
D0S9FI	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
D0S9FI	INDICATI	Malignant pleural effusion [ICD-11: 2D72] Phase 1
D0S9FI	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
D0S9FI	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1

D0G9PD	TTDDRUID	D0G9PD
D0G9PD	DRUGNAME	IChorcumab
D0G9PD	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0W2BK	TTDDRUID	D0W2BK
D0W2BK	DRUGNAME	ICo-007
D0W2BK	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
D0W2BK	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 1

D0H6UL	TTDDRUID	D0H6UL
D0H6UL	DRUGNAME	ICON-1
D0H6UL	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D09NBH	TTDDRUID	D09NBH
D09NBH	DRUGNAME	ICT-121
D09NBH	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D09NBH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0RZ9V	TTDDRUID	D0RZ9V
D0RZ9V	DRUGNAME	IDH305
D0RZ9V	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1

D07UAR	TTDDRUID	D07UAR
D07UAR	DRUGNAME	Idhifaenasidenib
D07UAR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0L9WL	TTDDRUID	D0L9WL
D0L9WL	DRUGNAME	IDO inhibitor
D0L9WL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R0ME	TTDDRUID	D0R0ME
D0R0ME	DRUGNAME	IDP-204040
D0R0ME	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0O7RY	TTDDRUID	D0O7RY
D0O7RY	DRUGNAME	IDR-1018
D0O7RY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D09APB	TTDDRUID	D09APB
D09APB	DRUGNAME	IDX-189
D09APB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D08NZG	TTDDRUID	D08NZG
D08NZG	DRUGNAME	Ifabotuzumab
D08NZG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D08NZG	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D08NZG	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0SX1X	TTDDRUID	D0SX1X
D0SX1X	DRUGNAME	IGF-methotrexate conjugate
D0SX1X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01RQP	TTDDRUID	D01RQP
D01RQP	DRUGNAME	IGN002
D01RQP	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0OQ5R	TTDDRUID	D0OQ5R
D0OQ5R	DRUGNAME	IGN523
D0OQ5R	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D09JMW	TTDDRUID	D09JMW
D09JMW	DRUGNAME	IHV001
D09JMW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0B6NP	TTDDRUID	D0B6NP
D0B6NP	DRUGNAME	IHV001
D0B6NP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D05KOP	TTDDRUID	D05KOP
D05KOP	DRUGNAME	Ii-Key hybrid peptide vaccine
D05KOP	INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1

D08BIJ	TTDDRUID	D08BIJ
D08BIJ	DRUGNAME	IL-1 Monoclonal Antibody
D08BIJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D03XZP	TTDDRUID	D03XZP
D03XZP	DRUGNAME	IL-12 gene therapy
D03XZP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D07JSX	TTDDRUID	D07JSX
D07JSX	DRUGNAME	IL-2 pDNA
D07JSX	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D04HWK	TTDDRUID	D04HWK
D04HWK	DRUGNAME	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine
D04HWK	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D09QYD	TTDDRUID	D09QYD
D09QYD	DRUGNAME	ILS920
D09QYD	INDICATI	Stroke [ICD-11: 8B20] Phase 1

D0A9GI	TTDDRUID	D0A9GI
D0A9GI	DRUGNAME	ILV-095
D0A9GI	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0Q5DT	TTDDRUID	D0Q5DT
D0Q5DT	DRUGNAME	IM156
D0Q5DT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04BVL	TTDDRUID	D04BVL
D04BVL	DRUGNAME	IM19
D04BVL	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D04BVL	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D05XNF	TTDDRUID	D05XNF
D05XNF	DRUGNAME	IM21 CART
D05XNF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D00HAN	TTDDRUID	D00HAN
D00HAN	DRUGNAME	IM23
D00HAN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0NY5Y	TTDDRUID	D0NY5Y
D0NY5Y	DRUGNAME	IMA-026
D0NY5Y	INDICATI	Asthma [ICD-11: CA23] Phase 1

D05KGG	TTDDRUID	D05KGG
D05KGG	DRUGNAME	IMA101
D05KGG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09FDN	TTDDRUID	D09FDN
D09FDN	DRUGNAME	IMA201
D09FDN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D09FDN	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D0FL6L	TTDDRUID	D0FL6L
D0FL6L	DRUGNAME	IMA202
D0FL6L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G0FQ	TTDDRUID	D0G0FQ
D0G0FQ	DRUGNAME	IMA-950
D0G0FQ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D09JSM	TTDDRUID	D09JSM
D09JSM	DRUGNAME	IMC-3C5
D09JSM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CN7I	TTDDRUID	D0CN7I
D0CN7I	DRUGNAME	IMC-CS4
D0CN7I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07ZNF	TTDDRUID	D07ZNF
D07ZNF	DRUGNAME	IMC-EB10
D07ZNF	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0Y4CN	TTDDRUID	D0Y4CN
D0Y4CN	DRUGNAME	IMC-TR1
D0Y4CN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Z5DM	TTDDRUID	D0Z5DM
D0Z5DM	DRUGNAME	IMD-0354
D0Z5DM	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1

D0A2PA	TTDDRUID	D0A2PA
D0A2PA	DRUGNAME	IMF-001
D0A2PA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00ESU	TTDDRUID	D00ESU
D00ESU	DRUGNAME	Imfinzidurvalumab
D00ESU	INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 2
D00ESU	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D00ESU	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D00ESU	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D00ESU	INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2
D00ESU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D04HSH	TTDDRUID	D04HSH
D04HSH	DRUGNAME	IMGN289
D04HSH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07HKV	TTDDRUID	D07HKV
D07HKV	DRUGNAME	IMGN-388
D07HKV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03BNF	TTDDRUID	D03BNF
D03BNF	DRUGNAME	IMGN632
D03BNF	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0ZR1Z	TTDDRUID	D0ZR1Z
D0ZR1Z	DRUGNAME	IMGN779
D0ZR1Z	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D07DPC	TTDDRUID	D07DPC
D07DPC	DRUGNAME	IMGN-853
D07DPC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X4VA	TTDDRUID	D0X4VA
D0X4VA	DRUGNAME	Imlygictalimogene laherparepvec
D0X4VA	INDICATI	Peripheral nervous system tumour [ICD-11: 2B5E] Phase 1

D0P5PD	TTDDRUID	D0P5PD
D0P5PD	DRUGNAME	IMMU-114
D0P5PD	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0P5PD	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D07KGC	TTDDRUID	D07KGC
D07KGC	DRUGNAME	Immune globulin
D07KGC	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1

D0C7CF	TTDDRUID	D0C7CF
D0C7CF	DRUGNAME	Immunotoxins
D0C7CF	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Phase 1

D0KV1Z	TTDDRUID	D0KV1Z
D0KV1Z	DRUGNAME	ImmunoVEX HSV2
D0KV1Z	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D0FM5M	TTDDRUID	D0FM5M
D0FM5M	DRUGNAME	IMO-2125
D0FM5M	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
D0FM5M	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0FM5M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08OXU	TTDDRUID	D08OXU
D08OXU	DRUGNAME	IMO-3100
D08OXU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0UF8M	TTDDRUID	D0UF8M
D0UF8M	DRUGNAME	IMO-9200
D0UF8M	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D02IYC	TTDDRUID	D02IYC
D02IYC	DRUGNAME	IMP-701
D02IYC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
D02IYC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02HWU	TTDDRUID	D02HWU
D02HWU	DRUGNAME	IMT-1012
D02HWU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D02HWU	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0Y9VC	TTDDRUID	D0Y9VC
D0Y9VC	DRUGNAME	IMT-1012 immunotherapeutic vaccine
D0Y9VC	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D08RKZ	TTDDRUID	D08RKZ
D08RKZ	DRUGNAME	IN0-3106
D08RKZ	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D0E4YR	TTDDRUID	D0E4YR
D0E4YR	DRUGNAME	IN0-3112
D0E4YR	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1

D0PH5J	TTDDRUID	D0PH5J
D0PH5J	DRUGNAME	IN0-8000
D0PH5J	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D08JWM	TTDDRUID	D08JWM
D08JWM	DRUGNAME	In-111-DAC imaging agent
D08JWM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XI3E	TTDDRUID	D0XI3E
D0XI3E	DRUGNAME	INCB01158
D0XI3E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06KNE	TTDDRUID	D06KNE
D06KNE	DRUGNAME	INCB15050
D06KNE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0B8BY	TTDDRUID	D0B8BY
D0B8BY	DRUGNAME	INdoximod + temozolomide
D0B8BY	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1

D0E4MT	TTDDRUID	D0E4MT
D0E4MT	DRUGNAME	Influenza A virus H3N2 vaccine
D0E4MT	INDICATI	Influenza A virus H3N2 infection [ICD-11: 1E30] Phase 1

D08DRU	TTDDRUID	D08DRU
D08DRU	DRUGNAME	Influenza A virus H5N1 cell culture-based vaccine
D08DRU	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1

D0QM9P	TTDDRUID	D0QM9P
D0QM9P	DRUGNAME	INfluenza A virus H5N8 vaccine
D0QM9P	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0G1WM	TTDDRUID	D0G1WM
D0G1WM	DRUGNAME	Influenza A virus H7N1 vaccine
D0G1WM	INDICATI	Influenza A virus H7N1 infection [ICD-11: 1E30] Phase 1

D0M2FH	TTDDRUID	D0M2FH
D0M2FH	DRUGNAME	Influenza A virus vaccine H1N1
D0M2FH	INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1
D0M2FH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D08WUF	TTDDRUID	D08WUF
D08WUF	DRUGNAME	Influenza DNA vaccine
D08WUF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0H2MM	TTDDRUID	D0H2MM
D0H2MM	DRUGNAME	INfluenza H3N2 vaccine
D0H2MM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0JB0D	TTDDRUID	D0JB0D
D0JB0D	DRUGNAME	Influenza subunit vaccines
D0JB0D	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D01KXE	TTDDRUID	D01KXE
D01KXE	DRUGNAME	Influenza vaccine
D01KXE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D04ASP	TTDDRUID	D04ASP
D04ASP	DRUGNAME	Influenza virus DNA vaccine
D04ASP	INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1

D04UQF	TTDDRUID	D04UQF
D04UQF	DRUGNAME	Influvac tC cell culture-derived influenza vaccine
D04UQF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D05DOY	TTDDRUID	D05DOY
D05DOY	DRUGNAME	ING-1
D05DOY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S6MV	TTDDRUID	D0S6MV
D0S6MV	DRUGNAME	INK-1117
D0S6MV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0BH9I	TTDDRUID	D0BH9I
D0BH9I	DRUGNAME	INN-108
D0BH9I	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D08KYN	TTDDRUID	D08KYN
D08KYN	DRUGNAME	INNO-105
D08KYN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P2ZY	TTDDRUID	D0P2ZY
D0P2ZY	DRUGNAME	INNO-305
D0P2ZY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0P2ZY	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1

D00IFH	TTDDRUID	D00IFH
D00IFH	DRUGNAME	INO-1400
D00IFH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D00IFH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05WLE	TTDDRUID	D05WLE
D05WLE	DRUGNAME	INO-1800
D05WLE	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D0J5NA	TTDDRUID	D0J5NA
D0J5NA	DRUGNAME	INO-3106
D0J5NA	INDICATI	Aerodigestive tract cancer [ICD-11: 2C29.Z] Phase 1
D0J5NA	INDICATI	Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1

D0K6JQ	TTDDRUID	D0K6JQ
D0K6JQ	DRUGNAME	INO-3401
D0K6JQ	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1

D05ZEW	TTDDRUID	D05ZEW
D05ZEW	DRUGNAME	INO-3510
D05ZEW	INDICATI	Influenza A virus H1N1/H5N1 infection [ICD-11: 1E30] Phase 1

D0SH7J	TTDDRUID	D0SH7J
D0SH7J	DRUGNAME	INO-4212
D0SH7J	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D02SME	TTDDRUID	D02SME
D02SME	DRUGNAME	INO-4885
D02SME	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0R6VV	TTDDRUID	D0R6VV
D0R6VV	DRUGNAME	INO-5150
D0R6VV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
D0R6VV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0BJ8Q	TTDDRUID	D0BJ8Q
D0BJ8Q	DRUGNAME	INO-8000
D0BJ8Q	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0SD2J	TTDDRUID	D0SD2J
D0SD2J	DRUGNAME	INP104
D0SD2J	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D04RWV	TTDDRUID	D04RWV
D04RWV	DRUGNAME	INS1009
D04RWV	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1

D08JXW	TTDDRUID	D08JXW
D08JXW	DRUGNAME	INS-117548
D08JXW	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1

D0H3PV	TTDDRUID	D0H3PV
D0H3PV	DRUGNAME	Insulin + pramlintide
D0H3PV	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D0F0NB	TTDDRUID	D0F0NB
D0F0NB	DRUGNAME	Insulin adjustable basal
D0F0NB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D00HGY	TTDDRUID	D00HGY
D00HGY	DRUGNAME	Insulin B chain vaccine
D00HGY	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 1
D00HGY	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D0S4FQ	TTDDRUID	D0S4FQ
D0S4FQ	DRUGNAME	Insulin glargine biosimilar
D0S4FQ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
D0S4FQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0D5EJ	TTDDRUID	D0D5EJ
D0D5EJ	DRUGNAME	Insulin oral sublingual
D0D5EJ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D08TGG	TTDDRUID	D08TGG
D08TGG	DRUGNAME	Insulin transdermal
D08TGG	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1

D0L8RD	TTDDRUID	D0L8RD
D0L8RD	DRUGNAME	INT-0003/2005
D0L8RD	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 1

D00FDD	TTDDRUID	D00FDD
D00FDD	DRUGNAME	INT-0020
D00FDD	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 1

D01JYT	TTDDRUID	D01JYT
D01JYT	DRUGNAME	INT-0022
D01JYT	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1

D05GUK	TTDDRUID	D05GUK
D05GUK	DRUGNAME	INTOPLICINE
D05GUK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L6XU	TTDDRUID	D0L6XU
D0L6XU	DRUGNAME	Intranasal influenza vaccine
D0L6XU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0VO0A	TTDDRUID	D0VO0A
D0VO0A	DRUGNAME	INV-21
D0VO0A	INDICATI	Hand, foot and mouth disease [ICD-11: 1F05.0] Phase 1

D06SYN	TTDDRUID	D06SYN
D06SYN	DRUGNAME	Ioflubenzamide (131I)
D06SYN	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D04KRV	TTDDRUID	D04KRV
D04KRV	DRUGNAME	Iofolastat I-124
D04KRV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D00RGU	TTDDRUID	D00RGU
D00RGU	DRUGNAME	Ion Channel Therapy
D00RGU	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 1

D0Z6AM	TTDDRUID	D0Z6AM
D0Z6AM	DRUGNAME	Ipafricept
D0Z6AM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0GO4T	TTDDRUID	D0GO4T
D0GO4T	DRUGNAME	IPH4102
D0GO4T	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1

D0I3LO	TTDDRUID	D0I3LO
D0I3LO	DRUGNAME	IPI-549
D0I3LO	INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1
D0I3LO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0I3LO	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0I3LO	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0I3LO	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
D0I3LO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CR4Z	TTDDRUID	D0CR4Z
D0CR4Z	DRUGNAME	IPI-940
D0CR4Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01KGP	TTDDRUID	D01KGP
D01KGP	DRUGNAME	IPL 550,260
D01KGP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D04MBQ	TTDDRUID	D04MBQ
D04MBQ	DRUGNAME	iPSC-derived RPE (autologous)
D04MBQ	INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1

D0S1BN	TTDDRUID	D0S1BN
D0S1BN	DRUGNAME	Iptakalim hydrochloride
D0S1BN	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D00RNB	TTDDRUID	D00RNB
D00RNB	DRUGNAME	IQB-9302
D00RNB	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D09SZY	TTDDRUID	D09SZY
D09SZY	DRUGNAME	IQ-DAA
D09SZY	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1

D0R2OU	TTDDRUID	D0R2OU
D0R2OU	DRUGNAME	Irdabisant
D0R2OU	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D05CHN	TTDDRUID	D05CHN
D05CHN	DRUGNAME	Irofulven/Taxotere
D05CHN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05XLH	TTDDRUID	D05XLH
D05XLH	DRUGNAME	Iroxanadine
D05XLH	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1

D09DJC	TTDDRUID	D09DJC
D09DJC	DRUGNAME	IRX4204
D09DJC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D09DJC	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D09DJC	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D09DJC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0T3DO	TTDDRUID	D0T3DO
D0T3DO	DRUGNAME	IRX-5183
D0T3DO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
D0T3DO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0JB2J	TTDDRUID	D0JB2J
D0JB2J	DRUGNAME	Isatuximab
D0JB2J	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0I0KP	TTDDRUID	D0I0KP
D0I0KP	DRUGNAME	ISC-hpNSC
D0I0KP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D07DLA	TTDDRUID	D07DLA
D07DLA	DRUGNAME	ISF-402
D07DLA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D05LTJ	TTDDRUID	D05LTJ
D05LTJ	DRUGNAME	ISIS 325568
D05LTJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0T3RR	TTDDRUID	D0T3RR
D0T3RR	DRUGNAME	ISIS-ANGPTL3
D0T3RR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D09LVD	TTDDRUID	D09LVD
D09LVD	DRUGNAME	ISIS-APOARx
D09LVD	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1

D0F6KM	TTDDRUID	D0F6KM
D0F6KM	DRUGNAME	ISIS-APOCIII
D0F6KM	INDICATI	Atherosclerosis [ICD-11: BD40] Phase 1
D0F6KM	INDICATI	Hyperlipemia [ICD-11: 5C80] Phase 1
D0F6KM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
D0F6KM	INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 1

D03POY	TTDDRUID	D03POY
D03POY	DRUGNAME	ISIS-AR
D03POY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D06CIJ	TTDDRUID	D06CIJ
D06CIJ	DRUGNAME	ISIS-CRP
D06CIJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
D06CIJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D0KY7S	TTDDRUID	D0KY7S
D0KY7S	DRUGNAME	ISIS-FXI
D0KY7S	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 1

D0G8LN	TTDDRUID	D0G8LN
D0G8LN	DRUGNAME	ISIS-SGLT2
D0G8LN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0S1MO	TTDDRUID	D0S1MO
D0S1MO	DRUGNAME	ISIS-SGLT2rx
D0S1MO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D05BYO	TTDDRUID	D05BYO
D05BYO	DRUGNAME	ISIS-SOD1
D05BYO	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1

D02VBX	TTDDRUID	D02VBX
D02VBX	DRUGNAME	ISIS-SOD1Rx
D02VBX	INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 1

D0Y9HW	TTDDRUID	D0Y9HW
D0Y9HW	DRUGNAME	ISIS-TTR
D0Y9HW	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1

D03GNI	TTDDRUID	D03GNI
D03GNI	DRUGNAME	ISOQUINE
D03GNI	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D0Q4LG	TTDDRUID	D0Q4LG
D0Q4LG	DRUGNAME	IT-139
D0Q4LG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K6QU	TTDDRUID	D0K6QU
D0K6QU	DRUGNAME	IT-141
D0K6QU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02NIP	TTDDRUID	D02NIP
D02NIP	DRUGNAME	ITASETRON
D02NIP	INDICATI	Nausea [ICD-11: MD90] Phase 1

D00XVL	TTDDRUID	D00XVL
D00XVL	DRUGNAME	ITI-214
D00XVL	INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
D00XVL	INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1
D00XVL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
D00XVL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0TX5P	TTDDRUID	D0TX5P
D0TX5P	DRUGNAME	ITX-5061
D0TX5P	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D00KGI	TTDDRUID	D00KGI
D00KGI	DRUGNAME	IVN-201
D00KGI	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D0MG0F	TTDDRUID	D0MG0F
D0MG0F	DRUGNAME	IW-001
D0MG0F	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1

D09SYB	TTDDRUID	D09SYB
D09SYB	DRUGNAME	J5dLPS/OMP
D09SYB	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 1

D06WCR	TTDDRUID	D06WCR
D06WCR	DRUGNAME	JAIVAC-1
D06WCR	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D0U0BN	TTDDRUID	D0U0BN
D0U0BN	DRUGNAME	JCAR014
D0U0BN	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0U0BN	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D0U0BN	INDICATI	Mediastinal large B-cell lymphoma [ICD-11: 2A60.32] Phase 1

D08BPS	TTDDRUID	D08BPS
D08BPS	DRUGNAME	JCAR017
D08BPS	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D08BPS	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D08BPS	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
D08BPS	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
D08BPS	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D08BPS	INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 1

D0JG2X	TTDDRUID	D0JG2X
D0JG2X	DRUGNAME	JCAR018
D0JG2X	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0JG2X	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0I0FA	TTDDRUID	D0I0FA
D0I0FA	DRUGNAME	JCAR020
D0I0FA	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0M9TO	TTDDRUID	D0M9TO
D0M9TO	DRUGNAME	JCAR023
D0M9TO	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1

D07SLJ	TTDDRUID	D07SLJ
D07SLJ	DRUGNAME	JCAR024
D07SLJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D07SLJ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0S5SM	TTDDRUID	D0S5SM
D0S5SM	DRUGNAME	JCARH125
D0S5SM	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D09MEV	TTDDRUID	D09MEV
D09MEV	DRUGNAME	JES-9501
D09MEV	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0F4NP	TTDDRUID	D0F4NP
D0F4NP	DRUGNAME	JNJ-17305600
D0F4NP	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0U3XL	TTDDRUID	D0U3XL
D0U3XL	DRUGNAME	JNJ-26483327
D0U3XL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0B3GF	TTDDRUID	D0B3GF
D0B3GF	DRUGNAME	JNJ-26854165
D0B3GF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0B3GF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
D0B3GF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K9YJ	TTDDRUID	D0K9YJ
D0K9YJ	DRUGNAME	JNJ-3534
D0K9YJ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D09MSE	TTDDRUID	D09MSE
D09MSE	DRUGNAME	JNJ-38224342
D09MSE	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1

D0YT8P	TTDDRUID	D0YT8P
D0YT8P	DRUGNAME	JNJ-38877605
D0YT8P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0EM4S	TTDDRUID	D0EM4S
D0EM4S	DRUGNAME	JNJ-39439335
D0EM4S	INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 1

D07GVM	TTDDRUID	D07GVM
D07GVM	DRUGNAME	JNJ-42491293
D07GVM	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Discontinued in Phase 1

D0DA6X	TTDDRUID	D0DA6X
D0DA6X	DRUGNAME	JNJ-47910382
D0DA6X	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0VI4N	TTDDRUID	D0VI4N
D0VI4N	DRUGNAME	JNJ-54175446
D0VI4N	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D00TED	TTDDRUID	D00TED
D00TED	DRUGNAME	JNJ-54728518
D00TED	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0OQ1A	TTDDRUID	D0OQ1A
D0OQ1A	DRUGNAME	JNJ-55308942
D0OQ1A	INDICATI	Anhedonia [ICD-11: MB24.2] Phase 1
D0OQ1A	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1
D0OQ1A	INDICATI	Neuroinflammation [ICD-11: 1D0Y] Phase 1

D0GU1S	TTDDRUID	D0GU1S
D0GU1S	DRUGNAME	JNJ-55920839
D0GU1S	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D05AVL	TTDDRUID	D05AVL
D05AVL	DRUGNAME	JNJ-61178104
D05AVL	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D0V1AV	TTDDRUID	D0V1AV
D0V1AV	DRUGNAME	JNJ-61186372
D0V1AV	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0P9QR	TTDDRUID	D0P9QR
D0P9QR	DRUGNAME	JNJ-61187165
D0P9QR	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D0A9PR	TTDDRUID	D0A9PR
D0A9PR	DRUGNAME	JNJ-61187191
D0A9PR	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D0PE3Z	TTDDRUID	D0PE3Z
D0PE3Z	DRUGNAME	JNJ-61610588
D0PE3Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0PT2W	TTDDRUID	D0PT2W
D0PT2W	DRUGNAME	JNJ-63709178
D0PT2W	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D07PFU	TTDDRUID	D07PFU
D07PFU	DRUGNAME	JNJ-63733657
D07PFU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D03AFF	TTDDRUID	D03AFF
D03AFF	DRUGNAME	JNJ-64007957
D03AFF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D02BWY	TTDDRUID	D02BWY
D02BWY	DRUGNAME	JNJ-64041757
D02BWY	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1

D09HJU	TTDDRUID	D09HJU
D09HJU	DRUGNAME	JNJ-64041757
D09HJU	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
D09HJU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D03QHM	TTDDRUID	D03QHM
D03QHM	DRUGNAME	JNJ-64041809
D03QHM	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0QQ9V	TTDDRUID	D0QQ9V
D0QQ9V	DRUGNAME	JNJ-64041809
D0QQ9V	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0BS6F	TTDDRUID	D0BS6F
D0BS6F	DRUGNAME	JNJ-64400141
D0BS6F	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D0DA4B	TTDDRUID	D0DA4B
D0DA4B	DRUGNAME	JNJ-64407564
D0DA4B	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0TV0E	TTDDRUID	D0TV0E
D0TV0E	DRUGNAME	JNJ-64457107
D0TV0E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09PCL	TTDDRUID	D09PCL
D09PCL	DRUGNAME	JNJ-64565111
D09PCL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0ZT4J	TTDDRUID	D0ZT4J
D0ZT4J	DRUGNAME	JSM 6427
D0ZT4J	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D0W2RI	TTDDRUID	D0W2RI
D0W2RI	DRUGNAME	JTE-451
D0W2RI	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1

D0E3EO	TTDDRUID	D0E3EO
D0E3EO	DRUGNAME	JTT-251
D0E3EO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0L4GX	TTDDRUID	D0L4GX
D0L4GX	DRUGNAME	JTT-252
D0L4GX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0B8WU	TTDDRUID	D0B8WU
D0B8WU	DRUGNAME	JTZ-951
D0B8WU	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D05XPZ	TTDDRUID	D05XPZ
D05XPZ	DRUGNAME	JWCAR029
D05XPZ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0VS0G	TTDDRUID	D0VS0G
D0VS0G	DRUGNAME	JWCAR029
D0VS0G	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0H2YY	TTDDRUID	D0H2YY
D0H2YY	DRUGNAME	JX-929
D0H2YY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06JDV	TTDDRUID	D06JDV
D06JDV	DRUGNAME	K-312
D06JDV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0J8MA	TTDDRUID	D0J8MA
D0J8MA	DRUGNAME	KA2237
D0J8MA	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D0O6SA	TTDDRUID	D0O6SA
D0O6SA	DRUGNAME	KA2507
D0O6SA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XV6L	TTDDRUID	D0XV6L
D0XV6L	DRUGNAME	Kanglaite injection
D0XV6L	INDICATI	Cachexia [ICD-11: MG20] Phase 1

D0VS3W	TTDDRUID	D0VS3W
D0VS3W	DRUGNAME	KAR5585
D0VS3W	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1

D0V9WX	TTDDRUID	D0V9WX
D0V9WX	DRUGNAME	KarXT
D0V9WX	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0K0IN	TTDDRUID	D0K0IN
D0K0IN	DRUGNAME	KBSA-301
D0K0IN	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1

D09XKO	TTDDRUID	D09XKO
D09XKO	DRUGNAME	KD-101
D09XKO	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1

D0M7FX	TTDDRUID	D0M7FX
D0M7FX	DRUGNAME	KD-247
D0M7FX	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D01PVV	TTDDRUID	D01PVV
D01PVV	DRUGNAME	KD3010
D01PVV	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
D01PVV	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0WA1R	TTDDRUID	D0WA1R
D0WA1R	DRUGNAME	Keratinocyte growth factor (KGF)
D0WA1R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XI1P	TTDDRUID	D0XI1P
D0XI1P	DRUGNAME	Ketoprofen topical
D0XI1P	INDICATI	Migraine [ICD-11: 8A80] Phase 2
D0XI1P	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
D0XI1P	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0L5VS	TTDDRUID	D0L5VS
D0L5VS	DRUGNAME	KF-17837
D0L5VS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0C4BD	TTDDRUID	D0C4BD
D0C4BD	DRUGNAME	KH-901
D0C4BD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08XDL	TTDDRUID	D08XDL
D08XDL	DRUGNAME	KHK2455
D08XDL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S4KJ	TTDDRUID	D0S4KJ
D0S4KJ	DRUGNAME	KHK-2866
D0S4KJ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0D1HS	TTDDRUID	D0D1HS
D0D1HS	DRUGNAME	Ki23819
D0D1HS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02SQZ	TTDDRUID	D02SQZ
D02SQZ	DRUGNAME	Kibow Biotics
D02SQZ	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 1

D0UE6R	TTDDRUID	D0UE6R
D0UE6R	DRUGNAME	Kidney disease medicine
D0UE6R	INDICATI	Kidney failure [ICD-11: GB6Z] Phase 1

D0IM5A	TTDDRUID	D0IM5A
D0IM5A	DRUGNAME	KITE-439
D0IM5A	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1

D0C8QA	TTDDRUID	D0C8QA
D0C8QA	DRUGNAME	KITE-585
D0C8QA	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0O4ZP	TTDDRUID	D0O4ZP
D0O4ZP	DRUGNAME	KITE-585
D0O4ZP	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D09QJT	TTDDRUID	D09QJT
D09QJT	DRUGNAME	KITE-718
D09QJT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01JTL	TTDDRUID	D01JTL
D01JTL	DRUGNAME	KM-023
D01JTL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D03BKV	TTDDRUID	D03BKV
D03BKV	DRUGNAME	KML-001
D03BKV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0GF2R	TTDDRUID	D0GF2R
D0GF2R	DRUGNAME	KN035
D0GF2R	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D0GF2R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A1DG	TTDDRUID	D0A1DG
D0A1DG	DRUGNAME	KO-947
D0A1DG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08WBJ	TTDDRUID	D08WBJ
D08WBJ	DRUGNAME	KOS-2187
D08WBJ	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1
D08WBJ	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 1

D0O1EH	TTDDRUID	D0O1EH
D0O1EH	DRUGNAME	KP415
D0O1EH	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1

D0QI4Z	TTDDRUID	D0QI4Z
D0QI4Z	DRUGNAME	KP484
D0QI4Z	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1

D0Z8PO	TTDDRUID	D0Z8PO
D0Z8PO	DRUGNAME	KPE-06001
D0Z8PO	INDICATI	Arthritis [ICD-11: FA20] Phase 1

D09KEW	TTDDRUID	D09KEW
D09KEW	DRUGNAME	KPL-716
D09KEW	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
D09KEW	INDICATI	Nodular prurigo [ICD-11: EC91.0] Phase 1

D04ZQB	TTDDRUID	D04ZQB
D04ZQB	DRUGNAME	KPT-9274
D04ZQB	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D04ZQB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y4MJ	TTDDRUID	D0Y4MJ
D0Y4MJ	DRUGNAME	KQ-791
D0Y4MJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D03JUF	TTDDRUID	D03JUF
D03JUF	DRUGNAME	KRL-104
D03JUF	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 1

D0I3BS	TTDDRUID	D0I3BS
D0I3BS	DRUGNAME	KRL-401
D0I3BS	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1

D07AUS	TTDDRUID	D07AUS
D07AUS	DRUGNAME	KRL-901
D07AUS	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1

D07HRU	TTDDRUID	D07HRU
D07HRU	DRUGNAME	KRN633
D07HRU	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
D07HRU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0B3DV	TTDDRUID	D0B3DV
D0B3DV	DRUGNAME	KTE-C19
D0B3DV	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D00EQY	TTDDRUID	D00EQY
D00EQY	DRUGNAME	KTN3379
D00EQY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K4UV	TTDDRUID	D0K4UV
D0K4UV	DRUGNAME	KU-5039
D0K4UV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D03QKW	TTDDRUID	D03QKW
D03QKW	DRUGNAME	KUC-7483
D03QKW	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 1

D04UNO	TTDDRUID	D04UNO
D04UNO	DRUGNAME	KUL-7211
D04UNO	INDICATI	Neurogenic bladder dysfunction [ICD-11: GC01.4] Phase 1

D09TGD	TTDDRUID	D09TGD
D09TGD	DRUGNAME	KUR-112
D09TGD	INDICATI	Bone disease [ICD-11: FC0Z] Phase 1

D03GSN	TTDDRUID	D03GSN
D03GSN	DRUGNAME	KVD001
D03GSN	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1

D00ABO	TTDDRUID	D00ABO
D00ABO	DRUGNAME	KW-2449
D00ABO	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D08ZRR	TTDDRUID	D08ZRR
D08ZRR	DRUGNAME	KW-5092
D08ZRR	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D02RID	TTDDRUID	D02RID
D02RID	DRUGNAME	KX-02
D02RID	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1

D0RE4L	TTDDRUID	D0RE4L
D0RE4L	DRUGNAME	KX2-361
D0RE4L	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D08MCI	TTDDRUID	D08MCI
D08MCI	DRUGNAME	L1Q-001
D08MCI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0Q5VW	TTDDRUID	D0Q5VW
D0Q5VW	DRUGNAME	L-778123
D0Q5VW	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0I2XM	TTDDRUID	D0I2XM
D0I2XM	DRUGNAME	L-796568
D0I2XM	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D06ZHN	TTDDRUID	D06ZHN
D06ZHN	DRUGNAME	Lactermin
D06ZHN	INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 1

D03INQ	TTDDRUID	D03INQ
D03INQ	DRUGNAME	Laevo-Bambuterol
D03INQ	INDICATI	Asthma [ICD-11: CA23] Phase 1

D05WKQ	TTDDRUID	D05WKQ
D05WKQ	DRUGNAME	LAI287
D05WKQ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
D05WKQ	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1
D05WKQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0QN5M	TTDDRUID	D0QN5M
D0QN5M	DRUGNAME	LAM-001
D0QN5M	INDICATI	Lymphangioleiomyomatosis [ICD-11: CB07] Phase 1

D0JW6R	TTDDRUID	D0JW6R
D0JW6R	DRUGNAME	LAM-002
D0JW6R	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D08WQS	TTDDRUID	D08WQS
D08WQS	DRUGNAME	LAM-003
D08WQS	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D08WQS	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D09PFR	TTDDRUID	D09PFR
D09PFR	DRUGNAME	LAMB3-transduced autologous epidermal stem cells
D09PFR	INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 1

D02CXV	TTDDRUID	D02CXV
D02CXV	DRUGNAME	Lartruvoolaratumab
D02CXV	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 1

D0F1JY	TTDDRUID	D0F1JY
D0F1JY	DRUGNAME	LAS-186323
D0F1JY	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D07EHB	TTDDRUID	D07EHB
D07EHB	DRUGNAME	Latrunculin B
D07EHB	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1

D02RNR	TTDDRUID	D02RNR
D02RNR	DRUGNAME	LB-100
D02RNR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05YQT	TTDDRUID	D05YQT
D05YQT	DRUGNAME	LBR-101
D05YQT	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D0V5AL	TTDDRUID	D0V5AL
D0V5AL	DRUGNAME	LC-1
D0V5AL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0I5JM	TTDDRUID	D0I5JM
D0I5JM	DRUGNAME	LC-350189
D0I5JM	INDICATI	Gout [ICD-11: FA25] Phase 1

D0I1PF	TTDDRUID	D0I1PF
D0I1PF	DRUGNAME	LCAR-B4822M CAR-T Cell
D0I1PF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0V7PL	TTDDRUID	D0V7PL
D0V7PL	DRUGNAME	Lefradafiban
D0V7PL	INDICATI	Angina pectoris [ICD-11: BA40] Phase 1

D07RPT	TTDDRUID	D07RPT
D07RPT	DRUGNAME	Lentiviral RNAi therapy
D07RPT	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D02SYV	TTDDRUID	D02SYV
D02SYV	DRUGNAME	Lenzilumab
D02SYV	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1

D0B0OA	TTDDRUID	D0B0OA
D0B0OA	DRUGNAME	LEO-27847
D0B0OA	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 1

D0QJ2K	TTDDRUID	D0QJ2K
D0QJ2K	DRUGNAME	LEO-27989
D0QJ2K	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D09UMN	TTDDRUID	D09UMN
D09UMN	DRUGNAME	LEQ-506
D09UMN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W9QI	TTDDRUID	D0W9QI
D0W9QI	DRUGNAME	LErafAON
D0W9QI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P1JA	TTDDRUID	D0P1JA
D0P1JA	DRUGNAME	LETRAZURIL
D0P1JA	INDICATI	Isosporiasis [ICD-11: 1A33] Phase 1

D0U0RJ	TTDDRUID	D0U0RJ
D0U0RJ	DRUGNAME	Leukocyte interleukin
D0U0RJ	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0U0RJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0F1ZB	TTDDRUID	D0F1ZB
D0F1ZB	DRUGNAME	LFA-102
D0F1ZB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04RFX	TTDDRUID	D04RFX
D04RFX	DRUGNAME	LFn-p24
D04RFX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D07EFB	TTDDRUID	D07EFB
D07EFB	DRUGNAME	LFn-p24-B-C
D07EFB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0P9CB	TTDDRUID	D0P9CB
D0P9CB	DRUGNAME	LG631
D0P9CB	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Discontinued in Phase 1
D0P9CB	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D08LAE	TTDDRUID	D08LAE
D08LAE	DRUGNAME	LGD-4033
D08LAE	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 1

D0J5HR	TTDDRUID	D0J5HR
D0J5HR	DRUGNAME	LGK974
D0J5HR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S9EK	TTDDRUID	D0S9EK
D0S9EK	DRUGNAME	LIlotomab satetraxetan
D0S9EK	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1

D0BV0U	TTDDRUID	D0BV0U
D0BV0U	DRUGNAME	Lintuzumab Ac-226
D0BV0U	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0T7LV	TTDDRUID	D0T7LV
D0T7LV	DRUGNAME	LIPO-4
D0T7LV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0L2OT	TTDDRUID	D0L2OT
D0L2OT	DRUGNAME	Lipovaxin-MM
D0L2OT	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D01SPJ	TTDDRUID	D01SPJ
D01SPJ	DRUGNAME	Litenimod
D01SPJ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D05ISV	TTDDRUID	D05ISV
D05ISV	DRUGNAME	Live attenuated human parainfluenza virus type 2 vaccine
D05ISV	INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1

D07RDQ	TTDDRUID	D07RDQ
D07RDQ	DRUGNAME	LMB-100
D07RDQ	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
D07RDQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D06MMU	TTDDRUID	D06MMU
D06MMU	DRUGNAME	LM-CD45
D06MMU	INDICATI	Transplant rejection [ICD-11: NE84] Phase 1

D0S9OH	TTDDRUID	D0S9OH
D0S9OH	DRUGNAME	L-MDAM
D0S9OH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Z6RW	TTDDRUID	D0Z6RW
D0Z6RW	DRUGNAME	LMP-1/LMP-2 CTLs
D0Z6RW	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0Y4HO	TTDDRUID	D0Y4HO
D0Y4HO	DRUGNAME	LMV-601
D0Y4HO	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D03BXU	TTDDRUID	D03BXU
D03BXU	DRUGNAME	LNK-754
D03BXU	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1

D04UTH	TTDDRUID	D04UTH
D04UTH	DRUGNAME	Long-acting erythropoietin conjugate
D04UTH	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D0MS6B	TTDDRUID	D0MS6B
D0MS6B	DRUGNAME	LOR 253
D0MS6B	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1

D0PK3W	TTDDRUID	D0PK3W
D0PK3W	DRUGNAME	Lotilibcin dermatological cream
D0PK3W	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0M4PH	TTDDRUID	D0M4PH
D0M4PH	DRUGNAME	LOXO-101
D0M4PH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
D0M4PH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03UDF	TTDDRUID	D03UDF
D03UDF	DRUGNAME	LOXO-195
D03UDF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01KOA	TTDDRUID	D01KOA
D01KOA	DRUGNAME	LOXO-292
D01KOA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00KVX	TTDDRUID	D00KVX
D00KVX	DRUGNAME	LP-261
D00KVX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07UZY	TTDDRUID	D07UZY
D07UZY	DRUGNAME	Lpathomab
D07UZY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TN6K	TTDDRUID	D0TN6K
D0TN6K	DRUGNAME	LSZ102
D0TN6K	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D00YUP	TTDDRUID	D00YUP
D00YUP	DRUGNAME	LT-3001
D00YUP	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1

D0TA8O	TTDDRUID	D0TA8O
D0TA8O	DRUGNAME	LTT462
D0TA8O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0MC6Y	TTDDRUID	D0MC6Y
D0MC6Y	DRUGNAME	LTX-04
D0MC6Y	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D09UDL	TTDDRUID	D09UDL
D09UDL	DRUGNAME	LTX-315
D09UDL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A9PD	TTDDRUID	D0A9PD
D0A9PD	DRUGNAME	Lu AF20513
D0A9PD	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0CH4T	TTDDRUID	D0CH4T
D0CH4T	DRUGNAME	Lu-02-750
D0CH4T	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0B9DI	TTDDRUID	D0B9DI
D0B9DI	DRUGNAME	Lu-AE04621
D0B9DI	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D08WAN	TTDDRUID	D08WAN
D08WAN	DRUGNAME	Lu-AF11167
D08WAN	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1

D0A8WR	TTDDRUID	D0A8WR
D0A8WR	DRUGNAME	LUpartumab amadotin
D0A8WR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02XTT	TTDDRUID	D02XTT
D02XTT	DRUGNAME	LV305
D02XTT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D02XTT	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D02XTT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D05IQI	TTDDRUID	D05IQI
D05IQI	DRUGNAME	LX9211
D05IQI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D0T4QA	TTDDRUID	D0T4QA
D0T4QA	DRUGNAME	LXH254
D0T4QA	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0R4EN	TTDDRUID	D0R4EN
D0R4EN	DRUGNAME	LXR 623
D0R4EN	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D0R7HL	TTDDRUID	D0R7HL
D0R7HL	DRUGNAME	LXS196
D0R7HL	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D02QYY	TTDDRUID	D02QYY
D02QYY	DRUGNAME	LY01005
D02QYY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0J8PR	TTDDRUID	D0J8PR
D0J8PR	DRUGNAME	LY03003
D0J8PR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0WL3H	TTDDRUID	D0WL3H
D0WL3H	DRUGNAME	LY03005
D0WL3H	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
D0WL3H	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D0D6XH	TTDDRUID	D0D6XH
D0D6XH	DRUGNAME	LY-203725
D0D6XH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F2JY	TTDDRUID	D0F2JY
D0F2JY	DRUGNAME	LY-2334737
D0F2JY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02ANO	TTDDRUID	D02ANO
D02ANO	DRUGNAME	LY-2393910
D02ANO	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1

D0VO5S	TTDDRUID	D0VO5S
D0VO5S	DRUGNAME	LY-2584702
D0VO5S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03RYI	TTDDRUID	D03RYI
D03RYI	DRUGNAME	LY2606368 MsOH H2O
D03RYI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O5BW	TTDDRUID	D0O5BW
D0O5BW	DRUGNAME	LY-2624587
D0O5BW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q0PO	TTDDRUID	D0Q0PO
D0Q0PO	DRUGNAME	LY2780301
D0Q0PO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N1BF	TTDDRUID	D0N1BF
D0N1BF	DRUGNAME	LY-2811376
D0N1BF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0EO2C	TTDDRUID	D0EO2C
D0EO2C	DRUGNAME	LY-2881835
D0EO2C	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0IN8Z	TTDDRUID	D0IN8Z
D0IN8Z	DRUGNAME	LY2928057
D0IN8Z	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D02XLI	TTDDRUID	D02XLI
D02XLI	DRUGNAME	LY-2979165
D02XLI	INDICATI	Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 1

D0SD7G	TTDDRUID	D0SD7G
D0SD7G	DRUGNAME	LY3002813
D0SD7G	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D04AHQ	TTDDRUID	D04AHQ
D04AHQ	DRUGNAME	LY3009120
D04AHQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00OTM	TTDDRUID	D00OTM
D00OTM	DRUGNAME	LY3022855
D00OTM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08WOW	TTDDRUID	D08WOW
D08WOW	DRUGNAME	LY3039478
D08WOW	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D08WOW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D08WOW	INDICATI	T-cell acute lymphoblastic leukaemia [ICD-11: 2A90.5] Phase 1/2

D08ZJX	TTDDRUID	D08ZJX
D08ZJX	DRUGNAME	LY3076226
D08ZJX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09JVK	TTDDRUID	D09JVK
D09JVK	DRUGNAME	LY3090106
D09JVK	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D09JVK	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1

D0IZ1A	TTDDRUID	D0IZ1A
D0IZ1A	DRUGNAME	LY309887
D0IZ1A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03WOQ	TTDDRUID	D03WOQ
D03WOQ	DRUGNAME	LY3127804
D03WOQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01IJM	TTDDRUID	D01IJM
D01IJM	DRUGNAME	LY3164530
D01IJM	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D01IJM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06BGZ	TTDDRUID	D06BGZ
D06BGZ	DRUGNAME	LY3200882
D06BGZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TN3Q	TTDDRUID	D0TN3Q
D0TN3Q	DRUGNAME	LY3214996
D0TN3Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08HSS	TTDDRUID	D08HSS
D08HSS	DRUGNAME	LY3300054
D08HSS	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D08HSS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02DZK	TTDDRUID	D02DZK
D02DZK	DRUGNAME	LY3303560
D02DZK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D08FIB	TTDDRUID	D08FIB
D08FIB	DRUGNAME	LY3316531
D08FIB	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D09YXT	TTDDRUID	D09YXT
D09YXT	DRUGNAME	LY3321367
D09YXT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C4PB	TTDDRUID	D0C4PB
D0C4PB	DRUGNAME	LY3381916
D0C4PB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08RBW	TTDDRUID	D08RBW
D08RBW	DRUGNAME	LY900014
D08RBW	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
D08RBW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D00DXH	TTDDRUID	D00DXH
D00DXH	DRUGNAME	LYS-6KAKT1
D00DXH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0BX5L	TTDDRUID	D0BX5L
D0BX5L	DRUGNAME	LZM009
D0BX5L	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D0BX5L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03MIN	TTDDRUID	D03MIN
D03MIN	DRUGNAME	M-0004
D03MIN	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1

D0MK9W	TTDDRUID	D0MK9W
D0MK9W	DRUGNAME	M1 agonist
D0MK9W	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0MK9W	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D06HYF	TTDDRUID	D06HYF
D06HYF	DRUGNAME	M2698
D06HYF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09VAS	TTDDRUID	D09VAS
D09VAS	DRUGNAME	M281
D09VAS	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D08YTQ	TTDDRUID	D08YTQ
D08YTQ	DRUGNAME	M2e influenza vaccine
D08YTQ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0NW8C	TTDDRUID	D0NW8C
D0NW8C	DRUGNAME	M3541
D0NW8C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H3UR	TTDDRUID	D0H3UR
D0H3UR	DRUGNAME	M3814
D0H3UR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G3UK	TTDDRUID	D0G3UK
D0G3UK	DRUGNAME	M4 agonist
D0G3UK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0IE9L	TTDDRUID	D0IE9L
D0IE9L	DRUGNAME	M4344
D0IE9L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08SGE	TTDDRUID	D08SGE
D08SGE	DRUGNAME	M7583
D08SGE	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D02SHI	TTDDRUID	D02SHI
D02SHI	DRUGNAME	M8891
D02SHI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02IKF	TTDDRUID	D02IKF
D02IKF	DRUGNAME	M9831
D02IKF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07QDT	TTDDRUID	D07QDT
D07QDT	DRUGNAME	MA-0211
D07QDT	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D05OWB	TTDDRUID	D05OWB
D05OWB	DRUGNAME	mab-216
D05OWB	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D05TMA	TTDDRUID	D05TMA
D05TMA	DRUGNAME	MAGE-A4 TCR
D05TMA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X3JV	TTDDRUID	D0X3JV
D0X3JV	DRUGNAME	MalariVax
D0X3JV	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D06YCR	TTDDRUID	D06YCR
D06YCR	DRUGNAME	Marburg virus DNA vaccine
D06YCR	INDICATI	Marburg virus infection [ICD-11: 1D60.1] Phase 1

D03CBO	TTDDRUID	D03CBO
D03CBO	DRUGNAME	Marizomib IV
D03CBO	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
D03CBO	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0EG5P	TTDDRUID	D0EG5P
D0EG5P	DRUGNAME	Matrix M
D0EG5P	INDICATI	Vaccination [ICD-11: N.A.] Phase 1

D0D1ZF	TTDDRUID	D0D1ZF
D0D1ZF	DRUGNAME	Mavacamten
D0D1ZF	INDICATI	Cardiomyopathy [ICD-11: BC43] Phase 1
D0D1ZF	INDICATI	Obstructive hypertrophic cardiomyopathy [ICD-11: BC43.12] Phase 2

D0T2EO	TTDDRUID	D0T2EO
D0T2EO	DRUGNAME	MAXY-4
D0T2EO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D06FZH	TTDDRUID	D06FZH
D06FZH	DRUGNAME	MazF gene therapy, HIV
D06FZH	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0YN9Y	TTDDRUID	D0YN9Y
D0YN9Y	DRUGNAME	MB-101
D0YN9Y	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D0C3JB	TTDDRUID	D0C3JB
D0C3JB	DRUGNAME	MB-102
D0C3JB	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0WY1E	TTDDRUID	D0WY1E
D0WY1E	DRUGNAME	MB-106
D0WY1E	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D04SJT	TTDDRUID	D04SJT
D04SJT	DRUGNAME	MB-11040
D04SJT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D06SCK	TTDDRUID	D06SCK
D06SCK	DRUGNAME	MB-311
D06SCK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0NH2O	TTDDRUID	D0NH2O
D0NH2O	DRUGNAME	MB66 microbicide
D0NH2O	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D06MKG	TTDDRUID	D06MKG
D06MKG	DRUGNAME	MBP(75-95)
D06MKG	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0K9OU	TTDDRUID	D0K9OU
D0K9OU	DRUGNAME	MBX400
D0K9OU	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1

D0DA7Z	TTDDRUID	D0DA7Z
D0DA7Z	DRUGNAME	MBX-400/cyclopropavir
D0DA7Z	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1

D0J2OC	TTDDRUID	D0J2OC
D0J2OC	DRUGNAME	MBX-700
D0J2OC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0V9AL	TTDDRUID	D0V9AL
D0V9AL	DRUGNAME	MCAF5352A
D0V9AL	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D04SIU	TTDDRUID	D04SIU
D04SIU	DRUGNAME	MCD-386
D04SIU	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D01AKU	TTDDRUID	D01AKU
D01AKU	DRUGNAME	MCP-201
D01AKU	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D09FOP	TTDDRUID	D09FOP
D09FOP	DRUGNAME	MCP-202
D09FOP	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 1

D08FXE	TTDDRUID	D08FXE
D08FXE	DRUGNAME	MD-920
D08FXE	INDICATI	Wound healing [ICD-11: EL8Y] Phase 1

D0DO5J	TTDDRUID	D0DO5J
D0DO5J	DRUGNAME	MDAM (y-methylene-10-deazaaminopterin)
D0DO5J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L1ZK	TTDDRUID	D0L1ZK
D0L1ZK	DRUGNAME	MDCO-216
D0L1ZK	INDICATI	Acute coronary syndrome [ICD-11: BA41] Preclinical
D0L1ZK	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D0TT5K	TTDDRUID	D0TT5K
D0TT5K	DRUGNAME	MDL-27531
D0TT5K	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0Z9ZT	TTDDRUID	D0Z9ZT
D0Z9ZT	DRUGNAME	MDNA55
D0Z9ZT	INDICATI	Brain metastases [ICD-11: 2D50] Phase 1
D0Z9ZT	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D0W4HA	TTDDRUID	D0W4HA
D0W4HA	DRUGNAME	MDX-018
D0W4HA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
D0W4HA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03KLF	TTDDRUID	D03KLF
D03KLF	DRUGNAME	MDX-1203
D03KLF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03KVW	TTDDRUID	D03KVW
D03KVW	DRUGNAME	MDX-1411
D03KVW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V3BZ	TTDDRUID	D0V3BZ
D0V3BZ	DRUGNAME	ME-1071
D0V3BZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D01CYK	TTDDRUID	D01CYK
D01CYK	DRUGNAME	ME1100
D01CYK	INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Phase 1

D0O9LN	TTDDRUID	D0O9LN
D0O9LN	DRUGNAME	ME-143
D0O9LN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08WLY	TTDDRUID	D08WLY
D08WLY	DRUGNAME	ME-401
D08WLY	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D08WLY	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D08WLY	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D08WLY	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0O0GX	TTDDRUID	D0O0GX
D0O0GX	DRUGNAME	MedChew-1401
D0O0GX	INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 1

D0ZO5K	TTDDRUID	D0ZO5K
D0ZO5K	DRUGNAME	MEDI0562
D0ZO5K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07MPI	TTDDRUID	D07MPI
D07MPI	DRUGNAME	MEDI-0639
D07MPI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01CXW	TTDDRUID	D01CXW
D01CXW	DRUGNAME	MEDI0680
D01CXW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03LAV	TTDDRUID	D03LAV
D03LAV	DRUGNAME	MEDI0700
D03LAV	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D01UYA	TTDDRUID	D01UYA
D01UYA	DRUGNAME	MEDI1341
D01UYA	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D04AZT	TTDDRUID	D04AZT
D04AZT	DRUGNAME	MEDI1814
D04AZT	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0J9PS	TTDDRUID	D0J9PS
D0J9PS	DRUGNAME	MEDI1841
D0J9PS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0H7AM	TTDDRUID	D0H7AM
D0H7AM	DRUGNAME	MEDI1873
D0H7AM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05UCW	TTDDRUID	D05UCW
D05UCW	DRUGNAME	MEDI-2338
D05UCW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0C2QS	TTDDRUID	D0C2QS
D0C2QS	DRUGNAME	MEDI-3617
D0C2QS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0MH1F	TTDDRUID	D0MH1F
D0MH1F	DRUGNAME	MEDI3726
D0MH1F	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0O5CV	TTDDRUID	D0O5CV
D0O5CV	DRUGNAME	MEDI4212
D0O5CV	INDICATI	Asthma [ICD-11: CA23] Phase 1

D08UDG	TTDDRUID	D08UDG
D08UDG	DRUGNAME	MEDI4276
D08UDG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06HNO	TTDDRUID	D06HNO
D06HNO	DRUGNAME	MEDI4920
D06HNO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D06HNO	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1

D07HPH	TTDDRUID	D07HPH
D07HPH	DRUGNAME	MEDI5083
D07HPH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0DT8Y	TTDDRUID	D0DT8Y
D0DT8Y	DRUGNAME	MEDI5117
D0DT8Y	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0B8MS	TTDDRUID	D0B8MS
D0B8MS	DRUGNAME	MEDI-547
D0B8MS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X1BR	TTDDRUID	D0X1BR
D0X1BR	DRUGNAME	MEDI-550
D0X1BR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D08DSF	TTDDRUID	D08DSF
D08DSF	DRUGNAME	MEDI-557
D08DSF	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D0PY3L	TTDDRUID	D0PY3L
D0PY3L	DRUGNAME	MEDI-565
D0PY3L	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1

D0E6NH	TTDDRUID	D0E6NH
D0E6NH	DRUGNAME	MEDI-570
D0E6NH	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D0F2IM	TTDDRUID	D0F2IM
D0F2IM	DRUGNAME	MEDI-573
D0F2IM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0JA3Y	TTDDRUID	D0JA3Y
D0JA3Y	DRUGNAME	MEDI-578
D0JA3Y	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D02UBC	TTDDRUID	D02UBC
D02UBC	DRUGNAME	MEDI6383
D02UBC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E9ME	TTDDRUID	D0E9ME
D0E9ME	DRUGNAME	MEDI7247
D0E9ME	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0WR9U	TTDDRUID	D0WR9U
D0WR9U	DRUGNAME	MEDI7352
D0WR9U	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
D0WR9U	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0H0ZV	TTDDRUID	D0H0ZV
D0H0ZV	DRUGNAME	MEDI7814
D0H0ZV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0ZY3R	TTDDRUID	D0ZY3R
D0ZY3R	DRUGNAME	MEDI8111
D0ZY3R	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 1

D04OFR	TTDDRUID	D04OFR
D04OFR	DRUGNAME	MEDI8897
D04OFR	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D0L8HB	TTDDRUID	D0L8HB
D0L8HB	DRUGNAME	MEDI9197
D0L8HB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Z5LI	TTDDRUID	D0Z5LI
D0Z5LI	DRUGNAME	MEDI9447
D0Z5LI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04KWO	TTDDRUID	D04KWO
D04KWO	DRUGNAME	MEDl-551
D04KWO	INDICATI	Scleroderma [ICD-11: 4A42] Phase 1

D02XXQ	TTDDRUID	D02XXQ
D02XXQ	DRUGNAME	MEDl-557
D02XXQ	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D0K0YO	TTDDRUID	D0K0YO
D0K0YO	DRUGNAME	Melanoma antigens
D0K0YO	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D07YZQ	TTDDRUID	D07YZQ
D07YZQ	DRUGNAME	Melanoma DNA vaccine
D07YZQ	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D03CWX	TTDDRUID	D03CWX
D03CWX	DRUGNAME	MEM-1414
D03CWX	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1

D04YHJ	TTDDRUID	D04YHJ
D04YHJ	DRUGNAME	Meninge B
D04YHJ	INDICATI	Meningitis [ICD-11: 1D01] Phase 1

D01YLK	TTDDRUID	D01YLK
D01YLK	DRUGNAME	Meningitis ACYW conj.
D01YLK	INDICATI	Meningitis [ICD-11: 1D01] Phase 1

D06LEA	TTDDRUID	D06LEA
D06LEA	DRUGNAME	MER-102
D06LEA	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0I1HI	TTDDRUID	D0I1HI
D0I1HI	DRUGNAME	MER-4101
D0I1HI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0I7UQ	TTDDRUID	D0I7UQ
D0I7UQ	DRUGNAME	MER-5101
D0I7UQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
D0I7UQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0N5MI	TTDDRUID	D0N5MI
D0N5MI	DRUGNAME	Merestinib, LY2801653
D0N5MI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0RI7N	TTDDRUID	D0RI7N
D0RI7N	DRUGNAME	Mesenchymal bone marrow-derived stem cell therapy
D0RI7N	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D0M6AR	TTDDRUID	D0M6AR
D0M6AR	DRUGNAME	Mesenchymal stem cell therapy
D0M6AR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0M6AR	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
D0M6AR	INDICATI	Skin photoaging [ICD-11: EJ20] Phase 1

D01GQO	TTDDRUID	D01GQO
D01GQO	DRUGNAME	Mesenchymal stem cell therapy, ischemic-tolerant stem cells
D01GQO	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 1

D0D2LE	TTDDRUID	D0D2LE
D0D2LE	DRUGNAME	Meso-CART
D0D2LE	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0O2XK	TTDDRUID	D0O2XK
D0O2XK	DRUGNAME	Mesothelin-targeted T cells
D0O2XK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0IJ7O	TTDDRUID	D0IJ7O
D0IJ7O	DRUGNAME	Metastat
D0IJ7O	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1

D0U2QI	TTDDRUID	D0U2QI
D0U2QI	DRUGNAME	METH-mab
D0U2QI	INDICATI	Methamphetamine dependence [ICD-11: 6C46.2] Phase 1

D0Y6CU	TTDDRUID	D0Y6CU
D0Y6CU	DRUGNAME	Methotrexate subcutaneous auto-injection
D0Y6CU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D02XAC	TTDDRUID	D02XAC
D02XAC	DRUGNAME	MG-1102
D02XAC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06UOU	TTDDRUID	D06UOU
D06UOU	DRUGNAME	MGA271
D06UOU	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1

D00JDL	TTDDRUID	D00JDL
D00JDL	DRUGNAME	MGD006
D00JDL	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D00JDL	INDICATI	Acute myeloid lymphoma [ICD-11: 2A80] Phase 1

D00PEN	TTDDRUID	D00PEN
D00PEN	DRUGNAME	MGD007
D00PEN	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D00PEN	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1

D05FHZ	TTDDRUID	D05FHZ
D05FHZ	DRUGNAME	MGD009
D05FHZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0QO6N	TTDDRUID	D0QO6N
D0QO6N	DRUGNAME	MGD010
D0QO6N	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D0MY0F	TTDDRUID	D0MY0F
D0MY0F	DRUGNAME	MGD013
D0MY0F	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D0MY0F	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0MY0F	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
D0MY0F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U8LD	TTDDRUID	D0U8LD
D0U8LD	DRUGNAME	MGN-1706
D0U8LD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W8XT	TTDDRUID	D0W8XT
D0W8XT	DRUGNAME	Mibefradil
D0W8XT	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D0W8XT	INDICATI	Ovarian cancer [ICD-11: 2C73] Withdrawn from market

D0FS1B	TTDDRUID	D0FS1B
D0FS1B	DRUGNAME	Micro-dystrophin gene therapy
D0FS1B	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D0GR1Y	TTDDRUID	D0GR1Y
D0GR1Y	DRUGNAME	Minnelide
D0GR1Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05UFJ	TTDDRUID	D05UFJ
D05UFJ	DRUGNAME	Minnelide 001
D05UFJ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D05UFJ	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1

D0E1AN	TTDDRUID	D0E1AN
D0E1AN	DRUGNAME	MINT-1526A
D0E1AN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H1IC	TTDDRUID	D0H1IC
D0H1IC	DRUGNAME	MiRNA mimetics
D0H1IC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D08CPL	TTDDRUID	D08CPL
D08CPL	DRUGNAME	MIST-B03
D08CPL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D0FE3P	TTDDRUID	D0FE3P
D0FE3P	DRUGNAME	MIV 150 + zinc acetate
D0FE3P	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0M2TS	TTDDRUID	D0M2TS
D0M2TS	DRUGNAME	Mivebresib
D0M2TS	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0M2TS	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0M2TS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03HDL	TTDDRUID	D03HDL
D03HDL	DRUGNAME	MK 8719
D03HDL	INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1

D0V2YJ	TTDDRUID	D0V2YJ
D0V2YJ	DRUGNAME	MK-0731
D0V2YJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A3CF	TTDDRUID	D0A3CF
D0A3CF	DRUGNAME	MK-1248
D0A3CF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08MWC	TTDDRUID	D08MWC
D08MWC	DRUGNAME	MK-1308
D08MWC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0T1TT	TTDDRUID	D0T1TT
D0T1TT	DRUGNAME	MK-1454
D0T1TT	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0T1TT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05RGV	TTDDRUID	D05RGV
D05RGV	DRUGNAME	MK-1496
D05RGV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P5PJ	TTDDRUID	D0P5PJ
D0P5PJ	DRUGNAME	MK-1972
D0P5PJ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0Z1UD	TTDDRUID	D0Z1UD
D0Z1UD	DRUGNAME	MK-2118
D0Z1UD	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0Z1UD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y3AZ	TTDDRUID	D0Y3AZ
D0Y3AZ	DRUGNAME	MK-2637
D0Y3AZ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0LR1Z	TTDDRUID	D0LR1Z
D0LR1Z	DRUGNAME	MK-2640
D0LR1Z	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D0OW9L	TTDDRUID	D0OW9L
D0OW9L	DRUGNAME	MK-3134
D0OW9L	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1

D06IPZ	TTDDRUID	D06IPZ
D06IPZ	DRUGNAME	MK-3281
D06IPZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D09PYZ	TTDDRUID	D09PYZ
D09PYZ	DRUGNAME	MK-3328
D09PYZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0H6YK	TTDDRUID	D0H6YK
D0H6YK	DRUGNAME	MK-3614
D0H6YK	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D04SOU	TTDDRUID	D04SOU
D04SOU	DRUGNAME	MK-4074
D04SOU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0Y2XZ	TTDDRUID	D0Y2XZ
D0Y2XZ	DRUGNAME	MK-4166
D0Y2XZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0RY3N	TTDDRUID	D0RY3N
D0RY3N	DRUGNAME	MK-4280
D0RY3N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H7AR	TTDDRUID	D0H7AR
D0H7AR	DRUGNAME	MK-51
D0H7AR	INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 1

D0J6AB	TTDDRUID	D0J6AB
D0J6AB	DRUGNAME	MK-5108
D0J6AB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07WMD	TTDDRUID	D07WMD
D07WMD	DRUGNAME	MK-5478
D07WMD	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0K6LX	TTDDRUID	D0K6LX
D0K6LX	DRUGNAME	MK-5823
D0K6LX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0F9IE	TTDDRUID	D0F9IE
D0F9IE	DRUGNAME	MK-5890
D0F9IE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03PKJ	TTDDRUID	D03PKJ
D03PKJ	DRUGNAME	MK-6186
D03PKJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D08YGY	TTDDRUID	D08YGY
D08YGY	DRUGNAME	MK-6302
D08YGY	INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 1

D02BAW	TTDDRUID	D02BAW
D02BAW	DRUGNAME	MK-6325
D02BAW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D01SIB	TTDDRUID	D01SIB
D01SIB	DRUGNAME	MK-6349
D01SIB	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1

D05HIX	TTDDRUID	D05HIX
D05HIX	DRUGNAME	MK-6406
D05HIX	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1

D0L9QM	TTDDRUID	D0L9QM
D0L9QM	DRUGNAME	MK-7145
D0L9QM	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0U0RX	TTDDRUID	D0U0RX
D0U0RX	DRUGNAME	MK-7162
D0U0RX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0I3TU	TTDDRUID	D0I3TU
D0I3TU	DRUGNAME	MK-7246
D0I3TU	INDICATI	Respiratory disease [ICD-11: CB40] Phase 1

D0P6YD	TTDDRUID	D0P6YD
D0P6YD	DRUGNAME	MK-7252
D0P6YD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00GCA	TTDDRUID	D00GCA
D00GCA	DRUGNAME	MK-7288
D00GCA	INDICATI	Excessive daytime sleepiness [ICD-11: MG42] Phase 1

D0I2KE	TTDDRUID	D0I2KE
D0I2KE	DRUGNAME	MK-7684
D0I2KE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05OMT	TTDDRUID	D05OMT
D05OMT	DRUGNAME	MK-8033
D05OMT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J0HE	TTDDRUID	D0J0HE
D0J0HE	DRUGNAME	MK-8150
D0J0HE	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D01JKV	TTDDRUID	D01JKV
D01JKV	DRUGNAME	MK-8266
D01JKV	INDICATI	Essential hypertension [ICD-11: BA00] Phase 1

D0L1GD	TTDDRUID	D0L1GD
D0L1GD	DRUGNAME	MK-8353
D0L1GD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H1UK	TTDDRUID	D0H1UK
D0H1UK	DRUGNAME	MK-8591
D0H1UK	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D03BZS	TTDDRUID	D03BZS
D03BZS	DRUGNAME	MK-8655
D03BZS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0K0IM	TTDDRUID	D0K0IM
D0K0IM	DRUGNAME	MK-8666
D0K0IM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0C9WN	TTDDRUID	D0C9WN
D0C9WN	DRUGNAME	MKC-1106-PP
D0C9WN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q4CX	TTDDRUID	D0Q4CX
D0Q4CX	DRUGNAME	MLN-3126
D0Q4CX	INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1

D0Y1GJ	TTDDRUID	D0Y1GJ
D0Y1GJ	DRUGNAME	MLN-576
D0Y1GJ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0Z0FA	TTDDRUID	D0Z0FA
D0Z0FA	DRUGNAME	MLN7243
D0Z0FA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A5MC	TTDDRUID	D0A5MC
D0A5MC	DRUGNAME	MLN8054
D0A5MC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01NAP	TTDDRUID	D01NAP
D01NAP	DRUGNAME	MM-151
D01NAP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07USV	TTDDRUID	D07USV
D07USV	DRUGNAME	MM-302
D07USV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0WW1V	TTDDRUID	D0WW1V
D0WW1V	DRUGNAME	MM-310
D0WW1V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00XEX	TTDDRUID	D00XEX
D00XEX	DRUGNAME	MN-201
D00XEX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K8BJ	TTDDRUID	D0K8BJ
D0K8BJ	DRUGNAME	MNK-010
D0K8BJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0II7M	TTDDRUID	D0II7M
D0II7M	DRUGNAME	Modified adenovirus delta24-RGD
D0II7M	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0U0HX	TTDDRUID	D0U0HX
D0U0HX	DRUGNAME	Molgramostim
D0U0HX	INDICATI	Wound healing [ICD-11: EL8Y] Phase 1

D0RI6Q	TTDDRUID	D0RI6Q
D0RI6Q	DRUGNAME	Monalizumab
D0RI6Q	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
D0RI6Q	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
D0RI6Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00DIM	TTDDRUID	D00DIM
D00DIM	DRUGNAME	Monohydroxyethylrutoside
D00DIM	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0B0VD	TTDDRUID	D0B0VD
D0B0VD	DRUGNAME	MORAb-022
D0B0VD	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
D0B0VD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0H8PX	TTDDRUID	D0H8PX
D0H8PX	DRUGNAME	MORAb-066
D0H8PX	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0H8PX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G2OZ	TTDDRUID	D0G2OZ
D0G2OZ	DRUGNAME	MORAb-202
D0G2OZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06SNV	TTDDRUID	D06SNV
D06SNV	DRUGNAME	MORAb-28
D06SNV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IM1B	TTDDRUID	D0IM1B
D0IM1B	DRUGNAME	MOv18IgE
D0IM1B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0T7CR	TTDDRUID	D0T7CR
D0T7CR	DRUGNAME	MOv19-BBz CAR T cells
D0T7CR	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D0T7CR	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0T7CR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0V3HP	TTDDRUID	D0V3HP
D0V3HP	DRUGNAME	MP-0112
D0V3HP	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D0YU1L	TTDDRUID	D0YU1L
D0YU1L	DRUGNAME	MP-124
D0YU1L	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1
D0YU1L	INDICATI	Stroke [ICD-11: 8B20] Phase 1

D03VWB	TTDDRUID	D03VWB
D03VWB	DRUGNAME	MP-157
D03VWB	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D04YAK	TTDDRUID	D04YAK
D04YAK	DRUGNAME	MPC-2130
D04YAK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08ONJ	TTDDRUID	D08ONJ
D08ONJ	DRUGNAME	MPC-3100
D08ONJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N3PC	TTDDRUID	D0N3PC
D0N3PC	DRUGNAME	MR1-1
D0N3PC	INDICATI	Brain cancer [ICD-11: 2A00] Phase 1

D01SZA	TTDDRUID	D01SZA
D01SZA	DRUGNAME	MR-1817
D01SZA	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0A5WQ	TTDDRUID	D0A5WQ
D0A5WQ	DRUGNAME	MRF-008
D0A5WQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D08WZQ	TTDDRUID	D08WZQ
D08WZQ	DRUGNAME	MRG-201
D08WZQ	INDICATI	Scleroderma [ICD-11: 4A42] Phase 1

D0R5GF	TTDDRUID	D0R5GF
D0R5GF	DRUGNAME	MRKAd5/ALVAC
D0R5GF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0Q2VU	TTDDRUID	D0Q2VU
D0Q2VU	DRUGNAME	MRNA MRK-1777
D0Q2VU	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1

D0O6EQ	TTDDRUID	D0O6EQ
D0O6EQ	DRUGNAME	MRNA-1388
D0O6EQ	INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 1

D0F3FV	TTDDRUID	D0F3FV
D0F3FV	DRUGNAME	MRNA-1440
D0F3FV	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0Z2BI	TTDDRUID	D0Z2BI
D0Z2BI	DRUGNAME	MRNA-1851
D0Z2BI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D09WDS	TTDDRUID	D09WDS
D09WDS	DRUGNAME	MRNA-2416
D09WDS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D09WDS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U5WS	TTDDRUID	D0U5WS
D0U5WS	DRUGNAME	MRNA-4157
D0U5WS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08SJY	TTDDRUID	D08SJY
D08SJY	DRUGNAME	MRX34
D08SJY	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1

D0N8GC	TTDDRUID	D0N8GC
D0N8GC	DRUGNAME	MRX-4TZT
D0N8GC	INDICATI	Spastic paralysis [ICD-11: MB5Y] Phase 1

D0GL0K	TTDDRUID	D0GL0K
D0GL0K	DRUGNAME	MRZ-8456
D0GL0K	INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Phase 1

D0LB2L	TTDDRUID	D0LB2L
D0LB2L	DRUGNAME	MS201408-0005A
D0LB2L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03BKN	TTDDRUID	D03BKN
D03BKN	DRUGNAME	MS201408-0005B
D03BKN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CJ3R	TTDDRUID	D0CJ3R
D0CJ3R	DRUGNAME	MS201408-0005C
D0CJ3R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A8AU	TTDDRUID	D0A8AU
D0A8AU	DRUGNAME	MSB2311
D0A8AU	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D0A8AU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08DWC	TTDDRUID	D08DWC
D08DWC	DRUGNAME	MSC2015103B
D08DWC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04ZXE	TTDDRUID	D04ZXE
D04ZXE	DRUGNAME	MSC2363318A
D04ZXE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XB1M	TTDDRUID	D0XB1M
D0XB1M	DRUGNAME	MSH-372
D0XB1M	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0E5JC	TTDDRUID	D0E5JC
D0E5JC	DRUGNAME	MSX-122
D0E5JC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00YOV	TTDDRUID	D00YOV
D00YOV	DRUGNAME	MT-110
D00YOV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N6QB	TTDDRUID	D0N6QB
D0N6QB	DRUGNAME	MT-112
D0N6QB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N6JC	TTDDRUID	D0N6JC
D0N6JC	DRUGNAME	MT-3724
D0N6JC	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1
D0N6JC	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0N6JC	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0L4CN	TTDDRUID	D0L4CN
D0L4CN	DRUGNAME	MTIG7192A
D0L4CN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01SSK	TTDDRUID	D01SSK
D01SSK	DRUGNAME	MTRN-2696
D01SSK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P1ID	TTDDRUID	D0P1ID
D0P1ID	DRUGNAME	MTRX-1011A
D0P1ID	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0U4KJ	TTDDRUID	D0U4KJ
D0U4KJ	DRUGNAME	MTV273
D0U4KJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0LS8H	TTDDRUID	D0LS8H
D0LS8H	DRUGNAME	MTX110
D0LS8H	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1

D0FC7H	TTDDRUID	D0FC7H
D0FC7H	DRUGNAME	MUC-1 CD40L dendritic cell vaccine
D0FC7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O0RG	TTDDRUID	D0O0RG
D0O0RG	DRUGNAME	MUC-1 dendritic cancer vaccine
D0O0RG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01NGH	TTDDRUID	D01NGH
D01NGH	DRUGNAME	Multi-envelope HIV vaccine
D01NGH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0R2LY	TTDDRUID	D0R2LY
D0R2LY	DRUGNAME	Multipeptide vaccine combination
D0R2LY	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0VO2O	TTDDRUID	D0VO2O
D0VO2O	DRUGNAME	Multiple sclerosis therapeutic
D0VO2O	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0C8JW	TTDDRUID	D0C8JW
D0C8JW	DRUGNAME	Muscular dystrophy gene therapy
D0C8JW	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D04AYF	TTDDRUID	D04AYF
D04AYF	DRUGNAME	Musculoskeletal disorder/metabolic disease therapy
D04AYF	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1

D05ATQ	TTDDRUID	D05ATQ
D05ATQ	DRUGNAME	MVA HER-2 AutoVac
D05ATQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0IG2Y	TTDDRUID	D0IG2Y
D0IG2Y	DRUGNAME	MVA p53 vaccine
D0IG2Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00XIP	TTDDRUID	D00XIP
D00XIP	DRUGNAME	MVA-BN Brachyury
D00XIP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0SB2U	TTDDRUID	D0SB2U
D0SB2U	DRUGNAME	MVA-BN brachyury vaccine
D0SB2U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08GFN	TTDDRUID	D08GFN
D08GFN	DRUGNAME	MVA-BN Breast
D08GFN	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0U1WP	TTDDRUID	D0U1WP
D0U1WP	DRUGNAME	MV-CEA
D0U1WP	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0G6OL	TTDDRUID	D0G6OL
D0G6OL	DRUGNAME	MVI-118
D0G6OL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D00IFQ	TTDDRUID	D00IFQ
D00IFQ	DRUGNAME	MVT-1075
D00IFQ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D00IFQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q5QV	TTDDRUID	D0Q5QV
D0Q5QV	DRUGNAME	MVT-5873
D0Q5QV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0Q5QV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0Q5QV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
D0Q5QV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S1YN	TTDDRUID	D0S1YN
D0S1YN	DRUGNAME	MYK-491
D0S1YN	INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 1

D0V6TY	TTDDRUID	D0V6TY
D0V6TY	DRUGNAME	MYO-201
D0V6TY	INDICATI	Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1

D00VOE	TTDDRUID	D00VOE
D00VOE	DRUGNAME	Myoblast cell transplantation
D00VOE	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1

D0L3VT	TTDDRUID	D0L3VT
D0L3VT	DRUGNAME	Myoblast cell transplantation therapy
D0L3VT	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1

D09ORA	TTDDRUID	D09ORA
D09ORA	DRUGNAME	Myocardial perfusion imaging agent
D09ORA	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1

D05EHS	TTDDRUID	D05EHS
D05EHS	DRUGNAME	MyoDys
D05EHS	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D0E8AE	TTDDRUID	D0E8AE
D0E8AE	DRUGNAME	Myolimus
D0E8AE	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1

D00CQL	TTDDRUID	D00CQL
D00CQL	DRUGNAME	N-8295
D00CQL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0E0BE	TTDDRUID	D0E0BE
D0E0BE	DRUGNAME	Na-APR-1
D0E0BE	INDICATI	Hookworm infection [ICD-11: 1F68] Phase 1

D02PMT	TTDDRUID	D02PMT
D02PMT	DRUGNAME	Nagrestipen
D02PMT	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 1

D0XA3L	TTDDRUID	D0XA3L
D0XA3L	DRUGNAME	Naloxone buccal gel
D0XA3L	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1

D04TIJ	TTDDRUID	D04TIJ
D04TIJ	DRUGNAME	Namitecan
D04TIJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01PXH	TTDDRUID	D01PXH
D01PXH	DRUGNAME	NAM-NK cells + IL-2
D01PXH	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D01PXH	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0T9GM	TTDDRUID	D0T9GM
D0T9GM	DRUGNAME	Nanoflu
D0T9GM	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 1

D0Y4RJ	TTDDRUID	D0Y4RJ
D0Y4RJ	DRUGNAME	Nasal influenza vaccine
D0Y4RJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0N6GW	TTDDRUID	D0N6GW
D0N6GW	DRUGNAME	NASPANVAC
D0N6GW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0H6FY	TTDDRUID	D0H6FY
D0H6FY	DRUGNAME	Natural killer cell therapy
D0H6FY	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D00IVN	TTDDRUID	D00IVN
D00IVN	DRUGNAME	Navicixizumab
D00IVN	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D00IVN	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D00IVN	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1
D00IVN	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D00IVN	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1

D0M9XT	TTDDRUID	D0M9XT
D0M9XT	DRUGNAME	NB-003
D0M9XT	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1

D0N4KK	TTDDRUID	D0N4KK
D0N4KK	DRUGNAME	NB-1008
D0N4KK	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 1

D07QWW	TTDDRUID	D07QWW
D07QWW	DRUGNAME	NBI-34041
D07QWW	INDICATI	Eating disorder [ICD-11: 6B82] Phase 1

D04ZIO	TTDDRUID	D04ZIO
D04ZIO	DRUGNAME	NBI-640756
D04ZIO	INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 1

D02VKC	TTDDRUID	D02VKC
D02VKC	DRUGNAME	NBQX
D02VKC	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1

D0M9EV	TTDDRUID	D0M9EV
D0M9EV	DRUGNAME	NBTX-001
D0M9EV	INDICATI	Panic disorder [ICD-11: 6B01] Phase 1

D0AY8D	TTDDRUID	D0AY8D
D0AY8D	DRUGNAME	NBXT-001+Nobilis inhalation device
D0AY8D	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0D7XM	TTDDRUID	D0D7XM
D0D7XM	DRUGNAME	NC-4016
D0D7XM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FG2Z	TTDDRUID	D0FG2Z
D0FG2Z	DRUGNAME	NC-6004
D0FG2Z	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D0FG2Z	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1

D0E2QG	TTDDRUID	D0E2QG
D0E2QG	DRUGNAME	NC-6300
D0E2QG	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 1
D0E2QG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0OS8C	TTDDRUID	D0OS8C
D0OS8C	DRUGNAME	NCX-1015
D0OS8C	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0H0FX	TTDDRUID	D0H0FX
D0H0FX	DRUGNAME	NCX-6560
D0H0FX	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D01AYF	TTDDRUID	D01AYF
D01AYF	DRUGNAME	ND-1.1
D01AYF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0I2VT	TTDDRUID	D0I2VT
D0I2VT	DRUGNAME	ND7001
D0I2VT	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1

D0E3CX	TTDDRUID	D0E3CX
D0E3CX	DRUGNAME	NDX-1017
D0E3CX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D06XFV	TTDDRUID	D06XFV
D06XFV	DRUGNAME	Neo-Kidney Augment
D06XFV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0Q6AU	TTDDRUID	D0Q6AU
D0Q6AU	DRUGNAME	NEO-PV-01
D0Q6AU	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
D0Q6AU	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0B6LP	TTDDRUID	D0B6LP
D0B6LP	DRUGNAME	Neo-Urinary Conduit
D0B6LP	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1

D0JY2X	TTDDRUID	D0JY2X
D0JY2X	DRUGNAME	Neu-2000
D0JY2X	INDICATI	Cardiac arrest [ICD-11: MC82] Phase 1

D0RU5R	TTDDRUID	D0RU5R
D0RU5R	DRUGNAME	NEV-801
D0RU5R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IQ2P	TTDDRUID	D0IQ2P
D0IQ2P	DRUGNAME	NexVax2
D0IQ2P	INDICATI	Coeliac disease [ICD-11: DA95] Phase 1
D0IQ2P	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D0LO3F	TTDDRUID	D0LO3F
D0LO3F	DRUGNAME	NG-348
D0LO3F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L3JI	TTDDRUID	D0L3JI
D0L3JI	DRUGNAME	NGD 94-1
D0L3JI	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0DJ0S	TTDDRUID	D0DJ0S
D0DJ0S	DRUGNAME	NGM313
D0DJ0S	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0EV5O	TTDDRUID	D0EV5O
D0EV5O	DRUGNAME	NGP 555
D0EV5O	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D00BVJ	TTDDRUID	D00BVJ
D00BVJ	DRUGNAME	NHS-IL 12
D00BVJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04MZP	TTDDRUID	D04MZP
D04MZP	DRUGNAME	NI-0101
D04MZP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D02MVA	TTDDRUID	D02MVA
D02MVA	DRUGNAME	NI-0701
D02MVA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D09BZY	TTDDRUID	D09BZY
D09BZY	DRUGNAME	Nibentan
D09BZY	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 1

D0SI9L	TTDDRUID	D0SI9L
D0SI9L	DRUGNAME	Nicotinamide riboside
D0SI9L	INDICATI	Mitochondrial myopathy [ICD-11: 8C73] Phase 1

D00CLM	TTDDRUID	D00CLM
D00CLM	DRUGNAME	NIP-004
D00CLM	INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1

D0KW4D	TTDDRUID	D0KW4D
D0KW4D	DRUGNAME	Niraparib
D0KW4D	INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 1
D0KW4D	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0KW4D	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D07VHU	TTDDRUID	D07VHU
D07VHU	DRUGNAME	NIS793
D07VHU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0X7HQ	TTDDRUID	D0X7HQ
D0X7HQ	DRUGNAME	NitroSense PA6
D0X7HQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D0IX9E	TTDDRUID	D0IX9E
D0IX9E	DRUGNAME	NIZ985
D0IX9E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03OFN	TTDDRUID	D03OFN
D03OFN	DRUGNAME	NK-314
D03OFN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08SIT	TTDDRUID	D08SIT
D08SIT	DRUGNAME	NKP-1339
D08SIT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08YHE	TTDDRUID	D08YHE
D08YHE	DRUGNAME	NKR-2 CAR-T Cells
D08YHE	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D08YHE	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0QR2K	TTDDRUID	D0QR2K
D0QR2K	DRUGNAME	NKR-2 cells
D0QR2K	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D02QQE	TTDDRUID	D02QQE
D02QQE	DRUGNAME	NKTR 214
D02QQE	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
D02QQE	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D02QQE	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
D02QQE	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D02QQE	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
D02QQE	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2
D02QQE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D02QQE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D0W1TK	TTDDRUID	D0W1TK
D0W1TK	DRUGNAME	NKTR-105
D0W1TK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01DIA	TTDDRUID	D01DIA
D01DIA	DRUGNAME	NKTR-262
D01DIA	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D01DIA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D5LX	TTDDRUID	D0D5LX
D0D5LX	DRUGNAME	NKTT-120
D0D5LX	INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1

D0N4VB	TTDDRUID	D0N4VB
D0N4VB	DRUGNAME	NLG802
D0N4VB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06MHZ	TTDDRUID	D06MHZ
D06MHZ	DRUGNAME	NLG919
D06MHZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F8HS	TTDDRUID	D0F8HS
D0F8HS	DRUGNAME	NLX-101
D0F8HS	INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 1

D09HFJ	TTDDRUID	D09HFJ
D09HFJ	DRUGNAME	NM-3
D09HFJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TJ9S	TTDDRUID	D0TJ9S
D0TJ9S	DRUGNAME	N-methanocarbathymidine
D0TJ9S	INDICATI	Herpes zoster [ICD-11: 1E91] Phase 1
D0TJ9S	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0AN4K	TTDDRUID	D0AN4K
D0AN4K	DRUGNAME	NMS-1286937
D0AN4K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J9CG	TTDDRUID	D0J9CG
D0J9CG	DRUGNAME	NmVac
D0J9CG	INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 1

D07YIX	TTDDRUID	D07YIX
D07YIX	DRUGNAME	NmVac4
D07YIX	INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 1

D08XFJ	TTDDRUID	D08XFJ
D08XFJ	DRUGNAME	NN-1218
D08XFJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D08XFJ	INDICATI	Type-1 diabetes [ICD-11: 5A10] Application submitted
D08XFJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted

D0I6MR	TTDDRUID	D0I6MR
D0I6MR	DRUGNAME	NN1406
D0I6MR	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
D0I6MR	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D06SWS	TTDDRUID	D06SWS
D06SWS	DRUGNAME	NN-1952
D06SWS	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 1

D02ZPN	TTDDRUID	D02ZPN
D02ZPN	DRUGNAME	NN-414
D02ZPN	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D0U0XL	TTDDRUID	D0U0XL
D0U0XL	DRUGNAME	NN-7415
D0U0XL	INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1

D05ZSX	TTDDRUID	D05ZSX
D05ZSX	DRUGNAME	NN-8828
D05ZSX	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D06BKK	TTDDRUID	D06BKK
D06BKK	DRUGNAME	NN9748
D06BKK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D08NIN	TTDDRUID	D08NIN
D08NIN	DRUGNAME	NN-9926
D08NIN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0W4YO	TTDDRUID	D0W4YO
D0W4YO	DRUGNAME	NOCICEPTIN
D0W4YO	INDICATI	Headache [ICD-11: 8A80-8A84] Phase 1

D07ELT	TTDDRUID	D07ELT
D07ELT	DRUGNAME	NOX-700
D07ELT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0D8MG	TTDDRUID	D0D8MG
D0D8MG	DRUGNAME	NOX-A12
D0D8MG	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D0D6OO	TTDDRUID	D0D6OO
D0D6OO	DRUGNAME	NP-500
D0D6OO	INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 1
D0D6OO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0M3YX	TTDDRUID	D0M3YX
D0M3YX	DRUGNAME	NPC-09
D0M3YX	INDICATI	Myopathy [ICD-11: 8C7Y] Phase 1

D0C2NT	TTDDRUID	D0C2NT
D0C2NT	DRUGNAME	NP-G2-044
D0C2NT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0KN7Y	TTDDRUID	D0KN7Y
D0KN7Y	DRUGNAME	NPT088
D0KN7Y	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0KN7Y	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1

D0NH1P	TTDDRUID	D0NH1P
D0NH1P	DRUGNAME	NPT-200-11
D0NH1P	INDICATI	Multiple system atrophy [ICD-11: 8D87.0] Phase 1
D0NH1P	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D08LLM	TTDDRUID	D08LLM
D08LLM	DRUGNAME	NS-8
D08LLM	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 1

D0TJ3M	TTDDRUID	D0TJ3M
D0TJ3M	DRUGNAME	NSC-281612
D0TJ3M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07JAI	TTDDRUID	D07JAI
D07JAI	DRUGNAME	NSC-639829
D07JAI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05RWL	TTDDRUID	D05RWL
D05RWL	DRUGNAME	NSD-788
D05RWL	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1

D0D0GH	TTDDRUID	D0D0GH
D0D0GH	DRUGNAME	NsG-0202
D0D0GH	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D09WYE	TTDDRUID	D09WYE
D09WYE	DRUGNAME	NST-001
D09WYE	INDICATI	Tinnitus [ICD-11: MC41] Phase 1

D08TWQ	TTDDRUID	D08TWQ
D08TWQ	DRUGNAME	NTHi
D08TWQ	INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 1

D0HR6E	TTDDRUID	D0HR6E
D0HR6E	DRUGNAME	NTHI vaccine
D0HR6E	INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 1

D08JVS	TTDDRUID	D08JVS
D08JVS	DRUGNAME	NU-206
D08JVS	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 1

D0I7HB	TTDDRUID	D0I7HB
D0I7HB	DRUGNAME	NuroPro
D0I7HB	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D03KJU	TTDDRUID	D03KJU
D03KJU	DRUGNAME	NV-04
D03KJU	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0I5BN	TTDDRUID	D0I5BN
D0I5BN	DRUGNAME	NV-196
D0I5BN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07YEK	TTDDRUID	D07YEK
D07YEK	DRUGNAME	NV-52
D07YEK	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1

D01SXY	TTDDRUID	D01SXY
D01SXY	DRUGNAME	NVB-302
D01SXY	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1

D0E3DT	TTDDRUID	D0E3DT
D0E3DT	DRUGNAME	NVS antibody
D0E3DT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D06TUU	TTDDRUID	D06TUU
D06TUU	DRUGNAME	NVS therapy
D06TUU	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 1

D09QRI	TTDDRUID	D09QRI
D09QRI	DRUGNAME	NX-001
D09QRI	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 1

D0L1VP	TTDDRUID	D0L1VP
D0L1VP	DRUGNAME	NX-CP105
D0L1VP	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D09XOF	TTDDRUID	D09XOF
D09XOF	DRUGNAME	NY-ESO-1 vaccine
D09XOF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05NDY	TTDDRUID	D05NDY
D05NDY	DRUGNAME	OAP-189
D05NDY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0J6OH	TTDDRUID	D0J6OH
D0J6OH	DRUGNAME	Oblinutuzumab
D0J6OH	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D00SSZ	TTDDRUID	D00SSZ
D00SSZ	DRUGNAME	OBP-801
D00SSZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00YBZ	TTDDRUID	D00YBZ
D00YBZ	DRUGNAME	OC-10X
D00YBZ	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
D00YBZ	INDICATI	Proliferative diabetic retinopathy [ICD-11: 9B71.01] Phase 1

D0G1WC	TTDDRUID	D0G1WC
D0G1WC	DRUGNAME	OC-L vaccine
D0G1WC	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1

D0DC0S	TTDDRUID	D0DC0S
D0DC0S	DRUGNAME	Octaplas LG
D0DC0S	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0X9YB	TTDDRUID	D0X9YB
D0X9YB	DRUGNAME	OCV-105
D0X9YB	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0J6AU	TTDDRUID	D0J6AU
D0J6AU	DRUGNAME	Odanacatib
D0J6AU	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0U9NN	TTDDRUID	D0U9NN
D0U9NN	DRUGNAME	OG987SC
D0U9NN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0B2HF	TTDDRUID	D0B2HF
D0B2HF	DRUGNAME	OI287GT
D0B2HF	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1

D00KMQ	TTDDRUID	D00KMQ
D00KMQ	DRUGNAME	OI362GT
D00KMQ	INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1

D02GRR	TTDDRUID	D02GRR
D02GRR	DRUGNAME	Oleclumab
D02GRR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09POQ	TTDDRUID	D09POQ
D09POQ	DRUGNAME	OM-174
D09POQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0NR9E	TTDDRUID	D0NR9E
D0NR9E	DRUGNAME	Omeprazole-lansoprazole with buffer
D0NR9E	INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 1

D0J8AE	TTDDRUID	D0J8AE
D0J8AE	DRUGNAME	OMN-54
D0J8AE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00GPY	TTDDRUID	D00GPY
D00GPY	DRUGNAME	OMP-18R5
D00GPY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0GS9X	TTDDRUID	D0GS9X
D0GS9X	DRUGNAME	OMP-21M18
D0GS9X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04XCK	TTDDRUID	D04XCK
D04XCK	DRUGNAME	OMP-313M32
D04XCK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0B8ZJ	TTDDRUID	D0B8ZJ
D0B8ZJ	DRUGNAME	OMP-336B11
D0B8ZJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X3YY	TTDDRUID	D0X3YY
D0X3YY	DRUGNAME	OMP-52M51
D0X3YY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G3ZX	TTDDRUID	D0G3ZX
D0G3ZX	DRUGNAME	Omri-Hep-B
D0G3ZX	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D05WUQ	TTDDRUID	D05WUQ
D05WUQ	DRUGNAME	Omtriptolide
D05WUQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02ESL	TTDDRUID	D02ESL
D02ESL	DRUGNAME	ON-01210.Na
D02ESL	INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 1
D02ESL	INDICATI	Radiation syndrome [ICD-11: NF00] Phase 1

D07BQP	TTDDRUID	D07BQP
D07BQP	DRUGNAME	Oncolytic virus
D07BQP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0P8ED	TTDDRUID	D0P8ED
D0P8ED	DRUGNAME	Oncoquest-CLL
D0P8ED	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D0P8ED	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0O0VE	TTDDRUID	D0O0VE
D0O0VE	DRUGNAME	Oncoquest-L
D0O0VE	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D0O0VE	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D00NBW	TTDDRUID	D00NBW
D00NBW	DRUGNAME	ONCOS-102
D00NBW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
D00NBW	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D00NBW	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2

D08YLC	TTDDRUID	D08YLC
D08YLC	DRUGNAME	ONO-01210
D08YLC	INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 1

D02MRX	TTDDRUID	D02MRX
D02MRX	DRUGNAME	ONO-4059
D02MRX	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D02STG	TTDDRUID	D02STG
D02STG	DRUGNAME	ONO-4232
D02STG	INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 1

D03UHV	TTDDRUID	D03UHV
D03UHV	DRUGNAME	ONO-4578
D03UHV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0VH4T	TTDDRUID	D0VH4T
D0VH4T	DRUGNAME	ONO-7475
D0VH4T	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0MI8Z	TTDDRUID	D0MI8Z
D0MI8Z	DRUGNAME	ONS-3010
D0MI8Z	INDICATI	Crohn disease [ICD-11: DD70] Phase 1
D0MI8Z	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
D0MI8Z	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
D0MI8Z	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0MI8Z	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D04CYD	TTDDRUID	D04CYD
D04CYD	DRUGNAME	ONT-10
D04CYD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07OWC	TTDDRUID	D07OWC
D07OWC	DRUGNAME	OntecizumabAmatuximab
D07OWC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0I8DH	TTDDRUID	D0I8DH
D0I8DH	DRUGNAME	ONX-0801
D0I8DH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F9BT	TTDDRUID	D0F9BT
D0F9BT	DRUGNAME	ONX-0912
D0F9BT	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
D0F9BT	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0F9BT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0G7YS	TTDDRUID	D0G7YS
D0G7YS	DRUGNAME	ONYX-015
D0G7YS	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1

D0UN8L	TTDDRUID	D0UN8L
D0UN8L	DRUGNAME	OPB-111077
D0UN8L	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0UN8L	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D0UN8L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01FFC	TTDDRUID	D01FFC
D01FFC	DRUGNAME	OPB-51602
D01FFC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S6RY	TTDDRUID	D0S6RY
D0S6RY	DRUGNAME	OPC 108459
D0S6RY	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1

D0F4RX	TTDDRUID	D0F4RX
D0F4RX	DRUGNAME	OPC-14117
D0F4RX	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1

D0U9VV	TTDDRUID	D0U9VV
D0U9VV	DRUGNAME	Opdivonivolumab
D0U9VV	INDICATI	Central nervous system lymphoma [ICD-11: 2B33.5] Phase 2
D0U9VV	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
D0U9VV	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
D0U9VV	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
D0U9VV	INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3
D0U9VV	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
D0U9VV	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
D0U9VV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D0U9VV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D0U9VV	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D09ODP	TTDDRUID	D09ODP
D09ODP	DRUGNAME	Ophthalmological agents
D09ODP	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 1

D0O8SB	TTDDRUID	D0O8SB
D0O8SB	DRUGNAME	OPK-0018
D0O8SB	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0U7PM	TTDDRUID	D0U7PM
D0U7PM	DRUGNAME	OPL-CCL2-LPM
D0U7PM	INDICATI	Arthritis [ICD-11: FA20] Phase 1

D0OK5R	TTDDRUID	D0OK5R
D0OK5R	DRUGNAME	OP-R003
D0OK5R	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0Y6KY	TTDDRUID	D0Y6KY
D0Y6KY	DRUGNAME	Optiquel
D0Y6KY	INDICATI	Uveitis [ICD-11: 9A96.Z] Phase 1

D06WAM	TTDDRUID	D06WAM
D06WAM	DRUGNAME	Oradoxel
D06WAM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05KME	TTDDRUID	D05KME
D05KME	DRUGNAME	ORADUR-ADHD
D05KME	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1

D0Y2ZN	TTDDRUID	D0Y2ZN
D0Y2ZN	DRUGNAME	Oral azacitidine
D0Y2ZN	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D05BNS	TTDDRUID	D05BNS
D05BNS	DRUGNAME	Oral-Vimo-001
D05BNS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P5AA	TTDDRUID	D0P5AA
D0P5AA	DRUGNAME	Oratecan
D0P5AA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y3VT	TTDDRUID	D0Y3VT
D0Y3VT	DRUGNAME	ORB-101
D0Y3VT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04ZWQ	TTDDRUID	D04ZWQ
D04ZWQ	DRUGNAME	Org-25435
D04ZWQ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0M3TD	TTDDRUID	D0M3TD
D0M3TD	DRUGNAME	Org-43902
D0M3TD	INDICATI	Infertility [ICD-11: GB04] Phase 1

D0HE7C	TTDDRUID	D0HE7C
D0HE7C	DRUGNAME	ORIC-101
D0HE7C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N8RV	TTDDRUID	D0N8RV
D0N8RV	DRUGNAME	OSI-930
D0N8RV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05MIQ	TTDDRUID	D05MIQ
D05MIQ	DRUGNAME	O-SPC/rBRU vaccine
D05MIQ	INDICATI	Shigella infection [ICD-11: 1A02] Phase 1

D0N2YY	TTDDRUID	D0N2YY
D0N2YY	DRUGNAME	OSPC-rDT vaccine
D0N2YY	INDICATI	Shigella infection [ICD-11: 1A02] Phase 1

D08FIX	TTDDRUID	D08FIX
D08FIX	DRUGNAME	OTSSP167
D08FIX	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D08FIX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D08FIX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D08FIX	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D08FIX	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D08FIX	INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1

D02YNI	TTDDRUID	D02YNI
D02YNI	DRUGNAME	OTX-015
D02YNI	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D02YNI	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D02YNI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J9GR	TTDDRUID	D0J9GR
D0J9GR	DRUGNAME	OX-27
D0J9GR	INDICATI	Cancer related pain [ICD-11: MG30] Phase 1

D03RJZ	TTDDRUID	D03RJZ
D03RJZ	DRUGNAME	Oxeglitazar
D03RJZ	INDICATI	Gout [ICD-11: FA25] Phase 1

D0AE5K	TTDDRUID	D0AE5K
D0AE5K	DRUGNAME	Oxyntomodulin
D0AE5K	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0FP9N	TTDDRUID	D0FP9N
D0FP9N	DRUGNAME	P11187
D0FP9N	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0O7KV	TTDDRUID	D0O7KV
D0O7KV	DRUGNAME	P1201-07
D0O7KV	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1

D0DX4J	TTDDRUID	D0DX4J
D0DX4J	DRUGNAME	P1446A-05
D0DX4J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02USG	TTDDRUID	D02USG
D02USG	DRUGNAME	P-2745
D02USG	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1

D0E2AJ	TTDDRUID	D0E2AJ
D0E2AJ	DRUGNAME	P-27A
D0E2AJ	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D00ZMU	TTDDRUID	D00ZMU
D00ZMU	DRUGNAME	P28 cell penetrating peptide
D00ZMU	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1

D06ZAP	TTDDRUID	D06ZAP
D06ZAP	DRUGNAME	P28 peptide
D06ZAP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M1EG	TTDDRUID	D0M1EG
D0M1EG	DRUGNAME	P2X4 inhibitora
D0M1EG	INDICATI	Endometriosis [ICD-11: GA10] Phase 1

D04SZA	TTDDRUID	D04SZA
D04SZA	DRUGNAME	P-3914
D04SZA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D0VH6V	TTDDRUID	D0VH6V
D0VH6V	DRUGNAME	P53 cell pentrating peptide
D0VH6V	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1

D0R8ID	TTDDRUID	D0R8ID
D0R8ID	DRUGNAME	P-7170
D0R8ID	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M4HL	TTDDRUID	D0M4HL
D0M4HL	DRUGNAME	P-7435
D0M4HL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D05CBJ	TTDDRUID	D05CBJ
D05CBJ	DRUGNAME	PA-799
D05CBJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01YIF	TTDDRUID	D01YIF
D01YIF	DRUGNAME	PAC1
D01YIF	INDICATI	Anaplastic astrocytoma [ICD-11: 2A00.0] Phase 1
D01YIF	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D00EGU	TTDDRUID	D00EGU
D00EGU	DRUGNAME	PACAP38
D00EGU	INDICATI	Nerve injury [ICD-11: ND56.4] Phase 1

D06JCO	TTDDRUID	D06JCO
D06JCO	DRUGNAME	Palomid-529 inhaled
D06JCO	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0F7LI	TTDDRUID	D0F7LI
D0F7LI	DRUGNAME	PAN-301-1
D0F7LI	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0U6XE	TTDDRUID	D0U6XE
D0U6XE	DRUGNAME	PAN-90806
D0U6XE	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 1
D0U6XE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01PYH	TTDDRUID	D01PYH
D01PYH	DRUGNAME	PANFLUVAC
D01PYH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0D6BT	TTDDRUID	D0D6BT
D0D6BT	DRUGNAME	Parathyroid hormone analog
D0D6BT	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0IA1G	TTDDRUID	D0IA1G
D0IA1G	DRUGNAME	PAT-001
D0IA1G	INDICATI	Autosomal recessive congenital ichthyosis [ICD-11: EC20.02] Phase 1
D0IA1G	INDICATI	Non-syndromic ichthyosis [ICD-11: EC20.0Y] Phase 2

D02BAA	TTDDRUID	D02BAA
D02BAA	DRUGNAME	Patient-derived CD19- and CD22 specific CAR
D02BAA	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D02BAA	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0N2QW	TTDDRUID	D0N2QW
D0N2QW	DRUGNAME	Patritumab
D0N2QW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0G9JQ	TTDDRUID	D0G9JQ
D0G9JQ	DRUGNAME	PB1046
D0G9JQ	INDICATI	Cardiomyopathy [ICD-11: BC43] Phase 1
D0G9JQ	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
D0G9JQ	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
D0G9JQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
D0G9JQ	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2

D00EXZ	TTDDRUID	D00EXZ
D00EXZ	DRUGNAME	PB-357
D00EXZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K2KD	TTDDRUID	D0K2KD
D0K2KD	DRUGNAME	PB-6
D0K2KD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D03LFO	TTDDRUID	D03LFO
D03LFO	DRUGNAME	P-BCMA-101
D03LFO	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D09JKN	TTDDRUID	D09JKN
D09JKN	DRUGNAME	P-BCMA-101
D09JKN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0NK6K	TTDDRUID	D0NK6K
D0NK6K	DRUGNAME	P-BCMA-101 CAR-T cells
D0NK6K	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0HF2D	TTDDRUID	D0HF2D
D0HF2D	DRUGNAME	PBF-1129
D0HF2D	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D07YWM	TTDDRUID	D07YWM
D07YWM	DRUGNAME	Pbi-shRNA STMN1 LP
D07YWM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05UJF	TTDDRUID	D05UJF
D05UJF	DRUGNAME	PBSVax
D05UJF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0A8NW	TTDDRUID	D0A8NW
D0A8NW	DRUGNAME	PC-1005
D0A8NW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0L2YF	TTDDRUID	D0L2YF
D0L2YF	DRUGNAME	Pc4 (topical formulation
D0L2YF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D09WSR	TTDDRUID	D09WSR
D09WSR	DRUGNAME	PCA062
D09WSR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D09WSR	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1
D09WSR	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D09WSR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03HUX	TTDDRUID	D03HUX
D03HUX	DRUGNAME	PCM-075
D03HUX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D03HUX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D03HUX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03NHS	TTDDRUID	D03NHS
D03NHS	DRUGNAME	PCO371
D03NHS	INDICATI	Hypoparathyroidism [ICD-11: 5A50] Phase 1

D05EBY	TTDDRUID	D05EBY
D05EBY	DRUGNAME	PCSK9 Adnectin
D05EBY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D09AIH	TTDDRUID	D09AIH
D09AIH	DRUGNAME	PCUR-101
D09AIH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0TJ7S	TTDDRUID	D0TJ7S
D0TJ7S	DRUGNAME	PDC-41
D0TJ7S	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 1

D0ZJ0R	TTDDRUID	D0ZJ0R
D0ZJ0R	DRUGNAME	PDC-APB
D0ZJ0R	INDICATI	Contact dermatitis [ICD-11: EK0Z] Phase 1

D0IW6R	TTDDRUID	D0IW6R
D0IW6R	DRUGNAME	PD-L1 mAb + LY
D0IW6R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01PGJ	TTDDRUID	D01PGJ
D01PGJ	DRUGNAME	PDM-08
D01PGJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N8IG	TTDDRUID	D0N8IG
D0N8IG	DRUGNAME	PdpSC18
D0N8IG	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1

D05BAJ	TTDDRUID	D05BAJ
D05BAJ	DRUGNAME	PDR001
D05BAJ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D05BAJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D05BAJ	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
D05BAJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H8ZI	TTDDRUID	D0H8ZI
D0H8ZI	DRUGNAME	PDS-0101
D0H8ZI	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative
D0H8ZI	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1

D0XL1T	TTDDRUID	D0XL1T
D0XL1T	DRUGNAME	PDT with Photofrin
D0XL1T	INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
D0XL1T	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D03JNS	TTDDRUID	D03JNS
D03JNS	DRUGNAME	Peanut allergy vaccine
D03JNS	INDICATI	Peanut hypersensitivity [ICD-11: 4A83] Phase 1

D0PF8B	TTDDRUID	D0PF8B
D0PF8B	DRUGNAME	PEDF gene therapy
D0PF8B	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D00VJC	TTDDRUID	D00VJC
D00VJC	DRUGNAME	Peg. Adrenomedullin
D00VJC	INDICATI	Lung disease [ICD-11: CA60-CA8Z] Phase 1

D0S3BF	TTDDRUID	D0S3BF
D0S3BF	DRUGNAME	Pegadricase
D0S3BF	INDICATI	Gout [ICD-11: FA25] Phase 1

D0KB0Y	TTDDRUID	D0KB0Y
D0KB0Y	DRUGNAME	Pegargiminase
D0KB0Y	INDICATI	Argininosuccinate synthase deficiency [ICD-11: 5C50.A3] Phase 1
D0KB0Y	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1/2
D0KB0Y	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D0KB0Y	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0KB0Y	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2/3
D0KB0Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C2HI	TTDDRUID	D0C2HI
D0C2HI	DRUGNAME	PegCNTF
D0C2HI	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0GM6E	TTDDRUID	D0GM6E
D0GM6E	DRUGNAME	Pegdinetanib
D0GM6E	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0S0NX	TTDDRUID	D0S0NX
D0S0NX	DRUGNAME	Peginterferon beta
D0S0NX	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0D1XW	TTDDRUID	D0D1XW
D0D1XW	DRUGNAME	PEG-Interferon lambda (IL-29)
D0D1XW	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1

D02NJE	TTDDRUID	D02NJE
D02NJE	DRUGNAME	PEK fusion protein vaccine
D02NJE	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1

D0PR6H	TTDDRUID	D0PR6H
D0PR6H	DRUGNAME	PENCLOMEDINE
D0PR6H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G7LC	TTDDRUID	D0G7LC
D0G7LC	DRUGNAME	PENNVAX-6
D0G7LC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0SF5Q	TTDDRUID	D0SF5Q
D0SF5Q	DRUGNAME	Pennvax-B
D0SF5Q	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0X0OF	TTDDRUID	D0X0OF
D0X0OF	DRUGNAME	Pennvax-G
D0X0OF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0J6FF	TTDDRUID	D0J6FF
D0J6FF	DRUGNAME	PENNVAX-GP/MVA-CMDR HIV vaccine regime
D0J6FF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0V8UJ	TTDDRUID	D0V8UJ
D0V8UJ	DRUGNAME	PEP-6409
D0V8UJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0R1VU	TTDDRUID	D0R1VU
D0R1VU	DRUGNAME	Perifosine
D0R1VU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04EZI	TTDDRUID	D04EZI
D04EZI	DRUGNAME	Peru-15 pCTB
D04EZI	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 1

D0G9NN	TTDDRUID	D0G9NN
D0G9NN	DRUGNAME	PEV-6A
D0G9NN	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D07GLB	TTDDRUID	D07GLB
D07GLB	DRUGNAME	PEV-7
D07GLB	INDICATI	Candidiasis [ICD-11: 1F23] Phase 1

D0ZI5A	TTDDRUID	D0ZI5A
D0ZI5A	DRUGNAME	PF-00337210
D0ZI5A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04JZH	TTDDRUID	D04JZH
D04JZH	DRUGNAME	PF-01247324
D04JZH	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0T4YH	TTDDRUID	D0T4YH
D0T4YH	DRUGNAME	PF-03716539
D0T4YH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0E5WX	TTDDRUID	D0E5WX
D0E5WX	DRUGNAME	PF-04518600
D0E5WX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08FYH	TTDDRUID	D08FYH
D08FYH	DRUGNAME	PF-04776548
D08FYH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D04OMR	TTDDRUID	D04OMR
D04OMR	DRUGNAME	PF-04840082
D04OMR	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D00IKI	TTDDRUID	D00IKI
D00IKI	DRUGNAME	PF-04895162
D00IKI	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D02YKI	TTDDRUID	D02YKI
D02YKI	DRUGNAME	PF-04995274
D02YKI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D01ZLR	TTDDRUID	D01ZLR
D01ZLR	DRUGNAME	PF-05082566
D01ZLR	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D01ZLR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09NAW	TTDDRUID	D09NAW
D09NAW	DRUGNAME	PF-05105679
D09NAW	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0RE0K	TTDDRUID	D0RE0K
D0RE0K	DRUGNAME	PF-05161704
D0RE0K	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1

D07GHV	TTDDRUID	D07GHV
D07GHV	DRUGNAME	PF-05180999
D07GHV	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0SD3E	TTDDRUID	D0SD3E
D0SD3E	DRUGNAME	PF-05186462
D0SD3E	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01HLO	TTDDRUID	D01HLO
D01HLO	DRUGNAME	PF-05190457
D01HLO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0OS3C	TTDDRUID	D0OS3C
D0OS3C	DRUGNAME	PF-05230901
D0OS3C	INDICATI	Cachexia [ICD-11: MG20] Phase 1

D0Y0FZ	TTDDRUID	D0Y0FZ
D0Y0FZ	DRUGNAME	PF-05230905
D0Y0FZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0JS0W	TTDDRUID	D0JS0W
D0JS0W	DRUGNAME	PF-05230907
D0JS0W	INDICATI	Nontraumatic intracerebral hemorrhage [ICD-11: 8B00.4] Phase 1

D0WK6V	TTDDRUID	D0WK6V
D0WK6V	DRUGNAME	PF-05231023
D0WK6V	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0BT0Z	TTDDRUID	D0BT0Z
D0BT0Z	DRUGNAME	PF-05241328
D0BT0Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D03AGK	TTDDRUID	D03AGK
D03AGK	DRUGNAME	PF-05251749
D03AGK	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0I2HV	TTDDRUID	D0I2HV
D0I2HV	DRUGNAME	PF-05402536
D0I2HV	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 1

D0DK5X	TTDDRUID	D0DK5X
D0DK5X	DRUGNAME	PF-06263276
D0DK5X	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D03JZC	TTDDRUID	D03JZC
D03JZC	DRUGNAME	PF-06263507
D03JZC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0B4KU	TTDDRUID	D0B4KU
D0B4KU	DRUGNAME	PF-06273340
D0B4KU	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D09DXX	TTDDRUID	D09DXX
D09DXX	DRUGNAME	PF-06282999
D09DXX	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 1

D0K4IS	TTDDRUID	D0K4IS
D0K4IS	DRUGNAME	PF-06293620
D0K4IS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0K9IF	TTDDRUID	D0K9IF
D0K9IF	DRUGNAME	PF-06305591
D0K9IF	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D0Q7IX	TTDDRUID	D0Q7IX
D0Q7IX	DRUGNAME	PF-06342674
D0Q7IX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
D0Q7IX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0T7MJ	TTDDRUID	D0T7MJ
D0T7MJ	DRUGNAME	PF-06412562
D0T7MJ	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D05BYJ	TTDDRUID	D05BYJ
D05BYJ	DRUGNAME	PF-06413367
D05BYJ	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0UL2I	TTDDRUID	D0UL2I
D0UL2I	DRUGNAME	PF-06427878
D0UL2I	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
D0UL2I	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D0K2HU	TTDDRUID	D0K2HU
D0K2HU	DRUGNAME	PF-06444752
D0K2HU	INDICATI	Asthma [ICD-11: CA23] Phase 1

D03IQD	TTDDRUID	D03IQD
D03IQD	DRUGNAME	PF-06480605
D03IQD	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D0QU8I	TTDDRUID	D0QU8I
D0QU8I	DRUGNAME	PF-06482077
D0QU8I	INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 1

D0AD3V	TTDDRUID	D0AD3V
D0AD3V	DRUGNAME	PF-06647020
D0AD3V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0WB8J	TTDDRUID	D0WB8J
D0WB8J	DRUGNAME	PF-06647020 
D0WB8J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W7NL	TTDDRUID	D0W7NL
D0W7NL	DRUGNAME	PF-06647263
D0W7NL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TQ4Y	TTDDRUID	D0TQ4Y
D0TQ4Y	DRUGNAME	PF-06648671
D0TQ4Y	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0K7ZH	TTDDRUID	D0K7ZH
D0K7ZH	DRUGNAME	PF-06649751
D0K7ZH	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D00OVE	TTDDRUID	D00OVE
D00OVE	DRUGNAME	PF-06650808
D00OVE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07NUL	TTDDRUID	D07NUL
D07NUL	DRUGNAME	PF-06650833
D07NUL	INDICATI	Lupus [ICD-11: 4A40] Phase 1

D0G4RI	TTDDRUID	D0G4RI
D0G4RI	DRUGNAME	PF-06664178
D0G4RI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0T7BD	TTDDRUID	D0T7BD
D0T7BD	DRUGNAME	PF-06669571
D0T7BD	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D0Y0HC	TTDDRUID	D0Y0HC
D0Y0HC	DRUGNAME	PF-06671008
D0Y0HC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G5HI	TTDDRUID	D0G5HI
D0G5HI	DRUGNAME	PF-06678552
D0G5HI	INDICATI	Hyperkalemia [ICD-11: 5C76] Phase 1

D0JB9C	TTDDRUID	D0JB9C
D0JB9C	DRUGNAME	PF-06688992
D0JB9C	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0JB9C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09FYW	TTDDRUID	D09FYW
D09FYW	DRUGNAME	PF-06743649
D09FYW	INDICATI	Gout [ICD-11: FA25] Phase 1

D0LC5L	TTDDRUID	D0LC5L
D0LC5L	DRUGNAME	PF-06747143
D0LC5L	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0R0LB	TTDDRUID	D0R0LB
D0R0LB	DRUGNAME	PF-06747775
D0R0LB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y5NA	TTDDRUID	D0Y5NA
D0Y5NA	DRUGNAME	PF-06751979
D0Y5NA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0XO7I	TTDDRUID	D0XO7I
D0XO7I	DRUGNAME	PF-06753512
D0XO7I	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D06HUS	TTDDRUID	D06HUS
D06HUS	DRUGNAME	PF-06755347
D06HUS	INDICATI	Chronic inflammatory demyelinating polyneuropathy [ICD-11: 8C01.3] Phase 1

D01UKK	TTDDRUID	D01UKK
D01UKK	DRUGNAME	PF-06760805
D01UKK	INDICATI	Streptococcal B infection [ICD-11: 1G40] Phase 1

D0CN8U	TTDDRUID	D0CN8U
D0CN8U	DRUGNAME	PF-06763809
D0CN8U	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1

D05BPO	TTDDRUID	D05BPO
D05BPO	DRUGNAME	PF-06801591
D05BPO	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D05BPO	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D05BPO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09ATR	TTDDRUID	D09ATR
D09ATR	DRUGNAME	PF-06804103
D09ATR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W6YR	TTDDRUID	D0W6YR
D0W6YR	DRUGNAME	PF-06817024
D0W6YR	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1

D08RDD	TTDDRUID	D08RDD
D08RDD	DRUGNAME	PF-06823859
D08RDD	INDICATI	Lupus [ICD-11: 4A40] Phase 1
D08RDD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0M3XE	TTDDRUID	D0M3XE
D0M3XE	DRUGNAME	PF-06826647
D0M3XE	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1

D0J1HB	TTDDRUID	D0J1HB
D0J1HB	DRUGNAME	PF-06840003
D0J1HB	INDICATI	Glioma [ICD-11: 2A00.0] Phase 1

D01JSI	TTDDRUID	D01JSI
D01JSI	DRUGNAME	PF-06863135
D01JSI	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0V2LL	TTDDRUID	D0V2LL
D0V2LL	DRUGNAME	PF-06873600
D0V2LL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0B7MO	TTDDRUID	D0B7MO
D0B7MO	DRUGNAME	PF-06886992
D0B7MO	INDICATI	Serogroups meningococcal infection [ICD-11: 1C1C.0] Phase 1

D0XS7I	TTDDRUID	D0XS7I
D0XS7I	DRUGNAME	PF-06939926
D0XS7I	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D0K2HA	TTDDRUID	D0K2HA
D0K2HA	DRUGNAME	PF-2413873
D0K2HA	INDICATI	Endometriosis [ICD-11: GA10] Phase 1

D0T2RU	TTDDRUID	D0T2RU
D0T2RU	DRUGNAME	PF-277343
D0T2RU	INDICATI	Alopecia [ICD-11: ED70] Phase 1

D0P9KD	TTDDRUID	D0P9KD
D0P9KD	DRUGNAME	PF-3732010
D0P9KD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08MHM	TTDDRUID	D08MHM
D08MHM	DRUGNAME	PF-3758309
D08MHM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02XGC	TTDDRUID	D02XGC
D02XGC	DRUGNAME	PF-3864086
D02XGC	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01LCC	TTDDRUID	D01LCC
D01LCC	DRUGNAME	PF-4217903
D01LCC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08XZQ	TTDDRUID	D08XZQ
D08XZQ	DRUGNAME	PF-4287881
D08XZQ	INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 1

D0S5EF	TTDDRUID	D0S5EF
D0S5EF	DRUGNAME	PF-4418948
D0S5EF	INDICATI	Endometriosis [ICD-11: GA10] Phase 1

D04JAT	TTDDRUID	D04JAT
D04JAT	DRUGNAME	PF-4427429
D04JAT	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D00SVP	TTDDRUID	D00SVP
D00SVP	DRUGNAME	PF-4455242
D00SVP	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1

D00BZZ	TTDDRUID	D00BZZ
D00BZZ	DRUGNAME	PF-4603629
D00BZZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D00XLE	TTDDRUID	D00XLE
D00XLE	DRUGNAME	PF-4764793
D00XLE	INDICATI	Respiratory disease [ICD-11: CB40] Phase 1

D0T1FC	TTDDRUID	D0T1FC
D0T1FC	DRUGNAME	PF-4878691
D0T1FC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0Q4OV	TTDDRUID	D0Q4OV
D0Q4OV	DRUGNAME	PF530
D0Q4OV	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D01SJT	TTDDRUID	D01SJT
D01SJT	DRUGNAME	PF-562271
D01SJT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00SBU	TTDDRUID	D00SBU
D00SBU	DRUGNAME	PF614
D00SBU	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D0W7LO	TTDDRUID	D0W7LO
D0W7LO	DRUGNAME	PF9601N
D0W7LO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0H9OT	TTDDRUID	D0H9OT
D0H9OT	DRUGNAME	PfAMA-1
D0H9OT	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D0H3ID	TTDDRUID	D0H3ID
D0H3ID	DRUGNAME	Pfizer 10
D0H3ID	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1

D0WY3J	TTDDRUID	D0WY3J
D0WY3J	DRUGNAME	Pfizer 4
D0WY3J	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1

D0W0VR	TTDDRUID	D0W0VR
D0W0VR	DRUGNAME	PFK-158
D0W0VR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0TY1Y	TTDDRUID	D0TY1Y
D0TY1Y	DRUGNAME	PfSPZ-Cvac
D0TY1Y	INDICATI	Plasmodium falciparum malaria [ICD-11: 1F40] Phase 1

D0N7JS	TTDDRUID	D0N7JS
D0N7JS	DRUGNAME	PG11047
D0N7JS	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D04KNL	TTDDRUID	D04KNL
D04KNL	DRUGNAME	PG-545
D04KNL	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 1

D0P1CV	TTDDRUID	D0P1CV
D0P1CV	DRUGNAME	PHA-793887
D0P1CV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0EK1C	TTDDRUID	D0EK1C
D0EK1C	DRUGNAME	PHE-377
D0EK1C	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D07OBJ	TTDDRUID	D07OBJ
D07OBJ	DRUGNAME	PHX-1766
D07OBJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D08AJF	TTDDRUID	D08AJF
D08AJF	DRUGNAME	PI-0824
D08AJF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0J2YR	TTDDRUID	D0J2YR
D0J2YR	DRUGNAME	PI-166
D0J2YR	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1

D01QNR	TTDDRUID	D01QNR
D01QNR	DRUGNAME	PIM447
D01QNR	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1

D0PT6W	TTDDRUID	D0PT6W
D0PT6W	DRUGNAME	PIN-2
D0PT6W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R8PE	TTDDRUID	D0R8PE
D0R8PE	DRUGNAME	Pivagabine
D0R8PE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
D0R8PE	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1

D0P9OW	TTDDRUID	D0P9OW
D0P9OW	DRUGNAME	PL-225B
D0P9OW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02NHY	TTDDRUID	D02NHY
D02NHY	DRUGNAME	PLADD
D02NHY	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D04JMI	TTDDRUID	D04JMI
D04JMI	DRUGNAME	Plasma derived human butyrylcholinesterase
D04JMI	INDICATI	Neurotoxicity [ICD-11: NE61] Phase 1

D06NQA	TTDDRUID	D06NQA
D06NQA	DRUGNAME	Plasmid IL-12 immunotherapy
D06NQA	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1

D07GHA	TTDDRUID	D07GHA
D07GHA	DRUGNAME	PLX2853
D07GHA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03JLR	TTDDRUID	D03JLR
D03JLR	DRUGNAME	PLX51107
D03JLR	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D03JLR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W1YV	TTDDRUID	D0W1YV
D0W1YV	DRUGNAME	PLX-5622
D0W1YV	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0PL8D	TTDDRUID	D0PL8D
D0PL8D	DRUGNAME	PLX73086
D0PL8D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07PSL	TTDDRUID	D07PSL
D07PSL	DRUGNAME	PLX7486
D07PSL	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D07PSL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03MDY	TTDDRUID	D03MDY
D03MDY	DRUGNAME	PLX9486
D03MDY	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
D03MDY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W5YY	TTDDRUID	D0W5YY
D0W5YY	DRUGNAME	PM-060184
D0W5YY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04DUH	TTDDRUID	D04DUH
D04DUH	DRUGNAME	PMI-005
D04DUH	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1

D04OXG	TTDDRUID	D04OXG
D04OXG	DRUGNAME	PMZ-2123
D04OXG	INDICATI	Cerebral oedema in diabetic ketoacidosis [ICD-11: 8D60.1] Phase 1

D03IRG	TTDDRUID	D03IRG
D03IRG	DRUGNAME	PNK-007
D03IRG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D03IRG	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D01OGV	TTDDRUID	D01OGV
D01OGV	DRUGNAME	POL-6014
D01OGV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
D01OGV	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1

D0W0XS	TTDDRUID	D0W0XS
D0W0XS	DRUGNAME	PolyPEPI1018
D0W0XS	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D05VAE	TTDDRUID	D05VAE
D05VAE	DRUGNAME	Posiphen R-phenserine
D05VAE	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D01KKF	TTDDRUID	D01KKF
D01KKF	DRUGNAME	PP2A stimulator
D01KKF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0E2ZA	TTDDRUID	D0E2ZA
D0E2ZA	DRUGNAME	PPC-5650
D0E2ZA	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0KR1N	TTDDRUID	D0KR1N
D0KR1N	DRUGNAME	PPI-2458
D0KR1N	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D02RVC	TTDDRUID	D02RVC
D02RVC	DRUGNAME	PPI-383
D02RVC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0C0QT	TTDDRUID	D0C0QT
D0C0QT	DRUGNAME	PPI-461
D0C0QT	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0TU7B	TTDDRUID	D0TU7B
D0TU7B	DRUGNAME	PQR309
D0TU7B	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0DP0J	TTDDRUID	D0DP0J
D0DP0J	DRUGNAME	PR-924
D0DP0J	INDICATI	T lymphoblastic leukaemia [ICD-11: 2B33.4] Phase 1

D0PY0W	TTDDRUID	D0PY0W
D0PY0W	DRUGNAME	PRAME antigen-specific cancer
D0PY0W	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D00AHT	TTDDRUID	D00AHT
D00AHT	DRUGNAME	PRAME antigen-specific cancer immunotherapeutic
D00AHT	INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Phase 1
D00AHT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0R0JN	TTDDRUID	D0R0JN
D0R0JN	DRUGNAME	PRAX-330
D0R0JN	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0N9ZT	TTDDRUID	D0N9ZT
D0N9ZT	DRUGNAME	Prednisone microencapsulated
D0N9ZT	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
D0N9ZT	INDICATI	Eczema [ICD-11: EA80-EA89] Phase 1

D0NX8G	TTDDRUID	D0NX8G
D0NX8G	DRUGNAME	Pre-pandemic Avian influenza vaccine
D0NX8G	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1

D0A7ZX	TTDDRUID	D0A7ZX
D0A7ZX	DRUGNAME	Pretargeting TF2
D0A7ZX	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0H9FR	TTDDRUID	D0H9FR
D0H9FR	DRUGNAME	PRN1371
D0H9FR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09NVR	TTDDRUID	D09NVR
D09NVR	DRUGNAME	PRN2246
D09NVR	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0W8PU	TTDDRUID	D0W8PU
D0W8PU	DRUGNAME	Prohibitin targeting peptide-1
D0W8PU	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D01NZT	TTDDRUID	D01NZT
D01NZT	DRUGNAME	Prohibitin-TP-01
D01NZT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0DO4S	TTDDRUID	D0DO4S
D0DO4S	DRUGNAME	Prolactin receptor antagonist
D0DO4S	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0J1OG	TTDDRUID	D0J1OG
D0J1OG	DRUGNAME	Prolanta
D0J1OG	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D0J1OG	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0J1OG	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1

D0BR1S	TTDDRUID	D0BR1S
D0BR1S	DRUGNAME	ProscaVax
D0BR1S	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0R5QY	TTDDRUID	D0R5QY
D0R5QY	DRUGNAME	Protein subunit vaccine (Mycobacterium tuberculosis, intranasal)
D0R5QY	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1

D04RFT	TTDDRUID	D04RFT
D04RFT	DRUGNAME	Protein subunit vaccine, Novartis
D04RFT	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 1

D06RBN	TTDDRUID	D06RBN
D06RBN	DRUGNAME	Protein vaccines
D06RBN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06FGJ	TTDDRUID	D06FGJ
D06FGJ	DRUGNAME	Protexia
D06FGJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0AC8L	TTDDRUID	D0AC8L
D0AC8L	DRUGNAME	Proxinium
D0AC8L	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D06MNC	TTDDRUID	D06MNC
D06MNC	DRUGNAME	PRS-050
D06MNC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00LRP	TTDDRUID	D00LRP
D00LRP	DRUGNAME	PRS-080
D00LRP	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D0WZ9R	TTDDRUID	D0WZ9R
D0WZ9R	DRUGNAME	PRS-343
D0WZ9R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R9IU	TTDDRUID	D0R9IU
D0R9IU	DRUGNAME	PRT-062607
D0R9IU	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D0A1PS	TTDDRUID	D0A1PS
D0A1PS	DRUGNAME	PRT-105
D0A1PS	INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 1

D0C0SZ	TTDDRUID	D0C0SZ
D0C0SZ	DRUGNAME	PRT6207
D0C0SZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L0DA	TTDDRUID	D0L0DA
D0L0DA	DRUGNAME	PRX003
D0L0DA	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D03ZPX	TTDDRUID	D03ZPX
D03ZPX	DRUGNAME	PRX-07034
D03ZPX	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0JA7V	TTDDRUID	D0JA7V
D0JA7V	DRUGNAME	PRX-105
D0JA7V	INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 1

D04XWX	TTDDRUID	D04XWX
D04XWX	DRUGNAME	PS-178990
D04XWX	INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 1

D09QHP	TTDDRUID	D09QHP
D09QHP	DRUGNAME	PS-873266
D09QHP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D0ZA0W	TTDDRUID	D0ZA0W
D0ZA0W	DRUGNAME	PSA/IL-2/GM-CSF vaccine
D0ZA0W	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0Z0AM	TTDDRUID	D0Z0AM
D0Z0AM	DRUGNAME	PSI-697
D0Z0AM	INDICATI	Atherosclerosis [ICD-11: BD40] Phase 1
D0Z0AM	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D06QOA	TTDDRUID	D06QOA
D06QOA	DRUGNAME	PSI-938
D06QOA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D09QSC	TTDDRUID	D09QSC
D09QSC	DRUGNAME	PSMA protein vaccine
D09QSC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D08JYV	TTDDRUID	D08JYV
D08JYV	DRUGNAME	PSMA subunit vaccine
D08JYV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0BY6W	TTDDRUID	D0BY6W
D0BY6W	DRUGNAME	PSMA VRP therapeutic vaccine
D0BY6W	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0O0JB	TTDDRUID	D0O0JB
D0O0JB	DRUGNAME	PSMA-targeted tubulysin B conjugates
D0O0JB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D07KHR	TTDDRUID	D07KHR
D07KHR	DRUGNAME	PSMA-VRP
D07KHR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D07ZVO	TTDDRUID	D07ZVO
D07ZVO	DRUGNAME	PT1.2
D07ZVO	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1

D06KXS	TTDDRUID	D06KXS
D06KXS	DRUGNAME	PT-112
D06KXS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0YJ5F	TTDDRUID	D0YJ5F
D0YJ5F	DRUGNAME	PT-112phosphaplatin
D0YJ5F	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D08KDU	TTDDRUID	D08KDU
D08KDU	DRUGNAME	PT-201
D08KDU	INDICATI	Urinary dysfunction [ICD-11: GC2Z] Phase 1

D0NU8J	TTDDRUID	D0NU8J
D0NU8J	DRUGNAME	PT2977
D0NU8J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D0NU8J	INDICATI	Von hippel-lindau disease [ICD-11: 5A75] Phase 2

D07EKK	TTDDRUID	D07EKK
D07EKK	DRUGNAME	PTC596
D07EKK	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D07EKK	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D07EKK	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1

D0FU1J	TTDDRUID	D0FU1J
D0FU1J	DRUGNAME	PTG-100
D0FU1J	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D0H2DS	TTDDRUID	D0H2DS
D0H2DS	DRUGNAME	PTH(7-34) liposomal cream
D0H2DS	INDICATI	Alopecia [ICD-11: ED70] Phase 1

D0X2HJ	TTDDRUID	D0X2HJ
D0X2HJ	DRUGNAME	PTI-125
D0X2HJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0Y7SN	TTDDRUID	D0Y7SN
D0Y7SN	DRUGNAME	PTI-188
D0Y7SN	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0YN4Y	TTDDRUID	D0YN4Y
D0YN4Y	DRUGNAME	PTI-202
D0YN4Y	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0P8YJ	TTDDRUID	D0P8YJ
D0P8YJ	DRUGNAME	PTI-80
D0P8YJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0NX0S	TTDDRUID	D0NX0S
D0NX0S	DRUGNAME	PTX-100
D0NX0S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02PGP	TTDDRUID	D02PGP
D02PGP	DRUGNAME	PU3
D02PGP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01FYA	TTDDRUID	D01FYA
D01FYA	DRUGNAME	PU-H71
D01FYA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D01FYA	INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1
D01FYA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O9FH	TTDDRUID	D0O9FH
D0O9FH	DRUGNAME	PUMVC3-hIGFBP-2
D0O9FH	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D09ZRB	TTDDRUID	D09ZRB
D09ZRB	DRUGNAME	PUR0200
D09ZRB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D0H5FW	TTDDRUID	D0H5FW
D0H5FW	DRUGNAME	PUR-118
D0H5FW	INDICATI	Respiratory disease [ICD-11: CB40] Phase 1

D08EEM	TTDDRUID	D08EEM
D08EEM	DRUGNAME	PV-701
D08EEM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y0FE	TTDDRUID	D0Y0FE
D0Y0FE	DRUGNAME	PWT-33597
D0Y0FE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06ZVO	TTDDRUID	D06ZVO
D06ZVO	DRUGNAME	PX-478
D06ZVO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0JZ4C	TTDDRUID	D0JZ4C
D0JZ4C	DRUGNAME	Px563L
D0JZ4C	INDICATI	Anthrax [ICD-11: 1B97] Phase 1

D00VFH	TTDDRUID	D00VFH
D00VFH	DRUGNAME	PXS-25
D00VFH	INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 1

D0U3GW	TTDDRUID	D0U3GW
D0U3GW	DRUGNAME	PXVX0047
D0U3GW	INDICATI	Adenovirus infection [ICD-11: 1A20] Phase 1

D0M8YM	TTDDRUID	D0M8YM
D0M8YM	DRUGNAME	Pyrotinib
D0M8YM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09SAH	TTDDRUID	D09SAH
D09SAH	DRUGNAME	PZ01 CAR-T cells
D09SAH	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D09SAH	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1

D03SQT	TTDDRUID	D03SQT
D03SQT	DRUGNAME	Q203
D03SQT	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 1

D02PYM	TTDDRUID	D02PYM
D02PYM	DRUGNAME	QAK-423
D02PYM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D06DKD	TTDDRUID	D06DKD
D06DKD	DRUGNAME	QBI-139
D06DKD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IX9O	TTDDRUID	D0IX9O
D0IX9O	DRUGNAME	Q-Derp1
D0IX9O	INDICATI	Various major chronic disease [ICD-11: N.A.] Phase 1

D08UUD	TTDDRUID	D08UUD
D08UUD	DRUGNAME	R-1663
D08UUD	INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 1

D07FPR	TTDDRUID	D07FPR
D07FPR	DRUGNAME	R4996
D07FPR	INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1

D0E9HQ	TTDDRUID	D0E9HQ
D0E9HQ	DRUGNAME	R7334
D0E9HQ	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D0E5XA	TTDDRUID	D0E5XA
D0E5XA	DRUGNAME	R763
D0E5XA	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D09ZLZ	TTDDRUID	D09ZLZ
D09ZLZ	DRUGNAME	RAD-140
D09ZLZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D09ZLZ	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D02VER	TTDDRUID	D02VER
D02VER	DRUGNAME	Radavirsen
D02VER	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0LY0C	TTDDRUID	D0LY0C
D0LY0C	DRUGNAME	Radiolabelled-huA33
D0LY0C	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0X2UN	TTDDRUID	D0X2UN
D0X2UN	DRUGNAME	Radiprodil
D0X2UN	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0H3JC	TTDDRUID	D0H3JC
D0H3JC	DRUGNAME	Ragweed allergy immunotherapy vaccine
D0H3JC	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1

D0CL5D	TTDDRUID	D0CL5D
D0CL5D	DRUGNAME	Ragweed allergy vaccine
D0CL5D	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0MD7Y	TTDDRUID	D0MD7Y
D0MD7Y	DRUGNAME	Ragweed mix vaccine
D0MD7Y	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 1
D0MD7Y	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1

D0X1LW	TTDDRUID	D0X1LW
D0X1LW	DRUGNAME	Ragweed pollen allergen sublingual immunotherapy
D0X1LW	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D0EX1C	TTDDRUID	D0EX1C
D0EX1C	DRUGNAME	RASV-Sp
D0EX1C	INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 1

D03LAL	TTDDRUID	D03LAL
D03LAL	DRUGNAME	RBBX-01
D03LAL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03JWU	TTDDRUID	D03JWU
D03JWU	DRUGNAME	REC-01
D03JWU	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 1

D0K6NW	TTDDRUID	D0K6NW
D0K6NW	DRUGNAME	REC-02
D0K6NW	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1

D0UL7L	TTDDRUID	D0UL7L
D0UL7L	DRUGNAME	Recombinant human Erbb3 fragment therapeutic tumor vaccine
D0UL7L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M0FY	TTDDRUID	D0M0FY
D0M0FY	DRUGNAME	Recombinant human hepatocyte growth factor
D0M0FY	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Phase 1

D02JMZ	TTDDRUID	D02JMZ
D02JMZ	DRUGNAME	Recombinant human keratinocyte growth factor-2
D02JMZ	INDICATI	Wound healing [ICD-11: EL8Y] Phase 1

D0I9ZV	TTDDRUID	D0I9ZV
D0I9ZV	DRUGNAME	Recombinant soluble PSMA protein vaccine
D0I9ZV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D06TTT	TTDDRUID	D06TTT
D06TTT	DRUGNAME	Recombinant Tat protein vaccine
D06TTT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0EM6S	TTDDRUID	D0EM6S
D0EM6S	DRUGNAME	Recombinant viral vector vaccine
D0EM6S	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D08ZXM	TTDDRUID	D08ZXM
D08ZXM	DRUGNAME	REG2
D08ZXM	INDICATI	Venous thrombosis [ICD-11: BA43] Phase 1

D0UK7B	TTDDRUID	D0UK7B
D0UK7B	DRUGNAME	REGN1400
D0UK7B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0AU2T	TTDDRUID	D0AU2T
D0AU2T	DRUGNAME	REGN1979
D0AU2T	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0AU2T	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0AU2T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05VSH	TTDDRUID	D05VSH
D05VSH	DRUGNAME	REGN3767
D05VSH	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D05VSH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06VCC	TTDDRUID	D06VCC
D06VCC	DRUGNAME	REGN-421
D06VCC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P4IL	TTDDRUID	D0P4IL
D0P4IL	DRUGNAME	REGN-728
D0P4IL	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D03YEG	TTDDRUID	D03YEG
D03YEG	DRUGNAME	REGN-910
D03YEG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01UFZ	TTDDRUID	D01UFZ
D01UFZ	DRUGNAME	REL-1017
D01UFZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D0XD0N	TTDDRUID	D0XD0N
D0XD0N	DRUGNAME	REL-1028
D0XD0N	INDICATI	Chronic pain [ICD-11: MG30] Phase 1
D0XD0N	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1

D0A3WJ	TTDDRUID	D0A3WJ
D0A3WJ	DRUGNAME	Relatlimab
D0A3WJ	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2/3
D0A3WJ	INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
D0A3WJ	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
D0A3WJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D06UDH	TTDDRUID	D06UDH
D06UDH	DRUGNAME	REMD-477
D06UDH	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
D06UDH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D0J3KY	TTDDRUID	D0J3KY
D0J3KY	DRUGNAME	ReN-001
D0J3KY	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D04CRM	TTDDRUID	D04CRM
D04CRM	DRUGNAME	Renazorb
D04CRM	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 1

D0CW2N	TTDDRUID	D0CW2N
D0CW2N	DRUGNAME	Reolysinpelareorep
D0CW2N	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D01GXL	TTDDRUID	D01GXL
D01GXL	DRUGNAME	REP8839
D01GXL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0WJ1H	TTDDRUID	D0WJ1H
D0WJ1H	DRUGNAME	Replication-defective HIV vaccine
D0WJ1H	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0Y2NN	TTDDRUID	D0Y2NN
D0Y2NN	DRUGNAME	Replication-defective HIV-1 vaccine
D0Y2NN	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0E9XP	TTDDRUID	D0E9XP
D0E9XP	DRUGNAME	Respiratory syncytial virus VLPvaccine
D0E9XP	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D09BJH	TTDDRUID	D09BJH
D09BJH	DRUGNAME	Retroviral MGMT-transduced hematopoietic cells
D09BJH	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1

D0PO0L	TTDDRUID	D0PO0L
D0PO0L	DRUGNAME	Retroviral vector-transduced autologous T cells to express CD22-specific CARs
D0PO0L	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
D0PO0L	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D0PO0L	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1

D0H6VZ	TTDDRUID	D0H6VZ
D0H6VZ	DRUGNAME	REV-576
D0H6VZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0U0SD	TTDDRUID	D0U0SD
D0U0SD	DRUGNAME	RG-125
D0U0SD	INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 1

D0GE5B	TTDDRUID	D0GE5B
D0GE5B	DRUGNAME	RG-2833
D0GE5B	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1

D0KV6C	TTDDRUID	D0KV6C
D0KV6C	DRUGNAME	RG3039
D0KV6C	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 1

D0L4VD	TTDDRUID	D0L4VD
D0L4VD	DRUGNAME	RG6058
D0L4VD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01EJG	TTDDRUID	D01EJG
D01EJG	DRUGNAME	RG6100
D01EJG	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2

D0X8RS	TTDDRUID	D0X8RS
D0X8RS	DRUGNAME	RG6125
D0X8RS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D08KSV	TTDDRUID	D08KSV
D08KSV	DRUGNAME	RG6146
D08KSV	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D08KSV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00SIZ	TTDDRUID	D00SIZ
D00SIZ	DRUGNAME	RG6180
D00SIZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0LZ7Z	TTDDRUID	D0LZ7Z
D0LZ7Z	DRUGNAME	RG6264
D0LZ7Z	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1

D03WNN	TTDDRUID	D03WNN
D03WNN	DRUGNAME	RG-7010
D03WNN	INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 1

D0S7UQ	TTDDRUID	D0S7UQ
D0S7UQ	DRUGNAME	RG-7103
D0S7UQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D08EOW	TTDDRUID	D08EOW
D08EOW	DRUGNAME	RG7112
D08EOW	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D08EOW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D04RHJ	TTDDRUID	D04RHJ
D04RHJ	DRUGNAME	RG7116
D04RHJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O8UB	TTDDRUID	D0O8UB
D0O8UB	DRUGNAME	RG7129
D0O8UB	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0LB6D	TTDDRUID	D0LB6D
D0LB6D	DRUGNAME	RG7203
D0LB6D	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
D0LB6D	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D06EFW	TTDDRUID	D06EFW
D06EFW	DRUGNAME	RG7304
D06EFW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L2GX	TTDDRUID	D0L2GX
D0L2GX	DRUGNAME	RG7342
D0L2GX	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0YH8F	TTDDRUID	D0YH8F
D0YH8F	DRUGNAME	RG7347
D0YH8F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0HN6Q	TTDDRUID	D0HN6Q
D0HN6Q	DRUGNAME	RG-7348
D0HN6Q	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0L4ZK	TTDDRUID	D0L4ZK
D0L4ZK	DRUGNAME	RG-7351
D0L4ZK	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D0XR7R	TTDDRUID	D0XR7R
D0XR7R	DRUGNAME	RG7386
D0XR7R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G0TT	TTDDRUID	D0G0TT
D0G0TT	DRUGNAME	RG7410
D0G0TT	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1

D0O2FN	TTDDRUID	D0O2FN
D0O2FN	DRUGNAME	RG7420
D0O2FN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y9SB	TTDDRUID	D0Y9SB
D0Y9SB	DRUGNAME	RG7444
D0Y9SB	INDICATI	Refractory metastatic multiple myeloma [ICD-11: 2A83.1] Phase 1

D0O6YE	TTDDRUID	D0O6YE
D0O6YE	DRUGNAME	RG7450
D0O6YE	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0V7GS	TTDDRUID	D0V7GS
D0V7GS	DRUGNAME	RG7461
D0V7GS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02VBO	TTDDRUID	D02VBO
D02VBO	DRUGNAME	RG7604
D02VBO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00UQW	TTDDRUID	D00UQW
D00UQW	DRUGNAME	RG7741
D00UQW	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D00UQW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08TNG	TTDDRUID	D08TNG
D08TNG	DRUGNAME	RG7775
D08TNG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D03BZU	TTDDRUID	D03BZU
D03BZU	DRUGNAME	RG7802
D03BZU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M3GK	TTDDRUID	D0M3GK
D0M3GK	DRUGNAME	RG7813
D0M3GK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09TOL	TTDDRUID	D09TOL
D09TOL	DRUGNAME	RG-7816
D09TOL	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 1

D0A0UU	TTDDRUID	D0A0UU
D0A0UU	DRUGNAME	RG7828
D0A0UU	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0Y3WY	TTDDRUID	D0Y3WY
D0Y3WY	DRUGNAME	RG7841
D0Y3WY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0PH4R	TTDDRUID	D0PH4R
D0PH4R	DRUGNAME	RG7842
D0PH4R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00RGX	TTDDRUID	D00RGX
D00RGX	DRUGNAME	RG7876
D00RGX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G5BL	TTDDRUID	D0G5BL
D0G5BL	DRUGNAME	RG7880
D0G5BL	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1
D0G5BL	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D0V7QW	TTDDRUID	D0V7QW
D0V7QW	DRUGNAME	RG7882
D0V7QW	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0V7QW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0PB0U	TTDDRUID	D0PB0U
D0PB0U	DRUGNAME	RG7893
D0PB0U	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0E8SV	TTDDRUID	D0E8SV
D0E8SV	DRUGNAME	RG7906
D0E8SV	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 1

D0UF1D	TTDDRUID	D0UF1D
D0UF1D	DRUGNAME	RG7986
D0UF1D	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D05JMW	TTDDRUID	D05JMW
D05JMW	DRUGNAME	RGA-1512
D05JMW	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D03DKV	TTDDRUID	D03DKV
D03DKV	DRUGNAME	RGB-286638
D03DKV	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D05MVA	TTDDRUID	D05MVA
D05MVA	DRUGNAME	RGD-891
D05MVA	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0Y7DM	TTDDRUID	D0Y7DM
D0Y7DM	DRUGNAME	RGN-352 injectable
D0Y7DM	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 1
D0Y7DM	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1
D0Y7DM	INDICATI	Stroke [ICD-11: 8B20] Phase 1

D0YZ1Q	TTDDRUID	D0YZ1Q
D0YZ1Q	DRUGNAME	RGX-104
D0YZ1Q	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0YZ1Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0I5FP	TTDDRUID	D0I5FP
D0I5FP	DRUGNAME	RHAMM-R3 peptide vaccine
D0I5FP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y3AR	TTDDRUID	D0Y3AR
D0Y3AR	DRUGNAME	RhASM enzyme replacement therapy (acid sphingomyelinase deficiency)
D0Y3AR	INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 1

D07BNG	TTDDRUID	D07BNG
D07BNG	DRUGNAME	RHIgM12B7
D07BNG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03YGL	TTDDRUID	D03YGL
D03YGL	DRUGNAME	RHIgM22
D03YGL	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D08DTR	TTDDRUID	D08DTR
D08DTR	DRUGNAME	RHPIV1 84/del/170/942A
D08DTR	INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1

D02EWF	TTDDRUID	D02EWF
D02EWF	DRUGNAME	RiVax
D02EWF	INDICATI	Ricin poisoning [ICD-11: NE61] Phase 1

D04MUQ	TTDDRUID	D04MUQ
D04MUQ	DRUGNAME	RiVax + TVax
D04MUQ	INDICATI	Ricin poisoning [ICD-11: NE61] Phase 1

D0D7BX	TTDDRUID	D0D7BX
D0D7BX	DRUGNAME	Rivoceranib
D0D7BX	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D0D7BX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FN4T	TTDDRUID	D0FN4T
D0FN4T	DRUGNAME	RM-1929
D0FN4T	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D03GGN	TTDDRUID	D03GGN
D03GGN	DRUGNAME	RO-09-4889
D03GGN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08FNJ	TTDDRUID	D08FNJ
D08FNJ	DRUGNAME	RO-14
D08FNJ	INDICATI	Phlebothrombosis [ICD-11: GB90.3] Phase 1

D00CGH	TTDDRUID	D00CGH
D00CGH	DRUGNAME	RO-23-7553
D00CGH	INDICATI	Prostate disease [ICD-11: GA91] Phase 1

D06DQF	TTDDRUID	D06DQF
D06DQF	DRUGNAME	RO-5095932
D06DQF	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1

D0M6BD	TTDDRUID	D0M6BD
D0M6BD	DRUGNAME	RO-5126766
D0M6BD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G0PU	TTDDRUID	D0G0PU
D0G0PU	DRUGNAME	RO-5212054
D0G0PU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0WP4E	TTDDRUID	D0WP4E
D0WP4E	DRUGNAME	RO-5271983
D0WP4E	INDICATI	Asthma [ICD-11: CA23] Phase 1

D02YZK	TTDDRUID	D02YZK
D02YZK	DRUGNAME	RO-5303253
D02YZK	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0Y1FP	TTDDRUID	D0Y1FP
D0Y1FP	DRUGNAME	RO-5310074
D0Y1FP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0F4NW	TTDDRUID	D0F4NW
D0F4NW	DRUGNAME	RO-5428029
D0F4NW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0F3ZG	TTDDRUID	D0F3ZG
D0F3ZG	DRUGNAME	RO-5458640
D0F3ZG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02XTN	TTDDRUID	D02XTN
D02XTN	DRUGNAME	RO5545965
D02XTN	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0SF8V	TTDDRUID	D0SF8V
D0SF8V	DRUGNAME	RO7082859
D0SF8V	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0V4YO	TTDDRUID	D0V4YO
D0V4YO	DRUGNAME	ROCICLOVIR
D0V4YO	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1

D0V3XO	TTDDRUID	D0V3XO
D0V3XO	DRUGNAME	Rogaratinib
D0V3XO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q1YJ	TTDDRUID	D0Q1YJ
D0Q1YJ	DRUGNAME	RON mab
D0Q1YJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0PL6T	TTDDRUID	D0PL6T
D0PL6T	DRUGNAME	RON Monoclonal Antibody
D0PL6T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0JW7I	TTDDRUID	D0JW7I
D0JW7I	DRUGNAME	RON8 mab
D0JW7I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O8JW	TTDDRUID	D0O8JW
D0O8JW	DRUGNAME	Ronomilast
D0O8JW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1

D09WGH	TTDDRUID	D09WGH
D09WGH	DRUGNAME	Ropidoxuridine
D09WGH	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1
D09WGH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q8ML	TTDDRUID	D0Q8ML
D0Q8ML	DRUGNAME	ROR1 CAR-specific Autologous T-Lymphocytes
D0Q8ML	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0Q8ML	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0Q8ML	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1

D0L5KK	TTDDRUID	D0L5KK
D0L5KK	DRUGNAME	ROR1R-CAR-T Cell
D0L5KK	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0J3TI	TTDDRUID	D0J3TI
D0J3TI	DRUGNAME	Rosmantuzumab
D0J3TI	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0J3TI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V8RV	TTDDRUID	D0V8RV
D0V8RV	DRUGNAME	Rotavin
D0V8RV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D09MJJ	TTDDRUID	D09MJJ
D09MJJ	DRUGNAME	RP4010
D09MJJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0LG7X	TTDDRUID	D0LG7X
D0LG7X	DRUGNAME	RP6530
D0LG7X	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1

D0A1FB	TTDDRUID	D0A1FB
D0A1FB	DRUGNAME	RPA gene based adenovirus 4 vector vaccine
D0A1FB	INDICATI	Anthrax [ICD-11: 1B97] Phase 1

D05FVK	TTDDRUID	D05FVK
D05FVK	DRUGNAME	RPI-78M injectable
D05FVK	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
D05FVK	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0K3JQ	TTDDRUID	D0K3JQ
D0K3JQ	DRUGNAME	RPI-MN
D0K3JQ	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
D0K3JQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
D0K3JQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0KW9T	TTDDRUID	D0KW9T
D0KW9T	DRUGNAME	RSIFN-co
D0KW9T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09EYN	TTDDRUID	D09EYN
D09EYN	DRUGNAME	RSV F protein vaccine
D09EYN	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3

D0H8WX	TTDDRUID	D0H8WX
D0H8WX	DRUGNAME	RSV/PIV-3 vaccine
D0H8WX	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1

D0ME2T	TTDDRUID	D0ME2T
D0ME2T	DRUGNAME	RTA-901
D0ME2T	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1

D04KWY	TTDDRUID	D04KWY
D04KWY	DRUGNAME	RTI-336
D04KWY	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 1

D0M1DG	TTDDRUID	D0M1DG
D0M1DG	DRUGNAME	RTL-1000
D0M1DG	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1

D0UP2Y	TTDDRUID	D0UP2Y
D0UP2Y	DRUGNAME	RVEc
D0UP2Y	INDICATI	Intoxication [ICD-11: 6C40-6C4B] Phase 1

D07LCY	TTDDRUID	D07LCY
D07LCY	DRUGNAME	RVSVIN HIV-1 gag vaccine
D07LCY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0S1KR	TTDDRUID	D0S1KR
D0S1KR	DRUGNAME	RVT-103+RVT-104
D0S1KR	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0ZW2I	TTDDRUID	D0ZW2I
D0ZW2I	DRUGNAME	RVT-104
D0ZW2I	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D0ZW2I	INDICATI	Lewy body dementia [ICD-11: 6D82] Phase 1

D00LOB	TTDDRUID	D00LOB
D00LOB	DRUGNAME	RWJ-671818
D00LOB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0L6XQ	TTDDRUID	D0L6XQ
D0L6XQ	DRUGNAME	RWJ-676070
D0L6XQ	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1

D06OZJ	TTDDRUID	D06OZJ
D06OZJ	DRUGNAME	RWJ-67657
D06OZJ	INDICATI	Arthritis [ICD-11: FA20] Phase 1

D04UPW	TTDDRUID	D04UPW
D04UPW	DRUGNAME	RWJ-68023
D04UPW	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 1

D05ECQ	TTDDRUID	D05ECQ
D05ECQ	DRUGNAME	RX-10001
D05ECQ	INDICATI	Asthma [ICD-11: CA23] Phase 1
D05ECQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0NG1C	TTDDRUID	D0NG1C
D0NG1C	DRUGNAME	S. aureus type 336 vaccine
D0NG1C	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D09SHL	TTDDRUID	D09SHL
D09SHL	DRUGNAME	S. epidermidis vaccine
D09SHL	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 1

D01LFN	TTDDRUID	D01LFN
D01LFN	DRUGNAME	S. mutans Replacement Therapy
D01LFN	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1

D02NXR	TTDDRUID	D02NXR
D02NXR	DRUGNAME	S-117957
D02NXR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D09RJN	TTDDRUID	D09RJN
D09RJN	DRUGNAME	S-17092-1
D09RJN	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
D09RJN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial

D0P0PC	TTDDRUID	D0P0PC
D0P0PC	DRUGNAME	S-265744 LAP
D0P0PC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0G9SH	TTDDRUID	D0G9SH
D0G9SH	DRUGNAME	SA-5845
D0G9SH	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
D0G9SH	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Preclinical

D07CAQ	TTDDRUID	D07CAQ
D07CAQ	DRUGNAME	SAFINGOL
D07CAQ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0P2BD	TTDDRUID	D0P2BD
D0P2BD	DRUGNAME	SAFIRONIL
D0P2BD	INDICATI	Transplant rejection [ICD-11: NE84] Phase 1

D0O3AJ	TTDDRUID	D0O3AJ
D0O3AJ	DRUGNAME	SAGE-324
D0O3AJ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0JX6K	TTDDRUID	D0JX6K
D0JX6K	DRUGNAME	SAGE-718
D0JX6K	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D02JBI	TTDDRUID	D02JBI
D02JBI	DRUGNAME	SAL-200
D02JBI	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1

D06EXA	TTDDRUID	D06EXA
D06EXA	DRUGNAME	SALVINORIN A
D06EXA	INDICATI	Cerebral vasospasm [ICD-11: BA85.Z] Phase 1

D06PZC	TTDDRUID	D06PZC
D06PZC	DRUGNAME	SAM-6
D06PZC	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0F9IX	TTDDRUID	D0F9IX
D0F9IX	DRUGNAME	Samatasvir
D0F9IX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D01JWH	TTDDRUID	D01JWH
D01JWH	DRUGNAME	SAN-134
D01JWH	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1

D0L4BU	TTDDRUID	D0L4BU
D0L4BU	DRUGNAME	Sanaria PfSPZ Vaccine
D0L4BU	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D0LO5N	TTDDRUID	D0LO5N
D0LO5N	DRUGNAME	SAR-103168
D0LO5N	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0V6JF	TTDDRUID	D0V6JF
D0V6JF	DRUGNAME	SAR-104772
D0V6JF	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D0T6RG	TTDDRUID	D0T6RG
D0T6RG	DRUGNAME	SAR113244
D0T6RG	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D08KIB	TTDDRUID	D08KIB
D08KIB	DRUGNAME	SAR-114137
D08KIB	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0W8NP	TTDDRUID	D0W8NP
D0W8NP	DRUGNAME	SAR-115740
D0W8NP	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01NXX	TTDDRUID	D01NXX
D01NXX	DRUGNAME	SAR-126119
D01NXX	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D01NTQ	TTDDRUID	D01NTQ
D01NTQ	DRUGNAME	SAR127963
D01NTQ	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 1

D09IMN	TTDDRUID	D09IMN
D09IMN	DRUGNAME	SAR153192
D09IMN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01CIB	TTDDRUID	D01CIB
D01CIB	DRUGNAME	SAR164653
D01CIB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0R8RO	TTDDRUID	D0R8RO
D0R8RO	DRUGNAME	SAR-21609
D0R8RO	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0N9JB	TTDDRUID	D0N9JB
D0N9JB	DRUGNAME	SAR228810
D0N9JB	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0XE5M	TTDDRUID	D0XE5M
D0XE5M	DRUGNAME	SAR247799
D0XE5M	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D06GAP	TTDDRUID	D06GAP
D06GAP	DRUGNAME	SAR252067
D06GAP	INDICATI	Crohn disease [ICD-11: DD70] Phase 1
D06GAP	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D0HP8Q	TTDDRUID	D0HP8Q
D0HP8Q	DRUGNAME	SAR339375
D0HP8Q	INDICATI	Syndromic genetic deafness [ICD-11: LD2H] Phase 1

D04NJS	TTDDRUID	D04NJS
D04NJS	DRUGNAME	SAR351034
D04NJS	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
D04NJS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0AR7L	TTDDRUID	D0AR7L
D0AR7L	DRUGNAME	SAR-389644
D0AR7L	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D04LFR	TTDDRUID	D04LFR
D04LFR	DRUGNAME	SAR404460
D04LFR	INDICATI	Pre-sarcopenia [ICD-11: FB32.Y] Phase 1

D03YSQ	TTDDRUID	D03YSQ
D03YSQ	DRUGNAME	SAR-405838
D03YSQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
D03YSQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0KL4E	TTDDRUID	D0KL4E
D0KL4E	DRUGNAME	SAR422459
D0KL4E	INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1

D02URD	TTDDRUID	D02URD
D02URD	DRUGNAME	SAR425899
D02URD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D02URD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0VC8Y	TTDDRUID	D0VC8Y
D0VC8Y	DRUGNAME	SAR428926
D0VC8Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FY4L	TTDDRUID	D0FY4L
D0FY4L	DRUGNAME	SAR438335
D0FY4L	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0EI2V	TTDDRUID	D0EI2V
D0EI2V	DRUGNAME	SAR439459
D0EI2V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09ONL	TTDDRUID	D09ONL
D09ONL	DRUGNAME	SAR439794
D09ONL	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D0O1TJ	TTDDRUID	D0O1TJ
D0O1TJ	DRUGNAME	SAR439859
D0O1TJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0O1TJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07FGU	TTDDRUID	D07FGU
D07FGU	DRUGNAME	SAR440067
D07FGU	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
D07FGU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0HI1T	TTDDRUID	D0HI1T
D0HI1T	DRUGNAME	SAR440181
D0HI1T	INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 1

D02HUW	TTDDRUID	D02HUW
D02HUW	DRUGNAME	SAR-548304
D02HUW	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1

D0OF4A	TTDDRUID	D0OF4A
D0OF4A	DRUGNAME	SART3 peptide cancer vaccine
D0OF4A	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D01HVR	TTDDRUID	D01HVR
D01HVR	DRUGNAME	SAV-001
D01HVR	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D00RYA	TTDDRUID	D00RYA
D00RYA	DRUGNAME	SB-1578
D00RYA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04ZSL	TTDDRUID	D04ZSL
D04ZSL	DRUGNAME	SB-313-xTZ
D04ZSL	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D02UYM	TTDDRUID	D02UYM
D02UYM	DRUGNAME	SB414
D02UYM	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
D02UYM	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D0PQ8T	TTDDRUID	D0PQ8T
D0PQ8T	DRUGNAME	SB-436811
D0PQ8T	INDICATI	Asthma [ICD-11: CA23] Phase 1

D07FPY	TTDDRUID	D07FPY
D07FPY	DRUGNAME	SB-639
D07FPY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04HQC	TTDDRUID	D04HQC
D04HQC	DRUGNAME	SB-9200
D04HQC	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1

D0VE9F	TTDDRUID	D0VE9F
D0VE9F	DRUGNAME	SBP-101
D0VE9F	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0VE9F	INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 1

D05NUP	TTDDRUID	D05NUP
D05NUP	DRUGNAME	SBS-1000
D05NUP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0D8NG	TTDDRUID	D0D8NG
D0D8NG	DRUGNAME	Sc Veltuzumab
D0D8NG	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 1
D0D8NG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0D4OL	TTDDRUID	D0D4OL
D0D4OL	DRUGNAME	SC-002
D0D4OL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
D0D4OL	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0D4OL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0SZ2G	TTDDRUID	D0SZ2G
D0SZ2G	DRUGNAME	SC-003
D0SZ2G	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0SZ2G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W8NB	TTDDRUID	D0W8NB
D0W8NB	DRUGNAME	SC-005
D0W8NB	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1

D03MBU	TTDDRUID	D03MBU
D03MBU	DRUGNAME	SC-006
D03MBU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D03MBU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0K1AI	TTDDRUID	D0K1AI
D0K1AI	DRUGNAME	Sch-58500
D0K1AI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0NI0X	TTDDRUID	D0NI0X
D0NI0X	DRUGNAME	SCH-721015
D0NI0X	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1

D08YWY	TTDDRUID	D08YWY
D08YWY	DRUGNAME	SCH-900117
D08YWY	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0C0SX	TTDDRUID	D0C0SX
D0C0SX	DRUGNAME	SCH-900353
D0C0SX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G5LY	TTDDRUID	D0G5LY
D0G5LY	DRUGNAME	SCP-1
D0G5LY	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D07LYC	TTDDRUID	D07LYC
D07LYC	DRUGNAME	SCYX-7158
D07LYC	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 1

D0W6NW	TTDDRUID	D0W6NW
D0W6NW	DRUGNAME	SD-118
D0W6NW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1

D07DWC	TTDDRUID	D07DWC
D07DWC	DRUGNAME	SDX-7320
D07DWC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y9XO	TTDDRUID	D0Y9XO
D0Y9XO	DRUGNAME	SDZ-FOX-988
D0Y9XO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D02PYB	TTDDRUID	D02PYB
D02PYB	DRUGNAME	SDZ-GPI-562
D02PYB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D00FMK	TTDDRUID	D00FMK
D00FMK	DRUGNAME	SDZ-LAV-694
D00FMK	INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 1

D02ADC	TTDDRUID	D02ADC
D02ADC	DRUGNAME	SDZ-MKS-492
D02ADC	INDICATI	Asthma [ICD-11: CA23] Phase 1

D09MJH	TTDDRUID	D09MJH
D09MJH	DRUGNAME	SEA-CD40
D09MJH	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D09MJH	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D09MJH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04OGH	TTDDRUID	D04OGH
D04OGH	DRUGNAME	SEL-068
D04OGH	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 1

D03ZLN	TTDDRUID	D03ZLN
D03ZLN	DRUGNAME	SEL-403
D03ZLN	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
D03ZLN	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D00ZDO	TTDDRUID	D00ZDO
D00ZDO	DRUGNAME	SELA-070
D00ZDO	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 1

D0S0ZJ	TTDDRUID	D0S0ZJ
D0S0ZJ	DRUGNAME	Selective BACE 1 inhibitor
D0S0ZJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0QQ0W	TTDDRUID	D0QQ0W
D0QQ0W	DRUGNAME	Selicrelumab
D0QQ0W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08SHE	TTDDRUID	D08SHE
D08SHE	DRUGNAME	SEP-228432
D08SHE	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
D08SHE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D0I4XW	TTDDRUID	D0I4XW
D0I4XW	DRUGNAME	SEphB4-HSA
D0I4XW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S6GY	TTDDRUID	D0S6GY
D0S6GY	DRUGNAME	SER-101
D0S6GY	INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1

D0DN7Y	TTDDRUID	D0DN7Y
D0DN7Y	DRUGNAME	SER-214
D0DN7Y	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D04AKG	TTDDRUID	D04AKG
D04AKG	DRUGNAME	SER-287
D04AKG	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D01IGH	TTDDRUID	D01IGH
D01IGH	DRUGNAME	SERA5-targeted malaria vaccine
D01IGH	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D0YZ4T	TTDDRUID	D0YZ4T
D0YZ4T	DRUGNAME	SFLT-01
D0YZ4T	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D02ZAR	TTDDRUID	D02ZAR
D02ZAR	DRUGNAME	SGC activator 2
D02ZAR	INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 1

D0B3HP	TTDDRUID	D0B3HP
D0B3HP	DRUGNAME	SGC-1061
D0B3HP	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D02XAS	TTDDRUID	D02XAS
D02XAS	DRUGNAME	SGM-1019
D02XAS	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1

D06JBV	TTDDRUID	D06JBV
D06JBV	DRUGNAME	SGN LIV1A
D06JBV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0Z8KU	TTDDRUID	D0Z8KU
D0Z8KU	DRUGNAME	SGN-2FF
D0Z8KU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09PQP	TTDDRUID	D09PQP
D09PQP	DRUGNAME	SGN-70
D09PQP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D01BRD	TTDDRUID	D01BRD
D01BRD	DRUGNAME	SGN-CD123A
D01BRD	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0UT5A	TTDDRUID	D0UT5A
D0UT5A	DRUGNAME	SGN-CD19A
D0UT5A	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0UT5A	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D02HHM	TTDDRUID	D02HHM
D02HHM	DRUGNAME	SGN-CD19B
D02HHM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D09RUO	TTDDRUID	D09RUO
D09RUO	DRUGNAME	SGN-CD352A
D09RUO	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0S5CY	TTDDRUID	D0S5CY
D0S5CY	DRUGNAME	SGN-CD48A
D0S5CY	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0E2ZX	TTDDRUID	D0E2ZX
D0E2ZX	DRUGNAME	SGN-CD70A
D0E2ZX	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D02EOH	TTDDRUID	D02EOH
D02EOH	DRUGNAME	SGT-53
D02EOH	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D02EOH	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
D02EOH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0ZU5F	TTDDRUID	D0ZU5F
D0ZU5F	DRUGNAME	SGX523
D0ZU5F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01ZUH	TTDDRUID	D01ZUH
D01ZUH	DRUGNAME	Short-acting thrombosis inhibitor
D01ZUH	INDICATI	Disseminated intravascular coagulation [ICD-11: 3B20] Phase 1

D0M1ON	TTDDRUID	D0M1ON
D0M1ON	DRUGNAME	SHP-141
D0M1ON	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1

D06SHZ	TTDDRUID	D06SHZ
D06SHZ	DRUGNAME	SHP616
D06SHZ	INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 1

D0X0WQ	TTDDRUID	D0X0WQ
D0X0WQ	DRUGNAME	SHP680
D0X0WQ	INDICATI	Neurologic conditions associated with aminoacylase 1 deficiency [ICD-11: 5C50.E1] Phase 1

D0LB8B	TTDDRUID	D0LB8B
D0LB8B	DRUGNAME	Sialyl Lea-KLH conjugate vaccine
D0LB8B	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0G4OS	TTDDRUID	D0G4OS
D0G4OS	DRUGNAME	SII Rmab
D0G4OS	INDICATI	Rabies [ICD-11: 1C82] Phase 1

D02RRX	TTDDRUID	D02RRX
D02RRX	DRUGNAME	SILTENZEPINE
D02RRX	INDICATI	Stomach disease [ICD-11: DA43-DA4Y] Phase 1

D03XCR	TTDDRUID	D03XCR
D03XCR	DRUGNAME	Simotaxel
D03XCR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S9FU	TTDDRUID	D0S9FU
D0S9FU	DRUGNAME	Simotinib
D0S9FU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N6ZP	TTDDRUID	D0N6ZP
D0N6ZP	DRUGNAME	SKF-105494
D0N6ZP	INDICATI	Diuretic vasodilator [ICD-11: BA00] Phase 1

D0Y4OI	TTDDRUID	D0Y4OI
D0Y4OI	DRUGNAME	SKF-105809
D0Y4OI	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01IDW	TTDDRUID	D01IDW
D01IDW	DRUGNAME	SKI-O-703
D01IDW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D02JGD	TTDDRUID	D02JGD
D02JGD	DRUGNAME	SKL-10406
D02JGD	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D07CBH	TTDDRUID	D07CBH
D07CBH	DRUGNAME	SKL13865
D07CBH	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1

D0CQ5A	TTDDRUID	D0CQ5A
D0CQ5A	DRUGNAME	SKL20540
D0CQ5A	INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
D0CQ5A	INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1

D0R8EW	TTDDRUID	D0R8EW
D0R8EW	DRUGNAME	SL-017
D0R8EW	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1

D0H4IP	TTDDRUID	D0H4IP
D0H4IP	DRUGNAME	SL-052
D0H4IP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0SP6A	TTDDRUID	D0SP6A
D0SP6A	DRUGNAME	SL-801
D0SP6A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01WCL	TTDDRUID	D01WCL
D01WCL	DRUGNAME	SLV 354
D01WCL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D00CLC	TTDDRUID	D00CLC
D00CLC	DRUGNAME	SLV-338
D00CLC	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D07ZZI	TTDDRUID	D07ZZI
D07ZZI	DRUGNAME	SLV-341
D07ZZI	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1

D0Y9YG	TTDDRUID	D0Y9YG
D0Y9YG	DRUGNAME	SLV-342
D0Y9YG	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D0P5XM	TTDDRUID	D0P5XM
D0P5XM	DRUGNAME	SM04755
D0P5XM	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
D0P5XM	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1

D09YPJ	TTDDRUID	D09YPJ
D09YPJ	DRUGNAME	SM08502
D09YPJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02SYQ	TTDDRUID	D02SYQ
D02SYQ	DRUGNAME	Sm-14
D02SYQ	INDICATI	Schistosomiasis [ICD-11: 1F86] Phase 1

D0Q0IM	TTDDRUID	D0Q0IM
D0Q0IM	DRUGNAME	SNA-125
D0Q0IM	INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
D0Q0IM	INDICATI	Pruritus [ICD-11: EC90] Phase 1
D0Q0IM	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D04CTD	TTDDRUID	D04CTD
D04CTD	DRUGNAME	SNDX-6352
D04CTD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S5RC	TTDDRUID	D0S5RC
D0S5RC	DRUGNAME	SNS-032
D0S5RC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0OA5G	TTDDRUID	D0OA5G
D0OA5G	DRUGNAME	SNS-314
D0OA5G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0KJ2F	TTDDRUID	D0KJ2F
D0KJ2F	DRUGNAME	Solid tumor immunotherapy
D0KJ2F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L2XU	TTDDRUID	D0L2XU
D0L2XU	DRUGNAME	Solulin
D0L2XU	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0P1KJ	TTDDRUID	D0P1KJ
D0P1KJ	DRUGNAME	SOM1201
D0P1KJ	INDICATI	Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 1

D0XT8W	TTDDRUID	D0XT8W
D0XT8W	DRUGNAME	SOM3355
D0XT8W	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
D0XT8W	INDICATI	Tardive dyskinesia [ICD-11: 8A02.10] Phase 1

D0KV2E	TTDDRUID	D0KV2E
D0KV2E	DRUGNAME	Sonepcizumab
D0KV2E	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1

D06UWF	TTDDRUID	D06UWF
D06UWF	DRUGNAME	SOR-C13
D06UWF	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
D06UWF	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D06UWF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N1EZ	TTDDRUID	D0N1EZ
D0N1EZ	DRUGNAME	SPC-3
D0N1EZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0X1IL	TTDDRUID	D0X1IL
D0X1IL	DRUGNAME	SPC4955
D0X1IL	INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Phase 1

D0U3GA	TTDDRUID	D0U3GA
D0U3GA	DRUGNAME	SPC5001
D0U3GA	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D09MPX	TTDDRUID	D09MPX
D09MPX	DRUGNAME	SPF66
D09MPX	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1

D07UGA	TTDDRUID	D07UGA
D07UGA	DRUGNAME	Sphingosine-1-phosphate
D07UGA	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1

D08XKL	TTDDRUID	D08XKL
D08XKL	DRUGNAME	SPI-014
D08XKL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0S9UO	TTDDRUID	D0S9UO
D0S9UO	DRUGNAME	SPI-3608
D0S9UO	INDICATI	Spinal disease [ICD-11: FA72] Phase 1

D06YPQ	TTDDRUID	D06YPQ
D06YPQ	DRUGNAME	SPI-452
D06YPQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0QL0D	TTDDRUID	D0QL0D
D0QL0D	DRUGNAME	SPIF
D0QL0D	INDICATI	Autoimmune hepatitis [ICD-11: DB96.0] Phase 1

D0A9ZH	TTDDRUID	D0A9ZH
D0A9ZH	DRUGNAME	SPL-108
D0A9ZH	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0A9ZH	INDICATI	Ovarian epithelial cancer [ICD-11: 2C73] Phase 2

D0CQ2P	TTDDRUID	D0CQ2P
D0CQ2P	DRUGNAME	SPL-7013
D0CQ2P	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0E8TK	TTDDRUID	D0E8TK
D0E8TK	DRUGNAME	SPN-802
D0E8TK	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1

D02DXC	TTDDRUID	D02DXC
D02DXC	DRUGNAME	SPN-803
D02DXC	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0YI6W	TTDDRUID	D0YI6W
D0YI6W	DRUGNAME	SPN-805
D0YI6W	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1

D05RIM	TTDDRUID	D05RIM
D05RIM	DRUGNAME	SPN-808
D05RIM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1

D03BFS	TTDDRUID	D03BFS
D03BFS	DRUGNAME	SPN-809
D03BFS	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
D03BFS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1

D0T7QN	TTDDRUID	D0T7QN
D0T7QN	DRUGNAME	SPN-811
D0T7QN	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1

D03AVS	TTDDRUID	D03AVS
D03AVS	DRUGNAME	SR13668
D03AVS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Z3LC	TTDDRUID	D0Z3LC
D0Z3LC	DRUGNAME	SR-4554
D0Z3LC	INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1

D0DR4O	TTDDRUID	D0DR4O
D0DR4O	DRUGNAME	SRF231
D0DR4O	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0DR4O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01CBG	TTDDRUID	D01CBG
D01CBG	DRUGNAME	SRP-5051
D01CBG	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D0O3EP	TTDDRUID	D0O3EP
D0O3EP	DRUGNAME	SRT2379
D0O3EP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0X3TI	TTDDRUID	D0X3TI
D0X3TI	DRUGNAME	SRT3025
D0X3TI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0PB0D	TTDDRUID	D0PB0D
D0PB0D	DRUGNAME	SRX-251
D0PB0D	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 1

D0Q7QY	TTDDRUID	D0Q7QY
D0Q7QY	DRUGNAME	SSR-125047
D0Q7QY	INDICATI	Diabetic cataract [ICD-11: 9B10.21] Withdrawn from market
D0Q7QY	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0T6ES	TTDDRUID	D0T6ES
D0T6ES	DRUGNAME	SSR-125329A
D0T6ES	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1

D02UIC	TTDDRUID	D02UIC
D02UIC	DRUGNAME	SSR-128428
D02UIC	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0K0GF	TTDDRUID	D0K0GF
D0K0GF	DRUGNAME	SSR-181507
D0K0GF	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D03BGG	TTDDRUID	D03BGG
D03BGG	DRUGNAME	ST-1141
D03BGG	INDICATI	Functional bowel disorder [ICD-11: DD91] Phase 1

D01RRF	TTDDRUID	D01RRF
D01RRF	DRUGNAME	STA-5312
D01RRF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U3VH	TTDDRUID	D0U3VH
D0U3VH	DRUGNAME	STEBVax
D0U3VH	INDICATI	Endotoxic shock [ICD-11: 1G41] Phase 1
D0U3VH	INDICATI	Toxic shock syndrome [ICD-11: 1B52] Phase 1

D0X6DC	TTDDRUID	D0X6DC
D0X6DC	DRUGNAME	STM 434
D0X6DC	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0E7BY	TTDDRUID	D0E7BY
D0E7BY	DRUGNAME	StMN1 Lp
D0E7BY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D3UQ	TTDDRUID	D0D3UQ
D0D3UQ	DRUGNAME	Streptococcus mutans vaccine
D0D3UQ	INDICATI	Dental caries [ICD-11: DA08.0] Phase 1

D0X2TZ	TTDDRUID	D0X2TZ
D0X2TZ	DRUGNAME	Streptococcus pneumoniae vaccine
D0X2TZ	INDICATI	Meningitis [ICD-11: 1D01] Phase 1
D0X2TZ	INDICATI	Pneumonia [ICD-11: CA40] Phase 1

D0UB5F	TTDDRUID	D0UB5F
D0UB5F	DRUGNAME	Streptococcus pneumoniae vaccine, sanofi pasteur
D0UB5F	INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 1

D0E7FC	TTDDRUID	D0E7FC
D0E7FC	DRUGNAME	STRO-001
D0E7FC	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0E7FC	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0Q2YA	TTDDRUID	D0Q2YA
D0Q2YA	DRUGNAME	Stroke polyfunctional therapeutic
D0Q2YA	INDICATI	Stroke [ICD-11: 8B20] Phase 1

D0J2DQ	TTDDRUID	D0J2DQ
D0J2DQ	DRUGNAME	Stroke therapeutic
D0J2DQ	INDICATI	Stroke [ICD-11: 8B20] Phase 1

D07SYO	TTDDRUID	D07SYO
D07SYO	DRUGNAME	Stromal stem cell therapy
D07SYO	INDICATI	Liver failure [ICD-11: DB99.7] Phase 1

D05NJI	TTDDRUID	D05NJI
D05NJI	DRUGNAME	STX 64
D05NJI	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D05PWX	TTDDRUID	D05PWX
D05PWX	DRUGNAME	Sulfatinib
D05PWX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05YEI	TTDDRUID	D05YEI
D05YEI	DRUGNAME	SUN-K0706
D05YEI	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D05YEI	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0E7AS	TTDDRUID	D0E7AS
D0E7AS	DRUGNAME	SUN-N8075
D0E7AS	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Phase 1

D0KQ8W	TTDDRUID	D0KQ8W
D0KQ8W	DRUGNAME	SurVaxM
D0KQ8W	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0KQ8W	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2

D07WJU	TTDDRUID	D07WJU
D07WJU	DRUGNAME	SUVN-911
D07WJU	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
D07WJU	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D0M9RI	TTDDRUID	D0M9RI
D0M9RI	DRUGNAME	SUVN-D4010
D0M9RI	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D02SUB	TTDDRUID	D02SUB
D02SUB	DRUGNAME	SWT-06101
D02SUB	INDICATI	Fibromyalgia [ICD-11: MG30.01] Investigative
D02SUB	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 1

D09OHR	TTDDRUID	D09OHR
D09OHR	DRUGNAME	SY-1365
D09OHR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0HY3D	TTDDRUID	D0HY3D
D0HY3D	DRUGNAME	SY-1425
D0HY3D	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0HY3D	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1

D0D4TC	TTDDRUID	D0D4TC
D0D4TC	DRUGNAME	Sym021
D0D4TC	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D0D4TC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0D4TC	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
D0D4TC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00KML	TTDDRUID	D00KML
D00KML	DRUGNAME	SYN004
D00KML	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C8KY	TTDDRUID	D0C8KY
D0C8KY	DRUGNAME	SYN-1001
D0C8KY	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D07ANO	TTDDRUID	D07ANO
D07ANO	DRUGNAME	Synthetic neutrophil inhibitor peptide
D07ANO	INDICATI	Rhinitis [ICD-11: FA20] Phase 1

D03MWZ	TTDDRUID	D03MWZ
D03MWZ	DRUGNAME	Syntropin
D03MWZ	INDICATI	Dwarfism [ICD-11: 5B11] Phase 1

D08QDF	TTDDRUID	D08QDF
D08QDF	DRUGNAME	Systebryl
D08QDF	INDICATI	Amyloidosis [ICD-11: 5D00] Investigative
D08QDF	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1

D0V5JO	TTDDRUID	D0V5JO
D0V5JO	DRUGNAME	T-0128
D0V5JO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01MHL	TTDDRUID	D01MHL
D01MHL	DRUGNAME	T-2307
D01MHL	INDICATI	Mycoses [ICD-11: 1F2Z] Phase 1

D07YMP	TTDDRUID	D07YMP
D07YMP	DRUGNAME	TAB001
D07YMP	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1

D07DAU	TTDDRUID	D07DAU
D07DAU	DRUGNAME	Tafluposide
D07DAU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0XO4K	TTDDRUID	D0XO4K
D0XO4K	DRUGNAME	TA-HPV
D0XO4K	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1

D0VS3U	TTDDRUID	D0VS3U
D0VS3U	DRUGNAME	TAK-020
D0VS3U	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0E2HS	TTDDRUID	D0E2HS
D0E2HS	DRUGNAME	TAK-021
D0E2HS	INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 1

D01GTC	TTDDRUID	D01GTC
D01GTC	DRUGNAME	TAK-041
D01GTC	INDICATI	XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4] Phase 1

D0OU3Q	TTDDRUID	D0OU3Q
D0OU3Q	DRUGNAME	TAK-058
D0OU3Q	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
D0OU3Q	INDICATI	XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4] Phase 1

D09BBA	TTDDRUID	D09BBA
D09BBA	DRUGNAME	TAK-071
D09BBA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0J0BN	TTDDRUID	D0J0BN
D0J0BN	DRUGNAME	TAK-079
D0J0BN	INDICATI	Pheumatoid arthritis [ICD-11: FA2Z] Phase 1

D01RCM	TTDDRUID	D01RCM
D01RCM	DRUGNAME	TAK-114
D01RCM	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D0D3XM	TTDDRUID	D0D3XM
D0D3XM	DRUGNAME	TAK-137
D0D3XM	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 1

D08DJV	TTDDRUID	D08DJV
D08DJV	DRUGNAME	TAK-195
D08DJV	INDICATI	Poliovirus infection [ICD-11: 1C8Y] Phase 1

D0DT2S	TTDDRUID	D0DT2S
D0DT2S	DRUGNAME	TAK-202
D0DT2S	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0DT2S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O9UC	TTDDRUID	D0O9UC
D0O9UC	DRUGNAME	Tak-220
D0O9UC	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1

D0BL0G	TTDDRUID	D0BL0G
D0BL0G	DRUGNAME	TAK-233
D0BL0G	INDICATI	Pheumatoid arthritis [ICD-11: FA2Z] Phase 1

D0T4PA	TTDDRUID	D0T4PA
D0T4PA	DRUGNAME	TAK-243
D0T4PA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D02UFQ	TTDDRUID	D02UFQ
D02UFQ	DRUGNAME	TAK-285
D02UFQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L5FB	TTDDRUID	D0L5FB
D0L5FB	DRUGNAME	TAK-329
D0L5FB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0Q4JM	TTDDRUID	D0Q4JM
D0Q4JM	DRUGNAME	TAK-441
D0Q4JM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0LC9U	TTDDRUID	D0LC9U
D0LC9U	DRUGNAME	TAK-573
D0LC9U	INDICATI	Refractory multiple myeloma [ICD-11: 2A83] Phase 1

D0T2ER	TTDDRUID	D0T2ER
D0T2ER	DRUGNAME	TAK-593
D0T2ER	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H9HT	TTDDRUID	D0H9HT
D0H9HT	DRUGNAME	TAK-701
D0H9HT	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1

D0I3RD	TTDDRUID	D0I3RD
D0I3RD	DRUGNAME	TAK-733
D0I3RD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0D7CH	TTDDRUID	D0D7CH
D0D7CH	DRUGNAME	TAK-828
D0D7CH	INDICATI	Crohn disease [ICD-11: DD70] Phase 1

D03RXS	TTDDRUID	D03RXS
D03RXS	DRUGNAME	TAK-831
D03RXS	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
D03RXS	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D08HFW	TTDDRUID	D08HFW
D08HFW	DRUGNAME	TAK-901
D08HFW	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1

D0LL4Y	TTDDRUID	D0LL4Y
D0LL4Y	DRUGNAME	TAK-931
D0LL4Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09JGK	TTDDRUID	D09JGK
D09JGK	DRUGNAME	TAK-960
D09JGK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08VBV	TTDDRUID	D08VBV
D08VBV	DRUGNAME	TAP311
D08VBV	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1

D09RTK	TTDDRUID	D09RTK
D09RTK	DRUGNAME	Tapet
D09RTK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0WM3D	TTDDRUID	D0WM3D
D0WM3D	DRUGNAME	TAR-200
D0WM3D	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1

D00ZRS	TTDDRUID	D00ZRS
D00ZRS	DRUGNAME	TARP peptide vaccines
D00ZRS	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D06PDT	TTDDRUID	D06PDT
D06PDT	DRUGNAME	TARP peptide-pulsed autologous dendritic cell vaccine
D06PDT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D09OMK	TTDDRUID	D09OMK
D09OMK	DRUGNAME	Tarvacin Anti-Viral
D09OMK	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1

D0E2LA	TTDDRUID	D0E2LA
D0E2LA	DRUGNAME	TAS-103
D0E2LA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F3NF	TTDDRUID	D0F3NF
D0F3NF	DRUGNAME	TAS-116
D0F3NF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L3RO	TTDDRUID	D0L3RO
D0L3RO	DRUGNAME	TAS-119
D0L3RO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N5NC	TTDDRUID	D0N5NC
D0N5NC	DRUGNAME	TAS3681
D0N5NC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0J4MY	TTDDRUID	D0J4MY
D0J4MY	DRUGNAME	Tasidotin hydrochloride
D0J4MY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0R6WL	TTDDRUID	D0R6WL
D0R6WL	DRUGNAME	TAu mAb
D0R6WL	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0W1MU	TTDDRUID	D0W1MU
D0W1MU	DRUGNAME	TBC-M4
D0W1MU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D00EZO	TTDDRUID	D00EZO
D00EZO	DRUGNAME	TC-2216
D00EZO	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1

D0G2XR	TTDDRUID	D0G2XR
D0G2XR	DRUGNAME	TCD-717
D0G2XR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V5ZG	TTDDRUID	D0V5ZG
D0V5ZG	DRUGNAME	TCN-202
D0V5ZG	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1

D07TWK	TTDDRUID	D07TWK
D07TWK	DRUGNAME	TCN-P
D07TWK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D06WTQ	TTDDRUID	D06WTQ
D06WTQ	DRUGNAME	TD-0714
D06WTQ	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0K4IV	TTDDRUID	D0K4IV
D0K4IV	DRUGNAME	TD-1439
D0K4IV	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1

D0Z1QR	TTDDRUID	D0Z1QR
D0Z1QR	DRUGNAME	TD-1473
D0Z1QR	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1

D09MKL	TTDDRUID	D09MKL
D09MKL	DRUGNAME	TD-1607
D09MKL	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 1

D0L9BV	TTDDRUID	D0L9BV
D0L9BV	DRUGNAME	TDM-621
D0L9BV	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 1

D0O8WH	TTDDRUID	D0O8WH
D0O8WH	DRUGNAME	Tecentriq
D0O8WH	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
D0O8WH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0O8WH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0O8WH	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D0O8WH	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0O8WH	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D0O8WH	INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 1
D0O8WH	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
D0O8WH	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3
D0O8WH	INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 3

D0L1SK	TTDDRUID	D0L1SK
D0L1SK	DRUGNAME	Tecentriqatezolizumab
D0L1SK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0L1SK	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
D0L1SK	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0L1SK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
D0L1SK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0L1SK	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D0L1SK	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D0L1SK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
D0L1SK	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0VJ7G	TTDDRUID	D0VJ7G
D0VJ7G	DRUGNAME	TECHNETIUM-99M-MRP20
D0VJ7G	INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1

D08ZOY	TTDDRUID	D08ZOY
D08ZOY	DRUGNAME	Tecogalan sodium
D08ZOY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Q8WG	TTDDRUID	D0Q8WG
D0Q8WG	DRUGNAME	Tedalinab
D0Q8WG	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01XUE	TTDDRUID	D01XUE
D01XUE	DRUGNAME	Tedatioxetine
D01XUE	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 1
D01XUE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1

D09TLE	TTDDRUID	D09TLE
D09TLE	DRUGNAME	Tefinostat
D09TLE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0V6XW	TTDDRUID	D0V6XW
D0V6XW	DRUGNAME	Teglarinad
D0V6XW	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D04DSD	TTDDRUID	D04DSD
D04DSD	DRUGNAME	TEI-5178
D04DSD	INDICATI	Nephritis [ICD-11: GB40] Phase 1

D04VVD	TTDDRUID	D04VVD
D04VVD	DRUGNAME	TeloB-Vax
D04VVD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0R9KG	TTDDRUID	D0R9KG
D0R9KG	DRUGNAME	Temanogrel
D0R9KG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1

D0B5PK	TTDDRUID	D0B5PK
D0B5PK	DRUGNAME	TEN010
D0B5PK	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
D0B5PK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07EPV	TTDDRUID	D07EPV
D07EPV	DRUGNAME	Teneligliptin
D07EPV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0DX0G	TTDDRUID	D0DX0G
D0DX0G	DRUGNAME	Tergenpumatucel-L + indoximod + chemotherapy
D0DX0G	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D05VNP	TTDDRUID	D05VNP
D05VNP	DRUGNAME	TESTOSTERONE BUCICLATE
D05VNP	INDICATI	Contraception [ICD-11: QA21] Phase 1

D0G4ES	TTDDRUID	D0G4ES
D0G4ES	DRUGNAME	Tetrandrine
D0G4ES	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 3
D0G4ES	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1

D0MR0B	TTDDRUID	D0MR0B
D0MR0B	DRUGNAME	TEW-7197
D0MR0B	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
D0MR0B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L6KK	TTDDRUID	D0L6KK
D0L6KK	DRUGNAME	TF2
D0L6KK	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0K6YM	TTDDRUID	D0K6YM
D0K6YM	DRUGNAME	TG4040 (MVA-HCV)
D0K6YM	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1

D0P7KU	TTDDRUID	D0P7KU
D0P7KU	DRUGNAME	TGF-BR2 mab
D0P7KU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03QUT	TTDDRUID	D03QUT
D03QUT	DRUGNAME	Therapeutic peptide subunit vaccine
D03QUT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0X3CD	TTDDRUID	D0X3CD
D0X3CD	DRUGNAME	Thiarabine
D0X3CD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03TDW	TTDDRUID	D03TDW
D03TDW	DRUGNAME	Thiopilocarpine
D03TDW	INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1

D0B9NG	TTDDRUID	D0B9NG
D0B9NG	DRUGNAME	Thioureidobutyronitrile
D0B9NG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0FY1W	TTDDRUID	D0FY1W
D0FY1W	DRUGNAME	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy
D0FY1W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0UN1S	TTDDRUID	D0UN1S
D0UN1S	DRUGNAME	Tigapotide
D0UN1S	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0K2RV	TTDDRUID	D0K2RV
D0K2RV	DRUGNAME	Timothy grass extract
D0K2RV	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D0R4IZ	TTDDRUID	D0R4IZ
D0R4IZ	DRUGNAME	Timothy grass pollen extracts
D0R4IZ	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1

D0HU0A	TTDDRUID	D0HU0A
D0HU0A	DRUGNAME	TK216
D0HU0A	INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 1

D0O9AF	TTDDRUID	D0O9AF
D0O9AF	DRUGNAME	TKM-Ebola
D0O9AF	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0VH3H	TTDDRUID	D0VH3H
D0VH3H	DRUGNAME	TM38837
D0VH3H	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
D0VH3H	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0D8II	TTDDRUID	D0D8II
D0D8II	DRUGNAME	TMB-607
D0D8II	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0Y8BW	TTDDRUID	D0Y8BW
D0Y8BW	DRUGNAME	TMC-647055
D0Y8BW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0Z6GW	TTDDRUID	D0Z6GW
D0Z6GW	DRUGNAME	TMC649128
D0Z6GW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D08IID	TTDDRUID	D08IID
D08IID	DRUGNAME	TNO155
D08IID	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X1EV	TTDDRUID	D0X1EV
D0X1EV	DRUGNAME	TNT009
D0X1EV	INDICATI	Bullous pemphigoid [ICD-11: EB41.0] Phase 1
D0X1EV	INDICATI	Cold type autoimmune haemolytic anemia [ICD-11: 3A20.1] Phase 1

D0R5HA	TTDDRUID	D0R5HA
D0R5HA	DRUGNAME	Tobacco plant-derived anti-idiotype vaccine
D0R5HA	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D01NCS	TTDDRUID	D01NCS
D01NCS	DRUGNAME	TOL-463
D01NCS	INDICATI	Vaginal disease [ICD-11: GA1Y] Phase 1

D0S8BT	TTDDRUID	D0S8BT
D0S8BT	DRUGNAME	TOpiramate injection
D0S8BT	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D07ZEZ	TTDDRUID	D07ZEZ
D07ZEZ	DRUGNAME	Topotecan liposomes injection
D07ZEZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D07ZEZ	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D02FYI	TTDDRUID	D02FYI
D02FYI	DRUGNAME	TOzaride
D02FYI	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D00LGR	TTDDRUID	D00LGR
D00LGR	DRUGNAME	TP-0903
D00LGR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W8AG	TTDDRUID	D0W8AG
D0W8AG	DRUGNAME	TPIV 100/110 vaccine
D0W8AG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0W9MJ	TTDDRUID	D0W9MJ
D0W9MJ	DRUGNAME	TPIV 110
D0W9MJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0Q4QV	TTDDRUID	D0Q4QV
D0Q4QV	DRUGNAME	TPIV100
D0Q4QV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0BS2S	TTDDRUID	D0BS2S
D0BS2S	DRUGNAME	TPU-002
D0BS2S	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D09RYU	TTDDRUID	D09RYU
D09RYU	DRUGNAME	Tractinostat
D09RYU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D09RYU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O9HF	TTDDRUID	D0O9HF
D0O9HF	DRUGNAME	TrasGEX
D0O9HF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07APS	TTDDRUID	D07APS
D07APS	DRUGNAME	TRC093
D07APS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0SD9Z	TTDDRUID	D0SD9Z
D0SD9Z	DRUGNAME	TRC-253
D0SD9Z	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0U0EC	TTDDRUID	D0U0EC
D0U0EC	DRUGNAME	TRemelimumab + MEDI0562
D0U0EC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0E0WU	TTDDRUID	D0E0WU
D0E0WU	DRUGNAME	TRIN-2755
D0E0WU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08ZUC	TTDDRUID	D08ZUC
D08ZUC	DRUGNAME	TRK-950
D08ZUC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O3QW	TTDDRUID	D0O3QW
D0O3QW	DRUGNAME	Trodusquemine
D0O3QW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0O3QW	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0SN4Y	TTDDRUID	D0SN4Y
D0SN4Y	DRUGNAME	TRospium intravesicular
D0SN4Y	INDICATI	Neurogenic detrusor overactivity [ICD-11: GC01] Phase 1

D09PRN	TTDDRUID	D09PRN
D09PRN	DRUGNAME	TROVIRDINE HYDROCHLORIDE
D09PRN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D08DWK	TTDDRUID	D08DWK
D08DWK	DRUGNAME	TRPC4 and TRPC5 inhibitor
D08DWK	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
D08DWK	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1

D0Q1HD	TTDDRUID	D0Q1HD
D0Q1HD	DRUGNAME	TRV250
D0Q1HD	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D0OK6F	TTDDRUID	D0OK6F
D0OK6F	DRUGNAME	TRV734
D0OK6F	INDICATI	Chronic pain [ICD-11: MG30] Phase 1

D0E0NL	TTDDRUID	D0E0NL
D0E0NL	DRUGNAME	TRX-1
D0E0NL	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D00VUN	TTDDRUID	D00VUN
D00VUN	DRUGNAME	TRX-818
D00VUN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05TDJ	TTDDRUID	D05TDJ
D05TDJ	DRUGNAME	TS01
D05TDJ	INDICATI	Stroke [ICD-11: 8B20] Phase 1

D09LKR	TTDDRUID	D09LKR
D09LKR	DRUGNAME	TS-011
D09LKR	INDICATI	Stroke [ICD-11: 8B20] Phase 1

D07WSR	TTDDRUID	D07WSR
D07WSR	DRUGNAME	TS-032
D07WSR	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D09AJU	TTDDRUID	D09AJU
D09AJU	DRUGNAME	TS-111
D09AJU	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1

D0K7QQ	TTDDRUID	D0K7QQ
D0K7QQ	DRUGNAME	TS-134
D0K7QQ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0V9WE	TTDDRUID	D0V9WE
D0V9WE	DRUGNAME	TS23
D0V9WE	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0C9KX	TTDDRUID	D0C9KX
D0C9KX	DRUGNAME	TSD-0014
D0C9KX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1

D0J5YU	TTDDRUID	D0J5YU
D0J5YU	DRUGNAME	TSR-022
D0J5YU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F8TB	TTDDRUID	D0F8TB
D0F8TB	DRUGNAME	TSR-033
D0F8TB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N5VK	TTDDRUID	D0N5VK
D0N5VK	DRUGNAME	TSR-042
D0N5VK	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D0N5VK	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1
D0N5VK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01NSM	TTDDRUID	D01NSM
D01NSM	DRUGNAME	TST-10088
D01NSM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00SKM	TTDDRUID	D00SKM
D00SKM	DRUGNAME	TT12
D00SKM	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
D00SKM	INDICATI	Oropharyngeal cancer [ICD-11: 2B6A] Phase 1

D01XQQ	TTDDRUID	D01XQQ
D01XQQ	DRUGNAME	TT-30
D01XQQ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D00EHX	TTDDRUID	D00EHX
D00EHX	DRUGNAME	TT-301
D00EHX	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0NZ3C	TTDDRUID	D0NZ3C
D0NZ3C	DRUGNAME	TTC-352
D0NZ3C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D01CUO	TTDDRUID	D01CUO
D01CUO	DRUGNAME	TTI-621
D01CUO	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D01CUO	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D01CUO	INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
D01CUO	INDICATI	Mycosis fungoides [ICD-11: 2B01] Phase 1
D01CUO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
D01CUO	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D0I0YS	TTDDRUID	D0I0YS
D0I0YS	DRUGNAME	TTP-4000
D0I0YS	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0G0ZE	TTDDRUID	D0G0ZE
D0G0ZE	DRUGNAME	TTP-547
D0G0ZE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0Z1UW	TTDDRUID	D0Z1UW
D0Z1UW	DRUGNAME	TTPABC
D0Z1UW	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1

D01WMO	TTDDRUID	D01WMO
D01WMO	DRUGNAME	Tularemia vaccine
D01WMO	INDICATI	Tularemia [ICD-11: 1B94] Phase 1

D01SYU	TTDDRUID	D01SYU
D01SYU	DRUGNAME	Turofexorate isopropyl
D01SYU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1

D05NPD	TTDDRUID	D05NPD
D05NPD	DRUGNAME	TYrosine kinase 2 inhibitor
D05NPD	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D0WJ8M	TTDDRUID	D0WJ8M
D0WJ8M	DRUGNAME	U3-1402
D0WJ8M	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D06ZXF	TTDDRUID	D06ZXF
D06ZXF	DRUGNAME	U3-1565
D06ZXF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y4IR	TTDDRUID	D0Y4IR
D0Y4IR	DRUGNAME	UBC1967
D0Y4IR	INDICATI	Ophthalmic graves disease [ICD-11: 5A02.0] Phase 1

D0NF1Z	TTDDRUID	D0NF1Z
D0NF1Z	DRUGNAME	UBX0101
D0NF1Z	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1

D00BTW	TTDDRUID	D00BTW
D00BTW	DRUGNAME	UC-781
D00BTW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0DJ9Y	TTDDRUID	D0DJ9Y
D0DJ9Y	DRUGNAME	UCART123
D0DJ9Y	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0DJ9Y	INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1

D0Z7QK	TTDDRUID	D0Z7QK
D0Z7QK	DRUGNAME	UCART123
D0Z7QK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
D0Z7QK	INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1

D02KPJ	TTDDRUID	D02KPJ
D02KPJ	DRUGNAME	UCART19
D02KPJ	INDICATI	Burkitt cell leukaemia [ICD-11: 2A85.6] Phase 1

D06SDQ	TTDDRUID	D06SDQ
D06SDQ	DRUGNAME	UCB0599
D06SDQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0N7BL	TTDDRUID	D0N7BL
D0N7BL	DRUGNAME	UK-240455
D0N7BL	INDICATI	Nerve injury [ICD-11: ND56.4] Phase 1

D09OCK	TTDDRUID	D09OCK
D09OCK	DRUGNAME	UK-371800
D09OCK	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 1

D05WSP	TTDDRUID	D05WSP
D05WSP	DRUGNAME	UK-396082
D05WSP	INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1

D0J0RG	TTDDRUID	D0J0RG
D0J0RG	DRUGNAME	UK-66914
D0J0RG	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 1

D07WTH	TTDDRUID	D07WTH
D07WTH	DRUGNAME	UltraCD40L
D07WTH	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1

D00ZEG	TTDDRUID	D00ZEG
D00ZEG	DRUGNAME	Umespirone
D00ZEG	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1

D01TDY	TTDDRUID	D01TDY
D01TDY	DRUGNAME	Unacylated ghrelin
D01TDY	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D04TSO	TTDDRUID	D04TSO
D04TSO	DRUGNAME	UNBS-1450
D04TSO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0F0FZ	TTDDRUID	D0F0FZ
D0F0FZ	DRUGNAME	UNBS-5162
D0F0FZ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0FP4R	TTDDRUID	D0FP4R
D0FP4R	DRUGNAME	UR-13870
D0FP4R	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D0U2PY	TTDDRUID	D0U2PY
D0U2PY	DRUGNAME	UTI vaccine
D0U2PY	INDICATI	Urinary tract infection [ICD-11: GC08] Phase 1

D09UMR	TTDDRUID	D09UMR
D09UMR	DRUGNAME	UV1 + GM-CSF vaccine
D09UMR	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0T7BI	TTDDRUID	D0T7BI
D0T7BI	DRUGNAME	V160
D0T7BI	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1

D06UBF	TTDDRUID	D06UBF
D06UBF	DRUGNAME	V180
D06UBF	INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1

D09KYZ	TTDDRUID	D09KYZ
D09KYZ	DRUGNAME	V-24343
D09KYZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D04NQZ	TTDDRUID	D04NQZ
D04NQZ	DRUGNAME	V502
D04NQZ	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1

D0D0OR	TTDDRUID	D0D0OR
D0D0OR	DRUGNAME	V520/V526 combination vaccine
D0D0OR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0T4ME	TTDDRUID	D0T4ME
D0T4ME	DRUGNAME	V930
D0T4ME	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C2UH	TTDDRUID	D0C2UH
D0C2UH	DRUGNAME	V930/V932
D0C2UH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06RSE	TTDDRUID	D06RSE
D06RSE	DRUGNAME	V935
D06RSE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0X5FV	TTDDRUID	D0X5FV
D0X5FV	DRUGNAME	V-950
D0X5FV	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0Z2HG	TTDDRUID	D0Z2HG
D0Z2HG	DRUGNAME	V950 vaccine
D0Z2HG	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0LT2Z	TTDDRUID	D0LT2Z
D0LT2Z	DRUGNAME	Vaccimel
D0LT2Z	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0L8CS	TTDDRUID	D0L8CS
D0L8CS	DRUGNAME	Vaccine, tetravalent, small-cell lung cancer, mabVax
D0L8CS	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0D6PP	TTDDRUID	D0D6PP
D0D6PP	DRUGNAME	Vaccinia virus therapy
D0D6PP	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D01PCB	TTDDRUID	D01PCB
D01PCB	DRUGNAME	VALERGEN-DS (subcutaneous)
D01PCB	INDICATI	Asthma [ICD-11: CA23] Phase 1

D06FPF	TTDDRUID	D06FPF
D06FPF	DRUGNAME	Valortim
D06FPF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0I5NN	TTDDRUID	D0I5NN
D0I5NN	DRUGNAME	Valtorim
D0I5NN	INDICATI	Anthrax [ICD-11: 1B97] Phase 1

D08KNG	TTDDRUID	D08KNG
D08KNG	DRUGNAME	VAN-10-4-eluting stent
D08KNG	INDICATI	Artery stenosis [ICD-11: BD52] Phase 1

D0E6VF	TTDDRUID	D0E6VF
D0E6VF	DRUGNAME	VAX-128
D0E6VF	INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1

D04YFA	TTDDRUID	D04YFA
D04YFA	DRUGNAME	VAX-161
D04YFA	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 1

D0T5HO	TTDDRUID	D0T5HO
D0T5HO	DRUGNAME	Vaxfectin plasmid DNA pandemic influenza vaccine
D0T5HO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D0K8DW	TTDDRUID	D0K8DW
D0K8DW	DRUGNAME	VBI-1501A
D0K8DW	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1

D07ODC	TTDDRUID	D07ODC
D07ODC	DRUGNAME	VBY- 036
D07ODC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D01REJ	TTDDRUID	D01REJ
D01REJ	DRUGNAME	VBY- 891
D01REJ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1

D07UKF	TTDDRUID	D07UKF
D07UKF	DRUGNAME	VBY-129
D07UKF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
D07UKF	INDICATI	Crohn disease [ICD-11: DD70] Phase 1
D07UKF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1

D02YEG	TTDDRUID	D02YEG
D02YEG	DRUGNAME	VBY-376
D02YEG	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D09XXH	TTDDRUID	D09XXH
D09XXH	DRUGNAME	VCH-286
D09XXH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0ZM5E	TTDDRUID	D0ZM5E
D0ZM5E	DRUGNAME	VCL-1M01
D0ZM5E	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0H6GI	TTDDRUID	D0H6GI
D0H6GI	DRUGNAME	VE-822
D0H6GI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0Y1VT	TTDDRUID	D0Y1VT
D0Y1VT	DRUGNAME	VEGF-2 gene therapy
D0Y1VT	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1

D01JPL	TTDDRUID	D01JPL
D01JPL	DRUGNAME	VEGFR3 Monoclonal Antibody
D01JPL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G6GB	TTDDRUID	D0G6GB
D0G6GB	DRUGNAME	Veglin
D0G6GB	INDICATI	Kaposi sarcoma [ICD-11: 2B57] Phase 1
D0G6GB	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D07BIK	TTDDRUID	D07BIK
D07BIK	DRUGNAME	VEL-0230
D07BIK	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D0V0YA	TTDDRUID	D0V0YA
D0V0YA	DRUGNAME	Veltuzumab/epratuzumab Y-90
D0V0YA	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1

D0A0TS	TTDDRUID	D0A0TS
D0A0TS	DRUGNAME	VesiculoVax
D0A0TS	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0S0ZQ	TTDDRUID	D0S0ZQ
D0S0ZQ	DRUGNAME	Vesimune
D0S0ZQ	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
D0S0ZQ	INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 2

D0GP0H	TTDDRUID	D0GP0H
D0GP0H	DRUGNAME	VGX-100
D0GP0H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03QEB	TTDDRUID	D03QEB
D03QEB	DRUGNAME	VGX-1027
D03QEB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D03TAY	TTDDRUID	D03TAY
D03TAY	DRUGNAME	VGX-3400
D03TAY	INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1

D0JC9K	TTDDRUID	D0JC9K
D0JC9K	DRUGNAME	VI7734
D0JC9K	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
D0JC9K	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 1

D07IFZ	TTDDRUID	D07IFZ
D07IFZ	DRUGNAME	VIA-3196
D07IFZ	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 1

D00RTC	TTDDRUID	D00RTC
D00RTC	DRUGNAME	Vicinium
D00RTC	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3

D0S8AF	TTDDRUID	D0S8AF
D0S8AF	DRUGNAME	Visceral leishmaniasis vaccine
D0S8AF	INDICATI	Visceral leishmaniasis [ICD-11: 1F54.0] Phase 1

D0Q0LF	TTDDRUID	D0Q0LF
D0Q0LF	DRUGNAME	Vitatropin
D0Q0LF	INDICATI	Growth failure [ICD-11: LD2F.1Y] Phase 1

D01IMN	TTDDRUID	D01IMN
D01IMN	DRUGNAME	VLA15-101
D01IMN	INDICATI	Lyme disease [ICD-11: 1C1G] Phase 1

D06HYC	TTDDRUID	D06HYC
D06HYC	DRUGNAME	VLI-01B
D06HYC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0G7IF	TTDDRUID	D0G7IF
D0G7IF	DRUGNAME	VLX1570
D0G7IF	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D08AAB	TTDDRUID	D08AAB
D08AAB	DRUGNAME	VLX600
D08AAB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D08WVL	TTDDRUID	D08WVL
D08WVL	DRUGNAME	VM1500a
D08WVL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0H7ZN	TTDDRUID	D0H7ZN
D0H7ZN	DRUGNAME	VM-206
D0H7ZN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0A8TA	TTDDRUID	D0A8TA
D0A8TA	DRUGNAME	Volanesorsen
D0A8TA	INDICATI	Familial chylomicronemia syndrome [ICD-11: 5C80] Application submitted
D0A8TA	INDICATI	Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 1

D0E4SX	TTDDRUID	D0E4SX
D0E4SX	DRUGNAME	VP20629
D0E4SX	INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1

D09VIX	TTDDRUID	D09VIX
D09VIX	DRUGNAME	VRC01LS
D09VIX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D08CGG	TTDDRUID	D08CGG
D08CGG	DRUGNAME	VRC-EBOADV018-00-VP
D08CGG	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0N2HU	TTDDRUID	D0N2HU
D0N2HU	DRUGNAME	VRC-EBODNA023-00-VP
D0N2HU	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1

D0W3WD	TTDDRUID	D0W3WD
D0W3WD	DRUGNAME	VRC-HIVADV027-00-VP
D0W3WD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D05EPE	TTDDRUID	D05EPE
D05EPE	DRUGNAME	VRC-SRSDNA015-00-VP
D05EPE	INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1

D0I5CN	TTDDRUID	D0I5CN
D0I5CN	DRUGNAME	VRS-859
D0I5CN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0A6VD	TTDDRUID	D0A6VD
D0A6VD	DRUGNAME	VS-4718
D0A6VD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0U3DP	TTDDRUID	D0U3DP
D0U3DP	DRUGNAME	VS-5584
D0U3DP	INDICATI	Malignant mesothelioma [ICD-11: 2C26.0] Phase 1
D0U3DP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
D0U3DP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0EF9Y	TTDDRUID	D0EF9Y
D0EF9Y	DRUGNAME	VSV-IFN-beta-NIS
D0EF9Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0AZ4S	TTDDRUID	D0AZ4S
D0AZ4S	DRUGNAME	VT1021
D0AZ4S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05VKS	TTDDRUID	D05VKS
D05VKS	DRUGNAME	VT-122
D05VKS	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D05VKS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D01QSG	TTDDRUID	D01QSG
D01QSG	DRUGNAME	VTP-27999
D01QSG	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0VB4X	TTDDRUID	D0VB4X
D0VB4X	DRUGNAME	VTP-43742
D0VB4X	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
D0VB4X	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2

D05ASV	TTDDRUID	D05ASV
D05ASV	DRUGNAME	VTX-1463
D05ASV	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D0V5HA	TTDDRUID	D0V5HA
D0V5HA	DRUGNAME	VX-128
D0V5HA	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D0N1SH	TTDDRUID	D0N1SH
D0N1SH	DRUGNAME	VX-15
D0N1SH	INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
D0N1SH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
D0N1SH	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D02MMP	TTDDRUID	D02MMP
D02MMP	DRUGNAME	VX-500
D02MMP	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0L0HV	TTDDRUID	D0L0HV
D0L0HV	DRUGNAME	VX-916
D0L0HV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D06DMQ	TTDDRUID	D06DMQ
D06DMQ	DRUGNAME	VX-970
D06DMQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H4PP	TTDDRUID	D0H4PP
D0H4PP	DRUGNAME	VXA-G1.1-NN
D0H4PP	INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1

D0R0ZP	TTDDRUID	D0R0ZP
D0R0ZP	DRUGNAME	VXA-RSV-f
D0R0ZP	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1

D03SZK	TTDDRUID	D03SZK
D03SZK	DRUGNAME	VXM-01
D03SZK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0W3OU	TTDDRUID	D0W3OU
D0W3OU	DRUGNAME	VY-AADC01 gene therapy
D0W3OU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0GS2W	TTDDRUID	D0GS2W
D0GS2W	DRUGNAME	W-198
D0GS2W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06CWV	TTDDRUID	D06CWV
D06CWV	DRUGNAME	W-205GBA2ED
D06CWV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0Q6GD	TTDDRUID	D0Q6GD
D0Q6GD	DRUGNAME	WCK-1152
D0Q6GD	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Phase 1

D0MA0F	TTDDRUID	D0MA0F
D0MA0F	DRUGNAME	WF-11605
D0MA0F	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1

D0M1EP	TTDDRUID	D0M1EP
D0M1EP	DRUGNAME	WNV DNA vaccine
D0M1EP	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1

D07XEV	TTDDRUID	D07XEV
D07XEV	DRUGNAME	WPP-201
D07XEV	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1

D0H2QL	TTDDRUID	D0H2QL
D0H2QL	DRUGNAME	WRSs2
D0H2QL	INDICATI	Shigella infection [ICD-11: 1A02] Phase 1

D04GGJ	TTDDRUID	D04GGJ
D04GGJ	DRUGNAME	WST-057
D04GGJ	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1

D07OTW	TTDDRUID	D07OTW
D07OTW	DRUGNAME	WT2725
D07OTW	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
D07OTW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06SZU	TTDDRUID	D06SZU
D06SZU	DRUGNAME	WVE-210201
D06SZU	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1

D0L2ZY	TTDDRUID	D0L2ZY
D0L2ZY	DRUGNAME	X-82
D0L2ZY	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
D0L2ZY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0M3IN	TTDDRUID	D0M3IN
D0M3IN	DRUGNAME	Xanthine
D0M3IN	INDICATI	Apnea [ICD-11: MD11.0] Phase 1

D06SJZ	TTDDRUID	D06SJZ
D06SJZ	DRUGNAME	XB-947
D06SJZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0ZL5J	TTDDRUID	D0ZL5J
D0ZL5J	DRUGNAME	XCUR17
D0ZL5J	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1

D03CCY	TTDDRUID	D03CCY
D03CCY	DRUGNAME	XEL 001HP
D03CCY	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1

D0A3MJ	TTDDRUID	D0A3MJ
D0A3MJ	DRUGNAME	XEN007
D0A3MJ	INDICATI	Migraine [ICD-11: 8A80] Phase 1

D0WW3O	TTDDRUID	D0WW3O
D0WW3O	DRUGNAME	XEN1101
D0WW3O	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0JB4V	TTDDRUID	D0JB4V
D0JB4V	DRUGNAME	XEN-403
D0JB4V	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1

D01QTJ	TTDDRUID	D01QTJ
D01QTJ	DRUGNAME	XEN901
D01QTJ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D0X6ZG	TTDDRUID	D0X6ZG
D0X6ZG	DRUGNAME	XEN-D0101
D0X6ZG	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1

D05DXT	TTDDRUID	D05DXT
D05DXT	DRUGNAME	XEN-D0103
D05DXT	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1

D0ZI5U	TTDDRUID	D0ZI5U
D0ZI5U	DRUGNAME	XeriJect
D0ZI5U	INDICATI	Acute repetitive seizure [ICD-11: 8A67] Phase 1

D04FMB	TTDDRUID	D04FMB
D04FMB	DRUGNAME	XK-469
D04FMB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0L0DZ	TTDDRUID	D0L0DZ
D0L0DZ	DRUGNAME	XL-041
D0L0DZ	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1

D03ZXZ	TTDDRUID	D03ZXZ
D03ZXZ	DRUGNAME	XL-228
D03ZXZ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0X2JM	TTDDRUID	D0X2JM
D0X2JM	DRUGNAME	XL418
D0X2JM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D09UKH	TTDDRUID	D09UKH
D09UKH	DRUGNAME	XL550
D09UKH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0O5XJ	TTDDRUID	D0O5XJ
D0O5XJ	DRUGNAME	XL652/XL014
D0O5XJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
D0O5XJ	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1

D05UGJ	TTDDRUID	D05UGJ
D05UGJ	DRUGNAME	XL844
D05UGJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0J2RV	TTDDRUID	D0J2RV
D0J2RV	DRUGNAME	XL-888
D0J2RV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07PNT	TTDDRUID	D07PNT
D07PNT	DRUGNAME	XL999
D07PNT	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1

D0L2JE	TTDDRUID	D0L2JE
D0L2JE	DRUGNAME	XmAb13676
D0L2JE	INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
D0L2JE	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D0I4BK	TTDDRUID	D0I4BK
D0I4BK	DRUGNAME	XmAb14045
D0I4BK	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1

D0FU0O	TTDDRUID	D0FU0O
D0FU0O	DRUGNAME	XmAb18087
D0FU0O	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
D0FU0O	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1

D00RSA	TTDDRUID	D00RSA
D00RSA	DRUGNAME	XmAb-20717
D00RSA	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D00RSA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06ALK	TTDDRUID	D06ALK
D06ALK	DRUGNAME	Xmab-2513
D06ALK	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0SQ1O	TTDDRUID	D0SQ1O
D0SQ1O	DRUGNAME	XmAb5981
D0SQ1O	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1

D0JQ4S	TTDDRUID	D0JQ4S
D0JQ4S	DRUGNAME	Xmab-7195
D0JQ4S	INDICATI	Asthma [ICD-11: CA23] Phase 1

D0Z7FK	TTDDRUID	D0Z7FK
D0Z7FK	DRUGNAME	XMT-1001
D0Z7FK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07FZF	TTDDRUID	D07FZF
D07FZF	DRUGNAME	XMT-1522
D07FZF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D07FZF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D02TGN	TTDDRUID	D02TGN
D02TGN	DRUGNAME	XMT-1536
D02TGN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0RD1I	TTDDRUID	D0RD1I
D0RD1I	DRUGNAME	XOMA-3AB
D0RD1I	INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1

D0Q5TH	TTDDRUID	D0Q5TH
D0Q5TH	DRUGNAME	XR-5944
D0Q5TH	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1

D0R2GU	TTDDRUID	D0R2GU
D0R2GU	DRUGNAME	XRX-001
D0R2GU	INDICATI	Yellow fever virus infection [ICD-11: 1D47] Phase 1

D0MU1F	TTDDRUID	D0MU1F
D0MU1F	DRUGNAME	XTL-6865
D0MU1F	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1

D0U4YD	TTDDRUID	D0U4YD
D0U4YD	DRUGNAME	YKP10461
D0U4YD	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0N4NJ	TTDDRUID	D0N4NJ
D0N4NJ	DRUGNAME	YKP-1358
D0N4NJ	INDICATI	Schizoaffective disorder [ICD-11: 6A21] Phase 1
D0N4NJ	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1

D0D2LF	TTDDRUID	D0D2LF
D0D2LF	DRUGNAME	YM-116
D0D2LF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0P9KA	TTDDRUID	D0P9KA
D0P9KA	DRUGNAME	YM-16151-4
D0P9KA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0K2NA	TTDDRUID	D0K2NA
D0K2NA	DRUGNAME	YM-57158
D0K2NA	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1

D00HZA	TTDDRUID	D00HZA
D00HZA	DRUGNAME	YPEG-Somatropin
D00HZA	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 1

D0O4NJ	TTDDRUID	D0O4NJ
D0O4NJ	DRUGNAME	Z-100
D0O4NJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D05EPU	TTDDRUID	D05EPU
D05EPU	DRUGNAME	ZD7114
D05EPU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D06RYY	TTDDRUID	D06RYY
D06RYY	DRUGNAME	ZD-9379
D06RYY	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1

D09UGG	TTDDRUID	D09UGG
D09UGG	DRUGNAME	Zemab
D09UGG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0IT1V	TTDDRUID	D0IT1V
D0IT1V	DRUGNAME	Zika virus vaccine
D0IT1V	INDICATI	Semliki forest virus infection [ICD-11: 1D9Y] Phase 1

D00VNH	TTDDRUID	D00VNH
D00VNH	DRUGNAME	ZK-200775
D00VNH	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1

D09NVU	TTDDRUID	D09NVU
D09NVU	DRUGNAME	ZP-1848
D09NVU	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1

D0FW0B	TTDDRUID	D0FW0B
D0FW0B	DRUGNAME	ZP2929
D0FW0B	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
D0FW0B	INDICATI	Obesity [ICD-11: 5B81] Preclinical
D0FW0B	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1

D0O1LD	TTDDRUID	D0O1LD
D0O1LD	DRUGNAME	ZSTK474
D0O1LD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05REB	TTDDRUID	D05REB
D05REB	DRUGNAME	ZT-1
D05REB	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1

D0AJ9V	TTDDRUID	D0AJ9V
D0AJ9V	DRUGNAME	ZW25
D0AJ9V	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D0AJ9V	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1

D0D3UI	TTDDRUID	D0D3UI
D0D3UI	DRUGNAME	ZY01
D0D3UI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D0D3UI	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D0BA5E	TTDDRUID	D0BA5E
D0BA5E	DRUGNAME	ZYDPLA 1
D0BA5E	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0M0UU	TTDDRUID	D0M0UU
D0M0UU	DRUGNAME	ZYGK-1
D0M0UU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D0A0FB	TTDDRUID	D0A0FB
D0A0FB	DRUGNAME	ZYOG1
D0A0FB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1

D05DCL	TTDDRUID	D05DCL
D05DCL	DRUGNAME	ZYT-1
D05DCL	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1

D0M8KY	TTDDRUID	D0M8KY
D0M8KY	DRUGNAME	(S)-DRF-1042
D0M8KY	INDICATI	Bladder cancer [ICD-11: 2C94] Clinical trial

D05TKW	TTDDRUID	D05TKW
D05TKW	DRUGNAME	alpha-ketothiazole analogue 36
D05TKW	INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial

D0Z4XI	TTDDRUID	D0Z4XI
D0Z4XI	DRUGNAME	Anti-depressant medicine
D0Z4XI	INDICATI	Depression [ICD-11: 6A70-6A7Z] Clinical trial

D00XKB	TTDDRUID	D00XKB
D00XKB	DRUGNAME	AZ-4217
D00XKB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Clinical trial

D08QWQ	TTDDRUID	D08QWQ
D08QWQ	DRUGNAME	bimatoprost (free acid form)
D08QWQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial

D0PK7J	TTDDRUID	D0PK7J
D0PK7J	DRUGNAME	bis-triazole derivative 10
D0PK7J	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Clinical trial

D0E6EF	TTDDRUID	D0E6EF
D0E6EF	DRUGNAME	BMS-986192
D0E6EF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial

D0SW1D	TTDDRUID	D0SW1D
D0SW1D	DRUGNAME	Cellspan esophageal implant
D0SW1D	INDICATI	Esophageal cancer [ICD-11: 2B70] Clinical trial

D05CMT	TTDDRUID	D05CMT
D05CMT	DRUGNAME	COMBO Stent
D05CMT	INDICATI	Coronary artery disease [ICD-11: BA80] Clinical trial

D0I2FI	TTDDRUID	D0I2FI
D0I2FI	DRUGNAME	dequalinium
D0I2FI	INDICATI	Myelopathy [ICD-11: 8B42] Clinical trial

D0Y9FX	TTDDRUID	D0Y9FX
D0Y9FX	DRUGNAME	example 7 [US8664233]
D0Y9FX	INDICATI	Bladder cancer [ICD-11: 2C94] Clinical trial

D0O7HP	TTDDRUID	D0O7HP
D0O7HP	DRUGNAME	example 98 (WO2011020806)
D0O7HP	INDICATI	Focal segmental glomerulosclerosis [ICD-11: MF8Y] Clinical trial

D0GR6I	TTDDRUID	D0GR6I
D0GR6I	DRUGNAME	Ganitumab
D0GR6I	INDICATI	Ewing sarcoma [ICD-11: 2B52] Clinical trial

D05EMV	TTDDRUID	D05EMV
D05EMV	DRUGNAME	GR148672X
D05EMV	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial

D02NHW	TTDDRUID	D02NHW
D02NHW	DRUGNAME	GSK-264220A
D02NHW	INDICATI	Coagulation defect [ICD-11: 3B10.0] Clinical trial

D02ZQS	TTDDRUID	D02ZQS
D02ZQS	DRUGNAME	GSK269962A
D02ZQS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Clinical trial

D0J3SU	TTDDRUID	D0J3SU
D0J3SU	DRUGNAME	isatin sulfonamide 34
D0J3SU	INDICATI	Cystic fibrosis [ICD-11: CA25] Clinical trial

D07QTG	TTDDRUID	D07QTG
D07QTG	DRUGNAME	JNJ-479655
D07QTG	INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial

D0X6QL	TTDDRUID	D0X6QL
D0X6QL	DRUGNAME	KGP94
D0X6QL	INDICATI	Coagulation defect [ICD-11: 3B10.0] Clinical trial

D0LB0X	TTDDRUID	D0LB0X
D0LB0X	DRUGNAME	KH064
D0LB0X	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Clinical trial

D0FY9P	TTDDRUID	D0FY9P
D0FY9P	DRUGNAME	KPAX002
D0FY9P	INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial
D0FY9P	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Clinical trial
D0FY9P	INDICATI	Parkinson disease [ICD-11: 8A00.0] Clinical trial

D02NUT	TTDDRUID	D02NUT
D02NUT	DRUGNAME	KU-60019
D02NUT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial

D0L4VI	TTDDRUID	D0L4VI
D0L4VI	DRUGNAME	L-cysteine
D0L4VI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial

D0I8HJ	TTDDRUID	D0I8HJ
D0I8HJ	DRUGNAME	lormetazepam
D0I8HJ	INDICATI	Nasal polyp [ICD-11: CA0J] Clinical trial

D0R7EA	TTDDRUID	D0R7EA
D0R7EA	DRUGNAME	methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate
D0R7EA	INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial

D0M9RQ	TTDDRUID	D0M9RQ
D0M9RQ	DRUGNAME	MK-0249
D0M9RQ	INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Clinical trial

D0V0WE	TTDDRUID	D0V0WE
D0V0WE	DRUGNAME	NIA-114
D0V0WE	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Clinical trial

D00HHV	TTDDRUID	D00HHV
D00HHV	DRUGNAME	Nicotine transmucosal
D00HHV	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Clinical trial

D0QA3C	TTDDRUID	D0QA3C
D0QA3C	DRUGNAME	OMB157
D0QA3C	INDICATI	Multiple sclerosis [ICD-11: 8A40] Clinical trial

D0CG8S	TTDDRUID	D0CG8S
D0CG8S	DRUGNAME	oxazine 89
D0CG8S	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Clinical trial

D0Y4LI	TTDDRUID	D0Y4LI
D0Y4LI	DRUGNAME	PF-4708671
D0Y4LI	INDICATI	Ulcerative colitis [ICD-11: DD71] Clinical trial

D00HTY	TTDDRUID	D00HTY
D00HTY	DRUGNAME	PGF2alpha
D00HTY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial

D0FE7H	TTDDRUID	D0FE7H
D0FE7H	DRUGNAME	PMID10498202C1
D0FE7H	INDICATI	Multiple sclerosis [ICD-11: 8A40] Clinical trial

D0A8UP	TTDDRUID	D0A8UP
D0A8UP	DRUGNAME	PMID15026062C41
D0A8UP	INDICATI	Pancreatitis [ICD-11: DC31-DC34] Clinical trial

D0A4RF	TTDDRUID	D0A4RF
D0A4RF	DRUGNAME	PMID17935984C1
D0A4RF	INDICATI	Pain [ICD-11: MG30-MG3Z] Clinical trial

D00EPS	TTDDRUID	D00EPS
D00EPS	DRUGNAME	PMID18163548C4
D00EPS	INDICATI	Myocardial ischemia [ICD-11: BA6Z] Clinical trial
D00EPS	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Clinical trial

D0T7BV	TTDDRUID	D0T7BV
D0T7BV	DRUGNAME	PMID22911925C2
D0T7BV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Clinical trial

D0H6AG	TTDDRUID	D0H6AG
D0H6AG	DRUGNAME	PMID23981898C11d 
D0H6AG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Clinical trial

D0U3WO	TTDDRUID	D0U3WO
D0U3WO	DRUGNAME	RTA 408
D0U3WO	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Clinical trial

D0Q6NN	TTDDRUID	D0Q6NN
D0Q6NN	DRUGNAME	TAK-070
D0Q6NN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial

D0S6TK	TTDDRUID	D0S6TK
D0S6TK	DRUGNAME	tamatinib
D0S6TK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial

D0J6XC	TTDDRUID	D0J6XC
D0J6XC	DRUGNAME	tiratricol
D0J6XC	INDICATI	Wound healing [ICD-11: EL8Y] Clinical trial

D06ENM	TTDDRUID	D06ENM
D06ENM	DRUGNAME	TRV130
D06ENM	INDICATI	Thyroid disease [ICD-11: 5A00-5A06] Clinical trial

D0G0YZ	TTDDRUID	D0G0YZ
D0G0YZ	DRUGNAME	UK-356202
D0G0YZ	INDICATI	Myocardial hypertrophy [ICD-11: BC45] Clinical trial

D03JRG	TTDDRUID	D03JRG
D03JRG	DRUGNAME	VU0364739
D03JRG	INDICATI	Coagulation defect [ICD-11: 3B10.0] Clinical trial

D0S3RX	TTDDRUID	D0S3RX
D0S3RX	DRUGNAME	1,2,3-triazole derivative 1
D0S3RX	INDICATI	Obesity [ICD-11: 5B81] Patented

D0FS0D	TTDDRUID	D0FS0D
D0FS0D	DRUGNAME	1,2,3-triazole derivative 2
D0FS0D	INDICATI	Obesity [ICD-11: 5B81] Patented

D0KX2W	TTDDRUID	D0KX2W
D0KX2W	DRUGNAME	1,2,4,5-tetra-substituted imidazole derivative 1
D0KX2W	INDICATI	Obesity [ICD-11: 5B81] Patented

D0TI3Q	TTDDRUID	D0TI3Q
D0TI3Q	DRUGNAME	1,2,4,5-tetra-substituted imidazole derivative 2
D0TI3Q	INDICATI	Obesity [ICD-11: 5B81] Patented

D0V1HO	TTDDRUID	D0V1HO
D0V1HO	DRUGNAME	1,2,4-oxadiazole and thiadiazole derivative 1
D0V1HO	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0V1HO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0V1HO	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0V1HO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0MZ4V	TTDDRUID	D0MZ4V
D0MZ4V	DRUGNAME	1,2,4-oxadiazole derivative 1
D0MZ4V	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0MZ4V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0MZ4V	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0MZ4V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03PSA	TTDDRUID	D03PSA
D03PSA	DRUGNAME	1,2,4-oxadiazole derivative 2
D03PSA	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D03PSA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D03PSA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D03PSA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08UFI	TTDDRUID	D08UFI
D08UFI	DRUGNAME	1,2,4-oxadiazole derivative 3
D08UFI	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D08UFI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D08UFI	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D08UFI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0EY9S	TTDDRUID	D0EY9S
D0EY9S	DRUGNAME	1,2,4-oxadiazole derivative 4
D0EY9S	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0EY9S	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0EY9S	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0EY9S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0HE8M	TTDDRUID	D0HE8M
D0HE8M	DRUGNAME	1,2,4-oxadiazole derivative 5
D0HE8M	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0HE8M	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0HE8M	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0HE8M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0X5IV	TTDDRUID	D0X5IV
D0X5IV	DRUGNAME	1,2,4-oxadiazole derivative 6
D0X5IV	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0X5IV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0X5IV	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0X5IV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0W0PC	TTDDRUID	D0W0PC
D0W0PC	DRUGNAME	1,2,4-oxadiazole derivative 7
D0W0PC	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0W0PC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0W0PC	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0W0PC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0NM6O	TTDDRUID	D0NM6O
D0NM6O	DRUGNAME	1,2,4-oxadiazole derivative 8
D0NM6O	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0NM6O	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0NM6O	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0NM6O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02NNZ	TTDDRUID	D02NNZ
D02NNZ	DRUGNAME	1,2,4-triazole derivative 1
D02NNZ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0TT0B	TTDDRUID	D0TT0B
D0TT0B	DRUGNAME	1,2,4-triazole derivative 2
D0TT0B	INDICATI	Obesity [ICD-11: 5B81] Patented

D04QVK	TTDDRUID	D04QVK
D04QVK	DRUGNAME	1,2,4-tri-substituted imidazoline derivative 1
D04QVK	INDICATI	Obesity [ICD-11: 5B81] Patented

D0PJ7M	TTDDRUID	D0PJ7M
D0PJ7M	DRUGNAME	1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1
D0PJ7M	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0PJ7M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0X1CK	TTDDRUID	D0X1CK
D0X1CK	DRUGNAME	1,3,4-oxadiazole and thiadiazole compound 1
D0X1CK	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0X1CK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0X1CK	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0X1CK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0H9FH	TTDDRUID	D0H9FH
D0H9FH	DRUGNAME	1,3,4-oxadiazole and thiadiazole compound 2
D0H9FH	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0H9FH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0H9FH	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0H9FH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0FN3C	TTDDRUID	D0FN3C
D0FN3C	DRUGNAME	1,3,4-oxadiazole and thiadiazole compound 3
D0FN3C	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0FN3C	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0FN3C	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0FN3C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0SY5L	TTDDRUID	D0SY5L
D0SY5L	DRUGNAME	1,3,4-oxadiazole and thiadiazole compound 4
D0SY5L	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0SY5L	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0SY5L	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0SY5L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0LM6D	TTDDRUID	D0LM6D
D0LM6D	DRUGNAME	1,3,4-oxadiazole derivative 1
D0LM6D	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0LM6D	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0LM6D	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0LM6D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0P3EG	TTDDRUID	D0P3EG
D0P3EG	DRUGNAME	1,3,4-oxadiazole derivative 2
D0P3EG	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0P3EG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0P3EG	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0P3EG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0YK8M	TTDDRUID	D0YK8M
D0YK8M	DRUGNAME	1,3,4-oxadiazole derivative 3
D0YK8M	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0YK8M	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0YK8M	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0YK8M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0H6AL	TTDDRUID	D0H6AL
D0H6AL	DRUGNAME	1,3,4-oxadiazole derivative 4
D0H6AL	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0H6AL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0H6AL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0H6AL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0H0MO	TTDDRUID	D0H0MO
D0H0MO	DRUGNAME	1,3,4-oxadiazole derivative 5
D0H0MO	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0H0MO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0H0MO	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0H0MO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Z0KL	TTDDRUID	D0Z0KL
D0Z0KL	DRUGNAME	1,3,4-oxadiazole derivative 6
D0Z0KL	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0Z0KL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0Z0KL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0Z0KL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0I0JE	TTDDRUID	D0I0JE
D0I0JE	DRUGNAME	1,3,4-thiadiazole derivative 1
D0I0JE	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0I0JE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0I0JE	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0I0JE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0N6NA	TTDDRUID	D0N6NA
D0N6NA	DRUGNAME	1,3,4-thiadiazole derivative 2
D0N6NA	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0N6NA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0N6NA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0N6NA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0O8FI	TTDDRUID	D0O8FI
D0O8FI	DRUGNAME	1,3-dihydroxy phenyl derivative 1
D0O8FI	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0O8FI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0O8FI	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0O8FI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0XV7Y	TTDDRUID	D0XV7Y
D0XV7Y	DRUGNAME	1,3-dihydroxy phenyl derivative 2
D0XV7Y	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0XV7Y	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0XV7Y	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0XV7Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0GF9M	TTDDRUID	D0GF9M
D0GF9M	DRUGNAME	1,3-dihydroxy phenyl derivative 3
D0GF9M	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0GF9M	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0GF9M	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0GF9M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0VB2M	TTDDRUID	D0VB2M
D0VB2M	DRUGNAME	1,5-diphenylpyrrolidin-2-one derivative 1
D0VB2M	INDICATI	Obesity [ICD-11: 5B81] Patented

D09XUI	TTDDRUID	D09XUI
D09XUI	DRUGNAME	1,5-diphenylpyrrolidin-2-one derivative 2
D09XUI	INDICATI	Obesity [ICD-11: 5B81] Patented

D05UGL	TTDDRUID	D05UGL
D05UGL	DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1
D05UGL	INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
D05UGL	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented

D0J2VS	TTDDRUID	D0J2VS
D0J2VS	DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2
D0J2VS	INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
D0J2VS	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented

D00THJ	TTDDRUID	D00THJ
D00THJ	DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3
D00THJ	INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
D00THJ	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented

D06YEK	TTDDRUID	D06YEK
D06YEK	DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4
D06YEK	INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
D06YEK	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented

D0TD9H	TTDDRUID	D0TD9H
D0TD9H	DRUGNAME	2-acetic acid derivative 1
D0TD9H	INDICATI	Brain injury [ICD-11: NA07.Z] Patented
D0TD9H	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0TD9H	INDICATI	Huntington disease [ICD-11: 8A01.10] Patented
D0TD9H	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
D0TD9H	INDICATI	Spinocerebellar ataxia [ICD-11: 8A03.16] Patented

D0Z1LJ	TTDDRUID	D0Z1LJ
D0Z1LJ	DRUGNAME	3-(phenoxymethyl) benzylamine derivative 1
D0Z1LJ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0Z1LJ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0Z1LJ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0Z1LJ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0Z1LJ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0VY9O	TTDDRUID	D0VY9O
D0VY9O	DRUGNAME	3-(phenoxymethyl) benzylamine derivative 2
D0VY9O	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0VY9O	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0VY9O	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0VY9O	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0VY9O	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0XO4I	TTDDRUID	D0XO4I
D0XO4I	DRUGNAME	3-(phenoxymethyl) benzylamine derivative 3
D0XO4I	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0XO4I	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0XO4I	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0XO4I	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0XO4I	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0MA7A	TTDDRUID	D0MA7A
D0MA7A	DRUGNAME	3-(phenoxymethyl) benzylamine derivative 4
D0MA7A	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0MA7A	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0MA7A	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0MA7A	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0MA7A	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0CP6B	TTDDRUID	D0CP6B
D0CP6B	DRUGNAME	3-(phenoxymethyl) benzylamine derivative 5
D0CP6B	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0CP6B	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0CP6B	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0CP6B	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0CP6B	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0Q1NF	TTDDRUID	D0Q1NF
D0Q1NF	DRUGNAME	3-(phenoxymethyl) benzylamine derivative 6
D0Q1NF	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0Q1NF	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0Q1NF	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0Q1NF	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0Q1NF	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0AU4G	TTDDRUID	D0AU4G
D0AU4G	DRUGNAME	3-amino-5-benzyl-substituted indazole derivative 1
D0AU4G	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0AU4G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0AU4G	INDICATI	Pruritus [ICD-11: EC90] Patented
D0AU4G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0AU4G	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D09WPL	TTDDRUID	D09WPL
D09WPL	DRUGNAME	3-hetaryl-substituted pyrrolo[2,3-b]pyridine derivative 1
D09WPL	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D09WPL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D01SHF	TTDDRUID	D01SHF
D01SHF	DRUGNAME	3-hetaryl-substituted pyrrolo[2,3-b]pyridine derivative 2
D01SHF	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D01SHF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0T1GG	TTDDRUID	D0T1GG
D0T1GG	DRUGNAME	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1
D0T1GG	INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
D0T1GG	INDICATI	Cell proliferative disorder [ICD-11: FB86] Patented
D0T1GG	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Patented

D06PRB	TTDDRUID	D06PRB
D06PRB	DRUGNAME	3-substituted-1,2,4-oxadiazole and thiadiazol derivative 1
D06PRB	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D06PRB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D06PRB	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D06PRB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Z4QT	TTDDRUID	D0Z4QT
D0Z4QT	DRUGNAME	3-substituted-1,2,4-oxadiazole derivative 1
D0Z4QT	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0Z4QT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0Z4QT	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0Z4QT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0MG6V	TTDDRUID	D0MG6V
D0MG6V	DRUGNAME	3-substituted-1,2,4-oxadiazole derivative 2
D0MG6V	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0MG6V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0MG6V	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0MG6V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03WCJ	TTDDRUID	D03WCJ
D03WCJ	DRUGNAME	4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1
D03WCJ	INDICATI	Obesity [ICD-11: 5B81] Patented

D07AVV	TTDDRUID	D07AVV
D07AVV	DRUGNAME	Ac-YVAD-cmk
D07AVV	INDICATI	Allergic contact dermatitis [ICD-11: EK00] Patented
D07AVV	INDICATI	Irritant contact dermatitis [ICD-11: EK02] Patented
D07AVV	INDICATI	Photocontact dermatitis [ICD-11: EK20] Patented

D04KIH	TTDDRUID	D04KIH
D04KIH	DRUGNAME	Ac-YVAD-FMK
D04KIH	INDICATI	Allergic contact dermatitis [ICD-11: EK00] Patented
D04KIH	INDICATI	Irritant contact dermatitis [ICD-11: EK02] Patented
D04KIH	INDICATI	Photocontact dermatitis [ICD-11: EK20] Patented

D0VA1D	TTDDRUID	D0VA1D
D0VA1D	DRUGNAME	Alkyl mannoside derivative 1
D0VA1D	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0VA1D	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0VA1D	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0DI6U	TTDDRUID	D0DI6U
D0DI6U	DRUGNAME	Alkyl mannoside derivative 10
D0DI6U	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0DI6U	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0DI6U	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0E3DS	TTDDRUID	D0E3DS
D0E3DS	DRUGNAME	Alkyl mannoside derivative 11
D0E3DS	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0E3DS	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0E3DS	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07POS	TTDDRUID	D07POS
D07POS	DRUGNAME	Alkyl mannoside derivative 12
D07POS	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07POS	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07POS	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Z6PF	TTDDRUID	D0Z6PF
D0Z6PF	DRUGNAME	Alkyl mannoside derivative 2
D0Z6PF	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Z6PF	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Z6PF	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0SE7V	TTDDRUID	D0SE7V
D0SE7V	DRUGNAME	Alkyl mannoside derivative 3
D0SE7V	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0SE7V	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0SE7V	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0L1PO	TTDDRUID	D0L1PO
D0L1PO	DRUGNAME	Alkyl mannoside derivative 4
D0L1PO	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0L1PO	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0L1PO	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0MO0Z	TTDDRUID	D0MO0Z
D0MO0Z	DRUGNAME	Alkyl mannoside derivative 5
D0MO0Z	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0MO0Z	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0MO0Z	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0UB8U	TTDDRUID	D0UB8U
D0UB8U	DRUGNAME	Alkyl mannoside derivative 6
D0UB8U	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0UB8U	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0UB8U	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0D6OM	TTDDRUID	D0D6OM
D0D6OM	DRUGNAME	Alkyl mannoside derivative 7
D0D6OM	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0D6OM	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0D6OM	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07RQA	TTDDRUID	D07RQA
D07RQA	DRUGNAME	Alkyl mannoside derivative 8
D07RQA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07RQA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07RQA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07HOP	TTDDRUID	D07HOP
D07HOP	DRUGNAME	Alkyl mannoside derivative 9
D07HOP	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07HOP	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07HOP	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0JW7T	TTDDRUID	D0JW7T
D0JW7T	DRUGNAME	Amide derivative 1
D0JW7T	INDICATI	Obesity [ICD-11: 5B81] Patented

D0VN2U	TTDDRUID	D0VN2U
D0VN2U	DRUGNAME	Amidine compound 1
D0VN2U	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented

D0WH1K	TTDDRUID	D0WH1K
D0WH1K	DRUGNAME	Amidine compound 2
D0WH1K	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented

D07HJT	TTDDRUID	D07HJT
D07HJT	DRUGNAME	Amidine compound 3
D07HJT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented

D0AK6L	TTDDRUID	D0AK6L
D0AK6L	DRUGNAME	Amidine compound 4
D0AK6L	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented

D0JT0B	TTDDRUID	D0JT0B
D0JT0B	DRUGNAME	Amidine compound 5
D0JT0B	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented

D0G2EP	TTDDRUID	D0G2EP
D0G2EP	DRUGNAME	Amidine compound 6
D0G2EP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented

D01HJQ	TTDDRUID	D01HJQ
D01HJQ	DRUGNAME	Aminoazetidine derivative 1
D01HJQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D02OBW	TTDDRUID	D02OBW
D02OBW	DRUGNAME	Aminoazetidine derivative 2
D02OBW	INDICATI	Obesity [ICD-11: 5B81] Patented

D0VL5E	TTDDRUID	D0VL5E
D0VL5E	DRUGNAME	Aminoazetidine derivative 3
D0VL5E	INDICATI	Obesity [ICD-11: 5B81] Patented

D0J8GO	TTDDRUID	D0J8GO
D0J8GO	DRUGNAME	Aminoazetidine derivative 4
D0J8GO	INDICATI	Obesity [ICD-11: 5B81] Patented

D0T8VE	TTDDRUID	D0T8VE
D0T8VE	DRUGNAME	Aminoazetidine derivative 5
D0T8VE	INDICATI	Obesity [ICD-11: 5B81] Patented

D03UIS	TTDDRUID	D03UIS
D03UIS	DRUGNAME	Aminoazetidine derivative 6
D03UIS	INDICATI	Obesity [ICD-11: 5B81] Patented

D0C0KI	TTDDRUID	D0C0KI
D0C0KI	DRUGNAME	Aminoazetidine derivative 7
D0C0KI	INDICATI	Obesity [ICD-11: 5B81] Patented

D0LX2Y	TTDDRUID	D0LX2Y
D0LX2Y	DRUGNAME	Aminoazetidine derivative 8
D0LX2Y	INDICATI	Obesity [ICD-11: 5B81] Patented

D0U3VU	TTDDRUID	D0U3VU
D0U3VU	DRUGNAME	Aminoazetidine derivative 9
D0U3VU	INDICATI	Obesity [ICD-11: 5B81] Patented

D01AXK	TTDDRUID	D01AXK
D01AXK	DRUGNAME	Antibodie derivative 10
D01AXK	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
D01AXK	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Patented

D0CE1R	TTDDRUID	D0CE1R
D0CE1R	DRUGNAME	Antibodie derivative 7
D0CE1R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0WL5P	TTDDRUID	D0WL5P
D0WL5P	DRUGNAME	Antibodie derivative 9
D0WL5P	INDICATI	Carotid artery disease [ICD-11: 8B10] Patented
D0WL5P	INDICATI	Corneal neovascularization [ICD-11: 9A78] Patented
D0WL5P	INDICATI	Macular degeneration [ICD-11: 9B78.3] Patented
D0WL5P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0A3MV	TTDDRUID	D0A3MV
D0A3MV	DRUGNAME	AR-A014418
D0A3MV	INDICATI	Ovarian cancer [ICD-11: 2C73] Patented

D0RK4V	TTDDRUID	D0RK4V
D0RK4V	DRUGNAME	Aromatic acetylene derivative 1
D0RK4V	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0RK4V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0RK4V	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0RK4V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0OP0O	TTDDRUID	D0OP0O
D0OP0O	DRUGNAME	Aromatic acetylene derivative 2
D0OP0O	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0OP0O	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0OP0O	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0OP0O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0A5OT	TTDDRUID	D0A5OT
D0A5OT	DRUGNAME	Aromatic ethylene derivative 1
D0A5OT	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0A5OT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0A5OT	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0A5OT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07DFC	TTDDRUID	D07DFC
D07DFC	DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 1
D07DFC	INDICATI	Albinism [ICD-11: EC23.2] Patented
D07DFC	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D07DFC	INDICATI	Melasma [ICD-11: ED60.1] Patented
D07DFC	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D07DFC	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0UT0X	TTDDRUID	D0UT0X
D0UT0X	DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 2
D0UT0X	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0UT0X	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0UT0X	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0UT0X	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0UT0X	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0P0PT	TTDDRUID	D0P0PT
D0P0PT	DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 3
D0P0PT	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0P0PT	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0P0PT	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0P0PT	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0P0PT	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D05XAH	TTDDRUID	D05XAH
D05XAH	DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 4
D05XAH	INDICATI	Albinism [ICD-11: EC23.2] Patented
D05XAH	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D05XAH	INDICATI	Melasma [ICD-11: ED60.1] Patented
D05XAH	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D05XAH	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03BRP	TTDDRUID	D03BRP
D03BRP	DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 5
D03BRP	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03BRP	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03BRP	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03BRP	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03BRP	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D02EGY	TTDDRUID	D02EGY
D02EGY	DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 6
D02EGY	INDICATI	Albinism [ICD-11: EC23.2] Patented
D02EGY	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D02EGY	INDICATI	Melasma [ICD-11: ED60.1] Patented
D02EGY	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D02EGY	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D09BGB	TTDDRUID	D09BGB
D09BGB	DRUGNAME	Aryl mannoside derivative 1
D09BGB	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09BGB	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09BGB	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0R6FO	TTDDRUID	D0R6FO
D0R6FO	DRUGNAME	Aryl mannoside derivative 10
D0R6FO	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0R6FO	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0R6FO	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0SD4Q	TTDDRUID	D0SD4Q
D0SD4Q	DRUGNAME	Aryl mannoside derivative 11
D0SD4Q	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0SD4Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0SD4Q	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0DH0Y	TTDDRUID	D0DH0Y
D0DH0Y	DRUGNAME	Aryl mannoside derivative 12
D0DH0Y	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0DH0Y	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0DH0Y	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D09SLI	TTDDRUID	D09SLI
D09SLI	DRUGNAME	Aryl mannoside derivative 13
D09SLI	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09SLI	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09SLI	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0B8RU	TTDDRUID	D0B8RU
D0B8RU	DRUGNAME	Aryl mannoside derivative 14
D0B8RU	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0B8RU	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0B8RU	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0AM0A	TTDDRUID	D0AM0A
D0AM0A	DRUGNAME	Aryl mannoside derivative 15
D0AM0A	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0AM0A	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0AM0A	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0R1GD	TTDDRUID	D0R1GD
D0R1GD	DRUGNAME	Aryl mannoside derivative 16
D0R1GD	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0R1GD	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0R1GD	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0D9MV	TTDDRUID	D0D9MV
D0D9MV	DRUGNAME	Aryl mannoside derivative 17
D0D9MV	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0D9MV	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0D9MV	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0WW9B	TTDDRUID	D0WW9B
D0WW9B	DRUGNAME	Aryl mannoside derivative 18
D0WW9B	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0WW9B	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0WW9B	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02WWT	TTDDRUID	D02WWT
D02WWT	DRUGNAME	Aryl mannoside derivative 19
D02WWT	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02WWT	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02WWT	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0G9KS	TTDDRUID	D0G9KS
D0G9KS	DRUGNAME	Aryl mannoside derivative 2
D0G9KS	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0G9KS	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0G9KS	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0T7VN	TTDDRUID	D0T7VN
D0T7VN	DRUGNAME	Aryl mannoside derivative 20
D0T7VN	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0T7VN	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0T7VN	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07PVX	TTDDRUID	D07PVX
D07PVX	DRUGNAME	Aryl mannoside derivative 21
D07PVX	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07PVX	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07PVX	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07KCA	TTDDRUID	D07KCA
D07KCA	DRUGNAME	Aryl mannoside derivative 22
D07KCA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07KCA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07KCA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D08BLZ	TTDDRUID	D08BLZ
D08BLZ	DRUGNAME	Aryl mannoside derivative 23
D08BLZ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D08BLZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D08BLZ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0FT4P	TTDDRUID	D0FT4P
D0FT4P	DRUGNAME	Aryl mannoside derivative 3
D0FT4P	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0FT4P	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0FT4P	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03ITZ	TTDDRUID	D03ITZ
D03ITZ	DRUGNAME	Aryl mannoside derivative 4
D03ITZ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03ITZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03ITZ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D06SWT	TTDDRUID	D06SWT
D06SWT	DRUGNAME	Aryl mannoside derivative 5
D06SWT	INDICATI	Crohn disease [ICD-11: DD70] Patented
D06SWT	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D06SWT	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0KX1A	TTDDRUID	D0KX1A
D0KX1A	DRUGNAME	Aryl mannoside derivative 6
D0KX1A	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0KX1A	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0KX1A	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Y0SI	TTDDRUID	D0Y0SI
D0Y0SI	DRUGNAME	Aryl mannoside derivative 7
D0Y0SI	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Y0SI	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Y0SI	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0L3JL	TTDDRUID	D0L3JL
D0L3JL	DRUGNAME	Aryl mannoside derivative 8
D0L3JL	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0L3JL	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0L3JL	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0VB4T	TTDDRUID	D0VB4T
D0VB4T	DRUGNAME	Aryl mannoside derivative 9
D0VB4T	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0VB4T	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0VB4T	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Y1NH	TTDDRUID	D0Y1NH
D0Y1NH	DRUGNAME	Azaindazole amide derivative 1
D0Y1NH	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0Y1NH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0Y1NH	INDICATI	Pruritus [ICD-11: EC90] Patented
D0Y1NH	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0I5SD	TTDDRUID	D0I5SD
D0I5SD	DRUGNAME	Azetidine derivative 1
D0I5SD	INDICATI	Obesity [ICD-11: 5B81] Patented

D0P7LP	TTDDRUID	D0P7LP
D0P7LP	DRUGNAME	Azetidine derivative 3
D0P7LP	INDICATI	Obesity [ICD-11: 5B81] Patented

D0RC5I	TTDDRUID	D0RC5I
D0RC5I	DRUGNAME	Azetidine derivative 4
D0RC5I	INDICATI	Obesity [ICD-11: 5B81] Patented

D0DF6B	TTDDRUID	D0DF6B
D0DF6B	DRUGNAME	Azetidine-1-carboxamide derivative 1
D0DF6B	INDICATI	Obesity [ICD-11: 5B81] Patented

D0ZE8B	TTDDRUID	D0ZE8B
D0ZE8B	DRUGNAME	Azetidine-1-carboxamide derivative 2
D0ZE8B	INDICATI	Obesity [ICD-11: 5B81] Patented

D00TMQ	TTDDRUID	D00TMQ
D00TMQ	DRUGNAME	Azetidine-1-carboxamide derivative 3
D00TMQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D03TFJ	TTDDRUID	D03TFJ
D03TFJ	DRUGNAME	Benzimidazole
D03TFJ	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D06WAN	TTDDRUID	D06WAN
D06WAN	DRUGNAME	Benzimidazole and imidazopyridine derivative 1
D06WAN	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06WAN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0V5BV	TTDDRUID	D0V5BV
D0V5BV	DRUGNAME	Benzimidazole derivative 1
D0V5BV	INDICATI	Obesity [ICD-11: 5B81] Patented

D0K6GI	TTDDRUID	D0K6GI
D0K6GI	DRUGNAME	Benzimidazole derivative 2
D0K6GI	INDICATI	Obesity [ICD-11: 5B81] Patented

D00JQA	TTDDRUID	D00JQA
D00JQA	DRUGNAME	Benzimidazole derivative 3
D00JQA	INDICATI	Albinism [ICD-11: EC23.2] Patented
D00JQA	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D00JQA	INDICATI	Melasma [ICD-11: ED60.1] Patented
D00JQA	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D00JQA	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0MT3J	TTDDRUID	D0MT3J
D0MT3J	DRUGNAME	Benzimidazole derivative 4
D0MT3J	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0MT3J	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0MT3J	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0MT3J	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0MT3J	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0T3TZ	TTDDRUID	D0T3TZ
D0T3TZ	DRUGNAME	Benzimidazole derivative 6
D0T3TZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0QC9I	TTDDRUID	D0QC9I
D0QC9I	DRUGNAME	Benzoic acid linked peptide analog 1
D0QC9I	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0QC9I	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0QC9I	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0QC9I	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0QC9I	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0F0VF	TTDDRUID	D0F0VF
D0F0VF	DRUGNAME	Benzoic acid linked peptide analog 2
D0F0VF	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0F0VF	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0F0VF	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0F0VF	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0F0VF	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0CI2U	TTDDRUID	D0CI2U
D0CI2U	DRUGNAME	Benzoic acid linked peptide analog 3
D0CI2U	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0CI2U	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0CI2U	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0CI2U	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0CI2U	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D08OJB	TTDDRUID	D08OJB
D08OJB	DRUGNAME	Benzoic acid linked peptide analog 4
D08OJB	INDICATI	Albinism [ICD-11: EC23.2] Patented
D08OJB	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D08OJB	INDICATI	Melasma [ICD-11: ED60.1] Patented
D08OJB	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D08OJB	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0X4EC	TTDDRUID	D0X4EC
D0X4EC	DRUGNAME	Benzoic acid linked peptide analog 5
D0X4EC	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0X4EC	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0X4EC	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0X4EC	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0X4EC	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0AG7M	TTDDRUID	D0AG7M
D0AG7M	DRUGNAME	Benzoic acid linked peptide analog 6
D0AG7M	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0AG7M	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0AG7M	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0AG7M	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0AG7M	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0U3IS	TTDDRUID	D0U3IS
D0U3IS	DRUGNAME	Benzonaphthyridine derivative 1
D0U3IS	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0U3IS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0IR8B	TTDDRUID	D0IR8B
D0IR8B	DRUGNAME	Benzonaphthyridine derivative 2
D0IR8B	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0IR8B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0P7UB	TTDDRUID	D0P7UB
D0P7UB	DRUGNAME	Benzothiazine-carboxamide compound 1
D0P7UB	INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented

D06XWQ	TTDDRUID	D06XWQ
D06XWQ	DRUGNAME	Benzothiazine-carboxamide compound 2
D06XWQ	INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented

D0K9QH	TTDDRUID	D0K9QH
D0K9QH	DRUGNAME	Benzothiazine-carboxamide compound 3
D0K9QH	INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented

D07OVM	TTDDRUID	D07OVM
D07OVM	DRUGNAME	Benzothiazine-carboxamide compound 4
D07OVM	INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented

D0Q8MQ	TTDDRUID	D0Q8MQ
D0Q8MQ	DRUGNAME	Benzothiazine-carboxamide compound 5
D0Q8MQ	INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented

D0H4SE	TTDDRUID	D0H4SE
D0H4SE	DRUGNAME	Benzothiazine-carboxamide compound 6
D0H4SE	INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented

D00DYI	TTDDRUID	D00DYI
D00DYI	DRUGNAME	Benzothiazole analog 1
D00DYI	INDICATI	Albinism [ICD-11: EC23.2] Patented
D00DYI	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D00DYI	INDICATI	Melasma [ICD-11: ED60.1] Patented
D00DYI	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D00DYI	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0WT1C	TTDDRUID	D0WT1C
D0WT1C	DRUGNAME	Benzothiazole analog 2
D0WT1C	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0WT1C	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0WT1C	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0WT1C	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0WT1C	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03PLQ	TTDDRUID	D03PLQ
D03PLQ	DRUGNAME	Benzothiazole analog 3
D03PLQ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03PLQ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03PLQ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03PLQ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03PLQ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0AE8D	TTDDRUID	D0AE8D
D0AE8D	DRUGNAME	Benzothiazole analog 4
D0AE8D	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0AE8D	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0AE8D	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0AE8D	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0AE8D	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0Z0DX	TTDDRUID	D0Z0DX
D0Z0DX	DRUGNAME	Benzothiazole analog 5
D0Z0DX	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0Z0DX	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0Z0DX	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0Z0DX	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0Z0DX	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D01CFL	TTDDRUID	D01CFL
D01CFL	DRUGNAME	Benzothiazoline derivative 1
D01CFL	INDICATI	Albinism [ICD-11: EC23.2] Patented
D01CFL	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D01CFL	INDICATI	Melasma [ICD-11: ED60.1] Patented
D01CFL	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D01CFL	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0Y8TV	TTDDRUID	D0Y8TV
D0Y8TV	DRUGNAME	Benzothienyl pyrimidine derivative 1
D0Y8TV	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented
D0Y8TV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0B2VS	TTDDRUID	D0B2VS
D0B2VS	DRUGNAME	Benzyl phenyl ether derivative 1
D0B2VS	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0B2VS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0B2VS	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0B2VS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0I6RC	TTDDRUID	D0I6RC
D0I6RC	DRUGNAME	Benzyl phenyl ether derivative 2
D0I6RC	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0I6RC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0I6RC	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0I6RC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0AY7Y	TTDDRUID	D0AY7Y
D0AY7Y	DRUGNAME	Benzyl phenyl ether derivative 3
D0AY7Y	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0AY7Y	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0AY7Y	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0AY7Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0M7XB	TTDDRUID	D0M7XB
D0M7XB	DRUGNAME	Beta-cyclodextrin conjugate derivative 1
D0M7XB	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0M7XB	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0M7XB	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0QQ5W	TTDDRUID	D0QQ5W
D0QQ5W	DRUGNAME	Beta-cyclodextrin conjugate derivative 2
D0QQ5W	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0QQ5W	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0QQ5W	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D00XEM	TTDDRUID	D00XEM
D00XEM	DRUGNAME	Beta-cyclodextrin conjugate derivative 3
D00XEM	INDICATI	Crohn disease [ICD-11: DD70] Patented
D00XEM	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D00XEM	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0CD7Q	TTDDRUID	D0CD7Q
D0CD7Q	DRUGNAME	Beta-cyclodextrin conjugate derivative 4
D0CD7Q	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0CD7Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0CD7Q	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0WV9J	TTDDRUID	D0WV9J
D0WV9J	DRUGNAME	Beta-cyclodextrin conjugate derivative 5
D0WV9J	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0WV9J	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0WV9J	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0N7BW	TTDDRUID	D0N7BW
D0N7BW	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1
D0N7BW	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0N7BW	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0N7BW	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0N7BW	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0N7BW	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D09JLP	TTDDRUID	D09JLP
D09JLP	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10
D09JLP	INDICATI	Albinism [ICD-11: EC23.2] Patented
D09JLP	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D09JLP	INDICATI	Melasma [ICD-11: ED60.1] Patented
D09JLP	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D09JLP	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0J0BB	TTDDRUID	D0J0BB
D0J0BB	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11
D0J0BB	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0J0BB	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0J0BB	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0J0BB	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0J0BB	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0HO0I	TTDDRUID	D0HO0I
D0HO0I	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12
D0HO0I	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0HO0I	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0HO0I	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0HO0I	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0HO0I	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D09EFW	TTDDRUID	D09EFW
D09EFW	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13
D09EFW	INDICATI	Albinism [ICD-11: EC23.2] Patented
D09EFW	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D09EFW	INDICATI	Melasma [ICD-11: ED60.1] Patented
D09EFW	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D09EFW	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D07RUH	TTDDRUID	D07RUH
D07RUH	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14
D07RUH	INDICATI	Albinism [ICD-11: EC23.2] Patented
D07RUH	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D07RUH	INDICATI	Melasma [ICD-11: ED60.1] Patented
D07RUH	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D07RUH	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0G7XW	TTDDRUID	D0G7XW
D0G7XW	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2
D0G7XW	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0G7XW	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0G7XW	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0G7XW	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0G7XW	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03NCL	TTDDRUID	D03NCL
D03NCL	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3
D03NCL	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03NCL	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03NCL	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03NCL	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03NCL	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0JR0P	TTDDRUID	D0JR0P
D0JR0P	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4
D0JR0P	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0JR0P	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0JR0P	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0JR0P	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0JR0P	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0K5JG	TTDDRUID	D0K5JG
D0K5JG	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5
D0K5JG	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0K5JG	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0K5JG	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0K5JG	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0K5JG	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D09MHU	TTDDRUID	D09MHU
D09MHU	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6
D09MHU	INDICATI	Albinism [ICD-11: EC23.2] Patented
D09MHU	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D09MHU	INDICATI	Melasma [ICD-11: ED60.1] Patented
D09MHU	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D09MHU	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03PZZ	TTDDRUID	D03PZZ
D03PZZ	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7
D03PZZ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03PZZ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03PZZ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03PZZ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03PZZ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0SJ1U	TTDDRUID	D0SJ1U
D0SJ1U	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8
D0SJ1U	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0SJ1U	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0SJ1U	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0SJ1U	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0SJ1U	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0A8UJ	TTDDRUID	D0A8UJ
D0A8UJ	DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9
D0A8UJ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0A8UJ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0A8UJ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0A8UJ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0A8UJ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0D3RS	TTDDRUID	D0D3RS
D0D3RS	DRUGNAME	Biaryl compound 1
D0D3RS	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0D3RS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0D3RS	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0D3RS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0N5NV	TTDDRUID	D0N5NV
D0N5NV	DRUGNAME	Biaryl compound 2
D0N5NV	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0N5NV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0N5NV	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0N5NV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04XKA	TTDDRUID	D04XKA
D04XKA	DRUGNAME	Biaryl compound 3
D04XKA	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D04XKA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D04XKA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D04XKA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0R1SQ	TTDDRUID	D0R1SQ
D0R1SQ	DRUGNAME	Biaryl mannoside derivative 1
D0R1SQ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0R1SQ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0R1SQ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02DFJ	TTDDRUID	D02DFJ
D02DFJ	DRUGNAME	Biaryl mannoside derivative 10
D02DFJ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02DFJ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02DFJ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0K2AA	TTDDRUID	D0K2AA
D0K2AA	DRUGNAME	Biaryl mannoside derivative 11
D0K2AA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0K2AA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0K2AA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07GAN	TTDDRUID	D07GAN
D07GAN	DRUGNAME	Biaryl mannoside derivative 12
D07GAN	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07GAN	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07GAN	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0FI3Q	TTDDRUID	D0FI3Q
D0FI3Q	DRUGNAME	Biaryl mannoside derivative 13
D0FI3Q	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0FI3Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0FI3Q	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0EA9Y	TTDDRUID	D0EA9Y
D0EA9Y	DRUGNAME	Biaryl mannoside derivative 14
D0EA9Y	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0EA9Y	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0EA9Y	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02ZYV	TTDDRUID	D02ZYV
D02ZYV	DRUGNAME	Biaryl mannoside derivative 15
D02ZYV	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02ZYV	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02ZYV	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0DI1T	TTDDRUID	D0DI1T
D0DI1T	DRUGNAME	Biaryl mannoside derivative 16
D0DI1T	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0DI1T	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0DI1T	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07QAH	TTDDRUID	D07QAH
D07QAH	DRUGNAME	Biaryl mannoside derivative 17
D07QAH	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07QAH	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07QAH	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D09EIQ	TTDDRUID	D09EIQ
D09EIQ	DRUGNAME	Biaryl mannoside derivative 18
D09EIQ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09EIQ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09EIQ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0H1BZ	TTDDRUID	D0H1BZ
D0H1BZ	DRUGNAME	Biaryl mannoside derivative 19
D0H1BZ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0H1BZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0H1BZ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0GV9F	TTDDRUID	D0GV9F
D0GV9F	DRUGNAME	Biaryl mannoside derivative 2
D0GV9F	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0GV9F	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0GV9F	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0B1HT	TTDDRUID	D0B1HT
D0B1HT	DRUGNAME	Biaryl mannoside derivative 20
D0B1HT	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0B1HT	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0B1HT	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D01ZKE	TTDDRUID	D01ZKE
D01ZKE	DRUGNAME	Biaryl mannoside derivative 21
D01ZKE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D01ZKE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D01ZKE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0RG1Z	TTDDRUID	D0RG1Z
D0RG1Z	DRUGNAME	Biaryl mannoside derivative 22
D0RG1Z	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0RG1Z	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0RG1Z	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0QL0X	TTDDRUID	D0QL0X
D0QL0X	DRUGNAME	Biaryl mannoside derivative 23
D0QL0X	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0QL0X	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0QL0X	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D00COH	TTDDRUID	D00COH
D00COH	DRUGNAME	Biaryl mannoside derivative 24
D00COH	INDICATI	Crohn disease [ICD-11: DD70] Patented
D00COH	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D00COH	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0OW1V	TTDDRUID	D0OW1V
D0OW1V	DRUGNAME	Biaryl mannoside derivative 25
D0OW1V	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0OW1V	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0OW1V	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D06PNN	TTDDRUID	D06PNN
D06PNN	DRUGNAME	Biaryl mannoside derivative 26
D06PNN	INDICATI	Crohn disease [ICD-11: DD70] Patented
D06PNN	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D06PNN	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0K7TE	TTDDRUID	D0K7TE
D0K7TE	DRUGNAME	Biaryl mannoside derivative 27
D0K7TE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0K7TE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0K7TE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0XR1C	TTDDRUID	D0XR1C
D0XR1C	DRUGNAME	Biaryl mannoside derivative 28
D0XR1C	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0XR1C	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0XR1C	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0R2GA	TTDDRUID	D0R2GA
D0R2GA	DRUGNAME	Biaryl mannoside derivative 29
D0R2GA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0R2GA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0R2GA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0ZD6N	TTDDRUID	D0ZD6N
D0ZD6N	DRUGNAME	Biaryl mannoside derivative 3
D0ZD6N	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0ZD6N	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0ZD6N	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0ET9M	TTDDRUID	D0ET9M
D0ET9M	DRUGNAME	Biaryl mannoside derivative 30
D0ET9M	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0ET9M	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0ET9M	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02AAD	TTDDRUID	D02AAD
D02AAD	DRUGNAME	Biaryl mannoside derivative 31
D02AAD	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02AAD	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02AAD	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0A8RV	TTDDRUID	D0A8RV
D0A8RV	DRUGNAME	Biaryl mannoside derivative 4
D0A8RV	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0A8RV	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0A8RV	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D08BNB	TTDDRUID	D08BNB
D08BNB	DRUGNAME	Biaryl mannoside derivative 5
D08BNB	INDICATI	Crohn disease [ICD-11: DD70] Patented
D08BNB	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D08BNB	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0ZR2O	TTDDRUID	D0ZR2O
D0ZR2O	DRUGNAME	Biaryl mannoside derivative 6
D0ZR2O	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0ZR2O	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0ZR2O	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D09TKY	TTDDRUID	D09TKY
D09TKY	DRUGNAME	Biaryl mannoside derivative 7
D09TKY	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09TKY	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09TKY	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D00RQW	TTDDRUID	D00RQW
D00RQW	DRUGNAME	Biaryl mannoside derivative 8
D00RQW	INDICATI	Crohn disease [ICD-11: DD70] Patented
D00RQW	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D00RQW	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02HPF	TTDDRUID	D02HPF
D02HPF	DRUGNAME	Biaryl mannoside derivative 9
D02HPF	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02HPF	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02HPF	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0HF1A	TTDDRUID	D0HF1A
D0HF1A	DRUGNAME	Bicyclic heteroaryl benzamide derivative 1
D0HF1A	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0HF1A	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0HF1A	INDICATI	Pruritus [ICD-11: EC90] Patented
D0HF1A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0HF1A	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0F8BF	TTDDRUID	D0F8BF
D0F8BF	DRUGNAME	Bicyclic heteroaryl benzamide derivative 2
D0F8BF	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0F8BF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0F8BF	INDICATI	Pruritus [ICD-11: EC90] Patented
D0F8BF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0F8BF	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0O0GZ	TTDDRUID	D0O0GZ
D0O0GZ	DRUGNAME	Bicyclic heteroaryl benzamide derivative 3
D0O0GZ	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0O0GZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0O0GZ	INDICATI	Pruritus [ICD-11: EC90] Patented
D0O0GZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0O0GZ	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0I9FU	TTDDRUID	D0I9FU
D0I9FU	DRUGNAME	Bicyclic heteroaryl benzamide derivative 4
D0I9FU	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0I9FU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0I9FU	INDICATI	Pruritus [ICD-11: EC90] Patented
D0I9FU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0I9FU	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0KC8X	TTDDRUID	D0KC8X
D0KC8X	DRUGNAME	Bicyclic heteroaryl benzamide derivative 5
D0KC8X	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0KC8X	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0KC8X	INDICATI	Pruritus [ICD-11: EC90] Patented
D0KC8X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0KC8X	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D07CPL	TTDDRUID	D07CPL
D07CPL	DRUGNAME	Bicyclic heteroaryl benzamide derivative 6
D07CPL	INDICATI	Chronic pain [ICD-11: MG30] Patented
D07CPL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07CPL	INDICATI	Pruritus [ICD-11: EC90] Patented
D07CPL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D07CPL	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0N6NG	TTDDRUID	D0N6NG
D0N6NG	DRUGNAME	Bicyclic heteroaryl benzamide derivative 7
D0N6NG	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0N6NG	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0N6NG	INDICATI	Pruritus [ICD-11: EC90] Patented
D0N6NG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0N6NG	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0DY5R	TTDDRUID	D0DY5R
D0DY5R	DRUGNAME	Bicyclic heteroaryl benzamide derivative 8
D0DY5R	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0DY5R	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DY5R	INDICATI	Pruritus [ICD-11: EC90] Patented
D0DY5R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0DY5R	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D07AJO	TTDDRUID	D07AJO
D07AJO	DRUGNAME	Bicyclic heteroaryl benzamide derivative 9
D07AJO	INDICATI	Chronic pain [ICD-11: MG30] Patented
D07AJO	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07AJO	INDICATI	Pruritus [ICD-11: EC90] Patented
D07AJO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D07AJO	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0AX9N	TTDDRUID	D0AX9N
D0AX9N	DRUGNAME	Biphenyl derivative 4
D0AX9N	INDICATI	Histamine H3-associated disorder [ICD-11: NE61] Patented

D0SU0E	TTDDRUID	D0SU0E
D0SU0E	DRUGNAME	Biphenyl mannoside derivative 1
D0SU0E	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0SU0E	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0SU0E	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03CTH	TTDDRUID	D03CTH
D03CTH	DRUGNAME	Biphenyl mannoside derivative 10
D03CTH	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03CTH	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03CTH	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0N4TO	TTDDRUID	D0N4TO
D0N4TO	DRUGNAME	Biphenyl mannoside derivative 11
D0N4TO	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0N4TO	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0N4TO	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03KAV	TTDDRUID	D03KAV
D03KAV	DRUGNAME	Biphenyl mannoside derivative 12
D03KAV	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03KAV	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03KAV	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0RE0F	TTDDRUID	D0RE0F
D0RE0F	DRUGNAME	Biphenyl mannoside derivative 13
D0RE0F	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0RE0F	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0RE0F	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05WWX	TTDDRUID	D05WWX
D05WWX	DRUGNAME	Biphenyl mannoside derivative 14
D05WWX	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05WWX	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05WWX	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0E9GD	TTDDRUID	D0E9GD
D0E9GD	DRUGNAME	Biphenyl mannoside derivative 15
D0E9GD	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0E9GD	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0E9GD	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Z1YF	TTDDRUID	D0Z1YF
D0Z1YF	DRUGNAME	Biphenyl mannoside derivative 16
D0Z1YF	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Z1YF	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Z1YF	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0RZ5E	TTDDRUID	D0RZ5E
D0RZ5E	DRUGNAME	Biphenyl mannoside derivative 17
D0RZ5E	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0RZ5E	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0RZ5E	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0HE3B	TTDDRUID	D0HE3B
D0HE3B	DRUGNAME	Biphenyl mannoside derivative 18
D0HE3B	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0HE3B	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0HE3B	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0N2AI	TTDDRUID	D0N2AI
D0N2AI	DRUGNAME	Biphenyl mannoside derivative 19
D0N2AI	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0N2AI	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0N2AI	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0BR9C	TTDDRUID	D0BR9C
D0BR9C	DRUGNAME	Biphenyl mannoside derivative 2
D0BR9C	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0BR9C	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0BR9C	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0W7VE	TTDDRUID	D0W7VE
D0W7VE	DRUGNAME	Biphenyl mannoside derivative 20
D0W7VE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0W7VE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0W7VE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0BS3E	TTDDRUID	D0BS3E
D0BS3E	DRUGNAME	Biphenyl mannoside derivative 21
D0BS3E	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0BS3E	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0BS3E	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0GR3C	TTDDRUID	D0GR3C
D0GR3C	DRUGNAME	Biphenyl mannoside derivative 22
D0GR3C	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0GR3C	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0GR3C	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0VG0F	TTDDRUID	D0VG0F
D0VG0F	DRUGNAME	Biphenyl mannoside derivative 23
D0VG0F	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0VG0F	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0VG0F	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D09ZCA	TTDDRUID	D09ZCA
D09ZCA	DRUGNAME	Biphenyl mannoside derivative 24
D09ZCA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09ZCA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09ZCA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03WJB	TTDDRUID	D03WJB
D03WJB	DRUGNAME	Biphenyl mannoside derivative 25
D03WJB	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03WJB	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03WJB	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0CR8J	TTDDRUID	D0CR8J
D0CR8J	DRUGNAME	Biphenyl mannoside derivative 26
D0CR8J	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0CR8J	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0CR8J	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0L2QZ	TTDDRUID	D0L2QZ
D0L2QZ	DRUGNAME	Biphenyl mannoside derivative 27
D0L2QZ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0L2QZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0L2QZ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0UE3F	TTDDRUID	D0UE3F
D0UE3F	DRUGNAME	Biphenyl mannoside derivative 28
D0UE3F	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0UE3F	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0UE3F	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0T6NX	TTDDRUID	D0T6NX
D0T6NX	DRUGNAME	Biphenyl mannoside derivative 29
D0T6NX	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0T6NX	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0T6NX	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03RXE	TTDDRUID	D03RXE
D03RXE	DRUGNAME	Biphenyl mannoside derivative 3
D03RXE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03RXE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03RXE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05AZE	TTDDRUID	D05AZE
D05AZE	DRUGNAME	Biphenyl mannoside derivative 30
D05AZE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05AZE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05AZE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0A3PP	TTDDRUID	D0A3PP
D0A3PP	DRUGNAME	Biphenyl mannoside derivative 4
D0A3PP	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0A3PP	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0A3PP	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05JAS	TTDDRUID	D05JAS
D05JAS	DRUGNAME	Biphenyl mannoside derivative 5
D05JAS	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05JAS	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05JAS	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D01PBX	TTDDRUID	D01PBX
D01PBX	DRUGNAME	Biphenyl mannoside derivative 6
D01PBX	INDICATI	Crohn disease [ICD-11: DD70] Patented
D01PBX	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D01PBX	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0UG9S	TTDDRUID	D0UG9S
D0UG9S	DRUGNAME	Biphenyl mannoside derivative 7
D0UG9S	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0UG9S	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0UG9S	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0NB5P	TTDDRUID	D0NB5P
D0NB5P	DRUGNAME	Biphenyl mannoside derivative 8
D0NB5P	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0NB5P	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0NB5P	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0GM6O	TTDDRUID	D0GM6O
D0GM6O	DRUGNAME	Biphenyl mannoside derivative 9
D0GM6O	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0GM6O	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0GM6O	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0DM2G	TTDDRUID	D0DM2G
D0DM2G	DRUGNAME	Bis-indolylmaleimide derivative 1
D0DM2G	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0DM2G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D01AYP	TTDDRUID	D01AYP
D01AYP	DRUGNAME	Bromo benzyl ether derivative 1
D01AYP	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D01AYP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D01AYP	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D01AYP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0R7CP	TTDDRUID	D0R7CP
D0R7CP	DRUGNAME	Bromo benzyl ether derivative 2
D0R7CP	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0R7CP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0R7CP	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0R7CP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0S0WJ	TTDDRUID	D0S0WJ
D0S0WJ	DRUGNAME	Bromo benzyl ether derivative 3
D0S0WJ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0S0WJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0S0WJ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0S0WJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Z7EV	TTDDRUID	D0Z7EV
D0Z7EV	DRUGNAME	Carboxamide derivative 1
D0Z7EV	INDICATI	Obesity [ICD-11: 5B81] Patented

D00PHK	TTDDRUID	D00PHK
D00PHK	DRUGNAME	Carboxylic acid derivative 1
D00PHK	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
D00PHK	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Patented

D0YK9D	TTDDRUID	D0YK9D
D0YK9D	DRUGNAME	CHIR-99021
D0YK9D	INDICATI	Allergic inflammation [ICD-11: 4A80-4A85] Patented
D0YK9D	INDICATI	Graft rejection [ICD-11: NE84] Patented

D0H4CL	TTDDRUID	D0H4CL
D0H4CL	DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 1
D0H4CL	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0H4CL	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0H4CL	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0US5I	TTDDRUID	D0US5I
D0US5I	DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 2
D0US5I	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0US5I	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0US5I	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0XH4K	TTDDRUID	D0XH4K
D0XH4K	DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 3
D0XH4K	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0XH4K	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0XH4K	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03WXM	TTDDRUID	D03WXM
D03WXM	DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 4
D03WXM	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03WXM	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03WXM	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0B3CU	TTDDRUID	D0B3CU
D0B3CU	DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 5
D0B3CU	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0B3CU	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0B3CU	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02XNH	TTDDRUID	D02XNH
D02XNH	DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 6
D02XNH	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02XNH	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02XNH	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0F1FD	TTDDRUID	D0F1FD
D0F1FD	DRUGNAME	Complex heterocyclic compound 1
D0F1FD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented

D04PKQ	TTDDRUID	D04PKQ
D04PKQ	DRUGNAME	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1
D04PKQ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Patented

D03XZT	TTDDRUID	D03XZT
D03XZT	DRUGNAME	Cyclic compound 1
D03XZT	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D03XZT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D03XZT	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D03XZT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07PJR	TTDDRUID	D07PJR
D07PJR	DRUGNAME	Cyclic compound 2
D07PJR	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D07PJR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D07PJR	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D07PJR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D00ZRO	TTDDRUID	D00ZRO
D00ZRO	DRUGNAME	Cyclic compound 3
D00ZRO	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D00ZRO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D00ZRO	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D00ZRO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0BN0H	TTDDRUID	D0BN0H
D0BN0H	DRUGNAME	Cyclic compound 4
D0BN0H	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0BN0H	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0BN0H	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0BN0H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D01PJZ	TTDDRUID	D01PJZ
D01PJZ	DRUGNAME	Cyclic peptidomimetic derivative 1
D01PJZ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D01PJZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D01PJZ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D01PJZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04TLQ	TTDDRUID	D04TLQ
D04TLQ	DRUGNAME	Cyclic peptidomimetic derivative 2
D04TLQ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D04TLQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D04TLQ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D04TLQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0EW3O	TTDDRUID	D0EW3O
D0EW3O	DRUGNAME	Cyclic peptidomimetic derivative 3
D0EW3O	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0EW3O	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0EW3O	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0EW3O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07VHH	TTDDRUID	D07VHH
D07VHH	DRUGNAME	Cyclic peptidomimetic derivative 4
D07VHH	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D07VHH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D07VHH	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D07VHH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0J2HH	TTDDRUID	D0J2HH
D0J2HH	DRUGNAME	Cyclohexyl carbamate derivative 1
D0J2HH	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0J2HH	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0J2HH	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0J2HH	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0J2HH	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0F3HA	TTDDRUID	D0F3HA
D0F3HA	DRUGNAME	Cyclohexyl carbamate derivative 2
D0F3HA	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0F3HA	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0F3HA	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0F3HA	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0F3HA	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03PYA	TTDDRUID	D03PYA
D03PYA	DRUGNAME	Cyclohexyl carbamate derivative 3
D03PYA	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03PYA	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03PYA	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03PYA	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03PYA	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0L1SV	TTDDRUID	D0L1SV
D0L1SV	DRUGNAME	Cyclohexyl carbamate derivative 4
D0L1SV	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0L1SV	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0L1SV	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0L1SV	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0L1SV	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0UT9H	TTDDRUID	D0UT9H
D0UT9H	DRUGNAME	Cyclohexyl carbamate derivative 5
D0UT9H	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0UT9H	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0UT9H	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0UT9H	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0UT9H	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D09VRO	TTDDRUID	D09VRO
D09VRO	DRUGNAME	Cyclohexyl carbamate derivative 6
D09VRO	INDICATI	Albinism [ICD-11: EC23.2] Patented
D09VRO	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D09VRO	INDICATI	Melasma [ICD-11: ED60.1] Patented
D09VRO	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D09VRO	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0LC2G	TTDDRUID	D0LC2G
D0LC2G	DRUGNAME	Cyclohexyl carbamate derivative 7
D0LC2G	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0LC2G	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0LC2G	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0LC2G	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0LC2G	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D06LIQ	TTDDRUID	D06LIQ
D06LIQ	DRUGNAME	Cyclohexyl carbamate derivative 8
D06LIQ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D06LIQ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D06LIQ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D06LIQ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D06LIQ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D01QYA	TTDDRUID	D01QYA
D01QYA	DRUGNAME	Diamine derivative 1
D01QYA	INDICATI	Albinism [ICD-11: EC23.2] Patented
D01QYA	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D01QYA	INDICATI	Melasma [ICD-11: ED60.1] Patented
D01QYA	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D01QYA	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0L0CV	TTDDRUID	D0L0CV
D0L0CV	DRUGNAME	Diamine derivative 2
D0L0CV	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0L0CV	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0L0CV	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0L0CV	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0L0CV	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0QU3G	TTDDRUID	D0QU3G
D0QU3G	DRUGNAME	Diamine derivative 3
D0QU3G	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0QU3G	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0QU3G	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0QU3G	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0QU3G	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0KX8N	TTDDRUID	D0KX8N
D0KX8N	DRUGNAME	Diaryl morpholine derivative 1
D0KX8N	INDICATI	Obesity [ICD-11: 5B81] Patented

D0CH3J	TTDDRUID	D0CH3J
D0CH3J	DRUGNAME	Diaryl morpholine derivative 2
D0CH3J	INDICATI	Obesity [ICD-11: 5B81] Patented

D0LJ2Q	TTDDRUID	D0LJ2Q
D0LJ2Q	DRUGNAME	Diaryl morpholine derivative 3
D0LJ2Q	INDICATI	Obesity [ICD-11: 5B81] Patented

D0ZY6C	TTDDRUID	D0ZY6C
D0ZY6C	DRUGNAME	Diaryl piperazine derivative 1
D0ZY6C	INDICATI	Obesity [ICD-11: 5B81] Patented

D0AM1D	TTDDRUID	D0AM1D
D0AM1D	DRUGNAME	Diaryl piperazine derivative 2
D0AM1D	INDICATI	Obesity [ICD-11: 5B81] Patented

D09QQS	TTDDRUID	D09QQS
D09QQS	DRUGNAME	Diazepinone derivative 1
D09QQS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
D09QQS	INDICATI	Reflux disease [ICD-11: DA22] Patented

D0MM8M	TTDDRUID	D0MM8M
D0MM8M	DRUGNAME	Diazepinone derivative 2
D0MM8M	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
D0MM8M	INDICATI	Reflux disease [ICD-11: DA22] Patented

D0Q4ST	TTDDRUID	D0Q4ST
D0Q4ST	DRUGNAME	Diazepinone derivative 3
D0Q4ST	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
D0Q4ST	INDICATI	Reflux disease [ICD-11: DA22] Patented

D0DL7P	TTDDRUID	D0DL7P
D0DL7P	DRUGNAME	Diazepinone derivative 4
D0DL7P	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
D0DL7P	INDICATI	Reflux disease [ICD-11: DA22] Patented

D0J4QE	TTDDRUID	D0J4QE
D0J4QE	DRUGNAME	Diazepinone derivative 5
D0J4QE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
D0J4QE	INDICATI	Reflux disease [ICD-11: DA22] Patented

D0I5KI	TTDDRUID	D0I5KI
D0I5KI	DRUGNAME	Dibenzo [c,f]-[2,7]naphthyridine derivative 1
D0I5KI	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0I5KI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0LA2R	TTDDRUID	D0LA2R
D0LA2R	DRUGNAME	Dihydroxyfumaric acid derivative 1
D0LA2R	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0LA2R	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0LA2R	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0LA2R	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0LA2R	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0UX4J	TTDDRUID	D0UX4J
D0UX4J	DRUGNAME	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1
D0UX4J	INDICATI	Cerebral ischemia [ICD-11: 8B11] Patented

D07PND	TTDDRUID	D07PND
D07PND	DRUGNAME	Diphenyl purine derivative 1
D07PND	INDICATI	Obesity [ICD-11: 5B81] Patented

D0DE0C	TTDDRUID	D0DE0C
D0DE0C	DRUGNAME	Diphenyl purine derivative 2
D0DE0C	INDICATI	Obesity [ICD-11: 5B81] Patented

D0I1XE	TTDDRUID	D0I1XE
D0I1XE	DRUGNAME	Diphenyl purine derivative 3
D0I1XE	INDICATI	Obesity [ICD-11: 5B81] Patented

D02ZVY	TTDDRUID	D02ZVY
D02ZVY	DRUGNAME	Diphenyl purine derivative 4
D02ZVY	INDICATI	Obesity [ICD-11: 5B81] Patented

D0D1EI	TTDDRUID	D0D1EI
D0D1EI	DRUGNAME	Diphenyl purine derivative 5
D0D1EI	INDICATI	Obesity [ICD-11: 5B81] Patented

D0T4CF	TTDDRUID	D0T4CF
D0T4CF	DRUGNAME	Five membered heterocyclic benzamide derivative 1
D0T4CF	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0T4CF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0T4CF	INDICATI	Pruritus [ICD-11: EC90] Patented
D0T4CF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0T4CF	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D04BRW	TTDDRUID	D04BRW
D04BRW	DRUGNAME	Five membered heterocyclic benzamide derivative 2
D04BRW	INDICATI	Chronic pain [ICD-11: MG30] Patented
D04BRW	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D04BRW	INDICATI	Pruritus [ICD-11: EC90] Patented
D04BRW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D04BRW	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0CY3U	TTDDRUID	D0CY3U
D0CY3U	DRUGNAME	Five membered heterocyclic benzamide derivative 3
D0CY3U	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0CY3U	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0CY3U	INDICATI	Pruritus [ICD-11: EC90] Patented
D0CY3U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0CY3U	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D02XYT	TTDDRUID	D02XYT
D02XYT	DRUGNAME	Furopyridine derivative 1
D02XYT	INDICATI	Obesity [ICD-11: 5B81] Patented

D0T0OQ	TTDDRUID	D0T0OQ
D0T0OQ	DRUGNAME	Furopyridine derivative 2
D0T0OQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0H7SO	TTDDRUID	D0H7SO
D0H7SO	DRUGNAME	Heteroaryl-carboxamide derivative 1
D0H7SO	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0H7SO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0TB2H	TTDDRUID	D0TB2H
D0TB2H	DRUGNAME	Heteroaryl-carboxamide derivative 10
D0TB2H	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0TB2H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08SNT	TTDDRUID	D08SNT
D08SNT	DRUGNAME	Heteroaryl-carboxamide derivative 2
D08SNT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D08SNT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D00ZXR	TTDDRUID	D00ZXR
D00ZXR	DRUGNAME	Heteroaryl-carboxamide derivative 3
D00ZXR	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D00ZXR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D00LMA	TTDDRUID	D00LMA
D00LMA	DRUGNAME	Heteroaryl-carboxamide derivative 4
D00LMA	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D00LMA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0MG4D	TTDDRUID	D0MG4D
D0MG4D	DRUGNAME	Heteroaryl-carboxamide derivative 5
D0MG4D	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0MG4D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0GH9W	TTDDRUID	D0GH9W
D0GH9W	DRUGNAME	Heteroaryl-carboxamide derivative 6
D0GH9W	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0GH9W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0MW7L	TTDDRUID	D0MW7L
D0MW7L	DRUGNAME	Heteroaryl-carboxamide derivative 7
D0MW7L	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0MW7L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0WT9J	TTDDRUID	D0WT9J
D0WT9J	DRUGNAME	Heteroaryl-carboxamide derivative 8
D0WT9J	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0WT9J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03WFI	TTDDRUID	D03WFI
D03WFI	DRUGNAME	Heteroaryl-carboxamide derivative 9
D03WFI	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D03WFI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07IQE	TTDDRUID	D07IQE
D07IQE	DRUGNAME	Heterocyclic derivative 10
D07IQE	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D07IQE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D09BNP	TTDDRUID	D09BNP
D09BNP	DRUGNAME	Heterocyclic derivative 11
D09BNP	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D09BNP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04BBT	TTDDRUID	D04BBT
D04BBT	DRUGNAME	Heterocyclic derivative 12
D04BBT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04BBT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0HI8X	TTDDRUID	D0HI8X
D0HI8X	DRUGNAME	Heterocyclic derivative 13
D0HI8X	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0HI8X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0EH9Z	TTDDRUID	D0EH9Z
D0EH9Z	DRUGNAME	Heterocyclic derivative 14
D0EH9Z	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0EH9Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02USE	TTDDRUID	D02USE
D02USE	DRUGNAME	Heterocyclic derivative 15
D02USE	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D02USE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0RH6G	TTDDRUID	D0RH6G
D0RH6G	DRUGNAME	Heterocyclic derivative 16
D0RH6G	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0RH6G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04MHV	TTDDRUID	D04MHV
D04MHV	DRUGNAME	Heterocyclic derivative 17
D04MHV	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04MHV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0FW3M	TTDDRUID	D0FW3M
D0FW3M	DRUGNAME	Heterocyclic derivative 18
D0FW3M	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0FW3M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0WX4H	TTDDRUID	D0WX4H
D0WX4H	DRUGNAME	Heterocyclic derivative 19
D0WX4H	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0WX4H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D05OTD	TTDDRUID	D05OTD
D05OTD	DRUGNAME	Heterocyclic derivative 4
D05OTD	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D05OTD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0J9DI	TTDDRUID	D0J9DI
D0J9DI	DRUGNAME	Heterocyclic derivative 5
D0J9DI	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0J9DI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0D0ML	TTDDRUID	D0D0ML
D0D0ML	DRUGNAME	Heterocyclic derivative 6
D0D0ML	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0D0ML	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0W3JC	TTDDRUID	D0W3JC
D0W3JC	DRUGNAME	Heterocyclic derivative 7
D0W3JC	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0W3JC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0AM2D	TTDDRUID	D0AM2D
D0AM2D	DRUGNAME	Heterocyclic derivative 8
D0AM2D	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0AM2D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07HOA	TTDDRUID	D07HOA
D07HOA	DRUGNAME	Heterocyclic derivative 9
D07HOA	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D07HOA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0RY6M	TTDDRUID	D0RY6M
D0RY6M	DRUGNAME	Heterocyclic-carboxamide derivative 1
D0RY6M	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0RY6M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0CQ1M	TTDDRUID	D0CQ1M
D0CQ1M	DRUGNAME	Heterocyclic-carboxamide derivative 2
D0CQ1M	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0CQ1M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0SV6D	TTDDRUID	D0SV6D
D0SV6D	DRUGNAME	Heterocyclic-substituted 3-alkyl azetidine derivative 1
D0SV6D	INDICATI	Obesity [ICD-11: 5B81] Patented

D0I1VK	TTDDRUID	D0I1VK
D0I1VK	DRUGNAME	Heterocyclic-substituted 3-alkyl azetidine derivative 2
D0I1VK	INDICATI	Obesity [ICD-11: 5B81] Patented

D0TS3S	TTDDRUID	D0TS3S
D0TS3S	DRUGNAME	Heterocyclic-substituted 3-alkyl azetidine derivative 3
D0TS3S	INDICATI	Obesity [ICD-11: 5B81] Patented

D0R9PD	TTDDRUID	D0R9PD
D0R9PD	DRUGNAME	Hydrazide derivative 1
D0R9PD	INDICATI	Obesity [ICD-11: 5B81] Patented

D0OE4F	TTDDRUID	D0OE4F
D0OE4F	DRUGNAME	Imatinib and nilotinib derivative 1
D0OE4F	INDICATI	Cas mediated disorder [ICD-11: N.A.] Patented

D07DGA	TTDDRUID	D07DGA
D07DGA	DRUGNAME	Imatinib and nilotinib derivative 2
D07DGA	INDICATI	Cas mediated disorder [ICD-11: N.A.] Patented

D0WI7N	TTDDRUID	D0WI7N
D0WI7N	DRUGNAME	Imidazo pyridine derivative 1
D0WI7N	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0WI7N	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0WI7N	INDICATI	Pruritus [ICD-11: EC90] Patented
D0WI7N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0WI7N	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0D5YE	TTDDRUID	D0D5YE
D0D5YE	DRUGNAME	Imidazo quinoline derivative 1
D0D5YE	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0D5YE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0T8XD	TTDDRUID	D0T8XD
D0T8XD	DRUGNAME	Imidazo[1,2-b]pyridazine derivative 1
D0T8XD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0M8UO	TTDDRUID	D0M8UO
D0M8UO	DRUGNAME	Imidazo[1,2-b]pyridazine derivative 2
D0M8UO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0N1CF	TTDDRUID	D0N1CF
D0N1CF	DRUGNAME	Imidazo[1,2-b]pyridazine derivative 3
D0N1CF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0F8KE	TTDDRUID	D0F8KE
D0F8KE	DRUGNAME	Imidazole benzamide derivative 1
D0F8KE	INDICATI	Knee pain [ICD-11: ME82] Patented

D03GLK	TTDDRUID	D03GLK
D03GLK	DRUGNAME	Imidazole derivative 1
D03GLK	INDICATI	Obesity [ICD-11: 5B81] Patented

D05VIN	TTDDRUID	D05VIN
D05VIN	DRUGNAME	Imidazole derivative 2
D05VIN	INDICATI	Obesity [ICD-11: 5B81] Patented

D0BI0F	TTDDRUID	D0BI0F
D0BI0F	DRUGNAME	Imidazole derivative 3
D0BI0F	INDICATI	Obesity [ICD-11: 5B81] Patented

D0JK3V	TTDDRUID	D0JK3V
D0JK3V	DRUGNAME	Imidazole derivative 4
D0JK3V	INDICATI	Obesity [ICD-11: 5B81] Patented

D06FOF	TTDDRUID	D06FOF
D06FOF	DRUGNAME	Imidazole derivative 5
D06FOF	INDICATI	Obesity [ICD-11: 5B81] Patented

D0K3FJ	TTDDRUID	D0K3FJ
D0K3FJ	DRUGNAME	Imidazole derivative 6
D0K3FJ	INDICATI	Obesity [ICD-11: 5B81] Patented

D00TBI	TTDDRUID	D00TBI
D00TBI	DRUGNAME	Imidazole derivative 7
D00TBI	INDICATI	Obesity [ICD-11: 5B81] Patented

D0FZ5R	TTDDRUID	D0FZ5R
D0FZ5R	DRUGNAME	Imidazolidine-2,4-dione derivative 1
D0FZ5R	INDICATI	Obesity [ICD-11: 5B81] Patented

D0LH9E	TTDDRUID	D0LH9E
D0LH9E	DRUGNAME	Imidazolidine-2,4-dione derivative 2
D0LH9E	INDICATI	Obesity [ICD-11: 5B81] Patented

D0UD6X	TTDDRUID	D0UD6X
D0UD6X	DRUGNAME	Imidazopyridazine derivative 3
D0UD6X	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D0UD6X	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D0UN9X	TTDDRUID	D0UN9X
D0UN9X	DRUGNAME	Imidazopyridazine derivative 4
D0UN9X	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D0UN9X	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D0G7KY	TTDDRUID	D0G7KY
D0G7KY	DRUGNAME	Imidazopyridazine derivative 5
D0G7KY	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D0G7KY	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D0W9AB	TTDDRUID	D0W9AB
D0W9AB	DRUGNAME	Imidazopyridazine derivative 6
D0W9AB	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D0W9AB	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D0N3AF	TTDDRUID	D0N3AF
D0N3AF	DRUGNAME	Imidazopyridazine derivative 7
D0N3AF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D0N3AF	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D02SJB	TTDDRUID	D02SJB
D02SJB	DRUGNAME	Imidazopyridazine derivative 8
D02SJB	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D02SJB	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D0CK8H	TTDDRUID	D0CK8H
D0CK8H	DRUGNAME	Indazole derivative 1
D0CK8H	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0CK8H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0ZE5U	TTDDRUID	D0ZE5U
D0ZE5U	DRUGNAME	Indolinone derivative 1
D0ZE5U	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0ZE5U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0RL4J	TTDDRUID	D0RL4J
D0RL4J	DRUGNAME	Indolocarbazole derivative 1
D0RL4J	INDICATI	Atopic dermatitis [ICD-11: EA80] Patented
D0RL4J	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented

D0TC7X	TTDDRUID	D0TC7X
D0TC7X	DRUGNAME	Isoquinoline derivative 1
D0TC7X	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented

D0D1TS	TTDDRUID	D0D1TS
D0D1TS	DRUGNAME	Isoquinoline derivative 2
D0D1TS	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented

D0ZM1H	TTDDRUID	D0ZM1H
D0ZM1H	DRUGNAME	Isoquinoline derivative 3
D0ZM1H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented

D0YZ8I	TTDDRUID	D0YZ8I
D0YZ8I	DRUGNAME	JWH-015
D0YZ8I	INDICATI	Organ transplant rejection [ICD-11: NE84] Patented

D06VTI	TTDDRUID	D06VTI
D06VTI	DRUGNAME	Macrocycle derivative 1
D06VTI	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D06VTI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D06VTI	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D06VTI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0SR2Y	TTDDRUID	D0SR2Y
D0SR2Y	DRUGNAME	Macrocycle derivative 10
D0SR2Y	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0SR2Y	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0SR2Y	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0SR2Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0NS1Z	TTDDRUID	D0NS1Z
D0NS1Z	DRUGNAME	Macrocycle derivative 11
D0NS1Z	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0NS1Z	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0NS1Z	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0NS1Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06AIF	TTDDRUID	D06AIF
D06AIF	DRUGNAME	Macrocycle derivative 12
D06AIF	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D06AIF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D06AIF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D06AIF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D00DXC	TTDDRUID	D00DXC
D00DXC	DRUGNAME	Macrocycle derivative 13
D00DXC	INDICATI	Cell proliferative disorder [ICD-11: FB86] Patented

D08EHL	TTDDRUID	D08EHL
D08EHL	DRUGNAME	Macrocycle derivative 2
D08EHL	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D08EHL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D08EHL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D08EHL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0J4UO	TTDDRUID	D0J4UO
D0J4UO	DRUGNAME	Macrocycle derivative 3
D0J4UO	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0J4UO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0J4UO	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0J4UO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0R7JW	TTDDRUID	D0R7JW
D0R7JW	DRUGNAME	Macrocycle derivative 4
D0R7JW	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0R7JW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0R7JW	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0R7JW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0NI2B	TTDDRUID	D0NI2B
D0NI2B	DRUGNAME	Macrocycle derivative 5
D0NI2B	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0NI2B	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0NI2B	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0NI2B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03BCV	TTDDRUID	D03BCV
D03BCV	DRUGNAME	Macrocycle derivative 6
D03BCV	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D03BCV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D03BCV	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D03BCV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0QF4W	TTDDRUID	D0QF4W
D0QF4W	DRUGNAME	Macrocycle derivative 7
D0QF4W	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0QF4W	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0QF4W	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0QF4W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0N4TZ	TTDDRUID	D0N4TZ
D0N4TZ	DRUGNAME	Macrocycle derivative 8
D0N4TZ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0N4TZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0N4TZ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0N4TZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07ZQS	TTDDRUID	D07ZQS
D07ZQS	DRUGNAME	Macrocycle derivative 9
D07ZQS	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D07ZQS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D07ZQS	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D07ZQS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0S0OF	TTDDRUID	D0S0OF
D0S0OF	DRUGNAME	Macrocyclic peptide analog 1
D0S0OF	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0S0OF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0S0OF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0S0OF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0CH8E	TTDDRUID	D0CH8E
D0CH8E	DRUGNAME	Macrocyclic peptide analog 2
D0CH8E	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0CH8E	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0CH8E	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0CH8E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0MK2F	TTDDRUID	D0MK2F
D0MK2F	DRUGNAME	Macrocyclic peptide analog 3
D0MK2F	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0MK2F	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0MK2F	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0MK2F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Y8AS	TTDDRUID	D0Y8AS
D0Y8AS	DRUGNAME	Macrocyclic peptide analog 4
D0Y8AS	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0Y8AS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0Y8AS	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0Y8AS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0ME1I	TTDDRUID	D0ME1I
D0ME1I	DRUGNAME	Macrocyclic peptide analog 5
D0ME1I	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0ME1I	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0ME1I	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0ME1I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0OQ2R	TTDDRUID	D0OQ2R
D0OQ2R	DRUGNAME	Mannoside derivative 1
D0OQ2R	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0OQ2R	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0OQ2R	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05BUD	TTDDRUID	D05BUD
D05BUD	DRUGNAME	Mannoside derivative 10
D05BUD	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05BUD	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05BUD	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0H7UR	TTDDRUID	D0H7UR
D0H7UR	DRUGNAME	Mannoside derivative 11
D0H7UR	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0H7UR	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0H7UR	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0D6HS	TTDDRUID	D0D6HS
D0D6HS	DRUGNAME	Mannoside derivative 12
D0D6HS	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0D6HS	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0D6HS	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Q7QK	TTDDRUID	D0Q7QK
D0Q7QK	DRUGNAME	Mannoside derivative 13
D0Q7QK	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Q7QK	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Q7QK	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Z1ZA	TTDDRUID	D0Z1ZA
D0Z1ZA	DRUGNAME	Mannoside derivative 2
D0Z1ZA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Z1ZA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Z1ZA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0R7YN	TTDDRUID	D0R7YN
D0R7YN	DRUGNAME	Mannoside derivative 3
D0R7YN	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0R7YN	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0R7YN	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0X8AB	TTDDRUID	D0X8AB
D0X8AB	DRUGNAME	Mannoside derivative 4
D0X8AB	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0X8AB	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0X8AB	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0XP5X	TTDDRUID	D0XP5X
D0XP5X	DRUGNAME	Mannoside derivative 5
D0XP5X	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0XP5X	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0XP5X	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0F6TN	TTDDRUID	D0F6TN
D0F6TN	DRUGNAME	Mannoside derivative 6
D0F6TN	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0F6TN	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0F6TN	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D09LWZ	TTDDRUID	D09LWZ
D09LWZ	DRUGNAME	Mannoside derivative 7
D09LWZ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09LWZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09LWZ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D08OXD	TTDDRUID	D08OXD
D08OXD	DRUGNAME	Mannoside derivative 8
D08OXD	INDICATI	Crohn disease [ICD-11: DD70] Patented
D08OXD	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D08OXD	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0TY1Q	TTDDRUID	D0TY1Q
D0TY1Q	DRUGNAME	Mannoside derivative 9
D0TY1Q	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0TY1Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0TY1Q	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0XM9M	TTDDRUID	D0XM9M
D0XM9M	DRUGNAME	Methyl-piperidine compound 1
D0XM9M	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
D0XM9M	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Patented

D02TIY	TTDDRUID	D02TIY
D02TIY	DRUGNAME	Monoamine derivative 1
D02TIY	INDICATI	Albinism [ICD-11: EC23.2] Patented
D02TIY	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D02TIY	INDICATI	Melasma [ICD-11: ED60.1] Patented
D02TIY	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D02TIY	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D00EGV	TTDDRUID	D00EGV
D00EGV	DRUGNAME	Monoamine derivative 2
D00EGV	INDICATI	Albinism [ICD-11: EC23.2] Patented
D00EGV	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D00EGV	INDICATI	Melasma [ICD-11: ED60.1] Patented
D00EGV	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D00EGV	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03KNZ	TTDDRUID	D03KNZ
D03KNZ	DRUGNAME	Monoamine derivative 3
D03KNZ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03KNZ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03KNZ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03KNZ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03KNZ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0X5VH	TTDDRUID	D0X5VH
D0X5VH	DRUGNAME	Monoamine derivative 4
D0X5VH	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0X5VH	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0X5VH	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0X5VH	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0X5VH	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0SD9L	TTDDRUID	D0SD9L
D0SD9L	DRUGNAME	Monoamine derivative 5
D0SD9L	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0SD9L	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0SD9L	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0SD9L	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0SD9L	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D04ZLC	TTDDRUID	D04ZLC
D04ZLC	DRUGNAME	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1
D04ZLC	INDICATI	Obesity [ICD-11: 5B81] Patented

D05GDS	TTDDRUID	D05GDS
D05GDS	DRUGNAME	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2
D05GDS	INDICATI	Obesity [ICD-11: 5B81] Patented

D0C3RK	TTDDRUID	D0C3RK
D0C3RK	DRUGNAME	N-(phenylpyrazolyl)benzamide derivative 1
D0C3RK	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0C3RK	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0C3RK	INDICATI	Pruritus [ICD-11: EC90] Patented
D0C3RK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0C3RK	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D07IHT	TTDDRUID	D07IHT
D07IHT	DRUGNAME	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1
D07IHT	INDICATI	Osteoporosis [ICD-11: FB83.0] Patented

D0WJ3F	TTDDRUID	D0WJ3F
D0WJ3F	DRUGNAME	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2
D0WJ3F	INDICATI	Osteoporosis [ICD-11: FB83.0] Patented

D0FA2L	TTDDRUID	D0FA2L
D0FA2L	DRUGNAME	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3
D0FA2L	INDICATI	Osteoporosis [ICD-11: FB83.0] Patented

D00XXZ	TTDDRUID	D00XXZ
D00XXZ	DRUGNAME	N-acylpiperidine ether derivative 1
D00XXZ	INDICATI	Chronic pain [ICD-11: MG30] Patented
D00XXZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00XXZ	INDICATI	Pruritus [ICD-11: EC90] Patented
D00XXZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D00XXZ	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D04RXX	TTDDRUID	D04RXX
D04RXX	DRUGNAME	N-acylpiperidine ether derivative 2
D04RXX	INDICATI	Chronic pain [ICD-11: MG30] Patented
D04RXX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D04RXX	INDICATI	Pruritus [ICD-11: EC90] Patented
D04RXX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D04RXX	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0X1LP	TTDDRUID	D0X1LP
D0X1LP	DRUGNAME	N-acylpiperidine ether derivative 3
D0X1LP	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0X1LP	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0X1LP	INDICATI	Pruritus [ICD-11: EC90] Patented
D0X1LP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0X1LP	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D00FJH	TTDDRUID	D00FJH
D00FJH	DRUGNAME	N-acylpiperidine ether derivative 4
D00FJH	INDICATI	Chronic pain [ICD-11: MG30] Patented
D00FJH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00FJH	INDICATI	Pruritus [ICD-11: EC90] Patented
D00FJH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D00FJH	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D03BAY	TTDDRUID	D03BAY
D03BAY	DRUGNAME	N-acylpiperidine ether derivative 5
D03BAY	INDICATI	Chronic pain [ICD-11: MG30] Patented
D03BAY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03BAY	INDICATI	Pruritus [ICD-11: EC90] Patented
D03BAY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D03BAY	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D04GCC	TTDDRUID	D04GCC
D04GCC	DRUGNAME	N-acylpiperidine ether derivative 6
D04GCC	INDICATI	Chronic pain [ICD-11: MG30] Patented
D04GCC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D04GCC	INDICATI	Pruritus [ICD-11: EC90] Patented
D04GCC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D04GCC	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D02OLJ	TTDDRUID	D02OLJ
D02OLJ	DRUGNAME	N-acylpiperidine ether derivative 7
D02OLJ	INDICATI	Chronic pain [ICD-11: MG30] Patented
D02OLJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02OLJ	INDICATI	Pruritus [ICD-11: EC90] Patented
D02OLJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D02OLJ	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0X4LA	TTDDRUID	D0X4LA
D0X4LA	DRUGNAME	N-acylpyrrolidine ether derivative 1
D0X4LA	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0X4LA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0X4LA	INDICATI	Pruritus [ICD-11: EC90] Patented
D0X4LA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0X4LA	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D08BIH	TTDDRUID	D08BIH
D08BIH	DRUGNAME	N-acylpyrrolidine ether derivative 2
D08BIH	INDICATI	Chronic pain [ICD-11: MG30] Patented
D08BIH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D08BIH	INDICATI	Pruritus [ICD-11: EC90] Patented
D08BIH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D08BIH	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0FQ3D	TTDDRUID	D0FQ3D
D0FQ3D	DRUGNAME	Nicotinyl hydroxamic acid derivative 1
D0FQ3D	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0FQ3D	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0FQ3D	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0FQ3D	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0FQ3D	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0IC3K	TTDDRUID	D0IC3K
D0IC3K	DRUGNAME	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1
D0IC3K	INDICATI	Obesity [ICD-11: 5B81] Patented

D0K0DV	TTDDRUID	D0K0DV
D0K0DV	DRUGNAME	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2
D0K0DV	INDICATI	Obesity [ICD-11: 5B81] Patented

D0QH5I	TTDDRUID	D0QH5I
D0QH5I	DRUGNAME	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3
D0QH5I	INDICATI	Obesity [ICD-11: 5B81] Patented

D0F4IF	TTDDRUID	D0F4IF
D0F4IF	DRUGNAME	N-phenyl-pyridine-2-carboxamide derivative 1
D0F4IF	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0F4IF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0F4IF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0F4IF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0EI4B	TTDDRUID	D0EI4B
D0EI4B	DRUGNAME	N-phenyl-pyridine-2-carboxamide derivative 2
D0EI4B	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0EI4B	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0EI4B	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0EI4B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08XYL	TTDDRUID	D08XYL
D08XYL	DRUGNAME	N-phenyl-pyridine-2-carboxamide derivative 3
D08XYL	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D08XYL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D08XYL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D08XYL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03VXQ	TTDDRUID	D03VXQ
D03VXQ	DRUGNAME	Oxetane 3,3-dicarboxamide compound 1
D03VXQ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Patented

D0ZE2J	TTDDRUID	D0ZE2J
D0ZE2J	DRUGNAME	Oxetane 3,3-dicarboxamide compound 2
D0ZE2J	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Patented

D0QM0D	TTDDRUID	D0QM0D
D0QM0D	DRUGNAME	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1
D0QM0D	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D0O3JR	TTDDRUID	D0O3JR
D0O3JR	DRUGNAME	P-coumaric acid derivative 1
D0O3JR	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0O3JR	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0O3JR	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0O3JR	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0O3JR	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0SF6C	TTDDRUID	D0SF6C
D0SF6C	DRUGNAME	P-coumaric acid derivative 2
D0SF6C	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0SF6C	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0SF6C	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0SF6C	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0SF6C	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0J4YH	TTDDRUID	D0J4YH
D0J4YH	DRUGNAME	P-coumaric acid derivative 3
D0J4YH	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0J4YH	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0J4YH	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0J4YH	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0J4YH	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D06LMS	TTDDRUID	D06LMS
D06LMS	DRUGNAME	P-coumaric acid derivative 4
D06LMS	INDICATI	Albinism [ICD-11: EC23.2] Patented
D06LMS	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D06LMS	INDICATI	Melasma [ICD-11: ED60.1] Patented
D06LMS	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D06LMS	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0SJ4S	TTDDRUID	D0SJ4S
D0SJ4S	DRUGNAME	P-coumaric acid derivative 5
D0SJ4S	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0SJ4S	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0SJ4S	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0SJ4S	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0SJ4S	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D01VTT	TTDDRUID	D01VTT
D01VTT	DRUGNAME	P-coumaric acid derivative 6
D01VTT	INDICATI	Albinism [ICD-11: EC23.2] Patented
D01VTT	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D01VTT	INDICATI	Melasma [ICD-11: ED60.1] Patented
D01VTT	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D01VTT	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0VB9M	TTDDRUID	D0VB9M
D0VB9M	DRUGNAME	Peptide analog 1
D0VB9M	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0VB9M	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0VB9M	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0VB9M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02SES	TTDDRUID	D02SES
D02SES	DRUGNAME	Peptide analog 2
D02SES	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D02SES	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D02SES	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D02SES	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0HF7V	TTDDRUID	D0HF7V
D0HF7V	DRUGNAME	Peptide analog 3
D0HF7V	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0HF7V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0HF7V	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0HF7V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Z9UJ	TTDDRUID	D0Z9UJ
D0Z9UJ	DRUGNAME	Peptide analog 4
D0Z9UJ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0Z9UJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0Z9UJ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0Z9UJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0FK6N	TTDDRUID	D0FK6N
D0FK6N	DRUGNAME	Peptide analog 5
D0FK6N	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0FK6N	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0FK6N	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0FK6N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0I7UZ	TTDDRUID	D0I7UZ
D0I7UZ	DRUGNAME	Peptide analog 6
D0I7UZ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0I7UZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0I7UZ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0I7UZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D01MKD	TTDDRUID	D01MKD
D01MKD	DRUGNAME	Phenylalanine derivative 1
D01MKD	INDICATI	Glioma [ICD-11: 2A00.0] Patented

D00CRQ	TTDDRUID	D00CRQ
D00CRQ	DRUGNAME	Phenylate derivative 1
D00CRQ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D00CRQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D00CRQ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D00CRQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02XVC	TTDDRUID	D02XVC
D02XVC	DRUGNAME	Phenylate derivative 2
D02XVC	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D02XVC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D02XVC	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D02XVC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0JJ1Y	TTDDRUID	D0JJ1Y
D0JJ1Y	DRUGNAME	Phenylate derivative 3
D0JJ1Y	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0JJ1Y	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0JJ1Y	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0JJ1Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0W3RA	TTDDRUID	D0W3RA
D0W3RA	DRUGNAME	Phenylsulfonyl derivative 1
D0W3RA	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented

D04DUF	TTDDRUID	D04DUF
D04DUF	DRUGNAME	Phenylsulfonyl derivative 2
D04DUF	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented

D0D8LP	TTDDRUID	D0D8LP
D0D8LP	DRUGNAME	Phenylsulfonyl derivative 3
D0D8LP	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented

D0ZC7W	TTDDRUID	D0ZC7W
D0ZC7W	DRUGNAME	Phenylsulfonyl derivative 4
D0ZC7W	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented

D0IG6J	TTDDRUID	D0IG6J
D0IG6J	DRUGNAME	Piperazine derivative 1
D0IG6J	INDICATI	Obesity [ICD-11: 5B81] Patented

D0PK0R	TTDDRUID	D0PK0R
D0PK0R	DRUGNAME	Piperazine derivative 2
D0PK0R	INDICATI	Obesity [ICD-11: 5B81] Patented

D0LT5Y	TTDDRUID	D0LT5Y
D0LT5Y	DRUGNAME	Piperazine derivative 5
D0LT5Y	INDICATI	Atopic dermatitis [ICD-11: EA80] Patented

D0H1JS	TTDDRUID	D0H1JS
D0H1JS	DRUGNAME	Piperazine urea derivative 3
D0H1JS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D0H1JS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04GIJ	TTDDRUID	D04GIJ
D04GIJ	DRUGNAME	Piperazine urea derivative 4
D04GIJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D04GIJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04YKO	TTDDRUID	D04YKO
D04YKO	DRUGNAME	Piperidine derivative 2
D04YKO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D04YKO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0S6SJ	TTDDRUID	D0S6SJ
D0S6SJ	DRUGNAME	Piperidine derivative 3
D0S6SJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
D0S6SJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0S7KA	TTDDRUID	D0S7KA
D0S7KA	DRUGNAME	PMID25399762-Compound-Table 8-(-)-deprenyl
D0S7KA	INDICATI	Alopecia [ICD-11: ED70] Patented

D0YY8N	TTDDRUID	D0YY8N
D0YY8N	DRUGNAME	PMID25470667-Compound-GO-CoA-Tat
D0YY8N	INDICATI	Obesity [ICD-11: 5B81] Patented
D0YY8N	INDICATI	Type-2 diabetes [ICD-11: 5A11] Patented

D0E7ZN	TTDDRUID	D0E7ZN
D0E7ZN	DRUGNAME	PMID25553724-Compound-US2011000295210
D0E7ZN	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0Y2RN	TTDDRUID	D0Y2RN
D0Y2RN	DRUGNAME	PMID25553724-Compound-US2011788838110
D0Y2RN	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0BQ8A	TTDDRUID	D0BQ8A
D0BQ8A	DRUGNAME	PMID25553724-Compound-US2011796857710
D0BQ8A	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0BL3X	TTDDRUID	D0BL3X
D0BL3X	DRUGNAME	PMID25553724-Compound-US2011799419010
D0BL3X	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0DL3R	TTDDRUID	D0DL3R
D0DL3R	DRUGNAME	PMID25553724-Compound-US2011801300410
D0DL3R	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0GN7U	TTDDRUID	D0GN7U
D0GN7U	DRUGNAME	PMID25553724-Compound-US2011803494010
D0GN7U	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0F9GL	TTDDRUID	D0F9GL
D0F9GL	DRUGNAME	PMID25553724-Compound-US2011806744710
D0F9GL	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0LT6Z	TTDDRUID	D0LT6Z
D0LT6Z	DRUGNAME	PMID25553724-Compound-US2012810604610
D0LT6Z	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0Q5YJ	TTDDRUID	D0Q5YJ
D0Q5YJ	DRUGNAME	PMID25553724-Compound-US2012819831110
D0Q5YJ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D08NGV	TTDDRUID	D08NGV
D08NGV	DRUGNAME	PMID25553724-Compound-US2012820715110
D08NGV	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D04NMJ	TTDDRUID	D04NMJ
D04NMJ	DRUGNAME	PMID25553724-Compound-US2012830453910
D04NMJ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0F5TR	TTDDRUID	D0F5TR
D0F5TR	DRUGNAME	PMID25553724-Compound-US2012832440110
D0F5TR	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented

D0Z4QJ	TTDDRUID	D0Z4QJ
D0Z4QJ	DRUGNAME	PMID25623274-Compound-WO2014132220C1
D0Z4QJ	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Patented

D0S6IA	TTDDRUID	D0S6IA
D0S6IA	DRUGNAME	PMID25623274-Compound-WO2014132220C2
D0S6IA	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Patented

D0Y4EU	TTDDRUID	D0Y4EU
D0Y4EU	DRUGNAME	PMID25656651-Compound-11a
D0Y4EU	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented

D0DC7I	TTDDRUID	D0DC7I
D0DC7I	DRUGNAME	PMID25656651-Compound-11b
D0DC7I	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented

D05YAD	TTDDRUID	D05YAD
D05YAD	DRUGNAME	PMID25656651-Compound-11c
D05YAD	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented

D0WL1U	TTDDRUID	D0WL1U
D0WL1U	DRUGNAME	PMID25656651-Compound-5
D0WL1U	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented

D0KB2Z	TTDDRUID	D0KB2Z
D0KB2Z	DRUGNAME	PMID25666693-Compound-1
D0KB2Z	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0KB2Z	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0KB2Z	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0KB2Z	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0C1MZ	TTDDRUID	D0C1MZ
D0C1MZ	DRUGNAME	PMID25666693-Compound-10
D0C1MZ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0C1MZ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0C1MZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0C1MZ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0Y1SI	TTDDRUID	D0Y1SI
D0Y1SI	DRUGNAME	PMID25666693-Compound-100
D0Y1SI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0Y1SI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0Y1SI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0Y1SI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0F3HP	TTDDRUID	D0F3HP
D0F3HP	DRUGNAME	PMID25666693-Compound-101
D0F3HP	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0F3HP	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0F3HP	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0F3HP	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0IK1S	TTDDRUID	D0IK1S
D0IK1S	DRUGNAME	PMID25666693-Compound-102
D0IK1S	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0IK1S	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0IK1S	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0IK1S	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D01LGQ	TTDDRUID	D01LGQ
D01LGQ	DRUGNAME	PMID25666693-Compound-103
D01LGQ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D01LGQ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D01LGQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D01LGQ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D01RUK	TTDDRUID	D01RUK
D01RUK	DRUGNAME	PMID25666693-Compound-104
D01RUK	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D01RUK	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D01RUK	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D01RUK	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0ZP2C	TTDDRUID	D0ZP2C
D0ZP2C	DRUGNAME	PMID25666693-Compound-105
D0ZP2C	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0ZP2C	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0ZP2C	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZP2C	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0R2VB	TTDDRUID	D0R2VB
D0R2VB	DRUGNAME	PMID25666693-Compound-106
D0R2VB	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0R2VB	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0R2VB	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0R2VB	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0ZE1M	TTDDRUID	D0ZE1M
D0ZE1M	DRUGNAME	PMID25666693-Compound-107
D0ZE1M	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0ZE1M	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0ZE1M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZE1M	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0D4NX	TTDDRUID	D0D4NX
D0D4NX	DRUGNAME	PMID25666693-Compound-108
D0D4NX	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0D4NX	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0D4NX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0D4NX	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0MY3K	TTDDRUID	D0MY3K
D0MY3K	DRUGNAME	PMID25666693-Compound-109
D0MY3K	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0MY3K	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0MY3K	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0MY3K	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0HE7X	TTDDRUID	D0HE7X
D0HE7X	DRUGNAME	PMID25666693-Compound-11
D0HE7X	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0HE7X	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0HE7X	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0HE7X	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0E0SA	TTDDRUID	D0E0SA
D0E0SA	DRUGNAME	PMID25666693-Compound-110
D0E0SA	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0E0SA	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0E0SA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0E0SA	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D08YAL	TTDDRUID	D08YAL
D08YAL	DRUGNAME	PMID25666693-Compound-111
D08YAL	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D08YAL	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D08YAL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D08YAL	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0PT0U	TTDDRUID	D0PT0U
D0PT0U	DRUGNAME	PMID25666693-Compound-112
D0PT0U	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0PT0U	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0PT0U	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0PT0U	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0A8LU	TTDDRUID	D0A8LU
D0A8LU	DRUGNAME	PMID25666693-Compound-113
D0A8LU	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0A8LU	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0A8LU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0A8LU	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0C5NT	TTDDRUID	D0C5NT
D0C5NT	DRUGNAME	PMID25666693-Compound-114
D0C5NT	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0C5NT	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0C5NT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0C5NT	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0D2CF	TTDDRUID	D0D2CF
D0D2CF	DRUGNAME	PMID25666693-Compound-115
D0D2CF	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0D2CF	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0D2CF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0D2CF	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D05SMP	TTDDRUID	D05SMP
D05SMP	DRUGNAME	PMID25666693-Compound-116
D05SMP	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D05SMP	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D05SMP	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D05SMP	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07FWF	TTDDRUID	D07FWF
D07FWF	DRUGNAME	PMID25666693-Compound-117
D07FWF	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07FWF	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07FWF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07FWF	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0EH2T	TTDDRUID	D0EH2T
D0EH2T	DRUGNAME	PMID25666693-Compound-118
D0EH2T	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0EH2T	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0EH2T	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0EH2T	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07XVL	TTDDRUID	D07XVL
D07XVL	DRUGNAME	PMID25666693-Compound-119
D07XVL	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07XVL	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07XVL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07XVL	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0C8ZZ	TTDDRUID	D0C8ZZ
D0C8ZZ	DRUGNAME	PMID25666693-Compound-12
D0C8ZZ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0C8ZZ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0C8ZZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0C8ZZ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0WX4W	TTDDRUID	D0WX4W
D0WX4W	DRUGNAME	PMID25666693-Compound-120
D0WX4W	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0WX4W	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0WX4W	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0WX4W	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D00KTN	TTDDRUID	D00KTN
D00KTN	DRUGNAME	PMID25666693-Compound-121
D00KTN	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D00KTN	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D00KTN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00KTN	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0R2QV	TTDDRUID	D0R2QV
D0R2QV	DRUGNAME	PMID25666693-Compound-122
D0R2QV	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0R2QV	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0R2QV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0R2QV	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D08CLA	TTDDRUID	D08CLA
D08CLA	DRUGNAME	PMID25666693-Compound-123
D08CLA	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D08CLA	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D08CLA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D08CLA	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0DT7M	TTDDRUID	D0DT7M
D0DT7M	DRUGNAME	PMID25666693-Compound-124
D0DT7M	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0DT7M	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0DT7M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DT7M	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0U5ON	TTDDRUID	D0U5ON
D0U5ON	DRUGNAME	PMID25666693-Compound-125
D0U5ON	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0U5ON	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0U5ON	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0U5ON	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D02EKO	TTDDRUID	D02EKO
D02EKO	DRUGNAME	PMID25666693-Compound-126
D02EKO	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D02EKO	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D02EKO	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02EKO	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07MNI	TTDDRUID	D07MNI
D07MNI	DRUGNAME	PMID25666693-Compound-127
D07MNI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07MNI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07MNI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07MNI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D09SMA	TTDDRUID	D09SMA
D09SMA	DRUGNAME	PMID25666693-Compound-128
D09SMA	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D09SMA	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D09SMA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D09SMA	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0PJ8O	TTDDRUID	D0PJ8O
D0PJ8O	DRUGNAME	PMID25666693-Compound-129
D0PJ8O	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0PJ8O	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0PJ8O	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0PJ8O	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D08ICT	TTDDRUID	D08ICT
D08ICT	DRUGNAME	PMID25666693-Compound-13
D08ICT	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D08ICT	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D08ICT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D08ICT	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0DI1R	TTDDRUID	D0DI1R
D0DI1R	DRUGNAME	PMID25666693-Compound-130
D0DI1R	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0DI1R	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0DI1R	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DI1R	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07RYM	TTDDRUID	D07RYM
D07RYM	DRUGNAME	PMID25666693-Compound-131
D07RYM	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07RYM	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07RYM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07RYM	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0WT1W	TTDDRUID	D0WT1W
D0WT1W	DRUGNAME	PMID25666693-Compound-132
D0WT1W	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0WT1W	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0WT1W	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0WT1W	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D01GEK	TTDDRUID	D01GEK
D01GEK	DRUGNAME	PMID25666693-Compound-133
D01GEK	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D01GEK	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D01GEK	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D01GEK	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07XZR	TTDDRUID	D07XZR
D07XZR	DRUGNAME	PMID25666693-Compound-134
D07XZR	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07XZR	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07XZR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07XZR	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D08UEC	TTDDRUID	D08UEC
D08UEC	DRUGNAME	PMID25666693-Compound-135
D08UEC	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D08UEC	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D08UEC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D08UEC	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0O3TG	TTDDRUID	D0O3TG
D0O3TG	DRUGNAME	PMID25666693-Compound-136
D0O3TG	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0O3TG	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0O3TG	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0O3TG	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0KM0W	TTDDRUID	D0KM0W
D0KM0W	DRUGNAME	PMID25666693-Compound-137
D0KM0W	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0KM0W	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0KM0W	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0KM0W	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0CR0H	TTDDRUID	D0CR0H
D0CR0H	DRUGNAME	PMID25666693-Compound-138
D0CR0H	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0CR0H	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0CR0H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0CR0H	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0RC7L	TTDDRUID	D0RC7L
D0RC7L	DRUGNAME	PMID25666693-Compound-139
D0RC7L	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0RC7L	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0RC7L	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0RC7L	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0R8GA	TTDDRUID	D0R8GA
D0R8GA	DRUGNAME	PMID25666693-Compound-14
D0R8GA	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0R8GA	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0R8GA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0R8GA	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D02JQB	TTDDRUID	D02JQB
D02JQB	DRUGNAME	PMID25666693-Compound-140
D02JQB	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D02JQB	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D02JQB	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02JQB	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0K0ZI	TTDDRUID	D0K0ZI
D0K0ZI	DRUGNAME	PMID25666693-Compound-141
D0K0ZI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0K0ZI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0K0ZI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0K0ZI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0NH2M	TTDDRUID	D0NH2M
D0NH2M	DRUGNAME	PMID25666693-Compound-142
D0NH2M	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0NH2M	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0NH2M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0NH2M	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0G6IQ	TTDDRUID	D0G6IQ
D0G6IQ	DRUGNAME	PMID25666693-Compound-143
D0G6IQ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0G6IQ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0G6IQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0G6IQ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0Z5HH	TTDDRUID	D0Z5HH
D0Z5HH	DRUGNAME	PMID25666693-Compound-144
D0Z5HH	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0Z5HH	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0Z5HH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0Z5HH	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D03VXP	TTDDRUID	D03VXP
D03VXP	DRUGNAME	PMID25666693-Compound-145
D03VXP	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D03VXP	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D03VXP	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03VXP	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0N0QN	TTDDRUID	D0N0QN
D0N0QN	DRUGNAME	PMID25666693-Compound-146
D0N0QN	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0N0QN	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0N0QN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0N0QN	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0JT8B	TTDDRUID	D0JT8B
D0JT8B	DRUGNAME	PMID25666693-Compound-147
D0JT8B	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0JT8B	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0JT8B	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0JT8B	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0K3KM	TTDDRUID	D0K3KM
D0K3KM	DRUGNAME	PMID25666693-Compound-148
D0K3KM	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0K3KM	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0K3KM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0K3KM	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D00OLY	TTDDRUID	D00OLY
D00OLY	DRUGNAME	PMID25666693-Compound-149
D00OLY	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D00OLY	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D00OLY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00OLY	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0F4YX	TTDDRUID	D0F4YX
D0F4YX	DRUGNAME	PMID25666693-Compound-15
D0F4YX	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0F4YX	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0F4YX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0F4YX	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D01DNH	TTDDRUID	D01DNH
D01DNH	DRUGNAME	PMID25666693-Compound-150
D01DNH	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D01DNH	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D01DNH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D01DNH	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0YU9B	TTDDRUID	D0YU9B
D0YU9B	DRUGNAME	PMID25666693-Compound-151
D0YU9B	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0YU9B	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0YU9B	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0YU9B	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0ZS3E	TTDDRUID	D0ZS3E
D0ZS3E	DRUGNAME	PMID25666693-Compound-152
D0ZS3E	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0ZS3E	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0ZS3E	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZS3E	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0AQ3U	TTDDRUID	D0AQ3U
D0AQ3U	DRUGNAME	PMID25666693-Compound-153
D0AQ3U	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0AQ3U	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0AQ3U	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0AQ3U	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D04TIU	TTDDRUID	D04TIU
D04TIU	DRUGNAME	PMID25666693-Compound-154
D04TIU	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D04TIU	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D04TIU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D04TIU	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0K3KE	TTDDRUID	D0K3KE
D0K3KE	DRUGNAME	PMID25666693-Compound-155
D0K3KE	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0K3KE	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0K3KE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0K3KE	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0N0TF	TTDDRUID	D0N0TF
D0N0TF	DRUGNAME	PMID25666693-Compound-156
D0N0TF	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0N0TF	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0N0TF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0N0TF	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0NV2M	TTDDRUID	D0NV2M
D0NV2M	DRUGNAME	PMID25666693-Compound-157
D0NV2M	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0NV2M	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0NV2M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0NV2M	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D01HED	TTDDRUID	D01HED
D01HED	DRUGNAME	PMID25666693-Compound-158
D01HED	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D01HED	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D01HED	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D01HED	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0I3ZW	TTDDRUID	D0I3ZW
D0I3ZW	DRUGNAME	PMID25666693-Compound-159
D0I3ZW	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0I3ZW	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0I3ZW	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0I3ZW	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0SD4G	TTDDRUID	D0SD4G
D0SD4G	DRUGNAME	PMID25666693-Compound-16
D0SD4G	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0SD4G	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0SD4G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0SD4G	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0Z4QQ	TTDDRUID	D0Z4QQ
D0Z4QQ	DRUGNAME	PMID25666693-Compound-160
D0Z4QQ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0Z4QQ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0Z4QQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0Z4QQ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0XX8R	TTDDRUID	D0XX8R
D0XX8R	DRUGNAME	PMID25666693-Compound-161
D0XX8R	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0XX8R	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0XX8R	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0XX8R	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0LA0Q	TTDDRUID	D0LA0Q
D0LA0Q	DRUGNAME	PMID25666693-Compound-162
D0LA0Q	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0LA0Q	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0LA0Q	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0LA0Q	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07JNJ	TTDDRUID	D07JNJ
D07JNJ	DRUGNAME	PMID25666693-Compound-17
D07JNJ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07JNJ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07JNJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07JNJ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0ZM8H	TTDDRUID	D0ZM8H
D0ZM8H	DRUGNAME	PMID25666693-Compound-18
D0ZM8H	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0ZM8H	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0ZM8H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZM8H	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0NM3D	TTDDRUID	D0NM3D
D0NM3D	DRUGNAME	PMID25666693-Compound-19
D0NM3D	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0NM3D	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0NM3D	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0NM3D	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D00YXA	TTDDRUID	D00YXA
D00YXA	DRUGNAME	PMID25666693-Compound-2
D00YXA	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D00YXA	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D00YXA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00YXA	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0HS1D	TTDDRUID	D0HS1D
D0HS1D	DRUGNAME	PMID25666693-Compound-20
D0HS1D	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0HS1D	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0HS1D	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0HS1D	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0YR4E	TTDDRUID	D0YR4E
D0YR4E	DRUGNAME	PMID25666693-Compound-21
D0YR4E	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0YR4E	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0YR4E	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0YR4E	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0JK2N	TTDDRUID	D0JK2N
D0JK2N	DRUGNAME	PMID25666693-Compound-22
D0JK2N	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0JK2N	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0JK2N	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0JK2N	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D02QJE	TTDDRUID	D02QJE
D02QJE	DRUGNAME	PMID25666693-Compound-23
D02QJE	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D02QJE	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D02QJE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02QJE	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0N2UQ	TTDDRUID	D0N2UQ
D0N2UQ	DRUGNAME	PMID25666693-Compound-24
D0N2UQ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0N2UQ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0N2UQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0N2UQ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0A3XC	TTDDRUID	D0A3XC
D0A3XC	DRUGNAME	PMID25666693-Compound-25
D0A3XC	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0A3XC	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0A3XC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0A3XC	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0EV3G	TTDDRUID	D0EV3G
D0EV3G	DRUGNAME	PMID25666693-Compound-26
D0EV3G	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0EV3G	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0EV3G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0EV3G	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0IR7H	TTDDRUID	D0IR7H
D0IR7H	DRUGNAME	PMID25666693-Compound-27
D0IR7H	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0IR7H	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0IR7H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0IR7H	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D05SWL	TTDDRUID	D05SWL
D05SWL	DRUGNAME	PMID25666693-Compound-28
D05SWL	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D05SWL	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D05SWL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D05SWL	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0M4WY	TTDDRUID	D0M4WY
D0M4WY	DRUGNAME	PMID25666693-Compound-29
D0M4WY	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0M4WY	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0M4WY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0M4WY	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D06VYF	TTDDRUID	D06VYF
D06VYF	DRUGNAME	PMID25666693-Compound-3
D06VYF	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D06VYF	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D06VYF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D06VYF	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0F4DI	TTDDRUID	D0F4DI
D0F4DI	DRUGNAME	PMID25666693-Compound-30
D0F4DI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0F4DI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0F4DI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0F4DI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0JC8L	TTDDRUID	D0JC8L
D0JC8L	DRUGNAME	PMID25666693-Compound-31
D0JC8L	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0JC8L	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0JC8L	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0JC8L	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0R9RP	TTDDRUID	D0R9RP
D0R9RP	DRUGNAME	PMID25666693-Compound-32
D0R9RP	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0R9RP	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0R9RP	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0R9RP	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0W4AA	TTDDRUID	D0W4AA
D0W4AA	DRUGNAME	PMID25666693-Compound-33
D0W4AA	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0W4AA	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0W4AA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0W4AA	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0A0YI	TTDDRUID	D0A0YI
D0A0YI	DRUGNAME	PMID25666693-Compound-34
D0A0YI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0A0YI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0A0YI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0A0YI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0NB5M	TTDDRUID	D0NB5M
D0NB5M	DRUGNAME	PMID25666693-Compound-35
D0NB5M	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0NB5M	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0NB5M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0NB5M	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0V3PI	TTDDRUID	D0V3PI
D0V3PI	DRUGNAME	PMID25666693-Compound-36
D0V3PI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0V3PI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0V3PI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0V3PI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D06JHW	TTDDRUID	D06JHW
D06JHW	DRUGNAME	PMID25666693-Compound-37
D06JHW	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D06JHW	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D06JHW	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D06JHW	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0TZ2W	TTDDRUID	D0TZ2W
D0TZ2W	DRUGNAME	PMID25666693-Compound-38
D0TZ2W	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0TZ2W	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0TZ2W	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0TZ2W	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0X1OO	TTDDRUID	D0X1OO
D0X1OO	DRUGNAME	PMID25666693-Compound-39
D0X1OO	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0X1OO	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0X1OO	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0X1OO	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0GZ4G	TTDDRUID	D0GZ4G
D0GZ4G	DRUGNAME	PMID25666693-Compound-4
D0GZ4G	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0GZ4G	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0GZ4G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0GZ4G	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D09ZWU	TTDDRUID	D09ZWU
D09ZWU	DRUGNAME	PMID25666693-Compound-40
D09ZWU	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D09ZWU	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D09ZWU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D09ZWU	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07EAV	TTDDRUID	D07EAV
D07EAV	DRUGNAME	PMID25666693-Compound-41
D07EAV	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07EAV	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07EAV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07EAV	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0DE5K	TTDDRUID	D0DE5K
D0DE5K	DRUGNAME	PMID25666693-Compound-42
D0DE5K	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0DE5K	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0DE5K	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DE5K	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0P9KJ	TTDDRUID	D0P9KJ
D0P9KJ	DRUGNAME	PMID25666693-Compound-43
D0P9KJ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0P9KJ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0P9KJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0P9KJ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D04FRL	TTDDRUID	D04FRL
D04FRL	DRUGNAME	PMID25666693-Compound-44
D04FRL	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D04FRL	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D04FRL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D04FRL	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0U8YZ	TTDDRUID	D0U8YZ
D0U8YZ	DRUGNAME	PMID25666693-Compound-45
D0U8YZ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0U8YZ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0U8YZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0U8YZ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0K4SZ	TTDDRUID	D0K4SZ
D0K4SZ	DRUGNAME	PMID25666693-Compound-46
D0K4SZ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0K4SZ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0K4SZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0K4SZ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0MU3S	TTDDRUID	D0MU3S
D0MU3S	DRUGNAME	PMID25666693-Compound-47
D0MU3S	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0MU3S	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0MU3S	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0MU3S	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0IN5E	TTDDRUID	D0IN5E
D0IN5E	DRUGNAME	PMID25666693-Compound-48
D0IN5E	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0IN5E	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0IN5E	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0IN5E	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0P5SB	TTDDRUID	D0P5SB
D0P5SB	DRUGNAME	PMID25666693-Compound-49
D0P5SB	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0P5SB	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0P5SB	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0P5SB	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D02OAH	TTDDRUID	D02OAH
D02OAH	DRUGNAME	PMID25666693-Compound-5
D02OAH	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D02OAH	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D02OAH	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02OAH	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07FIY	TTDDRUID	D07FIY
D07FIY	DRUGNAME	PMID25666693-Compound-50
D07FIY	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07FIY	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07FIY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07FIY	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0B0WJ	TTDDRUID	D0B0WJ
D0B0WJ	DRUGNAME	PMID25666693-Compound-51
D0B0WJ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0B0WJ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0B0WJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0B0WJ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0IU1H	TTDDRUID	D0IU1H
D0IU1H	DRUGNAME	PMID25666693-Compound-52
D0IU1H	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0IU1H	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0IU1H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0IU1H	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0OA1P	TTDDRUID	D0OA1P
D0OA1P	DRUGNAME	PMID25666693-Compound-53
D0OA1P	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0OA1P	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0OA1P	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0OA1P	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0U5CQ	TTDDRUID	D0U5CQ
D0U5CQ	DRUGNAME	PMID25666693-Compound-54
D0U5CQ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0U5CQ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0U5CQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0U5CQ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0G3UV	TTDDRUID	D0G3UV
D0G3UV	DRUGNAME	PMID25666693-Compound-55
D0G3UV	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0G3UV	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0G3UV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0G3UV	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07EGF	TTDDRUID	D07EGF
D07EGF	DRUGNAME	PMID25666693-Compound-56
D07EGF	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07EGF	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07EGF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07EGF	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0P0MR	TTDDRUID	D0P0MR
D0P0MR	DRUGNAME	PMID25666693-Compound-57
D0P0MR	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0P0MR	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0P0MR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0P0MR	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D01PLJ	TTDDRUID	D01PLJ
D01PLJ	DRUGNAME	PMID25666693-Compound-58
D01PLJ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D01PLJ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D01PLJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D01PLJ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0J9CS	TTDDRUID	D0J9CS
D0J9CS	DRUGNAME	PMID25666693-Compound-59
D0J9CS	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0J9CS	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0J9CS	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0J9CS	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0O7IQ	TTDDRUID	D0O7IQ
D0O7IQ	DRUGNAME	PMID25666693-Compound-6
D0O7IQ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0O7IQ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0O7IQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0O7IQ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D00QEZ	TTDDRUID	D00QEZ
D00QEZ	DRUGNAME	PMID25666693-Compound-60
D00QEZ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D00QEZ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D00QEZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00QEZ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D03QAW	TTDDRUID	D03QAW
D03QAW	DRUGNAME	PMID25666693-Compound-61
D03QAW	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D03QAW	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D03QAW	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03QAW	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0JX4I	TTDDRUID	D0JX4I
D0JX4I	DRUGNAME	PMID25666693-Compound-62
D0JX4I	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0JX4I	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0JX4I	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0JX4I	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0O9GI	TTDDRUID	D0O9GI
D0O9GI	DRUGNAME	PMID25666693-Compound-63
D0O9GI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0O9GI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0O9GI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0O9GI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0Y9ST	TTDDRUID	D0Y9ST
D0Y9ST	DRUGNAME	PMID25666693-Compound-64
D0Y9ST	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0Y9ST	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0Y9ST	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0Y9ST	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0F5NQ	TTDDRUID	D0F5NQ
D0F5NQ	DRUGNAME	PMID25666693-Compound-65
D0F5NQ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0F5NQ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0F5NQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0F5NQ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0GV5G	TTDDRUID	D0GV5G
D0GV5G	DRUGNAME	PMID25666693-Compound-66
D0GV5G	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0GV5G	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0GV5G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0GV5G	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0YM1M	TTDDRUID	D0YM1M
D0YM1M	DRUGNAME	PMID25666693-Compound-67
D0YM1M	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0YM1M	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0YM1M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0YM1M	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0ZZ8F	TTDDRUID	D0ZZ8F
D0ZZ8F	DRUGNAME	PMID25666693-Compound-68
D0ZZ8F	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0ZZ8F	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0ZZ8F	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZZ8F	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0E8UP	TTDDRUID	D0E8UP
D0E8UP	DRUGNAME	PMID25666693-Compound-69
D0E8UP	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0E8UP	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0E8UP	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0E8UP	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0N9FJ	TTDDRUID	D0N9FJ
D0N9FJ	DRUGNAME	PMID25666693-Compound-7
D0N9FJ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0N9FJ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0N9FJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0N9FJ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D03EEA	TTDDRUID	D03EEA
D03EEA	DRUGNAME	PMID25666693-Compound-70
D03EEA	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D03EEA	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D03EEA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03EEA	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D03YFL	TTDDRUID	D03YFL
D03YFL	DRUGNAME	PMID25666693-Compound-71
D03YFL	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D03YFL	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D03YFL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03YFL	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0H6CX	TTDDRUID	D0H6CX
D0H6CX	DRUGNAME	PMID25666693-Compound-72
D0H6CX	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0H6CX	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0H6CX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0H6CX	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D03FSF	TTDDRUID	D03FSF
D03FSF	DRUGNAME	PMID25666693-Compound-73
D03FSF	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D03FSF	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D03FSF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03FSF	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0DC4O	TTDDRUID	D0DC4O
D0DC4O	DRUGNAME	PMID25666693-Compound-74
D0DC4O	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0DC4O	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0DC4O	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DC4O	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0OC6A	TTDDRUID	D0OC6A
D0OC6A	DRUGNAME	PMID25666693-Compound-75
D0OC6A	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0OC6A	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0OC6A	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0OC6A	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0CX4C	TTDDRUID	D0CX4C
D0CX4C	DRUGNAME	PMID25666693-Compound-76
D0CX4C	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0CX4C	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0CX4C	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0CX4C	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0B4NI	TTDDRUID	D0B4NI
D0B4NI	DRUGNAME	PMID25666693-Compound-77
D0B4NI	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0B4NI	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0B4NI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0B4NI	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0DE5I	TTDDRUID	D0DE5I
D0DE5I	DRUGNAME	PMID25666693-Compound-78
D0DE5I	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0DE5I	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0DE5I	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DE5I	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D09QXC	TTDDRUID	D09QXC
D09QXC	DRUGNAME	PMID25666693-Compound-79
D09QXC	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D09QXC	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D09QXC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D09QXC	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0ON4M	TTDDRUID	D0ON4M
D0ON4M	DRUGNAME	PMID25666693-Compound-8
D0ON4M	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0ON4M	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0ON4M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ON4M	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0H4TR	TTDDRUID	D0H4TR
D0H4TR	DRUGNAME	PMID25666693-Compound-80
D0H4TR	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0H4TR	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0H4TR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0H4TR	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0QP4N	TTDDRUID	D0QP4N
D0QP4N	DRUGNAME	PMID25666693-Compound-81
D0QP4N	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0QP4N	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0QP4N	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0QP4N	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0EC3Z	TTDDRUID	D0EC3Z
D0EC3Z	DRUGNAME	PMID25666693-Compound-82
D0EC3Z	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0EC3Z	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0EC3Z	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0EC3Z	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0UE9K	TTDDRUID	D0UE9K
D0UE9K	DRUGNAME	PMID25666693-Compound-83
D0UE9K	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0UE9K	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0UE9K	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0UE9K	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D08ZBB	TTDDRUID	D08ZBB
D08ZBB	DRUGNAME	PMID25666693-Compound-84
D08ZBB	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D08ZBB	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D08ZBB	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D08ZBB	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D07BZW	TTDDRUID	D07BZW
D07BZW	DRUGNAME	PMID25666693-Compound-85
D07BZW	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D07BZW	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D07BZW	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07BZW	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0O0UG	TTDDRUID	D0O0UG
D0O0UG	DRUGNAME	PMID25666693-Compound-86
D0O0UG	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0O0UG	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0O0UG	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0O0UG	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0C9FN	TTDDRUID	D0C9FN
D0C9FN	DRUGNAME	PMID25666693-Compound-87
D0C9FN	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0C9FN	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0C9FN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0C9FN	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D03SHM	TTDDRUID	D03SHM
D03SHM	DRUGNAME	PMID25666693-Compound-88
D03SHM	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D03SHM	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D03SHM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03SHM	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0V9RM	TTDDRUID	D0V9RM
D0V9RM	DRUGNAME	PMID25666693-Compound-89
D0V9RM	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0V9RM	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0V9RM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0V9RM	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0IP5E	TTDDRUID	D0IP5E
D0IP5E	DRUGNAME	PMID25666693-Compound-9
D0IP5E	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0IP5E	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0IP5E	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0IP5E	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D05ZWR	TTDDRUID	D05ZWR
D05ZWR	DRUGNAME	PMID25666693-Compound-90
D05ZWR	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D05ZWR	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D05ZWR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D05ZWR	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0WJ8R	TTDDRUID	D0WJ8R
D0WJ8R	DRUGNAME	PMID25666693-Compound-91
D0WJ8R	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0WJ8R	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0WJ8R	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0WJ8R	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0O6VU	TTDDRUID	D0O6VU
D0O6VU	DRUGNAME	PMID25666693-Compound-92
D0O6VU	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0O6VU	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0O6VU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0O6VU	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D04HCS	TTDDRUID	D04HCS
D04HCS	DRUGNAME	PMID25666693-Compound-93
D04HCS	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D04HCS	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D04HCS	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D04HCS	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0IT4N	TTDDRUID	D0IT4N
D0IT4N	DRUGNAME	PMID25666693-Compound-94
D0IT4N	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0IT4N	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0IT4N	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0IT4N	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D00ODY	TTDDRUID	D00ODY
D00ODY	DRUGNAME	PMID25666693-Compound-95
D00ODY	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D00ODY	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D00ODY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00ODY	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0ZQ2W	TTDDRUID	D0ZQ2W
D0ZQ2W	DRUGNAME	PMID25666693-Compound-96
D0ZQ2W	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0ZQ2W	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0ZQ2W	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZQ2W	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D03ZOZ	TTDDRUID	D03ZOZ
D03ZOZ	DRUGNAME	PMID25666693-Compound-97
D03ZOZ	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D03ZOZ	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D03ZOZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D03ZOZ	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0KF3A	TTDDRUID	D0KF3A
D0KF3A	DRUGNAME	PMID25666693-Compound-98
D0KF3A	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D0KF3A	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D0KF3A	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0KF3A	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D05RBF	TTDDRUID	D05RBF
D05RBF	DRUGNAME	PMID25666693-Compound-99
D05RBF	INDICATI	Cancer related pain [ICD-11: MG30] Patented
D05RBF	INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
D05RBF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D05RBF	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented

D0YD1Q	TTDDRUID	D0YD1Q
D0YD1Q	DRUGNAME	PMID25684022-Compound-EP20041486488
D0YD1Q	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0YD1Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0YR5W	TTDDRUID	D0YR5W
D0YR5W	DRUGNAME	PMID25684022-Compound-US20120003668
D0YR5W	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0YR5W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D09FQP	TTDDRUID	D09FQP
D09FQP	DRUGNAME	PMID25684022-Compound-US20120277229 39(1.1)
D09FQP	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D09FQP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06LSZ	TTDDRUID	D06LSZ
D06LSZ	DRUGNAME	PMID25684022-Compound-US20120277229 40(1.2)
D06LSZ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06LSZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04EDM	TTDDRUID	D04EDM
D04EDM	DRUGNAME	PMID25684022-Compound-US20120277229 41(1.3)
D04EDM	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04EDM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0RE3R	TTDDRUID	D0RE3R
D0RE3R	DRUGNAME	PMID25684022-Compound-US20120277229 44(1.4)
D0RE3R	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0RE3R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07ZKE	TTDDRUID	D07ZKE
D07ZKE	DRUGNAME	PMID25684022-Compound-US20120277229 45(1.5)
D07ZKE	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D07ZKE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0SB4A	TTDDRUID	D0SB4A
D0SB4A	DRUGNAME	PMID25684022-Compound-US20130053382 35(1-11)
D0SB4A	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0SB4A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07XBA	TTDDRUID	D07XBA
D07XBA	DRUGNAME	PMID25684022-Compound-US20130053382 36(3-5)
D07XBA	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D07XBA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Y0RG	TTDDRUID	D0Y0RG
D0Y0RG	DRUGNAME	PMID25684022-Compound-US20130053382 37(4-6)
D0Y0RG	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0Y0RG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07FMW	TTDDRUID	D07FMW
D07FMW	DRUGNAME	PMID25684022-Compound-US20130053382 38(5-7)
D07FMW	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D07FMW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0HR1G	TTDDRUID	D0HR1G
D0HR1G	DRUGNAME	PMID25684022-Compound-US20140017701
D0HR1G	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0HR1G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06RGW	TTDDRUID	D06RGW
D06RGW	DRUGNAME	PMID25684022-Compound-WO2004087707
D06RGW	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06RGW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0RP4U	TTDDRUID	D0RP4U
D0RP4U	DRUGNAME	PMID25684022-Compound-WO2006015124
D0RP4U	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0RP4U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08EGT	TTDDRUID	D08EGT
D08EGT	DRUGNAME	PMID25684022-Compound-WO2008005457
D08EGT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D08EGT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04UHW	TTDDRUID	D04UHW
D04UHW	DRUGNAME	PMID25684022-Compound-WO2008079988
D04UHW	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04UHW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0MI3E	TTDDRUID	D0MI3E
D0MI3E	DRUGNAME	PMID25684022-Compound-WO2008107444
D0MI3E	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0MI3E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06LLS	TTDDRUID	D06LLS
D06LLS	DRUGNAME	PMID25684022-Compound-WO2009153313
D06LLS	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06LLS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0C6VX	TTDDRUID	D0C6VX
D0C6VX	DRUGNAME	PMID25684022-Compound-WO2010127754
D0C6VX	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0C6VX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0P0WF	TTDDRUID	D0P0WF
D0P0WF	DRUGNAME	PMID25684022-Compound-WO2011137219 35(1-11)
D0P0WF	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0P0WF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0B8OB	TTDDRUID	D0B8OB
D0B8OB	DRUGNAME	PMID25684022-Compound-WO2011137219 36(3-5)
D0B8OB	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0B8OB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D00SVK	TTDDRUID	D00SVK
D00SVK	DRUGNAME	PMID25684022-Compound-WO2011137219 37(4-6)
D00SVK	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D00SVK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0IO2X	TTDDRUID	D0IO2X
D0IO2X	DRUGNAME	PMID25684022-Compound-WO2011137219 38(5-7)
D0IO2X	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0IO2X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04ICD	TTDDRUID	D04ICD
D04ICD	DRUGNAME	PMID25684022-Compound-WO2012135799 39(1.1)
D04ICD	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04ICD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0F3QQ	TTDDRUID	D0F3QQ
D0F3QQ	DRUGNAME	PMID25684022-Compound-WO2012135799 40(1.2)
D0F3QQ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0F3QQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0PP8Y	TTDDRUID	D0PP8Y
D0PP8Y	DRUGNAME	PMID25684022-Compound-WO2012135799 41(1.3)
D0PP8Y	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0PP8Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0DC2P	TTDDRUID	D0DC2P
D0DC2P	DRUGNAME	PMID25684022-Compound-WO2012135799 42(1.4)
D0DC2P	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0DC2P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0R0SJ	TTDDRUID	D0R0SJ
D0R0SJ	DRUGNAME	PMID25684022-Compound-WO2012135799 43(1.5)
D0R0SJ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0R0SJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08HYE	TTDDRUID	D08HYE
D08HYE	DRUGNAME	PMID25747044-Compound-IgG1-iS18
D08HYE	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D05GJK	TTDDRUID	D05GJK
D05GJK	DRUGNAME	PMID26161824-Compound-116
D05GJK	INDICATI	Obesity [ICD-11: 5B81] Patented

D0DN4Q	TTDDRUID	D0DN4Q
D0DN4Q	DRUGNAME	PMID26161824-Compound-117
D0DN4Q	INDICATI	Obesity [ICD-11: 5B81] Patented

D0F4BD	TTDDRUID	D0F4BD
D0F4BD	DRUGNAME	PMID26161824-Compound-118
D0F4BD	INDICATI	Obesity [ICD-11: 5B81] Patented

D01GDJ	TTDDRUID	D01GDJ
D01GDJ	DRUGNAME	PMID26161824-Compound-119
D01GDJ	INDICATI	Obesity [ICD-11: 5B81] Patented

D07GJH	TTDDRUID	D07GJH
D07GJH	DRUGNAME	PMID26161824-Compound-68
D07GJH	INDICATI	Obesity [ICD-11: 5B81] Patented

D03FDN	TTDDRUID	D03FDN
D03FDN	DRUGNAME	PMID26161824-Compound-69
D03FDN	INDICATI	Obesity [ICD-11: 5B81] Patented

D0HJ7O	TTDDRUID	D0HJ7O
D0HJ7O	DRUGNAME	PMID26161824-Compound-96
D0HJ7O	INDICATI	Obesity [ICD-11: 5B81] Patented

D09LWP	TTDDRUID	D09LWP
D09LWP	DRUGNAME	PMID26651364-Compound-105
D09LWP	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09LWP	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09LWP	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0N4WW	TTDDRUID	D0N4WW
D0N4WW	DRUGNAME	PMID26651364-Compound-106
D0N4WW	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0N4WW	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0N4WW	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0VF5B	TTDDRUID	D0VF5B
D0VF5B	DRUGNAME	PMID26651364-Compound-107
D0VF5B	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0VF5B	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0VF5B	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03JFJ	TTDDRUID	D03JFJ
D03JFJ	DRUGNAME	PMID26651364-Compound-108
D03JFJ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03JFJ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03JFJ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D00XKE	TTDDRUID	D00XKE
D00XKE	DRUGNAME	PMID26651364-Compound-109
D00XKE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D00XKE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D00XKE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0GB6Y	TTDDRUID	D0GB6Y
D0GB6Y	DRUGNAME	PMID26651364-Compound-10a
D0GB6Y	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0GB6Y	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0GB6Y	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0O4TC	TTDDRUID	D0O4TC
D0O4TC	DRUGNAME	PMID26651364-Compound-10b
D0O4TC	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0O4TC	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0O4TC	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0AY0H	TTDDRUID	D0AY0H
D0AY0H	DRUGNAME	PMID26651364-Compound-10c
D0AY0H	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0AY0H	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0AY0H	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0MZ8J	TTDDRUID	D0MZ8J
D0MZ8J	DRUGNAME	PMID26651364-Compound-10d
D0MZ8J	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0MZ8J	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0MZ8J	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0IF4J	TTDDRUID	D0IF4J
D0IF4J	DRUGNAME	PMID26651364-Compound-110
D0IF4J	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0IF4J	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0IF4J	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0WO2I	TTDDRUID	D0WO2I
D0WO2I	DRUGNAME	PMID26651364-Compound-111
D0WO2I	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0WO2I	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0WO2I	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0K3DA	TTDDRUID	D0K3DA
D0K3DA	DRUGNAME	PMID26651364-Compound-112
D0K3DA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0K3DA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0K3DA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0TP8T	TTDDRUID	D0TP8T
D0TP8T	DRUGNAME	PMID26651364-Compound-113
D0TP8T	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0TP8T	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0TP8T	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D01CND	TTDDRUID	D01CND
D01CND	DRUGNAME	PMID26651364-Compound-114
D01CND	INDICATI	Crohn disease [ICD-11: DD70] Patented
D01CND	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D01CND	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0GP7L	TTDDRUID	D0GP7L
D0GP7L	DRUGNAME	PMID26651364-Compound-115
D0GP7L	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0GP7L	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0GP7L	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D00RDO	TTDDRUID	D00RDO
D00RDO	DRUGNAME	PMID26651364-Compound-116
D00RDO	INDICATI	Crohn disease [ICD-11: DD70] Patented
D00RDO	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D00RDO	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0IB8D	TTDDRUID	D0IB8D
D0IB8D	DRUGNAME	PMID26651364-Compound-117a
D0IB8D	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0IB8D	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0IB8D	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0D2QE	TTDDRUID	D0D2QE
D0D2QE	DRUGNAME	PMID26651364-Compound-117b
D0D2QE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0D2QE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0D2QE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0X4TV	TTDDRUID	D0X4TV
D0X4TV	DRUGNAME	PMID26651364-Compound-118
D0X4TV	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0X4TV	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0X4TV	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D07RAA	TTDDRUID	D07RAA
D07RAA	DRUGNAME	PMID26651364-Compound-119
D07RAA	INDICATI	Crohn disease [ICD-11: DD70] Patented
D07RAA	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D07RAA	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05OMO	TTDDRUID	D05OMO
D05OMO	DRUGNAME	PMID26651364-Compound-11b
D05OMO	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05OMO	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05OMO	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0OW6O	TTDDRUID	D0OW6O
D0OW6O	DRUGNAME	PMID26651364-Compound-11c
D0OW6O	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0OW6O	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0OW6O	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0FS9V	TTDDRUID	D0FS9V
D0FS9V	DRUGNAME	PMID26651364-Compound-120
D0FS9V	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0FS9V	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0FS9V	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D03HHG	TTDDRUID	D03HHG
D03HHG	DRUGNAME	PMID26651364-Compound-121
D03HHG	INDICATI	Crohn disease [ICD-11: DD70] Patented
D03HHG	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D03HHG	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0LZ1W	TTDDRUID	D0LZ1W
D0LZ1W	DRUGNAME	PMID26651364-Compound-122
D0LZ1W	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0LZ1W	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0LZ1W	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05HKC	TTDDRUID	D05HKC
D05HKC	DRUGNAME	PMID26651364-Compound-123
D05HKC	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05HKC	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05HKC	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0SR8I	TTDDRUID	D0SR8I
D0SR8I	DRUGNAME	PMID26651364-Compound-124
D0SR8I	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0SR8I	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0SR8I	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D04PKX	TTDDRUID	D04PKX
D04PKX	DRUGNAME	PMID26651364-Compound-125
D04PKX	INDICATI	Crohn disease [ICD-11: DD70] Patented
D04PKX	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D04PKX	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0UK1S	TTDDRUID	D0UK1S
D0UK1S	DRUGNAME	PMID26651364-Compound-126a
D0UK1S	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0UK1S	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0UK1S	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0YX4L	TTDDRUID	D0YX4L
D0YX4L	DRUGNAME	PMID26651364-Compound-126b
D0YX4L	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0YX4L	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0YX4L	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05BTL	TTDDRUID	D05BTL
D05BTL	DRUGNAME	PMID26651364-Compound-126c
D05BTL	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05BTL	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05BTL	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0J8HJ	TTDDRUID	D0J8HJ
D0J8HJ	DRUGNAME	PMID26651364-Compound-127
D0J8HJ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0J8HJ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0J8HJ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D04NXG	TTDDRUID	D04NXG
D04NXG	DRUGNAME	PMID26651364-Compound-128
D04NXG	INDICATI	Crohn disease [ICD-11: DD70] Patented
D04NXG	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D04NXG	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0J0LC	TTDDRUID	D0J0LC
D0J0LC	DRUGNAME	PMID26651364-Compound-4
D0J0LC	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0J0LC	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0J0LC	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0C8EB	TTDDRUID	D0C8EB
D0C8EB	DRUGNAME	PMID26651364-Compound-45
D0C8EB	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0C8EB	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0C8EB	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0KE8Q	TTDDRUID	D0KE8Q
D0KE8Q	DRUGNAME	PMID26651364-Compound-46
D0KE8Q	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0KE8Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0KE8Q	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0QU6N	TTDDRUID	D0QU6N
D0QU6N	DRUGNAME	PMID26651364-Compound-47
D0QU6N	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0QU6N	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0QU6N	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D08WZC	TTDDRUID	D08WZC
D08WZC	DRUGNAME	PMID26651364-Compound-48
D08WZC	INDICATI	Crohn disease [ICD-11: DD70] Patented
D08WZC	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D08WZC	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0WO6C	TTDDRUID	D0WO6C
D0WO6C	DRUGNAME	PMID26651364-Compound-49
D0WO6C	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0WO6C	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0WO6C	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D00KKD	TTDDRUID	D00KKD
D00KKD	DRUGNAME	PMID26651364-Compound-5
D00KKD	INDICATI	Crohn disease [ICD-11: DD70] Patented
D00KKD	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D00KKD	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0X7HN	TTDDRUID	D0X7HN
D0X7HN	DRUGNAME	PMID26651364-Compound-50
D0X7HN	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0X7HN	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0X7HN	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D09JDV	TTDDRUID	D09JDV
D09JDV	DRUGNAME	PMID26651364-Compound-5a
D09JDV	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09JDV	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09JDV	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0W1SE	TTDDRUID	D0W1SE
D0W1SE	DRUGNAME	PMID26651364-Compound-5b
D0W1SE	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0W1SE	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0W1SE	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0CN6Q	TTDDRUID	D0CN6Q
D0CN6Q	DRUGNAME	PMID26651364-Compound-5c
D0CN6Q	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0CN6Q	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0CN6Q	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D01RHK	TTDDRUID	D01RHK
D01RHK	DRUGNAME	PMID26651364-Compound-5d
D01RHK	INDICATI	Crohn disease [ICD-11: DD70] Patented
D01RHK	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D01RHK	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05ZHZ	TTDDRUID	D05ZHZ
D05ZHZ	DRUGNAME	PMID26651364-Compound-5e
D05ZHZ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05ZHZ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05ZHZ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0QM2O	TTDDRUID	D0QM2O
D0QM2O	DRUGNAME	PMID26651364-Compound-5f
D0QM2O	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0QM2O	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0QM2O	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0E1GC	TTDDRUID	D0E1GC
D0E1GC	DRUGNAME	PMID26651364-Compound-5g
D0E1GC	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0E1GC	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0E1GC	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0FL3H	TTDDRUID	D0FL3H
D0FL3H	DRUGNAME	PMID26651364-Compound-6a
D0FL3H	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0FL3H	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0FL3H	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0DW7A	TTDDRUID	D0DW7A
D0DW7A	DRUGNAME	PMID26651364-Compound-6b
D0DW7A	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0DW7A	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0DW7A	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0L5OP	TTDDRUID	D0L5OP
D0L5OP	DRUGNAME	PMID26651364-Compound-6c
D0L5OP	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0L5OP	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0L5OP	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0UZ2S	TTDDRUID	D0UZ2S
D0UZ2S	DRUGNAME	PMID26651364-Compound-6d
D0UZ2S	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0UZ2S	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0UZ2S	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05XGH	TTDDRUID	D05XGH
D05XGH	DRUGNAME	PMID26651364-Compound-6e
D05XGH	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05XGH	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05XGH	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02NDP	TTDDRUID	D02NDP
D02NDP	DRUGNAME	PMID26651364-Compound-7a
D02NDP	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02NDP	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02NDP	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0AK2Y	TTDDRUID	D0AK2Y
D0AK2Y	DRUGNAME	PMID26651364-Compound-7b
D0AK2Y	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0AK2Y	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0AK2Y	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0CN7A	TTDDRUID	D0CN7A
D0CN7A	DRUGNAME	PMID26651364-Compound-7c
D0CN7A	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0CN7A	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0CN7A	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Y3UB	TTDDRUID	D0Y3UB
D0Y3UB	DRUGNAME	PMID26651364-Compound-7d
D0Y3UB	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Y3UB	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Y3UB	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Q1SX	TTDDRUID	D0Q1SX
D0Q1SX	DRUGNAME	PMID26651364-Compound-7e
D0Q1SX	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Q1SX	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Q1SX	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D09EXQ	TTDDRUID	D09EXQ
D09EXQ	DRUGNAME	PMID26651364-Compound-8a
D09EXQ	INDICATI	Crohn disease [ICD-11: DD70] Patented
D09EXQ	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D09EXQ	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0B9LM	TTDDRUID	D0B9LM
D0B9LM	DRUGNAME	PMID26651364-Compound-8b
D0B9LM	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0B9LM	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0B9LM	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0O8EX	TTDDRUID	D0O8EX
D0O8EX	DRUGNAME	PMID26651364-Compound-8c
D0O8EX	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0O8EX	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0O8EX	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0P3SL	TTDDRUID	D0P3SL
D0P3SL	DRUGNAME	PMID26651364-Compound-8d
D0P3SL	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0P3SL	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0P3SL	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D05CBP	TTDDRUID	D05CBP
D05CBP	DRUGNAME	PMID26651364-Compound-9a
D05CBP	INDICATI	Crohn disease [ICD-11: DD70] Patented
D05CBP	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D05CBP	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0KG5U	TTDDRUID	D0KG5U
D0KG5U	DRUGNAME	PMID26651364-Compound-9b
D0KG5U	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0KG5U	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0KG5U	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0Q0XC	TTDDRUID	D0Q0XC
D0Q0XC	DRUGNAME	PMID26651364-Compound-9c
D0Q0XC	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0Q0XC	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0Q0XC	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D02UDO	TTDDRUID	D02UDO
D02UDO	DRUGNAME	PMID26651364-Compound-9d
D02UDO	INDICATI	Crohn disease [ICD-11: DD70] Patented
D02UDO	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D02UDO	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0A8GW	TTDDRUID	D0A8GW
D0A8GW	DRUGNAME	PMID26651364-Compound-9e
D0A8GW	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0A8GW	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0A8GW	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D0I2MR	TTDDRUID	D0I2MR
D0I2MR	DRUGNAME	PMID26651364-Compound-9f
D0I2MR	INDICATI	Crohn disease [ICD-11: DD70] Patented
D0I2MR	INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
D0I2MR	INDICATI	Urinary tract infection [ICD-11: GC08] Patented

D06FUM	TTDDRUID	D06FUM
D06FUM	DRUGNAME	PMID26815044-Compound-114
D06FUM	INDICATI	Albinism [ICD-11: EC23.2] Patented
D06FUM	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D06FUM	INDICATI	Melasma [ICD-11: ED60.1] Patented
D06FUM	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D06FUM	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D07PNX	TTDDRUID	D07PNX
D07PNX	DRUGNAME	PMID26815044-Compound-115
D07PNX	INDICATI	Albinism [ICD-11: EC23.2] Patented
D07PNX	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D07PNX	INDICATI	Melasma [ICD-11: ED60.1] Patented
D07PNX	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D07PNX	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0W8RV	TTDDRUID	D0W8RV
D0W8RV	DRUGNAME	PMID26815044-Compound-116
D0W8RV	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0W8RV	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0W8RV	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0W8RV	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0W8RV	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0EH4P	TTDDRUID	D0EH4P
D0EH4P	DRUGNAME	PMID26815044-Compound-117
D0EH4P	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0EH4P	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0EH4P	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0EH4P	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0EH4P	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D01ZCC	TTDDRUID	D01ZCC
D01ZCC	DRUGNAME	PMID26815044-Compound-118
D01ZCC	INDICATI	Albinism [ICD-11: EC23.2] Patented
D01ZCC	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D01ZCC	INDICATI	Melasma [ICD-11: ED60.1] Patented
D01ZCC	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D01ZCC	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03FQY	TTDDRUID	D03FQY
D03FQY	DRUGNAME	PMID26815044-Compound-121
D03FQY	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03FQY	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03FQY	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03FQY	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03FQY	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0KR9E	TTDDRUID	D0KR9E
D0KR9E	DRUGNAME	PMID26815044-Compound-122
D0KR9E	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0KR9E	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0KR9E	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0KR9E	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0KR9E	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D02CXZ	TTDDRUID	D02CXZ
D02CXZ	DRUGNAME	PMID26815044-Compound-123
D02CXZ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D02CXZ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D02CXZ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D02CXZ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D02CXZ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D02WJB	TTDDRUID	D02WJB
D02WJB	DRUGNAME	PMID26815044-Compound-124
D02WJB	INDICATI	Albinism [ICD-11: EC23.2] Patented
D02WJB	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D02WJB	INDICATI	Melasma [ICD-11: ED60.1] Patented
D02WJB	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D02WJB	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0U5GU	TTDDRUID	D0U5GU
D0U5GU	DRUGNAME	PMID26815044-Compound-125
D0U5GU	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0U5GU	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0U5GU	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0U5GU	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0U5GU	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D00LSQ	TTDDRUID	D00LSQ
D00LSQ	DRUGNAME	PMID26815044-Compound-126
D00LSQ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D00LSQ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D00LSQ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D00LSQ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D00LSQ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0A2RI	TTDDRUID	D0A2RI
D0A2RI	DRUGNAME	PMID26815044-Compound-127
D0A2RI	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0A2RI	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0A2RI	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0A2RI	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0A2RI	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0W6ZO	TTDDRUID	D0W6ZO
D0W6ZO	DRUGNAME	PMID26815044-Compound-30
D0W6ZO	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0W6ZO	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0W6ZO	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0W6ZO	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0W6ZO	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D01NJW	TTDDRUID	D01NJW
D01NJW	DRUGNAME	PMID26815044-Compound-31
D01NJW	INDICATI	Albinism [ICD-11: EC23.2] Patented
D01NJW	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D01NJW	INDICATI	Melasma [ICD-11: ED60.1] Patented
D01NJW	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D01NJW	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D04HEW	TTDDRUID	D04HEW
D04HEW	DRUGNAME	PMID26815044-Compound-32
D04HEW	INDICATI	Albinism [ICD-11: EC23.2] Patented
D04HEW	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D04HEW	INDICATI	Melasma [ICD-11: ED60.1] Patented
D04HEW	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D04HEW	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0X0RV	TTDDRUID	D0X0RV
D0X0RV	DRUGNAME	PMID26815044-Compound-47
D0X0RV	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0X0RV	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0X0RV	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0X0RV	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0X0RV	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0M4EQ	TTDDRUID	D0M4EQ
D0M4EQ	DRUGNAME	PMID26815044-Compound-48
D0M4EQ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0M4EQ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0M4EQ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0M4EQ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0M4EQ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D02SGL	TTDDRUID	D02SGL
D02SGL	DRUGNAME	PMID26815044-Compound-49
D02SGL	INDICATI	Albinism [ICD-11: EC23.2] Patented
D02SGL	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D02SGL	INDICATI	Melasma [ICD-11: ED60.1] Patented
D02SGL	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D02SGL	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D06KKO	TTDDRUID	D06KKO
D06KKO	DRUGNAME	PMID26815044-Compound-50
D06KKO	INDICATI	Albinism [ICD-11: EC23.2] Patented
D06KKO	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D06KKO	INDICATI	Melasma [ICD-11: ED60.1] Patented
D06KKO	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D06KKO	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0A0RM	TTDDRUID	D0A0RM
D0A0RM	DRUGNAME	PMID26815044-Compound-51
D0A0RM	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0A0RM	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0A0RM	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0A0RM	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0A0RM	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0PN6U	TTDDRUID	D0PN6U
D0PN6U	DRUGNAME	PMID26815044-Compound-52
D0PN6U	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0PN6U	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0PN6U	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0PN6U	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0PN6U	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0I3KT	TTDDRUID	D0I3KT
D0I3KT	DRUGNAME	PMID26815044-Compound-64
D0I3KT	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0I3KT	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0I3KT	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0I3KT	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0I3KT	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0DW3Z	TTDDRUID	D0DW3Z
D0DW3Z	DRUGNAME	PMID26815044-Compound-93
D0DW3Z	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0DW3Z	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0DW3Z	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0DW3Z	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0DW3Z	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D00YRS	TTDDRUID	D00YRS
D00YRS	DRUGNAME	PMID26815044-Compound-H
D00YRS	INDICATI	Albinism [ICD-11: EC23.2] Patented
D00YRS	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D00YRS	INDICATI	Melasma [ICD-11: ED60.1] Patented
D00YRS	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D00YRS	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0K2XK	TTDDRUID	D0K2XK
D0K2XK	DRUGNAME	PMID26815044-Compound-I
D0K2XK	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0K2XK	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0K2XK	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0K2XK	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0K2XK	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D09EIX	TTDDRUID	D09EIX
D09EIX	DRUGNAME	PMID26936077-Compound-13
D09EIX	INDICATI	Gastric ulcer [ICD-11: DA60] Patented
D09EIX	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Patented
D09EIX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Patented

D0I2RS	TTDDRUID	D0I2RS
D0I2RS	DRUGNAME	PMID26936077-Compound-34
D0I2RS	INDICATI	Gastric ulcer [ICD-11: DA60] Patented
D0I2RS	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Patented
D0I2RS	INDICATI	Type-2 diabetes [ICD-11: 5A11] Patented

D0U9BC	TTDDRUID	D0U9BC
D0U9BC	DRUGNAME	PMID27215781-Compound-0-1966
D0U9BC	INDICATI	Organ transplant rejection [ICD-11: NE84] Patented

D03YAA	TTDDRUID	D03YAA
D03YAA	DRUGNAME	PMID27215781-Compound-28
D03YAA	INDICATI	Endometriosis [ICD-11: GA10] Patented

D07BFP	TTDDRUID	D07BFP
D07BFP	DRUGNAME	PMID27215781-Compound-37
D07BFP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Patented

D03SNE	TTDDRUID	D03SNE
D03SNE	DRUGNAME	PMID27828716-Compound-BIO-acetoxime
D03SNE	INDICATI	Malignant glioma [ICD-11: 2A00.0] Patented

D04QHD	TTDDRUID	D04QHD
D04QHD	DRUGNAME	PMID27828716-Compound-L803mts
D04QHD	INDICATI	Malignant glioma [ICD-11: 2A00.0] Patented

D0J0WG	TTDDRUID	D0J0WG
D0J0WG	DRUGNAME	PMID27998201-Compound-1
D0J0WG	INDICATI	Coronavirus infection [ICD-11: 1D92] Patented
D0J0WG	INDICATI	Henipavirus Encephalitis [ICD-11: 1D63] Patented

D0BR6D	TTDDRUID	D0BR6D
D0BR6D	DRUGNAME	PMID27998201-Compound-10
D0BR6D	INDICATI	Osteoporosis [ICD-11: FB83.0] Patented

D0A2NA	TTDDRUID	D0A2NA
D0A2NA	DRUGNAME	PMID27998201-Compound-11
D0A2NA	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented

D06XCD	TTDDRUID	D06XCD
D06XCD	DRUGNAME	PMID27998201-Compound-12
D06XCD	INDICATI	Bone cancer [ICD-11: 2B5Z] Patented
D06XCD	INDICATI	Cancer related pain [ICD-11: MG30] Patented

D0L1PP	TTDDRUID	D0L1PP
D0L1PP	DRUGNAME	PMID27998201-Compound-13
D0L1PP	INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Patented

D0MR9V	TTDDRUID	D0MR9V
D0MR9V	DRUGNAME	PMID27998201-Compound-15
D0MR9V	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D06XTA	TTDDRUID	D06XTA
D06XTA	DRUGNAME	PMID27998201-Compound-17
D06XTA	INDICATI	Hair loss [ICD-11: ED70] Patented

D0ZN3M	TTDDRUID	D0ZN3M
D0ZN3M	DRUGNAME	PMID27998201-Compound-19
D0ZN3M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0E2AF	TTDDRUID	D0E2AF
D0E2AF	DRUGNAME	PMID27998201-Compound-2
D0E2AF	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D0KG9M	TTDDRUID	D0KG9M
D0KG9M	DRUGNAME	PMID27998201-Compound-22
D0KG9M	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
D0KG9M	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented
D0KG9M	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Patented
D0KG9M	INDICATI	Pancreatitis [ICD-11: DC31-DC34] Patented

D0WO4T	TTDDRUID	D0WO4T
D0WO4T	DRUGNAME	PMID27998201-Compound-24
D0WO4T	INDICATI	Glioma [ICD-11: 2A00.0] Patented
D0WO4T	INDICATI	Meningioma tumour [ICD-11: 2A01] Patented

D05OIU	TTDDRUID	D05OIU
D05OIU	DRUGNAME	PMID27998201-Compound-5
D05OIU	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
D05OIU	INDICATI	Cirrhosis [ICD-11: DB93] Patented
D05OIU	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
D05OIU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
D05OIU	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented

D0JD5W	TTDDRUID	D0JD5W
D0JD5W	DRUGNAME	PMID27998201-Compound-7
D0JD5W	INDICATI	Abdominal aortic aneurysm [ICD-11: BD50.4] Patented

D04VGR	TTDDRUID	D04VGR
D04VGR	DRUGNAME	PMID27998201-Compound-9
D04VGR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Patented

D0N8YJ	TTDDRUID	D0N8YJ
D0N8YJ	DRUGNAME	PMID28270010-Compound-Figure21-b
D0N8YJ	INDICATI	Brain metastases [ICD-11: 2D50] Patented

D0J4CA	TTDDRUID	D0J4CA
D0J4CA	DRUGNAME	PMID28270021-Compound-WO2010077680 103
D0J4CA	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0J4CA	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0J4CA	INDICATI	Pruritus [ICD-11: EC90] Patented
D0J4CA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0J4CA	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0T0HM	TTDDRUID	D0T0HM
D0T0HM	DRUGNAME	PMID28270021-Compound-WO2010077680 109
D0T0HM	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0T0HM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0T0HM	INDICATI	Pruritus [ICD-11: EC90] Patented
D0T0HM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0T0HM	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0PY0G	TTDDRUID	D0PY0G
D0PY0G	DRUGNAME	PMID28270021-Compound-WO2010077680 201
D0PY0G	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0PY0G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0PY0G	INDICATI	Pruritus [ICD-11: EC90] Patented
D0PY0G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0PY0G	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0FL8A	TTDDRUID	D0FL8A
D0FL8A	DRUGNAME	PMID28270021-Compound-WO2010077680 481
D0FL8A	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0FL8A	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0FL8A	INDICATI	Pruritus [ICD-11: EC90] Patented
D0FL8A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0FL8A	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0K6IM	TTDDRUID	D0K6IM
D0K6IM	DRUGNAME	PMID28270021-Compound-WO2010077680 495
D0K6IM	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0K6IM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0K6IM	INDICATI	Pruritus [ICD-11: EC90] Patented
D0K6IM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0K6IM	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0F2BF	TTDDRUID	D0F2BF
D0F2BF	DRUGNAME	PMID28270021-Compound-WO2010077680 803
D0F2BF	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0F2BF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0F2BF	INDICATI	Pruritus [ICD-11: EC90] Patented
D0F2BF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0F2BF	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D07KVL	TTDDRUID	D07KVL
D07KVL	DRUGNAME	PMID28270021-Compound-WO2010077680 811
D07KVL	INDICATI	Chronic pain [ICD-11: MG30] Patented
D07KVL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07KVL	INDICATI	Pruritus [ICD-11: EC90] Patented
D07KVL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D07KVL	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D07IHJ	TTDDRUID	D07IHJ
D07IHJ	DRUGNAME	PMID28270021-Compound-WO2013009582
D07IHJ	INDICATI	Chronic pain [ICD-11: MG30] Patented
D07IHJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07IHJ	INDICATI	Pruritus [ICD-11: EC90] Patented
D07IHJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D07IHJ	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D02ZQN	TTDDRUID	D02ZQN
D02ZQN	DRUGNAME	PMID28270021-Compound-WO2013009582Example16
D02ZQN	INDICATI	Chronic pain [ICD-11: MG30] Patented
D02ZQN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02ZQN	INDICATI	Pruritus [ICD-11: EC90] Patented
D02ZQN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D02ZQN	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0Y0XJ	TTDDRUID	D0Y0XJ
D0Y0XJ	DRUGNAME	PMID28270021-Compound-WO2013009582Example76
D0Y0XJ	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0Y0XJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0Y0XJ	INDICATI	Pruritus [ICD-11: EC90] Patented
D0Y0XJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0Y0XJ	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0I2OO	TTDDRUID	D0I2OO
D0I2OO	DRUGNAME	PMID28270021-Compound-WO2013161919Example85-117
D0I2OO	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0I2OO	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0I2OO	INDICATI	Pruritus [ICD-11: EC90] Patented
D0I2OO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0I2OO	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0NQ3S	TTDDRUID	D0NQ3S
D0NQ3S	DRUGNAME	PMID28270021-Compound-WO2013176970
D0NQ3S	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0NQ3S	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0NQ3S	INDICATI	Pruritus [ICD-11: EC90] Patented
D0NQ3S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0NQ3S	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D05AQT	TTDDRUID	D05AQT
D05AQT	DRUGNAME	PMID28270021-Compound-WO2014078408Example1
D05AQT	INDICATI	Chronic pain [ICD-11: MG30] Patented
D05AQT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D05AQT	INDICATI	Pruritus [ICD-11: EC90] Patented
D05AQT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D05AQT	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0YN0I	TTDDRUID	D0YN0I
D0YN0I	DRUGNAME	PMID28270021-Compound-WO2014078408Example26
D0YN0I	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0YN0I	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0YN0I	INDICATI	Pruritus [ICD-11: EC90] Patented
D0YN0I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0YN0I	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0QT8L	TTDDRUID	D0QT8L
D0QT8L	DRUGNAME	PMID28270021-Compound-WO2014129431Example8-1
D0QT8L	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0QT8L	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0QT8L	INDICATI	Pruritus [ICD-11: EC90] Patented
D0QT8L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0QT8L	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D02ETU	TTDDRUID	D02ETU
D02ETU	DRUGNAME	PMID28270021-Compound-WO2014152663 701
D02ETU	INDICATI	Chronic pain [ICD-11: MG30] Patented
D02ETU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02ETU	INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
D02ETU	INDICATI	Pruritus [ICD-11: EC90] Patented
D02ETU	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0U5XI	TTDDRUID	D0U5XI
D0U5XI	DRUGNAME	PMID28270021-Compound-WO2015042088Example11
D0U5XI	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0U5XI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0U5XI	INDICATI	Pruritus [ICD-11: EC90] Patented
D0U5XI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0U5XI	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0VD5J	TTDDRUID	D0VD5J
D0VD5J	DRUGNAME	PMID28270021-Compound-WO2015042088Example12
D0VD5J	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0VD5J	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0VD5J	INDICATI	Pruritus [ICD-11: EC90] Patented
D0VD5J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0VD5J	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0M8VS	TTDDRUID	D0M8VS
D0M8VS	DRUGNAME	PMID28270021-Compound-WO2015042088Example4
D0M8VS	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0M8VS	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0M8VS	INDICATI	Pruritus [ICD-11: EC90] Patented
D0M8VS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0M8VS	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0P1OS	TTDDRUID	D0P1OS
D0P1OS	DRUGNAME	PMID28270021-Compound-WO2015170218Example557
D0P1OS	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0P1OS	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0P1OS	INDICATI	Pruritus [ICD-11: EC90] Patented
D0P1OS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0P1OS	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0ZV5U	TTDDRUID	D0ZV5U
D0ZV5U	DRUGNAME	PMID28270021-Compound-WO2016054807
D0ZV5U	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0ZV5U	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZV5U	INDICATI	Pruritus [ICD-11: EC90] Patented
D0ZV5U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0ZV5U	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D00MGO	TTDDRUID	D00MGO
D00MGO	DRUGNAME	PMID28270021-Compound-WO2016054807Example1
D00MGO	INDICATI	Chronic pain [ICD-11: MG30] Patented
D00MGO	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00MGO	INDICATI	Pruritus [ICD-11: EC90] Patented
D00MGO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D00MGO	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0LK8E	TTDDRUID	D0LK8E
D0LK8E	DRUGNAME	PMID28270021-Compound-WO2016054807Example112
D0LK8E	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0LK8E	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0LK8E	INDICATI	Pruritus [ICD-11: EC90] Patented
D0LK8E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0LK8E	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D08CZY	TTDDRUID	D08CZY
D08CZY	DRUGNAME	PMID28270021-Compound-WO2016054807Example71
D08CZY	INDICATI	Chronic pain [ICD-11: MG30] Patented
D08CZY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D08CZY	INDICATI	Pruritus [ICD-11: EC90] Patented
D08CZY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D08CZY	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0BO1H	TTDDRUID	D0BO1H
D0BO1H	DRUGNAME	PMID28270021-Compound-WO2016054807Example80
D0BO1H	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0BO1H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0BO1H	INDICATI	Pruritus [ICD-11: EC90] Patented
D0BO1H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0BO1H	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D00EUL	TTDDRUID	D00EUL
D00EUL	DRUGNAME	PMID28270021-Compound-WO2016054807Example82
D00EUL	INDICATI	Chronic pain [ICD-11: MG30] Patented
D00EUL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00EUL	INDICATI	Pruritus [ICD-11: EC90] Patented
D00EUL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D00EUL	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D04NCC	TTDDRUID	D04NCC
D04NCC	DRUGNAME	PMID28350212-Compound-18
D04NCC	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D09UJB	TTDDRUID	D09UJB
D09UJB	DRUGNAME	PMID28350212-Compound-19
D09UJB	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D0I9VU	TTDDRUID	D0I9VU
D0I9VU	DRUGNAME	PMID28350212-Compound-20
D0I9VU	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D08VTV	TTDDRUID	D08VTV
D08VTV	DRUGNAME	PMID28350212-Compound-7
D08VTV	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Patented

D0IH3I	TTDDRUID	D0IH3I
D0IH3I	DRUGNAME	PMID28460551-Compound-1
D0IH3I	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Patented
D0IH3I	INDICATI	Colon cancer [ICD-11: 2B90.Z] Patented
D0IH3I	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Patented
D0IH3I	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Patented
D0IH3I	INDICATI	Lung cancer [ICD-11: 2C25.0] Patented
D0IH3I	INDICATI	Pancreatic cancer [ICD-11: 2C10] Patented
D0IH3I	INDICATI	Prostate cancer [ICD-11: 2C82.0] Patented

D0T9DV	TTDDRUID	D0T9DV
D0T9DV	DRUGNAME	PMID28621580-Compound-WO2013036866C66
D0T9DV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D05LBH	TTDDRUID	D05LBH
D05LBH	DRUGNAME	PMID28621580-Compound-WO2013112959C68
D05LBH	INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented

D07AVU	TTDDRUID	D07AVU
D07AVU	DRUGNAME	PMID28621580-Compound-WO2015089220C70
D07AVU	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Patented
D07AVU	INDICATI	Retinopathy [ICD-11: 9B71] Patented

D0C4LJ	TTDDRUID	D0C4LJ
D0C4LJ	DRUGNAME	PMID28885866-Compound-123
D0C4LJ	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented

D0TU3S	TTDDRUID	D0TU3S
D0TU3S	DRUGNAME	PMID28885866-Compound-53
D0TU3S	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented

D0O1EA	TTDDRUID	D0O1EA
D0O1EA	DRUGNAME	PMID28885866-Compound-MJL-001i
D0O1EA	INDICATI	Huntington disease [ICD-11: 8A01.10] Patented

D0XN7U	TTDDRUID	D0XN7U
D0XN7U	DRUGNAME	PMID28885866-Compound-MJL-002i
D0XN7U	INDICATI	Huntington disease [ICD-11: 8A01.10] Patented

D06YUE	TTDDRUID	D06YUE
D06YUE	DRUGNAME	PMID28885866-Compound-MJL-003i
D06YUE	INDICATI	Huntington disease [ICD-11: 8A01.10] Patented

D0N8QY	TTDDRUID	D0N8QY
D0N8QY	DRUGNAME	PMID28885866-Compound-Z-VEID-FMK
D0N8QY	INDICATI	Immune disorder [ICD-11: 4B00-4B07] Patented

D0F8PG	TTDDRUID	D0F8PG
D0F8PG	DRUGNAME	PMID29334795-Compound-21
D0F8PG	INDICATI	Corticobasal degeneration [ICD-11: 8A00.1Y] Patented
D0F8PG	INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Patented

D0B2NV	TTDDRUID	D0B2NV
D0B2NV	DRUGNAME	PMID29334795-Compound-22
D0B2NV	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
D0B2NV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented

D0RV0O	TTDDRUID	D0RV0O
D0RV0O	DRUGNAME	PMID29334795-Compound-23
D0RV0O	INDICATI	Schizophrenia [ICD-11: 6A20] Patented

D02SKQ	TTDDRUID	D02SKQ
D02SKQ	DRUGNAME	PMID29334795-Compound-28
D02SKQ	INDICATI	Histamine H3-associated disorder [ICD-11: NE61] Patented

D0H2KL	TTDDRUID	D0H2KL
D0H2KL	DRUGNAME	PMID29338548-Compound-13
D0H2KL	INDICATI	Schizophrenia [ICD-11: 6A20] Patented

D0W7FS	TTDDRUID	D0W7FS
D0W7FS	DRUGNAME	PMID29338548-Compound-21
D0W7FS	INDICATI	Schizophrenia [ICD-11: 6A20] Patented

D0WQ9X	TTDDRUID	D0WQ9X
D0WQ9X	DRUGNAME	PMID30107136-Compound-Example1
D0WQ9X	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0WQ9X	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0WQ9X	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0WQ9X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0M6WW	TTDDRUID	D0M6WW
D0M6WW	DRUGNAME	PMID30107136-Compound-Example11
D0M6WW	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0M6WW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0M6WW	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0M6WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04PCT	TTDDRUID	D04PCT
D04PCT	DRUGNAME	PMID30107136-Compound-Example12
D04PCT	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D04PCT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D04PCT	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D04PCT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0R7YI	TTDDRUID	D0R7YI
D0R7YI	DRUGNAME	PMID30107136-Compound-Example13
D0R7YI	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0R7YI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0R7YI	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0R7YI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04CCX	TTDDRUID	D04CCX
D04CCX	DRUGNAME	PMID30107136-Compound-Example14
D04CCX	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D04CCX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D04CCX	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D04CCX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08VDV	TTDDRUID	D08VDV
D08VDV	DRUGNAME	PMID30107136-Compound-Example15
D08VDV	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D08VDV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D08VDV	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D08VDV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0K7NC	TTDDRUID	D0K7NC
D0K7NC	DRUGNAME	PMID30107136-Compound-Example16
D0K7NC	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0K7NC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0K7NC	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0K7NC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0OK1S	TTDDRUID	D0OK1S
D0OK1S	DRUGNAME	PMID30107136-Compound-Example2
D0OK1S	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0OK1S	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0OK1S	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0OK1S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D01MSP	TTDDRUID	D01MSP
D01MSP	DRUGNAME	PMID30107136-Compound-Example3
D01MSP	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D01MSP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D01MSP	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D01MSP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03TWD	TTDDRUID	D03TWD
D03TWD	DRUGNAME	PMID30107136-Compound-Example4
D03TWD	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D03TWD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D03TWD	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D03TWD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0HC9K	TTDDRUID	D0HC9K
D0HC9K	DRUGNAME	PMID30107136-Compound-Example41
D0HC9K	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0HC9K	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0HC9K	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0HC9K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0FJ1N	TTDDRUID	D0FJ1N
D0FJ1N	DRUGNAME	PMID30107136-Compound-Example42
D0FJ1N	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0FJ1N	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0FJ1N	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0FJ1N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08JWY	TTDDRUID	D08JWY
D08JWY	DRUGNAME	PMID30107136-Compound-Example43
D08JWY	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D08JWY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D08JWY	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D08JWY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0W1RQ	TTDDRUID	D0W1RQ
D0W1RQ	DRUGNAME	PMID30107136-Compound-Example44
D0W1RQ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0W1RQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0W1RQ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0W1RQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03HAA	TTDDRUID	D03HAA
D03HAA	DRUGNAME	PMID30107136-Compound-Example45
D03HAA	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D03HAA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D03HAA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D03HAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06BSV	TTDDRUID	D06BSV
D06BSV	DRUGNAME	PMID30107136-Compound-Example46
D06BSV	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D06BSV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D06BSV	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D06BSV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08RET	TTDDRUID	D08RET
D08RET	DRUGNAME	PMID30107136-Compound-Example47
D08RET	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D08RET	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D08RET	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D08RET	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0FK4P	TTDDRUID	D0FK4P
D0FK4P	DRUGNAME	PMID30107136-Compound-Example48
D0FK4P	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0FK4P	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0FK4P	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0FK4P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02UJS	TTDDRUID	D02UJS
D02UJS	DRUGNAME	PMID30107136-Compound-Example49
D02UJS	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D02UJS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D02UJS	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D02UJS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D01OQQ	TTDDRUID	D01OQQ
D01OQQ	DRUGNAME	PMID30107136-Compound-Example50
D01OQQ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D01OQQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D01OQQ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D01OQQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0W0MT	TTDDRUID	D0W0MT
D0W0MT	DRUGNAME	PMID30107136-Compound-Example51
D0W0MT	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0W0MT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0W0MT	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0W0MT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D05COE	TTDDRUID	D05COE
D05COE	DRUGNAME	PMID30107136-Compound-Example52
D05COE	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D05COE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D05COE	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D05COE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0J4LV	TTDDRUID	D0J4LV
D0J4LV	DRUGNAME	PMID30107136-Compound-Example53
D0J4LV	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0J4LV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0J4LV	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0J4LV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0H0CH	TTDDRUID	D0H0CH
D0H0CH	DRUGNAME	PMID30107136-Compound-Example54
D0H0CH	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0H0CH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0H0CH	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0H0CH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0DP8E	TTDDRUID	D0DP8E
D0DP8E	DRUGNAME	PMID30107136-Compound-Example57
D0DP8E	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0DP8E	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0DP8E	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0DP8E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0TJ4D	TTDDRUID	D0TJ4D
D0TJ4D	DRUGNAME	PMID30107136-Compound-Example58
D0TJ4D	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0TJ4D	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0TJ4D	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0TJ4D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04HBL	TTDDRUID	D04HBL
D04HBL	DRUGNAME	PMID30107136-Compound-Example59
D04HBL	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D04HBL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D04HBL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D04HBL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0FM9V	TTDDRUID	D0FM9V
D0FM9V	DRUGNAME	PMID30107136-Compound-Example60
D0FM9V	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0FM9V	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0FM9V	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0FM9V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0KA7I	TTDDRUID	D0KA7I
D0KA7I	DRUGNAME	PMID30107136-Compound-Example7
D0KA7I	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0KA7I	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0KA7I	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0KA7I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04ESH	TTDDRUID	D04ESH
D04ESH	DRUGNAME	PMID30107136-Compound-Example8
D04ESH	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D04ESH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D04ESH	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D04ESH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0SJ2R	TTDDRUID	D0SJ2R
D0SJ2R	DRUGNAME	PMID30107136-Compound-General structure1
D0SJ2R	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0SJ2R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0SJ2R	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0SJ2R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02NBZ	TTDDRUID	D02NBZ
D02NBZ	DRUGNAME	PMID30107136-Compound-General structure2
D02NBZ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D02NBZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D02NBZ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D02NBZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0F8JA	TTDDRUID	D0F8JA
D0F8JA	DRUGNAME	PMID30107136-Compound-General structure21
D0F8JA	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0F8JA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0F8JA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0F8JA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0K3SR	TTDDRUID	D0K3SR
D0K3SR	DRUGNAME	PMID30107136-Compound-General structure22
D0K3SR	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0K3SR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0K3SR	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0K3SR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02QCP	TTDDRUID	D02QCP
D02QCP	DRUGNAME	PMID30107136-Compound-General structure23
D02QCP	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D02QCP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D02QCP	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D02QCP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07WUF	TTDDRUID	D07WUF
D07WUF	DRUGNAME	PMID30107136-Compound-General structure24
D07WUF	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D07WUF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D07WUF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D07WUF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Q5VS	TTDDRUID	D0Q5VS
D0Q5VS	DRUGNAME	PMID30107136-Compound-General structure25
D0Q5VS	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0Q5VS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0Q5VS	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0Q5VS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Y9CQ	TTDDRUID	D0Y9CQ
D0Y9CQ	DRUGNAME	PMID30107136-Compound-General structure26
D0Y9CQ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0Y9CQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0Y9CQ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0Y9CQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0V8SL	TTDDRUID	D0V8SL
D0V8SL	DRUGNAME	PMID30107136-Compound-General structure27
D0V8SL	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0V8SL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0V8SL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0V8SL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03PUK	TTDDRUID	D03PUK
D03PUK	DRUGNAME	PMID30107136-Compound-General structure29
D03PUK	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D03PUK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D03PUK	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D03PUK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0CS0L	TTDDRUID	D0CS0L
D0CS0L	DRUGNAME	PMID30107136-Compound-General structure30
D0CS0L	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0CS0L	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0CS0L	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0CS0L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0JR1L	TTDDRUID	D0JR1L
D0JR1L	DRUGNAME	PMID30107136-Compound-General structure4
D0JR1L	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0JR1L	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0JR1L	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0JR1L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0T2WW	TTDDRUID	D0T2WW
D0T2WW	DRUGNAME	PMID30107136-Compound-General structure6
D0T2WW	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0T2WW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0T2WW	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0T2WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0DO6D	TTDDRUID	D0DO6D
D0DO6D	DRUGNAME	PMID30107136-Compound-General structure7
D0DO6D	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0DO6D	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0DO6D	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0DO6D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0T0AZ	TTDDRUID	D0T0AZ
D0T0AZ	DRUGNAME	PMID30107136-Compound-General structure8
D0T0AZ	INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
D0T0AZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
D0T0AZ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
D0T0AZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0F4NB	TTDDRUID	D0F4NB
D0F4NB	DRUGNAME	PMID30124346-Compound-13TABLE4
D0F4NB	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented

D0L1QJ	TTDDRUID	D0L1QJ
D0L1QJ	DRUGNAME	PMID30124346-Compound-14TABLE5
D0L1QJ	INDICATI	Dyskinesia [ICD-11: MB47.4] Patented
D0L1QJ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented

D01NVP	TTDDRUID	D01NVP
D01NVP	DRUGNAME	PMID30124346-Compound-18TABLE5
D01NVP	INDICATI	Dyskinesia [ICD-11: MB47.4] Patented
D01NVP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented

D0E4EJ	TTDDRUID	D0E4EJ
D0E4EJ	DRUGNAME	PMID30124346-Compound-1TABLE5
D0E4EJ	INDICATI	Dyskinesia [ICD-11: MB47.4] Patented
D0E4EJ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented

D0VW2R	TTDDRUID	D0VW2R
D0VW2R	DRUGNAME	PMID30124346-Compound-23TABLE4
D0VW2R	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented

D04BCC	TTDDRUID	D04BCC
D04BCC	DRUGNAME	PMID30124346-Compound-24TABLE4
D04BCC	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented

D09BCJ	TTDDRUID	D09BCJ
D09BCJ	DRUGNAME	PMID30124346-Compound-34TABLE4
D09BCJ	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented

D0IU7B	TTDDRUID	D0IU7B
D0IU7B	DRUGNAME	PMID30124346-Compound-39TABLE5
D0IU7B	INDICATI	Dyskinesia [ICD-11: MB47.4] Patented
D0IU7B	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented

D0CC7Q	TTDDRUID	D0CC7Q
D0CC7Q	DRUGNAME	PMID30124346-Compound-54TABLE5
D0CC7Q	INDICATI	Dyskinesia [ICD-11: MB47.4] Patented
D0CC7Q	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented

D0E7FT	TTDDRUID	D0E7FT
D0E7FT	DRUGNAME	PMID30124346-Compound-60TABLE5
D0E7FT	INDICATI	Dyskinesia [ICD-11: MB47.4] Patented
D0E7FT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented

D0QT3L	TTDDRUID	D0QT3L
D0QT3L	DRUGNAME	PMID30124346-Compound-66TABLE4
D0QT3L	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented

D05EVW	TTDDRUID	D05EVW
D05EVW	DRUGNAME	PMID30124346-Compound-Figure4
D05EVW	INDICATI	Functional gastrointestinal disorder [ICD-11: DD90-DD95] Patented

D0SG8X	TTDDRUID	D0SG8X
D0SG8X	DRUGNAME	PMID30124346-Compound-LDT66
D0SG8X	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Patented

D0EO8F	TTDDRUID	D0EO8F
D0EO8F	DRUGNAME	PMID30124346-Compound-LDT8
D0EO8F	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Patented

D0P8VT	TTDDRUID	D0P8VT
D0P8VT	DRUGNAME	PMID30280939-Compound-US20170128558
D0P8VT	INDICATI	Malaria [ICD-11: 1F40-1F45] Patented

D07NEI	TTDDRUID	D07NEI
D07NEI	DRUGNAME	PMID30280939-Compound-US20179642901
D07NEI	INDICATI	Malaria [ICD-11: 1F40-1F45] Patented

D0IH8R	TTDDRUID	D0IH8R
D0IH8R	DRUGNAME	PMID30280939-Compound-WO2008009652
D0IH8R	INDICATI	Malaria [ICD-11: 1F40-1F45] Patented

D0H9SD	TTDDRUID	D0H9SD
D0H9SD	DRUGNAME	PMID30280939-Compound-WO2013148426
D0H9SD	INDICATI	Malaria [ICD-11: 1F40-1F45] Patented

D0T8XY	TTDDRUID	D0T8XY
D0T8XY	DRUGNAME	PMID30280939-Compound-WO2015091734
D0T8XY	INDICATI	Malaria [ICD-11: 1F40-1F45] Patented

D09YKI	TTDDRUID	D09YKI
D09YKI	DRUGNAME	Polyhydroxy benzamide derivative 1
D09YKI	INDICATI	Albinism [ICD-11: EC23.2] Patented
D09YKI	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D09YKI	INDICATI	Melasma [ICD-11: ED60.1] Patented
D09YKI	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D09YKI	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0MM1Y	TTDDRUID	D0MM1Y
D0MM1Y	DRUGNAME	Polyhydroxy benzamide derivative 2
D0MM1Y	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0MM1Y	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0MM1Y	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0MM1Y	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0MM1Y	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0D2JW	TTDDRUID	D0D2JW
D0D2JW	DRUGNAME	Polyhydroxy benzamide derivative 3
D0D2JW	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0D2JW	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0D2JW	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0D2JW	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0D2JW	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D01RTO	TTDDRUID	D01RTO
D01RTO	DRUGNAME	Polyhydroxy benzamide derivative 4
D01RTO	INDICATI	Albinism [ICD-11: EC23.2] Patented
D01RTO	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D01RTO	INDICATI	Melasma [ICD-11: ED60.1] Patented
D01RTO	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D01RTO	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0GW5H	TTDDRUID	D0GW5H
D0GW5H	DRUGNAME	Polyhydroxy benzamide derivative 5
D0GW5H	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0GW5H	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0GW5H	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0GW5H	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0GW5H	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D04KUJ	TTDDRUID	D04KUJ
D04KUJ	DRUGNAME	Purine derivative 1
D04KUJ	INDICATI	Obesity [ICD-11: 5B81] Patented

D06STK	TTDDRUID	D06STK
D06STK	DRUGNAME	Purine derivative 2
D06STK	INDICATI	Obesity [ICD-11: 5B81] Patented

D06CEA	TTDDRUID	D06CEA
D06CEA	DRUGNAME	Purine derivative 3
D06CEA	INDICATI	Obesity [ICD-11: 5B81] Patented

D0R1PX	TTDDRUID	D0R1PX
D0R1PX	DRUGNAME	Pyrano[2,3-b]pyridine derivative 1
D0R1PX	INDICATI	Obesity [ICD-11: 5B81] Patented

D0U3YY	TTDDRUID	D0U3YY
D0U3YY	DRUGNAME	Pyrano[2,3-b]pyridine derivative 2
D0U3YY	INDICATI	Obesity [ICD-11: 5B81] Patented

D0GX6V	TTDDRUID	D0GX6V
D0GX6V	DRUGNAME	Pyrazole derivative 1
D0GX6V	INDICATI	Obesity [ICD-11: 5B81] Patented

D01PTN	TTDDRUID	D01PTN
D01PTN	DRUGNAME	Pyrazole derivative 10
D01PTN	INDICATI	Obesity [ICD-11: 5B81] Patented

D0KT1Q	TTDDRUID	D0KT1Q
D0KT1Q	DRUGNAME	Pyrazole derivative 11
D0KT1Q	INDICATI	Obesity [ICD-11: 5B81] Patented

D08WTW	TTDDRUID	D08WTW
D08WTW	DRUGNAME	Pyrazole derivative 12
D08WTW	INDICATI	Obesity [ICD-11: 5B81] Patented

D0P7HQ	TTDDRUID	D0P7HQ
D0P7HQ	DRUGNAME	Pyrazole derivative 13
D0P7HQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0P7QA	TTDDRUID	D0P7QA
D0P7QA	DRUGNAME	Pyrazole derivative 14
D0P7QA	INDICATI	Obesity [ICD-11: 5B81] Patented

D04MPV	TTDDRUID	D04MPV
D04MPV	DRUGNAME	Pyrazole derivative 15
D04MPV	INDICATI	Obesity [ICD-11: 5B81] Patented

D0YW3K	TTDDRUID	D0YW3K
D0YW3K	DRUGNAME	Pyrazole derivative 16
D0YW3K	INDICATI	Obesity [ICD-11: 5B81] Patented

D0RV2E	TTDDRUID	D0RV2E
D0RV2E	DRUGNAME	Pyrazole derivative 17
D0RV2E	INDICATI	Obesity [ICD-11: 5B81] Patented

D0Q5FS	TTDDRUID	D0Q5FS
D0Q5FS	DRUGNAME	Pyrazole derivative 18
D0Q5FS	INDICATI	Obesity [ICD-11: 5B81] Patented

D0FC8P	TTDDRUID	D0FC8P
D0FC8P	DRUGNAME	Pyrazole derivative 19
D0FC8P	INDICATI	Obesity [ICD-11: 5B81] Patented

D0M2RT	TTDDRUID	D0M2RT
D0M2RT	DRUGNAME	Pyrazole derivative 2
D0M2RT	INDICATI	Obesity [ICD-11: 5B81] Patented

D01RIT	TTDDRUID	D01RIT
D01RIT	DRUGNAME	Pyrazole derivative 20
D01RIT	INDICATI	Obesity [ICD-11: 5B81] Patented

D0K7XA	TTDDRUID	D0K7XA
D0K7XA	DRUGNAME	Pyrazole derivative 21
D0K7XA	INDICATI	Obesity [ICD-11: 5B81] Patented

D0C4TB	TTDDRUID	D0C4TB
D0C4TB	DRUGNAME	Pyrazole derivative 22
D0C4TB	INDICATI	Obesity [ICD-11: 5B81] Patented

D0D7ZU	TTDDRUID	D0D7ZU
D0D7ZU	DRUGNAME	Pyrazole derivative 23
D0D7ZU	INDICATI	Obesity [ICD-11: 5B81] Patented

D0S5NS	TTDDRUID	D0S5NS
D0S5NS	DRUGNAME	Pyrazole derivative 24
D0S5NS	INDICATI	Obesity [ICD-11: 5B81] Patented

D0J5NB	TTDDRUID	D0J5NB
D0J5NB	DRUGNAME	Pyrazole derivative 25
D0J5NB	INDICATI	Obesity [ICD-11: 5B81] Patented

D0BB2F	TTDDRUID	D0BB2F
D0BB2F	DRUGNAME	Pyrazole derivative 26
D0BB2F	INDICATI	Obesity [ICD-11: 5B81] Patented

D0D5MQ	TTDDRUID	D0D5MQ
D0D5MQ	DRUGNAME	Pyrazole derivative 27
D0D5MQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D06MPH	TTDDRUID	D06MPH
D06MPH	DRUGNAME	Pyrazole derivative 28
D06MPH	INDICATI	Obesity [ICD-11: 5B81] Patented

D0N0XU	TTDDRUID	D0N0XU
D0N0XU	DRUGNAME	Pyrazole derivative 29
D0N0XU	INDICATI	Obesity [ICD-11: 5B81] Patented

D0I0VJ	TTDDRUID	D0I0VJ
D0I0VJ	DRUGNAME	Pyrazole derivative 3
D0I0VJ	INDICATI	Obesity [ICD-11: 5B81] Patented

D05TQG	TTDDRUID	D05TQG
D05TQG	DRUGNAME	Pyrazole derivative 30
D05TQG	INDICATI	Obesity [ICD-11: 5B81] Patented

D0KD5X	TTDDRUID	D0KD5X
D0KD5X	DRUGNAME	Pyrazole derivative 31
D0KD5X	INDICATI	Obesity [ICD-11: 5B81] Patented

D04BXA	TTDDRUID	D04BXA
D04BXA	DRUGNAME	Pyrazole derivative 32
D04BXA	INDICATI	Obesity [ICD-11: 5B81] Patented

D0UA6W	TTDDRUID	D0UA6W
D0UA6W	DRUGNAME	Pyrazole derivative 33
D0UA6W	INDICATI	Obesity [ICD-11: 5B81] Patented

D0NJ0S	TTDDRUID	D0NJ0S
D0NJ0S	DRUGNAME	Pyrazole derivative 34
D0NJ0S	INDICATI	Obesity [ICD-11: 5B81] Patented

D0A2PY	TTDDRUID	D0A2PY
D0A2PY	DRUGNAME	Pyrazole derivative 35
D0A2PY	INDICATI	Obesity [ICD-11: 5B81] Patented

D05NUN	TTDDRUID	D05NUN
D05NUN	DRUGNAME	Pyrazole derivative 36
D05NUN	INDICATI	Obesity [ICD-11: 5B81] Patented

D06MIW	TTDDRUID	D06MIW
D06MIW	DRUGNAME	Pyrazole derivative 37
D06MIW	INDICATI	Obesity [ICD-11: 5B81] Patented

D0T7QY	TTDDRUID	D0T7QY
D0T7QY	DRUGNAME	Pyrazole derivative 38
D0T7QY	INDICATI	Obesity [ICD-11: 5B81] Patented

D00BXK	TTDDRUID	D00BXK
D00BXK	DRUGNAME	Pyrazole derivative 39
D00BXK	INDICATI	Obesity [ICD-11: 5B81] Patented

D01KJZ	TTDDRUID	D01KJZ
D01KJZ	DRUGNAME	Pyrazole derivative 4
D01KJZ	INDICATI	Obesity [ICD-11: 5B81] Patented

D00XDN	TTDDRUID	D00XDN
D00XDN	DRUGNAME	Pyrazole derivative 40
D00XDN	INDICATI	Obesity [ICD-11: 5B81] Patented

D03RJI	TTDDRUID	D03RJI
D03RJI	DRUGNAME	Pyrazole derivative 41
D03RJI	INDICATI	Obesity [ICD-11: 5B81] Patented

D05TPJ	TTDDRUID	D05TPJ
D05TPJ	DRUGNAME	Pyrazole derivative 42
D05TPJ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0AJ7O	TTDDRUID	D0AJ7O
D0AJ7O	DRUGNAME	Pyrazole derivative 43
D0AJ7O	INDICATI	Obesity [ICD-11: 5B81] Patented

D0C8HW	TTDDRUID	D0C8HW
D0C8HW	DRUGNAME	Pyrazole derivative 44
D0C8HW	INDICATI	Obesity [ICD-11: 5B81] Patented

D0TG6J	TTDDRUID	D0TG6J
D0TG6J	DRUGNAME	Pyrazole derivative 45
D0TG6J	INDICATI	Obesity [ICD-11: 5B81] Patented

D0Q4XR	TTDDRUID	D0Q4XR
D0Q4XR	DRUGNAME	Pyrazole derivative 46
D0Q4XR	INDICATI	Obesity [ICD-11: 5B81] Patented

D0V5NT	TTDDRUID	D0V5NT
D0V5NT	DRUGNAME	Pyrazole derivative 47
D0V5NT	INDICATI	Obesity [ICD-11: 5B81] Patented

D0C5WG	TTDDRUID	D0C5WG
D0C5WG	DRUGNAME	Pyrazole derivative 48
D0C5WG	INDICATI	Obesity [ICD-11: 5B81] Patented

D05PHR	TTDDRUID	D05PHR
D05PHR	DRUGNAME	Pyrazole derivative 49
D05PHR	INDICATI	Obesity [ICD-11: 5B81] Patented

D0H1IX	TTDDRUID	D0H1IX
D0H1IX	DRUGNAME	Pyrazole derivative 5
D0H1IX	INDICATI	Obesity [ICD-11: 5B81] Patented

D0X9WN	TTDDRUID	D0X9WN
D0X9WN	DRUGNAME	Pyrazole derivative 50
D0X9WN	INDICATI	Obesity [ICD-11: 5B81] Patented

D00AHQ	TTDDRUID	D00AHQ
D00AHQ	DRUGNAME	Pyrazole derivative 51
D00AHQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0KS8S	TTDDRUID	D0KS8S
D0KS8S	DRUGNAME	Pyrazole derivative 52
D0KS8S	INDICATI	Obesity [ICD-11: 5B81] Patented

D00XFT	TTDDRUID	D00XFT
D00XFT	DRUGNAME	Pyrazole derivative 53
D00XFT	INDICATI	Obesity [ICD-11: 5B81] Patented

D0YN2I	TTDDRUID	D0YN2I
D0YN2I	DRUGNAME	Pyrazole derivative 54
D0YN2I	INDICATI	Obesity [ICD-11: 5B81] Patented

D0TE8O	TTDDRUID	D0TE8O
D0TE8O	DRUGNAME	Pyrazole derivative 55
D0TE8O	INDICATI	Obesity [ICD-11: 5B81] Patented

D03HPG	TTDDRUID	D03HPG
D03HPG	DRUGNAME	Pyrazole derivative 56
D03HPG	INDICATI	Obesity [ICD-11: 5B81] Patented

D01WWN	TTDDRUID	D01WWN
D01WWN	DRUGNAME	Pyrazole derivative 57
D01WWN	INDICATI	Obesity [ICD-11: 5B81] Patented

D09IYH	TTDDRUID	D09IYH
D09IYH	DRUGNAME	Pyrazole derivative 58
D09IYH	INDICATI	Obesity [ICD-11: 5B81] Patented

D0Q9AD	TTDDRUID	D0Q9AD
D0Q9AD	DRUGNAME	Pyrazole derivative 59
D0Q9AD	INDICATI	Obesity [ICD-11: 5B81] Patented

D0M9FZ	TTDDRUID	D0M9FZ
D0M9FZ	DRUGNAME	Pyrazole derivative 6
D0M9FZ	INDICATI	Obesity [ICD-11: 5B81] Patented

D07PIH	TTDDRUID	D07PIH
D07PIH	DRUGNAME	Pyrazole derivative 60
D07PIH	INDICATI	Obesity [ICD-11: 5B81] Patented

D00MLJ	TTDDRUID	D00MLJ
D00MLJ	DRUGNAME	Pyrazole derivative 61
D00MLJ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D00MLJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07QLD	TTDDRUID	D07QLD
D07QLD	DRUGNAME	Pyrazole derivative 7
D07QLD	INDICATI	Obesity [ICD-11: 5B81] Patented

D02SNQ	TTDDRUID	D02SNQ
D02SNQ	DRUGNAME	Pyrazole derivative 8
D02SNQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0G8AN	TTDDRUID	D0G8AN
D0G8AN	DRUGNAME	Pyrazole derivative 9
D0G8AN	INDICATI	Obesity [ICD-11: 5B81] Patented

D0ET9U	TTDDRUID	D0ET9U
D0ET9U	DRUGNAME	Pyrazoline derivative 1
D0ET9U	INDICATI	Obesity [ICD-11: 5B81] Patented

D0N6GL	TTDDRUID	D0N6GL
D0N6GL	DRUGNAME	Pyrazoline derivative 10
D0N6GL	INDICATI	Obesity [ICD-11: 5B81] Patented

D0D7AJ	TTDDRUID	D0D7AJ
D0D7AJ	DRUGNAME	Pyrazoline derivative 11
D0D7AJ	INDICATI	Obesity [ICD-11: 5B81] Patented

D01XVK	TTDDRUID	D01XVK
D01XVK	DRUGNAME	Pyrazoline derivative 2
D01XVK	INDICATI	Obesity [ICD-11: 5B81] Patented

D0CF8Y	TTDDRUID	D0CF8Y
D0CF8Y	DRUGNAME	Pyrazoline derivative 3
D0CF8Y	INDICATI	Obesity [ICD-11: 5B81] Patented

D03HHD	TTDDRUID	D03HHD
D03HHD	DRUGNAME	Pyrazoline derivative 4
D03HHD	INDICATI	Obesity [ICD-11: 5B81] Patented

D0S2ME	TTDDRUID	D0S2ME
D0S2ME	DRUGNAME	Pyrazoline derivative 5
D0S2ME	INDICATI	Obesity [ICD-11: 5B81] Patented

D0T5YU	TTDDRUID	D0T5YU
D0T5YU	DRUGNAME	Pyrazoline derivative 6
D0T5YU	INDICATI	Obesity [ICD-11: 5B81] Patented

D0B8DF	TTDDRUID	D0B8DF
D0B8DF	DRUGNAME	Pyrazoline derivative 7
D0B8DF	INDICATI	Obesity [ICD-11: 5B81] Patented

D0BN8U	TTDDRUID	D0BN8U
D0BN8U	DRUGNAME	Pyrazoline derivative 8
D0BN8U	INDICATI	Obesity [ICD-11: 5B81] Patented

D0R6DL	TTDDRUID	D0R6DL
D0R6DL	DRUGNAME	Pyrazoline derivative 9
D0R6DL	INDICATI	Obesity [ICD-11: 5B81] Patented

D0DN3Q	TTDDRUID	D0DN3Q
D0DN3Q	DRUGNAME	Pyrazolo[1,5-a]pyridine derivative 1
D0DN3Q	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0DN3Q	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DN3Q	INDICATI	Pruritus [ICD-11: EC90] Patented
D0DN3Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0DN3Q	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0V9ZJ	TTDDRUID	D0V9ZJ
D0V9ZJ	DRUGNAME	Pyrazolo[1,5-a]pyridine derivative 2
D0V9ZJ	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0V9ZJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0V9ZJ	INDICATI	Pruritus [ICD-11: EC90] Patented
D0V9ZJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0V9ZJ	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0X7DZ	TTDDRUID	D0X7DZ
D0X7DZ	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 1
D0X7DZ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0OT3G	TTDDRUID	D0OT3G
D0OT3G	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 10
D0OT3G	INDICATI	Obesity [ICD-11: 5B81] Patented

D0B6NT	TTDDRUID	D0B6NT
D0B6NT	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 11
D0B6NT	INDICATI	Obesity [ICD-11: 5B81] Patented

D0L2MA	TTDDRUID	D0L2MA
D0L2MA	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 12
D0L2MA	INDICATI	Obesity [ICD-11: 5B81] Patented

D0GH4B	TTDDRUID	D0GH4B
D0GH4B	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 13
D0GH4B	INDICATI	Obesity [ICD-11: 5B81] Patented

D06IPV	TTDDRUID	D06IPV
D06IPV	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 2
D06IPV	INDICATI	Obesity [ICD-11: 5B81] Patented

D07SYY	TTDDRUID	D07SYY
D07SYY	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 3
D07SYY	INDICATI	Obesity [ICD-11: 5B81] Patented

D0EQ3O	TTDDRUID	D0EQ3O
D0EQ3O	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 4
D0EQ3O	INDICATI	Obesity [ICD-11: 5B81] Patented

D0F0VY	TTDDRUID	D0F0VY
D0F0VY	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 5
D0F0VY	INDICATI	Obesity [ICD-11: 5B81] Patented

D0LU7K	TTDDRUID	D0LU7K
D0LU7K	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 6
D0LU7K	INDICATI	Obesity [ICD-11: 5B81] Patented

D0LZ1Z	TTDDRUID	D0LZ1Z
D0LZ1Z	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 7
D0LZ1Z	INDICATI	Obesity [ICD-11: 5B81] Patented

D0G8LH	TTDDRUID	D0G8LH
D0G8LH	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 8
D0G8LH	INDICATI	Obesity [ICD-11: 5B81] Patented

D0U6PA	TTDDRUID	D0U6PA
D0U6PA	DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 9
D0U6PA	INDICATI	Obesity [ICD-11: 5B81] Patented

D0RK6W	TTDDRUID	D0RK6W
D0RK6W	DRUGNAME	Pyrazolo[4,3-c]pyridine derivative 1
D0RK6W	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0RK6W	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0RK6W	INDICATI	Pruritus [ICD-11: EC90] Patented
D0RK6W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0RK6W	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0O8SX	TTDDRUID	D0O8SX
D0O8SX	DRUGNAME	Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1
D0O8SX	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0O8SX	INDICATI	Malignant thymoma [ICD-11: 2C27.2] Patented
D0O8SX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0O8SX	INDICATI	Pruritus [ICD-11: EC90] Patented
D0O8SX	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0I1YQ	TTDDRUID	D0I1YQ
D0I1YQ	DRUGNAME	Pyrazolopyridines and imidazopyridine derivative 1
D0I1YQ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0I1YQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07UNH	TTDDRUID	D07UNH
D07UNH	DRUGNAME	Pyridine and pyrimidine derivative 1
D07UNH	INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
D07UNH	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
D07UNH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0M9KZ	TTDDRUID	D0M9KZ
D0M9KZ	DRUGNAME	Pyridine derivative 4
D0M9KZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D05GMT	TTDDRUID	D05GMT
D05GMT	DRUGNAME	Pyridinone carboxamide derivative 1
D05GMT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D05GMT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02BGU	TTDDRUID	D02BGU
D02BGU	DRUGNAME	Pyrido/pyrrolo-fused pyrimidine derivative 1
D02BGU	INDICATI	Pain [ICD-11: MG30-MG3Z] Patented

D0J5XM	TTDDRUID	D0J5XM
D0J5XM	DRUGNAME	Pyrido[2,3-d]pyrimidine derivative 1
D0J5XM	INDICATI	Obesity [ICD-11: 5B81] Patented

D08RCV	TTDDRUID	D08RCV
D08RCV	DRUGNAME	Pyrido[2,3-d]pyrimidine derivative 2
D08RCV	INDICATI	Obesity [ICD-11: 5B81] Patented

D00JBK	TTDDRUID	D00JBK
D00JBK	DRUGNAME	Pyrido[3,2-d]pyrimidine derivative 1
D00JBK	INDICATI	Chronic pain [ICD-11: MG30] Patented
D00JBK	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D00JBK	INDICATI	Pruritus [ICD-11: EC90] Patented
D00JBK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D00JBK	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0RR8O	TTDDRUID	D0RR8O
D0RR8O	DRUGNAME	Pyrido[3,2-d]pyrimidine derivative 2
D0RR8O	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0RR8O	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0RR8O	INDICATI	Pruritus [ICD-11: EC90] Patented
D0RR8O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0RR8O	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0U3RD	TTDDRUID	D0U3RD
D0U3RD	DRUGNAME	Pyrido[3,2-d]pyrimidine derivative 3
D0U3RD	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0U3RD	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0U3RD	INDICATI	Pruritus [ICD-11: EC90] Patented
D0U3RD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0U3RD	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0ZV9P	TTDDRUID	D0ZV9P
D0ZV9P	DRUGNAME	Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1
D0ZV9P	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0ZV9P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0F1DK	TTDDRUID	D0F1DK
D0F1DK	DRUGNAME	Pyridotriazolopyrimidine derivative 1
D0F1DK	INDICATI	Obesity [ICD-11: 5B81] Patented

D0V0UW	TTDDRUID	D0V0UW
D0V0UW	DRUGNAME	Pyridotriazolopyrimidine derivative 2
D0V0UW	INDICATI	Obesity [ICD-11: 5B81] Patented

D0Z8WF	TTDDRUID	D0Z8WF
D0Z8WF	DRUGNAME	Pyridotriazolopyrimidine derivative 3
D0Z8WF	INDICATI	Obesity [ICD-11: 5B81] Patented

D02MMG	TTDDRUID	D02MMG
D02MMG	DRUGNAME	Pyrimidine derivative 3
D02MMG	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D02MMG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D05GVV	TTDDRUID	D05GVV
D05GVV	DRUGNAME	Pyrimidine derivative 5
D05GVV	INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
D05GVV	INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
D05GVV	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented

D0V7OF	TTDDRUID	D0V7OF
D0V7OF	DRUGNAME	Pyrimidine derivative 6
D0V7OF	INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
D0V7OF	INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
D0V7OF	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented

D09KYB	TTDDRUID	D09KYB
D09KYB	DRUGNAME	Pyrimidine derivative 7
D09KYB	INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
D09KYB	INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
D09KYB	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented

D0P1VT	TTDDRUID	D0P1VT
D0P1VT	DRUGNAME	Pyrimidinone derivative 1
D0P1VT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0P1VT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0M6PB	TTDDRUID	D0M6PB
D0M6PB	DRUGNAME	Pyrrole derivative 1
D0M6PB	INDICATI	Obesity [ICD-11: 5B81] Patented

D0GW8L	TTDDRUID	D0GW8L
D0GW8L	DRUGNAME	Pyrrole derivative 2
D0GW8L	INDICATI	Obesity [ICD-11: 5B81] Patented

D0H2GT	TTDDRUID	D0H2GT
D0H2GT	DRUGNAME	Pyrrole derivative 3
D0H2GT	INDICATI	Obesity [ICD-11: 5B81] Patented

D0NB2K	TTDDRUID	D0NB2K
D0NB2K	DRUGNAME	Pyrrole derivative 4
D0NB2K	INDICATI	Obesity [ICD-11: 5B81] Patented

D0CW1J	TTDDRUID	D0CW1J
D0CW1J	DRUGNAME	Pyrrole derivative 5
D0CW1J	INDICATI	Obesity [ICD-11: 5B81] Patented

D0HD7S	TTDDRUID	D0HD7S
D0HD7S	DRUGNAME	Pyrrole derivative 6
D0HD7S	INDICATI	Obesity [ICD-11: 5B81] Patented

D0P8SR	TTDDRUID	D0P8SR
D0P8SR	DRUGNAME	Pyrrolo[2,3-b]pyridine derivative 1
D0P8SR	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0P8SR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0P8SR	INDICATI	Pruritus [ICD-11: EC90] Patented
D0P8SR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0P8SR	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D06GOT	TTDDRUID	D06GOT
D06GOT	DRUGNAME	Pyrrolo[2,3-b]pyridine derivative 2
D06GOT	INDICATI	Chronic pain [ICD-11: MG30] Patented
D06GOT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D06GOT	INDICATI	Pruritus [ICD-11: EC90] Patented
D06GOT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D06GOT	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D02IBX	TTDDRUID	D02IBX
D02IBX	DRUGNAME	Pyrrolo[2,3-b]pyridine derivative 3
D02IBX	INDICATI	Chronic pain [ICD-11: MG30] Patented
D02IBX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D02IBX	INDICATI	Pruritus [ICD-11: EC90] Patented
D02IBX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D02IBX	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D06ZNU	TTDDRUID	D06ZNU
D06ZNU	DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 16
D06ZNU	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Patented
D06ZNU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0V8JZ	TTDDRUID	D0V8JZ
D0V8JZ	DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 17
D0V8JZ	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Patented
D0V8JZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0S0II	TTDDRUID	D0S0II
D0S0II	DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 3
D0S0II	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0S0II	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0S0II	INDICATI	Pruritus [ICD-11: EC90] Patented
D0S0II	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0S0II	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0AG2A	TTDDRUID	D0AG2A
D0AG2A	DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 4
D0AG2A	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0AG2A	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0AG2A	INDICATI	Pruritus [ICD-11: EC90] Patented
D0AG2A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0AG2A	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D06ALN	TTDDRUID	D06ALN
D06ALN	DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 5
D06ALN	INDICATI	Chronic pain [ICD-11: MG30] Patented
D06ALN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D06ALN	INDICATI	Pruritus [ICD-11: EC90] Patented
D06ALN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D06ALN	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0DQ5G	TTDDRUID	D0DQ5G
D0DQ5G	DRUGNAME	Pyrrolo[3,2-c]pyridine derivative 1
D0DQ5G	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0DQ5G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0DQ5G	INDICATI	Pruritus [ICD-11: EC90] Patented
D0DQ5G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0DQ5G	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0CM5P	TTDDRUID	D0CM5P
D0CM5P	DRUGNAME	Quinazoline derivative 10
D0CM5P	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
D0CM5P	INDICATI	Cirrhosis [ICD-11: DB93] Patented
D0CM5P	INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
D0CM5P	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented

D08ZEM	TTDDRUID	D08ZEM
D08ZEM	DRUGNAME	Quinazoline derivative 11
D08ZEM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
D08ZEM	INDICATI	Cirrhosis [ICD-11: DB93] Patented
D08ZEM	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
D08ZEM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
D08ZEM	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented

D0EC3H	TTDDRUID	D0EC3H
D0EC3H	DRUGNAME	Quinazoline derivative 12
D0EC3H	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
D0EC3H	INDICATI	Cirrhosis [ICD-11: DB93] Patented
D0EC3H	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
D0EC3H	INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
D0EC3H	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented

D0P2BJ	TTDDRUID	D0P2BJ
D0P2BJ	DRUGNAME	Quinazoline derivative 13
D0P2BJ	INDICATI	Arteriosclerosis [ICD-11: BD40] Patented
D0P2BJ	INDICATI	Atopic dermatitis [ICD-11: EA80] Patented
D0P2BJ	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
D0P2BJ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented

D0HR7W	TTDDRUID	D0HR7W
D0HR7W	DRUGNAME	Quinoline-3-carboxamide derivative 1
D0HR7W	INDICATI	Neuroinflammation [ICD-11: 1D0Y] Patented

D07GOO	TTDDRUID	D07GOO
D07GOO	DRUGNAME	Quinoline-3-carboxamide derivative 2
D07GOO	INDICATI	Neuroinflammation [ICD-11: 1D0Y] Patented

D0G5CV	TTDDRUID	D0G5CV
D0G5CV	DRUGNAME	Resorcinol compound 1
D0G5CV	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0G5CV	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0G5CV	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0G5CV	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0G5CV	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0E6LU	TTDDRUID	D0E6LU
D0E6LU	DRUGNAME	Resorcinol compound 10
D0E6LU	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0E6LU	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0E6LU	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0E6LU	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0E6LU	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0JC3U	TTDDRUID	D0JC3U
D0JC3U	DRUGNAME	Resorcinol compound 11
D0JC3U	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0JC3U	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0JC3U	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0JC3U	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0JC3U	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0H0UC	TTDDRUID	D0H0UC
D0H0UC	DRUGNAME	Resorcinol compound 12
D0H0UC	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0H0UC	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0H0UC	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0H0UC	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0H0UC	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0PI1Z	TTDDRUID	D0PI1Z
D0PI1Z	DRUGNAME	Resorcinol compound 13
D0PI1Z	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0PI1Z	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0PI1Z	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0PI1Z	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0PI1Z	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0P6ZB	TTDDRUID	D0P6ZB
D0P6ZB	DRUGNAME	Resorcinol compound 14
D0P6ZB	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0P6ZB	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0P6ZB	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0P6ZB	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0P6ZB	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D03MKE	TTDDRUID	D03MKE
D03MKE	DRUGNAME	Resorcinol compound 15
D03MKE	INDICATI	Albinism [ICD-11: EC23.2] Patented
D03MKE	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D03MKE	INDICATI	Melasma [ICD-11: ED60.1] Patented
D03MKE	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D03MKE	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0CH3F	TTDDRUID	D0CH3F
D0CH3F	DRUGNAME	Resorcinol compound 16
D0CH3F	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0CH3F	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0CH3F	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0CH3F	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0CH3F	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D01EVP	TTDDRUID	D01EVP
D01EVP	DRUGNAME	Resorcinol compound 17
D01EVP	INDICATI	Albinism [ICD-11: EC23.2] Patented
D01EVP	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D01EVP	INDICATI	Melasma [ICD-11: ED60.1] Patented
D01EVP	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D01EVP	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0TL2C	TTDDRUID	D0TL2C
D0TL2C	DRUGNAME	Resorcinol compound 18
D0TL2C	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0TL2C	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0TL2C	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0TL2C	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0TL2C	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0X7EQ	TTDDRUID	D0X7EQ
D0X7EQ	DRUGNAME	Resorcinol compound 19
D0X7EQ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0X7EQ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0X7EQ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0X7EQ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0X7EQ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D07RJD	TTDDRUID	D07RJD
D07RJD	DRUGNAME	Resorcinol compound 2
D07RJD	INDICATI	Albinism [ICD-11: EC23.2] Patented
D07RJD	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D07RJD	INDICATI	Melasma [ICD-11: ED60.1] Patented
D07RJD	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D07RJD	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D05NHA	TTDDRUID	D05NHA
D05NHA	DRUGNAME	Resorcinol compound 20
D05NHA	INDICATI	Albinism [ICD-11: EC23.2] Patented
D05NHA	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D05NHA	INDICATI	Melasma [ICD-11: ED60.1] Patented
D05NHA	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D05NHA	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D04ZZM	TTDDRUID	D04ZZM
D04ZZM	DRUGNAME	Resorcinol compound 21
D04ZZM	INDICATI	Albinism [ICD-11: EC23.2] Patented
D04ZZM	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D04ZZM	INDICATI	Melasma [ICD-11: ED60.1] Patented
D04ZZM	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D04ZZM	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D06YKN	TTDDRUID	D06YKN
D06YKN	DRUGNAME	Resorcinol compound 22
D06YKN	INDICATI	Albinism [ICD-11: EC23.2] Patented
D06YKN	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D06YKN	INDICATI	Melasma [ICD-11: ED60.1] Patented
D06YKN	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D06YKN	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D00QVY	TTDDRUID	D00QVY
D00QVY	DRUGNAME	Resorcinol compound 23
D00QVY	INDICATI	Albinism [ICD-11: EC23.2] Patented
D00QVY	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D00QVY	INDICATI	Melasma [ICD-11: ED60.1] Patented
D00QVY	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D00QVY	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D07PSJ	TTDDRUID	D07PSJ
D07PSJ	DRUGNAME	Resorcinol compound 24
D07PSJ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D07PSJ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D07PSJ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D07PSJ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D07PSJ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0K6TN	TTDDRUID	D0K6TN
D0K6TN	DRUGNAME	Resorcinol compound 25
D0K6TN	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0K6TN	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0K6TN	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0K6TN	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0K6TN	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0IH6G	TTDDRUID	D0IH6G
D0IH6G	DRUGNAME	Resorcinol compound 26
D0IH6G	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0IH6G	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0IH6G	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0IH6G	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0IH6G	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0QR0E	TTDDRUID	D0QR0E
D0QR0E	DRUGNAME	Resorcinol compound 27
D0QR0E	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0QR0E	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0QR0E	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0QR0E	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0QR0E	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0Q1HU	TTDDRUID	D0Q1HU
D0Q1HU	DRUGNAME	Resorcinol compound 28
D0Q1HU	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0Q1HU	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0Q1HU	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0Q1HU	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0Q1HU	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0ZT3U	TTDDRUID	D0ZT3U
D0ZT3U	DRUGNAME	Resorcinol compound 29
D0ZT3U	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0ZT3U	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0ZT3U	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0ZT3U	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0ZT3U	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0ZJ4M	TTDDRUID	D0ZJ4M
D0ZJ4M	DRUGNAME	Resorcinol compound 3
D0ZJ4M	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0ZJ4M	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0ZJ4M	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0ZJ4M	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0ZJ4M	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0K1UO	TTDDRUID	D0K1UO
D0K1UO	DRUGNAME	Resorcinol compound 30
D0K1UO	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0K1UO	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0K1UO	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0K1UO	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0K1UO	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0K7LI	TTDDRUID	D0K7LI
D0K7LI	DRUGNAME	Resorcinol compound 31
D0K7LI	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0K7LI	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0K7LI	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0K7LI	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0K7LI	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D09QZB	TTDDRUID	D09QZB
D09QZB	DRUGNAME	Resorcinol compound 32
D09QZB	INDICATI	Albinism [ICD-11: EC23.2] Patented
D09QZB	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D09QZB	INDICATI	Melasma [ICD-11: ED60.1] Patented
D09QZB	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D09QZB	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0FL1E	TTDDRUID	D0FL1E
D0FL1E	DRUGNAME	Resorcinol compound 33
D0FL1E	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0FL1E	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0FL1E	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0FL1E	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0FL1E	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0T7BH	TTDDRUID	D0T7BH
D0T7BH	DRUGNAME	Resorcinol compound 34
D0T7BH	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0T7BH	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0T7BH	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0T7BH	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0T7BH	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0EQ3V	TTDDRUID	D0EQ3V
D0EQ3V	DRUGNAME	Resorcinol compound 4
D0EQ3V	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0EQ3V	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0EQ3V	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0EQ3V	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0EQ3V	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0KU5J	TTDDRUID	D0KU5J
D0KU5J	DRUGNAME	Resorcinol compound 5
D0KU5J	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0KU5J	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0KU5J	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0KU5J	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0KU5J	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0NR2A	TTDDRUID	D0NR2A
D0NR2A	DRUGNAME	Resorcinol compound 6
D0NR2A	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0NR2A	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0NR2A	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0NR2A	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0NR2A	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D02JVX	TTDDRUID	D02JVX
D02JVX	DRUGNAME	Resorcinol compound 7
D02JVX	INDICATI	Albinism [ICD-11: EC23.2] Patented
D02JVX	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D02JVX	INDICATI	Melasma [ICD-11: ED60.1] Patented
D02JVX	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D02JVX	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D06WGO	TTDDRUID	D06WGO
D06WGO	DRUGNAME	Resorcinol compound 8
D06WGO	INDICATI	Albinism [ICD-11: EC23.2] Patented
D06WGO	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D06WGO	INDICATI	Melasma [ICD-11: ED60.1] Patented
D06WGO	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D06WGO	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0RC7R	TTDDRUID	D0RC7R
D0RC7R	DRUGNAME	Resorcinol compound 9
D0RC7R	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0RC7R	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0RC7R	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0RC7R	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0RC7R	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D05RJG	TTDDRUID	D05RJG
D05RJG	DRUGNAME	Schiff base compound 1
D05RJG	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D0DW5P	TTDDRUID	D0DW5P
D0DW5P	DRUGNAME	Schiff base compound 2
D0DW5P	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D0ZE6H	TTDDRUID	D0ZE6H
D0ZE6H	DRUGNAME	Six-membered heterocyclic benzamide derivative 1
D0ZE6H	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0ZE6H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0ZE6H	INDICATI	Pruritus [ICD-11: EC90] Patented
D0ZE6H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0ZE6H	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0H3ZG	TTDDRUID	D0H3ZG
D0H3ZG	DRUGNAME	Six-membered heterocyclic benzamide derivative 2
D0H3ZG	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0H3ZG	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0H3ZG	INDICATI	Pruritus [ICD-11: EC90] Patented
D0H3ZG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0H3ZG	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D07VFQ	TTDDRUID	D07VFQ
D07VFQ	DRUGNAME	Six-membered heterocyclic benzamide derivative 3
D07VFQ	INDICATI	Chronic pain [ICD-11: MG30] Patented
D07VFQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D07VFQ	INDICATI	Pruritus [ICD-11: EC90] Patented
D07VFQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D07VFQ	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0EC4Z	TTDDRUID	D0EC4Z
D0EC4Z	DRUGNAME	Six-membered heterocyclic benzamide derivative 4
D0EC4Z	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0EC4Z	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0EC4Z	INDICATI	Pruritus [ICD-11: EC90] Patented
D0EC4Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0EC4Z	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0UN4M	TTDDRUID	D0UN4M
D0UN4M	DRUGNAME	Six-membered heterocyclic benzamide derivative 5
D0UN4M	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0UN4M	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0UN4M	INDICATI	Pruritus [ICD-11: EC90] Patented
D0UN4M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0UN4M	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D04JCD	TTDDRUID	D04JCD
D04JCD	DRUGNAME	Six-membered heterocyclic benzamide derivative 6
D04JCD	INDICATI	Chronic pain [ICD-11: MG30] Patented
D04JCD	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D04JCD	INDICATI	Pruritus [ICD-11: EC90] Patented
D04JCD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D04JCD	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D05MRY	TTDDRUID	D05MRY
D05MRY	DRUGNAME	Six-membered heterocyclic benzamide derivative 7
D05MRY	INDICATI	Chronic pain [ICD-11: MG30] Patented
D05MRY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D05MRY	INDICATI	Pruritus [ICD-11: EC90] Patented
D05MRY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D05MRY	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D03TDK	TTDDRUID	D03TDK
D03TDK	DRUGNAME	Sulfonamide derivative 1
D03TDK	INDICATI	Obesity [ICD-11: 5B81] Patented

D0CU9M	TTDDRUID	D0CU9M
D0CU9M	DRUGNAME	Sulfonamide derivative 2
D0CU9M	INDICATI	Obesity [ICD-11: 5B81] Patented

D00LZP	TTDDRUID	D00LZP
D00LZP	DRUGNAME	Sulfonamide derivative 3
D00LZP	INDICATI	Obesity [ICD-11: 5B81] Patented

D0MB1E	TTDDRUID	D0MB1E
D0MB1E	DRUGNAME	Sulfonamide derivative 4
D0MB1E	INDICATI	Obesity [ICD-11: 5B81] Patented

D0VH4J	TTDDRUID	D0VH4J
D0VH4J	DRUGNAME	Sulfonamide derivative 5
D0VH4J	INDICATI	Obesity [ICD-11: 5B81] Patented

D0CX1F	TTDDRUID	D0CX1F
D0CX1F	DRUGNAME	Sulfonylated piperazine derivative 1
D0CX1F	INDICATI	Obesity [ICD-11: 5B81] Patented

D0WK8I	TTDDRUID	D0WK8I
D0WK8I	DRUGNAME	Sulfonylated piperazine derivative 2
D0WK8I	INDICATI	Obesity [ICD-11: 5B81] Patented

D0FR1Q	TTDDRUID	D0FR1Q
D0FR1Q	DRUGNAME	Sulfonylated piperazine derivative 3
D0FR1Q	INDICATI	Obesity [ICD-11: 5B81] Patented

D07NAA	TTDDRUID	D07NAA
D07NAA	DRUGNAME	Sulfonylated piperazine derivative 4
D07NAA	INDICATI	Obesity [ICD-11: 5B81] Patented

D0O4RN	TTDDRUID	D0O4RN
D0O4RN	DRUGNAME	Sulfonylated piperazine derivative 5
D0O4RN	INDICATI	Obesity [ICD-11: 5B81] Patented

D06KNK	TTDDRUID	D06KNK
D06KNK	DRUGNAME	TDZD-8
D06KNK	INDICATI	Malignant glioma [ICD-11: 2A00.0] Patented

D0HD6C	TTDDRUID	D0HD6C
D0HD6C	DRUGNAME	Tetra-hydro-1H-1,2,6-triazaazulene derivative 1
D0HD6C	INDICATI	Obesity [ICD-11: 5B81] Patented

D0SW2Q	TTDDRUID	D0SW2Q
D0SW2Q	DRUGNAME	Tetra-hydro-1H-1,2,6-triazaazulene derivative 2
D0SW2Q	INDICATI	Obesity [ICD-11: 5B81] Patented

D06STX	TTDDRUID	D06STX
D06STX	DRUGNAME	Thiadiazolyl carboxamide derivative 1
D06STX	INDICATI	Alzheimer disease [ICD-11: 8A20] Patented

D0Q6RC	TTDDRUID	D0Q6RC
D0Q6RC	DRUGNAME	Thiazole carboxamide derivative 1
D0Q6RC	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0Q6RC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0K8XT	TTDDRUID	D0K8XT
D0K8XT	DRUGNAME	Thiazole carboxamide derivative 10
D0K8XT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0K8XT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07MSB	TTDDRUID	D07MSB
D07MSB	DRUGNAME	Thiazole carboxamide derivative 11
D07MSB	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D07MSB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06PTW	TTDDRUID	D06PTW
D06PTW	DRUGNAME	Thiazole carboxamide derivative 12
D06PTW	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06PTW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0ZG0K	TTDDRUID	D0ZG0K
D0ZG0K	DRUGNAME	Thiazole carboxamide derivative 13
D0ZG0K	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0ZG0K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06WXJ	TTDDRUID	D06WXJ
D06WXJ	DRUGNAME	Thiazole carboxamide derivative 14
D06WXJ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06WXJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Q8JK	TTDDRUID	D0Q8JK
D0Q8JK	DRUGNAME	Thiazole carboxamide derivative 15
D0Q8JK	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0Q8JK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0D8PF	TTDDRUID	D0D8PF
D0D8PF	DRUGNAME	Thiazole carboxamide derivative 16
D0D8PF	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0D8PF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0GE6F	TTDDRUID	D0GE6F
D0GE6F	DRUGNAME	Thiazole carboxamide derivative 17
D0GE6F	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0GE6F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0FJ4A	TTDDRUID	D0FJ4A
D0FJ4A	DRUGNAME	Thiazole carboxamide derivative 18
D0FJ4A	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0FJ4A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0GY8G	TTDDRUID	D0GY8G
D0GY8G	DRUGNAME	Thiazole carboxamide derivative 19
D0GY8G	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0GY8G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0HP8K	TTDDRUID	D0HP8K
D0HP8K	DRUGNAME	Thiazole carboxamide derivative 2
D0HP8K	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0HP8K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0B2GM	TTDDRUID	D0B2GM
D0B2GM	DRUGNAME	Thiazole carboxamide derivative 20
D0B2GM	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0B2GM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0P6PT	TTDDRUID	D0P6PT
D0P6PT	DRUGNAME	Thiazole carboxamide derivative 21
D0P6PT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0P6PT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0KN7T	TTDDRUID	D0KN7T
D0KN7T	DRUGNAME	Thiazole carboxamide derivative 22
D0KN7T	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0KN7T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0DO6K	TTDDRUID	D0DO6K
D0DO6K	DRUGNAME	Thiazole carboxamide derivative 23
D0DO6K	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0DO6K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04BBA	TTDDRUID	D04BBA
D04BBA	DRUGNAME	Thiazole carboxamide derivative 24
D04BBA	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04BBA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0JR0F	TTDDRUID	D0JR0F
D0JR0F	DRUGNAME	Thiazole carboxamide derivative 25
D0JR0F	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0JR0F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0U7LW	TTDDRUID	D0U7LW
D0U7LW	DRUGNAME	Thiazole carboxamide derivative 26
D0U7LW	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0U7LW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04QRX	TTDDRUID	D04QRX
D04QRX	DRUGNAME	Thiazole carboxamide derivative 27
D04QRX	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04QRX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0QV1E	TTDDRUID	D0QV1E
D0QV1E	DRUGNAME	Thiazole carboxamide derivative 28
D0QV1E	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0QV1E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D07ZMG	TTDDRUID	D07ZMG
D07ZMG	DRUGNAME	Thiazole carboxamide derivative 29
D07ZMG	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D07ZMG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0R3VG	TTDDRUID	D0R3VG
D0R3VG	DRUGNAME	Thiazole carboxamide derivative 3
D0R3VG	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0R3VG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Z3HW	TTDDRUID	D0Z3HW
D0Z3HW	DRUGNAME	Thiazole carboxamide derivative 30
D0Z3HW	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0Z3HW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0HA0X	TTDDRUID	D0HA0X
D0HA0X	DRUGNAME	Thiazole carboxamide derivative 31
D0HA0X	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0HA0X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0VE7T	TTDDRUID	D0VE7T
D0VE7T	DRUGNAME	Thiazole carboxamide derivative 32
D0VE7T	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0VE7T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0PO8M	TTDDRUID	D0PO8M
D0PO8M	DRUGNAME	Thiazole carboxamide derivative 33
D0PO8M	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0PO8M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0BK3M	TTDDRUID	D0BK3M
D0BK3M	DRUGNAME	Thiazole carboxamide derivative 34
D0BK3M	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0BK3M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D02WJZ	TTDDRUID	D02WJZ
D02WJZ	DRUGNAME	Thiazole carboxamide derivative 35
D02WJZ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D02WJZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D04TCL	TTDDRUID	D04TCL
D04TCL	DRUGNAME	Thiazole carboxamide derivative 36
D04TCL	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D04TCL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0O9WX	TTDDRUID	D0O9WX
D0O9WX	DRUGNAME	Thiazole carboxamide derivative 37
D0O9WX	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0O9WX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0T3FS	TTDDRUID	D0T3FS
D0T3FS	DRUGNAME	Thiazole carboxamide derivative 38
D0T3FS	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0T3FS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0II5K	TTDDRUID	D0II5K
D0II5K	DRUGNAME	Thiazole carboxamide derivative 39
D0II5K	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0II5K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0H6AF	TTDDRUID	D0H6AF
D0H6AF	DRUGNAME	Thiazole carboxamide derivative 4
D0H6AF	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0H6AF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0AA9W	TTDDRUID	D0AA9W
D0AA9W	DRUGNAME	Thiazole carboxamide derivative 40
D0AA9W	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0AA9W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0G6ED	TTDDRUID	D0G6ED
D0G6ED	DRUGNAME	Thiazole carboxamide derivative 41
D0G6ED	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0G6ED	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0EG3F	TTDDRUID	D0EG3F
D0EG3F	DRUGNAME	Thiazole carboxamide derivative 42
D0EG3F	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0EG3F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0UQ5H	TTDDRUID	D0UQ5H
D0UQ5H	DRUGNAME	Thiazole carboxamide derivative 43
D0UQ5H	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0UQ5H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0J3IJ	TTDDRUID	D0J3IJ
D0J3IJ	DRUGNAME	Thiazole carboxamide derivative 44
D0J3IJ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0J3IJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0W5FT	TTDDRUID	D0W5FT
D0W5FT	DRUGNAME	Thiazole carboxamide derivative 45
D0W5FT	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0W5FT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0U5HB	TTDDRUID	D0U5HB
D0U5HB	DRUGNAME	Thiazole carboxamide derivative 5
D0U5HB	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0U5HB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0Z5HL	TTDDRUID	D0Z5HL
D0Z5HL	DRUGNAME	Thiazole carboxamide derivative 6
D0Z5HL	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0Z5HL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D08YPQ	TTDDRUID	D08YPQ
D08YPQ	DRUGNAME	Thiazole carboxamide derivative 7
D08YPQ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D08YPQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0PD2I	TTDDRUID	D0PD2I
D0PD2I	DRUGNAME	Thiazole carboxamide derivative 8
D0PD2I	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D0PD2I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D06LCB	TTDDRUID	D06LCB
D06LCB	DRUGNAME	Thiazole carboxamide derivative 9
D06LCB	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06LCB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0YX1C	TTDDRUID	D0YX1C
D0YX1C	DRUGNAME	Thiazole derivative 1
D0YX1C	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0YX1C	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0YX1C	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0YX1C	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0YX1C	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0HH4L	TTDDRUID	D0HH4L
D0HH4L	DRUGNAME	Thiazolidine derivative 1
D0HH4L	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0HH4L	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0HH4L	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0HH4L	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0HH4L	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0J6DS	TTDDRUID	D0J6DS
D0J6DS	DRUGNAME	Thiazolidine derivative 2
D0J6DS	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0J6DS	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0J6DS	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0J6DS	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0J6DS	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0IB3Z	TTDDRUID	D0IB3Z
D0IB3Z	DRUGNAME	Thiazolidine derivative 3
D0IB3Z	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0IB3Z	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0IB3Z	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0IB3Z	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0IB3Z	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D0H4LK	TTDDRUID	D0H4LK
D0H4LK	DRUGNAME	Thiazoline derivative 1
D0H4LK	INDICATI	Albinism [ICD-11: EC23.2] Patented
D0H4LK	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D0H4LK	INDICATI	Melasma [ICD-11: ED60.1] Patented
D0H4LK	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D0H4LK	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D07UBZ	TTDDRUID	D07UBZ
D07UBZ	DRUGNAME	Thiazoline derivative 2
D07UBZ	INDICATI	Albinism [ICD-11: EC23.2] Patented
D07UBZ	INDICATI	Ephelides [ICD-11: ED61.0] Patented
D07UBZ	INDICATI	Melasma [ICD-11: ED60.1] Patented
D07UBZ	INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
D07UBZ	INDICATI	Senile lentigines [ICD-11: ED61.0] Patented

D06BSG	TTDDRUID	D06BSG
D06BSG	DRUGNAME	Thieno[3,2-c]pyridine-7-carboxamide derivative 1
D06BSG	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D06BSG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D03GFZ	TTDDRUID	D03GFZ
D03GFZ	DRUGNAME	Thieno[3,2-c]pyridine-7-carboxamide derivative 2
D03GFZ	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
D03GFZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented

D0OY0Q	TTDDRUID	D0OY0Q
D0OY0Q	DRUGNAME	Tihotungstate derivative 1
D0OY0Q	INDICATI	Aberrant vascularization [ICD-11: BE2Z] Patented
D0OY0Q	INDICATI	Copper metabolism disorder [ICD-11: 5C64.0] Patented
D0OY0Q	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Patented
D0OY0Q	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented

D0MZ7K	TTDDRUID	D0MZ7K
D0MZ7K	DRUGNAME	Triazolo[4,3-b]pyridazine derivative 2
D0MZ7K	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0MZ7K	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0MZ7K	INDICATI	Pruritus [ICD-11: EC90] Patented
D0MZ7K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0MZ7K	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D09GJQ	TTDDRUID	D09GJQ
D09GJQ	DRUGNAME	Tricyclic phytocannabinoid derivative 1
D09GJQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented

D02TOI	TTDDRUID	D02TOI
D02TOI	DRUGNAME	Tricyclic phytocannabinoid derivative 2
D02TOI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented

D0G1BQ	TTDDRUID	D0G1BQ
D0G1BQ	DRUGNAME	Trifluoromethyl piperidine derivative 1
D0G1BQ	INDICATI	Obesity [ICD-11: 5B81] Patented

D0UQ2G	TTDDRUID	D0UQ2G
D0UQ2G	DRUGNAME	Tri-substituted urea derivative 1
D0UQ2G	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0UQ2G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0UQ2G	INDICATI	Pruritus [ICD-11: EC90] Patented
D0UQ2G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0UQ2G	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D0CG8N	TTDDRUID	D0CG8N
D0CG8N	DRUGNAME	Tri-substituted urea derivative 2
D0CG8N	INDICATI	Chronic pain [ICD-11: MG30] Patented
D0CG8N	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
D0CG8N	INDICATI	Pruritus [ICD-11: EC90] Patented
D0CG8N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
D0CG8N	INDICATI	Thymic cancer [ICD-11: 2C27] Patented

D00RJA	TTDDRUID	D00RJA
D00RJA	DRUGNAME	VX-148
D00RJA	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D0IJ0B	TTDDRUID	D0IJ0B
D0IJ0B	DRUGNAME	VX-765
D0IJ0B	INDICATI	Allergic contact dermatitis [ICD-11: EK00] Patented
D0IJ0B	INDICATI	Irritant contact dermatitis [ICD-11: EK02] Patented
D0IJ0B	INDICATI	Photocontact dermatitis [ICD-11: EK20] Patented

D0ZG8X	TTDDRUID	D0ZG8X
D0ZG8X	DRUGNAME	YVAD-CHO
D0ZG8X	INDICATI	Allergic contact dermatitis [ICD-11: EK00] Patented
D0ZG8X	INDICATI	Irritant contact dermatitis [ICD-11: EK02] Patented
D0ZG8X	INDICATI	Photocontact dermatitis [ICD-11: EK20] Patented

D0K1NP	TTDDRUID	D0K1NP
D0K1NP	DRUGNAME	z-WEHD-FMK
D0K1NP	INDICATI	Allergic contact dermatitis [ICD-11: EK00] Patented
D0K1NP	INDICATI	Irritant contact dermatitis [ICD-11: EK02] Patented
D0K1NP	INDICATI	Photocontact dermatitis [ICD-11: EK20] Patented

D0J0EL	TTDDRUID	D0J0EL
D0J0EL	DRUGNAME	1,8-dihydroxy-anthraquinone
D0J0EL	INDICATI	Laxative [ICD-11: FA34.1] Withdrawn from market

D0Y8UB	TTDDRUID	D0Y8UB
D0Y8UB	DRUGNAME	Agomelatine
D0Y8UB	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market

D01VAB	TTDDRUID	D01VAB
D01VAB	DRUGNAME	Alprenolol
D01VAB	INDICATI	Hypertension [ICD-11: BA00-BA04] Withdrawn from market

D08QUV	TTDDRUID	D08QUV
D08QUV	DRUGNAME	Amineptine
D08QUV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market

D0D2RN	TTDDRUID	D0D2RN
D0D2RN	DRUGNAME	Aminopterin
D0D2RN	INDICATI	leukaemia [ICD-11: 2A60-2B33] Withdrawn from market

D0Y2HR	TTDDRUID	D0Y2HR
D0Y2HR	DRUGNAME	Astemizole
D0Y2HR	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Withdrawn from market

D0A4BR	TTDDRUID	D0A4BR
D0A4BR	DRUGNAME	Aurothioglucose
D0A4BR	INDICATI	Arthritis [ICD-11: FA20] Withdrawn from market

D01EQG	TTDDRUID	D01EQG
D01EQG	DRUGNAME	Azapropazone
D01EQG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market

D07KYU	TTDDRUID	D07KYU
D07KYU	DRUGNAME	Benactyzine
D07KYU	INDICATI	Depression [ICD-11: 6A70-6A7Z] Withdrawn from market

D07XCF	TTDDRUID	D07XCF
D07XCF	DRUGNAME	Benfluorex
D07XCF	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Withdrawn from market

D00CCI	TTDDRUID	D00CCI
D00CCI	DRUGNAME	Benoxaprofen
D00CCI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market

D0JP4H	TTDDRUID	D0JP4H
D0JP4H	DRUGNAME	Bethanidine
D0JP4H	INDICATI	Heart arrhythmia [ICD-11: BC65] Approved

D0QQ1J	TTDDRUID	D0QQ1J
D0QQ1J	DRUGNAME	BITHIONOL
D0QQ1J	INDICATI	Trematode infection [ICD-11: 1F8Y] Withdrawn from market

D00IKH	TTDDRUID	D00IKH
D00IKH	DRUGNAME	Carmofur
D00IKH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market

D00ZGA	TTDDRUID	D00ZGA
D00ZGA	DRUGNAME	Casopitant
D00ZGA	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Withdrawn from market

D0F8IO	TTDDRUID	D0F8IO
D0F8IO	DRUGNAME	Cephaloridine
D0F8IO	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Withdrawn from market

D03CGS	TTDDRUID	D03CGS
D03CGS	DRUGNAME	CHF-3098
D03CGS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Withdrawn from market

D0X0KJ	TTDDRUID	D0X0KJ
D0X0KJ	DRUGNAME	Chlorotrianisene
D0X0KJ	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D06UWD	TTDDRUID	D06UWD
D06UWD	DRUGNAME	Clobutinol
D06UWD	INDICATI	Cough [ICD-11: MD12] Withdrawn from market

D0F9SG	TTDDRUID	D0F9SG
D0F9SG	DRUGNAME	Dexfenfluramine
D0F9SG	INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market

D0R6AB	TTDDRUID	D0R6AB
D0R6AB	DRUGNAME	Droxicam
D0R6AB	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market

D0R8FM	TTDDRUID	D0R8FM
D0R8FM	DRUGNAME	Ebrotidine
D0R8FM	INDICATI	Duodenal ulcer [ICD-11: DA63] Withdrawn from market

D06PAZ	TTDDRUID	D06PAZ
D06PAZ	DRUGNAME	Encainide
D06PAZ	INDICATI	Heart arrhythmia [ICD-11: BC65] Withdrawn from market

D01MXV	TTDDRUID	D01MXV
D01MXV	DRUGNAME	Etilefrine
D01MXV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Withdrawn from market

D0P3DM	TTDDRUID	D0P3DM
D0P3DM	DRUGNAME	Fencamfamine
D0P3DM	INDICATI	Depressive fatigue [ICD-11: MG22] Withdrawn from market

D02FEA	TTDDRUID	D02FEA
D02FEA	DRUGNAME	FENDILINE
D02FEA	INDICATI	Coronary artery disease [ICD-11: BA80] Withdrawn from market

D09WNK	TTDDRUID	D09WNK
D09WNK	DRUGNAME	Fenfluramine
D09WNK	INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market

D0AK5R	TTDDRUID	D0AK5R
D0AK5R	DRUGNAME	Floctafenine
D0AK5R	INDICATI	Arthritis [ICD-11: FA20] Withdrawn from market

D0OC3J	TTDDRUID	D0OC3J
D0OC3J	DRUGNAME	Flupenthixol
D0OC3J	INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market

D0B6PZ	TTDDRUID	D0B6PZ
D0B6PZ	DRUGNAME	FORMESTANE
D0B6PZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Withdrawn from market

D07KDE	TTDDRUID	D07KDE
D07KDE	DRUGNAME	Fusafungine
D07KDE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market

D0EC5X	TTDDRUID	D0EC5X
D0EC5X	DRUGNAME	Gemeprost
D0EC5X	INDICATI	Cervical dilation [ICD-11: JB02.0] Withdrawn from market

D0C4FT	TTDDRUID	D0C4FT
D0C4FT	DRUGNAME	HEXESTROL
D0C4FT	INDICATI	Irregularities [ICD-11: N.A.] Withdrawn from market

D0U2CB	TTDDRUID	D0U2CB
D0U2CB	DRUGNAME	Ibuproxam
D0U2CB	INDICATI	Respiratory disease [ICD-11: CB40] Withdrawn from market

D0Q5PL	TTDDRUID	D0Q5PL
D0Q5PL	DRUGNAME	INDOPROFEN
D0Q5PL	INDICATI	Gout [ICD-11: FA25] Withdrawn from market

D02LHR	TTDDRUID	D02LHR
D02LHR	DRUGNAME	INDORAMIN
D02LHR	INDICATI	Hypertension [ICD-11: BA00-BA04] Withdrawn from market

D0G1GP	TTDDRUID	D0G1GP
D0G1GP	DRUGNAME	ISIS 2922
D0G1GP	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Withdrawn from market

D03JPH	TTDDRUID	D03JPH
D03JPH	DRUGNAME	Isoxicam
D03JPH	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Withdrawn from market

D0O8OB	TTDDRUID	D0O8OB
D0O8OB	DRUGNAME	Isoxsuprine
D0O8OB	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Withdrawn from market

D0M7LV	TTDDRUID	D0M7LV
D0M7LV	DRUGNAME	LYSERGIC ACID DIETHYLAMIDE
D0M7LV	INDICATI	Addictive disorder [ICD-11: 6C50-6C5Z] Withdrawn from market

D05RUM	TTDDRUID	D05RUM
D05RUM	DRUGNAME	Melperone
D05RUM	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Withdrawn from market

D06JRD	TTDDRUID	D06JRD
D06JRD	DRUGNAME	Metamizole
D06JRD	INDICATI	Fever [ICD-11: MG26] Withdrawn from market
D06JRD	INDICATI	Pain [ICD-11: MG30-MG3Z] Withdrawn from market

D0T7XI	TTDDRUID	D0T7XI
D0T7XI	DRUGNAME	Methaqualone
D0T7XI	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Withdrawn from market

D0GU4Q	TTDDRUID	D0GU4Q
D0GU4Q	DRUGNAME	Mithramycin
D0GU4Q	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
D0GU4Q	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
D0GU4Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market

D0C0JT	TTDDRUID	D0C0JT
D0C0JT	DRUGNAME	Nimesulide
D0C0JT	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Terminated
D0C0JT	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Terminated
D0C0JT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Terminated

D06BPG	TTDDRUID	D06BPG
D06BPG	DRUGNAME	Nomifensine
D06BPG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Withdrawn from market

D0O2IE	TTDDRUID	D0O2IE
D0O2IE	DRUGNAME	Phenacetin
D0O2IE	INDICATI	Analgesia [ICD-11: MB40.8] Withdrawn from market

D07XPE	TTDDRUID	D07XPE
D07XPE	DRUGNAME	Phenformin
D07XPE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Withdrawn from market

D03FDT	TTDDRUID	D03FDT
D03FDT	DRUGNAME	Phenolphthalein
D03FDT	INDICATI	Constipation [ICD-11: DD91.1] Withdrawn from market

D09JXM	TTDDRUID	D09JXM
D09JXM	DRUGNAME	Phenylpropanolamine
D09JXM	INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market

D04YCE	TTDDRUID	D04YCE
D04YCE	DRUGNAME	Pidotimod
D04YCE	INDICATI	Urinary tract infection [ICD-11: GC08] Withdrawn from market

D01PIL	TTDDRUID	D01PIL
D01PIL	DRUGNAME	Remoxipride
D01PIL	INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market

D0X7GL	TTDDRUID	D0X7GL
D0X7GL	DRUGNAME	Retigabine
D0X7GL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
D0X7GL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Withdrawn from market

D0E0ZR	TTDDRUID	D0E0ZR
D0E0ZR	DRUGNAME	Rimonabant
D0E0ZR	INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market

D0Y4FL	TTDDRUID	D0Y4FL
D0Y4FL	DRUGNAME	Roxithromycin
D0Y4FL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market

D0OS6O	TTDDRUID	D0OS6O
D0OS6O	DRUGNAME	Sertindole
D0OS6O	INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market

D0T1RG	TTDDRUID	D0T1RG
D0T1RG	DRUGNAME	Sitaxsentan
D0T1RG	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Withdrawn from market

D0F0OK	TTDDRUID	D0F0OK
D0F0OK	DRUGNAME	Sulfametopyrazine
D0F0OK	INDICATI	Urinary tract infection [ICD-11: GC08] Withdrawn from market

D02EAS	TTDDRUID	D02EAS
D02EAS	DRUGNAME	TBC 11251 (TBC)
D02EAS	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Withdrawn from market

D04SBX	TTDDRUID	D04SBX
D04SBX	DRUGNAME	Temafloxacin
D04SBX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market

D08SOF	TTDDRUID	D08SOF
D08SOF	DRUGNAME	Terfenadine
D08SOF	INDICATI	Allergy [ICD-11: 4A80-4A85] Withdrawn from market

D05TLR	TTDDRUID	D05TLR
D05TLR	DRUGNAME	Tetramune
D05TLR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market

D0T0TZ	TTDDRUID	D0T0TZ
D0T0TZ	DRUGNAME	Ticrynafen
D0T0TZ	INDICATI	Congestive heart failure [ICD-11: BD10] Withdrawn from market

D0JQ7Y	TTDDRUID	D0JQ7Y
D0JQ7Y	DRUGNAME	Ximelagatran
D0JQ7Y	INDICATI	Coagulation defect [ICD-11: 3B10.0] Withdrawn from market

D06NMB	TTDDRUID	D06NMB
D06NMB	DRUGNAME	Zimeldine
D06NMB	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market

D0C1XS	TTDDRUID	D0C1XS
D0C1XS	DRUGNAME	ZIMELIDINE
D0C1XS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Withdrawn from market

D0SU1G	TTDDRUID	D0SU1G
D0SU1G	DRUGNAME	Zomepirac
D0SU1G	INDICATI	Pain [ICD-11: MG30-MG3Z] Withdrawn from market

D0QU8H	TTDDRUID	D0QU8H
D0QU8H	DRUGNAME	(S)-amisulpride
D0QU8H	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 4

D05HDX	TTDDRUID	D05HDX
D05HDX	DRUGNAME	GW-501516
D05HDX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 4

D07EGW	TTDDRUID	D07EGW
D07EGW	DRUGNAME	AE-0047
D07EGW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration

D07MEL	TTDDRUID	D07MEL
D07MEL	DRUGNAME	Amiprilose
D07MEL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Preregistration

D06HPA	TTDDRUID	D06HPA
D06HPA	DRUGNAME	Argidene gel
D06HPA	INDICATI	Dermatological disease [ICD-11: DA24.Y] Discontinued in Preregistration

D01IRW	TTDDRUID	D01IRW
D01IRW	DRUGNAME	Bermoprofen
D01IRW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Preregistration

D03UFM	TTDDRUID	D03UFM
D03UFM	DRUGNAME	BMS-200980
D03UFM	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Preregistration

D05RQX	TTDDRUID	D05RQX
D05RQX	DRUGNAME	Cefaclidine
D05RQX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration

D0X8DU	TTDDRUID	D0X8DU
D0X8DU	DRUGNAME	Clinprost
D0X8DU	INDICATI	Asthma [ICD-11: CA23] Discontinued in Preregistration

D01HRR	TTDDRUID	D01HRR
D01HRR	DRUGNAME	Domitroban
D01HRR	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Preregistration

D0Y0ZQ	TTDDRUID	D0Y0ZQ
D0Y0ZQ	DRUGNAME	Ecabapide
D0Y0ZQ	INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Preregistration

D0K1ZD	TTDDRUID	D0K1ZD
D0K1ZD	DRUGNAME	Edobacomab
D0K1ZD	INDICATI	Endotoxic shock [ICD-11: 1G41] Discontinued in Preregistration

D0G9SD	TTDDRUID	D0G9SD
D0G9SD	DRUGNAME	EF-13
D0G9SD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration

D0R6IF	TTDDRUID	D0R6IF
D0R6IF	DRUGNAME	EF-4
D0R6IF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Preregistration

D0U2CT	TTDDRUID	D0U2CT
D0U2CT	DRUGNAME	EMITEFUR
D0U2CT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration

D0Y0GG	TTDDRUID	D0Y0GG
D0Y0GG	DRUGNAME	Epanolol
D0Y0GG	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration

D08OAS	TTDDRUID	D08OAS
D08OAS	DRUGNAME	Flavimun
D08OAS	INDICATI	Yellow fever virus infection [ICD-11: 1D47] Discontinued in Preregistration

D0F1JB	TTDDRUID	D0F1JB
D0F1JB	DRUGNAME	Globorix
D0F1JB	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Preregistration

D06TVG	TTDDRUID	D06TVG
D06TVG	DRUGNAME	Inaperisone
D06TVG	INDICATI	Pollakiuria [ICD-11: MF50.1] Discontinued in Preregistration

D0OO6A	TTDDRUID	D0OO6A
D0OO6A	DRUGNAME	Isbogrel
D0OO6A	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration

D04DAL	TTDDRUID	D04DAL
D04DAL	DRUGNAME	LAS-41001
D04DAL	INDICATI	Rosacea [ICD-11: ED90.0] Discontinued in Preregistration

D0QZ4S	TTDDRUID	D0QZ4S
D0QZ4S	DRUGNAME	LEMINOPRAZOLE
D0QZ4S	INDICATI	Ulcerative colitis [ICD-11: DD71] Discontinued in Preregistration

D08DKA	TTDDRUID	D08DKA
D08DKA	DRUGNAME	Levcromakalim
D08DKA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Preregistration

D08LDS	TTDDRUID	D08LDS
D08LDS	DRUGNAME	LUBELUZOLE
D08LDS	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Preregistration

D0P0TR	TTDDRUID	D0P0TR
D0P0TR	DRUGNAME	Meluadrine
D0P0TR	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Discontinued in Preregistration

D01LPK	TTDDRUID	D01LPK
D01LPK	DRUGNAME	MGX-006
D01LPK	INDICATI	Vomiting [ICD-11: MD90] Discontinued in Preregistration

D0TR0Z	TTDDRUID	D0TR0Z
D0TR0Z	DRUGNAME	MOGUISTEINE
D0TR0Z	INDICATI	Cough [ICD-11: MD12] Discontinued in Preregistration

D00KOV	TTDDRUID	D00KOV
D00KOV	DRUGNAME	Monatepil maleate
D00KOV	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration

D05NBD	TTDDRUID	D05NBD
D05NBD	DRUGNAME	MONTIRELIN TETRAHYDRATE
D05NBD	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Preregistration

D06LDC	TTDDRUID	D06LDC
D06LDC	DRUGNAME	Palonidipine hydrochloride
D06LDC	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration

D0E0JF	TTDDRUID	D0E0JF
D0E0JF	DRUGNAME	Pirazolac
D0E0JF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Preregistration

D06IVN	TTDDRUID	D06IVN
D06IVN	DRUGNAME	PolongaTab
D06IVN	INDICATI	Poison intoxication [ICD-11: NE6Z] Discontinued in Preregistration

D01KKB	TTDDRUID	D01KKB
D01KKB	DRUGNAME	PW-2101
D01KKB	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration

D00CIT	TTDDRUID	D00CIT
D00CIT	DRUGNAME	Regavirumab
D00CIT	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Preregistration

D0I8LS	TTDDRUID	D0I8LS
D0I8LS	DRUGNAME	Rubratin
D0I8LS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration

D0L0MO	TTDDRUID	D0L0MO
D0L0MO	DRUGNAME	Satigrel
D0L0MO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Preregistration

D0KT8U	TTDDRUID	D0KT8U
D0KT8U	DRUGNAME	Semotiadil
D0KT8U	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration

D02HKL	TTDDRUID	D02HKL
D02HKL	DRUGNAME	Suriclone
D02HKL	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Preregistration

D0FX4J	TTDDRUID	D0FX4J
D0FX4J	DRUGNAME	Telenzepine
D0FX4J	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Preregistration

D0D4DY	TTDDRUID	D0D4DY
D0D4DY	DRUGNAME	Tetracel
D0D4DY	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Discontinued in Preregistration

D03DSB	TTDDRUID	D03DSB
D03DSB	DRUGNAME	Trospectomycin
D03DSB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration

D00FCW	TTDDRUID	D00FCW
D00FCW	DRUGNAME	ViaScint
D00FCW	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Preregistration

D0NS0S	TTDDRUID	D0NS0S
D0NS0S	DRUGNAME	Vinconate
D0NS0S	INDICATI	Amnesia [ICD-11: MB21.1] Discontinued in Preregistration

D0D6ZK	TTDDRUID	D0D6ZK
D0D6ZK	DRUGNAME	15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon
D0D6ZK	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Discontinued in Phase 3

D0J6TN	TTDDRUID	D0J6TN
D0J6TN	DRUGNAME	2085-P
D0J6TN	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Discontinued in Phase 3

D0Y1MK	TTDDRUID	D0Y1MK
D0Y1MK	DRUGNAME	99mTc-nitrocade
D0Y1MK	INDICATI	Diagnostic imaging [ICD-11: N.A.] Discontinued in Phase 3

D0T9YF	TTDDRUID	D0T9YF
D0T9YF	DRUGNAME	A-74187
D0T9YF	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3

D08MTG	TTDDRUID	D08MTG
D08MTG	DRUGNAME	Abafungin
D08MTG	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 3

D0WR3D	TTDDRUID	D0WR3D
D0WR3D	DRUGNAME	Abetimus sodium
D0WR3D	INDICATI	Lupus [ICD-11: 4A40] Discontinued in Phase 3

D09DIG	TTDDRUID	D09DIG
D09DIG	DRUGNAME	Ablukast
D09DIG	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D04BQR	TTDDRUID	D04BQR
D04BQR	DRUGNAME	Acecainide
D04BQR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D0K1HO	TTDDRUID	D0K1HO
D0K1HO	DRUGNAME	Acifran
D0K1HO	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3

D01GFU	TTDDRUID	D01GFU
D01GFU	DRUGNAME	ADCON(R)
D01GFU	INDICATI	Wound healing [ICD-11: EL8Y] Discontinued in Phase 3

D0O4EV	TTDDRUID	D0O4EV
D0O4EV	DRUGNAME	ADI
D0O4EV	INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 3

D0M5VS	TTDDRUID	D0M5VS
D0M5VS	DRUGNAME	Aerugen
D0M5VS	INDICATI	Pseudomonas infection [ICD-11: 1B92] Discontinued in Phase 3

D0JB7Z	TTDDRUID	D0JB7Z
D0JB7Z	DRUGNAME	AIT-034
D0JB7Z	INDICATI	Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 3

D0B9EN	TTDDRUID	D0B9EN
D0B9EN	DRUGNAME	Aleglitazar
D0B9EN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 3

D03LQQ	TTDDRUID	D03LQQ
D03LQQ	DRUGNAME	Alinidine
D03LQQ	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3

D0XV3Z	TTDDRUID	D0XV3Z
D0XV3Z	DRUGNAME	Allervax Ragweed
D0XV3Z	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 3

D0Z0CH	TTDDRUID	D0Z0CH
D0Z0CH	DRUGNAME	Almokalant
D0Z0CH	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 3

D0Y0RW	TTDDRUID	D0Y0RW
D0Y0RW	DRUGNAME	Alniditan
D0Y0RW	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 3

D0NJ1A	TTDDRUID	D0NJ1A
D0NJ1A	DRUGNAME	Aloxistatin
D0NJ1A	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 3

D09ESW	TTDDRUID	D09ESW
D09ESW	DRUGNAME	Anipamil
D09ESW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 3

D0RT5T	TTDDRUID	D0RT5T
D0RT5T	DRUGNAME	ARANOSE
D0RT5T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D0W5RL	TTDDRUID	D0W5RL
D0W5RL	DRUGNAME	Asoprisnil
D0W5RL	INDICATI	Endometriosis [ICD-11: GA10] Discontinued in Phase 3

D00LWS	TTDDRUID	D00LWS
D00LWS	DRUGNAME	Ataprost
D00LWS	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D0N5BC	TTDDRUID	D0N5BC
D0N5BC	DRUGNAME	Autolymphocyte therapy
D0N5BC	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 3

D0O1KX	TTDDRUID	D0O1KX
D0O1KX	DRUGNAME	Avasimibe
D0O1KX	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3

D01BPF	TTDDRUID	D01BPF
D01BPF	DRUGNAME	Avitriptan
D01BPF	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 3

D01OKS	TTDDRUID	D01OKS
D01OKS	DRUGNAME	Axokine
D01OKS	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3

D06FBB	TTDDRUID	D06FBB
D06FBB	DRUGNAME	Azithromycin/chloroquine
D06FBB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D0P8YC	TTDDRUID	D0P8YC
D0P8YC	DRUGNAME	Batimastat
D0P8YC	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Discontinued in Phase 3

D09LPI	TTDDRUID	D09LPI
D09LPI	DRUGNAME	BCG65-E7
D09LPI	INDICATI	Anal intraepithelial neoplasia [ICD-11: 2E92.5] Discontinued in Phase 3
D09LPI	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 3

D0N1FR	TTDDRUID	D0N1FR
D0N1FR	DRUGNAME	BECATECARIN
D0N1FR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D05WEP	TTDDRUID	D05WEP
D05WEP	DRUGNAME	Befloxatone
D05WEP	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3

D0E3SA	TTDDRUID	D0E3SA
D0E3SA	DRUGNAME	Betafectin
D0E3SA	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 3

D0YG4I	TTDDRUID	D0YG4I
D0YG4I	DRUGNAME	Bevasiranib
D0YG4I	INDICATI	Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Discontinued in Phase 3

D04DZD	TTDDRUID	D04DZD
D04DZD	DRUGNAME	Bidisomide
D04DZD	INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 3

D01DAW	TTDDRUID	D01DAW
D01DAW	DRUGNAME	Bifeprunox
D01DAW	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 3

D05KFA	TTDDRUID	D05KFA
D05KFA	DRUGNAME	BL-1832
D05KFA	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3

D01EUF	TTDDRUID	D01EUF
D01EUF	DRUGNAME	BMS 275291
D01EUF	INDICATI	Kaposi sarcoma [ICD-11: 2B57] Discontinued in Phase 3
D01EUF	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3
D01EUF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3

D01YOC	TTDDRUID	D01YOC
D01YOC	DRUGNAME	BMS-181100
D01YOC	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 3

D0S6QR	TTDDRUID	D0S6QR
D0S6QR	DRUGNAME	BMS-204352
D0S6QR	INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 3

D0G2RE	TTDDRUID	D0G2RE
D0G2RE	DRUGNAME	BN 50730
D0G2RE	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D07RPR	TTDDRUID	D07RPR
D07RPR	DRUGNAME	Bropirimine
D07RPR	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 3

D0OR2S	TTDDRUID	D0OR2S
D0OR2S	DRUGNAME	Broxaterol
D0OR2S	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D0N1KC	TTDDRUID	D0N1KC
D0N1KC	DRUGNAME	B-type natriuretic peptide
D0N1KC	INDICATI	Heart disease [ICD-11: BA41-BA42] Discontinued in Phase 3

D0B1WU	TTDDRUID	D0B1WU
D0B1WU	DRUGNAME	C-101
D0B1WU	INDICATI	Muscular dystrophy [ICD-11: 8C70] Discontinued in Phase 3

D0S2GT	TTDDRUID	D0S2GT
D0S2GT	DRUGNAME	CDP571
D0S2GT	INDICATI	Crohn disease [ICD-11: DD70] Discontinued in Phase 3

D04KHH	TTDDRUID	D04KHH
D04KHH	DRUGNAME	CEFCANEL DALOXATE HYDROCHLORIDE
D04KHH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D0K1QO	TTDDRUID	D0K1QO
D0K1QO	DRUGNAME	CEFETECOL
D0K1QO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D00USX	TTDDRUID	D00USX
D00USX	DRUGNAME	CEFMATILEN HYDROCHLORIDE HYDRATE
D00USX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D0C8RH	TTDDRUID	D0C8RH
D0C8RH	DRUGNAME	Cericlamine
D0C8RH	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D0W7UO	TTDDRUID	D0W7UO
D0W7UO	DRUGNAME	CGP71683A
D0W7UO	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3

D09KIP	TTDDRUID	D09KIP
D09KIP	DRUGNAME	Chondrogel
D09KIP	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D02EMR	TTDDRUID	D02EMR
D02EMR	DRUGNAME	Cilomilast
D02EMR	INDICATI	Bronchitis [ICD-11: CA20] Discontinued in Phase 3
D02EMR	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
D02EMR	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 3
D02EMR	INDICATI	Emphysema [ICD-11: CA21] Discontinued in Phase 3

D0R1TF	TTDDRUID	D0R1TF
D0R1TF	DRUGNAME	CNTF
D0R1TF	INDICATI	Motor neurone disease [ICD-11: 8B60] Discontinued in Phase 3

D0J0AE	TTDDRUID	D0J0AE
D0J0AE	DRUGNAME	CP-945598
D0J0AE	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3

D0V3RZ	TTDDRUID	D0V3RZ
D0V3RZ	DRUGNAME	Crisnatol
D0V3RZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D06USG	TTDDRUID	D06USG
D06USG	DRUGNAME	CS-560
D06USG	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 3

D09GGJ	TTDDRUID	D09GGJ
D09GGJ	DRUGNAME	CVT-124
D09GGJ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3

D0I0VY	TTDDRUID	D0I0VY
D0I0VY	DRUGNAME	DA-7101
D0I0VY	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Discontinued in Phase 3

D0Y9XD	TTDDRUID	D0Y9XD
D0Y9XD	DRUGNAME	Dalvastatin
D0Y9XD	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 3

D0L5UO	TTDDRUID	D0L5UO
D0L5UO	DRUGNAME	Darapladib
D0L5UO	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3

D07OGZ	TTDDRUID	D07OGZ
D07OGZ	DRUGNAME	Darexaban maleate
D07OGZ	INDICATI	Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 3

D0QH3H	TTDDRUID	D0QH3H
D0QH3H	DRUGNAME	DCVax-Prostate
D0QH3H	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 3
D0QH3H	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0L7SY	TTDDRUID	D0L7SY
D0L7SY	DRUGNAME	Delequamine hydrochloride
D0L7SY	INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 3

D09EDW	TTDDRUID	D09EDW
D09EDW	DRUGNAME	Deligoparin sodium
D09EDW	INDICATI	Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3

D0E6UA	TTDDRUID	D0E6UA
D0E6UA	DRUGNAME	Deramciclane
D0E6UA	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D0TL7L	TTDDRUID	D0TL7L
D0TL7L	DRUGNAME	Dexloxiglumide
D0TL7L	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Phase 2

D0I5OM	TTDDRUID	D0I5OM
D0I5OM	DRUGNAME	Dextrin-2-sulphate (D2S) intravaginal gel
D0I5OM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3

D0S6VB	TTDDRUID	D0S6VB
D0S6VB	DRUGNAME	DG031
D0S6VB	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D00LVA	TTDDRUID	D00LVA
D00LVA	DRUGNAME	Dianicline
D00LVA	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Discontinued in Phase 3

D04KKE	TTDDRUID	D04KKE
D04KKE	DRUGNAME	Diaziquone
D04KKE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D0BQ5X	TTDDRUID	D0BQ5X
D0BQ5X	DRUGNAME	Diphtheria, tetanus, pertussis, HBV, Haemophilus influenzae vaccine
D0BQ5X	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 3

D0H0EM	TTDDRUID	D0H0EM
D0H0EM	DRUGNAME	Dofequidar fumarate
D0H0EM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D0B4GZ	TTDDRUID	D0B4GZ
D0B4GZ	DRUGNAME	E6014
D0B4GZ	INDICATI	Oral mucositis [ICD-11: DA01.11] Discontinued in Phase 3

D0CZ0D	TTDDRUID	D0CZ0D
D0CZ0D	DRUGNAME	EF-12
D0CZ0D	INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 3

D0HQ3A	TTDDRUID	D0HQ3A
D0HQ3A	DRUGNAME	ELGODIPINE HYDROCHLORIDE
D0HQ3A	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3

D0B8YZ	TTDDRUID	D0B8YZ
D0B8YZ	DRUGNAME	ELTANOLONE
D0B8YZ	INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Discontinued in Phase 3

D0MU0S	TTDDRUID	D0MU0S
D0MU0S	DRUGNAME	EM-800
D0MU0S	INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Discontinued in Phase 3

D0YE2N	TTDDRUID	D0YE2N
D0YE2N	DRUGNAME	Eperezolid
D0YE2N	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D0CV7Z	TTDDRUID	D0CV7Z
D0CV7Z	DRUGNAME	Epothilone B
D0CV7Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D02WGY	TTDDRUID	D02WGY
D02WGY	DRUGNAME	Eprotirome
D02WGY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D0FQ6O	TTDDRUID	D0FQ6O
D0FQ6O	DRUGNAME	Etarotene
D0FQ6O	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3

D06SEY	TTDDRUID	D06SEY
D06SEY	DRUGNAME	Etilevodopa
D06SEY	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 3

D0LA5G	TTDDRUID	D0LA5G
D0LA5G	DRUGNAME	Evernimicin
D0LA5G	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D0I8TF	TTDDRUID	D0I8TF
D0I8TF	DRUGNAME	EXO-226
D0I8TF	INDICATI	Diabetic kidney disease [ICD-11: GB61.Z] Discontinued in Phase 3

D08OJE	TTDDRUID	D08OJE
D08OJE	DRUGNAME	Femoxetine
D08OJE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3

D0AF7N	TTDDRUID	D0AF7N
D0AF7N	DRUGNAME	Fibrimage
D0AF7N	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3

D0LF1U	TTDDRUID	D0LF1U
D0LF1U	DRUGNAME	Flavopiridol
D0LF1U	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D0LF1U	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 3

D02VZP	TTDDRUID	D02VZP
D02VZP	DRUGNAME	Flesinoxan
D02VZP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D02VCK	TTDDRUID	D02VCK
D02VCK	DRUGNAME	FLUPAROXAN
D02VCK	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3

D05YUK	TTDDRUID	D05YUK
D05YUK	DRUGNAME	FOROPAFANT
D05YUK	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D0Z5SR	TTDDRUID	D0Z5SR
D0Z5SR	DRUGNAME	Fosfructose
D0Z5SR	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D0K8MQ	TTDDRUID	D0K8MQ
D0K8MQ	DRUGNAME	FP-1096
D0K8MQ	INDICATI	Endometriosis [ICD-11: GA10] Discontinued in Phase 3

D0X9VP	TTDDRUID	D0X9VP
D0X9VP	DRUGNAME	Furnidipine
D0X9VP	INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 3

D0Y4AZ	TTDDRUID	D0Y4AZ
D0Y4AZ	DRUGNAME	GALOCITABINE
D0Y4AZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D00RSK	TTDDRUID	D00RSK
D00RSK	DRUGNAME	GW-406381
D00RSK	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 3
D00RSK	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3

D0G6SZ	TTDDRUID	D0G6SZ
D0G6SZ	DRUGNAME	GW873140
D0G6SZ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 3

D06IQE	TTDDRUID	D06IQE
D06IQE	DRUGNAME	H1N1 influenza vaccine
D06IQE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 3

D03IKZ	TTDDRUID	D03IKZ
D03IKZ	DRUGNAME	HBP-347
D03IKZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3

D0G6EO	TTDDRUID	D0G6EO
D0G6EO	DRUGNAME	Hemoximer
D0G6EO	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 3

D0L4UN	TTDDRUID	D0L4UN
D0L4UN	DRUGNAME	HIV-IG
D0L4UN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3

D02YWW	TTDDRUID	D02YWW
D02YWW	DRUGNAME	IDM-1
D02YWW	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3

D0GR2J	TTDDRUID	D0GR2J
D0GR2J	DRUGNAME	Idoxifene
D0GR2J	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 3

D0CY3A	TTDDRUID	D0CY3A
D0CY3A	DRUGNAME	Idraparinux
D0CY3A	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3

D0B1GX	TTDDRUID	D0B1GX
D0B1GX	DRUGNAME	Iferanserin-Ventrus
D0B1GX	INDICATI	Hemorrhoids [ICD-11: DB60] Discontinued in Phase 3

D0Q7AW	TTDDRUID	D0Q7AW
D0Q7AW	DRUGNAME	IMIRESTAT
D0Q7AW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 3

D02SDC	TTDDRUID	D02SDC
D02SDC	DRUGNAME	Inactine
D02SDC	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 3

D0Z7FU	TTDDRUID	D0Z7FU
D0Z7FU	DRUGNAME	INS 316
D0Z7FU	INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3

D01OML	TTDDRUID	D01OML
D01OML	DRUGNAME	IoGen
D01OML	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3

D00BVF	TTDDRUID	D00BVF
D00BVF	DRUGNAME	IP-889
D00BVF	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3

D03GAI	TTDDRUID	D03GAI
D03GAI	DRUGNAME	IR-103
D03GAI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3

D0T0LE	TTDDRUID	D0T0LE
D0T0LE	DRUGNAME	IRX-4310
D0T0LE	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3

D0S6GJ	TTDDRUID	D0S6GJ
D0S6GJ	DRUGNAME	KC-764
D0S6GJ	INDICATI	Platelet aggregation disorder [ICD-11: 3B62] Discontinued in Phase 3

D07UQR	TTDDRUID	D07UQR
D07UQR	DRUGNAME	Keyhole limpet hemocyanin
D07UQR	INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 3

D02XHD	TTDDRUID	D02XHD
D02XHD	DRUGNAME	KI-0805
D02XHD	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3

D0A2IH	TTDDRUID	D0A2IH
D0A2IH	DRUGNAME	KU-1257
D0A2IH	INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3

D0L5BK	TTDDRUID	D0L5BK
D0L5BK	DRUGNAME	KW-2149
D0L5BK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D00XPA	TTDDRUID	D00XPA
D00XPA	DRUGNAME	L-759274
D00XPA	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3
D00XPA	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 3

D0Q6SD	TTDDRUID	D0Q6SD
D0Q6SD	DRUGNAME	Lamectacin
D0Q6SD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D01QQM	TTDDRUID	D01QQM
D01QQM	DRUGNAME	LAMIFIBAN
D01QQM	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3

D02FXU	TTDDRUID	D02FXU
D02FXU	DRUGNAME	Lapaquistat acetate
D02FXU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 3

D03GYK	TTDDRUID	D03GYK
D03GYK	DRUGNAME	Laropiprant+niacin
D03GYK	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 3

D0J0RV	TTDDRUID	D0J0RV
D0J0RV	DRUGNAME	Larotaxel
D0J0RV	INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 3
D0J0RV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 3

D06QRW	TTDDRUID	D06QRW
D06QRW	DRUGNAME	Lazabemide
D06QRW	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3
D06QRW	INDICATI	Skin imperfections [ICD-11: EK71] Patented

D0K0GN	TTDDRUID	D0K0GN
D0K0GN	DRUGNAME	LDI-200
D0K0GN	INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 3

D0H6CA	TTDDRUID	D0H6CA
D0H6CA	DRUGNAME	Lenercept
D0H6CA	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3

D08NLQ	TTDDRUID	D08NLQ
D08NLQ	DRUGNAME	Licarbazepine
D08NLQ	INDICATI	Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 3

D07FGV	TTDDRUID	D07FGV
D07FGV	DRUGNAME	LLL-2011
D07FGV	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 3

D0V4RH	TTDDRUID	D0V4RH
D0V4RH	DRUGNAME	Lobucavir
D0V4RH	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 3

D09SIR	TTDDRUID	D09SIR
D09SIR	DRUGNAME	Lonidamine
D09SIR	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Discontinued in Phase 3

D0C1QB	TTDDRUID	D0C1QB
D0C1QB	DRUGNAME	LOSIGAMONE
D0C1QB	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 3

D0SV7D	TTDDRUID	D0SV7D
D0SV7D	DRUGNAME	LOTRAFIBAN
D0SV7D	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D06DCL	TTDDRUID	D06DCL
D06DCL	DRUGNAME	LY335979
D06DCL	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3

D0P4BQ	TTDDRUID	D0P4BQ
D0P4BQ	DRUGNAME	LY-544344
D0P4BQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D05YIX	TTDDRUID	D05YIX
D05YIX	DRUGNAME	LymphoScan
D05YIX	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 3

D0RJ0J	TTDDRUID	D0RJ0J
D0RJ0J	DRUGNAME	M-5010
D0RJ0J	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 3

D0BT2P	TTDDRUID	D0BT2P
D0BT2P	DRUGNAME	MBP(82-98)
D0BT2P	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 3

D05MFO	TTDDRUID	D05MFO
D05MFO	DRUGNAME	MDL-11939
D05MFO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D00LBD	TTDDRUID	D00LBD
D00LBD	DRUGNAME	Metazosin
D00LBD	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D0ZI7Q	TTDDRUID	D0ZI7Q
D0ZI7Q	DRUGNAME	Miboplatin
D0ZI7Q	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3

D0HK7R	TTDDRUID	D0HK7R
D0HK7R	DRUGNAME	Midafotel
D0HK7R	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3

D0UX0T	TTDDRUID	D0UX0T
D0UX0T	DRUGNAME	Milameline
D0UX0T	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3

D0J6JZ	TTDDRUID	D0J6JZ
D0J6JZ	DRUGNAME	MINALRESTAT
D0J6JZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 3

D02VFB	TTDDRUID	D02VFB
D02VFB	DRUGNAME	Miproxifene
D02VFB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D0V1RX	TTDDRUID	D0V1RX
D0V1RX	DRUGNAME	Mivazerol
D0V1RX	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3

D01LAC	TTDDRUID	D01LAC
D01LAC	DRUGNAME	MOFEGILINE
D01LAC	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3

D00DQX	TTDDRUID	D00DQX
D00DQX	DRUGNAME	Motesanib
D00DQX	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3

D0R9ON	TTDDRUID	D0R9ON
D0R9ON	DRUGNAME	MR-889
D0R9ON	INDICATI	Phlegmy cough [ICD-11: SA80-SA8Z] Discontinued in Phase 3

D0Y0UK	TTDDRUID	D0Y0UK
D0Y0UK	DRUGNAME	MX-6
D0Y0UK	INDICATI	Cervical cancer [ICD-11: 2C77.0] Discontinued in Phase 3

D07VZV	TTDDRUID	D07VZV
D07VZV	DRUGNAME	N-0861
D07VZV	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D0X0OT	TTDDRUID	D0X0OT
D0X0OT	DRUGNAME	Needle-free ETEC vaccine
D0X0OT	INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3

D0T4BL	TTDDRUID	D0T4BL
D0T4BL	DRUGNAME	Neovastat
D0T4BL	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0T4BL	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D0VW2Z	TTDDRUID	D0VW2Z
D0VW2Z	DRUGNAME	Nerelimomab
D0VW2Z	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 3

D0G9LP	TTDDRUID	D0G9LP
D0G9LP	DRUGNAME	Neutralase
D0G9LP	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Discontinued in Phase 3

D02ALD	TTDDRUID	D02ALD
D02ALD	DRUGNAME	NOLOMIROLE HYDROCHLORIDE
D02ALD	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 3

D0J6GO	TTDDRUID	D0J6GO
D0J6GO	DRUGNAME	NRP409
D0J6GO	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 3

D0PE0D	TTDDRUID	D0PE0D
D0PE0D	DRUGNAME	Nuleusin
D0PE0D	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 3

D08YYY	TTDDRUID	D08YYY
D08YYY	DRUGNAME	Ocinaplon
D08YYY	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Discontinued in Phase 3

D0Q0SZ	TTDDRUID	D0Q0SZ
D0Q0SZ	DRUGNAME	OLAMUFLOXACIN MESILATE
D0Q0SZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D08JCL	TTDDRUID	D08JCL
D08JCL	DRUGNAME	ONO-3805
D08JCL	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 3

D00VAJ	TTDDRUID	D00VAJ
D00VAJ	DRUGNAME	ORBOFIBAN
D00VAJ	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
D00VAJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D00KEF	TTDDRUID	D00KEF
D00KEF	DRUGNAME	Org-2766
D00KEF	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3

D09YTY	TTDDRUID	D09YTY
D09YTY	DRUGNAME	Osutidine
D09YTY	INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3

D0E2MJ	TTDDRUID	D0E2MJ
D0E2MJ	DRUGNAME	Otamixaban
D0E2MJ	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3

D0B9GM	TTDDRUID	D0B9GM
D0B9GM	DRUGNAME	Oxibendazole
D0B9GM	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D0L8ZX	TTDDRUID	D0L8ZX
D0L8ZX	DRUGNAME	OX-NLA
D0L8ZX	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 3

D03HVN	TTDDRUID	D03HVN
D03HVN	DRUGNAME	P-1
D03HVN	INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 3

D0G6ZW	TTDDRUID	D0G6ZW
D0G6ZW	DRUGNAME	Panimun Bioral
D0G6ZW	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 3

D0ZE9C	TTDDRUID	D0ZE9C
D0ZE9C	DRUGNAME	PAZINACLONE
D0ZE9C	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D0P6MB	TTDDRUID	D0P6MB
D0P6MB	DRUGNAME	Pexelizumab
D0P6MB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D07ESH	TTDDRUID	D07ESH
D07ESH	DRUGNAME	PF-1913539
D07ESH	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3

D01YDF	TTDDRUID	D01YDF
D01YDF	DRUGNAME	Pibutidine
D01YDF	INDICATI	Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3

D0G2SZ	TTDDRUID	D0G2SZ
D0G2SZ	DRUGNAME	Piliel
D0G2SZ	INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 3

D08FOX	TTDDRUID	D08FOX
D08FOX	DRUGNAME	Piroximone
D08FOX	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Discontinued in Phase 3

D0I9LH	TTDDRUID	D0I9LH
D0I9LH	DRUGNAME	PMI-001
D0I9LH	INDICATI	Lupus [ICD-11: 4A40] Discontinued in Phase 3

D0U9TM	TTDDRUID	D0U9TM
D0U9TM	DRUGNAME	Ponalrestat
D0U9TM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
D0U9TM	INDICATI	Gout [ICD-11: FA25] Discontinued in Phase 3

D0J8RM	TTDDRUID	D0J8RM
D0J8RM	DRUGNAME	Posatirelin
D0J8RM	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Discontinued in Phase 3

D0V7HI	TTDDRUID	D0V7HI
D0V7HI	DRUGNAME	PRINOMIDE TROMETHAMINE
D0V7HI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 3

D08LIF	TTDDRUID	D08LIF
D08LIF	DRUGNAME	Propiram fumarate
D08LIF	INDICATI	Cancer related pain [ICD-11: MG30] Discontinued in Phase 3

D0M8HH	TTDDRUID	D0M8HH
D0M8HH	DRUGNAME	PUMAPRAZOLE
D0M8HH	INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3

D0Z2WQ	TTDDRUID	D0Z2WQ
D0Z2WQ	DRUGNAME	Quinelorane
D0Z2WQ	INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 3

D0VE6X	TTDDRUID	D0VE6X
D0VE6X	DRUGNAME	R1549 (formerly pemtumomab)
D0VE6X	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3

D0N5AY	TTDDRUID	D0N5AY
D0N5AY	DRUGNAME	Ranagengliotucel-T
D0N5AY	INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 3

D03MCV	TTDDRUID	D03MCV
D03MCV	DRUGNAME	RB-006
D03MCV	INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 3
D03MCV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3
D03MCV	INDICATI	Vascular disease [ICD-11: BE2Z] Discontinued in Phase 3

D0D5ZX	TTDDRUID	D0D5ZX
D0D5ZX	DRUGNAME	RG-12915
D0D5ZX	INDICATI	Nausea [ICD-11: MD90] Discontinued in Phase 3

D00OEG	TTDDRUID	D00OEG
D00OEG	DRUGNAME	RhTPO
D00OEG	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Discontinued in Phase 3

D01OSN	TTDDRUID	D01OSN
D01OSN	DRUGNAME	Riferminogene pecaplasmid
D01OSN	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Discontinued in Phase 3

D0K8NW	TTDDRUID	D0K8NW
D0K8NW	DRUGNAME	Ritanserin
D0K8NW	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D0B3LP	TTDDRUID	D0B3LP
D0B3LP	DRUGNAME	Ro-16-6028
D0B3LP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D0AK5G	TTDDRUID	D0AK5G
D0AK5G	DRUGNAME	RPAF-AH
D0AK5G	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 3

D0G2XN	TTDDRUID	D0G2XN
D0G2XN	DRUGNAME	S-12968
D0G2XN	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 3

D00NGN	TTDDRUID	D00NGN
D00NGN	DRUGNAME	Sabeluzole
D00NGN	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 3

D0S4LL	TTDDRUID	D0S4LL
D0S4LL	DRUGNAME	Sanfetrinem
D0S4LL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D05WJQ	TTDDRUID	D05WJQ
D05WJQ	DRUGNAME	Saredutant
D05WJQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
D05WJQ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3

D03SKF	TTDDRUID	D03SKF
D03SKF	DRUGNAME	SC-124a
D03SKF	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 3

D0D3PX	TTDDRUID	D0D3PX
D0D3PX	DRUGNAME	SCH 727965
D0D3PX	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Discontinued in Phase 3

D07AWM	TTDDRUID	D07AWM
D07AWM	DRUGNAME	Segard
D07AWM	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 3

D0L9AJ	TTDDRUID	D0L9AJ
D0L9AJ	DRUGNAME	Seletracetam
D0L9AJ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 3

D0H1FV	TTDDRUID	D0H1FV
D0H1FV	DRUGNAME	Selfotel
D0H1FV	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 3

D0N7WR	TTDDRUID	D0N7WR
D0N7WR	DRUGNAME	Sepimostat mesylate
D0N7WR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D04SPK	TTDDRUID	D04SPK
D04SPK	DRUGNAME	Seratrodast
D04SPK	INDICATI	Allergic asthma [ICD-11: CA23.0] Discontinued in Phase 3

D0C5PA	TTDDRUID	D0C5PA
D0C5PA	DRUGNAME	Sibenadet
D0C5PA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 3

D0N0BI	TTDDRUID	D0N0BI
D0N0BI	DRUGNAME	SIBRAFIBAN
D0N0BI	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
D0N0BI	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D06NHK	TTDDRUID	D06NHK
D06NHK	DRUGNAME	Sitagliptin + atorvastatin
D06NHK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D0W8RX	TTDDRUID	D0W8RX
D0W8RX	DRUGNAME	Sitimagene ceradenovec
D0W8RX	INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 3

D08JAT	TTDDRUID	D08JAT
D08JAT	DRUGNAME	Skeletal targeted radiotherapy
D08JAT	INDICATI	Bone metastases [ICD-11: 2D50] Discontinued in Phase 3

D02THB	TTDDRUID	D02THB
D02THB	DRUGNAME	SKF-96067
D02THB	INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 3

D0DQ7T	TTDDRUID	D0DQ7T
D0DQ7T	DRUGNAME	Sporidin-G
D0DQ7T	INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3

D05VYJ	TTDDRUID	D05VYJ
D05VYJ	DRUGNAME	SUN-09
D05VYJ	INDICATI	Hypertonia [ICD-11: KB08.1] Discontinued in Phase 3

D0B7MU	TTDDRUID	D0B7MU
D0B7MU	DRUGNAME	SYNSORB-Cd
D0B7MU	INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3

D01TVR	TTDDRUID	D01TVR
D01TVR	DRUGNAME	Tagatose
D01TVR	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3

D0QE5B	TTDDRUID	D0QE5B
D0QE5B	DRUGNAME	Tagorizine
D0QE5B	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 3

D0Q1CD	TTDDRUID	D0Q1CD
D0Q1CD	DRUGNAME	Tanomastat
D0Q1CD	INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3
D0Q1CD	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3
D0Q1CD	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3
D0Q1CD	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 3

D06YXD	TTDDRUID	D06YXD
D06YXD	DRUGNAME	Taprostene
D06YXD	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3

D06TGE	TTDDRUID	D06TGE
D06TGE	DRUGNAME	Taranabant
D06TGE	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3

D00YSJ	TTDDRUID	D00YSJ
D00YSJ	DRUGNAME	Tecadenoson
D00YSJ	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 3
D00YSJ	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 3

D0Z5VQ	TTDDRUID	D0Z5VQ
D0Z5VQ	DRUGNAME	Terutroban sodium
D0Z5VQ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3

D0Y4EM	TTDDRUID	D0Y4EM
D0Y4EM	DRUGNAME	Thrombomodulin
D0Y4EM	INDICATI	Disseminated intravascular coagulation [ICD-11: 3B20] Discontinued in Phase 3

D0W7IL	TTDDRUID	D0W7IL
D0W7IL	DRUGNAME	Thrombopoietin
D0W7IL	INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 3

D0P8EU	TTDDRUID	D0P8EU
D0P8EU	DRUGNAME	Thymocartin
D0P8EU	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Discontinued in Phase 3

D0PS2W	TTDDRUID	D0PS2W
D0PS2W	DRUGNAME	TILNOPROFEN ARBAMEL
D0PS2W	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 3

D0M9ZT	TTDDRUID	D0M9ZT
D0M9ZT	DRUGNAME	TJ-960
D0M9ZT	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 3

D0O9JI	TTDDRUID	D0O9JI
D0O9JI	DRUGNAME	Transferrin CRM-107
D0O9JI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3

D0K0ZB	TTDDRUID	D0K0ZB
D0K0ZB	DRUGNAME	Tresperimus
D0K0ZB	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3

D03VTN	TTDDRUID	D03VTN
D03VTN	DRUGNAME	TRIMOPROSTIL
D03VTN	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 3

D0W6YS	TTDDRUID	D0W6YS
D0W6YS	DRUGNAME	Vaccine, Lyme disease
D0W6YS	INDICATI	Lyme disease [ICD-11: 1C1G] Discontinued in Phase 3

D09TGX	TTDDRUID	D09TGX
D09TGX	DRUGNAME	Valspodar
D09TGX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3

D0L8QQ	TTDDRUID	D0L8QQ
D0L8QQ	DRUGNAME	VELNACRINE
D0L8QQ	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3

D01MSJ	TTDDRUID	D01MSJ
D01MSJ	DRUGNAME	Veronate
D01MSJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3

D06VJK	TTDDRUID	D06VJK
D06VJK	DRUGNAME	Verpasep caltespen
D06VJK	INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Discontinued in Phase 3

D0U0AM	TTDDRUID	D0U0AM
D0U0AM	DRUGNAME	VGV-1
D0U0AM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3

D07EXV	TTDDRUID	D07EXV
D07EXV	DRUGNAME	XEMILOFIBAN
D07EXV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
D07EXV	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3

D0C9JL	TTDDRUID	D0C9JL
D0C9JL	DRUGNAME	Y-23684
D0C9JL	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3

D00QFY	TTDDRUID	D00QFY
D00QFY	DRUGNAME	YM533
D00QFY	INDICATI	Chronic renal failure [ICD-11: GB61.Z] Discontinued in Phase 3

D04SBH	TTDDRUID	D04SBH
D04SBH	DRUGNAME	Zamifenacin
D04SBH	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 3

D0AM8W	TTDDRUID	D0AM8W
D0AM8W	DRUGNAME	Zanapezil
D0AM8W	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3

D02HVW	TTDDRUID	D02HVW
D02HVW	DRUGNAME	Zibotentan
D02HVW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3

D0J3YX	TTDDRUID	D0J3YX
D0J3YX	DRUGNAME	BAY 86-6150
D0J3YX	INDICATI	Hemophilia [ICD-11: 3B10.0] Discontinued in Phase 2/3

D0YW4R	TTDDRUID	D0YW4R
D0YW4R	DRUGNAME	IDM-2
D0YW4R	INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 2/3

D0K6SM	TTDDRUID	D0K6SM
D0K6SM	DRUGNAME	Ilepatril
D0K6SM	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2/3
D0K6SM	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2/3
D0K6SM	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2/3
D0K6SM	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2/3

D0IP6X	TTDDRUID	D0IP6X
D0IP6X	DRUGNAME	Osanetant
D0IP6X	INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated
D0IP6X	INDICATI	Schizoaffective disorder [ICD-11: 6A21] Discontinued in Phase 2b
D0IP6X	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2b

D0L9YS	TTDDRUID	D0L9YS
D0L9YS	DRUGNAME	Octopamine
D0L9YS	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2a

D04VIP	TTDDRUID	D04VIP
D04VIP	DRUGNAME	4030W92
D04VIP	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D01EBJ	TTDDRUID	D01EBJ
D01EBJ	DRUGNAME	4991W93
D01EBJ	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D0V9OL	TTDDRUID	D0V9OL
D0V9OL	DRUGNAME	534U87
D0V9OL	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2

D03FVI	TTDDRUID	D03FVI
D03FVI	DRUGNAME	97-139
D03FVI	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Discontinued in Phase 2

D0D2SG	TTDDRUID	D0D2SG
D0D2SG	DRUGNAME	99mTc-ciprofloxacin, DRAXIS
D0D2SG	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 2

D0X2KY	TTDDRUID	D0X2KY
D0X2KY	DRUGNAME	99mTc-Hynic-Annexin V
D0X2KY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0XQ6J	TTDDRUID	D0XQ6J
D0XQ6J	DRUGNAME	99mTC-NC-100668
D0XQ6J	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0WU3G	TTDDRUID	D0WU3G
D0WU3G	DRUGNAME	99mTc-RP-527
D0WU3G	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0FH3X	TTDDRUID	D0FH3X
D0FH3X	DRUGNAME	A-437203
D0FH3X	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2

D04RZZ	TTDDRUID	D04RZZ
D04RZZ	DRUGNAME	A-5021
D04RZZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D07MPJ	TTDDRUID	D07MPJ
D07MPJ	DRUGNAME	A-75925
D07MPJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D0W8VY	TTDDRUID	D0W8VY
D0W8VY	DRUGNAME	A-86719.1
D0W8VY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D05RZI	TTDDRUID	D05RZI
D05RZI	DRUGNAME	AA-193
D05RZI	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2

D0B2OL	TTDDRUID	D0B2OL
D0B2OL	DRUGNAME	AA-2379
D0B2OL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2

D0D8UH	TTDDRUID	D0D8UH
D0D8UH	DRUGNAME	ABIO-08-01
D0D8UH	INDICATI	Amnesia [ICD-11: MB21.1] Discontinued in Phase 2

D0L1DP	TTDDRUID	D0L1DP
D0L1DP	DRUGNAME	ABT-089
D0L1DP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
D0L1DP	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2
D0L1DP	INDICATI	Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 2
D0L1DP	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D09ADT	TTDDRUID	D09ADT
D09ADT	DRUGNAME	ABT-418
D09ADT	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D03TNA	TTDDRUID	D03TNA
D03TNA	DRUGNAME	ABT-724
D03TNA	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2

D08CPT	TTDDRUID	D08CPT
D08CPT	DRUGNAME	AC 137-164594
D08CPT	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D04VJH	TTDDRUID	D04VJH
D04VJH	DRUGNAME	ACREOZAST
D04VJH	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0O2ET	TTDDRUID	D0O2ET
D0O2ET	DRUGNAME	AD-5467
D0O2ET	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0PU5L	TTDDRUID	D0PU5L
D0PU5L	DRUGNAME	Adaprolol maleate-SME
D0PU5L	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2

D0X2TO	TTDDRUID	D0X2TO
D0X2TO	DRUGNAME	Adatanserin
D0X2TO	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D00KUD	TTDDRUID	D00KUD
D00KUD	DRUGNAME	ADL 10-0101
D00KUD	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D09MTC	TTDDRUID	D09MTC
D09MTC	DRUGNAME	ADL-5945
D09MTC	INDICATI	Constipation [ICD-11: DD91.1] Discontinued in Phase 2

D0X5UH	TTDDRUID	D0X5UH
D0X5UH	DRUGNAME	ADOZELESIN
D0X5UH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0N5JJ	TTDDRUID	D0N5JJ
D0N5JJ	DRUGNAME	ADROGOLIDE HYDROCHLORIDE
D0N5JJ	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0K5LT	TTDDRUID	D0K5LT
D0K5LT	DRUGNAME	Adult stem cell therapy
D0K5LT	INDICATI	Stroke [ICD-11: 8B20] Discontinued in Phase 2

D0S0GM	TTDDRUID	D0S0GM
D0S0GM	DRUGNAME	ADX-10061
D0S0GM	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2

D02CQL	TTDDRUID	D02CQL
D02CQL	DRUGNAME	Adyvia
D02CQL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D06BVT	TTDDRUID	D06BVT
D06BVT	DRUGNAME	Affitope AD-02
D06BVT	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D08CCC	TTDDRUID	D08CCC
D08CCC	DRUGNAME	AFP-Scan
D08CCC	INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 2

D0D5FQ	TTDDRUID	D0D5FQ
D0D5FQ	DRUGNAME	Agatolimod
D0D5FQ	INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 2

D08NYL	TTDDRUID	D08NYL
D08NYL	DRUGNAME	AGN211745
D08NYL	INDICATI	Choroidal neovascularization [ICD-11: 9B76] Discontinued in Phase 2

D05DBZ	TTDDRUID	D05DBZ
D05DBZ	DRUGNAME	AGS-8M4
D05DBZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2

D0N5BL	TTDDRUID	D0N5BL
D0N5BL	DRUGNAME	AJA-777
D0N5BL	INDICATI	Dyspepsia [ICD-11: MD92] Discontinued in Phase 2

D05CKF	TTDDRUID	D05CKF
D05CKF	DRUGNAME	AJD-101
D05CKF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0J8WJ	TTDDRUID	D0J8WJ
D0J8WJ	DRUGNAME	AKL-0707
D0J8WJ	INDICATI	Lipodystrophy [ICD-11: EF01] Discontinued in Phase 2

D05LSY	TTDDRUID	D05LSY
D05LSY	DRUGNAME	AKP-020
D05LSY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0A4HD	TTDDRUID	D0A4HD
D0A4HD	DRUGNAME	Allotrap-2702
D0A4HD	INDICATI	Transplant rejection [ICD-11: NE84] Discontinued in Phase 2

D0V5GO	TTDDRUID	D0V5GO
D0V5GO	DRUGNAME	Allox
D0V5GO	INDICATI	Wound healing [ICD-11: EL8Y] Discontinued in Phase 2

D01QKR	TTDDRUID	D01QKR
D01QKR	DRUGNAME	ALNESPIRONE
D01QKR	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D01NMN	TTDDRUID	D01NMN
D01NMN	DRUGNAME	ALORACETAM
D01NMN	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0D5DE	TTDDRUID	D0D5DE
D0D5DE	DRUGNAME	ALPRENOXIME HYDROCHLORIDE
D0D5DE	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2

D0H2KV	TTDDRUID	D0H2KV
D0H2KV	DRUGNAME	ALS 2-0426
D0H2KV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D06UYI	TTDDRUID	D06UYI
D06UYI	DRUGNAME	AM103
D06UYI	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D01PSI	TTDDRUID	D01PSI
D01PSI	DRUGNAME	AM-3301
D01PSI	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D07FNG	TTDDRUID	D07FNG
D07FNG	DRUGNAME	AM336
D07FNG	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D06HUF	TTDDRUID	D06HUF
D06HUF	DRUGNAME	AM-365
D06HUF	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2

D0T6MM	TTDDRUID	D0T6MM
D0T6MM	DRUGNAME	AM-94
D0T6MM	INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Discontinued in Phase 2

D0ZF1D	TTDDRUID	D0ZF1D
D0ZF1D	DRUGNAME	Ambasilide
D0ZF1D	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0V7MA	TTDDRUID	D0V7MA
D0V7MA	DRUGNAME	AMESERGIDE
D0V7MA	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D0W7VG	TTDDRUID	D0W7VG
D0W7VG	DRUGNAME	AMG 108
D0W7VG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0MP2U	TTDDRUID	D0MP2U
D0MP2U	DRUGNAME	AN-9
D0MP2U	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D0Q8OW	TTDDRUID	D0Q8OW
D0Q8OW	DRUGNAME	AnergiX.MS
D0Q8OW	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2

D07BEE	TTDDRUID	D07BEE
D07BEE	DRUGNAME	AnergiX.RA
D07BEE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0M8PL	TTDDRUID	D0M8PL
D0M8PL	DRUGNAME	Angiozyme
D0M8PL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08XRX	TTDDRUID	D08XRX
D08XRX	DRUGNAME	ANGX-3227
D08XRX	INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Discontinued in Phase 2

D03CVV	TTDDRUID	D03CVV
D03CVV	DRUGNAME	Anisperimus
D03CVV	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2

D07RYX	TTDDRUID	D07RYX
D07RYX	DRUGNAME	Antide
D07RYX	INDICATI	Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2

D0O7XO	TTDDRUID	D0O7XO
D0O7XO	DRUGNAME	AOD-9604
D0O7XO	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D0Q2RF	TTDDRUID	D0Q2RF
D0Q2RF	DRUGNAME	AP-1101
D0Q2RF	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D01XAR	TTDDRUID	D01XAR
D01XAR	DRUGNAME	AP-521
D01XAR	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0U1IR	TTDDRUID	D0U1IR
D0U1IR	DRUGNAME	AP-5346
D0U1IR	INDICATI	Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 2

D08RMH	TTDDRUID	D08RMH
D08RMH	DRUGNAME	APC-2059
D08RMH	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D0N9WB	TTDDRUID	D0N9WB
D0N9WB	DRUGNAME	APC-366
D0N9WB	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0NN0I	TTDDRUID	D0NN0I
D0NN0I	DRUGNAME	APC-8020
D0NN0I	INDICATI	Amyloidosis [ICD-11: 5D00] Discontinued in Phase 2

D00PZK	TTDDRUID	D00PZK
D00PZK	DRUGNAME	APD-405
D00PZK	INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 2

D0AF7D	TTDDRUID	D0AF7D
D0AF7D	DRUGNAME	APL-180
D0AF7D	INDICATI	Heart disease [ICD-11: BA41-BA42] Discontinued in Phase 2

D0S7IZ	TTDDRUID	D0S7IZ
D0S7IZ	DRUGNAME	Apricoxib
D0S7IZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2
D0S7IZ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2
D0S7IZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0F6JI	TTDDRUID	D0F6JI
D0F6JI	DRUGNAME	AR-D-111421
D0F6JI	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D03EZB	TTDDRUID	D03EZB
D03EZB	DRUGNAME	AR-H047108
D03EZB	INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 2

D0T2LP	TTDDRUID	D0T2LP
D0T2LP	DRUGNAME	ARM036
D0T2LP	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2

D01LFA	TTDDRUID	D01LFA
D01LFA	DRUGNAME	ARX-201
D01LFA	INDICATI	Growth failure [ICD-11: LD2F.1Y] Discontinued in Phase 2

D0B6EU	TTDDRUID	D0B6EU
D0B6EU	DRUGNAME	AS-35
D0B6EU	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0KY4O	TTDDRUID	D0KY4O
D0KY4O	DRUGNAME	ASF-1075
D0KY4O	INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2

D0Z5LB	TTDDRUID	D0Z5LB
D0Z5LB	DRUGNAME	AT1022
D0Z5LB	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D05OVC	TTDDRUID	D05OVC
D05OVC	DRUGNAME	Atipamezole
D05OVC	INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 2

D08ODH	TTDDRUID	D08ODH
D08ODH	DRUGNAME	Atiratecan
D08ODH	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2

D06SBK	TTDDRUID	D06SBK
D06SBK	DRUGNAME	Atocalcitol
D06SBK	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D04VKO	TTDDRUID	D04VKO
D04VKO	DRUGNAME	ATON-004
D04VKO	INDICATI	Heavy metal poisoning [ICD-11: NE60] Discontinued in Phase 2

D0G1EE	TTDDRUID	D0G1EE
D0G1EE	DRUGNAME	ATRINOSITOL
D0G1EE	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0Q1IH	TTDDRUID	D0Q1IH
D0Q1IH	DRUGNAME	ATX-201
D0Q1IH	INDICATI	Actinic keratosis [ICD-11: EK90.0] Discontinued in Phase 2

D0L8WA	TTDDRUID	D0L8WA
D0L8WA	DRUGNAME	AVAC
D0L8WA	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
D0L8WA	INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2

D07AOY	TTDDRUID	D07AOY
D07AOY	DRUGNAME	Avarofloxacin
D07AOY	INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Discontinued in Phase 2

D0W2IU	TTDDRUID	D0W2IU
D0W2IU	DRUGNAME	AVE-0847
D0W2IU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0OM0M	TTDDRUID	D0OM0M
D0OM0M	DRUGNAME	AVE1625
D0OM0M	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2

D00BPE	TTDDRUID	D00BPE
D00BPE	DRUGNAME	AVE-1642
D00BPE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0R5QQ	TTDDRUID	D0R5QQ
D0R5QQ	DRUGNAME	AVE-8134
D0R5QQ	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2

D0J7EP	TTDDRUID	D0J7EP
D0J7EP	DRUGNAME	AVN 397
D0J7EP	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
D0J7EP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0J2IH	TTDDRUID	D0J2IH
D0J2IH	DRUGNAME	Avosentan
D0J2IH	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2

D03WRN	TTDDRUID	D03WRN
D03WRN	DRUGNAME	AVT-02 UE
D03WRN	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Discontinued in Phase 2

D0H4NQ	TTDDRUID	D0H4NQ
D0H4NQ	DRUGNAME	AWD-5239
D0H4NQ	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0SX7F	TTDDRUID	D0SX7F
D0SX7F	DRUGNAME	AZALANSTAT
D0SX7F	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0Q9RR	TTDDRUID	D0Q9RR
D0Q9RR	DRUGNAME	AZD0328
D0Q9RR	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D0B1KK	TTDDRUID	D0B1KK
D0B1KK	DRUGNAME	AZD0837
D0B1KK	INDICATI	Nonvalvular atrial fibrillation [ICD-11: BC81.3Y] Discontinued in Phase 2
D0B1KK	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0E5YG	TTDDRUID	D0E5YG
D0E5YG	DRUGNAME	AZD1236
D0E5YG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D04PMM	TTDDRUID	D04PMM
D04PMM	DRUGNAME	AZD1386
D04PMM	INDICATI	Esophagus sensitivity [ICD-11: DA2Y-DA2Z] Discontinued in Phase 2
D04PMM	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2

D09GPB	TTDDRUID	D09GPB
D09GPB	DRUGNAME	AZD2066
D09GPB	INDICATI	Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2
D09GPB	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2
D09GPB	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0J1TS	TTDDRUID	D0J1TS
D0J1TS	DRUGNAME	AZD2207
D0J1TS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
D0J1TS	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D06UDV	TTDDRUID	D06UDV
D06UDV	DRUGNAME	AZD2516
D06UDV	INDICATI	Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2

D03FFY	TTDDRUID	D03FFY
D03FFY	DRUGNAME	AZD3355
D03FFY	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2

D09RGW	TTDDRUID	D09RGW
D09RGW	DRUGNAME	AZD-3778
D09RGW	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D00PFW	TTDDRUID	D00PFW
D00PFW	DRUGNAME	AZD4818
D00PFW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D09UFV	TTDDRUID	D09UFV
D09UFV	DRUGNAME	AZD-5423
D09UFV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0R3RO	TTDDRUID	D0R3RO
D0R3RO	DRUGNAME	AZD-5455
D0R3RO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D08RGA	TTDDRUID	D08RGA
D08RGA	DRUGNAME	AZD6370
D08RGA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0OK9X	TTDDRUID	D0OK9X
D0OK9X	DRUGNAME	AZD6765
D0OK9X	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D01FUB	TTDDRUID	D01FUB
D01FUB	DRUGNAME	AZD8529
D01FUB	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D02PHE	TTDDRUID	D02PHE
D02PHE	DRUGNAME	AZD9668
D02PHE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0F7FX	TTDDRUID	D0F7FX
D0F7FX	DRUGNAME	AZD-9684
D0F7FX	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D07QWZ	TTDDRUID	D07QWZ
D07QWZ	DRUGNAME	AZT-P-DDI
D07QWZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D07AIE	TTDDRUID	D07AIE
D07AIE	DRUGNAME	BAL-2299
D07AIE	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D01LNG	TTDDRUID	D01LNG
D01LNG	DRUGNAME	Balicatib
D01LNG	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D02KKQ	TTDDRUID	D02KKQ
D02KKQ	DRUGNAME	BAM-1110
D02KKQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2

D0ZC7P	TTDDRUID	D0ZC7P
D0ZC7P	DRUGNAME	BAMAQUIMAST
D0ZC7P	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0D3PB	TTDDRUID	D0D3PB
D0D3PB	DRUGNAME	BAY 60-4552
D0D3PB	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2

D0E6NR	TTDDRUID	D0E6NR
D0E6NR	DRUGNAME	BAY-Y-3118
D0E6NR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D01VPR	TTDDRUID	D01VPR
D01VPR	DRUGNAME	BBR-3438
D01VPR	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2

D01PCE	TTDDRUID	D01PCE
D01PCE	DRUGNAME	BCH-2687
D01PCE	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0P1QW	TTDDRUID	D0P1QW
D0P1QW	DRUGNAME	Becampanel
D0P1QW	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2

D06FJO	TTDDRUID	D06FJO
D06FJO	DRUGNAME	Benzydamine
D06FJO	INDICATI	Chemotherapy or radiotherapy-induced mucositis [ICD-11: DA42-DA60] Discontinued in Phase 2

D0L1LJ	TTDDRUID	D0L1LJ
D0L1LJ	DRUGNAME	Bervastatin
D0L1LJ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0R7OZ	TTDDRUID	D0R7OZ
D0R7OZ	DRUGNAME	BGC-20-0166
D0R7OZ	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Discontinued in Phase 2

D00NTW	TTDDRUID	D00NTW
D00NTW	DRUGNAME	BIBR-363
D00NTW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0M4LW	TTDDRUID	D0M4LW
D0M4LW	DRUGNAME	BIM-23268
D0M4LW	INDICATI	Acromegaly [ICD-11: 5A60.0] Discontinued in Phase 2

D0U1SI	TTDDRUID	D0U1SI
D0U1SI	DRUGNAME	Bimoclomol
D0U1SI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0T3ME	TTDDRUID	D0T3ME
D0T3ME	DRUGNAME	BIRB 796
D0T3ME	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D01WQO	TTDDRUID	D01WQO
D01WQO	DRUGNAME	BIRT 2584
D01WQO	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D0M0VN	TTDDRUID	D0M0VN
D0M0VN	DRUGNAME	BISNAFIDE MESILATE
D0M0VN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0C7OQ	TTDDRUID	D0C7OQ
D0C7OQ	DRUGNAME	BIWB-1
D0C7OQ	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D0VS3J	TTDDRUID	D0VS3J
D0VS3J	DRUGNAME	BM-17.0249.2NA
D0VS3J	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0Q8UU	TTDDRUID	D0Q8UU
D0Q8UU	DRUGNAME	BM-17.0744
D0Q8UU	INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2

D08WCU	TTDDRUID	D08WCU
D08WCU	DRUGNAME	BMS-180448
D08WCU	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D00QXV	TTDDRUID	D00QXV
D00QXV	DRUGNAME	BMS-181101
D00QXV	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D04SOS	TTDDRUID	D04SOS
D04SOS	DRUGNAME	BMS-181168
D04SOS	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0W1MX	TTDDRUID	D0W1MX
D0W1MX	DRUGNAME	BMS-187745
D0W1MX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0B5PU	TTDDRUID	D0B5PU
D0B5PU	DRUGNAME	BMS-193884
D0B5PU	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2

D09EVZ	TTDDRUID	D09EVZ
D09EVZ	DRUGNAME	BMS-488043
D09EVZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0GT8W	TTDDRUID	D0GT8W
D0GT8W	DRUGNAME	BMS-587101
D0GT8W	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D04NCJ	TTDDRUID	D04NCJ
D04NCJ	DRUGNAME	BMY-21950
D04NCJ	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0W9JH	TTDDRUID	D0W9JH
D0W9JH	DRUGNAME	BMY-30123
D0W9JH	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2

D08VGT	TTDDRUID	D08VGT
D08VGT	DRUGNAME	BMY-30129
D08VGT	INDICATI	Pruritus [ICD-11: EC90] Discontinued in Phase 2

D0R0TF	TTDDRUID	D0R0TF
D0R0TF	DRUGNAME	BN50727
D0R0TF	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D04HIZ	TTDDRUID	D04HIZ
D04HIZ	DRUGNAME	BO-653
D04HIZ	INDICATI	Artery stenosis [ICD-11: BD52] Discontinued in Phase 2

D0B8SC	TTDDRUID	D0B8SC
D0B8SC	DRUGNAME	BOF-4272
D0B8SC	INDICATI	Gout [ICD-11: FA25] Discontinued in Phase 2

D0P9LO	TTDDRUID	D0P9LO
D0P9LO	DRUGNAME	BP-2.94
D0P9LO	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0EE6L	TTDDRUID	D0EE6L
D0EE6L	DRUGNAME	BP-897
D0EE6L	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Discontinued in Phase 2

D0I7RO	TTDDRUID	D0I7RO
D0I7RO	DRUGNAME	BPC-157
D0I7RO	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D0YA0N	TTDDRUID	D0YA0N
D0YA0N	DRUGNAME	BR3-Fc
D0YA0N	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Discontinued in Phase 2
D0YA0N	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0V0FQ	TTDDRUID	D0V0FQ
D0V0FQ	DRUGNAME	Brain derived neurotrophic factor
D0V0FQ	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2

D07FJM	TTDDRUID	D07FJM
D07FJM	DRUGNAME	BRECANAVIR
D07FJM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D08WSW	TTDDRUID	D08WSW
D08WSW	DRUGNAME	BRL-32872A
D08WSW	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D07QAA	TTDDRUID	D07QAA
D07QAA	DRUGNAME	BRL-46470
D07QAA	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0GT4N	TTDDRUID	D0GT4N
D0GT4N	DRUGNAME	BRL-55834
D0GT4N	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0K2BQ	TTDDRUID	D0K2BQ
D0K2BQ	DRUGNAME	BRL-61063
D0K2BQ	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2

D0IZ1D	TTDDRUID	D0IZ1D
D0IZ1D	DRUGNAME	Brofaromine
D0IZ1D	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D09VWI	TTDDRUID	D09VWI
D09VWI	DRUGNAME	BRX-005
D09VWI	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2

D0P2MH	TTDDRUID	D0P2MH
D0P2MH	DRUGNAME	BTS-67582
D0P2MH	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0Z9OS	TTDDRUID	D0Z9OS
D0Z9OS	DRUGNAME	BT-VACC
D0Z9OS	INDICATI	Yersinia infection [ICD-11: 1B93] Discontinued in Phase 2

D0UO2N	TTDDRUID	D0UO2N
D0UO2N	DRUGNAME	BUTIXOCORT
D0UO2N	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D09NEE	TTDDRUID	D09NEE
D09NEE	DRUGNAME	BVT-115959
D09NEE	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D07VPG	TTDDRUID	D07VPG
D07VPG	DRUGNAME	BW-773U82
D07VPG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D09PGM	TTDDRUID	D09PGM
D09PGM	DRUGNAME	BY-1949
D09PGM	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0R6MH	TTDDRUID	D0R6MH
D0R6MH	DRUGNAME	Cadrofloxacin
D0R6MH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0Q9ZD	TTDDRUID	D0Q9ZD
D0Q9ZD	DRUGNAME	Camobucol
D0Q9ZD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0C9HE	TTDDRUID	D0C9HE
D0C9HE	DRUGNAME	Campyvax
D0C9HE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D00LLI	TTDDRUID	D00LLI
D00LLI	DRUGNAME	Candistat-G
D00LLI	INDICATI	Candidiasis [ICD-11: 1F23] Discontinued in Phase 2

D0R5UZ	TTDDRUID	D0R5UZ
D0R5UZ	DRUGNAME	Caracemide
D0R5UZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0N8QQ	TTDDRUID	D0N8QQ
D0N8QQ	DRUGNAME	CARIPORIDE
D0N8QQ	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0O1MP	TTDDRUID	D0O1MP
D0O1MP	DRUGNAME	CARZELESIN
D0O1MP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D09NYB	TTDDRUID	D09NYB
D09NYB	DRUGNAME	CASTANOSPERMINE
D09NYB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0IH4M	TTDDRUID	D0IH4M
D0IH4M	DRUGNAME	CB-10-01 cancer vaccine
D0IH4M	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D07ZHV	TTDDRUID	D07ZHV
D07ZHV	DRUGNAME	CB1954
D07ZHV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D05BWX	TTDDRUID	D05BWX
D05BWX	DRUGNAME	CB-2431
D05BWX	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2

D05JCG	TTDDRUID	D05JCG
D05JCG	DRUGNAME	CBF-BS2
D05JCG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D00ECB	TTDDRUID	D00ECB
D00ECB	DRUGNAME	CD-349
D00ECB	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0UG4T	TTDDRUID	D0UG4T
D0UG4T	DRUGNAME	CDP840
D0UG4T	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D00WOT	TTDDRUID	D00WOT
D00WOT	DRUGNAME	CDP-850
D00WOT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08PAV	TTDDRUID	D08PAV
D08PAV	DRUGNAME	CDP-860
D08PAV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0T5GT	TTDDRUID	D0T5GT
D0T5GT	DRUGNAME	CE-1037
D0T5GT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0W9ZY	TTDDRUID	D0W9ZY
D0W9ZY	DRUGNAME	CE-326597
D0W9ZY	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D0C6HM	TTDDRUID	D0C6HM
D0C6HM	DRUGNAME	Cebaracetam
D0C6HM	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0W5KA	TTDDRUID	D0W5KA
D0W5KA	DRUGNAME	Cefpiroxime
D0W5KA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D09TXG	TTDDRUID	D09TXG
D09TXG	DRUGNAME	CEMADOTIN HYDROCHLORIDE
D09TXG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0RW4F	TTDDRUID	D0RW4F
D0RW4F	DRUGNAME	CereCRIB
D0RW4F	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D05NRI	TTDDRUID	D05NRI
D05NRI	DRUGNAME	Ceronapril
D05NRI	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0J4KC	TTDDRUID	D0J4KC
D0J4KC	DRUGNAME	CETi-1
D0J4KC	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2

D0Q4UY	TTDDRUID	D0Q4UY
D0Q4UY	DRUGNAME	CFC-222
D0Q4UY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0VO3H	TTDDRUID	D0VO3H
D0VO3H	DRUGNAME	CG7060
D0VO3H	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2

D0N1PA	TTDDRUID	D0N1PA
D0N1PA	DRUGNAME	CGP-49823
D0N1PA	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D01SPI	TTDDRUID	D01SPI
D01SPI	DRUGNAME	CGRP
D01SPI	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D09PYD	TTDDRUID	D09PYD
D09PYD	DRUGNAME	CGS-25462
D09PYD	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0C0EV	TTDDRUID	D0C0EV
D0C0EV	DRUGNAME	ChimeriVax-West Nile
D0C0EV	INDICATI	West nile virus infection [ICD-11: 1D46] Discontinued in Phase 2

D00DBE	TTDDRUID	D00DBE
D00DBE	DRUGNAME	CI-1018
D00DBE	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0KV4Z	TTDDRUID	D0KV4Z
D0KV4Z	DRUGNAME	CI-949
D0KV4Z	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0D1XG	TTDDRUID	D0D1XG
D0D1XG	DRUGNAME	CI-976
D0D1XG	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D03GWY	TTDDRUID	D03GWY
D03GWY	DRUGNAME	Ciglitazone
D03GWY	INDICATI	Endometriosis [ICD-11: GA10] Discontinued in Phase 2

D0Q5YF	TTDDRUID	D0Q5YF
D0Q5YF	DRUGNAME	Cipralisant
D0Q5YF	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2

D01DAD	TTDDRUID	D01DAD
D01DAD	DRUGNAME	CJ-13610
D01DAD	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D06NEU	TTDDRUID	D06NEU
D06NEU	DRUGNAME	CJ-23423
D06NEU	INDICATI	Arthralgia [ICD-11: ME82] Discontinued in Phase 2

D0L1JE	TTDDRUID	D0L1JE
D0L1JE	DRUGNAME	CJC-1131
D0L1JE	INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2

D00PMA	TTDDRUID	D00PMA
D00PMA	DRUGNAME	CL-246738
D00PMA	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2

D0E1UZ	TTDDRUID	D0E1UZ
D0E1UZ	DRUGNAME	CL-283796
D0E1UZ	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0T2EP	TTDDRUID	D0T2EP
D0T2EP	DRUGNAME	CLOTURIN
D0T2EP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0J9NJ	TTDDRUID	D0J9NJ
D0J9NJ	DRUGNAME	CLX-0901
D0J9NJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D08FZT	TTDDRUID	D08FZT
D08FZT	DRUGNAME	Corus 1030
D08FZT	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0R6RM	TTDDRUID	D0R6RM
D0R6RM	DRUGNAME	CP-118
D0R6RM	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D0SU1F	TTDDRUID	D0SU1F
D0SU1F	DRUGNAME	CP-122288
D0SU1F	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D0R2KV	TTDDRUID	D0R2KV
D0R2KV	DRUGNAME	CP-316,311
D0R2KV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
D0R2KV	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D0Q2JB	TTDDRUID	D0Q2JB
D0Q2JB	DRUGNAME	CP-640922
D0Q2JB	INDICATI	Dermatomycosis [ICD-11: EA60] Discontinued in Phase 2

D0G6PG	TTDDRUID	D0G6PG
D0G6PG	DRUGNAME	CPA-926
D0G6PG	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2

D0I5QL	TTDDRUID	D0I5QL
D0I5QL	DRUGNAME	CRD-5
D0I5QL	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D03CKX	TTDDRUID	D03CKX
D03CKX	DRUGNAME	Cromafiban
D03CKX	INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 2

D0XH1P	TTDDRUID	D0XH1P
D0XH1P	DRUGNAME	CRx-102
D0XH1P	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2

D0VA2I	TTDDRUID	D0VA2I
D0VA2I	DRUGNAME	CRx-191
D0VA2I	INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2

D0BZ1Q	TTDDRUID	D0BZ1Q
D0BZ1Q	DRUGNAME	CRx-401
D0BZ1Q	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0I7OE	TTDDRUID	D0I7OE
D0I7OE	DRUGNAME	CryptoGAM
D0I7OE	INDICATI	Cryptosporidium infection [ICD-11: 1A32] Discontinued in Phase 2

D03ZKE	TTDDRUID	D03ZKE
D03ZKE	DRUGNAME	CS-003
D03ZKE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0F3EH	TTDDRUID	D0F3EH
D0F3EH	DRUGNAME	CS-712
D0F3EH	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D0H9DE	TTDDRUID	D0H9DE
D0H9DE	DRUGNAME	CS-722
D0H9DE	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2

D06AVN	TTDDRUID	D06AVN
D06AVN	DRUGNAME	CS-891B
D06AVN	INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 2

D00ZKC	TTDDRUID	D00ZKC
D00ZKC	DRUGNAME	CS-92
D00ZKC	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 2

D0E0FY	TTDDRUID	D0E0FY
D0E0FY	DRUGNAME	CTL-102-GDEPT
D0E0FY	INDICATI	Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 2

D0Q2BG	TTDDRUID	D0Q2BG
D0Q2BG	DRUGNAME	CU-2010
D0Q2BG	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 2

D01MVK	TTDDRUID	D01MVK
D01MVK	DRUGNAME	CV-787
D01MVK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2

D0BQ8M	TTDDRUID	D0BQ8M
D0BQ8M	DRUGNAME	CY-208243
D0BQ8M	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0O8LW	TTDDRUID	D0O8LW
D0O8LW	DRUGNAME	CYANIDIN CHLORIDE MONOHYDRATE
D0O8LW	INDICATI	Ulcer [ICD-11: CA02-CB40] Discontinued in Phase 2

D0L7OY	TTDDRUID	D0L7OY
D0L7OY	DRUGNAME	D-7193
D0L7OY	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2

D06GDH	TTDDRUID	D06GDH
D06GDH	DRUGNAME	DA-5018
D06GDH	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2
D06GDH	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Discontinued in Phase 2

D0Z3UP	TTDDRUID	D0Z3UP
D0Z3UP	DRUGNAME	Dabuzalgron
D0Z3UP	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D09CFM	TTDDRUID	D09CFM
D09CFM	DRUGNAME	DANOFLOXACIN
D09CFM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D03STA	TTDDRUID	D03STA
D03STA	DRUGNAME	Darotropium
D03STA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0K2QG	TTDDRUID	D0K2QG
D0K2QG	DRUGNAME	DASANTAFIL
D0K2QG	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2

D0SB6K	TTDDRUID	D0SB6K
D0SB6K	DRUGNAME	DAT-582
D0SB6K	INDICATI	Nausea [ICD-11: MD90] Discontinued in Phase 2

D0H4TC	TTDDRUID	D0H4TC
D0H4TC	DRUGNAME	Davalintide
D0H4TC	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D0Y6OH	TTDDRUID	D0Y6OH
D0Y6OH	DRUGNAME	Davunetide intranasal
D0Y6OH	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
D0Y6OH	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0I0GM	TTDDRUID	D0I0GM
D0I0GM	DRUGNAME	Daxalipram
D0I0GM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2

D0EI1U	TTDDRUID	D0EI1U
D0EI1U	DRUGNAME	DCDT-2980S
D0EI1U	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Discontinued in Phase 2
D0EI1U	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Discontinued in Phase 2

D05PZZ	TTDDRUID	D05PZZ
D05PZZ	DRUGNAME	DDP-200
D05PZZ	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D0CB8W	TTDDRUID	D0CB8W
D0CB8W	DRUGNAME	DE-081
D0CB8W	INDICATI	Conjunctivitis [ICD-11: 9A60] Discontinued in Phase 2
D0CB8W	INDICATI	Ocular allergy [ICD-11: 4A81] Terminated

D04YPZ	TTDDRUID	D04YPZ
D04YPZ	DRUGNAME	Decapeptide allergy vaccine
D04YPZ	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2

D09EEV	TTDDRUID	D09EEV
D09EEV	DRUGNAME	Declopramide
D09EEV	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D03ABH	TTDDRUID	D03ABH
D03ABH	DRUGNAME	Deriglidole
D03ABH	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0B9EH	TTDDRUID	D0B9EH
D0B9EH	DRUGNAME	Dermolastin
D0B9EH	INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2

D0B1MJ	TTDDRUID	D0B1MJ
D0B1MJ	DRUGNAME	Dexniguldipine
D0B1MJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D01BBR	TTDDRUID	D01BBR
D01BBR	DRUGNAME	Dezinamide
D01BBR	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2

D0YS0B	TTDDRUID	D0YS0B
D0YS0B	DRUGNAME	DF-1012
D0YS0B	INDICATI	Cough [ICD-11: MD12] Discontinued in Phase 2

D08QHS	TTDDRUID	D08QHS
D08QHS	DRUGNAME	DG041
D08QHS	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2

D06XEL	TTDDRUID	D06XEL
D06XEL	DRUGNAME	DG051
D06XEL	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2

D02BGL	TTDDRUID	D02BGL
D02BGL	DRUGNAME	DHAC
D02BGL	INDICATI	Mesothelioma [ICD-11: 2C51.2] Discontinued in Phase 2

D04FXS	TTDDRUID	D04FXS
D04FXS	DRUGNAME	Didox
D04FXS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D02UAR	TTDDRUID	D02UAR
D02UAR	DRUGNAME	DiffGAM
D02UAR	INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2

D09OXR	TTDDRUID	D09OXR
D09OXR	DRUGNAME	Diffistat-G
D09OXR	INDICATI	Clostridium infection [ICD-11: 1A04] Discontinued in Phase 2

D0Z8UQ	TTDDRUID	D0Z8UQ
D0Z8UQ	DRUGNAME	DM-83
D0Z8UQ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0W7IR	TTDDRUID	D0W7IR
D0W7IR	DRUGNAME	DMP-543
D0W7IR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2

D05SFD	TTDDRUID	D05SFD
D05SFD	DRUGNAME	DMP-961
D05SFD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0C9FF	TTDDRUID	D0C9FF
D0C9FF	DRUGNAME	DNK-333
D0C9FF	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2

D0B3IC	TTDDRUID	D0B3IC
D0B3IC	DRUGNAME	Dopropidil
D0B3IC	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0Y1YP	TTDDRUID	D0Y1YP
D0Y1YP	DRUGNAME	DOQUALAST
D0Y1YP	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2

D0H9GQ	TTDDRUID	D0H9GQ
D0H9GQ	DRUGNAME	DOV-216303
D0H9GQ	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D0I4PL	TTDDRUID	D0I4PL
D0I4PL	DRUGNAME	DPC-543
D0I4PL	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D0G1YN	TTDDRUID	D0G1YN
D0G1YN	DRUGNAME	DPI-3290
D0G1YN	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D04NWP	TTDDRUID	D04NWP
D04NWP	DRUGNAME	DRAFLAZINE
D04NWP	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0R2JS	TTDDRUID	D0R2JS
D0R2JS	DRUGNAME	Droloxifene
D0R2JS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0F4IG	TTDDRUID	D0F4IG
D0F4IG	DRUGNAME	DS-4574
D0F4IG	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0U4FW	TTDDRUID	D0U4FW
D0U4FW	DRUGNAME	DU 125530
D0U4FW	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D06UVO	TTDDRUID	D06UVO
D06UVO	DRUGNAME	DuP-654
D06UVO	INDICATI	Pruritus [ICD-11: EC90] Discontinued in Phase 2

D0T3VO	TTDDRUID	D0T3VO
D0T3VO	DRUGNAME	DX-619
D0T3VO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0V2OS	TTDDRUID	D0V2OS
D0V2OS	DRUGNAME	DX-9065
D0V2OS	INDICATI	Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 2

D0JH6W	TTDDRUID	D0JH6W
D0JH6W	DRUGNAME	DX-9065a
D0JH6W	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0R1LT	TTDDRUID	D0R1LT
D0R1LT	DRUGNAME	E047/1
D0R1LT	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D04OXU	TTDDRUID	D04OXU
D04OXU	DRUGNAME	E-2078
D04OXU	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0JY4Y	TTDDRUID	D0JY4Y
D0JY4Y	DRUGNAME	E-3040
D0JY4Y	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0Y0SY	TTDDRUID	D0Y0SY
D0Y0SY	DRUGNAME	E-3620
D0Y0SY	INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2

D00SPK	TTDDRUID	D00SPK
D00SPK	DRUGNAME	E-4021
D00SPK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D0E2PX	TTDDRUID	D0E2PX
D0E2PX	DRUGNAME	E-4031
D0E2PX	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0M7PS	TTDDRUID	D0M7PS
D0M7PS	DRUGNAME	E-4177
D0M7PS	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0W2UY	TTDDRUID	D0W2UY
D0W2UY	DRUGNAME	E-5050
D0W2UY	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2

D01IDE	TTDDRUID	D01IDE
D01IDE	DRUGNAME	E-5324
D01IDE	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0X0EU	TTDDRUID	D0X0EU
D0X0EU	DRUGNAME	E-5531
D0X0EU	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D0D9KQ	TTDDRUID	D0D9KQ
D0D9KQ	DRUGNAME	E-6006 CITRATE
D0D9KQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D00HFD	TTDDRUID	D00HFD
D00HFD	DRUGNAME	E-6080
D00HFD	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0R0EV	TTDDRUID	D0R0EV
D0R0EV	DRUGNAME	E-6123
D0R0EV	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0N4YX	TTDDRUID	D0N4YX
D0N4YX	DRUGNAME	EAA-090
D0N4YX	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2

D0B5KE	TTDDRUID	D0B5KE
D0B5KE	DRUGNAME	EB-1053
D0B5KE	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D05PWZ	TTDDRUID	D05PWZ
D05PWZ	DRUGNAME	Ecromeximab
D05PWZ	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D03MUM	TTDDRUID	D03MUM
D03MUM	DRUGNAME	EDONENTAN HYDRATE
D03MUM	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2

D0XK4R	TTDDRUID	D0XK4R
D0XK4R	DRUGNAME	EFLETIRIZINE
D0XK4R	INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2

D0W0ED	TTDDRUID	D0W0ED
D0W0ED	DRUGNAME	Eflucimibe
D0W0ED	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0UG4P	TTDDRUID	D0UG4P
D0UG4P	DRUGNAME	Egaptivon pegol
D0UG4P	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0N4JG	TTDDRUID	D0N4JG
D0N4JG	DRUGNAME	Eladem
D0N4JG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2

D0S3RB	TTDDRUID	D0S3RB
D0S3RB	DRUGNAME	ELAROFIBAN
D0S3RB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D01NAM	TTDDRUID	D01NAM
D01NAM	DRUGNAME	ELB-139
D01NAM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D09WRI	TTDDRUID	D09WRI
D09WRI	DRUGNAME	ELINAFIDE MESILATE
D09WRI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0CE6T	TTDDRUID	D0CE6T
D0CE6T	DRUGNAME	Elisartan potassium
D0CE6T	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D04IBA	TTDDRUID	D04IBA
D04IBA	DRUGNAME	Ellipravin
D04IBA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0K2PH	TTDDRUID	D0K2PH
D0K2PH	DRUGNAME	Elvucitabine
D0K2PH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D03SFN	TTDDRUID	D03SFN
D03SFN	DRUGNAME	Elzasonan hydrochloride
D03SFN	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D05UXF	TTDDRUID	D05UXF
D05UXF	DRUGNAME	Emapunil
D05UXF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0O8HL	TTDDRUID	D0O8HL
D0O8HL	DRUGNAME	EML-16257
D0O8HL	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0F1MU	TTDDRUID	D0F1MU
D0F1MU	DRUGNAME	EML-336
D0F1MU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0X1LO	TTDDRUID	D0X1LO
D0X1LO	DRUGNAME	EMR-62203
D0X1LO	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2

D09ELW	TTDDRUID	D09ELW
D09ELW	DRUGNAME	Enalkiren
D09ELW	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2

D0O4ZX	TTDDRUID	D0O4ZX
D0O4ZX	DRUGNAME	Encapsulated cells
D0O4ZX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0V9RU	TTDDRUID	D0V9RU
D0V9RU	DRUGNAME	ENIPORIDE
D0V9RU	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D07YHT	TTDDRUID	D07YHT
D07YHT	DRUGNAME	ENRASENTAN
D07YHT	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2

D0YQ3M	TTDDRUID	D0YQ3M
D0YQ3M	DRUGNAME	EP-2104R
D0YQ3M	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D09DYT	TTDDRUID	D09DYT
D09DYT	DRUGNAME	EP-5001
D09DYT	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D03RNX	TTDDRUID	D03RNX
D03RNX	DRUGNAME	EPC-K1
D03RNX	INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2

D07EIJ	TTDDRUID	D07EIJ
D07EIJ	DRUGNAME	EPI-12323
D07EIJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0QH0B	TTDDRUID	D0QH0B
D0QH0B	DRUGNAME	EPI-2010
D0QH0B	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0N4OZ	TTDDRUID	D0N4OZ
D0N4OZ	DRUGNAME	Epothilone D
D0N4OZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0O2FF	TTDDRUID	D0O2FF
D0O2FF	DRUGNAME	Epstein-Barr vaccine
D0O2FF	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D0R8TB	TTDDRUID	D0R8TB
D0R8TB	DRUGNAME	ERA-923
D0R8TB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D09PKU	TTDDRUID	D09PKU
D09PKU	DRUGNAME	ERBULOZOLE
D09PKU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D02QWJ	TTDDRUID	D02QWJ
D02QWJ	DRUGNAME	EREMOMYCIN
D02QWJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D01NJT	TTDDRUID	D01NJT
D01NJT	DRUGNAME	Esreboxetine
D01NJT	INDICATI	Fibromyalgia [ICD-11: MG30.01] Discontinued in Phase 2

D0Y6ZS	TTDDRUID	D0Y6ZS
D0Y6ZS	DRUGNAME	Esterom
D0Y6ZS	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0ZM5W	TTDDRUID	D0ZM5W
D0ZM5W	DRUGNAME	ESUPRONE
D0ZM5W	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0S3MY	TTDDRUID	D0S3MY
D0S3MY	DRUGNAME	ET-642
D0S3MY	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2

D0H7GH	TTDDRUID	D0H7GH
D0H7GH	DRUGNAME	ETH615
D0H7GH	INDICATI	Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2

D05EEJ	TTDDRUID	D05EEJ
D05EEJ	DRUGNAME	ETRX-101
D05EEJ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2

D0A5TS	TTDDRUID	D0A5TS
D0A5TS	DRUGNAME	EVT-101
D0A5TS	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2

D09TGZ	TTDDRUID	D09TGZ
D09TGZ	DRUGNAME	Examorelin
D09TGZ	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 2

D01TBN	TTDDRUID	D01TBN
D01TBN	DRUGNAME	Ezlopitant
D01TBN	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2
D01TBN	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
D01TBN	INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 2

D05HYC	TTDDRUID	D05HYC
D05HYC	DRUGNAME	F-50077
D05HYC	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Discontinued in Phase 2

D02ZLM	TTDDRUID	D02ZLM
D02ZLM	DRUGNAME	F-991
D02ZLM	INDICATI	Allergic skin disorder [ICD-11: 4A82] Discontinued in Phase 2

D04DMQ	TTDDRUID	D04DMQ
D04DMQ	DRUGNAME	Fabesetron
D04DMQ	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2

D0W7KD	TTDDRUID	D0W7KD
D0W7KD	DRUGNAME	FANDOFLOXACIN HYDROCHLORIDE
D0W7KD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0L2IQ	TTDDRUID	D0L2IQ
D0L2IQ	DRUGNAME	Fasidotril
D0L2IQ	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2

D02SKA	TTDDRUID	D02SKA
D02SKA	DRUGNAME	FCE-22716
D02SKA	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0H7WA	TTDDRUID	D0H7WA
D0H7WA	DRUGNAME	FCP-3P1
D0H7WA	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2

D0A6VE	TTDDRUID	D0A6VE
D0A6VE	DRUGNAME	FIDUXOSIN HYDROCHLORIDE
D0A6VE	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2

D0H9KW	TTDDRUID	D0H9KW
D0H9KW	DRUGNAME	Filaminast
D0H9KW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D04PSL	TTDDRUID	D04PSL
D04PSL	DRUGNAME	FINROZOLE
D04PSL	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2

D04HHW	TTDDRUID	D04HHW
D04HHW	DRUGNAME	FK-011
D04HHW	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D02FIJ	TTDDRUID	D02FIJ
D02FIJ	DRUGNAME	FK-224
D02FIJ	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0SH5O	TTDDRUID	D0SH5O
D0SH5O	DRUGNAME	FK-317
D0SH5O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D03JHJ	TTDDRUID	D03JHJ
D03JHJ	DRUGNAME	FK-352
D03JHJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D01VPK	TTDDRUID	D01VPK
D01VPK	DRUGNAME	FK-453
D01VPK	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2

D0IJ2H	TTDDRUID	D0IJ2H
D0IJ2H	DRUGNAME	FK-584
D0IJ2H	INDICATI	Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Discontinued in Phase 2

D0W8QV	TTDDRUID	D0W8QV
D0W8QV	DRUGNAME	FK-613
D0W8QV	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0W4OL	TTDDRUID	D0W4OL
D0W4OL	DRUGNAME	FK-633
D0W4OL	INDICATI	Artery stenosis [ICD-11: BD52] Discontinued in Phase 2

D0E6UD	TTDDRUID	D0E6UD
D0E6UD	DRUGNAME	FK-664
D0E6UD	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D0P4IK	TTDDRUID	D0P4IK
D0P4IK	DRUGNAME	FK-706
D0P4IK	INDICATI	Pulmonary emphysema [ICD-11: CA21.Z] Discontinued in Phase 2

D03OKG	TTDDRUID	D03OKG
D03OKG	DRUGNAME	FK-739
D03OKG	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0X4IA	TTDDRUID	D0X4IA
D0X4IA	DRUGNAME	FK778
D0X4IA	INDICATI	Kidney/heart transplant rejection [ICD-11: NE84] Discontinued in Phase 2

D0EK6D	TTDDRUID	D0EK6D
D0EK6D	DRUGNAME	FK-838
D0EK6D	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D05UKK	TTDDRUID	D05UKK
D05UKK	DRUGNAME	FK-888
D05UKK	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D01SGM	TTDDRUID	D01SGM
D01SGM	DRUGNAME	FK-906
D01SGM	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D00RMD	TTDDRUID	D00RMD
D00RMD	DRUGNAME	FK-960
D00RMD	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D05YLL	TTDDRUID	D05YLL
D05YLL	DRUGNAME	FL-386
D05YLL	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0TX8Z	TTDDRUID	D0TX8Z
D0TX8Z	DRUGNAME	FLOSATIDIL
D0TX8Z	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0D3JQ	TTDDRUID	D0D3JQ
D0D3JQ	DRUGNAME	Flovagatran
D0D3JQ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0E8JO	TTDDRUID	D0E8JO
D0E8JO	DRUGNAME	FO-152
D0E8JO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08CKJ	TTDDRUID	D08CKJ
D08CKJ	DRUGNAME	Fonsartan
D08CKJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0N4ND	TTDDRUID	D0N4ND
D0N4ND	DRUGNAME	Fontolizumab
D0N4ND	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
D0N4ND	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0X8QP	TTDDRUID	D0X8QP
D0X8QP	DRUGNAME	FOSOPAMINE
D0X8QP	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D04PLC	TTDDRUID	D04PLC
D04PLC	DRUGNAME	FOV1101
D04PLC	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Discontinued in Phase 2

D0A0MU	TTDDRUID	D0A0MU
D0A0MU	DRUGNAME	FOZIVUDINE TIDOXIL
D0A0MU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0GY1D	TTDDRUID	D0GY1D
D0GY1D	DRUGNAME	FP0011
D0GY1D	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2

D04WHX	TTDDRUID	D04WHX
D04WHX	DRUGNAME	FP-21399
D04WHX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D04QVN	TTDDRUID	D04QVN
D04QVN	DRUGNAME	FPL-64170
D04QVN	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D0N1HL	TTDDRUID	D0N1HL
D0N1HL	DRUGNAME	Frakefamide
D0N1HL	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0E2CZ	TTDDRUID	D0E2CZ
D0E2CZ	DRUGNAME	FS-205-397
D0E2CZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D05RUJ	TTDDRUID	D05RUJ
D05RUJ	DRUGNAME	G-1128
D05RUJ	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Discontinued in Phase 2

D05WTZ	TTDDRUID	D05WTZ
D05WTZ	DRUGNAME	Galarubicin
D05WTZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D05ACQ	TTDDRUID	D05ACQ
D05ACQ	DRUGNAME	Gallium maltolate
D05ACQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0H9WO	TTDDRUID	D0H9WO
D0H9WO	DRUGNAME	Gantofiban
D0H9WO	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2

D0O6AQ	TTDDRUID	D0O6AQ
D0O6AQ	DRUGNAME	Gavestinel
D0O6AQ	INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2

D03PKI	TTDDRUID	D03PKI
D03PKI	DRUGNAME	Geldanamycin
D03PKI	INDICATI	Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 2
D03PKI	INDICATI	Peripheral nerve damage [ICD-11: ND56.4] Discontinued in Phase 2

D01IPI	TTDDRUID	D01IPI
D01IPI	DRUGNAME	Gemopatrilat
D01IPI	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2

D0F6CT	TTDDRUID	D0F6CT
D0F6CT	DRUGNAME	GI 181771
D0F6CT	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D07HTX	TTDDRUID	D07HTX
D07HTX	DRUGNAME	GL-331
D07HTX	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2

D0EO6S	TTDDRUID	D0EO6S
D0EO6S	DRUGNAME	Glaspimod
D0EO6S	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2

D0U5NU	TTDDRUID	D0U5NU
D0U5NU	DRUGNAME	GLENVASTATIN
D0U5NU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D06NPB	TTDDRUID	D06NPB
D06NPB	DRUGNAME	GLPG-0259
D06NPB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0A0ZX	TTDDRUID	D0A0ZX
D0A0ZX	DRUGNAME	Glutathionarsenoxide
D0A0ZX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D03PVY	TTDDRUID	D03PVY
D03PVY	DRUGNAME	GlycoPEGylated erythropoietin
D03PVY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0D6EW	TTDDRUID	D0D6EW
D0D6EW	DRUGNAME	Glypromate
D0D6EW	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2

D0V4CL	TTDDRUID	D0V4CL
D0V4CL	DRUGNAME	GN-1140
D0V4CL	INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 2

D0Z5AC	TTDDRUID	D0Z5AC
D0Z5AC	DRUGNAME	Gonadimmune
D0Z5AC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2

D0S8RY	TTDDRUID	D0S8RY
D0S8RY	DRUGNAME	GP-531
D0S8RY	INDICATI	Myocardial ischemia [ICD-11: BA6Z] Discontinued in Phase 2

D00NWT	TTDDRUID	D00NWT
D00NWT	DRUGNAME	GR-213487
D00NWT	INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2

D0C2QJ	TTDDRUID	D0C2QJ
D0C2QJ	DRUGNAME	GR-270773
D0C2QJ	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D09RNP	TTDDRUID	D09RNP
D09RNP	DRUGNAME	GSK 679769
D09RNP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
D09RNP	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 2
D09RNP	INDICATI	Incontinence [ICD-11: MF50.2] Discontinued in Phase 2
D09RNP	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0N8MQ	TTDDRUID	D0N8MQ
D0N8MQ	DRUGNAME	GSK-159797
D0N8MQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0YL3E	TTDDRUID	D0YL3E
D0YL3E	DRUGNAME	GSK159802
D0YL3E	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0B7SP	TTDDRUID	D0B7SP
D0B7SP	DRUGNAME	GSK163090
D0B7SP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
D0B7SP	INDICATI	Episode [ICD-11: N.A.] Discontinued in Phase 2
D0B7SP	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0R3EL	TTDDRUID	D0R3EL
D0R3EL	DRUGNAME	GSK184072
D0R3EL	INDICATI	Colon cancer [ICD-11: 2B90.Z] Discontinued in Phase 2
D0R3EL	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Discontinued in Phase 2
D0R3EL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D07ATG	TTDDRUID	D07ATG
D07ATG	DRUGNAME	GSK2190914
D07ATG	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D05MCS	TTDDRUID	D05MCS
D05MCS	DRUGNAME	GSK2190915
D05MCS	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0U7PS	TTDDRUID	D0U7PS
D0U7PS	DRUGNAME	GSK256066
D0U7PS	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D05HVY	TTDDRUID	D05HVY
D05HVY	DRUGNAME	GSK-644784
D05HVY	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2

D0S6KX	TTDDRUID	D0S6KX
D0S6KX	DRUGNAME	GSK-677954
D0S6KX	INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Discontinued in Phase 2

D02ESK	TTDDRUID	D02ESK
D02ESK	DRUGNAME	GSK-732461
D02ESK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D04IFU	TTDDRUID	D04IFU
D04IFU	DRUGNAME	GSK835726
D04IFU	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D01NUG	TTDDRUID	D01NUG
D01NUG	DRUGNAME	GSK870086
D01NUG	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D07WMH	TTDDRUID	D07WMH
D07WMH	DRUGNAME	GT102-279
D07WMH	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 2

D0Y1VZ	TTDDRUID	D0Y1VZ
D0Y1VZ	DRUGNAME	GT-389255
D0Y1VZ	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D0X4AV	TTDDRUID	D0X4AV
D0X4AV	DRUGNAME	GV-150013
D0X4AV	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D05ERT	TTDDRUID	D05ERT
D05ERT	DRUGNAME	GV-196771
D05ERT	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D0O0FF	TTDDRUID	D0O0FF
D0O0FF	DRUGNAME	GW 468816
D0O0FF	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Discontinued in Phase 2

D09AUP	TTDDRUID	D09AUP
D09AUP	DRUGNAME	GW-215864
D09AUP	INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2

D09IZX	TTDDRUID	D09IZX
D09IZX	DRUGNAME	GW-275919
D09IZX	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0UH4T	TTDDRUID	D0UH4T
D0UH4T	DRUGNAME	GW-493838
D0UH4T	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2

D0F9QP	TTDDRUID	D0F9QP
D0F9QP	DRUGNAME	GW-559090
D0F9QP	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D0N2FI	TTDDRUID	D0N2FI
D0N2FI	DRUGNAME	GW-766994
D0N2FI	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0F3BY	TTDDRUID	D0F3BY
D0F3BY	DRUGNAME	GW842470X
D0F3BY	INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2

D01KKE	TTDDRUID	D01KKE
D01KKE	DRUGNAME	GW876008
D01KKE	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2

D0U0QI	TTDDRUID	D0U0QI
D0U0QI	DRUGNAME	GYKI-16084
D0U0QI	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2

D0GA1Q	TTDDRUID	D0GA1Q
D0GA1Q	DRUGNAME	H-345/52
D0GA1Q	INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2

D03GAY	TTDDRUID	D03GAY
D03GAY	DRUGNAME	H-409/22
D03GAY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D07VTD	TTDDRUID	D07VTD
D07VTD	DRUGNAME	HBV-MF59
D07VTD	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2

D05DDN	TTDDRUID	D05DDN
D05DDN	DRUGNAME	HCV-796
D05DDN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D0F7WQ	TTDDRUID	D0F7WQ
D0F7WQ	DRUGNAME	HE-2000
D0F7WQ	INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2

D0L3MZ	TTDDRUID	D0L3MZ
D0L3MZ	DRUGNAME	Heptazyme
D0L3MZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D05YLO	TTDDRUID	D05YLO
D05YLO	DRUGNAME	Her-2-Bi-armed ATC
D05YLO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D02TYL	TTDDRUID	D02TYL
D02TYL	DRUGNAME	HER-801
D02TYL	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2

D0S8YV	TTDDRUID	D0S8YV
D0S8YV	DRUGNAME	HGP-30
D0S8YV	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 2

D0O0VW	TTDDRUID	D0O0VW
D0O0VW	DRUGNAME	HGP-30W
D0O0VW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0L1DU	TTDDRUID	D0L1DU
D0L1DU	DRUGNAME	HIF-1 alpha gene therapy
D0L1DU	INDICATI	Occlusive arterial disease [ICD-11: BD4Z] Discontinued in Phase 2

D07QKM	TTDDRUID	D07QKM
D07QKM	DRUGNAME	HL-1225
D07QKM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0Y2IP	TTDDRUID	D0Y2IP
D0Y2IP	DRUGNAME	HLA-B7.75-84
D0Y2IP	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2

D00ZNP	TTDDRUID	D00ZNP
D00ZNP	DRUGNAME	HMR-1426
D00ZNP	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D08CSZ	TTDDRUID	D08CSZ
D08CSZ	DRUGNAME	HMR-3004
D08CSZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0C1TJ	TTDDRUID	D0C1TJ
D0C1TJ	DRUGNAME	HN-10200
D0C1TJ	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Discontinued in Phase 2

D09PTA	TTDDRUID	D09PTA
D09PTA	DRUGNAME	HP-290
D09PTA	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2

D0SX4K	TTDDRUID	D0SX4K
D0SX4K	DRUGNAME	HR325
D0SX4K	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0S3XA	TTDDRUID	D0S3XA
D0S3XA	DRUGNAME	HRG-214
D0S3XA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D08RZV	TTDDRUID	D08RZV
D08RZV	DRUGNAME	HSR-609
D08RZV	INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2

D0W7GH	TTDDRUID	D0W7GH
D0W7GH	DRUGNAME	IC-747
D0W7GH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D00EBH	TTDDRUID	D00EBH
D00EBH	DRUGNAME	ICI-170809
D00EBH	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0B9NA	TTDDRUID	D0B9NA
D0B9NA	DRUGNAME	ICI-192605
D0B9NA	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0F2HA	TTDDRUID	D0F2HA
D0F2HA	DRUGNAME	ICI-D-8731
D0F2HA	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0B2BQ	TTDDRUID	D0B2BQ
D0B2BQ	DRUGNAME	Icopezil maleate
D0B2BQ	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0PH0M	TTDDRUID	D0PH0M
D0PH0M	DRUGNAME	IDD-3
D0PH0M	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D04ZLG	TTDDRUID	D04ZLG
D04ZLG	DRUGNAME	IDEC-151
D04ZLG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0E2ED	TTDDRUID	D0E2ED
D0E2ED	DRUGNAME	IdioVax
D0E2ED	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 2

D0P3TT	TTDDRUID	D0P3TT
D0P3TT	DRUGNAME	IDR-90104
D0P3TT	INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 2

D08DWH	TTDDRUID	D08DWH
D08DWH	DRUGNAME	Idrapril
D08DWH	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D02IRL	TTDDRUID	D02IRL
D02IRL	DRUGNAME	IDX375
D02IRL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D07XMG	TTDDRUID	D07XMG
D07XMG	DRUGNAME	IFN-alpha 2B-XL
D07XMG	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2

D0J9KC	TTDDRUID	D0J9KC
D0J9KC	DRUGNAME	IGN-101
D0J9KC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2

D0D1YY	TTDDRUID	D0D1YY
D0D1YY	DRUGNAME	IGN-2098
D0D1YY	INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 2

D0K4UW	TTDDRUID	D0K4UW
D0K4UW	DRUGNAME	Imitrodast
D0K4UW	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0I9MG	TTDDRUID	D0I9MG
D0I9MG	DRUGNAME	IMM-308
D0I9MG	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2

D0E5MJ	TTDDRUID	D0E5MJ
D0E5MJ	DRUGNAME	INCB19602
D0E5MJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0HB4E	TTDDRUID	D0HB4E
D0HB4E	DRUGNAME	INCB47986
D0HB4E	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D09OHP	TTDDRUID	D09OHP
D09OHP	DRUGNAME	Indeglitazar
D09OHP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D01MFA	TTDDRUID	D01MFA
D01MFA	DRUGNAME	Infusible platelet membrane
D01MFA	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 2

D05AHK	TTDDRUID	D05AHK
D05AHK	DRUGNAME	INGN-234
D05AHK	INDICATI	Oral cancer [ICD-11: 2B6E] Discontinued in Phase 2

D0D2SX	TTDDRUID	D0D2SX
D0D2SX	DRUGNAME	INNO-101
D0D2SX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D0H4UJ	TTDDRUID	D0H4UJ
D0H4UJ	DRUGNAME	INOGATRAN
D0H4UJ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2

D0A9CV	TTDDRUID	D0A9CV
D0A9CV	DRUGNAME	INX-3280
D0A9CV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0I2MA	TTDDRUID	D0I2MA
D0I2MA	DRUGNAME	IO-21
D0I2MA	INDICATI	Ulcer [ICD-11: CA02-CB40] Discontinued in Phase 2

D0B4EV	TTDDRUID	D0B4EV
D0B4EV	DRUGNAME	IPENOXAZONE
D0B4EV	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D01IDQ	TTDDRUID	D01IDQ
D01IDQ	DRUGNAME	IPH-1101
D01IDQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 2

D08CCF	TTDDRUID	D08CCF
D08CCF	DRUGNAME	IPX-159
D08CCF	INDICATI	Restless legs syndrome [ICD-11: 7A80] Discontinued in Phase 2

D08UHN	TTDDRUID	D08UHN
D08UHN	DRUGNAME	Irtemazole
D08UHN	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2

D09WCE	TTDDRUID	D09WCE
D09WCE	DRUGNAME	IS-159
D09WCE	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D05VAA	TTDDRUID	D05VAA
D05VAA	DRUGNAME	Isbufylline
D05VAA	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0F7ZJ	TTDDRUID	D0F7ZJ
D0F7ZJ	DRUGNAME	Iseganan
D0F7ZJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0FX3P	TTDDRUID	D0FX3P
D0FX3P	DRUGNAME	ISIS 104838
D0FX3P	INDICATI	Crohn disease [ICD-11: DD70] Discontinued in Phase 2
D0FX3P	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0VB9J	TTDDRUID	D0VB9J
D0VB9J	DRUGNAME	ISIS 14803
D0VB9J	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D0NC9Y	TTDDRUID	D0NC9Y
D0NC9Y	DRUGNAME	ISIS 2105
D0NC9Y	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 2

D0D4JZ	TTDDRUID	D0D4JZ
D0D4JZ	DRUGNAME	Isoleucine thiazolidide DPP IV
D0D4JZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0AB4Q	TTDDRUID	D0AB4Q
D0AB4Q	DRUGNAME	Ispronicline
D0AB4Q	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
D0AB4Q	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D06HIO	TTDDRUID	D06HIO
D06HIO	DRUGNAME	Istaroxime
D06HIO	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D06NOR	TTDDRUID	D06NOR
D06NOR	DRUGNAME	IVL745
D06NOR	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0X2PQ	TTDDRUID	D0X2PQ
D0X2PQ	DRUGNAME	IX207-887
D0X2PQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D05VZJ	TTDDRUID	D05VZJ
D05VZJ	DRUGNAME	J-104132
D05VZJ	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2

D07HDC	TTDDRUID	D07HDC
D07HDC	DRUGNAME	JB-991 ophthalmological
D07HDC	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Discontinued in Phase 2

D08SNL	TTDDRUID	D08SNL
D08SNL	DRUGNAME	JTC-801
D08SNL	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0E6FO	TTDDRUID	D0E6FO
D0E6FO	DRUGNAME	JTE-607
D0E6FO	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D06WOJ	TTDDRUID	D06WOJ
D06WOJ	DRUGNAME	JTH-601
D06WOJ	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2

D00TQN	TTDDRUID	D00TQN
D00TQN	DRUGNAME	JTK-003
D00TQN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D03BHO	TTDDRUID	D03BHO
D03BHO	DRUGNAME	JTP-2942
D03BHO	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D01XGX	TTDDRUID	D01XGX
D01XGX	DRUGNAME	JTP-4819
D01XGX	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D06PYP	TTDDRUID	D06PYP
D06PYP	DRUGNAME	JTS-653
D06PYP	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2
D06PYP	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0N8JB	TTDDRUID	D0N8JB
D0N8JB	DRUGNAME	JTT-552
D0N8JB	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2

D08VMO	TTDDRUID	D08VMO
D08VMO	DRUGNAME	JTT-811
D08VMO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D08PIJ	TTDDRUID	D08PIJ
D08PIJ	DRUGNAME	JTV-506
D08PIJ	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0L4PY	TTDDRUID	D0L4PY
D0L4PY	DRUGNAME	KB-5492
D0L4PY	INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2

D07SCN	TTDDRUID	D07SCN
D07SCN	DRUGNAME	KC-11458
D07SCN	INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2

D0Y2HH	TTDDRUID	D0Y2HH
D0Y2HH	DRUGNAME	KC706
D0Y2HH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
D0Y2HH	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
D0Y2HH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
D0Y2HH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D03NDI	TTDDRUID	D03NDI
D03NDI	DRUGNAME	KCO-912
D03NDI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0P8MG	TTDDRUID	D0P8MG
D0P8MG	DRUGNAME	KDS-2000
D0P8MG	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Discontinued in Phase 2

D0LF5B	TTDDRUID	D0LF5B
D0LF5B	DRUGNAME	KN-38-7271
D0LF5B	INDICATI	Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 2

D03REC	TTDDRUID	D03REC
D03REC	DRUGNAME	KP-736
D03REC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0J2NB	TTDDRUID	D0J2NB
D0J2NB	DRUGNAME	KRH-594
D0J2NB	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0S6SU	TTDDRUID	D0S6SU
D0S6SU	DRUGNAME	KRN-2391
D0S6SU	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0B8JQ	TTDDRUID	D0B8JQ
D0B8JQ	DRUGNAME	KRP-101
D0B8JQ	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D07VSA	TTDDRUID	D07VSA
D07VSA	DRUGNAME	KRX-0403
D07VSA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D07BKL	TTDDRUID	D07BKL
D07BKL	DRUGNAME	KW-2170
D07BKL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D03ZVD	TTDDRUID	D03ZVD
D03ZVD	DRUGNAME	KW-4490
D03ZVD	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D04JFT	TTDDRUID	D04JFT
D04JFT	DRUGNAME	KW-5139
D04JFT	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0I3BB	TTDDRUID	D0I3BB
D0I3BB	DRUGNAME	KW-7158
D0I3BB	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D0Z1RQ	TTDDRUID	D0Z1RQ
D0Z1RQ	DRUGNAME	L-365260
D0Z1RQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0J5DL	TTDDRUID	D0J5DL
D0J5DL	DRUGNAME	L-4-OXALYSINE
D0J5DL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0E3NZ	TTDDRUID	D0E3NZ
D0E3NZ	DRUGNAME	L-696229
D0E3NZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0LL9K	TTDDRUID	D0LL9K
D0LL9K	DRUGNAME	L-771688
D0LL9K	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2

D0G0IZ	TTDDRUID	D0G0IZ
D0G0IZ	DRUGNAME	Labradimil
D0G0IZ	INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 2

D00FQP	TTDDRUID	D00FQP
D00FQP	DRUGNAME	LAGATIDE
D00FQP	INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2

D0A5MI	TTDDRUID	D0A5MI
D0A5MI	DRUGNAME	LANIQUIDAR
D0A5MI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0V2CN	TTDDRUID	D0V2CN
D0V2CN	DRUGNAME	LAS-37779
D0V2CN	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D0J3CC	TTDDRUID	D0J3CC
D0J3CC	DRUGNAME	Latranal
D0J3CC	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D08OQQ	TTDDRUID	D08OQQ
D08OQQ	DRUGNAME	Lavoltidine
D08OQQ	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2

D0G5TU	TTDDRUID	D0G5TU
D0G5TU	DRUGNAME	LESOPITRON DIHYDROCHLORIDE
D0G5TU	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D0B7HX	TTDDRUID	D0B7HX
D0B7HX	DRUGNAME	Levosemotiadil
D0B7HX	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0RF9T	TTDDRUID	D0RF9T
D0RF9T	DRUGNAME	Lexacalcitol
D0RF9T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08GRF	TTDDRUID	D08GRF
D08GRF	DRUGNAME	LG-1550
D08GRF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0I8GU	TTDDRUID	D0I8GU
D0I8GU	DRUGNAME	LI 401
D0I8GU	INDICATI	Gingivitis [ICD-11: DA0B] Discontinued in Phase 2

D0LK8O	TTDDRUID	D0LK8O
D0LK8O	DRUGNAME	LIFARIZINE HYDROCHLORIDE
D0LK8O	INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2

D0BC4Q	TTDDRUID	D0BC4Q
D0BC4Q	DRUGNAME	Lifibrol
D0BC4Q	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2

D0TM0C	TTDDRUID	D0TM0C
D0TM0C	DRUGNAME	LIMAZOCIC
D0TM0C	INDICATI	Liver disease [ICD-11: DB90-BD99] Discontinued in Phase 2

D0E8UV	TTDDRUID	D0E8UV
D0E8UV	DRUGNAME	Linetastine
D0E8UV	INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2

D01LPX	TTDDRUID	D01LPX
D01LPX	DRUGNAME	Linotroban
D01LPX	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D01ZXW	TTDDRUID	D01ZXW
D01ZXW	DRUGNAME	Lintitript
D01ZXW	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
D01ZXW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2

D01RNL	TTDDRUID	D01RNL
D01RNL	DRUGNAME	Lintuzumab
D01RNL	INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 2

D0O0DF	TTDDRUID	D0O0DF
D0O0DF	DRUGNAME	Lirequinil
D0O0DF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0O3IT	TTDDRUID	D0O3IT
D0O3IT	DRUGNAME	L-NMMA
D0O3IT	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D06HKB	TTDDRUID	D06HKB
D06HKB	DRUGNAME	Lodenosine
D06HKB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0B2WQ	TTDDRUID	D0B2WQ
D0B2WQ	DRUGNAME	Lomeguatrib
D0B2WQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0H6PN	TTDDRUID	D0H6PN
D0H6PN	DRUGNAME	LORECLEZOLE
D0H6PN	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2

D04ZLJ	TTDDRUID	D04ZLJ
D04ZLJ	DRUGNAME	LOSOXANTRONE
D04ZLJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D09TYS	TTDDRUID	D09TYS
D09TYS	DRUGNAME	Loviride
D09TYS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D00FBM	TTDDRUID	D00FBM
D00FBM	DRUGNAME	LP-2307
D00FBM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0NA8W	TTDDRUID	D0NA8W
D0NA8W	DRUGNAME	LTA
D0NA8W	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D06XRA	TTDDRUID	D06XRA
D06XRA	DRUGNAME	LU AA24493
D06XRA	INDICATI	Stroke [ICD-11: 8B20] Discontinued in Phase 2

D0T5MB	TTDDRUID	D0T5MB
D0T5MB	DRUGNAME	Lu-35138
D0T5MB	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2

D0T1MP	TTDDRUID	D0T1MP
D0T1MP	DRUGNAME	Lurosetron
D0T1MP	INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 2

D0Q7FC	TTDDRUID	D0Q7FC
D0Q7FC	DRUGNAME	Lurtotecan
D0Q7FC	INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 1
D0Q7FC	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2

D0U9JL	TTDDRUID	D0U9JL
D0U9JL	DRUGNAME	LY-223982
D0U9JL	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D01MYN	TTDDRUID	D01MYN
D01MYN	DRUGNAME	LY-2523199
D01MYN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D00GNK	TTDDRUID	D00GNK
D00GNK	DRUGNAME	LY293111
D00GNK	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2

D0Q9HT	TTDDRUID	D0Q9HT
D0Q9HT	DRUGNAME	LY-307161 SR
D0Q9HT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0U5CS	TTDDRUID	D0U5CS
D0U5CS	DRUGNAME	LY354740
D0U5CS	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0N5HN	TTDDRUID	D0N5HN
D0N5HN	DRUGNAME	M-100240
D0N5HN	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2

D0R8CE	TTDDRUID	D0R8CE
D0R8CE	DRUGNAME	M-114
D0R8CE	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D08MRV	TTDDRUID	D08MRV
D08MRV	DRUGNAME	Male erectile dysfunction therapy
D08MRV	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2

D0O6QW	TTDDRUID	D0O6QW
D0O6QW	DRUGNAME	Manifaxine
D0O6QW	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0U3DX	TTDDRUID	D0U3DX
D0U3DX	DRUGNAME	Mannose phosphate
D0U3DX	INDICATI	Lesion [ICD-11: 8A00-8C12] Discontinued in Phase 2

D06KRZ	TTDDRUID	D06KRZ
D06KRZ	DRUGNAME	MC-4232
D06KRZ	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0G0CX	TTDDRUID	D0G0CX
D0G0CX	DRUGNAME	MCC-257
D0G0CX	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0S5FQ	TTDDRUID	D0S5FQ
D0S5FQ	DRUGNAME	MCPP
D0S5FQ	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D05HZI	TTDDRUID	D05HZI
D05HZI	DRUGNAME	MDL 101,731
D05HZI	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2

D03ZHE	TTDDRUID	D03ZHE
D03ZHE	DRUGNAME	MDX-070
D03ZHE	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2

D0R4GM	TTDDRUID	D0R4GM
D0R4GM	DRUGNAME	MDX-33
D0R4GM	INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 2

D0WL7V	TTDDRUID	D0WL7V
D0WL7V	DRUGNAME	ME-3738
D0WL7V	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2

D0C1EO	TTDDRUID	D0C1EO
D0C1EO	DRUGNAME	Melanoma vaccine (ALVAC)
D0C1EO	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D07FDV	TTDDRUID	D07FDV
D07FDV	DRUGNAME	Melaxin
D07FDV	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D02YBP	TTDDRUID	D02YBP
D02YBP	DRUGNAME	Mequitamium iodide
D02YBP	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D00VZF	TTDDRUID	D00VZF
D00VZF	DRUGNAME	Merbarone
D00VZF	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2

D02JUM	TTDDRUID	D02JUM
D02JUM	DRUGNAME	METIAPRIL
D02JUM	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2

D0F9ND	TTDDRUID	D0F9ND
D0F9ND	DRUGNAME	MGAWN-1
D0F9ND	INDICATI	West nile virus infection [ICD-11: 1D46] Discontinued in Phase 2

D05DON	TTDDRUID	D05DON
D05DON	DRUGNAME	MILACAINIDE TARTRATE
D05DON	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0DL2S	TTDDRUID	D0DL2S
D0DL2S	DRUGNAME	MILFASARTAN
D0DL2S	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D02KMG	TTDDRUID	D02KMG
D02KMG	DRUGNAME	Milveterol
D02KMG	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D04MOF	TTDDRUID	D04MOF
D04MOF	DRUGNAME	Milveterol+Fluticasone
D04MOF	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D01KZC	TTDDRUID	D01KZC
D01KZC	DRUGNAME	Minopafant
D01KZC	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D0O0AH	TTDDRUID	D0O0AH
D0O0AH	DRUGNAME	MIRFENTANIL HYDROCHLORIDE
D0O0AH	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D06SNS	TTDDRUID	D06SNS
D06SNS	DRUGNAME	Mirostipen
D06SNS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D01ORM	TTDDRUID	D01ORM
D01ORM	DRUGNAME	Mitonafide
D01ORM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D05UZO	TTDDRUID	D05UZO
D05UZO	DRUGNAME	MIVOBULIN ISETHIONATE
D05UZO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D05KQE	TTDDRUID	D05KQE
D05KQE	DRUGNAME	MK-287
D05KQE	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D0C1SI	TTDDRUID	D0C1SI
D0C1SI	DRUGNAME	MK-386
D0C1SI	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2

D02NGR	TTDDRUID	D02NGR
D02NGR	DRUGNAME	MK-499
D02NGR	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0M0QX	TTDDRUID	D0M0QX
D0M0QX	DRUGNAME	MK-591
D0M0QX	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0W5BY	TTDDRUID	D0W5BY
D0W5BY	DRUGNAME	MK-767 (KRP-297)
D0W5BY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0N6PV	TTDDRUID	D0N6PV
D0N6PV	DRUGNAME	MK-852
D0N6PV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0K2ER	TTDDRUID	D0K2ER
D0K2ER	DRUGNAME	MK-886
D0K2ER	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0J9AK	TTDDRUID	D0J9AK
D0J9AK	DRUGNAME	MK-944a
D0J9AK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0KF6X	TTDDRUID	D0KF6X
D0KF6X	DRUGNAME	MLN3897
D0KF6X	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0P1TZ	TTDDRUID	D0P1TZ
D0P1TZ	DRUGNAME	MLN-977
D0P1TZ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0E4FG	TTDDRUID	D0E4FG
D0E4FG	DRUGNAME	MOZENAVIR MESILATE
D0E4FG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0H0ZU	TTDDRUID	D0H0ZU
D0H0ZU	DRUGNAME	MP-435
D0H0ZU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0X9QI	TTDDRUID	D0X9QI
D0X9QI	DRUGNAME	MRPE allergic rhinitis (oral), Curalogic
D0X9QI	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D04ZOZ	TTDDRUID	D04ZOZ
D04ZOZ	DRUGNAME	MS-322
D04ZOZ	INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 2

D06PTT	TTDDRUID	D06PTT
D06PTT	DRUGNAME	MS-424
D06PTT	INDICATI	Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 2

D0L8CJ	TTDDRUID	D0L8CJ
D0L8CJ	DRUGNAME	MV-9411
D0L8CJ	INDICATI	Keratosis [ICD-11: ED56] Discontinued in Phase 2

D0NO8S	TTDDRUID	D0NO8S
D0NO8S	DRUGNAME	MVA3000
D0NO8S	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D0E9IT	TTDDRUID	D0E9IT
D0E9IT	DRUGNAME	N,N`-diacetyl-L-cystine
D0E9IT	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2

D0DT2P	TTDDRUID	D0DT2P
D0DT2P	DRUGNAME	Nafagrel
D0DT2P	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0T1ZJ	TTDDRUID	D0T1ZJ
D0T1ZJ	DRUGNAME	Naked DNA (B-cell lymphoma) Vical/Stanford
D0T1ZJ	INDICATI	B-cell lymphoma [ICD-11: 2A86] Discontinued in Phase 2

D06KOL	TTDDRUID	D06KOL
D06KOL	DRUGNAME	Napitane mesilate
D06KOL	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0Q3WN	TTDDRUID	D0Q3WN
D0Q3WN	DRUGNAME	Napsagatran
D0Q3WN	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2

D08HGY	TTDDRUID	D08HGY
D08HGY	DRUGNAME	Naronapride
D08HGY	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2

D0TH1Z	TTDDRUID	D0TH1Z
D0TH1Z	DRUGNAME	Naxagolide
D0TH1Z	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2

D0H2JQ	TTDDRUID	D0H2JQ
D0H2JQ	DRUGNAME	NB-506
D0H2JQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0B3MX	TTDDRUID	D0B3MX
D0B3MX	DRUGNAME	NBI-6024
D0B3MX	INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2

D0W6AB	TTDDRUID	D0W6AB
D0W6AB	DRUGNAME	NC-100150
D0W6AB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D03WPI	TTDDRUID	D03WPI
D03WPI	DRUGNAME	NC-190
D03WPI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D03CFJ	TTDDRUID	D03CFJ
D03CFJ	DRUGNAME	NCX-701
D03CFJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0BB9M	TTDDRUID	D0BB9M
D0BB9M	DRUGNAME	NE-0080
D0BB9M	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 2

D0N7DW	TTDDRUID	D0N7DW
D0N7DW	DRUGNAME	Needle-free influenza vaccine patch
D0N7DW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 2

D07GLF	TTDDRUID	D07GLF
D07GLF	DRUGNAME	Nemifitide
D07GLF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0S9KM	TTDDRUID	D0S9KM
D0S9KM	DRUGNAME	NGD 91-3
D0S9KM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0Z0PB	TTDDRUID	D0Z0PB
D0Z0PB	DRUGNAME	NGD-8243
D0Z0PB	INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Discontinued in Phase 2

D0FN6D	TTDDRUID	D0FN6D
D0FN6D	DRUGNAME	NGD-97-1
D0FN6D	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D08MYL	TTDDRUID	D08MYL
D08MYL	DRUGNAME	NIM-811
D08MYL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08LVF	TTDDRUID	D08LVF
D08LVF	DRUGNAME	Nitecapone
D08LVF	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D03ZAT	TTDDRUID	D03ZAT
D03ZAT	DRUGNAME	Nitric oxide topical
D03ZAT	INDICATI	Tinea pedis [ICD-11: 1F28.2] Discontinued in Phase 2

D0I3EI	TTDDRUID	D0I3EI
D0I3EI	DRUGNAME	NK-1001
D0I3EI	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 2

D05ZQV	TTDDRUID	D05ZQV
D05ZQV	DRUGNAME	NK-611
D05ZQV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0U9LL	TTDDRUID	D0U9LL
D0U9LL	DRUGNAME	NKS-01
D0U9LL	INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 2

D0VT0T	TTDDRUID	D0VT0T
D0VT0T	DRUGNAME	NLX-P101
D0VT0T	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2

D03RCP	TTDDRUID	D03RCP
D03RCP	DRUGNAME	NM-135
D03RCP	INDICATI	Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2

D0IU2F	TTDDRUID	D0IU2F
D0IU2F	DRUGNAME	NMED-160
D0IU2F	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0ZI0K	TTDDRUID	D0ZI0K
D0ZI0K	DRUGNAME	NMI-870
D0ZI0K	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Discontinued in Phase 2

D05ILZ	TTDDRUID	D05ILZ
D05ILZ	DRUGNAME	NN8209
D05ILZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0UT3F	TTDDRUID	D0UT3F
D0UT3F	DRUGNAME	Nolpitantium besilate
D0UT3F	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0K1SZ	TTDDRUID	D0K1SZ
D0K1SZ	DRUGNAME	Norcisapride
D0K1SZ	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2

D0B3DX	TTDDRUID	D0B3DX
D0B3DX	DRUGNAME	Norelin
D0B3DX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2

D0L7MA	TTDDRUID	D0L7MA
D0L7MA	DRUGNAME	NP-1998
D0L7MA	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2

D01AXT	TTDDRUID	D01AXT
D01AXT	DRUGNAME	NP-50301
D01AXT	INDICATI	Eye disorder [ICD-11: 9A01-9A0Z] Discontinued in Phase 2

D0E3EK	TTDDRUID	D0E3EK
D0E3EK	DRUGNAME	NP-619
D0E3EK	INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 2

D03ZBM	TTDDRUID	D03ZBM
D03ZBM	DRUGNAME	NPC-567
D03ZBM	INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2

D00DBH	TTDDRUID	D00DBH
D00DBH	DRUGNAME	NPS 1776
D00DBH	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2

D0G1RH	TTDDRUID	D0G1RH
D0G1RH	DRUGNAME	NPS-2143
D0G1RH	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D08LZI	TTDDRUID	D08LZI
D08LZI	DRUGNAME	NS-220
D08LZI	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0M9LB	TTDDRUID	D0M9LB
D0M9LB	DRUGNAME	NS-2389
D0M9LB	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D02ZSU	TTDDRUID	D02ZSU
D02ZSU	DRUGNAME	NS-49
D02ZSU	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D0LC2B	TTDDRUID	D0LC2B
D0LC2B	DRUGNAME	NSP-805
D0LC2B	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2

D00YUB	TTDDRUID	D00YUB
D00YUB	DRUGNAME	NT-3
D00YUB	INDICATI	Constipation [ICD-11: DD91.1] Discontinued in Phase 2

D0R4DN	TTDDRUID	D0R4DN
D0R4DN	DRUGNAME	NTC-121
D0R4DN	INDICATI	Glioma [ICD-11: 2A00.0] Discontinued in Phase 2

D0F2IC	TTDDRUID	D0F2IC
D0F2IC	DRUGNAME	NTx-488
D0F2IC	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2

D00FJC	TTDDRUID	D00FJC
D00FJC	DRUGNAME	Nuvanil
D00FJC	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D00FYF	TTDDRUID	D00FYF
D00FYF	DRUGNAME	NVP-DPP728
D00FYF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0Y9NE	TTDDRUID	D0Y9NE
D0Y9NE	DRUGNAME	NWP-08
D0Y9NE	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Discontinued in Phase 2

D02ZEM	TTDDRUID	D02ZEM
D02ZEM	DRUGNAME	OBERADILOL MONOETHYL MALEATE
D02ZEM	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D09URT	TTDDRUID	D09URT
D09URT	DRUGNAME	OCO-1112
D09URT	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0O6WZ	TTDDRUID	D0O6WZ
D0O6WZ	DRUGNAME	OcuNex
D0O6WZ	INDICATI	Wound healing [ICD-11: EL8Y] Discontinued in Phase 2

D0C2CH	TTDDRUID	D0C2CH
D0C2CH	DRUGNAME	OGT-719
D0C2CH	INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 2

D00LXD	TTDDRUID	D00LXD
D00LXD	DRUGNAME	Omega interferon
D00LXD	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D03MWM	TTDDRUID	D03MWM
D03MWM	DRUGNAME	Oncolysin B
D03MWM	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Discontinued in Phase 2

D0H0VW	TTDDRUID	D0H0VW
D0H0VW	DRUGNAME	Oncolysin S
D0H0VW	INDICATI	Nervous system cancer [ICD-11: 2A00] Discontinued in Phase 2

D00ZGE	TTDDRUID	D00ZGE
D00ZGE	DRUGNAME	Oncopurge
D00ZGE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D06PKS	TTDDRUID	D06PKS
D06PKS	DRUGNAME	ONO-4007
D06PKS	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2

D0Z0OT	TTDDRUID	D0Z0OT
D0Z0OT	DRUGNAME	ONO-4057
D0Z0OT	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D0O4XW	TTDDRUID	D0O4XW
D0O4XW	DRUGNAME	ONO-4819
D0O4XW	INDICATI	Fracture [ICD-11: ND56] Discontinued in Phase 2

D00ZUU	TTDDRUID	D00ZUU
D00ZUU	DRUGNAME	ONO-5334
D00ZUU	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D0X3ER	TTDDRUID	D0X3ER
D0X3ER	DRUGNAME	OP-145
D0X3ER	INDICATI	Bronchitis [ICD-11: CA20] Discontinued in Phase 2

D0G2GR	TTDDRUID	D0G2GR
D0G2GR	DRUGNAME	OP-2507
D0G2GR	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0V3CM	TTDDRUID	D0V3CM
D0V3CM	DRUGNAME	Opaviraline
D0V3CM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D08ORO	TTDDRUID	D08ORO
D08ORO	DRUGNAME	OPC-21268
D08ORO	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D06WJI	TTDDRUID	D06WJI
D06WJI	DRUGNAME	OPC-28326
D06WJI	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2

D06PQR	TTDDRUID	D06PQR
D06PQR	DRUGNAME	OPC-8490
D06PQR	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D05RBO	TTDDRUID	D05RBO
D05RBO	DRUGNAME	OPM-3023 oral
D05RBO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2

D0F8EU	TTDDRUID	D0F8EU
D0F8EU	DRUGNAME	Oralex
D0F8EU	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 2

D0C5KG	TTDDRUID	D0C5KG
D0C5KG	DRUGNAME	ORG-33628
D0C5KG	INDICATI	Contraception [ICD-11: QA21] Discontinued in Phase 2

D02GMT	TTDDRUID	D02GMT
D02GMT	DRUGNAME	Org-7797
D02GMT	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0C2HR	TTDDRUID	D0C2HR
D0C2HR	DRUGNAME	ORG-9273
D0C2HR	INDICATI	Paralysis [ICD-11: 8B60] Discontinued in Phase 2

D04OCC	TTDDRUID	D04OCC
D04OCC	DRUGNAME	Org-9616
D04OCC	INDICATI	Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2

D0S8DB	TTDDRUID	D0S8DB
D0S8DB	DRUGNAME	Org-9731
D0S8DB	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2

D0A2OW	TTDDRUID	D0A2OW
D0A2OW	DRUGNAME	Otenzepad
D0A2OW	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2

D02JNX	TTDDRUID	D02JNX
D02JNX	DRUGNAME	OxycoDex
D02JNX	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D02XBE	TTDDRUID	D02XBE
D02XBE	DRUGNAME	Oxygent
D02XBE	INDICATI	Respiratory failure [ICD-11: CB41] Discontinued in Phase 2

D00LWF	TTDDRUID	D00LWF
D00LWF	DRUGNAME	P-1075
D00LWF	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0P0RP	TTDDRUID	D0P0RP
D0P0RP	DRUGNAME	P113D
D0P0RP	INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2

D0R4ML	TTDDRUID	D0R4ML
D0R4ML	DRUGNAME	P1A
D0R4ML	INDICATI	Toxicity [ICD-11: N.A.] Discontinued in Phase 2

D01LQC	TTDDRUID	D01LQC
D01LQC	DRUGNAME	P45
D01LQC	INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 2

D09ZYW	TTDDRUID	D09ZYW
D09ZYW	DRUGNAME	P53
D09ZYW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0Q1HG	TTDDRUID	D0Q1HG
D0Q1HG	DRUGNAME	PA-1806
D0Q1HG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D08FGX	TTDDRUID	D08FGX
D08FGX	DRUGNAME	PALOSURAN
D08FGX	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2

D0SK2J	TTDDRUID	D0SK2J
D0SK2J	DRUGNAME	Palux
D0SK2J	INDICATI	Intermittent claudication [ICD-11: BD40.00] Discontinued in Phase 2

D04WCI	TTDDRUID	D04WCI
D04WCI	DRUGNAME	PAMAPIMOD
D04WCI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D00EZE	TTDDRUID	D00EZE
D00EZE	DRUGNAME	Panamesine
D00EZE	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2

D04HVB	TTDDRUID	D04HVB
D04HVB	DRUGNAME	Panomifene
D04HVB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0C9EE	TTDDRUID	D0C9EE
D0C9EE	DRUGNAME	PAZELLIPTINE TRIHYDROCHLORIDE
D0C9EE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0XJ0S	TTDDRUID	D0XJ0S
D0XJ0S	DRUGNAME	PD-134308
D0XJ0S	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0T4UL	TTDDRUID	D0T4UL
D0T4UL	DRUGNAME	PD-348292
D0T4UL	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D05TGV	TTDDRUID	D05TGV
D05TGV	DRUGNAME	PEG-Infergen
D05TGV	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2

D0P1LR	TTDDRUID	D0P1LR
D0P1LR	DRUGNAME	Pemedolac
D0P1LR	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0S7EQ	TTDDRUID	D0S7EQ
D0S7EQ	DRUGNAME	PEN-203
D0S7EQ	INDICATI	Gynecological disease [ICD-11: GA6Z] Discontinued in Phase 2

D0A9CY	TTDDRUID	D0A9CY
D0A9CY	DRUGNAME	Pentisomide
D0A9CY	INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2

D0S2HO	TTDDRUID	D0S2HO
D0S2HO	DRUGNAME	Perillyl alcohol
D0S2HO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D02VUX	TTDDRUID	D02VUX
D02VUX	DRUGNAME	PF-217830
D02VUX	INDICATI	Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 2
D02VUX	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D0J0KX	TTDDRUID	D0J0KX
D0J0KX	DRUGNAME	PF-275366
D0J0KX	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2

D0XJ4G	TTDDRUID	D0XJ4G
D0XJ4G	DRUGNAME	PF-3049423
D0XJ4G	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Discontinued in Phase 2

D00AJI	TTDDRUID	D00AJI
D00AJI	DRUGNAME	PF-4480682
D00AJI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2

D0AQ3H	TTDDRUID	D0AQ3H
D0AQ3H	DRUGNAME	PF-610355
D0AQ3H	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D08ZKN	TTDDRUID	D08ZKN
D08ZKN	DRUGNAME	PG-530742
D08ZKN	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2
D08ZKN	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2

D0S8VG	TTDDRUID	D0S8VG
D0S8VG	DRUGNAME	PGL-3001
D0S8VG	INDICATI	Female infertility [ICD-11: GA31.Z] Discontinued in Phase 2

D09JVV	TTDDRUID	D09JVV
D09JVV	DRUGNAME	Physostigmine
D09JVV	INDICATI	Xerostomia [ICD-11: DA02.1] Discontinued in Phase 2

D08UDF	TTDDRUID	D08UDF
D08UDF	DRUGNAME	PIBAXIZINE
D08UDF	INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 2

D0J0PR	TTDDRUID	D0J0PR
D0J0PR	DRUGNAME	PIBROZELESIN HYDROCHLORIDE
D0J0PR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0GP4R	TTDDRUID	D0GP4R
D0GP4R	DRUGNAME	Picumeterol
D0GP4R	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D02GVH	TTDDRUID	D02GVH
D02GVH	DRUGNAME	PIRODAVIR
D02GVH	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D07GFF	TTDDRUID	D07GFF
D07GFF	DRUGNAME	PKI166
D07GFF	INDICATI	Esophageal cancer [ICD-11: 2B70] Discontinued in Phase 2

D03SWH	TTDDRUID	D03SWH
D03SWH	DRUGNAME	PNU-142633
D03SWH	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D0M5XE	TTDDRUID	D0M5XE
D0M5XE	DRUGNAME	PP-9706642
D0M5XE	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 2

D0RL4M	TTDDRUID	D0RL4M
D0RL4M	DRUGNAME	Pranazepide
D0RL4M	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Discontinued in Phase 2

D0Z7MJ	TTDDRUID	D0Z7MJ
D0Z7MJ	DRUGNAME	Prednisolone sodium metazoate
D0Z7MJ	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D05ZQC	TTDDRUID	D05ZQC
D05ZQC	DRUGNAME	PRISOTINOL
D05ZQC	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0ZR3N	TTDDRUID	D0ZR3N
D0ZR3N	DRUGNAME	Pro 542
D0ZR3N	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D09FEN	TTDDRUID	D09FEN
D09FEN	DRUGNAME	PRO-515
D09FEN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D02RHV	TTDDRUID	D02RHV
D02RHV	DRUGNAME	PROXODOLOL
D02RHV	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2

D03ACT	TTDDRUID	D03ACT
D03ACT	DRUGNAME	PRS-211375 iv
D03ACT	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D08AWI	TTDDRUID	D08AWI
D08AWI	DRUGNAME	PRX-00023
D08AWI	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D06GCP	TTDDRUID	D06GCP
D06GCP	DRUGNAME	PSD-506
D06GCP	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2

D0X4IV	TTDDRUID	D0X4IV
D0X4IV	DRUGNAME	PSD-508
D0X4IV	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Discontinued in Phase 2

D0R6RB	TTDDRUID	D0R6RB
D0R6RB	DRUGNAME	PSD-597
D0R6RB	INDICATI	Interstitial cystitis [ICD-11: GC00.3] Discontinued in Phase 2

D0P7WJ	TTDDRUID	D0P7WJ
D0P7WJ	DRUGNAME	PSN357
D0P7WJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0FD0B	TTDDRUID	D0FD0B
D0FD0B	DRUGNAME	PSN-9301
D0FD0B	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D09XVQ	TTDDRUID	D09XVQ
D09XVQ	DRUGNAME	PT-14
D09XVQ	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2

D0FP1A	TTDDRUID	D0FP1A
D0FP1A	DRUGNAME	PTH 1-34
D0FP1A	INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2

D01YLF	TTDDRUID	D01YLF
D01YLF	DRUGNAME	PTI-701
D01YLF	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0V7IS	TTDDRUID	D0V7IS
D0V7IS	DRUGNAME	Pumafentrine
D0V7IS	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D00FMV	TTDDRUID	D00FMV
D00FMV	DRUGNAME	Putrescine
D00FMV	INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Discontinued in Phase 2

D05MEL	TTDDRUID	D05MEL
D05MEL	DRUGNAME	PV-705
D05MEL	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2

D0N7ML	TTDDRUID	D0N7ML
D0N7ML	DRUGNAME	PV-707
D0N7ML	INDICATI	Skin burns [ICD-11: ME65.0] Discontinued in Phase 2

D0B1NA	TTDDRUID	D0B1NA
D0B1NA	DRUGNAME	PVAC
D0B1NA	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D0WL0G	TTDDRUID	D0WL0G
D0WL0G	DRUGNAME	PYN-17
D0WL0G	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D0W9PG	TTDDRUID	D0W9PG
D0W9PG	DRUGNAME	Pyrazinoylguanidine
D0W9PG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0S2LQ	TTDDRUID	D0S2LQ
D0S2LQ	DRUGNAME	PYY3-36
D0S2LQ	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D0K0FV	TTDDRUID	D0K0FV
D0K0FV	DRUGNAME	QR-334
D0K0FV	INDICATI	Salivary gland dysfunction [ICD-11: 5B0Z] Discontinued in Phase 2

D0E4EZ	TTDDRUID	D0E4EZ
D0E4EZ	DRUGNAME	R-1438
D0E4EZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0Y3RY	TTDDRUID	D0Y3RY
D0Y3RY	DRUGNAME	R-1578
D0Y3RY	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D0Q1KP	TTDDRUID	D0Q1KP
D0Q1KP	DRUGNAME	R-18893
D0Q1KP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D08DBE	TTDDRUID	D08DBE
D08DBE	DRUGNAME	R-343
D08DBE	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0O7DZ	TTDDRUID	D0O7DZ
D0O7DZ	DRUGNAME	R-61837
D0O7DZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D0G5GJ	TTDDRUID	D0G5GJ
D0G5GJ	DRUGNAME	R-68151
D0G5GJ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D06QOF	TTDDRUID	D06QOF
D06QOF	DRUGNAME	R7128
D06QOF	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D0N7SG	TTDDRUID	D0N7SG
D0N7SG	DRUGNAME	R-84760
D0N7SG	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0K1LO	TTDDRUID	D0K1LO
D0K1LO	DRUGNAME	R-873
D0K1LO	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2

D05UMD	TTDDRUID	D05UMD
D05UMD	DRUGNAME	R-87366
D05UMD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0A5RD	TTDDRUID	D0A5RD
D0A5RD	DRUGNAME	Radafaxine
D0A5RD	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D01SWK	TTDDRUID	D01SWK
D01SWK	DRUGNAME	Rafabegron
D01SWK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D02GSA	TTDDRUID	D02GSA
D02GSA	DRUGNAME	RBx10558
D02GSA	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0S1PM	TTDDRUID	D0S1PM
D0S1PM	DRUGNAME	RBx-2258
D0S1PM	INDICATI	Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2

D0T3ZL	TTDDRUID	D0T3ZL
D0T3ZL	DRUGNAME	RC-552
D0T3ZL	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2

D04HXS	TTDDRUID	D04HXS
D04HXS	DRUGNAME	REC-15/3079
D04HXS	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D0P9FT	TTDDRUID	D0P9FT
D0P9FT	DRUGNAME	REC-15-2739
D0P9FT	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2

D0ZW5Y	TTDDRUID	D0ZW5Y
D0ZW5Y	DRUGNAME	Recombinant pox virus vaccine
D0ZW5Y	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D02ZKL	TTDDRUID	D02ZKL
D02ZKL	DRUGNAME	Reglixane
D02ZKL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0T5PH	TTDDRUID	D0T5PH
D0T5PH	DRUGNAME	Relacatib
D0T5PH	INDICATI	Bone metastases [ICD-11: 2D50] Discontinued in Phase 2
D0T5PH	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1

D09TEI	TTDDRUID	D09TEI
D09TEI	DRUGNAME	ReN-1869
D09TEI	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0P4RA	TTDDRUID	D0P4RA
D0P4RA	DRUGNAME	Repifermin
D0P4RA	INDICATI	Oral mucositis [ICD-11: DA01.11] Discontinued in Phase 2

D08LQD	TTDDRUID	D08LQD
D08LQD	DRUGNAME	RESEQUINIL
D08LQD	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2

D0C8KF	TTDDRUID	D0C8KF
D0C8KF	DRUGNAME	Resiquimod
D0C8KF	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1/2

D0EG5A	TTDDRUID	D0EG5A
D0EG5A	DRUGNAME	Retaspimycin
D0EG5A	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2

D05MWY	TTDDRUID	D05MWY
D05MWY	DRUGNAME	RF-1051
D05MWY	INDICATI	Genetic disease [ICD-11: 8E02] Discontinued in Phase 2

D03AUN	TTDDRUID	D03AUN
D03AUN	DRUGNAME	RG1512
D03AUN	INDICATI	Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 2

D08JNE	TTDDRUID	D08JNE
D08JNE	DRUGNAME	RG1578
D08JNE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0E2CQ	TTDDRUID	D0E2CQ
D0E2CQ	DRUGNAME	RG7160
D0E2CQ	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Discontinued in Phase 2

D01AFG	TTDDRUID	D01AFG
D01AFG	DRUGNAME	RG7414
D01AFG	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
D01AFG	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2

D0J9UB	TTDDRUID	D0J9UB
D0J9UB	DRUGNAME	RG7593
D0J9UB	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Discontinued in Phase 2

D0M4RX	TTDDRUID	D0M4RX
D0M4RX	DRUGNAME	RG7685
D0M4RX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D00YFP	TTDDRUID	D00YFP
D00YFP	DRUGNAME	RG7697
D00YFP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0C2KV	TTDDRUID	D0C2KV
D0C2KV	DRUGNAME	RGLP-1
D0C2KV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D01HBE	TTDDRUID	D01HBE
D01HBE	DRUGNAME	RHIZOXIN
D01HBE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0O1YF	TTDDRUID	D0O1YF
D0O1YF	DRUGNAME	RhLT28-171
D0O1YF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D07AOO	TTDDRUID	D07AOO
D07AOO	DRUGNAME	Rilotumumab
D07AOO	INDICATI	Grade IV malignant glioma [ICD-11: 2A00.0] Discontinued in Phase 2

D06TZT	TTDDRUID	D06TZT
D06TZT	DRUGNAME	RIPISARTAN
D06TZT	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D06QHT	TTDDRUID	D06QHT
D06QHT	DRUGNAME	Risotilide
D06QHT	INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2

D0XE5L	TTDDRUID	D0XE5L
D0XE5L	DRUGNAME	Rispenzepine
D0XE5L	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D03UID	TTDDRUID	D03UID
D03UID	DRUGNAME	RJR-2403
D03UID	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0L8GO	TTDDRUID	D0L8GO
D0L8GO	DRUGNAME	RK-28
D0L8GO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0Z1VS	TTDDRUID	D0Z1VS
D0Z1VS	DRUGNAME	RN6G
D0Z1VS	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Discontinued in Phase 2

D0K3LX	TTDDRUID	D0K3LX
D0K3LX	DRUGNAME	RNAPc2
D0K3LX	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2

D0K4ED	TTDDRUID	D0K4ED
D0K4ED	DRUGNAME	Ro-23-9424
D0K4ED	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0S4JY	TTDDRUID	D0S4JY
D0S4JY	DRUGNAME	Ro-24-4736
D0S4JY	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D0I4GI	TTDDRUID	D0I4GI
D0I4GI	DRUGNAME	RO-26-9228
D0I4GI	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D07OMK	TTDDRUID	D07OMK
D07OMK	DRUGNAME	RO-48-6791
D07OMK	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D08JAP	TTDDRUID	D08JAP
D08JAP	DRUGNAME	Robalzotan
D08JAP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0X9RN	TTDDRUID	D0X9RN
D0X9RN	DRUGNAME	Robatumumab
D0X9RN	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
D0X9RN	INDICATI	Osteosarcoma [ICD-11: 2B51] Discontinued in Phase 2
D0X9RN	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Discontinued in Phase 2

D0G9FP	TTDDRUID	D0G9FP
D0G9FP	DRUGNAME	Rofleponide
D0G9FP	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D0V7GC	TTDDRUID	D0V7GC
D0V7GC	DRUGNAME	Rolafagrel
D0V7GC	INDICATI	Nephritis [ICD-11: GB40] Discontinued in Phase 2

D0K1DC	TTDDRUID	D0K1DC
D0K1DC	DRUGNAME	Romergoline
D0K1DC	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D07XPT	TTDDRUID	D07XPT
D07XPT	DRUGNAME	Ronacaleret
D07XPT	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D06UPS	TTDDRUID	D06UPS
D06UPS	DRUGNAME	Rozrolimupab
D06UPS	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2

D07DBS	TTDDRUID	D07DBS
D07DBS	DRUGNAME	RP-64477
D07DBS	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D09UGP	TTDDRUID	D09UGP
D09UGP	DRUGNAME	RPR-106541
D09UGP	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0H1HP	TTDDRUID	D0H1HP
D0H1HP	DRUGNAME	RPR-109891
D0H1HP	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D02HLL	TTDDRUID	D02HLL
D02HLL	DRUGNAME	RQ-00317076
D02HLL	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D03BOZ	TTDDRUID	D03BOZ
D03BOZ	DRUGNAME	RS-130830
D03BOZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D06QOJ	TTDDRUID	D06QOJ
D06QOJ	DRUGNAME	RS-8359
D06QOJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D08XQA	TTDDRUID	D08XQA
D08XQA	DRUGNAME	RSD-921
D08XQA	INDICATI	Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2

D0B2OC	TTDDRUID	D0B2OC
D0B2OC	DRUGNAME	R-sibutramine metabolite
D0B2OC	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2
D0B2OC	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2

D01FEC	TTDDRUID	D01FEC
D01FEC	DRUGNAME	Rusalatide acetate
D01FEC	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2

D01JOJ	TTDDRUID	D01JOJ
D01JOJ	DRUGNAME	RX-77368
D01JOJ	INDICATI	Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 2

D0B2HE	TTDDRUID	D0B2HE
D0B2HE	DRUGNAME	RypVax
D0B2HE	INDICATI	Yersinia infection [ICD-11: 1B93] Discontinued in Phase 2

D0K4WT	TTDDRUID	D0K4WT
D0K4WT	DRUGNAME	S-1033
D0K4WT	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2

D0KX9Z	TTDDRUID	D0KX9Z
D0KX9Z	DRUGNAME	S-12363
D0KX9Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D01VWR	TTDDRUID	D01VWR
D01VWR	DRUGNAME	S-15261
D01VWR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D07YCR	TTDDRUID	D07YCR
D07YCR	DRUGNAME	S-16020-2
D07YCR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0M0HJ	TTDDRUID	D0M0HJ
D0M0HJ	DRUGNAME	S-18986
D0M0HJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D04DUJ	TTDDRUID	D04DUJ
D04DUJ	DRUGNAME	S-2474
D04DUJ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0G0LH	TTDDRUID	D0G0LH
D0G0LH	DRUGNAME	S-312-d
D0G0LH	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2

D0K0VH	TTDDRUID	D0K0VH
D0K0VH	DRUGNAME	S-5751
D0K0VH	INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2

D00TNC	TTDDRUID	D00TNC
D00TNC	DRUGNAME	S-8510
D00TNC	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0CO2M	TTDDRUID	D0CO2M
D0CO2M	DRUGNAME	S-9788
D0CO2M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0F3FB	TTDDRUID	D0F3FB
D0F3FB	DRUGNAME	S-9977
D0F3FB	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0X7NT	TTDDRUID	D0X7NT
D0X7NT	DRUGNAME	SAF-312
D0X7NT	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D00DBU	TTDDRUID	D00DBU
D00DBU	DRUGNAME	SA-IGIV
D00DBU	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 2

D0T5NI	TTDDRUID	D0T5NI
D0T5NI	DRUGNAME	Saperconazole
D0T5NI	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 2

D03JAO	TTDDRUID	D03JAO
D03JAO	DRUGNAME	Saridegib
D03JAO	INDICATI	Chondrosarcoma [ICD-11: 2B50] Discontinued in Phase 2

D0N8NC	TTDDRUID	D0N8NC
D0N8NC	DRUGNAME	SAVOXEPIN MESYLATE
D0N8NC	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2

D0B6JV	TTDDRUID	D0B6JV
D0B6JV	DRUGNAME	SB-201993
D0B6JV	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D0W6XL	TTDDRUID	D0W6XL
D0W6XL	DRUGNAME	SB-209670
D0W6XL	INDICATI	Arrhythmia [ICD-11: BC9Z] Discontinued in Phase 2

D03LFR	TTDDRUID	D03LFR
D03LFR	DRUGNAME	SB-756050
D03LFR	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D0D3KY	TTDDRUID	D0D3KY
D0D3KY	DRUGNAME	SC-106
D0D3KY	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D0U5EU	TTDDRUID	D0U5EU
D0U5EU	DRUGNAME	SC-45662
D0U5EU	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D02HBW	TTDDRUID	D02HBW
D02HBW	DRUGNAME	SCH-32615
D02HBW	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0H1GF	TTDDRUID	D0H1GF
D0H1GF	DRUGNAME	Sch-34826
D0H1GF	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0M0RN	TTDDRUID	D0M0RN
D0M0RN	DRUGNAME	SCH-42495
D0M0RN	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2

D04IME	TTDDRUID	D04IME
D04IME	DRUGNAME	SCH-48461
D04IME	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0D5CJ	TTDDRUID	D0D5CJ
D0D5CJ	DRUGNAME	SDZ-LAP-977
D0D5CJ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D09JXL	TTDDRUID	D09JXL
D09JXL	DRUGNAME	SEGLITIDE
D09JXL	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0BB1T	TTDDRUID	D0BB1T
D0BB1T	DRUGNAME	Semparatide
D0BB1T	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D0T4XQ	TTDDRUID	D0T4XQ
D0T4XQ	DRUGNAME	SEP-227162
D0T4XQ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D0B4JL	TTDDRUID	D0B4JL
D0B4JL	DRUGNAME	SERAZAPINE HYDROCHLORIDE
D0B4JL	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D0S5ZJ	TTDDRUID	D0S5ZJ
D0S5ZJ	DRUGNAME	SERGOLEXOLE MALEATE
D0S5ZJ	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2

D04MNL	TTDDRUID	D04MNL
D04MNL	DRUGNAME	SERM-3339
D04MNL	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D0A5TM	TTDDRUID	D0A5TM
D0A5TM	DRUGNAME	SGB-1534
D0A5TM	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2

D0G2GT	TTDDRUID	D0G2GT
D0G2GT	DRUGNAME	SGS-111
D0G2GT	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D00ECO	TTDDRUID	D00ECO
D00ECO	DRUGNAME	SIB-1553A
D00ECO	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D0R3WG	TTDDRUID	D0R3WG
D0R3WG	DRUGNAME	SILPERISONE HYDROCHLORIDE
D0R3WG	INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 2

D0D7XW	TTDDRUID	D0D7XW
D0D7XW	DRUGNAME	SINITRODIL
D0D7XW	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0F9WF	TTDDRUID	D0F9WF
D0F9WF	DRUGNAME	SINOMENINE
D0F9WF	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2

D0EC2K	TTDDRUID	D0EC2K
D0EC2K	DRUGNAME	SIPATRIGINE
D0EC2K	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2

D00AKY	TTDDRUID	D00AKY
D00AKY	DRUGNAME	SK&F-S-106203
D00AKY	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0O4LU	TTDDRUID	D0O4LU
D0O4LU	DRUGNAME	SK-896
D0O4LU	INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2

D08TKV	TTDDRUID	D08TKV
D08TKV	DRUGNAME	SKF-97426
D08TKV	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0F0YL	TTDDRUID	D0F0YL
D0F0YL	DRUGNAME	SL-25.1039
D0F0YL	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D09ZQX	TTDDRUID	D09ZQX
D09ZQX	DRUGNAME	SL65.0155
D09ZQX	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2

D0OQ3L	TTDDRUID	D0OQ3L
D0OQ3L	DRUGNAME	SL65.0472
D0OQ3L	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2

D01EDS	TTDDRUID	D01EDS
D01EDS	DRUGNAME	SL-65.1498
D01EDS	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2

D03USI	TTDDRUID	D03USI
D03USI	DRUGNAME	SL-87.0495
D03USI	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D04CON	TTDDRUID	D04CON
D04CON	DRUGNAME	SL-89.0591
D04CON	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2

D0ZY9U	TTDDRUID	D0ZY9U
D0ZY9U	DRUGNAME	SLV-305
D0ZY9U	INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2

D02JMI	TTDDRUID	D02JMI
D02JMI	DRUGNAME	SLV-310
D02JMI	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2

D0A9OR	TTDDRUID	D0A9OR
D0A9OR	DRUGNAME	SLV319
D0A9OR	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D04NPP	TTDDRUID	D04NPP
D04NPP	DRUGNAME	SLX-2101
D04NPP	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2
D04NPP	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
D04NPP	INDICATI	Raynaud disease [ICD-11: BD42.0] Discontinued in Phase 2

D0U7DI	TTDDRUID	D0U7DI
D0U7DI	DRUGNAME	SM-10661
D0U7DI	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D05UHJ	TTDDRUID	D05UHJ
D05UHJ	DRUGNAME	SM-10888
D05UHJ	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0Q0AJ	TTDDRUID	D0Q0AJ
D0Q0AJ	DRUGNAME	SM-8849
D0Q0AJ	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2

D0N2RF	TTDDRUID	D0N2RF
D0N2RF	DRUGNAME	SMART ABL-364
D0N2RF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D08KWQ	TTDDRUID	D08KWQ
D08KWQ	DRUGNAME	Sn-117m-DTPA
D08KWQ	INDICATI	Bone metastases [ICD-11: 2D50] Discontinued in Phase 2

D01JGG	TTDDRUID	D01JGG
D01JGG	DRUGNAME	Sodelglitazar
D01JGG	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D0D3BO	TTDDRUID	D0D3BO
D0D3BO	DRUGNAME	SOLPECAINOL HYDROCHLORIDE
D0D3BO	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2

D0Q0YN	TTDDRUID	D0Q0YN
D0Q0YN	DRUGNAME	SORAPRAZAN
D0Q0YN	INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2

D08OJU	TTDDRUID	D08OJU
D08OJU	DRUGNAME	SOU-001
D08OJU	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D0P5NY	TTDDRUID	D0P5NY
D0P5NY	DRUGNAME	SPD 535
D0P5NY	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0LU6N	TTDDRUID	D0LU6N
D0LU6N	DRUGNAME	SPD-473
D0LU6N	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2

D09EQA	TTDDRUID	D09EQA
D09EQA	DRUGNAME	SpirH
D09EQA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D0N2YN	TTDDRUID	D0N2YN
D0N2YN	DRUGNAME	Spirogermanium hydrochloride
D0N2YN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D00VQI	TTDDRUID	D00VQI
D00VQI	DRUGNAME	SQ-30741
D00VQI	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0N5HO	TTDDRUID	D0N5HO
D0N5HO	DRUGNAME	SQ-32709
D0N5HO	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2

D09AFJ	TTDDRUID	D09AFJ
D09AFJ	DRUGNAME	SR-121787
D09AFJ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0ZX7I	TTDDRUID	D0ZX7I
D0ZX7I	DRUGNAME	SR-57227
D0ZX7I	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D04BIG	TTDDRUID	D04BIG
D04BIG	DRUGNAME	SR-90067
D04BIG	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 2

D00QCB	TTDDRUID	D00QCB
D00QCB	DRUGNAME	SRI-62-834
D00QCB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0Q1KN	TTDDRUID	D0Q1KN
D0Q1KN	DRUGNAME	SRP 299
D0Q1KN	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0U3EP	TTDDRUID	D0U3EP
D0U3EP	DRUGNAME	SRT501
D0U3EP	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
D0U3EP	INDICATI	Giant cell arteritis [ICD-11: 4A44.2] Phase 3
D0U3EP	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
D0U3EP	INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 3

D06DUO	TTDDRUID	D06DUO
D06DUO	DRUGNAME	SSR-182289
D06DUO	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2

D0Q0JJ	TTDDRUID	D0Q0JJ
D0Q0JJ	DRUGNAME	Streptococcal B vaccine
D0Q0JJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D09DJU	TTDDRUID	D09DJU
D09DJU	DRUGNAME	SU-14813
D09DJU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0G8UG	TTDDRUID	D0G8UG
D0G8UG	DRUGNAME	Sulukast
D0G8UG	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D00WJE	TTDDRUID	D00WJE
D00WJE	DRUGNAME	SUN-1334H
D00WJE	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D0A6YN	TTDDRUID	D0A6YN
D0A6YN	DRUGNAME	SUN-C5174
D0A6YN	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2

D0T3CE	TTDDRUID	D0T3CE
D0T3CE	DRUGNAME	SUPER-LEU-DOX
D0T3CE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08CLN	TTDDRUID	D08CLN
D08CLN	DRUGNAME	Suritozole
D08CLN	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2

D09OAV	TTDDRUID	D09OAV
D09OAV	DRUGNAME	Syk kinase silencer
D09OAV	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0X1YF	TTDDRUID	D0X1YF
D0X1YF	DRUGNAME	T-1095
D0X1YF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0E6DI	TTDDRUID	D0E6DI
D0E6DI	DRUGNAME	T487
D0E6DI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
D0E6DI	INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2

D0ML9K	TTDDRUID	D0ML9K
D0ML9K	DRUGNAME	T-506
D0ML9K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D02LCL	TTDDRUID	D02LCL
D02LCL	DRUGNAME	T-5224
D02LCL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2

D03NZM	TTDDRUID	D03NZM
D03NZM	DRUGNAME	T-588
D03NZM	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2

D0W9SZ	TTDDRUID	D0W9SZ
D0W9SZ	DRUGNAME	T611
D0W9SZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D0R2CM	TTDDRUID	D0R2CM
D0R2CM	DRUGNAME	TA-383
D0R2CM	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2

D0ST5P	TTDDRUID	D0ST5P
D0ST5P	DRUGNAME	TA-5538
D0ST5P	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2

D0JA1Z	TTDDRUID	D0JA1Z
D0JA1Z	DRUGNAME	TA-6666
D0JA1Z	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2

D02RVE	TTDDRUID	D02RVE
D02RVE	DRUGNAME	TA-7552
D02RVE	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2

D0E7YQ	TTDDRUID	D0E7YQ
D0E7YQ	DRUGNAME	TABILAUTIDE
D0E7YQ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2

D0W9NH	TTDDRUID	D0W9NH
D0W9NH	DRUGNAME	Tacedinaline
D0W9NH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0J2BH	TTDDRUID	D0J2BH
D0J2BH	DRUGNAME	TA-GW
D0J2BH	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 2

D00VPV	TTDDRUID	D00VPV
D00VPV	DRUGNAME	TAK-013
D00VPV	INDICATI	Uterine fibroids [ICD-11: 2E86.0] Discontinued in Phase 2

D0P0DT	TTDDRUID	D0P0DT
D0P0DT	DRUGNAME	TAK-044
D0P0DT	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2

D01IYQ	TTDDRUID	D01IYQ
D01IYQ	DRUGNAME	TAK-201
D01IYQ	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2

D0G6ES	TTDDRUID	D0G6ES
D0G6ES	DRUGNAME	TAK-218
D0G6ES	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2

D0N0OG	TTDDRUID	D0N0OG
D0N0OG	DRUGNAME	TAK-361S
D0N0OG	INDICATI	Diphtheria [ICD-11: 1C17] Discontinued in Phase 2

D03UYI	TTDDRUID	D03UYI
D03UYI	DRUGNAME	TAK-427
D03UYI	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D0J8WO	TTDDRUID	D0J8WO
D0J8WO	DRUGNAME	TAK-428
D0J8WO	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2

D0D5RH	TTDDRUID	D0D5RH
D0D5RH	DRUGNAME	TAK-442
D0D5RH	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D0H6PX	TTDDRUID	D0H6PX
D0H6PX	DRUGNAME	TAK-603
D0H6PX	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D0J5CX	TTDDRUID	D0J5CX
D0J5CX	DRUGNAME	TAK-637
D0J5CX	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2

D0B2BY	TTDDRUID	D0B2BY
D0B2BY	DRUGNAME	TAK-661
D0B2BY	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2

D0SW2H	TTDDRUID	D0SW2H
D0SW2H	DRUGNAME	TAK-778
D0SW2H	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D03GAX	TTDDRUID	D03GAX
D03GAX	DRUGNAME	TAK-802
D03GAX	INDICATI	Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 2

D0VO9O	TTDDRUID	D0VO9O
D0VO9O	DRUGNAME	Talizumab
D0VO9O	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2

D05BTR	TTDDRUID	D05BTR
D05BTR	DRUGNAME	Tallimustine
D05BTR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D06ODM	TTDDRUID	D06ODM
D06ODM	DRUGNAME	Talsaclidine fumarate
D06ODM	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2

D0A4OT	TTDDRUID	D0A4OT
D0A4OT	DRUGNAME	TAMOLARIZINE HYDROCHLORIDE
D0A4OT	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0IT6Q	TTDDRUID	D0IT6Q
D0IT6Q	DRUGNAME	Tandutinib
D0IT6Q	INDICATI	Anaplastic mixed oligoastrocytoma [ICD-11: 2A00.0Y] Discontinued in Phase 2

D0V9HH	TTDDRUID	D0V9HH
D0V9HH	DRUGNAME	Taprizosin
D0V9HH	INDICATI	Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2

D03XDX	TTDDRUID	D03XDX
D03XDX	DRUGNAME	Tarazepide
D03XDX	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 2

D04RLX	TTDDRUID	D04RLX
D04RLX	DRUGNAME	Tariquidar
D04RLX	INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Discontinued in Phase 2

D06TAL	TTDDRUID	D06TAL
D06TAL	DRUGNAME	Tazofelone
D06TAL	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2

D05OFO	TTDDRUID	D05OFO
D05OFO	DRUGNAME	TC-2696
D05OFO	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D04ENK	TTDDRUID	D04ENK
D04ENK	DRUGNAME	TCV-309
D04ENK	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D0P3KA	TTDDRUID	D0P3KA
D0P3KA	DRUGNAME	TEBUFELONE
D0P3KA	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D01FCK	TTDDRUID	D01FCK
D01FCK	DRUGNAME	Teglicar
D01FCK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0SX3X	TTDDRUID	D0SX3X
D0SX3X	DRUGNAME	TEI-6122
D0SX3X	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D07HAD	TTDDRUID	D07HAD
D07HAD	DRUGNAME	Telbermin
D07HAD	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2

D04GWY	TTDDRUID	D04GWY
D04GWY	DRUGNAME	Telinavir
D04GWY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2

D07RUV	TTDDRUID	D07RUV
D07RUV	DRUGNAME	Terflavoxate
D07RUV	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D0X9PW	TTDDRUID	D0X9PW
D0X9PW	DRUGNAME	Tesmilifene
D0X9PW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D08NNR	TTDDRUID	D08NNR
D08NNR	DRUGNAME	Testosterone glucoside
D08NNR	INDICATI	Hypogonadism [ICD-11: 5A61.0] Discontinued in Phase 2

D09WFI	TTDDRUID	D09WFI
D09WFI	DRUGNAME	Tetramethylpyrazine
D09WFI	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2

D03PHU	TTDDRUID	D03PHU
D03PHU	DRUGNAME	Tetrazolast meglumine
D03PHU	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0Z9MR	TTDDRUID	D0Z9MR
D0Z9MR	DRUGNAME	TG-1042
D0Z9MR	INDICATI	B-cell lymphoma [ICD-11: 2A86] Discontinued in Phase 2

D09BLW	TTDDRUID	D09BLW
D09BLW	DRUGNAME	TgAAV-CFTR
D09BLW	INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2

D0B4XU	TTDDRUID	D0B4XU
D0B4XU	DRUGNAME	TGP-580
D0B4XU	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Discontinued in Phase 2

D0N8JA	TTDDRUID	D0N8JA
D0N8JA	DRUGNAME	Theradigm-HBV
D0N8JA	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D0U8MF	TTDDRUID	D0U8MF
D0U8MF	DRUGNAME	Theradigm-HPV
D0U8MF	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0W2EA	TTDDRUID	D0W2EA
D0W2EA	DRUGNAME	Theradigm-Melanoma
D0W2EA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0X1EX	TTDDRUID	D0X1EX
D0X1EX	DRUGNAME	TIBENELAST
D0X1EX	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D06TVC	TTDDRUID	D06TVC
D06TVC	DRUGNAME	Tienoxolol
D06TVC	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0Z5LZ	TTDDRUID	D0Z5LZ
D0Z5LZ	DRUGNAME	Tilmacoxib
D0Z5LZ	INDICATI	Colon polyp [ICD-11: DB35] Discontinued in Phase 2

D0T1YN	TTDDRUID	D0T1YN
D0T1YN	DRUGNAME	Tiqueside
D0T1YN	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2

D07BDY	TTDDRUID	D07BDY
D07BDY	DRUGNAME	Tisocalcitate
D07BDY	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D03TIJ	TTDDRUID	D03TIJ
D03TIJ	DRUGNAME	Titanocene dichloride
D03TIJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08NJQ	TTDDRUID	D08NJQ
D08NJQ	DRUGNAME	TJ-8117
D08NJQ	INDICATI	Nephritis [ICD-11: GB40] Discontinued in Phase 2

D0Q6FV	TTDDRUID	D0Q6FV
D0Q6FV	DRUGNAME	TJN-135
D0Q6FV	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D0X8GJ	TTDDRUID	D0X8GJ
D0X8GJ	DRUGNAME	TMA-230
D0X8GJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D00CQW	TTDDRUID	D00CQW
D00CQW	DRUGNAME	TNP-351
D00CQW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D09OAQ	TTDDRUID	D09OAQ
D09OAQ	DRUGNAME	TNP-470
D09OAQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D05YAS	TTDDRUID	D05YAS
D05YAS	DRUGNAME	Tolafentrine
D05YAS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0X7IW	TTDDRUID	D0X7IW
D0X7IW	DRUGNAME	Tolerizing peptide
D0X7IW	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2

D0WF1S	TTDDRUID	D0WF1S
D0WF1S	DRUGNAME	Tomeglovir
D0WF1S	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D07XDS	TTDDRUID	D07XDS
D07XDS	DRUGNAME	Tomopenem
D07XDS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D06DWQ	TTDDRUID	D06DWQ
D06DWQ	DRUGNAME	TOPIXANTRONE HYDROCHLORIDE
D06DWQ	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2

D07GDN	TTDDRUID	D07GDN
D07GDN	DRUGNAME	Torcetrapib
D07GDN	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
D07GDN	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2

D07QFM	TTDDRUID	D07QFM
D07QFM	DRUGNAME	TP10
D07QFM	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2

D0PB1C	TTDDRUID	D0PB1C
D0PB1C	DRUGNAME	TPM-02/Insulin
D0PB1C	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D01SJC	TTDDRUID	D01SJC
D01SJC	DRUGNAME	Transdur-sufentanil
D01SJC	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D03VAR	TTDDRUID	D03VAR
D03VAR	DRUGNAME	Trecovirsen sodium
D03VAR	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 2

D0IW4R	TTDDRUID	D0IW4R
D0IW4R	DRUGNAME	TREFENTANIL HYDROCHLORIDE
D0IW4R	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0V9RB	TTDDRUID	D0V9RB
D0V9RB	DRUGNAME	TriAb
D0V9RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0S1AD	TTDDRUID	D0S1AD
D0S1AD	DRUGNAME	Tridolgosir
D0S1AD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D08GEX	TTDDRUID	D08GEX
D08GEX	DRUGNAME	TriGem
D08GEX	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D06EIO	TTDDRUID	D06EIO
D06EIO	DRUGNAME	Trimelamol
D06EIO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D05VFQ	TTDDRUID	D05VFQ
D05VFQ	DRUGNAME	TriTAb
D05VFQ	INDICATI	Poison intoxication [ICD-11: NE6Z] Discontinued in Phase 2

D0HV6X	TTDDRUID	D0HV6X
D0HV6X	DRUGNAME	TRK-130
D0HV6X	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2

D0D5ZR	TTDDRUID	D0D5ZR
D0D5ZR	DRUGNAME	TRO-40303
D0D5ZR	INDICATI	Lateral sclerosis [ICD-11: 8B61] Discontinued in Phase 2

D08PNQ	TTDDRUID	D08PNQ
D08PNQ	DRUGNAME	Trombodipine
D08PNQ	INDICATI	Platelet aggregation disorder [ICD-11: 3B62] Discontinued in Phase 2

D08WGZ	TTDDRUID	D08WGZ
D08WGZ	DRUGNAME	TS-033
D08WGZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0B6GJ	TTDDRUID	D0B6GJ
D0B6GJ	DRUGNAME	TT-62
D0B6GJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2

D08BVM	TTDDRUID	D08BVM
D08BVM	DRUGNAME	TTP-355
D08BVM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D0P3TF	TTDDRUID	D0P3TF
D0P3TF	DRUGNAME	TU-2100
D0P3TF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D05UIL	TTDDRUID	D05UIL
D05UIL	DRUGNAME	TV-4710
D05UIL	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 2

D0GY4V	TTDDRUID	D0GY4V
D0GY4V	DRUGNAME	TY-11345
D0GY4V	INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2

D0ID2I	TTDDRUID	D0ID2I
D0ID2I	DRUGNAME	Typhella typhoid vaccine oral
D0ID2I	INDICATI	Salmonella infection [ICD-11: 1A09] Discontinued in Phase 2
D0ID2I	INDICATI	Typhoid fever [ICD-11: 1A07] Discontinued in Phase 2

D04ZWH	TTDDRUID	D04ZWH
D04ZWH	DRUGNAME	UK-279,276
D04ZWH	INDICATI	Stroke [ICD-11: 8B20] Discontinued in Phase 2

D0I6UU	TTDDRUID	D0I6UU
D0I6UU	DRUGNAME	UK-74505
D0I6UU	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2

D03KJV	TTDDRUID	D03KJV
D03KJV	DRUGNAME	Ultramorph
D03KJV	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D03VCF	TTDDRUID	D03VCF
D03VCF	DRUGNAME	Urtoxazumab
D03VCF	INDICATI	Escherichia coli infection [ICD-11: 1A03] Discontinued in Phase 2

D03DRW	TTDDRUID	D03DRW
D03DRW	DRUGNAME	UTIBAPRIL
D03DRW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0D0WP	TTDDRUID	D0D0WP
D0D0WP	DRUGNAME	V-0096 CR
D0D0WP	INDICATI	Urticaria [ICD-11: EB00-EB05] Discontinued in Phase 2

D0G3OF	TTDDRUID	D0G3OF
D0G3OF	DRUGNAME	V-073
D0G3OF	INDICATI	Enterovirus infection [ICD-11: 1D91] Discontinued in Phase 2

D08SNX	TTDDRUID	D08SNX
D08SNX	DRUGNAME	V-11294A
D08SNX	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0PW0G	TTDDRUID	D0PW0G
D0PW0G	DRUGNAME	Valategrast
D0PW0G	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0XT1M	TTDDRUID	D0XT1M
D0XT1M	DRUGNAME	VALROCEMIDE
D0XT1M	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2

D0X3LD	TTDDRUID	D0X3LD
D0X3LD	DRUGNAME	Valtorcitabine
D0X3LD	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2

D07MZC	TTDDRUID	D07MZC
D07MZC	DRUGNAME	Vasoflux
D07MZC	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2

D0K4NZ	TTDDRUID	D0K4NZ
D0K4NZ	DRUGNAME	Velneperit
D0K4NZ	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2

D04HLE	TTDDRUID	D04HLE
D04HLE	DRUGNAME	Vitaxin
D04HLE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0EY5A	TTDDRUID	D0EY5A
D0EY5A	DRUGNAME	VLTS-587
D0EY5A	INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 2

D0E0QS	TTDDRUID	D0E0QS
D0E0QS	DRUGNAME	VM-301
D0E0QS	INDICATI	Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2

D0IL2B	TTDDRUID	D0IL2B
D0IL2B	DRUGNAME	VML-252
D0IL2B	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Discontinued in Phase 2

D0CC1Y	TTDDRUID	D0CC1Y
D0CC1Y	DRUGNAME	VML-262
D0CC1Y	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2

D09VLQ	TTDDRUID	D09VLQ
D09VLQ	DRUGNAME	VP-50406
D09VLQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2

D0X6XF	TTDDRUID	D0X6XF
D0X6XF	DRUGNAME	VTP-201227
D0X6XF	INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2

D0AL3O	TTDDRUID	D0AL3O
D0AL3O	DRUGNAME	VX-366
D0AL3O	INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2

D0MF3C	TTDDRUID	D0MF3C
D0MF3C	DRUGNAME	WAY-123641
D0MF3C	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D0G2CQ	TTDDRUID	D0G2CQ
D0G2CQ	DRUGNAME	WC-3027
D0G2CQ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2

D0N1EC	TTDDRUID	D0N1EC
D0N1EC	DRUGNAME	WY-47766
D0N1EC	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2

D0G4OT	TTDDRUID	D0G4OT
D0G4OT	DRUGNAME	XL784
D0G4OT	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2

D03WSE	TTDDRUID	D03WSE
D03WSE	DRUGNAME	XomaZyme-Mel
D03WSE	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D09WYC	TTDDRUID	D09WYC
D09WYC	DRUGNAME	Y-26611
D09WYC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D08HFA	TTDDRUID	D08HFA
D08HFA	DRUGNAME	Y-27152
D08HFA	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0E4FM	TTDDRUID	D0E4FM
D0E4FM	DRUGNAME	Y-700
D0E4FM	INDICATI	Gout [ICD-11: FA25] Discontinued in Phase 2

D02WGN	TTDDRUID	D02WGN
D02WGN	DRUGNAME	YM-114
D02WGN	INDICATI	Nausea [ICD-11: MD90] Discontinued in Phase 2

D06BHQ	TTDDRUID	D06BHQ
D06BHQ	DRUGNAME	YM-17K
D06BHQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2

D0M5CU	TTDDRUID	D0M5CU
D0M5CU	DRUGNAME	YM-337
D0M5CU	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Discontinued in Phase 2

D0KL3K	TTDDRUID	D0KL3K
D0KL3K	DRUGNAME	YM-440
D0KL3K	INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2

D0E9XG	TTDDRUID	D0E9XG
D0E9XG	DRUGNAME	YM-46A
D0E9XG	INDICATI	Phlegmy cough [ICD-11: SA80-SA8Z] Discontinued in Phase 2

D0Y2OG	TTDDRUID	D0Y2OG
D0Y2OG	DRUGNAME	YM-511
D0Y2OG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2

D0F8BS	TTDDRUID	D0F8BS
D0F8BS	DRUGNAME	YM-796
D0F8BS	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D02TTF	TTDDRUID	D02TTF
D02TTF	DRUGNAME	YM-90K
D02TTF	INDICATI	Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 2

D01ESB	TTDDRUID	D01ESB
D01ESB	DRUGNAME	YM-992
D01ESB	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2

D06UCV	TTDDRUID	D06UCV
D06UCV	DRUGNAME	Z-335
D06UCV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2

D00FHI	TTDDRUID	D00FHI
D00FHI	DRUGNAME	Zabiciprilat
D00FHI	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0J5GT	TTDDRUID	D0J5GT
D0J5GT	DRUGNAME	ZANKIREN
D0J5GT	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D0J3TP	TTDDRUID	D0J3TP
D0J3TP	DRUGNAME	ZD-0870
D0J3TP	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 2

D0NF0Q	TTDDRUID	D0NF0Q
D0NF0Q	DRUGNAME	ZD-0947
D0NF0Q	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2

D07HBI	TTDDRUID	D07HBI
D07HBI	DRUGNAME	ZD-2138
D07HBI	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2

D06LGC	TTDDRUID	D06LGC
D06LGC	DRUGNAME	ZD-2486
D06LGC	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2

D0I7LB	TTDDRUID	D0I7LB
D0I7LB	DRUGNAME	ZD-4953
D0I7LB	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D0X7HV	TTDDRUID	D0X7HV
D0X7HV	DRUGNAME	ZD-6169
D0X7HV	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2

D0T2TK	TTDDRUID	D0T2TK
D0T2TK	DRUGNAME	ZD6416
D0T2TK	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2

D08ZCW	TTDDRUID	D08ZCW
D08ZCW	DRUGNAME	ZD-8321
D08ZCW	INDICATI	Acute lung injury [ICD-11: NB32.3] Discontinued in Phase 2

D09ORU	TTDDRUID	D09ORU
D09ORU	DRUGNAME	ZELANDOPAM HYDROCHLORIDE
D09ORU	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2

D00CFB	TTDDRUID	D00CFB
D00CFB	DRUGNAME	Zeniplatin
D00CFB	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2

D0F1VQ	TTDDRUID	D0F1VQ
D0F1VQ	DRUGNAME	ZIFROSILONE
D0F1VQ	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2

D0T4OT	TTDDRUID	D0T4OT
D0T4OT	DRUGNAME	Zilascorb (2H)
D0T4OT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2

D0E3XG	TTDDRUID	D0E3XG
D0E3XG	DRUGNAME	Zolasartan
D0E3XG	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2

D0O2QB	TTDDRUID	D0O2QB
D0O2QB	DRUGNAME	Zolimomab aritox
D0O2QB	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2

D06EDT	TTDDRUID	D06EDT
D06EDT	DRUGNAME	ZOPOLRESTAT
D06EDT	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2

D06YFO	TTDDRUID	D06YFO
D06YFO	DRUGNAME	AD-121
D06YFO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2

D0D0XF	TTDDRUID	D0D0XF
D0D0XF	DRUGNAME	AG-702
D0D0XF	INDICATI	Genital herpes [ICD-11: 1A94] Discontinued in Phase 1/2

D02XBY	TTDDRUID	D02XBY
D02XBY	DRUGNAME	AGS-005
D02XBY	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1/2

D0WY0N	TTDDRUID	D0WY0N
D0WY0N	DRUGNAME	ALKASAR-18
D0WY0N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2

D05RTF	TTDDRUID	D05RTF
D05RTF	DRUGNAME	AME-527
D05RTF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2

D03RUL	TTDDRUID	D03RUL
D03RUL	DRUGNAME	AP5280
D03RUL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2

D07EFA	TTDDRUID	D07EFA
D07EFA	DRUGNAME	AST-915
D07EFA	INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Discontinued in Phase 1/2

D0Y4GJ	TTDDRUID	D0Y4GJ
D0Y4GJ	DRUGNAME	AVE-5883
D0Y4GJ	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1/2

D0W8KT	TTDDRUID	D0W8KT
D0W8KT	DRUGNAME	AVI-4065
D0W8KT	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1/2

D0K1VK	TTDDRUID	D0K1VK
D0K1VK	DRUGNAME	AZD8055
D0K1VK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2

D0NK6Z	TTDDRUID	D0NK6Z
D0NK6Z	DRUGNAME	Beta LT
D0NK6Z	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1/2

D0Q2BM	TTDDRUID	D0Q2BM
D0Q2BM	DRUGNAME	CB-001
D0Q2BM	INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2

D05FVX	TTDDRUID	D05FVX
D05FVX	DRUGNAME	CDP-484
D05FVX	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1/2

D01CEQ	TTDDRUID	D01CEQ
D01CEQ	DRUGNAME	CER-227185
D01CEQ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2

D00NSM	TTDDRUID	D00NSM
D00NSM	DRUGNAME	CM-GLP-1
D00NSM	INDICATI	Brain injury [ICD-11: NA07.Z] Discontinued in Phase 1/2

D05VEU	TTDDRUID	D05VEU
D05VEU	DRUGNAME	Coagulin-B
D05VEU	INDICATI	Hemophilia [ICD-11: 3B10.0] Discontinued in Phase 1/2

D00PDG	TTDDRUID	D00PDG
D00PDG	DRUGNAME	CORT-108297
D00PDG	INDICATI	Weight gain [ICD-11: MG43.6] Discontinued in Phase 1/2

D04VGY	TTDDRUID	D04VGY
D04VGY	DRUGNAME	CYT-007-TNFQb
D04VGY	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1/2

D08KVK	TTDDRUID	D08KVK
D08KVK	DRUGNAME	CYT-009-GhrQb
D08KVK	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1/2

D09SAV	TTDDRUID	D09SAV
D09SAV	DRUGNAME	Dendritic cell PEG fusion cancer vaccine
D09SAV	INDICATI	Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 1/2

D0H3HB	TTDDRUID	D0H3HB
D0H3HB	DRUGNAME	EG-011
D0H3HB	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1/2

D01RLU	TTDDRUID	D01RLU
D01RLU	DRUGNAME	EG-016
D01RLU	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 1/2

D05PYB	TTDDRUID	D05PYB
D05PYB	DRUGNAME	Elstree-BN
D05PYB	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1/2

D03OCG	TTDDRUID	D03OCG
D03OCG	DRUGNAME	FGF-21
D03OCG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1/2

D09GDY	TTDDRUID	D09GDY
D09GDY	DRUGNAME	GNI-103
D09GDY	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2

D0A9JW	TTDDRUID	D0A9JW
D0A9JW	DRUGNAME	GPG
D0A9JW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2

D09HEV	TTDDRUID	D09HEV
D09HEV	DRUGNAME	GS-9005
D09HEV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2

D0S7LN	TTDDRUID	D0S7LN
D0S7LN	DRUGNAME	GS-9132
D0S7LN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2

D00VLF	TTDDRUID	D00VLF
D00VLF	DRUGNAME	HCV/MF59
D00VLF	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2

D0IJ1D	TTDDRUID	D0IJ1D
D0IJ1D	DRUGNAME	HuM-195-Bi-213
D0IJ1D	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2

D08RPV	TTDDRUID	D08RPV
D08RPV	DRUGNAME	IDM-4
D08RPV	INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2

D09VTB	TTDDRUID	D09VTB
D09VTB	DRUGNAME	IDX-320
D09VTB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2

D0S0DU	TTDDRUID	D0S0DU
D0S0DU	DRUGNAME	KSB-303
D0S0DU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1/2

D0M3OR	TTDDRUID	D0M3OR
D0M3OR	DRUGNAME	KW-2450
D0M3OR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1/2

D0S1LE	TTDDRUID	D0S1LE
D0S1LE	DRUGNAME	Lintuzumab Bi-213
D0S1LE	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2

D08PXM	TTDDRUID	D08PXM
D08PXM	DRUGNAME	MDX-214
D08PXM	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1/2

D0BH8C	TTDDRUID	D0BH8C
D0BH8C	DRUGNAME	MGVWN-1
D0BH8C	INDICATI	West nile virus infection [ICD-11: 1D46] Discontinued in Phase 1/2

D09QUE	TTDDRUID	D09QUE
D09QUE	DRUGNAME	MVA-BN HIV Polytope
D09QUE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2

D06CMW	TTDDRUID	D06CMW
D06CMW	DRUGNAME	MVA-BN polytope HIV vaccine
D06CMW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2

D08BNM	TTDDRUID	D08BNM
D08BNM	DRUGNAME	NAA-004
D08BNM	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1/2

D0X5ES	TTDDRUID	D0X5ES
D0X5ES	DRUGNAME	NCX 950
D0X5ES	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1/2

D06FSD	TTDDRUID	D06FSD
D06FSD	DRUGNAME	NN-9161
D06FSD	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1/2

D02FEJ	TTDDRUID	D02FEJ
D02FEJ	DRUGNAME	ODC-0501
D02FEJ	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1/2

D0B5TO	TTDDRUID	D0B5TO
D0B5TO	DRUGNAME	Onyvax-CR
D0B5TO	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1/2

D07MVE	TTDDRUID	D07MVE
D07MVE	DRUGNAME	PD-151832
D07MVE	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1/2

D0M2SR	TTDDRUID	D0M2SR
D0M2SR	DRUGNAME	R-803
D0M2SR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2

D08JRT	TTDDRUID	D08JRT
D08JRT	DRUGNAME	RhApo2L/TRAIL
D08JRT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2

D0Z2KU	TTDDRUID	D0Z2KU
D0Z2KU	DRUGNAME	S-288310
D0Z2KU	INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 1/2

D04WVL	TTDDRUID	D04WVL
D04WVL	DRUGNAME	SF-1
D04WVL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1/2

D0E6QN	TTDDRUID	D0E6QN
D0E6QN	DRUGNAME	Staphylococcus aureus vaccine conjugate pentavalent
D0E6QN	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 1/2

D0N5SC	TTDDRUID	D0N5SC
D0N5SC	DRUGNAME	UK-369003
D0N5SC	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 1/2

D0WY1B	TTDDRUID	D0WY1B
D0WY1B	DRUGNAME	Vaccine, non-Hodgkin's lymphoma
D0WY1B	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Discontinued in Phase 1/2

D01MQH	TTDDRUID	D01MQH
D01MQH	DRUGNAME	Vepalimomab
D01MQH	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1/2

D0N6PB	TTDDRUID	D0N6PB
D0N6PB	DRUGNAME	VM-106
D0N6PB	INDICATI	Chronic granulomatous disease [ICD-11: 4A00.0Y] Discontinued in Phase 1/2

D08INO	TTDDRUID	D08INO
D08INO	DRUGNAME	WX-UK1
D08INO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2

D04ODQ	TTDDRUID	D04ODQ
D04ODQ	DRUGNAME	447C88
D04ODQ	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D01PLH	TTDDRUID	D01PLH
D01PLH	DRUGNAME	7U85
D01PLH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D02QQB	TTDDRUID	D02QQB
D02QQB	DRUGNAME	A-216546
D02QQB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D09MON	TTDDRUID	D09MON
D09MON	DRUGNAME	A-75998
D09MON	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1

D0U7WN	TTDDRUID	D0U7WN
D0U7WN	DRUGNAME	A-80987
D0U7WN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0X5LG	TTDDRUID	D0X5LG
D0X5LG	DRUGNAME	ABJ-879
D0X5LG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D04MYO	TTDDRUID	D04MYO
D04MYO	DRUGNAME	ABN-912
D04MYO	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0GB3A	TTDDRUID	D0GB3A
D0GB3A	DRUGNAME	ABT-080
D0GB3A	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0Z0LJ	TTDDRUID	D0Z0LJ
D0Z0LJ	DRUGNAME	ABT-107
D0Z0LJ	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 1

D08VUJ	TTDDRUID	D08VUJ
D08VUJ	DRUGNAME	ABT-202
D08VUJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D0A1NU	TTDDRUID	D0A1NU
D0A1NU	DRUGNAME	ABT-279
D0A1NU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D07SGB	TTDDRUID	D07SGB
D07SGB	DRUGNAME	ABT-299
D07SGB	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1

D00UCC	TTDDRUID	D00UCC
D00UCC	DRUGNAME	ABT-518
D00UCC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0ZY0Z	TTDDRUID	D0ZY0Z
D0ZY0Z	DRUGNAME	ABT-560
D0ZY0Z	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1

D0G7YG	TTDDRUID	D0G7YG
D0G7YG	DRUGNAME	ABX-MA1
D0G7YG	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1

D0J6PR	TTDDRUID	D0J6PR
D0J6PR	DRUGNAME	AC-100
D0J6PR	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D03WMK	TTDDRUID	D03WMK
D03WMK	DRUGNAME	AC-162352
D03WMK	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D00RXR	TTDDRUID	D00RXR
D00RXR	DRUGNAME	AC-253
D00RXR	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0L8OE	TTDDRUID	D0L8OE
D0L8OE	DRUGNAME	AC3056
D0L8OE	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0Q9NJ	TTDDRUID	D0Q9NJ
D0Q9NJ	DRUGNAME	AC-625
D0Q9NJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D01VCB	TTDDRUID	D01VCB
D01VCB	DRUGNAME	ACH-2928
D01VCB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D0T1GV	TTDDRUID	D0T1GV
D0T1GV	DRUGNAME	ADD-17014
D0T1GV	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1

D03MNS	TTDDRUID	D03MNS
D03MNS	DRUGNAME	ADL-7445
D03MNS	INDICATI	Constipation [ICD-11: DD91.1] Discontinued in Phase 1

D0CO9B	TTDDRUID	D0CO9B
D0CO9B	DRUGNAME	Ad-p53
D0CO9B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06DET	TTDDRUID	D06DET
D06DET	DRUGNAME	AE-3763
D06DET	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D0ZM5B	TTDDRUID	D0ZM5B
D0ZM5B	DRUGNAME	AG-021541
D0ZM5B	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D0C4YA	TTDDRUID	D0C4YA
D0C4YA	DRUGNAME	AG-331
D0C4YA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0C7UR	TTDDRUID	D0C7UR
D0C7UR	DRUGNAME	AGI-1096
D0C7UR	INDICATI	Transplant rejection [ICD-11: NE84] Discontinued in Phase 1

D02DVB	TTDDRUID	D02DVB
D02DVB	DRUGNAME	AGN-191743
D02DVB	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1

D01DQR	TTDDRUID	D01DQR
D01DQR	DRUGNAME	AIR-Epinephrine
D01DQR	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1

D04ONP	TTDDRUID	D04ONP
D04ONP	DRUGNAME	ALBIFYLLINE
D04ONP	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1

D06JVV	TTDDRUID	D06JVV
D06JVV	DRUGNAME	ALD-151
D06JVV	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1

D0S7YU	TTDDRUID	D0S7YU
D0S7YU	DRUGNAME	ALD-601
D0S7YU	INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Discontinued in Phase 1

D0Z3YP	TTDDRUID	D0Z3YP
D0Z3YP	DRUGNAME	ALGRX-1207
D0Z3YP	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D05NUT	TTDDRUID	D05NUT
D05NUT	DRUGNAME	ALS-00T2-0501
D05NUT	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1

D0N9SJ	TTDDRUID	D0N9SJ
D0N9SJ	DRUGNAME	ALTU-237
D0N9SJ	INDICATI	Hyperoxaluria [ICD-11: 5C51.2Z] Discontinued in Phase 1

D08XWZ	TTDDRUID	D08XWZ
D08XWZ	DRUGNAME	ALX-0646
D08XWZ	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1

D0A8IE	TTDDRUID	D0A8IE
D0A8IE	DRUGNAME	AM-831
D0A8IE	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D07IIX	TTDDRUID	D07IIX
D07IIX	DRUGNAME	AMELTOLIDE
D07IIX	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1

D0X4MC	TTDDRUID	D0X4MC
D0X4MC	DRUGNAME	AMG 076
D0X4MC	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D09MKQ	TTDDRUID	D09MKQ
D09MKQ	DRUGNAME	AMG 317
D09MKQ	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D07EBU	TTDDRUID	D07EBU
D07EBU	DRUGNAME	AMG-221
D07EBU	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Discontinued in Phase 1

D0L5XI	TTDDRUID	D0L5XI
D0L5XI	DRUGNAME	AMG-517
D0L5XI	INDICATI	Chronic pain [ICD-11: MG30] Discontinued in Phase 1

D08PKF	TTDDRUID	D08PKF
D08PKF	DRUGNAME	AMI-HS
D08PKF	INDICATI	Liver disease [ICD-11: DB90-BD99] Discontinued in Phase 1

D08JOE	TTDDRUID	D08JOE
D08JOE	DRUGNAME	ANA971
D08JOE	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1

D03GNR	TTDDRUID	D03GNR
D03GNR	DRUGNAME	ANA-975
D03GNR	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1

D0N1DQ	TTDDRUID	D0N1DQ
D0N1DQ	DRUGNAME	ANQ-9040
D0N1DQ	INDICATI	Paralysis [ICD-11: 8B60] Discontinued in Phase 1

D06WGQ	TTDDRUID	D06WGQ
D06WGQ	DRUGNAME	Anthrax DNA vaccine
D06WGQ	INDICATI	Anthrax [ICD-11: 1B97] Discontinued in Phase 1

D07TRV	TTDDRUID	D07TRV
D07TRV	DRUGNAME	Anthrax vaccine
D07TRV	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Discontinued in Phase 1

D04QCY	TTDDRUID	D04QCY
D04QCY	DRUGNAME	Antineoplaston-A3
D04QCY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D09AYS	TTDDRUID	D09AYS
D09AYS	DRUGNAME	Antineoplaston-A5
D09AYS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0Q3ES	TTDDRUID	D0Q3ES
D0Q3ES	DRUGNAME	APD668
D0Q3ES	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0UI8K	TTDDRUID	D0UI8K
D0UI8K	DRUGNAME	Apogen MS
D0UI8K	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D03FPA	TTDDRUID	D03FPA
D03FPA	DRUGNAME	APP-018
D03FPA	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D02WQZ	TTDDRUID	D02WQZ
D02WQZ	DRUGNAME	Aprosulate sodium
D02WQZ	INDICATI	Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 1

D0W5XT	TTDDRUID	D0W5XT
D0W5XT	DRUGNAME	ARC-183
D0W5XT	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Discontinued in Phase 1

D04FTB	TTDDRUID	D04FTB
D04FTB	DRUGNAME	AR-H049020
D04FTB	INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 1

D0ML0L	TTDDRUID	D0ML0L
D0ML0L	DRUGNAME	ARRY-614
D0ML0L	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
D0ML0L	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Discontinued in Phase 1

D0JJ1B	TTDDRUID	D0JJ1B
D0JJ1B	DRUGNAME	Artilide
D0JJ1B	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 1

D03APL	TTDDRUID	D03APL
D03APL	DRUGNAME	AS-1403
D03APL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1

D0P9EL	TTDDRUID	D0P9EL
D0P9EL	DRUGNAME	AS-601811
D0P9EL	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1

D01OLO	TTDDRUID	D01OLO
D01OLO	DRUGNAME	AS602868
D01OLO	INDICATI	Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 1

D05AQP	TTDDRUID	D05AQP
D05AQP	DRUGNAME	ASP-0306
D05AQP	INDICATI	Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 1

D03JSO	TTDDRUID	D03JSO
D03JSO	DRUGNAME	ASP-2535
D03JSO	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D0SS4I	TTDDRUID	D0SS4I
D0SS4I	DRUGNAME	ASP-2905
D0SS4I	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D0BJ5O	TTDDRUID	D0BJ5O
D0BJ5O	DRUGNAME	ASP-4178
D0BJ5O	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1

D03MGV	TTDDRUID	D03MGV
D03MGV	DRUGNAME	ASP-5034
D03MGV	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1

D01XUG	TTDDRUID	D01XUG
D01XUG	DRUGNAME	ASP6432
D01XUG	INDICATI	Lower urinary tract symptom [ICD-11: GB71] Discontinued in Phase 1

D0B6XE	TTDDRUID	D0B6XE
D0B6XE	DRUGNAME	ASP9226
D0B6XE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1

D0NH5E	TTDDRUID	D0NH5E
D0NH5E	DRUGNAME	Autologous dendritic cell therapy
D0NH5E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0L4PM	TTDDRUID	D0L4PM
D0L4PM	DRUGNAME	AVE-3247
D0L4PM	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0X5BD	TTDDRUID	D0X5BD
D0X5BD	DRUGNAME	AVE-5997
D0X5BD	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D08CQE	TTDDRUID	D08CQE
D08CQE	DRUGNAME	AVE-9940
D08CQE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0TY6Y	TTDDRUID	D0TY6Y
D0TY6Y	DRUGNAME	Avicine
D0TY6Y	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1

D06SSR	TTDDRUID	D06SSR
D06SSR	DRUGNAME	AVP-26452
D06SSR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D06WSQ	TTDDRUID	D06WSQ
D06WSQ	DRUGNAME	AWD-140-190
D06WSQ	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1

D0MV3Q	TTDDRUID	D0MV3Q
D0MV3Q	DRUGNAME	Axovan-3
D0MV3Q	INDICATI	Eating disorder [ICD-11: 6B82] Discontinued in Phase 1
D0MV3Q	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0MC0O	TTDDRUID	D0MC0O
D0MC0O	DRUGNAME	AZD-1080
D0MC0O	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D0N5SS	TTDDRUID	D0N5SS
D0N5SS	DRUGNAME	AZD1175
D0N5SS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
D0N5SS	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
D0N5SS	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0N0UY	TTDDRUID	D0N0UY
D0N0UY	DRUGNAME	AZD1704
D0N0UY	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D09UXP	TTDDRUID	D09UXP
D09UXP	DRUGNAME	AZD-1744
D09UXP	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D08GKD	TTDDRUID	D08GKD
D08GKD	DRUGNAME	AZD-2315
D08GKD	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
D08GKD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D01CAJ	TTDDRUID	D01CAJ
D01CAJ	DRUGNAME	AZD-3342
D01CAJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D07BUO	TTDDRUID	D07BUO
D07BUO	DRUGNAME	AZD-3783
D07BUO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D0YP6F	TTDDRUID	D0YP6F
D0YP6F	DRUGNAME	AZD-4121
D0YP6F	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1

D0P3CF	TTDDRUID	D0P3CF
D0P3CF	DRUGNAME	AZD-4407
D0P3CF	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D09TMV	TTDDRUID	D09TMV
D09TMV	DRUGNAME	AZD-4619
D09TMV	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1

D0NQ5R	TTDDRUID	D0NQ5R
D0NQ5R	DRUGNAME	AZD-4750
D0NQ5R	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D02RZL	TTDDRUID	D02RZL
D02RZL	DRUGNAME	AZD4769
D02RZL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D08ORV	TTDDRUID	D08ORV
D08ORV	DRUGNAME	AZD-4992
D08ORV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1

D0E6SX	TTDDRUID	D0E6SX
D0E6SX	DRUGNAME	AZD-5069
D0E6SX	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D0D1LG	TTDDRUID	D0D1LG
D0D1LG	DRUGNAME	AZD-5099
D0D1LG	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0Y3LJ	TTDDRUID	D0Y3LJ
D0Y3LJ	DRUGNAME	AZD5904
D0Y3LJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
D0Y3LJ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D01RVS	TTDDRUID	D01RVS
D01RVS	DRUGNAME	AZD5985
D01RVS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D0Z9HW	TTDDRUID	D0Z9HW
D0Z9HW	DRUGNAME	AZD6280
D0Z9HW	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
D0Z9HW	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D09XHI	TTDDRUID	D09XHI
D09XHI	DRUGNAME	AZD-6538
D09XHI	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1

D0X7WK	TTDDRUID	D0X7WK
D0X7WK	DRUGNAME	AZD-6553
D0X7WK	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D03KWN	TTDDRUID	D03KWN
D03KWN	DRUGNAME	AZD-6703
D03KWN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0SN2Q	TTDDRUID	D0SN2Q
D0SN2Q	DRUGNAME	AZD-6714
D0SN2Q	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0LX8D	TTDDRUID	D0LX8D
D0LX8D	DRUGNAME	AZD6918
D0LX8D	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0TN3D	TTDDRUID	D0TN3D
D0TN3D	DRUGNAME	AZD-7140
D0TN3D	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
D0TN3D	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D06XSG	TTDDRUID	D06XSG
D06XSG	DRUGNAME	AZD8075
D06XSG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D07TTI	TTDDRUID	D07TTI
D07TTI	DRUGNAME	AZD-8309
D07TTI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
D07TTI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0P0HI	TTDDRUID	D0P0HI
D0P0HI	DRUGNAME	AZD8330
D0P0HI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06EMW	TTDDRUID	D06EMW
D06EMW	DRUGNAME	AZD8566
D06EMW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
D06EMW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0T8NS	TTDDRUID	D0T8NS
D0T8NS	DRUGNAME	AZD-8677
D0T8NS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0E3SD	TTDDRUID	D0E3SD
D0E3SD	DRUGNAME	AZD-9272
D0E3SD	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1

D01OYR	TTDDRUID	D01OYR
D01OYR	DRUGNAME	AZD-9343
D01OYR	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1

D00PIE	TTDDRUID	D00PIE
D00PIE	DRUGNAME	Banoxantrone
D00PIE	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Discontinued in Phase 1

D01TYB	TTDDRUID	D01TYB
D01TYB	DRUGNAME	Basulin
D01TYB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0Z6AX	TTDDRUID	D0Z6AX
D0Z6AX	DRUGNAME	BAY-27-9955
D0Z6AX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0W1HB	TTDDRUID	D0W1HB
D0W1HB	DRUGNAME	BAY-61-2116
D0W1HB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D04MRA	TTDDRUID	D04MRA
D04MRA	DRUGNAME	BAY-73-7977
D04MRA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0Y3RN	TTDDRUID	D0Y3RN
D0Y3RN	DRUGNAME	BAY-Y-1015
D0Y3RN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0RJ2P	TTDDRUID	D0RJ2P
D0RJ2P	DRUGNAME	BB-2983
D0RJ2P	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1

D01IBO	TTDDRUID	D01IBO
D01IBO	DRUGNAME	BCX-1470
D01IBO	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 1

D0Y2YV	TTDDRUID	D0Y2YV
D0Y2YV	DRUGNAME	BECIPARCIL
D0Y2YV	INDICATI	Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 1

D0W2PK	TTDDRUID	D0W2PK
D0W2PK	DRUGNAME	Beloxepin
D0W2PK	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1

D0VR5T	TTDDRUID	D0VR5T
D0VR5T	DRUGNAME	BEPH
D0VR5T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0X8MI	TTDDRUID	D0X8MI
D0X8MI	DRUGNAME	Berupipam
D0X8MI	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D06RCS	TTDDRUID	D06RCS
D06RCS	DRUGNAME	Besonprodil
D06RCS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1

D0T0SO	TTDDRUID	D0T0SO
D0T0SO	DRUGNAME	BI-K0376
D0T0SO	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1

D0Q8DM	TTDDRUID	D0Q8DM
D0Q8DM	DRUGNAME	BIM-26226
D0Q8DM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D05AAM	TTDDRUID	D05AAM
D05AAM	DRUGNAME	BINOSPIRONE MESYLATE
D05AAM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D06MXY	TTDDRUID	D06MXY
D06MXY	DRUGNAME	BL-1827
D06MXY	INDICATI	Cancer related pain [ICD-11: MG30] Discontinued in Phase 1

D0F0MU	TTDDRUID	D0F0MU
D0F0MU	DRUGNAME	BLX-883
D0F0MU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D01GIF	TTDDRUID	D01GIF
D01GIF	DRUGNAME	BM-113
D01GIF	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D04JGA	TTDDRUID	D04JGA
D04JGA	DRUGNAME	BMS-191095
D04JGA	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1

D07IMX	TTDDRUID	D07IMX
D07IMX	DRUGNAME	BMS-844421
D07IMX	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1

D0JT1P	TTDDRUID	D0JT1P
D0JT1P	DRUGNAME	Brain tumor vaccine
D0JT1P	INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 1

D0B6SO	TTDDRUID	D0B6SO
D0B6SO	DRUGNAME	BRL-44154
D0B6SO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D03PTZ	TTDDRUID	D03PTZ
D03PTZ	DRUGNAME	BTS-73947
D03PTZ	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D0E8UJ	TTDDRUID	D0E8UJ
D0E8UJ	DRUGNAME	BW-1370U87
D0E8UJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1

D08KZR	TTDDRUID	D08KZR
D08KZR	DRUGNAME	BXL-746
D08KZR	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0E7OL	TTDDRUID	D0E7OL
D0E7OL	DRUGNAME	C-0084
D0E7OL	INDICATI	Glioma [ICD-11: 2A00.0] Discontinued in Phase 1

D01CBV	TTDDRUID	D01CBV
D01CBV	DRUGNAME	C-5997
D01CBV	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0K0XW	TTDDRUID	D0K0XW
D0K0XW	DRUGNAME	C-9138
D0K0XW	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D01BUS	TTDDRUID	D01BUS
D01BUS	DRUGNAME	CA9-ADC
D01BUS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06ABM	TTDDRUID	D06ABM
D06ABM	DRUGNAME	CAB-175
D06ABM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0Q0OP	TTDDRUID	D0Q0OP
D0Q0OP	DRUGNAME	CAB-2
D0Q0OP	INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 1

D04LAQ	TTDDRUID	D04LAQ
D04LAQ	DRUGNAME	Candoxatrilat
D04LAQ	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1

D0L8EQ	TTDDRUID	D0L8EQ
D0L8EQ	DRUGNAME	CB-182804
D0L8EQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0M7LQ	TTDDRUID	D0M7LQ
D0M7LQ	DRUGNAME	CBD cannabis derivative
D0M7LQ	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D0AM1S	TTDDRUID	D0AM1S
D0AM1S	DRUGNAME	CCD-3693
D0AM1S	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D04HZX	TTDDRUID	D04HZX
D04HZX	DRUGNAME	CCX-832
D04HZX	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1

D0MT0A	TTDDRUID	D0MT0A
D0MT0A	DRUGNAME	CCX915
D0MT0A	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D0M5OI	TTDDRUID	D0M5OI
D0M5OI	DRUGNAME	CD40L
D0M5OI	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 1

D0F5NB	TTDDRUID	D0F5NB
D0F5NB	DRUGNAME	CD-581
D0F5NB	INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 1

D0C3HS	TTDDRUID	D0C3HS
D0C3HS	DRUGNAME	CDP-1050
D0C3HS	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1

D04MDJ	TTDDRUID	D04MDJ
D04MDJ	DRUGNAME	CEFDALOXIME PENTEXIL TOSILATE
D04MDJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D04KXF	TTDDRUID	D04KXF
D04KXF	DRUGNAME	CEFTRAZONAL BOPENTIL
D04KXF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0KX1E	TTDDRUID	D0KX1E
D0KX1E	DRUGNAME	CEP-2563
D0KX1E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0Z5BD	TTDDRUID	D0Z5BD
D0Z5BD	DRUGNAME	CER-627
D0Z5BD	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1

D00UCW	TTDDRUID	D00UCW
D00UCW	DRUGNAME	CEREBROCRAST
D00UCW	INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1

D07NTN	TTDDRUID	D07NTN
D07NTN	DRUGNAME	CERM-11956
D07NTN	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1

D03ESW	TTDDRUID	D03ESW
D03ESW	DRUGNAME	Cetefloxacin
D03ESW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D04FRB	TTDDRUID	D04FRB
D04FRB	DRUGNAME	CGP-13774
D04FRB	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D06DLQ	TTDDRUID	D06DLQ
D06DLQ	DRUGNAME	CGP-37849
D06DLQ	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1

D00BIY	TTDDRUID	D00BIY
D00BIY	DRUGNAME	CGP-48369
D00BIY	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0L6JX	TTDDRUID	D0L6JX
D0L6JX	DRUGNAME	CGP-50068
D0L6JX	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1

D01KIS	TTDDRUID	D01KIS
D01KIS	DRUGNAME	CGP-53437
D01KIS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0QA6Q	TTDDRUID	D0QA6Q
D0QA6Q	DRUGNAME	CGP-55847
D0QA6Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0H5PG	TTDDRUID	D0H5PG
D0H5PG	DRUGNAME	CGS-22652
D0H5PG	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1

D0Z6NK	TTDDRUID	D0Z6NK
D0Z6NK	DRUGNAME	CHB-111
D0Z6NK	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1

D04XEO	TTDDRUID	D04XEO
D04XEO	DRUGNAME	ChelASE
D04XEO	INDICATI	Retina disorder [ICD-11: 9B70-9B7Z] Discontinued in Phase 1

D0H5LC	TTDDRUID	D0H5LC
D0H5LC	DRUGNAME	CHPMPC
D0H5LC	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1

D07CIB	TTDDRUID	D07CIB
D07CIB	DRUGNAME	CI-1013
D07CIB	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1

D05UPB	TTDDRUID	D05UPB
D05UPB	DRUGNAME	CI-972
D05UPB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D05KTK	TTDDRUID	D05KTK
D05KTK	DRUGNAME	CJC-1004
D05KTK	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D06FCR	TTDDRUID	D06FCR
D06FCR	DRUGNAME	CL-277082
D06FCR	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0Y7HW	TTDDRUID	D0Y7HW
D0Y7HW	DRUGNAME	Clomet
D0Y7HW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D03ZCG	TTDDRUID	D03ZCG
D03ZCG	DRUGNAME	CMV vaccine
D03ZCG	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Phase 1

D01ZTR	TTDDRUID	D01ZTR
D01ZTR	DRUGNAME	Colon cancer vaccine
D01ZTR	INDICATI	Colon cancer [ICD-11: 2B90.Z] Discontinued in Phase 1

D0C0EO	TTDDRUID	D0C0EO
D0C0EO	DRUGNAME	CP-105696
D0C0EO	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1

D0L9PY	TTDDRUID	D0L9PY
D0L9PY	DRUGNAME	CP-66948
D0L9PY	INDICATI	Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1

D03MAD	TTDDRUID	D03MAD
D03MAD	DRUGNAME	CP-800569
D03MAD	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D07YHY	TTDDRUID	D07YHY
D07YHY	DRUGNAME	CR-2093
D07YHY	INDICATI	Intestine cancer [ICD-11: 2C0Z] Discontinued in Phase 1

D0U7CO	TTDDRUID	D0U7CO
D0U7CO	DRUGNAME	CRE-319M2
D0U7CO	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Discontinued in Phase 1

D09LZA	TTDDRUID	D09LZA
D09LZA	DRUGNAME	CS-4771
D09LZA	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1

D0R7GH	TTDDRUID	D0R7GH
D0R7GH	DRUGNAME	CS-526
D0R7GH	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1

D04KZN	TTDDRUID	D04KZN
D04KZN	DRUGNAME	CTP-354
D04KZN	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D02MHE	TTDDRUID	D02MHE
D02MHE	DRUGNAME	CVS-1123
D02MHE	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1

D0G1MZ	TTDDRUID	D0G1MZ
D0G1MZ	DRUGNAME	CY-1787
D0G1MZ	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1

D0I8TJ	TTDDRUID	D0I8TJ
D0I8TJ	DRUGNAME	CY-1788
D0I8TJ	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1

D0Z8LA	TTDDRUID	D0Z8LA
D0Z8LA	DRUGNAME	Cyclocreatine
D0Z8LA	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1

D0E8MW	TTDDRUID	D0E8MW
D0E8MW	DRUGNAME	D-1367
D0E8MW	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D01JOA	TTDDRUID	D01JOA
D01JOA	DRUGNAME	D-1927
D01JOA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0K1OA	TTDDRUID	D0K1OA
D0K1OA	DRUGNAME	D-4418
D0K1OA	INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Discontinued in Phase 1

D0C7LF	TTDDRUID	D0C7LF
D0C7LF	DRUGNAME	DACOPAFANT
D0C7LF	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1

D09GAG	TTDDRUID	D09GAG
D09GAG	DRUGNAME	DC-159a
D09GAG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0H2DN	TTDDRUID	D0H2DN
D0H2DN	DRUGNAME	DE-310
D0H2DN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0MF9H	TTDDRUID	D0MF9H
D0MF9H	DRUGNAME	Delucemine
D0MF9H	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1

D0X1BJ	TTDDRUID	D0X1BJ
D0X1BJ	DRUGNAME	Denibulin
D0X1BJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0W5OV	TTDDRUID	D0W5OV
D0W5OV	DRUGNAME	DF-1111301
D0W5OV	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1

D0FD2I	TTDDRUID	D0FD2I
D0FD2I	DRUGNAME	Discodermolide
D0FD2I	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1

D04NMF	TTDDRUID	D04NMF
D04NMF	DRUGNAME	DISC-PRO
D04NMF	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1

D0QW7D	TTDDRUID	D0QW7D
D0QW7D	DRUGNAME	DK-507k
D0QW7D	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0II5S	TTDDRUID	D0II5S
D0II5S	DRUGNAME	DMP-728
D0II5S	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0U8AR	TTDDRUID	D0U8AR
D0U8AR	DRUGNAME	DMP-851
D0U8AR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D03QJN	TTDDRUID	D03QJN
D03QJN	DRUGNAME	DPC 423
D03QJN	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D09PSB	TTDDRUID	D09PSB
D09PSB	DRUGNAME	DPC-082
D09PSB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0C2IA	TTDDRUID	D0C2IA
D0C2IA	DRUGNAME	DPC-168
D0C2IA	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1

D0N3ZY	TTDDRUID	D0N3ZY
D0N3ZY	DRUGNAME	DPC-681
D0N3ZY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D07JJC	TTDDRUID	D07JJC
D07JJC	DRUGNAME	DPC-684
D07JJC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0W3YW	TTDDRUID	D0W3YW
D0W3YW	DRUGNAME	DRF 10945
D0W3YW	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D0F8XI	TTDDRUID	D0F8XI
D0F8XI	DRUGNAME	DS-1442
D0F8XI	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1

D0Z6OI	TTDDRUID	D0Z6OI
D0Z6OI	DRUGNAME	DS-6930
D0Z6OI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0Z2QR	TTDDRUID	D0Z2QR
D0Z2QR	DRUGNAME	DS-7250
D0Z2QR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0FL6X	TTDDRUID	D0FL6X
D0FL6X	DRUGNAME	DS-8587
D0FL6X	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D09WHM	TTDDRUID	D09WHM
D09WHM	DRUGNAME	DU-29894
D09WHM	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D0YJ9T	TTDDRUID	D0YJ9T
D0YJ9T	DRUGNAME	DU-6681
D0YJ9T	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D08GRY	TTDDRUID	D08GRY
D08GRY	DRUGNAME	DUP 697
D08GRY	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D0N1EW	TTDDRUID	D0N1EW
D0N1EW	DRUGNAME	DuP-532
D0N1EW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0Z4QV	TTDDRUID	D0Z4QV
D0Z4QV	DRUGNAME	DUP-734
D0Z4QV	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D0Q5AS	TTDDRUID	D0Q5AS
D0Q5AS	DRUGNAME	DUP-860
D0Q5AS	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 1

D0T6PV	TTDDRUID	D0T6PV
D0T6PV	DRUGNAME	DV-7751A
D0T6PV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0I5PM	TTDDRUID	D0I5PM
D0I5PM	DRUGNAME	DW-908e
D0I5PM	INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1

D0E3VF	TTDDRUID	D0E3VF
D0E3VF	DRUGNAME	E coli vaccine
D0E3VF	INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 1

D05OEG	TTDDRUID	D05OEG
D05OEG	DRUGNAME	E-2001
D05OEG	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1

D05DSK	TTDDRUID	D05DSK
D05DSK	DRUGNAME	E2101
D05DSK	INDICATI	Cervical dystonia [ICD-11: 8A02.0Y] Discontinued in Phase 1
D05DSK	INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 1

D06PHO	TTDDRUID	D06PHO
D06PHO	DRUGNAME	E-3030
D06PHO	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D00EEP	TTDDRUID	D00EEP
D00EEP	DRUGNAME	E-3309
D00EEP	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1

D06LBV	TTDDRUID	D06LBV
D06LBV	DRUGNAME	E-4767
D06LBV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D05TLM	TTDDRUID	D05TLM
D05TLM	DRUGNAME	E-5065
D05TLM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D07RUC	TTDDRUID	D07RUC
D07RUC	DRUGNAME	E-6087
D07RUC	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D0BN4Y	TTDDRUID	D0BN4Y
D0BN4Y	DRUGNAME	Ebalzotan
D0BN4Y	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D00YZP	TTDDRUID	D00YZP
D00YZP	DRUGNAME	EBS-A42
D00YZP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0D2GW	TTDDRUID	D0D2GW
D0D2GW	DRUGNAME	EHC18
D0D2GW	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1

D09FGX	TTDDRUID	D09FGX
D09FGX	DRUGNAME	ELACRIDAR
D09FGX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0JF6O	TTDDRUID	D0JF6O
D0JF6O	DRUGNAME	Eltenac
D0JF6O	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D0N0KR	TTDDRUID	D0N0KR
D0N0KR	DRUGNAME	Emakalim
D0N0KR	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1

D00CIF	TTDDRUID	D00CIF
D00CIF	DRUGNAME	EMD-503982
D00CIF	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0Y6HV	TTDDRUID	D0Y6HV
D0Y6HV	DRUGNAME	EMD-53998
D0Y6HV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1

D00MMV	TTDDRUID	D00MMV
D00MMV	DRUGNAME	Enoticumab
D00MMV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0O9EM	TTDDRUID	D0O9EM
D0O9EM	DRUGNAME	Eptapirone
D0O9EM	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D0ZA2L	TTDDRUID	D0ZA2L
D0ZA2L	DRUGNAME	ER-35786
D0ZA2L	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D08HIH	TTDDRUID	D08HIH
D08HIH	DRUGNAME	ERB-196
D08HIH	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1

D08SUQ	TTDDRUID	D08SUQ
D08SUQ	DRUGNAME	ES-285
D08SUQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0R6EL	TTDDRUID	D0R6EL
D0R6EL	DRUGNAME	ETC-1001
D0R6EL	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D08HMK	TTDDRUID	D08HMK
D08HMK	DRUGNAME	ETC-276
D08HMK	INDICATI	Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 1

D0Z7AM	TTDDRUID	D0Z7AM
D0Z7AM	DRUGNAME	Ether lipid
D0Z7AM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D07YKJ	TTDDRUID	D07YKJ
D07YKJ	DRUGNAME	EVT-103
D07YKJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1

D0P1WB	TTDDRUID	D0P1WB
D0P1WB	DRUGNAME	EVT-301
D0P1WB	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D0O2EB	TTDDRUID	D0O2EB
D0O2EB	DRUGNAME	F-11105
D0O2EB	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D03QZB	TTDDRUID	D03QZB
D03QZB	DRUGNAME	F-1394
D03QZB	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0B0MA	TTDDRUID	D0B0MA
D0B0MA	DRUGNAME	F-2692
D0B0MA	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D07CQJ	TTDDRUID	D07CQJ
D07CQJ	DRUGNAME	F-50040
D07CQJ	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1

D0Z4KX	TTDDRUID	D0Z4KX
D0Z4KX	DRUGNAME	Farampator
D0Z4KX	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1
D0Z4KX	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D0Q9WN	TTDDRUID	D0Q9WN
D0Q9WN	DRUGNAME	FC EPO
D0Q9WN	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 1

D0V9ZL	TTDDRUID	D0V9ZL
D0V9ZL	DRUGNAME	FCE-28161
D0V9ZL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D08DVR	TTDDRUID	D08DVR
D08DVR	DRUGNAME	Fentanyl MDTS
D08DVR	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D0DQ9N	TTDDRUID	D0DQ9N
D0DQ9N	DRUGNAME	Fibrovax
D0DQ9N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0U6KH	TTDDRUID	D0U6KH
D0U6KH	DRUGNAME	Figitumumab
D0U6KH	INDICATI	Malignant adrenal gland cancer [ICD-11: 2D11] Discontinued in Phase 1

D00ROV	TTDDRUID	D00ROV
D00ROV	DRUGNAME	FK-041
D00ROV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0J5WI	TTDDRUID	D0J5WI
D0J5WI	DRUGNAME	FK-518
D0J5WI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0NK2U	TTDDRUID	D0NK2U
D0NK2U	DRUGNAME	FK-973
D0NK2U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0T8VV	TTDDRUID	D0T8VV
D0T8VV	DRUGNAME	FLM-5011
D0T8VV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0F8QM	TTDDRUID	D0F8QM
D0F8QM	DRUGNAME	FR-158999
D0F8QM	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D09MAS	TTDDRUID	D09MAS
D09MAS	DRUGNAME	FR-901483
D09MAS	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Discontinued in Phase 1

D0QX0K	TTDDRUID	D0QX0K
D0QX0K	DRUGNAME	FT-105
D0QX0K	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0H5KK	TTDDRUID	D0H5KK
D0H5KK	DRUGNAME	Garnocestim
D0H5KK	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Discontinued in Phase 1

D06XZM	TTDDRUID	D06XZM
D06XZM	DRUGNAME	GBL-100
D06XZM	INDICATI	Dermatological disease [ICD-11: DA24.Y] Discontinued in Phase 1

D0F8RK	TTDDRUID	D0F8RK
D0F8RK	DRUGNAME	GED-aPC
D0F8RK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1

D0U0TD	TTDDRUID	D0U0TD
D0U0TD	DRUGNAME	Gedocarnil
D0U0TD	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D0AP4O	TTDDRUID	D0AP4O
D0AP4O	DRUGNAME	Gem 92
D0AP4O	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 1

D0L7BV	TTDDRUID	D0L7BV
D0L7BV	DRUGNAME	Gevotroline
D0L7BV	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D0V7PY	TTDDRUID	D0V7PY
D0V7PY	DRUGNAME	Giracodazole
D0V7PY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D05WFF	TTDDRUID	D05WFF
D05WFF	DRUGNAME	GNI-102
D05WFF	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1

D0MC3R	TTDDRUID	D0MC3R
D0MC3R	DRUGNAME	Goxalapladib
D0MC3R	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0J0AH	TTDDRUID	D0J0AH
D0J0AH	DRUGNAME	GP-668
D0J0AH	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1

D0H4ZD	TTDDRUID	D0H4ZD
D0H4ZD	DRUGNAME	GPI-2A
D0H4ZD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D09CQB	TTDDRUID	D09CQB
D09CQB	DRUGNAME	GPs-0193
D09CQB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0R2LR	TTDDRUID	D0R2LR
D0R2LR	DRUGNAME	GR-108359
D0R2LR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D01DOY	TTDDRUID	D01DOY
D01DOY	DRUGNAME	GR-127607
D01DOY	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1

D0C2HF	TTDDRUID	D0C2HF
D0C2HF	DRUGNAME	GR-253035
D0C2HF	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D0SS6J	TTDDRUID	D0SS6J
D0SS6J	DRUGNAME	GR-328713
D0SS6J	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D07RVP	TTDDRUID	D07RVP
D07RVP	DRUGNAME	GR-63799X
D07RVP	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0V5DX	TTDDRUID	D0V5DX
D0V5DX	DRUGNAME	GR-79236
D0V5DX	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0B4TT	TTDDRUID	D0B4TT
D0B4TT	DRUGNAME	GSK1004723
D0B4TT	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1

D0WY2L	TTDDRUID	D0WY2L
D0WY2L	DRUGNAME	GSK1018921
D0WY2L	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D0L0ZC	TTDDRUID	D0L0ZC
D0L0ZC	DRUGNAME	GSK1059615
D0L0ZC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1
D0L0ZC	INDICATI	Endometrial cancer [ICD-11: 2C76] Discontinued in Phase 1
D0L0ZC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1

D0AL0S	TTDDRUID	D0AL0S
D0AL0S	DRUGNAME	GSK-1362885
D0AL0S	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D03SHP	TTDDRUID	D03SHP
D03SHP	DRUGNAME	GSK2849466
D03SHP	INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1

D0CA3J	TTDDRUID	D0CA3J
D0CA3J	DRUGNAME	GSK568859
D0CA3J	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0F1WR	TTDDRUID	D0F1WR
D0F1WR	DRUGNAME	GSK649868
D0F1WR	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Discontinued in Phase 1

D04LEK	TTDDRUID	D04LEK
D04LEK	DRUGNAME	GSK729327
D04LEK	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D06GMJ	TTDDRUID	D06GMJ
D06GMJ	DRUGNAME	GSK945237
D06GMJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D09RDT	TTDDRUID	D09RDT
D09RDT	DRUGNAME	GT-3021
D09RDT	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1

D01EDO	TTDDRUID	D01EDO
D01EDO	DRUGNAME	GW-250495
D01EDO	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D05MXK	TTDDRUID	D05MXK
D05MXK	DRUGNAME	GW-473178
D05MXK	INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1

D0N9AS	TTDDRUID	D0N9AS
D0N9AS	DRUGNAME	GW-549771
D0N9AS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0M6YW	TTDDRUID	D0M6YW
D0M6YW	DRUGNAME	GYKI-12743
D0M6YW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D00JNT	TTDDRUID	D00JNT
D00JNT	DRUGNAME	HCV-086
D00JNT	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1

D0H9FX	TTDDRUID	D0H9FX
D0H9FX	DRUGNAME	HCV-371
D0H9FX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D08DZZ	TTDDRUID	D08DZZ
D08DZZ	DRUGNAME	HE2100
D08DZZ	INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1

D00TAP	TTDDRUID	D00TAP
D00TAP	DRUGNAME	Helivax
D00TAP	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1

D01MNV	TTDDRUID	D01MNV
D01MNV	DRUGNAME	HER-2VAX
D01MNV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1

D06JBA	TTDDRUID	D06JBA
D06JBA	DRUGNAME	HGS-TR2J
D06JBA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0R7ID	TTDDRUID	D0R7ID
D0R7ID	DRUGNAME	HMN-214
D0R7ID	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1
D0R7ID	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1

D03VHI	TTDDRUID	D03VHI
D03VHI	DRUGNAME	HMR-3562
D03VHI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D02PIH	TTDDRUID	D02PIH
D02PIH	DRUGNAME	HO-221
D02PIH	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1

D0K7TX	TTDDRUID	D0K7TX
D0K7TX	DRUGNAME	HOE-065
D0K7TX	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1

D0S3WK	TTDDRUID	D0S3WK
D0S3WK	DRUGNAME	HRC-302
D0S3WK	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Discontinued in Phase 1

D0B6HS	TTDDRUID	D0B6HS
D0B6HS	DRUGNAME	HRT
D0B6HS	INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Discontinued in Phase 1

D04ZJP	TTDDRUID	D04ZJP
D04ZJP	DRUGNAME	HSR-113
D04ZJP	INDICATI	Nausea and vomiting [ICD-11: MD90] Discontinued in Phase 1

D09ZPX	TTDDRUID	D09ZPX
D09ZPX	DRUGNAME	HSR-6071
D09ZPX	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0O5QL	TTDDRUID	D0O5QL
D0O5QL	DRUGNAME	HT-1067
D0O5QL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1

D04UHX	TTDDRUID	D04UHX
D04UHX	DRUGNAME	HumaRAD-HN
D04UHX	INDICATI	Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 1

D0P0QG	TTDDRUID	D0P0QG
D0P0QG	DRUGNAME	HuMV833
D0P0QG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0W2JY	TTDDRUID	D0W2JY
D0W2JY	DRUGNAME	IC-47
D0W2JY	INDICATI	Streptococcus infection [ICD-11: 1B53] Discontinued in Phase 1

D0L3EW	TTDDRUID	D0L3EW
D0L3EW	DRUGNAME	ICI-D-6888
D0L3EW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0A2NH	TTDDRUID	D0A2NH
D0A2NH	DRUGNAME	IDEC-131
D0A2NH	INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1

D07JHJ	TTDDRUID	D07JHJ
D07JHJ	DRUGNAME	IGANIDIPINE HYDROCHLORIDE
D07JHJ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 1

D08DOQ	TTDDRUID	D08DOQ
D08DOQ	DRUGNAME	IGN301
D08DOQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0I1BQ	TTDDRUID	D0I1BQ
D0I1BQ	DRUGNAME	IL-18BP
D0I1BQ	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Discontinued in Phase 1
D0I1BQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0E8VF	TTDDRUID	D0E8VF
D0E8VF	DRUGNAME	IMC-1C11
D0E8VF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06BYS	TTDDRUID	D06BYS
D06BYS	DRUGNAME	Imepitoin
D06BYS	INDICATI	Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 1

D06VFK	TTDDRUID	D06VFK
D06VFK	DRUGNAME	Immunostimulant patch
D06VFK	INDICATI	Vaccination [ICD-11: N.A.] Discontinued in Phase 1

D00CGU	TTDDRUID	D00CGU
D00CGU	DRUGNAME	IMS
D00CGU	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1

D07VXT	TTDDRUID	D07VXT
D07VXT	DRUGNAME	INCB8696
D07VXT	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D07KOR	TTDDRUID	D07KOR
D07KOR	DRUGNAME	INOC-002
D07KOR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0S4XX	TTDDRUID	D0S4XX
D0S4XX	DRUGNAME	INOC-003
D0S4XX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0BM6S	TTDDRUID	D0BM6S
D0BM6S	DRUGNAME	IPI-493
D0BM6S	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 1

D0X2YI	TTDDRUID	D0X2YI
D0X2YI	DRUGNAME	IPLl576092
D0X2YI	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0JN3M	TTDDRUID	D0JN3M
D0JN3M	DRUGNAME	ITAMELINE
D0JN3M	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1

D0FY6Q	TTDDRUID	D0FY6Q
D0FY6Q	DRUGNAME	JTK-109
D0FY6Q	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D0A1KR	TTDDRUID	D0A1KR
D0A1KR	DRUGNAME	JTK-652
D0A1KR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D0F0OJ	TTDDRUID	D0F0OJ
D0F0OJ	DRUGNAME	JTK-656
D0F0OJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D01ZGH	TTDDRUID	D01ZGH
D01ZGH	DRUGNAME	JTK-853
D01ZGH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D0U5NY	TTDDRUID	D0U5NY
D0U5NY	DRUGNAME	JTT-553
D0U5NY	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D09HAL	TTDDRUID	D09HAL
D09HAL	DRUGNAME	JTT-651
D09HAL	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0N8JP	TTDDRUID	D0N8JP
D0N8JP	DRUGNAME	JTV-803
D0N8JP	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D03LXJ	TTDDRUID	D03LXJ
D03LXJ	DRUGNAME	KB-2683
D03LXJ	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D0T9MQ	TTDDRUID	D0T9MQ
D0T9MQ	DRUGNAME	KN-203
D0T9MQ	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1

D0X8AU	TTDDRUID	D0X8AU
D0X8AU	DRUGNAME	KNI-764
D0X8AU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0W6WD	TTDDRUID	D0W6WD
D0W6WD	DRUGNAME	KP106
D0W6WD	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 1

D0V8RY	TTDDRUID	D0V8RY
D0V8RY	DRUGNAME	KR-30450
D0V8RY	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D03KST	TTDDRUID	D03KST
D03KST	DRUGNAME	KT2-962
D03KST	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D06JWO	TTDDRUID	D06JWO
D06JWO	DRUGNAME	KT-362
D06JWO	INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1

D0VP2T	TTDDRUID	D0VP2T
D0VP2T	DRUGNAME	KU-2285
D0VP2T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0H5KO	TTDDRUID	D0H5KO
D0H5KO	DRUGNAME	KW-3635
D0H5KO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D01DPD	TTDDRUID	D01DPD
D01DPD	DRUGNAME	KW-6055
D01DPD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0Q8RX	TTDDRUID	D0Q8RX
D0Q8RX	DRUGNAME	L-368899
D0Q8RX	INDICATI	Miscarriage [ICD-11: JA00.0] Discontinued in Phase 1

D0B3CY	TTDDRUID	D0B3CY
D0B3CY	DRUGNAME	L-692429
D0B3CY	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 1

D01AUL	TTDDRUID	D01AUL
D01AUL	DRUGNAME	L-697639
D01AUL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0P8JX	TTDDRUID	D0P8JX
D0P8JX	DRUGNAME	L-734217
D0P8JX	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D06WEB	TTDDRUID	D06WEB
D06WEB	DRUGNAME	LAF-389
D06WEB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0R5AU	TTDDRUID	D0R5AU
D0R5AU	DRUGNAME	LASINAVIR
D0R5AU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D05CHR	TTDDRUID	D05CHR
D05CHR	DRUGNAME	LBY-135
D05CHR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D04ZNG	TTDDRUID	D04ZNG
D04ZNG	DRUGNAME	LF-08-0133
D04ZNG	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0YO4D	TTDDRUID	D0YO4D
D0YO4D	DRUGNAME	LG100268
D0YO4D	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 1

D09SLU	TTDDRUID	D09SLU
D09SLU	DRUGNAME	LG-101280
D09SLU	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D03KTE	TTDDRUID	D03KTE
D03KTE	DRUGNAME	LGD2941
D03KTE	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1

D0N1SU	TTDDRUID	D0N1SU
D0N1SU	DRUGNAME	Licofelone
D0N1SU	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 1

D09CKF	TTDDRUID	D09CKF
D09CKF	DRUGNAME	Licostinel
D09CKF	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1

D0Y8PM	TTDDRUID	D0Y8PM
D0Y8PM	DRUGNAME	LJP-1082
D0Y8PM	INDICATI	Hughes syndrome [ICD-11: 4A45.Z] Discontinued in Phase 1

D0K4OL	TTDDRUID	D0K4OL
D0K4OL	DRUGNAME	LOR-2501
D0K4OL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D03VLS	TTDDRUID	D03VLS
D03VLS	DRUGNAME	Lu-AA37096
D03VLS	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D06VPE	TTDDRUID	D06VPE
D06VPE	DRUGNAME	Lu-AA38466
D06VPE	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1

D06LEJ	TTDDRUID	D06LEJ
D06LEJ	DRUGNAME	Lu-AA44608
D06LEJ	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 1

D0LJ0L	TTDDRUID	D0LJ0L
D0LJ0L	DRUGNAME	Lu-AA47070
D0LJ0L	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1

D09UIM	TTDDRUID	D09UIM
D09UIM	DRUGNAME	LXR-0151
D09UIM	INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 1

D05XYC	TTDDRUID	D05XYC
D05XYC	DRUGNAME	LY-231617
D05XYC	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D0K5HD	TTDDRUID	D0K5HD
D0K5HD	DRUGNAME	LY-315902
D0K5HD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0LR1M	TTDDRUID	D0LR1M
D0LR1M	DRUGNAME	LY-444711
D0LR1M	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 1

D0B0EB	TTDDRUID	D0B0EB
D0B0EB	DRUGNAME	LY-929
D0B0EB	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1

D0T8YV	TTDDRUID	D0T8YV
D0T8YV	DRUGNAME	LymphoRad-131
D0T8YV	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1

D0J6EQ	TTDDRUID	D0J6EQ
D0J6EQ	DRUGNAME	M-512101
D0J6EQ	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1

D0C9AQ	TTDDRUID	D0C9AQ
D0C9AQ	DRUGNAME	MBI 1121
D0C9AQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0M4UY	TTDDRUID	D0M4UY
D0M4UY	DRUGNAME	MBI-853NL
D0M4UY	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 1

D09ANC	TTDDRUID	D09ANC
D09ANC	DRUGNAME	MC-02,479
D09ANC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0H1PN	TTDDRUID	D0H1PN
D0H1PN	DRUGNAME	ME-3277
D0H1PN	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0GC8F	TTDDRUID	D0GC8F
D0GC8F	DRUGNAME	MED-27
D0GC8F	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D00UOZ	TTDDRUID	D00UOZ
D00UOZ	DRUGNAME	MEDI-491
D00UOZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1

D0YT6Z	TTDDRUID	D0YT6Z
D0YT6Z	DRUGNAME	Mirisetron maleate
D0YT6Z	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D0J5FU	TTDDRUID	D0J5FU
D0J5FU	DRUGNAME	MIV-701
D0J5FU	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1

D06AGD	TTDDRUID	D06AGD
D06AGD	DRUGNAME	MK-0963
D06AGD	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 1

D07UOS	TTDDRUID	D07UOS
D07UOS	DRUGNAME	MK-434
D07UOS	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 1

D0M0KB	TTDDRUID	D0M0KB
D0M0KB	DRUGNAME	MK-6592
D0M0KB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0H3JR	TTDDRUID	D0H3JR
D0H3JR	DRUGNAME	MKC-121
D0H3JR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D06ZYC	TTDDRUID	D06ZYC
D06ZYC	DRUGNAME	MLN0415
D06ZYC	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D07NYF	TTDDRUID	D07NYF
D07NYF	DRUGNAME	MLN-2201
D07NYF	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1

D0V4ZC	TTDDRUID	D0V4ZC
D0V4ZC	DRUGNAME	MLN4760
D0V4ZC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0GT0Y	TTDDRUID	D0GT0Y
D0GT0Y	DRUGNAME	MN-246
D0GT0Y	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1

D0S2YX	TTDDRUID	D0S2YX
D0S2YX	DRUGNAME	Mofarotene
D0S2YX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0Z3XO	TTDDRUID	D0Z3XO
D0Z3XO	DRUGNAME	MP-136
D0Z3XO	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1

D0UF5I	TTDDRUID	D0UF5I
D0UF5I	DRUGNAME	MPC-0920
D0UF5I	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0F8TS	TTDDRUID	D0F8TS
D0F8TS	DRUGNAME	MPC-9055
D0F8TS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0QF4Z	TTDDRUID	D0QF4Z
D0QF4Z	DRUGNAME	MT-500
D0QF4Z	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1

D0R2QB	TTDDRUID	D0R2QB
D0R2QB	DRUGNAME	MT-7716
D0R2QB	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Discontinued in Phase 1

D05BCA	TTDDRUID	D05BCA
D05BCA	DRUGNAME	MX-4509
D05BCA	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1

D0S4AR	TTDDRUID	D0S4AR
D0S4AR	DRUGNAME	MX-68
D0S4AR	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0I4FL	TTDDRUID	D0I4FL
D0I4FL	DRUGNAME	N-1177-inh
D0I4FL	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1

D0GZ3J	TTDDRUID	D0GZ3J
D0GZ3J	DRUGNAME	NAMI-A
D0GZ3J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0D3ZP	TTDDRUID	D0D3ZP
D0D3ZP	DRUGNAME	NBI-42902
D0D3ZP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1

D00ACC	TTDDRUID	D00ACC
D00ACC	DRUGNAME	ND1251
D00ACC	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1

D0G6RU	TTDDRUID	D0G6RU
D0G6RU	DRUGNAME	NE-1530
D0G6RU	INDICATI	Bronchitis [ICD-11: CA20] Discontinued in Phase 1

D06VOM	TTDDRUID	D06VOM
D06VOM	DRUGNAME	NEBO-174
D06VOM	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1

D0S2WC	TTDDRUID	D0S2WC
D0S2WC	DRUGNAME	Nerisopam
D0S2WC	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D0N1AS	TTDDRUID	D0N1AS
D0N1AS	DRUGNAME	NGD-4715
D0N1AS	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0Q5YH	TTDDRUID	D0Q5YH
D0Q5YH	DRUGNAME	NGD-94-4
D0Q5YH	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D0A0FG	TTDDRUID	D0A0FG
D0A0FG	DRUGNAME	NICANARTINE
D0A0FG	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0J4WW	TTDDRUID	D0J4WW
D0J4WW	DRUGNAME	NIP-520
D0J4WW	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0N2LY	TTDDRUID	D0N2LY
D0N2LY	DRUGNAME	NN-2501
D0N2LY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D06AQI	TTDDRUID	D06AQI
D06AQI	DRUGNAME	NN344
D06AQI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0PF9G	TTDDRUID	D0PF9G
D0PF9G	DRUGNAME	NN-4201
D0PF9G	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0MT7W	TTDDRUID	D0MT7W
D0MT7W	DRUGNAME	NN8210
D0MT7W	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0V0IO	TTDDRUID	D0V0IO
D0V0IO	DRUGNAME	NN9223
D0V0IO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0W0IN	TTDDRUID	D0W0IN
D0W0IN	DRUGNAME	NN-9925
D0W0IN	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0V6LF	TTDDRUID	D0V6LF
D0V6LF	DRUGNAME	NN9928
D0V6LF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0KM3P	TTDDRUID	D0KM3P
D0KM3P	DRUGNAME	NOStentin
D0KM3P	INDICATI	Artery stenosis [ICD-11: BD52] Discontinued in Phase 1

D08AFD	TTDDRUID	D08AFD
D08AFD	DRUGNAME	NP-252
D08AFD	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D04UKJ	TTDDRUID	D04UKJ
D04UKJ	DRUGNAME	NP-61
D04UKJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D0OB7J	TTDDRUID	D0OB7J
D0OB7J	DRUGNAME	NPC-15669
D0OB7J	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D08HVD	TTDDRUID	D08HVD
D08HVD	DRUGNAME	NRLU-10
D08HVD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1

D08UNQ	TTDDRUID	D08UNQ
D08UNQ	DRUGNAME	NSD-644
D08UNQ	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1

D0O1UC	TTDDRUID	D0O1UC
D0O1UC	DRUGNAME	NTC-801
D0O1UC	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 1
D0O1UC	INDICATI	Atrial flutter [ICD-11: BC81.2Z] Discontinued in Phase 1

D02YOQ	TTDDRUID	D02YOQ
D02YOQ	DRUGNAME	NUCB-1000
D02YOQ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1

D0Q9EH	TTDDRUID	D0Q9EH
D0Q9EH	DRUGNAME	NV-18
D0Q9EH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06QPI	TTDDRUID	D06QPI
D06QPI	DRUGNAME	NY-ESO-1 tumour vaccine
D06QPI	INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 1

D02ANJ	TTDDRUID	D02ANJ
D02ANJ	DRUGNAME	NZ-107
D02ANJ	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D03DXS	TTDDRUID	D03DXS
D03DXS	DRUGNAME	Odapipam
D03DXS	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D0L4SB	TTDDRUID	D0L4SB
D0L4SB	DRUGNAME	Oncolysin CD6
D0L4SB	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D0E4EP	TTDDRUID	D0E4EP
D0E4EP	DRUGNAME	Oncolysin M
D0E4EP	INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1

D0R5XK	TTDDRUID	D0R5XK
D0R5XK	DRUGNAME	ONO-1714
D0R5XK	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1

D0U2WO	TTDDRUID	D0U2WO
D0U2WO	DRUGNAME	ONO-2231
D0U2WO	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1

D05PQF	TTDDRUID	D05PQF
D05PQF	DRUGNAME	ONO-4127Na
D05PQF	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1

D0W8QH	TTDDRUID	D0W8QH
D0W8QH	DRUGNAME	ONO-4817
D0W8QH	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1

D0SR4G	TTDDRUID	D0SR4G
D0SR4G	DRUGNAME	ONT-093
D0SR4G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D02WLS	TTDDRUID	D02WLS
D02WLS	DRUGNAME	Onyvax-105
D02WLS	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1

D0XT5F	TTDDRUID	D0XT5F
D0XT5F	DRUGNAME	Onyvax-O
D0XT5F	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1

D0AV0O	TTDDRUID	D0AV0O
D0AV0O	DRUGNAME	OPC-51803
D0AV0O	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1

D0W2FG	TTDDRUID	D0W2FG
D0W2FG	DRUGNAME	OPHD-001
D0W2FG	INDICATI	Clostridium infection [ICD-11: 1A04] Discontinued in Phase 1

D00ABW	TTDDRUID	D00ABW
D00ABW	DRUGNAME	Opterone
D00ABW	INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1

D0W2SO	TTDDRUID	D0W2SO
D0W2SO	DRUGNAME	Orazipone
D0W2SO	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1

D0OZ4F	TTDDRUID	D0OZ4F
D0OZ4F	DRUGNAME	Ordopidine
D0OZ4F	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D04KCT	TTDDRUID	D04KCT
D04KCT	DRUGNAME	Org-21465
D04KCT	INDICATI	Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 1

D03AZU	TTDDRUID	D03AZU
D03AZU	DRUGNAME	Org-31710
D03AZU	INDICATI	Contraception [ICD-11: QA21] Discontinued in Phase 1

D0R8LW	TTDDRUID	D0R8LW
D0R8LW	DRUGNAME	ORG-34167
D0R8LW	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1

D00HMQ	TTDDRUID	D00HMQ
D00HMQ	DRUGNAME	Ormaplatin
D00HMQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1

D0DI0B	TTDDRUID	D0DI0B
D0DI0B	DRUGNAME	OX 19
D0DI0B	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1

D0B1PC	TTDDRUID	D0B1PC
D0B1PC	DRUGNAME	OXECLOSPORIN
D0B1PC	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1

D07IXD	TTDDRUID	D07IXD
D07IXD	DRUGNAME	P-0654
D07IXD	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0FT2Z	TTDDRUID	D0FT2Z
D0FT2Z	DRUGNAME	P1025
D0FT2Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D08LDV	TTDDRUID	D08LDV
D08LDV	DRUGNAME	PA-1050040
D08LDV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D03ISE	TTDDRUID	D03ISE
D03ISE	DRUGNAME	PAFENOLOL
D03ISE	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D09KXA	TTDDRUID	D09KXA
D09KXA	DRUGNAME	PD-131112
D09KXA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
D09KXA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Q7HO	TTDDRUID	D0Q7HO
D0Q7HO	DRUGNAME	PD-153035
D0Q7HO	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1

D0H7AC	TTDDRUID	D0H7AC
D0H7AC	DRUGNAME	PF-03814735
D0H7AC	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0A7UT	TTDDRUID	D0A7UT
D0A7UT	DRUGNAME	PF-04605412
D0A7UT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D08YFD	TTDDRUID	D08YFD
D08YFD	DRUGNAME	PF-05212372
D08YFD	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0K3SV	TTDDRUID	D0K3SV
D0K3SV	DRUGNAME	PF-05236812
D0K3SV	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D0B8CK	TTDDRUID	D0B8CK
D0B8CK	DRUGNAME	PF-05335810
D0B8CK	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 1

D0S7UU	TTDDRUID	D0S7UU
D0S7UU	DRUGNAME	PF-06260414
D0S7UU	INDICATI	Cachexia [ICD-11: MG20] Discontinued in Phase 1

D07TUD	TTDDRUID	D07TUD
D07TUD	DRUGNAME	PF-2391677
D07TUD	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1

D0T2QN	TTDDRUID	D0T2QN
D0T2QN	DRUGNAME	PF-2393296
D0T2QN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1

D0F6GU	TTDDRUID	D0F6GU
D0F6GU	DRUGNAME	PF-2400013
D0F6GU	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D03CHE	TTDDRUID	D03CHE
D03CHE	DRUGNAME	PF-251802
D03CHE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0U9VO	TTDDRUID	D0U9VO
D0U9VO	DRUGNAME	PF-2575799
D0U9VO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0MF7U	TTDDRUID	D0MF7U
D0MF7U	DRUGNAME	PF-3052334
D0MF7U	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0K3GU	TTDDRUID	D0K3GU
D0K3GU	DRUGNAME	PF-3185043
D0K3GU	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0A1KU	TTDDRUID	D0A1KU
D0A1KU	DRUGNAME	PF-3274167
D0A1KU	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Discontinued in Phase 1

D07KGW	TTDDRUID	D07KGW
D07KGW	DRUGNAME	PF-3392455
D07KGW	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D09QIJ	TTDDRUID	D09QIJ
D09QIJ	DRUGNAME	PF-3491165
D09QIJ	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0Y2XQ	TTDDRUID	D0Y2XQ
D0Y2XQ	DRUGNAME	PF-3526299
D0Y2XQ	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0PZ4Y	TTDDRUID	D0PZ4Y
D0PZ4Y	DRUGNAME	PF-3557156
D0PZ4Y	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D05JXM	TTDDRUID	D05JXM
D05JXM	DRUGNAME	PF-3932295
D05JXM	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D01WOD	TTDDRUID	D01WOD
D01WOD	DRUGNAME	PF-4064900
D01WOD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D0G1NW	TTDDRUID	D0G1NW
D0G1NW	DRUGNAME	PF-4308515
D0G1NW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0U7GW	TTDDRUID	D0U7GW
D0U7GW	DRUGNAME	PF-431499
D0U7GW	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0L2RV	TTDDRUID	D0L2RV
D0L2RV	DRUGNAME	PF-4325667
D0L2RV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0Y0QB	TTDDRUID	D0Y0QB
D0Y0QB	DRUGNAME	PF-4522625
D0Y0QB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 1

D0N8AB	TTDDRUID	D0N8AB
D0N8AB	DRUGNAME	PF-4629991
D0N8AB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0U9IQ	TTDDRUID	D0U9IQ
D0U9IQ	DRUGNAME	PF-477736
D0U9IQ	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0U6DC	TTDDRUID	D0U6DC
D0U6DC	DRUGNAME	PF-4967544
D0U6DC	INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 1

D0H1FL	TTDDRUID	D0H1FL
D0H1FL	DRUGNAME	PF-514273
D0H1FL	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0Q8CW	TTDDRUID	D0Q8CW
D0Q8CW	DRUGNAME	PF-738502
D0Q8CW	INDICATI	Fibromyalgia [ICD-11: MG30.01] Discontinued in Phase 1

D00FGY	TTDDRUID	D00FGY
D00FGY	DRUGNAME	PF-755616
D00FGY	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D04GVN	TTDDRUID	D04GVN
D04GVN	DRUGNAME	PF-807925
D04GVN	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D07FHW	TTDDRUID	D07FHW
D07FHW	DRUGNAME	PF-915275
D07FHW	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0D6DB	TTDDRUID	D0D6DB
D0D6DB	DRUGNAME	Phytosel
D0D6DB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0K8HF	TTDDRUID	D0K8HF
D0K8HF	DRUGNAME	PLD-147
D0K8HF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06BUI	TTDDRUID	D06BUI
D06BUI	DRUGNAME	PN-355
D06BUI	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 1

D0T5SZ	TTDDRUID	D0T5SZ
D0T5SZ	DRUGNAME	PNU-142721
D0T5SZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0TD6L	TTDDRUID	D0TD6L
D0TD6L	DRUGNAME	Pretarget technology
D0TD6L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0T4SO	TTDDRUID	D0T4SO
D0T4SO	DRUGNAME	PRO-367
D0T4SO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0B7PY	TTDDRUID	D0B7PY
D0B7PY	DRUGNAME	Prostate cancer vaccine
D0B7PY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1

D0BZ1L	TTDDRUID	D0BZ1L
D0BZ1L	DRUGNAME	PS386113
D0BZ1L	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0S5UB	TTDDRUID	D0S5UB
D0S5UB	DRUGNAME	PS522501
D0S5UB	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Discontinued in Phase 1

D06QAJ	TTDDRUID	D06QAJ
D06QAJ	DRUGNAME	PS948115
D06QAJ	INDICATI	Respiratory failure [ICD-11: CB41] Discontinued in Phase 1

D00HIC	TTDDRUID	D00HIC
D00HIC	DRUGNAME	Pseudomonas aeruginosa vaccine
D00HIC	INDICATI	Pseudomonas infection [ICD-11: 1B92] Discontinued in Phase 1

D0G6LR	TTDDRUID	D0G6LR
D0G6LR	DRUGNAME	PTI-721
D0G6LR	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D09GUI	TTDDRUID	D09GUI
D09GUI	DRUGNAME	PTL-68001
D09GUI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06KEJ	TTDDRUID	D06KEJ
D06KEJ	DRUGNAME	PV903
D06KEJ	INDICATI	Infertility [ICD-11: GB04] Discontinued in Phase 1

D0N3SH	TTDDRUID	D0N3SH
D0N3SH	DRUGNAME	Pyroxamide
D0N3SH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0L3VA	TTDDRUID	D0L3VA
D0L3VA	DRUGNAME	QAN-747
D0L3VA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D03BDE	TTDDRUID	D03BDE
D03BDE	DRUGNAME	QRX-401
D03BDE	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 1

D0W0TH	TTDDRUID	D0W0TH
D0W0TH	DRUGNAME	R 80122
D0W0TH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1

D0I5LM	TTDDRUID	D0I5LM
D0I5LM	DRUGNAME	R-1065
D0I5LM	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0L9ZK	TTDDRUID	D0L9ZK
D0L9ZK	DRUGNAME	R-1068
D0L9ZK	INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 1

D05CDG	TTDDRUID	D05CDG
D05CDG	DRUGNAME	R-1164
D05CDG	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1

D0ZM2S	TTDDRUID	D0ZM2S
D0ZM2S	DRUGNAME	R1204
D0ZM2S	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1

D04XJM	TTDDRUID	D04XJM
D04XJM	DRUGNAME	R1295
D04XJM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D01ZJM	TTDDRUID	D01ZJM
D01ZJM	DRUGNAME	R-1479
D01ZJM	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D04YHW	TTDDRUID	D04YHW
D04YHW	DRUGNAME	R-1487
D04YHW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0V7XC	TTDDRUID	D0V7XC
D0V7XC	DRUGNAME	R-1518
D0V7XC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D04FHB	TTDDRUID	D04FHB
D04FHB	DRUGNAME	R547
D04FHB	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D07GZL	TTDDRUID	D07GZL
D07GZL	DRUGNAME	R-701
D07GZL	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1

D0B0UN	TTDDRUID	D0B0UN
D0B0UN	DRUGNAME	R7232
D0B0UN	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1

D09SFH	TTDDRUID	D09SFH
D09SFH	DRUGNAME	R-82150
D09SFH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0V6HS	TTDDRUID	D0V6HS
D0V6HS	DRUGNAME	R-82913
D0V6HS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D08JTU	TTDDRUID	D08JTU
D08JTU	DRUGNAME	R-944
D08JTU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0S6AQ	TTDDRUID	D0S6AQ
D0S6AQ	DRUGNAME	Ramorelix
D0S6AQ	INDICATI	Esophageal cancer [ICD-11: 2B70] Discontinued in Phase 1

D0R3HX	TTDDRUID	D0R3HX
D0R3HX	DRUGNAME	RB-6145
D0R3HX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D09WTQ	TTDDRUID	D09WTQ
D09WTQ	DRUGNAME	RC-8800
D09WTQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D02UQG	TTDDRUID	D02UQG
D02UQG	DRUGNAME	RDEA-436
D02UQG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0G6NA	TTDDRUID	D0G6NA
D0G6NA	DRUGNAME	REN-850
D0G6NA	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D09LMX	TTDDRUID	D09LMX
D09LMX	DRUGNAME	Revatropate
D09LMX	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D00RIB	TTDDRUID	D00RIB
D00RIB	DRUGNAME	RG-201
D00RIB	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 1

D0J8JF	TTDDRUID	D0J8JF
D0J8JF	DRUGNAME	RG-4934
D0J8JF	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D0B7KF	TTDDRUID	D0B7KF
D0B7KF	DRUGNAME	RG-7152
D0B7KF	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D04VUY	TTDDRUID	D04VUY
D04VUY	DRUGNAME	RG-7166
D04VUY	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1

D0ZG1Y	TTDDRUID	D0ZG1Y
D0ZG1Y	DRUGNAME	RG-7167
D0ZG1Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D01NGT	TTDDRUID	D01NGT
D01NGT	DRUGNAME	RG-7185
D01NGT	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0D3HM	TTDDRUID	D0D3HM
D0D3HM	DRUGNAME	RG7212
D0D3HM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0D3KG	TTDDRUID	D0D3KG
D0D3KG	DRUGNAME	RG-7236
D0D3KG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1

D0RV7J	TTDDRUID	D0RV7J
D0RV7J	DRUGNAME	RG-7256
D0RV7J	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1

D03JQR	TTDDRUID	D03JQR
D03JQR	DRUGNAME	RG-7273
D03JQR	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1

D0DC1I	TTDDRUID	D0DC1I
D0DC1I	DRUGNAME	RG-7356
D0DC1I	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Discontinued in Phase 1

D0MH1R	TTDDRUID	D0MH1R
D0MH1R	DRUGNAME	RG7418
D0MH1R	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0QH7G	TTDDRUID	D0QH7G
D0QH7G	DRUGNAME	RG-7432
D0QH7G	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D0G9ZJ	TTDDRUID	D0G9ZJ
D0G9ZJ	DRUGNAME	RG7458
D0G9ZJ	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1

D07EQJ	TTDDRUID	D07EQJ
D07EQJ	DRUGNAME	RG-7594
D07EQJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0S3BR	TTDDRUID	D0S3BR
D0S3BR	DRUGNAME	RG7598
D0S3BR	INDICATI	Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 1

D04TYP	TTDDRUID	D04TYP
D04TYP	DRUGNAME	RG7600
D04TYP	INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1
D04TYP	INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1

D0O3KA	TTDDRUID	D0O3KA
D0O3KA	DRUGNAME	RG7602
D0O3KA	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1

D0J0IJ	TTDDRUID	D0J0IJ
D0J0IJ	DRUGNAME	RG7636
D0J0IJ	INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1

D09LEB	TTDDRUID	D09LEB
D09LEB	DRUGNAME	RG7641
D09LEB	INDICATI	Kidney disease [ICD-11: GC2Z] Discontinued in Phase 1

D06UJO	TTDDRUID	D06UJO
D06UJO	DRUGNAME	Rhenex
D06UJO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0G1RA	TTDDRUID	D0G1RA
D0G1RA	DRUGNAME	Rhodamine-123
D0G1RA	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1

D00TLD	TTDDRUID	D00TLD
D00TLD	DRUGNAME	RIG-200
D00TLD	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D01KHX	TTDDRUID	D01KHX
D01KHX	DRUGNAME	Rilmakalim
D01KHX	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D04NXR	TTDDRUID	D04NXR
D04NXR	DRUGNAME	RO-16-8714
D04NXR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0B6ER	TTDDRUID	D0B6ER
D0B6ER	DRUGNAME	Ro-31-6930
D0B6ER	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0MT9G	TTDDRUID	D0MT9G
D0MT9G	DRUGNAME	RO-48-8684
D0MT9G	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D09GHB	TTDDRUID	D09GHB
D09GHB	DRUGNAME	RO-4987655
D09GHB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0G9ZW	TTDDRUID	D0G9ZW
D0G9ZW	DRUGNAME	Roquinimex
D0G9ZW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D04SFR	TTDDRUID	D04SFR
D04SFR	DRUGNAME	RPI-78
D04SFR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D0Z2UD	TTDDRUID	D0Z2UD
D0Z2UD	DRUGNAME	RS-100975
D0Z2UD	INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 1

D0V4LG	TTDDRUID	D0V4LG
D0V4LG	DRUGNAME	RS-8891
D0V4LG	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0L5KF	TTDDRUID	D0L5KF
D0L5KF	DRUGNAME	RU-58841
D0L5KF	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1

D0ZD6Y	TTDDRUID	D0ZD6Y
D0ZD6Y	DRUGNAME	RUS 3108
D0ZD6Y	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D05QMJ	TTDDRUID	D05QMJ
D05QMJ	DRUGNAME	RWJ-56423
D05QMJ	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0XK1F	TTDDRUID	D0XK1F
D0XK1F	DRUGNAME	S-16961
D0XK1F	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D0P1YH	TTDDRUID	D0P1YH
D0P1YH	DRUGNAME	S-1746
D0P1YH	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1

D0H2ZQ	TTDDRUID	D0H2ZQ
D0H2ZQ	DRUGNAME	S-18326
D0H2ZQ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1

D0A8FD	TTDDRUID	D0A8FD
D0A8FD	DRUGNAME	S-18327
D0A8FD	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D0E2KT	TTDDRUID	D0E2KT
D0E2KT	DRUGNAME	S-234462
D0E2KT	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D07NGJ	TTDDRUID	D07NGJ
D07NGJ	DRUGNAME	S-23906-1
D07NGJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0UZ1I	TTDDRUID	D0UZ1I
D0UZ1I	DRUGNAME	S-33138
D0UZ1I	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D08NES	TTDDRUID	D08NES
D08NES	DRUGNAME	S-3536
D08NES	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 1

D02QMQ	TTDDRUID	D02QMQ
D02QMQ	DRUGNAME	S-3578
D02QMQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1

D04LSH	TTDDRUID	D04LSH
D04LSH	DRUGNAME	SAR101099
D04LSH	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 1

D02EVT	TTDDRUID	D02EVT
D02EVT	DRUGNAME	SAR-152954
D02EVT	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Discontinued in Phase 1

D05HIJ	TTDDRUID	D05HIJ
D05HIJ	DRUGNAME	SAR260301
D05HIJ	INDICATI	Pten-deficient tumour [ICD-11: 2C50-2F93] Discontinued in Phase 1

D0W0AM	TTDDRUID	D0W0AM
D0W0AM	DRUGNAME	SB 235699
D0W0AM	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1

D07JQO	TTDDRUID	D07JQO
D07JQO	DRUGNAME	SB 249417
D07JQO	INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1

D00BKV	TTDDRUID	D00BKV
D00BKV	DRUGNAME	SB 418790
D00BKV	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D08AMQ	TTDDRUID	D08AMQ
D08AMQ	DRUGNAME	SB-234551
D08AMQ	INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1

D0A9KI	TTDDRUID	D0A9KI
D0A9KI	DRUGNAME	SB-242235
D0A9KI	INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1

D04DGE	TTDDRUID	D04DGE
D04DGE	DRUGNAME	SB-247853
D04DGE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D02VIP	TTDDRUID	D02VIP
D02VIP	DRUGNAME	SB-267268
D02VIP	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1

D0B9SR	TTDDRUID	D0B9SR
D0B9SR	DRUGNAME	SB-273005
D0B9SR	INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1

D0W3AX	TTDDRUID	D0W3AX
D0W3AX	DRUGNAME	SB-281832
D0W3AX	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D03PDY	TTDDRUID	D03PDY
D03PDY	DRUGNAME	SB-332235
D03PDY	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D09NBM	TTDDRUID	D09NBM
D09NBM	DRUGNAME	SB-435495
D09NBM	INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1

D0VJ5N	TTDDRUID	D0VJ5N
D0VJ5N	DRUGNAME	SB-705498
D0VJ5N	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1

D05JXR	TTDDRUID	D05JXR
D05JXR	DRUGNAME	SC-52012
D05JXR	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D02OHR	TTDDRUID	D02OHR
D02OHR	DRUGNAME	SC-57666
D02OHR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1

D08YVT	TTDDRUID	D08YVT
D08YVT	DRUGNAME	SCH-211803
D08YVT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1

D01FXD	TTDDRUID	D01FXD
D01FXD	DRUGNAME	SCH-351591
D01FXD	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D0G6JE	TTDDRUID	D0G6JE
D0G6JE	DRUGNAME	SCH-C
D0G6JE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0D1VJ	TTDDRUID	D0D1VJ
D0D1VJ	DRUGNAME	SDZ-210-086
D0D1VJ	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1

D0XQ1W	TTDDRUID	D0XQ1W
D0XQ1W	DRUGNAME	SDZ-62-434
D0XQ1W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0I3PG	TTDDRUID	D0I3PG
D0I3PG	DRUGNAME	SDZ-CPI-975
D0I3PG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0LE7P	TTDDRUID	D0LE7P
D0LE7P	DRUGNAME	SDZ-GLC-756
D0LE7P	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 1

D04RUP	TTDDRUID	D04RUP
D04RUP	DRUGNAME	SDZ-NKT-343
D04RUP	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D0C3CF	TTDDRUID	D0C3CF
D0C3CF	DRUGNAME	SDZ-NVI-085
D0C3CF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1

D0U8IJ	TTDDRUID	D0U8IJ
D0U8IJ	DRUGNAME	SDZ-PCO-400
D0U8IJ	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D08ZBT	TTDDRUID	D08ZBT
D08ZBT	DRUGNAME	SDZ-WAG-994
D08ZBT	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D03CFR	TTDDRUID	D03CFR
D03CFR	DRUGNAME	SEP-226332
D03CFR	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Discontinued in Phase 1

D0HY3P	TTDDRUID	D0HY3P
D0HY3P	DRUGNAME	SGN-10
D0HY3P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0W7ZN	TTDDRUID	D0W7ZN
D0W7ZN	DRUGNAME	SIM-916
D0W7ZN	INDICATI	Gynecological disease [ICD-11: GA6Z] Discontinued in Phase 1

D0R2EY	TTDDRUID	D0R2EY
D0R2EY	DRUGNAME	SKF-97574
D0R2EY	INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 1

D0E3JL	TTDDRUID	D0E3JL
D0E3JL	DRUGNAME	SL-25.1188
D0E3JL	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D03ZHN	TTDDRUID	D03ZHN
D03ZHN	DRUGNAME	SL-65.1708
D03ZHN	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1

D0B4ZQ	TTDDRUID	D0B4ZQ
D0B4ZQ	DRUGNAME	SL-90.0571
D0B4ZQ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 1

D0E3BJ	TTDDRUID	D0E3BJ
D0E3BJ	DRUGNAME	SLV-311
D0E3BJ	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 1

D03ZZH	TTDDRUID	D03ZZH
D03ZZH	DRUGNAME	SLV-313
D03ZZH	INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1

D00VPU	TTDDRUID	D00VPU
D00VPU	DRUGNAME	SLV-323
D00VPU	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 1
D00VPU	INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 1
D00VPU	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 1

D06HCD	TTDDRUID	D06HCD
D06HCD	DRUGNAME	SM-6586
D06HCD	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0L3XV	TTDDRUID	D0L3XV
D0L3XV	DRUGNAME	SMART anti-E/P selectin
D0L3XV	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D00WWU	TTDDRUID	D00WWU
D00WWU	DRUGNAME	SMP-028
D00WWU	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0N3IT	TTDDRUID	D0N3IT
D0N3IT	DRUGNAME	SNX-1012
D0N3IT	INDICATI	Mucositis [ICD-11: CA00] Discontinued in Phase 1

D03LSO	TTDDRUID	D03LSO
D03LSO	DRUGNAME	SPD-418
D03LSO	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 1

D0X4OM	TTDDRUID	D0X4OM
D0X4OM	DRUGNAME	SPD-701
D0X4OM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 1

D03MIP	TTDDRUID	D03MIP
D03MIP	DRUGNAME	SPI-256
D03MIP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0L4VZ	TTDDRUID	D0L4VZ
D0L4VZ	DRUGNAME	SPP-1148
D0L4VZ	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D02KEY	TTDDRUID	D02KEY
D02KEY	DRUGNAME	SPP-676
D02KEY	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0E9EE	TTDDRUID	D0E9EE
D0E9EE	DRUGNAME	SR 144190
D0E9EE	INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Discontinued in Phase 1
D0E9EE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
D0E9EE	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
D0E9EE	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1

D0T3EV	TTDDRUID	D0T3EV
D0T3EV	DRUGNAME	SR-146131
D0T3EV	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0S0XS	TTDDRUID	D0S0XS
D0S0XS	DRUGNAME	SR-271425
D0S0XS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0A8ZD	TTDDRUID	D0A8ZD
D0A8ZD	DRUGNAME	SR-33805
D0A8ZD	INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1

D0LG4V	TTDDRUID	D0LG4V
D0LG4V	DRUGNAME	SR-47063
D0LG4V	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 1

D09YUK	TTDDRUID	D09YUK
D09YUK	DRUGNAME	SS1(dsFv)-PE38
D09YUK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D03JIH	TTDDRUID	D03JIH
D03JIH	DRUGNAME	SSR-125180
D03JIH	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0C3AN	TTDDRUID	D0C3AN
D0C3AN	DRUGNAME	SSR-146977
D0C3AN	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1

D0X5ZO	TTDDRUID	D0X5ZO
D0X5ZO	DRUGNAME	SSR-162369
D0X5ZO	INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1

D0N9BU	TTDDRUID	D0N9BU
D0N9BU	DRUGNAME	SSR-97225
D0N9BU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0I3VP	TTDDRUID	D0I3VP
D0I3VP	DRUGNAME	SULOFENUR
D0I3VP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0T8KF	TTDDRUID	D0T8KF
D0T8KF	DRUGNAME	SUN-8399
D0T8KF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D0C1CU	TTDDRUID	D0C1CU
D0C1CU	DRUGNAME	SUN-9221
D0C1CU	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0I4OX	TTDDRUID	D0I4OX
D0I4OX	DRUGNAME	SURADISTA
D0I4OX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0G6XC	TTDDRUID	D0G6XC
D0G6XC	DRUGNAME	SW-33377
D0G6XC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0H7ZB	TTDDRUID	D0H7ZB
D0H7ZB	DRUGNAME	SX-013
D0H7ZB	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D00LCT	TTDDRUID	D00LCT
D00LCT	DRUGNAME	Symakalim
D00LCT	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D04VTV	TTDDRUID	D04VTV
D04VTV	DRUGNAME	SYN-114
D04VTV	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1

D05HSI	TTDDRUID	D05HSI
D05HSI	DRUGNAME	T-0632
D05HSI	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Discontinued in Phase 1

D0V5BJ	TTDDRUID	D0V5BJ
D0V5BJ	DRUGNAME	T-2000
D0V5BJ	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1

D0L3YX	TTDDRUID	D0L3YX
D0L3YX	DRUGNAME	T-62
D0L3YX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1

D02LCI	TTDDRUID	D02LCI
D02LCI	DRUGNAME	TA-5493
D02LCI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0H5MX	TTDDRUID	D0H5MX
D0H5MX	DRUGNAME	TAFA-93
D0H5MX	INDICATI	Transplant rejection [ICD-11: NE84] Discontinued in Phase 1

D0D7GE	TTDDRUID	D0D7GE
D0D7GE	DRUGNAME	TAK-029
D0D7GE	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0A2XD	TTDDRUID	D0A2XD
D0A2XD	DRUGNAME	TAK-065
D0A2XD	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D0Q4YP	TTDDRUID	D0Q4YP
D0Q4YP	DRUGNAME	TAK-100
D0Q4YP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1

D0A9OV	TTDDRUID	D0A9OV
D0A9OV	DRUGNAME	TAK165
D0A9OV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D04OIF	TTDDRUID	D04OIF
D04OIF	DRUGNAME	TAK-259
D04OIF	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1

D0A8EG	TTDDRUID	D0A8EG
D0A8EG	DRUGNAME	TAK-591
D0A8EG	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D0P9KL	TTDDRUID	D0P9KL
D0P9KL	DRUGNAME	TAK-683
D0P9KL	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
D0P9KL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1
D0P9KL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D06IYV	TTDDRUID	D06IYV
D06IYV	DRUGNAME	TAK-810
D06IYV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1

D03KTK	TTDDRUID	D03KTK
D03KTK	DRUGNAME	TAK-937
D03KTK	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1

D09FZI	TTDDRUID	D09FZI
D09FZI	DRUGNAME	TALTOBULIN
D09FZI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0IE4H	TTDDRUID	D0IE4H
D0IE4H	DRUGNAME	TAZOMELINE
D0IE4H	INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1

D0Q1NI	TTDDRUID	D0Q1NI
D0Q1NI	DRUGNAME	TBC-Thai
D0Q1NI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0U7VZ	TTDDRUID	D0U7VZ
D0U7VZ	DRUGNAME	TD-2749
D0U7VZ	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 1

D00CVT	TTDDRUID	D00CVT
D00CVT	DRUGNAME	TD-6301
D00CVT	INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1

D0B7CZ	TTDDRUID	D0B7CZ
D0B7CZ	DRUGNAME	Teloxantrone
D0B7CZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D01OWJ	TTDDRUID	D01OWJ
D01OWJ	DRUGNAME	TG-1024
D01OWJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D01LQZ	TTDDRUID	D01LQZ
D01LQZ	DRUGNAME	TG-4023
D01LQZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D00PNU	TTDDRUID	D00PNU
D00PNU	DRUGNAME	TGN-1412
D00PNU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1

D03JSS	TTDDRUID	D03JSS
D03JSS	DRUGNAME	Tidembersat
D03JSS	INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1

D02QBJ	TTDDRUID	D02QBJ
D02QBJ	DRUGNAME	TIPLASININ
D02QBJ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0H5NX	TTDDRUID	D0H5NX
D0H5NX	DRUGNAME	TOP-53
D0H5NX	INDICATI	Metastatic lung cancer [ICD-11: 2D70] Discontinued in Phase 1

D04TJP	TTDDRUID	D04TJP
D04TJP	DRUGNAME	Totrombopag
D04TJP	INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1

D0C7JH	TTDDRUID	D0C7JH
D0C7JH	DRUGNAME	TP-9201
D0C7JH	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D02WII	TTDDRUID	D02WII
D02WII	DRUGNAME	TR-14035
D02WII	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D01VSK	TTDDRUID	D01VSK
D01VSK	DRUGNAME	TR-14531
D01VSK	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0G1YR	TTDDRUID	D0G1YR
D0G1YR	DRUGNAME	TRI-1144
D0G1YR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0R1XI	TTDDRUID	D0R1XI
D0R1XI	DRUGNAME	TRK-851
D0R1XI	INDICATI	Cough [ICD-11: MD12] Discontinued in Phase 1

D0N3TO	TTDDRUID	D0N3TO
D0N3TO	DRUGNAME	TRM-115
D0N3TO	INDICATI	Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1

D0S9XR	TTDDRUID	D0S9XR
D0S9XR	DRUGNAME	TRx-0037
D0S9XR	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D0P6OS	TTDDRUID	D0P6OS
D0P6OS	DRUGNAME	TT-235
D0P6OS	INDICATI	Miscarriage [ICD-11: JA00.0] Discontinued in Phase 1

D06KPW	TTDDRUID	D06KPW
D06KPW	DRUGNAME	U-103017
D06KPW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0R0OC	TTDDRUID	D0R0OC
D0R0OC	DRUGNAME	U-104067F
D0R0OC	INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1

D05EVI	TTDDRUID	D05EVI
D05EVI	DRUGNAME	U-78875
D05EVI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D0G5ZL	TTDDRUID	D0G5ZL
D0G5ZL	DRUGNAME	U-93385
D0G5ZL	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D09CAC	TTDDRUID	D09CAC
D09CAC	DRUGNAME	U-96988
D09CAC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D0T7CM	TTDDRUID	D0T7CM
D0T7CM	DRUGNAME	UCL-2000 and butabindide
D0T7CM	INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1

D0G0XN	TTDDRUID	D0G0XN
D0G0XN	DRUGNAME	UK-156406
D0G0XN	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1

D08WVA	TTDDRUID	D08WVA
D08WVA	DRUGNAME	UK-224671
D08WVA	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1

D00XZP	TTDDRUID	D00XZP
D00XZP	DRUGNAME	UR-7198
D00XZP	INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1

D06CZS	TTDDRUID	D06CZS
D06CZS	DRUGNAME	V85546
D06CZS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0G7WR	TTDDRUID	D0G7WR
D0G7WR	DRUGNAME	Vaccine, colorectal tumor
D0G7WR	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1

D01RKY	TTDDRUID	D01RKY
D01RKY	DRUGNAME	VAG-624
D01RKY	INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1

D0N2HF	TTDDRUID	D0N2HF
D0N2HF	DRUGNAME	Vanoxerine
D0N2HF	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Discontinued in Phase 1

D0MY6Q	TTDDRUID	D0MY6Q
D0MY6Q	DRUGNAME	Vibrilase
D0MY6Q	INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Discontinued in Phase 1

D03RYS	TTDDRUID	D03RYS
D03RYS	DRUGNAME	VNA-932
D03RYS	INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1

D08WTE	TTDDRUID	D08WTE
D08WTE	DRUGNAME	Vorsetuzumab mafodotin
D08WTE	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Discontinued in Phase 1

D09ADN	TTDDRUID	D09ADN
D09ADN	DRUGNAME	VOXERGOLIDE HYDROCHLORIDE
D09ADN	INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1

D0J5XZ	TTDDRUID	D0J5XZ
D0J5XZ	DRUGNAME	VP004
D0J5XZ	INDICATI	Substance use disorder [ICD-11: 6C4Z] Discontinued in Phase 1

D0Y8IS	TTDDRUID	D0Y8IS
D0Y8IS	DRUGNAME	VP-025
D0Y8IS	INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1

D05AAW	TTDDRUID	D05AAW
D05AAW	DRUGNAME	VR-776
D05AAW	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Discontinued in Phase 1

D0S7VZ	TTDDRUID	D0S7VZ
D0S7VZ	DRUGNAME	WAY-100289
D0S7VZ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D06ZVC	TTDDRUID	D06ZVC
D06ZVC	DRUGNAME	WAY-181187
D06ZVC	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1

D07ZXE	TTDDRUID	D07ZXE
D07ZXE	DRUGNAME	Wetimicin
D07ZXE	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 1

D0PB4P	TTDDRUID	D0PB4P
D0PB4P	DRUGNAME	XM-323
D0PB4P	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1

D01GDH	TTDDRUID	D01GDH
D01GDH	DRUGNAME	XR-9051
D01GDH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0S5AL	TTDDRUID	D0S5AL
D0S5AL	DRUGNAME	XTL-2125
D0S5AL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1

D0IZ7T	TTDDRUID	D0IZ7T
D0IZ7T	DRUGNAME	YM-17E
D0IZ7T	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D0D9AD	TTDDRUID	D0D9AD
D0D9AD	DRUGNAME	YM-750
D0D9AD	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1

D0G6UP	TTDDRUID	D0G6UP
D0G6UP	DRUGNAME	YM-75466
D0G6UP	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0C7JT	TTDDRUID	D0C7JT
D0C7JT	DRUGNAME	YM-976
D0C7JT	INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1

D0T2MN	TTDDRUID	D0T2MN
D0T2MN	DRUGNAME	Z-300
D0T2MN	INDICATI	Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1

D08RUX	TTDDRUID	D08RUX
D08RUX	DRUGNAME	Z-321
D08RUX	INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1

D0O9UG	TTDDRUID	D0O9UG
D0O9UG	DRUGNAME	ZD-0490
D0O9UG	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1

D0WY9H	TTDDRUID	D0WY9H
D0WY9H	DRUGNAME	ZD-0892
D0WY9H	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D04NPX	TTDDRUID	D04NPX
D04NPX	DRUGNAME	ZD-1611
D04NPX	INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 1

D01GTB	TTDDRUID	D01GTB
D01GTB	DRUGNAME	ZD-2767
D01GTB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D0PG5J	TTDDRUID	D0PG5J
D0PG5J	DRUGNAME	ZD-4927
D0PG5J	INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1

D0F0PG	TTDDRUID	D0F0PG
D0F0PG	DRUGNAME	ZD-6804
D0F0PG	INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1

D03EIC	TTDDRUID	D03EIC
D03EIC	DRUGNAME	ZD-7349
D03EIC	INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1

D00VBT	TTDDRUID	D00VBT
D00VBT	DRUGNAME	ZK 304709
D00VBT	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1

D06KVU	TTDDRUID	D06KVU
D06KVU	DRUGNAME	ABP 215
D06KVU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted

D0T4MK	TTDDRUID	D0T4MK
D0T4MK	DRUGNAME	Andexanet alfa
D0T4MK	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Application submitted
D0T4MK	INDICATI	Harmful effects of drugs, medicaments or biological substances [ICD-11: NE60] Application submitted

D0UM3M	TTDDRUID	D0UM3M
D0UM3M	DRUGNAME	AQST-120
D0UM3M	INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Application submitted

D0I1NM	TTDDRUID	D0I1NM
D0I1NM	DRUGNAME	Avastinbevacizumab
D0I1NM	INDICATI	Ovarian cancer [ICD-11: 2C73] Application submitted

D0EJ0B	TTDDRUID	D0EJ0B
D0EJ0B	DRUGNAME	Axicabtagene ciloleucel
D0EJ0B	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
D0EJ0B	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3
D0EJ0B	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2/3
D0EJ0B	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2/3
D0EJ0B	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Application submitted
D0EJ0B	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
D0EJ0B	INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 2/3

D0R7LS	TTDDRUID	D0R7LS
D0R7LS	DRUGNAME	Bortezomib intravenous
D0R7LS	INDICATI	Multiple myeloma [ICD-11: 2A83] Application submitted

D0VO7K	TTDDRUID	D0VO7K
D0VO7K	DRUGNAME	Capzola
D0VO7K	INDICATI	Bladder cancer [ICD-11: 2C94] Application submitted

D0A6SD	TTDDRUID	D0A6SD
D0A6SD	DRUGNAME	CLS008
D0A6SD	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Application submitted

D02UYQ	TTDDRUID	D02UYQ
D02UYQ	DRUGNAME	Darzalexdaratumumab
D02UYQ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D05IBP	TTDDRUID	D05IBP
D05IBP	DRUGNAME	DFD-09
D05IBP	INDICATI	Rosacea [ICD-11: ED90.0] Application submitted

D0EF9B	TTDDRUID	D0EF9B
D0EF9B	DRUGNAME	DFD-11
D0EF9B	INDICATI	Head and body lice [ICD-11: 1G00.0] Application submitted

D0CU1O	TTDDRUID	D0CU1O
D0CU1O	DRUGNAME	Dolutegravir + rilpivirine
D0CU1O	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Application submitted

D06QMV	TTDDRUID	D06QMV
D06QMV	DRUGNAME	DWP-450
D06QMV	INDICATI	Glabellar frown line [ICD-11: NA0Z] Application submitted

D0O6VK	TTDDRUID	D0O6VK
D0O6VK	DRUGNAME	Enzalutamide
D0O6VK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D06QWS	TTDDRUID	D06QWS
D06QWS	DRUGNAME	Fluarix Quadrivalent
D06QWS	INDICATI	Seasonal influenza infection [ICD-11: 1E30] Application submitted

D0K9SS	TTDDRUID	D0K9SS
D0K9SS	DRUGNAME	GP2015
D0K9SS	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Application submitted
D0K9SS	INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Application submitted
D0K9SS	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
D0K9SS	INDICATI	Psoriatic arthritis [ICD-11: FA21] Application submitted
D0K9SS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Application submitted

D0H8ZY	TTDDRUID	D0H8ZY
D0H8ZY	DRUGNAME	HEPLISAV-B
D0H8ZY	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Application submitted

D0K5NG	TTDDRUID	D0K5NG
D0K5NG	DRUGNAME	HLD200
D0K5NG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Application submitted

D0M7SG	TTDDRUID	D0M7SG
D0M7SG	DRUGNAME	IDP-118
D0M7SG	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2

D00NUO	TTDDRUID	D00NUO
D00NUO	DRUGNAME	IDP-122 topical
D00NUO	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted

D0V6BS	TTDDRUID	D0V6BS
D0V6BS	DRUGNAME	Jemdel
D0V6BS	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted

D0CW3U	TTDDRUID	D0CW3U
D0CW3U	DRUGNAME	Kanjinti
D0CW3U	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Application submitted
D0CW3U	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Application submitted

D0AQ4J	TTDDRUID	D0AQ4J
D0AQ4J	DRUGNAME	Keytruda
D0AQ4J	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0AQ4J	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0AQ4J	INDICATI	Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 2
D0AQ4J	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3
D0AQ4J	INDICATI	Melanoma [ICD-11: 2C30] Application submitted

D04YZS	TTDDRUID	D04YZS
D04YZS	DRUGNAME	KIT-302
D04YZS	INDICATI	Hypertension [ICD-11: BA00-BA04] Application submitted
D04YZS	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Application submitted
D04YZS	INDICATI	Pain [ICD-11: MG30-MG3Z] Application submitted

D0Q7EL	TTDDRUID	D0Q7EL
D0Q7EL	DRUGNAME	Kymriah
D0Q7EL	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Application submitted
D0Q7EL	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
D0Q7EL	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
D0Q7EL	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2

D0KJ4B	TTDDRUID	D0KJ4B
D0KJ4B	DRUGNAME	Lenvimalenvatinib
D0KJ4B	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D0KJ4B	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted

D05QKI	TTDDRUID	D05QKI
D05QKI	DRUGNAME	LixiLan
D05QKI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted

D07CCJ	TTDDRUID	D07CCJ
D07CCJ	DRUGNAME	Naloxone intranasal
D07CCJ	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Application submitted

D00WEF	TTDDRUID	D00WEF
D00WEF	DRUGNAME	Opdivo
D00WEF	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3
D00WEF	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D00WEF	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3
D00WEF	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Application submitted
D00WEF	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D07WPQ	TTDDRUID	D07WPQ
D07WPQ	DRUGNAME	Oxycodone hydrochloride
D07WPQ	INDICATI	Chronic pain [ICD-11: MG30] Application submitted

D0C7LD	TTDDRUID	D0C7LD
D0C7LD	DRUGNAME	Pemfexy
D0C7LD	INDICATI	Mesothelioma [ICD-11: 2C51.2] Application submitted
D0C7LD	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted

D06XKM	TTDDRUID	D06XKM
D06XKM	DRUGNAME	Privigen
D06XKM	INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1

D0B7VH	TTDDRUID	D0B7VH
D0B7VH	DRUGNAME	Remoxy ER
D0B7VH	INDICATI	Chronic pain [ICD-11: MG30] Application submitted

D0HR7X	TTDDRUID	D0HR7X
D0HR7X	DRUGNAME	Riboflavin ophthalmic solution
D0HR7X	DRUGNAME	ultraviolet-A (UVA) irradiation
D0HR7X	INDICATI	Corneal deformity [ICD-11: 9A78.5] Application submitted
D0HR7X	INDICATI	Keratoconus [ICD-11: 9A78.50] Application submitted

D0NE5B	TTDDRUID	D0NE5B
D0NE5B	DRUGNAME	Rintatolimid
D0NE5B	INDICATI	Chronic fatigue syndrome [ICD-11: 8E49] Application submitted

D0GP8Q	TTDDRUID	D0GP8Q
D0GP8Q	DRUGNAME	Risankizumab
D0GP8Q	INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
D0GP8Q	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2

D0X7GU	TTDDRUID	D0X7GU
D0X7GU	DRUGNAME	Rizaport
D0X7GU	INDICATI	Migraine [ICD-11: 8A80] Application submitted

D0HD0G	TTDDRUID	D0HD0G
D0HD0G	DRUGNAME	SB3
D0HD0G	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Application submitted

D0EH9A	TTDDRUID	D0EH9A
D0EH9A	DRUGNAME	Semprana
D0EH9A	INDICATI	Migraine [ICD-11: 8A80] Application submitted

D0FU5Y	TTDDRUID	D0FU5Y
D0FU5Y	DRUGNAME	SequestOx
D0FU5Y	INDICATI	Chronic pain [ICD-11: MG30] Application submitted

D08WCY	TTDDRUID	D08WCY
D08WCY	DRUGNAME	Seysara
D08WCY	INDICATI	Acne vulgaris [ICD-11: ED80] Application submitted

D0MM5P	TTDDRUID	D0MM5P
D0MM5P	DRUGNAME	Subcutaneous furosemide
D0MM5P	INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2/3
D0MM5P	INDICATI	Chronic heart failure [ICD-11: BD1Z] Application submitted

D08RFA	TTDDRUID	D08RFA
D08RFA	DRUGNAME	TAK-816
D08RFA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Application submitted

D0IM6T	TTDDRUID	D0IM6T
D0IM6T	DRUGNAME	Tisagenlecleucel-T
D0IM6T	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
D0IM6T	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Application submitted
D0IM6T	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2

D01UFH	TTDDRUID	D01UFH
D01UFH	DRUGNAME	Trastuzumab biosimilar
D01UFH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Application submitted
D01UFH	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Application submitted
D01UFH	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Application submitted

D0X1KN	TTDDRUID	D0X1KN
D0X1KN	DRUGNAME	Venetoclax
D0X1KN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
D0X1KN	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3

D0XR1B	TTDDRUID	D0XR1B
D0XR1B	DRUGNAME	Vyndaqel
D0XR1B	INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
D0XR1B	INDICATI	Familial amyloid polyneuropathy [ICD-11: 5D00.20] Application submitted

D0I7SU	TTDDRUID	D0I7SU
D0I7SU	DRUGNAME	Warfarin breakable tablets
D0I7SU	INDICATI	Thrombosis [ICD-11: DB61-GB90] Application submitted

D0R6YZ	TTDDRUID	D0R6YZ
D0R6YZ	DRUGNAME	Xultophy
D0R6YZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted

D01QLM	TTDDRUID	D01QLM
D01QLM	DRUGNAME	AAB-002
D01QLM	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0

D0YM4F	TTDDRUID	D0YM4F
D0YM4F	DRUGNAME	ACC-002
D0YM4F	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0

D0U2PU	TTDDRUID	D0U2PU
D0U2PU	DRUGNAME	Anti-BCMA CAR T cells
D0U2PU	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0G5SK	TTDDRUID	D0G5SK
D0G5SK	DRUGNAME	Anti-CD19 CAR T cells
D0G5SK	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 0

D0H8UT	TTDDRUID	D0H8UT
D0H8UT	DRUGNAME	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
D0H8UT	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 0

D0D1HI	TTDDRUID	D0D1HI
D0D1HI	DRUGNAME	Autologous T Cells Expressing MET scFv CAR
D0D1HI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 0
D0D1HI	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0NG3T	TTDDRUID	D0NG3T
D0NG3T	DRUGNAME	BCMA CAR-T Cells
D0NG3T	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D0L6HU	TTDDRUID	D0L6HU
D0L6HU	DRUGNAME	CAR-T Cells targeting CEA
D0L6HU	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0ZQ6N	TTDDRUID	D0ZQ6N
D0ZQ6N	DRUGNAME	CAR-T Cells targeting EGFRvIII
D0ZQ6N	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D06XWD	TTDDRUID	D06XWD
D06XWD	DRUGNAME	CAR-T Cells targeting HER2
D06XWD	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0L7OJ	TTDDRUID	D0L7OJ
D0L7OJ	DRUGNAME	CAR-T Cells targeting Mesothelin
D0L7OJ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D06URX	TTDDRUID	D06URX
D06URX	DRUGNAME	CAR-T Cells targeting MUCI
D06URX	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D02MYI	TTDDRUID	D02MYI
D02MYI	DRUGNAME	CAR-T Cells targeting PSCA
D02MYI	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0M5II	TTDDRUID	D0M5II
D0M5II	DRUGNAME	CART-19 autologous T-cells
D0M5II	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1

D0P4KP	TTDDRUID	D0P4KP
D0P4KP	DRUGNAME	CART19 cells
D0P4KP	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 0

D0MD8S	TTDDRUID	D0MD8S
D0MD8S	DRUGNAME	CARTmeso/19
D0MD8S	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D08HKK	TTDDRUID	D08HKK
D08HKK	DRUGNAME	CD10-CART
D08HKK	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D0QE4F	TTDDRUID	D0QE4F
D0QE4F	DRUGNAME	CD19-CAR and CD28-CAR T Cells
D0QE4F	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1

D0E8ZL	TTDDRUID	D0E8ZL
D0E8ZL	DRUGNAME	CD20-CART
D0E8ZL	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D09AXQ	TTDDRUID	D09AXQ
D09AXQ	DRUGNAME	CD22-CART
D09AXQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1

D03GTO	TTDDRUID	D03GTO
D03GTO	DRUGNAME	C-Met/PD-L1 CAR-T Cell
D03GTO	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1

D0YU0L	TTDDRUID	D0YU0L
D0YU0L	DRUGNAME	GPA-TriMAR-T cells
D0YU0L	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D0P7BA	TTDDRUID	D0P7BA
D0P7BA	DRUGNAME	INP102
D0P7BA	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0

D02CUN	TTDDRUID	D02CUN
D02CUN	DRUGNAME	NM504
D02CUN	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
D02CUN	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 0

D0V9MT	TTDDRUID	D0V9MT
D0V9MT	DRUGNAME	PU-AD
D0V9MT	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0
D0V9MT	INDICATI	Encephalopathy [ICD-11: 8E47] Phase 1

D0V2FZ	TTDDRUID	D0V2FZ
D0V2FZ	DRUGNAME	111In-hEGF
D0V2FZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical

D05HCO	TTDDRUID	D05HCO
D05HCO	DRUGNAME	1954U89
D05HCO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0L5DZ	TTDDRUID	D0L5DZ
D0L5DZ	DRUGNAME	4SC-202
D0L5DZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0TF1E	TTDDRUID	D0TF1E
D0TF1E	DRUGNAME	A-366833
D0TF1E	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D07LRT	TTDDRUID	D07LRT
D07LRT	DRUGNAME	A-425619
D07LRT	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0O8EK	TTDDRUID	D0O8EK
D0O8EK	DRUGNAME	A-54145
D0O8EK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D09IJP	TTDDRUID	D09IJP
D09IJP	DRUGNAME	A-71378
D09IJP	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D02PSZ	TTDDRUID	D02PSZ
D02PSZ	DRUGNAME	A-74498
D02PSZ	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D06LYZ	TTDDRUID	D06LYZ
D06LYZ	DRUGNAME	A-841720
D06LYZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D04EIX	TTDDRUID	D04EIX
D04EIX	DRUGNAME	AA-102
D04EIX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical

D0I8FO	TTDDRUID	D0I8FO
D0I8FO	DRUGNAME	ABI-0043
D0I8FO	INDICATI	Respiratory tract infection [ICD-11: CA45] Preclinical

D0Y4BO	TTDDRUID	D0Y4BO
D0Y4BO	DRUGNAME	ABI-013
D0Y4BO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0D1RF	TTDDRUID	D0D1RF
D0D1RF	DRUGNAME	ABX-0401
D0D1RF	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Preclinical

D01ZCL	TTDDRUID	D01ZCL
D01ZCL	DRUGNAME	ACT-N
D01ZCL	INDICATI	Brain injury [ICD-11: NA07.Z] Preclinical

D09HDV	TTDDRUID	D09HDV
D09HDV	DRUGNAME	AD-529
D09HDV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Preclinical

D04MMJ	TTDDRUID	D04MMJ
D04MMJ	DRUGNAME	ADX-2 series
D04MMJ	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0B2RZ	TTDDRUID	D0B2RZ
D0B2RZ	DRUGNAME	ADX-71943
D0B2RZ	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical

D0G1EH	TTDDRUID	D0G1EH
D0G1EH	DRUGNAME	AEOL-10150
D0G1EH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Preclinical

D09DKY	TTDDRUID	D09DKY
D09DKY	DRUGNAME	AEZS-123
D09DKY	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Preclinical

D00IYM	TTDDRUID	D00IYM
D00IYM	DRUGNAME	AEZS-127
D00IYM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D04DNL	TTDDRUID	D04DNL
D04DNL	DRUGNAME	ALN-FLU01
D04DNL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Preclinical

D0V7VX	TTDDRUID	D0V7VX
D0V7VX	DRUGNAME	ALN-HTT
D0V7VX	INDICATI	Huntington disease [ICD-11: 8A01.10] Preclinical

D0H5HJ	TTDDRUID	D0H5HJ
D0H5HJ	DRUGNAME	ALN-PCS
D0H5HJ	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Preclinical

D0E8CZ	TTDDRUID	D0E8CZ
D0E8CZ	DRUGNAME	Amibegron
D0E8CZ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3
D0E8CZ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Preclinical
D0E8CZ	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 3
D0E8CZ	INDICATI	Obesity [ICD-11: 5B81] Preclinical
D0E8CZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D0M6OW	TTDDRUID	D0M6OW
D0M6OW	DRUGNAME	ANAVEX 1007
D0M6OW	INDICATI	Melanoma [ICD-11: 2C30] Preclinical
D0M6OW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Preclinical
D0M6OW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D0T0UC	TTDDRUID	D0T0UC
D0T0UC	DRUGNAME	ANAVEX 1-41
D0T0UC	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical

D0NL9N	TTDDRUID	D0NL9N
D0NL9N	DRUGNAME	Anti-CD19/20-CAR vector-transduced T cells
D0NL9N	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
D0NL9N	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Clinical trial
D0NL9N	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Clinical trial
D0NL9N	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Clinical trial
D0NL9N	INDICATI	Follicular lymphoma [ICD-11: 2A80] Clinical trial
D0NL9N	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Clinical trial
D0NL9N	INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Clinical trial

D03UNT	TTDDRUID	D03UNT
D03UNT	DRUGNAME	Anti-CD19-CAR vector-transduced T cells
D03UNT	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
D03UNT	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Clinical trial
D03UNT	INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
D03UNT	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Clinical trial
D03UNT	INDICATI	Follicular lymphoma [ICD-11: 2A80] Clinical trial
D03UNT	INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Clinical trial
D03UNT	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
D03UNT	INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Clinical trial

D0M9RE	TTDDRUID	D0M9RE
D0M9RE	DRUGNAME	ARI-809
D0M9RE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical

D0A1VL	TTDDRUID	D0A1VL
D0A1VL	DRUGNAME	AR-R-1589
D0A1VL	INDICATI	Eating disorder [ICD-11: 6B82] Preclinical
D0A1VL	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0P4FT	TTDDRUID	D0P4FT
D0P4FT	DRUGNAME	ART-123
D0P4FT	INDICATI	Disseminated intravascular coagulation [ICD-11: 3B20] Preclinical

D0Q6ED	TTDDRUID	D0Q6ED
D0Q6ED	DRUGNAME	ASP8497
D0Q6ED	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D0Z2NA	TTDDRUID	D0Z2NA
D0Z2NA	DRUGNAME	AT-005
D0Z2NA	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Preclinical

D0M1YN	TTDDRUID	D0M1YN
D0M1YN	DRUGNAME	ATI-17000
D0M1YN	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Preclinical

D01QKD	TTDDRUID	D01QKD
D01QKD	DRUGNAME	ATL-1101
D01QKD	INDICATI	Psoriatic disorder [ICD-11: EA90] Preclinical

D05LVL	TTDDRUID	D05LVL
D05LVL	DRUGNAME	AVR-147
D05LVL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D09KRX	TTDDRUID	D09KRX
D09KRX	DRUGNAME	AVR-168
D09KRX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0E2QN	TTDDRUID	D0E2QN
D0E2QN	DRUGNAME	AZD-1678
D0E2QN	INDICATI	Asthma [ICD-11: CA23] Preclinical

D05PQW	TTDDRUID	D05PQW
D05PQW	DRUGNAME	AZD-5180
D05PQW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D08IMD	TTDDRUID	D08IMD
D08IMD	DRUGNAME	AZD-6495
D08IMD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0KJ0U	TTDDRUID	D0KJ0U
D0KJ0U	DRUGNAME	AZD-7928
D0KJ0U	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical

D0SS2E	TTDDRUID	D0SS2E
D0SS2E	DRUGNAME	AZD-8450
D0SS2E	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Preclinical

D0G1SM	TTDDRUID	D0G1SM
D0G1SM	DRUGNAME	AZD-9335
D0G1SM	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical

D01UNF	TTDDRUID	D01UNF
D01UNF	DRUGNAME	BAL-0019764
D01UNF	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical

D05QXT	TTDDRUID	D05QXT
D05QXT	DRUGNAME	BAY-38-1315
D05QXT	INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical

D09ZGK	TTDDRUID	D09ZGK
D09ZGK	DRUGNAME	BCMA-CART
D09ZGK	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial

D0N8NT	TTDDRUID	D0N8NT
D0N8NT	DRUGNAME	BCMA-UCART
D0N8NT	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial

D02VBF	TTDDRUID	D02VBF
D02VBF	DRUGNAME	BI-D1870
D02VBF	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical

D04RAT	TTDDRUID	D04RAT
D04RAT	DRUGNAME	BIIR-777
D04RAT	INDICATI	Neurological disorder [ICD-11: 6B60] Preclinical

D01WVJ	TTDDRUID	D01WVJ
D01WVJ	DRUGNAME	BIO-306
D01WVJ	INDICATI	Migraine [ICD-11: 8A80] Preclinical

D09MUM	TTDDRUID	D09MUM
D09MUM	DRUGNAME	Bisquaternary salt
D09MUM	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D08MCT	TTDDRUID	D08MCT
D08MCT	DRUGNAME	BMS-192548
D08MCT	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0LF0O	TTDDRUID	D0LF0O
D0LF0O	DRUGNAME	BMS-695735
D0LF0O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D09UCO	TTDDRUID	D09UCO
D09UCO	DRUGNAME	BMS-986046
D09UCO	INDICATI	Heart failure [ICD-11: BD10-BD13] Preclinical

D06XGC	TTDDRUID	D06XGC
D06XGC	DRUGNAME	BMS-986202
D06XGC	INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Preclinical

D0G9OC	TTDDRUID	D0G9OC
D0G9OC	DRUGNAME	BMS-PCSK9
D0G9OC	INDICATI	Coronary artery disease [ICD-11: BA80] Preclinical

D0E6MW	TTDDRUID	D0E6MW
D0E6MW	DRUGNAME	BN-108
D0E6MW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0P5NU	TTDDRUID	D0P5NU
D0P5NU	DRUGNAME	BN-AA-003-NY
D0P5NU	INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Preclinical

D0TK2J	TTDDRUID	D0TK2J
D0TK2J	DRUGNAME	BN-AM-206
D0TK2J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D01EXY	TTDDRUID	D01EXY
D01EXY	DRUGNAME	BN-AO-014
D01EXY	INDICATI	Atrophy [ICD-11: 9A2Y-9C40] Preclinical

D0QI9N	TTDDRUID	D0QI9N
D0QI9N	DRUGNAME	BN-CB-045
D0QI9N	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Preclinical

D0N6YN	TTDDRUID	D0N6YN
D0N6YN	DRUGNAME	BN-DF-037
D0N6YN	INDICATI	Osteoporosis [ICD-11: FB83.0] Preclinical

D0QX9U	TTDDRUID	D0QX9U
D0QX9U	DRUGNAME	BN-GU-005-DHP
D0QX9U	INDICATI	Arthralgia [ICD-11: ME82] Preclinical

D06YGP	TTDDRUID	D06YGP
D06YGP	DRUGNAME	BN-OD-026
D06YGP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D01XEC	TTDDRUID	D01XEC
D01XEC	DRUGNAME	Botulinum toxin recombinant vaccine
D01XEC	INDICATI	Botulism [ICD-11: 1A11] Preclinical

D0J7WO	TTDDRUID	D0J7WO
D0J7WO	DRUGNAME	BSF-78438
D0J7WO	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D08DSC	TTDDRUID	D08DSC
D08DSC	DRUGNAME	BST-1005
D08DSC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D00LWR	TTDDRUID	D00LWR
D00LWR	DRUGNAME	BVT-A
D00LWR	INDICATI	Acromegaly [ICD-11: 5A60.0] Preclinical

D0PF1A	TTDDRUID	D0PF1A
D0PF1A	DRUGNAME	CAR-BCMA T cell
D0PF1A	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial

D0U5NO	TTDDRUID	D0U5NO
D0U5NO	DRUGNAME	CAR-CD19 T cell
D0U5NO	INDICATI	B-cell lymphoma [ICD-11: 2A86] Clinical trial
D0U5NO	INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial

D06CWZ	TTDDRUID	D06CWZ
D06CWZ	DRUGNAME	CAR-CLD18 T cell
D06CWZ	INDICATI	Adenocarcinoma [ICD-11: 2D40] Clinical trial
D06CWZ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Clinical trial

D0YS0A	TTDDRUID	D0YS0A
D0YS0A	DRUGNAME	Cardiovascular therapeutics
D0YS0A	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Preclinical

D09RPP	TTDDRUID	D09RPP
D09RPP	DRUGNAME	CAR-GPC3 T cell
D09RPP	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Clinical trial

D0P1BM	TTDDRUID	D0P1BM
D0P1BM	DRUGNAME	CAR-GPC3 T cells
D0P1BM	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Clinical trial

D06TKR	TTDDRUID	D06TKR
D06TKR	DRUGNAME	CART 19
D06TKR	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
D06TKR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Preclinical

D0LP1L	TTDDRUID	D0LP1L
D0LP1L	DRUGNAME	CAR-T cells targeting BCMA
D0LP1L	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial

D0TS2B	TTDDRUID	D0TS2B
D0TS2B	DRUGNAME	CAR-T cells targeting CD117
D0TS2B	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical

D0N4VG	TTDDRUID	D0N4VG
D0N4VG	DRUGNAME	CAR-T cells targeting CD123
D0N4VG	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical

D04JSI	TTDDRUID	D04JSI
D04JSI	DRUGNAME	CAR-T cells targeting CD133
D04JSI	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical

D0T6NG	TTDDRUID	D0T6NG
D0T6NG	DRUGNAME	CAR-T cells targeting CD138
D0T6NG	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial

D0JT0U	TTDDRUID	D0JT0U
D0JT0U	DRUGNAME	CAR-T cells targeting CD33
D0JT0U	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical

D08ABX	TTDDRUID	D08ABX
D08ABX	DRUGNAME	CAR-T cells targeting CD34
D08ABX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical

D0V6WU	TTDDRUID	D0V6WU
D0V6WU	DRUGNAME	CAR-T cells targeting CD38
D0V6WU	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
D0V6WU	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial

D0V6WW	TTDDRUID	D0V6WW
D0V6WW	DRUGNAME	CAR-T cells targeting CD56
D0V6WW	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
D0V6WW	INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial

D0JW9E	TTDDRUID	D0JW9E
D0JW9E	DRUGNAME	CAR-T cells targeting Mucl
D0JW9E	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical

D0B5PV	TTDDRUID	D0B5PV
D0B5PV	DRUGNAME	CART-EGFRvIII T cells
D0B5PV	INDICATI	Glioma [ICD-11: 2A00.0] Clinical trial
D0B5PV	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1

D04WZL	TTDDRUID	D04WZL
D04WZL	DRUGNAME	CART-meso cells
D04WZL	INDICATI	Pancreatic cancer [ICD-11: 2C10] Clinical trial

D0P6LP	TTDDRUID	D0P6LP
D0P6LP	DRUGNAME	CB-01-16
D0P6LP	INDICATI	Constipation [ICD-11: DD91.1] Preclinical

D0H4GB	TTDDRUID	D0H4GB
D0H4GB	DRUGNAME	CB1 antagonist, Bayer
D0H4GB	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D00OCB	TTDDRUID	D00OCB
D00OCB	DRUGNAME	CCT-018159
D00OCB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D01JCT	TTDDRUID	D01JCT
D01JCT	DRUGNAME	CD19-CAR T Cells
D01JCT	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial

D0B8BZ	TTDDRUID	D0B8BZ
D0B8BZ	DRUGNAME	CD19CART
D0B8BZ	INDICATI	B-cell lymphoma [ICD-11: 2A86] Clinical trial
D0B8BZ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial

D04PDI	TTDDRUID	D04PDI
D04PDI	DRUGNAME	CD19-targeted CAR-T cells
D04PDI	INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial

D09VYT	TTDDRUID	D09VYT
D09VYT	DRUGNAME	CD19-targeted CAR-T cells
D09VYT	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Clinical trial
D09VYT	INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial

D05FZM	TTDDRUID	D05FZM
D05FZM	DRUGNAME	CD19-UCART
D05FZM	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
D05FZM	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Clinical trial

D09MQQ	TTDDRUID	D09MQQ
D09MQQ	DRUGNAME	CDD-0199-J
D09MQQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical

D0I9XH	TTDDRUID	D0I9XH
D0I9XH	DRUGNAME	Celastrol
D0I9XH	INDICATI	Motor neurone disease [ICD-11: 8B60] Preclinical

D0I5VA	TTDDRUID	D0I5VA
D0I5VA	DRUGNAME	CF502
D0I5VA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical

D06PXT	TTDDRUID	D06PXT
D06PXT	DRUGNAME	CF602
D06PXT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical

D0UC6H	TTDDRUID	D0UC6H
D0UC6H	DRUGNAME	Chlamydocin
D0UC6H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D08SIR	TTDDRUID	D08SIR
D08SIR	DRUGNAME	CL-314698
D08SIR	INDICATI	Obesity [ICD-11: 5B81] Preclinical
D08SIR	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D07YVM	TTDDRUID	D07YVM
D07YVM	DRUGNAME	CLX-090700
D07YVM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical

D02CJA	TTDDRUID	D02CJA
D02CJA	DRUGNAME	CM-2236
D02CJA	INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Preclinical

D00CEI	TTDDRUID	D00CEI
D00CEI	DRUGNAME	CM-2501
D00CEI	INDICATI	Poison intoxication [ICD-11: NE6Z] Preclinical

D06GSA	TTDDRUID	D06GSA
D06GSA	DRUGNAME	CMV DNA vaccine
D06GSA	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Preclinical

D0T4YZ	TTDDRUID	D0T4YZ
D0T4YZ	DRUGNAME	CNSB-004
D0T4YZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D02PNH	TTDDRUID	D02PNH
D02PNH	DRUGNAME	COL-171
D02PNH	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Preclinical

D0F3II	TTDDRUID	D0F3II
D0F3II	DRUGNAME	COR100140
D0F3II	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical

D0J8II	TTDDRUID	D0J8II
D0J8II	DRUGNAME	Corticosteroid
D0J8II	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Preclinical

D00MIX	TTDDRUID	D00MIX
D00MIX	DRUGNAME	CP-114271
D00MIX	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D04ABS	TTDDRUID	D04ABS
D04ABS	DRUGNAME	CPH-102
D04ABS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0M5DH	TTDDRUID	D0M5DH
D0M5DH	DRUGNAME	CRA1000
D0M5DH	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical

D09IFW	TTDDRUID	D09IFW
D09IFW	DRUGNAME	Cruentaren
D09IFW	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D0G8NP	TTDDRUID	D0G8NP
D0G8NP	DRUGNAME	CS-00028
D0G8NP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0K5WM	TTDDRUID	D0K5WM
D0K5WM	DRUGNAME	CS-3030
D0K5WM	INDICATI	Thrombosis [ICD-11: DB61-GB90] Preclinical

D05GQD	TTDDRUID	D05GQD
D05GQD	DRUGNAME	CSA-13
D05GQD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D00KVE	TTDDRUID	D00KVE
D00KVE	DRUGNAME	Cutamesine
D00KVE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Preclinical

D0XM3S	TTDDRUID	D0XM3S
D0XM3S	DRUGNAME	CX-1501
D0XM3S	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical

D0FX5D	TTDDRUID	D0FX5D
D0FX5D	DRUGNAME	Cx-602
D0FX5D	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Preclinical

D06TGS	TTDDRUID	D06TGS
D06TGS	DRUGNAME	Cx-603
D06TGS	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Preclinical

D0WZ4J	TTDDRUID	D0WZ4J
D0WZ4J	DRUGNAME	CYC-800
D0WZ4J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D03RYN	TTDDRUID	D03RYN
D03RYN	DRUGNAME	Cytolin
D03RYN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical

D01GDO	TTDDRUID	D01GDO
D01GDO	DRUGNAME	Cytoporins
D01GDO	INDICATI	Respiratory tract infection [ICD-11: CA45] Preclinical

D03PDZ	TTDDRUID	D03PDZ
D03PDZ	DRUGNAME	D1 agonist D2 antagonist
D03PDZ	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D05ZCQ	TTDDRUID	D05ZCQ
D05ZCQ	DRUGNAME	DAP-81
D05ZCQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D04XLU	TTDDRUID	D04XLU
D04XLU	DRUGNAME	Dendritic cell vaccine
D04XLU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D0W8JE	TTDDRUID	D0W8JE
D0W8JE	DRUGNAME	Depudecin
D0W8JE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0I8TV	TTDDRUID	D0I8TV
D0I8TV	DRUGNAME	DLX-0201
D0I8TV	INDICATI	Vomiting [ICD-11: MD90] Preclinical

D0G5ML	TTDDRUID	D0G5ML
D0G5ML	DRUGNAME	Donitriptan
D0G5ML	INDICATI	Migraine [ICD-11: 8A80] Preclinical

D0YC1Z	TTDDRUID	D0YC1Z
D0YC1Z	DRUGNAME	Doxorubicin-hemoglobin conjugate
D0YC1Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D05VEP	TTDDRUID	D05VEP
D05VEP	DRUGNAME	DX-2802
D05VEP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D04BXJ	TTDDRUID	D04BXJ
D04BXJ	DRUGNAME	ED-1812
D04BXJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0TI4U	TTDDRUID	D0TI4U
D0TI4U	DRUGNAME	EGFR/IGFR tandem adnectin
D0TI4U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0Z4NA	TTDDRUID	D0Z4NA
D0Z4NA	DRUGNAME	EG-P119
D0Z4NA	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Preclinical

D0A5BJ	TTDDRUID	D0A5BJ
D0A5BJ	DRUGNAME	EndoAngio-GT
D0A5BJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0T8YK	TTDDRUID	D0T8YK
D0T8YK	DRUGNAME	EP-01492
D0T8YK	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0H3YC	TTDDRUID	D0H3YC
D0H3YC	DRUGNAME	EP-128504
D0H3YC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0QB8Q	TTDDRUID	D0QB8Q
D0QB8Q	DRUGNAME	EP-2167
D0QB8Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0T8DD	TTDDRUID	D0T8DD
D0T8DD	DRUGNAME	EPCAM-targeted CAR-T cells
D0T8DD	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Clinical trial
D0T8DD	INDICATI	Liver cancer [ICD-11: 2C12] Clinical trial

D0XL4I	TTDDRUID	D0XL4I
D0XL4I	DRUGNAME	ER-319711-15
D0XL4I	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D0A6UQ	TTDDRUID	D0A6UQ
D0A6UQ	DRUGNAME	ETX-1153a
D0A6UQ	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Preclinical

D07JPK	TTDDRUID	D07JPK
D07JPK	DRUGNAME	ETX-1153b
D07JPK	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Preclinical

D0AM6F	TTDDRUID	D0AM6F
D0AM6F	DRUGNAME	ETX-1153c
D0AM6F	INDICATI	Clostridium infection [ICD-11: 1A04] Preclinical

D05YRV	TTDDRUID	D05YRV
D05YRV	DRUGNAME	ETX-6107
D05YRV	INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical

D0D8CE	TTDDRUID	D0D8CE
D0D8CE	DRUGNAME	EVP-0334
D0D8CE	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical

D0R1PZ	TTDDRUID	D0R1PZ
D0R1PZ	DRUGNAME	F-15063
D0R1PZ	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0B7OM	TTDDRUID	D0B7OM
D0B7OM	DRUGNAME	F-15441
D0B7OM	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0R9WI	TTDDRUID	D0R9WI
D0R9WI	DRUGNAME	F-16242
D0R9WI	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Preclinical

D04RSI	TTDDRUID	D04RSI
D04RSI	DRUGNAME	FAS1
D04RSI	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D0T2ZQ	TTDDRUID	D0T2ZQ
D0T2ZQ	DRUGNAME	Felbinac prodrug
D0T2ZQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical

D09FQS	TTDDRUID	D09FQS
D09FQS	DRUGNAME	FG-3622
D09FQS	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D01MZT	TTDDRUID	D01MZT
D01MZT	DRUGNAME	FGFR2-ADC
D01MZT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D08GNX	TTDDRUID	D08GNX
D08GNX	DRUGNAME	FPL-14294
D08GNX	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D05QMG	TTDDRUID	D05QMG
D05QMG	DRUGNAME	FR167653
D05QMG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1

D02NMO	TTDDRUID	D02NMO
D02NMO	DRUGNAME	FR-79620
D02NMO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
D02NMO	INDICATI	Eating disorder [ICD-11: 6B82] Preclinical
D02NMO	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0R2SW	TTDDRUID	D0R2SW
D0R2SW	DRUGNAME	FSA2
D0R2SW	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D07SYN	TTDDRUID	D07SYN
D07SYN	DRUGNAME	FX-007
D07SYN	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D09WVR	TTDDRUID	D09WVR
D09WVR	DRUGNAME	FX-107
D09WVR	INDICATI	Dengue fever [ICD-11: 1D2Z] Preclinical

D03VGW	TTDDRUID	D03VGW
D03VGW	DRUGNAME	GCR-1087
D03VGW	INDICATI	Obesity [ICD-11: 5B81] Preclinical
D03VGW	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D0RI8E	TTDDRUID	D0RI8E
D0RI8E	DRUGNAME	GD2-targeted CAR-T cells
D0RI8E	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Clinical trial

D0W4OZ	TTDDRUID	D0W4OZ
D0W4OZ	DRUGNAME	GG-8573
D0W4OZ	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0R2CI	TTDDRUID	D0R2CI
D0R2CI	DRUGNAME	GI-264879A
D0R2CI	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0E2YV	TTDDRUID	D0E2YV
D0E2YV	DRUGNAME	Glial cell line-derived neurotrophic factor protein
D0E2YV	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Preclinical

D0BJ7W	TTDDRUID	D0BJ7W
D0BJ7W	DRUGNAME	GLPG-0492
D0BJ7W	INDICATI	Cachexia [ICD-11: MG20] Preclinical

D0T9HG	TTDDRUID	D0T9HG
D0T9HG	DRUGNAME	GM6001
D0T9HG	INDICATI	Corneal ulcer [ICD-11: 9A76] Discontinued in Phase 2

D0X6SZ	TTDDRUID	D0X6SZ
D0X6SZ	DRUGNAME	GNTI
D0X6SZ	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0U9OJ	TTDDRUID	D0U9OJ
D0U9OJ	DRUGNAME	GSK-326416
D0U9OJ	INDICATI	Gastroparesis [ICD-11: DA41.00] Preclinical

D08VWF	TTDDRUID	D08VWF
D08VWF	DRUGNAME	GSK-932121A
D08VWF	INDICATI	Malaria [ICD-11: 1F40-1F45] Preclinical

D03ESO	TTDDRUID	D03ESO
D03ESO	DRUGNAME	GW-3333
D03ESO	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical

D0I3TS	TTDDRUID	D0I3TS
D0I3TS	DRUGNAME	GW-594884A
D0I3TS	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0V9YW	TTDDRUID	D0V9YW
D0V9YW	DRUGNAME	GYKI-47261
D0V9YW	INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical

D04USK	TTDDRUID	D04USK
D04USK	DRUGNAME	H5N1 influenza vaccine
D04USK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Preclinical

D06RQU	TTDDRUID	D06RQU
D06RQU	DRUGNAME	HC-Toxin
D06RQU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D02SMV	TTDDRUID	D02SMV
D02SMV	DRUGNAME	Herpes simplex virus therapy
D02SMV	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Preclinical

D09MJO	TTDDRUID	D09MJO
D09MJO	DRUGNAME	HL-004
D09MJO	INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical

D04CIL	TTDDRUID	D04CIL
D04CIL	DRUGNAME	HMG-CoA reductase inhibitor
D04CIL	INDICATI	Chemotherapy or radiotherapy-induced mucositis [ICD-11: DA42-DA60] Preclinical

D0U1BU	TTDDRUID	D0U1BU
D0U1BU	DRUGNAME	HPP-851
D0U1BU	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical

D00QIJ	TTDDRUID	D00QIJ
D00QIJ	DRUGNAME	Huntingtin gene antisense
D00QIJ	INDICATI	Huntington disease [ICD-11: 8A01.10] Preclinical

D03WVP	TTDDRUID	D03WVP
D03WVP	DRUGNAME	IBU-PC
D03WVP	INDICATI	Inflammation associated with osteoarthritis [ICD-11: FA00-FA05] Preclinical
D03WVP	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0E2FZ	TTDDRUID	D0E2FZ
D0E2FZ	DRUGNAME	ICA-69673
D0E2FZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D02PTD	TTDDRUID	D02PTD
D02PTD	DRUGNAME	IDC-7181
D02PTD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D00AQY	TTDDRUID	D00AQY
D00AQY	DRUGNAME	IDDB-41331
D00AQY	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0J9CF	TTDDRUID	D0J9CF
D0J9CF	DRUGNAME	IDDBCP-150101
D0J9CF	INDICATI	Obesity [ICD-11: 5B81] Preclinical
D0J9CF	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Preclinical

D03LNN	TTDDRUID	D03LNN
D03LNN	DRUGNAME	IDX136
D03LNN	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Preclinical

D02ZWR	TTDDRUID	D02ZWR
D02ZWR	DRUGNAME	IMO-2134
D02ZWR	INDICATI	Allergy [ICD-11: 4A80-4A85] Preclinical
D02ZWR	INDICATI	Asthma [ICD-11: CA23] Preclinical

D02NEZ	TTDDRUID	D02NEZ
D02NEZ	DRUGNAME	IMX-942
D02NEZ	INDICATI	Mucositis [ICD-11: CA00] Preclinical

D0J6VN	TTDDRUID	D0J6VN
D0J6VN	DRUGNAME	Indol-3-carbinol
D0J6VN	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D07ZJC	TTDDRUID	D07ZJC
D07ZJC	DRUGNAME	INOC-005
D07ZJC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0WM3E	TTDDRUID	D0WM3E
D0WM3E	DRUGNAME	INP-341
D0WM3E	INDICATI	Skin burns [ICD-11: ME65.0] Preclinical

D0M8PM	TTDDRUID	D0M8PM
D0M8PM	DRUGNAME	IRX-4
D0M8PM	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D0SL8T	TTDDRUID	D0SL8T
D0SL8T	DRUGNAME	ISIS-FGFR4
D0SL8T	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0F8XK	TTDDRUID	D0F8XK
D0F8XK	DRUGNAME	ISIS-GCCR
D0F8XK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D04WIF	TTDDRUID	D04WIF
D04WIF	DRUGNAME	ISIS-GCGR
D04WIF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D07AZB	TTDDRUID	D07AZB
D07AZB	DRUGNAME	ISIS-PTP1B
D07AZB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D0B4MK	TTDDRUID	D0B4MK
D0B4MK	DRUGNAME	ISIS-STAT3
D0B4MK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D00GES	TTDDRUID	D00GES
D00GES	DRUGNAME	JD-5037
D00GES	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
D00GES	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0E8QK	TTDDRUID	D0E8QK
D0E8QK	DRUGNAME	JNJ-26070109
D0E8QK	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical

D06GFG	TTDDRUID	D06GFG
D06GFG	DRUGNAME	KD-3020
D06GFG	INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Preclinical

D03TJN	TTDDRUID	D03TJN
D03TJN	DRUGNAME	KOS-1803
D03TJN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0Z8EJ	TTDDRUID	D0Z8EJ
D0Z8EJ	DRUGNAME	KOS-1815
D0Z8EJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0X5YU	TTDDRUID	D0X5YU
D0X5YU	DRUGNAME	KOS-2484
D0X5YU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0MT5C	TTDDRUID	D0MT5C
D0MT5C	DRUGNAME	L-742791
D0MT5C	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0WS1V	TTDDRUID	D0WS1V
D0WS1V	DRUGNAME	L-751250
D0WS1V	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D08ECB	TTDDRUID	D08ECB
D08ECB	DRUGNAME	LAS-101057
D08ECB	INDICATI	Asthma [ICD-11: CA23] Preclinical

D07YLK	TTDDRUID	D07YLK
D07YLK	DRUGNAME	LE-300
D07YLK	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0O6DC	TTDDRUID	D0O6DC
D0O6DC	DRUGNAME	LY-2463665
D0O6DC	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D0C2QF	TTDDRUID	D0C2QF
D0C2QF	DRUGNAME	LY-25582
D0C2QF	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0E4VT	TTDDRUID	D0E4VT
D0E4VT	DRUGNAME	MAHDL01
D0E4VT	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Preclinical

D0X6LG	TTDDRUID	D0X6LG
D0X6LG	DRUGNAME	MC-1002
D0X6LG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical

D04GFO	TTDDRUID	D04GFO
D04GFO	DRUGNAME	MC-2001
D04GFO	INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical

D04PBS	TTDDRUID	D04PBS
D04PBS	DRUGNAME	MC-3001
D04PBS	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Preclinical

D08WOE	TTDDRUID	D08WOE
D08WOE	DRUGNAME	MC-3002
D08WOE	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical

D0SP0S	TTDDRUID	D0SP0S
D0SP0S	DRUGNAME	MC-4 agonist
D0SP0S	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D03SZR	TTDDRUID	D03SZR
D03SZR	DRUGNAME	M-carboxycinnamic acid bishydroxamide
D03SZR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D01ALG	TTDDRUID	D01ALG
D01ALG	DRUGNAME	MCH antagonist
D01ALG	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0V9ND	TTDDRUID	D0V9ND
D0V9ND	DRUGNAME	MCP-1
D0V9ND	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical

D0W8HP	TTDDRUID	D0W8HP
D0W8HP	DRUGNAME	MEDI-543
D0W8HP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D06SDP	TTDDRUID	D06SDP
D06SDP	DRUGNAME	Melanotetan II
D06SDP	INDICATI	Obesity [ICD-11: 5B81] Preclinical
D06SDP	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Preclinical
D06SDP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D03MFV	TTDDRUID	D03MFV
D03MFV	DRUGNAME	MNLP-18
D03MFV	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Preclinical

D00XBH	TTDDRUID	D00XBH
D00XBH	DRUGNAME	MNLP-462a
D00XBH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0MC2E	TTDDRUID	D0MC2E
D0MC2E	DRUGNAME	MOR-203
D0MC2E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0NO6E	TTDDRUID	D0NO6E
D0NO6E	DRUGNAME	Mteron-F1
D0NO6E	INDICATI	Mucositis [ICD-11: CA00] Preclinical

D03WUU	TTDDRUID	D03WUU
D03WUU	DRUGNAME	Multivalent (HIVIS 07) DNA vaccine Derma Vax/ZetaJet
D03WUU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical

D00KJO	TTDDRUID	D00KJO
D00KJO	DRUGNAME	MUT-056399
D00KJO	INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Preclinical

D05UJU	TTDDRUID	D05UJU
D05UJU	DRUGNAME	MV-2101
D05UJU	INDICATI	Vascular disease [ICD-11: BE2Z] Preclinical

D05DDZ	TTDDRUID	D05DDZ
D05DDZ	DRUGNAME	MV-6401
D05DDZ	INDICATI	Artery stenosis [ICD-11: BD52] Preclinical

D01ECN	TTDDRUID	D01ECN
D01ECN	DRUGNAME	MVA-BN DF
D01ECN	INDICATI	Flavivirus infection [ICD-11: 1C80] Preclinical

D06LBZ	TTDDRUID	D06LBZ
D06LBZ	DRUGNAME	MVA-BN JEV
D06LBZ	INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Preclinical

D0Q7CR	TTDDRUID	D0Q7CR
D0Q7CR	DRUGNAME	MX-76629
D0Q7CR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0Q7JJ	TTDDRUID	D0Q7JJ
D0Q7JJ	DRUGNAME	NA-808
D0Q7JJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Preclinical

D0K2CR	TTDDRUID	D0K2CR
D0K2CR	DRUGNAME	Nemorubicin
D0K2CR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D03JZD	TTDDRUID	D03JZD
D03JZD	DRUGNAME	Neurosolve
D03JZD	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical

D0G3CO	TTDDRUID	D0G3CO
D0G3CO	DRUGNAME	NHP-229
D0G3CO	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical

D0V2RK	TTDDRUID	D0V2RK
D0V2RK	DRUGNAME	NKP-46
D0V2RK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D09OUT	TTDDRUID	D09OUT
D09OUT	DRUGNAME	NN-818
D09OUT	INDICATI	Brain injury [ICD-11: NA07.Z] Preclinical

D09KAK	TTDDRUID	D09KAK
D09KAK	DRUGNAME	NOX-F37
D09KAK	INDICATI	Acute and chronic heart failure [ICD-11: BD1Z] Preclinical

D0JC7A	TTDDRUID	D0JC7A
D0JC7A	DRUGNAME	NP-50501
D0JC7A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0W0XM	TTDDRUID	D0W0XM
D0W0XM	DRUGNAME	NPS-2390
D0W0XM	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical

D0C9RC	TTDDRUID	D0C9RC
D0C9RC	DRUGNAME	NPY antagonist
D0C9RC	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0I5HE	TTDDRUID	D0I5HE
D0I5HE	DRUGNAME	NPY5RA-972
D0I5HE	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0I4EI	TTDDRUID	D0I4EI
D0I4EI	DRUGNAME	NSL-105
D0I4EI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Preclinical

D0XB4D	TTDDRUID	D0XB4D
D0XB4D	DRUGNAME	NTC-100
D0XB4D	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical

D0S0MR	TTDDRUID	D0S0MR
D0S0MR	DRUGNAME	NVB-333
D0S0MR	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical

D00NOP	TTDDRUID	D00NOP
D00NOP	DRUGNAME	OBP-401
D00NOP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D00INM	TTDDRUID	D00INM
D00INM	DRUGNAME	Occlusin
D00INM	INDICATI	Liver cancer [ICD-11: 2C12] Preclinical

D0US1X	TTDDRUID	D0US1X
D0US1X	DRUGNAME	OCT-1547
D0US1X	INDICATI	Osteoporosis [ICD-11: FB83.0] Preclinical

D0E3HJ	TTDDRUID	D0E3HJ
D0E3HJ	DRUGNAME	Oligotide
D0E3HJ	INDICATI	Kidney disease [ICD-11: GC2Z] Preclinical

D02MNY	TTDDRUID	D02MNY
D02MNY	DRUGNAME	ON-01135
D02MNY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0G5DK	TTDDRUID	D0G5DK
D0G5DK	DRUGNAME	ONO-1301
D0G5DK	INDICATI	Angina pectoris [ICD-11: BA40] Preclinical

D0N5NM	TTDDRUID	D0N5NM
D0N5NM	DRUGNAME	Org-23366
D0N5NM	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0U1HP	TTDDRUID	D0U1HP
D0U1HP	DRUGNAME	Org-24461
D0U1HP	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D07PNC	TTDDRUID	D07PNC
D07PNC	DRUGNAME	Organon
D07PNC	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0O5ZT	TTDDRUID	D0O5ZT
D0O5ZT	DRUGNAME	Organon-2
D0O5ZT	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0I6JG	TTDDRUID	D0I6JG
D0I6JG	DRUGNAME	Organon-3
D0I6JG	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0TG4K	TTDDRUID	D0TG4K
D0TG4K	DRUGNAME	Oxycyte
D0TG4K	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Preclinical

D04VLR	TTDDRUID	D04VLR
D04VLR	DRUGNAME	PA-161
D04VLR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical

D0U1FR	TTDDRUID	D0U1FR
D0U1FR	DRUGNAME	PBI-1393
D0U1FR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0D4AQ	TTDDRUID	D0D4AQ
D0D4AQ	DRUGNAME	PCI-45292
D0D4AQ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Preclinical

D0Q2VL	TTDDRUID	D0Q2VL
D0Q2VL	DRUGNAME	PD-157533
D0Q2VL	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0F6WV	TTDDRUID	D0F6WV
D0F6WV	DRUGNAME	PD-157695
D0F6WV	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D04UXX	TTDDRUID	D04UXX
D04UXX	DRUGNAME	PD-158771
D04UXX	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0Q3UL	TTDDRUID	D0Q3UL
D0Q3UL	DRUGNAME	PD-160170
D0Q3UL	INDICATI	Heart disease [ICD-11: BA41-BA42] Preclinical
D0Q3UL	INDICATI	Hypertension [ICD-11: BA00-BA04] Preclinical
D0Q3UL	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D00MQS	TTDDRUID	D00MQS
D00MQS	DRUGNAME	PD-165167
D00MQS	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D06DPS	TTDDRUID	D06DPS
D06DPS	DRUGNAME	PD-170292
D06DPS	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D08RUW	TTDDRUID	D08RUW
D08RUW	DRUGNAME	PD-176931
D08RUW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical

D0G7LP	TTDDRUID	D0G7LP
D0G7LP	DRUGNAME	Pepticlere
D0G7LP	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical

D00QAX	TTDDRUID	D00QAX
D00QAX	DRUGNAME	PF-708093
D00QAX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D04MGI	TTDDRUID	D04MGI
D04MGI	DRUGNAME	PF-821385
D04MGI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical

D0U1CL	TTDDRUID	D0U1CL
D0U1CL	DRUGNAME	PGX-200097
D0U1CL	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D00HDK	TTDDRUID	D00HDK
D00HDK	DRUGNAME	PGX-5188
D00HDK	INDICATI	Bipolar disorder [ICD-11: 6A60] Preclinical

D0A5MD	TTDDRUID	D0A5MD
D0A5MD	DRUGNAME	PHA-568487
D0A5MD	INDICATI	Cognitive impairment [ICD-11: 6D71] Preclinical

D0SR4T	TTDDRUID	D0SR4T
D0SR4T	DRUGNAME	PHENSERINE TARTRATE
D0SR4T	INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical

D02LYH	TTDDRUID	D02LYH
D02LYH	DRUGNAME	PMI-004
D02LYH	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Preclinical

D09QKI	TTDDRUID	D09QKI
D09QKI	DRUGNAME	PPL-100
D09QKI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical

D0QS6G	TTDDRUID	D0QS6G
D0QS6G	DRUGNAME	Prevecon
D0QS6G	INDICATI	Contraception [ICD-11: QA21] Preclinical

D0O9FW	TTDDRUID	D0O9FW
D0O9FW	DRUGNAME	Protein A mimetics
D0O9FW	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Preclinical

D04CEY	TTDDRUID	D04CEY
D04CEY	DRUGNAME	PYM-50018
D04CEY	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical

D04UOJ	TTDDRUID	D04UOJ
D04UOJ	DRUGNAME	PYN-7
D04UOJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D00KWF	TTDDRUID	D00KWF
D00KWF	DRUGNAME	PYN-9
D00KWF	INDICATI	Ileus [ICD-11: DA93.0] Preclinical

D09DER	TTDDRUID	D09DER
D09DER	DRUGNAME	QR-336
D09DER	INDICATI	Radiation syndrome [ICD-11: NF00] Preclinical

D0U9RR	TTDDRUID	D0U9RR
D0U9RR	DRUGNAME	Quinoxaline
D0U9RR	INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical

D01GHV	TTDDRUID	D01GHV
D01GHV	DRUGNAME	RANBEZOLID HYDROCHLORIDE
D01GHV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D05VOP	TTDDRUID	D05VOP
D05VOP	DRUGNAME	RAP-160
D05VOP	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Preclinical

D0X6TZ	TTDDRUID	D0X6TZ
D0X6TZ	DRUGNAME	RCD-1
D0X6TZ	INDICATI	Stress urinary incontinence [ICD-11: MF50.20] Preclinical

D09JDX	TTDDRUID	D09JDX
D09JDX	DRUGNAME	RCD-2
D09JDX	INDICATI	Fecal incontinence [ICD-11: ME07] Preclinical

D0U9GZ	TTDDRUID	D0U9GZ
D0U9GZ	DRUGNAME	Recombinant protein subunit vaccine, Emergent
D0U9GZ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Preclinical

D0C3RF	TTDDRUID	D0C3RF
D0C3RF	DRUGNAME	REP-9AC
D0C3RF	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Preclinical

D0Y4NY	TTDDRUID	D0Y4NY
D0Y4NY	DRUGNAME	Research programme: small molecule therapeutics, Boehringer Ingelheim
D0Y4NY	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0H5OR	TTDDRUID	D0H5OR
D0H5OR	DRUGNAME	RM-493
D0H5OR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
D0H5OR	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0I2LX	TTDDRUID	D0I2LX
D0I2LX	DRUGNAME	RMG-40083
D0I2LX	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0C0ME	TTDDRUID	D0C0ME
D0C0ME	DRUGNAME	RO-26-2853
D0C0ME	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0N0IQ	TTDDRUID	D0N0IQ
D0N0IQ	DRUGNAME	Ro-27-3225
D0N0IQ	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0U2FN	TTDDRUID	D0U2FN
D0U2FN	DRUGNAME	Romazarit
D0U2FN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical

D0R1JI	TTDDRUID	D0R1JI
D0R1JI	DRUGNAME	Rottlerin
D0R1JI	INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical

D0X4SI	TTDDRUID	D0X4SI
D0X4SI	DRUGNAME	RS-504393
D0X4SI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical

D0I9LO	TTDDRUID	D0I9LO
D0I9LO	DRUGNAME	RWJ-416457
D0I9LO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D02VOJ	TTDDRUID	D02VOJ
D02VOJ	DRUGNAME	RWJ-51204
D02VOJ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical

D0N4AB	TTDDRUID	D0N4AB
D0N4AB	DRUGNAME	Rx-01
D0N4AB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D02FHP	TTDDRUID	D02FHP
D02FHP	DRUGNAME	RX-01-423
D02FHP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D06KYU	TTDDRUID	D06KYU
D06KYU	DRUGNAME	Rycals
D06KYU	INDICATI	Heart failure [ICD-11: BD10-BD13] Preclinical

D0Q3GV	TTDDRUID	D0Q3GV
D0Q3GV	DRUGNAME	S32504
D0Q3GV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
D0Q3GV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical

D0K5EE	TTDDRUID	D0K5EE
D0K5EE	DRUGNAME	S-33084
D0K5EE	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Preclinical

D0X4UH	TTDDRUID	D0X4UH
D0X4UH	DRUGNAME	S-8184
D0X4UH	INDICATI	Ovarian cancer [ICD-11: 2C73] Preclinical

D0B1DA	TTDDRUID	D0B1DA
D0B1DA	DRUGNAME	SAND-5
D0B1DA	INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Preclinical

D00VPT	TTDDRUID	D00VPT
D00VPT	DRUGNAME	SB222200
D00VPT	INDICATI	Schizoaffective disorder [ICD-11: 6A21] Preclinical
D00VPT	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0E3SX	TTDDRUID	D0E3SX
D0E3SX	DRUGNAME	SCH-1359113
D0E3SX	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical

D04FAI	TTDDRUID	D04FAI
D04FAI	DRUGNAME	SCIO-323
D04FAI	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical

D0J8OC	TTDDRUID	D0J8OC
D0J8OC	DRUGNAME	Scriptaid
D0J8OC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0TP7T	TTDDRUID	D0TP7T
D0TP7T	DRUGNAME	SCY-641
D0TP7T	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Preclinical

D0IZ1I	TTDDRUID	D0IZ1I
D0IZ1I	DRUGNAME	SD-726
D0IZ1I	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0L4WO	TTDDRUID	D0L4WO
D0L4WO	DRUGNAME	SGN-19A
D0L4WO	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Preclinical

D06RVY	TTDDRUID	D06RVY
D06RVY	DRUGNAME	SIR-1076
D06RVY	INDICATI	Retinopathy [ICD-11: 9B71] Preclinical

D0UL5X	TTDDRUID	D0UL5X
D0UL5X	DRUGNAME	SK-7041
D0UL5X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0DO5U	TTDDRUID	D0DO5U
D0DO5U	DRUGNAME	SK-7068
D0DO5U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0CG9E	TTDDRUID	D0CG9E
D0CG9E	DRUGNAME	SL-11093
D0CG9E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D08MGU	TTDDRUID	D08MGU
D08MGU	DRUGNAME	SLIT TR-03
D08MGU	INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical

D02NMG	TTDDRUID	D02NMG
D02NMG	DRUGNAME	SLV-332
D02NMG	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Preclinical

D0M4GN	TTDDRUID	D0M4GN
D0M4GN	DRUGNAME	Small-cell lung cancer mab vaccine
D0M4GN	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Preclinical

D0U0YR	TTDDRUID	D0U0YR
D0U0YR	DRUGNAME	SNAP-7941
D0U0YR	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical
D0U0YR	INDICATI	Depression [ICD-11: 6A70-6A7Z] Preclinical
D0U0YR	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0N1RG	TTDDRUID	D0N1RG
D0N1RG	DRUGNAME	SoRI-9409
D0N1RG	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Preclinical

D0V7FG	TTDDRUID	D0V7FG
D0V7FG	DRUGNAME	SPH-1285
D0V7FG	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical

D04PVN	TTDDRUID	D04PVN
D04PVN	DRUGNAME	SPI-376
D04PVN	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0U7ZY	TTDDRUID	D0U7ZY
D0U7ZY	DRUGNAME	SP-MET-1
D0U7ZY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical

D07IND	TTDDRUID	D07IND
D07IND	DRUGNAME	SRD-285
D07IND	INDICATI	Wound healing [ICD-11: EL8Y] Preclinical

D0VF8Z	TTDDRUID	D0VF8Z
D0VF8Z	DRUGNAME	SRD-326
D0VF8Z	INDICATI	Raynaud disease [ICD-11: BD42.0] Preclinical

D0Y9KR	TTDDRUID	D0Y9KR
D0Y9KR	DRUGNAME	SSR-103800
D0Y9KR	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D06SBS	TTDDRUID	D06SBS
D06SBS	DRUGNAME	SSR-504734
D06SBS	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0BA0O	TTDDRUID	D0BA0O
D0BA0O	DRUGNAME	Syn-1002
D0BA0O	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0K6NS	TTDDRUID	D0K6NS
D0K6NS	DRUGNAME	T-226293
D0K6NS	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D0TV4N	TTDDRUID	D0TV4N
D0TV4N	DRUGNAME	T-226296
D0TV4N	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
D0TV4N	INDICATI	Obesity [ICD-11: 5B81] Preclinical

D05NOG	TTDDRUID	D05NOG
D05NOG	DRUGNAME	Targeted ranpirnase conjugates
D05NOG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D05HFU	TTDDRUID	D05HFU
D05HFU	DRUGNAME	TGX-6B4
D05HFU	INDICATI	Thrombosis [ICD-11: DB61-GB90] Preclinical

D02TNS	TTDDRUID	D02TNS
D02TNS	DRUGNAME	TMC-353121
D02TNS	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Preclinical

D06DFU	TTDDRUID	D06DFU
D06DFU	DRUGNAME	TP-023
D06DFU	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical

D0YH9A	TTDDRUID	D0YH9A
D0YH9A	DRUGNAME	TPT-43
D0YH9A	INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical

D0X1ZV	TTDDRUID	D0X1ZV
D0X1ZV	DRUGNAME	Trimidox
D0X1ZV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0X5OV	TTDDRUID	D0X5OV
D0X5OV	DRUGNAME	TTA-A8
D0X5OV	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Preclinical

D00TEN	TTDDRUID	D00TEN
D00TEN	DRUGNAME	TV-1390
D00TEN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Preclinical

D04LDK	TTDDRUID	D04LDK
D04LDK	DRUGNAME	TZP-202
D04LDK	INDICATI	Dyspepsia [ICD-11: MD92] Preclinical

D0N3RC	TTDDRUID	D0N3RC
D0N3RC	DRUGNAME	TZP-301
D0N3RC	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical

D0T3JW	TTDDRUID	D0T3JW
D0T3JW	DRUGNAME	U-99194A
D0T3JW	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0WQ5S	TTDDRUID	D0WQ5S
D0WQ5S	DRUGNAME	U-99363E
D0WQ5S	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D0KE7K	TTDDRUID	D0KE7K
D0KE7K	DRUGNAME	URG-302
D0KE7K	INDICATI	Overactive bladder [ICD-11: GC50.0] Preclinical

D0VC3N	TTDDRUID	D0VC3N
D0VC3N	DRUGNAME	Vaccine, HSV-2 infection
D0VC3N	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Preclinical

D0IY0R	TTDDRUID	D0IY0R
D0IY0R	DRUGNAME	Viquidacin
D0IY0R	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D08UZD	TTDDRUID	D08UZD
D08UZD	DRUGNAME	Viraplex
D08UZD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0WD6K	TTDDRUID	D0WD6K
D0WD6K	DRUGNAME	VPM-4-001
D0WD6K	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D0V9ME	TTDDRUID	D0V9ME
D0V9ME	DRUGNAME	VT-111
D0V9ME	INDICATI	Graft rejection in heart transplantation [ICD-11: NE84] Preclinical

D03BNU	TTDDRUID	D03BNU
D03BNU	DRUGNAME	XL-388
D03BNU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D09ODU	TTDDRUID	D09ODU
D09ODU	DRUGNAME	XL475
D09ODU	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D08TAB	TTDDRUID	D08TAB
D08TAB	DRUGNAME	XL-499
D08TAB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D04HMM	TTDDRUID	D04HMM
D04HMM	DRUGNAME	XP-20925
D04HMM	INDICATI	Migraine [ICD-11: 8A80] Preclinical

D04EIL	TTDDRUID	D04EIL
D04EIL	DRUGNAME	YM-344031
D04EIL	INDICATI	Asthma [ICD-11: CA23] Preclinical

D0Y6TI	TTDDRUID	D0Y6TI
D0Y6TI	DRUGNAME	YM-355179
D0Y6TI	INDICATI	Asthma [ICD-11: CA23] Preclinical

D07RMX	TTDDRUID	D07RMX
D07RMX	DRUGNAME	ZK-thiazolidinone
D07RMX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D07PMU	TTDDRUID	D07PMU
D07PMU	DRUGNAME	111In-OC-125 F(ab1/2)-DTPA
D07PMU	INDICATI	Ovarian cancer [ICD-11: 2C73] Terminated

D07ZKK	TTDDRUID	D07ZKK
D07ZKK	DRUGNAME	131I-81C6
D07ZKK	INDICATI	Brain cancer [ICD-11: 2A00] Terminated

D07CGH	TTDDRUID	D07CGH
D07CGH	DRUGNAME	1D09C3
D07CGH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0ZJ0A	TTDDRUID	D0ZJ0A
D0ZJ0A	DRUGNAME	2164U90
D0ZJ0A	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0GO7W	TTDDRUID	D0GO7W
D0GO7W	DRUGNAME	21-AMINOEPOTHILONE B
D0GO7W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0I7TN	TTDDRUID	D0I7TN
D0I7TN	DRUGNAME	3-DEAZAADENOSINE
D0I7TN	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0O6UF	TTDDRUID	D0O6UF
D0O6UF	DRUGNAME	403U76
D0O6UF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D0E8SE	TTDDRUID	D0E8SE
D0E8SE	DRUGNAME	443C81
D0E8SE	INDICATI	Asthma [ICD-11: CA23] Terminated

D0P5UE	TTDDRUID	D0P5UE
D0P5UE	DRUGNAME	50-235
D0P5UE	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0J8ID	TTDDRUID	D0J8ID
D0J8ID	DRUGNAME	5-HT4/D2 antagonists
D0J8ID	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0P2YS	TTDDRUID	D0P2YS
D0P2YS	DRUGNAME	A 77636
D0P2YS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D03XHD	TTDDRUID	D03XHD
D03XHD	DRUGNAME	A-11259
D03XHD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0S9XV	TTDDRUID	D0S9XV
D0S9XV	DRUGNAME	A-134974
D0S9XV	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0O7DB	TTDDRUID	D0O7DB
D0O7DB	DRUGNAME	A-204176
D0O7DB	INDICATI	Stress urinary incontinence [ICD-11: MF50.20] Terminated

D09GGO	TTDDRUID	D09GGO
D09GGO	DRUGNAME	A-252444.0
D09GGO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0Y6HY	TTDDRUID	D0Y6HY
D0Y6HY	DRUGNAME	A-364
D0Y6HY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D06JVU	TTDDRUID	D06JVU
D06JVU	DRUGNAME	A-68552
D06JVU	INDICATI	Obesity [ICD-11: 5B81] Terminated

D02NFA	TTDDRUID	D02NFA
D02NFA	DRUGNAME	A-68828
D02NFA	INDICATI	Kidney disease [ICD-11: GC2Z] Terminated

D0N1WM	TTDDRUID	D0N1WM
D0N1WM	DRUGNAME	A-68930
D0N1WM	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0OQ4H	TTDDRUID	D0OQ4H
D0OQ4H	DRUGNAME	A-69024
D0OQ4H	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D05LCX	TTDDRUID	D05LCX
D05LCX	DRUGNAME	A-70276
D05LCX	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D0V2WK	TTDDRUID	D0V2WK
D0V2WK	DRUGNAME	A-70826
D0V2WK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0C8ZD	TTDDRUID	D0C8ZD
D0C8ZD	DRUGNAME	A-71623
D0C8ZD	INDICATI	Obesity [ICD-11: 5B81] Terminated

D08YRD	TTDDRUID	D08YRD
D08YRD	DRUGNAME	A-717
D08YRD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D02VHE	TTDDRUID	D02VHE
D02VHE	DRUGNAME	A-72055
D02VHE	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0K1AF	TTDDRUID	D0K1AF
D0K1AF	DRUGNAME	A-74273
D0K1AF	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0R1DP	TTDDRUID	D0R1DP
D0R1DP	DRUGNAME	A-74283
D0R1DP	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D08IHF	TTDDRUID	D08IHF
D08IHF	DRUGNAME	A-74932
D08IHF	INDICATI	Lung cancer [ICD-11: 2C25.0] Terminated

D07SZJ	TTDDRUID	D07SZJ
D07SZJ	DRUGNAME	A-75169
D07SZJ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated

D03FAP	TTDDRUID	D03FAP
D03FAP	DRUGNAME	A-75729
D03FAP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0H9SF	TTDDRUID	D0H9SF
D0H9SF	DRUGNAME	A-76202M
D0H9SF	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Terminated

D0EF9I	TTDDRUID	D0EF9I
D0EF9I	DRUGNAME	A-76895
D0EF9I	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0X9KE	TTDDRUID	D0X9KE
D0X9KE	DRUGNAME	A-78773
D0X9KE	INDICATI	Asthma [ICD-11: CA23] Terminated

D0L1IH	TTDDRUID	D0L1IH
D0L1IH	DRUGNAME	A-79175
D0L1IH	INDICATI	Asthma [ICD-11: CA23] Terminated

D05DNH	TTDDRUID	D05DNH
D05DNH	DRUGNAME	A-79296
D05DNH	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated

D05SUA	TTDDRUID	D05SUA
D05SUA	DRUGNAME	A-798
D05SUA	INDICATI	Obesity [ICD-11: 5B81] Terminated

D0T4EL	TTDDRUID	D0T4EL
D0T4EL	DRUGNAME	A-80263
D0T4EL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0O0RK	TTDDRUID	D0O0RK
D0O0RK	DRUGNAME	A-81282
D0O0RK	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D06MUI	TTDDRUID	D06MUI
D06MUI	DRUGNAME	A-81988
D06MUI	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0IL8R	TTDDRUID	D0IL8R
D0IL8R	DRUGNAME	A-93178
D0IL8R	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D06XRQ	TTDDRUID	D06XRQ
D06XRQ	DRUGNAME	AA-861
D06XRQ	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D04DUG	TTDDRUID	D04DUG
D04DUG	DRUGNAME	AAV-GUS
D04DUG	INDICATI	Genetic disease [ICD-11: 8E02] Terminated

D03XIH	TTDDRUID	D03XIH
D03XIH	DRUGNAME	ABS-103
D03XIH	INDICATI	Bipolar disorder [ICD-11: 6A60] Terminated

D05GBZ	TTDDRUID	D05GBZ
D05GBZ	DRUGNAME	ABS-205
D05GBZ	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated

D03XUQ	TTDDRUID	D03XUQ
D03XUQ	DRUGNAME	ABS-212
D03XUQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D02UQU	TTDDRUID	D02UQU
D02UQU	DRUGNAME	ABS-301
D02UQU	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D00WEL	TTDDRUID	D00WEL
D00WEL	DRUGNAME	ABS-401
D00WEL	INDICATI	Amnesia [ICD-11: MB21.1] Terminated

D05XTO	TTDDRUID	D05XTO
D05XTO	DRUGNAME	ABT-100
D05XTO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D08LUT	TTDDRUID	D08LUT
D08LUT	DRUGNAME	ABT-702
D08LUT	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D04DYZ	TTDDRUID	D04DYZ
D04DYZ	DRUGNAME	ABT-839
D04DYZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Terminated

D02RAI	TTDDRUID	D02RAI
D02RAI	DRUGNAME	ABX-PTH
D02RAI	INDICATI	Parathyroid disease [ICD-11: 5A50-5A5Z] Terminated

D00PZH	TTDDRUID	D00PZH
D00PZH	DRUGNAME	AC-187
D00PZH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0J8UV	TTDDRUID	D0J8UV
D0J8UV	DRUGNAME	AC-260584
D0J8UV	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0KJ4U	TTDDRUID	D0KJ4U
D0KJ4U	DRUGNAME	ACEA-1011
D0KJ4U	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated

D09OTF	TTDDRUID	D09OTF
D09OTF	DRUGNAME	ACEA-1031
D09OTF	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0O4JH	TTDDRUID	D0O4JH
D0O4JH	DRUGNAME	ACEA-1328
D0O4JH	INDICATI	Cancer related pain [ICD-11: MG30] Terminated

D03HDP	TTDDRUID	D03HDP
D03HDP	DRUGNAME	ACEA-1416
D03HDP	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0B4AB	TTDDRUID	D0B4AB
D0B4AB	DRUGNAME	ACEA-2085
D0B4AB	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0Q6GR	TTDDRUID	D0Q6GR
D0Q6GR	DRUGNAME	Acetyl CoA carboxylase inhibitors, Bayer
D0Q6GR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D08OTG	TTDDRUID	D08OTG
D08OTG	DRUGNAME	Acteoside
D08OTG	INDICATI	Nephritis [ICD-11: GB40] Terminated

D03JMN	TTDDRUID	D03JMN
D03JMN	DRUGNAME	AD-177
D03JMN	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated

D01KWB	TTDDRUID	D01KWB
D01KWB	DRUGNAME	AD-313
D01KWB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated

D03VEZ	TTDDRUID	D03VEZ
D03VEZ	DRUGNAME	AD-439
D03VEZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0LB4T	TTDDRUID	D0LB4T
D0LB4T	DRUGNAME	AD-5075
D0LB4T	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0O3LC	TTDDRUID	D0O3LC
D0O3LC	DRUGNAME	AD-519
D0O3LC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0D8KI	TTDDRUID	D0D8KI
D0D8KI	DRUGNAME	Ad5-AC6
D0D8KI	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated

D0O7EC	TTDDRUID	D0O7EC
D0O7EC	DRUGNAME	ADCON-I
D0O7EC	INDICATI	Wound healing [ICD-11: EL8Y] Terminated

D0N8UU	TTDDRUID	D0N8UU
D0N8UU	DRUGNAME	ADX415
D0N8UU	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D07XAX	TTDDRUID	D07XAX
D07XAX	DRUGNAME	AEP-924
D07XAX	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D07SXO	TTDDRUID	D07SXO
D07SXO	DRUGNAME	AG-041R
D07SXO	INDICATI	Ulcerative colitis [ICD-11: DD71] Terminated

D0GM4S	TTDDRUID	D0GM4S
D0GM4S	DRUGNAME	AG-1284
D0GM4S	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D07PIA	TTDDRUID	D07PIA
D07PIA	DRUGNAME	AG-1350
D07PIA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0G2CL	TTDDRUID	D0G2CL
D0G2CL	DRUGNAME	AG-2024
D0G2CL	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0L4GF	TTDDRUID	D0L4GF
D0L4GF	DRUGNAME	AG-3296
D0L4GF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0GZ7B	TTDDRUID	D0GZ7B
D0GZ7B	DRUGNAME	AG490
D0GZ7B	INDICATI	Multiple myeloma [ICD-11: 2A83] Terminated
D0GZ7B	INDICATI	Renal transplantation [ICD-11: NE84] Terminated

D0T8BP	TTDDRUID	D0T8BP
D0T8BP	DRUGNAME	AH-9700
D0T8BP	INDICATI	Pollakiuria [ICD-11: MF50.1] Terminated

D0WV4N	TTDDRUID	D0WV4N
D0WV4N	DRUGNAME	AHR-14042
D0WV4N	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0Q6EN	TTDDRUID	D0Q6EN
D0Q6EN	DRUGNAME	AHR-16303B
D0Q6EN	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D04LRU	TTDDRUID	D04LRU
D04LRU	DRUGNAME	AHR-16462B
D04LRU	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D04MFY	TTDDRUID	D04MFY
D04MFY	DRUGNAME	AJ-3941
D04MFY	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D00QHT	TTDDRUID	D00QHT
D00QHT	DRUGNAME	AK-295
D00QHT	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated

D04JVX	TTDDRUID	D04JVX
D04JVX	DRUGNAME	AKP-320
D04JVX	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0TB1X	TTDDRUID	D0TB1X
D0TB1X	DRUGNAME	AL-0671
D0TB1X	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0U6RP	TTDDRUID	D0U6RP
D0U6RP	DRUGNAME	AL-072
D0U6RP	INDICATI	Legionella infection [ICD-11: 1C19] Terminated

D05VGS	TTDDRUID	D05VGS
D05VGS	DRUGNAME	ALB-127158(a)
D05VGS	INDICATI	Obesity [ICD-11: 5B81] Terminated

D0ZV6W	TTDDRUID	D0ZV6W
D0ZV6W	DRUGNAME	Albupoietin
D0ZV6W	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Terminated

D02RFA	TTDDRUID	D02RFA
D02RFA	DRUGNAME	Alkylisothioureas
D02RFA	INDICATI	Neurological disorder [ICD-11: 6B60] Terminated

D06BTF	TTDDRUID	D06BTF
D06BTF	DRUGNAME	Almorexant
D06BTF	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Terminated
D06BTF	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated

D05ITS	TTDDRUID	D05ITS
D05ITS	DRUGNAME	ALN-VEG01
D05ITS	INDICATI	Macular degeneration [ICD-11: 9B78.3] Terminated

D05OVR	TTDDRUID	D05OVR
D05OVR	DRUGNAME	ALP-242
D05OVR	INDICATI	Cystic fibrosis [ICD-11: CA25] Terminated

D0J1WJ	TTDDRUID	D0J1WJ
D0J1WJ	DRUGNAME	ALS-769
D0J1WJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0VS2M	TTDDRUID	D0VS2M
D0VS2M	DRUGNAME	ALS-886
D0VS2M	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Terminated

D0L1VR	TTDDRUID	D0L1VR
D0L1VR	DRUGNAME	ALT-946
D0L1VR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0X8MZ	TTDDRUID	D0X8MZ
D0X8MZ	DRUGNAME	Alvameline
D0X8MZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0DG0W	TTDDRUID	D0DG0W
D0DG0W	DRUGNAME	ALX-0625
D0DG0W	INDICATI	Migraine [ICD-11: 8A80] Terminated

D0X5CU	TTDDRUID	D0X5CU
D0X5CU	DRUGNAME	AM-491
D0X5CU	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated

D07XGT	TTDDRUID	D07XGT
D07XGT	DRUGNAME	AM-577
D07XGT	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0V1NI	TTDDRUID	D0V1NI
D0V1NI	DRUGNAME	AM-66
D0V1NI	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D02MVG	TTDDRUID	D02MVG
D02MVG	DRUGNAME	AMG-548
D02MVG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D07IEM	TTDDRUID	D07IEM
D07IEM	DRUGNAME	AMG-8562
D07IEM	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0U0FH	TTDDRUID	D0U0FH
D0U0FH	DRUGNAME	Amitivir
D0U0FH	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D0V4JO	TTDDRUID	D0V4JO
D0V4JO	DRUGNAME	AMPEROZIDE
D0V4JO	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Terminated

D0CQ8D	TTDDRUID	D0CQ8D
D0CQ8D	DRUGNAME	AMR-103
D0CQ8D	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D0M9WX	TTDDRUID	D0M9WX
D0M9WX	DRUGNAME	AMT-030
D0M9WX	INDICATI	Hyperoxaluria [ICD-11: 5C51.2Z] Terminated

D02TLD	TTDDRUID	D02TLD
D02TLD	DRUGNAME	AMT-050
D02TLD	INDICATI	Cholesterol metabolism disorder [ICD-11: 5C8Z] Terminated

D09RMS	TTDDRUID	D09RMS
D09RMS	DRUGNAME	AMT-070
D09RMS	INDICATI	Liver cirrhosis [ICD-11: DB93.1] Terminated

D0Q5QE	TTDDRUID	D0Q5QE
D0Q5QE	DRUGNAME	AN-10
D0Q5QE	INDICATI	Alopecia [ICD-11: ED70] Terminated

D03EZQ	TTDDRUID	D03EZQ
D03EZQ	DRUGNAME	AN-1006
D03EZQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09NKX	TTDDRUID	D09NKX
D09NKX	DRUGNAME	ANA-246
D09NKX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0W5NP	TTDDRUID	D0W5NP
D0W5NP	DRUGNAME	Anatumomab mafenatox
D0W5NP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D0R6OD	TTDDRUID	D0R6OD
D0R6OD	DRUGNAME	AnergiX-IDDM
D0R6OD	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Terminated

D04RFE	TTDDRUID	D04RFE
D04RFE	DRUGNAME	AnervaX.DB
D04RFE	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Terminated

D02ZPM	TTDDRUID	D02ZPM
D02ZPM	DRUGNAME	Anpirtoline
D02ZPM	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D03KJS	TTDDRUID	D03KJS
D03KJS	DRUGNAME	Antalarmin
D03KJS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated

D0L7KU	TTDDRUID	D0L7KU
D0L7KU	DRUGNAME	Antiarrhythmics
D0L7KU	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0A3HQ	TTDDRUID	D0A3HQ
D0A3HQ	DRUGNAME	Antibiotics
D0A3HQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D06QYJ	TTDDRUID	D06QYJ
D06QYJ	DRUGNAME	Anticancer glycosaminoglycans
D06QYJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0X4PX	TTDDRUID	D0X4PX
D0X4PX	DRUGNAME	Antifungals
D0X4PX	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D06HUV	TTDDRUID	D06HUV
D06HUV	DRUGNAME	Antihypercholesterolemics
D06HUV	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated

D0R4OD	TTDDRUID	D0R4OD
D0R4OD	DRUGNAME	Anti-IFN gamma
D0R4OD	INDICATI	Alopecia [ICD-11: ED70] Terminated

D00YWH	TTDDRUID	D00YWH
D00YWH	DRUGNAME	Anti-MRSA
D00YWH	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0H3MS	TTDDRUID	D0H3MS
D0H3MS	DRUGNAME	Antiparasitics
D0H3MS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0W5ZU	TTDDRUID	D0W5ZU
D0W5ZU	DRUGNAME	Antova
D0W5ZU	INDICATI	Thrombocytopenia [ICD-11: 3B64] Terminated

D0K3YG	TTDDRUID	D0K3YG
D0K3YG	DRUGNAME	ANX-201
D0K3YG	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated

D0C6XF	TTDDRUID	D0C6XF
D0C6XF	DRUGNAME	Anxiolytic
D0C6XF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D09WPN	TTDDRUID	D09WPN
D09WPN	DRUGNAME	AP22408
D09WPN	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0HV6O	TTDDRUID	D0HV6O
D0HV6O	DRUGNAME	AP-23588
D0HV6O	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0Z0RU	TTDDRUID	D0Z0RU
D0Z0RU	DRUGNAME	APC-6336
D0Z0RU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0Y8GL	TTDDRUID	D0Y8GL
D0Y8GL	DRUGNAME	APF-580
D0Y8GL	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D02ADJ	TTDDRUID	D02ADJ
D02ADJ	DRUGNAME	Apolipoprotein E
D02ADJ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated

D06XJP	TTDDRUID	D06XJP
D06XJP	DRUGNAME	APT-222
D06XJP	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0VZ3D	TTDDRUID	D0VZ3D
D0VZ3D	DRUGNAME	AQ-RA-741
D0VZ3D	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0TH6O	TTDDRUID	D0TH6O
D0TH6O	DRUGNAME	AR-132
D0TH6O	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated

D06SIG	TTDDRUID	D06SIG
D06SIG	DRUGNAME	AR177
D06SIG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D00GAV	TTDDRUID	D00GAV
D00GAV	DRUGNAME	AR-2474
D00GAV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D03ICO	TTDDRUID	D03ICO
D03ICO	DRUGNAME	AR-709
D03ICO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0F6AB	TTDDRUID	D0F6AB
D0F6AB	DRUGNAME	AR-C-89855
D0F6AB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated

D0O3PP	TTDDRUID	D0O3PP
D0O3PP	DRUGNAME	ARGENT
D0O3PP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D0BU5Z	TTDDRUID	D0BU5Z
D0BU5Z	DRUGNAME	Argyrin B
D0BU5Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0X5JF	TTDDRUID	D0X5JF
D0X5JF	DRUGNAME	AR-H050642
D0X5JF	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D03OBV	TTDDRUID	D03OBV
D03OBV	DRUGNAME	AS-1405
D03OBV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0W1YM	TTDDRUID	D0W1YM
D0W1YM	DRUGNAME	AS-1406
D0W1YM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0SK1W	TTDDRUID	D0SK1W
D0SK1W	DRUGNAME	AS-602305
D0SK1W	INDICATI	Androgen deficiency [ICD-11: 5A81.1] Terminated

D08KDP	TTDDRUID	D08KDP
D08KDP	DRUGNAME	AS-8112
D08KDP	INDICATI	Vomiting [ICD-11: MD90] Terminated

D09LIE	TTDDRUID	D09LIE
D09LIE	DRUGNAME	ASIbcl vaccine
D09LIE	INDICATI	B-cell lymphoma [ICD-11: 2A86] Terminated

D0J3PS	TTDDRUID	D0J3PS
D0J3PS	DRUGNAME	ASP-0265
D0J3PS	INDICATI	Endometriosis [ICD-11: GA10] Terminated

D0Y8LT	TTDDRUID	D0Y8LT
D0Y8LT	DRUGNAME	AstaFactor
D0Y8LT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05HHP	TTDDRUID	D05HHP
D05HHP	DRUGNAME	Astenose
D05HHP	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D03AKL	TTDDRUID	D03AKL
D03AKL	DRUGNAME	ATLIPROFEN METHYL ESTER
D03AKL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D07OUE	TTDDRUID	D07OUE
D07OUE	DRUGNAME	AUX-202
D07OUE	INDICATI	Bone metastases [ICD-11: 2D50] Terminated

D0B6WN	TTDDRUID	D0B6WN
D0B6WN	DRUGNAME	AVE0675
D0B6WN	INDICATI	Asthma [ICD-11: CA23] Terminated

D06ZWG	TTDDRUID	D06ZWG
D06ZWG	DRUGNAME	AVE-5997EF
D06ZWG	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D01TPU	TTDDRUID	D01TPU
D01TPU	DRUGNAME	AWD-160-275
D01TPU	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D03BVH	TTDDRUID	D03BVH
D03BVH	DRUGNAME	AWD-23-111
D03BVH	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D04JLW	TTDDRUID	D04JLW
D04JLW	DRUGNAME	AWD-72-011
D04JLW	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D0E4UB	TTDDRUID	D0E4UB
D0E4UB	DRUGNAME	AX-201
D0E4UB	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0D8ZU	TTDDRUID	D0D8ZU
D0D8ZU	DRUGNAME	AX-205
D0D8ZU	INDICATI	Motor neurone disease [ICD-11: 8B60] Terminated

D08ZXH	TTDDRUID	D08ZXH
D08ZXH	DRUGNAME	AX-208
D08ZXH	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D03DYB	TTDDRUID	D03DYB
D03DYB	DRUGNAME	AZD-0275
D03DYB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
D03DYB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0F1EI	TTDDRUID	D0F1EI
D0F1EI	DRUGNAME	AZD-0303
D0F1EI	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0F7LE	TTDDRUID	D0F7LE
D0F7LE	DRUGNAME	AZD-0902
D0F7LE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
D0F7LE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0K4PN	TTDDRUID	D0K4PN
D0K4PN	DRUGNAME	AZD-1134
D0K4PN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0M4LF	TTDDRUID	D0M4LF
D0M4LF	DRUGNAME	AZD-1283
D0M4LF	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0J1FL	TTDDRUID	D0J1FL
D0J1FL	DRUGNAME	AZD-2098
D0J1FL	INDICATI	Asthma [ICD-11: CA23] Terminated

D04WZK	TTDDRUID	D04WZK
D04WZK	DRUGNAME	AZD-2858
D04WZK	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0A4VI	TTDDRUID	D0A4VI
D0A4VI	DRUGNAME	AZD-2914
D0A4VI	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated

D09KKD	TTDDRUID	D09KKD
D09KKD	DRUGNAME	AZD-3118
D09KKD	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0NE3C	TTDDRUID	D0NE3C
D0NE3C	DRUGNAME	AZD3409
D0NE3C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09KLO	TTDDRUID	D09KLO
D09KLO	DRUGNAME	AZD-5106
D09KLO	INDICATI	Urinary incontinence [ICD-11: MF50.2] Terminated

D07GIB	TTDDRUID	D07GIB
D07GIB	DRUGNAME	AZD5672
D07GIB	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0OI7B	TTDDRUID	D0OI7B
D0OI7B	DRUGNAME	AZD-5745
D0OI7B	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D0Y2IF	TTDDRUID	D0Y2IF
D0Y2IF	DRUGNAME	AZD-6357
D0Y2IF	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated

D0D0QA	TTDDRUID	D0D0QA
D0D0QA	DRUGNAME	AZD6482
D0D0QA	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0N8NK	TTDDRUID	D0N8NK
D0N8NK	DRUGNAME	AZD-6605
D0N8NK	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated

D0I9YI	TTDDRUID	D0I9YI
D0I9YI	DRUGNAME	AZD-6942
D0I9YI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D03GFC	TTDDRUID	D03GFC
D03GFC	DRUGNAME	AZD-7545
D03GFC	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D02OCF	TTDDRUID	D02OCF
D02OCF	DRUGNAME	AZD-8294
D02OCF	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated

D0DG9M	TTDDRUID	D0DG9M
D0DG9M	DRUGNAME	AZD-9139
D0DG9M	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D0Y1YX	TTDDRUID	D0Y1YX
D0Y1YX	DRUGNAME	AZD-9935
D0Y1YX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D01GCT	TTDDRUID	D01GCT
D01GCT	DRUGNAME	AZM-090
D01GCT	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D09VRZ	TTDDRUID	D09VRZ
D09VRZ	DRUGNAME	AZM-131
D09VRZ	INDICATI	Obesity [ICD-11: 5B81] Terminated

D0I0TD	TTDDRUID	D0I0TD
D0I0TD	DRUGNAME	AZM-134
D0I0TD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0Y3OQ	TTDDRUID	D0Y3OQ
D0Y3OQ	DRUGNAME	AZM-145
D0Y3OQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D06AZH	TTDDRUID	D06AZH
D06AZH	DRUGNAME	B-220
D06AZH	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0K1PR	TTDDRUID	D0K1PR
D0K1PR	DRUGNAME	B-428
D0K1PR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D02YQJ	TTDDRUID	D02YQJ
D02YQJ	DRUGNAME	B-5354a
D02YQJ	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D03GQH	TTDDRUID	D03GQH
D03GQH	DRUGNAME	B-581
D03GQH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D07PAY	TTDDRUID	D07PAY
D07PAY	DRUGNAME	B-956
D07PAY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D02INZ	TTDDRUID	D02INZ
D02INZ	DRUGNAME	BABIM
D02INZ	INDICATI	Asthma [ICD-11: CA23] Terminated

D0BQ9A	TTDDRUID	D0BQ9A
D0BQ9A	DRUGNAME	Bacteriophage
D0BQ9A	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated

D08PUW	TTDDRUID	D08PUW
D08PUW	DRUGNAME	BAICALIN
D08PUW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0LV0R	TTDDRUID	D0LV0R
D0LV0R	DRUGNAME	Barixibat
D0LV0R	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D06HYG	TTDDRUID	D06HYG
D06HYG	DRUGNAME	Barucainide
D06HYG	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0VJ0M	TTDDRUID	D0VJ0M
D0VJ0M	DRUGNAME	Basal lamina-targeting antiangiogenic agent
D0VJ0M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0L7ZX	TTDDRUID	D0L7ZX
D0L7ZX	DRUGNAME	BAY-17-1998
D0L7ZX	INDICATI	Asthma [ICD-11: CA23] Terminated

D0O1PU	TTDDRUID	D0O1PU
D0O1PU	DRUGNAME	BAY-39-9624
D0O1PU	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0W7DD	TTDDRUID	D0W7DD
D0W7DD	DRUGNAME	BAY-44-3428
D0W7DD	INDICATI	Asthma [ICD-11: CA23] Terminated

D0T5ZC	TTDDRUID	D0T5ZC
D0T5ZC	DRUGNAME	BAY-50-9062
D0T5ZC	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D05UMO	TTDDRUID	D05UMO
D05UMO	DRUGNAME	BAY-793
D05UMO	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D05IZG	TTDDRUID	D05IZG
D05IZG	DRUGNAME	BAY-Z-4305
D05IZG	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D05VNG	TTDDRUID	D05VNG
D05VNG	DRUGNAME	BB-1101
D05VNG	INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated

D0V0RW	TTDDRUID	D0V0RW
D0V0RW	DRUGNAME	BB-1433
D0V0RW	INDICATI	Arthritis [ICD-11: FA20] Terminated

D01EYM	TTDDRUID	D01EYM
D01EYM	DRUGNAME	BB-2275
D01EYM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D08WBF	TTDDRUID	D08WBF
D08WBF	DRUGNAME	BB-3644
D08WBF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0WU8Z	TTDDRUID	D0WU8Z
D0WU8Z	DRUGNAME	BB-476
D0WU8Z	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0GH0O	TTDDRUID	D0GH0O
D0GH0O	DRUGNAME	BB-76163
D0GH0O	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0E1ZE	TTDDRUID	D0E1ZE
D0E1ZE	DRUGNAME	BBB-022
D0E1ZE	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0CH6Z	TTDDRUID	D0CH6Z
D0CH6Z	DRUGNAME	BBR 3576
D0CH6Z	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D0J8XO	TTDDRUID	D0J8XO
D0J8XO	DRUGNAME	BCH-150
D0J8XO	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D0HS3X	TTDDRUID	D0HS3X
D0HS3X	DRUGNAME	BCH-2051
D0HS3X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06ALB	TTDDRUID	D06ALB
D06ALB	DRUGNAME	BCH-2763
D06ALB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0V6RE	TTDDRUID	D0V6RE
D0V6RE	DRUGNAME	BCH-371
D0V6RE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0XJ0P	TTDDRUID	D0XJ0P
D0XJ0P	DRUGNAME	BCX-140
D0XJ0P	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated

D0V2ZJ	TTDDRUID	D0V2ZJ
D0V2ZJ	DRUGNAME	BCX-25
D0V2ZJ	INDICATI	Arthritis [ICD-11: FA20] Terminated

D09VHA	TTDDRUID	D09VHA
D09VHA	DRUGNAME	BDF-9148
D09VHA	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated

D0B3CT	TTDDRUID	D0B3CT
D0B3CT	DRUGNAME	BE-13793C
D0B3CT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0GA3M	TTDDRUID	D0GA3M
D0GA3M	DRUGNAME	BE-16627B
D0GA3M	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0H1YE	TTDDRUID	D0H1YE
D0H1YE	DRUGNAME	BE-22179
D0H1YE	INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated

D05MQO	TTDDRUID	D05MQO
D05MQO	DRUGNAME	BEA-005
D05MQO	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated

D0IJ5I	TTDDRUID	D0IJ5I
D0IJ5I	DRUGNAME	Befiperide
D0IJ5I	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0I2OP	TTDDRUID	D0I2OP
D0I2OP	DRUGNAME	Belaperidone
D0I2OP	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0N6OE	TTDDRUID	D0N6OE
D0N6OE	DRUGNAME	Benafentrine dimaleate
D0N6OE	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D0Y2ES	TTDDRUID	D0Y2ES
D0Y2ES	DRUGNAME	Bepafant
D0Y2ES	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D0V1HK	TTDDRUID	D0V1HK
D0V1HK	DRUGNAME	Berlafenone
D0V1HK	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0AX4E	TTDDRUID	D0AX4E
D0AX4E	DRUGNAME	Bertosamil
D0AX4E	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D09HIC	TTDDRUID	D09HIC
D09HIC	DRUGNAME	BF-388
D09HIC	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0RO7R	TTDDRUID	D0RO7R
D0RO7R	DRUGNAME	BhCG vaccine
D0RO7R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0R9NQ	TTDDRUID	D0R9NQ
D0R9NQ	DRUGNAME	Bi-51013
D0R9NQ	INDICATI	Transplant rejection [ICD-11: NE84] Terminated

D0I2YV	TTDDRUID	D0I2YV
D0I2YV	DRUGNAME	BIBB-515
D0I2YV	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D02JNY	TTDDRUID	D02JNY
D02JNY	DRUGNAME	BIBN-140
D02JNY	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0R1VL	TTDDRUID	D0R1VL
D0R1VL	DRUGNAME	BIBN-99
D0R1VL	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0V2GT	TTDDRUID	D0V2GT
D0V2GT	DRUGNAME	BIBP 3226
D0V2GT	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0N5CT	TTDDRUID	D0N5CT
D0N5CT	DRUGNAME	BIBS-222
D0N5CT	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D07LEW	TTDDRUID	D07LEW
D07LEW	DRUGNAME	BIBS-39
D07LEW	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0J6MS	TTDDRUID	D0J6MS
D0J6MS	DRUGNAME	BIBU-251
D0J6MS	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0E1SQ	TTDDRUID	D0E1SQ
D0E1SQ	DRUGNAME	BIBW-22
D0E1SQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0S1XO	TTDDRUID	D0S1XO
D0S1XO	DRUGNAME	BIBX-79
D0S1XO	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D02CGY	TTDDRUID	D02CGY
D02CGY	DRUGNAME	Bifemelane
D02CGY	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0U6AL	TTDDRUID	D0U6AL
D0U6AL	DRUGNAME	BI-L-357
D0U6AL	INDICATI	Asthma [ICD-11: CA23] Terminated

D08IDQ	TTDDRUID	D08IDQ
D08IDQ	DRUGNAME	BILA-2157BS
D08IDQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0HP3M	TTDDRUID	D0HP3M
D0HP3M	DRUGNAME	BILD-1263
D0HP3M	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated

D00FRY	TTDDRUID	D00FRY
D00FRY	DRUGNAME	BILD-1351
D00FRY	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated

D0U4WY	TTDDRUID	D0U4WY
D0U4WY	DRUGNAME	BILD-1357
D0U4WY	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated

D0QM0N	TTDDRUID	D0QM0N
D0QM0N	DRUGNAME	BILD-733
D0QM0N	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated

D0EH2O	TTDDRUID	D0EH2O
D0EH2O	DRUGNAME	BIMG80
D0EH2O	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D0P1JV	TTDDRUID	D0P1JV
D0P1JV	DRUGNAME	Bio-Flow
D0P1JV	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0R6EQ	TTDDRUID	D0R6EQ
D0R6EQ	DRUGNAME	Bivatuzumab mertansine
D0R6EQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D00ZZH	TTDDRUID	D00ZZH
D00ZZH	DRUGNAME	BK-218
D00ZZH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0F2PQ	TTDDRUID	D0F2PQ
D0F2PQ	DRUGNAME	BL-1050
D0F2PQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0VN2Y	TTDDRUID	D0VN2Y
D0VN2Y	DRUGNAME	BL-1825
D0VN2Y	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D01QIA	TTDDRUID	D01QIA
D01QIA	DRUGNAME	BL-1872
D01QIA	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0N3FJ	TTDDRUID	D0N3FJ
D0N3FJ	DRUGNAME	BL-1889
D0N3FJ	INDICATI	Pruritus [ICD-11: EC90] Terminated

D04GXS	TTDDRUID	D04GXS
D04GXS	DRUGNAME	BL-1893
D04GXS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06LAN	TTDDRUID	D06LAN
D06LAN	DRUGNAME	BlockAide/CR
D06LAN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0F4WS	TTDDRUID	D0F4WS
D0F4WS	DRUGNAME	BM-13.1180
D0F4WS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D00IZW	TTDDRUID	D00IZW
D00IZW	DRUGNAME	BM-13.1188
D00IZW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D02AEI	TTDDRUID	D02AEI
D02AEI	DRUGNAME	BM-13.1196
D02AEI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0W2DV	TTDDRUID	D0W2DV
D0W2DV	DRUGNAME	BM-13677
D0W2DV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D07SEB	TTDDRUID	D07SEB
D07SEB	DRUGNAME	BM-17.0505
D07SEB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D02ABS	TTDDRUID	D02ABS
D02ABS	DRUGNAME	BMS-180560
D02ABS	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0BW9R	TTDDRUID	D0BW9R
D0BW9R	DRUGNAME	BMS-181184
D0BW9R	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0Q7TH	TTDDRUID	D0Q7TH
D0Q7TH	DRUGNAME	BMS-181885
D0Q7TH	INDICATI	Migraine [ICD-11: 8A80] Terminated

D00XRK	TTDDRUID	D00XRK
D00XRK	DRUGNAME	BMS-182193
D00XRK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0W3OQ	TTDDRUID	D0W3OQ
D0W3OQ	DRUGNAME	BMS-182566
D0W3OQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04MBS	TTDDRUID	D04MBS
D04MBS	DRUGNAME	BMS-182657
D04MBS	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D01VUE	TTDDRUID	D01VUE
D01VUE	DRUGNAME	BMS-182874
D01VUE	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D05VQD	TTDDRUID	D05VQD
D05VQD	DRUGNAME	BMS-183729
D05VQD	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0I9AR	TTDDRUID	D0I9AR
D0I9AR	DRUGNAME	BMS-185857
D0I9AR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D01RCC	TTDDRUID	D01RCC
D01RCC	DRUGNAME	BMS-186318
D01RCC	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0G7YZ	TTDDRUID	D0G7YZ
D0G7YZ	DRUGNAME	BMS-189664
D0G7YZ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated

D03GLM	TTDDRUID	D03GLM
D03GLM	DRUGNAME	BMS-210285
D03GLM	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D08QTP	TTDDRUID	D08QTP
D08QTP	DRUGNAME	BMS-433771
D08QTP	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated

D0N8XL	TTDDRUID	D0N8XL
D0N8XL	DRUGNAME	BMS-605339
D0N8XL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0E2CO	TTDDRUID	D0E2CO
D0E2CO	DRUGNAME	BMY-22089
D0E2CO	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated

D0C7FN	TTDDRUID	D0C7FN
D0C7FN	DRUGNAME	BMY-40062
D0C7FN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0V7HD	TTDDRUID	D0V7HD
D0V7HD	DRUGNAME	BN-50726
D0V7HD	INDICATI	Nerve injury [ICD-11: ND56.4] Terminated

D0KW2A	TTDDRUID	D0KW2A
D0KW2A	DRUGNAME	BN50739
D0KW2A	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated

D0D0YG	TTDDRUID	D0D0YG
D0D0YG	DRUGNAME	BN52021
D0D0YG	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D0V4QE	TTDDRUID	D0V4QE
D0V4QE	DRUGNAME	BN-58705
D0V4QE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0J7AI	TTDDRUID	D0J7AI
D0J7AI	DRUGNAME	BN-80245
D0J7AI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0N0SB	TTDDRUID	D0N0SB
D0N0SB	DRUGNAME	BOF-12013
D0N0SB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0V1SD	TTDDRUID	D0V1SD
D0V1SD	DRUGNAME	BP4.879a
D0V1SD	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D07DGM	TTDDRUID	D07DGM
D07DGM	DRUGNAME	BQ-518
D07DGM	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D04DZE	TTDDRUID	D04DZE
D04DZE	DRUGNAME	BRL 26830A
D04DZE	INDICATI	Obesity [ICD-11: 5B81] Terminated

D08VWL	TTDDRUID	D08VWL
D08VWL	DRUGNAME	BRL-42715
D08VWL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0UB1J	TTDDRUID	D0UB1J
D0UB1J	DRUGNAME	BRL-44385
D0UB1J	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D0YS8C	TTDDRUID	D0YS8C
D0YS8C	DRUGNAME	BTA-188
D0YS8C	INDICATI	Rhinovirus infection [ICD-11: CA07] Terminated

D05IPO	TTDDRUID	D05IPO
D05IPO	DRUGNAME	BTS-79018
D05IPO	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0L8TN	TTDDRUID	D0L8TN
D0L8TN	DRUGNAME	BU-4514N
D0L8TN	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0C9RZ	TTDDRUID	D0C9RZ
D0C9RZ	DRUGNAME	BU-4601A
D0C9RZ	INDICATI	Asthma [ICD-11: CA23] Terminated

D02RCV	TTDDRUID	D02RCV
D02RCV	DRUGNAME	BVF-247
D02RCV	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0I0RF	TTDDRUID	D0I0RF
D0I0RF	DRUGNAME	BVT-142
D0I0RF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0U5NW	TTDDRUID	D0U5NW
D0U5NW	DRUGNAME	BVT-24834
D0U5NW	INDICATI	Obesity [ICD-11: 5B81] Terminated

D0E0GW	TTDDRUID	D0E0GW
D0E0GW	DRUGNAME	BVT-3498
D0E0GW	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Terminated

D05WPQ	TTDDRUID	D05WPQ
D05WPQ	DRUGNAME	BW A4C
D05WPQ	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0HJ1Y	TTDDRUID	D0HJ1Y
D0HJ1Y	DRUGNAME	BW B70C
D0HJ1Y	INDICATI	Asthma [ICD-11: CA23] Terminated

D00LYW	TTDDRUID	D00LYW
D00LYW	DRUGNAME	BW-1003C87
D00LYW	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0DP8P	TTDDRUID	D0DP8P
D0DP8P	DRUGNAME	BW755C
D0DP8P	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0R7GL	TTDDRUID	D0R7GL
D0R7GL	DRUGNAME	BW-A502U
D0R7GL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0Z0KE	TTDDRUID	D0Z0KE
D0Z0KE	DRUGNAME	BX-044
D0Z0KE	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D05CTS	TTDDRUID	D05CTS
D05CTS	DRUGNAME	C-202
D05CTS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D05SVQ	TTDDRUID	D05SVQ
D05SVQ	DRUGNAME	C-AFG
D05SVQ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D05HYB	TTDDRUID	D05HYB
D05HYB	DRUGNAME	Calcium-dependent lipopeptide antibiotics
D05HYB	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated

D01XPG	TTDDRUID	D01XPG
D01XPG	DRUGNAME	CAN-296
D01XPG	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0F1AX	TTDDRUID	D0F1AX
D0F1AX	DRUGNAME	CB-102930
D0F1AX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0KK4U	TTDDRUID	D0KK4U
D0KK4U	DRUGNAME	CB-1267
D0KK4U	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D09PRY	TTDDRUID	D09PRY
D09PRY	DRUGNAME	CB-28
D09PRY	INDICATI	Aging skin [ICD-11: EE40] Terminated

D0TP9A	TTDDRUID	D0TP9A
D0TP9A	DRUGNAME	CB-30865
D0TP9A	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04STQ	TTDDRUID	D04STQ
D04STQ	DRUGNAME	CBH-11
D04STQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D01ZLI	TTDDRUID	D01ZLI
D01ZLI	DRUGNAME	CBR-2092
D01ZLI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0E0WL	TTDDRUID	D0E0WL
D0E0WL	DRUGNAME	CCR5 receptor inhibitors
D0E0WL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0O9AZ	TTDDRUID	D0O9AZ
D0O9AZ	DRUGNAME	CCR5Qb
D0O9AZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0BX1S	TTDDRUID	D0BX1S
D0BX1S	DRUGNAME	CD-832
D0BX1S	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D00ZNS	TTDDRUID	D00ZNS
D00ZNS	DRUGNAME	CDE-5110
D00ZNS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0N4MR	TTDDRUID	D0N4MR
D0N4MR	DRUGNAME	CDE-5498
D0N4MR	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0J7CE	TTDDRUID	D0J7CE
D0J7CE	DRUGNAME	CDE-6960
D0J7CE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0YK7J	TTDDRUID	D0YK7J
D0YK7J	DRUGNAME	CDP-492
D0YK7J	INDICATI	Vomiting [ICD-11: MD90] Terminated

D02GYD	TTDDRUID	D02GYD
D02GYD	DRUGNAME	CDP-845
D02GYD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D07DCX	TTDDRUID	D07DCX
D07DCX	DRUGNAME	CDP-855
D07DCX	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0J8TH	TTDDRUID	D0J8TH
D0J8TH	DRUGNAME	CEB-925
D0J8TH	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated

D0R8YO	TTDDRUID	D0R8YO
D0R8YO	DRUGNAME	CEDO-8956
D0R8YO	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D01TCM	TTDDRUID	D01TCM
D01TCM	DRUGNAME	CEE-03-320
D01TCM	INDICATI	Substance use disorder [ICD-11: 6C4Z] Terminated

D09AGZ	TTDDRUID	D09AGZ
D09AGZ	DRUGNAME	CEE-04-421
D09AGZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0T9SJ	TTDDRUID	D0T9SJ
D0T9SJ	DRUGNAME	CEP-4186
D0T9SJ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Terminated

D0O7DN	TTDDRUID	D0O7DN
D0O7DN	DRUGNAME	CEP-427
D0O7DN	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D04RDT	TTDDRUID	D04RDT
D04RDT	DRUGNAME	CEP-431
D04RDT	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0H4GI	TTDDRUID	D0H4GI
D0H4GI	DRUGNAME	CEP-5214
D0H4GI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0J5TN	TTDDRUID	D0J5TN
D0J5TN	DRUGNAME	CEP-751
D0J5TN	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated

D0O6RU	TTDDRUID	D0O6RU
D0O6RU	DRUGNAME	Cepacidine A
D0O6RU	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0CY4V	TTDDRUID	D0CY4V
D0CY4V	DRUGNAME	Cetamolol
D0CY4V	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D09FJH	TTDDRUID	D09FJH
D09FJH	DRUGNAME	CFC-240
D09FJH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D02GJE	TTDDRUID	D02GJE
D02GJE	DRUGNAME	CG-8840
D02GJE	INDICATI	Bladder cancer [ICD-11: 2C94] Terminated

D04LFG	TTDDRUID	D04LFG
D04LFG	DRUGNAME	CGP-25454A
D04LFG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D04KMO	TTDDRUID	D04KMO
D04KMO	DRUGNAME	CGP-35348
D04KMO	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0S6VX	TTDDRUID	D0S6VX
D0S6VX	DRUGNAME	CGP-40215A
D0S6VX	INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Terminated

D0U8KA	TTDDRUID	D0U8KA
D0U8KA	DRUGNAME	CGP-43371
D0U8KA	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D00IPW	TTDDRUID	D00IPW
D00IPW	DRUGNAME	CGP-47969A
D00IPW	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D03QTP	TTDDRUID	D03QTP
D03QTP	DRUGNAME	CGP-52411
D03QTP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D01EFO	TTDDRUID	D01EFO
D01EFO	DRUGNAME	CGP-53716
D01EFO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0U2TQ	TTDDRUID	D0U2TQ
D0U2TQ	DRUGNAME	CGP-60474
D0U2TQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06FMY	TTDDRUID	D06FMY
D06FMY	DRUGNAME	CGP-70726
D06FMY	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0Q1ER	TTDDRUID	D0Q1ER
D0Q1ER	DRUGNAME	CGS-12066B
D0Q1ER	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D09QRO	TTDDRUID	D09QRO
D09QRO	DRUGNAME	CGS-13080
D09QRO	INDICATI	Asthma [ICD-11: CA23] Terminated

D06BFP	TTDDRUID	D06BFP
D06BFP	DRUGNAME	CGS-17867A
D06BFP	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Terminated

D0T0BS	TTDDRUID	D0T0BS
D0T0BS	DRUGNAME	CGS-18102A
D0T0BS	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D07EGS	TTDDRUID	D07EGS
D07EGS	DRUGNAME	CGS-23425
D07EGS	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0OL9V	TTDDRUID	D0OL9V
D0OL9V	DRUGNAME	CGS-24565
D0OL9V	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0DS4P	TTDDRUID	D0DS4P
D0DS4P	DRUGNAME	CGS-26393
D0DS4P	INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated

D02QGM	TTDDRUID	D02QGM
D02QGM	DRUGNAME	CGS-26529
D02QGM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0KR3X	TTDDRUID	D0KR3X
D0KR3X	DRUGNAME	CGS-30440
D0KR3X	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0I1BX	TTDDRUID	D0I1BX
D0I1BX	DRUGNAME	CGS-32359
D0I1BX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D08ZIH	TTDDRUID	D08ZIH
D08ZIH	DRUGNAME	CGX-1160
D08ZIH	INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Terminated

D04DVF	TTDDRUID	D04DVF
D04DVF	DRUGNAME	CHF-1522
D04DVF	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated

D0JB4W	TTDDRUID	D0JB4W
D0JB4W	DRUGNAME	CHIR-29498
D0JB4W	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D07FHI	TTDDRUID	D07FHI
D07FHI	DRUGNAME	Chlamydia vaccine
D07FHI	INDICATI	Chlamydia infection [ICD-11: 1A81] Terminated

D0XY4Q	TTDDRUID	D0XY4Q
D0XY4Q	DRUGNAME	Cholazol
D0XY4Q	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0M2GI	TTDDRUID	D0M2GI
D0M2GI	DRUGNAME	CI-1002
D0M2GI	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0O9IB	TTDDRUID	D0O9IB
D0O9IB	DRUGNAME	CI-933
D0O9IB	INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated

D0L8RG	TTDDRUID	D0L8RG
D0L8RG	DRUGNAME	CI-986
D0L8RG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D04TSV	TTDDRUID	D04TSV
D04TSV	DRUGNAME	CI-992
D04TSV	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0Y8PH	TTDDRUID	D0Y8PH
D0Y8PH	DRUGNAME	CI-996
D0Y8PH	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0PG0S	TTDDRUID	D0PG0S
D0PG0S	DRUGNAME	CI-999
D0PG0S	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0V6VL	TTDDRUID	D0V6VL
D0V6VL	DRUGNAME	Cilofungin
D0V6VL	INDICATI	Candidiasis [ICD-11: 1F23] Terminated

D02KBO	TTDDRUID	D02KBO
D02KBO	DRUGNAME	Ciprokiren
D02KBO	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0E9PT	TTDDRUID	D0E9PT
D0E9PT	DRUGNAME	CK-2289
D0E9PT	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated

D05RBL	TTDDRUID	D05RBL
D05RBL	DRUGNAME	CL-184005
D05RBL	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D03YIT	TTDDRUID	D03YIT
D03YIT	DRUGNAME	CL-186659
D03YIT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0E6JF	TTDDRUID	D0E6JF
D0E6JF	DRUGNAME	CL-329753
D0E6JF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0T7EZ	TTDDRUID	D0T7EZ
D0T7EZ	DRUGNAME	CL-387626
D0T7EZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D0F6GR	TTDDRUID	D0F6GR
D0F6GR	DRUGNAME	Clentiazem
D0F6GR	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D00ITG	TTDDRUID	D00ITG
D00ITG	DRUGNAME	Clinafloxacin
D00ITG	INDICATI	Pneumonia [ICD-11: CA40] Terminated

D09VQO	TTDDRUID	D09VQO
D09VQO	DRUGNAME	CLR-901
D09VQO	INDICATI	Neurological disorder [ICD-11: 6B60] Terminated

D06KJG	TTDDRUID	D06KJG
D06KJG	DRUGNAME	CLX-0301
D06KJG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D02IJP	TTDDRUID	D02IJP
D02IJP	DRUGNAME	CLX-0900
D02IJP	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated

D0Q0MH	TTDDRUID	D0Q0MH
D0Q0MH	DRUGNAME	CM-101
D0Q0MH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0YG7H	TTDDRUID	D0YG7H
D0YG7H	DRUGNAME	CM-2359
D0YG7H	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Terminated

D03AFX	TTDDRUID	D03AFX
D03AFX	DRUGNAME	CM-2397
D03AFX	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D07UAJ	TTDDRUID	D07UAJ
D07UAJ	DRUGNAME	CMB-401
D07UAJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D0V4GT	TTDDRUID	D0V4GT
D0V4GT	DRUGNAME	CMI-206
D0V4GT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0P7MF	TTDDRUID	D0P7MF
D0P7MF	DRUGNAME	CMLVAX100
D0P7MF	INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated

D08MLG	TTDDRUID	D08MLG
D08MLG	DRUGNAME	CNI-H0294
D08MLG	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D09PPF	TTDDRUID	D09PPF
D09PPF	DRUGNAME	CNS-1067
D09PPF	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0D1GV	TTDDRUID	D0D1GV
D0D1GV	DRUGNAME	CNS-1237
D0D1GV	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0U7VO	TTDDRUID	D0U7VO
D0U7VO	DRUGNAME	CNS-1307
D0U7VO	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D07GLX	TTDDRUID	D07GLX
D07GLX	DRUGNAME	CNS-1531
D07GLX	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Terminated

D03RZU	TTDDRUID	D03RZU
D03RZU	DRUGNAME	CNS-5788
D03RZU	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D04RMP	TTDDRUID	D04RMP
D04RMP	DRUGNAME	Co-111732
D04RMP	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0W8VI	TTDDRUID	D0W8VI
D0W8VI	DRUGNAME	Co-122739
D0W8VI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D01SBP	TTDDRUID	D01SBP
D01SBP	DRUGNAME	Co-152791
D01SBP	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D09XXW	TTDDRUID	D09XXW
D09XXW	DRUGNAME	Co-2-1068
D09XXW	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D03ZGV	TTDDRUID	D03ZGV
D03ZGV	DRUGNAME	Co-60549
D03ZGV	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0P6EL	TTDDRUID	D0P6EL
D0P6EL	DRUGNAME	Cordil
D0P6EL	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0H5PD	TTDDRUID	D0H5PD
D0H5PD	DRUGNAME	CP-0597
D0H5PD	INDICATI	Asthma [ICD-11: CA23] Terminated

D00HHP	TTDDRUID	D00HHP
D00HHP	DRUGNAME	CP-111905
D00HHP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D08MAR	TTDDRUID	D08MAR
D08MAR	DRUGNAME	CP-230821
D08MAR	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D03RGO	TTDDRUID	D03RGO
D03RGO	DRUGNAME	CP-331
D03RGO	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0L0CL	TTDDRUID	D0L0CL
D0L0CL	DRUGNAME	CP-471358
D0L0CL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0E7BP	TTDDRUID	D0E7BP
D0E7BP	DRUGNAME	CP-663427
D0E7BP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D03YLN	TTDDRUID	D03YLN
D03YLN	DRUGNAME	CP-67015
D03YLN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0A7VF	TTDDRUID	D0A7VF
D0A7VF	DRUGNAME	CP-79328
D0A7VF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D07QSA	TTDDRUID	D07QSA
D07QSA	DRUGNAME	CP-83101
D07QSA	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0A7PW	TTDDRUID	D0A7PW
D0A7PW	DRUGNAME	CP-903397
D0A7PW	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D01EWC	TTDDRUID	D01EWC
D01EWC	DRUGNAME	CR-2991
D01EWC	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D01JHN	TTDDRUID	D01JHN
D01JHN	DRUGNAME	CR-3124
D01JHN	INDICATI	Substance use disorder [ICD-11: 6C4Z] Terminated

D00XTS	TTDDRUID	D00XTS
D00XTS	DRUGNAME	CR-3834
D00XTS	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0K0IW	TTDDRUID	D0K0IW
D0K0IW	DRUGNAME	CRA-028129
D0K0IW	INDICATI	Psoriatic disorder [ICD-11: EA90] Terminated

D0O0HK	TTDDRUID	D0O0HK
D0O0HK	DRUGNAME	CRL-1018
D0O0HK	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated

D06NSS	TTDDRUID	D06NSS
D06NSS	DRUGNAME	Cromoglicate
D06NSS	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated

D05AXS	TTDDRUID	D05AXS
D05AXS	DRUGNAME	CRx-189
D05AXS	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated

D0V0TT	TTDDRUID	D0V0TT
D0V0TT	DRUGNAME	CS-204
D0V0TT	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Terminated

D03CUS	TTDDRUID	D03CUS
D03CUS	DRUGNAME	CS-207
D03CUS	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D00SIR	TTDDRUID	D00SIR
D00SIR	DRUGNAME	CS-461
D00SIR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0O7DU	TTDDRUID	D0O7DU
D0O7DU	DRUGNAME	CT-1746
D0O7DU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated

D09XNZ	TTDDRUID	D09XNZ
D09XNZ	DRUGNAME	CT-2408R
D09XNZ	INDICATI	Shock [ICD-11: MG40] Terminated

D0D2PQ	TTDDRUID	D0D2PQ
D0D2PQ	DRUGNAME	CT-2412
D0D2PQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D08MDV	TTDDRUID	D08MDV
D08MDV	DRUGNAME	CT-3501
D08MDV	INDICATI	Coronary artery disease [ICD-11: BA80] Terminated

D02IPI	TTDDRUID	D02IPI
D02IPI	DRUGNAME	CTA-002
D02IPI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05CEK	TTDDRUID	D05CEK
D05CEK	DRUGNAME	CV 6209
D05CEK	INDICATI	Asthma [ICD-11: CA23] Terminated

D0Q5RA	TTDDRUID	D0Q5RA
D0Q5RA	DRUGNAME	CVP S aureus vaccine
D0Q5RA	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated

D0C8PQ	TTDDRUID	D0C8PQ
D0C8PQ	DRUGNAME	CVS-3083
D0C8PQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0J6VU	TTDDRUID	D0J6VU
D0J6VU	DRUGNAME	CVS-995
D0J6VU	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated

D0GH1C	TTDDRUID	D0GH1C
D0GH1C	DRUGNAME	CVT-1
D0GH1C	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated

D04WIG	TTDDRUID	D04WIG
D04WIG	DRUGNAME	CY-1747
D04WIG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0J1RH	TTDDRUID	D0J1RH
D0J1RH	DRUGNAME	CY-1748
D0J1RH	INDICATI	Deep vein thrombosis [ICD-11: BD71] Terminated

D0A1GJ	TTDDRUID	D0A1GJ
D0A1GJ	DRUGNAME	CY-9652
D0A1GJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0Y6HA	TTDDRUID	D0Y6HA
D0Y6HA	DRUGNAME	CYC-103
D0Y6HA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0N8PG	TTDDRUID	D0N8PG
D0N8PG	DRUGNAME	CYC-700 series
D0N8PG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D00IOS	TTDDRUID	D00IOS
D00IOS	DRUGNAME	CYT-017-IL17Qb
D00IOS	INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated

D0E3QU	TTDDRUID	D0E3QU
D0E3QU	DRUGNAME	Cytovaxine
D0E3QU	INDICATI	Pseudomonas infection [ICD-11: 1B92] Terminated

D06UFH	TTDDRUID	D06UFH
D06UFH	DRUGNAME	CZ-112
D06UFH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0B6VQ	TTDDRUID	D0B6VQ
D0B6VQ	DRUGNAME	D-20450
D0B6VQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0QR4H	TTDDRUID	D0QR4H
D0QR4H	DRUGNAME	D-21151
D0QR4H	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0Y3ZX	TTDDRUID	D0Y3ZX
D0Y3ZX	DRUGNAME	D-21775
D0Y3ZX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0DD0O	TTDDRUID	D0DD0O
D0DD0O	DRUGNAME	D-21805
D0DD0O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0R1QJ	TTDDRUID	D0R1QJ
D0R1QJ	DRUGNAME	D-22888
D0R1QJ	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D01WJM	TTDDRUID	D01WJM
D01WJM	DRUGNAME	D-26344
D01WJM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D03RCV	TTDDRUID	D03RCV
D03RCV	DRUGNAME	D2A21
D03RCV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D00CEG	TTDDRUID	D00CEG
D00CEG	DRUGNAME	D-43787
D00CEG	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D09TRM	TTDDRUID	D09TRM
D09TRM	DRUGNAME	D-5410
D09TRM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D06NOU	TTDDRUID	D06NOU
D06NOU	DRUGNAME	D-9120
D06NOU	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated

D0K5IQ	TTDDRUID	D0K5IQ
D0K5IQ	DRUGNAME	DAA-1097
D0K5IQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0PU8Z	TTDDRUID	D0PU8Z
D0PU8Z	DRUGNAME	Dacetuzumab
D0PU8Z	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Terminated
D0PU8Z	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Terminated

D07TNU	TTDDRUID	D07TNU
D07TNU	DRUGNAME	DACTIMICIN
D07TNU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0D4XF	TTDDRUID	D0D4XF
D0D4XF	DRUGNAME	Daniplestim
D0D4XF	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0N1EF	TTDDRUID	D0N1EF
D0N1EF	DRUGNAME	DARGLITAZONE
D0N1EF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0B9TX	TTDDRUID	D0B9TX
D0B9TX	DRUGNAME	Darodipine
D0B9TX	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0T7WQ	TTDDRUID	D0T7WQ
D0T7WQ	DRUGNAME	Datelliptium chloride
D0T7WQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D04GSA	TTDDRUID	D04GSA
D04GSA	DRUGNAME	DAU-6285
D04GSA	INDICATI	Vomiting [ICD-11: MD90] Terminated

D0SG0N	TTDDRUID	D0SG0N
D0SG0N	DRUGNAME	DB-200
D0SG0N	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated

D0PE1A	TTDDRUID	D0PE1A
D0PE1A	DRUGNAME	DBO-11
D0PE1A	INDICATI	Cancer related pain [ICD-11: MG30] Terminated

D0XH1H	TTDDRUID	D0XH1H
D0XH1H	DRUGNAME	DBO-17
D0XH1H	INDICATI	Cancer related pain [ICD-11: MG30] Terminated

D05MSL	TTDDRUID	D05MSL
D05MSL	DRUGNAME	DC-756
D05MSL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D07ULS	TTDDRUID	D07ULS
D07ULS	DRUGNAME	DDG-39
D07ULS	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Terminated

D0X0QC	TTDDRUID	D0X0QC
D0X0QC	DRUGNAME	DES-6
D0X0QC	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated

D0Q5QF	TTDDRUID	D0Q5QF
D0Q5QF	DRUGNAME	Desferrithiocin
D0Q5QF	INDICATI	Metal intoxication [ICD-11: NE60] Terminated

D0DI3E	TTDDRUID	D0DI3E
D0DI3E	DRUGNAME	DHP-218
D0DI3E	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D08FDW	TTDDRUID	D08FDW
D08FDW	DRUGNAME	Diabetes (type I) vaccine
D08FDW	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Terminated

D0N5UA	TTDDRUID	D0N5UA
D0N5UA	DRUGNAME	Dianicline+rimonabant
D0N5UA	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Terminated

D0ZL9B	TTDDRUID	D0ZL9B
D0ZL9B	DRUGNAME	Diaspirin crosslinked hemoglobin
D0ZL9B	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0FC5T	TTDDRUID	D0FC5T
D0FC5T	DRUGNAME	DIAVERIDINE
D0FC5T	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0V3LD	TTDDRUID	D0V3LD
D0V3LD	DRUGNAME	DIO-901
D0V3LD	INDICATI	Type-1 diabetes [ICD-11: 5A10] Terminated

D0O9KW	TTDDRUID	D0O9KW
D0O9KW	DRUGNAME	Diphtheria/tetanus vaccine
D0O9KW	INDICATI	Clostridium infection [ICD-11: 1A04] Terminated

D0X4UA	TTDDRUID	D0X4UA
D0X4UA	DRUGNAME	DISC GM-CSF
D0X4UA	INDICATI	Melanoma [ICD-11: 2C30] Terminated

D02KLW	TTDDRUID	D02KLW
D02KLW	DRUGNAME	DIZOCILPINE
D02KLW	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D01HPI	TTDDRUID	D01HPI
D01HPI	DRUGNAME	DLX-0110
D01HPI	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated

D0G0GI	TTDDRUID	D0G0GI
D0G0GI	DRUGNAME	DMP-696
D0G0GI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0A8HL	TTDDRUID	D0A8HL
D0A8HL	DRUGNAME	DMP-811
D0A8HL	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D04NFB	TTDDRUID	D04NFB
D04NFB	DRUGNAME	DMP-963
D04NFB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0L0AU	TTDDRUID	D0L0AU
D0L0AU	DRUGNAME	DMPDDF
D0L0AU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0K3WN	TTDDRUID	D0K3WN
D0K3WN	DRUGNAME	DNP-004089
D0K3WN	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D05SSJ	TTDDRUID	D05SSJ
D05SSJ	DRUGNAME	Dotarizine
D05SSJ	INDICATI	Migraine [ICD-11: 8A80] Terminated

D0FZ1Z	TTDDRUID	D0FZ1Z
D0FZ1Z	DRUGNAME	Doxorubicin-CEA conjugate
D0FZ1Z	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D01DVX	TTDDRUID	D01DVX
D01DVX	DRUGNAME	DPC-333
D01DVX	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
D01DVX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0L0NE	TTDDRUID	D0L0NE
D0L0NE	DRUGNAME	DPC-A78277
D0L0NE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D05ZGW	TTDDRUID	D05ZGW
D05ZGW	DRUGNAME	DPI-201-106
D05ZGW	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0K9KS	TTDDRUID	D0K9KS
D0K9KS	DRUGNAME	Draculin
D0K9KS	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0V8PN	TTDDRUID	D0V8PN
D0V8PN	DRUGNAME	Droxinavir hydrochloride
D0V8PN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0M9SL	TTDDRUID	D0M9SL
D0M9SL	DRUGNAME	DSP-7238
D0M9SL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0RJ6R	TTDDRUID	D0RJ6R
D0RJ6R	DRUGNAME	Du-123015
D0RJ6R	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D05COG	TTDDRUID	D05COG
D05COG	DRUGNAME	DU-1777
D05COG	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D06EVC	TTDDRUID	D06EVC
D06EVC	DRUGNAME	Dual Pgp/MRP1 inhibitors, Xenova
D06EVC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0Z3JC	TTDDRUID	D0Z3JC
D0Z3JC	DRUGNAME	Dual-action antibiotics
D0Z3JC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0Y5EX	TTDDRUID	D0Y5EX
D0Y5EX	DRUGNAME	DuP 714
D0Y5EX	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0K8KJ	TTDDRUID	D0K8KJ
D0K8KJ	DRUGNAME	DuP-129
D0K8KJ	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated

D04ICN	TTDDRUID	D04ICN
D04ICN	DRUGNAME	DuP-630
D04ICN	INDICATI	Dermatitis [ICD-11: EA80-EA89] Terminated

D03PBT	TTDDRUID	D03PBT
D03PBT	DRUGNAME	DuP-983
D03PBT	INDICATI	Pruritus [ICD-11: EC90] Terminated

D01YSH	TTDDRUID	D01YSH
D01YSH	DRUGNAME	DV-7021
D01YSH	INDICATI	Liver disease [ICD-11: DB90-BD99] Terminated

D0F6XR	TTDDRUID	D0F6XR
D0F6XR	DRUGNAME	DV-7028
D0F6XR	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0A5ZJ	TTDDRUID	D0A5ZJ
D0A5ZJ	DRUGNAME	DW-1350
D0A5ZJ	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D06QOK	TTDDRUID	D06QOK
D06QOK	DRUGNAME	DW-2282
D06QOK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0B0GC	TTDDRUID	D0B0GC
D0B0GC	DRUGNAME	E-0722
D0B0GC	INDICATI	Diabetic cataract [ICD-11: 9B10.21] Terminated

D0G9AP	TTDDRUID	D0G9AP
D0G9AP	DRUGNAME	E-2011
D0G9AP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0P3IZ	TTDDRUID	D0P3IZ
D0P3IZ	DRUGNAME	E-2040
D0P3IZ	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0W6MA	TTDDRUID	D0W6MA
D0W6MA	DRUGNAME	E-2050
D0W6MA	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0T7XN	TTDDRUID	D0T7XN
D0T7XN	DRUGNAME	E-2070
D0T7XN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated

D09BWC	TTDDRUID	D09BWC
D09BWC	DRUGNAME	E-4080
D09BWC	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0Y2MP	TTDDRUID	D0Y2MP
D0Y2MP	DRUGNAME	E-5110
D0Y2MP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D00IRU	TTDDRUID	D00IRU
D00IRU	DRUGNAME	E-5842
D00IRU	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0B7BX	TTDDRUID	D0B7BX
D0B7BX	DRUGNAME	E-6276
D0B7BX	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0F2TY	TTDDRUID	D0F2TY
D0F2TY	DRUGNAME	EBV-related Hodgkin's disease vaccine
D0F2TY	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Terminated

D0KC7K	TTDDRUID	D0KC7K
D0KC7K	DRUGNAME	EC-154
D0KC7K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0R1QX	TTDDRUID	D0R1QX
D0R1QX	DRUGNAME	EC-708
D0R1QX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D0O6WJ	TTDDRUID	D0O6WJ
D0O6WJ	DRUGNAME	Ecalcidene
D0O6WJ	INDICATI	Acne vulgaris [ICD-11: ED80] Terminated

D0DJ5T	TTDDRUID	D0DJ5T
D0DJ5T	DRUGNAME	Ecomustine
D0DJ5T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D08MDX	TTDDRUID	D08MDX
D08MDX	DRUGNAME	ED-001
D08MDX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0T6VU	TTDDRUID	D0T6VU
D0T6VU	DRUGNAME	ED-110
D0T6VU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D08VKZ	TTDDRUID	D08VKZ
D08VKZ	DRUGNAME	Edaglitazone
D08VKZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D07QXG	TTDDRUID	D07QXG
D07QXG	DRUGNAME	EF-27
D07QXG	INDICATI	Radiation syndrome [ICD-11: NF00] Terminated

D0E1WY	TTDDRUID	D0E1WY
D0E1WY	DRUGNAME	EFIPLADIB
D0E1WY	INDICATI	Asthma [ICD-11: CA23] Terminated

D0M9ER	TTDDRUID	D0M9ER
D0M9ER	DRUGNAME	EHT-1864
D0M9ER	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0H1TA	TTDDRUID	D0H1TA
D0H1TA	DRUGNAME	EK-399
D0H1TA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D01EPP	TTDDRUID	D01EPP
D01EPP	DRUGNAME	EL-715
D01EPP	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0N9DZ	TTDDRUID	D0N9DZ
D0N9DZ	DRUGNAME	Elmustine
D0N9DZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09QOF	TTDDRUID	D09QOF
D09QOF	DRUGNAME	EM-2487
D09QOF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0P9JW	TTDDRUID	D0P9JW
D0P9JW	DRUGNAME	Emeriamine
D0P9JW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D05KRC	TTDDRUID	D05KRC
D05KRC	DRUGNAME	Emopamil
D05KRC	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0V6JP	TTDDRUID	D0V6JP
D0V6JP	DRUGNAME	Endixaprine
D0V6JP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0Y4ZS	TTDDRUID	D0Y4ZS
D0Y4ZS	DRUGNAME	Endovion
D0Y4ZS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0F5CO	TTDDRUID	D0F5CO
D0F5CO	DRUGNAME	Enloplatin
D0F5CO	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Terminated

D04VXS	TTDDRUID	D04VXS
D04VXS	DRUGNAME	ENT-102
D04VXS	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D01XMS	TTDDRUID	D01XMS
D01XMS	DRUGNAME	ENT-103
D01XMS	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0N4YU	TTDDRUID	D0N4YU
D0N4YU	DRUGNAME	Enterococcus faecalis conjugate vaccine
D0N4YU	INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Terminated

D0O2XI	TTDDRUID	D0O2XI
D0O2XI	DRUGNAME	Enterotoxigenic E Coli vaccine
D0O2XI	INDICATI	Escherichia coli infection [ICD-11: 1A03] Terminated

D00JZX	TTDDRUID	D00JZX
D00JZX	DRUGNAME	EP-012637
D00JZX	INDICATI	Asthma [ICD-11: CA23] Terminated

D02ERH	TTDDRUID	D02ERH
D02ERH	DRUGNAME	EP-2060
D02ERH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D03IIP	TTDDRUID	D03IIP
D03IIP	DRUGNAME	EP-3533
D03IIP	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated

D05PTG	TTDDRUID	D05PTG
D05PTG	DRUGNAME	EPD-clofarabine
D05PTG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D02MBO	TTDDRUID	D02MBO
D02MBO	DRUGNAME	EPICOAT cancer vaccine
D02MBO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05AHQ	TTDDRUID	D05AHQ
D05AHQ	DRUGNAME	Epiroprim
D05AHQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D09JYF	TTDDRUID	D09JYF
D09JYF	DRUGNAME	Epocarbazolin-A
D09JYF	INDICATI	Asthma [ICD-11: CA23] Terminated

D0M4LC	TTDDRUID	D0M4LC
D0M4LC	DRUGNAME	EPTALOPROST
D0M4LC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0SZ3B	TTDDRUID	D0SZ3B
D0SZ3B	DRUGNAME	ER-34122
D0SZ3B	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0NP8B	TTDDRUID	D0NP8B
D0NP8B	DRUGNAME	ERIC-1
D0NP8B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06WBE	TTDDRUID	D06WBE
D06WBE	DRUGNAME	ERTIPROTAFIB
D06WBE	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D05FTY	TTDDRUID	D05FTY
D05FTY	DRUGNAME	ES-1005
D05FTY	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D00UEQ	TTDDRUID	D00UEQ
D00UEQ	DRUGNAME	Etomoxir
D00UEQ	INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated

D0LS4U	TTDDRUID	D0LS4U
D0LS4U	DRUGNAME	Etrabamine
D0LS4U	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D0U1FZ	TTDDRUID	D0U1FZ
D0U1FZ	DRUGNAME	EUK-207
D0U1FZ	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated

D0Z7GJ	TTDDRUID	D0Z7GJ
D0Z7GJ	DRUGNAME	EUK-418
D0Z7GJ	INDICATI	Radiation syndrome [ICD-11: NF00] Terminated

D08VTA	TTDDRUID	D08VTA
D08VTA	DRUGNAME	EXP-6803
D08VTA	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D01XBW	TTDDRUID	D01XBW
D01XBW	DRUGNAME	External guide sequence oligozyme
D01XBW	INDICATI	Acute promyelocytic leukaemia [ICD-11: 2A60.0] Terminated

D0O0JH	TTDDRUID	D0O0JH
D0O0JH	DRUGNAME	F-12509A
D0O0JH	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0E4HZ	TTDDRUID	D0E4HZ
D0E4HZ	DRUGNAME	F-12682
D0E4HZ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D08VJI	TTDDRUID	D08VJI
D08VJI	DRUGNAME	F-14413
D08VJI	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0ZV0R	TTDDRUID	D0ZV0R
D0ZV0R	DRUGNAME	F-200
D0ZV0R	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Terminated

D00QOG	TTDDRUID	D00QOG
D00QOG	DRUGNAME	F-2833
D00QOG	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D09IUG	TTDDRUID	D09IUG
D09IUG	DRUGNAME	F-3796
D09IUG	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D01JEI	TTDDRUID	D01JEI
D01JEI	DRUGNAME	F-50003
D01JEI	INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Terminated

D06QJE	TTDDRUID	D06QJE
D06QJE	DRUGNAME	F-992
D06QJE	INDICATI	Urinary incontinence [ICD-11: MF50.2] Terminated

D00PXQ	TTDDRUID	D00PXQ
D00PXQ	DRUGNAME	Fananserin
D00PXQ	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0H0HB	TTDDRUID	D0H0HB
D0H0HB	DRUGNAME	FAV-201
D0H0HB	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Terminated

D04OOC	TTDDRUID	D04OOC
D04OOC	DRUGNAME	FCE-20696
D04OOC	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated

D0XP0Q	TTDDRUID	D0XP0Q
D0XP0Q	DRUGNAME	FCE-24265
D0XP0Q	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0MS1D	TTDDRUID	D0MS1D
D0MS1D	DRUGNAME	FCE-25876
D0MS1D	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D03GKP	TTDDRUID	D03GKP
D03GKP	DRUGNAME	FD-891
D03GKP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0V8KI	TTDDRUID	D0V8KI
D0V8KI	DRUGNAME	Fenspiride hydrochloride
D0V8KI	INDICATI	Asthma [ICD-11: CA23] Terminated

D0Z5HB	TTDDRUID	D0Z5HB
D0Z5HB	DRUGNAME	FH-510
D0Z5HB	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D0KD4U	TTDDRUID	D0KD4U
D0KD4U	DRUGNAME	FK-355
D0KD4U	INDICATI	Asthma [ICD-11: CA23] Terminated

D0Y7BV	TTDDRUID	D0Y7BV
D0Y7BV	DRUGNAME	Florifenine
D0Y7BV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0MP1C	TTDDRUID	D0MP1C
D0MP1C	DRUGNAME	Flosequinan
D0MP1C	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D05REH	TTDDRUID	D05REH
D05REH	DRUGNAME	Flosulide
D05REH	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D00JSG	TTDDRUID	D00JSG
D00JSG	DRUGNAME	Fluoratec
D00JSG	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Terminated

D0H9QX	TTDDRUID	D0H9QX
D0H9QX	DRUGNAME	FM-TP4000
D0H9QX	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated

D03BTP	TTDDRUID	D03BTP
D03BTP	DRUGNAME	Fosfluridine tidoxil
D03BTP	INDICATI	Keratosis [ICD-11: ED56] Terminated

D0ZE5V	TTDDRUID	D0ZE5V
D0ZE5V	DRUGNAME	FPL-55712
D0ZE5V	INDICATI	Asthma [ICD-11: CA23] Terminated

D06AKJ	TTDDRUID	D06AKJ
D06AKJ	DRUGNAME	FR-111142
D06AKJ	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0T6MU	TTDDRUID	D0T6MU
D0T6MU	DRUGNAME	FR-113680
D0T6MU	INDICATI	Asthma [ICD-11: CA23] Terminated

D02OTH	TTDDRUID	D02OTH
D02OTH	DRUGNAME	FR-115427
D02OTH	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0U7KR	TTDDRUID	D0U7KR
D0U7KR	DRUGNAME	FR-118487
D0U7KR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05EKM	TTDDRUID	D05EKM
D05EKM	DRUGNAME	FR-121196
D05EKM	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0R5TT	TTDDRUID	D0R5TT
D0R5TT	DRUGNAME	FR-123826
D0R5TT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D08EVM	TTDDRUID	D08EVM
D08EVM	DRUGNAME	FR-128998
D08EVM	INDICATI	Thrombocytopenia [ICD-11: 3B64] Terminated

D00KQT	TTDDRUID	D00KQT
D00KQT	DRUGNAME	FR-129169
D00KQT	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D04SVB	TTDDRUID	D04SVB
D04SVB	DRUGNAME	FR-133605
D04SVB	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0Q4US	TTDDRUID	D0Q4US
D0Q4US	DRUGNAME	FR-144420
D0Q4US	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0O2AC	TTDDRUID	D0O2AC
D0O2AC	DRUGNAME	FR-145237
D0O2AC	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D00MSP	TTDDRUID	D00MSP
D00MSP	DRUGNAME	FR-149581
D00MSP	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0J4GQ	TTDDRUID	D0J4GQ
D0J4GQ	DRUGNAME	FR-152558
D0J4GQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0Z4NX	TTDDRUID	D0Z4NX
D0Z4NX	DRUGNAME	FR-171113
D0Z4NX	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0NN5B	TTDDRUID	D0NN5B
D0NN5B	DRUGNAME	FR-172357
D0NN5B	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0C1MB	TTDDRUID	D0C1MB
D0C1MB	DRUGNAME	FR-180102
D0C1MB	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Terminated

D01IJL	TTDDRUID	D01IJL
D01IJL	DRUGNAME	FR-182877
D01IJL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05DNA	TTDDRUID	D05DNA
D05DNA	DRUGNAME	FR-183998
D05DNA	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D04DMO	TTDDRUID	D04DMO
D04DMO	DRUGNAME	FR-194738
D04DMO	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated

D01ZDR	TTDDRUID	D01ZDR
D01ZDR	DRUGNAME	FR-208419
D01ZDR	INDICATI	Dyspepsia [ICD-11: MD92] Terminated

D0W8QG	TTDDRUID	D0W8QG
D0W8QG	DRUGNAME	FR-229934
D0W8QG	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Terminated

D0RZ0N	TTDDRUID	D0RZ0N
D0RZ0N	DRUGNAME	FR-62765
D0RZ0N	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0IX7G	TTDDRUID	D0IX7G
D0IX7G	DRUGNAME	FR-76830
D0IX7G	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0F9IS	TTDDRUID	D0F9IS
D0F9IS	DRUGNAME	FR-900482
D0F9IS	INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated

D07FDM	TTDDRUID	D07FDM
D07FDM	DRUGNAME	FR-901379
D07FDM	INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Terminated

D06VWA	TTDDRUID	D06VWA
D06VWA	DRUGNAME	FR-901469
D06VWA	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0LK9N	TTDDRUID	D0LK9N
D0LK9N	DRUGNAME	Fradafiban
D0LK9N	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0J0JC	TTDDRUID	D0J0JC
D0J0JC	DRUGNAME	FRG-8701
D0J0JC	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated

D0O1OX	TTDDRUID	D0O1OX
D0O1OX	DRUGNAME	GA-FSH
D0O1OX	INDICATI	Female infertility [ICD-11: GA31.Z] Terminated

D04OKJ	TTDDRUID	D04OKJ
D04OKJ	DRUGNAME	Garenoxacin
D04OKJ	INDICATI	Endocarditis [ICD-11: BB40-BA42] Terminated

D08MVK	TTDDRUID	D08MVK
D08MVK	DRUGNAME	GCC-AP0341
D08MVK	INDICATI	Asthma [ICD-11: CA23] Terminated

D03FUO	TTDDRUID	D03FUO
D03FUO	DRUGNAME	GDC-0834
D03FUO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D02TGW	TTDDRUID	D02TGW
D02TGW	DRUGNAME	GE-20372A
D02TGW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0K0KP	TTDDRUID	D0K0KP
D0K0KP	DRUGNAME	GE-68
D0K0KP	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0L3GG	TTDDRUID	D0L3GG
D0L3GG	DRUGNAME	GEM-132
D0L3GG	INDICATI	Cytomegalovirus retinitis [ICD-11: 9B72.00] Terminated

D0I8NM	TTDDRUID	D0I8NM
D0I8NM	DRUGNAME	Gene therapy, IFN-alpha, PINC
D0I8NM	INDICATI	Head and neck cancer [ICD-11: 2D42] Terminated

D08OUU	TTDDRUID	D08OUU
D08OUU	DRUGNAME	Genevx
D08OUU	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0C9KQ	TTDDRUID	D0C9KQ
D0C9KQ	DRUGNAME	Genimune
D0C9KQ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0R5GS	TTDDRUID	D0R5GS
D0R5GS	DRUGNAME	Gepirone ER
D0R5GS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated

D0H5CD	TTDDRUID	D0H5CD
D0H5CD	DRUGNAME	GI-129471
D0H5CD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0O8SY	TTDDRUID	D0O8SY
D0O8SY	DRUGNAME	GI-197111
D0O8SY	INDICATI	Alopecia [ICD-11: ED70] Terminated

D06UXL	TTDDRUID	D06UXL
D06UXL	DRUGNAME	GI-248573
D06UXL	INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Terminated

D0RR4T	TTDDRUID	D0RR4T
D0RR4T	DRUGNAME	GI-270384X
D0RR4T	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated

D0II9K	TTDDRUID	D0II9K
D0II9K	DRUGNAME	Girisopam
D0II9K	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0Y5QO	TTDDRUID	D0Y5QO
D0Y5QO	DRUGNAME	GK-128
D0Y5QO	INDICATI	Vomiting [ICD-11: MD90] Terminated

D00DSD	TTDDRUID	D00DSD
D00DSD	DRUGNAME	GLI-5021
D00DSD	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0OL4S	TTDDRUID	D0OL4S
D0OL4S	DRUGNAME	GLY-515n
D0OL4S	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D00ZJZ	TTDDRUID	D00ZJZ
D00ZJZ	DRUGNAME	Glycogen synthase kinase-3 inhibitors
D00ZJZ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D07IGE	TTDDRUID	D07IGE
D07IGE	DRUGNAME	Glyfoline
D07IGE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0T2DL	TTDDRUID	D0T2DL
D0T2DL	DRUGNAME	GM-7050
D0T2DL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0A3OF	TTDDRUID	D0A3OF
D0A3OF	DRUGNAME	GMC-283
D0A3OF	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0E7BC	TTDDRUID	D0E7BC
D0E7BC	DRUGNAME	GM-CSF-expressing oncolytic adenovirus
D0E7BC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0VV3O	TTDDRUID	D0VV3O
D0VV3O	DRUGNAME	GNI-104
D0VV3O	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0V9ZR	TTDDRUID	D0V9ZR
D0V9ZR	DRUGNAME	GNI-105
D0V9ZR	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Terminated

D0JI1J	TTDDRUID	D0JI1J
D0JI1J	DRUGNAME	GP-683
D0JI1J	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D04PGB	TTDDRUID	D04PGB
D04PGB	DRUGNAME	Gpi-1046
D04PGB	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D06GSE	TTDDRUID	D06GSE
D06GSE	DRUGNAME	GPI-1337
D06GSE	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated

D0DJ8D	TTDDRUID	D0DJ8D
D0DJ8D	DRUGNAME	GPI-16552
D0DJ8D	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0V9TE	TTDDRUID	D0V9TE
D0V9TE	DRUGNAME	GPI-2138
D0V9TE	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Terminated

D00MFY	TTDDRUID	D00MFY
D00MFY	DRUGNAME	GPI-3000
D00MFY	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D06DZI	TTDDRUID	D06DZI
D06DZI	DRUGNAME	GR-127935
D06DZI	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D0B2CQ	TTDDRUID	D0B2CQ
D0B2CQ	DRUGNAME	GR-131663
D0B2CQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0B1VQ	TTDDRUID	D0B1VQ
D0B1VQ	DRUGNAME	GR-133347
D0B1VQ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0Y0AP	TTDDRUID	D0Y0AP
D0Y0AP	DRUGNAME	GR-144053
D0Y0AP	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D02YWV	TTDDRUID	D02YWV
D02YWV	DRUGNAME	GR-159897
D02YWV	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0EG1F	TTDDRUID	D0EG1F
D0EG1F	DRUGNAME	GR-199114X
D0EG1F	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated

D0Z7PI	TTDDRUID	D0Z7PI
D0Z7PI	DRUGNAME	GR-233548
D0Z7PI	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0M7VW	TTDDRUID	D0M7VW
D0M7VW	DRUGNAME	GR-65630
D0M7VW	INDICATI	Vomiting [ICD-11: MD90] Terminated

D05REL	TTDDRUID	D05REL
D05REL	DRUGNAME	GR-82334
D05REL	INDICATI	Vomiting [ICD-11: MD90] Terminated

D0M7BW	TTDDRUID	D0M7BW
D0M7BW	DRUGNAME	GR-89696
D0M7BW	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated

D02PIN	TTDDRUID	D02PIN
D02PIN	DRUGNAME	GR-94839
D02PIN	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0T4HS	TTDDRUID	D0T4HS
D0T4HS	DRUGNAME	GR-95168
D0T4HS	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D07GZZ	TTDDRUID	D07GZZ
D07GZZ	DRUGNAME	Grass allergy vaccine
D07GZZ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated

D05WDD	TTDDRUID	D05WDD
D05WDD	DRUGNAME	Group B streptococcal vaccine
D05WDD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0R3JE	TTDDRUID	D0R3JE
D0R3JE	DRUGNAME	GS-2992
D0R3JE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0Q3ZN	TTDDRUID	D0Q3ZN
D0Q3ZN	DRUGNAME	GS-3435
D0Q3ZN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated

D0PE9T	TTDDRUID	D0PE9T
D0PE9T	DRUGNAME	GS-438
D0PE9T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0S6XJ	TTDDRUID	D0S6XJ
D0S6XJ	DRUGNAME	GS-522
D0S6XJ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0M0UJ	TTDDRUID	D0M0UJ
D0M0UJ	DRUGNAME	GS-9148
D0M0UJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0V8HF	TTDDRUID	D0V8HF
D0V8HF	DRUGNAME	GS-9160
D0V8HF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0GE2F	TTDDRUID	D0GE2F
D0GE2F	DRUGNAME	GSK-2485852
D0GE2F	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D02AXS	TTDDRUID	D02AXS
D02AXS	DRUGNAME	GSK406725
D02AXS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D00XEU	TTDDRUID	D00XEU
D00XEU	DRUGNAME	GSK-923295
D00XEU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0YQ9G	TTDDRUID	D0YQ9G
D0YQ9G	DRUGNAME	GT-16-239
D0YQ9G	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D02YXQ	TTDDRUID	D02YXQ
D02YXQ	DRUGNAME	GT-2016
D02YXQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D02KAF	TTDDRUID	D02KAF
D02KAF	DRUGNAME	GT-2203
D02KAF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0O5LL	TTDDRUID	D0O5LL
D0O5LL	DRUGNAME	GT-2342
D0O5LL	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated

D08TCU	TTDDRUID	D08TCU
D08TCU	DRUGNAME	GT-4001
D08TCU	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0SF2R	TTDDRUID	D0SF2R
D0SF2R	DRUGNAME	GVX-3322
D0SF2R	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated

D0GH9Z	TTDDRUID	D0GH9Z
D0GH9Z	DRUGNAME	GW-275175
D0GH9Z	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D0T2OT	TTDDRUID	D0T2OT
D0T2OT	DRUGNAME	GW-278884
D0T2OT	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated

D01QUF	TTDDRUID	D01QUF
D01QUF	DRUGNAME	GW-3600
D01QUF	INDICATI	Asthma [ICD-11: CA23] Terminated

D0F9BX	TTDDRUID	D0F9BX
D0F9BX	DRUGNAME	GW-660511
D0F9BX	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D02YAQ	TTDDRUID	D02YAQ
D02YAQ	DRUGNAME	GW-974
D02YAQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D0A9VO	TTDDRUID	D0A9VO
D0A9VO	DRUGNAME	GYKI-52466
D0A9VO	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D04FYI	TTDDRUID	D04FYI
D04FYI	DRUGNAME	H pylori vaccine
D04FYI	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Terminated

D06XAK	TTDDRUID	D06XAK
D06XAK	DRUGNAME	H-216/44
D06XAK	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated

D0P9DL	TTDDRUID	D0P9DL
D0P9DL	DRUGNAME	HBV vaccine
D0P9DL	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated

D0U4WF	TTDDRUID	D0U4WF
D0U4WF	DRUGNAME	HCG contraceptive vaccine
D0U4WF	INDICATI	Contraception [ICD-11: QA21] Terminated

D04IDT	TTDDRUID	D04IDT
D04IDT	DRUGNAME	Helicobacter vaccine
D04IDT	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Terminated

D0WL1C	TTDDRUID	D0WL1C
D0WL1C	DRUGNAME	Hementin
D0WL1C	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D02GFZ	TTDDRUID	D02GFZ
D02GFZ	DRUGNAME	Heparin-EGF-like factor
D02GFZ	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D03DNI	TTDDRUID	D03DNI
D03DNI	DRUGNAME	Hepatitis C virus E2 protein vaccines
D03DNI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0OF9D	TTDDRUID	D0OF9D
D0OF9D	DRUGNAME	Hepatitis delta antigen
D0OF9D	INDICATI	Hepatitis D virus infection [ICD-11: 1E51.2] Terminated

D0M4UE	TTDDRUID	D0M4UE
D0M4UE	DRUGNAME	Herzyme
D0M4UE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D0KD1A	TTDDRUID	D0KD1A
D0KD1A	DRUGNAME	HF-0699
D0KD1A	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0Q1JW	TTDDRUID	D0Q1JW
D0Q1JW	DRUGNAME	Hirufaxin
D0Q1JW	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D05QLQ	TTDDRUID	D05QLQ
D05QLQ	DRUGNAME	HIV vaccine
D05QLQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D03HTI	TTDDRUID	D03HTI
D03HTI	DRUGNAME	HMR-3787
D03HTI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D00ACH	TTDDRUID	D00ACH
D00ACH	DRUGNAME	HMR-4004
D00ACH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D01FME	TTDDRUID	D01FME
D01FME	DRUGNAME	HNK-20
D01FME	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated

D03TAS	TTDDRUID	D03TAS
D03TAS	DRUGNAME	Hoe-33342
D03TAS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0K2CV	TTDDRUID	D0K2CV
D0K2CV	DRUGNAME	HOE-694
D0K2CV	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0W7WG	TTDDRUID	D0W7WG
D0W7WG	DRUGNAME	Hormone-dependent vaccine
D0W7WG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D0P5VX	TTDDRUID	D0P5VX
D0P5VX	DRUGNAME	Hormone-independent vaccine
D0P5VX	INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated

D01KKM	TTDDRUID	D01KKM
D01KKM	DRUGNAME	House dust mite allergy vaccine
D01KKM	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated

D09ZFF	TTDDRUID	D09ZFF
D09ZFF	DRUGNAME	HRC-101
D09ZFF	INDICATI	Blood transfusion [ICD-11: QB98] Terminated

D00XQK	TTDDRUID	D00XQK
D00XQK	DRUGNAME	HRC-102
D00XQK	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Terminated

D09ZCH	TTDDRUID	D09ZCH
D09ZCH	DRUGNAME	HRC-201
D09ZCH	INDICATI	Liver cancer [ICD-11: 2C12] Terminated

D07RPB	TTDDRUID	D07RPB
D07RPB	DRUGNAME	HT-90B
D07RPB	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0Z0HS	TTDDRUID	D0Z0HS
D0Z0HS	DRUGNAME	Hu Dreg 55
D0Z0HS	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated

D0L4BR	TTDDRUID	D0L4BR
D0L4BR	DRUGNAME	HuCD40L
D0L4BR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D00TTS	TTDDRUID	D00TTS
D00TTS	DRUGNAME	Human chorionic gonadotropin
D00TTS	INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated

D0R2KR	TTDDRUID	D0R2KR
D0R2KR	DRUGNAME	Human Cytomegalovirus vaccine
D0R2KR	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated

D0CY2Z	TTDDRUID	D0CY2Z
D0CY2Z	DRUGNAME	HuMax-HepC
D0CY2Z	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0Q4DT	TTDDRUID	D0Q4DT
D0Q4DT	DRUGNAME	HuMax-TAC
D0Q4DT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D00ARZ	TTDDRUID	D00ARZ
D00ARZ	DRUGNAME	Huntingtons disease therapy
D00ARZ	INDICATI	Huntington disease [ICD-11: 8A01.10] Terminated

D0Q7OA	TTDDRUID	D0Q7OA
D0Q7OA	DRUGNAME	HydrocoDex
D0Q7OA	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0B8NW	TTDDRUID	D0B8NW
D0B8NW	DRUGNAME	ICA-1
D0B8NW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09AAM	TTDDRUID	D09AAM
D09AAM	DRUGNAME	ICI-164384
D09AAM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D05KHN	TTDDRUID	D05KHN
D05KHN	DRUGNAME	ICI-169369
D05KHN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D01SEO	TTDDRUID	D01SEO
D01SEO	DRUGNAME	ICI-181037
D01SEO	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0J7UI	TTDDRUID	D0J7UI
D0J7UI	DRUGNAME	ICI-198615
D0J7UI	INDICATI	Asthma [ICD-11: CA23] Terminated

D01HVE	TTDDRUID	D01HVE
D01HVE	DRUGNAME	ICI-D-1542
D01HVE	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0JS4E	TTDDRUID	D0JS4E
D0JS4E	DRUGNAME	ICM-3
D0JS4E	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Terminated

D0M1UE	TTDDRUID	D0M1UE
D0M1UE	DRUGNAME	IDD-5
D0M1UE	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated

D0S0VZ	TTDDRUID	D0S0VZ
D0S0VZ	DRUGNAME	IDRA-21
D0S0VZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0X7YC	TTDDRUID	D0X7YC
D0X7YC	DRUGNAME	IGE-026
D0X7YC	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated

D08QJD	TTDDRUID	D08QJD
D08QJD	DRUGNAME	IGN-311
D08QJD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D08ZFC	TTDDRUID	D08ZFC
D08ZFC	DRUGNAME	IGN-312
D08ZFC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D03VFV	TTDDRUID	D03VFV
D03VFV	DRUGNAME	IL1aQb
D03VFV	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0N1QX	TTDDRUID	D0N1QX
D0N1QX	DRUGNAME	ImmStat
D0N1QX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D09BCC	TTDDRUID	D09BCC
D09BCC	DRUGNAME	ImmuDyn
D09BCC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D07KIJ	TTDDRUID	D07KIJ
D07KIJ	DRUGNAME	INCB3344
D07KIJ	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D08VKQ	TTDDRUID	D08VKQ
D08VKQ	DRUGNAME	INGN-007
D08VKQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06THT	TTDDRUID	D06THT
D06THT	DRUGNAME	INGN-402
D06THT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0M0UV	TTDDRUID	D0M0UV
D0M0UV	DRUGNAME	INXC-ICAM1
D0M0UV	INDICATI	Transplant rejection [ICD-11: NE84] Terminated

D07THJ	TTDDRUID	D07THJ
D07THJ	DRUGNAME	IPH-3102
D07THJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0J3VV	TTDDRUID	D0J3VV
D0J3VV	DRUGNAME	IPH-3201
D0J3VV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0F6HW	TTDDRUID	D0F6HW
D0F6HW	DRUGNAME	IPH-4201
D0F6HW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Terminated

D04BFX	TTDDRUID	D04BFX
D04BFX	DRUGNAME	IPL-423
D04BFX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D02FNU	TTDDRUID	D02FNU
D02FNU	DRUGNAME	Ipsapirone
D02FNU	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0V9HI	TTDDRUID	D0V9HI
D0V9HI	DRUGNAME	Irindalone
D0V9HI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D09DAQ	TTDDRUID	D09DAQ
D09DAQ	DRUGNAME	ISIS 353512
D09DAQ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0U6NV	TTDDRUID	D0U6NV
D0U6NV	DRUGNAME	ISIS-1082
D0U6NV	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D0B5HA	TTDDRUID	D0B5HA
D0B5HA	DRUGNAME	ISIS-5320
D0B5HA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D05VLN	TTDDRUID	D05VLN
D05VLN	DRUGNAME	Isomazole
D05VLN	INDICATI	Asthma [ICD-11: CA23] Terminated

D09PEV	TTDDRUID	D09PEV
D09PEV	DRUGNAME	Itazigrel
D09PEV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D07OCC	TTDDRUID	D07OCC
D07OCC	DRUGNAME	JSM-10292
D07OCC	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D01EZY	TTDDRUID	D01EZY
D01EZY	DRUGNAME	JTP-2724
D01EZY	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D00MIF	TTDDRUID	D00MIF
D00MIF	DRUGNAME	JTP-4761
D00MIF	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0DN1I	TTDDRUID	D0DN1I
D0DN1I	DRUGNAME	JTT-551
D0DN1I	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0J0MK	TTDDRUID	D0J0MK
D0J0MK	DRUGNAME	JTT-608
D0J0MK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D02RDE	TTDDRUID	D02RDE
D02RDE	DRUGNAME	JTV-605
D02RDE	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Terminated

D0QL3T	TTDDRUID	D0QL3T
D0QL3T	DRUGNAME	K-42
D0QL3T	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0VZ8S	TTDDRUID	D0VZ8S
D0VZ8S	DRUGNAME	KA-398
D0VZ8S	INDICATI	Asthma [ICD-11: CA23] Terminated

D0PM9P	TTDDRUID	D0PM9P
D0PM9P	DRUGNAME	KB-5246
D0PM9P	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0V1GK	TTDDRUID	D0V1GK
D0V1GK	DRUGNAME	KB-5359
D0V1GK	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated

D04APY	TTDDRUID	D04APY
D04APY	DRUGNAME	KC-11404
D04APY	INDICATI	Asthma [ICD-11: CA23] Terminated

D01LXG	TTDDRUID	D01LXG
D01LXG	DRUGNAME	KC-11425
D01LXG	INDICATI	Asthma [ICD-11: CA23] Terminated

D0X9FO	TTDDRUID	D0X9FO
D0X9FO	DRUGNAME	KC-399
D0X9FO	INDICATI	Alopecia [ICD-11: ED70] Terminated

D0Y9CV	TTDDRUID	D0Y9CV
D0Y9CV	DRUGNAME	Ketolides
D0Y9CV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D01YGF	TTDDRUID	D01YGF
D01YGF	DRUGNAME	KF-15570
D01YGF	INDICATI	Asthma [ICD-11: CA23] Terminated

D0H6VG	TTDDRUID	D0H6VG
D0H6VG	DRUGNAME	KF-15766
D0H6VG	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D0SI4C	TTDDRUID	D0SI4C
D0SI4C	DRUGNAME	KF-17625
D0SI4C	INDICATI	Asthma [ICD-11: CA23] Terminated

D0C8DC	TTDDRUID	D0C8DC
D0C8DC	DRUGNAME	Ki-1769
D0C8DC	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0AD9Y	TTDDRUID	D0AD9Y
D0AD9Y	DRUGNAME	Kifunensine
D0AD9Y	INDICATI	Muscular dystrophy [ICD-11: 8C70] Terminated

D0U8XD	TTDDRUID	D0U8XD
D0U8XD	DRUGNAME	KIN-806
D0U8XD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05GQL	TTDDRUID	D05GQL
D05GQL	DRUGNAME	KNI-102
D05GQL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D00KLH	TTDDRUID	D00KLH
D00KLH	DRUGNAME	KR-6346
D00KLH	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated

D09YUS	TTDDRUID	D09YUS
D09YUS	DRUGNAME	KRG-3332
D09YUS	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated

D00FJS	TTDDRUID	D00FJS
D00FJS	DRUGNAME	KRH-2731
D00FJS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0V5XL	TTDDRUID	D0V5XL
D0V5XL	DRUGNAME	KRI-1314
D0V5XL	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0BB1X	TTDDRUID	D0BB1X
D0BB1X	DRUGNAME	KRP-105
D0BB1X	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated

D02RAU	TTDDRUID	D02RAU
D02RAU	DRUGNAME	KRP-297
D02RAU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated

D0K7XR	TTDDRUID	D0K7XR
D0K7XR	DRUGNAME	KSB-304
D0K7XR	INDICATI	Ulcerative colitis [ICD-11: DD71] Terminated

D0M0WY	TTDDRUID	D0M0WY
D0M0WY	DRUGNAME	KSB-307
D0M0WY	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated

D03EFD	TTDDRUID	D03EFD
D03EFD	DRUGNAME	KT-95
D03EFD	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated

D04FXE	TTDDRUID	D04FXE
D04FXE	DRUGNAME	KW-3433
D04FXE	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D04QXK	TTDDRUID	D04QXK
D04QXK	DRUGNAME	KY-62
D04QXK	INDICATI	Leishmania infection [ICD-11: 1F54.0] Terminated

D0O1RH	TTDDRUID	D0O1RH
D0O1RH	DRUGNAME	KYN-54
D0O1RH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0GS7N	TTDDRUID	D0GS7N
D0GS7N	DRUGNAME	L-158809
D0GS7N	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D00UBK	TTDDRUID	D00UBK
D00UBK	DRUGNAME	L-159689
D00UBK	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D00FWB	TTDDRUID	D00FWB
D00FWB	DRUGNAME	L-163017
D00FWB	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D05WYW	TTDDRUID	D05WYW
D05WYW	DRUGNAME	L-373890
D05WYW	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0L6UZ	TTDDRUID	D0L6UZ
D0L6UZ	DRUGNAME	L-374,087
D0L6UZ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0J4EG	TTDDRUID	D0J4EG
D0J4EG	DRUGNAME	L-648051
D0J4EG	INDICATI	Asthma [ICD-11: CA23] Terminated

D0AN1Y	TTDDRUID	D0AN1Y
D0AN1Y	DRUGNAME	L-670596
D0AN1Y	INDICATI	Asthma [ICD-11: CA23] Terminated

D03UNN	TTDDRUID	D03UNN
D03UNN	DRUGNAME	L-689560
D03UNN	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated

D0G1RT	TTDDRUID	D0G1RT
D0G1RT	DRUGNAME	L-694247
D0G1RT	INDICATI	Migraine [ICD-11: 8A80] Terminated

D0I3CV	TTDDRUID	D0I3CV
D0I3CV	DRUGNAME	L-695256
D0I3CV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D03CNT	TTDDRUID	D03CNT
D03CNT	DRUGNAME	L-698532
D03CNT	INDICATI	Neurological disorder [ICD-11: 6B60] Terminated

D0AZ5V	TTDDRUID	D0AZ5V
D0AZ5V	DRUGNAME	L-698544
D0AZ5V	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0M1WN	TTDDRUID	D0M1WN
D0M1WN	DRUGNAME	L-701324
D0M1WN	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D00YQZ	TTDDRUID	D00YQZ
D00YQZ	DRUGNAME	L-702958
D00YQZ	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Terminated

D0U6BB	TTDDRUID	D0U6BB
D0U6BB	DRUGNAME	L-703014
D0U6BB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0W2ED	TTDDRUID	D0W2ED
D0W2ED	DRUGNAME	L-731735
D0W2ED	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D07TDT	TTDDRUID	D07TDT
D07TDT	DRUGNAME	L-733560
D07TDT	INDICATI	Aspergillosis [ICD-11: 1F20] Terminated

D09DLN	TTDDRUID	D09DLN
D09DLN	DRUGNAME	L-739749
D09DLN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04VDY	TTDDRUID	D04VDY
D04VDY	DRUGNAME	L-741671
D04VDY	INDICATI	Vomiting [ICD-11: MD90] Terminated

D0PC7I	TTDDRUID	D0PC7I
D0PC7I	DRUGNAME	L-742728
D0PC7I	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D05EYG	TTDDRUID	D05EYG
D05EYG	DRUGNAME	L-745337
D05EYG	INDICATI	Asthma [ICD-11: CA23] Terminated

D03OLA	TTDDRUID	D03OLA
D03OLA	DRUGNAME	L-745631
D03OLA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04TKP	TTDDRUID	D04TKP
D04TKP	DRUGNAME	L-748415
D04TKP	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0M4HC	TTDDRUID	D0M4HC
D0M4HC	DRUGNAME	L-757464
D0M4HC	INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated

D0B0TO	TTDDRUID	D0B0TO
D0B0TO	DRUGNAME	L-768277
D0B0TO	INDICATI	Hyperthermia [ICD-11: MG26] Terminated

D02KZI	TTDDRUID	D02KZI
D02KZI	DRUGNAME	L-786392
D02KZI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D08MYO	TTDDRUID	D08MYO
D08MYO	DRUGNAME	LAG-078
D08MYO	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated

D0F9KI	TTDDRUID	D0F9KI
D0F9KI	DRUGNAME	LAS-30538
D0F9KI	INDICATI	Hyperinsulinemia [ICD-11: 5A4Y] Terminated

D01OFY	TTDDRUID	D01OFY
D01OFY	DRUGNAME	LAS-31180
D01OFY	INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated

D05JHJ	TTDDRUID	D05JHJ
D05JHJ	DRUGNAME	LB-10522
D05JHJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0W9LP	TTDDRUID	D0W9LP
D0W9LP	DRUGNAME	LC-9018
D0W9LP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D00DAU	TTDDRUID	D00DAU
D00DAU	DRUGNAME	LCP-3301
D00DAU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D03EHR	TTDDRUID	D03EHR
D03EHR	DRUGNAME	Lecimibide
D03EHR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated

D06LCS	TTDDRUID	D06LCS
D06LCS	DRUGNAME	Legionella pneumophila vaccine
D06LCS	INDICATI	Legionella infection [ICD-11: 1C19] Terminated

D00JWL	TTDDRUID	D00JWL
D00JWL	DRUGNAME	LEX-028
D00JWL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D00KXQ	TTDDRUID	D00KXQ
D00KXQ	DRUGNAME	LF-13-0491c
D00KXQ	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0K0KJ	TTDDRUID	D0K0KJ
D0K0KJ	DRUGNAME	LF-521
D0K0KJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0EA7H	TTDDRUID	D0EA7H
D0EA7H	DRUGNAME	LF-7-0165c
D0EA7H	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D05QTO	TTDDRUID	D05QTO
D05QTO	DRUGNAME	LF-801
D05QTO	INDICATI	Asthma [ICD-11: CA23] Terminated

D0K9RR	TTDDRUID	D0K9RR
D0K9RR	DRUGNAME	LF-943
D0K9RR	INDICATI	Ischemia [ICD-11: 8B10-8B11] Terminated

D0ID0R	TTDDRUID	D0ID0R
D0ID0R	DRUGNAME	LF-984
D0ID0R	INDICATI	Fibrosis [ICD-11: GA14-GC01] Terminated

D0G6PL	TTDDRUID	D0G6PL
D0G6PL	DRUGNAME	LG-2293
D0G6PL	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D0PA0S	TTDDRUID	D0PA0S
D0PA0S	DRUGNAME	LJP-920
D0PA0S	INDICATI	Transplant rejection [ICD-11: NE84] Terminated

D06IAA	TTDDRUID	D06IAA
D06IAA	DRUGNAME	LK-410
D06IAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D00YOW	TTDDRUID	D00YOW
D00YOW	DRUGNAME	LM-1376
D00YOW	INDICATI	Asthma [ICD-11: CA23] Terminated

D0W5GP	TTDDRUID	D0W5GP
D0W5GP	DRUGNAME	LN-020
D0W5GP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0D5IJ	TTDDRUID	D0D5IJ
D0D5IJ	DRUGNAME	LN-030
D0D5IJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D0H2KE	TTDDRUID	D0H2KE
D0H2KE	DRUGNAME	LN-040
D0H2KE	INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated

D0Y7WL	TTDDRUID	D0Y7WL
D0Y7WL	DRUGNAME	Lorglumide
D0Y7WL	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Terminated

D05AON	TTDDRUID	D05AON
D05AON	DRUGNAME	LSI-518P
D05AON	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0T8HU	TTDDRUID	D0T8HU
D0T8HU	DRUGNAME	LU-29252
D0T8HU	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D01ESJ	TTDDRUID	D01ESJ
D01ESJ	DRUGNAME	Luzindole
D01ESJ	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated

D01FLN	TTDDRUID	D01FLN
D01FLN	DRUGNAME	LX-2932
D01FLN	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0LR2Q	TTDDRUID	D0LR2Q
D0LR2Q	DRUGNAME	LXR-015-2
D0LR2Q	INDICATI	Ischemia [ICD-11: 8B10-8B11] Terminated

D0W2JT	TTDDRUID	D0W2JT
D0W2JT	DRUGNAME	LXR-017
D0W2JT	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated

D0OP7B	TTDDRUID	D0OP7B
D0OP7B	DRUGNAME	LY-210073
D0OP7B	INDICATI	Asthma [ICD-11: CA23] Terminated

D01QAR	TTDDRUID	D01QAR
D01QAR	DRUGNAME	LY-221068
D01QAR	INDICATI	Arthritis [ICD-11: FA20] Terminated

D07VMC	TTDDRUID	D07VMC
D07VMC	DRUGNAME	LY-243062
D07VMC	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0Y2IH	TTDDRUID	D0Y2IH
D0Y2IH	DRUGNAME	LY-255283
D0Y2IH	INDICATI	Asthma [ICD-11: CA23] Terminated

D0X6PG	TTDDRUID	D0X6PG
D0X6PG	DRUGNAME	LY-274614
D0X6PG	INDICATI	Dementia [ICD-11: 6D80-6D86] Terminated

D00UEG	TTDDRUID	D00UEG
D00UEG	DRUGNAME	LY288513
D00UEG	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0D0XX	TTDDRUID	D0D0XX
D0D0XX	DRUGNAME	LY-290154
D0D0XX	INDICATI	Asthma [ICD-11: CA23] Terminated

D0Q2PF	TTDDRUID	D0Q2PF
D0Q2PF	DRUGNAME	LY-293284
D0Q2PF	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D09SFV	TTDDRUID	D09SFV
D09SFV	DRUGNAME	LY294002
D09SFV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0BM3R	TTDDRUID	D0BM3R
D0BM3R	DRUGNAME	LY-307853
D0BM3R	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D09BHA	TTDDRUID	D09BHA
D09BHA	DRUGNAME	LY-353433
D09BHA	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated

D04JQR	TTDDRUID	D04JQR
D04JQR	DRUGNAME	LY-367385
D04JQR	INDICATI	Neurological disorder [ICD-11: 6B60] Terminated

D08XOT	TTDDRUID	D08XOT
D08XOT	DRUGNAME	LY467711
D08XOT	INDICATI	Migraine [ICD-11: 8A80] Terminated
D08XOT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated

D04XMJ	TTDDRUID	D04XMJ
D04XMJ	DRUGNAME	LY525327
D04XMJ	INDICATI	Migraine [ICD-11: 8A80] Terminated
D04XMJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated

D05NQR	TTDDRUID	D05NQR
D05NQR	DRUGNAME	LyphoDerm
D05NQR	INDICATI	Wound healing [ICD-11: EL8Y] Terminated

D06TTS	TTDDRUID	D06TTS
D06TTS	DRUGNAME	LZ-8
D06TTS	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0H8ZB	TTDDRUID	D0H8ZB
D0H8ZB	DRUGNAME	M2 proton channel inhibitors
D0H8ZB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated

D0F7XN	TTDDRUID	D0F7XN
D0F7XN	DRUGNAME	M-216765
D0F7XN	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D02NVF	TTDDRUID	D02NVF
D02NVF	DRUGNAME	M-241247
D02NVF	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0U0PV	TTDDRUID	D0U0PV
D0U0PV	DRUGNAME	M-40401
D0U0PV	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D05BIT	TTDDRUID	D05BIT
D05BIT	DRUGNAME	Maxy-10
D05BIT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D08LFX	TTDDRUID	D08LFX
D08LFX	DRUGNAME	MB-300
D08LFX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D09EBJ	TTDDRUID	D09EBJ
D09EBJ	DRUGNAME	MC-02306
D09EBJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D08HES	TTDDRUID	D08HES
D08HES	DRUGNAME	MC-02331
D08HES	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated

D03XST	TTDDRUID	D03XST
D03XST	DRUGNAME	MC-207252
D03XST	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated

D0AB7G	TTDDRUID	D0AB7G
D0AB7G	DRUGNAME	MCI-826
D0AB7G	INDICATI	Asthma [ICD-11: CA23] Terminated

D0O6GN	TTDDRUID	D0O6GN
D0O6GN	DRUGNAME	Mdl 101,146
D0O6GN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0I9NC	TTDDRUID	D0I9NC
D0I9NC	DRUGNAME	MDL-101002
D0I9NC	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D01ZEY	TTDDRUID	D01ZEY
D01ZEY	DRUGNAME	MDL-201112
D01ZEY	INDICATI	Colitis [ICD-11: 1A40.Z] Terminated

D04PGO	TTDDRUID	D04PGO
D04PGO	DRUGNAME	MDL-28133A
D04PGO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0G5ZE	TTDDRUID	D0G5ZE
D0G5ZE	DRUGNAME	MDL-28170
D0G5ZE	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D07YUY	TTDDRUID	D07YUY
D07YUY	DRUGNAME	MDL-29311
D07YUY	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D09ZVR	TTDDRUID	D09ZVR
D09ZVR	DRUGNAME	MDL-43291
D09ZVR	INDICATI	Asthma [ICD-11: CA23] Terminated

D0PV3Y	TTDDRUID	D0PV3Y
D0PV3Y	DRUGNAME	ME-1036
D0PV3Y	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0T5SG	TTDDRUID	D0T5SG
D0T5SG	DRUGNAME	ME-3221
D0T5SG	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D06ZZL	TTDDRUID	D06ZZL
D06ZZL	DRUGNAME	MEDI-500
D06ZZL	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Terminated

D0I0SY	TTDDRUID	D0I0SY
D0I0SY	DRUGNAME	MEDI-542
D0I0SY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0IW0Y	TTDDRUID	D0IW0Y
D0IW0Y	DRUGNAME	MEN-10207
D0IW0Y	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D04RCG	TTDDRUID	D04RCG
D04RCG	DRUGNAME	MEN-10627
D04RCG	INDICATI	Asthma [ICD-11: CA23] Terminated

D01VCW	TTDDRUID	D01VCW
D01VCW	DRUGNAME	MEN-10690
D01VCW	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0M4HM	TTDDRUID	D0M4HM
D0M4HM	DRUGNAME	MEN-10880
D0M4HM	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0A8BK	TTDDRUID	D0A8BK
D0A8BK	DRUGNAME	MEN-10979
D0A8BK	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0T4IQ	TTDDRUID	D0T4IQ
D0T4IQ	DRUGNAME	MEN-11149
D0T4IQ	INDICATI	Asthma [ICD-11: CA23] Terminated

D0L0UF	TTDDRUID	D0L0UF
D0L0UF	DRUGNAME	MEN-11467
D0L0UF	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Terminated

D03KJP	TTDDRUID	D03KJP
D03KJP	DRUGNAME	Meningococcal CYW vaccine
D03KJP	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated

D04XIA	TTDDRUID	D04XIA
D04XIA	DRUGNAME	Meningococcus B vaccine
D04XIA	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated

D0E4WF	TTDDRUID	D0E4WF
D0E4WF	DRUGNAME	METHYLTHIOADENOSINE
D0E4WF	INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated

D06ZAM	TTDDRUID	D06ZAM
D06ZAM	DRUGNAME	MF268
D06ZAM	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0IA7K	TTDDRUID	D0IA7K
D0IA7K	DRUGNAME	MF-5137
D0IA7K	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated

D0K0XG	TTDDRUID	D0K0XG
D0K0XG	DRUGNAME	MF-8615
D0K0XG	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D05FFR	TTDDRUID	D05FFR
D05FFR	DRUGNAME	MGBG
D05FFR	INDICATI	Head and neck cancer [ICD-11: 2D42] Terminated

D09XPJ	TTDDRUID	D09XPJ
D09XPJ	DRUGNAME	Micacocidin A
D09XPJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D02XMM	TTDDRUID	D02XMM
D02XMM	DRUGNAME	Midaglizole
D02XMM	INDICATI	Asthma [ICD-11: CA23] Terminated

D07OLO	TTDDRUID	D07OLO
D07OLO	DRUGNAME	Milacemide
D07OLO	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D02UOE	TTDDRUID	D02UOE
D02UOE	DRUGNAME	Miltirone
D02UOE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0FS9K	TTDDRUID	D0FS9K
D0FS9K	DRUGNAME	MINAMESTANE
D0FS9K	INDICATI	Bladder cancer [ICD-11: 2C94] Terminated

D0KN7H	TTDDRUID	D0KN7H
D0KN7H	DRUGNAME	Mitoflaxone
D0KN7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04AUA	TTDDRUID	D04AUA
D04AUA	DRUGNAME	MIV-170
D04AUA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0RO0T	TTDDRUID	D0RO0T
D0RO0T	DRUGNAME	MKC-1313
D0RO0T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D00GDN	TTDDRUID	D00GDN
D00GDN	DRUGNAME	ML-03
D00GDN	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated

D0V1CG	TTDDRUID	D0V1CG
D0V1CG	DRUGNAME	MLI-1018
D0V1CG	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Terminated

D03ZBL	TTDDRUID	D03ZBL
D03ZBL	DRUGNAME	MMS-255
D03ZBL	INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated

D0K1UD	TTDDRUID	D0K1UD
D0K1UD	DRUGNAME	MMV00/0053
D0K1UD	INDICATI	Malaria [ICD-11: 1F40-1F45] Terminated

D0P9TS	TTDDRUID	D0P9TS
D0P9TS	DRUGNAME	MNX-160
D0P9TS	INDICATI	Cachexia [ICD-11: MG20] Terminated

D0S9MO	TTDDRUID	D0S9MO
D0S9MO	DRUGNAME	Modified BCG vaccine
D0S9MO	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated

D0P1YO	TTDDRUID	D0P1YO
D0P1YO	DRUGNAME	MOL-218
D0P1YO	INDICATI	Asthma [ICD-11: CA23] Terminated

D0F7SW	TTDDRUID	D0F7SW
D0F7SW	DRUGNAME	MOL-2591
D0F7SW	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0M8JF	TTDDRUID	D0M8JF
D0M8JF	DRUGNAME	MOR-102
D0M8JF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated

D0I9UH	TTDDRUID	D0I9UH
D0I9UH	DRUGNAME	MOXIFETIN HYDROGEN MALEATE
D0I9UH	INDICATI	Mood disorder [ICD-11: 6A60-6E23] Terminated

D03PCJ	TTDDRUID	D03PCJ
D03PCJ	DRUGNAME	MPI-461359
D03PCJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0T2QI	TTDDRUID	D0T2QI
D0T2QI	DRUGNAME	MPV-1743
D0T2QI	INDICATI	Obesity [ICD-11: 5B81] Terminated

D0S7VN	TTDDRUID	D0S7VN
D0S7VN	DRUGNAME	MRL-953
D0S7VN	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Terminated

D09OTG	TTDDRUID	D09OTG
D09OTG	DRUGNAME	MS-377
D09OTG	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0B0QX	TTDDRUID	D0B0QX
D0B0QX	DRUGNAME	MSC-204
D0B0QX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0H4GE	TTDDRUID	D0H4GE
D0H4GE	DRUGNAME	MSI-469
D0H4GE	INDICATI	Periodontal disease [ICD-11: DA0C] Terminated

D08BIN	TTDDRUID	D08BIN
D08BIN	DRUGNAME	Munumbicins
D08BIN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0RM5W	TTDDRUID	D0RM5W
D0RM5W	DRUGNAME	MX2/120
D0RM5W	INDICATI	Asthma [ICD-11: CA23] Terminated

D0NC1D	TTDDRUID	D0NC1D
D0NC1D	DRUGNAME	MX-6120
D0NC1D	INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated

D0F7EK	TTDDRUID	D0F7EK
D0F7EK	DRUGNAME	MX-6162
D0F7EK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D06REJ	TTDDRUID	D06REJ
D06REJ	DRUGNAME	MX-7065
D06REJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05URT	TTDDRUID	D05URT
D05URT	DRUGNAME	MX-7091
D05URT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0Y8IF	TTDDRUID	D0Y8IF
D0Y8IF	DRUGNAME	MX-781
D0Y8IF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D06MIU	TTDDRUID	D06MIU
D06MIU	DRUGNAME	Mycoprex
D06MIU	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0E4MX	TTDDRUID	D0E4MX
D0E4MX	DRUGNAME	Myomap
D0E4MX	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0P7KS	TTDDRUID	D0P7KS
D0P7KS	DRUGNAME	N-3601
D0P7KS	INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated

D02BHP	TTDDRUID	D02BHP
D02BHP	DRUGNAME	Nacolomab tafenatox
D02BHP	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated

D00ICM	TTDDRUID	D00ICM
D00ICM	DRUGNAME	NALTIAZEM HYDROCHLORIDE
D00ICM	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0S8RG	TTDDRUID	D0S8RG
D0S8RG	DRUGNAME	Nasalflu Berna
D0S8RG	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated

D0M9VZ	TTDDRUID	D0M9VZ
D0M9VZ	DRUGNAME	Navuridine
D0M9VZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D00PYP	TTDDRUID	D00PYP
D00PYP	DRUGNAME	NBI-37582
D00PYP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
D00PYP	INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated

D03DVV	TTDDRUID	D03DVV
D03DVV	DRUGNAME	NC-1006
D03DVV	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D00TKC	TTDDRUID	D00TKC
D00TKC	DRUGNAME	NCP-004
D00TKC	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0E4RG	TTDDRUID	D0E4RG
D0E4RG	DRUGNAME	NCX-4215
D0E4RG	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0A3AB	TTDDRUID	D0A3AB
D0A3AB	DRUGNAME	NCY-118
D0A3AB	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D0L1YS	TTDDRUID	D0L1YS
D0L1YS	DRUGNAME	NE-033
D0L1YS	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D09DRG	TTDDRUID	D09DRG
D09DRG	DRUGNAME	NE-100
D09DRG	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D03XGO	TTDDRUID	D03XGO
D03XGO	DRUGNAME	Nematode anticoagulant proteins
D03XGO	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0A0MJ	TTDDRUID	D0A0MJ
D0A0MJ	DRUGNAME	Nerve growth factor
D0A0MJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D04SIO	TTDDRUID	D04SIO
D04SIO	DRUGNAME	NGD-91-1
D04SIO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D05KTV	TTDDRUID	D05KTV
D05KTV	DRUGNAME	NGD-93-1
D05KTV	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D07UHY	TTDDRUID	D07UHY
D07UHY	DRUGNAME	NIK-616
D07UHY	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated

D01RBK	TTDDRUID	D01RBK
D01RBK	DRUGNAME	Nisin
D01RBK	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Terminated

D04XMN	TTDDRUID	D04XMN
D04XMN	DRUGNAME	NK-109
D04XMN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0I2HL	TTDDRUID	D0I2HL
D0I2HL	DRUGNAME	NLC-002
D0I2HL	INDICATI	Obesity [ICD-11: 5B81] Terminated

D0C5YK	TTDDRUID	D0C5YK
D0C5YK	DRUGNAME	NMI-102
D0C5YK	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D04SHO	TTDDRUID	D04SHO
D04SHO	DRUGNAME	NMI-1182
D04SHO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0Z5OJ	TTDDRUID	D0Z5OJ
D0Z5OJ	DRUGNAME	NMI-150
D0Z5OJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0R3SI	TTDDRUID	D0R3SI
D0R3SI	DRUGNAME	NNC-09-0026
D0R3SI	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0Y6LO	TTDDRUID	D0Y6LO
D0Y6LO	DRUGNAME	NNC-13-8119
D0Y6LO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0B4CO	TTDDRUID	D0B4CO
D0B4CO	DRUGNAME	NNC-14-0185
D0B4CO	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D07WDS	TTDDRUID	D07WDS
D07WDS	DRUGNAME	NNC-14-0189
D07WDS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D03NPZ	TTDDRUID	D03NPZ
D03NPZ	DRUGNAME	NNC-22-0031
D03NPZ	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D09MOD	TTDDRUID	D09MOD
D09MOD	DRUGNAME	NNC-252504
D09MOD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D01GCY	TTDDRUID	D01GCY
D01GCY	DRUGNAME	NNC-26-0762
D01GCY	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Terminated

D0WP7P	TTDDRUID	D0WP7P
D0WP7P	DRUGNAME	NNC-55-0118
D0WP7P	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Terminated

D09GRB	TTDDRUID	D09GRB
D09GRB	DRUGNAME	NNC-90-0270
D09GRB	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0N7QP	TTDDRUID	D0N7QP
D0N7QP	DRUGNAME	NO-antihypertensives
D0N7QP	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0V9NB	TTDDRUID	D0V9NB
D0V9NB	DRUGNAME	Non-Hodgkin lymphoma vaccine
D0V9NB	INDICATI	B-cell lymphoma [ICD-11: 2A86] Terminated

D01CJB	TTDDRUID	D01CJB
D01CJB	DRUGNAME	Novovac-M1
D01CJB	INDICATI	Melanoma [ICD-11: 2C30] Terminated

D0W2LW	TTDDRUID	D0W2LW
D0W2LW	DRUGNAME	NOX-151
D0W2LW	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0OX9Q	TTDDRUID	D0OX9Q
D0OX9Q	DRUGNAME	NOX-200
D0OX9Q	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D03DFY	TTDDRUID	D03DFY
D03DFY	DRUGNAME	NP-7557
D03DFY	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0B1PD	TTDDRUID	D0B1PD
D0B1PD	DRUGNAME	NPC-16377
D0B1PD	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D02MHD	TTDDRUID	D02MHD
D02MHD	DRUGNAME	NPC-16570
D02MHD	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D03WMY	TTDDRUID	D03WMY
D03WMY	DRUGNAME	NPC-17731
D03WMY	INDICATI	Asthma [ICD-11: CA23] Terminated

D0Z3AK	TTDDRUID	D0Z3AK
D0Z3AK	DRUGNAME	NPC-17923
D0Z3AK	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D05NTY	TTDDRUID	D05NTY
D05NTY	DRUGNAME	NPC-18166
D05NTY	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D0B6QO	TTDDRUID	D0B6QO
D0B6QO	DRUGNAME	NPI-1999
D0B6QO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0Q3SP	TTDDRUID	D0Q3SP
D0Q3SP	DRUGNAME	NPS-1392
D0Q3SP	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0A2IK	TTDDRUID	D0A2IK
D0A2IK	DRUGNAME	NPS-846
D0A2IK	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0RE9H	TTDDRUID	D0RE9H
D0RE9H	DRUGNAME	NR-LU-13
D0RE9H	INDICATI	Colon cancer [ICD-11: 2B90.Z] Terminated

D0FG6T	TTDDRUID	D0FG6T
D0FG6T	DRUGNAME	NRP-388
D0FG6T	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D07JOS	TTDDRUID	D07JOS
D07JOS	DRUGNAME	NS-004
D07JOS	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0V4UR	TTDDRUID	D0V4UR
D0V4UR	DRUGNAME	NS-1546
D0V4UR	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D0OY1V	TTDDRUID	D0OY1V
D0OY1V	DRUGNAME	NS-1608
D0OY1V	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D09BVL	TTDDRUID	D09BVL
D09BVL	DRUGNAME	NS-1619
D09BVL	INDICATI	Asthma [ICD-11: CA23] Terminated

D06WHL	TTDDRUID	D06WHL
D06WHL	DRUGNAME	NS-257
D06WHL	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0S8KE	TTDDRUID	D0S8KE
D0S8KE	DRUGNAME	NS-2979
D0S8KE	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0EP5O	TTDDRUID	D0EP5O
D0EP5O	DRUGNAME	NS-377
D0EP5O	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D09BKE	TTDDRUID	D09BKE
D09BKE	DRUGNAME	NS398
D09BKE	INDICATI	Endometriosis [ICD-11: GA10] Terminated

D00ZWG	TTDDRUID	D00ZWG
D00ZWG	DRUGNAME	NS-638
D00ZWG	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0G7HO	TTDDRUID	D0G7HO
D0G7HO	DRUGNAME	NS-649
D0G7HO	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D08ZZO	TTDDRUID	D08ZZO
D08ZZO	DRUGNAME	NS-696
D08ZZO	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D03QTB	TTDDRUID	D03QTB
D03QTB	DRUGNAME	NSD-551
D03QTB	INDICATI	Brain cancer [ICD-11: 2A00] Terminated

D0P6YO	TTDDRUID	D0P6YO
D0P6YO	DRUGNAME	NSD-721
D0P6YO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0V3QE	TTDDRUID	D0V3QE
D0V3QE	DRUGNAME	NSL-036
D0V3QE	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated

D03JRJ	TTDDRUID	D03JRJ
D03JRJ	DRUGNAME	NTE-122
D03JRJ	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0E3LW	TTDDRUID	D0E3LW
D0E3LW	DRUGNAME	NV-27
D0E3LW	INDICATI	Artery stenosis [ICD-11: BD52] Terminated

D08FHV	TTDDRUID	D08FHV
D08FHV	DRUGNAME	NY-008
D08FHV	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D00YEO	TTDDRUID	D00YEO
D00YEO	DRUGNAME	NZ-1002
D00YEO	INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Terminated

D0L7JE	TTDDRUID	D0L7JE
D0L7JE	DRUGNAME	OC104-26
D0L7JE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0V2YC	TTDDRUID	D0V2YC
D0V2YC	DRUGNAME	OC42-92
D0V2YC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05UQD	TTDDRUID	D05UQD
D05UQD	DRUGNAME	Omapatrilat
D05UQD	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0M9FT	TTDDRUID	D0M9FT
D0M9FT	DRUGNAME	Omniferon
D0M9FT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D02KQE	TTDDRUID	D02KQE
D02KQE	DRUGNAME	ON-09300
D02KQE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0J5QW	TTDDRUID	D0J5QW
D0J5QW	DRUGNAME	ON-579
D0J5QW	INDICATI	Asthma [ICD-11: CA23] Terminated

D06FWG	TTDDRUID	D06FWG
D06FWG	DRUGNAME	Oncomer
D06FWG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0K6DG	TTDDRUID	D0K6DG
D0K6DG	DRUGNAME	ONO-8130
D0K6DG	INDICATI	Pollakiuria [ICD-11: MF50.1] Terminated

D0X2OV	TTDDRUID	D0X2OV
D0X2OV	DRUGNAME	ONO-8711
D0X2OV	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D02RUO	TTDDRUID	D02RUO
D02RUO	DRUGNAME	ONO-8815Ly
D02RUO	INDICATI	Miscarriage [ICD-11: JA00.0] Terminated

D05MLX	TTDDRUID	D05MLX
D05MLX	DRUGNAME	ONYX-411
D05MLX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09CTY	TTDDRUID	D09CTY
D09CTY	DRUGNAME	OPHD-002
D09CTY	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated

D0L2QC	TTDDRUID	D0L2QC
D0L2QC	DRUGNAME	OPT-88
D0L2QC	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated

D0SG4W	TTDDRUID	D0SG4W
D0SG4W	DRUGNAME	Oral insulin
D0SG4W	INDICATI	Type-1 diabetes [ICD-11: 5A10] Terminated

D08IRR	TTDDRUID	D08IRR
D08IRR	DRUGNAME	Org-10490
D08IRR	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D0SE4D	TTDDRUID	D0SE4D
D0SE4D	DRUGNAME	Org-20599
D0SE4D	INDICATI	Anaesthesia [ICD-11: 9A78.6] Terminated

D06IVH	TTDDRUID	D06IVH
D06IVH	DRUGNAME	Org-20781
D06IVH	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D09ENA	TTDDRUID	D09ENA
D09ENA	DRUGNAME	Org-30035
D09ENA	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D08LDG	TTDDRUID	D08LDG
D08LDG	DRUGNAME	Org-31433
D08LDG	INDICATI	Dementia [ICD-11: 6D80-6D86] Terminated

D0SF5F	TTDDRUID	D0SF5F
D0SF5F	DRUGNAME	Org-34092
D0SF5F	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0I7EX	TTDDRUID	D0I7EX
D0I7EX	DRUGNAME	Org-34116
D0I7EX	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0U5EY	TTDDRUID	D0U5EY
D0U5EY	DRUGNAME	Org-37684
D0U5EY	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D08ULI	TTDDRUID	D08ULI
D08ULI	DRUGNAME	Org-4094
D08ULI	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0GN9J	TTDDRUID	D0GN9J
D0GN9J	DRUGNAME	Org-6632
D0GN9J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0PB6P	TTDDRUID	D0PB6P
D0PB6P	DRUGNAME	Org-9935
D0PB6P	INDICATI	Asthma [ICD-11: CA23] Terminated

D0PL5F	TTDDRUID	D0PL5F
D0PL5F	DRUGNAME	OT-4003
D0PL5F	INDICATI	Asthma [ICD-11: CA23] Terminated

D06BDP	TTDDRUID	D06BDP
D06BDP	DRUGNAME	OtiVax
D06BDP	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Terminated

D07ULK	TTDDRUID	D07ULK
D07ULK	DRUGNAME	OX-23
D07ULK	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0V4FP	TTDDRUID	D0V4FP
D0V4FP	DRUGNAME	OX-30
D0V4FP	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0U9SM	TTDDRUID	D0U9SM
D0U9SM	DRUGNAME	OX-641
D0U9SM	INDICATI	Migraine [ICD-11: 8A80] Terminated

D03YVR	TTDDRUID	D03YVR
D03YVR	DRUGNAME	Oxamflatin
D03YVR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0M4FO	TTDDRUID	D0M4FO
D0M4FO	DRUGNAME	PA-1093
D0M4FO	INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated

D02UCW	TTDDRUID	D02UCW
D02UCW	DRUGNAME	PA-2794
D02UCW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0W8ZW	TTDDRUID	D0W8ZW
D0W8ZW	DRUGNAME	PA-342
D0W8ZW	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated

D0T4OE	TTDDRUID	D0T4OE
D0T4OE	DRUGNAME	Palinavir
D0T4OE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0S7AR	TTDDRUID	D0S7AR
D0S7AR	DRUGNAME	Papillomavirus vaccine
D0S7AR	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Terminated

D0RO5K	TTDDRUID	D0RO5K
D0RO5K	DRUGNAME	Parkinsons disease cell therapy
D0RO5K	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D0CV7T	TTDDRUID	D0CV7T
D0CV7T	DRUGNAME	Patamostat
D0CV7T	INDICATI	Hypotension [ICD-11: BA20-BA21] Terminated

D0V6LH	TTDDRUID	D0V6LH
D0V6LH	DRUGNAME	PBI-1101
D0V6LH	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0JI5G	TTDDRUID	D0JI5G
D0JI5G	DRUGNAME	PCNU
D0JI5G	INDICATI	Brain cancer [ICD-11: 2A00] Terminated

D0Z0KD	TTDDRUID	D0Z0KD
D0Z0KD	DRUGNAME	PD-0183812
D0Z0KD	INDICATI	Retinoblastoma [ICD-11: 2D02.2] Terminated

D04BSZ	TTDDRUID	D04BSZ
D04BSZ	DRUGNAME	PD-0204318
D04BSZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D03GQC	TTDDRUID	D03GQC
D03GQC	DRUGNAME	PD-117596
D03GQC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0YO6E	TTDDRUID	D0YO6E
D0YO6E	DRUGNAME	PD-132301-2
D0YO6E	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0J8RS	TTDDRUID	D0J8RS
D0J8RS	DRUGNAME	PD-146176
D0J8RS	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0P6DF	TTDDRUID	D0P6DF
D0P6DF	DRUGNAME	PD-153103
D0P6DF	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0H0KK	TTDDRUID	D0H0KK
D0H0KK	DRUGNAME	PD-155080
D0H0KK	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0OU1V	TTDDRUID	D0OU1V
D0OU1V	DRUGNAME	PD-155392
D0OU1V	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0N5YX	TTDDRUID	D0N5YX
D0N5YX	DRUGNAME	PD-158473
D0N5YX	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D04LIR	TTDDRUID	D04LIR
D04LIR	DRUGNAME	PD-159913
D04LIR	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0N4SU	TTDDRUID	D0N4SU
D0N4SU	DRUGNAME	Pegorgotein
D0N4SU	INDICATI	Head injury [ICD-11: NA00-NA0Z] Terminated

D04ZIJ	TTDDRUID	D04ZIJ
D04ZIJ	DRUGNAME	Pepstatin
D04ZIJ	INDICATI	Malaria [ICD-11: 1F40-1F45] Terminated

D02KAU	TTDDRUID	D02KAU
D02KAU	DRUGNAME	PF-03882845
D02KAU	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Terminated

D0M0NT	TTDDRUID	D0M0NT
D0M0NT	DRUGNAME	PF-04620110
D0M0NT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0KX3A	TTDDRUID	D0KX3A
D0KX3A	DRUGNAME	PF-4194471
D0KX3A	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D01TGH	TTDDRUID	D01TGH
D01TGH	DRUGNAME	PF-572778
D01TGH	INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Terminated

D00FYP	TTDDRUID	D00FYP
D00FYP	DRUGNAME	PG-36
D00FYP	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated

D0X7YR	TTDDRUID	D0X7YR
D0X7YR	DRUGNAME	PGCvax
D0X7YR	INDICATI	Pneumonia [ICD-11: CA40] Terminated

D01NNL	TTDDRUID	D01NNL
D01NNL	DRUGNAME	Phosphonate
D01NNL	INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated

D09ZXX	TTDDRUID	D09ZXX
D09ZXX	DRUGNAME	Photodynamic immunotherapy
D09ZXX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D0F8UU	TTDDRUID	D0F8UU
D0F8UU	DRUGNAME	Photosensitizers
D0F8UU	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0B0WW	TTDDRUID	D0B0WW
D0B0WW	DRUGNAME	Physostigmine/scopolamine
D0B0WW	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Terminated

D0J3OV	TTDDRUID	D0J3OV
D0J3OV	DRUGNAME	PI-083
D0J3OV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06NSL	TTDDRUID	D06NSL
D06NSL	DRUGNAME	PIC-060
D06NSL	INDICATI	Dermatitis [ICD-11: EA80-EA89] Terminated

D02NYK	TTDDRUID	D02NYK
D02NYK	DRUGNAME	Pifithrin-alpha
D02NYK	INDICATI	Toxicity [ICD-11: N.A.] Terminated

D0OH5V	TTDDRUID	D0OH5V
D0OH5V	DRUGNAME	PIROXANTRONE
D0OH5V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0S0IW	TTDDRUID	D0S0IW
D0S0IW	DRUGNAME	PJ-3505
D0S0IW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0JC8G	TTDDRUID	D0JC8G
D0JC8G	DRUGNAME	PL2100
D0JC8G	INDICATI	Stroke [ICD-11: 8B20] Terminated

D01CNV	TTDDRUID	D01CNV
D01CNV	DRUGNAME	PL-611
D01CNV	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0M2OW	TTDDRUID	D0M2OW
D0M2OW	DRUGNAME	Plasmodium falciparum LSA-NRC vaccine
D0M2OW	INDICATI	Malaria [ICD-11: 1F40-1F45] Terminated

D02WUW	TTDDRUID	D02WUW
D02WUW	DRUGNAME	PLD-177
D02WUW	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated

D0T9ZG	TTDDRUID	D0T9ZG
D0T9ZG	DRUGNAME	PLD-180
D0T9ZG	INDICATI	Motor neurone disease [ICD-11: 8B60] Terminated

D0S2KX	TTDDRUID	D0S2KX
D0S2KX	DRUGNAME	PLR-15
D0S2KX	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Terminated

D0D3HV	TTDDRUID	D0D3HV
D0D3HV	DRUGNAME	PLR-21
D0D3HV	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Terminated

D05SXL	TTDDRUID	D05SXL
D05SXL	DRUGNAME	PLR-8
D05SXL	INDICATI	Asthma [ICD-11: CA23] Terminated

D0C4HZ	TTDDRUID	D0C4HZ
D0C4HZ	DRUGNAME	PLR-9
D0C4HZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D02QZL	TTDDRUID	D02QZL
D02QZL	DRUGNAME	PNQX
D02QZL	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0T1SF	TTDDRUID	D0T1SF
D0T1SF	DRUGNAME	PNU-109291
D0T1SF	INDICATI	Migraine [ICD-11: 8A80] Terminated

D0Z1HQ	TTDDRUID	D0Z1HQ
D0Z1HQ	DRUGNAME	PNU156804
D0Z1HQ	INDICATI	Renal transplantation [ICD-11: NE84] Terminated

D03AZY	TTDDRUID	D03AZY
D03AZY	DRUGNAME	PNU-177864
D03AZY	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D06LKM	TTDDRUID	D06LKM
D06LKM	DRUGNAME	PNU-282987
D06LKM	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0G3MH	TTDDRUID	D0G3MH
D0G3MH	DRUGNAME	PNU-96391A
D0G3MH	INDICATI	Substance use disorder [ICD-11: 6C4Z] Terminated

D0MA2J	TTDDRUID	D0MA2J
D0MA2J	DRUGNAME	POL-443
D0MA2J	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D02VFK	TTDDRUID	D02VFK
D02VFK	DRUGNAME	PPRT-152
D02VFK	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated

D05YOT	TTDDRUID	D05YOT
D05YOT	DRUGNAME	PPRT-321
D05YOT	INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated

D0A5PM	TTDDRUID	D0A5PM
D0A5PM	DRUGNAME	PPRT-550
D0A5PM	INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Terminated

D07SDE	TTDDRUID	D07SDE
D07SDE	DRUGNAME	Pranidipine
D07SDE	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D01KIU	TTDDRUID	D01KIU
D01KIU	DRUGNAME	PRE-084
D01KIU	INDICATI	Aging skin [ICD-11: EE40] Terminated

D08LHE	TTDDRUID	D08LHE
D08LHE	DRUGNAME	Prinoxodan
D08LHE	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated

D09BID	TTDDRUID	D09BID
D09BID	DRUGNAME	PRO-206
D09BID	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D06YSX	TTDDRUID	D06YSX
D06YSX	DRUGNAME	Pro-erectile agents
D06YSX	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Terminated

D00LWX	TTDDRUID	D00LWX
D00LWX	DRUGNAME	Promegapoietin
D00LWX	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Terminated

D05KOA	TTDDRUID	D05KOA
D05KOA	DRUGNAME	Prophylactic DNA vaccine
D05KOA	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated

D00MLQ	TTDDRUID	D00MLQ
D00MLQ	DRUGNAME	Protosufloxacin
D00MLQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0A4XN	TTDDRUID	D0A4XN
D0A4XN	DRUGNAME	PRS-639058
D0A4XN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated

D04YEY	TTDDRUID	D04YEY
D04YEY	DRUGNAME	PS-388023
D04YEY	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Terminated

D00QIK	TTDDRUID	D00QIK
D00QIK	DRUGNAME	PS-519
D00QIK	INDICATI	Ischemia-reperfusion injury [ICD-11: DB98.B] Terminated

D00RFZ	TTDDRUID	D00RFZ
D00RFZ	DRUGNAME	PSI-6130
D00RFZ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0K6ZH	TTDDRUID	D0K6ZH
D0K6ZH	DRUGNAME	PSI-661
D0K6ZH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated

D0F1KP	TTDDRUID	D0F1KP
D0F1KP	DRUGNAME	PSN821
D0F1KP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D0F3TI	TTDDRUID	D0F3TI
D0F3TI	DRUGNAME	PT-630
D0F3TI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D03CIN	TTDDRUID	D03CIN
D03CIN	DRUGNAME	PTX-007011
D03CIN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0W0RT	TTDDRUID	D0W0RT
D0W0RT	DRUGNAME	PTX-008313
D0W0RT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0O2PK	TTDDRUID	D0O2PK
D0O2PK	DRUGNAME	PV-802
D0O2PK	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D0T5IN	TTDDRUID	D0T5IN
D0T5IN	DRUGNAME	PX-867
D0T5IN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D01DTQ	TTDDRUID	D01DTQ
D01DTQ	DRUGNAME	PXS-2076
D01DTQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D05LXC	TTDDRUID	D05LXC
D05LXC	DRUGNAME	QA-241
D05LXC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0Y4PL	TTDDRUID	D0Y4PL
D0Y4PL	DRUGNAME	QAP-642
D0Y4PL	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated

D09KGZ	TTDDRUID	D09KGZ
D09KGZ	DRUGNAME	QG-AGC1
D09KGZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09GIP	TTDDRUID	D09GIP
D09GIP	DRUGNAME	QRS-5-005
D09GIP	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D00EML	TTDDRUID	D00EML
D00EML	DRUGNAME	Q-Vax
D00EML	INDICATI	Coxiella infection [ICD-11: 1C33] Terminated

D0C4JX	TTDDRUID	D0C4JX
D0C4JX	DRUGNAME	QX-314
D0C4JX	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0C5HV	TTDDRUID	D0C5HV
D0C5HV	DRUGNAME	R zileuton
D0C5HV	INDICATI	Asthma [ICD-11: CA23] Terminated

D0EN4G	TTDDRUID	D0EN4G
D0EN4G	DRUGNAME	R-102444
D0EN4G	INDICATI	Pancreatitis [ICD-11: DC31-DC34] Terminated

D06BPF	TTDDRUID	D06BPF
D06BPF	DRUGNAME	R-102557
D06BPF	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0CX2J	TTDDRUID	D0CX2J
D0CX2J	DRUGNAME	R-1315
D0CX2J	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0F6CI	TTDDRUID	D0F6CI
D0F6CI	DRUGNAME	R-1437
D0F6CI	INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated

D01TIN	TTDDRUID	D01TIN
D01TIN	DRUGNAME	R-1458
D01TIN	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated

D02RLS	TTDDRUID	D02RLS
D02RLS	DRUGNAME	R-1554
D02RLS	INDICATI	Overactive bladder [ICD-11: GC50.0] Terminated

D0B2LF	TTDDRUID	D0B2LF
D0B2LF	DRUGNAME	R-253
D0B2LF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D01XEQ	TTDDRUID	D01XEQ
D01XEQ	DRUGNAME	R348
D01XEQ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated

D08MJX	TTDDRUID	D08MJX
D08MJX	DRUGNAME	R-56865
D08MJX	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0NF7S	TTDDRUID	D0NF7S
D0NF7S	DRUGNAME	R-59494
D0NF7S	INDICATI	Ischemia [ICD-11: 8B10-8B11] Terminated

D0Q5MU	TTDDRUID	D0Q5MU
D0Q5MU	DRUGNAME	R-7025
D0Q5MU	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated

D05QFA	TTDDRUID	D05QFA
D05QFA	DRUGNAME	R-71762
D05QFA	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D08RDC	TTDDRUID	D08RDC
D08RDC	DRUGNAME	R-765
D08RDC	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated

D0C3DH	TTDDRUID	D0C3DH
D0C3DH	DRUGNAME	RAAV vaccine
D0C3DH	INDICATI	Melanoma [ICD-11: 2C30] Terminated

D0X6MO	TTDDRUID	D0X6MO
D0X6MO	DRUGNAME	Ralitoline
D0X6MO	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0C3LM	TTDDRUID	D0C3LM
D0C3LM	DRUGNAME	RAS-111
D0C3LM	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D0T9KF	TTDDRUID	D0T9KF
D0T9KF	DRUGNAME	RDEA-427
D0T9KF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0JI1S	TTDDRUID	D0JI1S
D0JI1S	DRUGNAME	RDEA-640
D0JI1S	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D00KWA	TTDDRUID	D00KWA
D00KWA	DRUGNAME	Recainam
D00KWA	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D03UXT	TTDDRUID	D03UXT
D03UXT	DRUGNAME	Recombinant house dust mite allergy desensitization injection
D03UXT	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D08VGS	TTDDRUID	D08VGS
D08VGS	DRUGNAME	Recombinant protein subunit vaccine  (seasonal influenza)
D08VGS	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated

D0X1TD	TTDDRUID	D0X1TD
D0X1TD	DRUGNAME	RemeStim-CEA
D0X1TD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0WR7U	TTDDRUID	D0WR7U
D0WR7U	DRUGNAME	REN-1053
D0WR7U	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Terminated

D0M9FF	TTDDRUID	D0M9FF
D0M9FF	DRUGNAME	ReN-1820
D0M9FF	INDICATI	Cystitis [ICD-11: GC00] Terminated

D0P3SH	TTDDRUID	D0P3SH
D0P3SH	DRUGNAME	ReN-1826
D0P3SH	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Terminated

D00TRL	TTDDRUID	D00TRL
D00TRL	DRUGNAME	REV-598
D00TRL	INDICATI	Carcinoid syndrome [ICD-11: 5B10] Terminated

D09LQP	TTDDRUID	D09LQP
D09LQP	DRUGNAME	RG-14893
D09LQP	INDICATI	Asthma [ICD-11: CA23] Terminated

D0RT2E	TTDDRUID	D0RT2E
D0RT2E	DRUGNAME	RG-83852
D0RT2E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09ZAV	TTDDRUID	D09ZAV
D09ZAV	DRUGNAME	RG-8803
D09ZAV	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Terminated

D0G2LT	TTDDRUID	D0G2LT
D0G2LT	DRUGNAME	RGH-1756
D0G2LT	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D01DRL	TTDDRUID	D01DRL
D01DRL	DRUGNAME	RGH-2721
D01DRL	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D00HNK	TTDDRUID	D00HNK
D00HNK	DRUGNAME	RHb1.1
D00HNK	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Terminated

D0M9GE	TTDDRUID	D0M9GE
D0M9GE	DRUGNAME	Rimcazole
D0M9GE	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D02LUP	TTDDRUID	D02LUP
D02LUP	DRUGNAME	RN-1005
D02LUP	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Terminated

D07FHZ	TTDDRUID	D07FHZ
D07FHZ	DRUGNAME	Ro 20-1724
D07FHZ	INDICATI	Asthma [ICD-11: CA23] Terminated

D0B1PE	TTDDRUID	D0B1PE
D0B1PE	DRUGNAME	Ro 5-4864
D0B1PE	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0ZV1F	TTDDRUID	D0ZV1F
D0ZV1F	DRUGNAME	Ro-09-1227
D0ZV1F	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D03OFA	TTDDRUID	D03OFA
D03OFA	DRUGNAME	Ro-09-1428
D03OFA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0Z7AN	TTDDRUID	D0Z7AN
D0Z7AN	DRUGNAME	Ro-19-8022
D0Z7AN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D03HSF	TTDDRUID	D03HSF
D03HSF	DRUGNAME	Ro-23-7777
D03HSF	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D01RFI	TTDDRUID	D01RFI
D01RFI	DRUGNAME	Ro-24-0238
D01RFI	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D0A5CU	TTDDRUID	D0A5CU
D0A5CU	DRUGNAME	Ro-24-1882
D0A5CU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D06DLO	TTDDRUID	D06DLO
D06DLO	DRUGNAME	Ro-24-7341
D06DLO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0W0KW	TTDDRUID	D0W0KW
D0W0KW	DRUGNAME	Ro-24-8138
D0W0KW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0R8RK	TTDDRUID	D0R8RK
D0R8RK	DRUGNAME	Ro-25-0534
D0R8RK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D01UDR	TTDDRUID	D01UDR
D01UDR	DRUGNAME	Ro-25-0993
D01UDR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D04CNX	TTDDRUID	D04CNX
D04CNX	DRUGNAME	Ro-25-1132
D04CNX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D02JIB	TTDDRUID	D02JIB
D02JIB	DRUGNAME	Ro-25-2016
D02JIB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0Z1TF	TTDDRUID	D0Z1TF
D0Z1TF	DRUGNAME	Ro-25-4094
D0Z1TF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0O6SQ	TTDDRUID	D0O6SQ
D0O6SQ	DRUGNAME	Ro-25-4835
D0O6SQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0F6ZS	TTDDRUID	D0F6ZS
D0F6ZS	DRUGNAME	Ro-25-6833
D0F6ZS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0K0DB	TTDDRUID	D0K0DB
D0K0DB	DRUGNAME	RO-25-6981
D0K0DB	INDICATI	Cancer related pain [ICD-11: MG30] Terminated

D0EF7V	TTDDRUID	D0EF7V
D0EF7V	DRUGNAME	Ro-31-4724
D0EF7V	INDICATI	Arthritis [ICD-11: FA20] Terminated

D06AHQ	TTDDRUID	D06AHQ
D06AHQ	DRUGNAME	Ro-31-8830
D06AHQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0E5GY	TTDDRUID	D0E5GY
D0E5GY	DRUGNAME	RO-319790
D0E5GY	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0TC1T	TTDDRUID	D0TC1T
D0TC1T	DRUGNAME	Ro-40-1641
D0TC1T	INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated

D0C5OF	TTDDRUID	D0C5OF
D0C5OF	DRUGNAME	Ro-44-3949
D0C5OF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0J5HU	TTDDRUID	D0J5HU
D0J5HU	DRUGNAME	Ro-46-2005
D0J5HU	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0TK0W	TTDDRUID	D0TK0W
D0TK0W	DRUGNAME	Ro-46-5934
D0TK0W	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0OM5M	TTDDRUID	D0OM5M
D0OM5M	DRUGNAME	Ro-48-1220
D0OM5M	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0Y6IJ	TTDDRUID	D0Y6IJ
D0Y6IJ	DRUGNAME	Ro-48-5545
D0Y6IJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D00MVK	TTDDRUID	D00MVK
D00MVK	DRUGNAME	Ro-48-8391
D00MVK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0H3CV	TTDDRUID	D0H3CV
D0H3CV	DRUGNAME	Ro-48-8724
D0H3CV	INDICATI	Multidrug resistant infection [ICD-11: MG51] Terminated

D06JUR	TTDDRUID	D06JUR
D06JUR	DRUGNAME	Rogletimide
D06JUR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D0U3OY	TTDDRUID	D0U3OY
D0U3OY	DRUGNAME	Rovelizumab
D0U3OY	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Terminated

D06FTW	TTDDRUID	D06FTW
D06FTW	DRUGNAME	RP135
D06FTW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D08FAT	TTDDRUID	D08FAT
D08FAT	DRUGNAME	RP-170
D08FAT	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Terminated

D0G7DP	TTDDRUID	D0G7DP
D0G7DP	DRUGNAME	RP-316
D0G7DP	INDICATI	Hemorrhagic shock [ICD-11: MG40.1] Terminated

D0J0ZM	TTDDRUID	D0J0ZM
D0J0ZM	DRUGNAME	RP-400C
D0J0ZM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0T0LO	TTDDRUID	D0T0LO
D0T0LO	DRUGNAME	RP-54745
D0T0LO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D08HDD	TTDDRUID	D08HDD
D08HDD	DRUGNAME	RP-58802B
D08HDD	INDICATI	Asthma [ICD-11: CA23] Terminated

D0B8QA	TTDDRUID	D0B8QA
D0B8QA	DRUGNAME	RP-66055
D0B8QA	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated

D04JJE	TTDDRUID	D04JJE
D04JJE	DRUGNAME	RP-66153
D04JJE	INDICATI	Asthma [ICD-11: CA23] Terminated

D05BBQ	TTDDRUID	D05BBQ
D05BBQ	DRUGNAME	RP-66364
D05BBQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0U5GI	TTDDRUID	D0U5GI
D0U5GI	DRUGNAME	RP-66784
D0U5GI	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D08KXE	TTDDRUID	D08KXE
D08KXE	DRUGNAME	RP-67580
D08KXE	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0J3NJ	TTDDRUID	D0J3NJ
D0J3NJ	DRUGNAME	RP-69698
D0J3NJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D03YPL	TTDDRUID	D03YPL
D03YPL	DRUGNAME	RP-70676
D03YPL	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated

D06KFR	TTDDRUID	D06KFR
D06KFR	DRUGNAME	RP-73163
D06KFR	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D09CRQ	TTDDRUID	D09CRQ
D09CRQ	DRUGNAME	RPK-739
D09CRQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D01QRG	TTDDRUID	D01QRG
D01QRG	DRUGNAME	RPR 200765A
D01QRG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D08ALQ	TTDDRUID	D08ALQ
D08ALQ	DRUGNAME	RPR-101821
D08ALQ	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D05HKB	TTDDRUID	D05HKB
D05HKB	DRUGNAME	RS 86
D05HKB	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D01NBX	TTDDRUID	D01NBX
D01NBX	DRUGNAME	RS-2135
D01NBX	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0Q7SO	TTDDRUID	D0Q7SO
D0Q7SO	DRUGNAME	RS-66252
D0Q7SO	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D08ZAX	TTDDRUID	D08ZAX
D08ZAX	DRUGNAME	RS-93522
D08ZAX	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0H4JN	TTDDRUID	D0H4JN
D0H4JN	DRUGNAME	RTI-113
D0H4JN	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Terminated

D05IVZ	TTDDRUID	D05IVZ
D05IVZ	DRUGNAME	RU-33965
D05IVZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0N4PC	TTDDRUID	D0N4PC
D0N4PC	DRUGNAME	RU-46556
D0N4PC	INDICATI	Endometrial cancer [ICD-11: 2C76] Terminated

D07FWH	TTDDRUID	D07FWH
D07FWH	DRUGNAME	RU-59863
D07FWH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0I8ZB	TTDDRUID	D0I8ZB
D0I8ZB	DRUGNAME	Ruthenium complexes
D0I8ZB	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0E6VL	TTDDRUID	D0E6VL
D0E6VL	DRUGNAME	RWJ-22108
D0E6VL	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D0R9PL	TTDDRUID	D0R9PL
D0R9PL	DRUGNAME	RWJ-25730
D0R9PL	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D0UU3J	TTDDRUID	D0UU3J
D0UU3J	DRUGNAME	RWJ-37868
D0UU3J	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0XI9O	TTDDRUID	D0XI9O
D0XI9O	DRUGNAME	RWJ-46458
D0XI9O	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D05ALG	TTDDRUID	D05ALG
D05ALG	DRUGNAME	RWJ-49815
D05ALG	INDICATI	Eating disorder [ICD-11: 6B82] Investigative
D05ALG	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
D05ALG	INDICATI	Obesity [ICD-11: 5B81] Investigative

D08ELM	TTDDRUID	D08ELM
D08ELM	DRUGNAME	RWJ-58259
D08ELM	INDICATI	Artery stenosis [ICD-11: BD52] Terminated

D08JKK	TTDDRUID	D08JKK
D08JKK	DRUGNAME	RWJ-63556
D08JKK	INDICATI	Arthritis [ICD-11: FA20] Terminated

D00JQQ	TTDDRUID	D00JQQ
D00JQQ	DRUGNAME	RX-465
D00JQQ	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Terminated

D04NSW	TTDDRUID	D04NSW
D04NSW	DRUGNAME	S-12340
D04NSW	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0IQ6O	TTDDRUID	D0IQ6O
D0IQ6O	DRUGNAME	S-1286
D0IQ6O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04WWG	TTDDRUID	D04WWG
D04WWG	DRUGNAME	S-1389
D04WWG	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0M6JP	TTDDRUID	D0M6JP
D0M6JP	DRUGNAME	S-14080
D0M6JP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0A6PL	TTDDRUID	D0A6PL
D0A6PL	DRUGNAME	S-14506
D0A6PL	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D06MTM	TTDDRUID	D06MTM
D06MTM	DRUGNAME	S-16276-1
D06MTM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0KC5X	TTDDRUID	D0KC5X
D0KC5X	DRUGNAME	S-18616
D0KC5X	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D05GOM	TTDDRUID	D05GOM
D05GOM	DRUGNAME	S-20928
D05GOM	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated

D0DR3I	TTDDRUID	D0DR3I
D0DR3I	DRUGNAME	S-33516
D0DR3I	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0L2BH	TTDDRUID	D0L2BH
D0L2BH	DRUGNAME	S-34109
D0L2BH	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated

D0K9TC	TTDDRUID	D0K9TC
D0K9TC	DRUGNAME	Sameridine
D0K9TC	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0M8QG	TTDDRUID	D0M8QG
D0M8QG	DRUGNAME	SAN-18
D0M8QG	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D07YNH	TTDDRUID	D07YNH
D07YNH	DRUGNAME	SAN-61
D07YNH	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0FN1P	TTDDRUID	D0FN1P
D0FN1P	DRUGNAME	Saviprazole
D0FN1P	INDICATI	Peptic ulcer [ICD-11: DA61] Terminated

D07AGR	TTDDRUID	D07AGR
D07AGR	DRUGNAME	SB-206284A
D07AGR	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0QH0R	TTDDRUID	D0QH0R
D0QH0R	DRUGNAME	SB-206343
D0QH0R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0I7EU	TTDDRUID	D0I7EU
D0I7EU	DRUGNAME	SB-208651
D0I7EU	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0G7SP	TTDDRUID	D0G7SP
D0G7SP	DRUGNAME	SB-209247
D0G7SP	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated

D0Y0ZB	TTDDRUID	D0Y0ZB
D0Y0ZB	DRUGNAME	SB-219825
D0Y0ZB	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D00YGA	TTDDRUID	D00YGA
D00YGA	DRUGNAME	SB-219994
D00YGA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D09ICC	TTDDRUID	D09ICC
D09ICC	DRUGNAME	SB220025
D09ICC	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0P5NW	TTDDRUID	D0P5NW
D0P5NW	DRUGNAME	SB-236049
D0P5NW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D06VXY	TTDDRUID	D06VXY
D06VXY	DRUGNAME	SB-237376
D06VXY	INDICATI	Arrhythmia [ICD-11: BC9Z] Terminated

D0YP7L	TTDDRUID	D0YP7L
D0YP7L	DRUGNAME	SB-269970
D0YP7L	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated

D0Y6SN	TTDDRUID	D0Y6SN
D0Y6SN	DRUGNAME	SB-277011
D0Y6SN	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0Q2JS	TTDDRUID	D0Q2JS
D0Q2JS	DRUGNAME	SB-282241
D0Q2JS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0G0UZ	TTDDRUID	D0G0UZ
D0G0UZ	DRUGNAME	SBP-002
D0G0UZ	INDICATI	Melanoma [ICD-11: 2C30] Terminated

D0O7BW	TTDDRUID	D0O7BW
D0O7BW	DRUGNAME	SC-102
D0O7BW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0H2UN	TTDDRUID	D0H2UN
D0H2UN	DRUGNAME	SC-108
D0H2UN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0W8NZ	TTDDRUID	D0W8NZ
D0W8NZ	DRUGNAME	SC-112
D0W8NZ	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Terminated

D09XMP	TTDDRUID	D09XMP
D09XMP	DRUGNAME	SC-114
D09XMP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D03NZV	TTDDRUID	D03NZV
D03NZV	DRUGNAME	SC-236
D03NZV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D07NWC	TTDDRUID	D07NWC
D07NWC	DRUGNAME	SC-241
D07NWC	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0Z9LD	TTDDRUID	D0Z9LD
D0Z9LD	DRUGNAME	SC-49992
D0Z9LD	INDICATI	Arterial thrombosis [ICD-11: DB61-DD30] Terminated

D0O0QG	TTDDRUID	D0O0QG
D0O0QG	DRUGNAME	SC-51316
D0O0QG	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0C5DM	TTDDRUID	D0C5DM
D0C5DM	DRUGNAME	SC-52150
D0C5DM	INDICATI	Vomiting [ICD-11: MD90] Terminated

D0ZG9N	TTDDRUID	D0ZG9N
D0ZG9N	DRUGNAME	SC-53116
D0ZG9N	INDICATI	Gastric motility disorder [ICD-11: DA21] Terminated

D0NK8D	TTDDRUID	D0NK8D
D0NK8D	DRUGNAME	SC-53228
D0NK8D	INDICATI	Asthma [ICD-11: CA23] Terminated

D06ZKG	TTDDRUID	D06ZKG
D06ZKG	DRUGNAME	SC-56525
D06ZKG	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0K9OL	TTDDRUID	D0K9OL
D0K9OL	DRUGNAME	SCH 50911
D0K9OL	INDICATI	Absence seizure [ICD-11: 8A68.2] Terminated

D0V3WQ	TTDDRUID	D0V3WQ
D0V3WQ	DRUGNAME	Sch-207758
D0V3WQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06MPF	TTDDRUID	D06MPF
D06MPF	DRUGNAME	Sch-40120
D06MPF	INDICATI	Pruritus [ICD-11: EC90] Terminated

D0Q8YN	TTDDRUID	D0Q8YN
D0Q8YN	DRUGNAME	Sch-40338
D0Q8YN	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D00MEV	TTDDRUID	D00MEV
D00MEV	DRUGNAME	Sch-45752
D00MEV	INDICATI	Asthma [ICD-11: CA23] Terminated

D0UJ8E	TTDDRUID	D0UJ8E
D0UJ8E	DRUGNAME	Sch-49209
D0UJ8E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0ZQ7P	TTDDRUID	D0ZQ7P
D0ZQ7P	DRUGNAME	Sch-49210
D0ZQ7P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D07IZF	TTDDRUID	D07IZF
D07IZF	DRUGNAME	Sch-57790
D07IZF	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D05SXC	TTDDRUID	D05SXC
D05SXC	DRUGNAME	SCR-44001
D05SXC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0K1CL	TTDDRUID	D0K1CL
D0K1CL	DRUGNAME	SDZ-224-015
D0K1CL	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0KE1V	TTDDRUID	D0KE1V
D0KE1V	DRUGNAME	SDZ-249482
D0KE1V	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0D2RZ	TTDDRUID	D0D2RZ
D0D2RZ	DRUGNAME	SDZ-267-489
D0D2RZ	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D01RKQ	TTDDRUID	D01RKQ
D01RKQ	DRUGNAME	SDZ-280-446
D01RKQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04TZT	TTDDRUID	D04TZT
D04TZT	DRUGNAME	SDZ-280-636
D04TZT	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0C5YQ	TTDDRUID	D0C5YQ
D0C5YQ	DRUGNAME	SDZ-62-826
D0C5YQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06MUZ	TTDDRUID	D06MUZ
D06MUZ	DRUGNAME	SDZ-87-469
D06MUZ	INDICATI	Coronary artery disease [ICD-11: BA80] Terminated

D03YJZ	TTDDRUID	D03YJZ
D03YJZ	DRUGNAME	SDZ-89-104
D03YJZ	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Terminated

D01LZC	TTDDRUID	D01LZC
D01LZC	DRUGNAME	SDZ-GLI-328
D01LZC	INDICATI	Genetic disease [ICD-11: 8E02] Terminated

D0I8RY	TTDDRUID	D0I8RY
D0I8RY	DRUGNAME	SDZ-ICM-567
D0I8RY	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0J5UC	TTDDRUID	D0J5UC
D0J5UC	DRUGNAME	SDZ-ISQ-844
D0J5UC	INDICATI	Asthma [ICD-11: CA23] Terminated

D0C0EX	TTDDRUID	D0C0EX
D0C0EX	DRUGNAME	SDZ-MTH-958
D0C0EX	INDICATI	Artery stenosis [ICD-11: BD52] Terminated

D0M5NK	TTDDRUID	D0M5NK
D0M5NK	DRUGNAME	SDZ-PGU-693
D0M5NK	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated

D0DX6L	TTDDRUID	D0DX6L
D0DX6L	DRUGNAME	SDZ-PSD-958
D0DX6L	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Terminated

D0Z4QC	TTDDRUID	D0Z4QC
D0Z4QC	DRUGNAME	SDZ-SER-082
D0Z4QC	INDICATI	Neurological disorder [ICD-11: 6B60] Terminated

D0OT3Y	TTDDRUID	D0OT3Y
D0OT3Y	DRUGNAME	Sebriplatin
D0OT3Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0G0KC	TTDDRUID	D0G0KC
D0G0KC	DRUGNAME	Second-generation cannabinoids
D0G0KC	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D04ICR	TTDDRUID	D04ICR
D04ICR	DRUGNAME	Second-generation leptin
D04ICR	INDICATI	Obesity [ICD-11: 5B81] Terminated

D0FQ4M	TTDDRUID	D0FQ4M
D0FQ4M	DRUGNAME	Selenotifen
D0FQ4M	INDICATI	Asthma [ICD-11: CA23] Terminated

D0XW4W	TTDDRUID	D0XW4W
D0XW4W	DRUGNAME	SEP-227900
D0XW4W	INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated

D0Q5ZN	TTDDRUID	D0Q5ZN
D0Q5ZN	DRUGNAME	Seprilose
D0Q5ZN	INDICATI	Arthritis [ICD-11: FA20] Terminated

D0U5PR	TTDDRUID	D0U5PR
D0U5PR	DRUGNAME	Seridopidine
D0U5PR	INDICATI	Neurological disorder [ICD-11: 6B60] Terminated

D0Y9HH	TTDDRUID	D0Y9HH
D0Y9HH	DRUGNAME	SIB-1508Y
D0Y9HH	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D01LRH	TTDDRUID	D01LRH
D01LRH	DRUGNAME	Sibopirdine
D01LRH	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D00PPV	TTDDRUID	D00PPV
D00PPV	DRUGNAME	Siderophore-conjugated monocarbams
D00PPV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0Q7VI	TTDDRUID	D0Q7VI
D0Q7VI	DRUGNAME	Siguazodan
D0Q7VI	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D0DM5A	TTDDRUID	D0DM5A
D0DM5A	DRUGNAME	SIM-6080
D0DM5A	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0OW6Z	TTDDRUID	D0OW6Z
D0OW6Z	DRUGNAME	Sipoglitazar
D0OW6Z	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D03SDH	TTDDRUID	D03SDH
D03SDH	DRUGNAME	Siratiazem
D03SDH	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D02RNJ	TTDDRUID	D02RNJ
D02RNJ	DRUGNAME	SK&F-104662
D02RNJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D03CCH	TTDDRUID	D03CCH
D03CCH	DRUGNAME	SK&F-95601
D03CCH	INDICATI	Peptic ulcer [ICD-11: DA61] Terminated

D0PN9E	TTDDRUID	D0PN9E
D0PN9E	DRUGNAME	SK-951
D0PN9E	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D0OU7P	TTDDRUID	D0OU7P
D0OU7P	DRUGNAME	SKF 38393
D0OU7P	INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated

D09SCI	TTDDRUID	D09SCI
D09SCI	DRUGNAME	SKF-104351
D09SCI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0ML0R	TTDDRUID	D0ML0R
D0ML0R	DRUGNAME	SKF-105685
D0ML0R	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D08GNA	TTDDRUID	D08GNA
D08GNA	DRUGNAME	SKF-106610
D08GNA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0M6YE	TTDDRUID	D0M6YE
D0M6YE	DRUGNAME	SKF-106760
D0M6YE	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D02DHU	TTDDRUID	D02DHU
D02DHU	DRUGNAME	SKF-81297
D02DHU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D0W8OH	TTDDRUID	D0W8OH
D0W8OH	DRUGNAME	SKF-96231
D0W8OH	INDICATI	Asthma [ICD-11: CA23] Terminated

D0HQ1W	TTDDRUID	D0HQ1W
D0HQ1W	DRUGNAME	SKF-96365
D0HQ1W	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D02ISP	TTDDRUID	D02ISP
D02ISP	DRUGNAME	SKI-2034R
D02ISP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0T4XV	TTDDRUID	D0T4XV
D0T4XV	DRUGNAME	SL-18.1616
D0T4XV	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Terminated

D0C5LI	TTDDRUID	D0C5LI
D0C5LI	DRUGNAME	SL-91.0893
D0C5LI	INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated

D0F0TW	TTDDRUID	D0F0TW
D0F0TW	DRUGNAME	SL-910102
D0F0TW	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0U4WG	TTDDRUID	D0U4WG
D0U4WG	DRUGNAME	SLV-307
D0U4WG	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D0G6US	TTDDRUID	D0G6US
D0G6US	DRUGNAME	SLV-322
D0G6US	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D0V4FK	TTDDRUID	D0V4FK
D0V4FK	DRUGNAME	SM 11044
D0V4FK	INDICATI	Asthma [ICD-11: CA23] Terminated

D0I4LB	TTDDRUID	D0I4LB
D0I4LB	DRUGNAME	SM-16
D0I4LB	INDICATI	Fibrosis [ICD-11: GA14-GC01] Terminated

D0M3JI	TTDDRUID	D0M3JI
D0M3JI	DRUGNAME	SM-19712
D0M3JI	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D06HRY	TTDDRUID	D06HRY
D06HRY	DRUGNAME	SNAP-5089
D06HRY	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D04QFV	TTDDRUID	D04QFV
D04QFV	DRUGNAME	SNX-024
D04QFV	INDICATI	Obesity [ICD-11: 5B81] Terminated

D01RAE	TTDDRUID	D01RAE
D01RAE	DRUGNAME	Sonepiprazole
D01RAE	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D02CGC	TTDDRUID	D02CGC
D02CGC	DRUGNAME	Sorbinil
D02CGC	INDICATI	Diabetic cataract [ICD-11: 9B10.21] Terminated

D08QYJ	TTDDRUID	D08QYJ
D08QYJ	DRUGNAME	SORETOLIDE
D08QYJ	INDICATI	Convulsion [ICD-11: 8A68.Z] Terminated

D00FSS	TTDDRUID	D00FSS
D00FSS	DRUGNAME	SPD-452
D00FSS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D01JRF	TTDDRUID	D01JRF
D01JRF	DRUGNAME	SPD-453
D01JRF	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0CI5O	TTDDRUID	D0CI5O
D0CI5O	DRUGNAME	SPD-474
D0CI5O	INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated

D08MCO	TTDDRUID	D08MCO
D08MCO	DRUGNAME	SPD-703
D08MCO	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Terminated

D0C6FL	TTDDRUID	D0C6FL
D0C6FL	DRUGNAME	SPD-704
D0C6FL	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated

D0S7DS	TTDDRUID	D0S7DS
D0S7DS	DRUGNAME	SPD-756
D0S7DS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D05SOF	TTDDRUID	D05SOF
D05SOF	DRUGNAME	SPM-3672
D05SOF	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D06HQG	TTDDRUID	D06HQG
D06HQG	DRUGNAME	SPM-5185
D06HQG	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D0WU0K	TTDDRUID	D0WU0K
D0WU0K	DRUGNAME	Sporeamicins
D0WU0K	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0X6FF	TTDDRUID	D0X6FF
D0X6FF	DRUGNAME	SPPI-339
D0X6FF	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Terminated

D0E6LC	TTDDRUID	D0E6LC
D0E6LC	DRUGNAME	SPR-210
D0E6LC	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0M0GJ	TTDDRUID	D0M0GJ
D0M0GJ	DRUGNAME	SPV-30
D0M0GJ	INDICATI	Chronic fatigue syndrome [ICD-11: 8E49] Terminated

D06WBA	TTDDRUID	D06WBA
D06WBA	DRUGNAME	SQ-28603
D06WBA	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D03ZPY	TTDDRUID	D03ZPY
D03ZPY	DRUGNAME	SQ-33351
D03ZPY	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0Y3OR	TTDDRUID	D0Y3OR
D0Y3OR	DRUGNAME	SQ-33600
D0Y3OR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated

D0M7HO	TTDDRUID	D0M7HO
D0M7HO	DRUGNAME	SQ-33800
D0M7HO	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0U7HD	TTDDRUID	D0U7HD
D0U7HD	DRUGNAME	SQ-33961
D0U7HD	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0O1AV	TTDDRUID	D0O1AV
D0O1AV	DRUGNAME	Squalestatin 1
D0O1AV	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D04QXG	TTDDRUID	D04QXG
D04QXG	DRUGNAME	SR 120819A
D04QXG	INDICATI	Eating disorder [ICD-11: 6B82] Terminated

D09YUQ	TTDDRUID	D09YUQ
D09YUQ	DRUGNAME	SR-11237
D09YUQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D08NHF	TTDDRUID	D08NHF
D08NHF	DRUGNAME	SR-11335
D08NHF	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated

D0C7RV	TTDDRUID	D0C7RV
D0C7RV	DRUGNAME	SR12813
D0C7RV	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0R7QW	TTDDRUID	D0R7QW
D0R7QW	DRUGNAME	SR-2566
D0R7QW	INDICATI	Eczema [ICD-11: EA80-EA89] Terminated

D03GII	TTDDRUID	D03GII
D03GII	DRUGNAME	SR-26831
D03GII	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0R3OR	TTDDRUID	D0R3OR
D0R3OR	DRUGNAME	SR-27950
D0R3OR	INDICATI	Eating disorder [ICD-11: 6B82] Terminated

D0MK2C	TTDDRUID	D0MK2C
D0MK2C	DRUGNAME	SR-31742A
D0MK2C	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D0I9QH	TTDDRUID	D0I9QH
D0I9QH	DRUGNAME	SR-58878
D0I9QH	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Terminated

D00TVI	TTDDRUID	D00TVI
D00TVI	DRUGNAME	SR-58894A
D00TVI	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D02ZWG	TTDDRUID	D02ZWG
D02ZWG	DRUGNAME	SR-80027A
D02ZWG	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D09PTL	TTDDRUID	D09PTL
D09PTL	DRUGNAME	SRI-3072
D09PTL	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated

D05VXQ	TTDDRUID	D05VXQ
D05VXQ	DRUGNAME	SRSC-355
D05VXQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated

D07MTL	TTDDRUID	D07MTL
D07MTL	DRUGNAME	SRSC-371
D07MTL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D0C9RV	TTDDRUID	D0C9RV
D0C9RV	DRUGNAME	SRSS-016
D0C9RV	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0L3OE	TTDDRUID	D0L3OE
D0L3OE	DRUGNAME	SRSS-021
D0L3OE	INDICATI	Vomiting [ICD-11: MD90] Terminated

D0O8UF	TTDDRUID	D0O8UF
D0O8UF	DRUGNAME	SRSS-023
D0O8UF	INDICATI	Migraine [ICD-11: 8A80] Terminated

D0B3MV	TTDDRUID	D0B3MV
D0B3MV	DRUGNAME	SSR-69071
D0B3MV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated

D0K7PQ	TTDDRUID	D0K7PQ
D0K7PQ	DRUGNAME	ST-570
D0K7PQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D03RZM	TTDDRUID	D03RZM
D03RZM	DRUGNAME	Steroid hormone conjugates
D03RZM	INDICATI	Cachexia [ICD-11: MG20] Terminated

D0YP5Z	TTDDRUID	D0YP5Z
D0YP5Z	DRUGNAME	Streptococcus pneumoniae vaccine, Cytovax
D0YP5Z	INDICATI	Streptococcus infection [ICD-11: 1B53] Terminated

D09QVT	TTDDRUID	D09QVT
D09QVT	DRUGNAME	Streptococcus vaccines
D09QVT	INDICATI	Streptococcus infection [ICD-11: 1B53] Terminated

D01MIP	TTDDRUID	D01MIP
D01MIP	DRUGNAME	SU5614
D01MIP	INDICATI	Airway inflammation [ICD-11: CA05] Terminated

D0R5ZJ	TTDDRUID	D0R5ZJ
D0R5ZJ	DRUGNAME	SU-740
D0R5ZJ	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated

D07JSK	TTDDRUID	D07JSK
D07JSK	DRUGNAME	Sulotroban
D07JSK	INDICATI	Asthma [ICD-11: CA23] Terminated

D0G2VT	TTDDRUID	D0G2VT
D0G2VT	DRUGNAME	SUN-11031
D0G2VT	INDICATI	Anorexia nervosa cachexia [ICD-11: 6B80] Terminated

D0F2PZ	TTDDRUID	D0F2PZ
D0F2PZ	DRUGNAME	SUN-E3001
D0F2PZ	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0V3XK	TTDDRUID	D0V3XK
D0V3XK	DRUGNAME	SWT-02.100
D0V3XK	INDICATI	Wound healing [ICD-11: EL8Y] Terminated

D0PQ3V	TTDDRUID	D0PQ3V
D0PQ3V	DRUGNAME	SYN-1134
D0PQ3V	INDICATI	Cystic fibrosis [ICD-11: CA25] Terminated

D0FB6T	TTDDRUID	D0FB6T
D0FB6T	DRUGNAME	SYN-987
D0FB6T	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D08EIX	TTDDRUID	D08EIX
D08EIX	DRUGNAME	T-686
D08EIX	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0M9CV	TTDDRUID	D0M9CV
D0M9CV	DRUGNAME	TA-993
D0M9CV	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D03WYV	TTDDRUID	D03WYV
D03WYV	DRUGNAME	TAK-225
D03WYV	INDICATI	Asthma [ICD-11: CA23] Terminated

D0W0LS	TTDDRUID	D0W0LS
D0W0LS	DRUGNAME	TAK-779
D0W0LS	INDICATI	Transplant rejection [ICD-11: NE84] Terminated

D0G9RW	TTDDRUID	D0G9RW
D0G9RW	DRUGNAME	TAN-1496
D0G9RW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0C4YF	TTDDRUID	D0C4YF
D0C4YF	DRUGNAME	TAN-1518A
D0C4YF	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Terminated

D07XHJ	TTDDRUID	D07XHJ
D07XHJ	DRUGNAME	TAN-950A
D07XHJ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0LG1K	TTDDRUID	D0LG1K
D0LG1K	DRUGNAME	TAR-1
D0LG1K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D05SBI	TTDDRUID	D05SBI
D05SBI	DRUGNAME	TBC-395
D05SBI	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D01BQJ	TTDDRUID	D01BQJ
D01BQJ	DRUGNAME	TCV-295
D01BQJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0OK8M	TTDDRUID	D0OK8M
D0OK8M	DRUGNAME	TEI-6522
D0OK8M	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0C3TE	TTDDRUID	D0C3TE
D0C3TE	DRUGNAME	TEI-9874
D0C3TE	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D0P5VZ	TTDDRUID	D0P5VZ
D0P5VZ	DRUGNAME	Tenecrin
D0P5VZ	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D00JNL	TTDDRUID	D00JNL
D00JNL	DRUGNAME	Tenilsetam
D00JNL	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D03CMR	TTDDRUID	D03CMR
D03CMR	DRUGNAME	TER-16998
D03CMR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0E6OA	TTDDRUID	D0E6OA
D0E6OA	DRUGNAME	TERIKALANT
D0E6OA	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Terminated

D08KDL	TTDDRUID	D08KDL
D08KDL	DRUGNAME	TES-23-NCS
D08KDL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0ZX0C	TTDDRUID	D0ZX0C
D0ZX0C	DRUGNAME	Tetanus vaccine
D0ZX0C	INDICATI	Clostridium infection [ICD-11: 1A04] Terminated

D0D2JD	TTDDRUID	D0D2JD
D0D2JD	DRUGNAME	TH-0318
D0D2JD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D0QQ7N	TTDDRUID	D0QQ7N
D0QQ7N	DRUGNAME	TH-9229
D0QQ7N	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Terminated

D0Y5ZG	TTDDRUID	D0Y5ZG
D0Y5ZG	DRUGNAME	Theradigm-HIV
D0Y5ZG	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated

D00ADV	TTDDRUID	D00ADV
D00ADV	DRUGNAME	THF carbapenems
D00ADV	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated

D0R7DW	TTDDRUID	D0R7DW
D0R7DW	DRUGNAME	Thiomarinols
D0R7DW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D05FYA	TTDDRUID	D05FYA
D05FYA	DRUGNAME	Thioperamide
D05FYA	INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated

D0Q1UR	TTDDRUID	D0Q1UR
D0Q1UR	DRUGNAME	TIAPAFANT
D0Q1UR	INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated

D05JQF	TTDDRUID	D05JQF
D05JQF	DRUGNAME	Tipredane
D05JQF	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D0I4RX	TTDDRUID	D0I4RX
D0I4RX	DRUGNAME	TJ-127
D0I4RX	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D00XRI	TTDDRUID	D00XRI
D00XRI	DRUGNAME	TJN-220
D00XRI	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D05RDE	TTDDRUID	D05RDE
D05RDE	DRUGNAME	TJN-505
D05RDE	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D01OUA	TTDDRUID	D01OUA
D01OUA	DRUGNAME	TJN-598
D01OUA	INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Terminated

D0U4WB	TTDDRUID	D0U4WB
D0U4WB	DRUGNAME	TLC-C-53
D0U4WB	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Terminated

D0Y9CC	TTDDRUID	D0Y9CC
D0Y9CC	DRUGNAME	TM-31
D0Y9CC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D06MJP	TTDDRUID	D06MJP
D06MJP	DRUGNAME	TNFQb therapeutic vaccines
D06MJP	INDICATI	Crohn disease [ICD-11: DD70] Terminated

D08NPB	TTDDRUID	D08NPB
D08NPB	DRUGNAME	TO-195
D08NPB	INDICATI	Nephritis [ICD-11: GB40] Terminated

D0V4PH	TTDDRUID	D0V4PH
D0V4PH	DRUGNAME	Tolerimab (anti-CD80/CD86)
D0V4PH	INDICATI	Transplant rejection [ICD-11: NE84] Terminated

D0S8YL	TTDDRUID	D0S8YL
D0S8YL	DRUGNAME	Tomelukast
D0S8YL	INDICATI	Asthma [ICD-11: CA23] Terminated

D0F7TV	TTDDRUID	D0F7TV
D0F7TV	DRUGNAME	Torbafylline
D0F7TV	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Terminated

D03QSR	TTDDRUID	D03QSR
D03QSR	DRUGNAME	TP-20
D03QSR	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D0U0OF	TTDDRUID	D0U0OF
D0U0OF	DRUGNAME	TPI-273
D0U0OF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0QF6E	TTDDRUID	D0QF6E
D0QF6E	DRUGNAME	Tridegin
D0QF6E	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0F4GJ	TTDDRUID	D0F4GJ
D0F4GJ	DRUGNAME	Trifenagrel
D0F4GJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0IJ3R	TTDDRUID	D0IJ3R
D0IJ3R	DRUGNAME	TRK-710
D0IJ3R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0N4DO	TTDDRUID	D0N4DO
D0N4DO	DRUGNAME	Troponin-I
D0N4DO	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Terminated

D01DJA	TTDDRUID	D01DJA
D01DJA	DRUGNAME	TSK-204
D01DJA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated

D0H3XB	TTDDRUID	D0H3XB
D0H3XB	DRUGNAME	TULOPAFANT
D0H3XB	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Terminated

D0B9CA	TTDDRUID	D0B9CA
D0B9CA	DRUGNAME	Tuvirumab
D0B9CA	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated

D00ARN	TTDDRUID	D00ARN
D00ARN	DRUGNAME	Tyloxapol
D00ARN	INDICATI	Cystic fibrosis [ICD-11: CA25] Terminated

D0PM1R	TTDDRUID	D0PM1R
D0PM1R	DRUGNAME	TZ-93
D0PM1R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0B7HJ	TTDDRUID	D0B7HJ
D0B7HJ	DRUGNAME	U-54494A
D0B7HJ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated

D07PSP	TTDDRUID	D07PSP
D07PSP	DRUGNAME	U-75875
D07PSP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D09BRE	TTDDRUID	D09BRE
D09BRE	DRUGNAME	U-78517F
D09BRE	INDICATI	Asthma [ICD-11: CA23] Terminated

D0X3KX	TTDDRUID	D0X3KX
D0X3KX	DRUGNAME	U-80816
D0X3KX	INDICATI	Amnesia [ICD-11: MB21.1] Terminated

D08BCU	TTDDRUID	D08BCU
D08BCU	DRUGNAME	U-90042
D08BCU	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D07PAG	TTDDRUID	D07PAG
D07PAG	DRUGNAME	U-97456
D07PAG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated

D0L9PL	TTDDRUID	D0L9PL
D0L9PL	DRUGNAME	UC-38
D0L9PL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D0L2QJ	TTDDRUID	D0L2QJ
D0L2QJ	DRUGNAME	UC-84
D0L2QJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated

D06TEO	TTDDRUID	D06TEO
D06TEO	DRUGNAME	UCL-1390
D06TEO	INDICATI	Eating disorder [ICD-11: 6B82] Terminated
D06TEO	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
D06TEO	INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated

D0Z4VA	TTDDRUID	D0Z4VA
D0Z4VA	DRUGNAME	UD-CG-212
D0Z4VA	INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated

D0S1RT	TTDDRUID	D0S1RT
D0S1RT	DRUGNAME	UK-290795
D0S1RT	INDICATI	Urinary incontinence [ICD-11: MF50.2] Terminated

D08LLR	TTDDRUID	D08LLR
D08LLR	DRUGNAME	UK-51656
D08LLR	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0G1VS	TTDDRUID	D0G1VS
D0G1VS	DRUGNAME	UK-78282
D0G1VS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D0X8QI	TTDDRUID	D0X8QI
D0X8QI	DRUGNAME	UP-116-77
D0X8QI	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0N0JE	TTDDRUID	D0N0JE
D0N0JE	DRUGNAME	UP-275-22
D0N0JE	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D09FQB	TTDDRUID	D09FQB
D09FQB	DRUGNAME	UR-12460
D09FQB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0B7ND	TTDDRUID	D0B7ND
D0B7ND	DRUGNAME	UR-8225
D0B7ND	INDICATI	Asthma [ICD-11: CA23] Terminated

D0R7UK	TTDDRUID	D0R7UK
D0R7UK	DRUGNAME	UR-8308
D0R7UK	INDICATI	Asthma [ICD-11: CA23] Terminated

D0Q7WW	TTDDRUID	D0Q7WW
D0Q7WW	DRUGNAME	UR-8328
D0Q7WW	INDICATI	Asthma [ICD-11: CA23] Terminated

D02PAJ	TTDDRUID	D02PAJ
D02PAJ	DRUGNAME	UR-9650
D02PAJ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D0Q8FE	TTDDRUID	D0Q8FE
D0Q8FE	DRUGNAME	UR-9660
D0Q8FE	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated

D00WYV	TTDDRUID	D00WYV
D00WYV	DRUGNAME	V-3526
D00WYV	INDICATI	Encephalitis virus infection [ICD-11: 1C83-1C84] Terminated

D0Y1OF	TTDDRUID	D0Y1OF
D0Y1OF	DRUGNAME	VA-045
D0Y1OF	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated

D07UMR	TTDDRUID	D07UMR
D07UMR	DRUGNAME	Vaccine, prostate tumor
D07UMR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated

D0K9VK	TTDDRUID	D0K9VK
D0K9VK	DRUGNAME	Vaccine, Shigella flexneri
D0K9VK	INDICATI	Shigella infection [ICD-11: 1A02] Terminated

D0VP8P	TTDDRUID	D0VP8P
D0VP8P	DRUGNAME	Vaccine, Streptococcus pneumoniae
D0VP8P	INDICATI	Streptococcus infection [ICD-11: 1B53] Terminated

D05YHW	TTDDRUID	D05YHW
D05YHW	DRUGNAME	Vapaliximab
D05YHW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated

D03ZVW	TTDDRUID	D03ZVW
D03ZVW	DRUGNAME	Vapiprost
D03ZVW	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D08NQG	TTDDRUID	D08NQG
D08NQG	DRUGNAME	VB2-011
D08NQG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0A3HF	TTDDRUID	D0A3HF
D0A3HF	DRUGNAME	VE-16084
D0A3HF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D02WEL	TTDDRUID	D02WEL
D02WEL	DRUGNAME	VG-106
D02WEL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0A0CC	TTDDRUID	D0A0CC
D0A0CC	DRUGNAME	Viperfav
D0A0CC	INDICATI	Poison intoxication [ICD-11: NE6Z] Terminated

D08OLZ	TTDDRUID	D08OLZ
D08OLZ	DRUGNAME	Vitronectin antagonists
D08OLZ	INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated

D0UO9T	TTDDRUID	D0UO9T
D0UO9T	DRUGNAME	VR-147
D0UO9T	INDICATI	Migraine [ICD-11: 8A80] Terminated

D09RTF	TTDDRUID	D09RTF
D09RTF	DRUGNAME	VT-1
D09RTF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D0NH6F	TTDDRUID	D0NH6F
D0NH6F	DRUGNAME	VUF-8929
D0NH6F	INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated

D04ZCL	TTDDRUID	D04ZCL
D04ZCL	DRUGNAME	VZ-564
D04ZCL	INDICATI	Asthma [ICD-11: CA23] Terminated

D07BCO	TTDDRUID	D07BCO
D07BCO	DRUGNAME	WAY-100635
D07BCO	INDICATI	Eating disorder [ICD-11: 6B82] Terminated

D0CS0D	TTDDRUID	D0CS0D
D0CS0D	DRUGNAME	WAY-121898
D0CS0D	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D06MLZ	TTDDRUID	D06MLZ
D06MLZ	DRUGNAME	WAY-123223
D06MLZ	INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated

D02ZKB	TTDDRUID	D02ZKB
D02ZKB	DRUGNAME	WAY-126227
D02ZKB	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D02HCU	TTDDRUID	D02HCU
D02HCU	DRUGNAME	WEB-2347
D02HCU	INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated

D04EET	TTDDRUID	D04EET
D04EET	DRUGNAME	West Nile virus vaccine
D04EET	INDICATI	West nile virus infection [ICD-11: 1D46] Terminated

D09BHF	TTDDRUID	D09BHF
D09BHF	DRUGNAME	WF-2421
D09BHF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated

D00AWA	TTDDRUID	D00AWA
D00AWA	DRUGNAME	WIN-63759
D00AWA	INDICATI	Emphysema [ICD-11: CA21] Terminated

D07PLK	TTDDRUID	D07PLK
D07PLK	DRUGNAME	WIN-64821
D07PLK	INDICATI	Asthma [ICD-11: CA23] Terminated

D0V3PN	TTDDRUID	D0V3PN
D0V3PN	DRUGNAME	Withaferin A
D0V3PN	INDICATI	Melanoma [ICD-11: 2C30] Terminated

D0P1JI	TTDDRUID	D0P1JI
D0P1JI	DRUGNAME	Wortmannin
D0P1JI	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Terminated

D08GQK	TTDDRUID	D08GQK
D08GQK	DRUGNAME	WS-75624B
D08GQK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated

D0H0IA	TTDDRUID	D0H0IA
D0H0IA	DRUGNAME	WY-28342
D0H0IA	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D04YNI	TTDDRUID	D04YNI
D04YNI	DRUGNAME	WY-48989
D04YNI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D04AAR	TTDDRUID	D04AAR
D04AAR	DRUGNAME	XB-513
D04AAR	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated

D00HTT	TTDDRUID	D00HTT
D00HTT	DRUGNAME	XE-9
D00HTT	INDICATI	Transplant rejection [ICD-11: NE84] Terminated

D0Y0BC	TTDDRUID	D0Y0BC
D0Y0BC	DRUGNAME	XL-541
D0Y0BC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D09XYU	TTDDRUID	D09XYU
D09XYU	DRUGNAME	XR-12890
D09XYU	INDICATI	Asthma [ICD-11: CA23] Terminated

D07MWY	TTDDRUID	D07MWY
D07MWY	DRUGNAME	XR-1853
D07MWY	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0O1XU	TTDDRUID	D0O1XU
D0O1XU	DRUGNAME	XR-3005
D0O1XU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated

D0H2AM	TTDDRUID	D0H2AM
D0H2AM	DRUGNAME	XR-3054
D0H2AM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0P6CN	TTDDRUID	D0P6CN
D0P6CN	DRUGNAME	XR-368
D0P6CN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated

D0J9JQ	TTDDRUID	D0J9JQ
D0J9JQ	DRUGNAME	XR-5082
D0J9JQ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D06EQN	TTDDRUID	D06EQN
D06EQN	DRUGNAME	XR-510
D06EQN	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0YK7C	TTDDRUID	D0YK7C
D0YK7C	DRUGNAME	XR-5118
D0YK7C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D02ONK	TTDDRUID	D02ONK
D02ONK	DRUGNAME	Y-20024
D02ONK	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D0Q0HR	TTDDRUID	D0Q0HR
D0Q0HR	DRUGNAME	Y-931
D0Q0HR	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D03SVZ	TTDDRUID	D03SVZ
D03SVZ	DRUGNAME	Yersinia pestis vaccine
D03SVZ	INDICATI	Yersinia infection [ICD-11: 1B93] Terminated

D05HYL	TTDDRUID	D05HYL
D05HYL	DRUGNAME	YM-022
D05HYL	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated

D03WUH	TTDDRUID	D03WUH
D03WUH	DRUGNAME	YM-099
D03WUH	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D07OGR	TTDDRUID	D07OGR
D07OGR	DRUGNAME	YM-26734
D07OGR	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated

D0OW1R	TTDDRUID	D0OW1R
D0OW1R	DRUGNAME	YM-43611
D0OW1R	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated

D0YB6P	TTDDRUID	D0YB6P
D0YB6P	DRUGNAME	YP-004
D0YB6P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0L8TL	TTDDRUID	D0L8TL
D0L8TL	DRUGNAME	YP-008
D0L8TL	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated

D01AJM	TTDDRUID	D01AJM
D01AJM	DRUGNAME	YP-009
D01AJM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D06PAW	TTDDRUID	D06PAW
D06PAW	DRUGNAME	Z-4105
D06PAW	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0FF7A	TTDDRUID	D0FF7A
D0FF7A	DRUGNAME	Z-6568
D0FF7A	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0F0CS	TTDDRUID	D0F0CS
D0F0CS	DRUGNAME	ZARDAVERINE
D0F0CS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated

D0NR3V	TTDDRUID	D0NR3V
D0NR3V	DRUGNAME	Zatebradine
D0NR3V	INDICATI	Angina pectoris [ICD-11: BA40] Terminated

D05RMW	TTDDRUID	D05RMW
D05RMW	DRUGNAME	ZD-3638
D05RMW	INDICATI	Schizophrenia [ICD-11: 6A20] Terminated

D07VUD	TTDDRUID	D07VUD
D07VUD	DRUGNAME	ZD-3980
D07VUD	INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated

D0L5YF	TTDDRUID	D0L5YF
D0L5YF	DRUGNAME	ZD-4190
D0L5YF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D0B6BQ	TTDDRUID	D0B6BQ
D0B6BQ	DRUGNAME	ZD-6003
D0B6BQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D07GQA	TTDDRUID	D07GQA
D07GQA	DRUGNAME	ZD-7155
D07GQA	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D06YOD	TTDDRUID	D06YOD
D06YOD	DRUGNAME	ZD-7717
D06YOD	INDICATI	Asthma [ICD-11: CA23] Terminated

D0J3QU	TTDDRUID	D0J3QU
D0J3QU	DRUGNAME	ZD-7944
D0J3QU	INDICATI	Asthma [ICD-11: CA23] Terminated

D05KWY	TTDDRUID	D05KWY
D05KWY	DRUGNAME	ZD-9063P
D05KWY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated

D04GJX	TTDDRUID	D04GJX
D04GJX	DRUGNAME	ZD-9720
D04GJX	INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated

D0C7KK	TTDDRUID	D0C7KK
D0C7KK	DRUGNAME	Zenarestat
D0C7KK	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Terminated

D0TR4Z	TTDDRUID	D0TR4Z
D0TR4Z	DRUGNAME	Zindoxifene
D0TR4Z	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated

D07OEY	TTDDRUID	D07OEY
D07OEY	DRUGNAME	ZK-118182
D07OEY	INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated

D0H5CV	TTDDRUID	D0H5CV
D0H5CV	DRUGNAME	ZK-119010
D0H5CV	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Terminated

D0US3C	TTDDRUID	D0US3C
D0US3C	DRUGNAME	ZK-90695
D0US3C	INDICATI	Arthritis [ICD-11: FA20] Terminated

D02UIE	TTDDRUID	D02UIE
D02UIE	DRUGNAME	ZK-91296
D02UIE	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D0P3IE	TTDDRUID	D0P3IE
D0P3IE	DRUGNAME	ZK-93426
D0P3IE	INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated

D06BBZ	TTDDRUID	D06BBZ
D06BBZ	DRUGNAME	ZM-224832
D06BBZ	INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated

D0D8MD	TTDDRUID	D0D8MD
D0D8MD	DRUGNAME	ZM-230487
D0D8MD	INDICATI	Asthma [ICD-11: CA23] Terminated

D07BBD	TTDDRUID	D07BBD
D07BBD	DRUGNAME	Zona pellucida contraceptive vaccine
D07BBD	INDICATI	Contraception [ICD-11: QA21] Terminated

D0N0LB	TTDDRUID	D0N0LB
D0N0LB	DRUGNAME	zoxazolamine
D0N0LB	INDICATI	Multiple myeloma [ICD-11: 2A83] Terminated

D0E8JL	TTDDRUID	D0E8JL
D0E8JL	DRUGNAME	ZT-386
D0E8JL	INDICATI	Asthma [ICD-11: CA23] Terminated

D0C7LA	TTDDRUID	D0C7LA
D0C7LA	DRUGNAME	36220
D0C7LA	INDICATI	Asthma [ICD-11: CA23] Investigative

D0C7NU	TTDDRUID	D0C7NU
D0C7NU	DRUGNAME	(S)-8-Hydroxy palmitic acid
D0C7NU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04ACD	TTDDRUID	D04ACD
D04ACD	DRUGNAME	[111In]B3
D04ACD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06JKV	TTDDRUID	D06JKV
D06JKV	DRUGNAME	[111In]SRVII23
D06JKV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0O1DS	TTDDRUID	D0O1DS
D0O1DS	DRUGNAME	[123I] iodobenzoyl 12-Ex4
D0O1DS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0EW9U	TTDDRUID	D0EW9U
D0EW9U	DRUGNAME	[18F]DCFPyL
D0EW9U	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0M9RM	TTDDRUID	D0M9RM
D0M9RM	DRUGNAME	[3H]CGS8216
D0M9RM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0E9SR	TTDDRUID	D0E9SR
D0E9SR	DRUGNAME	[3H]JNJ 7777120
D0E9SR	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0YM8K	TTDDRUID	D0YM8K
D0YM8K	DRUGNAME	[99mTc]Met
D0YM8K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05RLR	TTDDRUID	D05RLR
D05RLR	DRUGNAME	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
D05RLR	INDICATI	Conjunctival fibrosis [ICD-11: 9A61.3] Investigative

D07DZS	TTDDRUID	D07DZS
D07DZS	DRUGNAME	1,3-bis(1,3-benzothiazol-2-ylthio)acetone
D07DZS	INDICATI	Glioma [ICD-11: 2A00.0] Investigative
D07DZS	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0M5UL	TTDDRUID	D0M5UL
D0M5UL	DRUGNAME	1,5-Benzodiazepines series
D0M5UL	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0N7XY	TTDDRUID	D0N7XY
D0N7XY	DRUGNAME	111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico
D0N7XY	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0X1IB	TTDDRUID	D0X1IB
D0X1IB	DRUGNAME	111In-labeled LFA-1 targeted imaging agent (lymphoma/leukemia), NuView/University of New Mexico
D0X1IB	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D0K4WW	TTDDRUID	D0K4WW
D0K4WW	DRUGNAME	11A1
D0K4WW	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D02WRO	TTDDRUID	D02WRO
D02WRO	DRUGNAME	11-beta-HSD1 inhibitors
D02WRO	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0CG0G	TTDDRUID	D0CG0G
D0CG0G	DRUGNAME	11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitors
D0CG0G	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0XW8R	TTDDRUID	D0XW8R
D0XW8R	DRUGNAME	11C-R-129144
D0XW8R	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D01GAZ	TTDDRUID	D01GAZ
D01GAZ	DRUGNAME	123I-DRM-106
D01GAZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0IV7J	TTDDRUID	D0IV7J
D0IV7J	DRUGNAME	131I-COU-1
D0IV7J	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D0U5YJ	TTDDRUID	D0U5YJ
D0U5YJ	DRUGNAME	14F7 humanized mab, The Center of Molecular Immunology
D0U5YJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T8RQ	TTDDRUID	D0T8RQ
D0T8RQ	DRUGNAME	166Ho-phytate
D0T8RQ	INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative

D0Q7YU	TTDDRUID	D0Q7YU
D0Q7YU	DRUGNAME	17beta-HSD1 inhibitor
D0Q7YU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0H7TB	TTDDRUID	D0H7TB
D0H7TB	DRUGNAME	18F labeled ethanolamine derivatives (cancer imaging), Bayer Schering
D0H7TB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08GHI	TTDDRUID	D08GHI
D08GHI	DRUGNAME	18F-AV-45 dimer
D08GHI	INDICATI	Cerebral amyloid angiopathy [ICD-11: 5D00.0] Investigative

D0Y5OP	TTDDRUID	D0Y5OP
D0Y5OP	DRUGNAME	18F-fluoromethylallylcholine
D0Y5OP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02SZF	TTDDRUID	D02SZF
D02SZF	DRUGNAME	18F-SMIBR-K5
D02SZF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0NB5K	TTDDRUID	D0NB5K
D0NB5K	DRUGNAME	18F-VEGF binding peptides (PET imaging), Genentech
D0NB5K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08BKH	TTDDRUID	D08BKH
D08BKH	DRUGNAME	18-Methoxycoronaridine
D08BKH	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative

D0R0RW	TTDDRUID	D0R0RW
D0R0RW	DRUGNAME	1D05
D0R0RW	INDICATI	Coronary artery disease [ICD-11: BA80] Investigative

D04QFX	TTDDRUID	D04QFX
D04QFX	DRUGNAME	1-TDC
D04QFX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0NP8M	TTDDRUID	D0NP8M
D0NP8M	DRUGNAME	209-342
D0NP8M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D3LZ	TTDDRUID	D0D3LZ
D0D3LZ	DRUGNAME	20D75
D0D3LZ	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0Q0OY	TTDDRUID	D0Q0OY
D0Q0OY	DRUGNAME	213-Bi DOTA-PESIN
D0Q0OY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03SMB	TTDDRUID	D03SMB
D03SMB	DRUGNAME	2-18F-FE-5-Br-glyburide
D03SMB	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D00RTU	TTDDRUID	D00RTU
D00RTU	DRUGNAME	227Th-rituximab (cancer), Algeta
D00RTU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BY0Y	TTDDRUID	D0BY0Y
D0BY0Y	DRUGNAME	227Th-trastuzumab (cancer), Algeta
D0BY0Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08RUN	TTDDRUID	D08RUN
D08RUN	DRUGNAME	2-Bromopalmitate (autoimmune/inflammatory disease), MSKCC
D08RUN	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0LQ2Y	TTDDRUID	D0LQ2Y
D0LQ2Y	DRUGNAME	2CVV
D0LQ2Y	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D00GLQ	TTDDRUID	D00GLQ
D00GLQ	DRUGNAME	2LM20-4
D00GLQ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0P4MA	TTDDRUID	D0P4MA
D0P4MA	DRUGNAME	2-MOE phosphorothioate gapmers (myotonic dystrophy), Genzyme/Isis Pharmaceuticals
D0P4MA	INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Investigative

D0D2UA	TTDDRUID	D0D2UA
D0D2UA	DRUGNAME	2-NAP
D0D2UA	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D02SAK	TTDDRUID	D02SAK
D02SAK	DRUGNAME	2NTX-99
D02SAK	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D09YWX	TTDDRUID	D09YWX
D09YWX	DRUGNAME	2-quinolines series, Leishmaniasis, DNDi/CDRI/Advinus Therapeutics
D09YWX	INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative

D0H9GH	TTDDRUID	D0H9GH
D0H9GH	DRUGNAME	31.1Chi
D0H9GH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A3SQ	TTDDRUID	D0A3SQ
D0A3SQ	DRUGNAME	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile
D0A3SQ	INDICATI	Glioma [ICD-11: 2A00.0] Investigative
D0A3SQ	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0LL7C	TTDDRUID	D0LL7C
D0LL7C	DRUGNAME	3C23K
D0LL7C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09KSW	TTDDRUID	D09KSW
D09KSW	DRUGNAME	3-CLA
D09KSW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C9DB	TTDDRUID	D0C9DB
D0C9DB	DRUGNAME	424C79
D0C9DB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D01BOE	TTDDRUID	D01BOE
D01BOE	DRUGNAME	44-Bu
D01BOE	INDICATI	Heart arrhythmia [ICD-11: BC65] Investigative

D06BTD	TTDDRUID	D06BTD
D06BTD	DRUGNAME	4Ab-028
D06BTD	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D0U2QX	TTDDRUID	D0U2QX
D0U2QX	DRUGNAME	4-ethynyl-2-fluoro-deoxyadenosine
D0U2QX	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D07KIB	TTDDRUID	D07KIB
D07KIB	DRUGNAME	4-fluoroselegiline
D07KIB	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D09RPU	TTDDRUID	D09RPU
D09RPU	DRUGNAME	4'-GALACTOSYLLACTOSE
D09RPU	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D0S9QJ	TTDDRUID	D0S9QJ
D0S9QJ	DRUGNAME	4-IPP
D0S9QJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G6BU	TTDDRUID	D0G6BU
D0G6BU	DRUGNAME	4pox
D0G6BU	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D05NSF	TTDDRUID	D05NSF
D05NSF	DRUGNAME	4SC-207
D05NSF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A3AJ	TTDDRUID	D0A3AJ
D0A3AJ	DRUGNAME	4SC-301
D0A3AJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0R5NB	TTDDRUID	D0R5NB
D0R5NB	DRUGNAME	4SC-302
D0R5NB	INDICATI	Flavivirus infection [ICD-11: 1C80] Investigative

D0AS0V	TTDDRUID	D0AS0V
D0AS0V	DRUGNAME	5,8-Dihydroxy-1,4-naphthoquinone
D0AS0V	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D08IKV	TTDDRUID	D08IKV
D08IKV	DRUGNAME	58-1066
D08IKV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06BFH	TTDDRUID	D06BFH
D06BFH	DRUGNAME	5-fluoro-1H-indole-2-carboxylic acid
D06BFH	INDICATI	Glioma [ICD-11: 2A00.0] Investigative
D06BFH	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0L8RC	TTDDRUID	D0L8RC
D0L8RC	DRUGNAME	5-FU, Galectin
D0L8RC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D0UU5O	TTDDRUID	D0UU5O
D0UU5O	DRUGNAME	5-HT 2c receptor agonists (obesity/schizophrenia), Galenea
D0UU5O	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0F4HJ	TTDDRUID	D0F4HJ
D0F4HJ	DRUGNAME	5-HT 6 antagonists
D0F4HJ	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0PN6C	TTDDRUID	D0PN6C
D0PN6C	DRUGNAME	5-HT 6 receptor antagonists
D0PN6C	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0T4XJ	TTDDRUID	D0T4XJ
D0T4XJ	DRUGNAME	5-HT2c agonists (metabolic disorders), Boehringer
D0T4XJ	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0K2ZG	TTDDRUID	D0K2ZG
D0K2ZG	DRUGNAME	5-LO (pain/neuro-inflammation), St Charles Pharmaceuticals
D0K2ZG	INDICATI	Nervous system inflammation [ICD-11: 1D0Y] Investigative

D0OQ5H	TTDDRUID	D0OQ5H
D0OQ5H	DRUGNAME	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
D0OQ5H	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0F4FN	TTDDRUID	D0F4FN
D0F4FN	DRUGNAME	68Ga-DOTA-AE-105
D0F4FN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y0ID	TTDDRUID	D0Y0ID
D0Y0ID	DRUGNAME	6-azacytidine, National Academy of Sciences of Ukraine
D0Y0ID	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08WYO	TTDDRUID	D08WYO
D08WYO	DRUGNAME	6F4
D08WYO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G9ZY	TTDDRUID	D0G9ZY
D0G9ZY	DRUGNAME	76Br-16alpha,17alpha-dioxolane progestin
D0G9ZY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0HY4Q	TTDDRUID	D0HY4Q
D0HY4Q	DRUGNAME	98mTC-CIM-ANT
D0HY4Q	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Investigative

D0B7TH	TTDDRUID	D0B7TH
D0B7TH	DRUGNAME	99mTc-biciromab
D0B7TH	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0Z9BU	TTDDRUID	D0Z9BU
D0Z9BU	DRUGNAME	99mTc-EC-0652
D0Z9BU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D04WSK	TTDDRUID	D04WSK
D04WSK	DRUGNAME	99mTc-ImmuRAID-LL1
D04WSK	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0K3GB	TTDDRUID	D0K3GB
D0K3GB	DRUGNAME	99mTc-MIP-1340
D0K3GB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D06WYG	TTDDRUID	D06WYG
D06WYG	DRUGNAME	99mTc-MIP-1407
D06WYG	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Investigative

D08QRT	TTDDRUID	D08QRT
D08QRT	DRUGNAME	99mTc-siboroxime
D08QRT	INDICATI	Diagnostic imaging [ICD-11: N.A.] Investigative

D0Q6JY	TTDDRUID	D0Q6JY
D0Q6JY	DRUGNAME	A-003
D0Q6JY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D00QTA	TTDDRUID	D00QTA
D00QTA	DRUGNAME	A-058
D00QTA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0N3OH	TTDDRUID	D0N3OH
D0N3OH	DRUGNAME	A-317920
D0N3OH	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative

D0J6XO	TTDDRUID	D0J6XO
D0J6XO	DRUGNAME	A-331440
D0J6XO	INDICATI	Obesity [ICD-11: 5B81] Investigative

D03WZJ	TTDDRUID	D03WZJ
D03WZJ	DRUGNAME	A33-Ac-225
D03WZJ	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D0A6NP	TTDDRUID	D0A6NP
D0A6NP	DRUGNAME	A35566-A
D0A6NP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03GAN	TTDDRUID	D03GAN
D03GAN	DRUGNAME	A-558693
D03GAN	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0VY5O	TTDDRUID	D0VY5O
D0VY5O	DRUGNAME	A-620223
D0VY5O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M8LN	TTDDRUID	D0M8LN
D0M8LN	DRUGNAME	A-690344
D0M8LN	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D09LTO	TTDDRUID	D09LTO
D09LTO	DRUGNAME	A-76341
D09LTO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D08TXL	TTDDRUID	D08TXL
D08TXL	DRUGNAME	A-796260
D08TXL	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0FF6S	TTDDRUID	D0FF6S
D0FF6S	DRUGNAME	A-803467
D0FF6S	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0XG0Z	TTDDRUID	D0XG0Z
D0XG0Z	DRUGNAME	A-82186
D0XG0Z	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D04ZEP	TTDDRUID	D04ZEP
D04ZEP	DRUGNAME	A-849531
D04ZEP	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D04TPS	TTDDRUID	D04TPS
D04TPS	DRUGNAME	A-887755
D04TPS	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D02RUZ	TTDDRUID	D02RUZ
D02RUZ	DRUGNAME	A-922500
D02RUZ	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D05RFO	TTDDRUID	D05RFO
D05RFO	DRUGNAME	A-928605
D05RFO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U9UF	TTDDRUID	D0U9UF
D0U9UF	DRUGNAME	A-967079
D0U9UF	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0M7NA	TTDDRUID	D0M7NA
D0M7NA	DRUGNAME	A-993610
D0M7NA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0JQ4R	TTDDRUID	D0JQ4R
D0JQ4R	DRUGNAME	AA-10022
D0JQ4R	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D01HWK	TTDDRUID	D01HWK
D01HWK	DRUGNAME	AA-10044
D01HWK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0B8ES	TTDDRUID	D0B8ES
D0B8ES	DRUGNAME	AA-123
D0B8ES	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0F8VH	TTDDRUID	D0F8VH
D0F8VH	DRUGNAME	AA-166
D0F8VH	INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Investigative

D00LZY	TTDDRUID	D00LZY
D00LZY	DRUGNAME	AA-184
D00LZY	INDICATI	Kidney injury [ICD-11: NB92.0] Investigative

D04JCT	TTDDRUID	D04JCT
D04JCT	DRUGNAME	AA-204
D04JCT	INDICATI	Kidney disease [ICD-11: GC2Z] Investigative

D02ZMI	TTDDRUID	D02ZMI
D02ZMI	DRUGNAME	AA-29504
D02ZMI	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D00NYL	TTDDRUID	D00NYL
D00NYL	DRUGNAME	AAV2/8-CBA-hSMN1
D00NYL	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Investigative

D0MF3F	TTDDRUID	D0MF3F
D0MF3F	DRUGNAME	AAV8-773
D0MF3F	INDICATI	Achromatopsia [ICD-11: 9B70] Investigative

D0E9DP	TTDDRUID	D0E9DP
D0E9DP	DRUGNAME	AAV-IGF
D0E9DP	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0S8MN	TTDDRUID	D0S8MN
D0S8MN	DRUGNAME	AAV-miApoB
D0S8MN	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D02DWN	TTDDRUID	D02DWN
D02DWN	DRUGNAME	AB-0440a
D02DWN	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0C5VP	TTDDRUID	D0C5VP
D0C5VP	DRUGNAME	AB-1003
D0C5VP	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative

D0P3ZA	TTDDRUID	D0P3ZA
D0P3ZA	DRUGNAME	AB-3001
D0P3ZA	INDICATI	Syndrome X [ICD-11: 5C53.4] Investigative

D0F6DF	TTDDRUID	D0F6DF
D0F6DF	DRUGNAME	AB-3D3
D0F6DF	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D05KHP	TTDDRUID	D05KHP
D05KHP	DRUGNAME	ABC-3
D05KHP	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D08HZN	TTDDRUID	D08HZN
D08HZN	DRUGNAME	ABC-4
D08HZN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BG2L	TTDDRUID	D0BG2L
D0BG2L	DRUGNAME	ABC-7
D0BG2L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0HB2F	TTDDRUID	D0HB2F
D0HB2F	DRUGNAME	ABD-035
D0HB2F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OT9U	TTDDRUID	D0OT9U
D0OT9U	DRUGNAME	Abeta retroparticles
D0OT9U	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0I9GA	TTDDRUID	D0I9GA
D0I9GA	DRUGNAME	AbGn-100
D0I9GA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I6UN	TTDDRUID	D0I6UN
D0I6UN	DRUGNAME	AbGn-150
D0I6UN	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0S5NN	TTDDRUID	D0S5NN
D0S5NN	DRUGNAME	ABI-010
D0S5NN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A5CL	TTDDRUID	D0A5CL
D0A5CL	DRUGNAME	ABI-200
D0A5CL	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D07ELC	TTDDRUID	D07ELC
D07ELC	DRUGNAME	ABI-2088
D07ELC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01EPO	TTDDRUID	D01EPO
D01EPO	DRUGNAME	ABIO 09-01
D01EPO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0E5CX	TTDDRUID	D0E5CX
D0E5CX	DRUGNAME	Abloid
D0E5CX	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D03HMM	TTDDRUID	D03HMM
D03HMM	DRUGNAME	ABS-201
D03HMM	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative

D05APW	TTDDRUID	D05APW
D05APW	DRUGNAME	ABT-116
D05APW	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D04HTL	TTDDRUID	D04HTL
D04HTL	DRUGNAME	ABX-0402
D04HTL	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0L0RX	TTDDRUID	D0L0RX
D0L0RX	DRUGNAME	ABX-101
D0L0RX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06YAG	TTDDRUID	D06YAG
D06YAG	DRUGNAME	ABX-102
D06YAG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D3SW	TTDDRUID	D0D3SW
D0D3SW	DRUGNAME	ABX-103
D0D3SW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06LUH	TTDDRUID	D06LUH
D06LUH	DRUGNAME	ABX-201
D06LUH	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D04IBI	TTDDRUID	D04IBI
D04IBI	DRUGNAME	ABX-301
D04IBI	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0S6NJ	TTDDRUID	D0S6NJ
D0S6NJ	DRUGNAME	AC-03-636
D0S6NJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03TOH	TTDDRUID	D03TOH
D03TOH	DRUGNAME	AC-0523
D03TOH	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D02KYP	TTDDRUID	D02KYP
D02KYP	DRUGNAME	AC-101
D02KYP	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D04OCO	TTDDRUID	D04OCO
D04OCO	DRUGNAME	AC-163954
D04OCO	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0NY1R	TTDDRUID	D0NY1R
D0NY1R	DRUGNAME	AC-3174
D0NY1R	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative

D03TDE	TTDDRUID	D03TDE
D03TDE	DRUGNAME	AC-4402
D03TDE	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0E1UY	TTDDRUID	D0E1UY
D0E1UY	DRUGNAME	AC-501
D0E1UY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D0V4EX	TTDDRUID	D0V4EX
D0V4EX	DRUGNAME	AC-710
D0V4EX	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0T0RU	TTDDRUID	D0T0RU
D0T0RU	DRUGNAME	AC-8
D0T0RU	INDICATI	Herpetic keratitis [ICD-11: 1F00.10] Investigative

D0P7HI	TTDDRUID	D0P7HI
D0P7HI	DRUGNAME	AC-8632
D0P7HI	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0S0CW	TTDDRUID	D0S0CW
D0S0CW	DRUGNAME	AcALY-18
D0S0CW	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D07EVV	TTDDRUID	D07EVV
D07EVV	DRUGNAME	Acamprosate prodrugs
D07EVV	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative

D0IM3P	TTDDRUID	D0IM3P
D0IM3P	DRUGNAME	ACC2 project
D0IM3P	INDICATI	Obesity [ICD-11: 5B81] Investigative

D05YYB	TTDDRUID	D05YYB
D05YYB	DRUGNAME	ACE-06X
D05YYB	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0S5TT	TTDDRUID	D0S5TT
D0S5TT	DRUGNAME	ACE-435
D0S5TT	INDICATI	Cachexia [ICD-11: MG20] Investigative

D0X1NX	TTDDRUID	D0X1NX
D0X1NX	DRUGNAME	ACE-920
D0X1NX	INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative

D09LZN	TTDDRUID	D09LZN
D09LZN	DRUGNAME	ACER-001
D09LZN	INDICATI	Maple-syrup-urine disease [ICD-11: 5C50.D0] Investigative

D01PNV	TTDDRUID	D01PNV
D01PNV	DRUGNAME	Acetyl CoA carboxylase inhibitors
D01PNV	INDICATI	Obesity [ICD-11: 5B81] Investigative

D01ZDQ	TTDDRUID	D01ZDQ
D01ZDQ	DRUGNAME	ACH-1095
D01ZDQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0XR6B	TTDDRUID	D0XR6B
D0XR6B	DRUGNAME	ACH-2881
D0XR6B	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0UZ0X	TTDDRUID	D0UZ0X
D0UZ0X	DRUGNAME	ACH-2892
D0UZ0X	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D05LOY	TTDDRUID	D05LOY
D05LOY	DRUGNAME	ACH-702
D05LOY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0F0VD	TTDDRUID	D0F0VD
D0F0VD	DRUGNAME	ACHP
D0F0VD	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D07KMI	TTDDRUID	D07KMI
D07KMI	DRUGNAME	ACI-518
D07KMI	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D06MBR	TTDDRUID	D06MBR
D06MBR	DRUGNAME	ACI-636
D06MBR	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09PJK	TTDDRUID	D09PJK
D09PJK	DRUGNAME	ACK-1 inhibitors
D09PJK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U2EF	TTDDRUID	D0U2EF
D0U2EF	DRUGNAME	ACN-1052
D0U2EF	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0P3FY	TTDDRUID	D0P3FY
D0P3FY	DRUGNAME	Acne therapy, transdermal/ TPM
D0P3FY	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D0M2JA	TTDDRUID	D0M2JA
D0M2JA	DRUGNAME	ACP-106
D0M2JA	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0T6NS	TTDDRUID	D0T6NS
D0T6NS	DRUGNAME	ACPC
D0T6NS	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D01VAA	TTDDRUID	D01VAA
D01VAA	DRUGNAME	ACR-125
D01VAA	INDICATI	Keratosis [ICD-11: ED56] Investigative

D0P8VZ	TTDDRUID	D0P8VZ
D0P8VZ	DRUGNAME	ACS-14
D0P8VZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D05JLG	TTDDRUID	D05JLG
D05JLG	DRUGNAME	ACS-6
D05JLG	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Investigative

D06IGC	TTDDRUID	D06IGC
D06IGC	DRUGNAME	ACT-0932
D06IGC	INDICATI	Glioma [ICD-11: 2A00.0] Investigative

D0R6OM	TTDDRUID	D0R6OM
D0R6OM	DRUGNAME	ACTB-1003
D0R6OM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00FRQ	TTDDRUID	D00FRQ
D00FRQ	DRUGNAME	Actinomycetes metabolites
D00FRQ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0B5QK	TTDDRUID	D0B5QK
D0B5QK	DRUGNAME	Activated adult marrow stromal cells
D0B5QK	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0R9QW	TTDDRUID	D0R9QW
D0R9QW	DRUGNAME	Activin-like kinase 5 inhibitor
D0R9QW	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative

D02AWC	TTDDRUID	D02AWC
D02AWC	DRUGNAME	ActoBiotic
D02AWC	INDICATI	Gastrointestinal infection [ICD-11: 1A40.Z] Investigative

D0JX7K	TTDDRUID	D0JX7K
D0JX7K	DRUGNAME	ActoBiotics
D0JX7K	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D09MRY	TTDDRUID	D09MRY
D09MRY	DRUGNAME	ACU-0101979
D09MRY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0GK9J	TTDDRUID	D0GK9J
D0GK9J	DRUGNAME	ACVR2B
D0GK9J	INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative

D0F3GA	TTDDRUID	D0F3GA
D0F3GA	DRUGNAME	Acyclic nucleoside phosphonates
D0F3GA	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D08YRO	TTDDRUID	D08YRO
D08YRO	DRUGNAME	Ad VEGF-C
D08YRO	INDICATI	Lymphatic disease [ICD-11: BD9Z] Investigative

D01IHV	TTDDRUID	D01IHV
D01IHV	DRUGNAME	AD-0027
D01IHV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y9ES	TTDDRUID	D0Y9ES
D0Y9ES	DRUGNAME	AD-0802
D0Y9ES	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0KC9V	TTDDRUID	D0KC9V
D0KC9V	DRUGNAME	AD10-1025
D0KC9V	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0M2AN	TTDDRUID	D0M2AN
D0M2AN	DRUGNAME	AD-412
D0M2AN	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D04UYY	TTDDRUID	D04UYY
D04UYY	DRUGNAME	AD5-10
D04UYY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q8PF	TTDDRUID	D0Q8PF
D0Q8PF	DRUGNAME	Ad5f35-LMPd1-2-transduced autologous dendritic cells
D0Q8PF	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D03VUV	TTDDRUID	D03VUV
D03VUV	DRUGNAME	Adarotene ester derivative back-up compounds
D03VUV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01NGB	TTDDRUID	D01NGB
D01NGB	DRUGNAME	ADC-1001
D01NGB	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0G0AQ	TTDDRUID	D0G0AQ
D0G0AQ	DRUGNAME	ADC-1012
D0G0AQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0TA3V	TTDDRUID	D0TA3V
D0TA3V	DRUGNAME	ADC-5510
D0TA3V	INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Investigative

D0K2MT	TTDDRUID	D0K2MT
D0K2MT	DRUGNAME	ADC-7828
D0K2MT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0U3YW	TTDDRUID	D0U3YW
D0U3YW	DRUGNAME	ADC-9971
D0U3YW	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D04AYH	TTDDRUID	D04AYH
D04AYH	DRUGNAME	ADE-CRAN
D04AYH	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0M0CU	TTDDRUID	D0M0CU
D0M0CU	DRUGNAME	ADE-DERM
D0M0CU	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative

D0O4RG	TTDDRUID	D0O4RG
D0O4RG	DRUGNAME	ADE-HYPT
D0O4RG	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D03MLR	TTDDRUID	D03MLR
D03MLR	DRUGNAME	ADE-LAM
D03MLR	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D07OQZ	TTDDRUID	D07OQZ
D07OQZ	DRUGNAME	Adenosine A2b antagonists
D07OQZ	INDICATI	Asthma [ICD-11: CA23] Investigative

D05RRO	TTDDRUID	D05RRO
D05RRO	DRUGNAME	Adenosine analog DNA ligase inhibitors
D05RRO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D01ATW	TTDDRUID	D01ATW
D01ATW	DRUGNAME	Adenovirus gene therapy (Maroteux-Lamy syndrome)
D01ATW	INDICATI	Maroteaux-lamy syndrome [ICD-11: 5C56.33] Investigative

D07SOJ	TTDDRUID	D07SOJ
D07SOJ	DRUGNAME	Adenovirus/Semliki Forest virus hybrid vector delivered IL-12 immunotherapy
D07SOJ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D07ZBO	TTDDRUID	D07ZBO
D07ZBO	DRUGNAME	ADepVac
D07ZBO	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D01OMO	TTDDRUID	D01OMO
D01OMO	DRUGNAME	AdHSV-2
D01OMO	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0Q7OR	TTDDRUID	D0Q7OR
D0Q7OR	DRUGNAME	AdHu5-ZGP
D0Q7OR	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D0R1DX	TTDDRUID	D0R1DX
D0R1DX	DRUGNAME	Adiponectin mimetics
D0R1DX	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0S6AH	TTDDRUID	D0S6AH
D0S6AH	DRUGNAME	Adiptin
D0S6AH	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0P2FC	TTDDRUID	D0P2FC
D0P2FC	DRUGNAME	ADMDD-15
D0P2FC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04VCF	TTDDRUID	D04VCF
D04VCF	DRUGNAME	ADR58
D04VCF	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D04DQP	TTDDRUID	D04DQP
D04DQP	DRUGNAME	ADRIAC-36
D04DQP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G9XS	TTDDRUID	D0G9XS
D0G9XS	DRUGNAME	ADS-0101
D0G9XS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0P6CQ	TTDDRUID	D0P6CQ
D0P6CQ	DRUGNAME	ADS-NPTMZ-1
D0P6CQ	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0F3ON	TTDDRUID	D0F3ON
D0F3ON	DRUGNAME	Adv-005
D0F3ON	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D02LMR	TTDDRUID	D02LMR
D02LMR	DRUGNAME	Adva-27a
D02LMR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05NLR	TTDDRUID	D05NLR
D05NLR	DRUGNAME	Adva-33c
D05NLR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E0IK	TTDDRUID	D0E0IK
D0E0IK	DRUGNAME	Adva-R46
D0E0IK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E0DL	TTDDRUID	D0E0DL
D0E0DL	DRUGNAME	ADX40-TB
D0E0DL	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0K0ZK	TTDDRUID	D0K0ZK
D0K0ZK	DRUGNAME	ADX-63365
D0K0ZK	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D05GQH	TTDDRUID	D05GQH
D05GQH	DRUGNAME	ADX-88178
D05GQH	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D08DJP	TTDDRUID	D08DJP
D08DJP	DRUGNAME	AE-298p
D08DJP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0IM7C	TTDDRUID	D0IM7C
D0IM7C	DRUGNAME	AE-9C90CB
D0IM7C	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D0AK2V	TTDDRUID	D0AK2V
D0AK2V	DRUGNAME	AEH-10p
D0AK2V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01VNQ	TTDDRUID	D01VNQ
D01VNQ	DRUGNAME	AEM-18
D01VNQ	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative

D0U4PG	TTDDRUID	D0U4PG
D0U4PG	DRUGNAME	AEOL-11207
D0U4PG	INDICATI	Asthma [ICD-11: CA23] Investigative

D07YRJ	TTDDRUID	D07YRJ
D07YRJ	DRUGNAME	AERAS-405
D07YRJ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D08XFR	TTDDRUID	D08XFR
D08XFR	DRUGNAME	AEZS-115
D08XFR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06KGC	TTDDRUID	D06KGC
D06KGC	DRUGNAME	AEZS-120
D06KGC	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D03FIE	TTDDRUID	D03FIE
D03FIE	DRUGNAME	AEZS-126
D03FIE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07NEE	TTDDRUID	D07NEE
D07NEE	DRUGNAME	AEZS-131
D07NEE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0IY2M	TTDDRUID	D0IY2M
D0IY2M	DRUGNAME	AF-11
D0IY2M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07QTB	TTDDRUID	D07QTB
D07QTB	DRUGNAME	AF-243
D07QTB	INDICATI	Deafness [ICD-11: AB52] Investigative

D00LWD	TTDDRUID	D00LWD
D00LWD	DRUGNAME	AF-3473
D00LWD	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0R8JN	TTDDRUID	D0R8JN
D0R8JN	DRUGNAME	AF-3485
D0R8JN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0N1ST	TTDDRUID	D0N1ST
D0N1ST	DRUGNAME	AFC-5128
D0N1ST	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D02MFK	TTDDRUID	D02MFK
D02MFK	DRUGNAME	Affinitak + Cisplatin
D02MFK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D0K4GI	TTDDRUID	D0K4GI
D0K4GI	DRUGNAME	Affinitak + Gemcitabine
D0K4GI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D04EXW	TTDDRUID	D04EXW
D04EXW	DRUGNAME	A-Fizz
D04EXW	INDICATI	Anal fistula [ICD-11: DB50.1] Investigative

D0E9KC	TTDDRUID	D0E9KC
D0E9KC	DRUGNAME	AFM-15
D0E9KC	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0F2OG	TTDDRUID	D0F2OG
D0F2OG	DRUGNAME	AFM-19
D0F2OG	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D08JTN	TTDDRUID	D08JTN
D08JTN	DRUGNAME	AFM-20
D08JTN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02FGG	TTDDRUID	D02FGG
D02FGG	DRUGNAME	AFM-21
D02FGG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07ISD	TTDDRUID	D07ISD
D07ISD	DRUGNAME	AFPep
D07ISD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0H1OO	TTDDRUID	D0H1OO
D0H1OO	DRUGNAME	AFT-EPO
D0H1OO	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0N6CC	TTDDRUID	D0N6CC
D0N6CC	DRUGNAME	AFX-300
D0N6CC	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D08GSM	TTDDRUID	D08GSM
D08GSM	DRUGNAME	AG-014
D08GSM	INDICATI	Coeliac disease [ICD-11: DA95] Investigative

D0SO0U	TTDDRUID	D0SO0U
D0SO0U	DRUGNAME	AG-122005
D0SO0U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A6WQ	TTDDRUID	D0A6WQ
D0A6WQ	DRUGNAME	AG-4070
D0A6WQ	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0CT3I	TTDDRUID	D0CT3I
D0CT3I	DRUGNAME	AgaDerm
D0CT3I	INDICATI	Dermatomycosis [ICD-11: EA60] Investigative

D0LP4X	TTDDRUID	D0LP4X
D0LP4X	DRUGNAME	Aganirsen
D0LP4X	INDICATI	Genitourinary tract cancer [ICD-11: 2C8Z] Investigative

D05VDI	TTDDRUID	D05VDI
D05VDI	DRUGNAME	Aggrecanase-2 inhibitors
D05VDI	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D05ORI	TTDDRUID	D05ORI
D05ORI	DRUGNAME	AGI-350
D05ORI	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative

D0DH1S	TTDDRUID	D0DH1S
D0DH1S	DRUGNAME	Aglycoristocetin derivatives
D0DH1S	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0I7YR	TTDDRUID	D0I7YR
D0I7YR	DRUGNAME	AG-NCA805
D0I7YR	INDICATI	Asthma [ICD-11: CA23] Investigative

D09AFE	TTDDRUID	D09AFE
D09AFE	DRUGNAME	AG-NDP803
D09AFE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D08QLL	TTDDRUID	D08QLL
D08QLL	DRUGNAME	AG-NDT802
D08QLL	INDICATI	Cough [ICD-11: MD12] Investigative

D08KEC	TTDDRUID	D08KEC
D08KEC	DRUGNAME	AG-NPN803
D08KEC	INDICATI	Nephritis [ICD-11: GB40] Investigative

D01YSU	TTDDRUID	D01YSU
D01YSU	DRUGNAME	AG-PPC709
D01YSU	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D0JO3X	TTDDRUID	D0JO3X
D0JO3X	DRUGNAME	AG-SDT102
D0JO3X	INDICATI	Genitourinary disease [ICD-11: GA0Z-GC8Z] Investigative

D0R6GB	TTDDRUID	D0R6GB
D0R6GB	DRUGNAME	AG-SFT103
D0R6GB	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0L6IF	TTDDRUID	D0L6IF
D0L6IF	DRUGNAME	AGT-0031
D0L6IF	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0C5WE	TTDDRUID	D0C5WE
D0C5WE	DRUGNAME	AGT-2000
D0C5WE	INDICATI	Brain cancer [ICD-11: 2A00] Investigative

D0Y4XN	TTDDRUID	D0Y4XN
D0Y4XN	DRUGNAME	AGX-1009
D0Y4XN	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0Y0TQ	TTDDRUID	D0Y0TQ
D0Y0TQ	DRUGNAME	AGX-1053
D0Y0TQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G5RQ	TTDDRUID	D0G5RQ
D0G5RQ	DRUGNAME	AGX-51
D0G5RQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T8EL	TTDDRUID	D0T8EL
D0T8EL	DRUGNAME	AHL
D0T8EL	INDICATI	Hearing disorder [ICD-11: AB50-AB57] Investigative

D03SSH	TTDDRUID	D03SSH
D03SSH	DRUGNAME	AI-1008
D03SSH	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Investigative

D00AJS	TTDDRUID	D00AJS
D00AJS	DRUGNAME	AIK11
D00AJS	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D04WLX	TTDDRUID	D04WLX
D04WLX	DRUGNAME	AIK-21
D04WLX	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0E3ZO	TTDDRUID	D0E3ZO
D0E3ZO	DRUGNAME	AIK33
D0E3ZO	INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative

D0U9AE	TTDDRUID	D0U9AE
D0U9AE	DRUGNAME	AIKa1
D0U9AE	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0N0SC	TTDDRUID	D0N0SC
D0N0SC	DRUGNAME	AIKb2
D0N0SC	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D02VUL	TTDDRUID	D02VUL
D02VUL	DRUGNAME	AIKO-151
D02VUL	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Investigative

D00YMN	TTDDRUID	D00YMN
D00YMN	DRUGNAME	AIKO-152
D00YMN	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Investigative

D06DPQ	TTDDRUID	D06DPQ
D06DPQ	DRUGNAME	AIM-101
D06DPQ	INDICATI	Asthma [ICD-11: CA23] Investigative

D0Y8KZ	TTDDRUID	D0Y8KZ
D0Y8KZ	DRUGNAME	AIM-501
D0Y8KZ	INDICATI	Artery stenosis [ICD-11: BD52] Investigative

D0Q8TX	TTDDRUID	D0Q8TX
D0Q8TX	DRUGNAME	Ajinomoto 1
D0Q8TX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D08UEJ	TTDDRUID	D08UEJ
D08UEJ	DRUGNAME	Ajinomoto 2
D08UEJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0S6YO	TTDDRUID	D0S6YO
D0S6YO	DRUGNAME	Ajinomoto 3
D0S6YO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0F5JG	TTDDRUID	D0F5JG
D0F5JG	DRUGNAME	AK-1
D0F5JG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08WGI	TTDDRUID	D08WGI
D08WGI	DRUGNAME	AK-2
D08WGI	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0DS1L	TTDDRUID	D0DS1L
D0DS1L	DRUGNAME	AK-20
D0DS1L	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative

D08JEA	TTDDRUID	D08JEA
D08JEA	DRUGNAME	AKB-4924
D08JEA	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative

D0W0JJ	TTDDRUID	D0W0JJ
D0W0JJ	DRUGNAME	AKB-9788
D0W0JJ	INDICATI	Edema [ICD-11: MG29] Investigative

D0D0TQ	TTDDRUID	D0D0TQ
D0D0TQ	DRUGNAME	AKN-028
D0D0TQ	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D0G1AA	TTDDRUID	D0G1AA
D0G1AA	DRUGNAME	AKP-001
D0G1AA	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D06FHD	TTDDRUID	D06FHD
D06FHD	DRUGNAME	AKT inhibitors [PMCID:PMC3086120]
D06FHD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05JFI	TTDDRUID	D05JFI
D05JFI	DRUGNAME	AKT protein kinase inhibitors
D05JFI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04ZUU	TTDDRUID	D04ZUU
D04ZUU	DRUGNAME	AKT-10081
D04ZUU	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0U5BV	TTDDRUID	D0U5BV
D0U5BV	DRUGNAME	AKT-10082
D0U5BV	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Investigative

D04THK	TTDDRUID	D04THK
D04THK	DRUGNAME	AL0-212
D04THK	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Investigative

D0K0OB	TTDDRUID	D0K0OB
D0K0OB	DRUGNAME	AL-18
D0K0OB	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D0Z2FX	TTDDRUID	D0Z2FX
D0Z2FX	DRUGNAME	AL-209
D0Z2FX	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D02FNJ	TTDDRUID	D02FNJ
D02FNJ	DRUGNAME	AL-309
D02FNJ	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0D2GZ	TTDDRUID	D0D2GZ
D0D2GZ	DRUGNAME	AL-408
D0D2GZ	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0U3RM	TTDDRUID	D0U3RM
D0U3RM	DRUGNAME	AL-508
D0U3RM	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D04BMR	TTDDRUID	D04BMR
D04BMR	DRUGNAME	AL-59640
D04BMR	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative

D0T7OS	TTDDRUID	D0T7OS
D0T7OS	DRUGNAME	AL-6802
D0T7OS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L8KK	TTDDRUID	D0L8KK
D0L8KK	DRUGNAME	ALB-137391(a)
D0L8KK	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative

D07MUI	TTDDRUID	D07MUI
D07MUI	DRUGNAME	Albitiazolium bromide prodrugs
D07MUI	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0Z3UX	TTDDRUID	D0Z3UX
D0Z3UX	DRUGNAME	Albumin-binding paclitaxel prodrug
D0Z3UX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D01ZQN	TTDDRUID	D01ZQN
D01ZQN	DRUGNAME	ALD-306
D01ZQN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0V2PG	TTDDRUID	D0V2PG
D0V2PG	DRUGNAME	ALD-701
D0V2PG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00FZA	TTDDRUID	D00FZA
D00FZA	DRUGNAME	ALD-805
D00FZA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T1YH	TTDDRUID	D0T1YH
D0T1YH	DRUGNAME	ALD-806
D0T1YH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A0ZY	TTDDRUID	D0A0ZY
D0A0ZY	DRUGNAME	ALD-901
D0A0ZY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0D9JB	TTDDRUID	D0D9JB
D0D9JB	DRUGNAME	ALERT
D0D9JB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W7FG	TTDDRUID	D0W7FG
D0W7FG	DRUGNAME	ALF-421
D0W7FG	INDICATI	Acute liver failure [ICD-11: DB91] Investigative

D0Y3TB	TTDDRUID	D0Y3TB
D0Y3TB	DRUGNAME	ALGRX 2872
D0Y3TB	INDICATI	Cluster headache [ICD-11: 8A81.0] Investigative
D0Y3TB	INDICATI	Migraine [ICD-11: 8A80] Investigative

D0Q6YG	TTDDRUID	D0Q6YG
D0Q6YG	DRUGNAME	Alkaloidal immunosuppresants
D0Q6YG	INDICATI	Transplant rejection [ICD-11: NE84] Investigative

D07FJC	TTDDRUID	D07FJC
D07FJC	DRUGNAME	ALL-3
D07FJC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R5UR	TTDDRUID	D0R5UR
D0R5UR	DRUGNAME	ALL-4
D0R5UR	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0V1ES	TTDDRUID	D0V1ES
D0V1ES	DRUGNAME	ALM-301
D0V1ES	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C7CS	TTDDRUID	D0C7CS
D0C7CS	DRUGNAME	ALN-HPN
D0C7CS	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D02SSV	TTDDRUID	D02SSV
D02SSV	DRUGNAME	ALN-RSV02
D02SSV	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D06VAF	TTDDRUID	D06VAF
D06VAF	DRUGNAME	Alpha amino acids
D06VAF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FR5V	TTDDRUID	D0FR5V
D0FR5V	DRUGNAME	Alpha crystallin inhibiting IgA mabs
D0FR5V	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0F7BO	TTDDRUID	D0F7BO
D0F7BO	DRUGNAME	Alpha melanotropin
D0F7BO	INDICATI	Lung injury [ICD-11: NB32.3Z] Investigative

D0G8OB	TTDDRUID	D0G8OB
D0G8OB	DRUGNAME	Alpha-arylamino hydroxamic acids
D0G8OB	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D0SN0U	TTDDRUID	D0SN0U
D0SN0U	DRUGNAME	Alpha-C-galactosyl ceramide
D0SN0U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U5WB	TTDDRUID	D0U5WB
D0U5WB	DRUGNAME	Alpha-type-1 polarized dendritic cells
D0U5WB	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative

D0CP3Z	TTDDRUID	D0CP3Z
D0CP3Z	DRUGNAME	ALS-012117
D0CP3Z	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D04NRP	TTDDRUID	D04NRP
D04NRP	DRUGNAME	ALS-2135
D04NRP	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D08NWY	TTDDRUID	D08NWY
D08NWY	DRUGNAME	ALS-2158
D08NWY	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D06VXE	TTDDRUID	D06VXE
D06VXE	DRUGNAME	ALS-2160
D06VXE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D00PGA	TTDDRUID	D00PGA
D00PGA	DRUGNAME	ALS-AAV9
D00PGA	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D05NJL	TTDDRUID	D05NJL
D05NJL	DRUGNAME	ALSE-100
D05NJL	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0W5LG	TTDDRUID	D0W5LG
D0W5LG	DRUGNAME	ALT-020
D0W5LG	INDICATI	Ocular infection [ICD-11: 1F00.1] Investigative

D0N3BU	TTDDRUID	D0N3BU
D0N3BU	DRUGNAME	ALT-020-02
D0N3BU	INDICATI	Ocular infection [ICD-11: 1F00.1] Investigative

D0L0ER	TTDDRUID	D0L0ER
D0L0ER	DRUGNAME	ALT-020-04
D0L0ER	INDICATI	Ocular infection [ICD-11: 1F00.1] Investigative

D0V1KD	TTDDRUID	D0V1KD
D0V1KD	DRUGNAME	ALT-022
D0V1KD	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0G1LP	TTDDRUID	D0G1LP
D0G1LP	DRUGNAME	ALT-802
D0G1LP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09SHC	TTDDRUID	D09SHC
D09SHC	DRUGNAME	ALT-804
D09SHC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N5QX	TTDDRUID	D0N5QX
D0N5QX	DRUGNAME	Alternaria peptide allergy desensitization agent
D0N5QX	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D07GET	TTDDRUID	D07GET
D07GET	DRUGNAME	ALTU-236
D07GET	INDICATI	Genetic disease [ICD-11: 8E02] Investigative

D06EBU	TTDDRUID	D06EBU
D06EBU	DRUGNAME	ALTU-242
D06EBU	INDICATI	Gout [ICD-11: FA25] Investigative

D0Q2IV	TTDDRUID	D0Q2IV
D0Q2IV	DRUGNAME	ALVAC-CEA/hB7.1
D0Q2IV	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D01QJY	TTDDRUID	D01QJY
D01QJY	DRUGNAME	Alzheimer's disease therapeutic
D01QJY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D03OGR	TTDDRUID	D03OGR
D03OGR	DRUGNAME	Alzheimers disease therapeutics
D03OGR	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0I8WN	TTDDRUID	D0I8WN
D0I8WN	DRUGNAME	Alzheimer's disease therapy, Cornell University
D0I8WN	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0U0OL	TTDDRUID	D0U0OL
D0U0OL	DRUGNAME	Alzheimer's disease therapy, Reyon
D0U0OL	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0W6ER	TTDDRUID	D0W6ER
D0W6ER	DRUGNAME	Alzheimers disease therapy, SK Life Science
D0W6ER	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0Y9PQ	TTDDRUID	D0Y9PQ
D0Y9PQ	DRUGNAME	AM-1101
D0Y9PQ	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D06EMQ	TTDDRUID	D06EMQ
D06EMQ	DRUGNAME	AM-112
D06EMQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0HK3U	TTDDRUID	D0HK3U
D0HK3U	DRUGNAME	AM-156
D0HK3U	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D03ZMY	TTDDRUID	D03ZMY
D03ZMY	DRUGNAME	AM-220
D03ZMY	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D09NCH	TTDDRUID	D09NCH
D09NCH	DRUGNAME	AM-230
D09NCH	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0F4IC	TTDDRUID	D0F4IC
D0F4IC	DRUGNAME	AM-250 SCI
D0F4IC	INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative

D0S1JV	TTDDRUID	D0S1JV
D0S1JV	DRUGNAME	AM-260
D0S1JV	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D00QUJ	TTDDRUID	D00QUJ
D00QUJ	DRUGNAME	AM-3005
D00QUJ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D04HBH	TTDDRUID	D04HBH
D04HBH	DRUGNAME	AM-3701
D04HBH	INDICATI	Bone metastases [ICD-11: 2D50] Investigative

D08WDP	TTDDRUID	D08WDP
D08WDP	DRUGNAME	AM-3840
D08WDP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D03NMM	TTDDRUID	D03NMM
D03NMM	DRUGNAME	AM-643
D03NMM	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D0YW6B	TTDDRUID	D0YW6B
D0YW6B	DRUGNAME	AM-679
D0YW6B	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative

D06NJB	TTDDRUID	D06NJB
D06NJB	DRUGNAME	AM-802
D06NJB	INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative

D06XXA	TTDDRUID	D06XXA
D06XXA	DRUGNAME	AMA-1-Dico
D06XXA	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D02RYE	TTDDRUID	D02RYE
D02RYE	DRUGNAME	AMA-237
D02RYE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0P2MD	TTDDRUID	D0P2MD
D0P2MD	DRUGNAME	AMB-8LK
D0P2MD	INDICATI	Liver cancer [ICD-11: 2C12] Investigative

D02CWZ	TTDDRUID	D02CWZ
D02CWZ	DRUGNAME	AMBAZONE
D02CWZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03FOT	TTDDRUID	D03FOT
D03FOT	DRUGNAME	AMD-AAV7
D03FOT	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D09NWW	TTDDRUID	D09NWW
D09NWW	DRUGNAME	AMG-247
D09NWW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09QWK	TTDDRUID	D09QWK
D09QWK	DRUGNAME	AMG-327
D09QWK	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0AK4H	TTDDRUID	D0AK4H
D0AK4H	DRUGNAME	AMG-429
D0AK4H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W8UW	TTDDRUID	D0W8UW
D0W8UW	DRUGNAME	AMG-628
D0W8UW	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D04FFY	TTDDRUID	D04FFY
D04FFY	DRUGNAME	AMG-8563
D04FFY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0W6EP	TTDDRUID	D0W6EP
D0W6EP	DRUGNAME	AMG-889436
D0W6EP	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D00MAM	TTDDRUID	D00MAM
D00MAM	DRUGNAME	AMG-JAK2-01
D00MAM	INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Investigative

D0H7AZ	TTDDRUID	D0H7AZ
D0H7AZ	DRUGNAME	Aminocandin
D0H7AZ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D07LVE	TTDDRUID	D07LVE
D07LVE	DRUGNAME	Aminocoumarin
D07LVE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D08FKE	TTDDRUID	D08FKE
D08FKE	DRUGNAME	Aminoglycosides
D08FKE	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Investigative

D06KZB	TTDDRUID	D06KZB
D06KZB	DRUGNAME	Aminopyridines
D06KZB	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D08LIU	TTDDRUID	D08LIU
D08LIU	DRUGNAME	Amooranin
D08LIU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0K1TM	TTDDRUID	D0K1TM
D0K1TM	DRUGNAME	AMP-423
D0K1TM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R7WY	TTDDRUID	D0R7WY
D0R7WY	DRUGNAME	AMPA receptor positive modulators
D0R7WY	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0D7YR	TTDDRUID	D0D7YR
D0D7YR	DRUGNAME	AMPE4L
D0D7YR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0B1CJ	TTDDRUID	D0B1CJ
D0B1CJ	DRUGNAME	Amphiregulin targeting human mabs
D0B1CJ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0Y0ME	TTDDRUID	D0Y0ME
D0Y0ME	DRUGNAME	Amphotericin B liposomal oral
D0Y0ME	INDICATI	Mycoses [ICD-11: 1F2Z] Investigative

D07AEZ	TTDDRUID	D07AEZ
D07AEZ	DRUGNAME	AMPK stimulators, oral, type 2 diabetes
D07AEZ	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0G8BE	TTDDRUID	D0G8BE
D0G8BE	DRUGNAME	AMPPL
D0G8BE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0B3IZ	TTDDRUID	D0B3IZ
D0B3IZ	DRUGNAME	AMPSL
D0B3IZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0I6XJ	TTDDRUID	D0I6XJ
D0I6XJ	DRUGNAME	AMP-X-0001
D0I6XJ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0V1VG	TTDDRUID	D0V1VG
D0V1VG	DRUGNAME	AMRS-001
D0V1VG	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D09CHX	TTDDRUID	D09CHX
D09CHX	DRUGNAME	AMR-SIX-1
D09CHX	INDICATI	Obesity [ICD-11: 5B81] Investigative

D02TOS	TTDDRUID	D02TOS
D02TOS	DRUGNAME	AMSH
D02TOS	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative

D0D4IL	TTDDRUID	D0D4IL
D0D4IL	DRUGNAME	AMT-021
D0D4IL	INDICATI	Acute intermittent hepatic porphyria [ICD-11: 5C58.11] Investigative

D0DY1N	TTDDRUID	D0DY1N
D0DY1N	DRUGNAME	AMT-080
D0DY1N	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D07BLC	TTDDRUID	D07BLC
D07BLC	DRUGNAME	AMT-090
D07BLC	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D00JDP	TTDDRUID	D00JDP
D00JDP	DRUGNAME	AMX-213
D00JDP	INDICATI	Cachexia [ICD-11: MG20] Investigative

D0P3PF	TTDDRUID	D0P3PF
D0P3PF	DRUGNAME	AMX-256
D0P3PF	INDICATI	Short bowel syndrome [ICD-11: KB89.1] Investigative

D01OHD	TTDDRUID	D01OHD
D01OHD	DRUGNAME	AMXT-1501
D01OHD	INDICATI	Head and neck cancer [ICD-11: 2D42] Investigative

D00SPM	TTDDRUID	D00SPM
D00SPM	DRUGNAME	Amyloid beta oligomers
D00SPM	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0D2UI	TTDDRUID	D0D2UI
D0D2UI	DRUGNAME	Amyotrophic lateral sclerosis therapeutics
D0D2UI	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0T2SK	TTDDRUID	D0T2SK
D0T2SK	DRUGNAME	AmZaar
D0T2SK	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D01XHU	TTDDRUID	D01XHU
D01XHU	DRUGNAME	AN-207
D01XHU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0SK9J	TTDDRUID	D0SK9J
D0SK9J	DRUGNAME	AN-3661
D0SK9J	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0GW2L	TTDDRUID	D0GW2L
D0GW2L	DRUGNAME	AN-5973
D0GW2L	INDICATI	Enterobacteriaceae infection [ICD-11: MG50.C] Investigative

D06WLV	TTDDRUID	D06WLV
D06WLV	DRUGNAME	ANA-01
D06WLV	INDICATI	Bone resorption [ICD-11: FC0Z] Investigative

D08TDK	TTDDRUID	D08TDK
D08TDK	DRUGNAME	ANA-011
D08TDK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X9GV	TTDDRUID	D0X9GV
D0X9GV	DRUGNAME	ANA-012
D0X9GV	INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative

D0V7HQ	TTDDRUID	D0V7HQ
D0V7HQ	DRUGNAME	ANA-02
D0V7HQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D04PAF	TTDDRUID	D04PAF
D04PAF	DRUGNAME	ANA-04
D04PAF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0N3XA	TTDDRUID	D0N3XA
D0N3XA	DRUGNAME	ANA-1
D0N3XA	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D04ZTA	TTDDRUID	D04ZTA
D04ZTA	DRUGNAME	ANA-5
D04ZTA	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D04BJC	TTDDRUID	D04BJC
D04BJC	DRUGNAME	Analgesic peptides
D04BJC	INDICATI	Temporomandibular joint syndrome [ICD-11: DA0E.8] Investigative

D0P9WA	TTDDRUID	D0P9WA
D0P9WA	DRUGNAME	Analgesics
D0P9WA	INDICATI	Migraine [ICD-11: 8A80] Investigative

D0SP7S	TTDDRUID	D0SP7S
D0SP7S	DRUGNAME	Androgen
D0SP7S	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D08DTT	TTDDRUID	D08DTT
D08DTT	DRUGNAME	Androgen receptor modulators
D08DTT	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0W8AI	TTDDRUID	D0W8AI
D0W8AI	DRUGNAME	Andromustine
D0W8AI	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0P8JC	TTDDRUID	D0P8JC
D0P8JC	DRUGNAME	ANG-1007
D0P8JC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08HUB	TTDDRUID	D08HUB
D08HUB	DRUGNAME	ANG-2004
D08HUB	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0R3GE	TTDDRUID	D0R3GE
D0R3GE	DRUGNAME	ANG-2010
D0R3GE	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D05APM	TTDDRUID	D05APM
D05APM	DRUGNAME	ANG-2684
D05APM	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D02JHW	TTDDRUID	D02JHW
D02JHW	DRUGNAME	ANG-2864
D02JHW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05ZVU	TTDDRUID	D05ZVU
D05ZVU	DRUGNAME	ANG-3062
D05ZVU	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0SY2O	TTDDRUID	D0SY2O
D0SY2O	DRUGNAME	ANG-3067
D0SY2O	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0J2IB	TTDDRUID	D0J2IB
D0J2IB	DRUGNAME	ANG-3070
D0J2IB	INDICATI	Scleroderma [ICD-11: 4A42] Investigative

D0M1YW	TTDDRUID	D0M1YW
D0M1YW	DRUGNAME	ANG-3407
D0M1YW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D06OUT	TTDDRUID	D06OUT
D06OUT	DRUGNAME	ANG-4011
D06OUT	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D08CMF	TTDDRUID	D08CMF
D08CMF	DRUGNAME	Angeloxin
D08CMF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00QBY	TTDDRUID	D00QBY
D00QBY	DRUGNAME	Angiogenesis promoters
D00QBY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D01WYV	TTDDRUID	D01WYV
D01WYV	DRUGNAME	Angiostatin/paclitaxel/carboplatin
D01WYV	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D05TZJ	TTDDRUID	D05TZJ
D05TZJ	DRUGNAME	Ankinara
D05TZJ	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
D05TZJ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
D05TZJ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0P7GV	TTDDRUID	D0P7GV
D0P7GV	DRUGNAME	Annexin A5
D0P7GV	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D07GGT	TTDDRUID	D07GGT
D07GGT	DRUGNAME	ANT-429
D07GGT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G2DR	TTDDRUID	D0G2DR
D0G2DR	DRUGNAME	ANT-G12
D0G2DR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D00ZRJ	TTDDRUID	D00ZRJ
D00ZRJ	DRUGNAME	Anti FGFR4 mab program
D00ZRJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04KHN	TTDDRUID	D04KHN
D04KHN	DRUGNAME	Anti melanoma oligopeptides
D04KHN	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D05OUI	TTDDRUID	D05OUI
D05OUI	DRUGNAME	Anti-aging glycopeptides
D05OUI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D07HNZ	TTDDRUID	D07HNZ
D07HNZ	DRUGNAME	Anti-AGX-020 mabs
D07HNZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D04YVI	TTDDRUID	D04YVI
D04YVI	DRUGNAME	Antiangiogenic Surrobodies
D04YVI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07MCT	TTDDRUID	D07MCT
D07MCT	DRUGNAME	Anti-arthritis drug
D07MCT	INDICATI	Arthritis [ICD-11: FA20] Investigative

D04OQQ	TTDDRUID	D04OQQ
D04OQQ	DRUGNAME	Anti-avian influenza agent
D04OQQ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0X8RA	TTDDRUID	D0X8RA
D0X8RA	DRUGNAME	Anti-BCR mabs
D0X8RA	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative

D06UMS	TTDDRUID	D06UMS
D06UMS	DRUGNAME	Antibiotic combination
D06UMS	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D01OIP	TTDDRUID	D01OIP
D01OIP	DRUGNAME	Antibiotic program, Gram negative bacterial infections
D01OIP	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0QN3K	TTDDRUID	D0QN3K
D0QN3K	DRUGNAME	Antibody vaccine, Araclon Biotech Sl
D0QN3K	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0JH9E	TTDDRUID	D0JH9E
D0JH9E	DRUGNAME	Anti-botulinum mabs
D0JH9E	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0A9VC	TTDDRUID	D0A9VC
D0A9VC	DRUGNAME	Anticachexia therapeutic
D0A9VC	INDICATI	Cachexia [ICD-11: MG20] Investigative

D07YAC	TTDDRUID	D07YAC
D07YAC	DRUGNAME	Anticalin
D07YAC	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0I9KL	TTDDRUID	D0I9KL
D0I9KL	DRUGNAME	Anticancer etherlipid prodrugs
D0I9KL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U6GQ	TTDDRUID	D0U6GQ
D0U6GQ	DRUGNAME	Anticancer pro-soft drugs
D0U6GQ	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative

D04SWE	TTDDRUID	D04SWE
D04SWE	DRUGNAME	Anticancer stem cell therapeutics
D04SWE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01APJ	TTDDRUID	D01APJ
D01APJ	DRUGNAME	Anticancer therapeutic
D01APJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D07HXJ	TTDDRUID	D07HXJ
D07HXJ	DRUGNAME	Anticancer therapy, Aurigene Discovery Technologies
D07HXJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03CKO	TTDDRUID	D03CKO
D03CKO	DRUGNAME	Anticancer Therapy, Endo
D03CKO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P5HD	TTDDRUID	D0P5HD
D0P5HD	DRUGNAME	Anticancer/antidiabetic protein
D0P5HD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G2FY	TTDDRUID	D0G2FY
D0G2FY	DRUGNAME	Anti-CCR5 mabs
D0G2FY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D09IAN	TTDDRUID	D09IAN
D09IAN	DRUGNAME	Anti-CD19 Chimeric Antigen Receptor T Cells
D09IAN	INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial

D0S4OH	TTDDRUID	D0S4OH
D0S4OH	DRUGNAME	Anti-CD20 engineered toxin bodies
D0S4OH	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative

D0V2QU	TTDDRUID	D0V2QU
D0V2QU	DRUGNAME	Anti-CD22/CD19 mab-toxin conjugate
D0V2QU	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative

D0V9LF	TTDDRUID	D0V9LF
D0V9LF	DRUGNAME	Anti-CD28
D0V9LF	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0Y6NO	TTDDRUID	D0Y6NO
D0Y6NO	DRUGNAME	Anti-CD326 humanized mab
D0Y6NO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V3HC	TTDDRUID	D0V3HC
D0V3HC	DRUGNAME	Anti-CD40-XTEN
D0V3HC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0A9JA	TTDDRUID	D0A9JA
D0A9JA	DRUGNAME	Anti-CD44 mab
D0A9JA	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D04SWT	TTDDRUID	D04SWT
D04SWT	DRUGNAME	Anti-CD47 mab
D04SWT	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D09MAB	TTDDRUID	D09MAB
D09MAB	DRUGNAME	Anti-CD5 humanized mab
D09MAB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09BPT	TTDDRUID	D09BPT
D09BPT	DRUGNAME	Anti-CD9 mab
D09BPT	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Investigative

D09RGS	TTDDRUID	D09RGS
D09RGS	DRUGNAME	Anti-CD97 mab
D09RGS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D08ENJ	TTDDRUID	D08ENJ
D08ENJ	DRUGNAME	Anti-CGEN-153 mab
D08ENJ	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0JW2Y	TTDDRUID	D0JW2Y
D0JW2Y	DRUGNAME	Anti-Clostridium difficile mabs
D0JW2Y	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0W9JP	TTDDRUID	D0W9JP
D0W9JP	DRUGNAME	Anti-Clostridium perfringens toxin mabs
D0W9JP	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D08MOL	TTDDRUID	D08MOL
D08MOL	DRUGNAME	Anti-CMV mabs
D08MOL	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D0C0VW	TTDDRUID	D0C0VW
D0C0VW	DRUGNAME	Anticonvulsants
D0C0VW	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0J2NS	TTDDRUID	D0J2NS
D0J2NS	DRUGNAME	Anti-D
D0J2NS	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Investigative

D00KAI	TTDDRUID	D00KAI
D00KAI	DRUGNAME	Antidepressant
D00KAI	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D00UYB	TTDDRUID	D00UYB
D00UYB	DRUGNAME	Anti-DLL-4 mab
D00UYB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R2RV	TTDDRUID	D0R2RV
D0R2RV	DRUGNAME	Anti-EGFR humanized mabs
D0R2RV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R1KR	TTDDRUID	D0R1KR
D0R1KR	DRUGNAME	Anti-emetics
D0R1KR	INDICATI	Nausea [ICD-11: MD90] Investigative

D03WBW	TTDDRUID	D03WBW
D03WBW	DRUGNAME	Anti-epileptics
D03WBW	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D07WAF	TTDDRUID	D07WAF
D07WAF	DRUGNAME	Anti-Fas mabs
D07WAF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00JZS	TTDDRUID	D00JZS
D00JZS	DRUGNAME	Anti-FGFR1 mab program
D00JZS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02VPS	TTDDRUID	D02VPS
D02VPS	DRUGNAME	Anti-FGFR2 humanized mab
D02VPS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01EHW	TTDDRUID	D01EHW
D01EHW	DRUGNAME	Antifibrinolytic agents
D01EHW	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0CQ5J	TTDDRUID	D0CQ5J
D0CQ5J	DRUGNAME	Antifolate
D0CQ5J	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D09IVP	TTDDRUID	D09IVP
D09IVP	DRUGNAME	Anti-folate receptor 1 humanized mab
D09IVP	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0Y8IJ	TTDDRUID	D0Y8IJ
D0Y8IJ	DRUGNAME	Antifungal agents
D0Y8IJ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0Y8YD	TTDDRUID	D0Y8YD
D0Y8YD	DRUGNAME	Antifungal oligonucleotides
D0Y8YD	INDICATI	Candidiasis [ICD-11: 1F23] Investigative

D0F8OB	TTDDRUID	D0F8OB
D0F8OB	DRUGNAME	Antifungal potentiators
D0F8OB	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0U1YQ	TTDDRUID	D0U1YQ
D0U1YQ	DRUGNAME	Antifungal therapy, NanoElectroplex
D0U1YQ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D06ULO	TTDDRUID	D06ULO
D06ULO	DRUGNAME	Antifungal/antibacterial therapeutics
D06ULO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D06RQD	TTDDRUID	D06RQD
D06RQD	DRUGNAME	Anti-GD2 mab
D06RQD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I8QC	TTDDRUID	D0I8QC
D0I8QC	DRUGNAME	Anti-GM-CSF human mabs
D0I8QC	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0R0MM	TTDDRUID	D0R0MM
D0R0MM	DRUGNAME	Anti-GP88 mabs
D0R0MM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02HQR	TTDDRUID	D02HQR
D02HQR	DRUGNAME	Anti-HBs human mab
D02HQR	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D07KGV	TTDDRUID	D07KGV
D07KGV	DRUGNAME	Anti-HCV agent
D07KGV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D07SBX	TTDDRUID	D07SBX
D07SBX	DRUGNAME	Anti-HCV peptides
D07SBX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0FV1R	TTDDRUID	D0FV1R
D0FV1R	DRUGNAME	Anti-heparanase mabs
D0FV1R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S4ZZ	TTDDRUID	D0S4ZZ
D0S4ZZ	DRUGNAME	Anti-HER2 bi-specific mabs
D0S4ZZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09CBI	TTDDRUID	D09CBI
D09CBI	DRUGNAME	Anti-Her-2 mab
D09CBI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00ACP	TTDDRUID	D00ACP
D00ACP	DRUGNAME	Anti-HER-2 mab-FcgR2- FcgR4 fusion proteins
D00ACP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L8YH	TTDDRUID	D0L8YH
D0L8YH	DRUGNAME	AntiHer2-XTEN-Docetaxel
D0L8YH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0LI9D	TTDDRUID	D0LI9D
D0LI9D	DRUGNAME	Antihistamine
D0LI9D	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D09YUH	TTDDRUID	D09YUH
D09YUH	DRUGNAME	Anti-HIV peptides
D09YUH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D01LZB	TTDDRUID	D01LZB
D01LZB	DRUGNAME	Anti-HM1.24
D01LZB	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0A6RX	TTDDRUID	D0A6RX
D0A6RX	DRUGNAME	Anti-hTfR IgG3-Av
D0A6RX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05FSX	TTDDRUID	D05FSX
D05FSX	DRUGNAME	Antihyperlipidemia agent
D05FSX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D0C4CI	TTDDRUID	D0C4CI
D0C4CI	DRUGNAME	Antihypertensive agent
D0C4CI	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D04LLE	TTDDRUID	D04LLE
D04LLE	DRUGNAME	Antihypertensives
D04LLE	INDICATI	Pulmonary hypertension [ICD-11: BB01] Investigative

D04KGB	TTDDRUID	D04KGB
D04KGB	DRUGNAME	Anti-IFN-alpha human mabs
D04KGB	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D03JUN	TTDDRUID	D03JUN
D03JUN	DRUGNAME	Anti-IL31
D03JUN	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0MO7R	TTDDRUID	D0MO7R
D0MO7R	DRUGNAME	Antiinfective therapeutic
D0MO7R	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0F4GS	TTDDRUID	D0F4GS
D0F4GS	DRUGNAME	Anti-inflammatory polysaccharides
D0F4GS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0DK2K	TTDDRUID	D0DK2K
D0DK2K	DRUGNAME	Antiinflammatory therapeutics
D0DK2K	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0P6JZ	TTDDRUID	D0P6JZ
D0P6JZ	DRUGNAME	Antiinflammatory/antimicrobial
D0P6JZ	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Investigative

D0IE3M	TTDDRUID	D0IE3M
D0IE3M	DRUGNAME	Anti-inflammatory/anti-proliferative agents
D0IE3M	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D0D1TZ	TTDDRUID	D0D1TZ
D0D1TZ	DRUGNAME	Anti-inflammatory/anti-spasmodic therapeutics
D0D1TZ	INDICATI	Asthma [ICD-11: CA23] Investigative

D0P4PS	TTDDRUID	D0P4PS
D0P4PS	DRUGNAME	Antimalarial peroxides
D0P4PS	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D01XIK	TTDDRUID	D01XIK
D01XIK	DRUGNAME	Antimalarials
D01XIK	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0S5IV	TTDDRUID	D0S5IV
D0S5IV	DRUGNAME	Anti-Marburg virus mabs
D0S5IV	INDICATI	Marburg virus infection [ICD-11: 1D60.1] Investigative

D0KI9N	TTDDRUID	D0KI9N
D0KI9N	DRUGNAME	Antimicrobial LL-37 cathelicidin
D0KI9N	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0JD1A	TTDDRUID	D0JD1A
D0JD1A	DRUGNAME	Antimicrobial peptide
D0JD1A	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D06KXA	TTDDRUID	D06KXA
D06KXA	DRUGNAME	Antimicrobials
D06KXA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0IC2O	TTDDRUID	D0IC2O
D0IC2O	DRUGNAME	Anti-miR-191 modified oligonucleotide
D0IC2O	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D0S7HW	TTDDRUID	D0S7HW
D0S7HW	DRUGNAME	Anti-miR-199a oligonucleotides
D0S7HW	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D0E9BQ	TTDDRUID	D0E9BQ
D0E9BQ	DRUGNAME	Anti-Neu5Gc mabs
D0E9BQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08EVF	TTDDRUID	D08EVF
D08EVF	DRUGNAME	Anti-Notch-1 mabs
D08EVF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X4VG	TTDDRUID	D0X4VG
D0X4VG	DRUGNAME	Anti-Notch-1 receptor mabs
D0X4VG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V0GF	TTDDRUID	D0V0GF
D0V0GF	DRUGNAME	Antiparasitic agents
D0V0GF	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0P5LY	TTDDRUID	D0P5LY
D0P5LY	DRUGNAME	Antiparasitic diamidines
D0P5LY	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D05IUQ	TTDDRUID	D05IUQ
D05IUQ	DRUGNAME	Anti-PECAM-1 mab
D05IUQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BX7G	TTDDRUID	D0BX7G
D0BX7G	DRUGNAME	Anti-PrP mabs
D0BX7G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y6QO	TTDDRUID	D0Y6QO
D0Y6QO	DRUGNAME	Antipruritic agents
D0Y6QO	INDICATI	Pruritus [ICD-11: EC90] Investigative

D0Z3AB	TTDDRUID	D0Z3AB
D0Z3AB	DRUGNAME	Anti-PSA mabs
D0Z3AB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0ZC3K	TTDDRUID	D0ZC3K
D0ZC3K	DRUGNAME	Anti-ricin mabs
D0ZC3K	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D07PWY	TTDDRUID	D07PWY
D07PWY	DRUGNAME	Anti-RON receptor mabs
D07PWY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0JS2L	TTDDRUID	D0JS2L
D0JS2L	DRUGNAME	Anti-RSV mab
D0JS2L	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D03ESU	TTDDRUID	D03ESU
D03ESU	DRUGNAME	Anti-SEB mabs
D03ESU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Q5TP	TTDDRUID	D0Q5TP
D0Q5TP	DRUGNAME	Anti-sortase mab
D0Q5TP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D05RTB	TTDDRUID	D05RTB
D05RTB	DRUGNAME	Anti-Staphylococcus enterotoxin B hyperimmune globulin
D05RTB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0U5HY	TTDDRUID	D0U5HY
D0U5HY	DRUGNAME	Anti-TAG-72 antibody
D0U5HY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06PCU	TTDDRUID	D06PCU
D06PCU	DRUGNAME	Anti-TB antibiotics
D06PCU	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0X6JG	TTDDRUID	D0X6JG
D0X6JG	DRUGNAME	Antithrombotics
D0X6JG	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0L8EO	TTDDRUID	D0L8EO
D0L8EO	DRUGNAME	Anti-TLR3 mabs
D0L8EO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0X8SM	TTDDRUID	D0X8SM
D0X8SM	DRUGNAME	Anti-TNF human mabs
D0X8SM	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0F7RU	TTDDRUID	D0F7RU
D0F7RU	DRUGNAME	Anti-TSLP mab
D0F7RU	INDICATI	Asthma [ICD-11: CA23] Investigative

D04MEB	TTDDRUID	D04MEB
D04MEB	DRUGNAME	Antituberculosis agents
D04MEB	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D00TYR	TTDDRUID	D00TYR
D00TYR	DRUGNAME	Anti-tubulin agents
D00TYR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T1RM	TTDDRUID	D0T1RM
D0T1RM	DRUGNAME	Antivaginolysin mabs
D0T1RM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0X3UG	TTDDRUID	D0X3UG
D0X3UG	DRUGNAME	Antivaginolysin single chain variable fragments
D0X3UG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0S7IQ	TTDDRUID	D0S7IQ
D0S7IQ	DRUGNAME	Anti-VEGF human mabs
D0S7IQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01JBJ	TTDDRUID	D01JBJ
D01JBJ	DRUGNAME	Antiviral agents
D01JBJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0B3UU	TTDDRUID	D0B3UU
D0B3UU	DRUGNAME	Antiviral BMS-1
D0B3UU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0P8SV	TTDDRUID	D0P8SV
D0P8SV	DRUGNAME	Antiviral hyperactivation limiting therapeutics
D0P8SV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D09HOF	TTDDRUID	D09HOF
D09HOF	DRUGNAME	Antiviral iminosugars
D09HOF	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D06NLG	TTDDRUID	D06NLG
D06NLG	DRUGNAME	Antiviral spray
D06NLG	INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative

D04XHR	TTDDRUID	D04XHR
D04XHR	DRUGNAME	Anti-virulence program, antibiotic, bacterial infections
D04XHR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D01ZLL	TTDDRUID	D01ZLL
D01ZLL	DRUGNAME	Aom-0755
D01ZLL	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Z2NY	TTDDRUID	D0Z2NY
D0Z2NY	DRUGNAME	Aom-0763
D0Z2NY	INDICATI	Gout [ICD-11: FA25] Investigative

D07UXJ	TTDDRUID	D07UXJ
D07UXJ	DRUGNAME	Aom-0785
D07UXJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D02KXE	TTDDRUID	D02KXE
D02KXE	DRUGNAME	Aom-0811
D02KXE	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Investigative

D0P7HM	TTDDRUID	D0P7HM
D0P7HM	DRUGNAME	Aom-0821
D0P7HM	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D04FIO	TTDDRUID	D04FIO
D04FIO	DRUGNAME	Aom-0871
D04FIO	INDICATI	Transplant rejection [ICD-11: NE84] Investigative

D0V3BI	TTDDRUID	D0V3BI
D0V3BI	DRUGNAME	Aom-0890
D0V3BI	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative

D0CY3F	TTDDRUID	D0CY3F
D0CY3F	DRUGNAME	Aom-0925
D0CY3F	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0B1RY	TTDDRUID	D0B1RY
D0B1RY	DRUGNAME	Aom-0977
D0B1RY	INDICATI	Obesity [ICD-11: 5B81] Investigative

D07URH	TTDDRUID	D07URH
D07URH	DRUGNAME	AP-004
D07URH	INDICATI	Proctitis [ICD-11: DB33.Z] Investigative

D06WSG	TTDDRUID	D06WSG
D06WSG	DRUGNAME	AP-005
D06WSG	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D00LMR	TTDDRUID	D00LMR
D00LMR	DRUGNAME	AP-006
D00LMR	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative

D0E3EA	TTDDRUID	D0E3EA
D0E3EA	DRUGNAME	AP-02-00
D0E3EA	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D06QIP	TTDDRUID	D06QIP
D06QIP	DRUGNAME	AP-022
D06QIP	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0K5QY	TTDDRUID	D0K5QY
D0K5QY	DRUGNAME	AP-101
D0K5QY	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D0N0YT	TTDDRUID	D0N0YT
D0N0YT	DRUGNAME	AP-10295
D0N0YT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00AIS	TTDDRUID	D00AIS
D00AIS	DRUGNAME	AP-11014
D00AIS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09QPE	TTDDRUID	D09QPE
D09QPE	DRUGNAME	AP-1189
D09QPE	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D04NYX	TTDDRUID	D04NYX
D04NYX	DRUGNAME	AP-15012
D04NYX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G4DF	TTDDRUID	D0G4DF
D0G4DF	DRUGNAME	AP-1600
D0G4DF	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative

D03KIK	TTDDRUID	D03KIK
D03KIK	DRUGNAME	AP-300
D03KIK	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D05YYK	TTDDRUID	D05YYK
D05YYK	DRUGNAME	AP-401
D05YYK	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0F9NN	TTDDRUID	D0F9NN
D0F9NN	DRUGNAME	AP-501
D0F9NN	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D04IUY	TTDDRUID	D04IUY
D04IUY	DRUGNAME	APC-001
D04IUY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R7IW	TTDDRUID	D0R7IW
D0R7IW	DRUGNAME	APC-0010
D0R7IW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01FRP	TTDDRUID	D01FRP
D01FRP	DRUGNAME	APC-0013
D01FRP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04EOH	TTDDRUID	D04EOH
D04EOH	DRUGNAME	APC-003
D04EOH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O6WS	TTDDRUID	D0O6WS
D0O6WS	DRUGNAME	APC-004
D0O6WS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YD6K	TTDDRUID	D0YD6K
D0YD6K	DRUGNAME	APC-200
D0YD6K	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D03ZWR	TTDDRUID	D03ZWR
D03ZWR	DRUGNAME	APC-300
D03ZWR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0T2UB	TTDDRUID	D0T2UB
D0T2UB	DRUGNAME	APCK-110
D0T2UB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02OGQ	TTDDRUID	D02OGQ
D02OGQ	DRUGNAME	APD
D02OGQ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0T7GQ	TTDDRUID	D0T7GQ
D0T7GQ	DRUGNAME	APETX2
D0T7GQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D05XKN	TTDDRUID	D05XKN
D05XKN	DRUGNAME	APG-101.10
D05XKN	INDICATI	Gout [ICD-11: FA25] Investigative

D0QA7X	TTDDRUID	D0QA7X
D0QA7X	DRUGNAME	APG-103
D0QA7X	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0Y1BF	TTDDRUID	D0Y1BF
D0Y1BF	DRUGNAME	APG-201
D0Y1BF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YZ1J	TTDDRUID	D0YZ1J
D0YZ1J	DRUGNAME	APG-2305
D0YZ1J	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0CC3O	TTDDRUID	D0CC3O
D0CC3O	DRUGNAME	APG-232
D0CC3O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07FIF	TTDDRUID	D07FIF
D07FIF	DRUGNAME	APH-0701
D07FIF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D04RKH	TTDDRUID	D04RKH
D04RKH	DRUGNAME	APH-0911
D04RKH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E4PN	TTDDRUID	D0E4PN
D0E4PN	DRUGNAME	API-003
D0E4PN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0W1PV	TTDDRUID	D0W1PV
D0W1PV	DRUGNAME	Apicidin
D0W1PV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01DBF	TTDDRUID	D01DBF
D01DBF	DRUGNAME	APIT
D01DBF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H6BL	TTDDRUID	D0H6BL
D0H6BL	DRUGNAME	APL-001
D0H6BL	INDICATI	Leukopenia [ICD-11: 4B00.0Z] Investigative

D0O2MW	TTDDRUID	D0O2MW
D0O2MW	DRUGNAME	APN-501
D0O2MW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07MLP	TTDDRUID	D07MLP
D07MLP	DRUGNAME	APN-601
D07MLP	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0V7PX	TTDDRUID	D0V7PX
D0V7PX	DRUGNAME	Apogossypol
D0V7PX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02TGF	TTDDRUID	D02TGF
D02TGF	DRUGNAME	Apolipoprotein E-derived peptides
D02TGF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0B0LG	TTDDRUID	D0B0LG
D0B0LG	DRUGNAME	Apomab
D0B0LG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09YYQ	TTDDRUID	D09YYQ
D09YYQ	DRUGNAME	Aponidin
D09YYQ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D06NPS	TTDDRUID	D06NPS
D06NPS	DRUGNAME	Apoptosis-inducing peptide
D06NPS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E7RV	TTDDRUID	D0E7RV
D0E7RV	DRUGNAME	Aposense probe-cytotoxic agent conjugates
D0E7RV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y3TX	TTDDRUID	D0Y3TX
D0Y3TX	DRUGNAME	Apovasc
D0Y3TX	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D05FRM	TTDDRUID	D05FRM
D05FRM	DRUGNAME	ApoVax104-HPV
D05FRM	INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative

D04GCV	TTDDRUID	D04GCV
D04GCV	DRUGNAME	APS-2010
D04GCV	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D03LZK	TTDDRUID	D03LZK
D03LZK	DRUGNAME	APS-3010
D03LZK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07QRB	TTDDRUID	D07QRB
D07QRB	DRUGNAME	APT project
D07QRB	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D0A9YZ	TTDDRUID	D0A9YZ
D0A9YZ	DRUGNAME	APT-102
D0A9YZ	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Investigative

D09UCU	TTDDRUID	D09UCU
D09UCU	DRUGNAME	APT3111
D09UCU	INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Investigative

D01HTH	TTDDRUID	D01HTH
D01HTH	DRUGNAME	Aptiganel HCl
D01HTH	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Investigative

D0U8TW	TTDDRUID	D0U8TW
D0U8TW	DRUGNAME	APV-001
D0U8TW	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0DL3W	TTDDRUID	D0DL3W
D0DL3W	DRUGNAME	APX-001
D0DL3W	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D06WXS	TTDDRUID	D06WXS
D06WXS	DRUGNAME	APX-002
D06WXS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D08LEZ	TTDDRUID	D08LEZ
D08LEZ	DRUGNAME	APX-005
D08LEZ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative

D00OAB	TTDDRUID	D00OAB
D00OAB	DRUGNAME	APX-007
D00OAB	INDICATI	Bone metastases [ICD-11: 2D50] Investigative

D04QWV	TTDDRUID	D04QWV
D04QWV	DRUGNAME	APX-008
D04QWV	INDICATI	Bone metastases [ICD-11: 2D50] Investigative

D01PRH	TTDDRUID	D01PRH
D01PRH	DRUGNAME	APX-009
D01PRH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D5XV	TTDDRUID	D0D5XV
D0D5XV	DRUGNAME	APX-E
D0D5XV	INDICATI	Asthma [ICD-11: CA23] Investigative

D00AUM	TTDDRUID	D00AUM
D00AUM	DRUGNAME	AQU-010
D00AUM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D03TTT	TTDDRUID	D03TTT
D03TTT	DRUGNAME	AR-00341677
D03TTT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05IBV	TTDDRUID	D05IBV
D05IBV	DRUGNAME	AR-12432
D05IBV	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D08VVI	TTDDRUID	D08VVI
D08VVI	DRUGNAME	AR-54
D08VVI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YT3Z	TTDDRUID	D0YT3Z
D0YT3Z	DRUGNAME	AR-7947
D0YT3Z	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0H5KG	TTDDRUID	D0H5KG
D0H5KG	DRUGNAME	AR-9273
D0H5KG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0S3HR	TTDDRUID	D0S3HR
D0S3HR	DRUGNAME	ARA-04
D0S3HR	INDICATI	Entamoeba histolytica infection [ICD-11: 1A36.Z] Investigative

D0L1YR	TTDDRUID	D0L1YR
D0L1YR	DRUGNAME	Ara-LAMP-vax
D0L1YR	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D04QXW	TTDDRUID	D04QXW
D04QXW	DRUGNAME	ARC-069
D04QXW	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D07XBZ	TTDDRUID	D07XBZ
D07XBZ	DRUGNAME	ARC-200
D07XBZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09WKT	TTDDRUID	D09WKT
D09WKT	DRUGNAME	ARD-412
D09WKT	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Investigative

D03LNV	TTDDRUID	D03LNV
D03LNV	DRUGNAME	Argotom-VAX
D03LNV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D07KVD	TTDDRUID	D07KVD
D07KVD	DRUGNAME	ARGX-109
D07KVD	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0E2MI	TTDDRUID	D0E2MI
D0E2MI	DRUGNAME	ARH-1029
D0E2MI	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative

D0K7VM	TTDDRUID	D0K7VM
D0K7VM	DRUGNAME	ARI-1778
D0K7VM	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D06CFZ	TTDDRUID	D06CFZ
D06CFZ	DRUGNAME	ARM-AK-105
D06CFZ	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D0Q2UI	TTDDRUID	D0Q2UI
D0Q2UI	DRUGNAME	Armed Probodies
D0Q2UI	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D0N9TK	TTDDRUID	D0N9TK
D0N9TK	DRUGNAME	AR-mTOR-26
D0N9TK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07DNV	TTDDRUID	D07DNV
D07DNV	DRUGNAME	ARN-2966
D07DNV	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0O5CL	TTDDRUID	D0O5CL
D0O5CL	DRUGNAME	ARO 087
D0O5CL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08OPW	TTDDRUID	D08OPW
D08OPW	DRUGNAME	ARRY-575
D08OPW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z7RR	TTDDRUID	D0Z7RR
D0Z7RR	DRUGNAME	ARRY-770
D0Z7RR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07SVE	TTDDRUID	D07SVE
D07SVE	DRUGNAME	ARRY-886
D07SVE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08OLR	TTDDRUID	D08OLR
D08OLR	DRUGNAME	ART-144
D08OLR	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D04WNA	TTDDRUID	D04WNA
D04WNA	DRUGNAME	ART-237
D04WNA	INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative

D02LCT	TTDDRUID	D02LCT
D02LCT	DRUGNAME	ARTELINIC ACID
D02LCT	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0T1GH	TTDDRUID	D0T1GH
D0T1GH	DRUGNAME	Artemisinin derivatives
D0T1GH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01RFU	TTDDRUID	D01RFU
D01RFU	DRUGNAME	Artemisinin trioxane dimers
D01RFU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LY6R	TTDDRUID	D0LY6R
D0LY6R	DRUGNAME	Artemisinin-based iron chelators
D0LY6R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G4SM	TTDDRUID	D0G4SM
D0G4SM	DRUGNAME	Artemisinin-peptide conjugates
D0G4SM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B7JJ	TTDDRUID	D0B7JJ
D0B7JJ	DRUGNAME	Arthritis therapeutics
D0B7JJ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0WI1L	TTDDRUID	D0WI1L
D0WI1L	DRUGNAME	Arthromir
D0WI1L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0FI1K	TTDDRUID	D0FI1K
D0FI1K	DRUGNAME	ARX-212
D0FI1K	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0Q4IE	TTDDRUID	D0Q4IE
D0Q4IE	DRUGNAME	ARX-618
D0Q4IE	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D01KER	TTDDRUID	D01KER
D01KER	DRUGNAME	ARX-8203 injectable
D01KER	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0GB7F	TTDDRUID	D0GB7F
D0GB7F	DRUGNAME	ARX-AHD
D0GB7F	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0YB5Z	TTDDRUID	D0YB5Z
D0YB5Z	DRUGNAME	ARX-Trail
D0YB5Z	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D02GTT	TTDDRUID	D02GTT
D02GTT	DRUGNAME	AR-XYZ
D02GTT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0AS4C	TTDDRUID	D0AS4C
D0AS4C	DRUGNAME	Arylimidamides
D0AS4C	INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative

D07QBZ	TTDDRUID	D07QBZ
D07QBZ	DRUGNAME	Arylpropenamides
D07QBZ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0Z2GH	TTDDRUID	D0Z2GH
D0Z2GH	DRUGNAME	AS-1387392
D0Z2GH	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0I5ZO	TTDDRUID	D0I5ZO
D0I5ZO	DRUGNAME	AS-1522489-00
D0I5ZO	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D0W9KE	TTDDRUID	D0W9KE
D0W9KE	DRUGNAME	AS-1708727
D0W9KE	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Investigative

D07UBK	TTDDRUID	D07UBK
D07UBK	DRUGNAME	AS-1892802
D07UBK	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00WVI	TTDDRUID	D00WVI
D00WVI	DRUGNAME	AS-1907417
D00WVI	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D09IKZ	TTDDRUID	D09IKZ
D09IKZ	DRUGNAME	AS-1949490
D09IKZ	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0T3KW	TTDDRUID	D0T3KW
D0T3KW	DRUGNAME	AS-337
D0T3KW	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0T2MV	TTDDRUID	D0T2MV
D0T2MV	DRUGNAME	AS-9705
D0T2MV	INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative
D0T2MV	INDICATI	Vomiting [ICD-11: MD90] Investigative

D0W6OB	TTDDRUID	D0W6OB
D0W6OB	DRUGNAME	ASB formulation
D0W6OB	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Investigative

D0T9GQ	TTDDRUID	D0T9GQ
D0T9GQ	DRUGNAME	ASB-010
D0T9GQ	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D0C3ET	TTDDRUID	D0C3ET
D0C3ET	DRUGNAME	ASB-16165
D0C3ET	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0N3YL	TTDDRUID	D0N3YL
D0N3YL	DRUGNAME	ASC-201
D0N3YL	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Investigative

D02RZC	TTDDRUID	D02RZC
D02RZC	DRUGNAME	ASC-JMX2
D02RZC	INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative

D0O0II	TTDDRUID	D0O0II
D0O0II	DRUGNAME	ASC-JMZ1
D0O0II	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0LY3D	TTDDRUID	D0LY3D
D0LY3D	DRUGNAME	Ascofuranone and analogs
D0LY3D	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D0D6KW	TTDDRUID	D0D6KW
D0D6KW	DRUGNAME	ASIC3 inhibitors
D0D6KW	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0CV7Q	TTDDRUID	D0CV7Q
D0CV7Q	DRUGNAME	ASO-1
D0CV7Q	INDICATI	Fatty liver disease [ICD-11: DB92.Z] Investigative

D04LBJ	TTDDRUID	D04LBJ
D04LBJ	DRUGNAME	ASOBAMAST
D04LBJ	INDICATI	Asthma [ICD-11: CA23] Investigative

D00RQQ	TTDDRUID	D00RQQ
D00RQQ	DRUGNAME	ASP-1120
D00RQQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D05SHQ	TTDDRUID	D05SHQ
D05SHQ	DRUGNAME	ASP-2002
D05SHQ	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D0N7HS	TTDDRUID	D0N7HS
D0N7HS	DRUGNAME	ASP-3258
D0N7HS	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative

D03QEC	TTDDRUID	D03QEC
D03QEC	DRUGNAME	ASP4131
D03QEC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
D03QEC	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D0J8NC	TTDDRUID	D0J8NC
D0J8NC	DRUGNAME	ASP-8370
D0J8NC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D00MFA	TTDDRUID	D00MFA
D00MFA	DRUGNAME	Aspartame
D00MFA	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D00OFV	TTDDRUID	D00OFV
D00OFV	DRUGNAME	Asperlicin
D00OFV	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D0Y4YN	TTDDRUID	D0Y4YN
D0Y4YN	DRUGNAME	Astaxanthin derivative
D0Y4YN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0E0MU	TTDDRUID	D0E0MU
D0E0MU	DRUGNAME	AstraStim
D0E0MU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V3BS	TTDDRUID	D0V3BS
D0V3BS	DRUGNAME	AT-002
D0V3BS	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D02AQL	TTDDRUID	D02AQL
D02AQL	DRUGNAME	AT-003
D02AQL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ET6F	TTDDRUID	D0ET6F
D0ET6F	DRUGNAME	AT-004
D0ET6F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R3DT	TTDDRUID	D0R3DT
D0R3DT	DRUGNAME	AT-006
D0R3DT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00ZWE	TTDDRUID	D00ZWE
D00ZWE	DRUGNAME	AT-007
D00ZWE	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D02MTK	TTDDRUID	D02MTK
D02MTK	DRUGNAME	AT-008
D02MTK	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D04ATE	TTDDRUID	D04ATE
D04ATE	DRUGNAME	AT-009
D04ATE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J7QX	TTDDRUID	D0J7QX
D0J7QX	DRUGNAME	AT-012
D0J7QX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01SSL	TTDDRUID	D01SSL
D01SSL	DRUGNAME	AT-027
D01SSL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U5ZV	TTDDRUID	D0U5ZV
D0U5ZV	DRUGNAME	AT-3375
D0U5ZV	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0H0SH	TTDDRUID	D0H0SH
D0H0SH	DRUGNAME	ATB-284
D0H0SH	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative

D00JVC	TTDDRUID	D00JVC
D00JVC	DRUGNAME	ATB-429
D00JVC	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0S0RX	TTDDRUID	D0S0RX
D0S0RX	DRUGNAME	ATGC-OP0359
D0S0RX	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0V4XA	TTDDRUID	D0V4XA
D0V4XA	DRUGNAME	ATH-90879
D0V4XA	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0Q4IR	TTDDRUID	D0Q4IR
D0Q4IR	DRUGNAME	Atherosclerosis/rheumatoid arthritis agents
D0Q4IR	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0B8JG	TTDDRUID	D0B8JG
D0B8JG	DRUGNAME	ATI-0409
D0B8JG	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D01HLF	TTDDRUID	D01HLF
D01HLF	DRUGNAME	ATI-0810
D01HLF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04VPP	TTDDRUID	D04VPP
D04VPP	DRUGNAME	ATI-1150
D04VPP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A7GH	TTDDRUID	D0A7GH
D0A7GH	DRUGNAME	ATI-2341
D0A7GH	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Investigative

D0W2EG	TTDDRUID	D0W2EG
D0W2EG	DRUGNAME	ATL-1222
D0W2EG	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Investigative

D0O3SA	TTDDRUID	D0O3SA
D0O3SA	DRUGNAME	ATL-801
D0O3SA	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D01QYQ	TTDDRUID	D01QYQ
D01QYQ	DRUGNAME	ATL-844
D01QYQ	INDICATI	Asthma [ICD-11: CA23] Investigative

D03BWQ	TTDDRUID	D03BWQ
D03BWQ	DRUGNAME	ATN-658
D03BWQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P7BQ	TTDDRUID	D0P7BQ
D0P7BQ	DRUGNAME	Atpenin B
D0P7BQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07WNG	TTDDRUID	D07WNG
D07WNG	DRUGNAME	Atrimer
D07WNG	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D02WRE	TTDDRUID	D02WRE
D02WRE	DRUGNAME	ATS-907
D02WRE	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D06GAQ	TTDDRUID	D06GAQ
D06GAQ	DRUGNAME	Atu-111
D06GAQ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0C7CV	TTDDRUID	D0C7CV
D0C7CV	DRUGNAME	Atu-134
D0C7CV	INDICATI	Lung injury [ICD-11: NB32.3Z] Investigative

D0Y6XG	TTDDRUID	D0Y6XG
D0Y6XG	DRUGNAME	Atu-195
D0Y6XG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K4JS	TTDDRUID	D0K4JS
D0K4JS	DRUGNAME	ATX-3105
D0K4JS	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0P1RV	TTDDRUID	D0P1RV
D0P1RV	DRUGNAME	ATX-GD
D0P1RV	INDICATI	Graves disease [ICD-11: 5A02.0] Investigative

D0A8IQ	TTDDRUID	D0A8IQ
D0A8IQ	DRUGNAME	ATX-MS2
D0A8IQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0O5HB	TTDDRUID	D0O5HB
D0O5HB	DRUGNAME	ATX-MS3
D0O5HB	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D07ZHM	TTDDRUID	D07ZHM
D07ZHM	DRUGNAME	ATX-S10
D07ZHM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09KVO	TTDDRUID	D09KVO
D09KVO	DRUGNAME	Atypical antipsychotics
D09KVO	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D0C4EQ	TTDDRUID	D0C4EQ
D0C4EQ	DRUGNAME	ATYR-0030
D0C4EQ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D00NIV	TTDDRUID	D00NIV
D00NIV	DRUGNAME	ATYR-1920
D00NIV	INDICATI	Genetic disease [ICD-11: 8E02] Investigative

D07VHX	TTDDRUID	D07VHX
D07VHX	DRUGNAME	Augmab
D07VHX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03HGN	TTDDRUID	D03HGN
D03HGN	DRUGNAME	Aurora A kinase inhibitors (cancer), Evotec
D03HGN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H5GW	TTDDRUID	D0H5GW
D0H5GW	DRUGNAME	Aurora A kinase inhibitors (cancer), Genentech
D0H5GW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F1GD	TTDDRUID	D0F1GD
D0F1GD	DRUGNAME	AuroVax
D0F1GD	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0N0SO	TTDDRUID	D0N0SO
D0N0SO	DRUGNAME	Autosomal dominant retinitis pigmentosa
D0N0SO	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative

D0M7VB	TTDDRUID	D0M7VB
D0M7VB	DRUGNAME	AV-1013
D0M7VB	INDICATI	Nervous system inflammation [ICD-11: 1D0Y] Investigative

D0HO9M	TTDDRUID	D0HO9M
D0HO9M	DRUGNAME	AV-2
D0HO9M	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D03HGW	TTDDRUID	D03HGW
D03HGW	DRUGNAME	AV-370
D03HGW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P0XX	TTDDRUID	D0P0XX
D0P0XX	DRUGNAME	Avermectins
D0P0XX	INDICATI	Pest attack [ICD-11: N.A.] Investigative

D0Z5YI	TTDDRUID	D0Z5YI
D0Z5YI	DRUGNAME	AVI-5038
D0Z5YI	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D0F8GT	TTDDRUID	D0F8GT
D0F8GT	DRUGNAME	AVI-6006
D0F8GT	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D04VHQ	TTDDRUID	D04VHQ
D04VHQ	DRUGNAME	AVI-7012
D04VHQ	INDICATI	Junin virus infection [ICD-11: 1D6Y] Investigative

D0R5VO	TTDDRUID	D0R5VO
D0R5VO	DRUGNAME	Avicin D
D0R5VO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09WIM	TTDDRUID	D09WIM
D09WIM	DRUGNAME	AviFluCide-I
D09WIM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0KL7C	TTDDRUID	D0KL7C
D0KL7C	DRUGNAME	Aviptadil
D0KL7C	INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative

D0P7RV	TTDDRUID	D0P7RV
D0P7RV	DRUGNAME	AVL-181
D0P7RV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0C9KW	TTDDRUID	D0C9KW
D0C9KW	DRUGNAME	AVN-457
D0C9KW	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0S4NZ	TTDDRUID	D0S4NZ
D0S4NZ	DRUGNAME	AVN-458
D0S4NZ	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0I9IF	TTDDRUID	D0I9IF
D0I9IF	DRUGNAME	AVN-492
D0I9IF	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0B3DE	TTDDRUID	D0B3DE
D0B3DE	DRUGNAME	AVN-628
D0B3DE	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D00YTS	TTDDRUID	D00YTS
D00YTS	DRUGNAME	AVP-13546
D00YTS	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Investigative

D01SWJ	TTDDRUID	D01SWJ
D01SWJ	DRUGNAME	AVP-13748
D01SWJ	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Investigative

D0U4IG	TTDDRUID	D0U4IG
D0U4IG	DRUGNAME	AVP-4
D0U4IG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08OLU	TTDDRUID	D08OLU
D08OLU	DRUGNAME	AVP-5
D08OLU	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative

D04ZZD	TTDDRUID	D04ZZD
D04ZZD	DRUGNAME	AVP-6
D04ZZD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D04WCA	TTDDRUID	D04WCA
D04WCA	DRUGNAME	AVP-7
D04WCA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J4TX	TTDDRUID	D0J4TX
D0J4TX	DRUGNAME	AVX-002
D0J4TX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D04URZ	TTDDRUID	D04URZ
D04URZ	DRUGNAME	AVX-003
D04URZ	INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Investigative

D05OAJ	TTDDRUID	D05OAJ
D05OAJ	DRUGNAME	AW-814141
D05OAJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0C3FN	TTDDRUID	D0C3FN
D0C3FN	DRUGNAME	AX-13057
D0C3FN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D6ZB	TTDDRUID	D0D6ZB
D0D6ZB	DRUGNAME	AX-9657
D0D6ZB	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative

D0Y5BV	TTDDRUID	D0Y5BV
D0Y5BV	DRUGNAME	AXImab
D0Y5BV	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0V1QX	TTDDRUID	D0V1QX
D0V1QX	DRUGNAME	Axogenesis Factor-1
D0V1QX	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D02MLA	TTDDRUID	D02MLA
D02MLA	DRUGNAME	AXP-107-08
D02MLA	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D05VWK	TTDDRUID	D05VWK
D05VWK	DRUGNAME	AXP-107-16
D05VWK	INDICATI	Gynecological disease [ICD-11: GA6Z] Investigative

D02BGZ	TTDDRUID	D02BGZ
D02BGZ	DRUGNAME	AXP-107-17
D02BGZ	INDICATI	Radiation syndrome [ICD-11: NF00] Investigative

D0VC8T	TTDDRUID	D0VC8T
D0VC8T	DRUGNAME	AZ-05
D0VC8T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03HJZ	TTDDRUID	D03HJZ
D03HJZ	DRUGNAME	AZ-11657312
D03HJZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02XUY	TTDDRUID	D02XUY
D02XUY	DRUGNAME	AZ-1297442
D02XUY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0K0CK	TTDDRUID	D0K0CK
D0K0CK	DRUGNAME	AZ-17
D0K0CK	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0O8AR	TTDDRUID	D0O8AR
D0O8AR	DRUGNAME	AZ-23
D0O8AR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04YLU	TTDDRUID	D04YLU
D04YLU	DRUGNAME	AZ-599
D04YLU	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0C0ZC	TTDDRUID	D0C0ZC
D0C0ZC	DRUGNAME	AZ-628
D0C0ZC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06UUE	TTDDRUID	D06UUE
D06UUE	DRUGNAME	AZ-AAV9
D06UUE	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0X2NB	TTDDRUID	D0X2NB
D0X2NB	DRUGNAME	AZD-6319
D0X2NB	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D06CWM	TTDDRUID	D06CWM
D06CWM	DRUGNAME	AZD-7507
D06CWM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OW6V	TTDDRUID	D0OW6V
D0OW6V	DRUGNAME	AZM-1
D0OW6V	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0Z0KH	TTDDRUID	D0Z0KH
D0Z0KH	DRUGNAME	Azole
D0Z0KH	INDICATI	Candidiasis [ICD-11: 1F23] Investigative

D0S1HI	TTDDRUID	D0S1HI
D0S1HI	DRUGNAME	Azoles
D0S1HI	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D0T2ST	TTDDRUID	D0T2ST
D0T2ST	DRUGNAME	Azotropin
D0T2ST	INDICATI	Growth failure [ICD-11: LD2F.1Y] Investigative

D09XWT	TTDDRUID	D09XWT
D09XWT	DRUGNAME	AZP-03
D09XWT	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D04MHP	TTDDRUID	D04MHP
D04MHP	DRUGNAME	AZP-2006
D04MHP	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0H9QN	TTDDRUID	D0H9QN
D0H9QN	DRUGNAME	AZ-TAK1
D0H9QN	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Investigative

D0VV2D	TTDDRUID	D0VV2D
D0VV2D	DRUGNAME	B-06
D0VV2D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y6XD	TTDDRUID	D0Y6XD
D0Y6XD	DRUGNAME	B-247
D0Y6XD	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0T0VA	TTDDRUID	D0T0VA
D0T0VA	DRUGNAME	B-4474
D0T0VA	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D00RIK	TTDDRUID	D00RIK
D00RIK	DRUGNAME	B7/CD28 costimulatory proteins
D00RIK	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0G1TX	TTDDRUID	D0G1TX
D0G1TX	DRUGNAME	BA-011
D0G1TX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0E8IG	TTDDRUID	D0E8IG
D0E8IG	DRUGNAME	BA-016
D0E8IG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01ZPK	TTDDRUID	D01ZPK
D01ZPK	DRUGNAME	BA-207
D01ZPK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0S5MI	TTDDRUID	D0S5MI
D0S5MI	DRUGNAME	Bacillus anthracis therapeutics
D0S5MI	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D04DBA	TTDDRUID	D04DBA
D04DBA	DRUGNAME	BAG956
D04DBA	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Investigative

D0R3VQ	TTDDRUID	D0R3VQ
D0R3VQ	DRUGNAME	BAL-27862
D0R3VQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07FCA	TTDDRUID	D07FCA
D07FCA	DRUGNAME	BAMLET
D07FCA	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0Q5VC	TTDDRUID	D0Q5VC
D0Q5VC	DRUGNAME	BAN-2203
D0Q5VC	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D01FJN	TTDDRUID	D01FJN
D01FJN	DRUGNAME	BAY-1006451
D01FJN	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0L2XO	TTDDRUID	D0L2XO
D0L2XO	DRUGNAME	BAY11-7082
D0L2XO	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0NX6F	TTDDRUID	D0NX6F
D0NX6F	DRUGNAME	BAY-85-3474
D0NX6F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H3FA	TTDDRUID	D0H3FA
D0H3FA	DRUGNAME	BB-101
D0H3FA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0Q3WW	TTDDRUID	D0Q3WW
D0Q3WW	DRUGNAME	BB-15600
D0Q3WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06AES	TTDDRUID	D06AES
D06AES	DRUGNAME	BB-16000
D06AES	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09RZB	TTDDRUID	D09RZB
D09RZB	DRUGNAME	BBI-11008
D09RZB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0D7RE	TTDDRUID	D0D7RE
D0D7RE	DRUGNAME	BBI-8000
D0D7RE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00MCA	TTDDRUID	D00MCA
D00MCA	DRUGNAME	BB-PTH 1-84
D00MCA	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0B6OG	TTDDRUID	D0B6OG
D0B6OG	DRUGNAME	BBT-007
D0B6OG	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D01ESC	TTDDRUID	D01ESC
D01ESC	DRUGNAME	BBT-009
D01ESC	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0HA2R	TTDDRUID	D0HA2R
D0HA2R	DRUGNAME	BBT-012
D0HA2R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01MMG	TTDDRUID	D01MMG
D01MMG	DRUGNAME	BBT-015
D01MMG	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D0W2FN	TTDDRUID	D0W2FN
D0W2FN	DRUGNAME	BBT-018
D0W2FN	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D0O6TD	TTDDRUID	D0O6TD
D0O6TD	DRUGNAME	BBT-021
D0O6TD	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0W1YX	TTDDRUID	D0W1YX
D0W1YX	DRUGNAME	BBT-031
D0W1YX	INDICATI	Growth failure [ICD-11: LD2F.1Y] Investigative

D0Z7GX	TTDDRUID	D0Z7GX
D0Z7GX	DRUGNAME	BBT-032
D0Z7GX	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D01MHT	TTDDRUID	D01MHT
D01MHT	DRUGNAME	BBT-046
D01MHT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03HOT	TTDDRUID	D03HOT
D03HOT	DRUGNAME	BC-19
D03HOT	INDICATI	Brain disease [ICD-11: 8C70-8E61] Investigative

D09CIB	TTDDRUID	D09CIB
D09CIB	DRUGNAME	BC-22
D09CIB	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0S6UH	TTDDRUID	D0S6UH
D0S6UH	DRUGNAME	BC-6213
D0S6UH	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D03IQK	TTDDRUID	D03IQK
D03IQK	DRUGNAME	BC-821
D03IQK	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0H0VB	TTDDRUID	D0H0VB
D0H0VB	DRUGNAME	BC-822
D0H0VB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V1OY	TTDDRUID	D0V1OY
D0V1OY	DRUGNAME	BC-DU-04
D0V1OY	INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative

D0NN5F	TTDDRUID	D0NN5F
D0NN5F	DRUGNAME	BChE inhibitors
D0NN5F	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0O8HK	TTDDRUID	D0O8HK
D0O8HK	DRUGNAME	BCL-003
D0O8HK	INDICATI	Glioma [ICD-11: 2A00.0] Investigative

D09KTE	TTDDRUID	D09KTE
D09KTE	DRUGNAME	BCL-004
D09KTE	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative

D0C6XD	TTDDRUID	D0C6XD
D0C6XD	DRUGNAME	BCL-005
D0C6XD	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D03DTU	TTDDRUID	D03DTU
D03DTU	DRUGNAME	BCL-5
D03DTU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0T1LX	TTDDRUID	D0T1LX
D0T1LX	DRUGNAME	BC-ONY-01
D0T1LX	INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative

D0M4TN	TTDDRUID	D0M4TN
D0M4TN	DRUGNAME	BCP-1071
D0M4TN	INDICATI	Upper respiratory infection [ICD-11: CA07] Investigative

D05AAQ	TTDDRUID	D05AAQ
D05AAQ	DRUGNAME	BCP-1081
D05AAQ	INDICATI	Asthma [ICD-11: CA23] Investigative

D07RIE	TTDDRUID	D07RIE
D07RIE	DRUGNAME	BC-PN-02
D07RIE	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Investigative

D0PM3G	TTDDRUID	D0PM3G
D0PM3G	DRUGNAME	BC-RD-03
D0PM3G	INDICATI	Raynaud disease [ICD-11: BD42.0] Investigative

D0P7VQ	TTDDRUID	D0P7VQ
D0P7VQ	DRUGNAME	BCTC
D0P7VQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D04MXO	TTDDRUID	D04MXO
D04MXO	DRUGNAME	BCX-5191
D04MXO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0E9VL	TTDDRUID	D0E9VL
D0E9VL	DRUGNAME	BDD-20617
D0E9VL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0CA7B	TTDDRUID	D0CA7B
D0CA7B	DRUGNAME	BDM-I
D0CA7B	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D02YYS	TTDDRUID	D02YYS
D02YYS	DRUGNAME	BDNA-001
D02YYS	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D01PZJ	TTDDRUID	D01PZJ
D01PZJ	DRUGNAME	BDNA-002
D01PZJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D03QQP	TTDDRUID	D03QQP
D03QQP	DRUGNAME	BDNA-003
D03QQP	INDICATI	Chlamydia infection [ICD-11: 1A81] Investigative

D06MPJ	TTDDRUID	D06MPJ
D06MPJ	DRUGNAME	BD-NP
D06MPJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0V5OG	TTDDRUID	D0V5OG
D0V5OG	DRUGNAME	BE-14106
D0V5OG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05ZCZ	TTDDRUID	D05ZCZ
D05ZCZ	DRUGNAME	Beifutai
D05ZCZ	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0D4QL	TTDDRUID	D0D4QL
D0D4QL	DRUGNAME	Benzimidazole 5-carboxamide
D0D4QL	INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative

D0CS6N	TTDDRUID	D0CS6N
D0CS6N	DRUGNAME	Benzodiazepine
D0CS6N	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0B1FH	TTDDRUID	D0B1FH
D0B1FH	DRUGNAME	Benzothiazinones
D0B1FH	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0E6JG	TTDDRUID	D0E6JG
D0E6JG	DRUGNAME	Benzyldihydroxyoctenone
D0E6JG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05HEJ	TTDDRUID	D05HEJ
D05HEJ	DRUGNAME	Beta 1-6 glucan-conjugated trastuzumab
D05HEJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D05EKQ	TTDDRUID	D05EKQ
D05EKQ	DRUGNAME	Beta amyloid lowering agents
D05EKQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D07IQK	TTDDRUID	D07IQK
D07IQK	DRUGNAME	Beta III tubulin targeting ddRNAi therapeutic
D07IQK	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D02GPZ	TTDDRUID	D02GPZ
D02GPZ	DRUGNAME	Beta-2 adrenergic receptor targeting mabs
D02GPZ	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D0M6FP	TTDDRUID	D0M6FP
D0M6FP	DRUGNAME	Beta-adrenoceptor ligands
D0M6FP	INDICATI	Urinary incontinence [ICD-11: MF50.2] Investigative

D0A2HK	TTDDRUID	D0A2HK
D0A2HK	DRUGNAME	Beta-catenin/Tcf-4 pathway inhibitors
D0A2HK	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D0Q9VW	TTDDRUID	D0Q9VW
D0Q9VW	DRUGNAME	Beta-Gly
D0Q9VW	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0W3NR	TTDDRUID	D0W3NR
D0W3NR	DRUGNAME	BetaGRAFT
D0W3NR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D05LXH	TTDDRUID	D05LXH
D05LXH	DRUGNAME	Beta-interferon
D05LXH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D03JRA	TTDDRUID	D03JRA
D03JRA	DRUGNAME	Beta-lactam
D03JRA	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative

D0F4CN	TTDDRUID	D0F4CN
D0F4CN	DRUGNAME	Beta-lactam antibiotics
D0F4CN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00NOY	TTDDRUID	D00NOY
D00NOY	DRUGNAME	BetaRx
D00NOY	INDICATI	Type-1 diabetes [ICD-11: 5A10] Investigative

D01ACE	TTDDRUID	D01ACE
D01ACE	DRUGNAME	BF/PC-13
D01ACE	INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative

D0P5RJ	TTDDRUID	D0P5RJ
D0P5RJ	DRUGNAME	BF/PC-18
D0P5RJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0V1UZ	TTDDRUID	D0V1UZ
D0V1UZ	DRUGNAME	BF/PC-21
D0V1UZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0WW7U	TTDDRUID	D0WW7U
D0WW7U	DRUGNAME	BFPT-12603
D0WW7U	INDICATI	Asthma [ICD-11: CA23] Investigative

D0XP3A	TTDDRUID	D0XP3A
D0XP3A	DRUGNAME	BFPT-16864
D0XP3A	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D06VMV	TTDDRUID	D06VMV
D06VMV	DRUGNAME	BHF-177
D06VMV	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D01OMY	TTDDRUID	D01OMY
D01OMY	DRUGNAME	BHT-3034
D01OMY	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Investigative

D0XT0I	TTDDRUID	D0XT0I
D0XT0I	DRUGNAME	BIA
D0XT0I	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0X8ZY	TTDDRUID	D0X8ZY
D0X8ZY	DRUGNAME	BIA-10
D0X8ZY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0UM7H	TTDDRUID	D0UM7H
D0UM7H	DRUGNAME	BIA-12
D0UM7H	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0WS5L	TTDDRUID	D0WS5L
D0WS5L	DRUGNAME	BIA-13
D0WS5L	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D0W8MN	TTDDRUID	D0W8MN
D0W8MN	DRUGNAME	Biaryl thiophenes
D0W8MN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0N1RE	TTDDRUID	D0N1RE
D0N1RE	DRUGNAME	BIBF100
D0N1RE	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0U0LG	TTDDRUID	D0U0LG
D0U0LG	DRUGNAME	Bicyclolide antibiotics
D0U0LG	INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative

D01HFI	TTDDRUID	D01HFI
D01HFI	DRUGNAME	Bifenazate Acequinocyl
D01HFI	INDICATI	Pest attack [ICD-11: N.A.] Investigative

D0NS9C	TTDDRUID	D0NS9C
D0NS9C	DRUGNAME	BIIB-513
D0NS9C	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D01BFA	TTDDRUID	D01BFA
D01BFA	DRUGNAME	BIK-381
D01BFA	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative

D0H3OZ	TTDDRUID	D0H3OZ
D0H3OZ	DRUGNAME	BIM-46187
D0H3OZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05SQU	TTDDRUID	D05SQU
D05SQU	DRUGNAME	BIM-64152
D05SQU	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D04IXJ	TTDDRUID	D04IXJ
D04IXJ	DRUGNAME	Bimetopyrole
D04IXJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D02YWM	TTDDRUID	D02YWM
D02YWM	DRUGNAME	BIO-500
D02YWM	INDICATI	Radiation syndrome [ICD-11: NF00] Investigative

D0G8MW	TTDDRUID	D0G8MW
D0G8MW	DRUGNAME	BIOLUP
D0G8MW	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative

D0PG2W	TTDDRUID	D0PG2W
D0PG2W	DRUGNAME	Biomin Peptide-II
D0PG2W	INDICATI	Bone injury [ICD-11: ND56.Y] Investigative

D0N1AT	TTDDRUID	D0N1AT
D0N1AT	DRUGNAME	BIOO-1
D0N1AT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05CPD	TTDDRUID	D05CPD
D05CPD	DRUGNAME	BIOO-2
D05CPD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W4RB	TTDDRUID	D0W4RB
D0W4RB	DRUGNAME	BIOO-3
D0W4RB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I4YP	TTDDRUID	D0I4YP
D0I4YP	DRUGNAME	BIOO-5
D0I4YP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09JTE	TTDDRUID	D09JTE
D09JTE	DRUGNAME	BIOO-6
D09JTE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I6OZ	TTDDRUID	D0I6OZ
D0I6OZ	DRUGNAME	Biosuperior protein therapeutic
D0I6OZ	INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative

D0ON3Q	TTDDRUID	D0ON3Q
D0ON3Q	DRUGNAME	Biotin carboxylase inhibitors
D0ON3Q	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0V2GZ	TTDDRUID	D0V2GZ
D0V2GZ	DRUGNAME	BioVant
D0V2GZ	INDICATI	Vaccination [ICD-11: N.A.] Investigative

D01BKD	TTDDRUID	D01BKD
D01BKD	DRUGNAME	Birch peptide allergy desensitization agent
D01BKD	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D09NGF	TTDDRUID	D09NGF
D09NGF	DRUGNAME	Bis-(indole) antibacterials
D09NGF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D04MIL	TTDDRUID	D04MIL
D04MIL	DRUGNAME	Bispecific antobody
D04MIL	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0V4ZA	TTDDRUID	D0V4ZA
D0V4ZA	DRUGNAME	Bisphosphonates
D0V4ZA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0M6EG	TTDDRUID	D0M6EG
D0M6EG	DRUGNAME	Bisplatinum complexes
D0M6EG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R1RQ	TTDDRUID	D0R1RQ
D0R1RQ	DRUGNAME	BJ-B11
D0R1RQ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D07ZCU	TTDDRUID	D07ZCU
D07ZCU	DRUGNAME	BKT-120
D07ZCU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ES9J	TTDDRUID	D0ES9J
D0ES9J	DRUGNAME	BL-4040
D0ES9J	INDICATI	Kidney injury [ICD-11: NB92.0] Investigative

D07OED	TTDDRUID	D07OED
D07OED	DRUGNAME	BL-5040
D07OED	INDICATI	Cachexia [ICD-11: MG20] Investigative

D03ONE	TTDDRUID	D03ONE
D03ONE	DRUGNAME	BL-6010
D03ONE	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D08QRO	TTDDRUID	D08QRO
D08QRO	DRUGNAME	BL-6020
D08QRO	INDICATI	Cachexia [ICD-11: MG20] Investigative

D0I6LR	TTDDRUID	D0I6LR
D0I6LR	DRUGNAME	BL-6030
D0I6LR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D04FHY	TTDDRUID	D04FHY
D04FHY	DRUGNAME	BL-7020
D04FHY	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0LE6K	TTDDRUID	D0LE6K
D0LE6K	DRUGNAME	BL-Angiostatin
D0LE6K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T9PL	TTDDRUID	D0T9PL
D0T9PL	DRUGNAME	BLV-0703
D0T9PL	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0JB0N	TTDDRUID	D0JB0N
D0JB0N	DRUGNAME	BLV-0704
D0JB0N	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06BBF	TTDDRUID	D06BBF
D06BBF	DRUGNAME	BLV-0801
D06BBF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06UUU	TTDDRUID	D06UUU
D06UUU	DRUGNAME	BLX-1017
D06UUU	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00WEP	TTDDRUID	D00WEP
D00WEP	DRUGNAME	BLX-155
D00WEP	INDICATI	Deep vein thrombosis [ICD-11: BD71] Investigative

D0K9HF	TTDDRUID	D0K9HF
D0K9HF	DRUGNAME	BLX-301
D0K9HF	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative

D0P0DA	TTDDRUID	D0P0DA
D0P0DA	DRUGNAME	BM-162115
D0P0DA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02HBI	TTDDRUID	D02HBI
D02HBI	DRUGNAME	Bmab-100
D02HBI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04GCH	TTDDRUID	D04GCH
D04GCH	DRUGNAME	Bmab-200
D04GCH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V3WN	TTDDRUID	D0V3WN
D0V3WN	DRUGNAME	BMN-103
D0V3WN	INDICATI	Pompe disease [ICD-11: 5C51.3] Investigative

D05TXS	TTDDRUID	D05TXS
D05TXS	DRUGNAME	BMN-168
D05TXS	INDICATI	Phenylketonuria [ICD-11: 5C50.0] Investigative

D07OZO	TTDDRUID	D07OZO
D07OZO	DRUGNAME	BMP-4
D07OZO	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D0A6OF	TTDDRUID	D0A6OF
D0A6OF	DRUGNAME	BMS-181321
D0A6OF	INDICATI	Diagnostic imaging [ICD-11: N.A.] Investigative

D00YTQ	TTDDRUID	D00YTQ
D00YTQ	DRUGNAME	BMS-345541
D00YTQ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D05RPN	TTDDRUID	D05RPN
D05RPN	DRUGNAME	BMS-488516
D05RPN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D04PEI	TTDDRUID	D04PEI
D04PEI	DRUGNAME	BMS-509744
D04PEI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0YC1R	TTDDRUID	D0YC1R
D0YC1R	DRUGNAME	BMS-520
D0YC1R	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D03KTU	TTDDRUID	D03KTU
D03KTU	DRUGNAME	BMS-561388
D03KTU	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D06NVN	TTDDRUID	D06NVN
D06NVN	DRUGNAME	BMS-599793
D06NVN	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0LI3H	TTDDRUID	D0LI3H
D0LI3H	DRUGNAME	BMS-633
D0LI3H	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D05MSG	TTDDRUID	D05MSG
D05MSG	DRUGNAME	BMS-694153
D05MSG	INDICATI	Migraine [ICD-11: 8A80] Investigative

D0Q9IE	TTDDRUID	D0Q9IE
D0Q9IE	DRUGNAME	BMS-707035
D0Q9IE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D06XLC	TTDDRUID	D06XLC
D06XLC	DRUGNAME	BMS-739562
D06XLC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09WMV	TTDDRUID	D09WMV
D09WMV	DRUGNAME	BMS-753951
D09WMV	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D09YJK	TTDDRUID	D09YJK
D09YJK	DRUGNAME	BMS-766
D09YJK	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D03RTC	TTDDRUID	D03RTC
D03RTC	DRUGNAME	BMS-812204
D03RTC	INDICATI	Obesity [ICD-11: 5B81] Investigative

D02XNT	TTDDRUID	D02XNT
D02XNT	DRUGNAME	BMS-A
D02XNT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D06XOI	TTDDRUID	D06XOI
D06XOI	DRUGNAME	BMY-41802
D06XOI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0GX8F	TTDDRUID	D0GX8F
D0GX8F	DRUGNAME	BN-82002
D0GX8F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y5MF	TTDDRUID	D0Y5MF
D0Y5MF	DRUGNAME	BND-001
D0Y5MF	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0X9IQ	TTDDRUID	D0X9IQ
D0X9IQ	DRUGNAME	BND-002
D0X9IQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z2UT	TTDDRUID	D0Z2UT
D0Z2UT	DRUGNAME	BNP-FIX
D0Z2UT	INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative

D0R3OQ	TTDDRUID	D0R3OQ
D0R3OQ	DRUGNAME	BNV-222
D0R3OQ	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative

D0I6UK	TTDDRUID	D0I6UK
D0I6UK	DRUGNAME	BO-0742
D0I6UK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I8SA	TTDDRUID	D0I8SA
D0I8SA	DRUGNAME	BO-110
D0I8SA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02SAM	TTDDRUID	D02SAM
D02SAM	DRUGNAME	Bone marrow therapy, oral, University of North Carolina
D02SAM	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D06FOA	TTDDRUID	D06FOA
D06FOA	DRUGNAME	Bone morphogenetic protein-2
D06FOA	INDICATI	Bone injury [ICD-11: ND56.Y] Investigative

D01HQQ	TTDDRUID	D01HQQ
D01HQQ	DRUGNAME	Bone morphogenetic protein-4
D01HQQ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D0E4QW	TTDDRUID	D0E4QW
D0E4QW	DRUGNAME	Bone synthesis-stimulating small molecule therapeutics, oral, osteoporosis
D0E4QW	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D08PJV	TTDDRUID	D08PJV
D08PJV	DRUGNAME	Boron-based compounds
D08PJV	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0R4EY	TTDDRUID	D0R4EY
D0R4EY	DRUGNAME	Boscalid
D0R4EY	INDICATI	Plant grey mould disease [ICD-11: N.A.] Investigative

D03BJX	TTDDRUID	D03BJX
D03BJX	DRUGNAME	Botulinum toxin
D03BJX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E0DS	TTDDRUID	D0E0DS
D0E0DS	DRUGNAME	Box-5
D0E0DS	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0Q5NZ	TTDDRUID	D0Q5NZ
D0Q5NZ	DRUGNAME	BP-100-1.02
D0Q5NZ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative

D00CMC	TTDDRUID	D00CMC
D00CMC	DRUGNAME	BP-9906
D00CMC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q9GJ	TTDDRUID	D0Q9GJ
D0Q9GJ	DRUGNAME	BP-C2
D0Q9GJ	INDICATI	Radiation syndrome [ICD-11: NF00] Investigative

D0PP5M	TTDDRUID	D0PP5M
D0PP5M	DRUGNAME	BPH-652
D0PP5M	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0M4SV	TTDDRUID	D0M4SV
D0M4SV	DRUGNAME	BPI-3006
D0M4SV	INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative

D0R7FS	TTDDRUID	D0R7FS
D0R7FS	DRUGNAME	BPI-704001
D0R7FS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01ZWF	TTDDRUID	D01ZWF
D01ZWF	DRUGNAME	BPI-711001
D01ZWF	INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative

D0J2XP	TTDDRUID	D0J2XP
D0J2XP	DRUGNAME	BPI-713001
D0J2XP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0U2MP	TTDDRUID	D0U2MP
D0U2MP	DRUGNAME	BP-Inter-014
D0U2MP	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0F2SA	TTDDRUID	D0F2SA
D0F2SA	DRUGNAME	BPKDi
D0F2SA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02SRB	TTDDRUID	D02SRB
D02SRB	DRUGNAME	BPL-001
D02SRB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0S6SP	TTDDRUID	D0S6SP
D0S6SP	DRUGNAME	BPL-002
D0S6SP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D06PKL	TTDDRUID	D06PKL
D06PKL	DRUGNAME	BPL-003
D06PKL	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0D7QY	TTDDRUID	D0D7QY
D0D7QY	DRUGNAME	BPL-004
D0D7QY	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D09VAB	TTDDRUID	D09VAB
D09VAB	DRUGNAME	BPR1K-0224
D09VAB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0UD5P	TTDDRUID	D0UD5P
D0UD5P	DRUGNAME	BPR-DC-2
D0UD5P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M2LD	TTDDRUID	D0M2LD
D0M2LD	DRUGNAME	BQCA
D0M2LD	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0Y3QR	TTDDRUID	D0Y3QR
D0Y3QR	DRUGNAME	BQS-481
D0Y3QR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05DPE	TTDDRUID	D05DPE
D05DPE	DRUGNAME	BR-05001
D05DPE	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D03BGP	TTDDRUID	D03BGP
D03BGP	DRUGNAME	Bradykinin B1 receptor antagonists
D03BGP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D06SRB	TTDDRUID	D06SRB
D06SRB	DRUGNAME	Brain-derived neurotrophic factor peptidomimetics
D06SRB	INDICATI	Rett syndrome [ICD-11: LD90.4] Investigative

D0BR7M	TTDDRUID	D0BR7M
D0BR7M	DRUGNAME	Breceptin
D0BR7M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09FZM	TTDDRUID	D09FZM
D09FZM	DRUGNAME	BreMel/rGel
D09FZM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D07YPP	TTDDRUID	D07YPP
D07YPP	DRUGNAME	BreMel/TNF alpha
D07YPP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D01JEO	TTDDRUID	D01JEO
D01JEO	DRUGNAME	Brevenal
D01JEO	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D0H2NH	TTDDRUID	D0H2NH
D0H2NH	DRUGNAME	BRIFENTANIL
D0H2NH	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0S2KM	TTDDRUID	D0S2KM
D0S2KM	DRUGNAME	Broad-spectrum antiviral
D0S2KM	INDICATI	Rhinovirus infection [ICD-11: CA07] Investigative

D01SUY	TTDDRUID	D01SUY
D01SUY	DRUGNAME	BRU-83-92
D01SUY	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0Q2EH	TTDDRUID	D0Q2EH
D0Q2EH	DRUGNAME	Brutieridin
D0Q2EH	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0MJ7W	TTDDRUID	D0MJ7W
D0MJ7W	DRUGNAME	BRX-1002
D0MJ7W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T1OR	TTDDRUID	D0T1OR
D0T1OR	DRUGNAME	BRX-3
D0T1OR	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D01MNK	TTDDRUID	D01MNK
D01MNK	DRUGNAME	BS-194
D01MNK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07DSK	TTDDRUID	D07DSK
D07DSK	DRUGNAME	BSI-302
D07DSK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V3HZ	TTDDRUID	D0V3HZ
D0V3HZ	DRUGNAME	BSP-C728
D0V3HZ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D04LUG	TTDDRUID	D04LUG
D04LUG	DRUGNAME	BSP-C801
D04LUG	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D00WDM	TTDDRUID	D00WDM
D00WDM	DRUGNAME	BST-204
D00WDM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W4WN	TTDDRUID	D0W4WN
D0W4WN	DRUGNAME	BT-101
D0W4WN	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D03WTE	TTDDRUID	D03WTE
D03WTE	DRUGNAME	BT-301
D03WTE	INDICATI	Periodontal disease [ICD-11: DA0C] Investigative

D01BHC	TTDDRUID	D01BHC
D01BHC	DRUGNAME	BTA-929
D01BHC	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0Z9YV	TTDDRUID	D0Z9YV
D0Z9YV	DRUGNAME	BT-D005
D0Z9YV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E6ZI	TTDDRUID	D0E6ZI
D0E6ZI	DRUGNAME	BTM-0512
D0E6ZI	INDICATI	Vascular disease [ICD-11: BE2Z] Investigative

D00GFU	TTDDRUID	D00GFU
D00GFU	DRUGNAME	BTma22
D00GFU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0VC3H	TTDDRUID	D0VC3H
D0VC3H	DRUGNAME	BT-V003
D0VC3H	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D07LFJ	TTDDRUID	D07LFJ
D07LFJ	DRUGNAME	BU-32
D07LFJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08HNA	TTDDRUID	D08HNA
D08HNA	DRUGNAME	Buccal SMT-D001
D08HNA	INDICATI	Hypersalivation [ICD-11: DA04.6] Investigative

D04ATY	TTDDRUID	D04ATY
D04ATY	DRUGNAME	Bulleyaconitine A
D04ATY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0S5GD	TTDDRUID	D0S5GD
D0S5GD	DRUGNAME	Buprenorphine prodrugs
D0S5GD	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Investigative

D0P5TC	TTDDRUID	D0P5TC
D0P5TC	DRUGNAME	BURKE-103
D0P5TC	INDICATI	Verruca vulgaris [ICD-11: 1E80] Investigative

D06LJG	TTDDRUID	D06LJG
D06LJG	DRUGNAME	BURKE-104
D06LJG	INDICATI	Verruca vulgaris [ICD-11: 1E80] Investigative

D0V6MQ	TTDDRUID	D0V6MQ
D0V6MQ	DRUGNAME	Burkholderia pseudomallei therapeutics
D0V6MQ	INDICATI	Melioidosis [ICD-11: 1C42] Investigative

D0Z6VR	TTDDRUID	D0Z6VR
D0Z6VR	DRUGNAME	Buthionine sulfoximine
D0Z6VR	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
D0Z6VR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01ALJ	TTDDRUID	D01ALJ
D01ALJ	DRUGNAME	BV-6481
D01ALJ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D06YWA	TTDDRUID	D06YWA
D06YWA	DRUGNAME	BVA-101
D06YWA	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0BR8N	TTDDRUID	D0BR8N
D0BR8N	DRUGNAME	BVA-201
D0BR8N	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0N8CN	TTDDRUID	D0N8CN
D0N8CN	DRUGNAME	BVB-808
D0N8CN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0PZ5R	TTDDRUID	D0PZ5R
D0PZ5R	DRUGNAME	BVS-212
D0PZ5R	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0U3EA	TTDDRUID	D0U3EA
D0U3EA	DRUGNAME	BVT 933
D0U3EA	INDICATI	Obesity [ICD-11: 5B81] Investigative

D08CWX	TTDDRUID	D08CWX
D08CWX	DRUGNAME	BVX-20-CD20
D08CWX	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative

D0PI4T	TTDDRUID	D0PI4T
D0PI4T	DRUGNAME	BW-42
D0PI4T	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0R2MQ	TTDDRUID	D0R2MQ
D0R2MQ	DRUGNAME	BW-858C
D0R2MQ	INDICATI	Asthma [ICD-11: CA23] Investigative

D0ZG7S	TTDDRUID	D0ZG7S
D0ZG7S	DRUGNAME	BXL-01-0029
D0ZG7S	INDICATI	Heart transplant rejection [ICD-11: NE84] Investigative

D09VYS	TTDDRUID	D09VYS
D09VYS	DRUGNAME	BXL-1H5
D09VYS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0D3CJ	TTDDRUID	D0D3CJ
D0D3CJ	DRUGNAME	BYK-191023
D0D3CJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D04LDH	TTDDRUID	D04LDH
D04LDH	DRUGNAME	BZ6
D04LDH	INDICATI	Ataxia-telangiectasia [ICD-11: 4A01.31] Investigative

D06ACI	TTDDRUID	D06ACI
D06ACI	DRUGNAME	BZYX
D06ACI	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D02YRX	TTDDRUID	D02YRX
D02YRX	DRUGNAME	C-0333158
D02YRX	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D01GSA	TTDDRUID	D01GSA
D01GSA	DRUGNAME	C-0334578
D01GSA	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative

D0F1WD	TTDDRUID	D0F1WD
D0F1WD	DRUGNAME	C-10068
D0F1WD	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D0XQ7J	TTDDRUID	D0XQ7J
D0XQ7J	DRUGNAME	C-101,606
D0XQ7J	INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Investigative

D0S6QJ	TTDDRUID	D0S6QJ
D0S6QJ	DRUGNAME	C10-1040
D0S6QJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00EFD	TTDDRUID	D00EFD
D00EFD	DRUGNAME	C-21191
D00EFD	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D03EIG	TTDDRUID	D03EIG
D03EIG	DRUGNAME	C3BS-GQR-1
D03EIG	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0S9VG	TTDDRUID	D0S9VG
D0S9VG	DRUGNAME	C4X-101
D0S9VG	INDICATI	Endocrine disease [ICD-11: 5B3Z] Investigative

D08ZHQ	TTDDRUID	D08ZHQ
D08ZHQ	DRUGNAME	C4X-301
D08ZHQ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0T1TC	TTDDRUID	D0T1TC
D0T1TC	DRUGNAME	C-5304
D0T1TC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G9EX	TTDDRUID	D0G9EX
D0G9EX	DRUGNAME	C5aR pepducins
D0G9EX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D07MXA	TTDDRUID	D07MXA
D07MXA	DRUGNAME	C75
D07MXA	INDICATI	Obesity [ICD-11: 5B81] Investigative

D02NWC	TTDDRUID	D02NWC
D02NWC	DRUGNAME	CA-01
D02NWC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06ZAK	TTDDRUID	D06ZAK
D06ZAK	DRUGNAME	CA-50040
D06ZAK	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D0X6OX	TTDDRUID	D0X6OX
D0X6OX	DRUGNAME	CAB-051
D0X6OX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00ENU	TTDDRUID	D00ENU
D00ENU	DRUGNAME	CAB-101
D00ENU	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00HBF	TTDDRUID	D00HBF
D00HBF	DRUGNAME	CAB-103
D00HBF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y1RU	TTDDRUID	D0Y1RU
D0Y1RU	DRUGNAME	CAL-102-R
D0Y1RU	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D04CKR	TTDDRUID	D04CKR
D04CKR	DRUGNAME	CAL-103-R
D04CKR	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0UP0A	TTDDRUID	D0UP0A
D0UP0A	DRUGNAME	CAL-201
D0UP0A	INDICATI	Metapneumovirus infection [ICD-11: CA40.13] Investigative

D0PP0Z	TTDDRUID	D0PP0Z
D0PP0Z	DRUGNAME	CAL-202
D0PP0Z	INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Investigative

D08STA	TTDDRUID	D08STA
D08STA	DRUGNAME	CAL-203
D08STA	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D0W8HW	TTDDRUID	D0W8HW
D0W8HW	DRUGNAME	CAL-301
D0W8HW	INDICATI	Klebsiella infection [ICD-11: 1C4Y] Investigative

D02YBD	TTDDRUID	D02YBD
D02YBD	DRUGNAME	CAL-401
D02YBD	INDICATI	Candidiasis [ICD-11: 1F23] Investigative

D01ZMR	TTDDRUID	D01ZMR
D01ZMR	DRUGNAME	Calcineurin
D01ZMR	INDICATI	T-cell mediated immune dysfunction [ICD-11: 4A01.1Y] Investigative

D0XT8V	TTDDRUID	D0XT8V
D0XT8V	DRUGNAME	Calcium nanoparticles
D0XT8V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J9QV	TTDDRUID	D0J9QV
D0J9QV	DRUGNAME	Calcium-activated small conductance potassium channel blockers
D0J9QV	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0XA3W	TTDDRUID	D0XA3W
D0XA3W	DRUGNAME	Calcium-sensing receptor antagonists
D0XA3W	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0ED6E	TTDDRUID	D0ED6E
D0ED6E	DRUGNAME	CAM-2036
D0ED6E	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D07YZK	TTDDRUID	D07YZK
D07YZK	DRUGNAME	CAMI-103
D07YZK	INDICATI	Heart failure [ICD-11: BD10-BD13] Investigative

D09HNO	TTDDRUID	D09HNO
D09HNO	DRUGNAME	CaMKII inhibitors
D09HNO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0N3IP	TTDDRUID	D0N3IP
D0N3IP	DRUGNAME	CAMPESTANOL ASCORBYL PHOSPHATE
D0N3IP	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D06EGC	TTDDRUID	D06EGC
D06EGC	DRUGNAME	Cancer therapy, Carigent Therapeutics Inc
D06EGC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01XUJ	TTDDRUID	D01XUJ
D01XUJ	DRUGNAME	Cancer therapy, ProMediTech Inc
D01XUJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z8XG	TTDDRUID	D0Z8XG
D0Z8XG	DRUGNAME	Cancer therapy, ProXara Biotechnology Ltd
D0Z8XG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02ODX	TTDDRUID	D02ODX
D02ODX	DRUGNAME	Cancer therapy, Revalesio Corp
D02ODX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T4BG	TTDDRUID	D0T4BG
D0T4BG	DRUGNAME	Cancer therapy, SP1
D0T4BG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04VWL	TTDDRUID	D04VWL
D04VWL	DRUGNAME	Cannabinoid 1 antagonists
D04VWL	INDICATI	Obesity [ICD-11: 5B81] Investigative

D01VEV	TTDDRUID	D01VEV
D01VEV	DRUGNAME	Cannabinoids
D01VEV	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D08ZRW	TTDDRUID	D08ZRW
D08ZRW	DRUGNAME	Cantide + Cisplatin
D08ZRW	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Investigative

D00AXZ	TTDDRUID	D00AXZ
D00AXZ	DRUGNAME	CAP-22
D00AXZ	INDICATI	Diabetic angiopathy [ICD-11: BD53.Y] Investigative

D08YXS	TTDDRUID	D08YXS
D08YXS	DRUGNAME	CAP-3.2
D08YXS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R5XL	TTDDRUID	D0R5XL
D0R5XL	DRUGNAME	CAPTAT-414
D0R5XL	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D0P3QR	TTDDRUID	D0P3QR
D0P3QR	DRUGNAME	Carbapenem antibacterials
D0P3QR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0M7DW	TTDDRUID	D0M7DW
D0M7DW	DRUGNAME	Carbapenem derivative
D0M7DW	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0G3KP	TTDDRUID	D0G3KP
D0G3KP	DRUGNAME	Carbon nanospheres
D0G3KP	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0WZ0Z	TTDDRUID	D0WZ0Z
D0WZ0Z	DRUGNAME	Cardiometabolic therapeutics
D0WZ0Z	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0X8ZZ	TTDDRUID	D0X8ZZ
D0X8ZZ	DRUGNAME	Cardioprotectants
D0X8ZZ	INDICATI	Congestive heart failure [ICD-11: BD10] Investigative

D0B0CE	TTDDRUID	D0B0CE
D0B0CE	DRUGNAME	Cardiospheres
D0B0CE	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative

D04WSL	TTDDRUID	D04WSL
D04WSL	DRUGNAME	Cardiotoxin
D04WSL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OL4R	TTDDRUID	D0OL4R
D0OL4R	DRUGNAME	CARM1 inhibitors
D0OL4R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05URZ	TTDDRUID	D05URZ
D05URZ	DRUGNAME	Carmeseal
D05URZ	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0A0JM	TTDDRUID	D0A0JM
D0A0JM	DRUGNAME	Carotegrast
D0A0JM	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09KLX	TTDDRUID	D09KLX
D09KLX	DRUGNAME	Cartistem-adipo
D09KLX	INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative

D03YSL	TTDDRUID	D03YSL
D03YSL	DRUGNAME	CAT-1000
D03YSL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0H8MR	TTDDRUID	D0H8MR
D0H8MR	DRUGNAME	CAT-1902
D0H8MR	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D03UWE	TTDDRUID	D03UWE
D03UWE	DRUGNAME	CAT-1904
D03UWE	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0Y7YR	TTDDRUID	D0Y7YR
D0Y7YR	DRUGNAME	CAT-1920
D0Y7YR	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D08VLN	TTDDRUID	D08VLN
D08VLN	DRUGNAME	CAT-2000
D08VLN	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D00XNC	TTDDRUID	D00XNC
D00XNC	DRUGNAME	CAT-2200
D00XNC	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0V2KD	TTDDRUID	D0V2KD
D0V2KD	DRUGNAME	CAT-3000
D0V2KD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0M7SZ	TTDDRUID	D0M7SZ
D0M7SZ	DRUGNAME	CAT-4000
D0M7SZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0V4NY	TTDDRUID	D0V4NY
D0V4NY	DRUGNAME	Cathepsin C inhibitors
D0V4NY	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0JJ8A	TTDDRUID	D0JJ8A
D0JJ8A	DRUGNAME	CaV2.2 blocker
D0JJ8A	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09FMO	TTDDRUID	D09FMO
D09FMO	DRUGNAME	Cavatak RNA
D09FMO	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0EY1K	TTDDRUID	D0EY1K
D0EY1K	DRUGNAME	CB1 antagonists Merck & Co
D0EY1K	INDICATI	Endocrine disease [ICD-11: 5B3Z] Investigative

D03CHA	TTDDRUID	D03CHA
D03CHA	DRUGNAME	CB1 antagonists, Esteve
D03CHA	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D09JPT	TTDDRUID	D09JPT
D09JPT	DRUGNAME	CB-183872
D09JPT	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D02SLV	TTDDRUID	D02SLV
D02SLV	DRUGNAME	CB-1922
D02SLV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D02IND	TTDDRUID	D02IND
D02IND	DRUGNAME	CBI-006
D02IND	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03AEG	TTDDRUID	D03AEG
D03AEG	DRUGNAME	CBI-008
D03AEG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N5DZ	TTDDRUID	D0N5DZ
D0N5DZ	DRUGNAME	CBI-009
D0N5DZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D04UYT	TTDDRUID	D04UYT
D04UYT	DRUGNAME	CBLB-612
D04UYT	INDICATI	Radiation syndrome [ICD-11: NF00] Investigative

D01YTX	TTDDRUID	D01YTX
D01YTX	DRUGNAME	CBLC-4H10
D01YTX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0WA3T	TTDDRUID	D0WA3T
D0WA3T	DRUGNAME	CBNU-06
D0WA3T	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0O8TL	TTDDRUID	D0O8TL
D0O8TL	DRUGNAME	CBS-9106
D0O8TL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LI7L	TTDDRUID	D0LI7L
D0LI7L	DRUGNAME	CC-0101
D0LI7L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01ULX	TTDDRUID	D01ULX
D01ULX	DRUGNAME	CC-0651
D01ULX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R3VL	TTDDRUID	D0R3VL
D0R3VL	DRUGNAME	CCR4 antagonists
D0R3VL	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D0DH1H	TTDDRUID	D0DH1H
D0DH1H	DRUGNAME	CCT-241533
D0DH1H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03LCX	TTDDRUID	D03LCX
D03LCX	DRUGNAME	CCX-662
D03LCX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P8HU	TTDDRUID	D0P8HU
D0P8HU	DRUGNAME	CCX-721
D0P8HU	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0U4SS	TTDDRUID	D0U4SS
D0U4SS	DRUGNAME	CD-160130
D0U4SS	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative

D0TS0R	TTDDRUID	D0TS0R
D0TS0R	DRUGNAME	CD19xCD3 DART
D0TS0R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03VLO	TTDDRUID	D03VLO
D03VLO	DRUGNAME	CD1-TB
D03VLO	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D07PNQ	TTDDRUID	D07PNQ
D07PNQ	DRUGNAME	CD200Fc
D07PNQ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0K9ZU	TTDDRUID	D0K9ZU
D0K9ZU	DRUGNAME	CD45RB
D0K9ZU	INDICATI	Glioma [ICD-11: 2A00.0] Investigative

D0D9KK	TTDDRUID	D0D9KK
D0D9KK	DRUGNAME	CD4-BFFI
D0D9KK	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D07GOY	TTDDRUID	D07GOY
D07GOY	DRUGNAME	CD59 gene therapy, AMD
D07GOY	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0M7EP	TTDDRUID	D0M7EP
D0M7EP	DRUGNAME	CD79-targeted immunotoxins
D0M7EP	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative

D0D7KR	TTDDRUID	D0D7KR
D0D7KR	DRUGNAME	CDD-0235-J
D0D7KR	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D01GBV	TTDDRUID	D01GBV
D01GBV	DRUGNAME	CDD-190
D01GBV	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0J8FE	TTDDRUID	D0J8FE
D0J8FE	DRUGNAME	CDK2 inhibitors
D0J8FE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A8PU	TTDDRUID	D0A8PU
D0A8PU	DRUGNAME	CDK5/p25 inhibitor
D0A8PU	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0N4IU	TTDDRUID	D0N4IU
D0N4IU	DRUGNAME	CDNF/MANF
D0N4IU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D01RSK	TTDDRUID	D01RSK
D01RSK	DRUGNAME	CDP-146
D01RSK	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D07LJR	TTDDRUID	D07LJR
D07LJR	DRUGNAME	CDR-267F018
D07LJR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0N0KG	TTDDRUID	D0N0KG
D0N0KG	DRUGNAME	CDRI-85/92
D0N0KG	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative

D0Z0AS	TTDDRUID	D0Z0AS
D0Z0AS	DRUGNAME	CDRI-93/478
D0Z0AS	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0E9LH	TTDDRUID	D0E9LH
D0E9LH	DRUGNAME	CDRI-99/411
D0E9LH	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D07LSU	TTDDRUID	D07LSU
D07LSU	DRUGNAME	CDRI-S002-333
D07LSU	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0E0JV	TTDDRUID	D0E0JV
D0E0JV	DRUGNAME	CDRI-S007-867
D0E0JV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D09TSX	TTDDRUID	D09TSX
D09TSX	DRUGNAME	CEL-011
D09TSX	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D00CBY	TTDDRUID	D00CBY
D00CBY	DRUGNAME	CEL-021
D00CBY	INDICATI	Interstitial cystitis [ICD-11: GC00.3] Investigative

D0F3VI	TTDDRUID	D0F3VI
D0F3VI	DRUGNAME	CEL-1000
D0F3VI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03XSX	TTDDRUID	D03XSX
D03XSX	DRUGNAME	CEL-2000
D03XSX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D01JIM	TTDDRUID	D01JIM
D01JIM	DRUGNAME	Cell therapies
D01JIM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C2VM	TTDDRUID	D0C2VM
D0C2VM	DRUGNAME	Cell-based TIV
D0C2VM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0Z7FY	TTDDRUID	D0Z7FY
D0Z7FY	DRUGNAME	CEM-301
D0Z7FY	INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative

D0P8QC	TTDDRUID	D0P8QC
D0P8QC	DRUGNAME	CEN-209
D0P8QC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0MP2S	TTDDRUID	D0MP2S
D0MP2S	DRUGNAME	Centanamycin
D0MP2S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03IDK	TTDDRUID	D03IDK
D03IDK	DRUGNAME	CEP-18050
D03IDK	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative

D09PTP	TTDDRUID	D09PTP
D09PTP	DRUGNAME	CEP-28122
D09PTP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LE3O	TTDDRUID	D0LE3O
D0LE3O	DRUGNAME	CEP-37248
D0LE3O	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0O3VK	TTDDRUID	D0O3VK
D0O3VK	DRUGNAME	CEP-37249
D0O3VK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00KMI	TTDDRUID	D00KMI
D00KMI	DRUGNAME	CEP-37309
D00KMI	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D04TXB	TTDDRUID	D04TXB
D04TXB	DRUGNAME	Ceplene/Peg-Intron/Rebetol
D04TXB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D04JMG	TTDDRUID	D04JMG
D04JMG	DRUGNAME	CEQ-626
D04JMG	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D06XPX	TTDDRUID	D06XPX
D06XPX	DRUGNAME	CERE-135
D06XPX	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D08BED	TTDDRUID	D08BED
D08BED	DRUGNAME	CERE-140
D08BED	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0A8IM	TTDDRUID	D0A8IM
D0A8IM	DRUGNAME	CF-238
D0A8IM	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0N4FJ	TTDDRUID	D0N4FJ
D0N4FJ	DRUGNAME	CFTR inhibitors
D0N4FJ	INDICATI	Diarrhea [ICD-11: ME05.1] Investigative

D0N5DW	TTDDRUID	D0N5DW
D0N5DW	DRUGNAME	CG-023132
D0N5DW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00EIL	TTDDRUID	D00EIL
D00EIL	DRUGNAME	CG-103065
D00EIL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J3QN	TTDDRUID	D0J3QN
D0J3QN	DRUGNAME	CG-1255
D0J3QN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D0LK8U	TTDDRUID	D0LK8U
D0LK8U	DRUGNAME	CG-1521
D0LK8U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05MDQ	TTDDRUID	D05MDQ
D05MDQ	DRUGNAME	CG-701338
D05MDQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O6OM	TTDDRUID	D0O6OM
D0O6OM	DRUGNAME	CGEN-15001
D0O6OM	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0C9RF	TTDDRUID	D0C9RF
D0C9RF	DRUGNAME	CGEN-25007
D0C9RF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D05VWX	TTDDRUID	D05VWX
D05VWX	DRUGNAME	CGEN-25008
D05VWX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02KTG	TTDDRUID	D02KTG
D02KTG	DRUGNAME	CGEN-25068
D02KTG	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0FN9X	TTDDRUID	D0FN9X
D0FN9X	DRUGNAME	CGEN-671
D0FN9X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07JFU	TTDDRUID	D07JFU
D07JFU	DRUGNAME	CGEN-712
D07JFU	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative

D0X4AN	TTDDRUID	D0X4AN
D0X4AN	DRUGNAME	CGEN-791
D0X4AN	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D01VFQ	TTDDRUID	D01VFQ
D01VFQ	DRUGNAME	CGEN-855
D01VFQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0B1PU	TTDDRUID	D0B1PU
D0B1PU	DRUGNAME	CGEN-856
D0B1PU	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0Q6MQ	TTDDRUID	D0Q6MQ
D0Q6MQ	DRUGNAME	CGEN-913
D0Q6MQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D07YPA	TTDDRUID	D07YPA
D07YPA	DRUGNAME	CGEN-920
D07YPA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D04VUM	TTDDRUID	D04VUM
D04VUM	DRUGNAME	CGEN-928
D04VUM	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0V1TV	TTDDRUID	D0V1TV
D0V1TV	DRUGNAME	CGEN-991
D0V1TV	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0H3JH	TTDDRUID	D0H3JH
D0H3JH	DRUGNAME	CGI-1316
D0H3JH	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0N6ZK	TTDDRUID	D0N6ZK
D0N6ZK	DRUGNAME	CGP-20376
D0N6ZK	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Investigative

D06NMP	TTDDRUID	D06NMP
D06NMP	DRUGNAME	CGP-29030A
D06NMP	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0WZ9T	TTDDRUID	D0WZ9T
D0WZ9T	DRUGNAME	CGP-44532
D0WZ9T	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative

D04ZTB	TTDDRUID	D04ZTB
D04ZTB	DRUGNAME	CGRP pepducins
D04ZTB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D01ASB	TTDDRUID	D01ASB
D01ASB	DRUGNAME	CGRP-A2 radioligand agent
D01ASB	INDICATI	Migraine [ICD-11: 8A80] Investigative

D04YJO	TTDDRUID	D04YJO
D04YJO	DRUGNAME	CGS-19480A
D04YJO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D05YEL	TTDDRUID	D05YEL
D05YEL	DRUGNAME	CH-3697
D05YEL	INDICATI	Asthma [ICD-11: CA23] Investigative

D0W5IF	TTDDRUID	D0W5IF
D0W5IF	DRUGNAME	CH-4933468
D0W5IF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0P2AC	TTDDRUID	D0P2AC
D0P2AC	DRUGNAME	CH-4938056
D0P2AC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08OLB	TTDDRUID	D08OLB
D08OLB	DRUGNAME	CH-5015765
D08OLB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P1HZ	TTDDRUID	D0P1HZ
D0P1HZ	DRUGNAME	CHAP1
D0P1HZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y2DW	TTDDRUID	D0Y2DW
D0Y2DW	DRUGNAME	CHAP31
D0Y2DW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09DYB	TTDDRUID	D09DYB
D09DYB	DRUGNAME	CHDI-00316226
D09DYB	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D05MXL	TTDDRUID	D05MXL
D05MXL	DRUGNAME	CHDI-003940246
D05MXL	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D06WNW	TTDDRUID	D06WNW
D06WNW	DRUGNAME	Chemopreventive
D06WNW	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D08CRS	TTDDRUID	D08CRS
D08CRS	DRUGNAME	Chemoprotectant
D08CRS	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D0K9PS	TTDDRUID	D0K9PS
D0K9PS	DRUGNAME	CHF-5480
D0K9PS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D01CLK	TTDDRUID	D01CLK
D01CLK	DRUGNAME	CHGN111
D01CLK	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Investigative

D08UZA	TTDDRUID	D08UZA
D08UZA	DRUGNAME	Chitosan/IL-12
D08UZA	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D03CQN	TTDDRUID	D03CQN
D03CQN	DRUGNAME	Chk1-A
D03CQN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LE8H	TTDDRUID	D0LE8H
D0LE8H	DRUGNAME	Chloromethylpyrrolindolines
D0LE8H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01MFG	TTDDRUID	D01MFG
D01MFG	DRUGNAME	Cholera EPVaccine
D01MFG	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Investigative

D05GLI	TTDDRUID	D05GLI
D05GLI	DRUGNAME	Cholinergic therapeutics
D05GLI	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D04MRX	TTDDRUID	D04MRX
D04MRX	DRUGNAME	Chondroitinase
D04MRX	INDICATI	Intervertebral disc displacement [ICD-11: FB1Y] Investigative

D03HYH	TTDDRUID	D03HYH
D03HYH	DRUGNAME	Chondroprotective agents
D03HYH	INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Investigative

D0J0OF	TTDDRUID	D0J0OF
D0J0OF	DRUGNAME	Choroid plexus cell-derived factors
D0J0OF	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0D7EL	TTDDRUID	D0D7EL
D0D7EL	DRUGNAME	CHR-3620
D0D7EL	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D01HHH	TTDDRUID	D01HHH
D01HHH	DRUGNAME	CHR-4125
D01HHH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06HWU	TTDDRUID	D06HWU
D06HWU	DRUGNAME	CHR-4487
D06HWU	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0B4DK	TTDDRUID	D0B4DK
D0B4DK	DRUGNAME	ChronVac-B
D0B4DK	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0MC3K	TTDDRUID	D0MC3K
D0MC3K	DRUGNAME	CID755673
D0MC3K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02XES	TTDDRUID	D02XES
D02XES	DRUGNAME	Cidofovir derivatives
D02XES	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D03DSP	TTDDRUID	D03DSP
D03DSP	DRUGNAME	Cidofovir prodrugs
D03DSP	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0Z1EN	TTDDRUID	D0Z1EN
D0Z1EN	DRUGNAME	CIGB-166
D0Z1EN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07MLA	TTDDRUID	D07MLA
D07MLA	DRUGNAME	CIGB-200
D07MLA	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0M0MX	TTDDRUID	D0M0MX
D0M0MX	DRUGNAME	CIGB-247
D0M0MX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02PXP	TTDDRUID	D02PXP
D02PXP	DRUGNAME	CIGB-370
D02PXP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08PSV	TTDDRUID	D08PSV
D08PSV	DRUGNAME	CIGB-428
D08PSV	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative

D09NQD	TTDDRUID	D09NQD
D09NQD	DRUGNAME	CIGB-55
D09NQD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D02TBU	TTDDRUID	D02TBU
D02TBU	DRUGNAME	CIGB-552
D02TBU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QG3E	TTDDRUID	D0QG3E
D0QG3E	DRUGNAME	CIGB-598a
D0QG3E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V5VA	TTDDRUID	D0V5VA
D0V5VA	DRUGNAME	CIGB-814
D0V5VA	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D03QNA	TTDDRUID	D03QNA
D03QNA	DRUGNAME	CIGB-845
D03QNA	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D07IGQ	TTDDRUID	D07IGQ
D07IGQ	DRUGNAME	C-Immune
D07IGQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0HR5Q	TTDDRUID	D0HR5Q
D0HR5Q	DRUGNAME	CIP-137401
D0HR5Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I3XA	TTDDRUID	D0I3XA
D0I3XA	DRUGNAME	Ciproxifan
D0I3XA	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
D0I3XA	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0R0BJ	TTDDRUID	D0R0BJ
D0R0BJ	DRUGNAME	Cirrhosis
D0R0BJ	INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative

D0X4FY	TTDDRUID	D0X4FY
D0X4FY	DRUGNAME	Cis-tetracosenoyl sulfatide
D0X4FY	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D00DJC	TTDDRUID	D00DJC
D00DJC	DRUGNAME	CJX-1
D00DJC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H7TD	TTDDRUID	D0H7TD
D0H7TD	DRUGNAME	CK-2018509
D0H7TD	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0R9IL	TTDDRUID	D0R9IL
D0R9IL	DRUGNAME	CK-2066260
D0R9IL	INDICATI	Neuromuscular disease [ICD-11: 8C6Y] Investigative

D05MSM	TTDDRUID	D05MSM
D05MSM	DRUGNAME	CK-37
D05MSM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06WAA	TTDDRUID	D06WAA
D06WAA	DRUGNAME	CKBP-004
D06WAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L6BU	TTDDRUID	D0L6BU
D0L6BU	DRUGNAME	CKD-10101
D0L6BU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09MQY	TTDDRUID	D09MQY
D09MQY	DRUGNAME	CKD-403
D09MQY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07WXQ	TTDDRUID	D07WXQ
D07WXQ	DRUGNAME	CKD-404
D07WXQ	INDICATI	Growth failure [ICD-11: LD2F.1Y] Investigative

D0L7PG	TTDDRUID	D0L7PG
D0L7PG	DRUGNAME	CKD-406
D0L7PG	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D06URK	TTDDRUID	D06URK
D06URK	DRUGNAME	CKD-533
D06URK	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative

D07NWZ	TTDDRUID	D07NWZ
D07NWZ	DRUGNAME	CL-301
D07NWZ	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D00FAW	TTDDRUID	D00FAW
D00FAW	DRUGNAME	CL-508
D00FAW	INDICATI	Vomiting [ICD-11: MD90] Investigative

D0VD7H	TTDDRUID	D0VD7H
D0VD7H	DRUGNAME	CL-5343
D0VD7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05BCF	TTDDRUID	D05BCF
D05BCF	DRUGNAME	Clavulanate+Amoxicillin
D05BCF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0RD6X	TTDDRUID	D0RD6X
D0RD6X	DRUGNAME	CLDC
D0RD6X	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D0G3DD	TTDDRUID	D0G3DD
D0G3DD	DRUGNAME	CL-H01
D0G3DD	INDICATI	Migraine [ICD-11: 8A80] Investigative

D03ONX	TTDDRUID	D03ONX
D03ONX	DRUGNAME	CL-H02
D03ONX	INDICATI	Headache [ICD-11: 8A80-8A84] Investigative

D0KT4B	TTDDRUID	D0KT4B
D0KT4B	DRUGNAME	CLP-1002
D0KT4B	INDICATI	Congestive heart failure [ICD-11: BD10] Investigative

D0V6KL	TTDDRUID	D0V6KL
D0V6KL	DRUGNAME	CLP-635
D0V6KL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0N7WB	TTDDRUID	D0N7WB
D0N7WB	DRUGNAME	CLR-151
D0N7WB	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative

D05BWY	TTDDRUID	D05BWY
D05BWY	DRUGNAME	CLR-300
D05BWY	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0W0UW	TTDDRUID	D0W0UW
D0W0UW	DRUGNAME	CLT-002
D0W0UW	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Investigative

D06QEW	TTDDRUID	D06QEW
D06QEW	DRUGNAME	CLT-003
D06QEW	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Investigative

D0L0OU	TTDDRUID	D0L0OU
D0L0OU	DRUGNAME	CLT-005
D0L0OU	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D0BT6B	TTDDRUID	D0BT6B
D0BT6B	DRUGNAME	CLT-009
D0BT6B	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D0C8LG	TTDDRUID	D0C8LG
D0C8LG	DRUGNAME	CLT-010
D0C8LG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08YKD	TTDDRUID	D08YKD
D08YKD	DRUGNAME	CLT-011
D08YKD	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0I0SG	TTDDRUID	D0I0SG
D0I0SG	DRUGNAME	CLVax 1.0
D0I0SG	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0J9VK	TTDDRUID	D0J9VK
D0J9VK	DRUGNAME	CM-156
D0J9VK	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative

D0I1HM	TTDDRUID	D0I1HM
D0I1HM	DRUGNAME	CM-182
D0I1HM	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0V8KB	TTDDRUID	D0V8KB
D0V8KB	DRUGNAME	CM-4612
D0V8KB	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative

D0T0PU	TTDDRUID	D0T0PU
D0T0PU	DRUGNAME	CME-548
D0T0PU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I2PS	TTDDRUID	D0I2PS
D0I2PS	DRUGNAME	CMET Avimer polypeptides
D0I2PS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07BZQ	TTDDRUID	D07BZQ
D07BZQ	DRUGNAME	C-Met kinase inhibitors
D07BZQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S7AN	TTDDRUID	D0S7AN
D0S7AN	DRUGNAME	C-met mabs
D0S7AN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06TQD	TTDDRUID	D06TQD
D06TQD	DRUGNAME	CMPD-167
D06TQD	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D05EOT	TTDDRUID	D05EOT
D05EOT	DRUGNAME	CM-PK
D05EOT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D09OBF	TTDDRUID	D09OBF
D09OBF	DRUGNAME	CMUS-100
D09OBF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08XPI	TTDDRUID	D08XPI
D08XPI	DRUGNAME	CMV-specific STAR fusions
D08XPI	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D03GHR	TTDDRUID	D03GHR
D03GHR	DRUGNAME	C-myb
D03GHR	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D07DQZ	TTDDRUID	D07DQZ
D07DQZ	DRUGNAME	CN-16
D07DQZ	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0HB5V	TTDDRUID	D0HB5V
D0HB5V	DRUGNAME	CN-2097
D0HB5V	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D06EPP	TTDDRUID	D06EPP
D06EPP	DRUGNAME	CNB-001
D06EPP	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D05KRH	TTDDRUID	D05KRH
D05KRH	DRUGNAME	CNDO-113
D05KRH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P3UZ	TTDDRUID	D0P3UZ
D0P3UZ	DRUGNAME	CNJ-H01
D0P3UZ	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative

D0A3XA	TTDDRUID	D0A3XA
D0A3XA	DRUGNAME	CNS-1169
D0A3XA	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D08SSO	TTDDRUID	D08SSO
D08SSO	DRUGNAME	CNSB-006
D08SSO	INDICATI	Arthralgia [ICD-11: ME82] Investigative

D07MBQ	TTDDRUID	D07MBQ
D07MBQ	DRUGNAME	CNTO-736
D07MBQ	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0I5ND	TTDDRUID	D0I5ND
D0I5ND	DRUGNAME	CNX-010
D0I5ND	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0O5UF	TTDDRUID	D0O5UF
D0O5UF	DRUGNAME	CNX-011
D0O5UF	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0P5TI	TTDDRUID	D0P5TI
D0P5TI	DRUGNAME	CNX-1351
D0P5TI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09YBZ	TTDDRUID	D09YBZ
D09YBZ	DRUGNAME	CO-12
D09YBZ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D06QUY	TTDDRUID	D06QUY
D06QUY	DRUGNAME	CO-18
D06QUY	INDICATI	Obesity [ICD-11: 5B81] Investigative

D09EMS	TTDDRUID	D09EMS
D09EMS	DRUGNAME	CO-8
D09EMS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0T9CD	TTDDRUID	D0T9CD
D0T9CD	DRUGNAME	Cobacan
D0T9CD	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Investigative

D07UDW	TTDDRUID	D07UDW
D07UDW	DRUGNAME	COG-112
D07UDW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S2QP	TTDDRUID	D0S2QP
D0S2QP	DRUGNAME	COG-248
D0S2QP	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D02XNJ	TTDDRUID	D02XNJ
D02XNJ	DRUGNAME	CogniXan
D02XNJ	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0Y2KX	TTDDRUID	D0Y2KX
D0Y2KX	DRUGNAME	COL-1777
D0Y2KX	INDICATI	Uterine fibroids [ICD-11: 2E86.0] Investigative

D0Q9MN	TTDDRUID	D0Q9MN
D0Q9MN	DRUGNAME	COL-204
D0Q9MN	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Investigative

D0N6HA	TTDDRUID	D0N6HA
D0N6HA	DRUGNAME	COL-2401
D0N6HA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0BQ4Q	TTDDRUID	D0BQ4Q
D0BQ4Q	DRUGNAME	Colostrinin-derived peptides
D0BQ4Q	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0B6YK	TTDDRUID	D0B6YK
D0B6YK	DRUGNAME	Combination therapy, prostate cancer, Molecular Express Inc
D0B6YK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D01MDH	TTDDRUID	D01MDH
D01MDH	DRUGNAME	Conjugated stigmines
D01MDH	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0C2CP	TTDDRUID	D0C2CP
D0C2CP	DRUGNAME	Conjugated-trastuzumab
D0C2CP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02EVI	TTDDRUID	D02EVI
D02EVI	DRUGNAME	Controlled-release agent
D02EVI	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0M1OX	TTDDRUID	D0M1OX
D0M1OX	DRUGNAME	COP1-LNP
D0M1OX	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D0E9QZ	TTDDRUID	D0E9QZ
D0E9QZ	DRUGNAME	Copper catalyst-based agent
D0E9QZ	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D02IUO	TTDDRUID	D02IUO
D02IUO	DRUGNAME	CORT-113083
D02IUO	INDICATI	Weight gain [ICD-11: MG43.6] Investigative

D0B4ML	TTDDRUID	D0B4ML
D0B4ML	DRUGNAME	Corticosteroids
D0B4ML	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D04BXH	TTDDRUID	D04BXH
D04BXH	DRUGNAME	COTI-001
D04BXH	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D04SZG	TTDDRUID	D04SZG
D04SZG	DRUGNAME	COTI-219
D04SZG	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D00AQV	TTDDRUID	D00AQV
D00AQV	DRUGNAME	COTI-4A
D00AQV	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D07SHZ	TTDDRUID	D07SHZ
D07SHZ	DRUGNAME	COTI-58
D07SHZ	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D0M5QD	TTDDRUID	D0M5QD
D0M5QD	DRUGNAME	COU-1
D0M5QD	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D05LSB	TTDDRUID	D05LSB
D05LSB	DRUGNAME	COX-2 inhibitors
D05LSB	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00LZM	TTDDRUID	D00LZM
D00LZM	DRUGNAME	CP1
D00LZM	INDICATI	Cough [ICD-11: MD12] Investigative

D0Q7MQ	TTDDRUID	D0Q7MQ
D0Q7MQ	DRUGNAME	CP-100263
D0Q7MQ	INDICATI	Vomiting [ICD-11: MD90] Investigative

D02IOC	TTDDRUID	D02IOC
D02IOC	DRUGNAME	CP154,526
D02IOC	INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative

D02ULG	TTDDRUID	D02ULG
D02ULG	DRUGNAME	CP-4033
D02ULG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OT1S	TTDDRUID	D0OT1S
D0OT1S	DRUGNAME	CP-4200
D0OT1S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A7AG	TTDDRUID	D0A7AG
D0A7AG	DRUGNAME	CP51-2705
D0A7AG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T8CQ	TTDDRUID	D0T8CQ
D0T8CQ	DRUGNAME	CP-70949
D0T8CQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D02YNH	TTDDRUID	D02YNH
D02YNH	DRUGNAME	CP-809101
D02YNH	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D07MUS	TTDDRUID	D07MUS
D07MUS	DRUGNAME	CPA-7
D07MUS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D1TB	TTDDRUID	D0D1TB
D0D1TB	DRUGNAME	CPC-410
D0D1TB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03VDX	TTDDRUID	D03VDX
D03VDX	DRUGNAME	CPD-0905
D03VDX	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D0F4UI	TTDDRUID	D0F4UI
D0F4UI	DRUGNAME	CPD-VO
D0F4UI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F0JZ	TTDDRUID	D0F0JZ
D0F0JZ	DRUGNAME	CPG23CARD
D0F0JZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0W0UU	TTDDRUID	D0W0UU
D0W0UU	DRUGNAME	CPG23DIAB
D0W0UU	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0K0LG	TTDDRUID	D0K0LG
D0K0LG	DRUGNAME	CPG23NEUR
D0K0LG	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0B0EO	TTDDRUID	D0B0EO
D0B0EO	DRUGNAME	CPG23STEM
D0B0EO	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0W4CC	TTDDRUID	D0W4CC
D0W4CC	DRUGNAME	CPI-005
D0W4CC	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative

D09YTH	TTDDRUID	D09YTH
D09YTH	DRUGNAME	CPU-228
D09YTH	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative

D0W4JY	TTDDRUID	D0W4JY
D0W4JY	DRUGNAME	CPZEN-45
D0W4JY	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0X2SY	TTDDRUID	D0X2SY
D0X2SY	DRUGNAME	CR-3663
D0X2SY	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D08JUO	TTDDRUID	D08JUO
D08JUO	DRUGNAME	CR-4056
D08JUO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0KX7A	TTDDRUID	D0KX7A
D0KX7A	DRUGNAME	CR-4174
D0KX7A	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09ZUM	TTDDRUID	D09ZUM
D09ZUM	DRUGNAME	CR-4892
D09ZUM	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0MI1N	TTDDRUID	D0MI1N
D0MI1N	DRUGNAME	CR-5259
D0MI1N	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0Q2RJ	TTDDRUID	D0Q2RJ
D0Q2RJ	DRUGNAME	CR-5542
D0Q2RJ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0F4QJ	TTDDRUID	D0F4QJ
D0F4QJ	DRUGNAME	CR-5790
D0F4QJ	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0D6TN	TTDDRUID	D0D6TN
D0D6TN	DRUGNAME	CR-8020
D0D6TN	INDICATI	Influenza A virus infection [ICD-11: 1E30] Investigative

D0Z1WH	TTDDRUID	D0Z1WH
D0Z1WH	DRUGNAME	CRAM 1-2
D0Z1WH	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0Q2CM	TTDDRUID	D0Q2CM
D0Q2CM	DRUGNAME	CRB-0016
D0Q2CM	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0F2QP	TTDDRUID	D0F2QP
D0F2QP	DRUGNAME	CRB-0022
D0F2QP	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06VRS	TTDDRUID	D06VRS
D06VRS	DRUGNAME	CRB-15
D06VRS	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0C0CF	TTDDRUID	D0C0CF
D0C0CF	DRUGNAME	CRD-103
D0C0CF	INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative

D0A4WL	TTDDRUID	D0A4WL
D0A4WL	DRUGNAME	Creaferon
D0A4WL	INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative

D0D9DP	TTDDRUID	D0D9DP
D0D9DP	DRUGNAME	CRF-1 antagonists
D0D9DP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0FD3D	TTDDRUID	D0FD3D
D0FD3D	DRUGNAME	Cripto-1 mabs
D0FD3D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I3TD	TTDDRUID	D0I3TD
D0I3TD	DRUGNAME	CRL-37212
D0I3TD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09QQE	TTDDRUID	D09QQE
D09QQE	DRUGNAME	Crodox
D09QQE	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0K6ES	TTDDRUID	D0K6ES
D0K6ES	DRUGNAME	CRT-0004592
D0K6ES	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03HQE	TTDDRUID	D03HQE
D03HQE	DRUGNAME	CRT0066101
D03HQE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02VNJ	TTDDRUID	D02VNJ
D02VNJ	DRUGNAME	CRTH2 antagonists
D02VNJ	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D0O7TO	TTDDRUID	D0O7TO
D0O7TO	DRUGNAME	CRTh2 receptor antagonists, Athersys
D0O7TO	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D02QTU	TTDDRUID	D02QTU
D02QTU	DRUGNAME	CRTh2 receptor antagonists, Novartis
D02QTU	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0D3QJ	TTDDRUID	D0D3QJ
D0D3QJ	DRUGNAME	CRTX-067
D0D3QJ	INDICATI	Cough [ICD-11: MD12] Investigative

D00IDV	TTDDRUID	D00IDV
D00IDV	DRUGNAME	CRTX-070
D00IDV	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D08RCI	TTDDRUID	D08RCI
D08RCI	DRUGNAME	CRTX-072
D08RCI	INDICATI	Cough [ICD-11: MD12] Investigative

D0S2BL	TTDDRUID	D0S2BL
D0S2BL	DRUGNAME	CRTX-074
D0S2BL	INDICATI	Cough [ICD-11: MD12] Investigative

D04TBW	TTDDRUID	D04TBW
D04TBW	DRUGNAME	C-Rx
D04TBW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0W2KR	TTDDRUID	D0W2KR
D0W2KR	DRUGNAME	CS-0240
D0W2KR	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0SZ8Q	TTDDRUID	D0SZ8Q
D0SZ8Q	DRUGNAME	CSC-500297
D0SZ8Q	INDICATI	Obesity [ICD-11: 5B81] Investigative

D08ODP	TTDDRUID	D08ODP
D08ODP	DRUGNAME	CSC-700008
D08ODP	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D01QXW	TTDDRUID	D01QXW
D01QXW	DRUGNAME	CSL-324
D01QXW	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D03TXW	TTDDRUID	D03TXW
D03TXW	DRUGNAME	CSP-9222
D03TXW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LD9P	TTDDRUID	D0LD9P
D0LD9P	DRUGNAME	CST-104
D0LD9P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00BTZ	TTDDRUID	D00BTZ
D00BTZ	DRUGNAME	CT-003230
D00BTZ	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0B6DV	TTDDRUID	D0B6DV
D0B6DV	DRUGNAME	CT-10
D0B6DV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X7LY	TTDDRUID	D0X7LY
D0X7LY	DRUGNAME	CT-100
D0X7LY	INDICATI	Kidney disease [ICD-11: GC2Z] Investigative

D0Y8BJ	TTDDRUID	D0Y8BJ
D0Y8BJ	DRUGNAME	CT-112
D0Y8BJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D06QOD	TTDDRUID	D06QOD
D06QOD	DRUGNAME	CT-120
D06QOD	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0N8NN	TTDDRUID	D0N8NN
D0N8NN	DRUGNAME	CT-12441
D0N8NN	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D05KRS	TTDDRUID	D05KRS
D05KRS	DRUGNAME	CT-340
D05KRS	INDICATI	Arthritis [ICD-11: FA20] Investigative

D06FTY	TTDDRUID	D06FTY
D06FTY	DRUGNAME	CT-400
D06FTY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S3EF	TTDDRUID	D0S3EF
D0S3EF	DRUGNAME	CT-400P
D0S3EF	INDICATI	Bone metastases [ICD-11: 2D50] Investigative

D03KLU	TTDDRUID	D03KLU
D03KLU	DRUGNAME	CT-406
D03KLU	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0A8NN	TTDDRUID	D0A8NN
D0A8NN	DRUGNAME	CT-637
D0A8NN	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0ZS8S	TTDDRUID	D0ZS8S
D0ZS8S	DRUGNAME	CT-750
D0ZS8S	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06ZIL	TTDDRUID	D06ZIL
D06ZIL	DRUGNAME	CTA-001
D06ZIL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00FRX	TTDDRUID	D00FRX
D00FRX	DRUGNAME	CTA-056
D00FRX	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D04UAZ	TTDDRUID	D04UAZ
D04UAZ	DRUGNAME	CTA-091
D04UAZ	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Investigative

D01KNO	TTDDRUID	D01KNO
D01KNO	DRUGNAME	CTA1-3M2e-DD
D01KNO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0DF8Y	TTDDRUID	D0DF8Y
D0DF8Y	DRUGNAME	CTA-192
D0DF8Y	INDICATI	Hyperparathyroidism [ICD-11: 5A51] Investigative

D0L3GH	TTDDRUID	D0L3GH
D0L3GH	DRUGNAME	CTCE-0324
D0L3GH	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Investigative

D0HS9Y	TTDDRUID	D0HS9Y
D0HS9Y	DRUGNAME	CTCE-0501
D0HS9Y	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0T4QX	TTDDRUID	D0T4QX
D0T4QX	DRUGNAME	CTEP
D0T4QX	INDICATI	Fragile X syndrome [ICD-11: LD55] Investigative

D0EZ9C	TTDDRUID	D0EZ9C
D0EZ9C	DRUGNAME	CTLA-4-XTEN
D0EZ9C	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D03HGP	TTDDRUID	D03HGP
D03HGP	DRUGNAME	CTP-conjugated WT1 peptide
D03HGP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M1NS	TTDDRUID	D0M1NS
D0M1NS	DRUGNAME	CTT-54
D0M1NS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08NLC	TTDDRUID	D08NLC
D08NLC	DRUGNAME	Cu64-CNND1-B
D08NLC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0NN7W	TTDDRUID	D0NN7W
D0NN7W	DRUGNAME	Cu64-CNND1-L
D0NN7W	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D0JD4S	TTDDRUID	D0JD4S
D0JD4S	DRUGNAME	CU-906
D0JD4S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B7JZ	TTDDRUID	D0B7JZ
D0B7JZ	DRUGNAME	CuraVac MG
D0B7JZ	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Investigative

D0U4LP	TTDDRUID	D0U4LP
D0U4LP	DRUGNAME	Curcumin-ND
D0U4LP	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Investigative

D06KCM	TTDDRUID	D06KCM
D06KCM	DRUGNAME	CUV-3
D06KCM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J6VW	TTDDRUID	D0J6VW
D0J6VW	DRUGNAME	CUV-9900
D0J6VW	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D0T5FO	TTDDRUID	D0T5FO
D0T5FO	DRUGNAME	CVA-21 DAF
D0T5FO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F1UW	TTDDRUID	D0F1UW
D0F1UW	DRUGNAME	C-Vaxin
D0F1UW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0XV8M	TTDDRUID	D0XV8M
D0XV8M	DRUGNAME	CVT-012000
D0XV8M	INDICATI	Coronary artery disease [ICD-11: BA80] Investigative

D0W4WP	TTDDRUID	D0W4WP
D0W4WP	DRUGNAME	CVT-10216
D0W4WP	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative

D0O7DP	TTDDRUID	D0O7DP
D0O7DP	DRUGNAME	CVT-12012
D0O7DP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0S3QK	TTDDRUID	D0S3QK
D0S3QK	DRUGNAME	CW-343
D0S3QK	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative

D00ONE	TTDDRUID	D00ONE
D00ONE	DRUGNAME	CWF-0710
D00ONE	INDICATI	Asthma [ICD-11: CA23] Investigative

D02OEP	TTDDRUID	D02OEP
D02OEP	DRUGNAME	CWF-07pre03
D02OEP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D09NEL	TTDDRUID	D09NEL
D09NEL	DRUGNAME	CWF-0804
D09NEL	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0W3WB	TTDDRUID	D0W3WB
D0W3WB	DRUGNAME	CWF-0808
D0W3WB	INDICATI	Transplant rejection [ICD-11: NE84] Investigative

D07ACP	TTDDRUID	D07ACP
D07ACP	DRUGNAME	CWF-0902
D07ACP	INDICATI	Migraine [ICD-11: 8A80] Investigative

D06EBJ	TTDDRUID	D06EBJ
D06EBJ	DRUGNAME	CX-02
D06EBJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0GZ5F	TTDDRUID	D0GZ5F
D0GZ5F	DRUGNAME	CX-1001
D0GZ5F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T0BA	TTDDRUID	D0T0BA
D0T0BA	DRUGNAME	CX-1010
D0T0BA	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0NE9W	TTDDRUID	D0NE9W
D0NE9W	DRUGNAME	CX-1020
D0NE9W	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0K9MB	TTDDRUID	D0K9MB
D0K9MB	DRUGNAME	CX-1030
D0K9MB	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0SB0X	TTDDRUID	D0SB0X
D0SB0X	DRUGNAME	CX-1040
D0SB0X	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0LH4P	TTDDRUID	D0LH4P
D0LH4P	DRUGNAME	CX-1846
D0LH4P	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0B4ME	TTDDRUID	D0B4ME
D0B4ME	DRUGNAME	CX-1942
D0B4ME	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Investigative

D05PVW	TTDDRUID	D05PVW
D05PVW	DRUGNAME	CX-2007
D05PVW	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative

D0Z5UB	TTDDRUID	D0Z5UB
D0Z5UB	DRUGNAME	CX-2076
D0Z5UB	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative

D0CR9I	TTDDRUID	D0CR9I
D0CR9I	DRUGNAME	CX-5011
D0CR9I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B7LU	TTDDRUID	D0B7LU
D0B7LU	DRUGNAME	CX-5461
D0B7LU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06SEA	TTDDRUID	D06SEA
D06SEA	DRUGNAME	CX-7000
D06SEA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XC1F	TTDDRUID	D0XC1F
D0XC1F	DRUGNAME	CX-9051
D0XC1F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E3JF	TTDDRUID	D0E3JF
D0E3JF	DRUGNAME	Cx-911
D0E3JF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D09EOZ	TTDDRUID	D09EOZ
D09EOZ	DRUGNAME	CX-99
D09EOZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09CJO	TTDDRUID	D09CJO
D09CJO	DRUGNAME	CXB-029
D09CJO	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0U5GX	TTDDRUID	D0U5GX
D0U5GX	DRUGNAME	CXB-724
D0U5GX	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D07PHS	TTDDRUID	D07PHS
D07PHS	DRUGNAME	CXCL8
D07PHS	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D02BJK	TTDDRUID	D02BJK
D02BJK	DRUGNAME	CXCR-2 targeting mabs
D02BJK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04QAE	TTDDRUID	D04QAE
D04QAE	DRUGNAME	CXCR3 antagonists, Amgen
D04QAE	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D05TYV	TTDDRUID	D05TYV
D05TYV	DRUGNAME	CXCR3 antagonists, GlaxoSmithKline
D05TYV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D04EDQ	TTDDRUID	D04EDQ
D04EDQ	DRUGNAME	CXCR3 antagonists, Merck Serono
D04EDQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D07VDF	TTDDRUID	D07VDF
D07VDF	DRUGNAME	CXCR4 gene disrupted T cells
D07VDF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D05RLT	TTDDRUID	D05RLT
D05RLT	DRUGNAME	CXCR7 pepducins
D05RLT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05AFP	TTDDRUID	D05AFP
D05AFP	DRUGNAME	CY-301
D05AFP	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0Y1XR	TTDDRUID	D0Y1XR
D0Y1XR	DRUGNAME	CY-403
D0Y1XR	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D01RLA	TTDDRUID	D01RLA
D01RLA	DRUGNAME	CYC-4068
D01RLA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07CBY	TTDDRUID	D07CBY
D07CBY	DRUGNAME	Cyclin A2
D07CBY	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0O9YG	TTDDRUID	D0O9YG
D0O9YG	DRUGNAME	Cycloguanil
D0O9YG	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D01HMN	TTDDRUID	D01HMN
D01HMN	DRUGNAME	Cyclohexenonic long-chain fatty alcohol derivatives
D01HMN	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0D0ED	TTDDRUID	D0D0ED
D0D0ED	DRUGNAME	Cyclosporin A-based peptides
D0D0ED	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D08BVR	TTDDRUID	D08BVR
D08BVR	DRUGNAME	Cyclosporin-based therapies
D08BVR	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D0F4MK	TTDDRUID	D0F4MK
D0F4MK	DRUGNAME	CyMVectin
D0F4MK	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D0L1VT	TTDDRUID	D0L1VT
D0L1VT	DRUGNAME	Cyprodine
D0L1VT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D09HVY	TTDDRUID	D09HVY
D09HVY	DRUGNAME	Cystatin C
D09HVY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0OV4A	TTDDRUID	D0OV4A
D0OV4A	DRUGNAME	Cystic fibrosis therapeutics
D0OV4A	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D01QZI	TTDDRUID	D01QZI
D01QZI	DRUGNAME	Cytochrome P450 3A inhibitors
D01QZI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0Q2HW	TTDDRUID	D0Q2HW
D0Q2HW	DRUGNAME	Cytochrome P450-targeting prodrugs
D0Q2HW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P1IJ	TTDDRUID	D0P1IJ
D0P1IJ	DRUGNAME	CytoCor
D0P1IJ	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D09XSH	TTDDRUID	D09XSH
D09XSH	DRUGNAME	Cytoreg
D09XSH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YB3D	TTDDRUID	D0YB3D
D0YB3D	DRUGNAME	CytoregUNO
D0YB3D	INDICATI	Skin cancer [ICD-11: 2C30-2C37] Investigative

D0V4YT	TTDDRUID	D0V4YT
D0V4YT	DRUGNAME	CytoRet
D0V4YT	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D0PL2Q	TTDDRUID	D0PL2Q
D0PL2Q	DRUGNAME	Cytoros
D0PL2Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P6GX	TTDDRUID	D0P6GX
D0P6GX	DRUGNAME	CZ-2645
D0P6GX	INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative

D0N8GR	TTDDRUID	D0N8GR
D0N8GR	DRUGNAME	CZ-775
D0N8GR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00LZO	TTDDRUID	D00LZO
D00LZO	DRUGNAME	CZC-19091
D00LZO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0LJ1Z	TTDDRUID	D0LJ1Z
D0LJ1Z	DRUGNAME	CZ-MD001
D0LJ1Z	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D08JYW	TTDDRUID	D08JYW
D08JYW	DRUGNAME	CZ-ON002
D08JYW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O7SC	TTDDRUID	D0O7SC
D0O7SC	DRUGNAME	D-11B
D0O7SC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03ILU	TTDDRUID	D03ILU
D03ILU	DRUGNAME	D17.4
D03ILU	INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Investigative

D0L1NF	TTDDRUID	D0L1NF
D0L1NF	DRUGNAME	D-420720
D0L1NF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D04OGZ	TTDDRUID	D04OGZ
D04OGZ	DRUGNAME	D-699126
D04OGZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OP2E	TTDDRUID	D0OP2E
D0OP2E	DRUGNAME	D-81050
D0OP2E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZE9T	TTDDRUID	D0ZE9T
D0ZE9T	DRUGNAME	DA-3811
D0ZE9T	INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative

D08ERB	TTDDRUID	D08ERB
D08ERB	DRUGNAME	Dabigatran etexilate neutralizer
D08ERB	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D09DTY	TTDDRUID	D09DTY
D09DTY	DRUGNAME	DABO-1047
D09DTY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0Q1MG	TTDDRUID	D0Q1MG
D0Q1MG	DRUGNAME	DAC:antiviral
D0Q1MG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0FL4G	TTDDRUID	D0FL4G
D0FL4G	DRUGNAME	DAF-3
D0FL4G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OR7P	TTDDRUID	D0OR7P
D0OR7P	DRUGNAME	DARPins
D0OR7P	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0G1WR	TTDDRUID	D0G1WR
D0G1WR	DRUGNAME	DasKloster 0014-01
D0G1WR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L2TT	TTDDRUID	D0L2TT
D0L2TT	DRUGNAME	DasKloster 0028-01
D0L2TT	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative

D01YHL	TTDDRUID	D01YHL
D01YHL	DRUGNAME	DasKloster 0039-01
D01YHL	INDICATI	Asbestosis [ICD-11: CA60.2] Investigative

D0I7MK	TTDDRUID	D0I7MK
D0I7MK	DRUGNAME	DasKloster 0080-01
D0I7MK	INDICATI	Lymphangioleiomyomatosis [ICD-11: CB07] Investigative

D03CKP	TTDDRUID	D03CKP
D03CKP	DRUGNAME	DasKloster 0182-01
D03CKP	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative

D04UPJ	TTDDRUID	D04UPJ
D04UPJ	DRUGNAME	DasKloster 0247-01
D04UPJ	INDICATI	Pulmonary hypertension [ICD-11: BB01] Investigative

D0E6GS	TTDDRUID	D0E6GS
D0E6GS	DRUGNAME	DasKloster 0249-01
D0E6GS	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D05NMU	TTDDRUID	D05NMU
D05NMU	DRUGNAME	DasKloster 0274-01
D05NMU	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D05SJD	TTDDRUID	D05SJD
D05SJD	DRUGNAME	DasKloster 0501-01
D05SJD	INDICATI	Scleroderma [ICD-11: 4A42] Investigative

D05CYX	TTDDRUID	D05CYX
D05CYX	DRUGNAME	DAV-121
D05CYX	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D04EHF	TTDDRUID	D04EHF
D04EHF	DRUGNAME	DAV-132
D04EHF	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D0E6RZ	TTDDRUID	D0E6RZ
D0E6RZ	DRUGNAME	DAV-147
D0E6RZ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D04YTT	TTDDRUID	D04YTT
D04YTT	DRUGNAME	DAV-148
D04YTT	INDICATI	Enterobacteriaceae infection [ICD-11: MG50.C] Investigative

D0FH8R	TTDDRUID	D0FH8R
D0FH8R	DRUGNAME	DB-160
D0FH8R	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D01ARG	TTDDRUID	D01ARG
D01ARG	DRUGNAME	DB-900
D01ARG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative

D08GLH	TTDDRUID	D08GLH
D08GLH	DRUGNAME	DBP-118
D08GLH	INDICATI	Vomiting [ICD-11: MD90] Investigative

D09BEO	TTDDRUID	D09BEO
D09BEO	DRUGNAME	DBP-192
D09BEO	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D07QVY	TTDDRUID	D07QVY
D07QVY	DRUGNAME	DBT-066
D07QVY	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D0HK7G	TTDDRUID	D0HK7G
D0HK7G	DRUGNAME	DBT-1339
D0HK7G	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D06CFJ	TTDDRUID	D06CFJ
D06CFJ	DRUGNAME	DC-480
D06CFJ	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0XQ0V	TTDDRUID	D0XQ0V
D0XQ0V	DRUGNAME	DC-9703
D0XQ0V	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D03DOC	TTDDRUID	D03DOC
D03DOC	DRUGNAME	DCC-2909
D03DOC	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative

D0V7SU	TTDDRUID	D0V7SU
D0V7SU	DRUGNAME	DD-20207
D0V7SU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D04EFG	TTDDRUID	D04EFG
D04EFG	DRUGNAME	DD-3
D04EFG	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00QBV	TTDDRUID	D00QBV
D00QBV	DRUGNAME	DD7
D00QBV	INDICATI	Acute respiratory distress syndrome [ICD-11: CB00] Investigative
D00QBV	INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Investigative
D00QBV	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0BJ0Q	TTDDRUID	D0BJ0Q
D0BJ0Q	DRUGNAME	DDD-64558
D0BJ0Q	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D0YS3H	TTDDRUID	D0YS3H
D0YS3H	DRUGNAME	Debio-0617
D0YS3H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V1WL	TTDDRUID	D0V1WL
D0V1WL	DRUGNAME	Debio-0826
D0V1WL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T0LR	TTDDRUID	D0T0LR
D0T0LR	DRUGNAME	Debio-0929
D0T0LR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C1OJ	TTDDRUID	D0C1OJ
D0C1OJ	DRUGNAME	Debio-0930
D0C1OJ	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D07SRN	TTDDRUID	D07SRN
D07SRN	DRUGNAME	Debio-1036
D07SRN	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D09OLR	TTDDRUID	D09OLR
D09OLR	DRUGNAME	Debio-1141
D09OLR	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0X6NU	TTDDRUID	D0X6NU
D0X6NU	DRUGNAME	Debio-1142
D0X6NU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M4YK	TTDDRUID	D0M4YK
D0M4YK	DRUGNAME	Decorin-like collagen-binding peptidoglycan
D0M4YK	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative

D02ZWO	TTDDRUID	D02ZWO
D02ZWO	DRUGNAME	DEF-201
D02ZWO	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D0Y9GA	TTDDRUID	D0Y9GA
D0Y9GA	DRUGNAME	Dehydroxymethylepoxyquinomicin
D0Y9GA	INDICATI	Cachexia [ICD-11: MG20] Investigative

D0W7ZS	TTDDRUID	D0W7ZS
D0W7ZS	DRUGNAME	Del 60 tetramer
D0W7ZS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09IXX	TTDDRUID	D09IXX
D09IXX	DRUGNAME	Delta-9-tetrahydrocannabinol prodrugs
D09IXX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D07OCM	TTDDRUID	D07OCM
D07OCM	DRUGNAME	Dendritic cell-based immunotherapy
D07OCM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D01DMT	TTDDRUID	D01DMT
D01DMT	DRUGNAME	Dendrogenin A
D01DMT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S5KZ	TTDDRUID	D0S5KZ
D0S5KZ	DRUGNAME	Dengue fever therapeutics
D0S5KZ	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D09AXV	TTDDRUID	D09AXV
D09AXV	DRUGNAME	Dengue virus methyltransferase inhibitors
D09AXV	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D08RQE	TTDDRUID	D08RQE
D08RQE	DRUGNAME	DepoVax
D08RQE	INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Investigative

D09VTS	TTDDRUID	D09VTS
D09VTS	DRUGNAME	Dermatological agent
D09VTS	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D04KWH	TTDDRUID	D04KWH
D04KWH	DRUGNAME	Des-Arg(9)-[Leu(8)]-BK
D04KWH	INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative

D0GP1W	TTDDRUID	D0GP1W
D0GP1W	DRUGNAME	Deuterated oxazolidinone antibiotics
D0GP1W	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0N3NI	TTDDRUID	D0N3NI
D0N3NI	DRUGNAME	Deuteroporphyrin
D0N3NI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05QBF	TTDDRUID	D05QBF
D05QBF	DRUGNAME	Devazepide
D05QBF	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D0G2UP	TTDDRUID	D0G2UP
D0G2UP	DRUGNAME	DF-152
D0G2UP	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D01MFK	TTDDRUID	D01MFK
D01MFK	DRUGNAME	DFU
D01MFK	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0CS2L	TTDDRUID	D0CS2L
D0CS2L	DRUGNAME	DG-1-66
D0CS2L	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D05TBI	TTDDRUID	D05TBI
D05TBI	DRUGNAME	DG-770
D05TBI	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0L3VC	TTDDRUID	D0L3VC
D0L3VC	DRUGNAME	DG-8
D0L3VC	INDICATI	Osteosarcoma [ICD-11: 2B51] Investigative

D0K9XI	TTDDRUID	D0K9XI
D0K9XI	DRUGNAME	DHF-18
D0K9XI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F2VZ	TTDDRUID	D0F2VZ
D0F2VZ	DRUGNAME	Diabetes therapy, BioCure
D0F2VZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0I7SL	TTDDRUID	D0I7SL
D0I7SL	DRUGNAME	Diabetes therapy, Reyon
D0I7SL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D04ZZR	TTDDRUID	D04ZZR
D04ZZR	DRUGNAME	Diazeniumdiolate NO releasing compounds
D04ZZR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09QLR	TTDDRUID	D09QLR
D09QLR	DRUGNAME	Dibenzothiazepines
D09QLR	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative

D02BDL	TTDDRUID	D02BDL
D02BDL	DRUGNAME	Dibenzoylmethane
D02BDL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05KKV	TTDDRUID	D05KKV
D05KKV	DRUGNAME	Dicaffeoylquinic acids
D05KKV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D05PMU	TTDDRUID	D05PMU
D05PMU	DRUGNAME	Dicaffeoyltartaric acids
D05PMU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0JD8N	TTDDRUID	D0JD8N
D0JD8N	DRUGNAME	Dicer-substrate small interfering RNAs
D0JD8N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08CZE	TTDDRUID	D08CZE
D08CZE	DRUGNAME	Dihydropyrone
D08CZE	INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative

D0Q2UW	TTDDRUID	D0Q2UW
D0Q2UW	DRUGNAME	DIMS-9054
D0Q2UW	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0V3EY	TTDDRUID	D0V3EY
D0V3EY	DRUGNAME	Dinucleotide analog prodrug
D0V3EY	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0N8ZJ	TTDDRUID	D0N8ZJ
D0N8ZJ	DRUGNAME	Dipeptide therapeutic
D0N8ZJ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0Q4DO	TTDDRUID	D0Q4DO
D0Q4DO	DRUGNAME	Dipeptidyl peptidase IV inhibitors
D0Q4DO	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D05YFE	TTDDRUID	D05YFE
D05YFE	DRUGNAME	Diphyllin
D05YFE	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D08YAD	TTDDRUID	D08YAD
D08YAD	DRUGNAME	Disarmin
D08YAD	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D09ZKU	TTDDRUID	D09ZKU
D09ZKU	DRUGNAME	DISBA-01
D09ZKU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00BMM	TTDDRUID	D00BMM
D00BMM	DRUGNAME	Dismutase mimetics
D00BMM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08LRU	TTDDRUID	D08LRU
D08LRU	DRUGNAME	Disorazol Z-LHRH conjugates
D08LRU	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0C4JI	TTDDRUID	D0C4JI
D0C4JI	DRUGNAME	DK-0141
D0C4JI	INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative

D0V7ES	TTDDRUID	D0V7ES
D0V7ES	DRUGNAME	DKC-215
D0V7ES	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D04MFW	TTDDRUID	D04MFW
D04MFW	DRUGNAME	DL-3
D04MFW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0C8XT	TTDDRUID	D0C8XT
D0C8XT	DRUGNAME	DLO6001
D0C8XT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D03OMK	TTDDRUID	D03OMK
D03OMK	DRUGNAME	DM-107
D03OMK	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D0WN1N	TTDDRUID	D0WN1N
D0WN1N	DRUGNAME	DM-204
D0WN1N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06TAR	TTDDRUID	D06TAR
D06TAR	DRUGNAME	DM-512
D06TAR	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0L2BT	TTDDRUID	D0L2BT
D0L2BT	DRUGNAME	DMARDs
D0L2BT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0MJ5E	TTDDRUID	D0MJ5E
D0MJ5E	DRUGNAME	DMB mabs
D0MJ5E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B2AH	TTDDRUID	D0B2AH
D0B2AH	DRUGNAME	DMP-695/696
D0B2AH	INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative

D0M7IJ	TTDDRUID	D0M7IJ
D0M7IJ	DRUGNAME	DM-PIT-1
D0M7IJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03KAM	TTDDRUID	D03KAM
D03KAM	DRUGNAME	DNA alkylating agents
D03KAM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZX5D	TTDDRUID	D0ZX5D
D0ZX5D	DRUGNAME	DNA gyrase inhibitors
D0ZX5D	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0B8HR	TTDDRUID	D0B8HR
D0B8HR	DRUGNAME	DNA intercalators
D0B8HR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J3FK	TTDDRUID	D0J3FK
D0J3FK	DRUGNAME	DNX-2000
D0J3FK	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D07UDO	TTDDRUID	D07UDO
D07UDO	DRUGNAME	DNX-3000
D07UDO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O5KN	TTDDRUID	D0O5KN
D0O5KN	DRUGNAME	Dog peptide allergy desensitization agent
D0O5KN	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0M9JJ	TTDDRUID	D0M9JJ
D0M9JJ	DRUGNAME	DOV-216419
D0M9JJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0O7NV	TTDDRUID	D0O7NV
D0O7NV	DRUGNAME	DOV-51892
D0O7NV	INDICATI	Panic disorder [ICD-11: 6B01] Investigative

D0K8KA	TTDDRUID	D0K8KA
D0K8KA	DRUGNAME	DOX-PSASP-BBN-RGD prodrugs
D0K8KA	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0L7RJ	TTDDRUID	D0L7RJ
D0L7RJ	DRUGNAME	DP-109
D0L7RJ	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0Z2BT	TTDDRUID	D0Z2BT
D0Z2BT	DRUGNAME	DP-266
D0Z2BT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0TW1Q	TTDDRUID	D0TW1Q
D0TW1Q	DRUGNAME	DP-3005
D0TW1Q	INDICATI	Angina pectoris [ICD-11: BA40] Investigative

D0W8GP	TTDDRUID	D0W8GP
D0W8GP	DRUGNAME	DP-3590
D0W8GP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T2GP	TTDDRUID	D0T2GP
D0T2GP	DRUGNAME	DP-5599
D0T2GP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0S4BP	TTDDRUID	D0S4BP
D0S4BP	DRUGNAME	DP-802
D0S4BP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D05NCT	TTDDRUID	D05NCT
D05NCT	DRUGNAME	DPC-1528
D05NCT	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D06UVZ	TTDDRUID	D06UVZ
D06UVZ	DRUGNAME	DPD-207
D06UVZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D02REM	TTDDRUID	D02REM
D02REM	DRUGNAME	DPI-221
D02REM	INDICATI	Urinary incontinence [ICD-11: MF50.2] Investigative

D0D4UO	TTDDRUID	D0D4UO
D0D4UO	DRUGNAME	DPK-DTSM-02
D0D4UO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09TDK	TTDDRUID	D09TDK
D09TDK	DRUGNAME	DPN-205-734
D09TDK	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Investigative

D08LZZ	TTDDRUID	D08LZZ
D08LZZ	DRUGNAME	DPO-1
D08LZZ	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D07YOX	TTDDRUID	D07YOX
D07YOX	DRUGNAME	DPP-IV inhibitors, Phenomix
D07YOX	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0R7HA	TTDDRUID	D0R7HA
D0R7HA	DRUGNAME	DPP-IV inhibitors, Santhera
D0R7HA	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0V4RK	TTDDRUID	D0V4RK
D0V4RK	DRUGNAME	DPP-IV inhibitors, Toray
D0V4RK	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D08UAT	TTDDRUID	D08UAT
D08UAT	DRUGNAME	DPS-151
D08UAT	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0GV0H	TTDDRUID	D0GV0H
D0GV0H	DRUGNAME	DPS-201
D0GV0H	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D0W7XH	TTDDRUID	D0W7XH
D0W7XH	DRUGNAME	DR2313
D0W7XH	INDICATI	Stroke [ICD-11: 8B20] Investigative

D0X3PN	TTDDRUID	D0X3PN
D0X3PN	DRUGNAME	DR-5/DR-4 cross reactive mabs
D0X3PN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K6CG	TTDDRUID	D0K6CG
D0K6CG	DRUGNAME	DRA-161
D0K6CG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0G2AV	TTDDRUID	D0G2AV
D0G2AV	DRUGNAME	DRH-12
D0G2AV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00IEB	TTDDRUID	D00IEB
D00IEB	DRUGNAME	DRL-21994
D00IEB	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D0VS1P	TTDDRUID	D0VS1P
D0VS1P	DRUGNAME	DRL-21995
D0VS1P	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D0I4VX	TTDDRUID	D0I4VX
D0I4VX	DRUGNAME	DRP-049
D0I4VX	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D07YIN	TTDDRUID	D07YIN
D07YIN	DRUGNAME	Drug combination
D07YIN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0I5GC	TTDDRUID	D0I5GC
D0I5GC	DRUGNAME	Dry-powder peptide YY(3-36)
D0I5GC	INDICATI	Obesity [ICD-11: 5B81] Investigative

D04ZSZ	TTDDRUID	D04ZSZ
D04ZSZ	DRUGNAME	DS-AH-14
D04ZSZ	INDICATI	Asthma [ICD-11: CA23] Investigative

D04OIG	TTDDRUID	D04OIG
D04OIG	DRUGNAME	DSLIM
D04OIG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07PUS	TTDDRUID	D07PUS
D07PUS	DRUGNAME	DSM1
D07PUS	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D09WBQ	TTDDRUID	D09WBQ
D09WBQ	DRUGNAME	DSM2
D09WBQ	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0E0UC	TTDDRUID	D0E0UC
D0E0UC	DRUGNAME	DSR-17759
D0E0UC	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0L2YR	TTDDRUID	D0L2YR
D0L2YR	DRUGNAME	DT-1687
D0L2YR	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D07TBD	TTDDRUID	D07TBD
D07TBD	DRUGNAME	DT-2228
D07TBD	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D08KBB	TTDDRUID	D08KBB
D08KBB	DRUGNAME	DT-310
D08KBB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X5BC	TTDDRUID	D0X5BC
D0X5BC	DRUGNAME	DT-320
D0X5BC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T0MY	TTDDRUID	D0T0MY
D0T0MY	DRUGNAME	DT-330
D0T0MY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09TXU	TTDDRUID	D09TXU
D09TXU	DRUGNAME	DT-831j
D09TXU	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0C0AA	TTDDRUID	D0C0AA
D0C0AA	DRUGNAME	DTS-108
D0C0AA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04RWF	TTDDRUID	D04RWF
D04RWF	DRUGNAME	Dual antigen vaccine, Aparna Biosciences
D04RWF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0H7MV	TTDDRUID	D0H7MV
D0H7MV	DRUGNAME	Dual attack synbiotics
D0H7MV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D07SMD	TTDDRUID	D07SMD
D07SMD	DRUGNAME	Dual norepinephrine reuptake inhibitors/5-HT1A partial agonists
D07SMD	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Investigative

D0I5QK	TTDDRUID	D0I5QK
D0I5QK	DRUGNAME	Dual PI3K/mTOR inhibitors
D0I5QK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08SAZ	TTDDRUID	D08SAZ
D08SAZ	DRUGNAME	Dual PI3K-alpha/mTOR inhibitors
D08SAZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K8YK	TTDDRUID	D0K8YK
D0K8YK	DRUGNAME	DVD-Ig
D0K8YK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q8YZ	TTDDRUID	D0Q8YZ
D0Q8YZ	DRUGNAME	DW-286
D0Q8YZ	INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative

D0A5CZ	TTDDRUID	D0A5CZ
D0A5CZ	DRUGNAME	DW-403
D0A5CZ	INDICATI	Asthma [ICD-11: CA23] Investigative

D0NT8Q	TTDDRUID	D0NT8Q
D0NT8Q	DRUGNAME	DW-514
D0NT8Q	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D0UO7V	TTDDRUID	D0UO7V
D0UO7V	DRUGNAME	DW-800
D0UO7V	INDICATI	Mucositis [ICD-11: CA00] Investigative

D0I9TV	TTDDRUID	D0I9TV
D0I9TV	DRUGNAME	DW-816
D0I9TV	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D0R4NJ	TTDDRUID	D0R4NJ
D0R4NJ	DRUGNAME	DW-908
D0R4NJ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D04RJM	TTDDRUID	D04RJM
D04RJM	DRUGNAME	DW-941
D04RJM	INDICATI	Coronavirus infection [ICD-11: 1D92] Investigative

D0B9RF	TTDDRUID	D0B9RF
D0B9RF	DRUGNAME	DW-953
D0B9RF	INDICATI	Dyspepsia [ICD-11: MD92] Investigative

D0E9OI	TTDDRUID	D0E9OI
D0E9OI	DRUGNAME	DWE-01
D0E9OI	INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative

D01YFR	TTDDRUID	D01YFR
D01YFR	DRUGNAME	DWJ-205
D01YFR	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D01LXZ	TTDDRUID	D01LXZ
D01LXZ	DRUGNAME	DWJ-206
D01LXZ	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative

D0D3TU	TTDDRUID	D0D3TU
D0D3TU	DRUGNAME	DWJ-207
D0D3TU	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0W5CI	TTDDRUID	D0W5CI
D0W5CI	DRUGNAME	DWJ-209
D0W5CI	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0B0EZ	TTDDRUID	D0B0EZ
D0B0EZ	DRUGNAME	DWJ-424
D0B0EZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I4MW	TTDDRUID	D0I4MW
D0I4MW	DRUGNAME	DWJ-425
D0I4MW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D05OBK	TTDDRUID	D05OBK
D05OBK	DRUGNAME	DwLIP-GCGRrx
D05OBK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D01LFQ	TTDDRUID	D01LFQ
D01LFQ	DRUGNAME	DWP-438
D01LFQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XR0V	TTDDRUID	D0XR0V
D0XR0V	DRUGNAME	DWP-451
D0XR0V	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D0F4FV	TTDDRUID	D0F4FV
D0F4FV	DRUGNAME	DX-2300
D0F4FV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D03XBB	TTDDRUID	D03XBB
D03XBB	DRUGNAME	DX-2400
D03XBB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R3KS	TTDDRUID	D0R3KS
D0R3KS	DRUGNAME	DX-2500
D0R3KS	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D01UBV	TTDDRUID	D01UBV
D01UBV	DRUGNAME	DXL-1215
D01UBV	INDICATI	Endometriosis [ICD-11: GA10] Investigative

D05QGH	TTDDRUID	D05QGH
D05QGH	DRUGNAME	DXL-625
D05QGH	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative

D0M1XY	TTDDRUID	D0M1XY
D0M1XY	DRUGNAME	DYB-186
D0M1XY	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D01WBT	TTDDRUID	D01WBT
D01WBT	DRUGNAME	DYN-15
D01WBT	INDICATI	Blindness [ICD-11: 9D90] Investigative

D0M3NF	TTDDRUID	D0M3NF
D0M3NF	DRUGNAME	DZ-13
D0M3NF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OH8O	TTDDRUID	D0OH8O
D0OH8O	DRUGNAME	E coli EPVaccine
D0OH8O	INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative

D09FWK	TTDDRUID	D09FWK
D09FWK	DRUGNAME	E-003
D09FWK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09AVZ	TTDDRUID	D09AVZ
D09AVZ	DRUGNAME	E1/E4-deleted adenoviral vector
D09AVZ	INDICATI	Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Investigative

D0S6WW	TTDDRUID	D0S6WW
D0S6WW	DRUGNAME	E12/DP3-117
D0S6WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M3GW	TTDDRUID	D0M3GW
D0M3GW	DRUGNAME	E-1210
D0M3GW	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0RS1Q	TTDDRUID	D0RS1Q
D0RS1Q	DRUGNAME	E-1413
D0RS1Q	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D00VSQ	TTDDRUID	D00VSQ
D00VSQ	DRUGNAME	E-1455
D00VSQ	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D03QAS	TTDDRUID	D03QAS
D03QAS	DRUGNAME	E-758
D03QAS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J3TT	TTDDRUID	D0J3TT
D0J3TT	DRUGNAME	Ear disorder therapeutics
D0J3TT	INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Investigative

D01ANE	TTDDRUID	D01ANE
D01ANE	DRUGNAME	EB-1,2,3 mab
D01ANE	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D01SUO	TTDDRUID	D01SUO
D01SUO	DRUGNAME	EBC-46
D01SUO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F2XC	TTDDRUID	D0F2XC
D0F2XC	DRUGNAME	EBMS therapy, cardiovascular regeneration
D0F2XC	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D02YWE	TTDDRUID	D02YWE
D02YWE	DRUGNAME	EBP-1597
D02YWE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D06AQP	TTDDRUID	D06AQP
D06AQP	DRUGNAME	EC-0531
D06AQP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H4KF	TTDDRUID	D0H4KF
D0H4KF	DRUGNAME	EC-0565
D0H4KF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FM4T	TTDDRUID	D0FM4T
D0FM4T	DRUGNAME	EC-0746
D0FM4T	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0A8ES	TTDDRUID	D0A8ES
D0A8ES	DRUGNAME	EC-0845
D0A8ES	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0C3WS	TTDDRUID	D0C3WS
D0C3WS	DRUGNAME	EC-301
D0C3WS	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative

D05ZIT	TTDDRUID	D05ZIT
D05ZIT	DRUGNAME	EC-400
D05ZIT	INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative

D08BPD	TTDDRUID	D08BPD
D08BPD	DRUGNAME	EC-70124
D08BPD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01EZA	TTDDRUID	D01EZA
D01EZA	DRUGNAME	EC-8042
D01EZA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01HPP	TTDDRUID	D01HPP
D01HPP	DRUGNAME	ECFCs
D01HPP	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0FY4M	TTDDRUID	D0FY4M
D0FY4M	DRUGNAME	Echinocandin
D0FY4M	INDICATI	Candidiasis [ICD-11: 1F23] Investigative
D0FY4M	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0A5NN	TTDDRUID	D0A5NN
D0A5NN	DRUGNAME	ECO-0501
D0A5NN	INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Investigative

D0G1SN	TTDDRUID	D0G1SN
D0G1SN	DRUGNAME	ED1
D0G1SN	INDICATI	Acute respiratory distress syndrome [ICD-11: CB00] Investigative
D0G1SN	INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Investigative
D0G1SN	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D01NJE	TTDDRUID	D01NJE
D01NJE	DRUGNAME	ED45
D01NJE	INDICATI	Acute respiratory distress syndrome [ICD-11: CB00] Investigative
D01NJE	INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Investigative
D01NJE	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0E6JY	TTDDRUID	D0E6JY
D0E6JY	DRUGNAME	EDC/IL-4
D0E6JY	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0Q2HM	TTDDRUID	D0Q2HM
D0Q2HM	DRUGNAME	EDD7H9
D0Q2HM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D09CNV	TTDDRUID	D09CNV
D09CNV	DRUGNAME	EDG-005
D09CNV	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D03IQH	TTDDRUID	D03IQH
D03IQH	DRUGNAME	EDG-006
D03IQH	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0Q4HA	TTDDRUID	D0Q4HA
D0Q4HA	DRUGNAME	EDG-007
D0Q4HA	INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Investigative

D0CO9Z	TTDDRUID	D0CO9Z
D0CO9Z	DRUGNAME	Edg5 antagonists
D0CO9Z	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D08PYQ	TTDDRUID	D08PYQ
D08PYQ	DRUGNAME	EDL-2000
D08PYQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D07ZDG	TTDDRUID	D07ZDG
D07ZDG	DRUGNAME	EDN-OL1
D07ZDG	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0NH1V	TTDDRUID	D0NH1V
D0NH1V	DRUGNAME	EDP-08
D0NH1V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O4SZ	TTDDRUID	D0O4SZ
D0O4SZ	DRUGNAME	EDP-09
D0O4SZ	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D0R6ZB	TTDDRUID	D0R6ZB
D0R6ZB	DRUGNAME	EDP-10
D0R6ZB	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0K3FG	TTDDRUID	D0K3FG
D0K3FG	DRUGNAME	EDP-13
D0K3FG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07GVE	TTDDRUID	D07GVE
D07GVE	DRUGNAME	EDP-14
D07GVE	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0LC8F	TTDDRUID	D0LC8F
D0LC8F	DRUGNAME	EDP-15
D0LC8F	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D05WVO	TTDDRUID	D05WVO
D05WVO	DRUGNAME	EDP-17
D05WVO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H0EP	TTDDRUID	D0H0EP
D0H0EP	DRUGNAME	EDP-18
D0H0EP	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D02JIF	TTDDRUID	D02JIF
D02JIF	DRUGNAME	EDP-19
D02JIF	INDICATI	Brain cancer [ICD-11: 2A00] Investigative

D04QHT	TTDDRUID	D04QHT
D04QHT	DRUGNAME	EDP-20
D04QHT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D1PQ	TTDDRUID	D0D1PQ
D0D1PQ	DRUGNAME	EDP-21
D0D1PQ	INDICATI	Obesity [ICD-11: 5B81] Investigative

D08DHR	TTDDRUID	D08DHR
D08DHR	DRUGNAME	EDP-22
D08DHR	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D03FIS	TTDDRUID	D03FIS
D03FIS	DRUGNAME	EDP-23
D03FIS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0RR9O	TTDDRUID	D0RR9O
D0RR9O	DRUGNAME	EDP-24
D0RR9O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M2RZ	TTDDRUID	D0M2RZ
D0M2RZ	DRUGNAME	EDP-MRSA-1
D0M2RZ	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative

D0L8OZ	TTDDRUID	D0L8OZ
D0L8OZ	DRUGNAME	EG-013
D0L8OZ	INDICATI	Fetal growth restriction [ICD-11: KA20.1Z] Investigative

D0I7VI	TTDDRUID	D0I7VI
D0I7VI	DRUGNAME	EG-10
D0I7VI	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0V1DG	TTDDRUID	D0V1DG
D0V1DG	DRUGNAME	EG-Decorin
D0V1DG	INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative

D0Z8ZW	TTDDRUID	D0Z8ZW
D0Z8ZW	DRUGNAME	EGF-SLiP fusion protein
D0Z8ZW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D05DBT	TTDDRUID	D05DBT
D05DBT	DRUGNAME	EG-HPV
D05DBT	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative

D07VRP	TTDDRUID	D07VRP
D07VRP	DRUGNAME	EG-Mirotin
D07VRP	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative

D03RKC	TTDDRUID	D03RKC
D03RKC	DRUGNAME	EG-Vac
D03RKC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08FJG	TTDDRUID	D08FJG
D08FJG	DRUGNAME	EHT/AGN-0002
D08FJG	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0V7YG	TTDDRUID	D0V7YG
D0V7YG	DRUGNAME	EHT/AGN-0003
D0V7YG	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D03DTW	TTDDRUID	D03DTW
D03DTW	DRUGNAME	EHT-107
D03DTW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L8TP	TTDDRUID	D0L8TP
D0L8TP	DRUGNAME	Ektomun
D0L8TP	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D00XPZ	TTDDRUID	D00XPZ
D00XPZ	DRUGNAME	ELB-WE-007
D00XPZ	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0P2TD	TTDDRUID	D0P2TD
D0P2TD	DRUGNAME	ElCams
D0P2TD	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0U4IV	TTDDRUID	D0U4IV
D0U4IV	DRUGNAME	Elfamycin
D0U4IV	INDICATI	Enterocolitis [ICD-11: 1A40.Z] Investigative

D0YA6U	TTDDRUID	D0YA6U
D0YA6U	DRUGNAME	ELN-864709
D0YA6U	INDICATI	Central nervous system injury [ICD-11: KA40] Investigative

D0Q6ZQ	TTDDRUID	D0Q6ZQ
D0Q6ZQ	DRUGNAME	ELND-007
D0Q6ZQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D06DRU	TTDDRUID	D06DRU
D06DRU	DRUGNAME	ELP-10
D06DRU	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D0Y7PJ	TTDDRUID	D0Y7PJ
D0Y7PJ	DRUGNAME	ELS-110
D0Y7PJ	INDICATI	Migraine [ICD-11: 8A80] Investigative

D0X2HD	TTDDRUID	D0X2HD
D0X2HD	DRUGNAME	ELS-120
D0X2HD	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0NF0P	TTDDRUID	D0NF0P
D0NF0P	DRUGNAME	ELS-130
D0NF0P	INDICATI	Raynaud disease [ICD-11: BD42.0] Investigative

D09VHS	TTDDRUID	D09VHS
D09VHS	DRUGNAME	EM-101
D09VHS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P4ZA	TTDDRUID	D0P4ZA
D0P4ZA	DRUGNAME	EM-2198
D0P4ZA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D09IOA	TTDDRUID	D09IOA
D09IOA	DRUGNAME	EM-3106B
D09IOA	INDICATI	Insulinoma [ICD-11: 2C10.1] Investigative

D0T0UM	TTDDRUID	D0T0UM
D0T0UM	DRUGNAME	EM-6110a
D0T0UM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z1YK	TTDDRUID	D0Z1YK
D0Z1YK	DRUGNAME	EM-703
D0Z1YK	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D01KRQ	TTDDRUID	D01KRQ
D01KRQ	DRUGNAME	EMC-0901
D01KRQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D07UEJ	TTDDRUID	D07UEJ
D07UEJ	DRUGNAME	Empagli ozin
D07UEJ	INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative

D0X4JO	TTDDRUID	D0X4JO
D0X4JO	DRUGNAME	EncorStat
D0X4JO	INDICATI	Corneal abrasion [ICD-11: NA06.4] Investigative

D09CYK	TTDDRUID	D09CYK
D09CYK	DRUGNAME	ENDG-3010
D09CYK	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D03CWO	TTDDRUID	D03CWO
D03CWO	DRUGNAME	ENDG-3020
D03CWO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0I1ZB	TTDDRUID	D0I1ZB
D0I1ZB	DRUGNAME	ENDG-4010
D0I1ZB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0GM0N	TTDDRUID	D0GM0N
D0GM0N	DRUGNAME	ENDG-6010
D0GM0N	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D08MMP	TTDDRUID	D08MMP
D08MMP	DRUGNAME	ENDG-8010
D08MMP	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0T8LL	TTDDRUID	D0T8LL
D0T8LL	DRUGNAME	EndocrineTherapy
D0T8LL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D03MER	TTDDRUID	D03MER
D03MER	DRUGNAME	Endogenous human peptide LL-37
D03MER	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D07GZG	TTDDRUID	D07GZG
D07GZG	DRUGNAME	Endomorphins
D07GZG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0B1LN	TTDDRUID	D0B1LN
D0B1LN	DRUGNAME	Endothelial lipase inhibitors
D0B1LN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D03NHZ	TTDDRUID	D03NHZ
D03NHZ	DRUGNAME	Engineered toxin bodies
D03NHZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00KCR	TTDDRUID	D00KCR
D00KCR	DRUGNAME	Enkastim-iv
D00KCR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0WX1N	TTDDRUID	D0WX1N
D0WX1N	DRUGNAME	Ensemblin macrocycle
D0WX1N	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0H2UU	TTDDRUID	D0H2UU
D0H2UU	DRUGNAME	Entecavir+lamivudine+adefovir
D0H2UU	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D08YQG	TTDDRUID	D08YQG
D08YQG	DRUGNAME	Entelon
D08YQG	INDICATI	Lymphatic disease [ICD-11: BD9Z] Investigative

D0N2NI	TTDDRUID	D0N2NI
D0N2NI	DRUGNAME	Entrectinib
D0N2NI	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D0N2NI	INDICATI	Mammary analogue secretory carcinoma [ICD-11: 2C60] Phase 1

D0V7YI	TTDDRUID	D0V7YI
D0V7YI	DRUGNAME	Enzyme mabs
D0V7YI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00YJI	TTDDRUID	D00YJI
D00YJI	DRUGNAME	EOS-013
D00YJI	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative

D0QM3Q	TTDDRUID	D0QM3Q
D0QM3Q	DRUGNAME	EP-102
D0QM3Q	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D04CTP	TTDDRUID	D04CTP
D04CTP	DRUGNAME	EP-200
D04CTP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q0XH	TTDDRUID	D0Q0XH
D0Q0XH	DRUGNAME	EP-342
D0Q0XH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q2VA	TTDDRUID	D0Q2VA
D0Q2VA	DRUGNAME	EP-37
D0Q2VA	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0H6IG	TTDDRUID	D0H6IG
D0H6IG	DRUGNAME	EP-400
D0H6IG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02ZWJ	TTDDRUID	D02ZWJ
D02ZWJ	DRUGNAME	EP-94
D02ZWJ	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D00RPV	TTDDRUID	D00RPV
D00RPV	DRUGNAME	EPB-200
D00RPV	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D04WCO	TTDDRUID	D04WCO
D04WCO	DRUGNAME	EPB-415
D04WCO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D00RZA	TTDDRUID	D00RZA
D00RZA	DRUGNAME	EPB-500
D00RZA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D06TLK	TTDDRUID	D06TLK
D06TLK	DRUGNAME	EPB-600
D06TLK	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D08FRG	TTDDRUID	D08FRG
D08FRG	DRUGNAME	EphA2-targeting BiTE molecules
D08FRG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03BMT	TTDDRUID	D03BMT
D03BMT	DRUGNAME	EphB4 inhibitors
D03BMT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q6GK	TTDDRUID	D0Q6GK
D0Q6GK	DRUGNAME	EphB4-131
D0Q6GK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T1DZ	TTDDRUID	D0T1DZ
D0T1DZ	DRUGNAME	EPI-001
D0T1DZ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0R3IK	TTDDRUID	D0R3IK
D0R3IK	DRUGNAME	EPI-0030
D0R3IK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01KIY	TTDDRUID	D01KIY
D01KIY	DRUGNAME	EPI-0031
D01KIY	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0K9UT	TTDDRUID	D0K9UT
D0K9UT	DRUGNAME	Epi-13
D0K9UT	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0I5TT	TTDDRUID	D0I5TT
D0I5TT	DRUGNAME	EPI-2221
D0I5TT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q6AE	TTDDRUID	D0Q6AE
D0Q6AE	DRUGNAME	EPI-288
D0Q6AE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02JOI	TTDDRUID	D02JOI
D02JOI	DRUGNAME	EPI-3905
D02JOI	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D0V1BY	TTDDRUID	D0V1BY
D0V1BY	DRUGNAME	EPI-6
D0V1BY	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D0R1RK	TTDDRUID	D0R1RK
D0R1RK	DRUGNAME	EpiCept
D0R1RK	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D08GZA	TTDDRUID	D08GZA
D08GZA	DRUGNAME	Epileptic therapeutics
D08GZA	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D05MEY	TTDDRUID	D05MEY
D05MEY	DRUGNAME	Epitinib
D05MEY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06QIW	TTDDRUID	D06QIW
D06QIW	DRUGNAME	EPO peptide mimetics
D06QIW	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D01IMY	TTDDRUID	D01IMY
D01IMY	DRUGNAME	EPO program, Medexgen
D01IMY	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0D5FB	TTDDRUID	D0D5FB
D0D5FB	DRUGNAME	EPO-derived peptide
D0D5FB	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative

D09SWM	TTDDRUID	D09SWM
D09SWM	DRUGNAME	Epostane
D09SWM	INDICATI	Abortion [ICD-11: JA00] Investigative

D0G3QF	TTDDRUID	D0G3QF
D0G3QF	DRUGNAME	Epoxyeicosatrienoic acid mimetics
D0G3QF	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09ENZ	TTDDRUID	D09ENZ
D09ENZ	DRUGNAME	EPZ-004777
D09ENZ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D0O8RL	TTDDRUID	D0O8RL
D0O8RL	DRUGNAME	EQ-1280
D0O8RL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D01FTU	TTDDRUID	D01FTU
D01FTU	DRUGNAME	EQ-317
D01FTU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0M3VU	TTDDRUID	D0M3VU
D0M3VU	DRUGNAME	EQ-318
D0M3VU	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0C1TO	TTDDRUID	D0C1TO
D0C1TO	DRUGNAME	EQ-818-1
D0C1TO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06DMV	TTDDRUID	D06DMV
D06DMV	DRUGNAME	ER-21018
D06DMV	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D0ZB9D	TTDDRUID	D0ZB9D
D0ZB9D	DRUGNAME	ER-21036
D0ZB9D	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0G5UH	TTDDRUID	D0G5UH
D0G5UH	DRUGNAME	ER-21041
D0G5UH	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0G6RK	TTDDRUID	D0G6RK
D0G6RK	DRUGNAME	ER-23006
D0G6RK	INDICATI	Asthma [ICD-11: CA23] Investigative

D0P5ZG	TTDDRUID	D0P5ZG
D0P5ZG	DRUGNAME	EradicAide
D0P5ZG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0XD4N	TTDDRUID	D0XD4N
D0XD4N	DRUGNAME	ERB-002
D0XD4N	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D03PBE	TTDDRUID	D03PBE
D03PBE	DRUGNAME	ERK inhibitors
D03PBE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00QGP	TTDDRUID	D00QGP
D00QGP	DRUGNAME	ERR alpha modulators
D00QGP	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0G5JW	TTDDRUID	D0G5JW
D0G5JW	DRUGNAME	Erythropoietin
D0G5JW	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0TD2F	TTDDRUID	D0TD2F
D0TD2F	DRUGNAME	ES-6864
D0TD2F	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D05ZNA	TTDDRUID	D05ZNA
D05ZNA	DRUGNAME	ESBA-903
D05ZNA	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0K7MY	TTDDRUID	D0K7MY
D0K7MY	DRUGNAME	ESI-014
D0K7MY	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0I3OX	TTDDRUID	D0I3OX
D0I3OX	DRUGNAME	ESN-XX
D0I3OX	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09RNI	TTDDRUID	D09RNI
D09RNI	DRUGNAME	ESN-YY
D09RNI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0V4DH	TTDDRUID	D0V4DH
D0V4DH	DRUGNAME	Estriol E3
D0V4DH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0C1ZQ	TTDDRUID	D0C1ZQ
D0C1ZQ	DRUGNAME	Estrogen receptor beta modulators
D0C1ZQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0P7WW	TTDDRUID	D0P7WW
D0P7WW	DRUGNAME	ET-001
D0P7WW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0Q8SN	TTDDRUID	D0Q8SN
D0Q8SN	DRUGNAME	ET-003
D0Q8SN	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D0W5WH	TTDDRUID	D0W5WH
D0W5WH	DRUGNAME	ET-004
D0W5WH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0V6CY	TTDDRUID	D0V6CY
D0V6CY	DRUGNAME	ET-005
D0V6CY	INDICATI	Acquired haemolytic anemia [ICD-11: 3A4Z] Investigative

D0L3LO	TTDDRUID	D0L3LO
D0L3LO	DRUGNAME	ET-006
D0L3LO	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D06LGZ	TTDDRUID	D06LGZ
D06LGZ	DRUGNAME	ET-007
D06LGZ	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D0G1QL	TTDDRUID	D0G1QL
D0G1QL	DRUGNAME	ET-008
D0G1QL	INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative

D0XT3G	TTDDRUID	D0XT3G
D0XT3G	DRUGNAME	ET-009
D0XT3G	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0R2HZ	TTDDRUID	D0R2HZ
D0R2HZ	DRUGNAME	ETHOXY-IDAZOXAN
D0R2HZ	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D06NHB	TTDDRUID	D06NHB
D06NHB	DRUGNAME	Ethyl esther derivative
D06NHB	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D0WT6A	TTDDRUID	D0WT6A
D0WT6A	DRUGNAME	Ethylene diamine
D0WT6A	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Investigative

D0EO3K	TTDDRUID	D0EO3K
D0EO3K	DRUGNAME	ETI-210
D0EO3K	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative

D0I0ZY	TTDDRUID	D0I0ZY
D0I0ZY	DRUGNAME	ETN-001
D0I0ZY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0LR4M	TTDDRUID	D0LR4M
D0LR4M	DRUGNAME	ETN-002
D0LR4M	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D01RFF	TTDDRUID	D01RFF
D01RFF	DRUGNAME	Etoxazole
D01RFF	INDICATI	Pest attack [ICD-11: N.A.] Investigative

D05TLQ	TTDDRUID	D05TLQ
D05TLQ	DRUGNAME	ETR-001
D05TLQ	INDICATI	Kidney disease [ICD-11: GC2Z] Investigative

D0L0DO	TTDDRUID	D0L0DO
D0L0DO	DRUGNAME	ETR-002
D0L0DO	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0I1ZT	TTDDRUID	D0I1ZT
D0I1ZT	DRUGNAME	ETV-002
D0I1ZT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D05EAJ	TTDDRUID	D05EAJ
D05EAJ	DRUGNAME	ETV-003
D05EAJ	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative

D0S4GR	TTDDRUID	D0S4GR
D0S4GR	DRUGNAME	ETV-004
D0S4GR	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D0AQ8F	TTDDRUID	D0AQ8F
D0AQ8F	DRUGNAME	ETV-005
D0AQ8F	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0U4QZ	TTDDRUID	D0U4QZ
D0U4QZ	DRUGNAME	EU-517
D0U4QZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01MND	TTDDRUID	D01MND
D01MND	DRUGNAME	EU-C-001
D01MND	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D0R7LX	TTDDRUID	D0R7LX
D0R7LX	DRUGNAME	EU-C-002
D0R7LX	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative

D0Y9OS	TTDDRUID	D0Y9OS
D0Y9OS	DRUGNAME	Euro-Celtique 1
D0Y9OS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D02LIY	TTDDRUID	D02LIY
D02LIY	DRUGNAME	Euro-Celtique 2
D02LIY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06PJK	TTDDRUID	D06PJK
D06PJK	DRUGNAME	Euro-Celtique 3
D06PJK	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0M3ON	TTDDRUID	D0M3ON
D0M3ON	DRUGNAME	Euro-Celtique 4
D0M3ON	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D08GAH	TTDDRUID	D08GAH
D08GAH	DRUGNAME	EV-075
D08GAH	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D04KEL	TTDDRUID	D04KEL
D04KEL	DRUGNAME	EV-086 oral/intravenous formulation
D04KEL	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D05CGH	TTDDRUID	D05CGH
D05CGH	DRUGNAME	Evatak
D05CGH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08VRQ	TTDDRUID	D08VRQ
D08VRQ	DRUGNAME	EVIRNA
D08VRQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0VE4O	TTDDRUID	D0VE4O
D0VE4O	DRUGNAME	EVP-4473
D0VE4O	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0T6TH	TTDDRUID	D0T6TH
D0T6TH	DRUGNAME	EVT-501
D0T6TH	INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Investigative

D0YJ5H	TTDDRUID	D0YJ5H
D0YJ5H	DRUGNAME	EX-1311
D0YJ5H	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0C4BI	TTDDRUID	D0C4BI
D0C4BI	DRUGNAME	EX-1314
D0C4BI	INDICATI	Cachexia [ICD-11: MG20] Investigative

D04RBY	TTDDRUID	D04RBY
D04RBY	DRUGNAME	EX-201
D04RBY	INDICATI	Mucositis [ICD-11: CA00] Investigative

D0C5TE	TTDDRUID	D0C5TE
D0C5TE	DRUGNAME	Expanded-spectrum neoglycosides
D0C5TE	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0X0ZD	TTDDRUID	D0X0ZD
D0X0ZD	DRUGNAME	EXRD-4605
D0X0ZD	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0L5LS	TTDDRUID	D0L5LS
D0L5LS	DRUGNAME	Extended-release opioid
D0L5LS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0W7CR	TTDDRUID	D0W7CR
D0W7CR	DRUGNAME	EZN-3889
D0W7CR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0VV5X	TTDDRUID	D0VV5X
D0VV5X	DRUGNAME	EZN-3920
D0VV5X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04ZWD	TTDDRUID	D04ZWD
D04ZWD	DRUGNAME	EZN-4150
D04ZWD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03QVY	TTDDRUID	D03QVY
D03QVY	DRUGNAME	EZN-4482
D03QVY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L9PX	TTDDRUID	D0L9PX
D0L9PX	DRUGNAME	F10
D0L9PX	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D09JYY	TTDDRUID	D09JYY
D09JYY	DRUGNAME	F-1013
D09JYY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08SZO	TTDDRUID	D08SZO
D08SZO	DRUGNAME	F-12458
D08SZO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0IW1Y	TTDDRUID	D0IW1Y
D0IW1Y	DRUGNAME	F-16915
D0IW1Y	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D0O0LF	TTDDRUID	D0O0LF
D0O0LF	DRUGNAME	F-18 exendin-4 derivative PET tracers
D0O0LF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D01SXE	TTDDRUID	D01SXE
D01SXE	DRUGNAME	F-18 T808
D01SXE	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0N1DG	TTDDRUID	D0N1DG
D0N1DG	DRUGNAME	F61F12
D0N1DG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L7MO	TTDDRUID	D0L7MO
D0L7MO	DRUGNAME	F-80002-RR
D0L7MO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00VCH	TTDDRUID	D00VCH
D00VCH	DRUGNAME	F-98214
D00VCH	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D09PDK	TTDDRUID	D09PDK
D09PDK	DRUGNAME	F-9TG
D09PDK	INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative

D01UPT	TTDDRUID	D01UPT
D01UPT	DRUGNAME	FA-70
D01UPT	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0S6OY	TTDDRUID	D0S6OY
D0S6OY	DRUGNAME	FabOvar
D0S6OY	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D06IGE	TTDDRUID	D06IGE
D06IGE	DRUGNAME	Factor IX-XTEN
D06IGE	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D07LRB	TTDDRUID	D07LRB
D07LRB	DRUGNAME	Factor VIII-XTEN
D07LRB	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D01NCC	TTDDRUID	D01NCC
D01NCC	DRUGNAME	Factor-VIIa-XTEN
D01NCC	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D0X6AU	TTDDRUID	D0X6AU
D0X6AU	DRUGNAME	FAS-031
D0X6AU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01TVT	TTDDRUID	D01TVT
D01TVT	DRUGNAME	FAS-115
D01TVT	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0TT5I	TTDDRUID	D0TT5I
D0TT5I	DRUGNAME	FAS-20013
D0TT5I	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D05AQB	TTDDRUID	D05AQB
D05AQB	DRUGNAME	FAS-89B
D05AQB	INDICATI	Obesity [ICD-11: 5B81] Investigative

D07AXA	TTDDRUID	D07AXA
D07AXA	DRUGNAME	Fatty acid amide hydrolase inhibitors
D07AXA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0N0DP	TTDDRUID	D0N0DP
D0N0DP	DRUGNAME	FB-1811
D0N0DP	INDICATI	Salmonella infection [ICD-11: 1A09] Investigative

D0H1XL	TTDDRUID	D0H1XL
D0H1XL	DRUGNAME	Fc-IFN alpha 2b
D0H1XL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L2VB	TTDDRUID	D0L2VB
D0L2VB	DRUGNAME	FE-203799
D0L2VB	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D0A9WW	TTDDRUID	D0A9WW
D0A9WW	DRUGNAME	FE-999040
D0A9WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04MYG	TTDDRUID	D04MYG
D04MYG	DRUGNAME	Fenbunafide
D04MYG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01CBU	TTDDRUID	D01CBU
D01CBU	DRUGNAME	FG-020318
D01CBU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V7BH	TTDDRUID	D0V7BH
D0V7BH	DRUGNAME	FG-4497
D0V7BH	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D01HTJ	TTDDRUID	D01HTJ
D01HTJ	DRUGNAME	FG-65155
D01HTJ	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative

D09DAJ	TTDDRUID	D09DAJ
D09DAJ	DRUGNAME	FG-6874
D09DAJ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D03TVE	TTDDRUID	D03TVE
D03TVE	DRUGNAME	FGF21-PKE Adnectin
D03TVE	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0X9IS	TTDDRUID	D0X9IS
D0X9IS	DRUGNAME	FGI-102
D0X9IS	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D02HPI	TTDDRUID	D02HPI
D02HPI	DRUGNAME	FGI-103-723
D02HPI	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D03NLJ	TTDDRUID	D03NLJ
D03NLJ	DRUGNAME	FGI-106
D03NLJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D04JAQ	TTDDRUID	D04JAQ
D04JAQ	DRUGNAME	FH-AAV8
D04JAQ	INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative

D08UXQ	TTDDRUID	D08UXQ
D08UXQ	DRUGNAME	FHT-1106
D08UXQ	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D0A0FI	TTDDRUID	D0A0FI
D0A0FI	DRUGNAME	FHT-401
D0A0FI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D04ALI	TTDDRUID	D04ALI
D04ALI	DRUGNAME	FHT-CT4
D04ALI	INDICATI	Asthma [ICD-11: CA23] Investigative

D0J5AD	TTDDRUID	D0J5AD
D0J5AD	DRUGNAME	FI-6
D0J5AD	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D06RRD	TTDDRUID	D06RRD
D06RRD	DRUGNAME	Fibrates
D06RRD	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Investigative

D0Q5FT	TTDDRUID	D0Q5FT
D0Q5FT	DRUGNAME	Fibroblast growth factor
D0Q5FT	INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Investigative

D07TQU	TTDDRUID	D07TQU
D07TQU	DRUGNAME	FibroStem
D07TQU	INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative

D06BGK	TTDDRUID	D06BGK
D06BGK	DRUGNAME	FiloVax
D06BGK	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D04BEL	TTDDRUID	D04BEL
D04BEL	DRUGNAME	FIV vectors
D04BEL	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative

D0L8UQ	TTDDRUID	D0L8UQ
D0L8UQ	DRUGNAME	FKB327
D0L8UQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0B5GC	TTDDRUID	D0B5GC
D0B5GC	DRUGNAME	Flavonols
D0B5GC	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D04KZH	TTDDRUID	D04KZH
D04KZH	DRUGNAME	FluBiovax
D04KZH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0DC3H	TTDDRUID	D0DC3H
D0DC3H	DRUGNAME	FluDrugStrategy
D0DC3H	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0R5IS	TTDDRUID	D0R5IS
D0R5IS	DRUGNAME	Flufenoxina
D0R5IS	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0A3OS	TTDDRUID	D0A3OS
D0A3OS	DRUGNAME	FLUINHIBIT
D0A3OS	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D05FQF	TTDDRUID	D05FQF
D05FQF	DRUGNAME	FLUNOPROST
D05FQF	INDICATI	Nasal congestion [ICD-11: MD11.9] Investigative

D0S8FT	TTDDRUID	D0S8FT
D0S8FT	DRUGNAME	Fluorescein derivative contrast agent
D0S8FT	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0OZ1M	TTDDRUID	D0OZ1M
D0OZ1M	DRUGNAME	Fluorine-18-labelled peptides
D0OZ1M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00ZMN	TTDDRUID	D00ZMN
D00ZMN	DRUGNAME	Fluorofenidone
D00ZMN	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0F2CQ	TTDDRUID	D0F2CQ
D0F2CQ	DRUGNAME	Fluoroglycoconjugates
D0F2CQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05LJK	TTDDRUID	D05LJK
D05LJK	DRUGNAME	Fluorovinyloxyacetamide anti-inflammatory drugs
D05LJK	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D02HUU	TTDDRUID	D02HUU
D02HUU	DRUGNAME	FluPro
D02HUU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D08NYJ	TTDDRUID	D08NYJ
D08NYJ	DRUGNAME	FluVac project
D08NYJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D07CIX	TTDDRUID	D07CIX
D07CIX	DRUGNAME	FM-101
D07CIX	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D03TKI	TTDDRUID	D03TKI
D03TKI	DRUGNAME	FM-201
D03TKI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0U5SU	TTDDRUID	D0U5SU
D0U5SU	DRUGNAME	FM-301
D0U5SU	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0Y0WW	TTDDRUID	D0Y0WW
D0Y0WW	DRUGNAME	FM-303
D0Y0WW	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D09HCR	TTDDRUID	D09HCR
D09HCR	DRUGNAME	FM-401
D09HCR	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0ZJ8G	TTDDRUID	D0ZJ8G
D0ZJ8G	DRUGNAME	FM-501
D0ZJ8G	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0C4NF	TTDDRUID	D0C4NF
D0C4NF	DRUGNAME	FMP-825
D0C4NF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0Y6QX	TTDDRUID	D0Y6QX
D0Y6QX	DRUGNAME	FOLIGO 002
D0Y6QX	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D05GKZ	TTDDRUID	D05GKZ
D05GKZ	DRUGNAME	Follistatin
D05GKZ	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D09SSY	TTDDRUID	D09SSY
D09SSY	DRUGNAME	FoscarnetAndOrCidofovir
D09SSY	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D00YXR	TTDDRUID	D00YXR
D00YXR	DRUGNAME	Foxy-5
D00YXR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0PV1U	TTDDRUID	D0PV1U
D0PV1U	DRUGNAME	FP-0210
D0PV1U	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0WK7B	TTDDRUID	D0WK7B
D0WK7B	DRUGNAME	FP-0220
D0WK7B	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0HM1S	TTDDRUID	D0HM1S
D0HM1S	DRUGNAME	FP-0230
D0HM1S	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D01NFK	TTDDRUID	D01NFK
D01NFK	DRUGNAME	FP-1069
D01NFK	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0I1TM	TTDDRUID	D0I1TM
D0I1TM	DRUGNAME	FP-1102
D0I1TM	INDICATI	Vascular disease [ICD-11: BE2Z] Investigative

D04SWF	TTDDRUID	D04SWF
D04SWF	DRUGNAME	FP-1302
D04SWF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0W6UV	TTDDRUID	D0W6UV
D0W6UV	DRUGNAME	FP-289
D0W6UV	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D03BCE	TTDDRUID	D03BCE
D03BCE	DRUGNAME	FPT-038
D03BCE	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0A2MA	TTDDRUID	D0A2MA
D0A2MA	DRUGNAME	FR-104
D0A2MA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0C0FA	TTDDRUID	D0C0FA
D0C0FA	DRUGNAME	FRAX-120
D0C0FA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I7NU	TTDDRUID	D0I7NU
D0I7NU	DRUGNAME	Fructose-1,6-bisphosphatase inhibitors
D0I7NU	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0W3SX	TTDDRUID	D0W3SX
D0W3SX	DRUGNAME	FSHR NAM
D0W3SX	INDICATI	Contraception [ICD-11: QA21] Investigative

D0M6ZA	TTDDRUID	D0M6ZA
D0M6ZA	DRUGNAME	Fsn-0306
D0M6ZA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G3PK	TTDDRUID	D0G3PK
D0G3PK	DRUGNAME	Fsn-0503
D0G3PK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OE2G	TTDDRUID	D0OE2G
D0OE2G	DRUGNAME	Fsn-1006
D0OE2G	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0YF9W	TTDDRUID	D0YF9W
D0YF9W	DRUGNAME	FST-200
D0YF9W	INDICATI	Otitis externa [ICD-11: AA00-AA13] Investigative

D06RUD	TTDDRUID	D06RUD
D06RUD	DRUGNAME	FT-011
D06RUD	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D06GMM	TTDDRUID	D06GMM
D06GMM	DRUGNAME	FT-026
D06GMM	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0U3XI	TTDDRUID	D0U3XI
D0U3XI	DRUGNAME	FT-061
D0U3XI	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D09FFS	TTDDRUID	D09FFS
D09FFS	DRUGNAME	FT-071
D09FFS	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0V1UQ	TTDDRUID	D0V1UQ
D0V1UQ	DRUGNAME	FT-101
D0V1UQ	INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative

D0M3YC	TTDDRUID	D0M3YC
D0M3YC	DRUGNAME	FT-201
D0M3YC	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D00RWU	TTDDRUID	D00RWU
D00RWU	DRUGNAME	FT-301
D00RWU	INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative

D09DDQ	TTDDRUID	D09DDQ
D09DDQ	DRUGNAME	FUB-130
D09DDQ	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0CU7V	TTDDRUID	D0CU7V
D0CU7V	DRUGNAME	Fullerene therapeutics
D0CU7V	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D07UHG	TTDDRUID	D07UHG
D07UHG	DRUGNAME	Fullerene-encapsulated MRI imaging agents
D07UHG	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D08VFX	TTDDRUID	D08VFX
D08VFX	DRUGNAME	Full-length Factor VIII molecule, hemophilia
D08VFX	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D0UI6L	TTDDRUID	D0UI6L
D0UI6L	DRUGNAME	Fully human mabs
D0UI6L	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0NF2P	TTDDRUID	D0NF2P
D0NF2P	DRUGNAME	Fully-deleted adenoviral vector-based immunosuppressants
D0NF2P	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative

D07XLU	TTDDRUID	D07XLU
D07XLU	DRUGNAME	Functional peptides
D07XLU	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D04PCQ	TTDDRUID	D04PCQ
D04PCQ	DRUGNAME	Fungicide
D04PCQ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0EL6Z	TTDDRUID	D0EL6Z
D0EL6Z	DRUGNAME	Fusicoccin derivatives
D0EL6Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F6XB	TTDDRUID	D0F6XB
D0F6XB	DRUGNAME	Fusion proteins
D0F6XB	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D06VCJ	TTDDRUID	D06VCJ
D06VCJ	DRUGNAME	Fusion toxin protein
D06VCJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C1GE	TTDDRUID	D0C1GE
D0C1GE	DRUGNAME	Fusolin
D0C1GE	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0Q1TX	TTDDRUID	D0Q1TX
D0Q1TX	DRUGNAME	Fusopin
D0Q1TX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0Q8TI	TTDDRUID	D0Q8TI
D0Q8TI	DRUGNAME	FX-141L
D0Q8TI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00FMQ	TTDDRUID	D00FMQ
D00FMQ	DRUGNAME	FX-300
D00FMQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0R4SE	TTDDRUID	D0R4SE
D0R4SE	DRUGNAME	FX-87L
D0R4SE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0F7ZH	TTDDRUID	D0F7ZH
D0F7ZH	DRUGNAME	FXI-AS1
D0F7ZH	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0Q5II	TTDDRUID	D0Q5II
D0Q5II	DRUGNAME	G009
D0Q5II	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D03LBD	TTDDRUID	D03LBD
D03LBD	DRUGNAME	G-115
D03LBD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0YL0L	TTDDRUID	D0YL0L
D0YL0L	DRUGNAME	G-256
D0YL0L	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Investigative

D04VCW	TTDDRUID	D04VCW
D04VCW	DRUGNAME	G-301
D04VCW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0XU9F	TTDDRUID	D0XU9F
D0XU9F	DRUGNAME	G3139 + cytarabine (ARA-C)
D0XU9F	INDICATI	Acute leukaemia [ICD-11: 2A60] Investigative

D0XU1I	TTDDRUID	D0XU1I
D0XU1I	DRUGNAME	G3139 + Dacarbazine
D0XU1I	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0W8ZE	TTDDRUID	D0W8ZE
D0W8ZE	DRUGNAME	G3139 + Dexamethasone
D0W8ZE	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0LM3T	TTDDRUID	D0LM3T
D0LM3T	DRUGNAME	G3139 + Fludarabine
D0LM3T	INDICATI	Acute leukaemia [ICD-11: 2A60] Investigative

D0B0HK	TTDDRUID	D0B0HK
D0B0HK	DRUGNAME	G3139 + G-CSF
D0B0HK	INDICATI	Acute leukaemia [ICD-11: 2A60] Investigative

D05IAN	TTDDRUID	D05IAN
D05IAN	DRUGNAME	G3139 + Irinotecan
D05IAN	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Investigative

D0S1FM	TTDDRUID	D0S1FM
D0S1FM	DRUGNAME	G3139 + Paclitaxel
D0S1FM	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D00DDR	TTDDRUID	D00DDR
D00DDR	DRUGNAME	G3139 + Thalidomide
D00DDR	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0TY0P	TTDDRUID	D0TY0P
D0TY0P	DRUGNAME	G-573
D0TY0P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08JPU	TTDDRUID	D08JPU
D08JPU	DRUGNAME	G6976
D08JPU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01BJO	TTDDRUID	D01BJO
D01BJO	DRUGNAME	GABA mimetics
D01BJO	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D07KYZ	TTDDRUID	D07KYZ
D07KYZ	DRUGNAME	GABA-B receptor PAM
D07KYZ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0RL4T	TTDDRUID	D0RL4T
D0RL4T	DRUGNAME	Gadolinium based C60 fullerene-paclitaxel-ZME-018 conjugates
D0RL4T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01VCE	TTDDRUID	D01VCE
D01VCE	DRUGNAME	Gadomelitol
D01VCE	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D03LXH	TTDDRUID	D03LXH
D03LXH	DRUGNAME	GAI-122
D03LXH	INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative

D05WRB	TTDDRUID	D05WRB
D05WRB	DRUGNAME	Galactofucan sulphate fraction
D05WRB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0L0SI	TTDDRUID	D0L0SI
D0L0SI	DRUGNAME	Galectin 2
D0L0SI	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0Y1IO	TTDDRUID	D0Y1IO
D0Y1IO	DRUGNAME	Galectin-3C
D0Y1IO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QC6Z	TTDDRUID	D0QC6Z
D0QC6Z	DRUGNAME	GALL-200
D0QC6Z	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Investigative

D0T1RT	TTDDRUID	D0T1RT
D0T1RT	DRUGNAME	Gamma secretase inhibitors
D0T1RT	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0J5SD	TTDDRUID	D0J5SD
D0J5SD	DRUGNAME	Gamma-secretase modulators
D0J5SD	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09YBF	TTDDRUID	D09YBF
D09YBF	DRUGNAME	Gamma-tocotrienol
D09YBF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D01PNR	TTDDRUID	D01PNR
D01PNR	DRUGNAME	Gastrin 17C diphtheria toxoid conjugate
D01PNR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D0R3NR	TTDDRUID	D0R3NR
D0R3NR	DRUGNAME	GATA-3-specific DNAzyme
D0R3NR	INDICATI	Asthma [ICD-11: CA23] Investigative

D0B2ZM	TTDDRUID	D0B2ZM
D0B2ZM	DRUGNAME	GB-2542
D0B2ZM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D5NI	TTDDRUID	D0D5NI
D0D5NI	DRUGNAME	GBP-1a
D0D5NI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D03HSQ	TTDDRUID	D03HSQ
D03HSQ	DRUGNAME	GBR-401
D03HSQ	INDICATI	B-cell lymphoma [ICD-11: 2A86] Investigative

D00LYE	TTDDRUID	D00LYE
D00LYE	DRUGNAME	GC-003
D00LYE	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D0QR3J	TTDDRUID	D0QR3J
D0QR3J	DRUGNAME	GC-2107
D0QR3J	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D06WJC	TTDDRUID	D06WJC
D06WJC	DRUGNAME	GC-24
D06WJC	INDICATI	Hyperthyroidism [ICD-11: 5A02] Investigative

D09UTQ	TTDDRUID	D09UTQ
D09UTQ	DRUGNAME	GC-7101
D09UTQ	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative

D08KMU	TTDDRUID	D08KMU
D08KMU	DRUGNAME	Gca-186
D08KMU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Clinical trial

D06LHI	TTDDRUID	D06LHI
D06LHI	DRUGNAME	GCH-01
D06LHI	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D07CNF	TTDDRUID	D07CNF
D07CNF	DRUGNAME	G-CSF
D07CNF	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D0T4EA	TTDDRUID	D0T4EA
D0T4EA	DRUGNAME	GD2 ganglioside peptide mimics
D0T4EA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q8CA	TTDDRUID	D0Q8CA
D0Q8CA	DRUGNAME	GD2-lm
D0Q8CA	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D09GBM	TTDDRUID	D09GBM
D09GBM	DRUGNAME	GD-AAV8
D09GBM	INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative

D08XUP	TTDDRUID	D08XUP
D08XUP	DRUGNAME	GE-37468A
D08XUP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0PS2X	TTDDRUID	D0PS2X
D0PS2X	DRUGNAME	GEM-ALS
D0PS2X	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0H2LE	TTDDRUID	D0H2LE
D0H2LE	DRUGNAME	Gene therapy, Huntington's disease, Medtronic
D0H2LE	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D07TEE	TTDDRUID	D07TEE
D07TEE	DRUGNAME	Gene therapy, mucopolysaccharidosis type I
D07TEE	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative

D0XO3E	TTDDRUID	D0XO3E
D0XO3E	DRUGNAME	Gene therapy, neurodegenerative diseases
D0XO3E	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D04ENF	TTDDRUID	D04ENF
D04ENF	DRUGNAME	Gene therapy, retinopathy, Copernicus
D04ENF	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D06BEX	TTDDRUID	D06BEX
D06BEX	DRUGNAME	Gene therapy, TheraPlas, congestive heart failure
D06BEX	INDICATI	Congestive heart failure [ICD-11: BD10] Investigative

D09YPM	TTDDRUID	D09YPM
D09YPM	DRUGNAME	Gene vectors
D09YPM	INDICATI	Genetic disease [ICD-11: 8E02] Investigative

D02RHJ	TTDDRUID	D02RHJ
D02RHJ	DRUGNAME	Gene-based dengue fever therapeutics
D02RHJ	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D0ZP7D	TTDDRUID	D0ZP7D
D0ZP7D	DRUGNAME	GenePro
D0ZP7D	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D05TNY	TTDDRUID	D05TNY
D05TNY	DRUGNAME	Generalized glucocorticoid
D05TNY	INDICATI	Adrenal adenoma [ICD-11: 2F37.Y] Investigative

D05DCX	TTDDRUID	D05DCX
D05DCX	DRUGNAME	Genetically modified allogeneic sertoli cells
D05DCX	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D05FOB	TTDDRUID	D05FOB
D05FOB	DRUGNAME	GenFusAb
D05FOB	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D0W8CA	TTDDRUID	D0W8CA
D0W8CA	DRUGNAME	Genz-667348
D0W8CA	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0S8MG	TTDDRUID	D0S8MG
D0S8MG	DRUGNAME	Genz-668764
D0S8MG	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D02QND	TTDDRUID	D02QND
D02QND	DRUGNAME	GF-011802-00
D02QND	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D02SOL	TTDDRUID	D02SOL
D02SOL	DRUGNAME	GF-15
D02SOL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03BND	TTDDRUID	D03BND
D03BND	DRUGNAME	GFC-001
D03BND	INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative

D0X8JN	TTDDRUID	D0X8JN
D0X8JN	DRUGNAME	GFC-003
D0X8JN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E7GN	TTDDRUID	D0E7GN
D0E7GN	DRUGNAME	GFC-012
D0E7GN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03QHR	TTDDRUID	D03QHR
D03QHR	DRUGNAME	GFC-036
D03QHR	INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative

D0K5NN	TTDDRUID	D0K5NN
D0K5NN	DRUGNAME	GFP-bacterial methioninase/selenomethionine GDEPT
D0K5NN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V0BD	TTDDRUID	D0V0BD
D0V0BD	DRUGNAME	GFT-1229
D0V0BD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0Z1PA	TTDDRUID	D0Z1PA
D0Z1PA	DRUGNAME	GG-818
D0Z1PA	INDICATI	Prostate disease [ICD-11: GA91] Investigative

D0Y8ZZ	TTDDRUID	D0Y8ZZ
D0Y8ZZ	DRUGNAME	GI-10001
D0Y8ZZ	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Investigative

D04RSZ	TTDDRUID	D04RSZ
D04RSZ	DRUGNAME	GI-13000
D04RSZ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0D0YK	TTDDRUID	D0D0YK
D0D0YK	DRUGNAME	GI-3000
D0D0YK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D0SD3Q	TTDDRUID	D0SD3Q
D0SD3Q	DRUGNAME	GIDAZEPAM
D0SD3Q	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0OB9V	TTDDRUID	D0OB9V
D0OB9V	DRUGNAME	Ginkgo biloba extract
D0OB9V	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0C0AC	TTDDRUID	D0C0AC
D0C0AC	DRUGNAME	GIT27-NO
D0C0AC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09XPD	TTDDRUID	D09XPD
D09XPD	DRUGNAME	GivaRex
D09XPD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04MLE	TTDDRUID	D04MLE
D04MLE	DRUGNAME	GKA-23
D04MLE	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D08RIL	TTDDRUID	D08RIL
D08RIL	DRUGNAME	GKT-03
D08RIL	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D03NXS	TTDDRUID	D03NXS
D03NXS	DRUGNAME	GKT-04
D03NXS	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D06UEP	TTDDRUID	D06UEP
D06UEP	DRUGNAME	GKT-136901
D06UEP	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0H7JC	TTDDRUID	D0H7JC
D0H7JC	DRUGNAME	GL-2045
D0H7JC	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0J5QD	TTDDRUID	D0J5QD
D0J5QD	DRUGNAME	GL-4001
D0J5QD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09AFV	TTDDRUID	D09AFV
D09AFV	DRUGNAME	GLG-101
D09AFV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y2TI	TTDDRUID	D0Y2TI
D0Y2TI	DRUGNAME	Glionitrin A
D0Y2TI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01MXG	TTDDRUID	D01MXG
D01MXG	DRUGNAME	GLP-1 receptor PAM
D01MXG	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0Q4AR	TTDDRUID	D0Q4AR
D0Q4AR	DRUGNAME	Glucagon-like peptide-1 analog
D0Q4AR	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D05XTY	TTDDRUID	D05XTY
D05XTY	DRUGNAME	Glucan synthase inhibitors
D05XTY	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0A3VX	TTDDRUID	D0A3VX
D0A3VX	DRUGNAME	Glucocorticoid mimetics
D0A3VX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D07LMD	TTDDRUID	D07LMD
D07LMD	DRUGNAME	Glucocorticoid receptor ligands
D07LMD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09UZB	TTDDRUID	D09UZB
D09UZB	DRUGNAME	Glucopyranoside derivatives
D09UZB	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D08MTN	TTDDRUID	D08MTN
D08MTN	DRUGNAME	Glucose analogue
D08MTN	INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative

D0H5GU	TTDDRUID	D0H5GU
D0H5GU	DRUGNAME	GlucoStem
D0H5GU	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D03QMG	TTDDRUID	D03QMG
D03QMG	DRUGNAME	Glutamate racemase inhibitors
D03QMG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
D03QMG	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative

D0Z7RA	TTDDRUID	D0Z7RA
D0Z7RA	DRUGNAME	GLY-220
D0Z7RA	INDICATI	Diabetic angiopathy [ICD-11: BD53.Y] Investigative

D0F4AP	TTDDRUID	D0F4AP
D0F4AP	DRUGNAME	Glycanics
D0F4AP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0TZ5E	TTDDRUID	D0TZ5E
D0TZ5E	DRUGNAME	Glycine type-1 transporter inhibitors
D0TZ5E	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative

D08ADK	TTDDRUID	D08ADK
D08ADK	DRUGNAME	Glycoferon
D08ADK	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0R8CN	TTDDRUID	D0R8CN
D0R8CN	DRUGNAME	Glycolipids
D0R8CN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0V1OG	TTDDRUID	D0V1OG
D0V1OG	DRUGNAME	Glycosaminoglycans
D0V1OG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D04HMD	TTDDRUID	D04HMD
D04HMD	DRUGNAME	Glyphosate
D04HMD	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0FZ8U	TTDDRUID	D0FZ8U
D0FZ8U	DRUGNAME	Glysopep
D0FZ8U	INDICATI	Deep vein thrombosis [ICD-11: BD71] Investigative

D07XLA	TTDDRUID	D07XLA
D07XLA	DRUGNAME	GM04-001
D07XLA	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D07OQJ	TTDDRUID	D07OQJ
D07OQJ	DRUGNAME	GM-CAIX
D07OQJ	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative

D02QUB	TTDDRUID	D02QUB
D02QUB	DRUGNAME	GM-CT-02
D02QUB	INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Investigative

D0NC8H	TTDDRUID	D0NC8H
D0NC8H	DRUGNAME	GMI-1051
D0NC8H	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D0C0HF	TTDDRUID	D0C0HF
D0C0HF	DRUGNAME	GM-MD-01
D0C0HF	INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Investigative

D0U2OS	TTDDRUID	D0U2OS
D0U2OS	DRUGNAME	GNE-652
D0U2OS	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D06QCS	TTDDRUID	D06QCS
D06QCS	DRUGNAME	GNF-156
D06QCS	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D04XJX	TTDDRUID	D04XJX
D04XJX	DRUGNAME	GP-1001
D04XJX	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D06MQW	TTDDRUID	D06MQW
D06MQW	DRUGNAME	GP-1002
D06MQW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0P5ZJ	TTDDRUID	D0P5ZJ
D0P5ZJ	DRUGNAME	GP-1100
D0P5ZJ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D01SUF	TTDDRUID	D01SUF
D01SUF	DRUGNAME	GP-1200
D01SUF	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D0E1HY	TTDDRUID	D0E1HY
D0E1HY	DRUGNAME	GPCR39 pepducins
D0E1HY	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0D7XS	TTDDRUID	D0D7XS
D0D7XS	DRUGNAME	GPG-290
D0D7XS	INDICATI	Angina pectoris [ICD-11: BA40] Investigative

D0N5RF	TTDDRUID	D0N5RF
D0N5RF	DRUGNAME	GPIba targeting mabs
D0N5RF	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D06KHX	TTDDRUID	D06KHX
D06KHX	DRUGNAME	GPR109A agonists, Merck
D06KHX	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0HS2Z	TTDDRUID	D0HS2Z
D0HS2Z	DRUGNAME	GPR119 agonists
D0HS2Z	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0M4EH	TTDDRUID	D0M4EH
D0M4EH	DRUGNAME	Gram positive antibacterials
D0M4EH	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative

D09XDR	TTDDRUID	D09XDR
D09XDR	DRUGNAME	Granulosin
D09XDR	INDICATI	Chronic granulomatous disease [ICD-11: 4A00.0Y] Investigative

D04IFD	TTDDRUID	D04IFD
D04IFD	DRUGNAME	GR-ARA1
D04IFD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04XJV	TTDDRUID	D04XJV
D04XJV	DRUGNAME	GRC-9332
D04XJV	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D00QFV	TTDDRUID	D00QFV
D00QFV	DRUGNAME	GR-DD1
D00QFV	INDICATI	Liver cancer [ICD-11: 2C12] Investigative

D0O2UF	TTDDRUID	D0O2UF
D0O2UF	DRUGNAME	Griffithsin vaginal gel
D0O2UF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D00FEA	TTDDRUID	D00FEA
D00FEA	DRUGNAME	GRL-0036A
D00FEA	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0H2VN	TTDDRUID	D0H2VN
D0H2VN	DRUGNAME	GRL-11097
D0H2VN	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0PU1O	TTDDRUID	D0PU1O
D0PU1O	DRUGNAME	GRN-510
D0PU1O	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative

D03TRO	TTDDRUID	D03TRO
D03TRO	DRUGNAME	GRN-529
D03TRO	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0V2MB	TTDDRUID	D0V2MB
D0V2MB	DRUGNAME	GRNCHND-1
D0V2MB	INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative

D0J5QA	TTDDRUID	D0J5QA
D0J5QA	DRUGNAME	GRNCM-1
D0J5QA	INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative

D0QZ9D	TTDDRUID	D0QZ9D
D0QZ9D	DRUGNAME	GRNIC-1
D0QZ9D	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D00QZJ	TTDDRUID	D00QZJ
D00QZJ	DRUGNAME	Growth hormone
D00QZJ	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Investigative

D0L4CW	TTDDRUID	D0L4CW
D0L4CW	DRUGNAME	Growth hormone releasing factor peptides
D0L4CW	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Investigative

D0QN9U	TTDDRUID	D0QN9U
D0QN9U	DRUGNAME	GS-156 mab
D0QN9U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05YWN	TTDDRUID	D05YWN
D05YWN	DRUGNAME	GS-168
D05YWN	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative

D0LI3A	TTDDRUID	D0LI3A
D0LI3A	DRUGNAME	GS-326
D0LI3A	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D00HZO	TTDDRUID	D00HZO
D00HZO	DRUGNAME	GS-497C
D00HZO	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D00SKS	TTDDRUID	D00SKS
D00SKS	DRUGNAME	GS-8374
D00SKS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0Z7LK	TTDDRUID	D0Z7LK
D0Z7LK	DRUGNAME	GSC-1
D0Z7LK	INDICATI	Hyperglycemia [ICD-11: MA18.0] Investigative

D02WQR	TTDDRUID	D02WQR
D02WQR	DRUGNAME	GSK-008A
D02WQR	INDICATI	Gynecological disease [ICD-11: GA6Z] Investigative

D08XIF	TTDDRUID	D08XIF
D08XIF	DRUGNAME	GSK-0862
D08XIF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0I4UY	TTDDRUID	D0I4UY
D0I4UY	DRUGNAME	GSK-1108167A
D0I4UY	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0N1WG	TTDDRUID	D0N1WG
D0N1WG	DRUGNAME	GSK-1137585
D0N1WG	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0C5XF	TTDDRUID	D0C5XF
D0C5XF	DRUGNAME	GSK-1344386B
D0C5XF	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D02CCA	TTDDRUID	D02CCA
D02CCA	DRUGNAME	GSK-172981
D02CCA	INDICATI	Asthma [ICD-11: CA23] Investigative

D0T4LT	TTDDRUID	D0T4LT
D0T4LT	DRUGNAME	GSK-1842799C
D0T4LT	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0H4TP	TTDDRUID	D0H4TP
D0H4TP	DRUGNAME	GSK189254A
D0H4TP	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D04VAR	TTDDRUID	D04VAR
D04VAR	DRUGNAME	GSK-2136773
D04VAR	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D0LP7W	TTDDRUID	D0LP7W
D0LP7W	DRUGNAME	GSK-2210875
D0LP7W	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0H6PH	TTDDRUID	D0H6PH
D0H6PH	DRUGNAME	GSK-2231260A
D0H6PH	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D08UDB	TTDDRUID	D08UDB
D08UDB	DRUGNAME	GSK-2263167
D08UDB	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0Y3KR	TTDDRUID	D0Y3KR
D0Y3KR	DRUGNAME	GSK-2302024A
D0Y3KR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0EU1R	TTDDRUID	D0EU1R
D0EU1R	DRUGNAME	GSK-2334470
D0EU1R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0DK2X	TTDDRUID	D0DK2X
D0DK2X	DRUGNAME	GSK-280
D0DK2X	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0CI9W	TTDDRUID	D0CI9W
D0CI9W	DRUGNAME	GSK-334429
D0CI9W	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0F3FC	TTDDRUID	D0F3FC
D0F3FC	DRUGNAME	GSK-650394
D0F3FC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D03QJA	TTDDRUID	D03QJA
D03QJA	DRUGNAME	GSK-812397
D03QJA	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0UV9F	TTDDRUID	D0UV9F
D0UV9F	DRUGNAME	GSK-894281
D0UV9F	INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative

D0R9DX	TTDDRUID	D0R9DX
D0R9DX	DRUGNAME	GsMTx4
D0R9DX	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D03IHA	TTDDRUID	D03IHA
D03IHA	DRUGNAME	GT 1061
D03IHA	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D01QTD	TTDDRUID	D01QTD
D01QTD	DRUGNAME	GT-038
D01QTD	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative

D0BD6A	TTDDRUID	D0BD6A
D0BD6A	DRUGNAME	GT-1282
D0BD6A	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0M4PY	TTDDRUID	D0M4PY
D0M4PY	DRUGNAME	GTP-0125
D0M4PY	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D04QFY	TTDDRUID	D04QFY
D04QFY	DRUGNAME	GTx-027
D04QFY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QX0H	TTDDRUID	D0QX0H
D0QX0H	DRUGNAME	GTx-134
D0QX0H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07YDO	TTDDRUID	D07YDO
D07YDO	DRUGNAME	GTx-186
D07YDO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FB1S	TTDDRUID	D0FB1S
D0FB1S	DRUGNAME	GTx-230
D0FB1S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05QIZ	TTDDRUID	D05QIZ
D05QIZ	DRUGNAME	GTx-822
D05QIZ	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D01MWF	TTDDRUID	D01MWF
D01MWF	DRUGNAME	GTx-878
D01MWF	INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative

D08ELN	TTDDRUID	D08ELN
D08ELN	DRUGNAME	Guanidine oseltamivir prodrug
D08ELN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0L0VV	TTDDRUID	D0L0VV
D0L0VV	DRUGNAME	GUT-70
D0L0VV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FJ3P	TTDDRUID	D0FJ3P
D0FJ3P	DRUGNAME	GW-2592X
D0FJ3P	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0PL4F	TTDDRUID	D0PL4F
D0PL4F	DRUGNAME	GW-3965
D0PL4F	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D02CFR	TTDDRUID	D02CFR
D02CFR	DRUGNAME	GW-559768X
D02CFR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C3AD	TTDDRUID	D0C3AD
D0C3AD	DRUGNAME	GW-788388
D0C3AD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09GMC	TTDDRUID	D09GMC
D09GMC	DRUGNAME	GX-101
D09GMC	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative

D00AVG	TTDDRUID	D00AVG
D00AVG	DRUGNAME	GX-110E
D00AVG	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0K8SH	TTDDRUID	D0K8SH
D0K8SH	DRUGNAME	GX-137
D0K8SH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D07RME	TTDDRUID	D07RME
D07RME	DRUGNAME	GX-401
D07RME	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0K2XB	TTDDRUID	D0K2XB
D0K2XB	DRUGNAME	GX-51
D0K2XB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02YSO	TTDDRUID	D02YSO
D02YSO	DRUGNAME	GX-C4
D02YSO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D09YXS	TTDDRUID	D09YXS
D09YXS	DRUGNAME	GX-E2
D09YXS	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D01TMK	TTDDRUID	D01TMK
D01TMK	DRUGNAME	GX-G6
D01TMK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0V3ZK	TTDDRUID	D0V3ZK
D0V3ZK	DRUGNAME	GX-H9
D0V3ZK	INDICATI	Dwarfism [ICD-11: 5B11] Investigative

D06UJD	TTDDRUID	D06UJD
D06UJD	DRUGNAME	H-102
D06UJD	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D08QIR	TTDDRUID	D08QIR
D08QIR	DRUGNAME	H2S-releasing latanoprost
D08QIR	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0VN3C	TTDDRUID	D0VN3C
D0VN3C	DRUGNAME	H2S-releasing L-dopa
D0VN3C	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D07DZT	TTDDRUID	D07DZT
D07DZT	DRUGNAME	H2TFPC-SGlc
D07DZT	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D0N6IG	TTDDRUID	D0N6IG
D0N6IG	DRUGNAME	H3 receptor inverse agonists
D0N6IG	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0R9JC	TTDDRUID	D0R9JC
D0R9JC	DRUGNAME	H5N1 influenza mab therapy
D0R9JC	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0J1RS	TTDDRUID	D0J1RS
D0J1RS	DRUGNAME	H5N1 pandemic influenza mab
D0J1RS	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D08YGD	TTDDRUID	D08YGD
D08YGD	DRUGNAME	Haempatch
D08YGD	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0IY2B	TTDDRUID	D0IY2B
D0IY2B	DRUGNAME	Hairpin RNA
D0IY2B	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D02DXV	TTDDRUID	D02DXV
D02DXV	DRUGNAME	HAP aniline mustard
D02DXV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04DVA	TTDDRUID	D04DVA
D04DVA	DRUGNAME	HAp-IFN
D04DVA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D01LBD	TTDDRUID	D01LBD
D01LBD	DRUGNAME	Haw-AD-14
D01LBD	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0R2MG	TTDDRUID	D0R2MG
D0R2MG	DRUGNAME	HB-1275
D0R2MG	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Investigative

D07RUR	TTDDRUID	D07RUR
D07RUR	DRUGNAME	HB-1345
D07RUR	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D01HEN	TTDDRUID	D01HEN
D01HEN	DRUGNAME	HBDt.Fc
D01HEN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G2UY	TTDDRUID	D0G2UY
D0G2UY	DRUGNAME	HBF-0259
D0G2UY	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0U5VM	TTDDRUID	D0U5VM
D0U5VM	DRUGNAME	HBN-1
D0U5VM	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D06ECM	TTDDRUID	D06ECM
D06ECM	DRUGNAME	HBN-2
D06ECM	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0L4GH	TTDDRUID	D0L4GH
D0L4GH	DRUGNAME	HBN-3
D0L4GH	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0I9UP	TTDDRUID	D0I9UP
D0I9UP	DRUGNAME	HBX-41108
D0I9UP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D6MC	TTDDRUID	D0D6MC
D0D6MC	DRUGNAME	HC-030031
D0D6MC	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D05PFE	TTDDRUID	D05PFE
D05PFE	DRUGNAME	HC-15
D05PFE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P8LR	TTDDRUID	D0P8LR
D0P8LR	DRUGNAME	HC3-1496
D0P8LR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0R1YJ	TTDDRUID	D0R1YJ
D0R1YJ	DRUGNAME	HCGRP8-37
D0R1YJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D01ZDC	TTDDRUID	D01ZDC
D01ZDC	DRUGNAME	HCV NS3 protease inhibitors
D01ZDC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D07LUH	TTDDRUID	D07LUH
D07LUH	DRUGNAME	HCV NS3/4A protease inhibitors
D07LUH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0Y0HJ	TTDDRUID	D0Y0HJ
D0Y0HJ	DRUGNAME	HCV NS5B polymerase inhibitors [PMCID:PMC2928549]
D0Y0HJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D05KSO	TTDDRUID	D05KSO
D05KSO	DRUGNAME	HCV therapeutics
D05KSO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0M0YE	TTDDRUID	D0M0YE
D0M0YE	DRUGNAME	HCV-specific STAR fusions
D0M0YE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0K5JE	TTDDRUID	D0K5JE
D0K5JE	DRUGNAME	HD-0701
D0K5JE	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D03MSN	TTDDRUID	D03MSN
D03MSN	DRUGNAME	HD-101
D03MSN	INDICATI	Asthma [ICD-11: CA23] Investigative

D09INA	TTDDRUID	D09INA
D09INA	DRUGNAME	HD-148
D09INA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0RC9X	TTDDRUID	D0RC9X
D0RC9X	DRUGNAME	HDAC inhibitors
D0RC9X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A8QZ	TTDDRUID	D0A8QZ
D0A8QZ	DRUGNAME	HDAC4 inhibtors
D0A8QZ	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D0S5MJ	TTDDRUID	D0S5MJ
D0S5MJ	DRUGNAME	HDL-based therapeutics
D0S5MJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D08EAR	TTDDRUID	D08EAR
D08EAR	DRUGNAME	HE2200
D08EAR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D0FA2N	TTDDRUID	D0FA2N
D0FA2N	DRUGNAME	HE-3177
D0FA2N	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0L1OF	TTDDRUID	D0L1OF
D0L1OF	DRUGNAME	HE-33
D0L1OF	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative

D0DM4K	TTDDRUID	D0DM4K
D0DM4K	DRUGNAME	Heat-killed Mycobacterium vaccae
D0DM4K	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D09SBY	TTDDRUID	D09SBY
D09SBY	DRUGNAME	Hebervis
D09SBY	INDICATI	Oral mucositis [ICD-11: DA01.11] Investigative

D03PEF	TTDDRUID	D03PEF
D03PEF	DRUGNAME	Hedgehog labelled stem cells
D03PEF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D04CXY	TTDDRUID	D04CXY
D04CXY	DRUGNAME	Hedgehog pathway antagonists
D04CXY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BX8E	TTDDRUID	D0BX8E
D0BX8E	DRUGNAME	Helicase inhibitors
D0BX8E	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D09TXA	TTDDRUID	D09TXA
D09TXA	DRUGNAME	HelicoVax
D09TXA	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative

D09SCO	TTDDRUID	D09SCO
D09SCO	DRUGNAME	Hemagglutinin inhibitors
D09SCO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D03BPU	TTDDRUID	D03BPU
D03BPU	DRUGNAME	Hematological disease agents
D03BPU	INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative

D0BA8H	TTDDRUID	D0BA8H
D0BA8H	DRUGNAME	HemoTech
D0BA8H	INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative

D0A5KS	TTDDRUID	D0A5KS
D0A5KS	DRUGNAME	Hemoxin (Niprisan)
D0A5KS	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0A1QC	TTDDRUID	D0A1QC
D0A1QC	DRUGNAME	Heparan sulfate
D0A1QC	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D0CB7L	TTDDRUID	D0CB7L
D0CB7L	DRUGNAME	Hepatitis B Hyperimmune
D0CB7L	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0YF2T	TTDDRUID	D0YF2T
D0YF2T	DRUGNAME	HepaVaxx C
D0YF2T	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D04YSQ	TTDDRUID	D04YSQ
D04YSQ	DRUGNAME	HepaXen
D04YSQ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0J1CF	TTDDRUID	D0J1CF
D0J1CF	DRUGNAME	Her2- and PSA-targeted TGX-D1
D0J1CF	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0S5VU	TTDDRUID	D0S5VU
D0S5VU	DRUGNAME	Herbicide amitrole
D0S5VU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0J1DE	TTDDRUID	D0J1DE
D0J1DE	DRUGNAME	Heterologous liver-derived stem cells
D0J1DE	INDICATI	Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Investigative

D0W6ZV	TTDDRUID	D0W6ZV
D0W6ZV	DRUGNAME	HF-0420
D0W6ZV	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D07RXX	TTDDRUID	D07RXX
D07RXX	DRUGNAME	HG-1051
D07RXX	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D07ZTB	TTDDRUID	D07ZTB
D07ZTB	DRUGNAME	HG-1068
D07ZTB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0CF3H	TTDDRUID	D0CF3H
D0CF3H	DRUGNAME	HG-1070
D0CF3H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0KE4C	TTDDRUID	D0KE4C
D0KE4C	DRUGNAME	HG-1071
D0KE4C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07SEZ	TTDDRUID	D07SEZ
D07SEZ	DRUGNAME	HG-1072
D07SEZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J9TO	TTDDRUID	D0J9TO
D0J9TO	DRUGNAME	HG-1076
D0J9TO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z8XI	TTDDRUID	D0Z8XI
D0Z8XI	DRUGNAME	HG-1077
D0Z8XI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q7TI	TTDDRUID	D0Q7TI
D0Q7TI	DRUGNAME	HG-1078
D0Q7TI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06RZQ	TTDDRUID	D06RZQ
D06RZQ	DRUGNAME	HG-1091
D06RZQ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0Z4VG	TTDDRUID	D0Z4VG
D0Z4VG	DRUGNAME	HG-1092
D0Z4VG	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D06ENR	TTDDRUID	D06ENR
D06ENR	DRUGNAME	HG-1096
D06ENR	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D00CED	TTDDRUID	D00CED
D00CED	DRUGNAME	HG-1097
D00CED	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0UX2H	TTDDRUID	D0UX2H
D0UX2H	DRUGNAME	HG-1109
D0UX2H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OA7W	TTDDRUID	D0OA7W
D0OA7W	DRUGNAME	HG-1141
D0OA7W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L6IJ	TTDDRUID	D0L6IJ
D0L6IJ	DRUGNAME	HG-1143
D0L6IJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F0LO	TTDDRUID	D0F0LO
D0F0LO	DRUGNAME	HG-1144
D0F0LO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01HSA	TTDDRUID	D01HSA
D01HSA	DRUGNAME	HG-1154
D01HSA	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D06TMH	TTDDRUID	D06TMH
D06TMH	DRUGNAME	HG-1164
D06TMH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07DDK	TTDDRUID	D07DDK
D07DDK	DRUGNAME	HG-1177
D07DDK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00GKH	TTDDRUID	D00GKH
D00GKH	DRUGNAME	HG-1179
D00GKH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N7CU	TTDDRUID	D0N7CU
D0N7CU	DRUGNAME	HG-1182
D0N7CU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08JXR	TTDDRUID	D08JXR
D08JXR	DRUGNAME	HG-1202
D08JXR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YN2F	TTDDRUID	D0YN2F
D0YN2F	DRUGNAME	HG-1209
D0YN2F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03HOP	TTDDRUID	D03HOP
D03HOP	DRUGNAME	HG-1220
D03HOP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AI3G	TTDDRUID	D0AI3G
D0AI3G	DRUGNAME	HG-1224
D0AI3G	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0VC4F	TTDDRUID	D0VC4F
D0VC4F	DRUGNAME	HG-1226
D0VC4F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02IKD	TTDDRUID	D02IKD
D02IKD	DRUGNAME	HG-1245
D02IKD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N1IL	TTDDRUID	D0N1IL
D0N1IL	DRUGNAME	HG-1246
D0N1IL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F4DW	TTDDRUID	D0F4DW
D0F4DW	DRUGNAME	HG-1300
D0F4DW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05CJN	TTDDRUID	D05CJN
D05CJN	DRUGNAME	HG-1336
D05CJN	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0J1HG	TTDDRUID	D0J1HG
D0J1HG	DRUGNAME	HG-1338
D0J1HG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X0ZK	TTDDRUID	D0X0ZK
D0X0ZK	DRUGNAME	HG-1343
D0X0ZK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G3UG	TTDDRUID	D0G3UG
D0G3UG	DRUGNAME	HG-1429
D0G3UG	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0D1IR	TTDDRUID	D0D1IR
D0D1IR	DRUGNAME	HG-1438
D0D1IR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00VCZ	TTDDRUID	D00VCZ
D00VCZ	DRUGNAME	HGT-2610
D00VCZ	INDICATI	Leukodystrophy [ICD-11: 8A44] Investigative

D05XRZ	TTDDRUID	D05XRZ
D05XRZ	DRUGNAME	HI-6
D05XRZ	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D0EU0L	TTDDRUID	D0EU0L
D0EU0L	DRUGNAME	HIE-124
D0EU0L	INDICATI	Anaesthesia [ICD-11: 9A78.6] Investigative

D00WUC	TTDDRUID	D00WUC
D00WUC	DRUGNAME	Histidase-PEG-20
D00WUC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08QUJ	TTDDRUID	D08QUJ
D08QUJ	DRUGNAME	Histone deacetylase inhibitors
D08QUJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06DPJ	TTDDRUID	D06DPJ
D06DPJ	DRUGNAME	HITOPK-032
D06DPJ	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D01NFW	TTDDRUID	D01NFW
D01NFW	DRUGNAME	HIV integrase inhibitors
D01NFW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0A6XW	TTDDRUID	D0A6XW
D0A6XW	DRUGNAME	HIV integrase inhibitors
D0A6XW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D03IRC	TTDDRUID	D03IRC
D03IRC	DRUGNAME	HIV-1 RNase H inhibitors
D03IRC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D08WNR	TTDDRUID	D08WNR
D08WNR	DRUGNAME	HIV-1 RNase H/HIV-1 integrase inhibitors
D08WNR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0M8YQ	TTDDRUID	D0M8YQ
D0M8YQ	DRUGNAME	HIVAX-2
D0M8YQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0RW9P	TTDDRUID	D0RW9P
D0RW9P	DRUGNAME	HiviCides I and II
D0RW9P	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D07MQY	TTDDRUID	D07MQY
D07MQY	DRUGNAME	HIV-LAMP-vax
D07MQY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0U2FD	TTDDRUID	D0U2FD
D0U2FD	DRUGNAME	HIV-PV
D0U2FD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D03EBK	TTDDRUID	D03EBK
D03EBK	DRUGNAME	HIV-specific STAR fusions
D03EBK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D07QBJ	TTDDRUID	D07QBJ
D07QBJ	DRUGNAME	HJP-272
D07QBJ	INDICATI	Premature labour [ICD-11: JB00] Investigative

D0UA0Y	TTDDRUID	D0UA0Y
D0UA0Y	DRUGNAME	HKI-46F08
D0UA0Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D5EW	TTDDRUID	D0D5EW
D0D5EW	DRUGNAME	HKI-9924129
D0D5EW	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0ZV4I	TTDDRUID	D0ZV4I
D0ZV4I	DRUGNAME	HL-020
D0ZV4I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FO1P	TTDDRUID	D0FO1P
D0FO1P	DRUGNAME	HL-021
D0FO1P	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AB2G	TTDDRUID	D0AB2G
D0AB2G	DRUGNAME	HL-022
D0AB2G	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F3JA	TTDDRUID	D0F3JA
D0F3JA	DRUGNAME	HL-023
D0F3JA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07YXD	TTDDRUID	D07YXD
D07YXD	DRUGNAME	HL-024
D07YXD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XU5Y	TTDDRUID	D0XU5Y
D0XU5Y	DRUGNAME	HL-025
D0XU5Y	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0IC8P	TTDDRUID	D0IC8P
D0IC8P	DRUGNAME	HL-026
D0IC8P	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0A1MK	TTDDRUID	D0A1MK
D0A1MK	DRUGNAME	HL-027
D0A1MK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D01BJS	TTDDRUID	D01BJS
D01BJS	DRUGNAME	HL-028
D01BJS	INDICATI	Asthma [ICD-11: CA23] Investigative

D06KTF	TTDDRUID	D06KTF
D06KTF	DRUGNAME	HL-029
D06KTF	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D00BZO	TTDDRUID	D00BZO
D00BZO	DRUGNAME	HL-035
D00BZO	INDICATI	Syndrome X [ICD-11: 5C53.4] Investigative

D09NXZ	TTDDRUID	D09NXZ
D09NXZ	DRUGNAME	HL-038
D09NXZ	INDICATI	Angina pectoris [ICD-11: BA40] Investigative

D0J3AN	TTDDRUID	D0J3AN
D0J3AN	DRUGNAME	HL-076
D0J3AN	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0G8EI	TTDDRUID	D0G8EI
D0G8EI	DRUGNAME	HL-1020
D0G8EI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D03URV	TTDDRUID	D03URV
D03URV	DRUGNAME	HL-1172
D03URV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FL6C	TTDDRUID	D0FL6C
D0FL6C	DRUGNAME	HL-130
D0FL6C	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0Q9RW	TTDDRUID	D0Q9RW
D0Q9RW	DRUGNAME	HL-135
D0Q9RW	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0X5UY	TTDDRUID	D0X5UY
D0X5UY	DRUGNAME	HL-146
D0X5UY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01HFP	TTDDRUID	D01HFP
D01HFP	DRUGNAME	HL-160
D01HFP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A2XV	TTDDRUID	D0A2XV
D0A2XV	DRUGNAME	HL-162
D0A2XV	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D03YPR	TTDDRUID	D03YPR
D03YPR	DRUGNAME	HL-1983
D03YPR	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0V6KV	TTDDRUID	D0V6KV
D0V6KV	DRUGNAME	HL-2353
D0V6KV	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D08FDD	TTDDRUID	D08FDD
D08FDD	DRUGNAME	HL-4130
D08FDD	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D00SJN	TTDDRUID	D00SJN
D00SJN	DRUGNAME	HLL1-Fab-A3B3
D00SJN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W9CU	TTDDRUID	D0W9CU
D0W9CU	DRUGNAME	HLM-008182
D0W9CU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R0PC	TTDDRUID	D0R0PC
D0R0PC	DRUGNAME	HM 401
D0R0PC	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D06XIZ	TTDDRUID	D06XIZ
D06XIZ	DRUGNAME	HM-2002
D06XIZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D02ELN	TTDDRUID	D02ELN
D02ELN	DRUGNAME	HM-5016699
D02ELN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05NUH	TTDDRUID	D05NUH
D05NUH	DRUGNAME	Hm61713
D05NUH	INDICATI	Lung cancer [ICD-11: 2C25.0] Approved

D01SQP	TTDDRUID	D01SQP
D01SQP	DRUGNAME	HM-61713B
D01SQP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07RXM	TTDDRUID	D07RXM
D07RXM	DRUGNAME	HM-90822
D07RXM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09IIX	TTDDRUID	D09IIX
D09IIX	DRUGNAME	HMAG-1 targeting GRSA
D09IIX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D09DEU	TTDDRUID	D09DEU
D09DEU	DRUGNAME	HMPL-342
D09DEU	INDICATI	Asthma [ICD-11: CA23] Investigative

D0V8HK	TTDDRUID	D0V8HK
D0V8HK	DRUGNAME	H-NOX proteins
D0V8HK	INDICATI	Hypoxia [ICD-11: MD11.1] Investigative

D0K8CP	TTDDRUID	D0K8CP
D0K8CP	DRUGNAME	HO/02/10
D0K8CP	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D07UDI	TTDDRUID	D07UDI
D07UDI	DRUGNAME	HO/04/08
D07UDI	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D0X9PB	TTDDRUID	D0X9PB
D0X9PB	DRUGNAME	HO/04/09
D0X9PB	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D0X1OV	TTDDRUID	D0X1OV
D0X1OV	DRUGNAME	HO/07/09
D0X1OV	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0Q1ZD	TTDDRUID	D0Q1ZD
D0Q1ZD	DRUGNAME	HO-4038
D0Q1ZD	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0AF4F	TTDDRUID	D0AF4F
D0AF4F	DRUGNAME	HO-4073
D0AF4F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00IQV	TTDDRUID	D00IQV
D00IQV	DRUGNAME	Homspera
D00IQV	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0H6UK	TTDDRUID	D0H6UK
D0H6UK	DRUGNAME	HOO-IFOS
D0H6UK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0DD9T	TTDDRUID	D0DD9T
D0DD9T	DRUGNAME	HP-05
D0DD9T	INDICATI	Fatigue [ICD-11: MG22] Investigative

D08QXE	TTDDRUID	D08QXE
D08QXE	DRUGNAME	HP-161
D08QXE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N6JF	TTDDRUID	D0N6JF
D0N6JF	DRUGNAME	H-PGDS inhibitors
D0N6JF	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0Z7KB	TTDDRUID	D0Z7KB
D0Z7KB	DRUGNAME	HPMA-docetaxel conjugate
D0Z7KB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W7OG	TTDDRUID	D0W7OG
D0W7OG	DRUGNAME	HPMA-gemcitabine conjugate
D0W7OG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00SRE	TTDDRUID	D00SRE
D00SRE	DRUGNAME	HPMPA prodrugs
D00SRE	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D07SDT	TTDDRUID	D07SDT
D07SDT	DRUGNAME	HPP-376
D07SDT	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09QPD	TTDDRUID	D09QPD
D09QPD	DRUGNAME	HPP-515
D09QPD	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative

D04YTX	TTDDRUID	D04YTX
D04YTX	DRUGNAME	HPy-HP 097
D04YTX	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative

D0VP7D	TTDDRUID	D0VP7D
D0VP7D	DRUGNAME	HR-004-1
D0VP7D	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0XM3W	TTDDRUID	D0XM3W
D0XM3W	DRUGNAME	HRA-072033
D0XM3W	INDICATI	Endocrine disease [ICD-11: 5B3Z] Investigative

D00FUD	TTDDRUID	D00FUD
D00FUD	DRUGNAME	HRA-081025
D00FUD	INDICATI	Contraception [ICD-11: QA21] Investigative

D00JMG	TTDDRUID	D00JMG
D00JMG	DRUGNAME	HRA-081035
D00JMG	INDICATI	Contraception [ICD-11: QA21] Investigative

D01TBL	TTDDRUID	D01TBL
D01TBL	DRUGNAME	HRGP
D01TBL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N4HH	TTDDRUID	D0N4HH
D0N4HH	DRUGNAME	HRI kinase inhibitors
D0N4HH	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0G4KD	TTDDRUID	D0G4KD
D0G4KD	DRUGNAME	HS-113
D0G4KD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H5HS	TTDDRUID	D0H5HS
D0H5HS	DRUGNAME	HS-1183
D0H5HS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XK6P	TTDDRUID	D0XK6P
D0XK6P	DRUGNAME	HS-210
D0XK6P	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0SF0U	TTDDRUID	D0SF0U
D0SF0U	DRUGNAME	HS-7
D0SF0U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0TJ9I	TTDDRUID	D0TJ9I
D0TJ9I	DRUGNAME	HSB-13
D0TJ9I	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0W7XX	TTDDRUID	D0W7XX
D0W7XX	DRUGNAME	HS-HCV
D0W7XX	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0A5NL	TTDDRUID	D0A5NL
D0A5NL	DRUGNAME	HS-HIV
D0A5NL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0F6AJ	TTDDRUID	D0F6AJ
D0F6AJ	DRUGNAME	Hsp 6/11
D0F6AJ	INDICATI	Condyloma [ICD-11: 1A61.3] Investigative

D08MFI	TTDDRUID	D08MFI
D08MFI	DRUGNAME	Hsp 90 inhibitors
D08MFI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00JKJ	TTDDRUID	D00JKJ
D00JKJ	DRUGNAME	HS-P1
D00JKJ	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D0R9AB	TTDDRUID	D0R9AB
D0R9AB	DRUGNAME	Hsp90 inhibitors
D0R9AB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YZ0B	TTDDRUID	D0YZ0B
D0YZ0B	DRUGNAME	HT-2678
D0YZ0B	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D03OSO	TTDDRUID	D03OSO
D03OSO	DRUGNAME	HT-61
D03OSO	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D0B7HH	TTDDRUID	D0B7HH
D0B7HH	DRUGNAME	HTERT-VISA-BikDD nanoparticles
D0B7HH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0G9UO	TTDDRUID	D0G9UO
D0G9UO	DRUGNAME	HTRA-1 mabs
D0G9UO	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0UX4A	TTDDRUID	D0UX4A
D0UX4A	DRUGNAME	HU-433
D0UX4A	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0JL3Y	TTDDRUID	D0JL3Y
D0JL3Y	DRUGNAME	HuGAL-F2
D0JL3Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N4LW	TTDDRUID	D0N4LW
D0N4LW	DRUGNAME	Human Alpha Antitrypsin
D0N4LW	INDICATI	Genetic disease [ICD-11: 8E02] Investigative

D0U5VX	TTDDRUID	D0U5VX
D0U5VX	DRUGNAME	Human AM/AMBP-1
D0U5VX	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D0Y1YA	TTDDRUID	D0Y1YA
D0Y1YA	DRUGNAME	Human embryonic stem cell-derived hepatocytes
D0Y1YA	INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative

D01BIQ	TTDDRUID	D01BIQ
D01BIQ	DRUGNAME	Human embryonic stem cell-derived motor neuron progenitors
D01BIQ	INDICATI	Neuromuscular disease [ICD-11: 8C6Y] Investigative

D0C0ON	TTDDRUID	D0C0ON
D0C0ON	DRUGNAME	Human embryonic stem cell-derived osteoblasts
D0C0ON	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0DP7T	TTDDRUID	D0DP7T
D0DP7T	DRUGNAME	Human embryonic stem cell-derived vascular progenitors
D0DP7T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02BJN	TTDDRUID	D02BJN
D02BJN	DRUGNAME	Human liver progenitor cells
D02BJN	INDICATI	Liver cirrhosis [ICD-11: DB93.1] Investigative

D0Z4BP	TTDDRUID	D0Z4BP
D0Z4BP	DRUGNAME	Human liver-engrafting cells
D0Z4BP	INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative

D04QPE	TTDDRUID	D04QPE
D04QPE	DRUGNAME	Human mab
D04QPE	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D08MYW	TTDDRUID	D08MYW
D08MYW	DRUGNAME	Human M-SAA3 peptide
D08MYW	INDICATI	Gastrointestinal infection [ICD-11: 1A40.Z] Investigative

D02PKV	TTDDRUID	D02PKV
D02PKV	DRUGNAME	Human recombinant factor VIIa
D02PKV	INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative

D09CTF	TTDDRUID	D09CTF
D09CTF	DRUGNAME	Human recombinant factor VIII
D09CTF	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative

D0V0IG	TTDDRUID	D0V0IG
D0V0IG	DRUGNAME	Human recombinant polyclonal anitbodies
D0V0IG	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0P4HR	TTDDRUID	D0P4HR
D0P4HR	DRUGNAME	Human recombinant protein
D0P4HR	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0OI5Y	TTDDRUID	D0OI5Y
D0OI5Y	DRUGNAME	Human serum albumin
D0OI5Y	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0T7NO	TTDDRUID	D0T7NO
D0T7NO	DRUGNAME	Humanized mab program
D0T7NO	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D02AOV	TTDDRUID	D02AOV
D02AOV	DRUGNAME	Humanized mabs
D02AOV	INDICATI	Chikungunya virus infection [ICD-11: 1D40] Investigative

D0Z1CQ	TTDDRUID	D0Z1CQ
D0Z1CQ	DRUGNAME	HumaRAD-OV
D0Z1CQ	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0B6YR	TTDDRUID	D0B6YR
D0B6YR	DRUGNAME	HuMax-CD32b
D0B6YR	INDICATI	B-cell lymphoma [ICD-11: 2A86] Investigative

D0N1QH	TTDDRUID	D0N1QH
D0N1QH	DRUGNAME	HuMax-CD38b
D0N1QH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S0RE	TTDDRUID	D0S0RE
D0S0RE	DRUGNAME	HuMax-CD74
D0S0RE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z4RX	TTDDRUID	D0Z4RX
D0Z4RX	DRUGNAME	HuMax-cMet
D0Z4RX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06YSK	TTDDRUID	D06YSK
D06YSK	DRUGNAME	HuMax-Her2
D06YSK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07FYK	TTDDRUID	D07FYK
D07FYK	DRUGNAME	HuMax-VEGF
D07FYK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K5UK	TTDDRUID	D0K5UK
D0K5UK	DRUGNAME	HuMax-Wnt
D0K5UK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02XOM	TTDDRUID	D02XOM
D02XOM	DRUGNAME	HX-01
D02XOM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08WDH	TTDDRUID	D08WDH
D08WDH	DRUGNAME	HXTC-901
D08WDH	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0CA2S	TTDDRUID	D0CA2S
D0CA2S	DRUGNAME	HYDAMTIQ
D0CA2S	INDICATI	Brain ischaemia [ICD-11: 8B1Z] Investigative

D0I6KC	TTDDRUID	D0I6KC
D0I6KC	DRUGNAME	HydroVAX
D0I6KC	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D0NH0U	TTDDRUID	D0NH0U
D0NH0U	DRUGNAME	HYG-440
D0NH0U	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D08NRG	TTDDRUID	D08NRG
D08NRG	DRUGNAME	HYP-10
D08NRG	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09FKC	TTDDRUID	D09FKC
D09FKC	DRUGNAME	Hypoglycemic agent
D09FKC	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0ZB0H	TTDDRUID	D0ZB0H
D0ZB0H	DRUGNAME	Hypoxic response inhibitors
D0ZB0H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P0NH	TTDDRUID	D0P0NH
D0P0NH	DRUGNAME	HZ-08
D0P0NH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06SAT	TTDDRUID	D06SAT
D06SAT	DRUGNAME	HZ-166
D06SAT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0RF6P	TTDDRUID	D0RF6P
D0RF6P	DRUGNAME	I kappa B kinase inhibitors
D0RF6P	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Q8QR	TTDDRUID	D0Q8QR
D0Q8QR	DRUGNAME	I-387
D0Q8QR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U6AI	TTDDRUID	D0U6AI
D0U6AI	DRUGNAME	I-A09
D0U6AI	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D06EHW	TTDDRUID	D06EHW
D06EHW	DRUGNAME	IAI-100
D06EHW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q9UL	TTDDRUID	D0Q9UL
D0Q9UL	DRUGNAME	IATX-FVIII
D0Q9UL	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative

D0K1OR	TTDDRUID	D0K1OR
D0K1OR	DRUGNAME	IB-06F259
D0K1OR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N4MK	TTDDRUID	D0N4MK
D0N4MK	DRUGNAME	IB-07A037
D0N4MK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D03LMK	TTDDRUID	D03LMK
D03LMK	DRUGNAME	IB-07A085
D03LMK	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0YO0Z	TTDDRUID	D0YO0Z
D0YO0Z	DRUGNAME	IB-08A099
D0YO0Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D09AYA	TTDDRUID	D09AYA
D09AYA	DRUGNAME	IB-08C175
D09AYA	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative

D0Y2EN	TTDDRUID	D0Y2EN
D0Y2EN	DRUGNAME	IB-09A133
D0Y2EN	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D0XG7H	TTDDRUID	D0XG7H
D0XG7H	DRUGNAME	IB-09A149
D0XG7H	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D06MXB	TTDDRUID	D06MXB
D06MXB	DRUGNAME	IB-09C190
D06MXB	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D0OM0X	TTDDRUID	D0OM0X
D0OM0X	DRUGNAME	IB-201
D0OM0X	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D08PVL	TTDDRUID	D08PVL
D08PVL	DRUGNAME	Ibulocydine
D08PVL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01BZR	TTDDRUID	D01BZR
D01BZR	DRUGNAME	IC-041
D01BZR	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D08TIA	TTDDRUID	D08TIA
D08TIA	DRUGNAME	IC-200214
D08TIA	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D05JTJ	TTDDRUID	D05JTJ
D05JTJ	DRUGNAME	IC-50
D05JTJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0W6EV	TTDDRUID	D0W6EV
D0W6EV	DRUGNAME	ICGD
D0W6EV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A1DT	TTDDRUID	D0A1DT
D0A1DT	DRUGNAME	ICI-245991
D0A1DT	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D05GIO	TTDDRUID	D05GIO
D05GIO	DRUGNAME	ICT-037
D05GIO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0WF7H	TTDDRUID	D0WF7H
D0WF7H	DRUGNAME	ICT-111
D0WF7H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AK0Z	TTDDRUID	D0AK0Z
D0AK0Z	DRUGNAME	ICT-69
D0AK0Z	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0KP2R	TTDDRUID	D0KP2R
D0KP2R	DRUGNAME	ID-12
D0KP2R	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0B1SA	TTDDRUID	D0B1SA
D0B1SA	DRUGNAME	IDC-G103
D0B1SA	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0V9MV	TTDDRUID	D0V9MV
D0V9MV	DRUGNAME	IDDBCP226234
D0V9MV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0MI8F	TTDDRUID	D0MI8F
D0MI8F	DRUGNAME	IdeS
D0MI8F	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D08VDJ	TTDDRUID	D08VDJ
D08VDJ	DRUGNAME	IDN-13389
D08VDJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N0VW	TTDDRUID	D0N0VW
D0N0VW	DRUGNAME	IDN-5174
D0N0VW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06QRY	TTDDRUID	D06QRY
D06QRY	DRUGNAME	IDN-5390
D06QRY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07VJK	TTDDRUID	D07VJK
D07VJK	DRUGNAME	IDN-6384
D07VJK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V6GT	TTDDRUID	D0V6GT
D0V6GT	DRUGNAME	IDN-6439
D0V6GT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05JMP	TTDDRUID	D05JMP
D05JMP	DRUGNAME	IDR-803
D05JMP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X4WV	TTDDRUID	D0X4WV
D0X4WV	DRUGNAME	IDV-007
D0X4WV	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D07NUH	TTDDRUID	D07NUH
D07NUH	DRUGNAME	IDX-15971
D07NUH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0T3BX	TTDDRUID	D0T3BX
D0T3BX	DRUGNAME	IFN-beta
D0T3BX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H5NF	TTDDRUID	D0H5NF
D0H5NF	DRUGNAME	IFN-beta-CTP
D0H5NF	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D06XXD	TTDDRUID	D06XXD
D06XXD	DRUGNAME	IG-AI-025
D06XXD	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D00FXQ	TTDDRUID	D00FXQ
D00FXQ	DRUGNAME	IG-CN-023
D00FXQ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0T7XO	TTDDRUID	D0T7XO
D0T7XO	DRUGNAME	IGEL1.2
D0T7XO	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D08GTE	TTDDRUID	D08GTE
D08GTE	DRUGNAME	IGF-1R inhibitors
D08GTE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04HBJ	TTDDRUID	D04HBJ
D04HBJ	DRUGNAME	IGFBP 2 variants
D04HBJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FX7U	TTDDRUID	D0FX7U
D0FX7U	DRUGNAME	IGF-drug conjugates
D0FX7U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P6BZ	TTDDRUID	D0P6BZ
D0P6BZ	DRUGNAME	IGFR1 kinase inhibitors
D0P6BZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QI0Z	TTDDRUID	D0QI0Z
D0QI0Z	DRUGNAME	IG-MD-009
D0QI0Z	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0Y3VN	TTDDRUID	D0Y3VN
D0Y3VN	DRUGNAME	Ii-key/MHC class II epitope hybrid peptides
D0Y3VN	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0DP8U	TTDDRUID	D0DP8U
D0DP8U	DRUGNAME	IKH-02
D0DP8U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00JIX	TTDDRUID	D00JIX
D00JIX	DRUGNAME	IKH-25
D00JIX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03JMF	TTDDRUID	D03JMF
D03JMF	DRUGNAME	IKI-1
D03JMF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06CHF	TTDDRUID	D06CHF
D06CHF	DRUGNAME	IKKbeta inhibitors
D06CHF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0P8GO	TTDDRUID	D0P8GO
D0P8GO	DRUGNAME	IKKbeta inhibitors
D0P8GO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D01QRF	TTDDRUID	D01QRF
D01QRF	DRUGNAME	IKS-04
D01QRF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04CKB	TTDDRUID	D04CKB
D04CKB	DRUGNAME	IkT-001
D04CKB	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0QM6Y	TTDDRUID	D0QM6Y
D0QM6Y	DRUGNAME	IkT-004
D0QM6Y	INDICATI	Polyomavirus infection [ICD-11: 1C80] Investigative

D0M5QU	TTDDRUID	D0M5QU
D0M5QU	DRUGNAME	IkT-014
D0M5QU	INDICATI	Polyomavirus infection [ICD-11: 1C80] Investigative

D0E8KK	TTDDRUID	D0E8KK
D0E8KK	DRUGNAME	IkT-041
D0E8KK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0P5BQ	TTDDRUID	D0P5BQ
D0P5BQ	DRUGNAME	IkT-051
D0P5BQ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0FA4Q	TTDDRUID	D0FA4Q
D0FA4Q	DRUGNAME	IL1R1 NAM
D0FA4Q	INDICATI	Gout [ICD-11: FA25] Investigative

D02TOK	TTDDRUID	D02TOK
D02TOK	DRUGNAME	IL-2 mimetic peptides
D02TOK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W8JY	TTDDRUID	D0W8JY
D0W8JY	DRUGNAME	IL-4
D0W8JY	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0WS8K	TTDDRUID	D0WS8K
D0WS8K	DRUGNAME	Ilatreotide
D0WS8K	INDICATI	Duodenal ulcer [ICD-11: DA63] Investigative

D0W7VQ	TTDDRUID	D0W7VQ
D0W7VQ	DRUGNAME	Imab-468
D0W7VQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02VXH	TTDDRUID	D02VXH
D02VXH	DRUGNAME	Imaging agent
D02VXH	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D09KWS	TTDDRUID	D09KWS
D09KWS	DRUGNAME	Imaging-theranostic nanoemulsion agents
D09KWS	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0V7YK	TTDDRUID	D0V7YK
D0V7YK	DRUGNAME	ImBryon
D0V7YK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M6GP	TTDDRUID	D0M6GP
D0M6GP	DRUGNAME	IMC-HIV
D0M6GP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0Z2TH	TTDDRUID	D0Z2TH
D0Z2TH	DRUGNAME	IMD-015213
D0Z2TH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N8UQ	TTDDRUID	D0N8UQ
D0N8UQ	DRUGNAME	IMD-026259
D0N8UQ	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0Y1HZ	TTDDRUID	D0Y1HZ
D0Y1HZ	DRUGNAME	IMD-026260
D0Y1HZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03KYI	TTDDRUID	D03KYI
D03KYI	DRUGNAME	IMD-1622
D03KYI	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0EW2D	TTDDRUID	D0EW2D
D0EW2D	DRUGNAME	IMD-4482
D0EW2D	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D07JXR	TTDDRUID	D07JXR
D07JXR	DRUGNAME	IMD-4852
D07JXR	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0Z8BI	TTDDRUID	D0Z8BI
D0Z8BI	DRUGNAME	IMGN-007
D0Z8BI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K4CH	TTDDRUID	D0K4CH
D0K4CH	DRUGNAME	IMGN-009
D0K4CH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T9YU	TTDDRUID	D0T9YU
D0T9YU	DRUGNAME	Imino sugars
D0T9YU	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D09SAU	TTDDRUID	D09SAU
D09SAU	DRUGNAME	IMM-160
D09SAU	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D01BRX	TTDDRUID	D01BRX
D01BRX	DRUGNAME	IMM-252
D01BRX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0E7XO	TTDDRUID	D0E7XO
D0E7XO	DRUGNAME	IMM-255
D0E7XO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D03RSI	TTDDRUID	D03RSI
D03RSI	DRUGNAME	IMMLG-5521
D03RSI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0EL6M	TTDDRUID	D0EL6M
D0EL6M	DRUGNAME	ImmuMax
D0EL6M	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0D0XY	TTDDRUID	D0D0XY
D0D0XY	DRUGNAME	ImmuneFx
D0D0XY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T7HT	TTDDRUID	D0T7HT
D0T7HT	DRUGNAME	Immunotherapeutic
D0T7HT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U3PR	TTDDRUID	D0U3PR
D0U3PR	DRUGNAME	Immunotoxin conjugate
D0U3PR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0WU2Y	TTDDRUID	D0WU2Y
D0WU2Y	DRUGNAME	ImmuStem
D0WU2Y	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative

D04QIL	TTDDRUID	D04QIL
D04QIL	DRUGNAME	IMP-111
D04QIL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05ZLH	TTDDRUID	D05ZLH
D05ZLH	DRUGNAME	IMP-731
D05ZLH	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0W4HO	TTDDRUID	D0W4HO
D0W4HO	DRUGNAME	IMT-504
D0W4HO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0NN9I	TTDDRUID	D0NN9I
D0NN9I	DRUGNAME	IMU-200
D0NN9I	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0T6PF	TTDDRUID	D0T6PF
D0T6PF	DRUGNAME	IMX-MEL1
D0T6PF	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0L7UT	TTDDRUID	D0L7UT
D0L7UT	DRUGNAME	IMX-MSP3
D0L7UT	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0F3IM	TTDDRUID	D0F3IM
D0F3IM	DRUGNAME	IMX-MSP4
D0F3IM	INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Investigative

D01KYG	TTDDRUID	D01KYG
D01KYG	DRUGNAME	INA-115E
D01KYG	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D0I6HJ	TTDDRUID	D0I6HJ
D0I6HJ	DRUGNAME	INC-106
D0I6HJ	INDICATI	Artery stenosis [ICD-11: BD52] Investigative

D00JXV	TTDDRUID	D00JXV
D00JXV	DRUGNAME	INCB-10820
D00JXV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00XNE	TTDDRUID	D00XNE
D00XNE	DRUGNAME	Incrementally modified drug
D00XNE	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D05DQF	TTDDRUID	D05DQF
D05DQF	DRUGNAME	Indole N -acetamide
D05DQF	INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative

D0M2QW	TTDDRUID	D0M2QW
D0M2QW	DRUGNAME	Indolecarboxamides
D0M2QW	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D0A8RP	TTDDRUID	D0A8RP
D0A8RP	DRUGNAME	INDOPY-1
D0A8RP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0O8FN	TTDDRUID	D0O8FN
D0O8FN	DRUGNAME	INDUS-815B
D0O8FN	INDICATI	Kidney disease [ICD-11: GC2Z] Investigative

D0IR8J	TTDDRUID	D0IR8J
D0IR8J	DRUGNAME	INDUS-815C
D0IR8J	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D08OXC	TTDDRUID	D08OXC
D08OXC	DRUGNAME	INDUS-82030
D08OXC	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0XA2G	TTDDRUID	D0XA2G
D0XA2G	DRUGNAME	INDUS-860
D0XA2G	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0M2ME	TTDDRUID	D0M2ME
D0M2ME	DRUGNAME	INDUSCA-1
D0M2ME	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0OH8F	TTDDRUID	D0OH8F
D0OH8F	DRUGNAME	Inflammation therapeutics
D0OH8F	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02IBS	TTDDRUID	D02IBS
D02IBS	DRUGNAME	INH-001
D02IBS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D03UMB	TTDDRUID	D03UMB
D03UMB	DRUGNAME	Inhaled retinoids
D03UMB	INDICATI	Respiratory tract cancer [ICD-11: 2C29.Z] Investigative

D09SLC	TTDDRUID	D09SLC
D09SLC	DRUGNAME	Inhaled supergeneric
D09SLC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I8GN	TTDDRUID	D0I8GN
D0I8GN	DRUGNAME	INK4a
D0I8GN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R0UW	TTDDRUID	D0R0UW
D0R0UW	DRUGNAME	INKP-102
D0R0UW	INDICATI	Gastrointestinal infection [ICD-11: 1A40.Z] Investigative

D06CTD	TTDDRUID	D06CTD
D06CTD	DRUGNAME	IN-N01
D06CTD	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D08AOV	TTDDRUID	D08AOV
D08AOV	DRUGNAME	INO-1002
D08AOV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T1MI	TTDDRUID	D0T1MI
D0T1MI	DRUGNAME	INP-01
D0T1MI	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D03RTR	TTDDRUID	D03RTR
D03RTR	DRUGNAME	INP-02
D03RTR	INDICATI	HIV-associated dementia [ICD-11: 6D85.3] Investigative

D05SXT	TTDDRUID	D05SXT
D05SXT	DRUGNAME	INP-03
D05SXT	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D0R7NP	TTDDRUID	D0R7NP
D0R7NP	DRUGNAME	INP-04
D0R7NP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G1SY	TTDDRUID	D0G1SY
D0G1SY	DRUGNAME	INP-05
D0G1SY	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0HX0P	TTDDRUID	D0HX0P
D0HX0P	DRUGNAME	INP-06
D0HX0P	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06CSR	TTDDRUID	D06CSR
D06CSR	DRUGNAME	INP-1750
D06CSR	INDICATI	Diarrhea [ICD-11: ME05.1] Investigative

D03END	TTDDRUID	D03END
D03END	DRUGNAME	Insecticide
D03END	INDICATI	Pest attack [ICD-11: N.A.] Investigative

D00BCS	TTDDRUID	D00BCS
D00BCS	DRUGNAME	INT-0015/2008
D00BCS	INDICATI	Panic disorder [ICD-11: 6B01] Investigative

D08ZXG	TTDDRUID	D08ZXG
D08ZXG	DRUGNAME	INT-2500
D08ZXG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0B7AH	TTDDRUID	D0B7AH
D0B7AH	DRUGNAME	INT-777
D0B7AH	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D08CGE	TTDDRUID	D08CGE
D08CGE	DRUGNAME	Integrin alpha 5/beta 1
D08CGE	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative

D0A5CH	TTDDRUID	D0A5CH
D0A5CH	DRUGNAME	Integrin alpha-V/beta-3 receptor mab
D0A5CH	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0W4SS	TTDDRUID	D0W4SS
D0W4SS	DRUGNAME	Interferon beta
D0W4SS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08IFG	TTDDRUID	D08IFG
D08IFG	DRUGNAME	Interferon-alpha dimers
D08IFG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0EU9Z	TTDDRUID	D0EU9Z
D0EU9Z	DRUGNAME	InterveXin-PCP
D0EU9Z	INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative

D0PM8B	TTDDRUID	D0PM8B
D0PM8B	DRUGNAME	Intranasal insulin
D0PM8B	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0S3PX	TTDDRUID	D0S3PX
D0S3PX	DRUGNAME	Intra-oral lozenge
D0S3PX	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D07ZEK	TTDDRUID	D07ZEK
D07ZEK	DRUGNAME	Intravenous immunostimulant
D07ZEK	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D06MDT	TTDDRUID	D06MDT
D06MDT	DRUGNAME	INV-155
D06MDT	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D01ZZG	TTDDRUID	D01ZZG
D01ZZG	DRUGNAME	INV-311
D01ZZG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09DJS	TTDDRUID	D09DJS
D09DJS	DRUGNAME	INV-400
D09DJS	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0M7TT	TTDDRUID	D0M7TT
D0M7TT	DRUGNAME	IP-1200
D0M7TT	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative

D05VNX	TTDDRUID	D05VNX
D05VNX	DRUGNAME	IPC-003
D05VNX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01NOI	TTDDRUID	D01NOI
D01NOI	DRUGNAME	IPH-1201
D01NOI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0ZH0X	TTDDRUID	D0ZH0X
D0ZH0X	DRUGNAME	IPH-24
D0ZH0X	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D09ZZF	TTDDRUID	D09ZZF
D09ZZF	DRUGNAME	IPH-41XX
D09ZZF	INDICATI	Mycoses [ICD-11: 1F2Z] Investigative

D05JBP	TTDDRUID	D05JBP
D05JBP	DRUGNAME	IPI-194
D05JBP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S8RN	TTDDRUID	D0S8RN
D0S8RN	DRUGNAME	IPN-100
D0S8RN	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D0A5KF	TTDDRUID	D0A5KF
D0A5KF	DRUGNAME	IPN-120
D0A5KF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D06EIM	TTDDRUID	D06EIM
D06EIM	DRUGNAME	IPN-200
D06EIM	INDICATI	Flavivirus infection [ICD-11: 1C80] Investigative

D0C5UE	TTDDRUID	D0C5UE
D0C5UE	DRUGNAME	Ipoxyn
D0C5UE	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D02ZYI	TTDDRUID	D02ZYI
D02ZYI	DRUGNAME	IPP-201007
D02ZYI	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D02QAO	TTDDRUID	D02QAO
D02QAO	DRUGNAME	IPP-203101
D02QAO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D09EYJ	TTDDRUID	D09EYJ
D09EYJ	DRUGNAME	IPS cell program
D09EYJ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0AC7C	TTDDRUID	D0AC7C
D0AC7C	DRUGNAME	IPS-01003
D0AC7C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W8YZ	TTDDRUID	D0W8YZ
D0W8YZ	DRUGNAME	IPZ-010
D0W8YZ	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D09YNJ	TTDDRUID	D09YNJ
D09YNJ	DRUGNAME	IQP-0410
D09YNJ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D01UZH	TTDDRUID	D01UZH
D01UZH	DRUGNAME	IQP-0528
D01UZH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D06NKA	TTDDRUID	D06NKA
D06NKA	DRUGNAME	IRC-083927
D06NKA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AG4J	TTDDRUID	D0AG4J
D0AG4J	DRUGNAME	IRX-01
D0AG4J	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09SXQ	TTDDRUID	D09SXQ
D09SXQ	DRUGNAME	IRX-02
D09SXQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D09EJC	TTDDRUID	D09EJC
D09EJC	DRUGNAME	IRX-03
D09EJC	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D0T6TQ	TTDDRUID	D0T6TQ
D0T6TQ	DRUGNAME	IS-0402
D0T6TQ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0C4JV	TTDDRUID	D0C4JV
D0C4JV	DRUGNAME	ISC-4
D0C4JV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F8CS	TTDDRUID	D0F8CS
D0F8CS	DRUGNAME	ISF-120
D0F8CS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O7JK	TTDDRUID	D0O7JK
D0O7JK	DRUGNAME	ISG15-LNP01
D0O7JK	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0O8BP	TTDDRUID	D0O8BP
D0O8BP	DRUGNAME	ISIS 13920
D0O8BP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08KOD	TTDDRUID	D08KOD
D08KOD	DRUGNAME	ISIS 15770
D08KOD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y3JR	TTDDRUID	D0Y3JR
D0Y3JR	DRUGNAME	ISIS 16507
D0Y3JR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02JFF	TTDDRUID	D02JFF
D02JFF	DRUGNAME	ISIS 16518
D02JFF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I3QU	TTDDRUID	D0I3QU
D0I3QU	DRUGNAME	ISIS 18078
D0I3QU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00XFY	TTDDRUID	D00XFY
D00XFY	DRUGNAME	ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine
D00XFY	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D01LAP	TTDDRUID	D01LAP
D01LAP	DRUGNAME	ISIS 2922 + Ganciclovir
D01LAP	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D02UJG	TTDDRUID	D02UJG
D02UJG	DRUGNAME	ISIS-387898
D02UJG	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D0B3YW	TTDDRUID	D0B3YW
D0B3YW	DRUGNAME	Isoquinoline alkaloids
D0B3YW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E1AZ	TTDDRUID	D0E1AZ
D0E1AZ	DRUGNAME	ISU-201
D0E1AZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D08QYL	TTDDRUID	D08QYL
D08QYL	DRUGNAME	ISV-102
D08QYL	INDICATI	Ocular infection [ICD-11: 1F00.1] Investigative

D0T0IE	TTDDRUID	D0T0IE
D0T0IE	DRUGNAME	ISV-215
D0T0IE	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0Z0LZ	TTDDRUID	D0Z0LZ
D0Z0LZ	DRUGNAME	IT-121
D0Z0LZ	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D07IZS	TTDDRUID	D07IZS
D07IZS	DRUGNAME	ITE
D07IZS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07UBB	TTDDRUID	D07UBB
D07UBB	DRUGNAME	ITI-003
D07UBB	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative

D0N5AS	TTDDRUID	D0N5AS
D0N5AS	DRUGNAME	ITI-014
D0N5AS	INDICATI	Hot flushes [ICD-11: GA30] Investigative

D0E9ZP	TTDDRUID	D0E9ZP
D0E9ZP	DRUGNAME	ITK inhibitors
D0E9ZP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0N0MZ	TTDDRUID	D0N0MZ
D0N0MZ	DRUGNAME	ITL-1636
D0N0MZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0N5TB	TTDDRUID	D0N5TB
D0N5TB	DRUGNAME	ITRI-305
D0N5TB	INDICATI	Thyroid cancer [ICD-11: 2D10] Investigative

D03ATI	TTDDRUID	D03ATI
D03ATI	DRUGNAME	ITV-2
D03ATI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0W3TC	TTDDRUID	D0W3TC
D0W3TC	DRUGNAME	ITV-3
D0W3TC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D09PZV	TTDDRUID	D09PZV
D09PZV	DRUGNAME	ITV-4
D09PZV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D01VMA	TTDDRUID	D01VMA
D01VMA	DRUGNAME	ITX-4520
D01VMA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0S4RB	TTDDRUID	D0S4RB
D0S4RB	DRUGNAME	ITX-7650
D0S4RB	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D01YJR	TTDDRUID	D01YJR
D01YJR	DRUGNAME	IVN-birch
D01YJR	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D06UNW	TTDDRUID	D06UNW
D06UNW	DRUGNAME	IVN-mite
D06UNW	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D07ENH	TTDDRUID	D07ENH
D07ENH	DRUGNAME	IVV-001
D07ENH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06AKC	TTDDRUID	D06AKC
D06AKC	DRUGNAME	IVVS-1001
D06AKC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0Q0GY	TTDDRUID	D0Q0GY
D0Q0GY	DRUGNAME	IW-1221
D0Q0GY	INDICATI	Asthma [ICD-11: CA23] Investigative

D08QKY	TTDDRUID	D08QKY
D08QKY	DRUGNAME	IXS-312
D08QKY	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0BP7C	TTDDRUID	D0BP7C
D0BP7C	DRUGNAME	J-104135
D0BP7C	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D02CBD	TTDDRUID	D02CBD
D02CBD	DRUGNAME	J-30
D02CBD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U3TE	TTDDRUID	D0U3TE
D0U3TE	DRUGNAME	J-555Y
D0U3TE	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D05UAO	TTDDRUID	D05UAO
D05UAO	DRUGNAME	J591-Ac-225
D05UAO	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D08JLC	TTDDRUID	D08JLC
D08JLC	DRUGNAME	J-607Y
D08JLC	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D04TCQ	TTDDRUID	D04TCQ
D04TCQ	DRUGNAME	J-775Y
D04TCQ	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0W5CT	TTDDRUID	D0W5CT
D0W5CT	DRUGNAME	Jak2 inhibitors
D0W5CT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02NJY	TTDDRUID	D02NJY
D02NJY	DRUGNAME	Jak2 tyrosine inhibitors
D02NJY	INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Investigative

D0C1RN	TTDDRUID	D0C1RN
D0C1RN	DRUGNAME	Japanese cedar peptide allergy desensitization agent
D0C1RN	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D08RAK	TTDDRUID	D08RAK
D08RAK	DRUGNAME	Japanese cedar pollen allergy sublingual immunotherapy
D08RAK	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0O0RY	TTDDRUID	D0O0RY
D0O0RY	DRUGNAME	JB-1
D0O0RY	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D09MUS	TTDDRUID	D09MUS
D09MUS	DRUGNAME	JBD-201
D09MUS	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D07YOP	TTDDRUID	D07YOP
D07YOP	DRUGNAME	JBD-401
D07YOP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08KXX	TTDDRUID	D08KXX
D08KXX	DRUGNAME	JBD-411
D08KXX	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0JR9V	TTDDRUID	D0JR9V
D0JR9V	DRUGNAME	JBP-1
D0JR9V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0EK5H	TTDDRUID	D0EK5H
D0EK5H	DRUGNAME	JCV-specific TCR a chains-CD3zeta fusion protein
D0EK5H	INDICATI	Progressive multifocal leukoencephalopathy [ICD-11: 8A45.02] Investigative

D09GQS	TTDDRUID	D09GQS
D09GQS	DRUGNAME	JD-0100
D09GQS	INDICATI	Obesity [ICD-11: 5B81] Investigative

D06EEM	TTDDRUID	D06EEM
D06EEM	DRUGNAME	JD-3000
D06EEM	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0PA2R	TTDDRUID	D0PA2R
D0PA2R	DRUGNAME	JD-4000
D0PA2R	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0FA4C	TTDDRUID	D0FA4C
D0FA4C	DRUGNAME	JDP-201
D0FA4C	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0A4JB	TTDDRUID	D0A4JB
D0A4JB	DRUGNAME	JDP-202
D0A4JB	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D07WYO	TTDDRUID	D07WYO
D07WYO	DRUGNAME	JI-3292
D07WYO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0X6XP	TTDDRUID	D0X6XP
D0X6XP	DRUGNAME	JIN-2011
D0X6XP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02LOB	TTDDRUID	D02LOB
D02LOB	DRUGNAME	JIN-2013
D02LOB	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0Q9BV	TTDDRUID	D0Q9BV
D0Q9BV	DRUGNAME	JIN-2019
D0Q9BV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P3VP	TTDDRUID	D0P3VP
D0P3VP	DRUGNAME	JKB-119
D0P3VP	INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative

D01VNL	TTDDRUID	D01VNL
D01VNL	DRUGNAME	JM-1232(-)
D01VNL	INDICATI	Anaesthesia [ICD-11: 9A78.6] Investigative

D0SR3T	TTDDRUID	D0SR3T
D0SR3T	DRUGNAME	JN-711
D0SR3T	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0V5LJ	TTDDRUID	D0V5LJ
D0V5LJ	DRUGNAME	JNJ-10329670
D0V5LJ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D01SUL	TTDDRUID	D01SUL
D01SUL	DRUGNAME	JNJ-10397049
D01SUL	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative

D0L9BW	TTDDRUID	D0L9BW
D0L9BW	DRUGNAME	JNJ-1136
D0L9BW	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0DY4E	TTDDRUID	D0DY4E
D0DY4E	DRUGNAME	JNJ-17203212
D0DY4E	INDICATI	Cough [ICD-11: MD12] Investigative

D08HTF	TTDDRUID	D08HTF
D08HTF	DRUGNAME	JNJ-1930942
D08HTF	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0S7QB	TTDDRUID	D0S7QB
D0S7QB	DRUGNAME	JNJ-28165722
D0S7QB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0Q4EQ	TTDDRUID	D0Q4EQ
D0Q4EQ	DRUGNAME	JNJ-38158471
D0Q4EQ	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D08JSE	TTDDRUID	D08JSE
D08JSE	DRUGNAME	JNJ-42041935
D08JSE	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D03QGB	TTDDRUID	D03QGB
D03QGB	DRUGNAME	JNJ-5207852
D03QGB	INDICATI	Narcolepsy [ICD-11: 7A20] Investigative

D0J8ED	TTDDRUID	D0J8ED
D0J8ED	DRUGNAME	JP-1201
D0J8ED	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D4ZE	TTDDRUID	D0D4ZE
D0D4ZE	DRUGNAME	JP-8019
D0D4ZE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08PNW	TTDDRUID	D08PNW
D08PNW	DRUGNAME	JPH-101
D08PNW	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative

D07JUL	TTDDRUID	D07JUL
D07JUL	DRUGNAME	JR-032
D07JUL	INDICATI	Hunter syndrome [ICD-11: 5C56.31] Investigative

D05GJJ	TTDDRUID	D05GJJ
D05GJJ	DRUGNAME	JR-051
D05GJJ	INDICATI	Fabry disease [ICD-11: 5C56.01] Investigative

D0N1RM	TTDDRUID	D0N1RM
D0N1RM	DRUGNAME	JR-101
D0N1RM	INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative

D0B2JL	TTDDRUID	D0B2JL
D0B2JL	DRUGNAME	JWB-1-84-1
D0B2JL	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D09DSK	TTDDRUID	D09DSK
D09DSK	DRUGNAME	JWH-051
D09DSK	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00MPX	TTDDRUID	D00MPX
D00MPX	DRUGNAME	JX-1395
D00MPX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G7KE	TTDDRUID	D0G7KE
D0G7KE	DRUGNAME	JX-2011
D0G7KE	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D05ZDA	TTDDRUID	D05ZDA
D05ZDA	DRUGNAME	JZAD-IV-22
D05ZDA	INDICATI	Narcolepsy [ICD-11: 7A20] Investigative

D0AK8E	TTDDRUID	D0AK8E
D0AK8E	DRUGNAME	K-101
D0AK8E	INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative

D01TJV	TTDDRUID	D01TJV
D01TJV	DRUGNAME	K-103-PA
D01TJV	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D08DJE	TTDDRUID	D08DJE
D08DJE	DRUGNAME	K-133W
D08DJE	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Investigative

D03DYT	TTDDRUID	D03DYT
D03DYT	DRUGNAME	K252a
D03DYT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I6QN	TTDDRUID	D0I6QN
D0I6QN	DRUGNAME	K-454
D0I6QN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZU2X	TTDDRUID	D0ZU2X
D0ZU2X	DRUGNAME	K-510
D0ZU2X	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D01SVG	TTDDRUID	D01SVG
D01SVG	DRUGNAME	KA-10X
D01SVG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00DRA	TTDDRUID	D00DRA
D00DRA	DRUGNAME	KA-20X
D00DRA	INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Investigative

D0U9FJ	TTDDRUID	D0U9FJ
D0U9FJ	DRUGNAME	KA-40X
D0U9FJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P5QR	TTDDRUID	D0P5QR
D0P5QR	DRUGNAME	KAC-776
D0P5QR	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0D8DA	TTDDRUID	D0D8DA
D0D8DA	DRUGNAME	KAG-308
D0D8DA	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D0G1AQ	TTDDRUID	D0G1AQ
D0G1AQ	DRUGNAME	KALA-617
D0G1AQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D07MOK	TTDDRUID	D07MOK
D07MOK	DRUGNAME	KANAb-071
D07MOK	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D06YYY	TTDDRUID	D06YYY
D06YYY	DRUGNAME	KAR-1880
D06YYY	INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative

D0L3VY	TTDDRUID	D0L3VY
D0L3VY	DRUGNAME	Karomab
D0L3VY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OX6I	TTDDRUID	D0OX6I
D0OX6I	DRUGNAME	KB-9520
D0OX6I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04UPM	TTDDRUID	D04UPM
D04UPM	DRUGNAME	KBAB-401
D04UPM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D04EXX	TTDDRUID	D04EXX
D04EXX	DRUGNAME	KBF-611
D04EXX	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0B2IB	TTDDRUID	D0B2IB
D0B2IB	DRUGNAME	KBPA-103
D0B2IB	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D0A3WZ	TTDDRUID	D0A3WZ
D0A3WZ	DRUGNAME	KBRV-201
D0A3WZ	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D0J3ZA	TTDDRUID	D0J3ZA
D0J3ZA	DRUGNAME	KBSA-302
D0J3ZA	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D09MFV	TTDDRUID	D09MFV
D09MFV	DRUGNAME	KC-7F2
D09MFV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01QNJ	TTDDRUID	D01QNJ
D01QNJ	DRUGNAME	KD-501
D01QNJ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0H4DU	TTDDRUID	D0H4DU
D0H4DU	DRUGNAME	KD-7332
D0H4DU	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0T6FY	TTDDRUID	D0T6FY
D0T6FY	DRUGNAME	KD-901
D0T6FY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0HZ1V	TTDDRUID	D0HZ1V
D0HZ1V	DRUGNAME	KDM-1001
D0HZ1V	INDICATI	Gastritis [ICD-11: DA42] Investigative

D06WHN	TTDDRUID	D06WHN
D06WHN	DRUGNAME	KDT-500
D06WHN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0D0NA	TTDDRUID	D0D0NA
D0D0NA	DRUGNAME	KDT-600
D0D0NA	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0E5VP	TTDDRUID	D0E5VP
D0E5VP	DRUGNAME	KF-66490
D0E5VP	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D0VD5X	TTDDRUID	D0VD5X
D0VD5X	DRUGNAME	KI-0001
D0VD5X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0VC8H	TTDDRUID	D0VC8H
D0VC8H	DRUGNAME	KI-0003
D0VC8H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N1SL	TTDDRUID	D0N1SL
D0N1SL	DRUGNAME	KI-0801
D0N1SL	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0LS6W	TTDDRUID	D0LS6W
D0LS6W	DRUGNAME	KI-0803
D0LS6W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XG4K	TTDDRUID	D0XG4K
D0XG4K	DRUGNAME	KI-0804
D0XG4K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02CND	TTDDRUID	D02CND
D02CND	DRUGNAME	KI-0901
D02CND	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09PWS	TTDDRUID	D09PWS
D09PWS	DRUGNAME	KI-0902
D09PWS	INDICATI	Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative

D0X6FB	TTDDRUID	D0X6FB
D0X6FB	DRUGNAME	KI-0903
D0X6FB	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0O8GZ	TTDDRUID	D0O8GZ
D0O8GZ	DRUGNAME	KI-0904
D0O8GZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00UHK	TTDDRUID	D00UHK
D00UHK	DRUGNAME	KI-0905
D00UHK	INDICATI	Asthma [ICD-11: CA23] Investigative

D0A2RF	TTDDRUID	D0A2RF
D0A2RF	DRUGNAME	KI-0906
D0A2RF	INDICATI	Arthritis [ICD-11: FA20] Investigative

D02CRM	TTDDRUID	D02CRM
D02CRM	DRUGNAME	KI-0907
D02CRM	INDICATI	Obesity [ICD-11: 5B81] Investigative

D09XKT	TTDDRUID	D09XKT
D09XKT	DRUGNAME	KI-1003
D09XKT	INDICATI	Eating disorder [ICD-11: 6B82] Investigative

D09TNR	TTDDRUID	D09TNR
D09TNR	DRUGNAME	Ki-23057
D09TNR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06JLQ	TTDDRUID	D06JLQ
D06JLQ	DRUGNAME	KIN-100
D06JLQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0J0ZU	TTDDRUID	D0J0ZU
D0J0ZU	DRUGNAME	KIN-3031
D0J0ZU	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06LCW	TTDDRUID	D06LCW
D06LCW	DRUGNAME	KIN-4044
D06LCW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D06MTH	TTDDRUID	D06MTH
D06MTH	DRUGNAME	KIN-4050
D06MTH	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D00TYP	TTDDRUID	D00TYP
D00TYP	DRUGNAME	KIN-4064
D00TYP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06BIB	TTDDRUID	D06BIB
D06BIB	DRUGNAME	Kinetochore-microtubule binding inhibitors
D06BIB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OG4A	TTDDRUID	D0OG4A
D0OG4A	DRUGNAME	Kirromycin
D0OG4A	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Clinical trial

D0EY3X	TTDDRUID	D0EY3X
D0EY3X	DRUGNAME	KLS-40
D0EY3X	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0B7AF	TTDDRUID	D0B7AF
D0B7AF	DRUGNAME	KLS-Bfr
D0B7AF	INDICATI	Osteonecrosis [ICD-11: FB81] Investigative

D01CQJ	TTDDRUID	D01CQJ
D01CQJ	DRUGNAME	KLS-HPV
D01CQJ	INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative

D09CNR	TTDDRUID	D09CNR
D09CNR	DRUGNAME	KLS-Npk
D09CNR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0Q6OL	TTDDRUID	D0Q6OL
D0Q6OL	DRUGNAME	KM-011
D0Q6OL	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D05QCE	TTDDRUID	D05QCE
D05QCE	DRUGNAME	KM-01221
D05QCE	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0IC6D	TTDDRUID	D0IC6D
D0IC6D	DRUGNAME	KM-133
D0IC6D	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D06OVM	TTDDRUID	D06OVM
D06OVM	DRUGNAME	KM-3413
D06OVM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F5TS	TTDDRUID	D0F5TS
D0F5TS	DRUGNAME	KM-3900
D0F5TS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A2BK	TTDDRUID	D0A2BK
D0A2BK	DRUGNAME	KM-391
D0A2BK	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Investigative

D0X1YZ	TTDDRUID	D0X1YZ
D0X1YZ	DRUGNAME	KM-4056
D0X1YZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02GNL	TTDDRUID	D02GNL
D02GNL	DRUGNAME	KMJ-372
D02GNL	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0F5UO	TTDDRUID	D0F5UO
D0F5UO	DRUGNAME	KMS-88009
D0F5UO	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0F6IL	TTDDRUID	D0F6IL
D0F6IL	DRUGNAME	KNW-001
D0F6IL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G4AE	TTDDRUID	D0G4AE
D0G4AE	DRUGNAME	KNX-Monoclonal204
D0G4AE	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D02IIL	TTDDRUID	D02IIL
D02IIL	DRUGNAME	KOSN1559
D02IIL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04BHY	TTDDRUID	D04BHY
D04BHY	DRUGNAME	KP-27
D04BHY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B0MQ	TTDDRUID	D0B0MQ
D0B0MQ	DRUGNAME	KP-303
D0B0MQ	INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative

D04THU	TTDDRUID	D04THU
D04THU	DRUGNAME	KP-624
D04THU	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Investigative

D0Z1MM	TTDDRUID	D0Z1MM
D0Z1MM	DRUGNAME	KP-9928
D0Z1MM	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0A4MI	TTDDRUID	D0A4MI
D0A4MI	DRUGNAME	KPC-34
D0A4MI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q7MI	TTDDRUID	D0Q7MI
D0Q7MI	DRUGNAME	KPE-00001113
D0Q7MI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D01WCW	TTDDRUID	D01WCW
D01WCW	DRUGNAME	KPPF-1
D01WCW	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D09XSX	TTDDRUID	D09XSX
D09XSX	DRUGNAME	KPT-XXX
D09XSX	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Q3XN	TTDDRUID	D0Q3XN
D0Q3XN	DRUGNAME	KR-31360
D0Q3XN	INDICATI	Nervous system inflammation [ICD-11: 1D0Y] Investigative

D05SYO	TTDDRUID	D05SYO
D05SYO	DRUGNAME	KR-33889
D05SYO	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D05LYC	TTDDRUID	D05LYC
D05LYC	DRUGNAME	KR-62436
D05LYC	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D09SXR	TTDDRUID	D09SXR
D09SXR	DRUGNAME	KRH-102053
D09SXR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F2DD	TTDDRUID	D0F2DD
D0F2DD	DRUGNAME	KRH-102140
D0F2DD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0IL7V	TTDDRUID	D0IL7V
D0IL7V	DRUGNAME	KRP-107
D0IL7V	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0WX3N	TTDDRUID	D0WX3N
D0WX3N	DRUGNAME	KRP-110
D0WX3N	INDICATI	Constipation [ICD-11: DD91.1] Investigative

D09PNV	TTDDRUID	D09PNV
D09PNV	DRUGNAME	KSG-504
D09PNV	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Investigative

D08QDB	TTDDRUID	D08QDB
D08QDB	DRUGNAME	KSI-4088
D08QDB	INDICATI	Nematode infection [ICD-11: 1F60-1F69] Investigative

D0G5FR	TTDDRUID	D0G5FR
D0G5FR	DRUGNAME	KST-213
D0G5FR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03WAX	TTDDRUID	D03WAX
D03WAX	DRUGNAME	KST-301
D03WAX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01KJM	TTDDRUID	D01KJM
D01KJM	DRUGNAME	KST-401
D01KJM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YF6L	TTDDRUID	D0YF6L
D0YF6L	DRUGNAME	KST-5468
D0YF6L	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D02VRN	TTDDRUID	D02VRN
D02VRN	DRUGNAME	KT-1
D02VRN	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0U5JJ	TTDDRUID	D0U5JJ
D0U5JJ	DRUGNAME	KT-105
D0U5JJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C8UN	TTDDRUID	D0C8UN
D0C8UN	DRUGNAME	KT-3799
D0C8UN	INDICATI	Carbacephem [ICD-11: 1A00-1C4Z] Investigative

D0L2FR	TTDDRUID	D0L2FR
D0L2FR	DRUGNAME	KU-135
D0L2FR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05USL	TTDDRUID	D05USL
D05USL	DRUGNAME	KU-55933
D05USL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G4ID	TTDDRUID	D0G4ID
D0G4ID	DRUGNAME	KUR-024
D0G4ID	INDICATI	Bone injury [ICD-11: ND56.Y] Investigative

D0F5NG	TTDDRUID	D0F5NG
D0F5NG	DRUGNAME	KUR-114
D0F5NG	INDICATI	Bone injury [ICD-11: ND56.Y] Investigative

D0E8NW	TTDDRUID	D0E8NW
D0E8NW	DRUGNAME	KUR-115
D0E8NW	INDICATI	Spinal disease [ICD-11: FA72] Investigative

D0U7GE	TTDDRUID	D0U7GE
D0U7GE	DRUGNAME	KUR-116
D0U7GE	INDICATI	Spinal disease [ICD-11: FA72] Investigative

D02PVS	TTDDRUID	D02PVS
D02PVS	DRUGNAME	KUR-213
D02PVS	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D09ZWI	TTDDRUID	D09ZWI
D09ZWI	DRUGNAME	KUR-521
D09ZWI	INDICATI	Back pain [ICD-11: ME84.Z] Investigative

D00PDQ	TTDDRUID	D00PDQ
D00PDQ	DRUGNAME	Kuzbanian
D00PDQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AX3M	TTDDRUID	D0AX3M
D0AX3M	DRUGNAME	KW-2581
D0AX3M	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0U7CP	TTDDRUID	D0U7CP
D0U7CP	DRUGNAME	KX-03
D0U7CP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0I0SH	TTDDRUID	D0I0SH
D0I0SH	DRUGNAME	KY-021
D0I0SH	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0V9MG	TTDDRUID	D0V9MG
D0V9MG	DRUGNAME	KY-382
D0V9MG	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0K5RX	TTDDRUID	D0K5RX
D0K5RX	DRUGNAME	KYS-05050
D0K5RX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05CRG	TTDDRUID	D05CRG
D05CRG	DRUGNAME	L-054852
D05CRG	INDICATI	Acromegaly [ICD-11: 5A60.0] Investigative

D0M3AR	TTDDRUID	D0M3AR
D0M3AR	DRUGNAME	L-168049
D0M3AR	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0W8DG	TTDDRUID	D0W8DG
D0W8DG	DRUGNAME	L-19-PDT
D0W8DG	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D06LKA	TTDDRUID	D06LKA
D06LKA	DRUGNAME	L2-05
D06LKA	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D05EPY	TTDDRUID	D05EPY
D05EPY	DRUGNAME	L-693612
D05EPY	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0QN6U	TTDDRUID	D0QN6U
D0QN6U	DRUGNAME	L-790070
D0QN6U	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0D0LD	TTDDRUID	D0D0LD
D0D0LD	DRUGNAME	L-873724
D0D0LD	INDICATI	Asthma [ICD-11: CA23] Investigative

D07DTC	TTDDRUID	D07DTC
D07DTC	DRUGNAME	L-97-1 intravenous
D07DTC	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D03MTY	TTDDRUID	D03MTY
D03MTY	DRUGNAME	LA22-radioimmunoconjugates
D03MTY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05GSI	TTDDRUID	D05GSI
D05GSI	DRUGNAME	LA-480
D05GSI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W3JA	TTDDRUID	D0W3JA
D0W3JA	DRUGNAME	LA-8045
D0W3JA	INDICATI	Acute coronary syndrome [ICD-11: BA41] Investigative

D0I1RW	TTDDRUID	D0I1RW
D0I1RW	DRUGNAME	Labeled FSH superagonist
D0I1RW	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0B5JV	TTDDRUID	D0B5JV
D0B5JV	DRUGNAME	Labeled LH superagonist
D0B5JV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0R6XI	TTDDRUID	D0R6XI
D0R6XI	DRUGNAME	Labeled TSH superagonists
D0R6XI	INDICATI	Thyroid cancer [ICD-11: 2D10] Investigative

D08GNY	TTDDRUID	D08GNY
D08GNY	DRUGNAME	Lactococcus lactis anti-IL-27
D08GNY	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0F8HX	TTDDRUID	D0F8HX
D0F8HX	DRUGNAME	Lactoquinomycin
D0F8HX	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Investigative

D0RH0J	TTDDRUID	D0RH0J
D0RH0J	DRUGNAME	LAM-111
D0RH0J	INDICATI	Muscular dystrophy [ICD-11: 8C70] Investigative

D01FRK	TTDDRUID	D01FRK
D01FRK	DRUGNAME	LA-N8
D01FRK	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative

D05RWN	TTDDRUID	D05RWN
D05RWN	DRUGNAME	Lanthanum polystyrene sulfonate
D05RWN	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative

D0VK9H	TTDDRUID	D0VK9H
D0VK9H	DRUGNAME	Lantibiotic-based proteins
D0VK9H	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D08WRI	TTDDRUID	D08WRI
D08WRI	DRUGNAME	Lantibiotic-based recombinant protein
D08WRI	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0TU0F	TTDDRUID	D0TU0F
D0TU0F	DRUGNAME	LAP-001
D0TU0F	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D03WCT	TTDDRUID	D03WCT
D03WCT	DRUGNAME	LAS-189913
D03WCT	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0O8TE	TTDDRUID	D0O8TE
D0O8TE	DRUGNAME	LASSBio-1524
D0O8TE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D01UXP	TTDDRUID	D01UXP
D01UXP	DRUGNAME	LASSBio-294
D01UXP	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0F4LI	TTDDRUID	D0F4LI
D0F4LI	DRUGNAME	LASSBio-881
D0F4LI	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0HJ9U	TTDDRUID	D0HJ9U
D0HJ9U	DRUGNAME	LAU-0901
D0HJ9U	INDICATI	Brain ischaemia [ICD-11: 8B1Z] Investigative

D0XN8W	TTDDRUID	D0XN8W
D0XN8W	DRUGNAME	LB-101
D0XN8W	INDICATI	Memory loss [ICD-11: MB21.1Z] Investigative

D0E6RE	TTDDRUID	D0E6RE
D0E6RE	DRUGNAME	LB-102
D0E6RE	INDICATI	Memory loss [ICD-11: MB21.1Z] Investigative

D01CFQ	TTDDRUID	D01CFQ
D01CFQ	DRUGNAME	LB-2.1
D01CFQ	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D09QTS	TTDDRUID	D09QTS
D09QTS	DRUGNAME	LC-01
D09QTS	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative

D0SW8L	TTDDRUID	D0SW8L
D0SW8L	DRUGNAME	LC-280126
D0SW8L	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D0K0LA	TTDDRUID	D0K0LA
D0K0LA	DRUGNAME	LC34AD3
D0K0LA	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0X5ZH	TTDDRUID	D0X5ZH
D0X5ZH	DRUGNAME	LC-445
D0X5ZH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O2TG	TTDDRUID	D0O2TG
D0O2TG	DRUGNAME	LCA-AAV7
D0O2TG	INDICATI	Visual disturbance [ICD-11: 9D90] Investigative

D0BI9W	TTDDRUID	D0BI9W
D0BI9W	DRUGNAME	Lck tyrosine kinase inhibitors
D0BI9W	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D09DGE	TTDDRUID	D09DGE
D09DGE	DRUGNAME	LD-101
D09DGE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03HTZ	TTDDRUID	D03HTZ
D03HTZ	DRUGNAME	LD201t1
D03HTZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D07INU	TTDDRUID	D07INU
D07INU	DRUGNAME	LDN-22684
D07INU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0D0RJ	TTDDRUID	D0D0RJ
D0D0RJ	DRUGNAME	LED-209
D0D0RJ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0X7ZG	TTDDRUID	D0X7ZG
D0X7ZG	DRUGNAME	Ledgins
D0X7ZG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D01ATS	TTDDRUID	D01ATS
D01ATS	DRUGNAME	LEO-90110
D01ATS	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D08KHD	TTDDRUID	D08KHD
D08KHD	DRUGNAME	Leonurine
D08KHD	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D0C6TL	TTDDRUID	D0C6TL
D0C6TL	DRUGNAME	Leptin
D0C6TL	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0U6DZ	TTDDRUID	D0U6DZ
D0U6DZ	DRUGNAME	L-erythro-3-hydroxyaspartate
D0U6DZ	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D00FIV	TTDDRUID	D00FIV
D00FIV	DRUGNAME	Leukotoxin
D00FIV	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0X8PU	TTDDRUID	D0X8PU
D0X8PU	DRUGNAME	Leukozene
D0X8PU	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative

D08KCA	TTDDRUID	D08KCA
D08KCA	DRUGNAME	Leupeptin
D08KCA	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D03HSS	TTDDRUID	D03HSS
D03HSS	DRUGNAME	LG-1041
D03HSS	INDICATI	Hunter syndrome [ICD-11: 5C56.31] Investigative

D0K2LR	TTDDRUID	D0K2LR
D0K2LR	DRUGNAME	LG-611
D0K2LR	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D01VZQ	TTDDRUID	D01VZQ
D01VZQ	DRUGNAME	LG-723
D01VZQ	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0Q7XA	TTDDRUID	D0Q7XA
D0Q7XA	DRUGNAME	LG-888
D0Q7XA	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative

D0P8ME	TTDDRUID	D0P8ME
D0P8ME	DRUGNAME	LG-889
D0P8ME	INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative

D0Z2JR	TTDDRUID	D0Z2JR
D0Z2JR	DRUGNAME	LG-911
D0Z2JR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02CXA	TTDDRUID	D02CXA
D02CXA	DRUGNAME	LG-912
D02CXA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0U3HU	TTDDRUID	D0U3HU
D0U3HU	DRUGNAME	LH superagonists
D0U3HU	INDICATI	Infertility [ICD-11: GB04] Investigative

D0AZ5O	TTDDRUID	D0AZ5O
D0AZ5O	DRUGNAME	LHD-4
D0AZ5O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V6KF	TTDDRUID	D0V6KF
D0V6KF	DRUGNAME	LHRH
D0V6KF	INDICATI	Endometriosis [ICD-11: GA10] Investigative

D0G6IH	TTDDRUID	D0G6IH
D0G6IH	DRUGNAME	LIBS project
D0G6IH	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative

D0E0GC	TTDDRUID	D0E0GC
D0E0GC	DRUGNAME	LIM-0723
D0E0GC	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D0C0QK	TTDDRUID	D0C0QK
D0C0QK	DRUGNAME	LIM-0744
D0C0QK	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D05KSY	TTDDRUID	D05KSY
D05KSY	DRUGNAME	LIM-0746
D05KSY	INDICATI	Cholesterol metabolism disorder [ICD-11: 5C8Z] Investigative

D0A7NI	TTDDRUID	D0A7NI
D0A7NI	DRUGNAME	LIM-5310
D0A7NI	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D02RXZ	TTDDRUID	D02RXZ
D02RXZ	DRUGNAME	LIM-kinase 2 inhibitors
D02RXZ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0VA3U	TTDDRUID	D0VA3U
D0VA3U	DRUGNAME	Lincosamide antibacterials
D0VA3U	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0J4HT	TTDDRUID	D0J4HT
D0J4HT	DRUGNAME	Lipid chaperones
D0J4HT	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D09KQC	TTDDRUID	D09KQC
D09KQC	DRUGNAME	Lipid soluble antioxidants
D09KQC	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0IW8I	TTDDRUID	D0IW8I
D0IW8I	DRUGNAME	LipoNeu
D0IW8I	INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative

D0B0BQ	TTDDRUID	D0B0BQ
D0B0BQ	DRUGNAME	Lipopeptide antibiotic program, bacterial infections
D0B0BQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D08PZF	TTDDRUID	D08PZF
D08PZF	DRUGNAME	Liposomal disintergrin
D08PZF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01LBI	TTDDRUID	D01LBI
D01LBI	DRUGNAME	LIV-1205
D01LBI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04OGS	TTDDRUID	D04OGS
D04OGS	DRUGNAME	LIV-2008
D04OGS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08FWO	TTDDRUID	D08FWO
D08FWO	DRUGNAME	Lixte-1.2
D08FWO	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D01LEO	TTDDRUID	D01LEO
D01LEO	DRUGNAME	LJJ-10
D01LEO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V6DF	TTDDRUID	D0V6DF
D0V6DF	DRUGNAME	LJP-1207
D0V6DF	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0M6TA	TTDDRUID	D0M6TA
D0M6TA	DRUGNAME	LK-157
D0M6TA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0K8HA	TTDDRUID	D0K8HA
D0K8HA	DRUGNAME	LL-6531
D0K8HA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0NS2U	TTDDRUID	D0NS2U
D0NS2U	DRUGNAME	LLL-12
D0NS2U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X6XC	TTDDRUID	D0X6XC
D0X6XC	DRUGNAME	Lm Ft
D0X6XC	INDICATI	Tularemia [ICD-11: 1B94] Investigative

D0R2YD	TTDDRUID	D0R2YD
D0R2YD	DRUGNAME	Lm Melanoma
D0R2YD	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0C6VK	TTDDRUID	D0C6VK
D0C6VK	DRUGNAME	Lm Prostate
D0C6VK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D01QNO	TTDDRUID	D01QNO
D01QNO	DRUGNAME	LM-13765
D01QNO	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D06EIY	TTDDRUID	D06EIY
D06EIY	DRUGNAME	Lm-Malaria
D06EIY	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0JS7E	TTDDRUID	D0JS7E
D0JS7E	DRUGNAME	LMS-611 inhalant
D0JS7E	INDICATI	Asthma [ICD-11: CA23] Investigative

D0QN3Q	TTDDRUID	D0QN3Q
D0QN3Q	DRUGNAME	LNA anti-miR-155
D0QN3Q	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative

D04TZK	TTDDRUID	D04TZK
D04TZK	DRUGNAME	LNK-3186
D04TZK	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D01ZFM	TTDDRUID	D01ZFM
D01ZFM	DRUGNAME	LNK-3248
D01ZFM	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0R9UQ	TTDDRUID	D0R9UQ
D0R9UQ	DRUGNAME	Long-acting Factor VII conjugate
D0R9UQ	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0C7GJ	TTDDRUID	D0C7GJ
D0C7GJ	DRUGNAME	Long-acting factor VIII
D0C7GJ	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D09HCE	TTDDRUID	D09HCE
D09HCE	DRUGNAME	Long-acting FSH conjugate
D09HCE	INDICATI	Female infertility [ICD-11: GA31.Z] Investigative

D0Y4QY	TTDDRUID	D0Y4QY
D0Y4QY	DRUGNAME	Long-acting IL-11 analog
D0Y4QY	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D08YRM	TTDDRUID	D08YRM
D08YRM	DRUGNAME	Long-acting interferon beta conjugate
D08YRM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0Z5DJ	TTDDRUID	D0Z5DJ
D0Z5DJ	DRUGNAME	Long-acting oxyntomodulin
D0Z5DJ	INDICATI	Obesity [ICD-11: 5B81] Investigative

D05EMW	TTDDRUID	D05EMW
D05EMW	DRUGNAME	Long-acting polysialic acid-interferon alpha 2b conjugate
D05EMW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D02WGD	TTDDRUID	D02WGD
D02WGD	DRUGNAME	LOR-220
D02WGD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00QLG	TTDDRUID	D00QLG
D00QLG	DRUGNAME	Lovaxin M
D00QLG	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0G3RW	TTDDRUID	D0G3RW
D0G3RW	DRUGNAME	Low toxic paclitaxel derivative
D0G3RW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q7XS	TTDDRUID	D0Q7XS
D0Q7XS	DRUGNAME	LP-0067
D0Q7XS	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0P3DC	TTDDRUID	D0P3DC
D0P3DC	DRUGNAME	LP-10
D0P3DC	INDICATI	Cystitis [ICD-11: GC00] Investigative

D0K0MB	TTDDRUID	D0K0MB
D0K0MB	DRUGNAME	LP-10218
D0K0MB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V6JJ	TTDDRUID	D0V6JJ
D0V6JJ	DRUGNAME	LP-1810
D0V6JJ	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0H6LE	TTDDRUID	D0H6LE
D0H6LE	DRUGNAME	LP-20104
D0H6LE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0WX5V	TTDDRUID	D0WX5V
D0WX5V	DRUGNAME	LP-205A1
D0WX5V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B1RM	TTDDRUID	D0B1RM
D0B1RM	DRUGNAME	LP-226A1
D0B1RM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K4MW	TTDDRUID	D0K4MW
D0K4MW	DRUGNAME	LP-30171
D0K4MW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QT9B	TTDDRUID	D0QT9B
D0QT9B	DRUGNAME	LPCN-1002
D0QT9B	INDICATI	Testosterone deficiency [ICD-11: 5A81.1] Investigative

D0U8GH	TTDDRUID	D0U8GH
D0U8GH	DRUGNAME	LPCN-1056
D0U8GH	INDICATI	Asthma [ICD-11: CA23] Investigative

D07FUH	TTDDRUID	D07FUH
D07FUH	DRUGNAME	LPCN-1087
D07FUH	INDICATI	Cough [ICD-11: MD12] Investigative

D0R3YT	TTDDRUID	D0R3YT
D0R3YT	DRUGNAME	LPCN-1090
D0R3YT	INDICATI	Cough [ICD-11: MD12] Investigative

D0X3GD	TTDDRUID	D0X3GD
D0X3GD	DRUGNAME	LPCVD
D0X3GD	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D08EQQ	TTDDRUID	D08EQQ
D08EQQ	DRUGNAME	LPD-1050
D08EQQ	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D06LEC	TTDDRUID	D06LEC
D06LEC	DRUGNAME	LPD-608
D06LEC	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D09UQS	TTDDRUID	D09UQS
D09UQS	DRUGNAME	LPG-1030I
D09UQS	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0P4QX	TTDDRUID	D0P4QX
D0P4QX	DRUGNAME	LPG-1030S
D0P4QX	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative

D0X9TM	TTDDRUID	D0X9TM
D0X9TM	DRUGNAME	LPMD
D0X9TM	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D06HGM	TTDDRUID	D06HGM
D06HGM	DRUGNAME	LPO-1010CA
D06HGM	INDICATI	Cataract [ICD-11: 9B10] Investigative

D0MH8K	TTDDRUID	D0MH8K
D0MH8K	DRUGNAME	LPO-1010CSR
D0MH8K	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D01MBM	TTDDRUID	D01MBM
D01MBM	DRUGNAME	LPO-1010DR
D01MBM	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative

D06WZQ	TTDDRUID	D06WZQ
D06WZQ	DRUGNAME	LPO-1010UV
D06WZQ	INDICATI	Uveitis [ICD-11: 9A96.Z] Investigative

D0W5EY	TTDDRUID	D0W5EY
D0W5EY	DRUGNAME	LpxCi-4
D0W5EY	INDICATI	Multidrug resistant infection [ICD-11: MG51] Investigative

D09QVI	TTDDRUID	D09QVI
D09QVI	DRUGNAME	LQB-118
D09QVI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W9XF	TTDDRUID	D0W9XF
D0W9XF	DRUGNAME	LRN-281
D0W9XF	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative

D07JDR	TTDDRUID	D07JDR
D07JDR	DRUGNAME	LRN-672
D07JDR	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0G1OS	TTDDRUID	D0G1OS
D0G1OS	DRUGNAME	LT-0301
D0G1OS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z3LN	TTDDRUID	D0Z3LN
D0Z3LN	DRUGNAME	LT-1945
D0Z3LN	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative

D00MZC	TTDDRUID	D00MZC
D00MZC	DRUGNAME	LTX-100
D00MZC	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0GG8N	TTDDRUID	D0GG8N
D0GG8N	DRUGNAME	LTX-200
D0GG8N	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0F6WW	TTDDRUID	D0F6WW
D0F6WW	DRUGNAME	LU-AA33810
D0F6WW	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D06MWU	TTDDRUID	D06MWU
D06MWU	DRUGNAME	LUF-5833
D06MWU	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D01BUT	TTDDRUID	D01BUT
D01BUT	DRUGNAME	LXT-101
D01BUT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D01NKF	TTDDRUID	D01NKF
D01NKF	DRUGNAME	LY-1-100
D01NKF	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0C5WK	TTDDRUID	D0C5WK
D0C5WK	DRUGNAME	LY-392098
D0C5WK	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D02CTZ	TTDDRUID	D02CTZ
D02CTZ	DRUGNAME	LY433221
D02CTZ	INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative

D09CKT	TTDDRUID	D09CKT
D09CKT	DRUGNAME	LY433222
D09CKT	INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative

D03SYC	TTDDRUID	D03SYC
D03SYC	DRUGNAME	LY-GSK-3i
D03SYC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00LZH	TTDDRUID	D00LZH
D00LZH	DRUGNAME	Lymphocyte-specific tyrosine kinase inhibitors
D00LZH	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0B7XF	TTDDRUID	D0B7XF
D0B7XF	DRUGNAME	Lymphozene
D0B7XF	INDICATI	B-cell lymphoma [ICD-11: 2A86] Investigative

D0Y8YE	TTDDRUID	D0Y8YE
D0Y8YE	DRUGNAME	Lysine-specific demethylase 1 inhibitors
D0Y8YE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0CW3B	TTDDRUID	D0CW3B
D0CW3B	DRUGNAME	M-101
D0CW3B	INDICATI	Blood transfusion [ICD-11: QB98] Investigative

D04EAZ	TTDDRUID	D04EAZ
D04EAZ	DRUGNAME	M102.4
D04EAZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0Z0ZJ	TTDDRUID	D0Z0ZJ
D0Z0ZJ	DRUGNAME	M-108101
D0Z0ZJ	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D03JCT	TTDDRUID	D03JCT
D03JCT	DRUGNAME	M-110101
D03JCT	INDICATI	Seborrhea [ICD-11: ED91.2] Investigative

D0XN2L	TTDDRUID	D0XN2L
D0XN2L	DRUGNAME	M-119
D0XN2L	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative

D09HYI	TTDDRUID	D09HYI
D09HYI	DRUGNAME	M-2001
D09HYI	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0X9NG	TTDDRUID	D0X9NG
D0X9NG	DRUGNAME	M2del11 H1N1
D0X9NG	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0L1EX	TTDDRUID	D0L1EX
D0L1EX	DRUGNAME	M2del11HAavir H5N1
D0L1EX	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0RI6L	TTDDRUID	D0RI6L
D0RI6L	DRUGNAME	M-3000
D0RI6L	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00BXZ	TTDDRUID	D00BXZ
D00BXZ	DRUGNAME	M-402
D00BXZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V9BP	TTDDRUID	D0V9BP
D0V9BP	DRUGNAME	M-410
D0V9BP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LJ7R	TTDDRUID	D0LJ7R
D0LJ7R	DRUGNAME	M5
D0LJ7R	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0Y8VC	TTDDRUID	D0Y8VC
D0Y8VC	DRUGNAME	M-5200
D0Y8VC	INDICATI	Skin allergy [ICD-11: 4A82] Investigative

D05JQD	TTDDRUID	D05JQD
D05JQD	DRUGNAME	M-6040
D05JQD	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0AD6Z	TTDDRUID	D0AD6Z
D0AD6Z	DRUGNAME	mab 224G11
D0AD6Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C1BL	TTDDRUID	D0C1BL
D0C1BL	DRUGNAME	mab 37.1
D0C1BL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04XSG	TTDDRUID	D04XSG
D04XSG	DRUGNAME	mab therapy, cancer, Igenica
D04XSG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LE4M	TTDDRUID	D0LE4M
D0LE4M	DRUGNAME	mab-338
D0LE4M	INDICATI	Metapneumovirus infection [ICD-11: CA40.13] Investigative

D0V0JV	TTDDRUID	D0V0JV
D0V0JV	DRUGNAME	mabionHER2
D0V0JV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0B1GB	TTDDRUID	D0B1GB
D0B1GB	DRUGNAME	mabs targeting human growth hormone
D0B1GB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZE8Q	TTDDRUID	D0ZE8Q
D0ZE8Q	DRUGNAME	mabs targeting PAR-1
D0ZE8Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H0KA	TTDDRUID	D0H0KA
D0H0KA	DRUGNAME	Macbecin
D0H0KA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J5EQ	TTDDRUID	D0J5EQ
D0J5EQ	DRUGNAME	Maclizumab
D0J5EQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0QW1V	TTDDRUID	D0QW1V
D0QW1V	DRUGNAME	MAD-001
D0QW1V	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative

D07GKS	TTDDRUID	D07GKS
D07GKS	DRUGNAME	MAGE-101
D07GKS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0FL9B	TTDDRUID	D0FL9B
D0FL9B	DRUGNAME	Magnesium/zinc/lithium salts
D0FL9B	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D04XOX	TTDDRUID	D04XOX
D04XOX	DRUGNAME	Malate synthase
D04XOX	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D01DGR	TTDDRUID	D01DGR
D01DGR	DRUGNAME	Male contraceptive
D01DGR	INDICATI	Contraception [ICD-11: QA21] Investigative

D08JNG	TTDDRUID	D08JNG
D08JNG	DRUGNAME	Malonic acid
D08JNG	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D00STZ	TTDDRUID	D00STZ
D00STZ	DRUGNAME	Mam-05.200
D00STZ	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D00DHT	TTDDRUID	D00DHT
D00DHT	DRUGNAME	Mammalian sterile 20-like kinase 1 gene eluting stent
D00DHT	INDICATI	Artery stenosis [ICD-11: BD52] Investigative

D0ZY7I	TTDDRUID	D0ZY7I
D0ZY7I	DRUGNAME	MAPKAP kinase 2 inhibitors
D0ZY7I	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0E2WE	TTDDRUID	D0E2WE
D0E2WE	DRUGNAME	Mapp-66
D0E2WE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D03OYY	TTDDRUID	D03OYY
D03OYY	DRUGNAME	MAR-531
D03OYY	INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative

D0R9GY	TTDDRUID	D0R9GY
D0R9GY	DRUGNAME	Marine natural products
D0R9GY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D05TUQ	TTDDRUID	D05TUQ
D05TUQ	DRUGNAME	MAT-302
D05TUQ	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0X7ZS	TTDDRUID	D0X7ZS
D0X7ZS	DRUGNAME	MAT-303
D0X7ZS	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0O6LY	TTDDRUID	D0O6LY
D0O6LY	DRUGNAME	MAT-304
D0O6LY	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00TPC	TTDDRUID	D00TPC
D00TPC	DRUGNAME	MAT-401
D00TPC	INDICATI	Aspergillosis [ICD-11: 1F20] Investigative

D00WHC	TTDDRUID	D00WHC
D00WHC	DRUGNAME	MB-03966
D00WHC	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Investigative

D0O4TF	TTDDRUID	D0O4TF
D0O4TF	DRUGNAME	MB-11262
D0O4TF	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D08QRE	TTDDRUID	D08QRE
D08QRE	DRUGNAME	MB-11319
D08QRE	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D08LJY	TTDDRUID	D08LJY
D08LJY	DRUGNAME	MB-312
D08LJY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02NUS	TTDDRUID	D02NUS
D02NUS	DRUGNAME	MB-314
D02NUS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01ALP	TTDDRUID	D01ALP
D01ALP	DRUGNAME	MBC-31
D01ALP	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D08QPJ	TTDDRUID	D08QPJ
D08QPJ	DRUGNAME	MBI-2401
D08QPJ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0D6PG	TTDDRUID	D0D6PG
D0D6PG	DRUGNAME	MBS-101
D0D6PG	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D03VKF	TTDDRUID	D03VKF
D03VKF	DRUGNAME	MBS-101C
D03VKF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0I5IS	TTDDRUID	D0I5IS
D0I5IS	DRUGNAME	MBS-103
D0I5IS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0T3NH	TTDDRUID	D0T3NH
D0T3NH	DRUGNAME	MBS-105
D0T3NH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0K0OU	TTDDRUID	D0K0OU
D0K0OU	DRUGNAME	MBX-1684
D0K0OU	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D0W0MD	TTDDRUID	D0W0MD
D0W0MD	DRUGNAME	MBX2329
D0W0MD	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D02UXK	TTDDRUID	D02UXK
D02UXK	DRUGNAME	MBX-3254
D02UXK	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0B4EG	TTDDRUID	D0B4EG
D0B4EG	DRUGNAME	MBX-500
D0B4EG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0G5RT	TTDDRUID	D0G5RT
D0G5RT	DRUGNAME	MC-113
D0G5RT	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D05BLG	TTDDRUID	D05BLG
D05BLG	DRUGNAME	MC-116
D05BLG	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0J4NR	TTDDRUID	D0J4NR
D0J4NR	DRUGNAME	MC-4001
D0J4NR	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D00GPZ	TTDDRUID	D00GPZ
D00GPZ	DRUGNAME	MCD inhibitors
D00GPZ	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0IL1B	TTDDRUID	D0IL1B
D0IL1B	DRUGNAME	MCD-386/glycopyrrolate
D0IL1B	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0PC8Q	TTDDRUID	D0PC8Q
D0PC8Q	DRUGNAME	MCF
D0PC8Q	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D07JCI	TTDDRUID	D07JCI
D07JCI	DRUGNAME	MCHR1 antagonists
D07JCI	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0KL7G	TTDDRUID	D0KL7G
D0KL7G	DRUGNAME	MCL-1-specific antisense oligonucleotide + midostaurin(PKC412)
D0KL7G	INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Investigative

D06GGT	TTDDRUID	D06GGT
D06GGT	DRUGNAME	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)
D06GGT	INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Investigative

D0QA1M	TTDDRUID	D0QA1M
D0QA1M	DRUGNAME	MCP-203
D0QA1M	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D00HDC	TTDDRUID	D00HDC
D00HDC	DRUGNAME	MCP-204
D00HDC	INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Investigative

D0O7NF	TTDDRUID	D0O7NF
D0O7NF	DRUGNAME	MCP-205
D0O7NF	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D0H7PS	TTDDRUID	D0H7PS
D0H7PS	DRUGNAME	MCT-175
D0H7PS	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D03TAP	TTDDRUID	D03TAP
D03TAP	DRUGNAME	MCT-275
D03TAP	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D09JJG	TTDDRUID	D09JJG
D09JJG	DRUGNAME	MCT-465
D09JJG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I4PB	TTDDRUID	D0I4PB
D0I4PB	DRUGNAME	MCT-485
D0I4PB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09VQW	TTDDRUID	D09VQW
D09VQW	DRUGNAME	MCTP-39
D09VQW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0F4RM	TTDDRUID	D0F4RM
D0F4RM	DRUGNAME	MD-2009
D0F4RM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0L6WT	TTDDRUID	D0L6WT
D0L6WT	DRUGNAME	MD-921
D0L6WT	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0G6CH	TTDDRUID	D0G6CH
D0G6CH	DRUGNAME	MD-990
D0G6CH	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D0PY5R	TTDDRUID	D0PY5R
D0PY5R	DRUGNAME	MDA-106
D0PY5R	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D06SRX	TTDDRUID	D06SRX
D06SRX	DRUGNAME	MDA-19
D06SRX	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D06NMY	TTDDRUID	D06NMY
D06NMY	DRUGNAME	MDC-1231
D06NMY	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D00JFN	TTDDRUID	D00JFN
D00JFN	DRUGNAME	MDC-917
D00JFN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00AXT	TTDDRUID	D00AXT
D00AXT	DRUGNAME	MDC-922
D00AXT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00QTL	TTDDRUID	D00QTL
D00QTL	DRUGNAME	MDDR 184045
D00QTL	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0N8JJ	TTDDRUID	D0N8JJ
D0N8JJ	DRUGNAME	MDDR 217769
D0N8JJ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D01EAG	TTDDRUID	D01EAG
D01EAG	DRUGNAME	MDDR 287569
D01EAG	INDICATI	Urinary incontinence [ICD-11: MF50.2] Investigative

D0P1MI	TTDDRUID	D0P1MI
D0P1MI	DRUGNAME	MDDR 347017
D0P1MI	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0WD8R	TTDDRUID	D0WD8R
D0WD8R	DRUGNAME	MDP-01
D0WD8R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00MRH	TTDDRUID	D00MRH
D00MRH	DRUGNAME	MDPTQ
D00MRH	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D02NJK	TTDDRUID	D02NJK
D02NJK	DRUGNAME	MDR-03030
D02NJK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D09CLX	TTDDRUID	D09CLX
D09CLX	DRUGNAME	MDT-006
D09CLX	INDICATI	Constipation [ICD-11: DD91.1] Investigative

D04OPS	TTDDRUID	D04OPS
D04OPS	DRUGNAME	MDT-011
D04OPS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0T1RJ	TTDDRUID	D0T1RJ
D0T1RJ	DRUGNAME	MDT-012
D0T1RJ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D07ZZX	TTDDRUID	D07ZZX
D07ZZX	DRUGNAME	MDX-1110
D07ZZX	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D03SXQ	TTDDRUID	D03SXQ
D03SXQ	DRUGNAME	MDX-1140
D03SXQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0IW9Q	TTDDRUID	D0IW9Q
D0IW9Q	DRUGNAME	MDX-1147
D0IW9Q	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0B8KE	TTDDRUID	D0B8KE
D0B8KE	DRUGNAME	MDX-1204
D0B8KE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07XCQ	TTDDRUID	D07XCQ
D07XCQ	DRUGNAME	MDX-1414
D07XCQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L6HF	TTDDRUID	D0L6HF
D0L6HF	DRUGNAME	MDX-1459
D0L6HF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06HGO	TTDDRUID	D06HGO
D06HGO	DRUGNAME	MDY-1001
D06HGO	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D0X2PR	TTDDRUID	D0X2PR
D0X2PR	DRUGNAME	MEDI-541
D0X2PR	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0Q3WP	TTDDRUID	D0Q3WP
D0Q3WP	DRUGNAME	MEDI-553
D0Q3WP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0K2EC	TTDDRUID	D0K2EC
D0K2EC	DRUGNAME	MEDI-77
D0K2EC	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0B3ID	TTDDRUID	D0B3ID
D0B3ID	DRUGNAME	Medi-NK
D0B3ID	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D09RSN	TTDDRUID	D09RSN
D09RSN	DRUGNAME	MediPhage MRPA
D09RSN	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D0A6RI	TTDDRUID	D0A6RI
D0A6RI	DRUGNAME	Meganucleases
D0A6RI	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0D1BC	TTDDRUID	D0D1BC
D0D1BC	DRUGNAME	Melanocortin-4 Receptor antagonist
D0D1BC	INDICATI	Anorexia nervosa cachexia [ICD-11: 6B80] Investigative

D0E0OI	TTDDRUID	D0E0OI
D0E0OI	DRUGNAME	Memex
D0E0OI	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0E6QI	TTDDRUID	D0E6QI
D0E6QI	DRUGNAME	MEN-14295
D0E6QI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T0BP	TTDDRUID	D0T0BP
D0T0BP	DRUGNAME	MenBioVax
D0T0BP	INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative

D05RPT	TTDDRUID	D05RPT
D05RPT	DRUGNAME	MER-2101
D05RPT	INDICATI	Asthma [ICD-11: CA23] Investigative

D0P4KV	TTDDRUID	D0P4KV
D0P4KV	DRUGNAME	MesoStem
D0P4KV	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0W5KO	TTDDRUID	D0W5KO
D0W5KO	DRUGNAME	MesoTarg
D0W5KO	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D08OKW	TTDDRUID	D08OKW
D08OKW	DRUGNAME	Metalfullerene
D08OKW	INDICATI	Alopecia [ICD-11: ED70] Investigative

D00HCM	TTDDRUID	D00HCM
D00HCM	DRUGNAME	Metallo-levodopa
D00HCM	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0Q6DV	TTDDRUID	D0Q6DV
D0Q6DV	DRUGNAME	Metallo-SAHA
D0Q6DV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N1AY	TTDDRUID	D0N1AY
D0N1AY	DRUGNAME	Metallothionein
D0N1AY	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D06XWF	TTDDRUID	D06XWF
D06XWF	DRUGNAME	Metallo-topiramate
D06XWF	INDICATI	Seizure disorder [ICD-11: 8A6Z] Investigative

D05JYW	TTDDRUID	D05JYW
D05JYW	DRUGNAME	Metallo-zanamivir
D05JYW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D00BBB	TTDDRUID	D00BBB
D00BBB	DRUGNAME	MetPril
D00BBB	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0WN7T	TTDDRUID	D0WN7T
D0WN7T	DRUGNAME	MFH-147
D0WN7T	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0S3LF	TTDDRUID	D0S3LF
D0S3LF	DRUGNAME	MFH-244
D0S3LF	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D0EV6U	TTDDRUID	D0EV6U
D0EV6U	DRUGNAME	MFQ
D0EV6U	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0YX8X	TTDDRUID	D0YX8X
D0YX8X	DRUGNAME	MG-1104
D0YX8X	INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative

D03UAO	TTDDRUID	D03UAO
D03UAO	DRUGNAME	MG-1105
D03UAO	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D07DIS	TTDDRUID	D07DIS
D07DIS	DRUGNAME	MG-1110
D07DIS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09IGF	TTDDRUID	D09IGF
D09IGF	DRUGNAME	MG-28
D09IGF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06YAK	TTDDRUID	D06YAK
D06YAK	DRUGNAME	MG-3
D06YAK	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D00QCV	TTDDRUID	D00QCV
D00QCV	DRUGNAME	MG-401
D00QCV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L3JR	TTDDRUID	D0L3JR
D0L3JR	DRUGNAME	MG-516
D0L3JR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BR0D	TTDDRUID	D0BR0D
D0BR0D	DRUGNAME	MGB-101
D0BR0D	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0E5KK	TTDDRUID	D0E5KK
D0E5KK	DRUGNAME	MGluR2 PAMs
D0E5KK	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D01ERN	TTDDRUID	D01ERN
D01ERN	DRUGNAME	MGluR5 antagonists (anxiety), Novartis
D01ERN	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0E9YI	TTDDRUID	D0E9YI
D0E9YI	DRUGNAME	MGMTP140K gene-modified hematopoietic progenitor cells
D0E9YI	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D02WDO	TTDDRUID	D02WDO
D02WDO	DRUGNAME	MGN-1333
D02WDO	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0S4MX	TTDDRUID	D0S4MX
D0S4MX	DRUGNAME	MGN-1374
D0S4MX	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D01MJT	TTDDRUID	D01MJT
D01MJT	DRUGNAME	MGN-2677
D01MJT	INDICATI	Artery stenosis [ICD-11: BD52] Investigative

D09MRD	TTDDRUID	D09MRD
D09MRD	DRUGNAME	MGN-4220
D09MRD	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0F0YM	TTDDRUID	D0F0YM
D0F0YM	DRUGNAME	MGN-4893
D0F0YM	INDICATI	Polycythemia vera [ICD-11: 2A20.4] Investigative

D09UXI	TTDDRUID	D09UXI
D09UXI	DRUGNAME	MGN-5804
D09UXI	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0QJ9Z	TTDDRUID	D0QJ9Z
D0QJ9Z	DRUGNAME	MGN-6114
D0QJ9Z	INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Investigative

D00YNK	TTDDRUID	D00YNK
D00YNK	DRUGNAME	MGN-7455
D00YNK	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D02DZI	TTDDRUID	D02DZI
D02DZI	DRUGNAME	MGN-8107
D02DZI	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D03TZG	TTDDRUID	D03TZG
D03TZG	DRUGNAME	MGN-9103
D03TZG	INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative

D0YH8T	TTDDRUID	D0YH8T
D0YH8T	DRUGNAME	MI-09018
D0YH8T	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D05XYH	TTDDRUID	D05XYH
D05XYH	DRUGNAME	MIC-31
D05XYH	INDICATI	Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative

D0Q1LH	TTDDRUID	D0Q1LH
D0Q1LH	DRUGNAME	Micacides
D0Q1LH	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D08JML	TTDDRUID	D08JML
D08JML	DRUGNAME	Microxine
D08JML	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09TLF	TTDDRUID	D09TLF
D09TLF	DRUGNAME	MIF antagonists
D09TLF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0C4KE	TTDDRUID	D0C4KE
D0C4KE	DRUGNAME	MIM-3Aa
D0C4KE	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0K5BY	TTDDRUID	D0K5BY
D0K5BY	DRUGNAME	MIM-3Ae
D0K5BY	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D01ZHQ	TTDDRUID	D01ZHQ
D01ZHQ	DRUGNAME	MIM-A2
D01ZHQ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D01BJK	TTDDRUID	D01BJK
D01BJK	DRUGNAME	Mimovax
D01BJK	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09NLK	TTDDRUID	D09NLK
D09NLK	DRUGNAME	Minokine
D09NLK	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D01HTS	TTDDRUID	D01HTS
D01HTS	DRUGNAME	MIP-1231
D01HTS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06XBG	TTDDRUID	D06XBG
D06XBG	DRUGNAME	MIP-1267
D06XBG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z5UD	TTDDRUID	D0Z5UD
D0Z5UD	DRUGNAME	MIP-1375
D0Z5UD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D06FUQ	TTDDRUID	D06FUQ
D06FUQ	DRUGNAME	MIQ-003
D06FUQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D01KZV	TTDDRUID	D01KZV
D01KZV	DRUGNAME	MIQ-004
D01KZV	INDICATI	Brain cancer [ICD-11: 2A00] Investigative

D0M9TD	TTDDRUID	D0M9TD
D0M9TD	DRUGNAME	MiR-34a mimics
D0M9TD	INDICATI	Liver cancer [ICD-11: 2C12] Investigative

D0PJ9Z	TTDDRUID	D0PJ9Z
D0PJ9Z	DRUGNAME	MiRNA targeting agent
D0PJ9Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q0BL	TTDDRUID	D0Q0BL
D0Q0BL	DRUGNAME	MiRNA-based therapeutics
D0Q0BL	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D08EDE	TTDDRUID	D08EDE
D08EDE	DRUGNAME	MIRNA-Rx07
D08EDE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03TTW	TTDDRUID	D03TTW
D03TTW	DRUGNAME	MIS-416/immunogen
D03TTW	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D0S9HV	TTDDRUID	D0S9HV
D0S9HV	DRUGNAME	MitoAscorbate
D0S9HV	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative

D09EPX	TTDDRUID	D09EPX
D09EPX	DRUGNAME	MitoLinoleic
D09EPX	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative

D0FZ4X	TTDDRUID	D0FZ4X
D0FZ4X	DRUGNAME	MitoPBN
D0FZ4X	INDICATI	Mitochondrial disease [ICD-11: 5C53.Y] Investigative

D04ZZX	TTDDRUID	D04ZZX
D04ZZX	DRUGNAME	Mi-TUMEX
D04ZZX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0MM4X	TTDDRUID	D0MM4X
D0MM4X	DRUGNAME	MIV-710
D0MM4X	INDICATI	Bone metastases [ICD-11: 2D50] Investigative

D00NOL	TTDDRUID	D00NOL
D00NOL	DRUGNAME	MK-0536
D00NOL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0U3RU	TTDDRUID	D0U3RU
D0U3RU	DRUGNAME	MK-1107
D0U3RU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0NY9Q	TTDDRUID	D0NY9Q
D0NY9Q	DRUGNAME	MK2 inhibitors
D0NY9Q	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D02MXT	TTDDRUID	D02MXT
D02MXT	DRUGNAME	MK-2894
D02MXT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D08GZJ	TTDDRUID	D08GZJ
D08GZJ	DRUGNAME	MK-2918
D08GZJ	INDICATI	Migraine [ICD-11: 8A80] Investigative

D04TGU	TTDDRUID	D04TGU
D04TGU	DRUGNAME	MK-3901
D04TGU	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D05LLJ	TTDDRUID	D05LLJ
D05LLJ	DRUGNAME	MK-4815
D05LLJ	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D04DDW	TTDDRUID	D04DDW
D04DDW	DRUGNAME	MK-49
D04DDW	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06QMA	TTDDRUID	D06QMA
D06QMA	DRUGNAME	MK-5286
D06QMA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0V0YM	TTDDRUID	D0V0YM
D0V0YM	DRUGNAME	MK-5596
D0V0YM	INDICATI	Obesity [ICD-11: 5B81] Investigative

D08UDZ	TTDDRUID	D08UDZ
D08UDZ	DRUGNAME	MK-6105
D08UDZ	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D09ZPN	TTDDRUID	D09ZPN
D09ZPN	DRUGNAME	MK-6892
D09ZPN	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0W6TB	TTDDRUID	D0W6TB
D0W6TB	DRUGNAME	MK-7285
D0W6TB	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D04JSE	TTDDRUID	D04JSE
D04JSE	DRUGNAME	MK-7725
D04JSE	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0PU1W	TTDDRUID	D0PU1W
D0PU1W	DRUGNAME	MKC-180
D0PU1W	INDICATI	Obesity [ICD-11: 5B81] Investigative

D02RGZ	TTDDRUID	D02RGZ
D02RGZ	DRUGNAME	MKC-204
D02RGZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00KIU	TTDDRUID	D00KIU
D00KIU	DRUGNAME	MKC-242844
D00KIU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative

D09YHL	TTDDRUID	D09YHL
D09YHL	DRUGNAME	MKG-02
D09YHL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0IJ0Q	TTDDRUID	D0IJ0Q
D0IJ0Q	DRUGNAME	ML-436
D0IJ0Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03WMT	TTDDRUID	D03WMT
D03WMT	DRUGNAME	ML-721
D03WMT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05QMQ	TTDDRUID	D05QMQ
D05QMQ	DRUGNAME	MLN-0905
D05QMQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative

D0D8GO	TTDDRUID	D0D8GO
D0D8GO	DRUGNAME	MLR-1045
D0D8GO	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative

D0DA3D	TTDDRUID	D0DA3D
D0DA3D	DRUGNAME	MLR-1130
D0DA3D	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D05XXQ	TTDDRUID	D05XXQ
D05XXQ	DRUGNAME	MLR-1326
D05XXQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0T9LH	TTDDRUID	D0T9LH
D0T9LH	DRUGNAME	MM-131
D0T9LH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04LMJ	TTDDRUID	D04LMJ
D04LMJ	DRUGNAME	MMB-4
D04LMJ	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D0S7NS	TTDDRUID	D0S7NS
D0S7NS	DRUGNAME	MMI-0100
D0S7NS	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D07SCP	TTDDRUID	D07SCP
D07SCP	DRUGNAME	MMP-12 inhibitors
D07SCP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D04USG	TTDDRUID	D04USG
D04USG	DRUGNAME	MMP-13 inhibitors
D04USG	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0V7GB	TTDDRUID	D0V7GB
D0V7GB	DRUGNAME	MMP-13 inhibitors
D0V7GB	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D00NPE	TTDDRUID	D00NPE
D00NPE	DRUGNAME	MMP-408
D00NPE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0MM6Q	TTDDRUID	D0MM6Q
D0MM6Q	DRUGNAME	MM-POD1
D0MM6Q	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D07LGU	TTDDRUID	D07LGU
D07LGU	DRUGNAME	MMPT
D07LGU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y9NA	TTDDRUID	D0Y9NA
D0Y9NA	DRUGNAME	MN-2011
D0Y9NA	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0R3KN	TTDDRUID	D0R3KN
D0R3KN	DRUGNAME	MN-462
D0R3KN	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0I8PA	TTDDRUID	D0I8PA
D0I8PA	DRUGNAME	MN-7105
D0I8PA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B9HH	TTDDRUID	D0B9HH
D0B9HH	DRUGNAME	MN-8001
D0B9HH	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0SM6Y	TTDDRUID	D0SM6Y
D0SM6Y	DRUGNAME	MNT-02-07
D0SM6Y	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0B7EF	TTDDRUID	D0B7EF
D0B7EF	DRUGNAME	MNT-03-01
D0B7EF	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0D6XD	TTDDRUID	D0D6XD
D0D6XD	DRUGNAME	MNX-200
D0D6XD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03TGB	TTDDRUID	D03TGB
D03TGB	DRUGNAME	MOD-1002
D03TGB	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0Q4XG	TTDDRUID	D0Q4XG
D0Q4XG	DRUGNAME	MOD-3012
D0Q4XG	INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative

D0O9RV	TTDDRUID	D0O9RV
D0O9RV	DRUGNAME	MOD-5023
D0O9RV	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D0T7FO	TTDDRUID	D0T7FO
D0T7FO	DRUGNAME	MOD-7023
D0T7FO	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0V7HB	TTDDRUID	D0V7HB
D0V7HB	DRUGNAME	Modified CCR5-transduced autologous hematopoietic stem cells
D0V7HB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0X0IQ	TTDDRUID	D0X0IQ
D0X0IQ	DRUGNAME	Modified GDNF
D0X0IQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0G7XT	TTDDRUID	D0G7XT
D0G7XT	DRUGNAME	Modified PT1.2
D0G7XT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D01XXF	TTDDRUID	D01XXF
D01XXF	DRUGNAME	Modified SDF-1
D01XXF	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0J6WJ	TTDDRUID	D0J6WJ
D0J6WJ	DRUGNAME	Modified vitamin A
D0J6WJ	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D08DNV	TTDDRUID	D08DNV
D08DNV	DRUGNAME	Molecularly imprinted polymers
D08DNV	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0K4VN	TTDDRUID	D0K4VN
D0K4VN	DRUGNAME	Molecule 21
D0K4VN	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00HDH	TTDDRUID	D00HDH
D00HDH	DRUGNAME	Molecule 22
D00HDH	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D05LUT	TTDDRUID	D05LUT
D05LUT	DRUGNAME	Molecule 23
D05LUT	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0P1ZR	TTDDRUID	D0P1ZR
D0P1ZR	DRUGNAME	Molecule 25
D0P1ZR	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0CW6S	TTDDRUID	D0CW6S
D0CW6S	DRUGNAME	Monoxanes
D0CW6S	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D08GSX	TTDDRUID	D08GSX
D08GSX	DRUGNAME	MOR-104
D08GSX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0L2PV	TTDDRUID	D0L2PV
D0L2PV	DRUGNAME	MOR-105
D0L2PV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0R0AO	TTDDRUID	D0R0AO
D0R0AO	DRUGNAME	MOR-205
D0R0AO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E8YS	TTDDRUID	D0E8YS
D0E8YS	DRUGNAME	MOR-206
D0E8YS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03RLC	TTDDRUID	D03RLC
D03RLC	DRUGNAME	MOR-6292
D03RLC	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0ZV7Y	TTDDRUID	D0ZV7Y
D0ZV7Y	DRUGNAME	MorphPlus
D0ZV7Y	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0A0EI	TTDDRUID	D0A0EI
D0A0EI	DRUGNAME	MP-0210
D0A0EI	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0YO2N	TTDDRUID	D0YO2N
D0YO2N	DRUGNAME	MP-0260
D0YO2N	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D09WCC	TTDDRUID	D09WCC
D09WCC	DRUGNAME	MP-0270
D09WCC	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0CI4B	TTDDRUID	D0CI4B
D0CI4B	DRUGNAME	MP-100
D0CI4B	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D08VMW	TTDDRUID	D08VMW
D08VMW	DRUGNAME	MP-529
D08VMW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C2IR	TTDDRUID	D0C2IR
D0C2IR	DRUGNAME	MP-AA-1
D0C2IR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04GGQ	TTDDRUID	D04GGQ
D04GGQ	DRUGNAME	MPC-0767
D04GGQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01WQL	TTDDRUID	D01WQL
D01WQL	DRUGNAME	MPC-9528
D01WQL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0MW1M	TTDDRUID	D0MW1M
D0MW1M	DRUGNAME	MPGES-1 inhibitors
D0MW1M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X3NK	TTDDRUID	D0X3NK
D0X3NK	DRUGNAME	MP-PN-1
D0X3NK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H9MR	TTDDRUID	D0H9MR
D0H9MR	DRUGNAME	MP-PN-2
D0H9MR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T4ZW	TTDDRUID	D0T4ZW
D0T4ZW	DRUGNAME	MP-RM-1
D0T4ZW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07QZO	TTDDRUID	D07QZO
D07QZO	DRUGNAME	MPS-AAV8
D07QZO	INDICATI	Maroteaux-lamy syndrome [ICD-11: 5C56.33] Investigative

D0T8QM	TTDDRUID	D0T8QM
D0T8QM	DRUGNAME	MQX-3016
D0T8QM	INDICATI	Keratosis [ICD-11: ED56] Investigative

D09PON	TTDDRUID	D09PON
D09PON	DRUGNAME	MRLP-098
D09PON	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0F4CT	TTDDRUID	D0F4CT
D0F4CT	DRUGNAME	MRLP-164
D0F4CT	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Investigative

D04HUC	TTDDRUID	D04HUC
D04HUC	DRUGNAME	MRNA-046
D04HUC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N9ET	TTDDRUID	D0N9ET
D0N9ET	DRUGNAME	MRSAid
D0N9ET	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00SWN	TTDDRUID	D00SWN
D00SWN	DRUGNAME	MS-806
D00SWN	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D05FSK	TTDDRUID	D05FSK
D05FSK	DRUGNAME	MSL-143438
D05FSK	INDICATI	Yersinia infection [ICD-11: 1B93] Investigative

D09VFU	TTDDRUID	D09VFU
D09VFU	DRUGNAME	MST-400
D09VFU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W4HJ	TTDDRUID	D0W4HJ
D0W4HJ	DRUGNAME	MSX-3
D0W4HJ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D03ZIK	TTDDRUID	D03ZIK
D03ZIK	DRUGNAME	MT-001
D03ZIK	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0AY6U	TTDDRUID	D0AY6U
D0AY6U	DRUGNAME	MT-003
D0AY6U	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06SYA	TTDDRUID	D06SYA
D06SYA	DRUGNAME	MT-061 lead
D06SYA	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D08RXW	TTDDRUID	D08RXW
D08RXW	DRUGNAME	MT-062
D08RXW	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D04EQF	TTDDRUID	D04EQF
D04EQF	DRUGNAME	MT-101
D04EQF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04CCK	TTDDRUID	D04CCK
D04CCK	DRUGNAME	MT-119
D04CCK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06CDP	TTDDRUID	D06CDP
D06CDP	DRUGNAME	MT-176 lead
D06CDP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D09LGV	TTDDRUID	D09LGV
D09LGV	DRUGNAME	MT-204
D09LGV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00KSU	TTDDRUID	D00KSU
D00KSU	DRUGNAME	MT-274 lead
D00KSU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D01HOI	TTDDRUID	D01HOI
D01HOI	DRUGNAME	MT-503
D01HOI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T2PT	TTDDRUID	D0T2PT
D0T2PT	DRUGNAME	MTbuVax
D0T2PT	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0G9JL	TTDDRUID	D0G9JL
D0G9JL	DRUGNAME	MTC-220
D0G9JL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01HVC	TTDDRUID	D01HVC
D01HVC	DRUGNAME	MTD-102
D01HVC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YB7F	TTDDRUID	D0YB7F
D0YB7F	DRUGNAME	MT-II
D0YB7F	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative

D0E7IZ	TTDDRUID	D0E7IZ
D0E7IZ	DRUGNAME	MTI-SAM3
D0E7IZ	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D06QCE	TTDDRUID	D06QCE
D06QCE	DRUGNAME	MTKi-328
D06QCE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P9WF	TTDDRUID	D0P9WF
D0P9WF	DRUGNAME	MTL-003
D0P9WF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L8SP	TTDDRUID	D0L8SP
D0L8SP	DRUGNAME	MTL-004
D0L8SP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A1FG	TTDDRUID	D0A1FG
D0A1FG	DRUGNAME	MTL-005
D0A1FG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A9TA	TTDDRUID	D0A9TA
D0A9TA	DRUGNAME	MTL-007
D0A9TA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0JY6R	TTDDRUID	D0JY6R
D0JY6R	DRUGNAME	MTL-101
D0JY6R	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0D7WS	TTDDRUID	D0D7WS
D0D7WS	DRUGNAME	MTL-102
D0D7WS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V1KA	TTDDRUID	D0V1KA
D0V1KA	DRUGNAME	MTL-104
D0V1KA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZX5I	TTDDRUID	D0ZX5I
D0ZX5I	DRUGNAME	MTOR inhibitors (cancer), Amgen
D0ZX5I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N9IN	TTDDRUID	D0N9IN
D0N9IN	DRUGNAME	MTX-25251
D0N9IN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08YNC	TTDDRUID	D08YNC
D08YNC	DRUGNAME	MU-1140-S
D08YNC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0A3EA	TTDDRUID	D0A3EA
D0A3EA	DRUGNAME	Mu5B3
D0A3EA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D07LLI	TTDDRUID	D07LLI
D07LLI	DRUGNAME	Mucin type glycoproteins
D07LLI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0Y8SS	TTDDRUID	D0Y8SS
D0Y8SS	DRUGNAME	MufroSyn
D0Y8SS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0O6JE	TTDDRUID	D0O6JE
D0O6JE	DRUGNAME	Multiform PI3K inhibitors
D0O6JE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09GPZ	TTDDRUID	D09GPZ
D09GPZ	DRUGNAME	Multi-targeted therapeutics
D09GPZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00CJQ	TTDDRUID	D00CJQ
D00CJQ	DRUGNAME	MurD ligase inhibitors
D00CJQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0ON4J	TTDDRUID	D0ON4J
D0ON4J	DRUGNAME	Muscle wasting protein therapeutics
D0ON4J	INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative

D0K2UJ	TTDDRUID	D0K2UJ
D0K2UJ	DRUGNAME	MUT-11931
D0K2UJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D02OEF	TTDDRUID	D02OEF
D02OEF	DRUGNAME	Mutant B-Raf kinase inhibitors
D02OEF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F2CH	TTDDRUID	D0F2CH
D0F2CH	DRUGNAME	Mutated growth hormone
D0F2CH	INDICATI	Acromegaly [ICD-11: 5A60.0] Investigative

D06JPG	TTDDRUID	D06JPG
D06JPG	DRUGNAME	Mutations in the dystrophin gene
D06JPG	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D05GBR	TTDDRUID	D05GBR
D05GBR	DRUGNAME	MVA CSP
D05GBR	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D08XVU	TTDDRUID	D08XVU
D08XVU	DRUGNAME	MVA-BN anthrax
D08XVU	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D0E2GH	TTDDRUID	D0E2GH
D0E2GH	DRUGNAME	MVAH5
D0E2GH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0P6YL	TTDDRUID	D0P6YL
D0P6YL	DRUGNAME	MX-35
D0P6YL	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D0R8VU	TTDDRUID	D0R8VU
D0R8VU	DRUGNAME	MyeloXen
D0R8VU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D04MFQ	TTDDRUID	D04MFQ
D04MFQ	DRUGNAME	Myotubularin
D04MFQ	INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Investigative

D05LST	TTDDRUID	D05LST
D05LST	DRUGNAME	Myrcludex B
D05LST	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D09EZU	TTDDRUID	D09EZU
D09EZU	DRUGNAME	Myrrhanol A
D09EZU	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00PLX	TTDDRUID	D00PLX
D00PLX	DRUGNAME	MystiLol
D00PLX	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D04VHL	TTDDRUID	D04VHL
D04VHL	DRUGNAME	MystiTears
D04VHL	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative

D0T1AO	TTDDRUID	D0T1AO
D0T1AO	DRUGNAME	MystiTrip
D0T1AO	INDICATI	Migraine [ICD-11: 8A80] Investigative

D0P5LX	TTDDRUID	D0P5LX
D0P5LX	DRUGNAME	N-6060
D0P5LX	INDICATI	Asthma [ICD-11: CA23] Investigative

D0VN6O	TTDDRUID	D0VN6O
D0VN6O	DRUGNAME	N-65 lacritin
D0VN6O	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative

D06ZXT	TTDDRUID	D06ZXT
D06ZXT	DRUGNAME	N-6547
D06ZXT	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0V1UV	TTDDRUID	D0V1UV
D0V1UV	DRUGNAME	N-885
D0V1UV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F4SI	TTDDRUID	D0F4SI
D0F4SI	DRUGNAME	N-9xxx
D0F4SI	INDICATI	Vascular disease [ICD-11: BE2Z] Investigative

D05WSD	TTDDRUID	D05WSD
D05WSD	DRUGNAME	NaAPR1M-74
D05WSD	INDICATI	Hookworm infection [ICD-11: 1F68] Investigative

D0V1KP	TTDDRUID	D0V1KP
D0V1KP	DRUGNAME	N-acetylardeemin
D0V1KP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M7MH	TTDDRUID	D0M7MH
D0M7MH	DRUGNAME	NAChR alpha 7 APLs
D0M7MH	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0T5ZM	TTDDRUID	D0T5ZM
D0T5ZM	DRUGNAME	NAChR APLs
D0T5ZM	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0T7PZ	TTDDRUID	D0T7PZ
D0T7PZ	DRUGNAME	NAI-107
D0T7PZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00TPI	TTDDRUID	D00TPI
D00TPI	DRUGNAME	Nalidixic Acid + Ampicillin
D00TPI	INDICATI	Typhoid fever [ICD-11: 1A07] Investigative

D05MKG	TTDDRUID	D05MKG
D05MKG	DRUGNAME	Nalmefene prodrugs
D05MKG	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative

D09JUL	TTDDRUID	D09JUL
D09JUL	DRUGNAME	Naltrexone prodrugs
D09JUL	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative

D0R3KY	TTDDRUID	D0R3KY
D0R3KY	DRUGNAME	Nanobody therapeutics
D0R3KY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0A4JI	TTDDRUID	D0A4JI
D0A4JI	DRUGNAME	NanoDisks
D0A4JI	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D0L6FF	TTDDRUID	D0L6FF
D0L6FF	DRUGNAME	NanoDTPA
D0L6FF	INDICATI	Iron overload disease [ICD-11: 5C64.10] Investigative

D03FEP	TTDDRUID	D03FEP
D03FEP	DRUGNAME	Nanofibers
D03FEP	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0C9RM	TTDDRUID	D0C9RM
D0C9RM	DRUGNAME	Nano-PGE1
D0C9RM	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Investigative

D0B9XM	TTDDRUID	D0B9XM
D0B9XM	DRUGNAME	Nano-steroid
D0B9XM	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0F2MM	TTDDRUID	D0F2MM
D0F2MM	DRUGNAME	Nanotherapeutics
D0F2MM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZU9P	TTDDRUID	D0ZU9P
D0ZU9P	DRUGNAME	NAPIRIMUS
D0ZU9P	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0W1JY	TTDDRUID	D0W1JY
D0W1JY	DRUGNAME	NAPQI
D0W1JY	INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Investigative

D04YKQ	TTDDRUID	D04YKQ
D04YKQ	DRUGNAME	NaQuinate
D04YKQ	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0OQ1I	TTDDRUID	D0OQ1I
D0OQ1I	DRUGNAME	Narciclasine
D0OQ1I	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0T5GL	TTDDRUID	D0T5GL
D0T5GL	DRUGNAME	Narrow spectrum antibiotics
D0T5GL	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0T3XK	TTDDRUID	D0T3XK
D0T3XK	DRUGNAME	Natriuretic peptides
D0T3XK	INDICATI	Congestive heart failure [ICD-11: BD10] Investigative

D02SZC	TTDDRUID	D02SZC
D02SZC	DRUGNAME	Natural product anti-infective therapeutics
D02SZC	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0S5RB	TTDDRUID	D0S5RB
D0S5RB	DRUGNAME	Naturally derived antibacterial agents
D0S5RB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0G9ME	TTDDRUID	D0G9ME
D0G9ME	DRUGNAME	NAX-5055
D0G9ME	INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Investigative

D0G5VT	TTDDRUID	D0G5VT
D0G5VT	DRUGNAME	Nazvax-PX
D0G5VT	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D08SHM	TTDDRUID	D08SHM
D08SHM	DRUGNAME	NB-007
D08SHM	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D04MOZ	TTDDRUID	D04MOZ
D04MOZ	DRUGNAME	NB3178
D04MOZ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0R4WT	TTDDRUID	D0R4WT
D0R4WT	DRUGNAME	NB-325
D0R4WT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0H4NN	TTDDRUID	D0H4NN
D0H4NN	DRUGNAME	NB3322
D0H4NN	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0L0KI	TTDDRUID	D0L0KI
D0L0KI	DRUGNAME	NB-401
D0L0KI	INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative

D0XI1B	TTDDRUID	D0XI1B
D0XI1B	DRUGNAME	NBI-18
D0XI1B	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Investigative

D03YSJ	TTDDRUID	D03YSJ
D03YSJ	DRUGNAME	NBI-29
D03YSJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D00FOR	TTDDRUID	D00FOR
D00FOR	DRUGNAME	NBI-80649
D00FOR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0G9XG	TTDDRUID	D0G9XG
D0G9XG	DRUGNAME	NBM-HD-1
D0G9XG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z9BN	TTDDRUID	D0Z9BN
D0Z9BN	DRUGNAME	NBRI-16716a
D0Z9BN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09SXJ	TTDDRUID	D09SXJ
D09SXJ	DRUGNAME	NC-0604
D09SXJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P1BK	TTDDRUID	D0P1BK
D0P1BK	DRUGNAME	NC1153
D0P1BK	INDICATI	Renal transplantation [ICD-11: NE84] Investigative

D05KKF	TTDDRUID	D05KKF
D05KKF	DRUGNAME	NC-2500
D05KKF	INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Investigative

D0HH9P	TTDDRUID	D0HH9P
D0HH9P	DRUGNAME	NCE-401
D0HH9P	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0H6VL	TTDDRUID	D0H6VL
D0H6VL	DRUGNAME	NCL-00016149
D0H6VL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03PCP	TTDDRUID	D03PCP
D03PCP	DRUGNAME	NCT-400
D03PCP	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D09WNQ	TTDDRUID	D09WNQ
D09WNQ	DRUGNAME	NCTX
D09WNQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0LV7F	TTDDRUID	D0LV7F
D0LV7F	DRUGNAME	NCX-1047
D0LV7F	INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative

D0KC7H	TTDDRUID	D0KC7H
D0KC7H	DRUGNAME	NCX-1236
D0KC7H	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D08MXB	TTDDRUID	D08MXB
D08MXB	DRUGNAME	NCX-125
D08MXB	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D05UQF	TTDDRUID	D05UQF
D05UQF	DRUGNAME	NCX-226
D05UQF	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative

D0I4WH	TTDDRUID	D0I4WH
D0I4WH	DRUGNAME	NCX-434
D0I4WH	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Investigative

D07TUT	TTDDRUID	D07TUT
D07TUT	DRUGNAME	ND-07
D07TUT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0G1YH	TTDDRUID	D0G1YH
D0G1YH	DRUGNAME	ND-201
D0G1YH	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D07IZP	TTDDRUID	D07IZP
D07IZP	DRUGNAME	ND-401
D07IZP	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D02BMJ	TTDDRUID	D02BMJ
D02BMJ	DRUGNAME	ND-601
D02BMJ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0P1QN	TTDDRUID	D0P1QN
D0P1QN	DRUGNAME	ND-701
D0P1QN	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D07GGQ	TTDDRUID	D07GGQ
D07GGQ	DRUGNAME	ND-801
D07GGQ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0QB6M	TTDDRUID	D0QB6M
D0QB6M	DRUGNAME	ND-901
D0QB6M	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0HM5Q	TTDDRUID	D0HM5Q
D0HM5Q	DRUGNAME	ND-AMB
D0HM5Q	INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative

D0H4RV	TTDDRUID	D0H4RV
D0H4RV	DRUGNAME	NDC-1022
D0H4RV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03XEV	TTDDRUID	D03XEV
D03XEV	DRUGNAME	NDC-1187
D03XEV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N2GS	TTDDRUID	D0N2GS
D0N2GS	DRUGNAME	NDC-KM
D0N2GS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z6WN	TTDDRUID	D0Z6WN
D0Z6WN	DRUGNAME	NDM-10107
D0Z6WN	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0E6VN	TTDDRUID	D0E6VN
D0E6VN	DRUGNAME	NDV-4
D0E6VN	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D0T1EU	TTDDRUID	D0T1EU
D0T1EU	DRUGNAME	Ndx-Peptide
D0T1EU	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D00PQS	TTDDRUID	D00PQS
D00PQS	DRUGNAME	NE-2
D00PQS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0TJ3X	TTDDRUID	D0TJ3X
D0TJ3X	DRUGNAME	Nell-1 protein therapeutic
D0TJ3X	INDICATI	Heart injury [ICD-11: NB31] Investigative

D0U0JL	TTDDRUID	D0U0JL
D0U0JL	DRUGNAME	Neo-1507
D0U0JL	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D03AZB	TTDDRUID	D03AZB
D03AZB	DRUGNAME	Neo-1528
D03AZB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D02ESX	TTDDRUID	D02ESX
D02ESX	DRUGNAME	Neomedi
D02ESX	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0N9GC	TTDDRUID	D0N9GC
D0N9GC	DRUGNAME	Neorphine
D0N9GC	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0GV0O	TTDDRUID	D0GV0O
D0GV0O	DRUGNAME	Nephesh-1000
D0GV0O	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D07UZX	TTDDRUID	D07UZX
D07UZX	DRUGNAME	Nerve growth factor conjugated RAP peptide
D07UZX	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0M1MB	TTDDRUID	D0M1MB
D0M1MB	DRUGNAME	NESS-200P
D0M1MB	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative

D02SNE	TTDDRUID	D02SNE
D02SNE	DRUGNAME	NeuGene
D02SNE	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D0L3KN	TTDDRUID	D0L3KN
D0L3KN	DRUGNAME	NeurArrest
D0L3KN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0X4DH	TTDDRUID	D0X4DH
D0X4DH	DRUGNAME	Neuroendocrine agent
D0X4DH	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D09VNY	TTDDRUID	D09VNY
D09VNY	DRUGNAME	Neurological therapeutics
D09VNY	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D05BLQ	TTDDRUID	D05BLQ
D05BLQ	DRUGNAME	Neuromed 2
D05BLQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D07APX	TTDDRUID	D07APX
D07APX	DRUGNAME	Neuromed 5
D07APX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0R7WK	TTDDRUID	D0R7WK
D0R7WK	DRUGNAME	Neuropeptide S antagonist
D0R7WK	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0Y5DW	TTDDRUID	D0Y5DW
D0Y5DW	DRUGNAME	Neuroprotectant therapeutics
D0Y5DW	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D03BID	TTDDRUID	D03BID
D03BID	DRUGNAME	Neuroprotectants
D03BID	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D0I7XE	TTDDRUID	D0I7XE
D0I7XE	DRUGNAME	Neuroprotective thioderivatives
D0I7XE	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0X1QN	TTDDRUID	D0X1QN
D0X1QN	DRUGNAME	Neurotrophic factor-producing stem cells
D0X1QN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0S0TR	TTDDRUID	D0S0TR
D0S0TR	DRUGNAME	NeurTriptin
D0S0TR	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0R1XO	TTDDRUID	D0R1XO
D0R1XO	DRUGNAME	Next generation recombinant soluble Fc receptors
D0R1XO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D09TBY	TTDDRUID	D09TBY
D09TBY	DRUGNAME	Next-generation lipid-based agents
D09TBY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0H7MB	TTDDRUID	D0H7MB
D0H7MB	DRUGNAME	Nextomabs
D0H7MB	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0U1GM	TTDDRUID	D0U1GM
D0U1GM	DRUGNAME	NexVas VI
D0U1GM	INDICATI	Vasculitis [ICD-11: 4A44] Investigative

D01TRU	TTDDRUID	D01TRU
D01TRU	DRUGNAME	NFTA-105
D01TRU	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D09TDG	TTDDRUID	D09TDG
D09TDG	DRUGNAME	NFTB-104
D09TDG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D06WRY	TTDDRUID	D06WRY
D06WRY	DRUGNAME	NFTC-103
D06WRY	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0NJ9W	TTDDRUID	D0NJ9W
D0NJ9W	DRUGNAME	Nfu-PA-D4-RNP
D0NJ9W	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D0J0BI	TTDDRUID	D0J0BI
D0J0BI	DRUGNAME	NG-049
D0J0BI	INDICATI	Dyspepsia [ICD-11: MD92] Investigative

D02RBQ	TTDDRUID	D02RBQ
D02RBQ	DRUGNAME	NG-2
D02RBQ	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative

D09JET	TTDDRUID	D09JET
D09JET	DRUGNAME	NGD 96-3
D09JET	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative

D01GNW	TTDDRUID	D01GNW
D01GNW	DRUGNAME	NGN-9076
D01GNW	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0T4CD	TTDDRUID	D0T4CD
D0T4CD	DRUGNAME	NGN-9077
D0T4CD	INDICATI	Multiple system atrophy [ICD-11: 8D87.0] Investigative

D0V8PQ	TTDDRUID	D0V8PQ
D0V8PQ	DRUGNAME	NGN-9078
D0V8PQ	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0F5IS	TTDDRUID	D0F5IS
D0F5IS	DRUGNAME	NGN-9079
D0F5IS	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09XEM	TTDDRUID	D09XEM
D09XEM	DRUGNAME	NGN-9080
D09XEM	INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative

D05XNX	TTDDRUID	D05XNX
D05XNX	DRUGNAME	NH-02D
D05XNX	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D08ZDM	TTDDRUID	D08ZDM
D08ZDM	DRUGNAME	Nh-125
D08ZDM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03LGX	TTDDRUID	D03LGX
D03LGX	DRUGNAME	NI-105
D03LGX	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D09PLZ	TTDDRUID	D09PLZ
D09PLZ	DRUGNAME	NI-1201
D09PLZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0LT4D	TTDDRUID	D0LT4D
D0LT4D	DRUGNAME	NI-1401
D0LT4D	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0RK8E	TTDDRUID	D0RK8E
D0RK8E	DRUGNAME	NI-202
D0RK8E	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D02OCD	TTDDRUID	D02OCD
D02OCD	DRUGNAME	NIBR-785
D02OCD	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0QG6A	TTDDRUID	D0QG6A
D0QG6A	DRUGNAME	NIP-142
D0QG6A	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D07RPK	TTDDRUID	D07RPK
D07RPK	DRUGNAME	NIP-151
D07RPK	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D0P1EB	TTDDRUID	D0P1EB
D0P1EB	DRUGNAME	NIS215
D0P1EB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative

D0QY4L	TTDDRUID	D0QY4L
D0QY4L	DRUGNAME	Nitroimidazole
D0QY4L	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D0Q9ZR	TTDDRUID	D0Q9ZR
D0Q9ZR	DRUGNAME	Nitroimidazoles
D0Q9ZR	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D05BKY	TTDDRUID	D05BKY
D05BKY	DRUGNAME	NK-1005
D05BKY	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D09PIH	TTDDRUID	D09PIH
D09PIH	DRUGNAME	NK-1007
D09PIH	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D0K6UO	TTDDRUID	D0K6UO
D0K6UO	DRUGNAME	NK-101
D0K6UO	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D05MBE	TTDDRUID	D05MBE
D05MBE	DRUGNAME	NK-102
D05MBE	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D00SJX	TTDDRUID	D00SJX
D00SJX	DRUGNAME	NK-110
D00SJX	INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative

D07KYK	TTDDRUID	D07KYK
D07KYK	DRUGNAME	NK-111
D07KYK	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D0P1DP	TTDDRUID	D0P1DP
D0P1DP	DRUGNAME	NK-2210
D0P1DP	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0NW2B	TTDDRUID	D0NW2B
D0NW2B	DRUGNAME	NK3 antagonist PET ligand
D0NW2B	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Investigative

D06UUP	TTDDRUID	D06UUP
D06UUP	DRUGNAME	NK-3 antagonists
D06UUP	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0I0NU	TTDDRUID	D0I0NU
D0I0NU	DRUGNAME	NKP-2235
D0I0NU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06XNW	TTDDRUID	D06XNW
D06XNW	DRUGNAME	NKP-3752
D06XNW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04BIY	TTDDRUID	D04BIY
D04BIY	DRUGNAME	NKTR-140
D04BIY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0PH0G	TTDDRUID	D0PH0G
D0PH0G	DRUGNAME	NKTR-171
D0PH0G	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0U1TJ	TTDDRUID	D0U1TJ
D0U1TJ	DRUGNAME	NKTR-194
D0U1TJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0O8EH	TTDDRUID	D0O8EH
D0O8EH	DRUGNAME	NKTT-320
D0O8EH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U8WW	TTDDRUID	D0U8WW
D0U8WW	DRUGNAME	NLCQ-1
D0U8WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01TAQ	TTDDRUID	D01TAQ
D01TAQ	DRUGNAME	NLP-44
D01TAQ	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D0K1BR	TTDDRUID	D0K1BR
D0K1BR	DRUGNAME	NLP-61
D0K1BR	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0U2RR	TTDDRUID	D0U2RR
D0U2RR	DRUGNAME	NLP-83
D0U2RR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q8PJ	TTDDRUID	D0Q8PJ
D0Q8PJ	DRUGNAME	NLP-91
D0Q8PJ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0AZ7F	TTDDRUID	D0AZ7F
D0AZ7F	DRUGNAME	NLX-E201
D0AZ7F	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D06ARI	TTDDRUID	D06ARI
D06ARI	DRUGNAME	NM-001
D06ARI	INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative

D0E8BD	TTDDRUID	D0E8BD
D0E8BD	DRUGNAME	NM-006-MENK
D0E8BD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00UMJ	TTDDRUID	D00UMJ
D00UMJ	DRUGNAME	NM-007-LENK
D00UMJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0W0BN	TTDDRUID	D0W0BN
D0W0BN	DRUGNAME	NM-2014
D0W0BN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D09PKZ	TTDDRUID	D09PKZ
D09PKZ	DRUGNAME	NM-9308
D09PKZ	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D08TQK	TTDDRUID	D08TQK
D08TQK	DRUGNAME	NM-9405
D08TQK	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D05PTL	TTDDRUID	D05PTL
D05PTL	DRUGNAME	NMB-T-BMX-OS01
D05PTL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07UPJ	TTDDRUID	D07UPJ
D07UPJ	DRUGNAME	NMDA NR2B antagonists
D07UPJ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D00SML	TTDDRUID	D00SML
D00SML	DRUGNAME	NMHSS1-1
D00SML	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D03BQD	TTDDRUID	D03BQD
D03BQD	DRUGNAME	NMS-1
D03BQD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H6JK	TTDDRUID	D0H6JK
D0H6JK	DRUGNAME	NMS-E628
D0H6JK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09HVH	TTDDRUID	D09HVH
D09HVH	DRUGNAME	NMS-E973
D09HVH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F6OF	TTDDRUID	D0F6OF
D0F6OF	DRUGNAME	NMS-P626
D0F6OF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0UO2H	TTDDRUID	D0UO2H
D0UO2H	DRUGNAME	NMS-P715
D0UO2H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05GMG	TTDDRUID	D05GMG
D05GMG	DRUGNAME	NNI-351
D05GMG	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D04OUP	TTDDRUID	D04OUP
D04OUP	DRUGNAME	NNI-AD
D04OUP	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0I5CO	TTDDRUID	D0I5CO
D0I5CO	DRUGNAME	NNI-PD
D0I5CO	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D03WHC	TTDDRUID	D03WHC
D03WHC	DRUGNAME	Nnrti
D03WHC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D06SEL	TTDDRUID	D06SEL
D06SEL	DRUGNAME	NNRTIs
D06SEL	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0KA4R	TTDDRUID	D0KA4R
D0KA4R	DRUGNAME	NNZ-2591
D0KA4R	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D03ZJK	TTDDRUID	D03ZJK
D03ZJK	DRUGNAME	NNZ-3006
D03ZJK	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D09EVP	TTDDRUID	D09EVP
D09EVP	DRUGNAME	NNZ-4921
D09EVP	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0VO5V	TTDDRUID	D0VO5V
D0VO5V	DRUGNAME	NNZ-4945
D0VO5V	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0L9YC	TTDDRUID	D0L9YC
D0L9YC	DRUGNAME	Nocathiacin I analogs
D0L9YC	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0J0ZQ	TTDDRUID	D0J0ZQ
D0J0ZQ	DRUGNAME	Nociceptin/orphanin FQ receptor PET ligands
D0J0ZQ	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Investigative

D0W9NZ	TTDDRUID	D0W9NZ
D0W9NZ	DRUGNAME	NO-containing nanoparticles
D0W9NZ	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative

D0M3FZ	TTDDRUID	D0M3FZ
D0M3FZ	DRUGNAME	NOD factors
D0M3FZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I6GC	TTDDRUID	D0I6GC
D0I6GC	DRUGNAME	NOGGIN
D0I6GC	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D09LTC	TTDDRUID	D09LTC
D09LTC	DRUGNAME	Non GC-C
D09LTC	INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative

D02VJI	TTDDRUID	D02VJI
D02VJI	DRUGNAME	Non-anticoagulation heparins
D02VJI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J3CG	TTDDRUID	D0J3CG
D0J3CG	DRUGNAME	Non-beta2 receptor bronchodilators
D0J3CG	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0N6LY	TTDDRUID	D0N6LY
D0N6LY	DRUGNAME	Non-nucleoside HCV NS5B polymerase inhibitors
D0N6LY	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D05CJJ	TTDDRUID	D05CJJ
D05CJJ	DRUGNAME	Non-nucleoside reverse transcriptase inhibitors
D05CJJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0F2DE	TTDDRUID	D0F2DE
D0F2DE	DRUGNAME	Non-nucleoside therapeutics
D0F2DE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0M2EH	TTDDRUID	D0M2EH
D0M2EH	DRUGNAME	Non-PEGylated butyrylcholinesterase
D0M2EH	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D0QI6W	TTDDRUID	D0QI6W
D0QI6W	DRUGNAME	Non-peptide TPO mimics
D0QI6W	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D03UVX	TTDDRUID	D03UVX
D03UVX	DRUGNAME	NOPPI
D03UVX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05GLT	TTDDRUID	D05GLT
D05GLT	DRUGNAME	Norisoboldine
D05GLT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D05IIB	TTDDRUID	D05IIB
D05IIB	DRUGNAME	NoroVAXX
D05IIB	INDICATI	Norovirus infection [ICD-11: 1A23] Investigative

D03JXR	TTDDRUID	D03JXR
D03JXR	DRUGNAME	NOSO-74
D03JXR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D02IAR	TTDDRUID	D02IAR
D02IAR	DRUGNAME	Nov-038
D02IAR	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0C7KB	TTDDRUID	D0C7KB
D0C7KB	DRUGNAME	Nova-EPO
D0C7KB	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D05PJJ	TTDDRUID	D05PJJ
D05PJJ	DRUGNAME	NOX 2137a/b
D05PJJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
D05PJJ	INDICATI	Stress [ICD-11: 6B40-6B45] Investigative

D05MUA	TTDDRUID	D05MUA
D05MUA	DRUGNAME	NOX 2149
D05MUA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
D05MUA	INDICATI	Stress [ICD-11: 6B40-6B45] Investigative

D0E7PZ	TTDDRUID	D0E7PZ
D0E7PZ	DRUGNAME	NOX-B11
D0E7PZ	INDICATI	Obesity [ICD-11: 5B81] Investigative

D06YTE	TTDDRUID	D06YTE
D06YTE	DRUGNAME	NOX-D14
D06YTE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0G6KH	TTDDRUID	D0G6KH
D0G6KH	DRUGNAME	NOX-S91
D0G6KH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AZ0T	TTDDRUID	D0AZ0T
D0AZ0T	DRUGNAME	NP-003
D0AZ0T	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0U0IS	TTDDRUID	D0U0IS
D0U0IS	DRUGNAME	NP-02
D0U0IS	INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative

D0W2SX	TTDDRUID	D0W2SX
D0W2SX	DRUGNAME	NP-0336
D0W2SX	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0L0XV	TTDDRUID	D0L0XV
D0L0XV	DRUGNAME	NP-05
D0L0XV	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0C2MS	TTDDRUID	D0C2MS
D0C2MS	DRUGNAME	NP-07
D0C2MS	INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative

D0D6WF	TTDDRUID	D0D6WF
D0D6WF	DRUGNAME	NP-103
D0D6WF	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D06FSC	TTDDRUID	D06FSC
D06FSC	DRUGNAME	NP-118809
D06FSC	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09HYG	TTDDRUID	D09HYG
D09HYG	DRUGNAME	NP16
D09HYG	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D05NIO	TTDDRUID	D05NIO
D05NIO	DRUGNAME	NP-17
D05NIO	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0M4DE	TTDDRUID	D0M4DE
D0M4DE	DRUGNAME	NP-184
D0M4DE	INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative

D0W8UV	TTDDRUID	D0W8UV
D0W8UV	DRUGNAME	NP-313
D0W8UV	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D01YLA	TTDDRUID	D01YLA
D01YLA	DRUGNAME	NP-432
D01YLA	INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative

D04GDI	TTDDRUID	D04GDI
D04GDI	DRUGNAME	NP93-31
D04GDI	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D01WSL	TTDDRUID	D01WSL
D01WSL	DRUGNAME	NPB-1
D01WSL	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D07OYT	TTDDRUID	D07OYT
D07OYT	DRUGNAME	NPB-2
D07OYT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09OPH	TTDDRUID	D09OPH
D09OPH	DRUGNAME	NPB-3
D09OPH	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D0J3MY	TTDDRUID	D0J3MY
D0J3MY	DRUGNAME	NPI-3114
D0J3MY	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D06OFJ	TTDDRUID	D06OFJ
D06OFJ	DRUGNAME	NPI-3304
D06OFJ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0FY2N	TTDDRUID	D0FY2N
D0FY2N	DRUGNAME	NPRx-30
D0FY2N	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D03HXO	TTDDRUID	D03HXO
D03HXO	DRUGNAME	NPS-1
D03HXO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L9XL	TTDDRUID	D0L9XL
D0L9XL	DRUGNAME	NPS-2
D0L9XL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0WP1L	TTDDRUID	D0WP1L
D0WP1L	DRUGNAME	NPS-3
D0WP1L	INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative

D0L1TB	TTDDRUID	D0L1TB
D0L1TB	DRUGNAME	NPS-4
D0L1TB	INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative

D0S6CD	TTDDRUID	D0S6CD
D0S6CD	DRUGNAME	NPS-P156
D0S6CD	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0X3OF	TTDDRUID	D0X3OF
D0X3OF	DRUGNAME	NPT-1162
D0X3OF	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D03ICS	TTDDRUID	D03ICS
D03ICS	DRUGNAME	NPT-500
D03ICS	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0N9WY	TTDDRUID	D0N9WY
D0N9WY	DRUGNAME	NPT-CLN
D0N9WY	INDICATI	Asthma [ICD-11: CA23] Investigative

D0RC0H	TTDDRUID	D0RC0H
D0RC0H	DRUGNAME	NPY Y5 antagonists
D0RC0H	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D06HXC	TTDDRUID	D06HXC
D06HXC	DRUGNAME	NPY-1 antagonist
D06HXC	INDICATI	Eating disorder [ICD-11: 6B82] Investigative

D0Y6MD	TTDDRUID	D0Y6MD
D0Y6MD	DRUGNAME	NRC-2694
D0Y6MD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E2YX	TTDDRUID	D0E2YX
D0E2YX	DRUGNAME	NRD-135S
D0E2YX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0O3TE	TTDDRUID	D0O3TE
D0O3TE	DRUGNAME	NRG-101
D0O3TE	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D0K3RP	TTDDRUID	D0K3RP
D0K3RP	DRUGNAME	NRI-1013
D0K3RP	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0K3MU	TTDDRUID	D0K3MU
D0K3MU	DRUGNAME	NRL-0301
D0K3MU	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative

D06WTI	TTDDRUID	D06WTI
D06WTI	DRUGNAME	NRP290
D06WTI	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0N5UU	TTDDRUID	D0N5UU
D0N5UU	DRUGNAME	NRT-100
D0N5UU	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0C0FG	TTDDRUID	D0C0FG
D0C0FG	DRUGNAME	NRT-300
D0C0FG	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D03JAF	TTDDRUID	D03JAF
D03JAF	DRUGNAME	Nrti
D03JAF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D07OTU	TTDDRUID	D07OTU
D07OTU	DRUGNAME	NRX-1050
D07OTU	INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative

D0H4BF	TTDDRUID	D0H4BF
D0H4BF	DRUGNAME	NS-11757
D0H4BF	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D0G4JB	TTDDRUID	D0G4JB
D0G4JB	DRUGNAME	NS-13001
D0G4JB	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D0JY2K	TTDDRUID	D0JY2K
D0JY2K	DRUGNAME	NS-1643
D0JY2K	INDICATI	Heart arrhythmia [ICD-11: BC65] Investigative

D07AJR	TTDDRUID	D07AJR
D07AJR	DRUGNAME	NS3 helicase protein-targeting agents
D07AJR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0GM8L	TTDDRUID	D0GM8L
D0GM8L	DRUGNAME	NS3 protease inhibitors
D0GM8L	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0N3RE	TTDDRUID	D0N3RE
D0N3RE	DRUGNAME	NS5a
D0N3RE	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0K5TW	TTDDRUID	D0K5TW
D0K5TW	DRUGNAME	NS5B HCV polymerase inhibitors
D0K5TW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0Z0JC	TTDDRUID	D0Z0JC
D0Z0JC	DRUGNAME	NS-640
D0Z0JC	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D08OQI	TTDDRUID	D08OQI
D08OQI	DRUGNAME	NSAID prodrugs
D08OQI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D06PZH	TTDDRUID	D06PZH
D06PZH	DRUGNAME	NSAIDs
D06PZH	INDICATI	Endometriosis [ICD-11: GA10] Investigative

D0ZU9T	TTDDRUID	D0ZU9T
D0ZU9T	DRUGNAME	NSC-134754
D0ZU9T	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04MYC	TTDDRUID	D04MYC
D04MYC	DRUGNAME	NSC-625487
D04MYC	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0W7TU	TTDDRUID	D0W7TU
D0W7TU	DRUGNAME	NSC-73306
D0W7TU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09KUE	TTDDRUID	D09KUE
D09KUE	DRUGNAME	NSC-88915
D09KUE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D8MS	TTDDRUID	D0D8MS
D0D8MS	DRUGNAME	NSD-726
D0D8MS	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D06MRS	TTDDRUID	D06MRS
D06MRS	DRUGNAME	NSD-761
D06MRS	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0TE8W	TTDDRUID	D0TE8W
D0TE8W	DRUGNAME	NSD-801
D0TE8W	INDICATI	Ataxia [ICD-11: MB45.0] Investigative

D0H1JN	TTDDRUID	D0H1JN
D0H1JN	DRUGNAME	NsG-0501
D0H1JN	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0M0JR	TTDDRUID	D0M0JR
D0M0JR	DRUGNAME	NsG-33
D0M0JR	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D01HXI	TTDDRUID	D01HXI
D01HXI	DRUGNAME	N-substituted amino-benzamides
D01HXI	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D01DVR	TTDDRUID	D01DVR
D01DVR	DRUGNAME	NT-001
D01DVR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D03IWT	TTDDRUID	D03IWT
D03IWT	DRUGNAME	NT-13317
D03IWT	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D09DRM	TTDDRUID	D09DRM
D09DRM	DRUGNAME	NT-1635
D09DRM	INDICATI	Sarcopenia [ICD-11: FB32.Y] Investigative

D0YZ5T	TTDDRUID	D0YZ5T
D0YZ5T	DRUGNAME	NT-345
D0YZ5T	INDICATI	Sarcopenia [ICD-11: FB32.Y] Investigative

D04YKY	TTDDRUID	D04YKY
D04YKY	DRUGNAME	NT-502
D04YKY	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0W2KG	TTDDRUID	D0W2KG
D0W2KG	DRUGNAME	NT-69-L
D0W2KG	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative

D0D7YF	TTDDRUID	D0D7YF
D0D7YF	DRUGNAME	NT-CC-017
D0D7YF	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D01NTR	TTDDRUID	D01NTR
D01NTR	DRUGNAME	NTF-1836
D01NTR	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0U3DE	TTDDRUID	D0U3DE
D0U3DE	DRUGNAME	NT-FV-007
D0U3DE	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D03QSC	TTDDRUID	D03QSC
D03QSC	DRUGNAME	NT-KC-005
D03QSC	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0M4UX	TTDDRUID	D0M4UX
D0M4UX	DRUGNAME	NT-KO-009
D0M4UX	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0O8BQ	TTDDRUID	D0O8BQ
D0O8BQ	DRUGNAME	NT-KO-012
D0O8BQ	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0VM8B	TTDDRUID	D0VM8B
D0VM8B	DRUGNAME	NTP-2014
D0VM8B	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D03ZMK	TTDDRUID	D03ZMK
D03ZMK	DRUGNAME	NTP-6009
D03ZMK	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0PX5F	TTDDRUID	D0PX5F
D0PX5F	DRUGNAME	NU-1001-41
D0PX5F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05TDS	TTDDRUID	D05TDS
D05TDS	DRUGNAME	Nu-2
D05TDS	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D08QVM	TTDDRUID	D08QVM
D08QVM	DRUGNAME	NU-400
D08QVM	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0G9FF	TTDDRUID	D0G9FF
D0G9FF	DRUGNAME	Nucleozin
D0G9FF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D06ZQK	TTDDRUID	D06ZQK
D06ZQK	DRUGNAME	Nucleozin analog 3061 (FA-2)
D06ZQK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D07BNL	TTDDRUID	D07BNL
D07BNL	DRUGNAME	NV.AT.08
D07BNL	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0O4MW	TTDDRUID	D0O4MW
D0O4MW	DRUGNAME	NV.BC.04
D0O4MW	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D03EIK	TTDDRUID	D03EIK
D03EIK	DRUGNAME	NV.RYM.09
D03EIK	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D05CTY	TTDDRUID	D05CTY
D05CTY	DRUGNAME	NV.TLM.10
D05CTY	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative

D02RDC	TTDDRUID	D02RDC
D02RDC	DRUGNAME	NV.XOD.09
D02RDC	INDICATI	Brain cancer [ICD-11: 2A00] Investigative

D0ZB2E	TTDDRUID	D0ZB2E
D0ZB2E	DRUGNAME	NV-07a
D0ZB2E	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0MG0H	TTDDRUID	D0MG0H
D0MG0H	DRUGNAME	NVC-612
D0MG0H	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D07PVT	TTDDRUID	D07PVT
D07PVT	DRUGNAME	NVC-638
D07PVT	INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative

D08OWA	TTDDRUID	D08OWA
D08OWA	DRUGNAME	NVC-704
D08OWA	INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative

D05HLC	TTDDRUID	D05HLC
D05HLC	DRUGNAME	NVC-727
D05HLC	INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative

D04ZBA	TTDDRUID	D04ZBA
D04ZBA	DRUGNAME	NVLS/FX-18A
D04ZBA	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D06NMZ	TTDDRUID	D06NMZ
D06NMZ	DRUGNAME	NVP-ADW742
D06NMZ	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0XA5N	TTDDRUID	D0XA5N
D0XA5N	DRUGNAME	NVP-LDE276
D0XA5N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04KFR	TTDDRUID	D04KFR
D04KFR	DRUGNAME	NVP-SAA164
D04KFR	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0R2WK	TTDDRUID	D0R2WK
D0R2WK	DRUGNAME	NVP-TAE684
D0R2WK	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative

D06VIZ	TTDDRUID	D06VIZ
D06VIZ	DRUGNAME	NVX-144
D06VIZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06DZZ	TTDDRUID	D06DZZ
D06DZZ	DRUGNAME	NVX-188
D06DZZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U1DU	TTDDRUID	D0U1DU
D0U1DU	DRUGNAME	NVX-207
D0U1DU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XL0E	TTDDRUID	D0XL0E
D0XL0E	DRUGNAME	NVX-272
D0XL0E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XU4O	TTDDRUID	D0XU4O
D0XU4O	DRUGNAME	NVX-412
D0XU4O	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0OW5Y	TTDDRUID	D0OW5Y
D0OW5Y	DRUGNAME	NW-1772
D0OW5Y	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D05HHZ	TTDDRUID	D05HHZ
D05HHZ	DRUGNAME	NX-002
D05HHZ	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0K7BF	TTDDRUID	D0K7BF
D0K7BF	DRUGNAME	NX-201
D0K7BF	INDICATI	Autism spectrum disorder [ICD-11: 6A02] Investigative

D0O8JM	TTDDRUID	D0O8JM
D0O8JM	DRUGNAME	NX-210
D0O8JM	INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative

D06BJP	TTDDRUID	D06BJP
D06BJP	DRUGNAME	NXB-4221
D06BJP	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0KI3U	TTDDRUID	D0KI3U
D0KI3U	DRUGNAME	NXB-5886
D0KI3U	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0K9PG	TTDDRUID	D0K9PG
D0K9PG	DRUGNAME	NXD-30001
D0K9PG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04UQS	TTDDRUID	D04UQS
D04UQS	DRUGNAME	NXD-9062
D04UQS	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D02NXQ	TTDDRUID	D02NXQ
D02NXQ	DRUGNAME	NXL-105
D02NXQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D08KWV	TTDDRUID	D08KWV
D08KWV	DRUGNAME	NXT-1021
D08KWV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D02NZF	TTDDRUID	D02NZF
D02NZF	DRUGNAME	NZ-17000
D02NZF	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D09WOI	TTDDRUID	D09WOI
D09WOI	DRUGNAME	NZ-39000
D09WOI	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0O7ZR	TTDDRUID	D0O7ZR
D0O7ZR	DRUGNAME	NZ-4
D0O7ZR	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D00QGB	TTDDRUID	D00QGB
D00QGB	DRUGNAME	O-2442
D00QGB	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Investigative

D0D0US	TTDDRUID	D0D0US
D0D0US	DRUGNAME	OB-14
D0D0US	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D05SEW	TTDDRUID	D05SEW
D05SEW	DRUGNAME	OB-24
D05SEW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0B7GE	TTDDRUID	D0B7GE
D0B7GE	DRUGNAME	OB-28
D0B7GE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J5KZ	TTDDRUID	D0J5KZ
D0J5KZ	DRUGNAME	OBE-102
D0J5KZ	INDICATI	Weight loss [ICD-11: MG43.5] Investigative

D01QCY	TTDDRUID	D01QCY
D01QCY	DRUGNAME	OBP-AI1
D01QCY	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0AC6O	TTDDRUID	D0AC6O
D0AC6O	DRUGNAME	OBP-AI2
D0AC6O	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0O3FS	TTDDRUID	D0O3FS
D0O3FS	DRUGNAME	OBR-5-340
D0O3FS	INDICATI	Coxsackie virus infection [ICD-11: 1D91] Investigative

D0S6MA	TTDDRUID	D0S6MA
D0S6MA	DRUGNAME	OCID-2987
D0S6MA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0QV3O	TTDDRUID	D0QV3O
D0QV3O	DRUGNAME	OCID-4681
D0QV3O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00QOH	TTDDRUID	D00QOH
D00QOH	DRUGNAME	OCT-SG815
D00QOH	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0V6FV	TTDDRUID	D0V6FV
D0V6FV	DRUGNAME	OcuXan
D0V6FV	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0Z6MW	TTDDRUID	D0Z6MW
D0Z6MW	DRUGNAME	ODS-656
D0Z6MW	INDICATI	Osteopetrosis [ICD-11: LD24.10] Investigative

D00YTX	TTDDRUID	D00YTX
D00YTX	DRUGNAME	OG-19
D00YTX	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D0K8AL	TTDDRUID	D0K8AL
D0K8AL	DRUGNAME	OG-232
D0K8AL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03XDD	TTDDRUID	D03XDD
D03XDD	DRUGNAME	OG-45
D03XDD	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D0YG4Q	TTDDRUID	D0YG4Q
D0YG4Q	DRUGNAME	OG-9
D0YG4Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04JIS	TTDDRUID	D04JIS
D04JIS	DRUGNAME	OG-Cx-833
D04JIS	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D01PUE	TTDDRUID	D01PUE
D01PUE	DRUGNAME	O-GlcNAcase (OGA)-targeting agents
D01PUE	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09MQU	TTDDRUID	D09MQU
D09MQU	DRUGNAME	OGX-225
D09MQU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D00ZBZ	TTDDRUID	D00ZBZ
D00ZBZ	DRUGNAME	OGX-427 + Paclitaxel
D00ZBZ	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
D00ZBZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
D00ZBZ	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
D00ZBZ	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
D00ZBZ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D09GVB	TTDDRUID	D09GVB
D09GVB	DRUGNAME	OL-135
D09GVB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D08TZZ	TTDDRUID	D08TZZ
D08TZZ	DRUGNAME	Oleuropein
D08TZZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0A3CW	TTDDRUID	D0A3CW
D0A3CW	DRUGNAME	Oleylphosphocholine
D0A3CW	INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative

D0OJ5M	TTDDRUID	D0OJ5M
D0OJ5M	DRUGNAME	OLPADRONIC ACID SODIUM SALT
D0OJ5M	INDICATI	Bone resorption [ICD-11: FC0Z] Investigative

D02SGT	TTDDRUID	D02SGT
D02SGT	DRUGNAME	OM-197-MP-AC
D02SGT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00GLW	TTDDRUID	D00GLW
D00GLW	DRUGNAME	OM-294-DP
D00GLW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T7AE	TTDDRUID	D0T7AE
D0T7AE	DRUGNAME	OMS-182410
D0T7AE	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D00HPX	TTDDRUID	D00HPX
D00HPX	DRUGNAME	ON-04
D00HPX	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0A7XQ	TTDDRUID	D0A7XQ
D0A7XQ	DRUGNAME	ON-044580
D0A7XQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02IZN	TTDDRUID	D02IZN
D02IZN	DRUGNAME	ON-123
D02IZN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0CY9O	TTDDRUID	D0CY9O
D0CY9O	DRUGNAME	ON-128
D0CY9O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04EPS	TTDDRUID	D04EPS
D04EPS	DRUGNAME	ON-24160
D04EPS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06FSV	TTDDRUID	D06FSV
D06FSV	DRUGNAME	Onco-D
D06FSV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03REU	TTDDRUID	D03REU
D03REU	DRUGNAME	Oncology therapeutics
D03REU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0O8YF	TTDDRUID	D0O8YF
D0O8YF	DRUGNAME	Oncoprev
D0O8YF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T3CB	TTDDRUID	D0T3CB
D0T3CB	DRUGNAME	Ono 1
D0T3CB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0V9MO	TTDDRUID	D0V9MO
D0V9MO	DRUGNAME	Ono 3
D0V9MO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0OE2Z	TTDDRUID	D0OE2Z
D0OE2Z	DRUGNAME	ONO-8809
D0OE2Z	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0Q4MO	TTDDRUID	D0Q4MO
D0Q4MO	DRUGNAME	ONX-0914
D0Q4MO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D01RYJ	TTDDRUID	D01RYJ
D01RYJ	DRUGNAME	OP-02
D01RYJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04EFB	TTDDRUID	D04EFB
D04EFB	DRUGNAME	OP-03
D04EFB	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0S0DY	TTDDRUID	D0S0DY
D0S0DY	DRUGNAME	OP-04
D0S0DY	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D02OIP	TTDDRUID	D02OIP
D02OIP	DRUGNAME	OP-05
D02OIP	INDICATI	Liver cancer [ICD-11: 2C12] Investigative

D0WM5H	TTDDRUID	D0WM5H
D0WM5H	DRUGNAME	OP-06
D0WM5H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K6LA	TTDDRUID	D0K6LA
D0K6LA	DRUGNAME	OPC-22575
D0K6LA	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D0F5TM	TTDDRUID	D0F5TM
D0F5TM	DRUGNAME	OPI-1100
D0F5TM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P5IS	TTDDRUID	D0P5IS
D0P5IS	DRUGNAME	Opioid prodrugs
D0P5IS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0F8ZD	TTDDRUID	D0F8ZD
D0F8ZD	DRUGNAME	OPN-302
D0F8ZD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00RDI	TTDDRUID	D00RDI
D00RDI	DRUGNAME	OPN-401
D00RDI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09WAY	TTDDRUID	D09WAY
D09WAY	DRUGNAME	OPN-501
D09WAY	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0O3YA	TTDDRUID	D0O3YA
D0O3YA	DRUGNAME	OPRX
D0O3YA	INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Investigative

D0O3ZI	TTDDRUID	D0O3ZI
D0O3ZI	DRUGNAME	OpsoVac
D0O3ZI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FJ4J	TTDDRUID	D0FJ4J
D0FJ4J	DRUGNAME	Oragens
D0FJ4J	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0M9HA	TTDDRUID	D0M9HA
D0M9HA	DRUGNAME	Oral anti-inflammatory agents
D0M9HA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0N3EF	TTDDRUID	D0N3EF
D0N3EF	DRUGNAME	Oral interferons
D0N3EF	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative

D0A6PD	TTDDRUID	D0A6PD
D0A6PD	DRUGNAME	Oralgen Tree Pollen
D0A6PD	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0Q6RX	TTDDRUID	D0Q6RX
D0Q6RX	DRUGNAME	Oravax-PX
D0Q6RX	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D01RSW	TTDDRUID	D01RSW
D01RSW	DRUGNAME	Orazamide orotate
D01RSW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0NH1E	TTDDRUID	D0NH1E
D0NH1E	DRUGNAME	Org-231295
D0NH1E	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D06BHK	TTDDRUID	D06BHK
D06BHK	DRUGNAME	ORG-9453
D06BHK	INDICATI	Paralysis [ICD-11: 8B60] Investigative

D04MEM	TTDDRUID	D04MEM
D04MEM	DRUGNAME	ORMD-1001
D04MEM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0K7KV	TTDDRUID	D0K7KV
D0K7KV	DRUGNAME	ORP-100
D0K7KV	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D0M8FF	TTDDRUID	D0M8FF
D0M8FF	DRUGNAME	OSL-95II
D0M8FF	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0FG6E	TTDDRUID	D0FG6E
D0FG6E	DRUGNAME	Osteoporosis therapy, Entera Bio Ltd
D0FG6E	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0R0HG	TTDDRUID	D0R0HG
D0R0HG	DRUGNAME	Osteoporosis therapy, FAES Farma SA
D0R0HG	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0L9ZF	TTDDRUID	D0L9ZF
D0L9ZF	DRUGNAME	OsteoStem
D0L9ZF	INDICATI	Bone injury [ICD-11: ND56.Y] Investigative

D03SLO	TTDDRUID	D03SLO
D03SLO	DRUGNAME	OSU-2S
D03SLO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XM6L	TTDDRUID	D0XM6L
D0XM6L	DRUGNAME	OT-010
D0XM6L	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D08QUC	TTDDRUID	D08QUC
D08QUC	DRUGNAME	OT-121
D08QUC	INDICATI	Asthma [ICD-11: CA23] Investigative

D0B6BE	TTDDRUID	D0B6BE
D0B6BE	DRUGNAME	OT-417
D0B6BE	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D02UWX	TTDDRUID	D02UWX
D02UWX	DRUGNAME	OT-440
D02UWX	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D06LKP	TTDDRUID	D06LKP
D06LKP	DRUGNAME	OTI-050
D06LKP	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0T1MT	TTDDRUID	D0T1MT
D0T1MT	DRUGNAME	OTK18 TF mabs
D0T1MT	INDICATI	Viral encephalitis [ICD-11: 1C80] Investigative

D01OVV	TTDDRUID	D01OVV
D01OVV	DRUGNAME	OVI-117
D01OVV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J9PK	TTDDRUID	D0J9PK
D0J9PK	DRUGNAME	OXA-01
D0J9PK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00ZZB	TTDDRUID	D00ZZB
D00ZZB	DRUGNAME	Oxaborole
D00ZZB	INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative

D0US8M	TTDDRUID	D0US8M
D0US8M	DRUGNAME	OX-CLI
D0US8M	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative

D0Q8YU	TTDDRUID	D0Q8YU
D0Q8YU	DRUGNAME	OX-ESI
D0Q8YU	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative

D0VC0I	TTDDRUID	D0VC0I
D0VC0I	DRUGNAME	Oxindole 94
D0VC0I	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06YUR	TTDDRUID	D06YUR
D06YUR	DRUGNAME	Oxindole derivative
D06YUR	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0X6EX	TTDDRUID	D0X6EX
D0X6EX	DRUGNAME	OX-MPI
D0X6EX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09QTL	TTDDRUID	D09QTL
D09QTL	DRUGNAME	Oxygen carrier
D09QTL	INDICATI	Skin burns [ICD-11: ME65.0] Investigative

D02LAP	TTDDRUID	D02LAP
D02LAP	DRUGNAME	Oxymera
D02LAP	INDICATI	Obesity [ICD-11: 5B81] Investigative

D04JRK	TTDDRUID	D04JRK
D04JRK	DRUGNAME	P-1104
D04JRK	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0J0GJ	TTDDRUID	D0J0GJ
D0J0GJ	DRUGNAME	P-1116
D0J0GJ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0W7TK	TTDDRUID	D0W7TK
D0W7TK	DRUGNAME	P-1118
D0W7TK	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Investigative

D08XOF	TTDDRUID	D08XOF
D08XOF	DRUGNAME	P-13
D08XOF	INDICATI	Otitis media [ICD-11: AA80-AB0Z] Investigative

D0LG9U	TTDDRUID	D0LG9U
D0LG9U	DRUGNAME	P-144, AMD
D0LG9U	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0N0EB	TTDDRUID	D0N0EB
D0N0EB	DRUGNAME	P-17 ophthalmic
D0N0EB	INDICATI	Bone metastases [ICD-11: 2D50] Investigative

D0AF8R	TTDDRUID	D0AF8R
D0AF8R	DRUGNAME	P-216CM
D0AF8R	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D08ZGG	TTDDRUID	D08ZGG
D08ZGG	DRUGNAME	P-218
D08ZGG	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D07NFT	TTDDRUID	D07NFT
D07NFT	DRUGNAME	P-2281
D07NFT	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D05SMV	TTDDRUID	D05SMV
D05SMV	DRUGNAME	P2B-002
D05SMV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I0XX	TTDDRUID	D0I0XX
D0I0XX	DRUGNAME	P2B-003
D0I0XX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03UOG	TTDDRUID	D03UOG
D03UOG	DRUGNAME	P2B-004
D03UOG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V6NX	TTDDRUID	D0V6NX
D0V6NX	DRUGNAME	P2X7 antagonists
D0V6NX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D02LSO	TTDDRUID	D02LSO
D02LSO	DRUGNAME	P2Y1 antagonists
D02LSO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0I8QY	TTDDRUID	D0I8QY
D0I8QY	DRUGNAME	P31-Protein
D0I8QY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00VMY	TTDDRUID	D00VMY
D00VMY	DRUGNAME	P-3378
D00VMY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G7TI	TTDDRUID	D0G7TI
D0G7TI	DRUGNAME	P38 MAP kinase alpha inhibitors
D0G7TI	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D06WLG	TTDDRUID	D06WLG
D06WLG	DRUGNAME	P53 fusion protein
D06WLG	INDICATI	Liver cancer [ICD-11: 2C12] Investigative

D00GNN	TTDDRUID	D00GNN
D00GNN	DRUGNAME	P53 mdm-2-binding domain peptides
D00GNN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02KLE	TTDDRUID	D02KLE
D02KLE	DRUGNAME	P-536
D02KLE	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0Y8YW	TTDDRUID	D0Y8YW
D0Y8YW	DRUGNAME	P53-MDM2 binding inhibitors
D0Y8YW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QE9F	TTDDRUID	D0QE9F
D0QE9F	DRUGNAME	P-6915
D0QE9F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08PET	TTDDRUID	D08PET
D08PET	DRUGNAME	P70S6 kinase inhibitors
D08PET	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00OTH	TTDDRUID	D00OTH
D00OTH	DRUGNAME	P-979
D00OTH	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0JV4A	TTDDRUID	D0JV4A
D0JV4A	DRUGNAME	PA08140
D0JV4A	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D03SSG	TTDDRUID	D03SSG
D03SSG	DRUGNAME	PA-10040
D03SSG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0W8VC	TTDDRUID	D0W8VC
D0W8VC	DRUGNAME	PA-1637
D0W8VC	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D09PGH	TTDDRUID	D09PGH
D09PGH	DRUGNAME	PA-508
D09PGH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D08DNA	TTDDRUID	D08DNA
D08DNA	DRUGNAME	PA-517
D08DNA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0YK4L	TTDDRUID	D0YK4L
D0YK4L	DRUGNAME	PAC-10649
D0YK4L	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0PD0F	TTDDRUID	D0PD0F
D0PD0F	DRUGNAME	Paeoniflorin
D0PD0F	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0A5HS	TTDDRUID	D0A5HS
D0A5HS	DRUGNAME	Pain therapeutic
D0A5HS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00WBY	TTDDRUID	D00WBY
D00WBY	DRUGNAME	Pain therapy, Sephoris
D00WBY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00SMC	TTDDRUID	D00SMC
D00SMC	DRUGNAME	PAN-22
D00SMC	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D0R9UO	TTDDRUID	D0R9UO
D0R9UO	DRUGNAME	PAN-622
D0R9UO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0HW1I	TTDDRUID	D0HW1I
D0HW1I	DRUGNAME	PAN-622-toxin conjugate
D0HW1I	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Investigative

D0F3BP	TTDDRUID	D0F3BP
D0F3BP	DRUGNAME	PAN-90716-DES
D0F3BP	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D00LXB	TTDDRUID	D00LXB
D00LXB	DRUGNAME	Panaecin
D00LXB	INDICATI	Lung infection [ICD-11: CA4Z] Investigative

D0K5CP	TTDDRUID	D0K5CP
D0K5CP	DRUGNAME	Pancreatic enzyme
D0K5CP	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Investigative

D0H1UB	TTDDRUID	D0H1UB
D0H1UB	DRUGNAME	PanCyte
D0H1UB	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0Q2ZQ	TTDDRUID	D0Q2ZQ
D0Q2ZQ	DRUGNAME	PAR-401
D0Q2ZQ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0V7OY	TTDDRUID	D0V7OY
D0V7OY	DRUGNAME	Paracetamol prodrugs
D0V7OY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D09ZNS	TTDDRUID	D09ZNS
D09ZNS	DRUGNAME	Paramyxovirus therapy, PiKe
D09ZNS	INDICATI	Paramyxovirus infection [ICD-11: 1C8E.Y] Investigative

D0W2PZ	TTDDRUID	D0W2PZ
D0W2PZ	DRUGNAME	Parasin I
D0W2PZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0E9NJ	TTDDRUID	D0E9NJ
D0E9NJ	DRUGNAME	PARCETASAL
D0E9NJ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D08ZSQ	TTDDRUID	D08ZSQ
D08ZSQ	DRUGNAME	Parke-Davis 1
D08ZSQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0A6MS	TTDDRUID	D0A6MS
D0A6MS	DRUGNAME	Parke-Davis 9
D0A6MS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0X3OU	TTDDRUID	D0X3OU
D0X3OU	DRUGNAME	Parkinsons therapeutic peptides
D0X3OU	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D01DQI	TTDDRUID	D01DQI
D01DQI	DRUGNAME	Parvovirus H-1
D01DQI	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D0X7ZH	TTDDRUID	D0X7ZH
D0X7ZH	DRUGNAME	PAT-CM-1
D0X7ZH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03MDV	TTDDRUID	D03MDV
D03MDV	DRUGNAME	PAT-CSL1
D03MDV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05GVO	TTDDRUID	D05GVO
D05GVO	DRUGNAME	PAT-NM-1
D05GVO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U9YV	TTDDRUID	D0U9YV
D0U9YV	DRUGNAME	PAT-PM-1
D0U9YV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D0X2NE	TTDDRUID	D0X2NE
D0X2NE	DRUGNAME	PAT-SM3
D0X2NE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0IP7M	TTDDRUID	D0IP7M
D0IP7M	DRUGNAME	PAT-SM4
D0IP7M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03NJN	TTDDRUID	D03NJN
D03NJN	DRUGNAME	PAT-SM5
D03NJN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03LIE	TTDDRUID	D03LIE
D03LIE	DRUGNAME	PAV-059
D03LIE	INDICATI	Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative

D0V2ZH	TTDDRUID	D0V2ZH
D0V2ZH	DRUGNAME	PAV-611
D0V2ZH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0GW3R	TTDDRUID	D0GW3R
D0GW3R	DRUGNAME	PAV-612
D0GW3R	INDICATI	Rabies [ICD-11: 1C82] Investigative

D0N8CM	TTDDRUID	D0N8CM
D0N8CM	DRUGNAME	PAV-616
D0N8CM	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0PC1A	TTDDRUID	D0PC1A
D0PC1A	DRUGNAME	PAV-617
D0PC1A	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D0RV8L	TTDDRUID	D0RV8L
D0RV8L	DRUGNAME	PAV-667
D0RV8L	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D0MJ9L	TTDDRUID	D0MJ9L
D0MJ9L	DRUGNAME	PB-102
D0MJ9L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q9DL	TTDDRUID	D0Q9DL
D0Q9DL	DRUGNAME	PB-108
D0Q9DL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0B9UB	TTDDRUID	D0B9UB
D0B9UB	DRUGNAME	PB-200a
D0B9UB	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0RB2H	TTDDRUID	D0RB2H
D0RB2H	DRUGNAME	PBI-1308
D0RB2H	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D06OUW	TTDDRUID	D06OUW
D06OUW	DRUGNAME	PBI-220
D06OUW	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D0C0TJ	TTDDRUID	D0C0TJ
D0C0TJ	DRUGNAME	PBI-230
D0C0TJ	INDICATI	Intoxication [ICD-11: 6C40-6C4B] Investigative

D08RDG	TTDDRUID	D08RDG
D08RDG	DRUGNAME	PBI-4419
D08RDG	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D02FAI	TTDDRUID	D02FAI
D02FAI	DRUGNAME	Pbi-shPDX-1 LP
D02FAI	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D0F1WQ	TTDDRUID	D0F1WQ
D0F1WQ	DRUGNAME	Pbi-shSTMN1 LP
D0F1WQ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0A2TJ	TTDDRUID	D0A2TJ
D0A2TJ	DRUGNAME	PBOX-15
D0A2TJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01MPX	TTDDRUID	D01MPX
D01MPX	DRUGNAME	PC-190723
D01MPX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0I2KZ	TTDDRUID	D0I2KZ
D0I2KZ	DRUGNAME	PC-2000
D0I2KZ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0E0UN	TTDDRUID	D0E0UN
D0E0UN	DRUGNAME	PC-22
D0E0UN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y5UC	TTDDRUID	D0Y5UC
D0Y5UC	DRUGNAME	PC-24
D0Y5UC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00OKK	TTDDRUID	D00OKK
D00OKK	DRUGNAME	PC4708
D00OKK	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0G9BH	TTDDRUID	D0G9BH
D0G9BH	DRUGNAME	PC-8608
D0G9BH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H5HT	TTDDRUID	D0H5HT
D0H5HT	DRUGNAME	PCAP-1
D0H5HT	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0Q5MC	TTDDRUID	D0Q5MC
D0Q5MC	DRUGNAME	PCI-34051
D0Q5MC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0GO9G	TTDDRUID	D0GO9G
D0GO9G	DRUGNAME	PC-mab
D0GO9G	INDICATI	Artery stenosis [ICD-11: BD52] Investigative

D0I8OE	TTDDRUID	D0I8OE
D0I8OE	DRUGNAME	PcTx1
D0I8OE	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0O5QT	TTDDRUID	D0O5QT
D0O5QT	DRUGNAME	PD-0805
D0O5QT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0D6LF	TTDDRUID	D0D6LF
D0D6LF	DRUGNAME	PD-156
D0D6LF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0PE8P	TTDDRUID	D0PE8P
D0PE8P	DRUGNAME	PD173212
D0PE8P	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0UB0T	TTDDRUID	D0UB0T
D0UB0T	DRUGNAME	PD176078
D0UB0T	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0WO8I	TTDDRUID	D0WO8I
D0WO8I	DRUGNAME	PD-2015
D0WO8I	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D05HJO	TTDDRUID	D05HJO
D05HJO	DRUGNAME	PD-2024
D05HJO	INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Investigative

D0X3QL	TTDDRUID	D0X3QL
D0X3QL	DRUGNAME	PD-3766
D0X3QL	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0J1KG	TTDDRUID	D0J1KG
D0J1KG	DRUGNAME	PD-4048
D0J1KG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0CE5S	TTDDRUID	D0CE5S
D0CE5S	DRUGNAME	PD-4074
D0CE5S	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0G7LT	TTDDRUID	D0G7LT
D0G7LT	DRUGNAME	PD-AAV9
D0G7LT	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D05SVN	TTDDRUID	D05SVN
D05SVN	DRUGNAME	PdB-W433F
D05SVN	INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative

D05DRG	TTDDRUID	D05DRG
D05DRG	DRUGNAME	PDC-31
D05DRG	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Investigative

D04QUD	TTDDRUID	D04QUD
D04QUD	DRUGNAME	PDE4 inhibitors, GlaxoSmithKline
D04QUD	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0G1YQ	TTDDRUID	D0G1YQ
D0G1YQ	DRUGNAME	PDE4 inhibitors, Scottich Biomedical
D0G1YQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D08NYO	TTDDRUID	D08NYO
D08NYO	DRUGNAME	PDGF gene therapy
D08NYO	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Investigative

D0N2DD	TTDDRUID	D0N2DD
D0N2DD	DRUGNAME	PDL-241
D0N2DD	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0H7OO	TTDDRUID	D0H7OO
D0H7OO	DRUGNAME	PDS-0102
D0H7OO	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0A7UK	TTDDRUID	D0A7UK
D0A7UK	DRUGNAME	PDS-0103
D0A7UK	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0R3JO	TTDDRUID	D0R3JO
D0R3JO	DRUGNAME	PEG-EPO
D0R3JO	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D03DQK	TTDDRUID	D03DQK
D03DQK	DRUGNAME	PEG-Hb/HS
D03DQK	INDICATI	Shock [ICD-11: MG40] Investigative

D0J3AV	TTDDRUID	D0J3AV
D0J3AV	DRUGNAME	PEG-LPA-2
D0J3AV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05VVT	TTDDRUID	D05VVT
D05VVT	DRUGNAME	PEG-PLA-TNP-470
D05VVT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08HUJ	TTDDRUID	D08HUJ
D08HUJ	DRUGNAME	PEG-TGF peptantagonist
D08HUJ	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative

D09WGU	TTDDRUID	D09WGU
D09WGU	DRUGNAME	PEG-VM-501
D09WGU	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D00EYF	TTDDRUID	D00EYF
D00EYF	DRUGNAME	PEGylated insulin
D00EYF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D06GZW	TTDDRUID	D06GZW
D06GZW	DRUGNAME	PEGylated leptin
D06GZW	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0U1HE	TTDDRUID	D0U1HE
D0U1HE	DRUGNAME	PEGylated PYY-3-36
D0U1HE	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D06BKF	TTDDRUID	D06BKF
D06BKF	DRUGNAME	PEGylated recombinant EPO
D06BKF	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D05VLB	TTDDRUID	D05VLB
D05VLB	DRUGNAME	PEGylated recombinant IFN-alpha2b
D05VLB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03IEB	TTDDRUID	D03IEB
D03IEB	DRUGNAME	Penecure
D03IEB	INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative

D0F3GK	TTDDRUID	D0F3GK
D0F3GK	DRUGNAME	Peniel 1000
D0F3GK	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0DA0C	TTDDRUID	D0DA0C
D0DA0C	DRUGNAME	Peniel-3000
D0DA0C	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0UU4D	TTDDRUID	D0UU4D
D0UU4D	DRUGNAME	Peniel-5000
D0UU4D	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Y4BF	TTDDRUID	D0Y4BF
D0Y4BF	DRUGNAME	Pentraxin 2/analog
D0Y4BF	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D0VG0G	TTDDRUID	D0VG0G
D0VG0G	DRUGNAME	PeproStat
D0VG0G	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D07POY	TTDDRUID	D07POY
D07POY	DRUGNAME	Peptagon
D07POY	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0RS5N	TTDDRUID	D0RS5N
D0RS5N	DRUGNAME	Peptide antibiotics
D0RS5N	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0R7II	TTDDRUID	D0R7II
D0R7II	DRUGNAME	Peptide therapy, asthma
D0R7II	INDICATI	Asthma [ICD-11: CA23] Investigative

D05WPE	TTDDRUID	D05WPE
D05WPE	DRUGNAME	Peptide therapy, autoimmune disease
D05WPE	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D08UDE	TTDDRUID	D08UDE
D08UDE	DRUGNAME	Peptide-conjugated phosphorodiamidate morpholino oligomers
D08UDE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0S1YQ	TTDDRUID	D0S1YQ
D0S1YQ	DRUGNAME	Peptides
D0S1YQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0M2OJ	TTDDRUID	D0M2OJ
D0M2OJ	DRUGNAME	Peptidomimetics
D0M2OJ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0P9UW	TTDDRUID	D0P9UW
D0P9UW	DRUGNAME	Periodontitis therapy, Sanofi
D0P9UW	INDICATI	Periodontitis [ICD-11: DA0C] Investigative

D0T9KR	TTDDRUID	D0T9KR
D0T9KR	DRUGNAME	PET imaging agent
D0T9KR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0CE7V	TTDDRUID	D0CE7V
D0CE7V	DRUGNAME	PET radiotracer
D0CE7V	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04ARO	TTDDRUID	D04ARO
D04ARO	DRUGNAME	PEV-4
D04ARO	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D03XLO	TTDDRUID	D03XLO
D03XLO	DRUGNAME	PEV-8
D03XLO	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0YD9E	TTDDRUID	D0YD9E
D0YD9E	DRUGNAME	PF-00212062
D0YD9E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G3ZN	TTDDRUID	D0G3ZN
D0G3ZN	DRUGNAME	PF-00614435
D0G3ZN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H2MF	TTDDRUID	D0H2MF
D0H2MF	DRUGNAME	PF-02367982
D0H2MF	INDICATI	Endometriosis [ICD-11: GA10] Investigative

D05RSS	TTDDRUID	D05RSS
D05RSS	DRUGNAME	PF-03772304
D05RSS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03TYT	TTDDRUID	D03TYT
D03TYT	DRUGNAME	PF-03800130
D03TYT	INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative

D06WDT	TTDDRUID	D06WDT
D06WDT	DRUGNAME	PF-04094667
D06WDT	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D04JPG	TTDDRUID	D04JPG
D04JPG	DRUGNAME	PF-04447943
D04JPG	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09TPW	TTDDRUID	D09TPW
D09TPW	DRUGNAME	PF-04475270
D09TPW	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0X6GP	TTDDRUID	D0X6GP
D0X6GP	DRUGNAME	PF-04577806
D0X6GP	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative

D04TZA	TTDDRUID	D04TZA
D04TZA	DRUGNAME	PF-04957325
D04TZA	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
D04TZA	INDICATI	Itching [ICD-11: 1F28-1G07] Investigative

D0Z2CP	TTDDRUID	D0Z2CP
D0Z2CP	DRUGNAME	PF-05
D0Z2CP	INDICATI	Constipation [ICD-11: DD91.1] Investigative

D03XRZ	TTDDRUID	D03XRZ
D03XRZ	DRUGNAME	PF-05094037
D03XRZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00DSG	TTDDRUID	D00DSG
D00DSG	DRUGNAME	PF-05313261
D00DSG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D03PBL	TTDDRUID	D03PBL
D03PBL	DRUGNAME	PF-08
D03PBL	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative

D05JJC	TTDDRUID	D05JJC
D05JJC	DRUGNAME	PF-14
D05JJC	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00TBJ	TTDDRUID	D00TBJ
D00TBJ	DRUGNAME	PF-271836
D00TBJ	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative

D0N2KU	TTDDRUID	D0N2KU
D0N2KU	DRUGNAME	PF-3409409
D0N2KU	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative

D0UI4S	TTDDRUID	D0UI4S
D0UI4S	DRUGNAME	PF-3475952
D0UI4S	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T6LF	TTDDRUID	D0T6LF
D0T6LF	DRUGNAME	PF-3823863
D0T6LF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M7TW	TTDDRUID	D0M7TW
D0M7TW	DRUGNAME	PF-3900422
D0M7TW	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D06NIT	TTDDRUID	D06NIT
D06NIT	DRUGNAME	PF-4181366
D06NIT	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0L1BS	TTDDRUID	D0L1BS
D0L1BS	DRUGNAME	PF-454583
D0L1BS	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0I7FH	TTDDRUID	D0I7FH
D0I7FH	DRUGNAME	PF-4859989
D0I7FH	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D0TE9G	TTDDRUID	D0TE9G
D0TE9G	DRUGNAME	PF-4957325-00
D0TE9G	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00JIV	TTDDRUID	D00JIV
D00JIV	DRUGNAME	PF-4989216
D00JIV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09BXJ	TTDDRUID	D09BXJ
D09BXJ	DRUGNAME	PF-5177624
D09BXJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08GZX	TTDDRUID	D08GZX
D08GZX	DRUGNAME	PF-613322
D08GZX	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0V6VQ	TTDDRUID	D0V6VQ
D0V6VQ	DRUGNAME	PF-956980
D0V6VQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0A8AL	TTDDRUID	D0A8AL
D0A8AL	DRUGNAME	PFK-015
D0A8AL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F9YJ	TTDDRUID	D0F9YJ
D0F9YJ	DRUGNAME	Pfs48
D0F9YJ	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D06QJG	TTDDRUID	D06QJG
D06QJG	DRUGNAME	PG-1014491
D06QJG	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0L8US	TTDDRUID	D0L8US
D0L8US	DRUGNAME	PG-11144
D0L8US	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A9BO	TTDDRUID	D0A9BO
D0A9BO	DRUGNAME	PG-120
D0A9BO	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D05BRZ	TTDDRUID	D05BRZ
D05BRZ	DRUGNAME	PG-140
D05BRZ	INDICATI	Transplant rejection [ICD-11: NE84] Investigative

D0Y0LA	TTDDRUID	D0Y0LA
D0Y0LA	DRUGNAME	PG2-2000
D0Y0LA	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D0U2XB	TTDDRUID	D0U2XB
D0U2XB	DRUGNAME	PGC GLP-1
D0U2XB	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D09TJV	TTDDRUID	D09TJV
D09TJV	DRUGNAME	PGC-lysostaphin
D09TJV	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D0TY8B	TTDDRUID	D0TY8B
D0TY8B	DRUGNAME	PGGA-PTX
D0TY8B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06LAX	TTDDRUID	D06LAX
D06LAX	DRUGNAME	PGI-02749
D06LAX	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D00XSQ	TTDDRUID	D00XSQ
D00XSQ	DRUGNAME	PGL-1001
D00XSQ	INDICATI	Female infertility [ICD-11: GA31.Z] Investigative

D05NJG	TTDDRUID	D05NJG
D05NJG	DRUGNAME	PH sensitive micelles
D05NJG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M2ZG	TTDDRUID	D0M2ZG
D0M2ZG	DRUGNAME	PHA-647A
D0M2ZG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00TBD	TTDDRUID	D00TBD
D00TBD	DRUGNAME	PHA-665752
D00TBD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L1NU	TTDDRUID	D0L1NU
D0L1NU	DRUGNAME	PHA-666859
D0L1NU	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative

D0T5AH	TTDDRUID	D0T5AH
D0T5AH	DRUGNAME	PHA-690509
D0T5AH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y4QU	TTDDRUID	D0Y4QU
D0Y4QU	DRUGNAME	Pharmacological chaperones
D0Y4QU	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0B1CF	TTDDRUID	D0B1CF
D0B1CF	DRUGNAME	PharmaPEG-EPO
D0B1CF	INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative

D06HOS	TTDDRUID	D06HOS
D06HOS	DRUGNAME	PharmaPEG-GM-CSF
D06HOS	INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative

D0LC0E	TTDDRUID	D0LC0E
D0LC0E	DRUGNAME	PharmaPEG-interferon-alpha
D0LC0E	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0MK5C	TTDDRUID	D0MK5C
D0MK5C	DRUGNAME	PharmaPEG-interferon-beta
D0MK5C	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D07SHM	TTDDRUID	D07SHM
D07SHM	DRUGNAME	Phenix project
D07SHM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D03PZY	TTDDRUID	D03PZY
D03PZY	DRUGNAME	PHER-O2
D03PZY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Z0EH	TTDDRUID	D0Z0EH
D0Z0EH	DRUGNAME	PheTQS
D0Z0EH	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0R6GM	TTDDRUID	D0R6GM
D0R6GM	DRUGNAME	Phosphate binding agent
D0R6GM	INDICATI	Kidney disease [ICD-11: GC2Z] Investigative

D0Q9VS	TTDDRUID	D0Q9VS
D0Q9VS	DRUGNAME	Phosphatonin
D0Q9VS	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative

D07NUZ	TTDDRUID	D07NUZ
D07NUZ	DRUGNAME	Phospho-aspirins
D07NUZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F3WF	TTDDRUID	D0F3WF
D0F3WF	DRUGNAME	Photo-labeled dapivirine derivative
D0F3WF	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D03CBU	TTDDRUID	D03CBU
D03CBU	DRUGNAME	PHY-626
D03CBU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D4WA	TTDDRUID	D0D4WA
D0D4WA	DRUGNAME	PHY-777
D0D4WA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V2PK	TTDDRUID	D0V2PK
D0V2PK	DRUGNAME	PHY-808
D0V2PK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W5WA	TTDDRUID	D0W5WA
D0W5WA	DRUGNAME	Phylomer peptides
D0W5WA	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Y5BR	TTDDRUID	D0Y5BR
D0Y5BR	DRUGNAME	Phylomers
D0Y5BR	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D0QV7L	TTDDRUID	D0QV7L
D0QV7L	DRUGNAME	Phytobacx
D0QV7L	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0XT5G	TTDDRUID	D0XT5G
D0XT5G	DRUGNAME	Phytocannabinoids
D0XT5G	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D0W8XH	TTDDRUID	D0W8XH
D0W8XH	DRUGNAME	PI-103
D0W8XH	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Investigative

D0C7SF	TTDDRUID	D0C7SF
D0C7SF	DRUGNAME	PI3K alpha inhibitors
D0C7SF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04RKA	TTDDRUID	D04RKA
D04RKA	DRUGNAME	PIM protein kinase inhibitors
D04RKA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04GHG	TTDDRUID	D04GHG
D04GHG	DRUGNAME	Pim1 inhibitors
D04GHG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H1NI	TTDDRUID	D0H1NI
D0H1NI	DRUGNAME	PINS
D0H1NI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D06UOL	TTDDRUID	D06UOL
D06UOL	DRUGNAME	PIROTIODECANE
D06UOL	INDICATI	Ophthalmic graves disease [ICD-11: 5A02.0] Investigative

D00ASX	TTDDRUID	D00ASX
D00ASX	DRUGNAME	PJ-015
D00ASX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D0U6NC	TTDDRUID	D0U6NC
D0U6NC	DRUGNAME	PJ-016
D0U6NC	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative

D0XO8D	TTDDRUID	D0XO8D
D0XO8D	DRUGNAME	PJJ-34
D0XO8D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01CYW	TTDDRUID	D01CYW
D01CYW	DRUGNAME	PK-236
D01CYW	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D05WKT	TTDDRUID	D05WKT
D05WKT	DRUGNAME	PK-44
D05WKT	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D07PMP	TTDDRUID	D07PMP
D07PMP	DRUGNAME	PKI-402
D07PMP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04YQS	TTDDRUID	D04YQS
D04YQS	DRUGNAME	PknB inhibitor
D04YQS	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D09VCC	TTDDRUID	D09VCC
D09VCC	DRUGNAME	PL-6983
D09VCC	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative

D0I5ED	TTDDRUID	D0I5ED
D0I5ED	DRUGNAME	Placental growth factor
D0I5ED	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0C0FO	TTDDRUID	D0C0FO
D0C0FO	DRUGNAME	Plant-based oncology candidate
D0C0FO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0Q7AZ	TTDDRUID	D0Q7AZ
D0Q7AZ	DRUGNAME	Plant-derived antibacterials
D0Q7AZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D07VWT	TTDDRUID	D07VWT
D07VWT	DRUGNAME	Platelet activating factor receptor inhibitors
D07VWT	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0D9YU	TTDDRUID	D0D9YU
D0D9YU	DRUGNAME	PLATENSIMYCIN
D0D9YU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0A9SS	TTDDRUID	D0A9SS
D0A9SS	DRUGNAME	Platinum-based chemotherapy or PARP inhibition
D0A9SS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D02VNY	TTDDRUID	D02VNY
D02VNY	DRUGNAME	Pleodrug
D02VNY	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Investigative

D0R5JP	TTDDRUID	D0R5JP
D0R5JP	DRUGNAME	Pleuromutilins
D0R5JP	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0F5JZ	TTDDRUID	D0F5JZ
D0F5JZ	DRUGNAME	PLX-4720
D0F5JZ	INDICATI	Cutaneous melanoma [ICD-11: 2C30] Phase 1

D06YMT	TTDDRUID	D06YMT
D06YMT	DRUGNAME	PLX-ORI3
D06YMT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BP6I	TTDDRUID	D0BP6I
D0BP6I	DRUGNAME	PM-102
D0BP6I	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0M1KH	TTDDRUID	D0M1KH
D0M1KH	DRUGNAME	PM-181104
D0M1KH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Q4GT	TTDDRUID	D0Q4GT
D0Q4GT	DRUGNAME	PM-181108
D0Q4GT	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0QE8K	TTDDRUID	D0QE8K
D0QE8K	DRUGNAME	PM-72G
D0QE8K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H8BD	TTDDRUID	D0H8BD
D0H8BD	DRUGNAME	PMA-101R
D0H8BD	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D08UHC	TTDDRUID	D08UHC
D08UHC	DRUGNAME	PMA-104R
D08UHC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M1DE	TTDDRUID	D0M1DE
D0M1DE	DRUGNAME	PMA-109R
D0M1DE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03CZX	TTDDRUID	D03CZX
D03CZX	DRUGNAME	PMA-201
D03CZX	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Y0GS	TTDDRUID	D0Y0GS
D0Y0GS	DRUGNAME	PMA-406
D0Y0GS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E5IT	TTDDRUID	D0E5IT
D0E5IT	DRUGNAME	PMA-411R
D0E5IT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00XND	TTDDRUID	D00XND
D00XND	DRUGNAME	PMA-511R
D00XND	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D01LVM	TTDDRUID	D01LVM
D01LVM	DRUGNAME	PMA-BB10
D01LVM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T8QY	TTDDRUID	D0T8QY
D0T8QY	DRUGNAME	PMI-008
D0T8QY	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0S4IK	TTDDRUID	D0S4IK
D0S4IK	DRUGNAME	PMI-016
D0S4IK	INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative

D0P3KH	TTDDRUID	D0P3KH
D0P3KH	DRUGNAME	PMUC5AC
D0P3KH	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative

D07BWU	TTDDRUID	D07BWU
D07BWU	DRUGNAME	PMX-10072
D07BWU	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D06EUC	TTDDRUID	D06EUC
D06EUC	DRUGNAME	PMX-10098
D06EUC	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0U3JZ	TTDDRUID	D0U3JZ
D0U3JZ	DRUGNAME	PMX-30024
D0U3JZ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0O1EI	TTDDRUID	D0O1EI
D0O1EI	DRUGNAME	PMX-500
D0O1EI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03DTQ	TTDDRUID	D03DTQ
D03DTQ	DRUGNAME	PMX-700
D03DTQ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D0C7YH	TTDDRUID	D0C7YH
D0C7YH	DRUGNAME	PMX-900
D0C7YH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V6WZ	TTDDRUID	D0V6WZ
D0V6WZ	DRUGNAME	PN-201
D0V6WZ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D05UFN	TTDDRUID	D05UFN
D05UFN	DRUGNAME	PN-202
D05UFN	INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative

D0SO1Z	TTDDRUID	D0SO1Z
D0SO1Z	DRUGNAME	PN-203
D0SO1Z	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0UP5N	TTDDRUID	D0UP5N
D0UP5N	DRUGNAME	PN-2107
D0UP5N	INDICATI	Gout [ICD-11: FA25] Investigative

D00EQD	TTDDRUID	D00EQD
D00EQD	DRUGNAME	PN-277
D00EQD	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D04HXP	TTDDRUID	D04HXP
D04HXP	DRUGNAME	PN-2XXX
D04HXP	INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative

D01FTK	TTDDRUID	D01FTK
D01FTK	DRUGNAME	PN-403
D01FTK	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D06WLY	TTDDRUID	D06WLY
D06WLY	DRUGNAME	PN-951
D06WLY	INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative

D0M1KK	TTDDRUID	D0M1KK
D0M1KK	DRUGNAME	PNB-03
D0M1KK	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0EW4M	TTDDRUID	D0EW4M
D0EW4M	DRUGNAME	PNB-04
D0EW4M	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0C0WI	TTDDRUID	D0C0WI
D0C0WI	DRUGNAME	PNB-05
D0C0WI	INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Investigative

D0D4JT	TTDDRUID	D0D4JT
D0D4JT	DRUGNAME	PND-1186
D0D4JT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z3OO	TTDDRUID	D0Z3OO
D0Z3OO	DRUGNAME	PneuGEM
D0Z3OO	INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative

D08CRO	TTDDRUID	D08CRO
D08CRO	DRUGNAME	PNH-192
D08CRO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03SCP	TTDDRUID	D03SCP
D03SCP	DRUGNAME	PNT-200
D03SCP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09ENF	TTDDRUID	D09ENF
D09ENF	DRUGNAME	PNT-300
D09ENF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0GK1M	TTDDRUID	D0GK1M
D0GK1M	DRUGNAME	PNT-400
D0GK1M	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AA2X	TTDDRUID	D0AA2X
D0AA2X	DRUGNAME	PNT-500
D0AA2X	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05PWA	TTDDRUID	D05PWA
D05PWA	DRUGNAME	PNT-600
D05PWA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05QAA	TTDDRUID	D05QAA
D05QAA	DRUGNAME	PNU-248686A
D05QAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03XET	TTDDRUID	D03XET
D03XET	DRUGNAME	POD-003
D03XET	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D06KFW	TTDDRUID	D06KFW
D06KFW	DRUGNAME	Pokeweed antiviral protein
D06KFW	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative

D03DII	TTDDRUID	D03DII
D03DII	DRUGNAME	Pollen allergen immunotherapy
D03DII	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Investigative

D0Q6YT	TTDDRUID	D0Q6YT
D0Q6YT	DRUGNAME	Poloxafuse-I
D0Q6YT	INDICATI	Injury [ICD-11: NA00-ND5Z] Investigative

D01LAX	TTDDRUID	D01LAX
D01LAX	DRUGNAME	Poloxafuse-R
D01LAX	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D0J7CD	TTDDRUID	D0J7CD
D0J7CD	DRUGNAME	Poly IC-poly arginine
D0J7CD	INDICATI	Keratosis [ICD-11: ED56] Investigative

D08RDB	TTDDRUID	D08RDB
D08RDB	DRUGNAME	Polyamine
D08RDB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D08SXS	TTDDRUID	D08SXS
D08SXS	DRUGNAME	Polyflu
D08SXS	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0O0BR	TTDDRUID	D0O0BR
D0O0BR	DRUGNAME	Poly-ICR
D0O0BR	INDICATI	Keratosis [ICD-11: ED56] Investigative

D0J0AN	TTDDRUID	D0J0AN
D0J0AN	DRUGNAME	Polymer-tubulysin A prodrug conjugate
D0J0AN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03BCF	TTDDRUID	D03BCF
D03BCF	DRUGNAME	Poly-microbial agents
D03BCF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0O1OL	TTDDRUID	D0O1OL
D0O1OL	DRUGNAME	Polymyxins
D0O1OL	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D08SMN	TTDDRUID	D08SMN
D08SMN	DRUGNAME	POP-1
D08SMN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00RSX	TTDDRUID	D00RSX
D00RSX	DRUGNAME	Porcine liver cells
D00RSX	INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative

D0M9PD	TTDDRUID	D0M9PD
D0M9PD	DRUGNAME	PP-200
D0M9PD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W7YA	TTDDRUID	D0W7YA
D0W7YA	DRUGNAME	PP-202
D0W7YA	INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative

D0SV6V	TTDDRUID	D0SV6V
D0SV6V	DRUGNAME	PP-303
D0SV6V	INDICATI	Alopecia [ICD-11: ED70] Investigative

D07MHM	TTDDRUID	D07MHM
D07MHM	DRUGNAME	PP-405
D07MHM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02OLS	TTDDRUID	D02OLS
D02OLS	DRUGNAME	PPAR delta agonists
D02OLS	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D03JBI	TTDDRUID	D03JBI
D03JBI	DRUGNAME	PPI-03306
D03JBI	INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Investigative

D0M4MW	TTDDRUID	D0M4MW
D0M4MW	DRUGNAME	PPI-1301
D0M4MW	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D03QFY	TTDDRUID	D03QFY
D03QFY	DRUGNAME	PPLs
D03QFY	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0Z5VL	TTDDRUID	D0Z5VL
D0Z5VL	DRUGNAME	PPMX-2017
D0Z5VL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07UGI	TTDDRUID	D07UGI
D07UGI	DRUGNAME	PPS14 PCMV
D07UGI	INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative

D05QML	TTDDRUID	D05QML
D05QML	DRUGNAME	PQ-1
D05QML	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N9UP	TTDDRUID	D0N9UP
D0N9UP	DRUGNAME	PR-21
D0N9UP	INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative

D06RYG	TTDDRUID	D06RYG
D06RYG	DRUGNAME	PRAME-SLP
D06RYG	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0O1UP	TTDDRUID	D0O1UP
D0O1UP	DRUGNAME	PRB-01022
D0O1UP	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0P8NR	TTDDRUID	D0P8NR
D0P8NR	DRUGNAME	PRB-6014
D0P8NR	INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative

D0G2LR	TTDDRUID	D0G2LR
D0G2LR	DRUGNAME	Preeclampsia diagnostic/treatment
D0G2LR	INDICATI	Pre-eclampsia [ICD-11: JA24] Investigative

D03DBW	TTDDRUID	D03DBW
D03DBW	DRUGNAME	Pretubulysin
D03DBW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FN3U	TTDDRUID	D0FN3U
D0FN3U	DRUGNAME	PRL-3 specific mabs
D0FN3U	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative

D0DS2M	TTDDRUID	D0DS2M
D0DS2M	DRUGNAME	PrLL-37
D0DS2M	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D05NTQ	TTDDRUID	D05NTQ
D05NTQ	DRUGNAME	PRO-015
D05NTQ	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative

D08DPV	TTDDRUID	D08DPV
D08DPV	DRUGNAME	PRO-052
D08DPV	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D0J8VV	TTDDRUID	D0J8VV
D0J8VV	DRUGNAME	PRO-055
D0J8VV	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D0G1CB	TTDDRUID	D0G1CB
D0G1CB	DRUGNAME	PRO-105
D0G1CB	INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Investigative

D0N7HT	TTDDRUID	D0N7HT
D0N7HT	DRUGNAME	PRO-135
D0N7HT	INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Investigative

D0NO7L	TTDDRUID	D0NO7L
D0NO7L	DRUGNAME	PRO-289
D0NO7L	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D09RAB	TTDDRUID	D09RAB
D09RAB	DRUGNAME	PRO-300
D09RAB	INDICATI	Mucositis [ICD-11: CA00] Investigative

D0T0AM	TTDDRUID	D0T0AM
D0T0AM	DRUGNAME	Proapoptotic Surrobodies
D0T0AM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y4KA	TTDDRUID	D0Y4KA
D0Y4KA	DRUGNAME	Probodies
D0Y4KA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D06YEE	TTDDRUID	D06YEE
D06YEE	DRUGNAME	Prodigiosin
D06YEE	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D04UZX	TTDDRUID	D04UZX
D04UZX	DRUGNAME	Prodrug
D04UZX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0A2AD	TTDDRUID	D0A2AD
D0A2AD	DRUGNAME	Prodrug antibiotics
D0A2AD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D04TSC	TTDDRUID	D04TSC
D04TSC	DRUGNAME	Proenzy
D04TSC	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D00OHP	TTDDRUID	D00OHP
D00OHP	DRUGNAME	PRO-GR-300
D00OHP	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D01BOD	TTDDRUID	D01BOD
D01BOD	DRUGNAME	Pro-Islet
D01BOD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D03AAV	TTDDRUID	D03AAV
D03AAV	DRUGNAME	ProLindaun
D03AAV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06ENH	TTDDRUID	D06ENH
D06ENH	DRUGNAME	Prostacyclin analog
D06ENH	INDICATI	Pulmonary hypertension [ICD-11: BB01] Investigative

D0M6IG	TTDDRUID	D0M6IG
D0M6IG	DRUGNAME	Prostaganin
D0M6IG	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0PD1W	TTDDRUID	D0PD1W
D0PD1W	DRUGNAME	Prostaglandin D2 antagonists
D0PD1W	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D0BK3Z	TTDDRUID	D0BK3Z
D0BK3Z	DRUGNAME	ProstaRex
D0BK3Z	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D03XBT	TTDDRUID	D03XBT
D03XBT	DRUGNAME	Prostatix
D03XBT	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D01QIV	TTDDRUID	D01QIV
D01QIV	DRUGNAME	Prostaview
D01QIV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D04JNZ	TTDDRUID	D04JNZ
D04JNZ	DRUGNAME	PROSTRATIN
D04JNZ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0S4RR	TTDDRUID	D0S4RR
D0S4RR	DRUGNAME	ProTarg
D0S4RR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0U4JY	TTDDRUID	D0U4JY
D0U4JY	DRUGNAME	Protease activated prodrug
D0U4JY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I4OJ	TTDDRUID	D0I4OJ
D0I4OJ	DRUGNAME	Protectaid
D0I4OJ	INDICATI	Contraception [ICD-11: QA21] Investigative

D08JHA	TTDDRUID	D08JHA
D08JHA	DRUGNAME	Protein kinase therapeutic
D08JHA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D09JPL	TTDDRUID	D09JPL
D09JPL	DRUGNAME	Protein misfolding therapies
D09JPL	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0NI7H	TTDDRUID	D0NI7H
D0NI7H	DRUGNAME	Protein tyrosine phosphatase 1B inhibitors
D0NI7H	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D05OIL	TTDDRUID	D05OIL
D05OIL	DRUGNAME	Protein-silencing drugs
D05OIL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05WDJ	TTDDRUID	D05WDJ
D05WDJ	DRUGNAME	Proteolytic mabs
D05WDJ	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D0WX1I	TTDDRUID	D0WX1I
D0WX1I	DRUGNAME	ProVax
D0WX1I	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D00OTQ	TTDDRUID	D00OTQ
D00OTQ	DRUGNAME	Proximab
D00OTQ	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0Q4FA	TTDDRUID	D0Q4FA
D0Q4FA	DRUGNAME	PR-P
D0Q4FA	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D07JCU	TTDDRUID	D07JCU
D07JCU	DRUGNAME	PRS-040
D07JCU	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D01BEX	TTDDRUID	D01BEX
D01BEX	DRUGNAME	PRS-060
D01BEX	INDICATI	Asthma [ICD-11: CA23] Investigative

D0M0SV	TTDDRUID	D0M0SV
D0M0SV	DRUGNAME	PRS-110
D0M0SV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R5PP	TTDDRUID	D0R5PP
D0R5PP	DRUGNAME	PRS-190
D0R5PP	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D03HLK	TTDDRUID	D03HLK
D03HLK	DRUGNAME	PRT-060096
D03HLK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D09KEB	TTDDRUID	D09KEB
D09KEB	DRUGNAME	PRT-060318
D09KEB	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D07SXG	TTDDRUID	D07SXG
D07SXG	DRUGNAME	PRT-061103
D07SXG	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0SP5Q	TTDDRUID	D0SP5Q
D0SP5Q	DRUGNAME	PRT-064445
D0SP5Q	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D01IUD	TTDDRUID	D01IUD
D01IUD	DRUGNAME	PRT-20
D01IUD	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D0B4MB	TTDDRUID	D0B4MB
D0B4MB	DRUGNAME	PRT-300
D0B4MB	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D04AGM	TTDDRUID	D04AGM
D04AGM	DRUGNAME	PRTT-100
D04AGM	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D06VFI	TTDDRUID	D06VFI
D06VFI	DRUGNAME	PRTT-200
D06VFI	INDICATI	Fibromyalgia [ICD-11: MG30.01] Investigative

D0TN0O	TTDDRUID	D0TN0O
D0TN0O	DRUGNAME	PRTT-300
D0TN0O	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D03BMR	TTDDRUID	D03BMR
D03BMR	DRUGNAME	PRX-1
D03BMR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D08MVV	TTDDRUID	D08MVV
D08MVV	DRUGNAME	PRX-111
D08MVV	INDICATI	Female infertility [ICD-11: GA31.Z] Investigative

D02OOB	TTDDRUID	D02OOB
D02OOB	DRUGNAME	PRX-12205
D02OOB	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D01XAE	TTDDRUID	D01XAE
D01XAE	DRUGNAME	PRX-12239
D01XAE	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D09UVX	TTDDRUID	D09UVX
D09UVX	DRUGNAME	PRX-12247
D09UVX	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D03LLL	TTDDRUID	D03LLL
D03LLL	DRUGNAME	PRX-12255
D03LLL	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0X2GM	TTDDRUID	D0X2GM
D0X2GM	DRUGNAME	PRX-12256
D0X2GM	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D09TBM	TTDDRUID	D09TBM
D09TBM	DRUGNAME	PRX-12261
D09TBM	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0E7BS	TTDDRUID	D0E7BS
D0E7BS	DRUGNAME	PRX-12266
D0E7BS	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D07MQC	TTDDRUID	D07MQC
D07MQC	DRUGNAME	PS-1145
D07MQC	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0A6OO	TTDDRUID	D0A6OO
D0A6OO	DRUGNAME	PSI 7851
D0A6OO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0XG8I	TTDDRUID	D0XG8I
D0XG8I	DRUGNAME	PSI-879
D0XG8I	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D04JPQ	TTDDRUID	D04JPQ
D04JPQ	DRUGNAME	PSN-101
D04JPQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0C2ZI	TTDDRUID	D0C2ZI
D0C2ZI	DRUGNAME	PSN-842
D0C2ZI	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0B8IN	TTDDRUID	D0B8IN
D0B8IN	DRUGNAME	PSP-D-CD40L
D0B8IN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03OTX	TTDDRUID	D03OTX
D03OTX	DRUGNAME	PSP-D-GITRL
D03OTX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00WKL	TTDDRUID	D00WKL
D00WKL	DRUGNAME	PSX-4206
D00WKL	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative

D0R7JE	TTDDRUID	D0R7JE
D0R7JE	DRUGNAME	Psychiatric therapeutics
D0R7JE	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Investigative

D0E5FF	TTDDRUID	D0E5FF
D0E5FF	DRUGNAME	PT
D0E5FF	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0KM1F	TTDDRUID	D0KM1F
D0KM1F	DRUGNAME	PT-00114
D0KM1F	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0K3JZ	TTDDRUID	D0K3JZ
D0K3JZ	DRUGNAME	PT-00311
D0K3JZ	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D04IWZ	TTDDRUID	D04IWZ
D04IWZ	DRUGNAME	PT2.0
D04IWZ	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0O3TW	TTDDRUID	D0O3TW
D0O3TW	DRUGNAME	PT4.0
D0O3TW	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0L6PZ	TTDDRUID	D0L6PZ
D0L6PZ	DRUGNAME	PT-401
D0L6PZ	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D01JPJ	TTDDRUID	D01JPJ
D01JPJ	DRUGNAME	PTC-725
D01JPJ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D01NPK	TTDDRUID	D01NPK
D01NPK	DRUGNAME	PTH-CBD
D01NPK	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0A3SX	TTDDRUID	D0A3SX
D0A3SX	DRUGNAME	PTHr pepducins
D0A3SX	INDICATI	Endocrine disease [ICD-11: 5B3Z] Investigative

D03PMB	TTDDRUID	D03PMB
D03PMB	DRUGNAME	PTI-601
D03PMB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0J6JC	TTDDRUID	D0J6JC
D0J6JC	DRUGNAME	PTL-101
D0J6JC	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative

D03VDA	TTDDRUID	D03VDA
D03VDA	DRUGNAME	PTL-303
D03VDA	INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative

D02QLH	TTDDRUID	D02QLH
D02QLH	DRUGNAME	PTL-43401
D02QLH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0KW8U	TTDDRUID	D0KW8U
D0KW8U	DRUGNAME	PTS-508a
D0KW8U	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0MI9F	TTDDRUID	D0MI9F
D0MI9F	DRUGNAME	PTX-001
D0MI9F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A7CZ	TTDDRUID	D0A7CZ
D0A7CZ	DRUGNAME	PTX-007
D0A7CZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0S6FE	TTDDRUID	D0S6FE
D0S6FE	DRUGNAME	PTX-008
D0S6FE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I8QF	TTDDRUID	D0I8QF
D0I8QF	DRUGNAME	PU-2049
D0I8QF	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D0D5KQ	TTDDRUID	D0D5KQ
D0D5KQ	DRUGNAME	PU24S
D0D5KQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06KKL	TTDDRUID	D06KKL
D06KKL	DRUGNAME	PulmoXen
D06KKL	INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative

D00YCO	TTDDRUID	D00YCO
D00YCO	DRUGNAME	Pulvomycin
D00YCO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0V6EY	TTDDRUID	D0V6EY
D0V6EY	DRUGNAME	Pumiliotoxin 251D
D0V6EY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Y0BZ	TTDDRUID	D0Y0BZ
D0Y0BZ	DRUGNAME	PUP-1
D0Y0BZ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0Z3PD	TTDDRUID	D0Z3PD
D0Z3PD	DRUGNAME	Purified secretory immunoglobulin
D0Z3PD	INDICATI	Enterocolitis [ICD-11: 1A40.Z] Investigative

D02HWR	TTDDRUID	D02HWR
D02HWR	DRUGNAME	PV-1019
D02HWR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V6IN	TTDDRUID	D0V6IN
D0V6IN	DRUGNAME	PV-267
D0V6IN	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0H7SG	TTDDRUID	D0H7SG
D0H7SG	DRUGNAME	PV-327
D0H7SG	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D01GAG	TTDDRUID	D01GAG
D01GAG	DRUGNAME	PV-921
D01GAG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZK5H	TTDDRUID	D0ZK5H
D0ZK5H	DRUGNAME	PW-4156
D0ZK5H	INDICATI	Muscle hypertonia [ICD-11: MB47.8] Investigative

D0R0FU	TTDDRUID	D0R0FU
D0R0FU	DRUGNAME	PXS-4159
D0R0FU	INDICATI	Asthma [ICD-11: CA23] Investigative

D0G6TX	TTDDRUID	D0G6TX
D0G6TX	DRUGNAME	PYC-38
D0G6TX	INDICATI	Respiratory distress syndrome [ICD-11: CB00] Investigative

D09KQM	TTDDRUID	D09KQM
D09KQM	DRUGNAME	PYK2 inhibitors
D09KQM	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D03QUJ	TTDDRUID	D03QUJ
D03QUJ	DRUGNAME	PYM-60001
D03QUJ	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0D3TO	TTDDRUID	D0D3TO
D0D3TO	DRUGNAME	PYN-22
D0D3TO	INDICATI	Obesity [ICD-11: 5B81] Investigative

D05NWM	TTDDRUID	D05NWM
D05NWM	DRUGNAME	Pyraclostrobin
D05NWM	INDICATI	Plant grey mould disease [ICD-11: N.A.] Investigative

D08PHZ	TTDDRUID	D08PHZ
D08PHZ	DRUGNAME	Pyrazole series, malaria DrexelMed/University of Washington/Medicines for Malaria Venture
D08PHZ	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0C9KY	TTDDRUID	D0C9KY
D0C9KY	DRUGNAME	Pyridobenzimidazole
D0C9KY	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0K2AR	TTDDRUID	D0K2AR
D0K2AR	DRUGNAME	Pyridocarbazole
D0K2AR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04ESM	TTDDRUID	D04ESM
D04ESM	DRUGNAME	Pyrimidinediones
D04ESM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D01UHU	TTDDRUID	D01UHU
D01UHU	DRUGNAME	Pyriplatin
D01UHU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08FLT	TTDDRUID	D08FLT
D08FLT	DRUGNAME	Pyrrole-imidazole polyamides
D08FLT	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative

D0JW1R	TTDDRUID	D0JW1R
D0JW1R	DRUGNAME	Pyrroles
D0JW1R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0A0YZ	TTDDRUID	D0A0YZ
D0A0YZ	DRUGNAME	PYZD-4409
D0A0YZ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D06TVU	TTDDRUID	D06TVU
D06TVU	DRUGNAME	Q-101
D06TVU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D00YAS	TTDDRUID	D00YAS
D00YAS	DRUGNAME	Q-102
D00YAS	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0IU0W	TTDDRUID	D0IU0W
D0IU0W	DRUGNAME	Q-201
D0IU0W	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D05RFI	TTDDRUID	D05RFI
D05RFI	DRUGNAME	QBI-206
D05RFI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00OJL	TTDDRUID	D00OJL
D00OJL	DRUGNAME	QBP1 mimetics
D00OJL	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D08FSR	TTDDRUID	D08FSR
D08FSR	DRUGNAME	QLT-091382
D08FSR	INDICATI	Sebaceous gland disease [ICD-11: EM0Z] Investigative

D07UTC	TTDDRUID	D07UTC
D07UTC	DRUGNAME	QNL-111
D07UTC	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D08VWM	TTDDRUID	D08VWM
D08VWM	DRUGNAME	QUAN-0806
D08VWM	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D08ZLL	TTDDRUID	D08ZLL
D08ZLL	DRUGNAME	Quick-acting insulin
D08ZLL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0P3PG	TTDDRUID	D0P3PG
D0P3PG	DRUGNAME	Quinoline methanols
D0P3PG	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0S9HJ	TTDDRUID	D0S9HJ
D0S9HJ	DRUGNAME	Quorum sensing blockers
D0S9HJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D04KKX	TTDDRUID	D04KKX
D04KKX	DRUGNAME	QX-30002222
D04KKX	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Y4WR	TTDDRUID	D0Y4WR
D0Y4WR	DRUGNAME	R-1
D0Y4WR	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative

D0L1PW	TTDDRUID	D0L1PW
D0L1PW	DRUGNAME	R112
D0L1PW	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D08MVY	TTDDRUID	D08MVY
D08MVY	DRUGNAME	R-116712
D08MVY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0I2JY	TTDDRUID	D0I2JY
D0I2JY	DRUGNAME	R-1206
D0I2JY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0DU6X	TTDDRUID	D0DU6X
D0DU6X	DRUGNAME	R-41D
D0DU6X	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D0X0NA	TTDDRUID	D0X0NA
D0X0NA	DRUGNAME	R-524
D0X0NA	INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative

D06PVN	TTDDRUID	D06PVN
D06PVN	DRUGNAME	R-65
D06PVN	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D07OIZ	TTDDRUID	D07OIZ
D07OIZ	DRUGNAME	R-84
D07OIZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09ZVJ	TTDDRUID	D09ZVJ
D09ZVJ	DRUGNAME	R-954
D09ZVJ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D07LBP	TTDDRUID	D07LBP
D07LBP	DRUGNAME	RabiCide
D07LBP	INDICATI	Rabies [ICD-11: 1C82] Investigative

D05ADE	TTDDRUID	D05ADE
D05ADE	DRUGNAME	RAD-100
D05ADE	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0F5AB	TTDDRUID	D0F5AB
D0F5AB	DRUGNAME	Rad51
D0F5AB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T2ZX	TTDDRUID	D0T2ZX
D0T2ZX	DRUGNAME	Radioimmunotherapy
D0T2ZX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06ICE	TTDDRUID	D06ICE
D06ICE	DRUGNAME	Radiolabeled anti-PSMA huJ591 minibodies
D06ICE	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0M7DU	TTDDRUID	D0M7DU
D0M7DU	DRUGNAME	Radiolabeled onartuzumab
D0M7DU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AT5Y	TTDDRUID	D0AT5Y
D0AT5Y	DRUGNAME	Radiolabeled VEGF
D0AT5Y	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0QF8B	TTDDRUID	D0QF8B
D0QF8B	DRUGNAME	Radioprotectants
D0QF8B	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D04YWS	TTDDRUID	D04YWS
D04YWS	DRUGNAME	RAGE-Fc fusion protein
D04YWS	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D09ZBJ	TTDDRUID	D09ZBJ
D09ZBJ	DRUGNAME	RAGE-immunoglobulin fusion protein
D09ZBJ	INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Investigative

D09SOD	TTDDRUID	D09SOD
D09SOD	DRUGNAME	RAP-102
D09SOD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D07RPC	TTDDRUID	D07RPC
D07RPC	DRUGNAME	RAP-103
D07RPC	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0W9OW	TTDDRUID	D0W9OW
D0W9OW	DRUGNAME	RAP-310
D0W9OW	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0CO3O	TTDDRUID	D0CO3O
D0CO3O	DRUGNAME	RAP-701
D0CO3O	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D09GXF	TTDDRUID	D09GXF
D09GXF	DRUGNAME	RB-105
D09GXF	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D08ZUG	TTDDRUID	D08ZUG
D08ZUG	DRUGNAME	RBT-05
D08ZUG	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0T3VY	TTDDRUID	D0T3VY
D0T3VY	DRUGNAME	RBT-201
D0T3VY	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative

D0I7HG	TTDDRUID	D0I7HG
D0I7HG	DRUGNAME	RBT-401
D0I7HG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0OY7A	TTDDRUID	D0OY7A
D0OY7A	DRUGNAME	RBx-343E48F0
D0OY7A	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0D6EK	TTDDRUID	D0D6EK
D0D6EK	DRUGNAME	RDX-002
D0D6EK	INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative

D0QA0B	TTDDRUID	D0QA0B
D0QA0B	DRUGNAME	RDX-008
D0QA0B	INDICATI	Hypernatremia [ICD-11: 5C71] Investigative

D0M2DP	TTDDRUID	D0M2DP
D0M2DP	DRUGNAME	REACTA
D0M2DP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01UJS	TTDDRUID	D01UJS
D01UJS	DRUGNAME	Rebelex
D01UJS	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D0K3QW	TTDDRUID	D0K3QW
D0K3QW	DRUGNAME	REC-0436
D0K3QW	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D0T1UH	TTDDRUID	D0T1UH
D0T1UH	DRUGNAME	REC-0467
D0T1UH	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative

D0Y6OC	TTDDRUID	D0Y6OC
D0Y6OC	DRUGNAME	REC-1819
D0Y6OC	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D0L5EA	TTDDRUID	D0L5EA
D0L5EA	DRUGNAME	REC-200
D0L5EA	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00MCY	TTDDRUID	D00MCY
D00MCY	DRUGNAME	REC2615
D00MCY	INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative

D0B4AH	TTDDRUID	D0B4AH
D0B4AH	DRUGNAME	RECALL-VAX
D0B4AH	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D03JXN	TTDDRUID	D03JXN
D03JXN	DRUGNAME	Recombinant anti-IgE Fabs
D03JXN	INDICATI	Asthma [ICD-11: CA23] Investigative

D03IJZ	TTDDRUID	D03IJZ
D03IJZ	DRUGNAME	Recombinant botulinum toxin
D03IJZ	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0K7NJ	TTDDRUID	D0K7NJ
D0K7NJ	DRUGNAME	Recombinant coagulation factors
D0K7NJ	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D08CEU	TTDDRUID	D08CEU
D08CEU	DRUGNAME	Recombinant Factor X
D08CEU	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D02FTU	TTDDRUID	D02FTU
D02FTU	DRUGNAME	Recombinant follicle stimulating hormone
D02FTU	INDICATI	Female infertility [ICD-11: GA31.Z] Investigative

D07LSV	TTDDRUID	D07LSV
D07LSV	DRUGNAME	Recombinant galectin-3
D07LSV	INDICATI	Corneal abrasion [ICD-11: NA06.4] Investigative

D0Z1CS	TTDDRUID	D0Z1CS
D0Z1CS	DRUGNAME	Recombinant glucocerebrosidase enzyme
D0Z1CS	INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative

D07VYO	TTDDRUID	D07VYO
D07VYO	DRUGNAME	Recombinant human alkaline phosphatase
D07VYO	INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative

D08MCL	TTDDRUID	D08MCL
D08MCL	DRUGNAME	Recombinant human biglycan
D08MCL	INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative

D06HUH	TTDDRUID	D06HUH
D06HUH	DRUGNAME	Recombinant human butyrylcholinesterase
D06HUH	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D05RZJ	TTDDRUID	D05RZJ
D05RZJ	DRUGNAME	Recombinant human CC10
D05RZJ	INDICATI	Endometriosis [ICD-11: GA10] Investigative

D05GPN	TTDDRUID	D05GPN
D05GPN	DRUGNAME	Recombinant human CFH protein
D05GPN	INDICATI	Kidney disease [ICD-11: GC2Z] Investigative

D0U7GA	TTDDRUID	D0U7GA
D0U7GA	DRUGNAME	Recombinant human fibrinogen
D0U7GA	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0G6TV	TTDDRUID	D0G6TV
D0G6TV	DRUGNAME	Recombinant human lubricin
D0G6TV	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0D1TX	TTDDRUID	D0D1TX
D0D1TX	DRUGNAME	Recombinant human pro-urokinase
D0D1TX	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0P4WI	TTDDRUID	D0P4WI
D0P4WI	DRUGNAME	Recombinant human TNF receptor
D0P4WI	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0Z6XQ	TTDDRUID	D0Z6XQ
D0Z6XQ	DRUGNAME	Recombinant human zinc alpha-2 glycoprotein (ZAG)
D0Z6XQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0I0BJ	TTDDRUID	D0I0BJ
D0I0BJ	DRUGNAME	Recombinant interleukin-2
D0I0BJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09ZNQ	TTDDRUID	D09ZNQ
D09ZNQ	DRUGNAME	Recombinant L-asparaginase
D09ZNQ	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative

D0R3MA	TTDDRUID	D0R3MA
D0R3MA	DRUGNAME	Recombinant mab-biocide fusion proteins
D0R3MA	INDICATI	Cryptosporidium infection [ICD-11: 1A32] Investigative

D04YSY	TTDDRUID	D04YSY
D04YSY	DRUGNAME	Recombinant NOV
D04YSY	INDICATI	Corneal disease [ICD-11: 9A78.Z] Investigative

D0VN2N	TTDDRUID	D0VN2N
D0VN2N	DRUGNAME	Recombinant opticin
D0VN2N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0UP1U	TTDDRUID	D0UP1U
D0UP1U	DRUGNAME	Recombinant plasmin
D0UP1U	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0Q9PP	TTDDRUID	D0Q9PP
D0Q9PP	DRUGNAME	Recombinant Slit-2-D1-D2-Fc
D0Q9PP	INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative

D04VWO	TTDDRUID	D04VWO
D04VWO	DRUGNAME	Recombinant soluble CD6
D04VWO	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0XJ8K	TTDDRUID	D0XJ8K
D0XJ8K	DRUGNAME	Recombinant soluble human CD5
D0XJ8K	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D04NNK	TTDDRUID	D04NNK
D04NNK	DRUGNAME	Recombinant therapeutic proteins
D04NNK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U2DY	TTDDRUID	D0U2DY
D0U2DY	DRUGNAME	Recombinant TSH superagonists
D0U2DY	INDICATI	Thyroid cancer [ICD-11: 2D10] Investigative

D00MET	TTDDRUID	D00MET
D00MET	DRUGNAME	Recombinant uteroglobin
D00MET	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative

D0N1NL	TTDDRUID	D0N1NL
D0N1NL	DRUGNAME	Recombinant Wolinella (rWS) asparaginase
D0N1NL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05IJM	TTDDRUID	D05IJM
D05IJM	DRUGNAME	Recruitin
D05IJM	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0L2OS	TTDDRUID	D0L2OS
D0L2OS	DRUGNAME	REG-3
D0L2OS	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0A5OG	TTDDRUID	D0A5OG
D0A5OG	DRUGNAME	ReN-002
D0A5OG	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D03OVN	TTDDRUID	D03OVN
D03OVN	DRUGNAME	ReN-003
D03OVN	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D0UO6M	TTDDRUID	D0UO6M
D0UO6M	DRUGNAME	ReN-004
D0UO6M	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0NY4H	TTDDRUID	D0NY4H
D0NY4H	DRUGNAME	ReN-005
D0NY4H	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D07KBJ	TTDDRUID	D07KBJ
D07KBJ	DRUGNAME	Renin inhibitors
D07KBJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0T0TH	TTDDRUID	D0T0TH
D0T0TH	DRUGNAME	Replicase
D0T0TH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D01GIG	TTDDRUID	D01GIG
D01GIG	DRUGNAME	RepliVec
D01GIG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L1GI	TTDDRUID	D0L1GI
D0L1GI	DRUGNAME	ReS8-T compounds
D0L1GI	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D05RWD	TTDDRUID	D05RWD
D05RWD	DRUGNAME	Research programme: farnesoid X receptor agonists, Roche
D05RWD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0Y4QP	TTDDRUID	D0Y4QP
D0Y4QP	DRUGNAME	Research programme: MAP kinase kinase 2 inhibitors, Pfizer
D0Y4QP	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D01JLH	TTDDRUID	D01JLH
D01JLH	DRUGNAME	RESP-3000
D01JLH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0V6SI	TTDDRUID	D0V6SI
D0V6SI	DRUGNAME	RESP-4000
D0V6SI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZE3S	TTDDRUID	D0ZE3S
D0ZE3S	DRUGNAME	RESP-6000
D0ZE3S	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D0G4UU	TTDDRUID	D0G4UU
D0G4UU	DRUGNAME	Respiratory disease therapeutics
D0G4UU	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D09FTX	TTDDRUID	D09FTX
D09FTX	DRUGNAME	Respiratory system therapeutics
D09FTX	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D04GTW	TTDDRUID	D04GTW
D04GTW	DRUGNAME	ReSX-i
D04GTW	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D05TKO	TTDDRUID	D05TKO
D05TKO	DRUGNAME	Retagliptin
D05TKO	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D03PUG	TTDDRUID	D03PUG
D03PUG	DRUGNAME	Revax-TBE
D03PUG	INDICATI	Flavivirus infection [ICD-11: 1C80] Investigative

D0N0XA	TTDDRUID	D0N0XA
D0N0XA	DRUGNAME	Reversed chloroquines
D0N0XA	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0E3UW	TTDDRUID	D0E3UW
D0E3UW	DRUGNAME	RG6046
D0E3UW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D01CHD	TTDDRUID	D01CHD
D01CHD	DRUGNAME	RG6061
D01CHD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01WMW	TTDDRUID	D01WMW
D01WMW	DRUGNAME	RG7232
D01WMW	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Investigative

D0H3UO	TTDDRUID	D0H3UO
D0H3UO	DRUGNAME	RGD-039
D0H3UO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0L2WW	TTDDRUID	D0L2WW
D0L2WW	DRUGNAME	RGel-Adnectin
D0L2WW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05IZC	TTDDRUID	D05IZC
D05IZC	DRUGNAME	RGI-1001
D05IZC	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0F2GK	TTDDRUID	D0F2GK
D0F2GK	DRUGNAME	RGI-3010
D0F2GK	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0W2VS	TTDDRUID	D0W2VS
D0W2VS	DRUGNAME	RGI-4100
D0W2VS	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0D7OE	TTDDRUID	D0D7OE
D0D7OE	DRUGNAME	RHAMLET
D0D7OE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01UUF	TTDDRUID	D01UUF
D01UUF	DRUGNAME	Rh-GDNF
D01UUF	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0I4LQ	TTDDRUID	D0I4LQ
D0I4LQ	DRUGNAME	RHIIP
D0I4LQ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0B5CN	TTDDRUID	D0B5CN
D0B5CN	DRUGNAME	Rh-MBL
D0B5CN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D06XIX	TTDDRUID	D06XIX
D06XIX	DRUGNAME	RHuA1AT
D06XIX	INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Investigative

D01UVG	TTDDRUID	D01UVG
D01UVG	DRUGNAME	RhVGF modulators, wound healing, Stainwei Biotech
D01UVG	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D09QZK	TTDDRUID	D09QZK
D09QZK	DRUGNAME	RIG-I adjuvant
D09QZK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F1PH	TTDDRUID	D0F1PH
D0F1PH	DRUGNAME	Rimeporide
D0F1PH	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0OZ3S	TTDDRUID	D0OZ3S
D0OZ3S	DRUGNAME	RJM-0035-K002
D0OZ3S	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0I2MD	TTDDRUID	D0I2MD
D0I2MD	DRUGNAME	RL-6A
D0I2MD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0Z2AY	TTDDRUID	D0Z2AY
D0Z2AY	DRUGNAME	RLIP76 protein
D0Z2AY	INDICATI	Sunburn [ICD-11: EJ40] Investigative

D06RYU	TTDDRUID	D06RYU
D06RYU	DRUGNAME	RLP-035
D06RYU	INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative

D0H1MV	TTDDRUID	D0H1MV
D0H1MV	DRUGNAME	RLP-068
D0H1MV	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0V7FX	TTDDRUID	D0V7FX
D0V7FX	DRUGNAME	RLP-073
D0V7FX	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D05QFO	TTDDRUID	D05QFO
D05QFO	DRUGNAME	RLY-106
D05QFO	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0U6WC	TTDDRUID	D0U6WC
D0U6WC	DRUGNAME	RM-4864
D0U6WC	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D01MSZ	TTDDRUID	D01MSZ
D01MSZ	DRUGNAME	RM-4865
D01MSZ	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0AH2V	TTDDRUID	D0AH2V
D0AH2V	DRUGNAME	RM-6427
D0AH2V	INDICATI	Cryptosporidium infection [ICD-11: 1A32] Investigative

D0I2TT	TTDDRUID	D0I2TT
D0I2TT	DRUGNAME	RMH-41
D0I2TT	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D07AKF	TTDDRUID	D07AKF
D07AKF	DRUGNAME	RNA stealth nucleosides
D07AKF	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D05NEN	TTDDRUID	D05NEN
D05NEN	DRUGNAME	RNA synthesis inhibitors
D05NEN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XX7E	TTDDRUID	D0XX7E
D0XX7E	DRUGNAME	RNA-144101
D0XX7E	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0V6YJ	TTDDRUID	D0V6YJ
D0V6YJ	DRUGNAME	RNAi therapeutic, AlphaGEN Co Ltd
D0V6YJ	INDICATI	Head and neck cancer [ICD-11: 2D42] Investigative

D02JFQ	TTDDRUID	D02JFQ
D02JFQ	DRUGNAME	RNAi therapeutics, Alnylam
D02JFQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q0KV	TTDDRUID	D0Q0KV
D0Q0KV	DRUGNAME	RNAi therapeutics, GeneSegues Inc
D0Q0KV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08IPU	TTDDRUID	D08IPU
D08IPU	DRUGNAME	RNAi therapy, Sirna
D08IPU	INDICATI	Asthma [ICD-11: CA23] Investigative

D08VRM	TTDDRUID	D08VRM
D08VRM	DRUGNAME	RO-0534
D08VRM	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D0C5ND	TTDDRUID	D0C5ND
D0C5ND	DRUGNAME	RO-17
D0C5ND	INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative

D05RTX	TTDDRUID	D05RTX
D05RTX	DRUGNAME	RO-1752
D05RTX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D07TPL	TTDDRUID	D07TPL
D07TPL	DRUGNAME	Ro-40-0655
D07TPL	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D00CFU	TTDDRUID	D00CFU
D00CFU	DRUGNAME	RO-4840700
D00CFU	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D0M7IG	TTDDRUID	D0M7IG
D0M7IG	DRUGNAME	RO-4920506
D0M7IG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05WDM	TTDDRUID	D05WDM
D05WDM	DRUGNAME	Ro5203280
D05WDM	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D00LMY	TTDDRUID	D00LMY
D00LMY	DRUGNAME	RO-5212651
D00LMY	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D03SHI	TTDDRUID	D03SHI
D03SHI	DRUGNAME	Ro-5287373
D03SHI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X7GA	TTDDRUID	D0X7GA
D0X7GA	DRUGNAME	RO-6036
D0X7GA	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0C8JY	TTDDRUID	D0C8JY
D0C8JY	DRUGNAME	Rociletinib
D0C8JY	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3

D0P1HI	TTDDRUID	D0P1HI
D0P1HI	DRUGNAME	ROCK-1 inhibitors
D0P1HI	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D05PTT	TTDDRUID	D05PTT
D05PTT	DRUGNAME	ROSMARINIC ACID
D05PTT	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0E4JL	TTDDRUID	D0E4JL
D0E4JL	DRUGNAME	Rotigitine
D0E4JL	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D02VMC	TTDDRUID	D02VMC
D02VMC	DRUGNAME	RP-1000
D02VMC	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0N6QO	TTDDRUID	D0N6QO
D0N6QO	DRUGNAME	RP-1040
D0N6QO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ZP4B	TTDDRUID	D0ZP4B
D0ZP4B	DRUGNAME	RP-3035
D0ZP4B	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D00TJV	TTDDRUID	D00TJV
D00TJV	DRUGNAME	RP-3120
D00TJV	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative

D0N2CS	TTDDRUID	D0N2CS
D0N2CS	DRUGNAME	RP-4000
D0N2CS	INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative

D08FXZ	TTDDRUID	D08FXZ
D08FXZ	DRUGNAME	RP-525
D08FXZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00IWE	TTDDRUID	D00IWE
D00IWE	DRUGNAME	RP-6000
D00IWE	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0Q7OB	TTDDRUID	D0Q7OB
D0Q7OB	DRUGNAME	RP-656
D0Q7OB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09CTH	TTDDRUID	D09CTH
D09CTH	DRUGNAME	RP-701
D09CTH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03YMD	TTDDRUID	D03YMD
D03YMD	DRUGNAME	RP-805
D03YMD	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0J7RP	TTDDRUID	D0J7RP
D0J7RP	DRUGNAME	RP-AAV8
D0J7RP	INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative

D00UPU	TTDDRUID	D00UPU
D00UPU	DRUGNAME	RPR-107836
D00UPU	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0H5TU	TTDDRUID	D0H5TU
D0H5TU	DRUGNAME	RQ-00000008
D0H5TU	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0H1UY	TTDDRUID	D0H1UY
D0H1UY	DRUGNAME	RQ-00000010
D0H1UY	INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative

D0D7LP	TTDDRUID	D0D7LP
D0D7LP	DRUGNAME	RQ-00201894
D0D7LP	INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative

D08RYN	TTDDRUID	D08RYN
D08RYN	DRUGNAME	RQ-00202730
D08RYN	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0NC0G	TTDDRUID	D0NC0G
D0NC0G	DRUGNAME	RQ-00203066
D0NC0G	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0A1UL	TTDDRUID	D0A1UL
D0A1UL	DRUGNAME	RQ-00203078
D0A1UL	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0GM9E	TTDDRUID	D0GM9E
D0GM9E	DRUGNAME	RQ-00310941
D0GM9E	INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative

D05UEF	TTDDRUID	D05UEF
D05UEF	DRUGNAME	RR-1
D05UEF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H7JE	TTDDRUID	D0H7JE
D0H7JE	DRUGNAME	RS-100302
D0H7JE	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D0Y0KV	TTDDRUID	D0Y0KV
D0Y0KV	DRUGNAME	RS-118641
D0Y0KV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0XH2N	TTDDRUID	D0XH2N
D0XH2N	DRUGNAME	RS-1748
D0XH2N	INDICATI	Asthma [ICD-11: CA23] Investigative

D0S1ZY	TTDDRUID	D0S1ZY
D0S1ZY	DRUGNAME	RSLV-125
D0S1ZY	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative

D07JPL	TTDDRUID	D07JPL
D07JPL	DRUGNAME	RT-401
D07JPL	INDICATI	Rhinitis [ICD-11: FA20] Investigative

D0XA1B	TTDDRUID	D0XA1B
D0XA1B	DRUGNAME	RTA-301
D0XA1B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06HGY	TTDDRUID	D06HGY
D06HGY	DRUGNAME	RTA-403 analog
D06HGY	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D05GQV	TTDDRUID	D05GQV
D05GQV	DRUGNAME	RTA-801
D05GQV	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D01VOJ	TTDDRUID	D01VOJ
D01VOJ	DRUGNAME	RTI-4229-982
D01VOJ	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D04EPP	TTDDRUID	D04EPP
D04EPP	DRUGNAME	RTL-342m
D04EPP	INDICATI	Optic neuritis [ICD-11: 9C40.1] Investigative

D06ZME	TTDDRUID	D06ZME
D06ZME	DRUGNAME	RTL-551
D06ZME	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D0F8KR	TTDDRUID	D0F8KR
D0F8KR	DRUGNAME	RTU-1096
D0F8KR	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D05LZG	TTDDRUID	D05LZG
D05LZG	DRUGNAME	R-type pyocins
D05LZG	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D0A6DK	TTDDRUID	D0A6DK
D0A6DK	DRUGNAME	Ruthenium (II) phosphine/picolinate complexes
D0A6DK	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D00PGF	TTDDRUID	D00PGF
D00PGF	DRUGNAME	RV-1088
D00PGF	INDICATI	Asthma [ICD-11: CA23] Investigative

D0V0UX	TTDDRUID	D0V0UX
D0V0UX	DRUGNAME	RVLYSIN
D0V0UX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0KQ2D	TTDDRUID	D0KQ2D
D0KQ2D	DRUGNAME	RVX-297
D0KQ2D	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D03CYF	TTDDRUID	D03CYF
D03CYF	DRUGNAME	RVX-408
D03CYF	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D05BIJ	TTDDRUID	D05BIJ
D05BIJ	DRUGNAME	RWJ-140998
D05BIJ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D04SDN	TTDDRUID	D04SDN
D04SDN	DRUGNAME	RWJ-3981
D04SDN	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D00VFM	TTDDRUID	D00VFM
D00VFM	DRUGNAME	RWJ-49968
D00VFM	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D02MQL	TTDDRUID	D02MQL
D02MQL	DRUGNAME	RWJ-61907
D02MQL	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D01QXS	TTDDRUID	D01QXS
D01QXS	DRUGNAME	RX-0201N
D01QXS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0HS2E	TTDDRUID	D0HS2E
D0HS2E	DRUGNAME	Rx-04
D0HS2E	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0L8ON	TTDDRUID	D0L8ON
D0L8ON	DRUGNAME	Rx-101
D0L8ON	INDICATI	Radiation syndrome [ICD-11: NF00] Investigative

D0P9XE	TTDDRUID	D0P9XE
D0P9XE	DRUGNAME	Rx-101005
D0P9XE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0Y1LD	TTDDRUID	D0Y1LD
D0Y1LD	DRUGNAME	RX-1792
D0Y1LD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04JFB	TTDDRUID	D04JFB
D04JFB	DRUGNAME	RX-20001
D04JFB	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D03QXD	TTDDRUID	D03QXD
D03QXD	DRUGNAME	RXP-470
D03QXD	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0OC6H	TTDDRUID	D0OC6H
D0OC6H	DRUGNAME	S-024
D0OC6H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P4DG	TTDDRUID	D0P4DG
D0P4DG	DRUGNAME	S-070
D0P4DG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I8BC	TTDDRUID	D0I8BC
D0I8BC	DRUGNAME	S-100
D0I8BC	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0EQ1J	TTDDRUID	D0EQ1J
D0EQ1J	DRUGNAME	S-111
D0EQ1J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0NY7A	TTDDRUID	D0NY7A
D0NY7A	DRUGNAME	S-19528
D0NY7A	INDICATI	Eating disorder [ICD-11: 6B82] Investigative

D08ROQ	TTDDRUID	D08ROQ
D08ROQ	DRUGNAME	S-25585
D08ROQ	INDICATI	Eating disorder [ICD-11: 6B82] Investigative

D0K7UL	TTDDRUID	D0K7UL
D0K7UL	DRUGNAME	S-2678
D0K7UL	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D01GIW	TTDDRUID	D01GIW
D01GIW	DRUGNAME	S3
D01GIW	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D08MUX	TTDDRUID	D08MUX
D08MUX	DRUGNAME	S33005
D08MUX	INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative

D00XSP	TTDDRUID	D00XSP
D00XSP	DRUGNAME	S-35678
D00XSP	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0U8EA	TTDDRUID	D0U8EA
D0U8EA	DRUGNAME	S-41744
D0U8EA	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0ZR2W	TTDDRUID	D0ZR2W
D0ZR2W	DRUGNAME	S-47445
D0ZR2W	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D07VWP	TTDDRUID	D07VWP
D07VWP	DRUGNAME	S-9947
D07VWP	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D0Q4BQ	TTDDRUID	D0Q4BQ
D0Q4BQ	DRUGNAME	SA-20896
D0Q4BQ	INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Investigative

D0U2GT	TTDDRUID	D0U2GT
D0U2GT	DRUGNAME	SA3C
D0U2GT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03UIF	TTDDRUID	D03UIF
D03UIF	DRUGNAME	SA-6541
D03UIF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D06ZCH	TTDDRUID	D06ZCH
D06ZCH	DRUGNAME	SA-ANP
D06ZCH	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D02TKX	TTDDRUID	D02TKX
D02TKX	DRUGNAME	Sac-0601
D02TKX	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative

D06EWW	TTDDRUID	D06EWW
D06EWW	DRUGNAME	Sacrovir
D06EWW	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D06OMH	TTDDRUID	D06OMH
D06OMH	DRUGNAME	Safflower seed-derived apolipoprotein A1
D06OMH	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D07QNH	TTDDRUID	D07QNH
D07QNH	DRUGNAME	SAIT301
D07QNH	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D0Y9RN	TTDDRUID	D0Y9RN
D0Y9RN	DRUGNAME	Salinosporamide B
D0Y9RN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0K1UF	TTDDRUID	D0K1UF
D0K1UF	DRUGNAME	Saliphenylhalamide
D0K1UF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00ZHR	TTDDRUID	D00ZHR
D00ZHR	DRUGNAME	Salmonella typhimurium A1-R
D00ZHR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01LNP	TTDDRUID	D01LNP
D01LNP	DRUGNAME	Samarium-153-DOTMP
D01LNP	INDICATI	Bone cancer [ICD-11: 2B5Z] Investigative

D07VQW	TTDDRUID	D07VQW
D07VQW	DRUGNAME	Sant7
D07VQW	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0F0VQ	TTDDRUID	D0F0VQ
D0F0VQ	DRUGNAME	SapC-DOPS
D0F0VQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01AVF	TTDDRUID	D01AVF
D01AVF	DRUGNAME	SAR-106881
D01AVF	INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Investigative

D04VFW	TTDDRUID	D04VFW
D04VFW	DRUGNAME	SAR-116242
D04VFW	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D08GBT	TTDDRUID	D08GBT
D08GBT	DRUGNAME	SAR-131675
D08GBT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00YMM	TTDDRUID	D00YMM
D00YMM	DRUGNAME	SAR-215500
D00YMM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00XQR	TTDDRUID	D00XQR
D00XQR	DRUGNAME	SAR-288233
D00XQR	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D0JC4J	TTDDRUID	D0JC4J
D0JC4J	DRUGNAME	SARMs
D0JC4J	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X3UW	TTDDRUID	D0X3UW
D0X3UW	DRUGNAME	Saurestat
D0X3UW	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D07USR	TTDDRUID	D07USR
D07USR	DRUGNAME	SAVX-1
D07USR	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D00WPU	TTDDRUID	D00WPU
D00WPU	DRUGNAME	Sazetidine-A
D00WPU	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D08LYB	TTDDRUID	D08LYB
D08LYB	DRUGNAME	SB 239063
D08LYB	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0W6YQ	TTDDRUID	D0W6YQ
D0W6YQ	DRUGNAME	SB therapeutics induced gene therapy, Ischemia
D0W6YQ	INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative

D0NQ0W	TTDDRUID	D0NQ0W
D0NQ0W	DRUGNAME	SB-101
D0NQ0W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I9ZQ	TTDDRUID	D0I9ZQ
D0I9ZQ	DRUGNAME	SB-104
D0I9ZQ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0D9CO	TTDDRUID	D0D9CO
D0D9CO	DRUGNAME	SB-221420-A
D0D9CO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0E1YN	TTDDRUID	D0E1YN
D0E1YN	DRUGNAME	SB-2280
D0E1YN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02YCL	TTDDRUID	D02YCL
D02YCL	DRUGNAME	SB-36131
D02YCL	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D05UTF	TTDDRUID	D05UTF
D05UTF	DRUGNAME	SB-41947
D05UTF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09WOY	TTDDRUID	D09WOY
D09WOY	DRUGNAME	SB-559457
D09WOY	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D0AC0A	TTDDRUID	D0AC0A
D0AC0A	DRUGNAME	SB-612111
D0AC0A	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0W4HW	TTDDRUID	D0W4HW
D0W4HW	DRUGNAME	SB-9000
D0W4HW	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D0H0VS	TTDDRUID	D0H0VS
D0H0VS	DRUGNAME	SBC-104
D0H0VS	INDICATI	Genetic disease [ICD-11: 8E02] Investigative

D03WTX	TTDDRUID	D03WTX
D03WTX	DRUGNAME	SBC-105
D03WTX	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D05GKN	TTDDRUID	D05GKN
D05GKN	DRUGNAME	SBC-106
D05GKN	INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative

D01ANN	TTDDRUID	D01ANN
D01ANN	DRUGNAME	SBIM therapeutics
D01ANN	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D01JSG	TTDDRUID	D01JSG
D01JSG	DRUGNAME	SBL-109
D01JSG	INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative

D0B8XK	TTDDRUID	D0B8XK
D0B8XK	DRUGNAME	SC-01
D0B8XK	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D07CUU	TTDDRUID	D07CUU
D07CUU	DRUGNAME	SC-02
D07CUU	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0H9XR	TTDDRUID	D0H9XR
D0H9XR	DRUGNAME	SC-435
D0H9XR	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0DQ2N	TTDDRUID	D0DQ2N
D0DQ2N	DRUGNAME	SC-72393
D0DQ2N	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative

D0FU7E	TTDDRUID	D0FU7E
D0FU7E	DRUGNAME	SCD-1 inhibitor
D0FU7E	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D01ZVK	TTDDRUID	D01ZVK
D01ZVK	DRUGNAME	SCD-211
D01ZVK	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0D0IF	TTDDRUID	D0D0IF
D0D0IF	DRUGNAME	ScFv23/rGel
D0D0IF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D05RKV	TTDDRUID	D05RKV
D05RKV	DRUGNAME	Sch-036
D05RKV	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0S3IG	TTDDRUID	D0S3IG
D0S3IG	DRUGNAME	SCH-10363
D0S3IG	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0Q6EA	TTDDRUID	D0Q6EA
D0Q6EA	DRUGNAME	SCH-1450206
D0Q6EA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09RKU	TTDDRUID	D09RKU
D09RKU	DRUGNAME	SCH-1518291
D09RKU	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D0C1WP	TTDDRUID	D0C1WP
D0C1WP	DRUGNAME	SCH-1595241
D0C1WP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QK2E	TTDDRUID	D0QK2E
D0QK2E	DRUGNAME	SCH-205831
D0QK2E	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0SE9S	TTDDRUID	D0SE9S
D0SE9S	DRUGNAME	SCH-221510
D0SE9S	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0T4SJ	TTDDRUID	D0T4SJ
D0T4SJ	DRUGNAME	SCH-546909
D0T4SJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BV3B	TTDDRUID	D0BV3B
D0BV3B	DRUGNAME	SCH-602539
D0BV3B	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D07KTP	TTDDRUID	D07KTP
D07KTP	DRUGNAME	SCH79687
D07KTP	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0EK9K	TTDDRUID	D0EK9K
D0EK9K	DRUGNAME	Sch-900875
D0EK9K	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0K8UN	TTDDRUID	D0K8UN
D0K8UN	DRUGNAME	SCIB-2
D0K8UN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0SI1Z	TTDDRUID	D0SI1Z
D0SI1Z	DRUGNAME	SCLERON
D0SI1Z	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0S9XM	TTDDRUID	D0S9XM
D0S9XM	DRUGNAME	Sclerostin-targeted small-molecule therapeutics
D0S9XM	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D00QCX	TTDDRUID	D00QCX
D00QCX	DRUGNAME	SCP-123
D00QCX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D08LSA	TTDDRUID	D08LSA
D08LSA	DRUGNAME	SCY-524
D08LSA	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0Q4TW	TTDDRUID	D0Q4TW
D0Q4TW	DRUGNAME	SCY-644
D0Q4TW	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0S2MQ	TTDDRUID	D0S2MQ
D0S2MQ	DRUGNAME	SD-102
D0S2MQ	INDICATI	Pneumonia [ICD-11: CA40] Investigative

D0U7IG	TTDDRUID	D0U7IG
D0U7IG	DRUGNAME	SD-281
D0U7IG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09QHU	TTDDRUID	D09QHU
D09QHU	DRUGNAME	SD-560
D09QHU	INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative

D0I3CP	TTDDRUID	D0I3CP
D0I3CP	DRUGNAME	SDX-7400
D0I3CP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0FH9O	TTDDRUID	D0FH9O
D0FH9O	DRUGNAME	SDX-7500
D0FH9O	INDICATI	Weight loss [ICD-11: MG43.5] Investigative

D00DHM	TTDDRUID	D00DHM
D00DHM	DRUGNAME	SDZ-208911
D00DHM	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative

D0S8BU	TTDDRUID	D0S8BU
D0S8BU	DRUGNAME	SE RNA
D0S8BU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0IK1U	TTDDRUID	D0IK1U
D0IK1U	DRUGNAME	SEA-0400
D0IK1U	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D09SVB	TTDDRUID	D09SVB
D09SVB	DRUGNAME	SEB-Humab
D09SVB	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D0V9NW	TTDDRUID	D0V9NW
D0V9NW	DRUGNAME	Second generation neuregulin mutants
D0V9NW	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D07CSA	TTDDRUID	D07CSA
D07CSA	DRUGNAME	Second generation taxoids
D07CSA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0YK4H	TTDDRUID	D0YK4H
D0YK4H	DRUGNAME	Secreted/transmembrane receptor proteins
D0YK4H	INDICATI	Cachexia [ICD-11: MG20] Investigative

D0KP0L	TTDDRUID	D0KP0L
D0KP0L	DRUGNAME	SE-ET-TP020d
D0KP0L	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D07NIT	TTDDRUID	D07NIT
D07NIT	DRUGNAME	SEH inhibitors
D07NIT	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0T0KQ	TTDDRUID	D0T0KQ
D0T0KQ	DRUGNAME	SEL-100130
D0T0KQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D00YJD	TTDDRUID	D00YJD
D00YJD	DRUGNAME	SEL-103
D00YJD	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D07DGR	TTDDRUID	D07DGR
D07DGR	DRUGNAME	SEL-113
D07DGR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0XZ3W	TTDDRUID	D0XZ3W
D0XZ3W	DRUGNAME	SEL-120
D0XZ3W	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P1XQ	TTDDRUID	D0P1XQ
D0P1XQ	DRUGNAME	SEL-73
D0P1XQ	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Investigative

D08VBB	TTDDRUID	D08VBB
D08VBB	DRUGNAME	Selective androgen receptor degraders
D08VBB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D02FKS	TTDDRUID	D02FKS
D02FKS	DRUGNAME	Selective estrogen receptor degraders
D02FKS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D02JXT	TTDDRUID	D02JXT
D02JXT	DRUGNAME	Selective Rac1/1b GTPase nucleotide binding inhibitors
D02JXT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BX0V	TTDDRUID	D0BX0V
D0BX0V	DRUGNAME	Sel-K1
D0BX0V	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0O7XG	TTDDRUID	D0O7XG
D0O7XG	DRUGNAME	SEM-606
D0O7XG	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D08CIN	TTDDRUID	D08CIN
D08CIN	DRUGNAME	Semaphorin-3E anti-platelet agent
D08CIN	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D07JKA	TTDDRUID	D07JKA
D07JKA	DRUGNAME	SEN-1500
D07JKA	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0J9TA	TTDDRUID	D0J9TA
D0J9TA	DRUGNAME	Sensor linked micelle
D0J9TA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00DSN	TTDDRUID	D00DSN
D00DSN	DRUGNAME	Sepcidin
D00DSN	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D04JIE	TTDDRUID	D04JIE
D04JIE	DRUGNAME	SER-201
D04JIE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z1VE	TTDDRUID	D0Z1VE
D0Z1VE	DRUGNAME	SER-203
D0Z1VE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0KR6E	TTDDRUID	D0KR6E
D0KR6E	DRUGNAME	SER-207
D0KR6E	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J6OE	TTDDRUID	D0J6OE
D0J6OE	DRUGNAME	Serine protease inhibitor Kazal type 1 (SPINK1)
D0J6OE	INDICATI	Chronic pancreatitis [ICD-11: DC32] Investigative

D0GY3R	TTDDRUID	D0GY3R
D0GY3R	DRUGNAME	SERMs
D0GY3R	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00LSD	TTDDRUID	D00LSD
D00LSD	DRUGNAME	SERX-1
D00LSD	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0RE8R	TTDDRUID	D0RE8R
D0RE8R	DRUGNAME	SF-101
D0RE8R	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0W5IC	TTDDRUID	D0W5IC
D0W5IC	DRUGNAME	SF-103
D0W5IC	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0C4CJ	TTDDRUID	D0C4CJ
D0C4CJ	DRUGNAME	SF-105
D0C4CJ	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D07DRO	TTDDRUID	D07DRO
D07DRO	DRUGNAME	SF-106
D07DRO	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D0O7AK	TTDDRUID	D0O7AK
D0O7AK	DRUGNAME	SF-107
D0O7AK	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D08XRD	TTDDRUID	D08XRD
D08XRD	DRUGNAME	SF-108
D08XRD	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0N6DD	TTDDRUID	D0N6DD
D0N6DD	DRUGNAME	SF-109
D0N6DD	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0UR4L	TTDDRUID	D0UR4L
D0UR4L	DRUGNAME	SF-110
D0UR4L	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02RHU	TTDDRUID	D02RHU
D02RHU	DRUGNAME	SF-111
D02RHU	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0I2AD	TTDDRUID	D0I2AD
D0I2AD	DRUGNAME	SF-113
D0I2AD	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D0CK5J	TTDDRUID	D0CK5J
D0CK5J	DRUGNAME	SF-116
D0CK5J	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D00NJE	TTDDRUID	D00NJE
D00NJE	DRUGNAME	SFc
D00NJE	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D08SHI	TTDDRUID	D08SHI
D08SHI	DRUGNAME	SG-1311
D08SHI	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative

D0Q6KV	TTDDRUID	D0Q6KV
D0Q6KV	DRUGNAME	SG-2274
D0Q6KV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09VZR	TTDDRUID	D09VZR
D09VZR	DRUGNAME	SGI-1252
D09VZR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06OBQ	TTDDRUID	D06OBQ
D06OBQ	DRUGNAME	SGLT-2 inhibitors
D06OBQ	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0Z9WV	TTDDRUID	D0Z9WV
D0Z9WV	DRUGNAME	Sharon-1000
D0Z9WV	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0F5ZZ	TTDDRUID	D0F5ZZ
D0F5ZZ	DRUGNAME	Sharon-2000
D0F5ZZ	INDICATI	Dental caries [ICD-11: DA08.0] Investigative

D0E4TD	TTDDRUID	D0E4TD
D0E4TD	DRUGNAME	Sharon-3000
D0E4TD	INDICATI	Periodontitis [ICD-11: DA0C] Investigative

D0SL4P	TTDDRUID	D0SL4P
D0SL4P	DRUGNAME	Sharon-4000
D0SL4P	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D08XLV	TTDDRUID	D08XLV
D08XLV	DRUGNAME	Sharon-5000
D08XLV	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative

D04FAC	TTDDRUID	D04FAC
D04FAC	DRUGNAME	SHEF-1
D04FAC	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0ME7S	TTDDRUID	D0ME7S
D0ME7S	DRUGNAME	Shikimate kinase inhibitors
D0ME7S	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D07NDL	TTDDRUID	D07NDL
D07NDL	DRUGNAME	Short-acting etomidate analogue
D07NDL	INDICATI	Anaesthesia [ICD-11: 9A78.6] Investigative

D07YJK	TTDDRUID	D07YJK
D07YJK	DRUGNAME	ShRNA apolipoprotein B100 gene siliencer
D07YJK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D04NVK	TTDDRUID	D04NVK
D04NVK	DRUGNAME	ShRNA molecule silencing DNAPK radiosensitizer
D04NVK	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0EC1Y	TTDDRUID	D0EC1Y
D0EC1Y	DRUGNAME	SIG-001
D0EC1Y	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D04EZR	TTDDRUID	D04EZR
D04EZR	DRUGNAME	SIG-003
D04EZR	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D01PSY	TTDDRUID	D01PSY
D01PSY	DRUGNAME	SIG-005
D01PSY	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D06ZIS	TTDDRUID	D06ZIS
D06ZIS	DRUGNAME	SIG-990
D06ZIS	INDICATI	Rosacea [ICD-11: ED90.0] Investigative

D0P3LQ	TTDDRUID	D0P3LQ
D0P3LQ	DRUGNAME	SIL-187
D0P3LQ	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D02ETJ	TTDDRUID	D02ETJ
D02ETJ	DRUGNAME	SIL-43
D02ETJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y4ZI	TTDDRUID	D0Y4ZI
D0Y4ZI	DRUGNAME	Silicon-modified indomethacin
D0Y4ZI	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0B5SC	TTDDRUID	D0B5SC
D0B5SC	DRUGNAME	Silvestrol
D0B5SC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M4QA	TTDDRUID	D0M4QA
D0M4QA	DRUGNAME	SIM-010603
D0M4QA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I7MF	TTDDRUID	D0I7MF
D0I7MF	DRUGNAME	SIM-0702
D0I7MF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G8MY	TTDDRUID	D0G8MY
D0G8MY	DRUGNAME	SIM-0710
D0G8MY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0R5TZ	TTDDRUID	D0R5TZ
D0R5TZ	DRUGNAME	SIM-071201
D0R5TZ	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Investigative

D0O1NF	TTDDRUID	D0O1NF
D0O1NF	DRUGNAME	Single mab therapy
D0O1NF	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0C3JZ	TTDDRUID	D0C3JZ
D0C3JZ	DRUGNAME	SiRNA agent, cancer, respiratory/metabolic/liver diseases
D0C3JZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0J8IC	TTDDRUID	D0J8IC
D0J8IC	DRUGNAME	SiRNA nanoparticles, non-small-cell lung cancer
D0J8IC	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D01TYY	TTDDRUID	D01TYY
D01TYY	DRUGNAME	SiRNA therapeutic, Lauriad/tablet, prostate cancer
D01TYY	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D02GCM	TTDDRUID	D02GCM
D02GCM	DRUGNAME	SiRNA therapeutics, CNS disorders, nasal
D02GCM	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0KI6J	TTDDRUID	D0KI6J
D0KI6J	DRUGNAME	SiRNA therapeutics, inflammation
D0KI6J	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0E5WJ	TTDDRUID	D0E5WJ
D0E5WJ	DRUGNAME	SiRNA therapeutics, prostate cancer
D0E5WJ	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0G7FX	TTDDRUID	D0G7FX
D0G7FX	DRUGNAME	SiRNA therapy, AMD
D0G7FX	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0AI1F	TTDDRUID	D0AI1F
D0AI1F	DRUGNAME	SiRNA therapy, bladder cancer
D0AI1F	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D07XMT	TTDDRUID	D07XMT
D07XMT	DRUGNAME	SiRNA therapy, breast cancer
D07XMT	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0Z5LR	TTDDRUID	D0Z5LR
D0Z5LR	DRUGNAME	SiRNA therapy, HCV infection
D0Z5LR	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0M6BO	TTDDRUID	D0M6BO
D0M6BO	DRUGNAME	SiRNA therapy, hepatoma
D0M6BO	INDICATI	Liver cancer [ICD-11: 2C12] Investigative

D0J1JE	TTDDRUID	D0J1JE
D0J1JE	DRUGNAME	SiRNA therapy, Huntington's disease
D0J1JE	INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative

D0W4GL	TTDDRUID	D0W4GL
D0W4GL	DRUGNAME	SiRNA therapy, lung injury/lung cancer/neurodegenerative disease
D0W4GL	INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative

D0S5VL	TTDDRUID	D0S5VL
D0S5VL	DRUGNAME	SiRNA, liposomal nanoparticles, cervical cancer
D0S5VL	INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative

D0I2EW	TTDDRUID	D0I2EW
D0I2EW	DRUGNAME	Site-specific gene targeting agents
D0I2EW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U1BW	TTDDRUID	D0U1BW
D0U1BW	DRUGNAME	SIVIG
D0U1BW	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Y1VI	TTDDRUID	D0Y1VI
D0Y1VI	DRUGNAME	SJ-3249
D0Y1VI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02DOK	TTDDRUID	D02DOK
D02DOK	DRUGNAME	SJ-8002
D02DOK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00OMJ	TTDDRUID	D00OMJ
D00OMJ	DRUGNAME	SJ-BRV
D00OMJ	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0L8PG	TTDDRUID	D0L8PG
D0L8PG	DRUGNAME	SK-126
D0L8PG	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0B6HE	TTDDRUID	D0B6HE
D0B6HE	DRUGNAME	SKI-2852
D0B6HE	INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Investigative

D0D9KV	TTDDRUID	D0D9KV
D0D9KV	DRUGNAME	SKL-18287
D0D9KV	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D0Q3OM	TTDDRUID	D0Q3OM
D0Q3OM	DRUGNAME	SKL-19014
D0Q3OM	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D09OWC	TTDDRUID	D09OWC
D09OWC	DRUGNAME	SKLB-010
D09OWC	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D05HRW	TTDDRUID	D05HRW
D05HRW	DRUGNAME	SKL-NP2
D05HRW	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D00AHV	TTDDRUID	D00AHV
D00AHV	DRUGNAME	SKL-PD
D00AHV	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D09CEY	TTDDRUID	D09CEY
D09CEY	DRUGNAME	SKL-PSY
D09CEY	INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Investigative

D0V2VW	TTDDRUID	D0V2VW
D0V2VW	DRUGNAME	Sky kinase inhibitors
D0V2VW	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0HN6X	TTDDRUID	D0HN6X
D0HN6X	DRUGNAME	SKYFlu
D0HN6X	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0I0NP	TTDDRUID	D0I0NP
D0I0NP	DRUGNAME	SL125
D0I0NP	INDICATI	Congestive heart failure [ICD-11: BD10] Investigative
D0I0NP	INDICATI	Hyperaldosteronism [ICD-11: 5A72] Investigative
D0I0NP	INDICATI	Myocardial fibrosis [ICD-11: BC43.20] Investigative

D07OBK	TTDDRUID	D07OBK
D07OBK	DRUGNAME	SL-201
D07OBK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01GGB	TTDDRUID	D01GGB
D01GGB	DRUGNAME	SL-301
D01GGB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QI1O	TTDDRUID	D0QI1O
D0QI1O	DRUGNAME	SL-601
D0QI1O	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0F6QN	TTDDRUID	D0F6QN
D0F6QN	DRUGNAME	SLP-0901
D0F6QN	INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative

D09TIW	TTDDRUID	D09TIW
D09TIW	DRUGNAME	SLP-0904
D09TIW	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D09IMY	TTDDRUID	D09IMY
D09IMY	DRUGNAME	SLP-0905
D09IMY	INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Investigative

D08OWW	TTDDRUID	D08OWW
D08OWW	DRUGNAME	SLP-0906
D08OWW	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0CT5Z	TTDDRUID	D0CT5Z
D0CT5Z	DRUGNAME	SLP-0907
D0CT5Z	INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative

D0C2GN	TTDDRUID	D0C2GN
D0C2GN	DRUGNAME	SLP-1001
D0C2GN	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D08ZTH	TTDDRUID	D08ZTH
D08ZTH	DRUGNAME	SLP-1002
D08ZTH	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0M9PI	TTDDRUID	D0M9PI
D0M9PI	DRUGNAME	SLP-1003
D0M9PI	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative

D0Q7RJ	TTDDRUID	D0Q7RJ
D0Q7RJ	DRUGNAME	SLP-1004
D0Q7RJ	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0P2ZM	TTDDRUID	D0P2ZM
D0P2ZM	DRUGNAME	SLX-1016
D0P2ZM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D04GIK	TTDDRUID	D04GIK
D04GIK	DRUGNAME	Smac mimetics
D04GIK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D9PH	TTDDRUID	D0D9PH
D0D9PH	DRUGNAME	Small molecule 18a
D0D9PH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02SUX	TTDDRUID	D02SUX
D02SUX	DRUGNAME	Small molecule 19a
D02SUX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05DCP	TTDDRUID	D05DCP
D05DCP	DRUGNAME	Small molecule 20a
D05DCP	INDICATI	Chikungunya virus infection [ICD-11: 1D40] Investigative

D01KCF	TTDDRUID	D01KCF
D01KCF	DRUGNAME	Small molecule 2a
D01KCF	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D0O2VM	TTDDRUID	D0O2VM
D0O2VM	DRUGNAME	Small molecule 32
D0O2VM	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0N7MQ	TTDDRUID	D0N7MQ
D0N7MQ	DRUGNAME	Small molecule 33
D0N7MQ	INDICATI	Congestive heart failure [ICD-11: BD10] Investigative

D04ZAQ	TTDDRUID	D04ZAQ
D04ZAQ	DRUGNAME	Small molecule boron-based therapeutics, acne
D04ZAQ	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D0Y6PH	TTDDRUID	D0Y6PH
D0Y6PH	DRUGNAME	Small molecule I
D0Y6PH	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0E4GZ	TTDDRUID	D0E4GZ
D0E4GZ	DRUGNAME	Small molecule program targeting Th17 cells, autoimmune diseases
D0E4GZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0R9LG	TTDDRUID	D0R9LG
D0R9LG	DRUGNAME	Small molecule program targeting Tregs, autoimmune diseases
D0R9LG	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D02BXP	TTDDRUID	D02BXP
D02BXP	DRUGNAME	Small-molecule cetuximab binding mimics
D02BXP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XK6O	TTDDRUID	D0XK6O
D0XK6O	DRUGNAME	SMaRT FVIII
D0XK6O	INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative

D01DLX	TTDDRUID	D01DLX
D01DLX	DRUGNAME	SMC-0001 prodrug
D01DLX	INDICATI	Vomiting [ICD-11: MD90] Investigative

D0W8PL	TTDDRUID	D0W8PL
D0W8PL	DRUGNAME	SMC-0006 prodrug
D0W8PL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09UHY	TTDDRUID	D09UHY
D09UHY	DRUGNAME	SMK-01/03
D09UHY	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D0E7FG	TTDDRUID	D0E7FG
D0E7FG	DRUGNAME	SMND-309
D0E7FG	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0Q1YX	TTDDRUID	D0Q1YX
D0Q1YX	DRUGNAME	SMNT-1
D0Q1YX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06MUB	TTDDRUID	D06MUB
D06MUB	DRUGNAME	SMOi2-17
D06MUB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S2LG	TTDDRUID	D0S2LG
D0S2LG	DRUGNAME	Smoothened receptor antagonist
D0S2LG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C6PL	TTDDRUID	D0C6PL
D0C6PL	DRUGNAME	Sm-p80-VR1020
D0C6PL	INDICATI	Schistosomiasis [ICD-11: 1F86] Investigative

D0F9IK	TTDDRUID	D0F9IK
D0F9IK	DRUGNAME	SMRX-11
D0F9IK	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D00AXG	TTDDRUID	D00AXG
D00AXG	DRUGNAME	SMT-14224
D00AXG	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D00JME	TTDDRUID	D00JME
D00JME	DRUGNAME	SMT-14400
D00JME	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D06SMP	TTDDRUID	D06SMP
D06SMP	DRUGNAME	SMT-15000
D06SMP	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0J8RV	TTDDRUID	D0J8RV
D0J8RV	DRUGNAME	SMT-A07
D0J8RV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z4YK	TTDDRUID	D0Z4YK
D0Z4YK	DRUGNAME	SMT-C2100
D0Z4YK	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D06SMU	TTDDRUID	D06SMU
D06SMU	DRUGNAME	SMT-D003
D06SMU	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D05SXB	TTDDRUID	D05SXB
D05SXB	DRUGNAME	SMT-D004
D05SXB	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D04DYA	TTDDRUID	D04DYA
D04DYA	DRUGNAME	SMTP-0
D04DYA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09OPS	TTDDRUID	D09OPS
D09OPS	DRUGNAME	SN-28049
D09OPS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03QAQ	TTDDRUID	D03QAQ
D03QAQ	DRUGNAME	SN429
D03QAQ	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D06FGM	TTDDRUID	D06FGM
D06FGM	DRUGNAME	Snake venom antisera
D06FGM	INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative

D05UVL	TTDDRUID	D05UVL
D05UVL	DRUGNAME	SND-121
D05UVL	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D01IZM	TTDDRUID	D01IZM
D01IZM	DRUGNAME	SND-121 prodrugs
D01IZM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D00AIZ	TTDDRUID	D00AIZ
D00AIZ	DRUGNAME	SND-159
D00AIZ	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D02CEO	TTDDRUID	D02CEO
D02CEO	DRUGNAME	SND-226
D02CEO	INDICATI	Toxoplasmosis [ICD-11: 1F57] Investigative

D09BDK	TTDDRUID	D09BDK
D09BDK	DRUGNAME	SNG-163
D09BDK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01NDN	TTDDRUID	D01NDN
D01NDN	DRUGNAME	SNG-8006
D01NDN	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D03NWC	TTDDRUID	D03NWC
D03NWC	DRUGNAME	SNG-8023
D03NWC	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D03AVA	TTDDRUID	D03AVA
D03AVA	DRUGNAME	SNG-8033
D03AVA	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D03GIV	TTDDRUID	D03GIV
D03GIV	DRUGNAME	SNP-001
D03GIV	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative

D03DWZ	TTDDRUID	D03DWZ
D03DWZ	DRUGNAME	SNP-002
D03DWZ	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative

D04IDW	TTDDRUID	D04IDW
D04IDW	DRUGNAME	SNS-314 prodrugs
D04IDW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0UY8U	TTDDRUID	D0UY8U
D0UY8U	DRUGNAME	SNX-002
D0UY8U	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0UM1Y	TTDDRUID	D0UM1Y
D0UM1Y	DRUGNAME	SNX-2
D0UM1Y	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0S3YG	TTDDRUID	D0S3YG
D0S3YG	DRUGNAME	SNX-9
D0S3YG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01LCT	TTDDRUID	D01LCT
D01LCT	DRUGNAME	Sodium glucose cotransporter 2 (SGLT2) inhibitor
D01LCT	INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative

D0BJ3B	TTDDRUID	D0BJ3B
D0BJ3B	DRUGNAME	Soluble CD83
D0BJ3B	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0F1OG	TTDDRUID	D0F1OG
D0F1OG	DRUGNAME	Soluble ErbB3 theragnostics
D0F1OG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01DRE	TTDDRUID	D01DRE
D01DRE	DRUGNAME	SOM-0002
D01DRE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D2AR	TTDDRUID	D0D2AR
D0D2AR	DRUGNAME	SOM-0003
D0D2AR	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D06YAI	TTDDRUID	D06YAI
D06YAI	DRUGNAME	SOM-0004
D06YAI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0M9NJ	TTDDRUID	D0M9NJ
D0M9NJ	DRUGNAME	SOM-0005
D0M9NJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0HT4H	TTDDRUID	D0HT4H
D0HT4H	DRUGNAME	SOM-0009
D0HT4H	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0Z3LY	TTDDRUID	D0Z3LY
D0Z3LY	DRUGNAME	SOM-0010
D0Z3LY	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D02ETP	TTDDRUID	D02ETP
D02ETP	DRUGNAME	SOM-0420
D02ETP	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0I9RB	TTDDRUID	D0I9RB
D0I9RB	DRUGNAME	SOM-0525
D0I9RB	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0BM8Z	TTDDRUID	D0BM8Z
D0BM8Z	DRUGNAME	SOM-0633
D0BM8Z	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D05PKF	TTDDRUID	D05PKF
D05PKF	DRUGNAME	SOM-0720
D05PKF	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D0Q8SI	TTDDRUID	D0Q8SI
D0Q8SI	DRUGNAME	SOM-0777
D0Q8SI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09ISJ	TTDDRUID	D09ISJ
D09ISJ	DRUGNAME	SOM-0856
D09ISJ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D03WGM	TTDDRUID	D03WGM
D03WGM	DRUGNAME	SOM-0888
D03WGM	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D04HER	TTDDRUID	D04HER
D04HER	DRUGNAME	SOM-0999
D04HER	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0D2ZI	TTDDRUID	D0D2ZI
D0D2ZI	DRUGNAME	SOM-1000
D0D2ZI	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0T2NG	TTDDRUID	D0T2NG
D0T2NG	DRUGNAME	SOM-1025
D0T2NG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0AX0V	TTDDRUID	D0AX0V
D0AX0V	DRUGNAME	SOM-1033
D0AX0V	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D01ODT	TTDDRUID	D01ODT
D01ODT	DRUGNAME	Sophorolipid isoforms
D01ODT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03QFO	TTDDRUID	D03QFO
D03QFO	DRUGNAME	SOR-N43
D03QFO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0O8WM	TTDDRUID	D0O8WM
D0O8WM	DRUGNAME	SP-003
D0O8WM	INDICATI	Asthma [ICD-11: CA23] Investigative

D0Y1FI	TTDDRUID	D0Y1FI
D0Y1FI	DRUGNAME	SP-03
D0Y1FI	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0C4WY	TTDDRUID	D0C4WY
D0C4WY	DRUGNAME	SP-08
D0C4WY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0K1YQ	TTDDRUID	D0K1YQ
D0K1YQ	DRUGNAME	SP-10
D0K1YQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0B9XD	TTDDRUID	D0B9XD
D0B9XD	DRUGNAME	SP-1000
D0B9XD	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D01WMI	TTDDRUID	D01WMI
D01WMI	DRUGNAME	SP-1031C
D01WMI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05TPA	TTDDRUID	D05TPA
D05TPA	DRUGNAME	SP-1062C-O
D05TPA	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D01LUH	TTDDRUID	D01LUH
D01LUH	DRUGNAME	SP-30
D01LUH	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D03YGX	TTDDRUID	D03YGX
D03YGX	DRUGNAME	SP-D
D03YGX	INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative

D0P2CZ	TTDDRUID	D0P2CZ
D0P2CZ	DRUGNAME	SPH-260-4
D0P2CZ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0AS2P	TTDDRUID	D0AS2P
D0AS2P	DRUGNAME	Spheron-based therapeutics
D0AS2P	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0C1TT	TTDDRUID	D0C1TT
D0C1TT	DRUGNAME	SPI-017
D0C1TT	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D07UFS	TTDDRUID	D07UFS
D07UFS	DRUGNAME	SPI-5557
D07UFS	INDICATI	Deafness [ICD-11: AB52] Investigative

D0O0YA	TTDDRUID	D0O0YA
D0O0YA	DRUGNAME	SPIO-Stasix nanoparticles
D0O0YA	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D00TBS	TTDDRUID	D00TBS
D00TBS	DRUGNAME	SPIRU-211
D00TBS	INDICATI	Constipation [ICD-11: DD91.1] Investigative

D0I1OX	TTDDRUID	D0I1OX
D0I1OX	DRUGNAME	SPL-2101
D0I1OX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06JQM	TTDDRUID	D06JQM
D06JQM	DRUGNAME	SPP-800
D06JQM	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D09KQX	TTDDRUID	D09KQX
D09KQX	DRUGNAME	SPRMs, oral, uterine fibroids, Tokai Pharmaceuticals
D09KQX	INDICATI	Uterine fibroids [ICD-11: 2E86.0] Investigative

D04LHG	TTDDRUID	D04LHG
D04LHG	DRUGNAME	SP-SAP
D04LHG	INDICATI	Cancer related pain [ICD-11: MG30] Investigative

D04NBY	TTDDRUID	D04NBY
D04NBY	DRUGNAME	SPVF-2801-10
D04NBY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X4MO	TTDDRUID	D0X4MO
D0X4MO	DRUGNAME	SPVF-2801-30
D0X4MO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0VB2K	TTDDRUID	D0VB2K
D0VB2K	DRUGNAME	SPX-601
D0VB2K	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0VZ2A	TTDDRUID	D0VZ2A
D0VZ2A	DRUGNAME	SQ-609
D0VZ2A	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0O1WJ	TTDDRUID	D0O1WJ
D0O1WJ	DRUGNAME	SR-1001
D0O1WJ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0M1WF	TTDDRUID	D0M1WF
D0M1WF	DRUGNAME	SR-13654
D0M1WF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0L8YY	TTDDRUID	D0L8YY
D0L8YY	DRUGNAME	SR-14136
D0L8YY	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0V6YT	TTDDRUID	D0V6YT
D0V6YT	DRUGNAME	SR-33805A
D0V6YT	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0J2GG	TTDDRUID	D0J2GG
D0J2GG	DRUGNAME	SR-3850
D0J2GG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04CUZ	TTDDRUID	D04CUZ
D04CUZ	DRUGNAME	SRG
D04CUZ	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D00PJK	TTDDRUID	D00PJK
D00PJK	DRUGNAME	SRI-21009
D00PJK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V4JW	TTDDRUID	D0V4JW
D0V4JW	DRUGNAME	SRPIN-340
D0V4JW	INDICATI	Choroidal neovascularization [ICD-11: 9B76] Investigative

D09UCV	TTDDRUID	D09UCV
D09UCV	DRUGNAME	SRW-LAMP-vax
D09UCV	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0B0TW	TTDDRUID	D0B0TW
D0B0TW	DRUGNAME	SSJ-183
D0B0TW	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0ZR4Q	TTDDRUID	D0ZR4Q
D0ZR4Q	DRUGNAME	SSS-08
D0ZR4Q	INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative

D0F1CN	TTDDRUID	D0F1CN
D0F1CN	DRUGNAME	SST-0001
D0F1CN	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02QXI	TTDDRUID	D02QXI
D02QXI	DRUGNAME	ST-04
D02QXI	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D0W7RZ	TTDDRUID	D0W7RZ
D0W7RZ	DRUGNAME	ST-05
D0W7RZ	INDICATI	Spinal disease [ICD-11: FA72] Investigative

D04OYW	TTDDRUID	D04OYW
D04OYW	DRUGNAME	ST-06
D04OYW	INDICATI	Injury [ICD-11: NA00-ND5Z] Investigative

D0W7PP	TTDDRUID	D0W7PP
D0W7PP	DRUGNAME	ST-0701
D0W7PP	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0V2DC	TTDDRUID	D0V2DC
D0V2DC	DRUGNAME	ST-0703
D0V2DC	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0C0BE	TTDDRUID	D0C0BE
D0C0BE	DRUGNAME	ST-148
D0C0BE	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0T0SK	TTDDRUID	D0T0SK
D0T0SK	DRUGNAME	ST-2987
D0T0SK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X1LE	TTDDRUID	D0X1LE
D0X1LE	DRUGNAME	ST-383
D0X1LE	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D0N4ZS	TTDDRUID	D0N4ZS
D0N4ZS	DRUGNAME	ST-4206
D0N4ZS	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D09TOS	TTDDRUID	D09TOS
D09TOS	DRUGNAME	ST-669
D09TOS	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D06BUS	TTDDRUID	D06BUS
D06BUS	DRUGNAME	ST-7
D06BUS	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D07IBY	TTDDRUID	D07IBY
D07IBY	DRUGNAME	STA-9584
D07IBY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03WXL	TTDDRUID	D03WXL
D03WXL	DRUGNAME	Staphguard
D03WXL	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D04GGA	TTDDRUID	D04GGA
D04GGA	DRUGNAME	StaphStop
D04GGA	INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative

D0Q3TF	TTDDRUID	D0Q3TF
D0Q3TF	DRUGNAME	Staphylocide
D0Q3TF	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0N2AY	TTDDRUID	D0N2AY
D0N2AY	DRUGNAME	Stapled peptides
D0N2AY	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Q1EC	TTDDRUID	D0Q1EC
D0Q1EC	DRUGNAME	STAT-3 DECOY (NSC-741763)
D0Q1EC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04BUA	TTDDRUID	D04BUA
D04BUA	DRUGNAME	STAT-3 inhibitors
D04BUA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W7VX	TTDDRUID	D0W7VX
D0W7VX	DRUGNAME	Statin
D0W7VX	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0N5OL	TTDDRUID	D0N5OL
D0N5OL	DRUGNAME	STD-052
D0N5OL	INDICATI	Constipation [ICD-11: DD91.1] Investigative

D0T9YV	TTDDRUID	D0T9YV
D0T9YV	DRUGNAME	STD-06
D0T9YV	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D04LTO	TTDDRUID	D04LTO
D04LTO	DRUGNAME	Steamchol
D04LTO	INDICATI	Gallstone [ICD-11: DC11.3] Investigative

D0Q7MG	TTDDRUID	D0Q7MG
D0Q7MG	DRUGNAME	Stearoyl CoA desaturase-1 inhibitors
D0Q7MG	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0M8TO	TTDDRUID	D0M8TO
D0M8TO	DRUGNAME	Stem cell therapeutics
D0M8TO	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0ET5E	TTDDRUID	D0ET5E
D0ET5E	DRUGNAME	Stem cell therapy, Dry AMD
D0ET5E	INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative

D0N3RU	TTDDRUID	D0N3RU
D0N3RU	DRUGNAME	Stem cell therapy, heart disease
D0N3RU	INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative

D05KOY	TTDDRUID	D05KOY
D05KOY	DRUGNAME	Stem cell therapy, spinal cord injury
D05KOY	INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative

D0Y3XF	TTDDRUID	D0Y3XF
D0Y3XF	DRUGNAME	Stem cell-derived astrocytes
D0Y3XF	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0O3TB	TTDDRUID	D0O3TB
D0O3TB	DRUGNAME	Steroid mimics
D0O3TB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D02VQU	TTDDRUID	D02VQU
D02VQU	DRUGNAME	STF-31
D02VQU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01CIN	TTDDRUID	D01CIN
D01CIN	DRUGNAME	STF-62247
D01CIN	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative

D02JWN	TTDDRUID	D02JWN
D02JWN	DRUGNAME	STNM-01
D02JWN	INDICATI	Pyloric stenosis [ICD-11: DA40.0] Investigative

D0H5LY	TTDDRUID	D0H5LY
D0H5LY	DRUGNAME	STNM-04
D0H5LY	INDICATI	Liver cirrhosis [ICD-11: DB93.1] Investigative

D0R8KF	TTDDRUID	D0R8KF
D0R8KF	DRUGNAME	STP-322
D0R8KF	INDICATI	Liver cancer [ICD-11: 2C12] Investigative

D0QR8B	TTDDRUID	D0QR8B
D0QR8B	DRUGNAME	STP-432
D0QR8B	INDICATI	Crohn disease [ICD-11: DD70] Investigative

D0OT8O	TTDDRUID	D0OT8O
D0OT8O	DRUGNAME	STP-601
D0OT8O	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative

D07MMC	TTDDRUID	D07MMC
D07MMC	DRUGNAME	STP-702
D07MMC	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0KE0C	TTDDRUID	D0KE0C
D0KE0C	DRUGNAME	STP-805
D0KE0C	INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative

D0Y8KM	TTDDRUID	D0Y8KM
D0Y8KM	DRUGNAME	STP-900
D0Y8KM	INDICATI	Organ transplant rejection [ICD-11: NE84] Investigative

D0K4GG	TTDDRUID	D0K4GG
D0K4GG	DRUGNAME	STP-902
D0K4GG	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D0F2DJ	TTDDRUID	D0F2DJ
D0F2DJ	DRUGNAME	Stroke program, Dong Wha
D0F2DJ	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D0AW7H	TTDDRUID	D0AW7H
D0AW7H	DRUGNAME	StromaCel
D0AW7H	INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative

D0C3GZ	TTDDRUID	D0C3GZ
D0C3GZ	DRUGNAME	STS-T4
D0C3GZ	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D0E6AP	TTDDRUID	D0E6AP
D0E6AP	DRUGNAME	STX
D0E6AP	INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Investigative

D07MFY	TTDDRUID	D07MFY
D07MFY	DRUGNAME	STX-200
D07MFY	INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative

D07SNN	TTDDRUID	D07SNN
D07SNN	DRUGNAME	STxB-E7
D07SNN	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative

D0A4XJ	TTDDRUID	D0A4XJ
D0A4XJ	DRUGNAME	SU5402
D0A4XJ	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0X4IO	TTDDRUID	D0X4IO
D0X4IO	DRUGNAME	Sulforaphane
D0X4IO	INDICATI	Skin disease [ICD-11: EA00-EM0Z] Investigative
D0X4IO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N5SW	TTDDRUID	D0N5SW
D0N5SW	DRUGNAME	Sulochrin
D0N5SW	INDICATI	Asthma [ICD-11: CA23] Investigative

D07BAE	TTDDRUID	D07BAE
D07BAE	DRUGNAME	SUN-0597
D07BAE	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D07XSD	TTDDRUID	D07XSD
D07XSD	DRUGNAME	SUN-13333
D07XSD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D03HQR	TTDDRUID	D03HQR
D03HQR	DRUGNAME	SUN-44
D03HQR	INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Investigative

D03KRF	TTDDRUID	D03KRF
D03KRF	DRUGNAME	Superoxide dismutase mimetics
D03KRF	INDICATI	Retinopathy [ICD-11: 9B71] Investigative

D0K9ES	TTDDRUID	D0K9ES
D0K9ES	DRUGNAME	Suprofenac
D0K9ES	INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative

D08SIL	TTDDRUID	D08SIL
D08SIL	DRUGNAME	Surrobodies
D08SIL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D06XXZ	TTDDRUID	D06XXZ
D06XXZ	DRUGNAME	Sustained release incrementally modified drug
D06XXZ	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative

D0TU7G	TTDDRUID	D0TU7G
D0TU7G	DRUGNAME	SUVN-1004028
D0TU7G	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D00PBI	TTDDRUID	D00PBI
D00PBI	DRUGNAME	SUVN-501
D00PBI	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0K8PH	TTDDRUID	D0K8PH
D0K8PH	DRUGNAME	SUVN-504
D0K8PH	INDICATI	Vomiting [ICD-11: MD90] Investigative

D0S3UH	TTDDRUID	D0S3UH
D0S3UH	DRUGNAME	SUVN-507
D0S3UH	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0G4SO	TTDDRUID	D0G4SO
D0G4SO	DRUGNAME	SUVN-F90101
D0G4SO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0HM7G	TTDDRUID	D0HM7G
D0HM7G	DRUGNAME	SUVN-G1031
D0HM7G	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D03QWC	TTDDRUID	D03QWC
D03QWC	DRUGNAME	SV-BR-1-GM
D03QWC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E1ZQ	TTDDRUID	D0E1ZQ
D0E1ZQ	DRUGNAME	SWA11-ZZ-PE38
D0E1ZQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S4PZ	TTDDRUID	D0S4PZ
D0S4PZ	DRUGNAME	SWT-01113
D0S4PZ	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D06KOR	TTDDRUID	D06KOR
D06KOR	DRUGNAME	SWT-05104
D06KOR	INDICATI	Vitiligo [ICD-11: ED63.0] Investigative

D0A1KP	TTDDRUID	D0A1KP
D0A1KP	DRUGNAME	SWT-05105
D0A1KP	INDICATI	Vitiligo [ICD-11: ED63.0] Investigative

D03DOW	TTDDRUID	D03DOW
D03DOW	DRUGNAME	SWT-05141
D03DOW	INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative

D09YHI	TTDDRUID	D09YHI
D09YHI	DRUGNAME	SX5
D09YHI	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D0O8SS	TTDDRUID	D0O8SS
D0O8SS	DRUGNAME	SX8
D0O8SS	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative

D0C1UP	TTDDRUID	D0C1UP
D0C1UP	DRUGNAME	SX-ARPC
D0C1UP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0N6EL	TTDDRUID	D0N6EL
D0N6EL	DRUGNAME	SX-AZD1
D0N6EL	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D09RUJ	TTDDRUID	D09RUJ
D09RUJ	DRUGNAME	SX-GLP1
D09RUJ	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D05UAA	TTDDRUID	D05UAA
D05UAA	DRUGNAME	SX-HIV1
D05UAA	INDICATI	Retrovirus infection [ICD-11: 1D9Y] Investigative

D05SOW	TTDDRUID	D05SOW
D05SOW	DRUGNAME	SX-MTR1
D05SOW	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0Z0QO	TTDDRUID	D0Z0QO
D0Z0QO	DRUGNAME	SX-PCK9
D0Z0QO	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative

D0N0HO	TTDDRUID	D0N0HO
D0N0HO	DRUGNAME	SX-RDS1
D0N0HO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F7FE	TTDDRUID	D0F7FE
D0F7FE	DRUGNAME	SY-300
D0F7FE	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D07YNX	TTDDRUID	D07YNX
D07YNX	DRUGNAME	Syk kinase inhibitors
D07YNX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0R3DQ	TTDDRUID	D0R3DQ
D0R3DQ	DRUGNAME	SYL-040003
D0R3DQ	INDICATI	Ocular hypertension [ICD-11: 9C61.01] Investigative

D0H6AT	TTDDRUID	D0H6AT
D0H6AT	DRUGNAME	SYM-005
D0H6AT	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M6XY	TTDDRUID	D0M6XY
D0M6XY	DRUGNAME	SYM-006
D0M6XY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0O1XO	TTDDRUID	D0O1XO
D0O1XO	DRUGNAME	SYM-007
D0O1XO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0KL5U	TTDDRUID	D0KL5U
D0KL5U	DRUGNAME	SYM-008
D0KL5U	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D09EED	TTDDRUID	D09EED
D09EED	DRUGNAME	SYM-009
D09EED	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D0Q8GX	TTDDRUID	D0Q8GX
D0Q8GX	DRUGNAME	SYM-011
D0Q8GX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y7WA	TTDDRUID	D0Y7WA
D0Y7WA	DRUGNAME	SYN-1003
D0Y7WA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0X2MZ	TTDDRUID	D0X2MZ
D0X2MZ	DRUGNAME	Syn-1020
D0X2MZ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D02CVF	TTDDRUID	D02CVF
D02CVF	DRUGNAME	SynGEM
D02CVF	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D01KSO	TTDDRUID	D01KSO
D01KSO	DRUGNAME	Synthetic peptide
D01KSO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0VH9C	TTDDRUID	D0VH9C
D0VH9C	DRUGNAME	Synuclere
D0VH9C	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D0M6TX	TTDDRUID	D0M6TX
D0M6TX	DRUGNAME	T-109
D0M6TX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0ZU6O	TTDDRUID	D0ZU6O
D0ZU6O	DRUGNAME	T-1106
D0ZU6O	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D09UXU	TTDDRUID	D09UXU
D09UXU	DRUGNAME	T1-1081
D09UXU	INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative

D08MID	TTDDRUID	D08MID
D08MID	DRUGNAME	T-115
D08MID	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L7FB	TTDDRUID	D0L7FB
D0L7FB	DRUGNAME	T1-IR
D0L7FB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q4BI	TTDDRUID	D0Q4BI
D0Q4BI	DRUGNAME	T-2
D0Q4BI	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0F0ET	TTDDRUID	D0F0ET
D0F0ET	DRUGNAME	T-270
D0F0ET	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D07ZES	TTDDRUID	D07ZES
D07ZES	DRUGNAME	T2CA
D07ZES	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative

D0A2HS	TTDDRUID	D0A2HS
D0A2HS	DRUGNAME	T-3.5
D0A2HS	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0R1HK	TTDDRUID	D0R1HK
D0R1HK	DRUGNAME	T-9001
D0R1HK	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D04BRF	TTDDRUID	D04BRF
D04BRF	DRUGNAME	TA-101
D04BRF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02TQE	TTDDRUID	D02TQE
D02TQE	DRUGNAME	TA-102
D02TQE	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D08SZP	TTDDRUID	D08SZP
D08SZP	DRUGNAME	TA-103
D08SZP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08GHX	TTDDRUID	D08GHX
D08GHX	DRUGNAME	TA-104
D08GHX	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D01ODC	TTDDRUID	D01ODC
D01ODC	DRUGNAME	TA-106
D01ODC	INDICATI	Asthma [ICD-11: CA23] Investigative

D0Q4BX	TTDDRUID	D0Q4BX
D0Q4BX	DRUGNAME	TA-111
D0Q4BX	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D07FUO	TTDDRUID	D07FUO
D07FUO	DRUGNAME	TA-264
D07FUO	INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative

D0V5YA	TTDDRUID	D0V5YA
D0V5YA	DRUGNAME	TA-381
D0V5YA	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Investigative

D02VJJ	TTDDRUID	D02VJJ
D02VJJ	DRUGNAME	TACE inhibitors
D02VJJ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0F4MI	TTDDRUID	D0F4MI
D0F4MI	DRUGNAME	TAK-075
D0F4MI	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0YN3T	TTDDRUID	D0YN3T
D0YN3T	DRUGNAME	Tamiphosphor
D0YN3T	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0V9NE	TTDDRUID	D0V9NE
D0V9NE	DRUGNAME	Tanaproget
D0V9NE	INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Investigative

D01RBX	TTDDRUID	D01RBX
D01RBX	DRUGNAME	Targeted gold nanoparticle
D01RBX	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0VW3F	TTDDRUID	D0VW3F
D0VW3F	DRUGNAME	Targeted nanoparticles
D0VW3F	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0Z6HB	TTDDRUID	D0Z6HB
D0Z6HB	DRUGNAME	Targeted vascular disrupting agent
D0Z6HB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0S1HX	TTDDRUID	D0S1HX
D0S1HX	DRUGNAME	TAS-203
D0S1HX	INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative

D01GDB	TTDDRUID	D01GDB
D01GDB	DRUGNAME	Tat Oyi-Cys22
D01GDB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0A7HY	TTDDRUID	D0A7HY
D0A7HY	DRUGNAME	TAT-120
D0A7HY	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D02GBZ	TTDDRUID	D02GBZ
D02GBZ	DRUGNAME	Tau phosphorylation inhibitors
D02GBZ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0Q3RC	TTDDRUID	D0Q3RC
D0Q3RC	DRUGNAME	Taxotere-mab
D0Q3RC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0P4FK	TTDDRUID	D0P4FK
D0P4FK	DRUGNAME	TB-010
D0P4FK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0EN0F	TTDDRUID	D0EN0F
D0EN0F	DRUGNAME	TB-09
D0EN0F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F4VK	TTDDRUID	D0F4VK
D0F4VK	DRUGNAME	TB-101
D0F4VK	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D03KFJ	TTDDRUID	D03KFJ
D03KFJ	DRUGNAME	TB-102
D03KFJ	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0Z0SI	TTDDRUID	D0Z0SI
D0Z0SI	DRUGNAME	TBD-2
D0Z0SI	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D05JGR	TTDDRUID	D05JGR
D05JGR	DRUGNAME	TBDT
D05JGR	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D08ELL	TTDDRUID	D08ELL
D08ELL	DRUGNAME	TBE-80E
D08ELL	INDICATI	Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative

D06OWF	TTDDRUID	D06OWF
D06OWF	DRUGNAME	TBI-301
D06OWF	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0E7TR	TTDDRUID	D0E7TR
D0E7TR	DRUGNAME	TBI-302
D0E7TR	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D0D3HF	TTDDRUID	D0D3HF
D0D3HF	DRUGNAME	TBI-304
D0D3HF	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0IS5V	TTDDRUID	D0IS5V
D0IS5V	DRUGNAME	TC-34
D0IS5V	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D08TPH	TTDDRUID	D08TPH
D08TPH	DRUGNAME	TC-5653
D08TPH	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Investigative

D03ZNK	TTDDRUID	D03ZNK
D03ZNK	DRUGNAME	Tc99-labeled 14F7 humanized mab
D03ZNK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0E2VA	TTDDRUID	D0E2VA
D0E2VA	DRUGNAME	T-cell receptor mimic mabs
D0E2VA	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D00YLI	TTDDRUID	D00YLI
D00YLI	DRUGNAME	T-cell receptors
D00YLI	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D09TVH	TTDDRUID	D09TVH
D09TVH	DRUGNAME	TCH-013
D09TVH	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D09MXE	TTDDRUID	D09MXE
D09MXE	DRUGNAME	TCK-1
D09MXE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0M9FA	TTDDRUID	D0M9FA
D0M9FA	DRUGNAME	TCR-transduced T-cell immunotherapy
D0M9FA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08VWJ	TTDDRUID	D08VWJ
D08VWJ	DRUGNAME	TD-1770
D08VWJ	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0A5KO	TTDDRUID	D0A5KO
D0A5KO	DRUGNAME	TD-3633
D0A5KO	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D08GUX	TTDDRUID	D08GUX
D08GUX	DRUGNAME	TD-4001
D08GUX	INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Investigative

D0V9BX	TTDDRUID	D0V9BX
D0V9BX	DRUGNAME	TD-6989
D0V9BX	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D05TVI	TTDDRUID	D05TVI
D05TVI	DRUGNAME	TD-9594
D05TVI	INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative

D0J2NI	TTDDRUID	D0J2NI
D0J2NI	DRUGNAME	TDI-0010
D0J2NI	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D02TTP	TTDDRUID	D02TTP
D02TTP	DRUGNAME	TDI-0015
D02TTP	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D07TIX	TTDDRUID	D07TIX
D07TIX	DRUGNAME	TDI-0018
D07TIX	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0Z1HA	TTDDRUID	D0Z1HA
D0Z1HA	DRUGNAME	TDI-0020
D0Z1HA	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D05YRG	TTDDRUID	D05YRG
D05YRG	DRUGNAME	TDI-0025
D05YRG	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D09LVK	TTDDRUID	D09LVK
D09LVK	DRUGNAME	TDI-0026
D09LVK	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D06VPT	TTDDRUID	D06VPT
D06VPT	DRUGNAME	TDI-0028
D06VPT	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0GD6J	TTDDRUID	D0GD6J
D0GD6J	DRUGNAME	TDI-0029
D0GD6J	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D07MUT	TTDDRUID	D07MUT
D07MUT	DRUGNAME	TDI-0032
D07MUT	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0Q8ZP	TTDDRUID	D0Q8ZP
D0Q8ZP	DRUGNAME	TDI-0033
D0Q8ZP	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D09BSI	TTDDRUID	D09BSI
D09BSI	DRUGNAME	TDI-0039
D09BSI	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0PH0U	TTDDRUID	D0PH0U
D0PH0U	DRUGNAME	TDI-0042
D0PH0U	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0W7NV	TTDDRUID	D0W7NV
D0W7NV	DRUGNAME	TDI-0043
D0W7NV	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0Z0JA	TTDDRUID	D0Z0JA
D0Z0JA	DRUGNAME	TDI-0046
D0Z0JA	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0SD8V	TTDDRUID	D0SD8V
D0SD8V	DRUGNAME	TDI-0047
D0SD8V	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0E2EN	TTDDRUID	D0E2EN
D0E2EN	DRUGNAME	TDI-0048
D0E2EN	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0FZ9N	TTDDRUID	D0FZ9N
D0FZ9N	DRUGNAME	TDI-0049
D0FZ9N	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D02REO	TTDDRUID	D02REO
D02REO	DRUGNAME	TDI-0050
D02REO	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D00HNQ	TTDDRUID	D00HNQ
D00HNQ	DRUGNAME	TDI-0051
D00HNQ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D07TWZ	TTDDRUID	D07TWZ
D07TWZ	DRUGNAME	TDI-0053
D07TWZ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D04TPF	TTDDRUID	D04TPF
D04TPF	DRUGNAME	TDI-0054
D04TPF	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D05DZJ	TTDDRUID	D05DZJ
D05DZJ	DRUGNAME	TDI-0055
D05DZJ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D00SNY	TTDDRUID	D00SNY
D00SNY	DRUGNAME	TDI-0057
D00SNY	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D04LRQ	TTDDRUID	D04LRQ
D04LRQ	DRUGNAME	TDI-0059
D04LRQ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0BT4P	TTDDRUID	D0BT4P
D0BT4P	DRUGNAME	TDI-0060
D0BT4P	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D01PFX	TTDDRUID	D01PFX
D01PFX	DRUGNAME	TDI-0065
D01PFX	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0LX4K	TTDDRUID	D0LX4K
D0LX4K	DRUGNAME	TDI-0066
D0LX4K	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D07IYC	TTDDRUID	D07IYC
D07IYC	DRUGNAME	TDI-0067
D07IYC	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0FK6A	TTDDRUID	D0FK6A
D0FK6A	DRUGNAME	TDI-0068
D0FK6A	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0C3RP	TTDDRUID	D0C3RP
D0C3RP	DRUGNAME	TDI-0074
D0C3RP	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D05SCQ	TTDDRUID	D05SCQ
D05SCQ	DRUGNAME	TDI-0079
D05SCQ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D09MPN	TTDDRUID	D09MPN
D09MPN	DRUGNAME	TDI-0087
D09MPN	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D09DHL	TTDDRUID	D09DHL
D09DHL	DRUGNAME	TDI-0090
D09DHL	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D06EYQ	TTDDRUID	D06EYQ
D06EYQ	DRUGNAME	TDI-0094
D06EYQ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0X6DK	TTDDRUID	D0X6DK
D0X6DK	DRUGNAME	TDI-0098
D0X6DK	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0C4UU	TTDDRUID	D0C4UU
D0C4UU	DRUGNAME	TDI-0099
D0C4UU	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D03JRL	TTDDRUID	D03JRL
D03JRL	DRUGNAME	TDI-0102
D03JRL	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0TY1U	TTDDRUID	D0TY1U
D0TY1U	DRUGNAME	TDI-0103
D0TY1U	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0H2LJ	TTDDRUID	D0H2LJ
D0H2LJ	DRUGNAME	TDI-0105
D0H2LJ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D02XUE	TTDDRUID	D02XUE
D02XUE	DRUGNAME	TDI-0106
D02XUE	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0W7DP	TTDDRUID	D0W7DP
D0W7DP	DRUGNAME	TDI-0107
D0W7DP	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0Z8UJ	TTDDRUID	D0Z8UJ
D0Z8UJ	DRUGNAME	TDI-0111
D0Z8UJ	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0XR6I	TTDDRUID	D0XR6I
D0XR6I	DRUGNAME	TDI-0113
D0XR6I	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0T5JG	TTDDRUID	D0T5JG
D0T5JG	DRUGNAME	TDI-0114
D0T5JG	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D0WT8Z	TTDDRUID	D0WT8Z
D0WT8Z	DRUGNAME	TDI-0115
D0WT8Z	INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative

D06PFK	TTDDRUID	D06PFK
D06PFK	DRUGNAME	TDT-044
D06PFK	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D02EVL	TTDDRUID	D02EVL
D02EVL	DRUGNAME	TDT-077
D02EVL	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Investigative

D01GEO	TTDDRUID	D01GEO
D01GEO	DRUGNAME	Telomestatin
D01GEO	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0LN9P	TTDDRUID	D0LN9P
D0LN9P	DRUGNAME	TELUDIPINE HYDROCHLORIDE
D0LN9P	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0DA6N	TTDDRUID	D0DA6N
D0DA6N	DRUGNAME	TEM-8-Fc
D0DA6N	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T3KZ	TTDDRUID	D0T3KZ
D0T3KZ	DRUGNAME	TENOSAL
D0T3KZ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D00QAQ	TTDDRUID	D00QAQ
D00QAQ	DRUGNAME	Terpenoid schweinfurthins
D00QAQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09XGK	TTDDRUID	D09XGK
D09XGK	DRUGNAME	Testetrol
D09XGK	INDICATI	Hypogonadism [ICD-11: 5A61.0] Investigative

D08MTA	TTDDRUID	D08MTA
D08MTA	DRUGNAME	Tetanolic acid
D08MTA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0J9MO	TTDDRUID	D0J9MO
D0J9MO	DRUGNAME	Tetrabranched peptides
D0J9MO	INDICATI	Multidrug resistant infection [ICD-11: MG51] Investigative

D0T6UW	TTDDRUID	D0T6UW
D0T6UW	DRUGNAME	Tetraoxane derivatives
D0T6UW	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0ND8N	TTDDRUID	D0ND8N
D0ND8N	DRUGNAME	Textilinin
D0ND8N	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0C3GW	TTDDRUID	D0C3GW
D0C3GW	DRUGNAME	TG-1022
D0C3GW	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0C8NK	TTDDRUID	D0C8NK
D0C8NK	DRUGNAME	TG-21
D0C8NK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0LD8U	TTDDRUID	D0LD8U
D0LD8U	DRUGNAME	TG-3003
D0LD8U	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00TYI	TTDDRUID	D00TYI
D00TYI	DRUGNAME	TG-3030
D00TYI	INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Investigative

D08SPP	TTDDRUID	D08SPP
D08SPP	DRUGNAME	TG-44
D08SPP	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative

D06MCH	TTDDRUID	D06MCH
D06MCH	DRUGNAME	TG-6002
D06MCH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0XR7V	TTDDRUID	D0XR7V
D0XR7V	DRUGNAME	TG-B
D0XR7V	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0D2RR	TTDDRUID	D0D2RR
D0D2RR	DRUGNAME	TgBSSL
D0D2RR	INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Investigative

D02BVQ	TTDDRUID	D02BVQ
D02BVQ	DRUGNAME	TGC-9
D02BVQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01XMP	TTDDRUID	D01XMP
D01XMP	DRUGNAME	TG-D
D01XMP	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0H3FX	TTDDRUID	D0H3FX
D0H3FX	DRUGNAME	TGF alpha
D0H3FX	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D00NCI	TTDDRUID	D00NCI
D00NCI	DRUGNAME	TGF beta 2 receptor peptantagonists
D00NCI	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0J1SZ	TTDDRUID	D0J1SZ
D0J1SZ	DRUGNAME	TGF-beta elevating agent
D0J1SZ	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D04FVP	TTDDRUID	D04FVP
D04FVP	DRUGNAME	TGF-beta receptor 1 kinase inhibitor
D04FVP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T6IX	TTDDRUID	D0T6IX
D0T6IX	DRUGNAME	TGF-beta receptor 1 kinase inhibitors
D0T6IX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0QJ4Y	TTDDRUID	D0QJ4Y
D0QJ4Y	DRUGNAME	TGF-beta Shield
D0QJ4Y	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09OSM	TTDDRUID	D09OSM
D09OSM	DRUGNAME	TGFTX-1
D09OSM	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0GL0J	TTDDRUID	D0GL0J
D0GL0J	DRUGNAME	TGFTX-2
D0GL0J	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0Y1BS	TTDDRUID	D0Y1BS
D0Y1BS	DRUGNAME	TGFTX-3
D0Y1BS	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D0R9XX	TTDDRUID	D0R9XX
D0R9XX	DRUGNAME	TG-N
D0R9XX	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D01ZGS	TTDDRUID	D01ZGS
D01ZGS	DRUGNAME	TGN-208
D01ZGS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01HGI	TTDDRUID	D01HGI
D01HGI	DRUGNAME	TGSC01AA(4)
D01HGI	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0W3TZ	TTDDRUID	D0W3TZ
D0W3TZ	DRUGNAME	Tgth-0100
D0W3TZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0A3OA	TTDDRUID	D0A3OA
D0A3OA	DRUGNAME	TGX-003
D0A3OA	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0C9QM	TTDDRUID	D0C9QM
D0C9QM	DRUGNAME	TH-1011
D0C9QM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00QTU	TTDDRUID	D00QTU
D00QTU	DRUGNAME	TH-1320
D00QTU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08JLV	TTDDRUID	D08JLV
D08JLV	DRUGNAME	TH-337
D08JLV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06MEC	TTDDRUID	D06MEC
D06MEC	DRUGNAME	THA-901
D06MEC	INDICATI	Cancer related pain [ICD-11: MG30] Investigative

D0BL6W	TTDDRUID	D0BL6W
D0BL6W	DRUGNAME	THA-902
D0BL6W	INDICATI	Fibromyalgia [ICD-11: MG30.01] Investigative

D07VOF	TTDDRUID	D07VOF
D07VOF	DRUGNAME	THA-904
D07VOF	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D05GHT	TTDDRUID	D05GHT
D05GHT	DRUGNAME	Thalassemia therapeutics
D05GHT	INDICATI	Thalassemia [ICD-11: 3A50] Investigative

D0J3EA	TTDDRUID	D0J3EA
D0J3EA	DRUGNAME	Theliatinib
D0J3EA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02DNH	TTDDRUID	D02DNH
D02DNH	DRUGNAME	Therapeutic mabs
D02DNH	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D03BRZ	TTDDRUID	D03BRZ
D03BRZ	DRUGNAME	Therapeutic program, Ironwood
D03BRZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0ZO5L	TTDDRUID	D0ZO5L
D0ZO5L	DRUGNAME	Therapy, Gram-negative bacterial infection
D0ZO5L	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0D7VT	TTDDRUID	D0D7VT
D0D7VT	DRUGNAME	Therapy, pre-eclampsia, Aggamin
D0D7VT	INDICATI	Pre-eclampsia [ICD-11: JA24] Investigative

D04JKG	TTDDRUID	D04JKG
D04JKG	DRUGNAME	TherAtoH
D04JKG	INDICATI	Hearing disorder [ICD-11: AB50-AB57] Investigative

D01SXG	TTDDRUID	D01SXG
D01SXG	DRUGNAME	ThermoStem
D01SXG	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0EW8Y	TTDDRUID	D0EW8Y
D0EW8Y	DRUGNAME	Thieno-phenanthridin-6-one
D0EW8Y	INDICATI	Brain ischaemia [ICD-11: 8B1Z] Investigative

D04JTY	TTDDRUID	D04JTY
D04JTY	DRUGNAME	Thiolactomycin
D04JTY	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
D04JTY	INDICATI	Urinary tract infection [ICD-11: GC08] Investigative

D00AUZ	TTDDRUID	D00AUZ
D00AUZ	DRUGNAME	Thiolated chitosan nanoparticle theophylline
D00AUZ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0W1NH	TTDDRUID	D0W1NH
D0W1NH	DRUGNAME	Thiophene sulfonamide
D0W1NH	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0N6KO	TTDDRUID	D0N6KO
D0N6KO	DRUGNAME	THIQ
D0N6KO	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative

D0LV4S	TTDDRUID	D0LV4S
D0LV4S	DRUGNAME	Third generation antibacterials
D0LV4S	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0EI7H	TTDDRUID	D0EI7H
D0EI7H	DRUGNAME	ThromboMer
D0EI7H	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D0LO5B	TTDDRUID	D0LO5B
D0LO5B	DRUGNAME	THZ1
D0LO5B	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative

D0U3SK	TTDDRUID	D0U3SK
D0U3SK	DRUGNAME	Tiapamil
D0U3SK	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D02QDX	TTDDRUID	D02QDX
D02QDX	DRUGNAME	Tie-1
D02QDX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D07SAQ	TTDDRUID	D07SAQ
D07SAQ	DRUGNAME	Tie-2 inhibitors
D07SAQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H2JS	TTDDRUID	D0H2JS
D0H2JS	DRUGNAME	Tin-117m-labeled annexin
D0H2JS	INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative

D03CXW	TTDDRUID	D03CXW
D03CXW	DRUGNAME	Tirapazamine derivatives
D03CXW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0PO5W	TTDDRUID	D0PO5W
D0PO5W	DRUGNAME	Tissuegene-Cs
D0PO5W	INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Investigative

D03LNM	TTDDRUID	D03LNM
D03LNM	DRUGNAME	TK-112690
D03LNM	INDICATI	Mucositis [ICD-11: CA00] Investigative

D06KSA	TTDDRUID	D06KSA
D06KSA	DRUGNAME	TK-115339
D06KSA	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D06LRQ	TTDDRUID	D06LRQ
D06LRQ	DRUGNAME	TKP-1001
D06LRQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0S7XR	TTDDRUID	D0S7XR
D0S7XR	DRUGNAME	TKP-1002
D0S7XR	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D01SAK	TTDDRUID	D01SAK
D01SAK	DRUGNAME	TL-14077
D01SAK	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D07MSL	TTDDRUID	D07MSL
D07MSL	DRUGNAME	TL-1836
D07MSL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00ZBQ	TTDDRUID	D00ZBQ
D00ZBQ	DRUGNAME	TL-1892
D00ZBQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U8AD	TTDDRUID	D0U8AD
D0U8AD	DRUGNAME	TLV-1
D0U8AD	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative

D0B8GN	TTDDRUID	D0B8GN
D0B8GN	DRUGNAME	TM-30089
D0B8GN	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D02UJQ	TTDDRUID	D02UJQ
D02UJQ	DRUGNAME	TM-400
D02UJQ	INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Investigative

D03TDB	TTDDRUID	D03TDB
D03TDB	DRUGNAME	TMB-358
D03TDB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D08UZL	TTDDRUID	D08UZL
D08UZL	DRUGNAME	TMPyP4
D08UZL	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0Z2IY	TTDDRUID	D0Z2IY
D0Z2IY	DRUGNAME	TMX-201
D0Z2IY	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D05TCC	TTDDRUID	D05TCC
D05TCC	DRUGNAME	TMX-202
D05TCC	INDICATI	Bladder cancer [ICD-11: 2C94] Investigative

D0I2GT	TTDDRUID	D0I2GT
D0I2GT	DRUGNAME	TMX-30X
D0I2GT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Y3OX	TTDDRUID	D0Y3OX
D0Y3OX	DRUGNAME	TN-14003
D0Y3OX	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative

D03SIP	TTDDRUID	D03SIP
D03SIP	DRUGNAME	TNAP inhibitors
D03SIP	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D03HKX	TTDDRUID	D03HKX
D03HKX	DRUGNAME	TNF-alpha production inhibitors
D03HKX	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0U4QQ	TTDDRUID	D0U4QQ
D0U4QQ	DRUGNAME	TNFcept
D0U4QQ	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D0B6WV	TTDDRUID	D0B6WV
D0B6WV	DRUGNAME	TNFmab
D0B6WV	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D00VOF	TTDDRUID	D00VOF
D00VOF	DRUGNAME	TNF-PEG-20
D00VOF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03IMU	TTDDRUID	D03IMU
D03IMU	DRUGNAME	TNFR1 NAM
D03IMU	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0P0YD	TTDDRUID	D0P0YD
D0P0YD	DRUGNAME	TNF-targeting small molecule therapeutic, oral, inflammation/autoimmune disease
D0P0YD	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D03JYD	TTDDRUID	D03JYD
D03JYD	DRUGNAME	Tnk-6123
D03JYD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0Z3ZF	TTDDRUID	D0Z3ZF
D0Z3ZF	DRUGNAME	TOCA-621
D0Z3ZF	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0Y3MW	TTDDRUID	D0Y3MW
D0Y3MW	DRUGNAME	Tolecine
D0Y3MW	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D09WJT	TTDDRUID	D09WJT
D09WJT	DRUGNAME	Toleragens
D09WJT	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D07KMA	TTDDRUID	D07KMA
D07KMA	DRUGNAME	T-oligos
D07KMA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0UG3F	TTDDRUID	D0UG3F
D0UG3F	DRUGNAME	Toll-like receptor 4 inhibition
D0UG3F	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D00EDB	TTDDRUID	D00EDB
D00EDB	DRUGNAME	Topical etoricoxib
D00EDB	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D06QOM	TTDDRUID	D06QOM
D06QOM	DRUGNAME	TP-101
D06QOM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0A6OJ	TTDDRUID	D0A6OJ
D0A6OJ	DRUGNAME	TP-102
D0A6OJ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0B7UD	TTDDRUID	D0B7UD
D0B7UD	DRUGNAME	TP-103
D0B7UD	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D09WUY	TTDDRUID	D09WUY
D09WUY	DRUGNAME	TP-104
D09WUY	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0A4VW	TTDDRUID	D0A4VW
D0A4VW	DRUGNAME	TP-110
D0A4VW	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0O5VR	TTDDRUID	D0O5VR
D0O5VR	DRUGNAME	TP-2758
D0O5VR	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0BS6B	TTDDRUID	D0BS6B
D0BS6B	DRUGNAME	TP-801
D0BS6B	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E4JB	TTDDRUID	D0E4JB
D0E4JB	DRUGNAME	TP-834
D0E4JB	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0D7EK	TTDDRUID	D0D7EK
D0D7EK	DRUGNAME	TPI-1361-17
D0D7EK	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0YG3U	TTDDRUID	D0YG3U
D0YG3U	DRUGNAME	Tpl2 kinase inhibitors
D0YG3U	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D08JAH	TTDDRUID	D08JAH
D08JAH	DRUGNAME	TPM-001
D08JAH	INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Investigative

D0XQ8A	TTDDRUID	D0XQ8A
D0XQ8A	DRUGNAME	TPN-729
D0XQ8A	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative

D0M9ZL	TTDDRUID	D0M9ZL
D0M9ZL	DRUGNAME	TPO gene plasmid
D0M9ZL	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D0B3VU	TTDDRUID	D0B3VU
D0B3VU	DRUGNAME	TPO therapy program, thrombocytopenia
D0B3VU	INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative

D0VW7E	TTDDRUID	D0VW7E
D0VW7E	DRUGNAME	TPR-100-Rx
D0VW7E	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D08YCS	TTDDRUID	D08YCS
D08YCS	DRUGNAME	TQ-1017
D08YCS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D03ROA	TTDDRUID	D03ROA
D03ROA	DRUGNAME	Tr-2
D03ROA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C7TO	TTDDRUID	D0C7TO
D0C7TO	DRUGNAME	Tr-3
D0C7TO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L7MK	TTDDRUID	D0L7MK
D0L7MK	DRUGNAME	TR-4
D0L7MK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F5DK	TTDDRUID	D0F5DK
D0F5DK	DRUGNAME	TRAIL-R Atrimer
D0F5DK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00HEA	TTDDRUID	D00HEA
D00HEA	DRUGNAME	Transcobalamin (vitamin B12) receptor-targeting mabTCR23-saporin conjugate
D00HEA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08NTD	TTDDRUID	D08NTD
D08NTD	DRUGNAME	Trappsol Cyclo
D08NTD	INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Investigative

D0G2ZV	TTDDRUID	D0G2ZV
D0G2ZV	DRUGNAME	TRC-6XXX
D0G2ZV	INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative

D05ETD	TTDDRUID	D05ETD
D05ETD	DRUGNAME	TRC-8XXX series
D05ETD	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D01UUW	TTDDRUID	D01UUW
D01UUW	DRUGNAME	Trecetilide fumarate
D01UUW	INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Investigative

D0N7XI	TTDDRUID	D0N7XI
D0N7XI	DRUGNAME	Tremetinib
D0N7XI	INDICATI	Cutaneous melanoma [ICD-11: 2C30] Approved

D02UGL	TTDDRUID	D02UGL
D02UGL	DRUGNAME	TR-Flu
D02UGL	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D04XML	TTDDRUID	D04XML
D04XML	DRUGNAME	TRI-002
D04XML	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D05GCM	TTDDRUID	D05GCM
D05GCM	DRUGNAME	TriAb/TriGem
D05GCM	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D0NF6F	TTDDRUID	D0NF6F
D0NF6F	DRUGNAME	Trichostatin A
D0NF6F	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04PFD	TTDDRUID	D04PFD
D04PFD	DRUGNAME	TriMixDC
D04PFD	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D09CON	TTDDRUID	D09CON
D09CON	DRUGNAME	Triple action antibiotic
D09CON	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D03INC	TTDDRUID	D03INC
D03INC	DRUGNAME	Triplelastat
D03INC	INDICATI	Kidney transplant rejection [ICD-11: NE84] Investigative

D00YPL	TTDDRUID	D00YPL
D00YPL	DRUGNAME	Triplex-forming oligonucleotides
D00YPL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X8NK	TTDDRUID	D0X8NK
D0X8NK	DRUGNAME	Tripropeptin C
D0X8NK	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D0E5MO	TTDDRUID	D0E5MO
D0E5MO	DRUGNAME	TrkA-XTEN
D0E5MO	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0D1HR	TTDDRUID	D0D1HR
D0D1HR	DRUGNAME	TrkB NAM
D0D1HR	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D01HXN	TTDDRUID	D01HXN
D01HXN	DRUGNAME	TRL-382
D01HXN	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D06YNK	TTDDRUID	D06YNK
D06YNK	DRUGNAME	TRM-88
D06YNK	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0X8UW	TTDDRUID	D0X8UW
D0X8UW	DRUGNAME	TRN-101
D0X8UW	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D02ZUT	TTDDRUID	D02ZUT
D02ZUT	DRUGNAME	TRP6-01
D02ZUT	INDICATI	Brain injury [ICD-11: NA07.Z] Investigative

D0TZ4M	TTDDRUID	D0TZ4M
D0TZ4M	DRUGNAME	TRPA1 antagonists
D0TZ4M	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0VW0X	TTDDRUID	D0VW0X
D0VW0X	DRUGNAME	TRPM8 antagonists
D0VW0X	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00CKQ	TTDDRUID	D00CKQ
D00CKQ	DRUGNAME	TRPV1 antagonists
D00CKQ	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0JN5H	TTDDRUID	D0JN5H
D0JN5H	DRUGNAME	Trunkamide
D0JN5H	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E0IG	TTDDRUID	D0E0IG
D0E0IG	DRUGNAME	TRX-385
D0E0IG	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0LL6K	TTDDRUID	D0LL6K
D0LL6K	DRUGNAME	TRX-585
D0LL6K	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V5YQ	TTDDRUID	D0V5YQ
D0V5YQ	DRUGNAME	TS antisense + raltitrexed
D0V5YQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0W1YZ	TTDDRUID	D0W1YZ
D0W1YZ	DRUGNAME	TSERaM
D0W1YZ	INDICATI	Menopause symptom [ICD-11: GA30.0] Investigative

D01SBC	TTDDRUID	D01SBC
D01SBC	DRUGNAME	TSRI-265
D01SBC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03GLL	TTDDRUID	D03GLL
D03GLL	DRUGNAME	TSS-HIG
D03GLL	INDICATI	Endotoxic shock [ICD-11: 1G41] Investigative

D06XME	TTDDRUID	D06XME
D06XME	DRUGNAME	TT-105
D06XME	INDICATI	Deep vein thrombosis [ICD-11: BD71] Investigative

D0DO0B	TTDDRUID	D0DO0B
D0DO0B	DRUGNAME	TT-111
D0DO0B	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D0Q5TW	TTDDRUID	D0Q5TW
D0Q5TW	DRUGNAME	TT-112
D0Q5TW	INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative

D05WUZ	TTDDRUID	D05WUZ
D05WUZ	DRUGNAME	TT-113
D05WUZ	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D02SUP	TTDDRUID	D02SUP
D02SUP	DRUGNAME	TT-114
D02SUP	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D01SAD	TTDDRUID	D01SAD
D01SAD	DRUGNAME	TT-115
D01SAD	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D05DAX	TTDDRUID	D05DAX
D05DAX	DRUGNAME	TT-120
D05DAX	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D0K8JE	TTDDRUID	D0K8JE
D0K8JE	DRUGNAME	TT-123
D0K8JE	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D0Y1BI	TTDDRUID	D0Y1BI
D0Y1BI	DRUGNAME	TT-124
D0Y1BI	INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative

D02ZNH	TTDDRUID	D02ZNH
D02ZNH	DRUGNAME	TT-310
D02ZNH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09LOZ	TTDDRUID	D09LOZ
D09LOZ	DRUGNAME	TTAC-0001
D09LOZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04OZR	TTDDRUID	D04OZR
D04OZR	DRUGNAME	TTH 02-001
D04OZR	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D02LQA	TTDDRUID	D02LQA
D02LQA	DRUGNAME	TTH 03-001
D02LQA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0EZ0M	TTDDRUID	D0EZ0M
D0EZ0M	DRUGNAME	TTH 03-002
D0EZ0M	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D0L5AK	TTDDRUID	D0L5AK
D0L5AK	DRUGNAME	TTI-1612 intravesicular
D0L5AK	INDICATI	Interstitial cystitis [ICD-11: GC00.3] Investigative

D05HUZ	TTDDRUID	D05HUZ
D05HUZ	DRUGNAME	TTI-314
D05HUZ	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0Y5WL	TTDDRUID	D0Y5WL
D0Y5WL	DRUGNAME	TTL-1177
D0Y5WL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04KQF	TTDDRUID	D04KQF
D04KQF	DRUGNAME	Tubacin
D04KQF	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0A4KP	TTDDRUID	D0A4KP
D0A4KP	DRUGNAME	Tuberculosis therapeutics
D0A4KP	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D01BZP	TTDDRUID	D01BZP
D01BZP	DRUGNAME	Tuberculosis therapy, Ithemba
D01BZP	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D08MLH	TTDDRUID	D08MLH
D08MLH	DRUGNAME	TUG-469
D08MLH	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D05RFC	TTDDRUID	D05RFC
D05RFC	DRUGNAME	Tumor vascular thrombogen
D05RFC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0X4DJ	TTDDRUID	D0X4DJ
D0X4DJ	DRUGNAME	Tumor-associated macrophage immunotherapy
D0X4DJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q2XN	TTDDRUID	D0Q2XN
D0Q2XN	DRUGNAME	Turmeric extracts
D0Q2XN	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0A3PF	TTDDRUID	D0A3PF
D0A3PF	DRUGNAME	TVX-001
D0A3PF	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0L4HK	TTDDRUID	D0L4HK
D0L4HK	DRUGNAME	TVX-002
D0L4HK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0C6DU	TTDDRUID	D0C6DU
D0C6DU	DRUGNAME	TVX-003
D0C6DU	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D03YCT	TTDDRUID	D03YCT
D03YCT	DRUGNAME	TVX-004
D03YCT	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0B1JE	TTDDRUID	D0B1JE
D0B1JE	DRUGNAME	TVX-005
D0B1JE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D00HQB	TTDDRUID	D00HQB
D00HQB	DRUGNAME	TX-MSD
D00HQB	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D0K8BO	TTDDRUID	D0K8BO
D0K8BO	DRUGNAME	TX-RAD
D0K8BO	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D02NEF	TTDDRUID	D02NEF
D02NEF	DRUGNAME	Type II secretion inhibitors
D02NEF	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D0S9PV	TTDDRUID	D0S9PV
D0S9PV	DRUGNAME	Type VII collagen therapeutic
D0S9PV	INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Investigative

D01BWJ	TTDDRUID	D01BWJ
D01BWJ	DRUGNAME	Tyrophostins
D01BWJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0E0GZ	TTDDRUID	D0E0GZ
D0E0GZ	DRUGNAME	TyrosineKinaseInhibitor-Ns
D0E0GZ	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Investigative
D0E0GZ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
D0E0GZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07GYP	TTDDRUID	D07GYP
D07GYP	DRUGNAME	TYT-1
D07GYP	INDICATI	West nile virus infection [ICD-11: 1D46] Investigative

D0W0HZ	TTDDRUID	D0W0HZ
D0W0HZ	DRUGNAME	TZ-101sm
D0W0HZ	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D05QXW	TTDDRUID	D05QXW
D05QXW	DRUGNAME	TZ-111
D05QXW	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D0W6AQ	TTDDRUID	D0W6AQ
D0W6AQ	DRUGNAME	TZP-201
D0W6AQ	INDICATI	Diarrhea [ICD-11: ME05.1] Investigative

D0L2NV	TTDDRUID	D0L2NV
D0L2NV	DRUGNAME	U-89854
D0L2NV	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0KM4T	TTDDRUID	D0KM4T
D0KM4T	DRUGNAME	UAI-101
D0KM4T	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0H8VM	TTDDRUID	D0H8VM
D0H8VM	DRUGNAME	UAI-201
D0H8VM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01PAK	TTDDRUID	D01PAK
D01PAK	DRUGNAME	Ubiquitin-specific protease-8 inhibitors
D01PAK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08EPK	TTDDRUID	D08EPK
D08EPK	DRUGNAME	UBP-551
D08EPK	INDICATI	Neurological disorder [ICD-11: 6B60] Investigative

D01YGY	TTDDRUID	D01YGY
D01YGY	DRUGNAME	UC-1011
D01YGY	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D01FJA	TTDDRUID	D01FJA
D01FJA	DRUGNAME	UC-2024
D01FJA	INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Investigative

D02FBG	TTDDRUID	D02FBG
D02FBG	DRUGNAME	UC-2029
D02FBG	INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Investigative

D00YRF	TTDDRUID	D00YRF
D00YRF	DRUGNAME	UCB-1277763
D00YRF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D06WCW	TTDDRUID	D06WCW
D06WCW	DRUGNAME	UCB-1350883
D06WCW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M4JK	TTDDRUID	D0M4JK
D0M4JK	DRUGNAME	UCB-2892
D0M4JK	INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative

D0L0LR	TTDDRUID	D0L0LR
D0L0LR	DRUGNAME	UCL-67022
D0L0LR	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D09PNS	TTDDRUID	D09PNS
D09PNS	DRUGNAME	UGP-281
D09PNS	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0W2ZX	TTDDRUID	D0W2ZX
D0W2ZX	DRUGNAME	UK-387618
D0W2ZX	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0U6TV	TTDDRUID	D0U6TV
D0U6TV	DRUGNAME	UltraGITRL
D0U6TV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09YGK	TTDDRUID	D09YGK
D09YGK	DRUGNAME	Ultragrivak
D09YGK	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0R3LH	TTDDRUID	D0R3LH
D0R3LH	DRUGNAME	UMN-01
D0R3LH	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0U9QT	TTDDRUID	D0U9QT
D0U9QT	DRUGNAME	UMN-03
D0U9QT	INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative

D0O4DE	TTDDRUID	D0O4DE
D0O4DE	DRUGNAME	Undecaprenyl pyrophosphate synthase inhibitors
D0O4DE	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D01NHO	TTDDRUID	D01NHO
D01NHO	DRUGNAME	Undisclosed protein
D01NHO	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0WC7S	TTDDRUID	D0WC7S
D0WC7S	DRUGNAME	Unsaturated long chain fatty acids
D0WC7S	INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative

D08QHJ	TTDDRUID	D08QHJ
D08QHJ	DRUGNAME	UPAR-lock
D08QHJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00LDI	TTDDRUID	D00LDI
D00LDI	DRUGNAME	UPA-targeted oncolytic Sendai virus
D00LDI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G1AK	TTDDRUID	D0G1AK
D0G1AK	DRUGNAME	UR-12510
D0G1AK	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D07JGH	TTDDRUID	D07JGH
D07JGH	DRUGNAME	UR-13756
D07JGH	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0J7XN	TTDDRUID	D0J7XN
D0J7XN	DRUGNAME	UR-5269
D0J7XN	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative

D00JBM	TTDDRUID	D00JBM
D00JBM	DRUGNAME	UR-5908
D00JBM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D09HUF	TTDDRUID	D09HUF
D09HUF	DRUGNAME	UR-60427
D09HUF	INDICATI	Asthma [ICD-11: CA23] Investigative

D0SB8E	TTDDRUID	D0SB8E
D0SB8E	DRUGNAME	UTL-5g
D0SB8E	INDICATI	Toxicity [ICD-11: N.A.] Investigative

D01BGU	TTDDRUID	D01BGU
D01BGU	DRUGNAME	UX-002
D01BGU	INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative

D00MWE	TTDDRUID	D00MWE
D00MWE	DRUGNAME	UX-004
D00MWE	INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative

D07PRA	TTDDRUID	D07PRA
D07PRA	DRUGNAME	UX-005
D07PRA	INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative

D0F8NE	TTDDRUID	D0F8NE
D0F8NE	DRUGNAME	V-103
D0F8NE	INDICATI	Contusion [ICD-11: ND56.0] Investigative

D02HDP	TTDDRUID	D02HDP
D02HDP	DRUGNAME	V-1810
D02HDP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0D9OM	TTDDRUID	D0D9OM
D0D9OM	DRUGNAME	V1A F/U
D0D9OM	INDICATI	Infertility [ICD-11: GB04] Investigative

D00LAA	TTDDRUID	D00LAA
D00LAA	DRUGNAME	VA-118020
D00LAA	INDICATI	Respiratory disease [ICD-11: CB40] Investigative

D0M9SD	TTDDRUID	D0M9SD
D0M9SD	DRUGNAME	VA-119930
D0M9SD	INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative

D0BD5F	TTDDRUID	D0BD5F
D0BD5F	DRUGNAME	Vaccine, antigen-specific immune cell activation technology, HIV infection
D0BD5F	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0G3LG	TTDDRUID	D0G3LG
D0G3LG	DRUGNAME	Vaccine, antimicrobial
D0G3LG	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0U3EJ	TTDDRUID	D0U3EJ
D0U3EJ	DRUGNAME	Vaccine, avian influenza
D0U3EJ	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D01DLK	TTDDRUID	D01DLK
D01DLK	DRUGNAME	Vaccine, cancer, Wistar Institute of Anatomy & Biology
D01DLK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05MBG	TTDDRUID	D05MBG
D05MBG	DRUGNAME	Vaccine, Chagas disease
D05MBG	INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative

D05OFK	TTDDRUID	D05OFK
D05OFK	DRUGNAME	Vaccine, CMV infection
D05OFK	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D0NH4G	TTDDRUID	D0NH4G
D0NH4G	DRUGNAME	Vaccine, Ebola virus infection
D0NH4G	INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative

D09NEW	TTDDRUID	D09NEW
D09NEW	DRUGNAME	Vaccine, gastrointestinal cancers
D09NEW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03NFE	TTDDRUID	D03NFE
D03NFE	DRUGNAME	Vaccine, gp 120
D03NFE	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0J6VT	TTDDRUID	D0J6VT
D0J6VT	DRUGNAME	Vaccine, influenza virus infection, VLP vaccine technology
D0J6VT	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D01QZR	TTDDRUID	D01QZR
D01QZR	DRUGNAME	Vaccine, japanese encephalitis virus
D01QZR	INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Investigative

D01UIE	TTDDRUID	D01UIE
D01UIE	DRUGNAME	Vaccine, Lauriad, influenza
D01UIE	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0I8XI	TTDDRUID	D0I8XI
D0I8XI	DRUGNAME	Vaccine, nanoparticle formulation, autoimmune disease/allergy/type I diabetes/transplant rejection
D0I8XI	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0D2VH	TTDDRUID	D0D2VH
D0D2VH	DRUGNAME	Vaccine, Nanopatch, influenza
D0D2VH	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D02POF	TTDDRUID	D02POF
D02POF	DRUGNAME	Vaccine, parasitic infection
D02POF	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Investigative

D0K3VP	TTDDRUID	D0K3VP
D0K3VP	DRUGNAME	Vaccine, respiratory syncytial virus infection
D0K3VP	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D01UMC	TTDDRUID	D01UMC
D01UMC	DRUGNAME	Vaccine, RSV infection
D01UMC	INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative

D0G1TC	TTDDRUID	D0G1TC
D0G1TC	DRUGNAME	Vaccine, Salmonella infection
D0G1TC	INDICATI	Salmonella infection [ICD-11: 1A09] Investigative

D0N0OS	TTDDRUID	D0N0OS
D0N0OS	DRUGNAME	Vaccine, Yersinia pestis infection
D0N0OS	INDICATI	Yersinia infection [ICD-11: 1B93] Investigative

D0O1KN	TTDDRUID	D0O1KN
D0O1KN	DRUGNAME	Vaccines, CLIPS, infection
D0O1KN	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative

D03PFD	TTDDRUID	D03PFD
D03PFD	DRUGNAME	Vaccines, Immunobody, colorectal cancer
D03PFD	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D09LMQ	TTDDRUID	D09LMQ
D09LMQ	DRUGNAME	Vaginal ring
D09LMQ	INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative

D0XS3T	TTDDRUID	D0XS3T
D0XS3T	DRUGNAME	Vagonixen
D0XS3T	INDICATI	Asthma [ICD-11: CA23] Investigative

D04YGT	TTDDRUID	D04YGT
D04YGT	DRUGNAME	VAL-001
D04YGT	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D0W7UC	TTDDRUID	D0W7UC
D0W7UC	DRUGNAME	VAL-101
D0W7UC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08AXM	TTDDRUID	D08AXM
D08AXM	DRUGNAME	VALERGENT-BT (subcutaneous)
D08AXM	INDICATI	Asthma [ICD-11: CA23] Investigative

D02OBU	TTDDRUID	D02OBU
D02OBU	DRUGNAME	Valpentin
D02OBU	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D01FLR	TTDDRUID	D01FLR
D01FLR	DRUGNAME	Vanilloid VR1 receptor antagonists
D01FLR	INDICATI	Urinary incontinence [ICD-11: MF50.2] Investigative

D05SPX	TTDDRUID	D05SPX
D05SPX	DRUGNAME	VAP-1
D05SPX	INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative

D00LPZ	TTDDRUID	D00LPZ
D00LPZ	DRUGNAME	Vapill
D00LPZ	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0V4KL	TTDDRUID	D0V4KL
D0V4KL	DRUGNAME	VAR-10200
D0V4KL	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D02AQM	TTDDRUID	D02AQM
D02AQM	DRUGNAME	VAR-10300
D02AQM	INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative

D04ZZQ	TTDDRUID	D04ZZQ
D04ZZQ	DRUGNAME	VAS-2870
D04ZZQ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0J5OS	TTDDRUID	D0J5OS
D0J5OS	DRUGNAME	Vasonex
D0J5OS	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0WT0E	TTDDRUID	D0WT0E
D0WT0E	DRUGNAME	VasoPET
D0WT0E	INDICATI	Coronary artery disease [ICD-11: BA80] Investigative

D02SJN	TTDDRUID	D02SJN
D02SJN	DRUGNAME	VBP
D02SJN	INDICATI	Asthma [ICD-11: CA23] Investigative

D0J0HV	TTDDRUID	D0J0HV
D0J0HV	DRUGNAME	VBY- 285
D0J0HV	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0JO0I	TTDDRUID	D0JO0I
D0JO0I	DRUGNAME	VBY- 825
D0JO0I	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0BP7W	TTDDRUID	D0BP7W
D0BP7W	DRUGNAME	VBY-106
D0BP7W	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D08WDT	TTDDRUID	D08WDT
D08WDT	DRUGNAME	VDA , HIV-1
D08WDT	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D06UZS	TTDDRUID	D06UZS
D06UZS	DRUGNAME	VDA-1124
D06UZS	INDICATI	Aortic aneurysm [ICD-11: BD50] Investigative

D04PPE	TTDDRUID	D04PPE
D04PPE	DRUGNAME	VE-04051645
D04PPE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0G0BJ	TTDDRUID	D0G0BJ
D0G0BJ	DRUGNAME	VE-821
D0G0BJ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Q8YI	TTDDRUID	D0Q8YI
D0Q8YI	DRUGNAME	VEGF kinoid
D0Q8YI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0F2RP	TTDDRUID	D0F2RP
D0F2RP	DRUGNAME	VEGF/rGel
D0F2RP	INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative

D0P5VH	TTDDRUID	D0P5VH
D0P5VH	DRUGNAME	VennVax
D0P5VH	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0H0AU	TTDDRUID	D0H0AU
D0H0AU	DRUGNAME	VER-155008
D0H0AU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0PC5A	TTDDRUID	D0PC5A
D0PC5A	DRUGNAME	VER-156084
D0PC5A	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0V1NK	TTDDRUID	D0V1NK
D0V1NK	DRUGNAME	VER-54505
D0V1NK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T9JK	TTDDRUID	D0T9JK
D0T9JK	DRUGNAME	VER-82160
D0T9JK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L9GR	TTDDRUID	D0L9GR
D0L9GR	DRUGNAME	Very low dose (VLD) cyclobenzaprine
D0L9GR	INDICATI	Fibromyalgia [ICD-11: MG30.01] Investigative

D0J6YZ	TTDDRUID	D0J6YZ
D0J6YZ	DRUGNAME	Very small embryonic-like stem cells
D0J6YZ	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D05NRX	TTDDRUID	D05NRX
D05NRX	DRUGNAME	VG-102
D05NRX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D01WFI	TTDDRUID	D01WFI
D01WFI	DRUGNAME	VG-FLU
D01WFI	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D0V6ZQ	TTDDRUID	D0V6ZQ
D0V6ZQ	DRUGNAME	VG-LC
D0V6ZQ	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D04MXV	TTDDRUID	D04MXV
D04MXV	DRUGNAME	VGV-L
D04MXV	INDICATI	Lyme disease [ICD-11: 1C1G] Investigative

D02ZAT	TTDDRUID	D02ZAT
D02ZAT	DRUGNAME	VGV-S
D02ZAT	INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative

D0Z0RR	TTDDRUID	D0Z0RR
D0Z0RR	DRUGNAME	VGV-X
D0Z0RR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D06JHN	TTDDRUID	D06JHN
D06JHN	DRUGNAME	VG-WNV
D06JHN	INDICATI	West nile virus infection [ICD-11: 1D46] Investigative

D08YSY	TTDDRUID	D08YSY
D08YSY	DRUGNAME	VGX-200
D08YSY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D07PMH	TTDDRUID	D07PMH
D07PMH	DRUGNAME	VH-0445 based conjugated therapeutics
D07PMH	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0G7UV	TTDDRUID	D0G7UV
D0G7UV	DRUGNAME	VI-0134
D0G7UV	INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Investigative

D0C6BJ	TTDDRUID	D0C6BJ
D0C6BJ	DRUGNAME	VII-7-B
D0C6BJ	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative

D0P1BR	TTDDRUID	D0P1BR
D0P1BR	DRUGNAME	VII-87-B
D0P1BR	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D0PB3X	TTDDRUID	D0PB3X
D0PB3X	DRUGNAME	Vinylsulphones
D0PB3X	INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative

D00EKM	TTDDRUID	D00EKM
D00EKM	DRUGNAME	Virapt
D00EKM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D03IEA	TTDDRUID	D03IEA
D03IEA	DRUGNAME	Virion project
D03IEA	INDICATI	Coronavirus infection [ICD-11: 1D92] Investigative

D08OIT	TTDDRUID	D08OIT
D08OIT	DRUGNAME	Viroprev
D08OIT	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0X8EE	TTDDRUID	D0X8EE
D0X8EE	DRUGNAME	VitiGam
D0X8EE	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D03RSQ	TTDDRUID	D03RSQ
D03RSQ	DRUGNAME	Vivia-007
D03RSQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D02YAD	TTDDRUID	D02YAD
D02YAD	DRUGNAME	Vivia-008
D02YAD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0V2YE	TTDDRUID	D0V2YE
D0V2YE	DRUGNAME	Vivia-009
D0V2YE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D05GOA	TTDDRUID	D05GOA
D05GOA	DRUGNAME	Vivia-1615
D05GOA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0AD8L	TTDDRUID	D0AD8L
D0AD8L	DRUGNAME	Vivia-577
D0AD8L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y4TQ	TTDDRUID	D0Y4TQ
D0Y4TQ	DRUGNAME	VK-11
D0Y4TQ	INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative

D0S7CP	TTDDRUID	D0S7CP
D0S7CP	DRUGNAME	VK-12
D0S7CP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0L7QR	TTDDRUID	D0L7QR
D0L7QR	DRUGNAME	VL-01
D0L7QR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0EL2L	TTDDRUID	D0EL2L
D0EL2L	DRUGNAME	VLCA- 04
D0EL2L	INDICATI	Clostridium infection [ICD-11: 1A04] Investigative

D0C1LF	TTDDRUID	D0C1LF
D0C1LF	DRUGNAME	VLD-01
D0C1LF	INDICATI	Diabetic cataract [ICD-11: 9B10.21] Investigative

D0E1ZR	TTDDRUID	D0E1ZR
D0E1ZR	DRUGNAME	VLD-517
D0E1ZR	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0ZE7B	TTDDRUID	D0ZE7B
D0ZE7B	DRUGNAME	VLD-631
D0ZE7B	INDICATI	Melanoma [ICD-11: 2C30] Investigative

D0TO0F	TTDDRUID	D0TO0F
D0TO0F	DRUGNAME	VLDM-01
D0TO0F	INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative

D06CML	TTDDRUID	D06CML
D06CML	DRUGNAME	VLF-02
D06CML	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D08IUW	TTDDRUID	D08IUW
D08IUW	DRUGNAME	VLI-03B
D08IUW	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative

D0W2NZ	TTDDRUID	D0W2NZ
D0W2NZ	DRUGNAME	VLI-04A
D0W2NZ	INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative

D0N7CY	TTDDRUID	D0N7CY
D0N7CY	DRUGNAME	VLI-27
D0N7CY	INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative

D0B1TN	TTDDRUID	D0B1TN
D0B1TN	DRUGNAME	VLIM-88
D0B1TN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative

D05XFQ	TTDDRUID	D05XFQ
D05XFQ	DRUGNAME	VLN-244
D05XFQ	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D0K0SW	TTDDRUID	D0K0SW
D0K0SW	DRUGNAME	VLST-002
D0K0SW	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D01JSO	TTDDRUID	D01JSO
D01JSO	DRUGNAME	VM-505
D01JSO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D03EDD	TTDDRUID	D03EDD
D03EDD	DRUGNAME	VN/107-1
D03EDD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D04ZJQ	TTDDRUID	D04ZJQ
D04ZJQ	DRUGNAME	VN/13-1RA
D04ZJQ	INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative

D0Z7FZ	TTDDRUID	D0Z7FZ
D0Z7FZ	DRUGNAME	VN-180
D0Z7FZ	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative

D0ZZ3U	TTDDRUID	D0ZZ3U
D0ZZ3U	DRUGNAME	Voltage-gated sodium channel blockers
D0ZZ3U	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D05XCZ	TTDDRUID	D05XCZ
D05XCZ	DRUGNAME	VPC-51299
D05XCZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T8TC	TTDDRUID	D0T8TC
D0T8TC	DRUGNAME	VPC-8
D0T8TC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00YNY	TTDDRUID	D00YNY
D00YNY	DRUGNAME	VPC-94075
D00YNY	INDICATI	Vascular disease [ICD-11: BE2Z] Investigative

D0IJ4G	TTDDRUID	D0IJ4G
D0IJ4G	DRUGNAME	VPM-2-001
D0IJ4G	INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative

D0P6AL	TTDDRUID	D0P6AL
D0P6AL	DRUGNAME	VPX-595
D0P6AL	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D03CZE	TTDDRUID	D03CZE
D03CZE	DRUGNAME	VPZ-758
D03CZE	INDICATI	Raynaud disease [ICD-11: BD42.0] Investigative

D05KZV	TTDDRUID	D05KZV
D05KZV	DRUGNAME	VR-461
D05KZV	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative

D0V4WG	TTDDRUID	D0V4WG
D0V4WG	DRUGNAME	VR-909
D0V4WG	INDICATI	Transplant rejection [ICD-11: NE84] Investigative

D04LGK	TTDDRUID	D04LGK
D04LGK	DRUGNAME	VRT-750018
D04LGK	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0U6PZ	TTDDRUID	D0U6PZ
D0U6PZ	DRUGNAME	VS1-011
D0U6PZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H8JM	TTDDRUID	D0H8JM
D0H8JM	DRUGNAME	VT-214
D0H8JM	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative

D0Y5NT	TTDDRUID	D0Y5NT
D0Y5NT	DRUGNAME	VT-224
D0Y5NT	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02JRD	TTDDRUID	D02JRD
D02JRD	DRUGNAME	VT-310
D02JRD	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D03YKO	TTDDRUID	D03YKO
D03YKO	DRUGNAME	VT-346
D03YKO	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02SJG	TTDDRUID	D02SJG
D02SJG	DRUGNAME	VT-362
D02SJG	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00TPQ	TTDDRUID	D00TPQ
D00TPQ	DRUGNAME	VT-384
D00TPQ	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D09TQI	TTDDRUID	D09TQI
D09TQI	DRUGNAME	VT-401
D09TQI	INDICATI	Muscular dystrophy [ICD-11: 8C70] Investigative

D07NCC	TTDDRUID	D07NCC
D07NCC	DRUGNAME	VTT-201
D07NCC	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0N1UH	TTDDRUID	D0N1UH
D0N1UH	DRUGNAME	VTT-301
D0N1UH	INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative

D0UI0B	TTDDRUID	D0UI0B
D0UI0B	DRUGNAME	VTX-763
D0UI0B	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0OH1O	TTDDRUID	D0OH1O
D0OH1O	DRUGNAME	VULM-1457
D0OH1O	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0YN9H	TTDDRUID	D0YN9H
D0YN9H	DRUGNAME	VVP-100X
D0YN9H	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D07GFZ	TTDDRUID	D07GFZ
D07GFZ	DRUGNAME	VVZ-138
D07GFZ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0M3IE	TTDDRUID	D0M3IE
D0M3IE	DRUGNAME	VVZ-140
D0M3IE	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D00CMA	TTDDRUID	D00CMA
D00CMA	DRUGNAME	VVZ-172
D00CMA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0G7YF	TTDDRUID	D0G7YF
D0G7YF	DRUGNAME	VX-467
D0G7YF	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D02UID	TTDDRUID	D02UID
D02UID	DRUGNAME	WAY-252623
D02UID	INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative

D0G5OV	TTDDRUID	D0G5OV
D0G5OV	DRUGNAME	WAY-255348
D0G5OV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0KS0I	TTDDRUID	D0KS0I
D0KS0I	DRUGNAME	WAY-256805
D0KS0I	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D07NDK	TTDDRUID	D07NDK
D07NDK	DRUGNAME	WAY-644
D07NDK	INDICATI	Aortic aneurysm [ICD-11: BD50] Investigative

D0X5LL	TTDDRUID	D0X5LL
D0X5LL	DRUGNAME	WBI-2000
D0X5LL	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03SGF	TTDDRUID	D03SGF
D03SGF	DRUGNAME	WBZ-7
D03SGF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D04IPX	TTDDRUID	D04IPX
D04IPX	DRUGNAME	WEHI-0103122
D04IPX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D03TAT	TTDDRUID	D03TAT
D03TAT	DRUGNAME	Weight regulating human endocrine peptide
D03TAT	INDICATI	Obesity [ICD-11: 5B81] Investigative

D08XNW	TTDDRUID	D08XNW
D08XNW	DRUGNAME	WHIP-154
D08XNW	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Investigative

D09AVX	TTDDRUID	D09AVX
D09AVX	DRUGNAME	WIB-901H
D09AVX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D06MRR	TTDDRUID	D06MRR
D06MRR	DRUGNAME	WilGraf
D06MRR	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D00ZFC	TTDDRUID	D00ZFC
D00ZFC	DRUGNAME	WilVent
D00ZFC	INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative

D08BYJ	TTDDRUID	D08BYJ
D08BYJ	DRUGNAME	WIN-902A
D08BYJ	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0A7CH	TTDDRUID	D0A7CH
D0A7CH	DRUGNAME	WIP-901
D0A7CH	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative

D06FEQ	TTDDRUID	D06FEQ
D06FEQ	DRUGNAME	WIT-301
D06FEQ	INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative

D07WGW	TTDDRUID	D07WGW
D07WGW	DRUGNAME	WJ-9708011
D07WGW	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D04HAA	TTDDRUID	D04HAA
D04HAA	DRUGNAME	WL-276
D04HAA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0H7VA	TTDDRUID	D0H7VA
D0H7VA	DRUGNAME	Wnt stimulator , osteoporosis
D0H7VA	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0D0JY	TTDDRUID	D0D0JY
D0D0JY	DRUGNAME	WNVax
D0D0JY	INDICATI	West nile virus infection [ICD-11: 1D46] Investigative

D01YHO	TTDDRUID	D01YHO
D01YHO	DRUGNAME	WP-1122
D01YHO	INDICATI	Glioma [ICD-11: 2A00.0] Investigative

D04RUA	TTDDRUID	D04RUA
D04RUA	DRUGNAME	WRR-276
D04RUA	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0J6WV	TTDDRUID	D0J6WV
D0J6WV	DRUGNAME	WRR605
D0J6WV	INDICATI	Amoebiasis [ICD-11: 1A36] Investigative

D0OH9B	TTDDRUID	D0OH9B
D0OH9B	DRUGNAME	WS-070117
D0OH9B	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D0N6FZ	TTDDRUID	D0N6FZ
D0N6FZ	DRUGNAME	WS-50030
D0N6FZ	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D06MOB	TTDDRUID	D06MOB
D06MOB	DRUGNAME	WSB-102
D06MOB	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0I8SC	TTDDRUID	D0I8SC
D0I8SC	DRUGNAME	WSB-290
D0I8SC	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D0BJ7G	TTDDRUID	D0BJ7G
D0BJ7G	DRUGNAME	WSB-961
D0BJ7G	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D03DZK	TTDDRUID	D03DZK
D03DZK	DRUGNAME	WSBI-19711A
D03DZK	INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative

D05SJY	TTDDRUID	D05SJY
D05SJY	DRUGNAME	WS-CoQ10
D05SJY	INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative

D06UPW	TTDDRUID	D06UPW
D06UPW	DRUGNAME	WSS-45
D06UPW	INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative

D08HJI	TTDDRUID	D08HJI
D08HJI	DRUGNAME	WT2527
D08HJI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D06NLP	TTDDRUID	D06NLP
D06NLP	DRUGNAME	WTC-01
D06NLP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08RBS	TTDDRUID	D08RBS
D08RBS	DRUGNAME	WX-037
D08RBS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0T6AY	TTDDRUID	D0T6AY
D0T6AY	DRUGNAME	WX-04554
D0T6AY	INDICATI	Bone disease [ICD-11: FC0Z] Investigative

D0B9AQ	TTDDRUID	D0B9AQ
D0B9AQ	DRUGNAME	WYE-130600
D0B9AQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0NJ3Q	TTDDRUID	D0NJ3Q
D0NJ3Q	DRUGNAME	WZ-3146
D0NJ3Q	INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative

D0U2OQ	TTDDRUID	D0U2OQ
D0U2OQ	DRUGNAME	X-071-NAB
D0U2OQ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D01HOT	TTDDRUID	D01HOT
D01HOT	DRUGNAME	X-072-NAB
D01HOT	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0M0KJ	TTDDRUID	D0M0KJ
D0M0KJ	DRUGNAME	X-081-NAB
D0M0KJ	INDICATI	Hypereosinophilic syndrome [ICD-11: 2A20.3] Investigative

D0G9CJ	TTDDRUID	D0G9CJ
D0G9CJ	DRUGNAME	X-082-NAB
D0G9CJ	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative

D04ASA	TTDDRUID	D04ASA
D04ASA	DRUGNAME	X-083-NAB
D04ASA	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative

D08BTX	TTDDRUID	D08BTX
D08BTX	DRUGNAME	X-387
D08BTX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0JV8Q	TTDDRUID	D0JV8Q
D0JV8Q	DRUGNAME	XB-05
D0JV8Q	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00YNJ	TTDDRUID	D00YNJ
D00YNJ	DRUGNAME	XB-387
D00YNJ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D07COV	TTDDRUID	D07COV
D07COV	DRUGNAME	XDR-TB RNA-based therapeutics
D07COV	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative

D0O8UM	TTDDRUID	D0O8UM
D0O8UM	DRUGNAME	XEL-002BG
D0O8UM	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0Y4IX	TTDDRUID	D0Y4IX
D0Y4IX	DRUGNAME	XEL-002BI
D0Y4IX	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0B9IV	TTDDRUID	D0B9IV
D0B9IV	DRUGNAME	XEL-002LG
D0B9IV	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0D2UU	TTDDRUID	D0D2UU
D0D2UU	DRUGNAME	XEL-003FL
D0D2UU	INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative

D0KD7E	TTDDRUID	D0KD7E
D0KD7E	DRUGNAME	XEL-003FP
D0KD7E	INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative

D06IZS	TTDDRUID	D06IZS
D06IZS	DRUGNAME	XEL-004FP
D06IZS	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D08NUS	TTDDRUID	D08NUS
D08NUS	DRUGNAME	XEL-005OP
D08NUS	INDICATI	Urinary tract disease [ICD-11: GC2Z] Investigative

D0S2RZ	TTDDRUID	D0S2RZ
D0S2RZ	DRUGNAME	XEL-007DO
D0S2RZ	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D0JG6T	TTDDRUID	D0JG6T
D0JG6T	DRUGNAME	XEN-401
D0JG6T	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D07JMX	TTDDRUID	D07JMX
D07JMX	DRUGNAME	XEN-600
D07JMX	INDICATI	Iron overload disease [ICD-11: 5C64.10] Investigative

D0M1OU	TTDDRUID	D0M1OU
D0M1OU	DRUGNAME	XEN-907
D0M1OU	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0T0VZ	TTDDRUID	D0T0VZ
D0T0VZ	DRUGNAME	XEN-D0104
D0T0VZ	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative

D0W5HA	TTDDRUID	D0W5HA
D0W5HA	DRUGNAME	XEP-018
D0W5HA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D0V6CZ	TTDDRUID	D0V6CZ
D0V6CZ	DRUGNAME	XG-5XX
D0V6CZ	INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative

D0N8TM	TTDDRUID	D0N8TM
D0N8TM	DRUGNAME	XGP-110
D0N8TM	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0F8BR	TTDDRUID	D0F8BR
D0F8BR	DRUGNAME	XGP-115
D0F8BR	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0G2GZ	TTDDRUID	D0G2GZ
D0G2GZ	DRUGNAME	XGP-120
D0G2GZ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0I9FQ	TTDDRUID	D0I9FQ
D0I9FQ	DRUGNAME	XGP-125
D0I9FQ	INDICATI	Arthritis [ICD-11: FA20] Investigative

D0X0EF	TTDDRUID	D0X0EF
D0X0EF	DRUGNAME	XGP-210
D0X0EF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D00VGP	TTDDRUID	D00VGP
D00VGP	DRUGNAME	XGP-215
D00VGP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0I8LL	TTDDRUID	D0I8LL
D0I8LL	DRUGNAME	XGP-310
D0I8LL	INDICATI	Migraine [ICD-11: 8A80] Investigative

D0Y9JY	TTDDRUID	D0Y9JY
D0Y9JY	DRUGNAME	XGP-410
D0Y9JY	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D0X8PD	TTDDRUID	D0X8PD
D0X8PD	DRUGNAME	XGP-510
D0X8PD	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D0Y7RR	TTDDRUID	D0Y7RR
D0Y7RR	DRUGNAME	XGP-515
D0Y7RR	INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative

D00BCZ	TTDDRUID	D00BCZ
D00BCZ	DRUGNAME	XGP-610
D00BCZ	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative

D02QOL	TTDDRUID	D02QOL
D02QOL	DRUGNAME	XMetD
D02QOL	INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative

D0C7QW	TTDDRUID	D0C7QW
D0C7QW	DRUGNAME	XMetS
D0C7QW	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative

D04HYR	TTDDRUID	D04HYR
D04HYR	DRUGNAME	XN-05
D04HYR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09EQZ	TTDDRUID	D09EQZ
D09EQZ	DRUGNAME	XN-0502
D09EQZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0M9XH	TTDDRUID	D0M9XH
D0M9XH	DRUGNAME	XP-21510
D0M9XH	INDICATI	Menorrhagia [ICD-11: GA20.50] Investigative

D03KOU	TTDDRUID	D03KOU
D03KOU	DRUGNAME	XPro-1595
D03KOU	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0A9TR	TTDDRUID	D0A9TR
D0A9TR	DRUGNAME	XT-101
D0A9TR	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D07JOW	TTDDRUID	D07JOW
D07JOW	DRUGNAME	XTL-Pseudomonas-mab
D07JOW	INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative

D03XJP	TTDDRUID	D03XJP
D03XJP	DRUGNAME	Y-175L
D03XJP	INDICATI	Lupus [ICD-11: 4A40] Investigative

D0L8PO	TTDDRUID	D0L8PO
D0L8PO	DRUGNAME	YC-12
D0L8PO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0B3KI	TTDDRUID	D0B3KI
D0B3KI	DRUGNAME	YD-101
D0B3KI	INDICATI	Arthritis [ICD-11: FA20] Investigative

D05JXF	TTDDRUID	D05JXF
D05JXF	DRUGNAME	YD-501
D05JXF	INDICATI	Obesity [ICD-11: 5B81] Investigative

D0K6UJ	TTDDRUID	D0K6UJ
D0K6UJ	DRUGNAME	Yeast-based malaria treatment
D0K6UJ	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0P2AL	TTDDRUID	D0P2AL
D0P2AL	DRUGNAME	YJP-40101
D0P2AL	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative

D01YCX	TTDDRUID	D01YCX
D01YCX	DRUGNAME	YJRN-0904
D01YCX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative

D05UDU	TTDDRUID	D05UDU
D05UDU	DRUGNAME	YK-3237
D05UDU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0N7YK	TTDDRUID	D0N7YK
D0N7YK	DRUGNAME	YPEG-EPO
D0N7YK	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D0C9LE	TTDDRUID	D0C9LE
D0C9LE	DRUGNAME	YPL-1101
D0C9LE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D00VXZ	TTDDRUID	D00VXZ
D00VXZ	DRUGNAME	YT-1006
D00VXZ	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0S6NH	TTDDRUID	D0S6NH
D0S6NH	DRUGNAME	ZAMI-633
D0S6NH	INDICATI	Urinary tract disease [ICD-11: GC2Z] Investigative

D03HKA	TTDDRUID	D03HKA
D03HKA	DRUGNAME	ZFP TF
D03HKA	INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative

D01RNF	TTDDRUID	D01RNF
D01RNF	DRUGNAME	ZG-451
D01RNF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09GGY	TTDDRUID	D09GGY
D09GGY	DRUGNAME	Zinc acetate vaginal gel
D09GGY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0B3YB	TTDDRUID	D0B3YB
D0B3YB	DRUGNAME	Zinc finger protein transcripition factors
D0B3YB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09TWH	TTDDRUID	D09TWH
D09TWH	DRUGNAME	Zinc finger protein transcription factors
D09TWH	INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative

D0B6BW	TTDDRUID	D0B6BW
D0B6BW	DRUGNAME	ZIO-102
D0B6BW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Y5DC	TTDDRUID	D0Y5DC
D0Y5DC	DRUGNAME	ZJM-289
D0Y5DC	INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative

D08HQT	TTDDRUID	D08HQT
D08HQT	DRUGNAME	ZK-005
D08HQT	INDICATI	Wound healing [ICD-11: EL8Y] Investigative

D0C4SH	TTDDRUID	D0C4SH
D0C4SH	DRUGNAME	ZK-209614
D0C4SH	INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative

D00SBX	TTDDRUID	D00SBX
D00SBX	DRUGNAME	ZL006
D00SBX	INDICATI	Fear-related disorder [ICD-11: 6B0Z] Investigative

D04JNC	TTDDRUID	D04JNC
D04JNC	DRUGNAME	ZL-N-91
D04JNC	INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative

D08SAO	TTDDRUID	D08SAO
D08SAO	DRUGNAME	ZN-1014
D08SAO	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative

D0C9JI	TTDDRUID	D0C9JI
D0C9JI	DRUGNAME	Zn-DPA-B
D0C9JI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0JD1R	TTDDRUID	D0JD1R
D0JD1R	DRUGNAME	Zn-DPA-G
D0JD1R	INDICATI	Glioma [ICD-11: 2A00.0] Investigative

D0W9ZS	TTDDRUID	D0W9ZS
D0W9ZS	DRUGNAME	Zn-DPA-H
D0W9ZS	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative

D0Q0MI	TTDDRUID	D0Q0MI
D0Q0MI	DRUGNAME	Zn-DPA-I
D0Q0MI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0R2PR	TTDDRUID	D0R2PR
D0R2PR	DRUGNAME	Zn-DPA-P
D0R2PR	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D09KMA	TTDDRUID	D09KMA
D09KMA	DRUGNAME	Zofroxia
D09KMA	INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative

D06VTL	TTDDRUID	D06VTL
D06VTL	DRUGNAME	ZO-Y49
D06VTL	INDICATI	Gynecological disease [ICD-11: GA6Z] Investigative

D0K7JC	TTDDRUID	D0K7JC
D0K7JC	DRUGNAME	ZP-001
D0K7JC	INDICATI	Contracture [ICD-11: FA30-FA34] Investigative

D03GWV	TTDDRUID	D03GWV
D03GWV	DRUGNAME	ZP-002
D03GWV	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0M6XE	TTDDRUID	D0M6XE
D0M6XE	DRUGNAME	ZP-003
D0M6XE	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0P1WR	TTDDRUID	D0P1WR
D0P1WR	DRUGNAME	ZP-004
D0P1WR	INDICATI	Cough [ICD-11: MD12] Investigative

D0H2ZN	TTDDRUID	D0H2ZN
D0H2ZN	DRUGNAME	ZP-005
D0H2ZN	INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative

D00DTP	TTDDRUID	D00DTP
D00DTP	DRUGNAME	ZP-006
D00DTP	INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative

D0XY8K	TTDDRUID	D0XY8K
D0XY8K	DRUGNAME	ZP-007
D0XY8K	INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative

D0R1RV	TTDDRUID	D0R1RV
D0R1RV	DRUGNAME	ZP-008
D0R1RV	INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative

D0Z6EQ	TTDDRUID	D0Z6EQ
D0Z6EQ	DRUGNAME	ZP-009
D0Z6EQ	INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative

D01COH	TTDDRUID	D01COH
D01COH	DRUGNAME	ZP-010
D01COH	INDICATI	Bronchitis [ICD-11: CA20] Investigative

D07FQS	TTDDRUID	D07FQS
D07FQS	DRUGNAME	ZP-011
D07FQS	INDICATI	Sinusitis [ICD-11: CA0A.Z] Investigative

D0U0GC	TTDDRUID	D0U0GC
D0U0GC	DRUGNAME	ZP-012
D0U0GC	INDICATI	Urinary tract infection [ICD-11: GC08] Investigative

D04OBS	TTDDRUID	D04OBS
D04OBS	DRUGNAME	ZP-013
D04OBS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative

D0S9YP	TTDDRUID	D0S9YP
D0S9YP	DRUGNAME	ZP-103
D0S9YP	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative

D0CK2C	TTDDRUID	D0CK2C
D0CK2C	DRUGNAME	ZP-10395
D0CK2C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D09FGM	TTDDRUID	D09FGM
D09FGM	DRUGNAME	ZP-10719
D09FGM	INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative

D0G3BK	TTDDRUID	D0G3BK
D0G3BK	DRUGNAME	ZP-2307
D0G3BK	INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative

D0G0KZ	TTDDRUID	D0G0KZ
D0G0KZ	DRUGNAME	ZP-2571
D0G0KZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0Z9WP	TTDDRUID	D0Z9WP
D0Z9WP	DRUGNAME	ZP-3022
D0Z9WP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative

D0K9MN	TTDDRUID	D0K9MN
D0K9MN	DRUGNAME	ZP-EPO
D0K9MN	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative

D02ILI	TTDDRUID	D02ILI
D02ILI	DRUGNAME	ZP-G-CSF
D02ILI	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D04ZVO	TTDDRUID	D04ZVO
D04ZVO	DRUGNAME	ZS-9
D04ZVO	INDICATI	Hyperkalemia [ICD-11: 5C76] Investigative

D03LRU-D07VIK	TTDDRUID	D03LRU-D07VIK
D03LRU-D07VIK	DRUGNAME	17-DMAG + Arsenic trioxide
D03LRU-D07VIK	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Preclinical

D05LEO-D06DWP	TTDDRUID	D05LEO-D06DWP
D05LEO-D06DWP	DRUGNAME	2'-Deoxyinosine + Fluorouracil
D05LEO-D06DWP	INDICATI	Colon cancer [ICD-11: 2B90.Z] Preclinical

D06NYA-D0U5HU	TTDDRUID	D06NYA-D0U5HU
D06NYA-D0U5HU	DRUGNAME	2-methoxyestradiol + Cisplatin
D06NYA-D0U5HU	INDICATI	Endometrial cancer [ICD-11: 2C76] Preclinical

D06NYA-D07VLY	TTDDRUID	D06NYA-D07VLY
D06NYA-D07VLY	DRUGNAME	2-methoxyestradiol + Doxorubicin
D06NYA-D07VLY	INDICATI	Endometrial cancer [ICD-11: 2C76] Preclinical

D06NYA-D0C4RB	TTDDRUID	D06NYA-D0C4RB
D06NYA-D0C4RB	DRUGNAME	2-methoxyestradiol + Paclitaxel
D06NYA-D0C4RB	INDICATI	Endometrial cancer [ICD-11: 2C76] Preclinical

D09FAZ-D0L7LC	TTDDRUID	D09FAZ-D0L7LC
D09FAZ-D0L7LC	DRUGNAME	5-azacitidine + romidepsin
D09FAZ-D0L7LC	INDICATI	Liposarcoma [ICD-11: 2B59] Phase 1
D09FAZ-D0L7LC	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0B6TW-D05LEO	TTDDRUID	D0B6TW-D05LEO
D0B6TW-D05LEO	DRUGNAME	5-fluorouracil + leucovorin
D0B6TW-D05LEO	INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 3

D05LEO-D0V7RH	TTDDRUID	D05LEO-D0V7RH
D05LEO-D0V7RH	DRUGNAME	5-fu + calcium levofolinate
D05LEO-D0V7RH	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D03UVS-D0V2KR	TTDDRUID	D03UVS-D0V2KR
D03UVS-D0V2KR	DRUGNAME	90y-hpam4 + gemcitabine
D03UVS-D0V2KR	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D07TQV-D0A4IJ	TTDDRUID	D07TQV-D0A4IJ
D07TQV-D0A4IJ	DRUGNAME	Abacavir + Lamivudine
D07TQV-D0A4IJ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4
D07TQV-D0A4IJ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved

D0UX6Z-D0P3TX	TTDDRUID	D0UX6Z-D0P3TX
D0UX6Z-D0P3TX	DRUGNAME	Abciximab + Heparin
D0UX6Z-D0P3TX	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 4

D0P3TX-D0T6DK	TTDDRUID	D0P3TX-D0T6DK
D0P3TX-D0T6DK	DRUGNAME	Abciximab + Rapamycin
D0P3TX-D0T6DK	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 4

D0P3TX-D0T1UJ	TTDDRUID	D0P3TX-D0T1UJ
D0P3TX-D0T1UJ	DRUGNAME	Abciximab + Reteplase
D0P3TX-D0T1UJ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 3

D06CNP-D0Y7KH	TTDDRUID	D06CNP-D0Y7KH
D06CNP-D0Y7KH	DRUGNAME	abiraterone acetate + degarelix
D06CNP-D0Y7KH	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D06CNP-D0IL7L	TTDDRUID	D06CNP-D0IL7L
D06CNP-D0IL7L	DRUGNAME	Abiraterone acetate + Prednisone
D06CNP-D0IL7L	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D06CNP-D0IL7L	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0E6XR-D0LB3Z	TTDDRUID	D0E6XR-D0LB3Z
D0E6XR-D0LB3Z	DRUGNAME	abl001 + dasatinib
D0E6XR-D0LB3Z	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
D0E6XR-D0LB3Z	INDICATI	Philadelphia chromosome positive acute lymphoblastic leukaemia [ICD-11: 2A20.0] Phase 1

D0AZ3C-D0LB3Z	TTDDRUID	D0AZ3C-D0LB3Z
D0AZ3C-D0LB3Z	DRUGNAME	abl001 + imatinib
D0AZ3C-D0LB3Z	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
D0AZ3C-D0LB3Z	INDICATI	Philadelphia chromosome positive acute lymphoblastic leukaemia [ICD-11: 2A20.0] Phase 1

D00STL-D0LB3Z	TTDDRUID	D00STL-D0LB3Z
D00STL-D0LB3Z	DRUGNAME	abl001 + nilotinib
D00STL-D0LB3Z	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
D00STL-D0LB3Z	INDICATI	Philadelphia chromosome positive acute lymphoblastic leukaemia [ICD-11: 2A20.0] Phase 1

D01HKL-D0JE2E	TTDDRUID	D01HKL-D0JE2E
D01HKL-D0JE2E	DRUGNAME	abt-335 + rosuvastatin
D01HKL-D0JE2E	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 3
D01HKL-D0JE2E	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 3

D0L8WH-D0U5HU	TTDDRUID	D0L8WH-D0U5HU
D0L8WH-D0U5HU	DRUGNAME	ABT-737 + Cisplatin
D0L8WH-D0U5HU	INDICATI	Head and neck cancer [ICD-11: 2D42] Preclinical

D0IT2G-D0L8WH	TTDDRUID	D0IT2G-D0L8WH
D0IT2G-D0L8WH	DRUGNAME	ABT-737 + Dexamethasone
D0IT2G-D0L8WH	INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical

D0B7EB-D0L8WH	TTDDRUID	D0B7EB-D0L8WH
D0B7EB-D0L8WH	DRUGNAME	ABT-737 + Etoposide
D0B7EB-D0L8WH	INDICATI	Head and neck cancer [ICD-11: 2D42] Preclinical

D09EHO-D0Y4GO	TTDDRUID	D09EHO-D0Y4GO
D09EHO-D0Y4GO	DRUGNAME	ABT-751 + Pemetrexed
D09EHO-D0Y4GO	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2

D08RBC-D0GC2M	TTDDRUID	D08RBC-D0GC2M
D08RBC-D0GC2M	DRUGNAME	Acamprosate + Escitalopram
D08RBC-D0GC2M	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D05BQK-D0U5QK	TTDDRUID	D05BQK-D0U5QK
D05BQK-D0U5QK	DRUGNAME	Acetaminophen + Butalbital
D05BQK-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03DIG-D0U5QK	TTDDRUID	D03DIG-D0U5QK
D03DIG-D0U5QK	DRUGNAME	Acetaminophen + Codeine
D03DIG-D0U5QK	INDICATI	Breast disease [ICD-11: GB23] Phase 3
D03DIG-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D03DIG-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0TG1H-D0U5QK	TTDDRUID	D0TG1H-D0U5QK
D0TG1H-D0U5QK	DRUGNAME	Acetaminophen + Diclofenac
D0TG1H-D0U5QK	INDICATI	Postoperative orthopaedic pain [ICD-11: MG30.2] Investigative

D0T6RC-D0U5QK	TTDDRUID	D0T6RC-D0U5QK
D0T6RC-D0U5QK	DRUGNAME	Acetaminophen + Dihydrocodeine
D0T6RC-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0U5QK-D0W9WF	TTDDRUID	D0U5QK-D0W9WF
D0U5QK-D0W9WF	DRUGNAME	Acetaminophen + Ketoprofen
D0U5QK-D0W9WF	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0U5QK-D0WE3O	TTDDRUID	D0U5QK-D0WE3O
D0U5QK-D0WE3O	DRUGNAME	Acetaminophen + Morphine
D0U5QK-D0WE3O	INDICATI	Urolithiasis [ICD-11: GB7Z] Phase 4

D03SKD-D0U5QK	TTDDRUID	D03SKD-D0U5QK
D03SKD-D0U5QK	DRUGNAME	Acetaminophen + Oxycodone
D03SKD-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0U5QK-D0W6DG	TTDDRUID	D0U5QK-D0W6DG
D0U5QK-D0W6DG	DRUGNAME	Acetaminophen + Pentazocine
D0U5QK-D0W6DG	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03HCZ-D0U5QK	TTDDRUID	D03HCZ-D0U5QK
D03HCZ-D0U5QK	DRUGNAME	Acetaminophen + Propoxyphene
D03HCZ-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0G5ME-D0U5QK	TTDDRUID	D0G5ME-D0U5QK
D0G5ME-D0U5QK	DRUGNAME	Acetaminophen + Telcagepant
D0G5ME-D0U5QK	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D06XGW-D0FJ8A	TTDDRUID	D06XGW-D0FJ8A
D06XGW-D0FJ8A	DRUGNAME	Acetylcysteine + Deferoxamine
D06XGW-D0FJ8A	INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2

D06XGW-D0I8FI	TTDDRUID	D06XGW-D0I8FI
D06XGW-D0I8FI	DRUGNAME	Acetylcysteine + Isoproterenol
D06XGW-D0I8FI	INDICATI	Chronic bronchopulmonary disease [ICD-11: CB40.Y] Approved

D06XGW-D0D1SG	TTDDRUID	D06XGW-D0D1SG
D06XGW-D0D1SG	DRUGNAME	Acetylcysteine + Prednisolone
D06XGW-D0D1SG	INDICATI	Alcoholic hepatitis [ICD-11: DB94.1] Phase 3

D0B5MP-D0KR5B	TTDDRUID	D0B5MP-D0KR5B
D0B5MP-D0KR5B	DRUGNAME	Aciclovir + Hydrocortisone
D0B5MP-D0KR5B	INDICATI	Recurrent herpes labialis [ICD-11: 1F00.01] Approved

D0B5MP-D0W9WF	TTDDRUID	D0B5MP-D0W9WF
D0B5MP-D0W9WF	DRUGNAME	Aciclovir + Ketoprofen
D0B5MP-D0W9WF	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Preclinical

D0B5MP-D0DJ1B	TTDDRUID	D0B5MP-D0DJ1B
D0B5MP-D0DJ1B	DRUGNAME	Aciclovir + Naproxen
D0B5MP-D0DJ1B	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Preclinical

D00HHS-D0O4EU	TTDDRUID	D00HHS-D0O4EU
D00HHS-D0O4EU	DRUGNAME	Acrivastine + Pseudoephedrine
D00HHS-D0O4EU	INDICATI	Sneezing [ICD-11: MD11.A] Approved

D04DXN-D0JC9N	TTDDRUID	D04DXN-D0JC9N
D04DXN-D0JC9N	DRUGNAME	Adapalene + Benzoyl peroxide
D04DXN-D0JC9N	INDICATI	Acne vulgaris [ICD-11: ED80] Investigative

D0JC9N-D0R0ZL	TTDDRUID	D0JC9N-D0R0ZL
D0JC9N-D0R0ZL	DRUGNAME	adapalene + clindamycin
D0JC9N-D0R0ZL	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 4

D03VUV-D09XZB	TTDDRUID	D03VUV-D09XZB
D03VUV-D09XZB	DRUGNAME	Adarotene + Gefitinib
D03VUV-D09XZB	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Preclinical

D0KR2J-D0ML1F	TTDDRUID	D0KR2J-D0ML1F
D0KR2J-D0ML1F	DRUGNAME	Adefovir + Entecavir
D0KR2J-D0ML1F	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D07TQV-D0ML1F	TTDDRUID	D07TQV-D0ML1F
D07TQV-D0ML1F	DRUGNAME	Adefovir + Lamivudine
D07TQV-D0ML1F	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 3
D07TQV-D0ML1F	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D06IAR-D0F9GE	TTDDRUID	D06IAR-D0F9GE
D06IAR-D0F9GE	DRUGNAME	adenosine + dipyridamole
D06IAR-D0F9GE	INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2

D06IAR-D0O2SR	TTDDRUID	D06IAR-D0O2SR
D06IAR-D0O2SR	DRUGNAME	Adenosine + Nicorandil
D06IAR-D0O2SR	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4

D0G2QH-D0K3QS	TTDDRUID	D0G2QH-D0K3QS
D0G2QH-D0K3QS	DRUGNAME	AEE788 + Everolimus
D0G2QH-D0K3QS	INDICATI	Malignant glioma [ICD-11: 2A00.0] Preclinical

D05UFG-D0N5OV	TTDDRUID	D05UFG-D0N5OV
D05UFG-D0N5OV	DRUGNAME	Afatinib + Cetuximab
D05UFG-D0N5OV	INDICATI	EGFR mutant lung cancer [ICD-11: 2C25.Y] Preclinical

D05UFG-D0C4RB	TTDDRUID	D05UFG-D0C4RB
D05UFG-D0C4RB	DRUGNAME	Afatinib + Paclitaxel
D05UFG-D0C4RB	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0C9ET-D0O5WP	TTDDRUID	D0C9ET-D0O5WP
D0C9ET-D0O5WP	DRUGNAME	Aflibercept + Docetaxel
D0C9ET-D0O5WP	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1/2

D01STB-D07JLM	TTDDRUID	D01STB-D07JLM
D01STB-D07JLM	DRUGNAME	Alagebrium + Ramipril
D01STB-D07JLM	INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical

D00KVO-D09YHJ	TTDDRUID	D00KVO-D09YHJ
D00KVO-D09YHJ	DRUGNAME	Albendazole + Ivermectin
D00KVO-D09YHJ	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Investigative

D00KVO-D0L9ZR	TTDDRUID	D00KVO-D0L9ZR
D00KVO-D0L9ZR	DRUGNAME	albendazole + praziquantel
D00KVO-D0L9ZR	INDICATI	Helminthiasis [ICD-11: 1F90] Phase 4
D00KVO-D0L9ZR	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 4
D00KVO-D0L9ZR	INDICATI	Schistosomiasis [ICD-11: 1F86] Phase 4

D00KVO-D0D1SG	TTDDRUID	D00KVO-D0D1SG
D00KVO-D0D1SG	DRUGNAME	Albendazole + Prednisolone
D00KVO-D0D1SG	INDICATI	Eosinophilic meningitis [ICD-11: 1F60.0] Investigative

D00TJX-D0H3WI	TTDDRUID	D00TJX-D0H3WI
D00TJX-D0H3WI	DRUGNAME	Albinterferon alfa-2b + Ribavirin
D00TJX-D0H3WI	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3

D05PUD-D0W5HK	TTDDRUID	D05PUD-D0W5HK
D05PUD-D0W5HK	DRUGNAME	Aldesleukin + Sorafenib
D05PUD-D0W5HK	INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 2

D01ZYG-D0F2XQ	TTDDRUID	D01ZYG-D0F2XQ
D01ZYG-D0F2XQ	DRUGNAME	alemtuzumab + fludarabine
D01ZYG-D0F2XQ	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2

D09KLR-D0K5WS	TTDDRUID	D09KLR-D0K5WS
D09KLR-D0K5WS	DRUGNAME	Alendronate + Cholecalciferol
D09KLR-D0K5WS	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D03SVX-D08JIV	TTDDRUID	D03SVX-D08JIV
D03SVX-D08JIV	DRUGNAME	Aliskiren + Amlodipine
D03SVX-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03SVX-D0I0EG	TTDDRUID	D03SVX-D0I0EG
D03SVX-D0I0EG	DRUGNAME	Aliskiren + Captopril
D03SVX-D0I0EG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D03SVX-D0U4UQ	TTDDRUID	D03SVX-D0U4UQ
D03SVX-D0U4UQ	DRUGNAME	Aliskiren + Hydrochlorothiazide
D03SVX-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00JAU-D03SVX	TTDDRUID	D00JAU-D03SVX
D00JAU-D03SVX	DRUGNAME	Aliskiren + Irbesartan
D00JAU-D03SVX	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D03SVX-D0DD0K	TTDDRUID	D03SVX-D0DD0K
D03SVX-D0DD0K	DRUGNAME	Aliskiren + Losartan
D03SVX-D0DD0K	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D01STB-D03SVX	TTDDRUID	D01STB-D03SVX
D01STB-D03SVX	DRUGNAME	Aliskiren + Ramipril
D01STB-D03SVX	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D03SVX-D06UDG	TTDDRUID	D03SVX-D06UDG
D03SVX-D06UDG	DRUGNAME	Aliskiren + Valsartan
D03SVX-D06UDG	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 4
D03SVX-D06UDG	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D05LYX-D0NJ5H	TTDDRUID	D05LYX-D0NJ5H
D05LYX-D0NJ5H	DRUGNAME	Alogliptin + Glyburide
D05LYX-D0NJ5H	INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative

D0NJ5H-D0R6CD	TTDDRUID	D0NJ5H-D0R6CD
D0NJ5H-D0R6CD	DRUGNAME	Alogliptin + Insulin
D0NJ5H-D0R6CD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0D7LA-D0NJ5H	TTDDRUID	D0D7LA-D0NJ5H
D0D7LA-D0NJ5H	DRUGNAME	Alogliptin + Metformin
D0D7LA-D0NJ5H	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0I0RJ-D0U4UQ	TTDDRUID	D0I0RJ-D0U4UQ
D0I0RJ-D0U4UQ	DRUGNAME	Alogliptin + Metformin
D0I0RJ-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03OFF-D0NJ5H	TTDDRUID	D03OFF-D0NJ5H
D03OFF-D0NJ5H	DRUGNAME	Alogliptin + Pioglitazone
D03OFF-D0NJ5H	INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative
D03OFF-D0NJ5H	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D04ZTY-D0NJ5H	TTDDRUID	D04ZTY-D0NJ5H
D04ZTY-D0NJ5H	DRUGNAME	Alogliptin + Voglibose
D04ZTY-D0NJ5H	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3

D0I1FQ-D0U5GB	TTDDRUID	D0I1FQ-D0U5GB
D0I1FQ-D0U5GB	DRUGNAME	aluvia + raltegravir
D0I1FQ-D0U5GB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0EP0C-D0X5ZI	TTDDRUID	D0EP0C-D0X5ZI
D0EP0C-D0X5ZI	DRUGNAME	ambrisentan + spironolactone
D0EP0C-D0X5ZI	INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 4

D07VLY-D0K8NR	TTDDRUID	D07VLY-D0K8NR
D07VLY-D0K8NR	DRUGNAME	amg 386 + doxorubicin
D07VLY-D0K8NR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C4RB-D0K8NR	TTDDRUID	D0C4RB-D0K8NR
D0C4RB-D0K8NR	DRUGNAME	amg 386 + paclitaxel
D0C4RB-D0K8NR	INDICATI	Renal impairment [ICD-11: GB6Z] Phase 1

D02PMO-D0K8NR	TTDDRUID	D02PMO-D0K8NR
D02PMO-D0K8NR	DRUGNAME	amg 386 + topotecan
D02PMO-D0K8NR	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04WFL-D0K8NR	TTDDRUID	D04WFL-D0K8NR
D04WFL-D0K8NR	DRUGNAME	amg 386 + trastuzumab
D04WFL-D0K8NR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00AKR-D0D7LA	TTDDRUID	D00AKR-D0D7LA
D00AKR-D0D7LA	DRUGNAME	amg 479 + metformin
D00AKR-D0D7LA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0PH5Z-D0Y3MO	TTDDRUID	D0PH5Z-D0Y3MO
D0PH5Z-D0Y3MO	DRUGNAME	Amikacin + Ceftazidime
D0PH5Z-D0Y3MO	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D07ACT-D0Y3MO	TTDDRUID	D07ACT-D0Y3MO
D07ACT-D0Y3MO	DRUGNAME	Amikacin + Ceftriaxone
D07ACT-D0Y3MO	INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative

D04OKJ-D0Y3MO	TTDDRUID	D04OKJ-D0Y3MO
D04OKJ-D0Y3MO	DRUGNAME	Amikacin + Garenoxacin
D04OKJ-D0Y3MO	INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Preclinical

D0G4OD-D0Y3MO	TTDDRUID	D0G4OD-D0Y3MO
D0G4OD-D0Y3MO	DRUGNAME	Amikacin + Tigecycline
D0G4OD-D0Y3MO	INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical

D09NIA-D0I0RJ	TTDDRUID	D09NIA-D0I0RJ
D09NIA-D0I0RJ	DRUGNAME	Amiloride + Chlorthalidone
D09NIA-D0I0RJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D03TYI-D0X5ZI	TTDDRUID	D03TYI-D0X5ZI
D03TYI-D0X5ZI	DRUGNAME	aminophylline + ambrisentan
D03TYI-D0X5ZI	INDICATI	High altitude pulmonary hypertension [ICD-11: BB01] Phase 1

D03TYI-D0F8RA	TTDDRUID	D03TYI-D0F8RA
D03TYI-D0F8RA	DRUGNAME	Aminophylline + Theophylline
D03TYI-D0F8RA	INDICATI	Myelogenous leukaemia [ICD-11: 2B33.1] Phase 2

D03HYQ-D0L5WM	TTDDRUID	D03HYQ-D0L5WM
D03HYQ-D0L5WM	DRUGNAME	amiodarone + ranolazine
D03HYQ-D0L5WM	INDICATI	Arrhythmia [ICD-11: BC9Z] Investigative

D01ZSO-D03ELL	TTDDRUID	D01ZSO-D03ELL
D01ZSO-D03ELL	DRUGNAME	Amisulpride + Moclobemide
D01ZSO-D03ELL	INDICATI	Hypersalivation [ICD-11: DA04.6] Phase 3

D06BEP-D0Y5UG	TTDDRUID	D06BEP-D0Y5UG
D06BEP-D0Y5UG	DRUGNAME	Amitriptyline + Chlordiazepoxide
D06BEP-D0Y5UG	INDICATI	Depression associated with anxiety [ICD-11: 6A70.4] Approved

D02HED-D0Y5UG	TTDDRUID	D02HED-D0Y5UG
D02HED-D0Y5UG	DRUGNAME	Amitriptyline + Perphenazine
D02HED-D0Y5UG	INDICATI	Agitation [ICD-11: 6A70.3] Approved
D02HED-D0Y5UG	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
D02HED-D0Y5UG	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D01QIN-D08JIV	TTDDRUID	D01QIN-D08JIV
D01QIN-D08JIV	DRUGNAME	Amlodipine + Atorvastatin
D01QIN-D08JIV	INDICATI	Arterial thrombosis [ICD-11: DB61-DD30] Phase 4
D01QIN-D08JIV	INDICATI	Chest pain [ICD-11: MD30] Approved
D01QIN-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D01QIN-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D08JIV-D0U3EC	TTDDRUID	D08JIV-D0U3EC
D08JIV-D0U3EC	DRUGNAME	Amlodipine + Benazepril
D08JIV-D0U3EC	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D08JIV-D0U3EC	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D03BJX-D08JIV	TTDDRUID	D03BJX-D08JIV
D03BJX-D08JIV	DRUGNAME	amlodipine + botulinum toxin
D03BJX-D08JIV	INDICATI	Focal dystonia [ICD-11: 8A02.1] Phase 2

D08JIV-D0G8QW	TTDDRUID	D08JIV-D0G8QW
D08JIV-D0G8QW	DRUGNAME	amlodipine + delapril
D08JIV-D0G8QW	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D08JIV-D0U4UQ	TTDDRUID	D08JIV-D0U4UQ
D08JIV-D0U4UQ	DRUGNAME	Amlodipine + Hydrochlorothiazide
D08JIV-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D00JAU-D08JIV	TTDDRUID	D00JAU-D08JIV
D00JAU-D08JIV	DRUGNAME	Amlodipine + Irbesartan
D00JAU-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D08JIV-D0DD0K	TTDDRUID	D08JIV-D0DD0K
D08JIV-D0DD0K	DRUGNAME	Amlodipine + Losartan
D08JIV-D0DD0K	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
D08JIV-D0DD0K	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
D08JIV-D0DD0K	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D08JIV-D0D7LA	TTDDRUID	D08JIV-D0D7LA
D08JIV-D0D7LA	DRUGNAME	amlodipine + metformin
D08JIV-D0D7LA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4
D08JIV-D0D7LA	INDICATI	Obesity [ICD-11: 5B81] Phase 4

D07UBG-D08JIV	TTDDRUID	D07UBG-D08JIV
D07UBG-D08JIV	DRUGNAME	Amlodipine + Olmesartan
D07UBG-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D07UBG-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D03KYG-D08JIV	TTDDRUID	D03KYG-D08JIV
D03KYG-D08JIV	DRUGNAME	Amlodipine + Perindopril
D03KYG-D08JIV	INDICATI	Coronary heart disease [ICD-11: BA80.Z] Investigative
D03KYG-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D08JIV-D0N0EQ	TTDDRUID	D08JIV-D0N0EQ
D08JIV-D0N0EQ	DRUGNAME	Amlodipine + Streptomycin
D08JIV-D0N0EQ	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D08JIV-D0N6RF	TTDDRUID	D08JIV-D0N6RF
D08JIV-D0N6RF	DRUGNAME	Amlodipine + Telmisartan
D08JIV-D0N6RF	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D08JIV-D0P9RF	TTDDRUID	D08JIV-D0P9RF
D08JIV-D0P9RF	DRUGNAME	amlodipine + terazosin
D08JIV-D0P9RF	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
D08JIV-D0P9RF	INDICATI	Lower urinary tract symptom [ICD-11: GB71] Investigative

D06UDG-D08JIV	TTDDRUID	D06UDG-D08JIV
D06UDG-D08JIV	DRUGNAME	Amlodipine + Valsartan
D06UDG-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D06UDG-D08JIV	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D04NQI-D0D4JO	TTDDRUID	D04NQI-D0D4JO
D04NQI-D0D4JO	DRUGNAME	Amodiaquine + Artesunate
D04NQI-D0D4JO	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 3
D04NQI-D0D4JO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 4

D0F6EO-D0X7JN	TTDDRUID	D0F6EO-D0X7JN
D0F6EO-D0X7JN	DRUGNAME	Amoxicillin + Clavulanate
D0F6EO-D0X7JN	INDICATI	Bronchitis [ICD-11: CA20] Approved
D0F6EO-D0X7JN	INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 4
D0F6EO-D0X7JN	INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Approved
D0F6EO-D0X7JN	INDICATI	Pneumonia [ICD-11: CA40] Approved
D0F6EO-D0X7JN	INDICATI	Sinusitis [ICD-11: CA0A.Z] Approved

D01XNB-D0F6EO	TTDDRUID	D01XNB-D0F6EO
D01XNB-D0F6EO	DRUGNAME	Amoxicillin + Omeprazole
D01XNB-D0F6EO	INDICATI	Peptic ulcer [ICD-11: DA61] Investigative

D05ATI-D0F6EO	TTDDRUID	D05ATI-D0F6EO
D05ATI-D0F6EO	DRUGNAME	Amoxicillin + Sodium lauryl sulfate
D05ATI-D0F6EO	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D05BMG-D0T3LF	TTDDRUID	D05BMG-D0T3LF
D05BMG-D0T3LF	DRUGNAME	Amphetamine + Dextroamphetamine
D05BMG-D0T3LF	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
D05BMG-D0T3LF	INDICATI	Narcolepsy [ICD-11: 7A20] Approved

D02DWM-D0F9BY	TTDDRUID	D02DWM-D0F9BY
D02DWM-D0F9BY	DRUGNAME	Amphotericin B + Anidulafungin
D02DWM-D0F9BY	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical

D02DWM-D0Q5UQ	TTDDRUID	D02DWM-D0Q5UQ
D02DWM-D0Q5UQ	DRUGNAME	Amphotericin B + Deferasirox
D02DWM-D0Q5UQ	INDICATI	Mucormycosis [ICD-11: 1F2C] Phase 2

D02DWM-D09LNI	TTDDRUID	D02DWM-D09LNI
D02DWM-D09LNI	DRUGNAME	Amphotericin B + Fluconazole
D02DWM-D09LNI	INDICATI	Cryptococcal meningitis infection [ICD-11: 1D01.10] Phase 2

D00FGR-D02DWM	TTDDRUID	D00FGR-D02DWM
D00FGR-D02DWM	DRUGNAME	Amphotericin B + Miltefosine
D00FGR-D02DWM	INDICATI	Leishmaniasis [ICD-11: 1F54] Phase 2

D02DWM-D07ABV	TTDDRUID	D02DWM-D07ABV
D02DWM-D07ABV	DRUGNAME	Amphotericin B + Posaconazole
D02DWM-D07ABV	INDICATI	Aspergillosis [ICD-11: 1F20] Preclinical

D05HPI-D0YA9Z	TTDDRUID	D05HPI-D0YA9Z
D05HPI-D0YA9Z	DRUGNAME	Ampicillin + Daptomycin
D05HPI-D0YA9Z	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Preclinical

D0L9UU-D0YA9Z	TTDDRUID	D0L9UU-D0YA9Z
D0L9UU-D0YA9Z	DRUGNAME	Ampicillin + Gentamicin
D0L9UU-D0YA9Z	INDICATI	Chorioamnionitis [ICD-11: JA88.1] Phase 2/3

D0H3TD-D0YA9Z	TTDDRUID	D0H3TD-D0YA9Z
D0H3TD-D0YA9Z	DRUGNAME	Ampicillin + Imipenem
D0H3TD-D0YA9Z	INDICATI	Vancomycin-resistant bacterial infection [ICD-11: 1C41] Preclinical

D0L7FM-D0YA9Z	TTDDRUID	D0L7FM-D0YA9Z
D0L7FM-D0YA9Z	DRUGNAME	Ampicillin + Probenecid
D0L7FM-D0YA9Z	INDICATI	Gonococcal infection [ICD-11: 1A70.0Y] Approved

D0H0BG-D0YA9Z	TTDDRUID	D0H0BG-D0YA9Z
D0H0BG-D0YA9Z	DRUGNAME	Ampicillin + Sulbactam
D0H0BG-D0YA9Z	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02DES-D0IT2G	TTDDRUID	D02DES-D0IT2G
D02DES-D0IT2G	DRUGNAME	Anakinra + Dexamethasone
D02DES-D0IT2G	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0JO7Y-D0W0BF	TTDDRUID	D0JO7Y-D0W0BF
D0JO7Y-D0W0BF	DRUGNAME	Anastrozole + Fulvestrant
D0JO7Y-D0W0BF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0JO7Y-D0W0BF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D09XZB-D0W0BF	TTDDRUID	D09XZB-D0W0BF
D09XZB-D0W0BF	DRUGNAME	Anastrozole + Gefitinib
D09XZB-D0W0BF	INDICATI	ER-positive breast cancer [ICD-11: 2C60-2C65] Phase 2

D0GL7U-D0W0BF	TTDDRUID	D0GL7U-D0W0BF
D0GL7U-D0W0BF	DRUGNAME	anastrozole + levonorgestrel
D0GL7U-D0W0BF	INDICATI	Endometriosis [ICD-11: GA10] Phase 2

D04OBB-D06FZX	TTDDRUID	D04OBB-D06FZX
D04OBB-D06FZX	DRUGNAME	Antazoline + Pheniramine
D04OBB-D06FZX	INDICATI	Minor allergic symptoms of the eye [ICD-11: 4A81] Approved

D0M7XS-D0O3YF	TTDDRUID	D0M7XS-D0O3YF
D0M7XS-D0O3YF	DRUGNAME	Anti-thymocyte globulin + Cyclosporine
D0M7XS-D0O3YF	INDICATI	Aplastic anemia [ICD-11: 3A70] Phase 2

D08CDI-D0O5WP	TTDDRUID	D08CDI-D0O5WP
D08CDI-D0O5WP	DRUGNAME	apatinib + docetaxel
D08CDI-D0O5WP	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1

D0GU4K-D0IT2G	TTDDRUID	D0GU4K-D0IT2G
D0GU4K-D0IT2G	DRUGNAME	aprepitant + po ondansetron + dexamethasone
D0GU4K-D0IT2G	INDICATI	Nausea [ICD-11: MD90] Phase 4

D0D1DI-D0P1WA	TTDDRUID	D0D1DI-D0P1WA
D0D1DI-D0P1WA	DRUGNAME	Arformoterol + Tiotropium
D0D1DI-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D00UOR-D07UWV	TTDDRUID	D00UOR-D07UWV
D00UOR-D07UWV	DRUGNAME	Argatroban + Desirudin
D00UOR-D07UWV	INDICATI	Heparin-induced thrombocytopenia [ICD-11: 3B64.12] Phase 4

D07WXT-D0H3HM	TTDDRUID	D07WXT-D0H3HM
D07WXT-D0H3HM	DRUGNAME	Aripiprazole + Lithium
D07WXT-D0H3HM	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 4

D0Y3KG-D0H3HM	TTDDRUID	D0Y3KG-D0H3HM
D0Y3KG-D0H3HM	DRUGNAME	Aripiprazole + Valproic Acid
D0Y3KG-D0H3HM	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 4

D07POC-D0ZI1F	TTDDRUID	D07POC-D0ZI1F
D07POC-D0ZI1F	DRUGNAME	arq 197 + erlotinib
D07POC-D0ZI1F	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D03UVS-D0W0VD	TTDDRUID	D03UVS-D0W0VD
D03UVS-D0W0VD	DRUGNAME	arq 501 + gemcitabine
D03UVS-D0W0VD	INDICATI	Adenocarcinoma [ICD-11: 2D40] Phase 2
D03UVS-D0W0VD	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D07VIK-D0AZ3C	TTDDRUID	D07VIK-D0AZ3C
D07VIK-D0AZ3C	DRUGNAME	Arsenic sulfide + Imatinib
D07VIK-D0AZ3C	INDICATI	BCR/ABL-associated leukaemia [ICD-11: 2A20.0] Preclinical

D07VIK-D0SC2J	TTDDRUID	D07VIK-D0SC2J
D07VIK-D0SC2J	DRUGNAME	Arsenic trioxide + Tanespimycin
D07VIK-D0SC2J	INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical

D02DGU-D07VIK	TTDDRUID	D02DGU-D07VIK
D02DGU-D07VIK	DRUGNAME	Arsenic trioxide + Tretinoin
D02DGU-D07VIK	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D06MQM-D0M9BW	TTDDRUID	D06MQM-D0M9BW
D06MQM-D0M9BW	DRUGNAME	Artemether + Lumefantrine
D06MQM-D0M9BW	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Investigative
D06MQM-D0M9BW	INDICATI	Fever [ICD-11: MG26] Phase 3
D06MQM-D0M9BW	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
D06MQM-D0M9BW	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D07SDQ-D0S3WH	TTDDRUID	D07SDQ-D0S3WH
D07SDQ-D0S3WH	DRUGNAME	Artemisinin + Curcumin
D07SDQ-D0S3WH	INDICATI	Malaria [ICD-11: 1F40-1F45] Preclinical

D09NYS-D0S3WH	TTDDRUID	D09NYS-D0S3WH
D09NYS-D0S3WH	DRUGNAME	Artemisinin + Methylene blue
D09NYS-D0S3WH	INDICATI	Malaria [ICD-11: 1F40-1F45] Preclinical

D03HJK-D0D4JO	TTDDRUID	D03HJK-D0D4JO
D03HJK-D0D4JO	DRUGNAME	Artesunate + Azithromycin
D03HJK-D0D4JO	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 2
D03HJK-D0D4JO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D09EGZ-D0D4JO	TTDDRUID	D09EGZ-D0D4JO
D09EGZ-D0D4JO	DRUGNAME	Artesunate + Chloroquine
D09EGZ-D0D4JO	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 2

D0D4JO-D0GQ7K	TTDDRUID	D0D4JO-D0GQ7K
D0D4JO-D0GQ7K	DRUGNAME	Artesunate + Mefloquine
D0D4JO-D0GQ7K	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
D0D4JO-D0GQ7K	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 4

D0D4JO-D0E0KQ	TTDDRUID	D0D4JO-D0E0KQ
D0D4JO-D0E0KQ	DRUGNAME	Artesunate + Pyronaridine
D0D4JO-D0E0KQ	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
D0D4JO-D0E0KQ	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D04PHC-D0I5HV	TTDDRUID	D04PHC-D0I5HV
D04PHC-D0I5HV	DRUGNAME	Articaine hydrochloride + Epinephrine
D04PHC-D0I5HV	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D06LOQ-D0YO4D	TTDDRUID	D06LOQ-D0YO4D
D06LOQ-D0YO4D	DRUGNAME	Arzoxifene + LG100268
D06LOQ-D0YO4D	INDICATI	ER-negative breast cancer [ICD-11: 2C60-2C65] Preclinical

D01QIN-D0GY5Z	TTDDRUID	D01QIN-D0GY5Z
D01QIN-D0GY5Z	DRUGNAME	Aspirin + Atorvastatin
D01QIN-D0GY5Z	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 4

D05BQK-D0GY5Z	TTDDRUID	D05BQK-D0GY5Z
D05BQK-D0GY5Z	DRUGNAME	Aspirin + Butalbital
D05BQK-D0GY5Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D05BQK-D0GY5Z	INDICATI	Tension headache [ICD-11: 8A81] Approved

D05PLH-D0GY5Z	TTDDRUID	D05PLH-D0GY5Z
D05PLH-D0GY5Z	DRUGNAME	Aspirin + Carisoprodol
D05PLH-D0GY5Z	INDICATI	Limited mobility [ICD-11: MB44] Approved
D05PLH-D0GY5Z	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
D05PLH-D0GY5Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0GY5Z-D0N0TZ	TTDDRUID	D0GY5Z-D0N0TZ
D0GY5Z-D0N0TZ	DRUGNAME	Aspirin + Clopidogrel
D0GY5Z-D0N0TZ	INDICATI	Cerebrovascular accident [ICD-11: 8B20] Phase 3
D0GY5Z-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
D0GY5Z-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3
D0GY5Z-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4
D0GY5Z-D0N0TZ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
D0GY5Z-D0N0TZ	INDICATI	Platelet aggregation disorder [ICD-11: 3B62] Phase 1

D0GY5Z-D0T6RC	TTDDRUID	D0GY5Z-D0T6RC
D0GY5Z-D0T6RC	DRUGNAME	Aspirin + Dihydrocodeine
D0GY5Z-D0T6RC	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0F9GE-D0GY5Z	TTDDRUID	D0F9GE-D0GY5Z
D0F9GE-D0GY5Z	DRUGNAME	Aspirin + Dipyridamole
D0F9GE-D0GY5Z	INDICATI	Atherosclerosis [ICD-11: BD40] Investigative
D0F9GE-D0GY5Z	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
D0F9GE-D0GY5Z	INDICATI	Carotid stenosis [ICD-11: BD55] Investigative
D0F9GE-D0GY5Z	INDICATI	Stroke [ICD-11: 8B20] Approved
D0F9GE-D0GY5Z	INDICATI	Stroke [ICD-11: 8B20] Investigative

D0C6DT-D0GY5Z	TTDDRUID	D0C6DT-D0GY5Z
D0C6DT-D0GY5Z	DRUGNAME	Aspirin + Esomeprazole
D0C6DT-D0GY5Z	INDICATI	Barrett esophagus [ICD-11: DA23.Z] Phase 2

D0UX6Z-D0GY5Z	TTDDRUID	D0UX6Z-D0GY5Z
D0UX6Z-D0GY5Z	DRUGNAME	Aspirin + Heparin
D0UX6Z-D0GY5Z	INDICATI	Recurrent abortion [ICD-11: GA33] Phase 2

D0GY5Z-D0X5KF	TTDDRUID	D0GY5Z-D0X5KF
D0GY5Z-D0X5KF	DRUGNAME	Aspirin + Hydrocodone
D0GY5Z-D0X5KF	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0GY5Z-D0Y4AW	TTDDRUID	D0GY5Z-D0Y4AW
D0GY5Z-D0Y4AW	DRUGNAME	Aspirin + Meprobamate
D0GY5Z-D0Y4AW	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0D7LA-D0GY5Z	TTDDRUID	D0D7LA-D0GY5Z
D0D7LA-D0GY5Z	DRUGNAME	aspirin + metformin
D0D7LA-D0GY5Z	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 2

D0FN7J-D0GY5Z	TTDDRUID	D0FN7J-D0GY5Z
D0FN7J-D0GY5Z	DRUGNAME	Aspirin + Methocarbamol
D0FN7J-D0GY5Z	INDICATI	Muscular pain [ICD-11: FB56] Approved

D00MAI-D0GY5Z	TTDDRUID	D00MAI-D0GY5Z
D00MAI-D0GY5Z	DRUGNAME	Aspirin + Niacin
D00MAI-D0GY5Z	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 3

D03SKD-D0GY5Z	TTDDRUID	D03SKD-D0GY5Z
D03SKD-D0GY5Z	DRUGNAME	Aspirin + Oxycodone
D03SKD-D0GY5Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0GY5Z-D0W6DG	TTDDRUID	D0GY5Z-D0W6DG
D0GY5Z-D0W6DG	DRUGNAME	Aspirin + Pentazocine
D0GY5Z-D0W6DG	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03OFF-D0GY5Z	TTDDRUID	D03OFF-D0GY5Z
D03OFF-D0GY5Z	DRUGNAME	Aspirin + Pioglitazone
D03OFF-D0GY5Z	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2

D02RQU-D0GY5Z	TTDDRUID	D02RQU-D0GY5Z
D02RQU-D0GY5Z	DRUGNAME	Aspirin + Pravastatin
D02RQU-D0GY5Z	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved

D03HCZ-D0GY5Z	TTDDRUID	D03HCZ-D0GY5Z
D03HCZ-D0GY5Z	DRUGNAME	Aspirin + Propoxyphene
D03HCZ-D0GY5Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0GY5Z-D0WF7L	TTDDRUID	D0GY5Z-D0WF7L
D0GY5Z-D0WF7L	DRUGNAME	Aspirin + Ticagrelor
D0GY5Z-D0WF7L	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D07IQS-D0S9SD	TTDDRUID	D07IQS-D0S9SD
D07IQS-D0S9SD	DRUGNAME	atazanavir + emtricitabine
D07IQS-D0S9SD	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4

D07IQS-D0I1FQ	TTDDRUID	D07IQS-D0I1FQ
D07IQS-D0I1FQ	DRUGNAME	Atazanavir + Raltegravir
D07IQS-D0I1FQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D07IQS-D0ZU9R	TTDDRUID	D07IQS-D0ZU9R
D07IQS-D0ZU9R	DRUGNAME	atazanavir + ritonavir
D07IQS-D0ZU9R	INDICATI	HIV-associated lipodystrophy [ICD-11: 1C62.1] Phase 4

D07IQS-D0D9HW	TTDDRUID	D07IQS-D0D9HW
D07IQS-D0D9HW	DRUGNAME	atazanavir + tenofovir
D07IQS-D0D9HW	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4

D01UXC-D09NIA	TTDDRUID	D01UXC-D09NIA
D01UXC-D09NIA	DRUGNAME	Atenolol + Chlorthalidone
D01UXC-D09NIA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D01UXC-D07UHS	TTDDRUID	D01UXC-D07UHS
D01UXC-D07UHS	DRUGNAME	Atenolol + Fingolimod
D01UXC-D07UHS	INDICATI	Irregular heartbeats [ICD-11: MC81] Investigative

D01UXC-D0DD0K	TTDDRUID	D01UXC-D0DD0K
D01UXC-D0DD0K	DRUGNAME	Atenolol + Losartan
D01UXC-D0DD0K	INDICATI	Marfan syndrome [ICD-11: LD28.01] Phase 2

D0SH3I-D0T8MA	TTDDRUID	D0SH3I-D0T8MA
D0SH3I-D0T8MA	DRUGNAME	atn-224 + bortezomib
D0SH3I-D0T8MA	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D01QIN-D0N0TZ	TTDDRUID	D01QIN-D0N0TZ
D01QIN-D0N0TZ	DRUGNAME	Atorvastatin + Clopidogrel
D01QIN-D0N0TZ	INDICATI	Chronic/stable angina [ICD-11: BA40.1] Phase 4

D01QIN-D09LWS	TTDDRUID	D01QIN-D09LWS
D01QIN-D09LWS	DRUGNAME	Atorvastatin + Ezetimibe
D01QIN-D09LWS	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4

D01QIN-D0L8PH	TTDDRUID	D01QIN-D0L8PH
D01QIN-D0L8PH	DRUGNAME	Atorvastatin + Interferon beta 1
D01QIN-D0L8PH	INDICATI	Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 2

D01QIN-D02FXU	TTDDRUID	D01QIN-D02FXU
D01QIN-D02FXU	DRUGNAME	Atorvastatin + Lapaquistat acetate
D01QIN-D02FXU	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2

D01QIN-D0PS6X	TTDDRUID	D01QIN-D0PS6X
D01QIN-D0PS6X	DRUGNAME	Atorvastatin + Lovaza
D01QIN-D0PS6X	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3

D01QIN-D0P8RS	TTDDRUID	D01QIN-D0P8RS
D01QIN-D0P8RS	DRUGNAME	Atorvastatin + Proguanil
D01QIN-D0P8RS	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D01QIN-D0JE2E	TTDDRUID	D01QIN-D0JE2E
D01QIN-D0JE2E	DRUGNAME	Atorvastatin + Rosuvastatin
D01QIN-D0JE2E	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3

D01QIN-D0H0ND	TTDDRUID	D01QIN-D0H0ND
D01QIN-D0H0ND	DRUGNAME	Atorvastatin + Simvastatin
D01QIN-D0H0ND	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
D01QIN-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4

D01QIN-D07GDN	TTDDRUID	D01QIN-D07GDN
D01QIN-D07GDN	DRUGNAME	Atorvastatin + Torcetrapib
D01QIN-D07GDN	INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical

D06ZEE-D0P8RS	TTDDRUID	D06ZEE-D0P8RS
D06ZEE-D0P8RS	DRUGNAME	Atovaquone + Proguanil
D06ZEE-D0P8RS	INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative

D0J2TN-D0RG3O	TTDDRUID	D0J2TN-D0RG3O
D0J2TN-D0RG3O	DRUGNAME	Atropine + Diphenoxylate
D0J2TN-D0RG3O	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0RG3O-D0S5LH	TTDDRUID	D0RG3O-D0S5LH
D0RG3O-D0S5LH	DRUGNAME	Atropine + Edrophonium chloride
D0RG3O-D0S5LH	INDICATI	Myopathy [ICD-11: 8C7Y] Approved

D00UYE-D0RG3O	TTDDRUID	D00UYE-D0RG3O
D00UYE-D0RG3O	DRUGNAME	Atropine + Meperidine
D00UYE-D0RG3O	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0RG3O-D0X7NU	TTDDRUID	D0RG3O-D0X7NU
D0RG3O-D0X7NU	DRUGNAME	Atropine + Pralidoxime
D0RG3O-D0X7NU	INDICATI	Organophosphorous disease [ICD-11: PB33] Approved

D0K5CB-D0S0AS	TTDDRUID	D0K5CB-D0S0AS
D0K5CB-D0S0AS	DRUGNAME	atrovent hfa + albuterol hfa
D0K5CB-D0S0AS	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D03UBW-D07POC	TTDDRUID	D03UBW-D07POC
D03UBW-D07POC	DRUGNAME	av-299 + erlotinib
D03UBW-D07POC	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D03UBW-D07POC	INDICATI	Malignant solid tumour [ICD-11: 2C10-2F32] Phase 1
D03UBW-D07POC	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D03UBW-D09XZB	TTDDRUID	D03UBW-D09XZB
D03UBW-D09XZB	DRUGNAME	av-299 + gefitinib
D03UBW-D09XZB	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D01ZRI-D0K3QS	TTDDRUID	D01ZRI-D0K3QS
D01ZRI-D0K3QS	DRUGNAME	axitinib + everolimus
D01ZRI-D0K3QS	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D01ZRI-D03UVS	TTDDRUID	D01ZRI-D03UVS
D01ZRI-D03UVS	DRUGNAME	Axitinib + Gemcitabine
D01ZRI-D03UVS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
D01ZRI-D03UVS	INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 3

D01ZRI-D04JPJ	TTDDRUID	D01ZRI-D04JPJ
D01ZRI-D04JPJ	DRUGNAME	axitinib + lomustine
D01ZRI-D04JPJ	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D09FAZ-D0Q5NX	TTDDRUID	D09FAZ-D0Q5NX
D09FAZ-D0Q5NX	DRUGNAME	Azacitidine + Lenalidomide
D09FAZ-D0Q5NX	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2
D09FAZ-D0Q5NX	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
D09FAZ-D0Q5NX	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D01PZD-D09FAZ	TTDDRUID	D01PZD-D09FAZ
D01PZD-D09FAZ	DRUGNAME	Azacitidine + Romiplostim
D01PZD-D09FAZ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D09FAZ-D0W5HK	TTDDRUID	D09FAZ-D0W5HK
D09FAZ-D0W5HK	DRUGNAME	Azacitidine + Sorafenib
D09FAZ-D0W5HK	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D09FAZ-D0C8EU	TTDDRUID	D09FAZ-D0C8EU
D09FAZ-D0C8EU	DRUGNAME	azacitidine + temozolomide
D09FAZ-D0C8EU	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
D09FAZ-D0C8EU	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 1

D00HHS-D0N7AD	TTDDRUID	D00HHS-D0N7AD
D00HHS-D0N7AD	DRUGNAME	Azatadine maleate + Pseudoephedrine
D00HHS-D0N7AD	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D07QCE-D0PG5G	TTDDRUID	D07QCE-D0PG5G
D07QCE-D0PG5G	DRUGNAME	Azathioprine + Infliximab
D07QCE-D0PG5G	INDICATI	Crohn disease [ICD-11: DD70] Phase 3
D07QCE-D0PG5G	INDICATI	Crohn disease [ICD-11: DD70] Phase 4

D07QCE-D0D1SG	TTDDRUID	D07QCE-D0D1SG
D07QCE-D0D1SG	DRUGNAME	Azathioprine + Prednisolone
D07QCE-D0D1SG	INDICATI	Lupus [ICD-11: 4A40] Phase 3

D00WUF-D0I6ZO	TTDDRUID	D00WUF-D0I6ZO
D00WUF-D0I6ZO	DRUGNAME	azd5213 + pregabalin
D00WUF-D0I6ZO	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2

D07POC-D0T5DP	TTDDRUID	D07POC-D0T5DP
D07POC-D0T5DP	DRUGNAME	azd6244 + erlotinib
D07POC-D0T5DP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0H9DA-D0X7HM	TTDDRUID	D0H9DA-D0X7HM
D0H9DA-D0X7HM	DRUGNAME	azd6738 + carboplatin
D0H9DA-D0X7HM	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0H9DA-D0X7HM	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0H9DA-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0H9DA-D0X7HM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04RRZ-D0H9DA	TTDDRUID	D04RRZ-D0H9DA
D04RRZ-D0H9DA	DRUGNAME	azd6738 + medi4736
D04RRZ-D0H9DA	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D04RRZ-D0H9DA	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D04RRZ-D0H9DA	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D04RRZ-D0H9DA	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0H9DA-D0J9HW	TTDDRUID	D0H9DA-D0J9HW
D0H9DA-D0J9HW	DRUGNAME	azd6738 + olaparib
D0H9DA-D0J9HW	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0H9DA-D0J9HW	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D0H9DA-D0J9HW	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0H9DA-D0J9HW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00JVR-D0LC6K	TTDDRUID	D00JVR-D0LC6K
D00JVR-D0LC6K	DRUGNAME	azelastine + fluticasone
D00JVR-D0LC6K	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 4
D00JVR-D0LC6K	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Approved

D00JVR-D03HYX	TTDDRUID	D00JVR-D03HYX
D00JVR-D03HYX	DRUGNAME	Azelastine + Mometasone
D00JVR-D03HYX	INDICATI	Perennial allergic rhinitis [ICD-11: CA08.03] Phase 3

D05FGG-D09NIA	TTDDRUID	D05FGG-D09NIA
D05FGG-D09NIA	DRUGNAME	Azilsartan + Chlorthalidone
D05FGG-D09NIA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03HJK-D0PH5Z	TTDDRUID	D03HJK-D0PH5Z
D03HJK-D0PH5Z	DRUGNAME	Azithromycin + Ceftazidime
D03HJK-D0PH5Z	INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical

D03HJK-D09EGZ	TTDDRUID	D03HJK-D09EGZ
D03HJK-D09EGZ	DRUGNAME	azithromycin + chloroquine
D03HJK-D09EGZ	INDICATI	Asymptomatic parasitemia in pregnancy [ICD-11: JB65.Y] Phase 3
D03HJK-D09EGZ	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2/3

D03HJK-D0H3TD	TTDDRUID	D03HJK-D0H3TD
D03HJK-D0H3TD	DRUGNAME	Azithromycin + Imipenem
D03HJK-D0H3TD	INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical

D03HJK-D09UZO	TTDDRUID	D03HJK-D09UZO
D03HJK-D09UZO	DRUGNAME	Azithromycin + Mercaptopurine
D03HJK-D09UZO	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical

D03HJK-D0A2ZX	TTDDRUID	D03HJK-D0A2ZX
D03HJK-D0A2ZX	DRUGNAME	azithromycin + metronidazole
D03HJK-D0A2ZX	INDICATI	Crohn disease [ICD-11: DD70] Phase 4

D03HJK-D0P0SZ	TTDDRUID	D03HJK-D0P0SZ
D03HJK-D0P0SZ	DRUGNAME	azithromycin + piperaquine phosphate
D03HJK-D0P0SZ	INDICATI	Clinical efficacy [ICD-11: N.A.] Phase 4
D03HJK-D0P0SZ	INDICATI	Drug kinetics [ICD-11: N.A.] Phase 4
D03HJK-D0P0SZ	INDICATI	Pregnancy [ICD-11: JA00-JA02] Phase 4

D03HJK-D0G3DL	TTDDRUID	D03HJK-D0G3DL
D03HJK-D0G3DL	DRUGNAME	Azithromycin + Rifampin
D03HJK-D0G3DL	INDICATI	Reactive arthritis [ICD-11: FA12.Y] Phase 3

D03HJK-D03WPA	TTDDRUID	D03HJK-D03WPA
D03HJK-D03WPA	DRUGNAME	Azithromycin + Trovafloxacin mesylate
D03HJK-D03WPA	INDICATI	Endocervical gonorrhea [ICD-11: 1A7Z] Approved

D04OKJ-D0F2XV	TTDDRUID	D04OKJ-D0F2XV
D04OKJ-D0F2XV	DRUGNAME	Aztreonam + Garenoxacin
D04OKJ-D0F2XV	INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Preclinical

D0B1IV-D0F2XV	TTDDRUID	D0B1IV-D0F2XV
D0B1IV-D0F2XV	DRUGNAME	Aztreonam + Vancomycin
D0B1IV-D0F2XV	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3

D09OOV-D0M1IO	TTDDRUID	D09OOV-D0M1IO
D09OOV-D0M1IO	DRUGNAME	Bacitracin + Polymyxin B Sulfate
D09OOV-D0M1IO	INDICATI	Ocular infection [ICD-11: 1F00.1] Approved

D06SBB-D0T6DK	TTDDRUID	D06SBB-D0T6DK
D06SBB-D0T6DK	DRUGNAME	Basiliximab + Rapamycin
D06SBB-D0T6DK	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 2/3

D06OMK-D06SBB	TTDDRUID	D06OMK-D06SBB
D06OMK-D06SBB	DRUGNAME	Basiliximab + Tacrolimus
D06OMK-D06SBB	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 2/3

D0C9SY-D0D3PB	TTDDRUID	D0C9SY-D0D3PB
D0C9SY-D0D3PB	DRUGNAME	bay60-4552 + vardenafil
D0C9SY-D0D3PB	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 2

D0JY8T-D0T0LU	TTDDRUID	D0JY8T-D0T0LU
D0JY8T-D0T0LU	DRUGNAME	Bazedoxifene + Conjugated Estrogen
D0JY8T-D0T0LU	INDICATI	Moderate-to-severe vasomotor symptom [ICD-11: CA08] Approved

D04KJO-D07DVK	TTDDRUID	D04KJO-D07DVK
D04KJO-D07DVK	DRUGNAME	Beclomethasone + Formoterol
D04KJO-D07DVK	INDICATI	Asthma [ICD-11: CA23] Investigative
D04KJO-D07DVK	INDICATI	Asthma [ICD-11: CA23] Phase 2
D04KJO-D07DVK	INDICATI	Asthma [ICD-11: CA23] Phase 3
D04KJO-D07DVK	INDICATI	Bronchial asthma [ICD-11: CA23] Phase 4

D00MVM-D07DVK	TTDDRUID	D00MVM-D07DVK
D00MVM-D07DVK	DRUGNAME	Beclomethasone + Salbutamol
D00MVM-D07DVK	INDICATI	Asthma [ICD-11: CA23] Phase 3

D07DVK-D0L5YV	TTDDRUID	D07DVK-D0L5YV
D07DVK-D0L5YV	DRUGNAME	Beclomethasone + Salmeterol
D07DVK-D0L5YV	INDICATI	Asthma [ICD-11: CA23] Phase 3

D02AYL-D0Y4QG	TTDDRUID	D02AYL-D0Y4QG
D02AYL-D0Y4QG	DRUGNAME	Bedaquiline + PA-824
D02AYL-D0Y4QG	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Phase 2

D0XF8W-D0Y4QG	TTDDRUID	D0XF8W-D0Y4QG
D0XF8W-D0Y4QG	DRUGNAME	Bedaquiline + Pyrazinamide
D0XF8W-D0Y4QG	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Phase 2

D0U3EC-D0U4UQ	TTDDRUID	D0U3EC-D0U4UQ
D0U3EC-D0U4UQ	DRUGNAME	Benazepril + Hydrochlorothiazide
D0U3EC-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D0U3EC-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D01CYA-D0E6XR	TTDDRUID	D01CYA-D0E6XR
D01CYA-D0E6XR	DRUGNAME	bendamustine + dasatinib
D01CYA-D0E6XR	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D02PAH-D05SHK	TTDDRUID	D02PAH-D05SHK
D02PAH-D05SHK	DRUGNAME	Bendroflumethiazide + Nadolol
D02PAH-D05SHK	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04DXN-D0R0ZL	TTDDRUID	D04DXN-D0R0ZL
D04DXN-D0R0ZL	DRUGNAME	Benzoyl peroxide + Clindamycin
D04DXN-D0R0ZL	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D02YIZ-D04DXN	TTDDRUID	D02YIZ-D04DXN
D02YIZ-D04DXN	DRUGNAME	Benzoyl peroxide + Erythromycin
D02YIZ-D04DXN	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D04DXN-D0BM5G	TTDDRUID	D04DXN-D0BM5G
D04DXN-D0BM5G	DRUGNAME	benzoyl peroxide + tazarotene
D04DXN-D0BM5G	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D09XQF-D0W0VD	TTDDRUID	D09XQF-D0W0VD
D09XQF-D0W0VD	DRUGNAME	Beta-lapachone + Isoniazid
D09XQF-D0W0VD	INDICATI	Non-tuberculous mycobacteria [ICD-11: 1B21] Preclinical

D01QUS-D0CW1P	TTDDRUID	D01QUS-D0CW1P
D01QUS-D0CW1P	DRUGNAME	Betamethasone + Calcipotriol
D01QUS-D0CW1P	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved

D09GOS-D0CW1P	TTDDRUID	D09GOS-D0CW1P
D09GOS-D0CW1P	DRUGNAME	Betamethasone + Clotrimazole
D09GOS-D0CW1P	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D03ROX-D09NIA	TTDDRUID	D03ROX-D09NIA
D03ROX-D09NIA	DRUGNAME	Betaxolol hydrochloride + Chlorthalidone
D03ROX-D09NIA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03ROX-D06HLY	TTDDRUID	D03ROX-D06HLY
D03ROX-D06HLY	DRUGNAME	Betaxolol hydrochloride + Pilocarpine
D03ROX-D06HLY	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D00HCQ-D04KBL	TTDDRUID	D00HCQ-D04KBL
D00HCQ-D04KBL	DRUGNAME	Bevacizumab + Capecitabine
D00HCQ-D04KBL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D00HCQ-D04KBL	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D04KBL-D0N5OV	TTDDRUID	D04KBL-D0N5OV
D04KBL-D0N5OV	DRUGNAME	Bevacizumab + Cetuximab
D04KBL-D0N5OV	INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative

D04KBL-D0S1ZB	TTDDRUID	D04KBL-D0S1ZB
D04KBL-D0S1ZB	DRUGNAME	Bevacizumab + Fotemustine
D04KBL-D0S1ZB	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D04KBL-D09PMV	TTDDRUID	D04KBL-D09PMV
D04KBL-D09PMV	DRUGNAME	Bevacizumab + Interferon alfa-2a
D04KBL-D09PMV	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D04KBL-D07BVI	TTDDRUID	D04KBL-D07BVI
D04KBL-D07BVI	DRUGNAME	bevacizumab + ipilimumab
D04KBL-D07BVI	INDICATI	Melanoma [ICD-11: 2C30] Phase 1

D04KBL-D08CDI	TTDDRUID	D04KBL-D08CDI
D04KBL-D08CDI	DRUGNAME	Bevacizumab + Lapatinib
D04KBL-D08CDI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04KBL-D0C4RB	TTDDRUID	D04KBL-D0C4RB
D04KBL-D0C4RB	DRUGNAME	Bevacizumab + Paclitaxel
D04KBL-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
D04KBL-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D04KBL-D0Y4GO	TTDDRUID	D04KBL-D0Y4GO
D04KBL-D0Y4GO	DRUGNAME	bevacizumab + pemetrexed
D04KBL-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D04KBL-D0R0MW	TTDDRUID	D04KBL-D0R0MW
D04KBL-D0R0MW	DRUGNAME	Bevacizumab + Sunitinib
D04KBL-D0R0MW	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
D04KBL-D0R0MW	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative

D04KBL-D0ES1Q	TTDDRUID	D04KBL-D0ES1Q
D04KBL-D0ES1Q	DRUGNAME	Bevacizumab + Temsirolimus
D04KBL-D0ES1Q	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D08SKH-D0N0RU	TTDDRUID	D08SKH-D0N0RU
D08SKH-D0N0RU	DRUGNAME	Bexarotene + Methoxsalen
D08SKH-D0N0RU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3

D0C4LF-D0VG0D	TTDDRUID	D0C4LF-D0VG0D
D0C4LF-D0VG0D	DRUGNAME	bez235 + mek162
D0C4LF-D0VG0D	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0C4RB-D0VG0D	TTDDRUID	D0C4RB-D0VG0D
D0C4RB-D0VG0D	DRUGNAME	bez235 + paclitaxel
D0C4RB-D0VG0D	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D0C4RB-D0VG0D	INDICATI	Metastatic or locally advanced solid tumour [ICD-11: 2D50-2E2Z] Phase 1

D04WFL-D0VG0D	TTDDRUID	D04WFL-D0VG0D
D04WFL-D0VG0D	DRUGNAME	bez235 + trastuzumab
D04WFL-D0VG0D	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D06FZS-D09JAR	TTDDRUID	D06FZS-D09JAR
D06FZS-D09JAR	DRUGNAME	Bicarbonate + Lactate
D06FZS-D09JAR	INDICATI	Chronic renal failure [ICD-11: GB61.Z] Phase 4

D05UVD-D0Q2XF	TTDDRUID	D05UVD-D0Q2XF
D05UVD-D0Q2XF	DRUGNAME	Bimatoprost + Timolol
D05UVD-D0Q2XF	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Investigative

D07IEF-D0IV3M	TTDDRUID	D07IEF-D0IV3M
D07IEF-D0IV3M	DRUGNAME	Bisacodyl + Polyethylene glycol
D07IEF-D0IV3M	INDICATI	Crohn disease [ICD-11: DD70] Phase 4

D0K3ZR-D0U4UQ	TTDDRUID	D0K3ZR-D0U4UQ
D0K3ZR-D0U4UQ	DRUGNAME	Bisoprolol + Hydrochlorothiazide
D0K3ZR-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D0K3ZR-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D0K3ZR-D0N6RF	TTDDRUID	D0K3ZR-D0N6RF
D0K3ZR-D0N6RF	DRUGNAME	Bisoprolol + Telmisartan
D0K3ZR-D0N6RF	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2/3

D01QSO-D08CDI	TTDDRUID	D01QSO-D08CDI
D01QSO-D08CDI	DRUGNAME	bkm120 + lapatinib
D01QSO-D08CDI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D01QSO-D0C4LF	TTDDRUID	D01QSO-D0C4LF
D01QSO-D0C4LF	DRUGNAME	bkm120 + mek162
D01QSO-D0C4LF	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01QSO-D0C4RB	TTDDRUID	D01QSO-D0C4RB
D01QSO-D0C4RB	DRUGNAME	bkm120 + paclitaxel
D01QSO-D0C4RB	INDICATI	Metastatic or locally advanced solid tumour [ICD-11: 2D50-2E2Z] Phase 1

D01QSO-D0C8EU	TTDDRUID	D01QSO-D0C8EU
D01QSO-D0C8EU	DRUGNAME	bkm120 + temozolomide
D01QSO-D0C8EU	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1

D0SH3I-D0U5HU	TTDDRUID	D0SH3I-D0U5HU
D0SH3I-D0U5HU	DRUGNAME	Bortezomib + Cisplatin
D0SH3I-D0U5HU	INDICATI	Ovarian cancer [ICD-11: 2C73] Preclinical

D0R5RR-D0SH3I	TTDDRUID	D0R5RR-D0SH3I
D0R5RR-D0SH3I	DRUGNAME	bortezomib + clofarabine
D0R5RR-D0SH3I	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
D0R5RR-D0SH3I	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1

D0SH3I-D0X5XU	TTDDRUID	D0SH3I-D0X5XU
D0SH3I-D0X5XU	DRUGNAME	Bortezomib + Decitabine
D0SH3I-D0X5XU	INDICATI	Adult acute myeloid leukaemia [ICD-11: 2A60.0] Phase 1

D07VLY-D0SH3I	TTDDRUID	D07VLY-D0SH3I
D07VLY-D0SH3I	DRUGNAME	Bortezomib + Doxorubicin
D07VLY-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0B7EB-D0SH3I	TTDDRUID	D0B7EB-D0SH3I
D0B7EB-D0SH3I	DRUGNAME	Bortezomib + Etoposide
D0B7EB-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Preclinical

D05ARP-D0SH3I	TTDDRUID	D05ARP-D0SH3I
D05ARP-D0SH3I	DRUGNAME	bortezomib + ganciclovir
D05ARP-D0SH3I	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D05ARP-D0SH3I	INDICATI	Lymphoproliferative disorder [ICD-11: 2B32] Phase 1

D01XDL-D0SH3I	TTDDRUID	D01XDL-D0SH3I
D01XDL-D0SH3I	DRUGNAME	Bortezomib + Idarubicin
D01XDL-D0SH3I	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1

D0Q5NX-D0SH3I	TTDDRUID	D0Q5NX-D0SH3I
D0Q5NX-D0SH3I	DRUGNAME	Bortezomib + Lenalidomide
D0Q5NX-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0SH3I-D0W4HZ	TTDDRUID	D0SH3I-D0W4HZ
D0SH3I-D0W4HZ	DRUGNAME	Bortezomib + Lonafarnib
D0SH3I-D0W4HZ	INDICATI	Multiple myeloma [ICD-11: 2A83] Preclinical

D09EXD-D0SH3I	TTDDRUID	D09EXD-D0SH3I
D09EXD-D0SH3I	DRUGNAME	bortezomib + rituximab
D09EXD-D0SH3I	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D04WFL-D0SH3I	TTDDRUID	D04WFL-D0SH3I
D04WFL-D0SH3I	DRUGNAME	Bortezomib + Trastuzumab
D04WFL-D0SH3I	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D0E7PQ-D0SH3I	TTDDRUID	D0E7PQ-D0SH3I
D0E7PQ-D0SH3I	DRUGNAME	Bortezomib + Vorinostat
D0E7PQ-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0E7PQ-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
D0E7PQ-D0SH3I	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D00SEB-D09LQK	TTDDRUID	D00SEB-D09LQK
D00SEB-D09LQK	DRUGNAME	BQ-123 + Enalapril
D00SEB-D09LQK	INDICATI	Hypertension [ICD-11: BA00-BA04] Preclinical

D03TIS-D0B4IF	TTDDRUID	D03TIS-D0B4IF
D03TIS-D0B4IF	DRUGNAME	Brentuximab vedotin + Ketoconazole
D03TIS-D0B4IF	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 1

D03TIS-D0U6LM	TTDDRUID	D03TIS-D0U6LM
D03TIS-D0U6LM	DRUGNAME	Brentuximab vedotin + Midazolam
D03TIS-D0U6LM	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 1

D03TIS-D0G3DL	TTDDRUID	D03TIS-D0G3DL
D03TIS-D0G3DL	DRUGNAME	Brentuximab vedotin + Rifampin
D03TIS-D0G3DL	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 1

D01MUR-D0AE3X	TTDDRUID	D01MUR-D0AE3X
D01MUR-D0AE3X	DRUGNAME	Brimonidine + Brinzolamide
D01MUR-D0AE3X	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved

D0AE3X-D0C6NM	TTDDRUID	D0AE3X-D0C6NM
D0AE3X-D0C6NM	DRUGNAME	Brimonidine + Latanoprost
D0AE3X-D0C6NM	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 4

D05UVD-D0AE3X	TTDDRUID	D05UVD-D0AE3X
D05UVD-D0AE3X	DRUGNAME	Brimonidine + Timolol
D05UVD-D0AE3X	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
D05UVD-D0AE3X	INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
D05UVD-D0AE3X	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Phase 4
D05UVD-D0AE3X	INDICATI	Retina disorder [ICD-11: 9B70-9B7Z] Investigative

D01MUR-D0C6NM	TTDDRUID	D01MUR-D0C6NM
D01MUR-D0C6NM	DRUGNAME	Brinzolamide + Latanoprost
D01MUR-D0C6NM	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 4

D01MUR-D05UVD	TTDDRUID	D01MUR-D05UVD
D01MUR-D05UVD	DRUGNAME	Brinzolamide + Timolol
D01MUR-D05UVD	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Investigative

D0HS5V-D0N5OV	TTDDRUID	D0HS5V-D0N5OV
D0HS5V-D0N5OV	DRUGNAME	brivanib + cetuximab
D0HS5V-D0N5OV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D03DIG-D0Y5GK	TTDDRUID	D03DIG-D0Y5GK
D03DIG-D0Y5GK	DRUGNAME	Bromodiphenhydramine + Codeine
D03DIG-D0Y5GK	INDICATI	Common cold [ICD-11: CA00] Approved

D08VXO-D0O6IU	TTDDRUID	D08VXO-D0O6IU
D08VXO-D0O6IU	DRUGNAME	brompheniramine + phenylephrine
D08VXO-D0O6IU	INDICATI	Nasal congestion [ICD-11: MD11.9] Phase 3
D08VXO-D0O6IU	INDICATI	Rhinitis [ICD-11: FA20] Phase 3

D00HHS-D08VXO	TTDDRUID	D00HHS-D08VXO
D00HHS-D08VXO	DRUGNAME	brompheniramine + pseudoephedrine
D00HHS-D08VXO	INDICATI	Nasal congestion [ICD-11: MD11.9] Phase 3
D00HHS-D08VXO	INDICATI	Rhinitis [ICD-11: FA20] Phase 3

D0IK5F-D0X7HM	TTDDRUID	D0IK5F-D0X7HM
D0IK5F-D0X7HM	DRUGNAME	bsi-201 + carboplatin
D0IK5F-D0X7HM	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D03UVS-D0IK5F	TTDDRUID	D03UVS-D0IK5F
D03UVS-D0IK5F	DRUGNAME	bsi-201 + gemcitabine
D03UVS-D0IK5F	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D0C4RB-D0IK5F	TTDDRUID	D0C4RB-D0IK5F
D0C4RB-D0IK5F	DRUGNAME	bsi-201 + paclitaxel
D0C4RB-D0IK5F	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D0C8EU-D0IK5F	TTDDRUID	D0C8EU-D0IK5F
D0C8EU-D0IK5F	DRUGNAME	bsi-201 + temozolomide
D0C8EU-D0IK5F	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D02PMO-D0IK5F	TTDDRUID	D02PMO-D0IK5F
D02PMO-D0IK5F	DRUGNAME	bsi-201 + topotecan
D02PMO-D0IK5F	INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1

D04KJO-D0Y7IU	TTDDRUID	D04KJO-D0Y7IU
D04KJO-D0Y7IU	DRUGNAME	Budesonide + Formoterol
D04KJO-D0Y7IU	INDICATI	Asthma [ICD-11: CA23] Approved
D04KJO-D0Y7IU	INDICATI	Asthma [ICD-11: CA23] Phase 3
D04KJO-D0Y7IU	INDICATI	Bronchiectasis [ICD-11: CA24] Investigative
D04KJO-D0Y7IU	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D06YYD-D0Y7IU	TTDDRUID	D06YYD-D0Y7IU
D06YYD-D0Y7IU	DRUGNAME	Budesonide + Lansoprazole
D06YYD-D0Y7IU	INDICATI	Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2

D0M8RC-D0Y7IU	TTDDRUID	D0M8RC-D0Y7IU
D0M8RC-D0Y7IU	DRUGNAME	Budesonide + Terbutaline
D0M8RC-D0Y7IU	INDICATI	Asthma [ICD-11: CA23] Phase 2
D0M8RC-D0Y7IU	INDICATI	Asthma [ICD-11: CA23] Phase 3

D04PHC-D0A0FL	TTDDRUID	D04PHC-D0A0FL
D04PHC-D0A0FL	DRUGNAME	Bupivacaine + Epinephrine
D04PHC-D0A0FL	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D04JHN-D0A0FL	TTDDRUID	D04JHN-D0A0FL
D04JHN-D0A0FL	DRUGNAME	Bupivacaine + Hydromorphone
D04JHN-D0A0FL	INDICATI	Postoperative ileus [ICD-11: DA91-DB30] Phase 3

D0A0FL-D0X4RN	TTDDRUID	D0A0FL-D0X4RN
D0A0FL-D0X4RN	DRUGNAME	Bupivacaine + Lidocaine
D0A0FL-D0X4RN	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0A0FL-D0WE3O	TTDDRUID	D0A0FL-D0WE3O
D0A0FL-D0WE3O	DRUGNAME	bupivacaine + morphine
D0A0FL-D0WE3O	INDICATI	Vasoplegia [ICD-11: BE10] Phase 1

D06AWE-D0X3FX	TTDDRUID	D06AWE-D0X3FX
D06AWE-D0X3FX	DRUGNAME	Buprenorphine + Naloxone
D06AWE-D0X3FX	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved
D06AWE-D0X3FX	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 4

D06AWE-D0PG8O	TTDDRUID	D06AWE-D0PG8O
D06AWE-D0PG8O	DRUGNAME	Buprenorphine + Naltrexone
D06AWE-D0PG8O	INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2/3
D06AWE-D0PG8O	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D08RBC-D0X4ZR	TTDDRUID	D08RBC-D0X4ZR
D08RBC-D0X4ZR	DRUGNAME	Bupropion + Escitalopram
D08RBC-D0X4ZR	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D0PG8O-D0X4ZR	TTDDRUID	D0PG8O-D0X4ZR
D0PG8O-D0X4ZR	DRUGNAME	Bupropion + Naltrexone
D0PG8O-D0X4ZR	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D0T8GD-D0X4ZR	TTDDRUID	D0T8GD-D0X4ZR
D0T8GD-D0X4ZR	DRUGNAME	bupropion + nicotine gum
D0T8GD-D0X4ZR	INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 4

D04GSY-D0J0LI	TTDDRUID	D04GSY-D0J0LI
D04GSY-D0J0LI	DRUGNAME	Buserelin + Pregnyl
D04GSY-D0J0LI	INDICATI	Ovarian hyperstimulation [ICD-11: GA32.0] Phase 4

D00FGO-D07SUG	TTDDRUID	D00FGO-D07SUG
D00FGO-D07SUG	DRUGNAME	Busulfan + Melphalan
D00FGO-D07SUG	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0C4LF-D0W7HE	TTDDRUID	D0C4LF-D0W7HE
D0C4LF-D0W7HE	DRUGNAME	byl719 + mek162
D0C4LF-D0W7HE	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2
D0C4LF-D0W7HE	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
D0C4LF-D0W7HE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D02HSB-D0IL7L	TTDDRUID	D02HSB-D0IL7L
D02HSB-D0IL7L	DRUGNAME	Cabazitaxel + Prednisone
D02HSB-D0IL7L	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 3

D01TSI-D0B3HD	TTDDRUID	D01TSI-D0B3HD
D01TSI-D0B3HD	DRUGNAME	Caffeine + Ergotamine
D01TSI-D0B3HD	INDICATI	Vascular headache [ICD-11: 8A84.Y] Approved

D01QUS-D0FL5V	TTDDRUID	D01QUS-D0FL5V
D01QUS-D0FL5V	DRUGNAME	Calcipotriol + Clobetasol
D01QUS-D0FL5V	INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 4

D03UVS-D0T2PL	TTDDRUID	D03UVS-D0T2PL
D03UVS-D0T2PL	DRUGNAME	calcitriol + gemcitabine
D03UVS-D0T2PL	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0PA5S-D0PJ4K	TTDDRUID	D0PA5S-D0PJ4K
D0PA5S-D0PJ4K	DRUGNAME	Calcium carbonate + Risedronate
D0PA5S-D0PJ4K	INDICATI	Osteoporosis [ICD-11: FB83.0] Approved

D08DFX-D0D7LA	TTDDRUID	D08DFX-D0D7LA
D08DFX-D0D7LA	DRUGNAME	Canagliflozin + Metformin
D08DFX-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0D7LA-D0TD2G	TTDDRUID	D0D7LA-D0TD2G
D0D7LA-D0TD2G	DRUGNAME	Canakinumab + Metformin
D0D7LA-D0TD2G	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3

D00SEB-D0D5SQ	TTDDRUID	D00SEB-D0D5SQ
D00SEB-D0D5SQ	DRUGNAME	Candesartan + Enalapril
D00SEB-D0D5SQ	INDICATI	Chronic renal failure [ICD-11: GB61.Z] Phase 4

D0D5SQ-D0U4UQ	TTDDRUID	D0D5SQ-D0U4UQ
D0D5SQ-D0U4UQ	DRUGNAME	Candesartan + Hydrochlorothiazide
D0D5SQ-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D0D5SQ-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
D0D5SQ-D0U4UQ	INDICATI	Stage II hypertension [ICD-11: BA00.Z] Phase 4

D0D5SQ-D0D7LA	TTDDRUID	D0D5SQ-D0D7LA
D0D5SQ-D0D7LA	DRUGNAME	candesartan + metformin
D0D5SQ-D0D7LA	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4
D0D5SQ-D0D7LA	INDICATI	Obesity [ICD-11: 5B81] Phase 4

D04OSE-D0D5SQ	TTDDRUID	D04OSE-D0D5SQ
D04OSE-D0D5SQ	DRUGNAME	Candesartan + Nifedipine
D04OSE-D0D5SQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D01STB-D0D5SQ	TTDDRUID	D01STB-D0D5SQ
D01STB-D0D5SQ	DRUGNAME	Candesartan + Ramipril
D01STB-D0D5SQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D07VLY-D0A9SA	TTDDRUID	D07VLY-D0A9SA
D07VLY-D0A9SA	DRUGNAME	Canfosfamide + Doxorubicin
D07VLY-D0A9SA	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D00HCQ-D0CT9C	TTDDRUID	D00HCQ-D0CT9C
D00HCQ-D0CT9C	DRUGNAME	Capecitabine + Cyclophosphamide
D00HCQ-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00HCQ-D0O5WP	TTDDRUID	D00HCQ-D0O5WP
D00HCQ-D0O5WP	DRUGNAME	Capecitabine + Docetaxel
D00HCQ-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D00HCQ-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D00HCQ-D0I6VU	TTDDRUID	D00HCQ-D0I6VU
D00HCQ-D0I6VU	DRUGNAME	Capecitabine + Enzastaurin
D00HCQ-D0I6VU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00HCQ-D07POC	TTDDRUID	D00HCQ-D07POC
D00HCQ-D07POC	DRUGNAME	capecitabine + erlotinib
D00HCQ-D07POC	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D00HCQ-D0I1QI	TTDDRUID	D00HCQ-D0I1QI
D00HCQ-D0I1QI	DRUGNAME	capecitabine + ganetespib
D00HCQ-D0I1QI	INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Phase 1

D00HCQ-D0AZ3C	TTDDRUID	D00HCQ-D0AZ3C
D00HCQ-D0AZ3C	DRUGNAME	Capecitabine + Imatinib
D00HCQ-D0AZ3C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D00HCQ-D07HOB	TTDDRUID	D00HCQ-D07HOB
D00HCQ-D07HOB	DRUGNAME	Capecitabine + Irinotecan
D00HCQ-D07HOB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D00HCQ-D0W2EK	TTDDRUID	D00HCQ-D0W2EK
D00HCQ-D0W2EK	DRUGNAME	Capecitabine + Ixabepilone
D00HCQ-D0W2EK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00HCQ-D08CDI	TTDDRUID	D00HCQ-D08CDI
D00HCQ-D08CDI	DRUGNAME	Capecitabine + Lapatinib
D00HCQ-D08CDI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00HCQ-D0Y3ME	TTDDRUID	D00HCQ-D0Y3ME
D00HCQ-D0Y3ME	DRUGNAME	Capecitabine + Oxaliplatin
D00HCQ-D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D00HCQ-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D00HCQ-D0Y3ME	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2

D00HCQ-D0C4RB	TTDDRUID	D00HCQ-D0C4RB
D00HCQ-D0C4RB	DRUGNAME	Capecitabine + Paclitaxel
D00HCQ-D0C4RB	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2

D00HCQ-D0W5HK	TTDDRUID	D00HCQ-D0W5HK
D00HCQ-D0W5HK	DRUGNAME	Capecitabine + Sorafenib
D00HCQ-D0W5HK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00HCQ-D0R0MW	TTDDRUID	D00HCQ-D0R0MW
D00HCQ-D0R0MW	DRUGNAME	Capecitabine + Sunitinib
D00HCQ-D0R0MW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0I0EG-D0U4UQ	TTDDRUID	D0I0EG-D0U4UQ
D0I0EG-D0U4UQ	DRUGNAME	Captopril + Hydrochlorothiazide
D0I0EG-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00JAU-D0I0EG	TTDDRUID	D00JAU-D0I0EG
D00JAU-D0I0EG	DRUGNAME	Captopril + Irbesartan
D00JAU-D0I0EG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D09QEI-D0I0EG	TTDDRUID	D09QEI-D0I0EG
D09QEI-D0I0EG	DRUGNAME	captopril + pentoxifylline
D09QEI-D0I0EG	INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2/3

D04MSM-D0J0ZS	TTDDRUID	D04MSM-D0J0ZS
D04MSM-D0J0ZS	DRUGNAME	Carbamazepine + Gabapentin
D04MSM-D0J0ZS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D03FLC-D04MSM	TTDDRUID	D03FLC-D04MSM
D03FLC-D04MSM	DRUGNAME	Carbamazepine + Lamotrigine
D03FLC-D04MSM	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical
D03FLC-D04MSM	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2/3

D04MSM-D0O2EM	TTDDRUID	D04MSM-D0O2EM
D04MSM-D0O2EM	DRUGNAME	Carbamazepine + Nevirapine
D04MSM-D0O2EM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D04MSM-D07VDZ	TTDDRUID	D04MSM-D07VDZ
D04MSM-D07VDZ	DRUGNAME	Carbamazepine + Topiramate
D04MSM-D07VDZ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D08HVR-D0P7JZ	TTDDRUID	D08HVR-D0P7JZ
D08HVR-D0P7JZ	DRUGNAME	Carbidopa + Levodopa
D08HVR-D0P7JZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
D08HVR-D0P7JZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 4

D03RTS-D0X7HM	TTDDRUID	D03RTS-D0X7HM
D03RTS-D0X7HM	DRUGNAME	carboplatin + celecoxib
D03RTS-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0O5WP-D0X7HM	TTDDRUID	D0O5WP-D0X7HM
D0O5WP-D0X7HM	DRUGNAME	Carboplatin + Docetaxel
D0O5WP-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0B7EB-D0X7HM	TTDDRUID	D0B7EB-D0X7HM
D0B7EB-D0X7HM	DRUGNAME	Carboplatin + Etoposide
D0B7EB-D0X7HM	INDICATI	Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 1
D0B7EB-D0X7HM	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D0B7EB-D0X7HM	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0B7EB-D0X7HM	INDICATI	High-risk medulloblastoma [ICD-11: 2A00.10] Phase 1/2
D0B7EB-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0B7EB-D0X7HM	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1
D0B7EB-D0X7HM	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0B7EB-D0X7HM	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0B7EB-D0X7HM	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
D0B7EB-D0X7HM	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1

D03UVS-D0X7HM	TTDDRUID	D03UVS-D0X7HM
D03UVS-D0X7HM	DRUGNAME	Carboplatin + Gemcitabine
D03UVS-D0X7HM	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
D03UVS-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0X7HM-D0Y4GO	TTDDRUID	D0X7HM-D0Y4GO
D0X7HM-D0Y4GO	DRUGNAME	Carboplatin + Pemetrexed
D0X7HM-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0X7HM-D0Y4GO	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0K5ER-D0X7HM	TTDDRUID	D0K5ER-D0X7HM
D0K5ER-D0X7HM	DRUGNAME	Carboplatin + Rosiglitazone
D0K5ER-D0X7HM	INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical

D0W5HK-D0X7HM	TTDDRUID	D0W5HK-D0X7HM
D0W5HK-D0X7HM	DRUGNAME	Carboplatin + Sorafenib
D0W5HK-D0X7HM	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3

D04WFL-D0X7HM	TTDDRUID	D04WFL-D0X7HM
D04WFL-D0X7HM	DRUGNAME	Carboplatin + Trastuzumab
D04WFL-D0X7HM	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Preclinical

D09VAZ-D0X7HM	TTDDRUID	D09VAZ-D0X7HM
D09VAZ-D0X7HM	DRUGNAME	Carboplatin + Trientine
D09VAZ-D0X7HM	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1

D06WUK-D0O5WP	TTDDRUID	D06WUK-D0O5WP
D06WUK-D0O5WP	DRUGNAME	carlumab + docetaxel
D06WUK-D0O5WP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0S0HA-D01OXI	TTDDRUID	D0S0HA-D01OXI
D0S0HA-D01OXI	DRUGNAME	Carmustine + O6-benzylguanine
D0S0HA-D01OXI	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D00SEB-D0W9LX	TTDDRUID	D00SEB-D0W9LX
D00SEB-D0W9LX	DRUGNAME	Carvedilol + Enalapril
D00SEB-D0W9LX	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D00ZGA-D0O5WP	TTDDRUID	D00ZGA-D0O5WP
D00ZGA-D0O5WP	DRUGNAME	Casopitant + Docetaxel
D00ZGA-D0O5WP	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 1

D04JPJ-D09VMI	TTDDRUID	D04JPJ-D09VMI
D04JPJ-D09VMI	DRUGNAME	Cediranib + Lomustine
D04JPJ-D09VMI	INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3

D09VMI-D0J9HW	TTDDRUID	D09VMI-D0J9HW
D09VMI-D0J9HW	DRUGNAME	Cediranib + Olaparib
D09VMI-D0J9HW	INDICATI	ER-negative breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D09KDN-D0PH5Z	TTDDRUID	D09KDN-D0PH5Z
D09KDN-D0PH5Z	DRUGNAME	cefazolin + ceftazidime
D09KDN-D0PH5Z	INDICATI	Peritoneal dialysis associated peritonitis [ICD-11: DC50.1Y] Phase 4

D04OKJ-D0A1CB	TTDDRUID	D04OKJ-D0A1CB
D04OKJ-D0A1CB	DRUGNAME	Cefepime + Garenoxacin
D04OKJ-D0A1CB	INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Preclinical

D0G7SR-D0Z1ZM	TTDDRUID	D0G7SR-D0Z1ZM
D0G7SR-D0Z1ZM	DRUGNAME	Ceftaroline fosamil + Clarithromycin
D0G7SR-D0Z1ZM	INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Phase 3

D0A2ZX-D0PH5Z	TTDDRUID	D0A2ZX-D0PH5Z
D0A2ZX-D0PH5Z	DRUGNAME	Ceftazidime + Metronidazole
D0A2ZX-D0PH5Z	INDICATI	Intra-abdominal infection [ICD-11: 1A40] Phase 2

D04NXQ-D0PH5Z	TTDDRUID	D04NXQ-D0PH5Z
D04NXQ-D0PH5Z	DRUGNAME	Ceftazidime + Pefloxacin
D04NXQ-D0PH5Z	INDICATI	Comamonas testosteroni [ICD-11: 5A81] Preclinical

D03IUD-D0QQ7D	TTDDRUID	D03IUD-D0QQ7D
D03IUD-D0QQ7D	DRUGNAME	Ceftolozane Sulfate + Tazobactam Sodium
D03IUD-D0QQ7D	INDICATI	Intra-abdominal infection [ICD-11: 1A40] Approved
D03IUD-D0QQ7D	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D07ACT-D0Z1ZM	TTDDRUID	D07ACT-D0Z1ZM
D07ACT-D0Z1ZM	DRUGNAME	Ceftriaxone + Clarithromycin
D07ACT-D0Z1ZM	INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Phase 3

D07ACT-D0Q1MS	TTDDRUID	D07ACT-D0Q1MS
D07ACT-D0Q1MS	DRUGNAME	Ceftriaxone + Ertapenem
D07ACT-D0Q1MS	INDICATI	Pyogenic liver abscess [ICD-11: DB90.0] Investigative

D02RSN-D07ACT	TTDDRUID	D02RSN-D07ACT
D02RSN-D07ACT	DRUGNAME	Ceftriaxone + Levofloxacin
D02RSN-D07ACT	INDICATI	Pneumonia [ICD-11: CA40] Phase 3

D07ACT-D0X4RN	TTDDRUID	D07ACT-D0X4RN
D07ACT-D0X4RN	DRUGNAME	Ceftriaxone + Lidocaine
D07ACT-D0X4RN	INDICATI	Arrhythmia [ICD-11: BC9Z] Approved

D07ACT-D07UYO	TTDDRUID	D07ACT-D07UYO
D07ACT-D07UYO	DRUGNAME	Ceftriaxone + Linezolid
D07ACT-D07UYO	INDICATI	Pneumonia [ICD-11: CA40] Phase 3

D07ACT-D0A2ZX	TTDDRUID	D07ACT-D0A2ZX
D07ACT-D0A2ZX	DRUGNAME	Ceftriaxone + Metronidazole
D07ACT-D0A2ZX	INDICATI	Appendicitis [ICD-11: DB10] Phase 4
D07ACT-D0A2ZX	INDICATI	Intra-abdominal infection [ICD-11: 1A40] Phase 3

D07ACT-D0MB8I	TTDDRUID	D07ACT-D0MB8I
D07ACT-D0MB8I	DRUGNAME	Ceftriaxone + Oxacillin
D07ACT-D0MB8I	INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 4

D0A2ZX-D0Y2IE	TTDDRUID	D0A2ZX-D0Y2IE
D0A2ZX-D0Y2IE	DRUGNAME	cefuroxime + metronidazole
D0A2ZX-D0Y2IE	INDICATI	Infection prophylaxis in colorectal surgery [ICD-11: DB33] Phase 4

D03RTS-D0U7OU	TTDDRUID	D03RTS-D0U7OU
D03RTS-D0U7OU	DRUGNAME	Celecoxib + Emodin
D03RTS-D0U7OU	INDICATI	Liver cancer [ICD-11: 2C12] Preclinical

D03RTS-D0R1VU	TTDDRUID	D03RTS-D0R1VU
D03RTS-D0R1VU	DRUGNAME	Celecoxib + Perifosine
D03RTS-D0R1VU	INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical

D0S9SD-D0YQ7U	TTDDRUID	D0S9SD-D0YQ7U
D0S9SD-D0YQ7U	DRUGNAME	cenicriviroc + truvada
D0S9SD-D0YQ7U	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0YV1Q-D0Z5EM	TTDDRUID	D0YV1Q-D0Z5EM
D0YV1Q-D0Z5EM	DRUGNAME	Cephalexin + Kanamycin
D0YV1Q-D0Z5EM	INDICATI	Escherichia coli infection [ICD-11: 1A03] Preclinical
D0YV1Q-D0Z5EM	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Preclinical
D0YV1Q-D0Z5EM	INDICATI	Streptococcus infection [ICD-11: 1B53] Preclinical

D03KIA-D05VIX	TTDDRUID	D03KIA-D05VIX
D03KIA-D05VIX	DRUGNAME	Cerivastatin + Gemfibrozil
D03KIA-D05VIX	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Preclinical

D03ZFG-D08HVR	TTDDRUID	D03ZFG-D08HVR
D03ZFG-D08HVR	DRUGNAME	Cerulenin + Levodopa
D03ZFG-D08HVR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical

D00HHS-D0DK8V	TTDDRUID	D00HHS-D0DK8V
D00HHS-D0DK8V	DRUGNAME	Cetirizine + Pseudoephedrine
D00HHS-D0DK8V	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved

D09OLZ-D0C1WH	TTDDRUID	D09OLZ-D0C1WH
D09OLZ-D0C1WH	DRUGNAME	Cetrorelix acetate + Letrozole
D09OLZ-D0C1WH	INDICATI	Infertility [ICD-11: GB04] Phase 2

D0N5OV-D0O5WP	TTDDRUID	D0N5OV-D0O5WP
D0N5OV-D0O5WP	DRUGNAME	Cetuximab + Docetaxel
D0N5OV-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D07POC-D0N5OV	TTDDRUID	D07POC-D0N5OV
D07POC-D0N5OV	DRUGNAME	cetuximab + erlotinib
D07POC-D0N5OV	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1

D05LEO-D0N5OV	TTDDRUID	D05LEO-D0N5OV
D05LEO-D0N5OV	DRUGNAME	Cetuximab + Fluorouracil
D05LEO-D0N5OV	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Investigative

D09XZB-D0N5OV	TTDDRUID	D09XZB-D0N5OV
D09XZB-D0N5OV	DRUGNAME	cetuximab + gefitinib
D09XZB-D0N5OV	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D03UVS-D0N5OV	TTDDRUID	D03UVS-D0N5OV
D03UVS-D0N5OV	DRUGNAME	Cetuximab + Gemcitabine
D03UVS-D0N5OV	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D07HOB-D0N5OV	TTDDRUID	D07HOB-D0N5OV
D07HOB-D0N5OV	DRUGNAME	cetuximab + irinotecan
D07HOB-D0N5OV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0N5OV-D0R3JB	TTDDRUID	D0N5OV-D0R3JB
D0N5OV-D0R3JB	DRUGNAME	Cetuximab + Mitoxantrone
D0N5OV-D0R3JB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0C4RB-D0N5OV	TTDDRUID	D0C4RB-D0N5OV
D0C4RB-D0N5OV	DRUGNAME	Cetuximab + Paclitaxel
D0C4RB-D0N5OV	INDICATI	Urethral cancer [ICD-11: 2C93] Phase 2

D09EXD-D0V8QT	TTDDRUID	D09EXD-D0V8QT
D09EXD-D0V8QT	DRUGNAME	Chlorambucil + Rituximab
D09EXD-D0V8QT	INDICATI	Mucosa-associated lymphoid tissue lymphoma [ICD-11: 2A85.1] Phase 3

D0KR5B-D0X6IU	TTDDRUID	D0KR5B-D0X6IU
D0KR5B-D0X6IU	DRUGNAME	Chloramphenicol + Hydrocortisone
D0KR5B-D0X6IU	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved

D09OOV-D0X6IU	TTDDRUID	D09OOV-D0X6IU
D09OOV-D0X6IU	DRUGNAME	Chloramphenicol + Polymyxin B Sulfate
D09OOV-D0X6IU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0D1SG-D0X6IU	TTDDRUID	D0D1SG-D0X6IU
D0D1SG-D0X6IU	DRUGNAME	Chloramphenicol + Prednisolone
D0D1SG-D0X6IU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06BEP-D0R6RE	TTDDRUID	D06BEP-D0R6RE
D06BEP-D0R6RE	DRUGNAME	Chlordiazepoxide + Estrogens, esterified
D06BEP-D0R6RE	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D0W7LK-D0V4GY	TTDDRUID	D0W7LK-D0V4GY
D0W7LK-D0V4GY	DRUGNAME	Chlorhexidine + Isopropyl alcohol
D0W7LK-D0V4GY	INDICATI	Preparation of the patient's skin prior to surgery [ICD-11: N.A.] Approved

D0V4GY-D0X4RN	TTDDRUID	D0V4GY-D0X4RN
D0V4GY-D0X4RN	DRUGNAME	Chlorhexidine + Lidocaine
D0V4GY-D0X4RN	INDICATI	Pharyngitis [ICD-11: CA02.Z] Phase 3

D09EGZ-D0T1LK	TTDDRUID	D09EGZ-D0T1LK
D09EGZ-D0T1LK	DRUGNAME	Chloroquine + Primaquine
D09EGZ-D0T1LK	INDICATI	High blood pressure [ICD-11: BA00] Approved
D09EGZ-D0T1LK	INDICATI	Plasmodium vivax malaria without complication [ICD-11: 1F41] Phase 3

D0J4JM-D0M9WM	TTDDRUID	D0J4JM-D0M9WM
D0J4JM-D0M9WM	DRUGNAME	Chlorothiazide + Reserpine
D0J4JM-D0M9WM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03DIG-D0B7NG	TTDDRUID	D03DIG-D0B7NG
D03DIG-D0B7NG	DRUGNAME	Chlorpheniramine + Codeine
D03DIG-D0B7NG	INDICATI	Nasal congestion [ICD-11: MD11.9] Approved

D0B7NG-D0X5KF	TTDDRUID	D0B7NG-D0X5KF
D0B7NG-D0X5KF	DRUGNAME	Chlorpheniramine + Hydrocodone
D0B7NG-D0X5KF	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
D0B7NG-D0X5KF	INDICATI	Bronchitis [ICD-11: CA20] Approved
D0B7NG-D0X5KF	INDICATI	Common cold [ICD-11: CA00] Approved
D0B7NG-D0X5KF	INDICATI	Hay fever [ICD-11: CA08.00] Approved
D0B7NG-D0X5KF	INDICATI	Sinusitis [ICD-11: CA0A.Z] Approved

D0B7NG-D0P6UB	TTDDRUID	D0B7NG-D0P6UB
D0B7NG-D0P6UB	DRUGNAME	Chlorpheniramine + Methamphetamine
D0B7NG-D0P6UB	INDICATI	Nasal congestion [ICD-11: MD11.9] Preclinical

D09JXM-D0B7NG	TTDDRUID	D09JXM-D0B7NG
D09JXM-D0B7NG	DRUGNAME	Chlorpheniramine + Phenylpropanolamine
D09JXM-D0B7NG	INDICATI	Common cold [ICD-11: CA00] Approved

D00HHS-D0B7NG	TTDDRUID	D00HHS-D0B7NG
D00HHS-D0B7NG	DRUGNAME	Chlorpheniramine + Pseudoephedrine
D00HHS-D0B7NG	INDICATI	Nasal congestion [ICD-11: MD11.9] Approved
D00HHS-D0B7NG	INDICATI	Rhinorrhea [ICD-11: CA0Y] Approved
D00HHS-D0B7NG	INDICATI	Sinus pressure [ICD-11: NF04.1] Approved

D03SKR-D09NIA	TTDDRUID	D03SKR-D09NIA
D03SKR-D09NIA	DRUGNAME	Chlorthalidone + Clonidine
D03SKR-D09NIA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09NIA-D0I2MK	TTDDRUID	D09NIA-D0I2MK
D09NIA-D0I2MK	DRUGNAME	Chlorthalidone + Metoprolol
D09NIA-D0I2MK	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09NIA-D0J4JM	TTDDRUID	D09NIA-D0J4JM
D09NIA-D0J4JM	DRUGNAME	Chlorthalidone + Reserpine
D09NIA-D0J4JM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0K5WS-D0R6CD	TTDDRUID	D0K5WS-D0R6CD
D0K5WS-D0R6CD	DRUGNAME	Cholecalciferol + Insulin glargine
D0K5WS-D0R6CD	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3

D0B7CH-D0K5WS	TTDDRUID	D0B7CH-D0K5WS
D0B7CH-D0K5WS	DRUGNAME	Cholecalciferol + Phenylbutyrate sodium
D0B7CH-D0K5WS	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Phase 2

D0K0TC-D0K5WS	TTDDRUID	D0K0TC-D0K5WS
D0K0TC-D0K5WS	DRUGNAME	Cholecalciferol + Sertraline
D0K0TC-D0K5WS	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3

D02HYK-D07NSU	TTDDRUID	D02HYK-D07NSU
D02HYK-D07NSU	DRUGNAME	chondroitin sulfate + glucosamine sulfate
D02HYK-D07NSU	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3

D0B9BU-D0T6DK	TTDDRUID	D0B9BU-D0T6DK
D0B9BU-D0T6DK	DRUGNAME	CI-1040 + Rapamycin
D0B9BU-D0T6DK	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Preclinical

D02GIU-D0H3TD	TTDDRUID	D02GIU-D0H3TD
D02GIU-D0H3TD	DRUGNAME	Cilastatin + Imipenem
D02GIU-D0H3TD	INDICATI	Serious infection of mild to moderate severity caused by certain bacteria [ICD-11: 1H0Z] Approved

D03VPC-D0H2DQ	TTDDRUID	D03VPC-D0H2DQ
D03VPC-D0H2DQ	DRUGNAME	cilostazol + probucol
D03VPC-D0H2DQ	INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Phase 4

D01KPV-D02DPA	TTDDRUID	D01KPV-D02DPA
D01KPV-D02DPA	DRUGNAME	Cimetidine + Fexofenadine
D01KPV-D02DPA	INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative

D03YGR-D0N1TP	TTDDRUID	D03YGR-D0N1TP
D03YGR-D0N1TP	DRUGNAME	Cinacalcet + Paricalcitol
D03YGR-D0N1TP	INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 4

D0O1WX-D0IT2G	TTDDRUID	D0O1WX-D0IT2G
D0O1WX-D0IT2G	DRUGNAME	Ciprofloxacin + Dexamethasone
D0O1WX-D0IT2G	INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Approved

D03CQE-D0O1WX	TTDDRUID	D03CQE-D0O1WX
D03CQE-D0O1WX	DRUGNAME	Ciprofloxacin + Gatifloxacin
D03CQE-D0O1WX	INDICATI	Pseudomonas infection [ICD-11: 1B92] Preclinical

D0O1WX-D0KR5B	TTDDRUID	D0O1WX-D0KR5B
D0O1WX-D0KR5B	DRUGNAME	Ciprofloxacin + Hydrocortisone
D0O1WX-D0KR5B	INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Approved

D0O1WX-D0A2ZX	TTDDRUID	D0O1WX-D0A2ZX
D0O1WX-D0A2ZX	DRUGNAME	ciprofloxacin + metronidazole
D0O1WX-D0A2ZX	INDICATI	Chronic periodontitis [ICD-11: DA0C.Y] Phase 4

D0O1WX-D0L7FM	TTDDRUID	D0O1WX-D0L7FM
D0O1WX-D0L7FM	DRUGNAME	Ciprofloxacin + Probenecid
D0O1WX-D0L7FM	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative

D0O1WX-D07BCT	TTDDRUID	D0O1WX-D07BCT
D0O1WX-D07BCT	DRUGNAME	Ciprofloxacin + Tobramycin
D0O1WX-D07BCT	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D0O1WX-D0AO5H	TTDDRUID	D0O1WX-D0AO5H
D0O1WX-D0AO5H	DRUGNAME	Ciprofloxacin + Trimethoprim
D0O1WX-D0AO5H	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Preclinical

D00HCQ-D0U5HU	TTDDRUID	D00HCQ-D0U5HU
D00HCQ-D0U5HU	DRUGNAME	cisplatin + capecitabine
D00HCQ-D0U5HU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0CT9C-D0U5HU	TTDDRUID	D0CT9C-D0U5HU
D0CT9C-D0U5HU	DRUGNAME	Cisplatin + Cyclophosphamide
D0CT9C-D0U5HU	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D07XSN-D0U5HU	TTDDRUID	D07XSN-D0U5HU
D07XSN-D0U5HU	DRUGNAME	Cisplatin + Cytarabine
D07XSN-D0U5HU	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D07VLY-D0U5HU	TTDDRUID	D07VLY-D0U5HU
D07VLY-D0U5HU	DRUGNAME	Cisplatin + Doxorubicin
D07VLY-D0U5HU	INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 2

D07POC-D0U5HU	TTDDRUID	D07POC-D0U5HU
D07POC-D0U5HU	DRUGNAME	Cisplatin + Erlotinib
D07POC-D0U5HU	INDICATI	Hypopharyngeal squamous cell carcinoma [ICD-11: 2B6D.0] Phase 2

D05LEO-D0U5HU	TTDDRUID	D05LEO-D0U5HU
D05LEO-D0U5HU	DRUGNAME	Cisplatin + Fluorouracil
D05LEO-D0U5HU	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 3
D05LEO-D0U5HU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03UVS-D0U5HU	TTDDRUID	D03UVS-D0U5HU
D03UVS-D0U5HU	DRUGNAME	Cisplatin + Gemcitabine
D03UVS-D0U5HU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
D03UVS-D0U5HU	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3
D03UVS-D0U5HU	INDICATI	Metastatic biliary tract neoplasms [ICD-11: 2C14-2C17] Phase 2
D03UVS-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D07HOB-D0U5HU	TTDDRUID	D07HOB-D0U5HU
D07HOB-D0U5HU	DRUGNAME	Cisplatin + Irinotecan
D07HOB-D0U5HU	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D0MW7S-D0U5HU	TTDDRUID	D0MW7S-D0U5HU
D0MW7S-D0U5HU	DRUGNAME	Cisplatin + Lexatumumab
D0MW7S-D0U5HU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0U5HU-D0Y3ME	TTDDRUID	D0U5HU-D0Y3ME
D0U5HU-D0Y3ME	DRUGNAME	Cisplatin + Oxaliplatin
D0U5HU-D0Y3ME	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0HU9H-D0U5HU	TTDDRUID	D0HU9H-D0U5HU
D0HU9H-D0U5HU	DRUGNAME	cisplatin + panitumumab
D0HU9H-D0U5HU	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D0U5HU-D0Y4GO	TTDDRUID	D0U5HU-D0Y4GO
D0U5HU-D0Y4GO	DRUGNAME	Cisplatin + Pemetrexed
D0U5HU-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D0U5HU-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D03YOS-D0U5HU	TTDDRUID	D03YOS-D0U5HU
D03YOS-D0U5HU	DRUGNAME	Cisplatin + Phenoxodiol
D03YOS-D0U5HU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D0U5HU-D0U5SI	TTDDRUID	D0U5HU-D0U5SI
D0U5HU-D0U5SI	DRUGNAME	Cisplatin + Procainamide
D0U5HU-D0U5SI	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical

D0T6DK-D0U5HU	TTDDRUID	D0T6DK-D0U5HU
D0T6DK-D0U5HU	DRUGNAME	Cisplatin + Rapamycin
D0T6DK-D0U5HU	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Investigative

D01UGG-D0U5HU	TTDDRUID	D01UGG-D0U5HU
D01UGG-D0U5HU	DRUGNAME	Cisplatin + Sabarubicin
D01UGG-D0U5HU	INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical

D0C8EU-D0U5HU	TTDDRUID	D0C8EU-D0U5HU
D0C8EU-D0U5HU	DRUGNAME	Cisplatin + Temozolomide
D0C8EU-D0U5HU	INDICATI	High-grade malignant glioma [ICD-11: 2A00.0] Preclinical

D02PMO-D0U5HU	TTDDRUID	D02PMO-D0U5HU
D02PMO-D0U5HU	DRUGNAME	Cisplatin + Topotecan
D02PMO-D0U5HU	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2

D03RTK-D0U5HU	TTDDRUID	D03RTK-D0U5HU
D03RTK-D0U5HU	DRUGNAME	Cisplatin + Trabectedin
D03RTK-D0U5HU	INDICATI	Ovarian cancer [ICD-11: 2C73] Preclinical
D03RTK-D0U5HU	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Preclinical

D04WFL-D0U5HU	TTDDRUID	D04WFL-D0U5HU
D04WFL-D0U5HU	DRUGNAME	Cisplatin + Trastuzumab
D04WFL-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D01HTL-D0U5HU	TTDDRUID	D01HTL-D0U5HU
D01HTL-D0U5HU	DRUGNAME	Cisplatin + Vinorelbine
D01HTL-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0TR5X-D0Y5DO	TTDDRUID	D0TR5X-D0Y5DO
D0TR5X-D0Y5DO	DRUGNAME	Citalopram + Fluoxetine
D0TR5X-D0Y5DO	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2/3

D00DBO-D0Y5DO	TTDDRUID	D00DBO-D0Y5DO
D00DBO-D0Y5DO	DRUGNAME	citalopram + pipamperone
D00DBO-D0Y5DO	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2

D02CFP-D0XN1F	TTDDRUID	D02CFP-D0XN1F
D02CFP-D0XN1F	DRUGNAME	Citicoline + Nimodipine
D02CFP-D0XN1F	INDICATI	Neuroprotective focal cerebral ischemia [ICD-11: 8B10-8B1Z] Preclinical

D09UZO-D0Z1ZM	TTDDRUID	D09UZO-D0Z1ZM
D09UZO-D0Z1ZM	DRUGNAME	Clarithromycin + Mercaptopurine
D09UZO-D0Z1ZM	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical

D0G3DL-D0Z1ZM	TTDDRUID	D0G3DL-D0Z1ZM
D0G3DL-D0Z1ZM	DRUGNAME	Clarithromycin + Rifampin
D0G3DL-D0Z1ZM	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical

D08USU-D0X7JN	TTDDRUID	D08USU-D0X7JN
D08USU-D0X7JN	DRUGNAME	Clavulanate + Ticarcillin
D08USU-D0X7JN	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02DGU-D0R0ZL	TTDDRUID	D02DGU-D0R0ZL
D02DGU-D0R0ZL	DRUGNAME	Clindamycin + Tretinoin
D02DGU-D0R0ZL	INDICATI	Nodular acne [ICD-11: ED80.3] Approved
D02DGU-D0R0ZL	INDICATI	Rosacea [ICD-11: ED90.0] Phase 2/3

D0BM5G-D0R0ZL	TTDDRUID	D0BM5G-D0R0ZL
D0BM5G-D0R0ZL	DRUGNAME	clindamycin gel + tazarotene cream
D0BM5G-D0R0ZL	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2

D06ABW-D08XAC	TTDDRUID	D06ABW-D08XAC
D06ABW-D08XAC	DRUGNAME	Clioquinol + Nystatin
D06ABW-D08XAC	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved

D0B4IF-D0FL5V	TTDDRUID	D0B4IF-D0FL5V
D0B4IF-D0FL5V	DRUGNAME	Clobetasol + Ketoconazole
D0B4IF-D0FL5V	INDICATI	Scalp seborrheic dermatitis [ICD-11: EA81.1] Phase 3

D07XSN-D0R5RR	TTDDRUID	D07XSN-D0R5RR
D07XSN-D0R5RR	DRUGNAME	Clofarabine + Cytarabine
D07XSN-D0R5RR	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2
D07XSN-D0R5RR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
D07XSN-D0R5RR	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D0CT9Y-D0D7LA	TTDDRUID	D0CT9Y-D0D7LA
D0CT9Y-D0D7LA	DRUGNAME	Clomifene + Metformin
D0CT9Y-D0D7LA	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 4

D0TR5X-D0ZS8P	TTDDRUID	D0TR5X-D0ZS8P
D0TR5X-D0ZS8P	DRUGNAME	Clomipramine + Fluoxetine
D0TR5X-D0ZS8P	INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Phase 4

D0CP4E-D0K0TC	TTDDRUID	D0CP4E-D0K0TC
D0CP4E-D0K0TC	DRUGNAME	Clonazepam + Sertraline
D0CP4E-D0K0TC	INDICATI	Panic disorder [ICD-11: 6B01] Phase 2/3

D03SKR-D0U3DU	TTDDRUID	D03SKR-D0U3DU
D03SKR-D0U3DU	DRUGNAME	Clonidine + Dexmedetomidine
D03SKR-D0U3DU	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0K3QS-D0N0TZ	TTDDRUID	D0K3QS-D0N0TZ
D0K3QS-D0N0TZ	DRUGNAME	Clopidogrel + Everolimus
D0K3QS-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4

D0C4RB-D0N0TZ	TTDDRUID	D0C4RB-D0N0TZ
D0C4RB-D0N0TZ	DRUGNAME	Clopidogrel + Paclitaxel
D0C4RB-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4

D07IRF-D0N0TZ	TTDDRUID	D07IRF-D0N0TZ
D07IRF-D0N0TZ	DRUGNAME	Clopidogrel + Prasugrel
D07IRF-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2

D0N0TZ-D0N6RF	TTDDRUID	D0N0TZ-D0N6RF
D0N0TZ-D0N6RF	DRUGNAME	Clopidogrel + Telmisartan
D0N0TZ-D0N6RF	INDICATI	Stroke [ICD-11: 8B20] Phase 4

D0N0TZ-D0V7WS	TTDDRUID	D0N0TZ-D0V7WS
D0N0TZ-D0V7WS	DRUGNAME	Clopidogrel + Zotarolimus
D0N0TZ-D0V7WS	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4

D09GOS-D0L9UU	TTDDRUID	D09GOS-D0L9UU
D09GOS-D0L9UU	DRUGNAME	clotrimazole + gentamicin
D09GOS-D0L9UU	INDICATI	Folliculitis [ICD-11: 1B74] Phase 2/3

D0TR5X-D0Z1RV	TTDDRUID	D0TR5X-D0Z1RV
D0TR5X-D0Z1RV	DRUGNAME	Clozapine + Fluoxetine
D0TR5X-D0Z1RV	INDICATI	Schizophrenia [ICD-11: 6A20] Investigative

D03HFG-D0Z1RV	TTDDRUID	D03HFG-D0Z1RV
D03HFG-D0Z1RV	DRUGNAME	clozapine + fluvoxamine
D03HFG-D0Z1RV	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 4

D03UVS-D06WUK	TTDDRUID	D03UVS-D06WUK
D03UVS-D06WUK	DRUGNAME	cnto888 + gemcitabine
D03UVS-D06WUK	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03DIG-D0T2XU	TTDDRUID	D03DIG-D0T2XU
D03DIG-D0T2XU	DRUGNAME	Codeine + Promethazine
D03DIG-D0T2XU	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
D03DIG-D0T2XU	INDICATI	Common cold [ICD-11: CA00] Approved
D03DIG-D0T2XU	INDICATI	Respiratory tract disease [ICD-11: CB7Z] Approved

D09DHY-D0L7FM	TTDDRUID	D09DHY-D0L7FM
D09DHY-D0L7FM	DRUGNAME	Colchicine + Probenecid
D09DHY-D0L7FM	INDICATI	Chronic gouty arthritis [ICD-11: FA25.0] Approved

D01YVT-D0D7LA	TTDDRUID	D01YVT-D0D7LA
D01YVT-D0D7LA	DRUGNAME	Colesevelam + Metformin
D01YVT-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0H3TD-D0K7NQ	TTDDRUID	D0H3TD-D0K7NQ
D0H3TD-D0K7NQ	DRUGNAME	Colistin + Imipenem
D0H3TD-D0K7NQ	INDICATI	Pneumonia due to Klebsiella pneumoniae [ICD-11: CA40.03] Preclinical

D0G4OD-D0K7NQ	TTDDRUID	D0G4OD-D0K7NQ
D0G4OD-D0K7NQ	DRUGNAME	Colistin + Tigecycline
D0G4OD-D0K7NQ	INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical

D0PQ3G-D0VU2X	TTDDRUID	D0PQ3G-D0VU2X
D0PQ3G-D0VU2X	DRUGNAME	Conivaptan + Furosemide
D0PQ3G-D0VU2X	INDICATI	Heart failure [ICD-11: BD10-BD13] Investigative

D0T0LU-D0Y4AW	TTDDRUID	D0T0LU-D0Y4AW
D0T0LU-D0Y4AW	DRUGNAME	Conjugated Estrogen + Meprobamate
D0T0LU-D0Y4AW	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D0BZ7W-D0T0LU	TTDDRUID	D0BZ7W-D0T0LU
D0BZ7W-D0T0LU	DRUGNAME	Conjugated Estrogen + Tolterodine
D0BZ7W-D0T0LU	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2/3

D0D6OH-D0U3DU	TTDDRUID	D0D6OH-D0U3DU
D0D6OH-D0U3DU	DRUGNAME	CP55940 + Dexmedetomidine
D0D6OH-D0U3DU	INDICATI	Acute pain [ICD-11: MG31] Preclinical

D0D6OH-D0WE3O	TTDDRUID	D0D6OH-D0WE3O
D0D6OH-D0WE3O	DRUGNAME	CP55940 + Morphine
D0D6OH-D0WE3O	INDICATI	Acute pain [ICD-11: MG31] Preclinical

D01ZRI-D03ZBT	TTDDRUID	D01ZRI-D03ZBT
D01ZRI-D03ZBT	DRUGNAME	crizotinib + axitinib
D01ZRI-D03ZBT	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D01ZRI-D03ZBT	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D01ZRI-D03ZBT	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D03ZBT-D04KBL	TTDDRUID	D03ZBT-D04KBL
D03ZBT-D04KBL	DRUGNAME	crizotinib + bevacizumab
D03ZBT-D04KBL	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D03ZBT-D04KBL	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D03ZBT-D04KBL	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D03ZBT-D0W5HK	TTDDRUID	D03ZBT-D0W5HK
D03ZBT-D0W5HK	DRUGNAME	crizotinib + sorafenib
D03ZBT-D0W5HK	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D03ZBT-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D03ZBT-D0W5HK	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D03ZBT-D0R0MW	TTDDRUID	D03ZBT-D0R0MW
D03ZBT-D0R0MW	DRUGNAME	crizotinib + sunitinib
D03ZBT-D0R0MW	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
D03ZBT-D0R0MW	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
D03ZBT-D0R0MW	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1

D02WSY-D0R0MW	TTDDRUID	D02WSY-D0R0MW
D02WSY-D0R0MW	DRUGNAME	cvx-060 + sunitinib
D02WSY-D0R0MW	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0B1EV-D0O6IU	TTDDRUID	D0B1EV-D0O6IU
D0B1EV-D0O6IU	DRUGNAME	Cyclopentolate + Phenylephrine
D0B1EV-D0O6IU	INDICATI	Mydriasis [ICD-11: LA11.62] Approved

D0C4RB-D0CT9C	TTDDRUID	D0C4RB-D0CT9C
D0C4RB-D0CT9C	DRUGNAME	Cyclophosphamide + Paclitaxel
D0C4RB-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0CT9C-D0Y4GO	TTDDRUID	D0CT9C-D0Y4GO
D0CT9C-D0Y4GO	DRUGNAME	Cyclophosphamide + Pemetrexed
D0CT9C-D0Y4GO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0CT9C-D0D1SG	TTDDRUID	D0CT9C-D0D1SG
D0CT9C-D0D1SG	DRUGNAME	Cyclophosphamide + Prednisolone
D0CT9C-D0D1SG	INDICATI	Lupus [ICD-11: 4A40] Phase 3

D04WFL-D0CT9C	TTDDRUID	D04WFL-D0CT9C
D04WFL-D0CT9C	DRUGNAME	Cyclophosphamide + Trastuzumab
D04WFL-D0CT9C	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Preclinical

D02WFK-D0U2BH	TTDDRUID	D02WFK-D0U2BH
D02WFK-D0U2BH	DRUGNAME	Cycloserine + Epigallocatechin
D02WFK-D0U2BH	INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Preclinical

D0O3YF-D0PG5G	TTDDRUID	D0O3YF-D0PG5G
D0O3YF-D0PG5G	DRUGNAME	Cyclosporine + Infliximab
D0O3YF-D0PG5G	INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 4

D0O3YF-D0T6DK	TTDDRUID	D0O3YF-D0T6DK
D0O3YF-D0T6DK	DRUGNAME	Cyclosporine + Rapamycin
D0O3YF-D0T6DK	INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
D0O3YF-D0T6DK	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 4

D0JE2E-D0O3YF	TTDDRUID	D0JE2E-D0O3YF
D0JE2E-D0O3YF	DRUGNAME	Cyclosporine + Rosuvastatin
D0JE2E-D0O3YF	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D06AEO-D08QMX	TTDDRUID	D06AEO-D08QMX
D06AEO-D08QMX	DRUGNAME	cyproterone acetate + estradiol
D06AEO-D08QMX	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Investigative

D06CTE-D08KAD	TTDDRUID	D06CTE-D08KAD
D06CTE-D08KAD	DRUGNAME	cyt004-melqbg10 + imiquimod
D06CTE-D08KAD	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D01XWG-D07XSN	TTDDRUID	D01XWG-D07XSN
D01XWG-D07XSN	DRUGNAME	Cytarabine + Daunorubicin
D01XWG-D07XSN	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 3
D01XWG-D07XSN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
D01XWG-D07XSN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D07XSN-D0AZ3C	TTDDRUID	D07XSN-D0AZ3C
D07XSN-D0AZ3C	DRUGNAME	Cytarabine + Imatinib
D07XSN-D0AZ3C	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 3

D01RNL-D07XSN	TTDDRUID	D01RNL-D07XSN
D01RNL-D07XSN	DRUGNAME	Cytarabine + Lintuzumab
D01RNL-D07XSN	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D05FWH-D07XSN	TTDDRUID	D05FWH-D07XSN
D05FWH-D07XSN	DRUGNAME	Cytarabine + SCH 900776
D05FWH-D07XSN	INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1

D07XSN-D0SC2J	TTDDRUID	D07XSN-D0SC2J
D07XSN-D0SC2J	DRUGNAME	Cytarabine + Tanespimycin
D07XSN-D0SC2J	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
D07XSN-D0SC2J	INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative

D07XSN-D0X1ZV	TTDDRUID	D07XSN-D0X1ZV
D07XSN-D0X1ZV	DRUGNAME	Cytarabine + Trimidox
D07XSN-D0X1ZV	INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical

D04XVN-D05ROI	TTDDRUID	D04XVN-D05ROI
D04XVN-D05ROI	DRUGNAME	dabrafenib + trametinib
D04XVN-D05ROI	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D07ISE-D0Y7ZU	TTDDRUID	D07ISE-D0Y7ZU
D07ISE-D0Y7ZU	DRUGNAME	dacarbazine + interferon alpha
D07ISE-D0Y7ZU	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D07BVI-D0Y7ZU	TTDDRUID	D07BVI-D0Y7ZU
D07BVI-D0Y7ZU	DRUGNAME	Dacarbazine + Ipilimumab
D07BVI-D0Y7ZU	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0C8EU-D0Y7ZU	TTDDRUID	D0C8EU-D0Y7ZU
D0C8EU-D0Y7ZU	DRUGNAME	Dacarbazine + Temozolomide
D0C8EU-D0Y7ZU	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D05AFC-D0E2OU	TTDDRUID	D05AFC-D0E2OU
D05AFC-D0E2OU	DRUGNAME	Dalfopristin + Quinupristin
D05AFC-D0E2OU	INDICATI	Staphylococci and vancomycin-resistant enterococcus faecium infection [ICD-11: 1A00-1A09] Approved

D01TNW-D0D7LA	TTDDRUID	D01TNW-D0D7LA
D01TNW-D0D7LA	DRUGNAME	Dapagliflozin + Metformin
D01TNW-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0JC9N-D0MA9N	TTDDRUID	D0JC9N-D0MA9N
D0JC9N-D0MA9N	DRUGNAME	dapsone + adapalene
D0JC9N-D0MA9N	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D04DXN-D0MA9N	TTDDRUID	D04DXN-D0MA9N
D04DXN-D0MA9N	DRUGNAME	dapsone + benzoyl peroxide
D04DXN-D0MA9N	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3

D05HPI-D0G3DL	TTDDRUID	D05HPI-D0G3DL
D05HPI-D0G3DL	DRUGNAME	Daptomycin + Rifampin
D05HPI-D0G3DL	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Preclinical

D03IGH-D0S9SD	TTDDRUID	D03IGH-D0S9SD
D03IGH-D0S9SD	DRUGNAME	darunavir + emtricitabine
D03IGH-D0S9SD	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4

D03IGH-D0ZU9R	TTDDRUID	D03IGH-D0ZU9R
D03IGH-D0ZU9R	DRUGNAME	Darunavir + Ritonavir
D03IGH-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D03IGH-D0D9HW	TTDDRUID	D03IGH-D0D9HW
D03IGH-D0D9HW	DRUGNAME	darunavir + tenofovir
D03IGH-D0D9HW	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4

D0E6XR-D0O5WP	TTDDRUID	D0E6XR-D0O5WP
D0E6XR-D0O5WP	DRUGNAME	Dasatinib + Docetaxel
D0E6XR-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2

D0AZ3C-D0E6XR	TTDDRUID	D0AZ3C-D0E6XR
D0AZ3C-D0E6XR	DRUGNAME	dasatinib + imatinib
D0AZ3C-D0E6XR	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 1

D07NVU-D0E6XR	TTDDRUID	D07NVU-D0E6XR
D07NVU-D0E6XR	DRUGNAME	Dasatinib + Midostaurin
D07NVU-D0E6XR	INDICATI	Mast cell leukaemia [ICD-11: 2A21.00] Preclinical

D0E6XR-D0Y3ME	TTDDRUID	D0E6XR-D0Y3ME
D0E6XR-D0Y3ME	DRUGNAME	Dasatinib + Oxaliplatin
D0E6XR-D0Y3ME	INDICATI	Colon cancer [ICD-11: 2B90.Z] Preclinical

D0C4RB-D0X5XU	TTDDRUID	D0C4RB-D0X5XU
D0C4RB-D0X5XU	DRUGNAME	Decitabine + Paclitaxel
D0C4RB-D0X5XU	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D01PZD-D0X5XU	TTDDRUID	D01PZD-D0X5XU
D01PZD-D0X5XU	DRUGNAME	Decitabine + Romiplostim
D01PZD-D0X5XU	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0Y3KG-D0X5XU	TTDDRUID	D0Y3KG-D0X5XU
D0Y3KG-D0X5XU	DRUGNAME	Decitabine + Valproic Acid
D0Y3KG-D0X5XU	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2

D09FAZ-D0Q5UQ	TTDDRUID	D09FAZ-D0Q5UQ
D09FAZ-D0Q5UQ	DRUGNAME	deferasirox + azacitidine
D09FAZ-D0Q5UQ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D0FJ8A-D0Q5UQ	TTDDRUID	D0FJ8A-D0Q5UQ
D0FJ8A-D0Q5UQ	DRUGNAME	Deferasirox + Deferoxamine
D0FJ8A-D0Q5UQ	INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 2
D0FJ8A-D0Q5UQ	INDICATI	Thalassemia [ICD-11: 3A50] Phase 1/2
D0FJ8A-D0Q5UQ	INDICATI	Thalassemia [ICD-11: 3A50] Phase 4

D0FJ8A-D0N0OU	TTDDRUID	D0FJ8A-D0N0OU
D0FJ8A-D0N0OU	DRUGNAME	Deferiprone + Deferoxamine
D0FJ8A-D0N0OU	INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 4

D08WSY-D0YA2L	TTDDRUID	D08WSY-D0YA2L
D08WSY-D0YA2L	DRUGNAME	Denosumab + Teriparatide
D08WSY-D0YA2L	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2

D09HDR-D0U4UQ	TTDDRUID	D09HDR-D0U4UQ
D09HDR-D0U4UQ	DRUGNAME	Deserpidine + Hydrochlorothiazide
D09HDR-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03GVC-D09HDR	TTDDRUID	D03GVC-D09HDR
D03GVC-D09HDR	DRUGNAME	Deserpidine + Methyclothiazide
D03GVC-D09HDR	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00HHS-D01GBY	TTDDRUID	D00HHS-D01GBY
D00HHS-D01GBY	DRUGNAME	Desloratadine + Pseudoephedrine
D00HHS-D01GBY	INDICATI	Hay fever [ICD-11: CA08.00] Approved

D06CGB-D06NXY	TTDDRUID	D06CGB-D06NXY
D06CGB-D06NXY	DRUGNAME	Desogestrel + Ethinyl Estradiol
D06CGB-D06NXY	INDICATI	Contraception [ICD-11: QA21] Approved

D0C5XC-D0IT2G	TTDDRUID	D0C5XC-D0IT2G
D0C5XC-D0IT2G	DRUGNAME	dexamethasone + clemastine
D0C5XC-D0IT2G	INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
D0C5XC-D0IT2G	INDICATI	Dermatitis [ICD-11: EA80-EA89] Phase 3

D0IT2G-D0Q5NX	TTDDRUID	D0IT2G-D0Q5NX
D0IT2G-D0Q5NX	DRUGNAME	Dexamethasone + Lenalidomide
D0IT2G-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
D0IT2G-D0Q5NX	INDICATI	Stage I multiple myeloma [ICD-11: 2A83] Phase 3

D0IT2G-D0X4RN	TTDDRUID	D0IT2G-D0X4RN
D0IT2G-D0X4RN	DRUGNAME	Dexamethasone + Lidocaine
D0IT2G-D0X4RN	INDICATI	Joint disease [ICD-11: FA5Z] Approved

D0IT2G-D05JNI	TTDDRUID	D0IT2G-D05JNI
D0IT2G-D05JNI	DRUGNAME	Dexamethasone + Neomycin
D0IT2G-D05JNI	INDICATI	Inflammatory ocular conditions [ICD-11: 9C20.2] Approved

D0A3ZU-D0IT2G	TTDDRUID	D0A3ZU-D0IT2G
D0A3ZU-D0IT2G	DRUGNAME	Dexamethasone + Pomalidomide
D0A3ZU-D0IT2G	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D09EXD-D0IT2G	TTDDRUID	D09EXD-D0IT2G
D09EXD-D0IT2G	DRUGNAME	Dexamethasone + Rituximab
D09EXD-D0IT2G	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3

D07BCT-D0IT2G	TTDDRUID	D07BCT-D0IT2G
D07BCT-D0IT2G	DRUGNAME	Dexamethasone + Tobramycin
D07BCT-D0IT2G	INDICATI	Conjunctivitis [ICD-11: 9A60] Phase 3
D07BCT-D0IT2G	INDICATI	Eye infection [ICD-11: 1A72] Approved
D07BCT-D0IT2G	INDICATI	Ocular tuberculosis [ICD-11: 1B12.1] Phase 4

D00HHS-D02WIW	TTDDRUID	D00HHS-D02WIW
D00HHS-D02WIW	DRUGNAME	Dexbrompheniramine + Pseudoephedrine
D00HHS-D02WIW	INDICATI	Sneezing [ICD-11: MD11.A] Approved

D0R5TA-D0U3DU	TTDDRUID	D0R5TA-D0U3DU
D0R5TA-D0U3DU	DRUGNAME	Dexmedetomidine + Endomorphin-1
D0R5TA-D0U3DU	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0T5OX-D0U3DU	TTDDRUID	D0T5OX-D0U3DU
D0T5OX-D0U3DU	DRUGNAME	dexmedetomidine + remifentanil
D0T5OX-D0U3DU	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 4

D02PPN-D0T3LF	TTDDRUID	D02PPN-D0T3LF
D02PPN-D0T3LF	DRUGNAME	Dextroamphetamine + Methylphenidate
D02PPN-D0T3LF	INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 4

D09OBB-D0T2XU	TTDDRUID	D09OBB-D0T2XU
D09OBB-D0T2XU	DRUGNAME	Dextromethorphan + Promethazine
D09OBB-D0T2XU	INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
D09OBB-D0T2XU	INDICATI	Common cold [ICD-11: CA00] Approved
D09OBB-D0T2XU	INDICATI	Hay fever [ICD-11: CA08.00] Approved
D09OBB-D0T2XU	INDICATI	Sinusitis [ICD-11: CA0A.Z] Approved

D03DDR-D09OBB	TTDDRUID	D03DDR-D09OBB
D03DDR-D09OBB	DRUGNAME	Dextromethorphan + Quinidine
D03DDR-D09OBB	INDICATI	Neurological disorder [ICD-11: 6B60] Approved

D09OBB-D09PNY	TTDDRUID	D09OBB-D09PNY
D09OBB-D09PNY	DRUGNAME	Dextromethorphan + Tropicamide
D09OBB-D09PNY	INDICATI	Mydriasis [ICD-11: LA11.62] Approved

D07JVL-D0E1WI	TTDDRUID	D07JVL-D0E1WI
D07JVL-D0E1WI	DRUGNAME	Diazepam + Fentanyl
D07JVL-D0E1WI	INDICATI	Hypertension [ICD-11: BA00-BA04] Preclinical

D00PLV-D07WEP	TTDDRUID	D00PLV-D07WEP
D00PLV-D07WEP	DRUGNAME	Diazoxide + Nitroprusside
D00PLV-D07WEP	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0T2PL-D0TG1H	TTDDRUID	D0T2PL-D0TG1H
D0T2PL-D0TG1H	DRUGNAME	diclofenac + calcitriol
D0T2PL-D0TG1H	INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 2

D0TG1H-D0X4RN	TTDDRUID	D0TG1H-D0X4RN
D0TG1H-D0X4RN	DRUGNAME	Diclofenac + Lidocaine
D0TG1H-D0X4RN	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
D0TG1H-D0X4RN	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D09ANG-D0TG1H	TTDDRUID	D09ANG-D0TG1H
D09ANG-D0TG1H	DRUGNAME	Diclofenac + Misoprostol
D09ANG-D0TG1H	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved

D01XNB-D0TG1H	TTDDRUID	D01XNB-D0TG1H
D01XNB-D0TG1H	DRUGNAME	Diclofenac + Omeprazole
D01XNB-D0TG1H	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4

D03DDR-D0TG1H	TTDDRUID	D03DDR-D0TG1H
D03DDR-D0TG1H	DRUGNAME	Diclofenac + Quinidine
D03DDR-D0TG1H	INDICATI	Arthritis [ICD-11: FA20] Preclinical
D03DDR-D0TG1H	INDICATI	Gout [ICD-11: FA25] Preclinical
D03DDR-D0TG1H	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D00BVS-D0TG1H	TTDDRUID	D00BVS-D0TG1H
D00BVS-D0TG1H	DRUGNAME	Diclofenac + Tanezumab
D00BVS-D0TG1H	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3

D08NQZ-D0TG1H	TTDDRUID	D08NQZ-D0TG1H
D08NQZ-D0TG1H	DRUGNAME	Diclofenac + Tetracycline
D08NQZ-D0TG1H	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D07VBA-D04CBI	TTDDRUID	D07VBA-D04CBI
D07VBA-D04CBI	DRUGNAME	Dienogest + Estradiol valerate
D07VBA-D04CBI	INDICATI	Contraception [ICD-11: QA21] Approved

D0N6FH-D0P0SZ	TTDDRUID	D0N6FH-D0P0SZ
D0N6FH-D0P0SZ	DRUGNAME	Dihydroartemisinin + Piperaquine
D0N6FH-D0P0SZ	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 3

D00SEB-D0OB1J	TTDDRUID	D00SEB-D0OB1J
D00SEB-D0OB1J	DRUGNAME	Diltiazem + Enalapril
D00SEB-D0OB1J	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07UHS-D0OB1J	TTDDRUID	D07UHS-D0OB1J
D07UHS-D0OB1J	DRUGNAME	Diltiazem + Fingolimod
D07UHS-D0OB1J	INDICATI	Irregular heartbeats [ICD-11: MC81] Investigative

D04XGU-D06UDG	TTDDRUID	D04XGU-D06UDG
D04XGU-D06UDG	DRUGNAME	diovan + crestor
D04XGU-D06UDG	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 3
D04XGU-D06UDG	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D01FGR-D0R1QE	TTDDRUID	D01FGR-D0R1QE
D01FGR-D0R1QE	DRUGNAME	Diphenhydramine + Ibuprofen
D01FGR-D0R1QE	INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved

D01FGR-D0DJ1B	TTDDRUID	D01FGR-D0DJ1B
D01FGR-D0DJ1B	DRUGNAME	Diphenhydramine + Naproxen
D01FGR-D0DJ1B	INDICATI	Occasional sleeplessness [ICD-11: 7A01] Approved

D00HHS-D01FGR	TTDDRUID	D00HHS-D01FGR
D00HHS-D01FGR	DRUGNAME	Diphenhydramine + Pseudoephedrine
D00HHS-D01FGR	INDICATI	Cough [ICD-11: MD12] Approved

D01FGR-D0ES1Q	TTDDRUID	D01FGR-D0ES1Q
D01FGR-D0ES1Q	DRUGNAME	Diphenhydramine + Temsirolimus
D01FGR-D0ES1Q	INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2

D01FGR-D0F8RA	TTDDRUID	D01FGR-D0F8RA
D01FGR-D0F8RA	DRUGNAME	Diphenhydramine + Theophylline
D01FGR-D0F8RA	INDICATI	Motion sickness [ICD-11: NF08.3] Approved
D01FGR-D0F8RA	INDICATI	Nausea [ICD-11: MD90] Approved

D0D1SG-D0F9GE	TTDDRUID	D0D1SG-D0F9GE
D0D1SG-D0F9GE	DRUGNAME	Dipyridamole + Prednisolone
D0D1SG-D0F9GE	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative

D0C4RB-D0FD2I	TTDDRUID	D0C4RB-D0FD2I
D0C4RB-D0FD2I	DRUGNAME	Discodermolide + Paclitaxel
D0C4RB-D0FD2I	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Preclinical

D0E0OG-D0X5SD	TTDDRUID	D0E0OG-D0X5SD
D0E0OG-D0X5SD	DRUGNAME	disulfiram + lorazepam
D0E0OG-D0X5SD	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 4
D0E0OG-D0X5SD	INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 4

D07MOX-D0J7RK	TTDDRUID	D07MOX-D0J7RK
D07MOX-D0J7RK	DRUGNAME	Dobutamine + Norepinephrine
D07MOX-D0J7RK	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2/3

D04KBL-D0O5WP	TTDDRUID	D04KBL-D0O5WP
D04KBL-D0O5WP	DRUGNAME	docetaxel + bevacizumab
D04KBL-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0O5WP-D0U5HU	TTDDRUID	D0O5WP-D0U5HU
D0O5WP-D0U5HU	DRUGNAME	docetaxel + cisplatin
D0O5WP-D0U5HU	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2/3
D0O5WP-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0G5CF-D0O5WP	TTDDRUID	D0G5CF-D0O5WP
D0G5CF-D0O5WP	DRUGNAME	docetaxel + doxercalciferol
D0G5CF-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D07VLY-D0O5WP	TTDDRUID	D07VLY-D0O5WP
D07VLY-D0O5WP	DRUGNAME	Docetaxel + Doxorubicin
D07VLY-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0C9XJ-D0O5WP	TTDDRUID	D0C9XJ-D0O5WP
D0C9XJ-D0O5WP	DRUGNAME	Docetaxel + Epirubicin
D0C9XJ-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D07POC-D0O5WP	TTDDRUID	D07POC-D0O5WP
D07POC-D0O5WP	DRUGNAME	Docetaxel + Erlotinib
D07POC-D0O5WP	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D07POC-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D09XZB-D0O5WP	TTDDRUID	D09XZB-D0O5WP
D09XZB-D0O5WP	DRUGNAME	Docetaxel + Gefitinib
D09XZB-D0O5WP	INDICATI	Metastatic squamous neck cancer [ICD-11: 2D60.0] Phase 3
D09XZB-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D03UVS-D0O5WP	TTDDRUID	D03UVS-D0O5WP
D03UVS-D0O5WP	DRUGNAME	Docetaxel + Gemcitabine
D03UVS-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D03UVS-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D03UVS-D0O5WP	INDICATI	Uterine cancer [ICD-11: 2C78] Investigative

D07HOB-D0O5WP	TTDDRUID	D07HOB-D0O5WP
D07HOB-D0O5WP	DRUGNAME	Docetaxel + Irinotecan
D07HOB-D0O5WP	INDICATI	Esophageal cancer [ICD-11: 2B70] Investigative

D0M9QZ-D0O5WP	TTDDRUID	D0M9QZ-D0O5WP
D0M9QZ-D0O5WP	DRUGNAME	Docetaxel + Linifanib
D0M9QZ-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0IL7L-D0O5WP	TTDDRUID	D0IL7L-D0O5WP
D0IL7L-D0O5WP	DRUGNAME	Docetaxel + Prednisone
D0IL7L-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
D0IL7L-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0O5WP-D0T5DP	TTDDRUID	D0O5WP-D0T5DP
D0O5WP-D0T5DP	DRUGNAME	docetaxel + selumetinib
D0O5WP-D0T5DP	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D04WFL-D0O5WP	TTDDRUID	D04WFL-D0O5WP
D04WFL-D0O5WP	DRUGNAME	Docetaxel + Trastuzumab
D04WFL-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D04WFL-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D05RHI-D0O5WP	TTDDRUID	D05RHI-D0O5WP
D05RHI-D0O5WP	DRUGNAME	Docetaxel + Trifluridine
D05RHI-D0O5WP	INDICATI	Colon cancer [ICD-11: 2B90.Z] Preclinical

D0G6QF-D0O5WP	TTDDRUID	D0G6QF-D0O5WP
D0G6QF-D0O5WP	DRUGNAME	Docetaxel + Vandetanib
D0G6QF-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D01HTL-D0O5WP	TTDDRUID	D01HTL-D0O5WP
D01HTL-D0O5WP	DRUGNAME	Docetaxel + Vinorelbine
D01HTL-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D02HVW-D0O5WP	TTDDRUID	D02HVW-D0O5WP
D02HVW-D0O5WP	DRUGNAME	Docetaxel + Zibotentan
D02HVW-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0B7YT-D0NS6H	TTDDRUID	D0B7YT-D0NS6H
D0B7YT-D0NS6H	DRUGNAME	donepezil + scopolamine
D0B7YT-D0NS6H	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1

D0PQ3G-D0T7OW	TTDDRUID	D0PQ3G-D0T7OW
D0PQ3G-D0T7OW	DRUGNAME	dopamine + furosemide
D0PQ3G-D0T7OW	INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 4

D0JE4D-D0P7EK	TTDDRUID	D0JE4D-D0P7EK
D0JE4D-D0P7EK	DRUGNAME	Dornase alfa + Mannitol
D0JE4D-D0P7EK	INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2

D05UVD-D05UYW	TTDDRUID	D05UVD-D05UYW
D05UVD-D05UYW	DRUGNAME	Dorzolamide + Timolol
D05UVD-D05UYW	INDICATI	High pressure inside the eye [ICD-11: 9C61] Approved
D05UVD-D05UYW	INDICATI	Open-angle glaucoma [ICD-11: 9C61] Phase 4

D07OZR-D0AZ3C	TTDDRUID	D07OZR-D0AZ3C
D07OZR-D0AZ3C	DRUGNAME	dovitinib + imatinib
D07OZR-D0AZ3C	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1

D07OZR-D0C4RB	TTDDRUID	D07OZR-D0C4RB
D07OZR-D0C4RB	DRUGNAME	dovitinib + paclitaxel
D07OZR-D0C4RB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03MIR-D0BZ7W	TTDDRUID	D03MIR-D0BZ7W
D03MIR-D0BZ7W	DRUGNAME	doxazosin + tolterodine
D03MIR-D0BZ7W	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Phase 4
D03MIR-D0BZ7W	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 4

D07VLY-D0CT9C	TTDDRUID	D07VLY-D0CT9C
D07VLY-D0CT9C	DRUGNAME	doxorubicin + cyclophosphamide
D07VLY-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
D07VLY-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D07VLY-D0D7LA	TTDDRUID	D07VLY-D0D7LA
D07VLY-D0D7LA	DRUGNAME	Doxorubicin + Metformin
D07VLY-D0D7LA	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical

D07VLY-D0Y0GH	TTDDRUID	D07VLY-D0Y0GH
D07VLY-D0Y0GH	DRUGNAME	Doxorubicin + Mitomycin
D07VLY-D0Y0GH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical

D07VLY-D08GIH	TTDDRUID	D07VLY-D08GIH
D07VLY-D08GIH	DRUGNAME	Doxorubicin + NGR-hTNF
D07VLY-D08GIH	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1

D07VLY-D0C4RB	TTDDRUID	D07VLY-D0C4RB
D07VLY-D0C4RB	DRUGNAME	Doxorubicin + Paclitaxel
D07VLY-D0C4RB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07VLY-D0W5HK	TTDDRUID	D07VLY-D0W5HK
D07VLY-D0W5HK	DRUGNAME	Doxorubicin + Sorafenib
D07VLY-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D03RTK-D07VLY	TTDDRUID	D03RTK-D07VLY
D03RTK-D07VLY	DRUGNAME	Doxorubicin + Trabectedin
D03RTK-D07VLY	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
D03RTK-D07VLY	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3

D04WFL-D07VLY	TTDDRUID	D04WFL-D07VLY
D04WFL-D07VLY	DRUGNAME	Doxorubicin + Trastuzumab
D04WFL-D07VLY	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Preclinical

D0Y3KG-D07VLY	TTDDRUID	D0Y3KG-D07VLY
D0Y3KG-D07VLY	DRUGNAME	Doxorubicin + Valproic Acid
D0Y3KG-D07VLY	INDICATI	Malignant mesothelioma [ICD-11: 2C26.0] Phase 2

D07VLY-D0VM2L	TTDDRUID	D07VLY-D0VM2L
D07VLY-D0VM2L	DRUGNAME	Doxorubicin + Zoledronate
D07VLY-D0VM2L	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D0G3DL-D0S0LZ	TTDDRUID	D0G3DL-D0S0LZ
D0G3DL-D0S0LZ	DRUGNAME	Doxycycline + Rifampin
D0G3DL-D0S0LZ	INDICATI	Reactive arthritis [ICD-11: FA12.Y] Phase 3

D03RKW-D0S0LZ	TTDDRUID	D03RKW-D0S0LZ
D03RKW-D0S0LZ	DRUGNAME	doxycycline + tauroursodeoxycholic acid
D03RKW-D0S0LZ	INDICATI	Amyloidosis [ICD-11: 5D00] Phase 2

D03CJL-D0E1WI	TTDDRUID	D03CJL-D0E1WI
D03CJL-D0E1WI	DRUGNAME	Droperidol + Fentanyl
D03CJL-D0E1WI	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D08QMX-D0Z4ZT	TTDDRUID	D08QMX-D0Z4ZT
D08QMX-D0Z4ZT	DRUGNAME	Drospirenone + Estradiol
D08QMX-D0Z4ZT	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D06NXY-D0Z4ZT	TTDDRUID	D06NXY-D0Z4ZT
D06NXY-D0Z4ZT	DRUGNAME	Drospirenone + Ethinyl Estradiol
D06NXY-D0Z4ZT	INDICATI	Contraception [ICD-11: QA21] Approved

D0MX5S-D0PG0G	TTDDRUID	D0MX5S-D0PG0G
D0MX5S-D0PG0G	DRUGNAME	Drotrecogin alfa + Enoxaparin
D0MX5S-D0PG0G	INDICATI	Pulmonary embolism [ICD-11: BB00] Phase 2

D01AXB-D08RBC	TTDDRUID	D01AXB-D08RBC
D01AXB-D08RBC	DRUGNAME	Duloxetine + Escitalopram
D01AXB-D08RBC	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D01AXB-D0J0ZS	TTDDRUID	D01AXB-D0J0ZS
D01AXB-D0J0ZS	DRUGNAME	Duloxetine + Gabapentin
D01AXB-D0J0ZS	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 4

D05MBZ-D0A9YA	TTDDRUID	D05MBZ-D0A9YA
D05MBZ-D0A9YA	DRUGNAME	Dutasteride + Tamsulosin
D05MBZ-D0A9YA	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
D05MBZ-D0A9YA	INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 4

D0UX6Z-D0C3BS	TTDDRUID	D0UX6Z-D0C3BS
D0UX6Z-D0C3BS	DRUGNAME	Edoxaban + Heparin
D0UX6Z-D0C3BS	INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 3

D0C3BS-D0MX5S	TTDDRUID	D0C3BS-D0MX5S
D0C3BS-D0MX5S	DRUGNAME	Edoxaban + LMWH
D0C3BS-D0MX5S	INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 3

D03SGR-D05QDC	TTDDRUID	D03SGR-D05QDC
D03SGR-D05QDC	DRUGNAME	efalizumab + acitretin
D03SGR-D05QDC	INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 4

D07HVY-D0S9SD	TTDDRUID	D07HVY-D0S9SD
D07HVY-D0S9SD	DRUGNAME	Efavirenz + Emtricitabine
D07HVY-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
D07HVY-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
D07HVY-D0S9SD	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Preclinical

D07HVY-D0D9HW	TTDDRUID	D07HVY-D0D9HW
D07HVY-D0D9HW	DRUGNAME	Efavirenz + Tenofovir
D07HVY-D0D9HW	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Preclinical

D0X7JR-D0Z5IU	TTDDRUID	D0X7JR-D0Z5IU
D0X7JR-D0Z5IU	DRUGNAME	eflornithine + sulindac
D0X7JR-D0Z5IU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D0X7JR-D0Z5IU	INDICATI	Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 3

D01XDL-D0PY5D	TTDDRUID	D01XDL-D0PY5D
D01XDL-D0PY5D	DRUGNAME	elacytarabine + idarubicin
D01XDL-D0PY5D	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D08QMX-D0UI3T	TTDDRUID	D08QMX-D0UI3T
D08QMX-D0UI3T	DRUGNAME	elagolix + estradiol
D08QMX-D0UI3T	INDICATI	Heavy uterine bleeding [ICD-11: GA20.1] Phase 2

D05IRV-D0C4RB	TTDDRUID	D05IRV-D0C4RB
D05IRV-D0C4RB	DRUGNAME	Elesclomol + Paclitaxel
D05IRV-D0C4RB	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0S9SD-D0U5GB	TTDDRUID	D0S9SD-D0U5GB
D0S9SD-D0U5GB	DRUGNAME	emtricitabine + lopinavir
D0S9SD-D0U5GB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
D0S9SD-D0U5GB	INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Phase 1

D0D9HW-D0S9SD	TTDDRUID	D0D9HW-D0S9SD
D0D9HW-D0S9SD	DRUGNAME	Emtricitabine + Tenofovir
D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4
D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved
D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D00SEB-D0WN0U	TTDDRUID	D00SEB-D0WN0U
D00SEB-D0WN0U	DRUGNAME	Enalapril + Felodipine
D00SEB-D0WN0U	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00SEB-D0Z0DW	TTDDRUID	D00SEB-D0Z0DW
D00SEB-D0Z0DW	DRUGNAME	enalapril + folic acid
D00SEB-D0Z0DW	INDICATI	Blood pressure [ICD-11: BA00] Phase 2
D00SEB-D0Z0DW	INDICATI	Homocysteine disorder [ICD-11: 5C50.B] Phase 2

D00SEB-D0U4UQ	TTDDRUID	D00SEB-D0U4UQ
D00SEB-D0U4UQ	DRUGNAME	Enalapril + Hydrochlorothiazide
D00SEB-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00SEB-D0P6ZH	TTDDRUID	D00SEB-D0P6ZH
D00SEB-D0P6ZH	DRUGNAME	Enalapril + Lercanidipine
D00SEB-D0P6ZH	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D00SEB-D0A1DH	TTDDRUID	D00SEB-D0A1DH
D00SEB-D0A1DH	DRUGNAME	Enalapril + Nitrendipine
D00SEB-D0A1DH	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D02RSN-D05LTY	TTDDRUID	D02RSN-D05LTY
D02RSN-D05LTY	DRUGNAME	Enbrel + Levofloxacin
D02RSN-D05LTY	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2/3

D05LTY-D0D3DU	TTDDRUID	D05LTY-D0D3DU
D05LTY-D0D3DU	DRUGNAME	Enbrel + Methotrexate Sodium
D05LTY-D0D3DU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 4

D0R5TA-D0UM7O	TTDDRUID	D0R5TA-D0UM7O
D0R5TA-D0UM7O	DRUGNAME	Endomorphin-1 + Ketamine
D0R5TA-D0UM7O	INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical

D0JE2E-D0MX5S	TTDDRUID	D0JE2E-D0MX5S
D0JE2E-D0MX5S	DRUGNAME	Enoxaparin + Rosuvastatin
D0JE2E-D0MX5S	INDICATI	Deep vein thrombosis [ICD-11: BD71] Phase 4

D0E3OF-D0MX5S	TTDDRUID	D0E3OF-D0MX5S
D0E3OF-D0MX5S	DRUGNAME	Enoxaparin + Warfarin
D0E3OF-D0MX5S	INDICATI	Venous thrombosis [ICD-11: BA43] Phase 3

D0D9HW-D0KR2J	TTDDRUID	D0D9HW-D0KR2J
D0D9HW-D0KR2J	DRUGNAME	entecavir + tenofovir
D0D9HW-D0KR2J	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 3
D0D9HW-D0KR2J	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D04PHC-D0G7DJ	TTDDRUID	D04PHC-D0G7DJ
D04PHC-D0G7DJ	DRUGNAME	Epinephrine + Etidocaine
D04PHC-D0G7DJ	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D04PHC-D0X4RN	TTDDRUID	D04PHC-D0X4RN
D04PHC-D0X4RN	DRUGNAME	Epinephrine + Lidocaine
D04PHC-D0X4RN	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D04PHC-D06LYG	TTDDRUID	D04PHC-D06LYG
D04PHC-D06LYG	DRUGNAME	Epinephrine + Prilocaine
D04PHC-D06LYG	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D04PHC-D0TZ1G	TTDDRUID	D04PHC-D0TZ1G
D04PHC-D0TZ1G	DRUGNAME	Epinephrine + Procaine
D04PHC-D0TZ1G	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D0C9XJ-D0CT9C	TTDDRUID	D0C9XJ-D0CT9C
D0C9XJ-D0CT9C	DRUGNAME	epirubicin + cyclophosphamide
D0C9XJ-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04WFL-D0C9XJ	TTDDRUID	D04WFL-D0C9XJ
D04WFL-D0C9XJ	DRUGNAME	Epirubicin + Trastuzumab
D04WFL-D0C9XJ	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Preclinical

D0T7US-D0U4UQ	TTDDRUID	D0T7US-D0U4UQ
D0T7US-D0U4UQ	DRUGNAME	Eprosartan + Hydrochlorothiazide
D0T7US-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0UX6Z-D09ZIO	TTDDRUID	D0UX6Z-D09ZIO
D0UX6Z-D09ZIO	DRUGNAME	Eptifibatide + Heparin
D0UX6Z-D09ZIO	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3

D07POC-D0KK2E	TTDDRUID	D07POC-D0KK2E
D07POC-D0KK2E	DRUGNAME	eribulin mesylate + erlotinib
D07POC-D0KK2E	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D07POC-D0Y4GO	TTDDRUID	D07POC-D0Y4GO
D07POC-D0Y4GO	DRUGNAME	Erlotinib + Pemetrexed
D07POC-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D07POC-D0JE2E	TTDDRUID	D07POC-D0JE2E
D07POC-D0JE2E	DRUGNAME	erlotinib + rosuvastatin
D07POC-D0JE2E	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D07POC-D0JE2E	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1

D03LJR-D07POC	TTDDRUID	D03LJR-D07POC
D03LJR-D07POC	DRUGNAME	erlotinib + sirolimus
D03LJR-D07POC	INDICATI	Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 1

D07POC-D0EN0W	TTDDRUID	D07POC-D0EN0W
D07POC-D0EN0W	DRUGNAME	Erlotinib + Teprotumumab
D07POC-D0EN0W	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D02YIZ-D09CPR	TTDDRUID	D02YIZ-D09CPR
D02YIZ-D09CPR	DRUGNAME	Erythromycin + Penicillin V
D02YIZ-D09CPR	INDICATI	Streptococcus infection [ICD-11: 1B53] Preclinical

D02YIZ-D09TBD	TTDDRUID	D02YIZ-D09TBD
D02YIZ-D09TBD	DRUGNAME	Erythromycin + Sulfisoxazole
D02YIZ-D09TBD	INDICATI	Acute otitis media [ICD-11: AB00] Approved

D08RBC-D0H3HM	TTDDRUID	D08RBC-D0H3HM
D08RBC-D0H3HM	DRUGNAME	escitalopram + aripiprazole
D08RBC-D0H3HM	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D00DEF-D08RBC	TTDDRUID	D00DEF-D08RBC
D00DEF-D08RBC	DRUGNAME	Escitalopram + Lisdexamfetamine
D00DEF-D08RBC	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2

D05ZIK-D08RBC	TTDDRUID	D05ZIK-D08RBC
D05ZIK-D08RBC	DRUGNAME	escitalopram + mirtazapine
D05ZIK-D08RBC	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D0C6DT-D0DJ1B	TTDDRUID	D0C6DT-D0DJ1B
D0C6DT-D0DJ1B	DRUGNAME	Esomeprazole + Naproxen
D0C6DT-D0DJ1B	INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Approved
D0C6DT-D0DJ1B	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
D0C6DT-D0DJ1B	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D08QMX-D0U5FF	TTDDRUID	D08QMX-D0U5FF
D08QMX-D0U5FF	DRUGNAME	Estradiol + Leuprolide acetate
D08QMX-D0U5FF	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Investigative

D08QMX-D0I2SD	TTDDRUID	D08QMX-D0I2SD
D08QMX-D0I2SD	DRUGNAME	Estradiol + Medroxyprogesterone
D08QMX-D0I2SD	INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 4
D08QMX-D0I2SD	INDICATI	Postmenopause [ICD-11: GA01-GA30] Phase 4

D08QMX-D0GL7U	TTDDRUID	D08QMX-D0GL7U
D08QMX-D0GL7U	DRUGNAME	Estradiol + Norethindrone
D08QMX-D0GL7U	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D08QMX-D09QZI	TTDDRUID	D08QMX-D09QZI
D08QMX-D09QZI	DRUGNAME	Estradiol + Norgestimate
D08QMX-D09QZI	INDICATI	Menopause symptom [ICD-11: GA30.0] Approved

D07BSQ-D08QMX	TTDDRUID	D07BSQ-D08QMX
D07BSQ-D08QMX	DRUGNAME	estradiol + progesterone
D07BSQ-D08QMX	INDICATI	In-vitro fertilization [ICD-11: QA30.10] Investigative
D07BSQ-D08QMX	INDICATI	Infertility [ICD-11: GB04] Investigative

D06XMU-D0U0XD	TTDDRUID	D06XMU-D0U0XD
D06XMU-D0U0XD	DRUGNAME	Estradiol cypionate + Testosterone
D06XMU-D0U0XD	INDICATI	Vasomotor symptom [ICD-11: CA08] Approved

D06XMU-D07VBA	TTDDRUID	D06XMU-D07VBA
D06XMU-D07VBA	DRUGNAME	Estradiol valerate + Testosterone
D06XMU-D07VBA	INDICATI	Contraception [ICD-11: QA21] Approved

D06TNL-D0K5ER	TTDDRUID	D06TNL-D0K5ER
D06TNL-D0K5ER	DRUGNAME	Ethacrynic acid + Rosiglitazone
D06TNL-D0K5ER	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2

D08QME-D09XQF	TTDDRUID	D08QME-D09XQF
D08QME-D09XQF	DRUGNAME	Ethambutol + Isoniazid
D08QME-D09XQF	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D06AEO-D06NXY	TTDDRUID	D06AEO-D06NXY
D06AEO-D06NXY	DRUGNAME	ethinyl estradiol + cyproterone acetate
D06AEO-D06NXY	INDICATI	Amenorrhea [ICD-11: GA20.0] Phase 4
D06AEO-D06NXY	INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 4
D06AEO-D06NXY	INDICATI	Hyperandrogenism [ICD-11: 5A81.0] Phase 4
D06AEO-D06NXY	INDICATI	Menstruation disturbance [ICD-11: GA20.3] Phase 4

D06NXY-D0R2KY	TTDDRUID	D06NXY-D0R2KY
D06NXY-D0R2KY	DRUGNAME	Ethinyl Estradiol + Ethynodiol Diacetate
D06NXY-D0R2KY	INDICATI	Contraception [ICD-11: QA21] Approved

D06NXY-D0GL7U	TTDDRUID	D06NXY-D0GL7U
D06NXY-D0GL7U	DRUGNAME	Ethinyl Estradiol + Levonorgestrel
D06NXY-D0GL7U	INDICATI	Contraception [ICD-11: QA21] Approved

D06NXY-D09QZI	TTDDRUID	D06NXY-D09QZI
D06NXY-D09QZI	DRUGNAME	Ethinyl Estradiol + Norgestimate
D06NXY-D09QZI	INDICATI	Contraception [ICD-11: QA21] Approved

D06NXY-D0BA9U	TTDDRUID	D06NXY-D0BA9U
D06NXY-D0BA9U	DRUGNAME	Ethinyl Estradiol + Norgestrel
D06NXY-D0BA9U	INDICATI	Contraception [ICD-11: QA21] Approved

D0Y3KG-D0Q4XQ	TTDDRUID	D0Y3KG-D0Q4XQ
D0Y3KG-D0Q4XQ	DRUGNAME	Ethosuximide + Valproic Acid
D0Y3KG-D0Q4XQ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D0J1ML-D0R2KY	TTDDRUID	D0J1ML-D0R2KY
D0J1ML-D0R2KY	DRUGNAME	Ethynodiol Diacetate + Mestranol
D0J1ML-D0R2KY	INDICATI	Contraception [ICD-11: QA21] Approved

D04JEE-D0N1WU	TTDDRUID	D04JEE-D0N1WU
D04JEE-D0N1WU	DRUGNAME	Etodolac + Propranolol
D04JEE-D0N1WU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D0B7EB-D0SC2J	TTDDRUID	D0B7EB-D0SC2J
D0B7EB-D0SC2J	DRUGNAME	Etoposide + Tanespimycin
D0B7EB-D0SC2J	INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical

D07NPS-D0B7EB	TTDDRUID	D07NPS-D0B7EB
D07NPS-D0B7EB	DRUGNAME	Etoposide + Tipifarnib
D07NPS-D0B7EB	INDICATI	Adult acute megakaryoblastic leukaemia [ICD-11: 2A60.36] Phase 1

D01XYJ-D05YAR	TTDDRUID	D01XYJ-D05YAR
D01XYJ-D05YAR	DRUGNAME	Eucalyptol + Zidovudine
D01XYJ-D05YAR	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical

D0K3QS-D0O3YF	TTDDRUID	D0K3QS-D0O3YF
D0K3QS-D0O3YF	DRUGNAME	everolimus + cyclosporine
D0K3QS-D0O3YF	INDICATI	Renal transplantation [ICD-11: NE84] Phase 3

D06MRY-D0K3QS	TTDDRUID	D06MRY-D0K3QS
D06MRY-D0K3QS	DRUGNAME	everolimus + enteric-coated mycophenolate sodium
D06MRY-D0K3QS	INDICATI	Renal transplantation [ICD-11: NE84] Phase 3

D0D2VS-D0K3QS	TTDDRUID	D0D2VS-D0K3QS
D0D2VS-D0K3QS	DRUGNAME	Everolimus + Exemestane
D0D2VS-D0K3QS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0D2VS-D0K3QS	INDICATI	Hormone receptor positive malignant neoplasm of breast [ICD-11: 2C60-2C65] Investigative

D0C1WH-D0K3QS	TTDDRUID	D0C1WH-D0K3QS
D0C1WH-D0K3QS	DRUGNAME	Everolimus + Letrozole
D0C1WH-D0K3QS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D0C1WH-D0K3QS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 4

D04FBR-D0K3QS	TTDDRUID	D04FBR-D0K3QS
D04FBR-D0K3QS	DRUGNAME	Everolimus + Mycophenolate acid
D04FBR-D0K3QS	INDICATI	Renal transplantation [ICD-11: NE84] Phase 4

D06OMK-D0K3QS	TTDDRUID	D06OMK-D0K3QS
D06OMK-D0K3QS	DRUGNAME	Everolimus + Tacrolimus
D06OMK-D0K3QS	INDICATI	Kidney transplant patients with intolerance to mycophenolate mofetil or mycophenolic acid [ICD-11: QB63.0] Investigative
D06OMK-D0K3QS	INDICATI	Liver transplantation [ICD-11: QB63.3] Phase 3

D07KSG-D0D2VS	TTDDRUID	D07KSG-D0D2VS
D07KSG-D0D2VS	DRUGNAME	Exemestane + Tamoxifen
D07KSG-D0D2VS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00YVF-D0R6CD	TTDDRUID	D00YVF-D0R6CD
D00YVF-D0R6CD	DRUGNAME	Exenatide + Insulin
D00YVF-D0R6CD	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 4

D00YVF-D0D7LA	TTDDRUID	D00YVF-D0D7LA
D00YVF-D0D7LA	DRUGNAME	Exenatide + Metformin
D00YVF-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D00YVF-D03OFF	TTDDRUID	D00YVF-D03OFF
D00YVF-D03OFF	DRUGNAME	Exenatide + Pioglitazone
D00YVF-D03OFF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D00YVF-D0D1SG	TTDDRUID	D00YVF-D0D1SG
D00YVF-D0D1SG	DRUGNAME	Exenatide + Prednisolone
D00YVF-D0D1SG	INDICATI	Glucocorticoid-induced glucometabolic abnormalities [ICD-11: 6D85] Investigative

D08GHB-D09LWS	TTDDRUID	D08GHB-D09LWS
D08GHB-D09LWS	DRUGNAME	Ezetimibe + Fluvastatin
D08GHB-D09LWS	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4

D00MAI-D09LWS	TTDDRUID	D00MAI-D09LWS
D00MAI-D09LWS	DRUGNAME	Ezetimibe + Niacin
D00MAI-D09LWS	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 4

D09LWS-D0H0ND	TTDDRUID	D09LWS-D0H0ND
D09LWS-D0H0ND	DRUGNAME	Ezetimibe + Simvastatin
D09LWS-D0H0ND	INDICATI	Acute coronary syndrome [ICD-11: BA41] Investigative
D09LWS-D0H0ND	INDICATI	Atherosclerosis [ICD-11: BD40] Phase 3
D09LWS-D0H0ND	INDICATI	Atherosclerosis [ICD-11: BD40] Phase 4
D09LWS-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
D09LWS-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3
D09LWS-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4
D09LWS-D0H0ND	INDICATI	Stable angina [ICD-11: BA40.1] Investigative
D09LWS-D0H0ND	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D0K0OZ-D0R1QE	TTDDRUID	D0K0OZ-D0R1QE
D0K0OZ-D0R1QE	DRUGNAME	Famotidine + Ibuprofen
D0K0OZ-D0R1QE	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
D0K0OZ-D0R1QE	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved

D0K0OZ-D0L7FM	TTDDRUID	D0K0OZ-D0L7FM
D0K0OZ-D0L7FM	DRUGNAME	Famotidine + Probenecid
D0K0OZ-D0L7FM	INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative

D00JAU-D0WN0U	TTDDRUID	D00JAU-D0WN0U
D00JAU-D0WN0U	DRUGNAME	Felodipine + Irbesartan
D00JAU-D0WN0U	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D0I2MK-D0WN0U	TTDDRUID	D0I2MK-D0WN0U
D0I2MK-D0WN0U	DRUGNAME	Felodipine + Metoprolol
D0I2MK-D0WN0U	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D02FXU-D07XGR	TTDDRUID	D02FXU-D07XGR
D02FXU-D07XGR	DRUGNAME	Fenofibrate + Lapaquistat acetate
D02FXU-D07XGR	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2

D07XGR-D0PS6X	TTDDRUID	D07XGR-D0PS6X
D07XGR-D0PS6X	DRUGNAME	Fenofibrate + Lovaza
D07XGR-D0PS6X	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 4

D07XGR-D0D7LA	TTDDRUID	D07XGR-D0D7LA
D07XGR-D0D7LA	DRUGNAME	fenofibrate + metformin
D07XGR-D0D7LA	INDICATI	Glucose metabolism disorder [ICD-11: 5C61.0] Phase 3

D07XGR-D0JE2E	TTDDRUID	D07XGR-D0JE2E
D07XGR-D0JE2E	DRUGNAME	fenofibrate + rosuvastatin
D07XGR-D0JE2E	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 4
D07XGR-D0JE2E	INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Phase 4

D07XGR-D0H0ND	TTDDRUID	D07XGR-D0H0ND
D07XGR-D0H0ND	DRUGNAME	Fenofibrate + Simvastatin
D07XGR-D0H0ND	INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 3
D07XGR-D0H0ND	INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Preclinical

D08JAC-D0I7IB	TTDDRUID	D08JAC-D0I7IB
D08JAC-D0I7IB	DRUGNAME	Fenretinide + Sodium butyrate
D08JAC-D0I7IB	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D0E1WI-D0WO8W	TTDDRUID	D0E1WI-D0WO8W
D0E1WI-D0WO8W	DRUGNAME	Fentanyl + Mepivacaine
D0E1WI-D0WO8W	INDICATI	Knee arthroscopy [ICD-11: FA2Z-FB82] Investigative

D0E1WI-D0U6LM	TTDDRUID	D0E1WI-D0U6LM
D0E1WI-D0U6LM	DRUGNAME	Fentanyl + Midazolam
D0E1WI-D0U6LM	INDICATI	Hypothermia [ICD-11: NF02] Phase 4

D01EKQ-D0Z0DW	TTDDRUID	D01EKQ-D0Z0DW
D01EKQ-D0Z0DW	DRUGNAME	Ferrous sulfate + Folic acid
D01EKQ-D0Z0DW	INDICATI	Folate-deficiency anemia [ICD-11: 3A02.Y] Approved

D01KPV-D0L7FM	TTDDRUID	D01KPV-D0L7FM
D01KPV-D0L7FM	DRUGNAME	Fexofenadine + Probenecid
D01KPV-D0L7FM	INDICATI	Hay fever [ICD-11: CA08.00] Preclinical

D00HHS-D01KPV	TTDDRUID	D00HHS-D01KPV
D00HHS-D01KPV	DRUGNAME	Fexofenadine + Pseudoephedrine
D00HHS-D01KPV	INDICATI	Sneezing [ICD-11: MD11.A] Approved

D01IXD-D0F6EO	TTDDRUID	D01IXD-D0F6EO
D01IXD-D0F6EO	DRUGNAME	finafloxacin + amoxicillin
D01IXD-D0F6EO	INDICATI	Dyspepsia [ICD-11: MD92] Phase 2
D01IXD-D0F6EO	INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Phase 2
D01IXD-D0F6EO	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 2

D01IXD-D0C6DT	TTDDRUID	D01IXD-D0C6DT
D01IXD-D0C6DT	DRUGNAME	finafloxacin + esomeprazole
D01IXD-D0C6DT	INDICATI	Dyspepsia [ICD-11: MD92] Phase 2
D01IXD-D0C6DT	INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Phase 2
D01IXD-D0C6DT	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 2

D07UHS-D0L8PH	TTDDRUID	D07UHS-D0L8PH
D07UHS-D0L8PH	DRUGNAME	Fingolimod + Interferon beta 1
D07UHS-D0L8PH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D09DHT-D0LF1U	TTDDRUID	D09DHT-D0LF1U
D09DHT-D0LF1U	DRUGNAME	Flavopiridol + Phorbol 12-myristate-13-acetate
D09DHT-D0LF1U	INDICATI	Human myeloid leukaemia [ICD-11: 2B33.1] Preclinical

D09EXD-D0F2XQ	TTDDRUID	D09EXD-D0F2XQ
D09EXD-D0F2XQ	DRUGNAME	Fludarabine + Rituximab
D09EXD-D0F2XQ	INDICATI	Follicular lymphoma [ICD-11: 2A80] Investigative
D09EXD-D0F2XQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
D09EXD-D0F2XQ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D02QJH-D05JNI	TTDDRUID	D02QJH-D05JNI
D02QJH-D05JNI	DRUGNAME	Fluocinolone Acetonide + Neomycin
D02QJH-D05JNI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
D02QJH-D05JNI	INDICATI	Itching [ICD-11: 1F28-1G07] Approved

D02QJH-D07BCT	TTDDRUID	D02QJH-D07BCT
D02QJH-D07BCT	DRUGNAME	Fluocinolone Acetonide + Tobramycin
D02QJH-D07BCT	INDICATI	Inflammatory ocular conditions [ICD-11: 9C20.2] Approved

D0M4VM-D0P0HT	TTDDRUID	D0M4VM-D0P0HT
D0M4VM-D0P0HT	DRUGNAME	Fluorometholone + Sulfacetamide
D0M4VM-D0P0HT	INDICATI	Steroid-responsive inflammatory ocular condition [ICD-11: 9C61] Approved

D07BCT-D0P0HT	TTDDRUID	D07BCT-D0P0HT
D07BCT-D0P0HT	DRUGNAME	Fluorometholone + Tobramycin
D07BCT-D0P0HT	INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved

D05LEO-D0B6TW	TTDDRUID	D05LEO-D0B6TW
D05LEO-D0B6TW	DRUGNAME	Fluorouracil + Leucovorin
D05LEO-D0B6TW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D02XIY-D05LEO	TTDDRUID	D02XIY-D05LEO
D02XIY-D05LEO	DRUGNAME	Fluorouracil + Octreotide
D02XIY-D05LEO	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2

D05LEO-D0W5HK	TTDDRUID	D05LEO-D0W5HK
D05LEO-D0W5HK	DRUGNAME	Fluorouracil + Sorafenib
D05LEO-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D03TGJ-D05LEO	TTDDRUID	D03TGJ-D05LEO
D03TGJ-D05LEO	DRUGNAME	Fluorouracil + Sorivudine
D03TGJ-D05LEO	INDICATI	Liver cancer [ICD-11: 2C12] Preclinical

D0TR5X-D0V4QS	TTDDRUID	D0TR5X-D0V4QS
D0TR5X-D0V4QS	DRUGNAME	Fluoxetine + Olanzapine
D0TR5X-D0V4QS	INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved

D0H7KF-D0TR5X	TTDDRUID	D0H7KF-D0TR5X
D0H7KF-D0TR5X	DRUGNAME	Fluoxetine + Quetiapine
D0H7KF-D0TR5X	INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Phase 4

D05JNI-D0Y2YP	TTDDRUID	D05JNI-D0Y2YP
D05JNI-D0Y2YP	DRUGNAME	Flurandrenolide + Neomycin
D05JNI-D0Y2YP	INDICATI	Skin inflammation [ICD-11: EF20.Y] Approved

D0LC6K-D0Z1ZM	TTDDRUID	D0LC6K-D0Z1ZM
D0LC6K-D0Z1ZM	DRUGNAME	Fluticasone + Clarithromycin
D0LC6K-D0Z1ZM	INDICATI	Asthma [ICD-11: CA23] Phase 3

D0L0GM-D0LC6K	TTDDRUID	D0L0GM-D0LC6K
D0L0GM-D0LC6K	DRUGNAME	Fluticasone furoate + Vilanterol
D0L0GM-D0LC6K	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D0D7LA-D0Z0DW	TTDDRUID	D0D7LA-D0Z0DW
D0D7LA-D0Z0DW	DRUGNAME	Folic acid + Metformin
D0D7LA-D0Z0DW	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 4

D04KJO-D0LC6K	TTDDRUID	D04KJO-D0LC6K
D04KJO-D0LC6K	DRUGNAME	Formoterol + Fluticasone
D04KJO-D0LC6K	INDICATI	Bronchial asthma [ICD-11: CA23] Phase 3

D03HYX-D04KJO	TTDDRUID	D03HYX-D04KJO
D03HYX-D04KJO	DRUGNAME	Formoterol + Mometasone
D03HYX-D04KJO	INDICATI	Asthma [ICD-11: CA23] Approved

D04KJO-D0L5YV	TTDDRUID	D04KJO-D0L5YV
D04KJO-D0L5YV	DRUGNAME	Formoterol + Salmeterol
D04KJO-D0L5YV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D04KJO-D0P1WA	TTDDRUID	D04KJO-D0P1WA
D04KJO-D0P1WA	DRUGNAME	Formoterol + Tiotropium
D04KJO-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D0U4UQ-D0X8KY	TTDDRUID	D0U4UQ-D0X8KY
D0U4UQ-D0X8KY	DRUGNAME	Fosinopril + Hydrochlorothiazide
D0U4UQ-D0X8KY	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07BVI-D0S1ZB	TTDDRUID	D07BVI-D0S1ZB
D07BVI-D0S1ZB	DRUGNAME	Fotemustine + Ipilimumab
D07BVI-D0S1ZB	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0S1ZB-D0Y9EW	TTDDRUID	D0S1ZB-D0Y9EW
D0S1ZB-D0Y9EW	DRUGNAME	fotemustine + vemurafenib
D0S1ZB-D0Y9EW	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D09XZB-D0JO7Y	TTDDRUID	D09XZB-D0JO7Y
D09XZB-D0JO7Y	DRUGNAME	Fulvestrant + Gefitinib
D09XZB-D0JO7Y	INDICATI	ER-positive breast cancer [ICD-11: 2C60-2C65] Phase 2

D07NPS-D0JO7Y	TTDDRUID	D07NPS-D0JO7Y
D07NPS-D0JO7Y	DRUGNAME	Fulvestrant + Tipifarnib
D07NPS-D0JO7Y	INDICATI	ER-positive breast cancer [ICD-11: 2C60-2C65] Phase 2

D0G6QF-D0JO7Y	TTDDRUID	D0G6QF-D0JO7Y
D0G6QF-D0JO7Y	DRUGNAME	fulvestrant + zactima
D0G6QF-D0JO7Y	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D02KOF-D0PQ3G	TTDDRUID	D02KOF-D0PQ3G
D02KOF-D0PQ3G	DRUGNAME	Furosemide + Lomefloxacin
D02KOF-D0PQ3G	INDICATI	Congestive heart failure [ICD-11: BD10] Investigative
D02KOF-D0PQ3G	INDICATI	Edema [ICD-11: MG29] Investigative

D0P7EK-D0PQ3G	TTDDRUID	D0P7EK-D0PQ3G
D0P7EK-D0PQ3G	DRUGNAME	Furosemide + Mannitol
D0P7EK-D0PQ3G	INDICATI	Contrast-induced nephropathy [ICD-11: GC2Z] Investigative

D0EP0C-D0PQ3G	TTDDRUID	D0EP0C-D0PQ3G
D0EP0C-D0PQ3G	DRUGNAME	Furosemide + Spironolactone
D0EP0C-D0PQ3G	INDICATI	Cirrhosis [ICD-11: DB93] Phase 4

D0G3DL-D0X7XG	TTDDRUID	D0G3DL-D0X7XG
D0G3DL-D0X7XG	DRUGNAME	Fusidic Acid + Rifampin
D0G3DL-D0X7XG	INDICATI	Methicillin-resistant coagulase-negative staphylococci infection [ICD-11: 1G40] Preclinical

D0J0ZS-D0X4RN	TTDDRUID	D0J0ZS-D0X4RN
D0J0ZS-D0X4RN	DRUGNAME	gabapentin + lidoderm
D0J0ZS-D0X4RN	INDICATI	Carpal tunnel syndrome [ICD-11: 8C10.0] Phase 4
D0J0ZS-D0X4RN	INDICATI	Complex regional pain syndrome [ICD-11: 8D8A.0] Phase 4
D0J0ZS-D0X4RN	INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 4
D0J0ZS-D0X4RN	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4
D0J0ZS-D0X4RN	INDICATI	Idiopathic sensory neuropathy [ICD-11: 8C02] Phase 4
D0J0ZS-D0X4RN	INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 4
D0J0ZS-D0X4RN	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 4

D0J0ZS-D0WE3O	TTDDRUID	D0J0ZS-D0WE3O
D0J0ZS-D0WE3O	DRUGNAME	Gabapentin + Morphine
D0J0ZS-D0WE3O	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative

D0J0ZS-D0QL3P	TTDDRUID	D0J0ZS-D0QL3P
D0J0ZS-D0QL3P	DRUGNAME	Gabapentin + Oxcarbazepine
D0J0ZS-D0QL3P	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D0ED7U-D0J0ZS	TTDDRUID	D0ED7U-D0J0ZS
D0ED7U-D0J0ZS	DRUGNAME	Gabapentin + Tiagabine
D0ED7U-D0J0ZS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D0Y3KG-D0J0ZS	TTDDRUID	D0Y3KG-D0J0ZS
D0Y3KG-D0J0ZS	DRUGNAME	Gabapentin + Valproic Acid
D0Y3KG-D0J0ZS	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D04AIT-D0EP8X	TTDDRUID	D04AIT-D0EP8X
D04AIT-D0EP8X	DRUGNAME	Gamma Hydroxybutyric Acid + Luteolin
D04AIT-D0EP8X	INDICATI	Depression [ICD-11: 6A70-6A7Z] Preclinical

D04OKJ-D0H3TD	TTDDRUID	D04OKJ-D0H3TD
D04OKJ-D0H3TD	DRUGNAME	Garenoxacin + Imipenem
D04OKJ-D0H3TD	INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Preclinical

D07HOB-D09XZB	TTDDRUID	D07HOB-D09XZB
D07HOB-D09XZB	DRUGNAME	Gefitinib + Irinotecan
D07HOB-D09XZB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D09XZB-D0H0ND	TTDDRUID	D09XZB-D0H0ND
D09XZB-D0H0ND	DRUGNAME	Gefitinib + Simvastatin
D09XZB-D0H0ND	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2

D09XZB-D0R0MW	TTDDRUID	D09XZB-D0R0MW
D09XZB-D0R0MW	DRUGNAME	Gefitinib + Sunitinib
D09XZB-D0R0MW	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D06NXD-D09XZB	TTDDRUID	D06NXD-D09XZB
D06NXD-D09XZB	DRUGNAME	Gefitinib + Taxane
D06NXD-D09XZB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04WFL-D09XZB	TTDDRUID	D04WFL-D09XZB
D04WFL-D09XZB	DRUGNAME	Gefitinib + Trastuzumab
D04WFL-D09XZB	INDICATI	HER2/NEU overexpressing breast cancer [ICD-11: 2C60-2C65] Preclinical

D00HCQ-D03UVS	TTDDRUID	D00HCQ-D03UVS
D00HCQ-D03UVS	DRUGNAME	gemcitabine + capecitabine
D00HCQ-D03UVS	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
D00HCQ-D03UVS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D03UVS-D0AZ3C	TTDDRUID	D03UVS-D0AZ3C
D03UVS-D0AZ3C	DRUGNAME	Gemcitabine + Imatinib
D03UVS-D0AZ3C	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2

D03UVS-D0Y3ME	TTDDRUID	D03UVS-D0Y3ME
D03UVS-D0Y3ME	DRUGNAME	Gemcitabine + Oxaliplatin
D03UVS-D0Y3ME	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 2

D03UVS-D0C4RB	TTDDRUID	D03UVS-D0C4RB
D03UVS-D0C4RB	DRUGNAME	Gemcitabine + Paclitaxel
D03UVS-D0C4RB	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
D03UVS-D0C4RB	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3

D03UVS-D0HU9H	TTDDRUID	D03UVS-D0HU9H
D03UVS-D0HU9H	DRUGNAME	gemcitabine + panitumumab
D03UVS-D0HU9H	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D03UVS-D0W5YY	TTDDRUID	D03UVS-D0W5YY
D03UVS-D0W5YY	DRUGNAME	gemcitabine + pm060184
D03UVS-D0W5YY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03UVS-D0T6DK	TTDDRUID	D03UVS-D0T6DK
D03UVS-D0T6DK	DRUGNAME	gemcitabine + rapamycin
D03UVS-D0T6DK	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2
D03UVS-D0T6DK	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 1/2

D03UVS-D04WFL	TTDDRUID	D03UVS-D04WFL
D03UVS-D04WFL	DRUGNAME	Gemcitabine + Trastuzumab
D03UVS-D04WFL	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Preclinical

D05VIX-D0JE2E	TTDDRUID	D05VIX-D0JE2E
D05VIX-D0JE2E	DRUGNAME	Gemfibrozil + Rosuvastatin
D05VIX-D0JE2E	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Preclinical

D0L7FM-D0VR7W	TTDDRUID	D0L7FM-D0VR7W
D0L7FM-D0VR7W	DRUGNAME	Gemifloxacin + Probenecid
D0L7FM-D0VR7W	INDICATI	Bronchitis [ICD-11: CA20] Investigative
D0L7FM-D0VR7W	INDICATI	Pneumonia [ICD-11: CA40] Investigative

D06EWO-D0E7PQ	TTDDRUID	D06EWO-D0E7PQ
D06EWO-D0E7PQ	DRUGNAME	Gemtuzumab ozogamicin + Vorinostat
D06EWO-D0E7PQ	INDICATI	Adult acute megakaryoblastic leukaemia [ICD-11: 2A60.36] Phase 2

D0L4FS-D0W5HK	TTDDRUID	D0L4FS-D0W5HK
D0L4FS-D0W5HK	DRUGNAME	Genistein + Sorafenib
D0L4FS-D0W5HK	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Preclinical

D02RSN-D0L9UU	TTDDRUID	D02RSN-D0L9UU
D02RSN-D0L9UU	DRUGNAME	Gentamicin + Levofloxacin
D02RSN-D0L9UU	INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2

D0D1SG-D0L9UU	TTDDRUID	D0D1SG-D0L9UU
D0D1SG-D0L9UU	DRUGNAME	Gentamicin + Prednisolone
D0D1SG-D0L9UU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0B1IV-D0L9UU	TTDDRUID	D0B1IV-D0L9UU
D0B1IV-D0L9UU	DRUGNAME	Gentamicin + Vancomycin
D0B1IV-D0L9UU	INDICATI	Penicillin-resistant bacterial infection [ICD-11: 1C41] Phase 4

D04CRL-D0L8PH	TTDDRUID	D04CRL-D0L8PH
D04CRL-D0L8PH	DRUGNAME	Glatiramer Acetate + Interferon beta 1
D04CRL-D0L8PH	INDICATI	Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 3

D04CRL-D08LTU	TTDDRUID	D04CRL-D08LTU
D04CRL-D08LTU	DRUGNAME	Glatiramer Acetate + Minocycline
D04CRL-D08LTU	INDICATI	Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 2

D0D7LA-D0M2MR	TTDDRUID	D0D7LA-D0M2MR
D0D7LA-D0M2MR	DRUGNAME	Gliclazide + Metformin
D0D7LA-D0M2MR	INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative

D0B2GI-D0D7LA	TTDDRUID	D0B2GI-D0D7LA
D0B2GI-D0D7LA	DRUGNAME	Glimepiride + Metformin
D0B2GI-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
D0B2GI-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D03OFF-D0B2GI	TTDDRUID	D03OFF-D0B2GI
D03OFF-D0B2GI	DRUGNAME	Glimepiride + Pioglitazone
D03OFF-D0B2GI	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0B2GI-D0K5ER	TTDDRUID	D0B2GI-D0K5ER
D0B2GI-D0K5ER	DRUGNAME	Glimepiride + Rosiglitazone
D0B2GI-D0K5ER	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0D7LA-D0Z4SB	TTDDRUID	D0D7LA-D0Z4SB
D0D7LA-D0Z4SB	DRUGNAME	Glipizide + Metformin
D0D7LA-D0Z4SB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D0D7LA-D0Z4SB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D05LYX-D0D7LA	TTDDRUID	D05LYX-D0D7LA
D05LYX-D0D7LA	DRUGNAME	Glyburide + Metformin
D05LYX-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0P3QR-D0PY5G	TTDDRUID	D0P3QR-D0PY5G
D0P3QR-D0PY5G	DRUGNAME	glycopeptide + carbapenem
D0P3QR-D0PY5G	INDICATI	Abdominal infection [ICD-11: 1C10.1] Phase 2/3

D01QWS-D05LEO	TTDDRUID	D01QWS-D05LEO
D01QWS-D05LEO	DRUGNAME	gm-ct-01 + 5-fluorouracil
D01QWS-D05LEO	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D09FSG-D0D3DU	TTDDRUID	D09FSG-D0D3DU
D09FSG-D0D3DU	DRUGNAME	Golimumab + Methotrexate Sodium
D09FSG-D0D3DU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D09FSG-D0D3DU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D00BCG-D0W0BF	TTDDRUID	D00BCG-D0W0BF
D00BCG-D0W0BF	DRUGNAME	Goserelin + Anastrozole
D00BCG-D0W0BF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00BCG-D0V9BD	TTDDRUID	D00BCG-D0V9BD
D00BCG-D0V9BD	DRUGNAME	Goserelin + Bicalutamide
D00BCG-D0V9BD	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D04XVN-D0K3QS	TTDDRUID	D04XVN-D0K3QS
D04XVN-D0K3QS	DRUGNAME	gsk1120212 + everolimus
D04XVN-D0K3QS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05MCS-D0LC6K	TTDDRUID	D05MCS-D0LC6K
D05MCS-D0LC6K	DRUGNAME	GSK2190915 + Fluticasone
D05MCS-D0LC6K	INDICATI	Asthma [ICD-11: CA23] Phase 2

D00SLY-D0FG6M	TTDDRUID	D00SLY-D0FG6M
D00SLY-D0FG6M	DRUGNAME	gsk573719 + gw642444
D00SLY-D0FG6M	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D0N3PE-D0U4UQ	TTDDRUID	D0N3PE-D0U4UQ
D0N3PE-D0U4UQ	DRUGNAME	Guanethidine + Hydrochlorothiazide
D0N3PE-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0D1AL-D0UM7O	TTDDRUID	D0D1AL-D0UM7O
D0D1AL-D0UM7O	DRUGNAME	haloperidol + ketamine
D0D1AL-D0UM7O	INDICATI	Postoperative delirium [ICD-11: 6D70] Phase 4

D0UX6Z-D0BN9X	TTDDRUID	D0UX6Z-D0BN9X
D0UX6Z-D0BN9X	DRUGNAME	heparin + tirofiban
D0UX6Z-D0BN9X	INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 4

D0UX6Z-D0E3OF	TTDDRUID	D0UX6Z-D0E3OF
D0UX6Z-D0E3OF	DRUGNAME	Heparin + Warfarin
D0UX6Z-D0E3OF	INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 3

D03KXO-D0O5WP	TTDDRUID	D03KXO-D0O5WP
D03KXO-D0O5WP	DRUGNAME	hgs1036 + docetaxel
D03KXO-D0O5WP	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0O5SZ-D0X5KF	TTDDRUID	D0O5SZ-D0X5KF
D0O5SZ-D0X5KF	DRUGNAME	Homatropine Methylbromide + Hydrocodone
D0O5SZ-D0X5KF	INDICATI	Cough [ICD-11: MD12] Approved

D0L6JE-D0R6CD	TTDDRUID	D0L6JE-D0R6CD
D0L6JE-D0R6CD	DRUGNAME	Humalog + Insulin glargine
D0L6JE-D0R6CD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D0K1XK-D0U4UQ	TTDDRUID	D0K1XK-D0U4UQ
D0K1XK-D0U4UQ	DRUGNAME	Hydralazine + Hydrochlorothiazide
D0K1XK-D0U4UQ	INDICATI	Diabetes insipidus [ICD-11: 5A61.5] Approved
D0K1XK-D0U4UQ	INDICATI	Edema [ICD-11: MG29] Approved
D0K1XK-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D0K1XK-D0U4UQ	INDICATI	Hypoparathyroidism [ICD-11: 5A50] Approved

D0I1SK-D0K1XK	TTDDRUID	D0I1SK-D0K1XK
D0I1SK-D0K1XK	DRUGNAME	Hydralazine + Isosorbide Dinitrate
D0I1SK-D0K1XK	INDICATI	Heart failure [ICD-11: BD10-BD13] Approved

D0J4JM-D0K1XK	TTDDRUID	D0J4JM-D0K1XK
D0J4JM-D0K1XK	DRUGNAME	Hydralazine + Reserpine
D0J4JM-D0K1XK	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00JAU-D0U4UQ	TTDDRUID	D00JAU-D0U4UQ
D00JAU-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Irbesartan
D00JAU-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0A8XN-D0U4UQ	TTDDRUID	D0A8XN-D0U4UQ
D0A8XN-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Labetalol
D0A8XN-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07HGR-D0U4UQ	TTDDRUID	D07HGR-D0U4UQ
D07HGR-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Lisinopril
D07HGR-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0DD0K-D0U4UQ	TTDDRUID	D0DD0K-D0U4UQ
D0DD0K-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Losartan
D0DD0K-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0BA6T-D0U4UQ	TTDDRUID	D0BA6T-D0U4UQ
D0BA6T-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Methyldopa
D0BA6T-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0I2MK-D0U4UQ	TTDDRUID	D0I2MK-D0U4UQ
D0I2MK-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Metoprolol
D0I2MK-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00HDU-D0U4UQ	TTDDRUID	D00HDU-D0U4UQ
D00HDU-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Moexipril
D00HDU-D0U4UQ	INDICATI	High blood pressure [ICD-11: BA00] Approved

D07UBG-D0U4UQ	TTDDRUID	D07UBG-D0U4UQ
D07UBG-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Olmesartan
D07UBG-D0U4UQ	INDICATI	Essential hypertension [ICD-11: BA00] Phase 3
D07UBG-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D07UBG-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D0F2PO-D0U4UQ	TTDDRUID	D0F2PO-D0U4UQ
D0F2PO-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Pindolol
D0F2PO-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04JEE-D0U4UQ	TTDDRUID	D04JEE-D0U4UQ
D04JEE-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Propranolol
D04JEE-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0I7SZ-D0U4UQ	TTDDRUID	D0I7SZ-D0U4UQ
D0I7SZ-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Quinapril
D0I7SZ-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0J4JM-D0U4UQ	TTDDRUID	D0J4JM-D0U4UQ
D0J4JM-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Reserpine
D0J4JM-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0EP0C-D0U4UQ	TTDDRUID	D0EP0C-D0U4UQ
D0EP0C-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Spironolactone
D0EP0C-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0N6RF-D0U4UQ	TTDDRUID	D0N6RF-D0U4UQ
D0N6RF-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Telmisartan
D0N6RF-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D05UVD-D0U4UQ	TTDDRUID	D05UVD-D0U4UQ
D05UVD-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Timolol
D05UVD-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00NKB-D0U4UQ	TTDDRUID	D00NKB-D0U4UQ
D00NKB-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Triamterene
D00NKB-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06UDG-D0U4UQ	TTDDRUID	D06UDG-D0U4UQ
D06UDG-D0U4UQ	DRUGNAME	Hydrochlorothiazide + Valsartan
D06UDG-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
D06UDG-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D0R1QE-D0X5KF	TTDDRUID	D0R1QE-D0X5KF
D0R1QE-D0X5KF	DRUGNAME	Hydrocodone + Ibuprofen
D0R1QE-D0X5KF	INDICATI	Acute pain [ICD-11: MG31] Approved
D0R1QE-D0X5KF	INDICATI	Odontalgia [ICD-11: DA0A.Y] Investigative

D09JXM-D0X5KF	TTDDRUID	D09JXM-D0X5KF
D09JXM-D0X5KF	DRUGNAME	Hydrocodone + Phenylpropanolamine
D09JXM-D0X5KF	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D00HHS-D0X5KF	TTDDRUID	D00HHS-D0X5KF
D00HHS-D0X5KF	DRUGNAME	Hydrocodone + Pseudoephedrine
D00HHS-D0X5KF	INDICATI	Cough [ICD-11: MD12] Approved

D0KR5B-D05JNI	TTDDRUID	D0KR5B-D05JNI
D0KR5B-D05JNI	DRUGNAME	Hydrocortisone + Neomycin
D0KR5B-D05JNI	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
D0KR5B-D05JNI	INDICATI	Otitis externa [ICD-11: AA00-AA13] Approved
D0KR5B-D05JNI	INDICATI	Rhinitis [ICD-11: FA20] Approved
D0KR5B-D05JNI	INDICATI	Sinusitis [ICD-11: CA0A.Z] Approved

D0J2NK-D0KR5B	TTDDRUID	D0J2NK-D0KR5B
D0J2NK-D0KR5B	DRUGNAME	Hydrocortisone + Oxytetracycline
D0J2NK-D0KR5B	INDICATI	Conjunctivitis [ICD-11: 9A60] Approved

D09OOV-D0KR5B	TTDDRUID	D09OOV-D0KR5B
D09OOV-D0KR5B	DRUGNAME	Hydrocortisone + Polymyxin B Sulfate
D09OOV-D0KR5B	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D0KR5B-D0V4UF	TTDDRUID	D0KR5B-D0V4UF
D0KR5B-D0V4UF	DRUGNAME	Hydrocortisone + Pramoxine
D0KR5B-D0V4UF	INDICATI	Anal itching [ICD-11: EG60] Approved
D0KR5B-D0V4UF	INDICATI	Hemorrhoids [ICD-11: DB60] Approved
D0KR5B-D0V4UF	INDICATI	Minor skin irritations [ICD-11: EK02.1] Approved
D0KR5B-D0V4UF	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D08NQZ-D0KR5B	TTDDRUID	D08NQZ-D0KR5B
D08NQZ-D0KR5B	DRUGNAME	Hydrocortisone + Tetracycline
D08NQZ-D0KR5B	INDICATI	Acne vulgaris [ICD-11: ED80] Approved
D08NQZ-D0KR5B	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D02XBW-D0KR5B	TTDDRUID	D02XBW-D0KR5B
D02XBW-D0KR5B	DRUGNAME	Hydrocortisone + Urea
D02XBW-D0KR5B	INDICATI	Rosacea [ICD-11: ED90.0] Approved

D00WAM-D0J4JM	TTDDRUID	D00WAM-D0J4JM
D00WAM-D0J4JM	DRUGNAME	Hydroflumethiazide + Reserpine
D00WAM-D0J4JM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09PNY-D0W1RY	TTDDRUID	D09PNY-D0W1RY
D09PNY-D0W1RY	DRUGNAME	Hydroxyamphetamine + Tropicamide
D09PNY-D0W1RY	INDICATI	Mydriasis [ICD-11: LA11.62] Approved

D0IL7L-D0OJ4L	TTDDRUID	D0IL7L-D0OJ4L
D0IL7L-D0OJ4L	DRUGNAME	hydroxychloroquine + prednisone
D0IL7L-D0OJ4L	INDICATI	Pulmonary sarcoidosis [ICD-11: 4B20.0] Phase 3

D07CWD-D0B8QB	TTDDRUID	D07CWD-D0B8QB
D07CWD-D0B8QB	DRUGNAME	Hydroxyurea + Magnesium pidolate
D07CWD-D0B8QB	INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Phase 1

D01TVQ-D09EXD	TTDDRUID	D01TVQ-D09EXD
D01TVQ-D09EXD	DRUGNAME	Ibritumomab + Rituximab
D01TVQ-D09EXD	INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2

D09KTS-D0Y8ZN	TTDDRUID	D09KTS-D0Y8ZN
D09KTS-D0Y8ZN	DRUGNAME	ibrutinib + ofatumumab
D09KTS-D0Y8ZN	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D0B3HD-D0R1QE	TTDDRUID	D0B3HD-D0R1QE
D0B3HD-D0R1QE	DRUGNAME	ibuprofen + caffeine
D0B3HD-D0R1QE	INDICATI	Headache [ICD-11: 8A80-8A84] Phase 3
D0B3HD-D0R1QE	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 3
D0B3HD-D0R1QE	INDICATI	Tooth disease [ICD-11: DA08-DA0E] Phase 3

D01KHH-D0R1QE	TTDDRUID	D01KHH-D0R1QE
D01KHH-D0R1QE	DRUGNAME	ibuprofen + cyclobenzaprine
D01KHH-D0R1QE	INDICATI	Cervical strain [ICD-11: NA23.4Y] Phase 2

D03SKD-D0R1QE	TTDDRUID	D03SKD-D0R1QE
D03SKD-D0R1QE	DRUGNAME	Ibuprofen + Oxycodone
D03SKD-D0R1QE	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0O6IU-D0R1QE	TTDDRUID	D0O6IU-D0R1QE
D0O6IU-D0R1QE	DRUGNAME	Ibuprofen + Phenylephrine
D0O6IU-D0R1QE	INDICATI	Sinus pressure [ICD-11: NF04.1] Approved

D00HHS-D0R1QE	TTDDRUID	D00HHS-D0R1QE
D00HHS-D0R1QE	DRUGNAME	Ibuprofen + Pseudoephedrine
D00HHS-D0R1QE	INDICATI	Cough [ICD-11: MD12] Approved

D0G5ME-D0R1QE	TTDDRUID	D0G5ME-D0R1QE
D0G5ME-D0R1QE	DRUGNAME	Ibuprofen + Telcagepant
D0G5ME-D0R1QE	INDICATI	Migraine [ICD-11: 8A80] Phase 2

D02TLO-D0C3YQ	TTDDRUID	D02TLO-D0C3YQ
D02TLO-D0C3YQ	DRUGNAME	Ifosfamide + Mesna
D02TLO-D0C3YQ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved

D05ZTH-D0Z7ZM	TTDDRUID	D05ZTH-D0Z7ZM
D05ZTH-D0Z7ZM	DRUGNAME	Iloprost + Sildenafil
D05ZTH-D0Z7ZM	INDICATI	Pulmonary hypertension [ICD-11: BB01] Preclinical

D0AZ3C-D0E3SH	TTDDRUID	D0AZ3C-D0E3SH
D0AZ3C-D0E3SH	DRUGNAME	imatinib + lbh589
D0AZ3C-D0E3SH	INDICATI	Chordoma [ICD-11: 5A61.0] Phase 1

D0AZ3C-D0D3DU	TTDDRUID	D0AZ3C-D0D3DU
D0AZ3C-D0D3DU	DRUGNAME	Imatinib + Methotrexate Sodium
D0AZ3C-D0D3DU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0AZ3C-D0D1XW	TTDDRUID	D0AZ3C-D0D1XW
D0AZ3C-D0D1XW	DRUGNAME	imatinib + peg-interferon
D0AZ3C-D0D1XW	INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 3

D08NWC-D0AZ3C	TTDDRUID	D08NWC-D0AZ3C
D08NWC-D0AZ3C	DRUGNAME	Imatinib + Peginterferon alfa-2b
D08NWC-D0AZ3C	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 2

D0AZ3C-D0T6DK	TTDDRUID	D0AZ3C-D0T6DK
D0AZ3C-D0T6DK	DRUGNAME	Imatinib + Rapamycin
D0AZ3C-D0T6DK	INDICATI	Prevention of restenosis after intimal injury [ICD-11: N.A.] Preclinical

D0AZ3C-D0C8EU	TTDDRUID	D0AZ3C-D0C8EU
D0AZ3C-D0C8EU	DRUGNAME	Imatinib + Temozolomide
D0AZ3C-D0C8EU	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2

D0AZ3C-D0E7PQ	TTDDRUID	D0AZ3C-D0E7PQ
D0AZ3C-D0E7PQ	DRUGNAME	Imatinib + Vorinostat
D0AZ3C-D0E7PQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2

D0O5WP-D0Z5XT	TTDDRUID	D0O5WP-D0Z5XT
D0O5WP-D0Z5XT	DRUGNAME	imexon + docetaxel
D0O5WP-D0Z5XT	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0G4OD-D0H3TD	TTDDRUID	D0G4OD-D0H3TD
D0G4OD-D0H3TD	DRUGNAME	Imipenem + Tigecycline
D0G4OD-D0H3TD	INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical

D02OME-D0X7HM	TTDDRUID	D02OME-D0X7HM
D02OME-D0X7HM	DRUGNAME	immu-132 + carboplatin
D02OME-D0X7HM	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D0N5OV-D0P6MW	TTDDRUID	D0N5OV-D0P6MW
D0N5OV-D0P6MW	DRUGNAME	imprime pgg + cetuximab
D0N5OV-D0P6MW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D03DJL-D0L5YV	TTDDRUID	D03DJL-D0L5YV
D03DJL-D0L5YV	DRUGNAME	Indacaterol maleate + Salmeterol
D03DJL-D0L5YV	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D03DJL-D0P1WA	TTDDRUID	D03DJL-D0P1WA
D03DJL-D0P1WA	DRUGNAME	Indacaterol maleate + Tiotropium
D03DJL-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D03KYG-D0H8FH	TTDDRUID	D03KYG-D0H8FH
D03KYG-D0H8FH	DRUGNAME	Indapamide + Perindopril
D03KYG-D0H8FH	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
D03KYG-D0H8FH	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D09DBY-D0R1RS	TTDDRUID	D09DBY-D0R1RS
D09DBY-D0R1RS	DRUGNAME	Indomethacin + Rilonacept
D09DBY-D0R1RS	INDICATI	Acute gout flare [ICD-11: FA25.0] Phase 3

D0IL7L-D0PG5G	TTDDRUID	D0IL7L-D0PG5G
D0IL7L-D0PG5G	DRUGNAME	infliximab + prednisone
D0IL7L-D0PG5G	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
D0IL7L-D0PG5G	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0IL7L-D0PG5G	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D07HOB-D0IK5F	TTDDRUID	D07HOB-D0IK5F
D07HOB-D0IK5F	DRUGNAME	iniparib + irinotecan
D07HOB-D0IK5F	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2

D02EHV-D0R6CD	TTDDRUID	D02EHV-D0R6CD
D02EHV-D0R6CD	DRUGNAME	Insulin + Isophane insulin
D02EHV-D0R6CD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D0K9MY-D0R6CD	TTDDRUID	D0K9MY-D0R6CD
D0K9MY-D0R6CD	DRUGNAME	Insulin + Saxagliptin
D0K9MY-D0R6CD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0D7LA-D0R6CD	TTDDRUID	D0D7LA-D0R6CD
D0D7LA-D0R6CD	DRUGNAME	Insulin aspart + Metformin
D0D7LA-D0R6CD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D0N5YA-D0R6CD	TTDDRUID	D0N5YA-D0R6CD
D0N5YA-D0R6CD	DRUGNAME	Insulin aspart + Repaglinide
D0N5YA-D0R6CD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D0M2XE-D0R6CD	TTDDRUID	D0M2XE-D0R6CD
D0M2XE-D0R6CD	DRUGNAME	Insulin glargine + Insulin glulisine
D0M2XE-D0R6CD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 4

D09PMV-D0ES1Q	TTDDRUID	D09PMV-D0ES1Q
D09PMV-D0ES1Q	DRUGNAME	Interferon alfa-2a + Temsirolimus
D09PMV-D0ES1Q	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D00EFO-D0H3WI	TTDDRUID	D00EFO-D0H3WI
D00EFO-D0H3WI	DRUGNAME	interferon alpha 2b + ribavirin
D00EFO-D0H3WI	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 2/3

D07QFP-D0L8PH	TTDDRUID	D07QFP-D0L8PH
D07QFP-D0L8PH	DRUGNAME	Interferon beta 1 + Teriflunomide
D07QFP-D0L8PH	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3

D0H0ND-D0V4JQ	TTDDRUID	D0H0ND-D0V4JQ
D0H0ND-D0V4JQ	DRUGNAME	Interferon beta 1a + Simvastatin
D0H0ND-D0V4JQ	INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 4

D0C8EU-D0E5HO	TTDDRUID	D0C8EU-D0E5HO
D0C8EU-D0E5HO	DRUGNAME	intrathecal liposomal ara-c + temozolomide
D0C8EU-D0E5HO	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2

D0EG5A-D0O5WP	TTDDRUID	D0EG5A-D0O5WP
D0EG5A-D0O5WP	DRUGNAME	ipi 504 + docetaxel
D0EG5A-D0O5WP	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D03JAO-D03UVS	TTDDRUID	D03JAO-D03UVS
D03JAO-D03UVS	DRUGNAME	ipi-926 + gemcitabine
D03JAO-D03UVS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2

D00MVM-D0S0AS	TTDDRUID	D00MVM-D0S0AS
D00MVM-D0S0AS	DRUGNAME	Ipratropium + Salbutamol
D00MVM-D0S0AS	INDICATI	Asthma [ICD-11: CA23] Approved

D00JAU-D01STB	TTDDRUID	D00JAU-D01STB
D00JAU-D01STB	DRUGNAME	Irbesartan + Ramipril
D00JAU-D01STB	INDICATI	Albuminuria [ICD-11: GB42] Phase 4

D07HOB-D0Y3ME	TTDDRUID	D07HOB-D0Y3ME
D07HOB-D0Y3ME	DRUGNAME	Irinotecan + Oxaliplatin
D07HOB-D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
D07HOB-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D00EPT-D00HCQ	TTDDRUID	D00EPT-D00HCQ
D00EPT-D00HCQ	DRUGNAME	irofulven + capecitabine
D00EPT-D00HCQ	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 2

D00EPT-D0Y3ME	TTDDRUID	D00EPT-D0Y3ME
D00EPT-D0Y3ME	DRUGNAME	irofulven + oxaliplatin
D00EPT-D0Y3ME	INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2

D0I1FQ-D0S9SD	TTDDRUID	D0I1FQ-D0S9SD
D0I1FQ-D0S9SD	DRUGNAME	isentress + truvada
D0I1FQ-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D09XQF-D0G3DL	TTDDRUID	D09XQF-D0G3DL
D09XQF-D0G3DL	DRUGNAME	Isoniazid + Rifampin
D09XQF-D0G3DL	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved

D09XQF-D0G9IU	TTDDRUID	D09XQF-D0G9IU
D09XQF-D0G9IU	DRUGNAME	Isoniazid + Rifapentine
D09XQF-D0G9IU	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0I8FI-D0O6IU	TTDDRUID	D0I8FI-D0O6IU
D0I8FI-D0O6IU	DRUGNAME	Isoproterenol + Phenylephrine
D0I8FI-D0O6IU	INDICATI	Asthma [ICD-11: CA23] Approved

D0K3ZR-D0S9QA	TTDDRUID	D0K3ZR-D0S9QA
D0K3ZR-D0S9QA	DRUGNAME	ivabradine + bisoprolol
D0K3ZR-D0S9QA	INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 4

D09YHJ-D0J1MI	TTDDRUID	D09YHJ-D0J1MI
D09YHJ-D0J1MI	DRUGNAME	Ivermectin + Mebendazole
D09YHJ-D0J1MI	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Investigative

D04KBL-D0W2EK	TTDDRUID	D04KBL-D0W2EK
D04KBL-D0W2EK	DRUGNAME	ixabepilone + bevacizumab
D04KBL-D0W2EK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0W2EK-D0X7HM	TTDDRUID	D0W2EK-D0X7HM
D0W2EK-D0X7HM	DRUGNAME	ixabepilone + carboplatin
D0W2EK-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0N5OV-D0W2EK	TTDDRUID	D0N5OV-D0W2EK
D0N5OV-D0W2EK	DRUGNAME	ixabepilone + cetuximab
D0N5OV-D0W2EK	INDICATI	Triple negative locally advanced non-resectable breast cancer [ICD-11: 2C60-2C65] Phase 2

D08CDI-D0W2EK	TTDDRUID	D08CDI-D0W2EK
D08CDI-D0W2EK	DRUGNAME	ixabepilone + lapatinib
D08CDI-D0W2EK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D03UVS-D0XV6L	TTDDRUID	D03UVS-D0XV6L
D03UVS-D0XV6L	DRUGNAME	kanglaite + gemcitabine
D03UVS-D0XV6L	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0UM7O-D0WE3O	TTDDRUID	D0UM7O-D0WE3O
D0UM7O-D0WE3O	DRUGNAME	Ketamine + Morphine
D0UM7O-D0WE3O	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Investigative

D07TQV-D0L3MP	TTDDRUID	D07TQV-D0L3MP
D07TQV-D0L3MP	DRUGNAME	Lamivudine + Nelfinavir
D07TQV-D0L3MP	INDICATI	Vertical transmission disease [ICD-11: N.A.] Phase 3

D07TQV-D0D9HW	TTDDRUID	D07TQV-D0D9HW
D07TQV-D0D9HW	DRUGNAME	Lamivudine + Tenofovir
D07TQV-D0D9HW	INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative

D01XYJ-D07TQV	TTDDRUID	D01XYJ-D07TQV
D01XYJ-D07TQV	DRUGNAME	Lamivudine + Zidovudine
D01XYJ-D07TQV	INDICATI	Diarrhea [ICD-11: ME05.1] Phase 3
D01XYJ-D07TQV	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved

D03FLC-D0H3HM	TTDDRUID	D03FLC-D0H3HM
D03FLC-D0H3HM	DRUGNAME	lamotrigine + aripiprazole
D03FLC-D0H3HM	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 4

D03FLC-D0QL3P	TTDDRUID	D03FLC-D0QL3P
D03FLC-D0QL3P	DRUGNAME	Lamotrigine + Oxcarbazepine
D03FLC-D0QL3P	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D03FLC-D06GDY	TTDDRUID	D03FLC-D06GDY
D03FLC-D06GDY	DRUGNAME	Lamotrigine + Paroxetine
D03FLC-D06GDY	INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative

D03FLC-D07VDZ	TTDDRUID	D03FLC-D07VDZ
D03FLC-D07VDZ	DRUGNAME	Lamotrigine + Topiramate
D03FLC-D07VDZ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D03FLC-D0Y3KG	TTDDRUID	D03FLC-D0Y3KG
D03FLC-D0Y3KG	DRUGNAME	Lamotrigine + Valproic Acid
D03FLC-D0Y3KG	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D0DJ1B-D06YYD	TTDDRUID	D0DJ1B-D06YYD
D0DJ1B-D06YYD	DRUGNAME	Lansoprazole + Naproxen
D0DJ1B-D06YYD	INDICATI	NSAID-associated gastric ulcer [ICD-11: DA60] Approved

D07NGZ-D0D7LA	TTDDRUID	D07NGZ-D0D7LA
D07NGZ-D0D7LA	DRUGNAME	lantus + glucophage
D07NGZ-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D02FXU-D0JE2E	TTDDRUID	D02FXU-D0JE2E
D02FXU-D0JE2E	DRUGNAME	Lapaquistat acetate + Rosuvastatin
D02FXU-D0JE2E	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D08CDI-D0KK2E	TTDDRUID	D08CDI-D0KK2E
D08CDI-D0KK2E	DRUGNAME	lapatinib + eribulin
D08CDI-D0KK2E	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D08CDI-D0C1WH	TTDDRUID	D08CDI-D0C1WH
D08CDI-D0C1WH	DRUGNAME	Lapatinib + Letrozole
D08CDI-D0C1WH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
D08CDI-D0C1WH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D08CDI-D0C4RB	TTDDRUID	D08CDI-D0C4RB
D08CDI-D0C4RB	DRUGNAME	Lapatinib + Paclitaxel
D08CDI-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 0
D08CDI-D0C4RB	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3

D02PMO-D08CDI	TTDDRUID	D02PMO-D08CDI
D02PMO-D08CDI	DRUGNAME	Lapatinib + Topotecan
D02PMO-D08CDI	INDICATI	Advanced stage cancer [ICD-11: 2A00-2F9Z] Phase 1

D01HTL-D08CDI	TTDDRUID	D01HTL-D08CDI
D01HTL-D08CDI	DRUGNAME	lapatinib + vinorelbine
D01HTL-D08CDI	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D00MAI-D0WL5V	TTDDRUID	D00MAI-D0WL5V
D00MAI-D0WL5V	DRUGNAME	Laropiprant + Niacin
D00MAI-D0WL5V	INDICATI	Primary hypercholesterolemia [ICD-11: 5C80.00] Phase 3

D05UVD-D0C6NM	TTDDRUID	D05UVD-D0C6NM
D05UVD-D0C6NM	DRUGNAME	Latanoprost + Timolol
D05UVD-D0C6NM	INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative

D0D4YZ-D0J9HO	TTDDRUID	D0D4YZ-D0J9HO
D0D4YZ-D0J9HO	DRUGNAME	Ledipasvir + Sofosbuvir
D0D4YZ-D0J9HO	INDICATI	HCV-1 infection [ICD-11: 1E51] Approved

D09EXD-D0Q5NX	TTDDRUID	D09EXD-D0Q5NX
D09EXD-D0Q5NX	DRUGNAME	Lenalidomide + Rituximab
D09EXD-D0Q5NX	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
D09EXD-D0Q5NX	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2

D09ETH-D0R0FO	TTDDRUID	D09ETH-D0R0FO
D09ETH-D0R0FO	DRUGNAME	lenvatinib + e7050
D09ETH-D0R0FO	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2

D0C1WH-D0R0FO	TTDDRUID	D0C1WH-D0R0FO
D0C1WH-D0R0FO	DRUGNAME	lenvatinib + letrozole
D0C1WH-D0R0FO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0C4AM-D0C6TL	TTDDRUID	D0C4AM-D0C6TL
D0C4AM-D0C6TL	DRUGNAME	leptin + pramlintide
D0C4AM-D0C6TL	INDICATI	Obesity [ICD-11: 5B81] Investigative

D06UDG-D0P6ZH	TTDDRUID	D06UDG-D0P6ZH
D06UDG-D0P6ZH	DRUGNAME	lercanidipine + valsartan
D06UDG-D0P6ZH	INDICATI	Essential hypertension [ICD-11: BA00] Phase 2

D0C1WH-D0U5FF	TTDDRUID	D0C1WH-D0U5FF
D0C1WH-D0U5FF	DRUGNAME	letrozole + leuprolide
D0C1WH-D0U5FF	INDICATI	Fibrolamellar liver cancer [ICD-11: 2C12.02] Phase 2

D0C1WH-D0GL7U	TTDDRUID	D0C1WH-D0GL7U
D0C1WH-D0GL7U	DRUGNAME	Letrozole + Norethindrone
D0C1WH-D0GL7U	INDICATI	Endometriosis-related pain [ICD-11: MG30-MG3Z] Investigative

D0GL7U-D0U5FF	TTDDRUID	D0GL7U-D0U5FF
D0GL7U-D0U5FF	DRUGNAME	Leuprolide acetate + Norethindrone
D0GL7U-D0U5FF	INDICATI	Endometriosis-related pain [ICD-11: MG30-MG3Z] Approved
D0GL7U-D0U5FF	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0U5FF-D0VM2L	TTDDRUID	D0U5FF-D0VM2L
D0U5FF-D0VM2L	DRUGNAME	Leuprolide acetate + Zoledronate
D0U5FF-D0VM2L	INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative

D0E1XL-D0QL3P	TTDDRUID	D0E1XL-D0QL3P
D0E1XL-D0QL3P	DRUGNAME	Levetiracetam + Oxcarbazepine
D0E1XL-D0QL3P	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D07VDZ-D0E1XL	TTDDRUID	D07VDZ-D0E1XL
D07VDZ-D0E1XL	DRUGNAME	Levetiracetam + Topiramate
D07VDZ-D0E1XL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D09QUQ-D0E1WI	TTDDRUID	D09QUQ-D0E1WI
D09QUQ-D0E1WI	DRUGNAME	levobupivacaine + fentanyl
D09QUQ-D0E1WI	INDICATI	Stillborn caesarean section [ICD-11: JB22] Phase 2/3

D02RSN-D0R0ZL	TTDDRUID	D02RSN-D0R0ZL
D02RSN-D0R0ZL	DRUGNAME	levofloxacin + clindamycin
D02RSN-D0R0ZL	INDICATI	Osteoarticular infection [ICD-11: 2B51] Investigative

D02RSN-D0IL7L	TTDDRUID	D02RSN-D0IL7L
D02RSN-D0IL7L	DRUGNAME	Levofloxacin + Prednisone
D02RSN-D0IL7L	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2/3

D02RSN-D0G4OD	TTDDRUID	D02RSN-D0G4OD
D02RSN-D0G4OD	DRUGNAME	Levofloxacin + Tigecycline
D02RSN-D0G4OD	INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical

D0E9VU-D0WO8W	TTDDRUID	D0E9VU-D0WO8W
D0E9VU-D0WO8W	DRUGNAME	Levonordefrin + Mepivacaine
D0E9VU-D0WO8W	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D06RGG-D0S6JG	TTDDRUID	D06RGG-D0S6JG
D06RGG-D0S6JG	DRUGNAME	levothyroxine + liothyronine
D06RGG-D0S6JG	INDICATI	Hypothyroidism [ICD-11: 5A00] Investigative

D03XTC-D0X4RN	TTDDRUID	D03XTC-D0X4RN
D03XTC-D0X4RN	DRUGNAME	lidocaine + esmolol
D03XTC-D0X4RN	INDICATI	Constipation [ICD-11: DD91.1] Phase 4
D03XTC-D0X4RN	INDICATI	Nausea [ICD-11: MD90] Phase 4
D03XTC-D0X4RN	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 4
D03XTC-D0X4RN	INDICATI	Vomiting [ICD-11: MD90] Phase 4

D03BLF-D0X4RN	TTDDRUID	D03BLF-D0X4RN
D03BLF-D0X4RN	DRUGNAME	lidocaine + kenalog
D03BLF-D0X4RN	INDICATI	Adhesive capsulitis [ICD-11: FB55.Z] Investigative

D07YDE-D0X4RN	TTDDRUID	D07YDE-D0X4RN
D07YDE-D0X4RN	DRUGNAME	Lidocaine + Nitroglycerin
D07YDE-D0X4RN	INDICATI	Cardiac catheterization [ICD-11: PK80] Phase 2/3

D0J2NK-D0X4RN	TTDDRUID	D0J2NK-D0X4RN
D0J2NK-D0X4RN	DRUGNAME	Lidocaine + Oxytetracycline
D0J2NK-D0X4RN	INDICATI	Trachoma [ICD-11: 1C23] Approved

D06LYG-D0X4RN	TTDDRUID	D06LYG-D0X4RN
D06LYG-D0X4RN	DRUGNAME	Lidocaine + Prilocaine
D06LYG-D0X4RN	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
D06LYG-D0X4RN	INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2

D08HQK-D0X4RN	TTDDRUID	D08HQK-D0X4RN
D08HQK-D0X4RN	DRUGNAME	Lidocaine + Tetracaine
D08HQK-D0X4RN	INDICATI	Itching [ICD-11: 1F28-1G07] Approved
D08HQK-D0X4RN	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D02EYG-D0D7LA	TTDDRUID	D02EYG-D0D7LA
D02EYG-D0D7LA	DRUGNAME	Linagliptin + Metformin
D02EYG-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D02EYG-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D02EYG-D03OFF	TTDDRUID	D02EYG-D03OFF
D02EYG-D03OFF	DRUGNAME	linagliptin + pioglitazone
D02EYG-D03OFF	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03GOI-D0D7LA	TTDDRUID	D03GOI-D0D7LA
D03GOI-D0D7LA	DRUGNAME	Liraglutide + Metformin
D03GOI-D0D7LA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
D03GOI-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
D03GOI-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D07HGR-D0DD0K	TTDDRUID	D07HGR-D0DD0K
D07HGR-D0DD0K	DRUGNAME	Lisinopril + Losartan
D07HGR-D0DD0K	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 3

D04MSM-D07WXT	TTDDRUID	D04MSM-D07WXT
D04MSM-D07WXT	DRUGNAME	lithium + carbamazepine
D04MSM-D07WXT	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 4

D0Y3KG-D07WXT	TTDDRUID	D0Y3KG-D07WXT
D0Y3KG-D07WXT	DRUGNAME	Lithium + Valproic Acid
D0Y3KG-D07WXT	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 3

D07WXT-D0R0FE	TTDDRUID	D07WXT-D0R0FE
D07WXT-D0R0FE	DRUGNAME	Lithium + Verapamil
D07WXT-D0R0FE	INDICATI	Mania [ICD-11: 6C40.6Z] Phase 3

D04UUH-D0H0KB	TTDDRUID	D04UUH-D0H0KB
D04UUH-D0H0KB	DRUGNAME	Lithium carbonate + Riluzole
D04UUH-D0H0KB	INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2/3

D05MKA-D0D7LA	TTDDRUID	D05MKA-D0D7LA
D05MKA-D0D7LA	DRUGNAME	Lixisenatide + Metformin
D05MKA-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
D05MKA-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0B6CC-D0O3IT	TTDDRUID	D0B6CC-D0O3IT
D0B6CC-D0O3IT	DRUGNAME	L-NMMA acetate + Trimethaphan
D0B6CC-D0O3IT	INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative

D02KOF-D0B8WN	TTDDRUID	D02KOF-D0B8WN
D02KOF-D0B8WN	DRUGNAME	Lomefloxacin + Ranitidine
D02KOF-D0B8WN	INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative

D0B2WQ-D0C8EU	TTDDRUID	D0B2WQ-D0C8EU
D0B2WQ-D0C8EU	DRUGNAME	Lomeguatrib + Temozolomide
D0B2WQ-D0C8EU	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2

D0C4RB-D0W4HZ	TTDDRUID	D0C4RB-D0W4HZ
D0C4RB-D0W4HZ	DRUGNAME	Lonafarnib + Paclitaxel
D0C4RB-D0W4HZ	INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical
D0C4RB-D0W4HZ	INDICATI	Mammary tumour [ICD-11: 2C60-2C6Z] Preclinical

D01XRP-D0CS2F	TTDDRUID	D01XRP-D0CS2F
D01XRP-D0CS2F	DRUGNAME	Loperamide + Simethicone
D01XRP-D0CS2F	INDICATI	Diarrhea [ICD-11: ME05.1] Approved

D0CQ2O-D0U5GB	TTDDRUID	D0CQ2O-D0U5GB
D0CQ2O-D0U5GB	DRUGNAME	lopinavir + interferon beta-1b
D0CQ2O-D0U5GB	INDICATI	Respiratory syndrome coronavirus infection [ICD-11: 1D92] Phase 2/3

D0U5GB-D0ZU9R	TTDDRUID	D0U5GB-D0ZU9R
D0U5GB-D0ZU9R	DRUGNAME	Lopinavir + Ritonavir
D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D0U5GB-D0WI3T	TTDDRUID	D0U5GB-D0WI3T
D0U5GB-D0WI3T	DRUGNAME	Lopinavir + Saquinavir
D0U5GB-D0WI3T	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D00QET-D06ABF	TTDDRUID	D00QET-D06ABF
D00QET-D06ABF	DRUGNAME	Loratadine + Montelukast
D00QET-D06ABF	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Investigative

D00HHS-D06ABF	TTDDRUID	D00HHS-D06ABF
D00HHS-D06ABF	DRUGNAME	Loratadine + Pseudoephedrine
D00HHS-D06ABF	INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Approved

D01JMC-D0U0RZ	TTDDRUID	D01JMC-D0U0RZ
D01JMC-D0U0RZ	DRUGNAME	lorcaserin + phentermine-hcl
D01JMC-D0U0RZ	INDICATI	Chronic weight management [ICD-11: 5B80] Phase 4

D01QIN-D0DD0K	TTDDRUID	D01QIN-D0DD0K
D01QIN-D0DD0K	DRUGNAME	losartan + atorvastatin
D01QIN-D0DD0K	INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
D01QIN-D0DD0K	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1

D0DD0K-D0Z1UA	TTDDRUID	D0DD0K-D0Z1UA
D0DD0K-D0Z1UA	DRUGNAME	Losartan + Nebivolol
D0DD0K-D0Z1UA	INDICATI	Marfan syndrome [ICD-11: LD28.01] Phase 3

D04JEE-D0DD0K	TTDDRUID	D04JEE-D0DD0K
D04JEE-D0DD0K	DRUGNAME	Losartan + Propranolol
D04JEE-D0DD0K	INDICATI	Marfan syndrome [ICD-11: LD28.01] Phase 2

D07BCT-D0X6GN	TTDDRUID	D07BCT-D0X6GN
D07BCT-D0X6GN	DRUGNAME	Loteprednol Etabonate + Tobramycin
D07BCT-D0X6GN	INDICATI	Conjunctivitis [ICD-11: 9A60] Phase 3
D07BCT-D0X6GN	INDICATI	Eye inflammation [ICD-11: 9A02] Approved
D07BCT-D0X6GN	INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 4

D00MAI-D06WTZ	TTDDRUID	D00MAI-D06WTZ
D00MAI-D06WTZ	DRUGNAME	Lovastatin + Niacin
D00MAI-D06WTZ	INDICATI	High cholesterol level [ICD-11: 5C80.0] Approved

D01XBA-D0PS6X	TTDDRUID	D01XBA-D0PS6X
D01XBA-D0PS6X	DRUGNAME	lovaza + raloxifene
D01XBA-D0PS6X	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0H0ND-D0PS6X	TTDDRUID	D0H0ND-D0PS6X
D0H0ND-D0PS6X	DRUGNAME	Lovaza + Simvastatin
D0H0ND-D0PS6X	INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3

D07BVI-D09UDL	TTDDRUID	D07BVI-D09UDL
D07BVI-D09UDL	DRUGNAME	ltx-315 + ipilimumab
D07BVI-D09UDL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
D07BVI-D09UDL	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
D07BVI-D09UDL	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D07BVI-D09UDL	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D07BVI-D09UDL	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1

D00CTS-D0IV3M	TTDDRUID	D00CTS-D0IV3M
D00CTS-D0IV3M	DRUGNAME	Lubiprostone + Polyethylene glycol
D00CTS-D0IV3M	INDICATI	Crohn disease [ICD-11: DD70] Phase 4

D0C4RB-D0Q0PO	TTDDRUID	D0C4RB-D0Q0PO
D0C4RB-D0Q0PO	DRUGNAME	ly2780301 + paclitaxel
D0C4RB-D0Q0PO	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D03SXS-D07POC	TTDDRUID	D03SXS-D07POC
D03SXS-D07POC	DRUGNAME	ly2875358 + erlotinib
D03SXS-D07POC	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1

D03SXS-D04XVN	TTDDRUID	D03SXS-D04XVN
D03SXS-D04XVN	DRUGNAME	ly2875358 + trametinib
D03SXS-D04XVN	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1

D05ADP-D09SFV	TTDDRUID	D05ADP-D09SFV
D05ADP-D09SFV	DRUGNAME	LY294002 + Roscovitine
D05ADP-D09SFV	INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical

D08TVA-D0G8QW	TTDDRUID	D08TVA-D0G8QW
D08TVA-D0G8QW	DRUGNAME	manidipine + delapril
D08TVA-D0G8QW	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D09MXS-D0P7EK	TTDDRUID	D09MXS-D0P7EK
D09MXS-D0P7EK	DRUGNAME	Mannitol + Sorbitol
D09MXS-D0P7EK	INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved

D0A0FL-D0E1WI	TTDDRUID	D0A0FL-D0E1WI
D0A0FL-D0E1WI	DRUGNAME	marcaine + fentanyl
D0A0FL-D0E1WI	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4
D0A0FL-D0E1WI	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 4

D0BZ7V-D0Y4GO	TTDDRUID	D0BZ7V-D0Y4GO
D0BZ7V-D0Y4GO	DRUGNAME	matuzumab + pemetrexed
D0BZ7V-D0Y4GO	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
D0BZ7V-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0B3HD-D0S9MU	TTDDRUID	D0B3HD-D0S9MU
D0B3HD-D0S9MU	DRUGNAME	maxalt + caffeine
D0B3HD-D0S9MU	INDICATI	Migraine with aura [ICD-11: 8A80.0] Phase 3

D07BVI-D0O5WP	TTDDRUID	D07BVI-D0O5WP
D07BVI-D0O5WP	DRUGNAME	mdx-010 + docetaxel
D07BVI-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D04RRZ-D0J6DQ	TTDDRUID	D04RRZ-D0J6DQ
D04RRZ-D0J6DQ	DRUGNAME	medi4736 + tremelimumab
D04RRZ-D0J6DQ	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D04RRZ-D0J6DQ	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D04RRZ-D0J6DQ	INDICATI	Oesophagogastric junction cancer [ICD-11: 2B71.Z] Phase 1/2
D04RRZ-D0J6DQ	INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2

D09NYS-D0GQ7K	TTDDRUID	D09NYS-D0GQ7K
D09NYS-D0GQ7K	DRUGNAME	Mefloquine + Methylene blue
D09NYS-D0GQ7K	INDICATI	Malaria [ICD-11: 1F40-1F45] Preclinical

D03AND-D0C4LF	TTDDRUID	D03AND-D0C4LF
D03AND-D0C4LF	DRUGNAME	mek162 + raf265
D03AND-D0C4LF	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1

D06HCP-D0X7JR	TTDDRUID	D06HCP-D0X7JR
D06HCP-D0X7JR	DRUGNAME	melarsoprol + eflornithine
D06HCP-D0X7JR	INDICATI	African trypanosomiasis [ICD-11: 1F51] Phase 3

D06HCP-D0FC1J	TTDDRUID	D06HCP-D0FC1J
D06HCP-D0FC1J	DRUGNAME	melarsoprol + nifurtimox
D06HCP-D0FC1J	INDICATI	African trypanosomiasis [ICD-11: 1F51] Phase 3

D01JEU-D0WY5Q	TTDDRUID	D01JEU-D0WY5Q
D01JEU-D0WY5Q	DRUGNAME	Memantine + Rivastigmine
D01JEU-D0WY5Q	INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 4

D00UYE-D0T2XU	TTDDRUID	D00UYE-D0T2XU
D00UYE-D0T2XU	DRUGNAME	Meperidine + Promethazine
D00UYE-D0T2XU	INDICATI	Cancer related pain [ICD-11: MG30] Approved

D05CHI-D09UZO	TTDDRUID	D05CHI-D09UZO
D05CHI-D09UZO	DRUGNAME	Mercaptopurine + Rifabutin
D05CHI-D09UZO	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical

D09UZO-D0G3DL	TTDDRUID	D09UZO-D0G3DL
D09UZO-D0G3DL	DRUGNAME	Mercaptopurine + Rifampin
D09UZO-D0G3DL	INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical

D0O5FY-D0ZV0Z	TTDDRUID	D0O5FY-D0ZV0Z
D0O5FY-D0ZV0Z	DRUGNAME	Meropenem + Moxifloxacin
D0O5FY-D0ZV0Z	INDICATI	Severe sepsis [ICD-11: 1G40-1G41] Phase 3

D07BCT-D0O5FY	TTDDRUID	D07BCT-D0O5FY
D07BCT-D0O5FY	DRUGNAME	Meropenem + Tobramycin
D07BCT-D0O5FY	INDICATI	Pseudomonas infection [ICD-11: 1B92] Preclinical

D0Y3KG-D0O5FY	TTDDRUID	D0Y3KG-D0O5FY
D0Y3KG-D0O5FY	DRUGNAME	Meropenem + Valproic Acid
D0Y3KG-D0O5FY	INDICATI	Depression [ICD-11: 6A70-6A7Z] Preclinical

D0GL7U-D0J1ML	TTDDRUID	D0GL7U-D0J1ML
D0GL7U-D0J1ML	DRUGNAME	Mestranol + Norethindrone
D0GL7U-D0J1ML	INDICATI	Contraception [ICD-11: QA21] Approved

D0C1WH-D0D7LA	TTDDRUID	D0C1WH-D0D7LA
D0C1WH-D0D7LA	DRUGNAME	metformin + letrozole
D0C1WH-D0D7LA	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 1

D03OFF-D0D7LA	TTDDRUID	D03OFF-D0D7LA
D03OFF-D0D7LA	DRUGNAME	Metformin + Pioglitazone
D03OFF-D0D7LA	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
D03OFF-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0D7LA-D0N5YA	TTDDRUID	D0D7LA-D0N5YA
D0D7LA-D0N5YA	DRUGNAME	Metformin + Repaglinide
D0D7LA-D0N5YA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0D7LA-D0K5ER	TTDDRUID	D0D7LA-D0K5ER
D0D7LA-D0K5ER	DRUGNAME	Metformin + Rosiglitazone
D0D7LA-D0K5ER	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D0D7LA-D0K5ER	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
D0D7LA-D0K5ER	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D0D7LA-D0JE2E	TTDDRUID	D0D7LA-D0JE2E
D0D7LA-D0JE2E	DRUGNAME	metformin + rosuvastatin
D0D7LA-D0JE2E	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 3
D0D7LA-D0JE2E	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D02SXZ-D0D7LA	TTDDRUID	D02SXZ-D0D7LA
D02SXZ-D0D7LA	DRUGNAME	metformin + s-707106 + metformin
D02SXZ-D0D7LA	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1

D0D7LA-D0K9MY	TTDDRUID	D0D7LA-D0K9MY
D0D7LA-D0K9MY	DRUGNAME	Metformin + Saxagliptin
D0D7LA-D0K9MY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved

D0D7LA-D0U2JP	TTDDRUID	D0D7LA-D0U2JP
D0D7LA-D0U2JP	DRUGNAME	Metformin + Sitagliptin
D0D7LA-D0U2JP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
D0D7LA-D0U2JP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D0D7LA-D0EP0C	TTDDRUID	D0D7LA-D0EP0C
D0D7LA-D0EP0C	DRUGNAME	Metformin + Spironolactone
D0D7LA-D0EP0C	INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Investigative

D02AXG-D0D7LA	TTDDRUID	D02AXG-D0D7LA
D02AXG-D0D7LA	DRUGNAME	metformin + testosterone undecanoate
D02AXG-D0D7LA	INDICATI	Hypogonadism [ICD-11: 5A61.0] Phase 3
D02AXG-D0D7LA	INDICATI	Obesity [ICD-11: 5B81] Phase 3

D09OJQ-D0UM7O	TTDDRUID	D09OJQ-D0UM7O
D09OJQ-D0UM7O	DRUGNAME	methadone + ketamine
D09OJQ-D0UM7O	INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 4

D0B2UZ-D0LR0R	TTDDRUID	D0B2UZ-D0LR0R
D0B2UZ-D0LR0R	DRUGNAME	Methdilazine + Prochlorperazine
D0B2UZ-D0LR0R	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D0D3DU-D0EW4L	TTDDRUID	D0D3DU-D0EW4L
D0D3DU-D0EW4L	DRUGNAME	Methotrexate Sodium + Abatacept
D0D3DU-D0EW4L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0D3DU-D0K5KS	TTDDRUID	D0D3DU-D0K5KS
D0D3DU-D0K5KS	DRUGNAME	Methotrexate Sodium + Adalimumab
D0D3DU-D0K5KS	INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3
D0D3DU-D0K5KS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 4
D0D3DU-D0K5KS	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical

D0D3DU-D0FL5V	TTDDRUID	D0D3DU-D0FL5V
D0D3DU-D0FL5V	DRUGNAME	Methotrexate Sodium + Clobetasol
D0D3DU-D0FL5V	INDICATI	Bullous pemphigoid [ICD-11: EB41.0] Phase 3

D0D3DU-D0I5QX	TTDDRUID	D0D3DU-D0I5QX
D0D3DU-D0I5QX	DRUGNAME	Methotrexate Sodium + Etanercept
D0D3DU-D0I5QX	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
D0D3DU-D0I5QX	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 4

D0D3DU-D0PG5G	TTDDRUID	D0D3DU-D0PG5G
D0D3DU-D0PG5G	DRUGNAME	Methotrexate Sodium + Infliximab
D0D3DU-D0PG5G	INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3
D0D3DU-D0PG5G	INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
D0D3DU-D0PG5G	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0D3DU-D0PG5G	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0D3DU-D0H0ZU	TTDDRUID	D0D3DU-D0H0ZU
D0D3DU-D0H0ZU	DRUGNAME	Methotrexate Sodium + MP-435
D0D3DU-D0H0ZU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D0D3DU-D0YV4F	TTDDRUID	D0D3DU-D0YV4F
D0D3DU-D0YV4F	DRUGNAME	Methotrexate Sodium + Ocrelizumab
D0D3DU-D0YV4F	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
D0D3DU-D0YV4F	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D0D3DU-D0T6XX	TTDDRUID	D0D3DU-D0T6XX
D0D3DU-D0T6XX	DRUGNAME	Methotrexate Sodium + Pantoprazole
D0D3DU-D0T6XX	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Investigative

D0D3DU-D0KL4J	TTDDRUID	D0D3DU-D0KL4J
D0D3DU-D0KL4J	DRUGNAME	Methotrexate Sodium + Rabeprazole
D0D3DU-D0KL4J	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Investigative

D03GVC-D0R0UJ	TTDDRUID	D03GVC-D0R0UJ
D03GVC-D0R0UJ	DRUGNAME	Methyclothiazide + Pargyline
D03GVC-D0R0UJ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03GVC-D0J4JM	TTDDRUID	D03GVC-D0J4JM
D03GVC-D0J4JM	DRUGNAME	Methyclothiazide + Reserpine
D03GVC-D0J4JM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D08PIQ-D0V4JQ	TTDDRUID	D08PIQ-D0V4JQ
D08PIQ-D0V4JQ	DRUGNAME	Methylprednisolone Acetate + Interferon beta-1a
D08PIQ-D0V4JQ	INDICATI	Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 2

D08PIQ-D05JNI	TTDDRUID	D08PIQ-D05JNI
D08PIQ-D05JNI	DRUGNAME	Methylprednisolone Acetate + Neomycin
D08PIQ-D05JNI	INDICATI	Acne vulgaris [ICD-11: ED80] Approved

D08PIQ-D0YV4F	TTDDRUID	D08PIQ-D0YV4F
D08PIQ-D0YV4F	DRUGNAME	Methylprednisolone Acetate + Ocrelizumab
D08PIQ-D0YV4F	INDICATI	Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 2

D08PIQ-D0IL7L	TTDDRUID	D08PIQ-D0IL7L
D08PIQ-D0IL7L	DRUGNAME	Methylprednisolone Acetate + Prednisone
D08PIQ-D0IL7L	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
D08PIQ-D0IL7L	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D08PIQ-D0IL7L	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2

D08PIQ-D09EXD	TTDDRUID	D08PIQ-D09EXD
D08PIQ-D09EXD	DRUGNAME	Methylprednisolone Acetate + Rituximab
D08PIQ-D09EXD	INDICATI	Immune thrombocytopenic purpura [ICD-11: 3B64.13] Phase 2

D0Z7ZM-D0Z1XD	TTDDRUID	D0Z7ZM-D0Z1XD
D0Z7ZM-D0Z1XD	DRUGNAME	Methyltestosterone + Sildenafil
D0Z7ZM-D0Z1XD	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 4

D08VYV-D0IT2G	TTDDRUID	D08VYV-D0IT2G
D08VYV-D0IT2G	DRUGNAME	metoclopramide + dexamethasone
D08VYV-D0IT2G	INDICATI	Vomiting [ICD-11: MD90] Phase 3

D08VYV-D0O6IU	TTDDRUID	D08VYV-D0O6IU
D08VYV-D0O6IU	DRUGNAME	Metoclopramide + Phenylephrine
D08VYV-D0O6IU	INDICATI	Cesarean delivery [ICD-11: JB22] Investigative

D08JIV-D0I2MK	TTDDRUID	D08JIV-D0I2MK
D08JIV-D0I2MK	DRUGNAME	metoprolol xl + amlodipine
D08JIV-D0I2MK	INDICATI	Primary hypertension [ICD-11: BA00] Phase 4

D0A2ZX-D0F6EO	TTDDRUID	D0A2ZX-D0F6EO
D0A2ZX-D0F6EO	DRUGNAME	metronidazole + amoxicillin
D0A2ZX-D0F6EO	INDICATI	Chronic periodontitis [ICD-11: DA0C.Y] Phase 4

D00OQW-D0A2ZX	TTDDRUID	D00OQW-D0A2ZX
D00OQW-D0A2ZX	DRUGNAME	metronidazole + n-acetyl cysteine
D00OQW-D0A2ZX	INDICATI	Bacterial vaginosis [ICD-11: MF3A] Phase 4

D00AXJ-D09OOV	TTDDRUID	D00AXJ-D09OOV
D00AXJ-D09OOV	DRUGNAME	Miconazole + Polymyxin B Sulfate
D00AXJ-D09OOV	INDICATI	Bacterial and yeast infection [ICD-11: 1B74-1G40] Preclinical

D08LDB-D0U6LM	TTDDRUID	D08LDB-D0U6LM
D08LDB-D0U6LM	DRUGNAME	midazolam + gsk1265744
D08LDB-D0U6LM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0A3HB-D0U6LM	TTDDRUID	D0A3HB-D0U6LM
D0A3HB-D0U6LM	DRUGNAME	Midazolam + Propofol
D0A3HB-D0U6LM	INDICATI	Chronic alcoholism [ICD-11: 6C40.2Z] Investigative
D0A3HB-D0U6LM	INDICATI	Procedural sedation [ICD-11: JB0C.3] Phase 4

D02XIY-D02XJY	TTDDRUID	D02XIY-D02XJY
D02XIY-D02XJY	DRUGNAME	Midodrine + Octreotide
D02XIY-D02XJY	INDICATI	Ascites [ICD-11: ME04] Phase 4

D07NVU-D0T6DK	TTDDRUID	D07NVU-D0T6DK
D07NVU-D0T6DK	DRUGNAME	Midostaurin + Rapamycin
D07NVU-D0T6DK	INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical

D09ANG-D0Z4EI	TTDDRUID	D09ANG-D0Z4EI
D09ANG-D0Z4EI	DRUGNAME	Mifepristone + Misoprostol
D09ANG-D0Z4EI	INDICATI	Abortion [ICD-11: JA00] Phase 4

D0M3FJ-D0Z4EI	TTDDRUID	D0M3FJ-D0Z4EI
D0M3FJ-D0Z4EI	DRUGNAME	Mifepristone + Oxytocin
D0M3FJ-D0Z4EI	INDICATI	Abortion [ICD-11: JA00] Phase 4

D00FGR-D06CTE	TTDDRUID	D00FGR-D06CTE
D00FGR-D06CTE	DRUGNAME	miltefosine + imiquimod
D00FGR-D06CTE	INDICATI	Cutaneous leishmaniasis [ICD-11: 1F54.1] Phase 2

D00FGR-D04NDM	TTDDRUID	D00FGR-D04NDM
D00FGR-D04NDM	DRUGNAME	Miltefosine + Paromomycin
D00FGR-D04NDM	INDICATI	Visceral leishmaniasis [ICD-11: 1F54.0] Phase 3

D02DGU-D08LTU	TTDDRUID	D02DGU-D08LTU
D02DGU-D08LTU	DRUGNAME	minocycline + tretinoin
D02DGU-D08LTU	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 4

D09ANG-D0N4OW	TTDDRUID	D09ANG-D0N4OW
D09ANG-D0N4OW	DRUGNAME	misoprostol + vasopressin
D09ANG-D0N4OW	INDICATI	Hemorrhage [ICD-11: MG27] Phase 4

D04FBR-D0G5AG	TTDDRUID	D04FBR-D0G5AG
D04FBR-D0G5AG	DRUGNAME	Mizoribine + Mycophenolate mofetil
D04FBR-D0G5AG	INDICATI	Heart transplant rejection [ICD-11: NE84] Preclinical

D0T5DP-D0W3RW	TTDDRUID	D0T5DP-D0W3RW
D0T5DP-D0W3RW	DRUGNAME	mk-2206 + azd6244
D0T5DP-D0W3RW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D0B7YT-D0OW9L	TTDDRUID	D0B7YT-D0OW9L
D0B7YT-D0OW9L	DRUGNAME	mk-3134 + scopolamine
D0B7YT-D0OW9L	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1

D0C0TT-D0C4RB	TTDDRUID	D0C0TT-D0C4RB
D0C0TT-D0C4RB	DRUGNAME	mln0128 + paclitaxel
D0C0TT-D0C4RB	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
D0C0TT-D0C4RB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D07HOH-D0CT9C	TTDDRUID	D07HOH-D0CT9C
D07HOH-D0CT9C	DRUGNAME	mm-398 + cyclophosphamide
D07HOH-D0CT9C	INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 1
D07HOH-D0CT9C	INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
D07HOH-D0CT9C	INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1
D07HOH-D0CT9C	INDICATI	Rhabdomyosarcoma [ICD-11: 2B55] Phase 1
D07HOH-D0CT9C	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00FHR-D03TIS	TTDDRUID	D00FHR-D03TIS
D00FHR-D03TIS	DRUGNAME	mocetinostat + brentuximab vedotin
D00FHR-D03TIS	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2

D00GOV-D0W2HD	TTDDRUID	D00GOV-D0W2HD
D00GOV-D0W2HD	DRUGNAME	mogamulizumab + nivolumab
D00GOV-D0W2HD	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 1/2
D00GOV-D0W2HD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D03HYX-D09EBS	TTDDRUID	D03HYX-D09EBS
D03HYX-D09EBS	DRUGNAME	Mometasone + Oxymetazoline
D03HYX-D09EBS	INDICATI	Adenoidal hypertrophy [ICD-11: CA0F.1] Phase 4

D00QET-D0LC6K	TTDDRUID	D00QET-D0LC6K
D00QET-D0LC6K	DRUGNAME	Montelukast + Fluticasone
D00QET-D0LC6K	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 4

D00QET-D0N4ZX	TTDDRUID	D00QET-D0N4ZX
D00QET-D0N4ZX	DRUGNAME	montelukast + mk-1029
D00QET-D0N4ZX	INDICATI	Asthma [ICD-11: CA23] Phase 2

D00QET-D0D1SG	TTDDRUID	D00QET-D0D1SG
D00QET-D0D1SG	DRUGNAME	Montelukast + Prednisolone
D00QET-D0D1SG	INDICATI	Bronchial asthma [ICD-11: CA23] Phase 2

D0PG8O-D0WE3O	TTDDRUID	D0PG8O-D0WE3O
D0PG8O-D0WE3O	DRUGNAME	Morphine + Naltrexone
D0PG8O-D0WE3O	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0T1GF-D0X7HM	TTDDRUID	D0T1GF-D0X7HM
D0T1GF-D0X7HM	DRUGNAME	mp-470 + carboplatin
D0T1GF-D0X7HM	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Phase 1

D0O5WP-D0T1GF	TTDDRUID	D0O5WP-D0T1GF
D0O5WP-D0T1GF	DRUGNAME	mp-470 + docetaxel
D0O5WP-D0T1GF	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Phase 1

D07POC-D0T1GF	TTDDRUID	D07POC-D0T1GF
D07POC-D0T1GF	DRUGNAME	mp-470 + erlotinib
D07POC-D0T1GF	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Phase 1

D0B7EB-D0T1GF	TTDDRUID	D0B7EB-D0T1GF
D0B7EB-D0T1GF	DRUGNAME	mp-470 + etoposide
D0B7EB-D0T1GF	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Phase 1

D0C4RB-D0T1GF	TTDDRUID	D0C4RB-D0T1GF
D0C4RB-D0T1GF	DRUGNAME	mp-470 + paclitaxel
D0C4RB-D0T1GF	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Phase 1

D02PMO-D0T1GF	TTDDRUID	D02PMO-D0T1GF
D02PMO-D0T1GF	DRUGNAME	mp-470 + topotecan
D02PMO-D0T1GF	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Phase 1

D04ZXE-D07KSG	TTDDRUID	D04ZXE-D07KSG
D04ZXE-D07KSG	DRUGNAME	msc2363318a + tamoxifen
D04ZXE-D07KSG	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04WFL-D04ZXE	TTDDRUID	D04WFL-D04ZXE
D04WFL-D04ZXE	DRUGNAME	msc2363318a + trastuzumab
D04WFL-D04ZXE	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04FBR-D0T6DK	TTDDRUID	D04FBR-D0T6DK
D04FBR-D0T6DK	DRUGNAME	Mycophenolate mofetil + Rapamycin
D04FBR-D0T6DK	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D04FBR-D0G3DL	TTDDRUID	D04FBR-D0G3DL
D04FBR-D0G3DL	DRUGNAME	Mycophenolate mofetil + Rifampin
D04FBR-D0G3DL	INDICATI	Organ transplant rejection [ICD-11: NE84] Preclinical

D04FBR-D06OMK	TTDDRUID	D04FBR-D06OMK
D04FBR-D06OMK	DRUGNAME	Mycophenolate mofetil + Tacrolimus
D04FBR-D06OMK	INDICATI	Heart transplant rejection [ICD-11: NE84] Phase 4
D04FBR-D06OMK	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 4
D04FBR-D06OMK	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D06MRY-D0O3TB	TTDDRUID	D06MRY-D0O3TB
D06MRY-D0O3TB	DRUGNAME	myfortic + steroid
D06MRY-D0O3TB	INDICATI	Lipoid nephrosis [ICD-11: GB41] Phase 4

D03SKD-D0X3FX	TTDDRUID	D03SKD-D0X3FX
D03SKD-D0X3FX	DRUGNAME	Naloxone + Oxycodone
D03SKD-D0X3FX	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D0W6DG-D0X3FX	TTDDRUID	D0W6DG-D0X3FX
D0W6DG-D0X3FX	DRUGNAME	Naloxone + Pentazocine
D0W6DG-D0X3FX	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D00OQW-D0PG8O	TTDDRUID	D00OQW-D0PG8O
D00OQW-D0PG8O	DRUGNAME	naltrexone + n-acetyl cysteine
D00OQW-D0PG8O	INDICATI	Methamphetamine dependence [ICD-11: 6C46.2] Phase 2

D0K0TC-D0PG8O	TTDDRUID	D0K0TC-D0PG8O
D0K0TC-D0PG8O	DRUGNAME	Naltrexone + Sertraline
D0K0TC-D0PG8O	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 4

D00HHS-D0DJ1B	TTDDRUID	D00HHS-D0DJ1B
D00HHS-D0DJ1B	DRUGNAME	Naproxen + Pseudoephedrine
D00HHS-D0DJ1B	INDICATI	Cough [ICD-11: MD12] Approved

D0DJ1B-D0Z6UC	TTDDRUID	D0DJ1B-D0Z6UC
D0DJ1B-D0Z6UC	DRUGNAME	Naproxen + Sumatriptan
D0DJ1B-D0Z6UC	INDICATI	Migraine [ICD-11: 8A80] Approved
D0DJ1B-D0Z6UC	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D08NQZ-D0DJ1B	TTDDRUID	D08NQZ-D0DJ1B
D08NQZ-D0DJ1B	DRUGNAME	Naproxen + Tetracycline
D08NQZ-D0DJ1B	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical

D0DJ1B-D0T3KI	TTDDRUID	D0DJ1B-D0T3KI
D0DJ1B-D0T3KI	DRUGNAME	naratriptan + naproxen
D0DJ1B-D0T3KI	INDICATI	Headache [ICD-11: 8A80-8A84] Phase 3
D0DJ1B-D0T3KI	INDICATI	Migraine [ICD-11: 8A80] Phase 3

D06PSS-D06UDG	TTDDRUID	D06PSS-D06UDG
D06PSS-D06UDG	DRUGNAME	Nateglinide + Valsartan
D06PSS-D06UDG	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D09OOV-D05JNI	TTDDRUID	D09OOV-D05JNI
D09OOV-D05JNI	DRUGNAME	Neomycin + Polymyxin B Sulfate
D09OOV-D05JNI	INDICATI	Bladder cancer [ICD-11: 2C94] Approved

D0D1SG-D05JNI	TTDDRUID	D0D1SG-D05JNI
D0D1SG-D05JNI	DRUGNAME	Neomycin + Prednisolone
D0D1SG-D05JNI	INDICATI	Infected skin disorder [ICD-11: 1A36-1F6A] Approved

D03BLF-D05JNI	TTDDRUID	D03BLF-D05JNI
D03BLF-D05JNI	DRUGNAME	Neomycin + Triamcinolone
D03BLF-D05JNI	INDICATI	Cutaneous or mucocutaneous mycotic infection [ICD-11: 1C10] Approved

D08USJ-D0RG3O	TTDDRUID	D08USJ-D0RG3O
D08USJ-D0RG3O	DRUGNAME	neostigmine + atropine
D08USJ-D0RG3O	INDICATI	Hypospadias [ICD-11: LB53] Phase 2/3

D0C4RB-D0Q9CY	TTDDRUID	D0C4RB-D0Q9CY
D0C4RB-D0Q9CY	DRUGNAME	Neratinib + Paclitaxel
D0C4RB-D0Q9CY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D01HTL-D0Q9CY	TTDDRUID	D01HTL-D0Q9CY
D01HTL-D0Q9CY	DRUGNAME	Neratinib + Vinorelbine
D01HTL-D0Q9CY	INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
D01HTL-D0Q9CY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
D01HTL-D0Q9CY	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D04FVU-D0G3YC	TTDDRUID	D04FVU-D0G3YC
D04FVU-D0G3YC	DRUGNAME	Netupitant + Palonosetron Hydrochloride
D04FVU-D0G3YC	INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Approved

D01XYJ-D0O2EM	TTDDRUID	D01XYJ-D0O2EM
D01XYJ-D0O2EM	DRUGNAME	Nevirapine + Zidovudine
D01XYJ-D0O2EM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D00MAI-D0H0ND	TTDDRUID	D00MAI-D0H0ND
D00MAI-D0H0ND	DRUGNAME	Niacin + Simvastatin
D00MAI-D0H0ND	INDICATI	High cholesterol level [ICD-11: 5C80.0] Approved

D0FC1J-D0X7JR	TTDDRUID	D0FC1J-D0X7JR
D0FC1J-D0X7JR	DRUGNAME	nifurtimox + eflornithine
D0FC1J-D0X7JR	INDICATI	African trypanosomiasis [ICD-11: 1F51] Phase 3

D00STL-D0N5OV	TTDDRUID	D00STL-D0N5OV
D00STL-D0N5OV	DRUGNAME	nilotinib + cetuximab
D00STL-D0N5OV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D00STL-D09BNZ	TTDDRUID	D00STL-D09BNZ
D00STL-D09BNZ	DRUGNAME	nilotinib + lde225
D00STL-D09BNZ	INDICATI	Philadelphia chromosome positive chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1

D08EBN-D08NWC	TTDDRUID	D08EBN-D08NWC
D08EBN-D08NWC	DRUGNAME	nitazoxanide + peginterferon alfa-2b
D08EBN-D08NWC	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D00GOV-D07BVI	TTDDRUID	D00GOV-D07BVI
D00GOV-D07BVI	DRUGNAME	nivolumab + ipilimumab
D00GOV-D07BVI	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
D00GOV-D07BVI	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D00GOV-D07BVI	INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2

D00GOV-D0ZE1O	TTDDRUID	D00GOV-D0ZE1O
D00GOV-D0ZE1O	DRUGNAME	nivolumab + plinabulin
D00GOV-D0ZE1O	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0H5IZ-D0N5OV	TTDDRUID	D0H5IZ-D0N5OV
D0H5IZ-D0N5OV	DRUGNAME	nktr-102 + cetuximab
D0H5IZ-D0N5OV	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
D0H5IZ-D0N5OV	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D07MOX-D0P4VX	TTDDRUID	D07MOX-D0P4VX
D07MOX-D0P4VX	DRUGNAME	Norepinephrine + Terlipressin
D07MOX-D0P4VX	INDICATI	Type 2 hepatorenal syndrome [ICD-11: DB99.2] Phase 3

D03QRS-D0GL7U	TTDDRUID	D03QRS-D0GL7U
D03QRS-D0GL7U	DRUGNAME	Norethindrone + Triptorelin
D03QRS-D0GL7U	INDICATI	Ovarian function restoration [ICD-11: 5A80.Y] Phase 2/3

D0E7PQ-D0N0RN	TTDDRUID	D0E7PQ-D0N0RN
D0E7PQ-D0N0RN	DRUGNAME	npi-0052 + vorinostat
D0E7PQ-D0N0RN	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
D0E7PQ-D0N0RN	INDICATI	Melanoma [ICD-11: 2C30] Phase 1
D0E7PQ-D0N0RN	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
D0E7PQ-D0N0RN	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0E7PQ-D0N0RN	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1

D0O5WP-D0ZE1O	TTDDRUID	D0O5WP-D0ZE1O
D0O5WP-D0ZE1O	DRUGNAME	npi-2358 + docetaxel
D0O5WP-D0ZE1O	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2

D04WFN-D0C4RB	TTDDRUID	D04WFN-D0C4RB
D04WFN-D0C4RB	DRUGNAME	NU6140 + Paclitaxel
D04WFN-D0C4RB	INDICATI	Cervical cancer [ICD-11: 2C77.0] Preclinical

D03BLF-D08XAC	TTDDRUID	D03BLF-D08XAC
D03BLF-D08XAC	DRUGNAME	Nystatin + Triamcinolone
D03BLF-D08XAC	INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved

D02OZK-D02PMO	TTDDRUID	D02OZK-D02PMO
D02OZK-D02PMO	DRUGNAME	Obatoclax mesylate + Topotecan
D02OZK-D02PMO	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D01CYA-D0Y8ZN	TTDDRUID	D01CYA-D0Y8ZN
D01CYA-D0Y8ZN	DRUGNAME	ofatumumab + bendamustine
D01CYA-D0Y8ZN	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
D01CYA-D0Y8ZN	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2

D0Y7ZU-D0Y8ZN	TTDDRUID	D0Y7ZU-D0Y8ZN
D0Y7ZU-D0Y8ZN	DRUGNAME	ofatumumab + dacarbazine
D0Y7ZU-D0Y8ZN	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0IT2G-D0Y8ZN	TTDDRUID	D0IT2G-D0Y8ZN
D0IT2G-D0Y8ZN	DRUGNAME	ofatumumab + dexamethasone
D0IT2G-D0Y8ZN	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D0K0TC-D0V4QS	TTDDRUID	D0K0TC-D0V4QS
D0K0TC-D0V4QS	DRUGNAME	Olanzapine + Sertraline
D0K0TC-D0V4QS	INDICATI	Major depression with psychotic feature [ICD-11: 6A70.4] Phase 3

D0Y3KG-D0V4QS	TTDDRUID	D0Y3KG-D0V4QS
D0Y3KG-D0V4QS	DRUGNAME	Olanzapine + Valproic Acid
D0Y3KG-D0V4QS	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 4

D0C4RB-D0J9HW	TTDDRUID	D0C4RB-D0J9HW
D0C4RB-D0J9HW	DRUGNAME	Olaparib + Paclitaxel
D0C4RB-D0J9HW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D02GEC-D0LC6K	TTDDRUID	D02GEC-D0LC6K
D02GEC-D0LC6K	DRUGNAME	Omalizumab + Fluticasone
D02GEC-D0LC6K	INDICATI	Asthma [ICD-11: CA23] Phase 3

D01XNB-D0D3DU	TTDDRUID	D01XNB-D0D3DU
D01XNB-D0D3DU	DRUGNAME	Omeprazole + Methotrexate Sodium
D01XNB-D0D3DU	INDICATI	Malignant disease [ICD-11: 2A21-2E2Z] Investigative

D01XNB-D02FLB	TTDDRUID	D01XNB-D02FLB
D01XNB-D02FLB	DRUGNAME	Omeprazole + Sodium bicarbonate
D01XNB-D02FLB	INDICATI	Heartburn or irritation of the esophagus [ICD-11: MD95] Approved

D0IT2G-D0K7WK	TTDDRUID	D0IT2G-D0K7WK
D0IT2G-D0K7WK	DRUGNAME	ondansetron + dexamethasone
D0IT2G-D0K7WK	INDICATI	Nausea [ICD-11: MD90] Phase 4

D02KRS-D0O5NK	TTDDRUID	D02KRS-D0O5NK
D02KRS-D0O5NK	DRUGNAME	oseltamivir + amantadine
D02KRS-D0O5NK	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D00NPP-D0O5NK	TTDDRUID	D00NPP-D0O5NK
D00NPP-D0O5NK	DRUGNAME	oseltamivir + zanamivir
D00NPP-D0O5NK	INDICATI	Gastric influenza [ICD-11: 1A40.Z] Phase 3
D00NPP-D0O5NK	INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2

D05LEO-D0Y3ME	TTDDRUID	D05LEO-D0Y3ME
D05LEO-D0Y3ME	DRUGNAME	oxaliplatin + 5fu
D05LEO-D0Y3ME	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3

D0O5WP-D0Y3ME	TTDDRUID	D0O5WP-D0Y3ME
D0O5WP-D0Y3ME	DRUGNAME	oxaliplatin + docetaxel
D0O5WP-D0Y3ME	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D07VDZ-D0QL3P	TTDDRUID	D07VDZ-D0QL3P
D07VDZ-D0QL3P	DRUGNAME	Oxcarbazepine + Topiramate
D07VDZ-D0QL3P	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D00WUF-D03SKD	TTDDRUID	D00WUF-D03SKD
D00WUF-D03SKD	DRUGNAME	Oxycodone + Pregabalin
D00WUF-D03SKD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D00MAI-D03SKD	TTDDRUID	D00MAI-D03SKD
D00MAI-D03SKD	DRUGNAME	oxycodone hcl + niacin
D00MAI-D03SKD	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2

D09OOV-D0J2NK	TTDDRUID	D09OOV-D0J2NK
D09OOV-D0J2NK	DRUGNAME	Oxytetracycline + Polymyxin B Sulfate
D09OOV-D0J2NK	INDICATI	Ocular infection [ICD-11: 1F00.1] Approved

D02AYL-D0XF8W	TTDDRUID	D02AYL-D0XF8W
D02AYL-D0XF8W	DRUGNAME	PA-824 + Pyrazinamide
D02AYL-D0XF8W	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D0C4RB-D0X7HM	TTDDRUID	D0C4RB-D0X7HM
D0C4RB-D0X7HM	DRUGNAME	paclitaxel + carboplatin
D0C4RB-D0X7HM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
D0C4RB-D0X7HM	INDICATI	Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 1
D0C4RB-D0X7HM	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D0C4RB-D0X7HM	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0C4RB-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
D0C4RB-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0C4RB-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
D0C4RB-D0X7HM	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1
D0C4RB-D0X7HM	INDICATI	Pulmonary large cell neuroendocrine carcinoma [ICD-11: 2B70-2C34] Phase 2
D0C4RB-D0X7HM	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0C4RB-D0X7HM	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
D0C4RB-D0X7HM	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1
D0C4RB-D0X7HM	INDICATI	Uterine cancer [ICD-11: 2C78] Phase 2

D0C4RB-D0U5HU	TTDDRUID	D0C4RB-D0U5HU
D0C4RB-D0U5HU	DRUGNAME	paclitaxel + cisplatin
D0C4RB-D0U5HU	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0C4RB-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative

D0C4RB-D0XA1B	TTDDRUID	D0C4RB-D0XA1B
D0C4RB-D0XA1B	DRUGNAME	Paclitaxel + Peloruside A
D0C4RB-D0XA1B	INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Preclinical
D0C4RB-D0XA1B	INDICATI	Ovarian cancer [ICD-11: 2C73] Preclinical

D04VFJ-D0C4RB	TTDDRUID	D04VFJ-D0C4RB
D04VFJ-D0C4RB	DRUGNAME	Paclitaxel + Toremifene
D04VFJ-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D03RTK-D0C4RB	TTDDRUID	D03RTK-D0C4RB
D03RTK-D0C4RB	DRUGNAME	Paclitaxel + Trabectedin
D03RTK-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical

D04WFL-D0C4RB	TTDDRUID	D04WFL-D0C4RB
D04WFL-D0C4RB	DRUGNAME	Paclitaxel + Trastuzumab
D04WFL-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D04WFL-D0C4RB	INDICATI	HER2-positive advanced breast cancer [ICD-11: 2C60-2C65] Investigative

D0C4RB-D0NF6F	TTDDRUID	D0C4RB-D0NF6F
D0C4RB-D0NF6F	DRUGNAME	Paclitaxel + Trichostatin A
D0C4RB-D0NF6F	INDICATI	Endometrial cancer [ICD-11: 2C76] Preclinical

D04KQF-D0C4RB	TTDDRUID	D04KQF-D0C4RB
D04KQF-D0C4RB	DRUGNAME	Paclitaxel + Tubacin
D04KQF-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
D04KQF-D0C4RB	INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical

D0AZ8C-D0PD0F	TTDDRUID	D0AZ8C-D0PD0F
D0AZ8C-D0PD0F	DRUGNAME	paeoniflorin + silymarin
D0AZ8C-D0PD0F	INDICATI	Hepatitis autoimmune [ICD-11: DB96.0] Phase 3

D0C4RB-D0HU9H	TTDDRUID	D0C4RB-D0HU9H
D0C4RB-D0HU9H	DRUGNAME	panitumumab + paclitaxel
D0C4RB-D0HU9H	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D03BQP-D0T6XX	TTDDRUID	D03BQP-D0T6XX
D03BQP-D0T6XX	DRUGNAME	Pantoprazole + Rebamipide
D03BQP-D0T6XX	INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative

D0R1QE-D0V7OY	TTDDRUID	D0R1QE-D0V7OY
D0R1QE-D0V7OY	DRUGNAME	paracetamol + ibuprofen
D0R1QE-D0V7OY	INDICATI	Long-bone fracture [ICD-11: ND56.2] Phase 3
D0R1QE-D0V7OY	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
D0R1QE-D0V7OY	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 4

D04NDM-D09BBW	TTDDRUID	D04NDM-D09BBW
D04NDM-D09BBW	DRUGNAME	Paromomycin + Sodium stibogluconate
D04NDM-D09BBW	INDICATI	Visceral leishmaniasis [ICD-11: 1F54.0] Phase 3

D06GDY-D0X4ZR	TTDDRUID	D06GDY-D0X4ZR
D06GDY-D0X4ZR	DRUGNAME	paroxetine + bupropion
D06GDY-D0X4ZR	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D06GDY-D07WXT	TTDDRUID	D06GDY-D07WXT
D06GDY-D07WXT	DRUGNAME	paroxetine + lithium
D06GDY-D07WXT	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D06GDY-D0P1UX	TTDDRUID	D06GDY-D0P1UX
D06GDY-D0P1UX	DRUGNAME	paroxetine + venlafaxine xr
D06GDY-D0P1UX	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 4

D0K3QS-D0TV0C	TTDDRUID	D0K3QS-D0TV0C
D0K3QS-D0TV0C	DRUGNAME	pasireotide lar + everolimus
D0K3QS-D0TV0C	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2

D04WFL-D0N2QW	TTDDRUID	D04WFL-D0N2QW
D04WFL-D0N2QW	DRUGNAME	patritumab + trastuzumab
D04WFL-D0N2QW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00HCQ-D0F0ZY	TTDDRUID	D00HCQ-D0F0ZY
D00HCQ-D0F0ZY	DRUGNAME	pazopanib + capecitabine
D00HCQ-D0F0ZY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D03UVS-D0F0ZY	TTDDRUID	D03UVS-D0F0ZY
D03UVS-D0F0ZY	DRUGNAME	pazopanib + gemcitabine
D03UVS-D0F0ZY	INDICATI	Uterine cancer [ICD-11: 2C78] Phase 2

D05DZK-D0F0ZY	TTDDRUID	D05DZK-D0F0ZY
D05DZK-D0F0ZY	DRUGNAME	pazopanib + interferon alpha 2a
D05DZK-D0F0ZY	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2

D0C4RB-D0F0ZY	TTDDRUID	D0C4RB-D0F0ZY
D0C4RB-D0F0ZY	DRUGNAME	pazopanib + paclitaxel
D0C4RB-D0F0ZY	INDICATI	Angiosarcoma [ICD-11: 2B56] Phase 2
D0C4RB-D0F0ZY	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0ML1F-D0Y8OK	TTDDRUID	D0ML1F-D0Y8OK
D0ML1F-D0Y8OK	DRUGNAME	peginterferon alfa-2a + adefovir
D0ML1F-D0Y8OK	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D0KR2J-D0Y8OK	TTDDRUID	D0KR2J-D0Y8OK
D0KR2J-D0Y8OK	DRUGNAME	peginterferon alfa-2a + entecavir
D0KR2J-D0Y8OK	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D07TQV-D0Y8OK	TTDDRUID	D07TQV-D0Y8OK
D07TQV-D0Y8OK	DRUGNAME	peginterferon alfa-2a + lamivudine
D07TQV-D0Y8OK	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D0H3WI-D0Y8OK	TTDDRUID	D0H3WI-D0Y8OK
D0H3WI-D0Y8OK	DRUGNAME	Peginterferon alfa-2a + Ribavirin
D0H3WI-D0Y8OK	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 3
D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Approved
D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Investigative
D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2
D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2/3
D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3
D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 4
D0H3WI-D0Y8OK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0H3WI-D0Y8OK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0D9HW-D0Y8OK	TTDDRUID	D0D9HW-D0Y8OK
D0D9HW-D0Y8OK	DRUGNAME	peginterferon alfa-2a + tenofovir
D0D9HW-D0Y8OK	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D08NWC-D0H3WI	TTDDRUID	D08NWC-D0H3WI
D08NWC-D0H3WI	DRUGNAME	Peginterferon alfa-2b + Ribavirin
D08NWC-D0H3WI	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3
D08NWC-D0H3WI	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 4
D08NWC-D0H3WI	INDICATI	Chronic HCV-2 or HCV-3 infection [ICD-11: 1E51.1] Approved

D08NWC-D0W5HK	TTDDRUID	D08NWC-D0W5HK
D08NWC-D0W5HK	DRUGNAME	Peginterferon alfa-2b + Sorafenib
D08NWC-D0W5HK	INDICATI	Melanoma [ICD-11: 2C30] Phase 2

D0D1XW-D0H3WI	TTDDRUID	D0D1XW-D0H3WI
D0D1XW-D0H3WI	DRUGNAME	peg-interferon alpha2a + ribavirin
D0D1XW-D0H3WI	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 4

D05TGV-D0H3WI	TTDDRUID	D05TGV-D0H3WI
D05TGV-D0H3WI	DRUGNAME	pegylated interferon + ribavirin
D05TGV-D0H3WI	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D03UVS-D0Y4GO	TTDDRUID	D03UVS-D0Y4GO
D03UVS-D0Y4GO	DRUGNAME	pemetrexed + gemcitabine
D03UVS-D0Y4GO	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2

D0C4RB-D0Y4GO	TTDDRUID	D0C4RB-D0Y4GO
D0C4RB-D0Y4GO	DRUGNAME	pemetrexed + paclitaxel
D0C4RB-D0Y4GO	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 2

D00MYT-D0F0YZ	TTDDRUID	D00MYT-D0F0YZ
D00MYT-D0F0YZ	DRUGNAME	Pentobarbital + Thiopental
D00MYT-D0F0YZ	INDICATI	Status epilepticus seizure [ICD-11: 8A66.1Y] Phase 3

D0ES1Q-D0R1VU	TTDDRUID	D0ES1Q-D0R1VU
D0ES1Q-D0R1VU	DRUGNAME	perifosine + temsirolimus
D0ES1Q-D0R1VU	INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1

D03KYG-D0U4UQ	TTDDRUID	D03KYG-D0U4UQ
D03KYG-D0U4UQ	DRUGNAME	perindopril + hydrochlorothiazide
D03KYG-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D04WFL-D0CI4E	TTDDRUID	D04WFL-D0CI4E
D04WFL-D0CI4E	DRUGNAME	Pertuzumab + Trastuzumab
D04WFL-D0CI4E	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D04WFL-D0CI4E	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0C1WH-D0N5JZ	TTDDRUID	D0C1WH-D0N5JZ
D0C1WH-D0N5JZ	DRUGNAME	pf-04691502 + letrozole
D0C1WH-D0N5JZ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00VUL-D0R9OH	TTDDRUID	D00VUL-D0R9OH
D00VUL-D0R9OH	DRUGNAME	Phenazopyridine hydrochloride + Sulfamethoxazole
D00VUL-D0R9OH	INDICATI	Bronchitis [ICD-11: CA20] Approved
D00VUL-D0R9OH	INDICATI	Prostate disease [ICD-11: GA91] Approved
D00VUL-D0R9OH	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D00VUL-D09TBD	TTDDRUID	D00VUL-D09TBD
D00VUL-D09TBD	DRUGNAME	Phenazopyridine hydrochloride + Sulfisoxazole
D00VUL-D09TBD	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D04OBB-D0O6IZ	TTDDRUID	D04OBB-D0O6IZ
D04OBB-D0O6IZ	DRUGNAME	Pheniramine + Naphazoline
D04OBB-D0O6IZ	INDICATI	Minor eye symptoms of itching and redness [ICD-11: MC10] Approved

D07VDZ-D0U0RZ	TTDDRUID	D07VDZ-D0U0RZ
D07VDZ-D0U0RZ	DRUGNAME	Phentermine + Topiramate
D07VDZ-D0U0RZ	INDICATI	Chronic weight management [ICD-11: 5B80] Approved

D0O6IU-D0T2XU	TTDDRUID	D0O6IU-D0T2XU
D0O6IU-D0T2XU	DRUGNAME	Phenylephrine + Promethazine
D0O6IU-D0T2XU	INDICATI	Upper respiratory tract symptom [ICD-11: CA0Z] Approved

D00HHS-D0O6IU	TTDDRUID	D00HHS-D0O6IU
D00HHS-D0O6IU	DRUGNAME	Phenylephrine + Pseudoephedrine
D00HHS-D0O6IU	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3

D01NJI-D0O6IU	TTDDRUID	D01NJI-D0O6IU
D01NJI-D0O6IU	DRUGNAME	Phenylephrine + Pyrilamine maleate
D01NJI-D0O6IU	INDICATI	Nasal congestion [ICD-11: MD11.9] Approved

D0Y3KG-D0E4DW	TTDDRUID	D0Y3KG-D0E4DW
D0Y3KG-D0E4DW	DRUGNAME	Phenytoin + Valproic Acid
D0Y3KG-D0E4DW	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D03OFF-D0K9MY	TTDDRUID	D03OFF-D0K9MY
D03OFF-D0K9MY	DRUGNAME	Pioglitazone + Saxagliptin
D03OFF-D0K9MY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03OFF-D0H0ND	TTDDRUID	D03OFF-D0H0ND
D03OFF-D0H0ND	DRUGNAME	pioglitazone + simvastatin
D03OFF-D0H0ND	INDICATI	Glucose metabolism disorder [ICD-11: 5C61.0] Phase 4

D03OFF-D0L3DK	TTDDRUID	D03OFF-D0L3DK
D03OFF-D0L3DK	DRUGNAME	Pioglitazone + Vildagliptin
D03OFF-D0L3DK	INDICATI	Type 2 diabetes [ICD-11: 5A11] Investigative

D04ZAH-D0F6EO	TTDDRUID	D04ZAH-D0F6EO
D04ZAH-D0F6EO	DRUGNAME	piperacillin + amoxicillin
D04ZAH-D0F6EO	INDICATI	Acute appendicitis [ICD-11: DB10.0] Investigative

D04ZAH-D0QQ7D	TTDDRUID	D04ZAH-D0QQ7D
D04ZAH-D0QQ7D	DRUGNAME	Piperacillin + Tazobactam
D04ZAH-D0QQ7D	INDICATI	Joint infection [ICD-11: FA10] Approved
D04ZAH-D0QQ7D	INDICATI	Pneumonia [ICD-11: CA40] Approved
D04ZAH-D0QQ7D	INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved
D04ZAH-D0QQ7D	INDICATI	Stomach infection [ICD-11: DA42.Z] Approved
D04ZAH-D0QQ7D	INDICATI	Urinary tract infection [ICD-11: GC08] Approved
D04ZAH-D0QQ7D	INDICATI	Vaginal infection [ICD-11: GA02.0] Approved

D07QJK-D0IT2G	TTDDRUID	D07QJK-D0IT2G
D07QJK-D0IT2G	DRUGNAME	plitidepsin + dexamethasone
D07QJK-D0IT2G	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D06YSM-D0J9HW	TTDDRUID	D06YSM-D0J9HW
D06YSM-D0J9HW	DRUGNAME	pm01183 + olaparib
D06YSM-D0J9HW	INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2

D03QWT-D09OOV	TTDDRUID	D03QWT-D09OOV
D03QWT-D09OOV	DRUGNAME	polymyxin b + doripenem
D03QWT-D09OOV	INDICATI	Bacteremia [ICD-11: 1A73] Phase 2/3
D03QWT-D09OOV	INDICATI	Healthcare-associated pneumonia [ICD-11: CA00-CA40] Phase 2/3
D03QWT-D09OOV	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2/3

D09OOV-D0AO5H	TTDDRUID	D09OOV-D0AO5H
D09OOV-D0AO5H	DRUGNAME	Polymyxin B Sulfate + Trimethoprim
D09OOV-D0AO5H	INDICATI	Ocular bacterial infection [ICD-11: 9C20] Approved

D06TNG-D0WV3U	TTDDRUID	D06TNG-D0WV3U
D06TNG-D0WV3U	DRUGNAME	Polythiazide + Prazosin
D06TNG-D0WV3U	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06TNG-D0J4JM	TTDDRUID	D06TNG-D0J4JM
D06TNG-D0J4JM	DRUGNAME	Polythiazide + Reserpine
D06TNG-D0J4JM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D07ABV-D0BZ7W	TTDDRUID	D07ABV-D0BZ7W
D07ABV-D0BZ7W	DRUGNAME	Posaconazole + Tolterodine
D07ABV-D0BZ7W	INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Phase 3

D07IRF-D0GY5Z	TTDDRUID	D07IRF-D0GY5Z
D07IRF-D0GY5Z	DRUGNAME	prasugrel + aspirin
D07IRF-D0GY5Z	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4
D07IRF-D0GY5Z	INDICATI	Myocardial ischemia [ICD-11: BA6Z] Phase 4
D07IRF-D0GY5Z	INDICATI	Vascular disease [ICD-11: BE2Z] Phase 4

D02RQU-D0H0ND	TTDDRUID	D02RQU-D0H0ND
D02RQU-D0H0ND	DRUGNAME	Pravastatin + Simvastatin
D02RQU-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4

D02RQU-D06UDG	TTDDRUID	D02RQU-D06UDG
D02RQU-D06UDG	DRUGNAME	Pravastatin + Valsartan
D02RQU-D06UDG	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D0D1SG-D0LC6K	TTDDRUID	D0D1SG-D0LC6K
D0D1SG-D0LC6K	DRUGNAME	Prednisolone + Fluticasone
D0D1SG-D0LC6K	INDICATI	Nasal polyp [ICD-11: CA0J] Phase 4

D09EXD-D0D1SG	TTDDRUID	D09EXD-D0D1SG
D09EXD-D0D1SG	DRUGNAME	prednisolone + mabthera
D09EXD-D0D1SG	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 3

D0D1SG-D0M4VM	TTDDRUID	D0D1SG-D0M4VM
D0D1SG-D0M4VM	DRUGNAME	Prednisolone + Sulfacetamide
D0D1SG-D0M4VM	INDICATI	Eye inflammation [ICD-11: 9A02] Approved

D04QJD-D0D1SG	TTDDRUID	D04QJD-D0D1SG
D04QJD-D0D1SG	DRUGNAME	prednisolone + valaciclovir
D04QJD-D0D1SG	INDICATI	Bell palsy [ICD-11: 8B88.0] Phase 4

D0DD0K-D0IL7L	TTDDRUID	D0DD0K-D0IL7L
D0DD0K-D0IL7L	DRUGNAME	prednisone + cozaar
D0DD0K-D0IL7L	INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Investigative

D04GKO-D0IL7L	TTDDRUID	D04GKO-D0IL7L
D04GKO-D0IL7L	DRUGNAME	prednisone + inhibace
D04GKO-D0IL7L	INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Investigative

D0IL7L-D0R3JB	TTDDRUID	D0IL7L-D0R3JB
D0IL7L-D0R3JB	DRUGNAME	Prednisone + Mitoxantrone
D0IL7L-D0R3JB	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 3

D09EXD-D0IL7L	TTDDRUID	D09EXD-D0IL7L
D09EXD-D0IL7L	DRUGNAME	Prednisone + Rituximab
D09EXD-D0IL7L	INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2/3

D0IL7L-D0U7GK	TTDDRUID	D0IL7L-D0U7GK
D0IL7L-D0U7GK	DRUGNAME	Prednisone + Thalidomide
D0IL7L-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D08NQZ-D0TZ1G	TTDDRUID	D08NQZ-D0TZ1G
D08NQZ-D0TZ1G	DRUGNAME	Procaine + Tetracycline
D08NQZ-D0TZ1G	INDICATI	Rocky mountain spotted fever [ICD-11: 1C31.0] Approved
D08NQZ-D0TZ1G	INDICATI	Tick fevers [ICD-11: 1D31-1D4Z] Approved
D08NQZ-D0TZ1G	INDICATI	Typhus fever [ICD-11: 1C30] Approved
D08NQZ-D0TZ1G	INDICATI	Upper respiratory infection [ICD-11: CA07] Approved

D0F8RA-D0TZ1G	TTDDRUID	D0F8RA-D0TZ1G
D0F8RA-D0TZ1G	DRUGNAME	Procaine + Theophylline
D0F8RA-D0TZ1G	INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved

D0A3HB-D0T5OX	TTDDRUID	D0A3HB-D0T5OX
D0A3HB-D0T5OX	DRUGNAME	Propofol + Remifentanil
D0A3HB-D0T5OX	INDICATI	Anaesthesia [ICD-11: 9A78.6] Phase 4
D0A3HB-D0T5OX	INDICATI	Hypothermia [ICD-11: NF02] Phase 4
D0A3HB-D0T5OX	INDICATI	Spinal puncture [ICD-11: NB62.6] Phase 3

D0A3HB-D0W6ZF	TTDDRUID	D0A3HB-D0W6ZF
D0A3HB-D0W6ZF	DRUGNAME	Propofol + Sevoflurane
D0A3HB-D0W6ZF	INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Investigative
D0A3HB-D0W6ZF	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D00HHS-D0E8CI	TTDDRUID	D00HHS-D0E8CI
D00HHS-D0E8CI	DRUGNAME	Pseudoephedrine + Triprolidine
D00HHS-D0E8CI	INDICATI	Rhinorrhea [ICD-11: CA0Y] Approved

D0C0SK-D07PAO	TTDDRUID	D0C0SK-D07PAO
D0C0SK-D07PAO	DRUGNAME	Pyrimethamine + Sulfadoxine
D0C0SK-D07PAO	INDICATI	Malaria [ICD-11: 1F40-1F45] Approved

D07VDZ-D0H7KF	TTDDRUID	D07VDZ-D0H7KF
D07VDZ-D0H7KF	DRUGNAME	quetiapine + topiramate
D07VDZ-D0H7KF	INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 4

D0J4JM-D0J8ZA	TTDDRUID	D0J4JM-D0J8ZA
D0J4JM-D0J8ZA	DRUGNAME	Quinethazone + Reserpine
D0J4JM-D0J8ZA	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03DDR-D0E3OF	TTDDRUID	D03DDR-D0E3OF
D03DDR-D0E3OF	DRUGNAME	Quinidine + Warfarin
D03DDR-D0E3OF	INDICATI	Coagulation defect [ICD-11: 3B10.0] Preclinical

D03DDR-D0R0ZL	TTDDRUID	D03DDR-D0R0ZL
D03DDR-D0R0ZL	DRUGNAME	quinine + clindamycin
D03DDR-D0R0ZL	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D07VDZ-D07MEH	TTDDRUID	D07VDZ-D07MEH
D07VDZ-D07MEH	DRUGNAME	Raclopride + Topiramate
D07VDZ-D07MEH	INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical

D00AKR-D0K3QS	TTDDRUID	D00AKR-D0K3QS
D00AKR-D0K3QS	DRUGNAME	rad001 + amg479
D00AKR-D0K3QS	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1

D0K3QS-D0VG0D	TTDDRUID	D0K3QS-D0VG0D
D0K3QS-D0VG0D	DRUGNAME	rad001 + bez235
D0K3QS-D0VG0D	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D07TQV-D0I1FQ	TTDDRUID	D07TQV-D0I1FQ
D07TQV-D0I1FQ	DRUGNAME	raltegravir + lamivudine
D07TQV-D0I1FQ	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 3

D0D9HW-D0I1FQ	TTDDRUID	D0D9HW-D0I1FQ
D0D9HW-D0I1FQ	DRUGNAME	raltegravir + tenofovir df
D0D9HW-D0I1FQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D01STB-D01UXC	TTDDRUID	D01STB-D01UXC
D01STB-D01UXC	DRUGNAME	ramipril + atenolol
D01STB-D01UXC	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative

D01STB-D0WN0U	TTDDRUID	D01STB-D0WN0U
D01STB-D0WN0U	DRUGNAME	ramipril + felodipine
D01STB-D0WN0U	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4

D01STB-D06UDG	TTDDRUID	D01STB-D06UDG
D01STB-D06UDG	DRUGNAME	ramipril + valsartan
D01STB-D06UDG	INDICATI	Heavy proteinuria [ICD-11: MF96] Phase 4

D04EYG-D0I3XG	TTDDRUID	D04EYG-D0I3XG
D04EYG-D0I3XG	DRUGNAME	Ranibizumab + Verteporfin
D04EYG-D0I3XG	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2/3
D04EYG-D0I3XG	INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 3
D04EYG-D0I3XG	INDICATI	Polypoidal choroidal vasculopathy [ICD-11: 9B75.Y] Phase 4

D06OMK-D0T6DK	TTDDRUID	D06OMK-D0T6DK
D06OMK-D0T6DK	DRUGNAME	Rapamycin + Tacrolimus
D06OMK-D0T6DK	INDICATI	Acute graft versus host disease [ICD-11: 4B24.0] Phase 2
D06OMK-D0T6DK	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 4

D0BN9X-D0T6DK	TTDDRUID	D0BN9X-D0T6DK
D0BN9X-D0T6DK	DRUGNAME	Rapamycin + Tirofiban
D0BN9X-D0T6DK	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 4

D06OMW-D08HVR	TTDDRUID	D06OMW-D08HVR
D06OMW-D08HVR	DRUGNAME	rasagiline mesylate + levodopa
D06OMW-D08HVR	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 4

D06OMW-D0G8NN	TTDDRUID	D06OMW-D0G8NN
D06OMW-D0G8NN	DRUGNAME	rasagiline mesylate + mirapex
D06OMW-D0G8NN	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 4

D06OMW-D0R9EQ	TTDDRUID	D06OMW-D0R9EQ
D06OMW-D0R9EQ	DRUGNAME	rasagiline mesylate + requip
D06OMW-D0R9EQ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 4

D01EKN-D03UVS	TTDDRUID	D01EKN-D03UVS
D01EKN-D03UVS	DRUGNAME	rav12 + gemcitabine
D01EKN-D03UVS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D09GDD-D0HU9H	TTDDRUID	D09GDD-D0HU9H
D09GDD-D0HU9H	DRUGNAME	regorafenib + panitumumab
D09GDD-D0HU9H	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1

D0J4JM-D0Y2IZ	TTDDRUID	D0J4JM-D0Y2IZ
D0J4JM-D0Y2IZ	DRUGNAME	Reserpine + Trichlormethiazide
D0J4JM-D0Y2IZ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D00OEG-D09EXD	TTDDRUID	D00OEG-D09EXD
D00OEG-D09EXD	DRUGNAME	rhtpo + rituximab
D00OEG-D09EXD	INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3
D00OEG-D09EXD	INDICATI	Purpura [ICD-11: 3B60-3B6Z] Phase 3

D0H3WI-D0V4JQ	TTDDRUID	D0H3WI-D0V4JQ
D0H3WI-D0V4JQ	DRUGNAME	ribavirin + interferon-beta-1a
D0H3WI-D0V4JQ	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0D4YZ-D0H3WI	TTDDRUID	D0D4YZ-D0H3WI
D0D4YZ-D0H3WI	DRUGNAME	Ribavirin + Sofosbuvir
D0D4YZ-D0H3WI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D00UJF-D04QST	TTDDRUID	D00UJF-D04QST
D00UJF-D04QST	DRUGNAME	riboflavin + dextran
D00UJF-D04QST	INDICATI	Keratoconus [ICD-11: 9A78.50] Phase 1/2

D04BOT-D0O3CV	TTDDRUID	D04BOT-D0O3CV
D04BOT-D0O3CV	DRUGNAME	ridaforolimus + dalotuzumab
D04BOT-D0O3CV	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D05CHI-D0AO5H	TTDDRUID	D05CHI-D0AO5H
D05CHI-D0AO5H	DRUGNAME	rifabutin + trimethoprim sulfamethoxazole
D05CHI-D0AO5H	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D05CHI-D0AO5H	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2

D0G3DL-D0R0ZL	TTDDRUID	D0G3DL-D0R0ZL
D0G3DL-D0R0ZL	DRUGNAME	rifampin + clindamycin
D0G3DL-D0R0ZL	INDICATI	Osteoarticular infection [ICD-11: 2B51] Investigative

D04ITO-D04JEE	TTDDRUID	D04ITO-D04JEE
D04ITO-D04JEE	DRUGNAME	rifaximin + propranolol
D04ITO-D04JEE	INDICATI	Liver cirrhosis [ICD-11: DB93.1] Phase 2/3
D04ITO-D04JEE	INDICATI	Portal hypertension [ICD-11: DB98.7] Phase 2/3

D01AZG-D01UTL	TTDDRUID	D01AZG-D01UTL
D01AZG-D01UTL	DRUGNAME	risperidone + desipramine
D01AZG-D01UTL	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
D01AZG-D01UTL	INDICATI	Dual diagnosis [ICD-11: N.A.] Phase 2
D01AZG-D01UTL	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D0S9SD-D0ZU9R	TTDDRUID	D0S9SD-D0ZU9R
D0S9SD-D0ZU9R	DRUGNAME	ritonavir + emtricitabine
D0S9SD-D0ZU9R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4

D0CQ2O-D0ZU9R	TTDDRUID	D0CQ2O-D0ZU9R
D0CQ2O-D0ZU9R	DRUGNAME	ritonavir + interferon beta-1b
D0CQ2O-D0ZU9R	INDICATI	Respiratory syndrome coronavirus infection [ICD-11: 1D92] Phase 2/3

D0I1FQ-D0ZU9R	TTDDRUID	D0I1FQ-D0ZU9R
D0I1FQ-D0ZU9R	DRUGNAME	ritonavir + raltegravir
D0I1FQ-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D0WI3T-D0ZU9R	TTDDRUID	D0WI3T-D0ZU9R
D0WI3T-D0ZU9R	DRUGNAME	Ritonavir + Saquinavir
D0WI3T-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
D0WI3T-D0ZU9R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D0EV6T-D0ZU9R	TTDDRUID	D0EV6T-D0ZU9R
D0EV6T-D0ZU9R	DRUGNAME	Ritonavir + Tipranavir
D0EV6T-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D01CYA-D09EXD	TTDDRUID	D01CYA-D09EXD
D01CYA-D09EXD	DRUGNAME	rituximab + bendamustine
D01CYA-D09EXD	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D03UVS-D09EXD	TTDDRUID	D03UVS-D09EXD
D03UVS-D09EXD	DRUGNAME	rituximab + gemcitabine
D03UVS-D09EXD	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D09EXD-D0D3DU	TTDDRUID	D09EXD-D0D3DU
D09EXD-D0D3DU	DRUGNAME	Rituximab + Methotrexate Sodium
D09EXD-D0D3DU	INDICATI	Central nervous system lymphoma [ICD-11: 2B33.5] Phase 1

D0GY5Z-D0KG3R	TTDDRUID	D0GY5Z-D0KG3R
D0GY5Z-D0KG3R	DRUGNAME	rivaroxaban + aspirin
D0GY5Z-D0KG3R	INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 2

D09RHQ-D0U3DU	TTDDRUID	D09RHQ-D0U3DU
D09RHQ-D0U3DU	DRUGNAME	ropivacaine + dexmedetomidine
D09RHQ-D0U3DU	INDICATI	Pregnancy [ICD-11: JA00-JA02] Investigative

D09RHQ-D0E1WI	TTDDRUID	D09RHQ-D0E1WI
D09RHQ-D0E1WI	DRUGNAME	ropivacaine + fentanyl
D09RHQ-D0E1WI	INDICATI	Stillborn caesarean section [ICD-11: JB22] Phase 2/3

D09RHQ-D0WO8W	TTDDRUID	D09RHQ-D0WO8W
D09RHQ-D0WO8W	DRUGNAME	ropivacaine + mepivacaine
D09RHQ-D0WO8W	INDICATI	Subgluteal sciatic block [ICD-11: ME84.3] Phase 4

D0K5ER-D0K9MY	TTDDRUID	D0K5ER-D0K9MY
D0K5ER-D0K9MY	DRUGNAME	Rosiglitazone + Saxagliptin
D0K5ER-D0K9MY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0K5ER-D0V2NJ	TTDDRUID	D0K5ER-D0V2NJ
D0K5ER-D0V2NJ	DRUGNAME	Rosiglitazone + Somatropin
D0K5ER-D0V2NJ	INDICATI	HIV-associated lipodystrophy [ICD-11: 1C62.1] Phase 1/2

D0JE2E-D0N0TZ	TTDDRUID	D0JE2E-D0N0TZ
D0JE2E-D0N0TZ	DRUGNAME	rosuvastatin + clopidogrel
D0JE2E-D0N0TZ	INDICATI	Myocardial fibrosis [ICD-11: BC43.20] Phase 4

D09LWS-D0JE2E	TTDDRUID	D09LWS-D0JE2E
D09LWS-D0JE2E	DRUGNAME	rosuvastatin + ezetimibe
D09LWS-D0JE2E	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
D09LWS-D0JE2E	INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Investigative
D09LWS-D0JE2E	INDICATI	Peripheral atherosclerotic Disease [ICD-11: BA80] Investigative

D0JE2E-D0WF7L	TTDDRUID	D0JE2E-D0WF7L
D0JE2E-D0WF7L	DRUGNAME	rosuvastatin + ticagrelor
D0JE2E-D0WF7L	INDICATI	Myocardial fibrosis [ICD-11: BC43.20] Phase 4

D08VHG-D0P1WA	TTDDRUID	D08VHG-D0P1WA
D08VHG-D0P1WA	DRUGNAME	rpl554 + tiotropium
D08VHG-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2

D0F6YW-D0X7HM	TTDDRUID	D0F6YW-D0X7HM
D0F6YW-D0X7HM	DRUGNAME	sagopilone + carboplatin
D0F6YW-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0L5YV-D0LC6K	TTDDRUID	D0L5YV-D0LC6K
D0L5YV-D0LC6K	DRUGNAME	salmeterol + fluticasone
D0L5YV-D0LC6K	INDICATI	Asthma [ICD-11: CA23] Approved
D0L5YV-D0LC6K	INDICATI	Asthma [ICD-11: CA23] Investigative
D0L5YV-D0LC6K	INDICATI	Bronchial asthma [ICD-11: CA23] Phase 3
D0L5YV-D0LC6K	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D0FX4J-D0K0TC	TTDDRUID	D0FX4J-D0K0TC
D0FX4J-D0K0TC	DRUGNAME	sertraline + telenzepine
D0FX4J-D0K0TC	INDICATI	Obesity [ICD-11: 5B81] Phase 1

D05MQK-D0Z7ZM	TTDDRUID	D05MQK-D0Z7ZM
D05MQK-D0Z7ZM	DRUGNAME	Sildenafil + Tadalafil
D05MQK-D0Z7ZM	INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 3

D00TLP-D0D4YZ	TTDDRUID	D00TLP-D0D4YZ
D00TLP-D0D4YZ	DRUGNAME	simeprevir + sofosbuvir
D00TLP-D0D4YZ	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Investigative
D00TLP-D0D4YZ	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 4
D00TLP-D0D4YZ	INDICATI	Cirrhosis [ICD-11: DB93] Investigative

D0H0ND-D0N0TZ	TTDDRUID	D0H0ND-D0N0TZ
D0H0ND-D0N0TZ	DRUGNAME	simvastatin + clopidogrel
D0H0ND-D0N0TZ	INDICATI	Myocardial fibrosis [ICD-11: BC43.20] Phase 4

D0H0ND-D0U2JP	TTDDRUID	D0H0ND-D0U2JP
D0H0ND-D0U2JP	DRUGNAME	Simvastatin + Sitagliptin
D0H0ND-D0U2JP	INDICATI	High cholesterol level [ICD-11: 5C80.0] Approved

D0H0ND-D0WF7L	TTDDRUID	D0H0ND-D0WF7L
D0H0ND-D0WF7L	DRUGNAME	simvastatin + ticagrelor
D0H0ND-D0WF7L	INDICATI	Myocardial fibrosis [ICD-11: BC43.20] Phase 4

D03OFF-D0U2JP	TTDDRUID	D03OFF-D0U2JP
D03OFF-D0U2JP	DRUGNAME	sitagliptin + pioglitazone
D03OFF-D0U2JP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D07MPL-D09KTS	TTDDRUID	D07MPL-D09KTS
D07MPL-D09KTS	DRUGNAME	snx-5422 + ibrutinib
D07MPL-D09KTS	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D05MBZ-D0L4YD	TTDDRUID	D05MBZ-D0L4YD
D05MBZ-D0L4YD	DRUGNAME	Solifenacin + Tamsulosin
D05MBZ-D0L4YD	INDICATI	Lower urinary tract symptom [ICD-11: GB71] Phase 2
D05MBZ-D0L4YD	INDICATI	Lower urinary tract symptom [ICD-11: GB71] Phase 3
D05MBZ-D0L4YD	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 4

D0L4YD-D0U9FD	TTDDRUID	D0L4YD-D0U9FD
D0L4YD-D0U9FD	DRUGNAME	Solifenacin + Trospium chloride
D0L4YD-D0U9FD	INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 3

D07POC-D0W5HK	TTDDRUID	D07POC-D0W5HK
D07POC-D0W5HK	DRUGNAME	sorafenib + erlotinib + tarceva
D07POC-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D0E3SH-D0W5HK	TTDDRUID	D0E3SH-D0W5HK
D0E3SH-D0W5HK	DRUGNAME	sorafenib + lbh589
D0E3SH-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1

D02RQU-D0W5HK	TTDDRUID	D02RQU-D0W5HK
D02RQU-D0W5HK	DRUGNAME	sorafenib + pravastatin
D02RQU-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
D02RQU-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3

D0R0MW-D0W5HK	TTDDRUID	D0R0MW-D0W5HK
D0R0MW-D0W5HK	DRUGNAME	Sorafenib + Sunitinib
D0R0MW-D0W5HK	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3

D09EXD-D0O3TB	TTDDRUID	D09EXD-D0O3TB
D09EXD-D0O3TB	DRUGNAME	steroid + rituximab
D09EXD-D0O3TB	INDICATI	Acquired haemophilia [ICD-11: 3B22] Phase 3

D05LKP-D0H1GJ	TTDDRUID	D05LKP-D0H1GJ
D05LKP-D0H1GJ	DRUGNAME	Sulfadiazine + Sulfamerazine
D05LKP-D0H1GJ	INDICATI	Toxoplasmosis [ICD-11: 1F57] Approved

D0AO5H-D0R9OH	TTDDRUID	D0AO5H-D0R9OH
D0AO5H-D0R9OH	DRUGNAME	Sulfamethoxazole + Trimethoprim
D0AO5H-D0R9OH	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
D0AO5H-D0R9OH	INDICATI	Cellulitis [ICD-11: GA00-GB07] Investigative
D0AO5H-D0R9OH	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D02ZTJ-D0D3DU	TTDDRUID	D02ZTJ-D0D3DU
D02ZTJ-D0D3DU	DRUGNAME	Sulfasalazine + Methotrexate Sodium
D02ZTJ-D0D3DU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 4

D0C4RB-D0R0MW	TTDDRUID	D0C4RB-D0R0MW
D0C4RB-D0R0MW	DRUGNAME	sunitinib + paclitaxel
D0C4RB-D0R0MW	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative

D0CR8H-D0X7HM	TTDDRUID	D0CR8H-D0X7HM
D0CR8H-D0X7HM	DRUGNAME	sym004 + carboplatin
D0CR8H-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0CR8H-D0U5HU	TTDDRUID	D0CR8H-D0U5HU
D0CR8H-D0U5HU	DRUGNAME	sym004 + cisplatin
D0CR8H-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D03UVS-D0CR8H	TTDDRUID	D03UVS-D0CR8H
D03UVS-D0CR8H	DRUGNAME	sym004 + gemcitabine
D03UVS-D0CR8H	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0C4RB-D0CR8H	TTDDRUID	D0C4RB-D0CR8H
D0C4RB-D0CR8H	DRUGNAME	sym004 + paclitaxel
D0C4RB-D0CR8H	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0CR8H-D0Y4GO	TTDDRUID	D0CR8H-D0Y4GO
D0CR8H-D0Y4GO	DRUGNAME	sym004 + pemetrexed
D0CR8H-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D06OMK-D0D3DU	TTDDRUID	D06OMK-D0D3DU
D06OMK-D0D3DU	DRUGNAME	Tacrolimus + Methotrexate Sodium
D06OMK-D0D3DU	INDICATI	Acute graft versus host disease [ICD-11: 4B24.0] Phase 2

D05BXY-D07BVI	TTDDRUID	D05BXY-D07BVI
D05BXY-D07BVI	DRUGNAME	talimogene laherparepvec + ipilimumab
D05BXY-D07BVI	INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2

D00BCG-D07KSG	TTDDRUID	D00BCG-D07KSG
D00BCG-D07KSG	DRUGNAME	tamoxifen + goserelin
D00BCG-D07KSG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D00BCG-D07KSG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00UZR-D07KSG	TTDDRUID	D00UZR-D07KSG
D00UZR-D07KSG	DRUGNAME	tamoxifen + palbociclib
D00UZR-D07KSG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04WFL-D07KSG	TTDDRUID	D04WFL-D07KSG
D04WFL-D07KSG	DRUGNAME	Tamoxifen + Trastuzumab
D04WFL-D07KSG	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0GD8Y-D0SC2J	TTDDRUID	D0GD8Y-D0SC2J
D0GD8Y-D0SC2J	DRUGNAME	Tanespimycin + U0126
D0GD8Y-D0SC2J	INDICATI	Anaplastic large cell lymphoma [ICD-11: 2A90.A] Preclinical

D07POC-D0S6KI	TTDDRUID	D07POC-D0S6KI
D07POC-D0S6KI	DRUGNAME	tarceva + at-101
D07POC-D0S6KI	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0C4RB-D0K3QS	TTDDRUID	D0C4RB-D0K3QS
D0C4RB-D0K3QS	DRUGNAME	taxol + everolimus
D0C4RB-D0K3QS	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D0CL9S-D0ML1F	TTDDRUID	D0CL9S-D0ML1F
D0CL9S-D0ML1F	DRUGNAME	telbivudine + adefovir
D0CL9S-D0ML1F	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D0CL9S-D0D9HW	TTDDRUID	D0CL9S-D0D9HW
D0CL9S-D0D9HW	DRUGNAME	telbivudine + tenofovir disproxil fumarate
D0CL9S-D0D9HW	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 2

D0D7LA-D0N6RF	TTDDRUID	D0D7LA-D0N6RF
D0D7LA-D0N6RF	DRUGNAME	telmisartan + metformin
D0D7LA-D0N6RF	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4
D0D7LA-D0N6RF	INDICATI	Obesity [ICD-11: 5B81] Phase 4

D0C8EU-D0U7GK	TTDDRUID	D0C8EU-D0U7GK
D0C8EU-D0U7GK	DRUGNAME	temozolomide + thalidomide
D0C8EU-D0U7GK	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2

D0C8EU-D0E7PQ	TTDDRUID	D0C8EU-D0E7PQ
D0C8EU-D0E7PQ	DRUGNAME	Temozolomide + Vorinostat
D0C8EU-D0E7PQ	INDICATI	Childhood atypical teratoid rhabdoid tumour [ICD-11: 2A00.1Y] Phase 1

D0ES1Q-D0W5HK	TTDDRUID	D0ES1Q-D0W5HK
D0ES1Q-D0W5HK	DRUGNAME	temsirolimus + sorafenib
D0ES1Q-D0W5HK	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2

D0D9HW-D0U5GB	TTDDRUID	D0D9HW-D0U5GB
D0D9HW-D0U5GB	DRUGNAME	tenofovir + lopinavir
D0D9HW-D0U5GB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0D9HW-D0ZU9R	TTDDRUID	D0D9HW-D0ZU9R
D0D9HW-D0ZU9R	DRUGNAME	tenofovir + ritonavir
D0D9HW-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D08HQK-D09EBS	TTDDRUID	D08HQK-D09EBS
D08HQK-D09EBS	DRUGNAME	Tetracaine + Oxymetazoline
D08HQK-D09EBS	INDICATI	Dental anesthesia efficacy [ICD-11: DA0C] Phase 2

D03TIS-D0O8SJ	TTDDRUID	D03TIS-D0O8SJ
D03TIS-D0O8SJ	DRUGNAME	tgr-1202 + brentuximab vedotin
D03TIS-D0O8SJ	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1

D07VLY-D0H1EA	TTDDRUID	D07VLY-D0H1EA
D07VLY-D0H1EA	DRUGNAME	th-302 + doxorubicin
D07VLY-D0H1EA	INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 3

D0H1EA-D0Y4GO	TTDDRUID	D0H1EA-D0Y4GO
D0H1EA-D0Y4GO	DRUGNAME	th-302 + pemetrexed
D0H1EA-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0H1EA-D0R0MW	TTDDRUID	D0H1EA-D0R0MW
D0H1EA-D0R0MW	DRUGNAME	th-302 + sunitinib
D0H1EA-D0R0MW	INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
D0H1EA-D0R0MW	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0I5HF-D0WF7L	TTDDRUID	D0I5HF-D0WF7L
D0I5HF-D0WF7L	DRUGNAME	ticagrelor + apixaban
D0I5HF-D0WF7L	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 1
D0I5HF-D0WF7L	INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1

D07DVK-D0P1WA	TTDDRUID	D07DVK-D0P1WA
D07DVK-D0P1WA	DRUGNAME	tiotropium + beclometasone
D07DVK-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4
D07DVK-D0P1WA	INDICATI	Emphysema [ICD-11: CA21] Phase 4
D07DVK-D0P1WA	INDICATI	Small airway disease [ICD-11: CA22] Phase 4

D04UTT-D0P1WA	TTDDRUID	D04UTT-D0P1WA
D04UTT-D0P1WA	DRUGNAME	tiotropium + olodaterol
D04UTT-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
D04UTT-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D00MVM-D0P1WA	TTDDRUID	D00MVM-D0P1WA
D00MVM-D0P1WA	DRUGNAME	tiotropium + salbutamol
D00MVM-D0P1WA	INDICATI	Bronchiectasis [ICD-11: CA24] Investigative
D00MVM-D0P1WA	INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
D00MVM-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
D00MVM-D0P1WA	INDICATI	Smoking dependence [ICD-11: 6C4A.2] Investigative

D0L5YV-D0P1WA	TTDDRUID	D0L5YV-D0P1WA
D0L5YV-D0P1WA	DRUGNAME	tiotropium + salmeterol
D0L5YV-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
D0L5YV-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D07NPS-D0SH3I	TTDDRUID	D07NPS-D0SH3I
D07NPS-D0SH3I	DRUGNAME	tipifarnib + bortezomib
D07NPS-D0SH3I	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2

D07NPS-D0VM2L	TTDDRUID	D07NPS-D0VM2L
D07NPS-D0VM2L	DRUGNAME	Tipifarnib + Zoledronate
D07NPS-D0VM2L	INDICATI	Epidermoid cancer squamous cell carcinoma [ICD-11: 2B60-2D01] Preclinical

D00HCQ-D0W7JZ	TTDDRUID	D00HCQ-D0W7JZ
D00HCQ-D0W7JZ	DRUGNAME	tivozanib + capecitabine
D00HCQ-D0W7JZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0C4RB-D0W7JZ	TTDDRUID	D0C4RB-D0W7JZ
D0C4RB-D0W7JZ	DRUGNAME	tivozanib + paclitaxel
D0C4RB-D0W7JZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D0ES1Q-D0W7JZ	TTDDRUID	D0ES1Q-D0W7JZ
D0ES1Q-D0W7JZ	DRUGNAME	tivozanib + temsirolimus
D0ES1Q-D0W7JZ	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
D0ES1Q-D0W7JZ	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative

D08HPZ-D0D3DU	TTDDRUID	D08HPZ-D0D3DU
D08HPZ-D0D3DU	DRUGNAME	Tocilizumab + Methotrexate Sodium
D08HPZ-D0D3DU	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D05MBZ-D0BZ7W	TTDDRUID	D05MBZ-D0BZ7W
D05MBZ-D0BZ7W	DRUGNAME	tolterodine + tamsulosin
D05MBZ-D0BZ7W	INDICATI	Lower urinary tract symptom [ICD-11: GB71] Phase 2/3
D05MBZ-D0BZ7W	INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2/3

D0Y3KG-D07VDZ	TTDDRUID	D0Y3KG-D07VDZ
D0Y3KG-D07VDZ	DRUGNAME	Topiramate + Valproic Acid
D0Y3KG-D07VDZ	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Preclinical

D05GKD-D0U5QK	TTDDRUID	D05GKD-D0U5QK
D05GKD-D0U5QK	DRUGNAME	Tramadol + Acetaminophen
D05GKD-D0U5QK	INDICATI	Acute pain [ICD-11: MG31] Approved
D05GKD-D0U5QK	INDICATI	Back pain [ICD-11: ME84.Z] Phase 3
D05GKD-D0U5QK	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4

D0M5OC-D0R0FE	TTDDRUID	D0M5OC-D0R0FE
D0M5OC-D0R0FE	DRUGNAME	Trandolapril + Verapamil
D0M5OC-D0R0FE	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04WFL-D0C1WH	TTDDRUID	D04WFL-D0C1WH
D04WFL-D0C1WH	DRUGNAME	trastuzumab + letrozole
D04WFL-D0C1WH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D04WFL-D0C1WH	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 4

D01HTL-D04WFL	TTDDRUID	D01HTL-D04WFL
D01HTL-D04WFL	DRUGNAME	Trastuzumab + Vinorelbine
D01HTL-D04WFL	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Preclinical

D04YPN-D07XSN	TTDDRUID	D04YPN-D07XSN
D04YPN-D07XSN	DRUGNAME	treosulfan + cytarabine
D04YPN-D07XSN	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D02DGU-D0NF6F	TTDDRUID	D02DGU-D0NF6F
D02DGU-D0NF6F	DRUGNAME	Tretinoin + Trichostatin A
D02DGU-D0NF6F	INDICATI	Renal cell carcinoma [ICD-11: 2C90] Preclinical

D02WCI-D03BLF	TTDDRUID	D02WCI-D03BLF
D02WCI-D03BLF	DRUGNAME	triamcinolone + pirfenidone
D02WCI-D03BLF	INDICATI	Keloid [ICD-11: EE60] Phase 3

D0L1OT-D0O5WP	TTDDRUID	D0L1OT-D0O5WP
D0L1OT-D0O5WP	DRUGNAME	trovax + docetaxel
D0L1OT-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D09KTS-D0T7QC	TTDDRUID	D09KTS-D0T7QC
D09KTS-D0T7QC	DRUGNAME	tru-016 + ibrutinib
D09KTS-D0T7QC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D0S8WA-D0T7QC	TTDDRUID	D0S8WA-D0T7QC
D0S8WA-D0T7QC	DRUGNAME	tru-016 + obinutuzumab
D0S8WA-D0T7QC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D09EXD-D0T7QC	TTDDRUID	D09EXD-D0T7QC
D09EXD-D0T7QC	DRUGNAME	tru-016 + rituximab
D09EXD-D0T7QC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D0A8GM-D0O8SJ	TTDDRUID	D0A8GM-D0O8SJ
D0A8GM-D0O8SJ	DRUGNAME	ublituximab + tgr-1202
D0A8GM-D0O8SJ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D0A8GM-D0O8SJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D06NXY-D0V4WD	TTDDRUID	D06NXY-D0V4WD
D06NXY-D0V4WD	DRUGNAME	ulipristal acetate + ethinylestradiol
D06NXY-D0V4WD	INDICATI	Contraception [ICD-11: QA21] Phase 4

D0GL7U-D0V4WD	TTDDRUID	D0GL7U-D0V4WD
D0GL7U-D0V4WD	DRUGNAME	ulipristal acetate + levonorgestrel
D0GL7U-D0V4WD	INDICATI	Contraception [ICD-11: QA21] Phase 4

D00SLY-D0L0GM	TTDDRUID	D00SLY-D0L0GM
D00SLY-D0L0GM	DRUGNAME	Umeclidinium bromide + Vilanterol
D00SLY-D0L0GM	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved

D05MFA-D0GY5Z	TTDDRUID	D05MFA-D0GY5Z
D05MFA-D0GY5Z	DRUGNAME	valacyclovir + aspirin
D05MFA-D0GY5Z	INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1

D06UDG-D0JE2E	TTDDRUID	D06UDG-D0JE2E
D06UDG-D0JE2E	DRUGNAME	valsartan + rosuvastatin
D06UDG-D0JE2E	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 3
D06UDG-D0JE2E	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D06UDG-D0H0ND	TTDDRUID	D06UDG-D0H0ND
D06UDG-D0H0ND	DRUGNAME	valsartan + simvastatin
D06UDG-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3
D06UDG-D0H0ND	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D04KBL-D0S4LV	TTDDRUID	D04KBL-D0S4LV
D04KBL-D0S4LV	DRUGNAME	vb-111 + bevacizumab
D04KBL-D0S4LV	INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3

D0D7LA-D0L3DK	TTDDRUID	D0D7LA-D0L3DK
D0D7LA-D0L3DK	DRUGNAME	vildagliptin + metformin
D0D7LA-D0L3DK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
D0D7LA-D0L3DK	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 4

D00STL-D0W9MM	TTDDRUID	D00STL-D0W9MM
D00STL-D0W9MM	DRUGNAME	vinblastine + nilotinib
D00STL-D0W9MM	INDICATI	Refractory low-grade glioma [ICD-11: 2A00.0] Phase 2

D09QVV-D0X7HM	TTDDRUID	D09QVV-D0X7HM
D09QVV-D0X7HM	DRUGNAME	vincristine + carboplatin
D09QVV-D0X7HM	INDICATI	Retinoblastoma [ICD-11: 2D02.2] Phase 3

D02PMO-D09QVV	TTDDRUID	D02PMO-D09QVV
D02PMO-D09QVV	DRUGNAME	vincristine + topotecan
D02PMO-D09QVV	INDICATI	Retinoblastoma [ICD-11: 2D02.2] Phase 3

D00HCQ-D0OT9S	TTDDRUID	D00HCQ-D0OT9S
D00HCQ-D0OT9S	DRUGNAME	vinflunine + capecitabine
D00HCQ-D0OT9S	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D03UVS-D0OT9S	TTDDRUID	D03UVS-D0OT9S
D03UVS-D0OT9S	DRUGNAME	vinflunine + gemcitabine
D03UVS-D0OT9S	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D01HTL-D0C9XJ	TTDDRUID	D01HTL-D0C9XJ
D01HTL-D0C9XJ	DRUGNAME	vinorelbine + epirubicin
D01HTL-D0C9XJ	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D07MUN-D0Y2LR	TTDDRUID	D07MUN-D0Y2LR
D07MUN-D0Y2LR	DRUGNAME	Vitamin B6 + Doxylamine
D07MUN-D0Y2LR	INDICATI	Nausea and vomiting [ICD-11: MD90] Approved

D09ZIS-D0V4QS	TTDDRUID	D09ZIS-D0V4QS
D09ZIS-D0V4QS	DRUGNAME	zonisamide sr + olanzapine
D09ZIS-D0V4QS	INDICATI	Schizoaffective disorder [ICD-11: 6A21] Phase 2
D09ZIS-D0V4QS	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2

D07IQS-D07TQV-D0A4IJ	TTDDRUID	D07IQS-D07TQV-D0A4IJ
D07IQS-D07TQV-D0A4IJ	DRUGNAME	Abacavir + Atazanavir + Lamivudine
D07IQS-D07TQV-D0A4IJ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D06FDR-D0A4IJ-D0U5GB	TTDDRUID	D06FDR-D0A4IJ-D0U5GB
D06FDR-D0A4IJ-D0U5GB	DRUGNAME	abacavir + didanosine + lopinavir
D06FDR-D0A4IJ-D0U5GB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D06FDR-D0A4IJ-D0ZU9R	TTDDRUID	D06FDR-D0A4IJ-D0ZU9R
D06FDR-D0A4IJ-D0ZU9R	DRUGNAME	abacavir + didanosine + ritonavir
D06FDR-D0A4IJ-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D01XYJ-D07TQV-D0A4IJ	TTDDRUID	D01XYJ-D07TQV-D0A4IJ
D01XYJ-D07TQV-D0A4IJ	DRUGNAME	Abacavir + Lamivudine + Zidovudine
D01XYJ-D07TQV-D0A4IJ	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved

D0A4IJ-D0H3WI-D0Y8OK	TTDDRUID	D0A4IJ-D0H3WI-D0Y8OK
D0A4IJ-D0H3WI-D0Y8OK	DRUGNAME	Abacavir + Peginterferon alfa-2a + Ribavirin
D0A4IJ-D0H3WI-D0Y8OK	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative

D0B3HD-D0GY5Z-D0U5QK	TTDDRUID	D0B3HD-D0GY5Z-D0U5QK
D0B3HD-D0GY5Z-D0U5QK	DRUGNAME	Acetaminophen + Aspirin + Caffeine
D0B3HD-D0GY5Z-D0U5QK	INDICATI	Migraine pain [ICD-11: 8A80.0] Approved

D03DIG-D0GY5Z-D0U5QK	TTDDRUID	D03DIG-D0GY5Z-D0U5QK
D03DIG-D0GY5Z-D0U5QK	DRUGNAME	Acetaminophen + Aspirin + Codeine
D03DIG-D0GY5Z-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D05BQK-D0B3HD-D0U5QK	TTDDRUID	D05BQK-D0B3HD-D0U5QK
D05BQK-D0B3HD-D0U5QK	DRUGNAME	Acetaminophen + Butalbital + Caffeine
D05BQK-D0B3HD-D0U5QK	INDICATI	Tension headache [ICD-11: 8A81] Approved

D0B3HD-D0T6RC-D0U5QK	TTDDRUID	D0B3HD-D0T6RC-D0U5QK
D0B3HD-D0T6RC-D0U5QK	DRUGNAME	Acetaminophen + Caffeine + Dihydrocodeine
D0B3HD-D0T6RC-D0U5QK	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D00HHS-D0C5XC-D0U5QK	TTDDRUID	D00HHS-D0C5XC-D0U5QK
D00HHS-D0C5XC-D0U5QK	DRUGNAME	Acetaminophen + Clemastine + Pseudoephedrine
D00HHS-D0C5XC-D0U5QK	INDICATI	Sneezing [ICD-11: MD11.A] Approved

D00HHS-D02WIW-D0U5QK	TTDDRUID	D00HHS-D02WIW-D0U5QK
D00HHS-D02WIW-D0U5QK	DRUGNAME	Acetaminophen + Dexbrompheniramine + Pseudoephedrine
D00HHS-D02WIW-D0U5QK	INDICATI	Fever [ICD-11: MG26] Approved

D0R1QE-D0TG1H-D0U5QK	TTDDRUID	D0R1QE-D0TG1H-D0U5QK
D0R1QE-D0TG1H-D0U5QK	DRUGNAME	Acetaminophen + Diclofenac + Ibuprofen
D0R1QE-D0TG1H-D0U5QK	INDICATI	Febrile seizure [ICD-11: 8A63.0] Phase 4

D01QUS-D0CW1P-D0K5KS	TTDDRUID	D01QUS-D0CW1P-D0K5KS
D01QUS-D0CW1P-D0K5KS	DRUGNAME	Adalimumab + Betamethasone + Calcipotriol
D01QUS-D0CW1P-D0K5KS	INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 3

D07TQV-D0KR2J-D0ML1F	TTDDRUID	D07TQV-D0KR2J-D0ML1F
D07TQV-D0KR2J-D0ML1F	DRUGNAME	Adefovir + Entecavir + Lamivudine
D07TQV-D0KR2J-D0ML1F	INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 4

D0C9ET-D0IT2G-D0O5WP	TTDDRUID	D0C9ET-D0IT2G-D0O5WP
D0C9ET-D0IT2G-D0O5WP	DRUGNAME	Aflibercept + Dexamethasone + Docetaxel
D0C9ET-D0IT2G-D0O5WP	INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 3

D00KVO-D09YHJ-D0L9ZR	TTDDRUID	D00KVO-D09YHJ-D0L9ZR
D00KVO-D09YHJ-D0L9ZR	DRUGNAME	Albendazole + Ivermectin + Praziquantel
D00KVO-D09YHJ-D0L9ZR	INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Investigative

D00DKK-D05PUD-D0XT5Y	TTDDRUID	D00DKK-D05PUD-D0XT5Y
D00DKK-D05PUD-D0XT5Y	DRUGNAME	Aldesleukin + Isotretinoin + Sargramostim
D00DKK-D05PUD-D0XT5Y	INDICATI	Disseminated neuroblastoma [ICD-11: 2D11] Phase 3

D03SVX-D08JIV-D0U4UQ	TTDDRUID	D03SVX-D08JIV-D0U4UQ
D03SVX-D08JIV-D0U4UQ	DRUGNAME	Aliskiren + Amlodipine + Hydrochlorothiazide
D03SVX-D08JIV-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D03SVX-D06UDG-D0U4UQ	TTDDRUID	D03SVX-D06UDG-D0U4UQ
D03SVX-D06UDG-D0U4UQ	DRUGNAME	Aliskiren + Hydrochlorothiazide + Valsartan
D03SVX-D06UDG-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3

D03OFF-D0D7LA-D0NJ5H	TTDDRUID	D03OFF-D0D7LA-D0NJ5H
D03OFF-D0D7LA-D0NJ5H	DRUGNAME	Alogliptin + Metformin + Pioglitazone
D03OFF-D0D7LA-D0NJ5H	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D02KRS-D0H3WI-D0P0WV	TTDDRUID	D02KRS-D0H3WI-D0P0WV
D02KRS-D0H3WI-D0P0WV	DRUGNAME	Amantadine + Interferon alfa-2b + Ribavirin
D02KRS-D0H3WI-D0P0WV	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2/3

D02KRS-D0H3WI-D0O5NK	TTDDRUID	D02KRS-D0H3WI-D0O5NK
D02KRS-D0H3WI-D0O5NK	DRUGNAME	Amantadine + Oseltamivir + Ribavirin
D02KRS-D0H3WI-D0O5NK	INDICATI	Influenza A virus infection [ICD-11: 1E30] Preclinical

D05GKD-D0TR5X-D0Y5UG	TTDDRUID	D05GKD-D0TR5X-D0Y5UG
D05GKD-D0TR5X-D0Y5UG	DRUGNAME	amitriptyline + fluoxetine + tramadol
D05GKD-D0TR5X-D0Y5UG	INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
D05GKD-D0TR5X-D0Y5UG	INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2

D07UBG-D08JIV-D0U4UQ	TTDDRUID	D07UBG-D08JIV-D0U4UQ
D07UBG-D08JIV-D0U4UQ	DRUGNAME	Amlodipine + Hydrochlorothiazide + Olmesartan
D07UBG-D08JIV-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D06UDG-D08JIV-D0U4UQ	TTDDRUID	D06UDG-D08JIV-D0U4UQ
D06UDG-D08JIV-D0U4UQ	DRUGNAME	Amlodipine + Hydrochlorothiazide + Valsartan
D06UDG-D08JIV-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D04NQI-D0D4JO-D0T1LK	TTDDRUID	D04NQI-D0D4JO-D0T1LK
D04NQI-D0D4JO-D0T1LK	DRUGNAME	Amodiaquine + Artesunate + Primaquine
D04NQI-D0D4JO-D0T1LK	INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Phase 3

D04NQI-D0C0SK-D07PAO	TTDDRUID	D04NQI-D0C0SK-D07PAO
D04NQI-D0C0SK-D07PAO	DRUGNAME	Amodiaquine + Pyrimethamine + Sulfadoxine
D04NQI-D0C0SK-D07PAO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D04NQI-D0C0SK-D0F0OK	TTDDRUID	D04NQI-D0C0SK-D0F0OK
D04NQI-D0C0SK-D0F0OK	DRUGNAME	Amodiaquine + Pyrimethamine + Sulfalene
D04NQI-D0C0SK-D0F0OK	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D06MQM-D0F6EO-D0M9BW	TTDDRUID	D06MQM-D0F6EO-D0M9BW
D06MQM-D0F6EO-D0M9BW	DRUGNAME	Amoxicillin + Artemether + Lumefantrine
D06MQM-D0F6EO-D0M9BW	INDICATI	Pneumonia [ICD-11: CA40] Investigative

D0F6EO-D06YYD-D0Z1ZM	TTDDRUID	D0F6EO-D06YYD-D0Z1ZM
D0F6EO-D06YYD-D0Z1ZM	DRUGNAME	Amoxicillin + Clarithromycin + Lansoprazole
D0F6EO-D06YYD-D0Z1ZM	INDICATI	Duodenal ulcer [ICD-11: DA63] Approved

D0A2ZX-D0F6EO-D0Z1ZM	TTDDRUID	D0A2ZX-D0F6EO-D0Z1ZM
D0A2ZX-D0F6EO-D0Z1ZM	DRUGNAME	Amoxicillin + Clarithromycin + Metronidazole
D0A2ZX-D0F6EO-D0Z1ZM	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 3

D01XNB-D0F6EO-D0Z1ZM	TTDDRUID	D01XNB-D0F6EO-D0Z1ZM
D01XNB-D0F6EO-D0Z1ZM	DRUGNAME	Amoxicillin + Clarithromycin + Omeprazole
D01XNB-D0F6EO-D0Z1ZM	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D0C6DT-D0F6EO-D0ZV0Z	TTDDRUID	D0C6DT-D0F6EO-D0ZV0Z
D0C6DT-D0F6EO-D0ZV0Z	DRUGNAME	Amoxicillin + Esomeprazole + Moxifloxacin
D0C6DT-D0F6EO-D0ZV0Z	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 4

D0H0BG-D0Y2IE-D0YA9Z	TTDDRUID	D0H0BG-D0Y2IE-D0YA9Z
D0H0BG-D0Y2IE-D0YA9Z	DRUGNAME	Ampicillin + Cefuroxime + Sulbactam
D0H0BG-D0Y2IE-D0YA9Z	INDICATI	Surgical site infection [ICD-11: NE81.2] Phase 4

D06OMK-D0M7XS-D0T6DK	TTDDRUID	D06OMK-D0M7XS-D0T6DK
D06OMK-D0M7XS-D0T6DK	DRUGNAME	Anti-thymocyte globulin + Rapamycin + Tacrolimus
D06OMK-D0M7XS-D0T6DK	INDICATI	End-stage renal disease [ICD-11: GB61.5] Investigative

D0E3OF-D0I5HF-D0MX5S	TTDDRUID	D0E3OF-D0I5HF-D0MX5S
D0E3OF-D0I5HF-D0MX5S	DRUGNAME	Apixaban + Enoxaparin + Warfarin
D0E3OF-D0I5HF-D0MX5S	INDICATI	Venous thrombosis [ICD-11: BA43] Phase 3

D04FVU-D0GU4K-D0IT2G	TTDDRUID	D04FVU-D0GU4K-D0IT2G
D04FVU-D0GU4K-D0IT2G	DRUGNAME	Aprepitant + Dexamethasone + Palonosetron
D04FVU-D0GU4K-D0IT2G	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D01KPV-D0GU4K-D0IL7L	TTDDRUID	D01KPV-D0GU4K-D0IL7L
D01KPV-D0GU4K-D0IL7L	DRUGNAME	Aprepitant + Fexofenadine + Prednisone
D01KPV-D0GU4K-D0IL7L	INDICATI	Pruritus [ICD-11: EC90] Phase 2

D0GU4K-D0IT2G-D0K7WK	TTDDRUID	D0GU4K-D0IT2G-D0K7WK
D0GU4K-D0IT2G-D0K7WK	DRUGNAME	aprepitant + ondansetron + dexamethasone
D0GU4K-D0IT2G-D0K7WK	INDICATI	Nausea [ICD-11: MD90] Phase 4

D06MQM-D09EGZ-D0M9BW	TTDDRUID	D06MQM-D09EGZ-D0M9BW
D06MQM-D09EGZ-D0M9BW	DRUGNAME	Artemether + Chloroquine + Lumefantrine
D06MQM-D09EGZ-D0M9BW	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 4

D0C0SK-D0D4JO-D07PAO	TTDDRUID	D0C0SK-D0D4JO-D07PAO
D0C0SK-D0D4JO-D07PAO	DRUGNAME	Artesunate + Pyrimethamine + Sulfadoxine
D0C0SK-D0D4JO-D07PAO	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 2
D0C0SK-D0D4JO-D07PAO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D0C0SK-D0D4JO-D0F0OK	TTDDRUID	D0C0SK-D0D4JO-D0F0OK
D0C0SK-D0D4JO-D0F0OK	DRUGNAME	Artesunate + Pyrimethamine + Sulfalene
D0C0SK-D0D4JO-D0F0OK	INDICATI	Schistosoma mansoni disease [ICD-11: 1F86] Phase 3

D05BQK-D0B3HD-D0GY5Z	TTDDRUID	D05BQK-D0B3HD-D0GY5Z
D05BQK-D0B3HD-D0GY5Z	DRUGNAME	Aspirin + Butalbital + Caffeine
D05BQK-D0B3HD-D0GY5Z	INDICATI	Tension headache [ICD-11: 8A81] Approved

D0B3HD-D0GY5Z-D0T6RC	TTDDRUID	D0B3HD-D0GY5Z-D0T6RC
D0B3HD-D0GY5Z-D0T6RC	DRUGNAME	Aspirin + Caffeine + Dihydrocodeine
D0B3HD-D0GY5Z-D0T6RC	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D0B3HD-D0D9FV-D0GY5Z	TTDDRUID	D0B3HD-D0D9FV-D0GY5Z
D0B3HD-D0D9FV-D0GY5Z	DRUGNAME	Aspirin + Caffeine + Orphenadrine
D0B3HD-D0D9FV-D0GY5Z	INDICATI	Musculoskeletal pain [ICD-11: MG30] Approved

D03HCZ-D0B3HD-D0GY5Z	TTDDRUID	D03HCZ-D0B3HD-D0GY5Z
D03HCZ-D0B3HD-D0GY5Z	DRUGNAME	Aspirin + Caffeine + Propoxyphene
D03HCZ-D0B3HD-D0GY5Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03DIG-D05PLH-D0GY5Z	TTDDRUID	D03DIG-D05PLH-D0GY5Z
D03DIG-D05PLH-D0GY5Z	DRUGNAME	Aspirin + Carisoprodol + Codeine
D03DIG-D05PLH-D0GY5Z	INDICATI	Abnormal mobility [ICD-11: MB44] Approved
D03DIG-D05PLH-D0GY5Z	INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
D03DIG-D05PLH-D0GY5Z	INDICATI	Pain [ICD-11: MG30-MG3Z] Approved

D03VPC-D0GY5Z-D0N0TZ	TTDDRUID	D03VPC-D0GY5Z-D0N0TZ
D03VPC-D0GY5Z-D0N0TZ	DRUGNAME	Aspirin + Cilostazol + Clopidogrel
D03VPC-D0GY5Z-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4
D03VPC-D0GY5Z-D0N0TZ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 4

D01XNB-D0GY5Z-D0N0TZ	TTDDRUID	D01XNB-D0GY5Z-D0N0TZ
D01XNB-D0GY5Z-D0N0TZ	DRUGNAME	Aspirin + Clopidogrel + Omeprazole
D01XNB-D0GY5Z-D0N0TZ	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3
D01XNB-D0GY5Z-D0N0TZ	INDICATI	Platelet aggregation disorder [ICD-11: 3B62] Phase 1

D07IRF-D0GY5Z-D0N0TZ	TTDDRUID	D07IRF-D0GY5Z-D0N0TZ
D07IRF-D0GY5Z-D0N0TZ	DRUGNAME	Aspirin + Clopidogrel + Prasugrel
D07IRF-D0GY5Z-D0N0TZ	INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4

D0E3OF-D0GY5Z-D0N0TZ	TTDDRUID	D0E3OF-D0GY5Z-D0N0TZ
D0E3OF-D0GY5Z-D0N0TZ	DRUGNAME	aspirin + clopidogrel + warfarin
D0E3OF-D0GY5Z-D0N0TZ	INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative

D0A3ZU-D0GY5Z-D0IT2G	TTDDRUID	D0A3ZU-D0GY5Z-D0IT2G
D0A3ZU-D0GY5Z-D0IT2G	DRUGNAME	Aspirin + Dexamethasone + Pomalidomide
D0A3ZU-D0GY5Z-D0IT2G	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0F9GE-D0GY5Z-D0N6RF	TTDDRUID	D0F9GE-D0GY5Z-D0N6RF
D0F9GE-D0GY5Z-D0N6RF	DRUGNAME	Aspirin + Dipyridamole + Telmisartan
D0F9GE-D0GY5Z-D0N6RF	INDICATI	Stroke [ICD-11: 8B20] Phase 4

D06FDR-D07IQS-D0S9SD	TTDDRUID	D06FDR-D07IQS-D0S9SD
D06FDR-D07IQS-D0S9SD	DRUGNAME	Atazanavir + Didanosine + Emtricitabine
D06FDR-D07IQS-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D07IQS-D07TQV-D0I1FQ	TTDDRUID	D07IQS-D07TQV-D0I1FQ
D07IQS-D07TQV-D0I1FQ	DRUGNAME	Atazanavir + Lamivudine + Raltegravir
D07IQS-D07TQV-D0I1FQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D07IQS-D0U5GB-D0ZU9R	TTDDRUID	D07IQS-D0U5GB-D0ZU9R
D07IQS-D0U5GB-D0ZU9R	DRUGNAME	Atazanavir + Lopinavir + Ritonavir
D07IQS-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D07IQS-D0X9CH-D0ZU9R	TTDDRUID	D07IQS-D0X9CH-D0ZU9R
D07IQS-D0X9CH-D0ZU9R	DRUGNAME	Atazanavir + Ritonavir + Telaprevir
D07IQS-D0X9CH-D0ZU9R	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 1

D01UXC-D04JEE-D0DD0K	TTDDRUID	D01UXC-D04JEE-D0DD0K
D01UXC-D04JEE-D0DD0K	DRUGNAME	Atenolol + Losartan + Propranolol
D01UXC-D04JEE-D0DD0K	INDICATI	Marfan syndrome [ICD-11: LD28.01] Phase 2

D01QIN-D09LWS-D0PJ4K	TTDDRUID	D01QIN-D09LWS-D0PJ4K
D01QIN-D09LWS-D0PJ4K	DRUGNAME	Atorvastatin + Calcium + Ezetimibe
D01QIN-D09LWS-D0PJ4K	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved

D01QIN-D07XGR-D09LWS	TTDDRUID	D01QIN-D07XGR-D09LWS
D01QIN-D07XGR-D09LWS	DRUGNAME	Atorvastatin + Ezetimibe + Fenofibrate
D01QIN-D07XGR-D09LWS	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 3

D01QIN-D09LWS-D0H0ND	TTDDRUID	D01QIN-D09LWS-D0H0ND
D01QIN-D09LWS-D0H0ND	DRUGNAME	Atorvastatin + Ezetimibe + Simvastatin
D01QIN-D09LWS-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D01QIN-D07HGR-D0DD0K	TTDDRUID	D01QIN-D07HGR-D0DD0K
D01QIN-D07HGR-D0DD0K	DRUGNAME	Atorvastatin + Lisinopril + Losartan
D01QIN-D07HGR-D0DD0K	INDICATI	Focal segmental glomerulosclerosis [ICD-11: MF8Y] Phase 2

D0IL7L-D0O5WP-D0Y6UU	TTDDRUID	D0IL7L-D0O5WP-D0Y6UU
D0IL7L-D0O5WP-D0Y6UU	DRUGNAME	Atrasentan + Docetaxel + Prednisone
D0IL7L-D0O5WP-D0Y6UU	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 3

D0Y3KG-D09FAZ-D0X7HM	TTDDRUID	D0Y3KG-D09FAZ-D0X7HM
D0Y3KG-D09FAZ-D0X7HM	DRUGNAME	Azacitidine + Carboplatin + Valproic Acid
D0Y3KG-D09FAZ-D0X7HM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D06EWO-D09FAZ-D0E7PQ	TTDDRUID	D06EWO-D09FAZ-D0E7PQ
D06EWO-D09FAZ-D0E7PQ	DRUGNAME	Azacitidine + Gemtuzumab ozogamicin + Vorinostat
D06EWO-D09FAZ-D0E7PQ	INDICATI	Adult acute megakaryoblastic leukaemia [ICD-11: 2A60.36] Phase 1/2

D02DGU-D0Y3KG-D09FAZ	TTDDRUID	D02DGU-D0Y3KG-D09FAZ
D02DGU-D0Y3KG-D09FAZ	DRUGNAME	Azacitidine + Tretinoin + Valproic Acid
D02DGU-D0Y3KG-D09FAZ	INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2

D07QCE-D08PIQ-D0PG5G	TTDDRUID	D07QCE-D08PIQ-D0PG5G
D07QCE-D08PIQ-D0PG5G	DRUGNAME	Azathioprine + Methylprednisolone Acetate + Infliximab
D07QCE-D08PIQ-D0PG5G	INDICATI	Crohn disease [ICD-11: DD70] Phase 4

D03HJK-D0C0SK-D07PAO	TTDDRUID	D03HJK-D0C0SK-D07PAO
D03HJK-D0C0SK-D07PAO	DRUGNAME	Azithromycin + Pyrimethamine + Sulfadoxine
D03HJK-D0C0SK-D07PAO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D09OOV-D0M1IO-D05JNI	TTDDRUID	D09OOV-D0M1IO-D05JNI
D09OOV-D0M1IO-D05JNI	DRUGNAME	Bacitracin + Neomycin + Polymyxin B Sulfate
D09OOV-D0M1IO-D05JNI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D01FUL-D0H3WI-D0Y8OK	TTDDRUID	D01FUL-D0H3WI-D0Y8OK
D01FUL-D0H3WI-D0Y8OK	DRUGNAME	Balapiravir + Peginterferon alfa-2a + Ribavirin
D01FUL-D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D06SBB-D0K3QS-D0O3YF	TTDDRUID	D06SBB-D0K3QS-D0O3YF
D06SBB-D0K3QS-D0O3YF	DRUGNAME	Basiliximab + Cyclosporine + Everolimus
D06SBB-D0K3QS-D0O3YF	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 3

D04FBR-D06SBB-D0O3YF	TTDDRUID	D04FBR-D06SBB-D0O3YF
D04FBR-D06SBB-D0O3YF	DRUGNAME	Basiliximab + Cyclosporine + Mycophenolate mofetil
D04FBR-D06SBB-D0O3YF	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 3

D06OMK-D06SBB-D0K3QS	TTDDRUID	D06OMK-D06SBB-D0K3QS
D06OMK-D06SBB-D0K3QS	DRUGNAME	Basiliximab + Everolimus + Tacrolimus
D06OMK-D06SBB-D0K3QS	INDICATI	Renal transplantation [ICD-11: NE84] Phase 4

D00UAE-D0C4RB-D0X7HM	TTDDRUID	D00UAE-D0C4RB-D0X7HM
D00UAE-D0C4RB-D0X7HM	DRUGNAME	bavituximab + paclitaxel + carboplatin
D00UAE-D0C4RB-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D01CYA-D0IT2G-D0SH3I	TTDDRUID	D01CYA-D0IT2G-D0SH3I
D01CYA-D0IT2G-D0SH3I	DRUGNAME	bendamustine + bortezomib + dexamethasone
D01CYA-D0IT2G-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D01CYA-D09EXD-D0SH3I	TTDDRUID	D01CYA-D09EXD-D0SH3I
D01CYA-D09EXD-D0SH3I	DRUGNAME	Bendamustine + Bortezomib + Rituximab
D01CYA-D09EXD-D0SH3I	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2

D01CYA-D0IT2G-D0U7GK	TTDDRUID	D01CYA-D0IT2G-D0U7GK
D01CYA-D0IT2G-D0U7GK	DRUGNAME	bendamustine + dexamethasone + thalidomide
D01CYA-D0IT2G-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D01CYA-D09EXD-D0Q4OW	TTDDRUID	D01CYA-D09EXD-D0Q4OW
D01CYA-D09EXD-D0Q4OW	DRUGNAME	bendamustine + rituximab + pixantrone
D01CYA-D09EXD-D0Q4OW	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2

D04DXN-D0BM5G-D0R0ZL	TTDDRUID	D04DXN-D0BM5G-D0R0ZL
D04DXN-D0BM5G-D0R0ZL	DRUGNAME	Benzoyl peroxide + Clindamycin + Tazarotene
D04DXN-D0BM5G-D0R0ZL	INDICATI	Acne vulgaris [ICD-11: ED80] Phase 4

D00HCQ-D04KBL-D07HOB	TTDDRUID	D00HCQ-D04KBL-D07HOB
D00HCQ-D04KBL-D07HOB	DRUGNAME	Bevacizumab + Capecitabine + Irinotecan
D00HCQ-D04KBL-D07HOB	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D00HCQ-D04KBL-D04WFL	TTDDRUID	D00HCQ-D04KBL-D04WFL
D00HCQ-D04KBL-D04WFL	DRUGNAME	Bevacizumab + Capecitabine + Trastuzumab
D00HCQ-D04KBL-D04WFL	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D03UVS-D04KBL-D0X7HM	TTDDRUID	D03UVS-D04KBL-D0X7HM
D03UVS-D04KBL-D0X7HM	DRUGNAME	Bevacizumab + Carboplatin + Gemcitabine
D03UVS-D04KBL-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D04KBL-D07HOB-D0X7HM	TTDDRUID	D04KBL-D07HOB-D0X7HM
D04KBL-D07HOB-D0X7HM	DRUGNAME	Bevacizumab + Carboplatin + Irinotecan
D04KBL-D07HOB-D0X7HM	INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 2

D04KBL-D0C4RB-D0X7HM	TTDDRUID	D04KBL-D0C4RB-D0X7HM
D04KBL-D0C4RB-D0X7HM	DRUGNAME	Bevacizumab + Carboplatin + Paclitaxel
D04KBL-D0C4RB-D0X7HM	INDICATI	Brenner tumour [ICD-11: 2F32] Phase 3
D04KBL-D0C4RB-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
D04KBL-D0C4RB-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D04KBL-D07POC-D0N5OV	TTDDRUID	D04KBL-D07POC-D0N5OV
D04KBL-D07POC-D0N5OV	DRUGNAME	Bevacizumab + Cetuximab + Erlotinib
D04KBL-D07POC-D0N5OV	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1

D03UVS-D04KBL-D0U5HU	TTDDRUID	D03UVS-D04KBL-D0U5HU
D03UVS-D04KBL-D0U5HU	DRUGNAME	Bevacizumab + Cisplatin + Gemcitabine
D03UVS-D04KBL-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D04KBL-D0U5HU-D0Y4GO	TTDDRUID	D04KBL-D0U5HU-D0Y4GO
D04KBL-D0U5HU-D0Y4GO	DRUGNAME	Bevacizumab + Cisplatin + Pemetrexed
D04KBL-D0U5HU-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D02PMO-D04KBL-D0U5HU	TTDDRUID	D02PMO-D04KBL-D0U5HU
D02PMO-D04KBL-D0U5HU	DRUGNAME	Bevacizumab + Cisplatin + Topotecan
D02PMO-D04KBL-D0U5HU	INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2

D04KBL-D04WFL-D0O5WP	TTDDRUID	D04KBL-D04WFL-D0O5WP
D04KBL-D04WFL-D0O5WP	DRUGNAME	Bevacizumab + Docetaxel + Trastuzumab
D04KBL-D04WFL-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D04KBL-D05LEO-D07HOB	TTDDRUID	D04KBL-D05LEO-D07HOB
D04KBL-D05LEO-D07HOB	DRUGNAME	Bevacizumab + Fluorouracil + Irinotecan
D04KBL-D05LEO-D07HOB	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2

D04KBL-D04WFL-D08CDI	TTDDRUID	D04KBL-D04WFL-D08CDI
D04KBL-D04WFL-D08CDI	DRUGNAME	Bevacizumab + Lapatinib + Trastuzumab
D04KBL-D04WFL-D08CDI	INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1

D04KBL-D0X7HM-D0Y4GO	TTDDRUID	D04KBL-D0X7HM-D0Y4GO
D04KBL-D0X7HM-D0Y4GO	DRUGNAME	bevacizumab + pemetrexed + carboplatin
D04KBL-D0X7HM-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D04WFL-D0C4RB-D0VG0D	TTDDRUID	D04WFL-D0C4RB-D0VG0D
D04WFL-D0C4RB-D0VG0D	DRUGNAME	bez235 + paclitaxel + trastuzumab
D04WFL-D0C4RB-D0VG0D	INDICATI	Metastatic or locally advanced solid tumour [ICD-11: 2D50-2E2Z] Phase 1

D03CUF-D08NQZ-D0OG5K	TTDDRUID	D03CUF-D08NQZ-D0OG5K
D03CUF-D08NQZ-D0OG5K	DRUGNAME	Bismuth Subsalicylate + Furazolidone + Tetracycline
D03CUF-D08NQZ-D0OG5K	INDICATI	Functional dyspepsia [ICD-11: DD90.3] Phase 4

D08NQZ-D0A2ZX-D0OG5K	TTDDRUID	D08NQZ-D0A2ZX-D0OG5K
D08NQZ-D0A2ZX-D0OG5K	DRUGNAME	Bismuth Subsalicylate + Metronidazole + Tetracycline
D08NQZ-D0A2ZX-D0OG5K	INDICATI	Duodenal ulcer [ICD-11: DA63] Approved
D08NQZ-D0A2ZX-D0OG5K	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved

D01QSO-D0C4RB-D0X7HM	TTDDRUID	D01QSO-D0C4RB-D0X7HM
D01QSO-D0C4RB-D0X7HM	DRUGNAME	bkm120 + paclitaxel + carboplatin
D01QSO-D0C4RB-D0X7HM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D01QSO-D04WFL-D0C4RB	TTDDRUID	D01QSO-D04WFL-D0C4RB
D01QSO-D04WFL-D0C4RB	DRUGNAME	bkm120 + paclitaxel + trastuzumab
D01QSO-D04WFL-D0C4RB	INDICATI	Metastatic or locally advanced solid tumour [ICD-11: 2D50-2E2Z] Phase 1

D08NWC-D0H3WI-D0V3YT	TTDDRUID	D08NWC-D0H3WI-D0V3YT
D08NWC-D0H3WI-D0V3YT	DRUGNAME	Boceprevir + Peginterferon alfa-2b + Ribavirin
D08NWC-D0H3WI-D0V3YT	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3
D08NWC-D0H3WI-D0V3YT	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D03UVS-D0SH3I-D0X7HM	TTDDRUID	D03UVS-D0SH3I-D0X7HM
D03UVS-D0SH3I-D0X7HM	DRUGNAME	Bortezomib + Carboplatin + Gemcitabine
D03UVS-D0SH3I-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0CT9C-D0IT2G-D0SH3I	TTDDRUID	D0CT9C-D0IT2G-D0SH3I
D0CT9C-D0IT2G-D0SH3I	DRUGNAME	Bortezomib + Cyclophosphamide + Dexamethasone
D0CT9C-D0IT2G-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D07XSN-D0IT2G-D0SH3I	TTDDRUID	D07XSN-D0IT2G-D0SH3I
D07XSN-D0IT2G-D0SH3I	DRUGNAME	Bortezomib + Cytarabine + Dexamethasone
D07XSN-D0IT2G-D0SH3I	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Investigative

D0IT2G-D0Q5NX-D0SH3I	TTDDRUID	D0IT2G-D0Q5NX-D0SH3I
D0IT2G-D0Q5NX-D0SH3I	DRUGNAME	Bortezomib + Dexamethasone + Lenalidomide
D0IT2G-D0Q5NX-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
D0IT2G-D0Q5NX-D0SH3I	INDICATI	Stage I multiple myeloma [ICD-11: 2A83] Phase 3

D0E3SH-D0IT2G-D0SH3I	TTDDRUID	D0E3SH-D0IT2G-D0SH3I
D0E3SH-D0IT2G-D0SH3I	DRUGNAME	Bortezomib + Dexamethasone + Panobinostat
D0E3SH-D0IT2G-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 4

D0IT2G-D0SH3I-D0U7GK	TTDDRUID	D0IT2G-D0SH3I-D0U7GK
D0IT2G-D0SH3I-D0U7GK	DRUGNAME	Bortezomib + Dexamethasone + Thalidomide
D0IT2G-D0SH3I-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
D0IT2G-D0SH3I-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D07VLY-D0IT2G-D0SH3I	TTDDRUID	D07VLY-D0IT2G-D0SH3I
D07VLY-D0IT2G-D0SH3I	DRUGNAME	bortezomib + Doxorubicin Hydrochloride + dexamethasone
D07VLY-D0IT2G-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D00FGO-D0IL7L-D0SH3I	TTDDRUID	D00FGO-D0IL7L-D0SH3I
D00FGO-D0IL7L-D0SH3I	DRUGNAME	Bortezomib + Melphalan + Prednisone
D00FGO-D0IL7L-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0IL7L-D0SH3I-D0U7GK	TTDDRUID	D0IL7L-D0SH3I-D0U7GK
D0IL7L-D0SH3I-D0U7GK	DRUGNAME	Bortezomib + Prednisone + Thalidomide
D0IL7L-D0SH3I-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0CT4D-D0E0OG-D0E1XL	TTDDRUID	D0CT4D-D0E0OG-D0E1XL
D0CT4D-D0E0OG-D0E1XL	DRUGNAME	Brivaracetam + Levetiracetam + Lorazepam
D0CT4D-D0E0OG-D0E1XL	INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1

D00HHS-D08VXO-D09OBB	TTDDRUID	D00HHS-D08VXO-D09OBB
D00HHS-D08VXO-D09OBB	DRUGNAME	Brompheniramine + Dextromethorphan + Pseudoephedrine
D00HHS-D08VXO-D09OBB	INDICATI	Sneezing [ICD-11: MD11.A] Approved

D04KJO-D0M8RC-D0Y7IU	TTDDRUID	D04KJO-D0M8RC-D0Y7IU
D04KJO-D0M8RC-D0Y7IU	DRUGNAME	Budesonide + Formoterol + Terbutaline
D04KJO-D0M8RC-D0Y7IU	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3

D03HJK-D0L5YV-D0Y7IU	TTDDRUID	D03HJK-D0L5YV-D0Y7IU
D03HJK-D0L5YV-D0Y7IU	DRUGNAME	budesonide + salmeterol + azithromycin
D03HJK-D0L5YV-D0Y7IU	INDICATI	Asthma [ICD-11: CA23] Phase 4

D00QET-D0L5YV-D0Y7IU	TTDDRUID	D00QET-D0L5YV-D0Y7IU
D00QET-D0L5YV-D0Y7IU	DRUGNAME	budesonide + salmeterol + montelukast
D00QET-D0L5YV-D0Y7IU	INDICATI	Asthma [ICD-11: CA23] Phase 4

D03SKR-D0A0FL-D0X4RN	TTDDRUID	D03SKR-D0A0FL-D0X4RN
D03SKR-D0A0FL-D0X4RN	DRUGNAME	Bupivacaine + Clonidine + Lidocaine
D03SKR-D0A0FL-D0X4RN	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 3

D03SKR-D0A0FL-D0WE3O	TTDDRUID	D03SKR-D0A0FL-D0WE3O
D03SKR-D0A0FL-D0WE3O	DRUGNAME	bupivacaine + clonidine + morphine
D03SKR-D0A0FL-D0WE3O	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 1/2

D04PHC-D0A0FL-D0E1WI	TTDDRUID	D04PHC-D0A0FL-D0E1WI
D04PHC-D0A0FL-D0E1WI	DRUGNAME	Bupivacaine + Epinephrine + Fentanyl
D04PHC-D0A0FL-D0E1WI	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4

D06AWE-D0T6WT-D0X3FX	TTDDRUID	D06AWE-D0T6WT-D0X3FX
D06AWE-D0T6WT-D0X3FX	DRUGNAME	Buprenorphine + Heroin + Naloxone
D06AWE-D0T6WT-D0X3FX	INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 3

D0K0TC-D0X4ZR-D0Y5DO	TTDDRUID	D0K0TC-D0X4ZR-D0Y5DO
D0K0TC-D0X4ZR-D0Y5DO	DRUGNAME	Bupropion + Citalopram + Sertraline
D0K0TC-D0X4ZR-D0Y5DO	INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 1/2

D00FGO-D07SUG-D0F2XQ	TTDDRUID	D00FGO-D07SUG-D0F2XQ
D00FGO-D07SUG-D0F2XQ	DRUGNAME	Busulfan + Fludarabine + Melphalan
D00FGO-D07SUG-D0F2XQ	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D0B2UZ-D0B3HD-D0R1RS	TTDDRUID	D0B2UZ-D0B3HD-D0R1RS
D0B2UZ-D0B3HD-D0R1RS	DRUGNAME	Caffeine + Indomethacin + Prochlorperazine
D0B2UZ-D0B3HD-D0R1RS	INDICATI	Migraine [ICD-11: 8A80] Investigative

D03UVS-D07POC-D0T2PL	TTDDRUID	D03UVS-D07POC-D0T2PL
D03UVS-D07POC-D0T2PL	DRUGNAME	calcitriol + gemcitabine + erlotinib
D03UVS-D07POC-D0T2PL	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D0B8QB-D0K0OZ-D0PJ4K	TTDDRUID	D0B8QB-D0K0OZ-D0PJ4K
D0B8QB-D0K0OZ-D0PJ4K	DRUGNAME	Calcium carbonate + Famotidine + Magnesium hydroxide
D0B8QB-D0K0OZ-D0PJ4K	INDICATI	Heartburn associated with acid indigestion and sour stomach [ICD-11: MD95] Approved

D00HCQ-D0C9XJ-D0U5HU	TTDDRUID	D00HCQ-D0C9XJ-D0U5HU
D00HCQ-D0C9XJ-D0U5HU	DRUGNAME	Capecitabine + Cisplatin + Epirubicin
D00HCQ-D0C9XJ-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D00HCQ-D0AZ3C-D0U5HU	TTDDRUID	D00HCQ-D0AZ3C-D0U5HU
D00HCQ-D0AZ3C-D0U5HU	DRUGNAME	Capecitabine + Cisplatin + Imatinib
D00HCQ-D0AZ3C-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1

D00HCQ-D04WFL-D0U5HU	TTDDRUID	D00HCQ-D04WFL-D0U5HU
D00HCQ-D04WFL-D0U5HU	DRUGNAME	Capecitabine + Cisplatin + Trastuzumab
D00HCQ-D04WFL-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
D00HCQ-D04WFL-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Preclinical

D00HCQ-D0C9XJ-D0O5WP	TTDDRUID	D00HCQ-D0C9XJ-D0O5WP
D00HCQ-D0C9XJ-D0O5WP	DRUGNAME	Capecitabine + Docetaxel + Epirubicin
D00HCQ-D0C9XJ-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00HCQ-D03UVS-D0W5HK	TTDDRUID	D00HCQ-D03UVS-D0W5HK
D00HCQ-D03UVS-D0W5HK	DRUGNAME	Capecitabine + Gemcitabine + Sorafenib
D00HCQ-D03UVS-D0W5HK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D00HCQ-D07HOB-D0Y3ME	TTDDRUID	D00HCQ-D07HOB-D0Y3ME
D00HCQ-D07HOB-D0Y3ME	DRUGNAME	Capecitabine + Irinotecan + Oxaliplatin
D00HCQ-D07HOB-D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2

D00HCQ-D08CDI-D0Y3ME	TTDDRUID	D00HCQ-D08CDI-D0Y3ME
D00HCQ-D08CDI-D0Y3ME	DRUGNAME	Capecitabine + Lapatinib + Oxaliplatin
D00HCQ-D08CDI-D0Y3ME	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1

D00HCQ-D0N5OV-D0Y3ME	TTDDRUID	D00HCQ-D0N5OV-D0Y3ME
D00HCQ-D0N5OV-D0Y3ME	DRUGNAME	capecitabine + oxaliplatin + cetuximab
D00HCQ-D0N5OV-D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D08HVR-D0J1VY-D0P7JZ	TTDDRUID	D08HVR-D0J1VY-D0P7JZ
D08HVR-D0J1VY-D0P7JZ	DRUGNAME	Carbidopa + Entacapone + Levodopa
D08HVR-D0J1VY-D0P7JZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
D08HVR-D0J1VY-D0P7JZ	INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3

D05LEO-D0N5OV-D0X7HM	TTDDRUID	D05LEO-D0N5OV-D0X7HM
D05LEO-D0N5OV-D0X7HM	DRUGNAME	Carboplatin + Cetuximab + Fluorouracil
D05LEO-D0N5OV-D0X7HM	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D0C4RB-D0N5OV-D0X7HM	TTDDRUID	D0C4RB-D0N5OV-D0X7HM
D0C4RB-D0N5OV-D0X7HM	DRUGNAME	Carboplatin + Cetuximab + Paclitaxel
D0C4RB-D0N5OV-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D04WFL-D0O5WP-D0X7HM	TTDDRUID	D04WFL-D0O5WP-D0X7HM
D04WFL-D0O5WP-D0X7HM	DRUGNAME	Carboplatin + Docetaxel + Trastuzumab
D04WFL-D0O5WP-D0X7HM	INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Preclinical

D04WFL-D07VLY-D0X7HM	TTDDRUID	D04WFL-D07VLY-D0X7HM
D04WFL-D07VLY-D0X7HM	DRUGNAME	Carboplatin + Doxorubicin + Trastuzumab
D04WFL-D07VLY-D0X7HM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0I6VU-D0X7HM-D0Y4GO	TTDDRUID	D0I6VU-D0X7HM-D0Y4GO
D0I6VU-D0X7HM-D0Y4GO	DRUGNAME	Carboplatin + Enzastaurin + Pemetrexed
D0I6VU-D0X7HM-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D03UVS-D0IK5F-D0X7HM	TTDDRUID	D03UVS-D0IK5F-D0X7HM
D03UVS-D0IK5F-D0X7HM	DRUGNAME	Carboplatin + Gemcitabine + Iniparib
D03UVS-D0IK5F-D0X7HM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D0C4RB-D0IK5F-D0X7HM	TTDDRUID	D0C4RB-D0IK5F-D0X7HM
D0C4RB-D0IK5F-D0X7HM	DRUGNAME	Carboplatin + Iniparib + Paclitaxel
D0C4RB-D0IK5F-D0X7HM	INDICATI	Uterine carcinosarcoma [ICD-11: 2C72.3] Phase 2

D06YWH-D0C4RB-D0X7HM	TTDDRUID	D06YWH-D0C4RB-D0X7HM
D06YWH-D0C4RB-D0X7HM	DRUGNAME	Carboplatin + Paclitaxel + Sepantronium bromide
D06YWH-D0C4RB-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2

D0C4RB-D0W5HK-D0X7HM	TTDDRUID	D0C4RB-D0W5HK-D0X7HM
D0C4RB-D0W5HK-D0X7HM	DRUGNAME	Carboplatin + Paclitaxel + Sorafenib
D0C4RB-D0W5HK-D0X7HM	INDICATI	Melanoma [ICD-11: 2C30] Phase 2
D0C4RB-D0W5HK-D0X7HM	INDICATI	Melanoma [ICD-11: 2C30] Phase 3
D0C4RB-D0W5HK-D0X7HM	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1

D02HVW-D0C4RB-D0X7HM	TTDDRUID	D02HVW-D0C4RB-D0X7HM
D02HVW-D0C4RB-D0X7HM	DRUGNAME	Carboplatin + Paclitaxel + Zibotentan
D02HVW-D0C4RB-D0X7HM	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2

D0C4RB-D0R0MW-D0X7HM	TTDDRUID	D0C4RB-D0R0MW-D0X7HM
D0C4RB-D0R0MW-D0X7HM	DRUGNAME	carboplatin + sunitinib + paclitaxel
D0C4RB-D0R0MW-D0X7HM	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1

D00UVA-D0IT2G-D0Q5NX	TTDDRUID	D00UVA-D0IT2G-D0Q5NX
D00UVA-D0IT2G-D0Q5NX	DRUGNAME	Carfilzomib + Dexamethasone + Lenalidomide
D00UVA-D0IT2G-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D00ZGA-D0IT2G-D0K7WK	TTDDRUID	D00ZGA-D0IT2G-D0K7WK
D00ZGA-D0IT2G-D0K7WK	DRUGNAME	Casopitant + Dexamethasone + Ondansetron
D00ZGA-D0IT2G-D0K7WK	INDICATI	Nausea and vomiting [ICD-11: MD90] Phase 3

D02NNN-D0U5HU-D0Y4GO	TTDDRUID	D02NNN-D0U5HU-D0Y4GO
D02NNN-D0U5HU-D0Y4GO	DRUGNAME	cbp501 + cisplatin + pemetrexed
D02NNN-D0U5HU-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D05LEO-D0N5OV-D0U5HU	TTDDRUID	D05LEO-D0N5OV-D0U5HU
D05LEO-D0N5OV-D0U5HU	DRUGNAME	cetuximab + cisplatin + 5-fu
D05LEO-D0N5OV-D0U5HU	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3

D01HTL-D0N5OV-D0U5HU	TTDDRUID	D01HTL-D0N5OV-D0U5HU
D01HTL-D0N5OV-D0U5HU	DRUGNAME	Cetuximab + Cisplatin + Vinorelbine
D01HTL-D0N5OV-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D0N5OV-D0O5WP-D0U5HU	TTDDRUID	D0N5OV-D0O5WP-D0U5HU
D0N5OV-D0O5WP-D0U5HU	DRUGNAME	cetuximab + docetaxel + cisplatin
D0N5OV-D0O5WP-D0U5HU	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2

D0N5OV-D0O5WP-D0Y3ME	TTDDRUID	D0N5OV-D0O5WP-D0Y3ME
D0N5OV-D0O5WP-D0Y3ME	DRUGNAME	Cetuximab + Docetaxel + Oxaliplatin
D0N5OV-D0O5WP-D0Y3ME	INDICATI	Metastatic gastric or gastroesophageal junction cancer [ICD-11: 2D8Y] Phase 2

D03UVS-D0N5OV-D0Y3ME	TTDDRUID	D03UVS-D0N5OV-D0Y3ME
D03UVS-D0N5OV-D0Y3ME	DRUGNAME	cetuximab + gemcitabine + oxaliplatin
D03UVS-D0N5OV-D0Y3ME	INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 2

D05LEO-D0N5OV-D0Y3ME	TTDDRUID	D05LEO-D0N5OV-D0Y3ME
D05LEO-D0N5OV-D0Y3ME	DRUGNAME	cetuximab + oxaliplatin + 5fu
D05LEO-D0N5OV-D0Y3ME	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3

D0J0KD-D0U6BJ-D0X6IU	TTDDRUID	D0J0KD-D0U6BJ-D0X6IU
D0J0KD-D0U6BJ-D0X6IU	DRUGNAME	Chloramphenicol + Desoxyribonuclease + Fibrinolysin
D0J0KD-D0U6BJ-D0X6IU	INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved

D09OOV-D0KR5B-D0X6IU	TTDDRUID	D09OOV-D0KR5B-D0X6IU
D09OOV-D0KR5B-D0X6IU	DRUGNAME	Chloramphenicol + Hydrocortisone + Polymyxin B Sulfate
D09OOV-D0KR5B-D0X6IU	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D03OFF-D06BEP-D0Y5DO	TTDDRUID	D03OFF-D06BEP-D0Y5DO
D03OFF-D06BEP-D0Y5DO	DRUGNAME	Chlordiazepoxide + Citalopram + Pioglitazone
D03OFF-D06BEP-D0Y5DO	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2/3

D00HHS-D0B7NG-D0X5KF	TTDDRUID	D00HHS-D0B7NG-D0X5KF
D00HHS-D0B7NG-D0X5KF	DRUGNAME	Chlorpheniramine + Hydrocodone + Pseudoephedrine
D00HHS-D0B7NG-D0X5KF	INDICATI	Cough [ICD-11: MD12] Approved

D0B7NG-D0O6IU-D0R1QE	TTDDRUID	D0B7NG-D0O6IU-D0R1QE
D0B7NG-D0O6IU-D0R1QE	DRUGNAME	Chlorpheniramine + Ibuprofen + Phenylephrine
D0B7NG-D0O6IU-D0R1QE	INDICATI	Upper respiratory tract symptom [ICD-11: CA0Z] Approved

D00HHS-D0B7NG-D0R1QE	TTDDRUID	D00HHS-D0B7NG-D0R1QE
D00HHS-D0B7NG-D0R1QE	DRUGNAME	Chlorpheniramine + Ibuprofen + Pseudoephedrine
D00HHS-D0B7NG-D0R1QE	INDICATI	Sneezing [ICD-11: MD11.A] Approved

D0O1WX-D0AO5H-D0R9OH	TTDDRUID	D0O1WX-D0AO5H-D0R9OH
D0O1WX-D0AO5H-D0R9OH	DRUGNAME	Ciprofloxacin + Sulfamethoxazole + Trimethoprim
D0O1WX-D0AO5H-D0R9OH	INDICATI	Pyogenic liver abscess [ICD-11: DB90.0] Investigative

D0MX5S-D0O5WP-D0U5HU	TTDDRUID	D0MX5S-D0O5WP-D0U5HU
D0MX5S-D0O5WP-D0U5HU	DRUGNAME	cisplatin + docetaxel + enoxaparin
D0MX5S-D0O5WP-D0U5HU	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3

D05LEO-D0O5WP-D0U5HU	TTDDRUID	D05LEO-D0O5WP-D0U5HU
D05LEO-D0O5WP-D0U5HU	DRUGNAME	Cisplatin + Docetaxel + Fluorouracil
D05LEO-D0O5WP-D0U5HU	INDICATI	Oropharyngeal cancer [ICD-11: 2B6A] Phase 1/2
D05LEO-D0O5WP-D0U5HU	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Investigative

D0O5WP-D0U5HU-D0Y4GO	TTDDRUID	D0O5WP-D0U5HU-D0Y4GO
D0O5WP-D0U5HU-D0Y4GO	DRUGNAME	Cisplatin + Docetaxel + Pemetrexed
D0O5WP-D0U5HU-D0Y4GO	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2

D05LEO-D07VLY-D0U5HU	TTDDRUID	D05LEO-D07VLY-D0U5HU
D05LEO-D07VLY-D0U5HU	DRUGNAME	Cisplatin + Doxorubicin + Fluorouracil
D05LEO-D07VLY-D0U5HU	INDICATI	Advanced epidermoid carcinoma [ICD-11: 2A00-2F9Z] Investigative

D05LEO-D0P0WV-D0U5HU	TTDDRUID	D05LEO-D0P0WV-D0U5HU
D05LEO-D0P0WV-D0U5HU	DRUGNAME	Cisplatin + Fluorouracil + Interferon alfa-2b
D05LEO-D0P0WV-D0U5HU	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D09XZB-D0U5HU-D0Y4GO	TTDDRUID	D09XZB-D0U5HU-D0Y4GO
D09XZB-D0U5HU-D0Y4GO	DRUGNAME	Cisplatin + Gefitinib + Pemetrexed
D09XZB-D0U5HU-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0BZ7W-D0CP4E-D0S9MC	TTDDRUID	D0BZ7W-D0CP4E-D0S9MC
D0BZ7W-D0CP4E-D0S9MC	DRUGNAME	Clobazam + Clonazepam + Tolterodine
D0BZ7W-D0CP4E-D0S9MC	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3

D0B7EB-D0CT9C-D0R5RR	TTDDRUID	D0B7EB-D0CT9C-D0R5RR
D0B7EB-D0CT9C-D0R5RR	DRUGNAME	Clofarabine + Cyclophosphamide + Etoposide
D0B7EB-D0CT9C-D0R5RR	INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2

D07DVK-D09GOS-D0L9UU	TTDDRUID	D07DVK-D09GOS-D0L9UU
D07DVK-D09GOS-D0L9UU	DRUGNAME	clotrimazole + gentamicin + beclomethasone
D07DVK-D09GOS-D0L9UU	INDICATI	Folliculitis [ICD-11: 1B74] Phase 2/3

D03DIG-D0O6IU-D0T2XU	TTDDRUID	D03DIG-D0O6IU-D0T2XU
D03DIG-D0O6IU-D0T2XU	DRUGNAME	Codeine + Phenylephrine + Promethazine
D03DIG-D0O6IU-D0T2XU	INDICATI	Cough [ICD-11: MD12] Approved
D03DIG-D0O6IU-D0T2XU	INDICATI	Upper respiratory tract symptom [ICD-11: CA0Z] Approved

D00HHS-D03DIG-D0E8CI	TTDDRUID	D00HHS-D03DIG-D0E8CI
D00HHS-D03DIG-D0E8CI	DRUGNAME	Codeine + Pseudoephedrine + Triprolidine
D00HHS-D03DIG-D0E8CI	INDICATI	Cough [ICD-11: MD12] Approved
D00HHS-D03DIG-D0E8CI	INDICATI	Upper respiratory tract symptom [ICD-11: CA0Z] Approved

D0CT9C-D0IT2G-D0Q5NX	TTDDRUID	D0CT9C-D0IT2G-D0Q5NX
D0CT9C-D0IT2G-D0Q5NX	DRUGNAME	Cyclophosphamide + Dexamethasone + Lenalidomide
D0CT9C-D0IT2G-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D07VLY-D0CT9C-D0O5WP	TTDDRUID	D07VLY-D0CT9C-D0O5WP
D07VLY-D0CT9C-D0O5WP	DRUGNAME	Cyclophosphamide + Docetaxel + Doxorubicin
D07VLY-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D05LEO-D07VLY-D0CT9C	TTDDRUID	D05LEO-D07VLY-D0CT9C
D05LEO-D07VLY-D0CT9C	DRUGNAME	Cyclophosphamide + Doxorubicin + Fluorouracil
D05LEO-D07VLY-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D0CT9C-D0F2XQ-D0Y8ZN	TTDDRUID	D0CT9C-D0F2XQ-D0Y8ZN
D0CT9C-D0F2XQ-D0Y8ZN	DRUGNAME	Cyclophosphamide + Fludarabine + Ofatumumab
D0CT9C-D0F2XQ-D0Y8ZN	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2

D09EXD-D0CT9C-D0F2XQ	TTDDRUID	D09EXD-D0CT9C-D0F2XQ
D09EXD-D0CT9C-D0F2XQ	DRUGNAME	Cyclophosphamide + Fludarabine + Rituximab
D09EXD-D0CT9C-D0F2XQ	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D0CT9C-D0D3DU-D0I2SD	TTDDRUID	D0CT9C-D0D3DU-D0I2SD
D0CT9C-D0D3DU-D0I2SD	DRUGNAME	Cyclophosphamide + Methotrexate Sodium + Medroxyprogesterone
D0CT9C-D0D3DU-D0I2SD	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04FBR-D0D1SG-D0O3YF	TTDDRUID	D04FBR-D0D1SG-D0O3YF
D04FBR-D0D1SG-D0O3YF	DRUGNAME	Cyclosporine + Mycophenolate mofetil + Prednisolone
D04FBR-D0D1SG-D0O3YF	INDICATI	Heart transplant rejection [ICD-11: NE84] Investigative

D04FBR-D0IL7L-D0O3YF	TTDDRUID	D04FBR-D0IL7L-D0O3YF
D04FBR-D0IL7L-D0O3YF	DRUGNAME	Cyclosporine + Mycophenolate mofetil + Prednisone
D04FBR-D0IL7L-D0O3YF	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 4

D01XWG-D07NVU-D07XSN	TTDDRUID	D01XWG-D07NVU-D07XSN
D01XWG-D07NVU-D07XSN	DRUGNAME	Cytarabine + Daunorubicin + Midostaurin
D01XWG-D07NVU-D07XSN	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D07XSN-D0AZ3C-D0P0WV	TTDDRUID	D07XSN-D0AZ3C-D0P0WV
D07XSN-D0AZ3C-D0P0WV	DRUGNAME	Cytarabine + Imatinib + Interferon alfa-2b
D07XSN-D0AZ3C-D0P0WV	INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 3

D0P0WV-D0S1ZB-D0Y7ZU	TTDDRUID	D0P0WV-D0S1ZB-D0Y7ZU
D0P0WV-D0S1ZB-D0Y7ZU	DRUGNAME	Dacarbazine + Fotemustine + Interferon alfa-2b
D0P0WV-D0S1ZB-D0Y7ZU	INDICATI	Melanoma [ICD-11: 2C30] Phase 3

D0H3WI-D0R9MN-D0Y8OK	TTDDRUID	D0H3WI-D0R9MN-D0Y8OK
D0H3WI-D0R9MN-D0Y8OK	DRUGNAME	Danoprevir + Peginterferon alfa-2a + Ribavirin
D0H3WI-D0R9MN-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D03IGH-D0I1FQ-D0ZU9R	TTDDRUID	D03IGH-D0I1FQ-D0ZU9R
D03IGH-D0I1FQ-D0ZU9R	DRUGNAME	Darunavir + Raltegravir + Ritonavir
D03IGH-D0I1FQ-D0ZU9R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2

D0E6XR-D0IL7L-D0O5WP	TTDDRUID	D0E6XR-D0IL7L-D0O5WP
D0E6XR-D0IL7L-D0O5WP	DRUGNAME	Dasatinib + Docetaxel + Prednisone
D0E6XR-D0IL7L-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D0E6XR-D0IT2G-D0Q5NX	TTDDRUID	D0E6XR-D0IT2G-D0Q5NX
D0E6XR-D0IT2G-D0Q5NX	DRUGNAME	dasatinib + lenalidomide + dexamethasone
D0E6XR-D0IT2G-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D04WFL-D0C4RB-D0E6XR	TTDDRUID	D04WFL-D0C4RB-D0E6XR
D04WFL-D0C4RB-D0E6XR	DRUGNAME	dasatinib + trastuzumab + paclitaxel
D04WFL-D0C4RB-D0E6XR	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D01XYJ-D0G6SD-D0O2EM	TTDDRUID	D01XYJ-D0G6SD-D0O2EM
D01XYJ-D0G6SD-D0O2EM	DRUGNAME	Delavirdine + Nevirapine + Zidovudine
D01XYJ-D0G6SD-D0O2EM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D01UTL-D06GDY-D0PG8O	TTDDRUID	D01UTL-D06GDY-D0PG8O
D01UTL-D06GDY-D0PG8O	DRUGNAME	Desipramine + Naltrexone + Paroxetine
D01UTL-D06GDY-D0PG8O	INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 3

D07VLY-D0IT2G-D0Q5NX	TTDDRUID	D07VLY-D0IT2G-D0Q5NX
D07VLY-D0IT2G-D0Q5NX	DRUGNAME	Dexamethasone + Doxorubicin + Lenalidomide
D07VLY-D0IT2G-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D03RTK-D07VLY-D0IT2G	TTDDRUID	D03RTK-D07VLY-D0IT2G
D03RTK-D07VLY-D0IT2G	DRUGNAME	Dexamethasone + Doxorubicin + Trabectedin
D03RTK-D07VLY-D0IT2G	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3

D0B2UZ-D0IT2G-D0J5KF	TTDDRUID	D0B2UZ-D0IT2G-D0J5KF
D0B2UZ-D0IT2G-D0J5KF	DRUGNAME	Dexamethasone + Granisetron + Prochlorperazine
D0B2UZ-D0IT2G-D0J5KF	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D09OOV-D0IT2G-D05JNI	TTDDRUID	D09OOV-D0IT2G-D05JNI
D09OOV-D0IT2G-D05JNI	DRUGNAME	Dexamethasone + Neomycin + Polymyxin B Sulfate
D09OOV-D0IT2G-D05JNI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D06FDR-D07HVY-D07TQV	TTDDRUID	D06FDR-D07HVY-D07TQV
D06FDR-D07HVY-D07TQV	DRUGNAME	Didanosine + Efavirenz + Lamivudine
D06FDR-D07HVY-D07TQV	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 3

D01XYJ-D06FDR-D07HVY	TTDDRUID	D01XYJ-D06FDR-D07HVY
D01XYJ-D06FDR-D07HVY	DRUGNAME	Didanosine + Efavirenz + Zidovudine
D01XYJ-D06FDR-D07HVY	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D01XYJ-D06FDR-D0V7CF	TTDDRUID	D01XYJ-D06FDR-D0V7CF
D01XYJ-D06FDR-D0V7CF	DRUGNAME	Didanosine + Indinavir + Zidovudine
D01XYJ-D06FDR-D0V7CF	INDICATI	Mother-to-fetus HIV transmission [ICD-11: JB63.7] Preclinical

D06FDR-D07TQV-D0O2EM	TTDDRUID	D06FDR-D07TQV-D0O2EM
D06FDR-D07TQV-D0O2EM	DRUGNAME	Didanosine + Lamivudine + Nevirapine
D06FDR-D07TQV-D0O2EM	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 3

D01XYJ-D06FDR-D0O2EM	TTDDRUID	D01XYJ-D06FDR-D0O2EM
D01XYJ-D06FDR-D0O2EM	DRUGNAME	Didanosine + Nevirapine + Zidovudine
D01XYJ-D06FDR-D0O2EM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D0N6FH-D0P0SZ-D0T1LK	TTDDRUID	D0N6FH-D0P0SZ-D0T1LK
D0N6FH-D0P0SZ-D0T1LK	DRUGNAME	Dihydroartemisinin + Piperaquine + Primaquine
D0N6FH-D0P0SZ-D0T1LK	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 4
D0N6FH-D0P0SZ-D0T1LK	INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Phase 3

D0I6VU-D0IL7L-D0O5WP	TTDDRUID	D0I6VU-D0IL7L-D0O5WP
D0I6VU-D0IL7L-D0O5WP	DRUGNAME	Docetaxel + Enzastaurin + Prednisone
D0I6VU-D0IL7L-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0C9XJ-D0CT9C-D0O5WP	TTDDRUID	D0C9XJ-D0CT9C-D0O5WP
D0C9XJ-D0CT9C-D0O5WP	DRUGNAME	docetaxel + epirubicin + cyclophosphamide
D0C9XJ-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2/3

D0AT8C-D0C9XJ-D0O5WP	TTDDRUID	D0AT8C-D0C9XJ-D0O5WP
D0AT8C-D0C9XJ-D0O5WP	DRUGNAME	Docetaxel + Epirubicin + Pegfilgrastim
D0AT8C-D0C9XJ-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D05YAG-D0C9XJ-D0O5WP	TTDDRUID	D05YAG-D0C9XJ-D0O5WP
D05YAG-D0C9XJ-D0O5WP	DRUGNAME	Docetaxel + Epirubicin + Recombinant human endostatin
D05YAG-D0C9XJ-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D03SRY-D0KR5B-D0O5WP	TTDDRUID	D03SRY-D0KR5B-D0O5WP
D03SRY-D0KR5B-D0O5WP	DRUGNAME	docetaxel + estramustine + hydrocortisone
D03SRY-D0KR5B-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3

D05LEO-D0O5WP-D0Y3ME	TTDDRUID	D05LEO-D0O5WP-D0Y3ME
D05LEO-D0O5WP-D0Y3ME	DRUGNAME	docetaxel + oxaliplatin + 5-fu
D05LEO-D0O5WP-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D00HCQ-D0O5WP-D0Y3ME	TTDDRUID	D00HCQ-D0O5WP-D0Y3ME
D00HCQ-D0O5WP-D0Y3ME	DRUGNAME	docetaxel + oxaliplatin + capecitabine
D00HCQ-D0O5WP-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D0G6QF-D0O5WP-D0Y3ME	TTDDRUID	D0G6QF-D0O5WP-D0Y3ME
D0G6QF-D0O5WP-D0Y3ME	DRUGNAME	Docetaxel + Oxaliplatin + Vandetanib
D0G6QF-D0O5WP-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1

D04WFL-D0C4RB-D0O5WP	TTDDRUID	D04WFL-D0C4RB-D0O5WP
D04WFL-D0C4RB-D0O5WP	DRUGNAME	Docetaxel + Paclitaxel + Trastuzumab
D04WFL-D0C4RB-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D04WFL-D0CI4E-D0O5WP	TTDDRUID	D04WFL-D0CI4E-D0O5WP
D04WFL-D0CI4E-D0O5WP	DRUGNAME	Docetaxel + Pertuzumab + Trastuzumab
D04WFL-D0CI4E-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
D04WFL-D0CI4E-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D02STN-D0IL7L-D0O5WP	TTDDRUID	D02STN-D0IL7L-D0O5WP
D02STN-D0IL7L-D0O5WP	DRUGNAME	docetaxel + prednisone + abiraterone
D02STN-D0IL7L-D0O5WP	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D0IL7L-D0O5WP-D0VM2L	TTDDRUID	D0IL7L-D0O5WP-D0VM2L
D0IL7L-D0O5WP-D0VM2L	DRUGNAME	docetaxel + prednisone + zoledronic acid
D0IL7L-D0O5WP-D0VM2L	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D04WFL-D08CDI-D0O5WP	TTDDRUID	D04WFL-D08CDI-D0O5WP
D04WFL-D08CDI-D0O5WP	DRUGNAME	docetaxel + trastuzumab + lapatinib
D04WFL-D08CDI-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2

D0B7YT-D0NS6H-D0OW9L	TTDDRUID	D0B7YT-D0NS6H-D0OW9L
D0B7YT-D0NS6H-D0OW9L	DRUGNAME	donepezil + mk-3134 + scopolamine
D0B7YT-D0NS6H-D0OW9L	INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1

D07VLY-D0U5HU-D0Y4GO	TTDDRUID	D07VLY-D0U5HU-D0Y4GO
D07VLY-D0U5HU-D0Y4GO	DRUGNAME	doxorubicin + cisplatin + cisplatin + pemetrexed
D07VLY-D0U5HU-D0Y4GO	INDICATI	Pleural mesothelioma [ICD-11: 2C26.0] Phase 2

D04KBL-D07VLY-D0CT9C	TTDDRUID	D04KBL-D07VLY-D0CT9C
D04KBL-D07VLY-D0CT9C	DRUGNAME	doxorubicin + cyclophosphamide + bevacizumab
D04KBL-D07VLY-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D06NXY-D0GL7U-D0S0LZ	TTDDRUID	D06NXY-D0GL7U-D0S0LZ
D06NXY-D0GL7U-D0S0LZ	DRUGNAME	Doxycycline + Ethinyl Estradiol + Levonorgestrel
D06NXY-D0GL7U-D0S0LZ	INDICATI	Contraception [ICD-11: QA21] Investigative

D0KR5B-D0PG0G-D0R7JT	TTDDRUID	D0KR5B-D0PG0G-D0R7JT
D0KR5B-D0PG0G-D0R7JT	DRUGNAME	Drotrecogin alfa + Fludrocortisone + Hydrocortisone
D0KR5B-D0PG0G-D0R7JT	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3

D06FDR-D07HVY-D0S9SD	TTDDRUID	D06FDR-D07HVY-D0S9SD
D06FDR-D07HVY-D0S9SD	DRUGNAME	efavirenz + didanosine + emtricitabine
D06FDR-D07HVY-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2

D07HVY-D0D9HW-D0S9SD	TTDDRUID	D07HVY-D0D9HW-D0S9SD
D07HVY-D0D9HW-D0S9SD	DRUGNAME	Efavirenz + Emtricitabine + Tenofovir
D07HVY-D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
D07HVY-D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4
D07HVY-D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved

D07HVY-D07TQV-D0Z8EX	TTDDRUID	D07HVY-D07TQV-D0Z8EX
D07HVY-D07TQV-D0Z8EX	DRUGNAME	Efavirenz + Lamivudine + Stavudine
D07HVY-D07TQV-D0Z8EX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D01XYJ-D07HVY-D07TQV	TTDDRUID	D01XYJ-D07HVY-D07TQV
D01XYJ-D07HVY-D07TQV	DRUGNAME	Efavirenz + Lamivudine + Zidovudine
D01XYJ-D07HVY-D07TQV	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4
D01XYJ-D07HVY-D07TQV	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
D01XYJ-D07HVY-D07TQV	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D03IGH-D0S9SD-D0ZU9R	TTDDRUID	D03IGH-D0S9SD-D0ZU9R
D03IGH-D0S9SD-D0ZU9R	DRUGNAME	emtricitabine + darunavir + ritonavir
D03IGH-D0S9SD-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0D9HW-D0O2EM-D0S9SD	TTDDRUID	D0D9HW-D0O2EM-D0S9SD
D0D9HW-D0O2EM-D0S9SD	DRUGNAME	Emtricitabine + Nevirapine + Tenofovir
D0D9HW-D0O2EM-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0D9HW-D0I1FQ-D0S9SD	TTDDRUID	D0D9HW-D0I1FQ-D0S9SD
D0D9HW-D0I1FQ-D0S9SD	DRUGNAME	Emtricitabine + Raltegravir + Tenofovir
D0D9HW-D0I1FQ-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0D9HW-D0S9SD-D0T6WN	TTDDRUID	D0D9HW-D0S9SD-D0T6WN
D0D9HW-D0S9SD-D0T6WN	DRUGNAME	Emtricitabine + Rilpivirine + Tenofovir
D0D9HW-D0S9SD-D0T6WN	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved

D01XYJ-D0D9HW-D0S9SD	TTDDRUID	D01XYJ-D0D9HW-D0S9SD
D01XYJ-D0D9HW-D0S9SD	DRUGNAME	Emtricitabine + Tenofovir + Zidovudine
D01XYJ-D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D05LTY-D0D1SG-D0D3DU	TTDDRUID	D05LTY-D0D1SG-D0D3DU
D05LTY-D0D1SG-D0D3DU	DRUGNAME	Enbrel + Prednisolone + Methotrexate Sodium
D05LTY-D0D1SG-D0D3DU	INDICATI	Juvenile chronic polyarthritis [ICD-11: FA24.1] Phase 4

D03UVS-D0U5HU-D0V6AH	TTDDRUID	D03UVS-D0U5HU-D0V6AH
D03UVS-D0U5HU-D0V6AH	DRUGNAME	endostatin + gemcitabine + cisplatin
D03UVS-D0U5HU-D0V6AH	INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 3

D04PHC-D09RHQ-D0D9JW	TTDDRUID	D04PHC-D09RHQ-D0D9JW
D04PHC-D09RHQ-D0D9JW	DRUGNAME	Epinephrine + Ketorolac + Ropivacaine
D04PHC-D09RHQ-D0D9JW	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Investigative

D04PHC-D08PIQ-D0N4OW	TTDDRUID	D04PHC-D08PIQ-D0N4OW
D04PHC-D08PIQ-D0N4OW	DRUGNAME	Epinephrine + Methylprednisolone Acetate + Vasopressin
D04PHC-D08PIQ-D0N4OW	INDICATI	Cardiac arrest [ICD-11: MC82] Phase 2

D05LEO-D0C9XJ-D0U5HU	TTDDRUID	D05LEO-D0C9XJ-D0U5HU
D05LEO-D0C9XJ-D0U5HU	DRUGNAME	epirubicin + cisplatin + fluorouracil
D05LEO-D0C9XJ-D0U5HU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D03UVS-D07POC-D0Y3ME	TTDDRUID	D03UVS-D07POC-D0Y3ME
D03UVS-D07POC-D0Y3ME	DRUGNAME	Erlotinib + Gemcitabine + Oxaliplatin
D03UVS-D07POC-D0Y3ME	INDICATI	Irresectable biliary tract cancer [ICD-11: 2C17] Phase 3

D08RBC-D0H3WI-D0Y8OK	TTDDRUID	D08RBC-D0H3WI-D0Y8OK
D08RBC-D0H3WI-D0Y8OK	DRUGNAME	Escitalopram + Peginterferon alfa-2a + Ribavirin
D08RBC-D0H3WI-D0Y8OK	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3

D08NQZ-D0A2ZX-D0C6DT	TTDDRUID	D08NQZ-D0A2ZX-D0C6DT
D08NQZ-D0A2ZX-D0C6DT	DRUGNAME	Esomeprazole + Metronidazole + Tetracycline
D08NQZ-D0A2ZX-D0C6DT	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 4

D08QMX-D0GL7U-D0UI3T	TTDDRUID	D08QMX-D0GL7U-D0UI3T
D08QMX-D0GL7U-D0UI3T	DRUGNAME	Estradiol + Norethindrone + Elagolix
D08QMX-D0GL7U-D0UI3T	INDICATI	Heavy uterine bleeding [ICD-11: GA20.1] Phase 2

D01EKQ-D06NXY-D0GL7U	TTDDRUID	D01EKQ-D06NXY-D0GL7U
D01EKQ-D06NXY-D0GL7U	DRUGNAME	Ethinyl Estradiol + Ferrous fumarate + Norethindrone
D01EKQ-D06NXY-D0GL7U	INDICATI	Contraception [ICD-11: QA21] Approved

D0D1SG-D0K3QS-D0O3YF	TTDDRUID	D0D1SG-D0K3QS-D0O3YF
D0D1SG-D0K3QS-D0O3YF	DRUGNAME	everolimus + cyclosporin a + prednisolone
D0D1SG-D0K3QS-D0O3YF	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 3

D0C1WH-D0K3QS-D0U5FF	TTDDRUID	D0C1WH-D0K3QS-D0U5FF
D0C1WH-D0K3QS-D0U5FF	DRUGNAME	everolimus + letrozole + leuprolide
D0C1WH-D0K3QS-D0U5FF	INDICATI	Fibrolamellar liver cancer [ICD-11: 2C12.02] Phase 2

D02XIY-D0D7LA-D0K3QS	TTDDRUID	D02XIY-D0D7LA-D0K3QS
D02XIY-D0D7LA-D0K3QS	DRUGNAME	everolimus + octreotide lar + metformin
D02XIY-D0D7LA-D0K3QS	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2

D00MAI-D09LWS-D0H0ND	TTDDRUID	D00MAI-D09LWS-D0H0ND
D00MAI-D09LWS-D0H0ND	DRUGNAME	Ezetimibe + Niacin + Simvastatin
D00MAI-D09LWS-D0H0ND	INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3

D0KR5B-D0R6CD-D0R7JT	TTDDRUID	D0KR5B-D0R6CD-D0R7JT
D0KR5B-D0R6CD-D0R7JT	DRUGNAME	Fludrocortisone + Hydrocortisone + Insulin
D0KR5B-D0R6CD-D0R7JT	INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3

D02DGU-D02QJH-D03UOT	TTDDRUID	D02DGU-D02QJH-D03UOT
D02DGU-D02QJH-D03UOT	DRUGNAME	Fluocinolone Acetonide + Hydroquinone + Tretinoin
D02DGU-D02QJH-D03UOT	INDICATI	Melasma [ICD-11: ED60.1] Approved

D05LEO-D0CT9C-D0D3DU	TTDDRUID	D05LEO-D0CT9C-D0D3DU
D05LEO-D0CT9C-D0D3DU	DRUGNAME	Fluorouracil + Cyclophosphamide + Methotrexate Sodium
D05LEO-D0CT9C-D0D3DU	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D05LEO-D07HOB-D0B6TW	TTDDRUID	D05LEO-D07HOB-D0B6TW
D05LEO-D07HOB-D0B6TW	DRUGNAME	Fluorouracil + Irinotecan + Leucovorin
D05LEO-D07HOB-D0B6TW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2/3

D05LEO-D0B6TW-D0Y3ME	TTDDRUID	D05LEO-D0B6TW-D0Y3ME
D05LEO-D0B6TW-D0Y3ME	DRUGNAME	Fluorouracil + Leucovorin + Oxaliplatin
D05LEO-D0B6TW-D0Y3ME	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 3

D05LEO-D0B6TW-D0D3DU	TTDDRUID	D05LEO-D0B6TW-D0D3DU
D05LEO-D0B6TW-D0D3DU	DRUGNAME	Fluorouracil + Leucovorin Calcium + Methotrexate Sodium
D05LEO-D0B6TW-D0D3DU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative

D01XBA-D05LEO-D0Y7TS	TTDDRUID	D01XBA-D05LEO-D0Y7TS
D01XBA-D05LEO-D0Y7TS	DRUGNAME	Fluorouracil + Raloxifene + Trimetrexate
D01XBA-D05LEO-D0Y7TS	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical

D04UUH-D0P1UX-D0TR5X	TTDDRUID	D04UUH-D0P1UX-D0TR5X
D04UUH-D0P1UX-D0TR5X	DRUGNAME	Fluoxetine + Lithium carbonate + Venlafaxine
D04UUH-D0P1UX-D0TR5X	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3

D0H7KF-D0P1UX-D0TR5X	TTDDRUID	D0H7KF-D0P1UX-D0TR5X
D0H7KF-D0P1UX-D0TR5X	DRUGNAME	Fluoxetine + Quetiapine + Venlafaxine
D0H7KF-D0P1UX-D0TR5X	INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3

D0H3WI-D0OM3A-D0Y8OK	TTDDRUID	D0H3WI-D0OM3A-D0Y8OK
D0H3WI-D0OM3A-D0Y8OK	DRUGNAME	Follitropin beta + Peginterferon alfa-2a + Ribavirin
D0H3WI-D0OM3A-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 4

D02GEC-D04KJO-D0L5YV	TTDDRUID	D02GEC-D04KJO-D0L5YV
D02GEC-D04KJO-D0L5YV	DRUGNAME	Formoterol + Omalizumab + Salmeterol
D02GEC-D04KJO-D0L5YV	INDICATI	Asthma [ICD-11: CA23] Phase 3

D07JVO-D0C4RB-D0X7HM	TTDDRUID	D07JVO-D0C4RB-D0X7HM
D07JVO-D0C4RB-D0X7HM	DRUGNAME	fosbretabulin + paclitaxel + carboplatin
D07JVO-D0C4RB-D0X7HM	INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 3

D0IT2G-D0J0ZS-D0UM7O	TTDDRUID	D0IT2G-D0J0ZS-D0UM7O
D0IT2G-D0J0ZS-D0UM7O	DRUGNAME	gabapentin + dexamethasone + ketamine
D0IT2G-D0J0ZS-D0UM7O	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 4

D04OKJ-D04ZAH-D0QQ7D	TTDDRUID	D04OKJ-D04ZAH-D0QQ7D
D04OKJ-D04ZAH-D0QQ7D	DRUGNAME	Garenoxacin + Piperacillin + Tazobactam
D04OKJ-D04ZAH-D0QQ7D	INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Preclinical

D03UVS-D0U5HU-D0W5HK	TTDDRUID	D03UVS-D0U5HU-D0W5HK
D03UVS-D0U5HU-D0W5HK	DRUGNAME	gemcitabine + cisplatin + sorafenib
D03UVS-D0U5HU-D0W5HK	INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2

D03UVS-D0F0ZY-D0O5WP	TTDDRUID	D03UVS-D0F0ZY-D0O5WP
D03UVS-D0F0ZY-D0O5WP	DRUGNAME	gemcitabine + docetaxel + pazopanib
D03UVS-D0F0ZY-D0O5WP	INDICATI	Histiocytoma [ICD-11: 2F23] Phase 1/2
D03UVS-D0F0ZY-D0O5WP	INDICATI	Leiomyosarcoma [ICD-11: 2B58] Phase 1/2
D03UVS-D0F0ZY-D0O5WP	INDICATI	Malignant fibrous [ICD-11: 2B54] Phase 1/2
D03UVS-D0F0ZY-D0O5WP	INDICATI	Malignant peripheral nerve sheath tumour [ICD-11: 2A02.10] Phase 1/2
D03UVS-D0F0ZY-D0O5WP	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1/2

D03UVS-D07HOB-D0HU9H	TTDDRUID	D03UVS-D07HOB-D0HU9H
D03UVS-D07HOB-D0HU9H	DRUGNAME	Gemcitabine + Irinotecan + Panitumumab
D03UVS-D07HOB-D0HU9H	INDICATI	Biliary cancer [ICD-11: 2E92.7] Phase 2

D03UVS-D0C4RB-D0Y4GO	TTDDRUID	D03UVS-D0C4RB-D0Y4GO
D03UVS-D0C4RB-D0Y4GO	DRUGNAME	gemcitabine + pemetrexed + paclitaxel
D03UVS-D0C4RB-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D0AO5H-D0R9OH-D0VR7W	TTDDRUID	D0AO5H-D0R9OH-D0VR7W
D0AO5H-D0R9OH-D0VR7W	DRUGNAME	Gemifloxacin + Sulfamethoxazole + Trimethoprim
D0AO5H-D0R9OH-D0VR7W	INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Preclinical

D0B2GI-D0D7LA-D0R6CD	TTDDRUID	D0B2GI-D0D7LA-D0R6CD
D0B2GI-D0D7LA-D0R6CD	DRUGNAME	Glimepiride + Insulin glargine + Metformin
D0B2GI-D0D7LA-D0R6CD	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 4

D0B2GI-D0D7LA-D0K5ER	TTDDRUID	D0B2GI-D0D7LA-D0K5ER
D0B2GI-D0D7LA-D0K5ER	DRUGNAME	Glimepiride + Metformin + Rosiglitazone
D0B2GI-D0D7LA-D0K5ER	INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical

D0B2GI-D0D7LA-D0U2JP	TTDDRUID	D0B2GI-D0D7LA-D0U2JP
D0B2GI-D0D7LA-D0U2JP	DRUGNAME	Glimepiride + Metformin + Sitagliptin
D0B2GI-D0D7LA-D0U2JP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D05LYX-D0D7LA-D0K9MY	TTDDRUID	D05LYX-D0D7LA-D0K9MY
D05LYX-D0D7LA-D0K9MY	DRUGNAME	Glyburide + Metformin + Saxagliptin
D05LYX-D0D7LA-D0K9MY	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D09OOV-D0J7XL-D05JNI	TTDDRUID	D09OOV-D0J7XL-D05JNI
D09OOV-D0J7XL-D05JNI	DRUGNAME	Gramicidin D + Neomycin + Polymyxin B Sulfate
D09OOV-D0J7XL-D05JNI	INDICATI	Ocular bacterial infection [ICD-11: 9C20] Approved

D05MCS-D0L5YV-D0LC6K	TTDDRUID	D05MCS-D0L5YV-D0LC6K
D05MCS-D0L5YV-D0LC6K	DRUGNAME	GSK2190915 + Salmeterol + Fluticasone
D05MCS-D0L5YV-D0LC6K	INDICATI	Asthma [ICD-11: CA23] Phase 2

D0UX6Z-D0V3ZA-D0X4RN	TTDDRUID	D0UX6Z-D0V3ZA-D0X4RN
D0UX6Z-D0V3ZA-D0X4RN	DRUGNAME	Heparin + Dihydroergotamine + Lidocaine
D0UX6Z-D0V3ZA-D0X4RN	INDICATI	Venous thrombosis [ICD-11: BA43] Approved

D03KXO-D0B7EB-D0U5HU	TTDDRUID	D03KXO-D0B7EB-D0U5HU
D03KXO-D0B7EB-D0U5HU	DRUGNAME	hgs1036 + cisplatin + etoposide
D03KXO-D0B7EB-D0U5HU	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D03KXO-D0C4RB-D0X7HM	TTDDRUID	D03KXO-D0C4RB-D0X7HM
D03KXO-D0C4RB-D0X7HM	DRUGNAME	hgs1036 + paclitaxel + carboplatin
D03KXO-D0C4RB-D0X7HM	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D0J4JM-D0K1XK-D0U4UQ	TTDDRUID	D0J4JM-D0K1XK-D0U4UQ
D0J4JM-D0K1XK-D0U4UQ	DRUGNAME	Hydralazine + Hydrochlorothiazide + Reserpine
D0J4JM-D0K1XK-D0U4UQ	INDICATI	Hypertension [ICD-11: BA00-BA04] Approved

D09OOV-D0KR5B-D05JNI	TTDDRUID	D09OOV-D0KR5B-D05JNI
D09OOV-D0KR5B-D05JNI	DRUGNAME	Hydrocortisone + Neomycin + Polymyxin B Sulfate
D09OOV-D0KR5B-D05JNI	INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Approved

D00PBX-D09KTS-D0S8WA	TTDDRUID	D00PBX-D09KTS-D0S8WA
D00PBX-D09KTS-D0S8WA	DRUGNAME	ibrutinib + ga101 + gdc-0199
D00PBX-D09KTS-D0S8WA	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2

D03DIG-D0R1QE-D0V7OY	TTDDRUID	D03DIG-D0R1QE-D0V7OY
D03DIG-D0R1QE-D0V7OY	DRUGNAME	ibuprofen + paracetamol + codeine
D03DIG-D0R1QE-D0V7OY	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 4

D01HTL-D02TLO-D03UVS	TTDDRUID	D01HTL-D02TLO-D03UVS
D01HTL-D02TLO-D03UVS	DRUGNAME	ifosfamide + gemcitabine + vinorelbine
D01HTL-D02TLO-D03UVS	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2

D05MKA-D0D7LA-D0R6CD	TTDDRUID	D05MKA-D0D7LA-D0R6CD
D05MKA-D0D7LA-D0R6CD	DRUGNAME	Insulin glargine + Lixisenatide + Metformin
D05MKA-D0D7LA-D0R6CD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D0D7LA-D0R6CD-D0U2JP	TTDDRUID	D0D7LA-D0R6CD-D0U2JP
D0D7LA-D0R6CD-D0U2JP	DRUGNAME	Insulin glargine + Metformin + Sitagliptin
D0D7LA-D0R6CD-D0U2JP	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D09PMV-D0D4YZ-D0H3WI	TTDDRUID	D09PMV-D0D4YZ-D0H3WI
D09PMV-D0D4YZ-D0H3WI	DRUGNAME	Interferon alfa-2a + Ribavirin + Sofosbuvir
D09PMV-D0D4YZ-D0H3WI	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2

D0H3WI-D0P0WV-D0U8US	TTDDRUID	D0H3WI-D0P0WV-D0U8US
D0H3WI-D0P0WV-D0U8US	DRUGNAME	Interferon alfa-2b + Interferon gamma-1b + Ribavirin
D0H3WI-D0P0WV-D0U8US	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2/3

D0D4YZ-D0H3WI-D0P0WV	TTDDRUID	D0D4YZ-D0H3WI-D0P0WV
D0D4YZ-D0H3WI-D0P0WV	DRUGNAME	Interferon alfa-2b + Ribavirin + Sofosbuvir
D0D4YZ-D0H3WI-D0P0WV	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D07UYO-D09XQF-D0G3DL	TTDDRUID	D07UYO-D09XQF-D0G3DL
D07UYO-D09XQF-D0G3DL	DRUGNAME	Isoniazid + Linezolid + Rifampin
D07UYO-D09XQF-D0G3DL	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Preclinical

D09XQF-D0G3DL-D0XF8W	TTDDRUID	D09XQF-D0G3DL-D0XF8W
D09XQF-D0G3DL-D0XF8W	DRUGNAME	Isoniazid + Pyrazinamide + Rifampin
D09XQF-D0G3DL-D0XF8W	INDICATI	Drug induced hepatotoxicity [ICD-11: DB95] Phase 4
D09XQF-D0G3DL-D0XF8W	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved

D09XQF-D0AO5H-D0R9OH	TTDDRUID	D09XQF-D0AO5H-D0R9OH
D09XQF-D0AO5H-D0R9OH	DRUGNAME	Isoniazid + Sulfamethoxazole + Trimethoprim
D09XQF-D0AO5H-D0R9OH	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3
D09XQF-D0AO5H-D0R9OH	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 3

D00HCQ-D08CDI-D0W2EK	TTDDRUID	D00HCQ-D08CDI-D0W2EK
D00HCQ-D08CDI-D0W2EK	DRUGNAME	ixabepilone + lapatinib + capecitabine
D00HCQ-D08CDI-D0W2EK	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1

D01MML-D0IT2G-D0Q5NX	TTDDRUID	D01MML-D0IT2G-D0Q5NX
D01MML-D0IT2G-D0Q5NX	DRUGNAME	ixazomib + lenalidomide + dexamethasone
D01MML-D0IT2G-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D09RHQ-D0D9JW-D0WE3O	TTDDRUID	D09RHQ-D0D9JW-D0WE3O
D09RHQ-D0D9JW-D0WE3O	DRUGNAME	Ketorolac + Morphine + Ropivacaine
D09RHQ-D0D9JW-D0WE3O	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4

D01XYJ-D07TQV-D0NR6S	TTDDRUID	D01XYJ-D07TQV-D0NR6S
D01XYJ-D07TQV-D0NR6S	DRUGNAME	Lamivudine + Maraviroc + Zidovudine
D01XYJ-D07TQV-D0NR6S	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D07TQV-D0O2EM-D0Z8EX	TTDDRUID	D07TQV-D0O2EM-D0Z8EX
D07TQV-D0O2EM-D0Z8EX	DRUGNAME	Lamivudine + Nevirapine + Stavudine
D07TQV-D0O2EM-D0Z8EX	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4
D07TQV-D0O2EM-D0Z8EX	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative

D01XYJ-D07TQV-D0O2EM	TTDDRUID	D01XYJ-D07TQV-D0O2EM
D01XYJ-D07TQV-D0O2EM	DRUGNAME	Lamivudine + Nevirapine + Zidovudine
D01XYJ-D07TQV-D0O2EM	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D07TQV-D0D9HW-D0I1FQ	TTDDRUID	D07TQV-D0D9HW-D0I1FQ
D07TQV-D0D9HW-D0I1FQ	DRUGNAME	Lamivudine + Raltegravir + Tenofovir
D07TQV-D0D9HW-D0I1FQ	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D04WFL-D08CDI-D0C4RB	TTDDRUID	D04WFL-D08CDI-D0C4RB
D04WFL-D08CDI-D0C4RB	DRUGNAME	Lapatinib + Paclitaxel + Trastuzumab
D04WFL-D08CDI-D0C4RB	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00MAI-D0JE2E-D0WL5V	TTDDRUID	D00MAI-D0JE2E-D0WL5V
D00MAI-D0JE2E-D0WL5V	DRUGNAME	Laropiprant + Niacin + Rosuvastatin
D00MAI-D0JE2E-D0WL5V	INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 4

D08ROP-D0D3DU-D0YV4F	TTDDRUID	D08ROP-D0D3DU-D0YV4F
D08ROP-D0D3DU-D0YV4F	DRUGNAME	Leflunomide + Methotrexate Sodium + Ocrelizumab
D08ROP-D0D3DU-D0YV4F	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D09EXD-D0IT2G-D0Q5NX	TTDDRUID	D09EXD-D0IT2G-D0Q5NX
D09EXD-D0IT2G-D0Q5NX	DRUGNAME	lenalidomide + dexamethasone + rituximab
D09EXD-D0IT2G-D0Q5NX	INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2

D00FGO-D0IL7L-D0Q5NX	TTDDRUID	D00FGO-D0IL7L-D0Q5NX
D00FGO-D0IL7L-D0Q5NX	DRUGNAME	Lenalidomide + Melphalan + Prednisone
D00FGO-D0IL7L-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D0E9VU-D0N6CR-D0TZ1G	TTDDRUID	D0E9VU-D0N6CR-D0TZ1G
D0E9VU-D0N6CR-D0TZ1G	DRUGNAME	Levonordefrin + Procaine + Propoxycaine hydrochloride
D0E9VU-D0N6CR-D0TZ1G	INDICATI	Nasal congestion [ICD-11: MD11.9] Approved

D04PHC-D0E1WI-D0X4RN	TTDDRUID	D04PHC-D0E1WI-D0X4RN
D04PHC-D0E1WI-D0X4RN	DRUGNAME	lidocaine + epinephrine + fentanyl
D04PHC-D0E1WI-D0X4RN	INDICATI	Pulpitis [ICD-11: DA09.0] Phase 2

D03GOI-D0D7LA-D0U2JP	TTDDRUID	D03GOI-D0D7LA-D0U2JP
D03GOI-D0D7LA-D0U2JP	DRUGNAME	Liraglutide + Metformin + Sitagliptin
D03GOI-D0D7LA-D0U2JP	INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3

D0I1FQ-D0U5GB-D0ZU9R	TTDDRUID	D0I1FQ-D0U5GB-D0ZU9R
D0I1FQ-D0U5GB-D0ZU9R	DRUGNAME	Lopinavir + Raltegravir + Ritonavir
D0I1FQ-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D0G3DL-D0U5GB-D0ZU9R	TTDDRUID	D0G3DL-D0U5GB-D0ZU9R
D0G3DL-D0U5GB-D0ZU9R	DRUGNAME	Lopinavir + Rifampin + Ritonavir
D0G3DL-D0U5GB-D0ZU9R	INDICATI	HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Investigative

D0NR6S-D0U5GB-D0ZU9R	TTDDRUID	D0NR6S-D0U5GB-D0ZU9R
D0NR6S-D0U5GB-D0ZU9R	DRUGNAME	lopinavir + ritonavir + maraviroc
D0NR6S-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D0H3WI-D0U5GB-D0ZU9R	TTDDRUID	D0H3WI-D0U5GB-D0ZU9R
D0H3WI-D0U5GB-D0ZU9R	DRUGNAME	lopinavir + ritonavir + ribavirin
D0H3WI-D0U5GB-D0ZU9R	INDICATI	Severe acute respiratory syndrome [ICD-11: 1D65] Investigative

D00FGO-D0D1SG-D0U7GK	TTDDRUID	D00FGO-D0D1SG-D0U7GK
D00FGO-D0D1SG-D0U7GK	DRUGNAME	Melphalan + Prednisolone + Thalidomide
D00FGO-D0D1SG-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D03OFF-D0D7LA-D0K9MY	TTDDRUID	D03OFF-D0D7LA-D0K9MY
D03OFF-D0D7LA-D0K9MY	DRUGNAME	Metformin + Pioglitazone + Saxagliptin
D03OFF-D0D7LA-D0K9MY	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D08PIQ-D0D3DU-D0PG5G	TTDDRUID	D08PIQ-D0D3DU-D0PG5G
D08PIQ-D0D3DU-D0PG5G	DRUGNAME	Methylprednisolone Acetate + Methotrexate Sodium + Infliximab
D08PIQ-D0D3DU-D0PG5G	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 4

D08PIQ-D09EXD-D0IL7L	TTDDRUID	D08PIQ-D09EXD-D0IL7L
D08PIQ-D09EXD-D0IL7L	DRUGNAME	Methylprednisolone Acetate + Rituximab + Prednisone
D08PIQ-D09EXD-D0IL7L	INDICATI	Vasculitis [ICD-11: 4A44] Phase 2/3

D04WFL-D0C0TT-D0C4RB	TTDDRUID	D04WFL-D0C0TT-D0C4RB
D04WFL-D0C0TT-D0C4RB	DRUGNAME	mln0128 + paclitaxel + trastuzumab
D04WFL-D0C0TT-D0C4RB	INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
D04WFL-D0C0TT-D0C4RB	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1

D00QET-D0L5YV-D0LC6K	TTDDRUID	D00QET-D0L5YV-D0LC6K
D00QET-D0L5YV-D0LC6K	DRUGNAME	Montelukast + Salmeterol + Fluticasone
D00QET-D0L5YV-D0LC6K	INDICATI	Asthma [ICD-11: CA23] Phase 3

D02AYL-D0XF8W-D0ZV0Z	TTDDRUID	D02AYL-D0XF8W-D0ZV0Z
D02AYL-D0XF8W-D0ZV0Z	DRUGNAME	Moxifloxacin + PA-824 + Pyrazinamide
D02AYL-D0XF8W-D0ZV0Z	INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Phase 2

D04FBR-D06OMK-D0IL7L	TTDDRUID	D04FBR-D06OMK-D0IL7L
D04FBR-D06OMK-D0IL7L	DRUGNAME	Mycophenolate acid + Prednisone + Tacrolimus
D04FBR-D06OMK-D0IL7L	INDICATI	Kidney disease [ICD-11: GC2Z] Phase 3

D04FBR-D0IL7L-D0T6DK	TTDDRUID	D04FBR-D0IL7L-D0T6DK
D04FBR-D0IL7L-D0T6DK	DRUGNAME	Mycophenolate mofetil + Prednisone + Rapamycin
D04FBR-D0IL7L-D0T6DK	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 4

D04FBR-D09EXD-D0IL7L	TTDDRUID	D04FBR-D09EXD-D0IL7L
D04FBR-D09EXD-D0IL7L	DRUGNAME	Mycophenolate mofetil + Prednisone + Rituximab
D04FBR-D09EXD-D0IL7L	INDICATI	Lupus [ICD-11: 4A40] Phase 3

D04FBR-D06OMK-D0T6DK	TTDDRUID	D04FBR-D06OMK-D0T6DK
D04FBR-D06OMK-D0T6DK	DRUGNAME	Mycophenolate mofetil + Rapamycin + Tacrolimus
D04FBR-D06OMK-D0T6DK	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D09OOV-D0D1SG-D05JNI	TTDDRUID	D09OOV-D0D1SG-D05JNI
D09OOV-D0D1SG-D05JNI	DRUGNAME	Neomycin + Polymyxin B Sulfate + Prednisolone
D09OOV-D0D1SG-D05JNI	INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved

D07YDE-D0R0FE-D0T0KA	TTDDRUID	D07YDE-D0R0FE-D0T0KA
D07YDE-D0R0FE-D0T0KA	DRUGNAME	nicardipine + verapamil + nitroglycerin
D07YDE-D0R0FE-D0T0KA	INDICATI	Cerebral vasospasm [ICD-11: BA85.Z] Phase 4

D08EBN-D0H3WI-D0Y8OK	TTDDRUID	D08EBN-D0H3WI-D0Y8OK
D08EBN-D0H3WI-D0Y8OK	DRUGNAME	Nitazoxanide + Peginterferon alfa-2a + Ribavirin
D08EBN-D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2/3

D0AO5H-D0R0BX-D0R9OH	TTDDRUID	D0AO5H-D0R0BX-D0R9OH
D0AO5H-D0R0BX-D0R9OH	DRUGNAME	Nitrofurantoin + Sulfamethoxazole + Trimethoprim
D0AO5H-D0R0BX-D0R9OH	INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2

D0H7KF-D0R1JV-D0V4QS	TTDDRUID	D0H7KF-D0R1JV-D0V4QS
D0H7KF-D0R1JV-D0V4QS	DRUGNAME	Olanzapine + Quetiapine + Ziprasidone
D0H7KF-D0R1JV-D0V4QS	INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 4

D0B6TW-D05LEO-D0Y3ME	TTDDRUID	D0B6TW-D05LEO-D0Y3ME
D0B6TW-D05LEO-D0Y3ME	DRUGNAME	oxaliplatin + 5-fluorouracil + leucovorin
D0B6TW-D05LEO-D0Y3ME	INDICATI	Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 1
D0B6TW-D05LEO-D0Y3ME	INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
D0B6TW-D05LEO-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D0B6TW-D05LEO-D0Y3ME	INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
D0B6TW-D05LEO-D0Y3ME	INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1
D0B6TW-D05LEO-D0Y3ME	INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
D0B6TW-D05LEO-D0Y3ME	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
D0B6TW-D05LEO-D0Y3ME	INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1

D05LEO-D0U5HU-D0Y3ME	TTDDRUID	D05LEO-D0U5HU-D0Y3ME
D05LEO-D0U5HU-D0Y3ME	DRUGNAME	oxaliplatin + cisplatin + 5-fluorouracil
D05LEO-D0U5HU-D0Y3ME	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2

D05LEO-D0R4PS-D0Y3ME	TTDDRUID	D05LEO-D0R4PS-D0Y3ME
D05LEO-D0R4PS-D0Y3ME	DRUGNAME	oxaliplatin + folinic acid + fluorouracil
D05LEO-D0R4PS-D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D05LEO-D0R4PS-D0Y3ME	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1
D05LEO-D0R4PS-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D05LEO-D0R4PS-D0Y3ME	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
D05LEO-D0R4PS-D0Y3ME	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D05LEO-D0R4PS-D0Y3ME	INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Phase 1

D09EBS-D0LC6K-D0WV3U	TTDDRUID	D09EBS-D0LC6K-D0WV3U
D09EBS-D0LC6K-D0WV3U	DRUGNAME	Oxymetazoline + Fluticasone + Prazosin
D09EBS-D0LC6K-D0WV3U	INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 4

D02AYL-D0G3DL-D0XF8W	TTDDRUID	D02AYL-D0G3DL-D0XF8W
D02AYL-D0G3DL-D0XF8W	DRUGNAME	PA-824 + Pyrazinamide + Rifampin
D02AYL-D0G3DL-D0XF8W	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Preclinical

D02AIC-D0C4RB-D0X7HM	TTDDRUID	D02AIC-D0C4RB-D0X7HM
D02AIC-D0C4RB-D0X7HM	DRUGNAME	paclitaxel + carboplatin + cp-870,893
D02AIC-D0C4RB-D0X7HM	INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1

D0HU9H-D0O5WP-D0U5HU	TTDDRUID	D0HU9H-D0O5WP-D0U5HU
D0HU9H-D0O5WP-D0U5HU	DRUGNAME	panitumumab + docetaxel + cisplatino
D0HU9H-D0O5WP-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D00WUF-D0IT2G-D0V7OY	TTDDRUID	D00WUF-D0IT2G-D0V7OY
D00WUF-D0IT2G-D0V7OY	DRUGNAME	paracetamol + pregabalin + dexamethasone
D00WUF-D0IT2G-D0V7OY	INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 4

D00HCQ-D0F0ZY-D0Y3ME	TTDDRUID	D00HCQ-D0F0ZY-D0Y3ME
D00HCQ-D0F0ZY-D0Y3ME	DRUGNAME	pazopanib + capecitabine + oxaliplatin
D00HCQ-D0F0ZY-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D00TLP-D0H3WI-D0Y8OK	TTDDRUID	D00TLP-D0H3WI-D0Y8OK
D00TLP-D0H3WI-D0Y8OK	DRUGNAME	Peginterferon alfa-2a + Ribavirin + Simeprevir
D00TLP-D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D0D4YZ-D0H3WI-D0Y8OK	TTDDRUID	D0D4YZ-D0H3WI-D0Y8OK
D0D4YZ-D0H3WI-D0Y8OK	DRUGNAME	Peginterferon alfa-2a + Ribavirin + Sofosbuvir
D0D4YZ-D0H3WI-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2

D0H3WI-D0X9CH-D0Y8OK	TTDDRUID	D0H3WI-D0X9CH-D0Y8OK
D0H3WI-D0X9CH-D0Y8OK	DRUGNAME	Peginterferon alfa-2a + Ribavirin + Telaprevir
D0H3WI-D0X9CH-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2
D0H3WI-D0X9CH-D0Y8OK	INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3

D0H3WI-D0I5KX-D0Y8OK	TTDDRUID	D0H3WI-D0I5KX-D0Y8OK
D0H3WI-D0I5KX-D0Y8OK	DRUGNAME	Peginterferon alfa-2a + Ribavirin + Thymalfasin
D0H3WI-D0I5KX-D0Y8OK	INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3

D09XZB-D0X7HM-D0Y4GO	TTDDRUID	D09XZB-D0X7HM-D0Y4GO
D09XZB-D0X7HM-D0Y4GO	DRUGNAME	pemetrexed + carboplatin + gefitinib
D09XZB-D0X7HM-D0Y4GO	INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2

D03UVS-D0O5WP-D0Y4GO	TTDDRUID	D03UVS-D0O5WP-D0Y4GO
D03UVS-D0O5WP-D0Y4GO	DRUGNAME	pemetrexed + docetaxel + gemcitabine
D03UVS-D0O5WP-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D03UVS-D04KBL-D0Y4GO	TTDDRUID	D03UVS-D04KBL-D0Y4GO
D03UVS-D04KBL-D0Y4GO	DRUGNAME	pemetrexed + gemcitabine + bevacizumab
D03UVS-D04KBL-D0Y4GO	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D00VUL-D0AO5H-D0R9OH	TTDDRUID	D00VUL-D0AO5H-D0R9OH
D00VUL-D0AO5H-D0R9OH	DRUGNAME	Phenazopyridine hydrochloride + Sulfamethoxazole + Trimethoprim
D00VUL-D0AO5H-D0R9OH	INDICATI	Urinary tract infection [ICD-11: GC08] Approved

D0C0SK-D07PAO-D0P0SZ	TTDDRUID	D0C0SK-D07PAO-D0P0SZ
D0C0SK-D07PAO-D0P0SZ	DRUGNAME	Piperaquine + Pyrimethamine + Sulfadoxine
D0C0SK-D07PAO-D0P0SZ	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D09OOV-D0AO5H-D0R9OH	TTDDRUID	D09OOV-D0AO5H-D0R9OH
D09OOV-D0AO5H-D0R9OH	DRUGNAME	Polymyxin B Sulfate + Sulfamethoxazole + Trimethoprim
D09OOV-D0AO5H-D0R9OH	INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical

D0C0SK-D07PAO-D0T1LK	TTDDRUID	D0C0SK-D07PAO-D0T1LK
D0C0SK-D07PAO-D0T1LK	DRUGNAME	Primaquine + Pyrimethamine + Sulfadoxine
D0C0SK-D07PAO-D0T1LK	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 2

D07XSN-D0B7EB-D0T6DK	TTDDRUID	D07XSN-D0B7EB-D0T6DK
D07XSN-D0B7EB-D0T6DK	DRUGNAME	rapamycin + etoposide + cytarabine
D07XSN-D0B7EB-D0T6DK	INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2

D05CHI-D07IQS-D0ZU9R	TTDDRUID	D05CHI-D07IQS-D0ZU9R
D05CHI-D07IQS-D0ZU9R	DRUGNAME	rifabutin + atazanavir + ritonavir
D05CHI-D07IQS-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1

D0G3DL-D0WI3T-D0ZU9R	TTDDRUID	D0G3DL-D0WI3T-D0ZU9R
D0G3DL-D0WI3T-D0ZU9R	DRUGNAME	Rifampin + Ritonavir + Saquinavir
D0G3DL-D0WI3T-D0ZU9R	INDICATI	HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Investigative

D09EXD-D0D3DU-D0IL7L	TTDDRUID	D09EXD-D0D3DU-D0IL7L
D09EXD-D0D3DU-D0IL7L	DRUGNAME	Rituximab + Methotrexate Sodium + Prednisone
D09EXD-D0D3DU-D0IL7L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2

D09RHQ-D0D9JW-D0I8FI	TTDDRUID	D09RHQ-D0D9JW-D0I8FI
D09RHQ-D0D9JW-D0I8FI	DRUGNAME	Ropivacaine + Ketorolac + Isoproterenol
D09RHQ-D0D9JW-D0I8FI	INDICATI	Chronic pain [ICD-11: MG30] Phase 4
D09RHQ-D0D9JW-D0I8FI	INDICATI	Knee related disease [ICD-11: FA01-FA26] Phase 4
D09RHQ-D0D9JW-D0I8FI	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 4

D0L5YV-D0LC6K-D0P1WA	TTDDRUID	D0L5YV-D0LC6K-D0P1WA
D0L5YV-D0LC6K-D0P1WA	DRUGNAME	Salmeterol + Fluticasone + Tiotropium
D0L5YV-D0LC6K-D0P1WA	INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4

D0S9SD-D0WI3T-D0ZU9R	TTDDRUID	D0S9SD-D0WI3T-D0ZU9R
D0S9SD-D0WI3T-D0ZU9R	DRUGNAME	saquinavir + ritonavir + truvada
D0S9SD-D0WI3T-D0ZU9R	INDICATI	Saquinavir and ritonavir BID or lopinavir and ritonavir BID [ICD-11: N.A.] Phase 2/3

D0F3SY-D0W5HK-D0Y0DG	TTDDRUID	D0F3SY-D0W5HK-D0Y0DG
D0F3SY-D0W5HK-D0Y0DG	DRUGNAME	Sorafenib + Tegafur + Uracil
D0F3SY-D0W5HK-D0Y0DG	INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2

D05LKP-D0H1GJ-D0V9YR	TTDDRUID	D05LKP-D0H1GJ-D0V9YR
D05LKP-D0H1GJ-D0V9YR	DRUGNAME	Sulfadiazine + Sulfamerazine + Sulfamethazine
D05LKP-D0H1GJ-D0V9YR	INDICATI	Toxoplasmosis [ICD-11: 1F57] Approved

D02ZTJ-D0D3DU-D0OJ4L	TTDDRUID	D02ZTJ-D0D3DU-D0OJ4L
D02ZTJ-D0D3DU-D0OJ4L	DRUGNAME	Sulfasalazine + Methotrexate Sodium + Hydroxychloroquine
D02ZTJ-D0D3DU-D0OJ4L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 4

D06OMK-D0D3DU-D0SH3I	TTDDRUID	D06OMK-D0D3DU-D0SH3I
D06OMK-D0D3DU-D0SH3I	DRUGNAME	Tacrolimus + Methotrexate Sodium + Bortezomib
D06OMK-D0D3DU-D0SH3I	INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2

D0C4RB-D0ES1Q-D0X7HM	TTDDRUID	D0C4RB-D0ES1Q-D0X7HM
D0C4RB-D0ES1Q-D0X7HM	DRUGNAME	temsirolimus + paclitaxel + carboplatin
D0C4RB-D0ES1Q-D0X7HM	INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
D0C4RB-D0ES1Q-D0X7HM	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2

D03IGH-D0D9HW-D0ZU9R	TTDDRUID	D03IGH-D0D9HW-D0ZU9R
D03IGH-D0D9HW-D0ZU9R	DRUGNAME	tenofovir + darunavir + ritonavir
D03IGH-D0D9HW-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D0D9HW-D0S9SD-D0U5GB	TTDDRUID	D0D9HW-D0S9SD-D0U5GB
D0D9HW-D0S9SD-D0U5GB	DRUGNAME	tenofovir + emtricitabine + lopinavir
D0D9HW-D0S9SD-D0U5GB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0D9HW-D0S9SD-D0U5GB	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4
D0D9HW-D0S9SD-D0U5GB	INDICATI	Human immunodeficiency virus-2 infection [ICD-11: 1C62] Phase 2/3

D0D9HW-D0S9SD-D0ZU9R	TTDDRUID	D0D9HW-D0S9SD-D0ZU9R
D0D9HW-D0S9SD-D0ZU9R	DRUGNAME	tenofovir + emtricitabine + ritonavir
D0D9HW-D0S9SD-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D0D9HW-D0S9SD-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D07HVY-D07TQV-D0D9HW	TTDDRUID	D07HVY-D07TQV-D0D9HW
D07HVY-D07TQV-D0D9HW	DRUGNAME	tenofovir + lamivudine + efavirenz
D07HVY-D07TQV-D0D9HW	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
D07HVY-D07TQV-D0D9HW	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 3

D07TQV-D0D9HW-D0U5GB	TTDDRUID	D07TQV-D0D9HW-D0U5GB
D07TQV-D0D9HW-D0U5GB	DRUGNAME	tenofovir + lamivudine + lopinavir
D07TQV-D0D9HW-D0U5GB	INDICATI	Human immunodeficiency virus-2 infection [ICD-11: 1C62] Phase 2/3

D07TQV-D0D9HW-D0ZU9R	TTDDRUID	D07TQV-D0D9HW-D0ZU9R
D07TQV-D0D9HW-D0ZU9R	DRUGNAME	tenofovir + lamivudine + ritonavir
D07TQV-D0D9HW-D0ZU9R	INDICATI	Human immunodeficiency virus-2 infection [ICD-11: 1C62] Phase 2/3

D01XYJ-D07TQV-D0D9HW	TTDDRUID	D01XYJ-D07TQV-D0D9HW
D01XYJ-D07TQV-D0D9HW	DRUGNAME	tenofovir + lamivudine + zidovudine
D01XYJ-D07TQV-D0D9HW	INDICATI	Human immunodeficiency virus-2 infection [ICD-11: 1C62] Phase 2/3

D0O8SJ-D0S8WA-D0V8QT	TTDDRUID	D0O8SJ-D0S8WA-D0V8QT
D0O8SJ-D0S8WA-D0V8QT	DRUGNAME	tgr-1202 + obinutuzumab + chlorambucil
D0O8SJ-D0S8WA-D0V8QT	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D08HPZ-D0D3DU-D0H0ND	TTDDRUID	D08HPZ-D0D3DU-D0H0ND
D08HPZ-D0D3DU-D0H0ND	DRUGNAME	Tocilizumab + Methotrexate Sodium + Simvastatin
D08HPZ-D0D3DU-D0H0ND	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1

D09EXD-D0J5VR-D0T7QC	TTDDRUID	D09EXD-D0J5VR-D0T7QC
D09EXD-D0J5VR-D0T7QC	DRUGNAME	tru-016 + idelalisib + rituximab
D09EXD-D0J5VR-D0T7QC	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1

D01CYA-D0A8GM-D0O8SJ	TTDDRUID	D01CYA-D0A8GM-D0O8SJ
D01CYA-D0A8GM-D0O8SJ	DRUGNAME	ublituximab + tgr-1202 + bendamustine
D01CYA-D0A8GM-D0O8SJ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D01CYA-D0A8GM-D0O8SJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D09KTS-D0A8GM-D0O8SJ	TTDDRUID	D09KTS-D0A8GM-D0O8SJ
D09KTS-D0A8GM-D0O8SJ	DRUGNAME	ublituximab + tgr-1202 + ibrutinib
D09KTS-D0A8GM-D0O8SJ	INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
D09KTS-D0A8GM-D0O8SJ	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D09QVV-D0B7EB-D0X7HM	TTDDRUID	D09QVV-D0B7EB-D0X7HM
D09QVV-D0B7EB-D0X7HM	DRUGNAME	vincristine + carboplatin + etoposide
D09QVV-D0B7EB-D0X7HM	INDICATI	Retinoblastoma [ICD-11: 2D02.2] Phase 3

D07VLY-D09QVV-D0CT9C	TTDDRUID	D07VLY-D09QVV-D0CT9C
D07VLY-D09QVV-D0CT9C	DRUGNAME	vincristine + cyclophosphamide + doxorubicin
D07VLY-D09QVV-D0CT9C	INDICATI	Retinoblastoma [ICD-11: 2D02.2] Phase 3

D07IQS-D07TQV-D0A4IJ-D0ZU9R	TTDDRUID	D07IQS-D07TQV-D0A4IJ-D0ZU9R
D07IQS-D07TQV-D0A4IJ-D0ZU9R	DRUGNAME	Abacavir + Atazanavir + Lamivudine + Ritonavir
D07IQS-D07TQV-D0A4IJ-D0ZU9R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3

D07TQV-D0A4IJ-D0U5GB-D0ZU9R	TTDDRUID	D07TQV-D0A4IJ-D0U5GB-D0ZU9R
D07TQV-D0A4IJ-D0U5GB-D0ZU9R	DRUGNAME	Abacavir + Lamivudine + Lopinavir + Ritonavir
D07TQV-D0A4IJ-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4

D03DIG-D05BQK-D0B3HD-D0U5QK	TTDDRUID	D03DIG-D05BQK-D0B3HD-D0U5QK
D03DIG-D05BQK-D0B3HD-D0U5QK	DRUGNAME	Acetaminophen + Butalbital + Caffeine + Codeine
D03DIG-D05BQK-D0B3HD-D0U5QK	INDICATI	Tension headache [ICD-11: 8A81] Approved

D02VVS-D05PUD-D0B7EB-D0CT9C	TTDDRUID	D02VVS-D05PUD-D0B7EB-D0CT9C
D02VVS-D05PUD-D0B7EB-D0CT9C	DRUGNAME	Aldesleukin + Cyclophosphamide + Etoposide + Filgrastim
D02VVS-D05PUD-D0B7EB-D0CT9C	INDICATI	Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 3

D01JUF-D0Z7ZM-D0I4DQ-D0NJ3V	TTDDRUID	D01JUF-D0Z7ZM-D0I4DQ-D0NJ3V
D01JUF-D0Z7ZM-D0I4DQ-D0NJ3V	DRUGNAME	Alprostadil + Papaverine + Phentolamine + Sildenafil
D01JUF-D0Z7ZM-D0I4DQ-D0NJ3V	INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2

D02LPF-D05LEO-D0CT9C-D0U5HU	TTDDRUID	D02LPF-D05LEO-D0CT9C-D0U5HU
D02LPF-D05LEO-D0CT9C-D0U5HU	DRUGNAME	Altretamine + Cisplatin + Cyclophosphamide + Fluorouracil
D02LPF-D05LEO-D0CT9C-D0U5HU	INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative

D02KRS-D09ZIS-D0D7LA-D0V4QS	TTDDRUID	D02KRS-D09ZIS-D0D7LA-D0V4QS
D02KRS-D09ZIS-D0D7LA-D0V4QS	DRUGNAME	Amantadine + Metformin + Olanzapine + Zonisamide
D02KRS-D09ZIS-D0D7LA-D0V4QS	INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3

D08JIV-D0H0ND-D0I0RJ-D0N6RF	TTDDRUID	D08JIV-D0H0ND-D0I0RJ-D0N6RF
D08JIV-D0H0ND-D0I0RJ-D0N6RF	DRUGNAME	Amiloride + Amlodipine + Simvastatin + Telmisartan
D08JIV-D0H0ND-D0I0RJ-D0N6RF	INDICATI	Essential hypertension [ICD-11: BA00] Phase 4

D04NQI-D0C0SK-D0D4JO-D07PAO	TTDDRUID	D04NQI-D0C0SK-D0D4JO-D07PAO
D04NQI-D0C0SK-D0D4JO-D07PAO	DRUGNAME	Amodiaquine + Artesunate + Pyrimethamine + Sulfadoxine
D04NQI-D0C0SK-D0D4JO-D07PAO	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D01XNB-D0A2ZX-D0F6EO-D0Z1ZM	TTDDRUID	D01XNB-D0A2ZX-D0F6EO-D0Z1ZM
D01XNB-D0A2ZX-D0F6EO-D0Z1ZM	DRUGNAME	Amoxicillin + Clarithromycin + Metronidazole + Omeprazole
D01XNB-D0A2ZX-D0F6EO-D0Z1ZM	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 3
D01XNB-D0A2ZX-D0F6EO-D0Z1ZM	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 4

D04ZAH-D0F6EO-D0QQ7D-D0X7JN	TTDDRUID	D04ZAH-D0F6EO-D0QQ7D-D0X7JN
D04ZAH-D0F6EO-D0QQ7D-D0X7JN	DRUGNAME	Amoxicillin + Clavulanate + Piperacillin + Tazobactam
D04ZAH-D0F6EO-D0QQ7D-D0X7JN	INDICATI	Abscess [ICD-11: 1B75.3] Phase 3

D04FBR-D06OMK-D0M7XS-D0T6DK	TTDDRUID	D04FBR-D06OMK-D0M7XS-D0T6DK
D04FBR-D06OMK-D0M7XS-D0T6DK	DRUGNAME	Anti-thymocyte globulin + Mycophenolate mofetil + Rapamycin + Tacrolimus
D04FBR-D06OMK-D0M7XS-D0T6DK	INDICATI	End-stage renal disease [ICD-11: GB61.5] Investigative

D09EGZ-D0C0SK-D0D4JO-D07PAO	TTDDRUID	D09EGZ-D0C0SK-D0D4JO-D07PAO
D09EGZ-D0C0SK-D0D4JO-D07PAO	DRUGNAME	Artesunate + Chloroquine + Pyrimethamine + Sulfadoxine
D09EGZ-D0C0SK-D0D4JO-D07PAO	INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 3

D02PMO-D09QVV-D0H5XB-D0IT2G	TTDDRUID	D02PMO-D09QVV-D0H5XB-D0IT2G
D02PMO-D09QVV-D0H5XB-D0IT2G	DRUGNAME	Asparaginase + Dexamethasone + Topotecan + Vincristine
D02PMO-D09QVV-D0H5XB-D0IT2G	INDICATI	Pediatric patients with acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 2

D01CYA-D0GY5Z-D0IT2G-D0Q5NX	TTDDRUID	D01CYA-D0GY5Z-D0IT2G-D0Q5NX
D01CYA-D0GY5Z-D0IT2G-D0Q5NX	DRUGNAME	Aspirin + Bendamustine + Dexamethasone + Lenalidomide
D01CYA-D0GY5Z-D0IT2G-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1

D03DIG-D05BQK-D0B3HD-D0GY5Z	TTDDRUID	D03DIG-D05BQK-D0B3HD-D0GY5Z
D03DIG-D05BQK-D0B3HD-D0GY5Z	DRUGNAME	Aspirin + Butalbital + Caffeine + Codeine
D03DIG-D05BQK-D0B3HD-D0GY5Z	INDICATI	Tension headache [ICD-11: 8A81] Approved

D00FGO-D0GY5Z-D0IL7L-D0Q5NX	TTDDRUID	D00FGO-D0GY5Z-D0IL7L-D0Q5NX
D00FGO-D0GY5Z-D0IL7L-D0Q5NX	DRUGNAME	Aspirin + Lenalidomide + Melphalan + Prednisone
D00FGO-D0GY5Z-D0IL7L-D0Q5NX	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D02VJP-D07IQS-D0D9HW-D0S9SD	TTDDRUID	D02VJP-D07IQS-D0D9HW-D0S9SD
D02VJP-D07IQS-D0D9HW-D0S9SD	DRUGNAME	Atazanavir + Cobicistat + Emtricitabine + Tenofovir
D02VJP-D07IQS-D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D07IQS-D0D9HW-D0S9SD-D0ZU9R	TTDDRUID	D07IQS-D0D9HW-D0S9SD-D0ZU9R
D07IQS-D0D9HW-D0S9SD-D0ZU9R	DRUGNAME	Atazanavir + Emtricitabine + Ritonavir + Tenofovir
D07IQS-D0D9HW-D0S9SD-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D07QCE-D08PIQ-D0CT9C-D0IL7L	TTDDRUID	D07QCE-D08PIQ-D0CT9C-D0IL7L
D07QCE-D08PIQ-D0CT9C-D0IL7L	DRUGNAME	Azathioprine + Methylprednisolone Acetate + Cyclophosphamide + Prednisone
D07QCE-D08PIQ-D0CT9C-D0IL7L	INDICATI	Vasculitis [ICD-11: 4A44] Phase 2/3

D09OOV-D0KR5B-D0M1IO-D05JNI	TTDDRUID	D09OOV-D0KR5B-D0M1IO-D05JNI
D09OOV-D0KR5B-D0M1IO-D05JNI	DRUGNAME	Bacitracin + Hydrocortisone + Neomycin + Polymyxin B Sulfate
D09OOV-D0KR5B-D0M1IO-D05JNI	INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved

D09OOV-D0M1IO-D05JNI-D0X4RN	TTDDRUID	D09OOV-D0M1IO-D05JNI-D0X4RN
D09OOV-D0M1IO-D05JNI-D0X4RN	DRUGNAME	Bacitracin + Lidocaine + Neomycin + Polymyxin B Sulfate
D09OOV-D0M1IO-D05JNI-D0X4RN	INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved

D04FBR-D06OMK-D06SBB-D0N4HB	TTDDRUID	D04FBR-D06OMK-D06SBB-D0N4HB
D04FBR-D06OMK-D06SBB-D0N4HB	DRUGNAME	Basiliximab + Belatacept + Mycophenolate mofetil + Tacrolimus
D04FBR-D06OMK-D06SBB-D0N4HB	INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2

D04FBR-D06SBB-D0IL7L-D0O3YF	TTDDRUID	D04FBR-D06SBB-D0IL7L-D0O3YF
D04FBR-D06SBB-D0IL7L-D0O3YF	DRUGNAME	Basiliximab + Cyclosporine + Mycophenolate mofetil + Prednisone
D04FBR-D06SBB-D0IL7L-D0O3YF	INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 3

D04FBR-D06SBB-D0D1SG-D0K3QS	TTDDRUID	D04FBR-D06SBB-D0D1SG-D0K3QS
D04FBR-D06SBB-D0D1SG-D0K3QS	DRUGNAME	Basiliximab + Everolimus + Mycophenolate acid + Prednisolone
D04FBR-D06SBB-D0D1SG-D0K3QS	INDICATI	Liver transplantation [ICD-11: QB63.3] Phase 2

D00HCQ-D04KBL-D0N5OV-D0Y3ME	TTDDRUID	D00HCQ-D04KBL-D0N5OV-D0Y3ME
D00HCQ-D04KBL-D0N5OV-D0Y3ME	DRUGNAME	Bevacizumab + Capecitabine + Cetuximab + Oxaliplatin
D00HCQ-D04KBL-D0N5OV-D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D00HCQ-D04KBL-D05LEO-D0U5HU	TTDDRUID	D00HCQ-D04KBL-D05LEO-D0U5HU
D00HCQ-D04KBL-D05LEO-D0U5HU	DRUGNAME	Bevacizumab + Capecitabine + Cisplatin + Fluorouracil
D00HCQ-D04KBL-D05LEO-D0U5HU	INDICATI	Adenocarcinoma [ICD-11: 2D40] Phase 3

D04KBL-D0C9XJ-D0CT9C-D0O5WP	TTDDRUID	D04KBL-D0C9XJ-D0CT9C-D0O5WP
D04KBL-D0C9XJ-D0CT9C-D0O5WP	DRUGNAME	Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin
D04KBL-D0C9XJ-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D04KBL-D05LEO-D0B6TW-D0I6VU	TTDDRUID	D04KBL-D05LEO-D0B6TW-D0I6VU
D04KBL-D05LEO-D0B6TW-D0I6VU	DRUGNAME	Bevacizumab + Enzastaurin + Fluorouracil + Leucovorin
D04KBL-D05LEO-D0B6TW-D0I6VU	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2

D04KBL-D05LEO-D07HOB-D0B6TW	TTDDRUID	D04KBL-D05LEO-D07HOB-D0B6TW
D04KBL-D05LEO-D07HOB-D0B6TW	DRUGNAME	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin
D04KBL-D05LEO-D07HOB-D0B6TW	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3

D04KBL-D05LEO-D0B6TW-D0Y3ME	TTDDRUID	D04KBL-D05LEO-D0B6TW-D0Y3ME
D04KBL-D05LEO-D0B6TW-D0Y3ME	DRUGNAME	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
D04KBL-D05LEO-D0B6TW-D0Y3ME	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 3

D01XNB-D08NQZ-D0A2ZX-D0OG5K	TTDDRUID	D01XNB-D08NQZ-D0A2ZX-D0OG5K
D01XNB-D08NQZ-D0A2ZX-D0OG5K	DRUGNAME	Bismuth subcitrate potassium + Metronidazole + Omeprazole + Tetracycline
D01XNB-D08NQZ-D0A2ZX-D0OG5K	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 3

D0CT9C-D0IT2G-D0Q5NX-D0SH3I	TTDDRUID	D0CT9C-D0IT2G-D0Q5NX-D0SH3I
D0CT9C-D0IT2G-D0Q5NX-D0SH3I	DRUGNAME	Bortezomib + Cyclophosphamide + Dexamethasone + Lenalidomide
D0CT9C-D0IT2G-D0Q5NX-D0SH3I	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D0CT9C-D0IT2G-D0SH3I-D0U7GK	TTDDRUID	D0CT9C-D0IT2G-D0SH3I-D0U7GK
D0CT9C-D0IT2G-D0SH3I-D0U7GK	DRUGNAME	Bortezomib + Cyclophosphamide + Dexamethasone + Thalidomide
D0CT9C-D0IT2G-D0SH3I-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2

D00FGO-D0IL7L-D0SH3I-D0U7GK	TTDDRUID	D00FGO-D0IL7L-D0SH3I-D0U7GK
D00FGO-D0IL7L-D0SH3I-D0U7GK	DRUGNAME	Bortezomib + Melphalan + Prednisone + Thalidomide
D00FGO-D0IL7L-D0SH3I-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative

D0IT2G-D0RV4P-D0SH3I-D0U7GK	TTDDRUID	D0IT2G-D0RV4P-D0SH3I-D0U7GK
D0IT2G-D0RV4P-D0SH3I-D0U7GK	DRUGNAME	bortezomib + thalidomide + dexamethasone + daratumumab
D0IT2G-D0RV4P-D0SH3I-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D00HCQ-D04WFL-D05LEO-D0U5HU	TTDDRUID	D00HCQ-D04WFL-D05LEO-D0U5HU
D00HCQ-D04WFL-D05LEO-D0U5HU	DRUGNAME	Capecitabine + Cisplatin + Fluorouracil + Trastuzumab
D00HCQ-D04WFL-D05LEO-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D00HCQ-D0IT2G-D0TS1Z-D0Y3ME	TTDDRUID	D00HCQ-D0IT2G-D0TS1Z-D0Y3ME
D00HCQ-D0IT2G-D0TS1Z-D0Y3ME	DRUGNAME	Capecitabine + Dexamethasone + Floxuridine + Oxaliplatin
D00HCQ-D0IT2G-D0TS1Z-D0Y3ME	INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 2

D00HCQ-D0C9XJ-D0HU9H-D0Y3ME	TTDDRUID	D00HCQ-D0C9XJ-D0HU9H-D0Y3ME
D00HCQ-D0C9XJ-D0HU9H-D0Y3ME	DRUGNAME	Capecitabine + Epirubicin + Oxaliplatin + Panitumumab
D00HCQ-D0C9XJ-D0HU9H-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3

D00HCQ-D03UVS-D0HU9H-D0Y3ME	TTDDRUID	D00HCQ-D03UVS-D0HU9H-D0Y3ME
D00HCQ-D03UVS-D0HU9H-D0Y3ME	DRUGNAME	Capecitabine + Gemcitabine + Oxaliplatin + Panitumumab
D00HCQ-D03UVS-D0HU9H-D0Y3ME	INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2

D05LEO-D0N5OV-D0U5HU-D0X7HM	TTDDRUID	D05LEO-D0N5OV-D0U5HU-D0X7HM
D05LEO-D0N5OV-D0U5HU-D0X7HM	DRUGNAME	Carboplatin + Cetuximab + Cisplatin + Fluorouracil
D05LEO-D0N5OV-D0U5HU-D0X7HM	INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2

D07HOB-D0B7EB-D0X7HM-D0Y3ME	TTDDRUID	D07HOB-D0B7EB-D0X7HM-D0Y3ME
D07HOB-D0B7EB-D0X7HM-D0Y3ME	DRUGNAME	Carboplatin + Etoposide + Irinotecan + Oxaliplatin
D07HOB-D0B7EB-D0X7HM-D0Y3ME	INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2

D05LEO-D07HOB-D0B6TW-D0N5OV	TTDDRUID	D05LEO-D07HOB-D0B6TW-D0N5OV
D05LEO-D07HOB-D0B6TW-D0N5OV	DRUGNAME	Cetuximab + Fluorouracil + Irinotecan + Leucovorin
D05LEO-D07HOB-D0B6TW-D0N5OV	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3

D05LEO-D0B6TW-D0N5OV-D0Y3ME	TTDDRUID	D05LEO-D0B6TW-D0N5OV-D0Y3ME
D05LEO-D0B6TW-D0N5OV-D0Y3ME	DRUGNAME	Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin
D05LEO-D0B6TW-D0N5OV-D0Y3ME	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3

D02TLO-D07VLY-D09QVV-D0U5HU	TTDDRUID	D02TLO-D07VLY-D09QVV-D0U5HU
D02TLO-D07VLY-D09QVV-D0U5HU	DRUGNAME	Cisplatin + Doxorubicin + Ifosfamide + Vincristine
D02TLO-D07VLY-D09QVV-D0U5HU	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2

D05CHI-D08QME-D09XQF-D0S5UH	TTDDRUID	D05CHI-D08QME-D09XQF-D0S5UH
D05CHI-D08QME-D09XQF-D0S5UH	DRUGNAME	Clofazimine + Ethambutol + Isoniazid + Rifabutin
D05CHI-D08QME-D09XQF-D0S5UH	INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Investigative

D04WFL-D07VLY-D0CT9C-D0O5WP	TTDDRUID	D04WFL-D07VLY-D0CT9C-D0O5WP
D04WFL-D07VLY-D0CT9C-D0O5WP	DRUGNAME	Cyclophosphamide + Docetaxel + Doxorubicin + Trastuzumab
D04WFL-D07VLY-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D08CDI-D0C9XJ-D0CT9C-D0O5WP	TTDDRUID	D08CDI-D0C9XJ-D0CT9C-D0O5WP
D08CDI-D0C9XJ-D0CT9C-D0O5WP	DRUGNAME	Cyclophosphamide + Docetaxel + Epirubicin + Lapatinib
D08CDI-D0C9XJ-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D03UVS-D07VLY-D0C4RB-D0CT9C	TTDDRUID	D03UVS-D07VLY-D0C4RB-D0CT9C
D03UVS-D07VLY-D0C4RB-D0CT9C	DRUGNAME	Cyclophosphamide + Doxorubicin + Gemcitabine + Paclitaxel
D03UVS-D07VLY-D0C4RB-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D04WFL-D07VLY-D0C4RB-D0CT9C	TTDDRUID	D04WFL-D07VLY-D0C4RB-D0CT9C
D04WFL-D07VLY-D0C4RB-D0CT9C	DRUGNAME	Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab
D04WFL-D07VLY-D0C4RB-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D00FGO-D02VVS-D0CT9C-D0Q5NX	TTDDRUID	D00FGO-D02VVS-D0CT9C-D0Q5NX
D00FGO-D02VVS-D0CT9C-D0Q5NX	DRUGNAME	Cyclophosphamide + Filgrastim + Lenalidomide + Melphalan
D00FGO-D02VVS-D0CT9C-D0Q5NX	INDICATI	Refractory multiple myeloma [ICD-11: 2A83] Phase 3

D09EXD-D09QVV-D0CT9C-D0IL7L	TTDDRUID	D09EXD-D09QVV-D0CT9C-D0IL7L
D09EXD-D09QVV-D0CT9C-D0IL7L	DRUGNAME	Cyclophosphamide + Prednisone + Rituximab + Vincristine
D09EXD-D09QVV-D0CT9C-D0IL7L	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3

D06OMK-D0K3QS-D0O3YF-D0Z4UN	TTDDRUID	D06OMK-D0K3QS-D0O3YF-D0Z4UN
D06OMK-D0K3QS-D0O3YF-D0Z4UN	DRUGNAME	Cyclosporine + Everolimus + Pimecrolimus + Tacrolimus
D06OMK-D0K3QS-D0O3YF-D0Z4UN	INDICATI	Heart transplant rejection [ICD-11: NE84] Phase 4

D07XSN-D0B7EB-D0L5RW-D0R3JB	TTDDRUID	D07XSN-D0B7EB-D0L5RW-D0R3JB
D07XSN-D0B7EB-D0L5RW-D0R3JB	DRUGNAME	Cytarabine + Etoposide + Plerixafor + Mitoxantrone
D07XSN-D0B7EB-D0L5RW-D0R3JB	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2

D00FGO-D0FM2W-D0IL7L-D0U7GK	TTDDRUID	D00FGO-D0FM2W-D0IL7L-D0U7GK
D00FGO-D0FM2W-D0IL7L-D0U7GK	DRUGNAME	Defibrotide + Melphalan + Prednisone + Thalidomide
D00FGO-D0FM2W-D0IL7L-D0U7GK	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2

D03SKR-D0A0FL-D0I8FI-D0IT2G	TTDDRUID	D03SKR-D0A0FL-D0I8FI-D0IT2G
D03SKR-D0A0FL-D0I8FI-D0IT2G	DRUGNAME	dexamethasone + clonidine + marcaine + adrenaline
D03SKR-D0A0FL-D0I8FI-D0IT2G	INDICATI	Chronic pain [ICD-11: MG30] Phase 4
D03SKR-D0A0FL-D0I8FI-D0IT2G	INDICATI	Knee related disease [ICD-11: FA01-FA26] Phase 4
D03SKR-D0A0FL-D0I8FI-D0IT2G	INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 4

D06FDR-D07HVY-D07TQV-D0G3DL	TTDDRUID	D06FDR-D07HVY-D07TQV-D0G3DL
D06FDR-D07HVY-D07TQV-D0G3DL	DRUGNAME	Didanosine + Efavirenz + Lamivudine + Rifampin
D06FDR-D07HVY-D07TQV-D0G3DL	INDICATI	HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Investigative

D01XYJ-D06FDR-D0U5GB-D0ZU9R	TTDDRUID	D01XYJ-D06FDR-D0U5GB-D0ZU9R
D01XYJ-D06FDR-D0U5GB-D0ZU9R	DRUGNAME	Didanosine + Lopinavir + Ritonavir + Zidovudine
D01XYJ-D06FDR-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4

D04PHC-D07MOX-D0J7RK-D0V7XF	TTDDRUID	D04PHC-D07MOX-D0J7RK-D0V7XF
D04PHC-D07MOX-D0J7RK-D0V7XF	DRUGNAME	Dobutamine + Dopexamine + Epinephrine + Norepinephrine
D04PHC-D07MOX-D0J7RK-D0V7XF	INDICATI	Oral cancer [ICD-11: 2B6E] Phase 4

D04KBL-D04WFL-D0O5WP-D0X7HM	TTDDRUID	D04KBL-D04WFL-D0O5WP-D0X7HM
D04KBL-D04WFL-D0O5WP-D0X7HM	DRUGNAME	docetaxel + carboplatin + trastuzumab + bevacizumab
D04KBL-D04WFL-D0O5WP-D0X7HM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04KBL-D07VLY-D0CT9C-D0O5WP	TTDDRUID	D04KBL-D07VLY-D0CT9C-D0O5WP
D04KBL-D07VLY-D0CT9C-D0O5WP	DRUGNAME	docetaxel + doxorubicin + cyclophosphamide + bevacizumab
D04KBL-D07VLY-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04WFL-D0C9XJ-D0O5WP-D0VM2L	TTDDRUID	D04WFL-D0C9XJ-D0O5WP-D0VM2L
D04WFL-D0C9XJ-D0O5WP-D0VM2L	DRUGNAME	Docetaxel + Epirubicin + Trastuzumab + Zoledronate
D04WFL-D0C9XJ-D0O5WP-D0VM2L	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D05LEO-D0B6TW-D0O5WP-D0Y3ME	TTDDRUID	D05LEO-D0B6TW-D0O5WP-D0Y3ME
D05LEO-D0B6TW-D0O5WP-D0Y3ME	DRUGNAME	Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin
D05LEO-D0B6TW-D0O5WP-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2/3

D01AXB-D08RBC-D0NS6H-D0P1UX	TTDDRUID	D01AXB-D08RBC-D0NS6H-D0P1UX
D01AXB-D08RBC-D0NS6H-D0P1UX	DRUGNAME	Donepezil + Duloxetine + Escitalopram + Venlafaxine
D01AXB-D08RBC-D0NS6H-D0P1UX	INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 4

D0D9HW-D0S9SD-D0U5GB-D0ZU9R	TTDDRUID	D0D9HW-D0S9SD-D0U5GB-D0ZU9R
D0D9HW-D0S9SD-D0U5GB-D0ZU9R	DRUGNAME	Emtricitabine + Lopinavir + Ritonavir + Tenofovir
D0D9HW-D0S9SD-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
D0D9HW-D0S9SD-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 4

D04PHC-D09RHQ-D0D9JW-D0WE3O	TTDDRUID	D04PHC-D09RHQ-D0D9JW-D0WE3O
D04PHC-D09RHQ-D0D9JW-D0WE3O	DRUGNAME	Epinephrine + Ketorolac + Morphine + Ropivacaine
D04PHC-D09RHQ-D0D9JW-D0WE3O	INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4

D04PHC-D08PIQ-D0KR5B-D0N4OW	TTDDRUID	D04PHC-D08PIQ-D0KR5B-D0N4OW
D04PHC-D08PIQ-D0KR5B-D0N4OW	DRUGNAME	Epinephrine + Methylprednisolone Acetate + Hydrocortisone + Vasopressin
D04PHC-D08PIQ-D0KR5B-D0N4OW	INDICATI	Cardiac arrest [ICD-11: MC82] Phase 3

D08QME-D09XQF-D0G3DL-D0XF8W	TTDDRUID	D08QME-D09XQF-D0G3DL-D0XF8W
D08QME-D09XQF-D0G3DL-D0XF8W	DRUGNAME	Ethambutol + Isoniazid + Pyrazinamide + Rifampin
D08QME-D09XQF-D0G3DL-D0XF8W	INDICATI	HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Investigative
D08QME-D09XQF-D0G3DL-D0XF8W	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2
D08QME-D09XQF-D0G3DL-D0XF8W	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 3

D08QME-D0G3DL-D0XF8W-D0ZV0Z	TTDDRUID	D08QME-D0G3DL-D0XF8W-D0ZV0Z
D08QME-D0G3DL-D0XF8W-D0ZV0Z	DRUGNAME	Ethambutol + Moxifloxacin + Pyrazinamide + Rifampin
D08QME-D0G3DL-D0XF8W-D0ZV0Z	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2

D07TQV-D09LNI-D0O2EM-D0Z8EX	TTDDRUID	D07TQV-D09LNI-D0O2EM-D0Z8EX
D07TQV-D09LNI-D0O2EM-D0Z8EX	DRUGNAME	Fluconazole + Lamivudine + Nevirapine + Stavudine
D07TQV-D09LNI-D0O2EM-D0Z8EX	INDICATI	Cryptococcal meningitis infection [ICD-11: 1D01.10] Investigative

D05LEO-D07HOB-D0B6TW-D0R0MW	TTDDRUID	D05LEO-D07HOB-D0B6TW-D0R0MW
D05LEO-D07HOB-D0B6TW-D0R0MW	DRUGNAME	Fluorouracil + Irinotecan + Leucovorin + Sunitinib
D05LEO-D07HOB-D0B6TW-D0R0MW	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3

D05LEO-D0B6TW-D0HU9H-D0Y3ME	TTDDRUID	D05LEO-D0B6TW-D0HU9H-D0Y3ME
D05LEO-D0B6TW-D0HU9H-D0Y3ME	DRUGNAME	Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab
D05LEO-D0B6TW-D0HU9H-D0Y3ME	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3

D0B2GI-D0D7LA-D0K5ER-D0R6CD	TTDDRUID	D0B2GI-D0D7LA-D0K5ER-D0R6CD
D0B2GI-D0D7LA-D0K5ER-D0R6CD	DRUGNAME	Glimepiride + Insulin + Metformin + Rosiglitazone
D0B2GI-D0D7LA-D0K5ER-D0R6CD	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D03OFF-D0D7LA-D0U2JP-D0Z4SB	TTDDRUID	D03OFF-D0D7LA-D0U2JP-D0Z4SB
D03OFF-D0D7LA-D0U2JP-D0Z4SB	DRUGNAME	Glipizide + Metformin + Pioglitazone + Sitagliptin
D03OFF-D0D7LA-D0U2JP-D0Z4SB	INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3

D00BCG-D0A9YA-D0B4IF-D0V9BD	TTDDRUID	D00BCG-D0A9YA-D0B4IF-D0V9BD
D00BCG-D0A9YA-D0B4IF-D0V9BD	DRUGNAME	Goserelin + Dutasteride + Ketoconazole + Bicalutamide
D00BCG-D0A9YA-D0B4IF-D0V9BD	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2

D01TVQ-D09EXD-D0CT9C-D0F2XQ	TTDDRUID	D01TVQ-D09EXD-D0CT9C-D0F2XQ
D01TVQ-D09EXD-D0CT9C-D0F2XQ	DRUGNAME	Ibritumomab + Rituximab + Cyclophosphamide + Fludarabine
D01TVQ-D09EXD-D0CT9C-D0F2XQ	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2

D01XDL-D02DGU-D09UZO-D0D3DU	TTDDRUID	D01XDL-D02DGU-D09UZO-D0D3DU
D01XDL-D02DGU-D09UZO-D0D3DU	DRUGNAME	Idarubicin + Tretinoin + Mercaptopurine + Methotrexate Sodium
D01XDL-D02DGU-D09UZO-D0D3DU	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D01XYJ-D07TQV-D0U5GB-D0ZU9R	TTDDRUID	D01XYJ-D07TQV-D0U5GB-D0ZU9R
D01XYJ-D07TQV-D0U5GB-D0ZU9R	DRUGNAME	Lamivudine + Lopinavir + Ritonavir + Zidovudine
D01XYJ-D07TQV-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
D01XYJ-D07TQV-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3
D01XYJ-D07TQV-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
D01XYJ-D07TQV-D0U5GB-D0ZU9R	INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3

D07TQV-D0G3DL-D0O2EM-D0Z8EX	TTDDRUID	D07TQV-D0G3DL-D0O2EM-D0Z8EX
D07TQV-D0G3DL-D0O2EM-D0Z8EX	DRUGNAME	Lamivudine + Nevirapine + Rifampin + Stavudine
D07TQV-D0G3DL-D0O2EM-D0Z8EX	INDICATI	Infection of HIV-1 and tuberculosis [ICD-11: 1C60.0] Investigative

D00HCQ-D0BZ7V-D0C9XJ-D0U5HU	TTDDRUID	D00HCQ-D0BZ7V-D0C9XJ-D0U5HU
D00HCQ-D0BZ7V-D0C9XJ-D0U5HU	DRUGNAME	matuzumab + Epirubicin + cisplatin + capecitabine
D00HCQ-D0BZ7V-D0C9XJ-D0U5HU	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2
D00HCQ-D0BZ7V-D0C9XJ-D0U5HU	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2

D08PIQ-D09EXD-D0D3DU-D0Z0DW	TTDDRUID	D08PIQ-D09EXD-D0D3DU-D0Z0DW
D08PIQ-D09EXD-D0D3DU-D0Z0DW	DRUGNAME	Methylprednisolone Acetate + Rituximab + Methotrexate Sodium + Folic Acid
D08PIQ-D09EXD-D0D3DU-D0Z0DW	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3

D04FBR-D08PIQ-D09EXD-D0IL7L	TTDDRUID	D04FBR-D08PIQ-D09EXD-D0IL7L
D04FBR-D08PIQ-D09EXD-D0IL7L	DRUGNAME	Mycophenolate mofetil + Methylprednisolone Acetate + Rituximab + Prednisone
D04FBR-D08PIQ-D09EXD-D0IL7L	INDICATI	Lupus [ICD-11: 4A40] Phase 3

D04KBL-D05LEO-D0R4PS-D0Y3ME	TTDDRUID	D04KBL-D05LEO-D0R4PS-D0Y3ME
D04KBL-D05LEO-D0R4PS-D0Y3ME	DRUGNAME	oxaliplatin + folinic acid + fluorouracil + bevacizumab
D04KBL-D05LEO-D0R4PS-D0Y3ME	INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
D04KBL-D05LEO-D0R4PS-D0Y3ME	INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1
D04KBL-D05LEO-D0R4PS-D0Y3ME	INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
D04KBL-D05LEO-D0R4PS-D0Y3ME	INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
D04KBL-D05LEO-D0R4PS-D0Y3ME	INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
D04KBL-D05LEO-D0R4PS-D0Y3ME	INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Phase 1

D02ZTJ-D08ROP-D0D3DU-D0OJ4L	TTDDRUID	D02ZTJ-D08ROP-D0D3DU-D0OJ4L
D02ZTJ-D08ROP-D0D3DU-D0OJ4L	DRUGNAME	Sulfasalazine + Leflunomide + Methotrexate Sodium + Hydroxychloroquine
D02ZTJ-D08ROP-D0D3DU-D0OJ4L	INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 4

D03CUF-D0C6DT-D0F6EO-D0OG5K-D0X7JN	TTDDRUID	D03CUF-D0C6DT-D0F6EO-D0OG5K-D0X7JN
D03CUF-D0C6DT-D0F6EO-D0OG5K-D0X7JN	DRUGNAME	Amoxicillin + Bismuth potassium citrate + Clavulanate + Esomeprazole + Furazolidone
D03CUF-D0C6DT-D0F6EO-D0OG5K-D0X7JN	INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative

D07ACT-D07BCT-D07JZF-D0D1HA-D0F6EO	TTDDRUID	D07ACT-D07BCT-D07JZF-D0D1HA-D0F6EO
D07ACT-D07BCT-D07JZF-D0D1HA-D0F6EO	DRUGNAME	Amoxicillin + Cefotaxime + Ceftriaxone + Netilmicin + Tobramycin
D07ACT-D07BCT-D07JZF-D0D1HA-D0F6EO	INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 4

D00HCQ-D04KBL-D07VLY-D0CT9C-D0O5WP	TTDDRUID	D00HCQ-D04KBL-D07VLY-D0CT9C-D0O5WP
D00HCQ-D04KBL-D07VLY-D0CT9C-D0O5WP	DRUGNAME	Bevacizumab + Capecitabine + Cyclophosphamide + Docetaxel + Doxorubicin
D00HCQ-D04KBL-D07VLY-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D04KBL-D05LEO-D0C4RB-D0C9XJ-D0CT9C	TTDDRUID	D04KBL-D05LEO-D0C4RB-D0C9XJ-D0CT9C
D04KBL-D05LEO-D0C4RB-D0C9XJ-D0CT9C	DRUGNAME	Bevacizumab + Cyclophosphamide + Epirubicin + Fluorouracil + Paclitaxel
D04KBL-D05LEO-D0C4RB-D0C9XJ-D0CT9C	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D04KBL-D05LEO-D07HOB-D0B6TW-D0Y3ME	TTDDRUID	D04KBL-D05LEO-D07HOB-D0B6TW-D0Y3ME
D04KBL-D05LEO-D07HOB-D0B6TW-D0Y3ME	DRUGNAME	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin
D04KBL-D05LEO-D07HOB-D0B6TW-D0Y3ME	INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2

D06UVD-D07VLY-D09EXD-D0W9MM-D0Y7ZU	TTDDRUID	D06UVD-D07VLY-D09EXD-D0W9MM-D0Y7ZU
D06UVD-D07VLY-D09EXD-D0W9MM-D0Y7ZU	DRUGNAME	Bleomycin sulfate + Dacarbazine + Doxorubicin + Rituximab + Vinblastine
D06UVD-D07VLY-D09EXD-D0W9MM-D0Y7ZU	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D06UVD-D07VLY-D08GYO-D0B7EB-D0IL7L	TTDDRUID	D06UVD-D07VLY-D08GYO-D0B7EB-D0IL7L
D06UVD-D07VLY-D08GYO-D0B7EB-D0IL7L	DRUGNAME	Bleomycin sulfate + Doxorubicin + Etoposide + Prednisone + Procarbazine
D06UVD-D07VLY-D08GYO-D0B7EB-D0IL7L	INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 3

D04WFL-D07VLY-D0CT9C-D0O5WP-D0X7HM	TTDDRUID	D04WFL-D07VLY-D0CT9C-D0O5WP-D0X7HM
D04WFL-D07VLY-D0CT9C-D0O5WP-D0X7HM	DRUGNAME	Carboplatin + Cyclophosphamide + Docetaxel + Doxorubicin + Trastuzumab
D04WFL-D07VLY-D0CT9C-D0O5WP-D0X7HM	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D02TLO-D07VLY-D09QVV-D0O7GU-D0U5HU	TTDDRUID	D02TLO-D07VLY-D09QVV-D0O7GU-D0U5HU
D02TLO-D07VLY-D09QVV-D0O7GU-D0U5HU	DRUGNAME	Cisplatin + Doxorubicin + Ifosfamide + Palifermin + Vincristine
D02TLO-D07VLY-D09QVV-D0O7GU-D0U5HU	INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2

D04WFL-D05LEO-D0C9XJ-D0CT9C-D0O5WP	TTDDRUID	D04WFL-D05LEO-D0C9XJ-D0CT9C-D0O5WP
D04WFL-D05LEO-D0C9XJ-D0CT9C-D0O5WP	DRUGNAME	Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil + Trastuzumab
D04WFL-D05LEO-D0C9XJ-D0CT9C-D0O5WP	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3

D07VLY-D09EXD-D09QVV-D0B7EB-D0CT9C	TTDDRUID	D07VLY-D09EXD-D09QVV-D0B7EB-D0CT9C
D07VLY-D09EXD-D09QVV-D0B7EB-D0CT9C	DRUGNAME	Cyclophosphamide + Doxorubicin + Etoposide + Rituximab + Vincristine
D07VLY-D09EXD-D09QVV-D0B7EB-D0CT9C	INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2

D04WFL-D07VLY-D08CDI-D0C4RB-D0CT9C	TTDDRUID	D04WFL-D07VLY-D08CDI-D0C4RB-D0CT9C
D04WFL-D07VLY-D08CDI-D0C4RB-D0CT9C	DRUGNAME	Cyclophosphamide + Doxorubicin + Lapatinib + Paclitaxel + Trastuzumab
D04WFL-D07VLY-D08CDI-D0C4RB-D0CT9C	INDICATI	Invasive breast cancer [ICD-11: 2C61] Phase 3

D04WFL-D07VLY-D0C4RB-D0CT9C-D0Q9CY	TTDDRUID	D04WFL-D07VLY-D0C4RB-D0CT9C-D0Q9CY
D04WFL-D07VLY-D0C4RB-D0CT9C-D0Q9CY	DRUGNAME	Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel + Trastuzumab
D04WFL-D07VLY-D0C4RB-D0CT9C-D0Q9CY	INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2

D07VLY-D09QVV-D0CT9C-D0IL7L-D0S8WA	TTDDRUID	D07VLY-D09QVV-D0CT9C-D0IL7L-D0S8WA
D07VLY-D09QVV-D0CT9C-D0IL7L-D0S8WA	DRUGNAME	Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine
D07VLY-D09QVV-D0CT9C-D0IL7L-D0S8WA	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1

D07VLY-D09EXD-D09QVV-D0CT9C-D0IL7L	TTDDRUID	D07VLY-D09EXD-D09QVV-D0CT9C-D0IL7L
D07VLY-D09EXD-D09QVV-D0CT9C-D0IL7L	DRUGNAME	Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine
D07VLY-D09EXD-D09QVV-D0CT9C-D0IL7L	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative
D07VLY-D09EXD-D09QVV-D0CT9C-D0IL7L	INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3

D09EXD-D09QVV-D0CT9C-D0IL7L-D0Q4OW	TTDDRUID	D09EXD-D09QVV-D0CT9C-D0IL7L-D0Q4OW
D09EXD-D09QVV-D0CT9C-D0IL7L-D0Q4OW	DRUGNAME	Cyclophosphamide + Pixantrone + Prednisone + Rituximab + Vincristine
D09EXD-D09QVV-D0CT9C-D0IL7L-D0Q4OW	INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3

D01XWG-D02VVS-D06DCL-D07XSN-D0XT5Y	TTDDRUID	D01XWG-D02VVS-D06DCL-D07XSN-D0XT5Y
D01XWG-D02VVS-D06DCL-D07XSN-D0XT5Y	DRUGNAME	Cytarabine + Daunorubicin + Filgrastim + Sargramostim + Zosuquidar trihydrochloride
D01XWG-D02VVS-D06DCL-D07XSN-D0XT5Y	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D01TNW-D03OFF-D0B2GI-D0D7LA-D0K5ER	TTDDRUID	D01TNW-D03OFF-D0B2GI-D0D7LA-D0K5ER
D01TNW-D03OFF-D0B2GI-D0D7LA-D0K5ER	DRUGNAME	Dapagliflozin + Glimepiride + Metformin + Pioglitazone + Rosiglitazone
D01TNW-D03OFF-D0B2GI-D0D7LA-D0K5ER	INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3

D01XYJ-D06FDR-D0O2EM-D0U5GB-D0ZU9R	TTDDRUID	D01XYJ-D06FDR-D0O2EM-D0U5GB-D0ZU9R
D01XYJ-D06FDR-D0O2EM-D0U5GB-D0ZU9R	DRUGNAME	Didanosine + Lopinavir + Nevirapine + Ritonavir + Zidovudine
D01XYJ-D06FDR-D0O2EM-D0U5GB-D0ZU9R	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2

D01XYJ-D07HVY-D07TQV-D0D9HW-D0S9SD	TTDDRUID	D01XYJ-D07HVY-D07TQV-D0D9HW-D0S9SD
D01XYJ-D07HVY-D07TQV-D0D9HW-D0S9SD	DRUGNAME	Efavirenz + Emtricitabine + Lamivudine + Tenofovir + Zidovudine
D01XYJ-D07HVY-D07TQV-D0D9HW-D0S9SD	INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3

D07HVY-D08QME-D09XQF-D0G3DL-D0O2EM	TTDDRUID	D07HVY-D08QME-D09XQF-D0G3DL-D0O2EM
D07HVY-D08QME-D09XQF-D0G3DL-D0O2EM	DRUGNAME	Efavirenz + Ethambutol + Isoniazid + Nevirapine + Rifampin
D07HVY-D08QME-D09XQF-D0G3DL-D0O2EM	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2/3

D02TLO-D09EXD-D0AT8C-D0B7EB-D0XT5Y	TTDDRUID	D02TLO-D09EXD-D0AT8C-D0B7EB-D0XT5Y
D02TLO-D09EXD-D0AT8C-D0B7EB-D0XT5Y	DRUGNAME	Etoposide + Ifosfamide + Pegfilgrastim + Rituximab + Sargramostim
D02TLO-D09EXD-D0AT8C-D0B7EB-D0XT5Y	INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2

D0A0JH-D0B1IV-D0K6MW-D0MB8I-D0Q2AT	TTDDRUID	D0A0JH-D0B1IV-D0K6MW-D0MB8I-D0Q2AT
D0A0JH-D0B1IV-D0K6MW-D0MB8I-D0Q2AT	DRUGNAME	Floxacillin + Nafcillin + Oxacillin + Teicoplanin + Vancomycin
D0A0JH-D0B1IV-D0K6MW-D0MB8I-D0Q2AT	INDICATI	Osteomyelitis [ICD-11: FB84] Phase 2

D01XYJ-D07HVY-D09XQF-D0A4IJ-D0G3DL-D0XF8W	TTDDRUID	D01XYJ-D07HVY-D09XQF-D0A4IJ-D0G3DL-D0XF8W
D01XYJ-D07HVY-D09XQF-D0A4IJ-D0G3DL-D0XF8W	DRUGNAME	Abacavir + Efavirenz + Isoniazid + Pyrazinamide + Rifampin + Zidovudine
D01XYJ-D07HVY-D09XQF-D0A4IJ-D0G3DL-D0XF8W	INDICATI	HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Investigative

D01XWG-D06EWO-D07SUG-D07XSN-D0CT9C-D0XT5Y	TTDDRUID	D01XWG-D06EWO-D07SUG-D07XSN-D0CT9C-D0XT5Y
D01XWG-D06EWO-D07SUG-D07XSN-D0CT9C-D0XT5Y	DRUGNAME	Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Sargramostim
D01XWG-D06EWO-D07SUG-D07XSN-D0CT9C-D0XT5Y	INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3

D00FGO-D07VLY-D09QVV-D0CT9C-D0IL7L-D0IT2G	TTDDRUID	D00FGO-D07VLY-D09QVV-D0CT9C-D0IL7L-D0IT2G
D00FGO-D07VLY-D09QVV-D0CT9C-D0IL7L-D0IT2G	DRUGNAME	Cyclophosphamide + Dexamethasone + Doxorubicin + Melphalan + Prednisone + Vincristine
D00FGO-D07VLY-D09QVV-D0CT9C-D0IL7L-D0IT2G	INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3

D01XWG-D02DGU-D07VIK-D07XSN-D09UZO-D0D3DU	TTDDRUID	D01XWG-D02DGU-D07VIK-D07XSN-D09UZO-D0D3DU
D01XWG-D02DGU-D07VIK-D07XSN-D09UZO-D0D3DU	DRUGNAME	Daunorubicin + Tretinoin + Arsenic trioxide + Cytarabine + Mercaptopurine + Methotrexate Sodium
D01XWG-D02DGU-D07VIK-D07XSN-D09UZO-D0D3DU	INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3

D06FDR-D07TQV-D09XQF-D0G3DL-D0WI3T-D0ZU9R	TTDDRUID	D06FDR-D07TQV-D09XQF-D0G3DL-D0WI3T-D0ZU9R
D06FDR-D07TQV-D09XQF-D0G3DL-D0WI3T-D0ZU9R	DRUGNAME	Didanosine + Isoniazid + Lamivudine + Rifampin + Ritonavir + Saquinavir
D06FDR-D07TQV-D09XQF-D0G3DL-D0WI3T-D0ZU9R	INDICATI	HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] Investigative

D07HVY-D07TQV-D08QME-D09XQF-D0G3DL-D0XF8W	TTDDRUID	D07HVY-D07TQV-D08QME-D09XQF-D0G3DL-D0XF8W
D07HVY-D07TQV-D08QME-D09XQF-D0G3DL-D0XF8W	DRUGNAME	Efavirenz + Ethambutol + Isoniazid + Lamivudine + Pyrazinamide + Rifampin
D07HVY-D07TQV-D08QME-D09XQF-D0G3DL-D0XF8W	INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2/3